FN Clarivate Analytics Web of Science
VR 1.0
PT J
AU Collignon, E
   Canale, A
   Al Wardi, C
   Bizet, M
   Calonne, E
   Dedeurwaerder, S
   Garaud, S
   Naveaux, C
   Barham, W
   Wilson, A
   Bouchat, S
   Hubert, P
   Van Lint, C
   Yull, F
   Sotiriou, C
   Willard-Gallo, K
   Noel, A
   Fuks, F
AF Collignon, Evelyne
   Canale, Annalisa
   Al Wardi, Clemence
   Bizet, Martin
   Calonne, Emilie
   Dedeurwaerder, Sarah
   Garaud, Soizic
   Naveaux, Celine
   Barham, Whitney
   Wilson, Andrew
   Bouchat, Sophie
   Hubert, Pascale
   Van Lint, Carine
   Yull, Fiona
   Sotiriou, Christos
   Willard-Gallo, Karen
   Noel, Agnes
   Fuks, Francois
TI Immunity drives <i>TET1</i> regulation in cancer through NF-κB
SO SCIENCE ADVANCES
LA English
DT Article
ID BREAST-CANCER; GENE-EXPRESSION; DNA DEMETHYLATION;
   5-HYDROXYMETHYLCYTOSINE; PROLIFERATION; ACTIVATION; METHYLATION; GROWTH;
   CELLS; TRANSCRIPTION
AB Ten-eleven translocation enzymes (TET1, TET2, and TET3), which induce DNA demethylation and gene regulation by converting 5-methylcytosine (5mC) to 5-hydroxymethylcytosine (5hmC), are often down-regulated in cancer. We uncover, in basal-like breast cancer (BLBC), genome-wide 5hmC changes related to TET1 regulation. We further demonstrate that TET1 repression is associated with high expression of immune markers and high infiltration by immune cells. We identify in BLBC tissues an anticorrelation between TET1 expression and the major immuno-regulator family nuclear factor kappa B (NF-kappa B). In vitro and in mice, TET1 is down-regulated in breast cancer cells upon NF-kappa B activation through binding of p65 to its consensus sequence in the TET1 promoter. We lastly show that these findings extend to other cancer types, including melanoma, lung, and thyroid cancers. Together, our data suggest a novel mode of regulation for TET1 in cancer and highlight a new paradigm in which the immune system can influence cancer cell epigenetics.
C1 [Collignon, Evelyne; Al Wardi, Clemence; Bizet, Martin; Calonne, Emilie; Dedeurwaerder, Sarah; Fuks, Francois] ULB, Fac Med, Cancer Res Ctr U CRC, Lab Canc Epigenet, Brussels, Belgium.
   [Collignon, Evelyne; Noel, Agnes] Univ Liege, Lab Tumor & Dev Biol, Grp Interdisciplinaire Genoprote Appl GIGA Canc, Liege, Belgium.
   [Garaud, Soizic; Naveaux, Celine; Willard-Gallo, Karen] ULB, Inst Jules Bordet, Mol Immunol Unit, Brussels, Belgium.
   [Barham, Whitney; Wilson, Andrew; Yull, Fiona] Vanderbilt Univ, Vanderbilt Ingram Canc Ctr, Dept Canc Biol, Nashville, TN 37232 USA.
   [Bouchat, Sophie; Van Lint, Carine] ULB, U CRC, Serv Mol Virol, Dept Mol Biol, Gosselies, Belgium.
   [Hubert, Pascale] Univ Liege, GIGA Canc, Lab Expt Pathol, Liege, Belgium.
   [Sotiriou, Christos] ULB, Inst Jules Bordet, Breast Canc Translat Res Lab, Brussels, Belgium.
C3 Universite Libre de Bruxelles; University of Liege; Institut Jules
   Bordet; Universite Libre de Bruxelles; Vanderbilt University; Universite
   Libre de Bruxelles; University of Liege; Universite Libre de Bruxelles;
   Institut Jules Bordet
RP Fuks, F (通讯作者)，ULB, Fac Med, Cancer Res Ctr U CRC, Lab Canc Epigenet, Brussels, Belgium.; Noel, A (通讯作者)，Univ Liege, Lab Tumor & Dev Biol, Grp Interdisciplinaire Genoprote Appl GIGA Canc, Liege, Belgium.
EM agnes.noel@ulg.ac.be; ffuks@ulb.ac.be
RI Van Lint, Carine/HNS-4077-2023; Fuks, Francois/HJY-8201-2023; Wilson,
   Andrew/KRQ-9512-2024
OI Noel, Agnes/0000-0002-7670-6179; Collignon, Evelyne/0000-0001-7617-5905;
   Wilson, Andrew/0000-0002-8656-7723; Garaud, Soizic/0000-0001-8758-1263;
   VAN LINT, Carine/0000-0002-2219-2862; Willard-Gallo,
   Karen/0000-0002-1150-1295; Al Wardi, Clemence/0000-0001-5714-6703;
   Barham, Whitney/0000-0002-1130-1971
FU L'Oreal "For Women In Science" fellowship; Belgian "Fonds de la
   Recherche Scientifique" (FNRS); Televie grants; Fondation Leon
   Fredericq; FNRS; Televie; Interuniversity Attraction Poles program
   [P7/03]; the "Action de Recherche Concertee" (ARC) (AUWB-2010-2015 ULB)
   [7]; Wallonie-Bruxelles Health program [CANDX 1318030]; Belgian
   "Fondation contre le Cancer" [FCC 2016-086 FAF-F/2016/872]; Fonds Gaston
   Ithier; Belgian FNRS; Centre Anti-Cancereux; "Fonds Speciaux" of the
   University of Liege; Les Amis de l'Institut Bordet; Plan Cancer of
   Belgium; MEDIC Foundation; Fondation Lambeau-Marteaux; NIH [R01
   CA214043]
FX We thank J. Jeschke for continued support and advice. E. Collignon was
   supported by a L'Oreal "For Women In Science" fellowship and by the
   Belgian "Fonds de la Recherche Scientifique" (FNRS). A.C., M.B., and
   C.A.W. were supported by Televie grants. A.C. was also supported by the
   "Fondation Leon Fredericq." F.F. is a ULB Full Professor. F.F.'s
   laboratory was funded by grants from the FNRS and Televie, the
   Interuniversity Attraction Poles (P7/03) program, the "Action de
   Recherche Concertee" (ARC) (AUWB-2010-2015 ULB-No 7), the
   Wallonie-Bruxelles Health program (CANDX 1318030), the Belgian
   "Fondation contre le Cancer" (FCC 2016-086 FAF-F/2016/872), and the
   Fonds Gaston Ithier. A.N.'s laboratory was supported by Belgian grants
   from the Belgian FNRS, Televie, the "Centre Anti-Cancereux," the
   Fondation Leon Fredericq, and the "Fonds Speciaux" of the University of
   Liege. K.W.-G.'s laboratory is supported by grants from the Belgian
   FNRS, Les Amis de l'Institut Bordet, Televie, Plan Cancer of Belgium,
   MEDIC Foundation, and Fondation Lambeau-Marteaux. F.Y.'s laboratory was
   supported by NIH R01 CA214043.
CR Ashburner BP, 2001, MOL CELL BIOL, V21, P7065, DOI 10.1128/MCB.21.20.7065-7077.2001
   Barham W, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1652-8
   Berdasco M, 2010, DEV CELL, V19, P698, DOI 10.1016/j.devcel.2010.10.005
   Brantley DM, 2001, MOL BIOL CELL, V12, P1445, DOI 10.1091/mbc.12.5.1445
   Buisseret L, 2017, MODERN PATHOL, V30, P1204, DOI 10.1038/modpathol.2017.43
   Capece D, 2018, SEMIN CELL DEV BIOL, V78, P51, DOI 10.1016/j.semcdb.2017.08.004
   Carty SA, 2018, J IMMUNOL, V200, P82, DOI 10.4049/jimmunol.1700559
   Chen F, 2008, INT REV IMMUNOL, V27, P183, DOI 10.1080/08830180802130327
   Chiappinelli KB, 2016, CANCER RES, V76, P1683, DOI 10.1158/0008-5472.CAN-15-2125
   Chiappinelli KB, 2015, CELL, V162, P974, DOI 10.1016/j.cell.2015.07.011
   Chua HL, 2007, ONCOGENE, V26, P711, DOI 10.1038/sj.onc.1209808
   Connelly L, 2011, ONCOGENE, V30, P1402, DOI 10.1038/onc.2010.521
   Dany M, 2016, HUM VACC IMMUNOTHER, V12, P2501, DOI 10.1080/21645515.2016.1190889
   Dedeurwaerder S, 2011, EMBO MOL MED, V3, P726, DOI 10.1002/emmm.201100801
   Delatte B, 2015, SCI REP-UK, V5, DOI 10.1038/srep12714
   Deng WG, 2003, ANAL BIOCHEM, V323, P12, DOI 10.1016/j.ab.2003.08.007
   Galon J, 2006, SCIENCE, V313, P1960, DOI 10.1126/science.1129139
   Gerondakis S, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a000182
   Grivennikov SI, 2010, CELL, V140, P883, DOI 10.1016/j.cell.2010.01.025
   Guo JU, 2011, CELL, V145, P423, DOI 10.1016/j.cell.2011.03.022
   Haffner MC, 2011, ONCOTARGET, V2, P627
   Hellweg CE, 2006, ANN NY ACAD SCI, V1091, P191, DOI 10.1196/annals.1378.066
   Hoesel B, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-86
   Hoffmann A, 2006, IMMUNOL REV, V210, P171, DOI 10.1111/j.0105-2896.2006.00375.x
   Hsu CH, 2012, CELL REP, V2, P568, DOI 10.1016/j.celrep.2012.08.030
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Ichiyama K, 2015, IMMUNITY, V42, P613, DOI 10.1016/j.immuni.2015.03.005
   Imam S, 2014, ENDOCR-RELAT CANCER, V21, P505, DOI 10.1530/ERC-13-0436
   Ito S, 2010, NATURE, V466, P1129, DOI 10.1038/nature09303
   Jeschke J, 2017, J CLIN INVEST, V127, P3090, DOI 10.1172/JCI91095
   Jókai H, 2012, PATHOL ONCOL RES, V18, P749, DOI 10.1007/s12253-012-9529-5
   Joyce D, 2001, CYTOKINE GROWTH F R, V12, P73, DOI 10.1016/S1359-6101(00)00018-6
   Kargl J, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14381
   Karin M, 2006, NATURE, V441, P431, DOI 10.1038/nature04870
   Kudo Y, 2012, CANCER SCI, V103, P670, DOI 10.1111/j.1349-7006.2012.02213.x
   Lee DH, 1998, TRENDS CELL BIOL, V8, P397, DOI 10.1016/S0962-8924(98)01346-4
   Lian CG, 2012, CELL, V150, P1135, DOI 10.1016/j.cell.2012.07.033
   Liu M, 2010, CANCER RES, V70, P10464, DOI 10.1158/0008-5472.CAN-10-0732
   Liu Y, 2012, ONCOGENE, V31, P1143, DOI 10.1038/onc.2011.308
   Lorsbach RB, 2003, LEUKEMIA, V17, P637, DOI 10.1038/sj.leu.2402834
   Lu HG, 2014, MOL MED REP, V10, P2595, DOI 10.3892/mmr.2014.2517
   Maeda S, 2005, CELL, V121, P977, DOI 10.1016/j.cell.2005.04.014
   Mantovani A, 2010, CURR MOL MED, V10, P369, DOI 10.2174/156652410791316968
   Mantovani A, 2004, TRENDS IMMUNOL, V25, P677, DOI 10.1016/j.it.2004.09.015
   Melichar B, 2014, ANTICANCER RES, V34, P1115
   Mohamed MM, 2012, CELL COMMUN SIGNAL, V10, DOI 10.1186/1478-811X-10-3
   Münzel M, 2011, ANGEW CHEM INT EDIT, V50, P6460, DOI 10.1002/anie.201101547
   Narendra BL, 2013, INFLAMM RES, V62, P823, DOI 10.1007/s00011-013-0645-9
   Naugler WE, 2008, CURR OPIN GENET DEV, V18, P19, DOI 10.1016/j.gde.2008.01.020
   Neri F, 2015, ONCOGENE, V34, P4168, DOI 10.1038/onc.2014.356
   Newman AM, 2015, NAT METHODS, V12, P453, DOI [10.1038/NMETH.3337, 10.1038/nmeth.3337]
   Oble Darryl A, 2009, Cancer Immun, V9, P3
   Oeckinghaus A, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a000034
   Pastor WA, 2013, NAT REV MOL CELL BIO, V14, P341, DOI 10.1038/nrm3589
   Pei YF, 2016, BBA-MOL BASIS DIS, V1862, P2177, DOI 10.1016/j.bbadis.2016.08.014
   Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093
   Price EM, 2013, EPIGENET CHROMATIN, V6, DOI 10.1186/1756-8935-6-4
   Rivenbark AG, 2013, AM J PATHOL, V183, P1113, DOI 10.1016/j.ajpath.2013.08.002
   Roulois D, 2015, CELL, V162, P961, DOI 10.1016/j.cell.2015.07.056
   SADOWSKI HB, 1993, NATURE, V362, P79, DOI 10.1038/362079a0
   Sang Yi, 2015, Asian Pac J Cancer Prev, V16, P1197
   Shibata W, 2010, GASTROENTEROLOGY, V138, P1022, DOI 10.1053/j.gastro.2009.11.054
   Sica A, 2012, J CLIN INVEST, V122, P787, DOI 10.1172/JCI59643
   Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100
   Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098
   Sotiriou C, 2003, P NATL ACAD SCI USA, V100, P10393, DOI 10.1073/pnas.1732912100
   Sun M, 2013, P NATL ACAD SCI USA, V110, P9920, DOI 10.1073/pnas.1305172110
   Tahiliani M, 2009, SCIENCE, V324, P930, DOI 10.1126/science.1170116
   Thienpont B, 2016, NATURE, V537, P63, DOI 10.1038/nature19081
   Tobin NP, 2015, ANN ONCOL, V26, P81, DOI 10.1093/annonc/mdu498
   Van Grembergen O, 2016, SCI ADV, V2, DOI 10.1126/sciadv.1600220
   Van Laere SJ, 2006, CLIN CANCER RES, V12, P3249, DOI 10.1158/1078-0432.CCR-05-2800
   Vlahopoulos SA, 2015, CYTOKINE GROWTH F R, V26, P389, DOI 10.1016/j.cytogfr.2015.06.001
   Xu YF, 2011, MOL CELL, V42, P451, DOI 10.1016/j.molcel.2011.04.005
   Yamaguchi N, 2009, CANCER SCI, V100, P1668, DOI 10.1111/j.1349-7006.2009.01228.x
   Yang C, 2016, GENE, V591, P201, DOI 10.1016/j.gene.2016.07.025
   Yang L, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133896
   Yang RL, 2015, IMMUNITY, V43, P251, DOI 10.1016/j.immuni.2015.07.017
   Yuan XX, 2016, SCI REP-UK, V6, DOI 10.1038/srep20005
   Zhang JY, 2005, J CELL BIOL, V168, P561, DOI 10.1083/jcb.200411060
   Zhang Q, 2015, NATURE, V525, P389, DOI 10.1038/nature15252
NR 81
TC 64
Z9 71
U1 0
U2 16
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 2375-2548
J9 SCI ADV
JI Sci. Adv.
PD JUN
PY 2018
VL 4
IS 6
AR eaap7309
DI 10.1126/sciadv.aap7309
PG 14
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA GS0IJ
UT WOS:000443175500012
PM 29938218
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Suárez-Cabrera, C
   de la Peña, B
   González, LL
   Page, A
   Martínez-Fernández, M
   Casanova, ML
   Paramio, JM
   Rojo-Sebastián, A
   Moreno-Bueno, G
   Maroto, A
   Ramírez, A
   Navarro, M
AF Suarez-Cabrera, Cristian
   de la Pena, Barbara
   Gonzalez, Laura L.
   Page, Angustias
   Martinez-Fernandez, Monica
   Llanos Casanova, M.
   Paramio, Jesus M.
   Rojo-Sebastian, Alejandro
   Moreno-Bueno, Gema
   Maroto, Alicia
   Ramirez, Angel
   Navarro, Manuel
TI The Ras-related gene <i>ERAS</i> is involved in human and murine breast
   cancer
SO SCIENTIFIC REPORTS
LA English
DT Article
ID MUTAGENESIS IDENTIFIES GENES; TO-MESENCHYMAL TRANSITION; IN-VITRO
   PROPAGATION; EPIGENETIC REGULATION; ENRICHMENT ANALYSIS;
   SLEEPING-BEAUTY; CLAUDIN-LOW; STEM-CELLS; EXPRESSION; TUMOR
AB Although Ras genes are frequently mutated in human tumors, these mutations are uncommon in breast cancer. However, many breast tumors show evidences of Ras pathway activation. In this manuscript, we have analyzed and characterized mouse mammary tumors generated by random Sleeping Beauty transposon mutagenesis and identify ERAS -a member of the RAS family silenced in adult tissues-as a new gene involved in progression and malignancy of breast cancer. Forced expression of ERAS in human non-transformed mammary gland cells induces a process of epithelial-to-mesenchymal transition and an increase in stem cells markers; these changes are mediated by miR-200c downregulation. ERAS expression in human tumorigenic mammary cells leads to the generation of larger and less differentiated tumors in xenotransplant experiments. Immunohistochemical, RT-qPCR and bioinformatics analysis of human samples show that ERAS is aberrantly expressed in 8-10% of breast tumors and this expression is associated with distant metastasis and reduced metastasis-free survival. In summary, our results reveal that inappropriate activation of ERAS may be important in the development of a subset of breast tumors. These findings open the possibility of new specific treatments for this subset of ERAS-expressing tumors.
C1 [Suarez-Cabrera, Cristian; de la Pena, Barbara; Gonzalez, Laura L.; Page, Angustias; Martinez-Fernandez, Monica; Llanos Casanova, M.; Paramio, Jesus M.; Ramirez, Angel; Navarro, Manuel] Ctr Invest Energet Medioambient & Tecnol CIEMAT, Mol Oncol Unit, Madrid 28040, Spain.
   [Suarez-Cabrera, Cristian; Page, Angustias; Martinez-Fernandez, Monica; Llanos Casanova, M.; Paramio, Jesus M.; Ramirez, Angel; Navarro, Manuel] Inst Invest Hosp 12 Octubre Imas12, Madrid, Spain.
   [Page, Angustias; Llanos Casanova, M.; Paramio, Jesus M.; Rojo-Sebastian, Alejandro; Moreno-Bueno, Gema; Ramirez, Angel; Navarro, Manuel] Ctr Invest Biomed Red Canc CIBERONC, Madrid 28029, Spain.
   [de la Pena, Barbara] Queensland Univ Technol, Inst Hlth & Biomed Innovat, Brisbane, Qld, Australia.
   [Gonzalez, Laura L.] Nottingham Trent Univ, Interdisciplinary Biomed Res Ctr, Nottingham, England.
   [Martinez-Fernandez, Monica] Univ Santiago de Compostela, CIMUS Mol Med & Chron Dis Res Ctr, Mobile Genomes & Dis Lab, Avda Barcelona S-N, Santiago De Compostela 15706, Spain.
   [Rojo-Sebastian, Alejandro; Moreno-Bueno, Gema] Fdn MD Anderson Int, Madrid 28033, Spain.
   [Rojo-Sebastian, Alejandro; Moreno-Bueno, Gema] MD Anderson Canc Ctr, Madrid 28033, Spain.
   [Moreno-Bueno, Gema] Univ Autonoma Madrid, Dept Bioquim, Inst Invest Biomed Alberto Sols, CSIC UAM,IdiPaz, Madrid 28029, Spain.
   [Maroto, Alicia] 12 Octubre Univ Hosp, Dept Pathol, Madrid, Spain.
C3 Centro de Investigaciones Energeticas, Medioambientales Tecnologicas;
   CIBER - Centro de Investigacion Biomedica en Red; CIBERONC; Queensland
   University of Technology (QUT); Nottingham Trent University;
   Universidade de Santiago de Compostela; University of Texas System; UTMD
   Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer
   Center; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC -
   Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Autonomous
   University of Madrid; Hospital Universitario 12 de Octubre
RP Ramírez, A; Navarro, M (通讯作者)，Ctr Invest Energet Medioambient & Tecnol CIEMAT, Mol Oncol Unit, Madrid 28040, Spain.; Ramírez, A; Navarro, M (通讯作者)，Inst Invest Hosp 12 Octubre Imas12, Madrid, Spain.; Ramírez, A; Navarro, M (通讯作者)，Ctr Invest Biomed Red Canc CIBERONC, Madrid 28029, Spain.
EM manuel.navarro@ciemat.es
RI Casanova, M Llanos/S-8241-2018; Rojo, Alejandro/Y-9674-2019; Page,
   Angustias/KEJ-0776-2024; Maroto, Alicia/AAA-7282-2019; Paramio, Jesus
   M/M-8482-2014; Ramirez, Angel/A-4800-2018; Moreno-Bueno,
   Gema/K-9354-2016; Suarez, Cristian/S-4235-2018
OI Paramio, Jesus M/0000-0001-7520-3177; Ramirez,
   Angel/0000-0001-7745-5108; Page, Angustias/0000-0002-0231-8536;
   Moreno-Bueno, Gema/0000-0002-5030-6687; de la Pena Avalos,
   Barbara/0000-0001-9796-8015; Suarez, Cristian/0000-0003-1897-1596;
   Rojo-Sebastian, Alejandro/0000-0001-6439-3518; Navarro,
   Manuel/0000-0003-1118-8531; Casanova, M. Llanos/0000-0001-7742-8265
FU ISCIII National Biobank Record [B.0000657]; MD Anderson Foundation
   Biobank (ISCIII National Biobank Record) [B.0000745]; Fondo Europeo de
   Desarrollo Regional (FEDER); Spanish Government from Instituto de Salud
   Carlos III (Ministerio de Economia y Competitividad) [PI16/00161,
   PI16/00134, PIE15/00076, PI17/00578, CB/16/00228, CB16/12/00295,
   RD12/0036/0009]; Ministerio de Economia y Competitividad
   [SAF-2015-66015-R]; Instituto de Salud Carlos III
FX We would like to thank Berta Hernanz and Rebeca Sanz for her excellent
   technical help, Federico Sanchez-Sierra and Pilar Hernandez Lorenzo for
   their assistance with the histological processing of the samples and
   Jesus Martinez, Edilia de Almeida and the personnel of the CIEMAT Animal
   Unit for their care of the mice used in this work. Thanks to Dr. Sergio
   Ruiz (CNIO) for providing miR-200c and miR-141 lentiviral vectors. We
   want to particularly acknowledge the patients enrolled in this study for
   their participation and the Biobanco i + 12 (B.0000657, ISCIII National
   Biobank Record). Tissue microarray samples were obtained with the
   support of MD Anderson Foundation Biobank (B.0000745, ISCIII National
   Biobank Record). The results are in part based upon data generated by
   the TCGA Research Network: http://cancergenome.nih.gov/. This research
   was supported partially by funds from Fondo Europeo de Desarrollo
   Regional (FEDER) and by grants from the Spanish Government PI16/00161,
   PI16/00134, PIE15/00076, PI17/00578, CB/16/00228, CB16/12/00295 and
   RD12/0036/0009 from Instituto de Salud Carlos III (Ministerio de
   Economia y Competitividad) and SAF-2015-66015-R from the Ministerio de
   Economia y Competitividad. Biobanco 1 + 12 is supported by Instituto de
   Salud Carlos III.
CR Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100
   Al-Hajj M, 2007, CURR OPIN ONCOL, V19, P61
   Andersen CL, 2004, CANCER RES, V64, P5245, DOI 10.1158/0008-5472.CAN-04-0496
   Nieto MA, 2016, CELL, V166, P21, DOI 10.1016/j.cell.2016.06.028
   Castilla MA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047709
   Aoyama M, 2010, INT J ONCOL, V37, P1011, DOI 10.3892/ijo_00000752
   Bermejo-Rodríguez C, 2015, CURR OPIN BIOTECH, V35, P103, DOI 10.1016/j.copbio.2015.05.005
   Borcherding N, 2014, PROTEIN CELL, V5, P496, DOI 10.1007/s13238-014-0059-7
   Chaligné R, 2015, GENOME RES, V25, P488, DOI 10.1101/gr.185926.114
   Chen J, 2009, NUCLEIC ACIDS RES, V37, pW305, DOI 10.1093/nar/gkp427
   Chien HP, 2016, VIRCHOWS ARCH, V468, P589, DOI 10.1007/s00428-016-1911-3
   Ciriello G, 2015, CELL, V163, P506, DOI 10.1016/j.cell.2015.09.033
   Collier LS, 2009, CANCER RES, V69, P8429, DOI 10.1158/0008-5472.CAN-09-1760
   Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X
   Debnath J, 2002, CELL, V111, P29, DOI 10.1016/S0092-8674(02)01001-2
   Dontu G, 2003, GENE DEV, V17, P1253, DOI 10.1101/gad.1061803
   Dupuy AJ, 2005, NATURE, V436, P221, DOI 10.1038/nature03691
   Ehrhardt A, 2002, EXP HEMATOL, V30, P1089, DOI 10.1016/S0301-472X(02)00904-9
   Feng ZM, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1655-5
   Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210
   Forbes SA, 2015, NUCLEIC ACIDS RES, V43, pD805, DOI 10.1093/nar/gku1075
   Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088
   Giltnane JM, 2014, DISCOV MED, V17, P275
   Hennessy BT, 2009, CANCER RES, V69, P4116, DOI 10.1158/0008-5472.CAN-08-3441
   Jonkers J, 2001, NAT GENET, V29, P418, DOI 10.1038/ng747
   Kaizaki R, 2009, ANTICANCER RES, V29, P2189
   Kawaguchi T, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-16112-y
   Kloosterman WP, 2017, CANCER RES, V77, P3814, DOI 10.1158/0008-5472.CAN-16-3563
   Knezevic J, 2015, ONCOGENE, V34, P5997, DOI 10.1038/onc.2015.48
   Kubota E, 2011, ANTICANCER RES, V31, P3353
   Kubota E, 2010, AM J PATHOL, V177, P955, DOI 10.2353/ajpath.2010.091056
   Liu SL, 2014, STEM CELL REP, V2, P78, DOI 10.1016/j.stemcr.2013.11.009
   Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027
   McLaughlin SK, 2013, CANCER CELL, V24, P365, DOI 10.1016/j.ccr.2013.08.004
   Moreno-Bueno G, 2011, EMBO MOL MED, V3, P528, DOI 10.1002/emmm.201100156
   Moriarity BS, 2015, NAT GENET, V47, P615, DOI 10.1038/ng.3293
   Moriya T, 2006, MED MOL MORPHOL, V39, P8, DOI 10.1007/s00795-006-0309-8
   Nakhaei-Rad S, 2016, J BIOL CHEM, V291, P8399, DOI 10.1074/jbc.M115.700088
   Nik-Zainal S, 2016, NATURE, V534, P47, DOI 10.1038/nature17676
   NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D
   Olsen SN, 2017, CANCER DISCOV, V7, P202, DOI 10.1158/2159-8290.CD-16-0520
   Perdigao-Henriques R, 2016, ONCOGENE, V35, P158, DOI 10.1038/onc.2015.69
   Perna D, 2015, P NATL ACAD SCI USA, V112, pE536, DOI 10.1073/pnas.1418163112
   Perou CM, 2010, ONCOLOGIST, V15, P39, DOI 10.1634/theoncologist.2010-S5-39
   Ponti D, 2005, CANCER RES, V65, P5506, DOI 10.1158/0008-5472.CAN-05-0626
   Prat A, 2011, MOL ONCOL, V5, P5, DOI 10.1016/j.molonc.2010.11.003
   Quintana RM, 2013, J INVEST DERMATOL, V133, P239, DOI 10.1038/jid.2012.245
   Rahrmann EP, 2013, NAT GENET, V45, P756, DOI 10.1038/ng.2641
   Rai H., 2014, INTERNET J ONCOL, V10, P1
   Ramirez A, 2004, GENESIS, V39, P52, DOI 10.1002/gene.20025
   Rangel R, 2016, P NATL ACAD SCI USA, V113, pE7749, DOI 10.1073/pnas.1613859113
   Richardson AL, 2006, CANCER CELL, V9, P121, DOI 10.1016/j.ccr.2006.01.013
   Ruiz S, 2012, J BIOL CHEM, V287, P40767, DOI 10.1074/jbc.M112.384024
   Sarrio D, 2012, STEM CELLS, V30, P292, DOI 10.1002/stem.791
   SOULE HD, 1990, CANCER RES, V50, P6075
   Stingl J, 2007, NAT REV CANCER, V7, P791, DOI 10.1038/nrc2212
   Suárez-Cabrera C, 2017, CANCER RES, V77, P1357, DOI 10.1158/0008-5472.CAN-16-1586
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Takahashi K, 2005, J BIOL CHEM, V280, P32768, DOI 10.1074/jbc.M506280200
   Takahashi K, 2003, NATURE, V423, P541, DOI 10.1038/nature01646
   Taube JH, 2010, P NATL ACAD SCI USA, V107, P15449, DOI 10.1073/pnas.1004900107
   Theodorou V, 2007, NAT GENET, V39, P759, DOI 10.1038/ng2034
   Tian XR, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/567305
   Uren AG, 2008, CELL, V133, P727, DOI 10.1016/j.cell.2008.03.021
   Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034
   Wu HL, 2009, CELL RES, V19, P439, DOI 10.1038/cr.2009.18
   Yashiro M, 2009, INT J ONCOL, V35, P997, DOI 10.3892/ijo_00000414
   Yasuda K, 2007, ANTICANCER RES, V27, P4071
   Zhang JL, 2017, J CANCER, V8, P1849, DOI 10.7150/jca.19858
   Zhang YJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088064
   Zhao ZA, 2015, OPEN BIOL, V5, DOI 10.1098/rsob.150092
NR 71
TC 13
Z9 15
U1 0
U2 18
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD AUG 29
PY 2018
VL 8
AR 13038
DI 10.1038/s41598-018-31326-4
PG 17
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA GR8TP
UT WOS:000443003800045
PM 30158566
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU da Cruz, RS
   Carney, EJ
   Clarke, J
   Cao, H
   Cruz, MI
   Benitez, C
   Jin, L
   Fu, Y
   Cheng, ZL
   Wang, Y
   de Assis, S
AF da Cruz, Raquel Santana
   Carney, Elissa J.
   Clarke, Johan
   Cao, Hong
   Cruz, M. Idalia
   Benitez, Carlos
   Jin, Lu
   Fu, Yi
   Cheng, Zuolin
   Wang, Yue
   de Assis, Sonia
TI Paternal malnutrition programs breast cancer risk and tumor metabolism
   in offspring
SO BREAST CANCER RESEARCH
LA English
DT Article
DE Ancestral nutrition; Paternal programming; Breast cancer; AMPK pathway
ID BIRTH-WEIGHT; GENE-EXPRESSION; DNA METHYLATION; SPERM RNAS; AGE;
   INHERITANCE; FATHERS; OBESITY; STRESS; GROWTH
AB Background: While many studies have shown that maternal factors in pregnancy affect the cancer risk for offspring, few studies have investigated the impact of paternal exposures on their progeny's risk of this disease. Population studies generally show a U-shaped association between birthweight and breast cancer risk, with both high and low birthweight increasing the risk compared with average birthweight. Here, we investigated whether paternal malnutrition would modulate the birthweight and later breast cancer risk of daughters.
   Methods: Male mice were fed AIN93G-based diets containing either 17.7% (control) or 8.9% (low-protein (LP)) energy from protein from 3 to 10 weeks of age. Males on either group were mated to females raised on a control diet Female offspring from control and LP fathers were treated with 7,12-dimethylbenz[a]anthracene (DMBA) to initiate mammary carcinogenesis. Mature sperm from fathers and mammary tissue and tumors from female offspring were used for epigenetic and other molecular analyses.
   Results: We found that paternal malnutrition reduces the birthweight of daughters and leads to epigenetic and metabolic reprogramming of their mammary tissue and tumors. Daughters of LP fathers have higher rates of mammary cancer, with tumors arising earlier and growing faster than in controls. The energy sensor, the AMP-activated protein kinase (AMPK) pathway, is suppressed in both mammary glands and tumors of LP daughters, with consequent activation of mammalian target of rapamycin (mTOR) signaling. Furthermore, LP mammary tumors show altered amino-acid metabolism with increased glutamine utilization. These changes are linked to alterations in noncoding RNAs regulating those pathways in mammary glands and tumors. Importantly, we detect alterations in some of the same microRNAs/ target genes found in our animal model in breast tumors of women from populations where low birthweight is prevalent.
   Conclusions: Our study suggests that ancestral paternal malnutrition plays a role in programming offspring cancer risk and phenotype by likely providing a metabolic advantage to cancer cells.
C1 [da Cruz, Raquel Santana; Carney, Elissa J.; Clarke, Johan; Cao, Hong; Cruz, M. Idalia; Benitez, Carlos; Jin, Lu; de Assis, Sonia] Georgetown Univ, Dept Oncol, Lombardi Comprehens Canc Ctr, 3970 Reservoir Rd NW,Res Bldg,Room E410, Washington, DC 20057 USA.
   [Fu, Yi; Cheng, Zuolin; Wang, Yue] Virginia Polytech Inst & State Univ, Res Ctr, Bradley Dept Elect & Comp Engn, Arlington, VA USA.
C3 Georgetown University; Virginia Polytechnic Institute & State University
RP de Assis, S (通讯作者)，Georgetown Univ, Dept Oncol, Lombardi Comprehens Canc Ctr, 3970 Reservoir Rd NW,Res Bldg,Room E410, Washington, DC 20057 USA.
EM deassiss@georgetown.edu
RI Cao, Hong/JDD-0125-2023; Santana, Raquel/ABF-2796-2020; Assis,
   Sonia/N-8274-2013
OI Santana Da Cruz, Raquel/0000-0002-9369-2733; de Assis,
   Sonia/0000-0001-5053-0614
FU Prevent Cancer Foundation [299045]; American Cancer Society; National
   Institutes of Health [1P30-CA51008]; National Center for Advancing
   Translational Sciences of the National Institutes of Health
   [TL1TR001431]
FX This study was supported in part by the Prevent Cancer Foundation
   (Research grant #299045 to SdA), The American Cancer Society (Research
   Scholar Grant to SdA), the National Institutes of Health (1P30-CA51008;
   Lombardi Comprehensive Cancer Center Support Grant to L. Weiner). EJC
   was supported in part by the National Center for Advancing Translational
   Sciences of the National Institutes of Health under Award TL1TR001431.
CR Altman BJ, 2016, NAT REV CANCER, V16, P619, DOI 10.1038/nrc.2016.71
   Apostoli AJ, 2014, INT J CANCER, V134, P1055, DOI 10.1002/ijc.28432
   Brenet F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014524
   Cao MD, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-941
   Carone BR, 2010, CELL, V143, P1084, DOI 10.1016/j.cell.2010.12.008
   CETIN I, 1988, AM J OBSTET GYNECOL, V158, P120, DOI 10.1016/0002-9378(88)90792-2
   Chen Q, 2016, NAT REV GENET, V17, P733, DOI 10.1038/nrg.2016.106
   Chen Q, 2016, SCIENCE, V351, P397, DOI 10.1126/science.aad7977
   Choi JY, 2005, BMC CANCER, V5, DOI 10.1186/1471-2407-5-143
   Clarke R, 2008, NAT REV CANCER, V8, P37, DOI 10.1038/nrc2294
   CURTHOYS NP, 1995, ANNU REV NUTR, V15, P133, DOI 10.1146/annurev.nu.15.070195.001025
   de Assis S, 2010, JOVE-J VIS EXP, V44, P2260, DOI [10.3791/2260, DOI 10.3791/2260]
   de Assis S, 2006, INT J CANCER, V119, P1537, DOI 10.1002/ijc.21936
   de Assis S, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2058
   Donkin I, 2016, CELL METAB, V23, P369, DOI 10.1016/j.cmet.2015.11.004
   Efeyan A, 2015, NATURE, V517, P302, DOI 10.1038/nature14190
   Fernandez-Twinn DS, 2010, CARCINOGENESIS, V31, P1873, DOI 10.1093/carcin/bgq095
   Fontelles CC, 2016, BREAST CANCER RES, V18, DOI 10.1186/s13058-016-0729-x
   Fontelles CC, 2016, SCI REP-UK, V6, DOI 10.1038/srep28602
   Gapp K, 2014, NAT NEUROSCI, V17, P667, DOI 10.1038/nn.3695
   Godlewski J, 2010, MOL CELL, V37, P620, DOI 10.1016/j.molcel.2010.02.018
   Griffiths LJ, 2007, INT J EPIDEMIOL, V36, P104, DOI 10.1093/ije/dyl210
   Guido LN, 2016, INT J CANCER, V139, P1873, DOI 10.1002/ijc.30223
   Izreig S, 2016, CELL REP, V16, P1915, DOI 10.1016/j.celrep.2016.07.036
   Ji BT, 1997, J NATL CANCER I, V89, P238, DOI 10.1093/jnci/89.3.238
   Jirtle RL, 2007, NAT REV GENET, V8, P253, DOI 10.1038/nrg2045
   Jones PA, 2012, NAT REV GENET, V13, P484, DOI 10.1038/nrg3230
   Kaati G, 2007, EUR J HUM GENET, V15, P784, DOI 10.1038/sj.ejhg.5201832
   Kohler BA, 2015, JNCI-J NATL CANCER I, V107, DOI 10.1093/jnci/djv048
   Lumpkins CY, 2017, HEALTHCARE-BASEL, V5, DOI 10.3390/healthcare5010006
   Master JS, 2015, J NUTR, V145, P876, DOI 10.3945/jn.114.205724
   Mellemkjær L, 2003, CANCER CAUSE CONTROL, V14, P61, DOI 10.1023/A:1022570305704
   Michels KB, 1996, LANCET, V348, P1542, DOI 10.1016/S0140-6736(96)03102-9
   Mulrane L, 2013, CANCER RES, V73, P6554, DOI 10.1158/0008-5472.CAN-13-1841
   Ng SF, 2010, NATURE, V467, P963, DOI 10.1038/nature09491
   Painter RC, 2006, AM J HUM BIOL, V18, P853, DOI 10.1002/ajhb.20564
   Pavlova NN, 2016, CELL METAB, V23, P27, DOI 10.1016/j.cmet.2015.12.006
   Pembrey ME, 2006, EUR J HUM GENET, V14, P159, DOI 10.1038/sj.ejhg.5201538
   Piao HL, 2012, J MAMMARY GLAND BIOL, V17, P33, DOI 10.1007/s10911-012-9245-5
   Rando OJ, 2015, CELL, V161, P93, DOI 10.1016/j.cell.2015.02.021
   Rhee JK, 2013, NUCLEIC ACIDS RES, V41, P8464, DOI 10.1093/nar/gkt643
   Ribel-Madsen A, 2016, PHYSL REP, V4
   Rodgers AB, 2015, P NATL ACAD SCI USA, V112, P13699, DOI 10.1073/pnas.1508347112
   Sanderson M, 1996, EPIDEMIOLOGY, V7, P34, DOI 10.1097/00001648-199601000-00007
   Sharma U, 2016, SCIENCE, V351, P391, DOI 10.1126/science.aad6780
   Sugita B, 2016, ONCOTARGET, V7, P79260, DOI 10.18632/oncotarget.13024
   Taylor PM, 2014, AM J CLIN NUTR, V99, p223S, DOI 10.3945/ajcn.113.070086
   Teras LR, 2015, AM J EPIDEMIOL, V182, P41, DOI 10.1093/aje/kwu487
   Wang Y, 2007, EPIDEMIOL REV, V29, P6, DOI 10.1093/epirev/mxm007
   Watkins AJ, 2017, BBA-MOL BASIS DIS, V1863, P1371, DOI 10.1016/j.bbadis.2017.02.009
   Weiss-Salz I, 2007, EUR J CANCER PREV, V16, P549, DOI 10.1097/CEJ.0b013e328032783f
   Wu L, 2016, CELL METAB, V23, P735, DOI 10.1016/j.cmet.2016.01.014
   Yu ZR, 2012, J MAMMARY GLAND BIOL, V17, P59, DOI 10.1007/s10911-012-9246-4
   Yuan XG, 2012, BMC GENOMICS, V13, DOI 10.1186/1471-2164-13-342
   Zhang B, 2014, BIOINFORMATICS, V30, P431, DOI 10.1093/bioinformatics/btt693
NR 55
TC 35
Z9 35
U1 0
U2 9
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1465-542X
EI 1465-5411
J9 BREAST CANCER RES
JI Breast Cancer Res.
PD AUG 30
PY 2018
VL 20
AR 99
DI 10.1186/s13058-018-1034-7
PG 14
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA GS0RQ
UT WOS:000443213600002
PM 30165877
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Dutta, B
   Park, JE
   Qing, ITY
   Kon, OL
   Sze, SK
AF Dutta, Bamaprasad
   Park, Jung Eun
   Qing, Ivan Toh Yi
   Kon, Oi Lion
   Sze, Siu Kivan
TI Soy-Derived Phytochemical Genistein Modifies Chromatome Topology to
   Restrict Cancer Cell Proliferation
SO PROTEOMICS
LA English
DT Article
DE cell proliferation; chromatome; epigenetic reprogram; euchromatin;
   genistein; heterochromatin; quantitative proteomics
ID TUMOR-SUPPRESSOR GENES; BREAST-CANCER; DNA METHYLATION; PHYTO-ESTROGENS;
   PROSTATE-CANCER; TYROSINE PHOSPHORYLATION; CYCLE PROGRESSION; COMPLEX;
   PHYTOESTROGENS; EXPOSURE
AB Epidemiological data indicate that human cancer risk is significantly reduced by the consumption of soy-based foods containing the "phytoestrogen" genistein, which can signal via host cell estrogen receptors. While additional chemoprotective effects of genistein induced by epigenetic factors have also been reported, the key molecules and mechanisms invoked are poorly defined. We therefore investigated genistein effects on chromatin-bound proteins in the estrogen receptor-deficient cell line M DA-M B-231 which is insensitive to phytoestrogen signaling. After exposure to low-dose genistein for >1 month, M DA-M B-231 cells exhibited stable epigenetic alterations that are analyzed via partial MNase digestion and TMT-based quantitative proteomics. 3177 chromatin-bound proteins are identified with high confidence, including 882 molecules that displayed altered binding topology after cell conditioning with genistein. Prolonged phytochemical exposure conferred heritable changes in the binding topology of key epigenetic regulators including ATRX, SUV3 9H1/H2, and HP1 BP3 that are preserved in untreated progeny, resulting in sustained downregulation of proliferation genes and reduced cell growth. These data indicate that soy derivative genistein exerts complex estrogen receptor-independent effects on the epigenome likely to influence tumorigenesis by restricting cell growth.
C1 [Dutta, Bamaprasad; Park, Jung Eun; Qing, Ivan Toh Yi; Sze, Siu Kivan] Nanyang Technol Univ, Sch Biol Sci, 60 Nanyang Dr, Singapore 637551, Singapore.
   [Kon, Oi Lion] Natl Canc Ctr Singapore, Div Med Sci, 11 Hosp Dr, Singapore 169610, Singapore.
C3 Nanyang Technological University; National Cancer Centre Singapore
   (NCCS)
RP Sze, SK (通讯作者)，Nanyang Technol Univ, Sch Biol Sci, 60 Nanyang Dr, Singapore 637551, Singapore.
EM sksze@ntu.edu.sg
RI Dutta, Bamaprasad/AAH-4006-2020; Sze, Siu Kwan/AAO-3342-2020
OI DUTTA, BAMAPRASAD/0000-0002-2309-8771; Sze, Siu Kwan/0000-0002-5652-1687
FU NTU iFood [S006]; Singapore Ministry of Education (Tier 2) [ARC9/15];
   National Medical Research Council of Singapore [NMRC-OF-IRG-0003-2016];
   NTU-NHG Ageing Research Grant [ARG/14017]
FX This work was supported by grants from the NTU iFood (grant #: S006),
   the Singapore Ministry of Education (Tier 2: Grant ARC9/15), National
   Medical Research Council of Singapore (NMRC-OF-IRG-0003-2016), and
   NTU-NHG Ageing Research Grant (Grant ARG/14017). The mass spectrometry
   proteomics raw data files along with Proteome Discoverer search data
   file (including protein summary) have been deposited to the
   ProteomeXchange Consortium (http://proteomecentral.proteomexchange.org)
   via the PRIDE partner repository[36] with the dataset identifier
   PXD006178. The proteins and peptides information from Proteome
   Discoverer search are available in Tables S3-S5, Supporting Information
   (Excel files).
CR Bantscheff M, 2011, NAT BIOTECHNOL, V29, P255, DOI 10.1038/nbt.1759
   Benetti R, 2007, J CELL BIOL, V178, P925, DOI 10.1083/jcb.200703081
   BERGAMASCHI G, 1993, LEUKEMIA, V7, P2012
   BOYER B, 1993, J CELL BIOL, V120, P767, DOI 10.1083/jcb.120.3.767
   Cai Y, 2014, ONCOGENE, V33, P2157, DOI 10.1038/onc.2013.178
   Dixon RA, 2002, PHYTOCHEMISTRY, V60, P205, DOI 10.1016/S0031-9422(02)00116-4
   Dolinoy DC, 2006, ENVIRON HEALTH PERSP, V114, P567, DOI 10.1289/ehp.8700
   Duffy C, 2007, CA-CANCER J CLIN, V57, P260, DOI 10.3322/CA.57.5.260
   Dutta B, 2014, MOL CELL PROTEOMICS, V13, P3236, DOI 10.1074/mcp.M114.038232
   Dutta B, 2014, MOL CELL PROTEOMICS, V13, P2183, DOI 10.1074/mcp.M113.034975
   Dutta B, 2012, J PROTEOMICS, V75, P5493, DOI 10.1016/j.jprot.2012.06.030
   Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245
   Ellis L, 2009, MOL CANCER THER, V8, P1409, DOI 10.1158/1535-7163.MCT-08-0860
   Elsässer SJ, 2015, NATURE, V522, P240, DOI 10.1038/nature14345
   Fang MZ, 2007, J NUTR, V137, p223S, DOI 10.1093/jn/137.1.223S
   Gamble MJ, 2010, CELL CYCLE, V9, P2568, DOI 10.4161/cc.9.13.12144
   Goldberg AD, 2010, CELL, V140, P678, DOI 10.1016/j.cell.2010.01.003
   Gravitz L, 2011, NATURE, V471, pS5, DOI 10.1038/471S5a
   Greathouse KL, 2012, MOL CANCER RES, V10, P546, DOI 10.1158/1541-7786.MCR-11-0605
   Han P, 2016, BBA-MOL CELL RES, V1863, P1772, DOI 10.1016/j.bbamcr.2016.03.002
   Hirose K, 2005, BRIT J CANCER, V93, P15, DOI 10.1038/sj.bjc.6602659
   Honda S, 2016, P NATL ACAD SCI USA, V113, pE6135, DOI 10.1073/pnas.1614279113
   Hsieh CY, 1998, CANCER RES, V58, P3833
   HUANG XY, 1993, CELL, V75, P1145, DOI 10.1016/0092-8674(93)90324-J
   Ingram D, 1997, LANCET, V350, P990, DOI 10.1016/S0140-6736(97)01339-1
   Kikuno N, 2008, INT J CANCER, V123, P552, DOI 10.1002/ijc.23590
   Knight DC, 1996, OBSTET GYNECOL, V87, P897
   Kurahashi N, 2008, J CLIN ONCOL, V26, P5923, DOI 10.1200/JCO.2008.16.8807
   Li YY, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-9
   Li YY, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0055108, 10.1371/journal.pone.0052093, 10.1371/journal.pone.0063648, 10.1371/journal.pone.0077685, 10.1371/journal.pone.0062036, 10.1371/journal.pone.0054369, 10.1371/journal.pone.0066567, 10.1371/journal.pone.0071994]
   Limer JL, 2004, BREAST CANCER RES, V6, P119, DOI 10.1186/bcr781
   MARKOVITS J, 1989, CANCER RES, V49, P5111
   MUELLER SC, 1992, J CELL BIOL, V119, P1309, DOI 10.1083/jcb.119.5.1309
   Murkies AL, 1998, J CLIN ENDOCR METAB, V83, P297, DOI 10.1210/jc.83.2.297
   Nijwening JH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025235
   Peters AHFM, 2001, CELL, V107, P323, DOI 10.1016/S0092-8674(01)00542-6
   Pudenz M, 2014, NUTRIENTS, V6, P4218, DOI 10.3390/nu6104218
   Ratnu VS, 2017, J NEUROSCI RES, V95, P301, DOI 10.1002/jnr.23886
   Setchell KDR, 1997, LANCET, V350, P23, DOI 10.1016/S0140-6736(96)09480-9
   Silberman DM, 2016, PHARMACOL RES, V109, P64, DOI 10.1016/j.phrs.2015.12.033
   Singh U, 2016, TUMOR BIOL, V37, P14427, DOI 10.1007/s13277-016-5308-3
   Su SJ, 2005, BIOCHEM PHARMACOL, V69, P307, DOI 10.1016/j.bcp.2004.09.025
   Tham DM, 1998, J CLIN ENDOCR METAB, V83, P2223, DOI 10.1210/jc.83.7.2223
   Tolstorukov MY, 2013, P NATL ACAD SCI USA, V110, P10165, DOI 10.1073/pnas.1302209110
   TRAGANOS F, 1992, CANCER RES, V52, P6200
   Tsuboy MS, 2014, J MED FOOD, V17, P218, DOI 10.1089/jmf.2013.0067
   UCKUN FM, 1995, SCIENCE, V267, P886, DOI 10.1126/science.7531365
   Vanhees K, 2011, FASEB J, V25, P797, DOI 10.1096/fj.10-172155
   Vizcaíno JA, 2014, NAT BIOTECHNOL, V32, P223, DOI 10.1038/nbt.2839
   Voon HPJ, 2015, CELL REP, V11, P405, DOI 10.1016/j.celrep.2015.03.036
   Whipple AV, 2016, FRONT GENET, V7, DOI 10.3389/fgene.2016.00189
   Xie Q, 2014, GENE CHROMOSOME CANC, V53, P422, DOI 10.1002/gcc.22154
   Xiong J, 2010, ONCOGENE, V29, P4980, DOI 10.1038/onc.2010.241
   Xu L, 2009, JNCI-J NATL CANCER I, V101, P1141, DOI 10.1093/jnci/djp227
   Zhang YF, 2013, MOL BIOL REP, V40, P1711, DOI 10.1007/s11033-012-2222-7
   Zhang YK, 2013, CARCINOGENESIS, V34, P1756, DOI 10.1093/carcin/bgt129
NR 56
TC 10
Z9 10
U1 0
U2 10
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1615-9853
EI 1615-9861
J9 PROTEOMICS
JI Proteomics
PD AUG
PY 2018
VL 18
IS 16
AR 1700474
DI 10.1002/pmic.201700474
PG 10
WC Biochemical Research Methods; Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA GR6EB
UT WOS:000442737000002
PM 29963755
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Patten, DK
   Corleone, G
   Gyorffy, B
   Perone, Y
   Slaven, N
   Barozzi, I
   Erdos, E
   Saiakhova, A
   Goddard, K
   Vingiani, A
   Shousha, S
   Pongor, LS
   Hadjiminas, DJ
   Schiavon, G
   Barry, P
   Palmieri, C
   Coombes, RC
   Scacheri, P
   Pruneri, G
   Magnani, L
AF Patten, Darren K.
   Corleone, Giacomo
   Gyorffy, Balazs
   Perone, Ylenia
   Slaven, Neil
   Barozzi, Iros
   Erdos, Edina
   Saiakhova, Alina
   Goddard, Kate
   Vingiani, Andrea
   Shousha, Sami
   Pongor, Lorinc Sandor
   Hadjiminas, Dimitri J.
   Schiavon, Gaia
   Barry, Peter
   Palmieri, Carlo
   Coombes, Raul C.
   Scacheri, Peter
   Pruneri, Giancarlo
   Magnani, Luca
TI Enhancer mapping uncovers phenotypic heterogeneity and evolution in
   patients with luminal breast cancer
SO NATURE MEDICINE
LA English
DT Article
ID ESTROGEN-RECEPTOR BINDING; GENE-EXPRESSION; HUMAN GENOME; TRANSCRIPTION
   FACTORS; MOLECULAR PORTRAITS; SUPER-ENHANCERS; PIONEER FACTORS;
   CHROMATIN; CELL; REVEALS
AB The degree of intrinsic and interpatient phenotypic heterogeneity and its role in tumor evolution is poorly understood. Phenotypic drifts can be transmitted via inheritable transcriptional programs. Cell-type specific transcription is maintained through the activation of epigenetically defined regulatory regions including promoters and enhancers. Here we have annotated the epigenome of 47 primary and metastatic estrogen-receptor (ER alpha)-positive breast cancer clinical specimens and inferred phenotypic heterogeneity from the regulatory landscape, identifying key regulatory elements commonly shared across patients. Shared regions contain a unique set of regulatory information including the motif for transcription factor YY1. We identify YY1 as a critical determinant of ER alpha transcriptional activity promoting tumor growth in most luminal patients. YY1 also contributes to the expression of genes mediating resistance to endocrine treatment. Finally, we used H3K27ac levels at active enhancer elements as a surrogate of intra-tumor phenotypic heterogeneity to track the expansion and contraction of phenotypic subpopulations throughout breast cancer progression. By tracking the clonality of SLC9A3R1-positive cells, a bona fide YY1-ER alpha-regulated gene, we show that endocrine therapies select for phenotypic clones under-represented at diagnosis. Collectively, our data show that epigenetic mechanisms significantly contribute to phenotypic heterogeneity and evolution in systemically treated breast cancer patients.
C1 [Patten, Darren K.; Corleone, Giacomo; Perone, Ylenia; Slaven, Neil; Barozzi, Iros; Coombes, Raul C.; Magnani, Luca] Imperial Coll London, Imperial Ctr Translat & Expt Med, Dept Surg & Canc, London, England.
   [Gyorffy, Balazs; Pongor, Lorinc Sandor] Hungarian Acad Sci, Inst Enzymol, MTA TTK Lendulet Canc Biomarker Res Grp, Budapest, Hungary.
   [Gyorffy, Balazs] Semmelweis Univ, Dept Pediat 2, Budapest, Hungary.
   [Erdos, Edina] Univ Debrecen, Dept Biochem & Mol Biol, Genom Med & Bioinformat Core Facil, Debrecen, Hungary.
   [Saiakhova, Alina; Scacheri, Peter] Case Western Reserve Univ, Case Comprehens Canc Ctr, Dept Genet & Genome Sci, Cleveland, OH 44106 USA.
   [Goddard, Kate] Imperial Coll Healthcare NHS Trust, Charing Cross Hosp, Dept Breast & Gen Surg, London, England.
   [Vingiani, Andrea] European Inst Oncol, Dept Pathol, Milan, Italy.
   [Shousha, Sami; Hadjiminas, Dimitri J.] Imperial Coll London, Ctr Pathol, Dept Med, London, England.
   [Schiavon, Gaia] AstraZeneca, IMED Biotech Unit, Cambridge, England.
   [Barry, Peter] Royal Marsden NHS Fdn Trust, Dept Breast Surg, Sutton, Surrey, England.
   [Palmieri, Carlo] Univ Liverpool, Inst Translat Med, Clatterbridge Canc Ctr NHS, NHS Fdn Trust, Liverpool, Merseyside, England.
   [Palmieri, Carlo] Royal Liverpool Univ Hosp, Liverpool, Merseyside, England.
   [Pruneri, Giancarlo] Fdn IRCCS Ist Nazl Tumori, Pathol Dept, Milan, Italy.
   [Pruneri, Giancarlo] Univ Milan, Sch Med, Milan, Italy.
C3 Imperial College London; Hungarian Academy of Sciences; Hungarian
   Research Network; HUN-REN Research Centre for Natural Sciences;
   Institute of Enzymology - HAS; Semmelweis University; University of
   Debrecen; University System of Ohio; Case Western Reserve University;
   Imperial College London; IRCCS European Institute of Oncology (IEO);
   Imperial College London; AstraZeneca; Royal Marsden NHS Foundation
   Trust; University of Liverpool; Oxford University Hospitals NHS
   Foundation Trust; Royal Liverpool & Broadgreen University Hospitals NHS
   Trust; Royal Liverpool University Hospital; University of Liverpool;
   Fondazione IRCCS Istituto Nazionale Tumori Milan; University of Milan
RP Magnani, L (通讯作者)，Imperial Coll London, Imperial Ctr Translat & Expt Med, Dept Surg & Canc, London, England.
EM l.magnani@imperial.ac.uk
RI Perone, Ylenia/E-5242-2016; Vingiani, Andrea/AAB-7874-2022; Pongor,
   Lorinc/AAA-9835-2021; Barozzi, Iros/GLQ-8907-2022; Gyorffy,
   Balazs/AAA-9135-2021; Corleone, Giacomo/W-7131-2019; Vingiani,
   Andrea/K-7343-2016; magnani, luca/N-1094-2015; Pruneri,
   Giancarlo/AAC-7767-2022; Corleone, Giacomo/HLQ-5620-2023
OI Erdos, Edina/0000-0001-7223-0946; Vingiani, Andrea/0000-0002-9827-3976;
   Barozzi, Iros/0000-0003-0690-3473; Coombes, Raoul
   Charles/0000-0002-4811-1100; magnani, luca/0000-0002-7534-0785; Pruneri,
   Giancarlo/0000-0002-7963-7172; Corleone, Giacomo/0000-0002-6170-9780;
   Gyorffy, Balazs/0000-0002-5772-3766
FU Breast Cancer Now Tissue Bank [TR0121]; CRUK fellowship [C46704/A23110];
   Imperial Junior Fellowship [G53019]; Wellcome Trust PhD studentship
   [103034/Z/13/Z]; Marie Sklodowska Curie Training Grant (EpiPredict)
   [642691]; AIRC [IG 2016-18696]; Wellcome Trust [103034/Z/13/Z] Funding
   Source: Wellcome Trust; Marie Curie Actions (MSCA) [642691] Funding
   Source: Marie Curie Actions (MSCA)
FX The authors acknowledge and thanks all patients and their families for
   support and for donating research samples. The authors thank the Breast
   Cancer Now Tissue Bank (project TR0121), Imperial Tissue Bank and the
   LEGACY study for contributing tissues. The authors acknowledge
   infrastructure support from the Cancer Research UK Imperial Centre, the
   Imperial Experimental Cancer Medicine Centre and the National Institute
   for Health Research Imperial Biomedical Research Centre. L.M. was
   supported by a CRUK fellowship (C46704/A23110) and an Imperial Junior
   Fellowship (G53019). D.P. was supported by a Wellcome Trust PhD
   studentship (103034/Z/13/Z). G.C. was supported by a Marie Sklodowska
   Curie Training Grant (642691, EpiPredict). G.P. was supported by AIRC IG
   2016-18696. The authors thank J.A. Buendia, L. Watson and J. Carrol for
   constructive comments on the manuscript.
CR Ali S, 2011, ANNU REV MED, V62, P217, DOI 10.1146/annurev-med-052209-100305
   Arduino S., 1996, European Journal of Gynaecological Oncology, V17, P535
   Beagan JA, 2017, GENOME RES, V27, P1139, DOI 10.1101/gr.215160.116
   Buenostro JD, 2015, NATURE, V523, P486, DOI 10.1038/nature14590
   Cai Y, 2007, NAT STRUCT MOL BIOL, V14, P872, DOI 10.1038/nsmb1276
   Cardone RA, 2005, NAT REV CANCER, V5, P786, DOI 10.1038/nrc1713
   Carroll JS, 2005, CELL, V122, P33, DOI 10.1016/j.cell.2005.05.008
   Cohen AJ, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14400
   Coleman RT, 2017, SCIENCE, V356, DOI 10.1126/science.aai8236
   Cowper-Sal-lari R, 2012, NAT GENET, V44, P1191, DOI 10.1038/ng.2416
   Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983
   Dowsett M, 2015, LANCET, V386, P1341, DOI 10.1016/S0140-6736(15)61074-1
   Dunham I, 2012, NATURE, V489, P57, DOI 10.1038/nature11247
   Ernst J, 2011, NATURE, V473, P43, DOI 10.1038/nature09906
   Falahi F, 2013, MOL CANCER RES, V11, P1029, DOI 10.1158/1541-7786.MCR-12-0567
   Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210
   Genestie C, 1998, ANTICANCER RES, V18, P571
   Gerlinger M, 2014, NAT GENET, V46, P225, DOI 10.1038/ng.2891
   Györffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9
   Harvey JM, 1999, J CLIN ONCOL, V17, P1474, DOI 10.1200/JCO.1999.17.5.1474
   Heintzman ND, 2007, NAT GENET, V39, P311, DOI 10.1038/ng1966
   Heintzman ND, 2009, NATURE, V459, P108, DOI 10.1038/nature07829
   Hnisz D, 2015, MOL CELL, V58, P362, DOI 10.1016/j.molcel.2015.02.014
   Hurtado A, 2011, NAT GENET, V43, P27, DOI 10.1038/ng.730
   Jeon Y, 2011, CELL, V146, P119, DOI 10.1016/j.cell.2011.06.026
   Jozwik KM, 2012, NAT REV CANCER, V12, P381, DOI 10.1038/nrc3263
   Juric D, 2015, NATURE, V518, P240, DOI 10.1038/nature13948
   Klymenko T, 2006, GENE DEV, V20, P1110, DOI 10.1101/gad.377406
   Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412
   Kundaje A, 2015, NATURE, V518, P317, DOI 10.1038/nature14248
   Lan XY, 2017, NATURE, V549, P227, DOI 10.1038/nature23666
   Laprell F, 2017, SCIENCE, V356, P85, DOI 10.1126/science.aai8266
   Levsky JM, 2003, TRENDS CELL BIOL, V13, P4, DOI 10.1016/S0962-8924(02)00002-8
   Magnani L, 2017, NAT GENET, V49, P444, DOI 10.1038/ng.3773
   Magnani L, 2011, TRENDS GENET, V27, P465, DOI 10.1016/j.tig.2011.07.002
   McGranahan N, 2015, CANCER CELL, V27, P15, DOI 10.1016/j.ccell.2014.12.001
   Michailidou K, 2017, NATURE, V551, P92, DOI 10.1038/nature24284
   Neph S, 2012, NATURE, V489, P83, DOI 10.1038/nature11212
   Nguyen VTM, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms10044
   Onder TT, 2012, NATURE, V483, P598, DOI 10.1038/nature10953
   Paakinaho V, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15896
   Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093
   Ross-Innes CS, 2012, NATURE, V481, P389, DOI 10.1038/nature10730
   Schmidt D, 2009, METHODS, V48, P240, DOI 10.1016/j.ymeth.2009.03.001
   Shah SP, 2009, NATURE, V461, P809, DOI 10.1038/nature08489
   Sigova AA, 2015, SCIENCE, V350, P978, DOI 10.1126/science.aad3346
   Tang ZH, 2015, CELL, V163, P1611, DOI 10.1016/j.cell.2015.11.024
   Thurman RE, 2012, NATURE, V489, P75, DOI 10.1038/nature11232
   Tirosh I, 2016, NATURE, V539, P309, DOI 10.1038/nature20123
   Vella P, 2012, NUCLEIC ACIDS RES, V40, P3403, DOI 10.1093/nar/gkr1290
   Wang S, 2013, NAT PROTOC, V8, P2502, DOI 10.1038/nprot.2013.150
   Wang XY, 2017, SCIENCE, V356, P88, DOI 10.1126/science.aaj2114
   Weintraub AS, 2017, CELL, V171, P1573, DOI 10.1016/j.cell.2017.11.008
   Whalen S, 2016, NAT GENET, V48, P488, DOI 10.1038/ng.3539
   Whyte WA, 2013, CELL, V153, P307, DOI 10.1016/j.cell.2013.03.035
   Williams MJ, 2016, NAT GENET, V48, P238, DOI 10.1038/ng.3489
   Yates LR, 2017, CANCER CELL, V32, P169, DOI 10.1016/j.ccell.2017.07.005
   Yates LR, 2015, NAT MED, V21, P751, DOI 10.1038/nm.3886
NR 58
TC 85
Z9 94
U1 0
U2 29
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1078-8956
EI 1546-170X
J9 NAT MED
JI Nat. Med.
PD SEP
PY 2018
VL 24
IS 9
BP 1469
EP +
DI 10.1038/s41591-018-0091-x
PG 14
WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research &
   Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental
   Medicine
GA GT0XF
UT WOS:000444174100032
PM 30038216
OA Green Accepted, Green Submitted
DA 2025-01-12
ER

PT J
AU Böck, J
   Appenzeller, S
   Haertle, L
   Schneider, T
   Gehrig, A
   Schröder, J
   Rost, S
   Wolf, B
   Bartram, CR
   Sutter, C
   Haaf, T
AF Boeck, Julia
   Appenzeller, Silke
   Haertle, Larissa
   Schneider, Tamara
   Gehrig, Andrea
   Schroeder, Joerg
   Rost, Simone
   Wolf, Beat
   Bartram, Claus R.
   Sutter, Christian
   Haaf, Thomas
TI Single CpG hypermethylation, allele methylation errors, and decreased
   expression of multiple tumor suppressor genes in normal body cells of
   mutation-negative early-onset and high-risk breast cancer patients
SO INTERNATIONAL JOURNAL OF CANCER
LA English
DT Article
DE allele methylation error; breast cancer susceptibility gene; deep
   bisulfite sequencing; epimutation; early onset breast cancer; familial
   breast cancer; single CpG hypermethylation; tumor suppressor gene
ID BRCA1 PROMOTER METHYLATION; SPORADIC BREAST; DNA METHYLATION; READ
   ALIGNMENT; BLOOD; DISEASE; PLASMA
AB To evaluate the role of constitutive epigenetic changes in normal body cells of BRCA1/BRCA2-mutation negative patients, we have developed a deep bisulfite sequencing assay targeting the promoter regions of 8 tumor suppressor (TS) genes (BRCA1, BRCA2, RAD51C, ATM, PTEN, TP53, MLH1, RB1) and the estrogene receptor gene (ESR1), which plays a role in tumor progression. We analyzed blood samples of two breast cancer (BC) cohorts with early onset (EO) and high risk (HR) for a heterozygous mutation, respectively, along with age-matched controls. Methylation analysis of up to 50,000 individual DNA molecules per gene and sample allowed quantification of epimutations (alleles with >50% methylated CpGs), which are associated with epigenetic silencing. Compared to ESR1, which is representative for an average promoter, TS genes were characterized by a very low (<1%) average methylation level and a very low mean epimutation rate (EMR; < 0.0001% to 0.1%). With exception of BRCA1, which showed an increased EMR in BC (0.31% vs. 0.06%), there was no significant difference between patients and controls. One of 36 HR BC patients exhibited a dramatically increased EMR (14.7%) in BRCA1, consistent with a disease-causing epimutation. Approximately one third (15 of 44) EO BC patients exhibited increased rates of single CpG methylation errors in multiple TS genes. Both EO and HR BC patients exhibited global underexpression of blood TS genes. We propose that epigenetic abnormalities in normal body cells are indicative of disturbed mechanisms for maintaining low methylation and appropriate expression levels and may be associated with an increased BC risk.
C1 [Boeck, Julia; Haertle, Larissa; Schneider, Tamara; Gehrig, Andrea; Schroeder, Joerg; Rost, Simone; Haaf, Thomas] Univ Wurzburg, Inst Human Genet, Wurzburg, Germany.
   [Appenzeller, Silke] Univ Hosp, Comprehens Canc Ctr, Wurzburg, Germany.
   [Wolf, Beat] Univ Appl Sci Western Switzerland, Fribourg, Switzerland.
   [Wolf, Beat] Univ Wurzburg, Dept Bioinformat, Wurzburg, Germany.
   [Bartram, Claus R.; Sutter, Christian] Univ Hosp, Inst Human Genet, Heidelberg, Germany.
C3 University of Wurzburg; University of Wurzburg; University of Applied
   Sciences & Arts Western Switzerland; University of Wurzburg; Ruprecht
   Karls University Heidelberg
RP Haaf, T (通讯作者)，Julius Maximilians Univ Wurzburg, Biozentrum, Inst Human Genet, D-97074 Wurzburg, Germany.
EM thomas.haaf@uni-wuerzburg.de
RI Haertle, Larissa/KZU-1498-2024; Schroeder, Joerg/S-2315-2016
OI Haertle, Larissa/0000-0002-3927-9163; Appenzeller,
   Silke/0000-0002-5472-8692; Wolf, Beat/0000-0002-9307-7212
CR Alix-Panabières C, 2013, CLIN CHEM, V59, P110, DOI 10.1373/clinchem.2012.194258
   Baldwin RL, 2000, CANCER RES, V60, P5329
   Bosviel R, 2012, CANCER EPIDEMIOL, V36, pE177, DOI 10.1016/j.canep.2012.02.001
   Carrol ED, 2007, BMC IMMUNOL, V8, DOI 10.1186/1471-2172-8-20
   Cobain EF, 2016, SEMIN ONCOL, V43, P528, DOI 10.1053/j.seminoncol.2016.10.001
   Cunningham JM, 1998, CANCER RES, V58, P3455
   Dulaimi E, 2004, CLIN CANCER RES, V10, P6189, DOI 10.1158/1078-0432.CCR-04-0597
   Ehrlich M, 2006, CURR TOP MICROBIOL, V310, P251
   Esteller M, 2000, JNCI-J NATL CANCER I, V92, P564, DOI 10.1093/jnci/92.7.564
   Fackler MJ, 2004, CANCER RES, V64, P4442, DOI 10.1158/0008-5472.CAN-03-3341
   Galetzka D, 2012, EPIGENETICS-US, V7, P47, DOI 10.4161/epi.7.1.18814
   GRAFF JR, 1995, CANCER RES, V55, P5195
   GREGER V, 1989, HUM GENET, V83, P155, DOI 10.1007/BF00286709
   Häntzsch M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113298
   Haertle L, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0184030
   Hansmann T, 2012, HUM MOL GENET, V21, P4669, DOI 10.1093/hmg/dds308
   Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075
   Iwamoto T, 2011, BREAST CANCER RES TR, V129, P69, DOI 10.1007/s10549-010-1188-1
   Jahr S, 2001, CANCER RES, V61, P1659
   Jeselsohn R, 2015, NAT REV CLIN ONCOL, V12, P573, DOI 10.1038/nrclinonc.2015.117
   Karakosta A, 2005, J EXP CLIN CANC RES, V24, P505
   Krueger F, 2011, BIOINFORMATICS, V27, P1571, DOI 10.1093/bioinformatics/btr167
   Kuhtz J, 2014, EPIGENETICS-US, V9, P1648, DOI 10.4161/15592294.2014.988063
   Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/NMETH.1923, 10.1038/nmeth.1923]
   Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324
   Magdinier F, 2000, FASEB J, V14, P1585, DOI 10.1096/fj.14.11.1585
   Majidinia M, 2017, DNA REPAIR, V54, P22, DOI 10.1016/j.dnarep.2017.03.009
   Martin M., 2011, EMBnet.journal, V17, P10, DOI DOI 10.14806/EJ.17.1.200
   Meng SD, 2004, CLIN CANCER RES, V10, P8152, DOI 10.1158/1078-0432.CCR-04-1110
   Mouliere F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023418
   Pliushch G, 2015, FERTIL STERIL, V103, P720, DOI 10.1016/j.fertnstert.2014.12.096
   Robinson JT, 2011, NAT BIOTECHNOL, V29, P24, DOI 10.1038/nbt.1754
   Runne H, 2007, P NATL ACAD SCI USA, V104, P14424, DOI 10.1073/pnas.0703652104
   Schneider E, 2010, NUCLEIC ACIDS RES, V38, P3880, DOI 10.1093/nar/gkq126
   Sedic M, 2016, CELL CYCLE, V15, P621, DOI 10.1080/15384101.2016.1141841
   Sedic M, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8505
   Sharma G, 2009, CELL ONCOL, V31, P487, DOI 10.3233/CLO-2009-0507
   Sloane MA, 2016, CLIN EPIGENETICS, V8, DOI 10.1186/s13148-016-0207-4
   Snell C, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1858
   Warnecke PM, 1997, NUCLEIC ACIDS RES, V25, P4422, DOI 10.1093/nar/25.21.4422
   Weber M, 2007, NAT GENET, V39, P457, DOI 10.1038/ng1990
   Wei MJ, 2005, CANCER RES, V65, P10692, DOI 10.1158/0008-5472.CAN-05-1277
   Wolf B, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/403497
   Wong EM, 2011, CANCER PREV RES, V4, P23, DOI 10.1158/1940-6207.CAPR-10-0212
   Xi Y, 2009, BMC BIOINFORMATICS, V10, P232, DOI DOI 10.1186/1471-2105-10-232
   Yu SCY, 2013, CLIN CHEM, V59, P1228, DOI 10.1373/clinchem.2013.203679
   Zubakov D, 2008, INT J LEGAL MED, V122, P135, DOI 10.1007/s00414-007-0182-6
NR 47
TC 13
Z9 15
U1 0
U2 11
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0020-7136
EI 1097-0215
J9 INT J CANCER
JI Int. J. Cancer
PD SEP 15
PY 2018
VL 143
IS 6
BP 1416
EP 1425
DI 10.1002/ijc.31526
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA GP7ZH
UT WOS:000441128700015
PM 29659014
OA Green Published, hybrid
DA 2025-01-12
ER

PT J
AU Woraruthai, T
   Charoenlap, C
   Hongsaprabhas, C
   Mutirangura, A
   Honsaweki, S
AF Woraruthai, Thamonwan
   Charoenlap, Chris
   Hongsaprabhas, Chindanai
   Mutirangura, Apiwat
   Honsaweki, Sittisak
TI Alu hypermethylation and high oxidative stress in patients with
   musculoskeletal tumors
SO PEERJ
LA English
DT Article
DE Alu methylation; 8-OHdG; Blood leukocytes; Oxidative stress;
   Musculoskeletal tumors
ID BLOOD-CELL DNA; REPETITIVE ELEMENTS; BREAST-CANCER; METHYLATION;
   HYPOMETHYLATION; CARCINOGENESIS; ASSOCIATION; CARCINOMA; SEQUENCES;
   REPEATS
AB Background. Alu is one of the non-autonomous element retrotransposons, constituting nearly 11% of the human DNA. Methylation changes of the Alu element can cause genomic instability, a hallmark of cancer development, ultimately leading to the development of cancer. Epigenetic factors may induce the aberrant methylation of Alu and also oxidative stress. However, current knowledge of Alu methylation and oxidative stress is limited. There are few studies that have evaluated Alu methylation and oxidative stress on musculoskeletal tumor progression. Therefore, the present study evaluated the status of Alu methylation in musculoskeletal (MS) tumor, adjacent tissues, and blood leukocytes from MS tumor subjects, as well as unaffected participants. Moreover, we also investigated the oxidative stress status in MS tumor subjects and the control participants and determined the correlation between Alu methylation in MS tumors and that in blood leukocytes.
   Methods. Musculoskeletal tumors from musculoskeletal tumor patients (n = 40) were compared to adjacent tissues (n = 40). The blood leukocytes from musculoskeletal tumor patients were compared to the blood leukocytes from controls (n = 107). Alu methylation status was analyzed using quantitative combined bisulfite restriction analysis (COBRA). In addition, 8-hydroxy 2'-deoxyguanosine (8-OHdG) values were determined using enzyme-linked immunosorbent assay.
   Results. Alu methylation values in MS tumors were statistically significantly higher than those in adjacent tissues (P = 0.035). Similarly, Alu methylation statuses in the blood leukocytes of MS tumor subjects were statistically greater than those of control participants (P < 0.001). Moreover, there was a positive association between Alu methylation levels in MS tumors and blood leukocytes (r = 0 .7 65 , P < 0.001). In addition, the highest tertile was significantly associated with the risk of MS tumors (OR = 14.17, 95% CI [5.08-39.51]; P < 0.001). The 8-OHdG values in MS tumors were statistically higher than in adjacent tissues (P < 0.001) and circulating 8-OHdG levels were substantially greater in MS tumor subjects than in the control participants (P < 0.001).
   Discussion. These findings suggest that Alu methylation in blood leukocytes and plasma 8-OHdG might represent non-invasive biomarkers to help diagnose MS tumors. Therefore, Alu hypermethylation and high oxidative stress might be involved in the pathogenesis of the musculoskeletal tumors.
C1 [Woraruthai, Thamonwan; Honsaweki, Sittisak] Chulalongkorn Univ, Osteoarthrit & Musculoskeleton Res Unit, Dept Biochem, Fac Med,King Chulalongkorn Mem Hosp,Thai Red Cros, Bangkok, Thailand.
   [Charoenlap, Chris; Hongsaprabhas, Chindanai] Chulalongkorn Univ, Vinai Parkpian Orthopaed Res Ctr, Dept Orthopaed, Fac Med,King Chulalongkorn Mem Hosp,Thai Red Cros, Bangkok, Thailand.
   [Mutirangura, Apiwat] Chulalongkorn Univ, Ctr Excellence Mol Genet Canc & Human Dis, Dept Anat, Fac Med,King Chulalongkorn Mem Hosp,Thai Red Cros, Bangkok, Thailand.
C3 Chulalongkorn University; Chulalongkorn University; Chulalongkorn
   University
RP Honsaweki, S (通讯作者)，Chulalongkorn Univ, Osteoarthrit & Musculoskeleton Res Unit, Dept Biochem, Fac Med,King Chulalongkorn Mem Hosp,Thai Red Cros, Bangkok, Thailand.
EM sittisak.h@chula.ac.th
OI Woraruthai, Thamonwan/0000-0003-3063-5448
FU 90th Anniversary of Chulalongkorn University; Ratchadaphiseksomphot
   Endowment Fund of Chulalongkorn University; Thailand Research Fund
   [DPG5980005]
FX This work was supported by the 90th Anniversary of Chulalongkorn
   University and the Ratchadaphiseksomphot Endowment Fund of Chulalongkorn
   University, and by the Thailand Research Fund (DPG5980005). The funders
   had no role in study design, data collection and analysis, decision to
   publish, or preparation of the manuscript.
CR Akers SN, 2014, GYNECOL ONCOL, V132, P462, DOI 10.1016/j.ygyno.2013.12.024
   Bae JM, 2012, INT J CANCER, V131, P1323, DOI 10.1002/ijc.27369
   Barzilai A, 2002, DNA REPAIR, V1, P3, DOI 10.1016/S1568-7864(01)00007-6
   Batzer MA, 2002, NAT REV GENET, V3, P370, DOI 10.1038/nrg798
   Chalitchagorn K, 2004, ONCOGENE, V23, P8841, DOI 10.1038/sj.onc.1208137
   Chen RZ, 1998, NATURE, V395, P89, DOI 10.1038/25779
   Dauksa A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037509
   Deininger PL, 2003, CURR OPIN GENET DEV, V13, P651, DOI 10.1016/j.gde.2003.10.013
   Donkena KV, 2010, OBSTET GYNECOL INT, V2010, DOI 10.1155/2010/302051
   Elis S, 2011, AGING CELL, V10, P547, DOI 10.1111/j.1474-9726.2011.00683.x
   Franco R, 2008, CANCER LETT, V266, P6, DOI 10.1016/j.canlet.2008.02.026
   HALLIWELL B, 1994, ENVIRON HEALTH PERSP, V102, P5, DOI 10.2307/3432205
   Jin Bilian, 2011, Genes Cancer, V2, P607, DOI 10.1177/1947601910393957
   Jintaridth P, 2010, PHYSIOL GENOMICS, V41, P194, DOI 10.1152/physiolgenomics.00146.2009
   Jordà M, 2017, GENOME RES, V27, P118, DOI 10.1101/gr.207522.116
   Kim BF, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087913
   Langevin SM, 2012, EPIGENETICS-US, V7, P291, DOI 10.4161/epi.7.3.19134
   Liao LM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027361
   Lunec J, 2002, FREE RADICAL BIO MED, V33, P875, DOI 10.1016/S0891-5849(02)00882-1
   Ma-On C, 2017, MED ONCOL, V34, DOI 10.1007/s12032-017-0914-5
   Mighell AJ, 1997, FEBS LETT, V417, P1, DOI 10.1016/S0014-5793(97)01259-3
   Mohamadkhani Ashraf, 2017, Asian Pac J Cancer Prev, V18, P1349
   Neale RE, 2014, CANCER EPIDEMIOL, V38, P576, DOI 10.1016/j.canep.2014.08.006
   Nishida N, 2013, DIGEST DIS, V31, P459, DOI 10.1159/000355245
   Ofluoglu Onder, 2010, Semin Intervent Radiol, V27, P185, DOI 10.1055/s-0030-1253516
   Pogribny IP, 2009, CELL MOL LIFE SCI, V66, P2249, DOI 10.1007/s00018-009-0015-5
   Pornthanakasem W, 2008, NUCLEIC ACIDS RES, V36, P3667, DOI 10.1093/nar/gkn261
   Rhee YY, 2015, VIRCHOWS ARCH, V466, P675, DOI 10.1007/s00428-015-1749-0
   Saito K, 2010, CLIN CANCER RES, V16, P2418, DOI 10.1158/1078-0432.CCR-09-2819
   Tiwawech D, 2014, ASIAN PAC J CANCER P, V15, P9797, DOI 10.7314/APJCP.2014.15.22.9797
   Udomsinprasert W, 2016, SCI REP-UK, V6, DOI 10.1038/srep26969
   Valko M, 2004, MOL CELL BIOCHEM, V266, P37, DOI 10.1023/B:MCBI.0000049134.69131.89
   Walters RJ, 2013, EPIGENETICS-US, V8, P748, DOI 10.4161/epi.25178
   Wu HC, 2012, CARCINOGENESIS, V33, P1946, DOI 10.1093/carcin/bgs201
   Wu QH, 2015, CURR DRUG TARGETS, V16, P13, DOI 10.2174/1389450116666150113121054
   Xu XR, 2012, FASEB J, V26, P2657, DOI 10.1096/fj.11-197251
   Ziech D, 2011, MUTAT RES-FUND MOL M, V711, P167, DOI 10.1016/j.mrfmmm.2011.02.015
NR 37
TC 3
Z9 3
U1 1
U2 4
PU PEERJ INC
PI LONDON
PA 341-345 OLD ST, THIRD FLR, LONDON, EC1V 9LL, ENGLAND
SN 2167-8359
J9 PEERJ
JI PeerJ
PD AUG 16
PY 2018
VL 6
AR e5492
DI 10.7717/peerj.5492
PG 17
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA GQ8IE
UT WOS:000441995700007
PM 30128216
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Surapaneni, SK
   Bashir, S
   Tikoo, K
AF Surapaneni, Sunil Kumar
   Bashir, Shafiya
   Tikoo, Kulbhushan
TI Gold nanoparticles-induced cytotoxicity in triple negative breast cancer
   involves different epigenetic alterations depending upon the surface
   charge
SO SCIENTIFIC REPORTS
LA English
DT Article
ID HISTONE H3; SERINE 10; PHOSPHORYLATION; ACTIVATION; PATHWAY; WNT;
   TOXICITY; PROTEINS; GLUCOSE; MCF-7
AB Gold nanoparticles (AuNPs) are used enormously in different cancers but very little is known regarding their molecular mechanism and surface charge role in the process of cell death. Here, we elucidate the molecular mechanism by which differentially charged AuNPs induce cytotoxicity in triple negative breast cancer (TNBC) cells. Cytotoxicity assay revealed that both negatively charged (citrate-capped) and positively charged (cysteamine-capped) AuNPs induced cell-death in a dose-dependent manner. We provide first evidence that AuNPs-induced oxidative stress alters Wnt signalling pathway in MDA-MB-231 and MDA-MB-468 cells. Although both differentially charged AuNPs induced cell death, the rate and mechanism involved in the process of cell death were different. Negatively charged AuNPs increased the expression of MKP-1, dephosphorylated and deacetylated histone H3 at Ser10 and K9/K14 residues respectively whereas, positively charged AuNPs decreased the expression of MKP-1, phosphorylated and acetylated histone H3 at Ser 10 and K9/K14 residues respectively. High-resolution transmission electron microscopy (HRTEM) studies revealed that AuNPs were localised in cytoplasm and mitochondria of MDA-MB-231 cells. Interestingly, AuNPs treatment makes MDA-MB-231 cells sensitive to 5-fluorouracil (5-FU) by decreasing the expression of thymidylate synthetase enzyme. This study highlights the role of surface charge (independent of size) in the mechanisms of toxicity and cell death.
C1 [Surapaneni, Sunil Kumar; Bashir, Shafiya; Tikoo, Kulbhushan] NIPER, Dept Pharmacol & Toxicol, Lab Epigenet & Dis, Sas Nagar, India.
C3 National Institute of Pharmaceutical Education & Research, S.A.S. Nagar
   (Mohali)
RP Tikoo, K (通讯作者)，NIPER, Dept Pharmacol & Toxicol, Lab Epigenet & Dis, Sas Nagar, India.
EM tikoo.k@gmail.com
OI SURAPANENI, SUNIL KUMAR/0000-0002-1121-1511
FU National Institute of Pharmaceutical Education and Research, S.A.S.
   Nagar, India
FX We are grateful to Jasmine Kaur, Venkateswara Rao Amara, Krishna Prahlad
   Maremanda and Vaibhav Sheth for their insightful discussion of this
   manuscript. This work was supported by grants from the National
   Institute of Pharmaceutical Education and Research, S.A.S. Nagar, India.
CR Al Zaki A, 2017, CANCER DRUG DISCOV D, P241, DOI 10.1007/978-3-319-40854-5_10
   Arachchige MP, 2017, MICRON, V92, P25, DOI 10.1016/j.micron.2016.10.005
   Berg JM, 2009, NANOTOXICOLOGY, V3, P276, DOI 10.3109/17435390903276941
   Bilir B, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-280
   Chocarro-Calvo A, 2013, MOL CELL, V49, P474, DOI 10.1016/j.molcel.2012.11.022
   Coulter JA, 2012, INT J NANOMED, V7, P2673, DOI 10.2147/IJN.S31751
   Ding Y, 2014, MOL THER, V22, P1075, DOI 10.1038/mt.2014.30
   Equilibrina Ilma, 2015, Chromosome Science, V18, P9
   Evangelopoulos M., 2016, FUTURE MED, V21, P5
   Falagan-Lotsch P, 2016, P NATL ACAD SCI USA, V113, P13318, DOI 10.1073/pnas.1616400113
   Grobmyer SR, 2011, J SURG ONCOL, V103, P317, DOI 10.1002/jso.21698
   Gui CY, 2004, P NATL ACAD SCI USA, V101, P1241, DOI 10.1073/pnas.0307708100
   Gupta C, 2013, J MOL ENDOCRINOL, V51, P119, DOI 10.1530/JME-13-0062
   He CB, 2010, BIOMATERIALS, V31, P3657, DOI 10.1016/j.biomaterials.2010.01.065
   Holloway KR, 2010, P NATL ACAD SCI USA, V107, P9216, DOI 10.1073/pnas.0911325107
   Kafshdooz L, 2016, ARTIF CELL NANOMED B, V44, P1222, DOI 10.3109/21691401.2015.1029625
   Kalimutho M, 2015, TRENDS PHARMACOL SCI, V36, P822, DOI 10.1016/j.tips.2015.08.009
   Karakoti AS, 2006, JOM-US, V58, P77, DOI 10.1007/s11837-006-0147-0
   Kaur J, 2013, FOOD CHEM TOXICOL, V51, P1, DOI 10.1016/j.fct.2012.08.044
   Kazi M.M., 2016, Cancer Translational Medicine, V2, P55, DOI DOI 10.4103/2395-3977.181437
   Khramtsov AI, 2010, AM J PATHOL, V176, P2911, DOI 10.2353/ajpath.2010.091125
   King TD, 2012, J CELL BIOCHEM, V113, P13, DOI 10.1002/jcb.23350
   Krishnaraj C, 2014, Biotechnol Rep (Amst), V4, P42, DOI 10.1016/j.btre.2014.08.002
   Lim ZZJ, 2011, ACTA PHARMACOL SIN, V32, P983, DOI 10.1038/aps.2011.82
   Mateo D, 2014, TOXICOL MECH METHOD, V24, P161, DOI 10.3109/15376516.2013.869783
   McCubrey JA, 2006, ANTIOXID REDOX SIGN, V8, P1775, DOI 10.1089/ars.2006.8.1775
   Murawala P, 2014, MAT SCI ENG C-MATER, V34, P158, DOI 10.1016/j.msec.2013.09.004
   O'Toole SA, 2013, J CLIN PATHOL, V66, P530, DOI 10.1136/jclinpath-2012-201361
   Pan Y, 2009, SMALL, V5, P2067, DOI 10.1002/smll.200900466
   Park CH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044307
   Peer D, 2007, NAT NANOTECHNOL, V2, P751, DOI 10.1038/nnano.2007.387
   Price MA, 2006, GENE DEV, V20, P399, DOI 10.1101/gad.1394306
   Schaeublin NM, 2011, NANOSCALE, V3, P410, DOI 10.1039/c0nr00478b
   Sharma AK, 2013, BIOINFORM BIOL INSIG, V7, P271, DOI 10.4137/BBI.S12449
   Taggart Laura E, 2014, Cancer Nanotechnol, V5, P5
   Thornton TM, 2008, SCIENCE, V320, P667, DOI 10.1126/science.1156037
   Tikoo K, 2001, MOL PHARMACOL, V60, P394, DOI 10.1124/mol.60.2.394
   Walter W, 2008, MOL CELL BIOL, V28, P2840, DOI 10.1128/MCB.01457-07
   Wang FL, 2016, INT J ENV RES PUB HE, V13, DOI 10.3390/ijerph13121182
   Wang JY, 2016, INT J NANOMED, V11, P3475, DOI 10.2147/IJN.S106073
   Xu JH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117097
   Zhang N, 2008, MOLECULES, V13, P1551, DOI 10.3390/molecules13081551
   Zuazua-Villar P, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.231
NR 43
TC 84
Z9 87
U1 1
U2 14
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD AUG 16
PY 2018
VL 8
AR 12295
DI 10.1038/s41598-018-30541-3
PG 12
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA GQ5ZG
UT WOS:000441775900059
PM 30115982
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU Vega-García, N
   Malatesta, R
   Estella, C
   Pérez-Jaume, S
   Esperanza-Cebollada, E
   Torrebadell, M
   Català, A
   Gassiot, S
   Berrueco, R
   Ruiz-Llobet, A
   Alonso-Saladrigues, A
   Mesegué, M
   Pont-Martí, S
   Rives, S
   Camós, M
AF Vega-Garcia, Nerea
   Malatesta, Roberta
   Estella, Camino
   Perez-Jaume, Sara
   Esperanza-Cebollada, Elena
   Torrebadell, Montserrat
   Catala, Albert
   Gassiot, Susanna
   Berrueco, Ruben
   Ruiz-Llobet, Anna
   Alonso-Saladrigues, Anna
   Mesegue, Montserrat
   Pont-Marti, Sandra
   Rives, Susana
   Camos, Mireia
TI Paediatric patients with acute leukaemia and <i>KMT2A</i> (<i>MLL</i>)
   rearrangement show a distinctive expression pattern of histone
   deacetylases
SO BRITISH JOURNAL OF HAEMATOLOGY
LA English
DT Article
DE paediatric acute leukaemia; KMT2A (MLL); histone deacetylases; HDAC
   inhibitors; epigenetics
ID ACUTE LYMPHOBLASTIC-LEUKEMIA; ACUTE MYELOID-LEUKEMIA; HDAC INHIBITORS;
   BREAST-CANCER; POOR-RESPONSE; CHILDHOOD; SURVIVAL; THERAPY; ADOLESCENTS;
   ACTIVATION
AB Histone deacetylase inhibitors (HDACi) had emerged as promising drugs in leukaemia, but their toxicity due to lack of specificity limited their use. Therefore, there is a need to elucidate the role of HDACs in specific settings. The study of HDAC expression in childhood leukaemia could help to choose more specific HDACi for selected candidates in a personalized approach. We analysed HDAC1-11, SIRT1, SIRT7, MEF2C and MEF2D mRNA expression in 211 paediatric patients diagnosed with acute leukaemia. There was a global overexpression of HDACs, while specific HDACs correlated with clinical and biological features, and some even predicted outcome. Thus, some HDAC and MEF2C profiles probably reflected the lineage and the maturation of the blasts and some profiles identified specific oncogenic pathways active in the leukaemic cells. Specifically, we identified a distinctive signature for patients with KMT2A (MLL) rearrangement, with high HDAC9 and MEF2D expression, regardless of age, KMT2A partner and lineage. Moreover, we observed an adverse prognostic value of HDAC9 overexpression, regardless of KMT2A rearrangement. Our results provide useful knowledge on the complex picture of HDAC expression in childhood leukaemia and support the directed use of specific HDACi to selected paediatric patients with acute leukaemia.
C1 [Vega-Garcia, Nerea; Malatesta, Roberta; Estella, Camino; Esperanza-Cebollada, Elena; Torrebadell, Montserrat; Gassiot, Susanna; Pont-Marti, Sandra; Camos, Mireia] Univ Barcelona, Hosp St Joan Deu Barcelona, Haematol Lab, Barcelona, Spain.
   [Vega-Garcia, Nerea; Malatesta, Roberta; Estella, Camino; Esperanza-Cebollada, Elena; Torrebadell, Montserrat; Catala, Albert; Gassiot, Susanna; Berrueco, Ruben; Ruiz-Llobet, Anna; Alonso-Saladrigues, Anna; Mesegue, Montserrat; Pont-Marti, Sandra; Rives, Susana; Camos, Mireia] Hosp St Joan Deu Barcelona, Inst Recerca, Barcelona, Spain.
   [Perez-Jaume, Sara] Hosp St Joan Deu Barcelona, Inst Recerca, Dev Tumor Biol Lab, Barcelona, Spain.
   [Torrebadell, Montserrat; Catala, Albert; Berrueco, Ruben; Rives, Susana; Camos, Mireia] Inst Salud Carlos III, Ctr Invest Biomed Red Enfermedades Raras CIBERER, Madrid, Spain.
   [Catala, Albert; Berrueco, Ruben; Ruiz-Llobet, Anna; Alonso-Saladrigues, Anna; Mesegue, Montserrat; Rives, Susana] Univ Barcelona, Hosp St Joan Deu Barcelona, Paediat Haematol & Oncol Dept, Barcelona, Spain.
C3 University of Barcelona; Autonomous University of Barcelona; Hospital
   Universitari Vall d'Hebron; Vall d'Hebron Institut de Recerca (VHIR);
   Autonomous University of Barcelona; Hospital Universitari Vall d'Hebron;
   Vall d'Hebron Institut de Recerca (VHIR); Instituto de Salud Carlos III;
   CIBER - Centro de Investigacion Biomedica en Red; CIBERER; University of
   Barcelona
RP Camós, M (通讯作者)，Hosp St Joan Deu, Haematol Lab, Passeig St Joan Deu 2, Barcelona 08950, Spain.
EM mcamos@sjdhospitalbarcelona.org
RI Rives, Susana/AHA-6765-2022; Gassiot, Susanna/L-2374-2017
OI Torrebadell, Montserrat/0000-0002-0027-3215; Berrueco,
   Ruben/0000-0002-1068-7489; Gassiot Riu, Susanna/0000-0001-5506-0244;
   CATALA, ALBERT/0000-0003-0133-1752; Rives, Susana/0000-0002-5658-1831
FU Obra Social from Hospital Sant Joan de Deu project; "Forca Miquel"
   project; "Asociacion Pulseras Candela" project; "Pirata Barballum"
   project; "Magic" project; "Mua" project; Plan Nacional de I+D+I
   [PI12/02417, PI16/00246]; ISCIII - Subdireccion General de Evaluacion y
   Fomento de la Investigacion Sanitaria; Fondo Europeo de Desarrollo
   Regional (FEDER); CIBERER; Fundacion AECC-Cancer Infantil 2012;
   Fundacion Cris contra el cancer; Fundacion Pelayo; Fundacion
   Unoentrecienmil
FX We are indebted to our patients and families for their help and to Obra
   Social from Hospital Sant Joan de Deu, "Forca Miquel", "Asociacion
   Pulseras Candela", "Pirata Barballum", "Magic" and "Mua" projects for
   their support. We also want to thank the excellent technical support by
   Ms. Lidia Ruiz. We are indebted to the "Biobanc de l'Hospital Infantil
   Sant Joan de Deu per a la Investigacio", integrated in the Spanish
   Biobank Network of ISCIII for the sample and data procurement. This
   study has been funded by projects PI12/02417, and PI16/00246, integrated
   into Plan Nacional de I+D+I and co-funded by ISCIII - Subdireccion
   General de Evaluacion y Fomento de la Investigacion Sanitaria and Fondo
   Europeo de Desarrollo Regional (FEDER), CIBERER, from Fundacion
   AECC-Cancer Infantil 2012, Fundacion Cris contra el cancer, Fundacion
   Pelayo and Fundacion Unoentrecienmil.
CR Ahmad K, 2014, ONCOGENESIS, V3, DOI 10.1038/oncsis.2014.39
   Ahmadzadeh Ahmad, 2015, Int J Hematol Oncol Stem Cell Res, V9, P203
   Balasubramanian S, 2009, CANCER LETT, V280, P211, DOI 10.1016/j.canlet.2009.02.013
   Barneda-Zahonero B, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2014.594
   Barneda-Zahonero B, 2012, MOL ONCOL, V6, P579, DOI 10.1016/j.molonc.2012.07.003
   Bolden JE, 2006, NAT REV DRUG DISCOV, V5, P769, DOI 10.1038/nrd2133
   Bose P, 2014, PHARMACOL THERAPEUT, V143, P323, DOI 10.1016/j.pharmthera.2014.04.004
   Bradbury C, 2005, LEUKEMIA, V19, P1751, DOI 10.1038/sj.leu.2403910
   Canté-Barrett K, 2014, ONCOGENE, V33, P403, DOI 10.1038/onc.2013.56
   Castro PG, 2018, LEUKEMIA, V32, P323, DOI 10.1038/leu.2017.216
   Ceccacci E, 2016, BRIT J CANCER, V114, P605, DOI 10.1038/bjc.2016.36
   Chrun ES, 2017, PATHOL RES PRACT, V213, P1329, DOI 10.1016/j.prp.2017.06.013
   Colomer-Lahiguera S, 2017, LEUKEMIA LYMPHOMA, V58, P2895, DOI 10.1080/10428194.2017.1312383
   Contal C, 1999, COMPUT STAT DATA AN, V30, P253, DOI 10.1016/S0167-9473(98)00096-6
   Coustan-Smith E, 2009, LANCET ONCOL, V10, P147, DOI 10.1016/S1470-2045(08)70314-0
   Eckschlager T, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18071414
   Gatta G, 2013, HAEMATOLOGICA, V98, P744, DOI 10.3324/haematol.2012.071597
   Gruhn B, 2013, LEUKEMIA RES, V37, P1200, DOI 10.1016/j.leukres.2013.07.016
   Gu Z, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13331
   Haberland M, 2009, NAT REV GENET, V10, P32, DOI 10.1038/nrg2485
   Haery Leila, 2015, Genes Cancer, V6, P184
   Homminga I, 2011, CANCER CELL, V19, P484, DOI 10.1016/j.ccr.2011.02.008
   Hua WK, 2017, BLOOD, V130, P2619, DOI 10.1182/blood-2017-03-771386
   Hunger SP, 2015, NEW ENGL J MED, V373, P1541, DOI 10.1056/NEJMra1400972
   Krämer OH, 2003, EMBO J, V22, P3411, DOI 10.1093/emboj/cdg315
   Krivtsov AV, 2006, NATURE, V442, P818, DOI 10.1038/nature04980
   Lapierre M, 2016, ONCOTARGET, V7, P19693, DOI 10.18632/oncotarget.7564
   Laszlo GS, 2015, J HEMATOL ONCOL, V8, DOI 10.1186/s13045-015-0215-4
   Li L, 2014, CELL STEM CELL, V15, P431, DOI 10.1016/j.stem.2014.08.001
   Liu N, 2017, ONCOTARGET, V8, P89315, DOI 10.18632/oncotarget.19167
   Liu YF, 2016, EBIOMEDICINE, V8, P173, DOI 10.1016/j.ebiom.2016.04.038
   Meyer C, 2018, LEUKEMIA, V32, P273, DOI 10.1038/leu.2017.213
   Milde T, 2010, CLIN CANCER RES, V16, P3240, DOI 10.1158/1078-0432.CCR-10-0395
   Moreno DA, 2010, BRIT J HAEMATOL, V150, P665, DOI 10.1111/j.1365-2141.2010.08301.x
   Pon JR, 2016, ONCOTARGET, V7, P2297, DOI 10.18632/oncotarget.6223
   Pui CH, 2015, J CLIN ONCOL, V33, P2938, DOI 10.1200/JCO.2014.59.1636
   Raetz EA, 2012, HEMATOL-AM SOC HEMAT, P129, DOI 10.1182/asheducation-2012.1.129
   Ropero S, 2007, MOL ONCOL, V1, P19, DOI 10.1016/j.molonc.2007.01.001
   Sahakian E, 2017, J LEUKOCYTE BIOL, V102, P475, DOI 10.1189/jlb.1A0415-176RRR
   Schwieger M, 2009, BLOOD, V114, P2476, DOI 10.1182/blood-2008-05-158196
   Stahl M, 2016, EXPERT OPIN INV DRUG, V25, P307, DOI 10.1517/13543784.2016.1146251
   Steinhilber D, 2018, BIOCHEM PHARMACOL, V147, P183, DOI 10.1016/j.bcp.2017.09.007
   Stubbs MC, 2015, CLIN CANCER RES, V21, P2348, DOI 10.1158/1078-0432.CCR-14-1290
   Stumpel DJPM, 2012, LEUKEMIA, V26, P682, DOI 10.1038/leu.2011.278
   Subramanian S, 2010, PHARMACEUTICALS, V3, P2751, DOI 10.3390/ph3092751
   Suzuki K, 2016, J CLIN ONCOL, V34, P3451, DOI 10.1200/JCO.2016.66.5547
   Tao YF, 2013, INT J MOL SCI, V14, P3376, DOI 10.3390/ijms14023376
   Wada T, 2009, J BIOL CHEM, V284, P30673, DOI 10.1074/jbc.M109.042242
   Ward E, 2014, CA-CANCER J CLIN, V64, P83, DOI 10.3322/caac.21219
   West AC, 2014, J CLIN INVEST, V124, P30, DOI 10.1172/JCI69738
   Zhang C, 2015, CLIN EPIGENETICS, V7, DOI 10.1186/s13148-015-0151-8
   Zhang JH, 2012, NATURE, V481, P157, DOI 10.1038/nature10725
   Zuurbier L, 2014, HAEMATOLOGICA, V99, P94, DOI 10.3324/haematol.2013.090233
NR 53
TC 6
Z9 8
U1 3
U2 7
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0007-1048
EI 1365-2141
J9 BRIT J HAEMATOL
JI Br. J. Haematol.
PD AUG
PY 2018
VL 182
IS 4
BP 542
EP 553
DI 10.1111/bjh.15436
PG 12
WC Hematology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Hematology
GA GQ6TO
UT WOS:000441858400012
PM 29978456
OA Bronze
DA 2025-01-12
ER

PT J
AU Assenov, Y
   Brocks, D
   Gerhäuser, C
AF Assenov, Yassen
   Brocks, David
   Gerhaeuser, Clarissa
TI Intratumor heterogeneity in epigenetic patterns
SO SEMINARS IN CANCER BIOLOGY
LA English
DT Article
DE Epigenetic intratumor heterogeneity; DNA methylation; Histone
   posttranscriptional modifications; Chromatin; (Sub-)clonal evolution;
   Single-cell analysis; Epigenetic therapy; Cancer stem cells
ID GLOBAL HISTONE MODIFICATION; CANCER STEM-CELLS; MODIFICATIONS PREDICT
   PROGNOSIS; SINGLE-CELL; DNA METHYLATION; CLONAL EVOLUTION;
   BREAST-CANCER; TUMOR HETEROGENEITY; POOR-PROGNOSIS; CHROMATIN
   ACCESSIBILITY
AB Analogous to life on earth, tumor cells evolve through space and time and adapt to different micro-environmental conditions. As a result, tumors are composed of millions of genetically diversified cells at the time of diagnosis. Profiling these variants contributes to understanding tumors' clonal origins and might help to better understand response to therapy. However, even genetically homogenous cell populations show remarkable diversity in their response to different environmental stimuli, suggesting that genetic heterogeneity does not explain the full spectrum of tumor plasticity. Understanding epigenetic diversity across cancer cells provides important additional information about the functional state of subclones and therefore allows better understanding of tumor evolution and resistance to current therapies.
C1 [Assenov, Yassen; Brocks, David; Gerhaeuser, Clarissa] German Canc Res Ctr, Epigen & Canc Risk Factors, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.
   [Brocks, David] Weizmann Inst Sci, Dept Regulat Biol, Dept Comp Sci & Appl Math, IL-76100 Rehovot, Israel.
C3 Helmholtz Association; German Cancer Research Center (DKFZ); Weizmann
   Institute of Science
RP Gerhäuser, C (通讯作者)，German Canc Res Ctr, Div Epigen & Canc Risk Factors C010, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.
EM c.gerhauser@dkfz.de
OI Gerhauser, Clarissa/0000-0002-5792-3901
FU German Federal Ministry of Education and Research (BMBF) [01KU1001A,
   01KU1505A]; German-Israeli Helmholtz Research School in Cancer Biology
   at the German Cancer Research Center (Heidelberg, Germany)
FX The authors are part of the ICGC-EOPCA (01KU1001A) and ICGC-Data Mining
   (01KU1505A) projects on early-onset prostate cancer funded by the German
   Federal Ministry of Education and Research (BMBF). David Brocks was
   supported by the German-Israeli Helmholtz Research School in Cancer
   Biology at the German Cancer Research Center (Heidelberg, Germany).
CR Abeshouse A, 2015, CELL, V163, P1011, DOI 10.1016/j.cell.2015.10.025
   Adamo P, 2016, ONCOGENE, V35, P403, DOI 10.1038/onc.2015.109
   Almendro V, 2014, CELL REP, V6, P514, DOI 10.1016/j.celrep.2013.12.041
   Balch C, 2009, ENDOCRINOLOGY, V150, P4003, DOI 10.1210/en.2009-0404
   Barlesi F, 2007, J CLIN ONCOL, V25, P4358, DOI 10.1200/JCO.2007.11.2599
   Barrett JE, 2017, BMC BIOINFORMATICS, V18, P1, DOI 10.1186/s12859-017-1753-2
   Baslan T, 2017, NAT REV CANCER, V17, P557, DOI 10.1038/nrc.2017.58
   Batlle E, 2017, NAT MED, V23, P1124, DOI 10.1038/nm.4409
   Baylin SB, 2011, NAT REV CANCER, V11, P726, DOI 10.1038/nrc3130
   Beca F, 2016, ADV EXP MED BIOL, V882, P169, DOI 10.1007/978-3-319-22909-6_7
   Berman BP, 2012, NAT GENET, V44, P40, DOI 10.1038/ng.969
   Bianco-Miotto T, 2010, CANCER EPIDEM BIOMAR, V19, P2611, DOI 10.1158/1055-9965.EPI-10-0555
   Bibikova M, 2011, GENOMICS, V98, P288, DOI 10.1016/j.ygeno.2011.07.007
   Börno ST, 2012, CANCER DISCOV, V2, P1024, DOI 10.1158/2159-8290.CD-12-0041
   Boutros PC, 2015, NAT GENET, V47, P736, DOI 10.1038/ng.3315
   Brocks D, 2017, NAT GENET, V49, P1052, DOI 10.1038/ng.3889
   Brocks D, 2014, CELL REP, V8, P798, DOI 10.1016/j.celrep.2014.06.053
   Buenostro JD, 2015, NATURE, V523, P486, DOI 10.1038/nature14590
   Buenrostro JD, 2013, NAT METHODS, V10, P1213, DOI [10.1038/NMETH.2688, 10.1038/nmeth.2688]
   Burrell RA, 2013, NATURE, V501, P338, DOI 10.1038/nature12625
   Cahill N, 2013, LEUKEMIA, V27, P150, DOI 10.1038/leu.2012.245
   Caiado F, 2016, FEBS J, V283, P2245, DOI 10.1111/febs.13705
   Chaffer CL, 2013, CELL, V154, P61, DOI 10.1016/j.cell.2013.06.005
   Chen HB, 2006, CANCER RES, V66, P9009, DOI 10.1158/0008-5472.CAN-06-0101
   Chen YW, 2013, CANCER-AM CANCER SOC, V119, P4259, DOI 10.1002/cncr.28356
   Cooper CS, 2015, NAT GENET, V47, P367, DOI 10.1038/ng.3221
   Cusanovich DA, 2015, SCIENCE, V348, P910, DOI 10.1126/science.aab1601
   De S, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003137
   Dominguez PM, 2017, CURR OPIN HEMATOL, V24, P402, DOI 10.1097/MOH.0000000000000348
   Eales KL, 2016, ONCOGENESIS, V5, DOI 10.1038/oncsis.2015.50
   Easwaran H, 2014, MOL CELL, V54, P716, DOI 10.1016/j.molcel.2014.05.015
   Easwaran H, 2012, GENOME RES, V22, P837, DOI 10.1101/gr.131169.111
   Ehrlich M, 2006, ONCOGENE, V25, P2636, DOI 10.1038/sj.onc.1209145
   Ellinger J, 2010, INT J CANCER, V127, P2360, DOI 10.1002/ijc.25250
   Ellinger J, 2010, PROSTATE, V70, P61, DOI 10.1002/pros.21038
   Farlik M, 2015, CELL REP, V10, P1386, DOI 10.1016/j.celrep.2015.02.001
   Feinberg AP, 2014, J INTERN MED, V276, P5, DOI 10.1111/joim.12224
   Feinberg AP, 2016, NAT REV GENET, V17, P284, DOI 10.1038/nrg.2016.13
   Ferlay J., 2012, GLOBOCAN V1 0 CANC I
   Flavahan WA, 2017, SCIENCE, V357, DOI 10.1126/science.aal2380
   Gerhäuser C, 2012, BIOMED RES-INDIA, V23, P69
   Gerlinger M, 2014, NAT GENET, V46, P225, DOI 10.1038/ng.2891
   Gerlinger M, 2012, NEW ENGL J MED, V366, P883, DOI 10.1056/NEJMoa1113205
   Greaves M, 2012, NATURE, V481, P306, DOI 10.1038/nature10762
   Greer EL, 2012, NAT REV GENET, V13, P343, DOI 10.1038/nrg3173
   Guo HS, 2015, NAT PROTOC, V10, P645, DOI 10.1038/nprot.2015.039
   Guo HS, 2013, GENOME RES, V23, P2126, DOI 10.1101/gr.161679.113
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Hancock RL, 2015, EPIGENOMICS-UK, V7, P791, DOI 10.2217/epi.15.24
   Hansen KD, 2011, NAT GENET, V43, P768, DOI 10.1038/ng.865
   Hao JJ, 2016, NAT GENET, V48, P1500, DOI 10.1038/ng.3683
   He LR, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-461
   HEPPNER GH, 1984, CANCER RES, V44, P2259
   HOLLIDAY R, 1979, BRIT J CANCER, V40, P513, DOI 10.1038/bjc.1979.216
   Hoseok I, 2010, CANCER EPIDEM BIOMAR, V19, P566, DOI 10.1158/1055-9965.EPI-09-0980
   Houseman EA, 2016, BMC BIOINFORMATICS, V17, DOI 10.1186/s12859-016-1140-4
   Houseman EA, 2012, BMC BIOINFORMATICS, V13, DOI 10.1186/1471-2105-13-86
   Huebschmann D., 2017, BIORXIV, DOI [10.1101/199547, DOI 10.1101/199547]
   Huntly BJP, 2005, NAT REV CANCER, V5, P311, DOI 10.1038/nrc1592
   Hyun K, 2017, EXP MOL MED, V49, DOI 10.1038/emm.2017.11
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Jones PA, 2016, NAT REV GENET, V17, P630, DOI 10.1038/nrg.2016.93
   Juliano CN, 2016, APPL IMMUNOHISTO M M, V24, P337, DOI 10.1097/PAI.0000000000000194
   Kelsey G, 2017, SCIENCE, V358, P69, DOI 10.1126/science.aan6826
   Knoechel B, 2014, NAT GENET, V46, P364, DOI 10.1038/ng.2913
   Kreso A, 2013, SCIENCE, V339, P543, DOI 10.1126/science.1227670
   Kurdistani SK, 2014, CURR OPIN GENET DEV, V26, P53, DOI 10.1016/j.gde.2014.06.002
   Kurdistani SK, 2011, PROG DRUG RES, V67, P91, DOI 10.1007/978-3-7643-8989-5_5
   Landan G, 2012, NAT GENET, V44, P1207, DOI 10.1038/ng.2442
   Landau DA, 2014, CANCER CELL, V26, P813, DOI 10.1016/j.ccell.2014.10.012
   Larkin J, 2012, NAT REV UROL, V9, P147, DOI 10.1038/nrurol.2011.236
   Li S, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0472-5
   Liao LL, 2015, CANCER GENET-NY, V208, P206, DOI 10.1016/j.cancergen.2015.02.008
   Lin DC, 2017, CANCER RES, V77, P2255, DOI 10.1158/0008-5472.CAN-16-2822
   Litzenburger UM, 2017, GENOME BIOL, V18, DOI 10.1186/s13059-016-1133-7
   Liu BL, 2010, CANCER EPIDEM BIOMAR, V19, P2888, DOI 10.1158/1055-9965.EPI-10-0454
   Lutsik P, 2017, GENOME BIOL, V18, DOI 10.1186/s13059-017-1182-6
   Macaulay IC, 2017, TRENDS GENET, V33, P155, DOI 10.1016/j.tig.2016.12.003
   Manuyakorn A, 2010, J CLIN ONCOL, V28, P1358, DOI 10.1200/JCO.2009.24.5639
   Martin-Subero JI, 2018, SEMIN CANCER BIOL, V51, P139, DOI 10.1016/j.semcancer.2017.08.008
   Martínez-Cardús A, 2016, GASTROENTEROLOGY, V151, P961, DOI 10.1053/j.gastro.2016.08.001
   Marusyk A, 2014, NATURE, V514, P54, DOI 10.1038/nature13556
   Marusyk A, 2012, NAT REV CANCER, V12, P323, DOI 10.1038/nrc3261
   Marzese DM, 2014, NEURO-ONCOLOGY, V16, P1499, DOI 10.1093/neuonc/nou107
   Mazor T, 2015, CANCER CELL, V28, P307, DOI 10.1016/j.ccell.2015.07.012
   Mazzucchelli R, 2011, INT J IMMUNOPATH PH, V24, P489, DOI 10.1177/039463201102400222
   McBrian MA, 2013, MOL CELL, V49, P310, DOI 10.1016/j.molcel.2012.10.025
   McGranahan N, 2017, CELL, V168, P613, DOI 10.1016/j.cell.2017.01.018
   Melvin A, 2012, CELL SIGNAL, V24, P35, DOI 10.1016/j.cellsig.2011.08.019
   Merlo LMF, 2006, NAT REV CANCER, V6, P924, DOI 10.1038/nrc2013
   Minner S, 2013, MODERN PATHOL, V26, P106, DOI 10.1038/modpathol.2012.130
   Moelans CB, 2014, MODERN PATHOL, V27, P869, DOI 10.1038/modpathol.2013.207
   Mosashvilli D, 2010, CANCER SCI, V101, P2664, DOI 10.1111/j.1349-7006.2010.01717.x
   Musselman CA, 2012, NAT STRUCT MOL BIOL, V19, P1218, DOI 10.1038/nsmb.2436
   Nagano T, 2017, NATURE, V547, P61, DOI 10.1038/nature23001
   Nagano T, 2015, NAT PROTOC, V10, P1986, DOI 10.1038/nprot.2015.127
   Nagano T, 2013, NATURE, V502, P59, DOI 10.1038/nature12593
   Navin N, 2011, NATURE, V472, P90, DOI 10.1038/nature09807
   Neelakantan D, 2015, CELL ADHES MIGR, V9, P265, DOI 10.4161/19336918.2014.972761
   Nestor C, 2010, BIOTECHNIQUES, V48, P317, DOI 10.2144/000113403
   Nik-Zainal S, 2012, CELL, V149, DOI 10.1016/j.cell.2012.04.023
   Noushmehr H, 2010, CANCER CELL, V17, P510, DOI 10.1016/j.ccr.2010.03.017
   NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840
   O'Hagan HM, 2011, CANCER CELL, V20, P606, DOI 10.1016/j.ccr.2011.09.012
   Oakes CC, 2014, CANCER DISCOV, V4, P348, DOI 10.1158/2159-8290.CD-13-0349
   Pan M, 2016, NAT CELL BIOL, V18, P1090, DOI 10.1038/ncb3410
   Park YS, 2008, ANN SURG ONCOL, V15, P1968, DOI 10.1245/s10434-008-9927-9
   Patel AP, 2014, SCIENCE, V344, P1396, DOI 10.1126/science.1254257
   Pepper JW, 2009, EVOL APPL, V2, P62, DOI 10.1111/j.1752-4571.2008.00063.x
   Pidsley R, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-1066-1
   Pistore C, 2017, ONCOGENE, V36, P5551, DOI 10.1038/onc.2017.159
   Plass C, 2013, NAT REV GENET, V14, P765, DOI 10.1038/nrg3554
   Prasetyanti PR, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0600-4
   Quek K, 2017, ONCOTARGET, V8, P21994, DOI 10.18632/oncotarget.15777
   Rahmani E, 2017, LECT N BIOINFORMAT, V10229, P207, DOI 10.1007/978-3-319-56970-3_13
   Ramani V, 2017, NAT METHODS, V14, P263, DOI [10.1038/NMETH.4155, 10.1038/nmeth.4155]
   Reuter S, 2010, FREE RADICAL BIO MED, V49, P1603, DOI 10.1016/j.freeradbiomed.2010.09.006
   Roesch A, 2016, EUR J CANCER, V59, P109, DOI 10.1016/j.ejca.2016.02.023
   Roesch A, 2010, CELL, V141, P583, DOI 10.1016/j.cell.2010.04.020
   Rogenhofer S, 2012, ANTICANCER RES, V32, P879
   Rogenhofer S, 2012, BJU INT, V109, P459, DOI 10.1111/j.1464-410X.2011.10278.x
   Rokavec M, 2016, CELL MOL LIFE SCI, V73, P23, DOI 10.1007/s00018-015-2045-5
   Rybinski B, 2016, ONCOTARGET, V7, P72322, DOI 10.18632/oncotarget.11875
   Schneider AC, 2011, BJU INT, V108, pE290, DOI 10.1111/j.1464-410X.2011.10203.x
   Schübeler D, 2015, NATURE, V517, P321, DOI 10.1038/nature14192
   Schwartzman O, 2015, NAT REV GENET, V16, P716, DOI 10.1038/nrg3980
   Seligson DB, 2009, AM J PATHOL, V174, P1619, DOI 10.2353/ajpath.2009.080874
   Seligson DB, 2005, NATURE, V435, P1262, DOI 10.1038/nature03672
   Shackleton M, 2009, CELL, V138, P822, DOI 10.1016/j.cell.2009.08.017
   Sharma SV, 2010, CELL, V141, P69, DOI 10.1016/j.cell.2010.02.027
   Shen H, 2013, CELL, V153, P38, DOI 10.1016/j.cell.2013.03.008
   Smallwood SA, 2014, NAT METHODS, V11, P817, DOI [10.1038/nmeth.3035, 10.1038/NMETH.3035]
   Song JS, 2012, PATHOL INT, V62, P182, DOI 10.1111/j.1440-1827.2011.02776.x
   Spencer DH, 2017, CELL, V168, P801, DOI 10.1016/j.cell.2017.01.021
   Sung MH, 2016, NAT METHODS, V13, P222, DOI 10.1038/nmeth.3766
   Suzuki J, 2009, CLIN CANCER RES, V15, P3163, DOI 10.1158/1078-0432.CCR-08-2319
   Tamagawa H, 2013, EJSO-EUR J SURG ONC, V39, P655, DOI 10.1016/j.ejso.2013.02.023
   Tomasetti C, 2015, SCIENCE, V347, P78, DOI 10.1126/science.1260825
   Torres CM, 2016, SCIENCE, V353, DOI 10.1126/science.aaf1644
   Tzao C, 2009, MODERN PATHOL, V22, P252, DOI 10.1038/modpathol.2008.172
   van den Beucken T, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6203
   Van Den Broeck A, 2008, CLIN CANCER RES, V14, P7237, DOI 10.1158/1078-0432.CCR-08-0869
   Venteicher AS, 2017, SCIENCE, V355, DOI 10.1126/science.aai8478
   VILLERS A, 1992, CANCER, V70, P2313, DOI 10.1002/1097-0142(19921101)70:9<2313::AID-CNCR2820700917>3.0.CO;2-T
   Visvader JE, 2008, NAT REV CANCER, V8, P755, DOI 10.1038/nrc2499
   Wainwright EN, 2017, TRENDS CANCER, V3, P372, DOI 10.1016/j.trecan.2017.04.004
   Wang Y, 2014, NATURE, V512, P155, DOI 10.1038/nature13600
   Weischenfeldt J, 2013, CANCER CELL, V23, P159, DOI 10.1016/j.ccr.2013.01.002
   Wen L, 2014, GENOME BIOL, V15, DOI 10.1186/gb-2014-15-3-r49
   Wu CT, 2001, SCIENCE, V293, P1103, DOI 10.1126/science.293.5532.1103
   Yatabe Y, 2001, P NATL ACAD SCI USA, V98, P10839, DOI 10.1073/pnas.191225998
   Yeo CD, 2017, KOREAN J INTERN MED, V32, P589, DOI 10.3904/kjim.2016.302
   Yokoyama Y, 2014, BREAST CANCER RES, V16, DOI 10.1186/bcr3681
   You JS, 2012, CANCER CELL, V22, P9, DOI 10.1016/j.ccr.2012.06.008
   Yu M, 2012, CELL, V149, P1368, DOI 10.1016/j.cell.2012.04.027
   Zhang YW, 2017, MOL CELL, V65, P323, DOI 10.1016/j.molcel.2016.12.013
NR 156
TC 40
Z9 45
U1 2
U2 8
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 1044-579X
EI 1096-3650
J9 SEMIN CANCER BIOL
JI Semin. Cancer Biol.
PD AUG
PY 2018
VL 51
BP 12
EP 21
DI 10.1016/j.semcancer.2018.01.010
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA GQ9DL
UT WOS:000442066000003
PM 29366906
OA hybrid
DA 2025-01-12
ER

PT J
AU Boyne, DJ
   King, WD
   Brenner, DR
   McIntyre, JB
   Courneya, KS
   Friedenreich, CM
AF Boyne, Devon J.
   King, Will D.
   Brenner, Darren R.
   McIntyre, John B.
   Courneya, Kerry S.
   Friedenreich, Christine M.
TI Aerobic exercise and DNA methylation in postmenopausal women: An
   ancillary analysis of the Alberta Physical Activity and Breast Cancer
   Prevention (ALPHA) Trial
SO PLOS ONE
LA English
DT Article
ID PROMOTER METHYLATION; GENOMIC INSTABILITY; WEIGHT-LOSS; ASSOCIATION;
   RISK; METAANALYSIS; APC; HYPERMETHYLATION; HYPOMETHYLATION;
   QUESTIONNAIRE
AB Physical activity is associated with a lower risk of breast, colon, and endometrial cancer. Epigenetic mechanisms such as changes in DNA methylation may help to explain these protective effects. We assessed the impact of a one year aerobic exercise intervention on DNA methylation biomarkers believed to play a role in carcinogenesis. The Alberta Physical Activity and Breast Cancer Prevention (ALPHA) Trial was a two-armed randomized controlled trial in 320 healthy, inactive, postmenopausal women with no history of cancer. In an ancillary analysis, frozen blood samples (n = 256) were reassessed for levels of DNA methylation within LINE-1 and Alu repeats as well as within the promoter regions of APC, BRCA1, RASSF1, and hTERT genes. Differences between the exercise and control arm at 12-months, after adjusting for baseline values, were estimated within an intent-to-treat and per-protocol analysis using linear regression. No significant differences in DNA methylation between the exercise and control arms were observed. In an exploratory analysis, we found that the prospective change in estimated VO(2)max was negatively associated with RASSF1 methylation in a dose-response manner (p-trend = 0.04). A year-long aerobic exercise intervention does not affect LINE-1, Alu, APC, BRCA1, RASSF1, or hTERT methylation in healthy, inactive, postmenopausal women. Changes in DNA methylation within these genomic regions may not mediate the association between physical activity and cancer in healthy postmenopausal women. Additional research is needed to validate our findings with RASSF1 methylation.
C1 [Boyne, Devon J.; Brenner, Darren R.; Friedenreich, Christine M.] Alberta Hlth Serv, CancerControl Alberta, Dept Canc Epidemiol Prevent Res, Calgary, AB, Canada.
   [Boyne, Devon J.; Brenner, Darren R.; Friedenreich, Christine M.] Univ Calgary, Cumming Sch Med, Dept Community Hlth Sci, Calgary, AB, Canada.
   [King, Will D.] Queens Univ, Dept Publ Hlth Sci, Kingston, ON, Canada.
   [Brenner, Darren R.; Friedenreich, Christine M.] Univ Calgary, Cumming Sch Med, Dept Oncol, Calgary, AB, Canada.
   [McIntyre, John B.] Univ Calgary, Dept Pathol & Lab Med, Tom Baker Canc Ctr, Translat Lab, Calgary, AB, Canada.
   [Courneya, Kerry S.] Univ Alberta, Fac Phys Educ & Recreat, Edmonton, AB, Canada.
C3 University of Calgary; Alberta Health Services (AHS); University of
   Calgary; Queens University - Canada; University of Calgary; Tom Baker
   Cancer Clinic; University of Calgary; University of Alberta
RP Friedenreich, CM (通讯作者)，Alberta Hlth Serv, CancerControl Alberta, Dept Canc Epidemiol Prevent Res, Calgary, AB, Canada.; Friedenreich, CM (通讯作者)，Univ Calgary, Cumming Sch Med, Dept Community Hlth Sci, Calgary, AB, Canada.; Friedenreich, CM (通讯作者)，Univ Calgary, Cumming Sch Med, Dept Oncol, Calgary, AB, Canada.
EM Christine.friedenreich@albertahealthservices.ca
RI Courneya, Kerry/AAJ-2712-2021; Friedenreich, Christine/LKJ-4397-2024;
   McIntyre, JB/ABE-9340-2021
OI Friedenreich, Christine/0000-0002-4783-1966
FU Canadian Breast Cancer Research Alliance [13576, 017468]; Alberta Cancer
   Foundation [22170]; Canadian Institutes for Health Research; Canadian
   Cancer Society [MOP-130238]; Alberta Cancer Foundation grant for the
   Biospecimen Processing Unit within the Translational Laboratories at the
   Tom Baker Cancer Centre; Queen's University Terry Fox Foundation
   Training Program in Transdisciplinary Cancer Research; Canadian
   Institutes for Health Research (CIHR); Ontario Graduate Scholarship;
   University of Calgary Ruby Doctoral Recruitment Scholarship; Faculty of
   Graduate Studies Doctoral Scholarship; Alberta Innovates Health
   Solutions Health Senior Scholar Award; Alberta Cancer Foundation Weekend
   to End Women's Cancers Breast Cancer Chair; Canada Research Chairs
   Program
FX The ALPHA Trial was originally funded by a research grant from the
   Canadian Breast Cancer Research Alliance (No. 13576 and No. 017468) and
   the Alberta Cancer Foundation (No. 22170) to Christine M Friedenreich.
   The ALPHA ancillary study was funded by grants from Canadian Institutes
   for Health Research and the Canadian Cancer Society (No. MOP-130238) to
   Christine M Friedenreich. Funding for the DNA extraction was provided by
   an Alberta Cancer Foundation grant for the Biospecimen Processing Unit
   within the Translational Laboratories at the Tom Baker Cancer Centre.
   The funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript. Devon J Boyne was
   supported by funding from the Queen's University Terry Fox Foundation
   Training Program in Transdisciplinary Cancer Research in partnership
   with the Canadian Institutes for Health Research (CIHR) and an Ontario
   Graduate Scholarship and is currently supported by the University of
   Calgary Ruby Doctoral Recruitment Scholarship and the Faculty of
   Graduate Studies Doctoral Scholarship. Christine M Friedenreich was
   supported by an Alberta Innovates Health Solutions Health Senior Scholar
   Award and by the Alberta Cancer Foundation Weekend to End Women's
   Cancers Breast Cancer Chair. Kerry S Courneya is supported by the Canada
   Research Chairs Program.
CR Adalsteinsson BT, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046705
   Ade C, 2013, CURR OPIN VIROL, V3, P639, DOI 10.1016/j.coviro.2013.09.002
   Barchitta M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109478
   Berdasco M, 2010, DEV CELL, V19, P698, DOI 10.1016/j.devcel.2010.10.005
   Brennan K, 2012, CANCER PREV RES, V5, P1345, DOI 10.1158/1940-6207.CAPR-12-0316
   Bryan AD, 2013, ANN BEHAV MED, V45, P89, DOI 10.1007/s12160-012-9411-4
   Campbell KL, 2012, J CLIN ONCOL, V30, P2314, DOI 10.1200/JCO.2011.37.9792
   Coyle YM, 2007, CANCER EPIDEM BIOMAR, V16, P192, DOI 10.1158/1055-9965.EPI-06-0700
   Csizmadi I, 2007, PUBLIC HEALTH NUTR, V10, P88, DOI 10.1017/S1368980007184287
   Daskalos A, 2009, INT J CANCER, V124, P81, DOI 10.1002/ijc.23849
   Denham J, 2014, SPORTS MED, V44, P189, DOI 10.1007/s40279-013-0114-1
   Ding D, 2016, LANCET, V388, P1311, DOI 10.1016/S0140-6736(16)30383-X
   Ding ZY, 2015, ONCOTARGETS THER, V8, P211, DOI 10.2147/OTT.S75827
   Duggan C, 2014, OBESITY, V22, P2091, DOI 10.1002/oby.20806
   Friedenreich CM, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-919
   Friedenreich CM, 2010, EUR J CANCER, V46, P2593, DOI 10.1016/j.ejca.2010.07.028
   Friedenreich CM, 2010, J CLIN ONCOL, V28, P1458, DOI 10.1200/JCO.2009.24.9557
   Friedenreich CM, 2006, AM J EPIDEMIOL, V163, P959, DOI 10.1093/aje/kwj112
   Garinis GA, 2002, HUM GENET, V111, P115, DOI 10.1007/s00439-002-0783-6
   Ho V, 2016, DATA BRIEF, V6, P39, DOI 10.1016/j.dib.2015.11.039
   Horsburgh S, 2015, EXERC IMMUNOL REV, V21, P26
   Jones MJ, 2015, AGING CELL, V14, P924, DOI 10.1111/acel.12349
   Joyce BT, 2016, BRIT J CANCER, V115, P465, DOI 10.1038/bjc.2016.205
   Kemp JR, 2015, FRONT CHEM, V3, DOI [10.3389/fchem.2075.00068, 10.3389/fchem.2015.00068]
   Kile ML, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013730
   Kochmanski J, 2017, TOXICOL SCI, V156, P325, DOI 10.1093/toxsci/kfx005
   Kyu HH, 2016, BMJ-BRIT MED J, V354, DOI 10.1136/bmj.i3857
   Lewis KA, 2016, FRONT GENET, V7, DOI 10.3389/fgene.2016.00083
   Lokk K, 2014, GENOME BIOL, V15, DOI 10.1186/gb-2014-15-4-r54
   Ma HX, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020466
   Monninkhof EM, 2007, BMC PUBLIC HEALTH, V7, DOI 10.1186/1471-2458-7-232
   Moore SC, 2016, JAMA INTERN MED, V176, P816, DOI 10.1001/jamainternmed.2016.1548
   Morabia A, 2012, PREV MED, V54, P229, DOI [10.1016/j.ypmed.2012.01.019, 10.1016/j.ypmed.2012.09.004]
   Nygaard V, 2016, BIOSTATISTICS, V17, P29, DOI 10.1093/biostatistics/kxv027
   Sandoval J, 2012, CURR OPIN GENET DEV, V22, P50, DOI 10.1016/j.gde.2012.02.008
   Sharma S, 2010, CARCINOGENESIS, V31, P27, DOI 10.1093/carcin/bgp220
   Shay JW, 2016, CANCER DISCOV, V6, P584, DOI 10.1158/2159-8290.CD-16-0062
   Shen CY, 2016, J OVARIAN RES, V9, DOI 10.1186/s13048-016-0271-6
   Shi DT, 2014, TUMOR BIOL, V35, P943, DOI 10.1007/s13277-013-1123-2
   Suchiman HED, 2015, FRONT GENET, V6, DOI 10.3389/fgene.2015.00287
   Tang QQ, 2016, CLIN EPIGENETICS, V8, DOI 10.1186/s13148-016-0282-6
   Teschendorff AE, 2017, BMC BIOINFORMATICS, V18, DOI 10.1186/s12859-017-1511-5
   van Gemert WAM, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-395
   Voisin S, 2015, ACTA PHYSIOL, V213, P39, DOI 10.1111/apha.12414
   White AJ, 2013, EUR J CANCER, V49, P2199, DOI 10.1016/j.ejca.2013.02.013
   Woo HD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034615
   Yu H, 2016, ENERG BALANCE CANCER, P251, DOI 10.1007/978-3-319-41610-6_11
   Zeng HM, 2012, BREAST CANCER RES TR, V133, P127, DOI 10.1007/s10549-011-1716-7
   Zhang FF, 2011, EPIGENETICS-US, V6, P293, DOI 10.4161/epi.6.3.14378
   Zhang L, 2015, SCI REP-UK, V5, DOI 10.1038/srep17869
NR 50
TC 7
Z9 8
U1 0
U2 9
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 28
PY 2018
VL 13
IS 6
AR e0198641
DI 10.1371/journal.pone.0198641
PG 13
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA GL0GK
UT WOS:000436645400006
PM 29953441
OA Green Published, Green Submitted, gold
DA 2025-01-12
ER

PT J
AU Lubecka, K
   Kaufman-Szymczyk, A
   Fabianowska-Majewska, K
AF Lubecka, Katarzyna
   Kaufman-Szymczyk, Agnieszka
   Fabianowska-Majewska, Krystyna
TI Inhibition of breast cancer cell growth by the combination of
   clofarabine and sulforaphane involves epigenetically mediated
   <i>CDKN2A</i> upregulation
SO NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS
LA English
DT Article
DE clofarabine; sulforaphane; DNA methylation; CDKN2A; tumour suppressor;
   breast cancer
ID TUMOR-SUPPRESSOR GENE; DNA METHYLATION; ADENOSINE-ANALOGS; RETINOIC
   ACID; EXPRESSION; MECHANISMS; SENESCENCE
AB Many antineoplastic nucleoside analogue-based combinatorial strategies focused on remodelling aberrant DNA methylation patterns have been developed. The number of studies demonstrate high efficacy of bioactive phytochemicals in support of conventional chemotherapy. Our recent discoveries of the epigenetic effects of clofarabine (2-deoxyadenosine analogue, antileukaemic drug) and clofarabine-based combinations with dietary bioactive compounds in breast cancer cells led us to look for more DNA methylation targets of these cancer-preventive agents. In the present study, using methylation-sensitive restriction analysis (MSRA) and qPCR, we showed that clofarabine in combination with sulforaphane, a phytochemical from cruciferous vegetables, significantly reactivates DNA methylation-silenced CDKN2A tumour suppressor and inhibits cancer cell growth at a non-invasive breast cancer stage.
C1 [Lubecka, Katarzyna; Kaufman-Szymczyk, Agnieszka; Fabianowska-Majewska, Krystyna] Med Univ Lodz, Dept Biomed Chem, 6-8 Mazowiecka St, PL-92215 Lodz, Poland.
   [Fabianowska-Majewska, Krystyna] Lazarski Univ, Fac Med, Warsaw, Poland.
C3 Medical University Lodz; Uczelnia Lazarskiego w Warszawie
RP Lubecka, K (通讯作者)，Med Univ Lodz, Dept Biomed Chem, 6-8 Mazowiecka St, PL-92215 Lodz, Poland.
EM katarzyna.lubecka-pietruszewska@umed.lodz.pl
RI Lubecka, Katarzyna/S-9731-2016; Kaufman-Szymczyk, Agnieszka/S-9624-2016
OI Fabianowska-Majewska, Krystyna/0000-0003-3386-6911; Kaufman-Szymczyk,
   Agnieszka/0000-0001-6014-7280; Lubecka-Gajewska,
   Katarzyna/0000-0002-4250-0922
FU National Science Centre in Poland [DEC-2011/01/N/NZ2/01697]; Medical
   University of Lodz [502-03/6-099-01/502-64-007,
   502-03/6-099-01/502-64-057, 503/6-099-01/503-61-001]
FX The National Science Centre in Poland [DEC-2011/01/N/NZ2/01697]; Medical
   University of Lodz
   [502-03/6-099-01/502-64-007,502-03/6-099-01/502-64-057,503/6-099-01/503-
   61-001].
CR Barrera LN, 2013, EUR J NUTR, V52, P1327, DOI 10.1007/s00394-012-0442-1
   Chou TC, 2008, LEUKEMIA LYMPHOMA, V49, P2059, DOI 10.1080/10428190802353591
   Danaei G, 2005, LANCET, V366, P1784, DOI 10.1016/S0140-6736(05)67725-2
   Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210
   Hara E, 1996, MOL CELL BIOL, V16, P859
   Iwase H, 1999, BRIT J CANCER, V80, P1982, DOI 10.1038/sj.bjc.6690631
   Kaufman-Szymczyk A, 2015, INT J MOL SCI, V16, P29732, DOI 10.3390/ijms161226195
   Kimura H, 2003, NUCLEIC ACIDS RES, V31, P3101, DOI 10.1093/nar/gkg406
   Lacroix M, 2006, ENDOCR-RELAT CANCER, V13, P293, DOI 10.1677/erc.1.01172
   Li JN, 2011, BIOCHEMISTRY-US, V50, P5566, DOI 10.1021/bi200642e
   Linnekamp JF, 2017, CANCER TREAT REV, V54, P10, DOI 10.1016/j.ctrv.2017.01.004
   Lubecka K, 2016, CARCINOGENESIS, V37, P656, DOI 10.1093/carcin/bgw048
   Lubecka-Pietruszewska K, 2015, J NUTRIGENET NUTRIGE, V8, P91, DOI 10.1159/000439111
   Lubecka-Pietruszewska K, 2014, EUR J PHARMACOL, V723, P276, DOI 10.1016/j.ejphar.2013.11.021
   Lubecka-Pietruszewska K, 2013, BIOCHEM BIOPH RES CO, V430, P623, DOI 10.1016/j.bbrc.2012.11.103
   Majda K, 2011, ACTA POL PHARM, V68, P459
   Mannargudi MB, 2017, J CANCER RES CLIN, V143, P1499, DOI 10.1007/s00432-017-2457-8
   Pfaffl MW, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.9.e36
   Rayess H, 2012, INT J CANCER, V130, P1715, DOI 10.1002/ijc.27316
   Stefanska B, 2012, BRIT J NUTR, V107, P781, DOI 10.1017/S0007114511003631
   Stefanska B, 2010, EUR J PHARMACOL, V638, P47, DOI 10.1016/j.ejphar.2010.04.032
NR 21
TC 17
Z9 17
U1 0
U2 3
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1525-7770
EI 1532-2335
J9 NUCLEOS NUCLEOT NUCL
JI Nucleosides Nucleotides Nucleic Acids
PY 2018
VL 37
IS 5
BP 280
EP 289
DI 10.1080/15257770.2018.1453075
PG 10
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA GQ4RZ
UT WOS:000441662400003
PM 29634384
DA 2025-01-12
ER

PT J
AU Abdallah, MOE
   Algizouli, UK
   Suliman, MA
   Abdulrahman, RA
   Koko, M
   Fessahaye, G
   Shakir, JH
   Fahal, AH
   Elhassan, AM
   Ibrahim, ME
   Mohamed, HS
AF Abdallah, Mohammad O. E.
   Algizouli, Ubai K.
   Suliman, Maram A.
   Abdulrahman, Rawya A.
   Koko, Mahmoud
   Fessahaye, Ghimja
   Shakir, Jamal H.
   Fahal, Ahmed H.
   Elhassan, Ahmed M.
   Ibrahim, Muntaser E.
   Mohamed, Hiba S.
TI EBV Associated Breast Cancer Whole Methylome Analysis Reveals Viral and
   Developmental Enriched Pathways
SO FRONTIERS IN ONCOLOGY
LA English
DT Article
DE methylome; breast cancer; epigenetics; DNA methylation; HM450; epigenome
   reference; EBV
ID EPSTEIN-BARR-VIRUS; DNA METHYLATION; PROMOTER HYPERMETHYLATION;
   EPITHELIAL-CELLS; GENE-EXPRESSION; STEM-CELLS; SUDAN; CARCINOMA; YAP;
   CARCINOGENESIS
AB Background: Breast cancer (BC) ranks among the most common cancers in Sudan and worldwide with hefty toll on female health and human resources. Recent studies have uncovered a common BC signature characterized by low frequency of oncogenic mutations and high frequency of epigenetic silencing of major BC tumor suppressor genes. Therefore, we conducted a pilot genome-wide methylome study to characterize aberrant DNA methylation in breast cancer.
   Results: Differential methylation analysis between primary tumor samples and normal samples from healthy adjacent tissues yielded 20,188 differentially methylated positions (DMPs), which is further divided into 13,633 hypermethylated sites corresponding to 5339 genes and 6,555 hypomethylated sites corresponding to 2811 genes. Moreover, bioinformatics analysis revealed epigenetic dysregulation of major developmental pathways including hippo signaling pathway. We also uncovered many clues to a possible role for EBV infection in BC.
   Conclusion: Our results clearly show the utility of epigenetic assays in interrogating breast cancer tumorigenesis, and pinpointing specific developmental and viral pathways dysregulation that might serve as potential biomarkers or targets for therapeutic interventions.
C1 [Abdallah, Mohammad O. E.; Algizouli, Ubai K.; Suliman, Maram A.; Abdulrahman, Rawya A.; Koko, Mahmoud; Fessahaye, Ghimja; Elhassan, Ahmed M.; Ibrahim, Muntaser E.; Mohamed, Hiba S.] Univ Khartoum, Inst Endem Dis, Dept Mol Biol, Khartoum, Sudan.
   [Shakir, Jamal H.] Khartoum Teaching Hosp, Dept Surg, Khartoum, Sudan.
   [Fahal, Ahmed H.] Univ Khartoum, Dept Surg, Fac Med, Khartoum, Sudan.
   [Mohamed, Hiba S.] Taibah Univ, Dept Biol, Medina, Saudi Arabia.
C3 University of Khartoum; University of Khartoum; Taibah University
RP Mohamed, HS (通讯作者)，Univ Khartoum, Inst Endem Dis, Dept Mol Biol, Khartoum, Sudan.; Mohamed, HS (通讯作者)，Taibah Univ, Dept Biol, Medina, Saudi Arabia.
EM hibasalah@iend.org
RI Fahal, Ahmed/H-9573-2012; Hassan, Ahmed/AAB-7241-2019; Koko,
   Mahmoud/U-7135-2018
OI Koko, Mahmoud/0000-0001-9512-0184; Mohamed, Hiba/0000-0003-4227-0212;
   Abdallah, Mohammed/0000-0002-5374-0657
FU international Centre for Genetic Engineering and Biotechnology (ICGEB)
   Project [CRP/SUD/10-01]
FX This work received financial support from the international Centre for
   Genetic Engineering and Biotechnology (ICGEB) Project CRP/SUD/10-01.
CR Ahmed Awad Ali Mohamed, 2014, Breast Dis, V34, P131, DOI 10.3233/BD-140363
   [Anonymous], 2004, Stat. Appl. Genet. Mol. Biol., DOI [10.2202/1544-6115.1027, DOI 10.2202/1544-6115.1027]
   Awadelkarim KD, 2008, HISTOPATHOLOGY, V52, P445, DOI 10.1111/j.1365-2559.2008.02966.x
   Bediaga NG, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2721
   Berman H, 2005, COLD SH Q B, V70, P317, DOI 10.1101/sqb.2005.70.051
   Blankenberg Daniel, 2010, Curr Protoc Mol Biol, VChapter 19, DOI 10.1002/0471142727.mb1910s89
   Bock C, 2009, EPIGENOMICS-UK, V1, P99, DOI [10.2217/epi.09.6, 10.2217/EPI.09.6]
   Chiang KC, 2015, SCI REP-UK, V5, DOI 10.1038/srep08686
   Cho JH, 2013, J BIOL CHEM, V288, P3406, DOI 10.1074/jbc.M112.422931
   Conway K, 2014, BREAST CANCER RES, V16, DOI 10.1186/s13058-014-0450-6
   Dedeurwaerder S, 2011, EPIGENOMICS-UK, V3, P771, DOI [10.2217/EPI.11.105, 10.2217/epi.11.105]
   Dumont N, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2457
   Elamin A, 2015, CANCER MED-US, V4, P447, DOI 10.1002/cam4.378
   Elgaili EM, 2010, INT J WOMENS HEALTH, V2, P77
   Fackler MJ, 2014, CANCER RES, V74, P2160, DOI 10.1158/0008-5472.CAN-13-3392
   Fleischer T, 2014, GENOME BIOL, V15, DOI [10.1186/s13059-014-0435-x, 10.1186/PREACCEPT-2333349012841587]
   Giardine B, 2005, GENOME RES, V15, P1451, DOI 10.1101/gr.4086505
   Goecks J, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-8-r86
   Gonzalez ME, 2014, P NATL ACAD SCI USA, V111, P3098, DOI 10.1073/pnas.1308953111
   Gulley ML, 2015, EXP MOL MED, V47, DOI 10.1038/emm.2014.93
   Hiemer SE, 2014, J BIOL CHEM, V289, P13461, DOI 10.1074/jbc.M113.529115
   Hon GC, 2012, GENOME RES, V22, P246, DOI 10.1101/gr.125872.111
   Huang WY, 2015, NUCLEIC ACIDS RES, V43, pD856, DOI 10.1093/nar/gku1151
   Kalari S, 2010, ADV GENET, V70, P277, DOI [10.1016/B978-0-12-380866-0.60010-1, 10.1016/S0065-2660(10)70010-9]
   Katz TA, 2014, ANN MED, V46, P397, DOI 10.3109/07853890.2014.923740
   Keren-Paz A, 2015, NAT GENET, V47, P193, DOI 10.1038/ng.3228
   Kundaje A, 2015, NATURE, V518, P317, DOI 10.1038/nature14248
   Lechner M, 2013, GENOME MED, V5, DOI 10.1186/gm419
   Li LL, 2014, CHIN J CANCER, V33, P604, DOI 10.5732/cjc.014.10191
   Lin DC, 2014, NAT GENET, V46, P866, DOI 10.1038/ng.3006
   Lin LP, 2015, NAT GENET, V47, P250, DOI 10.1038/ng.3218
   List M, 2014, J INTEGR BIOINFORMAT, V11, pCP4, DOI 10.2390/biecoll-jib-2014-236
   Liu HX, 2015, J ZHEJIANG UNIV-SC B, V16, P10, DOI 10.1631/jzus.B1400172
   Lokk K, 2014, GENOME BIOL, V15, DOI 10.1186/gb-2014-15-4-r54
   Marzese DM, 2012, J MOL DIAGN, V14, P613, DOI 10.1016/j.jmoldx.2012.07.001
   Masri MA, 2002, BREAST CANCER RES TR, V71, P145, DOI 10.1023/A:1013807830329
   McLean CY, 2010, NAT BIOTECHNOL, V28, P495, DOI 10.1038/nbt.1630
   Meier-Abt F, 2015, CANCER RES, V75, P803, DOI 10.1158/0008-5472.CAN-14-2717
   Moarii M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103986
   Naumov VA, 2013, EPIGENETICS-US, V8, P921, DOI 10.4161/epi.25577
   Nestor CE, 2015, GENOME BIOL, V16, DOI 10.1186/s13059-014-0576-y
   Niller HH, 2014, FRONT GENET, V5, DOI 10.3389/fgene.2014.00367
   Polytarchou C, 2012, P NATL ACAD SCI USA, V109, P14470, DOI 10.1073/pnas.1212811109
   Qin WY, 2014, NUTR CANCER, V66, P270, DOI 10.1080/01635581.2014.868910
   Reyngold M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103896
   Rhee JK, 2013, NUCLEIC ACIDS RES, V41, P8464, DOI 10.1093/nar/gkt643
   Ruike Y, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-137
   Saeed IE, 2014, CANCER MED-US, V3, P1075, DOI 10.1002/cam4.254
   Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303
   Shi PG, 2015, ACTA BIOCH BIOPH SIN, V47, P53, DOI 10.1093/abbs/gmu114
   Stefansson OA, 2015, MOL ONCOL, V9, P555, DOI 10.1016/j.molonc.2014.10.012
   Stirzaker C, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms6899
   Tommasi S, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2233
   Uozaki H, 2008, INT J CLIN EXP PATHO, V1, P198
   Urrutia G, 2015, CLIN EXP METASTAS, V32, P99, DOI 10.1007/s10585-015-9695-4
   van Vlerken LE, 2013, STEM CELL TRANSL MED, V2, P43, DOI 10.5966/sctm.2012-0036
   Wang D, 2014, MOL CELL BIOCHEM, V396, P67, DOI 10.1007/s11010-014-2143-y
   Wessely Frank, 2012, Frontiers in Genetics, V3, P161, DOI 10.3389/fgene.2012.00161
   Wizard R, GENOMIC DNA PURIFICA
   Wu GM, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-5-r53
   Xu JH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117097
   Yahia ZA, 2014, INFECT AGENTS CANCER, V9, DOI 10.1186/1750-9378-9-9
   Yeon S, 2012, MODERN PATHOL, V25, P185, DOI 10.1038/modpathol.2011.160
   Zhao JH, 2013, CANCER-AM CANCER SOC, V119, P304, DOI 10.1002/cncr.27724
   Zhu WZ, 2012, NUTR CANCER, V64, P393, DOI 10.1080/01635581.2012.654926
   Zhu WZ, 2010, INT J CANCER, V126, P474, DOI 10.1002/ijc.24728
NR 66
TC 12
Z9 12
U1 1
U2 4
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2234-943X
J9 FRONT ONCOL
JI Front. Oncol.
PD AUG 13
PY 2018
VL 8
AR 316
DI 10.3389/fonc.2018.00316
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA GQ1MW
UT WOS:000441397500001
PM 30151354
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Axelsson, U
   Rydén, L
   Johnsson, P
   Edén, P
   Månsson, J
   Hallberg, IR
   Borrebaeck, CAK
AF Axelsson, Ulrika
   Ryden, Lisa
   Johnsson, Per
   Eden, Patrik
   Mansson, Johanna
   Hallberg, Ingalill Rahm
   Borrebaeck, Carl A. K.
TI A multicenter study investigating the molecular fingerprint of
   psychological resilience in breast cancer patients: study protocol of
   the SCAN-B resilience study
SO BMC CANCER
LA English
DT Article
DE Psychological resilience; Body and mind; Biomolecular parameters; Breast
   cancer; Quality of life; CD-RISC; SF36; Epigenetics
ID HEALTH SURVEY; CD-RISC; INTERVENTIONS; PROGRESSION; STRESS; SF-36
AB Background: Individual patients differ in their psychological response when receiving a cancer diagnosis, in this case breast cancer. Given the same disease burden, some patients master the situation well, while others experience a great deal of stress, depression and lowered quality of life. Patients with high psychological resilience are likely to experience fewer stress reactions and better adapt to and manage the life threat and the demanding treatment that follows the diagnosis. If this phenomenon of mastering difficult situations is reflected also in biomolecular processes is not much studied, nor has its capacity for impacting the cancer prognosis been addressed. This project specifically aims, for the first time, to investigate how a breast cancer patient's psychological resilience is coupled to biomolecular parameters using advanced "omits" and, as a secondary aim, whether it relates to prognosis and quality of life one year after diagnosis.
   Method: The study population consists of newly diagnosed breast cancer patients enrolled in the Sweden Cancerome Analysis Network - Breast (SCAN-B) at four hospitals in Sweden. At the time of cancer diagnosis, the patient fills out the standardized method to measure psychological resilience, the "Connor-Davidson Resilience scale" (CD-RISC), the quality of life measure SF-36, as well as providing social and socioeconomic variables. In addition, one blood sample is collected. At the one-year follow-up, the patient will be subjected to the same assessments, and we also collect information regarding smoking, exercise habits, and BMI, as well as patients' trust in the treatment and their satisfaction with the care and treatment.
   Discussion: This explorative hypothesis-generating project will pave the way for larger validation studies, potentially leading to a standardized method of measuring psychological resilience as an important parameter in cancer care. Revealing the body-mind interaction, in terms of psychological resilience and quality of life, will herald the development of truly personalized psychosocial care and cancer intervention treatment strategies.
C1 [Axelsson, Ulrika; Borrebaeck, Carl A. K.] Lund Univ, Dept Immunotechnol, Medicon Village Bldg 406, S-22381 Lund, Sweden.
   [Axelsson, Ulrika; Borrebaeck, Carl A. K.] Lund Univ, CREATE Hlth Translat Canc Ctr, Medicon Village Bldg 406, S-22381 Lund, Sweden.
   [Ryden, Lisa] Lund Univ, Dept Clin Sci, Surg, Sodra Forstadsgatan 1, S-21428 Malmo, Sweden.
   [Ryden, Lisa] Skane Univ Hosp, Dept Surg, Sodra Forstadsgatan 1, S-21428 Malmo, Sweden.
   [Johnsson, Per; Mansson, Johanna] Lund Univ, Dept Psychol, Box 213, S-22100 Lund, Sweden.
   [Eden, Patrik] Lund Univ, Dept Astron & Theoret Phys, Computat Biol & Biol Phys, S-22362 Lund, Sweden.
   [Hallberg, Ingalill Rahm] Lund Univ, Dept Hlth Sci, Lund, Sweden.
   [Hallberg, Ingalill Rahm] Lund Univ, Pufendorf Inst, SE-22100 Lund, Sweden.
C3 Lund University; Lund University; Lund University; Lund University;
   Skane University Hospital; Lund University; Lund University; Lund
   University; Lund University
RP Axelsson, U (通讯作者)，Lund Univ, Dept Immunotechnol, Medicon Village Bldg 406, S-22381 Lund, Sweden.; Axelsson, U (通讯作者)，Lund Univ, CREATE Hlth Translat Canc Ctr, Medicon Village Bldg 406, S-22381 Lund, Sweden.
EM Ulrika.axelsson@immun.lth.se
RI Hallberg, Ingalill/AAP-5858-2021
OI Ryden, Lisa/0000-0001-7515-3130; Axelsson, Ulrika/0000-0002-3712-4897
FU Gunnar Nilsson foundation; VINNOVA
FX This study is funded by: Philanthropic donations, Gunnar Nilsson
   foundation and VINNOVA.
CR Connor KM, 2003, DEPRESS ANXIETY, V18, P76, DOI 10.1002/da.10113
   Craig A, 2011, J SPEECH LANG HEAR R, V54, P1485, DOI 10.1044/1092-4388(2011/10-0304)
   Ding Y, 2012, PSYCHO-ONCOLOGY, V21, P1205, DOI 10.1002/pon.2029
   Green KT, 2014, ASSESSMENT, V21, P443, DOI 10.1177/1073191114524014
   Herrman H, 2011, CAN J PSYCHOL, V56, P5
   Joreskog K.G., 1979, ADV FACTOR ANAL STRU, P21
   Lutgendorf SK, 2008, CLIN CANCER RES, V14, P6839, DOI 10.1158/1078-0432.CCR-08-0230
   Lutgendorf SK, 2015, AM PSYCHOL, V70, P186, DOI 10.1037/a0035730
   Lutgendorf SK, 2010, J CLIN ONCOL, V28, P4094, DOI 10.1200/JCO.2009.26.9357
   Min JA, 2013, SUPPORT CARE CANCER, V21, P2469, DOI 10.1007/s00520-013-1807-6
   Moreno-Smith M, 2010, FUTURE ONCOL, V6, P1863, DOI [10.2217/fon.10.142, 10.2217/FON.10.142]
   Roos JM, 2016, ONKOLOGI SVERIGE, V2, P32
   Rydén L, 2018, BRIT J SURG, V105, pE158, DOI 10.1002/bjs.10741
   Saal LH, 2015, GENOME MED, V7, DOI 10.1186/s13073-015-0131-9
   Smith-Osborne A, 2013, J EVID-INFORM SOC WO, V10, P111, DOI 10.1080/15433714.2011.597305
   Southwick SM, 2005, ANNU REV CLIN PSYCHO, V1, P255, DOI 10.1146/annurev.clinpsy.1.102803.143948
   SULLIVAN M, 1995, SOC SCI MED, V41, P1349, DOI 10.1016/0277-9536(95)00125-Q
   Sullivan M., 2002, SF-36 Health Survey. Swedish manual and interpretation guide
   WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002
   Windle G, 2011, HEALTH QUAL LIFE OUT, V9, DOI 10.1186/1477-7525-9-8
NR 20
TC 15
Z9 16
U1 1
U2 10
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471-2407
J9 BMC CANCER
JI BMC Cancer
PD AUG 6
PY 2018
VL 18
AR 789
DI 10.1186/s12885-018-4669-y
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Oncology
GA GP9FO
UT WOS:000441223100005
PM 30081937
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU Ulker, D
   Ersoy, YE
   Gucin, Z
   Muslurnanoglu, M
   Buyru, N
AF Ulker, Damla
   Ersoy, Yeliz Emine
   Gucin, Zuhal
   Muslurnanoglu, Mahmut
   Buyru, Nur
TI Downregulation of <i>SCARA5</i> may contribute to breast cancer via
   promoter hypermethylation
SO GENE
LA English
DT Article
DE SCARA5; Breast cancer; Expression; Promoter methylation
ID SCAVENGER RECEPTOR; SIGNALING PATHWAYS; EXPRESSION; GENE; METASTASIS;
   MACROPHAGE
AB Breast cancer is the most common malignant tumor in women worldwide. Breast tumors mostly exhibit aberrant gene expression and DNA hypermethylation patterns that predispose the disease. Understanding the genetic and epigenetic factors that contribute to breast cancer development is important to identify novel diagnostic and prognostic markers. SCARA5: Scavenger receptor class A, member 5; is a member of the scavenger receptor family located on chromosome 8p21 which is a frequently deleted region in human cancers. SCARA5 has been identified as a candidate tumor suppressor gene in various kinds of cancer. However, its role in breast cancer remains unclear. Therefore, in the present study SCARA5 expression levels in breast tumors and matched noncancerous tissue samples from 77 patients were analyzed by qRT-PCR and the expression levels were correlated with the methylation level of SCARA5 gene promoter. We found that SCARA5 expression was significantly decreased in tumors (92.2%) compared to non-cancerous tissue samples and this down-regulation was associated with hypermethylation of the promoter (p < 0.001). A significant correlation was also detected between SCARA5 expression and the histological grade of the breast tumors (p = 0.017). Taken together, our results indicate that SCARA5 may play an important role in tumorigenesis of breast cancer via promoter methylation.
C1 [Ulker, Damla; Buyru, Nur] Istanbul Univ, Cerrahpasa Med Fac, Dept Med Biol, TR-34098 Istanbul, Turkey.
   [Ersoy, Yeliz Emine] Bezmialem Vakif Univ, Med Fac, Dept Gen Surg, Istanbul, Turkey.
   [Gucin, Zuhal] Bezmialem Vakif Univ, Med Fac, Dept Med Pathol, Istanbul, Turkey.
   [Muslurnanoglu, Mahmut] Istanbul Univ, Cepa Med Fac, Dept Gen Surg, Istanbul, Turkey.
C3 Istanbul University; Istanbul University - Cerrahpasa; Bezmialem Vakif
   University; Bezmialem Vakif University; Istanbul University
RP Buyru, N (通讯作者)，Istanbul Univ, Cerrahpasa Med Fac, Dept Med Biol, TR-34098 Istanbul, Turkey.
EM nsayhan@istanbul.edu.tr
RI Ersoy, Yeliz/AAC-6326-2020; gucin, zuhal/AAK-9237-2020; Buyru,
   Nur/D-1810-2019
OI Buyru, Nur/0000-0002-6920-1455
FU Research Fund of Istanbul University [45027]
FX The present study was supported by the Research Fund of Istanbul
   University (Project No: 45027).
CR BROWN MS, 1983, ANNU REV BIOCHEM, V52, P223, DOI 10.1146/annurev.bi.52.070183.001255
   Coleman W.B, 2017, SERIES EDS SPRINGER
   Ezzat K, 2012, FASEB J, V26, P1172, DOI 10.1096/fj.11-191536
   FEINBERG AP, 1983, NATURE, V301, P89, DOI 10.1038/301089a0
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Hoffman RM, 2015, NAT REV CANCER, V15, P451, DOI 10.1038/nrc3972
   Huang J, 2010, J CLIN INVEST, V120, P223, DOI 10.1172/JCI38012
   JEMAL A, 2011, CA-CANCER J CLIN, V61, P69, DOI DOI 10.3322/CAAC.20107
   Khamas A, 2012, CANCER GENOM PROTEOM, V9, P67
   Li JY, 2009, DEV CELL, V16, P35, DOI 10.1016/j.devcel.2008.12.002
   Liu J, 2013, ONCOGENESIS, V2, DOI 10.1038/oncsis.2013.37
   Martin GS, 2001, NAT REV MOL CELL BIO, V2, P467, DOI 10.1038/35073094
   Menssen A, 2011, BMC GENOMICS, V12, DOI 10.1186/1471-2164-12-461
   Murphy JE, 2005, ATHEROSCLEROSIS, V182, P1, DOI 10.1016/j.atherosclerosis.2005.03.036
   Ohtani K, 2001, J BIOL CHEM, V276, P44222, DOI 10.1074/jbc.M103942200
   Plüddemann A, 2007, METHODS, V43, P207, DOI 10.1016/j.ymeth.2007.06.004
   Reiske HR, 2000, FEBS LETT, V486, P275, DOI 10.1016/S0014-5793(00)02295-X
   Sarraj MA, 2005, DEV DYNAM, V234, P1026, DOI 10.1002/dvdy.20594
   Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73
   Tabarés-Seisdedos R, 2009, MOL PSYCHIATR, V14, P563, DOI 10.1038/mp.2009.2
   Varkaris A, 2014, CANCER METAST REV, V33, P595, DOI 10.1007/s10555-013-9481-1
   Wen XZ, 2016, MOL MED REP, V13, P2885, DOI 10.3892/mmr.2016.4857
   Xu Z, 2016, BIOCHEM BIOPH RES CO, V480, P586, DOI 10.1016/j.bbrc.2016.10.097
   Yan N, 2012, CANCER SCI, V103, P1631, DOI 10.1111/j.1349-7006.2012.02350.x
   Yanyan JY, 2006, J BIOL CHEM, V281, P11834, DOI 10.1074/jbc.M507599200
   You K, 2017, MOL CELL BIOCHEM, V435, P47, DOI 10.1007/s11010-017-3055-4
NR 26
TC 29
Z9 31
U1 0
U2 11
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0378-1119
EI 1879-0038
J9 GENE
JI Gene
PD OCT 5
PY 2018
VL 673
BP 102
EP 106
DI 10.1016/j.gene.2018.06.036
PG 5
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA GP6AR
UT WOS:000440959800012
PM 29908284
DA 2025-01-12
ER

PT J
AU Li, YY
   Buckhaults, P
   Li, SZ
   Tollefsbol, T
AF Li, Yuanyuan
   Buckhaults, Phillip
   Li, Shizhao
   Tollefsbol, Trygve
TI Temporal Efficacy of a Sulforaphane-Based Broccoli Sprout Diet in
   Prevention of Breast Cancer through Modulation of Epigenetic Mechanisms
SO CANCER PREVENTION RESEARCH
LA English
DT Article
ID GENE-EXPRESSION; DNA METHYLATION; MATERNAL DIET; IMPACT; RISK
AB Breast cancer is the most common cancer and the second leading cause of cancer-related death among women. An important risk factor for breast cancer is individual genetic background, which is initially generated early in human life, for example, during the processes of embryogenesis and fetal development in utero. Bioactive dietary components such as sulforaphane (SFN), an isothiocyanate from cruciferous vegetables including broccoli sprouts (BSp), cabbage, and kale, has been shown to reduce the risk of developing many common cancers through regulation of epigenetic mechanisms. Our study indicates a prenatal/maternal BSp dietary treatment exhibited maximal preventive effects in inhibiting breast cancer development compared with postnatal early-life and adult BSp treatments in two transgenic mouse models that can develop breast cancer. Postnatal early-life BSp treatment starting prior to puberty onset showed protective effects in prevention of breast cancer but was not as effective as the prenatal/maternal BSp treatment. However, adulthood-administered BSp diet did not reduce mammary tumorigenesis. Our results suggest that the prenatal/maternal BSp bioactive natural plant product may impact early embryonic development by regulating global differential gene expression through affecting epigenetic profiles resulting in differential susceptibility to breast cancer later in life. These results suggest that a temporal exposure to epigenetic-modulating dietary components such as cruciferous vegetables could be a key factor for maximizing chemopreventive effects on human breast cancer. This study may lead to translational breast cancer chemopreventive potential by appropriate administration of key dietary components leading to early breast cancer prevention in humans. (C) 2018 AACR.
C1 [Li, Yuanyuan] Univ Alabama Birmingham, Dept Pharmacol & Toxicol, Birmingham, AL 35294 USA.
   [Li, Yuanyuan; Tollefsbol, Trygve] Univ Alabama Birmingham, Comprehens Canc Ctr, Birmingham, AL 35294 USA.
   [Li, Yuanyuan; Tollefsbol, Trygve] Univ Alabama Birmingham, Nutr Obes Res Ctr, Birmingham, AL 35294 USA.
   [Buckhaults, Phillip] Univ South Carolina, Dept Drug Discovery & Biomed Sci, Columbia, SC USA.
   [Li, Shizhao; Tollefsbol, Trygve] Univ Alabama Birmingham, Dept Biol, Birmingham, AL 35294 USA.
   [Tollefsbol, Trygve] Univ Alabama Birmingham, Comprehens Ctr Hlth Aging, Birmingham, AL 35294 USA.
C3 University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham;
   University of South Carolina System; University of South Carolina
   Columbia; University of Alabama System; University of Alabama
   Birmingham; University of Alabama System; University of Alabama
   Birmingham
RP Li, YY (通讯作者)，Univ Alabama Birmingham, CH 175,1300 Univ Blvd, Birmingham, AL 35294 USA.
EM lyy@uab.edu
RI Li, Shizhao/ABV-9057-2022
OI Li, Shizhao/0000-0002-3464-1450
FU NIH [R01 CA178441, R01 CA204346, K01 AT009373]; American Institute for
   Cancer Research [AICR 316184]
FX This work was supported by grants from the NIH R01 CA178441 (to T.
   Tollefsbol), R01 CA204346 (to T. Tollefsbol), and K01 AT009373 (to Y.
   Li) and the American Institute for Cancer Research AICR 316184 (to T.
   Tollefsbol).
CR Bjornsson HT, 2004, TRENDS GENET, V20, P350, DOI 10.1016/j.tig.2004.06.009
   Black AM, 2015, BEHAV BRAIN RES, V291, P289, DOI 10.1016/j.bbr.2015.05.033
   Cheung KL, 2010, AAPS J, V12, P87, DOI 10.1208/s12248-009-9162-8
   Cho HY, 2013, FASEB J, V27, P1142
   Dolinoy DC, 2006, ENVIRON HEALTH PERSP, V114, P567, DOI 10.1289/ehp.8700
   Eceles SA, 2001, J MAMMARY GLAND BIOL, V6, P393, DOI 10.1023/A:1014730829872
   Higdon JV, 2007, PHARMACOL RES, V55, P224, DOI 10.1016/j.phrs.2007.01.009
   Hilakivi-Clarke L, 1999, NUTRITION, V15, P392, DOI 10.1016/S0899-9007(99)00029-5
   Ho E, 2009, J NUTR, V139, P2393, DOI 10.3945/jn.109.113332
   Jaenisch R, 2003, NAT GENET, V33, P245, DOI 10.1038/ng1089
   King MC, 2003, SCIENCE, V302, P643, DOI 10.1126/science.1088759
   Li E, 2002, NAT REV GENET, V3, P662, DOI 10.1038/nrg887
   Li Y, 2010, CURR MED CHEM, V17, P2141, DOI 10.2174/092986710791299966
   Li YY, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-09764-3
   Li YY, 2016, EPIGENOMICS-UK, V8, P1019, DOI 10.2217/epi-2016-0024
   Li YY, 2014, AAPS J, V16, P27, DOI 10.1208/s12248-013-9538-7
   Li YY, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-9
   Li YY, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0055108, 10.1371/journal.pone.0052093, 10.1371/journal.pone.0063648, 10.1371/journal.pone.0077685, 10.1371/journal.pone.0062036, 10.1371/journal.pone.0054369, 10.1371/journal.pone.0066567, 10.1371/journal.pone.0071994]
   Lillycrop KA, 2007, BRIT J NUTR, V97, P1064, DOI 10.1017/S000711450769196X
   Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8
   MAROULAKOU IG, 1994, P NATL ACAD SCI USA, V91, P11236, DOI 10.1073/pnas.91.23.11236
   Meeran SM, 2010, CLIN EPIGENETICS, V1, DOI 10.1007/s13148-010-0011-5
   Meeran SM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011457
   Nelson NJ, 2006, J NATL CANCER I, V98, P436, DOI 10.1093/jnci/djj147
   Nguyen AT, 2016, BEHAV BRAIN RES, V307, P239, DOI 10.1016/j.bbr.2016.03.017
   Ostrand-Rosenberg S, 2004, CURR OPIN IMMUNOL, V16, P143, DOI 10.1016/j.coi.2004.01.003
   Pledgie-Tracy A, 2007, MOL CANCER THER, V6, P1013, DOI 10.1158/1535-7163.MCT-06-0494
   Sadikovic B, 2008, CURR GENOMICS, V9, P394, DOI 10.2174/138920208785699580
   Shen G, 2007, CANCER RES, V67, P9937, DOI 10.1158/0008-5472.CAN-07-1112
   Simmons RA, 2009, PEDIATR CLIN N AM, V56, P449, DOI 10.1016/j.pcl.2009.03.004
   Skinner MK, 2010, TRENDS ENDOCRIN MET, V21, P214, DOI 10.1016/j.tem.2009.12.007
   Wolff GL, 1998, FASEB J, V12, P949, DOI 10.1096/fasebj.12.11.949
   Yu Z, 2006, CARCINOGENESIS, V27, P2116, DOI 10.1093/carcin/bgl072
NR 33
TC 48
Z9 52
U1 0
U2 12
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1940-6207
EI 1940-6215
J9 CANCER PREV RES
JI Cancer Prev. Res.
PD AUG
PY 2018
VL 11
IS 8
BP 451
EP 463
DI 10.1158/1940-6207.CAPR-17-0423
PG 13
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA GP4FW
UT WOS:000440815800002
PM 29764806
OA Green Submitted, Green Accepted, Bronze
DA 2025-01-12
ER

PT J
AU Janostiak, R
   Vyas, M
   Cicek, AF
   Wajapeyee, N
   Harigopal, M
AF Janostiak, Radoslav
   Vyas, Monika
   Cicek, Ali Fuat
   Wajapeyee, Narendra
   Harigopal, Malini
TI Loss of of c-KIT expression in breast cancer correlates with malignant
   transformation of breast epithelium and is mediated by KIT gene promoter
   DNA hypermethylation
SO EXPERIMENTAL AND MOLECULAR PATHOLOGY
LA English
DT Article
DE Breast Cancer; c-KIT; Epigenetics; DNA methylation; Immunohistochemistry
ID RECEPTOR TYROSINE KINASE; BENIGN; IMMUNOHISTOCHEMISTRY; CARCINOMAS;
   PATHOLOGY; PATTERNS; LESIONS; CELLS
AB KIT Proto-Oncogene Receptor Tyrosine Kinase (KIT) is a transmembrane receptor tyrosine kinase which plays an important role in regulation of cell proliferation, survival and migration. Interestingly, the role of c-KIT in malignant transformation seems to be highly tissue-specific and it can act either as an oncogene or tumor suppressor gene. Here we analyzed the expression of c-KIT in normal breast tissues and tissues from different stages encompassing major steps of breast tumor development. Our study showed, that the c-KIT protein expression is gradually lost during the process of breast tissue transformation. The analysis of previously published datasets revealed that c-KIT expression in breast malignancies was downregulated at mRNA level. Because sequencing studies did not identify any recurrent mutations or copy number alterations, we proposed a potential epigenetic mechanism for the downregulation of c-KIT expression. In-silico analysis of the KIT promoter revealed the presence of CpG islands, therefore we performed bisulfite sequencing of normal breast epithelial tissues as well as breast tumor samples. We found, that KIT promoter is hypermethylated in breast tumors compared to normal breast tissues. Furthermore, treatment of breast cancer cell lines, that lack the expression of c-KIT, with methyltransferase inhibitor 5-Azacytidine (5Aza-2dC) resulted in increased expression of c-KIT mRNA. Collectively, our studies demonstrate that c-KIT expression is epigenetically downregulated during breast epithelium transformation and cancer development via KIT promoter hypermethylation.
C1 [Janostiak, Radoslav; Vyas, Monika; Cicek, Ali Fuat; Wajapeyee, Narendra; Harigopal, Malini] Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06510 USA.
C3 Yale University
RP Janostiak, R (通讯作者)，310 Cedar St, New Haven, CT 06520 USA.
EM radoslay.janostiak@yale.edu
RI Vyas, Monika/AAO-3797-2021; Janostiak, Radoslav/ABE-5349-2020; Cicek,
   Ali/AAG-5853-2019
OI Janostiak, Radoslav/0000-0002-6602-9389; Vyas,
   Monika/0000-0002-7020-9948
FU Chairman's challenge grant (Department of Pathology, Yale School of
   Medicine)
FX This work was supported by the Chairman's challenge grant (Department of
   Pathology, Yale School of Medicine).
CR Aoki H, 2015, J INVEST DERMATOL, V135, P1829, DOI 10.1038/jid.2015.83
   Banerji S, 2012, NATURE, V486, P405, DOI 10.1038/nature11154
   BESMER P, 1986, NATURE, V320, P415, DOI 10.1038/320415a0
   Bratthauer GL, 2002, HUM PATHOL, V33, P620, DOI 10.1053/hupa.2002.124789
   Buza N, 2010, VIRCHOWS ARCH, V457, P337, DOI 10.1007/s00428-010-0950-4
   Chui X, 1996, BRIT J CANCER, V73, P1233, DOI 10.1038/bjc.1996.236
   Dahl C, 2015, J INVEST DERMATOL, V135, P516, DOI 10.1038/jid.2014.372
   Deaton AM, 2011, GENE DEV, V25, P1010, DOI 10.1101/gad.2037511
   Esserman LJ, 2012, BREAST CANCER RES TR, V132, P1049, DOI 10.1007/s10549-011-1895-2
   Fleischer T, 2014, GENOME BIOL, V15, DOI [10.1186/s13059-014-0435-x, 10.1186/PREACCEPT-2333349012841587]
   Ghoncheh Mahshid, 2016, Asian Pac J Cancer Prev, V17, P43
   Huang SY, 1996, ONCOGENE, V13, P2339
   Kitamura Y, 2004, CELL MOL LIFE SCI, V61, P2924, DOI 10.1007/s00018-004-4273-y
   Koenig C, 2000, INT J SURG PATHOL, V8, P303, DOI 10.1177/106689690000800409
   Kohler BA, 2015, JNCI-J NATL CANCER I, V107, DOI 10.1093/jnci/djv048
   Kondi-Pafiti A, 2010, TUMORI J, V96, P978, DOI 10.1177/548.6519
   Lennartsson J, 2005, STEM CELLS, V23, P16, DOI 10.1634/stemcells.2004-0117
   Liu HY, 2014, ARCH PATHOL LAB MED, V138, P1629, DOI 10.5858/arpa.2014-0094-RA
   Liu HL, 2007, EMBO J, V26, P891, DOI 10.1038/sj.emboj.7601545
   Ma XJ, 2003, P NATL ACAD SCI USA, V100, P5974, DOI 10.1073/pnas.0931261100
   NATALI PG, 1992, INT J CANCER, V52, P713, DOI 10.1002/ijc.2910520508
   Ohta H, 2000, DEVELOPMENT, V127, P2125
   Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093
   Polat A, 2007, PATHOL RES PRACT, V203, P765, DOI 10.1016/j.prp.2007.08.010
   Radvanyi L, 2005, P NATL ACAD SCI USA, V102, P11005, DOI 10.1073/pnas.0500904102
   Rojas-Sutterlin S, 2014, CURR OPIN HEMATOL, V21, P256, DOI 10.1097/MOH.0000000000000052
   Santra MK, 2009, NATURE, V459, P722, DOI 10.1038/nature08011
   Siegel RL, 2016, CA-CANCER J CLIN, V66, P7, DOI 10.3322/caac.21332
   Simon R, 2004, CLIN CANCER RES, V10, P178, DOI 10.1158/1078-0432.CCR-0597-3
   Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100
   Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098
   Talaiezadeh A, 2012, WSPOLCZESNA ONKOL, V16, P306, DOI 10.5114/wo.2012.30058
   Tramm T, 2016, VIRCHOWS ARCH, V469, P285, DOI 10.1007/s00428-016-1966-1
   Ulivi P, 2004, BREAST CANCER RES TR, V83, P33, DOI 10.1023/B:BREA.0000010694.35023.9e
   YARDEN Y, 1987, EMBO J, V6, P3341, DOI 10.1002/j.1460-2075.1987.tb02655.x
   Yared Marwan A, 2004, Breast J, V10, P323, DOI 10.1111/j.1075-122X.2004.21351.x
   Zhao HJ, 2004, MOL BIOL CELL, V15, P2523, DOI 10.1091/mbc.E03-11-0786
   Zhao L, 2014, ARCH PATHOL LAB MED, V138, P16, DOI 10.5858/arpa.2012-0440-RA
NR 38
TC 29
Z9 32
U1 0
U2 4
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0014-4800
EI 1096-0945
J9 EXP MOL PATHOL
JI Exp. Mol. Pathol.
PD AUG
PY 2018
VL 105
IS 1
BP 41
EP 49
DI 10.1016/j.yexmp.2018.05.011
PG 9
WC Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pathology
GA GP6AE
UT WOS:000440958500006
PM 29852185
DA 2025-01-12
ER

PT J
AU Porretti, J
   Dalton, GN
   Massillo, C
   Scalise, GD
   Farré, PL
   Elble, R
   Gerez, EN
   Accialini, P
   Cabanillas, AM
   Gardner, K
   De Luca, P
   De Siervi, A
AF Porretti, Juliana
   Dalton, Guillermo N.
   Massillo, Cintia
   Scalise, Georgina D.
   Farre, Paula L.
   Elble, Randolph
   Gerez, Esther N.
   Accialini, Paula
   Cabanillas, Ana M.
   Gardner, Kevin
   De Luca, Paola
   De Siervi, Adriana
TI CLCA2 epigenetic regulation by CTBP1, HDACs, ZEB1, EP300 and miR-196b-5p
   impacts prostate cancer cell adhesion and EMT in metabolic syndrome
   disease
SO INTERNATIONAL JOURNAL OF CANCER
LA English
DT Article
DE metabolic syndrome; CTBP1; prostate cancer; CLCA2; miR-196b
ID BREAST-CANCER; HCLCA2; MIGRATION; GROWTH; RISK
AB Prostate cancer (PCa) is the most common cancer among men. Metabolic syndrome (MeS) is associated with increased PCa aggressiveness and recurrence. Previously, we proposed C-terminal binding protein 1 (CTBP1), a transcriptional co-repressor, as a molecular link between these two conditions. Notably, CTBP1 depletion decreased PCa growth in MeS mice. The aim of this study was to investigate the molecular mechanisms that explain the link between MeS and PCa mediated by CTBP1. We found that CTBP1 repressed chloride channel accessory 2 (CLCA2) expression in prostate xenografts developed in MeS animals. CTBP1 bound to CLCA2 promoter and repressed its transcription and promoter activity in PCa cell lines. Furthermore, we found that CTBP1 formed a repressor complex with ZEB1, EP300 and HDACs that modulates the CLCA2 promoter activity. CLCA2 promoted PCa cell adhesion inhibiting epithelial-mesenchymal transition (EMT) and activating CTNNB1 together with epithelial marker (CDH1) induction, and mesenchymal markers (SNAI2 and TWIST1) repression. Moreover, CLCA2 depletion in PCa cells injected subcutaneously in MeS mice increased the circulating tumor cells foci compared to control. A microRNA (miRNA) expression microarray from PCa xenografts developed in MeS mice, showed 21 miRNAs modulated by CTBP1 involved in angiogenesis, extracellular matrix organization, focal adhesion and adherents junctions, among others. We found that miR-196b-5p directly targets CLCA2 by cloning CLCA2 3UTR and performing reporter assays. Altogether, we identified a new molecular mechanism to explain PCa and MeS link based on CLCA2 repression by CTBP1 and miR-196b-5p molecules that might act as key factors in the progression onset of this disease.
C1 [Porretti, Juliana; Dalton, Guillermo N.; Massillo, Cintia; Scalise, Georgina D.; Farre, Paula L.; De Luca, Paola; De Siervi, Adriana] Consejo Nacl Invest Cient & Tecn, IBYME, Lab Oncol Mol & Nuevos Blancos Terapeut, Vuelta Obligado 2490,C1428ADN, Buenos Aires, DF, Argentina.
   [Elble, Randolph] Southern Illinois Univ, Simmons Canc Inst, Dept Pharmacol, Sch Med, Springfield, IL USA.
   [Gerez, Esther N.] Hosp Clin Buenos Aires, CIPYP, Buenos Aires, DF, Argentina.
   [Accialini, Paula] Consejo Nacl Invest Cient & Tecn, IBYME, Lab Fisiol & Biol Tumoral Ovario, Buenos Aires, DF, Argentina.
   [Cabanillas, Ana M.] Univ Nacl Cordoba, Lab Oncol Mol, Cordoba, Argentina.
   [Gardner, Kevin] Columbia Univ, Med Ctr, Dept Pathol & Cell Biol, New York, NY USA.
C3 Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET);
   Institute of Biology & Experimental Medicine; Southern Illinois
   University System; Southern Illinois University; University of Buenos
   Aires; Consejo Nacional de Investigaciones Cientificas y Tecnicas
   (CONICET); Institute of Biology & Experimental Medicine; National
   University of Cordoba; Columbia University
RP De Siervi, A (通讯作者)，Consejo Nacl Invest Cient & Tecn, IBYME, Lab Oncol Mol & Nuevos Blancos Terapeut, Vuelta Obligado 2490,C1428ADN, Buenos Aires, DF, Argentina.
EM adesiervi@dna.uba.ar
RI De Luca, Paola/I-6816-2017; Massillo, Cintia/AAD-2098-2020; De Siervi,
   Adriana/AAC-7177-2020
OI De Siervi, Adriana/0000-0002-1524-8063; Massillo,
   Cintia/0000-0002-7113-2030
FU Argentinean Agency of Science and Technology [ANPCyT PICT 2014-324,
   ANPCyT PICT 2013-2151, ANPCyT PICT 2015-1345]
FX Grant sponsor: Argentinean Agency of Science and Technology; Grant
   number: ANPCyT PICT 2014-324; ANPCyT PICT 2013-2151 and ANPCyT PICT
   2015-1345
CR Attard G, 2016, LANCET, V387, P70, DOI 10.1016/S0140-6736(14)61947-4
   Bashir Muhammad Naeem, 2015, Asian Pac J Cancer Prev, V16, P5137
   Fernández NB, 2016, MOL CARCINOGEN, V55, P1772, DOI 10.1002/mc.22426
   Llorens MC, 2016, J CELL PHYSIOL, V231, P2205, DOI 10.1002/jcp.25338
   Chakravarthi BVSK, 2014, ONCOTARGET, V5, P6654, DOI 10.18632/oncotarget.2208
   Chen CF, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni178
   Chen CY, 2011, J CELL MOL MED, V15, P14, DOI 10.1111/j.1582-4934.2010.01219.x
   Chinnadurai G, 2007, INT J BIOCHEM CELL B, V39, P1593, DOI 10.1016/j.biocel.2007.01.025
   De Luca P, 2016, ONCOTARGET, V7, P18798, DOI 10.18632/oncotarget.7711
   Elble RC, 2006, J BIOL CHEM, V281, P29448, DOI 10.1074/jbc.M605919200
   Gacci M, 2017, PROSTATE CANCER P D, V20, P146, DOI 10.1038/pcan.2017.1
   Gruber AD, 1999, CANCER RES, V59, P5488
   Grundy SM, 2002, CIRCULATION, V106, P3143, DOI 10.1161/circ.106.25.3143
   Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43
   Jeong JH, 2017, MOL CELL, V65, P154, DOI 10.1016/j.molcel.2016.11.034
   Li XR, 2004, ONCOGENE, V23, P1474, DOI 10.1038/sj.onc.1207249
   LIEBERT MA, 2001, DNA CELL BIOL, V20, P331
   Lu YC, 2016, J CANCER, V7, P650, DOI 10.7150/jca.13460
   Lu YC, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-218
   Mandair D, 2014, NUTR METAB, V11, DOI 10.1186/1743-7075-11-30
   Massillo C, 2017, REPRODUCTION, V154, pR81, DOI 10.1530/REP-17-0322
   Moiola CP, 2014, CLIN CANCER RES, V20, P4086, DOI 10.1158/1078-0432.CCR-14-0322
   Nunez C, 2017, CANCER EPIDEMIOL, V47, P56, DOI 10.1016/j.canep.2017.01.002
   Ramena G, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147489
   Riker AI, 2008, BMC MED GENOMICS, V1, DOI 10.1186/1755-8794-1-13
   Sasaki Y, 2012, CANCER BIOL THER, V13, P1512, DOI 10.4161/cbt.22280
   Shi YJ, 2003, NATURE, V422, P735, DOI 10.1038/nature01550
   Smith JL, 2004, P NATL ACAD SCI USA, V101, P11554, DOI 10.1073/pnas.0402156101
   Tanikawa C, 2012, NEOPLASIA, V14, P141, DOI 10.1593/neo.111700
   Walia V, 2012, ONCOGENE, V31, P2237, DOI 10.1038/onc.2011.392
   WALIA V, 2012, ONCOGENE, V57, P742
   Walia V, 2009, CANCER RES, V69, P6624, DOI 10.1158/0008-5472.CAN-08-4101
NR 32
TC 29
Z9 30
U1 0
U2 17
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0020-7136
EI 1097-0215
J9 INT J CANCER
JI Int. J. Cancer
PD AUG 15
PY 2018
VL 143
IS 4
BP 897
EP 906
DI 10.1002/ijc.31379
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA GM5TD
UT WOS:000438203500019
PM 29536528
OA Bronze, Green Published
DA 2025-01-12
ER

PT J
AU Elster, D
   Tollot, M
   Schlegelmilch, K
   Ori, A
   Rosenwald, A
   Sahai, E
   von Eyss, B
AF Elster, Dana
   Tollot, Marie
   Schlegelmilch, Karin
   Ori, Alessandro
   Rosenwald, Andreas
   Sahai, Erik
   von Eyss, Bjoern
TI TRPS1 shapes YAP/TEAD-dependent transcription in breast cancer cells
SO NATURE COMMUNICATIONS
LA English
DT Article
AB Yes-associated protein (YAP), the downstream transducer of the Hippo pathway, is a key regulator of organ size, differentiation and tumorigenesis. To uncover Hippo-independent YAP regulators, we performed a genome-wide CRISPR screen that identifies the transcriptional repressor protein Trichorhinophalangeal Syndrome 1 (TRPS1) as a potent repressor of YAP-dependent transactivation. We show that TRPS1 globally regulates YAP-dependent transcription by binding to a large set of joint genomic sites, mainly enhancers. TRPS1 represses YAP-dependent function by recruiting a spectrum of corepressor complexes to joint sites. Loss of TRPS1 leads to activation of enhancers due to increased H3K27 acetylation and an altered promoter-enhancer interaction landscape. TRPS1 is commonly amplified in breast cancer, which suggests that restrained YAP activity favours tumour growth. High TRPS1 activity is associated with decreased YAP activity and leads to decreased frequency of tumour-infiltrating immune cells. Our study uncovers TRPS1 as an epigenetic regulator of YAP activity in breast cancer.
C1 [Elster, Dana; Tollot, Marie; Ori, Alessandro; von Eyss, Bjoern] Fritz Lipmann Inst eV, Leibniz Inst Aging, Beutenbergstr 11, D-07745 Jena, Germany.
   [Schlegelmilch, Karin; Sahai, Erik] Francis Crick Inst, Tumour Cell Biol Lab, 1 Midland Rd, London NW1 1AT, England.
   [Rosenwald, Andreas] Univ Wurzburg, Inst Pathol, Josef Schneider Str 2, D-97080 Wurzburg, Germany.
   [Rosenwald, Andreas] Comprehens Canc Ctr Mainfranken CCCMF, Josef Schneider Str 2, D-97080 Wurzburg, Germany.
C3 Leibniz Association; Leibniz Institut fur Alternsforschung -
   Fritz-Lipmann-Institut (FLI); Francis Crick Institute; University of
   Wurzburg
RP von Eyss, B (通讯作者)，Fritz Lipmann Inst eV, Leibniz Inst Aging, Beutenbergstr 11, D-07745 Jena, Germany.
EM bjoern.voneyss@leibniz-fli.de
RI Ori, Alessandro/M-8586-2019; von Eyss, Bjoern/P-1077-2019; Ori,
   Alessandro/B-7067-2011
OI Schlegelmilch, Karin/0000-0003-3173-0914; Sahai,
   Erik/0000-0002-3932-5086; von Eyss, Bjoern/0000-0002-4731-6841; Ori,
   Alessandro/0000-0002-3046-0871
FU Else Kroner-Fresenius Foundation; Federal Government of Germany; State
   of Thuringia; Leibniz Graduate School on Aging (LGSA)
FX B.v.E. was supported by a grant from the Else Kroner-Fresenius
   Foundation. The Fritz Lipmann Institute (FLI) is a member of the Leibniz
   Association and is financially supported by the Federal Government of
   Germany and the State of Thuringia. D.E. has received a fellowship from
   the Leibniz Graduate School on Aging (LGSA). The DNA Sequencing, the
   Flow Cytometry and the Proteomics facilities of the FLI are gratefully
   acknowledged. We would like to thank Jason Carroll (Cambridge) and Jos
   Jonkers (Amsterdam) for sharing unpublished data. We would like to thank
   the members of the von Eyss lab, von Maltzahn lab and Kaether lab for
   helpful suggestions and Christin Ritter for excellent technical support.
   We would also like to thank Elmar Wolf and Julia von Maltzahn for
   critical reading of the manuscript.
NR 0
TC 60
Z9 63
U1 0
U2 12
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-1723
J9 NAT COMMUN
JI Nat. Commun.
PD AUG 6
PY 2018
VL 9
AR 3115
DI 10.1038/s41467-018-05370-7
PG 16
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA GP3TU
UT WOS:000440777100005
PM 30082728
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Munguía-Moreno, JA
   Díaz-Chavéz, J
   García-Villa, E
   Albino-Sanchez, ME
   Mendoza-Villanueva, D
   Ocadiz-Delgado, R
   Bonilla-Delgado, J
   Marín-Flores, A
   Cortés-Malagón, EM
   Alvarez-Rios, E
   Hidalgo-Miranda, A
   Üren, A
   Çelik, H
   Lambert, PF
   Gariglio, P
AF Antonio Munguia-Moreno, J.
   Diaz-Chavez, Jose
   Garcia-Villa, Enrique
   Estela Albino-Sanchez, M.
   Mendoza-Villanueva, Daniel
   Ocadiz-Delgado, Rodolfo
   Bonilla-Delgado, Jose
   Marin-Flores, Armando
   Cortes-Malagon, Enoc M.
   Alvarez-Rios, Elizabeth
   Hidalgo-Miranda, Alfredo
   Uren, Aykut
   Celik, Haydar
   Lambert, Paul F.
   Gariglio, Patricio
TI Early synergistic interactions between the HPV16-E7 oncoprotein and
   17-oestradiol for repressing the expression of Granzyme B in a cervical
   cancer model
SO INTERNATIONAL JOURNAL OF ONCOLOGY
LA English
DT Article
DE human papillomavirus type 16-E7; 17-oestradiol; microarrays;
   carcinogenesis; K14E7; Granzyme B
ID ESTROGEN-RECEPTOR-ALPHA; TRANSGENIC MOUSE MODEL; EXTRACELLULAR-MATRIX;
   HUMAN KERATINOCYTES; PROSTATE-CANCER; GENE-EXPRESSION; E7 ONCOPROTEIN;
   EPIGENETIC REPRESSION; MEDIATED APOPTOSIS; BREAST-CANCER
AB Although high-risk human papillomavirus (HR-HPV) infection has a prominent role in the aetiology of cervical cancer (CC), sex steroid hormones may also be involved in this process; however, the cooperation between oestrogen and HR-HPV in the early stages of cervical carcinogenesis is poorly understood. Since 17-oestradiol (E-2) and the HPV type 16-E7 oncoprotein induce CC in transgenic mice, a microarray analysis was performed in the present study to generate global gene expression profiles from 2-month-old FVB (non-transgenic) and K14E7 (transgenic) mice who were left untreated or were treated for 1 month with E-2. Upregulation of cancer-related genes that have not been previously reported in the context of CC, including glycerophosphodiester phosphodiesterase domain containing 3, interleukin 1 receptor type II, natriuretic peptide type C, MGAT4 family member C, lecithin-retinol acyltransferase (phosphatidylcholine-retinol-O-acyltransferase) and glucoside xylosyltransferase 2, was observed. Notably, upregulation of the serine (or cysteine) peptidase inhibitor clade B member 9 gene and downregulation of the Granzyme gene family were observed; the repression of the Granzyme B pathway may be a novel mechanism of immune evasion by cancer cells. The present results provide the basis for further studies on early biomarkers of CC risk and synergistic interactions between HR-HPV and oestrogen.
C1 [Antonio Munguia-Moreno, J.; Garcia-Villa, Enrique; Estela Albino-Sanchez, M.; Ocadiz-Delgado, Rodolfo; Marin-Flores, Armando; Alvarez-Rios, Elizabeth; Gariglio, Patricio] Natl Polytech Inst, Ctr Res & Adv Studies, Dept Genet & Mol Biol, 2508 Natl Polytech Inst Ave, Mexico City 07360, DF, Mexico.
   [Diaz-Chavez, Jose] Univ Nacl Autonoma Mexico, Natl Inst Canc, Biomed Unit Canc Res, Mexico City 14080, DF, Mexico.
   [Mendoza-Villanueva, Daniel] NCI, Lab Cell & Dev Signalling, Frederick, MD 21702 USA.
   [Bonilla-Delgado, Jose; Cortes-Malagon, Enoc M.] Juarez Hosp, Res Unit Genet & Canc, Mexico City 07760, DF, Mexico.
   [Hidalgo-Miranda, Alfredo] Natl Inst Genom Med, Dept Oncogenom, Mexico City 14610, DF, Mexico.
   [Uren, Aykut; Celik, Haydar] Georgetown Univ, Med Ctr, Lombardi Comprehens Canc Ctr, Dept Oncol, Washington, DC 20057 USA.
   [Lambert, Paul F.] Univ Wisconsin, Sch Med & Publ Hlth, McArdle Lab Canc Res, Madison, WI 53706 USA.
C3 Instituto Politecnico Nacional - Mexico; Universidad Nacional Autonoma
   de Mexico; National Institutes of Health (NIH) - USA; NIH National
   Cancer Institute (NCI); Instituto Nacional de Medicina Genomica;
   Georgetown University; University of Wisconsin System; University of
   Wisconsin Madison
RP Gariglio, P (通讯作者)，Natl Polytech Inst, Ctr Res & Adv Studies, Dept Genet & Mol Biol, 2508 Natl Polytech Inst Ave, Mexico City 07360, DF, Mexico.
EM vidal@cinvestav.mx
RI Ocadiz, Rodolfo/AAR-2733-2021; munguia, antonio/M-9346-2019; Cortés,
   Enoc/AAE-8389-2021; Albino, Martha/KDP-2877-2024; Díaz-Chávez,
   José/HGU-7481-2022; Bonilla-Delgado, José/AAS-4594-2020;
   Hidalgo-Miranda, Alfredo/B-2123-2010
OI Hidalgo-Miranda, Alfredo/0000-0003-2315-3977; Bonilla-Delgado,
   Jose/0000-0002-9690-1940; Celik, Haydar/0000-0003-4314-8438;
   Diaz-Chavez, Jose/0000-0001-9583-3790; Ocadiz-Delgado, Dr.
   Rodolfo/0000-0002-4576-881X; CORTES-MALAGON, ENOC
   MARIANO/0000-0002-6240-3468; Albino Sanchez, Martha
   Estela/0000-0001-6873-6610
FU Institute of Science and technology of Mexico City [PICSA10-190,
   326/2011]; National Council for Science and Technology [168896];
   Sectorial Funding for Research in Health and Social Security [261875]
FX This study was supported by government grants from the Institute of
   Science and technology of Mexico City (nos. PICSA10-190 and 326/2011),
   from the National Council for Science and Technology (no. 168896) and
   from the Sectorial Funding for Research in Health and Social Security
   (no. 261875).
CR Amann PM, 2015, SKIN PHARMACOL PHYS, V28, P205, DOI 10.1159/000368806
   Arbeit JM, 1996, P NATL ACAD SCI USA, V93, P2930, DOI 10.1073/pnas.93.7.2930
   Baenke F, 2013, DIS MODEL MECH, V6, P1353, DOI 10.1242/dmm.011338
   Banno T, 2003, ANTIVIR THER, V8, P541
   Barrie MB, 2004, J IMMUNOL, V172, P6453, DOI 10.4049/jimmunol.172.10.6453
   Berthou C, 1997, J IMMUNOL, V159, P5293
   Bird CH, 1998, MOL CELL BIOL, V18, P6387, DOI 10.1128/MCB.18.11.6387
   Black APB, 2007, EUR J IMMUNOL, V37, P1485, DOI 10.1002/eji.200636915
   Bladergroen BA, 2002, BLOOD, V99, P232, DOI 10.1182/blood.V99.1.232
   Boivin WA, 2009, LAB INVEST, V89, P1195, DOI 10.1038/labinvest.2009.91
   Brake T, 2005, P NATL ACAD SCI USA, V102, P2490, DOI 10.1073/pnas.0409883102
   Buzza MS, 2001, CELL IMMUNOL, V210, P21, DOI 10.1006/cimm.2001.1806
   Cairns RA, 2011, NAT REV CANCER, V11, P85, DOI 10.1038/nrc2981
   Chabas D, 2001, SCIENCE, V294, P1731, DOI 10.1126/science.1062960
   Chung SH, 2010, TRENDS ENDOCRIN MET, V21, P504, DOI 10.1016/j.tem.2010.03.005
   Chung SH, 2008, CANCER RES, V68, P9928, DOI 10.1158/0008-5472.CAN-08-2051
   Cortés-Malagón EM, 2013, VIROLOGY, V447, P155, DOI 10.1016/j.virol.2013.08.036
   Cunningham TD, 2007, CELL IMMUNOL, V245, P32, DOI 10.1016/j.cellimm.2007.03.004
   Deisting W, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0141669
   Demichelis F, 2012, P NATL ACAD SCI USA, V109, P6686, DOI 10.1073/pnas.1117405109
   den Boon JA, 2015, P NATL ACAD SCI USA, V112, pE3255, DOI 10.1073/pnas.1509322112
   Dozmorov MG, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-S10-S14
   Fang YJ, 2012, J ANDROL, V33, P752, DOI 10.2164/jandrol.111.015164
   Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210
   Fritsch K, 2013, ANN HEMATOL, V92, P1603, DOI 10.1007/s00277-013-1846-6
   Fukuoka N, 2016, GENES CELLS, V21, P146, DOI 10.1111/gtc.12328
   FURTH J, 1959, CANCER RES, V19, P241
   Grinde MT, 2014, BREAST CANCER RES, V16, DOI 10.1186/bcr3597
   HENDERSON BE, 1982, CANCER RES, V42, P3232
   Herber R, 1996, J VIROL, V70, P1873, DOI 10.1128/JVI.70.3.1873-1881.1996
   Hernandez-Pigeon H, 2006, J BIOL CHEM, V281, P13525, DOI 10.1074/jbc.M512694200
   Hernandez-Pigeon H, 2007, J BIOL CHEM, V282, P8157, DOI 10.1074/jbc.M607436200
   Hiebert PR, 2012, TRENDS MOL MED, V18, P732, DOI 10.1016/j.molmed.2012.09.009
   Sierra EI, 2012, VIROLOGY, V433, P337, DOI 10.1016/j.virol.2012.08.024
   Jadhav RR, 2015, CLIN EPIGENETICS, V7, DOI 10.1186/s13148-015-0045-9
   Jiang XG, 2006, ENDOCRINOLOGY, V147, P1419, DOI 10.1210/en.2005-0996
   Kainkaryam RM, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-299
   Kendziorski C, 2005, P NATL ACAD SCI USA, V102, P4252, DOI 10.1073/pnas.0500607102
   Khan MS, 2011, J AMINO ACIDS, V2011, DOI DOI 10.4061/2011/606797
   Lauricella M, 2016, INT J ONCOL, V49, P352, DOI 10.3892/ijo.2016.3495
   Laurson J, 2010, CARCINOGENESIS, V31, P918, DOI 10.1093/carcin/bgq027
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Mar AC, 2015, J BIOL CHEM, V290, P22212, DOI 10.1074/jbc.M115.644823
   McLane LM, 2013, J IMMUNOL, V190, P3207, DOI 10.4049/jimmunol.1201556
   McLaughlin-Drubin ME, 2013, P NATL ACAD SCI USA, V110, P16175, DOI 10.1073/pnas.1310432110
   McLaughlin-Drubin ME, 2011, P NATL ACAD SCI USA, V108, P2130, DOI 10.1073/pnas.1009933108
   Medema JP, 2001, P NATL ACAD SCI USA, V98, P11515, DOI 10.1073/pnas.201398198
   Menendez JA, 2007, NAT REV CANCER, V7, P763, DOI 10.1038/nrc2222
   Meyaard L, 2008, J LEUKOCYTE BIOL, V83, P799, DOI 10.1189/jlb.0907609
   Nickens KP, 2012, BBA-MOL CELL RES, V1823, P264, DOI 10.1016/j.bbamcr.2011.10.005
   Nielsen SJ, 2009, APMIS, V117, P60, DOI 10.1111/j.1600-0463.2008.00016.x
   Nielsen SJ, 2008, REGUL PEPTIDES, V146, P204, DOI 10.1016/j.regpep.2007.09.022
   Parkinson LG, 2015, AGING CELL, V14, P67, DOI 10.1111/acel.12298
   Provenzano PP, 2008, BMC MED, V6, DOI 10.1186/1741-7015-6-11
   Riley RR, 2003, CANCER RES, V63, P4862
   Röhrig F, 2016, NAT REV CANCER, V16, P732, DOI 10.1038/nrc.2016.89
   Rousalova I, 2010, INT J ONCOL, V37, P1361, DOI 10.3892/ijo_00000788
   Saito S, 2008, J RHEUMATOL, V35, P1932
   Salmon H, 2012, J CLIN INVEST, V122, P899, DOI 10.1172/JCI45817
   Scotland RS, 2005, PHARMACOL THERAPEUT, V105, P85, DOI 10.1016/j.pharmthera.2004.08.011
   Smith JS, 2007, INT J CANCER, V121, P621, DOI 10.1002/ijc.22527
   Soriano C, 2012, LUNG CANCER, V77, P38, DOI 10.1016/j.lungcan.2012.01.017
   Sorokin L, 2010, NAT REV IMMUNOL, V10, P712, DOI 10.1038/nri2852
   Vesely MD, 2011, ANNU REV IMMUNOL, V29, P235, DOI 10.1146/annurev-immunol-031210-101324
   Weathington NM, 2006, NAT MED, V12, P317, DOI 10.1038/nm1361
   Yim EK, 2006, BIOMARK INSIGHTS, V1, P215
   Zhang Feng, 2012, World J Biol Chem, V3, P167, DOI 10.4331/wjbc.v3.i8.167
   zur Hausen H, 2009, VIROLOGY, V384, P260, DOI 10.1016/j.virol.2008.11.046
NR 68
TC 11
Z9 11
U1 0
U2 6
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1019-6439
EI 1791-2423
J9 INT J ONCOL
JI Int. J. Oncol.
PD AUG
PY 2018
VL 53
IS 2
BP 579
EP 591
DI 10.3892/ijo.2018.4432
PG 13
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA GP1MZ
UT WOS:000440581500011
PM 29901186
OA Green Submitted, Green Published, hybrid
DA 2025-01-12
ER

PT J
AU Arechederra, M
   Daian, F
   Yim, A
   Bazai, SK
   Richelme, S
   Dono, R
   Saurin, AJ
   Habermann, BH
   Maina, F
AF Arechederra, Maria
   Daian, Fabrice
   Yim, Annie
   Bazai, Sehrish K.
   Richelme, Sylvie
   Dono, Rosanna
   Saurin, Andrew J.
   Habermann, Bianca H.
   Maina, Flavio
TI Hypermethylation of gene body CpG islands predicts high dosage of
   functional oncogenes in liver cancer
SO NATURE COMMUNICATIONS
LA English
DT Article
ID DNA METHYLATION; RNA-SEQ; HEPATOCELLULAR-CARCINOMA; BREAST-CANCER;
   EXPRESSION; CELLS; HYPOMETHYLATION; LANDSCAPE; EPIGENOME; EPIGENETICS
AB Epigenetic modifications such as aberrant DNA methylation reshape the gene expression repertoire in cancer. Here, we used a clinically relevant hepatocellular carcinoma (HCC) mouse model (Alb-R26(Met)) to explore the impact of DNA methylation on transcriptional switches associated with tumorigenesis. We identified a striking enrichment in genes simultaneously hypermethylated in CpG islands (CGIs) and overexpressed. These hypermethylated CGIs are located either in the 5'-UTR or in the gene body region. Remarkably, such CGI hypermethylation accompanied by gene upregulation also occurs in 56% of HCC patients, which belong to the "HCC proliferative-progenitor" subclass. Most of the genes upregulated and with hypermethylated CGIs in the Alb-R26Met HCC model undergo the same change. Among reprogrammed genes, several are well-known oncogenes. For others not previously linked to cancer, we demonstrate here their action together as an "oncogene module". Thus, hypermethylation of gene body CGIs is predictive of elevated oncogene levels in cancer, offering a novel stratification strategy and perspectives to normalise cancer gene dosages.
C1 [Arechederra, Maria; Daian, Fabrice; Bazai, Sehrish K.; Richelme, Sylvie; Dono, Rosanna; Saurin, Andrew J.; Habermann, Bianca H.; Maina, Flavio] Aix Marseille Univ, Dev Biol Inst Marseille IBDM, CNRS, Parc Sci Luminy, F-13009 Marseille, France.
   [Yim, Annie] Max Planck Inst Biochem, Computat Biol Grp, D-82152 Martinsried, Germany.
C3 Centre National de la Recherche Scientifique (CNRS); Aix-Marseille
   Universite; Max Planck Society
RP Maina, F (通讯作者)，Aix Marseille Univ, Dev Biol Inst Marseille IBDM, CNRS, Parc Sci Luminy, F-13009 Marseille, France.
EM flavio.maina@univ-amu.fr
RI DONO, ROSANNA/I-7821-2016; Maina, Flavio/J-9962-2019; Arechederra,
   María/L-9108-2019; Habermann, Bianca/N-4886-2016; Arechederra,
   Maria/F-4373-2016; zucman-rossi, Jessica/B-5098-2009
OI DONO, Rosanna/0000-0002-7200-9464; Daian, Fabrice/0000-0001-6036-1906;
   BAZAI, SEHRISH KHAN/0000-0002-0082-1760; Saurin,
   Andrew/0000-0001-5162-003X; Habermann, Bianca/0000-0002-2457-7504;
   Arechederra, Maria/0000-0002-4830-1924; zucman-rossi,
   Jessica/0000-0002-5687-0334
FU INCa (Institut National du Cancer); FdF (Fondation de France);
   GEFLUC-Les Entreprises contre le Cancer; FdF fellowship; DFG [HA
   6905/2-1]; Higher Education Commission (HEC) of Pakistan-France Campus
FX These results are in part based upon public data generated by TCGA
   Research Network: http://cancergenome.nih.gov/. We are particularly
   grateful to F. Helmbacher for extremely valuable feedback on the study.
   We thank: all members of our labs for helpful discussions and comments;
   F. Castets for advises on biochemical analysis; J. Zucman-Rossi and E.
   Letouze for valuable discussion and feedback on the bioinformatics; V.
   Girod-David and L. Jullien for excellent help with mouse husbandry; C.
   Giaccherini, A. Dobric and E. Chrabaszcz for their contributions to
   studies on molecular and functional characterisations of shRNA-targeted
   HCC cells. This work was funded by INCa (Institut National du Cancer),
   FdF (Fondation de France) and GEFLUC-Les Entreprises contre le Cancer to
   F.M. M.A. was supported by a FdF fellowship. A.Y. was supported by DFG
   grant HA 6905/2-1. S.K.B. was supported by the Higher Education
   Commission (HEC) of Pakistan-France Campus. The contribution of the
   Region Provence Alpes Cotes d'Azur and of the Aix-Marseille Universite
   to the IBDM animal facility is also acknowledged. The funders had no
   role in study design, data collection and analysis, decision to publish
   or preparation of the manuscript.
CR Azad N, 2013, NAT REV CLIN ONCOL, V10, P256, DOI 10.1038/nrclinonc.2013.42
   Ball MP, 2009, NAT BIOTECHNOL, V27, P361, DOI 10.1038/nbt.1533
   Baylin SB, 2011, NAT REV CANCER, V11, P726, DOI 10.1038/nrc3130
   Bender S, 2013, CANCER CELL, V24, P660, DOI 10.1016/j.ccr.2013.10.006
   Bhasin JM, 2015, CELL REP, V13, P2135, DOI 10.1016/j.celrep.2015.10.078
   Brien GL, 2016, CANCER CELL, V29, P464, DOI 10.1016/j.ccell.2016.03.007
   Dawson MA, 2012, CELL, V150, P12, DOI 10.1016/j.cell.2012.06.013
   Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635
   Esteller M., 2011, F1000 BIOL REP, V3, P9
   Fan YN, 2017, HEPATOLOGY, V66, P1644, DOI 10.1002/hep.29304
   Fan YN, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005533
   Feinberg AP, 2004, NAT REV CANCER, V4, P143, DOI 10.1038/nrc1279
   Forloni M, 2016, CELL REP, V16, P457, DOI 10.1016/j.celrep.2016.05.087
   Furlan A, 2011, CELL DEATH DIFFER, V18, P1608, DOI 10.1038/cdd.2011.23
   Furlan A, 2012, J HEPATOL, V57, P1292, DOI 10.1016/j.jhep.2012.07.044
   Furlan A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046738
   Genestine M, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.11
   Hahn MA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018844
   Heyn H, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-0879-2
   Hon GC, 2012, GENOME RES, V22, P246, DOI 10.1101/gr.125872.111
   Jjingo D, 2012, ONCOTARGET, V3, P462, DOI 10.18632/oncotarget.497
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   Jones PA, 2012, NAT REV GENET, V13, P484, DOI 10.1038/nrg3230
   Karch F, 2015, BMC BIOL, V13, DOI 10.1186/s12915-015-0182-9
   Krueger F, 2011, BIOINFORMATICS, V27, P1571, DOI 10.1093/bioinformatics/btr167
   Kulis M, 2012, NAT GENET, V44, P1236, DOI 10.1038/ng.2443
   Laird PW, 2010, NAT REV GENET, V11, P191, DOI 10.1038/nrg2732
   Lee SM, 2014, P NATL ACAD SCI USA, V111, P9555, DOI 10.1073/pnas.1400604111
   Lennartsson A, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-0884-5
   Li B, 2010, BIOINFORMATICS, V26, P493, DOI 10.1093/bioinformatics/btp692
   Lister R, 2009, NATURE, V462, P315, DOI 10.1038/nature08514
   Liu F, 2016, NAT REV CANCER, V16, P359, DOI 10.1038/nrc.2016.41
   Liu F, 2015, MOL CELL, V60, P307, DOI 10.1016/j.molcel.2015.09.002
   Lu C, 2016, SCIENCE, V352, P844, DOI 10.1126/science.aac7272
   Maina F, 2014, CURR MED CHEM, V21, P1607, DOI 10.2174/09298673113209990222
   Maunakea AK, 2010, NATURE, V466, P253, DOI 10.1038/nature09165
   Mortazavi A, 2008, NAT METHODS, V5, P621, DOI 10.1038/nmeth.1226
   Murtha M, 2016, TRENDS CANCER, V2, P572, DOI 10.1016/j.trecan.2016.08.004
   Nabet B, 2015, CELL REP, V12, P1300, DOI 10.1016/j.celrep.2015.06.078
   Scott MT, 2016, CANCER DISCOV, V6, P1248, DOI 10.1158/2159-8290.CD-16-0263
   Shukla S, 2011, NATURE, V479, P74, DOI 10.1038/nature10442
   Spangle JM, 2016, CELL REP, V15, P2692, DOI 10.1016/j.celrep.2016.05.046
   Spencer DH, 2017, CELL, V168, P801, DOI 10.1016/j.cell.2017.01.021
   Trapnell C, 2012, NAT PROTOC, V7, P562, DOI 10.1038/nprot.2012.016
   Trapnell C, 2010, NAT BIOTECHNOL, V28, P511, DOI 10.1038/nbt.1621
   Varley KE, 2013, GENOME RES, V23, P555, DOI 10.1101/gr.147942.112
   Villanueva A, 2015, HEPATOLOGY, V61, P1945, DOI 10.1002/hep.27732
   Wang K, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkq622
   Weinstein JN, 2013, NAT GENET, V45, P1113, DOI 10.1038/ng.2764
   Woo HG, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00991-w
   Yang XJ, 2014, CANCER CELL, V26, P577, DOI 10.1016/j.ccr.2014.07.028
   Yao XS, 2016, TRENDS CANCER, V2, P585, DOI 10.1016/j.trecan.2016.09.002
   Zucman-Rossi J, 2015, GASTROENTEROLOGY, V149, P1226, DOI 10.1053/j.gastro.2015.05.061
NR 53
TC 149
Z9 159
U1 0
U2 16
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-1723
J9 NAT COMMUN
JI Nat. Commun.
PD AUG 8
PY 2018
VL 9
AR 3164
DI 10.1038/s41467-018-05550-5
PG 16
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA GP6IQ
UT WOS:000440982800006
PM 30089774
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Bai, J
   Mu, R
   Dou, M
   Yan, DJ
   Liu, BY
   Wei, Q
   Wan, J
   Tang, Y
   Hu, YC
AF Bai, Jian
   Mu, Rong
   Dou, Man
   Yan, Daojiang
   Liu, Bingyu
   Wei, Qian
   Wan, Jun
   Tang, Yi
   Hu, Youcai
TI Epigenetic modification in histone deacetylase deletion strain of
   <i>Calcarisporium arbuscula</i> leads to diverse diterpenoids
SO ACTA PHARMACEUTICA SINICA B
LA English
DT Article
DE Calcarisporium arbuscula; Calcarisporic acids; Pimarane; Diterpenoid;
   Matrix metalloproteinases inhibitor; Epigenetic genome mining
ID FUNGUS PARACONIOTHYRIUM-HAWAIIENSE; MATRIX METALLOPROTEINASES;
   ENDOPHYTIC FUNGUS; NATURAL-PRODUCTS; AUROVERTIN-B; CLEISTANTHANE;
   MANIPULATION; CASSANE
AB Epigenetic modifications have been proved to be a powerful way to activate silent gene clusters and lead to diverse secondary metabolites in fungi. Previously, inactivation of a histone H3 deacetylase in Calcarisporium arbuscula had led to pleiotropic activation and overexpression of more than 75% of the biosynthetic genes and isolation of ten compounds. Further investigation of the crude extract of C. arbuscula Delta hdaA strain resulted in the isolation of twelve new diterpenoids including three cassanes (1-3), one cleistanthane (4), six pimaranes (5-10), and two isopimaranes (11 and 12) along with two know cleistanthane analogues. Their structures were elucidated by extensive NMR spectroscopic data analysis. Compounds 2 and 4 showed potent inhibitory effects on the expression of MMP1 and MMP2 (matrix metalloproteinases family) in human breast cancer (MCF-7) cells. (C) 2018 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V.
C1 [Bai, Jian; Mu, Rong; Dou, Man; Yan, Daojiang; Liu, Bingyu; Wei, Qian; Wan, Jun; Tang, Yi; Hu, Youcai] Chinese Acad Med Sci, State Key Lab Bioact Subst & Funct Nat Med, Inst Mat Med, Beijing 100050, Peoples R China.
   [Bai, Jian; Mu, Rong; Dou, Man; Yan, Daojiang; Liu, Bingyu; Wei, Qian; Wan, Jun; Tang, Yi; Hu, Youcai] Peking Union Med Coll, Beijing 100050, Peoples R China.
   [Tang, Yi] Univ Calif Los Angeles, Dept Chem & Biochem, Dept Chem & Biomol Engn, Los Angeles, CA 90095 USA.
C3 Chinese Academy of Medical Sciences - Peking Union Medical College;
   Institute of Materia Medica - CAMS; Chinese Academy of Medical Sciences
   - Peking Union Medical College; Peking Union Medical College; University
   of California System; University of California Los Angeles
RP Hu, YC (通讯作者)，Chinese Acad Med Sci, State Key Lab Bioact Subst & Funct Nat Med, Inst Mat Med, Beijing 100050, Peoples R China.; Hu, YC (通讯作者)，Peking Union Med Coll, Beijing 100050, Peoples R China.
EM huyoucai@imm.ac.cn
RI Hu, Youcai/I-9668-2014
FU National Natural Science Foundation of China [21502233, 81522043]; CAMS
   Initiative for Innovative Medicine [CAMS-I2M-1-010]; PUMC Youth Fund
   [33320140175]; State Key Laboratory Fund for Excellent Young Scientists
   [GTZB201401]
FX This work was supported financially by National Natural Science
   Foundation of China (Nos. 21502233 and 81522043), CAMS Initiative for
   Innovative Medicine (CAMS-I2M-1-010), the PUMC Youth Fund (33320140175),
   and the State Key Laboratory Fund for Excellent Young Scientists to
   Youcai Hu (GTZB201401). We are grateful to the Department of
   Instrumental Analysis, Institute of Materia Medica, Chinese Academy of
   Medical Sciences & Peking Union Medical College for the spectroscopic
   measurements and Prof. Xiaoguang Chen and Prof. Dan Zhang for the
   cytotoxicity, anti-inflammatory, and antioxidant assays.
CR Albright JC, 2015, ACS CHEM BIOL, V10, P1535, DOI 10.1021/acschembio.5b00025
   Allard PM, 2012, ORG LETT, V14, P342, DOI 10.1021/ol2030907
   Ayer WA, 1996, PHYTOCHEMISTRY, V42, P1647, DOI 10.1016/0031-9422(96)00150-1
   Bai J, 2012, PHYTOCHEMISTRY, V80, P137, DOI 10.1016/j.phytochem.2012.05.015
   Chen SX, 2014, FITOTERAPIA, V99, P236, DOI 10.1016/j.fitote.2014.09.021
   Chen SX, 2014, J NAT PROD, V77, P1513, DOI 10.1021/np500302e
   Cichewicz RH, 2010, NAT PROD REP, V27, P11, DOI 10.1039/b920860g
   Fan AL, 2017, ORG LETT, V19, P1686, DOI 10.1021/acs.orglett.7b00476
   Gao Y, 2012, NAT PROD REP, V29, P1153, DOI 10.1039/c2np20059g
   Hu YC, 2008, J NAT PROD, V71, P1800, DOI 10.1021/np800083x
   Khasigov PZ, 2003, BIOCHEMISTRY-MOSCOW+, V68, P711, DOI 10.1023/A:1025051214001
   KIRK DN, 1986, TETRAHEDRON, V42, P777, DOI 10.1016/S0040-4020(01)87486-X
   Li F, 2017, PHYTOCHEMISTRY, V135, P144, DOI 10.1016/j.phytochem.2016.12.008
   Li MH, 2013, ACTA PHARM SIN B, V3, P273, DOI 10.1016/j.apsb.2013.06.001
   Liu N, 2012, ACTA PHARM SIN B, V2, P256, DOI 10.1016/j.apsb.2012.03.003
   Ma SG, 2011, PHYTOCHEMISTRY, V72, P115, DOI 10.1016/j.phytochem.2010.10.021
   Mao XM, 2015, ANGEW CHEM INT EDIT, V54, P7592, DOI 10.1002/anie.201502452
   MORRIS SA, 1995, TETRAHEDRON LETT, V36, P9101, DOI 10.1016/0040-4039(95)01965-K
   MULHEIRN LJ, 1974, J CHEM SOC CHEM COMM, P874, DOI 10.1039/c39740000874
   OSSELTON M D, 1974, Biochemical Society Transactions, V2, P200
   Park M, 2013, EXP DERMATOL, V22, P336, DOI 10.1111/exd.12138
   Peters RJ, 2010, NAT PROD REP, V27, P1521, DOI 10.1039/c0np00019a
   Qu J, 2013, J NAT PROD, V76, P2203, DOI 10.1021/np4005536
   Shiono Y, 2010, Z NATURFORSCH B, V65, P753, DOI 10.1515/znb-2010-0611
   vanRaaij MJ, 1996, P NATL ACAD SCI USA, V93, P6913, DOI 10.1073/pnas.93.14.6913
   WATSON PAULINE, 1955, TRANS BRIT MYCOL SOC, V38, P409
   Wu GW, 2016, ORG LETT, V18, P1832, DOI 10.1021/acs.orglett.6b00562
   Zhang L, 2010, PHYTOCHEMISTRY, V71, P1879, DOI 10.1016/j.phytochem.2010.08.008
   Zhang L, 2010, ORG LETT, V12, P152, DOI 10.1021/ol9025638
   Zheng YJ, 2017, ORG LETT, V19, P4700, DOI 10.1021/acs.orglett.7b02346
NR 30
TC 18
Z9 20
U1 2
U2 53
PU INST MATERIA MEDICA, CHINESE ACAD MEDICAL SCIENCES
PI BEIJING
PA C/O EDITORIAL BOARD OF ACTA PHARMACEUTICA SINICA, 1 XIANNONGTAN ST,
   BEIJING, 100050, PEOPLES R CHINA
SN 2211-3835
EI 2211-3843
J9 ACTA PHARM SIN B
JI Acta Pharm. Sin. B
PD JUL
PY 2018
VL 8
IS 4
BP 687
EP 697
DI 10.1016/j.apsb.2017.12.012
PG 11
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA GO2MN
UT WOS:000439807300020
PM 30109192
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU Mao, C
   Wang, M
   Qian, BL
   Ouyang, LL
   Shi, Y
   Liu, N
   Chen, L
   Xiao, DS
   Wang, X
   Cao, Y
   Liu, S
   Tao, YG
   Liu, WL
AF Mao, Chao
   Wang, Min
   Qian, Banglun
   Ouyang, Lianlian
   Shi, Ying
   Liu, Na
   Chen, Ling
   Xiao, Desheng
   Wang, Xiang
   Cao, Ya
   Liu, Shuang
   Tao, Yongguang
   Liu, Wenliang
TI Aryl hydrocarbon receptor activated by benzo (a) pyrene promotes SMARCA6
   expression in NSCLC
SO AMERICAN JOURNAL OF CANCER RESEARCH
LA English
DT Article
DE SMARCA6; BaP; AhR; smoking; lung cancer
ID LYMPHOID-SPECIFIC HELICASE; METHYLATION PATTERNS; HEMATOPOIETIC STEM;
   DNA METHYLATION; BREAST-CANCER; LUNG-CANCER; CELLS; LSH; AHR; RESISTANCE
AB Recent studies suggest that individual subunits of chromatin-remodeling complexes generate epigenetically specific signaling in tumorigenicity. The impact of environmental factors on the chromatin-remodeling factor has not been thoroughly elucidated to date. We detected the expression level of SMARCA6 (SWI/SNF2-Related, Matrix-Associated, Actin-Dependent Regulator of Chromatin, Subfamily A, Member 6) in NSCLC (Non-small-cell lung carcinoma) and measured it through quantitative real-time PCR (qRT-PCR) and immunohistochemistry. The effects of BaP on proliferation and cell cycle progression were evaluated using MTT, colony formation and FACS analyses. Tumor growth in vivo was observed in a xenograft model. ChIP and qPCR were performed to validate that SMARCA6 was a potential target of AhR in NSCLC. As a result, BaP increased SMARCA6 expression. Smoking was linked with elevated SMARCA6 expression in NSCLC. BaP promoted cancer progression in vitro and in vivo. ChIP assay confirmed that BaP increases SMARCA6 expression via recruitment of AhR and induces SMARCA6 expression by facilitating AhR translocation to the nucleus. Furthermore, inhibition of AhR expression decreases SMARCA6 expression in NSCLC. Finally, knockdown of SMARCA6 attenuates BaP-induced cancer progression. This study demonstrates that BaP promotes proliferation by activation of AhR, which promotes SMARCA6 expression, and may identify new diagnostic and therapeutic targets in lung cancer.
C1 [Mao, Chao; Wang, Min; Ouyang, Lianlian; Shi, Ying; Liu, Na; Chen, Ling; Cao, Ya; Tao, Yongguang] Cent S Univ, Minist Educ, Key Lab Carcinogenesis & Canc Invas, Xiangya Hosp, Changsha 410078, Hunan, Peoples R China.
   [Mao, Chao; Wang, Min; Ouyang, Lianlian; Shi, Ying; Liu, Na; Chen, Ling; Cao, Ya; Tao, Yongguang] Cent S Univ, Minist Hlth, Key Lab Carcinogenesis, Canc Res Inst, Changsha 410078, Hunan, Peoples R China.
   [Wang, Min] Cent S Univ, Dept Histol & Embryol, Sch Basic Med, Changsha 410013, Hunan, Peoples R China.
   [Qian, Banglun; Wang, Xiang; Tao, Yongguang; Liu, Wenliang] Cent S Univ, Dept Thorac Surg, Xiangya Hosp 2, Changsha 410011, Hunan, Peoples R China.
   [Xiao, Desheng] Cent S Univ, Dept Pathol, Xiangya Hosp, Changsha 410008, Hunan, Peoples R China.
   [Liu, Shuang; Tao, Yongguang] Cent S Univ, Inst Med Sci, Xiangya Hosp, Changsha 410008, Hunan, Peoples R China.
C3 Central South University; Central South University; Central South
   University; Central South University; Central South University; Central
   South University
RP Tao, YG; Liu, WL (通讯作者)，Cent S Univ, Dept Thorac Surg, Xiangya Hosp 2, Changsha 410011, Hunan, Peoples R China.
EM taoyong@csu.edu.cn; liuwenliang@csu.edu.cn
RI Mao, Chao/AAM-6358-2020; Wang, Min/AAO-7324-2020
OI Mao, Chao/0000-0002-8685-8539
FU Fundamental Research Funds for the Central Universities [2018zzts829,
   2015zzts099]; National Natural Science Foundation of China [81672787,
   81372427, 81772927, 81672991, 81672307]; National Basic Research Program
   of China [2015CB553903]
FX This work was supported by the Fundamental Research Funds for the
   Central Universities [2018zzts829 (M. Wang), 2015zzts099 (C. Mao)], the
   National Natural Science Foundation of China [81672787 and 81372427 (Y.
   Tao), 81772927 (D. Xiao), 81672991 (S. Liu), 81672307 (X. Wang)]; and
   the National Basic Research Program of China [2015CB553903 (Y. Tao)].
CR Al-Dhfyan A, 2017, MOL CANCER, V16, DOI 10.1186/s12943-016-0570-y
   Bessede A, 2014, NATURE, V511, P184, DOI 10.1038/nature13323
   Bunaciu RP, 2011, CANCER RES, V71, P2371, DOI 10.1158/0008-5472.CAN-10-2299
   Burrage J, 2012, J CELL SCI, V125, P5524, DOI 10.1242/jcs.111252
   Chen WQ, 2016, CA-CANCER J CLIN, V66, P115, DOI 10.3322/caac.21338
   Clapier CR, 2017, NAT REV MOL CELL BIO, V18, P407, DOI 10.1038/nrm.2017.26
   D'Amato NC, 2015, CANCER RES, V75, P4651, DOI 10.1158/0008-5472.CAN-15-2011
   de Dieuleveult M, 2016, NATURE, V530, P113, DOI 10.1038/nature16505
   Dubey R, 2016, CANCER RES, V76, P5810, DOI 10.1158/0008-5472.CAN-16-0716
   Gazit R, 2013, STEM CELL REP, V1, P266, DOI 10.1016/j.stemcr.2013.07.004
   Gialitakis M, 2017, STEM CELL REP, V9, P1377, DOI 10.1016/j.stemcr.2017.09.025
   He XZ, 2016, CANCER RES, V76, P5743, DOI 10.1158/0008-5472.CAN-16-0268
   Helming KC, 2014, CANCER CELL, V26, P309, DOI 10.1016/j.ccr.2014.07.018
   Huang RJ, 2014, NATURE, V514, P218, DOI 10.1038/nature13774
   Jia JT, 2017, THERANOSTICS, V7, P3920, DOI 10.7150/thno.21389
   Jiang YQ, 2017, CHIN J CANCER, V36, DOI 10.1186/s40880-017-0248-x
   Jiang YQ, 2017, THERANOSTICS, V7, P3293, DOI 10.7150/thno.19988
   Keyes WM, 2011, CELL STEM CELL, V8, P164, DOI 10.1016/j.stem.2010.12.009
   Korzeniewski N, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-153
   Liu S, 2016, CHIN J CANCER, V35, DOI 10.1186/s40880-016-0138-7
   Mao C, 2018, CANCER RES, V78, P3484, DOI 10.1158/0008-5472.CAN-17-3454
   Mascanfroni ID, 2015, NAT MED, V21, P638, DOI 10.1038/nm.3868
   Masliah-Planchon J, 2015, ANNU REV PATHOL-MECH, V10, P145, DOI 10.1146/annurev-pathol-012414-040445
   Mathur R, 2017, NAT GENET, V49, P296, DOI 10.1038/ng.3744
   Moura-Alves P, 2014, NATURE, V512, P387, DOI 10.1038/nature13684
   Murray IA, 2014, NAT REV CANCER, V14, P801, DOI 10.1038/nrc3846
   Myant K, 2011, GENOME RES, V21, P83, DOI 10.1101/gr.108498.110
   Narlikar GJ, 2013, CELL, V154, P490, DOI 10.1016/j.cell.2013.07.011
   Opitz CA, 2011, NATURE, V478, P197, DOI 10.1038/nature10491
   Prud'homme GJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013831
   Reck M, 2013, LANCET, V382, P709, DOI 10.1016/S0140-6736(13)61502-0
   Rentas S, 2016, NATURE, V532, P508, DOI 10.1038/nature17665
   Schiering C, 2017, NATURE, V542, P242, DOI 10.1038/nature21080
   Shimizu Y, 2000, P NATL ACAD SCI USA, V97, P779, DOI 10.1073/pnas.97.2.779
   Sokol ES, 2017, P NATL ACAD SCI USA, V114, P4153, DOI 10.1073/pnas.1703931114
   Stanford EA, 2016, MOL CANCER RES, V14, P696, DOI 10.1158/1541-7786.MCR-16-0069
   Stanford EA, 2016, BMC BIOL, V14, DOI 10.1186/s12915-016-0240-y
   Stejskalova L, 2011, CURR DRUG METAB, V12, P198, DOI 10.2174/138920011795016818
   Tan KP, 2010, MOL PHARMACOL, V78, P175, DOI 10.1124/mol.110.065078
   Tao YG, 2011, P NATL ACAD SCI USA, V108, P5626, DOI 10.1073/pnas.1017000108
   Topper MJ, 2017, CELL, V171, P1284, DOI 10.1016/j.cell.2017.10.022
   Vaz M, 2017, CANCER CELL, V32, P360, DOI 10.1016/j.ccell.2017.08.006
   Villa M, 2017, EMBO J, V36, P116, DOI 10.15252/embj.201695027
   von Eyss B, 2012, EMBO J, V31, P972, DOI 10.1038/emboj.2011.451
   Wang GZ, 2014, NATURE, V514, P218
   Xiao DS, 2017, THERANOSTICS, V7, P132, DOI 10.7150/thno.17032
   Yan B, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0542-9
   Yu WS, 2014, GENOME RES, V24, P1613, DOI 10.1101/gr.172015.114
   Zemach A, 2013, CELL, V153, P193, DOI 10.1016/j.cell.2013.02.033
NR 49
TC 19
Z9 21
U1 0
U2 4
PU E-CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 2156-6976
J9 AM J CANCER RES
JI Am. J. Cancer Res.
PY 2018
VL 8
IS 7
BP 1214
EP 1227
PG 14
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA GO5MZ
UT WOS:000440068000008
PM 30094095
DA 2025-01-12
ER

PT J
AU Li, JQ
   Song, P
   Jiang, TT
   Dai, DJ
   Wang, HY
   Sun, J
   Zhu, LY
   Xu, WX
   Feng, LF
   Shin, VY
   Morrison, H
   Wang, X
   Jin, HC
AF Li, Jiaqiu
   Song, Ping
   Jiang, Tingting
   Dai, Dongjun
   Wang, Hanying
   Sun, Jie
   Zhu, Liyuan
   Xu, Wenxia
   Feng, Lifeng
   Shin, Vivian Y.
   Morrison, Helen
   Wang, Xian
   Jin, Hongchuan
TI Heat Shock Factor 1 Epigenetically Stimulates Glutaminase-1-Dependent
   mTOR Activation to Promote Colorectal Carcinogenesis
SO MOLECULAR THERAPY
LA English
DT Article
ID DNA METHYLATION; TRANSCRIPTION FACTOR-1; MULTIFACETED ROLES;
   GENE-EXPRESSION; BREAST-CANCER; HSF1; CARCINOMA; PROTEIN; KINASE;
   PROGRESSION
AB Heat shock factor 1 (HSF1) generally exhibits its properties under stress conditions. In tumors, HSF1 has a pleiotropic feature in regulating growth, survival, and aggressiveness of cancer cells. In this study, we found HSF1 was increased in colorectal cancer (CRC) and had a positive correlation with shorter disease-free survival (DFS). Knockdown of HSF1 in CRC cells attenuated their growth while inhibiting mTOR activation and glutamine metabolism. HSF1 inhibited the expression of microRNA137 (MIR137), which targeted GLS1 (glutaminase 1), thus stimulating GLS1 protein expression to promote glutaminolysis and mTOR activation. HSF1 bound DNA methyltransferase DNMT3a and recruited it to the promoter of lncRNA MIR137 host gene (MIR137HG), suppressing the generation of primary MIR137. The chemical inhibitor of HSF1 also reduced cell growth, increased apoptosis, and impaired glutamine metabolism in vitro. Moreover, both chemical inhibition and genetic knockout of HSF1 succeeded in increasing MIR137 expression, reducing GLS1 expression, and alleviating colorectal tumorigenesis in azoxymethane (AOM)/dextran sulfate sodium (DSS) mice. In conclusion, HSF1 expression was increased and associated-with poor prognosis inCRC. By recruitingDNMT3a to suppress the expression of MIR137 that targets GLS1 mRNA, HSF1 stimulated GLS1-dependent mTOR activation to promote colorectal carcinogenesis. Therefore, targeting HSF1 to attenuate glutaminolysis and mTOR activation could be a promising approach for CRC treatment.
C1 [Li, Jiaqiu; Song, Ping; Dai, Dongjun; Wang, Hanying; Wang, Xian] Zhejiang Univ, Sch Med, Sir Run Run Shaw Hosp, Dept Med Oncol, Hangzhou, Zhejiang, Peoples R China.
   [Jiang, Tingting; Sun, Jie; Zhu, Liyuan; Xu, Wenxia; Feng, Lifeng; Jin, Hongchuan] Zhejiang Univ, Sch Med, Sir Run Run Shaw Hosp, Lab Canc Biol,Key Lab Zhejiang Biotherapy, Hangzhou, Zhejiang, Peoples R China.
   [Shin, Vivian Y.] Univ Hong Kong, Fac Med, Dept Surg, Hong Kong, Hong Kong, Peoples R China.
   [Morrison, Helen] Fritz Lipmann Inst, Leibniz Inst Aging, Jena, Germany.
C3 Zhejiang University; Zhejiang University; University of Hong Kong;
   Leibniz Association; Leibniz Institut fur Alternsforschung -
   Fritz-Lipmann-Institut (FLI)
RP Wang, X (通讯作者)，Zhejiang Univ, Sch Med, Sir Run Run Shaw Hosp, Dept Med Oncol, Hangzhou, Zhejiang, Peoples R China.; Jin, HC (通讯作者)，Zhejiang Univ, Sch Med, Sir Run Run Shaw Hosp, Lab Canc Biol,Key Lab Zhejiang Biotherapy, Hangzhou, Zhejiang, Peoples R China.
EM wangx118@zju.edu.cn; jinhc@zju.edu.cn
RI Morrison, Helen/F-9748-2014; Jin, Hongchuan/C-3686-2009; Yu,
   Shi-Tong/H-3747-2018
OI Jin, Hongchuan/0000-0002-6697-3097; Wang, Hanying/0000-0002-9216-9342;
   li, jiaqiu/0000-0002-2292-6651
FU National Natural Science Foundation of China [81672360, 81772944];
   Natural Science Foundation of Zhejiang [LZ17H60003, LZ18H160001];
   Department of Healthcare in Zhejiang [WKJ-ZJ-1720]
FX This work was supported by the National Natural Science Foundation of
   China (81672360 and 81772944), the Natural Science Foundation of
   Zhejiang (LZ17H60003 and LZ18H160001), and the Department of Healthcare
   in Zhejiang (WKJ-ZJ-1720).
CR Bestor TH, 2000, HUM MOL GENET, V9, P2395, DOI 10.1093/hmg/9.16.2395
   Bukau B, 2006, CELL, V125, P443, DOI 10.1016/j.cell.2006.04.014
   Calderwood SK, 2012, CURR MOL MED, V12, P1102, DOI 10.2174/156652412803306675
   Chuma M, 2014, CARCINOGENESIS, V35, P272, DOI 10.1093/carcin/bgt343
   Dai C, 2007, CELL, V130, P1005, DOI 10.1016/j.cell.2007.07.020
   DeBerardinis RJ, 2010, ONCOGENE, V29, P313, DOI 10.1038/onc.2009.358
   Engerud H, 2014, BRIT J CANCER, V111, P78, DOI 10.1038/bjc.2014.262
   Fang F, 2012, CANCER-AM CANCER SOC, V118, P1782, DOI 10.1002/cncr.26482
   Gaedcke J, 2010, GENE CHROMOSOME CANC, V49, P1024, DOI 10.1002/gcc.20811
   Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9
   Hoang AT, 2000, AM J PATHOL, V156, P857, DOI 10.1016/S0002-9440(10)64954-1
   Hogart A, 2012, GENOME RES, V22, P1407, DOI 10.1101/gr.132878.111
   Isobe T, 2013, INT J CLIN ONCOL, V18, P293, DOI 10.1007/s10147-012-0378-8
   Jiang SF, 2015, TUMOR BIOL, V36, P4923, DOI 10.1007/s13277-015-3674-x
   Jin XJ, 2011, CELL METAB, V14, P91, DOI 10.1016/j.cmet.2011.03.025
   Jorissen RN, 2009, CLIN CANCER RES, V15, P7642, DOI 10.1158/1078-0432.CCR-09-1431
   Khaleque M, 2008, ONCOGENE, V27, P1886, DOI 10.1038/sj.onc.1210834
   Klutstein M, 2016, CANCER RES, V76, P3446, DOI 10.1158/0008-5472.CAN-15-3278
   Lamb J, 2006, SCIENCE, V313, P1929, DOI 10.1126/science.1132939
   Li RF, 2014, CELL METAB, V19, P702, DOI 10.1016/j.cmet.2014.03.012
   Magnani L, 2011, TRENDS GENET, V27, P465, DOI 10.1016/j.tig.2011.07.002
   Matés JM, 2013, CURR MOL MED, V13, P514
   Mendillo ML, 2012, CELL, V150, P549, DOI 10.1016/j.cell.2012.06.031
   Moghaddam AA, 2007, CANCER EPIDEM BIOMAR, V16, P2533, DOI 10.1158/1055-9965.EPI-07-0708
   Morandi L, 2017, CLIN EPIGENETICS, V9, DOI 10.1186/s13148-017-0386-7
   Neufert C, 2007, NAT PROTOC, V2, P1998, DOI 10.1038/nprot.2007.279
   Ni ZY, 2004, MOL CELL, V13, P55, DOI 10.1016/S1097-2765(03)00526-4
   Parkin DM, 2001, EUR J CANCER, V37, pS4, DOI 10.1016/S0959-8049(01)00267-2
   Richter K, 2010, MOL CELL, V40, P253, DOI 10.1016/j.molcel.2010.10.006
   Rieger Paula T, 2008, ONS Connect, V23, P27
   Ripke S, 2011, NAT GENET, V43, P969, DOI 10.1038/ng.940
   Röhrig F, 2016, NAT REV CANCER, V16, P732, DOI 10.1038/nrc.2016.89
   Rohan TE, 2003, AM J OBSTET GYNECOL, V189, pS37, DOI 10.1067/S0002-9378(03)01079-2
   Santagata S, 2013, SCIENCE, V341, P250, DOI 10.1126/science.1238303
   Santagata S, 2011, P NATL ACAD SCI USA, V108, P18378, DOI 10.1073/pnas.1115031108
   Shanware NP, 2011, J MOL MED, V89, P229, DOI 10.1007/s00109-011-0731-9
   Siegel R, 2014, CA-CANCER J CLIN, V64, P104, DOI [10.3322/caac.21220, 10.3322/caac.21395]
   Thangavelu K, 2014, SCI REP-UK, V4, DOI 10.1038/srep03827
   Velasco G, 2010, P NATL ACAD SCI USA, V107, P9281, DOI 10.1073/pnas.1000473107
   Viré E, 2006, NATURE, V439, P871, DOI 10.1038/nature04431
   Wang XZ, 2004, J BIOL CHEM, V279, P49460, DOI 10.1074/jbc.M406059200
   Wang YQ, 2004, J BIOL CHEM, V279, P32651, DOI 10.1074/jbc.M401475200
   Whitesell L, 2009, EXPERT OPIN THER TAR, V13, P469, DOI [10.1517/14728220902832697, 10.1517/14728220902832697 ]
   Wong SH, 2017, GASTROENTEROLOGY, V153, P1621, DOI 10.1053/j.gastro.2017.08.022
   Zaret KS, 2011, GENE DEV, V25, P2227, DOI 10.1101/gad.176826.111
   Zhao YH, 2009, ONCOGENE, V28, P3689, DOI 10.1038/onc.2009.229
   Zhao Y, 2016, CELL BIOSCI, V6, DOI 10.1186/s13578-016-0109-3
   Ziller MJ, 2013, NATURE, V500, P477, DOI 10.1038/nature12433
   ZIMARINO V, 1987, NATURE, V327, P727, DOI 10.1038/327727a0
NR 49
TC 66
Z9 69
U1 1
U2 16
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 1525-0016
EI 1525-0024
J9 MOL THER
JI Mol. Ther.
PD JUL 5
PY 2018
VL 26
IS 7
BP 1828
EP 1839
DI 10.1016/j.ymthe.2018.04.014
PG 12
WC Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine,
   Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Genetics & Heredity; Research &
   Experimental Medicine
GA GO1DN
UT WOS:000439688600021
PM 29730197
OA Green Published
DA 2025-01-12
ER

PT J
AU Evans, DGR
   van Veen, EM
   Byers, HJ
   Wallace, AJ
   Ellingford, JM
   Beaman, G
   Santoyo-Lopez, J
   Aitman, TJ
   Eccles, DM
   Lalloo, FI
   Smith, MJ
   Newman, WG
AF Evans, D. Gareth R.
   van Veen, Elke M.
   Byers, Helen J.
   Wallace, Andrew J.
   Ellingford, Jamie M.
   Beaman, Glenda
   Santoyo-Lopez, Javier
   Aitman, Timothy J.
   Eccles, Diana M.
   Lalloo, Fiona I.
   Smith, Miriam J.
   Newman, William G.
TI A Dominantly Inherited 5' UTR Variant Causing Methylation-Associated
   Silencing of <i>BRCA1</i> as a Cause of Breast and Ovarian Cancer
SO AMERICAN JOURNAL OF HUMAN GENETICS
LA English
DT Article
ID PROMOTER HYPERMETHYLATION; SPORADIC BREAST; EPIGENETIC INACTIVATION;
   SCORING SYSTEM; FAMILIES; RISK; SENSITIVITY; TUMORS; MLH1
AB Pathogenic variants in BRCA1 or BRCA2 are identified in similar to 20% of families with multiple individuals affected by early-onset breast and/or ovarian cancer. Extensive searches for additional highly penetrant genes or alternative mutational mechanisms altering BRCA1 or BRCA2 have not explained the missing heritability. Here, we report a dominantly inherited 5' UTR variant associated with epigenetic BRCA1 silencing due to promoter hypermethylation in two families affected by breast and ovarian cancer. BRCA1 promoter methylation of ten CpG dinucleotides in families who are affected by breast and/or ovarian cancer but do not have germline BRCA1 or BRCA2 pathogenic variants was assessed by pyrosequencing and clonal bisulfite sequencing. RNA and DNA sequencing of BRCA1 from lymphocytes was undertaken to establish allelic expression and the presence of germline variants. BRCA1 promoter hypermethylation was identified in 2 of 49 families in which multiple women are affected by grade 3 breast cancer or high-grade serous ovarian cancer. Soma-wide BRCA1 promoter hypermethylation was confirmed in blood, buccal mucosa, and hair follicles. Pyrosequencing showed that DNA was similar to 50% methylated, consistent with the silencing of one allele, which was confirmed by clonal bisulfite sequencing. RNA sequencing revealed the allelic loss of BRCA1 expression in both families and that this loss of expression segregated with the heterozygous variant c. -107A>T in the BRCA1 5' UTR. Our results establish a mechanism whereby familial breast and ovarian cancer is caused by an in cis 5' UTR variant associated with epigenetic silencing of the BRCA1 promoter in two independent families. We propose that methylation analyses be undertaken to establish the frequency of this mechanism in families affected by early-onset breast and/or ovarian cancer without a BRCA1 or BRCA2 pathogenic variant.
C1 [Evans, D. Gareth R.; van Veen, Elke M.; Byers, Helen J.; Ellingford, Jamie M.; Beaman, Glenda; Smith, Miriam J.; Newman, William G.] Univ Manchester, Manchester Acad Hlth Sci Ctr, Sch Biol Sci, Fac Biol Med & Hlth,Div Evolut & Genom Sci, Manchester M13 9PL, Lancs, England.
   [Evans, D. Gareth R.] Univ Hosp South Manchester, Prevent Breast Canc Ctr, Manchester M23 9LT, Lancs, England.
   [Evans, D. Gareth R.] Univ Hosp South Manchester, Nightingale Breast Screening Ctr, Manchester M23 9LT, Lancs, England.
   [Evans, D. Gareth R.] Christie NHS Fdn Trust, Manchester M20 4BX, Lancs, England.
   [Evans, D. Gareth R.; Newman, William G.] Univ Manchester, Manchester Canc Res Ctr, Manchester Breast Ctr, Manchester M20 4BX, Lancs, England.
   [van Veen, Elke M.; Byers, Helen J.; Wallace, Andrew J.; Ellingford, Jamie M.; Beaman, Glenda; Lalloo, Fiona I.; Smith, Miriam J.; Newman, William G.] St Marys Hosp, Manchester Univ NHS Fdn Trust, Manchester Acad Hlth Sci Ctr, Manchester Ctr Genom Med, Manchester M13 9WL, Lancs, England.
   [Santoyo-Lopez, Javier; Aitman, Timothy J.] Univ Edinburgh, Ctr Genom & Expt Med, Edinburgh EH4 2XU, Midlothian, Scotland.
   [Santoyo-Lopez, Javier; Aitman, Timothy J.] Univ Edinburgh, Edinburgh Genom, Edinburgh EH4 2XU, Midlothian, Scotland.
   [Eccles, Diana M.] Univ Southampton, Fac Med, Canc Sci Acad Unit, Southampton S016 6YD, Hants, England.
   [Eccles, Diana M.] Univ Southampton, Fac Med, Southampton Clin Trials Unit, Southampton S016 6YD, Hants, England.
   [Eccles, Diana M.] Univ Hosp Southampton Fdn Trust, Southampton S016 6YD, Hants, England.
C3 University of Manchester; Wythenshawe Hospital NHS Foundation Trust;
   Wythenshawe Hospital NHS Foundation Trust; Christie NHS Foundation
   Trust; University of Manchester; University of Manchester; University of
   Edinburgh; University of Edinburgh; University of Southampton;
   University of Southampton
RP Evans, DGR; Newman, WG (通讯作者)，Univ Manchester, Manchester Acad Hlth Sci Ctr, Sch Biol Sci, Fac Biol Med & Hlth,Div Evolut & Genom Sci, Manchester M13 9PL, Lancs, England.; Evans, DGR (通讯作者)，Univ Hosp South Manchester, Prevent Breast Canc Ctr, Manchester M23 9LT, Lancs, England.; Evans, DGR (通讯作者)，Univ Hosp South Manchester, Nightingale Breast Screening Ctr, Manchester M23 9LT, Lancs, England.; Evans, DGR (通讯作者)，Christie NHS Fdn Trust, Manchester M20 4BX, Lancs, England.; Evans, DGR; Newman, WG (通讯作者)，Univ Manchester, Manchester Canc Res Ctr, Manchester Breast Ctr, Manchester M20 4BX, Lancs, England.; Newman, WG (通讯作者)，St Marys Hosp, Manchester Univ NHS Fdn Trust, Manchester Acad Hlth Sci Ctr, Manchester Ctr Genom Med, Manchester M13 9WL, Lancs, England.
EM gareth.evans@mft.nhs.uk; william.newman@manchester.ac.uk
RI van Veen, Elke/ABA-3250-2021; Smith, Miriam/J-4001-2015; Eccles,
   Diana/K-6327-2019; Ellingford, Jamie/AAZ-7474-2020; Santoyo-Lopez,
   Javier/AHE-5002-2022; Evans, D/AAB-4308-2022; Santoyo-Lopez,
   Javier/C-9714-2012
OI van Veen, Elke/0000-0001-8618-2332; Ellingford,
   Jamie/0000-0003-1137-9768; Aitman, Timothy/0000-0002-7875-4502;
   Santoyo-Lopez, Javier/0000-0003-1988-5059; Newman,
   William/0000-0002-6382-4678; Eccles, Diana M/0000-0002-9935-3169; Evans,
   Gareth/0000-0002-8482-5784
FU Prevent Breast Cancer [GA 12-006, GA 15-002]; Manchester NIHR Biomedical
   Research Centre [IS-BRC-1215-20007]; NIHR [NF-SI-0513-10076]; Health
   Education England Genomics Education Programme (HEE GEP); MRC
   [MR/N005902/1, MC_PC_15080] Funding Source: UKRI
FX We thank the family members for their participation and co-operation.
   This work was funded by Prevent Breast Cancer (GA 12-006 and GA 15-002)
   and the Manchester NIHR Biomedical Research Centre (IS-BRC-1215-20007).
   D.G.R.E. is an NIHR Senior Investigator (NF-SI-0513-10076). J.M.E. is
   funded by a postdoctoral research fellowship from the Health Education
   England Genomics Education Programme (HEE GEP). The views expressed in
   this publication are those of the authors and not necessarily those of
   the HEE GEP. No funding bodies had a role in the design or conduct of
   the study; collection, management, analysis, or interpretation of the
   data; preparation, review, or approval of the manuscript; or decision to
   submit the manuscript for publication. D.G.R.E. and E.M.v.V. had full
   access to all the data in the study and take responsibility for the
   integrity of the data and the accuracy of the data analysis. All tested
   individuals gave consent to present their personal information in this
   manuscript. We thank Jeanette Rothwell for sample collection and Natasha
   Leo for technical assistance, as well as the Genome Aggregation Database
   (gnomAD) and the groups that provided exome and genome variant data to
   this resource. A full list of contributing groups can be found at
   http://gnomad.broadinstitute.org/about.
CR Alsop K, 2012, J CLIN ONCOL, V30, P2654, DOI 10.1200/JCO.2011.39.8545
   Byers H, 2016, EUR J HUM GENET, V24, P1591, DOI 10.1038/ejhg.2016.57
   Easton DF, 2015, NEW ENGL J MED, V372, P2243, DOI 10.1056/NEJMsr1501341
   Eccles SA, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3493
   Esteller M, 2000, JNCI-J NATL CANCER I, V92, P564, DOI 10.1093/jnci/92.7.564
   Evans DG, 2017, J MED GENET, V54, P674, DOI 10.1136/jmedgenet-2017-104584
   Evans DG, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-155
   Evans DGR, 2004, J MED GENET, V41, P474, DOI 10.1136/jmg.2003.017996
   Frosk P, 2007, GENET TEST, V11, P208, DOI 10.1089/gte.2006.0518
   Hansmann T, 2012, HUM MOL GENET, V21, P4669, DOI 10.1093/hmg/dds308
   Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075
   Hitchins MP, 2007, NEW ENGL J MED, V356, P697, DOI 10.1056/NEJMoa064522
   Hitchins MP, 2015, NAT REV CANCER, V15, DOI 10.1038/nrc4001
   Hitchins MP, 2011, CANCER CELL, V20, P200, DOI 10.1016/j.ccr.2011.07.003
   Lek M, 2016, NATURE, V536, P285, DOI 10.1038/nature19057
   Ligtenberg MJL, 2009, NAT GENET, V41, P112, DOI 10.1038/ng.283
   MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954
   Morak M, 2018, J MED GENET, V55, P240, DOI 10.1136/jmedgenet-2017-104744
   Moran A, 2012, FAM CANCER, V11, P235, DOI 10.1007/s10689-011-9506-2
   Palma MD, 2008, CANCER RES, V68, P7006, DOI 10.1158/0008-5472.CAN-08-0599
   Ponder BAJ, 2000, BRIT J CANCER, V83, P1301
   Rice JC, 1998, ONCOGENE, V17, P1807, DOI 10.1038/sj.onc.1202086
   Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166
   Sloane MA, 2016, CLIN EPIGENETICS, V8, DOI 10.1186/s13148-016-0207-4
   Stefansson OA, 2012, EPIGENETICS-US, V7, P1225, DOI 10.4161/epi.22561
   Tapia T, 2008, EPIGENETICS-US, V3, P157, DOI 10.4161/epi.3.3.6387
   Tutt A, 2010, LANCET, V376, P235, DOI 10.1016/S0140-6736(10)60892-6
   Yamashita N, 2015, CLIN BREAST CANCER, V15, P498, DOI 10.1016/j.clbc.2015.06.009
NR 28
TC 61
Z9 63
U1 0
U2 13
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 0002-9297
EI 1537-6605
J9 AM J HUM GENET
JI Am. J. Hum. Genet.
PD AUG 2
PY 2018
VL 103
IS 2
BP 213
EP 220
DI 10.1016/j.ajhg.2018.07.002
PG 8
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA GP1GR
UT WOS:000440563700004
PM 30075112
OA Green Published, hybrid, Green Accepted
DA 2025-01-12
ER

PT J
AU Huang, JF
   Wen, CJ
   Zhao, GZ
   Dai, Y
   Li, Y
   Wu, LX
   Zhou, HH
AF Huang, Jia-Feng
   Wen, Chun-Jie
   Zhao, Guo-Zhi
   Dai, Yi
   Li, Ying
   Wu, Lan-Xiang
   Zhou, Hong-Hao
TI Overexpression of ABCB4 contributes to acquired doxorubicin resistance
   in breast cancer cells in vitro
SO CANCER CHEMOTHERAPY AND PHARMACOLOGY
LA English
DT Article
DE ABCB4; Doxorubicin; Acquired resistance; Breast cancer cells
ID PACLITAXEL RESISTANCE; P-GLYCOPROTEIN; EXPRESSION; TRANSPORTERS; MDR1;
   PROMOTER; THERAPY; ABCG2; GENE; CHEMORESISTANCE
AB Doxorubicin is one of the most active agents in the first-line therapy for metastatic breast cancer, but its utility is partially limited by the frequent emergence of doxorubicin resistance. In this study, we aimed to investigate the role of ATP-binding cassette sub-family B, member 4 (ABCB4) in acquired doxorubicin resistance in breast cancer cells, as well as its potential mechanism.
   In doxorubicin-sensitive and -resistant breast cancer cell lines MCF-7 and MDA-MB-231, the expression levels of ABCB4 were detected using real-time quantitative PCR and Western blot analysis, the DNA methylation and histone acetylation status of ABCB4 gene were investigated by bisulfite-sequencing PCR (BSP) and chromatin immunoprecipitation (ChIP) assays, and the doxorubicin sensitivity and intracellular doxorubicin accumulation were observed using cell cytotoxicity assay and flow cytometry. In Madin-Darby Canine Kidney (MDCKII) cells, In vitro transport assay was used to assess the ABCB4-mediated transport of doxorubicin.
   ABCB4 was overexpressed in doxorubicin-resistant breast cancer cells compared to their doxorubicin-sensitive counterparts, which was associated with reduced DNA methylation as well as increased histone acetylation at the ABCB4 promoter. ABCB4 could actively pump doxorubicin out of the cells, and knockdown of ABCB4 increased doxorubicin sensitivity and intracellular accumulation in doxorubicin-resistant breast cancer cells.
   Our results indicate that ABCB4 is overexpressed in breast cancer cells with acquired doxorubicin resistance, which could be attributed, at least partially, to the epigenetic modifications of ABCB4 gene. ABCB4 mediates the efflux transport of doxorubicin, and contributes to the acquired resistance of doxorubicin in breast cancer cells.
C1 [Huang, Jia-Feng; Wen, Chun-Jie; Zhao, Guo-Zhi; Dai, Yi; Li, Ying; Wu, Lan-Xiang; Zhou, Hong-Hao] Chongqing Med Univ, Inst Life Sci, Chongqing 400016, Peoples R China.
   [Zhou, Hong-Hao] Cent S Univ, Inst Clin Pharmacol, Pharmacogenet Res Inst, Changsha 410078, Hunan, Peoples R China.
C3 Chongqing Medical University; Central South University
RP Wu, LX (通讯作者)，Chongqing Med Univ, Inst Life Sci, Chongqing 400016, Peoples R China.
EM lxwu2008@126.com
RI Zhou, Honghao/JWO-4641-2024; Dai, Yi/AAC-1336-2019; wang,
   lili/HDL-7210-2022
FU National Scientific Foundation of China [81473284, 81603201, 31501039];
   Natural Science Foundation of Chongqing [cstc2016jcyjA0305]; Scientific
   and Technological Program of Chongqing Yuzhong district [20140104];
   Project of Cancer Immunopathology in Ministry of Education [2012jszl10]
FX This work was supported by the National Scientific Foundation of China
   (nos. 81473284, 81603201, 31501039), Natural Science Foundation of
   Chongqing (no. cstc2016jcyjA0305), Scientific and Technological Program
   of Chongqing Yuzhong district (no. 20140104), and Project of Cancer
   Immunopathology in Ministry of Education (no. 2012jszl10).
CR Aniogo EC, 2017, EXPERT REV ANTICANC, V17, P693, DOI 10.1080/14737140.2017.1347505
   Arrigoni E, 2016, EXPERT OPIN DRUG MET, V12, P1419, DOI 10.1080/17425255.2016.1215423
   Bachour-El Azzi P, 2015, TOXICOL SCI, V145, P157, DOI 10.1093/toxsci/kfv041
   Baker EK, 2005, ONCOGENE, V24, P8061, DOI 10.1038/sj.onc.1208955
   Bao LL, 2012, AM J PATHOL, V180, P2490, DOI 10.1016/j.ajpath.2012.02.024
   Chen KG, 2005, CANCER RES, V65, P9388, DOI 10.1158/0008-5472.CAN-04-4133
   Chen SF, 2015, GENET MOL RES, V14, P14548, DOI 10.4238/2015.November.18.18
   Cihalova D, 2015, BIOCHEM PHARMACOL, V98, P465, DOI 10.1016/j.bcp.2015.08.099
   Citti A, 2012, INT J ONCOL, V41, P117, DOI 10.3892/ijo.2012.1433
   Duan ZF, 2004, MOL CANCER THER, V3, P833
   Falguières T, 2014, CLIN RES HEPATOL GAS, V38, P557, DOI 10.1016/j.clinre.2014.03.001
   Fojo T, 2007, CLIN BREAST CANCER, V7, P749, DOI 10.3816/CBC.2007.n.035
   Giacomini KM, 2010, NAT REV DRUG DISCOV, V9, P215, DOI 10.1038/nrd3028
   Goh LB, 2002, BIOCHEM PHARMACOL, V64, P1569, DOI 10.1016/S0006-2952(02)01355-2
   Gonzalez-Angulo AM, 2007, ADV EXP MED BIOL, V608, P1
   Hontecillas-Prieto L, 2017, ONCOTARGET, V8, P11173, DOI 10.18632/oncotarget.14491
   Januchowski R, 2014, BIOMED PHARMACOTHER, V68, P111, DOI 10.1016/j.biopha.2013.09.004
   Jung KA, 2015, MOL PHARMACOL, V87, P465, DOI 10.1124/mol.114.096065
   Kiehl S, 2014, SCI REP-UK, V4, DOI 10.1038/srep06899
   Lal S, 2010, CURR DRUG METAB, V11, P115, DOI 10.2174/138920010791110890
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Nemcová-Furstová V, 2016, TOXICOL APPL PHARM, V310, P215, DOI 10.1016/j.taap.2016.09.020
   Nicolini A, 2006, BIOMED PHARMACOTHER, V60, P548, DOI 10.1016/j.biopha.2006.07.086
   Shen F, 2008, J PHARMACOL EXP THER, V324, P95, DOI 10.1124/jpet.107.127704
   Smith AJ, 2000, J BIOL CHEM, V275, P23530, DOI 10.1074/jbc.M909002199
   Spencer ES, 2010, RES VET SCI, V89, P65, DOI 10.1016/j.rvsc.2010.01.012
   To KKW, 2008, MOL CANCER RES, V6, P151, DOI 10.1158/1541-7786.MCR-07-0175
   To KKW, 2006, MOL CELL BIOL, V26, P8572, DOI 10.1128/MCB.00650-06
   Toth M, 2012, CANCER SCI, V103, P659, DOI 10.1111/j.1349-7006.2012.02215.x
   Wang W, 2017, THROMB RES, V156, P126, DOI 10.1016/j.thromres.2017.06.020
   Yamasaki M, 2011, BRIT J CANCER, V104, P707, DOI 10.1038/sj.bjc.6606071
NR 31
TC 34
Z9 37
U1 2
U2 16
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0344-5704
EI 1432-0843
J9 CANCER CHEMOTH PHARM
JI Cancer Chemother. Pharmacol.
PD AUG
PY 2018
VL 82
IS 2
BP 199
EP 210
DI 10.1007/s00280-018-3603-y
PG 12
WC Oncology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Pharmacology & Pharmacy
GA GN8RV
UT WOS:000439439400003
PM 29777275
OA Bronze
DA 2025-01-12
ER

PT J
AU Ward, E
   Vareslija, D
   Charmsaz, S
   Fagan, A
   Browne, AL
   Cosgrove, N
   Cocchiglia, S
   Purcell, SP
   Hudson, L
   Das, S
   O'Connor, D
   O'Halloran, PJ
   Sims, AH
   Hill, AD
   Young, LS
AF Ward, Elspeth
   Vareslija, Damir
   Charmsaz, Sara
   Fagan, Ailis
   Browne, Alacoque L.
   Cosgrove, Nicola
   Cocchiglia, Sinead
   Purcell, Siobhan P.
   Hudson, Lance
   Das, Sudipto
   O'Connor, Darran
   O'Halloran, Philip J.
   Sims, Andrew H.
   Hill, Arnold D.
   Young, Leonie S.
TI Epigenome-wide SRC-1-Mediated Gene Silencing Represses Cellular
   Differentiation in Advanced Breast Cancer
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID RECEPTOR COACTIVATOR SRC-1; DNA METHYLATION; ENDOCRINE RESISTANCE;
   ESTROGEN-RECEPTOR; EPIGENETIC EVENTS; EXPRESSION; TUMORS; PROTEINS;
   THERAPY; GENOME
AB Purpose: Despite the clinical utility of endocrine therapies for estrogen receptor-positive (ER) breast cancer, up to 40% of patients eventually develop resistance, leading to disease progression. Themolecular determinants that drive this adaptation to treatment remain poorly understood. Methylome aberrations drive cancer growth yet the functional role andmechanism of these epimutations in drug resistance are poorly elucidated.
   Experimental Design: Genome-wide multi-omics sequencing approach identified a differentially methylated hub of pro-differentiation genes in endocrine resistant breast cancer patients and cell models. Clinical relevance of the functionally validated methyl-targets was assessed in a cohort of endocrine-treated human breast cancers and patient-derived ex vivo metastatic tumors.
   Results: Enhanced global hypermethylation was observed in endocrine treatment resistant cells and patient metastasis relative to sensitive parent cells and matched primary breast tumor, respectively. Using paired methylation and transcriptional profiles, we found that SRC-1-dependent alterations in endocrine resistance lead to aberrant hypermethylation that resulted in reduced expression of a set of differentiation genes. Analysis of ER-positive endocrine-treated human breast tumors (n = 669) demonstrated that low expression of this prodifferentiation gene set significantly associated with poor clinical outcome (P = 0.00009). We demonstrate that the reactivation of these genes in vitro and ex vivo reverses the aggressive phenotype.
   Conclusions: Our work demonstrates that SRC-1-dependent epigenetic remodeling is a ' high level' regulator of the poorly differentiated state in ER-positive breast cancer. Collectively these data revealed an epigenetic reprograming pathway, whereby concerted differential DNA methylation is potentiated by SRC-1 in the endocrine resistant setting. (C) 2018 AACR.
C1 [Ward, Elspeth; Vareslija, Damir; Charmsaz, Sara; Fagan, Ailis; Browne, Alacoque L.; Cosgrove, Nicola; Cocchiglia, Sinead; Purcell, Siobhan P.; Hudson, Lance; Hill, Arnold D.; Young, Leonie S.] Royal Coll Surgeons Ireland, Dept Surg, Endocrine Oncol Res Grp, Dublin 2, Ireland.
   [Das, Sudipto; O'Connor, Darran] Royal Coll Surgeons Ireland, Mol & Cellular Therapeut, Dublin, Ireland.
   [O'Halloran, Philip J.] Beaumont Hosp, Natl Neurosurg Ctr, Dept Neurosurg, Dublin, Ireland.
   [Sims, Andrew H.] Univ Edinburgh, Canc Res UK Ctr, MRC Inst Genet & Mol Med, Appl Bioinformat Canc Grp,Western Gen Hosp, Edinburgh, Midlothian, Scotland.
C3 Royal College of Surgeons - Ireland; Royal College of Surgeons -
   Ireland; University of Edinburgh
RP Young, LS (通讯作者)，Royal Coll Surgeons Ireland, Dept Surg, Endocrine Oncol Res Grp, Dublin 2, Ireland.
EM lyoung@rcsi.ie
RI Cosgrove, Nicola/LKJ-5762-2024; Hill, Arnold/F-8438-2011; Sims,
   Andrew/E-4819-2012
OI Vareslija, Damir/0000-0003-1000-0357; O'Connor,
   Darran/0000-0002-8835-1547; Sims, Andrew/0000-0001-9082-3665;
   O'Halloran, Philip J/0000-0001-9175-8682; Cosgrove,
   Nicola/0000-0002-8296-115X; Ward, Elspeth/0000-0002-7530-2279
FU Irish Cancer Society Collaborative Cancer Research Centre grant
   [CCRC13GAL]; Breast Cancer Research Foundation; Science Foundation
   Ireland; Breast Cancer Ireland
FX We kindly acknowledge the funding support from Irish Cancer Society
   Collaborative Cancer Research Centre grant, CCRC13GAL, Breast Cancer
   Research Foundation, Science Foundation Ireland and Breast Cancer
   Ireland.
CR Al-Azawi D, 2008, ONCOGENE, V27, P3021, DOI 10.1038/sj.onc.1210964
   Badia E, 2000, CANCER RES, V60, P4130
   Baylin SB, 2006, NAT REV CANCER, V6, P107, DOI 10.1038/nrc1799
   Bogdanovic O, 2009, CHROMOSOMA, V118, P549, DOI 10.1007/s00412-009-0221-9
   BRONZERT DA, 1985, ENDOCRINOLOGY, V117, P1409, DOI 10.1210/endo-117-4-1409
   Browne AL, 2018, ONCOGENE, V37, P2008, DOI 10.1038/s41388-017-0042-x
   Cedar H, 2009, NAT REV GENET, V10, P295, DOI 10.1038/nrg2540
   Charmsaz S, 2017, BMC MED, V15, DOI 10.1186/s12916-017-0836-2
   Chimonidou M, 2013, CLIN BIOCHEM, V46, P235, DOI 10.1016/j.clinbiochem.2012.09.015
   Clarke R, 2015, MOL CELL ENDOCRINOL, V418, P220, DOI 10.1016/j.mce.2015.09.035
   Dai MH, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni179
   Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X
   Dobrovolna J, 2012, MOL CELL BIOL, V32, P730, DOI 10.1128/MCB.06473-11
   Easwaran H, 2012, GENOME RES, V22, P837, DOI 10.1101/gr.131169.111
   Eden A, 2003, SCIENCE, V300, P455, DOI 10.1126/science.1083557
   Fackler MJ, 2011, CANCER RES, V71, P6195, DOI 10.1158/0008-5472.CAN-11-1630
   Fan MY, 2006, CANCER RES, V66, P11954, DOI 10.1158/0008-5472.CAN-06-1666
   Fang F, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3001875
   Fatemi M, 2006, J CELL SCI, V119, P3033, DOI 10.1242/jcs.03099
   Gaudet F, 2003, SCIENCE, V300, P489, DOI 10.1126/science.1083558
   Holm K, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2590
   Jeselsohn R, 2015, NAT REV CLIN ONCOL, V12, P573, DOI 10.1038/nrclinonc.2015.117
   Johnson WE, 2007, BIOSTATISTICS, V8, P118, DOI 10.1093/biostatistics/kxj037
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Jones PA, 2016, NAT REV GENET, V17, P630, DOI 10.1038/nrg.2016.93
   Jones PA, 2014, J CLIN INVEST, V124, P14, DOI 10.1172/JCI74145
   Jones PA, 2009, NAT REV GENET, V10, P805, DOI 10.1038/nrg2651
   Kittler R, 2013, CELL REP, V3, P538, DOI 10.1016/j.celrep.2013.01.004
   Lin X, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3588
   Liu MY, 2016, CURR OPIN CHEM BIOL, V33, P67, DOI 10.1016/j.cbpa.2016.05.029
   Martens JWM, 2009, FUTURE ONCOL, V5, P1245, DOI [10.2217/fon.09.89, 10.2217/FON.09.89]
   Martínez-Galán J, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-59
   McBryan J, 2015, CLIN CANCER RES, V21, P5371, DOI 10.1158/1078-0432.CCR-14-2155
   McBryan J, 2012, CANCER RES, V72, P548, DOI 10.1158/0008-5472.CAN-11-2073
   McCartan D, 2012, CANCER RES, V72, P220, DOI 10.1158/0008-5472.CAN-11-1976
   Mellén M, 2012, CELL, V151, P1417, DOI 10.1016/j.cell.2012.11.022
   Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764
   Navada SC, 2014, J CLIN INVEST, V124, P40, DOI 10.1172/JCI69739
   Nguyen VTM, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms10044
   O'Hara J, 2012, CLIN CANCER RES, V18, P3305, DOI 10.1158/1078-0432.CCR-11-3300
   Park S, 2010, ANN ONCOL, V21, P488, DOI 10.1093/annonc/mdp510
   Priedigkeit N, 2017, JAMA ONCOL, V3, P666, DOI 10.1001/jamaoncol.2016.5630
   Qin L, 2009, CANCER RES, V69, P3819, DOI 10.1158/0008-5472.CAN-08-4389
   Redmond AM, 2009, CLIN CANCER RES, V15, P2098, DOI 10.1158/1078-0432.CCR-08-1649
   Ross-Innes CS, 2012, NATURE, V481, P389, DOI 10.1038/nature10730
   Rountree MR, 2000, NAT GENET, V25, P269, DOI 10.1038/77023
   Sasaki H, 2008, NAT REV GENET, V9, P129, DOI 10.1038/nrg2295
   Schlesinger Y, 2007, NAT GENET, V39, P232, DOI 10.1038/ng1950
   Shaw FL, 2012, J MAMMARY GLAND BIOL, V17, P111, DOI 10.1007/s10911-012-9255-3
   Shen H, 2013, CELL, V153, P38, DOI 10.1016/j.cell.2013.03.008
   Simoes BM, 2015, CELL REP, V12, P1968, DOI 10.1016/j.celrep.2015.08.050
   Stone A, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8758
   Szyf M, 2012, GENOME MED, V4, DOI 10.1186/gm325
   Ting AH, 2006, GENE DEV, V20, P3215, DOI 10.1101/gad.1464906
   Tishkov I, 1989, Vutr Boles, V28, P104
   Uhlenhaut NH, 2013, MOL CELL, V49, P158, DOI 10.1016/j.molcel.2012.10.013
   Vareslija D, 2017, METHODS MOL BIOL, V1501, P327, DOI 10.1007/978-1-4939-6475-8_17
   Vareslija D, 2016, CLIN CANCER RES, V22, P2765, DOI 10.1158/1078-0432.CCR-15-1583
   Visvanathan K, 2017, J CLIN ONCOL, V35, P751, DOI 10.1200/JCO.2015.66.2080
   Walsh CA, 2014, CANCER RES, V74, P2533, DOI 10.1158/0008-5472.CAN-13-2133
   West AC, 2014, J CLIN INVEST, V124, P30, DOI 10.1172/JCI69738
   Widschwendter M, 2007, NAT GENET, V39, P157, DOI 10.1038/ng1941
   Xu JM, 2009, NAT REV CANCER, V9, P615, DOI 10.1038/nrc2695
   Xu JM, 1998, SCIENCE, V279, P1922, DOI 10.1126/science.279.5358.1922
   Xu ZL, 2013, JNCI-J NATL CANCER I, V105, P694, DOI 10.1093/jnci/djt045
   Zhao SS, 2017, CLIN CANCER RES, V23, P311, DOI 10.1158/1078-0432.CCR-16-0549
NR 66
TC 14
Z9 15
U1 0
U2 7
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
EI 1557-3265
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD AUG 1
PY 2018
VL 24
IS 15
BP 3692
EP 3703
DI 10.1158/1078-0432.CCR-17-2615
PG 12
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA GP1TP
UT WOS:000440600200023
PM 29567811
OA Green Accepted, Green Submitted
DA 2025-01-12
ER

PT J
AU Casey, AE
   Sinha, A
   Singhania, R
   Livingstone, J
   Waterhouse, P
   Tharmapalan, P
   Cruickshank, J
   Shehata, M
   Drysdale, E
   Fang, H
   Kim, H
   Isserlin, R
   Bailey, S
   Medina, T
   Deblois, G
   Shiah, YJ
   Barsyte-Lovejoy, D
   Hofer, S
   Bader, G
   Lupien, M
   Arrowsmith, C
   Knapp, S
   De Carvalho, D
   Berman, H
   Boutros, PC
   Kislinger, T
   Khokha, R
AF Casey, Alison E.
   Sinha, Ankit
   Singhania, Rajat
   Livingstone, Julie
   Waterhouse, Paul
   Tharmapalan, Pirashaanthy
   Cruickshank, Jennifer
   Shehata, Mona
   Drysdale, Erik
   Fang, Hui
   Kim, Hyeyeon
   Isserlin, Ruth
   Bailey, Swneke
   Medina, Tiago
   Deblois, Genevieve
   Shiah, Yu-Jia
   Barsyte-Lovejoy, Dalia
   Hofer, Stefan
   Bader, Gary
   Lupien, Mathieu
   Arrowsmith, Cheryl
   Knapp, Stefan
   De Carvalho, Daniel
   Berman, Hal
   Boutros, Paul C.
   Kislinger, Thomas
   Khokha, Rama
TI Mammary molecular portraits reveal lineage-specific features and
   progenitor cell vulnerabilities
SO JOURNAL OF CELL BIOLOGY
LA English
DT Article
ID EPITHELIAL STEM-CELLS; BREAST-CANCER; FUNCTIONAL INTERPRETATION;
   EXPRESSION; BRCA1; MOUSE; RISK; GLAND; PROLIFERATION; EPIGENOME
AB The mammary epithelium depends on specific lineages and their stem and progenitor function to accommodate hormone-triggered physiological demands in the adult female. Perturbations of these lineages underpin breast cancer risk, yet our understanding of normal mammary cell composition is incomplete. Here, we build a multimodal resource for the adult gland through comprehensive profiling of primary cell epigenomes, transcriptomes, and proteomes. We define systems-level relationships between chromatin-DNA-RNA-protein states, identify lineage-specific DNA methylation of transcription factor binding sites, and pinpoint proteins underlying progesterone responsiveness. Comparative proteomics of estrogen and progesterone receptor-positive and -negative cell populations, extensive target validation, and drug testing lead to discovery of stem and progenitor cell vulnerabilities. Top epigenetic drugs exert cytostatic effects; prevent adult mammary cell expansion, clonogenicity, and mammopoiesis; and deplete stem cell frequency. Select drugs also abrogate human breast progenitor cell activity in normal and high-risk patient samples. This integrative computational and functional study provides fundamental insight into mammary lineage and stem cell biology.
C1 [Casey, Alison E.; Sinha, Ankit; Singhania, Rajat; Waterhouse, Paul; Tharmapalan, Pirashaanthy; Cruickshank, Jennifer; Shehata, Mona; Fang, Hui; Kim, Hyeyeon; Bailey, Swneke; Medina, Tiago; Deblois, Genevieve; Hofer, Stefan; Lupien, Mathieu; Arrowsmith, Cheryl; De Carvalho, Daniel; Berman, Hal; Kislinger, Thomas; Khokha, Rama] Princess Margaret Canc Ctr, Toronto, ON, Canada.
   [Livingstone, Julie; Drysdale, Erik; Shiah, Yu-Jia; Boutros, Paul C.] Ontario Inst Canc Res, Informat & Biocomp Program, Toronto, ON, Canada.
   [Isserlin, Ruth; Bader, Gary] Univ Toronto, Donnelly Ctr, Toronto, ON, Canada.
   [Barsyte-Lovejoy, Dalia; Arrowsmith, Cheryl] Univ Toronto, Struct Genom Consortium, Toronto, ON, Canada.
   [Knapp, Stefan] Univ Oxford, Nuffield Dept Clin Med, Struct Genom Consortium, Oxford, England.
   [Lupien, Mathieu; Arrowsmith, Cheryl; De Carvalho, Daniel; Boutros, Paul C.; Kislinger, Thomas; Khokha, Rama] Univ Toronto, Dept Med Biophys, Toronto, ON, Canada.
   [Boutros, Paul C.] Univ Toronto, Dept Pharmacol & Toxicol, Toronto, ON, Canada.
   [Berman, Hal] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada.
C3 University of Toronto; University Health Network Toronto; Princess
   Margaret Cancer Centre; Ontario Institute for Cancer Research;
   University of Toronto; University of Toronto; Structural Genomics
   Consortium; University of Oxford; University of Toronto; University of
   Toronto; University of Toronto
RP Khokha, R (通讯作者)，Princess Margaret Canc Ctr, Toronto, ON, Canada.; Khokha, R (通讯作者)，Univ Toronto, Dept Med Biophys, Toronto, ON, Canada.
EM rama.khokha@uhnresearch.ca
RI Kislinger, Thomas/A-5934-2008; Knapp, Stefan/AAG-2347-2019; Boutros,
   Paul/A-1084-2009; De Carvalho, Daniel/J-5503-2014; Medina,
   Tiago/B-3084-2018; Lupien, Mathieu/KFB-6691-2024
OI Deblois, Genevieve/0000-0002-3067-2807; Medina,
   Tiago/0000-0001-8674-8842; Boutros, Paul/0000-0003-0553-7520;
   Cruickshank, Jennifer/0009-0007-4963-3430; Waterhouse,
   Paul/0000-0001-8745-5224; Livingstone, Julie/0000-0002-8424-3768;
   Lupien, Mathieu/0000-0003-0929-9478; Kislinger,
   Thomas/0000-0003-3525-5540
FU Canadian Breast Cancer Foundation (CBCF) [313420]; Canadian Cancer
   Society Research Institute [702294, 705458]; Prairie Women on
   Snowmobiles; Hold'em For Life; CBCF; Canadian Institutes of Health
   Research (CIHR); Frank Fletcher Memorial Fund scholarship; Terry Fox
   Research Institute; CIHR
FX This work is supported by funding from the Canadian Breast Cancer
   Foundation (CBCF; grant 313420), Canadian Cancer Society Research
   Institute (grants 702294 and 705458), Prairie Women on Snowmobiles, and
   Hold'em For Life. A.E. Casey holds a CBCF fellowship; A. Sinha received
   a Canadian Institutes of Health Research (CIHR) doctoral research award
   and holds a Frank Fletcher Memorial Fund scholarship; and P.C. Boutros
   received a Terry Fox Research Institute New Investigator Award and CIHR
   New Investigator Award.
CR Abe T, 2013, DEVELOPMENT, V140, P237, DOI 10.1242/dev.084111
   Akalin A, 2012, GENOME BIOL, V13, DOI [10.1186/gb-2012-13-10-R87, 10.1186/gb-2012-13-10-r87]
   [Anonymous], 2004, Stat. Appl. Genet. Mol. Biol., DOI [10.2202/1544-6115.1027, DOI 10.2202/1544-6115.1027]
   Asselin-Labat ML, 2010, NATURE, V465, P798, DOI 10.1038/nature09027
   Buenrostro JD, 2013, NAT METHODS, V10, P1213, DOI [10.1038/NMETH.2688, 10.1038/nmeth.2688]
   Cardiff RD, 1999, J MAMMARY GLAND BIOL, V4, P105, DOI 10.1023/A:1018712905244
   Cerami Ethan G, 2011, Nucleic Acids Res, V39, pD685, DOI 10.1093/nar/gkq1039
   Chlebowski RT, 2015, JAMA ONCOL, V1, P296, DOI 10.1001/jamaoncol.2015.0494
   Cox B, 2009, MOL SYST BIOL, V5, DOI 10.1038/msb.2009.37
   Cox J, 2014, MOL CELL PROTEOMICS, V13, P2513, DOI 10.1074/mcp.M113.031591
   Deugnier MA, 2002, BREAST CANCER RES, V4, P224, DOI 10.1186/bcr459
   dos Santos CO, 2015, CELL REP, V11, P1102, DOI 10.1016/j.celrep.2015.04.015
   Edgar R, 2002, NUCLEIC ACIDS RES, V30, P207, DOI 10.1093/nar/30.1.207
   Eirew P, 2010, NAT PROTOC, V5, P1945, DOI 10.1038/nprot.2010.148
   Eirew P, 2008, NAT MED, V14, P1384, DOI 10.1038/nm.1791
   Eisen A, 2005, J CLIN ONCOL, V23, P7491, DOI 10.1200/JCO.2004.00.7138
   Gascard P, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7351
   Gu HC, 2011, NAT PROTOC, V6, P468, DOI 10.1038/nprot.2010.190
   Heinz S, 2010, MOL CELL, V38, P576, DOI 10.1016/j.molcel.2010.05.004
   Hennighausen L, 2005, NAT REV MOL CELL BIO, V6, P715, DOI 10.1038/nrm1714
   Herschkowitz JI, 2012, P NATL ACAD SCI USA, V109, P2778, DOI 10.1073/pnas.1018862108
   Hu YF, 2009, J IMMUNOL METHODS, V347, P70, DOI 10.1016/j.jim.2009.06.008
   Huston A, 2015, NAT CHEM BIOL, V11, P542, DOI 10.1038/nchembio.1871
   Ignatchenko V, 2015, PROTEOMICS, V15, P1239, DOI 10.1002/pmic.201400320
   Jackson HW, 2015, NAT CELL BIOL, V17, P217, DOI 10.1038/ncb3118
   Joshi PA, 2015, STEM CELL REP, V5, P31, DOI 10.1016/j.stemcr.2015.05.012
   Joshi PA, 2015, JAMA ONCOL, V1, P283, DOI 10.1001/jamaoncol.2015.0512
   Joshi PA, 2010, NATURE, V465, P803, DOI 10.1038/nature09091
   Kaltenborn E, 2012, HUM MOL GENET, V21, P2793, DOI 10.1093/hmg/dds107
   Kauff ND, 2002, NEW ENGL J MED, V346, P1609, DOI 10.1056/NEJMoa020119
   KELSEY JL, 1993, EPIDEMIOL REV, V15, P36, DOI 10.1093/oxfordjournals.epirev.a036115
   Kendrick H, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-591
   Kiechl S, 2017, ONCOTARGET, V8, P3811, DOI 10.18632/oncotarget.14013
   Kislinger T, 2006, CELL, V125, P173, DOI 10.1016/j.cell.2006.01.044
   Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412
   Kotsopoulos J, 2016, JNCI-J NATL CANCER I, V109, P1
   Krueger F, 2011, BIOINFORMATICS, V27, P1571, DOI 10.1093/bioinformatics/btr167
   Kucera Mike, 2016, F1000Res, V5, P1717
   LaBarge MA, 2013, JOVE-J VIS EXP, DOI 10.3791/50011
   Li H, 2009, BIOINFORMATICS, V25, P1094, DOI [10.1093/bioinformatics/btp100, 10.1093/bioinformatics/btp324]
   Lim E, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2560
   Lim E, 2009, NAT MED, V15, P907, DOI 10.1038/nm.2000
   Lin CY, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-9-r66
   Loenen WAM, 2006, BIOCHEM SOC T, V34, P330, DOI 10.1042/BST0340330
   Lucas JJ, 2004, MOL CANCER RES, V2, P105
   Lydon JP, 1999, CANCER RES, V59, P4276
   Marotti JD, 2017, INT J BREAST CANCER, V2017, DOI 10.1155/2017/4537532
   Maruyama R, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1001369
   McLean CY, 2010, NAT BIOTECHNOL, V28, P495, DOI 10.1038/nbt.1630
   Meissner A, 2005, NUCLEIC ACIDS RES, V33, P5868, DOI 10.1093/nar/gki901
   Merico D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013984
   Michailidou K, 2017, NATURE, V551, P92, DOI 10.1038/nature24284
   Michalak EM, 2013, STEM CELLS, V31, P1910, DOI 10.1002/stem.1437
   Mohammed H, 2015, NATURE, V523, P313, DOI 10.1038/nature14583
   Molyneux G, 2010, CELL STEM CELL, V7, P403, DOI 10.1016/j.stem.2010.07.010
   Nguyen LV, 2015, NATURE, V528, P267, DOI 10.1038/nature15742
   Pal B, 2013, CELL REP, V3, P411, DOI 10.1016/j.celrep.2012.12.020
   Pathania R, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7910
   Pei XH, 2009, CANCER CELL, V15, P389, DOI 10.1016/j.ccr.2009.03.004
   Pellacani D, 2016, CELL REP, V17, P2060, DOI 10.1016/j.celrep.2016.10.058
   Reimand J, 2016, NUCLEIC ACIDS RES, V44, pW83, DOI 10.1093/nar/gkw199
   Rios AC, 2016, BREAST CANCER RES, V18, DOI 10.1186/s13058-016-0774-5
   Rios AC, 2014, NATURE, V506, P322, DOI 10.1038/nature12948
   Rugg-Gunn PJ, 2012, DEV CELL, V22, P887, DOI 10.1016/j.devcel.2012.01.005
   Schimanski S, 2010, HORM METAB RES, V42, P102, DOI 10.1055/s-0029-1241859
   Shackleton M, 2006, NATURE, V439, P84, DOI 10.1038/nature04372
   Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303
   Shehata M, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3334
   Shiah YJ, 2015, STEM CELL REP, V4, P313, DOI 10.1016/j.stemcr.2015.01.011
   Shu SK, 2016, NATURE, V529, P413, DOI 10.1038/nature16508
   Sigl V, 2016, CELL RES, V26, P761, DOI 10.1038/cr.2016.69
   Smyth GK, 2005, STAT BIOL HEALTH, P397, DOI 10.1007/0-387-29362-0_23
   Stingl J, 2006, NATURE, V439, P993, DOI 10.1038/nature04496
   Storey JD, 2003, P NATL ACAD SCI USA, V100, P9440, DOI 10.1073/pnas.1530509100
   Stunnenberg HG, 2016, CELL, V167, P1145, DOI 10.1016/j.cell.2016.11.007
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Tomasetti C, 2017, SCIENCE, V355, P1330, DOI 10.1126/science.aaf9011
   van Amerongen R, 2012, CELL STEM CELL, V11, P387, DOI 10.1016/j.stem.2012.05.023
   Van Keymeulen A, 2017, CELL REP, V20, P1525, DOI 10.1016/j.celrep.2017.07.066
   Van Keymeulen A, 2011, NATURE, V479, P189, DOI 10.1038/nature10573
   Visvader JE, 2011, NATURE, V469, P314, DOI 10.1038/nature09781
   Wang DS, 2015, NATURE, V517, P81, DOI 10.1038/nature13851
   Wojtowicz EE, 2016, CELL STEM CELL, V19, P383, DOI 10.1016/j.stem.2016.06.008
   Wuidart A, 2016, GENE DEV, V30, P1261, DOI 10.1101/gad.280057.116
   Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r137
NR 85
TC 25
Z9 31
U1 0
U2 7
PU ROCKEFELLER UNIV PRESS
PI NEW YORK
PA 950 THIRD AVE, 2ND FLR, NEW YORK, NY 10022 USA
SN 0021-9525
EI 1540-8140
J9 J CELL BIOL
JI J. Cell Biol.
PD AUG
PY 2018
VL 217
IS 8
BP 2951
EP 2974
DI 10.1083/jcb.201804042
PG 24
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA GP4DV
UT WOS:000440809000026
PM 29921600
OA Green Published, hybrid
DA 2025-01-12
ER

PT J
AU Yang, Y
   Huang, W
   Qiu, RF
   Liu, RQ
   Zeng, Y
   Gao, J
   Zheng, Y
   Hou, YQ
   Wang, S
   Yu, WQ
   Leng, S
   Feng, DD
   Wang, Y
AF Yang, Yang
   Huang, Wei
   Qiu, Rongfang
   Liu, Ruiqiong
   Zeng, Yi
   Gao, Jie
   Zheng, Yu
   Hou, Yongqiang
   Wang, Shuang
   Yu, Wenqian
   Leng, Shuai
   Feng, Dandan
   Wang, Yan
TI LSD1 coordinates with the SIN3A/HDAC complex and maintains sensitivity
   to chemotherapy in breast cancer
SO JOURNAL OF MOLECULAR CELL BIOLOGY
LA English
DT Article
DE LSD1; SIN3A; breast cancer; metastasis; chemotherapy sensitivity
ID HISTONE DEACETYLASE; TRANSCRIPTIONAL REPRESSION; RECEPTOR COACTIVATORS;
   LYSINE METHYLATION; INDUCED APOPTOSIS; GENE; PROTEIN; DEMETHYLASE;
   MSIN3A; P53
AB Lysine-specific demethylase 1 (LSD1) was the first histone demethylase identified as catalysing the removal of mono-and dimethylation marks on histone H3-K4. Despite the potential broad action of LSD1 in transcription regulation, recent studies indicate that LSD1 may coordinate with multiple epigenetic regulatory complexes including CoREST/HDAC complex, NuRD complex, SIRT1, and PRC2, implying complicated mechanistic actions of this seemingly simple enzyme. Here, we report that LSD1 is also an integral component of the SIN3A/HDAC complex. Transcriptional target analysis using ChIP-on-chip technology revealed that the LSD1/SIN3A/HDAC complex targets several cellular signalling pathways that are critically involved in cell proliferation, survival, metastasis, and apoptosis, especially the p53 signalling pathway. We have demonstrated that LSD1 coordinates with the SIN3A/HDAC complex in inhibiting a series of genes such as CASP7, TGFB2, CDKN1A(p21), HIF1A, TERT, and MDM2, some of which are oncogenic. Our experiments also found that LSD1 and SIN3A are required for optimal survival and growth of breast cancer cells while also essential for the maintenance of epithelial homoeostasis and chemosensitivity. Our data indicate that LSD1 is a functional alternative subunit of the SIN3A/HDAC complex, providing a molecular basis for the interplay of histone demethylation and deacetylation in chromatin remodelling, and suggest that the LSD1/SIN3A/HDAC complex could be a target for breast cancer therapeutic strategies.
C1 [Yang, Yang; Huang, Wei; Qiu, Rongfang; Liu, Ruiqiong; Zeng, Yi; Gao, Jie; Zheng, Yu; Hou, Yongqiang; Wang, Shuang; Yu, Wenqian; Leng, Shuai; Feng, Dandan; Wang, Yan] Tianjin Med Univ, Collaborat Innovat Ctr Tianjin Med Epigenet 2011, Tianjin Key Lab Cellular & Mol Immunol,Dept Bioch, Key Lab Immune Microenvironment & Dis,Minist Educ, Tianjin 300070, Peoples R China.
   [Zheng, Yu] Tianjin Med Univ Canc Inst & Hosp, Key Lab Canc Immunol & Biotherapy, Key Lab Canc Prevent & Therapy,Dept Biotherapy, Tianjin Clin Res Ctr Canc,Natl Clin Res Ctr Canc, Tianjin 300060, Peoples R China.
   [Wang, Yan] Capital Med Univ, Sch Basic Med Sci, Dept Biochem & Mol Biol, Beijing 100069, Peoples R China.
C3 Tianjin Medical University; Tianjin Medical University; Capital Medical
   University
RP Wang, Y (通讯作者)，Capital Med Univ, Sch Basic Med Sci, Dept Biochem & Mol Biol, Beijing 100069, Peoples R China.
EM yanwang@tmu.edu.cn
RI Gao, Jie/HCH-0174-2022; wang, yingying/M-6676-2015; Feng,
   Dandan/X-7524-2019
OI Wang, Yan/0000-0003-2563-255X; Gao, Jie/0000-0002-3366-3156
FU Major State Basic Research Development Program of China
   [2016YFA0102400]; National Natural Science Foundation of China
   [81773017, 81472733, 81402334, 81502446]; China Postdoctoral Science
   Foundation [2014M561192, 2015T80224]; Tianjin Municipal Science and
   Technology Commission [15JCQNJC11900]; Science & Technology Development
   Fund of Tianjin Education Commission for Higher Education [20140105]
FX This work was supported by grants from the Major State Basic Research
   Development Program of China (2016YFA0102400 to Y.W.), the National
   Natural Science Foundation of China (81773017 and 81472733 to Y.W.,
   81402334 to Y.Y., and 81502446 to R.Q.), China Postdoctoral Science
   Foundation (2014M561192 and 2015T80224 to Y.Y.), the Tianjin Municipal
   Science and Technology Commission (15JCQNJC11900 to Y.Y.), and the
   Science & Technology Development Fund of Tianjin Education Commission
   for Higher Education (20140105 to R.Q.).
CR Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0
   Avila-Gomez IC, 2008, ANN HEMATOL, V87, P671, DOI 10.1007/s00277-008-0467-y
   Cheng XD, 2007, MUTAT RES-FUND MOL M, V618, P102, DOI 10.1016/j.mrfmmm.2006.05.041
   Ciccone DN, 2009, NATURE, V461, P415, DOI 10.1038/nature08315
   Cowley SM, 2005, MOL CELL BIOL, V25, P6990, DOI 10.1128/MCB.25.16.6990-7004.2005
   Dannenberg JH, 2005, GENE DEV, V19, P1581, DOI 10.1101/gad.1286905
   Denslow SA, 2007, ONCOGENE, V26, P5433, DOI 10.1038/sj.onc.1210611
   Di Stefano L, 2007, CURR BIOL, V17, P808, DOI 10.1016/j.cub.2007.03.068
   Ellison-Zelski SJ, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-263
   Ellison-Zelski SJ, 2009, MOL CELL BIOL, V29, P4949, DOI 10.1128/MCB.00383-09
   Fang R, 2010, MOL CELL, V39, P222, DOI 10.1016/j.molcel.2010.07.008
   Fleischer TC, 2003, MOL CELL BIOL, V23, P3456, DOI 10.1128/MCB.23.10.3456-3467.2003
   Forneris F, 2008, TRENDS BIOCHEM SCI, V33, P181, DOI 10.1016/j.tibs.2008.01.003
   Harris LG, 2016, NUCLEIC ACIDS RES, V44, P3610, DOI 10.1093/nar/gkv1496
   Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7
   Hu X, 2009, P NATL ACAD SCI USA, V106, P10141, DOI 10.1073/pnas.0900437106
   Huang J, 2007, NATURE, V449, P105, DOI 10.1038/nature06092
   Huang S, 2000, MOL CELL BIOL, V20, P2248, DOI 10.1128/MCB.20.6.2248-2259.2000
   Huang YF, 1999, NAT NEUROSCI, V2, P867, DOI 10.1038/13165
   Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127
   Kahl P, 2006, CANCER RES, V66, P11341, DOI 10.1158/0008-5472.CAN-06-1570
   Kang KH, 1999, EXP CELL RES, V253, P403, DOI 10.1006/excr.1999.4644
   Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9
   Lan F, 2008, CURR OPIN CELL BIOL, V20, P316, DOI 10.1016/j.ceb.2008.03.004
   Le May N, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.0040013
   Lee MG, 2006, MOL CELL BIOL, V26, P6395, DOI 10.1128/MCB.00723-06
   Liang J, 2008, NAT CELL BIOL, V10, P731, DOI 10.1038/ncb1736
   Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981
   Lu P, 2011, J BIOL CHEM, V286, P18311, DOI 10.1074/jbc.M110.133603
   Marango J, 2008, BLOOD, V111, P3145, DOI 10.1182/blood-2007-06-092122
   Marcelli M, 1998, CANCER RES, V58, P76
   McDonel P, 2012, DEV BIOL, V363, P62, DOI 10.1016/j.ydbio.2011.12.019
   Meehan WJ, 2004, J BIOL CHEM, V279, P1562, DOI 10.1074/jbc.M307969200
   Metzger E, 2005, NATURE, V437, P436, DOI 10.1038/nature04020
   MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R
   Murphy M, 1999, GENE DEV, V13, P2490, DOI 10.1101/gad.13.19.2490
   Nascimento EM, 2011, NAT CELL BIOL, V13, P1395, DOI 10.1038/ncb2385
   Pavlopoulou A, 2016, CANCER LETT, V380, P485, DOI 10.1016/j.canlet.2016.07.018
   Pellegrino J, 2012, DEV BIOL, V369, P349, DOI 10.1016/j.ydbio.2012.07.006
   Perillo B, 2008, SCIENCE, V319, P202, DOI 10.1126/science.1147674
   Rampalli S, 2005, MOL CELL BIOL, V25, P8415, DOI 10.1128/MCB.25.19.8415-8429.2005
   Rao G, 1996, ONCOGENE, V12, P1165
   Scoumanne A, 2007, J BIOL CHEM, V282, P15471, DOI 10.1074/jbc.M701023200
   Shi Y, 2007, NAT REV GENET, V8, P829, DOI 10.1038/nrg2218
   Shi Y, 2007, MOL CELL, V25, P1, DOI 10.1016/j.molcel.2006.12.010
   Shi YJ, 2005, MOL CELL, V19, P857, DOI 10.1016/j.molcel.2005.08.027
   Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012
   Shiio Y, 2006, MOL CELL BIOL, V26, P1386, DOI 10.1128/MCB.26.4.1386-1397.2006
   Shin JA, 2011, J CELL BIOCHEM, V112, P179, DOI 10.1002/jcb.22929
   Silverstein RA, 2005, CURR GENET, V47, P1, DOI 10.1007/s00294-004-0541-5
   Sjöblom-Hallén A, 1999, J VIROL, V73, P2983
   Skowyra D, 2001, J BIOL CHEM, V276, P8734, DOI 10.1074/jbc.M007664200
   Suzuki H, 2008, LUNG CANCER, V59, P24, DOI 10.1016/j.lungcan.2007.08.002
   van Oevelen C, 2010, MOL CELL BIOL, V30, P5686, DOI 10.1128/MCB.00975-10
   Wang GG, 2007, TRENDS MOL MED, V13, P363, DOI 10.1016/j.molmed.2007.07.003
   Wang JX, 2007, NATURE, V446, P882, DOI 10.1038/nature05671
   Wang J, 2009, NAT GENET, V41, P125, DOI 10.1038/ng.268
   Wang Y., 2014, CANCER RES, V74, P531
   Wang Y, 2009, CELL, V138, P660, DOI 10.1016/j.cell.2009.05.050
   Whyte WA, 2012, NATURE, V482, P221, DOI 10.1038/nature10805
   Wissmann M, 2007, NAT CELL BIOL, V9, P347, DOI 10.1038/ncb1546
   Wright MH, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1855
   Yang MH, 2008, NAT CELL BIOL, V10, P295, DOI 10.1038/ncb1691
   Yang XY, 2002, CELL, V110, P69, DOI 10.1016/S0092-8674(02)00810-3
   Zhang Fengying, 2005, Lin Chuang Er Bi Yan Hou Ke Za Zhi, V19, P302
   Zhang H, 2004, GENE DEV, V18, P1753, DOI 10.1101/gad.1194704
   Zhang H, 2006, EMBO J, V25, P4223, DOI 10.1038/sj.emboj.7601306
   Zhang Y, 2007, EMBO J, V26, P2645, DOI 10.1038/sj.emboj.7601710
   Zhao HL, 2017, BRAIN RES, V1665, P1, DOI 10.1016/j.brainres.2017.03.029
NR 69
TC 53
Z9 59
U1 4
U2 28
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1674-2788
EI 1759-4685
J9 J MOL CELL BIOL
JI J. Mol. Cell Biol.
PD AUG
PY 2018
VL 10
IS 4
BP 285
EP 301
DI 10.1093/jmcb/mjy021
PG 17
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA HA7AQ
UT WOS:000450433500003
PM 29741645
OA Bronze
DA 2025-01-12
ER

PT J
AU Clines, KL
   Clines, GA
AF Clines, Katrina L.
   Clines, Gregory A.
TI DKK1 and Kremen Expression Predicts the Osteoblastic Response to Bone
   Metastasis
SO TRANSLATIONAL ONCOLOGY
LA English
DT Article
ID FREQUENT EPIGENETIC INACTIVATION; HORMONE-RELATED PROTEIN;
   PROSTATE-CANCER CELLS; MULTIPLE-MYELOMA; BREAST-CANCER; BETA-CATENIN;
   CAUSAL ROLE; WNT; DICKKOPF-1; SCLEROSTIN
AB Bone metastasis is a complication of advanced breast and prostate cancer. Tumor-secreted Dickkopf homolog 1 (DKK1), an inhibitor of canonical Wnt signaling and osteoblast differentiation, was proposed to regulate the osteoblastic response to metastatic cancer in bone. The objectives of this study were to compare DKK1 expression with the in vivo osteoblastic response in a panel of breast and prostate cancer cell lines, and to discover mechanisms that regulate cancer DKK1 expression. DKK1 expression was highest in MDA-MB-231 and PC3 cells that produce osteolytic lesions, and hence a suppressed osteoblastic response, in animal models of bone metastasis. LnCaP, C4-2B, LuCaP23.1, T47D, ZR-75-1, MCF-7, ARCaP and ARCaP(M) cancer cells that generate osteoblastic, mixed or no bone lesions had the lowest DKK1 expression. The cell lines with negligible expression, LnCaP, C4-2B and T47D, exhibited methylation of the DKK1 promoter. Canonical Wnt signaling activity was then determined and found in all cell lines tested, even in the MDA-MB-231 and PC3 cell lines despite sizeable amounts of DKK1 protein expression expected to block canonical Wnt signaling. A mechanism of DKK1 resistance in the osteolytic cell lines was investigated and determined to be at least partially due to down-regulation of the DKK1 receptors Kremen1 and Kremen2 in the MDA-MB-231 and PC3 cell lines. Combined DKK1 and Kremen expression in cancer cells may serve as predictive markers of the osteoblastic response of breast and prostate cancer bone metastasis.
C1 [Clines, Katrina L.; Clines, Gregory A.] Univ Michigan, Dept Internal Med, Div Metab Endocrinol & Diabet, Ann Arbor, MI 48109 USA.
   [Clines, Gregory A.] Vet Affairs Med Ctr, Ann Arbor, MI USA.
C3 University of Michigan System; University of Michigan; US Department of
   Veterans Affairs; Veterans Health Administration (VHA)
RP Clines, GA (通讯作者)，Univ Michigan, Endocrinol Sect, Dept Internal Med,Ann Arbor VA Med Serv, Div Metab Endocrinol & Diabet,Internal Med,Res 15, 2215 Fuller Rd, Ann Arbor, MI 48105 USA.
EM clines@umich.edu
FU Department of Defense Prostate Cancer Research Program [PC073756];
   NCI/NIH [CA118428]
FX This publication was made possible by grants PC073756 from the
   Department of Defense Prostate Cancer Research Program (GAC) and
   CA118428 from NCI/NIH (GAC).
CR Aguilera O, 2006, ONCOGENE, V25, P4116, DOI 10.1038/sj.onc.1209439
   Bisson I, 2009, CELL RES, V19, P683, DOI 10.1038/cr.2009.43
   Brunetti G, 2011, ANN NY ACAD SCI, V1237, P19, DOI 10.1111/j.1749-6632.2011.06196.x
   Bu GJ, 2008, INT J CANCER, V123, P1034, DOI 10.1002/ijc.23625
   Clines GA, 2005, J BONE MINER RES, V20, pS249
   Clines GA, 2007, MOL ENDOCRINOL, V21, P486, DOI 10.1210/me.2006-0346
   Dai JL, 2008, CANCER RES, V68, P5785, DOI 10.1158/0008-5472.CAN-07-6541
   Drake JM, 2010, CANCER BIOL THER, V9, P607, DOI 10.4161/cbt.9.8.11112
   Eda H, 2016, J BONE MINER RES, V31, P1225, DOI 10.1002/jbmr.2789
   Ellis WJ, 1996, CLIN CANCER RES, V2, P1039
   Ellwanger K, 2008, MOL CELL BIOL, V28, P4875, DOI 10.1128/MCB.00222-08
   Fillmore RA, 2009, INT J CANCER, V125, P556, DOI 10.1002/ijc.24276
   Forget MA, 2007, BRIT J CANCER, V96, P646, DOI 10.1038/sj.bjc.6603579
   Glinka A, 1998, NATURE, V391, P357, DOI 10.1038/34848
   Götze S, 2010, INT J CANCER, V126, P2584, DOI 10.1002/ijc.24981
   Grunda JM, 2013, CLIN EXP METASTAS, V30, P769, DOI 10.1007/s10585-013-9577-6
   Guise TA, 1996, J CLIN INVEST, V98, P1544, DOI 10.1172/JCI118947
   Guo J, 2010, CELL METAB, V11, P161, DOI 10.1016/j.cmet.2009.12.007
   Hall CL, 2008, PROSTATE, V68, P1396, DOI 10.1002/pros.20805
   Hall CL, 2005, CANCER RES, V65, P7554, DOI 10.1158/0008-5472.CAN-05-1317
   Iyer SP, 2014, BRIT J HAEMATOL, V167, P366, DOI 10.1111/bjh.13056
   Kim JH, 2011, GENOME RES, V21, P1028, DOI 10.1101/gr.119347.110
   Kocemba KA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030359
   Li J, 2006, BONE, V39, P754, DOI 10.1016/j.bone.2006.03.017
   Li XF, 2005, J BIOL CHEM, V280, P19883, DOI 10.1074/jbc.M413274200
   Li ZG, 2008, ONCOGENE, V27, P596, DOI 10.1038/sj.onc.1210694
   Liu CC, 2010, P NATL ACAD SCI USA, V107, P5136, DOI 10.1073/pnas.0911220107
   Lu WY, 2010, BIOCHEMISTRY-US, V49, P4635, DOI 10.1021/bi1001486
   Many AM, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2631
   Mao BY, 2001, NATURE, V411, P321, DOI 10.1038/35077108
   Mao BY, 2002, NATURE, V417, P664, DOI 10.1038/nature756
   Mao BY, 2003, GENE, V302, P179, DOI 10.1016/S0378-1119(02)01106-X
   McDonald MM, 2017, BLOOD, V129, P3452, DOI 10.1182/blood-2017-03-773341
   Mitra A, 2010, J BIOL CHEM, V285, P24686, DOI 10.1074/jbc.M109.094847
   Nelson JB, 2005, WORLD J UROL, V23, P19, DOI 10.1007/s00345-004-0478-9
   NELSON JB, 1995, NAT MED, V1, P944, DOI 10.1038/nm0995-944
   Niida A, 2004, ONCOGENE, V23, P8520, DOI 10.1038/sj.onc.1207892
   Pinzone JJ, 2009, BLOOD, V113, P517, DOI 10.1182/blood-2008-03-145169
   Pozzi S, 2013, BONE, V53, P487, DOI 10.1016/j.bone.2013.01.012
   Robinson DR, 2008, CURR DRUG TARGETS, V9, P571
   Sato H, 2007, CARCINOGENESIS, V28, P2459, DOI 10.1093/carcin/bgm178
   Schulze J, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010309
   Semënov MV, 2001, CURR BIOL, V11, P951, DOI 10.1016/S0960-9822(01)00290-1
   Shao JS, 2005, J CLIN INVEST, V115, P1210, DOI 10.1172/JCI200524140
   Soos G, 1997, ANTICANCER RES, V17, P4253
   Suzuki H, 2008, BRIT J CANCER, V98, P1147, DOI 10.1038/sj.bjc.6604259
   Suzuki R, 2007, BRIT J HAEMATOL, V138, P624, DOI 10.1111/j.1365-2141.2007.06702.x
   Tian E, 2003, NEW ENGL J MED, V349, P2483, DOI 10.1056/NEJMoa030847
   Voorzanger-Rousselot N, 2007, BRIT J CANCER, V97, P964, DOI 10.1038/sj.bjc.6603959
   Weilbaecher KN, 2011, NAT REV CANCER, V11, P411, DOI 10.1038/nrc3055
   Yin JJ, 2003, P NATL ACAD SCI USA, V100, P10954, DOI 10.1073/pnas.1830978100
   Yin JJ, 1999, J CLIN INVEST, V103, P197, DOI 10.1172/JCI3523
   Zhang H, 2014, ONCOGENE, V33, P2464, DOI 10.1038/onc.2013.203
   Zhau Haiyen E., 2000, Cancer, V88, P2995, DOI 10.1002/1097-0142(20000615)88:12+<2995::AID-CNCR15>3.0.CO;2-Y
NR 54
TC 24
Z9 27
U1 1
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1936-5233
J9 TRANSL ONCOL
JI Transl. Oncol.
PD AUG
PY 2018
VL 11
IS 4
BP 873
EP 882
DI 10.1016/j.tranon.2018.04.013
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA GN4GU
UT WOS:000438977600005
PM 29772510
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU Paul, B
   Li, YY
   Tollefsbol, TO
AF Paul, Bidisha
   Li, Yuanyuan
   Tollefsbol, Trygve O.
TI The Effects of Combinatorial Genistein and Sulforaphane in Breast Tumor
   Inhibition: Role in Epigenetic Regulation
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE genistein; sulforaphane; breast cancer; epigenetics; HDAC; KLF4;
   combination; synergy; broccoli; transgenic mouse model
ID PROSTATE-CANCER CELLS; HISTONE DEACETYLASE; SUPPRESSOR GENES;
   STEM-CELLS; BROCCOLI SPROUTS; DRUG-COMBINATION; DNA METHYLATION; DIETARY
   FACTORS; KLF4; CHEMOPREVENTION
AB Dietary compounds that possess the properties of altering epigenetic processes are gaining popularity as targets for cancer prevention studies. These compounds when administered at optimal concentrations and especially in combination can have enhanced effects in cancer prevention or therapy. It is important to study the interaction of two or more compounds in order to assess their role in enhancing prevention. Genistein (GEN), found in soy, has been extensively studied for its role as an epigenetic modifier especially as a DNA methyltransferase (DNMT) inhibitor and sulforaphane (SFN), found in cruciferous vegetables, is known as a histone deacetylase (HDAC) inhibitor. However, very little is known about the effects of these two compounds in conjunction in breast cancer prevention or therapy. In our current study, we determined that, at certain doses, the compounds have synergistic effects in decreasing cellular viability of breast cancer cell lines. Our results indicate that the combination of GEN and SFN is much more effective than their single doses in increasing the rate of apoptosis and lowering the colony forming potential of these cells. We determined that these compounds inhibit cell cycle progression to G2 phase in MDA-MB-231 and G1 phase in MCF-7 breast cancer cell lines. Additionally, we determined that the combination is effective as an HDAC and histone methyltransferase (HMT) inhibitor. Furthermore, we demonstrated that this combination downregulates the levels of HDAC2 and HDAC3 both at the mRNA and protein levels. We also found that these compounds have the potential to downregulate KLF4 levels, which plays an important role in stem cell formation. The combination of GEN and SFN is also effective in downregulating hTERT levels, which is known to be activated when KLF4 binds to its promoter region. Our hypothesis is further strengthened by in vivo studies, where the combination is administered to transgenic mice in the form of genistein and SFN-enriched broccoli sprouts. We have demonstrated that the combination is more effective in preventing or treating mammary cancer via extending tumor latency and reducing tumor volumes/sizes than either of these dietary components administered alone. These results are consistent with our in vitro study suggesting potential preventive and therapeutic effects of this novel dietary combinatorial approach against breast cancer.
C1 [Paul, Bidisha; Tollefsbol, Trygve O.] Univ Alabama Birmingham, Dept Biol, Birmingham, AL 35294 USA.
   [Li, Yuanyuan; Tollefsbol, Trygve O.] Univ Alabama Birmingham, Ctr Comprehens Canc, Birmingham, AL 35294 USA.
   [Li, Yuanyuan; Tollefsbol, Trygve O.] Univ Alabama Birmingham, Nutr Obes Res Ctr, Birmingham, AL 35294 USA.
   [Li, Yuanyuan] Univ Alabama Birmingham, Dept Pharmacol & Toxicol, Birmingham, AL 35294 USA.
   [Tollefsbol, Trygve O.] Univ Alabama Birmingham, Comprehens Diabet Ctr, Birmingham, AL 35294 USA.
   [Tollefsbol, Trygve O.] Univ Alabama Birmingham, Comprehens Ctr Hlth Aging, Birmingham, AL 35294 USA.
C3 University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham
RP Tollefsbol, TO (通讯作者)，Univ Alabama Birmingham, Dept Biol, Birmingham, AL 35294 USA.; Tollefsbol, TO (通讯作者)，Univ Alabama Birmingham, Ctr Comprehens Canc, Birmingham, AL 35294 USA.; Tollefsbol, TO (通讯作者)，Univ Alabama Birmingham, Nutr Obes Res Ctr, Birmingham, AL 35294 USA.; Tollefsbol, TO (通讯作者)，Univ Alabama Birmingham, Comprehens Diabet Ctr, Birmingham, AL 35294 USA.; Tollefsbol, TO (通讯作者)，Univ Alabama Birmingham, Comprehens Ctr Hlth Aging, Birmingham, AL 35294 USA.
EM bidishap@uab.edu; lyy@uab.edu; trygve@uab.edu
RI Paul, Bidisha/AAB-8948-2022
OI Paul, Bidisha/0000-0002-0101-8187; Tollefsbol,
   Trygve/0000-0002-0284-1511
FU National Institutes of Health [R01 CA178441, R01 CA204346, K01AT009373];
   American Institute for Cancer Research [AICR316184]
FX This work was supported by grants from the National Institutes of Health
   (R01 CA178441 and R01 CA204346 to T.O.T. and K01AT009373 to Y.L.) and
   the American Institute for Cancer Research (AICR316184) to T.O.T. We
   thank Kendra Royston for her valuable suggestions and assistance with
   experiments. We would also like to acknowledge the Tollefsbol lab
   members for their advice and support.
CR Atwell LL, 2015, MOL NUTR FOOD RES, V59, P424, DOI 10.1002/mnfr.201400674
   Chen HP, 2013, J ONCOL, V2013, DOI 10.1155/2013/872957
   Chou TC, 2005, CompuSyn for drug combinations: PC software and user's guide: a computer program for quantitation of synergism and antagonism in drug combinations, and the determination of IC50 and ED50 and LD50 values
   Chou TC, 2008, LEUKEMIA LYMPHOMA, V49, P2059, DOI 10.1080/10428190802353591
   Chou TC, 2010, CANCER RES, V70, P440, DOI 10.1158/0008-5472.CAN-09-1947
   Dashwood RH, 2008, NUTR REV, V66, pS36, DOI 10.1111/j.1753-4887.2008.00065.x
   DeSantis CE, 2017, CA-CANCER J CLIN, V67, P439, DOI 10.3322/caac.21412
   Ema M, 2008, CELL STEM CELL, V3, P555, DOI 10.1016/j.stem.2008.09.003
   Esteller M, 2002, J PATHOL, V196, P1, DOI 10.1002/path.1024
   Fahey JW, 1997, P NATL ACAD SCI USA, V94, P10367, DOI 10.1073/pnas.94.19.10367
   Ferralli J, 2016, ONCOTARGET, V7, P45608, DOI 10.18632/oncotarget.10058
   Ferrini K, 2015, ECANCERMEDICALSCIENC, V9, DOI 10.3332/ecancer.2015.557
   Fritz WA, 2002, MOL CELL ENDOCRINOL, V186, P89, DOI 10.1016/S0303-7207(01)00663-3
   Fu J., 2017, P AACR ANN M WASH DC
   Pons DG, 2014, J CELL BIOCHEM, V115, P949, DOI 10.1002/jcb.24737
   Ganai SA, 2016, BIOMED PHARMACOTHER, V81, P250, DOI 10.1016/j.biopha.2016.04.022
   Grosso G, 2017, NUTR REV, V75, P405, DOI 10.1093/nutrit/nux012
   Hardy TM, 2011, EPIGENOMICS-UK, V3, P503, DOI [10.2217/EPI.11.71, 10.2217/epi.11.71]
   Herceg Z, 2007, MUTAGENESIS, V22, P91, DOI 10.1093/mutage/gel068
   Hsieh MH, 2017, NUCLEIC ACIDS RES, V45, P10492, DOI 10.1093/nar/gkx683
   Hu R, 2006, CARCINOGENESIS, V27, P2038, DOI 10.1093/carcin/bgl049
   Hu WX, 2016, ONCOTARGET, V7, P52870, DOI 10.18632/oncotarget.9141
   Jin ZM, 2002, J NUTR, V132, P3186, DOI 10.1093/jn/131.10.3186
   Key T, 2004, PUBLIC HEALTH NUTR, V7, P187, DOI 10.1079/PHN2003588
   Kikuno N, 2008, INT J CANCER, V123, P552, DOI 10.1002/ijc.23590
   Kim S.-H., 2017, P AACR ANN M WASH DC
   Kotecha R, 2016, ONCOTARGET, V7, P52517, DOI 10.18632/oncotarget.9593
   Lacroix M, 2004, BREAST CANCER RES TR, V83, P249, DOI 10.1023/B:BREA.0000014042.54925.cc
   Lamartiniere CA, 2002, J NUTR, V132, p552S, DOI 10.1093/jn/132.3.552S
   Lee AV, 2015, JNCI-J NATL CANCER I, V107, DOI 10.1093/jnci/djv073
   Li RH, 2010, CELL STEM CELL, V7, P51, DOI 10.1016/j.stem.2010.04.014
   Li YY, 2010, CLIN CANCER RES, V16, P2580, DOI 10.1158/1078-0432.CCR-09-2937
   Li YY, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-09764-3
   Li YY, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-9
   Li YY, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-274
   Majid S, 2008, CANCER RES, V68, P2736, DOI 10.1158/0008-5472.CAN-07-2290
   Majid S, 2009, CARCINOGENESIS, V30, P662, DOI 10.1093/carcin/bgp042
   Meeran SM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037748
   Meeran SM, 2010, CLIN EPIGENETICS, V1, DOI 10.1007/s13148-010-0011-5
   Meeran SM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011457
   Murrell A., 2016, P UK BREAST CANC RES
   Myzak MC, 2004, CANCER RES, V64, P5767, DOI 10.1158/0008-5472.CAN-04-1326
   Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008
   Okuda H, 2013, CANCER RES, V73, P1434, DOI 10.1158/0008-5472.CAN-12-2037
   Pandya AY, 2004, CLIN CANCER RES, V10, P2709, DOI 10.1158/1078-0432.CCR-03-0484
   Park Jae-Ho, 2017, Mol Aspects Med, V54, P58, DOI 10.1016/j.mam.2017.01.008
   Paul B, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0189756
   Paul B, 2015, CLIN EPIGENETICS, V7, DOI 10.1186/s13148-015-0144-7
   Ray A, 2013, J BIOL CHEM, V288, P27232, DOI 10.1074/jbc.M113.481184
   Rowland BD, 2006, NAT REV CANCER, V6, P11, DOI 10.1038/nrc1780
   Royston KJ, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18051092
   Russo GL, 2017, CRIT REV FOOD SCI, V57, P2589, DOI 10.1080/10408398.2015.1062353
   Sasamura H, 2004, UROLOGY, V64, P389, DOI 10.1016/j.urology.2004.03.045
   Shen G, 2007, CANCER RES, V67, P9937, DOI 10.1158/0008-5472.CAN-07-1112
   Singh SV, 2009, CANCER RES, V69, P2117, DOI 10.1158/0008-5472.CAN-08-3502
   Sinha S, 2015, MOL CELL ENDOCRINOL, V406, P102, DOI 10.1016/j.mce.2015.02.020
   Su Y, 2009, CARCINOGENESIS, V30, P331, DOI 10.1093/carcin/bgn279
   Tahir AA, 2015, NUTR J, V14, DOI 10.1186/s12937-015-0015-2
   Tarapore RS, 2012, CARCINOGENESIS, V33, P483, DOI 10.1093/carcin/bgr305
   Tortorella SM, 2015, ANTIOXID REDOX SIGN, V22, P1382, DOI 10.1089/ars.2014.6097
   Traka MH, 2009, NUTR CANCER, V61, P137, DOI 10.1080/01635580802348641
   Wei DY, 2006, CARCINOGENESIS, V27, P23, DOI 10.1093/carcin/bgi243
   West AC, 2014, J CLIN INVEST, V124, P30, DOI 10.1172/JCI69738
   Wong CW, 2010, STEM CELLS, V28, P1510, DOI 10.1002/stem.477
   Xie Q, 2014, GENE CHROMOSOME CANC, V53, P422, DOI 10.1002/gcc.22154
   Yang YZ, 2005, CANCER BIOL THER, V4, P1216, DOI 10.4161/cbt.4.11.2090
   Yori JL, 2011, NEOPLASIA, V13, P601, DOI 10.1593/neo.11260
   Youlden Danny R., 2014, Cancer Biology Medicine, V11, P101, DOI 10.7497/j.issn.2095-3941.2014.02.005
   Yu F, 2011, ONCOGENE, V30, P2161, DOI 10.1038/onc.2010.591
NR 69
TC 70
Z9 74
U1 1
U2 15
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
SN 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD JUN
PY 2018
VL 19
IS 6
AR 1754
DI 10.3390/ijms19061754
PG 22
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA GK8UZ
UT WOS:000436506600209
PM 29899271
OA Green Submitted, Green Published, gold
DA 2025-01-12
ER

PT J
AU Shen, T
   Cai, LD
   Liu, YH
   Li, S
   Gan, WJ
   Li, XM
   Wang, JR
   Guo, PD
   Zhou, Q
   Lu, XX
   Sun, LN
   Li, JM
AF Shen, Tong
   Cai, Ling-Dong
   Liu, Yu-Hong
   Li, Shi
   Gan, Wen-Juan
   Li, Xiu-Ming
   Wang, Jing-Ru
   Guo, Peng-Da
   Zhou, Qun
   Lu, Xing-Xing
   Sun, Li-Na
   Li, Jian-Ming
TI Ube2v1-mediated ubiquitination and degradation of Sirt1 promotes
   metastasis of colorectal cancer by epigenetically suppressing autophagy
SO JOURNAL OF HEMATOLOGY & ONCOLOGY
LA English
DT Article
DE Ubiquitin-conjugating E2 enzyme; Autophagy; Epithelial mesenchymal
   transition; Metastasis; Colorectal cancer
ID EPITHELIAL-MESENCHYMAL TRANSITION; HUMAN BREAST-CANCER; SELECTIVE
   AUTOPHAGY; CONJUGATING ENZYME; ACTIVATION; PROTEIN; TUMORIGENESIS;
   CELLS; KINASE; INHIBITION
AB Background: Ubiquitination is a basic post-translational modification for cellular homeostasis, and members of the conjugating enzyme (E2) family are the key components of the ubiquitin-proteasome system. However, the role of E2 family in colorectal cancer (CRC) is largely unknown. Our study aimed to investigate the role of Ube2v1, one of the ubiquitin-conjugating E2 enzyme variant proteins (Ube2v) but without the conserved cysteine residue required for the catalytic activity of E2s, in CRC.
   Methods: Immunohistochemistry and real-time RT-PCR were used to study the expressions of Ube2v1 at protein and mRNA levels in CRC, respectively. Western blotting and immunofluorescence, transmission electron microscopy, and in vivo rescue experiments were used to study the functional effects of Ube2v1 on autophagy and EMT program. Quantitative mass spectrometry, immunoprecipitation, ubiquitination assay, western blotting, and real-time RT-PCR were used to analyze the effects of Ube2v1 on histone H4 lysine 16 acetylation, interaction with Sirt1, ubiquitination of Sirt1, and autophagy-related gene expression.
   Results: Ube2v1 was elevated in CRC samples, and its increased expression was correlated with poorer survival of CRC patients. Ube2v1 promoted migration and invasion of CRC cells in vitro and tumor growth and metastasis of CRC cells in vivo. Interestingly, Ube2v1suppressed autophagy program and promoted epithelial mesenchymal transition (EMT) and metastasis of CRC cells in an autophagy-dependent pattern in vitro and in vivo. Moreover, both rapamycin and trehalose attenuated the enhanced Ube2v1-mediated lung metastasis by inducing the autophagy pathway in an orthotropic mouse xenograft model of lung metastasis. Mechanistically, Ube2v1 promoted Ubc13-mediated ubiquitination and degradation of Sirt1 and inhibited histone H4 lysine 16 acetylation, and finally epigenetically suppressed autophagy gene expression in CRC.
   Conclusions: Our study functionally links Ube2v1, an E2 member in the ubiquitin-proteasome system, to autophagy program, thereby shedding light on developing Ube2v1 targeted therapy for CRC patients.
C1 [Shen, Tong; Cai, Ling-Dong; Li, Shi; Gan, Wen-Juan; Li, Xiu-Ming; Wang, Jing-Ru; Guo, Peng-Da; Zhou, Qun; Lu, Xing-Xing; Sun, Li-Na; Li, Jian-Ming] Soochow Univ, Med Sch, Dept Pathol, Suzhou 215123, Peoples R China.
   [Liu, Yu-Hong] Southern Med Univ, Baoan Hosp, Dept Pathol, Shenzhen 518101, Peoples R China.
C3 Soochow University - China; Southern Medical University - China
RP Li, JM (通讯作者)，Soochow Univ, Med Sch, Dept Pathol, Suzhou 215123, Peoples R China.
EM jianmingli@suda.edu.cn
RI wang, jing/HJA-5384-2022
FU National Nature Science Foundation of China [81525020, 81502033,
   81272300, 31570753]; Postdoctoral Science Foundation of Jiangsu Province
   [1302029B]; Science and Technology Foundation of Suzhou [SYS201412]
FX This work was supported by the National Nature Science Foundation of
   China (Grants81525020, 81502033, 81272300, and 31570753), the
   Postdoctoral Science Foundation (1302029B) of Jiangsu Province, and
   Science and Technology Foundation of Suzhou (SYS201412).
CR Bronsert P, 2014, J PATHOL, V234, P410, DOI 10.1002/path.4416
   Burger AM, 2004, EUR J CANCER, V40, P2217, DOI 10.1016/j.ejca.2004.07.006
   Catalano M, 2015, MOL ONCOL, V9, P1612, DOI 10.1016/j.molonc.2015.04.016
   Cicchini M, 2014, AUTOPHAGY, V10, P2036, DOI 10.4161/auto.34398
   Degenhardt K, 2006, CANCER CELL, V10, P51, DOI 10.1016/j.ccr.2006.06.001
   Deng L, 2000, CELL, V103, P351, DOI 10.1016/S0092-8674(00)00126-4
   Edinger AL, 2003, CANCER CELL, V4, P422, DOI 10.1016/S1535-6108(03)00306-4
   Füllgrabe J, 2013, AUTOPHAGY, V9, P1621, DOI 10.4161/auto.25803
   Füllgrabe J, 2013, NATURE, V500, P468, DOI 10.1038/nature12313
   Galluzzi L, 2015, EMBO J, V34, P856, DOI 10.15252/embj.201490784
   Grassi G, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.249
   Grimm WA, 2016, GUT, V65, P456, DOI 10.1136/gutjnl-2014-308735
   Guo JY, 2013, CELL, V155, P1216, DOI 10.1016/j.cell.2013.11.019
   He CC, 2009, ANNU REV GENET, V43, P67, DOI 10.1146/annurev-genet-102808-114910
   HERSHKO A, 1983, J BIOL CHEM, V258, P8206
   Hur K, 2013, GUT, V62, P1315, DOI 10.1136/gutjnl-2011-301846
   Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104
   Kirkin V, 2009, MOL CELL, V34, P259, DOI 10.1016/j.molcel.2009.04.026
   Kraft C, 2010, NAT CELL BIOL, V12, P836, DOI 10.1038/ncb0910-836
   Lamothe B, 2007, J BIOL CHEM, V282, P4102, DOI 10.1074/jbc.M609503200
   Li JP, 2015, DRUG DES DEV THER, V9, P1027, DOI 10.2147/DDDT.S74412
   Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257
   Liu H, 2014, AUTOPHAGY, V10, P372, DOI 10.4161/auto.27163
   Liu ZZ, 2014, CANCER CELL, V26, P106, DOI 10.1016/j.ccr.2014.05.015
   Lu KF, 2014, AUTOPHAGY, V10, P2381, DOI 10.4161/15548627.2014.981919
   Lv Q, 2012, AUTOPHAGY, V8, P1675, DOI 10.4161/auto.21438
   Lv Q, 2012, CANCER RES, V72, P3238, DOI 10.1158/0008-5472.CAN-11-3832
   Ma L, 1998, ONCOGENE, V17, P1321, DOI 10.1038/sj.onc.1202058
   Mathew R, 2007, NAT REV CANCER, V7, P961, DOI 10.1038/nrc2254
   Mathew R, 2009, CELL, V137, P1062, DOI 10.1016/j.cell.2009.03.048
   Moscat J, 2009, CELL, V137, P1001, DOI 10.1016/j.cell.2009.05.023
   Perera R, 2015, NATURE, V524, P361, DOI 10.1038/nature14587
   Petroski MD, 2007, J BIOL CHEM, V282, P29936, DOI 10.1074/jbc.M703911200
   Pulvino M, 2012, BLOOD, V120, P1668, DOI 10.1182/blood-2012-02-406074
   Qi JJ, 2016, GUT, V65, P1690, DOI 10.1136/gutjnl-2014-307900
   Qiang L, 2014, AUTOPHAGY, V10, P1864, DOI 10.4161/auto.32171
   Rogov V, 2014, MOL CELL, V53, P167, DOI 10.1016/j.molcel.2013.12.014
   Rothofsky ML, 1997, GENE, V195, P141, DOI 10.1016/S0378-1119(97)00097-8
   Ryall JG, 2015, CELL STEM CELL, V16, P171, DOI 10.1016/j.stem.2014.12.004
   Sheen JH, 2011, CANCER CELL, V19, P613, DOI 10.1016/j.ccr.2011.03.012
   Sun LN, 2013, JNCI-J NATL CANCER I, V105, P887, DOI 10.1093/jnci/djt118
   Sun LJ, 2004, MOL CELL, V14, P289, DOI 10.1016/S1097-2765(04)00236-9
   Thomson TM, 1998, FEBS LETT, V423, P49, DOI 10.1016/S0014-5793(98)00060-X
   Wang C, 2001, NATURE, V412, P346, DOI 10.1038/35085597
   White E, 2015, J CLIN INVEST, V125, P42, DOI 10.1172/JCI73941
   White E, 2012, NAT REV CANCER, V12, P401, DOI 10.1038/nrc3262
   White E, 2010, CURR OPIN CELL BIOL, V22, P212, DOI 10.1016/j.ceb.2009.12.008
   Wiener R, 2012, NATURE, V483, P618, DOI 10.1038/nature10911
   Wu ZJ, 2014, BREAST CANCER RES, V16, DOI 10.1186/bcr3692
   Xia ZP, 2009, NATURE, V461, P114, DOI 10.1038/nature08247
   Yang SH, 2011, GENE DEV, V25, P717, DOI 10.1101/gad.2016111
NR 51
TC 70
Z9 74
U1 0
U2 19
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1756-8722
J9 J HEMATOL ONCOL
JI J. Hematol. Oncol.
PD JUL 17
PY 2018
VL 11
AR 95
DI 10.1186/s13045-018-0638-9
PG 16
WC Oncology; Hematology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Hematology
GA GN6YE
UT WOS:000439249700001
PM 30016968
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Ogura, K
   Hosoda, F
   Arai, Y
   Nakamura, H
   Hama, N
   Totoki, Y
   Yoshida, A
   Nagai, M
   Kato, M
   Arakawa, E
   Mukai, W
   Rokutan, H
   Kawai, A
   Tanaka, S
   Shibata, T
AF Ogura, Koichi
   Hosoda, Fumie
   Arai, Yasuhito
   Nakamura, Hiromi
   Hama, Natsuko
   Totoki, Yasushi
   Yoshida, Akihiko
   Nagai, Momoko
   Kato, Mamoru
   Arakawa, Erika
   Mukai, Wakako
   Rokutan, Hirofumi
   Kawai, Akira
   Tanaka, Sakae
   Shibata, Tatsuhiro
TI Integrated genetic and epigenetic analysis of myxofibrosarcoma
SO NATURE COMMUNICATIONS
LA English
DT Article
ID NERVE SHEATH TUMORS; PANCREATIC NEUROENDOCRINE TUMORS; LUNG
   ADENOCARCINOMA; DEDIFFERENTIATED LIPOSARCOMAS; BREAST-CANCER; ATRX;
   MUTATIONS; SURVIVAL; EXPRESSION; OVEREXPRESSION
AB Myxofibrosarcoma (MFS) is a common adult soft tissue sarcoma characterized by an infiltrative growth pattern and a high local recurrence rate. Here we report the genetic and epigenetic landscape of MFS based on the results of whole-exome sequencing (N = 41), RNA sequencing (N = 29), and methylation analysis (N = 41), using 41 MFSs as a discovery set, and subsequent targeted sequencing of 140 genes in the entire cohort of 99 MFSs and 17 MFSs' data from TCGA. Fourteen driver genes are identified, including potentially actionable therapeutic targets seen in 37% of cases. There are frequent alterations in p53 signaling (51%) and cell cycle checkpoint genes (43%). Other conceivably actionable driver genes including ATRX, JAK1, NF1, NTRK1, and novel oncogenic BRAF fusion gene are identified. Methylation patterns cluster into three subtypes associated with unique combinations of driver mutations, clinical outcomes, and immune cell compositions. Our results provide a valuable genomic resource to enable the design of precision medicine for MFS.
C1 [Ogura, Koichi; Hosoda, Fumie; Arai, Yasuhito; Nakamura, Hiromi; Hama, Natsuko; Totoki, Yasushi; Nagai, Momoko; Kato, Mamoru; Arakawa, Erika; Mukai, Wakako; Rokutan, Hirofumi; Shibata, Tatsuhiro] Natl Canc Ctr, Res Inst, Div Canc Genom, Chuo Ku, 5-1-1 Tsukiji, Tokyo 1040045, Japan.
   [Ogura, Koichi; Kawai, Akira] Natl Canc Ctr, Dept Musculoskeletal Oncol, Chuo Ku, 5-1-1 Tsukiji, Tokyo 1040045, Japan.
   [Ogura, Koichi; Tanaka, Sakae] Univ Tokyo, Dept Orthopaed Surg, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138677, Japan.
   [Yoshida, Akihiko] Natl Canc Ctr, Dept Pathol & Clin Labs, Chuo Ku, 5-1-1 Tsukiji, Tokyo 1040045, Japan.
   [Shibata, Tatsuhiro] Univ Tokyo, Inst Med Sci, Human Genome Ctr, Lab Mol Med,Minato Ku, 4-6-1 Shirokanedai, Tokyo 1080071, Japan.
C3 National Cancer Center - Japan; National Cancer Center - Japan;
   University of Tokyo; National Cancer Center - Japan; University of Tokyo
RP Shibata, T (通讯作者)，Natl Canc Ctr, Res Inst, Div Canc Genom, Chuo Ku, 5-1-1 Tsukiji, Tokyo 1040045, Japan.; Shibata, T (通讯作者)，Univ Tokyo, Inst Med Sci, Human Genome Ctr, Lab Mol Med,Minato Ku, 4-6-1 Shirokanedai, Tokyo 1080071, Japan.
EM tashibat@ncc.go.jp
RI Shibata, Tatsuhiro/AAO-1278-2021; Tanaka, Sakae/Y-3061-2019
OI Arai, Yasuhito/0000-0001-6306-9409
FU Ministry of Education and Science [22390296]; National Cancer Center
   Research and Development Fund [28-A-16, 29-A-6]; National Cancer Center
   Research and Development Fund, Japan
FX This study was funded by a Grant-in-Aid for Scientific Research from the
   Ministry of Education and Science (B, no. 22390296), and by the National
   Cancer Center Research and Development Fund (28-A-16 and 29-A-6). The
   National Cancer Center Biobank is supported by the National Cancer
   Center Research and Development Fund, Japan.
CR Aguet F, 2017, NATURE, V550, P204, DOI 10.1038/nature24277
   Angelova M, 2015, GENOME BIOL, V16, DOI 10.1186/s13059-015-0620-6
   [Anonymous], 2017, CELL
   [Anonymous], 2013, WHO classification of tumours of soft tissue and bone
   Arcila ME, 2015, CLIN CANCER RES, V21, P1935, DOI 10.1158/1078-0432.CCR-14-2124
   Balko JM, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aad3001
   Barretina J, 2010, NAT GENET, V42, P715, DOI 10.1038/ng.619
   BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x
   Bérubé NG, 2005, J CLIN INVEST, V115, P258, DOI 10.1172/JCI200522329
   Bindea G, 2013, IMMUNITY, V39, P782, DOI 10.1016/j.immuni.2013.10.003
   Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095
   Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385
   Chmielecki J, 2013, NAT GENET, V45, P131, DOI 10.1038/ng.2522
   Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106
   Collisson EA, 2014, NATURE, V511, P543, DOI 10.1038/nature13385
   Delespaul L, 2017, CLIN CANCER RES, V23, P857, DOI 10.1158/1078-0432.CCR-16-0290
   Ding L, 2008, NATURE, V455, P1069, DOI 10.1038/nature07423
   Du P, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-587
   Farago AF, 2015, J THORAC ONCOL, V10, P1670, DOI 10.1097/01.JTO.0000473485.38553.f0
   Finn RS, 2015, LANCET ONCOL, V16, P25, DOI 10.1016/S1470-2045(14)71159-3
   Galon J, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-205
   Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088
   Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80
   Heaphy CM, 2011, SCIENCE, V333, P425, DOI 10.1126/science.1207313
   Helman LJ, 2003, NAT REV CANCER, V3, P685, DOI 10.1038/nrc1168
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Huang HY, 2010, ANN SURG ONCOL, V17, P3212, DOI 10.1245/s10434-010-1185-y
   Italiano A, 2008, INT J CANCER, V122, P2233, DOI 10.1002/ijc.23380
   Iwase S, 2011, NAT STRUCT MOL BIOL, V18, P769, DOI 10.1038/nsmb.2062
   Jeanes A, 2008, ONCOGENE, V27, P6920, DOI 10.1038/onc.2008.343
   Jiao YC, 2011, SCIENCE, V331, P1199, DOI 10.1126/science.1200609
   Kanojia D, 2015, ONCOTARGET, V6, P42429, DOI 10.18632/oncotarget.6464
   Kao YC, 2017, AM J SURG PATHOL, V41, P1456, DOI 10.1097/PAS.0000000000000899
   King AA, 2000, AM J MED GENET, V93, P388, DOI 10.1002/1096-8628(20000828)93:5<388::AID-AJMG8>3.0.CO;2-#
   Kohsaka S, 2014, NAT GENET, V46, P595, DOI 10.1038/ng.2969
   Lee JC, 2015, MODERN PATHOL, V28, P1064, DOI 10.1038/modpathol.2015.67
   Lee JC, 2010, MODERN PATHOL, V23, P1379, DOI 10.1038/modpathol.2010.128
   Lee W, 2014, NAT GENET, V46, P1227, DOI 10.1038/ng.3095
   Li B, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-1028-7
   Li CF, 2014, CLIN CANCER RES, V20, P6141, DOI 10.1158/1078-0432.CCR-14-1182
   Li CF, 2012, CLIN CANCER RES, V18, P1598, DOI 10.1158/1078-0432.CCR-11-3077
   Li H, 2009, BIOINFORMATICS, V25, P2078, DOI 10.1093/bioinformatics/btp352
   Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324
   Liau JY, 2015, AM J SURG PATHOL, V39, P236, DOI 10.1097/PAS.0000000000000324
   Maertens O, 2006, HUM MOL GENET, V15, P1015, DOI 10.1093/hmg/ddl016
   Mäkinen N, 2016, PLOS GENET, V12, DOI 10.1371/journal.pgen.1005850
   Malik G, 2010, CANCER RES, V70, P4327, DOI 10.1158/0008-5472.CAN-09-3312
   Marinoni I, 2014, GASTROENTEROLOGY, V146, P453, DOI 10.1053/j.gastro.2013.10.020
   Mentzel T, 1996, AM J SURG PATHOL, V20, P391, DOI 10.1097/00000478-199604000-00001
   Mermel CH, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-4-r41
   Mullighan CG, 2009, LEUKEMIA, V23, P1209, DOI 10.1038/leu.2009.18
   Nakamura H, 2015, NAT GENET, V47, P1003, DOI 10.1038/ng.3375
   Nakaoku T, 2014, CLIN CANCER RES, V20, P3087, DOI 10.1158/1078-0432.CCR-14-0107
   Nakayama R, 2007, MODERN PATHOL, V20, P749, DOI 10.1038/modpathol.3800794
   Newman AM, 2015, NAT METHODS, V12, P453, DOI [10.1038/NMETH.3337, 10.1038/nmeth.3337]
   Olshen AB, 2004, BIOSTATISTICS, V5, P557, DOI 10.1093/biostatistics/kxh008
   Palanisamy N, 2010, NAT MED, V16, P793, DOI 10.1038/nm.2166
   Robinson DR, 2013, NAT GENET, V45, P180, DOI 10.1038/ng.2509
   Rooney MS, 2015, CELL, V160, P48, DOI 10.1016/j.cell.2014.12.033
   Ross JS, 2016, INT J CANCER, V138, P881, DOI 10.1002/ijc.29825
   Saito M, 2016, CANCER SCI, V107, P713, DOI 10.1111/cas.12941
   Slatter TL, 2015, J PATHOL CLIN RES, V1, P95, DOI 10.1002/cjp2.11
   Totoki Y, 2014, NAT GENET, V46, P1267, DOI 10.1038/ng.3126
   Tsai JW, 2012, ANN SURG ONCOL, V19, P2716, DOI 10.1245/s10434-012-2317-3
   Vaishnavi A, 2013, NAT MED, V19, P1469, DOI 10.1038/nm.3352
   van Roy F, 2014, NAT REV CANCER, V14, P121, DOI 10.1038/nrc3647
   Wallander ML, 2012, ARCH PATHOL LAB MED, V136, P95, DOI 10.5858/arpa.2010-0729-OA
   Wu C, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-11-r130
   Xiang ZF, 2008, BLOOD, V111, P4809, DOI 10.1182/blood-2007-05-090308
   Yamaguchi T, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10060
   Yamaguchi T, 2012, CANCER CELL, V21, P348, DOI 10.1016/j.ccr.2012.02.008
   Yao ES, 2007, CANCER RES, V67, P659, DOI 10.1158/0008-5472.CAN-06-2768
NR 72
TC 61
Z9 62
U1 0
U2 6
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-1723
J9 NAT COMMUN
JI Nat. Commun.
PD JUL 17
PY 2018
VL 9
AR 2765
DI 10.1038/s41467-018-03891-9
PG 11
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA GN2UO
UT WOS:000438856900005
PM 30018380
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Huang, XX
   Guo, B
   Liu, S
   Wan, J
   Broxmeyer, HE
AF Huang, Xinxin
   Guo, Bin
   Liu, Sheng
   Wan, Jun
   Broxmeyer, Hal E.
TI Neutralizing negative epigenetic regulation by HDAC5 enhances human
   haematopoietic stem cell homing and engraftment
SO NATURE COMMUNICATIONS
LA English
DT Article
ID UMBILICAL-CORD BLOOD; NF-KAPPA-B; HISTONE DEACETYLASE INHIBITORS;
   PROGENITOR CELLS; BREAST-CANCER; POSTTRANSLATIONAL MODIFICATIONS;
   SIGNALING PATHWAY; VALPROIC ACID; SELF-RENEWAL; T-CELLS
AB Enhancement of hematopoietic stem cell (HSC) homing and engraftment is clinically critical, especially for cord blood (CB) hematopoietic cell transplantation. Here we report that specific HDAC5 inhibition highly upregulates CXCR4 surface expression in human CB HSCs and progenitor cells (HPCs). This results in enhanced SDF- 1/CXCR4- mediated chemotaxis and increased homing to the bone marrow environment, with elevated SCID-repopulating cell (SRC) frequency and enhanced long-term and secondary engraftment in NSG mice. HDAC5 inhibition increases acetylated p65 levels in the nucleus, which is important for CXCR4 transcription. Inhibition of nuclear factor-kappa B (NF-kappa B) signaling suppresses HDAC5 mediated CXCR4 upregulation, enhanced HSC homing, and engraftment. Furthermore, activation of the NF-beta B signaling pathway via TNF alpha also results in significantly increased CXCR4 surface expression, enhanced HSC homing, and engraftment. These results demonstrate a previously unknown negative epigenetic regulation of HSC homing and engraftment by HDAC5, and allow for a new and simple translational strategy to enhance HSC transplantation.
C1 [Huang, Xinxin; Guo, Bin; Broxmeyer, Hal E.] Indiana Univ Sch Med, Dept Microbiol & Immunol, Indianapolis, IN 46202 USA.
   [Liu, Sheng; Wan, Jun] Indiana Univ Sch Med, Dept Med & Mol Genet, Indianapolis, IN 46202 USA.
C3 Indiana University System; Indiana University Bloomington; Indiana
   University System; Indiana University Bloomington
RP Broxmeyer, HE (通讯作者)，Indiana Univ Sch Med, Dept Microbiol & Immunol, Indianapolis, IN 46202 USA.
EM hbroxmey@iupui.edu
RI Wan, Jun/AAN-1337-2020; Wan, Jun/H-7132-2013
OI Huang, Xinxin/0000-0002-4298-4859; Wan, Jun/0000-0001-9286-6562
FU NIH [R01 HL112669, R01 HL056416, R35 HL139599, U54 DK106846]; Indiana
   Genomic Initiative at Indiana University (INGEN); Lilly Endowment, Inc.;
   Walther Cancer Foundation [P30CA082709, P30CA023168]
FX This work was supported by Grants from the NIH to HEB: (R01 HL112669,
   R01 HL056416, R35 HL139599, U54 DK106846). RNA sequencing was carried
   out in the Center for Medical Genomics at Indiana University School of
   Medicine, which is partially supported by the Indiana Genomic Initiative
   at Indiana University (INGEN); INGEN is supported in part by the Lilly
   Endowment, Inc. The bioinformatics analysis was done by Collaborative
   Core for Cancer Bioinformatics (C3B) shared by Indiana University Simon
   Cancer Center (P30CA082709) and Purdue University Center for Cancer
   Research (P30CA023168) with support from the Walther Cancer Foundation.
   We also want to thank Broxmeyer laboratory personnel for helpful
   assistance and discussions, and the In Vivo Therapeutics Core and the
   Flow Cytometry Facility of the Indiana University School of Medicine,
   funded in part by U54 DK106846, for assistance.
CR Ballen KK, 2013, BLOOD, V122, P491, DOI 10.1182/blood-2013-02-453175
   Basu S, 2005, BLOOD, V106, P485, DOI 10.1182/blood-2004-10-4145
   Boitano AE, 2010, SCIENCE, V329, P1345, DOI 10.1126/science.1191536
   Broxmeyer HE, 2016, TRANSFUS APHER SCI, V54, P364, DOI 10.1016/j.transci.2016.05.013
   Broxmeyer HE, 2005, J EXP MED, V201, P1307, DOI 10.1084/jem.20041385
   BROXMEYER HE, 1989, P NATL ACAD SCI USA, V86, P3828, DOI 10.1073/pnas.86.10.3828
   Cao C, 2017, ONCOGENE, V36, P133, DOI 10.1038/onc.2016.186
   Capitano ML, 2015, STEM CELLS, V33, P1975, DOI 10.1002/stem.1988
   Chatterjee S, 2014, ADV CANCER RES, V124, P31, DOI 10.1016/B978-0-12-411638-2.00002-1
   Chaurasia P, 2014, J CLIN INVEST, V124, P2378, DOI 10.1172/JCI70313
   Cho YC, 2015, CELL, V161, P691, DOI 10.1016/j.cell.2015.04.019
   Christopherson KW, 2004, SCIENCE, V305, P1000, DOI 10.1126/science.1097071
   Chute JP, 2006, CURR OPIN HEMATOL, V13, P399, DOI 10.1097/01.moh.0000245698.62511.3d
   Copelan EA, 2006, NEW ENGL J MED, V354, P1813, DOI 10.1056/NEJMra052638
   Delcuve GP, 2012, CLIN EPIGENETICS, V4, DOI 10.1186/1868-7083-4-5
   Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635
   Doulatov S, 2012, CELL STEM CELL, V10, P120, DOI 10.1016/j.stem.2012.01.006
   Fares I, 2014, SCIENCE, V345, P1509, DOI 10.1126/science.1256337
   GLUCKMAN E, 1989, NEW ENGL J MED, V321, P1174, DOI 10.1056/NEJM198910263211707
   Goichberg P, 2006, BLOOD, V107, P870, DOI 10.1182/blood-2005-03-0941
   Guo B, 2018, NAT MED, V24, P360, DOI 10.1038/nm.4477
   Guo B, 2017, NAT MED, V23, P424, DOI 10.1038/nm.4298
   Helbig G, 2003, J BIOL CHEM, V278, P21631, DOI 10.1074/jbc.M300609200
   Hendrick E, 2017, ONCOGENE, V36, P4859, DOI 10.1038/onc.2017.103
   Hoesel B, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-86
   Hoggatt J, 2009, BLOOD, V113, P5444, DOI 10.1182/blood-2009-01-201335
   Huang B, 2010, CELL SIGNAL, V22, P1282, DOI 10.1016/j.cellsig.2010.03.017
   Huang DW, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-9-r183
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Huang X, 2016, LEUKEMIA, V30, P144, DOI 10.1038/leu.2015.189
   Kabra DG, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10782
   Kim YH, 2013, CELL IMMUNOL, V284, P139, DOI 10.1016/j.cellimm.2013.07.014
   Li AQ, 2016, ONCOTARGET, V7, P37966, DOI 10.18632/oncotarget.9274
   Liao Y, 2014, BIOINFORMATICS, V30, P923, DOI 10.1093/bioinformatics/btt656
   Liu CH, 2017, INT J ONCOL, V50, P2079, DOI 10.3892/ijo.2017.3967
   Marek L, 2013, J MED CHEM, V56, P427, DOI 10.1021/jm301254q
   Matalon S, 2010, JAIDS-J ACQ IMM DEF, V54, P1, DOI 10.1097/QAI.0b013e3181d3dca3
   McKinsey TA, 2000, NATURE, V408, P106, DOI 10.1038/35040593
   Mendelson A, 2014, NAT MED, V20, P833, DOI 10.1038/nm.3647
   Minucci S, 2006, NAT REV CANCER, V6, P38, DOI 10.1038/nrc1779
   Morrison SJ, 2014, NATURE, V505, P327, DOI 10.1038/nature12984
   Nayak RC, 2013, IMMUNOL REV, V256, P255, DOI 10.1111/imr.12119
   Peled A, 1999, SCIENCE, V283, P845, DOI 10.1126/science.283.5403.845
   Perkins ND, 2006, ONCOGENE, V25, P6717, DOI 10.1038/sj.onc.1209937
   Rettig MP, 2012, LEUKEMIA, V26, P34, DOI 10.1038/leu.2011.197
   Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616
   Seto E, 2014, CSH PERSPECT BIOL, V6, DOI 10.1101/cshperspect.a018713
   Stein SJ, 2013, BLOOD, V121, P5015, DOI 10.1182/blood-2013-02-486142
   Tsai LK, 2010, NEUROPSYCHOPHARMACOL, V35, P2225, DOI 10.1038/npp.2010.97
   Urbich C, 2009, BLOOD, V113, P5669, DOI 10.1182/blood-2009-01-196485
   Xiao HY, 2016, INT J CANCER, V138, P2477, DOI 10.1002/ijc.29979
   Yang XJ, 2007, ONCOGENE, V26, P5310, DOI 10.1038/sj.onc.1210599
   Young JC, 2004, CYTOTHERAPY, V6, P328, DOI 10.1080/14653240410004899
   Zhi YL, 2015, INT J MOL MED, V35, P349, DOI 10.3892/ijmm.2014.2032
NR 54
TC 52
Z9 57
U1 0
U2 13
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-1723
J9 NAT COMMUN
JI Nat. Commun.
PD JUL 16
PY 2018
VL 9
AR 2741
DI 10.1038/s41467-018-05178-5
PG 13
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA GN0RP
UT WOS:000438683100014
PM 30013077
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Zhang, Y
   Wang, XG
   Jiang, Q
   Hao, HS
   Ju, ZH
   Yang, CH
   Sun, Y
   Wang, CF
   Zhong, JF
   Huang, JM
   Zhu, HB
AF Zhang, Yan
   Wang, Xiuge
   Jiang, Qiang
   Hao, Haisheng
   Ju, Zhihua
   Yang, Chunhong
   Sun, Yan
   Wang, Changfa
   Zhong, Jifeng
   Huang, Jinming
   Zhu, Huabin
TI DNA methylation rather than single nucleotide polymorphisms regulates
   the production of an aberrant splice variant of <i>IL6R</i> in mastitic
   cows
SO CELL STRESS & CHAPERONES
LA English
DT Article
DE IL6R; Splice variant; Single nucleotide polymorphism; Cattle; Mastitis;
   DNA methylation
ID DAIRY-CATTLE; TARGETED MICRORNAS; ESCHERICHIA-COLI; EPITHELIAL-CELLS;
   IMMUNE-RESPONSE; BREAST-CANCER; MAMMARY-GLAND; GENE; EXPRESSION;
   PROMOTER
AB Interleukin-6 receptor-alpha (IL6R) interacts with IL6 and forms a ligand-receptor complex, which can stimulate various cellular responses, such as cell proliferation, cell differentiation, and activation of inflammatory processes. Both genetic mutation and epigenetic modification regulate gene transcription. We identified a novel splice variant of bovine IL6R, designated as IL6R-TV, which is characterized by the skipping of exon 2 of the NCBI-referenced IL6R gene (IL6R-reference). The expression levels of IL6R-TV and IL6R-reference transcripts were lower in normal mammary gland tissues. These transcripts play a potential role during inflammatory infection. We also detected two putative functional SNPs (g.19711 T > C and g.19731 G > C) located within the upstream 100 bp of exon 2. These SNPs formed two haplotypes (T-G and C-C). Two mutant pSPL3 exon-trapping plasmids (pSPL3-T-G and pSPL3-C-C) were transferred into the bovine mammary epithelial cells (MAC-T) and human embryonic kidney 293 T cells (HEK293T) to investigate the relationship between the two SNPs and the aberrant splicing of IL6R. DNA methylation levels of the alternatively spliced exon in normal and mastitis-infected mammary gland tissues were quantified through nested bisulfate sequencing PCR (BSP) and cloning sequencing. We found that DNA methylation regulated IL6R transcription. The DNA methylation level was high in mastitis-infected mammary gland tissues and stimulated IL6R expression, thereby promoting the inclusion of the alternatively spliced exon. The upregulated expression of the two transcripts was due to DNA methylation modification rather than genetic mutations.
C1 [Zhang, Yan; Hao, Haisheng; Huang, Jinming; Zhu, Huabin] Chinese Acad Agr Sci, Inst Anim Sci, Beijing 100193, Peoples R China.
   [Zhang, Yan; Wang, Xiuge; Jiang, Qiang; Ju, Zhihua; Yang, Chunhong; Sun, Yan; Wang, Changfa; Zhong, Jifeng; Huang, Jinming] Shandong Acad Agr Sci, Dairy Cattle Res Ctr, Jinan 250131, Shandong, Peoples R China.
   [Huang, Jinming] Shandong Normal Univ, Coll Life Sci, Jinan, Shandong, Peoples R China.
C3 Chinese Academy of Agricultural Sciences; Institute of Animal Science,
   CAAS; Shandong Academy of Agricultural Sciences; Shandong Normal
   University
RP Huang, JM; Zhu, HB (通讯作者)，Chinese Acad Agr Sci, Inst Anim Sci, Beijing 100193, Peoples R China.; Huang, JM (通讯作者)，Shandong Acad Agr Sci, Dairy Cattle Res Ctr, Jinan 250131, Shandong, Peoples R China.; Huang, JM (通讯作者)，Shandong Normal Univ, Coll Life Sci, Jinan, Shandong, Peoples R China.
EM huangjinm@sina.com; zhuhuabin@caas.cn
OI zhu, huabin/0000-0001-7970-9183; wang, changfa/0000-0002-5186-1703
FU National Natural Science Foundation of China [31401049, 31671286,
   31672397]; Agricultural Science and Technology Innovation Program
   [ASTIP-IA S06]; Key Research and Development Program of Shandong
   [2015GNC110002]
FX This work was supported by grants from the National Natural Science
   Foundation of China (31401049, 31671286 and 31672397), the Agricultural
   Science and Technology Innovation Program (ASTIP-IA S06), and the Key
   Research and Development Program of Shandong (2015GNC110002).
CR Aitken SL, 2011, J MAMMARY GLAND BIOL, V16, P291, DOI 10.1007/s10911-011-9230-4
   [Anonymous], 2016, VET RES
   Benakanakere M, 2015, J DENT RES, V94, P183, DOI 10.1177/0022034514557545
   Bradley T, 2015, RNA, V21, P75, DOI 10.1261/rna.043893.113
   Breiling A, 2015, EPIGENET CHROMATIN, V8, DOI 10.1186/s13072-015-0016-6
   Brett D, 2002, NAT GENET, V30, P29, DOI 10.1038/ng803
   Buitenhuis B, 2011, BMC GENOMICS, V12, DOI 10.1186/1471-2164-12-130
   Chang GJ, 2015, VET J, V203, P339, DOI 10.1016/j.tvjl.2014.12.023
   ElSharawy A, 2006, HUM MUTAT, V27, P1129, DOI 10.1002/humu.20377
   Fontes JA, 2015, CYTOKINE, V74, P62, DOI 10.1016/j.cyto.2014.12.024
   Gao Q, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0084355
   Garbers C, 2015, CURR OPIN IMMUNOL, V34, P75, DOI 10.1016/j.coi.2015.02.008
   Garcia-Blanco MA, 2004, NAT BIOTECHNOL, V22, P535, DOI 10.1038/nbt964
   García-Ruiz A, 2016, P NATL ACAD SCI USA, V113, pE3995, DOI 10.1073/pnas.1519061113
   Gomes F, 2016, CURR MICROBIOL, V72, P377, DOI 10.1007/s00284-015-0958-8
   Günther J, 2011, INFECT IMMUN, V79, P695, DOI 10.1128/IAI.01071-10
   Heyn H, 2013, GENOME RES, V23, P1363, DOI 10.1101/gr.154187.112
   Hinrichs D, 2011, J DAIRY SCI, V94, P471, DOI 10.3168/jds.2010-3374
   Hou QL, 2012, DNA CELL BIOL, V31, P739, DOI 10.1089/dna.2011.1402
   Huang CS, 2007, CLIN CHIM ACTA, V384, P69, DOI 10.1016/j.cca.2007.06.001
   Huang JM, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-839
   Hunter CA, 2015, NAT IMMUNOL, V16, P448, DOI 10.1038/ni.3153
   Iannone C, 2013, CHROMOSOMA, V122, P465, DOI 10.1007/s00412-013-0425-x
   Jones SA, 2011, J CLIN INVEST, V121, P3375, DOI 10.1172/JCI57158
   Ju ZH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0143705
   Kumar H, 2015, J NUCL MED RAD THER, V6
   Larriba E, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17040452
   Lewandowska-Sabat AM, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-891
   Li HH, 2015, ONCOTARGET, V6, P14026, DOI 10.18632/oncotarget.4334
   Li LM, 2013, ANIM GENET, V44, P241, DOI 10.1111/age.12007
   Lopez-Lasanta M, 2015, ARTHRITIS RES THER, V17, DOI 10.1186/s13075-015-0737-8
   LUND T, 1994, LIVEST PROD SCI, V39, P243, DOI 10.1016/0301-6226(94)90203-8
   Maor GL, 2015, TRENDS GENET, V31, P274, DOI 10.1016/j.tig.2015.03.002
   Maunakea AK, 2013, CELL RES, V23, P1256, DOI 10.1038/cr.2013.110
   Messier TL, 2016, ONCOTARGET, V7, P5094, DOI 10.18632/oncotarget.6922
   Niwa T, 2010, CANCER RES, V70, P1430, DOI 10.1158/0008-5472.CAN-09-2755
   Oviedo-Boyso J, 2007, J INFECTION, V54, P399, DOI 10.1016/j.jinf.2006.06.010
   Rainard P, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0154172
   Rawstron AC, 2000, BLOOD, V96, P3880, DOI 10.1182/blood.V96.12.3880.h8003880_3880_3886
   Resch A, 2004, NUCLEIC ACIDS RES, V32, P1261, DOI 10.1093/nar/gkh284
   Runyon RS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048796
   Song M, 2016, SCI REP, V6
   Tryndyak VP, 2016, BMC GENOMICS, V17, DOI 10.1186/s12864-016-2617-2
   Vanselow J, 2006, J MOL ENDOCRINOL, V37, P463, DOI 10.1677/jme.1.02131
   Wang XS, 2013, GENET MOL RES, V12, P6228, DOI 10.4238/2013.December.4.10
   Wang XX, 2013, ASIAN PAC J CANCER P, V14, P2295, DOI 10.7314/APJCP.2013.14.4.2295
   Wang XG, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-630
   Wiggans GR, 2016, ANN REV ANIM BIOSCI
   Yang XJ, 2014, CANCER CELL, V26, P577, DOI 10.1016/j.ccr.2014.07.028
   Yearim A, 2015, CELL REP, V10, P1122, DOI 10.1016/j.celrep.2015.01.038
   Zhang GT, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062284
   Zhang ZJ, 2015, MICROBIOL RES, V174, P24, DOI 10.1016/j.micres.2015.03.005
NR 52
TC 19
Z9 22
U1 0
U2 16
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1355-8145
EI 1466-1268
J9 CELL STRESS CHAPERON
JI Cell Stress Chaperones
PD JUL
PY 2018
VL 23
IS 4
BP 617
EP 628
DI 10.1007/s12192-017-0871-0
PG 12
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA GN0TV
UT WOS:000438691200015
PM 29353404
OA Green Published, hybrid
DA 2025-01-12
ER

PT J
AU Fuertes, M
   Sapochnik, M
   Tedesco, L
   Senin, S
   Attorresi, A
   Ajler, P
   Carrizo, G
   Cervio, A
   Sevlever, G
   Bonfiglio, JJ
   Stalla, GK
   Arzt, E
AF Fuertes, M.
   Sapochnik, M.
   Tedesco, L.
   Senin, S.
   Attorresi, A.
   Ajler, P.
   Carrizo, G.
   Cervio, A.
   Sevlever, G.
   Bonfiglio, J. J.
   Stalla, G. K.
   Arzt, E.
TI Protein stabilization by RSUME accounts for PTTG pituitary tumor
   abundance and oncogenicity
SO ENDOCRINE-RELATED CANCER
LA English
DT Article
DE pituitary tumors; PTTG; RSUME
ID TRANSFORMING GENE PTTG; SQUAMOUS-CELL CARCINOMA; THYROID-CANCER;
   PROLACTINOMA PATHOGENESIS; PROSTATE-CANCER; POOR-PROGNOSIS;
   BREAST-CANCER; HUMAN HOMOLOG; CYCLE CONTROL; EXPRESSION
AB Increased levels of the proto-oncogene pituitary tumor-transforming gene 1 (PTTG) have been repeatedly reported in several human solid tumors, especially in endocrine-related tumors such as pituitary adenomas. Securin PTTG has a critical role in pituitary tumorigenesis. However, the cause of upregulation has not been found yet, despite analyses made at the gene, promoter and mRNA level that show that no mutations, epigenetic modifications or other mechanisms that deregulate its expression may explain its overexpression and action as an oncogene. We describe that high PTTG protein levels are induced by the RWD-containing sumoylation enhancer (RWDD3 or RSUME), a protein originally identified in the same pituitary tumor cell line in which PTTG was also cloned. We demonstrate that PTTG and RSUME have a positive expression correlation in human pituitary adenomas. RSUME increases PTTG protein in pituitary tumor cell lines, prolongs the half-life of PTTG protein and regulates the PTTG induction by estradiol. As a consequence, RSUME enhances PTTG transcription factor and securin activities. PTTG hyperactivity on the cell cycle resulted in recurrent and unequal divisions without cytokinesis, and the consequential appearance of aneuploidies and multinucleated cells in the tumor. RSUME knockdown diminishes securin PTTG and reduces its tumorigenic potential in a xenograft mouse model. Taken together, our findings show that PTTG high protein steady state levels account for PTTG tumor abundance and demonstrate a critical role of RSUME in this process in pituitary tumor cells.
C1 [Fuertes, M.; Sapochnik, M.; Tedesco, L.; Senin, S.; Attorresi, A.; Bonfiglio, J. J.; Arzt, E.] Max Planck Gesell, Partner Inst, CONICET, Inst Invest Biomed Buenos Aires IBioBA, Buenos Aires, DF, Argentina.
   [Ajler, P.; Carrizo, G.] Hosp Italiano Buenos Aires, Serv Neurocirugia, Buenos Aires, DF, Argentina.
   [Cervio, A.; Sevlever, G.] FLENI, Dept Neurocirugia, Buenos Aires, DF, Argentina.
   [Stalla, G. K.] Max Planck Inst Psychiat, Dept Clin Res, Munich, Germany.
   [Arzt, E.] Univ Buenos Aires, Fac Ciencias Exactas & Nat, Dept Fisiol & Biol Mol & Celular, Buenos Aires, DF, Argentina.
C3 Max Planck Society; Consejo Nacional de Investigaciones Cientificas y
   Tecnicas (CONICET); Hospital Italiano de Buenos Aires; University of
   Buenos Aires; Max Planck Society; University of Buenos Aires
RP Arzt, E (通讯作者)，Max Planck Gesell, Partner Inst, CONICET, Inst Invest Biomed Buenos Aires IBioBA, Buenos Aires, DF, Argentina.; Arzt, E (通讯作者)，Univ Buenos Aires, Fac Ciencias Exactas & Nat, Dept Fisiol & Biol Mol & Celular, Buenos Aires, DF, Argentina.
EM earzt@ibioba-mpsp-conicet.gov.ar
RI ; Sevlever, Gustavo/Q-2219-2015; Bonfiglio, Juan Jose/B-5853-2013
OI Stalla, Guenter/0000-0002-1975-3294; Sevlever,
   Gustavo/0000-0002-9567-7553; Cervio, Andres/0000-0001-7617-1605;
   Fuertes, Mariana/0000-0002-3015-9560; Bonfiglio, Juan
   Jose/0000-0001-7767-0799
FU Max Planck Society from Germany [2012/2016]; University of Buenos Aires
   (UBA) from Argentina [20020100100078, 20020130100427BA]; Consejo
   Nacional de Investigaciones Cientificas y Tecnicas (CONICET) from
   Argentina [D449]; Agencia Nacional de Promocion Cientifica y Tecnologica
   (ANPCyT) from Argentina [PICT2014-3634, PICT2016-1620]; Fondo para la
   Convergencia Estructural de Mercosur (FOCEM) [COF 03/11]
FX This work was supported by the Max Planck Society from Germany (grant
   number 2012/2016); University of Buenos Aires (UBA) from Argentina
   (grant numbers No 20020100100078, No 20020130100427BA); the Consejo
   Nacional de Investigaciones Cientificas y Tecnicas (CONICET) from
   Argentina (D449 (01-03-2016)); the Agencia Nacional de Promocion
   Cientifica y Tecnologica (ANPCyT) from Argentina (grant numbers
   PICT2014-3634, PICT2016-1620); and Fondo para la Convergencia
   Estructural de Mercosur (FOCEM) (grant number COF 03/11).
CR Arzt E, 1999, FRONT NEUROENDOCRIN, V20, P71, DOI 10.1006/frne.1998.0176
   Beckers A, 2010, CLIN ENDOCRINOL, V72, P290, DOI 10.1111/j.1365-2265.2009.03726.x
   Boelaert K, 2003, J CLIN ENDOCR METAB, V88, P2341, DOI 10.1210/jc.2002-021113
   Boggio R, 2004, MOL CELL, V16, P549, DOI 10.1016/j.molcel.2004.11.007
   Carbia-Nagashima A, 2007, CELL, V131, P309, DOI 10.1016/j.cell.2007.07.044
   Castro CP, 2003, ENDOCRINOLOGY, V144, P693, DOI 10.1210/en.2002-220891
   Chesnokova V, 2008, P NATL ACAD SCI USA, V105, P17498, DOI 10.1073/pnas.0804810105
   Chesnokova V, 2007, CANCER RES, V67, P10564, DOI 10.1158/0008-5472.CAN-07-0974
   CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4
   Clayton RN, 2004, FRONT HORM RES, V32, P186
   Creighton CJ, 2013, NATURE, V499, P43, DOI 10.1038/nature12222
   Domínguez A, 1998, ONCOGENE, V17, P2187, DOI 10.1038/sj.onc.1202140
   Drouin J, 2010, FRONT HORM RES, V38, P15, DOI 10.1159/000318490
   Druker J, 2013, MOL CELL BIOL, V33, P2116, DOI 10.1128/MCB.01470-12
   Dworakowska D, 2012, MINERVA ENDOCRINOL, V37, P157
   Farrell WE, 2014, CURR OPIN ENDOCRINOL, V21, P299, DOI 10.1097/MED.0000000000000078
   Fernandez A, 2010, CLIN ENDOCRINOL, V72, P377, DOI 10.1111/j.1365-2265.2009.03667.x
   Fowkes RC, 2012, ENDOCR-RELAT CANCER, V19, pC1, DOI 10.1530/ERC-11-0297
   Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088
   Gatto F, 2013, ENDOCRINOLOGY, V154, P4715, DOI 10.1210/en.2013-1672
   Geiss-Friedlander R, 2007, NAT REV MOL CELL BIO, V8, P947, DOI 10.1038/nrm2293
   Genkai N, 2006, ONCOL REP, V15, P1569
   Gerez J, 2015, ONCOGENE, V34, P4855, DOI 10.1038/onc.2014.407
   Gerez J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057795
   Haji Amousha Mohamad Reza, 2015, Acta Med Iran, V53, P236
   Hay RT, 2005, MOL CELL, V18, P1, DOI 10.1016/j.molcel.2005.03.012
   He W, 2017, GENE, V603, P54, DOI 10.1016/j.gene.2016.12.012
   Heaney AP, 1999, NAT MED, V5, P1317, DOI 10.1038/15275
   Heaney AP, 2000, LANCET, V355, P716, DOI 10.1016/S0140-6736(99)10238-1
   Horwitz GA, 2003, MOL ENDOCRINOL, V17, P600, DOI 10.1210/me.2001-0006
   Huang CC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076421
   Huang SQ, 2018, CANCER SCI, V109, P678, DOI 10.1111/cas.13493
   Ito T, 2008, CANCER RES, V68, P3214, DOI 10.1158/0008-5472.CAN-07-3043
   Lewy GD, 2012, J ENDOCRINOL INVEST, V35, P425, DOI 10.3275/8332
   Liu J, 2015, EXP THER MED, V10, P763, DOI 10.3892/etm.2015.2566
   Mastronardi L, 2001, SURG NEUROL, V56, P27, DOI 10.1016/S0090-3019(01)00455-4
   McCabe CJ, 1999, J ENDOCRINOL, V162, P163, DOI 10.1677/joe.0.1620163
   Melmed S, 2011, NAT REV ENDOCRINOL, V7, P257, DOI 10.1038/nrendo.2011.40
   Musat M, 2004, FRONT HORM RES, V32, P34
   Ogbagabriel S, 2005, MODERN PATHOL, V18, P985, DOI 10.1038/modpathol.3800382
   Páez-Pereda M, 2003, P NATL ACAD SCI USA, V100, P1034, DOI 10.1073/pnas.0237312100
   Panguluri SK, 2008, J OVARIAN RES, V1, DOI 10.1186/1757-2215-1-6
   Pei L, 1998, J BIOL CHEM, V273, P5219, DOI 10.1074/jbc.273.9.5219
   Pei L, 1999, J BIOL CHEM, V274, P3151, DOI 10.1074/jbc.274.5.3151
   Pei L, 1997, MOL ENDOCRINOL, V11, P433, DOI 10.1210/me.11.4.433
   Perez-Castro C, 2012, PHYSIOL REV, V92, P1, DOI 10.1152/physrev.00003.2011
   Quereda V, 2009, J MOL ENDOCRINOL, V42, P75, DOI 10.1677/JME-08-0146
   Ramos-Morales F, 2000, ONCOGENE, V19, P403, DOI 10.1038/sj.onc.1203320
   Read ML, 2017, ONCOGENE, V36, P5296, DOI 10.1038/onc.2017.154
   Romero F, 2001, NUCLEIC ACIDS RES, V29, P1300, DOI 10.1093/nar/29.6.1300
   Sáez C, 1999, ONCOGENE, V18, P5473, DOI 10.1038/sj.onc.1202914
   Salehi F, 2013, ANTICANCER RES, V33, P119
   Sapochnik M, 2017, ONCOTARGET, V8, P4690, DOI 10.18632/oncotarget.13577
   Schneider BP, 2015, CLIN CANCER RES, V21, P5082, DOI 10.1158/1078-0432.CCR-15-0586
   Shan B, 2012, ENDOCR-RELAT CANCER, V19, P13, DOI 10.1530/ERC-11-0211
   Smith VE, 2010, EXPERT REV MOL MED, V12, DOI 10.1017/S1462399410001699
   Solbach C, 2004, BREAST, V13, P80, DOI 10.1016/j.breast.2003.09.008
   Tong Y, 2008, ONCOGENE, V27, P6385, DOI 10.1038/onc.2008.234
   Tong Y, 2007, ONCOGENE, V26, P5596, DOI 10.1038/sj.onc.1210339
   Tong YG, 2009, J MOL ENDOCRINOL, V43, P179, DOI 10.1677/JME-08-0176
   Tsai SJ, 2005, J CLIN ENDOCR METAB, V90, P3715, DOI 10.1210/jc.2004-2303
   Uccella S, 2005, ANAL QUANT CYTOL, V27, P241
   Wang ZY, 2003, P NATL ACAD SCI USA, V100, P3428, DOI 10.1073/pnas.0638052100
   Wang ZY, 2001, MOL ENDOCRINOL, V15, P1870, DOI 10.1210/me.15.11.1870
   Yu R, 2003, ENDOCRINOLOGY, V144, P4991, DOI 10.1210/en.2003-0305
   Zhang JF, 2014, ACTA HISTOCHEM, V116, P435, DOI 10.1016/j.acthis.2013.09.011
   Zhang X, 1999, MOL ENDOCRINOL, V13, P156, DOI 10.1210/me.13.1.156
   Zhang X, 1999, J CLIN ENDOCR METAB, V84, P761, DOI 10.1210/jc.84.2.761
   Zhou C, 2014, ONCOGENE, V33, P851, DOI 10.1038/onc.2013.16
   Zhu XH, 2006, ANTICANCER RES, V26, P1253
   Zou H, 1999, SCIENCE, V285, P418, DOI 10.1126/science.285.5426.418
NR 71
TC 10
Z9 12
U1 0
U2 5
PU BIOSCIENTIFICA LTD
PI BRISTOL
PA EURO HOUSE, 22 APEX COURT WOODLANDS, BRADLEY STOKE, BRISTOL BS32 4JT,
   ENGLAND
SN 1351-0088
EI 1479-6821
J9 ENDOCR-RELAT CANCER
JI Endocr.-Relat. Cancer
PD JUN
PY 2018
VL 25
IS 6
BP 665
EP 676
DI 10.1530/ERC-18-0028
PG 12
WC Oncology; Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Endocrinology & Metabolism
GA GM4GS
UT WOS:000438075300011
PM 29622689
OA Bronze, Green Published
DA 2025-01-12
ER

PT J
AU Gely-Pernot, A
   Hao, CX
   Legoff, L
   Multigner, L
   D'Cruz, SC
   Kervarrec, C
   Jégou, B
   Tevosian, S
   Smagulova, F
AF Gely-Pernot, Aurore
   Hao, Chunxiang
   Legoff, Louis
   Multigner, Luc
   D'Cruz, Shereen Cynthia
   Kervarrec, Christine
   Jegou, Bernard
   Tevosian, Sergei
   Smagulova, Fatima
TI Gestational exposure to chlordecone promotes transgenerational changes
   in the murine reproductive system of males
SO SCIENTIFIC REPORTS
LA English
DT Article
ID ESTROGEN-RECEPTOR BINDING; HISTONE MODIFICATIONS; EPIGENETIC REGULATION;
   BREAST-CANCER; GENE; CHROMATIN; ZFP57; IDENTIFICATION; SPECIFICATION;
   TRANSCRIPTION
AB Environmental factors can affect epigenetic events during germline reprogramming and impose distinctive transgenerational consequences onto the offspring. In this study, we examined the transgenerational effects of chlordecone (CD), an organochlorine insecticide with well-known estrogenic properties. We exposed pregnant mice to CD from embryonic day 6.5 to 15.5 and observed a reduction in spermatogonia (SG) numbers in F3, meiotic defects in spermatocytes and decrease in spermatozoa number in the first and third generation of male progeny. The RNA qRT-PCR expression analysis in F1 and transcriptomics analysis in F3 males using the whole testes revealed changes in the expression of genes associated with chromosome segregation, cell division and DNA repair. The expression of the master regulator of pluripotency, Pou5f1, decreased in foetal and increased in adult F1, but not in F3 adult testes. Analysis of histone H3K4me3 distribution revealed widespread changes in its occupancy in the genome of F1 and F3 generations. We established that 7.1% of altered epigenetic marks were conserved between F1 and F3 generations. The overlapping changes common to F1 and F3 include genes implicated in cell adhesion and transcription factor activities functions. Differential peaks observed in F1 males are significantly enriched in predicted ESR1 binding sites, some of which we confirmed to be functional. Our data demonstrate that CD-mediated impairment of reproductive functions could be transmitted to subsequent generations.
C1 [Gely-Pernot, Aurore; Legoff, Louis; Multigner, Luc; D'Cruz, Shereen Cynthia; Kervarrec, Christine; Jegou, Bernard; Smagulova, Fatima] Univ Rennes, Inserm, EHESP, Irset UMR S1085, F-35000 Rennes, France.
   [Hao, Chunxiang] Linyi Univ, Coll Pharm, Linyi 276000, Peoples R China.
   [Tevosian, Sergei] Univ Florida, Dept Physiol Sci, Box 100144,1333 Ctr Dr, Gainesville, FL 32610 USA.
C3 Universite de Rennes; Institut National de la Sante et de la Recherche
   Medicale (Inserm); Ecole des Hautes Etudes en Sante Publique (EHESP);
   Linyi University; State University System of Florida; University of
   Florida
RP Smagulova, F (通讯作者)，Univ Rennes, Inserm, EHESP, Irset UMR S1085, F-35000 Rennes, France.
EM fatima.smagulova@inserm.fr
RI Jégou, Bernard/I-4742-2015; Multigner, Luc/AAA-6214-2020; DCRUZ,
   Shereen/AAK-3311-2021; Smagulova, Fatima/K-5459-2015; Multigner,
   Luc/I-2926-2015
OI Smagulova, Fatima/0000-0001-6883-1968; JEGOU,
   Bernard/0000-0003-0623-3609; Multigner, Luc/0000-0003-3205-8568; D'Cruz,
   Shereen Cynthia/0000-0002-1306-0016; LEGOFF, Louis/0000-0003-2864-1654
FU Microarray and Sequencing platform at Strasbourg of the 'France
   Genomique' consortium [ANR-10-INBS-0009]; Chair of Excellence programme
   of the European University of Brittany; Atip-Avenir program from INSERM
   [R13139NS]; Shandong Provincial Natural Science Foundation, China
   [ZR2017LB018]; Inserm/ARED
FX The authors would like to thank the Microarray and Sequencing platform
   at Strasbourg, a member of the 'France Genomique' consortium
   (ANR-10-INBS-0009). We also thank the GenOuest bioinformatics core
   facility for providing computing resources and assistance. We are
   indebted to Pierre-Yves Kernanec for animal care and treatment in
   addition to help with dissections and Madina Ahmad Ibrahim and Tuyen Ha
   Nguyen for help during cell quantification. This work was supported by
   the Chair of Excellence programme of the European University of
   Brittany, Atip-Avenir program (R13139NS) from INSERM to F.S. C.H. was
   supported by Shandong Provincial Natural Science Foundation, China
   (ZR2017LB018). L.L. is supported by a fellowship from Inserm/ARED.
CR Akagi T, 2005, BIOCHEM BIOPH RES CO, V331, P23, DOI 10.1016/j.bbrc.2005.03.118
   Annab LA, 2012, DIFFERENTIATION, V84, P330, DOI 10.1016/j.diff.2012.07.006
   [Anonymous], TOX PROF MIR CHLORD
   Anway MD, 2008, REPROD TOXICOL, V26, P100, DOI 10.1016/j.reprotox.2008.07.008
   Anway MD, 2005, SCIENCE, V308, P1466, DOI 10.1126/science.1108190
   Bao JQ, 2016, REPRODUCTION, V151, pR55, DOI 10.1530/REP-15-0562
   Barski A, 2007, CELL, V129, P823, DOI 10.1016/j.cell.2007.05.009
   Beck D, 2017, ENVIRON EPIGENETICS, V3, DOI 10.1093/eep/dvx016
   Boucher O, 2013, NEUROTOXICOLOGY, V35, P162, DOI 10.1016/j.neuro.2013.01.007
   Bourdeau V, 2004, MOL ENDOCRINOL, V18, P1411, DOI 10.1210/me.2003-0441
   Brykczynska U, 2010, NAT STRUCT MOL BIOL, V17, P679, DOI 10.1038/nsmb.1821
   CANNON SB, 1978, AM J EPIDEMIOL, V107, P529, DOI 10.1093/oxfordjournals.aje.a112572
   Carroll JS, 2006, NAT GENET, V38, P1289, DOI 10.1038/ng1901
   Chen EY, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-128
   Christophersen NS, 2010, J EXP MED, V207, P2287, DOI 10.1084/jem.20101438
   Costet N, 2015, ENVIRON RES, V142, P123, DOI 10.1016/j.envres.2015.06.023
   David H, 2016, ENVIRON RES, V151, P436, DOI 10.1016/j.envres.2016.08.004
   Diaz A, 2012, GENOME BIOL, V13, DOI 10.1186/gb-2012-13-10-r98
   Ding JY, 2017, ONCOTARGET, V8, P10714, DOI 10.18632/oncotarget.12956
   Dong XJ, 2013, EPIGENOMICS-UK, V5, P113, DOI [10.2217/EPI.13.13, 10.2217/epi.13.13]
   Dong XJ, 2012, GENOME BIOL, V13, DOI 10.1186/gb-2012-13-9-r53
   Ellem SJ, 2009, ANN NY ACAD SCI, V1155, P174, DOI 10.1111/j.1749-6632.2009.04360.x
   Faroon O, 1995, TOXICOL IND HEALTH, V11, P1, DOI 10.1177/074823379501100601
   Feng JX, 2012, NAT PROTOC, V7, P1728, DOI 10.1038/nprot.2012.101
   GANDOLFI O, 1984, BRAIN RES, V303, P117, DOI 10.1016/0006-8993(84)90218-X
   Garcia TX, 2013, CELL CYCLE, V12, P2538, DOI 10.4161/cc.25627
   Gely-Pernot A, 2015, BMC GENOMICS, V16, DOI 10.1186/s12864-015-2095-y
   Gloerich M, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms13996
   Goode DK, 2016, DEV CELL, V36, P572, DOI 10.1016/j.devcel.2016.01.024
   Goudarzi A, 2016, MOL CELL, V62, P169, DOI 10.1016/j.molcel.2016.03.014
   Grant CE, 2011, BIOINFORMATICS, V27, P1017, DOI 10.1093/bioinformatics/btr064
   Hajkova P, 2002, MECH DEVELOP, V117, P15, DOI 10.1016/S0925-4773(02)00181-8
   Hao CX, 2016, NUCLEIC ACIDS RES, V44, P9784, DOI 10.1093/nar/gkw840
   Hayashi K, 2007, SCIENCE, V316, P394, DOI 10.1126/science.1137545
   Heard E, 2014, CELL, V157, P95, DOI 10.1016/j.cell.2014.02.045
   Henderson KA, 2004, P NATL ACAD SCI USA, V101, P4519, DOI 10.1073/pnas.0400843101
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Joshi SR, 2011, MOL ENDOCRINOL, V25, P980, DOI 10.1210/me.2010-0302
   Kadhel P, 2014, AM J EPIDEMIOL, V179, P536, DOI 10.1093/aje/kwt313
   Kehler J, 2004, EMBO REP, V5, P1078, DOI 10.1038/sj.embor.7400279
   Kent J, 1996, DEVELOPMENT, V122, P2813
   Kim D, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-4-r36
   Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005
   Kuiper GGJM, 1998, ENDOCRINOLOGY, V139, P4252, DOI 10.1210/en.139.10.4252
   Kuleshov MV, 2016, NUCLEIC ACIDS RES, V44, pW90, DOI 10.1093/nar/gkw377
   Lachmann A, 2010, BIOINFORMATICS, V26, P2438, DOI 10.1093/bioinformatics/btq466
   LARSON PS, 1979, TOXICOL APPL PHARM, V48, P29, DOI 10.1016/S0041-008X(79)80005-8
   Lemaire G, 2006, LIFE SCI, V79, P1160, DOI 10.1016/j.lfs.2006.03.023
   Lesch BJ, 2013, P NATL ACAD SCI USA, V110, P16061, DOI 10.1073/pnas.1315204110
   Li HJ, 2016, ONCOGENE, V35, P2266, DOI 10.1038/onc.2015.289
   Li XJ, 2008, DEV CELL, V15, P547, DOI 10.1016/j.devcel.2008.08.014
   Li ZF, 1997, P NATL ACAD SCI USA, V94, P11221, DOI 10.1073/pnas.94.21.11221
   LINDER RE, 1983, J TOXICOL ENV HEALTH, V12, P183, DOI 10.1080/15287398309530417
   Mackay DJG, 2008, NAT GENET, V40, P949, DOI 10.1038/ng.187
   Magnani L, 2014, MOL CELL ENDOCRINOL, V382, P633, DOI 10.1016/j.mce.2013.04.026
   McLean CY, 2010, NAT BIOTECHNOL, V28, P495, DOI 10.1038/nbt.1630
   McLeay RC, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-165
   Mikkelsen TS, 2007, NATURE, V448, P553, DOI 10.1038/nature06008
   Multigner L, 2010, J CLIN ONCOL, V28, P3457, DOI 10.1200/JCO.2009.27.2153
   Ohinata Y, 2005, NATURE, V436, P207, DOI 10.1038/nature03813
   Pesce M, 2001, STEM CELLS, V19, P271, DOI 10.1634/stemcells.19-4-271
   Peters AHFM, 1997, CHROMOSOME RES, V5, P66, DOI 10.1023/A:1018445520117
   REUBER MD, 1979, J ENVIRON PATHOL TOX, V2, P671
   REUBER MD, 1979, NEOPLASMA, V26, P231
   Ribeiro MPC, 2014, CANCER LETT, V353, P17, DOI 10.1016/j.canlet.2014.07.009
   Riso V, 2016, NUCLEIC ACIDS RES, V44, P8165, DOI 10.1093/nar/gkw505
   Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007
   Samans B, 2014, DEV CELL, V30, P23, DOI 10.1016/j.devcel.2014.05.023
   Schuster Andrew, 2016, Environ Epigenet, V2
   Sfeir A, 2012, SCIENCE, V336, P593, DOI 10.1126/science.1218498
   Shin HJ, 2009, BIOINFORMATICS, V25, P2605, DOI 10.1093/bioinformatics/btp479
   Siklenka K, 2015, SCIENCE, V350, DOI 10.1126/science.aab2006
   SIRICA AE, 1989, CARCINOGENESIS, V10, P1047, DOI 10.1093/carcin/10.6.1047
   Skinner MK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066318
   Strogantsev R, 2012, BRIEF FUNCT GENOMICS, V11, P227, DOI 10.1093/bfgp/els018
   Takahashi N, 2015, COLD SH Q B, V80, P177, DOI 10.1101/sqb.2015.80.027466
   TAYLOR JR, 1978, NEUROLOGY, V28, P626, DOI 10.1212/WNL.28.7.626
   Thorvaldsdóttir H, 2013, BRIEF BIOINFORM, V14, P178, DOI 10.1093/bib/bbs017
   Tracey R, 2013, REPROD TOXICOL, V36, P104, DOI 10.1016/j.reprotox.2012.11.011
   Trapnell C, 2012, NAT PROTOC, V7, P562, DOI 10.1038/nprot.2012.016
   Trerotola M, 2015, HUM GENOMICS, V9, DOI 10.1186/s40246-015-0041-3
   Vallet-Erdtmann V, 2004, J BIOL CHEM, V279, P42875, DOI 10.1074/jbc.M403495200
   Vermeulen M, 2010, CELL, V142, P967, DOI 10.1016/j.cell.2010.08.020
   Woo YH, 2012, MOL BIOL EVOL, V29, P1757, DOI 10.1093/molbev/mss022
   Xiao S, 2012, CELL, V149, P1381, DOI 10.1016/j.cell.2012.04.029
   Xu B, 2017, CANCER MED-US, V6, P1062, DOI 10.1002/cam4.1039
   Zeineddine D, 2014, AM J STEM CELLS, V3, P74
   Zhang BJ, 2016, NATURE, V537, P553, DOI 10.1038/nature19361
   Zhang XN, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0173402
   Zhao XD, 2007, CELL STEM CELL, V1, P286, DOI 10.1016/j.stem.2007.08.004
   Zheng H, 2016, MOL CELL, V63, P1066, DOI 10.1016/j.molcel.2016.08.032
   Zsarnovszky A, 2018, FRONT NEUROENDOCRIN, V48, P23, DOI 10.1016/j.yfrne.2017.10.001
NR 92
TC 21
Z9 22
U1 2
U2 25
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD JUL 6
PY 2018
VL 8
AR 10274
DI 10.1038/s41598-018-28670-w
PG 18
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA GL9RD
UT WOS:000437673200048
PM 29980752
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Zhou, Y
   Li, ZH
   Ding, YL
   Zhang, P
   Wang, JQ
   Zhang, JL
   Wang, H
AF Zhou, Yong
   Li, Zhaohua
   Ding, Yinlu
   Zhang, Peng
   Wang, Jinqing
   Zhang, Jianliang
   Wang, Hao
TI Promoter methylation of WNT inhibitory factor-1 may be associated with
   the pathogenesis of multiple human tumors
SO JOURNAL OF CANCER RESEARCH AND THERAPEUTICS
LA English
DT Article
DE Cohort study; meta-analysis; methylation; WNT inhibitory factor-1
ID EPIGENETIC ALTERATION; CANCER STATISTICS; BREAST-CANCER; WIF-1 GENES;
   METAANALYSIS; HYPERMETHYLATION; NASOPHARYNGEAL; INACTIVATION;
   ANTAGONIST; EXPRESSION
AB Aim: We investigated the association of WNT inhibitory factor-1 (WIF-1) gene methylation with the pathogenesis of multiple human tumors, using a meta-analysis based approach.
   Materials and Methods: Electronic databases and manual search was additionally employed to retrieve relevant published literature. The cohort studies relating to tumor and WIF-1 were screened based on predefined selection criteria, and all extracted data from the selected studies were analyzed through STATA software.
   Results: Sixteen studies were finally enrolled in our study involved 1112 tumor samples and 612 adjacent normal samples. The study result showed that WIF-1 gene methylations in tumor tissues were significantly higher compared with adjacent/normal tissues. The result of subgroup analysis on ethnicity revealed that in the Caucasians, Asians, and Africans, the methylation status of WIF-1 gene in tumor tissues was higher than adjacent/normal tissues. Further subgroup analysis on disease types revealed that WIF-1 gene methylation status is a widespread phenomenon that is, observed in tumor tissues of patients with multiple human tumors compared with that in adjacent/normal tissues. Interestingly, there was no significant difference in WIF-1 gene methylation between tumor tissues among patients with lung cancer, gastric cancer, astrocytoma, and adjacent/normal tissues, indicating the WIF-1 gene methylation not a general nonspecific phenomenon.
   Conclusion: WIF-1 gene methylation in tumor tissues was significantly more frequent as compared to that in adjacent normal tissues, indicating that WIF-1 gene methylation may be an important event in the pathogenesis of multiple human tumors.
C1 [Zhou, Yong; Ding, Yinlu; Zhang, Peng; Wang, Jinqing; Zhang, Jianliang; Wang, Hao] Shandong Univ, Hosp 2, Dept Gen Surg, 247 North Pk St, Jinan 250033, Shandong, Peoples R China.
   [Li, Zhaohua] Shandong Univ, Hosp 2, Dept Med Imaging, Jinan 250033, Shandong, Peoples R China.
C3 Shandong University; Shandong University
RP Zhang, JL (通讯作者)，Shandong Univ, Hosp 2, Dept Gen Surg, 247 North Pk St, Jinan 250033, Shandong, Peoples R China.
EM zhangjianliang0810@163.com
RI Zhang, Peng/W-7640-2019; Ran, Chen/JMR-1744-2023
FU Shandong University Second Hospital Youth Fund Project [Y2013010046]
FX This project was supported by the Shandong University Second Hospital
   Youth Fund Project (Y2013010046), and The author is grateful for the
   critical comments of the reviewers on this manuscript.
CR Ai LB, 2006, CARCINOGENESIS, V27, P1341, DOI 10.1093/carcin/bgi379
   [Anonymous], J MOD LAB MED
   [Anonymous], J CLIN SURG
   [Anonymous], J HEPATOBILIARY SURG
   [Anonymous], J CLIN UROL
   Assi HA, 2013, J THORAC DIS, V5, pS2, DOI 10.3978/j.issn.2072-1439.2013.05.24
   Atkin WS, 2010, LANCET, V375, P1624, DOI 10.1016/S0140-6736(10)60551-X
   Batra S, 2006, BIOCHEM BIOPH RES CO, V342, P1228, DOI 10.1016/j.bbrc.2006.02.084
   Bishop MJ, 2014, FRONT PHYSIOL, V5, DOI 10.3389/fphys.2014.00338
   Chan SL, 2007, LAB INVEST, V87, P644, DOI 10.1038/labinvest.3700547
   Clement G, 2008, CANCER SCI, V99, P46, DOI 10.1111/j.1349-7006.2007.00663.x
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   DerSimonian R, 1996, STAT MED, V15, P1237, DOI 10.1002/(SICI)1097-0258(19960630)15:12<1237::AID-SIM301>3.0.CO;2-N
   Ding Z, 2009, WORLD J GASTROENTERO, V15, P2595, DOI 10.3748/wjg.15.2595
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Fendri A, 2010, CANCER INVEST, V28, P896, DOI 10.3109/07357907.2010.494324
   Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516
   Gao Z, 2009, ANTICANCER RES, V29, P2025
   [郭艳丽 Guo Yanli], 2010, [肿瘤防治研究, Cancer Research on Prevention and Treatment], V37, P1044
   Guzmán L, 2012, DIAGN PATHOL, V7, DOI 10.1186/1746-1596-7-87
   Higgins JPT, 2003, BMJ-BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Kawakami K, 2009, CANCER RES, V69, P8603, DOI 10.1158/0008-5472.CAN-09-2534
   Kim J, 2007, J THORAC CARDIOV SUR, V133, P733, DOI 10.1016/j.jtcvs.2006.09.053
   Kim JT, 2013, CARCINOGENESIS, V34, P953, DOI 10.1093/carcin/bgt018
   Kim J, 2010, J IMMUNOL, V185, P1274, DOI 10.4049/jimmunol.1000181
   Kohno H, 2010, ONCOL REP, V24, P423, DOI 10.3892/or_00000875
   Lee BB, 2009, CLIN CANCER RES, V15, P6185, DOI 10.1158/1078-0432.CCR-09-0111
   Lin YC, 2007, HUM GENE THER, V18, P379, DOI 10.1089/hum.2006.005
   [刘梅冬 LIU Mei-dong], 2009, [生命科学研究, Life Science Research], V13, P443
   Lombardi Ana Paola G, 2013, Spermatogenesis, V3, pe23181
   MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016
   Nosho K, 2007, CARCINOGENESIS, V28, P1364, DOI 10.1093/carcin/bgl246
   Peters JL, 2008, J CLIN EPIDEMIOL, V61, P991, DOI 10.1016/j.jclinepi.2007.11.010
   Queimado L, 2008, ARCH OTOLARYNGOL, V134, P94, DOI 10.1001/archotol.134.1.94
   Ramachandran I, 2012, ONCOGENE, V31, P2725, DOI 10.1038/onc.2011.455
   Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166
   Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138
   Urakami S, 2006, CLIN CANCER RES, V12, P383, DOI 10.1158/1078-0432.CCR-05-1344
   Urakami S, 2006, CLIN CANCER RES, V12, P6989, DOI 10.1158/1078-0432.CCR-06-1194
   van Vlodrop IJH, 2011, CLIN CANCER RES, V17, P4225, DOI 10.1158/1078-0432.CCR-10-3394
   Veeck J, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-217
   Yang XR, 2011, JNCI-J NATL CANCER I, V103, P250, DOI 10.1093/jnci/djq526
   Yang ZY, 2010, J EXP CLIN CANC RES, V29, DOI 10.1186/1756-9966-29-26
   Yee DS, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-162
   Yoshino M, 2009, INT J ONCOL, V35, P1201, DOI 10.3892/ijo_00000437
NR 45
TC 8
Z9 9
U1 0
U2 2
PU WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI MUMBAI
PA WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2
   VILLAGE MAROL, ANDHERI EAST, MUMBAI, Maharashtra, INDIA
SN 0973-1482
EI 1998-4138
J9 J CANCER RES THER
JI J. Canc. Res. Ther.
PD JUN
PY 2018
VL 14
SU 2
BP S381
EP S387
DI 10.4103/0973-1482.235357
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA GM1NQ
UT WOS:000437836000019
PM 29970693
OA gold
DA 2025-01-12
ER

PT J
AU Rodrigues, P
   Patel, SA
   Harewood, L
   Olan, I
   Vojtasova, E
   Syafruddin, SE
   Zaini, MN
   Richardson, EK
   Burge, J
   Warren, AY
   Stewart, GD
   Saeb-Parsy, K
   Samarajiwa, SA
   Vanharanta, S
AF Rodrigues, Paulo
   Patel, Saroor A.
   Harewood, Louise
   Olan, Ioana
   Vojtasova, Erika
   Syafruddin, Saiful E.
   Zaini, M. Nazhif
   Richardson, Emma K.
   Burge, Johanna
   Warren, Anne Y.
   Stewart, Grant D.
   Saeb-Parsy, Kourosh
   Samarajiwa, Shamith A.
   Vanharanta, Sakari
TI NF-κB-Dependent Lymphoid Enhancer Co-option Promotes Renal Carcinoma
   Metastasis
SO CANCER DISCOVERY
LA English
DT Article
ID BREAST-CANCER METASTASIS; CELL-CARCINOMA; RADICAL NEPHRECTOMY;
   SUPER-ENHANCERS; SNP RS6983267; MYC ENHANCER; TRANSCRIPTION; ELEMENTS;
   PREDISPOSITION; SUPPRESSION
AB Metastases, the spread of cancer cells to distant organs, cause the majority of cancer-related deaths. Few metastasis-specific driver mutations have been identified, suggesting aberrant gene regulation as a source of metastatic traits. However, how metastatic gene expression programs arise is poorly understood. Here, using human-derived metastasis models of renal cancer, we identify transcriptional enhancers that promote metastatic carcinoma progression. Specific enhancers and enhancer clusters are activated in metastatic cancer cell populations, and the associated gene expression patterns are predictive of poor patient outcome in clinical samples. We find that the renal cancer metastasis-associated enhancer complement consists of multiple coactivated tissue-specific enhancer modules. Specifically, we identify and functionally characterize a coregulatory enhancer cluster, activated by the renal cancer driver HIF2A and an NF-kappa B-driven lymphoid element, as a mediator of metastasis in vivo. We conclude that oncogenic pathways can acquire metastatic phenotypes through cross-lineage co-option of physiologic epigenetic enhancer states.
   SIGNIFICANCE; Renal cancer is associated with significant mortality due to metastasis. We show that in metastatic renal cancer, functionally important metastasis genes are activated via co-option of gene regulatory enhancer modules from distant developmental lineages, thus providing clues to the origins of metastatic cancer. (C) 2018 AACR.
C1 [Rodrigues, Paulo; Patel, Saroor A.; Olan, Ioana; Vojtasova, Erika; Syafruddin, Saiful E.; Zaini, M. Nazhif; Richardson, Emma K.; Samarajiwa, Shamith A.; Vanharanta, Sakari] Univ Cambridge, Hutchison MRC Res Ctr, MRC, Canc Unit, Cambridge CB2 0XZ, England.
   [Harewood, Louise] Univ Cambridge, Li Ka Shing Ctr, Canc Res UK Cambridge Inst, Cambridge, England.
   [Syafruddin, Saiful E.] Univ Kebangsaan Malaysia, UKM Med Mol Biol Inst, Jalan Yaacob Latiff, Kuala Lumpur, Malaysia.
   [Burge, Johanna; Stewart, Grant D.] Univ Cambridge, Addenbrookes Hosp, Dept Surg, Acad Urol Grp, Biomed Campus, Cambridge, England.
   [Warren, Anne Y.] Cambridge Univ Hosp NHS Fdn Trust, Dept Histopathol, Cambridge, England.
   [Saeb-Parsy, Kourosh] Univ Cambridge, Dept Surg, Cambridge, England.
   [Saeb-Parsy, Kourosh] NIHR Cambridge Biomed Res Ctr, Cambridge, England.
C3 University of Cambridge; University of Cambridge; Cancer Research UK;
   CRUK Cambridge Institute; Universiti Kebangsaan Malaysia; University of
   Cambridge; Cambridge University Hospitals NHS Foundation Trust;
   Addenbrooke's Hospital; University of Cambridge; University of
   Cambridge; University of Cambridge
RP Vanharanta, S (通讯作者)，Univ Cambridge, Hutchison MRC Res Ctr, MRC, Canc Unit, Cambridge CB2 0XZ, England.
EM sv358@mrc-cu.cam.ac.uk
RI Samarajiwa, Shamith/B-1601-2013; Saeb-Parsy, Kourosh/AGK-9107-2022;
   Syafruddin, Saiful/U-9324-2019; Stewart, Grant/B-6283-2008
OI Patel, Saroor A/0000-0002-6331-1557; Harewood,
   Louise/0000-0002-6398-6714; Stewart, Grant D./0000-0003-3188-9140;
   Saeb-Parsy, Kourosh/0000-0002-0633-3696; Olan,
   Ioana/0000-0003-0692-1831; Rodrigues, Paulo/0000-0002-5380-2715;
   Syafruddin, Saiful Effendi/0000-0002-9960-4888
FU Cambridge Biomedical Research Campus and CRUK Cambridge Centre; NIHR
   Cambridge Biomedical Research Centre; Medical Research Council
   [MC_UU_12022/7]; MRC [MR/N501876/1, MC_UU_12022/7, MC_UU_12022/10]
   Funding Source: UKRI
FX We thank A. Speed for technical assistance, P. Jones for discussion, A.
   Obenauf for discussion and the CRISPR activator construct, and V.
   Gnanapragasam for administration of the DIAMOND study, which allowed
   access to clinical RCC samples. Infrastructure for the Cambridge
   Urological Bio-repository was funded by the Cambridge Biomedical
   Research Campus and CRUK Cambridge Centre. The Human Research Tissue
   Bank is supported by the NIHR Cambridge Biomedical Research Centre. This
   work was supported by the Medical Research Council (MC_UU_12022/7).
CR Akdemir KC, 2015, GENOME BIOL, V16, DOI 10.1186/s13059-015-0767-1
   An JB, 2005, MOL CELL BIOL, V25, P7546, DOI 10.1128/MCB.25.17.7546-7556.2005
   Anders S, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-10-r106
   Boehm JS, 2007, CELL, V129, P1065, DOI 10.1016/j.cell.2007.03.052
   Chavez A, 2015, NAT METHODS, V12, P326, DOI [10.1038/NMETH.3312, 10.1038/nmeth.3312]
   Chen WF, 2016, NATURE, V539, P112, DOI 10.1038/nature19796
   Cho H, 2016, NATURE, V539, P107, DOI 10.1038/nature19795
   Ciancio G, 2010, EUR UROL, V57, P667, DOI 10.1016/j.eururo.2009.06.009
   Creighton CJ, 2013, NATURE, V499, P43, DOI 10.1038/nature12222
   Creyghton MP, 2010, P NATL ACAD SCI USA, V107, P21931, DOI 10.1073/pnas.1016071107
   David CJ, 2016, CELL, V164, P1015, DOI 10.1016/j.cell.2016.01.009
   Denny SK, 2016, CELL, V166, P328, DOI 10.1016/j.cell.2016.05.052
   Doench JG, 2014, NAT BIOTECHNOL, V32, P1262, DOI 10.1038/nbt.3026
   Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210
   Fidler IJ, 2003, NAT REV CANCER, V3, P453, DOI 10.1038/nrc1098
   Ge YJ, 2017, CELL, V169, P636, DOI 10.1016/j.cell.2017.03.042
   Gilbert LA, 2014, CELL, V159, P647, DOI 10.1016/j.cell.2014.09.029
   Gilbert LA, 2013, CELL, V154, P442, DOI 10.1016/j.cell.2013.06.044
   Grant CE, 2011, BIOINFORMATICS, V27, P1017, DOI 10.1093/bioinformatics/btr064
   Gupta S, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-2-r24
   Heinz S, 2010, MOL CELL, V38, P576, DOI 10.1016/j.molcel.2010.05.004
   Hermann PC, 2007, CELL STEM CELL, V1, P313, DOI 10.1016/j.stem.2007.06.002
   Herranz D, 2014, NAT MED, V20, P1130, DOI 10.1038/nm.3665
   Hnisz D, 2013, CELL, V155, P934, DOI 10.1016/j.cell.2013.09.053
   Jacob LS, 2015, CANCER RES, V75, P3713, DOI 10.1158/0008-5472.CAN-15-0562
   Jermann P, 2014, P NATL ACAD SCI USA, V111, pE3415, DOI 10.1073/pnas.1400672111
   Kaelin WG, 2007, ANNU REV PATHOL-MECH, V2, P145, DOI 10.1146/annurev.pathol.2.010506.092049
   Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6
   Koike-Yusa H, 2014, NAT BIOTECHNOL, V32, P267, DOI 10.1038/nbt.2800
   Kundaje A, 2015, NATURE, V518, P317, DOI 10.1038/nature14248
   Kwiatkowski N, 2014, NATURE, V511, P616, DOI 10.1038/nature13393
   Lambert AW, 2017, CELL, V168, P670, DOI 10.1016/j.cell.2016.11.037
   Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/NMETH.1923, 10.1038/nmeth.1923]
   Lawrence M, 2013, PLOS COMPUT BIOL, V9, DOI 10.1371/journal.pcbi.1003118
   Li B, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-323
   Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324
   Li LJ, 2007, MOL CELL BIOL, V27, P5381, DOI 10.1128/MCB.00282-07
   Lieberman-Aiden E, 2009, SCIENCE, V326, P289, DOI 10.1126/science.1181369
   Lin CY, 2016, NATURE, V530, P57, DOI 10.1038/nature16546
   Long HK, 2016, CELL, V167, P1170, DOI 10.1016/j.cell.2016.09.018
   Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8
   Lovén J, 2013, CELL, V153, P320, DOI 10.1016/j.cell.2013.03.036
   Makohon-Moore AP, 2017, NAT GENET, V49, P358, DOI 10.1038/ng.3764
   Mansour MR, 2014, SCIENCE, V346, P1373, DOI 10.1126/science.1259037
   Margueron R, 2011, NATURE, V469, P343, DOI 10.1038/nature09784
   Massagué J, 2016, NATURE, V529, P298, DOI 10.1038/nature17038
   Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860
   Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799
   Morrow JJ, 2018, NAT MED, V24, P176, DOI 10.1038/nm.4475
   Müller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016
   Nagano T, 2015, GENOME BIOL, V16, DOI 10.1186/s13059-015-0753-7
   Neph S, 2012, BIOINFORMATICS, V28, P1919, DOI 10.1093/bioinformatics/bts277
   Nguyen DX, 2007, NAT REV GENET, V8, P341, DOI 10.1038/nrg2101
   Oldridge DA, 2015, NATURE, V528, P418, DOI 10.1038/nature15540
   Oya M, 2001, ONCOGENE, V20, P3888, DOI 10.1038/sj.onc.1204525
   Peri S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076746
   Qi H, 2003, CANCER RES, V63, P7076
   Riising EM, 2014, MOL CELL, V55, P347, DOI 10.1016/j.molcel.2014.06.005
   Roe JS, 2017, CELL, V170, P875, DOI 10.1016/j.cell.2017.07.007
   Sanjana NE, 2014, NAT METHODS, V11, P783, DOI 10.1038/nmeth.3047
   Schlesinger-Raab A, 2008, EUR J CANCER, V44, P2485, DOI 10.1016/j.ejca.2008.07.039
   Schödel J, 2012, NAT GENET, V44, P420, DOI 10.1038/ng.2204
   Serra F., 2016, BIORXIV, DOI [10.1101/036764, DOI 10.1101/036764]
   Servant N, 2015, GENOME BIOL, V16, DOI 10.1186/s13059-015-0831-x
   Shen C, 2011, CANCER DISCOV, V1, P222, DOI 10.1158/2159-8290.CD-11-0098
   Shuch B, 2015, EUR UROL, V67, P85, DOI 10.1016/j.eururo.2014.04.029
   Sourbier C, 2007, CANCER RES, V67, P11668, DOI 10.1158/0008-5472.CAN-07-0632
   Staller P, 2003, NATURE, V425, P307, DOI 10.1038/nature01874
   Sur I, 2016, NAT REV CANCER, V16, P483, DOI 10.1038/nrc.2016.62
   Sur IK, 2012, SCIENCE, V338, P1360, DOI 10.1126/science.1228606
   SWIERZEWSKI DJ, 1994, AM J SURG, V168, P205, DOI 10.1016/S0002-9610(94)80069-3
   Tak YG, 2016, NUCLEIC ACIDS RES, V44, P4123, DOI 10.1093/nar/gkv1530
   Turajlic S, 2016, SCIENCE, V352, P169, DOI 10.1126/science.aaf2784
   Tuupanen S, 2009, NAT GENET, V41, P885, DOI 10.1038/ng.406
   Vanharanta S, 2013, CANCER CELL, V24, P410, DOI 10.1016/j.ccr.2013.09.007
   Vanharanta S, 2013, NAT MED, V19, P50, DOI 10.1038/nm.3029
   Visel A, 2009, NATURE, V457, P854, DOI 10.1038/nature07730
   Vogelstein B, 2013, SCIENCE, V339, P1546, DOI 10.1126/science.1235122
   Wassef M, 2015, GENE DEV, V29, P2547, DOI 10.1101/gad.269522.115
   Webster DE, 2014, GENOME RES, V24, P751, DOI 10.1101/gr.166231.113
   Yang H, 2007, MOL CELL, V28, P15, DOI 10.1016/j.molcel.2007.09.010
   Yao XS, 2017, CANCER DISCOV, V7, P1284, DOI 10.1158/2159-8290.CD-17-0375
   Young AC, 2009, CLIN CANCER RES, V15, P7582, DOI 10.1158/1078-0432.CCR-09-2131
   Yue F, 2014, NATURE, V515, P355, DOI 10.1038/nature13992
   Zhang XHF, 2013, CELL, V154, P1060, DOI 10.1016/j.cell.2013.07.036
   Zhang XY, 2016, NAT GENET, V48, P176, DOI 10.1038/ng.3470
   Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r137
   Zhao B, 2014, CELL REP, V8, P1595, DOI 10.1016/j.celrep.2014.07.037
NR 88
TC 39
Z9 42
U1 0
U2 6
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 2159-8274
EI 2159-8290
J9 CANCER DISCOV
JI Cancer Discov.
PD JUL
PY 2018
VL 8
IS 7
BP 850
EP 865
DI 10.1158/2159-8290.CD-17-1211
PG 16
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA GL5MG
UT WOS:000437210800023
PM 29875134
OA Green Accepted, Green Submitted
DA 2025-01-12
ER

PT J
AU Pulliam, N
   Fang, F
   Ozes, AR
   Tang, J
   Adewuyi, A
   Keer, H
   Lyons, J
   Baylin, SB
   Matei, D
   Nakshatri, H
   Rassool, FV
   Miller, KD
   Nephew, KP
AF Pulliam, Nicholas
   Fang, Fang
   Ozes, Ali R.
   Tang, Jessica
   Adewuyi, Adeoluwa
   Keer, Harold
   Lyons, John
   Baylin, Stephen B.
   Matei, Daniela
   Nakshatri, Harikrishna
   Rassool, Feyruz V.
   Miller, Kathy D.
   Nephew, Kenneth P.
TI An Effective Epigenetic-PARP Inhibitor Combination Therapy for Breast
   and Ovarian Cancers Independent of BRCA Mutations
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID DNA-DAMAGE RESPONSE; DEPENDENT PROTEIN-KINASE; POLY(ADP-RIBOSE)
   POLYMERASE; SECONDARY MUTATIONS; OXIDATIVE STRESS; LEUKEMIA-CELLS;
   RESISTANCE; ROS; METHYLATION; EXPRESSION
AB Purpose: PARP inhibitors (PARPi) are primarily effective against BRCA1/2-mutated breast and ovarian cancers, but resistance due to reversion of mutated BRCA1/2 and other mechanisms is common. Based on previous reports demonstrating a functional role for DNMT1 in DNA repair and our previous studies demonstrating an ability of DNA methyltransferase inhibitor (DNMTi) to resensitize tumors to primary therapies, we hypothesized that combining a DNMTi with PARPi would sensitize PARPi-resistant breast and ovarian cancers to PARPi therapy, independent of BRCA status.
   Experimental Design: Breast and ovarian cancer cell lines (BRCA-wild-type/mutant) were treated with PARPi talazoparib and DNMTi guadecitabine. Effects on cell survival, ROS accumulation, and cAMP levels were examined. In vivo, mice bearing either BRCA-proficient breast or ovarian cancer cells were treated with talazoparib and guadecitabine, alone or in combination. Tumor progression, gene expression, and overall survival were analyzed.
   Results: Combination of guadecitabine and talazoparib synergized to enhance PARPi efficacy, irrespective of BRCA mutation status. Coadministration of guadecitabine with talazoparib increased accumulation of ROS, promoted PARP activation, and further sensitized, in a cAMP/PKA-dependent manner, breast and ovarian cancer cells to PARPi. In addition, DNMTienhanced PARP "trapping" by talazoparib. Guadecitabine plus talazoparib decreased xenograft tumor growth and increased overall survival in BRCA-proficient high-grade serous ovarian and triple-negative breast cancer models.
   Conclusions: The novel combination of the next-generation DNMTi guadecitabine and the first-in-class PARPi talazoparib inhibited breast and ovarian cancers harboring either wild-type- or mutant-BRCA, supporting further clinical exploration of this drug combination in PARPi-resistant cancers. (C) 2018 AACR.
C1 [Pulliam, Nicholas; Ozes, Ali R.; Nephew, Kenneth P.] Indiana Univ, Dept Mol & Cellular Biochem, Bloomington, IN USA.
   [Pulliam, Nicholas; Fang, Fang; Ozes, Ali R.; Tang, Jessica; Nephew, Kenneth P.] Indiana Univ Sch Med, Med Sci Program, Bloomington, IN USA.
   [Adewuyi, Adeoluwa; Rassool, Feyruz V.] Univ Maryland, Sch Med, Dept Radiat Oncol, Baltimore, MD 21201 USA.
   [Keer, Harold] Astex Pharmaceut Inc, Pleasanton, CA USA.
   [Lyons, John] Astex Therapeut Ltd, Cambridge, England.
   [Baylin, Stephen B.] Johns Hopkins Sch Med, Dept Oncol, Baltimore, MD USA.
   [Matei, Daniela] Northwestern Univ, Feinberg Sch Med, Dept Obstet & Gynecol, Chicago, IL 60611 USA.
   [Nakshatri, Harikrishna] Indiana Univ Sch Med, Dept Surg, Indianapolis, IN 46202 USA.
   [Miller, Kathy D.] Indiana Univ Sch Med, Dept Med, Indianapolis, IN 46202 USA.
   [Nephew, Kenneth P.] Indiana Univ Sch Med, Dept Cellular & Integrat Physiol, Indianapolis, IN 46202 USA.
   [Nephew, Kenneth P.] Indiana Univ Sch Med, Dept Obstet & Gynecol, Indianapolis, IN 46202 USA.
C3 Indiana University System; Indiana University Bloomington; Indiana
   University System; Indiana University Bloomington; University System of
   Maryland; University of Maryland Baltimore; Astex Pharmaceuticals; Johns
   Hopkins University; Johns Hopkins Medicine; Northwestern University;
   Feinberg School of Medicine; Indiana University System; Indiana
   University Bloomington; Indiana University System; Indiana University
   Bloomington; Indiana University System; Indiana University Bloomington;
   Indiana University System; Indiana University Bloomington
RP Nephew, KP (通讯作者)，Indiana Univ Sch Med, Jordan Hall 302,1001 E Third St, Bloomington, IN 47405 USA.
EM knephew@indiana.edu
RI Matei, Deliu/A-1899-2013
OI Nakshatri, Harikrishna/0000-0001-8876-0052; Tang,
   Jessica/0000-0001-8224-6407; Matei, Daniela/0000-0003-2169-5035
FU NIH [R01-CA182832]; V Foundation for Cancer Research Translational
   Grant; Indiana Clinical and Translational Sciences Institute TL1
   [UL1TR001108]; Adelson Medical Research Foundation
FX We thank Dr. Ryan Jensen (Yale University) for 2X-MBP and 2X-MBP-tagged
   BRCA2 overexpression constructs, as well as BRCA2 knockdown and control
   constructs. We thank Sue Childress for preparation of H&E-stained in
   vivo tumor slide preparation. We thank Dr. Susan Perkins (Professor of
   Biostatistics and Biostatistics Core member at the IS Simon Cancer
   Center) for assistance with statistical analysis and review of the
   article. We thank Dr. R. Daniel Lodge-Rigal for initial H&E slide
   visualization. We thank Pietro Taverna (former: Astex Pharmaceuticals
   Inc., currently Sunesis Pharmaceuticals) and Len Post (former: BioMarin
   Pharmaceutical Inc.). This work was supported by NIH R01-CA182832, The V
   Foundation for Cancer Research Translational Grant (Cary, NC), Indiana
   Clinical and Translational Sciences Institute TL1 (UL1TR001108; A.
   Shekhar), and the Adelson Medical Research Foundation.
CR Balch C, 2009, ENDOCRINOLOGY, V150, P4003, DOI 10.1210/en.2009-0404
   Barber LJ, 2013, J PATHOL, V229, P422, DOI 10.1002/path.4140
   Brunyanszki A, 2014, MOL PHARMACOL, V86, P450, DOI 10.1124/mol.114.094318
   Bryant HE, 2005, NATURE, V434, P913, DOI 10.1038/nature03443
   Chen DH, 2013, CANCER RES, V73, P5821, DOI 10.1158/0008-5472.CAN-13-1080
   Chiarugi A, 2012, TRENDS PHARMACOL SCI, V33, P42, DOI 10.1016/j.tips.2011.10.001
   CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4
   de Bono J, 2017, CANCER DISCOV, V7, P620, DOI 10.1158/2159-8290.CD-16-1250
   Du Y, 2016, NAT MED, V22, P194, DOI 10.1038/nm.4032
   El-Khamisy SF, 2003, NUCLEIC ACIDS RES, V31, P5526, DOI 10.1093/nar/gkg761
   Fan MY, 2006, CANCER RES, V66, P11954, DOI 10.1158/0008-5472.CAN-06-1666
   Fandy TE, 2014, CLIN CANCER RES, V20, P1249, DOI 10.1158/1078-0432.CCR-13-1453
   Fang F, 2018, CANCER RES, V78, P631, DOI 10.1158/0008-5472.CAN-17-1492
   Fang F, 2014, CLIN CANCER RES, V20, P6504, DOI 10.1158/1078-0432.CCR-14-1553
   Fang F, 2010, CANCER-AM CANCER SOC, V116, P4043, DOI 10.1002/cncr.25204
   Farmer H, 2005, NATURE, V434, P917, DOI 10.1038/nature03445
   Fruehauf JP, 2007, CLIN CANCER RES, V13, P789, DOI 10.1158/1078-0432.CCR-06-2082
   Fu SQ, 2011, CANCER-AM CANCER SOC, V117, P1661, DOI 10.1002/cncr.25701
   Gelmon KA, 2011, LANCET ONCOL, V12, P852, DOI 10.1016/S1470-2045(11)70214-5
   Ghoshal K, 2005, MOL CELL BIOL, V25, P4727, DOI 10.1128/MCB.25.11.4727-4741.2005
   Ha K, 2011, HUM MOL GENET, V20, P126, DOI 10.1093/hmg/ddq451
   Ibrahim YH, 2012, CANCER DISCOV, V2, P1036, DOI 10.1158/2159-8290.CD-11-0348
   Jensen RB, 2013, DNA REPAIR, V12, P306, DOI 10.1016/j.dnarep.2012.12.007
   Jensen RB, 2010, NATURE, V467, P678, DOI 10.1038/nature09399
   Jones PA, 2016, NAT REV GENET, V17, P630, DOI 10.1038/nrg.2016.93
   Kaufman B, 2015, J CLIN ONCOL, V33, P244, DOI 10.1200/JCO.2014.56.2728
   Kim J, 2009, J BIOL CHEM, V284, P14396, DOI 10.1074/jbc.M808116200
   Kim MY, 2005, GENE DEV, V19, P1951, DOI 10.1101/gad.1331805
   Kondrashova O, 2017, CANCER DISCOV, V7, P984, DOI 10.1158/2159-8290.CD-17-0419
   LANGDON SP, 1988, CANCER RES, V48, P6166
   Lord CJ, 2017, SCIENCE, V355, P1152, DOI 10.1126/science.aam7344
   Lord CJ, 2013, NAT MED, V19, P1381, DOI 10.1038/nm.3369
   Orta ML, 2014, NUCLEIC ACIDS RES, V42, P9108, DOI 10.1093/nar/gku638
   Luo X, 2012, GENE DEV, V26, P417, DOI 10.1101/gad.183509.111
   Martínez-Reyes I, 2014, BBA-BIOENERGETICS, V1837, P1099, DOI 10.1016/j.bbabio.2014.03.010
   Matei D, 2012, CANCER RES, V72, P2197, DOI 10.1158/0008-5472.CAN-11-3909
   Murai J, 2012, CANCER RES, V72, P5588, DOI 10.1158/0008-5472.CAN-12-2753
   Muvarak NE, 2016, CANCER CELL, V30, P637, DOI 10.1016/j.ccell.2016.09.002
   NISHIO K, 1992, JPN J CANCER RES, V83, P754, DOI 10.1111/j.1349-7006.1992.tb01976.x
   O'Connor MJ, 2015, MOL CELL, V60, P547, DOI 10.1016/j.molcel.2015.10.040
   O'Hagan HM, 2011, CANCER CELL, V20, P606, DOI 10.1016/j.ccr.2011.09.012
   Özes AR, 2016, ONCOGENE, V35, P5350, DOI 10.1038/onc.2016.75
   Robertson KD, 2001, ONCOGENE, V20, P3139, DOI 10.1038/sj.onc.1204341
   ROHLFF C, 1993, MOL PHARMACOL, V43, P372
   Sakai W, 2008, NATURE, V451, P1116, DOI 10.1038/nature06633
   Swindall Amanda F, 2013, Cancers (Basel), V5, P943, DOI 10.3390/cancers5030943
   Syed YY, 2017, DRUGS, V77, P585, DOI 10.1007/s40265-017-0716-2
   Trachootham D, 2009, NAT REV DRUG DISCOV, V8, P579, DOI 10.1038/nrd2803
   Villena J, 2008, FREE RADICAL BIO MED, V44, P1146, DOI 10.1016/j.freeradbiomed.2007.12.017
   Wang YN, 2014, CANCER RES, V74, P4922, DOI 10.1158/0008-5472.CAN-14-1022
NR 50
TC 82
Z9 96
U1 1
U2 25
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
EI 1557-3265
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD JUL 1
PY 2018
VL 24
IS 13
BP 3163
EP 3175
DI 10.1158/1078-0432.CCR-18-0204
PG 13
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA GL6DS
UT WOS:000437270800022
PM 29615458
OA Green Submitted, Green Accepted, Bronze
DA 2025-01-12
ER

PT J
AU Wang, P
   Wang, FF
   Wang, L
   Pan, JH
AF Wang, Ping
   Wang, Feifei
   Wang, Lin
   Pan, Jihong
TI Proprotein convertase subtilisin/kexin type 6 activates the
   extracellular signal-regulated kinase 1/2 and Wnt family member 3A
   pathways and promotes <i>in vitro</i> proliferation, migration and
   invasion of breast cancer MDA-MB-231 cells
SO ONCOLOGY LETTERS
LA English
DT Article
DE proprotein convertase subtilisinikexin type 6; breast cancer; pathway
ID TRANSGENIC MICE; PACE4; INHIBITORS; CARCINOGENESIS; PROGRESSION
AB Breast cancer progression results from the acquisition of genetic and epigenetic alterations that promote tumor cell proliferation and survival. Proprotein convertase subtilisin/kexin type 6 (PCSK6) is a proteinase that regulates the proteolytic activity of various precursor proteins as well as protein maturation. PCSK6 also influences cancer cell proliferation, invasion and migration. Therefore, to investigate the effects of PCSK6 in breast cancer, human breast cancer MDA-MB-231 cells were treated with recombinant human PCSK6 in vitro. Treatment with recombinant PCSK6 significantly increased the proliferation, invasion and migration abilities of MDA-MB-231 cells. In addition, PCSK6 treatment reduced cell cycle arrest and prevented apoptosis of MDA-MB-231 cells. This provides further support for the hypothesis that PCSK6 serves a role in promoting tumor cell proliferation. PCSK6 treatment also increased the expression of phosphorylated extracellular signal-regulated kinase 1/2 and Wnt family member 3A, suggesting that these pathways are activated by PCSK6. The results of the present study suggested that PCSK6 may promote the proliferation of breast cancer MDA-MB-231 cells by disturbing cell cycle arrest via the mitogen-activated protein kinase pathway. Therefore, PCSK6 may be a potential therapeutic target for breast cancer.
C1 [Wang, Ping; Wang, Feifei; Wang, Lin; Pan, Jihong] Shandong Univ, Shandong Prov Hosp, Anesthesia Dept, Jinan 250000, Shandong, Peoples R China.
   [Wang, Feifei; Wang, Lin; Pan, Jihong] Shandong Med Biotechnol Ctr, 18877 Jingshi Rd, Jinan 250062, Shandong, Peoples R China.
   [Wang, Feifei; Wang, Lin; Pan, Jihong] Minist Hlth, Key Lab Biotechnol Drugs, Jinan 250062, Shandong, Peoples R China.
   [Wang, Feifei; Wang, Lin; Pan, Jihong] Key Lab Rare & Uncommon Dis, Jinan 250062, Shandong, Peoples R China.
C3 Shandong First Medical University & Shandong Academy of Medical
   Sciences; Shandong University
RP Pan, JH (通讯作者)，Shandong Med Biotechnol Ctr, 18877 Jingshi Rd, Jinan 250062, Shandong, Peoples R China.
EM pjh933@sohu.com
RI ping, wang/JJC-2265-2023
FU National Natural Science Foundation of China [81671624]; Natural Science
   Foundation of Shandong Province [ZR2015LY029]; Innovation Program of
   Shandong Academy of Medical Sciences
FX The present study was supported by the National Natural Science
   Foundation of China (grant no. 81671624), the Natural Science Foundation
   of Shandong Province (grant no. ZR2015LY029) and the Innovation Program
   of Shandong Academy of Medical Sciences (2016).
CR Akiyama T, 2006, ONCOGENE, V25, P7538, DOI 10.1038/sj.onc.1210063
   Basak A, 2005, J MOL MED, V83, P844, DOI 10.1007/s00109-005-0710-0
   Bassi DE, 2010, NEOPLASIA, V12, P516, DOI 10.1593/neo.92030
   Bontemps Y, 2007, MED RES REV, V27, P631, DOI 10.1002/med.20072
   Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5
   Byler S, 2014, ANTICANCER RES, V34, P1071
   Couture F, 2012, NEOPLASIA, V14, P1032, DOI 10.1593/neo.121368
   Fu J, 2013, NEOPLASIA, V15, P169, DOI 10.1593/neo.121846
   La Vecchia C, 2010, ANN ONCOL, V21, P1323, DOI 10.1093/annonc/mdp530
   Lai SL, 2009, CELL RES, V19, P532, DOI 10.1038/cr.2009.41
   Lapierre M, 2007, CANCER RES, V67, P9030, DOI 10.1158/0008-5472.CAN-07-0807
   Larue L, 2006, FRONT BIOSCI-LANDMRK, V11, P733, DOI 10.2741/1831
   Li ML, 2000, ONCOGENE, V19, P1010, DOI 10.1038/sj.onc.1203271
   Longuespee R, 2014, TRANSL ONCOL, pS1936
   Mains RE, 1997, BIOCHEM J, V321, P587, DOI 10.1042/bj3210587
   Nagahama M, 1998, FEBS LETT, V434, P155, DOI 10.1016/S0014-5793(98)00970-3
   Sansone P, 2012, J CLIN ONCOL, V30, P1005, DOI 10.1200/JCO.2010.31.8907
   Seidah NG, 1999, BRAIN RES, V848, P45, DOI 10.1016/S0006-8993(99)01909-5
   Teo JL, 2010, ADV DRUG DELIVER REV, V62, P1149, DOI 10.1016/j.addr.2010.09.012
   Wang FF, 2015, J RHEUMATOL, V42, P161, DOI 10.3899/jrheum.140435
   Wang FF, 2015, MOL MED REP, V11, P698, DOI 10.3892/mmr.2014.2691
NR 21
TC 9
Z9 9
U1 0
U2 4
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1792-1074
EI 1792-1082
J9 ONCOL LETT
JI Oncol. Lett.
PD JUL
PY 2018
VL 16
IS 1
BP 145
EP 150
DI 10.3892/ol.2018.8654
PG 6
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA GL4KQ
UT WOS:000437120300020
PM 29928395
OA gold, Green Published, Green Submitted
DA 2025-01-12
ER

PT J
AU Pooladanda, V
   Bandi, S
   Mondi, SR
   Gottumukkala, KM
   Godugu, C
AF Pooladanda, Venkatesh
   Bandi, Soumya
   Mondi, Sandhya Rani
   Gottumukkala, Krishna Mohan
   Godugu, Chandraiah
TI Nimbolide epigenetically regulates autophagy and apoptosis in breast
   cancer
SO TOXICOLOGY IN VITRO
LA English
DT Article
DE Nimbolide; Autophagy; Apoptosis; HDAC-2; H3K27Ac
ID CELL-LINES; INDUCTION; ACETYLATION; INHIBITION; ARREST; GROWTH; DAMAGE;
   ROS
AB Autophagy is a critical regulator of cellular homeostasis and its dysregulation often results in various disease manifestations, including cancer. Nimbolide, an active chemical constituent of neem (Azadirachta indica) exhibits potent anticancer effects. Although, nimbolide mediated apoptosis activation in breast cancer cells is well known. Nevertheless, its role in autophagy induction mechanism and epigenetic alteration is not explored previously. Our current study intended to bridge the gaps in the existing research by exploring the potential of nimbolide in inducing autophagy, which could counter regulate the transformations in breast cancer. In our studies, nimbolide significantly inhibited the cell proliferation of MDA-MB-231 and MCF-7 cells with IC50 values of 1.97 +/- 0.24 and 5.04 +/- 0.25 mu M, respectively. Nimbolide markedly arrested the cell cycle progression and cell survival with loss of mitochondrial membrane potential by reducing Bcl-2 concomitantly inducing Bax and caspases protein expression with modulation of HDAC-2 and H3K27Ac expression. Consequently, characteristic autophagolysosome accumulation was observed by acridine orange, monodansylcadaverine (MDC) and Lysotracker Red staining. Moreover, nimbolide induced autophagy signaling by increasing Beclin 1 and LC3B along with decreased p62 and mTOR protein expression. Thus, our findings imply that nimbolide induces autophagy mediated apoptotic cell death in breast cancer with epigenetic modifications.
C1 [Pooladanda, Venkatesh; Godugu, Chandraiah] NIPER, Dept Regulatory Toxicol, Hyderabad 500037, Telangana, India.
   [Bandi, Soumya; Mondi, Sandhya Rani; Gottumukkala, Krishna Mohan] Jawaharlal Nehru Technol Univ, Ctr Pharmaceut Sci, Inst Sci & Technol, Hyderabad 500085, Telangana, India.
C3 National Institute of Pharmaceutical Education & Research, S.A.S. Nagar
   (Mohali); National Institute of Pharmaceutical Education & Research,
   Hyderabad; Jawaharlal Nehru Technological University - Hyderabad
RP Godugu, C (通讯作者)，NIPER, Dept Regulatory Toxicol, Hyderabad 500037, Telangana, India.
EM chandra.niperhyd@gov.in
RI Pooladanda, Venkatesh/ABF-9051-2021; Godugu, Chandraiah/F-4741-2018
OI Godugu, Chandraiah/0000-0001-5904-3134
FU DST-Science and Engineering Board-Early Career Research Award (SERB-ECR)
   [ECR/2016/000007]; Department of Biotechnology (DBT), Govt. of India
   [MAP/2015/58, DBT/IC-2/Indo-Brazil/2016-19/01]
FX The authors would like to thank DST-Science and Engineering Board-Early
   Career Research Award (SERB-ECR), Grant: ECR/2016/000007 and Department
   of Biotechnology (DBT), Govt. of India for the financial support via
   North East-Twinning Grant: MAP/2015/58, Indo-Brazil Grant:
   DBT/IC-2/Indo-Brazil/2016-19/01. Authors are also thankful to Department
   of Pharmaceuticals, Ministry of Chemicals and Fertilizers for providing
   research facilities. We acknowledge Mr. Anil Kumar Kalvala, Research
   scholar, NIPER-Hyderabad for his kind technical support.
CR Bodduluru LN, 2014, TOXICOL IN VITRO, V28, P1026, DOI 10.1016/j.tiv.2014.04.011
   Chazotte B., 2011, LABELING NUCL DNA US, P80
   Decuypere Jean-Paul, 2012, Cells, V1, P284, DOI 10.3390/cells1030284
   Eisenberg-Lerner A, 2009, CELL DEATH DIFFER, V16, P966, DOI 10.1038/cdd.2009.33
   Elumalai P, 2012, TOXICOL LETT, V215, P131, DOI 10.1016/j.toxlet.2012.10.008
   Elumalai P, 2014, CELL BIOCHEM FUNCT, V32, P476, DOI 10.1002/cbf.3040
   Eskelinen EL, 2011, CURR OPIN PHARMACOL, V11, P294, DOI 10.1016/j.coph.2011.03.009
   Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210
   Gammoh N, 2012, P NATL ACAD SCI USA, V109, P6561, DOI 10.1073/pnas.1204429109
   Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088
   Godugu C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089919
   Goussetis DJ, 2010, J BIOL CHEM, V285, P29989, DOI 10.1074/jbc.M109.090530
   Holliday DL, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2889
   Hsieh YH, 2015, TUMOR BIOL, V36, P7539, DOI 10.1007/s13277-015-3477-0
   Huang JP, 2017, ONCOL LETT, V14, P5735, DOI 10.3892/ol.2017.6912
   Ito K, 2000, METH MOLEC MED, V44, P309, DOI 10.1385/1-59259-072-1:309
   Jain A, 2017, NANOMED-NANOTECHNOL, V13, P2251, DOI 10.1016/j.nano.2017.06.009
   Jia T, 2014, CANCER CELL INT, V14, DOI 10.1186/s12935-014-0126-4
   Jovanovic J, 2010, MOL ONCOL, V4, P242, DOI 10.1016/j.molonc.2010.04.002
   Kaur J, 2013, BBA-MOL CELL RES, V1833, P1028, DOI 10.1016/j.bbamcr.2013.01.029
   Khan MI, 2012, BIOMATERIALS, V33, P1477, DOI 10.1016/j.biomaterials.2011.10.080
   Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717
   Landero James, 2012, J Clin Aesthet Dermatol, V5, P33
   Marquez RT, 2012, AM J CANCER RES, V2, P214
   Müller BM, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-215
   Nair A, 2018, NAT MED, V24, P505, DOI 10.1038/nm.4507
   Nekkanti S., 2017, SYNTHESIS 1 2 3 TRIA
   Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008
   Nicholson T.B., 2015, EPIGENETIC CANC, VTherapy, P31, DOI DOI 10.1016/B978-0-12-800206-3.00003-3
   Park J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023211
   Parton M, 2001, BRIT MED J, V322, P1528, DOI 10.1136/bmj.322.7301.1528
   Ranjan A, 2016, SCI REP-UK, V6, DOI 10.1038/srep26165
   Subramani R, 2016, SCI REP-UK, V6, DOI 10.1038/srep19819
   Suresh G, 2002, J AGR FOOD CHEM, V50, P4484, DOI 10.1021/jf025534t
   Tanida Isei, 2008, V445, P77, DOI 10.1007/978-1-59745-157-4_4
   Thorburn A, 2008, APOPTOSIS, V13, P1, DOI 10.1007/s10495-007-0154-9
   Wahl AF, 1996, NAT MED, V2, P72, DOI 10.1038/nm0196-72
   Wang DJ, 2017, 3RD INTERNATIONAL CONFERENCE ON INTELLIGENT ENERGY AND POWER SYSTEMS (IEPS 2017), P7, DOI 10.23977/ieps.2017.1002
   Yuan XL, 2005, VIROL J, V2, DOI 10.1186/1743-422X-2-66
   Zarzynska JM, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/710345
   Zhang HY, 2009, TOXICOL SCI, V110, P376, DOI 10.1093/toxsci/kfp101
   Zhang JB, 2015, AUTOPHAGY, V11, P629, DOI 10.1080/15548627.2015.1023981
NR 42
TC 44
Z9 44
U1 0
U2 23
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0887-2333
J9 TOXICOL IN VITRO
JI Toxicol. Vitro
PD SEP
PY 2018
VL 51
BP 114
EP 128
DI 10.1016/j.tiv.2018.05.010
PG 15
WC Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Toxicology
GA GL3XT
UT WOS:000437079000013
PM 29778718
DA 2025-01-12
ER

PT J
AU Alam, H
   Li, N
   Dhar, SS
   Wu, SJ
   Lv, J
   Chen, KF
   Flores, ER
   Baseler, L
   Lee, MG
AF Alam, Hunain
   Li, Na
   Dhar, Shilpa S.
   Wu, Sarah J.
   Lv, Jie
   Chen, Kaifu
   Flores, Elsa R.
   Baseler, Laura
   Lee, Min Gyu
TI HP1γ Promotes Lung Adenocarcinoma by Downregulating the
   Transcription-Repressive Regulators NCOR2 and ZBTB7A
SO CANCER RESEARCH
LA English
DT Article
ID TUMOR-SUPPRESSOR FUNCTION; CANCER-CELLS; HISTONE H3; BREAST-CANCER;
   LYSINE 9; EXPRESSION; HETEROCHROMATIN; HP1; METHYLATION; METASTASIS
AB Lung adenocarcinoma is a major form of lung cancer, which is the leading cause of cancer death. Histone methylation reader proteins mediate the effect of histone methylation, a hallmark of epigenetic and transcriptional regulation of gene expression. However, their roles in lung adenocarcinoma are poorly understood. Here, our bioinformatic screening and analysis in search of a lung adenocarcinoma-promoting histone methylation reader protein show that heterochromatin protein 1 gamma (HP1 gamma; also called CBX3) is among the most frequently overexpressed and amplified histone reader proteins in human lung adenocarcinoma, and that high HP1 gamma mRNA levels are associated with poor prognosis in patients with lung adenocarcinoma. In vivo depletion of HP1 gamma reduced K-Ras(G12D)-driven lung adenocarcinoma and lengthened survival of mice bearing K-Ras(G12D)-induced lung adenocarcinoma. HP1 gamma and its binding activity to methylated histone H3 lysine 9 were required for the proliferation, colony formation, and migration of lung adenocarcinoma cells. HP1 gamma directly repressed expression of the transcription-repressive regulators NCOR2 and ZBTB7A. Knockdown of NCOR2 or ZBTB7A significantly restored defects in proliferation, colony formation, and migration in HP1 gamma-depleted lung adenocarcinoma cells. Low NCOR2 or ZBTB7A mRNA levels were associated with poor prognosis in patients with lung adenocarcinoma and correlated with high HP1 gamma mRNA levels in lung adenocarcinoma samples. NCOR2 and ZBTB7A downregulated expression of tumor-promoting factors such as ELK1 and AXL, respectively. These findings highlight the importance of HP1 gamma and its reader activity in lung adenocarcinoma tumorigenesis and reveal a unique lung adenocarcinoma-promoting mechanism in which HP1 gamma downregulates NCOR2 and ZBTB7A to enhance expression of protumorigenic genes.
   Significance: Direct epigenetic repression of the transcription-r epressive regulators NCOR2 and ZBTB7A by the histone reader protein HP1g leads to activation of protumorigenic genes in lung adenocarcinoma. (C) 2018 AACR.
C1 [Alam, Hunain; Li, Na; Dhar, Shilpa S.; Wu, Sarah J.; Lee, Min Gyu] Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA.
   [Wu, Sarah J.; Lee, Min Gyu] Univ Texas Grad Sch Biomed Sci Houston, Houston, TX USA.
   [Lv, Jie; Chen, Kaifu] Methodist Hosp, Res Inst, Inst Acad Med, 6535 Fannin, Houston, TX 77030 USA.
   [Lv, Jie; Chen, Kaifu] Methodist Hosp, Res Inst, Dept Cardiovasc Sci, Ctr Cardiovasc Regenerat, 6535 Fannin, Houston, TX 77030 USA.
   [Lv, Jie; Chen, Kaifu] Cornell Univ, Weill Cornell Med Coll, New York, NY 10021 USA.
   [Flores, Elsa R.] H Lee Moffitt Canc Ctr & Res Inst, Dept Mol Oncol, Tampa, FL USA.
   [Baseler, Laura] Univ Texas MD Anderson Canc Ctr, Dept Vet Med & Surg, Houston, TX 77030 USA.
   [Baseler, Laura] Univ British Columbia, Sch Populat & Publ Hlth, 2329 West Mall, Vancouver, BC V6T 1Z4, Canada.
   [Baseler, Laura] Minist Agr, Ctr Anim Hlth, 1767 Angus Campbell Rd, Abbotsford, BC V3G 2M3, Canada.
C3 University of Texas System; UTMD Anderson Cancer Center; Houston
   Methodist; Houston Methodist; Cornell University; Weill Cornell
   Medicine; H Lee Moffitt Cancer Center & Research Institute; University
   of Texas System; UTMD Anderson Cancer Center; University of British
   Columbia
RP Lee, MG (通讯作者)，Univ Texas MD Anderson Canc Ctr, 1515 Holcombe Blvd, Houston, TX 77030 USA.
EM mglee@mdanderson.org
RI Li, Na/AAV-8761-2020; Alam, Hunain/H-2984-2019; Chen,
   Kaifu/AGR-6758-2022; Lee, Ji Hyung/HNI-8824-2023
OI Wu, Sarah/0000-0003-1755-6454; Alam, Hunain/0000-0002-6183-3677
FU NIH Cancer Center [P30CA016672]; NIH [R01 CA157919, R01 CA207109, R01
   CA207098, R35CA197452]; Cancer Prevention and Research Institute of
   Texas [RP140271]; Center for Cancer Epigenetics at the University of
   Texas MD Anderson Cancer Center; Odyssey program at the University of
   Texas MD Anderson Cancer Center
FX We thank Kenneth L. Scott and Tyler Jacks for providing their reagents,
   and Zhenbo Han, Su Zhang, and Charles Kingsley for their technical
   assistance. We are also thankful to Michael Worley (Department of
   Scientific Publications, the University of Texas MD Anderson Cancer
   Center) for the editorial assistance. Experimental and technical support
   was provided by Sequencing and Microarray Facility, Small Animal Imaging
   Facility, and Histopathology Core Lab at the University of Texas MD
   Anderson Cancer Center (the NIH Cancer Center Support Grant
   P30CA016672). This work was supported by grants to M.G. Lee from the NIH
   (R01 CA157919, R01 CA207109, and R01 CA207098), the Cancer Prevention
   and Research Institute of Texas (RP140271), and the Center for Cancer
   Epigenetics at the University of Texas MD Anderson Cancer Center, by a
   grant to E.R. Flores from the NIH (R35CA197452), and by a fellowship to
   H. Alam from the Odyssey program at the University of Texas MD Anderson
   Cancer Center.
CR Abe K, 2011, BIOL REPROD, V85, P1013, DOI 10.1095/biolreprod.111.091512
   Bachman KE, 2003, CANCER CELL, V3, P89, DOI 10.1016/S1535-6108(02)00234-9
   Baker LA, 2008, MUTAT RES-FUND MOL M, V647, P3, DOI 10.1016/j.mrfmmm.2008.07.004
   Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138
   Boulay PL, 2011, ONCOGENE, V30, P3846, DOI 10.1038/onc.2011.100
   Cangemi R, 2008, ONCOGENE, V27, P2877, DOI 10.1038/sj.onc.1210953
   Chang C, 2018, ONCOGENE, V37, P415, DOI 10.1038/onc.2017.332
   Chen MW, 2010, CANCER RES, V70, P7830, DOI 10.1158/0008-5472.CAN-10-0833
   Collisson EA, 2014, NATURE, V511, P543, DOI 10.1038/nature13385
   Cui M, 2016, BIOCHEM BIOPH RES CO, V471, P10, DOI 10.1016/j.bbrc.2015.12.101
   De Koning L, 2009, EMBO MOL MED, V1, P178, DOI 10.1002/emmm.200900022
   du Chéné I, 2007, EMBO J, V26, P424, DOI 10.1038/sj.emboj.7601517
   DuPage M, 2009, NAT PROTOC, V4, P1064, DOI 10.1038/nprot.2009.95
   Ghoshal P, 2009, CANCER RES, V69, P4380, DOI 10.1158/0008-5472.CAN-08-3467
   Hartmann L, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11733
   Imielinski M, 2012, CELL, V150, P1107, DOI 10.1016/j.cell.2012.08.029
   Jacobs SA, 2001, EMBO J, V20, P5232, DOI 10.1093/emboj/20.18.5232
   Kawahara T, 2015, ONCOTARGET, V6, P29860, DOI 10.18632/oncotarget.5007
   Kirschmann DA, 2000, CANCER RES, V60, P3359
   Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132
   Li N, 2016, MOL CELL, V63, P470, DOI 10.1016/j.molcel.2016.06.035
   Li N, 2016, CANCER RES, V76, P831, DOI 10.1158/0008-5472.CAN-15-0906
   Liu M, 2015, CANCER RES, V75, P4593, DOI 10.1158/0008-5472.CAN-14-3735
   Liu XS, 2014, GENE DEV, V28, P1917, DOI 10.1101/gad.245910.114
   Lomberk G, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-7-228
   Maeda T, 2005, NATURE, V433, P278, DOI 10.1038/nature03203
   Maison C, 2004, NAT REV MOL CELL BIO, V5, P296, DOI 10.1038/nrm1355
   Martin C, 2005, NAT REV MOL CELL BIO, V6, P838, DOI 10.1038/nrm1761
   Minc E, 2000, CYTOGENET CELL GENET, V90, P279, DOI 10.1159/000056789
   Musselman CA, 2012, NAT STRUCT MOL BIOL, V19, P1218, DOI 10.1038/nsmb.2436
   Ogawa H, 2002, SCIENCE, V296, P1132, DOI 10.1126/science.1069861
   Paccez JD, 2014, INT J CANCER, V134, P1024, DOI 10.1002/ijc.28246
   Rosnoblet C, 2011, BIOCHEM BIOPH RES CO, V413, P206, DOI 10.1016/j.bbrc.2011.08.059
   Shieh YS, 2005, NEOPLASIA, V7, P1058, DOI 10.1593/neo.05640
   Shiota M, 2010, ENDOCR-RELAT CANCER, V17, P455, DOI 10.1677/ERC-09-0321
   Smallwood A, 2012, GENOME RES, V22, P1426, DOI 10.1101/gr.124818.111
   Smith CL, 2012, BREAST CANCER RES TR, V136, P253, DOI 10.1007/s10549-012-2262-7
   Song L, 2005, CANCER RES, V65, P4554, DOI 10.1158/0008-5472.CAN-04-4108
   Takanashi M, 2009, AM J PATHOL, V174, P309, DOI 10.2353/ajpath.2009.080148
   Tugores A, 2001, J BIOL CHEM, V276, P20397, DOI 10.1074/jbc.M010930200
   Vakoc CR, 2005, MOL CELL, V19, P381, DOI 10.1016/j.molcel.2005.06.011
   Wagner KW, 2013, J CLIN INVEST, V123, P5231, DOI 10.1172/JCI68642
   Wang GG, 2009, NATURE, V459, P847, DOI 10.1038/nature08036
   Xia LM, 2017, CANCER CELL, V31, P653, DOI 10.1016/j.ccell.2017.04.005
   Xu Y, 2017, NUCLEIC ACIDS RES, V45, pD264, DOI 10.1093/nar/gkw1011
   Yang YR, 2014, INT J CLIN EXP PATHO, V7, P6929
   Yi SA, 2014, INT J ONCOL, V45, P2541, DOI 10.3892/ijo.2014.2646
   You SH, 2013, NAT STRUCT MOL BIOL, V20, P182, DOI 10.1038/nsmb.2476
   Young NP, 2010, P NATL ACAD SCI USA, V107, P10184, DOI 10.1073/pnas.1004796107
   Zhou J, 2014, TUMOR BIOL, V35, P9777, DOI 10.1007/s13277-014-2182-8
NR 50
TC 59
Z9 61
U1 0
U2 6
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD JUL 15
PY 2018
VL 78
IS 14
BP 3834
EP 3848
DI 10.1158/0008-5472.CAN-17-3571
PG 15
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA GN6LY
UT WOS:000439199100009
PM 29764865
OA Green Accepted, Bronze, Green Submitted
DA 2025-01-12
ER

PT J
AU Daino, K
   Nishimura, M
   Imaoka, T
   Takabatake, M
   Morioka, T
   Nishimura, Y
   Shimada, Y
   Kakinuma, S
AF Daino, Kazuhiro
   Nishimura, Mayumi
   Imaoka, Tatsuhiko
   Takabatake, Masaru
   Morioka, Takamitsu
   Nishimura, Yukiko
   Shimada, Yoshiya
   Kakinuma, Shizuko
TI Epigenetic dysregulation of key developmental genes in radiation-induced
   rat mammary carcinomas
SO INTERNATIONAL JOURNAL OF CANCER
LA English
DT Article
DE breast cancer; ionizing radiation; DNA methylation
ID POLYCOMB TARGET GENES; BREAST-CANCER; DNA METHYLATION; SIGNALING
   PATHWAY; CHROMOSOMAL INSTABILITY; CELL FATE; DISEASE; TUMORS;
   RADIOTHERAPY; EXPRESSION
AB With the increase in the number of long-term cancer survivors worldwide, there is a growing concern about the risk of secondary cancers induced by radiotherapy. Epigenetic modifications of genes associated with carcinogenesis are attractive targets for the prevention of cancer owing to their reversible nature. To identify genes with possible changes in functionally relevant DNA methylation patterns in mammary carcinomas induced by radiation exposure, we performed microarray-based global DNA methylation and expression profiling in gamma-ray-induced rat mammary carcinomas and normal mammary glands. The gene expression profiling identified dysregulation of developmentally related genes, including the downstream targets of polycomb repressive complex 2 (PRC2) and overexpression of enhancer of zeste homolog 2, a component of PRC2, in the carcinomas. By integrating expression and DNA methylation profiles, we identified ten hypermethylated and three hypomethylated genes that possibly act as tumor-suppressor genes and oncogenes dysregulated by aberrant DNA methylation; half of these genes encode developmental transcription factors. Bisulfite sequencing and quantitative PCR confirmed the dysregulation of the polycomb-regulated developmentally related transcription-factor genes Dmrt2, Hoxa7, Foxb1, Sox17, Lhx8, Gata3 and Runx1. Silencing of Hoxa7 was further verified by immunohistochemistry. These results suggest that, in radiation-induced mammary gland carcinomas, PRC2-mediated aberrant DNA methylation leads to dysregulation of developmentally related transcription-factor genes. Our findings provide clues to molecular mechanisms linking epigenetic regulation and radiation-induced breast carcinogenesis and underscore the potential of such epigenetic mechanisms as targets for cancer prevention.
   What's new?
   Development of a secondary cancer after radiotherapy is of growing concern for long-term cancer survivors. Here the authors examined epigenetic marks in radiation-induced rat mammary carcinomas. They found polycomb repressive complex 2-mediated aberrant DNA methylation of developmentally relevant transcription factor-encoding genes and a consequent dysregulation of downstream gene targets during carcinogenesis, underscoring the potential of epigenetics in secondary cancer prevention.
C1 [Daino, Kazuhiro; Nishimura, Mayumi; Imaoka, Tatsuhiko; Takabatake, Masaru; Morioka, Takamitsu; Nishimura, Yukiko; Kakinuma, Shizuko] Natl Inst Quantum & Radiol Sci & Technol QST, Natl Inst Radiol Sci, Dept Radiat Effects Res, Chiba, Japan.
   [Imaoka, Tatsuhiko] QST, QST Adv Study Lab, Chiba, Japan.
   [Imaoka, Tatsuhiko; Takabatake, Masaru; Shimada, Yoshiya] Tokyo Metropolitan Univ, Grad Sch Human Hlth Sci, Dept Radiol Sci, Tokyo, Japan.
   [Shimada, Yoshiya] QST, Chiba, Japan.
C3 National Institutes for Quantum Science & Technology; National
   Institutes for Quantum Science & Technology; Tokyo Metropolitan
   University; National Institutes for Quantum Science & Technology
RP Kakinuma, S (通讯作者)，Natl Inst Quantum & Radiol Sci & Technol, Dept Radiat Effects Res, Natl Inst Radiol Sci, Inage Ku, 4-9-1 Anagawa, Chiba 2638555, Japan.
EM kakinuma.shizuko@qst.go.jp
RI jin gang, da yan/E-5134-2012
OI jin gang, da yan/0000-0003-1507-585X; Kakinuma,
   Shizuko/0000-0001-9635-8813
FU Japan Society for the Promotion of Science [26740022]; Ministry of
   Health, Labor and Welfare of Japan; Grants-in-Aid for Scientific
   Research [26350955, 17K01938, 15H01834, 26740022] Funding Source: KAKEN
FX Grant sponsor: Japan Society for the Promotion of Science; Grant number:
   26740022; Grant sponsor: Ministry of Health, Labor and Welfare of Japan
CR Abate-Shen C, 2002, NAT REV CANCER, V2, P777, DOI 10.1038/nrc907
   Allred DC, 1998, MODERN PATHOL, V11, P155
   Asselin-Labat ML, 2007, NAT CELL BIOL, V9, P201, DOI 10.1038/ncb1530
   Balasubramanian S, 2010, CARCINOGENESIS, V31, P496, DOI 10.1093/carcin/bgp314
   Baylin SB, 2001, HUM MOL GENET, V10, P687, DOI 10.1093/hmg/10.7.687
   Baylin Stephen B, 2005, Nat Clin Pract Oncol, V2 Suppl 1, pS4, DOI 10.1038/ncponc0354
   Bracken AP, 2006, GENE DEV, V20, P1123, DOI 10.1101/gad.381706
   Browne G, 2015, J CELL PHYSIOL, V230, P2522, DOI 10.1002/jcp.24989
   Chase A, 2011, CLIN CANCER RES, V17, P2613, DOI 10.1158/1078-0432.CCR-10-2156
   Daino K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074013
   Datta K, 2012, RADIAT ONCOL, V7, DOI 10.1186/1748-717X-7-205
   Delaney G, 2005, CANCER-AM CANCER SOC, V104, P1129, DOI 10.1002/cncr.21324
   Dimri M, 2010, CARCINOGENESIS, V31, P489, DOI 10.1093/carcin/bgp305
   Eden A, 2003, SCIENCE, V300, P455, DOI 10.1126/science.1083557
   Fu DY, 2010, BREAST CANCER RES TR, V119, P601, DOI 10.1007/s10549-009-0339-8
   Gaudet F, 2003, SCIENCE, V300, P489, DOI 10.1126/science.1083558
   Harleman JH, 2012, TOXICOL PATHOL, V40, P926, DOI 10.1177/0192623312444621
   Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075
   Herranz M, 2006, BLOOD, V107, P1174, DOI 10.1182/blood-2005-05-2033
   Hong D, 2017, ONCOTARGET, V8, P17610, DOI 10.18632/oncotarget.15381
   Howard G, 2008, ONCOGENE, V27, P404, DOI 10.1038/sj.onc.1210631
   Imaoka T, 2016, INT J RADIAT BIOL, V92, P289, DOI 10.3109/09553002.2016.1152413
   Ip MM, 2000, METHODS MAMMARY GLAN, P31
   Issa JPJ, 2009, CLIN CANCER RES, V15, P3938, DOI 10.1158/1078-0432.CCR-08-2783
   Issa JPJ, 1996, CANCER RES, V56, P3655
   Jia Y, 2010, EPIGENETICS-US, V5, P743, DOI 10.4161/epi.5.8.13104
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   Kim JG, 2013, INT J MOL SCI, V14, P15059, DOI 10.3390/ijms140715059
   Kirmizis A, 2004, GENE DEV, V18, P1592, DOI 10.1101/gad.1200204
   Kloetzli JM, 2001, GENESIS, V29, P60, DOI 10.1002/1526-968X(200102)29:2<60::AID-GENE1006>3.0.CO;2-L
   Knutson SK, 2012, NAT CHEM BIOL, V8, P890, DOI [10.1038/NCHEMBIO.1084, 10.1038/nchembio.1084]
   Lewis MT, 2000, BREAST CANCER RES, V2, P158, DOI 10.1186/bcr49
   Li WX, 2017, ONCOTARGET, V8, P6775, DOI 10.18632/oncotarget.14286
   Marsit CJ, 2006, CARCINOGENESIS, V27, P112, DOI 10.1093/carcin/bgi172
   MATTSSON A, 1993, J NATL CANCER I, V85, P1679, DOI 10.1093/jnci/85.20.1679
   McPherson K, 2000, BMJ-BRIT MED J, V321, P624, DOI 10.1136/bmj.321.7261.624
   Merrifield Matt, 2013, Frontiers in Genetics, V4, P40, DOI 10.3389/fgene.2013.00040
   Nakajima Takeshi, 2008, Environmental Health and Preventive Medicine, V13, P8, DOI 10.1007/s12199-007-0005-x
   Ong TP, 2011, J NUTRIGENET NUTRIGE, V4, P275, DOI 10.1159/000334585
   Preston DL, 2007, RADIAT RES, V168, P1, DOI 10.1667/RR0763.1
   RAINIER S, 1993, NATURE, V362, P747, DOI 10.1038/362747a0
   Rodriguez J, 2006, CANCER RES, V66, P8462, DOI 10.1158/0008-5472.CAN-06-0293
   Ronckers CM, 2005, BREAST CANCER RES, V7, P21, DOI 10.1186/bcr970
   Scheitz CJF, 2012, EMBO J, V31, P4124, DOI 10.1038/emboj.2012.270
   Shah N, 2010, NAT REV CANCER, V10, P361, DOI 10.1038/nrc2826
   Sharma S, 2010, CARCINOGENESIS, V31, P27, DOI 10.1093/carcin/bgp220
   Showler K, 2017, J RADIAT RES, V58, P183, DOI 10.1093/jrr/rrw097
   Sparmann A, 2006, NAT REV CANCER, V6, P846, DOI 10.1038/nrc1991
   Suit H, 2007, RADIAT RES, V167, P12, DOI 10.1667/RR0527.1
   Suman S, 2012, INT J RADIAT ONCOL, V84, P500, DOI 10.1016/j.ijrobp.2011.12.033
   Takabatake M, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0164194
   Tan J, 2007, GENE DEV, V21, P1050, DOI 10.1101/gad.1524107
   Travis LB, 2003, JAMA-J AM MED ASSOC, V290, P465, DOI 10.1001/jama.290.4.465
   Travis LB, 2012, JNCI-J NATL CANCER I, V104, P357, DOI 10.1093/jnci/djr533
   Verma M, 2002, LANCET ONCOL, V3, P755, DOI 10.1016/S1470-2045(02)00932-4
   Xu J, 2015, MOL CELL, V57, P304, DOI 10.1016/j.molcel.2014.12.009
   Yamaguchi H, 2014, CANCER RES TREAT, V46, P209, DOI 10.4143/crt.2014.46.3.209
   Yin DT, 2012, DISCOV MED, V14, P33
   Yoon NK, 2010, HUM PATHOL, V41, P1794, DOI 10.1016/j.humpath.2010.06.010
   Zhang W, 2008, CANCER RES, V68, P2764, DOI 10.1158/0008-5472.CAN-07-6349
NR 60
TC 15
Z9 16
U1 1
U2 9
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0020-7136
EI 1097-0215
J9 INT J CANCER
JI Int. J. Cancer
PD JUL 15
PY 2018
VL 143
IS 2
BP 343
EP 354
DI 10.1002/ijc.31309
PG 12
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA GI1FO
UT WOS:000434116300013
PM 29435983
OA Bronze
DA 2025-01-12
ER

PT J
AU Vaiserman, AM
AF Vaiserman, Alexander M.
TI Birth weight predicts aging trajectory: A hypothesis
SO MECHANISMS OF AGEING AND DEVELOPMENT
LA English
DT Article
DE Aging; Birth weight; Developmental programming; Epigenetics;
   Insulin-like growth factor-1
ID GROWTH-FACTOR-I; EARLY-LIFE NUTRITION; CATCH-UP GROWTH; IGF-I; DNA
   METHYLATION; GENE-EXPRESSION; BREAST-CANCER; TRANSCRIPTIONAL REGULATION;
   CARDIOVASCULAR-DISEASES; DEVELOPMENTAL ORIGINS
AB Increasing evidence suggests that risk for age-related disease and longevity can be programmed early in life. In human populations, convincing evidence has been accumulated indicating that intrauterine growth restriction (IUGR) resulting in low birth weight (< 2.5 kg) followed by postnatal catch-up growth is associated with various aspects of metabolic syndrome, type 2 diabetes and cardiovascular disease in adulthood. Fetal macrosomia (birth weight > 4.5 kg), by contrast, is associated with high risk of non-diabetic obesity and cancers in later life. Developmental modification of epigenetic patterns is considered to be a central mechanism in determining such developmentally programmed phenotypes. Growth hormone/insulin-like growth factor (GH/IGF) axis is likely a key driver of these processes. In this review, evidence is discussed that suggests that different aging trajectories can be realized depending on developmentally programmed life-course dynamics of IGF-1. In this hypothetical scenario, IUGR-induced deficit of IGF-1 causes "diabetic" aging trajectory associated with various metabolic disorders in adulthood, while fetal macrosomia-induced excessive levels of IGF-1 lead to "cancerous" aging trajectory. If the above reasoning is correct, then both low and high birth weights are predictors of short life expectancy, while the normal birth weight is a predictor of "normal" aging and maximum longevity.
C1 [Vaiserman, Alexander M.] Inst Gerontol NAMS Ukraine, Vyshgorodskaya St 67, UA-04114 Kiev, Ukraine.
C3 National Academy of Medical Sciences of Ukraine; D. F. Chebotarev
   Institute of Gerontology of the National Academy of Medical Sciences of
   Ukraine
RP Vaiserman, AM (通讯作者)，Inst Gerontol NAMS Ukraine, Vyshgorodskaya St 67, UA-04114 Kiev, Ukraine.
EM vaiserman@geront.kiev.ua
OI Vaiserman, Alexander/0000-0003-0597-0439
CR Aguirre GA, 2016, J TRANSL MED, V14, DOI 10.1186/s12967-015-0762-z
   Ashpole NM, 2017, GEROSCIENCE, V39, P129, DOI 10.1007/s11357-017-9971-0
   Ashpole NM, 2015, EXP GERONTOL, V68, P76, DOI 10.1016/j.exger.2014.10.002
   Aulinas A, 2013, CLIN ENDOCRINOL, V79, P751, DOI 10.1111/cen.12310
   Aviv A, 2018, PHILOS T R SOC B, V373, DOI 10.1098/rstb.2016.0436
   Bach LA, 2015, PEDIATR ENDOCR REV P, V13, P521
   Baker JL, 2008, EPIDEMIOLOGY, V19, P197, DOI 10.1097/EDE.0b013e31816339c6
   Barbieri M, 2009, MECH AGEING DEV, V130, P771, DOI 10.1016/j.mad.2009.10.002
   BARKER DJP, 1993, LANCET, V341, P938, DOI 10.1016/0140-6736(93)91224-A
   Bartke A, 2016, EXP GERONTOL, V86, P22, DOI 10.1016/j.exger.2015.12.011
   Bartke A, 2017, BEST PRACT RES CL EN, V31, P113, DOI 10.1016/j.beem.2017.02.005
   Bartke A, 2016, MAMM GENOME, V27, P289, DOI 10.1007/s00335-016-9621-3
   Bateson P, 2014, J PHYSIOL-LONDON, V592, P2357, DOI 10.1113/jphysiol.2014.271460
   Ben-Shlomo Y, 2005, CANCER EPIDEM BIOMAR, V14, P1336, DOI 10.1158/1055-9965.EPI-04-0908
   Bergman D, 2013, GERONTOLOGY, V59, P240, DOI 10.1159/000343995
   Bianco-Miotto T, 2017, J DEV ORIG HLTH DIS, V8, P513, DOI 10.1017/S2040174417000733
   Blackburn EH, 2015, SCIENCE, V350, P1193, DOI 10.1126/science.aab3389
   Butler Robert N, 2003, J Gerontol A Biol Sci Med Sci, V58, P581
   Carolan-Olah M, 2015, J CLIN NURS, V24, P3716, DOI 10.1111/jocn.12951
   Chrun ES, 2017, PATHOL RES PRACT, V213, P1329, DOI 10.1016/j.prp.2017.06.013
   CLEMMONS DR, 1991, ANNU REV NUTR, V11, P393, DOI 10.1146/annurev.nu.11.070191.002141
   Cortessis VK, 2012, HUM GENET, V131, P1565, DOI 10.1007/s00439-012-1189-8
   Darcy J, 2017, ADIPOCYTE, V6, P69, DOI 10.1080/21623945.2017.1308990
   Delahaye F, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6187
   Devaskar SU, 2016, PHYSIOLOGY, V31, P131, DOI 10.1152/physiol.00033.2015
   deZegher F, 1997, J CLIN ENDOCR METAB, V82, P2021, DOI 10.1210/jcem.82.7.4007
   Tran D, 2014, AGING CELL, V13, P669, DOI 10.1111/acel.12219
   Dulloo AG, 2008, BEST PRACT RES CL EN, V22, P155, DOI 10.1016/j.beem.2007.08.001
   Eide MG, 2005, EPIDEMIOLOGY, V16, P175, DOI 10.1097/01.ede.0000152524.89074.bf
   Ekbom A, 1998, SEMIN CANCER BIOL, V8, P237, DOI 10.1006/scbi.1998.0073
   Ekbom A, 1996, BMJ-BRIT MED J, V313, P337, DOI 10.1136/bmj.313.7053.337
   Entringer Sonja, 2012, Sci Signal, V5, ppt12, DOI 10.1126/scisignal.2003580
   Estivariz CF, 1997, ENDOCRINE, V7, P65, DOI 10.1007/BF02778066
   Ezzat VA, 2008, DIABETES OBES METAB, V10, P198, DOI 10.1111/j.1463-1326.2007.00709.x
   Fernandez-Capetillo O, 2010, EMBO REP, V11, P32, DOI 10.1038/embor.2009.262
   Fowden AL, 2005, EARLY HUM DEV, V81, P723, DOI 10.1016/j.earlhumdev.2005.06.007
   Fowden AL, 2006, PHYSIOLOGY, V21, P29, DOI 10.1152/physiol.00050.2005
   Fu Q, 2015, FASEB J, V29, P1176, DOI 10.1096/fj.14-258442
   Fu Q, 2009, FASEB J, V23, P2438, DOI 10.1096/fj.08-124768
   Georgakis MK, 2017, EUR J CANCER, V75, P117, DOI 10.1016/j.ejca.2016.12.033
   Ghosh HS, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009199
   Godfrey KM, 2017, LANCET DIABETES ENDO, V5, P53, DOI 10.1016/S2213-8587(16)30107-3
   Gong L, 2010, EPIGENETICS-US, V5, P619, DOI 10.4161/epi.5.7.12882
   Gonzalez-Rodriguez P, 2016, AM J OBSTET GYNECOL, V214, DOI 10.1016/j.ajog.2016.01.194
   Harder T, 2007, AM J EPIDEMIOL, V165, P849, DOI 10.1093/aje/kwk071
   Hawkes CP, 2015, PEDIATR ENDOCR REV P, V13, P499
   He QM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094385
   Heijmans BT, 2008, P NATL ACAD SCI USA, V105, P17046, DOI 10.1073/pnas.0806560105
   Heo HJ, 2016, AGING CELL, V15, P964, DOI 10.1111/acel.12505
   Hochberg Z, 2011, ENDOCR REV, V32, P159, DOI 10.1210/er.2009-0039
   Holly JMP, 1998, GROWTH HORM IGF RES, V8, P183, DOI 10.1016/S1096-6374(98)80109-3
   Holt RIG, 2002, TRENDS ENDOCRIN MET, V13, P392, DOI 10.1016/S1043-2760(02)00697-5
   Houshmand-Oeregaard A, 2017, CLIN EPIGENETICS, V9, DOI 10.1186/s13148-017-0338-2
   Huang RC, 2012, CLIN EPIGENETICS, V4, DOI 10.1186/1868-7083-4-21
   Huxley R, 2002, LANCET, V360, P659, DOI 10.1016/S0140-6736(02)09834-3
   Huxley RR, 2004, BRIT J NUTR, V91, P459, DOI 10.1079/BJN20031052
   Iurlaro M, 2017, CURR OPIN GENET DEV, V43, P101, DOI 10.1016/j.gde.2017.02.003
   Jenkins PJ, 2004, EUR J ENDOCRINOL, V151, pS17, DOI 10.1530/eje.0.151S017
   Jensen RBB, 2003, HORM RES, V60, P136, DOI 10.1159/000074515
   Junnila RK, 2013, NAT REV ENDOCRINOL, V9, P366, DOI 10.1038/nrendo.2013.67
   Juul A, 2002, CIRCULATION, V106, P939, DOI 10.1161/01.CIR.0000027563.44593.CC
   Kadakia R, 2016, CLIN ENDOCRINOL, V85, P70, DOI 10.1111/cen.13057
   Kadakia R, 2016, HORM RES PAEDIAT, V85, P75, DOI 10.1159/000443500
   Kajantie E, 2003, J CLIN ENDOCR METAB, V88, P1059, DOI 10.1210/jc.2002-021380
   Kaplan RC, 2009, J GERONTOL A-BIOL, V64, P1103, DOI 10.1093/gerona/glp036
   Kasprzak A, 2017, MUTAT RES-REV MUTAT, V772, P78, DOI 10.1016/j.mrrev.2016.08.007
   Kelstrup L, 2016, DIABETES, V65, P2900, DOI 10.2337/db16-0227
   Kistner A, 2004, J INTERN MED, V255, P82, DOI 10.1046/j.0954-6820.2003.01257.x
   Kitsiou-Tzeli S, 2017, CURR OPIN ENDOCRINOL, V24, P43, DOI 10.1097/MED.0000000000000305
   Koliada AK, 2015, FRONT GENET, V6, DOI 10.3389/fgene.2015.00082
   Kulis M, 2013, BBA-GENE REGUL MECH, V1829, P1161, DOI 10.1016/j.bbagrm.2013.08.001
   Kurtoglu S, 2016, J ENDOCRINOL INVEST, V39, P19, DOI 10.1007/s40618-015-0327-2
   Langie SAS, 2012, BEST PRACT RES CL EN, V26, P613, DOI 10.1016/j.beem.2012.03.004
   Larnkjær A, 2012, CURR OPIN CLIN NUTR, V15, P285, DOI 10.1097/MCO.0b013e328351c472
   Laron Z, 2008, HORM-INT J ENDOCRINO, V7, P24, DOI 10.14310/horm.2002.1111034
   Laron Z, 2017, MUTAT RES-REV MUTAT, V772, P123, DOI 10.1016/j.mrrev.2016.08.002
   Levine ME, 2014, CELL METAB, V19, P407, DOI 10.1016/j.cmet.2014.02.006
   Lillycrop KA, 2011, INT J OBESITY, V35, P72, DOI 10.1038/ijo.2010.122
   Liu YJ, 1996, ENDOCR J, V43, P221, DOI 10.1507/endocrj.43.221
   Lowe D, 2016, ONCOTARGET, V7, P8524, DOI 10.18632/oncotarget.7383
   Lumey LH, 2015, LANCET DIABETES ENDO, V3, P787, DOI 10.1016/S2213-8587(15)00279-X
   Ma RCW, 2015, PROG BIOPHYS MOL BIO, V118, P55, DOI 10.1016/j.pbiomolbio.2015.02.010
   Martin RM, 2011, NESTLE NUTR WORKS SE, V67, P79, DOI 10.1159/000325577
   Martín-Estal I, 2016, REV PHYSIOL BIOCH P, V170, P1, DOI 10.1007/112_2015_5001
   Mathew R, 2017, BIOGERONTOLOGY, V18, P35, DOI 10.1007/s10522-016-9670-8
   McKnight RA, 2015, PHYSIOL GENOMICS, V47, P634, DOI 10.1152/physiolgenomics.00082.2015
   Meas T, 2010, DIABETES METAB, V36, P11, DOI 10.1016/j.diabet.2009.09.001
   Mercken EM, 2013, AGING CELL, V12, P645, DOI 10.1111/acel.12088
   Milman S, 2014, AGING CELL, V13, P769, DOI 10.1111/acel.12213
   Monk D, 2015, INT J BIOCHEM CELL B, V67, P128, DOI 10.1016/j.biocel.2015.04.014
   Morison IM, 1998, MOL MED TODAY, V4, P110, DOI 10.1016/S1357-4310(97)01197-0
   Mueller CA, 2015, COMP BIOCHEM PHYS A, V184, P113, DOI 10.1016/j.cbpa.2015.02.013
   Nettle D, 2015, P ROY SOC B-BIOL SCI, V282, P23, DOI 10.1098/rspb.2015.1005
   Nobili Valerio, 2008, Pediatr Endocrinol Rev, V6, P241
   O'Connor JC, 2008, CELL IMMUNOL, V252, P91, DOI 10.1016/j.cellimm.2007.09.010
   Olshansky SJ, 2016, CSH PERSPECT MED, V6, DOI 10.1101/cshperspect.a025940
   Palatianou ME, 2014, HORM METAB RES, V46, P911, DOI 10.1055/s-0034-1395561
   Panici JA, 2010, FASEB J, V24, P5073, DOI 10.1096/fj.10-163253
   Park JH, 2017, MOL ASPECTS MED, V54, P58, DOI 10.1016/j.mam.2017.01.008
   Park SK, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1850
   Pinney SE, 2010, TRENDS ENDOCRIN MET, V21, P223, DOI 10.1016/j.tem.2009.10.002
   Podlutsky A, 2017, GEROSCIENCE, V39, P147, DOI 10.1007/s11357-017-9966-x
   Prins GS, 2015, ENDOCRINOLOGY, V156, P3451, DOI 10.1210/en.2015-1357
   Puche JE, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-224
   Ravelli ACJ, 1999, AM J CLIN NUTR, V70, P811
   Ravlie S., 2017, MECH AGEING DEV
   Ren J, 2015, BIOCHEM PHARMACOL, V93, P409, DOI 10.1016/j.bcp.2014.12.006
   Renehan AG, 2004, LANCET, V363, P1346, DOI 10.1016/S0140-6736(04)16044-3
   Reynolds CM, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18081729
   Reynolds CM, 2015, NUTRIENTS, V7, P8090, DOI 10.3390/nu7095384
   Rincon M, 2005, EXP GERONTOL, V40, P873, DOI 10.1016/j.exger.2005.06.014
   Rincon M, 2004, MECH AGEING DEV, V125, P397, DOI 10.1016/j.mad.2004.03.006
   Risnes KR, 2011, INT J EPIDEMIOL, V40, P647, DOI 10.1093/ije/dyq267
   Roseboom TJ, 2011, MATURITAS, V70, P141, DOI 10.1016/j.maturitas.2011.06.017
   Rotwein P, 1991, Growth Factors, V5, P3, DOI 10.3109/08977199109000267
   Salminen A, 2010, CELL SIGNAL, V22, P573, DOI 10.1016/j.cellsig.2009.10.006
   Samaras Thomas T., 2012, Nutrition and Health (Bicester), V21, P247, DOI 10.1177/0260106013510996
   Samaras TT, 2003, LIFE SCI, V72, P1781, DOI 10.1016/S0024-3205(02)02503-1
   Sandhu MS, 2005, ENDOCR DEV, V9, P44, DOI 10.1159/000085755
   Sansone L, 2013, J CELL PHYSIOL, V228, P1754, DOI 10.1002/jcp.24334
   Setia S, 2009, HORM METAB RES, V41, P791, DOI 10.1055/s-0029-1231026
   Shanmugalingam T, 2016, CANCER MED-US, V5, P3353, DOI 10.1002/cam4.871
   Sharp AN, 2010, AM J REPROD IMMUNOL, V64, P159, DOI 10.1111/j.1600-0897.2010.00837.x
   Sharples AP, 2015, AGING CELL, V14, P511, DOI 10.1111/acel.12342
   Smith NR, 2016, CANCER EPIDEMIOL, V42, P181, DOI 10.1016/j.canep.2016.05.003
   Smith TJ, 2010, PHARMACOL REV, V62, P199, DOI 10.1124/pr.109.002469
   Smith T, 2014, ENDOCRINE, V46, P70, DOI 10.1007/s12020-013-0034-8
   Sorensen HT, 1999, AM J EPIDEMIOL, V149, P726
   Spracklen CN, 2014, CANCER EPIDEMIOL, V38, P538, DOI 10.1016/j.canep.2014.07.004
   Stewart CEH, 1996, PHYSIOL REV, V76, P1005, DOI 10.1152/physrev.1996.76.4.1005
   Strazhesko ID, 2017, FRONT GENET, V8, DOI 10.3389/fgene.2017.00198
   Sun LY, 2017, ELIFE, V6, DOI 10.7554/eLife.24059
   Takaya J, 2017, ENDOCR J, V64, P431, DOI 10.1507/endocrj.EJ16-0378
   Tanner JM., 1990, Fetus into man-physical growth from conception to maturity
   Tanvig M, 2014, DAN MED J, V61
   Tarry-Adkins JL, 2011, AM J CLIN NUTR, V94, p1765S, DOI 10.3945/ajcn.110.000620
   Tettamanti G, 2016, CANCER EPIDEM BIOMAR, V25, P678, DOI 10.1158/1055-9965.EPI-15-1096
   TRICHOPOULOS D, 1990, LANCET, V335, P939, DOI 10.1016/0140-6736(90)91000-Z
   Troncoso R, 2014, TRENDS ENDOCRIN MET, V25, P128, DOI 10.1016/j.tem.2013.12.002
   Tzschoppe A, 2015, CLIN ENDOCRINOL, V83, P739, DOI 10.1111/cen.12844
   Vaag A, 2009, INT J GYNECOL OBSTET, V104, pS32, DOI 10.1016/j.ijgo.2008.11.026
   Vaiserman AM, 2014, J DEV ORIG HLTH DIS, V5, P325, DOI 10.1017/S2040174414000294
   Vaiserman A. M., 2012, Frontiers in Genetics, V3, P224, DOI 10.3389/fgene.2012.00224
   Vaiserman A, 2015, CLIN EPIGENETICS, V7, DOI 10.1186/s13148-015-0130-0
   Vaiserman AM, 2017, NUTRIENTS, V9, DOI 10.3390/nu9030236
   van Heemst D, 2010, AGING DIS, V1, P147
   Verkauskiene R, 2007, EUR J ENDOCRINOL, V157, P605, DOI 10.1530/EJE-07-0286
   Verkauskiene R, 2005, J CLIN ENDOCR METAB, V90, P5672, DOI 10.1210/jc.2005-0423
   Vitale G, 2017, MECH AGEING DEV, V165, P107, DOI 10.1016/j.mad.2016.12.001
   Waddington C. H., 1957, The strategy of the genes. A discussion of some aspects of theoretical biology. With an appendix by H. Kacser.
   Walker CL, 2012, NAT REV CANCER, V12, P479, DOI 10.1038/nrc3220
   Wang NJ, 2017, DIABETOLOGIA, V60, P262, DOI 10.1007/s00125-016-4148-4
   Wei JW, 2017, ONCOL REP, V37, P3, DOI 10.3892/or.2016.5236
   Wells JCK, 2011, AM J HUM BIOL, V23, P65, DOI 10.1002/ajhb.21100
   Wennerström ECM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0138594
   Whincup PH, 2008, JAMA-J AM MED ASSOC, V300, P2886, DOI 10.1001/jama.2008.886
   Wiznitzer A, 1998, AM J PERINAT, V15, P23, DOI 10.1055/s-2007-993893
   Xue F, 2007, LANCET ONCOL, V8, P1088, DOI 10.1016/S1470-2045(07)70377-7
   Yamada L, 2017, J DEV ORIG HLTH DIS, V8, P30, DOI 10.1017/S2040174416000507
   Ziegler EE, 2015, NESTLE NUTR WORKS SE, V81, P135, DOI 10.1159/000365902
NR 160
TC 21
Z9 23
U1 0
U2 6
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0047-6374
EI 1872-6216
J9 MECH AGEING DEV
JI Mech. Ageing Dev.
PD JUL
PY 2018
VL 173
BP 61
EP 70
DI 10.1016/j.mad.2018.04.003
PG 10
WC Cell Biology; Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Cell Biology; Geriatrics & Gerontology
GA GL3UT
UT WOS:000437068900007
PM 29626501
DA 2025-01-12
ER

PT J
AU Brandao, YD
   Toledo, MB
   Chequin, A
   Cristo, TG
   Sousa, RS
   Ramos, EAS
   Klassen, G
AF Brandao, Yara de Oliveira
   Toledo, Mariana Busato
   Chequin, Andressa
   Cristo, Thierry Grima
   Sousa, Renato Silva
   Souza Ramos, Edneia Amancio
   Klassen, Giseli
TI DNA Methylation Status of the Estrogen Receptor α Gene in Canine Mammary
   Tumors
SO VETERINARY PATHOLOGY
LA English
DT Article
DE canine mammary tumor; breast cancer; estrogen receptor gene (ESR1); DNA
   methylation; epigenetics
ID MESSENGER-RNA EXPRESSION; BREAST-CANCER; SUPPRESSOR GENE; CPG ISLANDS;
   HYPERMETHYLATION; PROMOTER; PATTERNS
AB Estrogen receptor (ER) has an important role in mammary carcinogenesis, prognosis, and treatment. In human and canine mammary cancer, the most aggressive tumors show loss of ER expression, which in human breast cancer has been attributed to methylation of the cytosine followed by guanine (CpG) island within the estrogen receptor gene (ESR1) promoter. This study aimed to investigate the role of ESR1 CpG island (CGI) methylation in ER expression in canine mammary tumors. Twenty-one canine mammary samples were sorted into three groups: malignant tumor (n = 9), benign tumor (n = 8), and normal gland (n = 4). Immunohistochemical analysis and reverse-transcription quantitative real-time PCR were performed to assess ER expression and ESR1 mRNA levels. The methylation status was determined using sodium-bisulfite-treated DNA sequencing. All normal mammary glands and benign tumors showed high ER expression (score range, 5-8). Six of the nine malignant tumors did not show ER expression (score 0), two had score 2, and one had score 4. Lower ER (P < .005) and ESR1 mRNA levels (P < .005) were found in malignant mammary tumors than in the other two groups. Canine ESR1 has an intragenic and non-promoter-associated CGI, different from humans. No significant variation in methylation percentage was observed among the groups, suggesting that ESR1 is not regulated by DNA methylation, unlike that in humans. This difference should be considered in further research using ER as a biomarker for mammary tumors in canine studies on ER-targeting therapy.
C1 [Brandao, Yara de Oliveira; Toledo, Mariana Busato; Chequin, Andressa; Souza Ramos, Edneia Amancio; Klassen, Giseli] Univ Fed Parana, Dept Basic Pathol, Epigenet Lab, Curitiba, Parana, Brazil.
   [Cristo, Thierry Grima; Sousa, Renato Silva] Univ Fed Parana, Vet Hosp, Lab Vet Pathol, Curitiba, Parana, Brazil.
C3 Universidade Federal do Parana; Universidade Federal do Parana
RP Klassen, G (通讯作者)，Univ Fed Parana, Setor Ciencias Biol, Dept Patol Basica, Campus Politecn,Av Cel Francisco H dos Santos, BR-81531970 Curitiba, Parana, Brazil.
EM giseli.ufpr@gmail.com
RI Cavalieri, Edneia/Q-9636-2019; Klassen, Giseli/F-8753-2012
OI Klassen, Giseli/0000-0001-5336-6178; ASR Cavalieri,
   Edneia/0000-0002-8855-5988; Grima de Cristo, Thierry/0000-0003-4650-0687
CR Aporntewan C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017934
   Auton A, PLOS GENETICS, V9, P1
   Barazandeh A, 2016, CZECH J ANIM SCI, V61, P487, DOI 10.17221/78/2015-CJAS
   Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102
   Blackburn J, 2016, MOL CARCINOGEN, V55, P1940, DOI 10.1002/mc.22441
   Brenet F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014524
   Bronzini I, 2017, VET COMP ONCOL, V15, P910, DOI 10.1111/vco.12231
   de las Mulas JM, 2005, VET PATHOL, V42, P200, DOI 10.1354/vp.42-2-200
   Dong YY, 2014, BIOMED REP, V2, P326, DOI 10.3892/br.2014.237
   ELSTON CW, 1991, HISTOPATHOLOGY, V19, P403, DOI 10.1111/j.1365-2559.1991.tb00229.x
   Fujiwara-Igarashi A, 2014, RES VET SCI, V97, P60, DOI 10.1016/j.rvsc.2014.04.008
   Goldschmidt M, 2011, VET PATHOL, V48, P117, DOI 10.1177/0300985810393258
   Han L, 2009, GENOMICS, V94, P117, DOI 10.1016/j.ygeno.2009.04.007
   Harman RM, 2016, J MAMMARY GLAND BIOL, V21, P51, DOI 10.1007/s10911-016-9350-y
   Iwao K, 2000, CANCER, V89, P1732, DOI 10.1002/1097-0142(20001015)89:8<1732::AID-CNCR13>3.0.CO;2-2
   Karayannopoulou M, 2016, REV MED VET-TOULOUSE, V167, P192
   Kim NH, 2014, J COMP PATHOL, V151, P42, DOI 10.1016/j.jcpa.2014.04.001
   Klopfleisch R, 2010, VET PATHOL, V47, P446, DOI 10.1177/0300985810363904
   Kosti I, 2016, SCI REP-UK, V6, DOI 10.1038/srep24799
   Lamp O, 2013, VET COMP ONCOL, V11, P70, DOI 10.1111/j.1476-5829.2011.00303.x
   Lee SM, 2014, P NATL ACAD SCI USA, V111, P9555, DOI 10.1073/pnas.1400604111
   Li SY, 2006, CANCER LETT, V237, P272, DOI 10.1016/j.canlet.2005.06.011
   Mainenti M, 2014, VET J, V202, P62, DOI 10.1016/j.tvjl.2014.06.003
   Martínez-Galán J, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-59
   Millanta F, 2005, RES VET SCI, V79, P225, DOI 10.1016/j.rvsc.2005.02.002
   Miller KD, 2016, CA-CANCER J CLIN, V66, P271, DOI 10.3322/caac.21349
   Mohr A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0163311
   Nieto A, 2000, VET PATHOL, V37, P239, DOI 10.1354/vp.37-3-239
   OTTAVIANO YL, 1994, CANCER RES, V54, P2552
   Peña L, 2014, VET PATHOL, V51, P127, DOI 10.1177/0300985813509388
   Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45
   Prabhu JS, 2012, TUMOR BIOL, V33, P315, DOI 10.1007/s13277-012-0343-1
   Riccardo F, 2015, CANCER IMMUNOL IMMUN, V64, P137, DOI 10.1007/s00262-014-1645-5
   Rowell JL, 2011, TRENDS MOL MED, V17, P380, DOI 10.1016/j.molmed.2011.02.004
   Sakamoto A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0145630
   Schuler SL, 2008, JPEN-PARENTER ENTER, V32, P184, DOI 10.1177/0148607108314387
   Shann YJ, 2008, GENOME RES, V18, P791, DOI 10.1101/gr.070961.107
   Shimizu R, 2016, LEUKEMIA RES, V50, P85, DOI 10.1016/j.leukres.2016.09.018
   Sleeckx N, 2011, REPROD DOMEST ANIM, V46, P1112, DOI 10.1111/j.1439-0531.2011.01816.x
   Sorenmo KU, 2011, VET PATHOL, V48, P85, DOI 10.1177/0300985810389480
   Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098
   Spoerri M, 2015, BMC VET RES, V11, DOI 10.1186/s12917-015-0546-y
   Stuart-Harris R, 2010, WOMENS HEALTH, V6, P383, DOI [10.2217/whe.10.25, 10.2217/WHE.10.25]
   Uva P, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-135
   Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034
   Yue W, 2013, STEROIDS, V78, P161, DOI 10.1016/j.steroids.2012.11.001
NR 46
TC 18
Z9 18
U1 0
U2 6
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0300-9858
EI 1544-2217
J9 VET PATHOL
JI Vet. Pathol.
PD JUL
PY 2018
VL 55
IS 4
BP 510
EP 516
DI 10.1177/0300985818763711
PG 7
WC Pathology; Veterinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pathology; Veterinary Sciences
GA GK3VC
UT WOS:000436075800006
PM 29566609
OA Bronze
DA 2025-01-12
ER

PT J
AU Li, C
   Lee, J
   Ding, J
   Sun, SY
AF Li, Catherine
   Lee, Juyon
   Ding, Jessica
   Sun, Shuying
TI Integrative analysis of gene expression and methylation data for breast
   cancer cell lines
SO BIODATA MINING
LA English
DT Article
DE DNA methylation; Gene expression; Data integration; Pathway analysis;
   Breast cancer
ID DNA METHYLATION; NORMALIZATION
AB Background: The deadly costs of cancer and necessity for an accurate method of early cancer detection have demanded the identification of genetic and epigenetic factors associated with cancer. DNA methylation, an epigenetic event, plays an important role in cancer susceptibility. In this paper, we use DNA methylation and gene expression data integration and pathway analysis to further explore and understand the complex relationship between methylation and gene expression.
   Results: Through linear modeling and analysis of variance, we obtain genes that show a significant correlation between methylation and gene expression. We then examine the functions and relationships of these genes using bioinformatic tools and databases. In particular, using ConsensusPathDB, we analyze the networks of statistically significant genes to identify hub genes, genes with a large number of links to other genes. We identify eight major hub genes, all in strong association with cancer susceptibility. Through further analysis of the function, gene expression level, and methylation level of these hub genes, we conclude that they are novel potential biomarkers for breast cancer.
   Conclusions: Our findings have various implications for cancer screening, early detection methods, and potential novel treatments for cancer. Researchers can also use our results to develop more effective methods for cancer study.
C1 [Li, Catherine] Westwood High Sch, Austin, TX USA.
   [Lee, Juyon] Korea Int Sch, Pangyo Campus, Seongnam, South Korea.
   [Ding, Jessica] Liberal Arts & Sci Acad, Austin, TX USA.
   [Sun, Shuying] Texas State Univ, Dept Math, San Marcos, TX 78666 USA.
C3 Texas State University System; Texas State University San Marcos
RP Sun, SY (通讯作者)，Texas State Univ, Dept Math, San Marcos, TX 78666 USA.
EM ssun@txstate.edu
RI Ding, Jessica/HMW-1179-2023
FU Texas State University Research Enhancement Program; Dr. Sun's start-up
   funds
FX This project is supported by Dr. Sun's start-up funds and the Texas
   State University Research Enhancement Program.
CR [Anonymous], INT J BIOMED DATA MI
   Chari R, 2010, BMC SYST BIOL, V4, DOI 10.1186/1752-0509-4-67
   Cho YH, 2015, J CANCER, V6, P819, DOI 10.7150/jca.12174
   Gomez-Cabrero D, 2014, BMC SYST BIOL, V8, DOI 10.1186/1752-0509-8-S2-I1
   Hinshelwood RA, 2008, J MOL MED, V86, P1315, DOI 10.1007/s00109-008-0386-3
   Huang J, 2016, FRONT GENET, V7, DOI [10.3389/fgene.2017.00084, 10.3389/fgene.2016.00084]
   Huang THM, 1999, HUM MOL GENET, V8, P459, DOI 10.1093/hmg/8.3.459
   Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249
   Kamburov A, 2013, NUCLEIC ACIDS RES, V41, pD793, DOI 10.1093/nar/gks1055
   Kamburov A, 2011, NUCLEIC ACIDS RES, V39, pD712, DOI 10.1093/nar/gkq1156
   Kamburov A, 2009, NUCLEIC ACIDS RES, V37, pD623, DOI 10.1093/nar/gkn698
   Li WY, 2012, BIOINFORMATICS, V28, P2458, DOI 10.1093/bioinformatics/bts476
   Lim DH, 2010, OBSTET GYNAECOLOGIST, V12, P6
   Louhimo R, 2011, BIOINFORMATICS, V27, P887, DOI 10.1093/bioinformatics/btr019
   Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008
   Smyth GK, 2003, METHODS, V31, P265, DOI 10.1016/S1046-2023(03)00155-5
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Sun SY, 2011, BIODATA MIN, V4, DOI 10.1186/1756-0381-4-13
   Sun ZF, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017490
   Wang X, 2013, STAT MED, V32, P16
   Xiao GH, 2011, J AM STAT ASSOC, V106, P61, DOI 10.1198/jasa.2010.ap09504
   Yan Pearlly S., 2009, V507, P89, DOI 10.1007/978-1-59745-522-0_8
   Yan PS, 2002, J NUTR, V132, p2430S, DOI 10.1093/jn/132.8.2430S
   Yang X, 2001, ENDOCR-RELAT CANCER, V8, P115, DOI 10.1677/erc.0.0080115
NR 24
TC 11
Z9 11
U1 0
U2 8
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1756-0381
J9 BIODATA MIN
JI BioData Min.
PD JUN 25
PY 2018
VL 11
AR 13
DI 10.1186/s13040-018-0174-8
PG 16
WC Mathematical & Computational Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Mathematical & Computational Biology
GA GL2XV
UT WOS:000436991200001
PM 29983747
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU Zhao, YF
   He, J
   Yang, L
   Luo, QC
   Liu, Z
AF Zhao, Yunfei
   He, Jiao
   Yang, Ling
   Luo, Qichi
   Liu, Zhi
TI Histone Deacetylase-3 Modification of MicroRNA-31 Promotes Cell
   Proliferation and Aerobic Glycolysis in Breast Cancer and Is Predictive
   of Poor Prognosis
SO JOURNAL OF BREAST CANCER
LA English
DT Article
DE Breast neoplasms; Glycolysis; Histone code; Histone deacetylase 3;
   Prognosis
ID EXPRESSION; HDAC3; IDENTIFICATION; METHYLATION; CARCINOMAS; INVASION;
   THERAPY; GROWTH
AB Purpose: The incidence and mortality of breast cancer is increasing worldwide. There is a constant quest to understand the underlying molecular biology of breast cancer so as to plan better treatment options. The purpose of the current study was to characterize the expression of histone deacetylases-3 (HDAC3), a member of class I HDACs, and assess the clinical significance of HDAC3 in breast cancer. Methods: Quantitative real-time polymerase chain reaction, immunohistochemistry, and western blot analysis were used to examine messenger RNA and protein expression levels. The relationships between HDAC3 expression and clinicopathological variables were analyzed. MTT assays were used to detect cell proliferation. Glucose-uptake, lactate, adenosine triphosphate, and lactate dehydrogenase assays were employed to detect aerobic glycolysis. Chromatin immunoprecipitation was used to detect microRNA-31 (miR-31) promoter binding. Results: Our data revealed that HDAC3 was upregulated in breast cancer tissue compared with matched para-carcinoma tissues, and high levels of HDAC3 were positively correlated with advanced TNM stage and N stage of cancer. Furthermore, overexpression of HDAC3 promoted breast cancer cell-proliferation and aerobic glycolysis. The functional involvement of HDAC3 was related in part to the repression of miR-31 transcription via decreased histone H3 acetylation at lysine K9 levels of the miR-31 promoter. Survival analysis revealed that the level of HDAC3 was an independent prognostic factor for breast cancer patients. Conclusion: Our findings revealed that HDAC3 served as an oncogene that could promote cell proliferation and aerobic glycolysis and was predictive of a poor prognosis in breast cancer. HDAC3 participated in the cell proliferation of breast cancer, which may prove to be a pivotal epigenetic target against this devastating disease.
C1 [Zhao, Yunfei; He, Jiao; Yang, Ling; Luo, Qichi; Liu, Zhi] Suining Cent Hosp, Dept Pathol, 127 West Desheng Rd, Suining 629000, Peoples R China.
RP Zhao, YF (通讯作者)，Suining Cent Hosp, Dept Pathol, 127 West Desheng Rd, Suining 629000, Peoples R China.
EM zhyf3270@163.com
FU Municipal Scientific research funds [2015y03]
FX The present study was funded in part by the Municipal Scientific
   research funds (2015y03).
CR Bayat S, 2018, BIOMED PHARMACOTHER, V97, P1445, DOI 10.1016/j.biopha.2017.11.065
   Brooks MD, 2015, CELL STEM CELL, V17, P260, DOI 10.1016/j.stem.2015.08.014
   Buchwald M, 2009, CANCER LETT, V280, P160, DOI 10.1016/j.canlet.2009.02.028
   Creighton CJ, 2010, CANCER RES, V70, P1906, DOI 10.1158/0008-5472.CAN-09-3875
   Jiao F, 2016, ONCOTARGET, V7, P16505, DOI 10.18632/oncotarget.7663
   Jiao F, 2014, INT J ONCOL, V45, P1523, DOI 10.3892/ijo.2014.2568
   Koumangoye RB, 2015, MOL CANCER, V14, DOI 10.1186/s12943-014-0284-y
   Kroemer G, 2015, NAT MED, V21, P1128, DOI 10.1038/nm.3944
   Krusche CA, 2005, BREAST CANCER RES TR, V90, P15, DOI 10.1007/s10549-004-1668-2
   Legube G, 2003, EMBO REP, V4, P944, DOI 10.1038/sj.embor.embor941
   Liu ZY, 2017, BIOCHEM BIOPH RES CO, V490, P62, DOI 10.1016/j.bbrc.2017.06.012
   Lv C, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01059-5
   Ma YN, 2015, AM J CANCER RES, V5, P663
   Marks PA, 2001, NAT REV CANCER, V1, P194, DOI 10.1038/35106079
   Marmot MG, 2013, BRIT J CANCER, V108, P2205, DOI 10.1038/bjc.2013.177
   Müller BM, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-215
   Mulrane L, 2014, BREAST CANCER RES, V16, DOI 10.1186/s13058-014-0467-x
   O'Shaughnessy JA, 2006, NEW ENGL J MED, V355, P615, DOI 10.1056/NEJMe068145
   Paszkowski J, 2001, CURR OPIN PLANT BIOL, V4, P123, DOI 10.1016/S1369-5266(00)00147-3
   Pilarsky C, 2004, NEOPLASIA, V6, P744, DOI 10.1593/neo.04277
   Rasheed SAK, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0337-x
   Rice JC, 2001, CURR OPIN CELL BIOL, V13, P263, DOI 10.1016/S0955-0674(00)00208-8
   Seo J, 2014, J BREAST CANCER, V17, P323, DOI 10.4048/jbc.2014.17.4.323
   Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387
   Staaf J, 2010, J CLIN ONCOL, V28, P1813, DOI 10.1200/JCO.2009.22.8775
   Stepicheva NA, 2016, MOL REPROD DEV, V83, P654, DOI 10.1002/mrd.22678
   Valastyan S, 2010, CELL CYCLE, V9, P2124, DOI 10.4161/cc.9.11.11843
   Wei J, 2017, BIOMED RES INT-UK, V2017, DOI 10.1155/2017/5348490
   Zhang MM, 2017, ONCOTARGET, V8, P99402, DOI 10.18632/oncotarget.19660
NR 29
TC 21
Z9 24
U1 0
U2 0
PU KOREAN BREAST CANCER SOC
PI SEOUL
PA 163 SINMUNRO 1-GA JONGRO-GU, OFFICIA  BUILDING, SUITE 2024, SEOUL,
   110-999, SOUTH KOREA
SN 1738-6756
EI 2092-9900
J9 J BREAST CANCER
JI J. Breast Canc.
PD JUN
PY 2018
VL 21
IS 2
BP 112
EP 123
DI 10.4048/jbc.2018.21.2.112
PG 12
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA GK6CN
UT WOS:000436269800002
PM 29963106
OA gold, Green Published, Green Submitted
DA 2025-01-12
ER

PT J
AU Zhang, SM
   Wang, YH
   Gu, Y
   Zhu, J
   Ci, C
   Guo, ZF
   Chen, CG
   Wei, YJ
   Lv, WH
   Liu, HB
   Zhang, DW
   Zhang, Y
AF Zhang, Shumei
   Wang, Yihan
   Gu, Yue
   Zhu, Jiang
   Ci, Ce
   Guo, Zhongfu
   Chen, Chuangeng
   Wei, Yanjun
   Lv, Wenhua
   Liu, Hongbo
   Zhang, Dongwei
   Zhang, Yan
TI Specific breast cancer prognosis-subtype distinctions based on DNA
   methylation patterns
SO MOLECULAR ONCOLOGY
LA English
DT Article
DE breast cancer; consensus clustering; DNA methylation; molecular subtypes
ID GENE-EXPRESSION; MOLECULAR PORTRAITS; PRECISION MEDICINE; TUMORS;
   HISTAMINE; SURVIVAL; TARGET; GROWTH
AB Tumour heterogeneity is an obstacle to effective breast cancer diagnosis and therapy. DNA methylation is an important regulator of gene expression, thus characterizing tumour heterogeneity by epigenetic features can be clinically informative. In this study, we explored specific prognosis-subtypes based on DNA methylation status using 669 breast cancers from the TCGA database. Nine subgroups were distinguished by consensus clustering using 3869 CpGs that significantly influenced survival. The specific DNA methylation patterns were reflected by different races, ages, tumour stages, receptor status, histological types, metastasis status and prognosis. Compared with the PAM50 subtypes, which use gene expression clustering, DNA methylation subtypes were more elaborate and classified the Basal-like subtype into two different prognosis-subgroups. Additionally, 1252 CpGs (corresponding to 888 genes) were identified as specific hyper/hypomethylation sites for each specific subgroup. Finally, a prognosis model based on Bayesian network classification was constructed and used to classify the test set into DNA methylation subgroups, which corresponded to the classification results of the train set. These specific classifications by DNA methylation can explain the heterogeneity of previous molecular subgroups in breast cancer and will help in the development of personalized treatments for the new specific subtypes.
C1 [Zhang, Shumei; Wang, Yihan; Gu, Yue; Zhu, Jiang; Ci, Ce; Chen, Chuangeng; Wei, Yanjun; Lv, Wenhua; Liu, Hongbo; Zhang, Yan] Harbin Med Univ, Coll Bioinformat Sci & Technol, 157 Baojian Rd, Harbin, Heilongjiang, Peoples R China.
   [Guo, Zhongfu; Zhang, Dongwei] Harbin Med Univ, Affiliated Hosp 2, Dept Gen Surg, Harbin, Heilongjiang, Peoples R China.
C3 Harbin Medical University; Harbin Medical University
RP Zhang, Y (通讯作者)，Harbin Med Univ, Coll Bioinformat Sci & Technol, 157 Baojian Rd, Harbin, Heilongjiang, Peoples R China.; Zhang, DW (通讯作者)，Harbin Med Univ, Affiliated Hosp 2, Dept Gen Surg, Harbin, Heilongjiang, Peoples R China.
EM mugong0@163.com; tyozhang@ems.hrbmu.edu.cn
RI Liu, Hongbo/ABC-7190-2021; wang, yihan/HTN-8802-2023; Gu,
   Yue/HOA-4958-2023
OI Wei, Yanjun/0000-0003-4200-2859; Wang, Yihan/0000-0002-1163-4610; Chen,
   Chuangeng/0000-0002-5525-2788
FU National Natural Science Foundation of China [81573021]; Natural Science
   Foundation of Heilongjiang Province [ZD2015003]; Graduate Innovation
   Research Project of Harbin Medical University [YJSCX2014-24HYD]
FX This work was supported by National Natural Science Foundation of China
   (grant number 81573021), the Natural Science Foundation of Heilongjiang
   Province (grant number ZD2015003) and the Graduate Innovation Research
   Project of Harbin Medical University (grant number YJSCX2014-24HYD). We
   thank James P. Mahaffey, PhD, from Liwen Bianji, Edanz Editing China
   (www.liwenbianji.cn/ac), for editing the English text of a draft of this
   manuscript.
CR ANTEQUERA F, 1993, P NATL ACAD SCI USA, V90, P11995, DOI 10.1073/pnas.90.24.11995
   Arnedos M, 2015, NAT REV CLIN ONCOL, V12, P693, DOI 10.1038/nrclinonc.2015.123
   Ateeq B, 2009, CELL CYCLE, V8, P3794, DOI 10.4161/cc.8.23.9976
   Bu LL, 2016, ANN TRANSL MED, V4, DOI 10.3978/j.issn.2305-5839.2016.01.21
   Carey LA, 2006, JAMA-J AM MED ASSOC, V295, P2492, DOI 10.1001/jama.295.21.2492
   Cheang MCU, 2008, CLIN CANCER RES, V14, P1368, DOI 10.1158/1078-0432.CCR-07-1658
   Chen HL, 2015, CHINESE J CANCER RES, V27, P428, DOI 10.3978/j.issn.1000-9604.2015.08.02
   Chen YL, 2009, CANCER SCI, V100, P1663, DOI 10.1111/j.1349-7006.2009.01225.x
   Conway K, 2014, BREAST CANCER RES, V16, DOI 10.1186/s13058-014-0450-6
   CRICCO GP, 1994, AGENTS ACTIONS, V43, P17, DOI 10.1007/BF02005757
   Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983
   DAVIO CA, 1994, AGENTS ACTIONS, V41, pC115, DOI 10.1007/BF02007792
   de Ronde JJ, 2013, BREAST CANCER RES TR, V137, P213, DOI 10.1007/s10549-012-2340-x
   Edgar R, 2002, NUCLEIC ACIDS RES, V30, P207, DOI 10.1093/nar/30.1.207
   Eterno V, 2014, ONCOTARGET, V5, P613, DOI 10.18632/oncotarget.1359
   Fleischer T, 2017, ONCOTARGET, V8, P1074, DOI 10.18632/oncotarget.13718
   Fleischer T, 2014, GENOME BIOL, V15, DOI [10.1186/s13059-014-0435-x, 10.1186/PREACCEPT-2333349012841587]
   Holm K, 2016, BREAST CANCER RES, V18, DOI 10.1186/s13058-016-0685-5
   Holm K, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2590
   Hu WL, 2017, BMC MED GENOMICS, V10, DOI 10.1186/s12920-017-0307-9
   Jeschke J, 2017, J CLIN INVEST, V127, P3090, DOI 10.1172/JCI91095
   Jeschke J, 2015, FEBS J, V282, P1801, DOI 10.1111/febs.13125
   Ju WJ, 2013, GENOME RES, V23, P1862, DOI 10.1101/gr.155697.113
   Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412
   Kolacinska A, 2012, MOL BIOL REP, V39, P7435, DOI 10.1007/s11033-012-1576-1
   Leek JT, 2012, BIOINFORMATICS, V28, P882, DOI 10.1093/bioinformatics/bts034
   Martinez-Outschoorn UE, 2012, CELL CYCLE, V11, P3956, DOI 10.4161/cc.22136
   Mehner Christine, 2015, Genes Cancer, V6, P480
   Moazzeni H, 2017, MOL CELL PROBE, V34, P45, DOI 10.1016/j.mcp.2017.05.005
   Parshad R, 2005, Indian J Cancer, V42, P185
   Pasculli B, 2018, SEMIN CANCER BIOL, V51, P22, DOI 10.1016/j.semcancer.2018.01.007
   Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093
   Prados MD, 2015, NEURO-ONCOLOGY, V17, P1051, DOI 10.1093/neuonc/nov031
   Prat A, 2011, MOL ONCOL, V5, P5, DOI 10.1016/j.molonc.2010.11.003
   Prat A, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2635
   Quigley D, 2015, MOL CANCER RES, V13, P493, DOI 10.1158/1541-7786.MCR-14-0387
   Reimand J, 2016, NUCLEIC ACIDS RES, V44, pW83, DOI 10.1093/nar/gkw199
   Reitz C, 2016, ANN TRANSL MED, V4, DOI 10.21037/atm.2016.03.05
   Ronneberg JA, 2011, MOL ONCOL, V5, P61, DOI 10.1016/j.molonc.2010.11.004
   Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098
   Tazaki E, 2013, PATHOL INT, V63, P297, DOI 10.1111/pin.12065
   Tomczak Katarzyna, 2015, Contemp Oncol (Pozn), V19, pA68, DOI 10.5114/wo.2014.47136
   Weinstein JN, 2013, NAT GENET, V45, P1113, DOI 10.1038/ng.2764
   Wilkerson MD, 2010, BIOINFORMATICS, V26, P1572, DOI 10.1093/bioinformatics/btq170
   Zhang Y, 2011, NUCLEIC ACIDS RES, V39, DOI 10.1093/nar/gkr053
NR 45
TC 66
Z9 68
U1 0
U2 14
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1574-7891
EI 1878-0261
J9 MOL ONCOL
JI Mol. Oncol.
PD JUN
PY 2018
VL 12
IS 7
BP 1047
EP 1060
DI 10.1002/1878-0261.12309
PG 14
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA GL2ID
UT WOS:000436942300005
PM 29675884
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Kiweler, N
   Brill, B
   Wirth, M
   Breuksch, I
   Laguna, T
   Dietrich, C
   Strand, S
   Schneider, G
   Groner, B
   Butter, F
   Heinzel, T
   Brenner, W
   Krämer, OH
AF Kiweler, Nicole
   Brill, Boris
   Wirth, Matthias
   Breuksch, Ines
   Laguna, Teresa
   Dietrich, Cornelia
   Strand, Susanne
   Schneider, Guenter
   Groner, Bernd
   Butter, Falk
   Heinzel, Thorsten
   Brenner, Walburgis
   Kraemer, Oliver H.
TI The histone deacetylases HDAC1 and HDAC2 are required for the growth and
   survival of renal carcinoma cells
SO ARCHIVES OF TOXICOLOGY
LA English
DT Article
DE EMT; HDACi; HDAC1; HDAC2; Renal cancer; Proteomics
ID BREAST-CANCER CELLS; EPITHELIAL-MESENCHYMAL TRANSITIONS; VALPROIC ACID;
   E-CADHERIN; CLINICAL-IMPLICATIONS; INHIBITOR VORINOSTAT;
   DRUG-RESISTANCE; LUNG-CANCER; IN-VIVO; METASTASIS
AB Novel therapies are required for the treatment of metastatic renal cell carcinoma (RCC), which is associated with inoperable disease and patient death. Histone deacetylases (HDACs) are epigenetic modifiers and potential drug targets. Additional information on molecular pathways that are altered by histone deacetylase inhibitors (HDACi) in RCC cells is warranted. It should equally be delineated further which individual members of the 18 mammalian HDACs determine the survival and tumor-associated gene expression programs of such cells. Most importantly, an ongoing dispute whether HDACi promote or suppress metastasis-associated epithelial-to-mesenchymal transition (EMT) has to be resolved before HDACi are considered further as clinically relevant drugs. Here we show how HDACi affect murine and primary human RCC cells. We find that these agents induce morphological alterations resembling the metastasis-associated EMT. However, individual and proteomics-based analyses of epithelial and mesenchymal marker proteins and of EMT-associated transcription factors (EMT-TFs) reveal that HDACi do not trigger EMT. Pathway deconvolution analysis identifies reduced proliferation and apoptosis induction as key effects of HDACi. Furthermore, these drugs lead to a reduction of the cell adhesion molecule E-cadherin and of the platelet-derived growth factor receptor-beta (PDGFR beta), which is a key driver of RCC metastasis formation. Accordingly, HDACi reduce the pulmonary spread of syngeneic transplanted renal carcinoma cells in mice. Specific genetic elimination of the histone deacetylases HDAC1/HDAC2 reflects the effects of pharmacological HDAC inhibition regarding growth suppression, apoptosis, and the downregulation of E-cadherin and PDGFR beta. Thus, these epigenetic modifiers are non-redundant gatekeepers of cell fate and precise pharmacological targets.
C1 [Kiweler, Nicole; Dietrich, Cornelia; Kraemer, Oliver H.] Univ Med Ctr Mainz, Dept Toxicol, D-55131 Mainz, Germany.
   [Brill, Boris; Groner, Bernd] Inst Tumor Biol & Expt Therapy, Georg Speyer Haus, D-60596 Frankfurt, Germany.
   [Wirth, Matthias; Schneider, Guenter] Tech Univ Munich, Klin & Poliklin Innere Med 2, D-81675 Munich, Germany.
   [Wirth, Matthias] Heinrich Heine Univ, Inst Pathol, Dusseldorf, Germany.
   [Breuksch, Ines; Brenner, Walburgis] Univ Med Ctr Mainz, Clin Obstet & Womens Hlth, D-55131 Mainz, Germany.
   [Breuksch, Ines; Brenner, Walburgis] Univ Med Ctr Mainz, Dept Urol, D-55131 Mainz, Germany.
   [Laguna, Teresa; Butter, Falk] IMB, D-55128 Mainz, Germany.
   [Strand, Susanne] Univ Med Ctr, Dept Internal Med 1, D-55131 Mainz, Germany.
   [Heinzel, Thorsten] Friedrich Schiller Univ Jena, Inst Biochem, CMB, D-07745 Jena, Germany.
C3 Johannes Gutenberg University of Mainz; Technical University of Munich;
   Heinrich Heine University Dusseldorf; Johannes Gutenberg University of
   Mainz; Johannes Gutenberg University of Mainz; Institute of Molecular
   Biology (IMB); Johannes Gutenberg University of Mainz; Friedrich
   Schiller University of Jena
RP Krämer, OH (通讯作者)，Univ Med Ctr Mainz, Dept Toxicol, D-55131 Mainz, Germany.
EM okraemer@uni-mainz.de
RI Heinzel, Thorsten/B-1013-2015; Wirth, Matthias/AEG-6333-2022; Dietrich,
   Cornelia/LFV-6139-2024; Kramer, Oliver/L-9266-2015; Laguna,
   Teresa/IAP-9879-2023
OI Kramer, Oliver/0000-0003-3973-045X; Heinzel,
   Thorsten/0009-0003-8937-6089; Kiweler, Nicole/0000-0001-7493-703X;
   Laguna, Teresa/0000-0002-6690-5684; Butter, Falk/0000-0002-7197-7279
FU Wilhelm Sander-Stiftung [2010.078]; Deutsche Forschungsgemeinschaft
   [KR2291/4-1, KR2291/5-1, KR2291/7-1]; Deutsche Krebshilfe (German Cancer
   Aid) [110909]; University Medical Center Mainz;
   Naturwissenschaftlichmedizinisches Forschungszentrum Mainz, NMFZ
FX The Wilhelm Sander-Stiftung (2010.078 to O.H.K) supported the major part
   of this work. The laboratory of O.H.K is additionally supported by the
   Deutsche Forschungsgemeinschaft (KR2291/4-1, KR2291/5-1 and KR2291/7-1
   to O.H.K), the Deutsche Krebshilfe (110909 to O.H.K; German Cancer Aid)
   and intramural funding (University Medical Center Mainz and
   Naturwissenschaftlichmedizinisches Forschungszentrum Mainz, NMFZ). We
   thank Franziska Muller, Dagmar Faust and Tina Brachetti for excellent
   technical assistance.
CR Nieto MA, 2016, CELL, V166, P21, DOI 10.1016/j.cell.2016.06.028
   Beyer M, 2017, METHODS MOL BIOL, V1510, P355, DOI 10.1007/978-1-4939-6527-4_26
   Blaheta RA, 2005, MED RES REV, V25, P383, DOI 10.1002/med.20027
   Brabletz T, 2012, NAT REV CANCER, V12, P425, DOI 10.1038/nrc3265
   Bradner JE, 2010, P NATL ACAD SCI USA, V107, P12617, DOI 10.1073/pnas.1006774107
   Carew RM, 2012, CELL TISSUE RES, V347, P103, DOI 10.1007/s00441-011-1227-1
   Cha TL, 2009, CLIN CANCER RES, V15, P840, DOI 10.1158/1078-0432.CCR-08-1918
   Christmann M, 2013, NUCLEIC ACIDS RES, V41, P8403, DOI 10.1093/nar/gkt635
   Dejung M, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005439
   Falcon S, 2007, BIOINFORMATICS, V23, P257, DOI 10.1093/bioinformatics/btl567
   Falkenberg KJ, 2014, NAT REV DRUG DISCOV, V13, P673, DOI 10.1038/nrd4360
   Fischer KR, 2015, NATURE, V527, P472, DOI 10.1038/nature15748
   Fritzsche FR, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-381
   Giudice FS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058672
   Göttlicher M, 2001, EMBO J, V20, P6969, DOI 10.1093/emboj/20.24.6969
   Han HJ, 2014, INT J BIOL SCI, V10, P490, DOI 10.7150/ijbs.7495
   Jiang GM, 2013, BBA-MOL CELL RES, V1833, P663, DOI 10.1016/j.bbamcr.2012.12.002
   Jones J, 2009, J CELL MOL MED, V13, P2342, DOI 10.1111/j.1582-4934.2008.00603.x
   Jones J, 2009, J CELL MOL MED, V13, P2376, DOI 10.1111/j.1582-4934.2008.00436.x
   Juengel E, 2011, WORLD J UROL, V29, P779, DOI 10.1007/s00345-010-0582-y
   Juengel E, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-152
   Kanao K, 2008, J UROLOGY, V180, P1131, DOI 10.1016/j.juro.2008.04.136
   Korfei M, 2015, THORAX, V70, P1022, DOI 10.1136/thoraxjnl-2014-206411
   Lagger G, 2002, EMBO J, V21, P2672, DOI 10.1093/emboj/21.11.2672
   Li YX, 2016, CSH PERSPECT MED, V6, DOI 10.1101/cshperspect.a026831
   Li ZM, 2014, INT J BIOL SCI, V10, P757, DOI 10.7150/ijbs.9067
   Mahalingam D, 2010, CLIN CANCER RES, V16, P141, DOI 10.1158/1078-0432.CCR-09-1385
   Maurer-Gebhard M, 1999, HYBRIDOMA, V18, P69, DOI 10.1089/hyb.1999.18.69
   Meidhof S, 2015, EMBO MOL MED, V7, P831, DOI 10.15252/emmm.201404396
   Menegola E, 2005, BIRTH DEFECTS RES B, V74, P392, DOI 10.1002/bdrb.20053
   Mikami S, 2016, PATHOL INT, V66, P481, DOI 10.1111/pin.12433
   Nikolova T, 2017, TRENDS PHARMACOL SCI, V38, P822, DOI 10.1016/j.tips.2017.05.009
   Park KC, 2015, BMC CANCER, V15, DOI 10.1186/s12885-014-1003-1
   Pili R, 2017, BRIT J CANCER, V116, P874, DOI 10.1038/bjc.2017.33
   Piva F, 2016, MOL DIAGN THER, V20, P111, DOI 10.1007/s40291-016-0192-5
   Poreba M, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a008680
   Ramakrishnan S, 2013, CANCER J, V19, P333, DOI 10.1097/PPO.0b013e3182a09e07
   Rhodes LV, 2014, BREAST CANCER RES TR, V145, P593, DOI 10.1007/s10549-014-2979-6
   Roy SS, 2014, ONCOGENE, V33, P3707, DOI 10.1038/onc.2013.332
   Ruscetti M, 2016, ONCOGENE, V35, P3781, DOI 10.1038/onc.2015.444
   Schech A, 2015, MOL CANCER THER, V14, P1848, DOI 10.1158/1535-7163.MCT-14-0778
   Shibue T, 2017, NAT REV CLIN ONCOL, V14, P611, DOI 10.1038/nrclinonc.2017.44
   Society AC, 2017, CANC FACTS FIGS
   Srivastava RK, 2010, MOL CANCER THER, V9, P3254, DOI 10.1158/1535-7163.MCT-10-0582
   Tang HM, 2016, CELL DEATH DISCOV, V2, DOI 10.1038/cddiscovery.2016.41
   Voon DC, 2017, MOL ONCOL, V11, P878, DOI 10.1002/1878-0261.12082
   Wu S, 2016, BIOL CHEM, V397, P75, DOI 10.1515/hsz-2015-0215
   Wu Y, 2016, SCI REP-UK, V6, DOI 10.1038/srep31093
   Xu L, 2005, CANCER RES, V65, P5711, DOI 10.1158/0008-5472.CAN-04-4313
   Yamada T, 2013, INT J ONCOL, V43, P1080, DOI 10.3892/ijo.2013.2042
   Yao X, 2014, BIOCHEM BIOPH RES CO, V455, P277, DOI 10.1016/j.bbrc.2014.11.007
   Ye Y, 2010, ONCOGENE, V29, P1451, DOI 10.1038/onc.2009.433
   Yoo CB, 2012, CELL COMMUN ADHES, V19, P11, DOI 10.3109/15419061.2012.665969
   Zeisberg M, 2009, J CLIN INVEST, V119, P1429, DOI 10.1172/JCI36183
   Zheng XF, 2015, NATURE, V527, P525, DOI 10.1038/nature16064
   Zhou XG, 2014, NEOPLASIA, V16, P1028, DOI 10.1016/j.neo.2014.09.012
   Zibelman M, 2015, INVEST NEW DRUG, V33, P1040, DOI 10.1007/s10637-015-0261-3
   Zimmermann S, 2007, CANCER RES, V67, P9047, DOI 10.1158/0008-5472.CAN-07-0312
NR 58
TC 47
Z9 48
U1 1
U2 6
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0340-5761
EI 1432-0738
J9 ARCH TOXICOL
JI Arch. Toxicol.
PD JUL
PY 2018
VL 92
IS 7
BP 2227
EP 2243
DI 10.1007/s00204-018-2229-5
PG 17
WC Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Toxicology
GA GK4DL
UT WOS:000436105400007
PM 29845424
DA 2025-01-12
ER

PT J
AU Sondergaard, JN
   Van Heeringen, SJ
   Looman, MWG
   Tang, C
   Triantis, V
   Louche, P
   Janssen-Megens, EM
   Sieuwerts, AM
   Martens, JWM
   Logie, C
   Stunnenberg, HG
   Ansems, M
   Adema, GJ
AF Sondergaard, Jonas Norskov
   Van Heeringen, Simon J.
   Looman, Maaike W. G.
   Tang, Chunling
   Triantis, Vassilis
   Louche, Pauline
   Janssen-Megens, Eva M.
   Sieuwerts, Anieta M.
   Martens, John W. M.
   Logie, Colin
   Stunnenberg, Hendrik G.
   Ansems, Marleen
   Adema, Gosse J.
TI Dendritic Cells Actively Limit Interleukin-10 Production Under
   Inflammatory Conditions via DC-SCRIPT and Dual-Specificity Phosphatase 4
SO FRONTIERS IN IMMUNOLOGY
LA English
DT Article
DE ZNF366; ERK; chromatin immunoprecipitation sequencing; dual-specificity
   phosphatase 4; dendritic cells; MAPK; DC-SCRIPT; IL-10
ID ACTIVATED PROTEIN-KINASE; NUCLEAR RECEPTOR MODULATION; ADVANCED
   MELANOMA; BREAST-CANCER; IL-10 PRODUCTION; HUMAN GENOME; EXPRESSION;
   RESPONSES; IMMUNITY; SAFETY
AB Dendritic cell (DC)-based immunotherapy makes use of the DC's ability to direct the adaptive immune response toward activation or inhibition. DCs perform this immune orchestration in part by secretion of selected cytokines. The most potent anti-inflammatory cytokine interleukin-10 (IL-10) is under tight regulation, as it needs to be predominantly expressed during the resolution phase of the immune response. Currently it is not clear whether there is active suppression of IL-10 by DCs at the initial pro-inflammatory stage of the immune response. Previously, knockdown of the DC-specific transcription factor DC-SCRIPT has been demonstrated to mediate an extensive increase in IL-10 production upon encounter with pro-inflammatory immune stimuli. Here, we explored how DC-SCRIPT contributes to IL-10 suppression under pro-inflammatory conditions by applying chromatin immunoprecipitation sequencing analysis of DC-SCRIPT and the epigenetic marks H3K4me3 and H3K27ac in human DCs. The data showed binding of DC-SCRIPT to a GA-rich motif at H3K27ac-marked genomic enhancers that associated with genes encoding MAPK dual-specificity phosphatases (DUSPs). Functional studies revealed that upon knockdown of DC-SCRIPT, human DCs express much less DUSP4 and exhibit increased phosphorylation of the three major MAPKs (ERK, JNK, and p38). Enhanced ERK signaling in DC-SCRIPT-knockdown-DCs led to higher production of IL-10, which was reverted by rescuing DUSP4 expression. Finally, DC-SCRIPT-knockdown-DCs induced less IFN-gamma and increased IL-10 production in naive T cells, indicative for a more anti-inflammatory phenotype. In conclusion, we have delineated a new mechanism by which DC-SCRIPT allows DCs to limit IL-10 production under inflammatory conditions and potentiate pro-inflammatory Th1 responses. These insights may be exploited to improve DC-based immunotherapies.
C1 [Sondergaard, Jonas Norskov; Looman, Maaike W. G.; Tang, Chunling; Triantis, Vassilis; Louche, Pauline; Ansems, Marleen; Adema, Gosse J.] Radboud Univ Nijmegen, Med Ctr, Radiotherapy & Oncolmmunol Lab, Dept Radiat Oncol,Radboud Inst Mol Life Sci, Nijmegen, Netherlands.
   [Van Heeringen, Simon J.] Radboud Univ Nijmegen, Fac Sci, Radboud Inst Mol Life Sci, Dept Mol Dev Biol, Nijmegen, Netherlands.
   [Janssen-Megens, Eva M.; Logie, Colin; Stunnenberg, Hendrik G.] Radboud Univ Nijmegen, Fac Sci & Med, Radboud Inst Mol Life Sci, Dept Mol Biol, Nijmegen, Netherlands.
   [Sieuwerts, Anieta M.; Martens, John W. M.] Erasmus Univ, Erasmus MC Canc Inst, Dept Med Oncol & Canc Genom Netherlands, Med Ctr, Rotterdam, Netherlands.
   [Sondergaard, Jonas Norskov] Karolinska Inst, Sci Life Lab, Dept Microbiol Tumor & Cell Biol, Stockholm, Sweden.
   [Triantis, Vassilis] FrieslandCampina, Amersfoort, Netherlands.
C3 Radboud University Nijmegen; Radboud University Nijmegen; Radboud
   University Nijmegen; Erasmus University Rotterdam; Erasmus MC; Erasmus
   MC Cancer Institute; Karolinska Institutet
RP Ansems, M; Adema, GJ (通讯作者)，Radboud Univ Nijmegen, Med Ctr, Radiotherapy & Oncolmmunol Lab, Dept Radiat Oncol,Radboud Inst Mol Life Sci, Nijmegen, Netherlands.
EM marleen.ansems@radboudumc.nl; gosse.adema@radboudumc.nl
RI Looman, Maaike/Q-8611-2017; Adema, G.J./H-8007-2014; Logie,
   Colin/A-1528-2010; Tang, Chunling/KSL-6603-2024; Ansems,
   Marleen/R-1287-2017; van Heeringen, Simon/Q-8530-2017; Norskov
   Sondergaard, Jonas/P-6147-2015
OI Tang, Chunling/0000-0002-5930-8742; Norskov Sondergaard,
   Jonas/0000-0002-4438-6756
FU Dutch Cancer Society (PI GA) [KUN2011-5229, KUN2009-4402]; Chinese
   Scholarship Council
FX This work was supported by grant KUN2011-5229 and KUN2009-4402 from the
   Dutch Cancer Society (PI GA), and a grant from the Chinese Scholarship
   Council to CT.
CR Adris SK, 1999, GENE THER, V6, P1705, DOI 10.1038/sj.gt.3301012
   Ansems M, 2010, BBA-REV CANCER, V1806, P193, DOI 10.1016/j.bbcan.2010.05.001
   Ansems M, 2010, JNCI-J NATL CANCER I, V102, P54, DOI 10.1093/jnci/djp441
   Ansems M, 2015, BREAST CANCER RES TR, V149, P693, DOI 10.1007/s10549-015-3281-y
   Ansems M, 2012, PROSTATE, V72, P1708, DOI 10.1002/pros.22522
   Arthur JSC, 2013, NAT REV IMMUNOL, V13, P679, DOI 10.1038/nri3495
   Bailey TL, 2009, NUCLEIC ACIDS RES, V37, pW202, DOI 10.1093/nar/gkp335
   Bakdash G, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00053
   Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588
   Barski A, 2007, CELL, V129, P823, DOI 10.1016/j.cell.2007.05.009
   Boulland ML, 1998, AM J PATHOL, V153, P1229, DOI 10.1016/S0002-9440(10)65667-2
   Boullart ACI, 2008, CANCER IMMUNOL IMMUN, V57, P1589, DOI 10.1007/s00262-008-0489-2
   Boyano MD, 2000, BRIT J CANCER, V83, P847, DOI 10.1054/bjoc.2000.1402
   Brahmer JR, 2012, NEW ENGL J MED, V366, P2455, DOI 10.1056/NEJMoa1200694
   Brahmer JR, 2010, J CLIN ONCOL, V28, P3167, DOI 10.1200/JCO.2009.26.7609
   Brondello JM, 1997, J BIOL CHEM, V272, P1368, DOI 10.1074/jbc.272.2.1368
   Brooks DG, 2010, P NATL ACAD SCI USA, V107, P3018, DOI 10.1073/pnas.0914500107
   CHEN QY, 1994, INT J CANCER, V56, P755, DOI 10.1002/ijc.2910560524
   de Vries IJM, 2002, J IMMUNOTHER, V25, P429, DOI 10.1097/00002371-200209000-00007
   Dixon JR, 2015, NATURE, V518, P331, DOI 10.1038/nature14222
   Dixon JR, 2012, NATURE, V485, P376, DOI 10.1038/nature11082
   Georgiev O, 1996, GENE, V168, P165, DOI 10.1016/0378-1119(95)00764-4
   Georgiou G, 2016, PEERJ, V4, DOI 10.7717/peerj.2209
   Gregori S, 2010, BLOOD, V116, P935, DOI 10.1182/blood-2009-07-234872
   Grivennikov SI, 2010, CELL, V140, P883, DOI 10.1016/j.cell.2010.01.025
   GUAN KL, 1995, J BIOL CHEM, V270, P7197, DOI 10.1074/jbc.270.13.7197
   Hamid O, 2013, NEW ENGL J MED, V369, P134, DOI 10.1056/NEJMoa1305133
   Heinz S, 2015, NAT REV MOL CELL BIO, V16, P144, DOI 10.1038/nrm3949
   Hontelez S, 2013, J IMMUNOL, V190, P3172, DOI 10.4049/jimmunol.1201776
   Hontelez S, 2012, J IMMUNOL, V189, P138, DOI 10.4049/jimmunol.1103709
   Jeffrey KL, 2007, NAT REV DRUG DISCOV, V6, P391, DOI 10.1038/nrd2289
   Jonuleit H, 1997, EUR J IMMUNOL, V27, P3135, DOI 10.1002/eji.1830271209
   Kawai T, 2006, CELL DEATH DIFFER, V13, P816, DOI 10.1038/sj.cdd.4401850
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lopez-Garcia J, 2006, NUCLEIC ACIDS RES, V34, P6126, DOI 10.1093/nar/gkl875
   Mannino MH, 2015, CANCER LETT, V367, P103, DOI 10.1016/j.canlet.2015.07.009
   McLean CY, 2010, NAT BIOTECHNOL, V28, P495, DOI 10.1038/nbt.1630
   Muda M, 1996, J BIOL CHEM, V271, P4319
   Nemunaitis J, 2001, CANCER INVEST, V19, P239, DOI 10.1081/CNV-100102550
   Palucka K, 2013, IMMUNITY, V39, P38, DOI 10.1016/j.immuni.2013.07.004
   Quinlan AR, 2010, BIOINFORMATICS, V26, P841, DOI 10.1093/bioinformatics/btq033
   Rao SSP, 2014, CELL, V159, P1665, DOI 10.1016/j.cell.2014.11.021
   Reber L, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004393
   Saraiva M, 2010, NAT REV IMMUNOL, V10, P170, DOI 10.1038/nri2711
   Sato T, 1996, CLIN CANCER RES, V2, P1383
   Schreibelt G, 2010, BLOOD, V116, P564, DOI 10.1182/blood-2009-11-251884
   Schuurhuis DH, 2009, CANCER IMMUNOL IMMUN, V58, P1109, DOI 10.1007/s00262-008-0626-y
   Sieuwerts AM, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2786
   Sondergaard JN, 2015, J IMMUNOL, V195, P1498, DOI 10.4049/jimmunol.1402924
   Steinbrink K, 2002, BLOOD, V99, P2468, DOI 10.1182/blood.V99.7.2468
   Steinman RM, 2007, NATURE, V449, P419, DOI 10.1038/nature06175
   Triantis V, 2006, J IMMUNOL, V176, P1081, DOI 10.4049/jimmunol.176.2.1081
   Triantis V, 2006, J LEUKOCYTE BIOL, V79, P1083, DOI 10.1189/jlb.1005588
   van Heeringen SJ, 2011, BIOINFORMATICS, V27, P270, DOI 10.1093/bioinformatics/btq636
   Wayteck L, 2014, CANCER LETT, V352, P113, DOI 10.1016/j.canlet.2013.09.016
   Weber JS, 2013, J CLIN ONCOL, V31, P4311, DOI 10.1200/JCO.2013.51.4802
   Welstead GG, 2012, P NATL ACAD SCI USA, V109, P13004, DOI 10.1073/pnas.1210787109
   Wolchok JD, 2013, NEW ENGL J MED, V369, P122, DOI 10.1056/NEJMoa1302369
   Yuan JD, 2011, P NATL ACAD SCI USA, V108, P16723, DOI 10.1073/pnas.1110814108
   Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r137
NR 60
TC 16
Z9 17
U1 0
U2 4
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-3224
J9 FRONT IMMUNOL
JI Front. Immunol.
PD JUN 22
PY 2018
VL 9
AR 1420
DI 10.3389/fimmu.2018.01420
PG 13
WC Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology
GA GK4MK
UT WOS:000436133800001
PM 29988341
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Yu, Y
   Zhang, MJ
   Wang, N
   Li, QP
   Yang, J
   Yan, S
   He, XZ
   Ji, GZ
   Miao, L
AF Yu, Yang
   Zhang, Mingjiong
   Wang, Ni
   Li, Quanpeng
   Yang, Jian
   Yan, Shuai
   He, Xuezhi
   Ji, Guozhong
   Miao, Lin
TI Epigenetic silencing of tumor suppressor gene <i>CDKN1A</i> by oncogenic
   long non-coding RNA <i>SNHG1</i> in cholangiocarcinoma
SO CELL DEATH & DISEASE
LA English
DT Article
ID SQUAMOUS-CELL CARCINOMA; INTRAHEPATIC CHOLANGIOCARCINOMA;
   HEPATOCELLULAR-CARCINOMA; INHIBITS GROWTH; POOR-PROGNOSIS;
   GASTRIC-CANCER; OVARIAN-CANCER; BREAST-CANCER; CYCLE ARREST; EXPRESSION
AB Cholangiocarcinoma (CCA) is the as the most frequently observed biliary tract malignancy, which has low survival rate in addition to constrained treatment options; nevertheless, the fundamental molecular phenomenon underlying malignant progression of CCA is quite ambiguous. Recently long non-coding RNAs (lncRNAs) have been found to have significant regulatory functions in several human cancers. Herein, we have figured out that lncRNA SNHG1, with substantially enhanced expression in CCA, is capable of acting as the oncogenic molecule of CCA. As revealed by our data, SNHG1 knockdown extensively inhibited CCA cell migration as well as proliferation in vitro and in vivo. In addition, in accordance with the findings of the RNA-Seq analysis, SNHG1 knockdown exhibited a significant impact on the target genes that were linked to cell migration and regulation of cell proliferation, in addition to the apoptotic phenomenon. In a mechanistic manner, we also showed that SNHG1 bound to the histone methyltransferase enhancer of the zeste homolog 2 (EZH2, which is regarded as the catalytic subunit of the polycomb repressive complex 2 (PRC2), which is an extremely conserved protein complex regulating gene expression with the help of methylating lysine 27 on histone H3), specifying the histone alteration pattern on the target genes, including CDKN1A, and, as a result, altered the CCA cell biology. These data verified a major function of the epigenetic regulation of SNHG1 in CCA oncogenesis, in addition to its likely function as a target for CCA interruption.
C1 [Yu, Yang; Zhang, Mingjiong; Wang, Ni; Li, Quanpeng; Ji, Guozhong; Miao, Lin] Nanjing Med Univ, Affiliated Hosp 2, Med Ctr Digest Dis, Nanjing, Jiangsu, Peoples R China.
   [Yang, Jian] Nanjing Med Univ, Affiliated Hosp 2, Dept Urol, Nanjing, Jiangsu, Peoples R China.
   [Yan, Shuai] Southeast Univ Med Coll, Dept Oncol, Affiliated Jiangyin Hosp, Jiangyin, Jiangsu, Peoples R China.
   [He, Xuezhi] Nanjing Med Univ, Res Ctr Bone & Stem Cells, Nanjing, Jiangsu, Peoples R China.
C3 Nanjing Medical University; Nanjing Medical University; Southeast
   University - China; Nanjing Medical University
RP Miao, L (通讯作者)，Nanjing Med Univ, Affiliated Hosp 2, Med Ctr Digest Dis, Nanjing, Jiangsu, Peoples R China.
EM linmiao@njmu.edu.cn
OI Miao, Lin/0000-0003-0248-2544
FU Project of Standard Diagnosis and Treatment of Key Disease of Jiangsu
   Province [BE2015722]; Project of the peak of the six talents of Jiangsu
   Province [WSN-018]; Scientific Research Foundation for Health of Jiangsu
   Province [H201408]
FX This study was supported by the Project of Standard Diagnosis and
   Treatment of Key Disease of Jiangsu Province (BE2015722); Project of the
   peak of the six talents of Jiangsu Province (WSN-018); and Scientific
   Research Foundation for Health of Jiangsu Province (H201408). We also
   thank NovelBio Bio-Pharm Technology Co., Ltd for the support of
   next-generation sequencing and bioinformatics analysis with NovelBrain
   Cloud Analysis Platform (www.novelbrain.com)
CR Akizu N, 2016, OPEN BIOL, V6, DOI 10.1098/rsob.150227
   [Anonymous], 2017, ONCOTARGET
   Askari M, 2013, MOL CELL BIOCHEM, V382, P19, DOI 10.1007/s11010-013-1696-5
   Fan T, 2011, MOL CANCER RES, V9, P418, DOI 10.1158/1541-7786.MCR-10-0511
   Gartel AL, 2005, CANCER RES, V65, P3980, DOI 10.1158/0008-5472.CAN-04-3995
   Gulappa T, 2013, CANCER LETT, V337, P177, DOI 10.1016/j.canlet.2013.05.014
   Guo H, 2015, TUMOR BIOL, V36, P8511, DOI 10.1007/s13277-015-3592-y
   Gupta R, 2014, P NATL ACAD SCI USA, V111, pE3062, DOI 10.1073/pnas.1411370111
   Hu YB, 2017, BIOCHEM BIOPH RES CO, V491, P926, DOI 10.1016/j.bbrc.2017.07.137
   Jalili A, 2012, J NATL CANCER I, V104, P1673, DOI 10.1093/jnci/djs373
   Jia H, 2010, RNA, V16, P1478, DOI 10.1261/rna.1951310
   Jiang XM, 2017, EUR REV MED PHARMACO, V21, P1242
   Kotake Y, 2011, ONCOGENE, V30, P1956, DOI 10.1038/onc.2010.568
   Lee S, 2016, CELL, V164, P69, DOI 10.1016/j.cell.2015.12.017
   Liu YW, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0588-9
   Lu X, 2017, CELL PHYSIOL BIOCHEM, V42, P222, DOI 10.1159/000477319
   Ma SL, 2015, MOL MED REP, V12, P7915, DOI 10.3892/mmr.2015.4435
   Marchese FP, 2014, EPIGENETICS-US, V9, P21, DOI 10.4161/epi.27472
   Merry CR, 2015, HUM MOL GENET, V24, P6240, DOI 10.1093/hmg/ddv343
   Niazi F, 2012, RNA, V18, P825, DOI 10.1261/rna.029520.111
   Rizvi S, 2018, NAT REV CLIN ONCOL, V15, P95, DOI 10.1038/nrclinonc.2017.157
   Saha A, 2016, SCI REP-UK, V6, DOI 10.1038/srep27476
   Seward S, 2013, CANCER LETT, V336, P53, DOI 10.1016/j.canlet.2013.04.012
   Shen XH, 2008, MOL CELL, V32, P491, DOI 10.1016/j.molcel.2008.10.016
   Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501
   Tan XY, 2017, J CELL BIOCHEM, V118, P3643, DOI 10.1002/jcb.25862
   Tian T, 2018, ONCOTARGET, V9, P2128, DOI 10.18632/oncotarget.23255
   Wang C, 2017, NEOPLASMA, V64, P725, DOI 10.4149/neo_2017_510
   Wang JG, 2016, TRANSL RES, V168, P107, DOI 10.1016/j.trsl.2015.07.007
   Wei CY, 2015, INT J CLIN EXP PATHO, V8, P14619
   Wu YS, 2015, INT J ONCOL, V46, P2586, DOI 10.3892/ijo.2015.2976
   Xia X, 2015, EUR J GYNAECOL ONCOL, V36, P662
   Xu YT, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.503
   Yamaguchi H, 2014, CANCER RES TREAT, V46, P209, DOI 10.4143/crt.2014.46.3.209
   Zhang FM, 2017, BIOMED PHARMACOTHER, V94, P55, DOI 10.1016/j.biopha.2017.07.025
   Zhang HY, 2017, BIOMED PHARMACOTHER, V90, P650, DOI 10.1016/j.biopha.2017.03.104
   Zhang H, 2016, MED SCI MONITOR, V22, P4820, DOI 10.12659/MSM.898574
   Zhang M, 2016, BIOMED PHARMACOTHER, V80, P73, DOI 10.1016/j.biopha.2016.02.036
   Zhang SH, 2017, DIGEST DIS SCI, V62, P3050, DOI 10.1007/s10620-017-4759-8
   Zhang YJ, 2018, CANCER BIOMARK, V21, P89, DOI 10.3233/CBM-170286
   Zhao J, 2015, CELL CYCLE, V14, P3112, DOI 10.1080/15384101.2015.1078034
NR 41
TC 41
Z9 42
U1 0
U2 6
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-4889
J9 CELL DEATH DIS
JI Cell Death Dis.
PD JUL 3
PY 2018
VL 9
AR 746
DI 10.1038/s41419-018-0768-6
PG 13
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA GL9GH
UT WOS:000437539700011
PM 29970899
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU Nguyen, DD
   Lee, DG
   Kim, S
   Kang, K
   Rhee, JK
   Chang, S
AF Dinh-Duc Nguyen
   Lee, Dong Gyu
   Kim, Sinae
   Kang, Keunsoo
   Rhee, Je-keun
   Chang, Suhwan
TI Integrative Bioinformatics and Functional Analyses of GEO, ENCODE, and
   TCGA Reveal <i>FADD</i> as a Direct Target of the Tumor Suppressor BRCA1
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE BRCA1; ENCODE; ChIP-seq; GEO; FADD
ID DEATH DOMAIN; TRANSCRIPTIONAL ACTIVATION; ESTROGEN-RECEPTOR; INDUCED
   APOPTOSIS; BREAST-CANCER; DNA-DAMAGE; PROTEIN; INTERACTS;
   PHOSPHORYLATION; MICRORNA
AB BRCA1 is a multifunctional tumor suppressor involved in several essential cellular processes. Although many of these functions are driven by or related to its transcriptional/epigenetic regulator activity, there has been no genome-wide study to reveal the transcriptional/epigenetic targets of BRCA1. Therefore, we conducted a comprehensive analysis of genomics/transcriptomics data to identify novel BRCA1 target genes. We first analyzed ENCODE data with BRCA1 chromatin immunoprecipitation (ChIP)-sequencing results and identified a set of genes with a promoter occupied by BRCA1. We collected 3085 loci with a BRCA1 ChIP signal from four cell lines and calculated the distance between the loci and the nearest gene transcription start site (TSS). Overall, 66.5% of the BRCA1-bound loci fell into a 2-kb region around the TSS, suggesting a role in transcriptional regulation. We selected 45 candidate genes based on gene expression correlation data, obtained from two GEO (Gene Expression Omnibus) datasets and TCGA data of human breast cancer, compared to BRCA1 expression levels. Among them, we further tested three genes (MEIS2, CKS1B and FADD) and verified FADD as a novel direct target of BRCA1 by ChIP, RT-PCR, and a luciferase reporter assay. Collectively, our data demonstrate genome-wide transcriptional regulation by BRCA1 and suggest target genes as biomarker candidates for BRCA1-associated breast cancer.
C1 [Dinh-Duc Nguyen; Lee, Dong Gyu; Kim, Sinae; Chang, Suhwan] Univ Ulsan, Dept Biomed Sci, Asan Med Ctr, Sch Med, Seoul 05505, South Korea.
   [Dinh-Duc Nguyen; Chang, Suhwan] Univ Ulsan, Dept Physiol, Asan Med Ctr, Sch Med, Seoul 05505, South Korea.
   [Kang, Keunsoo] Dankook Univ, Dept Microbiol, Coll Nat Sci, Cheonan 31116, South Korea.
   [Rhee, Je-keun] Catholic Univ Korea, Canc Res Inst, Seoul 06591, South Korea.
C3 University of Ulsan; University of Ulsan; Dankook University; Catholic
   University of Korea
RP Chang, S (通讯作者)，Univ Ulsan, Dept Biomed Sci, Asan Med Ctr, Sch Med, Seoul 05505, South Korea.; Chang, S (通讯作者)，Univ Ulsan, Dept Physiol, Asan Med Ctr, Sch Med, Seoul 05505, South Korea.
EM michaelnguyen1986@gmail.com; que002@hanmail.net; skim368@gmail.com;
   kangk1204@gmail.com; jkrhee@catholic.ac.kr; suhwan.chang@amc.seoul.kr
RI Kang, Keunsoo/AFM-7746-2022; Kim, Yoon/J-2746-2012; Nguyen,
   Dinh-Duc/J-2674-2019
OI Chang, Suhwan/0000-0002-0282-0120; Kang, Keunsoo/0000-0003-0611-9320;
   Rhee, Je-Keun/0000-0003-4811-8895; Nguyen, Dinh-Duc/0000-0001-9366-9253
FU National Research Foundation of Korea (NRF) - Korean government (MEST)
   [2018R1A2B2004922]; Asan Institute for Life Sciences (AILS) [2014-606]
FX This work was supported by the National Research Foundation of Korea
   (NRF) grant funded by the Korean government (MEST) (No.
   2018R1A2B2004922) and a grant from Asan Institute for Life Sciences
   (AILS), No. 2014-606.
CR Barrett T, 2013, NUCLEIC ACIDS RES, V41, pD991, DOI 10.1093/nar/gks1193
   Benezra M, 2003, J BIOL CHEM, V278, P26333, DOI 10.1074/jbc.M303076200
   BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795
   Chang S, 2013, TRANSCR-AUSTIN, V4, P24, DOI 10.4161/trns.22600
   Chang SW, 2012, ONCOTARGET, V3, P5, DOI 10.18632/oncotarget.433
   Chang SH, 2011, NAT MED, V17, P1275, DOI 10.1038/nm.2459
   Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0
   Chen JL, 2012, CLIN CANCER RES, V18, P4291, DOI 10.1158/1078-0432.CCR-12-0373
   CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3
   Cohen Marie, 2014, Oncoscience, V1, P262
   Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162
   Deans AJ, 2006, CANCER RES, V66, P8219, DOI 10.1158/0008-5472.CAN-05-3945
   Fan SJ, 2001, ONCOGENE, V20, P77, DOI 10.1038/sj.onc.1204073
   Fan WH, 2002, J BIOL CHEM, V277, P8061, DOI 10.1074/jbc.M110225200
   Feingold EA, 2004, SCIENCE, V306, P636, DOI 10.1126/science.1105136
   Goswami CP, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-970
   Gupta S, 2004, J CLIN IMMUNOL, V24, P24, DOI 10.1023/B:JOCI.0000018059.56924.99
   James CR, 2007, ONCOLOGIST, V12, P142, DOI 10.1634/theoncologist.12-2-142
   Jin SQ, 2000, ONCOGENE, V19, P4050, DOI 10.1038/sj.onc.1203759
   Kim S, 2015, CANCER LETT, V357, P488, DOI 10.1016/j.canlet.2014.11.058
   MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954
   Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595
   Quinn JE, 2003, CANCER RES, V63, P6221
   Reddy RB, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147409
   Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6
   Scully R, 1997, P NATL ACAD SCI USA, V94, P5605, DOI 10.1073/pnas.94.11.5605
   Shao NS, 1996, ONCOGENE, V13, P1
   Shi L, 2010, ONCOTARGET, V1, P22, DOI 10.18632/oncotarget.105
   Tanic M, 2012, BREAST CANCER RES TR, V134, P41, DOI 10.1007/s10549-011-1905-4
   Thangaraju M, 2000, J BIOL CHEM, V275, P33487, DOI 10.1074/jbc.M005824200
   Yan Y, 2002, J BIOL CHEM, V277, P33422, DOI 10.1074/jbc.M201147200
   Yarden RI, 1999, P NATL ACAD SCI USA, V96, P4983, DOI 10.1073/pnas.96.9.4983
   Zhang HB, 1998, ONCOGENE, V16, P1713, DOI 10.1038/sj.onc.1201932
   Zheng L, 2001, P NATL ACAD SCI USA, V98, P9587, DOI 10.1073/pnas.171174298
   Zheng L, 2000, MOL CELL, V6, P757, DOI 10.1016/S1097-2765(00)00075-7
NR 35
TC 7
Z9 7
U1 0
U2 11
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD MAY
PY 2018
VL 19
IS 5
AR 1458
DI 10.3390/ijms19051458
PG 13
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA GJ4BO
UT WOS:000435297000194
PM 29757984
OA gold, Green Published, Green Submitted
DA 2025-01-12
ER

PT J
AU Hirukawa, A
   Smith, HW
   Zuo, DM
   Dufour, CR
   Savage, P
   Bertos, N
   Johnson, RM
   Bui, T
   Bourque, G
   Basik, M
   Giguère, V
   Park, M
   Muller, WJ
AF Hirukawa, Alison
   Smith, Harvey W.
   Zuo, Dongmei
   Dufour, Catherine R.
   Savage, Paul
   Bertos, Nicholas
   Johnson, Radia M.
   Bui, Tung
   Bourque, Guillaume
   Basik, Mark
   Giguere, Vincent
   Park, Morag
   Muller, William J.
TI Targeting EZH2 reactivates a breast cancer subtype-specific
   anti-metastatic transcriptional program
SO NATURE COMMUNICATIONS
LA English
DT Article
ID GROUP PROTEIN EZH2; METHYLTRANSFERASE EZH2; DNA METHYLATION; CELL
   IDENTITY; FOXC1; INHIBITION; EXPRESSION; CARCINOMA; TUMORS; PROGRESSION
AB Emerging evidence has illustrated the importance of epigenomic reprogramming in cancer, with altered post-translational modifications of histones contributing to pathogenesis. However, the contributions of histone modifiers to breast cancer progression are unclear, and how these processes vary between molecular subtypes has yet to be adequately addressed. Here we report that genetic or pharmacological targeting of the epigenetic modifier Ezh2 dramatically hinders metastatic behaviour in both a mouse model of breast cancer and patient-derived xenografts reflective of the Luminal B subtype. We further define a subtype-specific molecular mechanism whereby EZH2 maintains H3K27me3-mediated repression of the FOXC1 gene, thereby inactivating a FOXC1-driven, anti-invasive transcriptional program. We demonstrate that higher FOXC1 is predictive of favourable outcome specifically in Luminal B breast cancer patients and establish the use of EZH2 methyltransferase inhibitors as a viable strategy to block metastasis in Luminal B breast cancer, where options for targeted therapy are limited.
C1 [Hirukawa, Alison; Smith, Harvey W.; Zuo, Dongmei; Dufour, Catherine R.; Savage, Paul; Bertos, Nicholas; Johnson, Radia M.; Bui, Tung; Giguere, Vincent; Park, Morag; Muller, William J.] McGill Univ, Goodman Canc Res Ctr, Montreal, PQ H3A 1A3, Canada.
   [Hirukawa, Alison; Bui, Tung; Giguere, Vincent; Park, Morag; Muller, William J.] McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada.
   [Bourque, Guillaume] McGill Univ, Genome Quebec Innovat Ctr, Montreal, PQ H3A 0G1, Canada.
   [Bourque, Guillaume] McGill Univ, Dept Human Genet, Montreal, PQ H3A 1A3, Canada.
   [Basik, Mark] Jewish Gen Hosp, Dept Surg & Oncol, Montreal, PQ H3T 1E2, Canada.
   [Basik, Mark; Giguere, Vincent; Park, Morag; Muller, William J.] McGill Univ, Dept Med, Montreal, PQ H3G 1Y6, Canada.
   [Basik, Mark; Giguere, Vincent; Park, Morag; Muller, William J.] McGill Univ, Dept Oncol, Montreal, PQ H3G 1Y6, Canada.
C3 McGill University; McGill University; McGill University; McGill
   University; McGill University; McGill University; McGill University
RP Muller, WJ (通讯作者)，McGill Univ, Goodman Canc Res Ctr, Montreal, PQ H3A 1A3, Canada.; Muller, WJ (通讯作者)，McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada.; Muller, WJ (通讯作者)，McGill Univ, Dept Med, Montreal, PQ H3G 1Y6, Canada.
EM william.muller@mcgill.ca
RI Zuo, Dongmei/KXS-2151-2024; Johnson, Radia/GYV-4663-2022; Bourque,
   Guillaume/AFR-2927-2022
OI Giguere, Vincent/0000-0001-9567-3694; Hirukawa,
   Alison/0009-0009-3083-0332; Dufour, Catherine Rosa/0000-0001-7324-3458;
   Savage, Paul/0000-0003-2881-6717
FU Canadian Institute of Health Research; Fonds de Recherche du
   Quebec-Sante; Canadian Institute of Health Research Epigenetics grant
   [TEC-128089]; DOD CDMRP Breast Cancer Fellowship [W81XWH-11-1-0046];
   McGill Integrated Cancer Research Training Program; Systems Biology
   Program of the Canadian Institutes of Health Research; Canada Research
   Chair in Molecular Oncology; Database and Tissue Bank Axis of the Reseau
   de Recherche en Cancer of the Fonds de Recherche du Quebec-Sante; Quebec
   Breast Cancer Foundation
FX We would like to acknowledge Cynthia Lavoie, Vasilios Papavasiliou, the
   Goodman Cancer Research Center Histology Core and the McGill Comparative
   Medicine & Animal Resources Center for their technical assistance. This
   work was funded by a Strategic Team Grant funded by the Canadian
   Institute of Health Research and the Fonds de Recherche du Quebec-Sante
   and the Canadian Institute of Health Research Epigenetics grant
   (TEC-128089), a DOD CDMRP Breast Cancer Fellowship W81XWH-11-1-0046 (to
   H.W.S.), the McGill Integrated Cancer Research Training Program (to
   H.W.S. and A.H.), the Systems Biology Program of the Canadian Institutes
   of Health Research (to A.H.), and a Canada Research Chair in Molecular
   Oncology (to W.M.). The breast tissue and data bank at McGill University
   is supported by funding from the Database and Tissue Bank Axis of the
   Reseau de Recherche en Cancer of the Fonds de Recherche du Quebec-Sante
   and the Quebec Breast Cancer Foundation.
CR Amenta PS, 2003, J PATHOL, V199, P298, DOI 10.1002/path.1303
   Amin S, 2015, DEV CELL, V32, P265, DOI 10.1016/j.devcel.2014.12.024
   Bae WK, 2015, MOL CARCINOGEN, V54, P1172, DOI 10.1002/mc.22188
   Bartke T, 2010, CELL, V143, P470, DOI 10.1016/j.cell.2010.10.012
   Brinkman AB, 2012, GENOME RES, V22, P1128, DOI 10.1101/gr.133728.111
   Chen EY, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-128
   Comet I, 2016, NAT REV CANCER, V16, P803, DOI 10.1038/nrc.2016.83
   DeRose YS, 2011, NAT MED, V17, P1514, DOI 10.1038/nm.2454
   Gonzalez ME, 2014, P NATL ACAD SCI USA, V111, P3098, DOI 10.1073/pnas.1308953111
   Gunther EJ, 2002, FASEB J, V16, DOI 10.1096/fj.01-0551com
   GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954
   Györffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9
   He LH, 2013, BIOCHEM BIOPH RES CO, V438, P433, DOI 10.1016/j.bbrc.2013.07.093
   Heinz S, 2010, MOL CELL, V38, P576, DOI 10.1016/j.molcel.2010.05.004
   Holm K, 2012, MOL ONCOL, V6, P494, DOI 10.1016/j.molonc.2012.06.002
   Ikeda K, 2006, AM J PATHOL, V168, P856, DOI 10.2353/ajpath.2006.050384
   Kim E, 2013, CANCER CELL, V23, P839, DOI 10.1016/j.ccr.2013.04.008
   Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100
   Knutson SK, 2014, MOL CANCER THER, V13, P842, DOI 10.1158/1535-7163.MCT-13-0773
   Knutson SK, 2013, P NATL ACAD SCI USA, V110, P7922, DOI 10.1073/pnas.1303800110
   Koppens M, 2016, ONCOGENE, V35, P1341, DOI 10.1038/onc.2015.195
   Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324
   Li J., 2014, CANCER RES, V69, P6158
   Li J, 2012, CURR SIGNAL TRANSD T, V7, P149, DOI 10.2174/157436212800376690
   Lin EY, 2003, AM J PATHOL, V163, P2113, DOI 10.1016/S0002-9440(10)63568-7
   Mani SA, 2007, P NATL ACAD SCI USA, V104, P10069, DOI 10.1073/pnas.0703900104
   Margueron R, 2011, NATURE, V469, P343, DOI 10.1038/nature09784
   McCabe MT, 2012, NATURE, V492, P108, DOI 10.1038/nature11606
   Mertins P, 2016, NATURE, V534, P55, DOI 10.1038/nature18003
   Michalak EM, 2013, STEM CELLS, V31, P1910, DOI 10.1002/stem.1437
   Muggerud AA, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2466
   Pal B, 2013, CELL REP, V3, P411, DOI 10.1016/j.celrep.2012.12.020
   Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093
   Pfefferle AD, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-11-r125
   Prat A, 2011, MOL ONCOL, V5, P5, DOI 10.1016/j.molonc.2010.11.003
   Quinlan AR, 2010, BIOINFORMATICS, V26, P841, DOI 10.1093/bioinformatics/btq033
   Rao T., 2014, BREAST CANCER RES, V16, P542
   Ray PS, 2010, CANCER RES, V70, P3870, DOI 10.1158/0008-5472.CAN-09-4120
   Sassano A, 2015, MOL CELL BIOL, V35, P2684, DOI 10.1128/MCB.00019-15
   Seo S, 2006, DEV BIOL, V294, P458, DOI 10.1016/j.ydbio.2006.03.035
   Shen XH, 2008, MOL CELL, V32, P491, DOI 10.1016/j.molcel.2008.10.016
   Shi B, 2007, MOL CELL BIOL, V27, P5105, DOI 10.1128/MCB.00162-07
   Szász AM, 2016, ONCOTARGET, V7, P49322, DOI 10.18632/oncotarget.10337
   Tenbaum S, 2012, PROTOC EXCH, DOI [10.1038/protex.2012.008, DOI 10.1038/PROTEX.2012.008]
   Tiwari N, 2013, CANCER CELL, V23, P768, DOI 10.1016/j.ccr.2013.04.020
   Tofigh A, 2014, CELL REP, V9, P129, DOI 10.1016/j.celrep.2014.08.073
   Viré E, 2006, NATURE, V439, P871, DOI 10.1038/nature04431
   Wang J, 2012, ONCOGENE, V31, P4798, DOI 10.1038/onc.2011.635
   Wang JH, 2017, CANCER MED-US, V6, P275, DOI 10.1002/cam4.990
   Wassef M, 2015, GENE DEV, V29, P2547, DOI 10.1101/gad.269522.115
   Xu KX, 2012, SCIENCE, V338, P1465, DOI 10.1126/science.1227604
   Yu-Rice Y, 2016, ONCOGENE, V35, P5400, DOI 10.1038/onc.2016.78
   Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r137
   Zhu JC, 2009, NAT METHODS, V6, P239, DOI 10.1038/nmeth0409-239
NR 54
TC 64
Z9 75
U1 0
U2 5
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-1723
J9 NAT COMMUN
JI Nat. Commun.
PD JUN 29
PY 2018
VL 9
AR 2547
DI 10.1038/s41467-018-04864-8
PG 15
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA GL0PF
UT WOS:000436791400008
PM 29959321
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Dery, KJ
   Silver, C
   Yang, L
   Shively, JE
AF Dery, Kenneth J.
   Silver, Craig
   Yang, Lu
   Shively, John E.
TI Interferon regulatory factor 1 and a variant of heterogeneous nuclear
   ribonucleoprotein L coordinately silence the gene for adhesion protein
   CEACAM1
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
DE chromatin remodeling; translation regulation; alternative splicing;
   transcription; RNA; CEACAM1; hnRNP L; IFN-gamma; IRF1
ID BILIARY GLYCOPROTEIN CD66A; NF-KAPPA-B; CARCINOEMBRYONIC ANTIGEN;
   HNRNP-L; BREAST-CANCER; TUMOR-SUPPRESSOR; EPITHELIAL-CELLS; DNA
   METHYLATION; CARCINOMA CELLS; DOWN-REGULATION
AB The adhesion protein carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) is widely expressed in epithelial cells as a short cytoplasmic isoform (S-iso) and in leukocytes as a long cytoplasmic isoform (L-iso) and is frequently silenced in cancer by unknown mechanisms. Previously, we reported that interferon response factor 1 (IRF1) biases alternative splicing (AS) to include the variable exon 7 (E7) in CEACAM1, generating long cytoplasmic isoforms. We now show that IRF1 and a variant of heterogeneous nuclear ribonucleoprotein L (Lv1) coordinately silence the CEACAM1 gene. RNAi-mediated Lv1 depletion in IRF1-treated HeLa and melanoma cells induced significant CEACAM1 protein expression, reversed by ectopic Lv1 expression. The Lv1-mediated CEACAM1 repression resided in residues Gly(71)-Gly(89) and Ala(38)-Gly(89) in Lv1's N-terminal extension. ChIP analysis of IRF1- and FLAG-tagged Lv1-treated HeLa cells and global treatment with the global epigenetic modifiers 5-aza-2-deoxycytidine and trichostatin A indicated that IRF1 and Lv1 together induce chromatin remodeling, restricting IRF1 access to the CEACAM1 promoter. In interferon -treated HeLa cells, the transcription factor SP1 did not associate with the CEACAM1 promoter, but binding by upstream transcription factor 1 (USF1), a known CEACAM1 regulator, was greatly enhanced. ChIP-sequencing revealed that Lv1 overexpression in IRF1-treated cells induces transcriptional silencing across many genes, including DCC (deleted in colorectal carcinoma), associated with CEACAM5 in colon cancer. Notably, IRF1, but not IRF3 and IRF7, affected CEACAM1 expression via translational repression. We conclude that IRF1 and Lv1 coordinately regulate CEACAM1 transcription, alternative splicing, and translation and may significantly contribute to CEACAM1 silencing in cancer.
C1 [Dery, Kenneth J.; Shively, John E.] City Hope Natl Med Ctr, Dept Mol Immunol, Beckman Res Inst, Duarte, CA 91010 USA.
   [Silver, Craig] Calif State Polytech Univ Pomona, Dept Biol Sci, Pomona, CA 91768 USA.
   [Yang, Lu] City Hope Natl Med Ctr, Integrat Genom & Bioinformat Core, Beckman Res Inst, Duarte, CA 91010 USA.
C3 City of Hope; Beckman Research Institute of City of Hope; California
   State University System; California State Polytechnic University Pomona;
   City of Hope; Beckman Research Institute of City of Hope
RP Shively, JE (通讯作者)，City Hope Natl Med Ctr, Dept Mol Immunol, Beckman Res Inst, Duarte, CA 91010 USA.
EM jshively@coh.org
OI Shively, John/0000-0002-7763-770X
FU NCI NIH HHS [P30 CA033572] Funding Source: Medline
CR Bidwell BN, 2012, NAT MED, V18, P1224, DOI 10.1038/nm.2830
   Bieberstein NI, 2016, SCI REP-UK, V6, DOI 10.1038/srep29961
   Bodaghi S, 2009, VIROLOGY, V386, P32, DOI 10.1016/j.virol.2008.12.037
   Busch C, 2002, HUM PATHOL, V33, P290, DOI 10.1053/hupa.2002.32218
   Cartegni L, 1996, J MOL BIOL, V259, P337, DOI 10.1006/jmbi.1996.0324
   Chao CH, 2006, CANCER RES, V66, P6579, DOI 10.1158/0008-5472.CAN-05-2415
   Chen CJ, 2004, J IMMUNOL, V172, P3544, DOI 10.4049/jimmunol.172.6.3544
   D'Agostino L, 2010, CELL CYCLE, V9, P1131, DOI 10.4161/cc.9.6.10991
   Dai P, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17010069
   Dai WJ, 2012, NUCLEIC ACIDS RES, V40, P787, DOI 10.1093/nar/gkr783
   DANSKYULLMANN C, 1995, CYTOKINE, V7, P118, DOI 10.1006/cyto.1995.1016
   Dery KJ, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-64
   Dery KJ, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.204057
   Fitzgerald KA, 2003, J EXP MED, V198, P1043, DOI 10.1084/jem.20031023
   Gaur S, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-46
   Gencheva M, 2010, BMC MOL BIOL, V11, DOI 10.1186/1471-2199-11-79
   Goehe RW, 2010, J CLIN INVEST, V120, P3923, DOI 10.1172/JCI43552
   Gray-Owen SD, 2006, NAT REV IMMUNOL, V6, P433, DOI 10.1038/nri1864
   Hillebrand F, 2017, BBA-GENE REGUL MECH, V1860, P205, DOI 10.1016/j.bbagrm.2016.12.001
   Hu SE, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0182771
   Huang Y, 2012, MOL CELL, V45, P459, DOI 10.1016/j.molcel.2011.12.022
   Huber M, 1999, J BIOL CHEM, V274, P335, DOI 10.1074/jbc.274.1.335
   Hung LH, 2008, RNA, V14, P284, DOI 10.1261/rna.725208
   Jiang HW, 2015, GENET MOL RES, V14, P10273, DOI 10.4238/2015.August.28.12
   Jurica MS, 2003, MOL CELL, V12, P5, DOI 10.1016/S1097-2765(03)00270-3
   Kammerer R, 1998, EUR J IMMUNOL, V28, P3664, DOI 10.1002/(SICI)1521-4141(199811)28:11<3664::AID-IMMU3664>3.0.CO;2-D
   Kent WJ, 2002, GENOME RES, V12, P996, DOI 10.1101/gr.229102
   Kirshner J, 2003, P NATL ACAD SCI USA, V100, P521, DOI 10.1073/pnas.232711199
   KLINGELHUTZ AJ, 1993, ONCOGENE, V8, P95
   Koren R, 2003, BREAST CANCER RES TR, V80, P215, DOI 10.1023/A:1024581508474
   Lai MC, 1999, J BIOL CHEM, V274, P11832, DOI 10.1074/jbc.274.17.11832
   Li JP, 2012, J PROTEOMICS, V75, P2879, DOI 10.1016/j.jprot.2011.12.040
   Liu C, 2016, ONCOTARGET, V7, P71556, DOI 10.18632/oncotarget.12253
   Lu RZ, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002597
   Lu RZ, 2011, J BIOL CHEM, V286, P27528, DOI 10.1074/jbc.M111.235762
   Luco RF, 2011, CELL, V144, P16, DOI 10.1016/j.cell.2010.11.056
   Luco RF, 2010, SCIENCE, V327, P996, DOI 10.1126/science.1184208
   Luo CL, 2017, CANCER RES, V77, P1168, DOI 10.1158/0008-5472.CAN-16-1919
   Marié I, 1998, EMBO J, V17, P6660, DOI 10.1093/emboj/17.22.6660
   Mayeda A, 1998, RNA, V4, P1111, DOI 10.1017/S135583829898089X
   Morales VM, 1999, J IMMUNOL, V163, P1363
   Muñoz MJ, 2010, TRENDS BIOCHEM SCI, V35, P497, DOI 10.1016/j.tibs.2010.03.010
   NAJJAR SM, 1993, J BIOL CHEM, V268, P1201
   Nishiyama A, 2016, J BIOCHEM, V159, P9, DOI 10.1093/jb/mvv113
   NOLL M, 1974, NATURE, V251, P249, DOI 10.1038/251249a0
   Nyati KK, 2017, NUCLEIC ACIDS RES, V45, P2687, DOI 10.1093/nar/gkx064
   Robertson KD, 2002, ONCOGENE, V21, P5361, DOI 10.1038/sj.onc.1205609
   Rogelj B., 2011, RNA Binding Proteins, P1
   Rosonina E, 2004, RNA, V10, P581, DOI 10.1261/rna.5207204
   Rossbach O, 2009, MOL CELL BIOL, V29, P1442, DOI 10.1128/MCB.01689-08
   Ruan K, 2015, SCI REP-UK, V5, DOI 10.1038/srep12720
   Ruggiero T, 2003, NUCLEIC ACIDS RES, V31, P6561, DOI 10.1093/nar/gkg858
   Shankarling G, 2013, BIOCHEM J, V453, P271, DOI 10.1042/BJ20130432
   Shingler V, 1996, MOL MICROBIOL, V19, P409, DOI 10.1046/j.1365-2958.1996.388920.x
   Simon JM, 2014, GENOME RES, V24, P241, DOI 10.1101/gr.158253.113
   Singer BB, 2000, CANCER RES, V60, P1236
   TAKAHASHI H, 1993, CANCER RES, V53, P1612
   Topp JD, 2008, RNA, V14, P2038, DOI 10.1261/rna.1212008
   Tsompana M, 2014, EPIGENET CHROMATIN, V7, DOI 10.1186/1756-8935-7-33
   TURLEY H, 1995, CANCER RES, V55, P5628
   Vitenshtein A, 2016, CELL REP, V15, P2331, DOI 10.1016/j.celrep.2016.05.036
   Wang Y, 2014, CANCER CELL, V26, P374, DOI 10.1016/j.ccr.2014.07.010
   Yabas M, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17010003
   Yang CC, 2015, ACTA BIOCH BIOPH SIN, V47, P788, DOI 10.1093/abbs/gmv075
   Yim JH, 2003, J INTERF CYTOK RES, V23, P501, DOI 10.1089/10799900360708623
   Yuan W, 2009, J BIOL CHEM, V284, P15701, DOI 10.1074/jbc.M808431200
   Zerbino DR, 2018, NUCLEIC ACIDS RES, V46, pD754, DOI 10.1093/nar/gkx1098
   Zhou XM, 2017, ONCOTARGET, V8, P19342, DOI 10.18632/oncotarget.14258
   Zhou ZL, 2002, NATURE, V419, P182, DOI 10.1038/nature01031
NR 69
TC 15
Z9 16
U1 0
U2 10
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI ROCKVILLE
PA 11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES
SN 0021-9258
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD JUN 15
PY 2018
VL 293
IS 24
BP 9277
EP 9291
DI 10.1074/jbc.RA117.001507
PG 15
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA GJ5SA
UT WOS:000435441400014
PM 29720400
OA Green Published
DA 2025-01-12
ER

PT J
AU Farman, FU
   Haq, F
   Muhammad, N
   Ali, N
   Rahman, H
   Saeed, M
AF Farman, Farman Ullah
   Haq, Farhan
   Muhammad, Noor
   Ali, Nawab
   Rahman, Hazir
   Saeed, Muhammad
TI Aberrant promoter methylation status is associated with upregulation of
   the E2F4 gene in breast cancer
SO ONCOLOGY LETTERS
LA English
DT Article
DE breast neoplasms; E2F4 transcription factor; promoter methylation; MSP
ID TUMOR-SUPPRESSOR; PROGENITOR CELLS; TRANSCRIPTION; EXPRESSION; MUTATION;
   MARKERS; FAMILY; MEMBER
AB E2F4 is an important basal transcription factor with the potential to promote tumor growth. Its upregulation in various types of cancer has been linked to numerous genetic factors; however, the nature of the involvement of epigenetic mechanisms, including DNA methylation, remains elusive. In the present study, E2F4 expression profiles were determined in 100 paired breast tumor and control samples, through RT-qPCR using the SYBR (R) green method. Furthermore, the E2F4 promoter methylation status in each of these samples was assessed using methylation specific PCR, in order to evaluate its impact on gene expression. A two-fold increase in E2F4 gene expression was observed in the breast tumors compared with in their respective controls ( P=0.022); of these tumors, similar to 72% were under-methylated. The change in methylation status was also significantly higher (P<0.001) in the tumor samples. Methylation status was negatively correlated (r=-30) with E2F4 expression profiles, indicating that a decrease in methylation may promote higher expression of E2F4. The two study cohorts (>45 and <= 45 years) had comparable methylation profiles, though they had significantly decreased methylation status compared with controls. Various histo-pathological types also have different methylation profiles, indicating the presence of a tissue specific methylation signature. The results of the present study demonstrated that E2F4 methylation status can have a notable influence on its expression, and that it may have prognostic value in breast carcinogenesis.
C1 [Farman, Farman Ullah; Haq, Farhan; Saeed, Muhammad] COMSATS Inst Informat Technol, Canc Genet & Epigenet Lab, Dept Biosci, Pk Rd, Islamabad 45550, Pakistan.
   [Muhammad, Noor; Ali, Nawab] Kohat Univ Sci & Technol, Dept Biotechnol & Genet Engn, Kohat 26000, Pakistan.
   [Rahman, Hazir] Abdul Wali Khan Univ Mardan, Dept Microbiol, Khyber Pakhtunkhwa 23200, Pakistan.
C3 COMSATS University Islamabad (CUI); Kohat University of Science &
   Technology
RP Saeed, M (通讯作者)，COMSATS Inst Informat Technol, Canc Genet & Epigenet Lab, Dept Biosci, Pk Rd, Islamabad 45550, Pakistan.
EM muhammad.saeed@comsats.edu.pk
RI Muhammad, Noor/GYD-7914-2022; Rahman, Hazir/Q-8976-2019; /I-1343-2018;
   Haq, Farhan/Q-3067-2017
OI Haq, Farhan/0000-0001-9190-4360; Ali, Nawab/0000-0002-4651-9946
CR Ali A, 2016, J BREAST CANCER, V19, P133, DOI 10.4048/jbc.2016.19.2.133
   Almén MS, 2014, GENE, V548, P61, DOI 10.1016/j.gene.2014.07.009
   BANDARA LR, 1993, EMBO J, V12, P4317, DOI 10.1002/j.1460-2075.1993.tb06116.x
   Baxter E, 2014, CELL BIOSCI, V4, DOI 10.1186/2045-3701-4-45
   BEIJERSBERGEN RL, 1994, GENE DEV, V8, P2680, DOI 10.1101/gad.8.22.2680
   Bertoli C, 2013, NAT REV MOL CELL BIO, V14, P518, DOI 10.1038/nrm3629
   Chen HZ, 2009, NAT REV CANCER, V9, P785, DOI 10.1038/nrc2696
   Chong JL, 2009, NATURE, V462, P930, DOI 10.1038/nature08677
   Crijns APG, 2009, PLOS MED, V6, P181, DOI 10.1371/journal.pmed.1000024
   Crosby ME, 2007, ONCOGENE, V26, P1897, DOI 10.1038/sj.onc.1209998
   Enos ME, 2008, J IMMUNOL, V180, P3699, DOI 10.4049/jimmunol.180.6.3699
   Fearon ER, 2011, ANNU REV PATHOL-MECH, V6, P479, DOI 10.1146/annurev-pathol-011110-130235
   Fuchs B, 2001, GENE, V278, P245, DOI 10.1016/S0378-1119(01)00731-4
   GINSBERG D, 1994, GENE DEV, V8, P2665, DOI 10.1101/gad.8.22.2665
   Jin BL, 2013, ADV EXP MED BIOL, V754, P3, DOI 10.1007/978-1-4419-9967-2_1
   Khaleel SS, 2014, BREAST CANCER RES, V16, DOI 10.1186/s13058-014-0486-7
   Kim Eunyoung, 2005, Journal of Pathology and Translational Medicine, V39, P301
   Lassmann S, 2007, J MOL MED-JMM, V85, P289, DOI 10.1007/s00109-006-0126-5
   Le Cam L, 1999, EMBO J, V18, P1878, DOI 10.1093/emboj/18.7.1878
   Lee BK, 2011, NUCLEIC ACIDS RES, V39, P3558, DOI 10.1093/nar/gkq1313
   Lee EY, 2002, CANCER CELL, V2, P463, DOI 10.1016/S1535-6108(02)00207-6
   Lee JTY., 2011, J BIOMATERIALS NANOB, V2, P41, DOI [10.4236/jbnb.2011.21006, DOI 10.4236/JBNB.2011.21006]
   Lee TA, 2000, ONCOGENE, V19, P2257, DOI 10.1038/sj.onc.1203556
   Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Ma YH, 2004, CANCER BIOL THER, V3, P1262, DOI 10.4161/cbt.3.12.1239
   Mott JL, 2009, HEPATOLOGY, V50, P630, DOI 10.1002/hep.23010
   NEVINS JR, 1992, SCIENCE, V258, P424
   Ng JMK, 2015, INT J MOL SCI, V16, P2472, DOI 10.3390/ijms16022472
   Popov B, 2005, BIOCHEM BIOPH RES CO, V336, P762, DOI 10.1016/j.bbrc.2005.08.163
   Sabir M, 2014, CELL ONCOL, V37, P203, DOI 10.1007/s13402-014-0173-9
   Schwemmle S, 2000, INT J CANCER, V86, P672, DOI 10.1002/(SICI)1097-0215(20000601)86:5<672::AID-IJC11>3.0.CO;2-X
   Sharma S, 2010, CARCINOGENESIS, V31, P27, DOI 10.1093/carcin/bgp220
   Souza RF, 1997, CANCER RES, V57, P2350
   Strauss WM., 2001, CURR PROTOC MOL BIOL
   Ullah F, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134687
   Wang DW, 2000, MOL CELL BIOL, V20, P3417, DOI 10.1128/MCB.20.10.3417-3424.2000
   Wang YM, 2006, METHODS, V39, P356, DOI 10.1016/j.ymeth.2006.06.010
   Zhang XT, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116979
   Zhu WG, 2003, MOL CELL BIOL, V23, P4056, DOI 10.1128/MCB.23.12.4056-4065.2003
NR 40
TC 5
Z9 6
U1 0
U2 3
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1792-1074
EI 1792-1082
J9 ONCOL LETT
JI Oncol. Lett.
PD JUN
PY 2018
VL 15
IS 6
BP 8461
EP 8469
DI 10.3892/ol.2018.8382
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA GJ3BK
UT WOS:000435149700036
PM 29805583
OA Green Submitted, Green Published, gold
DA 2025-01-12
ER

PT J
AU Rahimian, A
   Barati, G
   Mehrandish, R
   Mellati, AA
AF Rahimian, A.
   Barati, G.
   Mehrandish, R.
   Mellati, A. A.
TI Inhibition of Histone Deacetylases Reverses Epithelial-Mesenchymal
   Transition in Triple-Negative Breast Cancer Cells through a Slug
   Mediated Mechanism
SO MOLECULAR BIOLOGY
LA English
DT Article
DE breast cancer; metastasis; E-cadherin; cell invasion; Slug;
   epithelial-mesenchymal transition; histone deacetylases
ID TRANSCRIPTION FACTOR SLUG; PROSTATE-CANCER; COLORECTAL-CANCER;
   EXPRESSION; METASTASIS; SUPPRESSES; CARCINOMA; DISEASE; SNAIL; LUNG
AB High metastatic ability and poor clinical outcome are the most known clinical features of the triple- negative breast tumors. Given that the tumor cells undergoing epithelial-mesenchymal transition (EMT) often gain malignant and invasive features, we have investigated the possibility of EMT reversal in triple-negative breast cancer cells by targeting the epigenetic-modifying enzymatic complexes named histone deacetylases (HDACs) and examined the possible mechanism underlying the HDACs-based inversion in model MDA-MB-231 cells. Cells were treated with a maximal tolerable 200 nM concentrations of classical HDACs inhibitor Trichostatin A (TSA) for 48 h and afterwards the invasiveness and immigration of the cells were evaluated in TransWell Invasion Scratch Wound Healing assays. Then, in treated and control cells, quantitative real time-PCRreacions were performed for assessing the gene expression of EMT biomarkers E-cadherin, Vimentin and transcriptional factor Slug. After TSA treatment, the invasion and migration properties MDAMB- 231 cells significantly decreased, gene expression of E-cadherin was significantly up-regulated, while the levels of Slug and Vimentin encoding mRNAs were suppressed. We conclude that inhibition of HDACs in triple- negative breast cancer cells may lead to inversion of EMT and the decrease of invasiveness by down-regulating the gene expression of Slug. Since EMT is known as a pre-metastatic process, triple-negative breast tumors, the EMT reversal effects of HDACs inhibition may reduce tumor cell metastasis.
C1 [Rahimian, A.; Mehrandish, R.; Mellati, A. A.] Zanjan Univ Med Sci, Sch Med, Dept Biochem, Zanjan, Iran.
   [Barati, G.] Zanjan Univ Med Sci, Sch Med, Dept Med Biotechnol & Nanotechnol, Zanjan, Iran.
RP Mellati, AA (通讯作者)，Zanjan Univ Med Sci, Sch Med, Dept Biochem, Zanjan, Iran.
EM Mellati3000@yahoo.com
RI Barati, Ghasem/AAD-3540-2020
OI Rahimian, Aliasghar/0000-0003-2423-1455
FU Zanjan University of Medical Sciences
FX This research was based on an MSc thesis and funded by the Zanjan
   University of Medical Sciences.
CR Bolós V, 2003, J CELL SCI, V116, P499, DOI 10.1242/jcs.00224
   Brunyen A., 2016, MANAGEMENT BREAST DI, P125
   Chikina AS, 2014, MOL BIOL+, V48, P165, DOI 10.1134/S0026893314020046
   CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2
   Ferlay J, 2010, BREAST CANCER EPIDEMIOLOGY, P1, DOI 10.1007/978-1-4419-0685-4_1
   FRANKE WW, 1978, P NATL ACAD SCI USA, V75, P5034, DOI 10.1073/pnas.75.10.5034
   Haberland M, 2009, NAT REV GENET, V10, P32, DOI 10.1038/nrg2485
   Hasan MR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082846
   Jing YF, 2014, CANCER LETT, V348, P135, DOI 10.1016/j.canlet.2014.03.018
   Kaimori A, 2010, HEPATOLOGY, V52, P1033, DOI 10.1002/hep.23765
   Kalluri R, 2003, J CLIN INVEST, V112, P1776, DOI 10.1172/JCI200320530
   Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104
   Kovacs EM, 2002, J BIOL CHEM, V277, P6708, DOI 10.1074/jbc.M109640200
   Li Y, 2014, CANCER LETT, V355, P130, DOI 10.1016/j.canlet.2014.09.007
   Liu YN, 2012, MOL CELL BIOL, V32, P941, DOI 10.1128/MCB.06306-11
   Mason SD, 2011, TRENDS CELL BIOL, V21, P228, DOI 10.1016/j.tcb.2010.12.002
   Minamiya Y, 2011, LUNG CANCER, V74, P300, DOI 10.1016/j.lungcan.2011.02.019
   Peinado H, 2004, MOL CELL BIOL, V24, P306, DOI 10.1128/MCB.24.1.306-319.2004
   Rikimaru T, 2007, ONCOLOGY-BASEL, V72, P69, DOI 10.1159/000111106
   Shih JY, 2011, CARCINOGENESIS, V32, P1299, DOI 10.1093/carcin/bgr110
   Tang YL, 2010, J ORAL PATHOL MED, V39, P775, DOI 10.1111/j.1600-0714.2010.00913.x
   Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007
   Vuoriluoto K, 2011, ONCOGENE, V30, P1436, DOI 10.1038/onc.2010.509
   Wang XX, 2015, BIOCHEM BIOPH RES CO, V456, P320, DOI 10.1016/j.bbrc.2014.11.079
   Weichert W, 2008, BRIT J CANCER, V98, P604, DOI 10.1038/sj.bjc.6604199
   Weichert W, 2008, CLIN CANCER RES, V14, P1669, DOI 10.1158/1078-0432.CCR-07-0990
   West AC, 2014, J CLIN INVEST, V124, P30, DOI 10.1172/JCI69738
   Yoshikawa M, 2007, J AM SOC NEPHROL, V18, P58, DOI 10.1681/ASN.2005111187
   Zeisberg M, 2009, J CLIN INVEST, V119, P1429, DOI 10.1172/JCI36183
   Zentner GE, 2013, NAT STRUCT MOL BIOL, V20, P259, DOI 10.1038/nsmb.2470
   Zhang WY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031450
NR 31
TC 3
Z9 4
U1 0
U2 7
PU MAIK NAUKA/INTERPERIODICA/SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013-1578 USA
SN 0026-8933
EI 1608-3245
J9 MOL BIOL+
JI Mol. Biol.
PD MAY
PY 2018
VL 52
IS 3
BP 406
EP 413
DI 10.1134/S0026893318030111
PG 8
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA GJ5HT
UT WOS:000435412800010
DA 2025-01-12
ER

PT J
AU Kozomara, Z
   Supic, G
   Krivokuca, A
   Magic, Z
   Dzodic, R
   Milovanovic, Z
   Brankovic-Magic, M
AF Kozomara, Zoran
   Supic, Gordana
   Krivokuca, Ana
   Magic, Zvonko
   Dzodic, Radan
   Milovanovic, Zorka
   Brankovic-Magic, Mirjana
TI Promoter hypermethylation of <i>p16</i>, <i>BRCA1</i> and <i>RASSF1A</i>
   genes in triple-negative breast cancer patients from Serbia
SO JOURNAL OF BUON
LA English
DT Article
DE breast cancer; BRCA1; epigenetic changes; hypermethylation; p16; RASSF1A
ID DNA METHYLATION; METAANALYSIS; BIOMARKERS; DISEASE
AB Purpose: In order to investigate if aberrant promoter methylation of p16, BRCA1 and RASSFIA genes contributes to biological behavior of triple-negative breast cancer (TNBC), marked as the most aggressive phenotype of breast cancer, we compared the hypermethylation pattern between TNBC and ER+PR+Her2- breast cancer.
   Methods: 131 patients with histologically confirmed breast cancers were included - 61 TNBC and 70 ER+PR+Her2- cases. The patients were followed up for 1-87 months (median 78). DNA from tumor tissues was isolated by the salting out procedure. The methylation status was assessed by nested methylation-specific PCR after bisulfite modification of DNA.
   Results: The frequency of p16 hypermethylated breast cancer cases was significantly higher in TNBC than in ER+PR+Her2- group (33; 54.1% vs. 20; 28.6%, p=0.00298). Co-methylated p16 and RASSF1A genes were more frequent in the TNBC than in ER+PR+Her2- group (20; 32.8% vs. 10; 14.3%, p=0.0225). The same result was observed when hypermethylated BRCA1 gene was added in the analysis: 12; 19.7% vs. 3; 4.3%, p=0.00791. Although there was significant difference in disease-free survival (DFS) and overall survival (OS) between TNBC and ER+PR+Her2- group, further analysis of co-methylation of pI6 and RASSF1A (p16+RASSF1A+) showed that DFS was significantly shorter in the patients with both genes co-methylated in TNBC than in ER+PR+Her-2- group (8/20; 40% vs. 2/10; 20%, p=0.03272).
   Conclusions: The obtained data indicate that hypermethylated p16 and RASSF1A cell-cycle inhibitor genes might be considered as biomarkers for bad prognosis in breast cancer. Hypermethylation of these genes may influence the clinical disease course, distinguishing a particular group of TNBC patients with even more aggressive phenotype.
C1 [Kozomara, Zoran; Krivokuca, Ana; Dzodic, Radan; Milovanovic, Zorka; Brankovic-Magic, Mirjana] Inst Oncol & Radiol Serbia, Pasterova 14, Belgrade 11000, Serbia.
   [Supic, Gordana; Magic, Zvonko] Mil Med Acad, Inst Med Res, Belgrade, Serbia.
   [Supic, Gordana; Magic, Zvonko] Univ Def, Mil Med Acad, Sch Med, Belgrade, Serbia.
   [Dzodic, Radan] Univ Belgrade, Sch Med, Belgrade, Serbia.
C3 Institute for Oncology & Radiology of Serbia (IORS); University of
   Belgrade; University of Belgrade
RP Brankovic-Magic, M (通讯作者)，Inst Oncol & Radiol Serbia, Pasterova 14, Belgrade 11000, Serbia.
EM brankovicm@ncrc.ac.rs
RI Supic, Gordana/GSN-3402-2022
OI Supic, Gordana/0000-0003-0350-4733; Kozomara, Zoran/0000-0003-2977-4037
FU Ministry of Education, Science and Technological Development of Serbia
   [MFMMA/11/16-18, 41026]
FX This work was done as part of the research project "Pharmacodynamic and
   Pharmacogenomic Investigations of New Drugs in the Treatment of Solid
   Tumors" No. 41026, and the research project "Significance of Genetic and
   Epigenetic Changes in Prognosis, Prediction and Risk for Solid Tumor
   Development (MFMMA/11/16-18)." No 41026 of Ministry of Education,
   Science and Technological Development of Serbia.
CR Ballinger T, 2016, EUROPEAN ONCOL HAEMA, V12, P112
   Basse C, 2015, INT J CANCER, V137, P2785, DOI 10.1002/ijc.29347
   Bediaga NG, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2721
   Belinsky SA, 2002, CANCER RES, V62, P2370
   Bentzon N, 2008, INT J CANCER, V122, P1089, DOI 10.1002/ijc.22892
   Carey L, 2010, NAT REV CLIN ONCOL, V7, P683, DOI 10.1038/nrclinonc.2010.154
   Dworkin AM, 2009, SEMIN CANCER BIOL, V19, P165, DOI 10.1016/j.semcancer.2009.02.007
   Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075
   Holm K, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2590
   Jamdade VS, 2015, BRIT J PHARMACOL, V172, P4228, DOI 10.1111/bph.13211
   Jiang Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036780
   Jitariu AA, 2017, ONCOTARGET, V8, P46652, DOI 10.18632/oncotarget.16938
   Klajic J, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-456
   Lee JJ, 2012, KOREAN J PATHOL, V46, P554
   Lin SY, 2013, J BUON, V18, P891
   Lips EH, 2013, BRIT J CANCER, V108, P2172, DOI 10.1038/bjc.2013.144
   Roll JD, 2013, EXP MOL PATHOL, V95, P276, DOI 10.1016/j.yexmp.2013.09.001
   Sheng XN, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000007476
   Spitzwieser M, 2015, BREAST CANCER RES, V17, DOI 10.1186/s13058-015-0637-5
   Supic G, 2011, ORAL ONCOL, V47, P702, DOI 10.1016/j.oraloncology.2011.05.014
   Tollefsbol T., 2009, Cancer Epigenetics
   Wang L, 2012, MOL MED REP, V6, P904, DOI 10.3892/mmr.2012.1001
   Widschwendter M, 2002, ONCOGENE, V21, P5462, DOI 10.1038/sj.onc.1205606
   Wu L, 2013, BREAST CANCER RES TR, V142, P619, DOI 10.1007/s10549-013-2774-9
   Yang X, 2001, ENDOCR-RELAT CANCER, V8, P115, DOI 10.1677/erc.0.0080115
   Zhu X, 2015, BREAST CANCER RES TR, V150, P479, DOI 10.1007/s10549-015-3338-y
NR 26
TC 10
Z9 13
U1 0
U2 2
PU IMPRIMATUR PUBLICATIONS
PI ATHENS
PA 30 DEM POLIORKETES ST, ATHENS, 136 76, GREECE
SN 1107-0625
EI 2241-6293
J9 J BUON
JI J. BUON
PD MAY-JUN
PY 2018
VL 23
IS 3
BP 684
EP 691
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA GJ3BZ
UT WOS:000435151300022
PM 30003738
DA 2025-01-12
ER

PT J
AU Sundaram, MK
   Ansari, MZ
   Al Mutery, A
   Ashraf, M
   Nasab, R
   Rai, S
   Rais, N
   Hussain, A
AF Sundaram, Madhumitha Kedhari
   Ansari, Mohammad Zeeshan
   Al Mutery, Abdullah
   Ashraf, Maryam
   Nasab, Reem
   Rai, Sheethal
   Rais, Naushad
   Hussain, Arif
TI Genistein Induces Alterations of Epigenetic Modulatory Signatures in
   Human Cervical Cancer Cells
SO ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY
LA English
DT Article
DE DNA methyltransferases (DNMTs); histone deacetylases (HDACs); genistein;
   chemoprevention; epigenetics; methylation; tumor suppressor genes
ID TUMOR-SUPPRESSOR GENES; HISTONE DEACETYLASE INHIBITORS; DNA
   METHYLTRANSFERASE; BREAST-CANCER; EXPRESSION; DIETARY; IMPACT; DNMT1;
   EPIGENOME; THERAPY
AB Introduction: Epidemiological studies indicate that diet rich in fruits and vegetables is associated with decreased cancer risk thereby indicating that dietary polyphenols can be potential chemo-preventive agents. The reversible nature of epigenetic modifications makes them a favorable target for cancer prevention. Polyphenols have been shown to reverse aberrant epigenetic patterns by targeting the regulatory enzymes, DNA methyl-transferases (DNMTs) and histone deacetylases (HDACs). In vitro and in silico studies of DNMTs and HDACs were planned to examine genistein's role as a natural epigenetic modifier in human cervical cancer cells, HeLa.
   Methods: Expression of the tumour suppressor genes (TSGs) [MGMT, RAR beta, p21, E-cadherin, DAPK1] as well the methylation status of their promoters were examined along with the activity levels of DNMT and HDAC enzymes after treatment with genistein. Expression of DNMTs and HDACs was also studied. In-silico studies were performed to determine the interaction of genistein with DNMTs and HDACs.
   Results: Genistein treatment significantly reduced the expression and enzymatic activity of both DNMTs and HDACs in a time-dependent way. Molecular modeling data suggest that genistein can interact with various members of DNMT and HDAC families and support genistein mediated inhibition of their activity. Time-dependent exposure of genistein reversed the promoter region methylation of the TSGs and re-established their expression.
   Conclusions: In this study, we find that genistein is able to reinstate the expression of the TSGs studied by inhibiting the action of DNMTs and HDACs. This shows that genistein could be an important arsenal in the development of epigenetic based cancer therapy.
C1 [Sundaram, Madhumitha Kedhari; Ansari, Mohammad Zeeshan; Ashraf, Maryam; Nasab, Reem; Rai, Sheethal; Rais, Naushad; Hussain, Arif] Manipal Univ, Sch Life Sci, Dubai, U Arab Emirates.
   [Al Mutery, Abdullah] Univ Sharjah, Dept Appl Biol, Sharjah, U Arab Emirates.
C3 University of Sharjah
RP Hussain, A (通讯作者)，Manipal Univ, Sch Life Sci, Dubai, U Arab Emirates.
EM dr.arifhussain@yahoo.co.in
RI Kedhari Sundaram, Madhumitha/ABC-6223-2021; Hussain, Arif/H-6286-2018
OI Hussain, Arif/0000-0002-0851-4845; Kedhari Sundaram,
   Madhumitha/0000-0002-5717-1789
FU Manipal University, Dubai, UAE [R&DP/MUD/RL-41/2016]; Dunia Finance
FX This work was financially supported by internal research grant (Grant
   No: R&DP/MUD/RL-41/2016) Manipal University, Dubai, UAE. This work was
   supported by Dunia Finance though award of scholarship to Ms. Madhumitha
   Kedhari Sundaram. The funding body had no role in the design of the
   study, collection, analysis, and interpretation of data and in writing
   the manuscript.
CR Ali Khan M., 2015, EVID BASED COMP ALTE, V2015, P412
   Apweiler R, 2004, NUCLEIC ACIDS RES, V32, pD115, DOI [10.1093/nar/gkw1099, 10.1093/nar/gkh131]
   Bahnassy AA, 2012, EXP MOL PATHOL, V93, P154, DOI 10.1016/j.yexmp.2012.04.001
   Banerjee S, 2008, CANCER LETT, V269, P226, DOI 10.1016/j.canlet.2008.03.052
   Bottomley MJ, 2008, J BIOL CHEM, V283, P26694, DOI 10.1074/jbc.M803514200
   Brown KD, 2007, NAT GENET, V39, P289, DOI 10.1038/ng0307-289
   Bürli RW, 2013, J MED CHEM, V56, P9934, DOI 10.1021/jm4011884
   Chang LC, 2016, BIOMEDICINE-TAIWAN, V6, P9, DOI 10.7603/s40681-016-0002-8
   Chen J, 2010, ADV GENET, V71, P237, DOI [10.1016/S0065-2660(10)71009-9, 10.1016/B978-0-12-380864-6.00008-0]
   Chen TP, 2007, NAT GENET, V39, P391, DOI 10.1038/ng1982
   Chi P, 2010, NAT REV CANCER, V10, P457, DOI 10.1038/nrc2876
   Chik F, 2011, CARCINOGENESIS, V32, P224, DOI 10.1093/carcin/bgq221
   Coronel J, 2011, MED ONCOL, V28, pS540, DOI 10.1007/s12032-010-9700-3
   Dashwood RH, 2007, SEMIN CANCER BIOL, V17, P363, DOI 10.1016/j.semcancer.2007.04.001
   Dhe-Paganon Sirano, 2011, Int J Biochem Mol Biol, V2, P58
   Dundas J, 2006, NUCLEIC ACIDS RES, V34, pW116, DOI 10.1093/nar/gkl282
   Esteller M, 2000, CANCER RES, V60, P2368
   Fischle W, 2002, MOL CELL, V9, P45, DOI 10.1016/S1097-2765(01)00429-4
   Füllgrabe J, 2011, ONCOGENE, V30, P3391, DOI 10.1038/onc.2011.121
   Gerhauser C, 2013, TOP CURR CHEM, V329, P73, DOI 10.1007/128_2012_360
   Go JH, 2003, MODERN PATHOL, V16, P752, DOI 10.1097/01.MP.0000081728.21368.85
   Griffiths EA, 2008, SEMIN HEMATOL, V45, P23, DOI 10.1053/j.seminhematol.2007.11.007
   Grosdidier A, 2011, NUCLEIC ACIDS RES, V39, pW270, DOI 10.1093/nar/gkr366
   Hardy TM, 2011, EPIGENOMICS-UK, V3, P503, DOI [10.2217/EPI.11.71, 10.2217/epi.11.71]
   Hashimoto H., STRUCTURE HUMAN DNMT
   Hattori N, 2016, GENOME MED, V8, DOI 10.1186/s13073-016-0267-2
   He F.-J., 2013, Food Science and Human Wellness, V2, P146, DOI DOI 10.1016/J.FSHW.2013.08.002
   Henning SM, 2013, EPIGENOMICS-UK, V5, P729, DOI 10.2217/epi.13.57
   Hussain A, 2012, CANCER EPIDEMIOL, V36, pE387, DOI 10.1016/j.canep.2012.07.005
   Irwin JJ, 2012, J CHEM INF MODEL, V52, P1757, DOI 10.1021/ci3001277
   Jakob J, 2012, RADIAT ONCOL, V7, DOI 10.1186/1748-717X-7-180
   Jia D, 2007, NATURE, V449, P248, DOI 10.1038/nature06146
   Johnson TL, 2010, EVID-BASED COMPL ALT, V7, P351, DOI 10.1093/ecam/nen011
   Kanherkar RR, 2014, FRONT CELL DEV BIOL, V2, DOI 10.3389/fcell.2014.00049
   Khan MA, 2015, ONCOL REP, V33, P1976, DOI 10.3892/or.2015.3802
   Khan S, 2016, EXPERT OPIN THER TAR, V20, P689, DOI 10.1517/14728222.2016.1132702
   Kovacs JJ, 2005, MOL CELL, V18, P601, DOI 10.1016/j.molcel.2005.04.021
   Krusche CA, 2005, BREAST CANCER RES TR, V90, P15, DOI 10.1007/s10549-004-1668-2
   Kuck D, 2010, MOL CANCER THER, V9, P3015, DOI 10.1158/1535-7163.MCT-10-0609
   Lauffer BEL, 2013, J BIOL CHEM, V288, P26926, DOI 10.1074/jbc.M113.490706
   Li Y, 2010, CURR MED CHEM, V17, P2141, DOI 10.2174/092986710791299966
   Link A, 2010, BIOCHEM PHARMACOL, V80, P1771, DOI 10.1016/j.bcp.2010.06.036
   Liu YH, 2014, NEUROCHEM RES, V39, P2105, DOI 10.1007/s11064-014-1401-4
   Majid S, 2008, CANCER RES, V68, P2736, DOI 10.1158/0008-5472.CAN-07-2290
   Min J. R., PDB ID 2NVR
   Minamiya Y, 2011, LUNG CANCER, V74, P300, DOI 10.1016/j.lungcan.2011.02.019
   Moison C, 2014, EPIGENETICS-US, V9, P477, DOI 10.4161/epi.27869
   Mottet D, 2009, ONCOGENE, V28, P243, DOI 10.1038/onc.2008.371
   Mutze K, 2011, EUR J CANCER, V47, P1817, DOI 10.1016/j.ejca.2011.02.024
   Narayan Gopeshwar, 2003, Mol Cancer, V2, P24, DOI 10.1186/1476-4598-2-24
   Oehme I, 2009, CLIN CANCER RES, V15, P91, DOI 10.1158/1078-0432.CCR-08-0684
   Ong TP, 2011, J NUTRIGENET NUTRIGE, V4, P275, DOI 10.1159/000334585
   Ouaïssi M, 2008, CANCER BIOL THER, V7, P523, DOI 10.4161/cbt.7.4.5480
   Özdag H, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-90
   Park SY, 2011, ONCOL REP, V25, P1677, DOI 10.3892/or.2011.1236
   Pathania R, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7910
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   Portela A, 2010, NAT BIOTECHNOL, V28, P1057, DOI 10.1038/nbt.1685
   Pradhan M, 2008, BIOCHEMISTRY-US, V47, P10000, DOI 10.1021/bi8011725
   Rajendran G, 2011, J NEURO-ONCOL, V104, P483, DOI 10.1007/s11060-010-0520-2
   Recio MC, 2012, CURR MED CHEM, V19, P2088
   Shanmugam MK, 2011, NUTR CANCER, V63, P161, DOI 10.1080/01635581.2011.523502
   Sharma S, 2010, CARCINOGENESIS, V31, P27, DOI 10.1093/carcin/bgp220
   Somoza JR, 2004, STRUCTURE, V12, P1325, DOI 10.1016/j.str.2004.04.012
   Subramaniam D, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00080
   Sun JB, 2015, INT J CLIN EXP PATHO, V8, P4755
   Taby R, 2010, CA-CANCER J CLIN, V60, P376, DOI 10.3322/caac.20085
   Unterberger A, 2008, BIOL PROCED ONLINE, V10, P47, DOI 10.1251/bpo142
   Varier RA, 2011, BBA-REV CANCER, V1815, P75, DOI 10.1016/j.bbcan.2010.10.002
   Vassiliou GS, 2006, HAEMATOLOGICA, V91, P1100
   Wang ZG, 2010, ANTICANCER RES, V30, P4537
   Watson PJ, 2012, NATURE, V481, P335, DOI 10.1038/nature10728
   Weichert W, 2008, CLIN CANCER RES, V14, P1669, DOI 10.1158/1078-0432.CCR-07-0990
   Wen YD, 2000, P NATL ACAD SCI USA, V97, P7202, DOI 10.1073/pnas.97.13.7202
   Zhang FL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016795
   Zhang JS, 2002, MOL CELL, V9, P611, DOI 10.1016/S1097-2765(02)00468-9
   Zhang YK, 2011, EPIGENETICS-US, V6, P888, DOI 10.4161/epi.6.7.16315
NR 77
TC 47
Z9 50
U1 0
U2 5
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1871-5206
EI 1875-5992
J9 ANTI-CANCER AGENT ME
JI Anti-Cancer Agents Med. Chem.
PY 2018
VL 18
IS 3
BP 412
EP 421
DI 10.2174/1871520617666170918142114
PG 10
WC Oncology; Chemistry, Medicinal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Pharmacology & Pharmacy
GA GJ0UF
UT WOS:000434969100010
PM 28925878
DA 2025-01-12
ER

PT J
AU Koval, A
   Katanaev, VL
AF Koval, Alexey
   Katanaev, Vladimir L.
TI Dramatic dysbalancing of the Wnt pathway in breast cancers
SO SCIENTIFIC REPORTS
LA English
DT Article
ID COEXPRESSION NETWORK ANALYSIS; MAMMARY-GLAND DEVELOPMENT; GENE
   COEXPRESSION; SIGNALING PATHWAY; ANALYSIS REVEALS; UP-REGULATION;
   EXPRESSION; PROTEIN; PROGRESSION; PROGNOSIS
AB Wnt signaling is important for breast development and remodeling during pregnancy and lactation. Epigenetic modifications change expression levels of components of the Wnt pathway, underlying oncogenic transformation. However, no clear Wnt component increasing expression universally across breast cancer (BC) or its most Wnt-dependent triple-negative BC (TNBC) subgroup has been identified, delaying development of targeted therapies. Here we perform network correlation analysis of expression of >100 Wnt pathway components in hundreds of healthy and cancerous breast tissues. Varying in expression levels among people, Wnt components remarkably coordinate their production; this coordination is dramatically decreased in BC. Clusters with coordinated gene expression exist within the healthy cohort, highlighting Wnt signaling subtypes. Different BC subgroups are identified, characterized by different remaining Wnt signaling signatures, providing the rational for patient stratification for personalizing the therapeutic applications. Key pairwise interactions within the Wnt pathway (some inherited and some established de novo) emerge as targets for future drug discovery against BC.
C1 [Koval, Alexey; Katanaev, Vladimir L.] Univ Lausanne, Fac Biol & Med, Dept Pharmacol & Toxicol, CH-1011 Lausanne, Switzerland.
   [Katanaev, Vladimir L.] Far Eastern Fed Univ, Sch Biomed, Vladivostok, Russia.
C3 University of Lausanne; Far Eastern Federal University
RP Katanaev, VL (通讯作者)，Univ Lausanne, Fac Biol & Med, Dept Pharmacol & Toxicol, CH-1011 Lausanne, Switzerland.; Katanaev, VL (通讯作者)，Far Eastern Fed Univ, Sch Biomed, Vladivostok, Russia.
EM Vladimir.katanaev@unil.ch
RI Koval, Alexey/AAU-4766-2020; Katanaev, Vladimir/F-9480-2014; Koval,
   Alexey/IAP-2281-2023
OI Katanaev, Vladimir/0000-0002-7909-5617; Koval,
   Alexey/0000-0002-8920-4426
FU ERA.Net RUS Plus program
FX We thank Sven Bergmann and Gonzalo Solis for critically reading the
   manuscript and fruitful discussions, and Kamal Ahmed for assistance in
   analysis of clinical data for TNBC patients. This work was supported by
   the ERA.Net RUS Plus program to VLK.
CR Anglani R, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087075
   [Anonymous], 2016, A Language and Environment for Statistical Computing
   [Anonymous], 2016, Various R Programming Tools for Plotting Data
   [Anonymous], 2024, Package 'Hmisc'
   Aran D, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9971
   Ardlie KG, 2015, SCIENCE, V348, P648, DOI 10.1126/science.1262110
   Barker N, 2006, NAT REV DRUG DISCOV, V5, P997, DOI 10.1038/nrd2154
   Benhaj K, 2006, ONCOL REP, V15, P701
   Blagodatski Artem, 2014, Mol Cell Ther, V2, P28
   Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095
   Chou WC, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-300
   Clarke C, 2013, CARCINOGENESIS, V34, P2300, DOI 10.1093/carcin/bgt208
   Clevers H, 2012, CELL, V149, P1192, DOI 10.1016/j.cell.2012.05.012
   Dijksterhuis JP, 2014, BRIT J PHARMACOL, V171, P1195, DOI 10.1111/bph.12364
   Dong Y, 2015, ONCOTARGET, V6, P22126, DOI 10.18632/oncotarget.4244
   Egger-Adam D, 2008, FRONT BIOSCI-LANDMRK, V13, P4740, DOI 10.2741/3036
   Fu C, 2009, MOL BIOSYST, V5, P1809, DOI [10.1039/b905382d, 10.1039/B905382D]
   Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2
   Grechkin M, 2016, PLOS COMPUT BIOL, V12, DOI 10.1371/journal.pcbi.1004888
   Ho KYK, 1999, HISTOPATHOLOGY, V35, P249
   Hödar C, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-348
   Ihmels J, 2005, PLOS GENET, V1, P380, DOI 10.1371/journal.pgen.0010039
   Incassati A, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2723
   Jessen JR, 2009, ZEBRAFISH, V6, P21, DOI 10.1089/zeb.2008.0571
   Jönsson M, 2002, CANCER RES, V62, P409
   Jönsson M, 2000, EUR J CANCER, V36, P242, DOI 10.1016/S0959-8049(99)00276-2
   Kandasamy K, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-1-r3
   Klopocki E, 2004, INT J ONCOL, V25, P641
   Koval A, 2011, BIOCHEM PHARMACOL, V82, P1311, DOI 10.1016/j.bcp.2011.06.005
   Lane TF, 1997, ONCOGENE, V15, P2133, DOI 10.1038/sj.onc.1201593
   Li L, 2012, GENOME RES, V22, P1222, DOI 10.1101/gr.128819.111
   Li Y, 2000, ONCOGENE, V19, P1002, DOI 10.1038/sj.onc.1203273
   Liu CC, 2010, P NATL ACAD SCI USA, V107, P5136, DOI 10.1073/pnas.0911220107
   Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126
   McGee SR, 2017, GENOM PROTEOM BIOINF, V15, P121, DOI 10.1016/j.gpb.2017.02.002
   Moasser MM, 2007, ONCOGENE, V26, P6469, DOI 10.1038/sj.onc.1210477
   Nagahata T, 2003, CANCER SCI, V94, P515, DOI 10.1111/j.1349-7006.2003.tb01475.x
   Nakamura Y, 2016, DEVELOPMENT, V143, P1914, DOI 10.1242/dev.131664
   Planutis K, 2007, BMC CELL BIOL, V8, DOI 10.1186/1471-2121-8-12
   Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303
   Tomczak Katarzyna, 2015, Contemp Oncol (Pozn), V19, pA68, DOI 10.5114/wo.2014.47136
   Turashvili G, 2006, PATHOBIOLOGY, V73, P213, DOI 10.1159/000098207
   Ugolini F, 1999, ONCOGENE, V18, P1903, DOI 10.1038/sj.onc.1202739
   Veeck J, 2008, CARCINOGENESIS, V29, P991, DOI 10.1093/carcin/bgn076
   Wang E, 2015, SEMIN CANCER BIOL, V30, P4, DOI 10.1016/j.semcancer.2014.04.002
   Wang HY, 2013, J BIOL CHEM, V288, P6478, DOI 10.1074/jbc.M112.419184
   Wicker CA, 2016, BMC GENOMICS, V17, DOI 10.1186/s12864-016-3313-y
   Wissmann C, 2003, J PATHOL, V201, P204, DOI 10.1002/path.1449
   Xiang Y, 2012, BMC BIOINFORMATICS, V13, DOI 10.1186/1471-2105-13-S2-S12
   Yang L, 2011, ONCOGENE, V30, P4437, DOI 10.1038/onc.2011.145
   Yang Y, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4231
   Yu QC, 2016, CANCERS, V8, DOI 10.3390/cancers8070065
   Zhang ZY, 2009, J MOL CELL CARDIOL, V46, P370, DOI 10.1016/j.yjmcc.2008.11.016
   Zhou ZJ, 1998, INT J CANCER, V78, P95, DOI 10.1002/(SICI)1097-0215(19980925)78:1<95::AID-IJC15>3.0.CO;2-4
NR 54
TC 59
Z9 63
U1 0
U2 11
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD MAY 9
PY 2018
VL 8
AR 7329
DI 10.1038/s41598-018-25672-6
PG 10
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA GF1ZX
UT WOS:000431737300015
PM 29743726
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU Vdovikova, S
   Gilfillan, S
   Wang, SX
   Dongre, M
   Wai, SN
   Hurtado, A
AF Vdovikova, Svitlana
   Gilfillan, Siv
   Wang, Shixiong
   Dongre, Mitesh
   Wai, Sun Nyunt
   Hurtado, Antoni
TI Modulation of gene transcription and epigenetics of colon carcinoma
   cells by bacterial membrane vesicles
SO SCIENTIFIC REPORTS
LA English
DT Article
ID BREAST-CANCER CELLS; LEGIONELLA-PNEUMOPHILA; HELICOBACTER-PYLORI;
   TUMOR-GROWTH; RELEASE; MECHANISMS; INFECTION; DIFFERENTIATION;
   CARCINOGENESIS; BIOGENESIS
AB Interactions between bacteria and colon cancer cells influence the transcription of the host cell. Yet is it undetermined whether the bacteria itself or the communication between the host and bacteria is responsible for the genomic changes in the eukaryotic cell. Now, we have investigated the genomic and epigenetic consequences of co-culturing colorectal carcinoma cells with membrane vesicles from pathogenic bacteria Vibrio cholerae and non-pathogenic commensal bacteria Escherichia coli. Our study reveals that membrane vesicles from pathogenic and commensal bacteria have a global impact on the gene expression of colon-carcinoma cells. The changes in gene expression correlate positively with both epigenetic changes and chromatin accessibility of promoters at transcription start sites of genes induced by both types of membrane vesicles. Moreover, we have demonstrated that membrane vesicles obtained only from V. cholerae induced the expression of genes associated with epithelial cell differentiation. Altogether, our study suggests that the observed genomic changes in host cells might be due to specific components of membrane vesicles and do not require communication by direct contact with the bacteria.
C1 [Vdovikova, Svitlana; Dongre, Mitesh; Wai, Sun Nyunt] Umea Univ, Dept Mol Biol, S-90187 Umea, Sweden.
   [Vdovikova, Svitlana; Dongre, Mitesh; Wai, Sun Nyunt] Umea Univ, Lab Mol Infect Med Sweden MIMS, S-90187 Umea, Sweden.
   [Vdovikova, Svitlana; Dongre, Mitesh; Wai, Sun Nyunt] Umea Univ, UCMR, S-90187 Umea, Sweden.
   [Gilfillan, Siv; Wang, Shixiong; Hurtado, Antoni] Univ Oslo, Breast Canc Res Grp, Nord EMBL Partnership, NCMM, N-0318 Oslo, Norway.
C3 Umea University; Umea University; Umea University; University of Oslo
RP Wai, SN (通讯作者)，Umea Univ, Dept Mol Biol, S-90187 Umea, Sweden.; Wai, SN (通讯作者)，Umea Univ, Lab Mol Infect Med Sweden MIMS, S-90187 Umea, Sweden.; Wai, SN (通讯作者)，Umea Univ, UCMR, S-90187 Umea, Sweden.; Hurtado, A (通讯作者)，Univ Oslo, Breast Canc Res Grp, Nord EMBL Partnership, NCMM, N-0318 Oslo, Norway.
EM sun.nyunt.wai@umu.se; a.h.rodriguez@ncmm.uio.no
OI Hurtado, Antoni/0000-0002-0145-4763; dongre, mitesh/0000-0002-7151-1137;
   Wai, Sun Nyunt/0000-0003-4793-4671
CR Alaniz RC, 2007, J IMMUNOL, V179, P7692, DOI 10.4049/jimmunol.179.11.7692
   Alto NM, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a006114
   Amini Rana, 2015, Worm, V4, pe992665, DOI 10.4161/21624054.2014.992665
   Aung KM, 2016, J INNATE IMMUN, V8, P269, DOI 10.1159/000443646
   Balakrishnan L, 2017, VIRUSES-BASEL, V9, DOI 10.3390/v9110346
   Balsalobre C, 2006, MOL MICROBIOL, V59, P99, DOI 10.1111/j.1365-2958.2005.04938.x
   Bielig H, 2011, INFECT IMMUN, V79, P1418, DOI 10.1128/IAI.00754-10
   Bierne H, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a010272
   Cole J, 2016, PHARMACOL THERAPEUT, V167, P85, DOI 10.1016/j.pharmthera.2016.07.013
   Cougnoux A, 2014, GUT, V63, P1932, DOI 10.1136/gutjnl-2013-305257
   Davie JR, 2003, J NUTR, V133, p2485S, DOI 10.1093/jn/133.7.2485S
   De Santa F, 2009, EMBO J, V28, P3341, DOI 10.1038/emboj.2009.271
   Deatherage BL, 2012, INFECT IMMUN, V80, P1948, DOI 10.1128/IAI.06014-11
   Deatherage BL, 2009, MOL MICROBIOL, V72, P1395, DOI 10.1111/j.1365-2958.2009.06731.x
   Doulberis M, 2015, CARCINOGENESIS, V36, P280, DOI 10.1093/carcin/bgu325
   Duperthuy M, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003620
   Elluri S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106731
   Fábrega MJ, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.01274
   Galka F, 2008, INFECT IMMUN, V76, P1825, DOI 10.1128/IAI.01396-07
   GarciadelPortillo F, 1997, INFECT IMMUN, V65, P24, DOI 10.1128/IAI.65.1.24-34.1997
   Gilfillan S, 2012, J MAMMARY GLAND BIOL, V17, P147, DOI 10.1007/s10911-012-9254-4
   Haller D, 2003, J BIOL CHEM, V278, P23851, DOI 10.1074/jbc.M300075200
   Hamon MA, 2008, CELL HOST MICROBE, V4, P100, DOI 10.1016/j.chom.2008.07.009
   Hattori N, 2016, GENOME MED, V8, DOI 10.1186/s13073-016-0267-2
   Jan AT, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.01053
   Kouokam JC, 2006, INFECT IMMUN, V74, P2022, DOI 10.1128/IAI.74.4.2022-2030.2006
   Kulp A, 2010, ANNU REV MICROBIOL, V64, P163, DOI 10.1146/annurev.micro.091208.073413
   Lindmark B, 2009, BMC MICROBIOL, V9, DOI 10.1186/1471-2180-9-220
   Martins MD, 2016, J DENT RES, V95, P215, DOI 10.1177/0022034515611876
   Matsusaka K, 2014, WORLD J GASTROENTERO, V20, P3916, DOI 10.3748/wjg.v20.i14.3916
   Namork E, 2002, LANCET, V360, P1741, DOI 10.1016/S0140-6736(02)11721-1
   Nardone G, 2007, DIGEST DIS, V25, P225, DOI 10.1159/000103890
   Necchi V, 2007, GASTROENTEROLOGY, V132, P1009, DOI 10.1053/j.gastro.2007.01.049
   Nishizawa T, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/794378
   O'Donoghue EJ, 2016, CELL MICROBIOL, V18, P1508, DOI 10.1111/cmi.12655
   Opitz B, 2006, J IMMUNOL, V176, P484, DOI 10.4049/jimmunol.176.1.484
   Pálmer HG, 2001, J CELL BIOL, V154, P369, DOI 10.1083/jcb.200102028
   Pidoux G, 2010, AM J PHYSIOL-CELL PH, V298, pC1517, DOI 10.1152/ajpcell.00484.2008
   Radman-Livaja M, 2010, DEV BIOL, V339, P258, DOI 10.1016/j.ydbio.2009.06.012
   Ray T, 2016, APOPTOSIS, V21, P609, DOI 10.1007/s10495-016-1229-2
   Ray T, 2016, APOPTOSIS, V21, P143, DOI 10.1007/s10495-015-1194-1
   Rompikuntal PK, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134098
   Rompikuntal PK, 2012, INFECT IMMUN, V80, P31, DOI 10.1128/IAI.06069-11
   Schmeck B, 2005, J IMMUNOL, V175, P2843, DOI 10.4049/jimmunol.175.5.2843
   Schmeck B, 2008, J IMMUNOL, V181, P940, DOI 10.4049/jimmunol.181.2.940
   Sepulveda Antonia R, 2013, Curr Pathobiol Rep, V1, P9
   Shen Y, 2012, CELL HOST MICROBE, V12, P509, DOI 10.1016/j.chom.2012.08.004
   Sjöström AE, 2015, SCI REP-UK, V5, DOI 10.1038/srep15329
   Strickertsson JAB, 2014, GENES-BASEL, V5, P726, DOI 10.3390/genes5030726
   Tahara T, 2014, CANCER RES, V74, P1311, DOI 10.1158/0008-5472.CAN-13-1865
   Takahashi K, 2011, J BIOL CHEM, V286, P35755, DOI 10.1074/jbc.M111.271007
   Tolg C, 2011, LAB INVEST, V91, P825, DOI 10.1038/labinvest.2010.197
   Vdovikova S, 2017, FRONT CELL INFECT MI, V7, DOI 10.3389/fcimb.2017.00154
   Verma S, 2015, MOL CELL BIOL, V35, P2932, DOI 10.1128/MCB.00397-15
   Wai SN, 2003, CELL, V115, P25, DOI 10.1016/S0092-8674(03)00754-2
   Yin L, 2011, MUCOSAL IMMUNOL, V4, P409, DOI 10.1038/mi.2010.83
   Zhang YY, 2017, ONCOTARGET, V8, P96323, DOI 10.18632/oncotarget.22036
   Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r137
NR 58
TC 18
Z9 18
U1 0
U2 10
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD MAY 9
PY 2018
VL 8
AR 7434
DI 10.1038/s41598-018-25308-9
PG 10
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA GF1ZX
UT WOS:000431737300120
PM 29743643
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Cao, X
   Tang, QQ
   Holland-Letz, T
   Gündert, M
   Cuk, K
   Schott, S
   Heil, J
   Golatta, M
   Sohn, C
   Schneeweiss, A
   Burwinkel, B
AF Cao, Xue
   Tang, Qiuqiong
   Holland-Letz, Tim
   Guendert, Melanie
   Cuk, Katarina
   Schott, Sarah
   Heil, Joerg
   Golatta, Michael
   Sohn, Christof
   Schneeweiss, Andreas
   Burwinkel, Barbara
TI Evaluation of Promoter Methylation of <i>RASSF1A</i> and <i>ATM</i> in
   Peripheral Blood of Breast Cancer Patients and Healthy Control
   Individuals
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE breast cancer; DNA methylation; RASSF1A; ATM
ID CELL-FREE DNA; ABERRANT METHYLATION; EPIGENETIC ALTERATIONS; POTENTIAL
   BIOMARKER; EARLY EVENT; PLASMA DNA; FETAL DNA; HYPERMETHYLATION; TUMOR;
   GENE
AB Breast cancer (BC) is the most common cancer among women and has high mortality rates. Early detection is supposed to be critical for the patient's prognosis. In recent years, several studies have investigated global DNA methylation profiles and gene-specific DNA methylation in blood-based DNA to develop putative screening markers for cancer. However, most of the studies have not yet been validated. In our study, we analyzed the promoter methylation of RASSF1A and ATM in peripheral blood DNA of 229 sporadic patients and 151 healthy controls by the MassARRAY EpiTYPER assay. There were no significant differences in DNA methylation levels of RASSF1A and ATM between the sporadic BC cases and the healthy controls. Furthermore, we performed the Infinium HumanMethylation450 BeadChip (450K) array analysis using 48 sporadic BC cases and 48 healthy controls (cases and controls are the same from those of the MassARRAY EpiTYPER assay) and made a comparison with the published data. No significant differences were presented in DNA methylation levels of RASSF1A and ATM between the sporadic BC cases and the healthy controls. So far, the evidence for powerful blood-based methylation markers is still limited and the identified markers need to be further validated.
C1 [Cao, Xue; Tang, Qiuqiong; Guendert, Melanie; Cuk, Katarina; Schott, Sarah; Sohn, Christof; Schneeweiss, Andreas; Burwinkel, Barbara] Heidelberg Univ, Dept Gynecol & Obstet, Mol Biol Breast Canc, D-69120 Heidelberg, Germany.
   [Cao, Xue; Tang, Qiuqiong; Guendert, Melanie; Cuk, Katarina; Burwinkel, Barbara] German Canc Res Ctr, Div Mol Epidemiol C080, Heidelberg 69120, Germany.
   [Holland-Letz, Tim] German Canc Res Ctr, Div Biostat C060, D-69120 Heidelberg, Germany.
   [Heil, Joerg; Golatta, Michael] Univ Womens Clin, Dept Gynecol & Obstet, D-69120 Heidelberg, Germany.
   [Schneeweiss, Andreas] Natl Ctr Tumor Dis, D-69120 Heidelberg, Germany.
C3 Ruprecht Karls University Heidelberg; Helmholtz Association; German
   Cancer Research Center (DKFZ); Helmholtz Association; German Cancer
   Research Center (DKFZ); Helmholtz Association; German Cancer Research
   Center (DKFZ); Ruprecht Karls University Heidelberg
RP Cao, X; Burwinkel, B (通讯作者)，Heidelberg Univ, Dept Gynecol & Obstet, Mol Biol Breast Canc, D-69120 Heidelberg, Germany.; Cao, X; Burwinkel, B (通讯作者)，German Canc Res Ctr, Div Mol Epidemiol C080, Heidelberg 69120, Germany.
EM cxuecmu@outlook.com; tangqiuqiong2017@foxmail.com;
   t.holland-letz@Dkfz-Heidelberg.de; melanie.guendert@t-online.de;
   k.cuk@Dkfz-Heidelberg.de; Sarah.Schott@med.uni-heidelberg.de;
   Joerg.Heil@med.uni-heidelberg.de; Michael.Golatta@med.uni-heidelberg.de;
   Christof.Sohn@med.uni-heidelberg.de;
   Andreas.Schneeweiss@med.uni-heidelberg.de;
   B.Burwinkel@dkfz-heidelberg.de
RI Golatta, Michael/AAH-8735-2021; Heil, Joerg/M-4998-2017; Schott,
   Sarah/D-5242-2018; Schneeweiss, Andreas/HHS-4098-2022
OI Golatta, Michael/0000-0002-2605-0060
FU German Cancer Research Center (DKFZ); University Women's Clinic,
   Heidelberg; China Scholarship Council (CSC)
FX We thank Sabine Serick and Yanxiang Jiang for their technical support.
   This study was supported by the German Cancer Research Center (DKFZ) and
   University Women's Clinic, Heidelberg. Xue Cao was financed by the China
   Scholarship Council (CSC).
CR Ahmed IA, 2010, CANCER GENET CYTOGEN, V199, P96, DOI 10.1016/j.cancergencyto.2010.02.007
   Ahmed M, 2006, ONCOGENE, V25, P5906, DOI 10.1038/sj.onc.1209873
   ALAGARATNAM TT, 1985, CLIN RADIOL, V36, P175, DOI 10.1016/S0009-9260(85)80104-5
   Bai AHC, 2004, INT J CANCER, V112, P846, DOI 10.1002/ijc.20485
   Baylin SB, 1998, ADV CANCER RES, V72, P141
   Baylin Stephen B, 2005, Nat Clin Pract Oncol, V2 Suppl 1, pS4, DOI 10.1038/ncponc0354
   Begam Nasrin, 2017, Asian Pac J Cancer Prev, V18, P3003
   Belinsky SA, 1998, P NATL ACAD SCI USA, V95, P11891, DOI 10.1073/pnas.95.20.11891
   Brennan K, 2012, CANCER RES, V72, P2304, DOI 10.1158/0008-5472.CAN-11-3157
   Brooks JD, 2010, CANCER EPIDEMIOL, V34, P717, DOI 10.1016/j.canep.2010.05.006
   Chan KCA, 2004, CLIN CHEM, V50, P88, DOI 10.1373/clinchem.2003.024893
   Cho YH, 2015, J CANCER, V6, P819, DOI 10.7150/jca.12174
   Cho YH, 2010, ANTICANCER RES, V30, P2489
   Choi YL, 2006, VIRCHOWS ARCH, V448, P331, DOI 10.1007/s00428-005-0091-3
   Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083
   Dulaimi E, 2004, CLIN CANCER RES, V10, P6189, DOI 10.1158/1078-0432.CCR-04-0597
   Edge SB, 2010, ANN SURG ONCOL, V17, P1471, DOI 10.1245/s10434-010-0985-4
   Ehrich M, 2005, P NATL ACAD SCI USA, V102, P15785, DOI 10.1073/pnas.0507816102
   Ehrlich M, 2002, J NUTR, V132, p2424S, DOI 10.1093/jn/132.8.2424S
   Elmore G, 1998, NEW ENGL J MED, V338, P1089, DOI 10.1056/NEJM199804163381601
   Esteller M, 2000, CANCER RES, V60, P4366
   Evron E, 2001, LANCET, V357, P1335, DOI 10.1016/S0140-6736(00)04501-3
   Evron E, 2001, CANCER RES, V61, P2782
   Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210
   Flanagan JM, 2009, HUM MOL GENET, V18, P1332, DOI 10.1093/hmg/ddp033
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Harrison K, 2015, CLIN EPIGENETICS, V7, DOI 10.1186/s13148-015-0125-x
   Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870
   Hoque MO, 2006, J CLIN ONCOL, V24, P4262, DOI 10.1200/JCO.2005.01.3516
   Huang Q, 2007, LEUKEMIA LYMPHOMA, V48, P1988, DOI 10.1080/10428190701573224
   Ito Y, 2008, HUM MOL GENET, V17, P2633, DOI 10.1093/hmg/ddn163
   Jung K, 2010, CLIN CHIM ACTA, V411, P1611, DOI 10.1016/j.cca.2010.07.032
   Kim JH, 2010, GYNECOL ONCOL, V118, P176, DOI 10.1016/j.ygyno.2010.04.016
   Kloten V, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3375
   Kristensen LS, 2012, ONCOTARGET, V3, P450, DOI 10.18632/oncotarget.480
   Leonhardt H, 2000, J CELL BIOCHEM, P78
   Li L, 2012, J EPIDEMIOL, V22, P384, DOI 10.2188/jea.JE20120003
   Li Y, 2004, CLIN CHEM, V50, P1002, DOI 10.1373/clinchem.2003.029835
   Liu LM, 2002, ONCOGENE, V21, P6835, DOI 10.1038/sj.onc.1205814
   Majchrzak-Celinska A, 2015, TUMOR BIOL, V36, P3831, DOI 10.1007/s13277-014-3025-3
   MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686
   Momparler RL, 2003, ONCOGENE, V22, P6479, DOI 10.1038/sj.onc.1206774
   Papadopoulou E, 2006, ANN NY ACAD SCI, V1075, P235, DOI 10.1196/annals.1368.032
   Pfeifer GP, 2005, BIOCHEMISTRY-MOSCOW+, V70, P576, DOI 10.1007/s10541-005-0151-y
   Radpour R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016080
   Radpour R, 2009, J PROTEOME RES, V8, P5264, DOI 10.1021/pr900591w
   Richter AM, 2016, CANCERS, V8, DOI 10.3390/cancers8030026
   Robertson KD, 2000, CARCINOGENESIS, V21, P461, DOI 10.1093/carcin/21.3.461
   Sadikovic B, 2008, CURR GENOMICS, V9, P394, DOI 10.2174/138920208785699580
   Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166
   Tang QQ, 2016, CLIN EPIGENETICS, V8, DOI 10.1186/s13148-016-0282-6
   Tang QQ, 2016, ONCOTARGET, V7, P64191, DOI 10.18632/oncotarget.11640
   Umbricht CB, 2001, ONCOGENE, V20, P3348, DOI 10.1038/sj.onc.1204438
   Van der Auwera I, 2009, BRIT J CANCER, V100, P1277, DOI 10.1038/sj.bjc.6605013
   van der Vaart M, 2007, CLIN CHEM, V53, P2215, DOI 10.1373/clinchem.2007.092734
   Widschwendter M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002656
   Wu HC, 2012, CARCINOGENESIS, V33, P1946, DOI 10.1093/carcin/bgs201
   Xu XR, 2012, FASEB J, V26, P2657, DOI 10.1096/fj.11-197251
   Yazici H, 2009, CANCER EPIDEM BIOMAR, V18, P2723, DOI 10.1158/1055-9965.EPI-08-1237
   Yuan YF, 2005, INT J CANCER, V113, P654, DOI 10.1002/ijc.20628
   Zmetakova I, 2013, NEOPLASMA, V60, P635, DOI 10.4149/neo_2013_082
NR 61
TC 14
Z9 16
U1 0
U2 2
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD MAR
PY 2018
VL 19
IS 3
AR 900
DI 10.3390/ijms19030900
PG 12
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA GA4OO
UT WOS:000428309800257
PM 29562656
OA Green Submitted, Green Published, gold
DA 2025-01-12
ER

PT J
AU Sengupta, D
   Deb, M
   Patra, SK
AF Sengupta, Dipta
   Deb, Moonmoon
   Patra, Samir Kumar
TI Antagonistic activities of miR-148a and DNMT1: Ectopic expression of
   miR-148a impairs DNMT1 mRNA and dwindle cell proliferation and survival
SO GENE
LA English
DT Article
DE miRNA; Epigenetics; DNA methyltransferase; Apoptosis; Differentiation
ID HUMAN BREAST-CANCER; PROSTATE-CANCER; DNA METHYLATION; BLADDER-CANCER;
   TUMOR-SUPPRESSOR; COMET ASSAY; IN-VITRO; MICRORNA; METASTASIS;
   BIOMARKERS
AB Functional analyses of noncoding RNAs have associated many micro RNAs (miRNA, miR) with various physiological processes, including proliferation, differentiation, development, cell metabolism, and apoptosis. Aberrant expression of miRNA and imbalance in their functions may lead to cellular aberration and different disease development, including cancer. In silico analysis of miRNA target prediction suggested that miR-148a possess a binding site in the 3' UTR of DNMT1 mRNA which can cause silencing of DNMT1 gene. Accordingly, we performed in vitro cell culture experiments to confirm the effect miR-148a on DNMT1 gene expression in prostate cancer cell lines. We demonstrated that there is a physical association between DNMT1 mRNA and miR-148a. We found that (i) ectopic expression of miR-148a induces programmed cell death and represses cell proliferation by targeting DNMT1; (ii) miR-148a gene is regulated by DNA methylation and DNMT1 in prostate cancer. We conclude that miR-148a is silenced by DNA methylation and ectopic expression of miR-148a suppresses DNMT1 expression and induced apoptotic genes expression in hormone-refractory prostate cancer cells.
C1 [Sengupta, Dipta; Deb, Moonmoon; Patra, Samir Kumar] Natl Inst Technol, Dept Life Sci, Epigenet & Canc Res Lab, Biochem & Mol Biol Grp, Rourkela 769008, Odisha, India.
   [Sengupta, Dipta] Univ Edinburgh, Western Gen Hosp, MRC Inst Genet & Mol Med, MRC Human Genet Unit,Prof Wendy Bickmores Grp, Crewe Rd South, Edinburgh EH4 2XU, Midlothian, Scotland.
   [Deb, Moonmoon] Texas Tech Univ, Hlth Sci Ctr, Dr Hiranmoy Dass Lab, Biomed Sci, Amarillo, TX USA.
C3 National Institute of Technology (NIT System); National Institute of
   Technology Rourkela; University of Edinburgh; Texas Tech University
   System; Texas Tech University Health Science Center; Texas Tech
   University Health Sciences Center Amarillo
RP Patra, SK (通讯作者)，Natl Inst Technol, Dept Life Sci, Rourkela 769008, Odisha, India.
EM samirp@nitrkl.ac.in
RI Sengupta, Dipta/H-3707-2019; PATRA, Samir/AAS-6639-2020
OI PATRA, SAMIR/0000-0001-5641-1835; Sengupta, Dipta/0000-0002-7836-4774
FU NIT Rourkela
FX DS and MD are thankful to the NIT Rourkela for providing them,
   fellowship. We are extremely grateful to Professor Moshe Szyf,
   Department of Pharmacology and Therapeutics, McGill University,
   Montreal, Quebec, Canada for appreciation of the quality and novelty,
   critical comments and correcting the language of the manuscript.
CR Ahmad J, 2013, INDIAN J MED RES, V137, P680
   Antonov AV, 2013, CELL DEATH DIFFER, V20, P367, DOI 10.1038/cdd.2012.137
   Bhattacharyya SN, 2006, CELL, V125, P1111, DOI 10.1016/j.cell.2006.04.031
   Borowicz S, 2014, JOVE-J VIS EXP, DOI 10.3791/51998
   Chen Y, 2010, J GASTROINTEST SURG, V14, P1170, DOI 10.1007/s11605-010-1202-2
   Conaway JW, 2012, ANNU REV BIOCHEM, V81, P61, DOI 10.1146/annurev-biochem-090711-093103
   Deb M, 2016, GENE, V581, P75, DOI 10.1016/j.gene.2016.01.029
   Deb M, 2014, TUMOR BIOL, V35, P12031, DOI 10.1007/s13277-014-2502-z
   Deb M, 2014, CELL MOL LIFE SCI, V71, P3439, DOI 10.1007/s00018-014-1605-4
   Dhawan D, 2013, UROL ONCOL-SEMIN ORI, V31, P1761, DOI 10.1016/j.urolonc.2012.03.015
   Esteller M, 2006, BRIT J CANCER, V94, P179, DOI 10.1038/sj.bjc.6602918
   Fabian MR, 2010, ANNU REV BIOCHEM, V79, P351, DOI 10.1146/annurev-biochem-060308-103103
   Franken NAP, 2006, NAT PROTOC, V1, P2315, DOI 10.1038/nprot.2006.339
   Fujita Y, 2010, J BIOL CHEM, V285, P19076, DOI 10.1074/jbc.M109.079525
   Garzon R, 2009, ANNU REV MED, V60, P167, DOI [10.1146/annurev.med.59.053006.104707, 10.1146/annurev.pathol.4.110807.092222]
   Guzel E, 2015, INT J CANCER, V136, P875, DOI 10.1002/ijc.29054
   Inns J, 2015, BREAST, V24, P364, DOI 10.1016/j.breast.2015.04.001
   Jin N, 2015, MOL MED REP, V12, P3170, DOI 10.3892/mmr.2015.3739
   Kar S, 2014, CELL MOL LIFE SCI, V71, P1017, DOI 10.1007/s00018-013-1482-2
   Kweldam CF, 2015, BJU INT, V116, P230, DOI 10.1111/bju.12879
   Lehmann U, 2008, J PATHOL, V214, P17, DOI 10.1002/path.2251
   Lehmann U, 2014, CELL TISSUE RES, V356, P657, DOI 10.1007/s00441-014-1793-0
   Lombard AP, 2016, MOL CARCINOGEN, V55, P757, DOI 10.1002/mc.22319
   Lujambio A, 2008, P NATL ACAD SCI USA, V105, P13556, DOI 10.1073/pnas.0803055105
   Mattie MD, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-24
   Monroig-Bosque PD, 2015, EXPERT OPIN BIOL TH, V15, P1381, DOI 10.1517/14712598.2015.1074999
   Nandhakumar S, 2011, J PHARMACOL PHARMACO, V2, P107, DOI 10.4103/0976-500X.81903
   Olive PL, 2006, NAT PROTOC, V1, P23, DOI 10.1038/nprot.2006.5
   Patra SK, 2008, FEBS J, V275, P5217, DOI 10.1111/j.1742-4658.2008.06658.x
   Patra SK, 2008, CANCER METAST REV, V27, P315, DOI 10.1007/s10555-008-9118-y
   Patra SK, 2002, MOL CARCINOGEN, V33, P163, DOI 10.1002/mc.10033
   Porkka KP, 2007, CANCER RES, V67, P6130, DOI 10.1158/0008-5472.CAN-07-0533
   Previdi MC, 2017, FUTURE ONCOL, V13, P443, DOI 10.2217/fon-2016-0253
   Sengupta D, 2016, EXP CELL RES, V346, P176, DOI 10.1016/j.yexcr.2016.07.023
   Shilatifard A, 2012, ANNU REV BIOCHEM, V81, P65, DOI 10.1146/annurev-biochem-051710-134100
   Toné S, 2007, EXP CELL RES, V313, P3635, DOI 10.1016/j.yexcr.2007.06.018
   Walter BA, 2013, J CANCER, V4, P350, DOI 10.7150/jca.6394
   Wang J, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/823620
   Wu CT, 2011, CANCER-AM CANCER SOC, V117, P5221, DOI 10.1002/cncr.26150
   Yaqinuddin A, 2008, CANCER CELL INT, V8, DOI 10.1186/1475-2867-8-13
   Zhang H, 2011, CELL DEATH DIFFER, V18, P1702, DOI 10.1038/cdd.2011.28
   Zhang SL, 2009, J HUAZHONG U SCI-MED, V29, P215, DOI 10.1007/s11596-009-0216-z
NR 42
TC 23
Z9 23
U1 0
U2 14
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0378-1119
EI 1879-0038
J9 GENE
JI Gene
PD JUN 20
PY 2018
VL 660
BP 68
EP 79
DI 10.1016/j.gene.2018.03.075
PG 12
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA GG7MF
UT WOS:000432881700009
PM 29596883
DA 2025-01-12
ER

PT J
AU Wang, T
   Holt, MV
   Young, NL
AF Wang, Tao
   Holt, Matthew V.
   Young, Nicolas L.
TI The histone H4 proteoform dynamics in response to SUV4-20 inhibition
   reveals single molecule mechanisms of inhibitor resistance
SO EPIGENETICS & CHROMATIN
LA English
DT Article
DE Histone methyltransferase; SUV4-20; Histone post-translational
   modifications; Epigenetic inhibitor; Breast cancer; Top-down proteomics
ID FUNCTIONAL-CHARACTERIZATION; H4K20 METHYLTRANSFERASES; METHYLATION;
   CHROMATIN; TRIMETHYLATION; PURIFICATION; ACETYLATION; LYSINE-20;
   INTEGRITY; APOPTOSIS
AB Background: The dynamics of histone post-translational modifications (PTMs) are sparsely described, especially in their true physiological context of proteoforms (single histone molecules harboring combinations of PTMs).
   Methods: Here we time-resolve the response of cells to SUV4-20 methyltransferase inhibition and unbiasedly quantitate the dynamic response of histone H4 PTMs and proteoforms.
   Results: Contrary to the prevailing dogma, cells exhibit an immediate-early response with changes to histone proteoforms. Cells also recover to basal-like conditions upon removal of epigenetic inhibitors rapidly. Inhibition of SUV4-20 results in decreased H4{K20me2}; however, no effects on H4{K20me3} are observed, implying that another enzyme mediates H4K20me3. Most surprisingly, SUV4-20 inhibition results in an increase in histone H4 acetylation attributable to proteoforms containing K20me2. This led us to hypothesize that hyperacetylated proteoforms protect K20me2 from demethylation as an evolved compensatory mechanism. This concept is supported by subsequent results that pretreatment with an HDACi substantially diminishes the effects of SUV4-20 inhibition in prone cells and is further confirmed by HATi-facilitating SUV4-20 inhibition to decrease discrete H4{K20me2} in resistant cells.
   Conclusions: The chromatin response of cells to sudden perturbations is significantly faster, nuanced and complex than previously described. The persistent nature of chromatin regulation may be achieved by a network of dynamic equilibria with compensatory mechanisms that operate at the proteoform level.
C1 [Wang, Tao; Holt, Matthew V.; Young, Nicolas L.] Baylor Coll Med, Verna & Marrs McLean Dept Biochem & Mol Biol, Houston, TX 77030 USA.
   [Young, Nicolas L.] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA.
C3 Baylor College of Medicine; Baylor College of Medicine
RP Young, NL (通讯作者)，Baylor Coll Med, Verna & Marrs McLean Dept Biochem & Mol Biol, Houston, TX 77030 USA.; Young, NL (通讯作者)，Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA.
EM Nicolas.Young@bcm.edu
RI Young, Nicolas/AAI-5242-2020
OI Holt, Matthew/0000-0002-1418-6139; Wang, Tao/0000-0002-9641-6558; Young,
   Nicolas/0000-0002-3323-2815
FU NIH [P01 GM085354-08]
FX We thank James T. Kadonaga, William N. Pappano, Richard I. Morimoto,
   Jerry L. Workman, and Benjamin A. Garcia for helpful discussions and
   feedback throughout the production of this work. We also thank NIH P01
   GM085354-08 for support.
CR Arif M, 2010, CHEM BIOL, V17, P903, DOI 10.1016/j.chembiol.2010.06.014
   Barrasa JI, 2012, BBA-MOL CELL RES, V1823, P2201, DOI 10.1016/j.bbamcr.2012.08.008
   Barth TK, 2010, TRENDS BIOCHEM SCI, V35, P618, DOI 10.1016/j.tibs.2010.05.006
   Bromberg KD, 2017, NAT CHEM BIOL, V13, P317, DOI [10.1038/NCHEMBIO.2282, 10.1038/nchembio.2282]
   Carvalho S, 2013, NUCLEIC ACIDS RES, V41, P2881, DOI 10.1093/nar/gks1472
   Chen S, 2017, CELL BIOCHEM BIOPHYS, V75, P119, DOI 10.1007/s12013-016-0777-y
   DiMaggio PA, 2009, MOL CELL PROTEOMICS, V8, P2527, DOI 10.1074/mcp.M900144-MCP200
   Fang J, 2002, CURR BIOL, V12, P1086, DOI 10.1016/S0960-9822(02)00924-7
   Fischle W, 2003, NATURE, V425, P475, DOI 10.1038/nature02017
   Foreman KW, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022290
   Fraga MF, 2005, NAT GENET, V37, P391, DOI 10.1038/ng1531
   Garcia BA, 2007, NAT PROTOC, V2, P933, DOI 10.1038/nprot.2007.106
   Gardner KE, 2011, J MOL BIOL, V409, P36, DOI 10.1016/j.jmb.2011.01.040
   Gupta A, 2008, MOL CELL BIOL, V28, P397, DOI 10.1128/MCB.01045-07
   Halsall JA, 2015, EPIGENET CHROMATIN, V8, DOI 10.1186/s13072-015-0021-9
   Hsiao KY, 2013, J MOL CELL BIOL, V5, P157, DOI 10.1093/jmcb/mjs066
   Hurd PJ, 2009, J BIOL CHEM, V284, P16575, DOI 10.1074/jbc.M109.005421
   Kimura A, 1998, GENES CELLS, V3, P789, DOI 10.1046/j.1365-2443.1998.00229.x
   Larschan E, 2007, MOL CELL, V28, P121, DOI 10.1016/j.molcel.2007.08.011
   Mentch SJ, 2015, CELL METAB, V22, P861, DOI 10.1016/j.cmet.2015.08.024
   Nishioka K, 2002, MOL CELL, V9, P1201, DOI 10.1016/S1097-2765(02)00548-8
   Pesavento JJ, 2008, MOL CELL BIOL, V28, P468, DOI 10.1128/MCB.01517-07
   PHILLIPS DM, 1963, BIOCHEM J, V87, P258, DOI 10.1042/bj0870258
   Plazas-Mayorca MD, 2009, J PROTEOME RES, V8, P5367, DOI 10.1021/pr900777e
   Qian P, 2017, J CHEM THEORY COMPUT, V13, P2977, DOI 10.1021/acs.jctc.7b00069
   Rice JC, 2002, GENE DEV, V16, P2225, DOI 10.1101/gad.1014902
   Riffo-Campos AL, 2015, J BIOL CHEM, V290, P197, DOI 10.1074/jbc.M114.579292
   Sakaguchi A, 2008, GENETICS, V179, P317, DOI 10.1534/genetics.108.087650
   Saksouk N, 2015, EPIGENET CHROMATIN, V8, DOI 10.1186/1756-8935-8-3
   Schotta G, 2004, GENE DEV, V18, P1251, DOI 10.1101/gad.300704
   Schotta G, 2008, GENE DEV, V22, P2048, DOI 10.1101/gad.476008
   Shechter D, 2007, NAT PROTOC, V2, P1445, DOI 10.1038/nprot.2007.202
   Sidoli S, 2016, JOVE-J VIS EXP, DOI 10.3791/54112
   Southall SM, 2014, NUCLEIC ACIDS RES, V42, P661, DOI 10.1093/nar/gkt776
   Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412
   Suganuma T, 2011, ANNU REV BIOCHEM, V80, P473, DOI 10.1146/annurev-biochem-061809-175347
   Sweet SMM, 2010, J BIOL CHEM, V285, P32778, DOI 10.1074/jbc.M110.145094
   Wu H, 2013, FEBS LETT, V587, P3859, DOI 10.1016/j.febslet.2013.10.020
   Yang HB, 2009, BIOCHEM CELL BIOL, V87, P151, DOI 10.1139/O08-131
   Young NL, 2009, MOL CELL PROTEOMICS, V8, P2266, DOI 10.1074/mcp.M900238-MCP200
   Zee BM, 2010, EPIGENET CHROMATIN, V3, DOI 10.1186/1756-8935-3-22
   Zheng YP, 2014, PROTEOMICS, V14, P2190, DOI 10.1002/pmic.201400060
NR 42
TC 28
Z9 31
U1 0
U2 5
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1756-8935
J9 EPIGENET CHROMATIN
JI Epigenetics Chromatin
PD JUN 7
PY 2018
VL 11
AR 29
DI 10.1186/s13072-018-0198-9
PG 18
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA GI7FR
UT WOS:000434668400001
PM 29880017
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU Maupetit-Mehouas, S
   Court, F
   Bourgne, C
   Guerci-Bresler, A
   Cony-Makhoul, P
   Johnson, H
   Etienne, G
   Rousselot, P
   Guyotat, D
   Janel, A
   Hermet, E
   Saugues, S
   Berger, J
   Arnaud, P
   Berger, MG
AF Maupetit-Mehouas, Stephanie
   Court, Franck
   Bourgne, Celine
   Guerci-Bresler, Agnes
   Cony-Makhoul, Pascale
   Johnson, Hyacinthe
   Etienne, Gabriel
   Rousselot, Philippe
   Guyotat, Denis
   Janel, Alexandre
   Hermet, Eric
   Saugues, Sandrine
   Berger, Juliette
   Arnaud, Philippe
   Berger, Marc G.
TI DNA methylation profiling reveals a pathological signature that
   contributes to transcriptional defects of
   CD34<SUP>+</SUP>CD15<SUP>-</SUP> cells in early chronic-phase chronic
   myeloid leukemia
SO MOLECULAR ONCOLOGY
LA English
DT Article
DE CML; DNA methylation; epigenetics; leukemic stem cells; transcriptional
   defects
ID CHRONIC MYELOGENOUS LEUKEMIA; HEMATOPOIETIC STEM; ABERRANT METHYLATION;
   PROGENITOR CELLS; BREAST-CANCER; BLAST CRISIS; CPG ISLAND;
   DIFFERENTIATION; HYPERMETHYLATION; GENOME
AB Despite the high efficiency of tyrosine kinase inhibitors (TKI), some patients with chronic myeloid leukemia (CML) will display residual disease that can become resistant to treatment, indicating intraclonal heterogeneity in chronic-phase CML (CP-CML). To determine the basis of this heterogeneity, we conducted the first exhaustive characterization of the DNA methylation pattern of sorted CP-CML CD34(+)CD15(-) (immature) and CD34(-)CD15(+) (mature) cells at diagnosis (prior to any treatment) and compared it to that of CD34(+)CD15(-) and CD34(-)CD15(+) cells isolated from healthy donors (HD). In both cell types, we identified several hundreds of differentially methylated regions (DMRs) showing DNA methylation changes between CP-CML and HD samples, with only a subset of them in common between CD34(+)CD15(-) and CD34(-)CD15(+) cells. This suggested DNA methylation variability within the same CML clone. We also identified 70 genes that could be aberrantly repressed upon hypermethylation and 171 genes that could be aberrantly expressed upon hypomethylation of some of these DMRs in CP-CML cells, among which 18 and 81, respectively, were in CP-CML CD34(+)CD15(-) cells only. We then validated the DNA methylation and expression defects of selected candidate genes. Specifically, we identified GAS2, a candidate oncogene, as a new example of gene the hypomethylation of which is associated with robust overexpression in CP-CML cells. Altogether, we demonstrated that DNA methylation abnormalities exist at early stages of CML and can affect the transcriptional landscape of malignant cells. These observations could lead to the development of combination treatments with epigenetic drugs and TKI for CP-CML.
C1 [Maupetit-Mehouas, Stephanie; Court, Franck; Arnaud, Philippe] Univ Clermont Auvergne, CNRS, GReD, INSERM, BP 38, F-63001 Clermont Ferrand, France.
   [Maupetit-Mehouas, Stephanie; Bourgne, Celine; Janel, Alexandre; Saugues, Sandrine; Berger, Juliette; Berger, Marc G.] CHU Clermont Ferrand, Hop Estaing, Hematol Biol, 1 Pl Lucie & Raymond Aubrac, F-63003 Clermont Ferrand 1, France.
   [Bourgne, Celine; Janel, Alexandre; Berger, Juliette; Berger, Marc G.] Univ Clermont Auvergne, Hop Estaing, CHU Clermont Ferrand, Equipe Accueil CHELTER 7453, Clermont Ferrand 1, France.
   [Guerci-Bresler, Agnes] CHRU Nancy, Hop Brabois, Hematol Clin, Vandoeuvre Les Nancy, France.
   [Cony-Makhoul, Pascale] CH Annecy Genevois, Hematol Clin, Epagny Metz Tessy, France.
   [Johnson, Hyacinthe] CHU Caen, Inst Hematol Basse Normandie, Caen 9, France.
   [Etienne, Gabriel] Inst Bergonie, Hematol Clin, Bordeaux, France.
   [Rousselot, Philippe] Ctr Hosp Versailles, Serv Hematol & Oncol, Le Chesnay, France.
   [Guyotat, Denis] Inst Cancerol Lucien Neuwirth, Dept Hematol, St Priest En Jarez, France.
   [Hermet, Eric] CHU Clermont Ferrand, Hematol Clin Adulte, Hop Estaing, Clermont Ferrand 1, France.
   [Saugues, Sandrine; Berger, Juliette; Berger, Marc G.] CHU Clermont Ferrand, CRB Auvergne, Hop Estaing, Clermont Ferrand 1, France.
C3 Centre National de la Recherche Scientifique (CNRS); Institut National
   de la Sante et de la Recherche Medicale (Inserm); Universite Clermont
   Auvergne (UCA); CHU Clermont Ferrand; Universite Clermont Auvergne
   (UCA); CHU Clermont Ferrand; CHU de Nancy; Centre Hospitalier Annecy
   Genevois; CHU de Caen NORMANDIE; UNICANCER; Institut Bergonie;
   Universite Paris Saclay; Centre Hospitalier de Versailles; Institut de
   Cancerologie de la Loire; CHU Clermont Ferrand; CHU Clermont Ferrand
RP Arnaud, P (通讯作者)，Univ Clermont Auvergne, CNRS, GReD, INSERM, BP 38, F-63001 Clermont Ferrand, France.; Berger, MG (通讯作者)，CHU Clermont Ferrand, Hop Estaing, Hematol Biol, 1 Pl Lucie & Raymond Aubrac, F-63003 Clermont Ferrand 1, France.
EM philippe.arnaud@uca.fr; mberger@chu-clermontferrand.fr
RI ; arnaud, Philippe/O-9507-2015
OI court, franck/0000-0003-0327-9708; arnaud, Philippe/0000-0002-7937-8764
FU Plan Cancer-INSERM [CS14085]; Fonds de dotation Patrick Brou de
   Lauriere; Regional Clinical Research Hospital Projects (PHRC, CHU
   Clermont-Ferrand); Ligue Contre le Cancer (Comite de l'Allier); EA
   CHELTER (Universite Clermont Auvergne); French Government IDEX-ISITE
   Initiative [16-IDEX-0001 (CAP 20-25)]
FX This study was funded by the Plan Cancer-INSERM (CS14085) (PA), the
   Fonds de dotation Patrick Brou de Lauriere (PA), the Regional Clinical
   Research Hospital Projects (PHRC, CHU Clermont-Ferrand) (MGB & PA), the
   Ligue Contre le Cancer (Comite de l'Allier) (MGB), and EA CHELTER
   (Universite Clermont Auvergne) (MGB). This research is supported by the
   French Government IDEX-ISITE Initiative 16-IDEX-0001 (CAP 20-25).
CR Arnaud P, 2006, HUM MOL GENET, V15, P589, DOI 10.1093/hmg/ddi475
   Bert SA, 2013, CANCER CELL, V23, P9, DOI 10.1016/j.ccr.2012.11.006
   Bocker MT, 2011, BLOOD, V117, pE182, DOI 10.1182/blood-2011-01-331926
   Challen GA, 2014, CELL STEM CELL, V15, P350, DOI 10.1016/j.stem.2014.06.018
   Chomel JC, 2016, ONCOTARGET, V7, P35293, DOI 10.18632/oncotarget.9182
   Cortes JE, 2009, LEUKEMIA, V23, P1537, DOI 10.1038/leu.2009.88
   Court F, 2017, ONCOTARGET, V8, P4110, DOI 10.18632/oncotarget.13746
   Court F, 2014, GENOME RES, V24, P554, DOI 10.1101/gr.164913.113
   Deneberg S, 2011, BLOOD, V118, P5573, DOI 10.1182/blood-2011-01-332353
   Druker BJ, 2006, NEW ENGL J MED, V354, P2594, DOI 10.1056/NEJMe068073
   Dunwell T, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-44
   Etienne G, 2017, J CLIN ONCOL, V35, P298, DOI 10.1200/JCO.2016.68.2914
   Farlik M, 2016, CELL STEM CELL, V19, P808, DOI 10.1016/j.stem.2016.10.019
   Frolova O, 2014, BRIT J HAEMATOL, V166, P862, DOI 10.1111/bjh.12978
   Gambacorti-Passerini C, 2011, JNCI-J NATL CANCER I, V103, P553, DOI 10.1093/jnci/djr060
   Gerber JM, 2011, AM J HEMATOL, V86, P31, DOI 10.1002/ajh.21915
   Guillamot M, 2016, TRENDS CANCER, V2, P70, DOI 10.1016/j.trecan.2015.12.006
   Heller G, 2016, LEUKEMIA, V30, P1861, DOI 10.1038/leu.2016.143
   Hjort EE, 2016, ONCOTARGET, V7, P77635, DOI 10.18632/oncotarget.12749
   Hochhaus A, 2017, NEW ENGL J MED, V376, P917, DOI 10.1056/NEJMoa1609324
   Hodges E, 2011, MOL CELL, V44, P17, DOI 10.1016/j.molcel.2011.08.026
   Hon GC, 2012, GENOME RES, V22, P246, DOI 10.1101/gr.125872.111
   Huang WQ, 2017, ONCOTARGET, V8, P50629, DOI 10.18632/oncotarget.16884
   Janssen JJWM, 2010, HAEMATOL-HEMATOL J, V95, P1036, DOI 10.3324/haematol.2009.015693
   Jelinek J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022110
   Jiang XY, 1999, P NATL ACAD SCI USA, V96, P12804, DOI 10.1073/pnas.96.22.12804
   Kim M, 2017, EXP MOL MED, V49, DOI 10.1038/emm.2017.10
   Langlois T, 2014, STEM CELLS, V32, P2084, DOI 10.1002/stem.1718
   Ohm JE, 2007, NAT GENET, V39, P237, DOI 10.1038/ng1972
   Pronier E, 2011, BLOOD, V118, P2551, DOI 10.1182/blood-2010-12-324707
   Qian J, 2009, EUR J HAEMATOL, V82, P119, DOI 10.1111/j.1600-0609.2008.01178.x
   Radich JP, 2006, P NATL ACAD SCI USA, V103, P2794, DOI 10.1073/pnas.0510423103
   Rassenti LZ, 2004, NEW ENGL J MED, V351, P893, DOI 10.1056/NEJMoa040857
   Rosenfeld C, 2003, LEUKEMIA, V17, P1301, DOI 10.1038/sj.leu.2402988
   Schenk T, 2007, GENE CHROMOSOME CANC, V46, P796, DOI 10.1002/gcc.20465
   Shi CS, 1999, BLOOD, V93, P1338, DOI 10.1182/blood.V93.4.1338.404k27_1338_1345
   Shi R, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/978984
   Soverini S, 2006, CLIN CANCER RES, V12, P7374, DOI 10.1158/1078-0432.CCR-06-1516
   Sproul D, 2013, BRIEF FUNCT GENOMICS, V12, P174, DOI 10.1093/bfgp/els063
   Sproul D, 2012, GENOME BIOL, V13, DOI [10.1186/gb-2012-13-10-r84, 10.1186/gb-2012-13-10-R84]
   Sproul D, 2011, P NATL ACAD SCI USA, V108, P4364, DOI 10.1073/pnas.1013224108
   Strathdee G, 2007, CLIN CANCER RES, V13, P5048, DOI 10.1158/1078-0432.CCR-07-0919
   Sun BD, 2001, CANCER RES, V61, P6931
   Tekpli X, 2016, EPIGENET CHROMATIN, V9, DOI 10.1186/s13072-016-0070-8
   Trowbridge JJ, 2009, CELL STEM CELL, V5, P442, DOI 10.1016/j.stem.2009.08.016
   Uehara E, 2012, ONCOL LETT, V3, P190, DOI 10.3892/ol.2011.419
   Uribe-Lewis S, 2015, GENOME BIOL, V16, DOI 10.1186/s13059-015-0605-5
   van der Loeff IS, 2014, J IMMUNOL, V193, P2873, DOI 10.4049/jimmunol.1400858
   Van Tongelen A, 2017, CANCER LETT, V396, P130, DOI 10.1016/j.canlet.2017.03.029
   Watari K, 2000, FEBS LETT, V466, P367, DOI 10.1016/S0014-5793(00)01112-1
   Weber M, 2007, NAT GENET, V39, P457, DOI 10.1038/ng1990
NR 51
TC 20
Z9 21
U1 0
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1878-0261
J9 MOL ONCOL
JI Mol. Oncol.
PD JUN
PY 2018
VL 12
IS 6
BP 814
EP 829
DI 10.1002/1878-0261.12191
PG 16
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA GI1TD
UT WOS:000434152600004
PM 29575763
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Jiang, TT
   Hoover, ME
   Holt, MV
   Freitas, MA
   Marshall, AG
   Young, NL
AF Jiang, Tingting
   Hoover, Michael E.
   Holt, Matthew V.
   Freitas, Michael A.
   Marshall, Alan G.
   Young, Nicolas L.
TI Middle-Down Characterization of the Cell Cycle Dependence of Histone H4
   Posttranslational Modifications and Proteoforms
SO PROTEOMICS
LA English
DT Article
DE epigenetics; ETD; FT-ICR; mass spectrometry; PTM; WCX-HILIC
ID ION-CYCLOTRON RESONANCE; MASS-SPECTROMETRY REVEALS; TOP-DOWN;
   BREAST-CANCER; CHROMATIN; ACETYLATION; MITOSIS; TESLA; PHOSPHORYLATION;
   METHYLATION
AB Post-translational modifications (PTMs) of histones are important epigenetic regulatory mechanisms that are often dysregulated in cancer. We employ middle-down proteomics to investigate the PTMs and proteoforms of histone H4 during cell cycle progression. We use pH gradient weak cation exchange-hydrophilic interaction liquid chromatography (WCX-HILIC) for on-line liquid chromatography-mass spectrometry analysis to separate and analyze the proteoforms of histone H4. This procedure provides enhanced separation of proteoforms, including positional isomers, and simplifies downstream data analysis. We use ultrahigh mass accuracy and resolution Fourier transform-ion cyclotron resonance (FT-ICR) mass spectrometer to unambiguously distinguish between acetylation and tri-methylation (m=0.036Da). In total, we identify and quantify 233 proteoforms of histone H4 in two breast cancer cell lines. We observe significant increases in S1 phosphorylation during mitosis, implicating an important role in mitotic chromatin condensation. A decrease of K20 unmodified proteoforms is observed as the cell cycle progresses, corresponding to an increase of K20 mono- and di-methylation. Acetylation at K5, K8, K12, and K16 declines as cells traverse from S phase to mitosis, suggesting cell cycle-dependence and an important role during chromatin replication and condensation. These new insights into the epigenetics of the cell cycle may provide new diagnostic and prognostic biomarkers.
C1 [Jiang, Tingting; Marshall, Alan G.] Florida State Univ, Dept Chem & Biochem, 95 Chieftain Way, Tallahassee, FL 32306 USA.
   [Hoover, Michael E.; Freitas, Michael A.] Ohio State Univ, Dept Canc Biol & Genet, 460 West 12th Ave, Columbus, OH 43210 USA.
   [Holt, Matthew V.; Young, Nicolas L.] Baylor Coll Med, Verna & Marrs McLean Dept Biochem & Mol Biol, One Baylor Plaza, Houston, TX 77030 USA.
   [Marshall, Alan G.] Natl High Magnet Field Lab, Ion Cyclotron Resonance Program, 1800 East Paul Dirac Dr, Tallahassee, FL 32310 USA.
   [Young, Nicolas L.] Baylor Coll Med, Dept Mol & Cellular Biol, One Baylor Plaza, Houston, TX 77030 USA.
C3 State University System of Florida; Florida State University; University
   System of Ohio; Ohio State University; Baylor College of Medicine; State
   University System of Florida; Florida State University; Baylor College
   of Medicine
RP Young, NL (通讯作者)，Baylor Coll Med, Verna & Marrs McLean Dept Biochem & Mol Biol, One Baylor Plaza, Houston, TX 77030 USA.; Young, NL (通讯作者)，Baylor Coll Med, Dept Mol & Cellular Biol, One Baylor Plaza, Houston, TX 77030 USA.
EM Nicolas.Young@bcm.edu
RI Freitas, Michael/C-8953-2009; Jiang, Tingting/GLS-5518-2022; Young,
   Nicolas/AAI-5242-2020
OI Young, Nicolas/0000-0002-3323-2815
FU NSF Division of Materials Research [DMR 11-57490]; State of Florida; NIH
   [CA016058, OD018056]; Ohio State University
FX This work was supported by NSF Division of Materials Research through
   DMR 11-57490, and the State of Florida. This work was supported by NIH
   awards CA016058, OD018056 and support from the Ohio State University.
   Rawmass spectrometry data was deposited into ProteomeXchange via the
   PRIDE partner repository with the dataset identifier PXD008296.
CR Banerjee T, 2011, MOL CELL BIOL, V31, P4858, DOI 10.1128/MCB.05631-11
   Bannister AJ, 2011, CELL RES, V21, P381, DOI 10.1038/cr.2011.22
   Barber CM, 2004, CHROMOSOMA, V112, P360, DOI 10.1007/s00412-004-0281-9
   Bönisch C, 2008, EXPERT REV PROTEOMIC, V5, P105, DOI 10.1586/14789450.5.1.105
   Brustel J, 2011, TRENDS CELL BIOL, V21, P452, DOI 10.1016/j.tcb.2011.04.006
   Chen Y, 2016, MOL CELL PROTEOMICS, V15, P818, DOI 10.1074/mcp.M114.046441
   Chi P, 2010, NAT REV CANCER, V10, P457, DOI 10.1038/nrc2876
   Dang XB, 2014, PROTEOMICS, V14, P1130, DOI 10.1002/pmic.201300438
   DiMaggio PA, 2009, MOL CELL PROTEOMICS, V8, P2527, DOI 10.1074/mcp.M900144-MCP200
   Dion MF, 2005, P NATL ACAD SCI USA, V102, P5501, DOI 10.1073/pnas.0500136102
   Doerks T, 2002, GENOME RES, V12, P47, DOI 10.1101/gr.203201
   Fuchs SM, 2011, CURR BIOL, V21, P53, DOI 10.1016/j.cub.2010.11.058
   Harshman SW, 2014, J PROTEOME RES, V13, P2453, DOI 10.1021/pr401248f
   Hendrickson CL, 2015, J AM SOC MASS SPECTR, V26, P1626, DOI 10.1007/s13361-015-1182-2
   Jorgensen S, 2013, NUCLEIC ACIDS RES, V41, P2797, DOI 10.1093/nar/gkt012
   Kaiser NK, 2011, J AM SOC MASS SPECTR, V22, P1343, DOI 10.1007/s13361-011-0141-9
   Kelleher NL, 2004, ANAL CHEM, V76, p196A, DOI 10.1021/ac0415657
   Koprinarova MA, 2008, CELL CYCLE, V7, P414, DOI 10.4161/cc.7.3.5314
   Kornberg RD, 1999, CELL, V98, P285, DOI 10.1016/S0092-8674(00)81958-3
   Kruhlak MJ, 2001, J BIOL CHEM, V276, P38307
   Kurdistani SK, 2004, CELL, V117, P721, DOI 10.1016/j.cell.2004.05.023
   LEDFORD EB, 1984, ANAL CHEM, V56, P2744, DOI 10.1021/ac00278a027
   Li B, 2007, SCIENCE, V316, P1050, DOI 10.1126/science.1139004
   Liu CL, 2005, PLOS BIOL, V3, P1753, DOI 10.1371/journal.pbio.0030328
   Lo PK, 2008, PHARMACOGENOMICS, V9, P1879, DOI 10.2217/14622416.9.12.1879
   Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444
   Maddika S, 2007, DRUG RESIST UPDATE, V10, P13, DOI 10.1016/j.drup.2007.01.003
   Marshall AG, 1998, MASS SPECTROM REV, V17, P1, DOI 10.1002/(SICI)1098-2787(1998)17:1<1::AID-MAS1>3.0.CO;2-K
   Moradian A, 2014, PROTEOMICS, V14, P489, DOI 10.1002/pmic.201300256
   Morinière J, 2009, NATURE, V461, P664, DOI 10.1038/nature08397
   Pesavento JJ, 2008, J BIOL CHEM, V283, P14927, DOI 10.1074/jbc.M709796200
   Pesavento JJ, 2008, MOL CELL BIOL, V28, P468, DOI 10.1128/MCB.01517-07
   Pesavento JJ, 2006, ANAL CHEM, V78, P4271, DOI 10.1021/ac0600050
   Phanstiel D, 2008, P NATL ACAD SCI USA, V105, P4093, DOI 10.1073/pnas.0710515105
   Rea M, 2016, MOL CELL PROTEOMICS, V15, P2411, DOI 10.1074/mcp.M116.058412
   Ruthenburg AJ, 2007, NAT REV MOL CELL BIO, V8, P983, DOI 10.1038/nrm2298
   Saksouk N, 2009, MOL CELL, V33, P257, DOI 10.1016/j.molcel.2009.01.007
   Schaub TM, 2008, ANAL CHEM, V80, P3985, DOI 10.1021/ac800386h
   Sharma S, 2010, CARCINOGENESIS, V31, P27, DOI 10.1093/carcin/bgp220
   Sidoli S, 2014, PROTEOMICS, V14, P2200, DOI 10.1002/pmic.201400084
   Smith LM, 2013, NAT METHODS, V10, P186, DOI 10.1038/nmeth.2369
   Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412
   Tian ZX, 2012, GENOME BIOL, V13, DOI [10.1186/gb-2012-13-10-R86, 10.1186/gb-2012-13-10-r86]
   Trojer P, 2007, CELL, V129, P915, DOI 10.1016/j.cell.2007.03.048
   Vaquero A, 2006, GENE DEV, V20, P1256, DOI 10.1101/gad.1412706
   Weisbrod CR, 2017, J AM SOC MASS SPECTR, V28, P1787, DOI 10.1007/s13361-017-1702-3
   Yamamoto Kazuki, 2015, Mass Spectrom (Tokyo), V4, pA0039, DOI 10.5702/massspectrometry.A0039
   Young NL, 2010, CELL MOL LIFE SCI, V67, P3983, DOI 10.1007/s00018-010-0475-7
   Young NL, 2009, MOL CELL PROTEOMICS, V8, P2266, DOI 10.1074/mcp.M900238-MCP200
   Yun MY, 2011, CELL RES, V21, P564, DOI 10.1038/cr.2011.42
NR 50
TC 30
Z9 33
U1 0
U2 20
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1615-9853
EI 1615-9861
J9 PROTEOMICS
JI Proteomics
PD JUN
PY 2018
VL 18
IS 11
AR 1700442
DI 10.1002/pmic.201700442
PG 11
WC Biochemical Research Methods; Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA GI4TE
UT WOS:000434363300005
PM 29667342
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Schlensog, M
   Magnus, L
   Heide, T
   Eschenbruch, J
   Steib, F
   Tator, M
   Kloten, V
   Rose, M
   Noetzel, E
   Gaisa, NT
   Knüchel, R
   Dahl, E
AF Schlensog, Martin
   Magnus, Lara
   Heide, Timon
   Eschenbruch, Julian
   Steib, Florian
   Tator, Maximilian
   Kloten, Vera
   Rose, Michael
   Noetzel, Erik
   Gaisa, Nadine T.
   Knuechel, Ruth
   Dahl, Edgar
TI Epigenetic loss of putative tumor suppressor <i>SFRP3</i> correlates
   with poor prognosis of lung adenocarcinoma patients
SO EPIGENETICS
LA English
DT Article
DE Lung cancer; NSCLC; WNT signaling; SFRP3; DNA methylation
ID BETA-CATENIN; BREAST-CANCER; PROMOTER METHYLATION; SPEMANN ORGANIZER;
   COLON-CARCINOMA; WNT ANTAGONIST; CYCLIN D1; EXPRESSION; CELLS; GROWTH
AB Secreted frizzled related protein 3 (SFRP3) contains a cysteine-rich domain (CRD) that shares homology with Frizzled CRD and regulates WNT signaling. Independent studies showed epigenetic silencing of SFRP3 in melanoma and hepatocellular carcinoma. Moreover, a tumor suppressive function of SFRP3 was shown in androgen-independent prostate and gastric cancer cells. The current study is the first to investigate SFRP3 expression and its potential clinical impact on non-small cell lung carcinoma (NSCLC). WNT signaling components present on NSCLC subtypes were preliminary elucidated by expression data of The Cancer Genome Atlas (TCGA). We identified a distinct expression signature of relevant WNT signaling components that differ between adenocarcinoma (LUAD) and squamous cell carcinoma (LUSC). Of interest, canonical WNT signaling is predominant in LUAD samples and non-canonical WNT signaling is predominant in LUSC. In line, high SFRP3 expression resulted in beneficial clinical outcome for LUAD but not for LUSC patients. Furthermore, SFRP3 mRNA expression was significantly decreased in NSCLC tissue compared to normal lung samples. TCGA data verified the reduction of SFRP3 in LUAD and LUSC patients. Moreover, DNA hypermethylation of SFRP3 was evaluated in the TCGA methylation dataset resulting in epigenetic inactivation of SFRP3 expression in LUAD, but not in LUSC, and was validated by pyrosequencing of our NSCLC tissue cohort and in vitro demethylation experiments. Immunohistochemistry confirmed SFRP3 protein downregulation in primary NSCLC and indicated abundant expression in normal lung tissue. Two adenocarcinoma gain-of-function models were used to analyze the functional impact of SFRP3 on cell proliferation and regulation of CyclinD1 expression in vitro. Our results indicate that SFRP3 acts as a novel putative tumor suppressor gene in adenocarcinoma of the lung possibly regulating canonical WNT signaling.
C1 [Schlensog, Martin; Magnus, Lara; Heide, Timon; Eschenbruch, Julian; Steib, Florian; Tator, Maximilian; Kloten, Vera; Rose, Michael; Gaisa, Nadine T.; Knuechel, Ruth; Dahl, Edgar] Rhein Westfal TH Aachen, Inst Pathol, Med Fac, Aachen, Germany.
   [Noetzel, Erik] Res Ctr Julich, Inst Complex Syst, Julich, Germany.
   [Dahl, Edgar] Rhein Westfal TH Aachen, Inst Pathol, Med Fac, RWTH Centralized Biomat Bank RWTH CBMB, Aachen, Germany.
C3 RWTH Aachen University; Helmholtz Association; Research Center Julich;
   RWTH Aachen University
RP Dahl, E (通讯作者)，Hosp RWTH Aachen Univ, Inst Pathol, Mol Oncol Grp, Pauwelsstr 30, D-52074 Aachen, Germany.
EM edahl@ukaachen.de
RI Noetzel-Reiss, Erik/GYV-0999-2022
OI Eschenbruch, Julian/0000-0002-3430-3590; Gaisa,
   Nadine/0000-0002-4762-3964; Steib, Florian/0009-0007-9416-1508
CR Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018
   ConnellCrowley L, 1997, MOL BIOL CELL, V8, P287, DOI 10.1091/mbc.8.2.287
   Ekström EJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018674
   Fink L, 1998, NAT MED, V4, P1329, DOI 10.1038/3327
   Gyorffy B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082241
   He B, 2004, NEOPLASIA, V6, P7, DOI 10.1016/S1476-5586(04)80048-4
   Hoang B, 1996, J BIOL CHEM, V271, P26131, DOI 10.1074/jbc.271.42.26131
   Hommura F, 2002, CANCER-AM CANCER SOC, V94, P752, DOI 10.1002/cncr.10213
   Katoh M, 2005, ONCOL REP, V14, P783
   Katoh M, 2005, ONCOL REP, V14, P1583
   Kawano Y, 2003, J CELL SCI, V116, P2627, DOI 10.1242/jcs.00623
   Kongkham PN, 2010, ONCOGENE, V29, P3017, DOI 10.1038/onc.2010.32
   Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784
   Leyns L, 1997, CELL, V88, P747, DOI 10.1016/S0092-8674(00)81921-2
   Lin KM, 1997, P NATL ACAD SCI USA, V94, P11196, DOI 10.1073/pnas.94.21.11196
   Lin YW, 2014, DIS MARKERS, V2014, DOI 10.1155/2014/351863
   Marsit CJ, 2010, PLOS ONE, P5
   Mazieres J, 2005, CANCER LETT, V222, P1, DOI 10.1016/j.canlet.2004.08.040
   McRonald FE, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-31
   Minna JD, 1998, HARRISONS PRINCIPLES, P552
   Mizushima T, 2002, CANCER RES, V62, P277
   Mori M, 2001, MODERN PATHOL, V14, P72, DOI 10.1038/modpathol.3880259
   Morin PJ, 1999, BIOESSAYS, V21, P1021, DOI 10.1002/(SICI)1521-1878(199912)22:1<1021::AID-BIES6>3.0.CO;2-P
   Nakashima T, 2008, ONCOL REP, V19, P203
   Noetzel E, 2010, ONCOGENE, V29, P4814, DOI 10.1038/onc.2010.229
   Noetzel E, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-154
   Parkin DM, 2001, EUR J CANCER, V37, pS4, DOI 10.1016/S0959-8049(01)00267-2
   Person AD, 2005, DEV BIOL, V278, P35, DOI 10.1016/j.ydbio.2004.10.013
   Polakis P, 2000, GENE DEV, V14, P1837
   Pourreyron C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031827
   Qu Y, 2008, J CANCER RES CLIN, V134, P353, DOI 10.1007/s00432-007-0291-0
   REMMELE W, 1987, PATHOLOGE, V8, P138
   Sekido Y, 1998, BBA-REV CANCER, V1378, pF21, DOI 10.1016/S0304-419X(98)00010-9
   Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522
   Stacey DW, 2003, CURR OPIN CELL BIOL, V15, P158, DOI 10.1016/S0955-0674(03)00008-5
   Sunaga N, 2001, GENE CHROMOSOME CANC, V30, P316, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1097>3.0.CO;2-9
   Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884
   Ueda M, 2001, BRIT J CANCER, V85, P64, DOI 10.1054/bjoc.2001.1863
   Uematsu K, 2003, ONCOGENE, V22, P7218, DOI 10.1038/sj.onc.1206817
   Veeck J, 2008, ONCOGENE, V27, P865, DOI 10.1038/sj.onc.1210669
   Veeck J, 2006, ONCOGENE, V25, P3479, DOI 10.1038/sj.onc.1209386
   Veeman MT, 2003, DEV CELL, V5, P367, DOI 10.1016/S1534-5807(03)00266-1
   Wang SW, 1997, CELL, V88, P757, DOI 10.1016/S0092-8674(00)81922-4
   Winn RA, 2002, ONCOGENE, V21, P7497, DOI 10.1038/sj.onc.1205963
   You L, 2004, CANCER RES, V64, P3474, DOI 10.1158/0008-5472.CAN-04-0115
   Yuzugullu H, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-90
   Zi XL, 2005, CANCER RES, V65, P9762, DOI 10.1158/0008-5472.CAN-05-0103
NR 47
TC 16
Z9 17
U1 1
U2 3
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1559-2294
EI 1559-2308
J9 EPIGENETICS-US
JI Epigenetics
PY 2018
VL 13
IS 3
BP 214
EP 227
DI 10.1080/15592294.2016.1229730
PG 14
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA GI4FO
UT WOS:000434326600002
PM 27623992
OA Green Published, Bronze
DA 2025-01-12
ER

PT J
AU Zheng, YZ
   Xue, MZ
   Shen, HJ
   Li, XG
   Ma, D
   Gong, Y
   Liu, YR
   Qiao, F
   Xie, HY
   Lian, B
   Sun, WL
   Zhao, HY
   Yao, L
   Zuo, WJ
   Li, DQ
   Wang, P
   Hu, X
   Shao, ZM
AF Zheng, Yi-Zi
   Xue, Meng-Zhu
   Shen, Hong-Jie
   Li, Xiao-Guang
   Ma, Ding
   Gong, Yue
   Liu, Yi-Rong
   Qiao, Feng
   Xie, Hong-Yan
   Lian, Bi
   Sun, Wei-Li
   Zhao, Hai-Yun
   Yao, Ling
   Zuo, Wen-Jia
   Li, Da-Qiang
   Wang, Peng
   Hu, Xin
   Shao, Zhi-Ming
TI PHF5A Epigenetically Inhibits Apoptosis to Promote Breast Cancer
   Progression
SO CANCER RESEARCH
LA English
DT Article
ID GENE-EXPRESSION PROFILES; SPLICING REGULATION; CLASSIFICATION; ISOFORM;
   REVEALS
AB Alternative splicing (AS) and its regulation play critical roles in cancer, yet the dysregulation of AS and its molecular bases in breast cancer development have not yet been elucidated. Using an in vivo CRISPR screen targeting RNA-binding proteins, we identified PHD finger protein 5A (PHF5A) as a key splicing factor involved in tumor progression. PHF5A expression was frequently upregulated in breast cancer and correlated with poor survival, and knockdown of PHF5A significantly suppressed cell proliferation, migration, and tumor formation. PHF5A was required For SF3b Spliceosome stability and linked the complex to histones, and the PHF5A-SF3b complex modulated AS changes in apoptoticsignaling. In addition, expression of a short truncated FAS-activated serine/threonine kinase (FASTK) protein was increased after PHF5A ablation and facilitated has-mediated apoptosis. This PHF5A-modulated FASTK-AS axis was widely present in breast cancer specimens, particularly those of the triple-negative subtype. Taken together, our findings reveal that PHF5A serves as an epigenetic suppressor of apoptosis and thus provides a mechanistic basis for breast cancer progression and may be a valuable therapeutic target.
   Significance: This study provides an epigenetic mechanistic basis for the aggressive biology of breast cancer and identifies translatable therapeutic target. (C)2018 AACR.
C1 [Zheng, Yi-Zi; Li, Xiao-Guang; Ma, Ding; Gong, Yue; Liu, Yi-Rong; Qiao, Feng; Xie, Hong-Yan; Lian, Bi; Sun, Wei-Li; Zhao, Hai-Yun; Yao, Ling; Zuo, Wen-Jia; Li, Da-Qiang; Hu, Xin; Shao, Zhi-Ming] Fudan Univ, Shanghai Canc Ctr, Dept Breast Surg, Key Lab Breast Canc Shanghai, Shanghai, Peoples R China.
   [Zheng, Yi-Zi; Ma, Ding; Gong, Yue; Liu, Yi-Rong; Xie, Hong-Yan; Lian, Bi; Zhao, Hai-Yun; Zuo, Wen-Jia; Hu, Xin; Shao, Zhi-Ming] Fudan Univ, Shanghai Med Coll, Dept Oncol, Shanghai, Peoples R China.
   [Xue, Meng-Zhu] Chinese Acad Sci, SARI Ctr Stem Cell & Nanomed, Shanghai Adv Res Inst, Shanghai, Peoples R China.
   [Shen, Hong-Jie] Fudan Univ, Shanghai Med Coll, Epigenet Lab, Inst Biomed Sci, Shanghai, Peoples R China.
   [Shen, Hong-Jie] Fudan Univ, Shanghai Med Coll, Sch Basic Med, Shanghai, Peoples R China.
   [Wang, Peng] Chinese Acad Sci, Biomed Big Data Ctr, Key Lab Computat Biol, Shanghai Inst Biol Sci,CAS MPG Partner Inst Compu, Shanghai, Peoples R China.
C3 Fudan University; Fudan University; Chinese Academy of Sciences;
   Shanghai Advanced Research Institute, CAS; Fudan University; Fudan
   University; Chinese Academy of Sciences
RP Hu, X (通讯作者)，Fudan Univ, Key Lab Breast Canc Shanghai, Shanghai Canc Ctr, 270 DongAn Rd, Shanghai 200032, Peoples R China.; Shao, ZM (通讯作者)，Fudan Univ, Dept Breast Surg, Shanghai Canc Ctr, 270 DongAn Rd, Shanghai 200032, Peoples R China.
EM xinhu@fudan.edu.cn; zhimingshao@fudan.edu.cn
RI Zheng, Yi-Zi/AAC-1440-2022; XUE, MENG/JZD-0120-2024; shen,
   hong/HTQ-6147-2023; Hu, Xin/JEP-4891-2023; Gong, Yue/IAN-5129-2023;
   Zheng, Yi-Zi/ADB-3126-2022
OI wang, peng/0000-0002-2972-7495; Zheng, Yi-Zi/0000-0002-3847-8494; Shen,
   Hongjie/0000-0001-9771-7988; Liu, Yirong/0000-0003-4019-6901; Hu,
   Xin/0000-0002-8915-3526
FU Ministry of Science and Technology of China (National Key R&D Program of
   China) [MOST2016YFC0900300]; National Natural Science Foundation of
   China [81572583, 81672601]; Shanghai Committee of Science and Technology
   Funds [15410724000]
FX We thank Fei Lan for providing expert advice, reagents, and technical
   support. This study was supported by grants from the Ministry of Science
   and Technology of China (National Key R&D Program of China,
   MOST2016YFC0900300 to X. Hu), the National Natural Science Foundation of
   China (81572583 to Z.M. Shao and 81672601 to X. Hu) and the Shanghai
   Committee of Science and Technology Funds (15410724000 to X. Hu).
CR Barbie DA, 2009, NATURE, V462, P108, DOI 10.1038/nature08460
   BROSI R, 1993, SCIENCE, V262, P102, DOI 10.1126/science.8211112
   Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095
   Chen M, 2009, NAT REV MOL CELL BIO, V10, P741, DOI 10.1038/nrm2777
   Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983
   David CJ, 2010, GENE DEV, V24, P2343, DOI 10.1101/gad.1973010
   Fu XD, 2014, NAT REV GENET, V15, P689, DOI 10.1038/nrg3778
   Gerstberger S, 2014, NAT REV GENET, V15, P829, DOI 10.1038/nrg3813
   Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531
   Guo R, 2014, MOL CELL, V56, P298, DOI 10.1016/j.molcel.2014.08.022
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Hu M, 2008, CANCER CELL, V13, P394, DOI 10.1016/j.ccr.2008.03.007
   Hu X, 2011, J BIOL CHEM, V286, P11734, DOI 10.1074/jbc.M110.200857
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923
   Hubert CG, 2013, GENE DEV, V27, P1032, DOI 10.1101/gad.212548.112
   Katz Y, 2010, NAT METHODS, V7, P1009, DOI 10.1038/NMETH.1528
   Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412
   Kornblihtt AR, 2017, J CLIN INVEST, V127, P3287, DOI 10.1172/JCI96497
   Lee SCW, 2016, NAT MED, V22, P976, DOI 10.1038/nm.4165
   Li W, 2004, MOL CELL BIOL, V24, P10718, DOI 10.1128/MCB.24.24.10718-10732.2004
   Li W, 2004, BIOCHEM BIOPH RES CO, V318, P95, DOI 10.1016/j.bbrc.2004.03.188
   Lu FM, 2003, CANCER RES, V63, P7056
   Luco RF, 2010, SCIENCE, V327, P996, DOI 10.1126/science.1184208
   Luger K, 1999, METHOD ENZYMOL, V304, P3
   Luger K, 1997, J MOL BIOL, V272, P301, DOI 10.1006/jmbi.1997.1235
   Luo B, 2008, P NATL ACAD SCI USA, V105, P20380, DOI 10.1073/pnas.0810485105
   Ma XJ, 2003, P NATL ACAD SCI USA, V100, P5974, DOI 10.1073/pnas.0931261100
   Musselman CA, 2011, NUCLEIC ACIDS RES, V39, P9061, DOI 10.1093/nar/gkr613
   Nagaraja GM, 2006, ONCOGENE, V25, P2328, DOI 10.1038/sj.onc.1209265
   Oltean S, 2014, ONCOGENE, V33, P5311, DOI 10.1038/onc.2013.533
   Parker JS, 2009, J CLIN ONCOL, V27, P1160, DOI 10.1200/JCO.2008.18.1370
   Saltzman AL, 2011, GENE DEV, V25, P373, DOI 10.1101/gad.2004811
   Sanchez R, 2011, TRENDS BIOCHEM SCI, V36, P364, DOI 10.1016/j.tibs.2011.03.005
   Shalem O, 2014, SCIENCE, V343, P84, DOI 10.1126/science.1247005
   Shi XB, 2006, NATURE, V442, P96, DOI 10.1038/nature04835
   Sims RJ, 2007, MOL CELL, V28, P665, DOI 10.1016/j.molcel.2007.11.010
   Sotiriou C, 2003, P NATL ACAD SCI USA, V100, P10393, DOI 10.1073/pnas.1732912100
   SOULE HD, 1990, CANCER RES, V50, P6075
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Sveen A, 2016, ONCOGENE, V35, P2413, DOI 10.1038/onc.2015.318
   Teng T, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15522
   Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262
   Venables JP, 2004, CANCER RES, V64, P7647, DOI 10.1158/0008-5472.CAN-04-1910
   Wang ET, 2008, NATURE, V456, P470, DOI 10.1038/nature07509
   Wong JJL, 2016, BIOESSAYS, V38, P41, DOI 10.1002/bies.201500117
   Yao J, 2006, CANCER RES, V66, P4065, DOI 10.1158/0008-5472.CAN-05-4083
   Yuan HR, 2017, J CLIN INVEST, V127, P3381, DOI 10.1172/JCI94292
   Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r137
NR 49
TC 60
Z9 62
U1 1
U2 29
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD JUN 15
PY 2018
VL 78
IS 12
BP 3190
EP 3206
DI 10.1158/0008-5472.CAN-17-3514
PG 17
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA GJ5ZJ
UT WOS:000435462000008
PM 29700004
OA Green Submitted
DA 2025-01-12
ER

PT J
AU Nair, VS
   El Salhat, H
   Taha, RZ
   John, A
   Ali, BR
   Elkord, E
AF Nair, Varun Sasidharan
   El Salhat, Haytham
   Taha, Rowaida Z.
   John, Anne
   Ali, Bassam R.
   Elkord, Eyad
TI DNA methylation and repressive H3K9 and H3K27 trimethylation in the
   promoter regions of PD-1, CTLA-4, TIM-3, LAG-3, TIGIT, and PD-L1 genes
   in human primary breast cancer
SO CLINICAL EPIGENETICS
LA English
DT Article
DE Breast cancer; Immune checkpoints; PD-L1; DNA methylation; Histone
   trimethylation
ID T-CELLS; HISTONE MODIFICATIONS; IMMUNE CHECKPOINTS; FOXP3 ENHANCER;
   CPG-ISLANDS; DEMETHYLATION; ASSOCIATION; HYPOMETHYLATION; IMMUNOTHERAPY;
   MODULATION
AB Background: High expression of immune checkpoints in tumor microenvironment plays significant roles in inhibiting anti-tumor immunity, which is associated with poor prognosis and cancer progression. Major epigenetic modifications in both DNA and histone could be involved in upregulation of immune checkpoints in cancer.
   Methods: Expressions of different immune checkpoint genes and PD-L1 were assessed using qRT-PCR, and the underlying epigenetic modifications including CpG methylation and repressive histone abundance were determined using bisulfite sequencing, and histone 3 lysine 9 trimethylation (H3K9me3) and histone 3 lysine 27 trimethylation (H3K27me3) chromatin immunoprecipitation assays (ChIP), respectively.
   Results: We first assessed the expression level of six immune checkpoints/ligands and found that PD-1, CTLA-4, TIM-3, and LAG-3 were significantly upregulated in breast tumor tissues (TT), compared with breast normal tissues (NT). We investigated the epigenetic modifications beyond this upregulation in immune checkpoint genes. Interestingly, we found that CpG islands in the promoter regions of PD-1, CTLA-4, and TIM-3 were significantly hypomethylated in tumor compared with normal tissues. Additionally, CpG islands of PD-L1 promoter were completely demethylated (100%), LAG-3 were highly hypomethylated (80-90%), and TIGIT were poorly hypomethylated (20-30%), in both NT and TT. These demethylation findings are in accordance with the relative expression data that, out of all these genes, PD-L1 was highly expressed and completely demethylated and TIGIT was poorly expressed and hypermethylated in both NT and TT. Moreover, bindings of H3K9me3 and H3K27me3 were found to be reduced in the promoter loci of PD-1, CTLA-4, TIM-3, and LAG-3 in tumor tissues.
   Conclusion: Our data demonstrate that both DNA and histone modifications are involved in upregulation of PD-1, CTLA-4, TIM-3, and LAG-3 in breast tumor tissue and these epigenetic modifications could be useful as diagnostic/prognostic biomarkers and/or therapeutic targets in breast cancer.
C1 [Nair, Varun Sasidharan; Taha, Rowaida Z.; Elkord, Eyad] Hamad Bin Khalifa Univ, Canc Res Ctr, Qatar Biomed Res Inst, Coll Sci & Engn,Qatar Fdn, Doha, Qatar.
   [El Salhat, Haytham] Al Noor Hosp, Oncol Dept, Abu Dhabi, U Arab Emirates.
   [El Salhat, Haytham] Tawam Hosp, Oncol Dept, Al Ain, U Arab Emirates.
   [John, Anne; Ali, Bassam R.] United Arab Emirates Univ, Dept Pathol, Coll Med & Hlth Sci, Al Ain, U Arab Emirates.
   [Ali, Bassam R.] United Arab Emirates Univ, Zayed Ctr Hlth Sci, Al Ain, U Arab Emirates.
   [Elkord, Eyad] Univ Manchester, Inst Canc Sci, Manchester, Lancs, England.
C3 Qatar Foundation (QF); Hamad Bin Khalifa University-Qatar; Qatar
   Biomedical Research Institute (QBRI); United Arab Emirates University;
   United Arab Emirates University; University of Manchester
RP Elkord, E (通讯作者)，Hamad Bin Khalifa Univ, Canc Res Ctr, Qatar Biomed Res Inst, Coll Sci & Engn,Qatar Fdn, Doha, Qatar.; Elkord, E (通讯作者)，Univ Manchester, Inst Canc Sci, Manchester, Lancs, England.
EM eelkord@hbku.edu.qa
RI Elkord, Eyad/AAE-1136-2020; Nair, Varun/AAQ-5533-2021; Ali, Bassam
   R/J-7014-2012
OI Elkord, Eyad/0000-0002-3868-0318; Taha, Rowaida Z./0000-0001-6119-8389;
   Sasidharan Nair, Varun/0000-0001-5047-2338; Ali, Bassam
   R/0000-0003-1306-6618
FU Qatar Biomedical research Institute, Qatar Foundation [VR04]
FX This work was supported by a start-up grant [VR04] for Dr. Eyad Elkord
   from Qatar Biomedical research Institute, Qatar Foundation.
CR Ali MA, 2017, IMMUNOTHERAPY-UK, V9, P99, DOI 10.2217/imt-2016-0111
   Antoniou AC, 2006, ONCOGENE, V25, P5898, DOI 10.1038/sj.onc.1209879
   Bediaga NG, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2721
   Briere D, 2018, CANCER IMMUNOL IMMUN, V67, P381, DOI 10.1007/s00262-017-2091-y
   Burugu S, 2017, ANN ONCOL, V28, P2977, DOI 10.1093/annonc/mdx557
   Cedar H, 2009, NAT REV GENET, V10, P295, DOI 10.1038/nrg2540
   Chaudhary B, 2016, VACCINES-BASEL, V4, DOI 10.3390/vaccines4030028
   Daver N, 2018, LEUKEMIA, V32, P1094, DOI 10.1038/s41375-018-0070-8
   Deaton AM, 2011, GENE DEV, V25, P1010, DOI 10.1101/gad.2037511
   Dworkin AM, 2009, SEMIN CANCER BIOL, V19, P165, DOI 10.1016/j.semcancer.2009.02.007
   Ehrlich M, 2009, EPIGENOMICS-UK, V1, P239, DOI [10.2217/epi.09.33, 10.2217/EPI.09.33]
   Emens LA, 2012, EXPERT REV ANTICANC, V12, P1597, DOI [10.1586/era.12.147, 10.1586/ERA.12.147]
   Fleischer T, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00510-x
   Gallagher SJ, 2017, CURR OPIN PHARMACOL, V35, P48, DOI 10.1016/j.coph.2017.05.006
   Geiman TM, 2002, J CELL BIOCHEM, V87, P117, DOI 10.1002/jcb.10286
   Guerriero JL, 2017, NATURE, V543, P428, DOI 10.1038/nature21409
   Healey MA, 2014, BREAST CANCER RES TR, V147, P639, DOI 10.1007/s10549-014-3089-1
   Jovanovic J, 2010, MOL ONCOL, V4, P242, DOI 10.1016/j.molonc.2010.04.002
   Judes G, 2016, EPIGENOMICS-UK, V8, P909, DOI 10.2217/epi-2016-0015
   Kanwal R, 2012, CLIN GENET, V81, P303, DOI 10.1111/j.1399-0004.2011.01809.x
   Karachaliou N, 2017, ANN TRANSL MED, V5, DOI 10.21037/atm.2017.06.47
   Karsli-Ceppioglu S, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-06790-z
   Khaja ASS, 2017, ONCOTARGET, V8, P33159, DOI 10.18632/oncotarget.16565
   Lee A, 2018, CANCER TREAT REV, V62, P110, DOI 10.1016/j.ctrv.2017.11.003
   Liu F, 2016, NAT REV CANCER, V16, P359, DOI 10.1038/nrc.2016.41
   Liu J, 2015, P NATL ACAD SCI USA, V112, P6682, DOI 10.1073/pnas.1420370112
   Mao H, 2010, CURR CANCER DRUG TAR, V10, P728, DOI 10.2174/156800910793605811
   Marwitz S, 2017, CLIN EPIGENETICS, V9, DOI 10.1186/s13148-017-0354-2
   Michailidou K, 2017, NATURE, V551, P92, DOI 10.1038/nature24284
   Miller Jaime L, 2013, Subcell Biochem, V61, P289, DOI 10.1007/978-94-007-4525-4_13
   MONK M, 1987, DEVELOPMENT, V99, P371
   Nair VS, 2018, IMMUNOL CELL BIOL, V96, P21, DOI 10.1111/imcb.1003
   Nair VS, 2016, MOL CELLS, V39, P888, DOI 10.14348/molcells.2016.0276
   Nair VS, 2016, J IMMUNOL, V196, P2119, DOI 10.4049/jimmunol.1502352
   Nielsen FC, 2016, NAT REV CANCER, V16, P599, DOI 10.1038/nrc.2016.72
   Nirschl CJ, 2013, CLIN CANCER RES, V19, P4917, DOI 10.1158/1078-0432.CCR-12-1972
   Ooi SKT, 2007, NATURE, V448, P714, DOI 10.1038/nature05987
   Orskov AD, 2015, ONCOTARGET, V6, P9612, DOI 10.18632/oncotarget.3324
   Pardoll DM, 2012, NAT REV CANCER, V12, P252, DOI 10.1038/nrc3239
   Rasmussen KD, 2016, GENE DEV, V30, P733, DOI 10.1101/gad.276568.115
   Ribas A, 2016, JAMA-J AM MED ASSOC, V315, P1600, DOI 10.1001/jama.2016.4059
   Sadakierska-Chudy A, 2015, NEUROTOX RES, V27, P84, DOI 10.1007/s12640-014-9497-5
   Sigalotti L, 2014, PHARMACOL THERAPEUT, V142, P339, DOI 10.1016/j.pharmthera.2013.12.015
   Solinas C, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01412
   Swart M, 2016, FRONT ONCOL, V6, DOI 10.3389/fonc.2016.00233
   Tahiliani M, 2009, SCIENCE, V324, P930, DOI 10.1126/science.1170116
   Takai D, 2002, P NATL ACAD SCI USA, V99, P3740, DOI 10.1073/pnas.052410099
   Terranova-Barberio M, 2017, ONCOTARGET, V8
   Terry MB, 2016, ADV EXP MED BIOL, V882, P33, DOI 10.1007/978-3-319-22909-6_2
   Troester M, 2016, BREAST CANC, V2, P16007
   van Hoesel AQ, 2013, BRIT J CANCER, V108, P2033, DOI 10.1038/bjc.2013.136
   Wei J, 2016, NEURO-ONCOLOGY, V18, P639, DOI 10.1093/neuonc/nov292
   Woods DM, 2015, CANCER IMMUNOL RES, V3, P1375, DOI 10.1158/2326-6066.CIR-15-0077-T
   Wu MJ, 2017, ONCOGENE, V36, P3193, DOI 10.1038/onc.2016.467
   Wu MZ, 2015, CANCER RES, V75, P3912, DOI 10.1158/0008-5472.CAN-14-3208
   Wu XJ, 2017, NAT REV GENET, V18, P517, DOI 10.1038/nrg.2017.33
   Xu SH, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11406
   Yang H, 2014, LEUKEMIA, V28, P1280, DOI 10.1038/leu.2013.355
   Zhang M, 2017, FRONT IMMUNOL, V8, P1, DOI 10.3389/fimmu.2017.00942
   Zhang TY, 2015, EMBO REP, V16, P1467, DOI 10.15252/embr.201540945
   Zheng H, 2016, CLIN CANCER RES, V22, P4119, DOI 10.1158/1078-0432.CCR-15-2584
   Zhu SG, 2016, IMMUNOBIOLOGY, V221, P986, DOI 10.1016/j.imbio.2016.04.005
NR 62
TC 106
Z9 113
U1 1
U2 23
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1868-7075
EI 1868-7083
J9 CLIN EPIGENETICS
JI Clin. Epigenetics
PD JUN 15
PY 2018
VL 10
AR 78
DI 10.1186/s13148-018-0512-1
PG 12
WC Oncology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Genetics & Heredity
GA GJ4XO
UT WOS:000435386000001
PM 29983831
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU Calixto, PD
   Lopes, OS
   Maia, MD
   Herrero, SST
   Longui, CA
   Melo, CGF
   de Carvalho, IR
   Soares, LF
   de Medeiros, AC
   Delatorre, P
   Khayat, AS
   Burbano, RR
   Lima, EM
AF Calixto, Poliane da Silva
   Lopes, Otavio Sergio
   Maia, Mayara dos Santos
   Takeno Herrero, Sylvia Satomi
   Longui, Carlos Alberto
   Farias Melo, Cynthia Germoglio
   de Carvalho Filho, Ivan Rodrigues
   Soares, Leonardo Ferreira
   de Medeiros, Arnaldo Correia
   Delatorre, Plinio
   Khayat, Andre Salim
   Burbano, Rommel Rodriguez
   Lima, Eleonidas Moura
TI Single-Nucleotide Polymorphisms of the MSH2 and MLH1 Genes, Potential
   Molecular Markers for Susceptibility to the Development of Basal Cell
   Carcinoma in the Brazilian Population
SO PATHOLOGY & ONCOLOGY RESEARCH
LA English
DT Article
DE Basal cell carcinoma; Mismatch repair; Single nucleotide polymorphism;
   DSASP; Genotyping; Molecular markers
ID DNA MISMATCH REPAIR; BREAST-CANCER CELLS; RISK; ASSOCIATION; EXPRESSION;
   VARIANTS
AB Basal cell carcinoma - BCC is considered a multifactorial neoplasm involving genetic, epigenetic and environmental factors. Where UVB radiation is considered the main physical agent involved in BCC carcinogenesis. The Brazil and state of Paraiba are exposed to high levels of UVB rays. The mismatch repair - MMR is important DNA repair mechanisms to maintain replication fidelity. Therefore, single nucleotide polymorphisms (SNPs) in genes encoding proteins involved in MMR may be potential molecular markers of susceptibility to BCC. The objective of this study was to evaluate and describe for the first time the SNPs rs560246973, rs2303425 and rs565410865 and risk of developing BCC. The present study analyzed 100 samples of paraffin-embedded tissue from patients with histopathological diagnosis of BCC and 100 control samples. The results were obtained by genotyping method, Dideoxy Unique Allele Specific - PCR (DSASP). The SNPs rs2303425 were not associated with Basal Cell Carcinoma. However, the SNPs rs560246973 and rs565410865 was shown to be associated with the development of BCC when compared to control samples (P < 0.0001). The SNPs rs565410865 was also statistical significance between the genotypes of and the age group (p = 0.0027) and tumor location (p = 0,0191). The result suggests that SNPs rs2303425 and rs565410865 are associated with susceptibility to the development of BCC in the Brazilian population and may be considered as potential molecular markers for BCC.
C1 [Calixto, Poliane da Silva; Maia, Mayara dos Santos; Takeno Herrero, Sylvia Satomi; Farias Melo, Cynthia Germoglio; Delatorre, Plinio; Lima, Eleonidas Moura] Univ Fed Paraiba, LBMEO, Joao Pessoa, PB, Brazil.
   [Calixto, Poliane da Silva; Maia, Mayara dos Santos; Delatorre, Plinio; Lima, Eleonidas Moura] Univ Fed Paraiba, Programa Posgrad Biol Celular & Mol, Joao Pessoa, PB, Brazil.
   [Lopes, Otavio Sergio] Clin Dermatol Santa Catarina, Dept Dermatol, Joao Pessoa, PB, Brazil.
   [Lopes, Otavio Sergio; Longui, Carlos Alberto] Fac Ciencias Med Santa Casa Sao Paulo, Programa Posgrad Ciencias Saude, Sao Paulo, SP, Brazil.
   [de Carvalho Filho, Ivan Rodrigues] UNILAB, Lab Anal Med, Dept Patol, Joao Pessoa, PB, Brazil.
   [Soares, Leonardo Ferreira] Univ Estadual Paraiba, Dept Farm, Campina Grande, PB, Brazil.
   [de Medeiros, Arnaldo Correia] Univ Fed Paraiba, Dept Med, Joao Pessoa, PB, Brazil.
   [Delatorre, Plinio; Lima, Eleonidas Moura] Univ Fed Paraiba, Dept Biol Mol, Joao Pessoa, PB, Brazil.
   [Khayat, Andre Salim; Burbano, Rommel Rodriguez] Univ Fed Para, Inst Ciencias Biol, Belem, PA, Brazil.
C3 Universidade Federal da Paraiba; Universidade Federal da Paraiba;
   Faculdade de Ciencias Medicas Santa Casa de Sao Paulo; Universidade
   Estadual da Paraiba; Universidade Federal da Paraiba; Universidade
   Federal da Paraiba; Universidade Federal do Para
RP Lima, EM (通讯作者)，Univ Fed Paraiba, LBMEO, Joao Pessoa, PB, Brazil.; Lima, EM (通讯作者)，Univ Fed Paraiba, Programa Posgrad Biol Celular & Mol, Joao Pessoa, PB, Brazil.; Lima, EM (通讯作者)，Univ Fed Paraiba, Dept Biol Mol, Joao Pessoa, PB, Brazil.
EM eleonidas@pq.cnpq.br
RI Soares, Leonardo/AAW-5914-2020; Longui, Carlos/B-8112-2013; Khayat,
   Andre/AAF-2415-2019; Burbano, Rommel/C-4149-2012
OI Burbano, Rommel/0000-0002-4872-234X
FU CAPES; CNPq; Clinica Dermatologica Santa Catarina; Joao Pessoa - PB -
   Brasil
FX This work was supported by grants of CAPES, CNPq and Clinica
   Dermatologica Santa Catarina; Joao Pessoa - PB - Brasil.
CR Birch-Johansen F, 2010, INT J CANCER, V127, P2190, DOI 10.1002/ijc.25411
   Dahlman-Wright K, 2012, CARCINOGENESIS, V33, P1684, DOI 10.1093/carcin/bgs223
   Depry JL, 2011, CLIN DERMATOL, V29, P602, DOI 10.1016/j.clindermatol.2011.08.009
   Dizdaroglu M, 2015, MUTAT RES-REV MUTAT, V763, P212, DOI 10.1016/j.mrrev.2014.11.002
   Erie DA, 2014, DNA REPAIR, V20, P71, DOI 10.1016/j.dnarep.2014.03.007
   FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3
   Fukuhara S, 2014, ONCOTARGET, V5, P11297, DOI 10.18632/oncotarget.2315
   Hsieh YC, 2017, ANN SURG ONCOL, V24, P603, DOI 10.1245/s10434-016-5168-5
   Kim S, 2007, ANNU REV BIOMED ENG, V9, P289, DOI 10.1146/annurev.bioeng.9.060906.152037
   KOLODNER RD, 1994, GENOMICS, V24, P516, DOI 10.1006/geno.1994.1661
   Langeberg WJ, 2010, CANCER EPIDEM BIOMAR, V19, P258, DOI 10.1158/1055-9965.EPI-09-0800
   Lee WR, 2006, J CELL BIOCHEM, V99, P209, DOI 10.1002/jcb.20902
   Lichter MD, 2000, ARCH DERMATOL, V136, P1007, DOI 10.1001/archderm.136.8.1007
   Lima EM, 2015, BRAZ ARCH BIOL TECHN, V58, P414, DOI 10.1590/S1516-8913201500434
   Miyamoto T, 2006, ENDOCRINOLOGY, V147, P4863, DOI 10.1210/en.2006-0632
   Mjelle R, 2015, DNA REPAIR, V30, P53, DOI 10.1016/j.dnarep.2015.03.007
   Mrkonjic M, 2007, CARCINOGENESIS, V28, P2575, DOI 10.1093/carcin/bgm229
   NAN HJ, 1995, HUM MOL GENET, V4, P237, DOI 10.1093/hmg/4.2.237
   Nikolaou V, 2012, SEMIN CUTAN MED SURG, V31, P204, DOI 10.1016/j.sder.2012.08.005
   Nishi R, 2005, MOL CELL BIOL, DOI [10.1128/MCB.25.13.5664-5674, DOI 10.1128/MCB.25.13.5664-5674]
   Noubissi FK, 2014, J INVEST DERMATOL, V134, P1718, DOI 10.1038/jid.2014.17
   Reyes GX, 2015, CHROMOSOMA, V124, P443, DOI 10.1007/s00412-015-0514-0
   Slováková P, 2015, ADV EXP MED BIOL, V833, P15, DOI 10.1007/5584_2014_83
   Smith CE, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003869
   Smith TR, 2008, CARCINOGENESIS, V29, P2132, DOI 10.1093/carcin/bgn193
   Smolarz B, 2015, FAM CANCER, V14, P81, DOI 10.1007/s10689-014-9746-z
   Srivastava K, 2010, CANCER-AM CANCER SOC, V116, P3160, DOI 10.1002/cncr.25063
   Stojic L, 2004, DNA REPAIR, V3, P1091, DOI 10.1016/j.dnarep.2004.06.006
   Sun MZ, 2014, INT J CLIN EXP MED, V7, P2329
   van der Klift HM, 2015, MOL GENET GENOM MED, V3, P327, DOI 10.1002/mgg3.145
   Ward AJ, 2010, J PATHOL, V220, P152, DOI 10.1002/path.2649
   Wibom C, 2012, ACTA ONCOL, V51, P325, DOI 10.3109/0284186X.2011.616284
   Xiao XQ, 2012, ONCOL LETT, V3, P591, DOI 10.3892/ol.2011.517
   Zahary MN, 2012, WORLD J GASTROENTERO, V18, P814, DOI 10.3748/wjg.v18.i8.814
   Zink B., 2014, REV HUPE, V13, P76
NR 35
TC 4
Z9 4
U1 0
U2 4
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1219-4956
EI 1532-2807
J9 PATHOL ONCOL RES
JI Pathol. Oncol. Res.
PD JUL
PY 2018
VL 24
IS 3
BP 489
EP 496
DI 10.1007/s12253-017-0265-8
PG 8
WC Oncology; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Pathology
GA GH4KI
UT WOS:000433372000007
PM 28667494
DA 2025-01-12
ER

PT J
AU Zhang, T
   Li, JJ
   Ma, XJ
   Yang, Y
   Sun, W
   Jin, WR
   Wang, L
   He, Y
   Yang, FF
   Yi, ZF
   Hua, YQ
   Liu, MY
   Chen, YH
   Cai, ZD
AF Zhang, Tao
   Li, Jingjie
   Ma, Xiaojun
   Yang, Yang
   Sun, Wei
   Jin, Wangrui
   Wang, Lei
   He, Yuan
   Yang, Feifei
   Yi, Zhengfang
   Hua, Yingqi
   Liu, Mingyao
   Chen, Yihua
   Cai, Zhengdong
TI Inhibition of HDACs-EphA2 Signaling Axis with WW437 Demonstrates
   Promising Preclinical Antitumor Activity in Breast Cancer
SO EBIOMEDICINE
LA English
DT Article
DE HDACs; EphA2; WW437; Breast cancer; Growth; Metastasis
ID HISTONE DEACETYLASE INHIBITOR; RECEPTOR TYROSINE KINASE;
   TUMOR-METASTASIS; EPHA2; PROGRESSION; GROWTH; ACID; DESIGN;
   ANGIOGENESIS; PROTEINS
AB Histone deacetylase inhibitors (HDACi) are small molecules targeting epigenetic enzymes approved for hematologic neoplasms, which have also demonstrated clinical activities in solid tumors. In our present study, we screened our internal compound library and discovered a novel HDACi, WW437, with potent anti-breast cancer ability in vitro and in vivo. WW437 significantly inhibited phosphorylated EphA2 and EphA2 expression. Further study demonstrated WW437 blocked HDACs-EphA2 signaling axis in breast cancer. In parallel, we found that EphA2 expression positively correlates with breast cancer progression; and combined use of WW437 and an EphA2 inhibitor (ALW-II-41-27) exerted more remarkable effect on breast cancer growth than either drug alone. Our findings suggested inhibition of HDACs-EphA2 signaling axis with WW437 alone or in combination with other agents may be a promising therapeutic strategy for advanced breast cancer. (C) 2018 The Authors. Published by Elsevier B.V.
C1 [Zhang, Tao; Ma, Xiaojun; Sun, Wei; Wang, Lei; Hua, Yingqi; Cai, Zhengdong] Shanghai Jiao Tong Univ, Sch Med, Shanghai Gen Hosp, Dept Orthoped, Shanghai 200080, Peoples R China.
   [Zhang, Tao; Hua, Yingqi; Cai, Zhengdong] Shanghai Bone Tumor Inst, Shanghai 201620, Peoples R China.
   [Li, Jingjie] Shanghai Jiao Tong Univ, Sch Med, Inst Translat Med, Shanghai Gen Hosp, Shanghai 200080, Peoples R China.
   [Yang, Yang; Jin, Wangrui; He, Yuan; Yi, Zhengfang; Liu, Mingyao; Chen, Yihua] East China Normal Univ, Shanghai Key Lab Regulatory Biol, Inst Biomed Sci, Sch Life Sci, 500 Dongchuan Rd, Shanghai 200241, Peoples R China.
   [Yang, Feifei] Univ Jinan, Sch Biol Sci & Technol, Jinan 250022, Shandong, Peoples R China.
   [Liu, Mingyao] Texas A&M Univ, Hlth Sci Ctr, Ctr Canc & Stem Cell Biol, Inst Biosci & Technol, Houston, TX 77030 USA.
C3 Shanghai Jiao Tong University; Shanghai Jiao Tong University; East China
   Normal University; University of Jinan; Texas A&M University System;
   Texas A&M University College Station; Texas A&M Health Science Center;
   University of Texas System; University of Texas Health Science Center
   Houston
RP Zhang, T; Cai, ZD (通讯作者)，Shanghai Jiao Tong Univ, Sch Med, Shanghai Gen Hosp, Dept Orthoped, Shanghai 200080, Peoples R China.; Chen, YH (通讯作者)，East China Normal Univ, Shanghai Key Lab Regulatory Biol, Inst Biomed Sci, Sch Life Sci, 500 Dongchuan Rd, Shanghai 200241, Peoples R China.
EM zhangtaoabc@2008.sina.com; yhchen@bio.ecnu.edu.cn;
   caizhengdong@sjtu.edu.cn
RI Sun, Weijie/GLU-8735-2022; Chen, Yihua/A-4323-2013
OI Sun, Weijie/0000-0003-0112-0461; Chen, Yihua/0000-0003-1733-7980
FU NSFC [81502604, 81673304, 81702328]; Shanghai Science and Technology
   Commission [14140904000, 15431902200]; Shanghai Hospital Development
   Center [SHDC12013107]
FX This work was supported by NSFC (81502604, 81673304 and 81702328);
   Shanghai Science and Technology Commission (14140904000 and
   15431902200), and Research Grant from Shanghai Hospital Development
   Center (SHDC12013107). Funding agencies played no role in the design,
   execution, interpretation or writing of this manuscript.
CR Bengtsson C, 2012, EUR J MED CHEM, V54, P637, DOI 10.1016/j.ejmech.2012.06.018
   Bin Fang W, 2005, ONCOGENE, V24, P7859, DOI 10.1038/sj.onc.1208937
   Bourne Y, 2004, P NATL ACAD SCI USA, V101, P1449, DOI 10.1073/pnas.0308206100
   Brantley DM, 2002, ONCOGENE, V21, P7011, DOI 10.1038/sj.onc.1205679
   Brantley-Sieders DM, 2008, J CLIN INVEST, V118, P64, DOI 10.1172/JCI33154
   Brantley-Sieders DM, 2006, CANCER RES, V66, P10315, DOI 10.1158/0008-5472.CAN-06-1560
   Chemama M, 2009, CHEM-EUR J, V15, P1929, DOI 10.1002/chem.200801563
   Chen JS, 2003, CURR CANCER DRUG TAR, V3, P219, DOI 10.2174/1568009033481994
   Dunne PD, 2016, CLIN CANCER RES, V22, P230, DOI 10.1158/1078-0432.CCR-15-0603
   Friedl P, 2003, NAT REV CANCER, V3, P362, DOI 10.1038/nrc1075
   Gediya LK, 2005, J MED CHEM, V48, P5047, DOI 10.1021/jm058214k
   Gherardini L, 2016, CURR PHARM BIOTECHNO, V17, P856, DOI 10.2174/1381612822666160527154757
   Gschwind A, 2004, NAT REV CANCER, V4, P361, DOI 10.1038/nrc1360
   Guo H, 2006, CANCER RES, V66, P7050, DOI 10.1158/0008-5472.CAN-06-0004
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   He YW, 2014, EUR J MED CHEM, V76, P245, DOI 10.1016/j.ejmech.2014.02.029
   Huang Y, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2925
   Hung JJ, 2006, MOL CELL BIOL, V26, P1770, DOI 10.1128/MCB.26.5.1770-1785.2006
   Kaczynski J, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-2-206
   Kinch MS, 2003, CLIN CANCER RES, V9, P613
   KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251
   Lee GY, 2007, NAT METHODS, V4, P359, DOI 10.1038/NMETH1015
   Li JJ, 2015, BRIT J PHARMACOL, V172, P3817, DOI 10.1111/bph.13165
   Lo PK, 2008, PHARMACOGENOMICS, V9, P1879, DOI 10.2217/14622416.9.12.1879
   Ma L, 2007, NATURE, V449, P682, DOI 10.1038/nature06174
   Minucci S, 2006, NAT REV CANCER, V6, P38, DOI 10.1038/nrc1779
   Münster P, 2007, J CLIN ONCOL, V25, P1979, DOI 10.1200/JCO.2006.08.6165
   Munster PN, 2011, BRIT J CANCER, V104, P1828, DOI 10.1038/bjc.2011.156
   Nimmo CM, 2011, BIOCONJUGATE CHEM, V22, P2199, DOI 10.1021/bc200281k
   Ogawa K, 2000, ONCOGENE, V19, P6043, DOI 10.1038/sj.onc.1204004
   Pasquale EB, 2010, NAT REV CANCER, V10, P165, DOI 10.1038/nrc2806
   Rhodes LV, 2014, BREAST CANCER RES TR, V145, P593, DOI 10.1007/s10549-014-2979-6
   Richon VM, 2000, P NATL ACAD SCI USA, V97, P10014, DOI 10.1073/pnas.180316197
   Singh A, 2010, ONCOGENE, V29, P4741, DOI 10.1038/onc.2010.215
   Song W, 2017, ONCOGENE, V36, P5620, DOI 10.1038/onc.2017.170
   Tate CR, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3192
   Truax AD, 2012, METHODS MOL BIOL, V809, P175, DOI 10.1007/978-1-61779-376-9_12
   VLODAVSKY I, 1990, CANCER METAST REV, V9, P203, DOI 10.1007/BF00046361
   Waby JS, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-275
   Walker-Daniels J, 1999, PROSTATE, V41, P275, DOI 10.1002/(SICI)1097-0045(19991201)41:4<275::AID-PROS8>3.0.CO;2-T
   West AC, 2014, J CLIN INVEST, V124, P30, DOI 10.1172/JCI69738
   Yang FF, 2014, J MED CHEM, V57, P9357, DOI 10.1021/jm5012148
   Yempala T, 2014, EUR J MED CHEM, V71, P160, DOI 10.1016/j.ejmech.2013.10.082
   Zhang T, 2017, ONCOGENE, V36, P6627, DOI 10.1038/onc.2017.270
   Zhang T, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.00227
   Zhang T, 2014, NEOPLASIA, V16, P665, DOI 10.1016/j.neo.2014.07.009
   Zhang T, 2012, BREAST CANCER RES TR, V135, P445, DOI 10.1007/s10549-012-2175-5
NR 47
TC 28
Z9 30
U1 1
U2 17
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2352-3964
J9 EBIOMEDICINE
JI EBioMedicine
PD MAY
PY 2018
VL 31
BP 276
EP 286
DI 10.1016/j.ebiom.2018.05.003
PG 11
WC Medicine, General & Internal; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine; Research & Experimental Medicine
GA GH0FS
UT WOS:000433078300033
PM 29759486
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Royston, KJ
   Paul, B
   Nozell, S
   Rajbhandari, R
   Tollefsbol, TO
AF Royston, Kendra J.
   Paul, Bidisha
   Nozell, Susan
   Rajbhandari, Rajani
   Tollefsbol, Trygve O.
TI Withaferin A and sulforaphane regulate breast cancer cell cycle
   progression through epigenetic mechanisms
SO EXPERIMENTAL CELL RESEARCH
LA English
DT Article
DE Withaferin A; Sulforaphane; Combinatorial therapy; Adjuvant; Breast
   cancer; Chemotherapy
ID TUMOR-SUPPRESSOR GENES; KINASE INHIBITOR P21; DNA-DAMAGE; MUTANT P53;
   HISTONE ACETYLATION; EXPRESSION; PROLIFERATION; APOPTOSIS;
   HYPOMETHYLATION; TRANSCRIPTION
AB Little is known about the effects of combinatorial dietary compounds on the regulation of epigenetic mechanisms involved in breast cancer prevention. The human diet consists of a multitude of components, and there is a need to elucidate how certain compounds interact in collaboration. Withaferin A (WA), found in the Indian winter cherry and documented as a DNA methyltransferase (DNMT) inhibitor, and sulforaphane (SFN), a well-known histone deacetylase (HDAC) inhibitor found in cruciferous vegetables, are two epigenetic modifying compounds that have only recently been studied in conjunction. The use of DNMT and HDAC inhibitors to reverse the malignant expression of certain genes in breast cancer has shown considerable promise. Previously, we found that SFN + WA synergistically promote breast cancer cell death. Herein, we determined that these compounds inhibit cell cycle progression from S to G2 phase in MDA-MB-231 and MCF-7 breast cancer. Furthermore, we demonstrate that this unique combination of epigenetic modifying compounds down-regulates the levels of Cyclin D1 and CDK4, and pRB; conversely, the levels of E2F mRNA and tumor suppressor p21 are increased independently of p53. We find these events coincide with an increase in unrestricted histone methylation. We propose SFN + WA-induced breast cancer cell death is attributed, in part, to epigenetic modifications that result in the modulated expression of key genes responsible for the regulation of cancer cell senescence.
C1 [Royston, Kendra J.; Paul, Bidisha; Tollefsbol, Trygve O.] Univ Alabama Birmingham, Dept Biol, 1300 Univ Blvd,175 Campbell Hall, Birmingham, AL 35294 USA.
   [Royston, Kendra J.; Tollefsbol, Trygve O.] Univ Alabama Birmingham, Comprehens Canc Ctr, 1802 6th Ave South, Birmingham, AL 35294 USA.
   [Nozell, Susan; Rajbhandari, Rajani] Univ Alabama Birmingham, Dept Radiat Oncol, 1700 6th Ave South, Birmingham, AL 35233 USA.
   [Tollefsbol, Trygve O.] Univ Alabama Birmingham, Comprehens Ctr Hlth Aging, 1530 3rd Ave South, Birmingham, AL 35294 USA.
   [Tollefsbol, Trygve O.] Univ Alabama Birmingham, Nutr Obes Res Ctr, 1675 Univ Blvd, Birmingham, AL 35294 USA.
   [Tollefsbol, Trygve O.] Univ Alabama Birmingham, Comprehens Diabet Ctr, 1825 Univ Blvd, Birmingham, AL 35294 USA.
C3 University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham
RP Tollefsbol, TO (通讯作者)，Univ Alabama Birmingham, Comprehens Canc Ctr, 1802 6th Ave South, Birmingham, AL 35294 USA.
EM trygve@uab.edu
RI Paul, Bidisha/AAB-8948-2022
OI Paul, Bidisha/0000-0002-0101-8187
FU National Cancer Institute [R01 CA178441, R01 CA204346]; Cancer
   Prevention and Control Training Program [R25 CA047888]; Susan G. Komen
   Graduate Training in Disparities Research program [GTDR15329376];
   American Institute for Cancer Research [316184]; Department of Radiation
   Oncology at UAB
FX This work was supported by grants from the National Cancer Institute
   (R01 CA178441 and R01 CA204346), The Cancer Prevention and Control
   Training Program (R25 CA047888), the Susan G. Komen Graduate Training in
   Disparities Research program (GTDR15329376), the American Institute for
   Cancer Research (316184), and the Department of Radiation Oncology at
   UAB (SN, RR).
CR Abbas T, 2009, NAT REV CANCER, V9, P400, DOI 10.1038/nrc2657
   Alkhalaf M, 2003, J ENDOCRINOL, V179, P55, DOI 10.1677/joe.0.1790055
   Arzenani MK, 2011, MOL CELL BIOL, V31, P4119, DOI 10.1128/MCB.01304-10
   Barr AR, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14728
   Benson EK, 2014, ONCOGENE, V33, P3959, DOI 10.1038/onc.2013.378
   Chen AJ, 2015, MED SCI MONIT BASIC, V21, P86, DOI 10.12659/MSMBR.893608
   da Costa Prando E., 2011, EPIGENETICS, V6, P1413
   Deppert W., 1993, Molecular Diagnostics of Cancer, P27
   Epe C., 2005, PARASITOL RES, V97
   Ferguson LR, 2015, SEMIN CANCER BIOL, V35, pS5, DOI 10.1016/j.semcancer.2015.03.005
   Gartel AL, 2002, MOL CANCER THER, V1, P639
   Gartel AL, 1998, ONCOGENE, V17, P3463, DOI 10.1038/sj.onc.1202240
   Giacinti C, 2006, ONCOGENE, V25, P5220, DOI 10.1038/sj.onc.1209615
   Hon GC, 2012, GENOME RES, V22, P246, DOI 10.1101/gr.125872.111
   Hui L, 2006, ONCOGENE, V25, P7305, DOI 10.1038/sj.onc.1209735
   Kala R, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0155057
   Karimian A, 2016, DNA REPAIR, V42, P63, DOI 10.1016/j.dnarep.2016.04.008
   Kazanets A, 2016, BBA-REV CANCER, V1865, P275, DOI 10.1016/j.bbcan.2016.04.001
   Kelly TK, 2010, NAT BIOTECHNOL, V28, P1069, DOI 10.1038/nbt.1678
   Ko T C, 1997, Prog Cell Cycle Res, V3, P43
   Lagger G, 2003, MOL CELL BIOL, V23, P2669, DOI 10.1128/MCB.23.8.2669-2679.2003
   Li YY, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-09764-3
   Li YY, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0055108, 10.1371/journal.pone.0052093, 10.1371/journal.pone.0063648, 10.1371/journal.pone.0077685, 10.1371/journal.pone.0062036, 10.1371/journal.pone.0054369, 10.1371/journal.pone.0066567, 10.1371/journal.pone.0071994]
   MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935
   Meeran SM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011457
   Nozell S, 2008, MOL CELL BIOL, V28, P6632, DOI 10.1128/MCB.00697-08
   Poole AJ, 2004, ONCOGENE, V23, P8128, DOI 10.1038/sj.onc.1207994
   Richon VM, 2000, P NATL ACAD SCI USA, V97, P10014, DOI 10.1073/pnas.180316197
   Rodríguez-Paredes M, 2011, NAT MED, V17, P330, DOI 10.1038/nm.2305
   Royston KJ, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18051092
   Sandor V, 2000, BRIT J CANCER, V83, P817, DOI 10.1054/bjoc.2000.1327
   Sharma S, 2010, CARCINOGENESIS, V31, P27, DOI 10.1093/carcin/bgp220
   Smith LT, 2006, P NATL ACAD SCI USA, V103, P982, DOI 10.1073/pnas.0510171102
   Soussi T, 2015, CELL DEATH DIFFER, V22, P1239, DOI 10.1038/cdd.2015.53
   Stanelle J, 2002, NUCLEIC ACIDS RES, V30, P1859, DOI 10.1093/nar/30.8.1859
   Strano S, 2007, ONCOGENE, V26, P2212, DOI 10.1038/sj.onc.1210296
   Viré E, 2006, NATURE, V439, P871, DOI 10.1038/nature04431
   Vogiatzi F, 2016, P NATL ACAD SCI USA, V113, pE8433, DOI 10.1073/pnas.1612711114
   Yasuda H, 2010, INT J ONCOL, V37, P1537, DOI 10.3892/ijo_0000087
   Yasuda K, 2007, ANTICANCER RES, V27, P4071
   Zupkovitz G, 2010, MOL CELL BIOL, V30, P1171, DOI 10.1128/MCB.01500-09
NR 41
TC 74
Z9 76
U1 1
U2 17
PU ELSEVIER INC
PI SAN DIEGO
PA 525 B STREET, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0014-4827
EI 1090-2422
J9 EXP CELL RES
JI Exp. Cell Res.
PD JUL 1
PY 2018
VL 368
IS 1
BP 67
EP 74
DI 10.1016/j.yexcr.2018.04.015
PG 8
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA GH2YI
UT WOS:000433267500008
PM 29689276
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Semaan, A
   Uhl, B
   Branchi, V
   Lingohr, P
   Bootz, F
   Kristiansen, G
   Kalff, JC
   Matthaei, H
   Pantelis, D
   Dietrich, D
AF Semaan, Alexander
   Uhl, Barbara
   Branchi, Vittorio
   Lingohr, Philipp
   Bootz, Friedrich
   Kristiansen, Glen
   Kalff, Joerg C.
   Matthaei, Hanno
   Pantelis, Dimitrios
   Dietrich, Dimo
TI Significance of <i>PITX2</i> Promoter Methylation in Colorectal
   Carcinoma Prognosis
SO CLINICAL COLORECTAL CANCER
LA English
DT Article
DE Biomarker; Colorectal cancer; Epigenetic; Methylation; PITX2
ID POSITIVE BREAST-CANCER; II COLON-CANCER; DNA-METHYLATION; STAGE-II;
   ADJUVANT CHEMOTHERAPY; CLINICAL VALIDATION; PROSTATE-CANCER; ANTIGEN
   RECURRENCE; GENE-EXPRESSION; MULTICENTER
AB Recent developments in colorectal cancer (CRC) patients have raised the need for prognostic biomarkers. Using 2 independent cohorts (cohort A, n = 179 and B, n = 443), we found that paired-like homeodomain transcription factor 2 promotor methylation level might be used as prognostic marker in CRC.
   Background: New treatment modalities and a growing understanding of the complex genetic tumor landscape have improved the outcome of colorectal cancer (CRC) patients. Nonetheless, more individualized treatment regimens, taking individual tumor characteristics into account, have been recently postulated and prognostic biomarkers are needed. We therefore evaluated the prognostic potential of paired-like homeodomain transcription factor 2 (PITX2) promoter methylation in CRC patients. Materials and Methods: Data of 2 independent cohorts were investigated. Tissue specimens of cohort A (n = 179) were analyzed for their methylation in the PITX2 promoter region using quantitative methylation-specific polymerase chain reaction and compared with publicly available data (PITX2 promoter methylation and PITX2 mRNA expression levels) from "The Cancer Genome Atlas Research Network" (cohort B, n = 443). Data were correlated with clinicopathological parameters and outcome. Results: Tumor samples of both cohorts showed a decreased PITX2 promoter methylation level (both P < .001) compared with nonmalignant tissue. Additionally, PITX2 promoter hypomethylation was prognostic in univariate and multivariate analysis (hazard ratio [HR], 1.97 [95% confidence interval (CI), 1.12-3.47], P = .018 and HR, 1.89 [95% CI, 1.09-3.29], P = .023), and Kaplan-Meier analysis (median overall survival, 53.2 vs. 70.4 months, P = .004). Subanalysis of high-risk vs. low-risk stage II CRC patients also showed a PITX2 hypomethylation of the promoter region in the high-risk group (P = .006). Conclusion: Our results suggest a prognostic role of PITX2 promoter methylation in CRC as biomarker for risk stratification in stage II CRC patients although the results need to be independently validated. (C) 2018 Elsevier Inc. All rights reserved.
C1 [Semaan, Alexander; Branchi, Vittorio; Lingohr, Philipp; Kalff, Joerg C.; Matthaei, Hanno; Pantelis, Dimitrios] Univ Hosp Bonn, Dept Gen Visceral Thorac & Vasc Surg, Bonn, Germany.
   [Uhl, Barbara; Kristiansen, Glen] Univ Hosp Bonn, Inst Pathol, Bonn, Germany.
   [Bootz, Friedrich; Dietrich, Dimo] Univ Hosp Bonn, Dept Otolaryngol Head & Neck Surg, Bonn, Germany.
C3 University of Bonn; University of Bonn; University of Bonn
RP Semaan, A (通讯作者)，Univ Bonn, Dept Gen Visceral Thorac & Vasc Surg, Sigmund Freud Str 25, D-53127 Bonn, Germany.
EM papers.semaan@gmail.de
RI Kalff, Joerg/U-8580-2017
OI Semaan, Alexander/0000-0001-5424-3217
FU University Medical Center, University of Bonn, Bonn, Germany
   [O-1120051]; German Research Foundation [SE26-16/2-1]
FX This work was supported by a Bonner Forschung grant (number: O-1120051)
   provided to H.M. by the University Medical Center, University of Bonn,
   Bonn, Germany; and by the German Research Foundation (grant number:
   SE26-16/2-1) provided to A.S.
CR Anastas JN, 2013, NAT REV CANCER, V13, P11, DOI 10.1038/nrc3419
   [Anonymous], 2011, TNM classification of malignant tumours
   [Anonymous], 2010, WHO Classification of tumors of the digestive system
   Arnold M, 2017, GUT, V66, P683, DOI 10.1136/gutjnl-2015-310912
   Bañez LL, 2010, J UROLOGY, V184, P149, DOI 10.1016/j.juro.2010.03.012
   Baylin Stephen B, 2005, Nat Clin Pract Oncol, V2 Suppl 1, pS4, DOI 10.1038/ncponc0354
   Benson AB, 2004, J CLIN ONCOL, V22, P3408, DOI 10.1200/JCO.2004.05.063
   Brenner H, 2014, LANCET, V383, P1490, DOI 10.1016/S0140-6736(13)61649-9
   Breugom AJ, 2016, EUR J CANCER, V63, P110, DOI 10.1016/j.ejca.2016.04.017
   Casadaban L, 2016, CANCER-AM CANCER SOC, V122, P3277, DOI 10.1002/cncr.30181
   Chen GT, 2016, CANCER CELL INT, V16, DOI 10.1186/s12935-016-0296-3
   CHO KR, 1992, CANCER, V70, P1727, DOI 10.1002/1097-0142(19920915)70:4+<1727::AID-CNCR2820701613>3.0.CO;2-P
   Di Costanzo F, 2003, ANN ONCOL, V14, P1365, DOI 10.1093/annonc/mdg359
   Dietrich D, 2013, J MOL DIAGN, V15, P270, DOI 10.1016/j.jmoldx.2012.11.002
   Dietrich D, 2012, DIAGN MOL PATHOL, V21, P93, DOI 10.1097/PDM.0b013e318240503b
   Dumenil TD, 2014, GENE CHROMOSOME CANC, V53, P537, DOI 10.1002/gcc.22164
   Esteller M, 2003, LANCET ONCOL, V4, P351, DOI 10.1016/S1470-2045(03)01115-X
   Fang SH, 2014, J AM COLL SURGEONS, V219, P1056, DOI 10.1016/j.jamcollsurg.2014.09.010
   Fearon ER, 2011, ANNU REV PATHOL-MECH, V6, P479, DOI 10.1146/annurev-pathol-011110-130235
   Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516
   Gill S, 2004, J CLIN ONCOL, V22, P1797, DOI 10.1200/JCO.2004.09.059
   Goltz D, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2016.1257454
   Gray R, 2007, LANCET, V370, P2020, DOI 10.1016/s0140-6736(07)61866-2
   Greytak SR, 2015, CANCER RES, V75, P1541, DOI 10.1158/0008-5472.CAN-14-2378
   Harbeck N, 2008, J CLIN ONCOL, V26, P5036, DOI 10.1200/JCO.2007.14.1697
   Hartmann O, 2009, CLIN CANCER RES, V15, P315, DOI 10.1158/1078-0432.CCR-08-0166
   Hirose H, 2011, ANN SURG ONCOL, V18, P3005, DOI 10.1245/s10434-011-1653-z
   Huang Y, 2010, CELL CYCLE, V9, P1333, DOI 10.4161/cc.9.7.11126
   Jezkova E, 2016, TUMOR BIOL, V37, P15707, DOI 10.1007/s13277-016-5324-3
   Jung M, 2017, METHODS MOL BIOL, V1589, P139, DOI 10.1007/7651_2015_260
   Kioussi C, 2002, CELL, V111, P673, DOI 10.1016/S0092-8674(02)01084-X
   Lavery IC, 2010, ONCOLOGY-NY, V24, P14
   Leggett B, 2010, GASTROENTEROLOGY, V138, P2088, DOI 10.1053/j.gastro.2009.12.066
   Leslie A, 2002, BRIT J SURG, V89, P845, DOI 10.1046/j.1365-2168.2002.02120.x
   Li CL, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2628-z
   Li JZ, 2015, ONCOTARGETS THER, V8, P3507, DOI 10.2147/OTT.S83914
   Lieberman DA, 2009, NEW ENGL J MED, V361, P1179, DOI 10.1056/NEJMcp0902176
   Maier S, 2007, EUR J CANCER, V43, P1679, DOI 10.1016/j.ejca.2007.04.025
   Markou A, 2013, LUNG CANCER, V81, P388, DOI 10.1016/j.lungcan.2013.05.007
   Mocellin S, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006875.pub3
   Murphy CC, 2015, JNCI-J NATL CANCER I, V107, DOI 10.1093/jnci/djv198
   Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252
   Nimmrich I, 2008, BREAST CANCER RES TR, V111, P429, DOI 10.1007/s10549-007-9800-8
   Oberli A, 2008, BMC MED GENOMICS, V1, DOI 10.1186/1755-8794-1-9
   Odze RD, 2015, ODZE GOLDBLUM SURG P, P621
   Quentien MH, 2002, ENDOCRINOLOGY, V143, P2839, DOI 10.1210/en.143.8.2839
   Rauscher GH, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1777-9
   Ryan AK, 1998, NATURE, V394, P545, DOI 10.1038/29004
   Sailer V, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0179412
   Sailer V, 2016, ONCOTARGET, V7, P75827, DOI 10.18632/oncotarget.12417
   Schobesberger M, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-343
   Shi CZ, 2016, GUT, V65, P1470, DOI 10.1136/gutjnl-2014-308455
   Shiratori H, 2001, MOL CELL, V7, P137, DOI 10.1016/S1097-2765(01)00162-9
   Uhl B, 2017, J MOL DIAGN, V19, P107, DOI 10.1016/j.jmoldx.2016.08.008
   Uhl B, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0165769
   van de Poll-Franse LV, 2012, DIABETOLOGIA, V55, P2163, DOI 10.1007/s00125-012-2555-8
   Vogelstein B, 2013, SCIENCE, V339, P1546, DOI 10.1126/science.1235122
   Wei JT, 2004, CANCER, V100, P1262, DOI 10.1002/cncr.20090
   White BD, 2012, GASTROENTEROLOGY, V142, P219, DOI 10.1053/j.gastro.2011.12.001
   Zhang JX, 2013, INT J CANCER, V132, P2567, DOI 10.1002/ijc.27930
NR 60
TC 11
Z9 11
U1 0
U2 6
PU CIG MEDIA GROUP, LP
PI DALLAS
PA 3500 MAPLE AVENUE, STE 750, DALLAS, TX 75219-3931 USA
SN 1533-0028
EI 1938-0674
J9 CLIN COLORECTAL CANC
JI Clin. Colorectal Canc.
PD JUN
PY 2018
VL 17
IS 2
BP E385
EP E393
DI 10.1016/j.clcc.2018.02.008
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA GG8WF
UT WOS:000432978800024
PM 29580650
DA 2025-01-12
ER

PT J
AU Yuan, BW
   Liu, YH
   Yu, XH
   Yin, LL
   Peng, YC
   Gao, YX
   Zhu, QL
   Cao, TY
   Yang, YK
   Fan, XG
   Li, X
AF Yuan, Bowen
   Liu, Youhong
   Yu, Xiaohui
   Yin, Linglong
   Peng, Yuchong
   Gao, Yingxue
   Zhu, Qianling
   Cao, Tuoyu
   Yang, Yinke
   Fan, Xuegong
   Li, Xiong
TI FOXM1 contributes to taxane resistance by regulating UHRF1-controlled
   cancer cell stemness
SO CELL DEATH & DISEASE
LA English
DT Article
ID BREAST-CANCER; MEDIATES RESISTANCE; UHRF1 EXPRESSION; GENE-EXPRESSION;
   PROSTATE-CANCER; SELF-RENEWAL; TRANSCRIPTION; DOCETAXEL; CARCINOMA;
   TARGET
AB Therapy-induced expansion of cancer stem cells (CSCs) has been identified as one of the most critical factors contributing to therapeutic resistance, but the mechanisms of this adaptation are not fully understood. UHRF1 is a key epigenetic regulator responsible for therapeutic resistance, and controls the self-renewal of stem cells. In the present study, taxane-resistant cancer cells were established and stem-like cancer cells were expanded. UHRF1 was overexpressed in the taxane-resistant cancer cells, which maintained CSC characteristics. UHRF1 depletion overcame taxane resistance in vitro and in vivo. Additionally, FOXM1 has been reported to play a role in therapeutic resistance and the self-renewal of CSCs. FOXM1 and UHRF1 are highly correlated in prostate cancer tissues and cells, FOXM1 regulates CSCs by regulating uhrf1 gene transcription in an E2F-independent manner, and FOXM1 protein directly binds to the FKH motifs at the uhrf1 gene promoter. This present study clarified a novel mechanism by which FOXM1 controls CSCs and taxane resistance through a UHRF1-mediated signaling pathway, and validated FOXM1 and UHRF1 as two potential therapeutic targets to overcome taxane resistance.
C1 [Yuan, Bowen; Liu, Youhong; Yu, Xiaohui; Yin, Linglong; Peng, Yuchong; Gao, Yingxue; Zhu, Qianling; Cao, Tuoyu; Li, Xiong] Cent S Univ, Xiangya Hosp, Ctr Mol Med, Xiangya, Peoples R China.
   [Yuan, Bowen; Liu, Youhong; Yu, Xiaohui; Yin, Linglong; Peng, Yuchong; Gao, Yingxue; Zhu, Qianling; Cao, Tuoyu; Li, Xiong] Cent S Univ, Xiangya Hosp, Hunan Key Lab Mol Radiat Oncol, Xiangya, Peoples R China.
   [Yang, Yinke] Shenzhen BioScien Pharmaceut Co Ltd, Shenzhen, Guangdong, Peoples R China.
   [Fan, Xuegong] Cent S Univ, Xiangya Hosp, Hunan Key Lab Viral Hepatitis, Xiangya, Peoples R China.
C3 Central South University; Central South University; Central South
   University
RP Li, X (通讯作者)，Cent S Univ, Xiangya Hosp, Ctr Mol Med, Xiangya, Peoples R China.; Li, X (通讯作者)，Cent S Univ, Xiangya Hosp, Hunan Key Lab Mol Radiat Oncol, Xiangya, Peoples R China.
EM lixiongxiangya@csu.edu.cn
RI Gao, Yingxue/LDQ-2854-2024; Qian, Zhong/E-8884-2016
OI yuan, bowen/0009-0009-0424-6378
FU National Natural Science Foundation of China (NSFC) [81572542]; Ministry
   of Education of China (RFDP) [20130162110029]; Scientific Research Funds
   for Returned Overseas Chinese Scholars, Ministry of Education of China
   (SRF for ROCS, SEM) [2014-1685]
FX This work was supported by grants from the National Natural Science
   Foundation of China (NSFC, 81572542), the Doctoral Fund of Ministry of
   Education of China (RFDP, 20130162110029), and Scientific Research Funds
   for Returned Overseas Chinese Scholars, Ministry of Education of China
   (SRF for ROCS, SEM, 2014-1685).
CR [Anonymous], CANCER
   Bosco DB, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128511
   Carr JR, 2010, CANCER RES, V70, P5054, DOI 10.1158/0008-5472.CAN-10-0545
   de Moraes GN, 2015, CELL SIGNAL, V27, P2496, DOI 10.1016/j.cellsig.2015.09.013
   Frederiks CN, 2015, CANCER TREAT REV, V41, P935, DOI 10.1016/j.ctrv.2015.10.010
   Gascoigne KE, 2009, J CELL SCI, V122, P2579, DOI 10.1242/jcs.039719
   Gong AH, 2012, CANCER RES, V72, P5658, DOI 10.1158/0008-5472.CAN-12-0953
   Hou YX, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.53
   Jin W, 2010, BREAST CANCER RES TR, V124, P39, DOI 10.1007/s10549-009-0683-8
   Jordan MA, 2004, NAT REV CANCER, V4, P253, DOI 10.1038/nrc1317
   Khongkow P, 2016, ONCOGENE, V35, P990, DOI 10.1038/onc.2015.152
   Kim KB, 2015, NUCLEIC ACIDS RES, V43, P3509, DOI 10.1093/nar/gkv183
   Kofunato Y, 2012, ONCOL REP, V28, P1997, DOI 10.3892/or.2012.2064
   Lam EWF, 2013, NAT REV CANCER, V13, P482, DOI 10.1038/nrc3539
   Li XX, 2014, J CELL MOL MED, V18, P811, DOI 10.1111/jcmm.12216
   Li XL, 2011, INT J RADIAT BIOL, V87, P263, DOI 10.3109/09553002.2011.530335
   Liu YH, 2014, BBA-GENE REGUL MECH, V1839, P297, DOI 10.1016/j.bbagrm.2014.02.016
   Liu YH, 2014, MOL CARCINOGEN, V53, P380, DOI 10.1002/mc.21989
   McGrogan BT, 2008, BBA-REV CANCER, V1785, P96, DOI 10.1016/j.bbcan.2007.10.004
   Park SA, 2015, JNCI-J NATL CANCER I, V107, DOI 10.1093/jnci/djv151
   Qi JF, 2013, CANCER CELL, V23, P332, DOI 10.1016/j.ccr.2013.02.016
   Sen GL, 2010, NATURE, V463, P563, DOI 10.1038/nature08683
   Unoki M, 2004, ONCOGENE, V23, P7601, DOI 10.1038/sj.onc.1208053
   Wang JX, 2011, EUR J PHARMACOL, V656, P33, DOI 10.1016/j.ejphar.2011.01.042
   Wang K, 2016, ACTA BIOCH BIOPH SIN, V48, P804, DOI 10.1093/abbs/gmw072
   Wiseman EF, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0339-8
   Wu SM, 2015, INT J CANCER, V137, P37, DOI 10.1002/ijc.29368
   Xiang HD, 2017, CELL DISCOV, V3, DOI 10.1038/celldisc.2017.19
   Xie ZQ, 2010, NUCLEIC ACIDS RES, V38, P8027, DOI 10.1093/nar/gkq715
   Yang CR, 2013, MOL BIOL REP, V40, P5225, DOI 10.1007/s11033-013-2559-6
   Yang N, 2017, ONCOGENE, V36, P3428, DOI 10.1038/onc.2016.490
   Zhang HX, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10201
   Zhang N, 2011, CANCER CELL, V20, P427, DOI 10.1016/j.ccr.2011.08.016
   Zhang XW, 2012, ANTI-CANCER DRUG, V23, P856, DOI 10.1097/CAD.0b013e3283548d73
   Zhao F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086486
   Zhao JY, 2017, P NATL ACAD SCI USA, V114, pE142, DOI 10.1073/pnas.1612967114
   Zhou ZJ, 2015, CANCER LETT, V363, P137, DOI 10.1016/j.canlet.2015.04.008
   Zona S, 2014, BBA-GENE REGUL MECH, V1839, P1316, DOI 10.1016/j.bbagrm.2014.09.016
NR 38
TC 41
Z9 44
U1 0
U2 7
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-4889
J9 CELL DEATH DIS
JI Cell Death Dis.
PD MAY 11
PY 2018
VL 9
AR 562
DI 10.1038/s41419-018-0631-9
PG 11
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA GH0KB
UT WOS:000433089800005
PM 29752436
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU Font-Clos, F
   Zapperi, S
   La Porta, CAM
AF Font-Clos, Francesc
   Zapperi, Stefano
   La Porta, Caterina A. M.
TI Topography of epithelial-mesenchymal plasticity
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE epithelial-mesenchymal transition; epigenetic landscape; Boolean
   networks
ID SPIN-GLASSES; KAUFFMAN MODEL; BREAST-CANCER; TRANSITION;
   DIFFERENTIATION; PHASE; LANDSCAPE; DYNAMICS; NETWORK; CELLS
AB The transition between epithelial and mesenchymal states has fundamental importance for embryonic development, stem cell reprogramming, and cancer progression. Here, we construct a topographic map underlying epithelial-mesenchymal transitions using a combination of numerical simulations of a Boolean network model and the analysis of bulk and single-cell gene expression data. The map reveals a multitude of metastable hybrid phenotypic states, separating stable epithelial and mesenchymal states, and is reminiscent of the free energy measured in glassy materials and disordered solids. Our work not only elucidates the nature of hybrid mesenchymal/epithelial states but also provides a general strategy to construct a topographic representation of phenotypic plasticity from gene expression data using statistical physics methods.
C1 [Font-Clos, Francesc; Zapperi, Stefano] Univ Milan, Dept Phys, Ctr Complex & Biosyst, I-20133 Milan, Italy.
   [Zapperi, Stefano] CNR, Ist Chim Mat Condensata & Tecnol Energia, I-20125 Milan, Italy.
   [La Porta, Caterina A. M.] Univ Milan, Dept Environm Sci & Policy, Ctr Complex & Biosyst, I-20133 Milan, Italy.
C3 University of Milan; Consiglio Nazionale delle Ricerche (CNR); Istituto
   di Chimica della Materia Condensata e di Tecnologie per l Energia
   (ICMATE-CNR); University of Milan
RP La Porta, CAM (通讯作者)，Univ Milan, Dept Environm Sci & Policy, Ctr Complex & Biosyst, I-20133 Milan, Italy.
EM caterina.laporta@unimi.it
RI Zapperi, Stefano/C-9473-2009; la porta, caterina/K-7345-2013
OI la porta, caterina/0000-0002-3010-8966; Font-Clos,
   Francesc/0000-0003-4938-2452
FU European Research Council Advanced Grant [291002 SIZEFFECTS]
FX F.F.-C. and S.Z. are supported by European Research Council Advanced
   Grant 291002 SIZEFFECTS.
CR Abnaof K, 2014, BMC SYST BIOL, V8, DOI 10.1186/1752-0509-8-55
   Aleskandarany MA, 2014, BREAST CANCER RES TR, V145, P339, DOI 10.1007/s10549-014-2927-5
   [Anonymous], 1957, The strategy of the genes, DOI DOI 10.4324/9781315765471
   Bargaje R, 2017, P NATL ACAD SCI USA, V114, P2271, DOI 10.1073/pnas.1621412114
   Bastolla U, 1996, PHYSICA D, V98, P1, DOI 10.1016/0167-2789(96)00060-7
   BITTERMAN P, 1990, AM J SURG PATHOL, V14, P317, DOI 10.1097/00000478-199004000-00002
   Bornholdt S, 2008, J R SOC INTERFACE, V5, pS85, DOI 10.1098/rsif.2008.0132.focus
   Carithers LJ, 2015, BIOPRESERV BIOBANK, V13, P311, DOI 10.1089/bio.2015.0032
   Chu LF, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-1033-x
   DERRIDA B, 1987, J PHYS A-MATH GEN, V20, pL721, DOI 10.1088/0305-4470/20/11/009
   DERRIDA B, 1986, J PHYS A-MATH GEN, V19, P1003, DOI 10.1088/0305-4470/19/16/010
   George JT, 2017, CANCER RES, V77, P6415, DOI 10.1158/0008-5472.CAN-16-3521
   GUTFREUND H, 1988, J PHYS A-MATH GEN, V21, P2775, DOI 10.1088/0305-4470/21/12/020
   Haraguchi S, 1999, PATHOL INT, V49, P903, DOI 10.1046/j.1440-1827.1999.00964.x
   Hed G, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.157201
   Hed G, 2001, PHYS REV LETT, V86, P3148, DOI 10.1103/PhysRevLett.86.3148
   Huang B, 2017, PLOS COMPUT BIOL, V13, DOI 10.1371/journal.pcbi.1005456
   Huang S, 2005, PHYS REV LETT, V94, DOI 10.1103/PhysRevLett.94.128701
   Huang S, 2007, DEV BIOL, V305, P695, DOI 10.1016/j.ydbio.2007.02.036
   Huang S, 2012, BIOESSAYS, V34, P149, DOI 10.1002/bies.201100031
   Huber MA, 2005, CURR OPIN CELL BIOL, V17, P548, DOI 10.1016/j.ceb.2005.08.001
   Jolly MK, 2016, ONCOTARGET, V7, P27067, DOI 10.18632/oncotarget.8166
   Jolly MK, 2014, J R SOC INTERFACE, V11, DOI 10.1098/rsif.2014.0962
   KAUFFMAN SA, 1969, J THEOR BIOL, V22, P437, DOI 10.1016/0022-5193(69)90015-0
   Li CH, 2013, J R SOC INTERFACE, V10, DOI 10.1098/rsif.2013.0787
   Li FT, 2004, P NATL ACAD SCI USA, V101, P4781, DOI 10.1073/pnas.0305937101
   Li RH, 2010, CELL STEM CELL, V7, P51, DOI 10.1016/j.stem.2010.04.014
   Liu ZQ, 2017, NATURE, V551, P100, DOI 10.1038/nature24454
   Mezard M., 1987, Spin Glass Theory and Beyond, V9
   MIRANDA EN, 1988, J PHYS A-MATH GEN, V21, pL357, DOI 10.1088/0305-4470/21/6/007
   Mondolfi AEP, 2013, HUM PATHOL, V44, P2853, DOI 10.1016/j.humpath.2013.07.014
   Pázmándi F, 1999, PHYS REV LETT, V83, P1034, DOI 10.1103/PhysRevLett.83.1034
   Puram SV, 2017, CELL, V171, P1611, DOI 10.1016/j.cell.2017.10.044
   Revenu C, 2009, CURR OPIN GENET DEV, V19, P338, DOI 10.1016/j.gde.2009.04.007
   Rhim AD, 2012, CELL, V148, P349, DOI 10.1016/j.cell.2011.11.025
   Samavarchi-Tehrani P, 2010, CELL STEM CELL, V7, P64, DOI 10.1016/j.stem.2010.04.015
   Sarrió D, 2008, CANCER RES, V68, P989, DOI 10.1158/0008-5472.CAN-07-2017
   Scialdone A, 2016, NATURE, V535, P289, DOI 10.1038/nature18633
   SETHNA JP, 1993, PHYS REV LETT, V70, P3347, DOI 10.1103/PhysRevLett.70.3347
   Steinway SN, 2015, NPJ SYST BIOL APPL, V1, DOI 10.1038/npjsba.2015.14
   Steinway SN, 2014, CANCER RES, V74, P5963, DOI 10.1158/0008-5472.CAN-14-0225
   Wang J, 2011, P NATL ACAD SCI USA, V108, P8257, DOI 10.1073/pnas.1017017108
   Wang J, 2010, BIOPHYS J, V99, P29, DOI 10.1016/j.bpj.2010.03.058
   Ye X, 2015, TRENDS CELL BIOL, V25, P675, DOI 10.1016/j.tcb.2015.07.012
   Yu M, 2013, SCIENCE, V339, P580, DOI 10.1126/science.1228522
NR 45
TC 78
Z9 83
U1 2
U2 16
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
EI 1091-6490
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD JUN 5
PY 2018
VL 115
IS 23
BP 5902
EP 5907
DI 10.1073/pnas.1722609115
PG 6
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA GI1FA
UT WOS:000434114900040
PM 29784817
OA Green Submitted, Green Published
DA 2025-01-12
ER

PT J
AU Parashar, S
   Cheishvili, D
   Mahmood, N
   Arakelian, A
   Tanvir, I
   Khan, HA
   Kremer, R
   Mihalcioiu, C
   Szyf, M
   Rabbani, SA
AF Parashar, Surabhi
   Cheishvili, David
   Mahmood, Niaz
   Arakelian, Ani
   Tanvir, Imrana
   Khan, Haseeb Ahmed
   Kremer, Richard
   Mihalcioiu, Catalin
   Szyf, Moshe
   Rabbani, Shafaat A.
TI DNA methylation signatures of breast cancer in peripheral T-cells
SO BMC CANCER
LA English
DT Article
DE Breast cancer; Biomarkers; Immune system; DNA methylation; Blood DNA;
   Epigenetic signature
ID EPIGENOME-WIDE ASSOCIATION; CHECKPOINT BLOCKADE; IN-VITRO; GENES; BLOOD;
   PATTERNS; REVEALS
AB Background: Immune surveillance acts as a defense mechanism in cancer, and its disruption is involved in cancer progression. DNA methylation reflects the phenotypic identity of cells and recent data suggested that DNA methylation profiles of T cells and peripheral blood mononuclear cells (PBMC) are altered in cancer progression.
   Methods: We enrolled 19 females with stage 1 and 2, nine with stage 3 and 4 and 9 age matched healthy women. T cells were isolated from peripheral blood and extracted DNA was subjected to Illumina 450 K DNA methylation array analysis. Raw data was analyzed by BMIQ, ChAMP and ComBat followed by validation of identified genes by pyrosequencing.
   Results: Analysis of data revealed similar to 10,000 sites that correlated with breast cancer progression and established a list of 89 CG sites that were highly correlated (p < 0.01, r > 0.7, r < - 0.7) with breast cancer progression. The vast majority of these sites were hypomethylated and enriched in genes with functions in the immune system.
   Conclusions: The study points to the possibility of using DNA methylation signatures as a noninvasive method for early detection of breast cancer and its progression which need to be tested in clinical studies.
C1 [Parashar, Surabhi; Mahmood, Niaz; Arakelian, Ani; Kremer, Richard; Mihalcioiu, Catalin; Rabbani, Shafaat A.] McGill Univ, Dept Med, Hlth Ctr, 1001 Decarie Blvd,Room EM1-3232, Montreal, PQ H4A 3J1, Canada.
   [Cheishvili, David; Szyf, Moshe] McGill Univ, Hlth Ctr, Dept Pharmacol & Therapeut, Montreal, PQ, Canada.
   [Tanvir, Imrana; Khan, Haseeb Ahmed] Fatima Mem Hosp, Lahore, Pakistan.
   [Cheishvili, David] Montreal EpiTerapia Inc, Montreal, PQ, Canada.
C3 McGill University; McGill University
RP Rabbani, SA (通讯作者)，McGill Univ, Dept Med, Hlth Ctr, 1001 Decarie Blvd,Room EM1-3232, Montreal, PQ H4A 3J1, Canada.
EM shafaat.rabbani@mcgill.ca
RI Cheishvili, David/AAL-1915-2020; Mahmood, Niaz/ADY-9016-2022
OI Mahmood, Niaz/0000-0003-4018-5516; Cheishvili,
   David/0000-0001-9136-8967; Kremer, Richard/0000-0002-7053-2139; rabbani,
   shafaat/0000-0001-5594-3899
FU Canadian Institutes for Health Research [MOP 130410]
FX This work was supported by a grant MOP 130410 from the Canadian
   Institutes for Health Research to S. A. Rabbani and M. Szyf.
CR Ambatipudi S, 2017, EUR J CANCER, V75, P299, DOI 10.1016/j.ejca.2017.01.014
   Anjum S, 2014, GENOME MED, V6, DOI 10.1186/gm567
   Bibikova M, 2011, GENOMICS, V98, P288, DOI 10.1016/j.ygeno.2011.07.007
   Bonini C, 2015, EUR J IMMUNOL, V45, P2457, DOI 10.1002/eji.201545552
   Breiling A, 2015, EPIGENET CHROMATIN, V8, DOI 10.1186/s13072-015-0016-6
   BURNET M, 1957, BRIT MED J, V1, P779, DOI 10.1136/bmj.1.5022.779
   Chavez-Valencia RA, 2018, J AUTOIMMUN, V86, P29, DOI 10.1016/j.jaut.2017.09.010
   Chik F, 2012, ADV EXP MED BIOL, V720, P91, DOI 10.1007/978-1-4614-0254-1_8
   Conway K, 2017, BREAST CANCER RES TR, V163, P349, DOI 10.1007/s10549-017-4178-8
   Dedeurwaerder S, 2011, EMBO MOL MED, V3, P726, DOI 10.1002/emmm.201100801
   Ehrlich P., 1909, JETZIGEN STAND KARZI
   Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210
   Fernandez-Jimenez N, 2017, EPIGENETICS-US, V12, P964, DOI 10.1080/15592294.2017.1373919
   Flanagan JM, 2009, HUM MOL GENET, V18, P1332, DOI 10.1093/hmg/ddp033
   Fridley BL, 2014, BMC MED GENOMICS, V7, DOI 10.1186/1755-8794-7-21
   Gubin MM, 2015, J CLIN INVEST, V125, P3413, DOI 10.1172/JCI80008
   Györffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9
   Huang WY, 2012, CANCER EPIDEM BIOMAR, V21, P2014, DOI 10.1158/1055-9965.EPI-12-0700-T
   Johnson WE, 2007, BIOSTATISTICS, V8, P118, DOI 10.1093/biostatistics/kxj037
   Jones HB., 1848, PHILOS T ROYAL SOC L, V138, P55, DOI DOI 10.1098/RSTL.1848.0003
   Kao WY, 2017, MOL CARCINOGEN, V56, P425, DOI 10.1002/mc.22505
   Klener P, 2015, CURR PHARM BIOTECHNO, V16, P771, DOI 10.2174/1389201016666150619114554
   Koestler DC, 2012, CANCER EPIDEM BIOMAR, V21, P1293, DOI 10.1158/1055-9965.EPI-12-0361
   Morris TJ, 2014, BIOINFORMATICS, V30, P428, DOI 10.1093/bioinformatics/btt684
   Nestor CE, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004059
   Nordlund J, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-9-r105
   Parashar S, 2015, CANCER MED-US, V4, P732, DOI 10.1002/cam4.386
   Paska AV, 2015, BIOCHEM MEDICA, V25, P161, DOI 10.11613/BM.2015.017
   Sagiv-Barfi I, 2015, P NATL ACAD SCI USA, V112, pE966, DOI 10.1073/pnas.1500712112
   Sawyers CL, 2008, NATURE, V452, P548, DOI 10.1038/nature06913
   Severi G, 2014, BREAST CANCER RES TR, V148, P665, DOI 10.1007/s10549-014-3209-y
   Shenker NS, 2013, HUM MOL GENET, V22, P843, DOI 10.1093/hmg/dds488
   Shukeir N, 2006, CANCER RES, V66, P9202, DOI 10.1158/0008-5472.CAN-06-1954
   Shukeir N, 2015, BRIT J PHARMACOL, V172, P2769, DOI 10.1111/bph.13102
   Smyth GK, 2005, STAT BIOL HEALTH, P397, DOI 10.1007/0-387-29362-0_23
   Stefanska B, 2014, CLIN CANCER RES, V20, P3118, DOI 10.1158/1078-0432.CCR-13-0283
   Teschendorff AE, 2013, BIOINFORMATICS, V29, P189, DOI 10.1093/bioinformatics/bts680
   Topalian SL, 2015, CANCER CELL, V27, P450, DOI 10.1016/j.ccell.2015.03.001
   Vainio H., 2002, IARC HDB CANC PREV, V7
   van Veldhoven K, 2015, CLIN EPIGENETICS, V7, DOI 10.1186/s13148-015-0104-2
   Xu ZL, 2013, JNCI-J NATL CANCER I, V105, P694, DOI 10.1093/jnci/djt045
   Zauri M, 2015, NATURE, V524, P114, DOI 10.1038/nature14948
NR 42
TC 29
Z9 31
U1 0
U2 6
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2407
J9 BMC CANCER
JI BMC Cancer
PD MAY 18
PY 2018
VL 18
AR 574
DI 10.1186/s12885-018-4482-7
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA GG5AD
UT WOS:000432706500007
PM 29776342
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU Pamplona-Silva, MT
   Mazzeo, DEC
   Bianchi, J
   Marin-Morales, MA
AF Pamplona-Silva, Maria Tereza
   Christofoletti Mazzeo, Dania Elisa
   Bianchi, Jaqueline
   Marin-Morales, Maria Aparecida
TI Estrogenic Compounds: Chemical Characteristics, Detection Methods,
   Biological and Environmental Effects
SO WATER AIR AND SOIL POLLUTION
LA English
DT Article
DE Endocrine disruptors; Environmental estrogenicity; Estrogen receptor;
   Estrogenic hormones; Bioassay; Epigenetic
ID ENDOCRINE-DISRUPTING CHEMICALS; POLYCYCLIC AROMATIC-HYDROCARBONS;
   TREATMENT-PLANT EFFLUENTS; NONMONOTONIC DOSE RESPONSES; PERSONAL CARE
   PRODUCTS; SEWAGE-TREATMENT PLANT; WASTE-WATER EFFLUENT; BISPHENOL-A;
   IN-VITRO; BREAST-CANCER
AB Several chemical compounds are being studied for their capacities to cause imbalances in several biological systems. Some of those are able to affect the endocrine system and are known as endocrine disruptors. Many negative effects can be induced in the organisms by the action of these chemicals, highlighting the capacity to cause a decrease in the fertility rate, sex inversion, and problems in embryonic development and even cancer in humans. Those contaminants can be found in different environmental conditions, in groundwater, sediments, residual waters, sludges, and even in drinking water. The purpose of this review is to provide a general overview of the main estrogenic endocrine disruptors and their effects on living organisms, showing the most frequently used tools to detect these contaminants in environmental matrices. According to the data found, there is a need to develop more studies and improve the techniques, in order to effectively determine the mechanism of action of these contaminants and, thus, establish appropriate strategies for their removal from the environment and reduce their actions on living beings.
C1 [Pamplona-Silva, Maria Tereza; Christofoletti Mazzeo, Dania Elisa; Bianchi, Jaqueline; Marin-Morales, Maria Aparecida] UNESP Univ Estadual Paulista, Inst Biosci, Dept Biol, Av 24-A 1515,13, BR-506900 Rio Claro, SP, Brazil.
   [Christofoletti Mazzeo, Dania Elisa] UNESP Univ Estadual Paulista, Inst Chem, Dept Analyt Chem, Araraquara, SP, Brazil.
C3 Universidade Estadual Paulista; Universidade Estadual Paulista
RP Marin-Morales, MA (通讯作者)，UNESP Univ Estadual Paulista, Inst Biosci, Dept Biol, Av 24-A 1515,13, BR-506900 Rio Claro, SP, Brazil.
EM mamm@rc.unesp.br
RI Bianchi, Jaqueline/F-6069-2012; Mazzeo, Dania/I-7682-2012;
   Pamplona-Silva, Maria/X-7696-2019; Pamplona-Silva, Maria
   Tereza/M-3351-2018
OI Pamplona-Silva, Maria Tereza/0000-0003-2698-8726
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo - FAPESP
   [2011/16552-7]; Brazilian National Research Council - CNPq
   [460962/2014-0]; Fundacao de Amparo a Pesquisa do Estado de Sao Paulo
   (FAPESP) [11/16552-7] Funding Source: FAPESP
FX This study was supported by the Fundacao de Amparo a Pesquisa do Estado
   de Sao Paulo - FAPESP Processo 2011/16552-7 and Brazilian National
   Research Council - CNPq, Universal Project, Process no. 460962/2014-0.
CR Andersen HR, 1999, ENVIRON HEALTH PERSP, V107, P89, DOI 10.2307/3434476
   Andersen HR, 2002, TOXICOL APPL PHARM, V179, P1, DOI 10.1006/taap.2001.9347
   Anderson MJ, 2003, BIOMARKERS, V8, P371, DOI 10.1080/13547500310001619293
   [Anonymous], 2017, ENVIRON HEALTH PERSP, DOI DOI 10.1289/EHP505
   Arukwe Augustine, 2003, Comp Hepatol, V2, P4
   Astiz M, 2014, NEUROTOX RES, V25, P271, DOI 10.1007/s12640-013-9417-0
   Baccarelli A, 2000, J ENDOCRINOL INVEST, V23, P771, DOI 10.1007/BF03345069
   Baldigo BP, 2015, ENVIRON TOXICOL CHEM, V34, P2803, DOI 10.1002/etc.3120
   Balest L, 2008, BIOCHEM ENG J, V41, P288, DOI 10.1016/j.bej.2008.05.015
   Barber LB, 2015, SCI TOTAL ENVIRON, V517, P195, DOI 10.1016/j.scitotenv.2015.02.035
   Barouki R, 2017, CR BIOL, V340, P410, DOI 10.1016/j.crvi.2017.07.005
   Beausoleil C, 2013, CHEMOSPHERE, V93, P847, DOI 10.1016/j.chemosphere.2013.06.043
   Bennie DT, 1997, SCI TOTAL ENVIRON, V193, P263, DOI 10.1016/S0048-9697(96)05386-7
   Bergeron RM, 1999, MOL CELL ENDOCRINOL, V150, P179, DOI 10.1016/S0303-7207(98)00202-0
   Bernstein BE, 2007, CELL, V128, P669, DOI 10.1016/j.cell.2007.01.033
   Bhatia H, 2014, AQUAT TOXICOL, V149, P103, DOI 10.1016/j.aquatox.2014.01.025
   Bhatt R. V., 2000, ENV INFLUENCE REPROD, P69
   Bicchi C, 2009, SCI TOTAL ENVIRON, V407, P1842, DOI 10.1016/j.scitotenv.2008.11.039
   Borman SM, 2000, TOXICOL APPL PHARM, V167, P191, DOI 10.1006/taap.2000.9006
   Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645
   Buckland R, 2015, DNA PRECURSOR ASYMME
   Campbell CG, 2006, CHEMOSPHERE, V65, P1265, DOI 10.1016/j.chemosphere.2006.08.003
   Cargouët M, 2004, SCI TOTAL ENVIRON, V324, P55, DOI 10.1016/j.scitotenv.2003.10.035
   Cavallin JE, 2016, ENVIRON TOXICOL CHEM, V35, P702, DOI 10.1002/etc.3228
   Charles GD, 2002, TOXICOL SCI, V68, P349, DOI 10.1093/toxsci/68.2.349
   Chen FA, 2004, CHEMOSPHERE, V55, P1377, DOI 10.1016/j.chemosphere.2003.11.058
   Chen TC, 2010, ENVIRON MONIT ASSESS, V161, P135, DOI 10.1007/s10661-008-0733-4
   Chen XP, 2014, INT J ENV RES PUB HE, V11, P3156, DOI 10.3390/ijerph110303156
   Choe SY, 2003, SCI TOTAL ENVIRON, V312, P15, DOI 10.1016/S0048-9697(03)00190-6
   Mazzeo DEC, 2016, CHEMOSPHERE, V163, P508, DOI 10.1016/j.chemosphere.2016.08.060
   CSABA G, 1993, J DEV PHYSIOL, V19, P67
   Darbre P. D., 2001, PRE POSTPARTUM NUTR, V26, P37
   Darbre P.D., 2015, Endocrine Disruption and Human Health, P3, DOI [DOI 10.1016/B978-0-12-801139-3.00001-6, DOI 10.1016/B978-0-12-821985-0.00001-3]
   Department of Health and Human Services, 2012, 4 CDCP, P75
   Bergamasco AMD, 2011, J ENVIRON MONITOR, V13, P3288, DOI 10.1039/c1em10464k
   Diamanti-Kandarakis E, 2010, HORM METAB RES, V42, P543, DOI 10.1055/s-0030-1252034
   Díaz-Cruz MS, 2003, J MASS SPECTROM, V38, P917, DOI 10.1002/jms.529
   Drummond AE, 2010, J ENDOCRINOL, V205, P15, DOI 10.1677/JOE-09-0379
   Erickson BE, 2002, ENVIRON SCI TECHNOL, V36, p140A, DOI 10.1021/es022497d
   Esplugas S, 2007, J HAZARD MATER, V149, P631, DOI 10.1016/j.jhazmat.2007.07.073
   Esteller M, 2007, NAT REV GENET, V8, P286, DOI 10.1038/nrg2005
   Fenet H, 2003, ARCH ENVIRON CON TOX, V44, P1, DOI 10.1007/s00244-002-1198-z
   Fernandez MP, 2007, SCI TOTAL ENVIRON, V373, P250, DOI 10.1016/j.scitotenv.2006.11.018
   Finkelman RB, 1999, P NATL ACAD SCI USA, V96, P3427, DOI 10.1073/pnas.96.7.3427
   Folmar LC, 2002, AQUAT TOXICOL, V60, P101, DOI 10.1016/S0166-445X(01)00276-4
   Foster PMD, 2006, INT J ANDROL, V29, P140, DOI 10.1111/j.1365-2605.2005.00563.x
   Furuichi T, 2004, WATER RES, V38, P4491, DOI 10.1016/j.watres.2004.08.007
   Gagné F, 2012, COMP BIOCHEM PHYS C, V155, P551, DOI 10.1016/j.cbpc.2012.01.004
   Garcia-Reyero N, 2005, ENVIRON SCI TECHNOL, V39, P1427, DOI 10.1021/es0400685
   Ghiselli G, 2007, QUIM NOVA, V30, P695, DOI 10.1590/S0100-40422007000300032
   Gilman A G., 2003, As bases farmacologicas da terapeutica
   Gioiosa L, 2015, DOSE-RESPONSE, V13, DOI 10.1177/1559325815610760
   Giudice BD, 2011, ENVIRON TOXICOL CHEM, V30, P2220, DOI 10.1002/etc.631
   Gorga M, 2015, SCI TOTAL ENVIRON, V503, P69, DOI 10.1016/j.scitotenv.2014.06.037
   Gou YY, 2016, ENVIRON SCI POLLUT R, V23, P8518, DOI 10.1007/s11356-015-5946-9
   Grung M, 2007, CHEMOSPHERE, V67, P108, DOI 10.1016/j.chemosphere.2006.09.021
   Halling-Sorensen B, 1998, CHEMOSPHERE, V36, P357, DOI 10.1016/S0045-6535(97)00354-8
   Hamilton LA, 2016, SCI TOTAL ENVIRON, V560, P101, DOI 10.1016/j.scitotenv.2016.04.003
   Harvey PW, 2002, J APPL TOXICOL, V22, P241, DOI 10.1002/jat.854
   Hashimoto S, 2000, MAR ENVIRON RES, V49, P37, DOI 10.1016/S0141-1136(99)00047-1
   Hemming JM, 2004, ECOTOX ENVIRON SAFE, V57, P303, DOI 10.1016/S0147-6513(03)00025-3
   Hilscherova K, 2000, ENVIRON SCI POLLUT R, V7, P159, DOI 10.1065/espr2000.02.017
   Hinck JE, 2007, SCI TOTAL ENVIRON, V378, P376, DOI 10.1016/j.scitotenv.2007.02.032
   Hseu ZY, 2006, CHEMOSPHERE, V64, P1769, DOI 10.1016/j.chemosphere.2005.12.042
   Hsieh TH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042750
   Hsieh TH, 2012, FASEB J, V26, P778, DOI 10.1096/fj.11-191742
   Hsu PY, 2009, CANCER RES, V69, P5936, DOI 10.1158/0008-5472.CAN-08-4914
   Jacobs M., 2001, PESTICIDES LIVELIHOO, V4, P14
   Janosek J, 2006, TOXICOL IN VITRO, V20, P18, DOI 10.1016/j.tiv.2005.06.001
   Jefferson WN, 2005, BIOL REPROD, V73, P798, DOI 10.1095/biolreprod.105.041277
   Jirtle RL, 2007, NAT REV GENET, V8, P253, DOI 10.1038/nrg2045
   Jobling S, 1998, ENVIRON SCI TECHNOL, V32, P2498, DOI 10.1021/es9710870
   Jobling S, 2002, BIOL REPROD, V67, P515, DOI 10.1095/biolreprod67.2.515
   Jones PD, 2000, WATER SCI TECHNOL, V42, P1
   Jugan ML, 2009, SCI TOTAL ENVIRON, V407, P3579, DOI 10.1016/j.scitotenv.2009.01.027
   Kang SC, 2005, J TOXICOL ENV HEAL A, V68, P1995, DOI 10.1080/15287390491008913
   Kavouras IG, 2001, ENVIRON SCI TECHNOL, V35, P2288, DOI 10.1021/es001540z
   Kawahata H, 2004, CHEMOSPHERE, V55, P1519, DOI 10.1016/j.chemosphere.2004.01.032
   Kelley KE, 2012, ENVIRON HEALTH PERSP, V120, P379, DOI 10.1289/ehp.1103998
   Kelly A, 2004, EVOL ECOL, V18, P121, DOI 10.1023/B:EVEC.0000021091.27606.3c
   Kime DE, 1999, AQUACULTURE, V177, P345, DOI 10.1016/S0044-8486(99)00097-6
   Kinch CD, 2015, P NATL ACAD SCI USA, V112, P1475, DOI 10.1073/pnas.1417731112
   Kiyama R, 2015, ENVIRON INT, V83, P11, DOI 10.1016/j.envint.2015.05.012
   Knower KC, 2014, ENDOCR-RELAT CANCER, V21, pT33, DOI 10.1530/ERC-13-0513
   Kojima H, 2004, ENVIRON HEALTH PERSP, V112, P524, DOI 10.1289/ehp.6649
   Kolpin DW, 2002, ENVIRON SCI TECHNOL, V36, P1202, DOI 10.1021/es011055j
   Kortenkamp A, 2007, ENVIRON HEALTH PERSP, V115, P98, DOI 10.1289/ehp.9357
   KRISHNAN AV, 1993, ENDOCRINOLOGY, V132, P2279, DOI 10.1210/en.132.6.2279
   Kurihara R, 2007, MAR POLLUT BULL, V54, P1315, DOI 10.1016/j.marpolbul.2007.06.007
   Kwon S, 2000, TOXICOL SCI, V55, P399, DOI 10.1093/toxsci/55.2.399
   Lafuente A, 2013, TOXICOLOGY, V311, P35, DOI 10.1016/j.tox.2013.05.001
   Lagarde F, 2015, ENVIRON HEALTH-GLOB, V14, DOI 10.1186/1476-069X-14-13
   Lavado R, 2004, TOXICOL APPL PHARM, V196, P247, DOI 10.1016/j.taap.2003.12.012
   Lester J., 2001, Pollut. Causes, Eff. Control, P113
   Letcher RJ, 2005, TOXICOL APPL PHARM, V209, P95, DOI 10.1016/j.taap.2005.03.013
   Levy G, 2004, ENVIRON RES, V94, P102, DOI 10.1016/S0013-9351(03)00086-0
   Lezcano V, 2017, BONE, V105, P301, DOI 10.1016/j.bone.2017.03.020
   Li XM, 2008, BIOMED ENVIRON SCI, V21, P381, DOI 10.1016/S0895-3988(08)60058-6
   Liney KE, 2006, ENVIRON HEALTH PERSP, V114, P81, DOI 10.1289/ehp.8058
   Lintelmann J, 2003, PURE APPL CHEM, V75, P631, DOI 10.1351/pac200375050631
   Liu B, 2017, ONCOTARGET, V8, P92359, DOI 10.18632/oncotarget.21308
   Ma M, 2007, ENVIRON POLLUT, V147, P331, DOI 10.1016/j.envpol.2006.05.032
   MACKENZIE KM, 1981, BIOL REPROD, V24, P183, DOI 10.1095/biolreprod24.1.183
   Bila DM, 2007, QUIM NOVA, V30, P651, DOI 10.1590/S0100-40422007000300027
   Mandich A, 2007, GEN COMP ENDOCR, V153, P15, DOI 10.1016/j.ygcen.2007.01.004
   Maniero MG, 2008, SCI TOTAL ENVIRON, V407, P105, DOI 10.1016/j.scitotenv.2008.08.011
   Manikkam M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055387
   Martin-Skilton R, 2006, ENVIRON POLLUT, V141, P60, DOI 10.1016/j.envpol.2005.08.016
   Maurício R, 2006, ENVIRON MONIT ASSESS, V118, P75, DOI 10.1007/s10661-006-0986-8
   Meeker JD, 2009, PHILOS T R SOC B, V364, P2097, DOI 10.1098/rstb.2008.0268
   Melnick Ronald, 2002, Environmental Health Perspectives, V110, P427
   Meyer A, 1999, Cad Saude Publica, V15, P845, DOI 10.1590/S0102-311X1999000400018
   Milesi MM, 2017, MOL CELL ENDOCRINOL, V454, P1, DOI 10.1016/j.mce.2017.05.028
   Milesi MM, 2015, MOL CELL ENDOCRINOL, V401, P248, DOI 10.1016/j.mce.2014.11.028
   Milesi MM, 2012, REPROD TOXICOL, V33, P85, DOI 10.1016/j.reprotox.2011.12.003
   Mills LJ, 2001, AQUAT TOXICOL, V52, P157, DOI 10.1016/S0166-445X(00)00139-9
   Mnif W, 2011, INT J ENV RES PUB HE, V8, P2265, DOI 10.3390/ijerph8062265
   Moresco RM, 2014, ENVIRON RES, V132, P6, DOI 10.1016/j.envres.2014.03.028
   Morissette M, 2018, NEUROPHARMACOLOGY, V133, P289, DOI 10.1016/j.neuropharm.2018.01.039
   Mueller SO, 2004, ANAL BIOANAL CHEM, V378, P582, DOI 10.1007/s00216-003-2238-x
   Nadal A, 2018, J STEROID BIOCHEM, V176, P16, DOI 10.1016/j.jsbmb.2017.01.014
   Nakata H, 2014, ECOTOX ENVIRON SAFE, V99, P61, DOI 10.1016/j.ecoenv.2013.10.005
   Nesaretnam K, 1997, J STEROID BIOCHEM, V62, P409, DOI 10.1016/S0960-0760(97)00062-9
   Niemuth NJ, 2015, CHEMOSPHERE, V135, P38, DOI 10.1016/j.chemosphere.2015.03.060
   Okoumassoun LE, 2002, SCI TOTAL ENVIRON, V299, P163, DOI 10.1016/S0048-9697(01)01053-1
   Oliveira DP, 2007, MUTAT RES-GEN TOX EN, V626, P135, DOI 10.1016/j.mrgentox.2006.09.008
   Osman A, 2015, REPROD BIOMED ONLINE, V30, P120, DOI 10.1016/j.rbmo.2014.10.018
   Patel S, 2017, REPROD TOXICOL, V74, P174, DOI 10.1016/j.reprotox.2017.09.014
   Patisaul HB, 2009, FRONT BEHAV NEUROSCI, V3, DOI 10.3389/neuro.08.010.2009
   Pawlowski S, 2004, TOXICOL IN VITRO, V18, P129, DOI 10.1016/j.tiv.2003.08.006
   Payne J, 2000, ENVIRON HEALTH PERSP, V108, P983, DOI 10.1289/ehp.00108983
   Payne J, 2001, ENVIRON HEALTH PERSP, V109, P391, DOI 10.2307/3454899
   Fontenele EGP, 2010, ARQ BRAS ENDOCRINOL, V54, P6, DOI 10.1590/S0004-27302010000100003
   Petrovic M, 2001, ANAL CHEM, V73, P5886, DOI 10.1021/ac010677k
   Pickford DB, 2015, ECOTOX ENVIRON SAFE, V117, P7, DOI 10.1016/j.ecoenv.2015.03.006
   Pimentel MF, 2016, ENVIRON MONIT ASSESS, V188, DOI 10.1007/s10661-016-5300-9
   Pinto B, 2008, ENVIRON MONIT ASSESS, V144, P445, DOI 10.1007/s10661-007-0007-6
   Pleil JD, 2004, P NATL ACAD SCI USA, V101, P11685, DOI 10.1073/pnas.0404499101
   Praveena SM, 2018, IRAN J SCI TECHNOL A, V42, P525, DOI 10.1007/s40995-016-0109-5
   Rasier G, 2006, MOL CELL ENDOCRINOL, V254, P187, DOI 10.1016/j.mce.2006.04.002
   Reungoat J, 2012, WATER RES, V46, P863, DOI 10.1016/j.watres.2011.11.064
   RIGDON RH, 1964, EXPERIENTIA, V20, P224, DOI 10.1007/BF02135417
   Rocha MJ, 2015, ENVIRON MONIT ASSESS, V187, DOI 10.1007/s10661-015-4679-z
   Rosa R.M. R., 2008, Contribuicao para o estudo de compostos desreguladores endocrinos (EDC) em estacoes de tratamento de aguas residuais (ETAR): Estudo da remocao de EDC's numa ETAR com tratamento terciario
   Sadikovic B, 2006, TOXICOL APPL PHARM, V216, P458, DOI 10.1016/j.taap.2006.06.012
   Salste L, 2007, SCI TOTAL ENVIRON, V378, P343, DOI 10.1016/j.scitotenv.2007.02.030
   Santodonato J, 1997, CHEMOSPHERE, V34, P835, DOI 10.1016/S0045-6535(97)00012-X
   Schecter A, 2013, ENVIRON HEALTH PERSP, V121, P473, DOI 10.1289/ehp.1206367
   Schiliró T, 2009, CHEMOSPHERE, V75, P335, DOI 10.1016/j.chemosphere.2008.12.028
   Schug TT, 2011, J STEROID BIOCHEM, V127, P204, DOI 10.1016/j.jsbmb.2011.08.007
   Schwaiger J, 2000, AQUAT TOXICOL, V51, P69, DOI 10.1016/S0166-445X(00)00098-9
   Selvaraj KK, 2015, ENVIRON GEOCHEM HLTH, V37, P83, DOI 10.1007/s10653-014-9632-5
   Servos MR, 1999, WATER QUAL RES J CAN, V34, P123, DOI 10.2166/wqrj.1999.005
   Shahidehnia M., 2016, J. Environ. Anal. Toxicol, DOI DOI 10.4172/2161-0525.1000381
   Shaw I, 2002, INT J FOOD SCI TECH, V37, P471, DOI 10.1046/j.1365-2621.2002.00595.x
   Shimada K, 2001, J CHROMATOGR A, V935, P141, DOI 10.1016/S0021-9673(01)00943-8
   SHORE LS, 1993, B ENVIRON CONTAM TOX, V51, P361, DOI 10.1007/BF00201753
   Sievers CK, 2013, TOXICOL SCI, V132, P359, DOI 10.1093/toxsci/kfs287
   Simpson MG, 2000, MAR ENVIRON RES, V50, P283, DOI 10.1016/S0141-1136(00)00089-1
   Snyder SA, 2003, ENVIRON ENG SCI, V20, P449, DOI 10.1089/109287503768335931
   Soares A, 2008, ENVIRON INT, V34, P1033, DOI 10.1016/j.envint.2008.01.004
   Song WT, 2016, B ENVIRON CONTAM TOX, V97, P763, DOI 10.1007/s00128-016-1930-4
   Srivastava S. K., 2015, BIOSENSORS J, V4, DOI [10.4172/2090-4967.1000114, DOI 10.4172/2090-4967.1000114]
   Staples CA, 1998, CHEMOSPHERE, V36, P2149, DOI 10.1016/S0045-6535(97)10133-3
   Stringer R, 2000, ENVIRON SCI POLLUT R, V7, P27, DOI 10.1065/espr199910.007
   Sun JQ, 2013, J HAZARD MATER, V248, P142, DOI 10.1016/j.jhazmat.2012.12.057
   Sun LW, 2009, CHEMOSPHERE, V75, P410, DOI 10.1016/j.chemosphere.2008.11.083
   Sweeney MF, 2015, REV ENDOCR METAB DIS, V16, P341, DOI 10.1007/s11154-016-9337-4
   Tammen SA, 2013, MOL ASPECTS MED, V34, P753, DOI 10.1016/j.mam.2012.07.018
   Trudeau V, 2007, GEN COMP ENDOCR, V153, P13, DOI 10.1016/j.ygcen.2007.06.003
   Tsay JJ, 2013, ANTICANCER RES, V33, P1247
   Upson K, 2013, ENVIRON RES, V126, P91, DOI 10.1016/j.envres.2013.07.003
   Urase T, 2005, WATER RES, V39, P1289, DOI 10.1016/j.watres.2005.01.015
   USEPA, 2010, NON NON ETH ACT PLAN
   USEPA, 2011, WHAT IS END DISR
   USEPA, 2012, GUID ENS MAX QUAL OB, V515, P1
   USEPA, 2006, AQ LIF AMB WAT QUAL
   Vagi SJ, 2014, BMC ENDOCR DISORD, V14, DOI 10.1186/1472-6823-14-86
   Vajda AM, 2008, ENVIRON SCI TECHNOL, V42, P3407, DOI 10.1021/es0720661
   Van de Wiele T, 2005, ENVIRON HEALTH PERSP, V113, P6, DOI 10.1289/ehp.7259
   Vandenberg LN, 2014, DOSE-RESPONSE, V12, P259, DOI 10.2203/dose-response.13-020.Vandenberg
   Vandenberg LN, 2012, ENDOCR REV, V33, P378, DOI 10.1210/er.2011-1050
   Varayoud J, 2008, REPROD TOXICOL, V26, P138, DOI 10.1016/j.reprotox.2008.08.004
   Vega-López A, 2007, COMP BIOCHEM PHYS C, V145, P394, DOI 10.1016/j.cbpc.2007.01.008
   Verderame M, 2016, ECOTOXICOLOGY, V25, P105, DOI 10.1007/s10646-015-1571-0
   Dias ACV, 2015, ECOTOX ENVIRON SAFE, V120, P41, DOI 10.1016/j.ecoenv.2015.05.013
   Vogel Sarah A, 2009, Am J Public Health, V99 Suppl 3, pS559, DOI 10.2105/AJPH.2008.159228
   vom Saal FS, 2006, ENVIRON RES, V100, P50, DOI 10.1016/j.envres.2005.09.001
   Wang B, 2016, ECOTOX ENVIRON SAFE, V128, P133, DOI 10.1016/j.ecoenv.2016.02.018
   Wang L, 2012, ENVIRON POLLUT, V165, P241, DOI 10.1016/j.envpol.2011.10.005
   Wenzel KD, 1998, ANAL CHEM, V70, P4827, DOI 10.1021/ac9806299
   Whirledge S, 2015, ENVIRON HEALTH PERSP, V123, P80, DOI 10.1289/ehp.1408437
   WHITE R, 1994, ENDOCRINOLOGY, V135, P175, DOI 10.1210/en.135.1.175
   Wu JY, 2006, ENVIRON TOXICOL, V21, P250, DOI 10.1002/tox.20178
   Wu MH, 2016, ENVIRON TOXICOL CHEM, V35, P182, DOI 10.1002/etc.3176
   Yamamoto H, 2003, ENVIRON SCI TECHNOL, V37, P2646, DOI 10.1021/es026405w
   Yang JY, 2007, TOXICOL IN VITRO, V21, P558, DOI 10.1016/j.tiv.2006.10.013
   Yang Oneyeol, 2015, J Cancer Prev, V20, P12, DOI 10.15430/JCP.2015.20.1.12
   Ying G.-G., 2012, ANAL ENDOCRINE DISRU, P3, DOI [10.1002/9781118346747.ch1, DOI 10.1002/9781118346747.CH1]
   Ying GG, 2002, ENVIRON INT, V28, P215, DOI 10.1016/S0160-4120(02)00017-X
   Ying GG, 2002, ENVIRON INT, V28, P545, DOI 10.1016/S0160-4120(02)00075-2
   Yu LD, 2016, CELL COMMUN SIGNAL, V14, DOI 10.1186/s12964-016-0141-2
   Zama AM, 2010, FRONT NEUROENDOCRIN, V31, P420, DOI 10.1016/j.yfrne.2010.06.003
   Zhang J, 2016, EXP BIOL MED, V241, P1516, DOI 10.1177/1535370216644530
   Zhao JL, 2011, ENVIRON TOXICOL CHEM, V30, P2208, DOI 10.1002/etc.625
   Zhou R, 2017, CHEMOSPHERE, V178, P378, DOI 10.1016/j.chemosphere.2017.03.040
NR 206
TC 18
Z9 21
U1 0
U2 47
PU SPRINGER INTERNATIONAL PUBLISHING AG
PI CHAM
PA GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND
SN 0049-6979
EI 1573-2932
J9 WATER AIR SOIL POLL
JI Water Air Soil Pollut.
PD MAY
PY 2018
VL 229
IS 5
AR 144
DI 10.1007/s11270-018-3796-z
PG 27
WC Environmental Sciences; Meteorology & Atmospheric Sciences; Water
   Resources
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Environmental Sciences & Ecology; Meteorology & Atmospheric Sciences;
   Water Resources
GA GG8PB
UT WOS:000432958800022
DA 2025-01-12
ER

PT J
AU Li, GC
   Wang, D
   Ma, WC
   An, K
   Liu, ZZ
   Wang, XY
   Yang, CY
   Du, FX
   Han, X
   Chang, S
   Yu, H
   Zhang, ZL
   Zhao, ZT
   Zhang, Y
   Wang, JY
   Sun, YL
AF Li, Guochao
   Wang, Dong
   Ma, Wencui
   An, Ke
   Liu, Zongzhi
   Wang, Xinyu
   Yang, Caiyun
   Du, Fengxia
   Han, Xiao
   Chang, Shuang
   Yu, Hui
   Zhang, Zilong
   Zhao, Zitong
   Zhang, Yan
   Wang, Junyun
   Sun, Yingli
TI Transcriptomic and epigenetic analysis of breast cancer stem cells
SO EPIGENOMICS
LA English
DT Article
DE breast cancer stem cells; DNA methylation; epigenome; histone
   modification; H3K27me3; H3K4me2; multiple omics analysis; transcriptome
ID TRANSLATION INITIATION; SIGNALING PATHWAY; READ ALIGNMENT; SELF-RENEWAL;
   EXPRESSION; GROWTH; EIF4E; METHYLATION; METASTASIS; CARCINOMA
AB Aim: Cancer stem cells (CSCs) drive triple-negative breast cancer recurrence via their properties of self-renewal, invasiveness and radio/chemotherapy resistance. This study examined how CSCs might sustain these properties. Materials & methods: Transcriptomes, DNA methylomes and histone modifications were compared between CSCs and non CSCs. Results: Transcriptome analysis revealed several pathways that were activated in CSCs, whereas cell cycle regulation pathways were inhibited. Cell development and signaling genes were differentially methylated, with histone methylation analysis suggesting distinct H3K4me2 and H3K27me3 enrichment profiles. An integrated analysis revealed several tumor suppressor genes downregulated in CSCs. Conclusion: Differential activation of various signaling pathways and genes contributes to the tumor-promoting properties of CSCs. Therapeutic targets identified in the analysis may contribute to improving treatment options for patients.
C1 [Li, Guochao; Wang, Dong; An, Ke; Liu, Zongzhi; Yang, Caiyun; Du, Fengxia; Han, Xiao; Chang, Shuang; Yu, Hui; Zhang, Zilong; Zhao, Zitong; Wang, Junyun; Sun, Yingli] Chinese Acad Sci, Beijing Inst Genom, China Gastrointestinal Canc Res Ctr, Key Lab Genom & Precis Med, Beijing 100101, Peoples R China.
   [Li, Guochao; Wang, Dong; An, Ke; Liu, Zongzhi; Yang, Caiyun; Du, Fengxia; Han, Xiao; Chang, Shuang; Yu, Hui; Zhang, Zilong; Zhao, Zitong; Wang, Junyun; Sun, Yingli] Univ Chinese Acad Sci, Beijing 100049, Peoples R China.
   [Ma, Wencui] Heze Third Peoples Hosp, Qingdao 274031, Shandong, Peoples R China.
   [Wang, Xinyu] Harbin Med Univ, Coll Bioinformat Sci & Technol, Harbin 150081, Heilongjiang, Peoples R China.
C3 Chinese Academy of Sciences; Beijing Institute of Genomics, CAS; Chinese
   Academy of Sciences; University of Chinese Academy of Sciences, CAS;
   Harbin Medical University
RP Wang, JY; Sun, YL (通讯作者)，Chinese Acad Sci, Beijing Inst Genom, China Gastrointestinal Canc Res Ctr, Key Lab Genom & Precis Med, Beijing 100101, Peoples R China.; Wang, JY; Sun, YL (通讯作者)，Univ Chinese Acad Sci, Beijing 100049, Peoples R China.
EM jywang@big.ac.cn; sunyl@big.ac.cn
RI zhang, yuhan/HLH-1222-2023; Yu, Huihui/AAT-7595-2021; An,
   Ke/JPX-5153-2023; Wang, Xinyu/R-8195-2019; Liu, Zongzhi/AAE-1856-2022;
   Li, Guochao/LCD-8185-2024; wang, jun yun/GYQ-7741-2022
OI Li, Guochao/0000-0002-1504-3471; wang, jun yun/0000-0003-0573-7856;
   Zhang, Zilong/0000-0003-2298-4533
FU Strategic Priority Research Program of the Chinese Academy of Sciences
   [XDA01040407]; National Natural Science Foundation of China [81702796];
   National Basic Research Program of China (973 Program) [2013CB911001];
   Precision Medicine Research Program of the Chinese Academy of Sciences
   [KJZD-EW-L14]
FX This work was supported by Strategic Priority Research Program of the
   Chinese Academy of Sciences (grant no. XDA01040407), National Natural
   Science Foundation of China (grant no. 81702796), the National Basic
   Research Program of China (973 Program, grant no. 2013CB911001), and
   Precision Medicine Research Program of the Chinese Academy of Sciences
   (grant no. KJZD-EW-L14). The authors have no other relevant affiliations
   or financial involvement with any organization or entity with a
   financial interest in or financial conflict with the subject matter or
   materials discussed in the manuscript apart from those disclosed.
CR Aguilar-Rojas A, 2016, INT J ONCOL, V48, P861, DOI 10.3892/ijo.2016.3346
   Aguilar-Rojas A, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-550
   Akalin A, 2012, GENOME BIOL, V13, DOI [10.1186/gb-2012-13-10-R87, 10.1186/gb-2012-13-10-r87]
   Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100
   An H, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0141919
   An K, 2018, J GENET GENOMICS, V45, P169, DOI 10.1016/j.jgg.2017.11.004
   Anders CK, 2009, CLIN BREAST CANCER, V9, pS73, DOI 10.3816/CBC.2009.s.008
   Anders S, 2015, BIOINFORMATICS, V31, P166, DOI 10.1093/bioinformatics/btu638
   Ballard MS, 2015, CELL REP, V13, P290, DOI 10.1016/j.celrep.2015.09.006
   Baylin Stephen B, 2005, Nat Clin Pract Oncol, V2 Suppl 1, pS4, DOI 10.1038/ncponc0354
   Baylin SB, 2011, NAT REV CANCER, V11, P726, DOI 10.1038/nrc3130
   Belle L, 2015, SCI SIGNAL, V8, DOI 10.1126/scisignal.2005547
   Bernstein BE, 2007, CELL, V128, P669, DOI 10.1016/j.cell.2007.01.033
   Chacón RD, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2574
   Chang PH, 2012, CANCER RES, V72, P4652, DOI 10.1158/0008-5472.CAN-12-0877
   Chen MS, 2007, J CELL SCI, V120, P468, DOI 10.1242/jcs.03348
   Choi YK, 2013, CANCER GENOM PROTEOM, V10, P265
   Cooper CS, 2009, BRIT J CANCER, V100, P240, DOI 10.1038/sj.bjc.6604771
   Dalerba P, 2007, P NATL ACAD SCI USA, V104, P10158, DOI 10.1073/pnas.0703478104
   De Laurentiis M, 2010, CANCER TREAT REV, V36, pS80, DOI 10.1016/S0305-7372(10)70025-6
   Dent R, 2007, CLIN CANCER RES, V13, P4429, DOI 10.1158/1078-0432.CCR-06-3045
   Elias AD, 2010, AM J CLIN ONCOL-CANC, V33, P637, DOI 10.1097/COC.0b013e3181b8afcf
   Esteller M, 2002, ONCOGENE, V21, P5427, DOI 10.1038/sj.onc.1205600
   Falcon S, 2007, BIOINFORMATICS, V23, P257, DOI 10.1093/bioinformatics/btl567
   Feinberg AP, 2004, NAT REV CANCER, V4, P143, DOI 10.1038/nrc1279
   Gansler T, 2010, CA-CANCER J CLIN, V60, P345, DOI 10.3322/caac.20088
   Genander M, 2010, CURR OPIN CELL BIOL, V22, P611, DOI 10.1016/j.ceb.2010.08.005
   Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80
   Ginestier C, 2007, CELL STEM CELL, V1, P555, DOI 10.1016/j.stem.2007.08.014
   Goldberg AD, 2007, CELL, V128, P635, DOI 10.1016/j.cell.2007.02.006
   Golovko A, 2016, CELL CYCLE, V15, P3115, DOI 10.1080/15384101.2016.1237324
   Graff JR, 2007, J CLIN INVEST, V117, P2638, DOI 10.1172/JCI32044
   Huang JM, 2013, ONCOGENE, V32, P2220, DOI 10.1038/onc.2012.231
   Hudis CA, 2011, ONCOLOGIST, V16, P1, DOI 10.1634/theoncologist.2011-S1-01
   Idowu MO, 2012, HUM PATHOL, V43, P364, DOI 10.1016/j.humpath.2011.05.005
   Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43
   Jiang W, 2013, CELL RES, V23, P122, DOI 10.1038/cr.2012.119
   Kim D, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-4-r36
   Krueger F, 2011, BIOINFORMATICS, V27, P1571, DOI 10.1093/bioinformatics/btr167
   Kuhnert F, 2004, P NATL ACAD SCI USA, V101, P266, DOI 10.1073/pnas.2536800100
   Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/NMETH.1923, 10.1038/nmeth.1923]
   Li BDL, 1998, ANN SURG, V227, P756, DOI 10.1097/00000658-199805000-00016
   Li H, 2009, BIOINFORMATICS, V25, P2078, DOI 10.1093/bioinformatics/btp352
   Li H, 2009, BIOINFORMATICS, V25, P1094, DOI [10.1093/bioinformatics/btp100, 10.1093/bioinformatics/btp324]
   Lindqvist L, 2009, FUTURE MED CHEM, V1, P1709, DOI [10.4155/fmc.09.122, 10.4155/FMC.09.122]
   Liu SL, 2014, STEM CELL REP, V2, P78, DOI 10.1016/j.stemcr.2013.11.009
   Luo WJ, 2013, BIOINFORMATICS, V29, P1830, DOI 10.1093/bioinformatics/btt285
   Ma F, 2014, CANCER LETT, V353, P153, DOI 10.1016/j.canlet.2014.06.022
   Marotta LLC, 2011, J CLIN INVEST, V121, P2723, DOI 10.1172/JCI44745
   McLaughlin N, 2013, EPIGENETICS-US, V8, P970, DOI 10.4161/epi.25753
   McLean CY, 2010, NAT BIOTECHNOL, V28, P495, DOI 10.1038/nbt.1630
   Meng E, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107142
   Morgan K, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-476
   Naor Z, 2013, FRONT NEUROENDOCRIN, V34, P88, DOI 10.1016/j.yfrne.2012.11.001
   Newman LA, 2015, ANN SURG ONCOL, V22, P874, DOI 10.1245/s10434-014-4279-0
   Ni F, 2016, CELL CYCLE, V15, P2539, DOI 10.1080/15384101.2016.1204851
   Niu C, 2011, IUBMB LIFE, V63, P764, DOI 10.1002/iub.502
   Noren NK, 2006, NAT CELL BIOL, V8, P815, DOI 10.1038/ncb1438
   Nusse R, 2005, CELL RES, V15, P28, DOI 10.1038/sj.cr.7290260
   Pinto D, 2003, GENE DEV, V17, P1709, DOI 10.1101/gad.267103
   Ponti D, 2005, CANCER RES, V65, P5506, DOI 10.1158/0008-5472.CAN-05-0626
   Qin FX, 2015, SCI REP-UK, V5, DOI 10.1038/srep14430
   Ricardo S, 2011, J CLIN PATHOL, V64, P937, DOI 10.1136/jcp.2011.090456
   Robertson KD, 2005, NAT REV GENET, V6, P597, DOI 10.1038/nrg1655
   Rosenwald IB, 2008, HUM PATHOL, V39, P910, DOI 10.1016/j.humpath.2007.10.021
   Salmon-Divon M, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-415
   Schneider BP, 2008, CLIN CANCER RES, V14, P8010, DOI 10.1158/1078-0432.CCR-08-1208
   Tao H, 2014, MOL CELL BIOCHEM, V394, P23, DOI 10.1007/s11010-014-2077-4
   Wang L, 2017, BIOINFORMATICS, V26, P136
   WANG XS, 2016, MEDICINE, V95
   Wendel HG, 2004, NATURE, V428, P332, DOI 10.1038/nature02369
   Wimmer-Kleikamp SH, 2005, IUBMB LIFE, V57, P421, DOI 10.1080/15216540500138337
   Xiao L, 2011, J BIOL CHEM, V286, P7788, DOI 10.1074/jbc.M110.173468
   Ye T, 2011, NUCLEIC ACIDS RES, V39, DOI 10.1093/nar/gkq1287
   Zhang JM, 2016, CARCINOGENESIS, V37, P951, DOI 10.1093/carcin/bgw077
   Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r137
NR 76
TC 21
Z9 22
U1 0
U2 20
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1750-1911
EI 1750-192X
J9 EPIGENOMICS-UK
JI Epigenomics
PD JUN
PY 2018
VL 10
IS 6
BP 765
EP 783
DI 10.2217/epi-2018-0008
PG 19
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA GN1MV
UT WOS:000438756600007
PM 29480027
DA 2025-01-12
ER

PT J
AU Wang, L
   Zhao, ZB
   Ozark, PA
   Fantini, D
   Marshall, SA
   Rendleman, EJ
   Cozzolino, KA
   Louis, N
   He, XY
   Morgan, MA
   Takahashi, YH
   Collings, CK
   Smith, ER
   Ntziachristos, P
   Savas, JN
   Zou, LH
   Hashizume, R
   Meeks, JJ
   Shilatifard, A
AF Wang, Lu
   Zhao, Zibo
   Ozark, Patrick A.
   Fantini, Damiano
   Marshall, Stacy A.
   Rendleman, Emily J.
   Cozzolino, Kira A.
   Louis, Nundia
   He, Xingyao
   Morgan, Marc A.
   Takahashi, Yoh-hei
   Collings, Clayton K.
   Smith, Edwin R.
   Ntziachristos, Panagiotis
   Savas, Jeffrey N.
   Zou, Lihua
   Hashizume, Rintaro
   Meeks, Joshua J.
   Shilatifard, Ali
TI Resetting the epigenetic balance of Polycomb and COMPASS function at
   enhancers for cancer therapy
SO NATURE MEDICINE
LA English
DT Article
ID EZH2 INHIBITION REGARDLESS; HISTONE H3K4 METHYLASES; ACUTE
   MYELOID-LEUKEMIA; UVEAL MELANOMA-CELLS; TUMOR-SUPPRESSOR; BREAST-CANCER;
   OVARIAN-CANCER; BAP1 STATUS; GENE; COMPLEXES
AB The lysine methyltransferase KMT2C (also known as MLL3), a subunit of the COMPASS complex, implements monomethylation of Lys4 on histone H3 (H3K4) at gene enhancers. KMT2C (hereafter referred to as MLL3) frequently incurs point mutations across a range of human tumor types, but precisely how these lesions alter MLL3 function and contribute to oncogenesis is unclear. Here we report a cancer mutational hotspot in MLL3 within the region encoding its plant homeodomain (PHD) repeats and demonstrate that this domain mediates association of MLL3 with the histone H2A deubiquitinase and tumor suppressor BAP1. Cancer-associated mutations in the sequence encoding the MLL3 PHD repeats disrupt the interaction between MLL3 and BAP1 and correlate with poor patient survival. Cancer cells that had PHD-associated MLL3 mutations or lacked BAP1 showed reduced recruitment of MLL3 and the H3K27 demethylase KDM6A (also known as UTX) to gene enhancers. As a result, inhibition of the H3K27 methyltransferase activity of the Polycomb repressive complex 2 (PRC2) in tumor cells harboring BAP1 or MLL3 mutations restored normal gene expression patterns and impaired cell proliferation in vivo. This study provides mechanistic insight into the oncogenic effects of PHD-associated mutations in MLL3 and suggests that restoration of a balanced state of Polycomb-COMPASS activity may have therapeutic efficacy in tumors that bear mutations in the genes encoding these epigenetic factors.
C1 [Wang, Lu; Zhao, Zibo; Ozark, Patrick A.; Fantini, Damiano; Marshall, Stacy A.; Rendleman, Emily J.; Morgan, Marc A.; Takahashi, Yoh-hei; Smith, Edwin R.; Ntziachristos, Panagiotis; Zou, Lihua; Meeks, Joshua J.; Shilatifard, Ali] Northwestern Univ, Feinberg Sch Med, Simpson Querrey Ctr Epigenet, Chicago, IL 60611 USA.
   [Wang, Lu; Zhao, Zibo; Ozark, Patrick A.; Marshall, Stacy A.; Rendleman, Emily J.; Cozzolino, Kira A.; Morgan, Marc A.; Takahashi, Yoh-hei; Collings, Clayton K.; Smith, Edwin R.; Ntziachristos, Panagiotis; Zou, Lihua; Hashizume, Rintaro; Meeks, Joshua J.; Shilatifard, Ali] Northwestern Univ, Dept Biochem & Mol Genet, Feinberg Sch Med, Chicago, IL 60611 USA.
   [Louis, Nundia; He, Xingyao; Hashizume, Rintaro] Northwestern Univ, Dept Neurol Surg, Feinberg Sch Med, Chicago, IL 60611 USA.
   [Savas, Jeffrey N.] Northwestern Univ, Feinberg Sch Med, Dept Neurol, Chicago, IL 60611 USA.
C3 Northwestern University; Feinberg School of Medicine; Northwestern
   University; Feinberg School of Medicine; Northwestern University;
   Feinberg School of Medicine; Northwestern University; Feinberg School of
   Medicine
RP Shilatifard, A (通讯作者)，Northwestern Univ, Feinberg Sch Med, Simpson Querrey Ctr Epigenet, Chicago, IL 60611 USA.; Shilatifard, A (通讯作者)，Northwestern Univ, Dept Biochem & Mol Genet, Feinberg Sch Med, Chicago, IL 60611 USA.
EM ash@northwestern.edu
RI Ntziachristos, Panagiotis/CAG-2071-2022; Zhao, Zibo/GWQ-3444-2022;
   Fantini, Damiano/M-7185-2017
OI Ozark, Patrick/0000-0002-4047-5102
FU Training Program in Signal Transduction and Cancer [T32 CA070085];
   Robert H. Lurie Comprehensive Cancer Center-Translational Bridge Program
   Fellowship in Lymphoma Research; NCI [R50CA211428]; NIDCD [DC013805];
   NCI's Outstanding Investigator Award [R35CA197569]
FX We would like to thank F. Zhang (MIT) for the kind gifts of the Px330
   and lentiCRISPR v2 vectors. L.W. is supported by the Training Program in
   Signal Transduction and Cancer (T32 CA070085). Z.Z. is supported by the
   Robert H. Lurie Comprehensive Cancer Center-Translational Bridge Program
   Fellowship in Lymphoma Research. E.R.S. is supported by NCI grant
   R50CA211428. Studies in J.N.S.'s laboratory are supported by NIDCD grant
   DC013805, and studies related to COMPASS in A.S.'s laboratory are
   supported by NCI's Outstanding Investigator Award R35CA197569.
CR Anders S, 2015, BIOINFORMATICS, V31, P166, DOI 10.1093/bioinformatics/btu638
   Bailey P, 2016, NATURE, V531, P47, DOI 10.1038/nature16965
   Carbone M, 2013, NAT REV CANCER, V13, P153, DOI 10.1038/nrc3459
   Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095
   Cha Y, 2013, CELL SIGNAL, V25, P1245, DOI 10.1016/j.cellsig.2013.01.016
   Chaudhuri AR, 2016, NATURE, V535, P382, DOI 10.1038/nature18325
   Chen C, 2014, CANCER CELL, V25, P652, DOI 10.1016/j.ccr.2014.03.016
   Cieply B, 2013, CANCER RES, V73, P6299, DOI 10.1158/0008-5472.CAN-12-4082
   Cui TT, 2012, CARCINOGENESIS, V33, P2326, DOI 10.1093/carcin/bgs273
   Dey A, 2012, SCIENCE, V337, P1541, DOI 10.1126/science.1221711
   Ellis MJ, 2012, NATURE, V486, P353, DOI 10.1038/nature11143
   Ferguson AD, 2011, STRUCTURE, V19, P1262, DOI 10.1016/j.str.2011.06.011
   Fujimoto A, 2012, NAT GENET, V44, P760, DOI 10.1038/ng.2291
   Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088
   Gui YT, 2011, NAT GENET, V43, P875, DOI 10.1038/ng.907
   Hamamoto R, 2004, NAT CELL BIOL, V6, P731, DOI 10.1038/ncb1151
   Heinz S, 2010, MOL CELL, V38, P576, DOI 10.1016/j.molcel.2010.05.004
   Herz HM, 2014, SCIENCE, V345, P1065, DOI 10.1126/science.1255104
   Herz HM, 2012, GENE DEV, V26, P2604, DOI 10.1101/gad.201327.112
   Hu DQ, 2016, GENE DEV, V30, P2021, DOI 10.1101/gad.284109.116
   Hu DQ, 2013, MOL CELL BIOL, V33, P4745, DOI 10.1128/MCB.01181-13
   Kandoth C, 2013, NATURE, V502, P333, DOI 10.1038/nature12634
   Klaus CR, 2014, J PHARMACOL EXP THER, V350, P646, DOI 10.1124/jpet.114.214577
   Kotake Y, 2007, GENE DEV, V21, P49, DOI 10.1101/gad.1499407
   Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005
   Kubicek S, 2007, MOL CELL, V25, P473, DOI 10.1016/j.molcel.2007.01.017
   LaFave LM, 2016, NAT MED, V22, P578, DOI 10.1038/nm.4094
   LaFave LM, 2015, NAT MED, V21, P1344, DOI 10.1038/nm.3947
   Li W, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0554-4
   Li WD, 2013, BLOOD, V121, P1478, DOI 10.1182/blood-2012-12-470559
   Li Y, 2011, CANCER RES, V71, P6106, DOI 10.1158/0008-5472.CAN-10-4291
   Lu ZH, 2010, CANCER RES, V70, P3287, DOI 10.1158/0008-5472.CAN-09-3467
   Mazur PK, 2014, NATURE, V510, P283, DOI 10.1038/nature13320
   McDonald ER III, 2017, CELL, V170, P577, DOI 10.1016/j.cell.2017.07.005
   McLean CY, 2010, NAT BIOTECHNOL, V28, P495, DOI 10.1038/nbt.1630
   Miller T, 2001, P NATL ACAD SCI USA, V98, P12902, DOI 10.1073/pnas.231473398
   Mohan M, 2012, CELL, V149, P498, DOI 10.1016/j.cell.2012.03.025
   Morgan MA, 2015, GENE DEV, V29, P238, DOI 10.1101/gad.255182.114
   Morgan MA, 2013, MOL CELL BIOL, V33, P1698, DOI 10.1128/MCB.00203-13
   Ortega-Molina A, 2015, NAT MED, V21, P1199, DOI 10.1038/nm.3943
   Paoletti AC, 2006, P NATL ACAD SCI USA, V103, P18928, DOI 10.1073/pnas.0606379103
   Piunti A, 2016, SCIENCE, V352, DOI 10.1126/science.aad9780
   Plass C, 2013, NAT REV GENET, V14, P765, DOI 10.1038/nrg3554
   Qin S, 2014, ONCOL REP, V31, P2351, DOI 10.3892/or.2014.3109
   Ramón-Maiques S, 2007, P NATL ACAD SCI USA, V104, P18993, DOI 10.1073/pnas.0709170104
   Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616
   Saldanha AJ, 2004, BIOINFORMATICS, V20, P3246, DOI 10.1093/bioinformatics/bth349
   Schoumacher M, 2016, NAT MED, V22, P577, DOI 10.1038/nm.4098
   Shen L, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-284
   Shilatifard A, 2012, ANNU REV BIOCHEM, V81, P65, DOI 10.1146/annurev-biochem-051710-134100
   Takahashi Y, 2011, P NATL ACAD SCI USA, V108, P20526, DOI 10.1073/pnas.1109360108
   Nguyen TMH, 2016, GYNECOL ONCOL, V140, P545, DOI 10.1016/j.ygyno.2015.12.006
   Toska E, 2017, SCIENCE, V355, P1324, DOI 10.1126/science.aah6893
   Tripathi S, 2015, CELL HOST MICROBE, V18, P723, DOI 10.1016/j.chom.2015.11.002
   Wang L, 2017, GENE DEV, V31, P2056, DOI 10.1101/gad.306092.117
   Wang S, 2015, ONCOGENE, V34, P2575, DOI 10.1038/onc.2014.201
   Yu BD, 1998, P NATL ACAD SCI USA, V95, P10632, DOI 10.1073/pnas.95.18.10632
   Zhang JY, 2015, NAT MED, V21, P1190, DOI 10.1038/nm.3940
   Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r137
NR 59
TC 118
Z9 132
U1 0
U2 30
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1078-8956
EI 1546-170X
J9 NAT MED
JI Nat. Med.
PD JUN
PY 2018
VL 24
IS 6
BP 758
EP +
DI 10.1038/s41591-018-0034-6
PG 14
WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research &
   Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental
   Medicine
GA GI3OQ
UT WOS:000434281300021
PM 29785026
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Noberini, R
   Osti, D
   Miccolo, C
   Richichi, C
   Lupia, M
   Corleone, G
   Hong, SP
   Colombo, P
   Pollo, B
   Fornasari, L
   Pruneri, G
   Magnani, L
   Cavallaro, U
   Chiocca, S
   Minucci, S
   Pelicci, G
   Bonaldi, T
AF Noberini, Roberta
   Osti, Daniela
   Miccolo, Claudia
   Richichi, Cristina
   Lupia, Michela
   Corleone, Giacomo
   Hong, Sung-Pil
   Colombo, Piergiuseppe
   Pollo, Bianca
   Fornasari, Lorenzo
   Pruneri, Giancarlo
   Magnani, Luca
   Cavallaro, Ugo
   Chiocca, Susanna
   Minucci, Saverio
   Pelicci, Giuliana
   Bonaldi, Tiziana
TI Extensive and systematic rewiring of histone post-translational
   modifications in cancer model systems
SO NUCLEIC ACIDS RESEARCH
LA English
DT Article
ID BREAST-CANCER; CELL-LINES; MASS-SPECTROMETRY; MODIFICATION PATTERNS;
   CLINICAL-TRIALS; GENE-EXPRESSION; IN-VITRO; METHYLATION; TUMORS;
   CHROMATIN
AB Histone post-translational modifications (PTMs) generate a complex combinatorial code that regulates gene expression and nuclear functions, and whose deregulation has been documented in different types of cancers. Therefore, the availability of relevant culture models that can be manipulated and that retain the epigenetic features of the tissue of origin is absolutely crucial for studying the epigenetic mechanisms underlying cancer and testing epigenetic drugs. In this study, we took advantage of quantitative mass spectrometry to comprehensively profile histone PTMs in patient tumor tissues, primary cultures and cell lines from three representative tumor models, breast cancer, glioblastoma and ovarian cancer, revealing an extensive and systematic rewiring of histone marks in cell culture conditions, which includes a decrease of H3K27me2/me3, H3K79me1 /me2 and H3K9ac/K14ac, and an increase of H3K36me1/me2. While some changes occur in short-term primary cultures, most of them are in- stead time-dependent and appear only in long-term cultures. Remarkably, such changes mostly revert in cell line- and primary cell-derived in vivo xenograft models. Taken together, these results support the use of xenografts as the most representative models of in vivo epigenetic processes, suggesting caution when using cultured cells, in particular cell lines and long-term primary cultures, for epigenetic investigations.
C1 [Noberini, Roberta] Ist Italiano Tecnol, Ctr Genom Sci IIT SEMM, I-20139 Milan, Italy.
   [Noberini, Roberta; Osti, Daniela; Miccolo, Claudia; Richichi, Cristina; Fornasari, Lorenzo; Chiocca, Susanna; Minucci, Saverio; Pelicci, Giuliana; Bonaldi, Tiziana] European Inst Oncol, Dept Expt Oncol, I-20139 Milan, Italy.
   [Lupia, Michela; Cavallaro, Ugo] European Inst Oncol, Unit Gynecol Oncol Res, I-20141 Milan, Italy.
   [Corleone, Giacomo; Hong, Sung-Pil; Magnani, Luca] Imperial Coll Hammersmith, Dept Surg & Canc, London W12, England.
   [Colombo, Piergiuseppe] Humanitas Clin & Res Ctr, Dept Pathol, I-20089 Milan, Italy.
   [Pollo, Bianca] IRCCS Fdn Neurol Inst C Besta, Dept Neuropathol, I-20133 Milan, Italy.
   [Pruneri, Giancarlo] European Inst Oncol, Dept Pathol, Biobank Translat Med Unit, I-20141 Milan, Italy.
   [Pruneri, Giancarlo] Univ Milan, Sch Med, I-20122 Milan, Italy.
   [Minucci, Saverio] European Inst Oncol, New Drugs Program, I-20139 Milan, Italy.
   [Minucci, Saverio] Univ Milan, Dept Biosci, I-20133 Milan, Italy.
   [Pelicci, Giuliana] Piemonte Orientale Univ Amedeo Avogadro, Dept Translat Med, I-28100 Novara, Italy.
C3 Istituto Italiano di Tecnologia - IIT; IRCCS European Institute of
   Oncology (IEO); IRCCS European Institute of Oncology (IEO); IRCCS
   European Institute of Oncology (IEO); University of Milan; IRCCS
   European Institute of Oncology (IEO); University of Milan; University of
   Eastern Piedmont Amedeo Avogadro
RP Bonaldi, T (通讯作者)，European Inst Oncol, Dept Expt Oncol, I-20139 Milan, Italy.
EM tiziana.bonaldi@ieo.eu
RI Miccolo, Claudia/AAR-8386-2020; Osti, Daniela/AAS-5063-2020; Minucci,
   Saverio/J-9669-2012; Noberini, Roberta/AAP-4527-2020; Corleone,
   Giacomo/W-7131-2019; Chiocca, Susanna/AAC-8863-2019; Pelicci,
   Giuliana/AAA-8921-2022; Cavallaro, Ugo/J-9745-2012; magnani,
   luca/N-1094-2015; Pruneri, Giancarlo/AAC-7767-2022; Bonaldi,
   Tiziana/K-5075-2016; Richichi, Cristina/K-4149-2016; Lupia,
   Michela/IYJ-3498-2023; Corleone, Giacomo/HLQ-5620-2023; Colombo,
   Piergiuseppe/AAA-9176-2019; Pollo, Bianca/K-5347-2018
OI magnani, luca/0000-0002-7534-0785; Pruneri,
   Giancarlo/0000-0002-7963-7172; Cavallaro, Ugo/0000-0002-0884-6460;
   Bonaldi, Tiziana/0000-0003-3556-1265; Richichi,
   Cristina/0000-0002-3184-0358; Lupia, Michela/0000-0002-4712-3708;
   Minucci, Saverio/0000-0001-5678-536X; Noberini,
   Roberta/0000-0002-7267-1079; Chiocca, Susanna/0000-0002-9721-0850;
   Corleone, Giacomo/0000-0002-6170-9780; Colombo,
   Piergiuseppe/0000-0002-6161-6138; Pollo, Bianca/0000-0002-5523-4256
FU Italian Association for Cancer Research (AIRC) [15741]; Italian Ministry
   of Health [GR-2011-02347880]; CNR-EPIGEN flagship project; Fondazione
   Umberto Veronesi (FUV); Fondazione IEO-CCM; AIRC-ASSOCIAZIONE ITALIANA
   PER LA RICERCA SUL CANCRO [15741]
FX Italian Association for Cancer Research (AIRC) (to T.B. [15741], S.C.,
   G. Pe, U.C.); Italian Ministry of Health [GR-2011-02347880] and the
   CNR-EPIGEN flagship project (to T.B.); Fondazione Umberto Veronesi (FUV)
   supported C.R.; Fondazione IEO-CCM supported M.L. and U.C. Funding for
   open access charge: AIRC-ASSOCIAZIONE ITALIANA PER LA RICERCA SUL CANCRO
   [15741].
CR Albert M, 2010, SEMIN CELL DEV BIOL, V21, P209, DOI 10.1016/j.semcdb.2009.10.007
   [Anonymous], J MED ONCOL THER
   AUSMAN JI, 1970, CANCER RES, V30, P2394
   Bannister AJ, 2011, CELL RES, V21, P381, DOI 10.1038/cr.2011.22
   Beyer S, 2008, J BIOL CHEM, V283, P36542, DOI 10.1074/jbc.M804578200
   Bonenfant D, 2007, MOL CELL PROTEOMICS, V6, P1917, DOI 10.1074/mcp.M700070-MCP200
   Bremang M, 2013, MOL BIOSYST, V9, P2231, DOI 10.1039/c3mb00009e
   Chiaradonna F, 2015, ANTIOXID REDOX SIGN, V23, P15, DOI 10.1089/ars.2014.6189
   Cope LM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105545
   Cox J, 2011, J PROTEOME RES, V10, P1794, DOI 10.1021/pr101065j
   Cuomo A, 2011, AMINO ACIDS, V41, P387, DOI 10.1007/s00726-010-0668-2
   Dairkee SH, 2004, BMC GENOMICS, V5, DOI 10.1186/1471-2164-5-47
   Daniel VC, 2009, CANCER RES, V69, P3364, DOI 10.1158/0008-5472.CAN-08-4210
   Doenecke D, 1996, INT J DEV BIOL, V40, P395
   Domcke S, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3126
   Eden E, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-48
   Elsheikh SE, 2009, CANCER RES, V69, P3802, DOI 10.1158/0008-5472.CAN-08-3907
   Ertel A, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-55
   Fichtner I, 2008, CLIN CANCER RES, V14, P6456, DOI 10.1158/1078-0432.CCR-08-0138
   Fraga MF, 2005, NAT GENET, V37, P391, DOI 10.1038/ng1531
   Francavilla C, 2017, CELL REP, V18, P3242, DOI 10.1016/j.celrep.2017.03.015
   Hancock RL, 2017, ACS CHEM BIOL, V12, P1011, DOI 10.1021/acschembio.6b00958
   Hergeth SP, 2015, EMBO REP, V16, P1439, DOI 10.15252/embr.201540749
   Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127
   Jiang GL, 2016, BMC GENOMICS, V17, DOI 10.1186/s12864-016-2911-z
   Johnson JI, 2001, BRIT J CANCER, V84, P1424, DOI 10.1054/bjoc.2001.1796
   Jung H. R., 2010, MOL CELL
   Kao J, 2009, MOL PROFILING BREAST
   Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005
   Lee J, 2006, CANCER CELL, V9, P391, DOI 10.1016/j.ccr.2006.03.030
   Mellor J, 2009, MOL CELL, V35, P729, DOI 10.1016/j.molcel.2009.09.010
   Nervi C, 2015, CLIN EPIGENETICS, V7, DOI 10.1186/s13148-015-0157-2
   Nestor CE, 2015, GENOME BIOL, V16, DOI 10.1186/s13059-014-0576-y
   Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008
   Noberini R, 2017, METHOD ENZYMOL, V586, P311, DOI 10.1016/bs.mie.2016.09.036
   Noberini R, 2017, CLIN EPIGENETICS, V9, DOI 10.1186/s13148-017-0369-8
   Noberini R, 2016, MOL CELL PROTEOMICS, V15, P866, DOI 10.1074/mcp.M115.054510
   Ong SE, 2004, NAT METHODS, V1, P119, DOI 10.1038/NMETH715
   Ortensi B, 2012, STEM CELLS, V30, P817, DOI 10.1002/stem.1056
   Pesavento JJ, 2006, ANAL CHEM, V78, P4271, DOI 10.1021/ac0600050
   Pollard PJ, 2008, BIOCHEM J, V416, P387, DOI 10.1042/BJ20081238
   Popovic R, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004566
   Portela A, 2010, NAT BIOTECHNOL, V28, P1057, DOI 10.1038/nbt.1685
   Richichi C, 2016, ONCOTARGET, V7, P71491, DOI 10.18632/oncotarget.11600
   Rona GB, 2017, ONCOTARGET, V8, P54068, DOI 10.18632/oncotarget.11253
   Sandberg R, 2005, P NATL ACAD SCI USA, V102, P2052, DOI 10.1073/pnas.0408105102
   Schmitges FW, 2011, MOL CELL, V42, P330, DOI 10.1016/j.molcel.2011.03.025
   Schulze JM, 2009, MOL CELL, V35, P626, DOI 10.1016/j.molcel.2009.07.017
   Seidel S, 2015, METHODS MOL BIOL, V1235, P263, DOI 10.1007/978-1-4939-1785-3_19
   Seligson DB, 2009, AM J PATHOL, V174, P1619, DOI 10.2353/ajpath.2009.080874
   Seligson DB, 2005, NATURE, V435, P1262, DOI 10.1038/nature03672
   Sinha R, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15165
   Speirs V, 1998, BRIT J CANCER, V78, P1421, DOI 10.1038/bjc.1998.702
   Supek F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021800
   Suvà ML, 2013, SCIENCE, V339, P1567, DOI 10.1126/science.1230184
   Tyanova S, 2016, NAT METHODS, V13, P731, DOI [10.1038/NMETH.3901, 10.1038/nmeth.3901]
   Vargo-Gogola T, 2007, NAT REV CANCER, V7, P659, DOI 10.1038/nrc2193
   Vincent KM, 2015, BREAST CANCER RES, V17, DOI 10.1186/s13058-015-0613-0
   Vizcaíno JA, 2014, NAT BIOTECHNOL, V32, P223, DOI 10.1038/nbt.2839
   Yuan W, 2011, J BIOL CHEM, V286, P7983, DOI 10.1074/jbc.M110.194027
   Zheng YP, 2012, P NATL ACAD SCI USA, V109, P13549, DOI 10.1073/pnas.1205707109
NR 61
TC 29
Z9 31
U1 0
U2 9
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0305-1048
EI 1362-4962
J9 NUCLEIC ACIDS RES
JI Nucleic Acids Res.
PD MAY 4
PY 2018
VL 46
IS 8
BP 3817
EP 3832
DI 10.1093/nar/gky224
PG 16
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA GF3ZC
UT WOS:000431895800010
PM 29618087
OA gold, Green Published, Green Submitted
DA 2025-01-12
ER

PT J
AU Li, F
   Qiao, CY
   Gao, S
   Fan, YC
   Chen, LY
   Wang, K
AF Li, Feng
   Qiao, Chen-Yang
   Gao, Shuai
   Fan, Yu-Chen
   Chen, Long-Yan
   Wang, Kai
TI Circulating cell-free DNA of methylated insulin-like growth
   factor-binding protein 7 predicts a poor prognosis in hepatitis B
   virus-associated hepatocellular carcinoma after hepatectomy
SO FREE RADICAL RESEARCH
LA English
DT Article
DE Circulating cell-free DNA; insulin-like growth factor-binding protein 7;
   methylation; hepatocellular carcinoma; prognosis; oxidative stress
ID OXIDATIVE STRESS; RISK-FACTORS; INTRAHEPATIC RECURRENCE; EPIGENETIC
   ALTERATIONS; PROMOTER METHYLATION; BREAST-CANCER; CPG ISLANDS; TUMOR;
   HEPATOCARCINOGENESIS; BLOOD
AB The initiation and progression of hepatocellular carcinoma (HCC) is a multistage process involving a variety of changes at the gene level. Methylation of insulin-like growth factor-binding protein 7 (IGFBP7) plays a crucial role in HCC development. The main purpose of this study was to investigate the relationship between oxidative stress, DNA methyltransferases (DNMTs) expression, and IGFBP7 methylation, and to evaluate the prognostic value of serum IGFBP7 methylation status in patients with HCC after hepatectomy. We enrolled 155 patients with HCC undergoing surgical resection. The IGFBP7 methylation status, DNMTs mRNA levels and malondialdehyde (MDA), xanthine oxidase (XOD), reduced glutathione hormone (GSH), and glutathione-S-transferases (GST) levels were detected. MDA and XOD levels were significantly higher in IGFBP7 methylated group than unmethylated group, while GSH level was lower in methylated group than unmethylated group. The DNMT1 and DNMT3a mRNA levels were higher in IGFBP7 methylated group than unmethylated group. Kaplan-Meier curve analysis revealed that IGFBP7 promoter methylation was significantly correlated with overall survival (OS) (p < .001). Moreover, IGFBP7 methylation was an independent prognostic predictor for OS (p = .000) and early tumour recurrence (ETR) (p = .008) in HCC after hepatectomy. Our results indicated that IGFBP7 promoter methylation was associated with oxidative stress and DNMTs expression. Meanwhile, IGFBP7 promoter methylation was associated with OS and ETR, indicating that it might serve as a potentially independent prognostic factor in patients with HCC after hepatectomy.
C1 [Li, Feng; Qiao, Chen-Yang; Gao, Shuai; Fan, Yu-Chen; Chen, Long-Yan; Wang, Kai] Shandong Univ, Dept Hepatol, Qilu Hosp, Wenhuaxi Rd 107, Jinan, Shandong, Peoples R China.
   [Gao, Shuai; Fan, Yu-Chen; Chen, Long-Yan; Wang, Kai] Shandong Univ, Inst Hepatol, Wenhuaxi Rd 107, Jinan, Shandong, Peoples R China.
C3 Shandong University; Shandong University
RP Wang, K (通讯作者)，Shandong Univ, Dept Hepatol, Qilu Hosp, Wenhuaxi Rd 107, Jinan, Shandong, Peoples R China.; Wang, K (通讯作者)，Shandong Univ, Inst Hepatol, Wenhuaxi Rd 107, Jinan, Shandong, Peoples R China.
EM wangdoc2010@163.com
RI Fan, Yu-Chen/A-8035-2013
OI Gao, Shuai/0000-0002-8444-5415; Wang, Kai/0000-0002-6297-0147; Fan,
   Yu-Chen/0000-0002-9126-679X
CR Alsina AE, 2014, P R HEALTH SCI J, V33, P170
   Anzola M, 2004, J GASTROEN HEPATOL, V19, P397, DOI 10.1111/j.1440-1746.2003.03305.x
   Bruix J, 2004, CANCER CELL, V5, P215, DOI 10.1016/S1535-6108(04)00058-3
   Bruix J, 2011, HEPATOLOGY, V53, P1020, DOI 10.1002/hep.24199
   Chan KCA, 2008, CLIN CHEM, V54, P1528, DOI 10.1373/clinchem.2008.104653
   Chan KCA, 2013, P NATL ACAD SCI USA, V110, P18761, DOI 10.1073/pnas.1313995110
   Chen CJ, 1997, J GASTROEN HEPATOL, V12, pS294, DOI 10.1111/j.1440-1746.1997.tb00513.x
   Chennareddy A., 2017, J ROBOTICS, V2017, P1
   Colombo M, 2015, LIVER INT, V35, P129, DOI 10.1111/liv.12713
   Crowley E, 2013, NAT REV CLIN ONCOL, V10, P472, DOI 10.1038/nrclinonc.2013.110
   Elshimali YI, 2013, INT J MOL SCI, V14, P18925, DOI 10.3390/ijms140918925
   Franco R, 2008, CANCER LETT, V266, P6, DOI 10.1016/j.canlet.2008.02.026
   Gao HP, 2014, CLIN CANCER RES, V20, P6418, DOI 10.1158/1078-0432.CCR-14-1170
   Halliwell B, 2007, BIOCHEM J, V401, P1, DOI 10.1042/BJ20061131
   Herath NI, 2006, J GASTROEN HEPATOL, V21, P15, DOI 10.1111/j.1440-1746.2005.04043.x
   Herceg Z, 2011, MUTAT RES-REV MUTAT, V727, P55, DOI 10.1016/j.mrrev.2011.04.001
   Ibrahim S, 2007, AM J SURG, V194, P17, DOI 10.1016/j.amjsurg.2006.06.051
   Kanai Y, 2001, INT J CANCER, V91, P205, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1040>3.0.CO;2-2
   Kang KA, 2012, TUMOR BIOL, V33, P403, DOI 10.1007/s13277-012-0322-6
   Lafaro KJ, 2015, SURG ONCOL CLIN N AM, V24, P1, DOI 10.1016/j.soc.2014.09.001
   Landberg G, 2001, ONCOGENE, V20, P3497, DOI 10.1038/sj.onc.1204471
   Li F, 2014, GENE CHROMOSOME CANC, V53, P90, DOI 10.1002/gcc.22120
   Lim SO, 2008, GASTROENTEROLOGY, V135, P2128, DOI 10.1053/j.gastro.2008.07.027
   Lok ASF, 2009, HEPATOLOGY, V50, P661, DOI 10.1002/hep.23190
   Lu X, 2009, J SURG ONCOL, V100, P488, DOI 10.1002/jso.21354
   Marra M, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-171
   Mizuno S, 2001, BLOOD, V97, P1172, DOI 10.1182/blood.V97.5.1172
   Nair L, 2010, MUTAT RES-FUND MOL M, V683, P23, DOI 10.1016/j.mrfmmm.2009.10.002
   Nishida N, 2013, DIGEST DIS, V31, P447, DOI 10.1159/000355243
   O'Hagan HM, 2011, CANCER CELL, V20, P606, DOI 10.1016/j.ccr.2011.09.012
   Poon RTP, 2000, CANCER, V89, P500, DOI 10.1002/1097-0142(20000801)89:3<500::AID-CNCR4>3.0.CO;2-O
   Ruan Wen-jing, 2006, J Zhejiang Univ Sci B, V7, P929, DOI 10.1631/jzus.2006.B0929
   Schlageter M, 2014, WORLD J GASTROENTERO, V20, P15955, DOI 10.3748/wjg.v20.i43.15955
   Shah SA, 2006, J AM COLL SURGEONS, V202, P275, DOI 10.1016/j.jamcollsurg.2005.10.005
   Smith P, 2007, CLIN CANCER RES, V13, P4061, DOI 10.1158/1078-0432.CCR-06-3052
   Stoyanov E, 2015, ONCOTARGET, V6, P11047, DOI 10.18632/oncotarget.3567
   Stroun M, 2000, ANN NY ACAD SCI, V906, P161
   Tsai SM, 2009, ANN CLIN BIOCHEM, V46, P394, DOI 10.1258/acb.2009.009029
   Unsal Velid, 2017, Open Access Maced J Med Sci, V5, P686, DOI 10.3889/oamjms.2017.101
   Villanueva A, 2011, GASTROENTEROLOGY, V140, P1501, DOI 10.1053/j.gastro.2011.02.006
   Wang JH, 2006, CLIN BIOCHEM, V39, P344, DOI 10.1016/j.clinbiochem.2006.01.008
   Williams C, 2014, CELL RES, V24, P766, DOI 10.1038/cr.2014.44
   Wong IHN, 2000, CLIN CANCER RES, V6, P3516
   Wongpaiboonwattana W, 2013, ASIAN PAC J CANCER P, V14, P3773, DOI 10.7314/APJCP.2013.14.6.3773
   Xu RH, 2017, NAT MATER, V16, P1155, DOI [10.1038/NMAT4997, 10.1038/nmat4997]
   Yuan RH, 2007, CLIN CANCER RES, V13, P5368, DOI 10.1158/1078-0432.CCR-07-1113
   Yuen MF, 2009, J GASTROEN HEPATOL, V24, P346, DOI 10.1111/j.1440-1746.2009.05784.x
   Zhao JY, 2011, NUTR J, V10, DOI 10.1186/1475-2891-10-49
   Ziech D, 2011, MUTAT RES-FUND MOL M, V711, P167, DOI 10.1016/j.mrfmmm.2011.02.015
NR 49
TC 23
Z9 25
U1 0
U2 9
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1071-5762
EI 1029-2470
J9 FREE RADICAL RES
JI Free Radic. Res.
PY 2018
VL 52
IS 4
BP 455
EP 464
DI 10.1080/10715762.2018.1443448
PG 10
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA GG4AC
UT WOS:000432633800008
PM 29463155
DA 2025-01-12
ER

PT J
AU Bermisheva, MA
   Takhirova, ZR
   Gilyazova, IR
   Khusnutdinova, EK
AF Bermisheva, M. A.
   Takhirova, Z. R.
   Gilyazova, I. R.
   Khusnutdinova, E. K.
TI MicroRNA Biogenesis Pathway Gene Polymorphisms Are Associated with
   Breast Cancer Risk
SO RUSSIAN JOURNAL OF GENETICS
LA English
DT Article
DE breast cancer; miRNA; association; SNP; disease risk
ID SINGLE-NUCLEOTIDE POLYMORPHISMS; MACHINERY GENES; EXPRESSION LEVELS;
   PROSTATE-CANCER; RAN; VARIANTS; RNA; PROTEINS; TARGET; GROWTH
AB MicroRNAs (miRNAs) play an important role as epigenetic regulators in cancer initiation and progression. One of the mechanisms of miRNA dysregulation is altered functioning of proteins involved in miRNA processing machinery. It has been suggested that single nucleotide polymorphisms (SNPs) within miRNA gene regions, miRNA target genes, and miRNA machinery genes may affect the miRNAs regulation. We selected 25 SNPs in the key genes of miRNA biosynthesis, including DROSHA/RNASEN, DGCR8, DICER1, XPO5, RAN, PIWIL1/HIWI, AGO1/EIF2C1, AGO2, GEMIN4, GEMIN3/DDX20, and DDX5, and investigated the association between these SNPs and the risk of breast cancer. The total number of breast cancer cases and cancer-free controls enrolled in the investigation were 778 (417 breast cancer patients and 361 healthy women). We found that rs11060845 and rs10773771 in the PIWIL1 gene, rs3809142/RAN, rs10719/DROSHA, rs1640299/DGCR8, rs563002/DDX20, rs595055/AGO1, and rs2740348/GEMIN4 were associated with breast cancer risk in Russians.
C1 [Bermisheva, M. A.; Takhirova, Z. R.; Gilyazova, I. R.; Khusnutdinova, E. K.] Russian Acad Sci, Ufa Sci Ctr, Inst Biochem & Genet, Ufa 450054, Russia.
   [Khusnutdinova, E. K.] Bashkir State Univ, Dept Genet & Fundamental Med, Ufa 450076, Russia.
C3 Institute of Biochemistry & Genetics of Ufa Science Centre of the RAS;
   Russian Academy of Sciences; Ufa University of Science & Technology
RP Bermisheva, MA (通讯作者)，Russian Acad Sci, Ufa Sci Ctr, Inst Biochem & Genet, Ufa 450054, Russia.
EM marina_berm@mail.ru
RI Takhirova, Zalina/D-3830-2019; Gilyazova, Irina/E-5798-2014
FU Program for the Development of Bioresource Collections of the Federal
   Agency for Scientific Organizations; Russian Foundation for Basic
   Research [17-44-020498 r_a, 17-29-06014 ofi-m]
FX The study was supported by the Program for the Development of
   Bioresource Collections of the Federal Agency for Scientific
   Organizations and the Russian Foundation for Basic Research nos.
   17-44-020498 r_a and 17-29-06014 ofi-m.
CR Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5
   Catalanotto C, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17101712
   Cheng C, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-9-r90
   Cho SH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131125
   Clarke PR, 2008, NAT REV MOL CELL BIO, V9, P464, DOI 10.1038/nrm2410
   Davis-Dusenbery BN, 2010, J BIOCHEM, V148, P381, DOI 10.1093/jb/mvq096
   Fardmanesh H, 2016, GENE, V581, P146, DOI 10.1016/j.gene.2016.01.033
   Finnegan EF, 2013, CRIT REV BIOCHEM MOL, V48, P51, DOI 10.3109/10409238.2012.738643
   Fu L, 2016, ONCOL LETT, V12, P269, DOI 10.3892/ol.2016.4582
   Gao YH, 2015, ONCOTARGETS THER, V8, P1735, DOI 10.2147/OTT.S86338
   Gregory Richard I., 2006, V342, P33, DOI 10.1385/1-59745-123-1:33
   Hashim A, 2014, ONCOTARGET, V5, P9901, DOI 10.18632/oncotarget.2476
   Hata A, 2016, CRIT REV BIOCHEM MOL, V51, P121, DOI 10.3109/10409238.2015.1117054
   Hatakeyama S, 2011, NAT REV CANCER, V11, P792, DOI 10.1038/nrc3139
   Honma K, 2009, INT J GEN MED, V2, P243
   Horikawa Y, 2008, CLIN CANCER RES, V14, P7956, DOI 10.1158/1078-0432.CCR-08-1199
   Huang JT, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00113
   Iliev R, 2016, ANTICANCER RES, V36, P6419, DOI 10.21873/anticanres.11239
   Iuliano R, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/591931
   Jiang Y, 2013, INT J CANCER, V133, P2216, DOI 10.1002/ijc.28237
   Ke HL, 2013, CARCINOGENESIS, V34, P1006, DOI 10.1093/carcin/bgt006
   Khan S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109973
   Kim JS, 2010, MOL CARCINOGEN, V49, P913, DOI 10.1002/mc.20672
   Kim MB, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0148466
   Kiselev F L, 2014, Mol Biol (Mosk), V48, P232
   Krishnan P, 2016, ONCOTARGET, V7, P37944, DOI 10.18632/oncotarget.9272
   Kumar MS, 2007, NAT GENET, V39, P673, DOI 10.1038/ng2003
   Kwon SY, 2014, PATHOL ONCOL RES, V20, P697, DOI 10.1007/s12253-014-9750-5
   Leaderer D, 2011, INT J MOL EPIDEMIOL, V2, P9
   Lee Y, 2003, NATURE, V425, P415, DOI 10.1038/nature01957
   Li YW, 2012, EPIGENETICS-US, V7, P940, DOI 10.4161/epi.21236
   Liang D, 2010, CANCER RES, V70, P9765, DOI 10.1158/0008-5472.CAN-10-0130
   Liu JM, 2012, DNA CELL BIOL, V31, P1296, DOI 10.1089/dna.2011.1600
   Lo PK, 2016, BRIEF FUNCT GENOMICS, V15, P200, DOI 10.1093/bfgp/elv055
   Loginov VI, 2016, MOL BIOL+, V50, P705, DOI 10.1134/S0026893316050101
   Ly TK, 2010, J BIOL CHEM, V285, P5815, DOI 10.1074/jbc.M109.071886
   Ma H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039649
   Mohammadi-Yeganeh S, 2016, TUMOR BIOL, V37, P8993, DOI 10.1007/s13277-015-4513-9
   Mourelatos Z, 2002, GENE DEV, V16, P720, DOI 10.1101/gad.974702
   Mullany LE, 2016, BMC MED GENOMICS, V9, DOI 10.1186/s12920-016-0181-x
   Murchison EP, 2004, CURR OPIN CELL BIOL, V16, P223, DOI 10.1016/j.ceb.2004.04.003
   Ng KW, 2016, MOL CANCER, V15, DOI 10.1186/s12943-016-0491-9
   Nikolic Z, 2017, WORLD J UROL, V35, P613, DOI 10.1007/s00345-016-1917-0
   Obsteter J, 2015, MOL GENET GENOM MED, V3, P30, DOI 10.1002/mgg3.110
   Osuch-Wojcikiewicz E, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/298378
   Paris O, 2012, ONCOGENE, V31, P4196, DOI 10.1038/onc.2011.583
   Rensen WM, 2008, FRONT BIOSCI-LANDMRK, V13, P4097, DOI 10.2741/2996
   Roy R, 2014, J BIOMED SCI, V21, DOI 10.1186/1423-0127-21-48
   Sasaki T, 2003, GENOMICS, V82, P323, DOI 10.1016/S0888-7543(03)00129-0
   Sethupathy P, 2008, TRENDS GENET, V24, P489, DOI 10.1016/j.tig.2008.07.004
   Sorokin A. V., 2007, USP BIOL KHIM, V47, P89
   Sun GH, 2009, RNA, V15, P1640, DOI 10.1261/rna.1560209
   Sung H, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-195
   Sung H, 2011, BREAST CANCER RES TR, V130, P939, DOI 10.1007/s10549-011-1656-2
   Suzuki Ryusuke, 2012, Frontiers in Genetics, V3, P204, DOI 10.3389/fgene.2012.00204
   Valdmanis PN, 2012, NUCLEIC ACIDS RES, V40, P3704, DOI 10.1093/nar/gkr1274
   Wang DW, 2014, ASIAN PAC J CANCER P, V15, P7553, DOI 10.7314/APJCP.2014.15.18.7553
   Woo IS, 2008, APOPTOSIS, V13, P1223, DOI 10.1007/s10495-008-0247-0
   Xia F, 2008, CANCER RES, V68, P1826, DOI 10.1158/0008-5472.CAN-07-5279
   Xie Y, 2015, ONCOTARGETS THER, V8, P567, DOI 10.2147/OTT.S79150
   Yang HS, 2008, CANCER RES, V68, P2530, DOI 10.1158/0008-5472.CAN-07-5991
   Yuen HF, 2012, CLIN CANCER RES, V18, P380, DOI 10.1158/1078-0432.CCR-11-2035
   Zhao YF, 2015, ONCOTARGETS THER, V8, DOI 10.2147/OTT.S78647
   Zhu J, 2014, FRONT GENET, V5, DOI [10.3389/fgene.2014.00149, 10.3389/fgene.2014.00187]
   Zhu WB, 2016, PEERJ, V4, DOI 10.7717/peerj.1724
NR 65
TC 12
Z9 12
U1 0
U2 8
PU MAIK NAUKA/INTERPERIODICA/SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013-1578 USA
SN 1022-7954
EI 1608-3369
J9 RUSS J GENET+
JI Russ. J. Genet.
PD MAY
PY 2018
VL 54
IS 5
BP 568
EP 575
DI 10.1134/S1022795418040051
PG 8
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA GG3WR
UT WOS:000432624900008
DA 2025-01-12
ER

PT J
AU Ding, H
   Lu, WC
   Hu, JC
   Liu, YC
   Zhang, CH
   Lian, FL
   Zhang, NX
   Meng, FW
   Luo, C
   Chen, KX
AF Ding, Hong
   Lu, Wen Chao
   Hu, Jun Chi
   Liu, Yu-Chih
   Zhang, Chen Hua
   Lian, Fu Lin
   Zhang, Nai Xia
   Meng, Fan Wang
   Luo, Cheng
   Chen, Kai Xian
TI Identification and Characterizations of Novel, Selective Histone
   Methyltransferase SET7 Inhibitors by Scaffold Hopping- and 2D-Molecular
   Fingerprint-Based Similarity Search
SO MOLECULES
LA English
DT Article
DE SET7; inhibitor; similarity search; ligand-based drug design; chemical
   biology probe
ID LYSINE METHYLTRANSFERASE; POSTTRANSLATIONAL MODIFICATIONS; EPIGENETIC
   MODIFICATIONS; CELL-PROLIFERATION; ACCURATE DOCKING; DRUG DISCOVERY;
   RECEPTOR-ALPHA; METHYLATION; EXPRESSION; PROTEIN
AB SET7, serving as the only histone methyltransferase that monomethylates 'Lys-4' of histone H3, has been proved to function as a key regulator in diverse biological processes, such as cell proliferation, transcriptional network regulation in embryonic stem cell, cell cycle control, protein stability, heart morphogenesis and development. What's more, SET7 is involved in the pathogenesis of alopecia aerate, breast cancer, tumor and cancer progression, atherosclerosis in human carotid plaques, chronic renal diseases, diabetes, obesity, ovarian cancer, prostate cancer, hepatocellular carcinoma, and pulmonary fibrosis. Therefore, there is urgent need to develop novel SET7 inhibitors. In this paper, based on DC-S239 which has been previously reported in our group, we employed scaffold hopping- and 2D fingerprint-based similarity searches and identified DC-S285 as the new hit compound targeting SET7 (IC50 = 9.3 mu M). Both radioactive tracing and NMR experiments validated the interactions between DC-S285 and SET7 followed by the second-round similarity search leading to the identification of DC-S303 with the IC50 value of 1.1 mu M. In cellular level, DC-S285 retarded tumor cell proliferation and showed selectivity against MCF7 (IC50 = 21.4 mu M), Jurkat (IC50 = 2.2 mu M), THP1 (IC50 = 3.5 mu M), U937 (IC50 = 3.9 mu M) cell lines. Docking calculations suggested that DC-S303 share similar binding mode with the parent compound DC-S239. What's more, it presented good selectivity against other epigenetic targets, including SETD1B, SETD8, G9a, SMYD2 and EZH2. DC-S303 can serve as a drug-like scaffold which may need further optimization for drug development, and can be used as chemical probe to help the community to better understand the SET7 biology.
C1 [Ding, Hong; Chen, Kai Xian] Shanghai Univ Tradit Chinese Med, Sch Pharm, 1200 Cailun Rd, Shanghai 201203, Peoples R China.
   [Ding, Hong; Lu, Wen Chao; Hu, Jun Chi; Lian, Fu Lin; Zhang, Nai Xia; Meng, Fan Wang; Luo, Cheng; Chen, Kai Xian] Chinese Acad Sci, Shanghai Inst Mat Med, State Key Lab Drug Res, CAS Key Lab Receptor Res, 555 Zuchongzhi Rd, Shanghai 201203, Peoples R China.
   [Liu, Yu-Chih; Zhang, Chen Hua] Shanghai ChemPartner Co Ltd, 5 Bldg,998 Halei Rd, Shanghai 201203, Peoples R China.
   [Meng, Fan Wang] McMaster Univ, Dept Chem & Chem Biol, 1280 Main St West, Hamilton, ON L8S 4L8, Canada.
C3 Shanghai University of Traditional Chinese Medicine; Chinese Academy of
   Sciences; Shanghai Institute of Materia Medica, CAS; McMaster University
RP Chen, KX (通讯作者)，Shanghai Univ Tradit Chinese Med, Sch Pharm, 1200 Cailun Rd, Shanghai 201203, Peoples R China.; Meng, FW; Chen, KX (通讯作者)，Chinese Acad Sci, Shanghai Inst Mat Med, State Key Lab Drug Res, CAS Key Lab Receptor Res, 555 Zuchongzhi Rd, Shanghai 201203, Peoples R China.; Meng, FW (通讯作者)，McMaster Univ, Dept Chem & Chem Biol, 1280 Main St West, Hamilton, ON L8S 4L8, Canada.
EM hding@simm.ac.cn; wenchaolu@simm.ac.cn; hujunchi@simm.ac.cn;
   yzhliu@chempartner.com; chhzhang@chempartner.com;
   fulinlian1986@simm.ac.cn; nxzhang@simm.ac.cn; mengf9@mcmaster.ca;
   e-cluo@simm.ac.cn; kxchen@simm.ac.cn
RI chen, yuling/JMQ-4121-2023; Lu, Wenchao/AAG-3983-2020; Meng,
   Fanwang/K-4079-2019
OI Meng, Fanwang/0000-0003-2886-7012; Lu, Wenchao/0000-0003-1175-365X;
   ding, hong/0000-0001-7923-0527
FU Ministry of Science and Technology of China (National Key R&D Program of
   China) [2017YFB0202600]; National Natural Science Foundation of China
   [21472208, 81430084]
FX We are extremely grateful to National Centre for Protein Science
   Shanghai (Shanghai Science Research Center, Protein Expression and
   Purification system) for their instrument support and technical
   assistance. We gratefully acknowledge Xiaojie Lu, Jingqiu Liu, Shien
   Liu, Kongkai Zhu for their support and help. We gratefully acknowledge
   financial support from the Ministry of Science and Technology of China
   (National Key R&D Program of China (2017YFB0202600 to H.D.)); the
   National Natural Science Foundation of China (21472208 and 81430084 to
   C.L.).
CR Adachi Y, 2010, CANCER INVEST, V28, P120, DOI 10.3109/07357900903124472
   Aguilo F, 2016, CELL REP, V14, P479, DOI 10.1016/j.celrep.2015.12.043
   Akiyama Y, 2016, ONCOTARGET, V7, P3966, DOI 10.18632/oncotarget.6681
   Al-Haddad R, 2016, NEUROSCI LETT, V625, P64, DOI 10.1016/j.neulet.2016.04.046
   Albacker C. E., 2013, PLOS ONE, P8
   Ali I, 2016, J BIOL CHEM, V291, P16240, DOI 10.1074/jbc.M116.735415
   Nguyen AT, 2011, GENE DEV, V25, P1345, DOI 10.1101/gad.2057811
   Arrowsmith CH, 2012, NAT REV DRUG DISCOV, V11, P384, DOI 10.1038/nrd3674
   Baek SH, 2016, BMB REP, V49, P245, DOI 10.5483/BMBRep.2016.49.5.053
   Baell J, 2014, NATURE, V513, P481, DOI 10.1038/513481a
   Baell JB, 2010, FUTURE MED CHEM, V2, P1529, DOI 10.4155/FMC.10.237
   Baell JB, 2010, J MED CHEM, V53, P2719, DOI 10.1021/jm901137j
   Balasubramaniyan N, 2012, AM J PHYSIOL-GASTR L, V302, pG937, DOI 10.1152/ajpgi.00441.2011
   Barsyte-Lovejoy D, 2014, P NATL ACAD SCI USA, V111, P12853, DOI 10.1073/pnas.1407358111
   Brasacchio D, 2009, DIABETES, V58, P1229, DOI 10.2337/db08-1666
   Calnan DR, 2012, AGING-US, V4, P462, DOI 10.18632/aging.100471
   Carr SM, 2011, CELL CYCLE, V10, P733, DOI 10.4161/cc.10.5.14958
   Carr SM, 2011, EMBO J, V30, P317, DOI 10.1038/emboj.2010.311
   Castaño J, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149502
   Chen YH, 2012, AM J TRANSL RES, V4, P364
   Cho HS, 2011, CANCER RES, V71, P655, DOI 10.1158/0008-5472.CAN-10-2446
   Ciccarelli M, 2016, DIABETOLOGIA, V59, P176, DOI 10.1007/s00125-015-3774-6
   Costantino S, 2015, EUR HEART J, V36, P112
   Couture JF, 2006, NAT STRUCT MOL BIOL, V13, P140, DOI 10.1038/nsmb1045
   D'Adamo CR, 2016, NUTRIENTS, V8, DOI 10.3390/nu8020082
   Dhayalan A, 2011, CHEM BIOL, V18, P111, DOI 10.1016/j.chembiol.2010.11.014
   Ea CK, 2009, P NATL ACAD SCI USA, V106, P18972, DOI 10.1073/pnas.0910439106
   Elkouris M, 2016, CELL REP, V15, P2733, DOI 10.1016/j.celrep.2016.05.051
   Estève PO, 2009, P NATL ACAD SCI USA, V106, P5076, DOI 10.1073/pnas.0810362106
   Friesner RA, 2004, J MED CHEM, V47, P1739, DOI 10.1021/jm0306430
   Friesner RA, 2006, J MED CHEM, V49, P6177, DOI 10.1021/jm051256o
   Fu L, 2016, ELIFE, V5, DOI 10.7554/eLife.15690
   Gaughan L, 2011, NUCLEIC ACIDS RES, V39, P1266, DOI 10.1093/nar/gkq861
   Gleeson MP, 2011, NAT REV DRUG DISCOV, V10, P197, DOI 10.1038/nrd3367
   Gong JY, 2013, BIOINFORMATICS, V29, P1827, DOI 10.1093/bioinformatics/btt270
   Goru SK, 2016, BIOCHEM J, V473, P3937, DOI 10.1042/BCJ20160595
   Greer EL, 2012, NAT REV GENET, V13, P343, DOI 10.1038/nrg3173
   Greissel A, 2016, CARDIOVASC PATHOL, V25, P79, DOI 10.1016/j.carpath.2015.11.001
   Guo Q, 2016, J SENSORS, V2016, DOI 10.1155/2016/4140175
   Gupta N, 2015, J BIOL CHEM, V290, P12101, DOI 10.1074/jbc.M114.620443
   Halgren TA, 2004, J MED CHEM, V47, P1750, DOI 10.1021/jm030644s
   Han P, 2015, LIFE SCI, V130, P103, DOI 10.1016/j.lfs.2015.02.022
   Han T, 2015, J IMMUNOL, V194, P2757, DOI 10.4049/jimmunol.1400583
   He SY, 2015, SCI REP-UK, V5, DOI 10.1038/srep14368
   Herz HM, 2013, TRENDS BIOCHEM SCI, V38, P621, DOI 10.1016/j.tibs.2013.09.004
   Hsu CH, 2012, ONCOGENE, V31, P2335, DOI 10.1038/onc.2011.415
   Huq MDM, 2007, MOL CELL PROTEOMICS, V6, P677, DOI 10.1074/mcp.M600223-MCP200
   Jones PA, 2016, NAT REV GENET, V17, P630, DOI 10.1038/nrg.2016.93
   Kassner I, 2013, OPEN BIOL, V3, DOI 10.1098/rsob.120173
   Kassner I, 2013, EPIGENET CHROMATIN, V6, DOI 10.1186/1756-8935-6-1
   Keating S, 2013, EPIGENETICS-US, V8, P361, DOI 10.4161/epi.24234
   Kim JD, 2015, MOL CELLS, V38, P580, DOI 10.14348/molcells.2015.0053
   Kim Y, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10347
   Kontaki H, 2010, MOL CELL, V39, P152, DOI 10.1016/j.molcel.2010.06.006
   Kouskouti A, 2004, MOL CELL, V14, P175, DOI 10.1016/S1097-2765(04)00182-0
   Lezina L, 2014, CELL DEATH DIFFER, V21, P1889, DOI 10.1038/cdd.2014.108
   Lezina L, 2015, ONCOTARGET, V6, P25843, DOI 10.18632/oncotarget.4584
   Li XJ, 2016, J DIABETES RES, V2016, DOI 10.1155/2016/3853242
   Lipinski CA, 2001, ADV DRUG DELIVER REV, V46, P3, DOI 10.1016/S0169-409X(00)00129-0
   Liu Q, 2015, BBA-MOL CELL RES, V1853, P881, DOI 10.1016/j.bbamcr.2015.01.011
   Liu XY, 2011, P NATL ACAD SCI USA, V108, P1925, DOI 10.1073/pnas.1019619108
   Liu X, 2015, NUCLEIC ACIDS RES, V43, P5081, DOI 10.1093/nar/gkv379
   Maganti AV, 2015, J BIOL CHEM, V290, P9812, DOI 10.1074/jbc.M114.616219
   Martens MB, 2016, SCI REP-UK, V6, DOI 10.1038/srep35756
   Masatsugu T, 2009, BIOCHEM BIOPH RES CO, V381, P22, DOI 10.1016/j.bbrc.2009.01.185
   Meng FW, 2015, J MED CHEM, V58, P8166, DOI 10.1021/acs.jmedchem.5b01154
   Muller PAJ, 2013, NAT CELL BIOL, V15, P2, DOI 10.1038/ncb2641
   Munro S, 2012, ONCOGENE, V31, P4343, DOI 10.1038/onc.2011.603
   Nishioka K, 2002, GENE DEV, V16, P479, DOI 10.1101/gad.967202
   Okabe J, 2012, CIRC RES, V110, P1067, DOI 10.1161/CIRCRESAHA.112.266171
   Oppenheimer H, 2014, J BONE MINER RES, V29, P348, DOI 10.1002/jbmr.2052
   Oudhoff MJ, 2016, DEV CELL, V37, P47, DOI 10.1016/j.devcel.2016.03.002
   Pagans S, 2010, CELL HOST MICROBE, V7, P234, DOI 10.1016/j.chom.2010.02.005
   Paneni F, 2015, CIRC-CARDIOVASC GENE, V8, P150, DOI 10.1161/CIRCGENETICS.114.000671
   Sasaki K, 2016, J AM SOC NEPHROL, V27, P203, DOI 10.1681/ASN.2014090850
   Shan Z, 2013, J BIOL CHEM, V288, P35093, DOI 10.1074/jbc.M113.511949
   Shelley JC, 2007, J COMPUT AID MOL DES, V21, P681, DOI 10.1007/s10822-007-9133-z
   Shen CC, 2015, FASEB J, V29, P4313, DOI 10.1096/fj.15-273540
   Son MJ, 2016, BMB REP, V49, P388, DOI 10.5483/BMBRep.2016.49.7.062
   Son MJ, 2016, MOL CELL ENDOCRINOL, V431, P46, DOI 10.1016/j.mce.2016.04.022
   Song YC, 2016, TUMOR BIOL, V37, P9311, DOI 10.1007/s13277-016-4822-7
   Spaeth JM, 2016, DIABETES OBES METAB, V18, P123, DOI 10.1111/dom.12730
   Subramanian K, 2008, MOL CELL, V30, P336, DOI 10.1016/j.molcel.2008.03.022
   Tajima K, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9257
   Tang Y, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0163324
   Toledo F, 2006, NAT REV CANCER, V6, P909, DOI 10.1038/nrc2012
   Tough DF, 2016, NAT REV DRUG DISCOV, V15, P835, DOI 10.1038/nrd.2016.185
   Tuano NK, 2016, NUCLEIC ACIDS RES, V44, P9206, DOI 10.1093/nar/gkw621
   van de Waterbeemd H, 2003, NAT REV DRUG DISCOV, V2, P192, DOI 10.1038/nrd1032
   Vasileva E, 2015, INT J MOL MED, V36, pS46
   Wagner T, 2012, NAT BIOTECHNOL, V30, P622, DOI 10.1038/nbt.2300
   Wang DL, 2013, P NATL ACAD SCI USA, V110, P5516, DOI 10.1073/pnas.1216596110
   Wang HB, 2001, MOL CELL, V8, P1207, DOI 10.1016/S1097-2765(01)00405-1
   Wang J, 2009, NAT GENET, V41, P125, DOI 10.1038/ng.268
   Wang WP, 2016, MOL CELL ENDOCRINOL, V428, P38, DOI 10.1016/j.mce.2016.03.019
   Whitty A, 2011, FUTURE MED CHEM, V3, P797, DOI [10.4155/FMC.11.44, 10.4155/fmc.11.44]
   Yang JB, 2010, P NATL ACAD SCI USA, V107, P21499, DOI 10.1073/pnas.1016147107
   Yang Z, 2015, CELL CYCLE, V14, P3820, DOI 10.1080/15384101.2015.1069926
   Yuan H, 2016, ANTIOXID REDOX SIGN, V24, P361, DOI 10.1089/ars.2015.6372
   Zhang WJ, 2016, SCI REP-UK, V6, DOI 10.1038/srep21718
   Zhang YA, 2016, ONCOTARGET, V7, P9859, DOI 10.18632/oncotarget.7126
   Zhao L, 2015, CELL DEATH DIFFER, V22, P1630, DOI 10.1038/cdd.2015.6
   Zhao M, 2012, BRIT J DERMATOL, V166, P266, DOI 10.1111/j.1365-2133.2011.10646.x
   Zhou J, 2015, ONCOL REP, V34, P111, DOI 10.3892/or.2015.3952
NR 104
TC 11
Z9 12
U1 0
U2 20
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1420-3049
J9 MOLECULES
JI Molecules
PD MAR
PY 2018
VL 23
IS 3
AR 567
DI 10.3390/molecules23030567
PG 21
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA GA7KD
UT WOS:000428514100058
PM 29498708
OA Green Published, Green Submitted, gold
DA 2025-01-12
ER

PT J
AU Lapthanasupkul, P
   Juengsomjit, R
   Poomsawat, S
   Arayapisit, T
AF Lapthanasupkul, Puangwan
   Juengsomjit, Rachai
   Poomsawat, Sopee
   Arayapisit, Tawepong
TI Expression profile of polycomb group proteins in odontogenic keratocyst
   and ameloblastoma
SO ACTA HISTOCHEMICA
LA English
DT Article
DE PcG proteins; Epigenetics; Odontogenic keratocyst; Ameloblastoma;
   Immunohistochemistry
ID CELL SELF-RENEWAL; BMI-1 EXPRESSION; BREAST-CANCER; PROGRESSION; TUMOR;
   PROLIFERATION; METHYLATION; SURVIVAL; GENES; SUZ12
AB Polycomb group (PcG) proteins are repressive chromatin modifiers required for proliferation and development. PcG proteins form two large repressive complexes, namely, Polycomb Repressive Complex 1 and 2. These proteins have been shown to drive tumorigenesis by repressing cell-type specific sets of target genes. Using immunohistochemistry, we investigated the expression patterns of five human PcG proteins, including Bmi-1, Ringlb, Mel-18, Ezh2, and Suz12, in various cellular components of odontogenic keratocysts (OKCs), ameloblastomas and, pericoronal follicles (PFs). In OKCs, expression of PcG proteins were found in the majority of cases while the expression pattern was relatively different for each PcG proteins. All PcG proteins were strongly expressed in the basal cells while some proteins showed variable expression in the parabasal and luminal cell layer of OKCs. In ameloblastomas, almost all PcG proteins showed a similar expression pattern of moderate to strong staining in the peripheral ameloblast-like cells and metaplastic squamous cells. Some of the central stellate reticulum-like cells also showed positive reaction to most PcG proteins. In PFs, most PcG proteins were intensely expressed in odontogenic epithelium lining the follicles, except Mel-18 and Suz12. The present study provides the initial evidence regarding epigenetic involvement by PcG proteins in these odontogenic lesions. Although these proteins are known to be in the same repressive group proteins, differential expression patterns of these proteins in OKCs and ameloblastomas indicates that these proteins may play different roles in pathogenesis of these odontogenic lesions.
C1 [Lapthanasupkul, Puangwan; Juengsomjit, Rachai; Poomsawat, Sopee] Mahidol Univ, Dept Oral & Maxillofacial Pathol, Fac Dent, 6 Yothi St, Bangkok 10400, Thailand.
   [Arayapisit, Tawepong] Mahidol Univ, Dept Anat, Fac Dent, Bangkok, Thailand.
C3 Mahidol University; Mahidol University
RP Lapthanasupkul, P (通讯作者)，Mahidol Univ, Dept Oral & Maxillofacial Pathol, Fac Dent, 6 Yothi St, Bangkok 10400, Thailand.
EM puangwan.lap@mahidol.ac.th
OI Arayapisit, Tawepong/0000-0002-9680-3347
FU Faculty of Dentistry, Mahidol University
FX We would like to thank Mrs. Unreun Meesakul for her help in preparing
   the tissue sections. This work was supported by the Research Grants from
   Faculty of Dentistry, Mahidol University.
CR Amaral Fabrício Rezende, 2012, Braz. Dent. J., V23, P91
   [Anonymous], 2005, World Health Organization Classification of Tumours: Pathology and Genetics of Head and Neck Tumours
   Bologna-Molina R, 2008, ORAL ONCOL, V44, P805, DOI 10.1016/j.oraloncology.2007.10.007
   El-Naggar AK., 2017, WHO CLASSIFICATION H, P123
   Farias LC, 2012, BMC CLIN PATHOL, V12, DOI 10.1186/1472-6890-12-11
   Gil J, 2005, DNA CELL BIOL, V24, P117, DOI 10.1089/dna.2005.24.117
   Gomes CC, 2009, ORAL ONCOL, V45, P1011, DOI 10.1016/j.oraloncology.2009.08.003
   Guo WJ, 2007, CANCER RES, V67, P5083, DOI 10.1158/0008-5472.CAN-06-4368
   Hatziapostolou M, 2011, CELL MOL LIFE SCI, V68, P1681, DOI 10.1007/s00018-010-0624-z
   Kang MK, 2007, BRIT J CANCER, V96, P126, DOI 10.1038/sj.bjc.6603529
   Kidani K, 2009, ORAL ONCOL, V45, P39, DOI 10.1016/j.oraloncology.2008.03.016
   Kitkumthorn N, 2010, ORAL DIS, V16, P286, DOI 10.1111/j.1601-0825.2009.01640.x
   Kumamoto H, 2006, J ORAL PATHOL MED, V35, P65, DOI 10.1111/j.1600-0714.2006.00380.x
   Kumamoto H, 2010, J ORAL PATHOL MED, V39, P87, DOI 10.1111/j.1600-0714.2009.00807.x
   Lee JY, 2008, CANCER RES, V68, P4201, DOI 10.1158/0008-5472.CAN-07-2570
   Liu CH, 2014, TUMOR BIOL, V35, P6073, DOI 10.1007/s13277-014-1804-5
   Luo HY, 2006, INT J ORAL MAX SURG, V35, P750, DOI 10.1016/j.ijom.2006.03.012
   Luo HY, 2009, ORAL ONCOL, V45, P706, DOI 10.1016/j.oraloncology.2008.11.001
   Martín-Pérez D, 2010, AM J PATHOL, V177, P930, DOI 10.2353/ajpath.2010.090769
   Martínez-Romero C, 2009, J PATHOL, V219, P205, DOI 10.1002/path.2585
   Molofsky AV, 2005, GENE DEV, V19, P1432, DOI 10.1101/gad.1299505
   Moreira PR, 2009, J ORAL PATHOL MED, V38, P99, DOI 10.1111/j.1600-0714.2008.00718.x
   Piunti A, 2011, FUTURE ONCOL, V7, P57, DOI [10.2217/fon.10.157, 10.2217/FON.10.157]
   Ringrose L, 2004, ANNU REV GENET, V38, P413, DOI 10.1146/annurev.genet.38.072902.091907
   Gurgel CAS, 2008, J MOL HISTOL, V39, P311, DOI 10.1007/s10735-008-9167-0
   Song LB, 2006, CANCER RES, V66, P6225, DOI 10.1158/0008-5472.CAN-06-0094
   Tawfik MA, 2010, ORAL SURG ORAL MED O, V109, pE67, DOI 10.1016/j.tripleo.2009.09.003
   Osterne RLV, 2011, ORAL SURG ORAL MED O, V111, P474, DOI 10.1016/j.tripleo.2010.10.018
NR 28
TC 1
Z9 1
U1 0
U2 3
PU ELSEVIER GMBH, URBAN & FISCHER VERLAG
PI JENA
PA OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY
SN 0065-1281
EI 1618-0372
J9 ACTA HISTOCHEM
JI Acta Histochem.
PY 2018
VL 120
IS 3
BP 215
EP 220
DI 10.1016/j.acthis.2018.01.009
PG 6
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA GE7CM
UT WOS:000431387600007
PM 29415809
DA 2025-01-12
ER

PT J
AU Hoffmann, JA
   Trottern, KW
   Ward, JM
   Archer, TK
AF Hoffmann, Jackson A.
   Trottern, Kevin W.
   Ward, James M.
   Archer, Trevor K.
TI BRG1 governs glucocorticoid receptor interactions with chromatin and
   pioneer factors across the genome
SO ELIFE
LA English
DT Article
ID REMODELING COMPLEX; TRANSCRIPTION FACTORS; GENE-EXPRESSION;
   BINDING-SITES; ACTIVATION; FOXA1; ACCESSIBILITY; RECRUITMENT; PROMOTER;
   ELEMENTS
AB The Glucocorticoid Receptor (GR) alters transcriptional activity in response to hormones by interacting with chromatin at GR binding sites (GBSs) throughout the genome. Our work in human breast cancer cells identifies three classes of GBSs with distinct epigenetic characteristics and reveals that BRG1 interacts with GBSs prior to hormone exposure. The GBSs pre-occupied by BRG1 are more accessible and transcriptionally active than other GBSs. BRG1 is required for a proper and robust transcriptional hormone response and knockdown of BRG1 blocks recruitment of the pioneer factors FOXA1 and GATA3 to GBSs. Finally, GR interaction with FOXA1 and GATA3 binding sites was restricted to sites pre-bound by BRG1. These findings demonstrate that BRG1 establishes specialized chromatin environments that define multiple classes of GBS. This in turn predicts that GR and other transcriptional activators function via multiple distinct chromatin based mechanisms to modulate the transcriptional response.
C1 [Hoffmann, Jackson A.; Trottern, Kevin W.; Archer, Trevor K.] NIEHS, Epigenet & Stem Cell Biol Lab, NIH, Durham, NC 27709 USA.
   [Ward, James M.] NIEHS, Integrat Bioinformat, NIH, Durham, NC USA.
C3 National Institutes of Health (NIH) - USA; NIH National Institute of
   Environmental Health Sciences (NIEHS); National Institutes of Health
   (NIH) - USA; NIH National Institute of Environmental Health Sciences
   (NIEHS)
RP Archer, TK (通讯作者)，NIEHS, Epigenet & Stem Cell Biol Lab, NIH, Durham, NC 27709 USA.
EM archer1@niehs.nih.goy
OI Hoffman, Jackson/0000-0002-6256-144X; Archer, Trevor
   K/0000-0001-7651-3644; Trotter, Kevin/0000-0002-4182-9523; Ward,
   James/0000-0002-9510-2848
FU National Institute of Environmental Health Sciences [Z01 ES071006-17]
FX National Institute of Environmental Health Sciences Z01 ES071006-17
   Trevor K Archer
CR ARCHER TK, 1994, MOL ENDOCRINOL, V8, P1154, DOI 10.1210/me.8.9.1154
   Biddie SC, 2011, MOL CELL, V43, P145, DOI 10.1016/j.molcel.2011.06.016
   Burd CJ, 2012, MOL CELL BIOL, V32, P1805, DOI 10.1128/MCB.06206-11
   Carroll JS, 2005, CELL, V122, P33, DOI 10.1016/j.cell.2005.05.008
   CORDINGLEY MG, 1987, CELL, V48, P261, DOI 10.1016/0092-8674(87)90429-6
   Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635
   Edgar R, 2002, NUCLEIC ACIDS RES, V30, P207, DOI 10.1093/nar/30.1.207
   Fryer CJ, 1998, NATURE, V393, P88, DOI 10.1038/30032
   Grontved L, 2013, EMBO J, V32, P1568, DOI 10.1038/emboj.2013.106
   Hakim O, 2009, J BIOL CHEM, V284, P6048, DOI 10.1074/jbc.C800212200
   Heinz S, 2010, MOL CELL, V38, P576, DOI 10.1016/j.molcel.2010.05.004
   Holmqvist PH, 2005, EXP CELL RES, V304, P593, DOI 10.1016/j.yexcr.2004.12.002
   Hsiao PW, 2003, MOL CELL BIOL, V23, P6210, DOI 10.1128/MCB.23.17.6210-6220.2003
   Hurtado A, 2011, NAT GENET, V43, P27, DOI 10.1038/ng.730
   Inoue H, 2002, J BIOL CHEM, V277, P41674, DOI 10.1074/jbc.M205961200
   John S, 2011, NAT GENET, V43, P264, DOI 10.1038/ng.759
   Johnson TA, 2008, MOL BIOL CELL, V19, P3308, DOI 10.1091/mbc.E08-02-0123
   Johnson TA, 2018, NUCLEIC ACIDS RES, V46, P203, DOI 10.1093/nar/gkx1044
   Joshi N.A., 2011, Sickle: a sliding-window, adaptive, quality-based trimming tool for FastQ files
   Jubb AW, 2017, CELL REP, V21, P3022, DOI 10.1016/j.celrep.2017.11.053
   Kadoch C, 2013, NAT GENET, V45, P592, DOI 10.1038/ng.2628
   Laganière J, 2005, P NATL ACAD SCI USA, V102, P11651, DOI 10.1073/pnas.0505575102
   Langlais D, 2012, MOL CELL, V47, P38, DOI 10.1016/j.molcel.2012.04.021
   Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/NMETH.1923, 10.1038/nmeth.1923]
   Lavender CA, 2016, PLOS GENET, V12, DOI 10.1371/journal.pgen.1006224
   Law CW, 2014, GENOME BIOL, V15, DOI 10.1186/gb-2014-15-2-r29
   Li H, 2009, BIOINFORMATICS, V25, P2078, DOI 10.1093/bioinformatics/btp352
   Martin M., 2011, EMBnet.journal, V17, P10, DOI DOI 10.14806/EJ.17.1.200
   McLeay RC, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-165
   Nie ZQ, 2000, MOL CELL BIOL, V20, P8879, DOI 10.1128/MCB.20.23.8879-8888.2000
   Paakinaho V, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15896
   Patro R, 2017, NAT METHODS, V14, P417, DOI 10.1038/nmeth.4197
   Quinlan AR, 2010, BIOINFORMATICS, V26, P841, DOI 10.1093/bioinformatics/btq033
   Ramírez F, 2016, NUCLEIC ACIDS RES, V44, pW160, DOI 10.1093/nar/gkw257
   Rao NAS, 2011, GENOME RES, V21, P1404, DOI 10.1101/gr.118042.110
   Shain AH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055119
   Starick SR, 2015, GENOME RES, V25, P825, DOI 10.1101/gr.185157.114
   Swinstead EE, 2016, CELL, V165, P593, DOI 10.1016/j.cell.2016.02.067
   Takaku M, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-0897-0
   Trotter KW, 2015, MOL CELL BIOL, V35, P2799, DOI 10.1128/MCB.00230-15
   Vockley CM, 2016, CELL, V166, P1269, DOI 10.1016/j.cell.2016.07.049
   Wallberg AE, 2000, MOL CELL BIOL, V20, P2004, DOI 10.1128/MCB.20.6.2004-2013.2000
   Wu Q, 2017, EPIGENOMICS-UK, V9, P919, DOI 10.2217/epi-2017-0034
   Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r137
NR 44
TC 43
Z9 46
U1 0
U2 6
PU ELIFE SCIENCES PUBLICATIONS LTD
PI CAMBRIDGE
PA SHERATON HOUSE, CASTLE PARK, CAMBRIDGE, CB3 0AX, ENGLAND
SN 2050-084X
J9 ELIFE
JI eLife
PD MAY 24
PY 2018
VL 7
AR e35073
DI 10.7554/eLife.35073
PG 20
WC Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Life Sciences & Biomedicine - Other Topics
GA GG7WY
UT WOS:000432910300001
PM 29792595
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Mauger, F
   Kernaleguen, M
   Lallemand, C
   Kristensen, VN
   Deleuze, JF
   Tost, J
AF Mauger, Florence
   Kernaleguen, Magali
   Lallemand, Celine
   Kristensen, Vessela N.
   Deleuze, Jean-Francois
   Tost, Jorg
TI Enrichment of methylated molecules using enhanced-ice-co-amplification
   at lower denaturation temperature-PCR (E-ice-COLD-PCR) for the sensitive
   detection of disease-related hypermethylation
SO EPIGENOMICS
LA English
DT Article
DE bisulfite converted DNA; E-ice-COLD-PCR; methylation; multiplex and
   circulating cell-free DNA; quantification
ID CIRCULATING TUMOR DNA; CELL-FREE DNA; COLORECTAL-CANCER; EPIGENETIC
   BIOMARKERS; BREAST-CANCER; CPG ISLANDS; IDENTIFICATION; PLASMA;
   MUTATIONS; QUANTIFICATION
AB Aim: The detection of specific DNA methylation patterns bears great promise as biomarker for personalized management of cancer patients. Co-amplification at lower denaturation temperature-PCR (COLDPCR) assays are sensitive methods, but have previously only been able to analyze loss of DNA methylation. Materials & methods: Enhanced (E)-ice-COLD-PCR reactions starting from 2 ng of bisulfite-converted DNA were developed to analyze methylation patterns in two promoters with locked nucleic acid (LNA) probes blocking amplification of unmethylated CpGs. The enrichment of methylated molecules was compared to quantitative (q) PCR and quantified using serial dilutions. Results: E-ice-COLD-PCR allowed the multiplexed enrichment and quantification of methylated DNA. Assays were validated in primary breast cancer specimens and circulating cell-free DNA from cancer patients. Conclusion: E-ice-COLD-PCR could prove a useful tool in the context of DNA methylation analysis for personalized medicine.
C1 [Mauger, Florence; Kernaleguen, Magali; Lallemand, Celine; Deleuze, Jean-Francois; Tost, Jorg] Inst Biol Francois Jacob, CEA, Ctr Natl Rech Genom Humaine, Lab Epigenet & Environm, Evry, France.
   [Kristensen, Vessela N.] Radiumhemmet, Oslo Univ Hosp, Inst Canc Res, Dept Canc Genet, Oslo, Norway.
   [Kristensen, Vessela N.] Akershus Univ Hosp, Div Med, Dept Clin Mol Biol & Lab Sci EpiGen, N-1476 Lorenskog, Norway.
   [Kristensen, Vessela N.] Univ Oslo, Fac Med, Inst Clin Med, Oslo, Norway.
   [Deleuze, Jean-Francois] CEPH Fdn Jean Dausset, Ctr Etud Polymorphisme Humain, Paris, France.
   [Deleuze, Jean-Francois] Lab Excellence GenMed, Paris, France.
C3 CEA; Universite Paris Saclay; University of Oslo; University of Oslo;
   University of Oslo
RP Tost, J (通讯作者)，Inst Biol Francois Jacob, CEA, Ctr Natl Rech Genom Humaine, Lab Epigenet & Environm, Evry, France.
EM tost@cng.fr
RI Tost, Jorg/H-7129-2019
OI Tost, Jorg/0000-0002-2683-0817
FU Centre National de Recherche en Genomique Humaine (CNRGH)
FX The study was funded from the institutional budget of the Centre
   National de Recherche en Genomique Humaine (CNRGH). The authors have no
   other relevant affiliations or financial involvement with any
   organization or entity with a financial interest in or financial
   conflict with the subject matter or materials discussed in the
   manuscript apart from those disclosed.
CR Alnaes GIG, 2015, GENES-BASEL, V6, P878, DOI 10.3390/genes6030878
   Bediaga NG, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2721
   Bock C, 2016, NAT BIOTECHNOL, V34, P726, DOI 10.1038/nbt.3605
   Castellanos-Rizaldos E, 2012, CLIN CHEM, V58, P1130, DOI 10.1373/clinchem.2012.183095
   Castellanos-Rizaldos E, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094103
   Castellanos-Rizaldos E, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051362
   Church TR, 2014, GUT, V63, P317, DOI 10.1136/gutjnl-2012-304149
   Costa-Pinheiro P, 2015, EPIGENOMICS-UK, V7, P1003, DOI 10.2217/epi.15.56
   Cottrell SE, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh008
   deVos T, 2009, CLIN CHEM, V55, P1337, DOI 10.1373/clinchem.2008.115808
   Dominguez PL, 2005, ONCOGENE, V24, P6830, DOI 10.1038/sj.onc.1208832
   Eads CA, 2000, NUCLEIC ACIDS RES, V28, DOI 10.1093/nar/28.8.e32
   Eckhardt F, 2006, NAT GENET, V38, P1378, DOI 10.1038/ng1909
   Geybels MS, 2016, CLIN EPIGENETICS, V8, DOI 10.1186/s13148-016-0260-z
   Guo SC, 2017, NAT GENET, V49, P635, DOI 10.1038/ng.3805
   Heitzer E, 2015, CLIN CHEM, V61, P112, DOI 10.1373/clinchem.2014.222679
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   How-Kit A, 2015, METHODS MOL BIOL, V1315, P83, DOI 10.1007/978-1-4939-2715-9_7
   How-Kit A, 2014, ANAL BIOANAL CHEM, V406, P5513, DOI 10.1007/s00216-014-7975-5
   Kang SL, 2017, GENOME BIOL, V18, DOI 10.1186/s13059-017-1191-5
   Kit AH, 2013, HUM MUTAT, V34, P1568, DOI 10.1002/humu.22427
   Kit AH, 2012, BIOCHIMIE, V94, P2314, DOI 10.1016/j.biochi.2012.07.014
   Klajic J, 2014, CLIN CANCER RES, V20, P6357, DOI 10.1158/1078-0432.CCR-14-0297
   Kristensen LS, 2008, NUCLEIC ACIDS RES, V36, DOI 10.1093/nar/gkn113
   Lehmann-Werman R, 2016, P NATL ACAD SCI USA, V113, pE1826, DOI 10.1073/pnas.1519286113
   Liu YB, 2017, NUCLEIC ACIDS RES, V45, DOI 10.1093/nar/gkw1166
   Mauger F, 2017, MOL DIAGN THER, V21, P269, DOI 10.1007/s40291-016-0254-8
   Mauger F, 2016, CLIN CHEM, V62, P1155, DOI 10.1373/clinchem.2016.258830
   Mauger F, 2015, ANAL BIOANAL CHEM, V407, P6873, DOI 10.1007/s00216-015-8846-4
   Mikeska T, 2010, EPIGENOMICS-UK, V2, P561, DOI 10.2217/EPI.10.32
   Milbury CA, 2011, NUCLEIC ACIDS RES, V39, DOI 10.1093/nar/gkq899
   Moison C, 2015, METHODS MOL BIOL, V1315, P315, DOI 10.1007/978-1-4939-2715-9_22
   Molnár B, 2015, EXPERT REV MOL DIAGN, V15, P171, DOI 10.1586/14737159.2015.975212
   Qiu JL, 2017, J CLIN ONCOL, V35, P734, DOI [10.1200/jco.2016.68.2153, 10.1200/JCO.2016.68.2153]
   Rasmussen SL, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0180809
   Sandoval J, 2013, J CLIN ONCOL, V31, P4140, DOI 10.1200/JCO.2012.48.5516
   Schmitt MW, 2016, NAT REV CLIN ONCOL, V13, P335, DOI 10.1038/nrclinonc.2015.175
   Schröck A, 2017, CLIN CHEM, V63, P1288, DOI 10.1373/clinchem.2016.270207
   Sefrioui D, 2017, CLIN CHIM ACTA, V465, P1, DOI 10.1016/j.cca.2016.12.004
   Tao MH, 2009, BREAST CANCER RES TR, V114, P559, DOI 10.1007/s10549-008-0028-z
   Tost J, 2003, BIOTECHNIQUES, V35, P152, DOI 10.2144/03351md02
   Tost J, 2007, NAT PROTOC, V2, P2265, DOI 10.1038/nprot.2007.314
   Tost J, 2016, EXPERT REV MOL DIAGN, V16, P265, DOI 10.1586/14737159.2016.1123623
   Tost J, 2016, ADV EXP MED BIOL, V945, P343, DOI 10.1007/978-3-319-43624-1_15
   Vinarskaja A, 2012, WORLD J UROL, V30, P319, DOI 10.1007/s00345-011-0750-8
   Wan JCM, 2017, NAT REV CANCER, V17, P223, DOI 10.1038/nrc.2017.7
   Warnecke PM, 1997, NUCLEIC ACIDS RES, V25, P4422, DOI 10.1093/nar/25.21.4422
   Warton K, 2016, ENDOCR-RELAT CANCER, V23, pR157, DOI 10.1530/ERC-15-0369
   Warton K, 2015, FRONT MOL BIOSCI, V2, DOI 10.3389/fmolb.2015.00013
   Zhang K, 2017, CLIN EPIGENETICS, V9, DOI 10.1186/s13148-017-0343-5
NR 50
TC 11
Z9 11
U1 0
U2 18
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
   1QB, ENGLAND
SN 1750-1911
EI 1750-192X
J9 EPIGENOMICS-UK
JI Epigenomics
PD MAY
PY 2018
VL 10
IS 5
BP 525
EP 537
DI 10.2217/epi-2017-0166
PG 13
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA GF8EL
UT WOS:000432201400002
PM 29697281
OA hybrid
DA 2025-01-12
ER

PT J
AU Cui, ZJ
   Li, HB
   Liang, F
   Mu, CL
   Mu, YH
   Zhang, XG
   Liu, JD
AF Cui, Zhoujun
   Li, Hongbo
   Liang, Feng
   Mu, Cuiling
   Mu, Yuhua
   Zhang, Xuegong
   Liu, Jundong
TI Effect of high WDR5 expression on the hepatocellular carcinoma prognosis
SO ONCOLOGY LETTERS
LA English
DT Article
DE hepatocellular carcinoma; WD repeat domain 5; histone H3 lysine 4; short
   hairpin RNA; prognosis
ID HISTONE H3; CANCER STATISTICS; LYSINE 4; EZH2; METHYLATION; PROSTATE;
   MLL1
AB WD repeat domain 5 (WDR5) serves an important role in various biological functions through the epigenetic regulation of gene transcription. Aberrant expression of WDR5 has been observed in various types of human cancer, including prostate cancer, breast cancer and leukemia. However, the role of WDR5 expression and its clinical implications in hepatocellular carcinoma (HCC) remain largely unknown. The present study investigated the WDR5 expression pattern in HCC. It was demonstrated that the mRNA and protein levels of WDR5 were upregulated in HCC cancer tissues compared with normal adjacent tissues using reverse transcription-quantitative polymerase chain reaction and western blotting. Furthermore, the elevated WDR5 protein level was significantly associated with the histological grade (P=0.038), tumor size (P=0.023), tumor-node-metastasis stage (P=0.035) and reduced long-term survival time. Additionally, it was demonstrated through the shRNA-mediated knockdown of WDR5 in HCC cells in vitro that WDR5 expression promotes cell proliferation using an MTT assay. Taken together, the results suggested that WDR5 overexpression may have an oncogenic effect in HCC, and may be a promising biomarker for the diagnosis and prognosis of HCC.
C1 [Cui, Zhoujun; Li, Hongbo; Liang, Feng; Mu, Cuiling; Mu, Yuhua; Zhang, Xuegong; Liu, Jundong] Peoples Hosp Rizhao, Dept Gen Surg, 126 Taian Rd, Rizhao 276800, Shandong, Peoples R China.
RP Li, HB (通讯作者)，Peoples Hosp Rizhao, Dept Gen Surg, 126 Taian Rd, Rizhao 276800, Shandong, Peoples R China.
EM hbong_li@foxmail.com
RI hongbo, li/HJH-9630-2023; Liang, Fenghua/HHM-3798-2022; Zhang,
   Xuegong/ABG-9911-2022
CR Ang YS, 2011, CELL, V145, P183, DOI 10.1016/j.cell.2011.03.003
   Bachmann IM, 2006, J CLIN ONCOL, V24, P268, DOI 10.1200/JCO.2005.01.5180
   Bannister AJ, 2011, CELL RES, V21, P381, DOI 10.1038/cr.2011.22
   Chen WQ, 2016, CA-CANCER J CLIN, V66, P115, DOI 10.3322/caac.21338
   Chen X, 2015, SCI REP-UK, V5, DOI 10.1038/srep08293
   Chen ZP, 2018, ONCOL LETT, V15, P2953, DOI 10.3892/ol.2017.7647
   Dai X, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126653
   Dou YL, 2006, NAT STRUCT MOL BIOL, V13, P713, DOI 10.1038/nsmb1128
   Forner A, 2012, LANCET, V379, P1245, DOI 10.1016/S0140-6736(11)61347-0
   Ge Z, 2016, ONCOTARGET, V7, P37740, DOI 10.18632/oncotarget.9312
   He CC, 2012, HUM PATHOL, V43, P1425, DOI 10.1016/j.humpath.2011.11.003
   Inokawa Y, 2013, J EXP CLIN CANC RES, V32, DOI 10.1186/1756-9966-32-65
   Kim JY, 2014, MOL CELL, V54, P613, DOI 10.1016/j.molcel.2014.03.043
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Margueron R, 2011, NATURE, V469, P343, DOI 10.1038/nature09784
   Ogunwobi OO, 2012, CRIT REV ONCOL HEMAT, V83, P319, DOI 10.1016/j.critrevonc.2011.11.007
   Schuetz A, 2006, EMBO J, V25, P4245, DOI 10.1038/sj.emboj.7601316
   Shinsky SA, 2014, J MOL BIOL, V426, P2283, DOI 10.1016/j.jmb.2014.03.011
   Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166
   Trievel RC, 2009, NAT STRUCT MOL BIOL, V16, P678, DOI 10.1038/nsmb0709-678
   Weikert S, 2005, INT J MOL MED, V16, P349
   Wittekind C, 2002, CANCER-AM CANCER SOC, V94, P2511, DOI 10.1002/cncr.10492.abs
   Wysocka J, 2005, CELL, V121, P859, DOI 10.1016/j.cell.2005.03.036
   Zhou L, 2008, WORLD J SURG, V32, P1748, DOI 10.1007/s00268-008-9615-8
NR 24
TC 18
Z9 22
U1 0
U2 4
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1792-1074
EI 1792-1082
J9 ONCOL LETT
JI Oncol. Lett.
PD MAY
PY 2018
VL 15
IS 5
BP 7864
EP 7870
DI 10.3892/ol.2018.8298
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA GF3DN
UT WOS:000431825900233
PM 29731905
OA Green Submitted, Green Published, gold
DA 2025-01-12
ER

PT J
AU Li, YF
   Dong, WY
   Shan, XJ
   Hong, H
   Liu, Y
   Liu, YK
   Liu, XH
   Zhang, XJ
   Zhang, JH
AF Li, Yufeng
   Dong, Wenyue
   Shan, Xijin
   Hong, Hui
   Liu, Yan
   Liu, Yankun
   Liu, Xiaohui
   Zhang, Xiaojun
   Zhang, Jinghua
TI The anti-tumor effects of Mfn2 in breast cancer are dependent on
   promoter DNA methylation, the P21<SUP>Ras</SUP> motif and PKA
   phosphorylation site
SO ONCOLOGY LETTERS
LA English
DT Article
DE human breast cancer; mitofusin 2; DNA methylation; Ras-extracellular
   signal-regulated kinase 1/2 signaling pathway
ID SMOOTH-MUSCLE-CELLS; HEPATOCELLULAR-CARCINOMA; INDEPENDENT PATHWAYS;
   EPIGENETIC THERAPY; MITOFUSIN 2; PROTEIN; GENE; PROLIFERATION;
   PROGRESSION; EXPRESSION
AB Mitofusin 2 (Mfn2) is expressed in numerous human tissues and serves a pivotal role in cell proliferation. However, Mfn2 is considered as an anti-tumor gene, and is silenced in human malignant tumors, including those of breast cancer. However, the mechanisms contributing to Mfn2 silencing and the mechanism of its anti-tumor function in breast cancer remain unclear. In the present study, hypoexpression of Mfn2, and hypermethylation of its promoter, was confirmed in human breast cancer cells and in breast cancer tissues by reverse transcription-quantitative polymerase chain reaction (PCR) and methylation specific PCR, respectively. Chemical demethylation treatment with 5-aza-2'-deoxycytidine upregulated the mRNA expression level of Mfn2 in MCF-7 cells in a dose-dependent manner. In addition, overexpression of Mfn2 repressed the proliferation, migration and invasion of MCF-7 cells, mediated by inhibition of the Ras-extracellular signal-regulated kinase (ERK)1/2 signaling pathway. However, overexpression of Mfn2 with deletion of the p21(Ras) motif (Mfn2(Delta)(Ras)) and protein kinase A (PKA) phosphorylation site (Mfn2(Delta)(PKA)) partially reduced the anti-tumor function of Mfn2, and inhibited the Ras-ERK1/2 signaling pathway. Taken together, the present study confirmed the anti-tumor effects of Mfn2 in human breast cancer and clarified that the mechanism of its anti-tumor functions includes promoter DNA methylation, the P21(Ras) binding site and PKA phosphorylation.
C1 [Li, Yufeng; Liu, Yankun; Zhang, Jinghua] North China Univ Sci & Technol, Affiliated Tangshan Peoples Hosp, Canc Inst, 65 Shengli Rd, Tangshan 063001, Hebei, Peoples R China.
   [Dong, Wenyue] North China Univ Sci & Technol, Affiliated Tangshan Peoples Hosp, Dept Anesthesiol, Tangshan 063001, Hebei, Peoples R China.
   [Shan, Xijin] Rizhao Port Hosp, Dept Surg, Rizhao 276800, Shandong, Peoples R China.
   [Hong, Hui] Shangrao Peoples Hosp, Dept Head Neck & Breast Surg, Shangrao 334000, Jiangxi, Peoples R China.
   [Liu, Yan] North China Univ Sci & Technol, Coll Life Sci, Dept Bioengn, Tangshan 063000, Hebei, Peoples R China.
   [Liu, Xiaohui] North China Univ Sci & Technol, Affiliated Tangshan Peoples Hosp, Dept Thorac Surg, Tangshan 063001, Hebei, Peoples R China.
   [Zhang, Xiaojun] North China Univ Sci & Technol, Affiliated Zunhua Peoples Hosp, Dept Internal Med, 316 Huaming,Rd, Zunhua 064200, Hebei, Peoples R China.
C3 North China University of Science & Technology; North China University
   of Science & Technology; North China University of Science & Technology;
   North China University of Science & Technology; North China University
   of Science & Technology
RP Zhang, JH (通讯作者)，North China Univ Sci & Technol, Affiliated Tangshan Peoples Hosp, Canc Inst, 65 Shengli Rd, Tangshan 063001, Hebei, Peoples R China.; Zhang, XJ (通讯作者)，North China Univ Sci & Technol, Affiliated Zunhua Peoples Hosp, Dept Internal Med, 316 Huaming,Rd, Zunhua 064200, Hebei, Peoples R China.
EM tech_ol@foxmail.com; jhzhang_sc@sina.com
RI Liu, Xiaohui/CAG-5979-2022; meng, meng/KHW-8303-2024
FU National Natural Science Foundation of China [81301779]
FX The present study was partially supported by the National Natural
   Science Foundation of China (grant no. 81301779).
CR Akhavan-Niaki H, 2013, CELL BIOCHEM BIOPHYS, V67, P501, DOI 10.1007/s12013-013-9555-2
   Ansurudeen I, 2009, MOL CELL ENDOCRINOL, V300, P66, DOI 10.1016/j.mce.2008.11.020
   ANTEQUERA F, 1993, P NATL ACAD SCI USA, V90, P11995, DOI 10.1073/pnas.90.24.11995
   Bergman Y, 2013, NAT STRUCT MOL BIOL, V20, P274, DOI 10.1038/nsmb.2518
   Caffarelli E, 2011, FRONT BIOSCI-LANDMRK, V16, P2682, DOI 10.2741/3880
   Chen HC, 2003, J CELL BIOL, V160, P189, DOI 10.1083/jcb.200211046
   Chen KH, 2004, NAT CELL BIOL, V6, P872, DOI 10.1038/ncb1161
   Chik F, 2011, CARCINOGENESIS, V32, P224, DOI 10.1093/carcin/bgq221
   Coppedè F, 2014, EXPERT REV GASTROENT, V8, P935, DOI 10.1586/17474124.2014.924397
   DeSantis CE, 2014, CA-CANCER J CLIN, V64, P252, DOI 10.3322/caac.21235
   Duffy MJ, 2009, EUR J CANCER, V45, P335, DOI 10.1016/j.ejca.2008.12.008
   Fojo T, 2007, DRUG RESIST UPDATE, V10, P59, DOI 10.1016/j.drup.2007.02.002
   Gnyszka A, 2013, ANTICANCER RES, V33, P2989
   Guo Y, 2002, ONCOGENE, V21, P7545, DOI 10.1038/sj.onc.1205907
   Jin BY, 2011, MED ONCOL, V28, pS373, DOI 10.1007/s12032-010-9662-5
   Jones PA, 2012, NAT REV GENET, V13, P484, DOI 10.1038/nrg3230
   Kannan A, 2016, CLIN CANCER RES, V22, P3348, DOI 10.1158/1078-0432.CCR-15-2456
   Kanwal R, 2012, CLIN GENET, V81, P303, DOI 10.1111/j.1399-0004.2011.01809.x
   Karbowski M, 2002, J CELL BIOL, V159, P931, DOI 10.1083/jcb.200209124
   Lee S, 2015, SCI REP-UK, V5, DOI 10.1038/srep08020
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lorenowicz MJ, 2008, EUR J CELL BIOL, V87, P779, DOI 10.1016/j.ejcb.2008.05.004
   Lou YQ, 2016, TUMOR BIOL, V37, P8643, DOI 10.1007/s13277-015-4702-6
   Lou YQ, 2015, MED ONCOL, V32, DOI 10.1007/s12032-015-0515-0
   Ma L, 2013, INT J ONCOL, V42, P1993, DOI 10.3892/ijo.2013.1903
   Martini CN, 2009, MOL CELL ENDOCRINOL, V298, P42, DOI 10.1016/j.mce.2008.10.023
   McConnachie G, 2006, TRENDS MOL MED, V12, P317, DOI 10.1016/j.molmed.2006.05.008
   Milavetz BI, 2015, METHODS MOL BIOL, V1238, P569, DOI 10.1007/978-1-4939-1804-1_30
   Omar B, 2009, CELL SIGNAL, V21, P760, DOI 10.1016/j.cellsig.2009.01.015
   Rehman J, 2012, FASEB J, V26, P2175, DOI 10.1096/fj.11-196543
   Rojo M, 2002, J CELL SCI, V115, P1663
   Santel A, 2001, J CELL SCI, V114, P867
   Sorianello E, 2012, CARDIOVASC RES, V94, P38, DOI 10.1093/cvr/cvs006
   Stefansson OA, 2011, EPIGENETICS-US, V6, P638, DOI 10.4161/epi.6.5.15667
   Tada M, 2008, CLIN CANCER RES, V14, P3768, DOI 10.1158/1078-0432.CCR-07-1181
   Tost J, 2011, EPIGENETICS-US, V6, P1035, DOI 10.4161/epi.6.8.16077
   Vucic EA, 2008, PHARMACOGENOMICS, V9, P215, DOI 10.2217/14622416.9.2.215
   Wang WL, 2013, FRONT BIOSCI-LANDMRK, V18, P1141, DOI 10.2741/4169
   Wang WL, 2012, BIOCHEM BIOPH RES CO, V421, P355, DOI 10.1016/j.bbrc.2012.04.015
   Wang WL, 2010, ONCOL REP, V24, P183, DOI 10.3892/or_00000844
   Wu YY, 2015, METHODS MOL BIOL, V1238, P425, DOI 10.1007/978-1-4939-1804-1_23
   Xia Y, 2008, J HUAZHONG U SCI-MED, V28, P185, DOI 10.1007/s11596-008-0218-2
   Xia Yun, 2007, Ai Zheng, V26, P815
   Xu JH, 2010, BREAST CANCER RES TR, V120, P593, DOI 10.1007/s10549-009-0422-1
   Yoo CB, 2006, NAT REV DRUG DISCOV, V5, P37, DOI 10.1038/nrd1930
   Zhang DD, 2012, MICROVASC RES, V84, P286, DOI 10.1016/j.mvr.2012.06.010
   Zhang GE, 2013, INT J MOL SCI, V14, P13005, DOI 10.3390/ijms140713005
   [Zhou Wei 周炜], 2010, [中国组织工程研究与临床康复, Journal of Clinical Rehabilitative Tissue Engineering Research], V14, P1322
   Zhou XH, 2016, CANCER SCI, V107, P424, DOI 10.1111/cas.12904
NR 49
TC 20
Z9 23
U1 0
U2 9
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1792-1074
EI 1792-1082
J9 ONCOL LETT
JI Oncol. Lett.
PD MAY
PY 2018
VL 15
IS 5
BP 8011
EP 8018
DI 10.3892/ol.2018.8314
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA GF3DN
UT WOS:000431825900252
PM 29731912
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU Qin, CD
   Ma, DN
   Zhang, SZ
   Zhang, N
   Ren, ZG
   Zhu, XD
   Jia, QA
   Chai, ZT
   Wang, CH
   Sun, HC
   Tang, ZY
AF Qin, Cheng-Dong
   Ma, De-Ning
   Zhang, Shi-Zhe
   Zhang, Ning
   Ren, Zheng-Gang
   Zhu, Xiao-Dong
   Jia, Qing-An
   Chai, Zong-Tao
   Wang, Cheng-Hao
   Sun, Hui-Chuan
   Tang, Zhao-You
TI The Rho GTPase Rnd1 inhibits epithelial-mesenchymal transition in
   hepatocellular carcinoma and is a favorable anti-metastasis target
SO CELL DEATH & DISEASE
LA English
DT Article
ID BREAST-CANCER CELLS; EPIGENETIC MODIFICATIONS; MOLECULAR INSIGHTS;
   EXPRESSION; SORAFENIB; ACTIVATION; OUTCOMES; PATHWAY; KINASE; EMT
AB Rnd1, a member of Rho GTPases, was found to be downregulated in human malignancies and downregulation of Rnd1 promotes tumor invasion via various mechanisms. However, the role of Rnd1 in hepatocellular carcinoma (HCC) progression remains unclear. In this study, our results demonstrated that Rnd1 was downregulated in HCC cells and in human HCC tissues. Low expression of Rnd1 was associated with aggressive clinic-pathologic characteristics, such as vascular invasion, and poor prognosis in patients who underwent curative surgery for HCC. Overexpression of Rnd1-suppressed cell growth, migration, invasion, and EMT processes in vitro and in vivo. Furthermore, Rnd1 blocked HCC progression by restricting EMT process through inhibition of the Raf/MEK/ERK cascade, and this was correlated with a reduction in RhoA activity. Combination of Rnd1 overexpression with sorafenib, a Raf signaling pathway inhibitor, showed a more potent inhibition on HCC metastasis. Moreover, epigenetic inhibitors (5-Aza and SAHA) increased the expression of Rnd1, and potentiated sorafenib-induced toxicity in HCC cells. In a conclusion, Rnd1-suppressed EMT-mediated metastasis of HCC by reducing the activity of the RhoA/Raf/MEK/ERK signaling pathway, functioning as a favorable anti-metastasis target for HCC patients. Rnd1 overexpression in combination with sorafenib may result in enhanced anti-metastasis efficacy in HCC.
C1 [Qin, Cheng-Dong] Zhejiang Canc Hosp, Dept Breast Surg, 1 Banshan East Rd, Hangzhou 310022, Zhejiang, Peoples R China.
   [Ma, De-Ning] Zhejiang Canc Hosp, Dept Colorectal Canc Surg, 1 Banshan East Rd, Hangzhou 310022, Zhejiang, Peoples R China.
   [Zhang, Shi-Zhe; Ren, Zheng-Gang; Zhu, Xiao-Dong; Sun, Hui-Chuan; Tang, Zhao-You] Fudan Univ, Liver Canc Inst, Zhongshan Hosp, Key Lab Carcinogenesis & Canc Invas,Minist Educ, 179 Fenglin Rd, Shanghai 200032, Peoples R China.
   [Zhang, Ning; Wang, Cheng-Hao] Shanghai Canc Ctr, Liver Surgey Dept, 270 Dongan Rd, Shanghai 200032, Peoples R China.
   [Jia, Qing-An] Xi An Jiao Tong Univ, Dept Hepatobiliary Surg, Affiliated Hosp 1, Xian 710061, Shaanxi, Peoples R China.
   [Chai, Zong-Tao] Second Mil Med Univ, Eastern Hepatobiliary Surg Hosp, Dept Hepat Surg, Shanghai 200433, Peoples R China.
C3 Zhejiang Cancer Hospital; Zhejiang Cancer Hospital; Fudan University;
   Xi'an Jiaotong University; Naval Medical University
RP Tang, ZY (通讯作者)，Fudan Univ, Liver Canc Inst, Zhongshan Hosp, Key Lab Carcinogenesis & Canc Invas,Minist Educ, 179 Fenglin Rd, Shanghai 200032, Peoples R China.
EM zytang88@163.com
RI Zhang, Ning/J-8879-2015; Li, Guoliang/M-6614-2014
OI Sun, Hui-Chuan/0000-0003-3761-7058
FU National Natural Science Foundation of China [81372655]; China National
   Key Projects for Infectious Disease [2012ZX10002-012]
FX This work was supported by the National Natural Science Foundation of
   China [grant number 81372655] and the China National Key Projects for
   Infectious Disease [grant number 2012ZX10002-012].
CR Aguirre AJ, 2004, P NATL ACAD SCI USA, V101, P9067, DOI 10.1073/pnas.0402932101
   Bist P, 2015, BIOCHEM BIOPH RES CO, V461, P47, DOI 10.1016/j.bbrc.2015.03.166
   Chang RM, 2014, HEPATOLOGY, V60, P1251, DOI 10.1002/hep.27221
   Delire B, 2015, EUR J CLIN INVEST, V45, P609, DOI 10.1111/eci.12441
   El-Serag HB, 2011, NEW ENGL J MED, V365, P1118, DOI 10.1056/NEJMra1001683
   Ellenbroek SIJ, 2007, CLIN EXP METASTAS, V24, P657, DOI 10.1007/s10585-007-9119-1
   Flavahan WA, 2017, SCIENCE, V357, DOI 10.1126/science.aal2380
   Gao Q, 2012, CANCER RES, V72, P3546, DOI 10.1158/0008-5472.CAN-11-4032
   Gilkes DM, 2014, P NATL ACAD SCI USA, V111, pE384, DOI 10.1073/pnas.1321510111
   Heerboth S, 2015, CLIN TRANSL MED, V4, DOI 10.1186/s40169-015-0048-3
   Huang XY, 2013, HEPATOLOGY, V57, P2235, DOI 10.1002/hep.26255
   Jaffe AB, 2005, ANNU REV CELL DEV BI, V21, P247, DOI 10.1146/annurev.cellbio.21.020604.150721
   Jemal Ahmedin, 2011, CA Cancer J Clin, V61, P69, DOI 10.3322/caac.20107
   Jia Y, 2015, ARCH ORAL BIOL, V60, P488, DOI 10.1016/j.archoralbio.2014.12.009
   Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104
   Kaowinn S, 2017, ONCOTARGET, V8, P5092, DOI 10.18632/oncotarget.13867
   Komatsu H, 2017, ANN SURG ONCOL, V24, P850, DOI 10.1245/s10434-016-5573-9
   Li Xiang, 2014, ScientificWorldJournal, V2014, P540496, DOI 10.1155/2014/540496
   Li Y, 2001, WORLD J GASTROENTERO, V7, P630
   Lin CC, 2013, CELL COMMUN SIGNAL, V11, DOI 10.1186/1478-811X-11-8
   Lin KT, 2016, ONCOGENE, V35, P5078, DOI 10.1038/onc.2016.62
   Lin Y, 2016, ORAL ONCOL, V60, P81, DOI 10.1016/j.oraloncology.2016.06.010
   Liu L, 2006, CANCER RES, V66, P11851, DOI 10.1158/0008-5472.CAN-06-1377
   Lu L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065023
   Ma DN, 2016, J HEMATOL ONCOL, V9, DOI 10.1186/s13045-015-0229-y
   Morris HT, 2015, BRIT J CANCER, V112, P613, DOI 10.1038/bjc.2014.658
   Nevins JR, 2007, NAT REV GENET, V8, P601, DOI 10.1038/nrg2137
   Nguyen Lan K, 2018, Small GTPases, V9, P316, DOI 10.1080/21541248.2016.1224399
   Oinuma I, 2003, J BIOL CHEM, V278, P25671, DOI 10.1074/jbc.M303047200
   Okada T, 2015, NAT CELL BIOL, V17, P81, DOI 10.1038/ncb3082
   Orgaz Jose L, 2014, Small GTPases, V5, pe29019, DOI 10.4161/sgtp.29019
   Porter Andrew P, 2016, Small GTPases, V7, P123, DOI 10.1080/21541248.2016.1173767
   Prieto-García E, 2017, MED ONCOL, V34, DOI 10.1007/s12032-017-0980-8
   Puisieux A, 2014, NAT CELL BIOL, V16, P488, DOI 10.1038/ncb2976
   Reffay M, 2014, NAT CELL BIOL, V16, P217, DOI 10.1038/ncb2917
   Riento K, 2003, NAT REV MOL CELL BIO, V4, P446, DOI 10.1038/nrm1128
   Rutherford S, 2005, LAB INVEST, V85, P1076, DOI 10.1038/labinvest.3700314
   Shindoh J, 2013, HPB, V15, P31, DOI 10.1111/j.1477-2574.2012.00552.x
   Vaiopoulos AG, 2014, BBA-MOL BASIS DIS, V1842, P971, DOI 10.1016/j.bbadis.2014.02.006
   Valastyan S, 2011, CELL, V147, P275, DOI 10.1016/j.cell.2011.09.024
   Amerongen GPV, 2007, ARTERIOSCL THROM VAS, V27, P2332, DOI 10.1161/ATVBAHA.107.152322
   Wang SC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101330
   Xiong W, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-219
   Yen CY, 2016, CANCER LETT, V373, P185, DOI 10.1016/j.canlet.2016.01.036
   Yeramian A, 2013, ONCOGENE, V32, P403, DOI 10.1038/onc.2012.76
   Zhang W, 2012, GASTROENTEROLOGY, V143, P1641, DOI 10.1053/j.gastro.2012.08.032
   Zhang Z, 2014, ONCOGENE, V33, P3374, DOI 10.1038/onc.2013.337
NR 47
TC 18
Z9 20
U1 0
U2 9
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 2041-4889
J9 CELL DEATH DIS
JI Cell Death Dis.
PD APR 30
PY 2018
VL 9
AR 486
DI 10.1038/s41419-018-0517-x
PG 18
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA GF2QT
UT WOS:000431785500005
PM 29706627
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU Stanta, G
   Bonin, S
AF Stanta, Giorgio
   Bonin, Serena
TI A Practical Approach to Tumor Heterogeneity in Clinical Research and
   Diagnostics
SO PATHOBIOLOGY
LA English
DT Article
DE Intratumor heterogeneity; Morphological heterogeneity;
   Genetic/epigenetic heterogeneity; Functional phenotypic plasticity;
   Stochastic plasticity; Cancer spreading; Genomic instability
ID COMPREHENSIVE MOLECULAR CHARACTERIZATION; BREAST-CANCER;
   COLORECTAL-CANCER; MICROSATELLITE INSTABILITY; GENETIC-HETEROGENEITY;
   CLONAL EVOLUTION; MUTATIONS; METASTASIS; EXPRESSION; DNA
AB This Pathobiology issue tries to better define the complex phenomenon of intratumor heterogeneity (ITH), mostly from a practical point of view. This topic has been chosen because ITH is a central issue in tumor development and has to be investigated directly in patient tissue and immediately applied in the treatment of the presenting patient. Different types of ITH should be considered: clonal genetic and epigenetic evolution, morphological heterogeneity, and tumor sampling, heterogeneity resulting from microenvironmental autocrine and paracrine interaction, and stochastic plasticity related to different functional cell efficiencies. For a higher level of reproducibility in clinical research and diagnostics, it is necessary to establish standardized analytical methods, including microdissection. In situ techniques can be pivotal to explore tumor microenvironment and can be improved with associated digital analysis. Liquid biopsies for plasma DNA analysis are at present the best method to study recurrent tumors with treatment adaptation, and wide-spread clinical use could be beneficial. The different types of tumor genomic instabilities could have pragmatic applications to rank ITH for clinical applications: treatment approaches differ in patients with a high nucleotide mutation rate and patients with high copy number alterations. (C) 2017 S. Karger AG, Basel.
C1 [Stanta, Giorgio; Bonin, Serena] Univ Trieste, Dept Med Sci DSM, Trieste, Italy.
C3 University of Trieste
RP Stanta, G (通讯作者)，Cattinara Hosp, Str Fiume 447, IT-34149 Trieste, Italy.
EM stanta@impactsnetwork.eu
RI Bonin, Serena/C-9332-2015
CR Abeshouse A, 2015, CELL, V163, P1011, DOI 10.1016/j.cell.2015.10.025
   Alamgeer M, 2013, CURR OPIN PHARMACOL, V13, P394, DOI 10.1016/j.coph.2013.03.010
   [Anonymous], 2013, ECONOMIST, V8858, P26
   Bardelli A, 2015, PRECISION MED CANC
   Bass AJ, 2014, NATURE, V513, P202, DOI 10.1038/nature13480
   Boland CR, 1998, CANCER RES, V58, P5248
   Bonin S, 2015, VIRCHOWS ARCH, V466, P571, DOI 10.1007/s00428-015-1748-1
   Brannon AR, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0454-7
   Briggs S, 2013, J PATHOL, V230, P148, DOI 10.1002/path.4185
   Burga A, 2011, NATURE, V480, P250, DOI 10.1038/nature10665
   Burrell RA, 2014, MOL ONCOL, V8, P1095, DOI 10.1016/j.molonc.2014.06.005
   Burrell RA, 2013, NATURE, V501, P338, DOI 10.1038/nature12625
   Campbell PJ, 2010, NATURE, V467, P1109, DOI 10.1038/nature09460
   Carethers JM, 2015, GENES-BASEL, V6, P185, DOI 10.3390/genes6020185
   Chan JY, 2011, INT J BIOL SCI, V7, P1122, DOI 10.7150/ijbs.7.1122
   Chien J, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00251
   Christensen E, 2017, EUR UROL, V71, P961, DOI 10.1016/j.eururo.2016.12.016
   Collisson EA, 2014, NATURE, V511, P543, DOI 10.1038/nature13385
   Comen EA, 2012, DISCOV MED, V14, P97
   Creighton CJ, 2013, NATURE, V499, P43, DOI 10.1038/nature12222
   Cummings MC, 2014, J PATHOL, V232, P23, DOI 10.1002/path.4288
   Diehl F, 2008, NAT MED, V14, P985, DOI 10.1038/nm.1789
   Donada M, 2013, BMC GASTROENTEROL, V13, DOI 10.1186/1471-230X-13-36
   Donnelly N, 2014, EMBO J, V33, P2374, DOI 10.15252/embj.201488648
   Douillard JY, 2014, BRIT J CANCER, V110, P55, DOI 10.1038/bjc.2013.721
   Douillard JY, 2014, J THORAC ONCOL, V9, P1345, DOI 10.1097/JTO.0000000000000263
   Dunn GP, 2002, NAT IMMUNOL, V3, P991, DOI 10.1038/ni1102-991
   Espinosa I, 2014, MODERN PATHOL, V27, P631, DOI 10.1038/modpathol.2013.131
   Fenizia F, 2015, FUTURE ONCOL, V11, P1611, DOI 10.2217/fon.15.23
   Gainor JF, 2013, J CLIN ONCOL, V31, P3987, DOI 10.1200/JCO.2012.45.2029
   Gerlinger M, 2014, NAT GENET, V46, P225, DOI 10.1038/ng.2891
   Gerlinger M, 2012, NEW ENGL J MED, V366, P883, DOI 10.1056/NEJMoa1113205
   Getz G, 2013, NATURE, V497, P67, DOI 10.1038/nature12113
   Godinho SA, 2014, PHILOS T R SOC B, V369, DOI 10.1098/rstb.2013.0467
   Gomez D, 2013, NAT METHODS, V10, P171, DOI [10.1038/NMETH.2332, 10.1038/nmeth.2332]
   Gooden MJM, 2011, BRIT J CANCER, V105, P93, DOI 10.1038/bjc.2011.189
   Gundem G, 2015, NATURE, V520, P353, DOI 10.1038/nature14347
   Haffner MC, 2013, J CLIN INVEST, V123, P4918, DOI 10.1172/JCI70354
   Hieronymus H, 2014, P NATL ACAD SCI USA, V111, P11139, DOI 10.1073/pnas.1411446111
   Hlubek F, 2007, INT J CANCER, V121, P1941, DOI 10.1002/ijc.22916
   Jass JR, 2007, HISTOPATHOLOGY, V50, P113, DOI 10.1111/j.1365-2559.2006.02549.x
   Jia M, 2016, CLIN EPIGENETICS, V8, DOI 10.1186/s13148-016-0191-8
   Kandoth C, 2013, NATURE, V502, P333, DOI 10.1038/nature12634
   Klement GL, 2016, ONCOTARGET, V7, P46813, DOI 10.18632/oncotarget.9488
   Kleppe M, 2014, NAT MED, V20, P342, DOI 10.1038/nm.3522
   Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412
   Kuukasjarvi T, 1997, CANCER RES, V57, P1597
   Landau DA, 2013, CELL, V152, P714, DOI 10.1016/j.cell.2013.01.019
   Le DT, 2015, NEW ENGL J MED, V372, P2509, DOI 10.1056/NEJMoa1500596
   Li GW, 2011, NATURE, V475, P308, DOI 10.1038/nature10315
   Liu L, 2015, CLIN CANCER RES, V21, P1639, DOI 10.1158/1078-0432.CCR-14-2339
   Mantovani A, 2010, CURR OPIN IMMUNOL, V22, P231, DOI 10.1016/j.coi.2010.01.009
   Marusyk A, 2014, NATURE, V514, P54, DOI 10.1038/nature13556
   Marusyk A, 2012, NAT REV CANCER, V12, P323, DOI 10.1038/nrc3261
   McBride M, 2015, MOL ASPECTS MED, V45, P3, DOI 10.1016/j.mam.2015.05.001
   Mengersen K., 2015, ESSENTIAL GUIDE N OF, P135
   Misale S, 2012, NATURE, V486, P532, DOI 10.1038/nature11156
   Mohn Fabio, 2009, V507, P55, DOI 10.1007/978-1-59745-522-0_5
   Müller MF, 2016, VIRCHOWS ARCH, V469, P125, DOI 10.1007/s00428-016-1956-3
   Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252
   Paek AL, 2016, CELL, V165, P631, DOI 10.1016/j.cell.2016.03.025
   Parsons HA, 2016, ADV EXP MED BIOL, V882, P259, DOI 10.1007/978-3-319-22909-6_11
   Patel SP, 2015, MOL CANCER THER, V14, P847, DOI 10.1158/1535-7163.MCT-14-0983
   Berbegall AP, 2011, GUIDELINES FOR MOLECULAR ANALYSIS IN ARCHIVE TISSUES, P215, DOI 10.1007/978-3-642-17890-0_33
   Ragusa M, 2015, WORLD J GASTROENTERO, V21, P11709, DOI 10.3748/wjg.v21.i41.11709
   Rashid A, 2004, GASTROENTEROLOGY, V127, P1578, DOI 10.1053/j.gastro.2004.09.007
   Russnes HG, 2011, J CLIN INVEST, V121, P3810, DOI 10.1172/JCI57088
   Santaguida S, 2015, NAT REV MOL CELL BIO, V16, P473, DOI 10.1038/nrm4025
   Schito L, 2012, P NATL ACAD SCI USA, V109, pE2707, DOI 10.1073/pnas.1214019109
   Schwaederle M, 2015, MOL CANCER THER, V14, P1488, DOI 10.1158/1535-7163.MCT-14-1061
   Seufferlein T, 1999, GASTROENTEROLOGY, V116, P1441, DOI 10.1016/S0016-5085(99)70509-3
   Spencer SL, 2009, NATURE, V459, P428, DOI 10.1038/nature08012
   Stanta G, 2016, VIRCHOWS ARCH, V469, P371, DOI 10.1007/s00428-016-1987-9
   Stanta Giorgio, 2015, Recent Results Cancer Res, V199, P35, DOI 10.1007/978-3-319-13957-9_4
   Suzuki H, 2014, BIOCHEM BIOPH RES CO, V455, P35, DOI 10.1016/j.bbrc.2014.07.007
   Talmadge JE, 2010, CANCER RES, V70, P5649, DOI 10.1158/0008-5472.CAN-10-1040
   Tang J, 2015, METHODS MOL BIOL, V1238, P653, DOI 10.1007/978-1-4939-1804-1_34
   Tang YC, 2011, CELL, V144, P499, DOI 10.1016/j.cell.2011.01.017
   Thirlwell C, 2010, GASTROENTEROLOGY, V138, P1441, DOI 10.1053/j.gastro.2010.01.033
   Toledo RA, 2017, ONCOTARGET, V8, P35289, DOI 10.18632/oncotarget.13311
   Tseng-Rogenski SS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050616
   Turajlic S, 2016, SCIENCE, V352, P169, DOI 10.1126/science.aaf2784
   Uzilov AV, 2016, GENOME MED, V8, DOI 10.1186/s13073-016-0313-0
   van Gool IC, 2015, CLIN CANCER RES, V21, P3347, DOI 10.1158/1078-0432.CCR-15-0057
   Vilar E, 2012, NATURE, V486, P482, DOI 10.1038/486482a
   Wang J, 2017, CLIN TRANSL MED, V6, DOI 10.1186/s40169-017-0139-4
   Wang Y, 2014, NATURE, V512, P155, DOI 10.1038/nature13600
   Weinstein JN, 2014, NATURE, V507, P315, DOI 10.1038/nature12965
   Williams BR, 2008, SCIENCE, V322, P703, DOI 10.1126/science.1160058
   Wilmott JS, 2012, CLIN CANCER RES, V18, P1386, DOI 10.1158/1078-0432.CCR-11-2479
   Yamada K, 2010, ONCOL REP, V23, P551, DOI 10.3892/or_00000669
   Yamamoto H, 2015, ARCH TOXICOL, V89, P899, DOI 10.1007/s00204-015-1474-0
   Yao ZX, 2014, MED ONCOL, V31, DOI 10.1007/s12032-013-0798-y
   Yates LR, 2015, NAT MED, V21, P751, DOI 10.1038/nm.3886
NR 94
TC 11
Z9 12
U1 0
U2 4
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 1015-2008
EI 1423-0291
J9 PATHOBIOLOGY
JI Pathobiology
PY 2018
VL 85
IS 1-2
BP 7
EP 17
DI 10.1159/000477813
PG 11
WC Cell Biology; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Pathology
GA GF1QI
UT WOS:000431709300002
PM 28750401
OA Bronze, Green Published
DA 2025-01-12
ER

PT J
AU Zhang, Y
   Yang, YL
   Zhang, FL
   Liao, XH
   Shao, ZM
   Li, DQ
AF Zhang, Ye
   Yang, Yin-Long
   Zhang, Fang-Lin
   Liao, Xiao-Hong
   Shao, Zhi-Min
   Li, Da-Qiang
TI Epigenetic silencing of RNF144A expression in breast cancer cells
   through promoter hypermethylation and MBD4
SO CANCER MEDICINE
LA English
DT Article
DE Breast cancer; DNA methylation; epigenetic regulation; MBD4; RNF 144A
ID BINDING DOMAIN PROTEINS; DNA METHYLATION; PARKINSONS-DISEASE; UBIQUITIN
   LIGASES; BRCA1 PROMOTER; METASTASIS; EPIGENOME; TARGETS; FAMILY
AB Emerging evidence shows that ring finger protein 144A (RNF144A), a poorly characterized member of the Ring-between-Ring (RBR) family of E3 ubiquitin ligases, is a potential tumor suppressor gene. However, its regulatory mechanism in breast cancer remains undefined. Here, we report that RNF144A promoter contains a putative CpG island and the methylation levels of RNF144A promoter are higher in primary breast tumors than those in normal breast tissues. Consistently, RNF144A promoter methylation levels are associated with its transcriptional silencing in breast cancer cells, and treatment with DNA methylation inhibitor 5-Aza-2-deoxycytidine (AZA) reactivates RNF144A expression in cells with RNF144A promoter hypermethylation. Furthermore, genetic knockdown or pharmacological inhibition of endogenous methyl-CpG-binding domain 4 (MBD4) results in increased RNF144A expression. These findings suggest that RNF144A is epigenetically silenced in breast cancer cells by promoter hypermethylation and MBD4.
C1 [Zhang, Ye; Yang, Yin-Long; Zhang, Fang-Lin; Liao, Xiao-Hong; Shao, Zhi-Min; Li, Da-Qiang] Fudan Univ, Shanghai Med Coll, Shanghai Canc Ctr, Shanghai 200032, Peoples R China.
   [Zhang, Ye; Yang, Yin-Long; Zhang, Fang-Lin; Liao, Xiao-Hong; Shao, Zhi-Min; Li, Da-Qiang] Fudan Univ, Shanghai Med Coll, Inst Biomed Sci, Shanghai 200032, Peoples R China.
   [Yang, Yin-Long; Zhang, Fang-Lin; Liao, Xiao-Hong; Shao, Zhi-Min; Li, Da-Qiang] Fudan Univ, Shanghai Med Coll, Shanghai Canc Ctr, Dept Oncol, Shanghai 200032, Peoples R China.
   [Yang, Yin-Long; Zhang, Fang-Lin; Liao, Xiao-Hong; Shao, Zhi-Min; Li, Da-Qiang] Fudan Univ, Shanghai Med Coll, Shanghai Canc Ctr, Canc Inst, Shanghai 200032, Peoples R China.
   [Yang, Yin-Long; Shao, Zhi-Min; Li, Da-Qiang] Fudan Univ, Shanghai Med Coll, Shanghai Canc Ctr, Dept Breast Surg, Shanghai 200032, Peoples R China.
   [Yang, Yin-Long; Shao, Zhi-Min; Li, Da-Qiang] Fudan Univ, Shanghai Med Coll, Key Lab Breast Canc Shanghai, Shanghai 200032, Peoples R China.
C3 Fudan University; Fudan University; Fudan University; Fudan University;
   Fudan University; Fudan University
RP Shao, ZM; Li, DQ (通讯作者)，Fudan Univ, Shanghai Med Coll, Shanghai Canc Ctr, Shanghai 200032, Peoples R China.; Shao, ZM; Li, DQ (通讯作者)，Fudan Univ, Shanghai Med Coll, Inst Biomed Sci, Shanghai 200032, Peoples R China.
EM zhimingshao@yahoo.com; daqiangli1974@fudan.edu.cn
RI Yang, Yinlong/GLR-7377-2022
FU National Natural Science Foundation of China [81572584]; Program for
   Professor of Special Appointment (Eastern Scholar) at Shanghai
   Institutions of Higher Learning, Shanghai Municipal Education Commission
   [2013-06]; New Investigator Start-up Fund from Fudan University
FX This work was supported by the National Natural Science Foundation of
   China (No. 81572584), the Program for Professor of Special Appointment
   (Eastern Scholar) at Shanghai Institutions of Higher Learning, Shanghai
   Municipal Education Commission (No. 2013-06), and New Investigator
   Start-up Fund from Fudan University.
CR Baylin SB, 2011, NAT REV CANCER, V11, P726, DOI 10.1038/nrc3130
   Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102
   Bogdanovic O, 2009, CHROMOSOMA, V118, P549, DOI 10.1007/s00412-009-0221-9
   Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095
   Chimonidou M, 2013, MOL CANCER RES, V11, P1248, DOI 10.1158/1541-7786.MCR-13-0096
   Cunha S, 2014, CELL REP, V6, P141, DOI 10.1016/j.celrep.2013.12.010
   Du Q, 2015, EPIGENOMICS-UK, V7, P1051, DOI 10.2217/epi.15.39
   Eisenhaber B, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-3-209
   Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI [10.1056/NEJMra072067, 10.1093/carcin/bgp220]
   Esteller M, 2007, NAT REV GENET, V8, P286, DOI 10.1038/nrg2005
   Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088
   GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9
   Giasson BI, 2001, NEURON, V31, P885, DOI 10.1016/S0896-6273(01)00439-1
   Gilkes DM, 2013, CANCER RES, V73, P3285, DOI 10.1158/0008-5472.CAN-12-3963
   Gonzalo S, 2010, J APPL PHYSIOL, V109, P586, DOI 10.1152/japplphysiol.00238.2010
   Gu F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060980
   Guo JP, 2016, SCIENCE, V353, P929, DOI 10.1126/science.aad5755
   Gupta S, 2014, BREAST CANCER RES TR, V148, P615, DOI 10.1007/s10549-014-3179-0
   Hendrich B, 1998, MOL CELL BIOL, V18, P6538, DOI 10.1128/MCB.18.11.6538
   Ho SR, 2014, P NATL ACAD SCI USA, V111, pE2646, DOI 10.1073/pnas.1323107111
   Issa JP, 2004, NAT REV CANCER, V4, P988, DOI 10.1038/nrc1507
   Iwamoto T, 2011, BREAST CANCER RES TR, V129, P69, DOI 10.1007/s10549-010-1188-1
   Jaenisch R, 2003, NAT GENET, V33, P245, DOI 10.1038/ng1089
   Klose RJ, 2006, TRENDS BIOCHEM SCI, V31, P89, DOI 10.1016/j.tibs.2005.12.008
   Kondo E, 2005, MOL CELL BIOL, V25, P4388, DOI 10.1128/MCB.25.11.4388-4396.2005
   Laget S, 2014, EPIGENETICS-US, V9, P546, DOI 10.4161/epi.27695
   Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427
   Marín I, 2004, PHYSIOL GENOMICS, V17, P253, DOI 10.1152/physiolgenomics.00226.2003
   Martins AT, 2011, BREAST CANCER RES TR, V129, P1, DOI 10.1007/s10549-010-1160-0
   Mizuno Y, 2001, CURR OPIN NEUROL, V14, P477, DOI 10.1097/00019052-200108000-00008
   Qi TG, 2014, MOL CELL PROTEOMICS, V13, P49, DOI 10.1074/mcp.M113.027813
   Rice P, 2000, TRENDS GENET, V16, P276, DOI 10.1016/S0168-9525(00)02024-2
   Sansom OJ, 2007, NAT CLIN PRACT ONCOL, V4, P305, DOI 10.1038/ncponc0812
   Shargh SA, 2014, MED ONCOL, V31, DOI 10.1007/s12032-014-0250-y
   Spratt DE, 2014, BIOCHEM J, V458, P421, DOI 10.1042/BJ20140006
   Tost J, 2007, NAT PROTOC, V2, P2265, DOI 10.1038/nprot.2007.314
   Wu CY, 2016, MOL CELL BIOL, V36, P1555, DOI 10.1128/MCB.00004-16
   Xiang TX, 2013, CHIN J CANCER, V32, P12, DOI 10.5732/cjc.011.10344
   Yamashita N, 2015, CLIN BREAST CANCER, V15, P498, DOI 10.1016/j.clbc.2015.06.009
   Zhang Y, 2017, ONCOTARGET, V8, P94505, DOI 10.18632/oncotarget.21784
NR 40
TC 14
Z9 17
U1 2
U2 9
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2045-7634
J9 CANCER MED-US
JI Cancer Med.
PD APR
PY 2018
VL 7
IS 4
BP 1317
EP 1325
DI 10.1002/cam4.1324
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA GD7BI
UT WOS:000430663300036
PM 29473320
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Chen, X
   Gu, JH
   Wang, X
   Jung, JG
   Wang, TL
   Hilakivi-Clarke, L
   Clarke, R
   Xuan, JH
AF Chen, Xi
   Gu, Jinghua
   Wang, Xiao
   Jung, Jin-Gyoung
   Wang, Tian-Li
   Hilakivi-Clarke, Leena
   Clarke, Robert
   Xuan, Jianhua
TI CRNET: an efficient sampling approach to infer functional regulatory
   networks by integrating large-scale ChIP-seq and time-course RNA-seq
   data
SO BIOINFORMATICS
LA English
DT Article
ID RECONSTRUCTION; TRANSCRIPTOME
AB Motivation: NGS techniques have been widely applied in genetic and epigenetic studies. Multiple ChIP-seq and RNA-seq profiles can now be jointly used to infer functional regulatory networks (FRNs). However, existing methods suffer from either oversimplified assumption on transcription factor (TF) regulation or slow convergence of sampling for FRN inference from large-scale ChIPseq and time-course RNA-seq data.
   Results: We developed an efficient Bayesian integration method (CRNET) for FRN inference using a two-stage Gibbs sampler to estimate iteratively hidden TF activities and the posterior probabilities of binding events. A novel statistic measure that jointly considers regulation strength and regression error enables the sampling process of CRNET to converge quickly, thus making CRNET very efficient for large-scale FRN inference. Experiments on synthetic and benchmark data showed a significantly improved performance of CRNET when compared with existing methods. CRNET was applied to breast cancer data to identify FRNs functional at promoter or enhancer regions in breast cancer MCF-7 cells. Transcription factor MYC is predicted as a key functional factor in both promoter and enhancer FRNs. We experimentally validated the regulation effects of MYC on CRNET-predicted target genes using appropriate RNAi approaches in MCF-7 cells.
C1 [Chen, Xi; Gu, Jinghua; Wang, Xiao; Xuan, Jianhua] Virginia Polytech Inst & State Univ, Bradley Dept Elect & Comp Engn, Arlington, VA 22203 USA.
   [Jung, Jin-Gyoung; Wang, Tian-Li] Johns Hopkins Med Inst, Dept Pathol, Baltimore, MD 21231 USA.
   [Hilakivi-Clarke, Leena; Clarke, Robert] Georgetown Univ, Dept Oncol, Med Ctr, Lombardi Comprehens Canc Ctr, Washington, DC 20057 USA.
C3 Virginia Polytechnic Institute & State University; Johns Hopkins
   University; Johns Hopkins Medicine; Georgetown University
RP Xuan, JH (通讯作者)，Virginia Polytech Inst & State Univ, Bradley Dept Elect & Comp Engn, Arlington, VA 22203 USA.
EM xuan@vt.edu
RI Chen, Xi/I-9399-2019; Clarke, Robert/A-6485-2008
OI Clarke, Robert/0000-0002-9278-0854
FU National Institutes of Health [CA149653, CA149147, CA184902, CA164384,
   CA148826, CA187512]
FX This work was supported in part by the National Institutes of Health
   (CA149653 to J.X., CA149147 & CA184902 to R.C., CA164384 to L, H.-C.,
   CA148826 & CA187512 to T.-L. W.).
CR Angelini C, 2014, FRONT CELL DEV BIOL, V2, DOI 10.3389/fcell.2014.00051
   Chen G, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-1-r4
   Chen X, 2016, NUCLEIC ACIDS RES, V44, DOI 10.1093/nar/gkv1491
   Chen X, 2013, IEEE ACM T COMPUT BI, V10, P1347, DOI 10.1109/TCBB.2012.146
   Cusanovich DA, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004226
   Dunning MJ, 2007, BIOINFORMATICS, V23, P2183, DOI 10.1093/bioinformatics/btm311
   GELmAN A., 1992, Statistical science, V7, P157
   Gu JH, 2012, BIOINFORMATICS, V28, P1990, DOI 10.1093/bioinformatics/bts296
   Huynh-Thu VA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012776
   Karlebach G, 2008, NAT REV MOL CELL BIO, V9, P770, DOI 10.1038/nrm2503
   LANGE KL, 1989, J AM STAT ASSOC, V84, P881, DOI 10.2307/2290063
   Li B, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-323
   Li GL, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-S12-S11
   Liao JC, 2003, P NATL ACAD SCI USA, V100, P15522, DOI 10.1073/pnas.2136632100
   Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8
   Marbach D, 2009, J COMPUT BIOL, V16, P229, DOI 10.1089/cmb.2008.09TT
   Phanstiel DH, 2015, BIOINFORMATICS, V31, P3092, DOI 10.1093/bioinformatics/btv336
   Qin J, 2014, METHODS, V67, P294, DOI 10.1016/j.ymeth.2014.03.006
   Ramos AI, 2013, PHILOS T R SOC B, V368, DOI 10.1098/rstb.2013.0018
   Sabatti C, 2006, BIOINFORMATICS, V22, P739, DOI 10.1093/bioinformatics/btk017
   Sanyal A, 2012, NATURE, V489, P109, DOI 10.1038/nature11279
   Schuster SC, 2008, NAT METHODS, V5, P16, DOI 10.1038/NMETH1156
   Servant N, 2015, GENOME BIOL, V16, DOI 10.1186/s13059-015-0831-x
   Spitz F, 2012, NAT REV GENET, V13, P613, DOI 10.1038/nrg3207
   van Berkum Nynke L, 2010, J Vis Exp, DOI 10.3791/1869
   Venet D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051013
   Wang S, 2013, NAT PROTOC, V8, P2502, DOI 10.1038/nprot.2013.150
   Weaver D C, 1999, Pac Symp Biocomput, P112
   Zhang XJ, 2013, BIOINFORMATICS, V29, P106, DOI 10.1093/bioinformatics/bts619
   Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r137
   Zhao F, 2005, NUCLEIC ACIDS RES, V33, pD103, DOI 10.1093/nar/gki004
NR 31
TC 9
Z9 9
U1 0
U2 12
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1367-4803
EI 1460-2059
J9 BIOINFORMATICS
JI Bioinformatics
PD MAY 15
PY 2018
VL 34
IS 10
BP 1733
EP 1740
DI 10.1093/bioinformatics/btx827
PG 8
WC Biochemical Research Methods; Biotechnology & Applied Microbiology;
   Computer Science, Interdisciplinary Applications; Mathematical &
   Computational Biology; Statistics & Probability
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Computer Science; Mathematical & Computational Biology; Mathematics
GA GF7TF
UT WOS:000432170400016
PM 29280996
OA Green Published, Bronze
DA 2025-01-12
ER

PT J
AU El Sherbini, MA
   Mansour, AA
   Sallam, MM
   Shaban, EA
   ElDin, ZAS
   El-Shalakany, AH
AF El Sherbini, Mustafa A.
   Mansour, Amal A.
   Sallam, Maha M.
   Shaban, Emtiaz A.
   ElDin, Zeinab A. Shehab
   El-Shalakany, Amr H.
TI <i>KLK10</i> exon 3 unmethylated PCR product concentration: a new
   potential early diagnostic marker in ovarian cancer? - A pilot study
SO JOURNAL OF OVARIAN RESEARCH
LA English
DT Article
DE Ovarian cancer; CA125; KLK10; KLK6; KLK10 exon 3 methylation
ID CPG ISLAND HYPERMETHYLATION; TUMOR-SUPPRESSOR GENE; DNA METHYLATION;
   BREAST-CANCER; SERINE-PROTEASE; GASTRIC-CANCER; KALLIKREIN-10;
   EXPRESSION; OVEREXPRESSION; BIOMARKER
AB Background: KLK10 exon 3 hypermethylation correlated to tumor-specific lack of KLK10 expression in cancer cell lines and primary tumors. In the present study we investigate the possible role of KLK10 exon 3 methylation in ovarian tumor diagnosis and prognosis.
   Results: Qualitative methylation-specific PCR (MSP) results did not show statistically significant differences in patient group samples (normal and tumor) where all samples were positive only for the unmethylated-specific PCR except for two malignant samples that were either doubly positive (serous carcinoma) or doubly negative (Sertoli-Leydig cell tumor) for the two MSP tests. However, KLK10 exon 3 unmethylated PCR product concentration (ng/mu l) showed statistically significant differences in benign and malignant patient group samples; mean +/- SD (n): tumor: 0.077 +/- 0.035 (14) and 0.047 +/- 0.021 (15), respectively, p-value = 0.011; and normal: 0.094 +/- 0.039 (7) and 0.046 +/- 0.027 (6), respectively, p-value = 0.031. Moreover, ROC curve analysis of KLK10 exon 3 unmethylated PCR product concentration in overall patient group samples showed good diagnostic ability (AUC = 0.778; p-value = 0.002). Patient survival (living and died) showed statistically significant difference according to preoperative serum CA125 concentration (U/ml); median (n): 101.25 (10) and 1252 (5), respectively, p-value = 0.037, but not KLK10 exon 3 unmethylated PCR product concentration (ng/mu l) in overall malignant patient samples; mean +/- SD (n): 0.042 +/- 0.015 (14) and 0.055 +/- 0.032 (7), p-value = 0.228.
   Conclusion: To the best of our knowledge, this is the first report on KLK10 exon 3 unmethylated PCR product concentration as potential early epigenetic diagnostic marker in primary ovarian tumors. Taken into account the limitations in our study (small sample size and semi-quantitative PCR product analysis) further studies are strongly recommended.
EM me_sherbini@yahoo.com
OI El Sherbini, Mustafa/0000-0003-3076-379X
FU Academy of Scientific Research and Technology in Cairo
FX This work was supported in part by cash money grant given once to PhD
   students (MAE) by The Academy of Scientific Research and Technology in
   Cairo. The funding body had no role in the design of the study and
   collection, analysis, and interpretation of data and in writing the
   manuscript.
CR Balgkouranidou I, 2009, 100 ANN M AM ASS CAN, V2009
   Bird A, 1995, J CELL SCI, P37
   BIRD AP, 1993, COLD SPRING HARB SYM, V58, P281, DOI 10.1101/SQB.1993.058.01.033
   Borgoño CA, 2004, NAT REV CANCER, V4, P876, DOI 10.1038/nrc1474
   Chow TFF, 2008, BIOL CHEM, V389, P731, DOI 10.1515/BC.2008.071
   COOPER DN, 1988, HUM GENET, V78, P151, DOI 10.1007/BF00278187
   Costello JF, 2001, J MED GENET, V38, P285, DOI 10.1136/jmg.38.5.285
   Crider KS, 2012, ADV NUTR, V3, P21, DOI 10.3945/an.111.000992
   Dhar S, 2001, CLIN CANCER RES, V7, P3393
   El Sherbini MAH, 2011, INT J GYNECOL CANCER, V21, P625, DOI 10.1097/IGC.0b013e31821283c3
   GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9
   Goyal J, 1998, CANCER RES, V58, P4782
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Horvath S, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-10-r115
   Hu J, 2015, SCI REP, DOI [10.1038/serp17426, DOI 10.1038/SERP17426]
   Huang W, 2008, WORLD J GASTROENTERO, V14, P5810, DOI 10.3748/wjg.14.5810
   Jiao X, 2013, WORLD J GASTROENTERO, V19, P9425, DOI 10.3748/wjg.v19.i48.9425
   Jones PA, 2009, NAT REV GENET, V10, P805, DOI 10.1038/nrg2651
   King LE, 2007, CLIN BIOCHEM, V40, P1057, DOI 10.1016/j.clinbiochem.2007.05.008
   Kioulafa M, 2009, ANN ONCOL, V20, P1020, DOI 10.1093/annonc/mdn733
   Li B, 2001, CANCER RES, V61, P8014
   Liu XL, 1996, CANCER RES, V56, P3371
   Luo LY, 2003, CLIN CHIM ACTA, V337, P115, DOI 10.1016/j.cccn.2003.07.008
   Luo LY, 2001, BRIT J CANCER, V85, P220, DOI 10.1054/bjoc.2001.1870
   Miller CA, 2007, NEURON, V53, P857, DOI 10.1016/j.neuron.2007.02.022
   Miranda TB, 2007, J CELL PHYSIOL, V213, P384, DOI 10.1002/jcp.21224
   Pépin D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026075
   Petraki CD, 2003, PROSTATE CANCER P D, V6, P223, DOI 10.1038/sj.pcan.4500674
   RIDEOUT WM, 1990, SCIENCE, V249, P1288, DOI 10.1126/science.1697983
   Roman-Gomez J, 2004, LEUKEMIA, V18, P362, DOI 10.1038/sj.leu.2403223
   Rückert F, 2008, BRIT J CANCER, V99, P1484, DOI 10.1038/sj.bjc.6604717
   Shaw JLV, 2007, CLIN CHEM, V53, P1423, DOI 10.1373/clinchem.2007.088104
   Shvartsman HS, 2003, GYNECOL ONCOL, V90, P44, DOI 10.1016/S0090-8258(03)00257-9
   Sidiropoulos M, 2005, TUMOR BIOL, V26, P324, DOI 10.1159/000089290
   Talieri M, 2011, TUMOR BIOL, V32, P737, DOI 10.1007/s13277-011-0175-4
   van Vlodrop IJH, 2011, CLIN CANCER RES, V17, P4225, DOI 10.1158/1078-0432.CCR-10-3394
   Wallace K, 2010, CANCER PREV RES, V3, P1552, DOI 10.1158/1940-6207.CAPR-10-0047
   Xu HY, 2013, GENET EPIDEMIOL, V37, P377, DOI 10.1002/gepi.21726
   Yousef GM, 2000, BIOCHEM BIOPH RES CO, V276, P125, DOI 10.1006/bbrc.2000.3448
   Zhang YW, 2010, CANCER SCI, V101, P934, DOI [10.1111/j.1349-7006.2009.01486.x, 10.1111/j.1349-7006.2010.01486.x]
NR 40
TC 2
Z9 2
U1 0
U2 1
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1757-2215
J9 J OVARIAN RES
JI J. Ovarian Res.
PD APR 24
PY 2018
VL 11
AR 32
DI 10.1186/s13048-018-0407-y
PG 10
WC Reproductive Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Reproductive Biology
GA GE1DW
UT WOS:000430958000001
PM 29690914
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU Cui, ZH
   Xie, MJ
   Wu, ZR
   Shi, YJ
AF Cui, Zhuhong
   Xie, Mingjun
   Wu, Zhenru
   Shi, Yujun
TI Relationship Between Histone Deacetylase 3 (HDAC3) and Breast Cancer
SO MEDICAL SCIENCE MONITOR
LA English
DT Article
DE Breast Neoplasms; Histone Deacetylases; Prognosis
ID EXPRESSION; COREPRESSORS; CELLS
AB Background: The modification of histone acetylation and deacetylation is the most important mechanism of chromatin remodeling. These modifications are a subset of epigenetic alterations which affect tumorigenesis and progression through changes in gene expression and cell growth. Results of histone modification studies prompted us to explore the therapeutic and prognostic significance of histone deacetylase 3 (HDAC3) expression in patients with breast cancer.
   Material/Methods: Immunohistochemical (IHC) staining was used to detect HDAC3 expression in a tissue microarray (TMA) that included 145 patients diagnosed with invasive ductal breast carcinoma. IHC scoring was used to evaluate the staining intensity and the proportion of positive cells.
   Results: HDAC3 expression was significantly correlated with estrogen receptor (ER)-negative expression (P=0.036) and progesterone receptor (PR)-negative expression (P=0.024). Additionally, HDAC3 expression was significantly positively correlated with human epidermal growth factor 2 (HER2) overexpression (P=0.037). Our study also indicated that high expression of HDAC3 was more frequently observed in breast tumors with PT2 classification (74%) versus PT1 (50.0%) and PT3 (71.4%) (P=0.040). Furthermore, HDAC3 was correlated with clinical stage II (P=0.046). Univariate and multivariate survival analyses showed that high expression of HDAC3 was correlated with poor overall survival (OS) (P=0.029 and P=0.033, respectively) in patients without lymph node involvement.
   Conclusions: High HDAC3 expression is closely correlated with ER-negative expression, PR-negative expression, HER2 overexpression, PT stage, and clinical stage of breast tumors. HDAC3 may be an appropriate prognostic indicator in patients with invasive ductal breast cancer.
C1 [Cui, Zhuhong; Xie, Mingjun] Southwest Med Univ, Sch Clin Med, Luzhou, Sichuan, Peoples R China.
   [Xie, Mingjun] First Peoples Hosp Yibin, Dept Breast Surg, Yibin, Sichuan, Peoples R China.
   [Wu, Zhenru; Shi, Yujun] Sichuan Univ, West China Hosp, Lab Pathol, Chengdu, Sichuan, Peoples R China.
C3 Southwest Medical University; Sichuan University
RP Xie, MJ (通讯作者)，Southwest Med Univ, Sch Clin Med, Luzhou, Sichuan, Peoples R China.; Xie, MJ (通讯作者)，First Peoples Hosp Yibin, Dept Breast Surg, Yibin, Sichuan, Peoples R China.
EM Xiege003@sina.com
RI Shi, Yujun/U-8819-2019
OI Shi, Yujun/0000-0003-0494-6023
CR Bali P, 2005, CLIN CANCER RES, V11, P6382, DOI 10.1158/1078-0432.CCR-05-0344
   Bhaskara S, 2011, CELL CYCLE, V10, P727, DOI 10.4161/cc.10.5.14866
   Codina A, 2005, P NATL ACAD SCI USA, V102, P6009, DOI 10.1073/pnas.0500299102
   Fortunati N, 2010, MOL CELL ENDOCRINOL, V314, P17, DOI 10.1016/j.mce.2009.09.011
   Gallinari P, 2007, CELL RES, V17, P195, DOI 10.1038/sj.cr.7310149
   Giacinti L, 2006, ONCOLOGIST, V11, P1, DOI 10.1634/theoncologist.11-1-1
   Glozak MA, 2007, ONCOGENE, V26, P5420, DOI 10.1038/sj.onc.1210610
   Goodarzi AA, 2009, BIOCHEM SOC T, V37, P569, DOI 10.1042/BST0370569
   Guenther MG, 2001, MOL CELL BIOL, V21, P6091, DOI 10.1128/MCB.21.18.6091-6101.2001
   Haberland M, 2009, NAT REV GENET, V10, P32, DOI 10.1038/nrg2485
   Huang XP, 2009, CANCER RES, V69, P8403, DOI 10.1158/0008-5472.CAN-09-2146
   Jang ER, 2004, ONCOGENE, V23, P1724, DOI 10.1038/sj.onc.1207315
   Ji J, 2016, MED SCI MONITOR, V22, P2363, DOI 10.12659/MSM.898597
   Jiang RS, 2016, MED SCI MONITOR, V22, P1318, DOI 10.12659/MSM.895755
   Kim YJ, 2013, ONCOGENE, V32, P2828, DOI 10.1038/onc.2013.32
   Kristensen LS, 2009, EUR J PHARMACOL, V625, P131, DOI 10.1016/j.ejphar.2009.10.011
   Krusche CA, 2005, BREAST CANCER RES TR, V90, P15, DOI 10.1007/s10549-004-1668-2
   Légaré S, 2016, MOL ENDOCRINOL, V30, P965, DOI 10.1210/me.2016-1072
   Maur M, 2017, AM J CASE REP, V18, P208, DOI 10.12659/AJCR.901812
   Müller BM, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-215
   Oie S, 2013, BIOCHEM BIOPH RES CO, V432, P236, DOI 10.1016/j.bbrc.2013.02.007
   Parbin S, 2014, J HISTOCHEM CYTOCHEM, V62, P11, DOI 10.1369/0022155413506582
   Seo J, 2014, J BREAST CANCER, V17, P323, DOI 10.4048/jbc.2014.17.4.323
   Thiagalingam S, 2003, ANN NY ACAD SCI, V983, P84, DOI 10.1111/j.1749-6632.2003.tb05964.x
   Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262
NR 25
TC 24
Z9 30
U1 0
U2 8
PU INT SCIENTIFIC INFORMATION, INC
PI MELVILLE
PA 150 BROADHOLLOW RD, STE 114, MELVILLE, NY 11747 USA
EI 1643-3750
J9 MED SCI MONITOR
JI Med. Sci. Monitor
PD APR 22
PY 2018
VL 24
BP 2456
EP 2464
DI 10.12659/MSM.906576
PG 9
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA GD9XE
UT WOS:000430865500003
PM 29680858
OA Green Published, Green Submitted
DA 2025-01-12
ER

PT J
AU Mondal, S
   Parelkar, SS
   Nagar, M
   Thompson, PR
AF Mondal, Santanu
   Parelkar, Sangram S.
   Nagar, Mitesh
   Thompson, Paul R.
TI Photochemical Control of Protein Arginine Deiminase (PAD) Activity
SO ACS CHEMICAL BIOLOGY
LA English
DT Article
ID PEPTIDYLARGININE DEIMINASE; OPTICAL CONTROL;
   PROTEIN-ARGININE-DEIMINASE-4 PAD4; ANTIBACTERIAL ACTIVITY; EPIGENETIC
   REGULATION; IMMUNE-RESPONSES; IN-VITRO; INHIBITORS; CITRULLINATION;
   DISEASE
AB Protein arginine deiminases (PADs) play an important role in the pathogenesis of various diseases, including rheumatoid arthritis, multiple sclerosis, lupus, ulcerative colitis, and breast cancer. Therefore, the development of PAD inhibitors has drawn significant research interest in recent years. Herein, we describe the development of the first photoswitchable PAD inhibitors. These compounds possess an azobenzene photoswitch to optically control PAD activity. Screening of a series of inhibitors structurally similar to BB-Cl-amidine afforded compounds 1 and 2 as the most promising candidates for the light-controlled inhibition of PAD2; the cis isomer of 1 is 10-fold more potent than its trans isomer, whereas the trans isomer of 2 is 45-fold more potent than the corresponding cis isomer. The altered inhibitory potency upon photoisomerization has been confirmed in a competitive activity-based protein profiling (ABPP) assay. Further investigations indicate that the trans isomer of 2 is an irreversible inhibitor, whereas the cis isomer acts as a competitive inhibitor. In cells, the trans isomer of compound 1 is completely inactive, whereas the cis isomer inhibits histone H3-citrullination in a dose-dependent manner. Taken together, 1 serves as the foundation for developing photopharmaceuticals that can be activated at the desired tissue, using light, to treat diseases where PAD activity is dysregulated.
C1 [Mondal, Santanu; Parelkar, Sangram S.; Nagar, Mitesh; Thompson, Paul R.] Univ Massachusetts, Dept Biochem & Mol Pharmacol, Sch Med, 364 Plantat St, Worcester, MA 01605 USA.
   [Mondal, Santanu; Parelkar, Sangram S.; Nagar, Mitesh; Thompson, Paul R.] Univ Massachusetts, Program Chem Biol, Sch Med, 364 Plantat St, Worcester, MA 01605 USA.
C3 University of Massachusetts System; University of Massachusetts
   Worcester; University of Massachusetts System; University of
   Massachusetts Worcester
RP Thompson, PR (通讯作者)，Univ Massachusetts, Dept Biochem & Mol Pharmacol, Sch Med, 364 Plantat St, Worcester, MA 01605 USA.; Thompson, PR (通讯作者)，Univ Massachusetts, Program Chem Biol, Sch Med, 364 Plantat St, Worcester, MA 01605 USA.
EM thompson@umassmed.edu
RI Mondal, Santanu/KFA-5483-2024; nagar, mitesh/P-5347-2019; Mondal,
   Santanu/L-9157-2015
OI Nagar, Mitesh/0000-0002-8568-0513; Thompson, Paul/0000-0002-1621-3372;
   Mondal, Santanu/0000-0002-7399-8364
FU National Institutes of Health [R35GM118112]
FX This work was supported in part by National Institutes of Health grant
   R35GM118112 (P.R.T.).
CR Barber DM, 2017, CHEM SCI, V8, P611, DOI 10.1039/c6sc01621a
   Broichhagen J, 2015, ANGEW CHEM INT EDIT, V54, P15565, DOI 10.1002/anie.201506384
   Broichhagen J, 2015, ACCOUNTS CHEM RES, V48, P1947, DOI 10.1021/acs.accounts.5b00129
   Broichhagen J, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6116
   Christophorou MA, 2014, NATURE, V507, P104, DOI 10.1038/nature12942
   Clancy KW, 2017, ACS CHEM BIOL, V12, P1691, DOI 10.1021/acschembio.7b00241
   Cuthbert GL, 2004, CELL, V118, P545, DOI 10.1016/j.cell.2004.08.020
   Damgaard D, 2014, ARTHRITIS RES THER, V16, DOI 10.1186/s13075-014-0498-9
   Fuhrmann J, 2016, ACS CHEM BIOL, V11, P654, DOI 10.1021/acschembio.5b00942
   Fuhrmann J, 2015, CHEM REV, V115, P5413, DOI 10.1021/acs.chemrev.5b00003
   Ghari F, 2016, SCI ADV, V2, DOI 10.1126/sciadv.1501257
   Jones JE, 2009, CURR OPIN DRUG DISC, V12, P616
   Kawalkowska J, 2016, SCI REP-UK, V6, DOI 10.1038/srep26430
   Kearney PL, 2005, BIOCHEMISTRY-US, V44, P10570, DOI 10.1021/bi050292m
   Knight JS, 2015, ANN RHEUM DIS, V74, P2199, DOI 10.1136/annrheumdis-2014-205365
   Knight JS, 2014, CIRC RES, V114, P947, DOI 10.1161/CIRCRESAHA.114.303312
   Knipp M, 2000, ANAL BIOCHEM, V286, P257, DOI 10.1006/abio.2000.4805
   Knuckley B, 2008, BIOORGAN MED CHEM, V16, P739, DOI 10.1016/j.bmc.2007.10.021
   Knuckley B, 2010, BIOCHEMISTRY-US, V49, P4852, DOI 10.1021/bi100363t
   Knuckley B, 2010, CHEMBIOCHEM, V11, P161, DOI 10.1002/cbic.200900698
   Lewallen DM, 2015, ACS CHEM BIOL, V10, P2520, DOI 10.1021/acschembio.5b00438
   Lewallen DM, 2014, ACS CHEM BIOL, V9, P913, DOI 10.1021/cb400841k
   Li PX, 2010, J EXP MED, V207, P1853, DOI 10.1084/jem.20100239
   Luo Y, 2006, J AM CHEM SOC, V128, P1092, DOI 10.1021/ja0576233
   Luo Y, 2006, J AM CHEM SOC, V128, P14468, DOI 10.1021/ja0656907
   Luo Y, 2006, BIOCHEMISTRY-US, V45, P11727, DOI 10.1021/bi061180d
   McElwee JL, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-500
   Mohanan S., 2012, Biochem. Res. Int, V2012, P11
   Moscarello MA, 2002, J NEUROCHEM, V81, P335, DOI 10.1046/j.1471-4159.2002.00834.x
   Muth A, 2017, J MED CHEM, V60, P3198, DOI 10.1021/acs.jmedchem.7b00274
   Nemmara V. V., 2018, ACS CHEM BIOL, DOI [10.1021/acschem-bio.7b00957, DOI 10.1021/ACSCHEM-BIO.7B00957]
   Reisinger B, 2014, ANGEW CHEM INT EDIT, V53, P595, DOI 10.1002/anie.201307207
   Slade DJ, 2015, ACS CHEM BIOL, V10, P1043, DOI 10.1021/cb500933j
   Slade DJ, 2014, NAT CHEM BIOL, V10, P327, DOI 10.1038/nchembio.1504
   Szymanski W, 2015, CHEM-EUR J, V21, P16517, DOI 10.1002/chem.201502809
   Velema WA, 2014, J AM CHEM SOC, V136, P2178, DOI 10.1021/ja413063e
   Velema WA, 2013, NAT CHEM, V5, P924, DOI [10.1038/NCHEM.1750, 10.1038/nchem.1750]
   Vossenaar ER, 2003, BIOESSAYS, V25, P1106, DOI 10.1002/bies.10357
   Wegener M, 2017, J AM CHEM SOC, V139, P17979, DOI 10.1021/jacs.7b09281
   Willis V, 2011, J IMMUNOL, V186, P4396, DOI 10.4049/jimmunol.1001620
   Zhang XS, 2012, P NATL ACAD SCI USA, V109, P13331, DOI 10.1073/pnas.1203280109
NR 41
TC 23
Z9 24
U1 0
U2 31
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1554-8929
EI 1554-8937
J9 ACS CHEM BIOL
JI ACS Chem. Biol.
PD APR
PY 2018
VL 13
IS 4
BP 1057
EP 1065
DI 10.1021/acschembio.8b00053
PG 9
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA GE0IX
UT WOS:000430898600027
PM 29517899
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Chu, MQ
   Zhao, Y
   Yu, S
   Hao, YA
   Zhang, PF
   Feng, YN
   Zhang, HF
   Ma, DX
   Liu, J
   Cheng, M
   Li, L
   Shen, W
   Cao, HF
   Li, Q
   Min, LJ
AF Chu, Meiqiang
   Zhao, Yong
   Yu, Shuai
   Hao, Yanan
   Zhang, Pengfei
   Feng, Yanni
   Zhang, Hongfu
   Ma, Dongxue
   Liu, Jing
   Cheng, Ming
   Li, Lan
   Shen, Wei
   Cao, Hongfang
   Li, Qiang
   Min, Lingjiang
TI MicroRNA-221 may be involved in lipid metabolism in mammary epithelial
   cells
SO INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
LA English
DT Article
DE MiR-221; Lipid; Metabolism; Estradiol; Progesterone; Lactation
ID BREAST-CANCER; IN-VIVO; CHOLESTEROL HOMEOSTASIS; EPIGENETIC REGULATION;
   GENE-EXPRESSION; LACTATING COWS; MESSENGER-RNA; HUMAN-MILK; GLAND;
   MIR-33
AB Milk lipids, important for infant growth and development, are produced and secreted by mammary gland under the regulation of steroid hormones, growth factors, and microRNAs (miRNAs). miR-221 has been identified in milk and adipocytes and it plays important roles in regulating normal mammary epithelial hierarchy and breast cancer stem cells; however, its roles in lipid metabolism in mammary epithelial cells (MECs), the cells of lipid synthesis and secretion, are as yet unknown. Through overexpression or inhibition of miR-221 expression, we found that it regulated lipid metabolism in MECs and was expressed differentially at various stages during murine mammary gland development. Inhibition of miR-221 expression increased lipid content in MECs through elevation of the lipid synthesis enzyme FASN, while overexpression of miR-221 reduced MEC lipid content. Moreover, the steroid hormones estradiol and progesterone decreased miR-221 expression with a subsequent increase in lipid formation in MECs. The expression of miR-221 was lower during lactation, which suggests that it may be involved in milk production. Therefore, miR-221 might be a useful target for influencing milk lipid production.
C1 [Chu, Meiqiang; Zhao, Yong; Yu, Shuai; Hao, Yanan; Zhang, Pengfei; Feng, Yanni; Ma, Dongxue; Li, Lan; Shen, Wei; Min, Lingjiang] Qingdao Agr Univ, Coll Anim Sci & Technol, Qingdao 266109, Peoples R China.
   [Zhang, Hongfu] Chinese Acad Agr Sci, Inst Anim Sci, State Key Lab Anim Nutr, Beijing, Peoples R China.
   [Liu, Jing] Qingdao Agr Univ, Core Labs, Qingdao 266109, Peoples R China.
   [Cheng, Ming] Qingdao Vet & Livestock Adm, Qingdao 266000, Peoples R China.
   [Cao, Hongfang; Li, Qiang] Laiwu Vet & Livestock Adm, Laiwu 271100, Peoples R China.
C3 Qingdao Agricultural University; Chinese Academy of Agricultural
   Sciences; Institute of Animal Science, CAAS; Qingdao Agricultural
   University
RP Min, LJ (通讯作者)，Qingdao Agr Univ, Coll Anim Sci & Technol, Qingdao 266109, Peoples R China.
EM mlj2963@qau.edu.cn
RI Zhang, Pengfei/GPC-5146-2022
OI Feng, Yanni/0000-0002-3590-788X; Zhao, Yong/0000-0003-3423-2718
FU Technology System of Modern Agricultural Industry in Shandong Province
   [SDAIT-10-08]
FX This work was supported by Technology System of Modern Agricultural
   Industry in Shandong Province (SDAIT-10-08).
CR Akers R.M., 2002, LACTATION MAMMARY GL
   Anderson SM, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1653
   Avril-Sassen S, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-548
   Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5
   Bastianelli C, 2017, EXPERT REV CLIN PHAR, V10, P315, DOI 10.1080/17512433.2017.1271708
   Bian YJ, 2015, J CELL PHYSIOL, V230, P2152, DOI 10.1002/jcp.24944
   Bionaz M, 2011, BIOINFORM BIOL INSIG, V5, P83, DOI 10.4137/BBI.S7003
   Chen JF, 2006, NAT GENET, V38, P228, DOI 10.1038/ng1725
   Cui M, 2014, BIOCHEM BIOPH RES CO, V444, P270, DOI 10.1016/j.bbrc.2014.01.051
   Cui W, 2011, MOL CELL BIOCHEM, V355, P17, DOI 10.1007/s11010-011-0834-1
   Delbecchi L, 2005, LIVEST PROD SCI, V98, P57, DOI 10.1016/j.livprodsci.2005.10.010
   Di Leva G, 2010, JNCI-J NATL CANCER I, V102, P706, DOI 10.1093/jnci/djq102
   EMKEN EA, 1989, J LIPID RES, V30, P395
   Ergun S, 2015, GENE, V555, P377, DOI 10.1016/j.gene.2014.11.036
   Esau C, 2006, CELL METAB, V3, P87, DOI 10.1016/j.cmet.2006.01.005
   Gerin I, 2010, J BIOL CHEM, V285, P33652, DOI 10.1074/jbc.M110.152090
   Hamilton MP, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3730
   Horie T, 2010, P NATL ACAD SCI USA, V107, P17321, DOI 10.1073/pnas.1008499107
   Howe EN, 2012, J MAMMARY GLAND BIOL, V17, P65, DOI 10.1007/s10911-012-9244-6
   Hu ZG, 2012, MOL CELL BIOL, V32, P5035, DOI 10.1128/MCB.01002-12
   Jabed A, 2012, P NATL ACAD SCI USA, V109, P16811, DOI 10.1073/pnas.1210057109
   Jonas S, 2015, NAT REV GENET, V16, P421, DOI 10.1038/nrg3965
   JUDGE SM, 1983, CANCER RES, V43, P4407
   Ke J, 2015, ONCOTARGET, V6, P3709, DOI 10.18632/oncotarget.2888
   Kim J, 2012, EXP NEUROL, V235, P476, DOI 10.1016/j.expneurol.2011.11.010
   LAMMIKEEFE CJ, 1984, J PEDIATR GASTR NUTR, V3, P172, DOI 10.1097/00005176-198403000-00004
   Lian S, 2016, J DAIRY SCI, V99, P3916, DOI 10.3168/jds.2015-10484
   Liao YL, 2010, J NUTR, V140, P1552, DOI 10.3945/jn.110.124289
   Lin XZ, 2013, GENE, V521, P15, DOI 10.1016/j.gene.2013.03.050
   Lin XZ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079258
   Liu XQ, 2016, TOXICOL LETT, V256, P19, DOI 10.1016/j.toxlet.2016.05.007
   Lu XM, 2009, MOL MED REP, V2, P651, DOI 10.3892/mmr_00000152
   Marquart TJ, 2010, P NATL ACAD SCI USA, V107, P12228, DOI 10.1073/pnas.1005191107
   Mohammad MA, 2013, AM J PHYSIOL-ENDOC M, V305, pE700, DOI 10.1152/ajpendo.00052.2013
   MOLLETT TA, 1976, J ANIM SCI, V42, P655, DOI 10.2527/jas1976.423655x
   Najafi-Shoushtari SH, 2010, SCIENCE, V328, P1566, DOI 10.1126/science.1189123
   Neville MC, 2006, KNOBIL AND NEILL'S PHYSIOLOGY OF REPRODUCTION, VOLS 1 AND 2, 3RD EDITON, P2993
   Piao HL, 2012, J MAMMARY GLAND BIOL, V17, P33, DOI 10.1007/s10911-012-9245-5
   Qu Y, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131285
   Ramírez CM, 2013, CIRC RES, V112, P1592, DOI 10.1161/CIRCRESAHA.112.300626
   Ramirez CM, 2011, ARTERIOSCL THROM VAS, V31, P2707, DOI 10.1161/ATVBAHA.111.232066
   Rayner KJ, 2011, J CLIN INVEST, V121, P2921, DOI 10.1172/JCI57275
   Rayner KJ, 2010, SCIENCE, V328, P1570, DOI 10.1126/science.1189862
   Reinhart BJ, 2000, NATURE, V403, P901, DOI 10.1038/35002607
   Rudolph MC, 2003, J MAMMARY GLAND BIOL, V8, P287, DOI 10.1023/B:JOMG.0000010030.73983.57
   Rudolph MC, 2011, AM J PHYSIOL-ENDOC M, V300, pE1059, DOI 10.1152/ajpendo.00083.2011
   Smith S, 2009, J MAMMARY GLAND BIOL, V14, P245, DOI 10.1007/s10911-009-9142-8
   Sun DS, 2012, FEBS LETT, V586, P1472, DOI 10.1016/j.febslet.2012.03.068
   TOPPER YJ, 1980, PHYSIOL REV, V60, P1049, DOI 10.1152/physrev.1980.60.4.1049
   Vickers KC, 2013, HEPATOLOGY, V57, P533, DOI 10.1002/hep.25846
   Vickers KC, 2011, NAT CELL BIOL, V13, P423, DOI 10.1038/ncb2210
   Wakil SJ, 2009, J LIPID RES, V50, pS138, DOI 10.1194/jlr.R800079-JLR200
   Wang H, 2015, J DAIRY SCI, V98, P9001, DOI 10.3168/jds.2015-9418
   Wang H, 2017, J CELL PHYSIOL, V232, P1030, DOI 10.1002/jcp.25499
   Wang L, 2013, MOL CELL BIOL, V33, P1956, DOI 10.1128/MCB.01580-12
   Wang M, 2012, J DAIRY SCI, V95, P6529, DOI 10.3168/jds.2012-5748
   Wang YD, 2016, TOXICOL APPL PHARM, V313, P149, DOI 10.1016/j.taap.2016.10.025
   Wu Cheng-Wei, 2014, Genomics Proteomics & Bioinformatics, V12, P284, DOI 10.1016/j.gpb.2014.08.003
   Xiao J, 2016, ONCOTARGETS THER, V9, P5181, DOI 10.2147/OTT.S105198
   Zhang CL, 2014, J NUTR, V144, P1142, DOI 10.3945/jn.114.192575
   Zhao Y, 2016, SCI REP-UK, V6, DOI 10.1038/srep37884
   Zhao Y, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0155865
   Zhao Y, 2010, TOXICOL SCI, V115, P214, DOI 10.1093/toxsci/kfq030
   Zhong D, 2013, CELL SIGNAL, V25, P1429, DOI 10.1016/j.cellsig.2013.03.003
   Zhong D, 2013, LIPIDS HEALTH DIS, V12, DOI 10.1186/1476-511X-12-32
NR 65
TC 26
Z9 31
U1 0
U2 16
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1357-2725
EI 1878-5875
J9 INT J BIOCHEM CELL B
JI Int. J. Biochem. Cell Biol.
PD APR
PY 2018
VL 97
BP 118
EP 127
DI 10.1016/j.biocel.2018.02.014
PG 10
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA GD8JG
UT WOS:000430758100014
PM 29474925
DA 2025-01-12
ER

PT J
AU Guo, L
   Wang, XH
   Yang, YG
   Xu, HC
   Zhang, ZH
   Yin, LL
   Wang, Y
   Yang, MP
   Zhao, S
   Bai, SP
   Zhao, L
   Wang, ZP
   Lian, X
   Liu, Y
   Zhang, QY
AF Guo, Li
   Wang, Xiaohong
   Yang, Yuguang
   Xu, Hongchun
   Zhang, Zhihong
   Yin, Lili
   Wang, Yan
   Yang, Maopeng
   Zhao, Shu
   Bai, Shuping
   Zhao, Ling
   Wang, Zhipeng
   Lian, Xin
   Liu, Ying
   Zhang, Qingyuan
TI Methylation of DACT2 contributes to the progression of breast cancer
   through activating WNT signaling pathway
SO ONCOLOGY LETTERS
LA English
DT Article
DE breast cancer; dishevelled-associated antagonist of beta-catenin homolog
   2; methylation; Wnt/beta-catenin
ID WNT/BETA-CATENIN PATHWAY; TUMOR-SUPPRESSOR GENES; BETA-CATENIN;
   EPIGENETIC REGULATION; EXPRESSION; CARCINOMA; IDENTIFICATION;
   ANTAGONIST; MICE
AB The activation of the Wnt/beta-catenin signaling pathway has been demonstrated to play important roles in breast carcinogenesis and to be associated with a poorer prognosis in breast cancer patients. However, genetic mutation is not the major reason for Wnt/beta-catenin activation in breast cancer. Dishevelled-associated antagonist of beta-catenin homolog 2 (DACT2) is a negative regulator of beta-catenin and acts as a tumor suppressor in numerous cancer types; however, the expression change and potential role of DACT2 in breast cancer is unknown. The present study detected the expression and function of DACT2 in breast cancer progression. It was identified that the expression of DACT2 significantly decreased in breast cancer tissues compared with paired adjacent normal breast tissues. Additional investigation demonstrated that the hypermethylation of DACT2 gene promoter contributes to the loss of the gene in breast cancer. It was also demonstrated that DACT2 is a tumor suppressor in breast cancer and inhibits the proliferation and invasion of breast cancer cells by repressing the expression of beta-catenin target genes associated with tumor growth and metastasis. The present study indicates that the loss of DACT2 may contribute to breast cancer progression and provides a promising therapeutic target for the treatment of breast cancer.
C1 [Guo, Li; Wang, Xiaohong; Yang, Yuguang; Wang, Yan; Yang, Maopeng; Zhao, Shu; Bai, Shuping; Zhao, Ling; Wang, Zhipeng; Lian, Xin; Zhang, Qingyuan] Harbin Med Univ, Dept Med Oncol, Canc Hosp, 150 Haping Rd, Harbin 150081, Heilongjiang, Peoples R China.
   [Xu, Hongchun] Mudanjiang Tumor Hosp, Dept Thorac Surg, Mudanjiang 157000, Heilongjiang, Peoples R China.
   [Zhang, Zhihong] Gen Hosp Daqing Oil Field, Obstet & Gynecol Dept, Daqing 163000, Heilongjiang, Peoples R China.
   [Yin, Lili] Heilongjiang Elect Power Hosp, Obstet & Gynecol Dept, Harbin 150090, Heilongjiang, Peoples R China.
   [Liu, Ying] Harbin Med Univ, Dept Nutr & Food Hyg, Publ Hlth Coll, 157 Baojian Rd, Harbin 150081, Heilongjiang, Peoples R China.
C3 Harbin Medical University; Harbin Medical University
RP Zhang, QY (通讯作者)，Harbin Med Univ, Dept Med Oncol, Canc Hosp, 150 Haping Rd, Harbin 150081, Heilongjiang, Peoples R China.; Liu, Y (通讯作者)，Harbin Med Univ, Dept Nutr & Food Hyg, Publ Hlth Coll, 157 Baojian Rd, Harbin 150081, Heilongjiang, Peoples R China.
EM liuying0223@sohu.com; zhma19650210@126.com
RI Wang, Zhipeng/GWM-8211-2022; li, danyang/HHS-3319-2022
CR Badders NM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006594
   Cheyette BNR, 2002, DEV CELL, V2, P449, DOI 10.1016/S1534-5807(02)00140-5
   Du WJ, 2014, J CELL MOL MED, V18, P1712, DOI 10.1111/jcmm.12340
   Fisher DA, 2006, DEV DYNAM, V235, P2620, DOI 10.1002/dvdy.20917
   Geyer FC, 2011, MODERN PATHOL, V24, P209, DOI 10.1038/modpathol.2010.205
   Girard L, 2000, CANCER RES, V60, P4894
   Ha NC, 2004, MOL CELL, V15, P511, DOI 10.1016/j.molcel.2004.08.010
   Howe LR, 2004, CANCER BIOL THER, V3, P36, DOI 10.4161/cbt.3.1.561
   Jia Y, 2013, J PATHOL, V230, P194, DOI 10.1002/path.4073
   Katoh M, 2003, INT J ONCOL, V22, P907
   Khramtsov AI, 2010, AM J PATHOL, V176, P2911, DOI 10.2353/ajpath.2010.091125
   King TD, 2012, J CELL BIOCHEM, V113, P13, DOI 10.1002/jcb.23350
   Kivimäe S, 2011, BMC BIOCHEM, V12, DOI 10.1186/1471-2091-12-33
   Li LL, 2015, EPIGENOMICS-UK, V7, P155, DOI [10.2217/epi.14.79, 10.2217/EPI.14.79]
   Li X, 2012, CELL DEATH DIFFER, V19, P378, DOI 10.1038/cdd.2011.127
   Lin SY, 2000, P NATL ACAD SCI USA, V97, P4262, DOI 10.1073/pnas.060025397
   Lindvall C, 2006, J BIOL CHEM, V281, P35081, DOI 10.1074/jbc.M607571200
   Lindvall C, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005813
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Matsuda Y, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2317
   Schussel JL, 2015, CANCER BIOMARK, V15, P11, DOI 10.3233/CBM-140436
   Steinemann D, 2003, GENE CHROMOSOME CANC, V37, P421, DOI 10.1002/gcc.10231
   Suzuki H, 2008, BRIT J CANCER, V98, P1147, DOI 10.1038/sj.bjc.6604259
   Teran E, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005522
   TSUKAMOTO AS, 1988, CELL, V55, P619, DOI 10.1016/0092-8674(88)90220-6
   Turashvili G, 2006, PATHOBIOLOGY, V73, P213, DOI 10.1159/000098207
   Wang S, 2015, ONCOGENE, V34, P2575, DOI 10.1038/onc.2014.201
   Willemsen RH, 2008, J CLIN ENDOCR METAB, V93, P452, DOI 10.1210/jc.2007-1913
   Yang L, 2011, ONCOGENE, V30, P4437, DOI 10.1038/onc.2011.145
   Yu YZ, 2014, AM J CANCER RES, V4, P710
   Zhang XM, 2013, EPIGENETICS-US, V8, P373, DOI 10.4161/epi.24113
   Zhao ZY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112336
NR 32
TC 11
Z9 12
U1 0
U2 4
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1792-1074
EI 1792-1082
J9 ONCOL LETT
JI Oncol. Lett.
PD MAR
PY 2018
VL 15
IS 3
BP 3287
EP 3294
DI 10.3892/ol.2017.7633
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA GD9FK
UT WOS:000430818300080
PM 29435071
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU Kudo, N
   Ito, A
   Arata, M
   Nakata, A
   Yoshida, M
AF Kudo, Norio
   Ito, Akihiro
   Arata, Mayumi
   Nakata, Akiko
   Yoshida, Minoru
TI Identification of a novel small molecule that inhibits deacetylase but
   not defatty-acylase reaction catalysed by SIRT2
SO PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES
LA English
DT Article
DE SIRT2; NAD(+)-dependent lysine deacetylase; deacylase; crystal
   structure; anti-cancer drug development; high-throughput screening
ID SUBCELLULAR-LOCALIZATION; HISTONE DEACETYLASE; STRUCTURAL BASIS;
   ANTICANCER ACTIVITY; SELECTIVITY POCKET; CRYSTAL-STRUCTURE; OXIDATIVE
   STRESS; BREAST-CANCER; ACETYLATION; POTENT
AB SIRT2 is a member of the human sirtuin family of proteins and possesses NAD(+)-dependent lysine deacetylase/deacylase activity. SIRT2 has been implicated in carcinogenesis in various cancers including leukaemia and is considered an attractive target for cancer therapy. Here, we identified NPD11033, a selective small-molecule SIRT2 inhibitor, by a high-throughput screen using the RIKEN NPDepo chemical library. NPD11033 was largely inactive against other sirtuins and zinc-dependent deacetylases. Crystallographic analysis revealed a unique mode of action, in which NPD11033 creates a hydrophobic cavity behind the substrate-binding pocket after a conformational change of the Zn-binding small domain of SIRT2. Furthermore, it forms a hydrogen bond to the active site histidine residue. In addition, NPD11033 inhibited cell growth of human pancreatic cancer PANC-1 cells with a concomitant increase in the acetylation of eukaryotic translation initiation factor 5A, a physiological substrate of SIRT2. Importantly, NPD11033 failed to inhibit defatty-acylase activity of SIRT2, despite its potent inhibitory effect on its deacetylase activity. Thus, NPD11033 will serve as a useful tool for both developing novel anti-cancer agents and elucidating the role of SIRT2 in various cellular biological processes.
   This article is part of a discussion meeting issue 'Frontiers in epigenetic chemical biology'.
C1 [Kudo, Norio; Arata, Mayumi; Nakata, Akiko; Yoshida, Minoru] RIKEN, Ctr Sustainable Resource Sci, Seed Cpds Exploratory Unit Drug Discovery Platfor, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.
   [Ito, Akihiro; Yoshida, Minoru] RIKEN, Ctr Sustainable Resource Sci, Chem Genom Res Grp, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.
   [Ito, Akihiro] Tokyo Univ Pharm & Life Sci, Sch Life Sci, 1432-1 Horinouchi, Hachioji, Tokyo 1920392, Japan.
   [Yoshida, Minoru] RIKEN, Chem Genet Lab, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.
   [Yoshida, Minoru] Univ Tokyo, Grad Sch Agr & Life Sci, Dept Biotechnol, Tokyo 1138657, Japan.
C3 RIKEN; RIKEN; Tokyo University of Pharmacy & Life Sciences; RIKEN;
   University of Tokyo
RP Yoshida, M (通讯作者)，RIKEN, Ctr Sustainable Resource Sci, Seed Cpds Exploratory Unit Drug Discovery Platfor, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.; Yoshida, M (通讯作者)，RIKEN, Ctr Sustainable Resource Sci, Chem Genom Res Grp, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.; Yoshida, M (通讯作者)，RIKEN, Chem Genet Lab, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.; Yoshida, M (通讯作者)，Univ Tokyo, Grad Sch Agr & Life Sci, Dept Biotechnol, Tokyo 1138657, Japan.
EM yoshidam@riken.jp
RI Kudo, Norio/C-8173-2017; Yoshida, Minoru/C-8049-2014
OI Kudo, Norio/0000-0001-6468-7006; Yoshida, Minoru/0000-0002-4376-5674
FU Japan Society for the Promotion of Science (JSPS) [26221204, 16K14674];
   Project for Development of Innovative Research on Cancer Therapeutics
   (P-DIRECT) from the Ministry of Education, Culture, Sports, Science and
   Technology of Japan; Grants-in-Aid for Scientific Research [16K14674]
   Funding Source: KAKEN
FX This work was supported, in part, by the Japan Society for the Promotion
   of Science (JSPS) under Grants-in-Aid for Scientific Research (S)
   (26221204) and for Challenging Exploratory Research (16K14674), and the
   Project for Development of Innovative Research on Cancer Therapeutics
   (P-DIRECT) from the Ministry of Education, Culture, Sports, Science and
   Technology of Japan. This work was inspired by the JSPS Asian Chemical
   Biology Initiative.
CR Bao XC, 2014, ELIFE, V3, DOI 10.7554/eLife.02999
   Bhuiyan MPI, 2006, BIOORGAN MED CHEM, V14, P3438, DOI 10.1016/j.bmc.2005.12.063
   Chen VB, 2010, ACTA CRYSTALLOGR D, V66, P12, DOI 10.1107/S0907444909042073
   Emsley P, 2010, ACTA CRYSTALLOGR D, V66, P486, DOI 10.1107/S0907444910007493
   Fanslau C, 2010, ANAL BIOCHEM, V402, P65, DOI 10.1016/j.ab.2010.03.025
   Feldman JL, 2015, BIOCHEMISTRY-US, V54, P3037, DOI 10.1021/acs.biochem.5b00150
   Feldman JL, 2013, J BIOL CHEM, V288, P31350, DOI 10.1074/jbc.C113.511261
   Finnin MS, 2001, NAT STRUCT BIOL, V8, P621, DOI 10.1038/89668
   Galleano I, 2016, J MED CHEM, V59, P2847, DOI 10.1021/acs.jmedchem.6b00239
   Ishfaq M, 2012, BIOSCI BIOTECH BIOCH, V76, P2165, DOI 10.1271/bbb.120620
   Ishfaq M, 2012, FEBS LETT, V586, P3236, DOI 10.1016/j.febslet.2012.06.042
   Ito A, 2015, SCI SIGNAL, V8, DOI 10.1126/scisignal.aad0667
   Jin J, 2016, J AM CHEM SOC, V138, P12304, DOI 10.1021/jacs.6b04977
   Jin L, 2009, J BIOL CHEM, V284, P24394, DOI 10.1074/jbc.M109.014928
   Jing EX, 2007, CELL METAB, V6, P105, DOI 10.1016/j.cmet.2007.07.003
   Jing H, 2016, CANCER CELL, V29, P297, DOI 10.1016/j.ccell.2016.02.007
   Kim HS, 2011, CANCER CELL, V20, P487, DOI 10.1016/j.ccr.2011.09.004
   Langer G, 2008, NAT PROTOC, V3, P1171, DOI 10.1038/nprot.2008.91
   Mellini P, 2017, CHEM SCI, V8, P6400, DOI 10.1039/c7sc02738a
   Moniot S, 2017, J MED CHEM, V60, P2344, DOI 10.1021/acs.jmedchem.6b01609
   Moniot S, 2013, J STRUCT BIOL, V182, P136, DOI 10.1016/j.jsb.2013.02.012
   Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255
   Narita K, 2016, EUR J MED CHEM, V121, P592, DOI 10.1016/j.ejmech.2016.05.031
   North BJ, 2003, MOL CELL, V11, P437, DOI 10.1016/S1097-2765(03)00038-8
   North BJ, 2014, EMBO J, V33, P1438, DOI 10.15252/embj.201386907
   Osada H, 2010, BIOSCI BIOTECH BIOCH, V74, P1135, DOI 10.1271/bbb.100061
   Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X
   Outeiro TF, 2007, SCIENCE, V317, P516, DOI 10.1126/science.1143780
   PABREZA LA, 1991, MOL PHARMACOL, V39, P9
   Park SH, 2016, CANCER RES, V76, P3802, DOI 10.1158/0008-5472.CAN-15-2498
   Peck B, 2010, MOL CANCER THER, V9, P844, DOI 10.1158/1535-7163.MCT-09-0971
   Rothgiesser KM, 2010, J CELL SCI, V123, P4251, DOI 10.1242/jcs.073783
   Rumpf T, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7263
   Schiedel M, 2016, J MED CHEM, V59, P1599, DOI 10.1021/acs.jmedchem.5b01517
   Schiedel M, 2016, ANGEW CHEM INT EDIT, V55, P2252, DOI 10.1002/anie.201509843
   Schuetz A, 2007, STRUCTURE, V15, P377, DOI 10.1016/j.str.2007.02.002
   Shah AA, 2016, BIOL PHARM BULL, V39, P1739, DOI 10.1248/bpb.b16-00520
   Sunami Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057633
   Sundriyal S, 2017, J MED CHEM, V60, P1928, DOI 10.1021/acs.jmedchem.6b01690
   Teng YB, 2015, SCI REP-UK, V5, DOI 10.1038/srep08529
   Trapp J, 2007, CHEMMEDCHEM, V2, P1419, DOI 10.1002/cmdc.200700003
   Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766
   Vaquero A, 2006, GENE DEV, V20, P1256, DOI 10.1101/gad.1412706
   Wang F, 2007, AGING CELL, V6, P505, DOI 10.1111/j.1474-9726.2007.00304.x
   Wang Y, 2017, CELL CHEM BIOL, V24, P339, DOI 10.1016/j.chembiol.2017.02.007
   Winn MD, 2011, ACTA CRYSTALLOGR D, V67, P235, DOI 10.1107/S0907444910045749
   Xu SC, 2016, SCI REP-UK, V6, DOI 10.1038/srep26619
   Xu YP, 2014, CANCER RES, V74, P3630, DOI 10.1158/0008-5472.CAN-13-3615
   Yamagata K, 2014, STRUCTURE, V22, P345, DOI 10.1016/j.str.2013.12.001
   YOSHIDA M, 1990, J BIOL CHEM, V265, P17174
   Yoshida M, 2017, P JPN ACAD B-PHYS, V93, P297, DOI 10.2183/pjab.93.019
   Zhao D, 2013, CANCER CELL, V23, P464, DOI 10.1016/j.ccr.2013.02.005
   Zhou WH, 2016, CELL REP, V17, P1302, DOI 10.1016/j.celrep.2016.10.006
   Zuo QQ, 2012, ONCOL REP, V27, P819, DOI 10.3892/or.2011.1553
NR 54
TC 47
Z9 53
U1 2
U2 13
PU ROYAL SOC
PI LONDON
PA 6-9 CARLTON HOUSE TERRACE, LONDON SW1Y 5AG, ENGLAND
SN 0962-8436
EI 1471-2970
J9 PHILOS T R SOC B
JI Philos. Trans. R. Soc. B-Biol. Sci.
PD JUN 5
PY 2018
VL 373
IS 1748
AR 20170070
DI 10.1098/rstb.2017.0070
PG 9
WC Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Life Sciences & Biomedicine - Other Topics
GA GD8BY
UT WOS:000430738400004
PM 29685974
OA Bronze, Green Published
DA 2025-01-12
ER

PT J
AU Alvarez-Fernández, M
   Sanz-Flores, M
   Sanz-Castillo, B
   Salazar-Roa, M
   Partida, D
   Zapatero-Solana, E
   Ali, HR
   Manchado, E
   Lowe, S
   VanArsdale, T
   Shields, D
   Caldas, C
   Quintela-Fandino, M
   Malumbres, M
AF Alvarez-Fernandez, Monica
   Sanz-Flores, Maria
   Sanz-Castillo, Belen
   Salazar-Roa, Maria
   Partida, David
   Zapatero-Solana, Elisabet
   Ali, H. Raza
   Manchado, Eusebio
   Lowe, Scott
   VanArsdale, Todd
   Shields, David
   Caldas, Carlos
   Quintela-Fandino, Miguel
   Malumbres, Marcos
TI Therapeutic relevance of the PP2A-B55 inhibitory kinase MASTL/Greatwall
   in breast cancer
SO CELL DEATH AND DIFFERENTIATION
LA English
DT Article
ID PROTEIN PHOSPHATASE 2A; GREATWALL KINASE; MITOTIC EXIT; MASTL; MITOSIS;
   VULNERABILITIES; RECURRENCE; EXPRESSION; PPP2R2B; TARGET
AB PP2A is a major tumor suppressor whose inactivation is frequently found in a wide spectrum of human tumors. In particular, deletion or epigenetic silencing of genes encoding the B55 family of PP2A regulatory subunits is a common feature of breast cancer cells. A key player in the regulation of PP2A/B55 phosphatase complexes is the cell cycle kinase MASTL (also known as Greatwall). During cell division, inhibition of PP2A-B55 by MASTL is required to maintain the mitotic state, whereas inactivation of MASTL and PP2A reactivation is required for mitotic exit. Despite its critical role in cell cycle progression in multiple organisms, its relevance as a therapeutic target in human cancer and its dependence of PP2A activity is mostly unknown. Here we show that MASTL overexpression predicts poor survival and shows prognostic value in breast cancer patients. MASTL knockdown or knockout using RNA interference or CRISPR/Cas9 systems impairs proliferation of a subset of breast cancer cells. The proliferative function of MASTL in these tumor cells requires its kinase activity and the presence of PP2A-B55 complexes. By using a new inducible CRISPR/Cas9 system in breast cancer cells, we show that genetic ablation of MASTL displays a significant therapeutic effect in vivo. All together, these data suggest that the PP2A inhibitory kinase MASTL may have both prognostic and therapeutic value in human breast cancer.
C1 [Alvarez-Fernandez, Monica; Sanz-Flores, Maria; Sanz-Castillo, Belen; Salazar-Roa, Maria; Partida, David; Zapatero-Solana, Elisabet; Malumbres, Marcos] Spanish Natl Canc Res Ctr CNIO, Cell Div, Madrid, Spain.
   [Alvarez-Fernandez, Monica; Sanz-Flores, Maria; Sanz-Castillo, Belen; Salazar-Roa, Maria; Partida, David; Zapatero-Solana, Elisabet; Malumbres, Marcos] Spanish Natl Canc Res Ctr CNIO, Canc Grp, Madrid, Spain.
   [Ali, H. Raza; Caldas, Carlos] Univ Cambridge, Canc Res UK Cambridge Inst, Cambridge, England.
   [Manchado, Eusebio; Lowe, Scott] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA.
   [VanArsdale, Todd; Shields, David] Pfizer Inc, Pfizer Worldwide Res & Dev, Oncol R&D Grp, New York, NY USA.
   [Quintela-Fandino, Miguel] CNIO, Breast Canc Clin Res Unit, Madrid, Spain.
C3 Centro Nacional de Investigaciones Oncologicas (CNIO); Centro Nacional
   de Investigaciones Oncologicas (CNIO); Cancer Research UK; University of
   Cambridge; CRUK Cambridge Institute; Memorial Sloan Kettering Cancer
   Center; Pfizer; Centro Nacional de Investigaciones Oncologicas (CNIO)
RP Malumbres, M (通讯作者)，Spanish Natl Canc Res Ctr CNIO, Cell Div, Madrid, Spain.; Malumbres, M (通讯作者)，Spanish Natl Canc Res Ctr CNIO, Canc Grp, Madrid, Spain.
EM malumbres@cnio.es
RI Quintela, María/E-2908-2012; Salazar, Maria/I-1168-2015; Malumbres,
   Marcos/E-8834-2011; Caldas, Carlos/U-7250-2019; Alvarez Fernandez,
   Monica/C-5972-2009
OI Sanz, Maria/0000-0002-4731-0060; quintela-fandino,
   miguel/0000-0003-1648-1964; Shields, David/0009-0003-5238-3912; Salazar,
   Maria/0000-0001-6784-9541; Malumbres, Marcos/0000-0002-0829-6315;
   Caldas, Carlos/0000-0003-3547-1489; Alvarez Fernandez,
   Monica/0000-0002-6454-5128
FU Spanish Ministry of Economy and Competitiveness (MINECO) (FEDER funds)
   [SAF2014-60442-JIN]; Ministry of Educacion, Cultura y Deporte; Fundacion
   La Caixa; Pfizer; MINECO [SAF2012-38215]; Consolider-Ingenio Programme
   [SAF2014-57791-REDC]; Excellence Network CellSYS [BFU2014-52125-REDT];
   OncoCycle Programme from the Comunidad de Madrid [S2010/BMD-2470];
   Worldwide Cancer Research (WCR) [15-0278]; European Union Seventh
   Framework Programme (MitoSys project) [HEALTH-F5-2010-241548]
FX We are fully indebted to Anna Castro and Thierry Lorca for reagents. We
   thank Marta Canamero, Alba de Martino and Manuel Morente for help with
   the histopathological analysis. We thank Giovanna Roncador for the
   generation of MASTL antibody. We also thank members of the Cell Division
   and Cancer Group for helpful discussions. M.A.F. was supported by a
   young investigator grant from the Spanish Ministry of Economy and
   Competitiveness (MINECO; SAF2014-60442-JIN; co-financed by FEDER funds).
   M.S.F. was supported by a fellowship from the Ministry of Educacion,
   Cultura y Deporte, and B.S.-C. was supported by Fundacion La Caixa. The
   research described in the manuscript was funded in part by Pfizer. Work
   in the M.M. laboratory was supported by grants from the MINECO
   (SAF2012-38215), Consolider-Ingenio 2010 Programme (SAF2014-57791-REDC),
   Excellence Network CellSYS (BFU2014-52125-REDT), the OncoCycle Programme
   (S2010/BMD-2470) from the Comunidad de Madrid, Worldwide Cancer Research
   (WCR no. 15-0278), and the European Union Seventh Framework Programme
   (MitoSys project; HEALTH-F5-2010-241548).
CR Alvarez-Fernández M, 2013, P NATL ACAD SCI USA, V110, P17374, DOI 10.1073/pnas.1310745110
   Anania MC, 2015, ONCOTARGET, V6, P34629, DOI 10.18632/oncotarget.5282
   Beca F, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1266-1
   Burgess A, 2010, P NATL ACAD SCI USA, V107, P12564, DOI 10.1073/pnas.0914191107
   Castilho PV, 2009, MOL BIOL CELL, V20, P4777, DOI 10.1091/mbc.E09-07-0643
   Cheang MCU, 2009, JNCI-J NATL CANCER I, V101, P736, DOI 10.1093/jnci/djp082
   Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983
   Dahlhaus M, 2016, CANCER LETT, V371, P79, DOI 10.1016/j.canlet.2015.11.025
   Diril MK, 2016, PLOS GENET, V12, DOI 10.1371/journal.pgen.1006310
   Eichhorn PJA, 2009, BBA-REV CANCER, V1795, P1, DOI 10.1016/j.bbcan.2008.05.005
   Gharbi-Ayachi A, 2010, SCIENCE, V330, P1673, DOI 10.1126/science.1197048
   Glover DM, 2012, OPEN BIOL, V2, DOI 10.1098/rsob.120023
   Guzmán C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092444
   Hsu PD, 2013, NAT BIOTECHNOL, V31, P827, DOI 10.1038/nbt.2647
   Manchado E, 2010, CANCER CELL, V18, P641, DOI 10.1016/j.ccr.2010.10.028
   MASHAL RD, 1995, NAT GENET, V9, P177, DOI 10.1038/ng0295-177
   Medema RH, 2010, CELL CYCLE, V9, P4264, DOI 10.4161/cc.9.21.13890
   Mochida S, 2010, SCIENCE, V330, P1670, DOI 10.1126/science.1195689
   Muggerud AA, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2466
   Nagel R, 2015, MOL CANCER THER, V14, P1434, DOI 10.1158/1535-7163.MCT-14-0846
   Perrotti D, 2013, LANCET ONCOL, V14, pE229, DOI 10.1016/S1470-2045(12)70558-2
   Seshacharyulu P, 2013, CANCER LETT, V335, P9, DOI 10.1016/j.canlet.2013.02.036
   Shalem O, 2014, SCIENCE, V343, P84, DOI 10.1126/science.1247005
   Tzelepis K, 2016, CELL REP, V17, P1193, DOI 10.1016/j.celrep.2016.09.079
   Vazquez A, 2011, INT J CANCER, V128, P2335, DOI 10.1002/ijc.25582
   Vera J, 2015, ELIFE, V4, DOI 10.7554/eLife.10115
   Vigneron S, 2009, EMBO J, V28, P2786, DOI 10.1038/emboj.2009.228
   Voets E, 2010, CELL CYCLE, V9, P3591, DOI 10.4161/cc.9.17.12832
   Wang L, 2014, ONCOTARGET, V5, P11479, DOI 10.18632/oncotarget.2565
   Wong PY, 2016, SCI REP-UK, V6, DOI 10.1038/srep22230
   Wurzenberger C, 2011, NAT REV MOL CELL BIO, V12, P469, DOI 10.1038/nrm3149
   Zhuge BZ, 2017, EUR REV MED PHARMACO, V21, P2413
   Zuber J, 2011, NAT BIOTECHNOL, V29, P79, DOI 10.1038/nbt.1720
NR 33
TC 71
Z9 72
U1 0
U2 11
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1350-9047
EI 1476-5403
J9 CELL DEATH DIFFER
JI Cell Death Differ.
PD MAY
PY 2018
VL 25
IS 5
BP 828
EP 840
DI 10.1038/s41418-017-0024-0
PG 13
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA GF2LG
UT WOS:000431770600003
PM 29229993
OA Green Published, hybrid
DA 2025-01-12
ER

PT J
AU Gao, Y
   Widschwendter, M
   Teschendorff, AE
AF Gao, Yang
   Widschwendter, Martin
   Teschendorff, Andrew E.
TI DNA Methylation Patterns in Normal Tissue Correlate more Strongly with
   Breast Cancer Status than Copy-Number Variants
SO EBIOMEDICINE
LA English
DT Article
DE Cancer; Cancer-risk; Early detection; DNA methylation; Epigenetic;
   Copy-number; Breast cancer
ID DETECTABLE CLONAL MOSAICISM; EPIGENETIC FIELD; PERIPHERAL-BLOOD;
   LUNG-CANCER; SOMATIC MUTATIONS; WIDE ASSOCIATION; CHROMOSOME Y;
   STEM-CELLS; RISK; AGE
AB Normal tissue at risk of neoplastic transformation is characterized by somatic mutations, copy-number variation and DNA methylation changes. It is unclear however, which type of alteration may be more informative of cancer risk We analyzed genome-wide DNA methylation and copy-number calls from the same DNA assay in a cohort of healthy breast samples and age-matched normal samples collected adjacent to breast cancer. Using statistical methods to adjust for cell type heterogeneity, we show that DNA methylation changes can discriminate normal-adjacent from normal samples better than somatic copy-number variants. We validate this important finding in an independent clataset. These results suggest that DNA methylation alterations in the normal cell of origin may offer better cancer risk prediction and early detection markers than copy-number changes. (C) 2018 The Authors. Published by Elsevier B.V.
C1 [Gao, Yang; Teschendorff, Andrew E.] Univ Chinese Acad Sci, Shanghai Inst Nutr & Hlth, Shanghai Inst Biol Sci,Chinese Acad Sci, CAS Key Lab Computat Biol,CAS MPG Partner Inst Co, 320 Yue Yang Rd, Shanghai 200031, Peoples R China.
   [Widschwendter, Martin; Teschendorff, Andrew E.] UCL, Dept Womens Canc, 74 Huntley St, London WC1E 6AU, England.
   [Teschendorff, Andrew E.] UCL, UCL Canc Inst, Paul OGorman Bldg, London WC1E 6BT, England.
C3 Chinese Academy of Sciences; Shanghai Institute of Nutrition & Health,
   CAS; University of Chinese Academy of Sciences, CAS; University of
   London; University College London; University of London; University
   College London
RP Teschendorff, AE (通讯作者)，Univ Chinese Acad Sci, Shanghai Inst Nutr & Hlth, Shanghai Inst Biol Sci,Chinese Acad Sci, CAS Key Lab Computat Biol,CAS MPG Partner Inst Co, 320 Yue Yang Rd, Shanghai 200031, Peoples R China.
EM a.teschendorff@ucl.ac.uk
RI Teschendorff, Andrew/AFP-1816-2022
OI Widschwendter, Martin/0000-0002-7778-8380
FU Eve Appeal; NSFC (National Science Foundation of China) [31571359,
   31401120]; Royal Society Newton Advanced Fellowship (NAF) [522438,
   164914]; European Union's Horizon Programme [634570]; European Research
   Council (ERC Advanced Grant ERC-BRCA); National Institute for Health
   Research (NIHR) University College London Hospitals (UCLH) Biomedical
   Research Centre
FX This work was supported by the Eve Appeal, NSFC (National Science
   Foundation of China) grants, grant numbers 31571359 and 31401120 and by
   a Royal Society Newton Advanced Fellowship (NAF project number: 522438,
   NAF award number: 164914). The authors are supported by the European
   Union's Horizon 2020 Programme (H2020/2014-2020) under grant agreement
   number 634570 (Project FORECEE: www.forecee.eu/) and MW also receives
   support from the European Research Council (ERC Advanced Grant ERC-BRCA)
   and the National Institute for Health Research (NIHR) University College
   London Hospitals (UCLH) Biomedical Research Centre.
CR [Anonymous], 2004, Stat. Appl. Genet. Mol. Biol., DOI [10.2202/1544-6115.1027, DOI 10.2202/1544-6115.1027]
   Aryee MJ, 2014, BIOINFORMATICS, V30, P1363, DOI 10.1093/bioinformatics/btu049
   Baglietto L, 2017, INT J CANCER, V140, P50, DOI 10.1002/ijc.30431
   Bernstein C, 2013, WORLD J GASTRO ONCOL, V5, P43, DOI 10.4251/wjgo.v5.i3.43
   Chen YT, 2017, GENOME BIOL, V18, DOI 10.1186/s13059-017-1366-0
   Chin SF, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-10-r215
   Cooper CS, 2015, NAT GENET, V47, P367, DOI 10.1038/ng.3221
   Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983
   Dumanski JP, 2015, SCIENCE, V347, P81, DOI 10.1126/science.1262092
   Fasanelli F, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms10192
   Feber A, 2014, GENOME BIOL, V15, DOI 10.1186/gb-2014-15-2-r30
   Feinberg AP, 2006, NAT REV GENET, V7, P21, DOI 10.1038/nrg1748
   Forsberg LA, 2014, NAT GENET, V46, P624, DOI 10.1038/ng.2966
   Friedman J, 2010, J STAT SOFTW, V33, P1, DOI 10.18637/jss.v033.i01
   Genovese G, 2014, NEW ENGL J MED, V371, P2477, DOI 10.1056/NEJMoa1409405
   Gerstein MB, 2012, NATURE, V489, P91, DOI 10.1038/nature11245
   Guo SC, 2017, NAT GENET, V49, P635, DOI 10.1038/ng.3805
   Hair BY, 2015, BREAST CANCER RES TR, V151, P453, DOI 10.1007/s10549-015-3401-8
   Hoang ML, 2016, P NATL ACAD SCI USA, V113, P9846, DOI 10.1073/pnas.1607794113
   Hovestadt Volker., 2017, conumee: Enhanced Copy-Number Variation Analysis Using Illumina DNA Methylation Arrays.
   Huang KK, 2018, CANCER CELL, V33, P137, DOI 10.1016/j.ccell.2017.11.018
   Issa JP, 2011, NAT GENET, V43, P724, DOI 10.1038/ng.897
   Jacobs KB, 2012, NAT GENET, V44, P651, DOI 10.1038/ng.2270
   Jaiswal S, 2014, NEW ENGL J MED, V371, P2488, DOI 10.1056/NEJMoa1408617
   Jones A, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001551
   Knoll M, 2017, BIOINFORMATICS, V33, P2266, DOI 10.1093/bioinformatics/btx156
   Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412
   Laurie CC, 2012, NAT GENET, V44, P642, DOI 10.1038/ng.2271
   Lehmann-Werman R, 2016, P NATL ACAD SCI USA, V113, pE1826, DOI 10.1073/pnas.1519286113
   Levine ME, 2015, AGING-US, V7, P690, DOI 10.18632/aging.100809
   Lowe R, 2015, GENOME BIOL, V16, DOI 10.1186/s13059-015-0748-4
   Marzouka NAD, 2016, BIOINFORMATICS, V32, P1080, DOI 10.1093/bioinformatics/btv652
   Nazor KL, 2012, CELL STEM CELL, V10, P620, DOI 10.1016/j.stem.2012.02.013
   Olshen AB, 2004, BIOSTATISTICS, V5, P557, DOI 10.1093/biostatistics/kxh008
   Paul DS, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13555
   Reinius LE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041361
   Severi G, 2014, BREAST CANCER RES TR, V148, P665, DOI 10.1007/s10549-014-3209-y
   Slieker RC, 2013, EPIGENET CHROMATIN, V6, DOI 10.1186/1756-8935-6-26
   Spira A, 2017, CANCER RES, V77, P1510, DOI 10.1158/0008-5472.CAN-16-2346
   Stunnenberg HG, 2016, CELL, V167, P1897, DOI 10.1016/j.cell.2016.12.002
   Stunnenberg HG, 2016, CELL, V167, P1145, DOI 10.1016/j.cell.2016.11.007
   Teschendorff AE, 2017, BMC BIOINFORMATICS, V18, DOI 10.1186/s12859-017-1511-5
   Teschendorff AE, 2016, GENOME MED, V8, DOI 10.1186/s13073-016-0342-8
   Teschendorff AE, 2016, BMC BIOINFORMATICS, V17, DOI 10.1186/s12859-016-1056-z
   Teschendorff AE, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10478
   Teschendorff AE, 2012, GENOME MED, V4, DOI 10.1186/gm323
   Teschendorff AE, 2010, GENOME RES, V20, P440, DOI 10.1101/gr.103606.109
   Tian L, 2011, BIOSTATISTICS, V12, P68, DOI 10.1093/biostatistics/kxq047
   Tomasetti C, 2013, P NATL ACAD SCI USA, V110, P1999, DOI 10.1073/pnas.1221068110
   Ushijima T, 2007, J BIOCHEM MOL BIOL, V40, P142
   Ushijima T, 2012, CLIN CANCER RES, V18, P923, DOI 10.1158/1078-0432.CCR-11-2011
   Waldmann Patrik, 2013, Frontiers in Genetics, V4, P270, DOI 10.3389/fgene.2013.00270
   Widschwendter M, 2017, GENOME MED, V9, DOI 10.1186/s13073-017-0499-9
   Widschwendter M, 2017, GENOME MED, V9, DOI 10.1186/s13073-017-0500-7
   Xu ZL, 2013, JNCI-J NATL CANCER I, V105, P694, DOI 10.1093/jnci/djt045
   Yamashita S, 2018, P NATL ACAD SCI USA, V115, P1328, DOI 10.1073/pnas.1717340115
   Yang Z, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-1064-3
NR 57
TC 23
Z9 24
U1 0
U2 11
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 2352-3964
J9 EBIOMEDICINE
JI EBioMedicine
PD MAY
PY 2018
VL 31
BP 243
EP 252
DI 10.1016/j.ebiom.2018.04.025
PG 10
WC Medicine, General & Internal; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine; Research & Experimental Medicine
GA GH0FS
UT WOS:000433078300030
PM 29735413
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Chen, Y
   Zhang, B
   Bao, L
   Jin, L
   Yang, MM
   Peng, Y
   Kumar, A
   Wang, JE
   Wang, CL
   Zou, X
   Xing, C
   Wang, YF
   Luo, WB
AF Chen, Yan
   Zhang, Bo
   Bao, Lei
   Jin, Lai
   Yang, Mingming
   Peng, Yan
   Kumar, Ashwani
   Wang, Jennifer E.
   Wang, Chenliang
   Zou, Xuan
   Xing, Chao
   Wang, Yingfei
   Luo, Weibo
TI ZMYND8 acetylation mediates HIF-dependent breast cancer progression and
   metastasis
SO JOURNAL OF CLINICAL INVESTIGATION
LA English
DT Article
ID HYPOXIA-INDUCIBLE FACTOR-1; EPITHELIAL-MESENCHYMAL TRANSITION;
   RNA-POLYMERASE-II; HISTONE; CHROMATIN; TRANSCRIPTION; COMPLEX; PROTEIN;
   ANGIOGENESIS; METHYLATION
AB Altered epigenetic reprogramming contributes to breast cancer progression and metastasis. How the epigenetic reader mediates breast cancer progression remains poorly understood. Here, we showed that the epigenetic reader zinc finger MYND-type containing 8 (ZMYND8) is induced by HIF-1 and HIF-2 in breast cancer cells and also upregulated in human breast tumors, and is correlated with poor survival of patients with breast cancer. Genetic deletion of ZMYND8 decreases breast cancer cell colony formation, migration, and invasion in vitro, and inhibits breast tumor growth and metastasis to the lungs in mice. The ZMYND8's oncogenic effect in breast cancer requires HIF-1 and HIF-2. We further showed that ZMYND8 interacts with HIF-1 alpha and HIF-2 alpha and enhances elongation of the global HIF-induced oncogenic genes by increasing recruitment of BRD4 and subsequent release of paused RNA polymerase II in breast cancer cells. ZMYND8 acetylation at lysines 1007 and 1034 by p300 is required for HIF activation and breast cancer progression and metastasis. These findings uncover a primary epigenetic mechanism of HIF activation and HIF-mediated breast cancer progression, and discover a possible molecular target for the diagnosis and treatment of breast cancer.
C1 [Chen, Yan; Zhang, Bo; Bao, Lei; Jin, Lai; Yang, Mingming; Peng, Yan; Wang, Jennifer E.; Wang, Chenliang; Zou, Xuan; Luo, Weibo] UT Southwestern Med Ctr, Dept Pathol, 5323 Harry Hines Blvd,NB6-460, Dallas, TX 75390 USA.
   [Chen, Yan; Zhang, Bo; Bao, Lei; Jin, Lai; Yang, Mingming; Peng, Yan; Wang, Jennifer E.; Wang, Chenliang; Zou, Xuan; Wang, Yingfei] UT Southwestern Med Ctr, Dept Pathol, 5323 Harry Hines Blvd,NB6-456, Dallas, TX 75390 USA.
   [Kumar, Ashwani; Xing, Chao] UT Southwestern Med Ctr, Eugene McDermott Ctr Human Growth & Dev, Dallas, TX USA.
   [Xing, Chao] UT Southwestern Med Ctr, Dept Bioinformat, Dallas, TX USA.
   [Xing, Chao] UT Southwestern Med Ctr, Dept Clin Sci, Dallas, TX USA.
   [Wang, Yingfei] UT Southwestern Med Ctr, Dept Neurol & Neurotherapeut, Dallas, TX USA.
   [Luo, Weibo] UT Southwestern Med Ctr, Dept Pharmacol, Dallas, TX USA.
C3 University of Texas System; University of Texas Southwestern Medical
   Center Dallas; University of Texas System; University of Texas
   Southwestern Medical Center Dallas; University of Texas System;
   University of Texas Southwestern Medical Center Dallas; University of
   Texas System; University of Texas Southwestern Medical Center Dallas;
   University of Texas System; University of Texas Southwestern Medical
   Center Dallas; University of Texas System; University of Texas
   Southwestern Medical Center Dallas; University of Texas System;
   University of Texas Southwestern Medical Center Dallas
RP Luo, WB (通讯作者)，UT Southwestern Med Ctr, Dept Pathol, 5323 Harry Hines Blvd,NB6-460, Dallas, TX 75390 USA.; Wang, YF (通讯作者)，UT Southwestern Med Ctr, Dept Pathol, 5323 Harry Hines Blvd,NB6-456, Dallas, TX 75390 USA.
EM yingfei.wang@utsouthwestern.edu; weibo.luo@utsouthwestern.edu
RI Zou, Xuan/A-6452-2015; Kumar, Ashwani/ABC-6594-2020; CHEN,
   YAN/N-4135-2018
OI CHEN, YAN/0000-0003-3516-9546; Xing, Chao/0000-0002-1838-0502; wang,
   chenliang/0000-0003-4388-681X; wang, yingfei/0000-0002-8723-252X; Luo,
   Weibo/0000-0002-1992-0320
FU NCI Cancer Center grant [P30CA142543]; Susan G. Komen [CCR16376227]; NIH
   [R00CA168746, R00NS078049, R35GM124693, UL1TR001105]; Cancer Prevention
   & Research Institute of Texas (CPRIT) [RR140036]; American Cancer
   Society/ UTSW Simmons Cancer Center [ACS-IRG-02-196]
FX We thank Gregg L. Semenza (Johns Hopkins) for HeLa, HEK293T, MCF-7,
   T47D, HCC1954, and SUM159 cells; Rolf Brekken (UT Southwestern) for
   MDA-MB-231 cells; Cheng-Ming Chiang (UT Southwestern) for BRD4 plasmids
   and purified p300, PCAF, and GCN5 proteins; Kyle Miller (The University
   of Texas at Austin) for SFB-ZMYND8 plasmids; and Lei Guo (UT
   Southwestern) for generation of FLAG-HIF-2 alpha plasmid. We also thank
   the UTSW Cancer Center Tissue Resource for assistance with
   immunohistochemistry (supported by NCI Cancer Center grant P30CA142543),
   the UTSW Next Generation Sequencing Core for assistance with RNA-seq and
   ChIP-seq, and the UTSW Pathology digital imaging core for TMA slide
   scanning. We are grateful to Carole Baas (Dallas, Texas, USA) for
   comments on the manuscript. This work was supported by grants from Susan
   G. Komen (CCR16376227), NIH (R00CA168746), the Cancer Prevention &
   Research Institute of Texas (CPRIT, RR140036), and the American Cancer
   Society/ UTSW Simmons Cancer Center (ACS-IRG-02-196) to WL, and grants
   from NIH (R00NS078049, R35GM124693) to YW. CX was partially supported by
   NIH grant UL1TR001105. WL is a CPRIT Scholar in Cancer Research.
CR Adhikary S, 2016, J BIOL CHEM, V291, P2664, DOI 10.1074/jbc.M115.679985
   Arany Z, 1996, P NATL ACAD SCI USA, V93, P12969, DOI 10.1073/pnas.93.23.12969
   Bradner JE, 2017, CELL, V168, P629, DOI 10.1016/j.cell.2016.12.013
   Chang CJ, 2011, CANCER CELL, V19, P86, DOI 10.1016/j.ccr.2010.10.035
   Cho MH, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8821
   Choudhry H, 2014, EMBO REP, V15, P70, DOI 10.1002/embr.201337642
   Dong CF, 2012, J CLIN INVEST, V122, P1469, DOI 10.1172/JCI57349
   Ell B, 2013, TRENDS CELL BIOL, V23, P603, DOI 10.1016/j.tcb.2013.06.001
   Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4
   Erler JT, 2009, CANCER CELL, V15, P35, DOI 10.1016/j.ccr.2008.11.012
   Esteva-Font C, 2014, FASEB J, V28, P1446, DOI 10.1096/fj.13-245621
   Filippakopoulos P, 2010, NATURE, V468, P1067, DOI 10.1038/nature09504
   Fossey SC, 2000, MAMM GENOME, V11, P919, DOI 10.1007/s003350010174
   Galbraith MD, 2013, CELL, V153, P1327, DOI 10.1016/j.cell.2013.04.048
   Gong FD, 2015, GENE DEV, V29, P197, DOI 10.1101/gad.252189.114
   Gu YZ, 1998, GENE EXPRESSION, V7, P205
   Hong XY, 2013, CELL BIOCHEM BIOPHYS, V67, P1487, DOI 10.1007/s12013-013-9650-4
   Jang MK, 2005, MOL CELL, V19, P523, DOI 10.1016/j.molcel.2005.06.027
   Kim JH, 2014, CANCER RES, V74, P1705, DOI 10.1158/0008-5472.CAN-13-1896
   Kuroyanagi J, 2014, FEBS LETT, V588, P3409, DOI 10.1016/j.febslet.2014.07.033
   Lee JS, 2011, P NATL ACAD SCI USA, V108, P13510, DOI 10.1073/pnas.1106106108
   Lee JS, 2010, MOL CELL, V39, P71, DOI 10.1016/j.molcel.2010.06.008
   Li N, 2016, MOL CELL, V63, P470, DOI 10.1016/j.molcel.2016.06.035
   Luo WB, 2018, CELL MOL LIFE SCI, V75, P1043, DOI 10.1007/s00018-017-2684-9
   Luo WB, 2012, P NATL ACAD SCI USA, V109, pE3367, DOI 10.1073/pnas.1217394109
   Luo ZJ, 2012, NAT REV MOL CELL BIO, V13, P543, DOI 10.1038/nrm3417
   Malovannaya A, 2011, CELL, V145, P787, DOI 10.1016/j.cell.2011.05.006
   Panagopoulos I, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063663
   Perez-Perri JI, 2016, CELL REP, V16, P37, DOI 10.1016/j.celrep.2016.05.082
   Pollard PJ, 2008, BIOCHEM J, V416, P387, DOI 10.1042/BJ20081238
   Pugh CW, 2003, NAT MED, V9, P677, DOI 10.1038/nm0603-677
   Ramadoss S, 2012, J BIOL CHEM, V287, P44508, DOI 10.1074/jbc.M112.424903
   Savitsky P, 2016, CELL REP, V17, P2724, DOI 10.1016/j.celrep.2016.11.014
   Semenza GL, 1996, J BIOL CHEM, V271, P32529, DOI 10.1074/jbc.271.51.32529
   Semenza GL, 2012, TRENDS PHARMACOL SCI, V33, P207, DOI 10.1016/j.tips.2012.01.005
   Shen HJ, 2016, CELL, V165, P331, DOI 10.1016/j.cell.2016.02.064
   Shi L, 2011, P NATL ACAD SCI USA, V108, P7541, DOI 10.1073/pnas.1017374108
   Shu SK, 2016, NATURE, V529, P413, DOI 10.1038/nature16508
   Tian H, 1997, GENE DEV, V11, P72, DOI 10.1101/gad.11.1.72
   Vaupel P, 2004, METHOD ENZYMOL, V381, P335
   Wada Yusaku, 2014, J Clin Bioinforma, V4, P3, DOI 10.1186/2043-9113-4-3
   WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510
   Wen H, 2014, NATURE, V508, P263, DOI 10.1038/nature13045
   Wong CCL, 2011, P NATL ACAD SCI USA, V108, P16369, DOI 10.1073/pnas.1113483108
   Wu MZ, 2011, MOL CELL, V43, P811, DOI 10.1016/j.molcel.2011.07.012
   Wu SY, 2013, MOL CELL, V49, P843, DOI 10.1016/j.molcel.2012.12.006
   Xia LM, 2017, CANCER CELL, V31, P653, DOI 10.1016/j.ccell.2017.04.005
   Yu M, 2015, SCIENCE, V350, P1383, DOI 10.1126/science.aad2338
   Zhang H, 2012, ONCOGENE, V31, P1757, DOI 10.1038/onc.2011.365
   Zhang J, 2015, EMBO J, V34, P2953, DOI 10.15252/embj.201591437
NR 50
TC 122
Z9 130
U1 2
U2 25
PU AMER SOC CLINICAL INVESTIGATION INC
PI ANN ARBOR
PA 2015 MANCHESTER RD, ANN ARBOR, MI 48104 USA
SN 0021-9738
EI 1558-8238
J9 J CLIN INVEST
JI J. Clin. Invest.
PD MAY 1
PY 2018
VL 128
IS 5
BP 1937
EP 1955
DI 10.1172/JCI95089
PG 19
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA GF4UK
UT WOS:000431959100023
PM 29629903
OA Bronze, Green Published
DA 2025-01-12
ER

PT J
AU Li, TB
   Liu, Q
   Garza, N
   Kornblau, S
   Jin, VX
AF Li, Tianbao
   Liu, Qi
   Garza, Nick
   Kornblau, Steven
   Jin, Victor X.
TI Integrative analysis reveals functional and regulatory roles of H3K79me2
   in mediating alternative splicing
SO GENOME MEDICINE
LA English
DT Article
DE Alternative Splicing; H3K79me2; DOT1L; AML
ID MLL-REARRANGED LEUKEMIA; HEMATOLOGICAL MALIGNANCIES; EPIGENETIC
   DYSREGULATION; HISTONE MODIFICATIONS; MAMMALIAN-CELLS; GENE-EXPRESSION;
   FUSION PROTEINS; BINDING-SITES; BREAST-CANCER; WEB SERVER
AB Background: Accumulating evidence suggests alternative splicing (AS) is a co-transcriptional splicing process not only controlled by RNA-binding splicing factors, but also mediated by epigenetic regulators, such as chromatin structure, nucleosome density, and histone modification. Aberrant AS plays an important role in regulating various diseases, including cancers.
   Methods: In this study, we integrated AS events derived from RNA-seq with H3K79me2 ChIP-seq data across 34 different normal and cancer cell types and found the higher enrichment of H3K79me2 in two AS types, skipping exon (SE) and alternative 3' splice site (A3SS).
   Results: Interestingly, by applying self-organizing map (SOM) clustering, we unveiled two clusters mainly comprised of blood cancer cell types with a strong correlation between H3K79me2 and SE. Remarkably, the expression of transcripts associated with SE was not significantly different from that of those not associated with SE, indicating the involvement of H3K79me2 in splicing has little impact on full mRNA transcription. We further showed that the deletion of DOT1L1, the sole H3K79 methyltransferase, impeded leukemia cell proliferation as well as switched exon skipping to the inclusion isoform in two MLL-rearranged acute myeloid leukemia cell lines. Our data demonstrate H3K79me2 was involved in mediating SE processing, which might in turn influence transformation and disease progression in leukemias.
   Conclusions: Collectively, our work for the first time reveals that H3K79me2 plays functional and regulatory roles through a co-transcriptional splicing mechanism.
C1 [Li, Tianbao] Jilin Univ, Coll Life Sci, Changchun 130012, Jilin, Peoples R China.
   [Li, Tianbao; Liu, Qi; Garza, Nick; Jin, Victor X.] Univ Texas Hlth, Dept Mol Med, 8403 Floyd Curl, San Antonio, TX 78229 USA.
   [Garza, Nick] Johns Hopkins Univ, Dept Biomed Engn, Baltimore, MD 21218 USA.
   [Kornblau, Steven] UT MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA.
C3 Jilin University; University of Texas System; University of Texas Health
   Science Center at San Antonio; Johns Hopkins University; University of
   Texas System; UTMD Anderson Cancer Center
RP Jin, VX (通讯作者)，Univ Texas Hlth, Dept Mol Med, 8403 Floyd Curl, San Antonio, TX 78229 USA.
EM JinV@uthscsa.edu
FU NIH [R01GM114142, U54CA217297]; Owens foundation; NIH; Scholarship of
   Jilin University; National Institute of General Medical Sciences
   [R01GM114142] Funding Source: NIH RePORTER
FX This study is partially supported by NIH R01GM114142 and U54CA217297, as
   well as Owens foundation. Funding for open access charge: NIH. The
   authors gratefully acknowledge financial support from Scholarship of
   Jilin University.
CR Agirre E, 2015, BMC BIOL, V13, DOI 10.1186/s12915-015-0141-5
   Andersson R, 2009, GENOME RES, V19, P1732, DOI 10.1101/gr.092353.109
   Nguyen AT, 2011, GENE DEV, V25, P1345, DOI 10.1101/gad.2057811
   Ayton PM, 2001, ONCOGENE, V20, P5695, DOI 10.1038/sj.onc.1204639
   Bernt KM, 2011, CANCER CELL, V20, P66, DOI 10.1016/j.ccr.2011.06.010
   Braunschweig U, 2014, GENOME RES, V24, P1774, DOI 10.1101/gr.177790.114
   Chen CW, 2015, NAT MED, V21, P335, DOI 10.1038/nm.3832
   Chen EY, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-128
   da Costa PJ, 2017, INT J BIOCHEM CELL B, V91, P168, DOI 10.1016/j.biocel.2017.07.013
   Daigle SR, 2013, BLOOD, V122, P1017, DOI 10.1182/blood-2013-04-497644
   Daser A, 2004, GENE DEV, V18, P965, DOI 10.1101/gad.1195504
   de Almeida SF, 2011, NAT STRUCT MOL BIOL, V18, P977, DOI 10.1038/nsmb.2123
   Deshpande AJ, 2014, CANCER CELL, V26, P896, DOI 10.1016/j.ccell.2014.10.009
   Feng Q, 2002, CURR BIOL, V12, P1052, DOI 10.1016/S0960-9822(02)00901-6
   He X, 2014, ONCOGENESIS, V3, DOI 10.1038/oncsis.2013.47
   Huyen Y, 2004, NATURE, V432, P406, DOI 10.1038/nature03114
   Ilagan JO, 2015, GENOME RES, V25, P14, DOI 10.1101/gr.181016.114
   Katz Y, 2010, NAT METHODS, V7, P1009, DOI 10.1038/NMETH.1528
   Keren H, 2010, NAT REV GENET, V11, P345, DOI 10.1038/nrg2776
   Kerry J, 2017, CELL REP, V18, P482, DOI 10.1016/j.celrep.2016.12.054
   Kim D, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-4-r36
   Kim W, 2012, J BIOL CHEM, V287, P5588, DOI 10.1074/jbc.M111.328138
   Kimura A, 2002, NAT GENET, V32, P370, DOI 10.1038/ng993
   Kolasinska-Zwierz P, 2009, NAT GENET, V41, P376, DOI 10.1038/ng.322
   Krivtsov AV, 2007, NAT REV CANCER, V7, P823, DOI 10.1038/nrc2253
   Kuleshov MV, 2016, NUCLEIC ACIDS RES, V44, pW90, DOI 10.1093/nar/gkw377
   Landau DA, 2013, GENOME MED, V5, DOI 10.1186/gm451
   Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/NMETH.1923, 10.1038/nmeth.1923]
   Li JZ, 2015, PROTEOMICS, V15, P68, DOI 10.1002/pmic.201400146
   Li TB, 2015, J GENET, V94, P125, DOI 10.1007/s12041-015-0475-3
   Listerman I, 2006, NAT STRUCT MOL BIOL, V13, P815, DOI 10.1038/nsmb1135
   Liu JF, 2012, GENOME RES, V22, P2315, DOI 10.1101/gr.140988.112
   Liu Q, 2017, BMC GENOMICS, V18, DOI 10.1186/s12864-017-3764-9
   Long L, 2014, J BIOL CHEM, V289, P8916, DOI 10.1074/jbc.M114.551754
   Luco RF, 2011, CELL, V144, P16, DOI 10.1016/j.cell.2010.11.056
   Mohan M, 2010, GENE DEV, V24, P574, DOI 10.1101/gad.1898410
   Mueller D, 2007, BLOOD, V110, P4445, DOI 10.1182/blood-2007-05-090514
   Nilsen TW, 2010, NATURE, V463, P457, DOI 10.1038/nature08909
   Ntziachristos P, 2016, NAT IMMUNOL, V17, P1016, DOI 10.1038/ni.3517
   Pan Q, 2008, NAT GENET, V40, P1413, DOI 10.1038/ng.259
   Paz I, 2014, NUCLEIC ACIDS RES, V42, pW361, DOI 10.1093/nar/gku406
   Riedel SS, 2016, J CLIN INVEST, V126, P1438, DOI 10.1172/JCI80825
   Roberts GC, 1998, NUCLEIC ACIDS RES, V26, P5568, DOI 10.1093/nar/26.24.5568
   Santoro M, 2013, MOL CELL BIOCHEM, V380, P259, DOI 10.1007/s11010-013-1681-z
   Singh NN, 2013, NUCLEIC ACIDS RES, V41, P8144, DOI 10.1093/nar/gkt609
   Spies N, 2009, MOL CELL, V36, P245, DOI 10.1016/j.molcel.2009.10.008
   Steger DJ, 2008, MOL CELL BIOL, V28, P2825, DOI 10.1128/MCB.02076-07
   Suka N, 2002, NAT GENET, V32, P378, DOI 10.1038/ng1017
   Sveen A, 2011, GENOME MED, V3, DOI 10.1186/gm248
   Takahashi H, 2015, MOL CANCER THER, V14, P1705, DOI 10.1158/1535-7163.MCT-14-0142
   Trincado JL, 2016, GENOME MED, V8, DOI 10.1186/s13073-016-0339-3
   Verma A, 2015, GENOME MED, V7, DOI 10.1186/s13073-015-0230-7
   Walter KR, 2017, MOL CANCER RES, V15, P1331, DOI 10.1158/1541-7786.MCR-17-0180
   Wang QF, 2011, BLOOD, V117, P6895, DOI 10.1182/blood-2010-12-324699
   Wang ZB, 2008, NAT GENET, V40, P897, DOI 10.1038/ng.154
   Wysocki R, 2005, MOL CELL BIOL, V25, P8430, DOI 10.1128/MCB.25.19.8430-8443.2005
   Xie D, 2013, CELL, V155, P713, DOI 10.1016/j.cell.2013.09.043
   Xu YF, 2014, NUCLEIC ACIDS RES, V42, P10960, DOI 10.1093/nar/gku781
   Ye ZQ, 2014, NUCLEIC ACIDS RES, V42, P2856, DOI 10.1093/nar/gkt1338
   Yuan HR, 2017, J CLIN INVEST, V127, P3381, DOI 10.1172/JCI94292
   Zhang XJ, 2016, J BIOL CHEM, V291, P12786, DOI 10.1074/jbc.M116.721159
   Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r137
   Zhou HL, 2011, P NATL ACAD SCI USA, V108, pE627, DOI 10.1073/pnas.1103344108
   Zhu JJ, 2015, NATURE, V525, P206, DOI 10.1038/nature15251
   Zhu L, 2014, HUM MOL GENET, V23, P1563, DOI 10.1093/hmg/ddt547
NR 65
TC 23
Z9 30
U1 0
U2 12
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1756-994X
J9 GENOME MED
JI Genome Med.
PD APR 17
PY 2018
VL 10
AR 30
DI 10.1186/s13073-018-0538-1
PG 11
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA GD6MT
UT WOS:000430623800001
PM 29665865
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU Liu, WS
   Chan, SH
   Chang, HT
   Li, GC
   Tu, YT
   Tseng, HH
   Fu, TY
   Chang, HY
   Liou, HH
   Ger, LP
   Tsai, KW
AF Liu, Wen-Shan
   Chan, Shih-Hsuan
   Chang, Hong-Tai
   Li, Guan-Cheng
   Tu, Ya-Ting
   Tseng, Hui-Hwa
   Fu, Ting-Ying
   Chang, Hui-Yu
   Liou, Huei-Han
   Ger, Luo-Ping
   Tsai, Kuo-Wang
TI Isocitrate dehydrogenase 1-snail axis dysfunction significantly
   correlates with breast cancer prognosis and regulates cell invasion
   ability
SO BREAST CANCER RESEARCH
LA English
DT Article
ID EPITHELIAL-MESENCHYMAL TRANSITION; IDH2 MUTATIONS; COMPETITIVE
   INHIBITOR; EXPRESSION; MIR-92B; PROLIFERATION; TUMORIGENESIS; MIGRATION;
   APOPTOSIS; PROMOTES
AB Background: The isocitrate dehydrogenase (IDH) gene family expresses key functional metabolic enzymes in the Krebs cycle and mediates the epigenetic reprogramming, which serves as an important biomarker of breast cancer. However, the expression levels of the IDH protein and their biological function in human breast cancer remain largely unknown.& para;& para;Methods: In this study, the clinical impact of IDH1 expression on the progression and prognosis of breast cancer was evaluated using immunohistochemistry assay (INC) of the corresponding tumor-adjacent normal, ductal carcinoma in situ (DCIS), and invasive ductal carcinoma (IDC) tissues from 309 patients with breast ductal carcinoma. The relationship between microRNA (miRNA) and IDH1 were examined by a bioinformatics approach, western blot and reporter assay. The biological functions of IDH1 were examined in breast cancer cells with IDH1 knockdown, including proliferation, migration and invasion.& para;& para;Results: The present findings revealed that the mRNA and protein expression levels of IDH1 were both significantly lower in breast cancer tissues than in adjacent normal tissues. A low expression level of IDH1 in breast cancer significantly correlated with advanced stage (p = 0.012), lymph node metastasis (p = 0.018), and poor disease-specific survival (DSS) (adjusted hazard ratio (AHR), 1.57, 95% confidence interval (CI), 1.08-230; p = 0.02). Furthermore, oncogenic miR-32 and miR-92b were identified to suppress IDH1 expression, leading to the inhibition of cell migration and invasion. We further explored whether reduced expression of IDH1 significantly increases snail expression by activating HIF alpha (hypoxia-inducible factor-1 alpha) and NF kappa B (nuclear factor kappa B) signaling. Multivariate Cox regression analysis revealed that the combination of low IDH1 and high snail expression could be an independent risk factor for shorter DSS (AHR, 2.34; 95% CI, 132-4.16; p = 0.004) and shorter disease-free survival (AHR, 2.50; 95% CI, 1.39 4.50; p = 0.002) in patients with breast cancer.& para;& para;Conclusion: Our findings revealed that a IDH1 1 'w/Snail hi g h molecular signature could serve as an independent biomarker for poor prognosis in breast cancer.
C1 [Liu, Wen-Shan] Kaohsiung Vet Gen Hosp, Dept Radiat Oncol, Kaohsiung, Taiwan.
   [Liu, Wen-Shan] Natl Def Med Ctr, Sch Med, Taipei, Taiwan.
   [Chan, Shih-Hsuan] Natl Hlth Res Inst, Inst Mol & Genom Med, Zhunan, Taiwan.
   [Chan, Shih-Hsuan] Natl Tsing Hua Univ, Coll Life Sci, Inst Mol Med, Hsinchu, Taiwan.
   [Chan, Shih-Hsuan] China Med Univ, Grad Inst Integrated Med, Taichung, Taiwan.
   [Chang, Hong-Tai] Kaohsiung Vet Gen Hosp, Dept Surg, Kaohsiung, Taiwan.
   [Li, Guan-Cheng; Tu, Ya-Ting; Chang, Hui-Yu; Liou, Huei-Han; Ger, Luo-Ping; Tsai, Kuo-Wang] Kaohsiung Vet Gen Hosp, Dept Med Educ & Res, Kaohsiung 813, Taiwan.
   [Tseng, Hui-Hwa; Fu, Ting-Ying] Kaohsiung Vet Gen Hosp, Dept Pathol & Lab Med, Kaohsiung, Taiwan.
   [Tsai, Kuo-Wang] Natl Pingtung Univ Educ, Dept Chem Biol, Pingtung, Taiwan.
   [Tsai, Kuo-Wang] Natl Sun Yat Sen Univ, Inst Biomed Sci, Kaohsiung, Taiwan.
C3 Kaohsiung Veterans General Hospital; National Defense Medical Center;
   National Health Research Institutes - Taiwan; National Tsing Hua
   University; China Medical University Taiwan; Kaohsiung Veterans General
   Hospital; Kaohsiung Veterans General Hospital; Kaohsiung Veterans
   General Hospital; National Pingtung University; National Sun Yat Sen
   University
RP Tsai, KW (通讯作者)，Kaohsiung Vet Gen Hosp, Dept Med Educ & Res, Kaohsiung 813, Taiwan.; Tsai, KW (通讯作者)，Natl Pingtung Univ Educ, Dept Chem Biol, Pingtung, Taiwan.; Tsai, KW (通讯作者)，Natl Sun Yat Sen Univ, Inst Biomed Sci, Kaohsiung, Taiwan.
EM kwtsai6733@gmail.com
RI Chung, Chi-Hsiang/AAY-3386-2021; Chan, Shih-Hsuan/AAW-6857-2020; Tsai,
   Kuo-Wang/AFS-8885-2022
OI Tsai, Kuo-Wang/0000-0002-9028-9834; Chan, Shih-Hsuan/0000-0002-8703-5139
FU Kaohsiung Veterans General Hospital [VGHKS106-118, VGHKS106-174,
   VGHKS107-171]
FX This study was supported by grants from Kaohsiung Veterans General
   Hospital (VGHKS106-118, VGHKS106-174 and VGHKS107-171).
CR Bleeker FE, 2009, HUM MUTAT, V30, P7, DOI 10.1002/humu.20937
   Calza S, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1517
   Cannito S, 2008, CARCINOGENESIS, V29, P2267, DOI 10.1093/carcin/bgn216
   Cheng HH, 2012, P NATL ACAD SCI USA, V109, P13231, DOI 10.1073/pnas.1209919109
   Cheng LN, 2016, GENE, V595, P31, DOI 10.1016/j.gene.2016.09.028
   Chou NH, 2016, ANTICANCER RES, V36, P3983
   D'Uva G, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080742
   Dang L, 2009, NATURE, V462, P739, DOI 10.1038/nature08617
   Duan WX, 2014, MOL MED REP, V10, P2505, DOI 10.3892/mmr.2014.2551
   Figueroa ME, 2010, CANCER CELL, V18, P553, DOI 10.1016/j.ccr.2010.11.015
   Hanauske-Abel HM, 2003, CURR MED CHEM, V10, P1005, DOI 10.2174/0929867033457601
   Hossain A, 2006, MOL CELL BIOL, V26, P8191, DOI 10.1128/MCB.00242-06
   Huang J, 2016, ONCOL REP, V36, P1693, DOI 10.3892/or.2016.4940
   Kim HJ, 2005, BIOCHEM BIOPH RES CO, V337, P685, DOI 10.1016/j.bbrc.2005.09.104
   Lee SM, 2002, FREE RADICAL BIO MED, V32, P1185, DOI 10.1016/S0891-5849(02)00815-8
   Lee SJ, 2014, BMB REP, V47, P209, DOI 10.5483/BMBRep.2014.47.4.137
   Liu SQ, 2015, HUM GENOMICS, V9, DOI 10.1186/s40246-015-0024-4
   Lu C, 2012, NATURE, V483, P474, DOI 10.1038/nature10860
   Ma G, 2017, ONCOTARGET, V8, P6681, DOI 10.18632/oncotarget.14259
   Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459
   McDonough MA, 2006, P NATL ACAD SCI USA, V103, P9814, DOI 10.1073/pnas.0601283103
   Morin A, 2014, INT J CANCER, V135, P2237, DOI 10.1002/ijc.29080
   Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093
   Rakheja D, 2012, HUM PATHOL, V43, P1541, DOI 10.1016/j.humpath.2012.05.003
   Raynaud S, 2010, ONCOL LETT, V1, P883, DOI 10.3892/ol_00000156
   Riehmer V, 2014, GENE CHROMOSOME CANC, V53, P589, DOI 10.1002/gcc.22169
   Shibata T, 2011, AM J PATHOL, V178, P1395, DOI 10.1016/j.ajpath.2010.12.011
   Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100
   Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098
   Tsai KW, 2016, SCI REP-UK, V6, DOI 10.1038/srep28176
   Tsai KW, 2015, BREAST CANCER RES TR, V153, P219, DOI 10.1007/s10549-015-3525-x
   Turcan S, 2012, NATURE, V483, P479, DOI 10.1038/nature10866
   Wang ZP, 2015, SCI REP-UK, V5, DOI 10.1038/srep09301
   Ward PS, 2010, CANCER CELL, V17, P225, DOI 10.1016/j.ccr.2010.01.020
   Wu Y, 2009, CANCER CELL, V15, P416, DOI 10.1016/j.ccr.2009.03.016
   Wu ZB, 2013, BRAIN RES, V1529, P16, DOI 10.1016/j.brainres.2013.07.031
   Xia HM, 2015, BIOMED PHARMACOTHER, V75, P105, DOI 10.1016/j.biopha.2015.07.037
   Xia W, 2017, CANCER CELL INT, V17, DOI 10.1186/s12935-017-0383-0
   Xu W, 2011, CANCER CELL, V19, P17, DOI 10.1016/j.ccr.2010.12.014
   Yan H, 2009, NEW ENGL J MED, V360, P765, DOI 10.1056/NEJMoa0808710
   Yang H, 2012, CLIN CANCER RES, V18, P5562, DOI 10.1158/1078-0432.CCR-12-1773
   Yang Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058915
   Zhao SM, 2009, SCIENCE, V324, P261, DOI 10.1126/science.1170944
   Zhu SM, 2007, J BIOL CHEM, V282, P14328, DOI 10.1074/jbc.M611393200
   Zhuang LK, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.100
NR 45
TC 32
Z9 38
U1 0
U2 12
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1465-542X
EI 1465-5411
J9 BREAST CANCER RES
JI Breast Cancer Res.
PD APR 16
PY 2018
VL 20
AR 25
DI 10.1186/s13058-018-0953-7
PG 17
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA GD4AI
UT WOS:000430444500001
PM 29661250
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Akinyemiju, T
   Do, AN
   Patki, A
   Aslibekyan, S
   Zhi, DG
   Hidalgo, B
   Tiwari, HK
   Absher, D
   Geng, X
   Arnett, DK
   Irvin, MR
AF Akinyemiju, Tomi
   Do, Anh N.
   Patki, Amit
   Aslibekyan, Stella
   Zhi, Degui
   Hidalgo, Bertha
   Tiwari, Hemant K.
   Absher, Devin
   Geng, Xin
   Arnett, Donna K.
   Irvin, Marguerite R.
TI Epigenome-wide association study of metabolic syndrome in
   African-American adults
SO CLINICAL EPIGENETICS
LA English
DT Article
ID ALL-CAUSE MORTALITY; DNA METHYLATION; CANCER PROJECT; BREAST-CANCER;
   RISK-FACTORS; ME-CAN; METAANALYSIS; ABCA1; DISEASE; PROFILE
AB Background: The high prevalence of obesity among US adults has resulted in significant increases in associated metabolic disorders such as diabetes, dyslipidemia, and high blood pressure. Together, these disorders constitute metabolic syndrome, a clinically defined condition highly prevalent among African-Americans. Identifying epigenetic alterations associated with metabolic syndrome may provide additional information regarding etiology beyond current evidence from genome-wide association studies.
   Methods: Data on metabolic syndrome and DNA methylation was assessed on 614 African-Americans from the Hypertension Genetic Epidemiology Network (HyperGEN) study. Metabolic syndrome was defined using the joint harmonized criteria, and DNA methylation was assessed using the Illumina HumanMethylation450K Bead Chip assay on DNA extracted from buffy coat. Linear mixed effects regression models were used to examine the association between CpG methylation at >450,000 CpG sites and metabolic syndrome adjusted for study covariates. Replication using DNA from a separate sample of 69 African-Americans, as well as meta-analysis combining both cohorts, was conducted.
   Results: Two differentially methylated CpG sites in the IGF2BP1 gene on chromosome 17 (cg06638433; p value = 3.10 x 10(-7)) and the ABCG1 gene on chromosome 21 (cg06500161; p value = 2.60 x 10(-8)) were identified. Results for the ABCG1 gene remained statistically significant in the replication dataset and meta-analysis.
   Conclusion: Metabolic syndrome was consistently associated with increased methylation in the ABCG1 gene in the discovery and replication datasets, a gene that encodes a protein in the ATP-binding cassette transporter family and is involved in intra-and extra-cellular signaling and lipid transport.
C1 [Akinyemiju, Tomi] Univ Kentucky, Dept Epidemiol, Lexington, KY 40506 USA.
   [Do, Anh N.; Aslibekyan, Stella; Hidalgo, Bertha; Irvin, Marguerite R.] Univ Alabama Birmingham, Dept Epidemiol, Birmingham, AL USA.
   [Patki, Amit; Tiwari, Hemant K.] Univ Alabama Birmingham, Dept Biostat, Birmingham, AL 35294 USA.
   [Zhi, Degui; Geng, Xin] Univ Texas Hlth Sci Ctr Houston, Sch Biomed Informat, Houston, TX 77030 USA.
   [Zhi, Degui] Univ Texas Hlth Sci Ctr Houston, Sch Publ Hlth, Houston, TX 77030 USA.
   [Absher, Devin] HudsonAlpha Inst Biotechnol, Huntsville, AL USA.
   [Arnett, Donna K.] Univ Kentucky, Coll Publ Hlth, Lexington, KY USA.
C3 University of Kentucky; University of Alabama System; University of
   Alabama Birmingham; University of Alabama System; University of Alabama
   Birmingham; University of Texas System; University of Texas Health
   Science Center Houston; University of Texas System; University of Texas
   Health Science Center Houston; University of Texas School Public Health;
   HudsonAlpha Institute for Biotechnology; University of Kentucky
RP Akinyemiju, T (通讯作者)，Univ Kentucky, Dept Epidemiol, Lexington, KY 40506 USA.
EM tomiakin@uky.edu
RI zhi, Degui/B-1748-2008
OI Arnett, Donna/0000-0003-2219-657X
FU FIC NIH HHS [K01 TW010271] Funding Source: Medline; NIDDK NIH HHS [P30
   DK056336, P30 DK079626] Funding Source: Medline
CR Alberti KGMM, 2009, CIRCULATION, V120, P1640, DOI 10.1161/CIRCULATIONAHA.109.192644
   Ali O, 2016, EPIGENETICS-US, V11, P699, DOI 10.1080/15592294.2016.1216284
   Almquist M, 2011, CANCER CAUSE CONTROL, V22, P743, DOI 10.1007/s10552-011-9747-2
   Arnett DK, 2011, CIRC RES, V108, P279, DOI 10.1161/CIRCRESAHA.110.239210
   Aronica L, 2017, EPIGENOMICS-UK, V9, P769, DOI 10.2217/epi-2016-0182
   Bjorge T, 2010, CANCER EPIDEM BIOMAR, V19, P1737, DOI 10.1158/1055-9965.EPI-10-0230
   Borena W, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089368
   Borena W, 2012, INT J CANCER, V131, P193, DOI 10.1002/ijc.26338
   Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095
   Das M, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0145789
   de las Fuentes Lisa, 2013, Frontiers in Genetics, V4, P304, DOI 10.3389/fgene.2013.00304
   Dekkers KF, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-1000-6
   Demerath EW, 2015, HUM MOL GENET, V24, P4464, DOI 10.1093/hmg/ddv161
   El Roz A, 2012, ANTICANCER RES, V32, P3007
   Flegal KM, 2016, JAMA-J AM MED ASSOC, V315, P2284, DOI 10.1001/jama.2016.6458
   Ford ES, 2005, DIABETES CARE, V28, P1769, DOI 10.2337/diacare.28.7.1769
   Frazier-Wood AC, 2014, J LIPID RES, V55, P1324, DOI 10.1194/jlr.M048504
   Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088
   Guay SP, 2012, EPIGENETICS-US, V7, P464, DOI 10.4161/epi.19633
   Han B, 2011, AM J HUM GENET, V88, P586, DOI 10.1016/j.ajhg.2011.04.014
   Hedman ÅK, 2017, CIRC-CARDIOVASC GENE, V10, DOI 10.1161/CIRCGENETICS.116.001487
   Hidalgo B, 2014, DIABETES, V63, P801, DOI 10.2337/db13-1100
   Houseman EA, 2012, BMC BIOINFORMATICS, V13, DOI 10.1186/1471-2105-13-86
   Howard VJ, 2005, NEUROEPIDEMIOLOGY, V25, P135, DOI 10.1159/000086678
   Howie B, 2012, NAT GENET, V44, P955, DOI 10.1038/ng.2354
   Hui WS, 2010, EUR J EPIDEMIOL, V25, P375, DOI 10.1007/s10654-010-9459-z
   Johansen D, 2010, CANCER EPIDEM BIOMAR, V19, P2307, DOI 10.1158/1055-9965.EPI-10-0234
   Kulkarni H, 2015, HUM MOL GENET, V24, P5330, DOI 10.1093/hmg/ddv232
   Lourenço VM, 2011, BIOINFORMATICS, V27, P815, DOI 10.1093/bioinformatics/btr006
   Maksimovic J, 2012, GENOME BIOL, V13, DOI 10.1186/gb-2012-13-6-r44
   Moore JX, 2017, PREV CHRONIC DIS, V14, DOI 10.5888/pcd14.160287
   Mottillo S, 2010, J AM COLL CARDIOL, V56, P1113, DOI 10.1016/j.jacc.2010.05.034
   Price AL, 2008, AM J HUM GENET, V83, P132, DOI 10.1016/j.ajhg.2008.06.005
   Sayols-Baixeras S, 2016, HUM MOL GENET, V25, P4556, DOI 10.1093/hmg/ddw285
   Stocks T, 2015, INT J EPIDEMIOL, V44, P1353, DOI 10.1093/ije/dyv001
   Trasino SE, 2009, MOL CANCER THER, V8, P1934, DOI 10.1158/1535-7163.MCT-09-0020
   Ulmer H, 2012, GYNECOL ONCOL, V125, P330, DOI 10.1016/j.ygyno.2012.01.052
   Van Eck M, 2002, P NATL ACAD SCI USA, V99, P6298, DOI 10.1073/pnas.092327399
   Yoon G, 2017, BMC BIOINFORMATICS, V18, DOI 10.1186/s12859-017-1568-1
NR 39
TC 42
Z9 44
U1 0
U2 6
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1868-7083
J9 CLIN EPIGENETICS
JI Clin. Epigenetics
PD APR 10
PY 2018
VL 10
AR 49
DI 10.1186/s13148-018-0483-2
PG 8
WC Oncology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Genetics & Heredity
GA GC5PX
UT WOS:000429841200003
PM 29643945
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Doello, K
AF Doello, Kevin
TI The role of trophoblastic epigenetic reprogrammation in benign tumor
   cells on malignant progression: A molecular hypothesis
SO MEDICAL HYPOTHESES
LA English
DT Article
DE Cancer; Trophoblast; Metastasis; Invasiveness; Immunosuppressive
   potential; IGF2
ID PLASMA PROTEIN-A; HLA-G; BREAST-CANCER; G EXPRESSION; PREGNANCY;
   MELANOMA; PLACENTA; GROWTH; TOLERANCE
AB Cancer tissues and placental ones share many properties such as invasiveness, metastasis and local immunosuppressive effects. The goal of the present article is to hypothesize a theory about cancer origin that links placental and cancerous tissues at molecular level. This hypothesis explain that cancer origin could be due to low hypoxic conditions in the peripheral zones of benign tumors which might up-regulate the expression of IGF2, and, consequently, trophoblastic genes. In fact, many phenotypic characteristics and molecular markers are shared between these two cell types (cancerous and trophoblastics ones), providing evidences to support this hypothesis. As a consequence, it could be interesting to demonstrate whether cancer start with a cellular reprogrammation towards a trophoblastic fate in order to design new antitumoral strategies focused on this fact.
C1 [Doello, Kevin] Virgen Nieves Hosp Granada, Med Oncol Serv, Av Fuerzas Armadas Sn, Granada 18014, Spain.
RP Doello, K (通讯作者)，Virgen Nieves Hosp Granada, Med Oncol Serv, Av Fuerzas Armadas Sn, Granada 18014, Spain.
EM kdoello@correo.ugr.es
RI Doello, Kevin/AAJ-2593-2021
CR Ameri Kurosh, 2015, Mol Cell Oncol, V2, pe1030537, DOI 10.1080/23723556.2015.1030537
   Ameri K, 2015, CELL REP, V10, P891, DOI 10.1016/j.celrep.2015.01.020
   Beard J, 1912, BRIT MED J, V1912, P460
   Beard J, 1904, LANCET, V2, P1447
   Beard J, 1911, BRIT MED J, V1911, P1678
   Becker MA, 2015, MOL CANCER THER, V14, P973, DOI 10.1158/1535-7163.MCT-14-0880
   Bennett WA, EXPRESSION PRODUCTIO
   Bronchud M., 2008, PRINCIPLES MOL ONCOL, DOI [10.1007/978-1-59745-470-4, DOI 10.1007/978-1-59745-470-4]
   Bulut I, 2009, AM J MED SCI, V337, P241, DOI 10.1097/MAJ.0b013e31818967a3
   D'Addio F, 2011, J IMMUNOL, V187, P4530, DOI 10.4049/jimmunol.1002031
   Dua P, 2013, CANCER RES, V73, P1934, DOI 10.1158/0008-5472.CAN-12-3682
   Elliott RL, 2011, CANCER BIOTHER RADIO, V26, P153, DOI 10.1089/cbr.2010.0924
   Frieling GW, 2014, AM J DERMATOPATH, V36, P189, DOI 10.1097/DAD.0b013e318284a586
   Gregori S, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00128
   Hu W, TUMOR ASS MACROPHAGE, DOI DOI 10.1007/S12094-015-1373-0
   Huang Q, 2014, CELL SIGNAL, V26, P648, DOI 10.1016/j.cellsig.2013.11.002
   Huang YS, 2014, MED RES REV, V34, P532, DOI 10.1002/med.21297
   Isaka K, 2003, PLACENTA, V24, P53, DOI 10.1053/plac.2002.0867
   Khanna R, 1998, IMMUNOL CELL BIOL, V76, P20, DOI 10.1046/j.1440-1711.1998.00717.x
   Kim KJ, 2012, EXP MOL MED, V44, P10, DOI 10.3858/emm.2012.44.1.023
   Kumpel BM, 2012, VOX SANG, V102, P2, DOI 10.1111/j.1423-0410.2011.01533.x
   Larsson LI, 2007, THESCIENTIFICWORLDJO, V7, P1193, DOI 10.1100/tsw.2007.212
   Larsson LI, 2007, HUM PATHOL, V38, P726, DOI 10.1016/j.humpath.2006.10.018
   Longo LD, 2013, PERSPECT PHYSIOL, V1, P1, DOI 10.1007/978-1-4614-7921-5
   Maeda H, 2012, J CONTROL RELEASE, V164, P138, DOI 10.1016/j.jconrel.2012.04.038
   Mahoney KM, 2015, NAT REV DRUG DISCOV, V14, P561, DOI 10.1038/nrd4591
   McNanley T., 2008, Placental physiology
   Neumann A, HUMAN PLACENTAL ALKA
   Perán M, 2013, CELL ONCOL, V36, P289, DOI 10.1007/s13402-013-0134-8
   Petroff MG, 2003, PLACENTA, V24, P122, DOI 10.1053/plac.2002.0898
   Prithviraj P, 2015, ONCOTARGET, V6, P15953, DOI 10.18632/oncotarget.3643
   proteinatlas.org, The Human Protein Atlas
   Ravenni N, 2014, MABS-AUSTIN, V6, P86, DOI 10.4161/mabs.27230
   Rebmann V, 2007, SEMIN CANCER BIOL, V17, P422, DOI 10.1016/j.semcancer.2007.06.010
   Rouas-Freiss N, 2005, CANCER RES, V65, P10139, DOI 10.1158/0008-5472.CAN-05-0097
   Rouas-Freiss N, 2014, J IMMUNOL RES, V2014, DOI 10.1155/2014/359748
   Sato T, 2011, IMMUNOL RES, V51, P170, DOI 10.1007/s12026-011-8262-6
   Shvartsur A, TROP2 ITS OVEREXPRES
   Soares M, 2005, PLACENTA RES METHODS
   Strick R, 2007, J MOL MED, V85, P23, DOI 10.1007/s00109-006-0104-y
   Svensson-Arvelund J, 2015, J IMMUNOL, V194, P1534, DOI 10.4049/jimmunol.1401536
   Théate I, 2015, CANCER IMMUNOL RES, V3, P161, DOI 10.1158/2326-6066.CIR-14-0137
   Tuncel T, 2013, ASIAN PAC J CANCER P, V14, P7681, DOI 10.7314/APJCP.2013.14.12.7681
   Wu YJ, 2009, STEM CELLS DEV, V18, P1127, DOI 10.1089/scd.2008.0338
   Xuan YH, EXPRESSION TGF BETA
NR 45
TC 0
Z9 0
U1 0
U2 1
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0306-9877
EI 1532-2777
J9 MED HYPOTHESES
JI Med. Hypotheses
PD APR
PY 2018
VL 113
BP 68
EP 71
DI 10.1016/j.mehy.2018.02.019
PG 4
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA GC4MU
UT WOS:000429759400016
PM 29523298
DA 2025-01-12
ER

PT J
AU Maia, LD
   Peterle, GT
   dos Santos, M
   Trivilin, LO
   Mendes, SO
   de Oliveira, MM
   dos Santos, JG
   Stur, E
   Agostini, LP
   Couto, CVMD
   Dalbó, J
   de Assisi, ALEM
   Archanjo, AB
   Mercante, AMD
   Lopez, RVM
   Nunes, FD
   de Carvalho, MB
   Tajara, EH
   Louro, LD
   Alvares-da-Silva, AM
AF Maia, Lucas de Lima
   Peterle, Gabriela Tonini
   dos Santos, Marcelo
   Trivilin, Leonardo Oliveira
   Mendes, Suzanny Oliveira
   de Oliveira, Mayara Mota
   dos Santos, Joaquim Gasparini
   Stur, Elaine
   Agostini, Lidiane Pignaton
   Monteiro da Silva Couto, Cinthia Vidal
   Dalbo, Juliana
   Evangelista Monteiro de Assisi, Aricia Leone
   Archanjo, Anderson Barros
   Da Cunha Mercante, Ana Maria
   Mendoza Lopez, Rossana Veronica
   Nunes, Fabio Daumas
   de Carvalho, Marcos Brasilino
   Tajara, Eloiza Helena
   Louro, Luri Drumond
   Alvares-da-Silva, Adriana Madeira
TI JMJD1A, H3K9me1, H3K9me2 and ADM expression as prognostic markers in
   oral and oropharyngeal squamous cell carcinoma
SO PLOS ONE
LA English
DT Article
ID HISTONE LYSINE DEMETHYLASES; HYPOXIA-INDUCED EXPRESSION; BREAST-CANCER;
   HEPATOCELLULAR-CARCINOMA; EPIGENETIC REGULATION; TISSUE MICROARRAYS;
   NECK-CANCER; ADRENOMEDULLIN; SURVIVAL; TUMOR
AB Aims
   Jumonji Domain-Containing 1 A (JMJD1A) protein promotes demethylation of histones, especially at lysin-9 of di-methylated histone H3 (H3K9me2) or mono-methylated (H3K9me1). Increased levels of H3 histone methylation at lysin-9 (H3K9) is related to tumor suppressor gene silencing. JMJD1A gene target Adrenomeduline (ADM) has shown to promote cell growth and tumorigenesis. JMJD1A and ADM expression, as well as H3K9 methylation level have been related with development risk and prognosis of several tumor types.
   Methods and results
   We aimed to evaluate JMJD1A, ADM, H3K9me1 and H3K9me2expression in paraffin embedded tissue microarrays from 84 oral and oropharyngeal squamous cell carcinoma samples through immunohistochemistry analysis. Our results showed that nuclear JMJD1A expression was related to lymph node metastasis risk. In addition, JMJD1A cytoplasmic expression was an independent risk marker for advanced tumor stages. H3K9me1 cytoplasmic expression was associated with reduced disease-specific death risk. Furthermore, high H3K9me2 nuclear expression was associated with worse specific-disease and disease-free survival. Finally, high ADM cytoplasmic expression was an independent marker of lymph node metastasis risk.
   Conclusion
   JMJD1A, H3K9me1/2 and ADM expression may be predictor markers of progression and prognosis in oral and oropharynx cancer patients, as well as putative therapeutic targets.
C1 [Maia, Lucas de Lima; Peterle, Gabriela Tonini; Trivilin, Leonardo Oliveira; Mendes, Suzanny Oliveira; de Oliveira, Mayara Mota; dos Santos, Joaquim Gasparini; Stur, Elaine; Agostini, Lidiane Pignaton; Monteiro da Silva Couto, Cinthia Vidal; Dalbo, Juliana; Evangelista Monteiro de Assisi, Aricia Leone; Archanjo, Anderson Barros; Louro, Luri Drumond; Alvares-da-Silva, Adriana Madeira] Univ Fed Espirito Santo, Programa Posgrad Biotecnol, Vitoria, ES, Brazil.
   [dos Santos, Marcelo] Univ Fed Rio Grande do Norte, Escola Multicampi Ciencias Med Rio Grande Norte, Caico, RN, Brazil.
   [Da Cunha Mercante, Ana Maria] Hosp Heliopolis, Dept Anat Patol, Sao Paulo, Brazil.
   [Mendoza Lopez, Rossana Veronica] Inst Canc Estado Sao Paulo, Ctr Invest Translac Oncol, Sao Paulo, Brazil.
   [Nunes, Fabio Daumas] Univ Sao Paulo, Dept Patol Bucal, Fac Odontol, Sao Paulo, Brazil.
   [de Carvalho, Marcos Brasilino] Hosp Heliopolis, Lab Biol Mol, Sao Paulo, Brazil.
   [Tajara, Eloiza Helena] Fac Med, Dept Biol Mol, Sao Paulo, Brazil.
C3 Universidade Federal do Espirito Santo; Universidade Federal do Rio
   Grande do Norte; Universidade de Sao Paulo
RP Maia, LD (通讯作者)，Univ Fed Espirito Santo, Programa Posgrad Biotecnol, Vitoria, ES, Brazil.
EM lucas_lmbio@hotmail.com
RI de Carvalho, Marcos/C-1869-2014; dos Santos, Marcelo/K-2582-2012;
   Mendoza Lopez, Rossana Veronica/ABA-2587-2021; Tajara,
   Eloiza/G-7586-2012; Tonini Peterle, Gabriela/GWU-6986-2022; Barros
   Archanjo, Anderson/Q-5245-2017; Nunes, Fabio Daumas/B-4543-2011; Madeira
   Alvares da Silva, Adriana/J-2912-2018
OI Barros Archanjo, Anderson/0000-0002-9305-271X; Trivilin,
   Leonardo/0000-0002-3039-3269; Nunes, Fabio Daumas/0000-0002-7785-6785;
   MOTA DE OLIVEIRA, MAYARA/0000-0003-2735-9788; Gasparini dos Santos,
   Joaquim/0000-0001-6096-116X; Madeira Alvares da Silva,
   Adriana/0000-0002-8078-0304; STUR, ELAINE/0000-0001-5962-0050
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
   [04/12054-9]; Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico (CNPq); Fundacao de Amparo a Pesquisa do Estado do Espirito
   Santo (FAPES); Coordenacao de Aperfeicoamento de Pessoal de Nivel
   Superior (CAPES)
FX This work was supported by the Fundacao de Amparo a Pesquisa do Estado
   de Sao Paulo (FAPESP) (http://www.fapesp.br/) grants 04/12054-9;
   Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)
   (http://cnpq.br/); Fundacao de Amparo a Pesquisa do Estado do Espirito
   Santo (FAPES) (https://fapes.es.gov.br/); and the Coordenacao de
   Aperfeicoamento de Pessoal de Nivel Superior (CAPES)
   (http://capes.gov.br/).
CR Amar A, 2013, BRAZ J OTORHINOLAR, V79, P734, DOI 10.5935/1808-8694.20130134
   [Anonymous], 1978, PLOS ONE
   Baranello C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040678
   Bauman JE, 2012, CURR OPIN ONCOL, V24, P235, DOI 10.1097/CCO.0b013e3283517920
   Benard A, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-531
   Bono P, 2004, CLIN CANCER RES, V10, P7144, DOI 10.1158/1078-0432.CCR-03-0826
   Bredell MG, 2016, ONCOTARGET, V7, P50781, DOI 10.18632/oncotarget.9549
   Cajaiba MM, 2006, PEDIATR DEVEL PATHOL, V9, P196, DOI 10.2350/05-12-0002.1
   Chakrabarti KR, 2015, ONCOTARGET, V6, P36292, DOI 10.18632/oncotarget.5345
   Dambacher S, 2013, CELL CYCLE, V12, P2925, DOI 10.4161/cc.26179
   dos Santos M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045228
   Du ZM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019137
   Fan L, 2016, ONCOGENE, V35, P2441, DOI 10.1038/onc.2015.309
   Gallì P, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-137
   Gao YQ, 2016, ONCOTARGET, V7, P63374, DOI 10.18632/oncotarget.11463
   Guo X, 2011, NEOPLASMA, V58, P153, DOI 10.4149/neo_2011_02_153
   Harris AL, 2004, NAT REV CANCER, V2, P38
   Hedvat CV, 2002, HUM PATHOL, V33, P968, DOI 10.1053/hupa.2002.127438
   Hsu FD, 2002, MODERN PATHOL, V15, P1374, DOI 10.1097/01.MP.0000039571.02827.CE
   Karpinich NO, 2013, FASEB J, V27, P590, DOI 10.1096/fj.12-214080
   Kasioulis I, 2014, MOL BIOL CELL, V25, P1216, DOI 10.1091/mbc.E13-08-0471
   Kaukonen R, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12237
   Keleg S, 2007, INT J CANCER, V121, P21, DOI 10.1002/ijc.22596
   Krieg AJ, 2010, MOL CELL BIOL, V30, P344, DOI 10.1128/MCB.00444-09
   Leemans CR, 2011, NAT REV CANCER, V11, P9, DOI 10.1038/nrc2982
   Li MQ, 2015, ONCOL LETT, V10, P1003, DOI 10.3892/ol.2015.3278
   Lim S, 2010, INT J CANCER, V127, P1991, DOI 10.1002/ijc.25538
   Liu J, 2016, ONCOTARGET, V7, P85151, DOI 10.18632/oncotarget.13208
   Müller-Tidow C, 2010, BLOOD, V116, P3564, DOI 10.1182/blood-2009-09-240978
   OCHOACALLEJERO L, 2017, SMALL MOL REL ADR, V7, DOI DOI 10.1038/S41598-017-17573-X
   Oehler MK, 2003, BRIT J CANCER, V89, P1927, DOI 10.1038/sj.bjc.6601397
   Park SJ, 2013, BIOCHEM BIOPH RES CO, V434, P722, DOI 10.1016/j.bbrc.2013.03.091
   Park YS, 2008, ANN SURG ONCOL, V15, P1968, DOI 10.1245/s10434-008-9927-9
   Ponnaluri VKC, 2011, BIOCHEM BIOPH RES CO, V415, P373, DOI 10.1016/j.bbrc.2011.10.075
   Puram SV, 2015, HEMATOL ONCOL CLIN N, V29, P971, DOI 10.1016/j.hoc.2015.07.003
   Rimm DL, 2001, EXP MOL PATHOL, V70, P255, DOI 10.1006/exmp.2001.2363
   Rogenhofer S, 2012, ANTICANCER RES, V32, P879
   Sobin LH, 2011, TNM CLASSIFICATION M
   Soini Y, 2000, BRIT J CANCER, V83, P880, DOI 10.1054/bjoc.2000.1384
   Song JS, 2012, PATHOL INT, V62, P182, DOI 10.1111/j.1440-1827.2011.02776.x
   Uemura M, 2010, CLIN CANCER RES, V16, P4636, DOI 10.1158/1078-0432.CCR-10-0407
   Vavilala DT, 2012, BIOCHEM BIOPH RES CO, V422, P369, DOI 10.1016/j.bbrc.2012.04.143
   Wellmann S, 2008, BIOCHEM BIOPH RES CO, V372, P892, DOI 10.1016/j.bbrc.2008.05.150
   Xia RH, 2013, ARCH PATHOL LAB MED, V137, P1761, DOI 10.5858/arpa.2012-0704-OA
   Yang HY, 2015, INT J CLIN EXP PATHO, V8, P11092
   Yang J, 2009, ANN NY ACAD SCI, V1177, P185, DOI 10.1111/j.1749-6632.2009.05027.x
   Zhang CJ, 2010, J HEPATOL, V53, P889, DOI 10.1016/j.jhep.2010.05.012
NR 47
TC 20
Z9 22
U1 0
U2 9
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAR 28
PY 2018
VL 13
IS 3
AR e0194884
DI 10.1371/journal.pone.0194884
PG 16
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA GA8PV
UT WOS:000428603100084
PM 29590186
OA Green Published, Green Submitted, gold
DA 2025-01-12
ER

PT J
AU Huang, S
   Chi, YY
   Qin, Y
   Wang, ZL
   Xiu, BQ
   Su, YH
   Guo, R
   Guo, L
   Sun, HF
   Zeng, CJ
   Zhou, SL
   Hu, X
   Liu, S
   Shao, ZM
   Wu, ZH
   Jin, W
   Wu, J
AF Huang, Sheng
   Chi, Yayun
   Qin, Yi
   Wang, Ziliang
   Xiu, Bingqiu
   Su, Yonghui
   Guo, Rong
   Guo, Liang
   Sun, Hefen
   Zeng, Chujia
   Zhou, Shuling
   Hu, Xin
   Liu, Sheng
   Shao, Zhimin
   Wu, Zhaohui
   Jin, Wei
   Wu, Jiong
TI CAPG enhances breast cancer metastasis by competing with PRMT5 to
   modulate STC-1 transcription
SO THERANOSTICS
LA English
DT Article
DE breast cancer; metastasis; CAPG; PRMT5; STC-1
ID STANNIOCALCIN 1; EXPRESSION; ACTIN; METHYLATION; PROTEIN; CELLS;
   ACTIVATION; HISTONE; FAMILY; GROWTH
AB Macrophage-capping protein (CAPG) has been shown to promote cancer cell metastasis, although the mechanism remains poorly understood.
   Methods: Breast cancer (BC) tissue microarray was used to test the role of CAPG in the prognosis of BC patients. Xenograft mice model was used to validate the metastasis promotion role of CAPG in vivo. Gene expression array, chromatin immunoprecipitation and luciferase report assay were performed to search for the target genes of CAPG. Protein immunoprecipitation, MS/MS analysis, tissue microarray and histone methyltransferase assay were used to explore the mechanism of CAPG regulating stanniocalcin 1 (STC-1) transcription.
   Results: We demonstrate a novel mechanism by which CAPG enhances BC metastasis via promoting the transcription of the pro-metastatic gene STC-1, contributing to increased metastasis in BC. Mechanistically, CAPG competes with the transcriptional repressor arginine methyltransferase 5 (PRMT5) for binding to the STC-1 promoter, leading to reduced histone H4R3 methylation and enhanced STC-1 transcription. Our study also indicates that both CAPG and PRMT5 are independent prognostic factors for BC patient survival. High CAPG level is associated with poor survival, while high PRMT5 expression favors a better prognosis in BC patients.
   Conclusion: Our findings identify a novel role of CAPG in the promotion of BC metastasis by epigenetically enhancing STC-1 transcription.
C1 [Huang, Sheng; Chi, Yayun; Xiu, Bingqiu; Su, Yonghui; Guo, Rong; Guo, Liang; Sun, Hefen; Zeng, Chujia; Hu, Xin; Shao, Zhimin; Jin, Wei; Wu, Jiong] Fudan Univ, Shanghai Med Coll, Shanghai Canc Ctr, Dept Oncol,Dept Breast Surg,Breast Canc Inst, Shanghai, Peoples R China.
   [Huang, Sheng] Kunming Med Univ, Tumor Hosp Yunnan Prov, Affiliated Hosp 3, Dept Breast Surg 2, Kunming, Yunnan, Peoples R China.
   [Qin, Yi] Fudan Univ, Dept Pancreas & Hepatobiliary Surg, Pancreas & Hepatobiliary Canc Inst, Shanghai Canc Ctr,Dept Oncol,Shanghai Med Coll, Shanghai, Peoples R China.
   [Wang, Ziliang] Fudan Univ, Shanghai Med Coll, Dept Oncol, Shanghai Canc Ctr,Canc Inst, Shanghai, Peoples R China.
   [Zhou, Shuling] Fudan Univ, Shanghai Canc Ctr, Dept Pathol, Shanghai, Peoples R China.
   [Liu, Sheng] Shanghai Univ Tradit Chinese Med, Long Hua Hosp, Lab Tradit Chinese Med, Dept Breast Surg & Pharmacol, Shanghai, Peoples R China.
   [Wu, Zhaohui] Univ Tennessee, Ctr Hlth Sci, Dept Pathol & Lab Med, Memphis, TN 38163 USA.
   [Wu, Zhaohui] Univ Tennessee, Ctr Hlth Sci, Ctr Canc Res, Memphis, TN 38163 USA.
C3 Fudan University; Kunming Medical University; Fudan University; Fudan
   University; Fudan University; Shanghai University of Traditional Chinese
   Medicine; University of Tennessee System; University of Tennessee Health
   Science Center; University of Tennessee System; University of Tennessee
   Health Science Center
RP Wu, J (通讯作者)，Dept Breast Surg, Bldg 2,270 Dong Rd, Shanghai 200032, Peoples R China.; Jin, W (通讯作者)，Breast Canc Inst, Bldg 7,270 Dong Rd, Shanghai 200032, Peoples R China.
EM jinwei7207@163.com; wujiong1122@vip.sina.com
RI Zhang, Lanjing/GZB-0260-2022; Hu, Xin/JEP-4891-2023; Wu,
   Jiong/LFT-4903-2024
OI Xiu, Bingqiu/0000-0002-0771-591X
FU National Basic Research Program of China [2010CB834305]; National
   Natural Scientific Foundation of China [81472456, 81528016]; Shanghai
   International Fund for scientific and technological cooperation
   [15410724100]
FX Supported by the National Basic Research Program of China
   (2010CB834305), the National Natural Scientific Foundation of China
   (81472456, 81528016) and the Shanghai International Fund for scientific
   and technological cooperation (15410724100).
CR Aggarwal P, 2010, CANCER CELL, V18, P329, DOI 10.1016/j.ccr.2010.08.012
   Chang A. C., 2015, Finance and Economics Discussion Series, P1, DOI [DOI 10.17016/FEDS.2015.083, 10.17016/FEDS.2015.083]
   CHANG ACM, 1995, MOL CELL ENDOCRINOL, V112, P241, DOI 10.1016/0303-7207(95)03601-3
   Chen M, 2014, J BIOL CHEM, V289, P24325, DOI 10.1074/jbc.M114.577494
   Chi YY, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-577
   Chi YY, 2011, J BIOL CHEM, V286, P1748, DOI 10.1074/jbc.M110.107367
   Chi YY, 2009, BIOCHEM BIOPH RES CO, V386, P493, DOI 10.1016/j.bbrc.2009.06.061
   Ching LY, 2012, J MOL ENDOCRINOL, V48, P241, DOI 10.1530/JME-11-0159
   De Corte V, 2004, J CELL SCI, V117, P5283, DOI 10.1242/jcs.01410
   de Lanerolle P, 2011, NAT CELL BIOL, V13, P1282, DOI 10.1038/ncb2364
   Eckert D, 2008, BMC DEV BIOL, V8, DOI 10.1186/1471-213X-8-106
   Fabbrizio E, 2002, EMBO REP, V3, P641, DOI 10.1093/embo-reports/kvf136
   Friesen WJ, 2002, J BIOL CHEM, V277, P8243, DOI 10.1074/jbc.M109984200
   Glaser J, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/379847
   Guderian G, 2011, J BIOL CHEM, V286, P1976, DOI 10.1074/jbc.M110.148486
   Hiraga T, 2007, CANCER RES, V67, P4157, DOI 10.1158/0008-5472.CAN-06-2355
   Hsu JM, 2011, NAT CELL BIOL, V13, P174, DOI 10.1038/ncb2158
   Jansson M, 2008, NAT CELL BIOL, V10, P1431, DOI 10.1038/ncb1802
   Jellinek DA, 2000, BIOCHEM J, V350, P453, DOI 10.1042/0264-6021:3500453
   JEMAL A, 2011, CA-CANCER J CLIN, V61, P69, DOI DOI 10.3322/CAAC.20107
   Jiang H, 2015, CANC RES
   Jiang HL, 2016, CANCER RES, V76, P952, DOI 10.1158/0008-5472.CAN-15-1630
   Jin W, 2012, MOL CELL BIOL, V32, P50, DOI 10.1128/MCB.06152-11
   JOHNSTON PA, 1990, J BIOL CHEM, V265, P17946
   Karkhanis V, 2011, TRENDS BIOCHEM SCI, V36, P633, DOI 10.1016/j.tibs.2011.09.001
   Kwak YT, 2003, MOL CELL, V11, P1055, DOI 10.1016/S1097-2765(03)00101-1
   Law AYS, 2008, EXP CELL RES, V314, P2975, DOI 10.1016/j.yexcr.2008.07.002
   Law AYS, 2011, J CELL BIOCHEM, V112, P2089, DOI 10.1002/jcb.23127
   Le Guezennec X, 2006, MOL CELL BIOL, V26, P843, DOI 10.1128/MCB.26.3.843-851.2006
   Li Y, 2015, CANCER DISCOV, V5, P288, DOI 10.1158/2159-8290.CD-14-0625
   Migliori V, 2012, NAT STRUCT MOL BIOL, V19, P136, DOI 10.1038/nsmb.2209
   Moffat J, 2006, CELL, V124, P1283, DOI 10.1016/j.cell.2006.01.040
   Murai R, 2014, CLIN EXP METASTAS, V31, P787, DOI 10.1007/s10585-014-9668-z
   Nakagawa T, 2007, CLIN CANCER RES, V13, P4105, DOI 10.1158/1078-0432.CCR-07-0419
   Nicholas C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074710
   Nurnberg A, 2011, NAT REV CANCER, V11, P177, DOI 10.1038/nrc3003
   Olsen HS, 1996, P NATL ACAD SCI USA, V93, P1792, DOI 10.1073/pnas.93.5.1792
   Oma Y, 2011, NUCLEUS-PHILA, V2, P38, DOI 10.4161/nucl.2.1.14510
   Pal S, 2004, MOL CELL BIOL, V24, P9630, DOI 10.1128/MCB.24.21.9630-9645.2004
   Pal S, 2007, EMBO J, V26, P3558, DOI 10.1038/sj.emboj.7601794
   Parikh SS, 2003, INFECT IMMUN, V71, P6582, DOI 10.1128/IAI.71.11.6582-6590.2003
   Peña C, 2013, CANCER RES, V73, P1287, DOI 10.1158/0008-5472.CAN-12-1875
   Pollard TD, 2000, ANNU REV BIOPH BIOM, V29, P545, DOI 10.1146/annurev.biophys.29.1.545
   PRENDERGAST GC, 1991, EMBO J, V10, P757, DOI 10.1002/j.1460-2075.1991.tb08007.x
   Redig AJ, 2013, J INTERN MED, V274, P113, DOI 10.1111/joim.12084
   Song HZ, 2012, J EXP CLIN CANC RES, V31, DOI 10.1186/1756-9966-31-35
   Stark AM, 2007, J NEURO-ONCOL, V81, P39, DOI 10.1007/s11060-006-9207-0
   Takagi K, 2014, CANCER SCI, V105, P600, DOI 10.1111/cas.12382
   Tamura S, 2011, ANTICANCER RES, V31, P325
   Thompson CC, 2007, GUT, V56, P95, DOI 10.1136/gut.2005.083691
   van den Abbeele A, 2007, CANCER LETT, V255, P57, DOI 10.1016/j.canlet.2007.03.023
   Van Impe K, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3585
   WAGNER GF, 1986, GEN COMP ENDOCR, V63, P481, DOI 10.1016/0016-6480(86)90149-8
   Wang L, 2008, MOL CELL BIOL, V28, P6262, DOI 10.1128/MCB.00923-08
   Wascher RA, 2003, CLIN CANCER RES, V9, P1427
   Watari A, 2006, ONCOGENE, V25, P7373, DOI 10.1038/sj.onc.1209732
   Witke W, 2001, J CELL BIOL, V154, P775, DOI 10.1083/jcb.200101113
   Xu SG, 2010, J CANCER RES CLIN, V136, P1545, DOI 10.1007/s00432-010-0812-0
   Yang YZ, 2013, NAT REV CANCER, V13, P37, DOI 10.1038/nrc3409
   Zhang RF, 2009, AM J RESP CELL MOL, V41, P467, DOI 10.1165/rcmb.2008-0333OC
   Zhao Q, 2009, NAT STRUCT MOL BIOL, V16, P304, DOI 10.1038/nsmb.1568
NR 61
TC 44
Z9 48
U1 0
U2 14
PU IVYSPRING INT PUBL
PI LAKE HAVEN
PA PO BOX 4546, LAKE HAVEN, NSW 2263, AUSTRALIA
SN 1838-7640
J9 THERANOSTICS
JI Theranostics
PY 2018
VL 8
IS 9
BP 2549
EP 2564
DI 10.7150/thno.22523
PG 16
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA GC6DN
UT WOS:000429880400009
PM 29721098
OA Green Published, gold, Green Submitted
DA 2025-01-12
ER

PT J
AU Pastushenko, I
   Brisebarre, A
   Sifrim, A
   Fioramonti, M
   Revenco, T
   Boumahdi, S
   Van Keymeulen, A
   Brown, D
   Moers, V
   Lemaire, S
   De Clercq, S
   Minguijón, E
   Balsat, C
   Sokolow, Y
   Dubois, C
   De Cock, F
   Scozzaro, S
   Sopena, F
   Lanas, A
   D'Haene, N
   Salmon, I
   Marine, JC
   Voet, T
   Sotiropoulou, PA
   Blanpain, C
AF Pastushenko, Ievgenia
   Brisebarre, Audrey
   Sifrim, Alejandro
   Fioramonti, Marco
   Revenco, Tatiana
   Boumahdi, Soufiane
   Van Keymeulen, Alexandra
   Brown, Daniel
   Moers, Virginie
   Lemaire, Sophie
   De Clercq, Sarah
   Minguijon, Esmeralda
   Balsat, Cedric
   Sokolow, Youri
   Dubois, Christine
   De Cock, Florian
   Scozzaro, Samuel
   Sopena, Federico
   Lanas, Angel
   D'Haene, Nicky
   Salmon, Isabelle
   Marine, Jean-Christophe
   Voet, Thierry
   Sotiropoulou, Panagiota A.
   Blanpain, Cedric
TI Identification of the tumour transition states occurring during EMT
SO NATURE
LA English
DT Article
ID EPITHELIAL-MESENCHYMAL TRANSITION; STEM-CELLS; BREAST-CANCER; METASTATIC
   COLONIZATION; TRANSCRIPTION FACTORS; PANCREATIC-CANCER; INITIATING
   CELLS; TGF-BETA; CHEMORESISTANCE; HETEROGENEITY
AB In cancer, the epithelial-to-mesenchymal transition (EMT) is associated with tumour stemness, metastasis and resistance to therapy. It has recently been proposed that, rather than being a binary process, EMT occurs through distinct intermediate states. However, there is no direct in vivo evidence for this idea. Here we screen a large panel of cell surface markers in skin and mammary primary tumours, and identify the existence of multiple tumour subpopulations associated with different EMT stages: from epithelial to completely mesenchymal states, passing through intermediate hybrid states. Although all EMT subpopulations presented similar tumour-propagating cell capacity, they displayed differences in cellular plasticity, invasiveness and metastatic potential. Their transcriptional and epigenetic landscapes identify the underlying gene regulatory networks, transcription factors and signalling pathways that control these different EMT transition states. Finally, these tumour subpopulations are localized in different niches that differentially regulate EMT transition states.
C1 [Pastushenko, Ievgenia; Brisebarre, Audrey; Fioramonti, Marco; Revenco, Tatiana; Boumahdi, Soufiane; Van Keymeulen, Alexandra; Moers, Virginie; Lemaire, Sophie; Dubois, Christine; De Cock, Florian; Scozzaro, Samuel; Sotiropoulou, Panagiota A.; Blanpain, Cedric] Univ Libre Buxelles, Lab Stem Cells & Canc, Brussels, Belgium.
   [Sifrim, Alejandro; Brown, Daniel; Voet, Thierry] Univ Leuven, Dept Human Genet, Leuven, Belgium.
   [Sifrim, Alejandro; Voet, Thierry] Wellcome Trust Sanger Inst, Sanger Inst, EBI Single Cell Genom Ctr, Hinxton, England.
   [Brown, Daniel; Marine, Jean-Christophe] VIB Ctr Canc Biol, Lab Mol Canc Biol, Leuven, Belgium.
   [De Clercq, Sarah; Minguijon, Esmeralda; D'Haene, Nicky; Salmon, Isabelle] Univ Libre Bruxelles, Erasme Univ Hosp, Pathol Dept, Brussels, Belgium.
   [Balsat, Cedric; Salmon, Isabelle] Univ Libre Bruxelles, Ctr Microscopy & Mol Imaging, DIAPath, Gosselies, Belgium.
   [Sokolow, Youri] Univ Libre Bruxelles, Erasme Univ Hosp, Thorac Surg, Brussels, Belgium.
   [Sopena, Federico] Hosp Clin Univ Lozano Blesa, IIS Aragon, Gastroenterol Dept, Zaragoza, Spain.
   [Lanas, Angel] Univ Zaragoza, IIS Aragon, CIBERehd, Zaragoza, Spain.
   [Marine, Jean-Christophe] Katholieke Univ Leuven, Dept Oncol, Lab Mol Canc Biol, Leuven, Belgium.
   [Blanpain, Cedric] Univ Libre Bruxelles, WELBIO, Brussels, Belgium.
C3 Universite Libre de Bruxelles; KU Leuven; Wellcome Trust Sanger
   Institute; Flanders Institute for Biotechnology (VIB); Universite Libre
   de Bruxelles; Universite Libre de Bruxelles; Universite Libre de
   Bruxelles; Lozano Blesa University Clinical Hospital; CIBER - Centro de
   Investigacion Biomedica en Red; CIBEREHD; KU Leuven; Universite Libre de
   Bruxelles; WELBIO
RP Blanpain, C (通讯作者)，Univ Libre Buxelles, Lab Stem Cells & Canc, Brussels, Belgium.; Blanpain, C (通讯作者)，Univ Libre Bruxelles, WELBIO, Brussels, Belgium.
EM cedric.blanpain@ulb.ac.be
RI Brisebarre, Audrey/ABE-4955-2020; Blanpain, Cedric/ABD-8392-2021; Voet,
   Thierry/E-8877-2017; Sifrim, Alejandro/AAY-2019-2021; Marine,
   Jean-Christophe/K-3292-2016
OI Marine, Jean-Christophe/0000-0003-2433-9837; Minguijon,
   Esmeralda/0000-0002-7801-7625; brisebarre, Audrey/0000-0003-0162-5195;
   Sifrim, Alejandro/0000-0001-8247-4020; Sotiropoulou,
   Peggy/0009-0001-7515-8975; Voet, Thierry/0000-0003-1204-9963; Brown,
   Daniel/0000-0002-3594-5851; Blanpain, Cedric/0000-0002-4028-4322
FU TELEVIE; FNRS; KULeuven SymBioSys; Stiching Tegen Kanker; FWO
   postdoctoral fellowship [12W7318N]; Marie Sklodowska-Curie fellowship
   [1205617N]; Fonds Erasme; WELBIO; Fondation Contre le Cancer; ULB
   Foundation; European Research Council; Worldwide Cancer Research;
   Foundation Baillet Latour
FX We thank the ULB animal facility, the ULB genomic core facility (F.
   Libert and A. Lefort), G. Berx (Ghent University) and M. Mazzone
   (VIB-KUL) for MMTV-PyMT mice. I.P TEL. is supported by TELEVIE. P.A.S.
   is supported by FNRS. A.S., D.B. and T.V. are supported by KULeuven
   SymBioSys, Stiching Tegen Kanker, FWO postdoctoral fellowship #12W7318N
   and Marie Sklodowska-Curie fellowship #1205617N. The Department of
   Pathology acknowledges Fonds Yvonne Boel. The PDX platform is supported
   by Fonds Erasme. C.Bla. is supported by WELBIO, FNRS, Fondation Contre
   le Cancer, ULB Foundation, European Research Council, Worldwide Cancer
   Research and the Foundation Baillet Latour.
CR Aiello NM, 2017, NATURE, V547, pE7, DOI 10.1038/nature22963
   Anders S, 2015, BIOINFORMATICS, V31, P166, DOI 10.1093/bioinformatics/btu638
   Nieto MA, 2016, CELL, V166, P21, DOI 10.1016/j.cell.2016.06.028
   Barker N, 2007, NATURE, V449, P1003, DOI 10.1038/nature06196
   Bierie B, 2017, P NATL ACAD SCI USA, V114, pE2337, DOI 10.1073/pnas.1618298114
   Chen Q, 2011, CANCER CELL, V20, P538, DOI 10.1016/j.ccr.2011.08.025
   Diepenbruck M, 2016, CURR OPIN CELL BIOL, V43, P7, DOI 10.1016/j.ceb.2016.06.002
   Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635
   Fischer KR, 2015, NATURE, V527, P472, DOI 10.1038/nature15748
   Heinz S, 2010, MOL CELL, V38, P576, DOI 10.1016/j.molcel.2010.05.004
   Hidalgo M, 2014, CANCER DISCOV, V4, P998, DOI 10.1158/2159-8290.CD-14-0001
   Hong T, 2015, PLOS COMPUT BIOL, V11, DOI 10.1371/journal.pcbi.1004569
   Hu YF, 2009, J IMMUNOL METHODS, V347, P70, DOI 10.1016/j.jim.2009.06.008
   Huang RYJ, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.442
   Jolly MK, 2016, ONCOTARGET, V7, P27067, DOI 10.18632/oncotarget.8166
   Jonkers J, 2001, NAT GENET, V29, P418, DOI 10.1038/ng747
   Kiselev VY, 2017, NAT METHODS, V14, P483, DOI [10.1038/NMETH.4236, 10.1038/nmeth.4236]
   Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/NMETH.1923, 10.1038/nmeth.1923]
   Lapouge G, 2012, EMBO J, V31, P4563, DOI 10.1038/emboj.2012.312
   Latil M, 2017, CELL STEM CELL, V20, P191, DOI 10.1016/j.stem.2016.10.018
   Li H, 2009, BIOINFORMATICS, V25, P2078, DOI 10.1093/bioinformatics/btp352
   Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027
   Martin YD, 2015, CELL REP, V13, P2456, DOI 10.1016/j.celrep.2015.11.025
   McLean CY, 2010, NAT BIOTECHNOL, V28, P495, DOI 10.1038/nbt.1630
   Meacham CE, 2013, NATURE, V501, P328, DOI 10.1038/nature12624
   Medina-Rivera A, 2015, NUCLEIC ACIDS RES, V43, pW50, DOI 10.1093/nar/gkv362
   Ocaña OH, 2012, CANCER CELL, V22, P709, DOI 10.1016/j.ccr.2012.10.012
   Puisieux A, 2014, NAT CELL BIOL, V16, P488, DOI 10.1038/ncb2976
   Puram SV, 2017, CELL, V171, P1611, DOI 10.1016/j.cell.2017.10.044
   Seguin L, 2014, NAT CELL BIOL, V16, P457, DOI 10.1038/ncb2953
   Siegel PM, 2003, NAT REV CANCER, V3, P807, DOI 10.1038/nrc1208
   Slack-Davis JK, 2009, CANCER RES, V69, P1469, DOI 10.1158/0008-5472.CAN-08-2678
   Srinivas S, 2001, BMC Dev Biol, V1, P4, DOI 10.1186/1471-213X-1-4
   Trapnell C, 2014, NAT BIOTECHNOL, V32, P381, DOI 10.1038/nbt.2859
   Tsai JH, 2012, CANCER CELL, V22, P725, DOI 10.1016/j.ccr.2012.09.022
   Tuveson DA, 2004, CANCER CELL, V5, P375, DOI 10.1016/S1535-6108(04)00085-6
   Van Keymeulen A, 2015, NATURE, V525, P119, DOI 10.1038/nature14665
   Van Keymeulen A, 2011, NATURE, V479, P189, DOI 10.1038/nature10573
   Wang J, 2017, ONCOGENE, V36, P1351, DOI 10.1038/onc.2016.299
   Ye X, 2017, NATURE, V547, pE1, DOI 10.1038/nature22816
   Ye X, 2015, TRENDS CELL BIOL, V25, P675, DOI 10.1016/j.tcb.2015.07.012
   Ye X, 2015, NATURE, V525, P256, DOI 10.1038/nature14897
   Zhang JY, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005304
   Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r137
   Zheng XF, 2015, NATURE, V527, P525, DOI 10.1038/nature16064
NR 45
TC 1004
Z9 1092
U1 7
U2 287
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0028-0836
EI 1476-4687
J9 NATURE
JI Nature
PD APR 26
PY 2018
VL 556
IS 7702
BP 463
EP +
DI 10.1038/s41586-018-0040-3
PG 22
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA GD8VX
UT WOS:000430793000039
PM 29670281
HC Y
HP N
DA 2025-01-12
ER

PT J
AU Corominas-Faja, B
   Cuyàs, E
   Lozano-Sánchez, J
   Cufí, S
   Verdura, S
   Fernández-Arroyo, S
   Borrás-Linares, I
   Martin-Castillo, B
   Martin, AG
   Lupu, R
   Nonell-Canals, A
   Sanchez-Martinez, M
   Micol, V
   Joven, J
   Segura-Carretero, A
   Menendez, JA
AF Corominas-Faja, Bruna
   Cuyas, Elisabet
   Lozano-Sanchez, Jesus
   Cufi, Silvia
   Verdura, Sara
   Fernandez-Arroyo, Salvador
   Borras-Linares, Isabel
   Martin-Castillo, Begona
   Martin, Angel G.
   Lupu, Ruth
   Nonell-Canals, Alfons
   Sanchez-Martinez, Melchor
   Micol, Vicente
   Joven, Jorge
   Segura-Carretero, Antonio
   Menendez, Javier A.
TI Extra-virgin olive oil contains a metabolo-epigenetic inhibitor of
   cancer stem cells
SO CARCINOGENESIS
LA English
DT Article
ID EPITHELIAL-MESENCHYMAL TRANSITION; PHENOTYPE MICROARRAYS; DRUG
   DISCOVERY; PROTEIN; GROWTH; DIFFERENTIATION; HETEROGENEITY;
   TUMORIGENESIS; COMMUNICATION; SANGUINARINE
AB Targeting tumor-initiating, drug-resistant populations of cancer stem cells (CSC) with phytochemicals is a novel paradigm for cancer prevention and treatment. We herein employed a phenotypic drug discovery approach coupled to mechanism-of-action profiling and target deconvolution to identify phenolic components of extra virgin olive oil (EVOO) capable of suppressing the functional traits of CSC in breast cancer (BC). In vitro screening revealed that the secoiridoid decarboxymethyl oleuropein aglycone (DOA) could selectively target subpopulations of epithelial-like, aldehyde dehydrogenase (ALDH)-positive and mesenchymal-like, CD44(+)CD24(-/low) CSC. DOA could potently block the formation of multicellular tumorspheres generated from single-founder stem-like cells in a panel of genetically diverse BC models. Pretreatment of BC populations with noncytotoxic doses of DOA dramatically reduced subsequent tumor-forming capacity in vivo. Mice orthotopically injected with CSC-enriched BC-cell populations pretreated with DOA remained tumor-free for several months. Phenotype microarray-based screening pointed to a synergistic interaction of DOA with the mTOR inhibitor rapamycin and the DNA methyltransferase (DNMT) inhibitor 5-azacytidine. In silico computational studies indicated that DOA binds and inhibits the ATP-binding kinase domain site of mTOR and the S-adenosyl-l-methionine (SAM) cofactor-binding pocket of DNMTs. FRET-based Z-LYTE (TM) and AlphaScreen-based in vitro assays confirmed the ability of DOA to function as an ATP-competitive mTOR inhibitor and to block the SAM-dependent methylation activity of DNMTs. Our systematic in vitro, in vivo and in silico approaches establish the phenol-conjugated oleoside DOA as a dual mTOR/DNMT inhibitor naturally occurring in EVOO that functionally suppresses CSC-like states responsible for maintaining tumor-initiating cell properties within BC populations.
C1 [Corominas-Faja, Bruna; Cuyas, Elisabet; Verdura, Sara; Menendez, Javier A.] Catalan Inst Oncol, Metab & Canc Grp, Program Canc Therapeut Resistance ProCURE, Girona, Spain.
   [Corominas-Faja, Bruna; Cuyas, Elisabet; Cufi, Silvia; Verdura, Sara; Menendez, Javier A.] Girona Biomed Res Inst IDIBGI, Mol Oncol Grp, Girona, Spain.
   [Lozano-Sanchez, Jesus; Segura-Carretero, Antonio] Univ Granada, Dept Analyt Chem, Fac Sci, Granada, Spain.
   [Lozano-Sanchez, Jesus; Borras-Linares, Isabel; Segura-Carretero, Antonio] PTS Granada, Res & Dev Funct Food Ctr CIDAF, Granada, Spain.
   [Fernandez-Arroyo, Salvador; Joven, Jorge] Univ Rovira & Virgili, Inst Invest Sanitaria Pere Virgili, Hosp Univ St Joan, Unitat Recerca Biomed, Reus, Spain.
   [Fernandez-Arroyo, Salvador; Joven, Jorge] Campus Int Excellence Southern Catalonia, Tarragona, Spain.
   [Martin-Castillo, Begona] Catalan Inst Oncol, Unit Clin Res, Girona, Spain.
   [Martin, Angel G.] StemTek Therapeut, Bilbao, Spain.
   [Lupu, Ruth] Mayo Clin, Dept Lab Med & Pathol, Div Expt Pathol, Rochester, MN USA.
   [Lupu, Ruth] Mayo Clin, Canc Ctr, Rochester, MN USA.
   [Nonell-Canals, Alfons; Sanchez-Martinez, Melchor] Mind Byte, Barcelona, Spain.
   [Micol, Vicente] Miguel Hernandez Univ UMH, IBMC, Alicante, Spain.
   [Micol, Vicente] Inst Salud Carlos III, CB12 03 30038, CIBERobn, CIBER,Fisiopatol Obesidad & Nutr, Madrid, Spain.
   [Menendez, Javier A.] Metabostem, Barcelona, Spain.
   [Cufi, Silvia] Fundacio Clin Recerca Biomed, Barcelona, Spain.
C3 Institut Catala d'Oncologia; Universitat de Girona; Girona University
   Hospital Dr. Josep Trueta; Institut d'Investigacio Biomedica de Girona
   (IDIBGI); University of Granada; Universitat Rovira i Virgili; Institut
   d'Investigacio Sanitaria Pere Virgili (IISPV); Institut Catala
   d'Oncologia; Mayo Clinic; Mayo Clinic; CIBER - Centro de Investigacion
   Biomedica en Red; CIBEROBN; Instituto de Salud Carlos III; University of
   Barcelona; Hospital Clinic de Barcelona
RP Menendez, JA (通讯作者)，Catalan Inst Oncol, Metab & Canc Grp, Program Canc Therapeut Resistance ProCURE, Girona, Spain.; Menendez, JA (通讯作者)，Girona Biomed Res Inst IDIBGI, Mol Oncol Grp, Girona, Spain.; Menendez, JA (通讯作者)，Metabostem, Barcelona, Spain.
EM jmenendez@iconcologia.net
RI Cuyas, Elisabet/G-8582-2018; LOZANO-SANCHEZ, JESUS/K-8987-2014; Joven,
   Jorge/B-3360-2016; Micol, Vicente/K-6841-2014; Giralt,
   Albert/M-7672-2015; Sanchez-Martinez, Melchor/A-3392-2014;
   Fernandez-Arroyo, Salvador/M-6955-2015; Verdura, Sara/AAC-3696-2022;
   segura Carretero, Antonio/B-6867-2014; Borras-Linares,
   Isabel/K-9154-2014; MENENDEZ MENENDEZ, JAVIER ABEL/C-6148-2016
OI Cuyas, Elisabet/0000-0001-5353-440X; Sanchez-Martinez,
   Melchor/0000-0002-3674-8577; Fernandez-Arroyo,
   Salvador/0000-0003-0147-1712; Verdura, Sara/0000-0001-8980-0423; Lozano
   Sanchez, Jesus/0000-0001-8769-3070; Cufi, Silvia/0000-0002-2476-748X;
   segura Carretero, Antonio/0000-0002-5564-5338; Borras-Linares,
   Isabel/0000-0002-5227-9002; Micol, Vicente/0000-0001-8089-0696;
   Martin-Castillo, Begona/0000-0001-8344-8174; MENENDEZ MENENDEZ, JAVIER
   ABEL/0000-0001-8733-4561
FU Ministerio de Ciencia e Innovacion [SAF2016-80639-P]; Plan Nacional de
   I+D+I, Spain; Agencia de Gestio d'Ajuts Universitaris i de Recerca
   (AGAUR) [2014 SGR229]; Departament d'Economia i Coneixement, Catalonia,
   Spain; Andalusian Regional Government Council of Innovation and Science
   [P11-CTS-7625]; Ministerio de Economia, Industria y Competitividad,
   Spain [AGL2015-67995-C2-3-R, AGL2015-67995-C3-1-R]; Conselleria
   d'Educacio, Investigacio, Cultura I Esport, Generalitat Valenciana,
   Spain [PROMETEO/2016/006]; Ministerio de Sanidad y Consumo, Fondo de
   Investigacion Sanitaria (FIS), Spain [CD15/00033]; IV Premio
   Internacional Castillo de Canena de Investigacion Oleicola 'LUIS
   VANO'(IV Edition of Castillo de Canena LUIS VANO Award for Research on
   Olive Cultivation and Olive Oil); IV Premio Internacional Castillo de
   Canena de Investigacion Oleicola 'LUIS VANO'(UC Davis Olive Center); IV
   Premio Internacional Castillo de Canena de Investigacion Oleicola 'LUIS
   VANO'(Castillo de Canena); IV Premio Internacional Castillo de Canena de
   Investigacion Oleicola 'LUIS VANO'(Universidad de Jaen)
FX This work was supported by grants from the Ministerio de Ciencia e
   Innovacion (Grant SAF2016-80639-P to J.A.M.), Plan Nacional de I+D+I,
   Spain, the Agencia de Gestio d'Ajuts Universitaris i de Recerca (AGAUR;
   Grant 2014 SGR229 to J.A.M.), Departament d'Economia i Coneixement,
   Catalonia, Spain, the Andalusian Regional Government Council of
   Innovation and Science (Grant P11-CTS-7625 to A.S.-C.), the Ministerio
   de Economia, Industria y Competitividad, Spain (Grants
   AGL2015-67995-C2-3-R and AGL2015-67995-C3-1-R to A.S.-C. and V.M.) and
   Conselleria d'Educacio, Investigacio, Cultura I Esport, Generalitat
   Valenciana, Spain (Grant PROMETEO/2016/006 to V.M). E.C. is supported by
   the Sara Borrell post doctoral contract (CD15/00033) from the Ministerio
   de Sanidad y Consumo, Fondo de Investigacion Sanitaria (FIS), Spain. We
   are grateful to Custodio Borrego for giving us free use of the
   photograph he took of EVOO and olive trees in Granada (Spain), which
   have been included in Figure 7. This work has been awarded with the IV
   Premio Internacional Castillo de Canena de Investigacion Oleicola 'LUIS
   VANO'(IV Edition of Castillo de Canena LUIS VANO Award for Research on
   Olive Cultivation and Olive Oil; UC Davis Olive Center, Castillo de
   Canena, and Universidad de Jaen).
CR Bochner BR, 2001, GENOME RES, V11, P1246, DOI 10.1101/gr.186501
   Bourne CR, 2012, J MOL RECOGNIT, V25, P216, DOI 10.1002/jmr.2174
   Brooks MD, 2015, CELL STEM CELL, V17, P260, DOI 10.1016/j.stem.2015.08.014
   Casaburi I, 2013, MOL NUTR FOOD RES, V57, P71, DOI 10.1002/mnfr.201200503
   Chaffer CL, 2015, CANCER DISCOV, V5, P22, DOI 10.1158/2159-8290.CD-14-0788
   Chaffer CL, 2011, P NATL ACAD SCI USA, V108, P7950, DOI 10.1073/pnas.1102454108
   Chandhoke AS, 2016, CELL DEATH DIFFER, V23, P876, DOI 10.1038/cdd.2015.152
   Charafe-Jauffret E, 2009, CANCER RES, V69, P1302, DOI 10.1158/0008-5472.CAN-08-2741
   Choi J, 2011, BIOCHEM BIOPH RES CO, V413, P259, DOI 10.1016/j.bbrc.2011.08.081
   Colomer Ramon, 2006, Clin Transl Oncol, V8, P15, DOI 10.1007/s12094-006-0090-0
   Corominas-Faja B, 2014, ONCOTARGET, V5, P8306, DOI 10.18632/oncotarget.2059
   Creighton CJ, 2009, P NATL ACAD SCI USA, V106, P13820, DOI 10.1073/pnas.0905718106
   Dennis PB, 1996, MOL CELL BIOL, V16, P6242
   Dogan F, 2018, GENE, V641, P235, DOI 10.1016/j.gene.2017.09.072
   Duru N, 2012, CLIN CANCER RES, V18, P6634, DOI 10.1158/1078-0432.CCR-12-1436
   Escrich E, 2011, PUBLIC HEALTH NUTR, V14, P2323, DOI 10.1017/S1368980011002588
   Friedmann-Morvinski D, 2014, EMBO REP, V15, P244, DOI 10.1002/embr.201338254
   Fujita J, 2008, CELL STEM CELL, V2, P595, DOI 10.1016/j.stem.2008.04.001
   Gupta PB, 2009, CELL, V138, P645, DOI 10.1016/j.cell.2009.06.034
   Hsieh AC, 2012, NATURE, V485, P55, DOI 10.1038/nature10912
   Hsieh Ching-Yi, 1999, Chinese Pharmaceutical Journal (Taipei), V51, P15
   Hu XQ, 2017, STEM CELL TRANSL MED, V6, P331, DOI 10.5966/sctm.2015-0289
   Jung JW, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028068
   Kakarala M, 2008, J CLIN ONCOL, V26, P2813, DOI 10.1200/JCO.2008.16.3931
   Kalogris C, 2014, BIOCHEM PHARMACOL, V90, P226, DOI 10.1016/j.bcp.2014.05.014
   Khanfar MA, 2015, PHYTOTHER RES, V29, P1776, DOI 10.1002/ptr.5434
   Kim YS, 2012, J NUTR BIOCHEM, V23, P691, DOI 10.1016/j.jnutbio.2012.03.002
   Korkaya H, 2008, ONCOGENE, V27, P6120, DOI 10.1038/onc.2008.207
   Lamb R, 2015, ONCOTARGET, V6, P4585, DOI 10.18632/oncotarget.3278
   Leone A, 2012, PHYTOCHEM REV, V11, P285, DOI 10.1007/s11101-012-9235-7
   Li YY, 2014, CANCER LETT, V346, P197, DOI 10.1016/j.canlet.2014.01.012
   Li YY, 2011, J NUTR BIOCHEM, V22, P799, DOI 10.1016/j.jnutbio.2010.11.001
   Li YY, 2010, CLIN CANCER RES, V16, P2580, DOI 10.1158/1078-0432.CCR-09-2937
   Liu XF, 2013, SCI REP-UK, V3, DOI 10.1038/srep02473
   Lozano-Sánchez J, 2010, J AGR FOOD CHEM, V58, P9942, DOI 10.1021/jf101502q
   Mackie AM, 2014, METHODS MOL BIOL, V1096, P123, DOI 10.1007/978-1-62703-712-9_10
   Magee JA, 2012, CANCER CELL, V21, P283, DOI 10.1016/j.ccr.2012.03.003
   Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027
   Iglesias JM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077281
   Martin-Castillo B, 2015, ONCOTARGET, V6, P32317, DOI 10.18632/oncotarget.6094
   Menendez JA, 2006, CURR PHARM BIOTECHNO, V7, P495, DOI 10.2174/138920106779116900
   Menendez JA, 2015, CURR PHARM DESIGN, V21, P3644, DOI 10.2174/1381612821666150710150327
   Menendez JA, 2013, CELL CYCLE, V12, P555, DOI 10.4161/cc.23756
   Mineva ND, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073464
   Moffat JG, 2017, NAT REV DRUG DISCOV, V16, P531, DOI 10.1038/nrd.2017.111
   Moffat JG, 2014, NAT REV DRUG DISCOV, V13, P588, DOI 10.1038/nrd4366
   Nakamura Y, 2005, CARCINOGENESIS, V26, P665, DOI 10.1093/carcin/bgi003
   Obied HK, 2008, NAT PROD REP, V25, P1167, DOI 10.1039/b719736e
   Pandey PR, 2011, BREAST CANCER RES TR, V130, P387, DOI 10.1007/s10549-010-1300-6
   Pathania R, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7910
   Sai K, 2000, CARCINOGENESIS, V21, P1671, DOI 10.1093/carcin/21.9.1671
   Smith JA, 2010, AGING CELL, V9, P580, DOI 10.1111/j.1474-9726.2010.00585.x
   Tai MH, 2005, CARCINOGENESIS, V26, P495, DOI 10.1093/carcin/bgh321
   Tomita H, 2016, ONCOTARGET, V7, P11018, DOI 10.18632/oncotarget.6920
   Trosko JE, 2006, ANN NY ACAD SCI, V1089, P36, DOI 10.1196/annals.1386.018
   Vazquez-Martin A, 2012, REJUV RES, V15, P3, DOI 10.1089/rej.2011.1203
   Visioli F, 2011, CURR PHARM DESIGN, V17, P786, DOI 10.2174/138161211795428885
   Wicha MS, 2006, CANCER RES, V66, P1883, DOI 10.1158/0008-5472.CAN-05-3153
   Wolter F, 2003, CARCINOGENESIS, V24, P469, DOI 10.1093/carcin/24.3.469
   Yoshida T, 2006, ONCOGENE, V25, P6056, DOI 10.1038/sj.onc.1209635
NR 60
TC 48
Z9 51
U1 0
U2 28
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0143-3334
EI 1460-2180
J9 CARCINOGENESIS
JI Carcinogenesis
PD APR
PY 2018
VL 39
IS 4
BP 601
EP 613
DI 10.1093/carcin/bgy023
PG 13
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA GC0MJ
UT WOS:000429471100010
PM 29452350
OA Green Published, hybrid
DA 2025-01-12
ER

PT J
AU Szczepny, A
   Carey, K
   McKenzie, L
   Jayasekara, WSN
   Rossello, F
   Gonzalez-Rajal, A
   Mccaw, AS
   Popovski, D
   Wang, D
   Sadler, AJ
   Mahar, A
   Russell, PA
   Wright, G
   McCloy, RA
   Garama, DJ
   Gough, DJ
   Baylin, SB
   Burgess, A
   Cain, JE
   Watkins, DN
AF Szczepny, Anette
   Carey, Kirstyn
   McKenzie, Lisa
   Jayasekara, W. Samantha N.
   Rossello, Fernando
   Gonzalez-Rajal, Alvaro
   Mccaw, Andrew S.
   Popovski, Dean
   Wang, Die
   Sadler, Anthony J.
   Mahar, Annabelle
   Russell, Prudence A.
   Wright, Gavin
   McCloy, Rachael A.
   Garama, Daniel J.
   Gough, Daniel J.
   Baylin, Stephen B.
   Burgess, Andrew
   Cain, Jason E.
   Watkins, D. Neil
TI The tumor suppressor Hic1 maintains chromosomal stability independent of
   Tp53
SO ONCOGENE
LA English
DT Article
ID ACUTE MYELOID-LEUKEMIA; DIRECT TARGET GENE; CANCER 1 HIC1; DNA-DAMAGE;
   BREAST-CANCER; LUNG ADENOCARCINOMA; DRIVES PROGRESSION; MI-2/NURD
   COMPLEX; P53; INSTABILITY
AB Hypermethylated-in-Cancer 1 (Hic1) is a tumor suppressor gene frequently inactivated by epigenetic silencing and loss-of-heterozygosity in a broad range of cancers. Loss of HIC1, a sequence-specific zinc finger transcriptional repressor, results in deregulation of genes that promote a malignant phenotype in a lineage-specific manner. In particular, upregulation of the HIC1 target gene SIRT1, a histone deacetylase, can promote tumor growth by inactivating TP53. An alternate line of evidence suggests that HIC1 can promote the repair of DNA double strand breaks through an interaction with MTA1, a component of the nucleosome remodeling and deacetylase (NuRD) complex. Using a conditional knockout mouse model of tumor initiation, we now show that inactivation of Hic1 results in cell cycle arrest, premature senescence, chromosomal instability and spontaneous transformation in vitro. This phenocopies the effects of deleting Brca1, a component of the homologous recombination DNA repair pathway, in mouse embryonic fibroblasts. These effects did not appear to be mediated by deregulation of Hic1 target gene expression or loss of Tp53 function, and rather support a role for Hic1 in maintaining genome integrity during sustained replicative stress. Loss of Hic1 function also cooperated with activation of oncogenic KRas in the adult airway epithelium of mice, resulting in the formation of highly pleomorphic adenocarcinomas with a micropapillary phenotype in vivo. These results suggest that loss of Hic1 expression in the early stages of tumor formation may contribute to malignant transformation through the acquisition of chromosomal instability.
C1 [Szczepny, Anette; Carey, Kirstyn; McKenzie, Lisa; Jayasekara, W. Samantha N.; Mccaw, Andrew S.; Popovski, Dean; Wang, Die; Sadler, Anthony J.; Garama, Daniel J.; Gough, Daniel J.; Cain, Jason E.] Hudson Inst Med Res, Ctr Canc Res, Clayton, Vic, Australia.
   [Szczepny, Anette; Carey, Kirstyn; McKenzie, Lisa; Popovski, Dean; Wang, Die; Sadler, Anthony J.; Garama, Daniel J.; Gough, Daniel J.] Monash Univ, Fac Med Nursing & Hlth Sci, Dept Mol & Translat Sci, Clayton, Vic, Australia.
   [Rossello, Fernando] Monash Univ, Fac Med Nursing & Hlth Sci, Dept Anat & Dev Biol, Clayton, Vic, Australia.
   [Rossello, Fernando] Monash Univ, Australian Regenerat Med Inst, Clayton, Vic, Australia.
   [Gonzalez-Rajal, Alvaro; Burgess, Andrew; Watkins, D. Neil] Garvan Inst Med Res, Kinghorn Canc Ctr, Darlinghurst, NSW, Australia.
   [Mahar, Annabelle] Royal Prince Alfred Hosp, Dept Tissue Pathol & Diagnost Oncol, Camperdown, NSW, Australia.
   [Russell, Prudence A.] St Vincents Hosp Melbourne, Dept Pathol, Fitzroy, Vic, Australia.
   [Wright, Gavin] St Vincents Hosp Melbourne, Dept Surg, Fitzroy, Vic, Australia.
   [Baylin, Stephen B.] Johns Hopkins, Sidney Kimmel Canc Ctr, Baltimore, MD USA.
   [Watkins, D. Neil] UNSW Fac Med, St Vincents Clin Sch, Sydney, NSW, Australia.
   [Watkins, D. Neil] St Vincents Hosp, Dept Thorac Med, Sydney, NSW, Australia.
C3 Hudson Institute of Medical Research; Monash University; Monash
   University; Monash University; Australian Regenerative Medicine
   Institute; The Kinghorn Cancer Centre; Garvan Institute of Medical
   Research; University of Sydney; NSW Health; Royal Prince Alfred
   Hospital; St Vincent's Health; St Vincent's Hospital Melbourne; St
   Vincent's Health; St Vincent's Hospital Melbourne; Johns Hopkins
   University; University of New South Wales Sydney; NSW Health; St
   Vincents Hospital Sydney
RP Cain, JE (通讯作者)，Hudson Inst Med Res, Ctr Canc Res, Clayton, Vic, Australia.; Watkins, DN (通讯作者)，Garvan Inst Med Res, Kinghorn Canc Ctr, Darlinghurst, NSW, Australia.; Watkins, DN (通讯作者)，UNSW Fac Med, St Vincents Clin Sch, Sydney, NSW, Australia.; Watkins, DN (通讯作者)，St Vincents Hosp, Dept Thorac Med, Sydney, NSW, Australia.
EM jason.cain@hudson.org.au; n.watkins@garvan.org.au
RI Wang, Die/H-8860-2017; Gonzalez-Rajal, Alvaro/ABA-6874-2020; sadler,
   anthony/ABA-5572-2020; Gough, Daniel/IYS-8767-2023; Watkins,
   David/I-6113-2013; Burgess, Andrew/H-3339-2019; Burgess,
   Andrew/C-7952-2009; Rossello, Fernando/B-1208-2015
OI McCloy, Rachael/0000-0001-7791-4044; Gonzalez-Rajal,
   Alvaro/0000-0002-9230-0339; Sadler, Anthony/0000-0002-7970-8030; Gough,
   Daniel/0000-0001-5725-8668; Carey, Kirstyn/0000-0003-4743-2700; Wang,
   Die/0000-0001-7628-7309; Burgess, Andrew/0000-0003-4536-9226; Gough,
   Daniel/0000-0001-6479-1735; Rossello, Fernando/0000-0003-3885-8777;
   Watkins, Neil/0000-0001-8218-4920; McKenzie, Lisa/0000-0002-1432-6496;
   Garama, Daniel/0000-0002-4484-3603
FU National Health and Medical Research Council (NHMRC) of Australia
   [GNT10838550]; Victorian Cancer Agency [TS10-01]; National Institutes of
   Health [NCI-RO1 NS054085]; Petre Foundation; Victorian Government's
   Operational Infrastructure Support Program; NHMRC [GNT1063914]; Cancer
   Institute NSW Fellowship [10/FRL/3-02]; Patricia Helen Guest Fellowship;
   National Health and Medical Research Council of Australia [GNT1063914,
   GNT1083855]
FX This work was supported by the National Health and Medical Research
   Council (NHMRC) of Australia (Project Grant GNT10838550, The Victorian
   Cancer Agency (TS10-01), The National Institutes of Health (NCI-RO1
   NS054085), The Petre Foundation, and the Victorian Government's
   Operational Infrastructure Support Program. Dr Gough is supported by an
   NHMRC Career Development Fellowship (GNT1063914). Dr Burgess is
   supported by Cancer Institute NSW Fellowship (10/FRL/3-02) and a
   Patricia Helen Guest Fellowship. The contents of this manuscript are
   solely the responsibility of the participating institutions and
   individual authors, and do not reflect the views of these funding
   agencies. We thank Dr Dominique LePrince for the gift of the Hic1-FLAG
   expression vector. National Health and Medical Research Council of
   Australia (GNT1083855): J.E.C., D.N.W.; (GNT1063914): D.J.G. National
   Institutes of Health (NINDS RO1 NS054085): D.N.W., S.B.B. The Petre
   Foundation: D.N.W. Cancer Institute of NSW Fellowship (10/FRL/3-02) and
   the Patricia Helen Guest Fellowship: A.B.
CR Aggerholm A, 2006, EUR J HAEMATOL, V76, P23, DOI 10.1111/j.1600-0609.2005.00559.x
   Badea TC, 2003, J NEUROSCI, V23, P2314
   Bakhoum SF, 2012, J CLIN INVEST, V122, P1138, DOI 10.1172/JCI59954
   Briggs KJ, 2008, CANCER RES, V68, P8654, DOI 10.1158/0008-5472.CAN-08-1904
   Briggs KJ, 2008, GENE DEV, V22, P770, DOI 10.1101/gad.1640908
   Britschgi C, 2008, BRIT J HAEMATOL, V141, P179, DOI 10.1111/j.1365-2141.2008.06992.x
   Cain Jason E., 2013, Sarcoma, V2013, P608964, DOI 10.1155/2013/608964
   Caldon CE, 2013, CELL CYCLE, V12, P606, DOI 10.4161/cc.23512
   Cao L, 2003, GENE DEV, V17, P201, DOI 10.1101/gad.1050003
   Carter MG, 2000, HUM MOL GENET, V9, P413, DOI 10.1093/hmg/9.3.413
   Chen WY, 2005, CELL, V123, P437, DOI 10.1016/j.cell.2005.08.011
   Chen WY, 2003, NAT GENET, V33, P197, DOI 10.1038/ng1077
   Chen WY, 2005, CELL CYCLE, V4, P10, DOI 10.4161/cc.4.1.1361
   Chen WY, 2004, CANCER CELL, V6, P387, DOI 10.1016/j.ccr.2004.08.030
   Cheng GC, 2014, CANCER RES, V74, P862, DOI 10.1158/0008-5472.CAN-13-2420
   Cohen SM, 2010, NUCLEIC ACIDS RES, V38, P6906, DOI 10.1093/nar/gkq559
   Collisson EA, 2014, NATURE, V511, P543, DOI 10.1038/nature13385
   Debacq-Chainiaux F, 2009, NAT PROTOC, V4, P1798, DOI 10.1038/nprot.2009.191
   Dehennaut V, 2013, J BIOL CHEM, V288, P10254, DOI 10.1074/jbc.M112.421610
   Deltour S, 1999, P NATL ACAD SCI USA, V96, P14831, DOI 10.1073/pnas.96.26.14831
   Deltour S, 1998, BBA-GENE STRUCT EXPR, V1443, P230, DOI 10.1016/S0167-4781(98)00219-X
   DuPage M, 2009, NAT PROTOC, V4, P1064, DOI 10.1038/nprot.2009.95
   Dykhuizen EC, 2013, NATURE, V497, P624, DOI 10.1038/nature12146
   Evers B, 2006, ONCOGENE, V25, P5885, DOI 10.1038/sj.onc.1209871
   Foveau B, 2012, J BIOL CHEM, V287, P5366, DOI 10.1074/jbc.M111.329466
   Fujii H, 1998, ONCOGENE, V16, P2159, DOI 10.1038/sj.onc.1201976
   Ganem NJ, 2012, J CELL BIOL, V199, P871, DOI 10.1083/jcb.201210040
   Geigl JB, 2008, TRENDS GENET, V24, P64, DOI 10.1016/j.tig.2007.11.006
   Guarente L, 2011, COLD SH Q B, V76, P81, DOI 10.1101/sqb.2011.76.010629
   Guerardel C, 2001, J BIOL CHEM, V276, P3078, DOI 10.1074/jbc.M008690200
   Heng HH, 2013, CANCER METAST REV, V32, P325, DOI 10.1007/s10555-013-9427-7
   Holland AJ, 2009, NAT REV MOL CELL BIO, V10, P478, DOI 10.1038/nrm2718
   Jackson EL, 2005, CANCER RES, V65, P10280, DOI 10.1158/0008-5472.CAN-05-2193
   Jackson EL, 2001, GENE DEV, V15, P3243, DOI 10.1101/gad.943001
   Janeckova L, 2015, MOL CANCER RES, V13, P1139, DOI 10.1158/1541-7786.MCR-15-0033
   Kuilman T, 2010, GENE DEV, V24, P2463, DOI 10.1101/gad.1971610
   Lai AY, 2011, NAT REV CANCER, V11, P588, DOI 10.1038/nrc3091
   Leibiger C, 2013, J HISTOCHEM CYTOCHEM, V61, P306, DOI 10.1369/0022155413476868
   Li DQ, 2010, CELL CYCLE, V9, P2071, DOI 10.4161/cc.9.11.11735
   Li P, 2015, ONCOTARGET, V6, P38151, DOI 10.18632/oncotarget.5832
   Lin YM, 2013, CELL CYCLE, V12, P2266, DOI 10.4161/cc.25365
   Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4
   Mannava S, 2013, AM J PATHOL, V182, P142, DOI 10.1016/j.ajpath.2012.09.011
   McCloy RA, 2014, CELL CYCLE, V13, P1400, DOI 10.4161/cc.28401
   Melki JR, 1999, CANCER RES, V59, P3730
   Mermoud JE, 2011, CELL CYCLE, V10, P4017, DOI 10.4161/cc.10.23.18558
   Mohammad HP, 2011, ONCOGENE, V30, P2659, DOI 10.1038/onc.2010.633
   Nagy A, 2008, CSH PROTOC, P2014
   Paget S, 2017, ONCOTARGET, V8, P2916, DOI 10.18632/oncotarget.13807
   Pinte S, 2004, J BIOL CHEM, V279, P38313, DOI 10.1074/jbc.M401610200
   Pinte S, 2004, ONCOGENE, V23, P4023, DOI 10.1038/sj.onc.1207504
   Prakash R, 2015, COLD SPRING HARB PER, V7
   Rood BR, 2002, CANCER RES, V62, P3794
   Russell PA, 2013, J THORAC ONCOL, V8, P461, DOI 10.1097/JTO.0b013e3182828fb8
   Sims JK, 2011, MOL BIOL CELL, V22, P3094, DOI 10.1091/mbc.E11-03-0258
   Stephen JK, 2010, CLIN EPIGENETICS, V1, DOI 10.1007/s13148-010-0005-3
   Stevens JB, 2013, CANCER METAST REV, V32, P391, DOI 10.1007/s10555-013-9428-6
   Sun Hong, 2007, V383, P303, DOI 10.1007/978-1-59745-335-6_19
   Szczepny A, 2017, ONCOGENE, V23, P2314
   Tarapore P, 2002, ONCOGENE, V21, P6234, DOI 10.1038/sj.onc.1205707
   Thomas A, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf6282
   Tseng RC, 2009, NEOPLASIA, V11, P763, DOI 10.1593/neo.09470
   Ung M, 2016, CLIN LUNG CANCER, V17, P391, DOI 10.1016/j.cllc.2016.03.001
   Valenta T, 2006, EMBO J, V25, P2326, DOI 10.1038/sj.emboj.7601147
   Van Rechem C, 2009, J BIOL CHEM, V284, P20927, DOI 10.1074/jbc.M109.022350
   Van Rechem C, 2009, BIOCHEM BIOPH RES CO, V385, P586, DOI 10.1016/j.bbrc.2009.05.115
   WALES MM, 1995, NAT MED, V1, P570, DOI 10.1038/nm0695-570
   Wallace MD, 2014, ONCOGENE, V33, P3688, DOI 10.1038/onc.2013.339
   Weyemi U, 2012, ONCOGENE, V31, P1117, DOI 10.1038/onc.2011.327
   Xu Jianming, 2005, Curr Protoc Mol Biol, VChapter 28, DOI 10.1002/0471142727.mb2801s70
   Zhang W, 2010, ONCOGENE, V29, P2467, DOI 10.1038/onc.2010.12
NR 71
TC 18
Z9 18
U1 0
U2 9
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-9232
EI 1476-5594
J9 ONCOGENE
JI Oncogene
PD APR
PY 2018
VL 37
IS 14
BP 1939
EP 1948
DI 10.1038/s41388-017-0022-1
PG 10
WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
GA GB8CU
UT WOS:000429303300010
PM 29367758
OA hybrid, Green Published
DA 2025-01-12
ER

PT J
AU Borgonio-Cuadra, VM
   Miranda-Duarte, A
   Rojas-Toledo, X
   Garcia-Hernandez, N
   Sierra-Ramirez, JA
   Cardenas-Garcia, M
   Hernandez-Caballero, ME
AF Marusa Borgonio-Cuadra, Veronica
   Miranda-Duarte, Antonio
   Rojas-Toledo, Xochitl
   Garcia-Hernandez, Normand
   Alfredo Sierra-Ramirez, Jose
   Cardenas-Garcia, Maura
   Elena Hernandez-Caballero, Marta
TI Association between promoter hypermethylation of the <i>DACT2</i> gene
   and tumor stages in breast cancer
SO JOURNAL OF BUON
LA English
DT Article
DE breast cancer; CpG island; DACT2; methylation; tumor grade
ID METHYLATION; SUPPRESSOR; EPIGENETICS
AB Purpose: Aberrant methylation of CpG islands in the promoter is a hallmark of cancer, leading to transcriptional silencing of tumor suppressor genes. The aim of this work was to evaluate the promoter methylation status of the DACT2 gene in breast cancer (BC) tissue and to analyze its possible effect on tumor type or grade.
   Methods: CpG island from the DACT2 promoter in region -240 to -14 from transcriptional start site (TSS) were obtained. Through the use of sodium bisulfite DNA conversion analysis, followed by detection with MSP (methylation specific PCR), we analyzed 79 BC and 15 adjacent healthy samples.
   Results: The cases analyzed were in stage I (2.5%), II (38%), or III (59.5%). The most frequent tumor type was invasive ductal carcinoma (71.4%). Methylation analysis comparing tumor tissues with adjacent non-cancerous tissues showed statistical significance. Methylation was observed in 32.9% (26/79) of the samples; no methylation was found in adjacent healthy tissue. DACT2 methylation was associated with tumor stage I-II (p=0.03) and stage III (p=0.004).
   Conclusion: An association was found of DACT2 promoter methylation with advanced tumor stages. This gene has been suggested as a potential biomarker, however, more investigation is required to validate this function.
C1 [Marusa Borgonio-Cuadra, Veronica; Miranda-Duarte, Antonio; Rojas-Toledo, Xochitl] Inst Nacl Rehabil, Lab Genet, Calzada Mexico Xochimilco 289, Mexico City 14389, DF, Mexico.
   [Garcia-Hernandez, Normand] CMN S XXI, UIMGH, Genom Func & Prote, IMSS Cuauhtemoc 330, Mexico City 06720, DF, Mexico.
   [Alfredo Sierra-Ramirez, Jose] Inst Politecn Nacl, Escuela Super Med, Plan San Luis & Diaz Miron S-N, Mexico City 11340, DF, Mexico.
   [Cardenas-Garcia, Maura; Elena Hernandez-Caballero, Marta] Benemerita Univ Autonoma Puebla, Fac Med, 13 Sur 2702 Col, Puebla 72410, Mexico.
C3 Instituto Politecnico Nacional - Mexico; Benemerita Universidad Autonoma
   de Puebla
RP Hernandez-Caballero, ME (通讯作者)，Benemerita Univ Autonoma Puebla, Fac Med, 13 Sur 2702 Col, Puebla 72420, Mexico.
EM ehdezc@yahoo.com
RI Duarte, Antonio/KFQ-6840-2024; CÁRDENAS-GARCÍA, MAURA/ABI-2371-2020;
   RAMIREZ, JOSE/L-3994-2019; García-Hernández, Normand/AAD-3029-2019;
   Hernández-Caballero, Marta/AAE-7707-2020
OI Miranda-Duarte, Antonio/0000-0001-6530-4636; Sierra-Ramirez, Jose
   Alfredo/0000-0001-5060-5882
FU PRODEP [DSA/103-5/15/7749]; Vicerrectoria y Estudios de Posgrado, BUAP
   [HECM-SAL-17]
FX This work was supported by PRODEP, register number DSA/103-5/15/7749 and
   Vicerrectoria y Estudios de Posgrado, BUAP, register number HECM-SAL-17.
CR Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210
   Hou J, 2013, CANCER PREV RES, V6, P791, DOI 10.1158/1940-6207.CAPR-12-0352
   Jia Y, 2013, J PATHOL, V230, P194, DOI 10.1002/path.4073
   Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947
   Li J, 2017, ONCOTARGET, V8, P80012, DOI 10.18632/oncotarget.20820
   Knaul FM, 2009, SALUD PUBLICA MEXICO, V51, pS335, DOI 10.1590/S0036-36342009000800026
   Osborne C, 2004, ONCOLOGIST, V9, P361, DOI 10.1634/theoncologist.9-4-361
   Reis AHO, 2016, TUMOR BIOL, V37, P13029, DOI 10.1007/s13277-016-5278-5
   Wang S, 2015, ONCOGENE, V34, P2575, DOI 10.1038/onc.2014.201
   Waxman JS, 2004, DEVELOPMENT, V131, P5909, DOI 10.1242/dev.01520
   Xiang TX, 2016, ONCOTARGET, V7, P70924, DOI 10.18632/oncotarget.12341
   Yu YZ, 2014, AM J CANCER RES, V4, P710
   Zhang LX, 2004, SCIENCE, V306, P114, DOI 10.1126/science.1100569
   Zhang MY, 2016, ONCOTARGET, V7, P17957, DOI 10.18632/oncotarget.7647
   Zhao ZY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112336
NR 15
TC 7
Z9 7
U1 0
U2 1
PU IMPRIMATUR PUBLICATIONS
PI ATHENS
PA 30 DEM POLIORKETES ST, ATHENS, 136 76, GREECE
SN 1107-0625
EI 2241-6293
J9 J BUON
JI J. BUON
PD MAR-APR
PY 2018
VL 23
IS 2
BP 361
EP 365
PG 5
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA GB0UB
UT WOS:000428762300012
PM 29745077
DA 2025-01-12
ER

PT J
AU Ji, XN
   Xue, YY
   Wu, Y
   Feng, F
   Gao, XD
AF Ji, Xiaonan
   Xue, Yayu
   Wu, Yu
   Feng, Fang
   Gao, Xiangdong
TI High-expressed CKS2 is associated with hepatocellular carcinoma cell
   proliferation through down-regulating PTEN
SO PATHOLOGY RESEARCH AND PRACTICE
LA English
DT Article
DE HCC; DEGs; CKS2; Cell proliferation; CCK8; Colony formation
ID CYCLIN KINASE SUBUNIT-2; CLINICAL-SIGNIFICANCE; BREAST-CANCER; GENES;
   CHOLANGIOCARCINOMA; IDENTIFICATION; TUMORIGENESIS; RECURRENCE;
   PREDICTION; PROTEIN
AB Background: Hepatocellular carcinoma (HCC) is a product of cumulative genetic, epigenetic, somatic, and endocrine aberrations. Identifying the differentially expressed genes (DEGs) in HCC is of critical importance for diagnosis and treatment. The purpose of the present study was to screen the key genes associated with hepatocellular carcinoma and to investigate the functions underlying hepatocellular carcinoma progression.
   Materials and methods: The gene expression profile of GSE64041, GSE40367 and GSE60502, including 100 specimens from HCC patients and 92 specimens from normal liver controls, was downloaded from the GEO database. DEGs were screened using the online analysis tool from the GCBI website and validated by Q-PCR and Kaplan-Meier survival analysis. After knockdown by siRNA in HepG2/C3A and Bel7402 HCC cells, the CCK-8 assay and colony formation assay were used to measure the clonogenic capacity of the tumor cells. Western blotting assay was used to measure the expression of PTEN.
   Results: Five up-regulated genes were identified as overlapping genes associated with tumor cell activation. Upon validation by Q-PCR and Kaplan-Meier survival analysis, CKS2 was selected for further study. Although the results of CCK-8 did not show a significant difference, the colony formation assay results indicated that the silencing of CKS2 significantly inhibited cancer cell proliferation. Further study found that CKS2 knockdown induced PTEN up-regulation and may associate with P53 pathway activation.
   Conclusion: These findings indicated that CKS2 play a role in tumor activation and serve as a useful potential target for the treatment of HCC.
C1 [Ji, Xiaonan; Xue, Yayu; Wu, Yu; Feng, Fang; Gao, Xiangdong] China Pharmaceut Univ, Sch Life Sci & Technol, Jiangsu Key Lab Druggabil Biopharmaceut, Nanjing 210009, Jiangsu, Peoples R China.
C3 China Pharmaceutical University
RP Gao, XD (通讯作者)，China Pharmaceut Univ, Sch Life Sci & Technol, Jiangsu Key Lab Druggabil Biopharmaceut, Nanjing 210009, Jiangsu, Peoples R China.
EM jxncpu@cpu.edu.cn; 443896450@qq.com; 4022198@qq.com; j0512@126.com;
   xdgao@cpu.edu.cn
RI Gao, Xiang/HDO-3543-2022; li, fangyu/KCY-0521-2024
FU College Students Innovation Project for the R&D of Novel Drugs
   [J1310032]; National Natural Science Foundation of China [81430082];
   Priority Academic Program Development of Jiangsu Higher Education
   Institutions (PAPD)
FX This work was supported by College Students Innovation Project for the
   R&D of Novel Drugs (J1310032), the National Natural Science Foundation
   of China (No. 81430082) and A Project Funded by the Priority Academic
   Program Development of Jiangsu Higher Education Institutions (PAPD).
CR Bi DB, 2015, COMPUT BIOL CHEM, V56, P71, DOI 10.1016/j.compbiolchem.2015.04.001
   Budhu A, 2006, CANCER CELL, V10, P99, DOI 10.1016/j.ccr.2006.06.016
   Cavard C, 2006, ONCOGENE, V25, P599, DOI 10.1038/sj.onc.1208860
   Forner A, 2012, LANCET ONCOL, V13, P750, DOI 10.1016/S1470-2045(12)70271-1
   Hsu CW, 2017, J CANCER, V8, P1378, DOI 10.7150/jca.17478
   Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010
   Khattar Vinayak, 2013, J Cancer Ther, V4, P1341
   Lan YS, 2008, INT J CANCER, V123, P543, DOI 10.1002/ijc.23548
   Makowska Z, 2016, J PATHOL CLIN RES, V2, P80, DOI 10.1002/cjp2.37
   Maluccio M, 2012, CA-CANCER J CLIN, V62, P394, DOI 10.3322/caac.21161
   Muñoz-Fontela C, 2016, NAT REV IMMUNOL, V16, P741, DOI 10.1038/nri.2016.99
   Rebouissou S, 2009, NATURE, V457, P200, DOI 10.1038/nature07475
   Roessler S, 2015, INT J BIOL SCI, V11, P88, DOI 10.7150/ijbs.10583
   Shen DY, 2013, LIVER INT, V33, P137, DOI 10.1111/liv.12014
   Shen DY, 2010, LIVER INT, V30, P119, DOI 10.1111/j.1478-3231.2009.02106.x
   Shi M, 2014, EUR J CANCER, V50, P928, DOI 10.1016/j.ejca.2013.11.026
   Wang JJ, 2013, DIS ESOPHAGUS, V26, P729, DOI 10.1111/dote.12013
   Wang JI, 2014, INT J CLIN EXP PATHO, V7, P8593
   Wang YH, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-815
   Wen DY, 2014, ANDROLOGIA, V46, P625, DOI 10.1111/and.12127
   Westbrook L, 2007, CANCER RES, V67, P11393, DOI 10.1158/0008-5472.CAN-06-4173
   WILLIAMS RT, 1993, J BIOL CHEM, V268, P8871
   Woo HG, 2008, CLIN CANCER RES, V14, P2056, DOI 10.1158/1078-0432.CCR-07-1473
   Woo HG, 2010, CANCER RES, V70, P3034, DOI 10.1158/0008-5472.CAN-09-2823
   Yu MH, 2013, ONCOL LETT, V6, P777, DOI 10.3892/ol.2013.1456
   Zhang YW, 2013, J HEPATOL, V58, P502, DOI 10.1016/j.jhep.2012.11.002
NR 26
TC 19
Z9 20
U1 1
U2 12
PU ELSEVIER GMBH, URBAN & FISCHER VERLAG
PI JENA
PA OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY
SN 0344-0338
J9 PATHOL RES PRACT
JI Pathol. Res. Pract.
PD MAR
PY 2018
VL 214
IS 3
BP 436
EP 441
DI 10.1016/j.prp.2017.12.006
PG 6
WC Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pathology
GA GB5EK
UT WOS:000429085700016
PM 29487004
DA 2025-01-12
ER

PT J
AU Miyagawa, Y
   Matsushita, Y
   Suzuki, H
   Komatsu, M
   Yoshimaru, T
   Kimura, R
   Yanai, A
   Honda, J
   Tangoku, A
   Sasa, M
   Miyoshi, Y
   Katagiri, T
AF Miyagawa, Yoshimasa
   Matsushita, Yosuke
   Suzuki, Hiromu
   Komatsu, Masato
   Yoshimaru, Tetsuro
   Kimura, Ryuichiro
   Yanai, Ayako
   Honda, Junko
   Tangoku, Akira
   Sasa, Mitsunori
   Miyoshi, Yasuo
   Katagiri, Toyomasa
TI Frequent downregulation of <i>LRRC26</i> by epigenetic alterations is
   involved in the malignant progression of triple-negative breast cancer
SO INTERNATIONAL JOURNAL OF ONCOLOGY
LA English
DT Article
DE LRRC26; triple-negative breast cancer; tumor suppressor;
   hypermethylation
ID LARGE GENE LISTS; ENDOPLASMIC-RETICULUM; KAPPA-B; ACTIVATION; PROTEIN;
   GROWTH; TUMORS; GLYCOSYLATION; CHEMOTHERAPY; METASTASIS
AB Triple-negative breast cancer (TNBC), defined as breast cancer lacking estrogen- and progesterone-receptor expression and human epidermal growth factor receptor 2 (HER2) amplification, is a heterogeneous disease. RNA-sequencing analysis of 15 TNBC specimens and The Cancer Genome Atlas-TNBC dataset analysis identified the frequent downregulation of leucine-rich repeat-containing 26 (LRRC26), which negatively regulates nuclear factor-B (NF-B) signaling, in TNBC tissues. Quantitative polymerase chain reaction and bisulfite pyrosequencing analyses revealed that LRRC26 was frequently silenced in TNBC tissues and cell lines as a result of promoter methylation. LRRC26 expression was restored by 5-aza-2-deoxycytidine (5-aza-dC) treatment in HCC1937 TNBC cells, which lack LRRC26 expression. Notably, small interfering RNA-mediated knockdown of LRRC26 expression significantly enhanced the anchorage-independent growth, invasion and migration of HCC70 cells, whereas ectopic overexpression of LRRC26 in BT20 cells suppressed their invasion and migration. Conversely, neither knockdown nor overexpression of LRRC26 had an effect on cell viability in the absence of tumor necrosis factor- (TNF-) stimulation. Meanwhile, overexpression of LRRC26 caused the reduction of TNF--mediated NF-B luciferase reporter activity, whereas depleting LRRC26 expression resulted in the upregulation of TNF--mediated NF-B downstream genes [interleukin-6 (IL-6), IL-8 and C-X-C motif chemokine ligand-1]. Taken together, these findings demonstrate that LRRC26 is frequently downregulated in TNBC due to DNA methylation and that it suppresses the TNF--independent anchorage-independent growth, invasion and migration of TNBC cells. Loss of LRRC26 function may be a critical event in the aggressiveness of TNBC cells through a TNF-/NF-B-independent mechanism.
C1 [Miyagawa, Yoshimasa; Matsushita, Yosuke; Komatsu, Masato; Yoshimaru, Tetsuro; Kimura, Ryuichiro; Yanai, Ayako; Katagiri, Toyomasa] Tokushima Univ, Inst Genome Res, Div Genome Med, 3-18-15 Kuramoto Cho, Tokushima 7708503, Japan.
   [Miyagawa, Yoshimasa; Yanai, Ayako; Miyoshi, Yasuo] Hyogo Coll Med, Div Breast & Endocrine Surg, Dept Surg, Nishinomiya, Hyogo 6638501, Japan.
   [Suzuki, Hiromu] Sapporo Med Univ, Dept Mol Biol, Sapporo, Hokkaido 0608556, Japan.
   [Honda, Junko] Natl Hosp Org Higashitokushima Med Ctr, Dept Surg, Tokushima 7790193, Japan.
   [Tangoku, Akira] Univ Tokushima, Inst Hlth Biosci, Dept Thorac & Endocrine Surg & Oncol, Grad Sch, Tokushima 7708503, Japan.
   [Sasa, Mitsunori] Tokushima Breast Care Clin, Dept Surg, Tokushima 7700052, Japan.
C3 Tokushima University; Hyogo Medical University; Sapporo Medical
   University; Tokushima University
RP Katagiri, T (通讯作者)，Tokushima Univ, Inst Genome Res, Div Genome Med, 3-18-15 Kuramoto Cho, Tokushima 7708503, Japan.
EM tkatagi@genome.tokushima-u.ac.jp
RI Yoshimaru, Tetsuro/AAE-5335-2020; Miyoshi, Yasuo/AAI-6321-2020
OI Yoshimaru, Tetsuro/0000-0001-8582-3011
FU Japan Agency for Medical Research and Development [13418656, 12103129];
   Grants-in-Aid for Scientific Research [16K19052, 17K10551, 17H06419,
   16H01575] Funding Source: KAKEN
FX This research was supported by the Tailor-Made Medical Treatment with
   the BBJ Project (grant no. 13418656) and Practical Research for
   Innovative Cancer Control (grant no. 12103129) from the Japan Agency for
   Medical Research and Development.
CR Annaert WG, 1997, J CELL BIOL, V139, P1397, DOI 10.1083/jcb.139.6.1397
   [Anonymous], 2011, TNM CLASSIFICATION M
   Carvalho S, 2016, ONCOTARGET, V7, P65231, DOI 10.18632/oncotarget.11245
   Colleoni M, 2006, J CLIN ONCOL, V24, P1332, DOI 10.1200/JCO.2005.03.0783
   Cortes J, 2011, LANCET, V377, P914, DOI 10.1016/S0140-6736(11)60070-6
   Couldrey C, 2000, BREAST CANCER RES, V2, P321, DOI 10.1186/bcr75
   Dall'Olio F, 2012, FRONT BIOSCI-LANDMRK, V17, P670, DOI 10.2741/3951
   Denkert C, 2017, LANCET, V389, P2430, DOI 10.1016/S0140-6736(16)32454-0
   Fisher B, 2001, J CLIN ONCOL, V19, P931, DOI 10.1200/JCO.2001.19.4.931
   Foulkes WD, 2010, NEW ENGL J MED, V363, P1938, DOI 10.1056/NEJMra1001389
   Gradishar WJ, 2016, J NATL COMPR CANC NE, V14, P324, DOI 10.6004/jnccn.2016.0037
   Hao JM, 2010, J PATHOL, V220, P475, DOI 10.1002/path.2668
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923
   Huszno J, 2016, WSPOLCZESNA ONKOL, V20, P1, DOI 10.5114/wo.2016.58495
   Kajiura K, 2017, ONCOTARGET, V8, P2890, DOI 10.18632/oncotarget.13761
   Kamimae S, 2015, ONCOTARGET, V6, P29975, DOI 10.18632/oncotarget.5034
   Kim JE, 2012, J BREAST CANCER, V15, P197, DOI 10.4048/jbc.2012.15.2.197
   Kim JW, 2009, CANCER SCI, V100, P1468, DOI 10.1111/j.1349-7006.2009.01209.x
   Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412
   Komatsu M, 2013, INT J ONCOL, V42, P478, DOI 10.3892/ijo.2012.1744
   Kurebayashi J, 1996, BRIT J CANCER, V74, P200, DOI 10.1038/bjc.1996.338
   Lehmann BD, 2011, J CLIN INVEST, V121, P2750, DOI 10.1172/JCI45014
   Liedtke C, 2008, J CLIN ONCOL, V26, P1275, DOI 10.1200/JCO.2007.14.4147
   Liu XF, 2012, ONCOGENE, V31, P1673, DOI 10.1038/onc.2011.355
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Locke WJ, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3237
   Merglen A, 2009, ANN ONCOL, V20, P857, DOI 10.1093/annonc/mdn688
   Ng FWH, 1997, J CELL BIOL, V139, P327, DOI 10.1083/jcb.139.2.327
   Nguyen HT, 2012, ONCOL REP, V28, P117, DOI 10.3892/or.2012.1764
   O'Shaughnessy J, 2011, NEW ENGL J MED, V364, P205, DOI 10.1056/NEJMoa1011418
   Park JH, 2006, CANCER RES, V66, P9186, DOI 10.1158/0008-5472.CAN-06-1601
   Peña-Chilet M, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-529
   Pereira B, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11479
   Pinho SS, 2015, NAT REV CANCER, V15, P540, DOI 10.1038/nrc3982
   Shah SP, 2012, NATURE, V486, P395, DOI 10.1038/nature10933
   Tutt A, 2010, LANCET, V376, P235, DOI 10.1016/S0140-6736(10)60892-6
   Wang XW, 2008, RNA, V14, P1012, DOI 10.1261/rna.965408
   Wolff AC, 2013, J CLIN ONCOL, V31, P3997, DOI [10.1200/JCO.2013.50.9984, 10.5858/arpa.2013-0953-SA]
   Yamaguchi N, 2009, CANCER SCI, V100, P1668, DOI 10.1111/j.1349-7006.2009.01228.x
   Yan JS, 2012, P NATL ACAD SCI USA, V109, P7917, DOI 10.1073/pnas.1205435109
   Yoshimaru T, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3443
NR 42
TC 12
Z9 14
U1 0
U2 10
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1019-6439
EI 1791-2423
J9 INT J ONCOL
JI Int. J. Oncol.
PD MAY
PY 2018
VL 52
IS 5
BP 1539
EP 1558
DI 10.3892/ijo.2018.4301
PG 20
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA GB5HV
UT WOS:000429096000015
PM 29512727
OA Bronze
DA 2025-01-12
ER

PT J
AU Cai, Y
   Lin, JR
   Zhang, QW
   O'Brien, K
   Montagna, C
   Zhang, ZDD
AF Cai, Ying
   Lin, Jhih-Rong
   Zhang, Quanwei
   O'Brien, Kelly
   Montagna, Cristina
   Zhang, Zhengdong D.
TI Epigenetic alterations to Polycomb targets precede malignant transition
   in a mouse model of breast cancer
SO SCIENTIFIC REPORTS
LA English
DT Article
ID GROUP PROTEIN EZH2; GENE-EXPRESSION PROFILES; DNA METHYLATION;
   E-CADHERIN; CHROMATIN; HYPOMETHYLATION; SUBTYPES; TUMORS; PROLIFERATION;
   PROGRESSION
AB Malignant breast cancer remains a major health threat to women of all ages worldwide and epigenetic variations on DNA methylation have been widely reported in cancers of different types. We profiled DNA methylation with ERRBS (Enhanced Reduced Representation Bisulfite Sequencing) across four main stages of tumor progression in the MMTV-PyMT mouse model (hyperplasia, adenoma/mammary intraepithelial neoplasia, early carcinoma and late carcinoma), during which malignant transition occurs. We identified a large number of differentially methylated cytosines (DMCs) in tumors relative to age-matched normal mammary glands from FVB mice. Despite similarities, the methylation differences of the premalignant stages were distinct from the malignant ones. Many differentially methylated loci were preserved from the first to the last stage throughout tumor progression. Genes affected by methylation gains were enriched in Polycomb repressive complex 2 (PRC2) targets, which may present biomarkers for early diagnosis and targets for treatment.
C1 [Cai, Ying; Lin, Jhih-Rong; Zhang, Quanwei; O'Brien, Kelly; Montagna, Cristina; Zhang, Zhengdong D.] Albert Einstein Coll Med, Dept Genet, Bronx, NY 10467 USA.
   [Montagna, Cristina] Albert Einstein Coll Med, Dept Pathol, Bronx, NY 10467 USA.
C3 Montefiore Medical Center; Albert Einstein College of Medicine; Yeshiva
   University; Yeshiva University; Montefiore Medical Center; Albert
   Einstein College of Medicine
RP Zhang, ZDD (通讯作者)，Albert Einstein Coll Med, Dept Genet, Bronx, NY 10467 USA.
EM zhengdong.zhang@einstein.yu.edu
FU NIH from National Library of Medicine [R00 LM009770]; National Human
   Genome Research Institute [R01 HG008153]; National Institutes of Health
   [P30 CA013330]
FX This work was supported by NIH grants R00 LM009770 from National Library
   of Medicine and R01 HG008153 from the National Human Genome Research
   Institute to Z. D. Z. We thank our colleagues at Albert Einstein College
   of Medicine - Drs John Greally, Jan Vijg, Yousin Suh, and Deyou Zheng -
   for their expert advice. We also thank the Einstein Center for
   Epigenomics, the Epigenomics Shared Facility, the Histotechnology and
   Comparative Pathology Facility (supported by the Albert Einstein Cancer
   Center Support Grant from the National Institutes of Health under award
   number P30 CA013330), the Genomics Shared Facility and the Computational
   Epigenomics Group for technical support.
CR Acosta D, 2011, MAMM GENOME, V22, P249, DOI 10.1007/s00335-011-9318-6
   Adorján P, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.5.e21
   Akalin A, 2012, GENOME BIOL, V13, DOI [10.1186/gb-2012-13-10-R87, 10.1186/gb-2012-13-10-r87]
   Akalin A, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002781
   Allred DC, 2001, ENDOCR-RELAT CANCER, V8, P47, DOI 10.1677/erc.0.0080047
   Ardlie KG, 2015, SCIENCE, V348, P648, DOI 10.1126/science.1262110
   Baylin Stephen B, 2005, Nat Clin Pract Oncol, V2 Suppl 1, pS4, DOI 10.1038/ncponc0354
   Baylin SB, 2011, NAT REV CANCER, V11, P726, DOI 10.1038/nrc3130
   Bediaga NG, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2721
   Bracken AP, 2003, EMBO J, V22, P5323, DOI 10.1093/emboj/cdg542
   Brinkman AB, 2012, GENOME RES, V22, P1128, DOI 10.1101/gr.133728.111
   Cai Y, 2017, BMC GENOMICS, V18, DOI 10.1186/s12864-017-3563-3
   Cao Q, 2008, ONCOGENE, V27, P7274, DOI 10.1038/onc.2008.333
   Carey LA, 2006, JAMA-J AM MED ASSOC, V295, P2492, DOI 10.1001/jama.295.21.2492
   Chae H, 2016, BMC SYST BIOL, V10, DOI 10.1186/s12918-016-0356-2
   Chen RZ, 1998, NATURE, V395, P89, DOI 10.1038/25779
   Ciriello G, 2013, NAT GENET, V45, P1127, DOI 10.1038/ng.2762
   Cogdell David, 2011, Chin J Cancer, V30, P247
   Dedeurwaerder S, 2011, EMBO MOL MED, V3, P726, DOI 10.1002/emmm.201100801
   Eden A, 2003, SCIENCE, V300, P455, DOI 10.1126/science.1083557
   Ehrlich M, 2002, ONCOGENE, V21, P5400, DOI 10.1038/sj.onc.1205651
   Ehrlich M, 2009, EPIGENOMICS-UK, V1, P239, DOI [10.2217/epi.09.33, 10.2217/EPI.09.33]
   Fackler MJ, 2011, CANCER RES, V71, P6195, DOI 10.1158/0008-5472.CAN-11-1630
   Fang F, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3001875
   FEINBERG AP, 1983, NATURE, V301, P89, DOI 10.1038/301089a0
   Feinberg AP, 2006, NAT REV GENET, V7, P21, DOI 10.1038/nrg1748
   Fleischer T, 2014, GENOME BIOL, V15, DOI [10.1186/s13059-014-0435-x, 10.1186/PREACCEPT-2333349012841587]
   Forbes SA, 2015, NUCLEIC ACIDS RES, V43, pD805, DOI 10.1093/nar/gku1075
   Gal-Yam EN, 2008, P NATL ACAD SCI USA, V105, P12979, DOI 10.1073/pnas.0806437105
   Gao Y, 2015, CLIN EPIGENETICS, V7, DOI 10.1186/s13148-015-0159-0
   Garcia Ana Maria, 2007, Methods Mol Biol, V371, P267
   Garrett-Bakelman FE, 2015, JOVE-J VIS EXP, DOI 10.3791/52246
   Gaudet F, 2003, SCIENCE, V300, P489, DOI 10.1126/science.1083558
   Griffith M, 2013, NAT METHODS, V10, P1209, DOI [10.1038/NMETH.2689, 10.1038/nmeth.2689]
   Gupta RA, 2010, NATURE, V464, P1071, DOI 10.1038/nature08975
   Hagarman JA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053880
   Herranz N, 2008, MOL CELL BIOL, V28, P4772, DOI 10.1128/MCB.00323-08
   Herschkowitz JI, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-5-r76
   Holm K, 2016, BREAST CANCER RES, V18, DOI 10.1186/s13058-016-0685-5
   Holm K, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2590
   Hon GC, 2012, GENOME RES, V22, P246, DOI 10.1101/gr.125872.111
   Hu ZJ, 2008, BRIEF BIOINFORM, V9, P317, DOI 10.1093/bib/bbn020
   Jene-Sanz A, 2013, MOL CELL BIOL, V33, P3951, DOI 10.1128/MCB.00426-13
   Jones A, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001551
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   Jones PA, 2012, NAT REV GENET, V13, P484, DOI 10.1038/nrg3230
   Kim KH, 2016, NAT MED, V22, P128, DOI 10.1038/nm.4036
   Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100
   Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412
   Krueger F, 2011, BIOINFORMATICS, V27, P1571, DOI 10.1093/bioinformatics/btr167
   Langfelder P, 2008, BIOINFORMATICS, V24, P719, DOI 10.1093/bioinformatics/btm563
   Langfelder P, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-559
   Li S, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-S5-S10
   Lin EY, 2003, AM J PATHOL, V163, P2113, DOI 10.1016/S0002-9440(10)63568-7
   Lin NJ, 2012, MOL CANCER RES, V10, P208, DOI 10.1158/1541-7786.MCR-10-0109
   Ma XJ, 2003, P NATL ACAD SCI USA, V100, P5974, DOI 10.1073/pnas.0931261100
   McCabe MT, 2005, CANCER RES, V65, P3624, DOI 10.1158/0008-5472.CAN-04-2158
   McLean CY, 2010, NAT BIOTECHNOL, V28, P495, DOI 10.1038/nbt.1630
   Müller H, 2001, GENE DEV, V15, P267, DOI 10.1101/gad.864201
   Nogales-Cadenas R, 2016, BREAST CANCER RES, V18, DOI 10.1186/s13058-016-0735-z
   OTTAVIANO YL, 1994, CANCER RES, V54, P2552
   Paquet ER, 2015, JNCI-J NATL CANCER I, V107, DOI 10.1093/jnci/dju357
   Park SY, 2011, VIRCHOWS ARCH, V458, P73, DOI 10.1007/s00428-010-1013-6
   Pfefferle AD, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-11-r125
   R Core Team, 2014, R LANG ENV STAT COMP
   Rhee JK, 2013, NUCLEIC ACIDS RES, V41, P8464, DOI 10.1093/nar/gkt643
   Ried Thomas, 2004, Breast Dis, V19, P59
   Ringnér M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017911
   Rinn JL, 2007, CELL, V129, P1311, DOI 10.1016/j.cell.2007.05.022
   Rush Margaret, 2009, Epigenetics, V4, P404
   Sauvageau M, 2010, CELL STEM CELL, V7, P299, DOI 10.1016/j.stem.2010.08.002
   Schlesinger Y, 2007, NAT GENET, V39, P232, DOI 10.1038/ng1950
   Sparmann A, 2006, NAT REV CANCER, V6, P846, DOI 10.1038/nrc1991
   Statham AL, 2012, GENOME RES, V22, P1120, DOI 10.1101/gr.132076.111
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Tam WL, 2013, NAT MED, V19, P1438, DOI 10.1038/nm.3336
   Tellez CS, 2011, CANCER RES, V71, P3087, DOI 10.1158/0008-5472.CAN-10-3035
   Teschendorff AE, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10478
   Teschendorff AE, 2012, GENOME MED, V4, DOI 10.1186/gm323
   van Kruijsbergen H, 2015, INT J BIOCHEM CELL B, V67, P177, DOI 10.1016/j.biocel.2015.05.006
   Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075
   Vincent A, 2011, CLIN CANCER RES, V17, P4341, DOI 10.1158/1078-0432.CCR-10-3431
   Viré E, 2006, NATURE, V439, P871, DOI 10.1038/nature04431
   Widschwendter M, 2007, NAT GENET, V39, P157, DOI 10.1038/ng1941
   Wijetunga NA, 2016, ONCOTARGET, V7, P62133, DOI 10.18632/oncotarget.11390
   Yeon S, 2012, MODERN PATHOL, V25, P185, DOI 10.1038/modpathol.2011.160
   Yu HX, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051239
   Yue F, 2014, NATURE, V515, P355, DOI 10.1038/nature13992
NR 88
TC 8
Z9 8
U1 0
U2 5
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD APR 3
PY 2018
VL 8
AR 5535
DI 10.1038/s41598-018-24005-x
PG 12
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA GB3ZK
UT WOS:000428999200071
PM 29615825
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Litwin, M
   Szczepanska-Buda, A
   Michalowska, D
   Grzegrzólka, J
   Piotrowska, A
   Gomulkiewicz, A
   Wojnar, A
   Dziegiel, P
   Witkiewicz, W
AF Litwin, Monika
   Szczepanska-Buda, Anna
   Michalowska, Dagmara
   Grzegrzolka, Jedrzej
   Piotrowska, Aleksandra
   Gomulkiewicz, Agnieszka
   Wojnar, Andrzej
   Dziegiel, Piotr
   Witkiewicz, Wojciech
TI Aberrant Expression of PIWIL1 and PIWIL2 and Their Clinical Significance
   in Ductal Breast Carcinoma
SO ANTICANCER RESEARCH
LA English
DT Article
DE PIWIL1; PIWIL2; breast cancer
ID INTERACTING RNAS; NONCODING RNA; CANCER; GENE; PROTEINS; HIWI;
   OVEREXPRESSION; PATTERNS; BIOLOGY; MARKER
AB Background/Aim: P-Element-induced wimpy testis (PIWI) proteins in complex with PIWI-interacting RNA (piRNA) are involved in epigenetic regulation of gene expression in germline cells. Aberrant expression of piRNA and PIWI proteins have been identified in various types of tumour cells. The aim of this study was to evaluate the expression profiles of PIWI-like protein-1, -2 (PIWIL1 and PIWIL2), their immunohistochemical (IHC) characteristics in ductal breast cancer, and determine their correlation with clinicopathological parameters of this type of cancer. Materials and Methods: Material for IHC studies comprised of 101 invasive ductal carcinoma (IDC) cases and 31 mastopathy tissues. Frozen fragments of paired tissue specimens (tumour and adjacent non-malignant breast tissue) taken from 55 patients with IDC and 18 samples of mastopathy were used for molecular studies using real-time polymerase chain reaction (RT-PCR). Results: A statistically significantly higher level of PIWIL1 and PIWIL2 was found in IDC compared to mastopathy samples (p <= 0.0001). Increased expression of PIWIL1 was correlated with increased PIWIL2 expression in breast cancer tissue. Surprisingly, PIWIL1 mRNA was detected only in cancer and mastopathy, but was not found in most normal breast tissues, although it is noteworthy that the PIWIL2 mRNA level was statistically significantly lower in mastopathy and IDC samples compared to normal breast tissues. Conclusion: Our results affirm the hypothesis that reactivation of PIWI expression in various caner types is crucial for cancer development.
C1 [Litwin, Monika; Szczepanska-Buda, Anna; Michalowska, Dagmara; Witkiewicz, Wojciech] Reg Specialist Hosp Wroclaw, Ctr Res & Dev, Wroclaw, Poland.
   [Grzegrzolka, Jedrzej; Piotrowska, Aleksandra; Gomulkiewicz, Agnieszka; Dziegiel, Piotr] Wroclaw Med Univ, Dept Histol & Embryol, Wroclaw, Poland.
   [Wojnar, Andrzej] Lower Silesian Oncol Ctr, Dept Pathomorphol, Wroclaw, Poland.
   [Dziegiel, Piotr] Univ Sch Phys Educ, Dept Physiotherapy, Wroclaw, Poland.
C3 Wroclaw Medical University
RP Litwin, M (通讯作者)，Novasome Sp Zoo, Ctr Res & Dev, PL-51423 Wroclaw, Poland.
EM m.litwin@cbr.novasome.pl
OI Gomulkiewicz, Agnieszka/0000-0003-2256-1055; Litwin,
   Monika/0000-0003-1165-6817; Dziegiel, Piotr/0000-0002-8292-1385;
   Grzegrzolka, Jedrzej/0000-0002-1548-279X; Piotrowska,
   Aleksandra/0000-0003-4093-7386
FU Leading National Research Center (KNOW) of Wroclaw Center for
   Biotechnology
FX This publication was supported by the Leading National Research Center
   (KNOW, 2014-2018) of Wroclaw Center for Biotechnology.
CR Al-Janabi O, 2014, BBA-MOL BASIS DIS, V1842, P686, DOI 10.1016/j.bbadis.2014.01.014
   Chen C, 2013, CANCER BIOMARK, V13, P315, DOI 10.3233/CBM-130360
   Cheng J, 2011, CLIN CHIM ACTA, V412, P1621, DOI 10.1016/j.cca.2011.05.015
   Grochola LF, 2008, BRIT J CANCER, V99, P1083, DOI 10.1038/sj.bjc.6604653
   Hashim A, 2014, ONCOTARGET, V5, P9901, DOI 10.18632/oncotarget.2476
   He G, 2010, AM J TRANSL RES, V2, P156
   He W, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-426
   Huang G, 2013, CLIN TRANSL ONCOL, V15, P563, DOI 10.1007/s12094-012-0966-0
   Iliev R, 2016, ANTICANCER RES, V36, P6419, DOI 10.21873/anticanres.11239
   Krishnan P, 2016, ONCOTARGET, V7, P37944, DOI 10.18632/oncotarget.9272
   Ku HY, 2014, NATL SCI REV, V1, P205, DOI 10.1093/nsr/nwu014
   Litwin M, 2017, ONCOL LETT, V13, P3354, DOI 10.3892/ol.2017.5932
   Litwin M, 2015, ANTICANCER RES, V35, P3317
   Liu JJ, 2010, INT J CLIN EXP PATHO, V3, P328
   Lobo NA, 2007, ANNU REV CELL DEV BI, V23, P675, DOI 10.1146/annurev.cellbio.22.010305.104154
   Martinez VD, 2015, SCI REP-UK, V5, DOI 10.1038/srep10423
   Ng KW, 2016, MOL CANCER, V15, DOI 10.1186/s12943-016-0491-9
   Nikpour P, 2009, CANCER EPIDEMIOL, V33, P271, DOI 10.1016/j.canep.2009.06.011
   Oh SJ, 2012, KOREAN J PATHOL, V46, P318, DOI 10.4132/KoreanJPathol.2012.46.4.318
   Öner Ç, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0159044
   Pardal R, 2003, NAT REV CANCER, V3, P895, DOI 10.1038/nrc1232
   Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45
   Qiao D, 2002, ONCOGENE, V21, P3988, DOI 10.1038/sj.onc.1205505
   REMMELE W, 1987, PATHOLOGE, V8, P138
   Sasaki T, 2003, GENOMICS, V82, P323, DOI 10.1016/S0888-7543(03)00129-0
   Siddiqi S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033711
   Siddiqi S, 2012, J CELL BIOCHEM, V113, P373, DOI 10.1002/jcb.23363
   Suzuki Ryusuke, 2012, Frontiers in Genetics, V3, P204, DOI 10.3389/fgene.2012.00204
   Tan Y, 2015, ACTA BIOCH BIOPH SIN, V47, P315, DOI 10.1093/abbs/gmv018
   Taubert H, 2007, ONCOGENE, V26, P1098, DOI 10.1038/sj.onc.1209880
   Torre LA., 2015, CA Cancer J Clin, V65, P87
   Wang Y, 2012, INT J CLIN EXP PATHO, V5, P315
   Watanabe T, 2014, MOL CELL, V56, P18, DOI 10.1016/j.molcel.2014.09.012
   Yang Feng, 2014, Zhonghua Wai Ke Za Zhi, V52, P1
   Yang YF, 2015, ONCOL LETT, V10, P1735, DOI 10.3892/ol.2015.3392
   Ye Y, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013406
   Zeng Y, 2011, CHINESE MED J-PEKING, V124, P2144, DOI 10.3760/cma.j.issn.0366-6999.2011.14.012
   Zhang H, 2013, SURG ONCOL, V22, P217, DOI 10.1016/j.suronc.2013.07.001
   Zhao YM, 2012, CANCER-AM CANCER SOC, V118, P2708, DOI 10.1002/cncr.26524
NR 39
TC 21
Z9 23
U1 0
U2 4
PU INT INST ANTICANCER RESEARCH
PI ATHENS
PA EDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22,
   ATHENS 19014, GREECE
SN 0250-7005
EI 1791-7530
J9 ANTICANCER RES
JI Anticancer Res.
PD APR
PY 2018
VL 38
IS 4
BP 2021
EP 2030
DI 10.21873/anticanres.12441
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA GB1GA
UT WOS:000428798000019
PM 29599319
OA Bronze
DA 2025-01-12
ER

PT J
AU Ooft, ML
   van Ipenburg, J
   van Loo, R
   de Jong, R
   Moelans, C
   Braunius, W
   de Bree, R
   van Diest, P
   Koljenovic, S
   de Jong, RB
   Hardillo, J
   Willems, SM
AF Ooft, Marc L.
   van Ipenburg, Jolique
   van Loo, Rob
   de Jong, Rick
   Moelans, Cathy
   Braunius, Weibel
   de Bree, Remco
   van Diest, Paul
   Koljenovic, Senada
   de Jong, Rob Baatenburg
   Hardillo, Jose
   Willems, Stefan M.
TI Molecular profile of nasopharyngeal carcinoma: analysing tumour
   suppressor gene promoter hypermethylation by multiplex
   ligation-dependent probe amplification
SO JOURNAL OF CLINICAL PATHOLOGY
LA English
DT Article
DE tumour biology; tumour Virology; molecular oncology; molecular
   pathology; oncology
ID EPSTEIN-BARR-VIRUS; SQUAMOUS-CELL CARCINOMA; BREAST-CANCER; ORAL-CANCER;
   IN-SITU; METHYLATION; DNA; EXPRESSION; THERAPY; RASSF1A
AB Aims To assess differences in methylation profiles, and thus pathogenesis, between Epstein-Barr virus (EBV)-positive and negative nasopharyngeal carcinomas (NPCs). Also, promoter hypermethylation is a common phenomenon in early carcinogenesis to inactivate tumour suppressor genes. Since epigenetic changes are reversible, the therapeutic application of methylation inhibitors could provide treatment options.
   Methods We evaluated promoter hypermethylation profiles of 22 common tumour suppressor genes in 108 NPCs using methylation-specific multiplex ligation-dependent probe amplification. Correlation between methylation, clinicopathological features (including EBV) and survival was examined. Cluster analysis was also performed.
   Results Hypermethylation of RASSF1A and ESR1 was significantly more frequent in EBV-positive NPC, while hypermethylation of DAPK1 was more frequent in EBV-negative NPC. In logistic regression, age, with EBV-positive NPC occurring at earlier age, and RASSF1, with RASSF1 hypermethylation being more frequent in EBV-positive NPC, remained significant. In EBV-positive NPC, hypermethylation of RASSF1A predicted worse overall survival (OS) (HR 3.058,95% CI 1.027 to 9.107). In EBV-negative NPC, hypermethylated adenomatous polyposis coli (APC) was a predictor of poor disease-free survival (DFS) (HR 6.868, 95%CI 2.142 to 22.022).
   Conclusion There are important epigenetic differences between EBV-negative and EBV-positive NPCs, with EBV-negative NPC having a more similar hypermethylation profile to other head and neck squamous cell carcinomas than EBV-positive NPC. Hypermethylation of RASSF1A might contribute to worse OS in EBV-positive NPC, and may be an important event in the pathogenesis of EBV-infected NPC. Hypermethylation of APC might contribute to worse DFS in EBV-negative NPC.
C1 [Ooft, Marc L.; van Loo, Rob; de Jong, Rick; Moelans, Cathy; van Diest, Paul; Willems, Stefan M.] Univ Med Ctr Utrecht, Dept Pathol, Heidelberglaan 100, NL-3583 CX Utrecht, Netherlands.
   [van Ipenburg, Jolique; Koljenovic, Senada] Erasmus MC, Univ Med Ctr Rotterdam, Dept Pathol, Rotterdam, Netherlands.
   [Braunius, Weibel] Univ Med Ctr Utrecht, Dept Otorhinolaryngol, Utrecht, Netherlands.
   [Braunius, Weibel; de Bree, Remco] Univ Med Ctr Utrecht, Dept Head & Neck Surg Oncol, UMC Utrecht Canc Ctr, Utrecht, Netherlands.
   [de Jong, Rob Baatenburg; Hardillo, Jose] Univ Med Ctr Rotterdam, Erasmus MC Canc Inst, Dept Otorhinolaryngol & Head & Neck Surg, Rotterdam, Netherlands.
C3 Utrecht University; Utrecht University Medical Center; Erasmus
   University Rotterdam; Erasmus MC; Utrecht University; Utrecht University
   Medical Center; Utrecht University; Utrecht University Medical Center;
   Erasmus University Rotterdam; Erasmus MC; Erasmus MC Cancer Institute
RP Ooft, ML (通讯作者)，Univ Med Ctr Utrecht, Dept Pathol, Heidelberglaan 100, NL-3583 CX Utrecht, Netherlands.
EM m.l.ooft@umcutrecht.nl
RI Hardillo, Jose/AAD-5079-2020
OI hardillo, jose angelito/0000-0001-5580-5613
CR Challouf S, 2012, CLIN CHIM ACTA, V413, P795, DOI 10.1016/j.cca.2012.01.018
   Chang ET, 2006, CANCER EPIDEM BIOMAR, V15, P1765, DOI 10.1158/1055-9965.EPI-06-0353
   Chen C, 2013, CANCER CHEMOTH PHARM, V71, P371, DOI 10.1007/s00280-012-2020-x
   Dai W, 2016, CHIN CLIN ONCOL, V5, DOI 10.21037/cco.2016.03.06
   Demokan S, 2011, CLIN EPIGENETICS, V2, P123, DOI 10.1007/s13148-011-0045-3
   Don K R, 2014, Indian J Dent Res, V25, P797, DOI 10.4103/0970-9290.152208
   Elston C W, 2002, Histopathology, V41, P154
   Er TK, 2015, ORAL DIS, V21, P872, DOI 10.1111/odi.12357
   Gylling A, 2007, GUT, V56, P926, DOI 10.1136/gut.2006.114876
   Hesson LB, 2007, DIS MARKERS, V23, P73, DOI 10.1155/2007/291538
   Hömig-Hölzel C, 2012, DIAGN MOL PATHOL, V21, P189, DOI 10.1097/PDM.0b013e3182595516
   Hutajulu SH, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-48
   Ji XM, 2011, INT J CANCER, V129, P724, DOI 10.1002/ijc.25696
   Kang GH, 2003, AM J PATHOL, V163, P1551, DOI 10.1016/S0002-9440(10)63511-0
   Kornegoor R, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3220
   Licht JD, 2015, CELL, V162, P938, DOI 10.1016/j.cell.2015.08.005
   Mani S, 2010, ADV GENET, V70, P327, DOI [10.1016/B978-0-12-380866-0.60012-5, 10.1016/S0065-2660(10)70012-2]
   Moelans CB, 2011, J PATHOL, V225, P222, DOI 10.1002/path.2930
   Niller HH, 2016, ADV EXP MED BIOL, V879, P39, DOI 10.1007/978-3-319-24738-0_3
   Noorlag R, 2015, HEAD NECK-J SCI SPEC, V37, P1130, DOI 10.1002/hed.23716
   Noorlag R, 2014, EPIGENETICS-US, V9, P1220, DOI 10.4161/epi.29785
   Nygren AOH, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni127
   Pavicic W, 2011, MOL MED, V17, P726, DOI 10.2119/molmed.2010.00239
   Robinson M, 2013, INFECT AGENTS CANCER, V8, DOI 10.1186/1750-9378-8-30
   Shaw R, 2006, INT J ORAL MAX SURG, V35, P101, DOI 10.1016/j.ijom.2005.06.014
   Suijkerbuijk KPM, 2008, ANN ONCOL, V19, P1870, DOI 10.1093/annonc/mdn409
   Tsai ST, 1996, CANCER, V77, P231, DOI 10.1002/(SICI)1097-0142(19960115)77:2<231::AID-CNCR2>3.3.CO;2-C
   Tsao SW, 2014, ORAL ONCOL, V50, P330, DOI 10.1016/j.oraloncology.2014.02.006
   van Diest PJ, 2002, BMJ-BRIT MED J, V325, P648, DOI 10.1136/bmj.325.7365.648
   van Kempen PMW, 2015, CANCER MED-US, V4, P1525, DOI 10.1002/cam4.499
   van Kempen PMW, 2014, CANCER MED-US, V3, P1185, DOI 10.1002/cam4.313
   Vasef MA, 1997, ANN OTO RHINOL LARYN, V106, P348, DOI 10.1177/000348949710600416
   Whang YM, 2009, CANCER-AM CANCER SOC, V115, P1253, DOI 10.1002/cncr.24113
   Young LS, 2016, NAT REV CANCER, V16, P789, DOI 10.1038/nrc.2016.92
   Zhou L, 2005, NEOPLASIA, V7, P809, DOI 10.1593/neo.05217
NR 35
TC 8
Z9 10
U1 0
U2 4
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0021-9746
EI 1472-4146
J9 J CLIN PATHOL
JI J. Clin. Pathol.
PD APR
PY 2018
VL 71
IS 4
BP 351
EP 359
DI 10.1136/jclinpath-2017-204661
PG 9
WC Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pathology
GA GB2VG
UT WOS:000428913200011
PM 28893862
DA 2025-01-12
ER

PT J
AU Mastoraki, S
   Strati, A
   Tzanikou, E
   Chimonidou, M
   Politaki, E
   Voutsina, A
   Psyrri, A
   Georgoulias, V
   Lianidou, E
AF Mastoraki, Sophia
   Strati, Areti
   Tzanikou, Eleni
   Chimonidou, Maria
   Politaki, Eleni
   Voutsina, Alexandra
   Psyrri, Amanda
   Georgoulias, Vassilis
   Lianidou, Evi
TI <i>ESR1</i> Methylation: A Liquid Biopsy-Based Epigenetic Assay for the
   Follow-up of Patients with Metastatic Breast Cancer Receiving Endocrine
   Treatment
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID CIRCULATING TUMOR-CELLS; DNA METHYLATION; PROMOTER METHYLATION;
   HEPATOCELLULAR-CARCINOMA; COLORECTAL-CANCER; SUPPRESSOR GENES;
   PERIPHERAL-BLOOD; PROGNOSTIC VALUE; SURVIVAL; EXPRESSION
AB Purpose: Liquid biopsy provides real-time monitoring of tumor evolution and response to therapy through analysis of circulating tumor cells (CTCs) and plasma-circulating tumor DNA (ctDNA). ESR1 epigenetic silencing potentially affects response to endocrine treatment. We evaluated ESR1 methylation in CTCs and paired plasma ctDNA. We evaluated ESR1 methylation in CTCs and paired plasma ctDNA as a potential biomarker for response to everolimus/exemestane treatment.
   Experimental Design: A highly sensitive and specific real-time MSP assay for ESR1 methylation was developed and validated in (i) 65 primary breast tumors formalin-fixed paraffin-embedded (FFPE), (ii) EpCAM(+) CTC fractions (122 patients and 30 healthy donors; HD), (iii) plasma ctDNA (108 patients and 30HD), and (iv) in CTCs (CellSearch) and in paired plasma ctDNA for 58 patients with breast cancer. ESR1 methylation status was investigated in CTCs isolated from serial peripheral blood samples of 19 patients with ER+/HER2(-) advanced breast cancer receiving everolimus/exemestane.
   Results: ESR1 methylation was detected in: (i) 25/65 (38.5%) FFPEs, (ii) EpCAM(+) CTC fractions: 26/112 (23.3%) patients and 1/30 (3.3%) HD, and (iii) plasma ctDNA: 8/108 (7.4%) patients and 1/30 (3.3%) HD. ESR1 methylation was highly concordant in 58 paired DNA samples, isolated from CTCs (Cell-Search) and corresponding plasma. In serial peripheral blood samples of patients treated with everolimus/exemestane, ESR1 methylation was observed in 10/36 (27.8%) CTC-positive samples, and was associated with lack of response to treatment (P = 0.023, Fisher exact test).
   Conclusions: We report for the first time the detection of ESR1 methylation in CTCs and a high concordance with paired plasma ctDNA. ESR1 methylation in CTCs was associated with lack of response to everolimus/exemestane regimen. ESR1 methylation should be further evaluated as a potential liquid biopsy-based biomarker. 2017 AACR.
C1 [Mastoraki, Sophia; Strati, Areti; Tzanikou, Eleni; Chimonidou, Maria; Lianidou, Evi] Univ Athens, Dept Chem, Analyt Chem Lab, Anal Circulating Tumor Cells, Athens, Greece.
   [Politaki, Eleni; Voutsina, Alexandra; Georgoulias, Vassilis] Univ Crete, Sch Med, Iraklion, Greece.
   [Psyrri, Amanda] Attikon Univ Hosp, Dept Internal Med Propaedeut 2, Oncol Unit, Haidari, Greece.
C3 National & Kapodistrian University of Athens; University of Crete;
   University Hospital Attikon
RP Lianidou, E (通讯作者)，Univ Athens, Univ Campus, Athens 15771, Greece.
EM lianidou@chem.uoa.gr
RI Strati, Areti/AIE-5421-2022; Voutsina, Alexandra/IUN-5361-2023
OI Mastoraki, Sofia/0000-0001-8140-6106; Lianidou, Evi/0000-0002-7796-5914;
   VOUTSINA, ALEXANDRA/0000-0002-8132-2348
FU IMI [115749]
FX This research has been financed by the IMI contract No. 115749
   CANCER-ID: "Cancer treatment and monitoring through identification of
   circulating tumour cells and tumour related nucleic acids in blood." We
   would like to thank Dr. G. Koutsodontis for technical assistance in the
   preparation of a subgroup of plasma samples.
CR Alix-Panabières C, 2016, CANCER DISCOV, V6, P479, DOI 10.1158/2159-8290.CD-15-1483
   [Anonymous], 2017, Tietz Textb Clin Chem Mol Diagnostics
   [Anonymous], GASTROENTEROL RES PR
   Bardelli A, 2017, CANCER CELL, V31, P172, DOI 10.1016/j.ccell.2017.01.002
   Bidard FC, 2014, LANCET ONCOL, V15, P406, DOI 10.1016/S1470-2045(14)70069-5
   Chimonidou M, 2017, ONCOTARGET, V8, P72054, DOI 10.18632/oncotarget.18679
   Chimonidou M, 2013, MOL CANCER RES, V11, P1248, DOI 10.1158/1541-7786.MCR-13-0096
   Chimonidou M, 2013, CLIN BIOCHEM, V46, P235, DOI 10.1016/j.clinbiochem.2012.09.015
   Chimonidou M, 2013, CLIN CHEM, V59, P270, DOI 10.1373/clinchem.2012.191551
   Chimonidou M, 2011, CLIN CHEM, V57, P1169, DOI 10.1373/clinchem.2011.165902
   Cristofanilli M, 2004, NEW ENGL J MED, V351, P781, DOI 10.1056/NEJMoa040766
   Dai BH, 2014, EXP BIOL MED, V239, P883, DOI 10.1177/1535370214536651
   De Mattos-Arruda L, 2016, MOL ONCOL, V10, P464, DOI 10.1016/j.molonc.2015.12.001
   Dou CY, 2016, DIGEST DIS SCI, V61, P1130, DOI 10.1007/s10620-015-3975-3
   Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI [10.1056/NEJMra072067, 10.1093/carcin/bgp220]
   Heitzer E, 2015, CLIN CHEM, V61, P112, DOI 10.1373/clinchem.2014.222679
   Ignatiadis M, 2015, CLIN CANCER RES, V21, P4786, DOI 10.1158/1078-0432.CCR-14-1190
   Jankowitz RC, 2017, CLIN CANCER RES, V23, P1126, DOI 10.1158/1078-0432.CCR-16-0591
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Joosse SA, 2015, EMBO MOL MED, V7, P1, DOI 10.15252/emmm.201303698
   Kanwal R, 2015, METHODS MOL BIOL, V1238, P3, DOI 10.1007/978-1-4939-1804-1_1
   Kirn V, 2014, J CANCER RES CLIN, V140, P1681, DOI 10.1007/s00432-014-1729-9
   Kulis M, 2010, ADV GENET, V70, P27, DOI [10.1016/S0065-2660(10)70002-X, 10.1016/B978-0-12-380866-0.60002-2]
   Kuo LT, 2016, CANCER MED-US, V5, P1830, DOI 10.1002/cam4.762
   Lianidou ES, 2014, CRIT REV CL LAB SCI, V51, P160, DOI 10.3109/10408363.2014.896316
   Lucci A, 2012, LANCET ONCOL, V13, P688, DOI 10.1016/S1470-2045(12)70209-7
   Martínez-Galán J, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-59
   Marzese DM, 2014, NEURO-ONCOLOGY, V16, P1499, DOI 10.1093/neuonc/nou107
   Marzese DM, 2013, EXPERT REV MOL DIAGN, V13, P827, DOI 10.1586/14737159.2013.845088
   Mok T, 2015, CLIN CANCER RES, V21, P3196, DOI 10.1158/1078-0432.CCR-14-2594
   Paoletti C, 2016, MOL ONCOL, V10, P1078, DOI 10.1016/j.molonc.2016.04.006
   Payne SR, 2010, EPIGENOMICS-UK, V2, P575, DOI 10.2217/EPI.10.35
   Pixberg CF, 2015, GENES-BASEL, V6, P1053, DOI 10.3390/genes6041053
   Rack B, 2014, NATL CANC I, V106
   Sahnane N, 2015, CLIN EPIGENETICS, V7, DOI 10.1186/s13148-015-0165-2
   Selli C, 2016, BREAST CANCER RES, V18, DOI 10.1186/s13058-016-0779-0
   Sequist LV, 2015, NEW ENGL J MED, V372, P1700, DOI 10.1056/NEJMoa1413654
   Sood S, 2015, CLIN ONCOL-UK, V27, P720, DOI 10.1016/j.clon.2015.08.001
   Stathopoulou A, 2002, J CLIN ONCOL, V20, P3404, DOI 10.1200/JCO.2002.08.135
   Stone A, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8758
   Tsuboi K, 2017, J STEROID BIOCH MOL
   Ung M, 2014, EPIGENETICS-US, V9, P523, DOI 10.4161/epi.27688
   Vorkas PA, 2010, J MOL DIAGN, V12, P697, DOI 10.2353/jmoldx.2010.100008
   Wan JCM, 2017, NAT REV CANCER, V17, P223, DOI 10.1038/nrc.2017.7
   Xenidis N, 2006, J CLIN ONCOL, V24, P3756, DOI 10.1200/JCO.2005.04.5948
NR 45
TC 119
Z9 123
U1 0
U2 23
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
EI 1557-3265
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD MAR 15
PY 2018
VL 24
IS 6
BP 1500
EP 1510
DI 10.1158/1078-0432.CCR-17-1181
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA FZ5JC
UT WOS:000427627400026
PM 29284708
OA Green Submitted
DA 2025-01-12
ER

PT J
AU Croes, L
   Beyens, M
   Fransen, E
   Ibrahim, J
   Berghe, WV
   Suls, A
   Peeters, M
   Pauwels, P
   Van Camp, G
   de Beeck, KO
AF Croes, Lieselot
   Beyens, Matthias
   Fransen, Erik
   Ibrahim, Joe
   Berghe, Wim Vanden
   Suls, Arvid
   Peeters, Marc
   Pauwels, Patrick
   Van Camp, Guy
   de Beeck, Ken Op
TI Large-scale analysis of <i>DFNA5</i> methylation reveals its potential
   as biomarker for breast cancer
SO CLINICAL EPIGENETICS
LA English
DT Article
DE DFNA5; Methylation; Breast cancer; Detection biomarker; Prognostic
   biomarker; TCGA
ID CIRCULATING TUMOR DNA; GENE-EXPRESSION; PROMOTER METHYLATION; ABERRANT
   METHYLATION; INCIDENCE RATES; EPIGENETICS; TARGET; EPIGENOMICS; ISLANDS;
   ORIGINS
AB Background: Breast cancer is the most frequent cancer among women worldwide. Biomarkers for early detection and prognosis of these patients are needed. We hypothesized that deafness, autosomal dominant 5 (DFNA5) may be a valuable biomarker, based upon strong indications for its role as tumor suppressor gene and its function in regulated cell death. In this study, we aimed to analyze DFNA5 methylation and expression in the largest breast cancer cohort to date using publicly available data from TCGA, in order to further unravel the role of DFNA5 as detection and/or prognostic marker in breast cancer. We analyzed Infinium HumanMethylation450k data, covering 22 different CpGs in the DFNA5 gene (668 breast adenocarcinomas and 85 normal breast samples) and DFNA5 expression (Agilent 244K Custom Gene Expression: 476 breast adenocarcinomas and 56 normal breast samples; RNA-sequencing: 666 breast adenocarcinomas and 71 normal breast samples).
   Results: DFNA5 methylation and expression were significantly different between breast cancer and normal breast samples. Overall, breast cancer samples showed higher DFNA5 methylation in the putative gene promoter compared to normal breast samples, whereas in the gene body and upstream of the putative gene promoter, the opposite is true. Furthermore, DFNA5 methylation, in 10 out of 22 CpGs, and expression were significantly higher in lobular compared to ductal breast cancers. An important result of this study was the identification of a combination of one CpG in the gene promoter (CpG07504598) and one CpG in the gene body (CpG12922093) of DFNA5, which was able to discriminate between breast cancer and normal breast samples (AUC = 0.93). This model was externally validated in three independent datasets. Moreover, we showed that estrogen receptor state is associated with DFNA5 methylation and expression. Finally, we were able to find a significant effect of DFNA5 gene body methylation on a 5-year overall survival time.
   Conclusions: We conclude that DFNA5 methylation shows strong potential as detection and prognostic biomarker for breast cancer.
C1 [Croes, Lieselot; Beyens, Matthias; Fransen, Erik; Ibrahim, Joe; Suls, Arvid; Van Camp, Guy; de Beeck, Ken Op] Univ Antwerp, Ctr Med Genet, Prins Boudewijnlaan 43-6, BE-2650 Antwerp, Belgium.
   [Croes, Lieselot; Beyens, Matthias; Fransen, Erik; Ibrahim, Joe; Suls, Arvid; Van Camp, Guy; de Beeck, Ken Op] Antwerp Univ Hosp, Prins Boudewijnlaan 43-6, BE-2650 Antwerp, Belgium.
   [Croes, Lieselot; Beyens, Matthias; Ibrahim, Joe; Peeters, Marc; Pauwels, Patrick; de Beeck, Ken Op] Univ Antwerp, Ctr Oncol Res, Univ Pl 1, BE-2610 Antwerp, Belgium.
   [Croes, Lieselot; Beyens, Matthias; Ibrahim, Joe; Peeters, Marc; Pauwels, Patrick; de Beeck, Ken Op] Antwerp Univ Hosp, Univ Pl 1, BE-2610 Antwerp, Belgium.
   [Fransen, Erik] Univ Antwerp, StatUa Ctr Stat, Prinsstr 13, BE-2000 Antwerp, Belgium.
   [Berghe, Wim Vanden] Univ Antwerp, Lab Prot Chem Prote & Epigenet Signaling PPES, Univ Pl 1, BE-2610 Antwerp, Belgium.
C3 University of Antwerp; University of Antwerp; University of Antwerp;
   University of Antwerp; University of Antwerp; University of Antwerp
RP Van Camp, G (通讯作者)，Univ Antwerp, Ctr Med Genet, Prins Boudewijnlaan 43-6, BE-2650 Antwerp, Belgium.; Van Camp, G (通讯作者)，Antwerp Univ Hosp, Prins Boudewijnlaan 43-6, BE-2650 Antwerp, Belgium.
EM guy.vancamp@uantwerpen.be
RI de Beeck, Ken/J-5248-2016; Peeters, Marc/C-5525-2013; Suls,
   Arvid/M-2694-2013; Fransen, Erik/C-4102-2015; Vanden Berghe,
   Wim/S-6425-2018; Van Camp, Guy/F-3386-2013
OI Vanden Berghe, Wim/0000-0003-0161-7355; Peeters,
   Marc/0000-0003-4969-2303; Van Camp, Guy/0000-0001-5105-9000; Ibrahim,
   Joe/0000-0001-9728-5273
FU Research Foundation-Flanders (FWO) [11Y9815N]
FX Lieselot Croes has a Ph.D. fellowship of the Research
   Foundation-Flanders (FWO; 11Y9815N).
CR Akino K, 2007, CANCER SCI, V98, P88, DOI 10.1111/j.1349-7006.2006.00351.x
   [Anonymous], 2011, Qvalue: Q-value estimation for false discovery rate control
   Balch C, 2005, FRONT BIOSCI-LANDMRK, V10, P1897, DOI 10.2741/1668
   Bates D, 2015, J STAT SOFTW, V67, P1, DOI 10.18637/jss.v067.i01
   Berdasco M, 2010, DEV CELL, V19, P698, DOI 10.1016/j.devcel.2010.10.005
   Chou CH, 2016, NUCLEIC ACIDS RES, V44, pD239, DOI 10.1093/nar/gkv1258
   Ciriello G, 2015, CELL, V163, P506, DOI 10.1016/j.cell.2015.09.033
   Croes L, 2017, ONCOTARGET, V8, P31948, DOI 10.18632/oncotarget.16654
   de Beeck KO, 2011, EUR J HUM GENET, V19, P965, DOI 10.1038/ejhg.2011.63
   Ehrlich M, 2014, EPIGENOMICS-UK, V6, P563, DOI [10.2217/EPI.14.48, 10.2217/epi.14.48]
   Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI [10.1056/NEJMra072067, 10.1093/carcin/bgp220]
   Esteller M, 2007, HUM MOL GENET, V16, pR50, DOI 10.1093/hmg/ddm018
   Esteller M, 2007, NAT REV GENET, V8, P286, DOI 10.1038/nrg2005
   Feinberg AP, 2006, NAT REV GENET, V7, P21, DOI 10.1038/nrg1748
   Feinberg AP, 2004, NAT REV CANCER, V4, P143, DOI 10.1038/nrc1279
   Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210
   Fleischer T, 2014, GENOME BIOL, V15, DOI [10.1186/s13059-014-0435-x, 10.1186/PREACCEPT-2333349012841587]
   Fu Y, 2014, NAT REV GENET, V15, P293, DOI 10.1038/nrg3724
   Fujikane T, 2010, BREAST CANCER RES TR, V122, P699, DOI 10.1007/s10549-009-0600-1
   Galluzzi L, 2017, TRENDS CANCER, V3, P1, DOI 10.1016/j.trecan.2016.12.001
   Garrigou S, 2016, CLIN CHEM, V62, P1129, DOI 10.1373/clinchem.2015.253609
   Gibney ER, 2010, HEREDITY, V105, P4, DOI 10.1038/hdy.2010.54
   Gotzsche P., 2013, Screening for breast cancer with mammography
   Hoque MO, 2006, J CLIN ONCOL, V24, P4262, DOI 10.1200/JCO.2005.01.3516
   Hoque MO, 2009, CANCER EPIDEM BIOMAR, V18, P2694, DOI 10.1158/1055-9965.EPI-08-0821
   Johnson KC, 2015, CLIN EPIGENETICS, V7, DOI 10.1186/s13148-015-0094-0
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   Jones PA, 2012, NAT REV GENET, V13, P484, DOI 10.1038/nrg3230
   Kim MS, 2008, ONCOGENE, V27, P3624, DOI 10.1038/sj.onc.1211021
   Kim MS, 2008, BIOCHEM BIOPH RES CO, V370, P38, DOI 10.1016/j.bbrc.2008.03.026
   Li B, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-323
   Li CI, 2007, CANCER EPIDEM BIOMAR, V16, P2773, DOI 10.1158/1055-9965.EPI-07-0546
   Li CI, 2003, JAMA-J AM MED ASSOC, V289, P1421, DOI 10.1001/jama.289.11.1421
   Lin IH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118453
   Lupiáñez DG, 2016, TRENDS GENET, V32, P225, DOI 10.1016/j.tig.2016.01.003
   Maor GL, 2015, TRENDS GENET, V31, P274, DOI 10.1016/j.tig.2015.03.002
   Meyer KD, 2014, NAT REV MOL CELL BIO, V15, P313, DOI 10.1038/nrm3785
   Neri F, 2017, NATURE, V543, P72, DOI 10.1038/nature21373
   Ponnaluri VKC, 2017, EPIGENETICS-US, V12, P123, DOI 10.1080/15592294.2016.1265713
   R Core Team, 2014, R LANG ENV STAT COMP
   Rakha EA, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2607
   Rogers C, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14128
   Roperch JP, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-566
   Shan M, 2016, ONCOTARGET, V7, P18485, DOI 10.18632/oncotarget.7608
   Sharma S, 2010, CARCINOGENESIS, V31, P27, DOI 10.1093/carcin/bgp220
   Song JH, 2017, ACS CHEM BIOL, V12, P316, DOI 10.1021/acschembio.6b00960
   Stoll G, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2017.1299302
   Strzyz P, 2017, NAT REV MOL CELL BIO, V18, P72, DOI 10.1038/nrm.2017.1
   Therneau TM., 2015, R TOP DOC, V128, P28, DOI DOI 10.1038/NATURE08851
   Thompson DA, 1998, EUR J BIOCHEM, V252, P169, DOI 10.1046/j.1432-1327.1998.2520169.x
   Umbricht CB, 2001, ONCOGENE, V20, P3348, DOI 10.1038/sj.onc.1204438
   Van Laer L, 1998, NAT GENET, V20, P194
   Van Rossom S, 2015, FRONT CELL NEUROSCI, V9, DOI 10.3389/fncel.2015.00231
   Van Rossom S, 2012, FRONT ONCOL, V2, DOI 10.3389/fonc.2012.00077
   Wang YP, 2017, NATURE, V547, P99, DOI 10.1038/nature22393
   Warton K, 2016, ENDOCR-RELAT CANCER, V23, pR157, DOI 10.1530/ERC-15-0369
   WHO, Breast cancer: Prevention and control
   Wittenberger T, 2014, EPIGENOMICS-UK, V6, P311, DOI [10.2217/EPI.14.20, 10.2217/epi.14.20]
   Yamada L, 2017, J DEV ORIG HLTH DIS, V8, P30, DOI 10.1017/S2040174416000507
   Yang XJ, 2014, CANCER CELL, V26, P577, DOI 10.1016/j.ccr.2014.07.028
   Yokomizo K, 2012, ANTICANCER RES, V32, P1319
NR 61
TC 83
Z9 92
U1 2
U2 15
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1868-7075
EI 1868-7083
J9 CLIN EPIGENETICS
JI Clin. Epigenetics
PD APR 11
PY 2018
VL 10
AR 51
DI 10.1186/s13148-018-0479-y
PG 13
WC Oncology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Genetics & Heredity
GA GC5QA
UT WOS:000429841500002
PM 29682089
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Cheng, SF
   Li, L
   Li, B
   Liu, JC
   Lai, FN
   Zhao, Y
   Zhang, XF
   Shen, W
   Li, L
AF Cheng, Shun-Feng
   Li, Ling
   Li, Bo
   Liu, Jing-Cai
   Lai, Fang-Nong
   Zhao, Yong
   Zhang, Xi-Feng
   Shen, Wei
   Li, Lan
TI Low-dose diethylhexyl phthalate exposure does not impair the expressive
   patterns of epigenetics-related genes and DNA methylation of breast
   cancer-related genes in mouse mammary glands
SO MOLECULAR & CELLULAR TOXICOLOGY
LA English
DT Article
DE DEHP; Mammary gland cells; Epigenetics; DNA methylation
ID BISPHENOL-A ALTERS; IN-UTERO EXPOSURE; DEHP; PROLIFERATION; MECHANISM;
   PROFILES; GROWTH
AB Backgrounds: Di-(2-ethylhexyl) phthalate (DEHP), as an endocrine-disrupting chemical (EDC), is widely used in plasticizer and other productions. Ubiquitous human exposure to DEHP has been proposed to be a potential risk to public health. Developmental exposure to DEHP could alter epigenetic programming and result in adult-onset disease.
   Methods: In this study, we investigated whether DEHP exposure to pregnant mice affected epigenetic changes as a result of increase in breast cancer incidence.
   Results: Our results showed that the expression of total 143 epigenetics-related genes in mammary gland cells, have no significantly altered after short time and low-dose treated with DEHP from 0.5 days post-coitum (dpc) to 3.5 dpc of pregnant mice. DNA methylation status of some neoplastic development genes, such as EGFr, Esr1, Pgr, Fos and Rassf5 also had no obvious change.
   Conclusion: These finding showed no impact of DEHP on the expressive patterns of epigenetics-related genes and DNA methylation of breast cancer-related genes in pregnant mouse mammary gland cells.
C1 [Cheng, Shun-Feng; Liu, Jing-Cai; Lai, Fang-Nong; Zhao, Yong; Shen, Wei; Li, Lan] Qingdao Agr Univ, Inst Reprod Sci, Coll Anim Sci & Technol, Qingdao 266109, Peoples R China.
   [Li, Ling] Tengzhou Peoples Hosp, Tengzhou 277500, Peoples R China.
   [Li, Bo] Chengguo Stn Anim Husb & Vet, Laizhou 261437, Peoples R China.
   [Zhang, Xi-Feng] Wuhan Polytech Univ, Coll Biol & Pharmaceut Engn, Wuhan 430023, Hubei, Peoples R China.
C3 Qingdao Agricultural University; Wuhan Polytechnic University
RP Li, L (通讯作者)，Qingdao Agr Univ, Inst Reprod Sci, Coll Anim Sci & Technol, Qingdao 266109, Peoples R China.
EM lilan9600@126.com
RI Shen, Wei/AAJ-2989-2020; Cheng, Shunfeng/AAG-2058-2021; Lai,
   Fangnong/HZH-2818-2023
FU Science and Technology Development Plan Project of Medicine and Health
   Department of Shandong Province [2016 WS0627]; Fund for Doctoral
   Scientific Research Startup of Qingdao Agricultural University
   [6631116019]
FX This work was supported by Science and Technology Development Plan
   Project of Medicine and Health Department of Shandong Province (2016
   WS0627) and the Fund for Doctoral Scientific Research Startup of Qingdao
   Agricultural University (6631116019).
CR Anway MD, 2008, GENOMICS, V91, P30, DOI 10.1016/j.ygeno.2007.10.002
   Ayyanan A, 2011, MOL ENDOCRINOL, V25, P1915, DOI 10.1210/me.2011-1129
   Bhan A, 2014, J STEROID BIOCHEM, V141, P160, DOI 10.1016/j.jsbmb.2014.02.002
   Choudhary D, 2003, ARCH BIOCHEM BIOPHYS, V414, P91, DOI 10.1016/S0003-9861(03)00174-7
   Dairkee SH, 2013, CARCINOGENESIS, V34, P703, DOI 10.1093/carcin/bgs379
   Dhimolea E, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099800
   Doherty Leo F., 2010, Hormones & Cancer, V1, P146, DOI 10.1007/s12672-010-0015-9
   Fan K, 2016, BIOMOL NMR ASSIGN, V10, P131, DOI 10.1007/s12104-015-9651-x
   Feinberg AP, 2007, NATURE, V447, P433, DOI 10.1038/nature05919
   Forzati F, 2014, BIOL OPEN, V3, P871, DOI 10.1242/bio.20147872
   Guida N, 2014, TOXICOL APPL PHARM, V280, P190, DOI 10.1016/j.taap.2014.07.014
   Guo Y, 2012, J AGR FOOD CHEM, V60, P6913, DOI 10.1021/jf3021128
   Hsieh TH, 2012, TOXICOL SCI, V128, P365, DOI 10.1093/toxsci/kfs163
   Hsieh TH, 2012, FASEB J, V26, P778, DOI 10.1096/fj.11-191742
   Kang SC, 2005, J TOXICOL ENV HEAL A, V68, P1995, DOI 10.1080/15287390491008913
   Kundakovic M, 2011, BRAIN BEHAV IMMUN, V25, P1084, DOI 10.1016/j.bbi.2011.02.005
   Lamartiniere CA, 2011, HORM MOL BIOL CLIN I, V5, P45, DOI 10.1515/HMBCI.2010.075
   Lawson C, 2011, BIOL REPROD, V84, P79, DOI 10.1095/biolreprod.110.084814
   Li L, 2015, HISTOCHEM CELL BIOL, V144, P389, DOI 10.1007/s00418-015-1348-9
   Li L, 2014, MOL BIOL REP, V41, P1227, DOI 10.1007/s11033-013-2967-7
   Martinez-Arguelles DB, 2015, ENDOCRINOLOGY, V156, P124, DOI 10.1210/en.2014-1436
   Mu XY, 2015, J HAZARD MATER, V298, P232, DOI 10.1016/j.jhazmat.2015.05.052
   Newbold Retha R, 2008, Fertil Steril, V89, pe55, DOI 10.1016/j.fertnstert.2008.01.062
   Pan YQ, 2014, NEOPLASMA, V61, P468, DOI 10.4149/neo_2014_058
   Paulose T, 2015, REPROD TOXICOL, V54, P58, DOI 10.1016/j.reprotox.2014.09.012
   Perera F, 2011, REPROD TOXICOL, V31, P363, DOI 10.1016/j.reprotox.2010.12.055
   Potischman N, 1999, CANCER CAUSE CONTROL, V10, P561, DOI 10.1023/A:1008955110868
   Rajesh P, 2014, J ENDOCRINOL, V223, P47, DOI 10.1530/JOE-14-0111
   Romani M, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/587983
   Schwartz D, 2007, SCIENCE, V316, P695, DOI 10.1126/science.1141331
   Singh S, 2012, INT J MOL SCI, V13, P10143, DOI 10.3390/ijms130810143
   Tharp AP, 2012, P NATL ACAD SCI USA, V109, P8190, DOI 10.1073/pnas.1120488109
   von Meyenn F, 2016, MOL CELL, V62, P983, DOI 10.1016/j.molcel.2016.06.005
   Wadia PR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063902
   Wu SD, 2010, INT J TOXICOL, V29, P193, DOI 10.1177/1091581809355488
   Xin F, 2015, SEMIN CELL DEV BIOL, V43, P66, DOI 10.1016/j.semcdb.2015.05.008
   Zhang T, 2014, ENVIRON MOL MUTAGEN, V55, P343, DOI 10.1002/em.21847
   Zhao S, 2016, MOL MED REP, V13, P1881, DOI 10.3892/mmr.2015.4723
NR 38
TC 3
Z9 3
U1 0
U2 27
PU KOREAN SOCIETY TOXICOGENOMICS & TOXICOPROTEOMICS-KSTT
PI GYEONGGI-DO
PA HANYANG UNIV, SCI & TECHNOL BLDG 1, RM 423, SA-DONG, SANGROK-GU, ANSAN,
   GYEONGGI-DO, 426 791, SOUTH KOREA
SN 1738-642X
EI 2092-8467
J9 MOL CELL TOXICOL
JI Mol. Cell. Toxicol.
PD APR
PY 2018
VL 14
IS 2
BP 143
EP 153
DI 10.1007/s13273-018-0016-2
PG 11
WC Biochemistry & Molecular Biology; Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Toxicology
GA GA5OW
UT WOS:000428384400003
DA 2025-01-12
ER

PT J
AU Yao, RS
   Han, DY
   Sun, XY
   Xie, Y
   Wu, QY
   Fu, CL
   Yao, Y
   Li, HJ
   Li, ZY
   Xu, KL
AF Yao, Ruosi
   Han, Danyang
   Sun, Xiaoyang
   Xie, Yu
   Wu, Qingyun
   Fu, Chunling
   Yao, Yao
   Li, Hujun
   Li, Zhenyu
   Xu, Kailin
TI Scriptaid inhibits cell survival, cell cycle, and promotes apoptosis in
   multiple myeloma via epigenetic regulation of p21
SO EXPERIMENTAL HEMATOLOGY
LA English
DT Article
ID HISTONE DEACETYLASE INHIBITORS; BREAST-CANCER; PHASE-I; PANOBINOSTAT;
   VORINOSTAT; EXPRESSION; PROGNOSIS; PROTEINS; PROGRESS; PATHWAY
AB Multiple myeloma (MM) is an extremely serious plasma cell malignancy. Despite the recent introduction of chemotherapies such as bortezomib and lenalidomide, it remains an incurable disease due to the high rate of relapse and the development of drug resistance. Epigenetic regulation is closely related to MM progression, but the epigenetic modification mechanism of MM cell apoptosis has remained unclear. As a novel histone deacetylase inhibitor (HDACi), Scriptaid's possible roles in MM progression have not been explored. Herein, we found that Scriptaid decreased several human MM cell viabilities in a dose-dependent manner. Scriptaid was also able to dose dependently and significantly induce MM cell cycle arrest at the G(2)/M phase. Moreover, Scriptaid facilitates p21 transcriptional activities by mediating H3Ac gene-activated modification, eventually leading to MM cell apoptosis. Overall, our results show that Scriptaid is an inducer of MM cell death, suggesting the possibility for Scriptaid-mediated therapeutics to cure refractory/relapsed MM. (C) 2018 ISEH - Society for Hematology and Stem Cells. Published by Elsevier Inc. All rights reserved.
C1 [Yao, Ruosi; Han, Danyang; Sun, Xiaoyang; Xie, Yu; Wu, Qingyun; Fu, Chunling; Yao, Yao; Xu, Kailin] Xuzhou Med Univ, Blood Dis Inst, Xuzhou, Jiangsu, Peoples R China.
   [Yao, Ruosi; Wu, Qingyun; Fu, Chunling; Yao, Yao; Li, Hujun; Li, Zhenyu; Xu, Kailin] Xuzhou Med Univ, Affliated Hosp, Dept Hematol, Xuzhou, Jiangsu, Peoples R China.
   [Yao, Ruosi; Han, Danyang; Sun, Xiaoyang; Xie, Yu; Wu, Qingyun; Fu, Chunling; Yao, Yao; Xu, Kailin] Key Lab Bone Marrow Stem Cell, Xuzhou, Jiangsu, Peoples R China.
C3 Xuzhou Medical University; Xuzhou Medical University
RP Xu, KL (通讯作者)，Xuzhou Med Univ, Blood Dis Inst, Xuzhou, Jiangsu, Peoples R China.
EM lihmd@163.com
RI li, zy/HZM-1892-2023
FU National Natural Science Foundation of China [81600173, 81400127];
   Natural Science Foundation of Jiangsu Province [BK20160230];
   Postdoctoral Science Foundation of China [2016M601895]; Postdoctoral
   Science Foundation of Jiangsu Province [1601092B]; Science and
   Technology Special Project in Clinical Medicine of Jiangsu Province
   [BL2013010]; Jiangsu Provincial Key Research and Development Program
   [BE2017638]
FX This work was supported by grants from the National Natural Science
   Foundation of China (81600173, 81400127); the Natural Science Foundation
   of Jiangsu Province (BK20160230); the Postdoctoral Science Foundation of
   China (2016M601895), and the Postdoctoral Science Foundation of Jiangsu
   Province (1601092B); the Science and Technology Special Project in
   Clinical Medicine of Jiangsu Province (BL2013010); and the Jiangsu
   Provincial Key Research and Development Program (BE2017638).
CR Badros A, 2009, CLIN CANCER RES, V15, P5250, DOI 10.1158/1078-0432.CCR-08-2850
   Dimopoulos K, 2014, BLOOD CANCER J, V4, DOI 10.1038/bcj.2014.29
   Esteller M, 2007, NAT REV GENET, V8, P286, DOI 10.1038/nrg2005
   Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210
   Frew AJ, 2009, CANCER LETT, V280, P125, DOI 10.1016/j.canlet.2009.02.042
   Fuks F, 2005, CURR OPIN GENET DEV, V15, P490, DOI 10.1016/j.gde.2005.08.002
   Giacinti L, 2012, J CELL PHYSIOL, V227, P3426, DOI 10.1002/jcp.24043
   Glavey Siobhan V, 2016, Cancer Treat Res, V169, P35
   Hou P, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.249
   Karimian A, 2016, DNA REPAIR, V42, P63, DOI 10.1016/j.dnarep.2016.04.008
   Kelloff GJ, 2000, J NUTR, V130, p467S, DOI 10.1093/jn/130.2.467S
   Kim EM, 2017, CANCER RES, V77, P3092, DOI 10.1158/0008-5472.CAN-16-2098
   Lane AA, 2009, J CLIN ONCOL, V27, P5459, DOI 10.1200/JCO.2009.22.1291
   Lee EJ, 2008, INT J ONCOL, V33, P767, DOI 10.3892/ijo_00000063
   Liu W, 2016, MOL MED REP, V13, P829, DOI 10.3892/mmr.2015.4617
   Mahindra A, 2012, NAT REV CLIN ONCOL, V9, P135, DOI 10.1038/nrclinonc.2012.15
   Martínez-Iglesias O, 2008, CLIN TRANSL ONCOL, V10, P395, DOI 10.1007/s12094-008-0221-x
   Mithraprabhu S, 2014, EPIGENETICS-US, V9, P1511, DOI 10.4161/15592294.2014.983367
   Moreaux J, 2013, BRIT J CANCER, V109, P676, DOI 10.1038/bjc.2013.392
   Neri P, 2012, EXPERT OPIN INV DRUG, V21, P733, DOI 10.1517/13543784.2012.668883
   Palumbo A, 2011, NEW ENGL J MED, V364, P1046, DOI 10.1056/NEJMra1011442
   Peart MJ, 2005, P NATL ACAD SCI USA, V102, P3697, DOI 10.1073/pnas.0500369102
   Rackov G, 2016, J CLIN INVEST, V126, P3089, DOI 10.1172/JCI83404
   Raedler Lisa A, 2016, Am Health Drug Benefits, V9, P84
   Richardson P, 2008, LEUKEMIA LYMPHOMA, V49, P502, DOI 10.1080/10428190701817258
   Richardson PG, 2015, EXPERT REV ANTICANC, V15, P737, DOI 10.1586/14737140.2015.1047770
   Schuler M, 2000, J BIOL CHEM, V275, P7337, DOI 10.1074/jbc.275.10.7337
   Siegel DS, 2014, BLOOD CANCER J, V4, DOI 10.1038/bcj.2014.23
   Su GH, 2000, CANCER RES, V60, P3137
   Sun Y, 2014, PANCREAS, V43, P619, DOI 10.1097/MPA.0000000000000074
   Takai N, 2006, INT J MOL MED, V17, P323
   Vazquez A, 2008, NAT REV DRUG DISCOV, V7, P979, DOI 10.1038/nrd2656
   XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0
   Yao RS, 2014, CANCER RES, V74, P5656, DOI 10.1158/0008-5472.CAN-14-0800
NR 34
TC 20
Z9 23
U1 0
U2 10
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0301-472X
EI 1873-2399
J9 EXP HEMATOL
JI Exp. Hematol.
PD APR
PY 2018
VL 60
BP 63
EP 72
DI 10.1016/j.exphem.2017.12.012
PG 10
WC Hematology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Hematology; Research & Experimental Medicine
GA GA5FK
UT WOS:000428358100008
PM 29305109
OA Bronze
DA 2025-01-12
ER

PT J
AU Wang, ZH
   Yang, B
   Zhang, M
   Guo, WW
   Wu, ZY
   Wang, Y
   Jia, L
   Li, S
   Xie, W
   Yang, D
AF Wang, Zehua
   Yang, Bo
   Zhang, Min
   Guo, Weiwei
   Wu, Zhiyuan
   Wang, Yue
   Jia, Lin
   Li, Song
   Xie, Wen
   Yang, Da
CA Canc Genome Atlas Res Network
TI lncRNA Epigenetic Landscape Analysis Identifies <i>EPIC1</i> as an
   Oncogenic lncRNA that Interacts with MYC and Promotes Cell-Cycle
   Progression in Cancer
SO CANCER CELL
LA English
DT Article
ID LONG NONCODING RNA; C-MYC; TRANSCRIPTIONAL NETWORK; GENE-EXPRESSION;
   ANALYSES REVEAL; BINDING-SITES; GENOME; PROTEIN; METHYLATION; SEQ
AB We characterized the epigenetic landscape of genes encoding long noncoding RNAs (lncRNAs) across 6,475 tumors and 455 cancer cell lines. In stark contrast to the CpG island hypermethylation phenotype in cancer, we observed a recurrent hypomethylation of 1,006 lncRNA genes in cancer, including EPIC1 (epigenetically-induced lncRNA1). Overexpression of EPIC1 is associated with poor prognosis in luminal B breast cancer patients and enhances tumor growth in vitro and in vivo. Mechanistically, EPIC1 promotes cell-cycle progression by interacting with MYC through EPIC1's 129-283 nt region. EPIC1 knockdown reduces the occupancy of MYC to its target genes (e.g., CDKN1A, CCNA2, CDC20, and CDC45). MYC depletion abolishes EPIC1's regulation of MYC target and luminal breast cancer tumorigenesis in vitro and in vivo.
C1 [Wang, Zehua; Yang, Bo; Zhang, Min; Guo, Weiwei; Wu, Zhiyuan; Wang, Yue; Jia, Lin; Li, Song; Xie, Wen; Yang, Da] Univ Pittsburgh, Dept Pharmaceut Sci, Ctr Pharmacogenet, Pittsburgh, PA 15261 USA.
   [Yang, Da] Univ Pittsburgh, Inst Canc, Pittsburgh, PA 15261 USA.
   [Yang, Da] Univ Pittsburgh, Dept Computat & Syst Biol, Pittsburgh, PA 15261 USA.
C3 Pennsylvania Commonwealth System of Higher Education (PCSHE); University
   of Pittsburgh; Pennsylvania Commonwealth System of Higher Education
   (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of
   Higher Education (PCSHE); University of Pittsburgh
RP Yang, D (通讯作者)，Univ Pittsburgh, Dept Pharmaceut Sci, Ctr Pharmacogenet, Pittsburgh, PA 15261 USA.; Yang, D (通讯作者)，Univ Pittsburgh, Inst Canc, Pittsburgh, PA 15261 USA.; Yang, D (通讯作者)，Univ Pittsburgh, Dept Computat & Syst Biol, Pittsburgh, PA 15261 USA.
EM dyang@pitt.edu
RI Yang, Da/I-9054-2012; Longatto-Filho, Adhemar/N-3397-2019; Wu,
   Zhiyuan/JLL-4644-2023; Xie, Wen/M-1768-2016; von Deimling,
   Andreas/F-7774-2013; De Rose, Agostino Maria/J-8414-2016; Carlotti
   Junior, Carlos Gilberto/C-1608-2012; Alvaro, Domenico/J-8600-2018;
   Moiseenko, Fedor/E-1775-2014; Perou, Charles/H-9934-2014;
   longatto-filho, adhemar/D-7039-2013; Yang, Ian/B-9609-2008; Long,
   Georgina/C-1771-2013; Schadendorf, Dirk/AAE-8206-2019; DiMeco,
   Francesco/Q-3785-2016; Calatozzolo, Chiara/HZI-1857-2023; Anderson,
   Matthew/C-4755-2019; Silveira, Henrique C. S./J-1730-2014; Wang,
   Zehua/I-6452-2018; Becker, Karl-Friedrich/D-3636-2015; Marino,
   Mirella/A-7548-2018; Mungall, Andrew/U-7067-2018; Mann,
   Graham/G-4758-2014; Reis, Rui Manuel/B-1744-2018; hayward,
   nicholas/C-1367-2015; Van Den Berg, David J/G-8598-2017; Dos Santos,
   Jose Sebastiao/A-2179-2008; Looijenga, Leendert/B-8145-2019; mattei,
   luca/K-7709-2016; Adebamowo, Clement/C-8778-2011; Asa, Sylvia
   L./ACI-8408-2022; Scolyer, Richard/AAE-8511-2019; Pollo,
   Bianca/K-5347-2018; de Carvalho, Ana Carolina/Q-4055-2019; LAIRD, PETER
   W/G-8683-2012; Holt, Robert/C-3303-2009; Lopes Carvalho,
   Andre/S-7053-2016
OI ma, deqin/0000-0002-8581-6345; von Deimling,
   Andreas/0000-0002-5863-540X; doddapaneni,
   harshavardhan/0000-0002-2433-633X; Feltmate,
   Colleen/0000-0002-7700-8575; De Rose, Agostino
   Maria/0000-0003-3310-8088; ROACH, Jeffrey/0000-0001-9817-5877;
   Giuliante, Felice/0000-0003-2087-2589; Carlotti Junior, Carlos
   Gilberto/0000-0002-7055-0564; Aredes, Natalia Del
   Angelo/0000-0002-1661-8601; Stuart, Joshua/0000-0002-2171-565X; Mills,
   Gordon/0000-0002-0144-9614; Rubin, Mark/0000-0002-8321-9950; Alvaro,
   Domenico/0000-0003-3771-9644; Wilkerson, Matthew/0000-0003-2727-0230;
   Moiseenko, Fedor/0000-0003-2544-9042; Perou,
   Charles/0000-0001-9827-2247; Boussioutas, Alex/0000-0002-8109-6897;
   Auman, James/0000-0002-9328-8829; Roberts, Lewis/0000-0001-7885-8574;
   Bryce, Alan Haruo/0000-0002-0206-3895; , Rameen/0000-0001-6303-3609;
   longatto-filho, adhemar/0000-0002-5779-9752; , Ashton Cole
   Berger/0000-0001-5195-2528; Ho, Thai/0000-0003-0023-2939; Jakrot,
   Valerie/0000-0002-8578-5964; Yang, Ian/0000-0001-8338-1993; Bragazzi,
   Maria Consiglia/0000-0003-3626-8546; Fan, Huihui/0000-0003-4233-5389;
   Creaney, Jenette/0000-0002-9391-9395; Wilmott,
   James/0000-0002-6750-5244; Cardinale, Vincenzo/0000-0003-0234-3341;
   Setdikova, Galiya/0000-0002-5262-4953; Bailey, Matthew
   H./0000-0003-4526-9727; Facciolo, Francesco/0000-0002-7137-8946; Ajani,
   Jaffer A/0000-0001-9946-0629; Long, Georgina/0000-0001-8894-3545;
   Schadendorf, Dirk/0000-0003-3524-7858; DiMeco,
   Francesco/0000-0001-6213-5793; Perin, Alessandro/0000-0002-6697-9835;
   Bossler, Aaron/0000-0002-8748-2510; Calatozzolo,
   Chiara/0000-0003-0165-3495; Pennell, Nathan/0000-0002-1458-0064; de
   Bruijn, Ino/0000-0001-5427-4750; Rathmell, Wendy
   Kimryn/0000-0002-4984-0225; Mariamidze, Armaz/0000-0002-9775-6116;
   Anderson, Matthew/0000-0002-2081-4672; Schlomm,
   Thorsten/0000-0001-9557-4653; Shannon, Kerwin/0000-0001-8538-3132;
   Silveira, Henrique C. S./0000-0001-8607-6206; Wang,
   Zehua/0000-0002-0769-8865; Becker, Karl-Friedrich/0000-0002-6801-4498;
   Thomas, George V/0000-0001-7416-8840; Marino,
   Mirella/0000-0002-0045-0234; Mungall, Andrew/0000-0002-0905-2742;
   Milhem, Mohammed/0000-0003-4663-6824; Mann, Graham/0000-0003-1301-405X;
   Ha, Gavin/0000-0001-7578-7272; Lacombe, Louis/0000-0003-4811-0308; Reis,
   Rui Manuel/0000-0002-9639-7940; Hersey, Peter/0000-0002-3064-737X;
   Omberg, Larsson/0000-0002-4719-9120; Jones, Steven/0000-0003-3394-2208;
   dhanasekaran, renumathy/0000-0001-8819-7511; hayward,
   nicholas/0000-0003-4760-1033; Van Den Berg, David J/0000-0002-5404-5218;
   Wang, Yue/0000-0002-7761-2721; Finocchiaro, Gaetano/0000-0003-3583-4040;
   Dos Santos, Jose Sebastiao/0000-0001-5118-0361; Khuri, Fadlo
   R./0000-0002-8638-7618; CARPINO, Guido/0000-0001-8570-2519; Cebulla,
   Colleen/0000-0002-5636-4968; Shinbrot, Eve/0000-0002-8879-3150; Marra,
   Marco/0000-0001-7146-7175; Birsoy, Kivanc/0000-0002-7579-9895;
   Bootwalla, Moiz/0000-0001-6158-7114; Looijenga,
   Leendert/0000-0002-8146-1911; Weinstein, John/0000-0001-9401-6908; Hu,
   Hai/0000-0001-5345-8371; mattei, luca/0000-0002-7330-502X; McCall,
   Shannon/0000-0003-3957-061X; Lyadov, Vladimir/0000-0002-7281-3591;
   Moncrieff, Marc/0000-0003-4492-235X; Hovens,
   Christopher/0000-0002-0610-1289; Bowen, Jay/0000-0001-6861-9043;
   Mieczkowski, Piotr/0000-0003-2418-0096; Tavobilov,
   Mikhail/0000-0003-0335-1204; Lazar, Alexander/0000-0002-6395-4499;
   Adebamowo, Clement/0000-0002-6571-2880; Bergeron,
   Alain/0000-0002-2875-0773; Gabra, Hani/0000-0002-3322-4399; deCarvalho,
   Ana C/0000-0003-1183-4548; Fong, Kwun/0000-0002-6507-1403; Yang,
   Da/0000-0002-8336-9457; Giordano, Thomas/0000-0003-0641-8873; Lipp,
   Eric/0000-0002-4372-5533; Tarnuzzer, Roy/0000-0002-3725-4173; Asa,
   Sylvia L./0000-0001-8418-5054; Barnholtz-Sloan,
   Jill/0000-0001-6190-9304; Adebamowo, Sally/0000-0003-4713-2433; Scolyer,
   Richard/0000-0002-8991-0013; Pollo, Bianca/0000-0002-5523-4256;
   MCLELLAN, MICHAEL/0000-0002-2703-8784; Sanchez-Vega,
   Francisco/0000-0002-2990-4893; catto, james/0000-0003-2787-8828;
   Kakavand, Hojabr/0000-0002-3458-7853; de Carvalho, Ana
   Carolina/0000-0002-0114-7659; Cuzzubbo, Stefania/0000-0003-0288-4607;
   LAIRD, PETER W/0000-0001-9117-3641; Holt, Robert/0000-0002-7259-1247;
   Shabunin, Alexey/0000-0002-4230-8033; Heiman, David/0000-0001-7895-4259;
   Kovatich, Albert/0000-0002-5169-4087; Hoadley,
   Katherine/0000-0002-1216-477X; Lopes Carvalho,
   Andre/0000-0001-7214-6402; Rai, Karan/0000-0001-6260-6268
FU Shear Family Foundation; Career Development Award of RPCI-UPCI Ovarian
   Cancer SPORE [P50 CA159981]; Elsa U. Pardee Foundation;  [P30CA047904]
FX This study was supported by a grant from the Shear Family Foundation (to
   D.Y.), a Career Development Award of RPCI-UPCI Ovarian Cancer SPORE (P50
   CA159981; to D.Y.), and a grant from the Elsa U. Pardee Foundation (to
   D.Y.). This project is supported in part by award P30CA047904. We thank
   The Center for Simulation and Modeling (SaM) at the University of
   Pittsburgh for computing assistance. We thank The Center for Biologic
   Imaging (CBI) at the University of Pittsburgh for imaging assistance. We
   thank Drs. Nara Lee, Barry Gold, Anil Sood, Wei Zhang, and Ilya
   Shmulevich for internal critical review.
CR AMATI B, 1993, CELL, V72, P233, DOI 10.1016/0092-8674(93)90663-B
   Amin V, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7370
   Anders S, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-10-r106
   Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003
   Batista PJ, 2013, CELL, V152, P1298, DOI 10.1016/j.cell.2013.02.012
   BAYLIN SB, 1986, CANCER RES, V46, P2917
   BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x
   BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410
   Brennan CW, 2013, CELL, V155, P462, DOI 10.1016/j.cell.2013.09.034
   Cawley S, 2004, CELL, V116, P499, DOI 10.1016/S0092-8674(04)00127-8
   Dang CV, 2012, CELL, V149, P22, DOI 10.1016/j.cell.2012.03.003
   Di Cello F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068630
   DiNardo DNM, 2001, ONCOGENE, V20, P5331, DOI 10.1038/sj.onc.1204697
   Doose G, 2015, P NATL ACAD SCI USA, V112, pE5261, DOI 10.1073/pnas.1505753112
   Du Z, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10982
   Du Z, 2013, NAT STRUCT MOL BIOL, V20, P908, DOI 10.1038/nsmb.2591
   Dunham I, 2012, NATURE, V489, P57, DOI 10.1038/nature11247
   Engel JR, 2000, J MED GENET, V37, P921, DOI 10.1136/jmg.37.12.921
   Fernandez PC, 2003, GENE DEV, V17, P1115, DOI 10.1101/gad.1067003
   Gartel AL, 2001, P NATL ACAD SCI USA, V98, P4510, DOI 10.1073/pnas.081074898
   Gartel AL, 2005, CANCER RES, V65, P3980, DOI 10.1158/0008-5472.CAN-04-3995
   Guo HY, 2016, NAT GENET, V48, P1142, DOI 10.1038/ng.3637
   Gupta RA, 2010, NATURE, V464, P1071, DOI 10.1038/nature08975
   Guttman M, 2009, NATURE, V458, P223, DOI 10.1038/nature07672
   Hancock AL, 2007, HUM MOL GENET, V16, P343, DOI 10.1093/hmg/ddl478
   Hu XW, 2014, CANCER CELL, V26, P344, DOI 10.1016/j.ccr.2014.07.009
   Hung CL, 2014, P NATL ACAD SCI USA, V111, P18697, DOI 10.1073/pnas.1415669112
   Iorio F, 2016, CELL, V166, P740, DOI 10.1016/j.cell.2016.06.017
   Irizarry RA, 2009, NAT GENET, V41, P178, DOI 10.1038/ng.298
   Iyer MK, 2015, NAT GENET, V47, P199, DOI 10.1038/ng.3192
   Izumi H, 2001, J CELL SCI, V114, P1533
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Kress TR, 2015, NAT REV CANCER, V15, P593, DOI 10.1038/nrc3984
   Lee BK, 2012, GENOME RES, V22, P9, DOI 10.1101/gr.127597.111
   Lehmann BD, 2011, J CLIN INVEST, V121, P2750, DOI 10.1172/JCI45014
   Leucci E, 2016, NATURE, V531, P518, DOI 10.1038/nature17161
   Li B, 2010, BIOINFORMATICS, V26, P493, DOI 10.1093/bioinformatics/btp692
   Li HL, 2014, ONCOTARGET, V5, P587, DOI 10.18632/oncotarget.1782
   Li JP, 2013, BIOCHEM BIOPH RES CO, V433, P200, DOI 10.1016/j.bbrc.2013.02.083
   Li Y, 2010, NAT MED, V16, P214, DOI 10.1038/nm.2090
   Li ZR, 2003, P NATL ACAD SCI USA, V100, P8164, DOI 10.1073/pnas.1332764100
   Lüscher B, 2001, GENE, V277, P1, DOI 10.1016/S0378-1119(01)00697-7
   Mei SL, 2017, NUCLEIC ACIDS RES, V45, pD658, DOI 10.1093/nar/gkw983
   Nelson JD, 2006, NAT PROTOC, V1, P179, DOI 10.1038/nprot.2006.27
   Niu YD, 2017, HEPATOLOGY, V65, P893, DOI 10.1002/hep.28924
   Noushmehr Houtan, 2010, Cancer Cell, V17, P510, DOI 10.1016/j.ccr.2010.03.017
   Peukert K, 1997, EMBO J, V16, P5672, DOI 10.1093/emboj/16.18.5672
   Prensner JR, 2011, CANCER DISCOV, V1, P391, DOI 10.1158/2159-8290.CD-11-0209
   ROY AL, 1993, NATURE, V365, P359, DOI 10.1038/365359a0
   Ruan WD, 2016, TUMOR BIOL, V37, P4065, DOI 10.1007/s13277-015-4256-7
   Sánchez Y, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6812
   Schmitt AM, 2016, NAT GENET, V48, P1370, DOI 10.1038/ng.3673
   Schmitt AM, 2016, CANCER CELL, V29, P452, DOI 10.1016/j.ccell.2016.03.010
   Scott RH, 2008, NAT GENET, V40, P1329, DOI 10.1038/ng.243
   Shen H, 2013, CELL, V153, P38, DOI 10.1016/j.cell.2013.03.008
   Shlyueva D., 2014, SCIENCE, V15, P272
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Tsai MC, 2010, SCIENCE, V329, P689, DOI 10.1126/science.1192002
   Tseng Y. Y., 2014, SCIENCE, V512, P82
   von der Lehr N, 2003, MOL CELL, V11, P1189, DOI 10.1016/S1097-2765(03)00193-X
   Wagner GP, 2012, THEOR BIOSCI, V131, P281, DOI 10.1007/s12064-012-0162-3
   Wijnen M, 2012, PEDIATR BLOOD CANCER, V59, P565, DOI 10.1002/pbc.23398
   Wu SC, 2010, CELL RES, V20, P1109, DOI 10.1038/cr.2010.114
   Xiang JF, 2014, CELL RES, V24, P513, DOI 10.1038/cr.2014.35
   Yan XH, 2015, CANCER CELL, V28, P529, DOI 10.1016/j.ccell.2015.09.006
   Yang F, 2014, FEBS J, V281, P802, DOI 10.1111/febs.12625
   Zeller KI, 2006, P NATL ACAD SCI USA, V103, P17834, DOI 10.1073/pnas.0604129103
   Zhou YL, 2012, J MOL ENDOCRINOL, V48, pR45, DOI 10.1530/JME-12-0008
   Zhu SY, 2016, NAT BIOTECHNOL, V34, P1279, DOI 10.1038/nbt.3715
NR 69
TC 369
Z9 394
U1 6
U2 100
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 1535-6108
EI 1878-3686
J9 CANCER CELL
JI Cancer Cell
PD APR 9
PY 2018
VL 33
IS 4
BP 706
EP +
DI 10.1016/j.ccell.2018.03.006
PG 24
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA GC1HI
UT WOS:000429531300015
PM 29622465
OA Green Accepted, hybrid, Green Published, Green Submitted
HC Y
HP N
DA 2025-01-12
ER

PT J
AU Lindner, K
   Eichelmann, AK
   Matuszcak, C
   Hussey, DJ
   Haier, J
   Hummel, R
AF Lindner, Kirsten
   Eichelmann, Ann-Kathrin
   Matuszcak, Christiane
   Hussey, Damian James
   Haier, Joerg
   Hummel, Richard
TI Complex Epigenetic Regulation of Chemotherapy Resistance and Biology in
   Esophageal Squamous Cell Carcinoma via MicroRNAs
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE microRNA; esophageal squamous cell carcinoma; chemotherapy; resistance;
   metastasis; K410: KYSE-410; K270: KYSE-270; miR: miRNA
ID OVARIAN-CANCER CELLS; HUMAN GASTRIC-CANCER; BREAST-CANCER; NEOADJUVANT
   CHEMOTHERAPY; PACLITAXEL RESISTANCE; PANCREATIC-CANCER; DRUG-RESISTANCE;
   PROSTATE-CANCER; GENE-EXPRESSION; GROWTH-FACTOR
AB Background: Resistance towards chemotherapy is a major obstacle in the treatment of esophageal squamous cell carcinoma (ESCC). We investigated the role of specific microRNAs in chemotherapy resistance and tumor biology. Methods: We selected three microRNAs from characteristic microRNA signatures of resistant ESCC (hsa-miR-125a-5p, hsa-miR-130a-3p, hsa-miR-1226-3p), and hsa-miR-148a-3p. Effects on chemotherapy, adhesion, migration, apoptosis and cell cycle were assessed in six ESCC cell lines. Target analyses were performed using Western blotting and luciferase techniques. Results: MiR-130a-3p sensitized cells towards cisplatin in 100% of cell lines, miR-148a-3p in 83%, miR-125a-5p in 67%, miR-1226-3p in 50% (p 0.04). MiR-130a-3p sensitized 83% of cell lines towards 5-FU, miR-148a-3p/miR-125a-5p/miR-1226-3p only 33% (p 0.015). Several resistance-relevant pathways seem to be targeted on various levels. Bcl-2 was confirmed as a direct target of miR-130a-3p and miR-148a-3p, and p53 as a target of miR-125a-5p. All microRNAs decreased migration and adhesion, except miR-130a-3p, and increased apoptosis. Simultaneous manipulation of two microRNAs exhibited additive sensitizing effects towards cisplatin in 50% (miR-125a-5p/miR-148a-3p), and 75% (miR-148a-3p/miR-130a-3p) of cell lines (p 0.006). Conclusion: Our data present strong evidence that specific microRNA signatures are responsible for drug resistance and aggressiveness of ESCC. Final functional readout of these complex processes appears to be more important than single microRNA-target interactions.
C1 [Lindner, Kirsten] Schoen Kliniken, Dept Endocrine Surg, Dehnhaide 120, D-22081 Hamburg, Germany.
   [Eichelmann, Ann-Kathrin] Univ Hosp Munster, Dept Gen & Visceral Surg, Waldeyerstr 1, D-48149 Munster, Germany.
   [Matuszcak, Christiane] Univ Hosp Hamburg Eppendorf, UCCH, Martinistr 52 O24, D-20246 Hamburg, Germany.
   [Hussey, Damian James] Flinders Univ Adelaide, Dept Surg, Flinders Med Ctr, Flinders Dr, Adelaide, SA 5042, Australia.
   [Haier, Joerg] Nordakad, Van der Smissen Str 9, D-22767 Hamburg, Germany.
   [Hummel, Richard] Univ Hosp Schleswig Holstein, Dept Surg, Campus Lubeck,Ratzeburger Allee 160, D-23538 Lubeck, Germany.
C3 University of Munster; University of Hamburg; University Medical Center
   Hamburg-Eppendorf; Flinders Medical Centre; Flinders University South
   Australia; University of Kiel; Schleswig Holstein University Hospital
RP Eichelmann, AK (通讯作者)，Univ Hosp Munster, Dept Gen & Visceral Surg, Waldeyerstr 1, D-48149 Munster, Germany.; Hummel, R (通讯作者)，Univ Hosp Schleswig Holstein, Dept Surg, Campus Lubeck,Ratzeburger Allee 160, D-23538 Lubeck, Germany.
EM thurauki@googlemail.com; ann-kathrin.eichelmann@ukmuenster.de;
   C.Matuszcak@uke.de; damian.hussey@flinders.edu.au;
   joerg.haier@nordakademie.de; richard.hummel@uksh.de
RI Haier, Joerg/JJF-6724-2023
OI Haier, Jorg/0000-0002-1278-9438; Hussey, Damian/0000-0002-6121-6740
FU Open Access Publication Fund of University of Muenster; Office of
   Faculty of Medicine, Westfalische Wilhelms-Universitat Munster [15-003];
   Faculty of Medicine, Westfalische Wilhelms-Universitat Munster; German
   Research Foundation (DFG) [Hu 1763/4-1]
FX We acknowledge support by Open Access Publication Fund of University of
   Muenster. Kirsten Lindner was supported by a Research Fellowship of the
   Dean's Office of the Faculty of Medicine, Westfalische
   Wilhelms-Universitat Munster ("Flexible Forschungszeit fur
   Nachwuchswissenschaftler zur Erhohung der Forschungsleitung von Frauen
   in klinischen Fachern"; No. 15-003). Ann-Kathrin Eichelmann was
   supported by a Research Fellowship of the Faculty of Medicine,
   Westfalische Wilhelms-Universitat Munster. Richard Hummel was supported
   by funding from the German Research Foundation (DFG) in the context of a
   Research Grant (Hu 1763/4-1).
CR Ambros V, 2003, CELL, V113, P673, DOI 10.1016/S0092-8674(03)00428-8
   Ancona E, 2001, CANCER, V91, P2165, DOI 10.1002/1097-0142(20010601)91:11<2165::AID-CNCR1245>3.0.CO;2-H
   Boren T, 2009, GYNECOL ONCOL, V113, P249, DOI 10.1016/j.ygyno.2009.01.014
   Brown I, 2004, BREAST CANCER RES, V6, pR601, DOI 10.1186/bcr918
   Cannell IG, 2008, BIOCHEM SOC T, V36, P1224, DOI 10.1042/BST0361224
   Chen Cen, 2016, Sichuan Da Xue Xue Bao Yi Xue Ban, V47, P60
   Chun EY, 2004, BIOCHEM BIOPH RES CO, V315, P771, DOI 10.1016/j.bbrc.2004.01.118
   Dai J, 2015, INT J ONCOL, V47, P1801, DOI 10.3892/ijo.2015.3171
   Delpu Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055513
   Fan Z, 2016, ONCOGENESIS, V5, DOI 10.1038/oncsis.2016.1
   Fujita Y, 2010, J BIOL CHEM, V285, P19076, DOI 10.1074/jbc.M109.079525
   Haier J, 2016, CANCER METAST REV, V35, P289, DOI 10.1007/s10555-016-9617-1
   Hashiguchi Y, 2012, INT J ONCOL, V40, P1477, DOI 10.3892/ijo.2012.1363
   Hölscher AH, 2014, EUR J CANCER, V50, P2950, DOI 10.1016/j.ejca.2014.08.020
   Hopper-Borge E, 2004, CANCER RES, V64, P4927, DOI 10.1158/0008-5472.CAN-03-3111
   Hu GH, 2009, CANCER CELL, V15, P9, DOI 10.1016/j.ccr.2008.11.013
   Hummel R, 2014, WORLD J GASTROENTERO, V20, P14904, DOI 10.3748/wjg.v20.i40.14904
   Hummel R, 2011, ONCOL REP, V26, P1011, DOI 10.3892/or.2011.1381
   Hummel R, 2011, J GASTROINTEST SURG, V15, P429, DOI 10.1007/s11605-011-1418-9
   Hummel R, 2010, EUR J CANCER, V46, P298, DOI 10.1016/j.ejca.2009.10.027
   Iorio MV, 2007, CANCER RES, V67, P8699, DOI 10.1158/0008-5472.CAN-07-1936
   Jiang H, 2015, ONCOL REP, V34, P1153, DOI 10.3892/or.2015.4099
   Jin CN, 2010, INT J ONCOL, V37, P61, DOI 10.3892/ijo_00000653
   Kastl L, 2012, BREAST CANCER RES TR, V131, P445, DOI 10.1007/s10549-011-1424-3
   Kawahigashi Yutaka, 2009, Journal of Nippon Medical School, V76, P188
   Kopczynska E, 2015, WSPOLCZESNA ONKOL, V19, P423, DOI 10.5114/wo.2015.56648
   Kovalchuk O, 2008, MOL CANCER THER, V7, P2152, DOI 10.1158/1535-7163.MCT-08-0021
   Krammer PH, 2007, NAT REV IMMUNOL, V7, P532, DOI 10.1038/nri2115
   Lakshmipathy U, 2008, STEM CELLS, V26, P356, DOI 10.1634/stemcells.2007-0625
   Li N, 2011, MECH AGEING DEV, V132, P75, DOI 10.1016/j.mad.2010.12.004
   Li Ning-wei, 2013, Sichuan Da Xue Xue Bao Yi Xue Ban, V44, P865
   Li NW, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128886
   Li XH, 2016, MOL CELLS, V39, P103, DOI 10.14348/molcells.2016.2179
   Lindner K, 2014, J EXP CLIN CANC RES, V33, DOI 10.1186/s13046-014-0073-x
   Liu XJ, 2015, INT J CLIN EXP PATHO, V8, P3811
   Liu Y, 2016, J EXP CLIN CANC RES, V35, DOI 10.1186/s13046-016-0296-0
   Miao CK, 2017, ONCOTARGET, V8, P43344, DOI 10.18632/oncotarget.17949
   Miyoshi Yasuo, 2005, Breast Cancer, V12, P11, DOI 10.2325/jbcs.12.11
   Ooe A, 2007, BREAST CANCER RES TR, V101, P305, DOI 10.1007/s10549-006-9293-x
   Pan YQ, 2015, INT J CLIN EXP PATHO, V8, P384
   Peng XH, 2006, J BIOL CHEM, V281, P25903, DOI 10.1074/jbc.M603414200
   Shang H, 2014, MOL MED REP, V10, P1839, DOI 10.3892/mmr.2014.2441
   Sharma P, 2015, CRIT REV ONCOL HEMAT, V96, P449, DOI 10.1016/j.critrevonc.2015.07.002
   Shende VR, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022586
   Sjoquist KM, 2011, LANCET ONCOL, V12, P681, DOI 10.1016/S1470-2045(11)70142-5
   Wang S, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.79
   Wen ZF, 2015, MOL MED REP, V12, P3775, DOI 10.3892/mmr.2015.3827
   Yang LY, 2012, ONCOL REP, V28, P592, DOI 10.3892/or.2012.1823
   Yao J, 2016, ACTA BIOCH BIOPH SIN, V48, P202, DOI 10.1093/abbs/gmv129
   Zhang R, 2014, TUMOR BIOL, V35, P837, DOI 10.1007/s13277-013-1115-2
   Zhang Z, 2014, BRATISL MED J, V115, P685, DOI 10.4149/BLL_2014_133
   Zheng Y, 2015, J CANCER, V6, P671, DOI 10.7150/jca.11616
NR 52
TC 26
Z9 27
U1 0
U2 10
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD FEB
PY 2018
VL 19
IS 2
AR 499
DI 10.3390/ijms19020499
PG 15
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA FZ3YN
UT WOS:000427527400183
PM 29414899
OA Green Published, gold, Green Submitted
DA 2025-01-12
ER

PT J
AU Song, Q
   Chen, Q
   Wang, QM
   Yang, LQ
   Lv, DD
   Jin, GL
   Liu, JY
   Li, BL
   Fei, XJ
AF Song, Qiong
   Chen, Qiu
   Wang, Qimin
   Yang, Longqiu
   Lv, Dongdong
   Jin, Guangli
   Liu, Jiaying
   Li, Baolin
   Fei, Xuejie
TI ATF-3/miR-590/GOLPH3 signaling pathway regulates proliferation of breast
   cancer
SO BMC CANCER
LA English
DT Article
DE Breast cancer; MiR-590-3p; ATF-3; GOLPH3; Proliferation; Cell cycle
ID ACTIVATING TRANSCRIPTION FACTOR-3; PROSTATE-CANCER; CERVICAL-CANCER;
   CELL-MIGRATION; EXPRESSION; PROTEIN; GOLPH3; OVEREXPRESSION;
   MICRORNA-590; RESTORATION
AB Background: Breast cancer is one of the leading causes of death in women worldwide. Fast growth is the important character of breast cancer, which makes sure the subsequent metastasize and invasion breast cancer. Golgi related genes GOLPH3 has been reported to regulate many kinds of cancers proliferation. However, its upregulator remains largely unknown. miRNA modulate gene expression by post-transcriptional repression to participate in many signaling pathway of breast cancer cell proliferation. miR-590 has been reported to regulate tumorgenesis and could be regulated by its own target ATF-3. But whether miR-590 can be the modulator of Golgi related genes to regulate the breast cancer proliferation is unclear.
   Methods: We performed the bioinformatics analysis of survival rate and expression differences of patients using the data of The Cancer Genome Atlas (TCGA). Both of MTS and BrdU assays were used for cell proliferation analysis. Cell cycle was detected by flow cytometry. qRT-PCR was used for detecting the cell cycle related gene expression. Student's t-test or One way anova was used for statistics.
   Results: We found the upregulation of GOLPH3 in breast cancer samples compared with normal breast tissues, which also was related to the poor prognosis. Overexpression of GOLPH3 significantly promoted proliferation both of MDA-MB-231 cells (ER negative) and MCF-7 cells (ER positive). We further found that miRNA-590-3p could directly target the 3'-UTR of GOLPH3 mRNA to repress its expression. Overexpression of miR-590-3p inhibited the proliferation of MDA-MB-231 and MCF-7 cells. The rescue experiments indicated that overexpression of GOLPH3 significantly resorted the proliferation inhibited by miR-590-3p. We also found that ATF-3 repressed miR-590-3p expression to modulate miR-590/GOLPH3 pathway to regulate breast cancer cells proliferation.
   Conclusions: This study not only suggests that the ATF-3/miR-590/GOLPH3 signaling pathway is critically involved in the proliferation of breast cancer cells, but provides a novel therapeutic target and new insight base on epigenetic regulation for future breast cancer diagnosis and clinical treatment.
C1 [Song, Qiong; Chen, Qiu; Wang, Qimin; Yang, Longqiu; Lv, Dongdong; Jin, Guangli; Liu, Jiaying; Li, Baolin] Zhengzhou Univ, Zhengzhou Cent Hosp, Dept Anesthesiol, 195 Tongbai Rd, Zhengzhou 450000, Henan, Peoples R China.
   [Fei, Xuejie] Shanghai Univ Tradit Chinese Med, Shuguang Hosp, Dept Hosp Infect, 187 Puan Rd, Shanghai 200021, Peoples R China.
C3 Zhengzhou University; Shanghai University of Traditional Chinese
   Medicine
RP Li, BL (通讯作者)，Zhengzhou Univ, Zhengzhou Cent Hosp, Dept Anesthesiol, 195 Tongbai Rd, Zhengzhou 450000, Henan, Peoples R China.; Fei, XJ (通讯作者)，Shanghai Univ Tradit Chinese Med, Shuguang Hosp, Dept Hosp Infect, 187 Puan Rd, Shanghai 200021, Peoples R China.
EM libaolin136@163.com; 1749336046@qq.com
RI Wang, Qimin/AAL-8196-2021; baolin, li/KZT-8538-2024
FU National Natural Science Foundation of China [U1404808]; Technical
   Cooperation of the International Division of Zhengzhou [20140966];
   General science and technology project of Henan Province [162102310229]
FX This research was supported by the National Natural Science Foundation
   of China (U1404808), the Technical Cooperation of the International
   Division of Zhengzhou (#20140966), the General science and technology
   project of Henan Province (162102310229).
CR Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322
   Ameri K, 2007, ONCOGENE, V26, P284, DOI 10.1038/sj.onc.1209781
   An Q, 2016, MOL MED REP, V14, P4042, DOI 10.3892/mmr.2016.5753
   Chu YX, 2014, J CELL BIOCHEM, V115, P847, DOI 10.1002/jcb.24726
   Di Leva G, 2014, ANNU REV PATHOL-MECH, V9, P287, DOI 10.1146/annurev-pathol-012513-104715
   Feng JP, 2013, INT J CLIN EXP PATHO, V6, P2064
   Fu SW, 2011, J CANCER, V2, P116, DOI 10.7150/jca.2.116
   Guinn D, 2017, CANCER MED-US, V6, P778, DOI 10.1002/cam4.996
   Howlader N, 2014, CANCER-AM CANCER SOC, V120, P3771, DOI 10.1002/cncr.29059
   Hu BS, 2013, TUMOR BIOL, V34, P515, DOI 10.1007/s13277-012-0576-z
   Janz M, 2006, BLOOD, V107, P2536, DOI 10.1182/blood-2005-07-2694
   JEMAL A, 2011, CA-CANCER J CLIN, V61, P69, DOI DOI 10.3322/CAAC.20107
   Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412
   Kojima S, 2014, J HUM GENET, V59, P78, DOI 10.1038/jhg.2013.121
   Kristiansen G, 2008, BRIT J CANCER, V99, P939, DOI 10.1038/sj.bjc.6604614
   Kunigou O, 2011, ONCOL REP, V26, P1337, DOI 10.3892/or.2011.1413
   Li HM, 2014, ONCOL REP, V32, P1225, DOI 10.3892/or.2014.3327
   Li WZ, 2015, J CANCER, V6, P420, DOI 10.7150/jca.11228
   Liu QD, 2014, STEM CELL REP, V3, P1103, DOI 10.1016/j.stemcr.2014.10.006
   Liu YQ, 2017, ONCOL REP, V37, P2441, DOI 10.3892/or.2017.5488
   Ma YC, 2014, TUMOR BIOL, V35, P11845, DOI 10.1007/s13277-014-2411-1
   Mak P, 2008, BIOCHEM BIOPH RES CO, V373, P618, DOI 10.1016/j.bbrc.2008.06.097
   Miao MH, 2016, ONCOTARGET, V7, P39527, DOI 10.18632/oncotarget.8414
   Miranda PJ, 2015, INT J BIOL MACROMOL, V72, P145, DOI 10.1016/j.ijbiomac.2014.07.051
   Pelzer AE, 2006, J UROLOGY, V175, P1517, DOI 10.1016/S0022-5347(05)00651-8
   Petrosyan A, 2014, MOL CANCER RES, V12, P1704, DOI 10.1158/1541-7786.MCR-14-0291-T
   Preisinger C, 2004, J CELL BIOL, V164, P1009, DOI 10.1083/jcb.200310061
   Scott KL, 2009, NATURE, V459, P1085, DOI 10.1038/nature08109
   Seeliger C, 2016, STEM CELLS DEV, V25, P1261, DOI 10.1089/scd.2016.0133
   Sheikholeslami A, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317697570
   Sun J, 2017, CANCER MED-US, V6, P834, DOI 10.1002/cam4.1040
   Takahashi S, 2003, INT J CANCER, V106, P310, DOI 10.1002/ijc.11205
   Tang WF, 2016, AM J TRANSL RES, V8, P1756
   Taylor MA, 2013, J CLIN INVEST, V123, P150, DOI 10.1172/JCI64946
   Tenorio MJ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0154719
   Tokuda E, 2014, CANCER RES, V74, P3054, DOI 10.1158/0008-5472.CAN-13-2441
   Varambally S, 2008, NEOPLASIA, V10, P1285, DOI 10.1593/neo.08922
   Wang CL, 2017, ONCOL RES, V25, P463, DOI 10.3727/096504016X14685034103879
   Wolford CC, 2013, J CLIN INVEST, V123, P2893, DOI 10.1172/JCI64410
   Yan IK, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0155888
   Yang G, 2014, CELL CYCLE, V13, P5, DOI 10.4161/cc.27019
   Zeng ZL, 2012, CLIN CANCER RES, V18, P4059, DOI 10.1158/1078-0432.CCR-11-3156
   Zhou L, 2017, EUR REV MED PHARMACO, V21, P87
   Zhu KL, 2016, ONCOTARGET, V7, P68328, DOI 10.18632/oncotarget.12008
NR 44
TC 28
Z9 35
U1 0
U2 13
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2407
J9 BMC CANCER
JI BMC Cancer
PD MAR 9
PY 2018
VL 18
AR 255
DI 10.1186/s12885-018-4031-4
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA FZ7IC
UT WOS:000427772900001
PM 29534690
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU Shin, DY
   Jeong, MH
   Bang, IJ
   Kim, HR
   Chung, KH
AF Shin, Da Young
   Jeong, Mi Ho
   Bang, In Jae
   Kim, Ha Ryong
   Chung, Kyu Hyuck
TI MicroRNA regulatory networks reflective of polyhexamethylene guanidine
   phosphate-induced fibrosis in A549 human alveolar adenocarcinoma cells
SO TOXICOLOGY LETTERS
LA English
DT Article
DE Polyhexamethyleneguanidine-phosphate; microRNA; Epithelial-mesenchymal
   transition; Microarray
ID EPITHELIAL-MESENCHYMAL TRANSITION; IDIOPATHIC PULMONARY-FIBROSIS;
   MESSENGER-RNA; FIBROTIC RESPONSES; SIGNALING PATHWAY; BREAST-CANCER; ER
   STRESS; MECHANISMS; PROMOTES; MIRNA
AB Polyhexamethylene guanidine phosphate (PHMG-phosphate), an active component of humidifier disinfectant, is suspected to be a major cause of pulmonary fibrosis. Fibrosis, induced by recurrent epithelial damage, is significantly affected by epigenetic regulation, including microRNAs (miRNAs). The aim of this study was to investigate the fibrogenic mechanisms of PHMG-phosphate through the profiling of miRNAs and their target genes. A549 cells were treated with 0.75 mu g/mL PHMG-phosphate for 24 and 48 h and miRNA microarray expression analysis was conducted. The putative mRNA targets of the miRNAs were identified and subjected to Gene Ontology analysis. After exposure to PHMG-phosphate for 24 and 48 h, 46 and 33 miRNAs, respectively, showed a significant change in expression over 1.5-fold compared with the control. The integrated analysis of miRNA and mRNA microarray results revealed the putative targets that were prominently enriched were associated with the epithelial-mesenchymal transition (EMT), cell cycle changes, and apoptosis. The dose-dependent induction of EMT by PHMG-phosphate exposure was confirmed by western blot. We identified 13 putative EMT-related targets that may play a role in PHMG-phosphate-induced fibrosis according to the Comparative Toxicogenomic Database. Our findings contribute to the comprehension of the fibrogenic mechanism of PHMG-phosphate and will aid further study on PHMG-phosphate-induced toxicity.
C1 [Shin, Da Young; Jeong, Mi Ho; Bang, In Jae; Chung, Kyu Hyuck] Sungkyunkwan Univ, Sch Pharm, Suwon 16419, Gyeonggi Do, South Korea.
   [Kim, Ha Ryong] Catholic Univ Daegu, Coll Pharm, Gyongsan 38430, Gyeongsangbuk D, South Korea.
C3 Sungkyunkwan University (SKKU); Catholic University of Daegu
RP Chung, KH (通讯作者)，Sungkyunkwan Univ, Sch Pharm, Suwon 16419, Gyeonggi Do, South Korea.; Kim, HR (通讯作者)，Catholic Univ Daegu, Coll Pharm, Gyongsan 38430, Gyeongsangbuk D, South Korea.
EM haryong.kim.81@gmail.com; khchung@skku.edu
RI Ryong, Kim/AAJ-4688-2020
FU Global Ph.D. Fellowship Program - Ministry of Education
   [NRF-2012H1A2A1001672]; Environmental Health Action Program - Korea
   Ministry of Environment (MOE) [2016001360006]
FX This work was supported by Global Ph.D. Fellowship Program funded by the
   Ministry of Education (NRF-2012H1A2A1001672) and the Environmental
   Health Action Program funded by the Korea Ministry of Environment (MOE)
   (2016001360006).
CR Armstrong DA, 2017, CLIN EPIGENETICS, V9, DOI 10.1186/s13148-017-0355-1
   Cao S, 2014, MOL BIOL CELL, V25, P1234, DOI 10.1091/mbc.E13-09-0560
   Chang CC, 2012, NANOTOXICOLOGY, V6, P600, DOI 10.3109/17435390.2011.594913
   Chang CJ, 2011, NAT CELL BIOL, V13, P317, DOI 10.1038/ncb2173
   Chapman HA, 2011, ANNU REV PHYSIOL, V73, P413, DOI 10.1146/annurev-physiol-012110-142225
   Chen YW, 2012, ARCH TOXICOL, V86, P1547, DOI 10.1007/s00204-012-0873-8
   Chilosi M, 2003, AM J PATHOL, V162, P1495, DOI 10.1016/S0002-9440(10)64282-4
   Davis AP, 2008, BMC MED GENOMICS, V1, DOI 10.1186/1755-8794-1-48
   Davis AP, 2017, NUCLEIC ACIDS RES, V45, pD972, DOI 10.1093/nar/gkw838
   Dong J, 2016, ARCH TOXICOL, V90, P385, DOI 10.1007/s00204-015-1589-3
   Dymacek J, 2015, TOXICOL SCI, V144, P51, DOI 10.1093/toxsci/kfu262
   Fu H, 2017, ONCOL REP, V37, P1093, DOI 10.3892/or.2017.5360
   Fukunaga S, 2015, TOXICOL APPL PHARM, V286, P188, DOI 10.1016/j.taap.2015.04.014
   Gonzalez DM, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005189
   Graham JR, 2014, J CELL BIOCHEM, V115, P1539, DOI 10.1002/jcb.24809
   Hevel JM, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-376
   Hong S, 2014, NEOPLASIA, V16, P279, DOI 10.1016/j.neo.2014.03.010
   Huang XL, 2015, INT J CLIN EXP PATHO, V8, P1515
   Jeong SC, 2017, ENVIRON TOXICOL, V32, P302, DOI 10.1002/tox.22236
   Judson R, 2016, TOXICOL SCI, V153, P409, DOI 10.1093/toxsci/kfw148
   Jung HM, 2013, MOL BIOL CELL, V24, P1638, DOI 10.1091/mbc.E12-12-0891
   KalantarMotamedi Y, 2016, CELL DEATH DISCOV, V2, DOI 10.1038/cddiscovery.2016.7
   Kanlikilicer P, 2016, CANCER RES, V76, P7194, DOI 10.1158/0008-5472.CAN-16-0714
   Kim HR, 2017, TOXICOL IN VITRO, V38, P1, DOI 10.1016/j.tiv.2016.10.006
   Kim HR, 2016, ARCH TOXICOL, V90, P617, DOI 10.1007/s00204-015-1486-9
   Kim HR, 2015, TOXICOL LETT, V233, P148, DOI 10.1016/j.toxlet.2015.01.005
   Kim HR, 2016, J TOXICOL SCI, V41, P711, DOI 10.2131/jts.41.711
   King BL, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0047149, 10.1371/journal.pone.0046524, 10.1371/journal.pone.0047981]
   Komina A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0168229
   Kong Lu, 2007, Zhongguo Yi Xue Ke Xue Yuan Xue Bao, V29, P782
   Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758
   Lee SJ, 2016, J TOXICOL PATHOL, V29, P95, DOI 10.1293/tox.2015-0067
   Ley B, 2014, AM J PHYSIOL-LUNG C, V307, pL681, DOI 10.1152/ajplung.00014.2014
   Meng J, 2016, J AM SOC NEPHROL, V27, P3006, DOI 10.1681/ASN.2015040422
   Mitsopoulos P, 2010, CHEM-BIOL INTERACT, V188, P427, DOI 10.1016/j.cbi.2010.09.022
   Mitsugi R, 2016, TOXICOL LETT, V263, P34, DOI 10.1016/j.toxlet.2016.10.002
   Miyamae M, 2015, BRIT J CANCER, V113, P1467, DOI 10.1038/bjc.2015.366
   Oda K, 2016, RESP RES, V17, DOI 10.1186/s12931-016-0357-0
   Park JH, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151849
   Perez-Pinera P, 2006, P NATL ACAD SCI USA, V103, P17795, DOI 10.1073/pnas.0607299103
   Qu JJ, 2015, INT J ONCOL, V47, P2141, DOI 10.3892/ijo.2015.3187
   Sarkar S, 2010, MOL BIOL CELL, V21, P2138, DOI 10.1091/mbc.E10-01-0062
   Selbach M, 2008, NATURE, V455, P58, DOI 10.1038/nature07228
   Selman M, 2014, AM J RESP CRIT CARE, V189, P1161, DOI 10.1164/rccm.201312-2221PP
   Shah PP, 2017, ONCOTARGET, V8, P22625, DOI 10.18632/oncotarget.15150
   Siddeek B, 2014, MUTAT RES-GEN TOX EN, V764, P46, DOI 10.1016/j.mrgentox.2014.01.010
   Smit MA, 2010, AGING-US, V2, P735, DOI 10.18632/aging.100209
   Sun KX, 2015, FEBS OPEN BIO, V5, P900, DOI 10.1016/j.fob.2015.11.001
   Tang QZ, 2015, ONCOL REP, V34, P2515, DOI 10.3892/or.2015.4217
   Wang TS, 2014, CHINESE MED J-PEKING, V127, P2357, DOI 10.3760/cma.j.issn.0366-6999.20140318
   Wells AU, 2016, AM J RESP CRIT CARE, V193, P112, DOI 10.1164/rccm.201510-2052ED
   Wendt MK, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2360
   WHEATLEY DN, 1974, BRIT J CANCER, V29, P117, DOI 10.1038/bjc.1974.48
   Xu N, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0115300
   Xu XF, 2016, CLIN RESPIR J, V10, P133, DOI 10.1111/crj.12190
   Zeng X, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046367
   Zeng XM, 2017, BMC CELL BIOL, V18, DOI 10.1186/s12860-016-0123-7
   Zhang YE, 2009, CELL RES, V19, P128, DOI 10.1038/cr.2008.328
   Zhou YH, 2016, J CELL MOL MED, V20, P495, DOI 10.1111/jcmm.12754
   Zhu DD, 2014, PARASITE VECTOR, V7, DOI 10.1186/1756-3305-7-148
   Zhu DY, 2016, BIOMED PHARMACOTHER, V81, P79, DOI 10.1016/j.biopha.2016.03.029
NR 61
TC 17
Z9 18
U1 1
U2 16
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0378-4274
EI 1879-3169
J9 TOXICOL LETT
JI Toxicol. Lett.
PD MAY 1
PY 2018
VL 287
BP 49
EP 58
DI 10.1016/j.toxlet.2018.01.010
PG 10
WC Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Toxicology
GA FZ4KU
UT WOS:000427561900006
PM 29337256
DA 2025-01-12
ER

PT J
AU Chen, TY
   Lee, SH
   Dhar, SS
   Lee, MG
AF Chen, Tsai-Yu
   Lee, Sung-Hun
   Dhar, Shilpa S.
   Lee, Min Gyu
TI Protein arginine methyltransferase 7-mediated <i>microRNA-221</i>
   repression maintains Oct4, Nanog, and Sox2 levels in mouse embryonic
   stem cells
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID BREAST-CANCER CELLS; POSTTRANSCRIPTIONAL REGULATION;
   HEPATOCELLULAR-CARCINOMA; PLURIPOTENCY FACTORS; ANIMAL DEVELOPMENT;
   EXPRESSION; DIFFERENTIATION; MIR-221; PROLIFERATION; RESISTANCE
AB The stemness maintenance of embryonic stem cells (ESCs) requires pluripotency transcription factors, including Oct4, Nanog, and Sox2. We have previously reported that protein arginine methyltransferase 7 (PRMT7), an epigenetic modifier, is an essential pluripotency factor that maintains the stemness of mouse ESCs, at least in part, by down-regulating the expression of the anti-stemness microRNA (miRNA) miR-24-2. To gain greater insight into the molecular basis underlying PRMT7-mediated maintenance of mouse ESC stemness, we searched for new PRMT7-down-regulated anti-stemness miRNAs. Here, we show that miR-221 gene-encoded miR-221-3p and miR-221-5p are anti-stemness miRNAs whose expression levels in mouse ESCs are directly repressed by PRMT7. Notably, both miR-221-3p and miR-221-5p targeted the 3'untranslated regions of mRNA transcripts of the major pluripotency factors Oct4, Nanog, and Sox2 to antagonize mouse ESC stemness. Moreover, miR-221-5p silenced also the expression of its own transcriptional repressor PRMT7. Transfection of miR-221-3p and miR-221-5p mimics induced spontaneous differentiation of mouse ESCs. CRISPR-mediated deletion of the miR-221 gene, as well as specific antisense inhibitors of miR-221-3p and miR221-5p, inhibited the spontaneous differentiation of PRMT7depleted mouse ESCs. Taken together, these findings reveal that the PRMT7-mediated repression of miR-221-3p and miR221- 5p expression plays a critical role in maintaining mouse ESC stemness. Our results also establish miR-221-3p and miR221- 5p as anti-stemness miRNAs that target Oct4, Nanog, and Sox2 mRNAs in mouse ESCs.
C1 [Chen, Tsai-Yu; Lee, Sung-Hun; Dhar, Shilpa S.; Lee, Min Gyu] Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA.
   [Chen, Tsai-Yu; Lee, Min Gyu] Univ Texas Grad Sch Biomed Sci Houston, Canc Biol Program, Houston, TX 77030 USA.
C3 University of Texas System; UTMD Anderson Cancer Center
RP Lee, MG (通讯作者)，Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA.
EM mglee@mdanderson.org
RI Lee, Ji Hyung/HNI-8824-2023
OI Chen, Tsai-Yu/0000-0001-6150-6361
FU National Institutes of Health through M. D. Anderson's Cancer Center
   Support Grant [CA016672]
FX We thank the research staff in the Flow Cytometry & Cellular Imaging
   Facility, which is supported in part by the National Institutes of
   Health through M. D. Anderson's Cancer Center Support Grant CA016672. We
   also thank Ann Sutton (Department of Scientific Publications, M. D.
   Anderson) for the editorial assistance.
CR Alvarez-Garcia I, 2005, DEVELOPMENT, V132, P4653, DOI 10.1242/dev.02073
   Boyer LA, 2005, CELL, V122, P947, DOI 10.1016/j.cell.2005.08.020
   Croce CM, 2009, NAT REV GENET, V10, P704, DOI 10.1038/nrg2634
   Dhar SS, 2016, NUCLEIC ACIDS RES, V44, P3659, DOI 10.1093/nar/gkv1516
   Dhar SS, 2012, GENE DEV, V26, P2749, DOI 10.1101/gad.203356.112
   Di Leva G, 2010, JNCI-J NATL CANCER I, V102, P706, DOI 10.1093/jnci/djq102
   Donovan PJ, 2001, NATURE, V414, P92, DOI 10.1038/35102154
   Filipowicz W, 2008, NAT REV GENET, V9, P102, DOI 10.1038/nrg2290
   Fornari F, 2008, ONCOGENE, V27, P5651, DOI 10.1038/onc.2008.178
   Fornari F, 2014, MOL CANCER RES, V12, P203, DOI 10.1158/1541-7786.MCR-13-0312-T
   Galardi S, 2007, J BIOL CHEM, V282, P23716, DOI 10.1074/jbc.M701805200
   Garofalo M, 2009, CANCER CELL, V16, P498, DOI 10.1016/j.ccr.2009.10.014
   Gregory RI, 2005, CELL, V123, P631, DOI 10.1016/j.cell.2005.10.022
   Gullà A, 2016, CLIN CANCER RES, V22, P1222, DOI 10.1158/1078-0432.CCR-15-0489
   Gulyaeva LF, 2016, J TRANSL MED, V14, DOI 10.1186/s12967-016-0893-x
   Hamada N, 2012, NEUROCHEM INT, V60, P743, DOI 10.1016/j.neuint.2012.03.010
   Howe EN, 2012, J MAMMARY GLAND BIOL, V17, P65, DOI 10.1007/s10911-012-9244-6
   Hutvágner G, 2002, SCIENCE, V297, P2056, DOI 10.1126/science.1073827
   Ivey KN, 2010, CELL STEM CELL, V7, P36, DOI 10.1016/j.stem.2010.06.012
   Kanellopoulou C, 2005, GENE DEV, V19, P489, DOI 10.1101/gad.1248505
   Kloosterman WP, 2006, DEV CELL, V11, P441, DOI 10.1016/j.devcel.2006.09.009
   Lee JH, 2005, J BIOL CHEM, V280, P3656, DOI 10.1074/jbc.M405295200
   Lee SH, 2016, NUCLEIC ACIDS RES, V44, P10603, DOI 10.1093/nar/gkw788
   Li J, 2015, STEM CELL REV REP, V11, P39, DOI 10.1007/s12015-014-9543-y
   Li MA, 2012, BIOESSAYS, V34, P670, DOI 10.1002/bies.201200019
   Li N, 2016, MOL CELL, V63, P470, DOI 10.1016/j.molcel.2016.06.035
   Loh KM, 2011, CELL STEM CELL, V8, P363, DOI 10.1016/j.stem.2011.03.013
   Loh YH, 2006, NAT GENET, V38, P431, DOI 10.1038/ng1760
   Ludwig N, 2016, NUCLEIC ACIDS RES, V44, P3865, DOI 10.1093/nar/gkw116
   Ma YN, 2015, EMBO J, V34, P361, DOI 10.15252/embj.201489957
   Meister G, 2004, MOL CELL, V15, P185, DOI 10.1016/j.molcel.2004.07.007
   Morin RD, 2008, GENOME RES, V18, P610, DOI 10.1101/gr.7179508
   Obernosterer G, 2006, RNA, V12, P1161, DOI 10.1261/rna.2322506
   Pandey A, 2015, J NEUROCHEM, V133, P640, DOI 10.1111/jnc.13089
   Park JK, 2009, PANCREAS, V38, pE190, DOI 10.1097/MPA.0b013e3181ba82e1
   Pogribny IP, 2010, INT J CANCER, V127, P1785, DOI 10.1002/ijc.25191
   Ran FA, 2013, NAT PROTOC, V8, P2281, DOI 10.1038/nprot.2013.143
   Ran FA, 2013, CELL, V154, P1380, DOI 10.1016/j.cell.2013.08.021
   Sayed D, 2011, PHYSIOL REV, V91, P827, DOI 10.1152/physrev.00006.2010
   Stadler B, 2010, STEM CELLS DEV, V19, P935, DOI 10.1089/scd.2009.0426
   Stinson S, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001538
   Suzuki H, 2012, MOL ONCOL, V6, P567, DOI 10.1016/j.molonc.2012.07.007
   Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145
   Thomson M, 2011, CELL, V145, P875, DOI 10.1016/j.cell.2011.05.017
   Wang YM, 2007, NAT GENET, V39, P380, DOI 10.1038/ng1969
   Wienholds E, 2005, SCIENCE, V309, P310, DOI 10.1126/science.1114519
   Wu LG, 2006, P NATL ACAD SCI USA, V103, P4034, DOI 10.1073/pnas.0510928103
   Xu N, 2009, CELL, V137, P647, DOI 10.1016/j.cell.2009.02.038
   Young RA, 2011, CELL, V144, P940, DOI 10.1016/j.cell.2011.01.032
   Zhao C, 2009, NAT STRUCT MOL BIOL, V16, P365, DOI 10.1038/nsmb.1576
   Zhou M, 2010, J BIOL CHEM, V285, P21496, DOI 10.1074/jbc.M109.083337
   Zurita-Lopez CI, 2012, J BIOL CHEM, V287, P7859, DOI 10.1074/jbc.M111.336271
NR 52
TC 19
Z9 21
U1 0
U2 11
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD MAR 16
PY 2018
VL 293
IS 11
BP 3925
EP 3936
DI 10.1074/jbc.RA117.000425
PG 12
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA FZ4UM
UT WOS:000427587500007
PM 29378844
OA Green Published
DA 2025-01-12
ER

PT J
AU Nikolaou, M
   Pavlopoulou, A
   Georgakilas, AG
   Kyrodimos, E
AF Nikolaou, Michail
   Pavlopoulou, Athanasia
   Georgakilas, Alexandros G.
   Kyrodimos, Efthymios
TI The challenge of drug resistance in cancer treatment: a current overview
SO CLINICAL & EXPERIMENTAL METASTASIS
LA English
DT Article
DE Drug resistance; Acquired resistance; Chemotherapy resistance; Multidrug
   resistance; Tumor microenvironment; Cancer
ID LURIA-DELBRUCK DISTRIBUTION; P-GLYCOPROTEIN EXPRESSION;
   BLOOD-BRAIN-BARRIER; MULTIDRUG-RESISTANCE; BREAST-CANCER; CELL-LINES;
   MDR1 GENE; OVARIAN-CANCER; INTRATUMOR HETEROGENEITY; PACLITAXEL
   SENSITIVITY
AB It is generally accepted that recent advances in anticancer agents have contributed significantly to the improvement of both the disease-free survival and quality of life in cancer patients. However, in many instances, a favorable initial response to treatment changes afterwards, thereby leading to cancer relapse and recurrence. This phenomenon of acquired resistance to therapy, it is a major problem for totally efficient anticancer therapy. The failure to obtain an initial response reflects a form of intrinsic resistance. Specific cell membrane transporter proteins are implicated in intrinsic drug resistance by altering drug transport and pumping drugs out of the tumor cells. Moreover, the gradual acquisition of specific genetic and epigenetic abnormalities in cancer cells could contribute greatly to acquired drug resistance. A critical issue in the clinical setting, is that the problem of drug resistance appears to have a negative effect on also the new molecularly-targeted anticancer drugs. Several ongoing efforts are being made by the medical community aimed to the identification of such resistance mechanisms and the development of novel drugs that could overcome them. In this review, the major drug resistance mechanisms and strategies to overcome them are critically discussed, and also possible future directions are suggested.
C1 [Nikolaou, Michail] Univ Athens, Hippokrateio Hosp, Dept Internal Med, Oncol Unit, Athens, Greece.
   [Pavlopoulou, Athanasia] Dokuz Eylul Univ, Izmir Int Biomed & Genome Inst, TR-35340 Izmir, Turkey.
   [Georgakilas, Alexandros G.] Natl Tech Univ Athens, Sch Appl Math & Phys Sci, Dept Phys, DNA Damage Lab, Athens 15780, Greece.
   [Kyrodimos, Efthymios] Univ Athens, Hippokrateio Hosp, Dept Otolaryngol Head & Neck Surg 1, Athens 11527, Greece.
C3 National & Kapodistrian University of Athens; Dokuz Eylul University;
   National Technical University of Athens; National & Kapodistrian
   University of Athens
RP Kyrodimos, E (通讯作者)，Univ Athens, Hippokrateio Hosp, Dept Otolaryngol Head & Neck Surg 1, Athens 11527, Greece.
EM timkirodimos@hotmail.com
RI Pavlopoulou, Athanasia/ABB-3275-2021; Kyrodimos,
   Efthymios/AAW-4151-2020; Georgakilas, Alexandros/AAG-9517-2020;
   Nikolaou, Michail/P-7547-2019
OI NIKOLAOU, MICHAIL/0000-0002-7215-6296; Kyrodimos,
   Efthymios/0000-0001-5236-7961; Pavlopoulou,
   Athanasia/0000-0002-0815-3808; Georgakilas,
   Alexandros/0000-0002-5971-0010
FU DAAD [57339330]
FX Dr. A.G. Georgakilas acknowledges funding from DAAD Grant "DNA Damage
   and Repair and Their Relevance to Carcinogenesis" (No. 57339330).
CR Alt F W, 1992, Biotechnology, V24, P397
   Ambudkar SV, 2003, ONCOGENE, V22, P7468, DOI 10.1038/sj.onc.1206948
   ANDOH T, 1987, P NATL ACAD SCI USA, V84, P5565, DOI 10.1073/pnas.84.16.5565
   Angerer WP, 2001, J MATH BIOL, V42, P145, DOI 10.1007/s002850000053
   Balch C, 2013, ADV EXP MED BIOL, V754, P285, DOI 10.1007/978-1-4419-9967-2_14
   Bates SE, 2001, J BIOENERG BIOMEMBR, V33, P503, DOI 10.1023/A:1012879205914
   Beck WT, 1999, DRUG RESIST UPDATE, V2, P382, DOI 10.1054/drup.1999.0110
   BEKETICORESKOVIC L, 1995, J NATL CANCER I, V87, P1593, DOI 10.1093/jnci/87.21.1593
   Benzekry S, 2015, SEMIN CANCER BIOL, V35, P53, DOI 10.1016/j.semcancer.2015.09.002
   Bhatla T, 2012, BLOOD, V119, P5201, DOI 10.1182/blood-2012-01-401687
   Bradshaw DM, 1998, J CLIN ONCOL, V16, P3674, DOI 10.1200/JCO.1998.16.11.3674
   Burg D, 2002, MOL PHARMACOL, V62, P1160, DOI 10.1124/mol.62.5.1160
   Callaghan R, 2014, DRUG METAB DISPOS, V42, P623, DOI 10.1124/dmd.113.056176
   CAMPOS L, 1992, BLOOD, V79, P473
   CAPRANICO G, 1989, BRIT J CANCER, V59, P682, DOI 10.1038/bjc.1989.141
   CARLSON RW, 1983, ANN INTERN MED, V99, P823, DOI 10.7326/0003-4819-99-6-823
   Carnero A, 2016, CANCER TREAT REV, V49, P25, DOI 10.1016/j.ctrv.2016.07.001
   CASSIDY J, 1994, ANN ONCOL, V5, pS25, DOI 10.1093/annonc/5.suppl_4.S25
   Ceppi P, 2006, ANN ONCOL, V17, P1818, DOI 10.1093/annonc/mdl300
   Chang XB, 2007, CANCER METAST REV, V26, P15, DOI 10.1007/s10555-007-9041-7
   CHEN G, 1994, CANCER RES, V54, P4980
   Chen KG, 2005, CANCER RES, V65, P9388, DOI 10.1158/0008-5472.CAN-04-4133
   CHEN YN, 1990, J BIOL CHEM, V265, P10073
   CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0
   Clarke R, 2005, SEMIN ONCOL, V32, pS9, DOI 10.1053/j.seminoncol.2005.09.009
   Clynes M, 1998, MULTIPLE DRUG RESIST
   COLDMAN AJ, 1986, B MATH BIOL, V48, P279, DOI 10.1016/S0092-8240(86)90028-5
   Comerford KM, 2002, CANCER RES, V62, P3387
   Cooper G.M, 2000, The Cell: A Molecular Approach, V2nd
   CORDONCARDO C, 1989, P NATL ACAD SCI USA, V86, P695, DOI 10.1073/pnas.86.2.695
   Cowan DSM, 2001, INT J CANCER, V91, P120, DOI 10.1002/1097-0215(20010101)91:1<120::AID-IJC1021>3.0.CO;2-Y
   DALTON WS, 1989, J CLIN ONCOL, V7, P415, DOI 10.1200/JCO.1989.7.4.415
   Deaton AM, 2011, GENE DEV, V25, P1010, DOI 10.1101/gad.2037511
   DEFFIE AM, 1989, CANCER RES, V49, P58
   Dewanji A, 2005, MATH BIOSCI, V197, P140, DOI 10.1016/j.mbs.2005.07.003
   Dumontet C, 1999, J CLIN ONCOL, V17, P1061, DOI 10.1200/JCO.1999.17.3.1061
   Dumontet C, 1996, CANCER RES, V56, P1091
   Ebos JML, 2015, CANCER RES, V75, P3427, DOI 10.1158/0008-5472.CAN-15-0308
   FAN SJ, 1994, CANCER RES, V54, P5824
   FISHER GA, 1995, HEMATOL ONCOL CLIN N, V9, P363, DOI 10.1016/S0889-8588(18)30099-6
   Fojo T, 2007, DRUG RESIST UPDATE, V10, P59, DOI 10.1016/j.drup.2007.02.002
   Frank SA, 2003, J THEOR BIOL, V223, P405, DOI 10.1016/S0022-5193(03)00117-6
   Gerlinger M, 2012, NEW ENGL J MED, V366, P883, DOI 10.1056/NEJMoa1113205
   Gerson SL, 2004, NAT REV CANCER, V4, P296, DOI 10.1038/nrc1319
   Glavinas Hristos, 2004, Current Drug Delivery, V1, P27, DOI 10.2174/1567201043480036
   GOLDIE JH, 1979, CANCER TREAT REP, V63, P1727
   GOLDIE JH, 1985, SEMIN ONCOL, V12, P222
   Gottesman Michael M, 2006, Discov Med, V6, P18
   Gottesman MM, 2002, ANNU REV MED, V53, P615, DOI 10.1146/annurev.med.53.082901.103929
   Gottesman MM, 2001, J BIOENERG BIOMEMBR, V33, P453, DOI 10.1023/A:1012866803188
   Greaves M, 2012, NATURE, V481, P306, DOI 10.1038/nature10762
   Groenendijk FH, 2014, MOL ONCOL, V8, P1067, DOI 10.1016/j.molonc.2014.05.004
   Haeno H, 2007, GENETICS, V177, P2209, DOI 10.1534/genetics.107.078915
   Hazlehurst LA, 2000, ONCOGENE, V19, P4319, DOI 10.1038/sj.onc.1203782
   HIRST DG, 1979, CELL TISSUE KINET, V12, P31, DOI 10.1111/j.1365-2184.1979.tb00111.x
   Housman G, 2014, CANCERS, V6, P1769, DOI 10.3390/cancers6031769
   Huang Y, 2007, CANCER METAST REV, V26, P183, DOI 10.1007/s10555-007-9050-6
   Issa ME, 2017, CLIN EPIGENETICS, V9, DOI 10.1186/s13148-017-0319-5
   Iwasa Y, 2006, GENETICS, V172, P2557, DOI 10.1534/genetics.105.049791
   JAFFREZOU JP, 1994, J NATL CANCER I, V86, P1152, DOI 10.1093/jnci/86.15.1152
   Joo WD, 2013, MATURITAS, V76, P308, DOI 10.1016/j.maturitas.2013.09.008
   Kaina B, 2002, INT J CLIN PHARM TH, V40, P354
   KENNEDY KA, 1987, ANTI-CANCER DRUG DES, V2, P181
   Kickhoefer VA, 1998, J BIOL CHEM, V273, P8971, DOI 10.1074/jbc.273.15.8971
   Komarova NL, 2005, J THEOR BIOL, V235, P338, DOI 10.1016/j.jtbi.2005.01.014
   Komarova NL, 2005, P NATL ACAD SCI USA, V102, P9714, DOI 10.1073/pnas.0501870102
   Kummar S, 2006, BRIT J CLIN PHARMACO, V62, P15, DOI 10.1111/j.1365-2125.2006.02713.x
   Kyle AH, 2007, CLIN CANCER RES, V13, P2804, DOI 10.1158/1078-0432.CCR-06-1941
   Lackner MR, 2012, FUTURE ONCOL, V8, P999, DOI [10.2217/FON.12.86, 10.2217/fon.12.86]
   Lee AJX, 2012, BIOCHEM PHARMACOL, V83, P1013, DOI 10.1016/j.bcp.2011.12.008
   List AF, 1996, BLOOD, V87, P2464, DOI 10.1182/blood.V87.6.2464.bloodjournal8762464
   Liu YY, 2001, FASEB J, V15, P719, DOI 10.1096/fj.00-0223com
   Ljungkvist ASE, 2002, INT J RADIAT ONCOL, V54, P215, DOI 10.1016/S0360-3016(02)02938-3
   LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0
   LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7
   Mahadevan D, 2004, BLOOD, V104, P1940, DOI 10.1182/blood-2003-07-2490
   Mansoori B, 2017, ADV PHARM BULL, V7, P339, DOI 10.15171/apb.2017.041
   Marangolo M, 2006, ONCOL REP, V16, P233
   MARIE JP, 1991, BLOOD, V78, P586
   Matei D, 2012, CANCER RES, V72, P2197, DOI 10.1158/0008-5472.CAN-11-3909
   Matsumoto S, 2011, CANCER RES, V71, P6350, DOI 10.1158/0008-5472.CAN-11-2025
   Matsumoto Y, 1997, CANCER RES, V57, P5086
   MILLER TP, 1991, J CLIN ONCOL, V9, P17, DOI 10.1200/JCO.1991.9.1.17
   Minchinton AI, 2006, NAT REV CANCER, V6, P583, DOI 10.1038/nrc1893
   NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840
   O'Hare T, 2007, BLOOD, V110, P2242, DOI 10.1182/blood-2007-03-066936
   Orr GA, 2003, ONCOGENE, V22, P7280, DOI 10.1038/sj.onc.1206934
   Pasquier E, 2010, NAT REV CLIN ONCOL, V7, P455, DOI 10.1038/nrclinonc.2010.82
   Pavlopoulou A, 2016, CANCER LETT, V380, P485, DOI 10.1016/j.canlet.2016.07.018
   Pouysségur J, 2006, NATURE, V441, P437, DOI 10.1038/nature04871
   Raghunand N, 1999, BRIT J CANCER, V80, P1005, DOI 10.1038/sj.bjc.6690455
   Raghunand N, 2003, BIOCHEM PHARMACOL, V66, P1219, DOI 10.1016/S0006-2952(03)00468-4
   Ribatti D, 2008, ANGIOGENESIS, V11, P3, DOI 10.1007/s10456-008-9092-6
   RICE GC, 1987, P NATL ACAD SCI USA, V84, P9261, DOI 10.1073/pnas.84.24.9261
   RICE GC, 1986, P NATL ACAD SCI USA, V83, P5978, DOI 10.1073/pnas.83.16.5978
   Robey RW, 2007, CANCER METAST REV, V26, P39, DOI 10.1007/s10555-007-9042-6
   Ross DD, 1999, J NATL CANCER I, V91, P429, DOI 10.1093/jnci/91.5.429
   Rouzier R, 2005, P NATL ACAD SCI USA, V102, P8315, DOI 10.1073/pnas.0408974102
   SCHINKEL AH, 1994, CELL, V77, P491, DOI 10.1016/0092-8674(94)90212-7
   Sève P, 2005, MOL CANCER THER, V4, P2001, DOI 10.1158/1535-7163.MCT-05-0244
   Shain KH, 2001, MOL CANCER THER, V1, P69
   Shaked Y, 2008, CANCER CELL, V14, P263, DOI 10.1016/j.ccr.2008.08.001
   Sherlach KS, 2014, FRONT PHYSIOL, V5, DOI 10.3389/fphys.2014.00108
   Shukla S, 2012, DRUG RESIST UPDATE, V15, P70, DOI 10.1016/j.drup.2012.01.005
   Siddik ZH, 2003, ONCOGENE, V22, P7265, DOI 10.1038/sj.onc.1206933
   SIKIC BI, 1993, J CLIN ONCOL, V11, P1629, DOI 10.1200/JCO.1993.11.9.1629
   Sikic BI, 1997, SEMIN HEMATOL, V34, P40
   SPEARS CP, 1995, HEMATOL ONCOL CLIN N, V9, P397
   STEUART CD, 1971, NATURE-NEW BIOL, V233, P109, DOI 10.1038/newbio233109a0
   Swanton C, 2012, CANCER RES, V72, P4875, DOI 10.1158/0008-5472.CAN-12-2217
   Synold TW, 2001, NAT MED, V7, P584, DOI 10.1038/87912
   Szakács G, 2006, NAT REV DRUG DISCOV, V5, P219, DOI 10.1038/nrd1984
   Szklarczyk D, 2017, NUCLEIC ACIDS RES, V45, pD362, DOI 10.1093/nar/gkw937
   TANIZAWA A, 1992, CANCER RES, V52, P1848
   TANNOCK I, 1978, CANCER TREAT REP, V62, P1117
   TANNOCK IF, 1968, BRIT J CANCER, V22, P258, DOI 10.1038/bjc.1968.34
   Torgovnick A, 2015, FRONT GENET, V6, DOI 10.3389/fgene.2015.00157
   Wagner P, 2005, CELL CYCLE, V4, P1149, DOI 10.4161/cc.4.9.2038
   Wang D, 2005, NAT REV DRUG DISCOV, V4, P307, DOI 10.1038/nrd1691
   WANG GL, 1995, J BIOL CHEM, V270, P1230, DOI 10.1074/jbc.270.3.1230
   Wang YC, 2006, GENE CHROMOSOME CANC, V45, P365, DOI 10.1002/gcc.20300
   Westover D, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0362-9
   Wilting RH, 2012, DRUG RESIST UPDATE, V15, P21, DOI 10.1016/j.drup.2012.01.008
   WOODHOUSE JR, 1995, ANN MED, V27, P157, DOI 10.3109/07853899509031953
   Xu Y, 2002, ANN ONCOL, V13, P1841, DOI 10.1093/annonc/mdf337
   Yusuf RZ, 2003, CURR CANCER DRUG TAR, V3, P1, DOI 10.2174/1568009033333754
   Zeller C, 2012, ONCOGENE, V31, P4567, DOI 10.1038/onc.2011.611
NR 127
TC 370
Z9 400
U1 7
U2 141
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0262-0898
EI 1573-7276
J9 CLIN EXP METASTAS
JI Clin. Exp. Metastasis
PD APR
PY 2018
VL 35
IS 4
SI SI
BP 309
EP 318
DI 10.1007/s10585-018-9903-0
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA GO5YM
UT WOS:000440110000008
PM 29799080
HC Y
HP N
DA 2025-01-12
ER

PT J
AU Li, LDXY
   Zhou, JX
   Calvet, JP
   Godwin, AK
   Jensen, RA
   Li, XG
AF Li, Linda Xiaoyan
   Zhou, Julie Xia
   Calvet, James P.
   Godwin, Andrew K.
   Jensen, Roy A.
   Li, Xiaogang
TI Lysine methyltransferase SMYD2 promotes triple negative breast cancer
   progression
SO CELL DEATH & DISEASE
LA English
DT Article
ID NF-KAPPA-B; HISTONE METHYLTRANSFERASE; CELL PROLIFERATION;
   ESTROGEN-RECEPTOR; METHYLATION; STAT3; PROTEIN; INFLAMMATION;
   ACTIVATION; DISEASE
AB We identified SMYD2, a SMYD (SET and MYND domain) family protein with lysine methyltransferase activity, as a novel breast cancer oncogene. SMYD2 was expressed at significantly higher levels in breast cancer cell lines and in breast tumor tissues. Silencing of SMYD2 by RNAi in triple-negative breast cancer (TNBC) cell lines or inhibition of SMYD2 with its specific inhibitor, AZ505, significantly reduced tumor growth in vivo. SMYD2 executes this activity via methylation and activation of its novel non-histone substrates, including STAT3 and the p65 subunit of NF-kappa B, leading to increased TNBC cell proliferation and survival. There are cross-talk and synergistic effects among SMYD2, STAT3, and NF-kappa B in TNBC cells, in that STAT3 can contribute to the modification of NF-kappa B p65 subunit post-translationally by recruitment of SMYD2, whereas the p65 subunit of NF-kappa B can also contribute to the modification of STAT3 post-translationally by recruitment of SMYD2, leading to methylation and activation of STAT3 and p65 in these cells. The expression of SMYD2 can be upregulated by IL-6-STAT3 and TNF alpha-NF-kappa B signaling, which integrates epigenetic regulation to inflammation in TNBC development. In addition, we have identified a novel SMYD2 transcriptional target gene, PTPN13, which links SMYD2 to other known breast cancer associated signaling pathways, including ERK, mTOR, and Akt signaling via PTPN13 mediated phosphorylation.
C1 [Li, Linda Xiaoyan; Zhou, Julie Xia; Li, Xiaogang] Univ Kansas, Dept Internal Med, Med Ctr, Kansas City, KS 66160 USA.
   [Calvet, James P.; Li, Xiaogang] Univ Kansas, Dept Biochem & Mol Biol, Med Ctr, Kansas City, KS 66160 USA.
   [Calvet, James P.; Li, Xiaogang] Univ Kansas, Dept Canc Biol, Med Ctr, Kansas City, KS 66160 USA.
   [Godwin, Andrew K.; Jensen, Roy A.] Univ Kansas, Dept Pathol & Lab Med, Med Ctr, Kansas City, KS 66160 USA.
C3 University of Kansas; University of Kansas Medical Center; University of
   Kansas; University of Kansas Medical Center; University of Kansas;
   University of Kansas Medical Center; University of Kansas; University of
   Kansas Medical Center
RP Li, XG (通讯作者)，Univ Kansas, Dept Internal Med, Med Ctr, Kansas City, KS 66160 USA.; Li, XG (通讯作者)，Univ Kansas, Dept Biochem & Mol Biol, Med Ctr, Kansas City, KS 66160 USA.; Li, XG (通讯作者)，Univ Kansas, Dept Canc Biol, Med Ctr, Kansas City, KS 66160 USA.
EM xli3@kumc.edu
RI Jensen, Roy/B-9739-2011
OI Jensen, Roy/0000-0003-4430-2281
FU National Institutes of Health [R01 DK084097, P30 DK106912, P30
   CA168524]; PKD Foundation; Kansas Research and Translation Core Center
   [P30 DK106912]; Institutional Development Award (IDeA) from the National
   Institute of General Medical Sciences [P20 GM103418]; NIH [K01 DK107729]
FX We acknowledge Dr. Joan Lewis-Wambi and Dr. Christy Hagan for providing
   us the T47D cells. We acknowledge Dr. Bruno Hagenbuch for helping us
   with the in vitro methylation assays. X. Li acknowledges support from
   National Institutes of Health grant R01 DK084097 and P30 DK106912. J.P.
   Calvet acknowledges support from the PKD Foundation and from the Kansas
   Research and Translation Core Center (P30 DK106912). A.K. Godwin and R.
   Jensen acknowledge support from National Institutes of Health grant P30
   CA168524. L.X. Li acknowledges support from a post-doctoral fellowship
   funded by an Institutional Development Award (IDeA) from the National
   Institute of General Medical Sciences (P20 GM103418). J.X. Zhou
   acknowledges support from the NIH K01 DK107729.
CR Abu-Farha M, 2008, MOL CELL PROTEOMICS, V7, P560, DOI 10.1074/mcp.M700271-MCP200
   Alonso A, 2004, CELL, V117, P699, DOI 10.1016/j.cell.2004.05.018
   Brenton JD, 2005, J CLIN ONCOL, V23, P7350, DOI 10.1200/JCO.2005.03.3845
   Brown MA, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-26
   Carey L, 2010, NAT REV CLIN ONCOL, V7, P683, DOI 10.1038/nrclinonc.2010.154
   Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095
   Claude-Taupin A, 2015, METHODS MOL BIOL, V1238, P487, DOI 10.1007/978-1-4939-1804-1_25
   Crown J, 2012, ANN ONCOL, V23, P56, DOI 10.1093/annonc/mds196
   Ferguson AD, 2011, STRUCTURE, V19, P1262, DOI 10.1016/j.str.2011.06.011
   Gao H, 2014, P NATL ACAD SCI USA, V111, P16532, DOI 10.1073/pnas.1403234111
   Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088
   Gluz O, 2009, ANN ONCOL, V20, P1913, DOI 10.1093/annonc/mdp492
   Gottlieb PD, 2002, NAT GENET, V31, P25, DOI 10.1038/ng866
   Greer EL, 2012, NAT REV GENET, V13, P343, DOI 10.1038/nrg3173
   Haffner MC, 2006, J MAMMARY GLAND BIOL, V11, P63, DOI 10.1007/s10911-006-9013-5
   Hamamoto R, 2004, NAT CELL BIOL, V6, P731, DOI 10.1038/ncb1151
   Hamamoto R, 2014, CANCER LETT, V351, P126, DOI 10.1016/j.canlet.2014.05.014
   He GB, 2011, CELL RES, V21, P159, DOI 10.1038/cr.2010.183
   Hu LP, 2009, CANCER RES, V69, P4067, DOI 10.1158/0008-5472.CAN-08-4097
   Huang J, 2006, NATURE, V444, P629, DOI 10.1038/nature05287
   Joshi CP, 1998, PLANT MOL BIOL, V37, P663, DOI 10.1023/A:1006035210889
   Karin M, 2005, NAT REV IMMUNOL, V5, P749, DOI 10.1038/nri1703
   Karin M, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a000141
   Karsli-Ceppioglu S, 2014, EPIGENOMICS-UK, V6, P651, DOI [10.2217/EPI.14.59, 10.2217/epi.14.59]
   Komatsu S, 2009, CARCINOGENESIS, V30, P1139, DOI 10.1093/carcin/bgp116
   Lee H, 2009, CANCER CELL, V15, P283, DOI 10.1016/j.ccr.2009.02.015
   Li LX, 2017, J CLIN INVEST, V127, P2751, DOI 10.1172/JCI90921
   Li XG, 2005, NAT CELL BIOL, V7, P1202, DOI 10.1038/ncb1326
   Liu LX, 2015, ONCOTARGET, V6, P2466, DOI 10.18632/oncotarget.2967
   Marotta LLC, 2011, J CLIN INVEST, V121, P2723, DOI 10.1172/JCI44745
   Oeckinghaus A, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a000034
   Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093
   Piao L, 2014, NEOPLASIA, V16, DOI 10.1016/j.neo.2014.03.002
   Qin S, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3633
   Roy DM, 2014, PROTEIN CELL, V5, P265, DOI 10.1007/s13238-014-0031-6
   Saddic LA, 2010, J BIOL CHEM, V285, P37733, DOI 10.1074/jbc.M110.137612
   Sardina JL, 2014, BBA-MOL CELL RES, V1843, P2886, DOI 10.1016/j.bbamcr.2014.08.014
   Schmidt D, 2009, METHODS, V48, P240, DOI 10.1016/j.ymeth.2009.03.001
   Shen H, 2013, CELL, V153, P38, DOI 10.1016/j.cell.2013.03.008
   Shuai K, 2003, NAT REV IMMUNOL, V3, P900, DOI 10.1038/nri1226
   Siddiquee K, 2007, P NATL ACAD SCI USA, V104, P7391, DOI 10.1073/pnas.0609757104
   Singh S, 2007, MOL CANCER THER, V6, P1973, DOI 10.1158/1535-7163.MCT-07-0063
   Skawran B, 2008, MODERN PATHOL, V21, P505, DOI 10.1038/modpathol.3800998
   Tian XJ, 2013, CURR CANCER DRUG TAR, V13, P558
   Voelkel T, 2013, BBA-MOL CELL RES, V1833, P812, DOI 10.1016/j.bbamcr.2012.09.012
   Wang YX, 2013, P NATL ACAD SCI USA, V110, P16975, DOI 10.1073/pnas.1315862110
   Xiao GT, 2000, ONCOGENE, V19, P5198, DOI 10.1038/sj.onc.1203894
   Xiao GT, 2011, AM J CANCER RES, V1, P192
   Yu H, 2009, NAT REV CANCER, V9, P798, DOI 10.1038/nrc2734
   Zhang X, 2013, P NATL ACAD SCI USA, V110, P17284, DOI 10.1073/pnas.1307959110
NR 50
TC 81
Z9 86
U1 0
U2 12
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-4889
J9 CELL DEATH DIS
JI Cell Death Dis.
PD FEB 27
PY 2018
VL 9
AR 326
DI 10.1038/s41419-018-0347-x
PG 17
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA FZ2NG
UT WOS:000427414600003
PM 29487338
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU Li, Y
   Zhang, WW
   Liu, PY
   Xu, YM
   Tang, L
   Chen, WW
   Guan, XX
AF Li, Yan
   Zhang, Wenwen
   Liu, Pengying
   Xu, Yumei
   Tang, Lin
   Chen, Weiwei
   Guan, Xiaoxiang
TI Long non-coding RNA FENDRR inhibits cell proliferation and is associated
   with good prognosis in breast cancer
SO ONCOTARGETS AND THERAPY
LA English
DT Article
DE breast cancer; FENDRR; lncRNA; prognosis; proliferation
ID TUMOR MICROENVIRONMENT; CARCINOMAS; EVOLUTION; GENE
AB Introduction: FENDRR is a long non-coding RNA (lncRNA) that mediates the modification of the epigenetic landscape of target promoters by binding to polycomb repressive complex 2. However, the role of FENDRR in breast cancer remains unknown.
   Materials and methods: We detected the expression of FENDRR in 52 breast cancer patients' tissues and five breast cancer cell lines. The association between FENDRR expression and clinicopathological features and prognosis of breast cancer patients was also analyzed. Moreover, cell proliferation assays, flow cytometry analysis, wound-healing assays, and transwell migration assays were performed to detect the biological effects of FENDRR in the breast cancer cells. A xenograft model was used to explore the role of FENDRR expression on tumor growth.
   Results: We found that FENDRR expression was lower in breast cancer cell lines and cancerous tissues than in the adjacent normal tissues. Low expression of FENDRR was associated with a shorter overall survival and a shorter progression-free survival in breast cancer patients (p<0.001, p<0.001, respectively). We found that FENDRR inhibits breast cancer cell proliferation and migration and promotes cell apoptosis, while FENDRR knockdown promotes breast cancer cell proliferation and migration and suppresses cell apoptosis. Finally, we also detected that FENDRR overexpression could inhibit tumor growth in a xenograft model.
   Conclusion: Our data suggested that FENDRR inhibits breast cancer cell proliferation, promotes cell apoptosis, and is associated with good prognosis in breast cancer. Thus, FENDRR plays an important role in the growth and progression of breast cancer.
C1 [Li, Yan; Liu, Pengying; Xu, Yumei; Guan, Xiaoxiang] Southern Med Univ, Jinling Hosp, Sch Med, Dept Med Oncol, Guangzhou 510282, Guangdong, Peoples R China.
   [Zhang, Wenwen] Nanjing Med Univ, Nanjing Hosp 1, Dept Oncol, Nanjing, Jiangsu, Peoples R China.
   [Tang, Lin; Chen, Weiwei; Guan, Xiaoxiang] Nanjing Univ, Med Sch, Jinling Hosp, Dept Med Oncol, Nanjing, Jiangsu, Peoples R China.
C3 Southern Medical University - China; Nanjing Medical University; Nanjing
   University
RP Guan, XX (通讯作者)，Southern Med Univ, Jinling Hosp, Sch Med, Dept Med Oncol, Guangzhou 510282, Guangdong, Peoples R China.
EM xguan@nju.edu.cn
RI Zhang, Wenwen/ABF-4970-2021
OI Zhang, Wenwen/0000-0003-1285-3118; Guan, Xiaoxiang/0000-0001-6145-0046
FU National Natural Science Foundation of China [81470357, 81773102]
FX This project was supported by National Natural Science Foundation of
   China (No 81470357, 81773102).
CR Bussard KM, 2016, BREAST CANCER RES, V18, DOI 10.1186/s13058-016-0740-2
   Calin GA, 2007, CANCER CELL, V12, P215, DOI 10.1016/j.ccr.2007.07.027
   Douglass S, 2012, CANCER METAST REV, V31, P843, DOI 10.1007/s10555-012-9395-3
   Fu XQ, 2006, DNA CELL BIOL, V25, P135, DOI 10.1089/dna.2006.25.135
   Grote P, 2013, RNA BIOL, V10, P1579, DOI 10.4161/rna.26165
   Grote P, 2013, DEV CELL, V24, P206, DOI 10.1016/j.devcel.2012.12.012
   Kessenbrock K, 2010, CELL, V141, P52, DOI 10.1016/j.cell.2010.03.015
   Khalil AM, 2009, P NATL ACAD SCI USA, V106, P11667, DOI 10.1073/pnas.0904715106
   Kim T, COMP BENEFITS OBTAIN
   Lin R, 2007, ONCOGENE, V26, P851, DOI 10.1038/sj.onc.1209846
   Lorusso G, 2008, HISTOCHEM CELL BIOL, V130, P1091, DOI 10.1007/s00418-008-0530-8
   Muers M, 2011, NAT REV GENET, V12, DOI 10.1038/nrg3088
   Pibouin L, 2002, CANCER GENET CYTOGEN, V133, P55, DOI 10.1016/S0165-4608(01)00634-3
   Ponting CP, 2010, HUM MOL GENET, V19, pR162, DOI 10.1093/hmg/ddq362
   Ponting CP, 2009, CELL, V136, P629, DOI 10.1016/j.cell.2009.02.006
   Qi P, 2013, MODERN PATHOL, V26, P155, DOI 10.1038/modpathol.2012.160
   Sauvageau M, 2013, ELIFE, V2, DOI 10.7554/eLife.01749
   Schuettengruber B, 2007, CELL, V128, P735, DOI 10.1016/j.cell.2007.02.009
   Wilusz JE, 2009, GENE DEV, V23, P1494, DOI 10.1101/gad.1800909
   Xu TP, 2014, J HEMATOL ONCOL, V7, DOI 10.1186/s13045-014-0063-7
NR 20
TC 50
Z9 53
U1 1
U2 4
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178-6930
J9 ONCOTARGETS THER
JI OncoTargets Ther.
PY 2018
VL 11
BP 1403
EP 1412
DI 10.2147/OTT.S149511
PG 10
WC Biotechnology & Applied Microbiology; Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Oncology
GA FZ2MH
UT WOS:000427411900001
PM 29559798
OA Green Published, Green Submitted, gold
DA 2025-01-12
ER

PT J
AU Kumari, K
   Das, B
   Adhya, A
   Chaudhary, S
   Senapati, S
   Mishra, SK
AF Kumari, Kanchan
   Das, Biswajit
   Adhya, Amit
   Chaudhary, Sanjib
   Senapati, Shantibhusan
   Mishra, Sandip K.
TI Nicotine associated breast cancer in smokers is mediated through high
   level of EZH2 expression which can be reversed by methyltransferase
   inhibitor DZNepA
SO CELL DEATH & DISEASE
LA English
DT Article
ID HISTONE METHYLTRANSFERASE; DEVELOPMENTAL GENES; CIGARETTE-SMOKING;
   CELLS; INVASION; GROWTH; OVEREXPRESSION; TUMORIGENESIS; METHYLATION;
   REPRESSION
AB Recent studies show substantial growth-promoting properties of nicotine (NIC) in cancer, which is a combined outcome of genetic and epigenetic alterations. However, the role of epigenetic modifiers in response to NIC in breast cancer is less studied. In the present study, for the first time we have shown NIC-induced enhanced EZH2 expression. Six pairs of smoking-associated breast cancer patient tissues were analyzed. Samples from smoking breast cancer patients showed distinguished enhanced EZH2 expression in comparison to non-smoking ones. The upregulation in EZH2, which is due to NIC, was further confirmed in breast carcinoma cell lines using 10 mu M NIC, 1 mu M DZNepA, and EZH2si. The upregulation of EZH2 was concomitant with upregulation in Myc and a9-nAChR. The xenograft of breast cancer cells in BALB/c nude mice in the presence or absence of NIC showed significantly higher tumor uptake in the NIC injected group, which clearly demonstrates the effect of NIC in breast cancer progression. Interestingly, DZNepA considerably suppressed the NIC-mediated tumor growth. CHIP-qPCR assay confirmed the increased Myc enrichment on EZH2 promoter upon NIC treatment, thereby strengthening our findings that there exists an association between NIC, Myc, and EZH2. Overall, the present study identifies a strong association between NIC and EZH2 particularly in the progression of breast cancer in smokers through a novel axis involving nAChR and Myc. Moreover, the findings provide preliminary evidence suggesting potential of high level of EZH2 expression as a prognostic marker in smoking-associated breast cancer.
C1 [Kumari, Kanchan; Mishra, Sandip K.] Inst Life Sci, Dept Gene Funct & Regulat, Canc Biol Lab, Bhubaneswar, Odisha, India.
   [Kumari, Kanchan] Utkal Univ, Bhubaneswar, Odisha, India.
   [Das, Biswajit; Senapati, Shantibhusan] Inst Life Sci, Dept Translat Res, Tumor Microenvironm & Anim Models Lab, Bhubaneswar, Odisha, India.
   [Das, Biswajit] Manipal Univ, Manipal, Karnataka, India.
   [Adhya, Amit] Hemalata Hosp, Pathol Dept, Chandrashekharpur Bhuban, Odisha, India.
   [Chaudhary, Sanjib] Univ Nebraska Med Ctr, Omaha, NE USA.
C3 Department of Biotechnology (DBT) India; Institute of Life Sciences
   India (ILS); Utkal University; Department of Biotechnology (DBT) India;
   Institute of Life Sciences India (ILS); Manipal Academy of Higher
   Education (MAHE); University of Nebraska System; University of Nebraska
   Medical Center
RP Mishra, SK (通讯作者)，Inst Life Sci, Dept Gene Funct & Regulat, Canc Biol Lab, Bhubaneswar, Odisha, India.; Mishra, SK (通讯作者)，Utkal Univ, Bhubaneswar, Odisha, India.
EM sandipkmishra@hotmail.com
RI Kumari, Kanchan/AAE-4773-2019; DAS, BISWAJIT/KBB-5213-2024; KUMARI,
   KANCHAN/KUD-7270-2024
OI Chaudhary, Sanjib/0000-0001-9630-1235; DAS,
   BISWAJIT/0000-0002-5657-5626; KUMARI, KANCHAN/0000-0001-7546-4174;
   Mishra, Sandip/0000-0002-0776-6581; Senapati,
   Shantibhusan/0000-0001-7108-8255
FU DBT, Govt. of India; DST, Govt. of India; Institute of Life Sciences
FX We acknowledge DBT, Govt. of India and DST, Govt. of India, for funding.
   We also acknowledge the Director, Institute of Life Sciences, for the
   core grant as well as his support in the performance of this project.
CR [Anonymous], 2014, J Vis Exp
   Bavarva JH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067252
   Behrens C, 2013, CLIN CANCER RES, V19, P6556, DOI 10.1158/1078-0432.CCR-12-3946
   Carreno BM, 2009, CLIN CANCER RES, V15, P3277, DOI 10.1158/1078-0432.CCR-08-2502
   Chase A, 2011, CLIN CANCER RES, V17, P2613, DOI 10.1158/1078-0432.CCR-10-2156
   Clarke R, 1996, BREAST CANCER RES TR, V39, P69, DOI 10.1007/BF01806079
   Conklin BS, 2002, AM J PATHOL, V160, P413, DOI 10.1016/S0002-9440(10)64859-6
   Conway K, 2002, CANCER RES, V62, P1987
   Dang XM, 2012, CANCER GENET-NY, V205, P113, DOI 10.1016/j.cancergen.2012.01.002
   Dasgupta P, 2006, P NATL ACAD SCI USA, V103, P6332, DOI 10.1073/pnas.0509313103
   Dasgupta P, 2009, INT J CANCER, V124, P36, DOI 10.1002/ijc.23894
   de Haan G, 2007, ANN NY ACAD SCI, V1106, P233, DOI 10.1196/annals.1392.008
   Dinicola S, 2013, TOXICOL IN VITRO, V27, P2256, DOI 10.1016/j.tiv.2013.09.020
   Dong W, 2011, ACTA BIOCH BIOPH SIN, V43, P840, DOI 10.1093/abbs/gmr085
   Faustino-Rocha A, 2013, LAB ANIMAL, V42, P217, DOI 10.1038/laban.254
   Fleming JM, 2010, J CELL PHYSIOL, V224, P795, DOI 10.1002/jcp.22190
   Goel HL, 2013, NAT REV CANCER, V13, P871, DOI 10.1038/nrc3627
   Goel S, 2014, SOUTH ASIAN J CANCER, V3, P200, DOI 10.4103/2278-330X.142958
   Govind AP, 2009, BIOCHEM PHARMACOL, V78, P756, DOI 10.1016/j.bcp.2009.06.011
   Hao JW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057495
   Hogg N, 2003, IMMUNOLOGY, V109, P329, DOI 10.1046/j.1365-2567.2003.01685.x
   Jin Q, 2008, CARCINOGENESIS, V29, P1614, DOI 10.1093/carcin/bgm234
   Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100
   Lee CH, 2010, JNCI-J NATL CANCER I, V102, P1322, DOI 10.1093/jnci/djq300
   Li DH, 1999, CANCER DETECT PREV, V23, P454, DOI 10.1046/j.1525-1500.1999.99059.x
   Lu JYD, 2017, PEERJ, V5, DOI 10.7717/peerj.3933
   Luo JH, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.d1016
   McAllister-Sistilli CG, 1998, PSYCHONEUROENDOCRINO, V23, P175, DOI 10.1016/S0306-4530(97)00080-2
   McDonald JW, 1999, HISTOPATHOLOGY, V34, P439
   Miranda TB, 2009, MOL CANCER THER, V8, P1579, DOI 10.1158/1535-7163.MCT-09-0013
   Morabia A, 1996, AM J EPIDEMIOL, V143, P918, DOI 10.1093/oxfordjournals.aje.a008835
   Neri F, 2012, MOL CELL BIOL, V32, P840, DOI 10.1128/MCB.06148-11
   Nouri-Shirazi M, 2003, IMMUNOLOGY, V109, P365, DOI 10.1046/j.1365-2567.2003.01655.x
   PALMER JR, 1993, EPIDEMIOL REV, V15, P145, DOI 10.1093/oxfordjournals.epirev.a036098
   Paul-Samojedny M, 2005, BBA-MOL BASIS DIS, V1741, P25, DOI 10.1016/j.bbadis.2004.11.021
   Pereira JD, 2010, P NATL ACAD SCI USA, V107, P15957, DOI 10.1073/pnas.1002530107
   Perrot-Applanat M, 2012, CELL ADHES MIGR, V6, P547, DOI 10.4161/cam.23332
   POMERLEAU OF, 1992, AM J MED, V93, pS2, DOI 10.1016/0002-9343(92)90619-M
   PRICE JE, 1990, CANCER RES, V50, P717
   Reynolds P, 2004, JNCI-J NATL CANCER I, V96, P29, DOI 10.1093/jnci/djh002
   Rio DC., 2010, COLD SPRING HARB PRO, V2010, ppdb.prot5439
   Rundle A, 2000, CARCINOGENESIS, V21, P1281, DOI 10.1093/carcin/21.7.1281
   Sander S, 2008, BLOOD, V112, P4202, DOI 10.1182/blood-2008-03-147645
   Shaul YD, 2016, NUCLEIC ACIDS RES, V44, pD560, DOI 10.1093/nar/gkv1337
   Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387
   Talhout R, 2011, INT J ENV RES PUB HE, V8, P613, DOI 10.3390/ijerph8020613
   Tan J, 2007, GENE DEV, V21, P1050, DOI 10.1101/gad.1524107
   Terry PD, 2002, CANCER EPIDEM BIOMAR, V11, P953
   Tran TQ, 2017, CLIN CANCER RES, V23, P4004, DOI 10.1158/1078-0432.CCR-16-2506
   van Meerloo J, 2011, METHODS MOL BIOL, V731, P237, DOI 10.1007/978-1-61779-080-5_20
   Varambally S, 2008, SCIENCE, V322, P1695, DOI 10.1126/science.1165395
   Wang L, 2014, HEPATOLOGY, V59, P1850, DOI 10.1002/hep.26720
   Watson Alexander S, 2015, Cold Spring Harb Protoc, V2015, P756, DOI 10.1101/pdb.prot086280
   Wu CH, 2011, CLIN CANCER RES, V17, P3533, DOI 10.1158/1078-0432.CCR-10-2434
   Yamaguchi H, 2014, CANCER RES TREAT, V46, P209, DOI 10.4143/crt.2014.46.3.209
   Yu MA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051967
   Zong Y, 2009, WORLD J GASTROENTERO, V15, P2500, DOI 10.3748/wjg.15.2500
NR 57
TC 14
Z9 15
U1 1
U2 5
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 2041-4889
J9 CELL DEATH DIS
JI Cell Death Dis.
PD FEB 2
PY 2018
VL 9
AR 152
DI 10.1038/s41419-017-0224-z
PG 14
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA FZ2EI
UT WOS:000427389100013
PM 29396474
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Förster, S
   Hehlgans, S
   Rödel, F
   Otto, B
   Cordes, N
AF Foerster, Sarah
   Hehlgans, Stephanie
   Roedel, Franz
   Otto, Benjamin
   Cordes, Nils
TI Differential effects of -catenin on the invasion and
   radiochemosensitivity of human colorectal cancer cells
SO INTERNATIONAL JOURNAL OF ONCOLOGY
LA English
DT Article
DE colorectal cancer; -catenin; radiochemotherapy; E-cadherin
ID E-CADHERIN; ALPHA-CATENIN; TUMOR PROGRESSION; GENE-EXPRESSION;
   BREAST-CANCER; IN-VITRO; CARCINOMA; LINES; METASTASIS; SURVIVAL
AB Driven by genetic and epigenetic alterations, progression, therapy resistance and metastasis are frequent events in colorectal cancer (CRC). Although often speculated, the function of cell-cell contact for radiochemosensitivity, particularly associated with E-cadherin/catenin complex, warrants further clarification. In this study, we investigated the role of the E-cadherin/catenin complex proteins under more physiological three-dimensional (3D) cell culture conditions in a panel of CRC cell lines. In contrast to floating spheroids and growth in the laminin-rich matrix, collagen type 1 induced the formation of two distinct growth phenotypes, i.e., cell groups and single cells, in 5 out of the 8 CRC cell lines. Further characterization of these subpopulations revealed that, intriguingly, cell-cell contact proteins are important for invasion, but negligible for radiochemosensitivity, proliferation and adhesion. Despite the generation of genomic and transcriptomic data, we were unable to elucidate the mechanisms through which -catenin affects collagen type 1 invasion. In a retrospective analysis of patients with rectal carcinoma, a low -catenin expression trended with overall survival, as well as locoregional and distant control. Our results suggest that the E-cadherin/catenin complex proteins forming cell-cell contacts are mainly involved in the invasion, rather than the radiochemosensitivity of 3D grown CRC cells. Further studies are warranted in order to provide a better understanding of the molecular mechanisms controlling cell-cell adhesion in the context of radiochemoresistance.
C1 [Foerster, Sarah; Cordes, Nils] Helmholtz Zentrum Dresden Rossendorf, Inst Radiooncol OncoRay, D-01328 Dresden, Germany.
   [Foerster, Sarah; Cordes, Nils] Tech Univ Dresden, Fac Med, OncoRay Natl Ctr Radiat Res Oncol, Helmholtz Zentrum Dresden Rossendorf, D-01307 Dresden, Germany.
   [Foerster, Sarah; Cordes, Nils] Tech Univ Dresden, Univ Hosp Carl Gustav Carus, Helmholtz Zentrum Dresden Rossendorf, D-01307 Dresden, Germany.
   [Hehlgans, Stephanie; Roedel, Franz] Goethe Univ Frankfurt, Dept Radiotherapy & Oncol, D-60590 Frankfurt, Germany.
   [Roedel, Franz] German Canc Consortium DKTK, Partner Site Frankfurt, D-60590 Frankfurt, Germany.
   [Roedel, Franz; Cordes, Nils] German Canc Res Ctr, D-69192 Heidelberg, Germany.
   [Otto, Benjamin] Eppendorf AG, D-22339 Hamburg, Germany.
   [Otto, Benjamin] Univ Med Ctr Hamburg Eppendorf, Dept Internal Med, D-20246 Hamburg, Germany.
   [Cordes, Nils] Tech Univ Dresden, Fac Med, Dept Radiotherapy & Radiat Oncol, D-01307 Dresden, Germany.
   [Cordes, Nils] Tech Univ Dresden, Univ Hosp Carl Gustav Carus, D-01307 Dresden, Germany.
   [Cordes, Nils] German Canc Consortium DKTK, Partner Site Dresden, D-69192 Heidelberg, Germany.
C3 Helmholtz Association; Helmholtz-Zentrum Dresden-Rossendorf (HZDR);
   Technische Universitat Dresden; Helmholtz Association; Helmholtz-Zentrum
   Dresden-Rossendorf (HZDR); Helmholtz Association; Helmholtz-Zentrum
   Dresden-Rossendorf (HZDR); Technische Universitat Dresden; Carl Gustav
   Carus University Hospital; Goethe University Frankfurt; Helmholtz
   Association; German Cancer Research Center (DKFZ); Helmholtz
   Association; German Cancer Research Center (DKFZ); University of
   Hamburg; University Medical Center Hamburg-Eppendorf; Technische
   Universitat Dresden; Technische Universitat Dresden; Carl Gustav Carus
   University Hospital; Helmholtz Association; German Cancer Research
   Center (DKFZ)
RP Cordes, N (通讯作者)，Tech Univ Dresden, Fac Med, OncoRay Natl Ctr Radiat Res Oncol, Fetscherstr 74,PF 41, D-01307 Dresden, Germany.; Cordes, N (通讯作者)，Tech Univ Dresden, Univ Hosp Carl Gustav Carus, Fetscherstr 74,PF 41, D-01307 Dresden, Germany.
EM nils.cordes@oncoray.de
OI Cordes, Nils/0000-0001-5684-629X
FU EFRE Europaische Fonds fur regionale Entwicklung, Europa fordert Sachsen
   [100066308]
FX The study and authors were in part supported by the EFRE Europaische
   Fonds fur regionale Entwicklung, Europa fordert Sachsen (100066308).
CR Abe K, 2008, P NATL ACAD SCI USA, V105, P13, DOI 10.1073/pnas.0710504105
   Bissell MJ, 2005, COLD SH Q B, V70, P343, DOI 10.1101/sqb.2005.70.013
   Burrell RA, 2013, NATURE, V501, P338, DOI 10.1038/nature12625
   Canel M, 2013, J CELL SCI, V126, P393, DOI 10.1242/jcs.100115
   Chen XJ, 2016, ONCOTARGET, V7, P55518, DOI 10.18632/oncotarget.10833
   Chen XB, 2012, MOL BIOL REP, V39, P6707, DOI 10.1007/s11033-012-1494-2
   Christou N, 2017, ONCOL LETT, V13, P4571, DOI 10.3892/ol.2017.6063
   Cordes N, 2003, BRIT J CANCER, V89, P2122, DOI 10.1038/sj.bjc.6601429
   Coulson-Thomas VJ, 2011, CELL TISSUE RES, V346, P223, DOI 10.1007/s00441-011-1254-y
   DANEKER GW, 1987, ARCH SURG-CHICAGO, V122, P1470
   Daugherty RL, 2014, P NATL ACAD SCI USA, V111, P5260, DOI 10.1073/pnas.1308663111
   DEXTER DL, 1981, AM J MED, V71, P949, DOI 10.1016/0002-9343(81)90312-0
   Eke I., 2015, J. Biol. Methods, V2, DOI [10.14440/jbm.2015.96, DOI 10.14440/JBM.2015.96]
   Eke I, 2011, RADIOTHER ONCOL, V99, P271, DOI 10.1016/j.radonc.2011.06.007
   Eke I, 2010, J CLIN INVEST, V120, P2516, DOI 10.1172/JCI41078
   El-Bahrawy M, 2004, INT J EXP PATHOL, V85, P65, DOI 10.1111/j.0959-9673.2004.0371.x
   Filiz AI, 2010, COLORECTAL DIS, V12, P1223, DOI 10.1111/j.1463-1318.2009.01994.x
   Fouad YA, 2017, AM J CANCER RES, V7, P1016
   Giannini AL, 2000, J BIOL CHEM, V275, P21883, DOI 10.1074/jbc.M001929200
   Herbst A, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-74
   Huber O, 2015, CELL COMMUN ADHES, V22, P15, DOI 10.3109/15419061.2015.1039642
   Ireton RC, 2002, J CELL BIOL, V159, P465, DOI 10.1083/jcb.200205115
   Jeanes A, 2008, ONCOGENE, V27, P6920, DOI 10.1038/onc.2008.343
   Kenny PA, 2007, MOL ONCOL, V1, P84, DOI 10.1016/j.molonc.2007.02.004
   Kuipers EJ, 2015, NAT REV DIS PRIMERS, V1, DOI 10.1038/nrdp.2015.65
   KWOK TT, 1991, RADIAT RES, V126, P52, DOI 10.2307/3578170
   Lee CC, 2012, J BIOL CHEM, V287, P2798, DOI 10.1074/jbc.M111.258947
   LEITH JT, 1982, CANCER RES, V42, P2556
   Luca AC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059689
   Ludwig K, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-221
   Mazzeo E, 2012, RADIAT RES, V178, P224, DOI 10.1667/RR2855.1
   Mège RM, 2006, CURR OPIN CELL BIOL, V18, P541, DOI 10.1016/j.ceb.2006.08.004
   Meineke V, 2002, STRAHLENTHER ONKOL, V178, P709, DOI 10.1007/s00066-002-0993-9
   Moussa H, 2000, INT J RADIAT BIOL, V76, P1245, DOI 10.1080/09553000050134474
   Mylonas CC, 2014, GASTROENT RES PRACT, V2014, DOI 10.1155/2014/580159
   Ni J, 2013, INT J BIOCHEM CELL B, V45, P2736, DOI 10.1016/j.biocel.2013.09.008
   Peng JF, 2016, FUTURE ONCOL, V12, P715, DOI 10.2217/fon.15.332
   Perez-Moreno M, 2003, CELL, V112, P535, DOI 10.1016/S0092-8674(03)00108-9
   Piao HL, 2014, NAT CELL BIOL, V16, P245, DOI 10.1038/ncb2909
   Plumb CL, 2009, AM J PATHOL, V175, P1662, DOI 10.2353/ajpath.2009.090007
   Poschau M, 2015, RADIOTHER ONCOL, V116, P510, DOI 10.1016/j.radonc.2015.06.005
   Raftopoulos I, 1998, J SURG ONCOL, V68, P92, DOI 10.1002/(SICI)1096-9098(199806)68:2<92::AID-JSO4>3.0.CO;2-F
   Rajwar YC, 2015, J CLIN DIAGN RES, V9, pZE5, DOI 10.7860/JCDR/2015/11964.5907
   Rodriguez FJ, 2012, BBA-REV CANCER, V1826, P23, DOI 10.1016/j.bbcan.2012.03.002
   Rödel C, 2007, J CLIN ONCOL, V25, P110, DOI 10.1200/JCO.2006.08.3675
   Schlingemann J, 2005, LAB INVEST, V85, P1024, DOI 10.1038/labinvest.3700293
   Stein A, 2014, WORLD J GASTROENTERO, V20, P899, DOI 10.3748/wjg.v20.i4.899
   Takaya Y, 2008, ANTICANCER RES, V28, P3665
   van Roy F, 2008, CELL MOL LIFE SCI, V65, P3756, DOI 10.1007/s00018-008-8281-1
   Vellinga TT, 2016, ONCOGENE, V35, P5263, DOI 10.1038/onc.2016.60
   VERMEULEN SJ, 1995, CANCER RES, V55, P4722
   Vermeulen SJ, 1998, CANCER GENET CYTOGEN, V107, P76, DOI 10.1016/S0165-4608(98)00081-8
   Yuan DD, 2015, J CANCER RES CLIN, V141, P647, DOI 10.1007/s00432-014-1814-0
   Zeisberg M, 2009, J CLIN INVEST, V119, P1429, DOI 10.1172/JCI36183
   Zschenker O, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034279
NR 55
TC 4
Z9 5
U1 0
U2 4
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1019-6439
EI 1791-2423
J9 INT J ONCOL
JI Int. J. Oncol.
PD APR
PY 2018
VL 52
IS 4
BP 1117
EP 1128
DI 10.3892/ijo.2018.4279
PG 12
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA FY9DA
UT WOS:000427164400007
PM 29484367
OA Green Published, Green Submitted, hybrid
DA 2025-01-12
ER

PT J
AU Gampenrieder, SP
   Rinnerthaler, G
   Hackl, H
   Pulverer, W
   Weinhaeusel, A
   Ilic, S
   Hufnagl, C
   Hauser-Kronberger, C
   Egle, A
   Risch, A
   Greil, R
AF Gampenrieder, Simon Peter
   Rinnerthaler, Gabriel
   Hackl, Hubert
   Pulverer, Walter
   Weinhaeusel, Andreas
   Ilic, Suzana
   Hufnagl, Clemens
   Hauser-Kronberger, Cornelia
   Egle, Alexander
   Risch, Angela
   Greil, Richard
TI DNA Methylation Signatures Predicting Bevacizumab Efficacy in Metastatic
   Breast Cancer
SO THERANOSTICS
LA English
DT Article
DE Metastatic breast cancer; bevacizumab; methylation; signature;
   predictive
ID PHASE-III TRIAL; PACLITAXEL PLUS BEVACIZUMAB; 1ST-LINE THERAPY;
   DRUG-RESISTANCE; GROWTH-FACTOR; BIOMARKER EVALUATION; DOUBLE-BLIND;
   CHEMOTHERAPY; COMBINATION; CONTRIBUTES
AB Background: Biomarkers predicting response to bevacizumab in breast cancer are still missing. Since epigenetic modifications can contribute to an aberrant regulation of angiogenesis and treatment resistance, we investigated the influence of DNA methylation patterns on bevacizumab efficacy.
   Methods: Genome-wide methylation profiling using the Illumina Infinium HumanMethylation450 BeadChip was performed in archival FFPE specimens of 36 patients with HER2-negative metastatic breast cancer treated with chemotherapy in combination with bevacizumab as first-line therapy (learning set). Based on objective response and progression-free survival (PFS) and considering ER expression, patients were divided in responders (R) and non-responders (NR). Significantly differentially methylated gene loci (CpGs) with a strong change in methylation levels (Delta beta>0.15 or Delta beta<-0.15) between R and NR were identified and further investigated in 80 bevacizumab-treated breast cancer patients (optimization set) and in 15 patients treated with chemotherapy alone (control set) using targeted deep amplicon bisulfite sequencing. Methylated gene loci were considered predictive if there was a significant association with outcome (PFS) in the optimization set but not in the control set using Spearman rank correlation, Cox regression, and logrank test.
   Results: Differentially methylated loci in 48 genes were identified, allowing a good separation between R and NR (odds ratio (OR) 101, p<0.0001). Methylation of at least one cytosine in 26 gene-regions was significantly associated with progression-free survival (PFS) in the optimization set, but not in the control set. Using information from the optimization set, the panel was reduced to a 9-gene signature, which could divide patients from the learning set into 2 clusters, thereby predicting response with an OR of 40 (p<0.001) and an AUC of 0.91 (LOOCV). A further restricted 3-gene methylation model showed a significant association of predicted responders with longer PFS in the learning and optimization set even in multivariate analysis with an excellent and good separation of R and NR with AUC=0.94 and AUC=0.86, respectively.
   Conclusion: Both a 9-gene and 3-gene methylation signature can discriminate between R and NR to a bevacizumab-based therapy in MBC and could help identify patients deriving greater benefit from bevacizumab.
C1 [Gampenrieder, Simon Peter; Rinnerthaler, Gabriel; Egle, Alexander; Greil, Richard] Paracelsus Med Univ Salzburg, Med Dept Hematol Med Oncol Hemostaseol Infect Dis, Oncol Ctr, Salzburg, Austria.
   [Gampenrieder, Simon Peter; Rinnerthaler, Gabriel; Egle, Alexander; Greil, Richard] Paracelsus Med Univ Salzburg, SCRI, LIMCR, Salzburg, Austria.
   [Gampenrieder, Simon Peter; Rinnerthaler, Gabriel; Egle, Alexander; Greil, Richard] Paracelsus Med Univ Salzburg, CCCIT, Salzburg, Austria.
   [Hackl, Hubert] Med Univ Innsbruck, Bioctr, Div Bioinformat, Innsbruck, Austria.
   [Pulverer, Walter; Weinhaeusel, Andreas; Ilic, Suzana] AIT Austrian Inst Technol GmbH, Business Unit Mol Diagnost, Ctr Hlth & Bioresources, Vienna, Austria.
   [Hufnagl, Clemens; Hauser-Kronberger, Cornelia] Paracelsus Med Univ Salzburg, Dept Pathol, Salzburg, Austria.
   [Risch, Angela] Univ Salzburg, Div Canc Genet Epigenet, Dept Mol Biol, Salzburg, Austria.
   [Risch, Angela; Greil, Richard] Canc Cluster Salzburg, Salzburg, Austria.
C3 Paracelsus Private Medical University; Paracelsus Private Medical
   University; Paracelsus Private Medical University; Medical University of
   Innsbruck; Austrian Institute of Technology (AIT); Paracelsus Private
   Medical University; Salzburg University
RP Greil, R (通讯作者)，Paracelsus Med Univ Salzburg, Dept Internal Med 3, Mullner Hauptstr 48, A-5020 Salzburg, Austria.
EM r.greil@salk.at
RI Egle, Alexander/AAC-3787-2020; Weinhaeusel, Andreas/A-7644-2018;
   Rinnerthaler, Gabriel/GZM-5613-2022; Gampenrieder, Simon/AFM-7798-2022;
   Greil, Richard/C-7673-2017; Hackl, Hubert/B-3168-2018; Risch,
   Angela/H-2669-2013
OI Rinnerthaler, Gabriel/0000-0001-7438-1465; Egle,
   Alexander/0000-0003-0648-4416; Hackl, Hubert/0000-0003-4055-3841;
   Weinhaeusel, Andreas/0000-0002-9318-1204; Risch,
   Angela/0000-0002-8026-5505
FU ROCHE Austria GmbH
FX This research project was partially supported by ROCHE Austria GmbH.
CR [Anonymous], 2010, ASCO GASTR CANC S OR
   [Anonymous], 2012, EVOLUTION TRANSLATIO
   Antequera F, 1999, CURR BIOL, V9, pR661, DOI 10.1016/S0960-9822(99)80418-7
   Bernstein BE, 2007, CELL, V128, P669, DOI 10.1016/j.cell.2007.01.033
   Brufsky AM, 2011, J CLIN ONCOL, V29, P4286, DOI 10.1200/JCO.2010.34.1255
   Burstein HJ, 2008, CLIN CANCER RES, V14, P7871, DOI 10.1158/1078-0432.CCR-08-0593
   Butcher LM, 2015, METHODS, V72, P21, DOI 10.1016/j.ymeth.2014.10.036
   Cameron D, 2013, LANCET ONCOL, V14, P933, DOI 10.1016/S1470-2045(13)70335-8
   Cardoso F, 2016, NEW ENGL J MED, V375, P717, DOI 10.1056/NEJMoa1602253
   Chae H, 2016, BMC SYST BIOL, V10, DOI 10.1186/s12918-016-0356-2
   Cheang MCU, 2012, CLIN CANCER RES, V18, P2402, DOI 10.1158/1078-0432.CCR-11-2956
   Chen CC, 2015, CANCER CELL INT, V15, DOI 10.1186/s12935-015-0248-3
   Cherny NI, 2015, ANN ONCOL, V26, P1547, DOI 10.1093/annonc/mdv249
   Chia SK, 2012, CLIN CANCER RES, V18, P4465, DOI 10.1158/1078-0432.CCR-12-0286
   Du M, 2014, MOL MED REP, V10, P1051, DOI 10.3892/mmr.2014.2276
   Egger G, 2012, EXPERT REV MOL DIAGN, V12, P75, DOI 10.1586/ERM.11.90
   Gampenrieder SP, 2014, ANTICANCER RES, V34, P227
   Gianni L, 2013, J CLIN ONCOL, V31, P1719, DOI 10.1200/JCO.2012.44.7912
   Gulyaeva LF, 2016, J TRANSL MED, V14, DOI 10.1186/s12967-016-0893-x
   Hurwitz HI, 2013, ONCOLOGIST, V18, P273, DOI 10.1634/theoncologist.2012-0339
   Jubb AM, 2011, CLIN CANCER RES, V17, P372, DOI 10.1158/1078-0432.CCR-10-1791
   Liu G, 2014, ONCOL REP, V32, P581, DOI 10.3892/or.2014.3224
   Long MD, 2017, BIOMOLECULES, V7, DOI 10.3390/biom7010015
   Lund RJ, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-01624-4
   Ma XK, 2017, BMC BIOINFORMATICS, V18, DOI 10.1186/s12859-017-1490-6
   Miles DW, 2013, ANN ONCOL, V24, P2773, DOI 10.1093/annonc/mdt276
   Miles D, 2017, EUR J CANCER, V70, P146, DOI 10.1016/j.ejca.2016.09.024
   Miles DW, 2010, J CLIN ONCOL, V28, P3239, DOI 10.1200/JCO.2008.21.6457
   Miles DW, 2013, BR J CANC
   Miller K, 2007, NEW ENGL J MED, V357, P2666, DOI 10.1056/NEJMoa072113
   Miller KD, 2005, J CLIN ONCOL, V23, P792, DOI 10.1200/JCO.2005.05.098
   Mohammad HP, 2015, CANCER CELL, V28, P57, DOI 10.1016/j.ccell.2015.06.002
   Morris TJ, 2014, BIOINFORMATICS, V30, P428, DOI 10.1093/bioinformatics/btt684
   Noehammer C, 2014, EPIGENOMICS-UK, V6, P603, DOI [10.2217/EPI.14.43, 10.2217/epi.14.43]
   Pabinger S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0160227
   Pandey RV, 2016, CLIN EPIGENETICS, V8, DOI 10.1186/s13148-016-0269-3
   Robert NJ, 2011, J CLIN ONCOL, V29, P1252, DOI 10.1200/JCO.2010.28.0982
   Rossari JR, 2012, J ONCOL, V2012, DOI 10.1155/2012/417673
   Schneider BP, 2008, J CLIN ONCOL, V26, P4672, DOI 10.1200/JCO.2008.16.1612
   Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098
   Touleimat N, 2012, EPIGENOMICS-UK, V4, P325, DOI [10.2217/EPI.12.21, 10.2217/epi.12.21]
   van Beijnum JR, 2015, PHARMACOL REV, V67, P441, DOI 10.1124/pr.114.010215
   Van Cutsem E, 2012, J CLIN ONCOL, V30, P2119, DOI 10.1200/JCO.2011.39.9824
   Vrdoljak E, 2016, ANN ONCOL, V27, P2046, DOI 10.1093/annonc/mdw316
   Wagner AD, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008941.pub2
   Wang D, 2012, BIOINFORMATICS, V28, P729, DOI 10.1093/bioinformatics/bts013
   Wang QY, 2015, FRONT BIOSCI-LANDMRK, V20, P728, DOI 10.2741/4333
   Weinhaeusel A, 2008, CLIN CHEM, V54, P1537, DOI 10.1373/clinchem.2008.104216
NR 48
TC 25
Z9 26
U1 0
U2 7
PU IVYSPRING INT PUBL
PI LAKE HAVEN
PA PO BOX 4546, LAKE HAVEN, NSW 2263, AUSTRALIA
SN 1838-7640
J9 THERANOSTICS
JI Theranostics
PY 2018
VL 8
IS 8
BP 2278
EP 2288
DI 10.7150/thno.23544
PG 11
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA FY8IJ
UT WOS:000427107300019
PM 29721079
OA Green Submitted, gold, Green Published
DA 2025-01-12
ER

PT J
AU Perrier, F
   Novoloaca, A
   Ambatipudi, S
   Baglietto, L
   Ghantous, A
   Perduca, V
   Barrdahl, M
   Harlid, S
   Ong, KK
   Cardona, A
   Polidoro, S
   Nost, TH
   Overvad, K
   Omichessan, H
   Dollé, M
   Bamia, C
   Huerta, JM
   Vineis, P
   Herceg, Z
   Romieu, I
   Ferrari, P
AF Perrier, Flavie
   Novoloaca, Alexei
   Ambatipudi, Srikant
   Baglietto, Laura
   Ghantous, Akram
   Perduca, Vittorio
   Barrdahl, Myrto
   Harlid, Sophia
   Ong, Ken K.
   Cardona, Alexia
   Polidoro, Silvia
   Nost, Therese Haugdahl
   Overvad, Kim
   Omichessan, Hanane
   Dolle, Martijn
   Bamia, Christina
   Maria Huerta, Jose
   Vineis, Paolo
   Herceg, Zdenko
   Romieu, Isabelle
   Ferrari, Pietro
TI Identifying and correcting epigenetics measurements for systematic
   sources of variation
SO CLINICAL EPIGENETICS
LA English
DT Article
DE Epigenetics; PC-PR2; Normalization; Methylation; Smoking status
ID DNA METHYLATION ARRAY; GENE-EXPRESSION DATA; UNWANTED VARIATION;
   MICROARRAY; CANCER; SMOKING; REGRESSION; FOLATE; BIAS
AB Background: Methylation measures quantified by microarray techniques can be affected by systematic variation due to the technical processing of samples, which may compromise the accuracy of the measurement process and contribute to bias the estimate of the association under investigation. The quantification of the contribution of the systematic source of variation is challenging in datasets characterized by hundreds of thousands of features. In this study, we introduce a method previously developed for the analysis of metabolomics data to evaluate the performance of existing normalizing techniques to correct for unwanted variation. Illumina Infinium HumanMethylation450K was used to acquire methylation levels in over 421,000 CpG sites for 902 study participants of a case-control study on breast cancer nested within the EPIC cohort. The principal component partial R-square (PC-PR2) analysis was used to identify and quantify the variability attributable to potential systematic sources of variation. Three correcting techniques, namely ComBat, surrogate variables analysis (SVA) and a linear regression model to compute residuals were applied. The impact of each correcting method on the association between smoking status and DNA methylation levels was evaluated, and results were compared with findings from a large meta-analysis.
   Results: A sizeable proportion of systematic variability due to variables expressing 'batch' and 'sample position' within 'chip' was identified, with values of the partial R-2 statistics equal to 9.5 and 11.4% of total variation, respectively. After application of ComBat or the residuals' methods, the contribution was 1.3 and 0.2%, respectively. The SVA technique resulted in a reduced variability due to 'batch' (1.3%) and 'sample position' (0.6%), and in a diminished variability attributable to 'chip' within a batch (0.9%). After ComBat or the residuals' corrections, a larger number of significant sites (k = 600 and k = 427, respectively) were associated to smoking status than the SVA correction (k = 96).
   Conclusions: The three correction methods removed systematic variation in DNA methylation data, as assessed by the PC-PR2, which lent itself as a useful tool to explore variability in large dimension data. SVA produced more conservative findings than ComBat in the association between smoking and DNA methylation.
C1 [Perrier, Flavie; Ferrari, Pietro] WHO, IARC, Nutr Methodol & Biostat Grp, 150 Cours Albert Thomas, F-69372 Lyon 08, France.
   [Novoloaca, Alexei; Ambatipudi, Srikant; Ghantous, Akram; Herceg, Zdenko] IARC, Epigenet Grp, Lyon, France.
   [Baglietto, Laura] Univ Pisa, Dept Clin & Expt Med, Pisa, Italy.
   [Perduca, Vittorio] Univ Paris 05, Sorbonne Paris Cite, CNRS, UMR 8145,MAP5, Paris, France.
   [Barrdahl, Myrto] German Canc Res Ctr, Div Canc Epidemiol, Heidelberg, Germany.
   [Harlid, Sophia] Umea Univ, Dept Radiat Sci, Oncol, Umea, Sweden.
   [Ong, Ken K.; Cardona, Alexia] Univ Cambridge, Sch Clin Med, Inst Metab Sci, MRC Epidemiol Unit, Cambridge, England.
   [Polidoro, Silvia] IIGM, Turin, Italy.
   [Nost, Therese Haugdahl] UiT Arctic Univ Norway, Dept Community Med, Tromso, Norway.
   [Overvad, Kim] Aarhus Univ, Dept Publ Hlth, Sect Epidemiol, Aarhus, Denmark.
   [Overvad, Kim] Aalborg Univ Hosp, Dept Cardiol, Aalborg, Denmark.
   [Omichessan, Hanane] Univ Paris Saclay, Univ Paris Sud, INSERM, CESP,Fac Med,UVSQ, Villejuif, France.
   [Omichessan, Hanane] Gustave Roussy, Villejuif, France.
   [Dolle, Martijn] Natl Inst Publ Hlth & Environm RIVM, Ctr Hlth Protect Pb12, Bilthoven, Netherlands.
   [Bamia, Christina] Hellenic Hlth Fdn, Athens, Greece.
   [Bamia, Christina] Univ Athens, WHO Collaborating Ctr Nutr & Hlth, Unit Nutr Epidemiol & Nutr Publ Hlth, Sch Med,Dept Hyg Epidemiol & Med Stat, Athens, Greece.
   [Maria Huerta, Jose] Murcia Reg Hlth Council, IMIB Arrixaca, Dept Epidemiol, Murcia, Spain.
   [Maria Huerta, Jose] CIBER Epidemiol & Salud Publ CIBERESP, Madrid, Spain.
   [Vineis, Paolo] Imperial Coll London, Sch Publ Hlth, MRC PHE Ctr Environm & Hlth, London, England.
   [Romieu, Isabelle] IARC, Nutr Epidemiol Grp, Lyon, France.
C3 World Health Organization; International Agency for Research on Cancer
   (IARC); World Health Organization; International Agency for Research on
   Cancer (IARC); University of Pisa; Universite Paris Cite; IMT - Institut
   Mines-Telecom; Institut Polytechnique de Paris; Telecom SudParis; Centre
   National de la Recherche Scientifique (CNRS); CNRS - National Institute
   for Mathematical Sciences (INSMI); Helmholtz Association; German Cancer
   Research Center (DKFZ); Umea University; University of Cambridge;
   Italian Institute for Genomic Medicine (IIGM); UiT The Arctic University
   of Tromso; Aarhus University; Aalborg University; Aalborg University
   Hospital; Universite Paris Saclay; Institut National de la Sante et de
   la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy; Netherlands
   National Institute for Public Health & the Environment; National &
   Kapodistrian University of Athens; Athens Medical School; Murcia
   Regional Health Council; Hospital Clinico Universitario Virgen de la
   Arrixaca; CIBER - Centro de Investigacion Biomedica en Red; CIBERESP;
   Imperial College London; World Health Organization; International Agency
   for Research on Cancer (IARC)
RP Ferrari, P (通讯作者)，WHO, IARC, Nutr Methodol & Biostat Grp, 150 Cours Albert Thomas, F-69372 Lyon 08, France.
EM ferrarip@iarc.fr
RI Ambatipudi, Srikant/GLV-6259-2022; Baglietto, Laura/AAB-9051-2019;
   GHANTOUS, Akram/C-1689-2017; Harlid, Sophia/AAJ-5809-2021; Herceg,
   Zdenko/JOZ-6188-2023; Perduca, Vittorio/ABF-4264-2020; Nøst,
   Therese/AGZ-1100-2022; Polidoro, Silvia/GYJ-3517-2022; Huerta, Jose
   Maria/N-8654-2015
OI Polidoro, Silvia/0000-0003-2968-0575; Perrier,
   Flavie/0000-0001-6979-9656; Overvad, Kim/0000-0001-6429-7921; Huerta,
   Jose Maria/0000-0002-9637-3869; Baglietto, Laura/0000-0002-8193-7529;
   Cardona, Alexia/0000-0002-7877-5565; Perduca,
   Vittorio/0000-0003-0339-0473; Novoloaca, Alexei/0009-0002-2080-2628;
   Ambatipudi, Srikant/0000-0003-3102-3603; Nost, Therese
   Haugdahl/0000-0001-6805-3094; Herceg, Zdenko/0000-0003-4109-3154
FU Fondation de France [2015 00060737]; Institut National du Cancer (INCa,
   France) [2012-070]; European Commission (EC); Fondation Association pour
   la Recherche contre le Cancer (ARC, France); EC FP7 EurocanPlatform: A
   European Platform for Translational Cancer Research [260791];
   International Agency for Research on Cancer; EC FP7 Marie Curie Actions;
   Swedish Cancer Society; Swedish Research Council; County Council of
   Skane; County Council of Vasterbotten; MRC [MC_UU_12015/1,
   MC_UU_12015/2, MR/L00002/1]; UiT - the Arctic University of Norway;
   EPIC-Greece; MRC [MC_UU_12015/1, MC_UU_12015/2] Funding Source: UKRI
FX This work was supported by 'Fondation de France' (2015 00060737) through
   a doctoral fellow to FP. A grant from the Institut National du Cancer
   (INCa, France) (2012-070) was awarded to IR and ZH. ZH was also
   supported by the European Commission (EC) Seventh Framework Programme
   (FP7) Translational Cancer Research (TRANSCAN) Framework, the Fondation
   Association pour la Recherche contre le Cancer (ARC, France) and the EC
   FP7 EurocanPlatform: A European Platform for Translational Cancer
   Research (grant number: 260791). In addition, this study was supported
   by postdoctoral fellowship to SA from the International Agency for
   Research on Cancer, partially supported by the EC FP7 Marie Curie
   Actions - People - Co-funding of regional, national and international
   programmes (COFUND). Swedish Cancer Society, Swedish Research Council
   and County Councils of Skane and Vasterbotten supports SH. AC and KKO
   are supported by MRC programme grants [MC_UU_12015/1, MC_UU_12015/2 and
   [MR/L00002/1]. THN is supported by UiT - the Arctic University of
   Norway. The Hellenic Health Foundation is supporting EPIC-Greece. The
   funders of the study had no role in study design, data collection, data
   analysis, data interpretation or writing of the manuscript.
CR Ambatipudi S, 2017, EUR J CANCER, V75, P299, DOI 10.1016/j.ejca.2017.01.014
   Ambatipudi S, 2016, EPIGENOMICS-UK, V8, P599, DOI 10.2217/epi-2016-0001
   [Anonymous], 2001, PROBE LEVEL QUANTILE
   [Anonymous], DNA METHYLATION MICR
   Ba Y, 2011, EUR J CLIN NUTR, V65, P480, DOI 10.1038/ejcn.2010.294
   Barrow TM, 2014, BIOCHEM BIOPH RES CO, V455, P70, DOI 10.1016/j.bbrc.2014.08.002
   Benito M, 2004, BIOINFORMATICS, V20, P105, DOI 10.1093/bioinformatics/btg385
   Berger SL, 2009, GENE DEV, V23, P781, DOI 10.1101/gad.1787609
   Bibikova M, 2011, GENOMICS, V98, P288, DOI 10.1016/j.ygeno.2011.07.007
   Chen C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017238
   Chen YA, 2013, EPIGENETICS-US, V8, P203, DOI 10.4161/epi.23470
   Du P, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-587
   Fages A, 2014, METABOLOMICS, V10, P1074, DOI 10.1007/s11306-014-0647-9
   Feil R, 2012, NAT REV GENET, V13, P97, DOI 10.1038/nrg3142
   GOWER JC, 1966, BIOMETRIKA, V53, P325, DOI 10.2307/2333639
   Guida F, 2015, HUM MOL GENET, V24, P2349, DOI 10.1093/hmg/ddu751
   Herceg Z, 2018, INT J CANCER, V142, P874, DOI 10.1002/ijc.31014
   Heyn H, 2012, P NATL ACAD SCI USA, V109, P10522, DOI 10.1073/pnas.1120658109
   Houseman EA, 2012, BMC BIOINFORMATICS, V13, DOI 10.1186/1471-2105-13-86
   Huber W, 2015, NAT METHODS, V12, P115, DOI [10.1038/NMETH.3252, 10.1038/nmeth.3252]
   Illumina, 2011, GEN BEADST SOFTW MET
   Jacob L, 2016, BIOSTATISTICS, V17, P16, DOI 10.1093/biostatistics/kxv026
   Joehanes R, 2016, CIRC-CARDIOVASC GENE, V9, P436, DOI 10.1161/CIRCGENETICS.116.001506
   Johnson WE, 2007, BIOSTATISTICS, V8, P118, DOI 10.1093/biostatistics/kxj037
   Joubert BR, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10577
   Kleinbaum D. G., 2013, Applied Regression Analysis and Other Multivariable Methods, V5th ed.
   Kruman II, 2014, J NEUROCHEM, V129, P770, DOI 10.1111/jnc.12677
   Leek JT, 2007, PLOS GENET, V3, P1724, DOI 10.1371/journal.pgen.0030161
   Leek JT, 2012, BIOINFORMATICS, V28, P882, DOI 10.1093/bioinformatics/bts034
   Leek JT, 2010, NAT REV GENET, V11, P733, DOI 10.1038/nrg2825
   Leek JT, 2008, P NATL ACAD SCI USA, V105, P18718, DOI 10.1073/pnas.0808709105
   Luo J, 2010, PHARMACOGENOMICS J, V10, P278, DOI 10.1038/tpj.2010.57
   Martin RF, 2000, CLIN CHEM, V46, P100
   Matejcic M, 2017, INT J CANCER, V140, P1246, DOI 10.1002/ijc.30536
   Müller C, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0156594
   PASSING H, 1983, J CLIN CHEM CLIN BIO, V21, P709
   Riboli E, 2002, PUBLIC HEALTH NUTR, V5, P1113, DOI 10.1079/PHN2002394
   Sims AH, 2008, BMC MED GENOMICS, V1, DOI 10.1186/1755-8794-1-42
   Teschendorff AE, 2013, BIOINFORMATICS, V29, P189, DOI 10.1093/bioinformatics/bts680
   van Iterson M, 2017, GENOME BIOL, V18, DOI 10.1186/s13059-016-1131-9
   Wilhelm-Benartzi CS, 2013, BRIT J CANCER, V109, P1394, DOI 10.1038/bjc.2013.496
   Workman C., 2002, Genome Biol, V3, P0048
NR 42
TC 26
Z9 29
U1 0
U2 9
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1868-7083
J9 CLIN EPIGENETICS
JI Clin. Epigenetics
PD MAR 21
PY 2018
VL 10
AR 38
DI 10.1186/s13148-018-0471-6
PG 12
WC Oncology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Genetics & Heredity
GA GA4AF
UT WOS:000428271200001
PM 29588806
OA Green Published, gold, Green Submitted
DA 2025-01-12
ER

PT J
AU Dolcino, M
   Pelosi, A
   Fiore, PF
   Patuzzo, G
   Tinazzi, E
   Lunardi, C
   Puccetti, A
AF Dolcino, Marzia
   Pelosi, Andrea
   Fiore, Piera Filomena
   Patuzzo, Giuseppe
   Tinazzi, Elisa
   Lunardi, Claudio
   Puccetti, Antonio
TI Gene Profiling in Patients with Systemic Sclerosis Reveals the Presence
   of Oncogenic Gene Signatures
SO FRONTIERS IN IMMUNOLOGY
LA English
DT Article
DE systemic sclerosis; cancer; gene expression; miRNA; gene module;
   protein-protein interaction network
ID ACUTE MYELOID-LEUKEMIA; BREAST-CANCER; HUMAN CYTOMEGALOVIRUS; SIGNALING
   PATHWAY; I INTERFERON; SOLID TUMORS; EXPRESSION; MICRORNAS; SCLERODERMA;
   FIBROBLASTS
AB Systemic sclerosis (SSc) is a rare connective tissue disease characterized by three pathogenetic hallmarks: vasculopathy, dysregulation of the immune system, and fibrosis. A particular feature of SSc is the increased frequency of some types of malignancies, namely breast, lung, and hematological malignancies. Moreover, SSc may also be a paraneoplastic disease, again indicating a strong link between cancer and scleroderma. The reason of this association is still unknown; therefore, we aimed at investigating whether particular genetic or epigenetic factors may play a role in promoting cancer development in patients with SSc and whether some features are shared by the two conditions. We therefore performed a gene expression profiling of peripheral blood mononuclear cells (PBMCs) derived from patients with limited and diffuse SSc, showing that the various classes of genes potentially linked to the pathogenesis of SSc (such as apoptosis, endothelial cell activation, extracellular matrix remodeling, immune response, and inflammation) include genes that directly participate in the development of malignancies or that are involved in pathways known to be associated with carcinogenesis. The transcriptional analysis was then complemented by a complex network analysis of modulated genes which further confirmed the presence of signaling pathways associated with carcinogenesis. Since epigenetic mechanisms, such as microRNAs (miRNAs), are believed to play a central role in the pathogenesis of SSc, we also evaluated whether specific cancer-related miRNAs could be deregulated in the serum of SSc patients. We focused our attention on miRNAs already found upregulated in SSc such as miR-21-5p, miR-92a-3p, and on miR-155-5p, miR 126-3p and miR-16-5p known to be deregulated in malignancies associated to SSc, i.e., breast, lung, and hematological malignancies. miR-21-5p, miR-92a-3p, miR-155-5p, and miR-16-5p expression was significantly higher in SSc sera compared to healthy controls. Our findings indicate the presence of modulated genes and miRNAs that can play a predisposing role in the development of malignancies in SSc and are important for a better risk stratification of patients and for the identification of a better individualized precision medicine strategy.
C1 [Dolcino, Marzia; Patuzzo, Giuseppe; Tinazzi, Elisa; Lunardi, Claudio] Univ Verona, Dept Med, Verona, Italy.
   [Pelosi, Andrea; Fiore, Piera Filomena; Puccetti, Antonio] Pediat Hosp Bambino Gesu, Immunol Area, Rome, Italy.
   [Puccetti, Antonio] Univ Genoa, Sect Histol, Dept Expt Med, Genoa, Italy.
C3 University of Verona; IRCCS Bambino Gesu; University of Genoa
RP Lunardi, C (通讯作者)，Univ Verona, Dept Med, Verona, Italy.
EM claudio.lunardi@univr.it
RI Tinazzi, Elisa/AAB-9450-2020; fiore, piera/AAA-1601-2020; Pelosi,
   Andrea/J-9690-2018
OI Pelosi, Andrea/0000-0003-2308-9215; FIORE, PIERA
   FILOMENA/0000-0002-6810-2172
FU University of Verona
FX The work was funded by the University of Verona and by donation of the
   Italian Association of Sclerodermic Patients (AILS).
CR Alsaab HO, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00561
   Aqeilan RI, 2010, CELL DEATH DIFFER, V17, P215, DOI 10.1038/cdd.2009.69
   Artlett CM, 2017, ARTHRITIS RES THER, V19, DOI 10.1186/s13075-017-1331-z
   Asano Y, 2004, J IMMUNOL, V172, P7123, DOI 10.4049/jimmunol.172.11.7123
   Atanackovic D, 2007, BLOOD, V109, P1103, DOI 10.1182/blood-2006-04-014480
   Babalola O, 2013, ARCH DERMATOL RES, V305, P763, DOI 10.1007/s00403-013-1410-1
   Balkwill F, 2001, LANCET, V357, P539, DOI 10.1016/S0140-6736(00)04046-0
   Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002
   Bergmann C, 2016, LAB INVEST, V96, P151, DOI 10.1038/labinvest.2015.154
   Bernal-Bello D, 2017, AUTOIMMUN REV, V16, P461, DOI 10.1016/j.autrev.2017.03.012
   Bien E, 2008, BIOMARKERS, V13, P1, DOI 10.1080/13547500701674063
   Bradham C, 2006, CELL CYCLE, V5, P824, DOI 10.4161/cc.5.8.2685
   Ceribelli A, 2012, CURR OPIN IMMUNOL, V24, P686, DOI 10.1016/j.coi.2012.07.011
   Chen YL, 2017, CANCER METAST REV, V36, P703, DOI 10.1007/s10555-017-9704-y
   Chiariello M, 2001, NAT CELL BIOL, V3, P580, DOI 10.1038/35078555
   Christmann RB, 2016, ARTHRITIS RES THER, V18, DOI 10.1186/s13075-016-1054-6
   Ciechomska M, 2014, GENES IMMUN, V15, P433, DOI 10.1038/gene.2014.44
   Cline MS, 2007, NAT PROTOC, V2, P2366, DOI 10.1038/nprot.2007.324
   Damiani D, 2015, ONCOTARGET, V6, P30212, DOI 10.18632/oncotarget.4901
   Denton CP, 2017, LANCET, V390, P1685, DOI 10.1016/S0140-6736(17)30933-9
   Devoy A, 2005, ESSAYS BIOCHEM, V41, P187, DOI 10.1042/EB0410187
   Dolcino M, 2015, LUPUS, V24, P419, DOI 10.1177/0961203314558677
   Dorr C, 2015, MOL CANCER RES, V13, P1238, DOI 10.1158/1541-7786.MCR-14-0674-T
   Erdogan B, 2017, BIOCHEM SOC T, V45, P229, DOI 10.1042/BST20160387
   Fallah Y, 2017, BIOMOLECULES, V7, DOI 10.3390/biom7030053
   Fernandez-Medarde Alberto, 2011, Genes Cancer, V2, P344, DOI 10.1177/1947601911411084
   Fish JE, 2008, DEV CELL, V15, P272, DOI 10.1016/j.devcel.2008.07.008
   Franceschini A, 2013, NUCLEIC ACIDS RES, V41, pD808, DOI 10.1093/nar/gks1094
   Gao SP, 2016, TUMOR BIOL, V37, P1279, DOI 10.1007/s13277-015-3878-0
   Garzon R, 2009, ANNU REV MED, V60, P167, DOI [10.1146/annurev.med.59.053006.104707, 10.1146/annurev.pathol.4.110807.092222]
   Gatenby RA, 2004, NAT REV CANCER, V4, P891, DOI 10.1038/nrc1478
   Goldszmid RS, 2014, CELL HOST MICROBE, V15, P295, DOI 10.1016/j.chom.2014.02.003
   Guo HM, 1998, GENE, V220, P99, DOI 10.1016/S0378-1119(98)00400-4
   Guo SJ, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0178823
   Gutierrez AN, 2017, CELL SIGNAL, V41, P65, DOI 10.1016/j.cellsig.2017.09.005
   Heldin CH, 2018, J INTERN MED, V283, P16, DOI 10.1111/joim.12690
   Heldin CH, 2013, CELL COMMUN SIGNAL, V11, DOI 10.1186/1478-811X-11-97
   Horiuchi D, 2016, NAT MED, V22, P1321, DOI 10.1038/nm.4213
   Houston A, 2004, CURR OPIN PHARMACOL, V4, P321, DOI 10.1016/j.coph.2004.03.008
   Hung JY, 2017, ONCOTARGET, V8, P63691, DOI 10.18632/oncotarget.19475
   Janku F, 2017, CANCER TREAT REV, V59, P93, DOI 10.1016/j.ctrv.2017.07.005
   Jensen LJ, 2009, NUCLEIC ACIDS RES, V37, pD412, DOI 10.1093/nar/gkn760
   Joyce CE, 2013, J CLIN ONCOL, V31, P2219, DOI 10.1200/JCO.2012.48.3180
   Kalkat M, 2017, GENES-BASEL, V8, DOI 10.3390/genes8060151
   Kim CG, 2018, SEMIN CANCER BIOL, V50, P142, DOI 10.1016/j.semcancer.2017.07.007
   Kumarswamy R, 2011, RNA BIOL, V8, P706, DOI 10.4161/rna.8.5.16154
   Leaf IA, 2017, J CLIN INVEST, V127, P321, DOI 10.1172/JCI87532
   Leask A, 2015, SEMIN IMMUNOPATHOL, V37, P559, DOI 10.1007/s00281-015-0508-2
   LEROY EC, 1988, J RHEUMATOL, V15, P202
   Li J, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/964842
   Li YM, 2012, BLOOD, V119, P4486, DOI 10.1182/blood-2011-09-378687
   Liu ZH, 2015, CANCER BIOL THER, V16, P353, DOI 10.1080/15384047.2015.1016662
   Lowe SW, 2000, CARCINOGENESIS, V21, P485, DOI 10.1093/carcin/21.3.485
   Lunardi C, 2000, NAT MED, V6, P1183, DOI 10.1038/80533
   Luo YY, 2013, J AUTOIMMUN, V41, P161, DOI 10.1016/j.jaut.2013.01.012
   Mi HY, 2009, METHODS MOL BIOL, V563, P123, DOI 10.1007/978-1-60761-175-2_7
   Miao CG, 2015, INT IMMUNOPHARMACOL, V28, P626, DOI 10.1016/j.intimp.2015.07.042
   Michie AM, 2005, IMMUNOL LETT, V96, P155, DOI 10.1016/j.imlet.2004.08.013
   Monfort J-B, 2016, J Mal Vasc, V41, P365, DOI 10.1016/j.jmv.2016.07.001
   Mulligan-Kehoe Mary Jo, 2007, Curr Rheumatol Rep, V9, P173, DOI 10.1007/s11926-007-0013-2
   Murdaca G, 2016, AUTOIMMUN REV, V15, P427, DOI 10.1016/j.autrev.2016.01.016
   Newman MEJ, 2004, PHYS REV E, V69, DOI 10.1103/PhysRevE.69.026113
   Ohura Norihiko, 2003, J Atheroscler Thromb, V10, P304
   Ozaki Toshinori, 2011, Cancers (Basel), V3, P994, DOI 10.3390/cancers3010994
   Pekarsky Y, 2018, CELL DEATH DIFFER, V25, P21, DOI 10.1038/cdd.2017.159
   Pencik J, 2016, CYTOKINE, V87, P26, DOI 10.1016/j.cyto.2016.06.017
   Pereira L, 2015, DRUG DISCOV TODAY, V20, P1152, DOI 10.1016/j.drudis.2015.06.010
   Pfeffer SR, 2015, DRUG DEVELOP RES, V76, P270, DOI 10.1002/ddr.21257
   Picard C, 2017, AUTOIMMUN REV, V16, P897, DOI 10.1016/j.autrev.2017.07.001
   Pignataro L, 2005, Acta Otorhinolaryngol Ital, V25, P75
   Podnos A, 2012, BREAST CANCER RES TR, V136, P117, DOI 10.1007/s10549-012-2258-3
   Randone SB, 2008, AUTOIMMUN REV, V8, P36, DOI 10.1016/j.autrev.2008.07.022
   Ren P, 2016, TUMOR BIOL, V37, P3215, DOI 10.1007/s13277-015-4150-3
   Reuter S, 2010, FREE RADICAL BIO MED, V49, P1603, DOI 10.1016/j.freeradbiomed.2010.09.006
   Riccioni R, 2015, LEUKEMIA RES, V39, P221, DOI 10.1016/j.leukres.2014.11.001
   Sasaki T, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/546318
   Shah AA, 2017, ARTHRITIS RHEUMATOL, V69, P1306, DOI 10.1002/art.40065
   Shah AA, 2015, CURR OPIN RHEUMATOL, V27, P563, DOI 10.1097/BOR.0000000000000222
   Shen W, 2017, CELL BIOSCI, V7, DOI 10.1186/s13578-017-0168-0
   Sing T, 2012, RHEUMATOLOGY, V51, P1550, DOI 10.1093/rheumatology/kes120
   Snell LM, 2017, TRENDS IMMUNOL, V38, P542, DOI 10.1016/j.it.2017.05.005
   Sun YQ, 2010, BIOCHEM BIOPH RES CO, V391, P1483, DOI 10.1016/j.bbrc.2009.12.098
   Tahiri A, 2014, CARCINOGENESIS, V35, P76, DOI 10.1093/carcin/bgt333
   van den Hoogen F, 2013, ANN RHEUM DIS, V72, P1747, DOI [10.1136/annrheumdis-2013-204424, 10.1002/art.38098]
   Vidya MK, 2018, INT REV IMMUNOL, V37, P20, DOI 10.1080/08830185.2017.1380200
   Wang C, 2017, CANCER LETT, V403, P271, DOI 10.1016/j.canlet.2017.06.011
   Wang JI, 2014, INT J CLIN EXP PATHO, V7, P8593
   Weng AP, 2003, CANCER CELL, V4, P417, DOI 10.1016/S1535-6108(03)00305-2
   Wu MH, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00266
   Xu XD, 2017, ONCOTARGETS THER, V10, P1827, DOI 10.2147/OTT.S93164
   Xue XY, 2016, ONCOTARGET, V7, P84508, DOI 10.18632/oncotarget.13022
   Zeineddine Nabil, 2016, J Clin Med Res, V8, P625, DOI 10.14740/jocmr2606w
   Zeng P, 2017, ONCOTARGET, V8, P5592, DOI 10.18632/oncotarget.13532
   Zhou B, 2017, SCI REP-UK, V7, DOI 10.1038/srep42899
   Zhou XD, 2006, ARTHRITIS RHEUM-US, V54, P2626, DOI 10.1002/art.21973
   Zhu HL, 2013, EXP MOL MED, V45, DOI 10.1038/emm.2013.71
   Zhu HL, 2013, J CLIN IMMUNOL, V33, P1100, DOI 10.1007/s10875-013-9896-z
NR 97
TC 38
Z9 40
U1 0
U2 3
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-3224
J9 FRONT IMMUNOL
JI Front. Immunol.
PD MAR 6
PY 2018
VL 9
AR 449
DI 10.3389/fimmu.2018.00449
PG 20
WC Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology
GA FY3OJ
UT WOS:000426729200002
PM 29559981
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU Matsui, S
   Kagara, N
   Mishima, C
   Naoi, Y
   Shimoda, M
   Shimomura, A
   Shimazu, K
   Kim, SJ
   Noguchi, S
AF Matsui, Saki
   Kagara, Naofumi
   Mishima, Chieko
   Naoi, Yasuto
   Shimoda, Masafumi
   Shimomura, Atsushi
   Shimazu, Kenzo
   Kim, Seung Jin
   Noguchi, Shinzaburo
TI <i>LATS2</i> promoter hypermethylation and its effect on gene expression
   in human breast cancer
SO ONCOLOGY LETTERS
LA English
DT Article
DE breast cancer; large tumor suppressor; homolog 2; epigenetics;
   methylation; expression
ID TUMOR-SUPPRESSOR GENES; DOWN-REGULATION; TARGETING LATS2; PROGNOSIS
AB Tumor-specific promoter hypermethylation of large tumor suppressor, homolog 2 (LATS2), a tumor suppressor gene, has been investigated using methylation-specific polymerase chain reaction (MSP) assays in different types of human cancer producing conflicting results. The aim of the present study was to evaluate the methylation status of the LATS2 promoter region using bisulfite sequencing with a next generation sequencer for breast cancer. In the 11 patients enrolled in the present study, the LATS2 promoter methylation index (MI) was uniformly high in tumor and normal tissues of the breast (median, 84.0 and 87.4%, respectively). The presence of LATS2 promoter hypermethylation was confirmed in isolated tumor cells and normal epithelial cells using the magnetic-activated cell sorting method. In situ hybridization for LATS2 messenger RNA (mRNA) revealed that the mRNA expression of LATS2 was higher in normal epithelial cells, compared with tumor cells, however, it was not significantly associated with LATS2 MI. In 12 breast cancer cell (BCC) lines and two normal breast cell lines, the LATS2 promoter was uniformly hypermethylated with no correlation between the mRNA expression of LATS2 and the LATS2 MI. In addition, treatment of the BCC lines with a demethylating reagent had minimal effect on the mRNA expression of LATS2 in any of these cell lines. These results demonstrated that LATS2 hypermethylation was not involved in silencing the mRNA expression of LATS2 mRNA. The lower mRNA expression level of LATS2 in tumor cells, compared with normal epithelial cells, suggested the possible involvement of downregulation in the mRNA expression of LATS2 in the pathogenesis of breast cancer. Therefore, the conflicting results previously reported for LATS2 promoter methylation in different types of cancer, detected using MSP assays may be attributable to the low fidelity of the MSP assay.
C1 [Matsui, Saki; Kagara, Naofumi; Mishima, Chieko; Naoi, Yasuto; Shimoda, Masafumi; Shimomura, Atsushi; Shimazu, Kenzo; Kim, Seung Jin; Noguchi, Shinzaburo] Osaka Univ, Grad Sch Med, Dept Breast & Endocrine Surg, 2-2-E10 Yamadaoka, Suita, Osaka 5650871, Japan.
C3 Osaka University
RP Kagara, N (通讯作者)，Osaka Univ, Grad Sch Med, Dept Breast & Endocrine Surg, 2-2-E10 Yamadaoka, Suita, Osaka 5650871, Japan.
EM kagaran@onsurg.med.osaka-u.ac.jp
RI Mishima, Chieko/LBH-8851-2024; 真史, 下田/GRS-6091-2022
CR Fang L, 2012, CELL CYCLE, V11, P4352, DOI 10.4161/cc.22670
   Feng SJ, 2014, TUMOR BIOL, V35, P12339, DOI 10.1007/s13277-014-2546-0
   Jiang Z, 2006, NEUROSCI RES, V56, P450, DOI 10.1016/j.neures.2006.09.006
   Jiménez-Velasco A, 2005, LEUKEMIA, V19, P2347, DOI 10.1038/sj.leu.2403974
   Lim B, 2014, CARCINOGENESIS, V35, P1020, DOI 10.1093/carcin/bgt409
   Liu X, 2010, J CLIN INVEST, V120, P1298, DOI 10.1172/JCI39566
   Mitamura T, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-97
   Otani Y, 2014, CANCER SCI, V105, P1369, DOI 10.1111/cas.12506
   Sasaki H, 2010, ONCOL LETT, V1, P303, DOI 10.3892/ol_00000054
   Steinmann K, 2009, ONCOL REP, V22, P1519, DOI 10.3892/or_00000596
   Takahashi Y, 2005, CLIN CANCER RES, V11, P1380, DOI 10.1158/1078-0432.CCR-04-1773
   Uji K, 2014, CANCER LETT, V342, P19, DOI 10.1016/j.canlet.2013.08.028
   Visser S, 2010, CELL CYCLE, V9, P3892, DOI 10.4161/cc.9.19.13386
   Yu T, 2015, PROTEIN CELL, V6, P6, DOI 10.1007/s13238-014-0122-4
   Yu T, 2013, GENETICS, V195, P1193, DOI 10.1534/genetics.113.156372
   Zhang Y, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-538
NR 16
TC 7
Z9 7
U1 0
U2 2
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1792-1074
EI 1792-1082
J9 ONCOL LETT
JI Oncol. Lett.
PD FEB
PY 2018
VL 15
IS 2
BP 2595
EP 2603
DI 10.3892/ol.2017.7535
PN B
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA FX5UE
UT WOS:000426145100078
PM 29434979
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU Kim, D
   Shivakumar, M
   Han, S
   Sinclair, MS
   Lee, YJ
   Zheng, YL
   Olopade, OI
   Kim, D
   Lee, Y
AF Kim, Dongwook
   Shivakumar, Manu
   Han, Seonggyun
   Sinclair, Michael S.
   Lee, Young-Ji
   Zheng, Yonglan
   Olopade, Olufunmilayo I.
   Kim, Dokyoon
   Lee, Younghee
TI Population-dependent Intron Retention and DNA Methylation in Breast
   Cancer
SO MOLECULAR CANCER RESEARCH
LA English
DT Article
ID TRANSLATIONAL BIOINFORMATICS; PROTEIN INTERACTIONS; HUMAN-DISEASE;
   ASSOCIATION; GENES; MECHANISMS; MEDICINE; INVASION; BIOLOGY; TUMORS
AB Regulation of gene expression by DNA methylation in gene promoter regions is well studied; however, the effects of methylation in the gene body (exons and introns) on gene expression are comparatively understudied. Recently, hypermethylation has been implicated in the inclusion of alternatively spliced exons; moreover, exon recognition can be enhanced by recruiting the methyl-CpG-binding protein (MeCP2) to hypermethylated sites. This study examines whether the methylation status of an intron is correlated with how frequently the intron is retained during splicing using DNA methylation and RNA sequencing data from breast cancer tissue specimens in The Cancer Genome Atlas. Interestingly, hypomethylation of introns is correlated with higher levels of intron expression in mRNA and the methylation level of an intron is inversely correlated with its retention in mRNA from the gene in which it is located. Furthermore, significant population differences were observed in the methylation level of retained introns. In African-American donors, retained introns were not only less methylated compared to European-American donors, but also were more highly expressed. This underscores the need for understanding epigenetic differences in populations and their correlation with breast cancer is an important step toward achieving personalized cancer care.
C1 [Kim, Dongwook; Han, Seonggyun; Sinclair, Michael S.; Lee, Younghee] Univ Utah, Sch Med, Dept Biomed Informat, Salt Lake City, UT USA.
   [Shivakumar, Manu; Kim, Dokyoon] Geisinger Hlth Syst, Dept Biomed & Translat Informat, Danville, PA USA.
   [Lee, Young-Ji] Univ Pittsburgh, Sch Nursing, Dept Hlth & Community Syst, Pittsburgh, PA 15261 USA.
   [Zheng, Yonglan; Olopade, Olufunmilayo I.] Univ Chicago, Dept Med, 5841 S Maryland Ave, Chicago, IL 60637 USA.
   [Kim, Dokyoon] Penn State Univ, Huck Inst Life Sci, University Pk, PA 16802 USA.
   [Lee, Younghee] Huntsman Canc Inst, Salt Lake City, UT USA.
C3 Utah System of Higher Education; University of Utah; Geisinger Health
   System; Pennsylvania Commonwealth System of Higher Education (PCSHE);
   University of Pittsburgh; University of Chicago; Pennsylvania
   Commonwealth System of Higher Education (PCSHE); Pennsylvania State
   University; Pennsylvania State University - University Park; Utah System
   of Higher Education; University of Utah; Huntsman Cancer Institute
RP Lee, Y (通讯作者)，Univ Utah, 421 Wakara Way, Salt Lake City, UT 84108 USA.; Kim, D (通讯作者)，Weis Ctr, Res Lab 123, 100 N Acad Ave, Danville, PA 17822 USA.
EM dkim@geisinger.edu; younghee.lee@utah.edu
RI Zheng, Yonglan/O-4112-2019; Lee, Joo/C-3851-2013
OI HAN, SEONGGYUN/0000-0003-2227-4953; Shivakumar,
   Manu/0000-0003-4733-7375; Zheng, Yonglan/0000-0001-6597-7072; Sinclair,
   Michael/0000-0002-3636-5920
FU NIGMS [P50GM115318]; Pennsylvania Department of Health [SAP 4100070267];
   National Library of Medicine Training [T15LM007124]; Center for High
   Performance Computing; Vice President's Clinical and Translational
   Research Scholar Program at the University of Utah
FX This work was partially funded by NIGMS grant P50GM115318 and a grant
   with the Pennsylvania Department of Health (#SAP 4100070267) for Dokyoon
   Kim. Michael S. Sinclair was supported by National Library of Medicine
   Training grant T15LM007124. The support and resources from the Center
   for High Performance Computing and Vice President's Clinical and
   Translational Research Scholar Program at the University of Utah are
   gratefully acknowledged. The authors wish to thank Brian Greene, EdD,
   Scientific Editor and Writer at the Center for Research and Evaluation
   at the University of Pittsburgh, School of Nursing, for his editorial
   assistance in the preparation of this manuscript for submission. In
   addition, we gratefully acknowledge the TCGA Consortium and all its
   members for the TCGA Project initiative, for providing a sample,
   tissues, data processing and making data and results available. The
   results published here are in whole or part based upon data generated by
   TCGA pilot project established by the NCI and NHGRI. Information about
   TCGA and the investigators and institutions that constitute the TCGA
   research network can be found at the following website:
   http://cancergenome.nih.gov.
CR Abba MC, 2015, CANCER RES, V75, P3980, DOI 10.1158/0008-5472.CAN-15-0506
   Altman RB, 2012, CLIN PHARMACOL THER, V91, P994, DOI 10.1038/clpt.2012.49
   Anastasiadou C, 2011, DNA CELL BIOL, V30, P267, DOI 10.1089/dna.2010.1094
   Barabási AL, 2011, NAT REV GENET, V12, P56, DOI 10.1038/nrg2918
   Braunschweig U, 2014, GENOME RES, V24, P1774, DOI 10.1101/gr.177790.114
   Butte AJ, 2008, J AM MED INFORM ASSN, V15, P709, DOI 10.1197/jamia.M2824
   Chlebowski RT, 2005, JNCI-J NATL CANCER I, V97, P439, DOI 10.1093/jnci/dji064
   Cho EH, 2010, CANCER BIOL THER, V9, P66, DOI 10.4161/cbt.9.1.10451
   Collins FS, 2015, NEW ENGL J MED, V372, P793, DOI 10.1056/NEJMp1500523
   Dvinge H, 2015, GENOME MED, V7, DOI 10.1186/s13073-015-0168-9
   Eswaran J, 2013, SCI REP-UK, V3, DOI 10.1038/srep01689
   Futreal PA, 2004, NAT REV CANCER, V4, P177, DOI 10.1038/nrc1299
   Gelfman S, 2013, GENOME RES, V23, P789, DOI 10.1101/gr.143503.112
   GRANT SG, 1988, ANNU REV GENET, V22, P199, DOI 10.1146/annurev.ge.22.120188.001215
   Hartwell LH, 1999, NATURE, V402, pC47, DOI 10.1038/35011540
   Heard E, 2014, CELL, V157, P95, DOI 10.1016/j.cell.2014.02.045
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Huo DZ, 2017, JAMA ONCOL, V3, P1654, DOI 10.1001/jamaoncol.2017.0595
   Jaillon O, 2008, NATURE, V451, P359, DOI 10.1038/nature06495
   Katz Y, 2010, NAT METHODS, V7, P1009, DOI 10.1038/NMETH.1528
   Kim D, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-4-r36
   Kiyama S, 2003, CANCER RES, V63, P3575
   Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412
   Kumar D, 2016, PROTEOMICS, V16, P2533, DOI 10.1002/pmic.201600140
   Lee Y, 2013, J AM MED INFORM ASSN, V20, P619, DOI 10.1136/amiajnl-2012-001519
   Lejeune F, 2005, CURR OPIN CELL BIOL, V17, P309, DOI 10.1016/j.ceb.2005.03.002
   Li H, 2011, BIOINFORMATICS, V27, P2987, DOI 10.1093/bioinformatics/btr509
   Li H, 2009, BIOINFORMATICS, V25, P2078, DOI 10.1093/bioinformatics/btp352
   Maor GL, 2015, TRENDS GENET, V31, P274, DOI 10.1016/j.tig.2015.03.002
   Maunakea AK, 2013, CELL RES, V23, P1256, DOI 10.1038/cr.2013.110
   Mohammed Sulma I, 2012, Methods Mol Biol, V863, P395, DOI 10.1007/978-1-61779-612-8_25
   Naftelberg S, 2015, ANNU REV BIOCHEM, V84, P165, DOI 10.1146/annurev-biochem-060614-034242
   Oti M, 2006, J MED GENET, V43, DOI 10.1136/jmg.2006.041376
   Paik S, 2004, NEW ENGL J MED, V351, P2817, DOI 10.1056/NEJMoa041588
   Poon E, 2009, EXPERT REV MOL MED, V11, DOI 10.1017/S1462399409001173
   Sakabe NJ, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-59
   Sammeth M, 2008, PLOS COMPUT BIOL, V4, DOI 10.1371/journal.pcbi.1000147
   Sharan R, 2007, MOL SYST BIOL, V3, DOI 10.1038/msb4100129
   Shen SH, 2014, P NATL ACAD SCI USA, V111, pE5593, DOI 10.1073/pnas.1419161111
   Song FF, 2015, ONCOL REP, V33, P2771, DOI 10.3892/or.2015.3905
   Spratt DE, 2016, JAMA ONCOL, V2, P1070, DOI 10.1001/jamaoncol.2016.1854
   Stadler MB, 2006, PLOS GENET, V2, P1849, DOI 10.1371/journal.pgen.0020191
   Szklarczyk D, 2017, NUCLEIC ACIDS RES, V45, pD362, DOI 10.1093/nar/gkw937
   Wang H, 2003, CANCER RES, V63, P4315
   Wang HM, 2008, BREAST J, V14, P261, DOI 10.1111/j.1524-4741.2008.00572.x
   Wang HM, 2006, MODERN PATHOL, V19, P1149, DOI 10.1038/modpathol.3800637
   Wong JJL, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15134
   Wong JJL, 2016, BIOESSAYS, V38, P41, DOI 10.1002/bies.201500117
   Wong JJL, 2013, CELL, V154, P583, DOI 10.1016/j.cell.2013.06.052
   Yan HH, 2016, AM J EPIDEMIOL, V183, P96, DOI 10.1093/aje/kwv187
NR 50
TC 21
Z9 24
U1 0
U2 6
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1541-7786
EI 1557-3125
J9 MOL CANCER RES
JI Mol. Cancer Res.
PD MAR
PY 2018
VL 16
IS 3
BP 461
EP 469
DI 10.1158/1541-7786.MCR-17-0227
PG 9
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA FY1MT
UT WOS:000426577100009
PM 29330282
OA Green Submitted, Green Accepted, Bronze
DA 2025-01-12
ER

PT J
AU Lewandowska, P
   Wozniak, K
AF Lewandowska, Patrycja
   Wozniak, Katarzyna
TI EFFECT OF NATURAL POLYPHENOLS ON EPIGENETIC MECHANISMS OF GENE
   EXPRESSION
SO POSTEPY BIOLOGII KOMORKI
LA Polish
DT Article
DE epigenetics; resveratrol; curcumin; genistein
ID BREAST-CANCER CELLS; TUMOR-SUPPRESSOR GENES; PROSTATE-CANCER; DNA
   METHYLATION; RESVERATROL SUPPLEMENTATION; HISTONE MODIFICATIONS;
   PROMOTER METHYLATION; SIRT1 ACTIVATION; IN-VITRO; RAR-BETA
AB In recent years, interest in nutrigenomics which studies the relationship between human diet and the expression of its genes has increased. The article presents data on the influence of selected dietary components resveratrol, genistein and curcumin on epigenetic mechanisms of gene expression control, such as DNA methylation and histone modifications methylation, acetylation and deacetylation. The ability of bioactive food components to epigenetic modulation of gene expression can be a key element in the prevention and treatment of diseases, such as type 2 diabetes, obesity, hypertension or cancer.
C1 [Lewandowska, Patrycja; Wozniak, Katarzyna] Uniwersytet Lodzki, Wydzial Biol & Ochrony Srodowiska, Katedra Genet Mol, Ul Pomorska 141-143, PL-90236 Lodz, Poland.
C3 University of Lodz
RP Wozniak, K (通讯作者)，Uniwersytet Lodzki, Wydzial Biol & Ochrony Srodowiska, Katedra Genet Mol, Ul Pomorska 141-143, PL-90236 Lodz, Poland.
EM katarzyna.wozniak@biol.uni.lodz.pl
CR Bagul PK, 2015, J NUTR BIOCHEM, V26, P1298, DOI 10.1016/j.jnutbio.2015.06.006
   Baur JA, 2006, NATURE, V444, P337, DOI 10.1038/nature05354
   Borra MT, 2005, J BIOL CHEM, V280, P17187, DOI 10.1074/jbc.M501250200
   Boyanapalli Sarandeep S S, 2015, Curr Pharmacol Rep, V1, P129
   Buhrmann C, 2016, NUTRIENTS, V8, DOI 10.3390/nu8030145
   Dhar S, 2015, BBA-MOL CELL RES, V1853, P265, DOI 10.1016/j.bbamcr.2014.11.004
   Fang MZ, 2005, CLIN CANCER RES, V11, P7033, DOI 10.1158/1078-0432.CCR-05-0406
   Goh KP, 2014, INT J SPORT NUTR EXE, V24, P2, DOI 10.1123/ijsnem.2013-0045
   Hu A, 2015, SCI REP-UK, V5, DOI 10.1038/srep13429
   Jiang AP, 2015, PHYTOTHER RES, V29, P1237, DOI 10.1002/ptr.5373
   Kai L, 2010, INT J CANCER, V126, P1538, DOI 10.1002/ijc.24928
   Kala R, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1693-z
   Kala R, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0155057
   Kavoosi Fraidoon, 2016, Adv Biomed Res, V5, P133, DOI 10.4103/2277-9175.187395
   Kopec A., 2011, Zywn. Nauka Technol Jakosc, V5, P5
   Li YY, 2009, INT J CANCER, V125, P286, DOI 10.1002/ijc.24398
   Li YY, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0055108, 10.1371/journal.pone.0052093, 10.1371/journal.pone.0063648, 10.1371/journal.pone.0077685, 10.1371/journal.pone.0062036, 10.1371/journal.pone.0054369, 10.1371/journal.pone.0066567, 10.1371/journal.pone.0071994]
   Lin SR, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18071412
   Liu SL, 2016, EXP THER MED, V11, P257, DOI 10.3892/etm.2015.2877
   Lu X, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103067
   Mahmoud AM, 2015, J STEROID BIOCHEM, V152, P62, DOI 10.1016/j.jsbmb.2015.04.018
   Majid S, 2008, CANCER RES, V68, P2736, DOI 10.1158/0008-5472.CAN-07-2290
   Majid S, 2010, CANCER-AM CANCER SOC, V116, P66, DOI 10.1002/cncr.24662
   Majid S, 2009, CARCINOGENESIS, V30, P662, DOI 10.1093/carcin/bgp042
   Paluszczak J, 2010, TOXICOL LETT, V192, P119, DOI 10.1016/j.toxlet.2009.10.010
   Papoutsis AJ, 2010, J NUTR, V140, P1607, DOI 10.3945/jn.110.123422
   Phillips CD, 2012, BMC GERIATR, V12, DOI 10.1186/1471-2318-12-73
   Picard F, 2004, NATURE, V429, P771, DOI 10.1038/nature02583
   Poulsen MM, 2013, DIABETES, V62, P1186, DOI 10.2337/db12-0975
   Qin WY, 2009, NUTR CANCER, V61, P238, DOI 10.1080/01635580802404196
   Sharma V, 2015, FOLIA BIOL-PRAGUE, V61, P81
   Sikora Ewa, 2014, Postepy Biochem, V60, P125
   Stefanska B, 2010, EUR J PHARMACOL, V638, P47, DOI 10.1016/j.ejphar.2010.04.032
   Timmers S, 2011, CELL METAB, V14, P612, DOI 10.1016/j.cmet.2011.10.002
   Vardi A, 2010, IN VIVO, V24, P393
   Wada TT, 2014, BIOCHEM BIOPH RES CO, V444, P682, DOI 10.1016/j.bbrc.2014.01.195
   Wang HH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033877
   Wang RH, 2008, MOL CELL, V32, P11, DOI 10.1016/j.molcel.2008.09.011
   Wang XL, 2016, BIOMED PHARMACOTHER, V83, P41, DOI 10.1016/j.biopha.2016.06.009
   Wang ZG, 2010, ANTICANCER RES, V30, P4537
   Wu P, 2016, CHIN J NAT MEDICINES, V14, P255, DOI 10.1016/S1875-5364(16)30025-5
   Xiao J, 2016, DRUG DES DEV THER, V10, P1267, DOI 10.2147/DDDT.S104925
   Xie Q, 2014, GENE CHROMOSOME CANC, V53, P422, DOI 10.1002/gcc.22154
   Yu JH, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0055934, 10.1371/journal.pone.0057564]
   Yun JM, 2011, J NUTR BIOCHEM, V22, P450, DOI 10.1016/j.jnutbio.2010.03.014
   Zhang YK, 2013, CARCINOGENESIS, V34, P1756, DOI 10.1093/carcin/bgt129
   Zhang YK, 2011, EXP BIOL MED, V236, P714, DOI 10.1258/ebm.2011.010347
NR 47
TC 1
Z9 1
U1 0
U2 5
PU POLSKIE TOWARZYSTWO ANATOMICZNE
PI WARSAW
PA CENTRUM MEDYCZNE KSZTALCENIA PODYPLOMOWEGO, UL. MARYMONCKA 99, WARSAW,
   POLAND
SN 0324-833X
EI 2080-2218
J9 POSTEPY BIOL KOMORKI
JI Postepy Biol. Komorki
PY 2017
VL 44
IS 2
BP 213
EP 225
PG 25
WC Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Life Sciences & Biomedicine - Other Topics; Cell Biology
GA FY0XA
UT WOS:000426534800007
DA 2025-01-12
ER

PT J
AU Nowak, E
   Wasinska, M
   Bednarek, I
AF Nowak, Ewa
   Wasinska, Magdalena
   Bednarek, Ilona
TI EPIGENETIC CHANGES IN BREAST CANCER AND OVARIAN CANCER PART I MECHANISMS
   OF EPIGENETIC CHANGES
SO POSTEPY BIOLOGII KOMORKI
LA Polish
DT Article
DE epigenetic; breast cancer; ovarian cancer
ID DNA METHYLATION; MELANOMA; MICRORNA
AB The term epigenetic defines a heritable modifications in the genetic material affecting its expression and without any changes in the nucleotide sequences in DNA. These epigenetic changes are based on biochemical reactions at the level of DNA, and the histones as well. Epigenetic modifications of DNA are limited to changes in its level of methylation, while histones modifications relate to the reactions of methylation, acetylation, phosphorylation, sumoylation, ubiquitination or ADP-ribosylation and all reverse reactions. In addition to genomic DNA. epigenetic modifications also include mitochondrial DNA. An important mechanism regulating gene activity at post-transcriptional and post-translational level is the non-coding RNAs eg. microRNA (miRNA).
   Changes at the epigenetic level with the accumulation of irreversible mutations in the genetic material play an important role in the formation and progression of cancers, including the etiology of breast and ovarian cancers. Modifications at the genetic level that cause tumor growth mainly refer to two groups of genes: proto-oncogenes and suppressor genes. Oncogenes, mutated protoonogenes, contribute to uncontrolled proliferation, while suppressor genes' protein products inhibit cell proliferation.
   Analysis and characterization of epigenetic changes typical of these tumors can be a potential point of therapy. Applying the methylation reversal strategies within promoter regions of suppressor genes by the use of DNA methyltransferase inhibitors can restore the expression of important regulatory genes and thus affect the cell phenotype.
C1 [Nowak, Ewa; Wasinska, Magdalena; Bednarek, Ilona] Slaski Uniwersytet Med Katowicach, Zaklad Biotechnol & Inzynierii Genetycznej, Wydzial Farmaceutyczny, Oddzialem Med Lab Sosnowcu, Ul Jednosci 8, PL-41200 Sosnowiec, Poland.
C3 Medical University Silesia
RP Nowak, E (通讯作者)，Slaski Uniwersytet Med Katowicach, Zaklad Biotechnol & Inzynierii Genetycznej, Wydzial Farmaceutyczny, Oddzialem Med Lab Sosnowcu, Ul Jednosci 8, PL-41200 Sosnowiec, Poland.
EM ewa.nowak@sum.edu.pl
RI Bednarek, Ilona/HJY-5137-2023
CR Aggarwal R, 2015, BIOCHEMISTRY-MOSCOW+, V80, P972, DOI 10.1134/S0006297915080027
   [Anonymous], 2015, GENOME MED, V7, P1
   Bannister AJ, 2011, CELL RES, V21, P381, DOI 10.1038/cr.2011.22
   Howell PM, 2010, OCHSNER J, V10, P83
   Iacobazzi V, 2013, MOL GENET METAB, V110, P25, DOI 10.1016/j.ymgme.2013.07.012
   Jin BL, 2013, ADV EXP MED BIOL, V754, P3, DOI 10.1007/978-1-4419-9967-2_1
   Kaiser Steffen, 2016, RNA BIOL, P1
   Larrea E, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17050627
   Lee JJ, 2014, LAB INVEST, V94, P822, DOI 10.1038/labinvest.2014.87
   Liu J, 2014, J GENET GENOMICS, V41, P21, DOI 10.1016/j.jgg.2013.10.002
   M SUN, 2014, CELL DEATH DIS, V5, P1
   Rose NR, 2014, BBA-GENE REGUL MECH, V1839, P1362, DOI 10.1016/j.bbagrm.2014.02.007
   Scourzic L, 2015, GENOME MED, V7, DOI 10.1186/s13073-015-0134-6
   Sun V, 2014, BRIT J DERMATOL, V171, P234, DOI 10.1111/bjd.12989
   WAWSZCZYK J, 2008, STUDIA MEDYCZNE, V10, P59
   Wieczorek K, 2012, POSTEP HIG MED DOSW, V66, P629, DOI 10.5604/17322693.1009706
   Yuan BF, 2014, ADV CLIN CHEM, V67, P151, DOI 10.1016/bs.acc.2014.09.003
NR 17
TC 0
Z9 0
U1 1
U2 7
PU POLSKIE TOWARZYSTWO ANATOMICZNE
PI WARSAW
PA CENTRUM MEDYCZNE KSZTALCENIA PODYPLOMOWEGO, UL. MARYMONCKA 99, WARSAW,
   POLAND
SN 0324-833X
EI 2080-2218
J9 POSTEPY BIOL KOMORKI
JI Postepy Biol. Komorki
PY 2017
VL 44
IS 3
BP 301
EP 312
PG 12
WC Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Life Sciences & Biomedicine - Other Topics; Cell Biology
GA FY0XC
UT WOS:000426535000006
DA 2025-01-12
ER

PT J
AU Nowak, E
   Wasinska, M
   Bednarek, I
AF Nowak, Ewa
   Wasinska, Magdalena
   Bednarek, Ilona
TI EPIGENETIC CHANGES IN BREAST CANCER AND OVARIAN CANCER - PART II
   MECHANISMS OF CARCINOGENESIS
SO POSTEPY BIOLOGII KOMORKI
LA Polish
DT Article
DE epigenetic; breast cancer; ovarian cancer
ID DNA METHYLATION; PROFILES; MICRORNA; THERAPY
AB The term epigenetic defines a heritable modifications in the genetic material affecting its expression and without any changes in the nucleotide sequences in DNA. These epigenetic changes are based on biochemical reactions at the level of DNA, and the histones as well. Epigenetic modifications of DNA are limited to changes in its level of methylation, while histones modifications relate to the reactions of methylation, acetylation, phosphorylation, sumoylation, ubiquitination or ADP-ribosylation and all reverse reactions. In addition to genomic DNA, epigenetic modifications also include mitochondrial DNA. An important mechanism regulating gene activity at post-transcriptional and post-translational level is the non-coding RNAs eg. microRNA (miRNA).
   Changes at the epigenetic level with the accumulation of irreversible mutations in the genetic material play an important role in the formation and progression of cancers, including the etiology of breast and ovarian cancers. Modifications at the genetic level that cause tumor growth mainly refer to two groups of genes: proto-oncogenes and suppressor genes. Oncogenes, mutated protoonogenes, contribute to uncontrolled proliferation, while suppressor genes' protein products inhibit cell proliferation.
   Analysis and characterization of epigenetic changes typical of these tumors can be a potential point of therapy. Applying the methylation reversal strategies within promoter regions of suppressor genes by the use of DNA methyltransferase inhibitors can restore the expression of important regulatory genes and thus affect the cell phenotype.
C1 [Nowak, Ewa; Wasinska, Magdalena; Bednarek, Ilona] Slaski Uniwersytet Med Katowicach, Zaklad Biotechnol & Inynierii Genetycznej, Wydzial Farmaceutyczny, Oddzialem Med Lab Sosnowcu, Ul Jednosci 8, PL-41200 Sosnowiec, Poland.
C3 Medical University Silesia
RP Nowak, E (通讯作者)，Slaski Uniwersytet Med Katowicach, Zaklad Biotechnol & Inynierii Genetycznej, Wydzial Farmaceutyczny, Oddzialem Med Lab Sosnowcu, Ul Jednosci 8, PL-41200 Sosnowiec, Poland.
EM ewa.nowak@sum.edu.pl
RI Bednarek, Ilona/HJY-5137-2023
CR Abbosh PH, 2006, CANCER RES, V66, P5582, DOI 10.1158/0008-5472.CAN-05-3575
   [Anonymous], ZACHOROWANIA ZGONY N
   BAL J, 2013, BIOL MOLEKULARNA MED, P226
   Balch C, 2009, ENDOCRINOLOGY, V150, P4003, DOI 10.1210/en.2009-0404
   Caslini C, 2006, ONCOGENE, V25, P5446, DOI 10.1038/sj.onc.1209533
   Cava C, 2015, BMC SYST BIOL, V9, DOI 10.1186/s12918-015-0211-x
   Cieplucha Anna, 2007, Acta Haematologica Polonica, V38, P425
   Earp MA, 2015, GENOMICS, V106, P311, DOI 10.1016/j.ygeno.2015.09.001
   Erickson BK, 2014, OBSTET GYNECOL, V124, P881, DOI 10.1097/AOG.0000000000000484
   Schoof CRG, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/634749
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   KAWIAK J, 2002, SEM CYT DLA STUD WET, P71
   KORDEK R, 2004, ONKOLOGIA PODRECZNIK, P119
   Koukoura O, 2014, MOL MED REP, V10, P3, DOI 10.3892/mmr.2014.2221
   KULAKOWSKI A, 2014, ONKOLOGIA, P30
   Kurman RJ, 2011, HUM PATHOL, V42, P918, DOI 10.1016/j.humpath.2011.03.003
   Lapierre M, 2016, ONCOTARGET, V7, P19693, DOI 10.18632/oncotarget.7564
   Lee JJ, 2014, LAB INVEST, V94, P822, DOI 10.1038/labinvest.2014.87
   McCluggage WG, 2011, PATHOLOGY, V43, P420, DOI 10.1097/PAT.0b013e328348a6e7
   Meng F, 2013, BRIT J CANCER, V108, P579, DOI 10.1038/bjc.2013.10
   Nam EJ, 2008, CLIN CANCER RES, V14, P2690, DOI 10.1158/1078-0432.CCR-07-1731
   Niemiec J, 2009, POL J PATHOL, V60, pS36
   Rose NR, 2014, BBA-GENE REGUL MECH, V1839, P1362, DOI 10.1016/j.bbagrm.2014.02.007
   Sandhu R, 2012, INT J ONCOL, V41, P721, DOI 10.3892/ijo.2012.1505
   Shortt J., 2012, COLD SPRING HARB PER, V4, P1
   TOSS A, 2015, BIOMED RES INT, P1
   UDDIN A, 2017, J CELL PHYSL, V13, P1
   Vang S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058226
   Wang B, 2017, ONCOL LETT, V14, P217, DOI 10.3892/ol.2017.6111
   WINTER PC, 2010, GENETYKA KROTKIE WYK, P82
   Wojciechowska U, 2016, NOWOTWORY ZLOSLIWE P
   Zalewski K, 2015, ONCOL CLIN PRACT, V11, P129
NR 32
TC 1
Z9 1
U1 0
U2 3
PU POLSKIE TOWARZYSTWO ANATOMICZNE
PI WARSAW
PA CENTRUM MEDYCZNE KSZTALCENIA PODYPLOMOWEGO, UL. MARYMONCKA 99, WARSAW,
   POLAND
SN 0324-833X
EI 2080-2218
J9 POSTEPY BIOL KOMORKI
JI Postepy Biol. Komorki
PY 2017
VL 44
IS 3
BP 313
EP 328
PG 16
WC Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Life Sciences & Biomedicine - Other Topics; Cell Biology
GA FY0XC
UT WOS:000426535000007
DA 2025-01-12
ER

PT J
AU Cao, KX
   Collings, CK
   Morgan, MA
   Marshall, SA
   Rendleman, EJ
   Ozark, PA
   Smith, ER
   Shilatifard, A
AF Cao, Kaixiang
   Collings, Clayton K.
   Morgan, Marc A.
   Marshall, Stacy A.
   Rendleman, Emily J.
   Ozark, Patrick A.
   Smith, Edwin R.
   Shilatifard, Ali
TI An Mll4/COMPASS-Lsd1 epigenetic axis governs enhancer function and
   pluripotency transition in embryonic stem cells
SO SCIENCE ADVANCES
LA English
DT Article
ID HISTONE H3K4 METHYLATION; GENE-EXPRESSION; PHD FINGER; COMPASS FAMILY;
   PRIMED PLURIPOTENCY; BIVALENT PROMOTERS; BREAST-CANCER; SELF-RENEWAL;
   MONOMETHYLATION; TRIMETHYLATION
AB Chromatin regulators control cellular differentiation by orchestrating dynamic developmental gene expression programs, and hence, malfunctions in the regulation of chromatin state contribute to both developmental disorders and disease state. Mll4 (Kmt2d), a member of the COMPASS (COMplex of Proteins ASsociated with Set1) protein family that implements histone H3 lysine 4 monomethylation (H3K4me1) at enhancers, is essential for embryonic development and functions as a pancancer tumor suppressor. We define the roles of Mll4/COMPASS and its catalytic activity in the maintenance and exit of ground-state pluripotency in murine embryonic stem cells (ESCs). Mll4 is required for ESC to exit the naive pluripotent state; however, its intrinsic catalytic activity is dispensable for this process. The depletion of the H3K4 demethylase Lsd1 (Kdm1a) restores the ability of Mll4 null ESCs to transition from naive to primed pluripotency. Thus, we define an opposing regulatory axis, wherein Lsd1 and associated co-repressors directly repress Mll4-activated gene targets. This finding has broad reaching implications for human developmental syndromes and the treatment of tumors carrying Mll4 mutations.
C1 [Cao, Kaixiang; Collings, Clayton K.; Morgan, Marc A.; Marshall, Stacy A.; Rendleman, Emily J.; Ozark, Patrick A.; Smith, Edwin R.; Shilatifard, Ali] Northwestern Univ, Feinberg Sch Med, Dept Biochem & Mol Genet, 303 East Super St, Chicago, IL 60611 USA.
   [Shilatifard, Ali] Northwestern Univ, Feinberg Sch Med, Simpson Querrey Ctr Epigenet, Chicago, IL 60611 USA.
C3 Northwestern University; Feinberg School of Medicine; Northwestern
   University; Feinberg School of Medicine
RP Shilatifard, A (通讯作者)，Northwestern Univ, Feinberg Sch Med, Dept Biochem & Mol Genet, 303 East Super St, Chicago, IL 60611 USA.; Shilatifard, A (通讯作者)，Northwestern Univ, Feinberg Sch Med, Simpson Querrey Ctr Epigenet, Chicago, IL 60611 USA.
EM ash@northwestern.edu
RI ; Smith, Edwin/N-4834-2015
OI Cao, Kaixiang/0000-0001-9953-1503; Smith, Edwin/0000-0002-4125-6294;
   Ozark, Patrick/0000-0002-4047-5102; Morgan, Marc/0000-0002-0141-6273;
   Collings, Clayton/0000-0002-3471-2132
FU National Cancer Institute [R50CA211428]; Outstanding Investigator Award
   from the National Cancer Institute [R35CA197569]
FX E.R.S. is supported by the National Cancer Institute (grant
   R50CA211428). This study was supported in part by the Outstanding
   Investigator Award from the National Cancer Institute (grant
   R35CA197569) to A.S.
CR Arnold SJ, 2009, NAT REV MOL CELL BIO, V10, P91, DOI 10.1038/nrm2618
   Bienz M, 2006, TRENDS BIOCHEM SCI, V31, P35, DOI 10.1016/j.tibs.2005.11.001
   Bledau AS, 2014, DEVELOPMENT, V141, P1022, DOI 10.1242/dev.098152
   Brons IGM, 2007, NATURE, V448, P191, DOI 10.1038/nature05950
   Buecker C, 2014, CELL STEM CELL, V14, P838, DOI 10.1016/j.stem.2014.04.003
   Cao KX, 2017, GENE DEV, V31, P787, DOI 10.1101/gad.294744.116
   Cheng J, 2014, MOL CELL, V53, P979, DOI 10.1016/j.molcel.2014.02.032
   De Los Angeles A, 2015, NATURE, V525, P469, DOI 10.1038/nature15515
   Denissov S, 2014, DEVELOPMENT, V141, P526, DOI 10.1242/dev.102681
   Dhar SS, 2012, GENE DEV, V26, P2749, DOI 10.1101/gad.203356.112
   Dorighi KM, 2017, MOL CELL, V66, P568, DOI 10.1016/j.molcel.2017.04.018
   Eskeland R, 2010, MOL CELL, V38, P452, DOI 10.1016/j.molcel.2010.02.032
   Flanagan JF, 2005, NATURE, V438, P1181, DOI 10.1038/nature04290
   Foster CT, 2010, MOL CELL BIOL, V30, P4851, DOI 10.1128/MCB.00521-10
   Gui YT, 2011, NAT GENET, V43, P875, DOI 10.1038/ng.907
   Hayashi K, 2011, CELL, V146, P519, DOI 10.1016/j.cell.2011.06.052
   Heintzman ND, 2007, NAT GENET, V39, P311, DOI 10.1038/ng1966
   Herz HM, 2012, GENE DEV, V26, P2604, DOI 10.1101/gad.201327.112
   Hu DQ, 2017, MOL CELL, V65, P460, DOI 10.1016/j.molcel.2017.01.013
   Hu DQ, 2013, MOL CELL BIOL, V33, P4745, DOI 10.1128/MCB.01181-13
   Hu DQ, 2013, NAT STRUCT MOL BIOL, V20, P1093, DOI 10.1038/nsmb.2653
   Illingworth RS, 2015, GENE DEV, V29, P1897, DOI 10.1101/gad.268151.115
   Krogan NJ, 2002, J BIOL CHEM, V277, P10753, DOI 10.1074/jbc.C200023200
   Lee JE, 2013, ELIFE, V2, DOI 10.7554/eLife.01503
   Li HT, 2006, NATURE, V442, P91, DOI 10.1038/nature04802
   Luo ZJ, 2015, MOL CELL, V57, P685, DOI 10.1016/j.molcel.2015.01.007
   Miller T, 2001, P NATL ACAD SCI USA, V98, P12902, DOI 10.1073/pnas.231473398
   Morgan MAJ, 2017, GENE DEV, V31, P2003, DOI 10.1101/gad.305201.117
   Morin RD, 2011, NATURE, V476, P298, DOI 10.1038/nature10351
   Ng SB, 2010, NAT GENET, V42, P790, DOI 10.1038/ng.646
   Ortega-Molina A, 2015, NAT MED, V21, P1199, DOI 10.1038/nm.3943
   Pasqualucci L, 2011, NAT GENET, V43, P830, DOI 10.1038/ng.892
   Piunti A, 2016, SCIENCE, V352, DOI 10.1126/science.aad9780
   Rickels R, 2017, NAT GENET, V49, P1647, DOI 10.1038/ng.3965
   Rickels R, 2016, MOL CELL, V63, P318, DOI 10.1016/j.molcel.2016.06.018
   Rinaldi L, 2016, CELL STEM CELL, V19, P491, DOI 10.1016/j.stem.2016.06.020
   Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616
   Saldanha AJ, 2004, BIOINFORMATICS, V20, P3246, DOI 10.1093/bioinformatics/bth349
   Sanchez R, 2011, TRENDS BIOCHEM SCI, V36, P364, DOI 10.1016/j.tibs.2011.03.005
   Shen L, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-284
   Shi YJ, 2005, MOL CELL, V19, P857, DOI 10.1016/j.molcel.2005.08.027
   Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012
   Shi YJ, 2003, NATURE, V422, P735, DOI 10.1038/nature01550
   Shilatifard A, 2012, ANNU REV BIOCHEM, V81, P65, DOI 10.1146/annurev-biochem-051710-134100
   Sims RJ, 2005, J BIOL CHEM, V280, P41789, DOI 10.1074/jbc.C500395200
   Sze CC, 2017, GENE DEV, V31, P1732, DOI 10.1101/gad.303768.117
   Sze CC, 2016, CSH PERSPECT MED, V6, DOI 10.1101/cshperspect.a026427
   Tan J, 2015, NAT GENET, V47, P1341, DOI 10.1038/ng.3409
   Tesar PJ, 2007, NATURE, V448, P196, DOI 10.1038/nature05972
   Vermeulen M, 2007, CELL, V131, P58, DOI 10.1016/j.cell.2007.08.016
   Voncken JW, 2003, P NATL ACAD SCI USA, V100, P2468, DOI 10.1073/pnas.0434312100
   Wang CC, 2016, P NATL ACAD SCI USA, V113, P11871, DOI 10.1073/pnas.1606857113
   Wang L, 2017, GENE DEV, V31, P2056, DOI 10.1101/gad.306092.117
   Wang PF, 2009, MOL CELL BIOL, V29, P6074, DOI 10.1128/MCB.00924-09
   Wang SP, 2017, MOL CELL, V67, P308, DOI 10.1016/j.molcel.2017.06.028
   Wang Y, 2009, CELL, V138, P660, DOI 10.1016/j.cell.2009.05.050
   Weinberger L, 2016, NAT REV MOL CELL BIO, V17, P155, DOI 10.1038/nrm.2015.28
   Whyte WA, 2013, CELL, V153, P307, DOI 10.1016/j.cell.2013.03.035
   Whyte WA, 2012, NATURE, V482, P221, DOI 10.1038/nature10805
   Wu M, 2008, MOL CELL BIOL, V28, P7337, DOI 10.1128/MCB.00976-08
   Wysocka J, 2006, NATURE, V442, P86, DOI 10.1038/nature04815
   Ying QL, 2008, NATURE, V453, P519, DOI 10.1038/nature06968
   Zhang JY, 2015, NAT MED, V21, P1190, DOI 10.1038/nm.3940
   Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r137
NR 64
TC 45
Z9 53
U1 1
U2 10
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 2375-2548
J9 SCI ADV
JI Sci. Adv.
PD JAN
PY 2018
VL 4
IS 1
AR eaap8747
DI 10.1126/sciadv.aap8747
PG 13
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA FY3CF
UT WOS:000426694200062
PM 29404406
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Yang, P
   Gong, YJ
   Cao, WC
   Wang, RX
   Wang, YX
   Liu, C
   Chen, YJ
   Huang, LL
   Ai, SH
   Lu, WQ
   Zeng, Q
AF Yang, Pan
   Gong, Ya-Jie
   Cao, Wen-Cheng
   Wang, Rui-Xin
   Wang, Yi-Xin
   Liu, Chong
   Chen, Ying-Jun
   Huang, Li-Li
   Ai, Song-Hua
   Lu, Wen-Qing
   Zeng, Qiang
TI Prenatal urinary polycyclic aromatic hydrocarbon metabolites, global DNA
   methylation in cord blood, and birth outcomes: A cohort study in China
SO ENVIRONMENTAL POLLUTION
LA English
DT Article
DE Birth outcomes; Cord blood; DNA methylation; Epigenetics; Polycyclic
   aromatic hydrocarbons
ID INTRAUTERINE GROWTH RESTRICTION; BREAST-CANCER; PROMOTER METHYLATION;
   GESTATIONAL-AGE; RISK-ASSESSMENT; FINE PARTICLES; DRINKING-WATER;
   AIR-POLLUTION; FETAL-GROWTH; EXPOSURE
AB Background: Prenatal exposure to polycyclic aromatic hydrocarbons (PAHs) is a potential risk factor for adverse birth outcomes. Epigenetic mechanisms may play a key role in which PAHs exert its effects. Objective: Our study aimed to examine whether prenatal PAH exposure was associated with adverse birth outcomes and altered DNA methylation and to explore potential mediating roles of DNA methylation.
   Methods: Ten urinary PAH metabolites were measured from 106 pregnant women during late pregnancy in a Chinese cohort study. Cord blood DNA methylation in long interspersed nucleotide element-1 (LINE-1) and Alu repetitive elements as surrogates of global DNA methylation was analyzed by bisulfite pyrosequencing. Multivariable linear regression was used to estimate the associations of urinary PAH metabolites with birth outcomes and DNA methylation, and a mediation analysis was also conducted.
   Results: Prenatal urinary 2-hydroxynaphthatene (2-OHNa), Sigma OHNa (sum of 1- and 2-OHNa), and sum of monohydroxy-PAH (Sigma OHNa-PAHs) were associated with lower birth length (e.g., -0.80%, 95% CI: -1.39%, -0.20% for the third vs. first tertile of 2-OHNa; p for trend = 0.01). Prenatal urinary 2-OHNa and 1-hydroxyphenanthrene (1-OHPh) were associated with lower Alu and LINE-1 methylation (e.g., -1.88%, 95% CI: -3.73%, 0.10% for the third vs. first tertile tertile of 2-OHNa in Alu methylation; p for trend = 0.04). Mediation analysis failed to show a mediator effect of global DNA methylation in the association between prenatal urinary OH-PAHs and birth outcomes.
   Conclusions: Prenatal specific PAH exposures are associated with decreased birth length and global DNA methylation. However, global DNA methylation does not mediate the associations of prenatal PAH exposure with birth outcomes. Further studies are needed to confirm the results. (C) 2017 Elsevier Ltd. All rights reserved.
C1 [Yang, Pan; Cao, Wen-Cheng; Wang, Rui-Xin; Wang, Yi-Xin; Liu, Chong; Chen, Ying-Jun; Huang, Li-Li; Ai, Song-Hua; Lu, Wen-Qing; Zeng, Qiang] Huazhong Univ Sci & Technol, Sch Publ Hlth, Dept Occupat & Environm Hlth, Tongji Med Coll, Wuhan, Hubei, Peoples R China.
   [Yang, Pan; Cao, Wen-Cheng; Wang, Rui-Xin; Wang, Yi-Xin; Liu, Chong; Chen, Ying-Jun; Huang, Li-Li; Ai, Song-Hua; Lu, Wen-Qing; Zeng, Qiang] Huazhong Univ Sci & Technol, Key Lab Environm & Hlth, Minist Educ, Sch Publ Hlth,Tongji Med Coll, Wuhan, Hubei, Peoples R China.
   [Yang, Pan; Cao, Wen-Cheng; Wang, Rui-Xin; Wang, Yi-Xin; Liu, Chong; Chen, Ying-Jun; Huang, Li-Li; Ai, Song-Hua; Lu, Wen-Qing; Zeng, Qiang] Huazhong Univ Sci & Technol, Minist Environm Protect, State Key Lab Environm Hlth Incubating, Sch Publ Hlth,Tongji Med Coll, Wuhan, Hubei, Peoples R China.
   [Gong, Ya-Jie] Huazhong Univ Sci & Technol, Sch Publ Hlth, Dept Epidemiol & Biostat, Tongji Med Coll, Wuhan, Hubei, Peoples R China.
C3 Huazhong University of Science & Technology; Huazhong University of
   Science & Technology; Huazhong University of Science & Technology;
   Huazhong University of Science & Technology
RP Zeng, Q (通讯作者)，Huazhong Univ Sci & Technol, Sch Publ Hlth, Dept Occupat & Environm Hlth, Tongji Med Coll, Wuhan, Hubei, Peoples R China.
EM zengqiang506@163.com
RI Wang, Yixin/AAI-2758-2021; Cai, Jingjing/JXN-8391-2024; Wang,
   ruixin/KTI-1761-2024; Liu, Chong/JGL-9530-2023; Wenqing,
   LU/GVS-4946-2022
OI Liu, Chong/0000-0003-2014-6464; Wang, Yi-Xin/0000-0003-4324-2408
FU National Natural Science Foundation of China [81472946, 81502784];
   Nature Science Foundation of Hubei Province [2015CFB308]; China
   Postdoctoral Science Foundation [2015M580645]
FX We thank all the participants for providing biological samples, and also
   thank the staff members in the hospital for contributing to this study.
   This research was funded by the National Natural Science Foundation of
   China (No. 81472946, 81502784), Nature Science Foundation of Hubei
   Province (No. 2015CFB308) and China Postdoctoral Science Foundation (No.
   2015M580645).
CR Alegría-Torres JA, 2013, CHEMOSPHERE, V91, P475, DOI 10.1016/j.chemosphere.2012.11.077
   Archibong AE, 2002, REPROD TOXICOL, V16, P801, DOI 10.1016/S0890-6238(02)00058-8
   Barr DB, 2007, REPROD TOXICOL, V23, P260, DOI 10.1016/j.reprotox.2007.03.003
   Bernstein BE, 2007, CELL, V128, P669, DOI 10.1016/j.cell.2007.01.033
   Bollati V, 2007, CANCER RES, V67, P876, DOI 10.1158/0008-5472.CAN-06-2995
   BUI QQ, 1986, TOXICOLOGY, V42, P195, DOI 10.1016/0300-483X(86)90009-0
   Button KS, 2013, NAT REV NEUROSCI, V14, P365, DOI 10.1038/nrn3475
   Cao WC, 2016, ENVIRON HEALTH PERSP, V124, P536, DOI 10.1289/ehp.1409234
   Choi H, 2008, ENVIRON HEALTH PERSP, V116, P658, DOI 10.1289/ehp.10958
   Choi H, 2006, ENVIRON HEALTH PERSP, V114, P1744, DOI 10.1289/ehp.8982
   De Prins S, 2013, ENVIRON INT, V59, P418, DOI 10.1016/j.envint.2013.07.007
   Dejmek J, 2000, ENVIRON HEALTH PERSP, V108, P1159, DOI 10.2307/3434828
   Fang XF, 2010, AQUAT TOXICOL, V98, P130, DOI 10.1016/j.aquatox.2010.02.004
   Guo L, 2008, DEV BIOL, V320, P79, DOI 10.1016/j.ydbio.2008.04.025
   Herbstman JB, 2012, ENVIRON HEALTH PERSP, V120, P733, DOI 10.1289/ehp.1104056
   Hoffmann MJ, 2005, BIOCHEM CELL BIOL, V83, P296, DOI 10.1139/o05-036
   Hou LF, 2012, INT J EPIDEMIOL, V41, P79, DOI 10.1093/ije/dyr154
   Jacob R, 2002, J CHROMATOGR B, V778, P31
   Jedrychowski WA, 2017, INT ARCH OCC ENV HEA, V90, P255, DOI 10.1007/s00420-016-1192-9
   Kile ML, 2012, ENVIRON HEALTH PERSP, V120, P1061, DOI 10.1289/ehp.1104173
   Kile ML, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013730
   Kim KH, 2013, ENVIRON INT, V60, P71, DOI 10.1016/j.envint.2013.07.019
   Kim YI, 2004, CANCER EPIDEM BIOMAR, V13, P511
   Lamichhane DK, 2016, PUBLIC HEALTH NUTR, V19, P2562, DOI 10.1017/S1368980016000550
   Larsen RK, 2003, ENVIRON SCI TECHNOL, V37, P1873, DOI 10.1021/es0206184
   Lee J, 2017, ENVIRON INT, V99, P315, DOI 10.1016/j.envint.2016.12.009
   Lee Ken W. K., 2013, Frontiers in Genetics, V4, P132, DOI 10.3389/fgene.2013.00132
   Lee KH, 2010, CANCER EPIDEM BIOMAR, V19, P877, DOI 10.1158/1055-9965.EPI-09-1098
   Li Z, 2008, ENVIRON RES, V107, P320, DOI 10.1016/j.envres.2008.01.013
   Li Z, 2012, CHEM RES TOXICOL, V25, P1452, DOI 10.1021/tx300108e
   Li Z, 2010, J EXPO SCI ENV EPID, V20, P526, DOI 10.1038/jes.2009.41
   Luderer U, 2017, ENVIRON INT, V100, P110, DOI 10.1016/j.envint.2016.12.021
   Maccani MA, 2009, AM J REPROD IMMUNOL, V62, P78, DOI 10.1111/j.1600-0897.2009.00716.x
   Makri A, 2004, J TOXICOL ENV HEAL B, V7, P417, DOI 10.1080/10937400490512465
   McMinn J, 2006, PLACENTA, V27, P540, DOI 10.1016/j.placenta.2005.07.004
   Pavanello S, 2009, INT J CANCER, V125, P1692, DOI 10.1002/ijc.24492
   Perera F, 2005, CANCER EPIDEM BIOMAR, V14, P709, DOI 10.1158/1055-9965.EPI-04-0457
   Perera FP, 2003, ENVIRON HEALTH PERSP, V111, P201, DOI 10.1289/ehp.5742
   Pieters N, 2016, ENVIRON HEALTH PERSP, V124, P943, DOI 10.1289/ehp.1509728
   Pilsner JR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037147
   Polanska K, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/408939
   Ramesh A, 2004, INT J TOXICOL, V23, P301, DOI 10.1080/10915810490517063
   Sadikovic B, 2006, TOXICOL APPL PHARM, V216, P458, DOI 10.1016/j.taap.2006.06.012
   Sievers CK, 2013, TOXICOL SCI, V132, P359, DOI 10.1093/toxsci/kfs287
   Singh VK, 2008, INT J HYG ENVIR HEAL, V211, P639, DOI 10.1016/j.ijheh.2007.11.004
   Straif K, 2005, LANCET ONCOL, V6, P931, DOI 10.1016/S1470-2045(05)70458-7
   Suzuki Y, 2010, ENVIRON INT, V36, P699, DOI 10.1016/j.envint.2010.05.003
   Tellez-Plaza M, 2014, ENVIRON HEALTH PERSP, V122, P946, DOI 10.1289/ehp.1306674
   Teneng I, 2011, EPIGENETICS-US, V6, P355, DOI 10.4161/epi.6.3.14282
   Valeri L, 2013, PSYCHOL METHODS, V18, P137, DOI 10.1037/a0031034
   Wang W, 2011, SCI TOTAL ENVIRON, V409, P4519, DOI 10.1016/j.scitotenv.2011.07.030
   White AJ, 2016, ENVIRON RES, V145, P93, DOI 10.1016/j.envres.2015.11.033
   WILSON VL, 1983, CELL, V32, P239, DOI 10.1016/0092-8674(83)90514-7
   Wu HC, 2011, EPIGENETICS-US, V6, P76, DOI 10.4161/epi.6.1.13391
   Wu J, 2010, SCI TOTAL ENVIRON, V408, P2312, DOI 10.1016/j.scitotenv.2010.02.028
   Yang AS, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh032
   Yang P, 2017, SCI TOTAL ENVIRON, V586, P313, DOI 10.1016/j.scitotenv.2017.01.224
   Yang P, 2017, J HAZARD MATER, V329, P241, DOI 10.1016/j.jhazmat.2017.01.053
   Yang P, 2017, ENVIRON SCI TECHNOL, V51, P958, DOI 10.1021/acs.est.6b04810
NR 59
TC 47
Z9 50
U1 1
U2 67
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0269-7491
EI 1873-6424
J9 ENVIRON POLLUT
JI Environ. Pollut.
PD MAR
PY 2018
VL 234
BP 396
EP 405
DI 10.1016/j.envpol.2017.11.082
PG 10
WC Environmental Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Environmental Sciences & Ecology
GA FX6VJ
UT WOS:000426225100041
PM 29202418
DA 2025-01-12
ER

PT J
AU Sanchez, GJ
   Richmond, PA
   Bunker, EN
   Karman, SS
   Azofeifa, J
   Garnett, AT
   Xu, QB
   Wheeler, GE
   Toomey, CM
   Zhang, QH
   Dowell, RD
   Liu, XD
AF Sanchez, Gilson J.
   Richmond, Phillip A.
   Bunker, Eric N.
   Karman, Samuel S.
   Azofeifa, Joseph
   Garnett, Aaron T.
   Xu, Quanbin
   Wheeler, Graycen E.
   Toomey, Cathryn M.
   Zhang, Qinghong
   Dowell, Robin D.
   Liu, Xuedong
TI Genome-wide dose-dependent inhibition of histone deacetylases studies
   reveal their roles in enhancer remodeling and suppression of oncogenic
   super-enhancers
SO NUCLEIC ACIDS RESEARCH
LA English
DT Article
ID TRANSCRIPTIONAL ENHANCERS; MACROPHAGE ACTIVATION; RNA-POLYMERASE; CELL
   IDENTITY; BREAST-CANCER; GENE; LARGAZOLE; ACETYLATION; ELONGATION;
   DROSOPHILA
AB Histone deacetylase inhibitors (HDACIs) are known to alter gene expression by both up-and down-regulation of protein-coding genes in normal and cancer cells. However, the exact regulatory mechanisms of action remain uncharacterized. Here we investigated genome wide dose-dependent epigenetic and transcriptome changes in response to HDACI largazole in a transformed and a non-transformed cell line. Exposure to low nanomolar largazole concentrations (<GI(50)) predominantly resulted in upregulation of gene transcripts whereas higher largazole doses (>= GI(50)) triggered a general decrease in mRNA accumulation. Largazole induces elevation of histone H3 acetylation at Lys-9 and Lys-27 along many gene bodies but does not correlate with up- or down-regulation of the associated transcripts. A higher dose of largazole results in more RNA polymerase II pausing at the promoters of actively transcribed genes and cell death. The most prevalent changes associated with transcriptional regulation occur at distal enhancer elements. Largazole promotes H3K27 acetylation at a subset of poised enhancers and unexpectedly, we also found active enhancers that become decommissioned in a dose and cell type-dependent manner. In particular, largazole decreases RNA polymerase II accumulation at super-enhancers (SEs) and preferentially suppresses SE-driven transcripts that are associated with oncogenic activities in transformed cells.
C1 [Sanchez, Gilson J.; Bunker, Eric N.; Karman, Samuel S.; Xu, Quanbin; Wheeler, Graycen E.; Toomey, Cathryn M.; Liu, Xuedong] Univ Colorado Boulder, Dept Chem & Biochem, Boulder, CO 80309 USA.
   [Richmond, Phillip A.; Azofeifa, Joseph; Dowell, Robin D.] Univ Colorado Boulder, BioFrontiers Inst, Boulder, CO 80303 USA.
   [Richmond, Phillip A.; Azofeifa, Joseph; Dowell, Robin D.] Univ Colorado Boulder, IQ Biol Program, Boulder, CO 80303 USA.
   [Richmond, Phillip A.; Dowell, Robin D.] Univ Colorado Boulder, Mol Cellular & Dev Biol, Boulder, CO 80309 USA.
   [Garnett, Aaron T.] Univ Colorado Boulder, Ecol & Evolutionary Biol, Boulder, CO 80309 USA.
   [Zhang, Qinghong] Univ Colorado Denver, Dept Dermatol, Aurora, CO 80045 USA.
C3 University of Colorado System; University of Colorado Boulder;
   University of Colorado System; University of Colorado Boulder;
   University of Colorado System; University of Colorado Boulder;
   University of Colorado System; University of Colorado Boulder;
   University of Colorado System; University of Colorado Boulder;
   Children's Hospital Colorado; University of Colorado System; University
   of Colorado Anschutz Medical Campus
RP Liu, XD (通讯作者)，Univ Colorado Boulder, Dept Chem & Biochem, Boulder, CO 80309 USA.; Dowell, RD (通讯作者)，Univ Colorado Boulder, BioFrontiers Inst, Boulder, CO 80303 USA.; Dowell, RD (通讯作者)，Univ Colorado Boulder, IQ Biol Program, Boulder, CO 80303 USA.; Dowell, RD (通讯作者)，Univ Colorado Boulder, Mol Cellular & Dev Biol, Boulder, CO 80309 USA.
EM Robin.Dowell@colorado.edu; liux@colorado.edu
RI Xu, Quanbin/K-1904-2019; Liu, Xuedong/IVV-8465-2023
OI Xu, Quanbin/0000-0002-2833-9773; LIU, XUEDONG/0000-0001-7209-4964;
   Wheeler, Graycen/0000-0003-4604-1097; Bunker, Eric/0000-0003-0368-9512
FU National Cancer Institute of the National Institutes of Health
   [CA107098, AR068254]; National Institute of Arthritis and
   Musculoskeletal and Skin Diseases of the National Institutes of Health
   [CA107098, AR068254]; National Cancer Institute [CA107098S1]; Bioscience
   Discovery Evaluation Grant Program from the State of Colorado
   [14BGF-28]; National Institute of General Medical Sciences [T32GM08759];
   National Center for Research Resources [S10 RR026680]; National
   Institutes of Health [S10OD021601, 1S10OD012300-01]; NIH/NIAMS
   [R01AR068254]
FX National Cancer Institute and National Institute of Arthritis and
   Musculoskeletal and Skin Diseases of the National Institutes of Health
   [CA107098, AR068254 to X.L.]; National Cancer Institute [CA107098S1 to
   G.S.]; Bioscience Discovery Evaluation Grant Program [14BGF-28] from the
   State of Colorado; National Institute of General Medical Sciences
   [T32GM08759 to E.B.]; ImageXpress MicroXL was supported by the National
   Center for Research Resources [S10 RR026680]; FACSAria was supported by
   the National Institutes of Health [S10OD021601]; high-memory
   supercomputer was supported by National Institutes of Health
   [1S10OD012300-01]. Funding for open access charge: NIH/NIAMS
   [R01AR068254].
CR Adelman K, 2012, NAT REV GENET, V13, P720, DOI 10.1038/nrg3293
   ALLEN MA, 2014, ELIFE, V2014, P1
   [Anonymous], 2010, GENOME BIOL
   Azofeifa JG, 2017, IEEE ACM T COMPUT BI, V14, P1070, DOI 10.1109/TCBB.2016.2520919
   Bailey TL, 2009, NUCLEIC ACIDS RES, V37, pW202, DOI 10.1093/nar/gkp335
   Bolger AM, 2014, BIOINFORMATICS, V30, P2114, DOI 10.1093/bioinformatics/btu170
   Bowers A, 2008, J AM CHEM SOC, V130, P11219, DOI 10.1021/ja8033763
   Carrozza MJ, 2005, CELL, V123, P581, DOI 10.1016/j.cell.2005.10.023
   Chen GQ, 1999, GENE DEV, V13, P2218, DOI 10.1101/gad.13.17.2218
   Doehn U, 2009, MOL CELL, V35, P511, DOI 10.1016/j.molcel.2009.08.002
   Frietze S, 2012, GENOME BIOL, V13, DOI 10.1186/gb-2012-13-9-r52
   Govind CK, 2010, MOL CELL, V39, P234, DOI 10.1016/j.molcel.2010.07.003
   Greer CB, 2015, CELL REP, V13, P1444, DOI 10.1016/j.celrep.2015.10.013
   Gupta S, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-2-r24
   Hasegawa Y, 2010, DEV CELL, V19, P469, DOI 10.1016/j.devcel.2010.08.006
   He HSHS, 2010, NAT GENET, V42, P343, DOI 10.1038/ng.545
   Heinz S, 2015, NAT REV MOL CELL BIO, V16, P144, DOI 10.1038/nrm3949
   Hnisz D, 2015, MOL CELL, V58, P362, DOI 10.1016/j.molcel.2015.02.014
   Hnisz D, 2013, CELL, V155, P934, DOI 10.1016/j.cell.2013.09.053
   Hu DQ, 2013, MOL CELL BIOL, V33, P4745, DOI 10.1128/MCB.01181-13
   Ji RR, 2011, BIOINFORMATICS, V27, P2921, DOI 10.1093/bioinformatics/btr489
   Jin QH, 2011, EMBO J, V30, P249, DOI 10.1038/emboj.2010.318
   Kaikkonen MU, 2013, MOL CELL, V51, P310, DOI 10.1016/j.molcel.2013.07.010
   Kent WJ, 2002, GENOME RES, V12, P996, DOI 10.1101/gr.229102
   Khan A, 2016, NUCLEIC ACIDS RES, V44, pD164, DOI 10.1093/nar/gkv1002
   Kim YJ, 2013, ONCOGENE, V32, P2828, DOI 10.1038/onc.2013.32
   Koenecke N, 2017, GENOME RES, V27, P64, DOI 10.1101/gr.209486.116
   Kwiatkowski N, 2014, NATURE, V511, P616, DOI 10.1038/nature13393
   Langmead B, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-3-r25
   Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324
   Liu YX, 2010, J PHARMACOL EXP THER, V335, P351, DOI 10.1124/jpet.110.172387
   Lovén J, 2013, CELL, V153, P320, DOI 10.1016/j.cell.2013.03.036
   Marks PA, 2010, BBA-GENE REGUL MECH, V1799, P717, DOI 10.1016/j.bbagrm.2010.05.008
   Mechta F, 1997, ONCOGENE, V14, P837, DOI 10.1038/sj.onc.1200900
   Minucci S, 2006, NAT REV CANCER, V6, P38, DOI 10.1038/nrc1779
   Muse GW, 2007, NAT GENET, V39, P1507, DOI 10.1038/ng.2007.21
   Nasveschuk CG, 2008, ORG LETT, V10, P3595, DOI 10.1021/ol8013478
   Ogawa S, 2004, P NATL ACAD SCI USA, V101, P14461, DOI 10.1073/pnas.0405786101
   Parker SCJ, 2013, P NATL ACAD SCI USA, V110, P17921, DOI 10.1073/pnas.1317023110
   Quinlan AR, 2010, BIOINFORMATICS, V26, P841, DOI 10.1093/bioinformatics/btq033
   Rada-Iglesias A, 2007, GENOME RES, V17, P708, DOI 10.1101/gr.5540007
   Rafehi H, 2014, GENOME RES, V24, P1271, DOI 10.1101/gr.168781.113
   Rahl PB, 2010, CELL, V141, P432, DOI 10.1016/j.cell.2010.03.030
   Reynolds N, 2012, CELL STEM CELL, V10, P583, DOI 10.1016/j.stem.2012.02.020
   Shlyueva D, 2014, NAT REV GENET, V15, P272, DOI 10.1038/nrg3682
   Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412
   Sundaresan NR, 2012, NAT MED, V18, P1643, DOI 10.1038/nm.2961
   Taori K, 2008, J AM CHEM SOC, V130, P1806, DOI 10.1021/ja7110064
   Turner NC, 2015, NEW ENGL J MED, V373, P209, DOI 10.1056/NEJMoa1505270
   Vallejo A, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14294
   Vial E, 2003, CANCER CELL, V4, P67, DOI 10.1016/S1535-6108(03)00162-4
   Wang ZB, 2009, CELL, V138, P1019, DOI 10.1016/j.cell.2009.06.049
   Whyte WA, 2013, CELL, V153, P307, DOI 10.1016/j.cell.2013.03.035
   Whyte WA, 2012, NATURE, V482, P221, DOI 10.1038/nature10805
   Wolf D, 2002, J BIOL CHEM, V277, P25562, DOI 10.1074/jbc.M201196200
   Xu M, 2003, EMBO J, V22, P893, DOI 10.1093/emboj/cdg094
   Yang XJ, 2008, NAT REV MOL CELL BIO, V9, P206, DOI 10.1038/nrm2346
   Zang CZ, 2009, BIOINFORMATICS, V25, P1952, DOI 10.1093/bioinformatics/btp340
   Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r137
   Zhao YM, 2005, BIOCHEM BIOPH RES CO, V326, P811, DOI 10.1016/j.bbrc.2004.11.118
NR 60
TC 55
Z9 62
U1 0
U2 4
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0305-1048
EI 1362-4962
J9 NUCLEIC ACIDS RES
JI Nucleic Acids Res.
PD FEB 28
PY 2018
VL 46
IS 4
BP 1756
EP 1776
DI 10.1093/nar/gkx1225
PG 21
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA FX7TG
UT WOS:000426293300022
PM 29240919
OA gold, Green Published, Green Submitted
DA 2025-01-12
ER

PT J
AU Mayr, C
   Helm, K
   Jakab, M
   Ritter, M
   Shrestha, R
   Makaju, R
   Wagner, A
   Pichler, M
   Beyreis, M
   Staettner, S
   Jaeger, T
   Klieser, E
   Kiesslich, T
   Neureiter, D
AF Mayr, Christian
   Helm, Katharina
   Jakab, Martin
   Ritter, Markus
   Shrestha, Rajeev
   Makaju, Ramesh
   Wagner, Andrej
   Pichler, Martin
   Beyreis, Marlena
   Staettner, Stefan
   Jaeger, Tarkan
   Klieser, Eckhard
   Kiesslich, Tobias
   Neureiter, Daniel
TI The histone methyltransferase G9a: a new therapeutic target in biliary
   tract cancer
SO HUMAN PATHOLOGY
LA English
DT Article
DE Biliary tract cancer; Epigenetics; Histone methyltransferase; G9a;
   H3K9me2
ID BREAST-CANCER; STEM-CELLS; E-CADHERIN; INHIBITOR; CARCINOMA; BIX-01294;
   INVASION; GROWTH; GLP; APOPTOSIS
AB The histone methyltransferase G9a (EHMT2) is a key enzyme for dimethylation of lysine 9 at his tone 3 (H3K9me2), a suppressive epigenetic mark. G9a is over-expressed in tumor cells and contributes to cancer aggressiveness. Biliary tract cancer (BTC) is a rare cancer with dismal prognosis due to a lack of effective therapies. Currently, there are no data on the role of G9a in BTC carcinogenesis. We analyzed G9a expression in n = 68 BTC patient specimens and correlated the data with clinicopathological and survival data. Moreover, we measured G9a expression in a panel of BTC cell lines and evaluated the cytotoxic effect of G9a inhibition in BTC cells using established small-molecule G9a inhibitors. G9a was considerably expressed in about half of BTC cases and was significantly associated with grading and tumor size. Additionally, we observed significant differences of G9a expression between growth type and tumor localization groups. G9a expression diametrically correlated with Vimentin (positive) and E-Cadherin (negative) expression. Importantly, survival analysis revealed G9a as a significant prognostic factor of poor survival in patients with BTC. In BTC cells, G9a and H3K9me2 were detectable in a cell line dependent manner on mRNA and/or protein level, respectively. Treatment of BTC cells with established small-molecule G9a inhibitors resulted in reduction of cell viability as well as reduced G9a and H3K9me2 protein levels. The present study strongly suggests that G9a contributes to BTC carcinogenesis and may represent a potential prognostic factor as well as a therapeutic target. (C) 2017 Elsevier Inc. All rights reserved.
C1 [Mayr, Christian; Helm, Katharina; Ritter, Markus; Beyreis, Marlena; Kiesslich, Tobias] Paracelsus Med Univ, Inst Physiol & Pathophysiol, Lab Tumour Biol & Expt Therapies TREAT, A-5020 Salzburg, Austria.
   [Mayr, Christian; Wagner, Andrej; Kiesslich, Tobias] Paracelsus Med Univ, Dept Internal Med 1, Salzburger Landeskliniken SALK, A-5020 Salzburg, Austria.
   [Helm, Katharina; Jakab, Martin; Ritter, Markus; Beyreis, Marlena] Paracelsus Med Univ, Inst Physiol & Pathophysiol, Lab Funct & Mol Membrane Physiol FMMP, A-5020 Salzburg, Austria.
   [Ritter, Markus] Paracelsus Med Univ, Inst Physiol & Pathophysiol, Ludwig Boltzmann Cluster Arthrit & Rehabil, Dept Radon Therapy Res, A-5020 Salzburg, Austria.
   [Shrestha, Rajeev] Kathmandu Univ, Dhulikhel Hosp, Dept Res & Dev, Canc Res Unit, Dhulikhel 45200, Nepal.
   [Makaju, Ramesh] Kathmandu Univ Hosp, Dhulikhel Hosp, Dept Pathol, Dhulikhel 45200, Nepal.
   [Pichler, Martin] Med Univ Graz, Dept Internal Med, Div Oncol, A-8036 Graz, Austria.
   [Pichler, Martin] UT MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA.
   [Staettner, Stefan] Med Univ Innsbruck, Dept Visceral Transplant & Thorac Surg, A-6020 Innsbruck, Austria.
   [Jaeger, Tarkan] Paracelsus Med Univ, Dept Surg, Salzburger Landeskliniken SALK, A-5020 Salzburg, Austria.
   [Klieser, Eckhard; Neureiter, Daniel] Paracelsus Med Univ, Salzburger Landeskliniken SALK, Inst Pathol, Canc Cluster Salzburg, A-5020 Salzburg, Austria.
C3 Paracelsus Private Medical University; Paracelsus Private Medical
   University; Paracelsus Private Medical University; Paracelsus Private
   Medical University; Kathmandu University; Kathmandu University; Medical
   University of Graz; University of Texas System; UTMD Anderson Cancer
   Center; Medical University of Innsbruck; Paracelsus Private Medical
   University; Paracelsus Private Medical University
RP Neureiter, D (通讯作者)，Paracelsus Med Univ, Salzburger Landeskliniken SALK, Inst Pathol, Canc Cluster Salzburg, A-5020 Salzburg, Austria.
EM ch.mayr@salk.at; katharina.helm@stud.pmu.ac.at; martin.jakab@pmu.ac.at;
   markus.ritter@pmu.ac.at; rmaleku@hotmail.com; makajuram@yahoo.com;
   and.wagner@salk.at; martin.pichler@medunigraz.at;
   marlena.beyreis@pmu.ac.at; stefan.staettner@tirol-kliniken.at;
   ta.jaeger@salk.at; e.klieser@salk.at; t.kiesslich@salk.at;
   d.neureiter@salk.at
RI Shrestha, Rajeev/N-5217-2018; Stättner, Stefan/F-7470-2016; Ritter,
   Markus/AAG-4987-2020; Jager, Tarkan/P-8966-2015
OI Ritter, Markus/0000-0001-7346-7750; Pichler, Martin/0000-0002-8701-9462;
   Stattner, Stefan/0000-0002-5226-7597; Kiesslich,
   Tobias/0000-0001-5403-9478; Jager, Tarkan/0000-0002-2390-0226; Jakab,
   Martin/0000-0003-2110-5090; Mayr, Christian/0000-0003-1898-8363
FU Oesterreichische Nationalbank (Austrian Central Bank) [14842];
   Paracelsus Medical University Salzburg [A12-02-006-KIE]
FX This study was supported by funds of the Oesterreichische Nationalbank
   (Austrian Central Bank, Anniversary Fund, project number: 14842) and the
   research fund of the Paracelsus Medical University Salzburg (grant No.
   A12-02-006-KIE).
CR Casciello F, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00487
   Chen MW, 2010, CANCER RES, V70, P7830, DOI 10.1158/0008-5472.CAN-10-0833
   Cui J, 2015, CANCER CELL INT, V15, DOI 10.1186/s12935-014-0149-x
   Curry E, 2015, CLIN EPIGENETICS, V7, DOI 10.1186/s13148-015-0118-9
   DETRE S, 1995, J CLIN PATHOL, V48, P876, DOI 10.1136/jcp.48.9.876
   Ding J, 2013, CELL METAB, V18, P896, DOI 10.1016/j.cmet.2013.11.004
   Dong CF, 2012, J CLIN INVEST, V122, P1469, DOI 10.1172/JCI57349
   Egger G, 2004, NATURE, V429, P457, DOI 10.1038/nature02625
   Estève PO, 2006, GENE DEV, V20, P3089, DOI 10.1101/gad.1463706
   Guo AS, 2016, MOL MED REP, V14, P4613, DOI 10.3892/mmr.2016.5815
   Hsiao SM, 2015, ANN SURG ONCOL, V22, pS1556, DOI 10.1245/s10434-015-4379-5
   Hua KT, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-189
   Huang J, 2010, J BIOL CHEM, V285, P9636, DOI 10.1074/jbc.M109.062588
   Huang TH, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.65
   Kim Y, 2013, AUTOPHAGY, V9, P2126, DOI 10.4161/auto.26308
   Kubicek S, 2007, MOL CELL, V25, P473, DOI 10.1016/j.molcel.2007.01.017
   Lin XL, 2016, ONCOL REP, V35, P3041, DOI 10.3892/or.2016.4692
   Liu F, 2013, J MED CHEM, V56, P8931, DOI 10.1021/jm401480r
   Mayr C, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/4805270
   Mayr C, 2016, ONCOTARGET, V7, P745, DOI 10.18632/oncotarget.6378
   Mayr C, 2015, ANTICANCER RES, V35, P4697
   MIYAGIWA M, 1989, IN VITRO CELL DEV B, V25, P503
   Mozzetta C, 2014, MOL CELL, V53, P277, DOI 10.1016/j.molcel.2013.12.005
   Oh SY, 2015, MOL CELLS, V38, P528, DOI 10.14348/molcells.2015.0026
   Pang ALY, 2014, ONCOL LETT, V7, P1819, DOI 10.3892/ol.2014.2034
   Razumilava N, 2014, LANCET, V383, P2168, DOI 10.1016/S0140-6736(13)61903-0
   Sauvageau M, 2010, CELL STEM CELL, V7, P299, DOI 10.1016/j.stem.2010.08.002
   Savickiene J, 2014, LEUKEMIA RES, V38, P822, DOI 10.1016/j.leukres.2014.04.003
   Urbas R, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17122053
   Valle JW, 2014, ANN ONCOL, V25, P391, DOI 10.1093/annonc/mdt540
   Wagner A, 2015, HEPATOLOGY, V62, P1456, DOI 10.1002/hep.27905
   Wei L, 2017, J HEPATOL, V67, P758, DOI 10.1016/j.jhep.2017.05.015
   Wu H, 2011, CELL RES, V21, P365, DOI 10.1038/cr.2010.157
   Yuan Y, 2012, ACS CHEM BIOL, V7, P1152, DOI 10.1021/cb300139y
   Zhong XW, 2015, HISTOPATHOLOGY, V66, P192, DOI 10.1111/his.12456
NR 35
TC 20
Z9 20
U1 0
U2 7
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0046-8177
EI 1532-8392
J9 HUM PATHOL
JI Hum. Pathol.
PD FEB
PY 2018
VL 72
BP 117
EP 126
DI 10.1016/j.humpath.2017.11.003
PG 10
WC Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pathology
GA FX4EC
UT WOS:000426024500014
PM 29133140
DA 2025-01-12
ER

PT J
AU Liao, B
   Zhang, YY
   Sun, Q
   Jiang, P
AF Liao, Bo
   Zhang, Yingying
   Sun, Quan
   Jiang, Ping
TI Vorinostat enhances the anticancer effect of oxaliplatin on
   hepatocellular carcinoma cells
SO CANCER MEDICINE
LA English
DT Article
DE BRCA1; combination; hepatocellular carcinoma; oxaliplatin; vorinostat
ID HISTONE DEACETYLASE INHIBITORS; SUBEROYLANILIDE HYDROXAMIC ACID;
   EPIGENETIC THERAPY; CANCER STATISTICS; BREAST-CANCER; BRCA1;
   COMBINATION; EXPRESSION; REPAIR; HDAC
AB Oxaliplatin-based systemic chemotherapy has been proposed to have efficacy in hepatocellular carcinoma (HCC). We investigated the combination of vorinostat and oxaliplatin for possible synergism in HCC cells. SMMC7721, BEL7402, and HepG2 cells were treated with vorinostat and oxaliplatin. Cytotoxicity assay, tumorigenicity assay in vitro, cell cycle analysis, apoptosis analysis, western blot analysis, animal model study, immunohistochemistry, and quantitative PCR were performed. We found that vorinostat and oxaliplatin inhibited the proliferation of SMMC7721, BEL7402, and HepG2 cells. The combination index (CI) values were all <1, and the dose-reduction index values were all greater than 1 in the three cell lines, indicating a synergistic effect of combination of the two agents. Coadministration of vorinostat and oxaliplatin induced G2/M phase arrest, triggered caspase-dependent apoptosis, and decreased tumorigenicity both in vitro and in vivo. Vorinostat suppressed the expression of BRCA1 induced by oxaliplatin. In conclusion, cotreatment with vorinostat and oxaliplatin exhibited synergism in HCC cells. The combination inhibited cell proliferation and tumorigenicity both in vitro and in vivo through induction of cell cycle arrest and apoptosis. Our results predict that a combination of vorinostat and oxaliplatin may be useful in the treatment of advanced HCC.
C1 [Liao, Bo; Sun, Quan; Jiang, Ping] Wuhan Univ, Zhongnan Hosp, Dept Hepatopancreatobiliary Surg, Wuhan, Hubei, Peoples R China.
   [Zhang, Yingying] Wuhan Univ, Zhongnan Hosp, Intens Care Unit, Wuhan, Hubei, Peoples R China.
C3 Wuhan University; Wuhan University
RP Jiang, P (通讯作者)，Wuhan Univ, Zhongnan Hosp, Dept Hepatopancreatobiliary Surg, Wuhan, Hubei, Peoples R China.
EM jiangp2003@whu.edu.cn
FU Fundamental Research Funds for the Central Universities of Ministry of
   Education of China [2042017kf0094]
FX This work was supported by the Fundamental Research Funds for the
   Central Universities of Ministry of Education of China (Grant No.
   2042017kf0094).
CR Alcindor T, 2011, CURR ONCOL, V18, P18
   Anestopoulos I, 2015, PHARMACOL THERAPEUT, V145, P103, DOI 10.1016/j.pharmthera.2014.09.005
   Bose P, 2014, PHARMACOL THERAPEUT, V143, P323, DOI 10.1016/j.pharmthera.2014.04.004
   Bots M, 2009, CLIN CANCER RES, V15, P3970, DOI 10.1158/1078-0432.CCR-08-2786
   Bruix J, 2011, HEPATOLOGY, V53, P1020, DOI 10.1002/hep.24199
   Carrato A, 2002, CRIT REV ONCOL HEMAT, V44, P29, DOI 10.1016/S1040-8428(01)00192-5
   Chao OS, 2014, MOL CANCER RES, V12, P1755, DOI 10.1158/1541-7786.MCR-14-0173
   Chen L, 2014, CELL COMMUN SIGNAL, V12, DOI 10.1186/1478-811X-12-18
   Chen L, 2012, CELL BIOCHEM FUNCT, V30, P588, DOI 10.1002/cbf.2838
   Chen PJ, 2010, LIVER INT, V30, P1427, DOI 10.1111/j.1478-3231.2010.02292.x
   Chen WQ, 2016, CA-CANCER J CLIN, V66, P115, DOI 10.3322/caac.21338
   Cheng AL, 2012, EUR J CANCER, V48, P1452, DOI 10.1016/j.ejca.2011.12.006
   Cheng AL, 2009, LANCET ONCOL, V10, P25, DOI 10.1016/S1470-2045(08)70285-7
   Chou TC, 2006, PHARMACOL REV, V58, P621, DOI 10.1124/pr.58.3.10
   Chou TC, 2010, CANCER RES, V70, P440, DOI 10.1158/0008-5472.CAN-09-1947
   Dever SM, 2012, CELL CYCLE, V11, P687, DOI 10.4161/cc.11.4.19212
   Ding ZY, 2014, HEPATOLOGY, V60, P1620, DOI 10.1002/hep.27273
   Diyabalanage HVK, 2013, CANCER LETT, V329, P1, DOI 10.1016/j.canlet.2012.09.018
   Duvic M, 2007, BLOOD, V109, P31, DOI 10.1182/blood-2006-06-025999
   Esteller M, 2007, NAT REV GENET, V8, P286, DOI 10.1038/nrg2005
   Fakih MG, 2009, CLIN CANCER RES, V15, P3189, DOI 10.1158/1078-0432.CCR-08-2999
   Fedier A, 2003, INT J ONCOL, V22, P1169
   Flis S, 2009, BIOCHEM BIOPH RES CO, V387, P336, DOI 10.1016/j.bbrc.2009.07.017
   Forner A, 2012, LANCET, V379, P1245, DOI 10.1016/S0140-6736(11)61347-0
   Fukuda T, 2015, CANCER SCI, V106, P1050, DOI 10.1111/cas.12717
   Görisch SM, 2005, J CELL SCI, V118, P5825, DOI 10.1242/jcs.02689
   Gustavsson B, 2015, CLIN COLORECTAL CANC, V14, P1, DOI 10.1016/j.clcc.2014.11.002
   HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   Kachhap SK, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011208
   Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798
   KIDANI Y, 1980, GANN, V71, P637
   Kim J, 2009, INT J COLORECTAL DIS, V24, P209, DOI 10.1007/s00384-008-0590-1
   Kim MS, 2003, CANCER RES, V63, P7291
   Konstantinopoulos PA, 2014, GYNECOL ONCOL, V133, P599, DOI 10.1016/j.ygyno.2014.03.007
   Lakshmaiah KC, 2014, J CANCER RES THER, V10, P469, DOI 10.4103/0973-1482.137937
   Lane AA, 2009, J CLIN ONCOL, V27, P5459, DOI 10.1200/JCO.2009.22.1291
   LEE DY, 1993, CELL, V72, P73, DOI 10.1016/0092-8674(93)90051-Q
   Lee Han Chu, 2008, Oncology, V75 Suppl 1, P114, DOI 10.1159/000173432
   Lee MJ, 2008, CURR OPIN ONCOL, V20, P639, DOI 10.1097/CCO.0b013e3283127095
   Llovet JM, 2008, NEW ENGL J MED, V359, P378, DOI 10.1056/NEJMoa0708857
   Monneret C., 2011, ANNALES PHARMACEUTIQUES FRANCAISES, V69, P286, DOI 10.1016/j.pharma.2011.10.001
   Na YS, 2010, ONCOL REP, V24, P1509, DOI 10.3892/or_00001012
   Olsen EA, 2007, J CLIN ONCOL, V25, P3109, DOI 10.1200/JCO.2006.10.2434
   Ozaki K, 2008, CANCER SCI, V99, P376, DOI 10.1111/j.1349-7006.2007.00669.x
   Petrelli F, 2014, CLIN ONCOL-UK, V26, P488, DOI 10.1016/j.clon.2014.04.031
   Piacentini P, 2006, VIRCHOWS ARCH, V448, P797, DOI 10.1007/s00428-006-0173-x
   Piccart MJ, 2001, ANN ONCOL, V12, P1195, DOI 10.1023/A:1012259625746
   Poon D, 2009, LANCET ONCOL, V10, P1111, DOI 10.1016/S1470-2045(09)70241-4
   Powell SN, 2003, ONCOGENE, V22, P5784, DOI 10.1038/sj.onc.1206678
   Qin SK, 2014, ONCOLOGIST, V19, P1169, DOI 10.1634/theoncologist.2014-0190
   Qin SK, 2013, J CLIN ONCOL, V31, P3501, DOI 10.1200/JCO.2012.44.5643
   Sun WJ, 2011, CANCER-AM CANCER SOC, V117, P3187, DOI 10.1002/cncr.25889
   Thompson LH, 2001, MUTAT RES-FUND MOL M, V477, P131, DOI 10.1016/S0027-5107(01)00115-4
   Todd RC, 2009, METALLOMICS, V1, P280, DOI 10.1039/b907567d
   Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262
   Wang S, 2016, MED SCI MONITOR, V22, P1999, DOI 10.12659/MSM.896606
   Weberpals JI, 2011, CANCER CELL INT, V11, DOI 10.1186/1475-2867-11-29
   Wei S, 2012, CARCINOGENESIS, V33, P538, DOI 10.1093/carcin/bgr319
   Wu JX, 2010, PROTEIN CELL, V1, P117, DOI 10.1007/s13238-010-0010-5
   Xu X, 2016, BIOCHEM BIOPH RES CO, V479, P893, DOI 10.1016/j.bbrc.2016.09.087
   Yarden RI, 1999, P NATL ACAD SCI USA, V96, P4983, DOI 10.1073/pnas.96.9.4983
   Yau T, 2009, LIVER INT, V29, P10, DOI 10.1111/j.1478-3231.2008.01916.x
   Zaanan A, 2013, J HEPATOL, V58, P81, DOI 10.1016/j.jhep.2012.09.006
   Zhang BX, 2010, GASTROENTEROLOGY, V138, P969, DOI 10.1053/j.gastro.2009.11.004
   Zhang Y, 2007, RADIAT RES, V168, P115, DOI 10.1667/RR0811.1
   Zhao JY, 2017, ONCOTARGET, V8, P6319, DOI 10.18632/oncotarget.14062
   Zhou CF, 2014, MOL MED REP, V10, P2729, DOI 10.3892/mmr.2014.2548
   Zhu AX, 2006, ONCOLOGIST, V11, P790, DOI 10.1634/theoncologist.11-7-790
NR 69
TC 19
Z9 19
U1 0
U2 16
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2045-7634
J9 CANCER MED-US
JI Cancer Med.
PD JAN
PY 2018
VL 7
IS 1
BP 196
EP 207
DI 10.1002/cam4.1278
PG 12
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA FX1OT
UT WOS:000425822300020
PM 29239146
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU Xi, YX
   Shi, JJ
   Li, WQ
   Tanaka, K
   Allton, KL
   Richardson, D
   Li, J
   Franco, HL
   Nagari, A
   Malladi, VS
   Della Coletta, L
   Simper, MS
   Keyomarsi, K
   Shen, JJ
   Bedford, MT
   Shi, XB
   Barton, MC
   Kraus, WL
   Li, W
   Dent, SYR
AF Xi, Yuanxin
   Shi, Jiejun
   Li, Wenqian
   Tanaka, Kaori
   Allton, Kendra L.
   Richardson, Dana
   Li, Jing
   Franco, Hector L.
   Nagari, Anusha
   Malladi, Venkat S.
   Della Coletta, Luis
   Simper, Melissa S.
   Keyomarsi, Khandan
   Shen, Jianjun
   Bedford, Mark T.
   Shi, Xiaobing
   Barton, Michelle C.
   Kraus, W. Lee
   Li, Wei
   Dent, Sharon Y. R.
TI Histone modification profiling in breast cancer cell lines highlights
   commonalities and differences among subtypes
SO BMC GENOMICS
LA English
DT Article
DE Breast cancer subtypes; Epigenetics; Histone modifications; Chromatin
   states
ID LONG NONCODING RNA; UCSC GENOME BROWSER; POOR-PROGNOSIS; HIGH
   EXPRESSION; AFAP1-AS1; CARCINOMA; OVEREXPRESSION; ADENOCARCINOMA;
   UPDATE; SEQ
AB Background: Epigenetic regulators are frequently mutated or aberrantly expressed in a variety of cancers, leading to altered transcription states that result in changes in cell identity, behavior, and response to therapy.
   Results: To define alterations in epigenetic landscapes in breast cancers, we profiled the distributions of 8 key histone modifications by ChIP-Seq, as well as primary (GRO-seq) and steady state (RNA-Seq) transcriptomes, across 13 distinct cell lines that represent 5 molecular subtypes of breast cancer and immortalized human mammary epithelial cells.
   Discussion: Using combinatorial patterns of distinct histone modification signals, we defined subtype-specific chromatin signatures to nominate potential biomarkers. This approach identified AFAP1-AS1 as a triple negative breast cancer-specific gene associated with cell proliferation and epithelial-mesenchymal-transition. In addition, our chromatin mapping data in basal TNBC cell lines are consistent with gene expression patterns in TCGA that indicate decreased activity of the androgen receptor pathway but increased activity of the vitamin D biosynthesis pathway.
   Conclusions: Together, these datasets provide a comprehensive resource for histone modification profiles that define epigenetic landscapes and reveal key chromatin signatures in breast cancer cell line subtypes with potential to identify novel and actionable targets for treatment.
C1 [Xi, Yuanxin; Shi, Jiejun; Li, Wei] Baylor Coll Med, Dept Mol & Cellular Biol, Dan L Duncan Canc Ctr, Houston, TX 77030 USA.
   [Xi, Yuanxin; Shi, Jiejun; Li, Wei] Baylor Coll Med, Div Biostat, Dan L Duncan Canc Ctr, Houston, TX 77030 USA.
   [Li, Wenqian; Tanaka, Kaori; Allton, Kendra L.; Li, Jing; Della Coletta, Luis; Simper, Melissa S.; Shen, Jianjun; Bedford, Mark T.; Shi, Xiaobing; Barton, Michelle C.; Dent, Sharon Y. R.] Univ Texas Houston, Grad Sch Biomed Sci, Dept Epigenet & Mol Carcinogenesis, Houston, TX 77030 USA.
   [Li, Wenqian; Tanaka, Kaori; Allton, Kendra L.; Li, Jing; Della Coletta, Luis; Simper, Melissa S.; Shen, Jianjun; Bedford, Mark T.; Shi, Xiaobing; Barton, Michelle C.; Dent, Sharon Y. R.] Univ Texas MD Anderson Canc Ctr, Ctr Canc Epigenet, Houston, TX 77030 USA.
   [Richardson, Dana; Keyomarsi, Khandan] Univ Texas MD Anderson Canc Ctr, Dept Expt Radiat Oncol, Houston, TX 77030 USA.
   [Franco, Hector L.; Nagari, Anusha; Malladi, Venkat S.; Kraus, W. Lee] Univ Texas Southwestern Med Ctr Dallas, Cecil H & Ida Green Ctr Reprod Biol Sci, Lab Signaling & Gene Regulat, Dallas, TX 75390 USA.
   [Franco, Hector L.; Nagari, Anusha; Malladi, Venkat S.; Kraus, W. Lee] Univ Texas Southwestern Med Ctr Dallas, Dept Obstet & Gynecol, Div Basic Reprod Biol Res, Dallas, TX 75390 USA.
C3 Baylor College of Medicine; Baylor College of Medicine; University of
   Texas System; University of Texas Health Science Center Houston;
   University of Texas System; UTMD Anderson Cancer Center; University of
   Texas System; UTMD Anderson Cancer Center; University of Texas System;
   University of Texas Southwestern Medical Center Dallas; University of
   Texas System; University of Texas Southwestern Medical Center Dallas
RP Dent, SYR (通讯作者)，Univ Texas Houston, Grad Sch Biomed Sci, Dept Epigenet & Mol Carcinogenesis, Houston, TX 77030 USA.; Dent, SYR (通讯作者)，Univ Texas MD Anderson Canc Ctr, Ctr Canc Epigenet, Houston, TX 77030 USA.
EM sroth@mdanderson.org
RI Li, Wei/AFW-2599-2022; Shi, Jiejun/LXB-3187-2024; Keyomarsi,
   Khandan/H-2716-2016; Xing, Puyuan/GMX-3723-2022; Dent,
   Sharon/F-1746-2011
OI Allton, KENDRA/0000-0002-4204-0807; Franco, Hector/0000-0001-9354-0679;
   Shi, Jiejun/0000-0001-9777-1183
FU LONESTAR Oncology Network for EpigeneticS Therapy and Research grant
   from the Cancer Prevention and Research Institiute of Texas [CPRIT
   RP100417]; CPRIT Core Facility Support Grant [RP120348]
FX This work was supported by the LONESTAR Oncology Network for EpigeneticS
   Therapy and Research grant from the Cancer Prevention and Research
   Institiute of Texas, CPRIT RP100417. This study also made use of the
   Science Park NGS Core, supported by CPRIT Core Facility Support Grant
   RP120348.
CR Anders S, 2015, BIOINFORMATICS, V31, P166, DOI 10.1093/bioinformatics/btu638
   Bo H, 2015, ONCOTARGET, V6, P20404, DOI 10.18632/oncotarget.4057
   Deng J, 2015, BIOMED PHARMACOTHER, V75, P8, DOI 10.1016/j.biopha.2015.07.003
   Ernst J, 2012, NAT METHODS, V9, P215, DOI 10.1038/nmeth.1906
   Glunde K, 2011, NAT REV CANCER, V11, P835, DOI 10.1038/nrc3162
   Grinde MT, 2014, BREAST CANCER RES, V16, DOI 10.1186/bcr3597
   Howe EA, 2011, BIOINFORMATICS, V27, P3209, DOI 10.1093/bioinformatics/btr490
   Kundaje A, 2015, NATURE, V518, P317, DOI 10.1038/nature14248
   Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/NMETH.1923, 10.1038/nmeth.1923]
   Lu X, 2016, TUMOR BIOL, V37, P9699, DOI 10.1007/s13277-016-4858-8
   Raney BJ, 2011, NUCLEIC ACIDS RES, V39, pD871, DOI 10.1093/nar/gkq1017
   Rosenbloom KR, 2012, NUCLEIC ACIDS RES, V40, pD912, DOI 10.1093/nar/gkr1012
   Rosenbloom KR, 2010, NUCLEIC ACIDS RES, V38, pD620, DOI 10.1093/nar/gkp961
   Saxena M, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00327
   Trapnell C, 2009, BIOINFORMATICS, V25, P1105, DOI 10.1093/bioinformatics/btp120
   Wang F, 2016, BIOMED PHARMACOTHER, V81, P152, DOI 10.1016/j.biopha.2016.04.009
   Wu WJ, 2013, GASTROENTEROLOGY, V144, P956, DOI 10.1053/j.gastro.2013.01.019
   Ye YB, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0490-4
   Zeng ZY, 2016, TUMOR BIOL, V37, P729, DOI 10.1007/s13277-015-3860-x
   Zhang JY, 2016, INT J ONCOL, V48, P1590, DOI 10.3892/ijo.2016.3385
   Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r137
   Zhou XL, 2016, MOL CARCINOGEN, V55, P2095, DOI 10.1002/mc.22454
NR 22
TC 57
Z9 64
U1 0
U2 25
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2164
J9 BMC GENOMICS
JI BMC Genomics
PD FEB 20
PY 2018
VL 19
AR 150
DI 10.1186/s12864-018-4533-0
PG 11
WC Biotechnology & Applied Microbiology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Genetics & Heredity
GA FW7QL
UT WOS:000425519100002
PM 29458327
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Bi, LX
   Zhou, B
   Li, HY
   He, LC
   Wang, CJ
   Wang, ZG
   Zhu, LQ
   Chen, MQ
   Gao, SM
AF Bi, Laixi
   Zhou, Bin
   Li, Haiying
   He, Licai
   Wang, Chunjing
   Wang, Zhonggai
   Zhu, Liqing
   Chen, Mengqian
   Gao, Shenmeng
TI A novel miR-375-HOXB3-CDCA3/DNMT3B regulatory circuitry contributes to
   leukemogenesis in acute myeloid leukemia
SO BMC CANCER
LA English
DT Article
DE miR-375; HOXB3; DNMT3B; DNA hypermethylation; AML
ID CELL LUNG-CANCER; PROSTATE-CANCER; HEMATOPOIETIC-CELLS; TARGETING HOXB3;
   POOR-PROGNOSIS; BREAST-CANCER; STEM-CELLS; MICRORNA-375; MIR-375; GENE
AB Background: Acute myeloid leukemia (AML) is a heterogeneous group of hematopoietic malignancies due to sophisticated genetic mutations and epigenetic dysregulation. MicroRNAs (miRNAs), a class of small non-coding RNAs, are important regulators of gene expression in all biological processes, including leukemogenesis. Recently, miR-375 has been reported to be a suppressive miRNA in multiple types of cancers, but its underlying anti-leukemia activity in AML is largely unknown.
   Methods: Quantitative reverse transcriptase PCR (qRT-PCR) was used to measure the expression of miR-375 and HOXB3 in leukemic cells and normal controls. Targets of miR-375 were confirmed by western blot and luciferase assay. Phenotypic effects of miR-375 overexpression and HOXB3 knockdown were assessed using viability (trypan blue exclusion assay), colony formation/replating, as well as tumor xenograft assays in vivo.
   Results: The expression of miR-375 was substantially decreased in leukemic cell lines and primary AML blasts compared with normal controls, because DNA hypermethylation of precursor-miR-375 (pre-miR-375) promoter was discovered in leukemic cells but not in normal controls. Lower expression of miR-375 predicted poor outcome in AML patients. Furthermore, forced expression of miR-375 not only decreased proliferation and colony formation in leukemic cells but also reduced xenograft tumor size and prolonged the survival time in a leukemia xenograft mouse model. Mechanistically, overexpression of miR-375 reduced HOXB3 expression and repressed the activity of a luciferase reporter through binding 3'-untranslated regions (3'-UTR) of HOXB3 mRNA. Overexpression of HOXB3 partially blocked miR-375-induced arrest of proliferation and reduction of colony number, suggesting that HOXB3 plays an important role in miR-375-induced anti-leukemia activity. Knockdown of HOXB3 by short hairpin RNAs reduced the expression of cell division cycle associated 3 (CDCA3), which decreased cell proliferation. Furthermore, HOXB3 induced DNA methyltransferase 3B (DNMT3B) expression to bind in the pre-miR-375 promoter and enhanced DNA hypermethylation of pre-miR-375, leading to the lower expression of miR-375.
   Conclusions: Collectively, we have identified a miR-375-HOXB3-CDCA3/DNMT3B regulatory
C1 [Bi, Laixi] Wenzhou Med Univ, Affiliated Hosp 1, Dept Hematol, Wenzhou 325000, Zhejiang, Peoples R China.
   [Zhou, Bin; Li, Haiying; Gao, Shenmeng] Wenzhou Med Univ, Affiliated Hosp 1, Lab Internal Med, Wenzhou 325000, Zhejiang, Peoples R China.
   [He, Licai; Wang, Chunjing; Wang, Zhonggai] Wenzhou Med Univ, Sch Lab Med, Wenzhou 325000, Zhejiang, Peoples R China.
   [He, Licai; Wang, Chunjing; Wang, Zhonggai] Wenzhou Med Univ, Sch Life Sci, Wenzhou 325000, Zhejiang, Peoples R China.
   [Zhu, Liqing] Wenzhou Med Univ, Affiliated Hosp 1, Dept Clin Lab, Wenzhou 325000, Zhejiang, Peoples R China.
   [Chen, Mengqian] Univ South Carolina, Coll Pharm, Dept Drug Discovery & Biomed Sci, Columbia, SC 29208 USA.
C3 Wenzhou Medical University; Wenzhou Medical University; Wenzhou Medical
   University; Wenzhou Medical University; Wenzhou Medical University;
   University of South Carolina System; University of South Carolina
   Columbia
RP Gao, SM (通讯作者)，Wenzhou Med Univ, Affiliated Hosp 1, Lab Internal Med, Wenzhou 325000, Zhejiang, Peoples R China.
EM gaoshenmeng77@126.com
RI Wang, Chun-Jing/J-7223-2019; li, haiying/KJL-3941-2024; Zhu,
   Liqin/N-8126-2018
OI Chen, Mengqian/0000-0003-1706-9509
FU National Natural Science Foundation of China [81672087, 81501809,
   81501810]
FX The authors are thankful for the financial support from the National
   Natural Science Foundation of China (81672087 to SMG; 81501809 to HYL;
   81501810 to LQZ). The funding body had no role in the design of the
   study and collection, analysis, and interpretation of data and in
   writing the manuscript.
CR ACAMPORA D, 1989, NUCLEIC ACIDS RES, V17, P10385, DOI 10.1093/nar/17.24.10385
   Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871
   Barchitta M, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3582-0
   Chen H, 2016, CANCER BIOTHER RADIO, V31, P225, DOI 10.1089/cbr.2016.1998
   Chen J, 2013, CANCER LETT, V330, P217, DOI 10.1016/j.canlet.2012.11.051
   Chen JJ, 2016, J EXP CLIN CANC RES, V35, DOI 10.1186/s13046-016-0450-8
   Choi N, 2015, ONCOTARGET, V6, P23533, DOI 10.18632/oncotarget.4372
   Costa-Pinheiro P, 2015, CLIN EPIGENETICS, V7, DOI 10.1186/s13148-015-0076-2
   Ding L, 2010, CELL RES, V20, P784, DOI 10.1038/cr.2010.79
   Dombret H, 2016, BLOOD, V127, P53, DOI 10.1182/blood-2015-08-604520
   Drabkin H, 2002, LEUKEMIA, V16, P186, DOI 10.1038/sj.leu.2402354
   Eklund EA, 2007, CURR OPIN HEMATOL, V14, P85, DOI 10.1097/MOH.0b013e32801684b6
   Fu H, 2017, ONCOL REP, V37, P1093, DOI 10.3892/or.2017.5360
   Gabert J, 2003, LEUKEMIA, V17, P2318, DOI 10.1038/sj.leu.2403135
   Garzon R, 2010, NAT REV DRUG DISCOV, V9, P775, DOI 10.1038/nrd3179
   Garcia JRG, 2006, BLOOD, V108, P3952, DOI 10.1182/blood-2006-06-031351
   Guazzi S, 1998, J BIOL CHEM, V273, P11092, DOI 10.1074/jbc.273.18.11092
   He XX, 2012, ONCOGENE, V31, P3357, DOI 10.1038/onc.2011.500
   Horton SJ, 2013, LEUKEMIA, V27, P1116, DOI 10.1038/leu.2012.343
   Lechman ER, 2016, CANCER CELL, V29, P214, DOI 10.1016/j.ccell.2015.12.011
   Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427
   Li QY, 2012, BIOCHEM BIOPH RES CO, V424, P28, DOI 10.1016/j.bbrc.2012.06.028
   Li Y, 2012, J INT MED RES, V40, P1662, DOI 10.1177/030006051204000505
   Li YH, 2013, BLOOD, V121, P499, DOI 10.1182/blood-2012-07-444729
   Lindblad O, 2015, BIOCHEM BIOPH RES CO, V467, P742, DOI 10.1016/j.bbrc.2015.10.071
   Mao QQ, 2016, TUMOR BIOL, V37, P463, DOI 10.1007/s13277-015-3809-0
   Mazar J, 2011, FEBS LETT, V585, P2467, DOI 10.1016/j.febslet.2011.06.025
   Palakurthy RK, 2009, MOL CELL, V36, P219, DOI 10.1016/j.molcel.2009.10.009
   Pollyea DA, 2017, BLOOD, V129, P1627, DOI 10.1182/blood-2016-10-696039
   RAZIN A, 1994, CELL, V77, P473, DOI 10.1016/0092-8674(94)90208-9
   Sauvageau G, 1997, IMMUNITY, V6, P13, DOI 10.1016/S1074-7613(00)80238-1
   Selth LA, 2017, ONCOGENE, V36, P24, DOI 10.1038/onc.2016.185
   Shen Y, 2011, BLOOD, V118, P5593, DOI 10.1182/blood-2011-03-343988
   Shi W, 2015, ONCOTARGET, V6, P40172, DOI 10.18632/oncotarget.5502
   Uchida F, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-321
   Umeda S, 2012, HEMATOLOGY, V17, P125, DOI 10.1179/102453312X13376952196250
   Wang FF, 2011, AM J PATHOL, V179, P2580, DOI 10.1016/j.ajpath.2011.07.037
   Wang XM, 2017, CELL BIOL INT, V41, P936, DOI 10.1002/cbin.10770
   Wang YH, 2014, BIOCHEM BIOPH RES CO, V444, P199, DOI 10.1016/j.bbrc.2014.01.028
   Wang ZY, 2013, MOL CELL BIOCHEM, V383, P59, DOI 10.1007/s11010-013-1754-z
   Wouters BJ, 2016, BLOOD, V127, P42, DOI 10.1182/blood-2015-07-604512
   Xu LL, 2016, ONCOTARGET, V7, P40644, DOI 10.18632/oncotarget.9811
   Xu YJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099516
   Yang DJ, 2016, AM J TRANSL RES, V8, P1551
   Yin LH, 2015, LEUKEMIA RES, V39, P471, DOI 10.1016/j.leukres.2015.01.009
   Yoda S, 2014, LUNG CANCER, V85, P366, DOI 10.1016/j.lungcan.2014.06.009
   Zhou N, 2016, TUMOR BIOL, V37, P2145, DOI 10.1007/s13277-015-3841-0
NR 47
TC 52
Z9 53
U1 0
U2 8
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2407
J9 BMC CANCER
JI BMC Cancer
PD FEB 13
PY 2018
VL 18
AR 182
DI 10.1186/s12885-018-4097-z
PG 17
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA FW7PP
UT WOS:000425516500007
PM 29439669
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Nojima, M
   Iwasaki, M
   Kasuga, Y
   Yokoyama, S
   Onuma, H
   Nishimura, H
   Kusama, R
   Yoshida, T
   Tsugane, S
AF Nojima, Masanori
   Iwasaki, Motoki
   Kasuga, Yoshio
   Yokoyama, Shiro
   Onuma, Hiroshi
   Nishimura, Hideki
   Kusama, Ritsu
   Yoshida, Teruhiko
   Tsugane, Shoichiro
TI Correlation between global methylation level of peripheral blood
   leukocytes and serum C reactive protein level modified by MTHFR
   polymorphism: a cross-sectional study
SO BMC CANCER
LA English
DT Article
DE DNA methylation; C reactive protein; Inflammation; Folate metabolism;
   Folate intake
ID BREAST-CANCER RISK; ONE-CARBON METABOLISM; METHYLENETETRAHYDROFOLATE
   REDUCTASE POLYMORPHISM; CPG ISLAND METHYLATION; LINE-1 HYPOMETHYLATION;
   METHIONINE SYNTHASE; ALCOHOL-CONSUMPTION; DNA HYPOMETHYLATION; C677T
   POLYMORPHISM; COLORECTAL-CANCER
AB Background: Chronic inflammatory conditions are associated with higher tumor incidence through epigenetic and genetic alterations. Here, we focused on an association between an inflammation marker, C-reactive-protein (CRP), and global DNA methylation levels of peripheral blood leukocytes.
   Methods: The subjects were 384 healthy Japanese women enrolled as the control group of a case-control study for breast cancer conducted from 2001 to 2005. Global DNA methylation was quantified by Luminometric Methylation Assay (LUMA).
   Results: With adjustment for lifestyle-related factors, including folate intake, the global DNA methylation level of peripheral blood leukocytes was significantly but weakly increased by 0.43% per quartile category for CRP (P for trend = 0.010). Estimated methylation levels stratified by CRP quartile were 70.0%, 70.8%, 71.4%, and 71.3%, respectively. In addition, interaction between polymorphism of MTHFR (rs1801133, known as C677T) and CRP was significant (P for interaction = 0.046); the global methylation level was significantly increased by 0.61% per quartile category for CRP in the CT/TT group (those with the minor allele T, P for trend = 0.001), whereas no association was observed in the CC group (wild type).
   Conclusions: Our study suggests that CRP concentration is weakly associated with global DNA methylation level. However, this association was observed more clearly in individuals with the minor allele of the MTHFR missense SNP rs1801133. By elucidating the complex mechanism of the regulation of DNA methylation by both acquired and genetic factors, our results may be important for cancer prevention.
C1 [Nojima, Masanori] Univ Tokyo, Inst Med Sci Hosp, Ctr Translat Res, Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.
   [Iwasaki, Motoki] Natl Canc Ctr, Res Ctr Canc Prevent & Screening, Div Epidemiol, Chuo Ku, 5-1-1 Tsukiji, Tokyo 1040045, Japan.
   [Kasuga, Yoshio] Nagano Matsushiro Gen Hosp, Dept Surg, 183 Matsushiro,Matsushiro Cho, Nagano, Nagano 3811231, Japan.
   [Yokoyama, Shiro; Onuma, Hiroshi] Nagano Red Cross Hosp, Dept Breast & Thyroid Surg, 5-22-1 Wakasato, Nagano, Nagano 3808582, Japan.
   [Nishimura, Hideki] Nagano Municipal Hosp, Dept Resp Surg & Breast Surg, 1333-1 Tomitake, Nagano, Nagano 3818551, Japan.
   [Kusama, Ritsu] Hokushin Gen Hosp, Dept Surg, 1-5-63 Nishi, Nakano City, Nagano 3838505, Japan.
   [Yoshida, Teruhiko] Natl Canc Ctr, Res Inst, Div Genet, Chuo Ku, 5-1-1 Tsukiji, Tokyo 1040045, Japan.
   [Tsugane, Shoichiro] Natl Canc Ctr, Res Ctr Canc Prevent & Screening, Chuo Ku, 5-1-1 Tsukiji, Tokyo 1040045, Japan.
C3 University of Tokyo; National Cancer Center - Japan; Nagano Red Cross
   Hospital; National Cancer Center - Japan; National Cancer Center - Japan
RP Iwasaki, M (通讯作者)，Natl Canc Ctr, Res Ctr Canc Prevent & Screening, Div Epidemiol, Chuo Ku, 5-1-1 Tsukiji, Tokyo 1040045, Japan.
EM moiwasak@ncc.go.jp
RI Tsugane, Shoichiro/A-2424-2015; Nojima, Masanori/ABE-2237-2020
OI Nojima, Masanori/0000-0002-8788-2522
FU Ministry of Health, Labour and Welfare of Japan [H18-3jigan-ippan-001,
   H21-3jigan-ippan-002, H23-jitsuyoka(gan)-ippan-002]; Program for
   Promotion of Fundamental Studies in Health Sciences of the National
   Institute of Biomedical Innovation (NIBIO) [10-41]; Health and Labour
   Sciences Research Grant for Research on the Risk of Chemical Substances
   from the Ministry of Health, Labour and Welfare of Japan [H14-shokuhin
   kagaku-015, H17-kagaku-014]
FX This study was supported by Grants-in-Aid for the Third Term
   Comprehensive Ten-Year Strategy for Cancer Control (H18-3jigan-ippan-001
   and H21-3jigan-ippan-002, S Tsugane) and for the Research on Applying
   Health Technology from the Ministry of Health, Labour and Welfare of
   Japan (H23-jitsuyoka(gan)-ippan-002, T Yoshida and M Iwasaki); by the
   Program for Promotion of Fundamental Studies in Health Sciences of the
   National Institute of Biomedical Innovation (NIBIO) (10-41, T Yoshida);
   and by a Health and Labour Sciences Research Grant for Research on the
   Risk of Chemical Substances from the Ministry of Health, Labour and
   Welfare of Japan (H14-shokuhin kagaku-015 and H17-kagaku-014, S Tsugane
   and M Iwasaki).
CR Abu-Remaileh M, 2015, CANCER RES, V75, P2120, DOI 10.1158/0008-5472.CAN-14-3295
   [Anonymous], EPIGENETICS
   Aoki Y, 2012, GENOME MED, V4, DOI 10.1186/gm402
   Cardenas A, 2016, EPIGENETICS IN PRESS
   Chen J, 1996, CANCER RES, V56, P4862
   de la Rocha C, 2016, SCI REP-UK, V6, DOI 10.1038/srep25867
   Dossus L, 2014, CANCER CAUSE CONTROL, V25, P533, DOI 10.1007/s10552-014-0355-9
   Ericson U, 2009, CANCER EPIDEM BIOMAR, V18, P1101, DOI 10.1158/1055-9965.EPI-08-0401
   FEINBERG AP, 1983, NATURE, V301, P89, DOI 10.1038/301089a0
   Friso S, 2002, P NATL ACAD SCI USA, V99, P5606, DOI 10.1073/pnas.062066299
   Friso S, 2013, CANCER EPIDEM BIOMAR, V22, P348, DOI 10.1158/1055-9965.EPI-12-0859
   FROSST P, 1995, NAT GENET, V10, P111, DOI 10.1038/ng0595-111
   He JM, 2014, GENET MOL RES, V13, P8925, DOI 10.4238/2014.October.31.7
   Ishihara J, 2006, J EPIDEMIOL, V16, P107, DOI 10.2188/jea.16.107
   Iso H, 2012, J ATHEROSCLER THROMB, V19, P756
   Issa JPJ, 2001, CANCER RES, V61, P3573
   Itoh H, 2009, CANCER CAUSE CONTROL, V20, P567, DOI 10.1007/s10552-008-9265-z
   Iwasaki M, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-323
   Jenkins TG, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004458
   Kaptoge S, 2012, NEW ENGL J MED, V367, P1310, DOI 10.1056/NEJMoa1107477
   Karimi M, 2006, EPIGENETICS-US, V1, P45
   Karimi M, 2006, EXP CELL RES, V312, P1989, DOI 10.1016/j.yexcr.2006.03.006
   Kim DS, 2016, BIOMARKERS, V21, P243, DOI 10.3109/1354750X.2015.1134661
   Ko YJ, 2012, CANCER EPIDEM BIOMAR, V21, P2076, DOI 10.1158/1055-9965.EPI-12-0611
   Kuchiba A, 2014, BRIT J CANCER, V110, P2765, DOI 10.1038/bjc.2014.223
   Lightfoot TJ, 2008, CANCER EPIDEM BIOMAR, V17, P2421, DOI 10.1158/1055-9965.EPI-08-0058
   Lin WY, 2004, ANTICANCER RES, V24, P3863
   Liu YM, 2013, HUM MOL GENET, V22, P5065, DOI 10.1093/hmg/ddt356
   Ma E, 2009, NUTR CANCER, V61, P447, DOI 10.1080/01635580802610123
   Ma J, 1999, CANCER EPIDEM BIOMAR, V8, P825
   Ma J, 1997, CANCER RES, V57, P1098
   Maegawa S, 2014, GENOME RES, V24, P580, DOI 10.1101/gr.157529.113
   Maruti SS, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2462
   Matsuo K, 2005, CARCINOGENESIS, V26, P2164, DOI 10.1093/carcin/bgi196
   Na Hye-Kyung, 2014, J Cancer Prev, V19, P259
   Ono H, 2012, CANCER SCI, V103, P2159, DOI 10.1111/cas.12013
   Perng W, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062587
   Platek ME, 2009, CANCER EPIDEM BIOMAR, V18, P2453, DOI 10.1158/1055-9965.EPI-09-0159
   Reynolds LM, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6366
   Semmler A, 2015, ALCOHOL, V49, P97, DOI 10.1016/j.alcohol.2015.01.004
   Shiels MS, 2013, JNCI-J NATL CANCER I, V105, P1871, DOI 10.1093/jnci/djt309
   Shrubsole MJ, 2004, CANCER EPIDEM BIOMAR, V13, P190, DOI 10.1158/1055-9965.EPI-03-0273
   Stern LL, 2000, CANCER EPIDEM BIOMAR, V9, P849
   Toriola AT, 2011, ANN ONCOL, V22, P1916, DOI 10.1093/annonc/mdq694
   Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681
   Tsubono Y, 1996, J Epidemiol, V6, P45
   Ullman TA, 2011, GASTROENTEROLOGY, V140, P1807, DOI 10.1053/j.gastro.2011.01.057
   Ulrich CM, 1999, CANCER EPIDEM BIOMAR, V8, P659
   Woo HD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034615
   Xu XR, 2012, FASEB J, V26, P2657, DOI 10.1096/fj.11-197251
   Yamamoto E, 2008, CANCER EPIDEM BIOMAR, V17, P2555, DOI 10.1158/1055-9965.EPI-08-0112
   Zhang FF, 2012, EPIGENETICS-US, V7, P606, DOI 10.4161/epi.20236
   Zhou DJ, 2012, INT J BIOL SCI, V8, P819, DOI 10.7150/ijbs.4462
NR 53
TC 15
Z9 16
U1 0
U2 3
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471-2407
J9 BMC CANCER
JI BMC Cancer
PD FEB 13
PY 2018
VL 18
AR 184
DI 10.1186/s12885-018-4089-z
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA FW7PP
UT WOS:000425516500009
PM 29439678
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU González-Vallinas, M
   Rodríguez-Paredes, M
   Albrecht, M
   Sticht, C
   Stichel, D
   Gutekunst, J
   Pitea, A
   Sass, S
   Sánchez-Rivera, FJ
   Lorenzo-Bermejo, J
   Schmitt, J
   De La Torre, C
   Warth, A
   Theis, FJ
   Müller, NS
   Gretz, N
   Muley, T
   Meister, M
   Tschaharganeh, DF
   Schirmacher, P
   Matthäus, F
   Breuhahn, K
AF Gonzalez-Vallinas, Margarita
   Rodriguez-Paredes, Manuel
   Albrecht, Marco
   Sticht, Carsten
   Stichel, Damian
   Gutekunst, Julian
   Pitea, Adriana
   Sass, Steffen
   Sanchez-Rivera, Francisco J.
   Lorenzo-Bermejo, Justo
   Schmitt, Jennifer
   De La Torre, Carolina
   Warth, Arne
   Theis, Fabian J.
   Mueller, Nikola S.
   Gretz, Norbert
   Muley, Thomas
   Meister, Michael
   Tschaharganeh, Darjus F.
   Schirmacher, Peter
   Matthaeus, Franziska
   Breuhahn, Kai
TI Epigenetically Regulated Chromosome 14q32 miRNA Cluster Induces
   Metastasis and Predicts Poor Prognosis in Lung Adenocarcinoma Patients
SO MOLECULAR CANCER RESEARCH
LA English
DT Article
ID TO-MESENCHYMAL TRANSITION; BREAST-CANCER CELLS; NODE METASTASIS; DNA
   METHYLATION; TARGETING MAGI2; MICRORNAS; MIGRATION; INVASION;
   ACTIVATION; EXPRESSION
AB Most lung cancer deaths are related to metastases, which indicates the necessity of detecting and inhibiting tumor cell dissemination. Here, we aimed to identify miRNAs involved in metastasis of lung adenocarcinoma as prognostic biomarkers and therapeutic targets. To that end, lymph node metastasis-associated miRNAs were identified in The Cancer Genome Atlas lung adenocarcinoma patient cohort (sequencing data; n = 449) and subsequently validated by qRT-PCR in an independent clinical cohort (n = 108). Overexpression of miRNAs located on chromosome 14q32 was associated with metastasis in lung adenocarcinoma patients. Importantly, Kaplan-Meier analysis and log-rank test revealed that higher expression levels of individual 14q32 miRNAs (mir-539, mir-323b, and mir-487a) associated with worse disease-free survival of never-smoker patients. Epigenetic analysis including DNA methylation microarray data and bisulfite sequencing validation demonstrated that the induction of 14q32 cluster correlated with genomic hypomethylation of the 14q32 locus. CRISPR activation technology, applied for the first time to functionally study the increase of clustered miRNA levels in a coordinated manner, showed that simultaneous overexpression of 14q32 miRNAs promoted tumor cell migratory and invasive properties. Analysis of individual miRNAs by mimic transfection further illustrated that miR-323b-3p, miR-487a-3p, and miR-539-5p significantly contributed to the invasive phenotype through the indirect regulation of different target genes. In conclusion, overexpression of 14q32 miRNAs, associated with the respective genomic hypomethylation, promotes metastasis and correlates with poor patient prognosis in lung adenocarcinoma.
C1 [Gonzalez-Vallinas, Margarita; Schmitt, Jennifer; Warth, Arne; Tschaharganeh, Darjus F.; Schirmacher, Peter; Breuhahn, Kai] Univ Hosp Heidelberg, Inst Pathol, Heidelberg, Germany.
   [Gonzalez-Vallinas, Margarita] German Canc Res Ctr, Syst Biol Signal Transduct, Heidelberg, Germany.
   [Rodriguez-Paredes, Manuel; Gutekunst, Julian] German Canc Res Ctr, DKFZ ZMBH Alliance, Div Epigenet, Heidelberg, Germany.
   [Albrecht, Marco; Stichel, Damian; Matthaeus, Franziska] Heidelberg Univ, Ctr Modeling & Simulat Biosci BIOMS, Heidelberg, Germany.
   [Albrecht, Marco] Univ Luxembourg, Life Sci Res Unit, Luxembourg, Luxembourg.
   [Sticht, Carsten; De La Torre, Carolina; Gretz, Norbert] Heidelberg Univ, Med Res Ctr, Mannheim, Germany.
   [Stichel, Damian] German Canc Res Ctr, Clin Cooperat Unit Neuropathol, Heidelberg, Germany.
   [Pitea, Adriana; Sass, Steffen; Theis, Fabian J.; Mueller, Nikola S.] Helmholtz Ctr Munich, Inst Computat Biol, German Res Ctr Environm Hlth, Neuherberg, Germany.
   [Sanchez-Rivera, Francisco J.] Mem Sloan Kettering Canc Ctr, Dept Canc Biol & Genet, 1275 York Ave, New York, NY 10021 USA.
   [Lorenzo-Bermejo, Justo] Heidelberg Univ, Inst Med Biometry & Informat, Heidelberg, Germany.
   [Warth, Arne; Muley, Thomas; Meister, Michael] TLRCH, Heidelberg, Germany.
   [Warth, Arne; Muley, Thomas; Meister, Michael] German Ctr Lung Res DZL, Heidelberg, Germany.
   [Muley, Thomas; Meister, Michael] Univ Hosp Heidelberg, Thoraxklin, Translat Res Unit, Heidelberg, Germany.
   [Tschaharganeh, Darjus F.] German Canc Res Ctr, Helmholtz Univ Grp Cell Plast & Epigenet Remodeli, Heidelberg, Germany.
   [Matthaeus, Franziska] Univ Wurzburg, Ctr Computat & Theoret Biol, Wurzburg, Germany.
C3 Ruprecht Karls University Heidelberg; Helmholtz Association; German
   Cancer Research Center (DKFZ); Helmholtz Association; German Cancer
   Research Center (DKFZ); Ruprecht Karls University Heidelberg; University
   of Luxembourg; Ruprecht Karls University Heidelberg; Helmholtz
   Association; German Cancer Research Center (DKFZ); Helmholtz
   Association; Helmholtz-Center Munich - German Research Center for
   Environmental Health; Memorial Sloan Kettering Cancer Center; Ruprecht
   Karls University Heidelberg; Ruprecht Karls University Heidelberg;
   Helmholtz Association; German Cancer Research Center (DKFZ); University
   of Wurzburg
RP Breuhahn, K (通讯作者)，Univ Hosp Heidelberg, Neuenheimer Feld 224, D-69120 Heidelberg, Germany.
EM kai.breuhahn@med.uni-heidelberg.de
RI Mueller, Nikola/I-6366-2013; Theis, Fabian/ABD-5212-2021;
   Sánchez-Rivera, Francisco/AAV-6985-2020; Muley, Thomas/AAY-9200-2020; De
   La Torre, Carolina/IQT-8364-2023; Matthäus, Franziska/AAE-5523-2022;
   Gonzalez-Vallinas, Margarita/K-3506-2016; Rodriguez-Paredes,
   Manuel/B-1480-2019
OI Matthaus, Franziska/0000-0001-6042-1366; Sanchez-Rivera, Francisco
   J./0000-0002-8466-8563; Gonzalez-Vallinas,
   Margarita/0000-0003-4968-6675; Rodriguez-Paredes,
   Manuel/0000-0001-5471-4277; Albrecht, Marco/0000-0002-1156-0623
FU BMBF (LungSysII) [FKZ 0316042B]; University of Heidelberg (Stiftung fur
   Krebs- und Scharlachforschung); Alfonso Martin Escudero Foundation
FX This work was supported in part by the BMBF (LungSysII, grant number FKZ
   0316042B to K. Breuhahn) and the University of Heidelberg (Stiftung fur
   Krebs- und Scharlachforschung to M. Gonzalez-Vallinas). M.
   Gonzalez-Vallinas was supported by the Alfonso Martin Escudero
   Foundation. We also thank the TCGA Research Network and the research
   groups involved in the lung adenocarcinoma project for making data
   public. Tissue samples were provided by the tissue bank of the National
   Center for Tumor Diseases (NCT; Heidelberg, Germany) in accordance with
   the regulations of the tissue bank and the approval of the Ethics
   Committee of Heidelberg University. We are especially grateful for the
   contribution of lung adenocarcinoma specimen donors.
CR ALTMAN DG, 1994, J NATL CANCER I, V86, P829, DOI 10.1093/jnci/86.11.829
   Aryee MJ, 2014, BIOINFORMATICS, V30, P1363, DOI 10.1093/bioinformatics/btu049
   Bender E, 2014, NATURE, V513, pS2, DOI 10.1038/513S2a
   Benetatos L, 2013, CELL MOL LIFE SCI, V70, P795, DOI 10.1007/s00018-012-1080-8
   Berman BP, 2012, NAT GENET, V44, P40, DOI 10.1038/ng.969
   Chan SW, 2008, CANCER RES, V68, P2592, DOI 10.1158/0008-5472.CAN-07-2696
   Chang RM, 2017, CLIN CANCER RES, V23, P2593, DOI 10.1158/1078-0432.CCR-16-0851
   Chavez A, 2015, NAT METHODS, V12, P326, DOI [10.1038/NMETH.3312, 10.1038/nmeth.3312]
   Chen X, 2016, ONCOL LETT, V12, P1171, DOI 10.3892/ol.2016.4735
   Cherni I, 2011, FUTURE ONCOL, V7, P1045, DOI [10.2217/fon.11.74, 10.2217/FON.11.74]
   Du LQ, 2010, CANCER METAST REV, V29, P109, DOI 10.1007/s10555-010-9204-9
   Eichhorn SW, 2014, MOL CELL, V56, P104, DOI 10.1016/j.molcel.2014.08.028
   Geyh S, 2016, LEUKEMIA, V30, P683, DOI 10.1038/leu.2015.325
   Grinberg-Rashi H, 2009, CLIN CANCER RES, V15, P1755, DOI 10.1158/1078-0432.CCR-08-2124
   Iorio MV, 2007, CANCER RES, V67, P8699, DOI 10.1158/0008-5472.CAN-07-1936
   Ishikawa M, 2013, ANN SURG ONCOL, V20, pS467, DOI 10.1245/s10434-012-2795-3
   Josson S, 2015, ONCOGENE, V34, P2690, DOI 10.1038/onc.2014.212
   Kagami M, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000992
   Kiani S, 2015, NAT METHODS, V12, P1051, DOI [10.1038/NMETH.3580, 10.1038/nmeth.3580]
   Kircher M, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-346
   Kitamura K, 2014, MOL CANCER THER, V13, P444, DOI 10.1158/1535-7163.MCT-13-0448
   Lin CY, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5620
   Liu J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0114586
   Liu L, 2010, J BIOL CHEM, V285, P19483, DOI 10.1074/jbc.M110.131995
   Ma MT, 2016, INT J BIOL SCI, V12, P397, DOI 10.7150/ijbs.13475
   MacDonagh L, 2015, CANCER TREAT REV, V41, P160, DOI 10.1016/j.ctrv.2014.12.009
   Manodoro F, 2014, BLOOD, V123, P2066, DOI 10.1182/blood-2012-12-469833
   Molina-Pinelo S, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-656
   Müller B, 2015, J PATHOL, V237, P390, DOI 10.1002/path.4588
   Nadal E, 2014, CLIN CANCER RES, V20, P3107, DOI 10.1158/1078-0432.CCR-13-3348
   Raja R, 2016, ONCOTARGET, V7, P61229, DOI 10.18632/oncotarget.11310
   Rodríguez-Paredes M, 2011, NAT MED, V17, P330, DOI 10.1038/nm.2305
   Saintigny P, 2012, MOL CANCER THER, V11, P2021, DOI 10.1158/1535-7163.MCT-12-0030
   Suzuki H, 2012, MOL ONCOL, V6, P567, DOI 10.1016/j.molonc.2012.07.007
   Valdmanis PN, 2015, ONCOGENE, V34, P94, DOI 10.1038/onc.2013.523
   Vannini I, 2013, CLIN BIOCHEM, V46, P918, DOI 10.1016/j.clinbiochem.2013.01.024
   Wang CQ, 2015, CANCER LETT, V368, P105, DOI 10.1016/j.canlet.2015.07.037
   Wang GZ, 2015, CANCER LETT, V363, P60, DOI 10.1016/j.canlet.2015.04.005
   Wang ZH, 2017, GENE, V600, P1, DOI 10.1016/j.gene.2016.11.034
   Williams AE, 2007, DEV DYNAM, V236, P572, DOI 10.1002/dvdy.21047
   Wood SL, 2014, CANCER TREAT REV, V40, P558, DOI 10.1016/j.ctrv.2013.10.001
   Yeh YC, 2016, EUR J CARDIO-THORAC, V49, pE9, DOI 10.1093/ejcts/ezv316
   Zhan P, 2016, CLIN RESP J
   Zhang WJ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0167449
   Zhang WC, 2013, MED ONCOL, V30, DOI 10.1007/s12032-013-0675-8
   Zhao BS, 2013, ASIAN PAC J CANCER P, V14, P139, DOI 10.7314/APJCP.2013.14.1.139
NR 46
TC 36
Z9 40
U1 0
U2 8
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1541-7786
EI 1557-3125
J9 MOL CANCER RES
JI Mol. Cancer Res.
PD MAR
PY 2018
VL 16
IS 3
BP 390
EP 402
DI 10.1158/1541-7786.MCR-17-0334
PG 13
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA FY1MT
UT WOS:000426577100003
PM 29330288
OA Green Submitted, Green Published, Bronze
DA 2025-01-12
ER

PT J
AU Jeong, YJ
   Oh, HK
   Park, SH
   Bong, JG
AF Jeong, Young Ju
   Oh, Hoon Kyu
   Park, Sung Hwan
   Bong, Jin Gu
TI Prognostic Significance of Activated Leukocyte Cell Adhesion Molecule
   (ALCAM) in Association with Promoter Methylation of the <i>ALCAM</i>
   Gene in Breast Cancer
SO MOLECULES
LA English
DT Article
DE activated leukocyte cell adhesion molecule; methylation; inflammation;
   epigenetics; breast cancer
ID TUMOR-INFILTRATING LYMPHOCYTES; DNA METHYLATION; CLINICAL-SIGNIFICANCE;
   POOR-PROGNOSIS; EXPRESSION; ALCAM/CD166; PROGRESSION; METASTASIS;
   CARCINOMA; SURVIVAL
AB Activated leukocyte cell adhesion molecule (ALCAM) has been implicated in tumorigenesis. In this study, we studied DNA methylation status of the ALCAM gene using pyrosequencing in breast cancer tissues. We analyzed the association between the methylation status of the ALCAM gene and its expression. Also, the effects of inflammation on the ALCAM gene methylation and its expression were investigated. The ALCAM gene methylation was associated with the ALCAM transcripts in tumor tissues. The methylation status of the ALCAM gene was not significantly different between tumor and normal tissues. The level of ALCAM transcripts was associated with the expression of TNF, NF-B p50, IL-4, and intratumoral inflammation. The IHC expression of ALCAM was associated with histologic grade, HER2 overexpression and molecular subtype. The expression of TNF, NF-B p50, and IL-4 showed significant association with the clinicopathologic characteristics. In conclusion, the ALCAM gene methylation was related to the level of ALCAM transcripts. Also, the level of ALCAM transcripts was associated with the inflammatory markers in breast cancer. Our results suggest that the methylation of the ALCAM gene contributes to the decreased expression of ALCAM. Also, ALCAM is linked to the inflammatory response in breast cancer.
C1 [Jeong, Young Ju; Park, Sung Hwan; Bong, Jin Gu] Catholic Univ Daegu, Sch Med, Dept Surg, Daegu 42471, South Korea.
   [Oh, Hoon Kyu] Catholic Univ Daegu, Sch Med, Dept Pathol, Daegu 42471, South Korea.
C3 Catholic University of Daegu; Catholic University of Daegu
RP Bong, JG (通讯作者)，Catholic Univ Daegu, Sch Med, Dept Surg, Daegu 42471, South Korea.
EM yjjeong@cu.ac.kr; ap510@cu.ac.kr; shwpark@cu.ac.kr; jgbong@hanmail.net
OI Jeong, Young Ju Jeong/0000-0002-7005-0850
FU Research Institute of Medical Science, Catholic University of Daegu
FX This work was supported by the grant of Research Institute of Medical
   Science, Catholic University of Daegu (2012).
CR Baysan M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094045
   BOWEN MA, 1995, J EXP MED, V181, P2213, DOI 10.1084/jem.181.6.2213
   Burandt E, 2014, ONCOL REP, V32, P2628, DOI 10.3892/or.2014.3523
   Burkhardt M, 2006, J CLIN PATHOL, V59, P403, DOI 10.1136/jcp.2005.028209
   Cohen MB, 1997, AM J CLIN PATHOL, V107, P56
   Davies S, 2010, ANTICANCER RES, V30, P1163
   Davies SR, 2008, ONCOL REP, V19, P555
   Dedeurwaerder S, 2011, EMBO MOL MED, V3, P726, DOI 10.1002/emmm.201100801
   Denkert C, 2010, J CLIN ONCOL, V28, P105, DOI 10.1200/JCO.2009.23.7370
   Epenetos A.A., 1995, CELL ADHESION MOL CA, P230
   Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI [10.1056/NEJMra072067, 10.1093/carcin/bgp220]
   Fernández MM, 2016, BBA-GEN SUBJECTS, V1860, P2255, DOI 10.1016/j.bbagen.2016.04.019
   Goldhirsch A, 2011, ANN ONCOL, V22, P1736, DOI 10.1093/annonc/mdr304
   Hassan NJ, 2006, MOL CELL BIOL, V26, P6727, DOI 10.1128/MCB.00688-06
   Hein S., 2014, BREAST CANC RES TREA, V129, P347, DOI [10. 1007/s10549-010-1219-y 20972617, DOI 10.1007/S10549-010-1219-Y20972617]
   Ishiguro F, 2013, J SURG RES, V179, P24, DOI 10.1016/j.jss.2012.08.044
   Jansen CF., 2003, UROONCOLOGY, V3, P121, DOI DOI 10.1080/15610950310001632322
   Jeong Y, 2017, GENE, V635, P48, DOI 10.1016/j.gene.2017.09.006
   Jeong YJ, 2013, ONCOL REP, V29, P1946, DOI 10.3892/or.2013.2335
   Jiang XG, 2014, MOL CELL ENDOCRINOL, V382, P673, DOI 10.1016/j.mce.2013.06.003
   Kahlert C, 2009, BRIT J CANCER, V101, P457, DOI 10.1038/sj.bjc.6605136
   King JA, 2004, BREAST CANCER RES, V6, pR478, DOI 10.1186/bcr815
   King JA, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-266
   Kristiansen G, 2003, PROSTATE, V54, P34, DOI 10.1002/pros.10161
   Kudo-Saito C, 2016, EUR J CANCER, V62, P54, DOI 10.1016/j.ejca.2016.04.013
   Mahmoud SMA, 2011, J CLIN ONCOL, V29, P1949, DOI 10.1200/JCO.2010.30.5037
   Makrilia N, 2009, CANCER INVEST, V27, P1023, DOI 10.3109/07357900902769749
   Mezzanzanica D, 2008, CLIN CANCER RES, V14, P1726, DOI 10.1158/1078-0432.CCR-07-0428
   Obeid E, 2013, INT J ONCOL, V43, P5, DOI 10.3892/ijo.2013.1938
   Ohneda O, 2001, BLOOD, V98, P2134, DOI 10.1182/blood.V98.7.2134
   Okegawa T, 2004, ACTA BIOCHIM POL, V51, P445
   Piao DX, 2012, MOL BIOL REP, V39, P661, DOI 10.1007/s11033-011-0783-5
   Stanton SE, 2016, JAMA ONCOL, V2, P1354, DOI 10.1001/jamaoncol.2016.1061
   Stanton SE, 2016, J IMMUNOTHER CANCER, V4, DOI 10.1186/s40425-016-0165-6
   Szklarczyk D, 2017, NUCLEIC ACIDS RES, V45, pD362, DOI 10.1093/nar/gkw937
   Vairapandi M, 2004, J CELL BIOCHEM, V91, P572, DOI 10.1002/jcb.10749
   van Kempen LCLT, 2001, J BIOL CHEM, V276, P25783, DOI 10.1074/jbc.M011272200
   van Kempen LCLT, 2000, AM J PATHOL, V156, P769, DOI 10.1016/S0002-9440(10)64943-7
   Verma A, 2005, ONCOLOGY-BASEL, V68, P462, DOI 10.1159/000086989
   Wang MN, 2017, J CANCER, V8, P761, DOI 10.7150/jca.17648
   Weichert W, 2004, J CLIN PATHOL, V57, P1160, DOI 10.1136/jcp.2004.016238
   Widschwendter M, 2002, ONCOGENE, V21, P5462, DOI 10.1038/sj.onc.1205606
   Zimmerman AW, 2006, BLOOD, V107, P3212, DOI 10.1182/blood-2005-09-3881
NR 43
TC 8
Z9 8
U1 1
U2 4
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1420-3049
J9 MOLECULES
JI Molecules
PD JAN
PY 2018
VL 23
IS 1
AR 131
DI 10.3390/molecules23010131
PG 12
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA FW1TM
UT WOS:000425082500125
PM 29315254
OA Green Submitted, gold, Green Published
DA 2025-01-12
ER

PT J
AU Xu, SP
   Wan, L
   Yin, HZ
   Xu, HB
   Zheng, W
   Shen, MY
   Zhang, ZM
   Pang, D
AF Xu, Shouping
   Wan, Lin
   Yin, Huizi
   Xu, Hongbiao
   Zheng, Wei
   Shen, Meiying
   Zhang, Zhongmin
   Pang, Da
TI Long Noncoding RNA Linc00152 Functions as a Tumor Propellant in
   Pan-Cancer
SO CELLULAR PHYSIOLOGY AND BIOCHEMISTRY
LA English
DT Article
DE Linc00152; Tumorigenesis; Pan-cancer; Breast cancer
ID PLASMINOGEN-ACTIVATOR INHIBITOR-1; COEXPRESSION NETWORK ANALYSIS;
   HEPATOCELLULAR-CARCINOMA; PROSTATE-CANCER; COLORECTAL-CANCER; SIGNALING
   PATHWAY; OVARIAN-CANCER; EXPRESSION; GENE; METASTASIS
AB Background/Aims: The oncogenic role of linc00152 in pan-cancer is unclear. Methods: In this study, RNA-Seq of 33 breast specimens was performed, and the expression of linc00152 was validated by qPCR using 50 paired breast cancer tissues and adjacent normal tissues. This result combined with the expression of linc00152 in pan-cancer was revalidated by Gene Expression Omnibus and The Cancer Genome Atlas data. Next, the oncogenic roles of linc00152 in view of prognosis, chemoresistance, genomic and epigenetic regulation, including DNA methylation and histone modification, potential biological function enrichment, and basic molecular function in pan-cancer, were also evaluated in vitro and in vivo. Results: Linc00152 is upregulated in pan-cancer, especially in progressive cancer, and the high expression of linc00152 may lead to a worse prognosis and chemoresistance in pan-cancer patients. Amplification, DNA hypomethylation, promoter-like lncRNA characteristics and super-enhancer regulation are the drivers that lead to the upregulation of linc00152 in pan-cancer. Meanwhile, linc00152 was involved in cancer-related pathways, infection and immune response-associated pathways by enriched analysis using TCGA data. Finally, linc00152 was confirmed to promote the proliferation, migration and invasion in MDA-MB-231, SGC-7901 and 786-O. Moreover, RIP and RNA pull-down assays indicated that linc00152 can bind to EZH2 directly. Conclusion: All of the results indicated that linc00152 acted as an oncogenic propellant from various perspectives, and it may be an effective therapy target in pan-cancer. (C) 2017 The Author(s) Published by S. Karger AG, Basel
C1 [Xu, Shouping; Wan, Lin; Yin, Huizi; Xu, Hongbiao; Zheng, Wei; Shen, Meiying; Zhang, Zhongmin; Pang, Da] Harbin Med Univ, Canc Hosp, Dept Breast Surg, 150 Haping Rd, Harbin 150040, Heilongjiang, Peoples R China.
   [Pang, Da] Heilongjiang Acad Med Sci, Harbin, Heilongjiang, Peoples R China.
C3 Harbin Medical University
RP Pang, D (通讯作者)，Harbin Med Univ, Canc Hosp, Dept Breast Surg, 150 Haping Rd, Harbin 150040, Heilongjiang, Peoples R China.
EM pangda@ems.hrbmu.edu.cn
RI Xu, Hongbiao/KHW-5291-2024; shen, meiying/IXW-8000-2023
FU Heilong Jiang province Health and Family Planning Commission Foundation
   Grant [2016-087]; National Natural Science Foundation of China
   [81602323]; China Postdoctoral Science Foundation Grant [2016M600262];
   Heilong Jiang postdoctoral Foundation Grant [LBH-Z16163]; Wu Lien-teh
   Science Foundation of Harbin Medical University [WLD-QN1706]; Young
   Elite Training Foundation Grant of Harbin Medical University Cancer
   Hospital [JY2016-02]
FX This work was supported by funding from the Heilong Jiang province
   Health and Family Planning Commission Foundation Grant (Grant Number
   2016-087), National Natural Science Foundation of China (Grant Number
   81602323), China Postdoctoral Science Foundation Grant (Grant Number
   2016M600262), Heilong Jiang postdoctoral Foundation Grant (Grant Number
   LBH-Z16163), Wu Lien-teh Science Foundation of Harbin Medical University
   (Grant Number WLD-QN1706), Young Elite Training Foundation Grant of
   Harbin Medical University Cancer Hospital (Grant Number JY2016-02).
CR Cai Q, 2016, AM J TRANSL RES, V8, P4068
   Chapuy B, 2013, CANCER CELL, V24, P777, DOI 10.1016/j.ccr.2013.11.003
   Chen H, 2015, SURGERY, V158, P1705, DOI 10.1016/j.surg.2015.04.053
   Chen J, 2015, CELL PHYSIOL BIOCHEM, V35, P722, DOI 10.1159/000369732
   Cogill SB, 2014, CANCER INFORM, V13, P49, DOI 10.4137/CIN.S14070
   DeSantis CE, 2016, CA-CANCER J CLIN, V66, P31, DOI 10.3322/caac.21320
   Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863
   Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210
   Fortenberry YM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0164288
   Fu YB, 2015, CELL BIOCHEM BIOPHYS, V71, P105, DOI 10.1007/s12013-014-0168-1
   Hibino S, 2014, ONCOGENESIS, V3, DOI 10.1038/oncsis.2014.17
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Huang JL, 2014, CARCINOGENESIS, V35, P507, DOI 10.1093/carcin/bgt405
   Huang XY, 2016, ONCOTARGET, V7, P57379, DOI 10.18632/oncotarget.10545
   Ji J, 2015, ONCOTARGET, V6, P42813, DOI 10.18632/oncotarget.5970
   Kunderfranco P, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010547
   Lara PC, 2012, STRAHLENTHER ONKOL, V188, P1139, DOI 10.1007/s00066-012-0216-y
   Ler LD, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aai8312
   Li C, 2015, CELL PHYSIOL BIOCHEM, V36, P423, DOI 10.1159/000430109
   Li Q, 2016, TUMOR BIOL, V37, P14537, DOI 10.1007/s13277-016-5299-0
   Liu HL, 2013, CELL PHYSIOL BIOCHEM, V32, P1497, DOI 10.1159/000356586
   Liu YB, 2015, CELL PHYSIOL BIOCHEM, V35, P1986, DOI 10.1159/000374006
   Luo G, 2015, CELL PHYSIOL BIOCHEM, V37, P2209, DOI 10.1159/000438577
   Marques AC, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-11-r131
   Mashiko S, 2015, CANCER BIOL THER, V16, P253, DOI 10.1080/15384047.2014.1001271
   Mercer TR, 2009, NAT REV GENET, V10, P155, DOI 10.1038/nrg2521
   Ning LF, 2015, GENET MOL RES, V14, P2146, DOI 10.4238/2015.March.27.1
   Ren G, 2012, CANCER RES, V72, P3091, DOI 10.1158/0008-5472.CAN-11-3546
   Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498
   Vyas AR, 2014, EUR J NUTR, V53, P843, DOI 10.1007/s00394-013-0588-5
   Wei YJ, 2016, NUCLEIC ACIDS RES, V44, pD172, DOI 10.1093/nar/gkv1243
   Xu CZ, 2016, CELL PHYSIOL BIOCHEM, V40, P1039, DOI 10.1159/000453160
   Xu J, 2017, CELL PHYSIOL BIOCHEM, V41, P635, DOI 10.1159/000457938
   Yu X, 2015, ONCOL LETT, V10, P1953, DOI 10.3892/ol.2015.3553
   Yue B, 2016, MOL THER, V24, P2064, DOI 10.1038/mt.2016.180
   Zhang B, 2005, STAT APPL GENET MOL, V4, DOI 10.2202/1544-6115.1128
   Zhang K, 2016, ONCOL REP, V36, P2911, DOI 10.3892/or.2016.5070
   Zhou JP, 2015, J EXP CLIN CANC RES, V34, DOI 10.1186/s13046-015-0250-6
NR 38
TC 27
Z9 27
U1 0
U2 21
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 1015-8987
EI 1421-9778
J9 CELL PHYSIOL BIOCHEM
JI Cell. Physiol. Biochem.
PY 2017
VL 44
IS 6
BP 2476
EP 2490
DI 10.1159/000486170
PG 15
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Physiology
GA FV9MZ
UT WOS:000424913800031
PM 29268251
OA gold
DA 2025-01-12
ER

PT J
AU Al-Kharashi, LA
   Al-Mohanna, FH
   Tulbah, A
   Aboussekhra, A
AF Al-Kharashi, Layla A.
   Al-Mohanna, Falah H.
   Tulbah, Asma
   Aboussekhra, Abdelilah
TI The DNA methyl-transferase protein DNMT1 enhances tumor-promoting
   properties of breast stromal fibroblasts
SO ONCOTARGET
LA English
DT Article
DE breast cancer; DNMT1; IL-6; mRNA decay; cancer-associated fibroblasts
ID CANCER-ASSOCIATED FIBROBLASTS; SUPPRESSOR GENE; STAT3; BINDING;
   TRANSCRIPTION; EXPRESSION; CARCINOMA; GROWTH; HUR
AB The activation of breast stromal fibroblasts is a crucial step toward tumor growth and spread. Therefore, it is extremely important to understand the molecular basis of this activation and determine the molecules and the mechanisms responsible for its sustainability. In the present report we have shown that the DNA methyl-transferase protein DNMT1 is critical for the activation of breast stromal fibroblasts as well as the persistence of their active status. Indeed, we have first revealed DNMT1 up-regulation in most cancer-associated fibroblasts relative to their corresponding adjacent normal fibroblasts. This effect resulted from HuR-dependent stabilization of the DNMT1 mRNA. Furthermore, ectopic expression of DNMT1 activated primary normal breast fibroblasts and promoted their pro-carcinogenic effects, both in vitro and in orthotopic tumor xenografts. By contrast, specific DNMT1 knockdown normalized breast myofibroblasts and repressed their cancer-promoting properties. These effects were sustained through inhibition of the IL-6/STAT3/NF-.B epigenetic cancer/inflammation positive feedback loop. Furthermore, we have shown that DNMT1-related activation of breast fibroblasts is mediated through upregulation of the RNA binding protein AUF1, which is also part of the loop. The present data demonstrate the critical function of DNMT1 in breast cancer-related sustained activation of breast stromal fibroblasts.
C1 [Al-Kharashi, Layla A.; Aboussekhra, Abdelilah] King Faisal Specialist Hosp & Res Ctr, Dept Mol Oncol, Riyadh 11211, Saudi Arabia.
   [Al-Kharashi, Layla A.] King Saud Univ, Dept Pharmacol & Toxicol, Fac Pharm, Riyadh 11451, Saudi Arabia.
   [Al-Mohanna, Falah H.] King Faisal Specialist Hosp & Res Ctr, Dept Comparat Med, Riyadh 11211, Saudi Arabia.
   [Tulbah, Asma] King Faisal Specialist Hosp & Res Ctr, Dept Pathol, Riyadh 11211, Saudi Arabia.
C3 King Faisal Specialist Hospital & Research Center; King Saud University;
   King Faisal Specialist Hospital & Research Center; King Faisal
   Specialist Hospital & Research Center
RP Aboussekhra, A (通讯作者)，King Faisal Specialist Hosp & Res Ctr, Dept Mol Oncol, Riyadh 11211, Saudi Arabia.
EM aboussekhra@kfshrc.edu.sa
RI Alkharashi, Layla/F-2598-2018; Aboussekhra, Abdelilah/JCD-8138-2023;
   Almohanna, Falah/IYJ-6603-2023
OI Almohanna, Falah/0000-0002-2426-0945
FU RAC [2160005]; King Faisal Specialist Hospital & Research Center
FX We are thankful to the Comparative Medicine staff for their help with
   animal experiments. We are also grateful to Dr. Huda Al-Khlaf for her
   continuous help and the preparation of the lentiviral supernatants. We
   also appreciate the continuous support of the Research Center
   administration. This work was performed under the RAC proposal #
   2160005, and was supported in totality by King Faisal Specialist
   Hospital & Research Center.
CR Aboussekhra A, 2011, INT J DEV BIOL, V55, P841, DOI 10.1387/ijdb.113362aa
   Al-Ansari MM, 2013, ONCOGENE, V32, P2356, DOI 10.1038/onc.2012.270
   Al-Mohanna MA, 2007, NUCLEIC ACIDS RES, V35, P223, DOI 10.1093/nar/gkl1075
   Albrengues J, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms10204
   Chen QM, 1998, BIOCHEM J, V332, P43, DOI 10.1042/bj3320043
   Clements EG, 2012, NUCLEIC ACIDS RES, V40, P4334, DOI 10.1093/nar/gks031
   Gascard P, 2016, GENE DEV, V30, P1002, DOI 10.1101/gad.279737.116
   Hawsawi NM, 2008, CANCER RES, V68, P2717, DOI 10.1158/0008-5472.CAN-08-0192
   Hendrayani SF, 2016, ONCOTARGET, V7, P41974, DOI 10.18632/oncotarget.9633
   Hendrayani SF, 2014, J BIOL CHEM, V289, P30962, DOI 10.1074/jbc.M114.594044
   Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075
   Iliopoulos D, 2010, MOL CELL, V39, P493, DOI 10.1016/j.molcel.2010.07.023
   Iliopoulos D, 2009, CELL, V139, P693, DOI 10.1016/j.cell.2009.10.014
   Jair KW, 2006, CANCER RES, V66, P682, DOI 10.1158/0008-5472.CAN-05-1980
   JEMAL A, 2011, CA-CANCER J CLIN, V61, P69, DOI DOI 10.3322/CAAC.20107
   Kalluri R, 2016, NAT REV CANCER, V16, P582, DOI 10.1038/nrc.2016.73
   Khabar KSA, 2017, WIRES RNA, V8, DOI 10.1002/wrna.1368
   Lal A, 2004, EMBO J, V23, P3092, DOI 10.1038/sj.emboj.7600305
   Lee H, 2012, P NATL ACAD SCI USA, V109, P7765, DOI 10.1073/pnas.1205132109
   de Silanes IL, 2009, NUCLEIC ACIDS RES, V37, P2658, DOI 10.1093/nar/gkp123
   Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034
   Pathania R, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7910
   Qiu W, 2008, NAT GENET, V40, P650, DOI 10.1038/ng.117
   Rhee I, 2002, NATURE, V416, P552, DOI 10.1038/416552a
   Schuebel KE, 2007, PLOS GENET, V3, P1709, DOI 10.1371/journal.pgen.0030157
   Shin E, 2016, J TRANSL MED, V14, DOI 10.1186/s12967-016-0840-x
   Silva G, 2016, MOL CARCINOGEN, V55, P525, DOI 10.1002/mc.22299
   Zhang Q, 2005, P NATL ACAD SCI USA, V102, P6948, DOI 10.1073/pnas.0501959102
   Zhang Q, 2006, BLOOD, V108, P1058, DOI 10.1182/blood-2005-08-007377
NR 29
TC 21
Z9 21
U1 0
U2 7
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD JAN 5
PY 2018
VL 9
IS 2
BP 2329
EP 2343
DI 10.18632/oncotarget.23411
PG 15
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA FS2QL
UT WOS:000419623200068
PM 29416775
OA Green Published, gold, Green Submitted
DA 2025-01-12
ER

PT J
AU Kim, K
   Son, MY
   Jung, CR
   Kim, DS
   Cho, HS
AF Kim, Kwangho
   Son, Mi-Young
   Jung, Cho-Rok
   Kim, Dae-Soo
   Cho, Hyun-Soo
TI EHMT2 is a metastasis regulator in breast cancer
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE Breast cancer; EHMT2; Migration; Invasion; Metastasis
ID HISTONE METHYLTRANSFERASE; G9A; REPRESSION; PROTEIN; CELLS; SET; H3
AB Various modes of epigenetic regulation of breast cancer proliferation and metastasis have been investigated, but epigenetic mechanisms involved in breast cancer metastasis remain elusive. Thus, in this study, EHMT2 (a histone methyltransferase) was determined to be significantly overexpressed in breast cancer tissues and in Oncomine data. In addition, knockdown of EHMT2 reduced cell migration/invasion and regulated the expression of EMT-related markers (E-cadherin, Claudin 1, and Vimentin). Furthermore, treatment with BIX-01294, a specific inhibitor of EHMT2, affected migration/invasion in MDA-MB-231 cells. Therefore, our findings demonstrate functions of EHMT2 in breast cancer metastasis and suggest that targeting EHMT2 may be an effective therapeutic strategy for preventing breast cancer metastasis. (C) 2018 Elsevier Inc. All rights reserved.
C1 [Kim, Kwangho; Son, Mi-Young; Jung, Cho-Rok; Kim, Dae-Soo; Cho, Hyun-Soo] Korea Res Inst Biosci & Biotechnol, Daejeon 305333, South Korea.
   [Son, Mi-Young; Jung, Cho-Rok; Kim, Dae-Soo; Cho, Hyun-Soo] Korea Univ Sci & Technol, Dept Funct Genom, Daejeon 305333, South Korea.
C3 Korea Research Institute of Bioscience & Biotechnology (KRIBB);
   University of Science & Technology (UST)
RP Cho, HS (通讯作者)，Korea Res Inst Biosci & Biotechnol, Daejeon 305333, South Korea.
EM chohs@kribb.re.kr
RI Kim, Young Hoon/F-5424-2012
OI cho, Hyun-soo/0000-0002-8242-9390; Kim, Kwangho/0000-0001-9387-7642;
   Son, Mi-Young/0000-0001-7590-8812; , cho-rok/0000-0002-4474-6563
FU National Research Foundation of Korea (NRF) - Ministry of Science, ICT
   and Future Planning [2017R1A2B4003757, 2016R1A2B4013501]; KRIBB Research
   Initiative Program
FX This work was supported by a grant from the National Research Foundation
   of Korea (NRF) grant funded by the Ministry of Science, ICT and Future
   Planning (2017R1A2B4003757 and 2016R1A2B4013501) and the KRIBB Research
   Initiative Program. The funders had no role in the study design, data
   collection or analysis, decision to publish, or preparation of the
   manuscript.
CR Casciello F, 2017, P NATL ACAD SCI USA, V114, P7077, DOI 10.1073/pnas.1618706114
   Chang YQ, 2009, NAT STRUCT MOL BIOL, V16, P312, DOI 10.1038/nsmb.1560
   Chavez Kathryn J, 2010, Breast Dis, V32, P35, DOI 10.3233/BD-2010-0307
   Chen MW, 2010, CANCER RES, V70, P7830, DOI 10.1158/0008-5472.CAN-10-0833
   Dent R, 2007, CLIN CANCER RES, V13, P4429, DOI 10.1158/1078-0432.CCR-06-3045
   Dong CF, 2012, J CLIN INVEST, V122, P1469, DOI 10.1172/JCI57349
   Hsu YL, 2013, ONCOGENE, V32, P4436, DOI 10.1038/onc.2012.444
   Huang L, 2017, AM J TRANSL RES, V9, P1
   Jandial R., 2017, CLIN BREAST CANCER, V17, P30417
   Jung KB, 2017, MOL BIOSYST, V13, P1565, DOI 10.1039/c7mb00174f
   Kim DS, 2017, HEPATOLOGY, V66, P1662, DOI 10.1002/hep.29324
   Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132
   Lee A, 2018, CANCER TREAT REV, V62, P110, DOI 10.1016/j.ctrv.2017.11.003
   Lee Jae-Hye, 2016, Oncotarget, V7, P79774, DOI 10.18632/oncotarget.12967
   Lee JY, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0141118
   Luo XG, 2014, CANCER LETT, V344, P129, DOI 10.1016/j.canlet.2013.10.026
   Norouzi S., 2017, CURR PHARM IN PRESS
   Son MY, 2017, NEUROPATH APPL NEURO, V43, P584, DOI 10.1111/nan.12396
   Tachibana M, 2001, J BIOL CHEM, V276, P25309, DOI 10.1074/jbc.M101914200
   Wang YF, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00350-9
   Yoon JY, 2016, MOL CARCINOGEN, V55, P387, DOI 10.1002/mc.22288
NR 21
TC 31
Z9 31
U1 0
U2 6
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
EI 1090-2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD FEB 5
PY 2018
VL 496
IS 2
BP 758
EP 762
DI 10.1016/j.bbrc.2018.01.074
PG 5
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA FV1IA
UT WOS:000424313500078
PM 29337058
DA 2025-01-12
ER

PT J
AU Li, JY
   Zhou, CC
   Wang, GL
   Wang, SM
   Ni, SM
   Ye, M
   Zhang, J
AF Li, Jinyun
   Zhou, Chongchang
   Wang, Guoli
   Wang, Shaomin
   Ni, Shuming
   Ye, Meng
   Zhang, Jian
TI Promoter hypermethylation of <i>SLIT2</i> is a risk factor and potential
   diagnostic biomarker for nasopharyngeal carcinoma
SO GENE
LA English
DT Article
DE NPC; SLIT2; DNA methylation; Metastasis; Diagnosis
ID FREQUENT EPIGENETIC INACTIVATION; CIRCULATING TUMOR DNA;
   COLORECTAL-CANCER; BREAST-CANCER; AXON GUIDANCE; LUNG-CANCER;
   NECK-CANCER; METHYLATION; GENE; RADIOTHERAPY
AB SLIT2 is a candidate tumor suppressor gene and recent studies have shown that SLIT2 expression is suppressed or reduced by hypermethylation in the promoter region in various cancers. The aim of this study was to investigate the association between SLIT2 promoter methylation and nasopharyngeal carcinoma (NPC) and its relative diagnostic ability for NPC. Bisulfite pyrosequencing technology was performed to measure methylation levels of the SLIT2 promoter in tissue and plasma samples from 61 NPC patients and 38 normal volunteers. The receiver operating characteristic (ROC) curve and area under the curve (AUC) were used to evaluate the diagnostic ability of SLIT2 methylation for diagnosing NPC. Our results showed that methylation levels of the SLIT2 promoter were significantly higher in NPC patients compared with individuals, both in tissue samples (P = 2.57E - 10) and plasma samples (plasma: P = 3.86E - 13). In addition, the frequency of SLIT2 promoter methylation markedly increased in the advanced stage (tissue: P = 3.50E - 05; plasma: P = 1.14E - 04) and advanced T classified (tissue: P = 9.00E - 06; plasma: P = 3.80E - 05), as well as in lymph node metastasis patients (tissue: P = 1.82E - 03; plasma: P = 2.22E - 03). In addition, the AUCs according to tissue and plasma samples were 0.846 and 0.866, respectively. When these two sample-types were combined, the AUC increased slightly to 0.874. Our study revealed that elevated SLIT2 promoter methylation contributed to the risk of NPC, as well as being involved in its progression and metastasis. Therefore, the methylated SLIT2 promoter could serve as a potential biomarker for diagnosing NPC.
C1 [Li, Jinyun; Wang, Shaomin; Ni, Shuming; Ye, Meng] Ningbo Univ, Affiliated Hosp, Dept Hematol & Oncol, Ningbo 315000, Zhejiang, Peoples R China.
   [Zhou, Chongchang; Wang, Guoli; Zhang, Jian] Ningbo Univ, Dept Otorhinolaryngol Head & Neck Surg, Lihuili Hosp, Ningbo 315040, Zhejiang, Peoples R China.
C3 Ningbo University; Ningbo University
RP Ye, M (通讯作者)，Ningbo Univ, Affiliated Hosp, Dept Hematol & Oncol, Ningbo 315000, Zhejiang, Peoples R China.; Zhou, CC; Zhang, J (通讯作者)，Ningbo Univ, Dept Otorhinolaryngol Head & Neck Surg, Lihuili Hosp, Ningbo 315040, Zhejiang, Peoples R China.
EM zhou900709900709@163.com; yemeng@nbu.edu.cn; zhangjianent@126.com
OI Zhou, Chongchang/0000-0002-8728-6819
FU Medical and Health Research Project of Zhejiang Province [2013KYB231,
   2014KYB229, 2017KY133]; Medical Association Clinical Research Project
   Funding of Zhejiang Province [2015ZYC-A49]; Ningbo Natural Science
   Foundation [2015A610221, 2017A610236]
FX This research was supported by grants from the Medical and Health
   Research Project of Zhejiang Province (No. 2013KYB231; No. 2014KYB229;
   No. 2017KY133); the Medical Association Clinical Research Project
   Funding of Zhejiang Province (No. 2015ZYC-A49), and the Ningbo Natural
   Science Foundation (No. 2015A610221 and 2017A610236).
CR Arantes LMRB, 2014, ORAL ONCOL, V50, P587, DOI 10.1016/j.oraloncology.2014.02.015
   Bettegowda C, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007094
   Brose K, 1999, CELL, V96, P795, DOI 10.1016/S0092-8674(00)80590-5
   Chan SL, 2012, EXPERT OPIN THER TAR, V16, pS63, DOI 10.1517/14728222.2011.635646
   Chen WQ, 2016, CA-CANCER J CLIN, V66, P115, DOI 10.3322/caac.21338
   Dallol A, 2003, ONCOGENE, V22, P4611, DOI 10.1038/sj.onc.1206687
   Dallol A, 2003, CANCER RES, V63, P1054
   Dallol A, 2002, CANCER RES, V62, P5874
   Dunwell TL, 2009, EPIGENETICS-US, V4, P265, DOI 10.4161/epi.9137
   Feng M, 2013, RADIAT ONCOL, V8, DOI 10.1186/1748-717X-8-208
   Fernandez-Cuesta L, 2016, EBIOMEDICINE, V10, P117, DOI 10.1016/j.ebiom.2016.06.032
   Jiang DJ, 2014, TUMOR BIOL, V35, P10449, DOI 10.1007/s13277-014-2300-7
   Jin J, 2009, BIOCHEM BIOPH RES CO, V379, P86, DOI 10.1016/j.bbrc.2008.12.022
   Kajiura K, 2017, ONCOTARGET, V8, P2890, DOI 10.18632/oncotarget.13761
   Kong L, 2016, J CANCER, V7, P774, DOI 10.7150/jca.14399
   Lee A. W. M., 1997, Hong Kong Medical Journal, V3, P355
   Li H, 2013, NANOSCALE RES LETT, V8, P1, DOI 10.1186/1556-276X-8-183
   Lo KW, 2004, CANCER CELL, V5, P423, DOI 10.1016/S1535-6108(04)00119-9
   Rosas SLB, 2001, CANCER RES, V61, P939
   Sarisahin M, 2011, AURIS NASUS LARYNX, V38, P250, DOI 10.1016/j.anl.2010.09.002
   Shakeri H, 2016, CLIN LAB, V62, P2333, DOI 10.7754/Clin.Lab.2016.160418
   SHAM JST, 1990, BRIT J RADIOL, V63, P51, DOI 10.1259/0007-1285-63-745-51
   SHAM JST, 1990, INT J RADIAT ONCOL, V19, P929, DOI 10.1016/0360-3016(90)90014-B
   Sloane MA, 2014, EPIGENETICS-US, V9, P1092, DOI 10.4161/epi.29222
   Smith C, 2013, IMMUNOTHERAPY-UK, V5, P821, DOI [10.2217/imt.13.68, 10.2217/IMT.13.68]
   Sozzi G, 2001, CANCER RES, V61, P4675
   Spratt DE, 2012, ONCOTARGETS THER, V5, P297, DOI 10.2147/OTT.S28032
   Stein E, 2001, SCIENCE, V291, P1928, DOI 10.1126/science.1058445
   Tang LL, 2016, CANCER LETT, V374, P22, DOI 10.1016/j.canlet.2016.01.040
   Tang LL, 2014, GENE, V547, P329, DOI 10.1016/j.gene.2014.06.062
   Tian FY, 2013, CANCER EPIDEMIOL, V37, P708, DOI 10.1016/j.canep.2013.05.012
   Trujillo KA, 2012, PROSTATE CANCER, V2012, DOI 10.1155/2012/302894
   Tsao SW, 2014, ORAL ONCOL, V50, P330, DOI 10.1016/j.oraloncology.2014.02.006
   Walters RJ, 2013, EPIGENETICS-US, V8, P748, DOI 10.4161/epi.25178
   Wang N, 2016, ARCH MED RES, V47, P285, DOI 10.1016/j.arcmed.2016.07.011
   Wei KR, 2010, ASIAN PAC J CANCER P, V11, P29
   Wong EM, 2011, CANCER PREV RES, V4, P23, DOI 10.1158/1940-6207.CAPR-10-0212
   Woo J.K., 1990, ENT J, V69, P251
   Wu Kun, 2015, Asian Pac J Cancer Prev, V16, P2283
   Xu FH, 2012, JNCI-J NATL CANCER I, V104, P1396, DOI 10.1093/jnci/djs320
   Zhou XF, 2007, COMP FUNCT GENOM, DOI 10.1155/2007/57513
NR 41
TC 5
Z9 5
U1 0
U2 7
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0378-1119
EI 1879-0038
J9 GENE
JI Gene
PD FEB 20
PY 2018
VL 644
BP 74
EP 79
DI 10.1016/j.gene.2017.10.059
PG 6
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA FV6VQ
UT WOS:000424720600010
PM 29107007
DA 2025-01-12
ER

PT J
AU Sanford, T
   Meng, MV
   Railkar, R
   Agarwal, PK
   Porten, SP
AF Sanford, Thomas
   Meng, Maxwell V.
   Railkar, Reema
   Agarwal, Piyush K.
   Porten, Sima P.
TI Integrative analysis of the epigenetic basis of muscle-invasive
   urothelial carcinoma
SO CLINICAL EPIGENETICS
LA English
DT Article
DE Epigenetics; Urothelial carcinoma; Integrative analyses
ID ABERRANT PROMOTER METHYLATION; ESTROGEN-RECEPTOR-ALPHA; DNA METHYLATION;
   BLADDER-CANCER; TUMOR-SUPPRESSOR; BREAST-CANCER; PREDICTIVE-VALUE; GENE;
   HYPERMETHYLATION; EXPRESSION
AB Background: Elucidation of epigenetic alterations in bladder cancer will lead to further understanding of the biology of the disease and hopefully improved therapies. Our aim was to perform an integrative epigenetic analysis of invasive urothelial carcinoma of the bladder to identify the epigenetic abnormalities involved in the development and progression of this cancer.
   Methods: Pre-processed methylation data and RNA-seq data were downloaded from The Cancer Genome Atlas (TCGA) and processed using the R package TCGA-Assembler. An R package MethylMix was used to perform an analysis incorporating both methylation and gene expression data on all samples, as well as a subset analysis comparing patients surviving less than 2 years and patients surviving more than 2 years. Genes associated with poor prognosis were individually queried. Pathway analysis was performed on statistically significant genes identified by MethylMix criteria using ConsensusPathDB. Validation was performed using flow cytometry on bladder cancer cell lines.
   Results: A total of 408 patients met all inclusion criteria. There were a total of 240 genes differentially methylated by MethylMix criteria. Review of individual genes specific to poor-prognosis patients revealed the majority to be candidate tumor suppressors in other cancer types. Pathway analysis showed increase in methylation of genes involved in antioxidant pathways including glutathione and NRF2. Genes involved in estrogen metabolism were also hypermethylated while genes involved in the EGFR pathway were found to be hypomethylated. EGFR expression was confirmed to be elevated in six bladder cancer cell lines.
   Conclusions: In patients with invasive urothelial carcinoma, we found differential methylation in patients with better and worse prognosis after cystectomy. Differentially methylated genes are involved in many relevant oncologic pathways, including EGFR and antioxidant pathways, that may be a target for therapy or chemoprevention.
C1 [Meng, Maxwell V.; Porten, Sima P.] Univ Calif San Francisco, Dept Urol, Mail Code 1695,550 16th St,6th Floor, San Francisco, CA 94143 USA.
   [Sanford, Thomas; Railkar, Reema; Agarwal, Piyush K.] NCI, Urol Oncol Branch, Ctr Canc Res, Bldg 10 Hatfield CRC,Room 2-5952, Bethesda, MD 20892 USA.
C3 University of California System; University of California San Francisco;
   National Institutes of Health (NIH) - USA; NIH National Cancer Institute
   (NCI)
RP Porten, SP (通讯作者)，Univ Calif San Francisco, Dept Urol, Mail Code 1695,550 16th St,6th Floor, San Francisco, CA 94143 USA.
EM sima.porten@ucsf.edu
RI Railkar, Reema/AAE-7258-2022
OI Railkar, Reema/0000-0002-6808-7814; Sanford, Thomas/0000-0002-7123-9807
CR [Anonymous], 2016, Oncotarget
   [Anonymous], J BIOM BIOSTAT
   [Anonymous], ANN SURG ONCOL
   Ashktorab H, 2014, EPIGENETICS-US, V9, P503, DOI 10.4161/epi.27644
   Bibikova M, 2011, GENOMICS, V98, P288, DOI 10.1016/j.ygeno.2011.07.007
   Black PC, 2007, UROL ONCOL-SEMIN ORI, V25, P433, DOI 10.1016/j.urolonc.2007.05.011
   Brait M, 2008, CANCER EPIDEM BIOMAR, V17, P2786, DOI 10.1158/1055-9965.EPI-08-0192
   Calvisi DF, 2011, J HEPATOL, V54, P311, DOI 10.1016/j.jhep.2010.06.036
   Catto JWF, 2007, J UROLOGY, V177, P1715, DOI 10.1016/j.juro.2007.01.030
   Catto JWF, 2005, J CLIN ONCOL, V23, P2903, DOI 10.1200/JCO.2005.03.163
   Cheng YD, 2010, CANCER RES, V70, P6516, DOI 10.1158/0008-5472.CAN-09-4566
   Chihara Y, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-275
   Dalbagni G, 2001, J UROLOGY, V165, P1111, DOI 10.1016/S0022-5347(05)66440-3
   de Groot JS, 2014, CELL ONCOL, V37, P297, DOI 10.1007/s13402-014-0189-1
   Dellagrammaticas D, 2001, J UROLOGY, V165, P1631, DOI 10.1016/S0022-5347(05)66370-7
   Dhawan D, 2006, J PATHOL, V209, P336, DOI 10.1002/path.1991
   Fan SC, 2009, BIOCHEM BIOPH RES CO, V383, P421, DOI 10.1016/j.bbrc.2009.04.023
   Gevaert O, 2015, BIOINFORMATICS, V31, P1839, DOI 10.1093/bioinformatics/btv020
   Gevaert O, 2015, GENOME BIOL, V16, DOI 10.1186/s13059-014-0579-8
   Ghoneim MA, 2008, J UROLOGY, V180, P121, DOI 10.1016/j.juro.2008.03.024
   Hoffman KL, 2013, HORM CANCER-US, V4, P24, DOI 10.1007/s12672-012-0123-9
   Iida K, 2004, CANCER RES, V64, P6424, DOI 10.1158/0008-5472.CAN-04-1906
   Issa JPJ, 2015, LANCET ONCOL, V16, P1099, DOI 10.1016/S1470-2045(15)00038-8
   Jarmalaite S, 2008, ONCOLOGY-BASEL, V75, P145, DOI 10.1159/000158665
   Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43
   Kalinina EV, 2014, BIOCHEMISTRY-MOSCOW+, V79, P1562, DOI 10.1134/S0006297914130082
   Kamburov A, 2009, NUCLEIC ACIDS RES, V37, pD623, DOI 10.1093/nar/gkn698
   Kandimalla R, 2012, EUR UROL, V61, P1245, DOI 10.1016/j.eururo.2012.01.011
   Kandoth C, 2013, NATURE, V502, P333, DOI 10.1038/nature12634
   Kanwal R, 2012, CLIN GENET, V81, P303, DOI 10.1111/j.1399-0004.2011.01809.x
   Kennedy MW, 2016, P NATL ACAD SCI USA, V113, P3545, DOI 10.1073/pnas.1519994113
   Kim YJ, 2013, INT J CANCER, V133, P1135, DOI 10.1002/ijc.28121
   Kim YH, 2011, ANN SURG ONCOL, V18, P2338, DOI 10.1245/s10434-011-1573-y
   Kitchen MO, 2016, EPIGENETICS-US, V11, P237, DOI 10.1080/15592294.2016.1154246
   Koga Y, 2009, GENOME RES, V19, P1462, DOI 10.1101/gr.091447.109
   Landa I, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000637
   Lauss M, 2012, EPIGENETICS-US, V7, P858, DOI 10.4161/epi.20837
   Lin CY, 2013, CANCER RES, V73, P3638, DOI 10.1158/0008-5472.CAN-12-4028
   Lindqvist BM, 2014, EPIGENETICS-US, V9, P1149, DOI 10.4161/epi.29632
   Liu YQ, 2013, BIOMARKERS, V18, P399, DOI 10.3109/1354750X.2013.798745
   Ma K, 2016, CLIN EPIGENETICS, V8, DOI 10.1186/s13148-016-0210-9
   Malats N, 2015, HEMATOL ONCOL CLIN N, V29, P177, DOI 10.1016/j.hoc.2014.10.001
   Marsit CJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012334
   Martin-Subero JI, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006986
   Menendez L, 2007, MOL CANCER, V6, DOI 10.1186/1476-4598-6-10
   Misawa K, 2016, ONCOTARGET, V7, P26087, DOI 10.18632/oncotarget.8317
   Mitchell SM, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-54
   Motohashi H, 2004, TRENDS MOL MED, V10, P549, DOI 10.1016/j.molmed.2004.09.003
   Ning B, 2016, ACTA BIOCH BIOPH SIN, V48, P97, DOI 10.1093/abbs/gmv116
   Park E, 2012, BIOCHEM BIOPH RES CO, V421, P532, DOI 10.1016/j.bbrc.2012.04.039
   Park SJ, 2012, CARCINOGENESIS, V33, P1494, DOI 10.1093/carcin/bgs178
   Reinert T, 2011, CLIN CANCER RES, V17, P5582, DOI 10.1158/1078-0432.CCR-10-2659
   Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007
   Robertson AG, 2017, CELL, V171, P540, DOI [10.1016/j.cell.2017.09.007, 10.1016/j.cell.2018.07.036]
   Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616
   RUBBEN H, 1988, J UROLOGY, V139, P283, DOI 10.1016/S0022-5347(17)42387-1
   Sandoval J, 2013, J CLIN ONCOL, V31, P4140, DOI 10.1200/JCO.2012.48.5516
   Schneider BP, 2013, CLIN CANCER RES, V19, P1281, DOI 10.1158/1078-0432.CCR-12-3029
   Sharma PK, 2013, UROL ANNALS, V5, P157, DOI 10.4103/0974-7796.115734
   Shen SS, 2006, CANCER-AM CANCER SOC, V106, P2610, DOI 10.1002/cncr.21945
   Shui IM, 2016, CANCER-AM CANCER SOC, V122, P2168, DOI 10.1002/cncr.30045
   Steenbergen RDM, 2013, J PATHOL, V231, P53, DOI 10.1002/path.4210
   Tham C, 2014, CANCER-AM CANCER SOC, V120, P3131, DOI 10.1002/cncr.28802
   Ushmorov A, 2008, LEUKEMIA, V22, P1942, DOI 10.1038/leu.2008.70
   Venza I, 2010, BRIT J DERMATOL, V162, P1093, DOI 10.1111/j.1365-2133.2009.09560.x
   Wei JH, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9699
   Weinstein JN, 2014, NATURE, V507, P315, DOI 10.1038/nature12965
   Welty C, 2015, J UROLOGY, V193, pE843, DOI 10.1016/j.juro.2015.02.2418
   Wolff EM, 2010, CANCER RES, V70, P8169, DOI 10.1158/0008-5472.CAN-10-1335
   Xu J, 2008, J MOL BIOL, V377, P28, DOI 10.1016/j.jmb.2007.12.038
   Yamada N, 2016, ONCOL REP, V35, P2228, DOI 10.3892/or.2016.4619
   Yates DR, 2007, CLIN CANCER RES, V13, P2046, DOI 10.1158/1078-0432.CCR-06-2476
   Yin DT, 2016, ONCOTARGET, V7, P5830, DOI 10.18632/oncotarget.6709
   Yoon HY, 2016, ONCOL REP, V35, P1195, DOI 10.3892/or.2015.4409
   Yu CP, 2012, CARCINOGENESIS, V33, P678, DOI 10.1093/carcin/bgr321
   Yuan H, 2013, CANCER RES, V73, P1581, DOI 10.1158/0008-5472.CAN-12-2377
   Zhang ZP, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-124
   Zhu YT, 2014, NAT METHODS, V11, P599, DOI 10.1038/nmeth.2956
NR 78
TC 22
Z9 23
U1 0
U2 4
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1868-7075
EI 1868-7083
J9 CLIN EPIGENETICS
JI Clin. Epigenetics
PD FEB 12
PY 2018
VL 10
AR 19
DI 10.1186/s13148-018-0451-x
PG 11
WC Oncology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Genetics & Heredity
GA FV7MH
UT WOS:000424768100001
PM 29456764
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Mijnes, J
   Veeck, J
   Gaisa, NT
   Burghardt, E
   de Ruijter, TC
   Gostek, S
   Dahl, E
   Pfister, D
   Schmid, SC
   Knüchel, R
   Rose, M
AF Mijnes, Jolein
   Veeck, Juergen
   Gaisa, Nadine T.
   Burghardt, Eduard
   de Ruijter, Tim C.
   Gostek, Sonja
   Dahl, Edgar
   Pfister, David
   Schmid, Sebastian C.
   Knuechel, Ruth
   Rose, Michael
TI Promoter methylation of DNA damage repair (DDR) genes in human tumor
   entities: <i>RBBP8/CtIP</i> is almost exclusively methylated in bladder
   cancer
SO CLINICAL EPIGENETICS
LA English
DT Article
DE RBBP8/CtIP; DNA repair; Bladder cancer/BLCA; Epigenetics; Infinium
   HumanMethylation450 BeadChip; Urine biomarker
ID HOMOLOGOUS RECOMBINATION REPAIR; PLATINUM-BASED CHEMOTHERAPY;
   MICROSATELLITE INSTABILITY; EPIGENETIC INACTIVATION; CELL-CYCLE;
   PREDICTIVE BIOMARKER; UROTHELIAL CARCINOMA; BREAST-CANCER; CTIP;
   EXPRESSION
AB Background: Genome-wide studies identified pan-cancer genes and shared biological networks affected by epigenetic dysregulation among diverse tumor entities. Here, we systematically screened for hypermethylation of DNA damage repair (DDR) genes in a comprehensive candidate-approach and exemplarily identify and validate candidate DDR genes as targets of epigenetic inactivation unique to bladder cancer (BLCA), which may serve as non-invasive biomarkers.
   Methods: Genome-wide DNA methylation datasets (2755 CpG probes of n = 7819 tumor and n = 659 normal samples) of the TCGA network covering 32 tumor entities were analyzed in silico for 177 DDR genes. Genes of interest were defined as differentially methylated between normal and cancerous tissues proximal to transcription start sites. The lead candidate gene was validated by methylation-specific PCR (MSP) and/or bisulfite-pyrosequencing in different human cell lines (n = 36), in primary BLCA tissues (n = 43), and in voided urine samples (n = 74) of BLCA patients. Urines from healthy donors and patients with urological benign and malignant diseases were included as controls (n = 78). mRNA expression was determined using qRT-PCR in vitro before (n = 5) and after decitabine treatment (n = 2). Protein expression was assessed by immunohistochemistry (n = 42). R 3.2.0. was used for statistical data acquisition and SPSS 21.0 for statistical analysis.
   Results: Overall, 39 DDR genes were hypermethylated in human cancers. Most exclusively and frequently methylated (37%) in primary BLCA was RBBP8, encoding endonuclease CtIP. RBBP8 hypermethylation predicted longer overall survival (OS) and was found in 2/4 bladder cancer cell lines but not in any of 33 cancer cell lines from entities with another origin like prostate. RBBP8 methylation was inversely correlated with RBBP8 mRNA and nuclear protein expression while RBBP8 was re-expressed after in vitro demethylation. RBBP8 methylation was associated with histological grade in primary BLCA and urine samples. RBBP8 methylation was detectable in urine samples of bladder cancer patients achieving a sensitivity of 52%, at 91% specificity.
   Conclusions: RBBP8 was identified as almost exclusively hypermethylated in BLCA. RBBP8/CtIP has a proven role in homologous recombination-mediated DNA double-strand break repair known to sensitize cancer cells for PARP1 inhibitors. Since RBBP8 methylation was detectable in urines, it may be a complementary marker of high specificity in urine for BLCA detection.
C1 [Mijnes, Jolein; Veeck, Juergen; Gaisa, Nadine T.; Burghardt, Eduard; Gostek, Sonja; Dahl, Edgar; Knuechel, Ruth; Rose, Michael] Rhein Westfal TH Aachen, Inst Pathol, Pauwelsstr 30, D-52074 Aachen, Germany.
   [Veeck, Juergen; de Ruijter, Tim C.] Maastricht Univ, Med Ctr, Div Med Oncol, Maastricht, Netherlands.
   [Veeck, Juergen; de Ruijter, Tim C.] Maastricht Univ, Med Ctr, GROW Sch Oncol & Dev Biol, Maastricht, Netherlands.
   [Veeck, Juergen; Dahl, Edgar; Rose, Michael] Rhein Westfal TH Aachen, Fac Med, RWTH Centralized Biomat Bank RWTH CBMB, Aachen, Germany.
   [Pfister, David] Rhein Westfal TH Aachen, Dept Urol, Aachen, Germany.
   [Pfister, David] Univ Hosp Cologne, Dept Urol Urooncol Robot Assisted & Reconstruct U, Cologne, Germany.
   [Schmid, Sebastian C.] Tech Univ Munich, Klinikum Rechts Isar, Dept Urol, Munich, Germany.
C3 RWTH Aachen University; Maastricht University; Maastricht University;
   RWTH Aachen University; RWTH Aachen University; University of Cologne;
   Technical University of Munich
RP Rose, M (通讯作者)，Rhein Westfal TH Aachen, Inst Pathol, Pauwelsstr 30, D-52074 Aachen, Germany.; Rose, M (通讯作者)，Rhein Westfal TH Aachen, Fac Med, RWTH Centralized Biomat Bank RWTH CBMB, Aachen, Germany.
EM mrose@ukaachen.de
FU Medical Faculty of the RWTH Aachen University (START program) [113/15]
FX This work was supported by a grant from the Medical Faculty of the RWTH
   Aachen University (START program project 113/15).
CR Abbotts R, 2014, CANCER MANAG RES, V6, P77, DOI 10.2147/CMAR.S50497
   Alexandrov LB, 2013, NATURE, V500, P415, DOI 10.1038/nature12477
   [Anonymous], 2014, MATH PROBL ENG
   Arcas A, 2014, MOL BIOL EVOL, V31, P940, DOI 10.1093/molbev/msu046
   Asakawa H, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2486
   Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482
   Bennardo N, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000110
   Bertz S, 2014, EUR UROL, V65, P218, DOI 10.1016/j.eururo.2012.05.033
   Bibikova M, 2011, GENOMICS, V98, P288, DOI 10.1016/j.ygeno.2011.07.007
   Cartharius K, 2005, BIOINFORMATICS, V21, P2933, DOI 10.1093/bioinformatics/bti473
   Chaudhry P, 2009, CANCER INVEST, V27, P877, DOI 10.1080/07357900902849699
   Chinnadurai G, 2006, BBA-REV CANCER, V1765, P67, DOI 10.1016/j.bbcan.2005.09.002
   Christmann M, 2011, BBA-REV CANCER, V1816, P179, DOI 10.1016/j.bbcan.2011.06.002
   Ciccia A, 2010, MOL CELL, V40, P179, DOI 10.1016/j.molcel.2010.09.019
   Ciriello G, 2013, NAT GENET, V45, P1127, DOI 10.1038/ng.2762
   Cline MS, 2013, SCI REP-UK, V3, DOI 10.1038/srep02652
   Costa-Pinheiro P, 2015, EPIGENOMICS-UK, V7, P1003, DOI 10.2217/epi.15.56
   Cruz-García A, 2014, CELL REP, V9, P451, DOI 10.1016/j.celrep.2014.08.076
   Drew Y, 2011, JNCI-J NATL CANCER I, V103, P334, DOI 10.1093/jnci/djq509
   Du P, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-587
   Eid W, 2010, EMBO REP, V11, P962, DOI 10.1038/embor.2010.157
   Emes RD, 2012, J MOL ENDOCRINOL, V49, pR19, DOI 10.1530/JME-12-0045
   Esteller M, 2000, JNCI-J NATL CANCER I, V92, P564, DOI 10.1093/jnci/92.7.564
   Esteller M, 2000, NEW ENGL J MED, V343, P1350, DOI 10.1056/NEJM200011093431901
   Esteller M, 2001, CANCER RES, V61, P3225
   Fink L, 1998, NAT MED, V4, P1329, DOI 10.1038/3327
   Galluzzi L, 2012, ONCOGENE, V31, P1869, DOI 10.1038/onc.2011.384
   Gao D, 2016, ONCOTARGET, V7, P37331, DOI 10.18632/oncotarget.7949
   Gaymes TJ, 2013, HAEMATOLOGICA, V98, P1397, DOI 10.3324/haematol.2012.079251
   Gkotzamanidou M, 2014, BRIT J CANCER, V111, P1293, DOI 10.1038/bjc.2014.410
   Gu BN, 2009, CELL CYCLE, V8, P1409, DOI 10.4161/cc.8.9.8322
   Hegi ME, 2005, NEW ENGL J MED, V352, P997, DOI 10.1056/NEJMoa043331
   Hoa NN, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124495
   Hoffmann AC, 2010, NEOPLASIA, V12, P628, DOI 10.1593/neo.10402
   Inman BA, 2017, CLIN CANCER RES, V23, P1886, DOI 10.1158/1078-0432.CCR-16-1417
   Kang J, 2012, JNCI-J NATL CANCER I, V104, P670, DOI 10.1093/jnci/djs177
   Kaufman DS, 2009, LANCET, V374, P239, DOI 10.1016/S0140-6736(09)60491-8
   Klatte T, 2015, J UROLOGY, V194, P1456, DOI 10.1016/j.juro.2015.06.099
   Knollman H, 2015, THER ADV UROL, V7, P312, DOI 10.1177/1756287215607418
   Koestler DC, 2014, TRANSL CANCER RES, V3, P217, DOI 10.3978/j.issn.2218-676X.2014.06.04
   Kuhlmann JD, 2014, CLIN CHEM, V60, P1282, DOI 10.1373/clinchem.2014.224808
   Lafranchi L, 2014, EMBO J, V33, P2860, DOI 10.15252/embj.201489017
   Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427
   Lin ZP, 2014, MOL CANCER RES, V12, P381, DOI 10.1158/1541-7786.MCR-13-0480
   Makharashvili N, 2014, MOL CELL, V54, P1022, DOI 10.1016/j.molcel.2014.04.011
   Maruyama R, 2001, CANCER RES, V61, P8659
   MASTERS JRW, 1986, CANCER RES, V46, P3630
   Miozzo M, 2015, FUTURE ONCOL, V11, P333, DOI [10.2217/fon.14.237, 10.2217/FON.14.237]
   Monteiro-Reis S, 2014, EUR J CANCER, V50, P226, DOI 10.1016/j.ejca.2013.08.025
   Moutinho C, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/djt322
   Otto W, 2011, BJU INT, V107, P404, DOI 10.1111/j.1464-410X.2010.09515.x
   Quennet V, 2011, NUCLEIC ACIDS RES, V39, P2144, DOI 10.1093/nar/gkq1175
   R. Development Core Team, 2016, R: A Language and Environment for Statistical Computing
   REMMELE W, 1987, PATHOLOGE, V8, P138
   Rose M, 2014, CARCINOGENESIS, V35, P727, DOI 10.1093/carcin/bgt375
   Sartori AA, 2007, NATURE, V450, P509, DOI 10.1038/nature06337
   Shinawi T, 2013, EPIGENETICS-US, V8, P149, DOI 10.4161/epi.23398
   Sievert KD, 2009, WORLD J UROL, V27, P295, DOI 10.1007/s00345-009-0395-z
   Sonpavde G, 2016, J CLIN ONCOL, V34, P780, DOI 10.1200/JCO.2015.65.4442
   Soria-Bretones I, 2013, CANCER MED-US, V2, P774, DOI 10.1002/cam4.141
   Stefansson OA, 2012, EPIGENETICS-US, V7, P1225, DOI 10.4161/epi.22561
   Sun JM, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-187
   Thibodeau SN, 1996, CANCER RES, V56, P4836
   Tumini E, 2016, SCI REP-UK, V6, DOI 10.1038/srep38873
   Usanova S, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-248
   van der Aa MNM, 2008, BJU INT, V101, P1106, DOI 10.1111/j.1464-410X.2007.07224.x
   Van Loo P, 2010, P NATL ACAD SCI USA, V107, P16910, DOI 10.1073/pnas.1009843107
   Veeck J, 2006, ONCOGENE, V25, P3479, DOI 10.1038/sj.onc.1209386
   Veeck J, 2010, J CLIN ONCOL, V28, pE563, DOI 10.1200/JCO.2010.30.1010
   Wan JCM, 2017, NAT REV CANCER, V17, P223, DOI 10.1038/nrc.2017.7
   Wang JH, 2016, ONCOTARGET, V7, P7701, DOI 10.18632/oncotarget.6715
   Weinstein JN, 2014, NATURE, V507, P315, DOI 10.1038/nature12965
   Weinstein JN, 2013, NAT GENET, V45, P1113, DOI 10.1038/ng.2764
   Weisenberger DJ, 2006, NAT GENET, V38, P787, DOI 10.1038/ng1834
   Wessely Frank, 2012, Frontiers in Genetics, V3, P161, DOI 10.3389/fgene.2012.00161
   WESTERVELD A, 1984, NATURE, V310, P425, DOI 10.1038/310425a0
   Witte T, 2014, GENOME MED, V6, DOI 10.1186/s13073-014-0066-6
   Wolff EM, 2010, CANCER RES, V70, P8169, DOI 10.1158/0008-5472.CAN-10-1335
   Wu XF, 2006, AM J HUM GENET, V78, P464, DOI 10.1086/500848
   Ye F, 2014, AM J CLIN EXP UROL, V2, P1
   Yu X, 2000, J BIOL CHEM, V275, P18541, DOI 10.1074/jbc.M909494199
   Yun MH, 2009, NATURE, V459, P460, DOI 10.1038/nature07955
   ZWEIG MH, 1993, CLIN CHEM, V39, P561
NR 83
TC 30
Z9 34
U1 0
U2 9
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1868-7075
EI 1868-7083
J9 CLIN EPIGENETICS
JI Clin. Epigenetics
PD FEB 6
PY 2018
VL 10
AR 15
DI 10.1186/s13148-018-0447-6
PG 20
WC Oncology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Genetics & Heredity
GA FV7LZ
UT WOS:000424767200001
PM 29445424
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU Hahn-Strömberg, V
   Askari, S
   Ahmad, A
   Befekadu, R
   Nilsson, TK
AF Hahn-Stromberg, Victoria
   Askari, Shlear
   Ahmad, Abrar
   Befekadu, Rahel
   Nilsson, Torbjorn K.
TI Expression of claudin 1, claudin 4, and claudin 7 in colorectal cancer
   and its relation with CLDN DNA methylation patterns
SO TUMOR BIOLOGY
LA English
DT Article
DE Tight junction; methylation; colon cancer; claudin
ID OVARIAN-CANCER; BREAST-CANCER; COLON-CANCER; CARCINOMA;
   HYPERMETHYLATION; OVEREXPRESSION; PROTEINS; PROMOTES; INVASION; TARGET
AB Altered claudin expression has been described in colon, prostatic, ovarian, and breast carcinoma. However, the role of epigenetic modifications in these genes and their role in colorectal cancer is unknown. We aimed our study to investigate whether claudin protein expression and methylation of CLDN can influence the tumorigenesis of colorectal cancer. A total of 31 patients diagnosed with colorectal carcinoma was used in this study. Immunohistochemical staining was used to study protein expression in both tumor and the adjacent nonneoplastic mucosa of claudin 1, 4, and 7. To detect the DNA methylation pattern of CLDN1, 4, and 7, genomic DNA was extracted from both the tumor and the adjacent nonneoplastic mucosa. Methylation analysis was carried out using bisulfite pyrosequencing. Cell membrane staining intensity of all claudins was found significantly lower in colorectal cancer tissues when compared to paired normal mucosa (p = 0.001). For claudin 4, the percentage of cells staining positively was also significantly reduced (p = 0.04). In normal mucosa, cytoplasm showed no staining for claudins in any patient, whereas in paired colorectal cancer tissues, significant cytoplasmic staining appeared both for claudin 1 (p = 0.04) and claudin 4 (p = 0.01). Tumor samples were significantly hypomethylated in CLDN1 (p < 0.05). In conclusion, our results show that CLDN1 is significantly hypomethylated in tumor samples and that the membrane staining intensity for claudin 1, 4, and 7 is significantly lower in colorectal cancer tissues than in adjacent nonneoplastic tissue. Colorectal cancer cells showed dystopic cytoplasmic location of claudins.
C1 [Hahn-Stromberg, Victoria] Uppsala Univ, Dept Med Cell Biol, SE-75105 Uppsala, Sweden.
   [Askari, Shlear; Ahmad, Abrar; Befekadu, Rahel] Orebro Univ, Fac Med & Hlth, Dept Clin Res, Orebro, Sweden.
   [Befekadu, Rahel] Orebro Univ, Fac Med & Hlth, Dept Lab Med, Orebro, Sweden.
   [Nilsson, Torbjorn K.] Umea Univ, Dept Med Biosci, Div Clin Chem, Umea, Sweden.
C3 Uppsala University; Orebro University; Orebro University; Umea
   University
RP Hahn-Strömberg, V (通讯作者)，Uppsala Univ, Dept Med Cell Biol, SE-75105 Uppsala, Sweden.
EM Victoria.Hahn_Stromberg.2886@student.uu.se
OI Befekadu, Rahel/0000-0003-1342-9060
FU Orebro Lans Landstings Forskningskommitte, Lions cancerfond,
   Uppsala-Orebro; Nyckelfonden, Orebro
FX This work was financially supported by Orebro Lans Landstings
   Forskningskommitte, Lions cancerfond, Uppsala-Orebro, and Nyckelfonden,
   Orebro.
CR Ahmad A BR, J GASTROINTEST CANC, V1, P105
   Ayrolles-Torro A, 2013, MOL CANCER THER, V12, DOI 10.1158/1535-7163.TARG-13-B245
   Baylin Stephen B, 2005, Nat Clin Pract Oncol, V2 Suppl 1, pS4, DOI 10.1038/ncponc0354
   Befekadu R, 2016, DIAGN PATHOL, V1, P113
   Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102
   Boireau S, 2007, CARCINOGENESIS, V28, P246, DOI 10.1093/carcin/bgl120
   Dhawan P, 2005, J CLIN INVEST, V115, P1765, DOI 10.1172/JCI24543
   Di Cello F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068630
   Ding L, 2016, J HUM GENET, V61, P711, DOI 10.1038/jhg.2016.35
   Karabulut M, 2015, MOL CLIN ONCOL, V3, P1255, DOI 10.3892/mco.2015.626
   Kinugasa T, 2012, ANTICANCER RES, V32, P2309
   Kominsky SL, 2003, ONCOGENE, V22, P2021, DOI 10.1038/sj.onc.1206199
   Kwon MJ, 2013, INT J MOL SCI, V14, P18148, DOI 10.3390/ijms140918148
   Kwon MJ, 2011, LAB INVEST, V91, P1652, DOI 10.1038/labinvest.2011.117
   Lioni M, 2007, AM J PATHOL, V170, P709, DOI 10.2353/ajpath.2007.060343
   Litkouhi B, 2007, NEOPLASIA, V9, P304, DOI 10.1593/neo.07118
   Liu YF, 2016, J EXP CLIN CANC RES, V35, DOI 10.1186/s13046-016-0396-x
   Matsuoka T, 2011, J SURG ONCOL, V103, P674, DOI 10.1002/jso.21854
   Morin PJ, 2005, CANCER RES, V65, P9603, DOI 10.1158/0008-5472.CAN-05-2782
   Morohashi S, 2007, INT J MOL MED, V20, P139
   Nakagawa S, 2011, INT J ONCOL, V39, P791, DOI 10.3892/ijo.2011.1102
   Nakayama F, 2008, PATHOBIOLOGY, V75, P177, DOI 10.1159/000124978
   Nefedova N. A., 2016, Arkhiv Patologii, V78, P11, DOI 10.17116/patol201678311-19
   Rangel LBA, 2003, CLIN CANCER RES, V9, P2567
   Rendon-Huerta Erika, 2010, J Gastrointest Cancer, V41, P52, DOI 10.1007/s12029-009-9110-y
   Singh AB, 2015, SEMIN CELL DEV BIOL, V42, P58, DOI 10.1016/j.semcdb.2015.05.001
   Swisshelm K, 2005, ADV DRUG DELIVER REV, V57, P919, DOI 10.1016/j.addr.2005.01.006
   Tang WJ, 2011, BIOFACTORS, V37, P65, DOI 10.1002/biof.138
   Walesch SK, 2015, CANCERS, V7, P1233, DOI 10.3390/cancers7030834
NR 29
TC 32
Z9 35
U1 0
U2 4
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD APR
PY 2017
VL 39
IS 4
AR 697569
DI 10.1177/1010428317697569
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA ET4QD
UT WOS:000400268800047
PM 28381183
OA gold, Green Submitted, Green Published
DA 2025-01-12
ER

PT J
AU Panagopoulou, M
   Lambropoulou, M
   Balgkouranidou, I
   Nena, E
   Karaglani, M
   Nicolaidou, C
   Asimaki, A
   Konstantinidis, T
   Constantinidis, TC
   Kolios, G
   Kakolyris, S
   Agorastos, T
   Chatzaki, E
AF Panagopoulou, Maria
   Lambropoulou, Maria
   Balgkouranidou, Ioanna
   Nena, Evangelia
   Karaglani, Makrina
   Nicolaidou, Christina
   Asimaki, Anthi
   Konstantinidis, Theocharis
   Constantinidis, Theodoros C.
   Kolios, George
   Kakolyris, Stylianos
   Agorastos, Theodoros
   Chatzaki, Ekaterini
TI Gene promoter methylation and protein expression of BRMS1 in uterine
   cervix in relation to high-risk human papilloma virus infection and
   cancer
SO TUMOR BIOLOGY
LA English
DT Article
DE Methylation; epigenetic; uterine cervix; human papilloma virus; BRMS1;
   cancer
ID CELL LUNG-CANCER; BRMS1-MEDIATED METASTASIS SUPPRESSION; PROVIDES
   PROGNOSTIC INFORMATION; HPV-POSITIVE WOMEN; DNA METHYLATION;
   BREAST-CANCER; CARCINOMA METASTASIS; PATIENT SURVIVAL; ENDOMETRIAL
   CANCER; BIOMARKERS
AB Cervical cancer is strongly related to certain high-risk types of human papilloma virus infection. Breast cancer metastasis suppressor 1 (BRMS1) is a tumor suppressor gene, its expression being regulated by DNA promoter methylation in several types of cancers. This study aims to evaluate the methylation status of BRMS1 promoter in relation to high-risk types of human papilloma virus infection and the development of pre-cancerous lesions and describe the pattern of BRMS1 protein expression in normal, high-risk types of human papilloma virus-infected pre-cancerous and malignant cervical epithelium. We compared the methylation status of BRMS1 in cervical smears of 64 women with no infection by high-risk types of human papilloma virus to 70 women with proven high-risk types of human papilloma virus infection, using real-time methylation-specific polymerase chain reaction. The expression of BRMS1 protein was described by immunohistochemistry in biopsies from cervical cancer, pre-cancerous lesions, and normal cervices. Methylation of BRMS1 promoter was detected in 37.5% of women with no high-risk types of human papilloma virus infection and was less frequent in smears with high-risk types of human papilloma virus (11.4%) and in women with pathological histology (cervical intraepithelial neoplasia) (11.9%). Methylation was detected also in HeLa cervical cancer cells. Immunohistochemistry revealed nuclear BRMS1 protein staining in normal high-risk types of human papilloma virus-free cervix, in cervical intraepithelial neoplasias, and in malignant tissues, where staining was occasionally also cytoplasmic. In cancer, expression was stronger in the more differentiated cancer blasts. In conclusion, BRMS1 promoter methylation and aberrant protein expression seem to be related to high-risk types of human papilloma virus-induced carcinogenesis in uterine cervix and is worthy of further investigation.
C1 [Panagopoulou, Maria; Balgkouranidou, Ioanna; Karaglani, Makrina; Kolios, George; Chatzaki, Ekaterini] Democritus Univ Thrace, Sch Med, Pharmacol Lab, Off 35,Bldg 5B, Dragana 68100, Alexandroupolis, Greece.
   [Lambropoulou, Maria; Nicolaidou, Christina] Democritus Univ Thrace, Sch Med, Lab Histol Embryol, Alexandroupolis, Greece.
   [Balgkouranidou, Ioanna; Kakolyris, Stylianos] Democritus Univ Thrace, Sch Med, Dept Oncol, Alexandroupolis, Greece.
   [Nena, Evangelia; Konstantinidis, Theocharis; Constantinidis, Theodoros C.] Democritus Univ Thrace, Sch Med, Lab Hyg & Environm Protect, Alexandroupolis, Greece.
   [Asimaki, Anthi; Agorastos, Theodoros] Aristotle Univ Thessaloniki, Hippokrate Hosp, Univ Clin Obstet & Gynecol 4, Thessaloniki, Greece.
C3 Democritus University of Thrace; Democritus University of Thrace;
   Democritus University of Thrace; Democritus University of Thrace;
   Aristotle University of Thessaloniki
RP Chatzaki, E (通讯作者)，Democritus Univ Thrace, Sch Med, Pharmacol Lab, Off 35,Bldg 5B, Dragana 68100, Alexandroupolis, Greece.
EM achatzak@med.duth.gr
RI Chatzaki, Ekaterini/AAW-9507-2020; Nena, Evangelia/AAD-9385-2019;
   Balgkouranidou, Ioanna/HJY-6461-2023; Karaglani, Makrina/JWO-3435-2024;
   Panagopoulou, Maria/KUD-6509-2024; Kolios, George/N-6641-2013
OI Konstantinidis, Theocharis/0000-0003-4296-3414; Nena,
   Evangelia/0000-0003-0381-4715; Chatzaki, Ekaterini/0000-0002-5832-4257;
   BALGKOURANIDOU, IOANNA/0000-0003-0609-8566; Panagopoulou,
   Maria/0000-0002-7107-4774; Karaglani, Makrina/0000-0002-9853-3571;
   LAMBROPOULOU, MARIA/0000-0001-8651-3680; Kolios,
   George/0000-0002-2066-4782
CR Agorastos T, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0119755
   Akiyama Y, 2003, AM J PATHOL, V163, P1911, DOI 10.1016/S0002-9440(10)63549-3
   Avraham A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091805
   Balgkouranidou I, 2014, BRIT J CANCER, V110, P2054, DOI 10.1038/bjc.2014.104
   Bierkens M, 2013, INT J CANCER, V133, P1293, DOI 10.1002/ijc.28138
   Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102
   Bray F, 2013, INT J CANCER, V132, P1133, DOI 10.1002/ijc.27711
   Castellsagué X, 2009, GYNECOL ONCOL, V115, pS15, DOI 10.1016/j.ygyno.2009.09.021
   Champine PJ, 2007, CLIN EXP METASTAS, V24, P551, DOI 10.1007/s10585-007-9092-8
   Chaturvedi AK, 2010, J ADOLESCENT HEALTH, V46, pS20, DOI 10.1016/j.jadohealth.2010.01.016
   Chimonidou M, 2013, MOL CANCER RES, V11, P1248, DOI 10.1158/1541-7786.MCR-13-0096
   Chimonidou M, 2011, CLIN CHEM, V57, P1169, DOI 10.1373/clinchem.2011.165902
   Cui RX, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-376
   Cuschieri K, 2013, DIAGN MOL PATHOL, V22, P85, DOI 10.1097/PDM.0b013e31827f3f7e
   De Strooper LMA, 2016, GYNECOL ONCOL, V141, P341, DOI 10.1016/j.ygyno.2016.02.012
   De Strooper LMA, 2014, J CLIN PATHOL, V67, P1067, DOI 10.1136/jclinpath-2014-202616
   Ehrlich M, 2009, EPIGENOMICS-UK, V1, P239, DOI [10.2217/epi.09.33, 10.2217/EPI.09.33]
   Frolova N, 2009, TUMOR BIOL, V30, P148, DOI 10.1159/000228908
   Herceg Z, 2007, MOL ONCOL, V1, P26, DOI 10.1016/j.molonc.2007.01.004
   Horn J, 2013, VACCINE, V31, P2372, DOI 10.1016/j.vaccine.2013.03.006
   Hurst DR, 2011, FEBS LETT, V585, P3185, DOI 10.1016/j.febslet.2011.07.045
   Hurst DR, 2009, CLIN EXP METASTAS, V26, P89, DOI 10.1007/s10585-008-9216-9
   Kim MK, 2016, J GYNECOL ONCOL, V27, DOI 10.3802/jgo.2016.27.e14
   Kodura MA, 2015, CANCER METAST REV, V34, P611, DOI 10.1007/s10555-015-9583-z
   Ladd-Acosta C, 2007, AM J HUM GENET, V81, P1304, DOI 10.1086/524110
   Lambropoulou M, 2016, MED ONCOL, V33, DOI 10.1007/s12032-015-0723-7
   Leonard SM, 2012, CARCINOGENESIS, V33, P1286, DOI 10.1093/carcin/bgs157
   Liu Y, 2006, MOL CELL BIOL, V26, P8683, DOI 10.1128/MCB.00940-06
   Liu Y, 2015, MOL CELL BIOL, V35, P303, DOI 10.1128/MCB.00869-14
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lokk K, 2014, GENOME BIOL, V15, DOI 10.1186/gb-2014-15-4-r54
   Luttmer R, 2016, INT J CANCER, V138, P992, DOI 10.1002/ijc.29824
   Markopoulou S, 2012, CLIN CHEM LAB MED, V50, P1723, DOI 10.1515/cclm-2012-0124
   Mei PJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098544
   Metge BJ, 2008, CLIN EXP METASTAS, V25, P753, DOI 10.1007/s10585-008-9187-x
   Moreira Paula Rocha, 2011, Braz. Dent. J., V22, P422
   Narayan G, 2016, GENE CHROMOSOME CANC, V55, P177, DOI 10.1002/gcc.22325
   Nikolaidis G, 2012, CANCER RES, V72, P5692, DOI 10.1158/0008-5472.CAN-12-2309
   Seraj MJ, 2000, CANCER RES, V60, P2764
   Shevde LA, 2002, EXP CELL RES, V273, P229, DOI 10.1006/excr.2001.5452
   Slipicevic A, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-73
   Slotkin RK, 2007, NAT REV GENET, V8, P272, DOI 10.1038/nrg2072
   Smith PW, 2009, CANCER LETT, V276, P196, DOI 10.1016/j.canlet.2008.11.024
   Wang Y.L., 2011, INT J ELECTROCHEM, V2011, P1, DOI DOI 10.1016/J.LITH0S.2011.07.027
   Yang JY, 2011, LUNG CANCER, V74, P305, DOI 10.1016/j.lungcan.2011.03.002
   Yeung CLA, 2010, ONCOL REP, V24, P1599, DOI 10.3892/or_00001023
   Zhang S, 2006, INT J GYNECOL CANCER, V16, P522, DOI 10.1111/j.1525-1438.2006.00547.x
   zur Hausen H, 2000, JNCI-J NATL CANCER I, V92, P690, DOI 10.1093/jnci/92.9.690
NR 48
TC 10
Z9 10
U1 0
U2 2
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD APR
PY 2017
VL 39
IS 4
AR 697557
DI 10.1177/1010428317697557
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA ET4QD
UT WOS:000400268800042
PM 28381193
OA gold
DA 2025-01-12
ER

PT J
AU Bhat, A
   Masood, A
   Wani, KA
   Bhat, YA
   Nissar, B
   Khan, NS
   Ganai, BA
AF Bhat, Aaliya
   Masood, A.
   Wani, K. A.
   Bhat, Younus Ahmad
   Nissar, Bushra
   Khan, Nuzhat Shaheen
   Ganai, B. A.
TI Promoter methylation and gene polymorphism are two independent events in
   regulation of GSTP1 gene expression
SO TUMOR BIOLOGY
LA English
DT Article
DE Breast cancer; glutathione-S-transferase; polymorphism; expression;
   promoter methylation; methylation-specific polymerase chain reaction;
   Kashmir
ID S-TRANSFERASE-PI; PROSTATE-CANCER; BREAST-CANCER; CPG ISLANDS; CATALYTIC
   EFFICIENCIES; ALLELIC VARIANTS; DUCTAL CARCINOMA; DNA METHYLATION;
   HYPERMETHYLATION; ASSOCIATION
AB Breast carcinogenesis is a multistep process, involving both genetic and epigenetic modification process of genes, involved in diverse pathways ranging from DNA repair to metabolic processes. This study was undertaken to assess the role of promoter methylation of GSTP1 gene, a member of glutathione-S-transferase family of enzymes, in relation to its expression, polymorphism, and clinicopathological parameters. Tissue samples were taken from breast cancer patients and paired with their normal adjacent tissues. A total of 51 subjects were studied, in which the frequency of promoter methylation in cancerous tissue was 37.25% as against 11% in the normal tissues (p = 0.001). The hypermethylated status of the gene was significantly associated with the loss of the protein expression (r = -0.449, p = 0.001, odds ratio = 7.42, 95% confidence interval = 2.05-26.92). Furthermore, when compared with the clinical parameters, the significant association was found between the promoter hypermethylation and lymph node metastasis (p = 0.001), tumor stage (p = 0.039), tumor grade (p = 0.028), estrogen receptor status (p = 0.018), and progesterone receptor status (p = 0.046). Our study is the first of its kind in Kashmiri population, which indicates that GSTP1 shows aberrant methylation pattern in the breast cancer with the consequent loss in the protein expression. Furthermore, it also shows that the gene polymorphism (Ile105Val) at codon 105 is not related to the promoter methylation and two are the independent events in breast cancer development.
C1 [Bhat, Aaliya; Masood, A.; Bhat, Younus Ahmad; Nissar, Bushra; Khan, Nuzhat Shaheen] Univ Kashmir, Dept Biochem, Srinagar, Jammu & Kashmir, India.
   [Ganai, B. A.] Univ Kashmir, CORD, Srinagar 190006, Jammu & Kashmir, India.
   [Wani, K. A.] SKIMS, Dept Gen & Minimal Invas Surg, Srinagar, Jammu & Kashmir, India.
C3 University of Kashmir; University of Kashmir; Sher-i-Kashmir Institute
   of Medical Sciences
RP Ganai, BA (通讯作者)，Univ Kashmir, CORD, Srinagar 190006, Jammu & Kashmir, India.
EM bbcganai@gmail.com
RI Khan, Nuzhat/LYO-5544-2024; Ganai, Bashir/KII-4537-2024
OI Ganai, Bashir/0000-0003-4178-5919
FU Department of Science and Technology (DST), New Delhi, India
FX This study was financially supported by the Department of Science and
   Technology (DST), New Delhi, India.
CR Adler V, 1999, EMBO J, V18, P1321, DOI 10.1093/emboj/18.5.1321
   AliOsman F, 1997, J BIOL CHEM, V272, P10004
   Antognelli C, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-115
   Arai T, 2006, BREAST CANCER RES TR, V100, P169, DOI 10.1007/s10549-006-9241-9
   Asiaf A, 2015, TUMOR BIOL, V36, P6485, DOI 10.1007/s13277-015-3339-9
   Bae YK, 2004, CLIN CANCER RES, V10, P5998, DOI 10.1158/1078-0432.CCR-04-0667
   Baylin SB, 2000, J NATL CANCER I, V92, P1460, DOI 10.1093/jnci/92.18.1460
   BELLAMY COC, 1994, BRIT J CANCER, V69, P183, DOI 10.1038/bjc.1994.31
   BLOOM HJG, 1957, BRIT J CANCER, V11, P359, DOI 10.1038/bjc.1957.43
   Brooks JD, 1998, CANCER EPIDEM BIOMAR, V7, P531
   Cairns P, 2001, CLIN CANCER RES, V7, P2727
   Cavalieri EL, 1997, P NATL ACAD SCI USA, V94, P10937, DOI 10.1073/pnas.94.20.10937
   D'souza ND, ASIAN PAC J CANC PRE, V14, P4379
   Dulaimi E, 2004, CLIN CANCER RES, V10, P6189, DOI 10.1158/1078-0432.CCR-04-0597
   Esteller M, 1998, CANCER RES, V58, P4515
   Fishman J, 1995, ANN NY ACAD SCI, V768, P91, DOI 10.1111/j.1749-6632.1995.tb12113.x
   Gonzalgo ML, 2003, CLIN CANCER RES, V9, P2673
   Gsur A, 2001, INT J CANCER, V95, P152, DOI 10.1002/1097-0215(20010520)95:3<152::AID-IJC1026>3.0.CO;2-S
   Harries LW, 1997, CARCINOGENESIS, V18, P641, DOI 10.1093/carcin/18.4.641
   Henderson CJ, 1998, CHEM-BIOL INTERACT, V112, P69, DOI 10.1016/S0009-2797(97)00176-2
   Henderson CJ, 1998, P NATL ACAD SCI USA, V95, P5275, DOI 10.1073/pnas.95.9.5275
   Hoque MO, 2009, CANCER EPIDEM BIOMAR, V18, P2694, DOI 10.1158/1055-9965.EPI-08-0821
   Hu X, 1998, CANCER RES, V58, P5340
   Issa JPJ, 2009, CLIN CANCER RES, V15, P3938, DOI 10.1158/1078-0432.CCR-08-2783
   Jerónimo C, 2002, CANCER EPIDEM BIOMAR, V11, P445
   Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561
   Jovanovic J, 2010, MOL ONCOL, V4, P242, DOI 10.1016/j.molonc.2010.04.002
   Kinzler KW, 1997, NATURE, V386, P761, DOI 10.1038/386761a0
   Lee JS, 2007, VIRCHOWS ARCH, V450, P637, DOI 10.1007/s00428-007-0421-8
   Lichtenstein P, 2000, NEW ENGL J MED, V343, P78, DOI 10.1056/NEJM200007133430201
   Lin XH, 2003, CANCER RES, V63, P498
   Lin XH, 2001, CANCER RES, V61, P8611
   MARIE-GENICA Consortium on Genetic Susceptibility for Menopausal Hormone Therapy Related Breast Cancer Risk, BREAST CANC RES TREA, V119, P463
   Mehrotra J, 2004, CLIN CANCER RES, V10, P2052, DOI 10.1158/1078-0432.CCR-03-0514
   Ntais C, 2005, CANCER EPIDEM BIOMAR, V14, P176
   Pal A, 2000, CANCER LETT, V154, P39, DOI 10.1016/S0304-3835(00)00390-6
   Park SY, 2011, VIRCHOWS ARCH, V458, P73, DOI 10.1007/s00428-010-1013-6
   Parrella P, 2004, CLIN CANCER RES, V10, P5349, DOI 10.1158/1078-0432.CCR-04-0555
   Plass C, 2002, EUR J HUM GENET, V10, P6, DOI 10.1038/sj.ejhg.5200768
   Pongtheerat T, ASIAN PAC J CANC PRE, V12, P2731
   Reding KW, 2009, CANCER EPIDEM BIOMAR, V18, P1461, DOI 10.1158/1055-9965.EPI-08-0917
   RUSHMORE TH, 1993, J BIOL CHEM, V268, P11475
   Saxena A, 2012, EXP THER MED, V4, P1097, DOI 10.3892/etm.2012.710
   Sharma G, 2010, LIFE SCI, V87, P83, DOI 10.1016/j.lfs.2010.05.001
   Shinozaki M, 2005, CLIN CANCER RES, V11, P2156, DOI 10.1158/1078-0432.CCR-04-1810
   Singal R, 2001, CANCER RES, V61, P4820
   Singletary SE, 2002, J CLIN ONCOL, V20, P3628, DOI 10.1200/JCO.2002.02.026
   Strange RC, 2001, MUTAT RES-FUND MOL M, V482, P21, DOI 10.1016/S0027-5107(01)00206-8
   Syeed N, 2010, MOL MED REP, V3, P883, DOI 10.3892/mmr.2010.348
   Waddington CH, 2012, INT J EPIDEMIOL, V41, P10, DOI 10.1093/ije/dyr184
   Wade PA, 1999, NAT GENET, V23, P62, DOI 10.1038/12664
   Wang T, 2001, J BIOL CHEM, V276, P20999, DOI 10.1074/jbc.M101355200
   Wani MA, 2014, INDIAN J CANCER, V51, P133, DOI 10.4103/0019-509X.138188
   Wojdacz TK, 2008, NAT PROTOC, V3, P1903, DOI 10.1038/nprot.2008.191
   Zhong S, 2002, CLIN CANCER RES, V8, P1087
NR 55
TC 5
Z9 7
U1 3
U2 7
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD APR
PY 2017
VL 39
IS 4
AR 697563
DI 10.1177/1010428317697563
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA ET4QD
UT WOS:000400268800044
PM 28443466
OA gold
DA 2025-01-12
ER

PT J
AU Kar, S
   Patra, SK
AF Kar, Swayamsiddha
   Patra, Samir Kumar
TI Overexpression of <i>OCT4</i> induced by modulation of histone marks
   plays crucial role in breast cancer progression
SO GENE
LA English
DT Article
DE OCT4; Breast cancer; DNA methylation; Histone modification; Active
   histone marks; H3K4me3 and H3K9acS10P
ID HUMAN PROSTATE-CANCER; STEM-CELLS; DNA-METHYLATION; ECTOPIC EXPRESSION;
   GENE-EXPRESSION; PLURIPOTENCY; DIFFERENTIATION; METHYLTRANSFERASE;
   OCT-3/4; PROTEIN
AB OCT4 is known as the gatekeeper of pluripotent embryonic state as it is responsible for maintenance of pluripotency via self-renewal of embryonic stem cells and acquisition of induced pluripotency via somatic cell reprogramming. OCT4 is responsible for oncogenic transformation by disrupting pre-scheduled differentiation programs and in general, favoring evolution of cancer cells into a more aggressive cancer stein cell phenotype. In this study, we have investigated in details, the epigenetic regulatory mechanisms responsible for over-expression and subsequent aberrant function of OCT4 in breast cancer. Expression of OCT4 in breast cancer tissues and cell lines was determined by qRT-PCR, Western blot, immunohistochemistry and immunocytochemistry followed by investigation of pro-tumorigenic properties such as cell proliferation, migration and apoptosis by gene knockdown and treatment with epigenetic modulators. Ectopic treatment of epigenetic modulators was done followed by MS-PCR and chromatin immunoprecipitation. OCT4 is over-expressed in both of the breast cancer cell lines; MCF7 and MDA-MB-231 and its inhibition resulted in drastic decrease in rate of cell proliferation, metastatic ability and induced apoptosis. After treatment with epigenetic modulators, general increase in expression of OCT4 was observed at both gene and protein levels; however, changes of promoter DNA methylation was not found to be significant during OCT4 over-expression. Active histone marks especially H3K4me3 and H3K9acS10p were enriched in the promoter region with very low levels of repressive marks H3K9me3 and H3K27me3 indicating that active histone modifications are the deciding factor in inducing over-expression of OCT4 during breast carcinogenesis. These findings could provide the basis on which epigenetic therapy, targeting reversible epigenetic modifications and their perpetuating enzymes, can be designed for effective treatment of aggressive breast cancer.
C1 [Kar, Swayamsiddha; Patra, Samir Kumar] Natl Inst Technol, Dept Life Sci, Biochem & Mol Biol Grp, Epigenet & Canc Res Lab, Rourkela 769008, Odisha, India.
C3 National Institute of Technology (NIT System); National Institute of
   Technology Rourkela
RP Patra, SK (通讯作者)，Natl Inst Technol, Dept Life Sci, Biochem & Mol Biol Grp, Epigenet & Canc Res Lab, Rourkela 769008, Odisha, India.
EM samirp@nitrld.ac.in
RI PATRA, Samir/AAS-6639-2020
OI PATRA, SAMIR/0000-0001-5641-1835
FU NIT Rourkela; Departmental operating grants of Life Science, NIT
   Rourkela
FX SK is thankful to NIT Rourkela for granting fellowship under the
   Institute Research Scheme. This research was supported in part by
   Departmental operating grants of Life Science, NIT Rourkela. We
   apologize to those whose works and related publications we have not been
   able to discuss and cite due to space limitations.
CR Athanasiadou R, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009937
   Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095
   Chang CC, 2008, CANCER RES, V68, P6281, DOI 10.1158/0008-5472.CAN-08-0094
   Chronis C., 2017, CELL, P31730
   Deb M, 2015, BBA-MOL BASIS DIS, V1852, P1630, DOI 10.1016/j.bbadis.2015.04.021
   Deshpande AM, 2009, J BIOL CHEM, V284, P6043, DOI 10.1074/jbc.C800158200
   Dhanasekaran Karthigeyan, 2013, Subcell Biochem, V61, P399, DOI 10.1007/978-94-007-4525-4_17
   Fagnocchi L, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11903
   Feinberg AP, 2016, NAT REV GENET, V17, P284, DOI 10.1038/nrg.2016.13
   Feinberg AP, 2006, NAT REV GENET, V7, P21, DOI 10.1038/nrg1748
   Feldman N, 2006, NAT CELL BIOL, V8, P188, DOI 10.1038/ncb1353
   Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088
   Györffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9
   Hadjimichael C, 2015, WORLD J STEM CELLS, V7, P1150, DOI 10.4252/wjsc.v7.i9.1150
   Hattori N, 2004, J BIOL CHEM, V279, P17063, DOI 10.1074/jbc.M309002200
   He S., 2017, J BIOL CHEM
   Hochedlinger K, 2005, CELL, V121, P465, DOI 10.1016/j.cell.2005.02.018
   Huang P, 2012, MED ONCOL, V29, P829, DOI 10.1007/s12032-011-9962-4
   Jerabek S, 2014, BBA-GENE REGUL MECH, V1839, P138, DOI 10.1016/j.bbagrm.2013.10.001
   Kar S, 2017, BBA-MOL BASIS DIS, V1863, P253, DOI 10.1016/j.bbadis.2016.11.001
   Kar S, 2014, CLIN EPIGENETICS, V6, DOI 10.1186/1868-7083-6-20
   Kar S, 2014, CELL MOL LIFE SCI, V71, P1017, DOI 10.1007/s00018-013-1482-2
   Kim JB, 2009, CELL, V136, P411, DOI 10.1016/j.cell.2009.01.023
   Klimczak Marta, 2015, Contemp Oncol (Pozn), V19, pA16, DOI 10.5114/wo.2014.47133
   Li JY, 2007, MOL CELL BIOL, V27, P8748, DOI 10.1128/MCB.01380-07
   Livigni A, 2013, DEV CELL, V25, P547, DOI 10.1016/j.devcel.2013.06.002
   Mathews LA, 2009, DIFFERENTIATION, V78, P1, DOI 10.1016/j.diff.2009.04.002
   Müller M, 2016, STEM CELL RES, V16, P349, DOI 10.1016/j.scr.2016.02.005
   Pan X, 2016, J BIOL CHEM, V291, P18353, DOI 10.1074/jbc.M116.745414
   Parbin S, 2016, MOL BIOSYST, V12, P48, DOI 10.1039/c5mb00412h
   Patra SK, 2008, EXP CELL RES, V314, P1193, DOI 10.1016/j.yexcr.2008.01.012
   Patra SK, 2011, CLIN EPIGENETICS, V2, P27, DOI 10.1007/s13148-010-0016-0
   Patra SK, 2002, MOL CARCINOGEN, V33, P163, DOI 10.1002/mc.10033
   Patra SK, 2003, BIOCHEM BIOPH RES CO, V302, P759, DOI 10.1016/S0006-291X(03)00253-5
   Patra SK, 2001, BIOCHEM BIOPH RES CO, V287, P705, DOI 10.1006/bbrc.2001.5639
   Pogribny I. P., 2010, Experimental Oncology, V32, P132
   Radzisheuskaya A, 2014, TRENDS CELL BIOL, V24, P275, DOI 10.1016/j.tcb.2013.11.010
   Rijlaarsdam MA, 2011, BRIT J CANCER, V105, P854, DOI 10.1038/bjc.2011.270
   Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73
   Sengupta D, 2016, EXP CELL RES, V346, P176, DOI 10.1016/j.yexcr.2016.07.023
   Sterneckert J, 2012, STEM CELLS, V30, P15, DOI 10.1002/stem.765
   Suvà ML, 2013, SCIENCE, V339, P1567, DOI 10.1126/science.1230184
   Szász AM, 2016, ONCOTARGET, V7, P49322, DOI 10.18632/oncotarget.10337
   Tan FZ, 2015, J BIOL CHEM, V290, P4500, DOI 10.1074/jbc.M114.609016
   Wang HR, 2016, J BIOL CHEM, V291, P8644, DOI 10.1074/jbc.M115.694208
   Wang YD, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.272
   Wernig M, 2007, NATURE, V448, P318, DOI 10.1038/nature05944
   Wu Guangming, 2014, Cell Regen, V3, P7, DOI 10.1186/2045-9769-3-7
   Yu HB, 2009, J BIOL CHEM, V284, P31327, DOI 10.1074/jbc.M109.016162
   Zhang XY, 2010, JPN J CLIN ONCOL, V40, P961, DOI 10.1093/jjco/hyq066
   Zuccotti M, 2011, BMC GENOMICS, V12, DOI 10.1186/1471-2164-12-345
NR 51
TC 21
Z9 22
U1 0
U2 18
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0378-1119
EI 1879-0038
J9 GENE
JI Gene
PD FEB 15
PY 2018
VL 643
BP 35
EP 45
DI 10.1016/j.gene.2017.11.077
PG 11
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA FU9JR
UT WOS:000424172700005
PM 29203199
DA 2025-01-12
ER

PT J
AU Earwaker, P
   Anderson, C
   Willenbrock, F
   Harris, AL
   Protheroe, AS
   Macaulay, VM
AF Earwaker, Philip
   Anderson, Caroline
   Willenbrock, Frances
   Harris, Adrian L.
   Protheroe, Andrew S.
   Macaulay, Valentine M.
TI RAPTOR up-regulation contributes to resistance of renal cancer cells to
   PI3K-mTOR inhibition
SO PLOS ONE
LA English
DT Article
ID ADVANCED SOLID TUMORS; GROWTH-FACTOR RECEPTOR; HISTONE DEACETYLASE
   INHIBITOR; MTOR KINASE INHIBITORS; PHASE-II TRIAL; MAMMALIAN TARGET;
   TYROSINE KINASE; DUAL INHIBITOR; PROTEIN-KINASE; BREAST-CANCER
AB The outlook for patients with advanced renal cell cancer (RCC) has been improved by targeted agents including inhibitors of the PI3 kinase (PI3K)-AKT-mTOR axis, although treatment resistance is a major problem. Here, we aimed to understand how RCC cells acquire resistance to PI3K-mTOR inhibition. We used the RCC4 cell line to generate a model of in vitro resistance by continuous culture in PI3K-mTOR kinase inhibitor NVP-BEZ235 (BEZ235, Dactolisib). Resistant cells were cross-resistant to mTOR inhibitor AZD2014. Sensitivity was regained after 4 months drug withdrawal, and resistance was partially suppressed by HDAC inhibition, supporting an epigenetic mechanism. BEZ235-resistant cells up-regulated and/or activated numerous proteins including MET, ABL, Notch, IGF-1R, INSR and MEK/ERK. However, resistance was not reversed by inhibiting or depleting these pathways, suggesting that many induced changes were passengers not drivers of resistance. BEZ235 blocked phosphorylation of mTOR targets S6 and 4E-BP1 in parental cells, but 4E-BP1 remained phosphorylated in resistant cells, suggesting BEZ235-refractory mTORC1 activity. Consistent with this, resistant cells over-expressed mTORC1 component RAPTOR at the mRNA and protein level. Furthermore, BEZ235 resistance was suppressed by RAPTOR depletion, or allosteric mTORC1 inhibitor rapamycin. These data reveal that RAPTOR up-regulation contributes to PI3K-mTOR inhibitor resistance, and suggest that RAPTOR expression should be included in the pharmacodynamic assessment of mTOR kinase inhibitor trials.
C1 [Earwaker, Philip; Anderson, Caroline; Willenbrock, Frances; Macaulay, Valentine M.] Dept Oncol, Oxford, England.
   [Harris, Adrian L.; Protheroe, Andrew S.; Macaulay, Valentine M.] Churchill Hosp, Oxford Univ Hosp NHS Trust, Oxford Canc & Haematol Ctr, Oxford, England.
   [Earwaker, Philip] Univ Hosp Birmingham NHS Fdn Trust, Ctr Canc, Birmingham, W Midlands, England.
C3 Oxford University Hospitals NHS Foundation Trust; University of Oxford;
   University of Birmingham
RP Macaulay, VM (通讯作者)，Dept Oncol, Oxford, England.; Macaulay, VM (通讯作者)，Churchill Hosp, Oxford Univ Hosp NHS Trust, Oxford Canc & Haematol Ctr, Oxford, England.
EM valentine.macaulay@oncology.ox.ac.uk
RI ; Harris, Adrian/ABA-3343-2020
OI Morrell, Caroline/0009-0001-8135-6927; Harris,
   Adrian/0000-0003-1376-8409
FU Cancer Research UK [C602/A6292]; Oxford University Clinical Academic
   Graduate School; Cancer Research UK award [C5255/A20758]; National
   Institute for Health Research (NIHR) Oxford Biomedical Research Centre
   [A93024]; Cancer Research UK program grant; Oxford University Clinical
   Academic Graduate School grant; Cancer Research UK Oxford Cancer
   Research Centre; National Institute for Health Research (NIHR) Oxford
   Biomedical Research Centre; MRC [G0300648, G0601061] Funding Source:
   UKRI
FX This study was supported by the award to PE of a Clinical Research
   Fellowship supported by Cancer Research UK (www.cancerresearchuk.org)
   program grant C602/A6292 to ALH, Oxford University Clinical Academic
   Graduate School (www.oucags.ox.ac.uk) grant to CA, support to FW from
   the Cancer Research UK award to the Oxford Cancer Research Centre
   (C5255/A20758) and to VMM from the National Institute for Health
   Research (NIHR; www.nihr.ac.uk) Oxford Biomedical Research Centre (award
   A93024). The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.This
   study was supported by the award to PE of a Clinical Research Fellowship
   supported by Cancer Research UK program grant to ALH, Oxford University
   Clinical Academic Graduate School grant to CA, support to FW from the
   Cancer Research UK Oxford Cancer Research Centre and to VMM from the
   National Institute for Health Research (NIHR) Oxford Biomedical Research
   Centre. We are grateful to Tamara Aleksic and Guillaume Rieunier for
   comments on the manuscript.
CR Alain T, 2012, CANCER RES, V72, P6468, DOI 10.1158/0008-5472.CAN-12-2395
   Aleksic T, 2010, CANCER RES, V70, P6412, DOI 10.1158/0008-5472.CAN-10-0052
   Alhamdani MSS, 2009, GENOME MED, V1, DOI 10.1186/gm68
   [Anonymous], 2017, Oncotarget
   Armengol G, 2007, CANCER RES, V67, P7551, DOI 10.1158/0008-5472.CAN-07-0881
   Bailey ST, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104413
   Basu B, 2015, CLIN CANCER RES, V21, P3412, DOI 10.1158/1078-0432.CCR-14-2422
   Behbahani TE, 2012, WORLD J UROL, V30, P559, DOI 10.1007/s00345-011-0767-z
   Bendell JC, 2015, INVEST NEW DRUG, V33, P187, DOI 10.1007/s10637-014-0177-3
   Bhola NE, 2016, CANCER RES, V76, P440, DOI 10.1158/0008-5472.CAN-15-1640-T
   Bianchi N, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121567
   Boulay A, 2004, CANCER RES, V64, P252, DOI 10.1158/0008-5472.CAN-3554-2
   Calvo E, 2016, CANCER TREAT REV, V50, P109, DOI 10.1016/j.ctrv.2016.09.002
   Carlo MI, 2016, ONCOLOGIST, V21, P787, DOI 10.1634/theoncologist.2016-0145
   Chen JZ, 2015, CLIN EXP PHARMACOL P, V42, P1317, DOI 10.1111/1440-1681.12493
   Chia S, 2015, CURR ONCOL, V22, P33, DOI 10.3747/co.22.2393
   Chitnis MM, 2008, CLIN CANCER RES, V14, P6364, DOI 10.1158/1078-0432.CCR-07-4879
   Cho DC, 2010, CLIN CANCER RES, V16, P3628, DOI 10.1158/1078-0432.CCR-09-3022
   Choo AY, 2008, P NATL ACAD SCI USA, V105, P17414, DOI 10.1073/pnas.0809136105
   Cope CL, 2014, J CELL SCI, V127, P788, DOI 10.1242/jcs.137588
   Darwish OM, 2013, UROLOGY, V81, P581, DOI 10.1016/j.urology.2012.11.030
   Dolly SO, 2016, CLIN CANCER RES, V22, P2874, DOI 10.1158/1078-0432.CCR-15-2225
   Dowling RJO, 2010, SCIENCE, V328, P1172, DOI 10.1126/science.1187532
   Ducker GS, 2014, ONCOGENE, V33, P1590, DOI 10.1038/onc.2013.92
   Ducker GS, 2013, ONCOGENE, DOI DOI 10.1208/s12248-011-9276-7
   Engelman JA, 2006, J CLIN INVEST, V116, P2695, DOI 10.1172/JCI28656
   Fazio N, 2016, ANTICANCER RES, V36, P713
   FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x
   Gibney GT, 2013, ANN ONCOL, V24, P343, DOI 10.1093/annonc/mds463
   GNARRA JR, 1994, NAT GENET, V7, P85, DOI 10.1038/ng0594-85
   Greef B, 2016, BRIT J CANCER, V115, P505, DOI 10.1038/bjc.2016.230
   Greuber EK, 2013, NAT REV CANCER, V13, P559, DOI 10.1038/nrc3563
   Gross JD, 2003, CELL, V115, P739, DOI 10.1016/S0092-8674(03)00975-9
   Guan LJ, 2007, J BIOL CHEM, V282, P14213, DOI 10.1074/jbc.M610513200
   Hainsworth JD, 2011, CANCER INVEST, V29, P451, DOI 10.3109/07357907.2011.590568
   Hara K, 2002, CELL, V110, P177, DOI 10.1016/S0092-8674(02)00833-4
   Heikkinen T, 2013, BREAST CANCER RES TR, V141, P79, DOI 10.1007/s10549-013-2671-2
   Hudes G, 2007, NEW ENGL J MED, V356, P2271, DOI 10.1056/NEJMoa066838
   Juengel E, 2016, ONCOTARGET, V7, P85208, DOI 10.18632/oncotarget.13421
   Juengel E, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-152
   Juengel E, 2012, CANCER LETT, V324, P83, DOI 10.1016/j.canlet.2012.05.003
   Kim S T., 2016, Annals of Oncology
   Laplante M, 2012, CELL, V149, P274, DOI 10.1016/j.cell.2012.03.017
   Liu JY, 2013, J BIOL CHEM, V288, P23225, DOI 10.1074/jbc.M113.492371
   Liu XD, 2011, CLIN CANCER RES, V17, P7127, DOI 10.1158/1078-0432.CCR-11-1157
   Maira SM, 2008, MOL CANCER THER, V7, P1851, DOI 10.1158/1535-7163.MCT-08-0017
   Maira SM, 2012, MOL CANCER THER, V11, P317, DOI 10.1158/1535-7163.MCT-11-0474
   Markman B, 2012, ANN ONCOL, V23, P2399, DOI 10.1093/annonc/mds011
   Maroun CR, 2014, PHARMACOL THERAPEUT, V142, P316, DOI 10.1016/j.pharmthera.2013.12.014
   Mateo F, 2017, ONCOGENE, V36, P2737, DOI 10.1038/onc.2016.427
   Miele L, 2006, CLIN CANCER RES, V12, P1074, DOI 10.1158/1078-0432.CCR-05-2570
   Mohan S, 2015, CLIN CANCER RES, V21, P3946, DOI 10.1158/1078-0432.CCR-14-3377
   Motzer RJ, 2010, CANCER-AM CANCER SOC, V116, P4256, DOI 10.1002/cncr.25219
   Naing A, 2012, BRIT J CANCER, V107, P1093, DOI 10.1038/bjc.2012.368
   Nojima H, 2003, J BIOL CHEM, V278, P15461, DOI 10.1074/jbc.C200665200
   Nyfeler B, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048548
   O'Reilly KE, 2006, CANCER RES, V66, P1500, DOI 10.1158/0008-5472.CAN-05-2925
   Patursky-Polischuk I, 2009, MOL CELL BIOL, V29, P640, DOI 10.1128/MCB.00980-08
   Piao JJ, 2016, ONCOTARGET, V7, P60169, DOI 10.18632/oncotarget.11109
   Pike KG, 2013, BIOORG MED CHEM LETT, V23, P1212, DOI 10.1016/j.bmcl.2013.01.019
   Powles T, 2016, EUR UROL, V69, P450, DOI 10.1016/j.eururo.2015.08.035
   Ramcharan R, 2015, ONCOTARGET, V6, P39877, DOI 10.18632/oncotarget.5631
   Ricci C, 2002, CANCER RES, V62, P5995
   Rodrik-Outmezguine VS, 2016, NATURE, V534, P272, DOI 10.1038/nature17963
   Ryan CW, 2011, INVEST NEW DRUG, V29, P374, DOI 10.1007/s10637-009-9365-y
   Sakre N, 2016, ONCOTARGET
   Sancak Y, 2007, MOL CELL, V25, P903, DOI 10.1016/j.molcel.2007.03.003
   Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148
   Saxton RA, 2017, CELL, V168, P960, DOI [10.1016/j.cell.2017.02.004, 10.1016/j.cell.2017.03.035]
   Shapiro GI, 2015, CLIN CANCER RES, V21, P1888, DOI 10.1158/1078-0432.CCR-14-1306
   Sharma SV, 2010, CELL, V141, P69, DOI 10.1016/j.cell.2010.02.027
   Sjölund J, 2008, J CLIN INVEST, V118, P217, DOI 10.1172/JCI32086
   Thomas HE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003923
   Venkannagari S, 2012, ONCOTARGET, V3, P1416
   Vo K, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-138
   Vuky J, 2006, INVEST NEW DRUG, V24, P85, DOI 10.1007/s10637-005-4543-z
   Wise-Draper TM, 2017, TARGET ONCOL, V12, P323, DOI 10.1007/s11523-017-0482-9
   Yeh TC, 2007, CLIN CANCER RES, V13, P1576, DOI 10.1158/1078-0432.CCR-06-1150
   Yip CK, 2010, MOL CELL, V38, P768, DOI 10.1016/j.molcel.2010.05.017
   Yuen JSP, 2009, MOL CANCER THER, V8, P1448, DOI 10.1158/1535-7163.MCT-09-0101
   Zhang YJ, 2012, CELL CYCLE, V11, P594, DOI 10.4161/cc.11.3.19096
   Zibelman M, 2015, INVEST NEW DRUG, V33, P1040, DOI 10.1007/s10637-015-0261-3
NR 82
TC 24
Z9 25
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 1
PY 2018
VL 13
IS 2
AR e0191890
DI 10.1371/journal.pone.0191890
PG 22
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA FU3ZZ
UT WOS:000423793400040
PM 29389967
OA Green Published, Green Submitted, gold
DA 2025-01-12
ER

PT J
AU Liu, Q
   Kulak, MV
   Borcherding, N
   Maina, PK
   Zhang, W
   Weigel, RJ
   Qi, HH
AF Liu, Q.
   Kulak, M. V.
   Borcherding, N.
   Maina, P. K.
   Zhang, W.
   Weigel, R. J.
   Qi, H. H.
TI A novel <i>HER2</i> gene body enhancer contributes to <i>HER2</i>
   expression
SO ONCOGENE
LA English
DT Article
ID BREAST-CANCER CELLS; NEGATIVE REGULATORY ELEMENTS; HUMAN ERBB-2 GENE;
   TRANSCRIPTION FACTOR; DNA METHYLATION; ACTIVATOR PROTEIN-2; PROMOTER;
   OVEREXPRESSION; IDENTIFICATION; RECEPTOR
AB The transcriptional regulation of the human epidermal growth factor receptor-2 (HER2) contributes to an enhanced HER2 expression in HER2-positive breast cancers with HER2 gene amplification and HER2-low or HER2-negative breast cancers following radiotherapy or endocrine therapy, and this drives tumorigenesis and the resistance to therapy. Epigenetic mechanisms are critical for transcription regulation, however, such mechanisms in the transcription regulation of HER2 are limited to the involvement of trimethylated histone 3 lysine 4 (H3K4me3) and acetylated histone 3 lysine 9 (H3K9ac) at the HER2 promoter region. Here, we report the identification of a novel enhancer in the HER2 3' gene body, which we have termed HER2 gene body enhancer (HGE). The HGE starts from the 3' end of intron 19 and extends into intron 22, possesses enhancer histone modification marks in specific cells and enhances the transcriptional activity of the HER2 promoters. We also found that TFAP2C, a known regulator of HER2, binds to HGE and is required for its enhancer function and that DNA methylation in the HGE region inhibits the histone modifications characterizing enhancer and is inversely correlated with HER2 expression in breast cancer samples. The identification of this novel enhancer sheds a light on the roles of epigenetic mechanisms in HER2 transcription, in both HER2-positive breast cancer samples and individuals with HER2-low or HER2-negative breast cancers undergoing radiotherapy or endocrine therapy.
C1 [Liu, Q.; Maina, P. K.; Qi, H. H.] Univ Iowa, Dept Anat & Cell Biol, Carver Coll Med, 1-632 BSB,51 Newton Rd, Iowa City, IA 52243 USA.
   [Kulak, M. V.; Weigel, R. J.] Univ Iowa, Dept Surg, Carver Coll Med, Iowa City, IA 52243 USA.
   [Borcherding, N.; Zhang, W.] Univ Iowa, Dept Pathol, Carver Coll Med, Iowa City, IA 52243 USA.
   [Weigel, R. J.] Univ Iowa, Dept Biochem, Carver Coll Med, Iowa City, IA 52243 USA.
C3 University of Iowa; University of Iowa; University of Iowa; University
   of Iowa
RP Qi, HH (通讯作者)，Univ Iowa, Dept Anat & Cell Biol, Carver Coll Med, 1-632 BSB,51 Newton Rd, Iowa City, IA 52243 USA.
EM hank-qi@uiowa.edu
OI Qi, Hank/0000-0002-3401-4940; Maina, Peterson/0000-0002-5909-190X;
   Borcherding, Nicholas/0000-0003-1427-6342; Kulak,
   Mikhail/0000-0002-4307-5868; Weigel, Ronald/0000-0002-9249-0793
FU Department of Anatomy and Cell Biology, the Carver College of Medicine,
   University of Iowa; Carver Trust Young Investigator Award from the Roy J
   Carver Charitable Trust [01-224]; Breast Cancer Research Award by the
   Holden Comprehensive Cancer Center at University of Iowa; NIH [P30
   CA086862, R01CA183702, CA200673, CA203834]; NIH MD/PhD fellowship [F30
   CA206255]; V Scholar award from Holden Comprehensive Cancer Center at
   the University of Iowa; Breast Cancer Research Award from Holden
   Comprehensive Cancer Center at the University of Iowa; Oberley Award
   (National Cancer Institute Award) from Holden Comprehensive Cancer
   Center at the University of Iowa [P30 CA086862]
FX We thank Dr Brad Amendt and his lab for helpful discussions, and the
   ENCODE Consortium and the ENCODE production laboratories for generating
   the relevant data sets. The results of the bioinformatical analysis are
   based, in whole or part, upon data generated by The Cancer Genome Atlas
   Research Network (http://cancergenome.nih.gov/). The K562 cell line was
   a kind gift from Dr Fenghuang Zhan. We also thank Drs Christine
   Blaumueller and Marie Gaine for editorial consultation. This work was
   supported by to HHQ start-up funds from the Department of Anatomy and
   Cell Biology, the Carver College of Medicine, University of Iowa; Carver
   Trust Young Investigator Award (01-224 to HHQ) from the Roy J Carver
   Charitable Trust; a Breast Cancer Research Award (to HHQ) by the Holden
   Comprehensive Cancer Center at University of Iowa; The NIH grant (P30
   CA086862) to the Genomics and Flow Cytometry core facilities at the
   University of Iowa. NIH grants R01CA183702 (PI: RJW) and by a generous
   gift from the Kristen Olewine Milke Breast Cancer Research Fund (PI:
   RJW). NB was supported by NIH MD/PhD fellowship (F30 CA206255); WZ was
   supported by NIH grants CA200673, and CA203834, the V Scholar award, a
   Breast Cancer Research Award and an Oberley Award (National Cancer
   Institute Award P30 CA086862) from Holden Comprehensive Cancer Center at
   the University of Iowa.
CR Allouche A, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1851
   Anido J, 2006, EMBO J, V25, P3234, DOI 10.1038/sj.emboj.7601191
   Baselga J, 2009, NAT REV CANCER, V9, P463, DOI 10.1038/nrc2656
   Begon DY, 2005, J BIOL CHEM, V280, P24428, DOI 10.1074/jbc.M503790200
   Benz CC, 2006, GENE CHROMOSOME CANC, V45, P983, DOI 10.1002/gcc.20364
   Bofin AM, 2004, AM J CLIN PATHOL, V122, P110, DOI 10.1309/8A2DJFT07NE6EWHE
   Bosher JM, 1996, ONCOGENE, V13, P1701
   Cao N, 2009, RADIAT RES, V171, P9, DOI 10.1667/RR1472.1
   Chen YY, 1997, J BIOL CHEM, V272, P14110, DOI 10.1074/jbc.272.22.14110
   Chen YY, 1996, J BIOL CHEM, V271, P5183
   CHEN YY, 1994, ONCOGENE, V9, P2269
   Choudhury A, 2004, INT J CANCER, V108, P71, DOI 10.1002/ijc.11497
   Contino F, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-81
   Crawford GE, 2006, GENOME RES, V16, P123, DOI 10.1101/gr.4074106
   Creyghton MP, 2010, P NATL ACAD SCI USA, V107, P21931, DOI 10.1073/pnas.1016071107
   Deblois G, 2010, CANCER RES, V70, P10277, DOI 10.1158/0008-5472.CAN-10-2840
   Delacroix L, 2005, DNA CELL BIOL, V24, P582, DOI 10.1089/dna.2005.24.582
   Dillon RL, 2007, MOL CELL BIOL, V27, P8648, DOI 10.1128/MCB.00866-07
   Dittrich A, 2014, J MAMMARY GLAND BIOL, V19, P253, DOI 10.1007/s10911-014-9329-5
   Dunham I, 2012, NATURE, V489, P57, DOI 10.1038/nature11247
   Duru N, 2012, CLIN CANCER RES, V18, P6634, DOI 10.1158/1078-0432.CCR-12-1436
   Greer EL, 2012, NAT REV GENET, V13, P343, DOI 10.1038/nrg3173
   GROOTECLAES M, 1994, CANCER RES, V54, P4193
   Hua GQ, 2009, MOL CANCER RES, V7, P402, DOI 10.1158/1541-7786.MCR-08-0175
   Huang WY, 2015, NUCLEIC ACIDS RES, V43, pD856, DOI 10.1093/nar/gku1151
   Hurtado A, 2008, NATURE, V456, P663, DOI 10.1038/nature07483
   KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x
   Kulak MV, 2013, ONCOGENE, V32, P4043, DOI 10.1038/onc.2012.400
   Malik S, 2010, NAT REV GENET, V11, P761, DOI 10.1038/nrg2901
   MIZUGUCHI G, 1995, J BIOL CHEM, V270, P9384, DOI 10.1074/jbc.270.16.9384
   Moarii M, 2015, BMC GENOMICS, V16, DOI 10.1186/s12864-015-1994-2
   Mungamuri SK, 2013, CELL REP, V5, P302, DOI 10.1016/j.celrep.2013.09.009
   Nezu M, 1999, BIOCHEM BIOPH RES CO, V258, P499, DOI 10.1006/bbrc.1999.0634
   Ong CT, 2011, NAT REV GENET, V12, P283, DOI 10.1038/nrg2957
   PASLEAU F, 1993, ONCOGENE, V8, P849
   Perissi V, 2000, ONCOGENE, V19, P280, DOI 10.1038/sj.onc.1203303
   Rada-Iglesias A, 2011, NATURE, V470, P279, DOI 10.1038/nature09692
   RENBAUM P, 1990, NUCLEIC ACIDS RES, V18, P1145, DOI 10.1093/nar/18.5.1145
   Rose NR, 2014, BBA-GENE REGUL MECH, V1839, P1362, DOI 10.1016/j.bbagrm.2014.02.007
   Roskoski R, 2014, PHARMACOL RES, V79, P34, DOI 10.1016/j.phrs.2013.11.002
   Schaefer KA, 2017, NAT METHODS, V14, P547, DOI 10.1038/nmeth.4293
   Scott GK, 2000, ONCOGENE, V19, P6490, DOI 10.1038/sj.onc.1204041
   SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106
   TAL M, 1987, MOL CELL BIOL, V7, P2597, DOI 10.1128/MCB.7.7.2597
   Tata PR, 2011, NUCLEIC ACIDS RES, V39, P3574, DOI 10.1093/nar/gkq1344
   Vernimmen D, 2003, BIOCHEM J, V370, P323, DOI 10.1042/BJ20021238
   Vojta A, 2016, NUCLEIC ACIDS RES, V44, P5615, DOI 10.1093/nar/gkw159
   Wang H, 2017, CANCER LETT, V385, P137, DOI 10.1016/j.canlet.2016.10.033
   Woodfield GW, 2010, GENE CHROMOSOME CANC, V49, P948, DOI 10.1002/gcc.20807
   Woodfield GW, 2009, CLIN CANCER RES, V15, P3672, DOI 10.1158/1078-0432.CCR-08-2343
   Wu J, 2006, CANCER RES, V66, P4872, DOI 10.1158/0008-5472.CAN-05-3561
   Xing XM, 2000, NAT MED, V6, P189, DOI 10.1038/72294
   Zuo T, 2007, CELL, V129, P1275, DOI 10.1016/j.cell.2007.04.034
NR 53
TC 29
Z9 31
U1 1
U2 9
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-9232
EI 1476-5594
J9 ONCOGENE
JI Oncogene
PD FEB 1
PY 2018
VL 37
IS 5
BP 687
EP 694
DI 10.1038/onc.2017.382
PG 8
WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
GA FU4GT
UT WOS:000423812200013
PM 29035388
OA Green Published, hybrid
DA 2025-01-12
ER

PT J
AU Bluemel, L
   von Wahlde, MK
   Tio, J
   Kiesel, L
   Bernemann, C
AF Bluemel, Lena
   von Wahlde, Marie-Kristin
   Tio, Joke
   Kiesel, Ludwig
   Bernemann, Christof
TI Reverse engineering of triple-negative breast cancer cells for targeted
   treatment
SO MATURITAS
LA English
DT Article
DE Triple-negative breast cancer; Personalized therapies; HER2 treatment;
   Reverse engineering
ID EPIGENETIC MEMORY; STEM-CELLS; HER2; TRASTUZUMAB; EXPRESSION; KINASE;
   SUBTYPES; THERAPY; EGFR; THERAPEUTICS
AB Objective: Targeting the human epidermal growth factor receptor HER2 has increased survival in HER2-positive breast cancer patients. In the contrast, for triple-negative breast cancer (TNBC) patients, no targeted agents are available. We hypothesized that artificial overexpression of HER2 in TNBC cells might induce sensitivity to anti-HER2 agents in these cells.
   Methods: TNBC cell lines were transduced using lentiviral HER2 overexpression particles. Functionality of HER2 was determined by protein analysis and localization studies. The tumorigenic potential of HER2 overexpressing cells was assessed by analysis of proliferation, migration and invasion capacity. Response to chemotherapeutic agents and anti-HER2 agents was determined by cell viability assays.
   Results: We demonstrated functional overexpression of HER2 in TNBC cell lines of different subtypes. Whereas in cell types with more pronounced epithelial features (e.g. MDA-MB-468) HER2 overexpression increases proliferation and migration, in mesenchymal cell lines (MDA-MB-231 and BT-549) HER2 was able to further increase invasive potential. No changes were found in cancer stem cell characteristics or in response to chemotherapy, a trait of TNBC. When treated with anti-HER2 agents, however, HER2 overexpressing TNBC cells showed increased sensitivity to these agents.
   Conclusion: This proof-of-principle study demonstrates that reverse engineering of TNBC cells might offer a novel targeted treatment strategy for this most aggressive subtype of breast cancer.
C1 [Bluemel, Lena; von Wahlde, Marie-Kristin; Tio, Joke; Kiesel, Ludwig; Bernemann, Christof] Univ Hosp, Dept Gynecol & Obstet, Munster, Germany.
   [Bernemann, Christof] Univ Hosp, Dept Urol, Munster, Germany.
C3 University of Munster; University of Munster
RP Bernemann, C (通讯作者)，Univ Hosp, Dept Gynecol & Obstet, Munster, Germany.; Bernemann, C (通讯作者)，Univ Hosp, Dept Urol, Munster, Germany.
EM christof.bernemann@ukmuenster.de
RI Kiesel, Ludwig/ABC-5333-2020
FU internal funds of the medical faculty of Muenster University IMF
   (Innovative Medizinische Forschung) [BE 1 1 12 02]
FX This project was partly funded by the internal funds of the medical
   faculty of Muenster University IMF (Innovative Medizinische Forschung) -
   BE 1 1 12 02.
CR Aigner A, 2001, ONCOGENE, V20, P2101, DOI 10.1038/sj.onc.1204305
   Arteaga CL, 2014, CANCER CELL, V25, P282, DOI 10.1016/j.ccr.2014.02.025
   Atkins GJ, 2003, J BONE MINER RES, V18, P1088, DOI 10.1359/jbmr.2003.18.6.1088
   Bernemann C, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-174
   Crown J, 2012, ANN ONCOL, V23, P56, DOI 10.1093/annonc/mds196
   Dhillon AS, 2007, ONCOGENE, V26, P3279, DOI 10.1038/sj.onc.1210421
   Gradishar WJ, 2012, NEW ENGL J MED, V366, P176, DOI 10.1056/NEJMe1113641
   Greve B, 2012, CYTOM PART A, V81A, P284, DOI 10.1002/cyto.a.22022
   Hortobagyi GN, 2005, NEW ENGL J MED, V353, P1734, DOI 10.1056/NEJMe058196
   Hudis CA, 2007, NEW ENGL J MED, V357, P39, DOI 10.1056/NEJMra043186
   Incorvati JA, 2013, J HEMATOL ONCOL, V6, DOI 10.1186/1756-8722-6-38
   Iqbal J, 2012, HISTOPATHOLOGY, V61, P652, DOI 10.1111/j.1365-2559.2012.04255.x
   Irwin ME, 2011, J CELL PHYSIOL, V226, P2316, DOI 10.1002/jcp.22570
   Ithimakin S, 2013, CANCER RES, V73, P1635, DOI 10.1158/0008-5472.CAN-12-3349
   Jarell AD, 2007, BIOL-TARGETS THER, V1, P407
   Jin X, 2015, ONCOTARGET, V6, P9600, DOI 10.18632/oncotarget.3292
   Jordan NV, 2016, NATURE, V537, P102, DOI 10.1038/nature19328
   Kim K, 2010, NATURE, V467, P285, DOI 10.1038/nature09342
   Korkaya H, 2008, ONCOGENE, V27, P6120, DOI 10.1038/onc.2008.207
   Lehmann BD, 2011, J CLIN INVEST, V121, P2750, DOI 10.1172/JCI45014
   Liedtke C, 2009, ANN ONCOL, V20, P1953, DOI 10.1093/annonc/mdp263
   Liedtke C, 2008, J CLIN ONCOL, V26, P1275, DOI 10.1200/JCO.2007.14.4147
   Maiello MR, 2015, J CELL BIOCHEM, V116, P2778, DOI 10.1002/jcb.25220
   Nahta R, 2005, CANCER RES, V65, P11118, DOI 10.1158/0008-5472.CAN-04-3841
   Nahta R, 2012, BREAST CANCER-TARGET, V4, P53, DOI 10.2147/BCTT.S24976
   Nashun B, 2015, EMBO J, V34, P1296, DOI 10.15252/embj.201490649
   Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008
   Rouzier R, 2005, CLIN CANCER RES, V11, P5678, DOI 10.1158/1078-0432.CCR-04-2421
   Scheuer W, 2009, CANCER RES, V69, P9330, DOI 10.1158/0008-5472.CAN-08-4597
   SCOTT GK, 1993, MOL CELL BIOL, V13, P2247, DOI 10.1128/MCB.13.4.2247
   Subik K, 2010, BREAST CANCER-BASIC, V4, P35
   Tai WY, 2010, J CONTROL RELEASE, V146, P264, DOI 10.1016/j.jconrel.2010.04.009
   Turner NH, 2013, CANCER TREAT REV, V39, P947, DOI 10.1016/j.ctrv.2013.05.003
   Yakes FM, 2002, CANCER RES, V62, P4132
   Yoshida R, 2012, CANCER IMMUNOL IMMUN, V61, P1905, DOI 10.1007/s00262-012-1249-x
NR 35
TC 3
Z9 3
U1 0
U2 10
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0378-5122
EI 1873-4111
J9 MATURITAS
JI Maturitas
PD FEB
PY 2018
VL 108
BP 24
EP 30
DI 10.1016/j.maturitas.2017.11.010
PG 7
WC Geriatrics & Gerontology; Obstetrics & Gynecology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Geriatrics & Gerontology; Obstetrics & Gynecology
GA FU1XA
UT WOS:000423641600006
PM 29290211
DA 2025-01-12
ER

PT J
AU Kokelaar, RF
   Jones, HG
   Williamson, J
   Williams, N
   Griffiths, AP
   Beynon, J
   Jenkins, GJ
   Harris, DA
AF Kokelaar, Rory F.
   Jones, Huw G.
   Williamson, Jeremy
   Williams, Namor
   Griffiths, A. Paul
   Beynon, John
   Jenkins, Gareth J.
   Harris, Dean A.
TI DNA hypermethylation as a predictor of extramural vascular invasion
   (EMVI) in rectal cancer
SO CANCER BIOLOGY & THERAPY
LA English
DT Article
DE Epigenetics; Rectal Cancer; Vascular Invasion; CIMP
ID ISLAND METHYLATOR PHENOTYPE; METASTATIC COLORECTAL-CANCER; CELL
   LUNG-CANCER; PROGNOSTIC-SIGNIFICANCE; VENOUS INVASION; NEOADJUVANT
   CHEMORADIOTHERAPY; CLINICAL-SIGNIFICANCE; MOLECULAR MARKERS; HISTOLOGIC
   FEATURES; BREAST-CANCER
AB Purpose: DNA hypermethylation in gene promoter regions (CpG islands) is emerging as an important pathway in colorectal cancer tumourigenesis. Whilst genetic mutations have been associated with extramural vascular invasion (EMVI) in rectal cancer, no such association has yet been made with epigenetic factors.Methods: 100 consecutive neoadjuvant-naive patients undergoing curative surgery for rectal were classified according to the presence or absence of EMVI on histopathological examination. DNA was extracted from tumours and subjected to bisulfite conversion and methylation-specific PCR to determine CIMP status (high, intermediate, or low; according to a validated panel of 8 genes). CIMP status was correlated with EMVI status, histopathological, clinical, and demographic variables, in addition to overall (OS) and disease free (DFS) survival.Results: 51 patients were characterised as CIMP-low, 48 CIMP-intermediate, and one patient CIMP-high. EMVI-positivity was associated with CIMP-intermediate epigenotype (p < 0.001). Patients with EMVI-positive tumours were found to have significantly more advanced disease by pT, pN, and pAJCC categorisation (p = 0.002, p < 0.001, and = p < 0.001, respectively). EMVI-positivity was significantly associated with the requirement for adjuvant chemotherapy (p < 0.001), and worse DFS but not OS (p = 0.012 and p = 0.052).Conclusions: Given the association between CIMP-intermediate epigenotype and EMVI-positivity, and the subsequent disadvantage in pathological stage, requirement for adjuvant therapy and worse survival, tumour epigenotyping could potentially play an important role in personalising patients' cancer care. Further work is required to understand the mechanisms that underlie the observed effect, with the hope that they may provide novel opportunities for intervention and inform treatment decisions in rectal cancer.
C1 [Kokelaar, Rory F.; Jones, Huw G.; Williamson, Jeremy; Beynon, John; Harris, Dean A.] Abertawe Bro Morgannwg Univ Hlth Board, Dept Colorectal Surg, Swansea, W Glam, Wales.
   [Kokelaar, Rory F.; Jones, Huw G.; Williamson, Jeremy; Beynon, John; Harris, Dean A.] Abertawe Bro Morgannwg Univ Hlth Board, Dept Pathol, Swansea, W Glam, Wales.
   [Williams, Namor; Griffiths, A. Paul] Abertawe Bro Morgannwg Univ Hlth Board, Pathol, Swansea, W Glam, Wales.
   [Kokelaar, Rory F.; Jenkins, Gareth J.] Swansea Univ, Inst Life Sci, Sch Med, Canc Biomarker Grp, Swansea, W Glam, Wales.
C3 Swansea University
RP Kokelaar, RF (通讯作者)，Abertawe Bro Morgannwg Univ Hlth Board, Singleton Hosp, Dept Colorectal Surg, Sketty Lane, Swansea SA2 8QA, W Glam, Wales.; Kokelaar, RF (通讯作者)，Abertawe Bro Morgannwg Univ Hlth Board, Singleton Hosp, Dept Pathol, Sketty Lane, Swansea SA2 8QA, W Glam, Wales.
EM rory.kokelaar@gmail.com
RI Jones, Huw Geraint/A-3766-2012; Harris, Dean/H-7870-2019
OI Jones, Huw Geraint/0000-0003-0365-9049; Harris,
   Dean/0000-0003-2673-8946; jenkins, gareth/0000-0002-5437-8389
CR Amado RG, 2008, J CLIN ONCOL, V26, P1626, DOI 10.1200/JCO.2007.14.7116
   Andrade AF, 2014, ANTI-CANCER DRUG, V25, P72, DOI 10.1097/CAD.0000000000000028
   Antelo M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045357
   Araki Y, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18050905
   Bonetti LR, 2017, WORLD J GASTROENTERO, V23, P1412, DOI 10.3748/wjg.v23.i8.1412
   Brown G, 2006, BRIT MED J, V333, P779, DOI 10.1136/bmj.38937.646400.55
   Brown G, 2003, BRIT J SURG, V90, P355, DOI 10.1002/bjs.4034
   Bugg WG, 2014, CLIN RADIOL, V69, P619, DOI 10.1016/j.crad.2014.01.010
   Cha Y, 2016, BRIT J CANCER, V115, P164, DOI 10.1038/bjc.2016.176
   Chand M, 2016, WORLD J GASTROENTERO, V22, P1721, DOI 10.3748/wjg.v22.i4.1721
   Chand M, 2015, ANN SURG, V261, P473, DOI 10.1097/SLA.0000000000000848
   Dienstmann R, 2017, NAT REV CANCER, V17, P79, DOI 10.1038/nrc.2016.126
   Donada M, 2013, BMC GASTROENTEROL, V13, DOI 10.1186/1471-230X-13-36
   Edwards BK, 2010, CANCER-AM CANCER SOC, V116, P544, DOI 10.1002/cncr.24760
   EISENBERG B, 1982, CANCER-AM CANCER SOC, V49, P1131, DOI 10.1002/1097-0142(19820315)49:6<1131::AID-CNCR2820490611>3.0.CO;2-T
   Gallois C, 2016, CRIT REV ONCOL HEMAT, V99, P74, DOI 10.1016/j.critrevonc.2015.11.001
   Gunal A, 2013, J CLIN GASTROENTEROL, V47, P509, DOI 10.1097/MCG.0b013e3182703030
   Harada H, 2015, ANN THORAC SURG, V99, P1746, DOI 10.1016/j.athoracsur.2014.12.058
   Hartmann C, 2011, CLIN CANCER RES, V17, P4588, DOI 10.1158/1078-0432.CCR-10-3194
   Jass JR, 2007, HISTOPATHOLOGY, V50, P113, DOI 10.1111/j.1365-2559.2006.02549.x
   Jo P, 2012, SURGERY, V151, P564, DOI 10.1016/j.surg.2011.08.013
   Jover R, 2011, GASTROENTEROLOGY, V140, P1174, DOI 10.1053/j.gastro.2010.12.035
   Kähäri VM, 1999, ANN MED, V31, P34, DOI 10.3109/07853899909019260
   Kaneda A, 2011, CANCER SCI, V102, P18, DOI 10.1111/j.1349-7006.2010.01712.x
   Kim CH, 2017, J GASTROEN HEPATOL, V32, P1469, DOI 10.1111/jgh.13734
   KRASNA MJ, 1988, CANCER-AM CANCER SOC, V61, P1018, DOI 10.1002/1097-0142(19880301)61:5<1018::AID-CNCR2820610527>3.0.CO;2-H
   Kretschmer C, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-15
   Larijani L, 2014, ASIAN PAC J CANCER P, V15, P33, DOI 10.7314/APJCP.2014.15.1.33
   Lin HF, 2017, J INVEST MED, V65, P794, DOI 10.1136/jim-2016-000277
   Loughrey MB, 2014, G049 STANDARDS DATAS
   Maughan NJ, 2007, BRIT J CANCER, V97, P1393, DOI 10.1038/sj.bjc.6604036
   McCarthy K, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008368.pub2
   Missiaglia E, 2014, ANN ONCOL, V25, P1995, DOI 10.1093/annonc/mdu275
   Montenegro MF, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.85
   Nazemalhosseini Mojarad Ehsan, 2013, Gastroenterol Hepatol Bed Bench, V6, P6
   NICE, 2014, COLORECTAL CANCER DI
   Ogino S, 2007, J MOL DIAGN, V9, P305, DOI 10.2353/jmoldx.2007.060170
   Ouchi K, 1996, CANCER, V78, P2313, DOI 10.1002/(SICI)1097-0142(19961201)78:11<2313::AID-CNCR7>3.0.CO;2-N
   Patel UB, 2017, ANN ONCOL, V28, P344, DOI 10.1093/annonc/mdw616
   Puli SR, 2009, ANN SURG ONCOL, V16, P1255, DOI 10.1245/s10434-009-0337-4
   RICH T, 1983, CANCER-AM CANCER SOC, V52, P1317, DOI 10.1002/1097-0142(19831001)52:7<1317::AID-CNCR2820520731>3.0.CO;2-6
   Shiovitz S, 2014, GASTROENTEROLOGY, V147, P637, DOI 10.1053/j.gastro.2014.05.009
   Sinclair RCF, 2016, BRIT J ANAESTH, V116, P140, DOI 10.1093/bja/aev419
   Smith NJ, 2008, BRIT J SURG, V95, P229, DOI 10.1002/bjs.5917
   Smith NJ, 2008, AM J ROENTGENOL, V191, P1517, DOI 10.2214/AJR.08.1298
   TALBOT IC, 1980, BRIT J SURG, V67, P439, DOI 10.1002/bjs.1800670619
   TALBOT IC, 1981, AM J SURG, V141, P15, DOI 10.1016/0002-9610(81)90004-0
   Taylor F, 2010, Cancer Imaging, V10 Spec no A, pS142, DOI 10.1102/1470-7330.2010.9092
   Taylor FGM, 2011, ANN SURG, V253, P711, DOI 10.1097/SLA.0b013e31820b8d52
   Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681
   Tripathi P, 2017, J DIGEST DIS, V18, P2, DOI 10.1111/1751-2980.12439
   Tsang JS, 2014, EJSO-EUR J SURG ONC, V40, P1459, DOI 10.1016/j.ejso.2014.06.008
   van den Bent MJ, 2013, CLIN CANCER RES, V19, P5513, DOI 10.1158/1078-0432.CCR-13-1157
   VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901
   Wang M, 2012, MOL MED REP, V5, P1514, DOI 10.3892/mmr.2012.828
   Weisenberger DJ, 2006, NAT GENET, V38, P787, DOI 10.1038/ng1834
   Williamson JS, 2015, CLIN EPIGENETICS, V7, DOI 10.1186/s13148-015-0111-3
   Williamson JS, 2017, WORLD J GASTRO ONCOL, V9, P209, DOI 10.4251/wjgo.v9.i5.209
   Wu F, 2015, INT J CLIN EXP PATHO, V8, P5457
   Yagi K, 2010, CLIN CANCER RES, V16, P21, DOI 10.1158/1078-0432.CCR-09-2006
   Yamauchi M, 2012, GUT, V61, P847, DOI 10.1136/gutjnl-2011-300865
   Yokoi K, 2017, BRIT J CANCER, V116, P1046, DOI 10.1038/bjc.2017.65
NR 62
TC 8
Z9 9
U1 0
U2 0
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1538-4047
EI 1555-8576
J9 CANCER BIOL THER
JI Cancer Biol. Ther.
PY 2018
VL 19
IS 3
BP 214
EP 221
DI 10.1080/15384047.2017.1416933
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA FU3QH
UT WOS:000423766100011
PM 29260978
OA Bronze, Green Published
DA 2025-01-12
ER

PT J
AU Song, MA
   Brasky, TM
   Weng, DY
   McElroy, JP
   Marian, C
   Higgins, MJ
   Ambrosone, C
   Spear, SL
   Llanos, AA
   Kallakury, BVS
   Freudenheim, JL
   Shields, PG
AF Song, Min-Ae
   Brasky, Theodore M.
   Weng, Daniel Y.
   McElroy, Joseph P.
   Marian, Catalin
   Higgins, Michael J.
   Ambrosone, Christine
   Spear, Scott L.
   Llanos, Adana A.
   Kallakury, Bhaskar V. S.
   Freudenheim, Jo L.
   Shields, Peter G.
TI Landscape of genome-wide age-related DNA methylation in breast tissue
SO ONCOTARGET
LA English
DT Article
DE genome-wide DNA methylation; age; breast; normal; cancer
ID GENE-EXPRESSION PROFILES; EPIGENETIC REGULATION; CHROMATIN STATE;
   NONCODING RNAS; X-CHROMOSOME; CELL-CYCLE; CANCER; HYPERMETHYLATION;
   ESTROGEN; DISCOVERY
AB Despite known age-related DNA methylation (aDNAm) changes in breast tumors, little is known about aDNAm in normal breast tissues. Breast tissues from a cross-sectional study of 121 cancer-free women, were assayed for genome-wide DNA methylation. mRNA expression was assayed by microarray technology. Analysis of covariance was used to identify aDNAm's. Altered methylation was correlated with expression of the corresponding gene and with DNA methyltransferase protein DNMT3A, assayed by immunohistochemistry. Publically-available TCGA-BRCA data were used for replication. 1,214 aDNAm's were identified; 97% with increased methylation, and all on autosomes. Sites with increased methylation were predominantly in CpG lslands and non-enhancers. aDNAm's with decreased methylation were generally located in intergenic regions, non-CpG Islands, and enhancers. Of the aDNAm's identified, 650 are known to be involved in cancer, including ESR1 and beta-estradiol responsive genes. Expression of DNMT3A was positively associated with age. Two aDNAm's showed borderline significant associations with DNMT3A expression; KRR1 (OR 6.57, 95% CI: 2.51-17.23) and DHRS12 (OR 6.08, 95% CI: 2.33-15.86). A subset of aDNAm's co-localized within vulnerable regions for somatic mutations in cancers including breast cancer. Expression of C19orf48 was inversely and significantly correlated with its methylation level. In the TCGA dataset, 84% and 64% of the previously identified aDNAm's were correlated with age in both normal-adjacent and tumor breast tissues, with differential associations by histological subtype. Given the similarity of findings in the breast tissues of healthy women and breast tumors, aDNAm's may be one pathway for increased breast cancer risk with age.
C1 [Song, Min-Ae; Brasky, Theodore M.; Weng, Daniel Y.; McElroy, Joseph P.; Shields, Peter G.] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA.
   [Song, Min-Ae; Brasky, Theodore M.; Weng, Daniel Y.; McElroy, Joseph P.; Shields, Peter G.] James Canc Hosp, Columbus, OH 43210 USA.
   [Song, Min-Ae] Ohio State Univ, Coll Publ Hlth, Columbus, OH 43210 USA.
   [McElroy, Joseph P.] Ohio State Univ, Ctr Biostat, Columbus, OH 43210 USA.
   [McElroy, Joseph P.] Ohio State Univ, Dept Bioinformat, Columbus, OH 43210 USA.
   [Marian, Catalin] Victor Babes Univ Med & Pharm, Biochem & Pharmacol Dept, Timisoara, Romania.
   [Higgins, Michael J.] Roswell Pk Canc Inst, Dept Mol & Cellular Biol, Buffalo, NY 14263 USA.
   [Ambrosone, Christine] Roswell Pk Canc Inst, Dept Canc Prevent & Control, Buffalo, NY 14263 USA.
   [Spear, Scott L.] Georgetown Univ, Dept Plast Surg, Washington, DC USA.
   [Llanos, Adana A.] Rutgers Sch Publ Hlth, Dept Epidemiol, New Brunswick, NJ USA.
   [Llanos, Adana A.] Rutgers Canc Inst New Jersey, New Brunswick, NJ USA.
   [Kallakury, Bhaskar V. S.] Georgetown Univ, Dept Pathol, Washington, DC USA.
   [Freudenheim, Jo L.] SUNY Buffalo, Sch Publ Hlth & Hlth Profess, Dept Epidemiol & Environm Hlth, Buffalo, NY USA.
C3 University System of Ohio; Ohio State University; James Cancer Hospital
   & Solove Research Institute; James Cancer Hospital & Solove Research
   Institute; University System of Ohio; Ohio State University; University
   System of Ohio; Ohio State University; University System of Ohio; Ohio
   State University; University System of Ohio; Ohio State University;
   Victor Babes University of Medicine & Pharmacy, Timisoara; Roswell Park
   Comprehensive Cancer Center; Roswell Park Comprehensive Cancer Center;
   Georgetown University; Rutgers University System; Rutgers University
   System; Rutgers University New Brunswick; Rutgers University Biomedical
   & Health Sciences; Rutgers Cancer Institute of New Jersey; Georgetown
   University; State University of New York (SUNY) System; University at
   Buffalo, SUNY
RP Shields, PG (通讯作者)，Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA.; Shields, PG (通讯作者)，James Canc Hosp, Columbus, OH 43210 USA.
EM Peter.Shields@osumc.edu
RI Shields, Peter/I-1644-2012; Llanos, Adana/J-8695-2019; Song,
   Min-Ae/AAF-9672-2021; Marian, Catalin/KHU-8477-2024; Marian,
   Catalin/P-2885-2019
OI Freudenheim, Jo/0000-0002-9301-0499; Marian, Catalin/0000-0002-7749-1384
FU DOD [BC022346, P30 CA016058, P30 CA016056]
FX This work was supported by grants, DOD BC022346, P30 CA016058, and P30
   CA016056. The sponsors had no role in the design of the study and
   collection, analysis, and interpretation of data, the writing of the
   manuscript, or the decision to submit the manuscript for publication.
CR Ambrosone CB, 2014, ONCOTARGET, V5, P237, DOI 10.18632/oncotarget.1599
   [Anonymous], SEER Cancer Statistics Review, 1975-2017
   [Anonymous], CARCINOGENESIS
   Bocklandt S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014821
   Bornstein C, 2011, MOL CELL BIOL, V31, P1679, DOI 10.1128/MCB.01072-10
   Catena CS, 2015, FRONT MED-LAUSANNE, V2, DOI 10.3389/fmed.2015.00085
   Chen YA, 2013, EPIGENETICS-US, V8, P203, DOI 10.4161/epi.23470
   Christensen BC, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000602
   Cotton AM, 2015, HUM MOL GENET, V24, P1528, DOI 10.1093/hmg/ddu564
   Di Leva G, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003311
   Dumitrescu RG, 2010, J CELL MOL MED, V14, P1468, DOI 10.1111/j.1582-4934.2009.00924.x
   Euhus DM, 2008, CANCER EPIDEM BIOMAR, V17, P1051, DOI 10.1158/1055-9965.EPI-07-2582
   Faucillion ML, 2015, GENOME BIOL EVOL, V7, P1039, DOI 10.1093/gbe/evv054
   Florath I, 2014, HUM MOL GENET, V23, P1186, DOI 10.1093/hmg/ddt531
   Gaudet MM, 2009, CANCER EPIDEM BIOMAR, V18, P3036, DOI 10.1158/1055-9965.EPI-09-0678
   Gupta RA, 2010, NATURE, V464, P1071, DOI 10.1038/nature08975
   Hervouet E, 2013, EPIGENETICS-US, V8, P237, DOI 10.4161/epi.23790
   Holoch D, 2015, NAT REV GENET, V16, P71, DOI 10.1038/nrg3863
   Horvath S, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-10-r115
   Huang YW, 2014, GYNECOL ONCOL, V133, P340, DOI 10.1016/j.ygyno.2014.02.009
   Johnson AA, 2012, REJUV RES, V15, P483, DOI 10.1089/rej.2012.1324
   Johnson KC, 2017, BREAST CANCER RES, V19, DOI 10.1186/s13058-017-0873-y
   Johnson KC, 2014, EPIGENETICS-US, V9, P268, DOI 10.4161/epi.27015
   Johnson SM, 2005, CELL, V120, P635, DOI 10.1016/j.cell.2005.01.014
   Jung M, 2015, NUCLEIC ACIDS RES, V43, pE100, DOI 10.1093/nar/gkv473
   Jung M, 2015, BMC BIOL, V13, DOI 10.1186/s12915-015-0118-4
   Kaikkonen MU, 2011, CARDIOVASC RES, V90, P430, DOI 10.1093/cvr/cvr097
   Kar S, 2014, CLIN EPIGENETICS, V6, DOI 10.1186/1868-7083-6-20
   Langevin SM, 2014, EPIGENOMICS-UK, V6, P367, DOI 10.2217/epi.14.28
   Liang J, 2013, ANNU REV PHYSIOL, V75, P225, DOI 10.1146/annurev-physiol-030212-183708
   Llanos AA, 2012, CANCER EPIDEM BIOMAR, V21, P1745, DOI 10.1158/1055-9965.EPI-12-0016
   López-Otín C, 2013, CELL, V153, P1194, DOI 10.1016/j.cell.2013.05.039
   Mansego ML, 2015, INT J MOL SCI, V16, P16816, DOI 10.3390/ijms160816816
   Luo QF, 2013, INT J ONCOL, V43, P1212, DOI 10.3892/ijo.2013.2034
   Maksimovic J, 2012, GENOME BIOL, V13, DOI 10.1186/gb-2012-13-6-r44
   Paris O, 2012, ONCOGENE, V31, P4196, DOI 10.1038/onc.2011.583
   Pekarsky Y, 2015, CELL DEATH DIFFER, V22, P6, DOI 10.1038/cdd.2014.87
   Price EM, 2013, EPIGENET CHROMATIN, V6, DOI 10.1186/1756-8935-6-4
   Rakyan VK, 2010, GENOME RES, V20, P434, DOI 10.1101/gr.103101.109
   Rivas MA, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3187
   Schaffner SF, 2004, NAT REV GENET, V5, P43, DOI 10.1038/nrg1247
   Siegel RL, 2015, CA-CANCER J CLIN, V65, P5, DOI 10.3322/caac.21254
   Smith ZD, 2013, NAT REV GENET, V14, P204, DOI 10.1038/nrg3354
   Song MA, 2015, EPIGENETICS-US, V10, P1177, DOI 10.1080/15592294.2015.1121362
   Sotiriou C, 2003, P NATL ACAD SCI USA, V100, P10393, DOI 10.1073/pnas.1732912100
   Steegenga Wilma T, 2014, Age (Dordr), V36, P9648, DOI 10.1007/s11357-014-9648-x
   Subramaniam D, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00080
   Sun J, 2015, SCI REP-UK, V5, DOI 10.1038/srep16553
   Sun M, 2015, MOL CELL, V59, P698, DOI 10.1016/j.molcel.2015.06.023
   Szyf M, 2012, GENOME MED, V4, DOI 10.1186/gm325
   Tserel L, 2015, SCI REP-UK, V5, DOI 10.1038/srep13107
   Xu Q, 2013, J MOL CELL BIOL, V5, P3, DOI 10.1093/jmcb/mjs049
   Xu ZL, 2014, CARCINOGENESIS, V35, P356, DOI 10.1093/carcin/bgt391
   Zampieri M, 2015, MECH AGEING DEV, V151, P60, DOI 10.1016/j.mad.2015.02.002
   Zhu H, 2016, NAT REV GENET, V17, P551, DOI 10.1038/nrg.2016.83
NR 55
TC 24
Z9 25
U1 0
U2 10
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD DEC 29
PY 2017
VL 8
IS 70
BP 114648
EP 114662
DI 10.18632/oncotarget.22754
PG 15
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA FS1XB
UT WOS:000419571000026
PM 29383109
OA Green Published, Green Submitted, gold
DA 2025-01-12
ER

PT J
AU Díaz-Valdivia, NI
   Calderón, CC
   Díaz, JE
   Lobos-González, L
   Sepulveda, H
   Ortíz, RJ
   Martinez, S
   Silva, V
   Maldonado, HJ
   Silva, P
   Wehinger, S
   Burzio, VA
   Torres, VA
   Montecino, M
   Leyton, L
   Quest, AFG
AF Diaz-Valdivia, Natalia I.
   Calderon, Claudia C.
   Diaz, Jorge E.
   Lobos-Gonzalez, Lorena
   Sepulveda, Hugo
   Ortiz, Rina J.
   Martinez, Samuel
   Silva, Veronica
   Maldonado, Horacio J.
   Silva, Patricio
   Wehinger, Sergio
   Burzio, Veronica A.
   Torres, Vicente A.
   Montecino, Martin
   Leyton, Lisette
   Quest, Andrew F. G.
TI Anti-neoplastic drugs increase caveolin-1-dependent migration, invasion
   and metastasis of cancer cells
SO ONCOTARGET
LA English
DT Article
DE caveolin-1; epigenetic silencing; chemotherapy; cell signaling; reactive
   oxygen species
ID TYROSINE PHOSPHORYLATION; UP-REGULATION; LIPID RAFTS; SRC KINASE; TUMOR;
   MECHANISMS; CAVEOLAE; ACTIVATION; EXPRESSION; PROMOTER
AB Expression of the scaffolding protein Caveolin-1 (CAV1) enhances migration and invasion of metastatic cancer cells. Yet, CAV1 also functions as a tumor suppressor in early stages of cancer, where expression is suppressed by epigenetic mechanisms. Thus, we sought to identify stimuli/ mechanisms that revert epigenetic CAV1 silencing in cancer cells and evaluate how this affects their metastatic potential. We reasoned that restricted tissue availability of anti-neoplastic drugs during chemotherapy might expose cancer cells to sub-therapeutic concentrations, which activate signaling pathways and the expression of CAV1 to favor the acquisition of more aggressive traits. Here, we used in vitro [2D, invasion] and in vivo (metastasis) assays, as well as genetic and biochemical approaches to address this question. Colon and breast cancer cells were identified where CAV1 levels were low due to epigenetic suppression and could be reverted by treatment with the methyltransferase inhibitor 5'-azacytidine. Exposure of these cells to anti-neoplastic drugs for short periods of time (24-48 h) increased CAV1 expression through ROS production and MEK/ ERK activation. In colon cancer cells, increased CAV1 expression enhanced migration and invasion in vitro via pathways requiring Src-family kinases, as well as Rac-1 activity. Finally, elevated CAV1 expression in colon cancer cells following exposure in vitro to sub-cytotoxic drug concentrations increased their metastatic potential in vivo. Therefore exposure of cancer cells to anti-neoplastic drugs at non-lethal drug concentrations induces signaling events and changes in transcription that favor CAV1-dependent migration, invasion and metastasis. Importantly, this may occur in the absence of selection for drug-resistance.
C1 [Diaz-Valdivia, Natalia I.; Calderon, Claudia C.; Diaz, Jorge E.; Lobos-Gonzalez, Lorena; Ortiz, Rina J.; Martinez, Samuel; Maldonado, Horacio J.; Leyton, Lisette; Quest, Andrew F. G.] Univ Chile, Adv Ctr Chron Dis ACCDiS, Ctr Mol Studies Cell CEMC, Cellular Commun Lab,Fac Med, Santiago, Chile.
   [Diaz, Jorge E.; Silva, Patricio; Torres, Vicente A.] Univ Chile, Inst Res Dent Sci, Fac Dent, Santiago, Chile.
   [Lobos-Gonzalez, Lorena; Silva, Veronica; Burzio, Veronica A.] Fdn Ciencia & Vida, Santiago, Chile.
   [Wehinger, Sergio] Univ Talca, Interdisciplinary Excellence Res Program Hlth Age, Fac Hlth Sci, Talca, Chile.
   [Sepulveda, Hugo; Montecino, Martin] Univ Andres Bello, Fac Biol Sci, Ctr Biomed Res, Gene Regulat Lab, Santiago, Chile.
   [Sepulveda, Hugo; Montecino, Martin] Univ Andres Bello, Fac Med, Santiago, Chile.
   [Burzio, Veronica A.] Univ Andres Bello, Fac Biol Sci, Santiago, Chile.
   [Ortiz, Rina J.] Univ Bernardo O Higgins, Fac Salud, Dept Ciencias Quim & Biol, Santiago, Chile.
C3 Universidad de Chile; Universidad de Chile; Universidad de Talca;
   Universidad Andres Bello; Universidad Andres Bello; Universidad Andres
   Bello; Universidad  Bernardo O'Higgins
RP Leyton, L; Quest, AFG (通讯作者)，Univ Chile, Adv Ctr Chron Dis ACCDiS, Ctr Mol Studies Cell CEMC, Cellular Commun Lab,Fac Med, Santiago, Chile.
EM lleyton@med.uchile.cl; aquest@med.uchile.cl
RI Torres, Vicente/I-2437-2013; Burzio, Veronica/HTP-0034-2023; Díaz
   Valdivia, Natalia/Z-1893-2019; Diban, Rina/T-6123-2019; wehinger,
   sergio/L-3610-2017
OI wehinger, sergio/0000-0001-7021-3544; Montecino,
   Martin/0000-0002-6025-0023; Diaz Valdivia, Natalia/0000-0002-8063-2598;
   Torres, Vicente A/0000-0002-5973-7248; Lobos-Gonzalez,
   Lorena/0000-0002-4957-9864; Maldonado, Horacio/0000-0002-7017-5215
FU CONICYT-FONDAP [15130011, 15090007]; FONDECYT [1130250, 1170925,
   1150744, 1140907, 11140204]; Anillo ACT [1111]; CONICYT; BASAL
   CCTE-PFB16 CONICYT
FX This work was supported by CONICYT-FONDAP 15130011 (AFGQ), FONDECYT
   1130250, 1170925 (AFGQ), Anillo ACT 1111 (AFGQ), CONICYT-FONDAP 15090007
   (MM), FONDECYT 1150744 (LL), FONDECYT 1140907 (VAT), and CONICYT PhD
   fellowships (NDV, RO, JD, HM, PS), FONDECYT 11140204 (LLG), BASAL
   CCTE-PFB16 CONICYT (LLG, VB).
CR Alevizos L, 2014, CLIN EXP METASTAS, V31, P511, DOI 10.1007/s10585-014-9645-6
   Arora H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064273
   Bender FC, 2000, CANCER RES, V60, P5870
   Bitar MS, 2013, AM J PHYSIOL-ENDOC M, V305, pE951, DOI 10.1152/ajpendo.00189.2013
   Böhle AS, 1999, LANGENBECK ARCH SURG, V384, P133, DOI 10.1007/s004230050183
   Boscher C, 2012, ADV EXP MED BIOL, V729, P29, DOI 10.1007/978-1-4614-1222-9_3
   Bragado P, 2007, APOPTOSIS, V12, P1733, DOI 10.1007/s10495-007-0082-8
   Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111
   Cao HM, 2004, EXP CELL RES, V294, P159, DOI 10.1016/j.yexcr.2003.11.010
   Carlin SM, 2005, FASEB J, V19, P195, DOI 10.1096/fj.04-1644com
   Castaldo SA, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/8413032
   Chetram MA., 2013, Front Biol (Beijing), V8, P273, DOI [10.1007/s11515-012-1204-4, DOI 10.1007/S11515-012-1204-4]
   Chiarugi P, 2007, CELL SIGNAL, V19, P672, DOI 10.1016/j.cellsig.2006.11.009
   Coccolini F, 2013, WORLD J GASTROENTERO, V19, P6979, DOI 10.3748/wjg.v19.i41.6979
   Coley HM, 2008, CANCER TREAT REV, V34, P378, DOI 10.1016/j.ctrv.2008.01.007
   Dasgupta N, 2015, EXP CELL RES, V334, P323, DOI 10.1016/j.yexcr.2015.03.020
   Deregowski V, 2002, BIOCHEM PHARMACOL, V64, P873, DOI 10.1016/S0006-2952(02)01151-6
   Díaz J, 2014, J CELL SCI, V127, P2401, DOI 10.1242/jcs.141689
   Diaz-Valdivia N, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1477-5
   Donkó A, 2005, PHILOS T R SOC B, V360, P2301, DOI 10.1098/rstb.2005.1767
   Engelman JA, 1999, J BIOL CHEM, V274, P32333, DOI 10.1074/jbc.274.45.32333
   Geho DH, 2005, PHYSIOLOGY, V20, P194, DOI 10.1152/physiol.00009.2005
   Gogvadze V, 2008, TRENDS CELL BIOL, V18, P165, DOI 10.1016/j.tcb.2008.01.006
   Grande-García A, 2007, J CELL BIOL, V177, P683, DOI 10.1083/jcb.200701006
   Hagenbuchner J, 2012, J CELL SCI, V125, P1191, DOI 10.1242/jcs.092098
   Han E, 2015, UROL CASE REP, V3, P170, DOI 10.1016/j.eucr.2015.06.008
   Ho CC, 2002, AM J PATHOL, V161, P1647, DOI 10.1016/S0002-9440(10)64442-2
   Hoek KS, 2010, PIGM CELL MELANOMA R, V23, P746, DOI 10.1111/j.1755-148X.2010.00757.x
   Holmström KM, 2014, NAT REV MOL CELL BIO, V15, P411, DOI 10.1038/nrm3801
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   Joshi B, 2008, CANCER RES, V68, P8210, DOI 10.1158/0008-5472.CAN-08-0343
   Kai WC, 2001, AM J PATHOL, V159, P1635, DOI 10.1016/S0002-9440(10)63010-6
   Kodama R, 2013, GENES CELLS, V18, P32, DOI 10.1111/gtc.12015
   KOLESKE AJ, 1995, P NATL ACAD SCI USA, V92, P1381, DOI 10.1073/pnas.92.5.1381
   Labrecque L, 2004, J BIOL CHEM, V279, P52132, DOI 10.1074/jbc.M409617200
   Lavie Y, 1998, J BIOL CHEM, V273, P32380, DOI 10.1074/jbc.273.49.32380
   Lavie Y, 2000, GLYCOCONJUGATE J, V17, P253, DOI 10.1023/A:1026553626537
   Lee H, 2000, MOL ENDOCRINOL, V14, P1750, DOI 10.1210/me.14.11.1750
   Lee SW, 1998, ONCOGENE, V16, P1391, DOI 10.1038/sj.onc.1201661
   Lee YS, 2015, EVID-BASED COMPL ALT, V2015, DOI 10.1155/2015/520578
   Li SW, 1996, J BIOL CHEM, V271, P3863
   Lin SY, 2004, ANTICANCER RES, V24, P1645
   Liou GY, 2010, FREE RADICAL RES, V44, P479, DOI 10.3109/10715761003667554
   Lobos-Gonzalez L, 2014, MELANOMA RES, V24, P108, DOI 10.1097/CMR.0000000000000046
   Lobos-González L, 2013, PIGM CELL MELANOMA R, V26, DOI 10.1111/pcmr.12085
   Ma YD, 2016, ENVIRON TOXICOL PHAR, V48, P63, DOI 10.1016/j.etap.2016.10.005
   Martin S, 2009, BBA-MOL CELL RES, V1793, P354, DOI 10.1016/j.bbamcr.2008.09.019
   Miyazono Y, 2004, SCAND J GASTROENTERO, V39, P1119, DOI 10.1080/00365520410003605
   Mohn Fabio, 2009, V507, P55, DOI 10.1007/978-1-59745-522-0_5
   Monteiro HP, 2000, FREE RADICAL BIO MED, V28, P174, DOI 10.1016/S0891-5849(99)00233-6
   Morton DB, 1995, ATLA-ALTERN LAB ANIM, V23, P812
   Núñez C, 2016, BIOMATERIALS, V97, P34, DOI 10.1016/j.biomaterials.2016.04.027
   Núñez-Wehinger S, 2014, CURR MOL MED, V14, P255, DOI 10.2174/1566524014666140128112827
   Ortiz R, 2016, ONCOTARGET, V7, P40571, DOI 10.18632/oncotarget.9738
   Pérez P, 2000, ARTHRITIS RHEUM-US, V43, P2807, DOI 10.1002/1529-0131(200012)43:12<2807::AID-ANR22>3.0.CO;2-M
   Quest AFG, 2004, BIOCHEM CELL BIOL, V82, P129, DOI 10.1139/o03-071
   Quest AFG, 2008, J CELL MOL MED, V12, P1130, DOI 10.1111/j.1582-4934.2008.00331.x
   Ren BJ, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17010041
   Rizzo V, 2003, AM J PHYSIOL-HEART C, V285, pH1720, DOI 10.1152/ajpheart.00344.2002
   Selga E, 2008, BMC MED GENOMICS, V1, DOI 10.1186/1755-8794-1-35
   Shen HM, 2006, FASEB J, V20, P1589, DOI 10.1096/fj.05-5603rev
   Singh A, 2016, CELL MOL IMMUNOL, V13, P747, DOI 10.1038/cmi.2015.62
   Sloan KA, 2009, CARCINOGENESIS, V30, P1433, DOI 10.1093/carcin/bgp129
   Storz P, 2005, FRONT BIOSCI-LANDMRK, V10, P1881, DOI 10.2741/1667
   Sunaga N, 2001, GENE CHROMOSOME CANC, V30, P316, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1097>3.0.CO;2-9
   Tencer L, 2008, ANTICANCER RES, V28, P895
   Thompson TC, 2010, PROSTATE CANCER P D, V13, P6, DOI 10.1038/pcan.2009.29
   Thompson TC, 1999, APOPTOSIS, V4, P233, DOI 10.1023/A:1009612708099
   Torres VA, 2007, MOL CELL BIOL, V27, P7703, DOI 10.1128/MCB.01991-06
   Townsend Paul, 1995, ILAR J, V37, P68
   Urra H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033085
   Weber M, 2005, NAT GENET, V37, P853, DOI 10.1038/ng1598
   Yuan SQ, 2016, BIOMED PHARMACOTHER, V84, P1776, DOI 10.1016/j.biopha.2016.10.104
   Zhang S, 2016, TUMOR BIOL, V37, P9189, DOI 10.1007/s13277-015-4778-z
NR 74
TC 15
Z9 15
U1 0
U2 10
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD DEC 19
PY 2017
VL 8
IS 67
BP 111943
EP 111965
DI 10.18632/oncotarget.22955
PG 23
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA FS1VO
UT WOS:000419567000096
PM 29340103
OA Green Published, gold, Green Submitted
DA 2025-01-12
ER

PT J
AU Elsherbini, AM
   Mohammed, MAR
   Ibrahim, FM
AF Elsherbini, Amira M.
   Mohammed, Mohammed A. R.
   Ibrahim, Fatma M.
TI Effect of Biochanin A versus 17β estradiol in rat submandibular salivary
   gland
SO JOURNAL OF ORAL SCIENCE
LA English
DT Article
DE Biochanin A; 17 beta estradiol; dimethyl sulfoxide; submandibular
   salivary gland; morphogenesis; endocrinal disruptor
ID EPIDERMAL-GROWTH-FACTOR; BREAST-CANCER CELLS; ESTROGEN-RECEPTOR-ALPHA;
   MESSENGER-RNA; FEMALE RATS; IN-VITRO; APOPTOSIS; BETA; PHYTOESTROGENS;
   EXPRESSION
AB The epigenetic nature of development mandates the observation of the effect of any exogenous substance, especially those with estrogenic activities, during critical phases of development. The submandibular gland (SMG) presents as a great model due to extensive postnatal development, and is known to be regulated and affected by hormones as well as growth factors. Herein, we observed postnatal development following low doses of Biochanin A (BCA) and 17 beta estradiol (E2) in rats. The pups were randomly divided into four groups: control, BCA, E2, and dimethyl sulfoxide (DMSO), and euthanized at the 6th, 15th, 30th, and 60th postnatal days (PND). SMG morphogenesis was assessed. The nuclear expression of estrogen receptor beta (ER beta) was evaluated immunohistochemically; ER beta expression was up-regulated by BCA and down-regulated by E2. Similarly, caspase three gene expression, assessed by real time polymerase chain reaction was increased in the BCA group but decreased in the E2 group. A significant decrease in epidermal growth factor gene expression was noted at PND 30. The results presented by this study provide evidence that the effect of a postnatal exposure of the SMG to Biochanin A during development could be linked to sex hormone-dependent disorders.
C1 [Elsherbini, Amira M.; Mohammed, Mohammed A. R.; Ibrahim, Fatma M.] Mansoura Univ, Fac Dent, Oral Biol Dept, Elgomhoria St, Mansoura 35516, Egypt.
C3 Egyptian Knowledge Bank (EKB); Mansoura University
RP Elsherbini, AM (通讯作者)，Mansoura Univ, Fac Dent, Oral Biol Dept, Elgomhoria St, Mansoura 35516, Egypt.
EM dramiraelsherbini2014@gmail.com
RI abdo, mohammed/ABD-2224-2020; Elsherbini, Amira/M-7018-2018;
   Abdulrahman, Mohamed/O-6384-2018
OI Abdulrahman, Mohamed/0000-0002-2986-4051; elsherbini,
   amira/0000-0001-7960-3557
CR Bhattacharyya J., 2005, TJPS, V18, P28
   Cestari Tania Mary, 2005, Brazilian Journal of Morphological Sciences, V22, P161
   Chen FP, 2014, CLIMACTERIC, V17, P385, DOI 10.3109/13697137.2013.869671
   Christoforou P, 2014, MOL MED, V20, P427, DOI 10.2119/molmed.2014.00105
   Da YM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121470
   de Ménorval MA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041733
   de Rijk EPCT, 2003, TOXICOL PATHOL, V31, P1, DOI 10.1080/01926230390173798
   Denny PC, 1997, CRIT REV ORAL BIOL M, V8, P51, DOI 10.1177/10454411970080010301
   Dornstauder E, 2001, J STEROID BIOCHEM, V78, P67, DOI 10.1016/S0960-0760(01)00075-9
   Galvao J, 2014, FASEB J, V28, P1317, DOI 10.1096/fj.13-235440
   GARDNER RM, 1989, J STEROID BIOCHEM, V32, P339, DOI 10.1016/0022-4731(89)90205-7
   GRESIK EW, 1994, MICROSC RES TECHNIQ, V27, P1, DOI 10.1002/jemt.1070270102
   Gresik EW, 1996, EUR J MORPHOL, V34, P221, DOI 10.1076/ejom.34.3.221.13033
   Guidozzi F, 2014, SAMJ S AFR MED J, V104, P537, DOI [10.7196/SAMJ.8423, 10.7196/samj.8423]
   Habermann H, 2001, ENDOCRINOLOGY, V142, P359, DOI 10.1210/en.142.1.359
   Han HJ, 2006, AM J PHYSIOL-CELL PH, V290, pC1067, DOI 10.1152/ajpcell.00222.2005
   Harris DM, 2005, EXP BIOL MED, V230, P558, DOI 10.1177/153537020523000807
   Hayashi H, 2000, J HISTOCHEM CYTOCHEM, V48, P695, DOI 10.1177/002215540004800513
   Hecht R, 2000, ANAT REC, V258, P349, DOI 10.1002/(SICI)1097-0185(20000401)258:4<349::AID-AR3>3.0.CO;2-9
   HEYDERMAN E, 1979, J CLIN PATHOL, V32, P971, DOI 10.1136/jcp.32.10.971
   HUETHUDSON YM, 1990, MOL ENDOCRINOL, V4, P510, DOI 10.1210/mend-4-3-510
   IGNARTROWBRIDGE DM, 1992, P NATL ACAD SCI USA, V89, P4658, DOI 10.1073/pnas.89.10.4658
   Jefferson WN, 2002, J CHROMATOGR B, V777, P179, DOI 10.1016/S1570-0232(02)00493-2
   Jonjic S, 2001, Curr Protoc Immunol, VChapter 1, DOI 10.1002/0471142735.im0111s43
   Klinge CM, 2001, NUCLEIC ACIDS RES, V29, P2905, DOI 10.1093/nar/29.14.2905
   Kole L, 2011, EUR J PHARMACOL, V653, P8, DOI 10.1016/j.ejphar.2010.11.026
   Kouidhi W, 2012, TOXICOL PATHOL, V40, P593, DOI 10.1177/0192623311436183
   Kuranaga E, 2012, GENES CELLS, V17, P83, DOI 10.1111/j.1365-2443.2011.01579.x
   Kuranaga E, 2011, DEV GROWTH DIFFER, V53, P137, DOI 10.1111/j.1440-169X.2010.01237.x
   Levin ER, 2005, MOL ENDOCRINOL, V19, P1951, DOI 10.1210/me.2004-0390
   Lin VC, 2011, BIOSCI BIOTECH BIOCH, V75, P914, DOI 10.1271/bbb.100878
   Mansoor TA, 2011, PHYTOTHER RES, V25, P1819, DOI 10.1002/ptr.3498
   Mishra P, 2009, PHYTOTHER RES, V23, P972, DOI 10.1002/ptr.2733
   Miura M., 2012, COLD SPRING HARB PER, V4
   Moon YJ, 2008, PHARM RES-DORDR, V25, P2158, DOI 10.1007/s11095-008-9583-6
   Öz OK, 2000, J BONE MINER RES, V15, P507, DOI 10.1359/jbmr.2000.15.3.507
   Patisaul HB, 1999, MOL BRAIN RES, V67, P165, DOI 10.1016/S0169-328X(99)00058-3
   Pelekanou V, 2011, INT J DEV BIOL, V55, P869, DOI 10.1387/ijdb.113369vp
   SAKABE K, 1988, ENDOCRINOL JAPON, V35, P709
   SAKABE K, 1987, Tokai Journal of Experimental and Clinical Medicine, V12, P353
   SIMINOSKI K, 1993, ENDOCRINOLOGY, V132, P2031, DOI 10.1210/en.132.5.2031
   Singhal P, 2016, J CLIN DIAGN RES, V10, pZC28, DOI 10.7860/JCDR/2016/19007.8236
   Smith CL, 2004, ENDOCR REV, V25, P45, DOI 10.1210/er.2003-0023
   TANAKA M, 1995, BIOCHEM BIOPH RES CO, V213, P550, DOI 10.1006/bbrc.1995.2166
   Tsinti M, 2009, EUR J ORAL SCI, V117, P498, DOI 10.1111/j.1600-0722.2009.00659.x
   Twombly R, 2011, J NATL CANCER I, V103, P920, DOI 10.1093/jnci/djr233
   Umehara K, 2009, J NAT PROD, V72, P2163, DOI 10.1021/np900676y
   Willard SP, 1998, ENDOCRINE, V8, P117, DOI 10.1385/ENDO:8:2:117
   Youssef MM, 2016, SCI REP-UK, V6, DOI 10.1038/srep30717
   Yuan C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107447
   Yue W, 1998, CANCER RES, V58, P927
NR 51
TC 2
Z9 2
U1 0
U2 1
PU NIHON UNIV, SCHOOL DENTISTRY
PI TOYKO
PA 1--13 KANDA-SURUGADAI, CHIYODA-KU, TOYKO, 101-8310, JAPAN
SN 1343-4934
EI 1880-4926
J9 J ORAL SCI
JI J. Oral Sci.
PD DEC
PY 2017
VL 59
IS 4
BP 579
EP 588
DI 10.2334/josnusd.16-0651
PG 10
WC Dentistry, Oral Surgery & Medicine; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Dentistry, Oral Surgery & Medicine; Materials Science
GA FT6AH
UT WOS:000423234500017
PM 28993577
OA gold
DA 2025-01-12
ER

PT J
AU Choi, SK
   Pandiyan, K
   Eun, JW
   Yang, X
   Hong, SH
   Nam, SW
   Jones, PA
   Liang, G
   You, JS
AF Choi, Sung Kyung
   Pandiyan, Kurinji
   Eun, Jung Woo
   Yang, Xiaojing
   Hong, Seong Hwi
   Nam, Suk Woo
   Jones, Peter A.
   Liang, Gangning
   You, Jueng Soo
TI Epigenetic landscape change analysis during human EMT sheds light on a
   key EMT mediator TRIM29
SO ONCOTARGET
LA English
DT Article
DE epigenetic landscape; EMT; DNA methylation; chromatin accessibility;
   TRIM29
ID EPITHELIAL-MESENCHYMAL TRANSITION; BREAST-CANCER; HUMAN GENOME; DNA
   DEMETHYLATION; GENE-EXPRESSION; STEM-CELLS; METHYLATION; CHROMATIN;
   DISEASE; TARGET
AB Epithelial to mesenchymal transition (EMT) is a key trans-differentiation process, which plays a critical role in physiology and pathology. Although gene expression changes in EMT have been scrutinized, study of epigenome is in its infancy. To understand epigenetic changes during TWIST-driven EMT, we used the AcceSssIble assay to study DNA methylation and chromatin accessibility in human mammary epithelial cells (HMECs). The DNA methylation changes were found to have functional significance in EMT-i.e. methylated genes were enriched for E-box motifs that can be recognized by TWIST, at the promoters suggesting a potential targeting phenomenon, whereas the demethylated regions were enriched for prometastatic genes, supporting the role of EMT in metastasis. TWIST-induced EMT triggers alterations in chromatin accessibility both independent of and dependent on DNA methylation changes, primarily resulting in closed chromatin conformation. By overlapping the genes, whose chromatin structure is changed during early EMT and a known "core EMT signature", we identified 18 driver candidate genes during EMT, 14 upregulated and 4 downregulated genes with corresponding chromatin structure changes. Among 18 genes, we focused on TRIM29 as a novel marker of EMT. Although loss of TRIM29 is insufficient to suppress CDH, it is enough to induce CDH2 and VIM. Gene functional annotation analysis shows the involvement of TRIM29 in epidermal development, cell differentiation and cell migration. Taken together, our results provide a robust snapshot of chromatin state during human EMT and identify TRIM29 as a core mediator of EMT.
C1 [Choi, Sung Kyung; Hong, Seong Hwi; You, Jueng Soo] Konkuk Univ, Sch Med, Dept Biochem, Seoul, South Korea.
   [Pandiyan, Kurinji; Yang, Xiaojing; Liang, Gangning] Univ Southern Calif, Keck Sch Med, Dept Urol, Los Angeles, CA USA.
   [Pandiyan, Kurinji] Johns Hopkins Sch Med, Dept Oncol, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA.
   [Eun, Jung Woo; Nam, Suk Woo] Catholic Univ, Dept Pathol, Coll Med, Seoul, South Korea.
   [Jones, Peter A.] Van Andel Res Inst, Grand Rapids, MI USA.
   [You, Jueng Soo] KonKuk Univ, Res Inst Med Sci, Sch Med, Seoul, South Korea.
C3 Konkuk University; Konkuk University Medical Center; University of
   Southern California; Johns Hopkins University; Johns Hopkins Medicine;
   Catholic University of Korea; Van Andel Institute; Konkuk University;
   Konkuk University Medical Center
RP You, JS (通讯作者)，Konkuk Univ, Sch Med, Dept Biochem, Seoul, South Korea.; You, JS (通讯作者)，KonKuk Univ, Res Inst Med Sci, Sch Med, Seoul, South Korea.
EM jsyou@kku.ac.kr
RI Eun, Jung Woo/ABB-5127-2020
FU Basic Science Research Program through the National Research Foundation
   of Korea (NRF) - Ministry of Science, ICT & Future Planning
   [2016R1C1B3007534, 2016R1A5A2012284]
FX This research was supported by the Basic Science Research Program
   through the National Research Foundation of Korea (NRF) funded by the
   Ministry of Science, ICT & Future Planning (2016R1C1B3007534 and
   2016R1A5A2012284)
CR Ai LB, 2014, CANCER RES, V74, P4875, DOI 10.1158/0008-5472.CAN-13-3579
   Nieto MA, 2013, SCIENCE, V342, P708, DOI 10.1126/science.1234850
   Bai L, 2010, TRENDS GENET, V26, P476, DOI 10.1016/j.tig.2010.08.003
   Barski A, 2007, CELL, V129, P823, DOI 10.1016/j.cell.2007.05.009
   Baylin SB, 2011, NAT REV CANCER, V11, P726, DOI 10.1038/nrc3130
   Brosh R, 2013, CELL DEATH DIFFER, V20, P312, DOI 10.1038/cdd.2012.125
   De Craene B, 2013, NAT REV CANCER, V13, P97, DOI 10.1038/nrc3447
   Elenbaas B, 2001, GENE DEV, V15, P50, DOI 10.1101/gad.828901
   Fougerousse F, 2000, HUM MOL GENET, V9, P165, DOI 10.1093/hmg/9.2.165
   Ginis I, 2004, DEV BIOL, V269, P360, DOI 10.1016/j.ydbio.2003.12.034
   Giresi PG, 2007, GENOME RES, V17, P877, DOI 10.1101/gr.5533506
   Hatakeyama S, 2011, NAT REV CANCER, V11, P792, DOI 10.1038/nrc3139
   Jackson SP, 2009, NATURE, V461, P1071, DOI 10.1038/nature08467
   Kelly TK, 2012, GENOME RES, V22, P2497, DOI 10.1101/gr.143008.112
   Kilgore JA, 2007, METHODS, V41, P320, DOI 10.1016/j.ymeth.2006.08.008
   Kolesnikoff N, 2014, J BIOL CHEM, V289, P11194, DOI 10.1074/jbc.M113.529172
   Kosaka Y, 2007, ANN SURG ONCOL, V14, P2543, DOI 10.1245/s10434-007-9461-1
   Liu J, 2012, AM J PATHOL, V180, P839, DOI 10.1016/j.ajpath.2011.10.020
   Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027
   Masuda Y, 2015, BBA-MOL CELL RES, V1853, P2296, DOI 10.1016/j.bbamcr.2015.05.035
   Masuda Y, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8299
   McDonald OG, 2011, NAT STRUCT MOL BIOL, V18, P867, DOI 10.1038/nsmb.2084
   Nam EH, 2014, CARCINOGENESIS, V35, P302, DOI 10.1093/carcin/bgt340
   Pandiyan K, 2013, NUCLEIC ACIDS RES, V41, P3973, DOI 10.1093/nar/gkt077
   Sadeh R, 2011, CELL, V147, P263, DOI 10.1016/j.cell.2011.09.042
   Sandoval J, 2011, EPIGENETICS-US, V6, P692, DOI 10.4161/epi.6.6.16196
   Savagner P, 1997, J CELL BIOL, V137, P1403, DOI 10.1083/jcb.137.6.1403
   Schones DE, 2008, CELL, V132, P887, DOI 10.1016/j.cell.2008.02.022
   Segal E, 2009, TRENDS GENET, V25, P335, DOI 10.1016/j.tig.2009.06.002
   Sharma S, 2010, CARCINOGENESIS, V31, P27, DOI 10.1093/carcin/bgp220
   Stefanis L, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a009399
   Stephens K, 1997, J INVEST DERMATOL, V108, P349, DOI 10.1111/1523-1747.ep12286486
   Taberlay PC, 2011, CELL, V147, P1283, DOI 10.1016/j.cell.2011.10.040
   Tam WL, 2013, NAT MED, V19, P1438, DOI 10.1038/nm.3336
   Taube JH, 2010, P NATL ACAD SCI USA, V107, P15449, DOI 10.1073/pnas.1004900107
   Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007
   Thiery JP, 2006, NAT REV MOL CELL BIO, V7, P131, DOI 10.1038/nrm1835
   Tiwari N, 2012, SEMIN CANCER BIOL, V22, P194, DOI 10.1016/j.semcancer.2012.02.013
   Villavicencio EH, 2002, GENESIS, V32, P247, DOI 10.1002/gene.10078
   Wu CY, 2012, TRENDS GENET, V28, P454, DOI 10.1016/j.tig.2012.05.005
   Wu SC, 2010, NAT REV MOL CELL BIO, V11, P607, DOI 10.1038/nrm2950
   Yang XJ, 2014, CANCER CELL, V26, P577, DOI 10.1016/j.ccr.2014.07.028
   You JS, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003459
   You JS, 2011, P NATL ACAD SCI USA, V108, P14497, DOI 10.1073/pnas.1111309108
   Yuan ZG, 2010, MOL CELL BIOL, V30, P3004, DOI 10.1128/MCB.01023-09
   Zhou ZY, 2012, J CHIN MED ASSOC, V75, P269, DOI 10.1016/j.jcma.2012.04.015
NR 46
TC 14
Z9 17
U1 0
U2 7
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD NOV 17
PY 2017
VL 8
IS 58
BP 98322
EP 98335
DI 10.18632/oncotarget.21681
PG 14
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA FR9KJ
UT WOS:000419392300049
PM 29228692
OA Green Submitted, Green Published, gold
DA 2025-01-12
ER

PT J
AU Kolendowski, B
   Hassan, H
   Krstic, M
   Isovic, M
   Thillainadesan, G
   Chambers, AF
   Tuck, AB
   Torchia, J
AF Kolendowski, Bart
   Hassan, Haider
   Krstic, Milica
   Isovic, Majdina
   Thillainadesan, Gobi
   Chambers, Ann F.
   Tuck, Alan B.
   Torchia, Joseph
TI Genome-wide analysis reveals a role for TDG in estrogen
   receptor-mediated enhancer RNA transcription and 3-dimensional
   reorganization
SO EPIGENETICS & CHROMATIN
LA English
DT Article
DE Cancer; Thymine DNA glycosylase; Estrogen receptor; eRNA; Estrogen
   signaling
ID THYMINE-DNA GLYCOSYLASE; BREAST-CANCER; EPIGENETIC SIGNATURES;
   ACTIVE-DEMETHYLATION; TUMOR-SUPPRESSOR; METHYLATION; 5-CARBOXYLCYTOSINE;
   5-FORMYLCYTOSINE; GENES; ALPHA
AB Background: The estrogen receptor (ER) is a ligand-dependant transcription factor expressed in many breast cancers and is the target of many endocrine-based cancer therapies. Genome-wide studies have shown that the ER binds to gene-specific enhancer regions in response to beta-estradiol (E2) which undergo transcription producing noncoding enhancer RNA (eRNA). While eRNAs are important for transcriptional activation of neighboring genes, the mechanism remains poorly understood.
   Results: Using ChIP-Seq we generate a global profile of thymine DNA glycosylase (TDG), an ER coactivator that plays an essential role in DNA demethylation, in response to E2 in the MCF7 breast cancer cell line. Remarkably, we found that in response to E2 TDG localized to enhancers which also recruit ERa, RNA Pol II and other coregulators and which are marked by histone modifications indicative of active enhancers. Importantly, depletion of TDG inhibits E2-mediated transcription of eRNAs and transcription of ER-target genes. Functionally, we find that TDG both sensitizes MCF7 cells to tamoxifen-mediated cytostasis and increases migration and invasion of MCF7 cells.
   Conclusions: Taken together we find that TDG plays a central role in mediating transcription at a subset of enhancers and governs how MCF7 cells respond to both estrogenic and anti-estrogenic compounds and may be an effective therapeutic target.
C1 [Kolendowski, Bart; Hassan, Haider; Thillainadesan, Gobi; Torchia, Joseph] Western Univ, Dept Biochem, London, ON, Canada.
   [Kolendowski, Bart; Hassan, Haider; Isovic, Majdina; Thillainadesan, Gobi; Tuck, Alan B.; Torchia, Joseph] Western Univ, Dept Oncol, London, ON, Canada.
   [Krstic, Milica; Tuck, Alan B.] Western Univ, Dept Pathol, London, ON, Canada.
   [Kolendowski, Bart; Hassan, Haider; Krstic, Milica; Chambers, Ann F.; Torchia, Joseph] Western Univ, London Reg Canc Program, London, ON, Canada.
   [Kolendowski, Bart; Hassan, Haider; Krstic, Milica; Chambers, Ann F.; Torchia, Joseph] Western Univ, Lawson Hlth Res Inst, London, ON, Canada.
   [Torchia, Joseph] London Reg Canc Program, Canc Res Lab, London, ON N6A 4L6, Canada.
C3 Western University (University of Western Ontario); Western University
   (University of Western Ontario); Western University (University of
   Western Ontario); Western University (University of Western Ontario);
   Western University (University of Western Ontario); Western University
   (University of Western Ontario)
RP Torchia, J (通讯作者)，Western Univ, Dept Biochem, London, ON, Canada.; Torchia, J (通讯作者)，Western Univ, Dept Oncol, London, ON, Canada.; Torchia, J (通讯作者)，Western Univ, London Reg Canc Program, London, ON, Canada.; Torchia, J (通讯作者)，Western Univ, Lawson Hlth Res Inst, London, ON, Canada.; Torchia, J (通讯作者)，London Reg Canc Program, Canc Res Lab, London, ON N6A 4L6, Canada.
EM jtorchia@uwo.ca
FU Canadian Institutes of Health Research [MOP84423]; Cancer Research and
   Technology Transfer (CARTT) Studentship; Translational Breast Cancer
   Research Unit of the London Regional Cancer Program - Breast Cancer
   Society of Canada; Ontario Graduate Scholarships (OGS); WorldDiscoveries
   Scholarship
FX This work was supported by operating grants from the Canadian Institutes
   of Health Research, grant numbers MOP84423 JT. BK was supported by a
   Cancer Research and Technology Transfer (CARTT) Studentship. BK and MK
   are supported by Studentships from the Translational Breast Cancer
   Research Unit of the London Regional Cancer Program, funded by the
   Breast Cancer Society of Canada. HH was supported by Ontario Graduate
   Scholarships (OGS) and a WorldDiscoveries Scholarship.
CR [Anonymous], 2014, BMC CANCER
   Aran D, 2013, CELL, V154, P11, DOI 10.1016/j.cell.2013.06.018
   Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X
   Borley AC, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2206
   Chen DS, 2003, J BIOL CHEM, V278, P38586, DOI 10.1074/jbc.M304286200
   Chen KF, 2015, NAT GENET, V47, P1149, DOI 10.1038/ng.3385
   Cortázar D, 2011, NATURE, V470, P419, DOI 10.1038/nature09672
   Cortellino S, 2011, CELL, V146, P67, DOI 10.1016/j.cell.2011.06.020
   Creyghton MP, 2010, P NATL ACAD SCI USA, V107, P21931, DOI 10.1073/pnas.1016071107
   DEPASQUALE JA, 1994, J CELL SCI, V107, P1241
   Ehrlich M, 1982, NUCL ACIDS, V10, P11
   Farooq A, 2015, CURR TOP MED CHEM, V15, P1372, DOI 10.2174/1568026615666150413154841
   Haaf T, 2006, CURR TOP MICROBIOL, V310, P13
   Hagège H, 2007, NAT PROTOC, V2, P1722, DOI 10.1038/nprot.2007.243
   Hashimoto H, 2013, DNA REPAIR, V12, P535, DOI 10.1016/j.dnarep.2013.04.003
   Hassan HM, 2017, CELL REP, V19, P1685, DOI 10.1016/j.celrep.2017.05.007
   Hsieh C-L, 2014, P NATL ACAD SCI USA, V111, P1
   Hsu PD, 2014, CELL, V157, P1262, DOI 10.1016/j.cell.2014.05.010
   Ito S, 2011, SCIENCE, V333, P1300, DOI 10.1126/science.1210597
   Jin CL, 2015, EPIGENETICS-US, V10, P1006, DOI 10.1080/15592294.2015.1091145
   KUBOTA T, 1983, JPN J SURG, V13, P381, DOI 10.1007/BF02469523
   Li WB, 2013, NATURE, V498, P516, DOI 10.1038/nature12210
   Lupien M, 2008, CELL, V132, P958, DOI 10.1016/j.cell.2008.01.018
   Maiti A, 2011, J BIOL CHEM, V286, P35334, DOI 10.1074/jbc.C111.284620
   Menafra R, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099603
   Métivier R, 2003, CELL, V115, P751, DOI 10.1016/S0092-8674(03)00934-6
   Métivier R, 2008, NATURE, V452, P45, DOI 10.1038/nature06544
   MILLON R, 1989, CLIN EXP METASTAS, V7, P405, DOI 10.1007/BF01753661
   Moore LD, 2013, NEUROPSYCHOPHARMACOL, V38, P23, DOI 10.1038/npp.2012.112
   Nabel CS, 2012, NAT CHEM BIOL, V8, P751, DOI [10.1038/NCHEMBIO.1042, 10.1038/nchembio.1042]
   Nguyen NT, 2014, MOL ONCOL, V8, P1441, DOI 10.1016/j.molonc.2014.05.013
   Periyasamy M, 2015, CELL REP, V13, P108, DOI 10.1016/j.celrep.2015.08.066
   Pulakanti K, 2013, EPIGENETICS-US, V8, P1303, DOI 10.4161/epi.26597
   Putnik M, 2012, BIOCHEM BIOPH RES CO, V426, P26, DOI 10.1016/j.bbrc.2012.08.007
   Raiber EA, 2012, GENOME BIOL, V13, DOI 10.1186/gb-2012-13-8-r69
   Ramírez F, 2016, NUCLEIC ACIDS RES, V44, pW160, DOI 10.1093/nar/gkw257
   Rodriguez M, 2008, CANCER RES, V68, P7872, DOI 10.1158/0008-5472.CAN-08-0301
   SAPINO A, 1986, CANCER RES, V46, P2526
   Saxonov S, 2006, P NATL ACAD SCI USA, V103, P1412, DOI 10.1073/pnas.0510310103
   Shen L, 2013, CELL, V153, P692, DOI 10.1016/j.cell.2013.04.002
   Smith ZD, 2013, NAT REV GENET, V14, P204, DOI 10.1038/nrg3354
   Song CX, 2013, CELL, V153, P678, DOI 10.1016/j.cell.2013.04.001
   Suspène R, 2005, J GEN VIROL, V86, P125, DOI 10.1099/vir.0.80426-0
   Theodorou V, 2013, GENOME RES, V23, P12, DOI 10.1101/gr.139469.112
   Thillainadesan G, 2012, MOL CELL, V46, P636, DOI 10.1016/j.molcel.2012.03.027
   Tini M, 2002, MOL CELL, V9, P265, DOI 10.1016/S1097-2765(02)00453-7
   van der Wijst MGP, 2015, EPIGENETICS-US, V10, P671, DOI 10.1080/15592294.2015.1062204
   Wu H, 2014, NAT BIOTECHNOL, V32, P1231, DOI 10.1038/nbt.3073
   Xu XH, 2014, J BIOL CHEM, V289, P8881, DOI 10.1074/jbc.M113.538835
   Zentner GE, 2011, GENOME RES, V21, P1273, DOI 10.1101/gr.122382.111
   Zheng Rena, 2010, Genes Cancer, V1, P1178, DOI 10.1177/1947601911404223
   Zhu YN, 2012, MOL CELL, V46, P408, DOI 10.1016/j.molcel.2012.05.011
NR 52
TC 20
Z9 22
U1 0
U2 9
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1756-8935
J9 EPIGENET CHROMATIN
JI Epigenetics Chromatin
PD JAN 29
PY 2018
VL 11
AR 5
DI 10.1186/s13072-018-0176-2
PG 19
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA FT8YB
UT WOS:000423438000001
PM 29378668
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Kohli, S
   Bhardwaj, A
   Kumari, R
   Das, S
AF Kohli, Saishruti
   Bhardwaj, Abhishek
   Kumari, Richa
   Das, Sanjeev
TI SIRT6 Is a Target of Regulation by UBE3A That Contributes to Liver
   Tumorigenesis in an ANXA2-Dependent Manner
SO CANCER RESEARCH
LA English
DT Article
ID HISTONE DEACETYLASE SIRT6; UBIQUITIN-PROTEIN LIGASE; ANNEXIN A2;
   TRANSCRIPTION FACTOR; TUMOR-SUPPRESSOR; BREAST-CANCER;
   HEPATOCELLULAR-CARCINOMA; PANCREATIC-CANCER; PROMOTES; CELLS
AB UBE3A is an E3 ubiquitin ligase well known for its role in the proteasomal degradation of p53 in human papillomavirus (HPV)- associated cancers. Here we report that UBE3A ubiquitylates and triggers degradation of the tumor-suppressive sirtuin SIRT6 in hepatocellular carcinoma. UBE3A ubiquitylated the highly conserved Lys160 residue on SIRT6. FOXO1-mediated transcriptional repression of UBE3A was sufficient to stabilize SIRT6 and to epigenetically repress ANXA2, a key mediator of UBE3A oncogenic function. Thus, UBE3A-mediated SIRT6 degradation promoted the proliferative capacity, migration potential, and invasiveness of cells. In mouse models of hepatocellular carcinoma, SIRT6 down-regulation and consequent induction of ANXA2 were critical for UBE3A-mediated tumorigenesis. Furthermore, in clinical specimens, increased UBE3A levels correlated with reduced SIRT6 levels and elevated ANXA2 levels in increasing tumor grades. Overall, our findings show how the tumor suppressor SIRT6 is regulated in hepatocellular carcinoma and establish the mechanism underlying UBE3A-mediated tumorigenesis in this disease. Significance: These findings provide mechanistic insights into regulation of the tumor suppressive sirtuin SIRT6 and its implications for the development of hepatocellular carcinoma. (C) 2017 AACR.
C1 [Kohli, Saishruti; Bhardwaj, Abhishek; Kumari, Richa; Das, Sanjeev] Natl Inst Immunol, Mol Oncol Lab, Aruna Asaf Ali Marg, New Delhi 110067, India.
C3 Department of Biotechnology (DBT) India; National Institute of
   Immunology (NII)
RP Das, S (通讯作者)，Natl Inst Immunol, Mol Oncol Lab, Aruna Asaf Ali Marg, New Delhi 110067, India.
EM sdas@nii.ac.in
RI BHARDWAJ, ABHISHEK/AAW-2502-2021
OI Das, Sanjeev/0000-0002-3594-1033; Bhardwaj, Abhishek/0000-0003-4539-7497
FU NII Core Fund; Council for Scientific and Industrial Research,
   Government of India; Department of Biotechnology, Government of India
   [BT/PR12875/BRB/10/1394/2015]
FX We thank the members of the Molecular Oncology Laboratory for helpful
   discussions. We are also thankful to Dr. Vivek Rao, CSIR-Institute of
   Genomics & Integrative Biology (IGIB) for helping with live animal
   imaging. The authors would also like to acknowledge the financial
   support received from NII Core Fund. S. Kohli is supported by a
   fellowship from the Council for Scientific and Industrial Research,
   Government of India and A. Bhardwaj was supported by a fellowship from
   the Department of Biotechnology, Government of India. This work was
   supported by a grant from the Department of Biotechnology, Government of
   India (BT/PR12875/BRB/10/1394/2015 to S. Das).
CR Bhardwaj A, 2016, P NATL ACAD SCI USA, V113, pE538, DOI 10.1073/pnas.1520045113
   Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4
   Cea M, 2016, BLOOD, V127, P1138, DOI 10.1182/blood-2015-06-649970
   Deng SS, 2007, BREAST CANCER RES TR, V104, P21, DOI 10.1007/s10549-006-9393-7
   Díaz VM, 2004, GUT, V53, P993, DOI 10.1136/gut.2003.026831
   Gossan NC, 2014, NUCLEIC ACIDS RES, V42, P5765, DOI 10.1093/nar/gku225
   Greer PL, 2010, CELL, V140, P704, DOI 10.1016/j.cell.2010.01.026
   Hattori T, 2013, J BIOL CHEM, V288, P35138, DOI 10.1074/jbc.M113.486795
   Huang BH, 2011, BLOOD, V118, P2918, DOI 10.1182/blood-2011-03-341214
   Jones RG, 2005, MOL CELL, V18, P283, DOI 10.1016/j.molcel.2005.03.027
   Kanfi Y, 2008, FEBS LETT, V582, P543, DOI [10.1016/j.febslet.2008.01.019, 10.1016/j.febslet.2008.06.005]
   Kugel S, 2016, CELL, V165, P1401, DOI 10.1016/j.cell.2016.04.033
   Kugel S, 2014, TRENDS BIOCHEM SCI, V39, P72, DOI 10.1016/j.tibs.2013.12.002
   Louria-Hayon I, 2009, CELL DEATH DIFFER, V16, P1156, DOI 10.1038/cdd.2009.31
   Marquardt JU, 2013, HEPATOLOGY, V58, P1054, DOI 10.1002/hep.26413
   Melino G, 2008, CELL DEATH DIFFER, V15, P1103, DOI 10.1038/cdd.2008.60
   Min LH, 2012, NAT CELL BIOL, V14, P1203, DOI 10.1038/ncb2590
   Mohammad HS, 2008, INT J ONCOL, V33, P1157, DOI 10.3892/ijo_00000105
   Moreau K, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9045
   Nakamura N, 2000, MOL CELL BIOL, V20, P8969, DOI 10.1128/MCB.20.23.8969-8982.2000
   Ramamoorthy S, 2012, BREAST CANCER RES TR, V132, P97, DOI 10.1007/s10549-011-1567-2
   Ramaswamy S, 2002, CANCER CELL, V2, P81, DOI 10.1016/S1535-6108(02)00086-7
   Ronnebaum SM, 2013, MOL CELL BIOL, V33, P4461, DOI 10.1128/MCB.00480-13
   Satija YK, 2016, ONCOGENE, V35, P513, DOI 10.1038/onc.2015.111
   SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3
   Sebastián C, 2012, CELL, V151, P1185, DOI 10.1016/j.cell.2012.10.047
   Srinivasan S, 2011, BBA-GENE REGUL MECH, V1809, P119, DOI 10.1016/j.bbagrm.2010.08.011
   Stöhr R, 2015, SCI REP-UK, V5, DOI 10.1038/srep09023
   Sundaresan NR, 2012, NAT MED, V18, P1643, DOI 10.1038/nm.2961
   Talis AL, 1998, J BIOL CHEM, V273, P6439, DOI 10.1074/jbc.273.11.6439
   Thirumurthi U, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005076
   Xu XH, 2015, ONCOL REP, V33, P2121, DOI 10.3892/or.2015.3837
   Zhong L, 2010, CELL, V140, P280, DOI 10.1016/j.cell.2009.12.041
   Zhou XF, 2015, MOL MED REP, V12, P1107, DOI 10.3892/mmr.2015.3549
NR 34
TC 31
Z9 35
U1 0
U2 14
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD FEB 1
PY 2018
VL 78
IS 3
BP 645
EP 658
DI 10.1158/0008-5472.CAN-17-1692
PG 14
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA FU5NC
UT WOS:000423899200007
PM 29217762
DA 2025-01-12
ER

PT J
AU Viotti, M
   Wilson, C
   McCleland, M
   Koeppen, H
   Haley, B
   Jhunjhunwala, S
   Klijn, C
   Modrusan, Z
   Arnott, D
   Classon, M
   Stephan, JP
   Mellman, I
AF Viotti, Manuel
   Wilson, Catherine
   McCleland, Mark
   Koeppen, Hartmut
   Haley, Benjamin
   Jhunjhunwala, Suchit
   Klijn, Christiaan
   Modrusan, Zora
   Arnott, David
   Classon, Marie
   Stephan, Jean-Philippe
   Mellman, Ira
TI SUV420H2 is an epigenetic regulator of epithelial/mesenchymal states in
   pancreatic cancer
SO JOURNAL OF CELL BIOLOGY
LA English
DT Article
ID EPITHELIAL-MESENCHYMAL TRANSITION; STEM-CELLS; E-CADHERIN;
   GENE-EXPRESSION; BREAST-CANCER; HISTONE H4; H4K20 TRIMETHYLATION;
   DRUG-RESISTANCE; DEMETHYLASE 1; COMPLEX
AB Epithelial-to-mesenchymal transition is implicated in metastasis, where carcinoma cells lose sessile epithelial traits and acquire mesenchymal migratory potential. The mesenchymal state is also associated with cancer stem cells and resistance to chemotherapy. It might therefore be therapeutically beneficial to promote epithelial identity in cancer. Because large-scale cell identity shifts are often orchestrated on an epigenetic level, we screened for candidate epigenetic factors and identified the histone methyltransferase SUV420H2 (KMT5C) as favoring the mesenchymal identity in pancreatic cancer cell lines. Through its repressive mark H4K20me3, SUV420H2 silences several key drivers of the epithelial state. Its knockdown elicited mesenchymal-to-epithelial transition on a molecular and functional level, and cells displayed decreased stemness and increased drug sensitivity. An analysis of human pancreatic cancer biopsies was concordant with these findings, because high levels of SUV420H2 correlated with a loss of epithelial characteristics in progressively invasive cancer. Together, these data indicate that SUV420H2 is an upstream epigenetic regulator of epithelial/mesenchymal state control.
C1 [Viotti, Manuel; Wilson, Catherine; McCleland, Mark; Koeppen, Hartmut; Haley, Benjamin; Jhunjhunwala, Suchit; Klijn, Christiaan; Modrusan, Zora; Arnott, David; Classon, Marie; Stephan, Jean-Philippe; Mellman, Ira] Genentech Inc, San Francisco, CA 94080 USA.
   [Stephan, Jean-Philippe] Inst Rech Servier, Croissy Sur Seine, France.
C3 Roche Holding; Genentech; Servier; Institut de Recherches
   Internationales Servier
RP Mellman, I (通讯作者)，Genentech Inc, San Francisco, CA 94080 USA.
EM mellman.ira@gene.com
RI Jhunjhunwala, Suchit/GNH-2256-2022; Mellman, Ira/ABG-5896-2020; Wilson,
   Catherine/JWB-0289-2024
OI Koeppen, Hartmut/0000-0003-0923-3110; Klijn,
   Christiaan/0000-0003-0878-4121; Viotti, Manuel/0000-0003-1844-2571
CR Nieto MA, 2013, SCIENCE, V342, P708, DOI 10.1126/science.1234850
   Arumugam T, 2009, CANCER RES, V69, P5820, DOI 10.1158/0008-5472.CAN-08-2819
   Bebee TW, 2015, ELIFE, V4, DOI 10.7554/eLife.08954
   Bierhoff H, 2014, MOL CELL, V54, P675, DOI 10.1016/j.molcel.2014.03.032
   Brabletz T, 2005, CELLS TISSUES ORGANS, V179, P56, DOI 10.1159/000084509
   Cao Q, 2008, ONCOGENE, V27, P7274, DOI 10.1038/onc.2008.333
   Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095
   Chen DS, 2017, NATURE, V541, P321, DOI 10.1038/nature21349
   Dawson MA, 2012, CELL, V150, P12, DOI 10.1016/j.cell.2012.06.013
   Deer EL, 2010, PANCREAS, V39, P425, DOI 10.1097/MPA.0b013e3181c15963
   Dong C, 2013, ONCOGENE, V32, P1351, DOI 10.1038/onc.2012.169
   Edgar R, 2002, NUCLEIC ACIDS RES, V30, P207, DOI 10.1093/nar/30.1.207
   Fraga MF, 2005, NAT GENET, V37, P391, DOI 10.1038/ng1531
   Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088
   Ghadban T, 2017, APOPTOSIS, V22, P369, DOI 10.1007/s10495-016-1332-4
   Ginnebaugh KR, 2014, EXPERT OPIN THER TAR, V18, P731, DOI 10.1517/14728222.2014.909807
   HERNANDEZ N, 1985, EMBO J, V4, P1827, DOI 10.1002/j.1460-2075.1985.tb03857.x
   Huang P, 2008, WORLD J GASTROENTERO, V14, P3903, DOI 10.3748/wjg.14.3903
   Jolly MK, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00155
   Jones PA, 2016, NAT REV GENET, V17, P630, DOI 10.1038/nrg.2016.93
   Karachentsev D, 2005, GENE DEV, V19, P431, DOI 10.1101/gad.1263005
   Klijn C, 2015, NAT BIOTECHNOL, V33, P306, DOI 10.1038/nbt.3080
   Kourmouli N, 2004, J CELL SCI, V117, P2491, DOI 10.1242/jcs.01238
   Kumar P, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-290
   Law CW, 2014, GENOME BIOL, V15, DOI 10.1186/gb-2014-15-2-r29
   Lee B, 2014, DEV CELL, V29, P47, DOI 10.1016/j.devcel.2014.03.005
   Li YW, 2013, CANCER LETT, V338, P94, DOI 10.1016/j.canlet.2012.03.018
   Li ZF, 2011, P NATL ACAD SCI USA, V108, P3116, DOI 10.1073/pnas.1009353108
   Liberzon A, 2015, CELL SYST, V1, P417, DOI 10.1016/j.cels.2015.12.004
   Liberzon A, 2011, BIOINFORMATICS, V27, P1739, DOI 10.1093/bioinformatics/btr260
   LIEBER M, 1975, INT J CANCER, V15, P741, DOI 10.1002/ijc.2910150505
   Lim S, 2010, CARCINOGENESIS, V31, P512, DOI 10.1093/carcin/bgp324
   Lin YW, 2010, EMBO J, V29, P1803, DOI 10.1038/emboj.2010.63
   Lo B, 2012, J CELL BIOL, V199, P1117, DOI 10.1083/jcb.201208080
   Maile TM, 2015, MOL CELL PROTEOMICS, V14, P1148, DOI 10.1074/mcp.O114.046573
   Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027
   Milne Thomas A., 2009, V538, P409, DOI 10.1007/978-1-59745-418-6_21
   Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008
   Pattabiraman DR, 2016, SCIENCE, V351, P1042, DOI 10.1126/science.aad3680
   Peinado H, 2005, EMBO J, V24, P3446, DOI 10.1038/sj.emboj.7600781
   Peinado H, 2004, MOL CELL BIOL, V24, P306, DOI 10.1128/MCB.24.1.306-319.2004
   Reeder J., 2014, HTSEQGENIE NGS ANAL
   Rhim AD, 2012, CELL, V148, P349, DOI 10.1016/j.cell.2011.11.025
   Roca H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076773
   Sayan AE, 2009, P NATL ACAD SCI USA, V106, P14884, DOI 10.1073/pnas.0902042106
   Scheel C, 2012, SEMIN CANCER BIOL, V22, P396, DOI 10.1016/j.semcancer.2012.04.001
   Schotta G, 2004, GENE DEV, V18, P1251, DOI 10.1101/gad.300704
   Schotta G, 2008, GENE DEV, V22, P2048, DOI 10.1101/gad.476008
   Shinchi Y, 2015, EXP CELL RES, V334, P90, DOI 10.1016/j.yexcr.2015.03.010
   Singh A, 2010, ONCOGENE, V29, P4741, DOI 10.1038/onc.2010.215
   Singh A, 2009, CANCER CELL, V15, P489, DOI 10.1016/j.ccr.2009.03.022
   Song Y, 2010, CANCER RES, V70, P2115, DOI 10.1158/0008-5472.CAN-09-2979
   Srinivasan K, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11295
   Talasz H, 2005, J BIOL CHEM, V280, P38814, DOI 10.1074/jbc.M505563200
   Tam WL, 2013, NAT MED, V19, P1438, DOI 10.1038/nm.3336
   Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007
   Thiery JP, 2003, CURR OPIN CELL BIOL, V15, P740, DOI 10.1016/j.ceb.2003.10.006
   Tsai JH, 2013, GENE DEV, V27, P2192, DOI 10.1101/gad.225334.113
   Vinogradova M, 2016, NAT CHEM BIOL, V12, P531, DOI 10.1038/nchembio.2085
   von Burstin J, 2009, GASTROENTEROLOGY, V137, P361, DOI 10.1053/j.gastro.2009.04.004
   Warzecha CC, 2012, SEMIN CANCER BIOL, V22, P417, DOI 10.1016/j.semcancer.2012.04.003
   Wilson C, 2014, CANCER RES, V74, P5878, DOI 10.1158/0008-5472.CAN-14-1009
   Wilson C, 2014, ONCOTARGET, V5, P7328, DOI 10.18632/oncotarget.2397
   Witta SE, 2006, CANCER RES, V66, P944, DOI 10.1158/0008-5472.CAN-05-1988
   Wu D, 2012, NUCLEIC ACIDS RES, V40, DOI 10.1093/nar/gks461
   Wu TD, 2010, BIOINFORMATICS, V26, P873, DOI 10.1093/bioinformatics/btq057
   Xiong HQ, 2006, DRUGS, V66, P1059, DOI 10.2165/00003495-200666080-00003
   Yang J, 2008, DEV CELL, V14, P818, DOI 10.1016/j.devcel.2008.05.009
   Yauch RL, 2005, CLIN CANCER RES, V11, P8686, DOI 10.1158/1078-0432.CCR-05-1492
   Yin T, 2011, INT J MOL SCI, V12, P1595, DOI 10.3390/ijms12031595
   Yokoyama Y, 2014, BREAST CANCER RES, V16, DOI 10.1186/bcr3681
NR 71
TC 30
Z9 36
U1 0
U2 5
PU ROCKEFELLER UNIV PRESS
PI NEW YORK
PA 950 THIRD AVE, 2ND FLR, NEW YORK, NY 10022 USA
SN 0021-9525
EI 1540-8140
J9 J CELL BIOL
JI J. Cell Biol.
PD FEB
PY 2018
VL 217
IS 2
BP 763
EP 777
DI 10.1083/jcb.201705031
PG 15
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA FV3ZV
UT WOS:000424514100029
PM 29229751
OA Green Published, hybrid
DA 2025-01-12
ER

PT J
AU Bukowska-Damska, A
   Reszka, E
   Kaluzny, P
   Wieczorek, E
   Przybek, M
   Zienolddiny, S
   Peplonska, B
AF Bukowska-Damska, Agnieszka
   Reszka, Edyta
   Kaluzny, Pawel
   Wieczorek, Edyta
   Przybek, Monika
   Zienolddiny, Shanbeh
   Peplonska, Beata
TI Sleep quality and methylation status of selected tumor suppressor genes
   among nurses and midwives
SO CHRONOBIOLOGY INTERNATIONAL
LA English
DT Article
DE DNA methylation; tumor suppressor genes; shiftwork; nurses and midwives
ID NIGHT-SHIFT WORK; WIDE DNA METHYLATION; CANCER-RISK; BREAST-CANCER;
   HYPERMETHYLATION; METAANALYSIS; ASSOCIATION; DEPRIVATION; EXPRESSION;
   PROMOTER
AB Chronic sleep restriction may affect metabolism, hormone secretion patterns and inflammatory responses. Limited reports suggest also epigenetic effects, such as changes in DNA methylation profiles. The study aims to assess the potential association between poor sleep quality or sleep duration and the levels of 5-methylcytosine in the promoter regions of selected tumor suppressor genes. A cross-sectional study was conducted on 710 nurses and midwives aged 40-60years. Data from interviews regarding sleep habits and potential confounders were used. The methylation status of tumor suppressor genes was determined via qMSP reactions using DNA samples derived from leucocytes. No significant findings were observed in the total study population or in the two subgroups of women stratified by the current system of work. A borderline significance association was observed between a shorter duration of sleep and an increased methylation level in CDKN2A among day working nurses and midwives. Further studies are warranted to explore this under-investigated topic.
C1 [Bukowska-Damska, Agnieszka; Kaluzny, Pawel; Peplonska, Beata] Nofer Inst Occupat Med, Dept Environm Epidemiol, 8 Teresy St, PL-91348 Lodz, Poland.
   [Reszka, Edyta; Wieczorek, Edyta; Przybek, Monika] Nofer Inst Occupat Med, Dept Mol Genet & Epigenet, Lodz, Poland.
   [Zienolddiny, Shanbeh] Natl Inst Occupat Hlth, Oslo, Norway.
C3 Nofer Institute of Occupational Medicine; Nofer Institute of
   Occupational Medicine
RP Bukowska-Damska, A (通讯作者)，Nofer Inst Occupat Med, Dept Environm Epidemiol, 8 Teresy St, PL-91348 Lodz, Poland.
EM bukowska@imp.lodz.pl
RI Zienolddiny, Shanbeh/O-7392-2015; Bukowska, Agnieszka/G-4906-2010;
   Peplonska, Beata/AAO-1265-2020; Kasperczyk, Edyta/F-7057-2010; Reszka,
   Edyta/F-6008-2010; Lesicka, Monika/G-7673-2015
OI Kasperczyk, Edyta/0000-0002-4390-2042; Peplonska,
   Beata/0000-0003-3915-2872; Kaluzny, Pawel/0000-0002-9559-5873; Reszka,
   Edyta/0000-0003-2153-4864; Zienolddiny-Narui, Shan/0000-0001-9747-9625;
   Lesicka, Monika/0000-0003-2095-8681; Bukowska-Damska,
   Agnieszka/0000-0002-3223-6750
FU Norway Grants, under the Polish-Norwegian Research Programme [PNRF - 243
   - AI - 1/07, Pol-Nor/196940/22/2013]
FX This project was supported by the Norway Grants, under the
   Polish-Norwegian Research Programme (Grant no. PNRF - 243 - AI - 1/07
   and Pol-Nor/196940/22/2013-clockshift).
CR Åkerstedt T, 2003, OCCUP MED-OXFORD, V53, P89, DOI 10.1093/occmed/kqg046
   Alegra-Torres JA, 2011, EPIGENOMICS-UK, V3, P267, DOI [10.2217/EPI.11.22, 10.2217/epi.11.22]
   Archer SN, 2015, J SLEEP RES, V24, P476, DOI 10.1111/jsr.12307
   Banks S, 2007, J CLIN SLEEP MED, V3, P519
   Bhatti P, 2015, CHRONOBIOL INT, V32, P103, DOI 10.3109/07420528.2014.956362
   Blask DE, 2009, SLEEP MED REV, V13, P257, DOI 10.1016/j.smrv.2008.07.007
   Bollati V, 2010, CHRONOBIOL INT, V27, P1093, DOI 10.3109/07420528.2010.490065
   Brudnowska J, 2011, MED PR, V62, P323
   BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4
   Chanda S, 2006, TOXICOL SCI, V89, P431, DOI 10.1093/toxsci/kfj030
   Eads CA, 2001, CANCER RES, V61, P3410
   Eads CA, 2000, NUCLEIC ACIDS RES, V28, DOI 10.1093/nar/28.8.e32
   Hardy TM, 2011, EPIGENOMICS-UK, V3, P503, DOI [10.2217/EPI.11.71, 10.2217/epi.11.71]
   Haus EL, 2013, SLEEP MED REV, V17, P273, DOI 10.1016/j.smrv.2012.08.003
   Hoffman AE, 2010, CANCER PREV RES, V3, P539, DOI 10.1158/1940-6207.CAPR-09-0127
   Hoffman AE, 2010, CANCER RES, V70, P1459, DOI 10.1158/0008-5472.CAN-09-3798
   HORNE J A, 1976, International Journal of Chronobiology, V4, P97
   IARC, 2010, IARC MON EV CARC RIS
   Jacobs DI, 2013, ENVIRON MOL MUTAGEN, V54, P141, DOI 10.1002/em.21752
   Jha AK, 2012, ONCOL LETT, V3, P1331, DOI 10.3892/ol.2012.655
   Kamdar BB, 2013, BREAST CANCER RES TR, V138, P291, DOI 10.1007/s10549-013-2433-1
   Lee Ken W. K., 2013, Frontiers in Genetics, V4, P132, DOI 10.3389/fgene.2013.00132
   Lu L, 2007, CANCER RES, V67, P10117, DOI 10.1158/0008-5472.CAN-07-2544
   Milagro FI, 2012, CHRONOBIOL INT, V29, P1180, DOI 10.3109/07420528.2012.719967
   Mollayeva T, 2016, SLEEP MED REV, V25, P52, DOI 10.1016/j.smrv.2015.01.009
   Newbold RF, 2005, INTRO CELLULAR MOL B
   Nilsson EK, 2016, OMICS, V20, P334, DOI 10.1089/omi.2016.0041
   Peplonska B, 2012, OCCUP ENVIRON MED, V69, P339, DOI 10.1136/oemed-2011-100273
   Portaluppi F, 2010, CHRONOBIOL INT, V27, P1911, DOI 10.3109/07420528.2010.516381
   Schernhammer ES, 2004, BRIT J CANCER, V90, P941, DOI 10.1038/sj.bjc.6601626
   Staalesen V, 2004, CLIN CANCER RES, V10, P3438, DOI 10.1158/1078-0432.CCR-03-0796
   Taillard J, 1999, J SLEEP RES, V8, P291, DOI 10.1046/j.1365-2869.1999.00176.x
   Terry MB, 2011, EPIGENETICS-US, V6, P828, DOI 10.4161/epi.6.7.16500
   White AJ, 2013, EUR J CANCER, V49, P2199, DOI 10.1016/j.ejca.2013.02.013
   WHO, 2004, WHO TECHN M SLEEP HL
   Yang P, 2012, CANCER EPIDEM BIOMAR, V21, P182, DOI 10.1158/1055-9965.EPI-11-0784
   Zhang B, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028882
   Zhu Y, 2011, CHRONOBIOL INT, V28, P852, DOI 10.3109/07420528.2011.618896
NR 38
TC 3
Z9 3
U1 1
U2 7
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0742-0528
EI 1525-6073
J9 CHRONOBIOL INT
JI Chronobiol. Int.
PY 2018
VL 35
IS 1
BP 122
EP 131
DI 10.1080/07420528.2017.1376219
PG 10
WC Biology; Physiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Life Sciences & Biomedicine - Other Topics; Physiology
GA FT5NE
UT WOS:000423199400012
PM 29144154
DA 2025-01-12
ER

PT J
AU Anjanappa, M
   Hao, Y
   Simpson, ER
   Bhat-Nakshatri, P
   Nelson, JB
   Tersey, SA
   Mirmira, RG
   Cohen-Gadol, AA
   Saadatzadeh, MR
   Li, L
   Fang, F
   Nephew, KP
   Miller, KD
   Liu, Y
   Nakshatri, H
AF Anjanappa, M.
   Hao, Y.
   Simpson, E. R.
   Bhat-Nakshatri, P.
   Nelson, J. B.
   Tersey, S. A.
   Mirmira, R. G.
   Cohen-Gadol, A. A.
   Saadatzadeh, M. R.
   Li, L.
   Fang, F.
   Nephew, K. P.
   Miller, K. D.
   Liu, Y.
   Nakshatri, H.
TI A system for detecting high impact-low frequency mutations in primary
   tumors and metastases
SO ONCOGENE
LA English
DT Article
ID BREAST-CANCER; H3K4 MONOMETHYLATION; EARLY DISSEMINATION; BRANCHED
   EVOLUTION; BRAIN METASTASES; STEM-CELLS; IDENTIFICATION; METABOLISM;
   REVEALS; PATHWAY
AB Tumor complexity and intratumor heterogeneity contribute to subclonal diversity. Despite advances in next-generation sequencing (NGS) and bioinformatics, detecting rare mutations in primary tumors and metastases contributing to subclonal diversity is a challenge for precision genomics. Here, in order to identify rare mutations, we adapted a recently described epithelial reprograming assay for short-term propagation of epithelial cells from primary and metastatic tumors. Using this approach, we expanded minor clones and obtained epithelial cell-specific DNA/RNA for quantitative NGS analysis. Comparative Ampliseq Comprehensive Cancer Panel sequence analyses were performed on DNA from unprocessed breast tumor and tumor cells propagated from the same tumor. We identified previously uncharacterized mutations present only in the cultured tumor cells, a subset of which has been reported in brain metastatic but not primary breast tumors. In addition, whole-genome sequencing identified mutations enriched in liver metastases of various cancers, including Notch pathway mutations/chromosomal inversions in 5/5 liver metastases, irrespective of cancer types. Mutations/rearrangements in FHIT, involved in purine metabolism, were detected in 4/5 liver metastases, and the same four liver metastases shared mutations in 32 genes, including mutations of different HLA-DR family members affecting OX40 signaling pathway, which could impact the immune response to metastatic cells. Pathway analyses of all mutated genes in liver metastases showed aberrant tumor necrosis factor and transforming growth factor signaling in metastatic cells. Epigenetic regulators including KMT2C/MLL3 and ARID1B, which are mutated in >50% of hepatocellular carcinomas, were also mutated in liver metastases. Thus, irrespective of cancer types, organ-specific metastases may share common genomic aberrations. Since recent studies show independent evolution of primary tumors and metastases and in most cases mutation burden is higher in metastases than primary tumors, the method described here may allow early detection of subclonal somatic alterations associated with metastatic progression and potentially identify therapeutically actionable, metastasis-specific genomic aberrations.
C1 [Anjanappa, M.; Bhat-Nakshatri, P.; Nakshatri, H.] Indiana Univ Sch Med, Dept Surg, Indianapolis, IN 46202 USA.
   [Hao, Y.; Simpson, E. R.; Li, L.; Liu, Y.] Indiana Univ Sch Med, Ctr Computat Biol & Bioinformat, Indianapolis, IN 46202 USA.
   [Nelson, J. B.; Tersey, S. A.; Mirmira, R. G.; Saadatzadeh, M. R.] Indiana Univ Sch Med, Dept Pediat, Indianapolis, IN 46202 USA.
   [Cohen-Gadol, A. A.] Indiana Univ Sch Med, Dept Neurosurg, Indianapolis, IN 46202 USA.
   [Li, L.; Liu, Y.] Indiana Univ Sch Med, Dept Med & Mol Genet, Indianapolis, IN 46202 USA.
   [Fang, F.; Nephew, K. P.] Indiana Univ, Med Sci Program, Bloomington, IN USA.
   [Miller, K. D.] Indiana Univ Sch Med, Dept Med, Div Hematol Oncol, Indianapolis, IN 46202 USA.
   [Nakshatri, H.] Indiana Univ Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA.
   [Nakshatri, H.] Roudebush VA Med Ctr, Indianapolis, IN USA.
C3 Indiana University System; Indiana University Bloomington; Indiana
   University System; Indiana University Bloomington; Indiana University
   System; Indiana University Bloomington; Indiana University System;
   Indiana University Bloomington; Indiana University System; Indiana
   University Bloomington; Indiana University System; Indiana University
   Bloomington; Indiana University System; Indiana University Bloomington;
   Indiana University System; Indiana University Bloomington; US Department
   of Veterans Affairs; Veterans Health Administration (VHA); Richard L.
   Roudebush VA Medical Center
RP Liu, Y; Nakshatri, H (通讯作者)，Indiana Univ Sch Med, Surg Biochem Mol Biol, C218C,980 West Walnut St, Indianapolis, IN 46202 USA.
EM Yunliu@iu.edu; hnakshat@iupui.edu
RI Mirmira, Raghavendra/AAD-7592-2020; Saadatzadeh, Mohammad/JPK-6782-2023;
   Simpson, Edward/G-1912-2015
OI Tersey, Sarah/0000-0003-0667-2361; Simpson, Edward/0000-0001-9015-9864;
   Cohen-Gadol, Aaron/0000-0002-4946-1524; Nakshatri,
   Harikrishna/0000-0001-8876-0052
FU IUPUI Signature Center for the Cure of Glioblastoma; Susan G Komen for
   the Cure [SAC110025]; Indiana CTSI Project development pilot grant; IU
   Simon Cancer Center Breast Cancer Program Pilot grant; National
   Institutes of Health [P30 DK097512]
FX We thank tissue collection team at the IU Simon Cancer Center, Clinical
   Research Office and Neurooncology Center at IU School of Medicine for
   collection of fresh tissues for the study. We also thank the flow
   cytometry core at the IU Simon Cancer Center. Excellent support from New
   York Genome Center, particularly Mr Benjamin Hubert, is highly
   appreciated. IUPUI Signature Center for the Cure of Glioblastoma
   supported brain metastases tissue collection. Susan G Komen for the Cure
   (SAC110025 to HN), Indiana CTSI Project development pilot grant (to HN,
   LL and KNP) and IU Simon Cancer Center Breast Cancer Program Pilot grant
   (to YL and HN) supported this study. This study utilized core services
   by National Institutes of Health Grant P30 DK097512 to the Indiana
   University School of Medicine.
CR Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100
   Arun B, 2005, CANCER EPIDEM BIOMAR, V14, P1681, DOI 10.1158/1055-9965.EPI-04-0278
   Bafna S, 2010, ONCOGENE, V29, P2893, DOI 10.1038/onc.2010.87
   Bass AJ, 2014, NATURE, V513, P202, DOI 10.1038/nature13480
   Brastianos PK, 2015, CANCER DISCOV, V5, P1164, DOI 10.1158/2159-8290.CD-15-0369
   Brodt P, 2016, CLIN CANCER RES, V22, P5971, DOI 10.1158/1078-0432.CCR-16-0460
   Burnett RM, 2015, ONCOTARGET, V6, P12682, DOI 10.18632/oncotarget.3707
   Buxton ILO, 2010, CANCER LETT, V291, P131, DOI 10.1016/j.canlet.2009.09.021
   Cejalvo JM, 2017, CANCER RES, V77, P2213, DOI 10.1158/0008-5472.CAN-16-2717
   Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095
   Chen DW, 2015, ONCOTARGET, V6, P40815, DOI 10.18632/oncotarget.5886
   Chen LX, 2017, SCIENCE, V355, P752, DOI 10.1126/science.aai8690
   Cheng J, 2014, MOL CELL, V53, P979, DOI 10.1016/j.molcel.2014.02.032
   Cheung LWT, 2014, CANCER CELL, V26, P479, DOI 10.1016/j.ccell.2014.08.017
   Chmielecki J, 2013, NAT GENET, V45, P131, DOI 10.1038/ng.2522
   Collins DC, 2017, TRENDS PHARMACOL SCI, V38, P25, DOI 10.1016/j.tips.2016.10.012
   Cormier S, 2004, GENE EXPR PATTERNS, V4, P713, DOI 10.1016/j.modgep.2004.04.003
   de Brachène AC, 2016, CELL MOL LIFE SCI, V73, P1159, DOI 10.1007/s00018-015-2112-y
   Eirew P, 2015, NATURE, V518, P422, DOI 10.1038/nature13952
   Fisher MM, 2015, DIABETES, V64, P3867, DOI 10.2337/db15-0430
   Flowers M, 2017, CANCER RES, V77, P3386, DOI 10.1158/0008-5472.CAN-17-0232
   Fujimoto A, 2012, NAT GENET, V44, P760, DOI 10.1038/ng.2291
   Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088
   Gerlinger M, 2012, NEW ENGL J MED, V366, P883, DOI 10.1056/NEJMoa1113205
   Giampieri R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072843
   Gruber TA, 2015, BLOOD, V126, P943, DOI 10.1182/blood-2015-05-567859
   Hao YY, 2017, J COMPUT BIOL, V24, P637, DOI 10.1089/cmb.2017.0057
   Hao YY, 2016, BMC GENOMICS, V17, DOI 10.1186/s12864-016-2905-x
   Harper KL, 2016, NATURE, V540, P588, DOI 10.1038/nature20609
   Hosseini H, 2016, NATURE, V540, P552, DOI 10.1038/nature20785
   Hu X, 2015, INT J MOL MED, V35, P1219, DOI 10.3892/ijmm.2015.2132
   Jozwik KM, 2016, CELL REP, V17, P2715, DOI 10.1016/j.celrep.2016.11.028
   Kim J, 2012, P NATL ACAD SCI USA, V109, P6124, DOI 10.1073/pnas.1203203109
   Kishi N, 2001, INT J DEV NEUROSCI, V19, P21, DOI 10.1016/S0736-5748(00)00071-X
   Kloosterman WP, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-10-r103
   Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412
   Kostadinov R, 2016, PLOS COMPUT BIOL, V12, DOI 10.1371/journal.pcbi.1004413
   Kumar R, 2006, MOL CANCER RES, V4, P655, DOI 10.1158/1541-7786.MCR-05-0249
   Linch SN, 2016, P NATL ACAD SCI USA, V113, pE319, DOI 10.1073/pnas.1510518113
   Liu XF, 2012, AM J PATHOL, V180, P599, DOI 10.1016/j.ajpath.2011.10.036
   McCreery MQ, 2015, NAT MED, V21, P1514, DOI 10.1038/nm.3979
   McDonald OG, 2017, NAT GENET, V49, P367, DOI 10.1038/ng.3753
   Miller CA, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12498
   Mitchell RA, 1999, J BIOL CHEM, V274, P18100, DOI 10.1074/jbc.274.25.18100
   Nakshatri H, 2015, SCI REP-UK, V5, DOI 10.1038/srep13526
   Odore E, 2016, CLIN PHARMACOKINET, V55, P397, DOI 10.1007/s40262-015-0327-6
   Park JT, 2015, ONCOGENE, V34, P2801, DOI 10.1038/onc.2014.223
   Pepe C, 2007, BREAST CANCER RES TR, V103, P29, DOI 10.1007/s10549-006-9349-y
   Pereira B, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11479
   Petit FM, 2013, HUM REPROD, V28, P852, DOI 10.1093/humrep/des452
   Prasad V, 2016, LANCET ONCOL, V17, pE81, DOI 10.1016/S1470-2045(15)00620-8
   Robinson DR, 2013, NAT GENET, V45, P180, DOI 10.1038/ng.2509
   Sebestyén E, 2015, NUCLEIC ACIDS RES, V43, P1345, DOI 10.1093/nar/gku1392
   Sheridan C, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1610
   Sholl LM, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.87062
   Sinha R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060142
   Steeg PS, 2011, NAT REV CANCER, V11, P352, DOI 10.1038/nrc3053
   Stephens PJ, 2012, NATURE, V486, P400, DOI 10.1038/nature11017
   Vainchenker W, 2017, BLOOD, V129, P667, DOI 10.1182/blood-2016-10-695940
   van Bon BWM, 2013, HUM MOL GENET, V22, P3138, DOI 10.1093/hmg/ddt170
   Vaqué JP, 2013, MOL CELL, V49, P94, DOI 10.1016/j.molcel.2012.10.018
   Visvader JE, 2014, GENE DEV, V28, P1143, DOI 10.1101/gad.242511.114
   Yan W, 2016, SCI REP-UK, V6, DOI 10.1038/srep19303
   Yates LR, 2015, NAT MED, V21, P751, DOI 10.1038/nm.3886
   Zhang Z, 2016, CELL REP, V16, P3146, DOI 10.1016/j.celrep.2016.08.048
NR 65
TC 18
Z9 19
U1 0
U2 12
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 0950-9232
EI 1476-5594
J9 ONCOGENE
JI Oncogene
PD JAN 11
PY 2018
VL 37
IS 2
BP 185
EP 196
DI 10.1038/onc.2017.322
PG 12
WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
GA FS8AN
UT WOS:000422631700005
PM 28892047
OA Green Accepted, Green Submitted
DA 2025-01-12
ER

PT J
AU Aztopal, N
   Erkisa, M
   Erturk, E
   Ulukaya, E
   Tokullugil, AH
   Ari, F
AF Aztopal, Nazlihan
   Erkisa, Merve
   Erturk, Elif
   Ulukaya, Engin
   Tokullugil, Asuman Hatice
   Ari, Ferda
TI Valproic acid, a histone deacetylase inhibitor, induces apoptosis in
   breast cancer stem cells
SO CHEMICO-BIOLOGICAL INTERACTIONS
LA English
DT Article
DE Valproic acid; Epigenetic modulators; Apoptosis; Breast cancer stem cell
ID POOR-PROGNOSIS; GROWTH ARREST; DIFFERENTIATION; NECROPTOSIS; EXPRESSION;
   MIGRATION; THERAPY; COMPLEX; AGENT; HDACS
AB Cancer stem-like cells (CSCs) are a cell subpopulation that can reinitiate tumors, resist chemotherapy, give rise to metastases and lead to disease relapse because of an acquired resistance to apoptosis. Especially, epigenetic alterations play a crucial role in the regulation of stemness and also have been implicated in the development of drug resistance. Hence, in the present study, we examined the cytotoxic and apoptotic activity of valproic acid (VPA) as an inhibitor of histone deacetylases (HDACs) against breast CSCs (BCSCs). Increased expression of stemness markers were determined by western blotting in mammospheres (MCF-7s, a cancer stem cell-enriched population) propagated from parental MCF-7 cells. Anti-growth activity of VPA was determined via ATP viability assay. The sphere formation assay (SFA) was performed to assess the inhibitory effect of VPA on the self-renewal capacity of MCF-7s cells. Acetylation of histon H3 was detected with ELISA assay. Cell death mode was performed by Hoechst dye 33342 and propidium iodide-based flouresent stainings (for pyknosis and membrane integrity), by M30 and M65 ELISA assays (for apoptosis and primary or secondary necrosis) as well as cyto-fluorimetric analysis (caspase 3/7 activity and annexin-V-FITC staining for early and late stage apoptosis). VPA exhibited anti-growth effect against both MCF-7 and MCF-7s cells in a dose (0.6-20 mM) and time (24, 48, 72 h) dependent manner. As expected, MCF-7s cells were found more resistant to VPA than MCF-7 cells. It was observed that VPA prevented mammosphere formation at relatively lower doses (2.5 and 5 mM) while the acetylation of histon H3 was increased. At the same doses, VPA increased the M30 levels, annexin-V-FITC positivity and caspase 3/7 activation, implying the induction of apoptosis. The secondary necrosis (late stage of apoptosis) was also evidenced by nuclear pyknosis with propidium iodide staining positivity. Taken together, inhibition of HDACs is cytotoxic to BCSCs by apoptosis. Our results suggested that targeting the epigenetic regulation of histones may be a novel approach and hold significant promise for successful treatment of breast cancer.
C1 [Aztopal, Nazlihan; Erkisa, Merve; Ulukaya, Engin] Istinye Univ, Fac Med, Dept Clin Biochem, Istanbul, Turkey.
   [Erturk, Elif] Uludag Univ, Vocat Sch Hlth Serv, Bursa, Turkey.
   [Aztopal, Nazlihan; Erkisa, Merve; Ari, Ferda] Uludag Univ, Sci & Art Fac, Dept Biol, TR-16059 Bursa, Turkey.
   [Tokullugil, Asuman Hatice] Uludag Univ, Fac Med, Dept Med Biochem, Bursa, Turkey.
C3 Istinye University; Uludag University; Uludag University; Uludag
   University
RP Ari, F (通讯作者)，Uludag Univ, Sci & Art Fac, Dept Biol, TR-16059 Bursa, Turkey.
EM ferdaoz@uludag.edu.tr
RI Ertürk, Elif/AAK-3371-2021; Erkısa, Merve/AAM-1001-2020; Arı,
   Ferda/AAG-7012-2021; Ulukaya, Engin/K-5792-2018; AZTOPAL,
   NAZLIHAN/L-6687-2018
OI AZTOPAL, NAZLIHAN/0000-0003-3118-8061; Erkisa Genel,
   Merve/0000-0002-3127-742X; Ulukaya, Engin/0000-0003-4875-5472
FU Uludag University (Bursa, Turkey) [KUAP(T)-2015/6]
FX This work was supported by the Research Fund of Uludag University
   (Bursa, Turkey) for the project that is numbered KUAP(T)-2015/6.
CR Angeloni V, 2015, SEMIN CANCER BIOL, V31, P43, DOI 10.1016/j.semcancer.2014.08.004
   Aztopal N, 2017, BIOORGAN MED CHEM, V25, P269, DOI 10.1016/j.bmc.2016.10.032
   Bao LM, 2016, CELL BIOL TOXICOL, V32, P469, DOI 10.1007/s10565-016-9347-8
   Brodie SA, 2014, EXPERT REV ANTICANC, V14, P1097, DOI 10.1586/14737140.2014.940329
   Chateauvieux S, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/479364
   Chikamatsu K, 2013, CANCER SCI, V104, P1468, DOI 10.1111/cas.12271
   Debeb BG, 2012, STEM CELLS, V30, P2366, DOI 10.1002/stem.1219
   Debeb BG, 2010, INT J RADIAT ONCOL, V76, P889, DOI 10.1016/j.ijrobp.2009.09.052
   Degterev A, 2005, NAT CHEM BIOL, V1, P112, DOI 10.1038/nchembio711
   Di Pompo G, 2015, J MED CHEM, V58, P4073, DOI 10.1021/acs.jmedchem.5b00126
   Elder EE, 2006, EJSO-EUR J SURG ONC, V32, P922, DOI 10.1016/j.ejso.2006.06.001
   Ellis L, 2013, ONCOTARGET, V4, P2225, DOI 10.18632/oncotarget.1314
   Elsheikh SE, 2009, CANCER RES, V69, P3802, DOI 10.1158/0008-5472.CAN-08-3907
   Fillmore CM, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1982
   Fortunati N, 2008, CANCER LETT, V259, P156, DOI 10.1016/j.canlet.2007.10.006
   Giaginis C, 2015, BMC GASTROENTEROL, V15, DOI 10.1186/s12876-015-0379-y
   Han WD, 2009, APOPTOSIS, V14, P674, DOI 10.1007/s10495-009-0334-x
   Hodges-Gallagher L, 2007, BREAST CANCER RES TR, V105, P297, DOI 10.1007/s10549-006-9459-6
   Hsieh CL, 2016, LIFE SCI, V151, P7, DOI 10.1016/j.lfs.2016.02.092
   Jeong J.B., 2011, FOOD NUTR SCI, V2, P4535
   Karakas D, 2015, BIOORGAN MED CHEM, V23, P5580, DOI 10.1016/j.bmc.2015.07.026
   Karakas D, 2014, TURK J BIOL, V38, P829, DOI 10.3906/biy-1406-93
   Landreville S, 2012, CLIN CANCER RES, V18, P408, DOI 10.1158/1078-0432.CCR-11-0946
   Leist M, 2001, NAT REV MOL CELL BIO, V2, P589, DOI 10.1038/35085008
   Li XX, 2008, JNCI-J NATL CANCER I, V100, P672, DOI 10.1093/jnci/djn123
   Linder S, 2010, EXPERT REV MOL DIAGN, V10, P353, DOI 10.1586/ERM.10.14
   Ly D, 2013, INT J CANCER, V132, P1918, DOI 10.1002/ijc.27841
   Minamiya Y, 2011, LUNG CANCER, V74, P300, DOI 10.1016/j.lungcan.2011.02.019
   Phillips TM, 2006, JNCI-J NATL CANCER I, V98, P1777, DOI 10.1093/jnci/djj495
   Polito L, 2016, PHYTOMEDICINE, V23, P32, DOI 10.1016/j.phymed.2015.11.006
   Ponti D, 2005, CANCER RES, V65, P5506, DOI 10.1158/0008-5472.CAN-05-0626
   Salvador MA, 2013, CLIN CANCER RES, V19, P6520, DOI 10.1158/1078-0432.CCR-13-0877
   Signore M, 2013, CANCER LETT, V332, P374, DOI 10.1016/j.canlet.2011.01.013
   Slee EA, 1996, BIOCHEM J, V315, P21, DOI 10.1042/bj3150021
   Sulaiman A, 2016, FEBS LETT, V590, P4606, DOI 10.1002/1873-3468.12496
   Suvà ML, 2013, SCIENCE, V339, P1567, DOI 10.1126/science.1230184
   Tate CR, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3192
   Travaglini L, 2009, INT J BIOCHEM CELL B, V41, P225, DOI 10.1016/j.biocel.2008.08.019
   Ulukaya E, 2011, CELL BIOCHEM FUNCT, V29, P468, DOI 10.1002/cbf.1774
   Vanden Berghe T, 2010, CELL DEATH DIFFER, V17, P922, DOI 10.1038/cdd.2009.184
   Wagner JM, 2010, CLIN EPIGENETICS, V1, DOI 10.1007/s13148-010-0012-4
   Weichert W, 2008, BRIT J CANCER, V98, P604, DOI 10.1038/sj.bjc.6604199
   Wicha MS, 2006, CANCER RES, V66, P1883, DOI 10.1158/0008-5472.CAN-05-3153
   Witt AE, 2017, ONCOGENE, V36, P1707, DOI 10.1038/onc.2016.337
   Yang XJ, 2007, ONCOGENE, V26, P5310, DOI 10.1038/sj.onc.1210599
   Yoo CB, 2006, NAT REV DRUG DISCOV, V5, P37, DOI 10.1038/nrd1930
   Zhang L, 2012, MOL CELL BIOCHEM, V361, P39, DOI 10.1007/s11010-011-1085-x
NR 47
TC 41
Z9 47
U1 0
U2 36
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0009-2797
EI 1872-7786
J9 CHEM-BIOL INTERACT
JI Chem.-Biol. Interact.
PD JAN 25
PY 2018
VL 280
BP 51
EP 58
DI 10.1016/j.cbi.2017.12.003
PG 8
WC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Toxicology
GA FS5KX
UT WOS:000419835000007
PM 29225137
DA 2025-01-12
ER

PT J
AU Aoki, H
   Yamamoto, E
   Takasawa, A
   Niinuma, T
   Yamano, HO
   Harada, T
   Matsushita, HO
   Yoshikawa, K
   Takagi, R
   Harada, E
   Tanaka, Y
   Yoshida, Y
   Aoyama, T
   Eizuka, M
   Yorozu, A
   Kitajima, H
   Kai, M
   Sawada, N
   Sugai, T
   Nakase, H
   Suzuki, H
AF Aoki, Hironori
   Yamamoto, Eiichiro
   Takasawa, Akira
   Niinuma, Takeshi
   Yamano, Hiro-O
   Harada, Taku
   Matsushita, Hiro-O
   Yoshikawa, Kenjiro
   Takagi, Ryo
   Harada, Eiji
   Tanaka, Yoshihito
   Yoshida, Yuko
   Aoyama, Tomoyuki
   Eizuka, Makoto
   Yorozu, Akira
   Kitajima, Hiroshi
   Kai, Masahiro
   Sawada, Norimasa
   Sugai, Tamotsu
   Nakase, Hiroshi
   Suzuki, Hiromu
TI Epigenetic silencing of <i>SMOC1</i> in traditional serrated adenoma and
   colorectal cancer
SO ONCOTARGET
LA English
DT Article
DE SMOC1; colorectal cancer; traditional serrated adenoma; DNA methylation;
   CIMP
ID ISLAND METHYLATOR PHENOTYPE; PROMOTER METHYLATION; SPARC EXPRESSION;
   TUMOR-SUPPRESSOR; GASTRIC-CANCER; BREAST-CANCER; LESIONS; GROWTH; GENE;
   FEZ1/LZTS1
AB Colorectal sessile serrated adenoma/polyps (SSA/Ps) are well-known precursors of colorectal cancer (CRC) characterized by BRAF mutation and microsatellite instability. By contrast, the molecular characteristics of traditional serrated adenoma (TSAs) are not fully understood. We analyzed genome-wide DNA methylation in TSAs having both protruding and flat components. We identified 11 genes, including SMOC1, methylation of which progressively increased during the development of TSAs. SMOC1 was prevalently methylated in TSAs, but was rarely methylated in SSA/Ps (p < 0.001). RT-PCR and immunohistochemistry revealed that SMOC1 was expressed in normal colon and SSA/Ps, but its expression was decreased in TSAs. Ectopic expression of SMOC1 suppressed proliferation, colony formation and in vivo tumor formation by CRC cells. Analysis of colorectal lesions (n = 847) revealed that SMOC1 is frequently methylated in TSAs, high-grade adenomas and CRCs. Among these, SMOC1 methylation was strongly associated with KRAS mutation and CpG island methylator phenotype (CIMP)-low. These results demonstrate that epigenetic silencing of SMOC1 is associated with TSA development but is rarely observed in SSA/Ps. SMOC1 expression could thus be a diagnostic marker of serrated lesions, and SMOC1 methylation could play a role in neoplastic pathways in TSAs and conventional adenomas.
C1 [Aoki, Hironori; Yamamoto, Eiichiro; Niinuma, Takeshi; Harada, Taku; Yorozu, Akira; Kitajima, Hiroshi; Kai, Masahiro; Suzuki, Hiromu] Sapporo Med Univ, Dept Mol Biol, Sch Med, Sapporo, Hokkaido, Japan.
   [Yamamoto, Eiichiro; Yamano, Hiro-O; Nakase, Hiroshi] Sapporo Med Univ, Sch Med, Dept Gastroenterol & Hepatol, Sapporo, Hokkaido, Japan.
   [Takasawa, Akira; Aoyama, Tomoyuki; Sawada, Norimasa] Sapporo Med Univ, Sch Med, Dept Pathol, Sapporo, Hokkaido, Japan.
   [Matsushita, Hiro-O; Yoshikawa, Kenjiro; Takagi, Ryo; Harada, Eiji; Tanaka, Yoshihito; Yoshida, Yuko] Akita Red Cross Hosp, Dept Digest Dis Ctr, Akita, Japan.
   [Eizuka, Makoto; Sugai, Tamotsu] Iwate Med Univ, Sch Med, Dept Mol Diagnost Pathol, Morioka, Iwate, Japan.
C3 Sapporo Medical University; Sapporo Medical University; Sapporo Medical
   University; Akita Red Cross Hospital; Iwate Medical University
RP Suzuki, H (通讯作者)，Sapporo Med Univ, Dept Mol Biol, Sch Med, Sapporo, Hokkaido, Japan.
EM hsuzuki@sapmed.ac.jp
RI Nakase, Hiroshi/AAZ-4425-2020
FU Japan Society for Promotion of Science (JSPS KAKENHI) [15K08973,
   15H04299, 15K18431, 15K19339]; JFE (The Japanese Foundation for Research
   and Promotion of Endoscopy) Grant; Takeda Science Foundation;
   Grants-in-Aid for Scientific Research [15K08973, 15H04299, 15K18431,
   15K19339, 16H06279, 16K19352, 17K15956] Funding Source: KAKEN
FX This study was supported in part by Grant-in-Aid for Scientific Research
   (C) from the Japan Society for Promotion of Science (JSPS KAKENHI
   15K08973, E. Yamamoto), Grant-in-Aid for Scientific Research (B) from
   the Japan Society for Promotion of Science (JSPS KAKENHI 15H04299, H.
   Suzuki) and Grants-in-Aid for Young Investigators (B) from Japan Society
   for Promotion of Science (JSPS KAKENHI 15K18431, T. Harada; JSPS KAKENHI
   15K19339, H. Aoki), JFE (The Japanese Foundation for Research and
   Promotion of Endoscopy) Grant (E. Yamamoto), The Takeda Science
   Foundation (E. Yamamoto).
CR Akimoto T, 2016, HISTOL HISTOPATHOL, V31, P921, DOI 10.14670/HH-11-729
   [Anonymous], GUT
   [Anonymous], 2010, WHO Classification of tumors of the digestive system
   Aoi W, 2013, GUT, V62, P882, DOI 10.1136/gutjnl-2011-300776
   Awwad K, 2015, CARDIOVASC RES, V106, P284, DOI 10.1093/cvr/cvv098
   Bettington M, 2016, HISTOPATHOLOGY, V68, P578, DOI 10.1111/his.12788
   Bettington ML, 2015, HUM PATHOL, V46, P933, DOI 10.1016/j.humpath.2015.04.002
   Bettington ML, 2015, MODERN PATHOL, V28, P414, DOI 10.1038/modpathol.2014.122
   Brellier F, 2011, MATRIX BIOL, V30, P225, DOI 10.1016/j.matbio.2011.02.001
   Cheetham S, 2008, BRIT J CANCER, V98, P1810, DOI 10.1038/sj.bjc.6604377
   Chen L, 2009, BREAST CANCER RES TR, V116, P471, DOI 10.1007/s10549-008-0147-6
   Choi YA, 2010, J PROTEOME RES, V9, P2946, DOI 10.1021/pr901110q
   De Sousa E Melo F, 2013, NAT MED, V19, P614, DOI 10.1038/nm.3174
   Fackler MJ, 2011, CANCER RES, V71, P6195, DOI 10.1158/0008-5472.CAN-11-1630
   Fang MG, 2014, MOL CELL, V55, P904, DOI 10.1016/j.molcel.2014.08.010
   FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I
   Gonzalo DH, 2013, J PATHOL, V230, P420, DOI 10.1002/path.4200
   Guweidhi A, 2005, ANN SURG, V242, P224, DOI 10.1097/01.sla.0000171866.45848.68
   IJspeert JEG, 2015, NAT REV GASTRO HEPAT, V12, P401, DOI 10.1038/nrgastro.2015.73
   Ishii H, 2001, P NATL ACAD SCI USA, V98, P10374, DOI 10.1073/pnas.181222898
   Kai M, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0168281
   Kamimae S, 2015, ONCOTARGET, V6, P29975, DOI 10.18632/oncotarget.5034
   Keira Y, 2015, VIRCHOWS ARCH, V466, P265, DOI 10.1007/s00428-014-1705-4
   Kim KM, 2010, AM J SURG PATHOL, V34, P667, DOI 10.1097/PAS.0b013e3181d40cb2
   Kimura T, 2012, AM J GASTROENTEROL, V107, P460, DOI 10.1038/ajg.2011.457
   Kudo SE, 1996, GASTROINTEST ENDOSC, V44, P8, DOI 10.1016/S0016-5107(96)70222-5
   Kudo SE, 2008, GASTROINTEST ENDOSC, V68, pS3, DOI 10.1016/j.gie.2008.07.052
   Leggett B, 2010, GASTROENTEROLOGY, V138, P2088, DOI 10.1053/j.gastro.2009.12.066
   Lei HZ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060369
   Mantoni TS, 2008, CANCER BIOL THER, V7, P1806, DOI 10.4161/cbt.7.11.6846
   Marcucci G, 2014, J CLIN ONCOL, V32, P548, DOI 10.1200/JCO.2013.50.6337
   Okada I, 2011, AM J HUM GENET, V88, P30, DOI 10.1016/j.ajhg.2010.11.012
   Peng XZ, 2017, ONCOTARGET, V8, P679, DOI 10.18632/oncotarget.13510
   REMMELE W, 1987, PATHOLOGE, V8, P138
   Rex DK, 2012, AM J GASTROENTEROL, V107, P1315, DOI 10.1038/ajg.2012.161
   Sakai E, 2016, INT J CANCER, V138, P1634, DOI 10.1002/ijc.29903
   Sekine S, 2016, J PATHOL, V239, P133, DOI 10.1002/path.4709
   Serra RW, 2014, ELIFE, V3, DOI 10.7554/eLife.02313
   Shiba N, 2016, BRIT J HAEMATOL, V172, P581, DOI 10.1111/bjh.13869
   Shvab A, 2016, ONCOGENE, V35, P549, DOI 10.1038/onc.2015.127
   Spring KJ, 2006, GASTROENTEROLOGY, V131, P1400, DOI 10.1053/j.gastro.2006.08.038
   Suzuki H, 2010, CARCINOGENESIS, V31, P2066, DOI 10.1093/carcin/bgq203
   Tan SX, 2014, INT J CLIN EXP PATHO, V7, P2305
   Torlakovic EE, 2008, AM J SURG PATHOL, V32, P21, DOI 10.1097/PAS.0b013e318157f002
   Toyota M, 2008, CANCER RES, V68, P4123, DOI 10.1158/0008-5472.CAN-08-0325
   Tsai JH, 2016, AM J SURG PATHOL, V40, P1352, DOI 10.1097/PAS.0000000000000664
   Vecchione A, 2001, CLIN CANCER RES, V7, P1546
   Viloria K, 2016, SCI REP-UK, V6, DOI 10.1038/srep37839
   Wiland HO, 2014, AM J SURG PATHOL, V38, P1290, DOI 10.1097/PAS.0000000000000253
   Yamamoto E, 2012, AM J PATHOL, V181, P1847, DOI 10.1016/j.ajpath.2012.08.007
NR 50
TC 11
Z9 11
U1 0
U2 1
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
SN 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD JAN 12
PY 2018
VL 9
IS 4
BP 4707
EP 4721
DI 10.18632/oncotarget.23523
PG 15
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA FS8HP
UT WOS:000422651700036
PM 29435136
OA Green Published, gold, Green Submitted
DA 2025-01-12
ER

PT J
AU Mahmood, N
   Cheishvili, D
   Arakelian, A
   Tanvir, I
   Khan, HA
   Pépin, AS
   Szyf, M
   Rabbani, SA
AF Mahmood, Niaz
   Cheishvili, David
   Arakelian, Ani
   Tanvir, Imrana
   Khan, Haseeb Ahmed
   Pepin, Anne-Sophie
   Szyf, Moshe
   Rabbani, Shafaat A.
TI Methyl donor S-adenosylmethionine (SAM) supplementation attenuates
   breast cancer growth, invasion, and metastasis <i>in vivo</i>;
   therapeutic and chemopreventive applications
SO ONCOTARGET
LA English
DT Article
DE DNA methylation; breast cancer; metastasis; SAM; epigenetics
ID ADENOSYL-L-METHIONINE; DNA HYPOMETHYLATION; PROSTATE-CANCER; PROMOTER
   HYPOMETHYLATION; GASTRIC-CANCER; COLON-CANCER; PHASE-I; GENE; CELLS;
   EXPRESSION
AB DNA hypomethylation coordinately targets various signaling pathways involved in tumor growth and metastasis. At present, there are no approved therapeutic modalities that target hypomethylation. In this regard, we examined the therapeutic plausibility of using universal methyl group donor S-adenosylmethionine (SAM) to block breast cancer development, growth, and metastasis through a series of studies in vitro using two different human breast cancer cell lines (MDA-MB-231 and Hs578T) and in vivo using an MDA-MB-231 xenograft model of breast cancer. We found that SAM treatment caused a significant dose-dependent decrease in cell proliferation, invasion, migration, anchorage-independent growth and increased apoptosis in vitro. These results were recapitulated in vivo where oral administration of SAM reduced tumor volume and metastasis in green fluorescent protein (GFP)-tagged MDA-MB-231 xenograft model. Gene expression analyses validated the ability of SAM to decrease the expression of several key genes implicated in cancer progression and metastasis in both cell lines and breast tumor xenografts. SAM was found to be bioavailable in the serum of experimental animals as determined by enzyme-linked immunosorbent assay and no notable adverse side effects were seen including any change in animal behavior. The results of this study provide compelling evidence to evaluate the therapeutic potential of methylating agents like SAM in patients with breast cancer to reduce cancer-associated morbidity and mortality.
C1 [Mahmood, Niaz; Arakelian, Ani; Rabbani, Shafaat A.] McGill Univ, Dept Med, Hlth Ctr, Montreal, PQ, Canada.
   [Cheishvili, David; Pepin, Anne-Sophie; Szyf, Moshe] McGill Univ, Dept Pharmacol & Therapeut, Montreal, PQ, Canada.
   [Tanvir, Imrana; Khan, Haseeb Ahmed] Fatima Mem Hosp, Dept Pathol, Lahore, Pakistan.
C3 McGill University; McGill University
RP Rabbani, SA (通讯作者)，McGill Univ, Dept Med, Hlth Ctr, Montreal, PQ, Canada.
EM shafaat.rabbani@mcgill.ca
RI Cheishvili, David/AAL-1915-2020; Mahmood, Niaz/ADY-9016-2022
OI Mahmood, Niaz/0000-0003-4018-5516; Pepin,
   Anne-Sophie/0000-0002-1894-9391; Cheishvili, David/0000-0001-9136-8967;
   rabbani, shafaat/0000-0001-5594-3899
FU Canadian Institutes for Health Research [MOP 130410]; studentship award
   from Research Institute, McGill University Health Centre
FX We thank Life Science Laboratories, Lakewood, NJ, USA for their kind
   gift of SAM. This work was supported by a grant from the Canadian
   Institutes for Health Research (MOP 130410) to S. A. R. and M. S. NM is
   the recipient of a studentship award from Research Institute, McGill
   University Health Centre.
CR Borowicz S, 2014, JOVE-J VIS EXP, DOI 10.3791/51998
   Bottiglieri T, 2002, AM J CLIN NUTR, V76, p1151S, DOI 10.1093/ajcn/76.5.1151S
   Bzyl J, 2011, EUR RADIOL, V21, P1988, DOI 10.1007/s00330-011-2138-y
   CANTONI GL, 1952, J AM CHEM SOC, V74, P2942, DOI 10.1021/ja01131a519
   Carvalho BS, 2010, BIOINFORMATICS, V26, P2363, DOI 10.1093/bioinformatics/btq431
   Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865
   Chiang PK, 1996, FASEB J, V10, P471, DOI 10.1096/fasebj.10.4.8647346
   Chik F, 2014, CARCINOGENESIS, V35, P138, DOI 10.1093/carcin/bgt284
   Chik F, 2012, ADV EXP MED BIOL, V720, P91, DOI 10.1007/978-1-4614-0254-1_8
   Christakis DA, 2012, SCI REP-UK, V2, DOI 10.1038/srep00546
   De Luca A, 2010, P NATL ACAD SCI USA, V107, P18628, DOI 10.1073/pnas.1010171107
   Dobrovic A, 1997, CANCER RES, V57, P3347
   Ehrlich M, 2009, EPIGENOMICS-UK, V1, P239, DOI [10.2217/epi.09.33, 10.2217/EPI.09.33]
   Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213
   Gören JL, 2004, PHARMACOTHERAPY, V24, P1501, DOI 10.1592/phco.24.16.1501.50943
   Györffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9
   Hoffmann MJ, 2005, BIOCHEM CELL BIOL, V83, P296, DOI 10.1139/o05-036
   Jones PA, 2016, NAT REV GENET, V17, P630, DOI 10.1038/nrg.2016.93
   Kamburov A, 2013, NUCLEIC ACIDS RES, V41, pD793, DOI 10.1093/nar/gks1055
   Li TWH, 2012, CARCINOGENESIS, V33, P427, DOI 10.1093/carcin/bgr295
   Liu HY, 2005, CANCER RES, V65, P7635, DOI 10.1158/0008-5472.CAN-05-1089
   Loenen W., 2006, S ADENOSYLMETHIONINE
   Lu SC, 2008, J GASTROEN HEPATOL, V23, pS73, DOI 10.1111/j.1440-1746.2007.05289.x
   Luo J, 2010, INT J BIOL SCI, V6, P784
   Mahmood N, 2017, TRENDS CANC RES, V12, P1
   Mason JM, 2017, P NATL ACAD SCI USA, V114, P3127, DOI 10.1073/pnas.1700234114
   Nishigaki M, 2005, CANCER RES, V65, P2115, DOI 10.1158/0008-5472.CAN-04-3340
   Ogishima T, 2005, CLIN CANCER RES, V11, P1028
   Pakneshan P, 2004, J BIOL CHEM, V279, P31735, DOI 10.1074/jbc.M401669200
   Pakneshan P, 2004, CLIN CANCER RES, V10, P3035, DOI 10.1158/1078-0432.CCR-03-0545
   Parashar S, 2015, CANCER MED-US, V4, P732, DOI 10.1002/cam4.386
   Paredes J, 2005, CLIN CANCER RES, V11, P5869, DOI 10.1158/1078-0432.CCR-05-0059
   Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093
   Pulukuri SMK, 2007, CANCER RES, V67, P930, DOI 10.1158/0008-5472.CAN-06-2892
   Rabbani SA, 2008, NEOPLASIA, V10, P266, DOI 10.1593/neo.07947
   Rabbani SA, 2007, CANCER METAST REV, V26, P663, DOI 10.1007/s10555-007-9085-8
   Ringnér M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017911
   Rizwan A, 2015, NPJ BREAST CANCER, V1, DOI 10.1038/npjbcancer.2015.17
   Sahin M, 2011, BIOCHEM BIOPH RES CO, V408, P145, DOI 10.1016/j.bbrc.2011.03.138
   Sato N, 2004, ONCOGENE, V23, P1531, DOI 10.1038/sj.onc.1207269
   Shteper PJ, 2003, ONCOGENE, V22, P7737, DOI 10.1038/sj.onc.1207056
   Shukeir N, 2006, CANCER RES, V66, P9202, DOI 10.1158/0008-5472.CAN-06-1954
   Shukeir N, 2015, BRIT J PHARMACOL, V172, P2769, DOI 10.1111/bph.13102
   Singletary SE, 2006, CA-CANCER J CLIN, V56, P37, DOI 10.3322/canjclin.56.1.37
   Stefanska B, 2011, CANCER RES, V71, P5891, DOI 10.1158/0008-5472.CAN-10-3823
   Stewart DJ, 2009, CLIN CANCER RES, V15, P3881, DOI 10.1158/1078-0432.CCR-08-2196
   Suzuki H, 2008, BRIT J CANCER, V98, P1147, DOI 10.1038/sj.bjc.6604259
   WEISS AJ, 1972, CANCER CHEMOTH REP 1, V56, P413
   Ye L, 2005, J ENDOCRINOL, V185, P337, DOI 10.1677/joe.1.05963
   Zhang B, 2005, NUCLEIC ACIDS RES, V33, pW741, DOI 10.1093/nar/gki475
NR 50
TC 49
Z9 55
U1 1
U2 17
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
SN 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD JAN 12
PY 2018
VL 9
IS 4
BP 5169
EP 5183
DI 10.18632/oncotarget.23704
PG 15
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA FS8HP
UT WOS:000422651700070
PM 29435170
OA Green Published, gold, Green Submitted
DA 2025-01-12
ER

PT J
AU Zhang, X
   Rong, X
   Chen, Y
   Su, L
AF Zhang, X.
   Rong, X.
   Chen, Y.
   Su, L.
TI Methylation-mediated loss of SFRP2 enhances invasiveness of non-small
   cell lung cancer cells
SO HUMAN & EXPERIMENTAL TOXICOLOGY
LA English
DT Article
DE Non-small cell lung cancer; secreted frizzled-related proteins;
   methylation; 5-aza-dCyd; cancer invasion
ID COLORECTAL-CANCER; EPIGENETIC INACTIVATION; BREAST-CANCER; NONINVASIVE
   BIOMARKER; TUMOR-METASTASIS; PROTEINS SFRPS; POOR-PROGNOSIS;
   GASTRIC-CANCER; HYPERMETHYLATION; EXPRESSION
AB The malignancy of non-small cell lung cancer (NSCLC) largely results from its invasive manner. Secreted frizzled-related proteins (SFRPs) have been recently found to suppress the invasiveness of some cancers. On the other hand, the methylation of SFRPs increases protein degradation to reduce the activity of SFRPs, resulting in increased tumor cell invasion and cancer metastasis. However, the role of SFRPs in the invasion of NSCLC has not been reported. Here we analyzed the regulation of SFRPs in NSCLC cells and its effects on cell invasion. We found that SFRP2 mRNA was significantly decreased and methylation of SFRP2 gene was significantly increased in NSCLC tissue, compared to the paired adjacent nontumor tissue. Moreover, SFRP2 expression was significantly decreased in NSCLC cell lines. In NSCLC cell lines, the SFRP2 expression would be restored by the demethylation of SFRP2 gene with 5-aza-deoxycytidine in NSCLC cell lines, at the levels of both mRNA and protein. Thus, the cell invasion would be suppressed. Furthermore, the demethylation of SFRP2 gene appeared to inhibit Zinc Finger E-Box Binding Homeobox 1 (ZEB1) and matrix metallopeptidase 9 (MMP9), two key factors that enhance NSCLC cell invasion. Thus, SFRP2 may inhibit NSCLC invasion by suppressing ZEB1 and MMP9, while its methylation promotes NSCLC invasion.
C1 [Zhang, X.; Rong, X.] Shandong Prov Chest Hosp, Dept Resp, Jinan, Shandong, Peoples R China.
   [Chen, Y.] Fourth Peoples Hosp Jinan, Taishan Med Coll, Jinan Clin Sch, Dept Internal Med, Jinan, Shandong, Peoples R China.
   [Su, L.] Fourth Peoples Hosp Jinan, Taishan Med Coll, Jinan Clin Sch, Dept Resp, 50 Shifan Rd, Jinan 250031, Shandong, Peoples R China.
C3 Shandong University; Shandong First Medical University & Shandong
   Academy of Medical Sciences; Shandong First Medical University &
   Shandong Academy of Medical Sciences
RP Su, L (通讯作者)，Fourth Peoples Hosp Jinan, Taishan Med Coll, Jinan Clin Sch, Dept Resp, 50 Shifan Rd, Jinan 250031, Shandong, Peoples R China.
EM slzxx323@126.com
CR Chang JS, 2015, ONCOTARGET, V6, P36278, DOI 10.18632/oncotarget.5531
   Cheng CW, 2015, ONCOTARGET, V6, P44222, DOI 10.18632/oncotarget.5826
   Drescher U, 2005, NAT NEUROSCI, V8, P1281, DOI 10.1038/nn1005-1281
   Duregon E, 2015, ONCOTARGET, V6, P29626, DOI 10.18632/oncotarget.4988
   Ehrlund A, 2013, J CLIN ENDOCR METAB, V98, pE503, DOI 10.1210/jc.2012-3416
   Feys L, 2015, ONCOTARGET, V6, P26615, DOI 10.18632/oncotarget.5666
   Fukui T, 2005, ONCOGENE, V24, P6323, DOI 10.1038/sj.onc.1208777
   Ho MY, 2015, ONCOTARGET, V6, P381, DOI 10.18632/oncotarget.2804
   Huang ZH, 2007, DIGEST DIS SCI, V52, P2287, DOI 10.1007/s10620-007-9755-y
   Jiang YN, 2015, ONCOTARGET, V6, P40719, DOI 10.18632/oncotarget.5825
   Kalmár A, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1687-x
   Kinoshita T, 2011, HEPATO-GASTROENTEROL, V58, P1051
   Klopocki E, 2004, INT J ONCOL, V25, P641
   Li XG, 2013, EXP THER MED, V6, P1225, DOI 10.3892/etm.2013.1298
   Marsit CJ, 2005, CANCER RES, V65, P7081, DOI 10.1158/0008-5472.CAN-05-0267
   Nathan E, 2009, NAT CELL BIOL, V11, P13, DOI 10.1038/ncb0109-13
   Nojima M, 2007, ONCOGENE, V26, P4699, DOI 10.1038/sj.onc.1210259
   Pehlivan S, 2010, CANCER GENET CYTOGEN, V201, P128, DOI 10.1016/j.cancergencyto.2010.05.019
   Qin Y, 2015, ONCOTARGET, V6, P40667, DOI 10.18632/oncotarget.5842
   Schmalhofer O, 2009, CANCER METAST REV, V28, P151, DOI 10.1007/s10555-008-9179-y
   Shi JG, 2016, EUR REV MED PHARMACO, V20, P3217
   Shin H, 2012, INT J ONCOL, V40, P1533, DOI 10.3892/ijo.2012.1327
   Sui CG, 2016, EUR J CANCER PREV, V25, P288, DOI 10.1097/CEJ.0000000000000185
   Sui CG, 2014, TUMOR BIOL, V35, P10457, DOI 10.1007/s13277-014-2313-2
   Sun YJ, 2015, ONCOTARGET, V6, P8244, DOI 10.18632/oncotarget.3135
   Suzuki H, 2004, NAT GENET, V36, P417, DOI 10.1038/ng1330
   Takeda M, 2011, ACTA MED OKAYAMA, V65, P169
   Tian GY, 2015, CELL PHYSIOL BIOCHEM, V37, P2405, DOI 10.1159/000438593
   Tseng RC, 2015, ONCOTARGET, V6, P44207, DOI 10.18632/oncotarget.6229
   Wang DR, 2008, WORLD J GASTROENTERO, V14, P524, DOI 10.3748/wjg.14.524
   Xia JJ, 2016, EUR REV MED PHARMACO, V20, P2805
   Xu FX, 2016, EUR REV MED PHARMACO, V20, P849
   Yang CJ, 2015, ONCOTARGET, V6, P30263, DOI 10.18632/oncotarget.4749
   Yang QH, 2016, SCI REP-UK, V6, DOI 10.1038/srep33339
   Zhang P, 2015, ONCOTARGET, V6, P13550, DOI 10.18632/oncotarget.3624
   Zhang W, 2015, CELL PHYSIOL BIOCHEM, V37, P1210, DOI 10.1159/000430244
   Zhang X, 2015, WORLD J GASTROENTERO, V21, P2629, DOI 10.3748/wjg.v21.i9.2629
   Zhao S, 2015, CELL PHYSIOL BIOCHEM, V37, P35, DOI 10.1159/000430331
   Zhou R, 2015, ONCOTARGET, V6, P44609, DOI 10.18632/oncotarget.6338
   Zhou X, 2015, SCI REP-UK, V5, DOI 10.1038/srep10071
NR 40
TC 12
Z9 13
U1 0
U2 11
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0960-3271
EI 1477-0903
J9 HUM EXP TOXICOL
JI Hum. Exp. Toxicol.
PD FEB
PY 2018
VL 37
IS 2
BP 155
EP 162
DI 10.1177/0960327117693071
PG 8
WC Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Toxicology
GA FS6DE
UT WOS:000419887300006
PM 29320940
DA 2025-01-12
ER

PT J
AU Singh, G
   Roy, J
   Rout, P
   Mallick, B
AF Singh, Garima
   Roy, Jyoti
   Rout, Pratiti
   Mallick, Bibekanand
TI Genome-wide profiling of the PIWI-interacting RNA-mRNA regulatory
   networks in epithelial ovarian cancers
SO PLOS ONE
LA English
DT Article
ID BREAST-CANCER; DNA HYPOMETHYLATION; CELL-PROLIFERATION; IN-VITRO;
   PIRNAS; PROTEIN; METASTASIS; EXPRESSION; RETROTRANSPOSONS; SUPPRESSES
AB PIWI-interacting (piRNAs), similar to 23-36 nucleotide-long small non-coding RNAs (sncRNAs), earlier believed to be germline-specific, have now been identified in somatic cells, including cancer cells. These sncRNAs impact critical biological processes by fine-tuning gene expression at post-transcriptional and epigenetic levels. The expression of piRNAs in ovarian cancer, the most lethal gynecologic cancer is largely uncharted. In this study, we investigated the expression of PIWILs by qRT-PCR and western blotting and then identified piRNA transcriptomes in tissues of normal ovary and two most prevalent epithelial ovarian cancer subtypes, serous and endometrioid by small RNA sequencing. We detected 219, 256 and 234 piRNAs in normal ovary, endometrioid and serous ovarian cancer samples respectively. We observed piRNAs are encoded from various genomic regions, among which introns harbor the majority of them. Surprisingly, piRNAs originated from different genomic contexts showed the varied level of conservations across vertebrates. The functional analysis of predicted targets of differentially expressed piRNAs revealed these could modulate key processes and pathways involved in ovarian oncogenesis. Our study provides the first comprehensive piRNA landscape in these samples and a useful resource for further functional studies to decipher new mechanistic views of piRNA-mediated gene regulatory networks affecting ovarian oncogenesis. The RNA-seq data is submitted to GEO database (GSE83794).
C1 [Singh, Garima; Roy, Jyoti; Rout, Pratiti; Mallick, Bibekanand] Natl Inst Technol, Dept Life Sci, RNAi & Funct Genom Lab, Rourkela, Odisha, India.
   [Roy, Jyoti] DKFZ ZMBH Alliance, German Canc Res Ctr, Div Mol Biol Cell 2, Heidelberg, Germany.
C3 National Institute of Technology (NIT System); National Institute of
   Technology Rourkela; Helmholtz Association; German Cancer Research
   Center (DKFZ)
RP Mallick, B (通讯作者)，Natl Inst Technol, Dept Life Sci, RNAi & Funct Genom Lab, Rourkela, Odisha, India.
EM vivek.iitian@gmail.com
RI ROY, JYOTI/ISS-9236-2023; Mallick, Bibekanand/AAT-7013-2021
OI ROY, JYOTI/0000-0001-7530-9705; Mallick, Prof.
   Bibekanand/0000-0003-4311-0720
FU Department of Science and Technology, Govt. of India
   [SR/WOS-A/LS-311/2013]; Department of Biotechnology, Govt. of India
   [BT/PR6772/GBD/27/468/2012]
FX This work was supported by Department of Science and Technology, Govt.
   of India (SR/WOS-A/LS-311/2013) awarded to G.S. and Department of
   Biotechnology, Govt. of India (BT/PR6772/GBD/27/468/2012) awarded to
   B.M.We acknowledge the grant support by Department of Science and
   Technology, Govt. of India (SR/WOS-A/LS-311/2013) awarded to G.S. and
   Department of Biotechnology, Govt. of India (BT/PR6772/GBD/27/468/2012)
   awarded to B.M. We are also thankful to Dr. Bhagyalaxmi Nayak and Dr.
   D.R. Mishra for assisting in providing us the tissue samples.
CR [Anonymous], 2009, Curr. Protoc. Bioinform, DOI [DOI 10.1002/0471250953.BI0410S25, 10.1002/0471250953.bi0410s25]
   [Anonymous], 2010, GENOME BIOL
   Bedi U, 2014, ONCOTARGET, V5, P2016, DOI 10.18632/oncotarget.1875
   Brennecke J, 2007, CELL, V128, P1089, DOI 10.1016/j.cell.2007.01.043
   Caffrey JJ, 2000, J BIOL CHEM, V275, P12730, DOI 10.1074/jbc.275.17.12730
   Caffrey JJ, 2001, GENE, V269, P53, DOI 10.1016/S0378-1119(01)00446-2
   Chen C, 2013, CANCER BIOMARK, V13, P315, DOI 10.3233/CBM-130360
   Cheng J, 2012, CANCER LETT, V315, P12, DOI 10.1016/j.canlet.2011.10.004
   Chu HY, 2015, CANCER LETT, V356, P561, DOI 10.1016/j.canlet.2014.10.004
   Cunningham JM, 2014, SCI REP-UK, V4, DOI 10.1038/srep04026
   Deng B, 2016, SCI REP-UK, V6, DOI 10.1038/srep28301
   Devouassoux-Shisheboran M, 2015, CHIN J CANCER, V34, P50, DOI 10.5732/cjc.014.10273
   Drerup CM, 2017, ELIFE, V6, DOI 10.7554/eLife.22234
   Ehrlich M, 2009, EPIGENOMICS-UK, V1, P239, DOI [10.2217/epi.09.33, 10.2217/EPI.09.33]
   Eisele SC, 2015, CLIN CANCER RES, V21, P1978, DOI 10.1158/1078-0432.CCR-14-2604
   Elbarbary RA, 2016, SCIENCE, V351, DOI 10.1126/science.aac7247
   Feuerecker B, 2012, CANCER BIOL THER, V13, P1425, DOI 10.4161/cbt.22003
   Girard A, 2006, NATURE, V442, P199, DOI 10.1038/nature04917
   Giurato G, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-362
   Goh WSS, 2015, GENE DEV, V29, P1032, DOI 10.1101/gad.260455.115
   Gou LT, 2014, CELL RES, V24, P680, DOI 10.1038/cr.2014.41
   Grudzien-Nogalska E, 2016, RNA, V22, P773, DOI 10.1261/rna.055699.115
   Gubbels JAA, 2010, J OVARIAN RES, V3, DOI 10.1186/1757-2215-3-8
   Hashim A, 2014, ONCOTARGET, V5, P9901, DOI 10.18632/oncotarget.2476
   Hendrix ND, 2006, CANCER RES, V66, P1354, DOI 10.1158/0008-5472.CAN-05-3694
   Homolka D, 2015, CELL REP, V12, P418, DOI 10.1016/j.celrep.2015.06.030
   Iorio MV, 2007, CANCER RES, V67, P8699, DOI 10.1158/0008-5472.CAN-07-1936
   James SJ, 2002, J NUTR, V132, p2361S, DOI 10.1093/jn/132.8.2361S
   Jilaveanu LB, 2015, CLIN CANCER RES, V21, P2138, DOI 10.1158/1078-0432.CCR-14-0861
   Kafara P, 2015, J OVARIAN RES, V8, DOI 10.1186/s13048-015-0165-z
   Kaur M, 2009, NUCLEIC ACIDS RES, V37, pD820, DOI 10.1093/nar/gkn593
   Kokura K, 2010, EMBO J, V29, P3673, DOI 10.1038/emboj.2010.239
   Langmead B, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-3-r25
   Malone CD, 2009, COLD SH Q B, V74, P225, DOI 10.1101/sqb.2009.74.052
   MOSIG RA, 2012, J OVARIAN RES, V5
   Mourier T, 2011, BMC GENOMICS, V12, DOI 10.1186/1471-2164-12-440
   Pantano L, 2015, RNA, V21, P1085, DOI 10.1261/rna.046482.114
   Qu YY, 2016, SCI REP-UK, V6, DOI 10.1038/srep36264
   Ravo M, 2015, ONCOTARGET, V6, P4677, DOI 10.18632/oncotarget.2911
   Rearick D, 2011, NUCLEIC ACIDS RES, V39, P2357, DOI 10.1093/nar/gkq1080
   Rizzo F, 2016, ONCOTARGET
   Roy J., 2017, GENOMICS
   Roy J, 2017, MOL BIOSYST, V13, P565, DOI 10.1039/c6mb00699j
   Saavedra OM, 2009, BIOORG MED CHEM LETT, V19, P2747, DOI 10.1016/j.bmcl.2009.03.113
   Samantarrai D, 2017, EXP CELL RES, V357, P33, DOI 10.1016/j.yexcr.2017.04.017
   Samantarrai D, 2013, MOL CANCER RES, V11, P315, DOI 10.1158/1541-7786.MCR-12-0649
   Shindo-Okada N, 2003, BIOCHEM BIOPH RES CO, V312, P889, DOI 10.1016/j.bbrc.2003.10.200
   Spilka R, 2013, CANCER LETT, V340, P9, DOI 10.1016/j.canlet.2013.06.019
   Sun L.N., 2015, IND SAFETY ENV PRO, V1, P8, DOI DOI 10.15252/EMBR.201439792
   Sung PL, 2014, GYNECOL ONCOL, V133, P147, DOI 10.1016/j.ygyno.2014.02.016
   Suzuki Ryusuke, 2012, Frontiers in Genetics, V3, P204, DOI 10.3389/fgene.2012.00204
   Vandewege MW, 2016, GENOME BIOL EVOL, V8, P1327, DOI 10.1093/gbe/evw078
   Watanabe T, 2015, GENOME RES, V25, P368, DOI 10.1101/gr.180802.114
   Wu JY, 2013, RNA BIOL, V10, P1087, DOI 10.4161/rna.25193
   Wyman SK, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005311
   Xiao BX, 2009, CLIN CHIM ACTA, V400, P97, DOI 10.1016/j.cca.2008.10.021
   Yan H, 2015, LEUKEMIA, V29, P196, DOI 10.1038/leu.2014.135
   Yang N, 2008, CANCER RES, V68, P10307, DOI 10.1158/0008-5472.CAN-08-1954
   Yogev Ohad, 2011, Silence, V2, P6, DOI 10.1186/1758-907X-2-6
   Zanni V, 2013, P NATL ACAD SCI USA, V110, P19842, DOI 10.1073/pnas.1313677110
   Zhang H, 2013, SURG ONCOL, V22, P217, DOI 10.1016/j.suronc.2013.07.001
   Zou Y, 2012, BIOCELL, V36, P127
NR 62
TC 50
Z9 52
U1 0
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JAN 10
PY 2018
VL 13
IS 1
AR e0190485
DI 10.1371/journal.pone.0190485
PG 24
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA FS3NS
UT WOS:000419689600053
PM 29320577
OA gold, Green Published, Green Submitted
DA 2025-01-12
ER

PT J
AU Masudo, K
   Suganuma, N
   Nakayama, H
   Oshima, T
   Rino, Y
   Iwasaki, H
   Matsuzu, K
   Sugino, K
   Ito, K
   Kondo, T
   Nakamura, Y
   Yoshihara, M
   Masuda, M
   Miyagi, Y
AF Masudo, Katsuhiko
   Suganuma, Nobuyasu
   Nakayama, Hirotaka
   Oshima, Takashi
   Rino, Yasushi
   Iwasaki, Hiroyuki
   Matsuzu, Kenichi
   Sugino, Kiminori
   Ito, Koichi
   Kondo, Tetsuo
   Nakamura, Yoshiyasu
   Yoshihara, Mitsuyo
   Masuda, Munetaka
   Miyagi, Yohei
TI EZH2 Overexpression as a Useful Prognostic Marker for Aggressive
   Behaviour in Thyroid Cancer
SO IN VIVO
LA English
DT Article
DE Thyroid cancer; EZH2; prognostic factor; epigenetics
ID BREAST-CANCER; METHYLTRANSFERASE EZH2; POLYCOMB; CARCINOMA; CELLS;
   METHYLATION; PAPILLARY
AB Background/Aim: Enhancer of zeste homolog 2 (EZH2) is a member of the polycomb group of genes, which are key factors in the regulation of cell proliferation and differentiation. EZH2 is overexpressed in many malignancies. We analyzed EZH2 protein expression levels in different histological subtypes of thyroid cancer to examine its utility as a prognostic factor. Materials and Methods: We examined EZH2 protein expression by immunohistochemistry in tissue samples from 67 cases of poorly differentiated (PDTC) and 48 cases of anaplastic thyroid carcinoma (ATC), and in samples of adjacent normal and differentiated thyroid carcinoma (DTC). We examined differences in expression of EZH2 among various histological types of thyroid cancer, and the relationship between EZH2 expression and patient outcome. Results: EZH2 protein was expressed in PDTC and ATC, but not in normal thyroid gland or DTC. EZH-positivity increased in the order of DTC, PDTC, and ATC (p<0.01). Higher EZH2 expression correlated with poorer survival in PDTC (p=0.004), and a similar but non-significant trend was observed in ATC (p=0.166). Multivariate analysis identified EZH2 as an independent prognostic factor similar to metastatic status in the Japanese Society of Thyroid Surgery (JSTS) classification of PDTC. Conclusion: EZH2 overexpression is associated with malignant potential in thyroid cancer, and may thus be a useful prognostic marker of aggressive thyroid cancer.
C1 [Masudo, Katsuhiko; Suganuma, Nobuyasu; Nakayama, Hirotaka; Oshima, Takashi; Rino, Yasushi; Masuda, Munetaka] Yokohama City Univ, Dept Surg, Yokohama, Kanagawa, Japan.
   [Suganuma, Nobuyasu; Iwasaki, Hiroyuki] Kanagawa Canc Ctr, Dept Breast & Endocrine Surg, Yokohama, Kanagawa, Japan.
   [Matsuzu, Kenichi; Sugino, Kiminori; Ito, Koichi] Ito Hosp, Dept Surg, Tokyo, Japan.
   [Kondo, Tetsuo] Univ Yamanashi, Dept Human Pathol, Yamanashi, Japan.
   [Nakamura, Yoshiyasu; Yoshihara, Mitsuyo; Miyagi, Yohei] Kanagawa Canc Ctr, Res Inst, Mol Pathol & Genet Div, Yokohama, Kanagawa, Japan.
C3 Yokohama City University; Kanagawa Prefectural Cancer Center; University
   of Yamanashi; Kanagawa Prefectural Cancer Center
RP Suganuma, N (通讯作者)，Yokohama City Univ, Dept Surg, Kanazawa Ku, 3-9 Fukuura, Yokohama, Kanagawa 2360004, Japan.
EM n-suga@vesta.dti.ne.jp
RI Iwasaki, Hiroyuki/J-9285-2019
OI Iwasaki, Hiroyuki/0000-0002-9724-8525; SUGINO,
   Kiminori/0000-0002-9692-9871
FU MEXT/JSPS KAKENHI Grant [JP 26461954]
FX This work was supported by grants from the MEXT/JSPS KAKENHI Grant
   Number JP 26461954. The Authors would like to express their gratitude to
   the staff in the Departments of Pathology, Kanagawa Cancer Centre and
   Ito Hospital for their technical assistance and for collecting cancer
   tissues. The Authors would also like to thank Susan Furness, PhD, from
   Edanz Group (www.edanzediting.com/ac) for editing a draft of this
   manuscript.
CR Ahn HS, 2014, NEW ENGL J MED, V371, P1765, DOI 10.1056/NEJMp1409841
   [Anonymous], 2005, JAPANESE SOC THYROID
   Asangani IA, 2013, MOL CELL, V49, P80, DOI 10.1016/j.molcel.2012.10.008
   Borbone E, 2011, J CLIN ENDOCR METAB, V96, P1029, DOI 10.1210/jc.2010-1784
   Boyer LA, 2006, NATURE, V441, P349, DOI 10.1038/nature04733
   Bracken AP, 2003, EMBO J, V22, P5323, DOI 10.1093/emboj/cdg542
   Cao R, 2002, SCIENCE, V298, P1039, DOI 10.1126/science.1076997
   Dang XM, 2012, CANCER GENET-NY, V205, P113, DOI 10.1016/j.cancergen.2012.01.002
   Davies L, 2006, JAMA-J AM MED ASSOC, V295, P2164, DOI 10.1001/jama.295.18.2164
   Derfoul A, 2011, CARCINOGENESIS, V32, P1607, DOI 10.1093/carcin/bgr184
   Esposito F, 2012, J CLIN ENDOCR METAB, V97, pE710, DOI 10.1210/jc.2011-3068
   Fujii S, 2011, ONCOGENE, V30, P4118, DOI 10.1038/onc.2011.118
   Inari H, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3154-3
   Ito Y, 2008, WORLD J SURG, V32, P1535, DOI 10.1007/s00268-007-9406-7
   Kazanets A, 2016, BBA-REV CANCER, V1865, P275, DOI 10.1016/j.bbcan.2016.04.001
   Knutson SK, 2013, P NATL ACAD SCI USA, V110, P7922, DOI 10.1073/pnas.1303800110
   Kondo Y, 2014, J BIOCHEM, V156, P249, DOI 10.1093/jb/mvu054
   Levine SS, 2002, MOL CELL BIOL, V22, P6070, DOI 10.1128/MCB.22.17.6070-6078.2002
   Nguyen QT, 2015, AM HEALTH DRUG BENEF, V8, P30
   SAKAMOTO A, 1983, CANCER-AM CANCER SOC, V52, P1849, DOI 10.1002/1097-0142(19831115)52:10<1849::AID-CNCR2820521015>3.0.CO;2-X
   Schuettengruber B, 2007, CELL, V128, P735, DOI 10.1016/j.cell.2007.02.009
   Smallridge RC, 2010, CLIN ONCOL-UK, V22, P486, DOI 10.1016/j.clon.2010.03.013
   Sobrinho-Simoes M., 2004, World Health Organization Classification of Tumours Pathology and Genetics Tumours of Endocrine Organs, P73
   Sponziello M, 2014, MOL CELL ENDOCRINOL, V392, P8, DOI 10.1016/j.mce.2014.04.016
   Sugitani I, 2012, WORLD J SURG, V36, P1247, DOI 10.1007/s00268-012-1437-z
   Volante M, 2007, AM J SURG PATHOL, V31, P1256, DOI 10.1097/PAS.0b013e3180309e6a
   Yoo KH, 2012, INT J BIOL SCI, V8, P59, DOI 10.7150/ijbs.8.59
NR 27
TC 27
Z9 28
U1 0
U2 3
PU INT INST ANTICANCER RESEARCH
PI ATHENS
PA EDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22,
   ATHENS 19014, GREECE
SN 0258-851X
EI 1791-7549
J9 IN VIVO
JI In Vivo
PD JAN-FEB
PY 2018
VL 32
IS 1
BP 25
EP 31
DI 10.21873/invivo.11200
PG 7
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA FR6PY
UT WOS:000419189400004
PM 29275295
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Phillips, JL
   Taberlay, PC
   Woodworth, AM
   Hardy, K
   Brettingham-Moore, KH
   Dickinson, JL
   Holloway, AF
AF Phillips, Jessica L.
   Taberlay, Phillippa C.
   Woodworth, Alexandra M.
   Hardy, Kristine
   Brettingham-Moore, Kate H.
   Dickinson, Joanne L.
   Holloway, Adele F.
TI Distinct mechanisms of regulation of the ITGA6 and ITGB4 genes by RUNX1
   in myeloid cells
SO JOURNAL OF CELLULAR PHYSIOLOGY
LA English
DT Article
DE gene expression; integrin; RUNX1; transcriptional regulation
ID ACUTE LYMPHOBLASTIC-LEUKEMIA; HEMATOPOIETIC STEM-CELLS; INTEGRIN
   EXPRESSION; BREAST-CANCER; EPIGENETIC REGULATION; ADHESION RECEPTORS;
   FETAL LIVER; DNA-BINDING; AML1; PROTEIN
AB Integrins are transmembrane adhesion receptors that play an important role in hematopoiesis by facilitating interactions between hematopoietic cells and extracellular matrix components of the bone marrow and hematopoietic tissues. These interactions are important in regulating the function, proliferation, and differentiation of hematopoietic cells, as well as their homing and mobilization in the bone marrow. Not surprisingly altered expression and function of integrins plays a key role in the development and progression of cancer including leukemias. However, the regulation of integrin gene expression is not well characterized and the mechanisms by which integrin genes are disrupted in cancer remain unclear. Here we demonstrate for the first time that a key regulator of hematopoiesis, RUNX1, binds to and regulates the promoters of both the ITGA6 and ITGB4 genes in myeloid cells. The ITGA6 and ITGB4 integrin genes form the 64 integrin receptor. However, our data indicate that RUNX1 functions differently at these two promoters. RUNX1 regulates ITGA6 through a consensus RUNX1 binding motif in its promoter. In contrast, although the ITGB4 promoter is also activated by RUNX1, it does so in the absence of a recognized consensus RUNX1 binding motif. Furthermore, our data suggest that regulation of ITGB4 may involve interactions between the promoter and upstream regulatory elements.
C1 [Phillips, Jessica L.; Dickinson, Joanne L.] Univ Tasmania, Menzies Inst Med Res, Hobart, Tas, Australia.
   [Taberlay, Phillippa C.; Woodworth, Alexandra M.; Brettingham-Moore, Kate H.; Holloway, Adele F.] Univ Tasmania, Sch Med, Private Bag 34, Hobart, Tas 7000, Australia.
   [Hardy, Kristine] Univ Canberra, Fac Educ Sci Technol & Math, Discipline Biomed Sci, Canberra, ACT, Australia.
C3 University of Tasmania; Menzies Institute for Medical Research;
   University of Tasmania; University of Canberra
RP Holloway, AF (通讯作者)，Univ Tasmania, Sch Med, Private Bag 34, Hobart, Tas 7000, Australia.
EM a.f.holloway@utas.edu.au
RI Hardy, Kristine/D-9985-2011; Dickinson, Joanne/J-7728-2014;
   Brettingham-Moore, Kate/N-7500-2017; Taberlay, Phillippa/C-9616-2010
OI Brettingham-Moore, Kate/0000-0002-4304-4586; Hardy,
   Kristine/0000-0003-1660-4477; Taberlay, Phillippa/0000-0002-5298-8730;
   Woodworth, Alex/0000-0002-3798-4627; Dickinson,
   Joanne/0000-0003-4621-1703
FU David Collins Leukaemia Foundation; Cancer Council Tasmania; University
   of Tasmania Foundation; Australian Research Council; National Health and
   Medical Research Council
FX David Collins Leukaemia Foundation; The Cancer Council Tasmania; The
   University of Tasmania Foundation; Australian Research Council; National
   Health and Medical Research Council
CR Barutcu AR, 2016, BBA-GENE REGUL MECH, V1859, P1389, DOI 10.1016/j.bbagrm.2016.08.003
   Beck D, 2013, BLOOD, V122, pE12, DOI 10.1182/blood-2013-03-490425
   Bert AG, 2000, PLASMID, V44, P173, DOI 10.1006/plas.2000.1474
   Bowers SR, 2010, NUCLEIC ACIDS RES, V38, P6124, DOI 10.1093/nar/gkq356
   Brettingham-Moore KH, 2005, NUCLEIC ACIDS RES, V33, P225, DOI 10.1093/nar/gki161
   Brouwer RE, 2001, BRIT J HAEMATOL, V115, P298, DOI 10.1046/j.1365-2141.2001.03085.x
   Chen M, 2009, J BIOL CHEM, V284, P1484, DOI 10.1074/jbc.M803997200
   Chen XX, 2005, MOL CELL BIOL, V25, P3209, DOI 10.1128/MCB.25.8.3209-3219.2005
   Cockerill PN, 1996, CELL GROWTH DIFFER, V7, P917
   Csanaky G, 1997, LEUKEMIA, V11, P408, DOI 10.1038/sj.leu.2400582
   Dal Cin P, 2001, GENE CHROMOSOME CANC, V30, P407, DOI 10.1002/1098-2264(2001)9999:9999<::AID-GCC1107>3.0.CO;2-C
   De Braekeleer E, 2011, FUTURE ONCOL, V7, P77, DOI [10.2217/fon.10.158, 10.2217/FON.10.158]
   de Guzman CG, 2002, MOL CELL BIOL, V22, P5506, DOI 10.1128/MCB.22.15.5506-5517.2002
   DeKelver RC, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003765
   Delforge M, 2005, LEUKEMIA, V19, P57, DOI 10.1038/sj.leu.2403551
   Elagib KE, 2003, BLOOD, V101, P4333, DOI 10.1182/blood-2002-09-2708
   Follows GA, 2003, EMBO J, V22, P2798, DOI 10.1093/emboj/cdg250
   Geijtenbeek TBH, 1999, BLOOD, V94, P754, DOI 10.1182/blood.V94.2.754.414k11_754_764
   Gerson KD, 2012, BIOL OPEN, V1, P658, DOI 10.1242/bio.20121628
   Harewood L, 2003, LEUKEMIA, V17, P547, DOI 10.1038/sj.leu.2402849
   Hebestreit K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039148
   Holloway AF, 2000, J BIOL CHEM, V275, P21668, DOI 10.1074/jbc.M909058199
   Huang H, 2009, MOL CELL BIOL, V29, P4103, DOI 10.1128/MCB.00090-09
   Ichikawa H, 2006, BRIT J HAEMATOL, V135, P336, DOI 10.1111/j.1365-2141.2006.06310.x
   Kitabayashi I, 1998, EMBO J, V17, P2994, DOI 10.1093/emboj/17.11.2994
   Lam K, 2012, FRONT BIOSCI-LANDMRK, V17, P1120, DOI 10.2741/3977
   LEVESQUE JP, 1995, J EXP MED, V181, P1805, DOI 10.1084/jem.181.5.1805
   Licht JD, 2001, ONCOGENE, V20, P5660, DOI 10.1038/sj.onc.1204593
   Lie-A-Ling M, 2014, BLOOD, V124, pE11, DOI 10.1182/blood-2014-04-572958
   Lu S, 2008, CLIN CANCER RES, V14, P1050, DOI 10.1158/1078-0432.CCR-07-4116
   Martens JHA, 2012, BLOOD, V120, P4038, DOI 10.1182/blood-2012-05-429050
   MEYERS S, 1995, MOL CELL BIOL, V15, P1974
   MEYERS S, 1993, MOL CELL BIOL, V13, P6336, DOI 10.1128/MCB.13.10.6336
   Michaud J, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-363
   Mikhail FM, 2002, LEUKEMIA, V16, P658, DOI 10.1038/sj.leu.2402399
   MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431
   MIYOSHI H, 1993, EMBO J, V12, P2715, DOI 10.1002/j.1460-2075.1993.tb05933.x
   Niini T, 2000, HAEMATOLOGICA, V85, P362
   Oakford PC, 2010, LEUKEMIA RES, V34, P1203, DOI 10.1016/j.leukres.2010.03.029
   OGAWA E, 1993, VIROLOGY, V194, P314, DOI 10.1006/viro.1993.1262
   Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1
   Osato M, 1999, BLOOD, V93, P1817, DOI 10.1182/blood.V93.6.1817.406k36_1817_1824
   Otto F, 2003, J CELL BIOCHEM, V89, P9, DOI 10.1002/jcb.10491
   PAPAYANNOPOULOU T, 1993, P NATL ACAD SCI USA, V90, P9374, DOI 10.1073/pnas.90.20.9374
   Peterson LF, 2007, LEUKEMIA, V21, P2010, DOI 10.1038/sj.leu.2404849
   Ponnusamy K, 2015, ONCOGENESIS, V4, DOI 10.1038/oncsis.2015.6
   Ponnusamy K, 2014, HAEMATOLOGICA, V99, DOI 10.3324/haematol.2014.106088
   Potocnik AJ, 2000, IMMUNITY, V12, P653, DOI 10.1016/S1074-7613(00)80216-2
   Prosper F, 1998, J CLIN INVEST, V101, P2456, DOI 10.1172/JCI188
   Prosper F, 2001, J LEUKOCYTE BIOL, V69, P307
   Ptasinska A, 2014, CELL REP, V8, P1974, DOI 10.1016/j.celrep.2014.08.024
   Puig-Kröger A, 2003, BLOOD, V102, P3252, DOI 10.1182/blood-2003-02-0618
   Rada-Iglesias A, 2011, NATURE, V470, P279, DOI 10.1038/nature09692
   Reed-Inderbitzin E, 2006, ONCOGENE, V25, P5777, DOI 10.1038/sj.onc.1209591
   Scott LM, 2003, MOL CELL BIOL, V23, P9349, DOI 10.1128/MCB.23.24.9349-9360.2003
   Speck NA, 2002, NAT REV CANCER, V2, P502, DOI 10.1038/nrc840
   Stewart RL, 2016, HUM PATHOL, V54, P174, DOI 10.1016/j.humpath.2016.04.003
   Stewart RL, 2015, LAB INVEST, V95, P976, DOI 10.1038/labinvest.2015.82
   Taberlay PC, 2011, CELL, V147, P1283, DOI 10.1016/j.cell.2011.10.040
   Takada Y, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-5-215
   Tanaka Y, 2012, DEV BIOL, V366, P404, DOI 10.1016/j.ydbio.2012.03.024
   Tijssen MR, 2011, DEV CELL, V20, P597, DOI 10.1016/j.devcel.2011.04.008
   Valk PJM, 2004, NEW ENGL J MED, V350, P1617, DOI 10.1056/NEJMoa040465
   van der Loo JCM, 1998, J CLIN INVEST, V102, P1051, DOI 10.1172/JCI3687
   VERFAILLIE CM, 1992, J CLIN INVEST, V90, P1232, DOI 10.1172/JCI115985
   Wierenga PK, 2006, BONE MARROW TRANSPL, V38, P789, DOI 10.1038/sj.bmt.1705534
   Wilson NK, 2010, MOL CELL BIOL, V30, P3853, DOI 10.1128/MCB.00032-10
   Wotton S, 2008, ONCOGENE, V27, P5856, DOI 10.1038/onc.2008.195
   Yan M, 2004, P NATL ACAD SCI USA, V101, P17468, DOI 10.1073/pnas.0406142101
   Yan M, 2006, NAT MED, V12, P945, DOI 10.1038/nm1443
   Yergeau DA, 1997, NAT GENET, V15, P303, DOI 10.1038/ng0397-303
NR 71
TC 12
Z9 13
U1 0
U2 13
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0021-9541
EI 1097-4652
J9 J CELL PHYSIOL
JI J. Cell. Physiol.
PD APR
PY 2018
VL 233
IS 4
BP 3439
EP 3453
DI 10.1002/jcp.26197
PG 15
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Physiology
GA FR0AL
UT WOS:000418723200070
PM 28926098
OA Green Published, Green Accepted
DA 2025-01-12
ER

PT J
AU McVeigh, TP
   Mulligan, RJ
   McVeigh, UM
   Owens, PW
   Miller, N
   Bell, M
   Sebag, F
   Guerin, C
   Quill, DS
   Weidhaas, JB
   Kerin, MJ
   Lowery, AJ
AF McVeigh, T. P.
   Mulligan, R. J.
   McVeigh, U. M.
   Owens, P. W.
   Miller, N.
   Bell, M.
   Sebag, F.
   Guerin, C.
   Quill, D. S.
   Weidhaas, J. B.
   Kerin, M. J.
   Lowery, A. J.
TI Investigating the association of rs2910164 with cancer predisposition in
   an Irish cohort
SO ENDOCRINE CONNECTIONS
LA English
DT Article
DE thyroid; endocrine cancers
ID MULTIPLE PRIMARY BREAST; THYROID-CANCER; MICRORNA POLYMORPHISMS;
   NONCODING RNA; MIR-146A; RISK; SUSCEPTIBILITY; EXPRESSION; GENE;
   PRE-MIR-146A
AB Introduction: MicroRNAs (miRNAs) are small noncoding RNA molecules that exert post-transcriptional effects on gene expression by binding with cis-regulatory regions in target messenger RNA (mRNA). Polymorphisms in genes encoding miRNAs or in miRNA-mRNA binding sites confer deleterious epigenetic effects on cancer risk. miR-146a has a role in inflammation and may have a role as a tumour suppressor. The polymorphism rs2910164 in the MIR146A gene encoding pre-miR-146a has been implicated in several inflammatory pathologies, including cancers of the breast and thyroid, although evidence for the associations has been conflicting in different populations. We aimed to further investigate the association of this variant with these two cancers in an Irish cohort.
   Methods: The study group comprised patients with breast cancer (BC), patients with differentiated thyroid cancer (DTC) and unaffected controls. Germline DNA was extracted from blood or from saliva collected using the DNA Genotek Oragene 575 collection kit, using crystallisation precipitation, and genotyped using TaqMan-based PCR. Data were analysed using SPSS, v22.
   Results: The total study group included 1516 participants. This comprised 1386 Irish participants; 724 unaffected individuals (controls), 523 patients with breast cancer (BC), 136 patients with differentiated thyroid cancer (DTC) and three patients with dual primary breast and thyroid cancer. An additional cohort of 130 patients with DTC from the South of France was also genotyped for the variant. The variant was detected with a minor allele frequency (MAF) of 0.19 in controls, 0.22 in BC and 0.27 and 0.26 in DTC cases from Ireland and France, respectively. The variant was not significantly associated with BC (per allele odds ratio = 1.20 (0.98-1.46), P = 0.07), but was associated with DTC in Irish patients (per allele OR = 1.59 (1.18-2.14), P = 0.002).
   Conclusion: The rs2910164 variant in MIR146A is significantly associated with DTC, but is not significantly associated with BC in this cohort.
C1 [McVeigh, T. P.; Mulligan, R. J.; McVeigh, U. M.; Owens, P. W.; Miller, N.; Quill, D. S.; Kerin, M. J.; Lowery, A. J.] NUI Galway, Discipline Surg, Lambe Inst Translat Res, Sch Med, Galway, Ireland.
   [Bell, M.] NUI Galway, Dept Endocrinol, Sch Med, Galway, Ireland.
   [Sebag, F.; Guerin, C.] Ctr Hosp Univ La Conception, AP HM, Dept Endocrine Surg, Marseille, France.
   [Sebag, F.; Guerin, C.] Aix Marseille Univ, Fac Med, Marseille, France.
   [Weidhaas, J. B.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
C3 Ollscoil na Gaillimhe-University of Galway; Ollscoil na
   Gaillimhe-University of Galway; Aix-Marseille Universite; Assistance
   Publique-Hopitaux de Marseille; Aix-Marseille Universite; University of
   California System; University of California Los Angeles; University of
   California Los Angeles Medical Center; David Geffen School of Medicine
   at UCLA
RP McVeigh, TP (通讯作者)，NUI Galway, Discipline Surg, Lambe Inst Translat Res, Sch Med, Galway, Ireland.
EM terri.mcveigh@gmail.com
RI Miller, Nicola/F-4009-2018; McVeigh, Terri/K-2330-2017; Kerin,
   Michael/D-6748-2013
OI Owens, Patrick/0000-0002-3419-7716; Kerin, Michael/0000-0003-4164-5561;
   LOWERY, AOIFE/0000-0002-8062-6235; McVeigh, Terri/0000-0001-9201-9216
FU Health Research Board/Health Service Executive National Academic
   Specialist Registrar Fellowship [NSAFP/2014/1]; Health Research Board
   Summer Student Scholarship; Breast Cancer Research; Health Research
   Board (HRB) [NSAFP-2014-1] Funding Source: Health Research Board (HRB)
FX Dr Terri McVeigh was supported by the Health Research Board/Health
   Service Executive National Academic Specialist Registrar Fellowship
   (NSAFP/2014/1), Dr Robert Mulligan was supported by a Health Research
   Board Summer Student Scholarship. Dr Patrick Owens and Ms Una McVeigh
   were supported by PhD scholarships from Breast Cancer Research.
CR Afsharzadeh SM, 2017, META GENE, V11, P20, DOI 10.1016/j.mgene.2016.11.004
   Alshatwi AA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030049
   Altshuler DM, 2015, NATURE, V526, P68, DOI 10.1038/nature15393
   An JH, 2015, THYROID, V25, P1330, DOI 10.1089/thy.2014.0561
   [Anonymous], PLOS ONE
   [Anonymous], PLOS ONE
   [Anonymous], END ABSTR
   [Anonymous], CENS POP 2016 PREL R
   [Anonymous], T123 TECHN B
   [Anonymous], 2017, OV UK POP JUL 2017
   [Anonymous], BRIT J SURG
   Bansal C, 2014, ECANCERMEDICALSCIENC, V8, DOI 10.3332/ecancer.2014.473
   Bao MH, 2015, INT J MOL SCI, V16, P14305, DOI 10.3390/ijms160714305
   Bhaumik D, 2008, ONCOGENE, V27, P5643, DOI 10.1038/onc.2008.171
   Bockmeyer CL, 2011, BREAST CANCER RES TR, V130, P735, DOI 10.1007/s10549-010-1303-3
   Boufraqech M, 2016, BEST PRACT RES CL EN, V30, P603, DOI 10.1016/j.beem.2016.10.001
   Catucci I, 2010, HUM MUTAT, V31, pE1052, DOI 10.1002/humu.21141
   Chaker L, 2016, NAT REV ENDOCRINOL, V12, P313, DOI 10.1038/nrendo.2016.48
   Chen AY, 2001, CANCER-AM CANCER SOC, V92, P225, DOI 10.1002/1097-0142(20010715)92:2<225::AID-CNCR1313>3.0.CO;2-B
   Chen JJ, 2015, INT J CLIN EXP MED, V8, P15852
   Chen QH, 2014, TUMOR BIOL, V35, P529, DOI 10.1007/s13277-013-1074-7
   Dai RJ, 2008, BLOOD, V112, P4591, DOI 10.1182/blood-2008-04-152488
   Dong G, 2015, INT J CLIN EXP PATHO, V8, P13450
   Cardeñosa EE, 2012, FAM CANCER, V11, P629, DOI 10.1007/s10689-012-9563-1
   Evans DG, 2017, J MED GENET, V54, P104, DOI 10.1136/jmedgenet-2016-104125
   Gao LB, 2011, BREAST CANCER RES TR, V125, P571, DOI 10.1007/s10549-010-0993-x
   Garcia AI, 2011, HUM MUTAT, V32, P1004, DOI 10.1002/humu.21539
   Garcia AI, 2011, EMBO MOL MED, V3, P279, DOI 10.1002/emmm.201100136
   Garraway LA, 2014, NEW ENGL J MED, V370, P1950, DOI 10.1056/NEJMcibr1402173
   Giani C, 1996, J CLIN ENDOCR METAB, V81, P990, DOI 10.1210/jc.81.3.990
   Gogas J, 2001, EUR J SURG ONCOL, V27, P626, DOI 10.1053/ejso.2001.1204
   Hou J, 2009, J IMMUNOL, V183, P2150, DOI 10.4049/jimmunol.0900707
   Hu ZB, 2009, HUM MUTAT, V30, P79, DOI 10.1002/humu.20837
   Hurst DR, 2009, CANCER RES, V69, P1279, DOI 10.1158/0008-5472.CAN-08-3559
   Jazdzewski K, 2008, P NATL ACAD SCI USA, V105, P7269, DOI 10.1073/pnas.0802682105
   Jazdzewski K, 2011, J CLIN ENDOCR METAB, V96, pE546, DOI 10.1210/jc.2010-1594
   Jazdzewski K, 2009, CELL CYCLE, V8, P1642
   Jazdzewski K, 2009, P NATL ACAD SCI USA, V106, P1502, DOI 10.1073/pnas.0812591106
   Jones AM, 2012, J MED GENET, V49, P158, DOI 10.1136/jmedgenet-2011-100586
   Kumaraswamy E, 2015, ONCOGENE, V34, P4333, DOI 10.1038/onc.2014.363
   Li CI, 2000, CANCER CAUSE CONTROL, V11, P805, DOI 10.1023/A:1008942616092
   Li Y, 2015, CELL PHYSIOL BIOCHEM, V35, P281, DOI 10.1159/000369695
   Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64
   Ling YQ, 2015, TUMORI, V101, P572, DOI 10.5301/tj.5000272
   Ma W, 2017, ONCOTARGET, V8, P28028, DOI 10.18632/oncotarget.15885
   Marino M, 2013, ENDOCR CONNECT, V2, P178, DOI 10.1530/EC-13-0066
   Meshkat M, 2016, CANCER BIOMARK, V17, P213, DOI 10.3233/CBM-160633
   Nielsen SM, 2016, CANCER EPIDEM BIOMAR, V25, P231, DOI 10.1158/1055-9965.EPI-15-0833
   Omrani M, 2014, BIOMARK MED, V8, P259, DOI 10.2217/bmm.13.118
   Pacifico F, 2010, J CLIN ENDOCR METAB, V95, P1421, DOI 10.1210/jc.2009-1128
   Pal T, 2001, Fam Cancer, V1, P17, DOI 10.1023/A:1011541424424
   Park R, 2016, AUTOIMMUNITY, V49, P451, DOI 10.3109/08916934.2016.1171854
   Pasquinelli AE, 2012, NAT REV GENET, V13, P271, DOI 10.1038/nrg3162
   Pastrello C, 2010, CARCINOGENESIS, V31, P2124, DOI 10.1093/carcin/bgq184
   Portulano C, 2014, ENDOCR REV, V35, P106, DOI 10.1210/er.2012-1036
   Qi P, 2015, GENET MOL RES, V14, P6289, DOI 10.4238/2015.June.11.2
   RON E, 1984, BRIT J CANCER, V49, P87, DOI 10.1038/bjc.1984.13
   Ryan J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016023
   Sand PG, 2007, BEHAV BRAIN FUNCT, V3, DOI 10.1186/1744-9081-3-65
   Sandhu R, 2014, CARCINOGENESIS, V35, P2567, DOI 10.1093/carcin/bgu175
   Savas S, 2009, ONCOLOGIST, V14, P657, DOI 10.1634/theoncologist.2009-0042
   Shen J, 2008, CARCINOGENESIS, V29, P1963, DOI 10.1093/carcin/bgn172
   Siolek M, 2015, INT J CANCER, V137, P548, DOI 10.1002/ijc.29426
   Smyth PPA, 1998, J CLIN ENDOCR METAB, V83, P2711, DOI 10.1210/jc.83.8.2711
   Sun M, 2015, CANCER BIOMARK, V15, P33, DOI 10.3233/CBM-140431
   Taganov KD, 2006, P NATL ACAD SCI USA, V103, P12481, DOI 10.1073/pnas.0605298103
   Upadhyaya A, 2016, GENE, V576, P256, DOI 10.1016/j.gene.2015.10.019
   Wang AX, 2012, GENET MOL RES, V11, P3051, DOI 10.4238/2012.August.31.2
   Wei WJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056638
   Xu B, 2015, PROSTATE, V75, P1896, DOI 10.1002/pros.23068
   Xu Z, 2014, BMC MED GENET, V15, DOI 10.1186/s12881-014-0117-2
   Zhang H, 2017, ONCOTARGET, V8, P393, DOI 10.18632/oncotarget.13426
   Zhang X, 2015, INT J ENDOCRINOL, V2015, DOI 10.1155/2015/802562
   Zhou XD, 2015, JOINT BONE SPINE, V82, P166, DOI 10.1016/j.jbspin.2014.12.009
   Zhu M, 2016, MOL MED REP, V13, P5297, DOI 10.3892/mmr.2016.5157
NR 75
TC 5
Z9 6
U1 0
U2 5
PU BIOSCIENTIFICA LTD
PI BRISTOL
PA STARLING HOUSE, 1600 BRISTOL PARKWAY N, BRISTOL, ENGLAND
EI 2049-3614
J9 ENDOCR CONNECT
JI Endocr. Connect.
PD NOV 1
PY 2017
VL 6
IS 8
BP 614
EP 624
DI 10.1530/EC-17-0196
PG 11
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Endocrinology & Metabolism
GA FQ6TS
UT WOS:000418497500012
PM 28899898
OA Green Published, gold, Green Submitted
DA 2025-01-12
ER

PT J
AU Soubry, A
AF Soubry, Adelheid
TI Epigenetics as a Driver of Developmental Origins of Health and Disease:
   Did We Forget the Fathers?
SO BIOESSAYS
LA English
DT Article
DE DOHaD; epigenetics; paternal exposome; POHaD
ID ORGANOPHOSPHATE FLAME RETARDANTS; HIGH-FAT DIET; DNA METHYLATION;
   TRANSGENERATIONAL INHERITANCE; PRENATAL EXPOSURE; PATERNAL OBESITY;
   ALCOHOL EXPOSURE; IMPRINTED GENES; BREAST-CANCER; SEMEN QUALITY
AB What are the effects of our environment on human development and the next generation? Numerous studies have provided ample evidence that a healthy environment and lifestyle of the mother is important for her offspring. Biological mechanisms underlying these environmental influences have been proposed to involve alterations in the epigenome. Is there enough evidence to suggest a similar contribution from the part of the father? Animal models provide proof of a transgenerational epigenetic effect through the paternal germ line, but can this be translated to humans? To date, literature on fathers is scarce. Human studies do not always incorporate appropriate tools to evaluate paternal influences or epigenetic effects. In reviewing the literature, I stress the need to explore and recognize paternal contributions to offspring's health within the Developmental Origins of Health and Disease hypothesis, and coin this new concept the Paternal Origins of Health and Disease paradigm (POHaD). A better understanding of preconceptional origins of disease through the totality of paternal exposures, or the paternal exposome, will provide evidence-based public health recommendations for future fathers.
C1 [Soubry, Adelheid] Univ Leuven, Dept Publ Hlth & Primary Care, Epidemiol Res Grp, Fac Med,KU Leuven, Leuven, Belgium.
C3 KU Leuven
RP Soubry, A (通讯作者)，Univ Leuven, Dept Publ Hlth & Primary Care, Epidemiol Res Grp, Fac Med,KU Leuven, Leuven, Belgium.
EM adelheid.soubry@hotmail.com
RI Soubry, Adelheid/LWI-5218-2024
FU KU Leuven University [OT/14/109]
FX Many thanks to Herlinda Vekemans for editing the text. This work was
   supported by a research grant from KU Leuven University (OT/14/109).
CR Agarwal A, 2015, REPROD BIOL ENDOCRIN, V13, DOI 10.1186/s12958-015-0032-1
   Binder NK, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052304
   Bohacek J, 2017, NAT METHODS, V14, P243, DOI [10.1038/NMETH.4181, 10.1038/nmeth.4181]
   Bohacek J, 2015, NAT REV GENET, V16, P641, DOI 10.1038/nrg3964
   Bowers ME, 2016, NEUROPSYCHOPHARMACOL, V41, P232, DOI 10.1038/npp.2015.247
   Butt CM, 2014, ENVIRON SCI TECHNOL, V48, P10432, DOI 10.1021/es5025299
   Cao-Lei L, 2016, EARLY HUM DEV, V103, P189, DOI 10.1016/j.earlhumdev.2016.09.013
   CAOLEI L, 2014, PLOS ONE, V0009
   Chen Q, 2016, SCIENCE, V351, P397, DOI 10.1126/science.aad7977
   De Roos AJ, 2001, AM J EPIDEMIOL, V154, P106, DOI 10.1093/aje/154.2.106
   De Rosa M, 2003, HUM REPROD, V18, P1055, DOI 10.1093/bumrep/deg226
   Denham J, 2015, EPIGENOMICS-UK, V7, P717, DOI 10.2217/epi.15.29
   Donkin I, 2016, CELL METAB, V23, P369, DOI 10.1016/j.cmet.2015.11.004
   El-Helaly M, 2011, INT J OCCUP MED ENV, V24, P218, DOI 10.2478/s13382-011-0019-x
   Eustache F, 2009, ENVIRON HEALTH PERSP, V117, P1272, DOI 10.1289/ehp.0800158
   Feinberg J. I., 2015, INT J EPIDEMIOL
   Fridman A, 2011, AGING MENT HEALTH, V15, P232, DOI 10.1080/13607863.2010.505232
   Fullston T, 2017, J ENDOCRINOL, V234, pF1, DOI [10.1530/joe-16-0382, 10.1530/JOE-16-0382]
   Fullston T, 2013, FASEB J, V27, P4226, DOI 10.1096/fj.12-224048
   Gapp K, 2014, NAT NEUROSCI, V17, P667, DOI 10.1038/nn.3695
   GARDNER MJ, 1990, BMJ-BRIT MED J, V300, P423, DOI 10.1136/bmj.300.6722.423
   Goel N, 2017, MECH AGEING DEV, V166, P33, DOI 10.1016/j.mad.2017.08.012
   Grandjean V, 2015, SCI REP-UK, V5, DOI 10.1038/srep18193
   Guerrero-Bosagna C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100194
   Håkonsen LB, 2011, REPROD HEALTH, V8, DOI 10.1186/1742-4755-8-24
   Heijmans BT, 2008, P NATL ACAD SCI USA, V105, P17046, DOI 10.1073/pnas.0806560105
   Hoffman K, 2015, ENVIRON HEALTH PERSP, V123, P160, DOI 10.1289/ehp.1408669
   Hooiveld M, 2006, OCCUP ENVIRON MED, V63, P538, DOI 10.1136/oem.2005.026013
   Hultman CM, 2011, MOL PSYCHIATR, V16, P1203, DOI 10.1038/mp.2010.121
   Hur SSJ, 2017, J MOL ENDOCRINOL, V58, pR159, DOI 10.1530/JME-16-0236
   Jenkins TG, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004458
   Jiménez-Chillarón JC, 2015, EPIGENETICS-US, V10, P259, DOI 10.1080/15592294.2015.1020267
   Józków P, 2017, FERTIL STERIL, V107, P373, DOI 10.1016/j.fertnstert.2016.11.004
   Knezovich Jaysen Gregory, 2012, Frontiers in Genetics, V3, P10, DOI 10.3389/fgene.2012.00010
   Kobayashi H, 2009, EUR J HUM GENET, V17, P1582, DOI 10.1038/ejhg.2009.68
   Kumar Naina, 2015, J Hum Reprod Sci, V8, P191, DOI 10.4103/0974-1208.170370
   Lambrot R, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3889
   Laubenthal J, 2012, FASEB J, V26, P3946, DOI 10.1096/fj.11-201194
   Liang F, 2015, ASIAN J ANDROL, V17, P985, DOI 10.4103/1008-682X.160267
   Lin CC, 2008, INT J OCCUP ENV HEAL, V14, P112, DOI 10.1179/oeh.2008.14.2.112
   Manikkam M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055387
   Marczylo EL, 2012, EPIGENETICS-US, V7, P432, DOI 10.4161/epi.19794
   Mayfield RD, 2017, ALCOHOL, V60, P31, DOI 10.1016/j.alcohol.2017.01.004
   McPherson NO, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071459
   Meeker John D, 2013, Endocr Disruptors (Austin), V1, pe26306
   Meeker JD, 2010, ENVIRON HEALTH PERSP, V118, P318, DOI 10.1289/ehp.0901332
   Mejia-Lancheros C., 2017, 24 ECO C PORT PORT
   Miska EA, 2016, SCIENCE, V354, P59, DOI 10.1126/science.aaf4945
   Ng SF, 2014, FASEB J, V28, P1830, DOI 10.1096/fj.13-244046
   Ng SF, 2010, NATURE, V467, P963, DOI 10.1038/nature09491
   Ngo AD, 2006, INT J EPIDEMIOL, V35, P1220, DOI 10.1093/ije/dyl038
   Northstone K, 2014, EUR J HUM GENET, V22, P1382, DOI 10.1038/ejhg.2014.31
   Ouko LA, 2009, ALCOHOL CLIN EXP RES, V33, P1615, DOI 10.1111/j.1530-0277.2009.00993.x
   Painter RC, 2006, AM J HUM BIOL, V18, P853, DOI 10.1002/ajhb.20564
   Painter RC, 2006, AM J CLIN NUTR, V84, P322
   Palmer NO, 2012, AM J PHYSIOL-ENDOC M, V302, pE768, DOI 10.1152/ajpendo.00401.2011
   Palmer NO, 2011, REPROD FERT DEVELOP, V23, P929, DOI 10.1071/RD10326
   Pembrey ME, 2006, EUR J HUM GENET, V14, P159, DOI 10.1038/sj.ejhg.5201538
   Ponomarev I, 2017, ALCOHOL, V60, P95, DOI 10.1016/j.alcohol.2017.01.016
   RAVELLI GP, 1976, NEW ENGL J MED, V295, P349, DOI 10.1056/NEJM197608122950701
   Reid A, 2011, CANCER CAUSE CONTROL, V22, P1575, DOI 10.1007/s10552-011-9834-4
   Romanus S, 2016, BREAST CANCER RES, V18, DOI 10.1186/s13058-016-0760-y
   Rompala GR, 2017, ALCOHOL, V60, P169, DOI 10.1016/j.alcohol.2016.11.001
   Rönn T, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003572
   Roseboom TJ, 1999, J HYPERTENS, V17, P325, DOI 10.1097/00004872-199917030-00004
   Schagdarsurengin U, 2016, NAT REV UROL, V13, P584, DOI 10.1038/nrurol.2016.157
   Sharma U, 2017, CELL METAB, V25, P544, DOI 10.1016/j.cmet.2017.02.003
   Sharma U, 2016, SCIENCE, V351, P391, DOI 10.1126/science.aad6780
   Shnorhavorian M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170085
   Skinner MK, 2015, EPIGENETICS-US, V10, P762, DOI 10.1080/15592294.2015.1062207
   Soubry A, 2015, INT J OBESITY, V39, P650, DOI 10.1038/ijo.2013.193
   Soubry A., 2014, BIOESSAYS
   Soubry A, 2017, ENVIRON EPIGENETICS, V3, DOI 10.1093/eep/dvx003
   Soubry A, 2016, CLIN EPIGENETICS, V8, DOI 10.1186/s13148-016-0217-2
   Soubry A, 2015, PROG BIOPHYS MOL BIO, V118, P79, DOI 10.1016/j.pbiomolbio.2015.02.008
   Soubry A, 2014, EUR J HUM GENET, V22, P1341, DOI 10.1038/ejhg.2014.206
   Soubry A, 2014, BIOESSAYS, V36, P359, DOI 10.1002/bies.201300113
   Soubry A, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-29
   Stouder C, 2011, REPROD TOXICOL, V31, P507, DOI 10.1016/j.reprotox.2011.02.009
   Stouder C, 2011, REPRODUCTION, V141, P207, DOI 10.1530/REP-10-0400
   Stouder C, 2010, REPRODUCTION, V139, P373, DOI 10.1530/REP-09-0340
   Sung TI, 2009, BIRTH DEFECTS RES A, V85, P119, DOI 10.1002/bdra.20496
   Svanes C, 2017, INT J EPIDEMIOL, V46, P235, DOI 10.1093/ije/dyw151
   Tawn EJ, 2015, J RADIOL PROT, V35, P21, DOI 10.1088/0952-4746/35/1/21
   Tracey R, 2013, REPROD TOXICOL, V36, P104, DOI 10.1016/j.reprotox.2012.11.011
   Tunc O, 2009, J ASSIST REPROD GEN, V26, P537, DOI 10.1007/s10815-009-9346-2
   Van den Eede N, 2013, J CHROMATOGR A, V1303, P48, DOI 10.1016/j.chroma.2013.06.042
   van den Eede N, 2011, ENVIRON INT, V37, P454, DOI 10.1016/j.envint.2010.11.010
   Waterland RA, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001252
   Wu HT, 2017, HUM REPROD, V32, P65, DOI 10.1093/humrep/dew301
   Wu L, 2016, CELL METAB, V23, P735, DOI 10.1016/j.cmet.2016.01.014
   Xu FC, 2016, ENVIRON SCI TECHNOL, V50, P7752, DOI 10.1021/acs.est.6b00246
   Yehuda R, 2016, BIOL PSYCHIAT, V80, P372, DOI 10.1016/j.biopsych.2015.08.005
   Yehuda R, 2009, BIOL PSYCHIAT, V66, P708, DOI 10.1016/j.biopsych.2009.02.034
NR 94
TC 65
Z9 73
U1 1
U2 32
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0265-9247
EI 1521-1878
J9 BIOESSAYS
JI Bioessays
PD JAN
PY 2018
VL 40
IS 1
AR 1700113
DI 10.1002/bies.201700113
PG 10
WC Biochemistry & Molecular Biology; Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
   Topics
GA FQ6AQ
UT WOS:000418445200005
PM 29168895
OA hybrid, Green Published
DA 2025-01-12
ER

PT J
AU Han, T
   Zhuo, M
   Hu, H
   Jiao, F
   Wang, LW
AF Han, Ting
   Zhuo, Meng
   Hu, Hai
   Jiao, Feng
   Wang, Li-Wei
TI Synergistic effects of the combination of 5-Aza-CdR and suberoylanilide
   hydroxamic acid on the anticancer property of pancreatic cancer
SO ONCOLOGY REPORTS
LA English
DT Article
DE 5-Aza-CdR; SAHA; pancreatic cancer; PTEN
ID HISTONE DEACETYLASE INHIBITOR; DNA METHYLTRANSFERASE INHIBITORS; LONG
   NONCODING RNA; PHASE-II TRIAL; BREAST-CANCER; SIGNALING PATHWAY;
   DOWN-REGULATION; SAHA; EXPRESSION; GEMCITABINE
AB Despite increasing advances in the diagnosis and treatment for pancreatic cancer, the mortality rate remains high world-wide. There is an urgent need for new therapies to improve survival and quality of life for pancreatic cancer patient. Epigenetic therapeutic agents such as 5-Aza-CdR and suberoylanilide hydroxamic acid (SAHA) have shown therapeutic effects for human cancers. We evaluated the efficacy of 5-Aza-CdR or SAHA and their combination as potential therapies for pancreatic cancer in vitro. Treatment with 5-Aza-CdR or SAHA inhibited pancreatic cancer cell proliferation, migration and induced cell arrest. However, 5-Aza-CdR alone can not induce cell apoptosis. Combination of the two agents enhanced the proliferation and migration inhibition, and induced more cells to G2 arrest and increased the cell apoptosis proportion. Furthermore, combination treatment with SAHA and 5-Aza-CdR significantly increased expression of TP53 and P16. The possible mechanism might be that the two agents inhibited the PI3K/AKT/PTEN signaling pathway. In conclusion, these data demonstrate a potential role for epigenetic modifier drugs for the management of pancreatic cancer.
C1 [Han, Ting; Zhuo, Meng; Jiao, Feng; Wang, Li-Wei] Shanghai Jiao Tong Univ, Sch Med, Ren Ji Hosp, Dept Oncol, Shanghai 201620, Peoples R China.
   [Hu, Hai] Shanghai Jiao Tong Univ, Sch Med, Shanghai Gen Hosp, Dept Med Oncol, Shanghai, Peoples R China.
   [Hu, Hai] Shanghai Jiao Tong Univ, Sch Med, Shanghai Gen Hosp, Pancreat Canc Ctr, Shanghai, Peoples R China.
C3 Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai
   Jiao Tong University
RP Jiao, F; Wang, LW (通讯作者)，Shanghai Jiao Tong Univ, Sch Med, Ren Ji Hosp, Dept Oncol, Shanghai 201620, Peoples R China.
EM jiao_f@outlook.com; yzwlw@hotmail.com
RI HAN, TINGTING/GQZ-8692-2022
FU National Natural Science Foundation of China [81502017, 81502018,
   81572315, 81171887, 91229117]; National Key Clinical Discipline-Oncology
FX This study was supported by the National Natural Science Foundation of
   China (grant nos. 81502017, 81502018, 81572315, 81171887 and 91229117),
   and in part by National Key Clinical Discipline-Oncology.
CR Amano M, 2012, FEBS J, V279, P4062, DOI 10.1111/febs.12001
   [Anonymous], PANCREATIC CANC
   [Anonymous], 2008, Cancer Facts Figures 2008
   [Anonymous], CANC FACTS FIG 2007
   Asano T, 2004, ONCOGENE, V23, P8571, DOI 10.1038/sj.onc.1207902
   Baruah P, 2015, BRIT J CANCER, V113, P653, DOI 10.1038/bjc.2015.251
   Batty N, 2009, CANCER LETT, V280, P192, DOI 10.1016/j.canlet.2009.03.013
   Blanco J, 2017, ARCH TOXICOL, V91, P651, DOI 10.1007/s00204-016-1773-0
   Brueckner B, 2007, CANCER J, V13, P17, DOI 10.1097/PPO.0b013e31803c7245
   Bu QG, 2014, CANCER BIOL THER, V15, P951, DOI 10.4161/cbt.28931
   Burris HA, 1997, J CLIN ONCOL, V15, P2403, DOI 10.1200/JCO.1997.15.6.2403
   Carmichael J, 1996, BRIT J CANCER, V73, P101, DOI 10.1038/bjc.1996.18
   CASPER ES, 1994, INVEST NEW DRUG, V12, P29, DOI 10.1007/BF00873232
   Chang DK, 2008, J GASTROEN HEPATOL, V23, P1036, DOI 10.1111/j.1440-1746.2008.05471.x
   Chang Z, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101452
   Egger G, 2004, NATURE, V429, P457, DOI 10.1038/nature02625
   Flotho C, 2009, LEUKEMIA, V23, P1019, DOI 10.1038/leu.2008.397
   Gao Y, 2017, NUCLEIC ACIDS RES, V45, P583, DOI 10.1093/nar/gkw1100
   Glaser KB, 2007, BIOCHEM PHARMACOL, V74, P659, DOI 10.1016/j.bcp.2007.04.007
   Gore Steven D, 2005, Nat Clin Pract Oncol, V2 Suppl 1, pS30, DOI 10.1038/ncponc0346
   Han T, 2016, CURR MOL MED, V16, P702, DOI 10.2174/1566524016666160927095812
   Herrero AB, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17122003
   Hockly E, 2003, P NATL ACAD SCI USA, V100, P2041, DOI 10.1073/pnas.0437870100
   Issa JPJ, 2005, SEMIN HEMATOL, V42, pS43, DOI 10.1053/j.seminhematol.2005.05.005
   Jemal A, 2010, CA-CANCER J CLIN, V60, P277, DOI [10.3322/caac.21254, 10.3322/caac.20073]
   Katsushima K, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13616
   Kumagai T, 2007, INT J CANCER, V121, P656, DOI 10.1002/ijc.22558
   Kumar Bhavna, 2015, Genes Cancer, V6, P169
   Laurenzana A, 2009, CANCER RES, V69, P55, DOI 10.1158/0008-5472.CAN-08-0245
   Lee TG, 2015, INT J CANCER, V136, P2717, DOI 10.1002/ijc.29320
   Liang BY, 2015, J HUAZHONG U SCI-MED, V35, P535, DOI 10.1007/s11596-015-1466-6
   Liu ZH, 2014, CANCER CELL INT, V14, DOI 10.1186/s12935-014-0112-x
   Lv DS, 2016, TUMOR BIOL, V37, P16259, DOI 10.1007/s13277-016-5426-y
   Min A, 2015, BREAST CANCER RES, V17, DOI 10.1186/s13058-015-0534-y
   Munster PN, 2001, CANCER RES, V61, P8492
   Pare R, 2016, HISTOPATHOLOGY, V69, P479, DOI 10.1111/his.12948
   Qian XL, 2012, CANCER RES, V72, P5900, DOI 10.1158/0008-5472.CAN-12-2368
   Ramadoss S, 2017, ONCOGENE, V36, P47, DOI 10.1038/onc.2016.174
   Rothenberg ML, 1996, ANN ONCOL, V7, P347
   Watanabe Y, 2010, ADV CLIN CHEM, V52, P145, DOI 10.1016/S0065-2423(10)52006-7
   Xing J, 2015, EUR J GYNAECOL ONCOL, V36, P117
   Yang XF, 2017, ONCOTARGET, V8, P3156, DOI 10.18632/oncotarget.13680
   Zhang ZH, 2006, MODERN PATHOL, V19, P1339, DOI 10.1038/modpathol.3800655
NR 43
TC 13
Z9 14
U1 0
U2 2
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1021-335X
EI 1791-2431
J9 ONCOL REP
JI Oncol. Rep.
PD JAN
PY 2018
VL 39
IS 1
BP 264
EP 270
DI 10.3892/or.2017.6059
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA FQ4WD
UT WOS:000418358200028
PM 29115632
OA Bronze
DA 2025-01-12
ER

PT J
AU Mishra, P
   Tang, W
   Putluri, V
   Dorsey, TH
   Jin, F
   Wang, F
   Zhu, DEW
   Amable, L
   Deng, T
   Zhang, SF
   Killian, JK
   Wang, YH
   Minas, TZ
   Yfantis, HG
   Lee, DH
   Sreekumar, A
   Bustin, M
   Liu, W
   Putluri, N
   Ambs, S
AF Mishra, Prachi
   Tang, Wei
   Putluri, Vasanta
   Dorsey, Tiffany H.
   Jin, Feng
   Wang, Fang
   Zhu, Donewei
   Amable, Lauren
   Deng, Tao
   Zhang, Shaofei
   Killian, J. Keith
   Wang, Yonghong
   Minas, Tsion Z.
   Yfantis, Harry G.
   Lee, Dong H.
   Sreekumar, Arun
   Bustin, Michael
   Liu, Wei
   Putluri, Nagireddy
   Ambs, Stefan
TI ADHFE1 is a breast cancer oncogene and induces metabolic reprogramming
SO JOURNAL OF CLINICAL INVESTIGATION
LA English
DT Article
ID EPITHELIAL-MESENCHYMAL TRANSITION; REDUCTIVE CARBOXYLATION;
   ALPHA-KETOGLUTARATE; ONCOMETABOLITE 2-HYDROXYGLUTARATE; EPIGENETIC
   MODIFIER; MUTATIONS; L-2-HYDROXYGLUTARATE; EXPRESSION; HYPOXIA; CELLS
AB Metabolic reprogramming in breast tumors is linked to increases in putative oncogenic metabolites that may contribute to malignant transformation. We previously showed that accumulation of the oncometabolite, 2-hydroxyglutarate (2HG), in breast tumors was associated with MYC signaling, but not with isocitrate dehydrogenase (IDH) mutations, suggesting a distinct mechanism for increased 2HG in breast cancer. Here, we determined that D-2HG is the predominant enantiomer in human breast tumors and show that the D-2HG-producing mitochondrial enzyme, alcohol dehydrogenase, iron-containing protein 1 (ADHFE1), is a breast cancer oncogene that decreases patient survival. We found that MYC upregulates ADHFE1 through changes in iron metabolism while coexpression of both ADHFE1 and MYC strongly enhanced orthotopic tumor growth in MCF7 cells. Moreover, ADHFE1 promoted metabolic reprogramming with increased formation of D-2HG and reactive oxygen, a reductive glutamine metabolism, and modifications of the epigenetic landscape, leading to cellular dedifferentiation, enhanced mesenchymal transition, and phenocopying alterations that occur with high D-2HG levels in cancer cells with IDH mutations. Together, our data support the hypothesis that ADHFE1 and MYC signaling contribute to D-2HG accumulation in breast tumors and show that D-2HG is an oncogenic metabolite and potential driver of disease progression.
C1 [Mishra, Prachi; Tang, Wei; Dorsey, Tiffany H.; Minas, Tsion Z.; Ambs, Stefan] NCI, Lab Human Carcinogenesis, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.
   [Putluri, Vasanta; Jin, Feng; Sreekumar, Arun; Putluri, Nagireddy] Baylor Coll Med, Verna & Marrs Mclean Dept Biochem, Dept Mol & Cell Biol, Houston, TX 77030 USA.
   [Putluri, Vasanta; Jin, Feng; Sreekumar, Arun; Putluri, Nagireddy] Baylor Coll Med, Alkek Ctr Mol Discovery, Houston, TX 77030 USA.
   [Putluri, Vasanta; Jin, Feng; Putluri, Nagireddy] Baylor Coll Med, Adv Technol Core, Houston, TX 77030 USA.
   [Wang, Fang; Zhu, Donewei; Liu, Wei] Agios Pharmaceut, Cambridge, MA USA.
   [Amable, Lauren] NCI, Natl Inst Minor Hlth & Hlth Dispar, Bethesda, MD 20892 USA.
   [Deng, Tao; Zhang, Shaofei; Bustin, Michael] NCI, Prot Sect, Lab Metab, CCR, Bethesda, MD 20892 USA.
   [Killian, J. Keith; Wang, Yonghong] NCI, Genet Branch, CCR, NIH, Bethesda, MD 20892 USA.
   [Killian, J. Keith; Wang, Yonghong] NCI, Clin Mol Profiling Core, NIH, Bethesda, MD 20892 USA.
   [Yfantis, Harry G.; Lee, Dong H.] Baltimore Vet Affairs Med Ctr, Pathol & Lab Med, Baltimore, MD USA.
C3 National Institutes of Health (NIH) - USA; NIH National Cancer Institute
   (NCI); Baylor College of Medicine; Baylor College of Medicine; Baylor
   College of Medicine; Agios Pharmaceuticals; National Institutes of
   Health (NIH) - USA; NIH National Cancer Institute (NCI); NIH National
   Institute on Minority Health & Health Disparities (NIMHD); National
   Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI);
   National Institutes of Health (NIH) - USA; NIH National Cancer Institute
   (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer
   Institute (NCI); US Department of Veterans Affairs; Veterans Health
   Administration (VHA); Baltimore VA Medical Center
RP Ambs, S (通讯作者)，NCI, Bldg 37 Room 3050B, Bethesda, MD 20892 USA.
EM ambss@mail.nih.gov
RI Bustin, Michael/G-6155-2015; Zhang, Shaofei/J-5273-2017; Tang,
   Wei/H-7103-2013
OI Bustin, Michael/0000-0002-5147-7242; Putluri,
   Nagireddy/0000-0003-4488-7400; Tang, Wei/0000-0002-7089-4391; Ambs,
   Stefan/0000-0001-7651-9309; Lee, Darrall/0000-0002-6990-4441
FU NIH, NCI, Center for Cancer Research; Department of Defense
   [W81XWH-12-546 1-0130]; National Science Foundation [DMS 1161759]; NIH
   [U01 CA167234, R21-CA185516-01]; NCI [2P30CA125123-09,
   127430-RSG-15-105-01-CNE]; CPRIT Metabolomics Core Facility Support
   Award [RP120092]
FX This research was supported by the Intramural Research Program of the
   NIH, NCI, Center for Cancer Research. In addition, grants to Arun
   Sreekumar and Nagireddy Putluri supported this work (W81XWH-12-546
   1-0130 from the Department of Defense; DMS 1161759 from the National
   Science Foundation; NIH U01 CA167234, R21-CA185516-01; NCI
   2P30CA125123-09, 127430-RSG-15-105-01-CNE; and CPRIT Metabolomics Core
   Facility Support Award RP120092 Alkek CMD grants).
CR Berger SL, 2007, NATURE, V447, P407, DOI 10.1038/nature05915
   Boersma BJ, 2006, J NATL CANCER I, V98, P911, DOI 10.1093/jnci/djj245
   Budczies J, 2013, J PROTEOMICS, V94, P279, DOI 10.1016/j.jprot.2013.10.002
   Chowdhury R, 2011, EMBO REP, V12, P463, DOI 10.1038/embor.2011.43
   Colvin H, 2016, SCI REP-UK, V6, DOI 10.1038/srep36289
   Dang L, 2009, NATURE, V462, P739, DOI 10.1038/nature08617
   Dasgupta S, 2015, J CLIN INVEST, V125, P1174, DOI 10.1172/JCI76029
   DeBerardinis RJ, 2016, SCI ADV, V2, DOI 10.1126/sciadv.1600200
   Fan J, 2015, ACS CHEM BIOL, V10, P510, DOI 10.1021/cb500683c
   Fathi AT, 2014, ONCOLOGIST, V19, P602, DOI 10.1634/theoncologist.2013-0417
   Fendt SM, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3236
   Figueroa ME, 2010, CANCER CELL, V18, P553, DOI 10.1016/j.ccr.2010.11.015
   Grassian AR, 2014, CANCER RES, V74, P3317, DOI 10.1158/0008-5472.CAN-14-0772-T
   Grassian AR, 2012, J BIOL CHEM, V287, P42180, DOI 10.1074/jbc.M112.417832
   Guo WJ, 2012, CELL, V148, P1015, DOI 10.1016/j.cell.2012.02.008
   Intlekofer AM, 2015, CELL METAB, V22, P304, DOI 10.1016/j.cmet.2015.06.023
   Jeselsohn R, 2017, P NATL ACAD SCI USA, V114, pE4482, DOI 10.1073/pnas.1620993114
   Kessler JD, 2012, SCIENCE, V335, P348, DOI 10.1126/science.1212728
   Kim JY, 2007, ARCH BIOCHEM BIOPHYS, V464, P100, DOI 10.1016/j.abb.2007.04.018
   Kruger RR, 2005, NAT REV MOL CELL BIO, V6, P789, DOI 10.1038/nrm1740
   Leonardi R, 2012, J BIOL CHEM, V287, P14615, DOI 10.1074/jbc.C112.353946
   Locasale JW, 2011, NAT GENET, V43, P869, DOI 10.1038/ng.890
   Losman JA, 2013, SCIENCE, V339, P1621, DOI 10.1126/science.1231677
   Lu C, 2012, NATURE, V483, P474, DOI 10.1038/nature10860
   Lyon RC, 2007, J BIOL CHEM, V282, P25986, DOI 10.1074/jbc.M702465200
   Lyon RC, 2009, CHEM-BIOL INTERACT, V178, P283, DOI 10.1016/j.cbi.2008.10.025
   Marques O, 2014, CANCER LETT, V347, P1, DOI 10.1016/j.canlet.2014.01.029
   McCleland ML, 2012, CANCER RES, V72, P5812, DOI 10.1158/0008-5472.CAN-12-1098
   Mertins P, 2016, NATURE, V534, P55, DOI 10.1038/nature18003
   Metallo CM, 2012, NATURE, V481, P380, DOI 10.1038/nature10602
   Mishra P, 2015, MOL CELL ONCOL, V2, DOI 10.4161/23723556.2014.992217
   Mullen AR, 2014, CELL REP, V7, P1679, DOI 10.1016/j.celrep.2014.04.037
   Oldham WM, 2015, CELL METAB, V22, P291, DOI 10.1016/j.cmet.2015.06.021
   Oster B, 2011, INT J CANCER, V129, P2855, DOI 10.1002/ijc.25951
   Pereira B, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11479
   Possemato R, 2011, NATURE, V476, P346, DOI 10.1038/nature10350
   Prueitt RL, 2007, INT J CANCER, V120, P796, DOI 10.1002/ijc.22336
   Radisky DC, 2005, NATURE, V436, P123, DOI 10.1038/nature03688
   Sarrió D, 2008, CANCER RES, V68, P989, DOI 10.1158/0008-5472.CAN-07-2017
   Sciacovelli M, 2016, NATURE, V537, P544, DOI 10.1038/nature19353
   Shim EH, 2014, CANCER DISCOV, V4, P1290, DOI 10.1158/2159-8290.CD-13-0696
   Smolková K, 2015, INT J BIOCHEM CELL B, V65, P125, DOI 10.1016/j.biocel.2015.05.012
   Struys EA, 2005, J INHERIT METAB DIS, V28, P921, DOI 10.1007/s10545-005-0114-x
   Struys EA, 2004, CLIN CHEM, V50, P1391, DOI 10.1373/clinchem.2004.033399
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Sullivan LB, 2016, NAT REV CANCER, V16, P680, DOI 10.1038/nrc.2016.85
   Tang HP, 2016, ONCOTARGET, V7, P38822, DOI 10.18632/oncotarget.9615
   Tang XH, 2014, BREAST CANCER RES, V16, DOI 10.1186/s13058-014-0415-9
   Tenhagen M, 2012, ENDOCR-RELAT CANCER, V19, pR115, DOI 10.1530/ERC-12-0060
   Terunuma A, 2014, J CLIN INVEST, V124, P398, DOI 10.1172/JCI71180
   Wang HY, 2013, J BIOL CHEM, V288, P6478, DOI 10.1074/jbc.M112.419184
   Ward PS, 2010, CANCER CELL, V17, P225, DOI 10.1016/j.ccr.2010.01.020
   Watson E, 2016, ELIFE, V5, DOI 10.7554/eLife.17670
   Wise DR, 2011, P NATL ACAD SCI USA, V108, P19611, DOI 10.1073/pnas.1117773108
   Wu KJ, 1999, SCIENCE, V283, P676, DOI 10.1126/science.283.5402.676
   Xu W, 2011, CANCER CELL, V19, P17, DOI 10.1016/j.ccr.2010.12.014
   Zhou YP, 2008, TRENDS BIOCHEM SCI, V33, P161, DOI 10.1016/j.tibs.2008.01.006
NR 57
TC 60
Z9 65
U1 0
U2 11
PU AMER SOC CLINICAL INVESTIGATION INC
PI ANN ARBOR
PA 2015 MANCHESTER RD, ANN ARBOR, MI 48104 USA
SN 0021-9738
EI 1558-8238
J9 J CLIN INVEST
JI J. Clin. Invest.
PD JAN 2
PY 2018
VL 128
IS 1
BP 323
EP 340
DI 10.1172/JCI93815
PG 18
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA FR7KX
UT WOS:000419248000030
PM 29202474
OA Green Published, Bronze
DA 2025-01-12
ER

PT J
AU Chen, LY
   Alexe, G
   Dharia, NV
   Ross, L
   Iniguez, AB
   Conway, AS
   Wang, EJ
   Veschi, V
   Lam, N
   Qi, J
   Gustafson, WC
   Nasholm, N
   Vazquez, F
   Weir, BA
   Cowley, GS
   Ali, LD
   Pantel, S
   Jiang, GZ
   Harrington, WF
   Lee, Y
   Goodale, A
   Lubonja, R
   Krill-Burger, JM
   Meyers, RM
   Tsherniak, A
   Root, DE
   Bradner, JE
   Golub, TR
   Roberts, CWM
   Hahn, WC
   Weiss, WA
   Thiele, CJ
   Stegmaier, K
AF Chen, Liying
   Alexe, Gabriela
   Dharia, Neekesh V.
   Ross, Linda
   Iniguez, Amanda Balboni
   Conway, Amy Saur
   Wang, Emily Jue
   Veschi, Veronica
   Lam, Norris
   Qi, Jun
   Gustafson, W. Clay
   Nasholm, Nicole
   Vazquez, Francisca
   Weir, Barbara A.
   Cowley, Glenn S.
   Ali, Levi D.
   Pantel, Sasha
   Jiang, Guozhi
   Harrington, William F.
   Lee, Yenarae
   Goodale, Amy
   Lubonja, Rakela
   Krill-Burger, John M.
   Meyers, Robin M.
   Tsherniak, Aviad
   Root, David E.
   Bradner, James E.
   Golub, Todd R.
   Roberts, Charles W. M.
   Hahn, William C.
   Weiss, William A.
   Thiele, Carol J.
   Stegmaier, Kimberly
TI CRISPR-Cas9 screen reveals a <i>MYCN</i>-amplified neuroblastoma
   dependency on EZH2
SO JOURNAL OF CLINICAL INVESTIGATION
LA English
DT Article
ID INDEPENDENT COMPONENT ANALYSIS; GROUP PROTEIN EZH2; N-MYC;
   BREAST-CANCER; GENETIC SCREENS; MICROARRAY DATA; CELL-SURVIVAL;
   PROGRESSION; INHIBITION; EXPRESSION
AB Pharmacologically difficult targets, such as MYC transcription factors, represent a major challenge in cancer therapy. For the childhood cancer neuroblastoma, amplification of the oncogene MYCN is associated with high-risk disease and poor prognosis. Here, we deployed genome-scale CRISPR-Cas9 screening of MYCN-amplified neuroblastoma and found a preferential dependency on genes encoding the polycomb repressive complex 2 (PRC2) components EZH2, EED, and SUZ12. Genetic and pharmacological suppression of EZH2 inhibited neuroblastoma growth in vitro and in vivo. Moreover, compared with neuroblastomas without MYCN amplification, MYCN-amplified neuroblastomas expressed higher levels of EZH2. ChIP analysis showed that MYCN binds at the EZH2 promoter, thereby directly driving expression. Transcriptomic and epigenetic analysis, as well as genetic rescue experiments, revealed that EZH2 represses neuronal differentiation in neuroblastoma in a PRC2-dependent manner. Moreover, MYCN-amplified and high-risk primary tumors from patients with neuroblastoma exhibited strong repression of EZH2-regulated genes. Additionally, overexpression of IGFBP3, a direct EZH2 target, suppressed neuroblastoma growth in vitro and in vivo. We further observed strong synergy between histone deacetylase inhibitors and EZH2 inhibitors. Together, these observations demonstrate that MYCN upregulates EZH2, leading to inactivation of a tumor suppressor program in neuroblastoma, and support testing EZH2 inhibitors in patients with MYCN-amplified neuroblastoma.
C1 [Chen, Liying; Alexe, Gabriela; Dharia, Neekesh V.; Ross, Linda; Iniguez, Amanda Balboni; Conway, Amy Saur; Wang, Emily Jue; Golub, Todd R.; Roberts, Charles W. M.; Stegmaier, Kimberly] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02215 USA.
   [Chen, Liying; Alexe, Gabriela; Dharia, Neekesh V.; Ross, Linda; Iniguez, Amanda Balboni; Conway, Amy Saur; Wang, Emily Jue; Golub, Todd R.; Roberts, Charles W. M.; Stegmaier, Kimberly] Boston Childrens Hosp, 450 Brookline Ave,Dana 630, Boston, MA 02215 USA.
   [Chen, Liying; Alexe, Gabriela; Dharia, Neekesh V.; Iniguez, Amanda Balboni; Vazquez, Francisca; Weir, Barbara A.; Cowley, Glenn S.; Ali, Levi D.; Pantel, Sasha; Jiang, Guozhi; Harrington, William F.; Lee, Yenarae; Goodale, Amy; Lubonja, Rakela; Krill-Burger, John M.; Meyers, Robin M.; Tsherniak, Aviad; Root, David E.; Golub, Todd R.; Hahn, William C.; Stegmaier, Kimberly] Broad Inst, Cambridge, MA USA.
   [Alexe, Gabriela; Dharia, Neekesh V.; Bradner, James E.; Golub, Todd R.; Hahn, William C.; Stegmaier, Kimberly] Harvard Med Sch, Boston, MA USA.
   [Alexe, Gabriela] Boston Univ, Bioinformat Grad Program, Boston, MA 02215 USA.
   [Veschi, Veronica; Lam, Norris; Thiele, Carol J.] NCI, Cell & Mol Biol Sect, Pediat Oncol Branch, Ctr Canc Res,NIH, Bethesda, MD 20892 USA.
   [Qi, Jun; Bradner, James E.; Hahn, William C.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
   [Gustafson, W. Clay; Nasholm, Nicole; Weiss, William A.] UCSF, Helen Diller Family Comprehens Canc Ctr, Dept Pediat, San Francisco, CA USA.
   [Bradner, James E.] Novartis Inst BioMed Res, Cambridge, MA USA.
   [Roberts, Charles W. M.] St Jude Childrens Res Hosp, Comprehens Canc Ctr, 332 N Lauderdale St, Memphis, TN 38105 USA.
   [Roberts, Charles W. M.] St Jude Childrens Res Hosp, Dept Oncol, 332 N Lauderdale St, Memphis, TN 38105 USA.
   [Weiss, William A.] UCSF, Brain Tumor Res Ctr, Dept Neurol, Neurol Surg, San Francisco, CA USA.
C3 Harvard University; Dana-Farber Cancer Institute; Harvard University;
   Boston Children's Hospital; Harvard University; Massachusetts Institute
   of Technology (MIT); Broad Institute; Harvard University; Harvard
   Medical School; Boston University; National Institutes of Health (NIH) -
   USA; NIH National Cancer Institute (NCI); Harvard University;
   Dana-Farber Cancer Institute; University of California System;
   University of California San Francisco; UCSF Medical Center; UCSF Helen
   Diller Family Comprehensive Cancer Center; Novartis; Novartis USA; St
   Jude Children's Research Hospital; St Jude Children's Research Hospital;
   University of California System; University of California San Francisco
RP Stegmaier, K (通讯作者)，Boston Childrens Hosp, 450 Brookline Ave,Dana 630, Boston, MA 02215 USA.; Stegmaier, K (通讯作者)，Dana Farber Canc Inst, Pediat Oncol, 450 Brookline Ave,Dana 630, Boston, MA 02215 USA.
EM kimberly_stegmaier@dfci.harvard.edu
RI chen, yuling/JMQ-4121-2023; Dharia, Neekesh/AAC-1245-2020; Veschi,
   Veronica/K-4143-2018; Hahn, Willliam/AEF-2878-2022; Vazquez,
   Francisca/AAA-3751-2020; Roberts, Charles/N-2541-2018
OI Roberts, Charles/0000-0003-1135-1896; Tsherniak,
   Aviad/0000-0002-3797-1877; Weiss, William/0000-0003-2230-9132; Vazquez,
   Francisca/0000-0002-2857-4685; Ali, Levi/0000-0003-1148-7355; Alexe,
   Gabriela/0000-0002-5668-6297; Veschi, Veronica/0000-0002-6379-7366;
   Dharia, Neekesh/0000-0001-5048-067X
FU US National Institute of Neurological Disorders and Stroke
   [R01-NS088355]; National Cancer Institute [U01-CA176058]; Cookies for
   Kids' Cancer; Cubans Curing Children's Cancers (4C's Fund); Friends for
   Life; National Cancer Center; NIH [T32-CA136432]; Damon Runyon Cancer
   Research Foundation [DRSG-12-15]; NCI, NIH
FX This research was supported with grants from the US National Institute
   of Neurological Disorders and Stroke (R01-NS088355; to KS and WAW), the
   National Cancer Institute (U01-CA176058; to WCH), Cookies for Kids'
   Cancer (to KS), Cubans Curing Children's Cancers (4C's Fund) (to KS and
   CWMR), and Friends for Life (to KS). LC was supported by a National
   Cancer Center Post-doctoral Fellowship. NVD is supported by NIH grant
   T32-CA136432. ABI is a Damon Runyon-Sohn Pediatric Fellow supported by
   the Damon Runyon Cancer Research Foundation (DRSG-12-15). VV, NL, and
   CJT are supported by the Intramural Research Program of the NCI, NIH.
CR Aguirre AJ, 2016, CANCER DISCOV, V6, P914, DOI 10.1158/2159-8290.CD-16-0154
   Aloia L, 2013, DEVELOPMENT, V140, P2525, DOI 10.1242/dev.091553
   Bachmann IM, 2006, J CLIN ONCOL, V24, P268, DOI 10.1200/JCO.2005.01.5180
   Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003
   Bate-Eya LT, 2017, EUR J CANCER, V75, P63, DOI 10.1016/j.ejca.2016.12.019
   Bitler BG, 2015, NAT MED, V21, P231, DOI 10.1038/nm.3799
   Biton A, 2014, CELL REP, V9, P1235, DOI 10.1016/j.celrep.2014.10.035
   Brockmann M, 2013, CANCER CELL, V24, P75, DOI 10.1016/j.ccr.2013.05.005
   BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137
   Brodeur GM, 2003, NAT REV CANCER, V3, P203, DOI 10.1038/nrc1014
   Cao R, 2002, SCIENCE, V298, P1039, DOI 10.1126/science.1076997
   Chen L, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-416
   Chesler L, 2006, CANCER RES, V66, P8139, DOI 10.1158/0008-5472.CAN-05-2769
   Chipumuro E, 2014, CELL, V159, P1126, DOI 10.1016/j.cell.2014.10.024
   COMON P, 1994, SIGNAL PROCESS, V36, P287, DOI 10.1016/0165-1684(94)90029-9
   Corvetta D, 2013, J BIOL CHEM, V288, P8332, DOI 10.1074/jbc.M113.454280
   Dardenne E, 2016, CANCER CELL, V30, P563, DOI 10.1016/j.ccell.2016.09.005
   DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0
   Di Marcotullio L, 2004, P NATL ACAD SCI USA, V101, P10833, DOI 10.1073/pnas.0400690101
   Doench JG, 2016, NAT BIOTECHNOL, V34, P184, DOI 10.1038/nbt.3437
   Evers B, 2016, NAT BIOTECHNOL, V34, P631, DOI 10.1038/nbt.3536
   Frigyesi A, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-290
   Frumm SM, 2013, CHEM BIOL, V20, P713, DOI 10.1016/j.chembiol.2013.03.020
   Galvez AS, 2009, MOL CELL BIOL, V29, P104, DOI 10.1128/MCB.01294-08
   Geng J, 2015, CANCER LETT, V359, P275, DOI 10.1016/j.canlet.2015.01.031
   Gu S, 2012, CELL, V151, P900, DOI 10.1016/j.cell.2012.09.042
   Henrich KO, 2016, CANCER RES, V76, P5523, DOI 10.1158/0008-5472.CAN-15-2507
   Herwig R, 2016, NAT PROTOC, V11, P1889, DOI 10.1038/nprot.2016.117
   Hyvärinen A, 2001, INDEPENDENT COMPONENT ANALYSIS: PRINCIPLES AND PRACTICE, P71
   Ikonen M, 2003, P NATL ACAD SCI USA, V100, P13042, DOI 10.1073/pnas.2135111100
   Janoueix-Lerosey I, 2008, NATURE, V455, P967, DOI 10.1038/nature07398
   Jolliffe IT, 2002, PRINCIPAL COMPONENT, P150, DOI DOI 10.1007/B98835
   Kennedy AL, 2015, ONCOTARGET, V6, P30178, DOI 10.18632/oncotarget.4903
   Kim KH, 2015, NAT MED, V21, P1491, DOI 10.1038/nm.3968
   Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100
   Korkmaz G, 2016, NAT BIOTECHNOL, V34, P192, DOI 10.1038/nbt.3450
   Lawrence MS, 2013, NATURE, V499, P214, DOI 10.1038/nature12213
   Lee HY, 2002, CANCER RES, V62, P3530
   Lee ST, 2011, MOL CELL, V43, P798, DOI 10.1016/j.molcel.2011.08.011
   Li H, 2008, BIOINFORMATICS, V24, P1874, DOI 10.1093/bioinformatics/btn332
   Liao JC, 2003, P NATL ACAD SCI USA, V100, P15522, DOI 10.1073/pnas.2136632100
   McCabe MT, 2012, NATURE, V492, P108, DOI 10.1038/nature11606
   Meyers RM, NAT GENET
   Modak S, 2010, CANCER TREAT REV, V36, P307, DOI 10.1016/j.ctrv.2010.02.006
   Moore NF, 2014, ONCOTARGET, V5, P8737, DOI 10.18632/oncotarget.2372
   Neff T, 2013, BLOOD, V121, P4847, DOI 10.1182/blood-2013-02-474833
   Otto T, 2009, CANCER CELL, V15, P67, DOI 10.1016/j.ccr.2008.12.005
   Parnas O, 2015, CELL, V162, P675, DOI 10.1016/j.cell.2015.06.059
   Pearson K, 1901, PHILOS MAG, V2, P559, DOI 10.1080/14786440109462720
   Perry JA, 2014, P NATL ACAD SCI USA, V111, pE5564, DOI 10.1073/pnas.1419260111
   Puissant A, 2013, CANCER DISCOV, V3, P308, DOI 10.1158/2159-8290.CD-12-0418
   Ruiz S, 2016, MOL CELL, V62, P307, DOI 10.1016/j.molcel.2016.03.006
   Saidi SA, 2004, ONCOGENE, V23, P6677, DOI 10.1038/sj.onc.1207562
   SCHWAB M, 1983, NATURE, V305, P245, DOI 10.1038/305245a0
   Score J, 2012, BLOOD, V119, P1208, DOI 10.1182/blood-2011-07-367243
   Seashore-Ludlow B, 2015, CANCER DISCOV, V5, P1210, DOI 10.1158/2159-8290.CD-15-0235
   SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802
   Shalem O, 2014, SCIENCE, V343, P84, DOI 10.1126/science.1247005
   Shi B, 2007, MOL CELL BIOL, V27, P5105, DOI 10.1128/MCB.00162-07
   Teschendorff AE, 2007, PLOS COMPUT BIOL, V3, P1539, DOI 10.1371/journal.pcbi.0030161
   THIELE CJ, 1985, NATURE, V313, P404, DOI 10.1038/313404a0
   Tsubota S, 2017, CANCER RES, V77, P5259, DOI 10.1158/0008-5472.CAN-16-3144
   Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075
   Wang C, 2014, NAT BIOTECHNOL, V32, P926, DOI 10.1038/nbt.3001
   Wang CX, 2012, CANCER RES, V72, P315, DOI 10.1158/0008-5472.CAN-11-0961
   Wang T, 2015, SCIENCE, V350, P1096, DOI 10.1126/science.aac7041
   Wang T, 2014, SCIENCE, V343, P80, DOI 10.1126/science.1246981
   Weiss WA, 1997, EMBO J, V16, P2985, DOI 10.1093/emboj/16.11.2985
   Wyce A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072967
   Xu KX, 2012, SCIENCE, V338, P1465, DOI 10.1126/science.1227604
   Yang CH, 2014, J BIOL CHEM, V289, P25079, DOI 10.1074/jbc.M114.593863
   Zhang HK, 2016, CANCER DISCOV, V6, P1006, DOI 10.1158/2159-8290.CD-16-0164
NR 72
TC 105
Z9 113
U1 1
U2 19
PU AMER SOC CLINICAL INVESTIGATION INC
PI ANN ARBOR
PA 2015 MANCHESTER RD, ANN ARBOR, MI 48104 USA
SN 0021-9738
EI 1558-8238
J9 J CLIN INVEST
JI J. Clin. Invest.
PD JAN 2
PY 2018
VL 128
IS 1
BP 446
EP 462
DI 10.1172/JCI90793
PG 17
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA FR7KX
UT WOS:000419248000039
PM 29202477
OA Green Submitted, Green Published, Bronze
DA 2025-01-12
ER

PT J
AU Li, Y
   Cheng, C
AF Li, Yong
   Cheng, Cai
TI Long noncoding RNA NEAT1 promotes the metastasis of osteosarcoma via
   interaction with the G9a-DNMT1-Snail complex
SO AMERICAN JOURNAL OF CANCER RESEARCH
LA English
DT Article
DE NEAT1; Snail; G9a; DNMT1; H3K9me2; DNA methylation
ID EPITHELIAL-MESENCHYMAL TRANSITION; BREAST-CANCER; GASTRIC-CANCER;
   CARCINOMA; CELLS; DYSREGULATION; TRANSCRIPTION; PROGRESSION
AB Osteosarcoma (OS) is the most common histological form of primary bone cancer. Long noncoding RNA nuclear enriched abundant transcript 1 (NEAT1) functions as an oncogene in some cancers. However, the functional role of NEAT1 in OS metastasis remains elusive. In the present study, we found that NEAT1 expression was significantly increased in OS tissues and cell lines. Overexpression of NEAT1 in OS tissues was correlated with higher clinical stage, distant metastasis and poorer prognosis. Loss-and gain-of-function assays showed that NEAT1 positively regulated metastasis in vitro and in vivo. In addition, ectopic expression of NEAT1 also induced epithelialmesenchymal transition (EMT). Mechanistic studies revealed that NEAT1 epigenetically suppresses E-cadherin expression through association with G9a-DNMT1-Snail complex. Taken together, our study reveals a critical epigenetic mechanism underlying NEAT1-mediated metastasis.
C1 [Li, Yong; Cheng, Cai] Cangzhou Cent Hosp, Dept Orthoped, Cangzhou 061000, Peoples R China.
RP Cheng, C (通讯作者)，Cangzhou Cent Hosp, Dept Orthoped, Cangzhou 061000, Peoples R China.
EM chengcaicz@hain-an.net
CR Anderson ME, 2016, ORTHOP CLIN N AM, V47, P283, DOI 10.1016/j.ocl.2015.08.022
   Ashaie MA, 2016, CURR PHARM DESIGN, V22, P616, DOI 10.2174/138161282205160127095338
   Chakravarty D, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6383
   Chen HN, 2016, CANCER RES, V76, P1122, DOI 10.1158/0008-5472.CAN-15-1962
   Cho MH, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8821
   Djebali S, 2012, NATURE, V489, P101, DOI 10.1038/nature11233
   Dong CF, 2012, J CLIN INVEST, V122, P1469, DOI 10.1172/JCI57349
   Fang L, 2017, AM J PHYSIOL-GASTR L, V313, pG150, DOI 10.1152/ajpgi.00426.2016
   Gan L, 2015, TUMOR BIOL, V36, P129, DOI 10.1007/s13277-014-2894-9
   Hu QP, 2016, INT J CANCER, V138, P2804, DOI 10.1002/ijc.29982
   Hu XW, 2014, CANCER CELL, V26, P344, DOI 10.1016/j.ccr.2014.07.009
   Li GB, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/780521
   Lu YY, 2016, TUMOR BIOL, V37, P11733, DOI 10.1007/s13277-015-4773-4
   Luetke A, 2014, CANCER TREAT REV, V40, P523, DOI 10.1016/j.ctrv.2013.11.006
   Monga SP, 2015, GASTROENTEROLOGY, V148, P1294, DOI 10.1053/j.gastro.2015.02.056
   Ning L, 2017, CANCER BIOMARK, V19, P75, DOI 10.3233/CBM-160376
   Qiu MT, 2013, TUMOR BIOL, V34, P613, DOI 10.1007/s13277-013-0658-6
   Sampson VB, 2015, FRONT PEDIATR, V3, DOI 10.3389/fped.2015.00069
   Sarkar D, 2015, EPIGENETICS-US, V10, P103, DOI 10.1080/15592294.2014.1003746
   Smith BN, 2016, J CLIN MED, V5, DOI 10.3390/jcm5020017
   Tian HP, 2015, J BIOL CHEM, V290, P19173, DOI 10.1074/jbc.M114.636126
   Vikram R, 2014, BREAST CANCER-TOKYO, V21, P515, DOI 10.1007/s12282-014-0554-y
   Voutsadakis IA, 2016, J CLIN MED, V5, DOI 10.3390/jcm5010011
   Wang J, 2015, GENE, V560, P1, DOI 10.1016/j.gene.2015.02.004
   Yang HG, 2014, ONCOL LETT, V8, P193, DOI 10.3892/ol.2014.2079
   Yang Q, 2015, WORLD J GASTROENTERO, V21, P10956, DOI 10.3748/wjg.v21.i39.10956
   Zhang LS, 2015, ONCOTARGET, V6, P9073, DOI 10.18632/oncotarget.3268
NR 27
TC 54
Z9 57
U1 0
U2 7
PU E-CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 2156-6976
J9 AM J CANCER RES
JI Am. J. Cancer Res.
PY 2018
VL 8
IS 1
BP 81
EP 90
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA FT9KE
UT WOS:000423470100008
PM 29416922
DA 2025-01-12
ER

PT J
AU Chu, MQ
   Zhao, Y
   Yu, S
   Hao, YN
   Zhang, PF
   Feng, YN
   Zhang, HF
   Ma, DX
   Liu, J
   Cheng, M
   Li, L
   Shen, W
   Cao, HF
   Li, Q
   Min, LJ
AF Chu, Meiqiang
   Zhao, Yong
   Yu, Shuai
   Hao, Yanan
   Zhang, Pengfei
   Feng, Yanni
   Zhang, Hongfu
   Ma, Dongxue
   Liu, Jing
   Cheng, Ming
   Li, Lan
   Shen, Wei
   Cao, Hongfang
   Li, Qiang
   Min, Lingjiang
TI miR-15b negatively correlates with lipid metabolism in mammary
   epithelial cells
SO AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY
LA English
DT Article
DE mammary epithelial cells; miR-15b; lipid; metabolism; estradiol;
   progesterone
ID MILK-FAT; EPIGENETIC REGULATION; MICRORNA EXPRESSION; GLAND DEVELOPMENT;
   GENE-EXPRESSION; LACTATING COWS; MESSENGER-RNA; BREAST-CANCER;
   COMPLEXITY; DIFFERENTIATION
AB Mammary epithelial cells are regulated by steroid hormones, growth factors, and even microRNAs. miR-15b has been found to regulate lipid metabolism in adipocytes; however, its effects on lipid metabolism in mammary epithelial cells, the cells of lipid synthesis and secretion, are as yet unknown. The main purpose of this investigation was to explore the effect of miR-15b on lipid metabolism in mammary epithelial cells, along with the underlying mechanisms. miR-15b was overexpressed or inhibited by miRNA mimics or inhibitors; subsequently, lipid formation in mammary epithelial cells, and proteins related to lipid metabolism, were investigated. Through overexpression or inhibition of miR-15b expression, the current investigation found that miR-15b downregulates lipid metabolism in mammary epithelial cells and is expressed differentially at various stages of mouse and goat mammary gland development. Inhibition of miR-15b expression increased lipid content in mammary epithelial cells through elevation of the lipid synthesis enzyme fatty acid synthetase (FASN), and overexpression of miR-15b reduced lipid content in mammary epithelial cells with decreasing levels of FASN. Moreover, the steroid hormones estradiol and progesterone decreased miR-15b expression with a subsequent increase in lipid formation in mammary epithelial cells. The expression of miR-15b was lower during lactation and negatively correlated with lipid synthesis proteins, which suggests that it may be involved in lipid synthesis and milk production. miR-15b might be a useful target for altering lipid production and milk yield.
C1 [Chu, Meiqiang; Zhao, Yong; Yu, Shuai; Hao, Yanan; Zhang, Pengfei; Feng, Yanni; Ma, Dongxue; Li, Lan; Shen, Wei; Min, Lingjiang] Qingdao Agr Univ, Coll Anim Sci & Technol, Qingdao 266109, Peoples R China.
   [Zhang, Hongfu] Chinese Acad Agr Sci, Inst Anim Sci, State Key Lab Anim Nutr, Beijing, Peoples R China.
   [Liu, Jing] Qingdao Agr Univ, Core Labs, Qingdao, Peoples R China.
   [Cheng, Ming] Qingdao Vet & Livestock Adm, Qingdao, Peoples R China.
   [Cao, Hongfang; Li, Qiang] Laiwu Vet & Livestock Adm, Laiwu, Peoples R China.
C3 Qingdao Agricultural University; Chinese Academy of Agricultural
   Sciences; Institute of Animal Science, CAAS; Qingdao Agricultural
   University
RP Min, LJ (通讯作者)，Qingdao Agr Univ, Coll Anim Sci & Technol, Qingdao 266109, Peoples R China.
EM mlj020963@hotmail.com
RI Zhang, Pengfei/GPC-5146-2022
OI Feng, Yanni/0000-0002-3590-788X; Zhao, Yong/0000-0003-3423-2718
FU Technology System of Modern Agricultural Industry in Shandong Province
   [SDAIT-10-08]
FX This work was supported by Technology System of Modern Agricultural
   Industry in Shandong Province (SDAIT-10-08).
CR Andersen DC, 2010, EXP CELL RES, V316, P1681, DOI 10.1016/j.yexcr.2010.04.002
   Anderson SM, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1653
   Avril-Sassen S, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-548
   Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5
   Bastianelli C, 2017, EXPERT REV CLIN PHAR, V10, P315, DOI 10.1080/17512433.2017.1271708
   Bian YJ, 2015, J CELL PHYSIOL, V230, P2152, DOI 10.1002/jcp.24944
   Brisken C, 2006, J MAMMARY GLAND BIOL, V11, P239, DOI 10.1007/s10911-006-9026-0
   Chen JF, 2006, NAT GENET, V38, P228, DOI 10.1038/ng1725
   Cui M, 2014, BIOCHEM BIOPH RES CO, V444, P270, DOI 10.1016/j.bbrc.2014.01.051
   Delbecchi L, 2005, LIVEST PROD SCI, V98, P57, DOI 10.1016/j.livprodsci.2005.10.010
   EMKEN EA, 1989, J LIPID RES, V30, P395
   Esau C, 2006, CELL METAB, V3, P87, DOI 10.1016/j.cmet.2006.01.005
   Finnerty JR, 2010, J MOL BIOL, V402, P491, DOI 10.1016/j.jmb.2010.07.051
   Hamilton MP, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3730
   Heimberg AM, 2008, P NATL ACAD SCI USA, V105, P2946, DOI 10.1073/pnas.0712259105
   Jabed A, 2012, P NATL ACAD SCI USA, V109, P16811, DOI 10.1073/pnas.1210057109
   Ji ZB, 2012, MOL BIOL REP, V39, P9361, DOI 10.1007/s11033-012-1779-5
   Jonas S, 2015, NAT REV GENET, V16, P421, DOI 10.1038/nrg3965
   JUDGE SM, 1983, CANCER RES, V43, P4407
   Kedmi M, 2015, SCI SIGNAL, V8, DOI 10.1126/scisignal.2005866
   LAMMIKEEFE CJ, 1984, J PEDIATR GASTR NUTR, V3, P172, DOI 10.1097/00005176-198403000-00004
   Lian S, 2016, J DAIRY SCI, V99, P3916, DOI 10.3168/jds.2015-10484
   Liao YL, 2010, J NUTR, V140, P1552, DOI 10.3945/jn.110.124289
   Lin XZ, 2013, GENE, V521, P15, DOI 10.1016/j.gene.2013.03.050
   Lin XZ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079258
   Liu XQ, 2016, TOXICOL LETT, V256, P19, DOI 10.1016/j.toxlet.2016.05.007
   Maningat PD, 2009, PHYSIOL GENOMICS, V37, P12, DOI 10.1152/physiolgenomics.90341.2008
   McManaman James L, 2012, Biomol Concepts, V3, P581
   Mohammad MA, 2013, AM J PHYSIOL-ENDOC M, V305, pE700, DOI 10.1152/ajpendo.00052.2013
   MOLLETT TA, 1976, J ANIM SCI, V42, P655, DOI 10.2527/jas1976.423655x
   Neville MC, 2006, KNOBIL AND NEILL'S PHYSIOLOGY OF REPRODUCTION, VOLS 1 AND 2, 3RD EDITON, P2993
   Nishi H, 2010, J BIOL CHEM, V285, P4920, DOI 10.1074/jbc.M109.082610
   Peterson KJ, 2009, BIOESSAYS, V31, P736, DOI 10.1002/bies.200900033
   Piao HL, 2012, J MAMMARY GLAND BIOL, V17, P33, DOI 10.1007/s10911-012-9245-5
   Qu Y, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131285
   Rayner KJ, 2010, SCIENCE, V328, P1570, DOI 10.1126/science.1189862
   Reinhart BJ, 2000, NATURE, V403, P901, DOI 10.1038/35002607
   Richert MM, 2000, J MAMMARY GLAND BIOL, V5, P227, DOI 10.1023/A:1026499523505
   Rudolph MC, 2003, J MAMMARY GLAND BIOL, V8, P287, DOI 10.1023/B:JOMG.0000010030.73983.57
   Rudolph MC, 2007, PHYSIOL GENOMICS, V28, P323, DOI 10.1152/physiolgenomics.00020.2006
   Sempere LF, 2006, J EXP ZOOL PART B, V306B, P575, DOI 10.1002/jez.b.21118
   Smith S, 2009, J MAMMARY GLAND BIOL, V14, P245, DOI 10.1007/s10911-009-9142-8
   Stingl John, 2011, Hormones & Cancer, V2, P85, DOI 10.1007/s12672-010-0055-1
   TOPPER YJ, 1980, PHYSIOL REV, V60, P1049, DOI 10.1152/physrev.1980.60.4.1049
   Wakil SJ, 2009, J LIPID RES, V50, pS138, DOI 10.1194/jlr.R800079-JLR200
   Wang H, 2015, J DAIRY SCI, V98, P9001, DOI 10.3168/jds.2015-9418
   Wang H, 2017, J CELL PHYSIOL, V232, P1030, DOI 10.1002/jcp.25499
   Wang M, 2012, J DAIRY SCI, V95, P6529, DOI 10.3168/jds.2012-5748
   Wang YD, 2016, TOXICOL APPL PHARM, V313, P149, DOI 10.1016/j.taap.2016.10.025
   Wang Y, 2017, ONCOTARGETS THER, V10, P1091, DOI 10.2147/OTT.S125724
   Xiao J, 2016, ONCOTARGETS THER, V9, P5181, DOI 10.2147/OTT.S105198
   Yue JM, 2010, MAMM GENOME, V21, P88, DOI 10.1007/s00335-009-9240-3
   Zhang CL, 2014, J NUTR, V144, P1142, DOI 10.3945/jn.114.192575
   Zhang Y. S., 2012, LIQUOR MAKING SCI TE, V11, P25, DOI DOI 10.1016/J.DIABRES.2012.11.025
   Zhao Y, 2016, SCI REP-UK, V6, DOI 10.1038/srep37884
   Zhao Y, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0155865
   Zhao Y, 2010, TOXICOL SCI, V115, P214, DOI 10.1093/toxsci/kfq030
NR 57
TC 26
Z9 36
U1 0
U2 18
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0363-6143
EI 1522-1563
J9 AM J PHYSIOL-CELL PH
JI Am. J. Physiol.-Cell Physiol.
PD JAN
PY 2018
VL 314
IS 1
BP C43
EP C52
DI 10.1152/ajpcell.00115.2017
PG 10
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Physiology
GA FU0TD
UT WOS:000423562400004
PM 28835435
OA Bronze
DA 2025-01-12
ER

PT J
AU Zhang, H
   Zhang, YQ
   Chen, C
   Zhu, XY
   Zhang, C
   Xia, YZ
   Zhao, YC
   Andrisani, OM
   Kong, LY
AF Zhang, Hao
   Zhang, Yanqiu
   Chen, Chen
   Zhu, Xiaoyun
   Zhang, Chao
   Xia, Yuanzheng
   Zhao, Yucheng
   Andrisani, Ourania M.
   Kong, Lingyi
TI A double-negative feedback loop between DEAD-box protein DDX21 and Snail
   regulates epithelial-mesenchymal transition and metastasis in breast
   cancer
SO CANCER LETTERS
LA English
DT Article
DE DDX21; EMT; Snail; miRNA; Breast cancer metastasis
ID TRANSCRIPTION FACTOR SNAIL; E-CADHERIN; GENE-EXPRESSION; STEM-CELL; RNA;
   EMT; REPRESSOR; COMPLEX; EZH2; PROGRESSION
AB DDX21, a DEAD-box protein, implicated in fundamental aspects of RNA metabolism such as gene transcription. DDX21 expression is dysregulated in cancer, but its specific contribution to tumor invasion and metastasis remains to be determined. Here, we demonstrate DDX21 down-regulation is associated with highly metastatic and poor prognosis human breast cancers. DDX21 overexpression inhibited, while DDX21 knockdown promoted epithelial-mesenchymal transition (EMT) in vitro and in vivo. Overexpression of Snail reversed DDX21 mediated inhibition of cell invasion. On the other hand, independent of its helicase activity, DDX21 suppressed Snail transcription by recruiting SUZ12 and EZH2, two core subunits of PRC2 (polycomb-repressive complex 2), to the Snail promoter. Furthermore, down-regulation of DDX21 is mediated by miR-218-5p. Surprisingly, Snail also modulates DDX21 transcription. Snail overexpression decreased DDX21 transcription, whereas Snail knockdown increased DDX21 expression. These novel observations demonstrate firstly, the antagonism/double negative feedback loop between DDX21 and Snail transcription, and secondly, the crucial role of miR-218-5p in promoting EMT, acting by decreasing the ratio of DDX21/Snail. Our results identify DDX21 as a breast cancer metastasis suppressor; blocking miR-218-5p will stabilize DDX21 and epigenetically suppress Snail expression and EMT.
C1 [Zhang, Hao; Zhang, Yanqiu; Chen, Chen; Zhu, Xiaoyun; Zhang, Chao; Xia, Yuanzheng; Zhao, Yucheng; Kong, Lingyi] China Pharmaceut Univ, Jiangsu Key Lab Bioact Nat Prod Res, Sch Tradit Chinese Pharm, Nan Jing 210009, Peoples R China.
   [Zhang, Hao; Zhang, Yanqiu; Chen, Chen; Zhu, Xiaoyun; Zhang, Chao; Xia, Yuanzheng; Zhao, Yucheng; Kong, Lingyi] China Pharmaceut Univ, State Key Lab Nat Med, Sch Tradit Chinese Pharm, Nan Jing 210009, Peoples R China.
   [Andrisani, Ourania M.] Purdue Univ, Dept Basic Med Sci, W Lafayette, IN 47907 USA.
   [Andrisani, Ourania M.] Purdue Univ, Purdue Ctr Canc Res, W Lafayette, IN 47907 USA.
C3 China Pharmaceutical University; China Pharmaceutical University; Purdue
   University System; Purdue University; Purdue University System; Purdue
   University
RP Kong, LY (通讯作者)，China Pharmaceut Univ, Dept Nat Med Chem, 24 Tong Jia Xiang, Nanjing 210009, Peoples R China.
EM hiaaron@sina.cn; zgjs199410@126.com; chenchen1601@126.com;
   zxy900912@163.com; zhangchao19860910@126.com; xiayz@cpu.edu.cn;
   zhaoyucheng1986@126.com; andrisao@purdue.edu; cpu_lykong@126.com
RI Zhu, Xiaoyun/ACE-1141-2022; Wang, Xiaobing/H-5927-2019
OI Zhang, Yanqiu/0000-0003-3922-4629; Zhang, Chao/0000-0002-8163-9716; Zhu,
   Xiaoyun/0009-0009-5719-7354
FU startup fund from China Pharmaceutical University; National Natural
   Science Foundation of China [81872889]; Priority Academic Program
   Development of Jiangsu Higher Education Institutions (PAPD); 111 project
   [818056]; Program for Changjiang Scholars and Innovative Research Team
   in University [PCSIRT-IRT1193]
FX This work was supported by startup fund from China Pharmaceutical
   University and National Natural Science Foundation of China
   (No.81872889) to H. Zhang, and the Priority Academic Program Development
   of Jiangsu Higher Education Institutions (PAPD), the 111 project
   (818056), the Program for Changjiang Scholars, and the Innovative
   Research Team in University to LY. Kong (Program No. PCSIRT-IRT1193).
CR Nieto MA, 2016, CELL, V166, P21, DOI 10.1016/j.cell.2016.06.028
   Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034
   Battistelli C, 2017, ONCOGENE, V36, P942, DOI 10.1038/onc.2016.260
   Calo E, 2018, NATURE, V554, P112, DOI 10.1038/nature25449
   Calo E, 2015, NATURE, V518, P249, DOI 10.1038/nature13923
   Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025
   Carter CL, 2010, ONCOGENE, V29, P5427, DOI 10.1038/onc.2010.276
   Cimino D, 2008, INT J CANCER, V123, P1327, DOI 10.1002/ijc.23660
   De Craene B, 2013, NAT REV CANCER, V13, P97, DOI 10.1038/nrc3447
   Dong CF, 2012, J CLIN INVEST, V122, P1469, DOI 10.1172/JCI57349
   Fuller-Pace FV, 2013, RNA BIOL, V10, P121, DOI 10.4161/rna.23312
   Garibaldi F, 2012, CELL DEATH DIFFER, V19, P937, DOI 10.1038/cdd.2011.175
   Gregory PA, 2011, MOL BIOL CELL, V22, P1686, DOI 10.1091/mbc.E11-02-0103
   Hajra KM, 2002, CANCER RES, V62, P1613
   Hassan MQ, 2012, J BIOL CHEM, V287, P42084, DOI 10.1074/jbc.M112.377515
   Henning D, 2003, J BIOL CHEM, V278, P52307, DOI 10.1074/jbc.M310846200
   Hwang WL, 2011, GASTROENTEROLOGY, V141, P279, DOI 10.1053/j.gastro.2011.04.008
   Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783
   Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758
   Lin YW, 2010, EMBO J, V29, P1803, DOI 10.1038/emboj.2010.63
   Lu Y, 2010, ONCOGENE, V29, P1041, DOI 10.1038/onc.2009.396
   Madden SF, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3444
   Margueron R, 2011, NATURE, V469, P343, DOI 10.1038/nature09784
   Nieto MA, 2002, NAT REV MOL CELL BIO, V3, P155, DOI 10.1038/nrm757
   OKA H, 1993, CANCER RES, V53, P1696
   Onder TT, 2008, CANCER RES, V68, P3645, DOI 10.1158/0008-5472.CAN-07-2938
   Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131
   Puisieux A, 2014, NAT CELL BIOL, V16, P488, DOI 10.1038/ncb2976
   Rao RA, 2015, SCI REP-UK, V5, DOI 10.1038/srep08229
   Ren G, 2012, CANCER RES, V72, P3091, DOI 10.1158/0008-5472.CAN-11-3546
   Sarma K, 2014, CELL, V159, P869, DOI 10.1016/j.cell.2014.10.019
   Siemens H, 2011, CELL CYCLE, V10, P4256, DOI 10.4161/cc.10.24.18552
   Sun MN, 2011, BBA-MOL CELL RES, V1813, P438, DOI 10.1016/j.bbamcr.2011.01.003
   Taipaleenmäki H, 2016, ONCOTARGET, V7, P79018, DOI 10.18632/oncotarget.12593
   Tong ZT, 2012, ONCOGENE, V31, P583, DOI 10.1038/onc.2011.254
   Tsai MC, 2010, SCIENCE, V329, P689, DOI 10.1126/science.1192002
   Wang L, 2012, ONCOGENE, V31, P2499, DOI 10.1038/onc.2011.444
   Wang YS, 2016, SCI REP-UK, V6, DOI 10.1038/srep20968
   Westermarck J, 2002, EMBO J, V21, P451, DOI 10.1093/emboj/21.3.451
   Xing YH, 2017, CELL, V169, P664, DOI 10.1016/j.cell.2017.04.011
   Yang HS, 2005, FEBS J, V272, P3788, DOI 10.1111/j.1742-4658.2005.04811.x
   Zhang H, 2017, ONCOGENE, V36, P3925, DOI 10.1038/onc.2017.39
   Zhang H, 2016, HEPATOLOGY, V64, P1033, DOI 10.1002/hep.28698
   Zhang H, 2015, ONCOTARGET, V6, P17039, DOI 10.18632/oncotarget.3636
   Zhang H, 2015, CANCER RES, V75, P2363, DOI 10.1158/0008-5472.CAN-14-2928
NR 45
TC 38
Z9 40
U1 0
U2 36
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0304-3835
EI 1872-7980
J9 CANCER LETT
JI Cancer Lett.
PY 2018
VL 437
BP 67
EP 78
DI 10.1016/j.canlet.2018.08.021
PG 12
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA GX1KL
UT WOS:000447476100007
PM 30165191
DA 2025-01-12
ER

PT J
AU Wu, HC
   Do, C
   Andrulis, IL
   John, EM
   Daly, MB
   Buys, SS
   Chung, WK
   Knight, JA
   Bradbury, AR
   Keegan, THM
   Schwartz, L
   Krupska, I
   Miller, RL
   Santella, RM
   Tycko, B
   Terry, MB
AF Wu, Hui-Chen
   Do, Catherine
   Andrulis, Irene L.
   John, Esther M.
   Daly, Mary B.
   Buys, Saundra S.
   Chung, Wendy K.
   Knight, Julia A.
   Bradbury, Angela R.
   Keegan, Theresa H. M.
   Schwartz, Lisa
   Krupska, Izabela
   Miller, Rachel L.
   Santella, Regina M.
   Tycko, Benjamin
   Terry, Mary Beth
TI Breast cancer family history and allele-specific DNA methylation in the
   legacy girls study
SO EPIGENETICS
LA English
DT Article
DE Breast cancer family history; DNA methylation; mQTL; white blood cells;
   childhood and adolescent cohort
ID GENOME-WIDE ASSOCIATION; PROMOTER HYPERMETHYLATION; PUBERTAL
   DEVELOPMENT; BRCA1 PROMOTER; RISK-FACTORS; SUSCEPTIBILITY; EXPRESSION;
   PATTERNS; EPIGENETICS; VARIANTS
AB Family history, a well-established risk factor for breast cancer, can have both genetic and environmental contributions. Shared environment in families as well as epigenetic changes that also may be influenced by shared genetics and environment may also explain familial clustering of cancers. Epigenetic regulation, such as DNA methylation, can change the activity of a DNA segment without a change in the sequence; environmental exposures experienced across the life course can induce such changes. However, genetic-epigenetic interactions, detected as methylation quantitative trait loci (mQTLs; a.k.a. meQTLs) and haplotype-dependent allele-specific methylation (hap-ASM), can also contribute to inter-individual differences in DNA methylation patterns. To identify differentially methylated regions (DMRs) associated with breast cancer susceptibility, we examined differences in white blood cell DNA methylation in 29 candidate genes in 426 girls (ages 6-13 years) from the LEGACY Girls Study, 239 with and 187 without a breast cancer family history (BCFH). We measured methylation by targeted massively parallel bisulfite sequencing (bis-seq) and observed BCFH DMRs in two genes: ESR1 (Delta 4.9%, P = 0.003) and SEC16B (Delta 3.6%, P = 0.026), each of which has been previously implicated in breast cancer susceptibility and pubertal development. These DMRs showed high inter-individual variability in methylation, suggesting the presence of mQTLs/hap-ASM. Using single nucleotide polymorphisms data in the bis-seq amplicon, we found strong hap-ASM in SEC16B (with allele specific-differences ranging from 42% to 74%). These findings suggest that differential methylation in genes relevant to breast cancer susceptibility may be present early in life, and that inherited genetic factors underlie some of these epigenetic differences.
C1 [Wu, Hui-Chen; Krupska, Izabela; Miller, Rachel L.; Santella, Regina M.; Terry, Mary Beth] Columbia Univ, Herbert Irving Comprehens Canc Ctr, Med Ctr, New York, NY 10032 USA.
   [Wu, Hui-Chen; Santella, Regina M.; Terry, Mary Beth] Columbia Univ, Dept Environm Hlth Sci, Mailman Sch Publ Hlth, New York, NY 10032 USA.
   [Do, Catherine; Tycko, Benjamin] Hackensack Univ Med Ctr, John Theurer Canc Ctr, Hackensack, NJ USA.
   [Andrulis, Irene L.; Knight, Julia A.] Sinai Hlth Syst, Lunenfeld Tanenbaum Res Inst, Toronto, ON, Canada.
   [Andrulis, Irene L.] Univ Toronto, Dept Mol Genet, Toronto, ON, Canada.
   [Andrulis, Irene L.] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada.
   [John, Esther M.] Canc Prevent Inst Calif, Fremont, CA USA.
   [John, Esther M.] Stanford Univ, Sch Med, Dept Hlth Res & Policy Epidemiol, Stanford, CA 94305 USA.
   [John, Esther M.] Stanford Univ, Sch Med, Stanford Canc Inst, Stanford, CA 94305 USA.
   [Daly, Mary B.] Fox Chase Canc Ctr, Dept Clin Genet, 7701 Burholme Ave, Philadelphia, PA 19111 USA.
   [Buys, Saundra S.] Univ Utah, Hlth Sci Ctr, Dept Med, Salt Lake City, UT 84112 USA.
   [Buys, Saundra S.] Univ Utah, Hlth Sci Ctr, Huntsman Canc Inst, Salt Lake City, UT 84112 USA.
   [Chung, Wendy K.; Miller, Rachel L.] Columbia Univ Coll Phys & Surg, Dept Pediat, New York, NY 10032 USA.
   [Chung, Wendy K.; Miller, Rachel L.] Columbia Univ Coll Phys & Surg, Dept Med, New York, NY USA.
   [Knight, Julia A.] Univ Toronto, Dalla Lana Sch Publ Hlth, Toronto, ON, Canada.
   [Bradbury, Angela R.] Univ Penn, Dept Med, Dept Med Eth & Hlth Policy, Perelman Sch Med,Div Hematol Oncol, Philadelphia, PA 19104 USA.
   [Keegan, Theresa H. M.] Ctr Oncol Hematol Outcomes Res & Training COHORT, Davis, CA USA.
   [Keegan, Theresa H. M.] Univ Calif Davis, Sch Med, Div Hematol & Oncol, Sacramento, CA 95817 USA.
   [Schwartz, Lisa] Univ Penn, Dept Pediat, Div Oncol, Perelman Sch Med, Philadelphia, PA 19104 USA.
   [Schwartz, Lisa] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA.
   [Tycko, Benjamin] Georgetown Univ, Lombardi Comprehens Canc Ctr, Washington, DC USA.
   [Terry, Mary Beth] Columbia Univ, Imprints Ctr, Med Ctr, New York, NY 10032 USA.
   [Terry, Mary Beth] Columbia Univ, Dept Epidemiol, Mailman Sch Publ Hlth, 722 West 168th St,1611, New York, NY 10032 USA.
C3 Columbia University; Columbia University; Hackensack University Medical
   Center; University of Toronto; Sinai Health System Toronto; Lunenfeld
   Tanenbaum Research Institute; University of Toronto; University of
   Toronto; Cancer Prevention Institute of California; Stanford University;
   Stanford Cancer Institute; Stanford University; Fox Chase Cancer Center;
   Utah System of Higher Education; University of Utah; Utah System of
   Higher Education; University of Utah; Huntsman Cancer Institute;
   Columbia University; Columbia University; University of Toronto;
   University of Pennsylvania; University of California System; University
   of California Davis; University of Pennsylvania; University of
   Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia;
   Georgetown University; Columbia University; Columbia University
RP Terry, MB (通讯作者)，Columbia Univ, Dept Epidemiol, Mailman Sch Publ Hlth, 722 West 168th St,1611, New York, NY 10032 USA.
EM mt146@columbia.edu
RI Knight, Julia/A-6843-2012; Wu, Lisa/JPA-4139-2023; Miller,
   Rachel/Q-9066-2017; Schwartz, Lisa/AET-1314-2022
OI John, Esther/0000-0003-3259-8003; do, catherine/0000-0002-9796-4345;
   Terry, Mary Beth/0000-0002-4106-5033
FU National Cancer Institute [R01CA138822, P30 CA013696]; National
   Institute of Environmental Health Sciences [P30 ES009089]; Breast Cancer
   Research Foundation; National Cancer Institute at the National
   Institutes of Health [CA138638, CA138819, CA138822, CA138844]; Canadian
   Breast Cancer Foundation; National Center for Advancing Translational
   Sciences, National Institutes of Health [UL1 TR000040]; National Center
   for Research Resources [UL1 RR024156]; Avon Foundation for Women
FX This work was supported by awards from the National Cancer Institute
   [R01CA138822 and P30 CA013696] and the National Institute of
   Environmental Health Sciences [P30 ES009089] and the Breast Cancer
   Research Foundation. The LEGACY Girls Study is funded by the National
   Cancer Institute at the National Institutes of Health (Grants CA138638
   to E. M. John, CA138819 to M. B. Daly and A. R. Bradbury, CA138822 to M.
   B. Terry, and CA138844 to I. L. Andrulis) and the Canadian Breast Cancer
   Foundation (I. L. Andrulis). The work at the New York site was also
   supported by the National Center for Advancing Translational Sciences,
   National Institutes of Health, through Grant Number UL1 TR000040,
   formerly the National Center for Research Resources, Grant Number UL1
   RR024156. Support was also provided by a grant from the Avon Foundation
   for Women, to M. B. Terry and B. Tycko. The content is solely the
   responsibility of the authors and does not necessarily represent the
   official views of the NIH.
CR Almstrup K, 2016, SCI REP-UK, V6, DOI 10.1038/srep28657
   Altshuler DM, 2015, NATURE, V526, P68, DOI 10.1038/nature15393
   Antoniou AC, 2004, BRIT J CANCER, V91, P1580, DOI 10.1038/sj.bjc.6602175
   Bell JT, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-1-r10
   Beral V, 2001, LANCET, V358, P1389, DOI 10.1016/S0140-6736(01)06524-2
   Cho YH, 2015, J CANCER, V6, P819, DOI 10.7150/jca.12174
   Choi J, 2018, PROG LIPID RES, V69, P11, DOI 10.1016/j.plipres.2017.11.002
   Cortijo S, 2014, SCIENCE, V343, P1145, DOI 10.1126/science.1248127
   Day K, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0165488
   Do C, 2017, GENOME BIOL, V18, DOI 10.1186/s13059-017-1250-y
   Do C, 2016, AM J HUM GENET, V98, P934, DOI 10.1016/j.ajhg.2016.03.027
   Dunning AM, 2016, NAT GENET, V48, P374, DOI 10.1038/ng.3521
   Dvornyk V, 2012, HUM REPROD UPDATE, V18, P198, DOI 10.1093/humupd/dmr050
   Engel SM, 2014, AM J EPIDEMIOL, V179, P834, DOI 10.1093/aje/kwt433
   Ernst J, 2011, NATURE, V473, P43, DOI 10.1038/nature09906
   Esteller M, 2000, JNCI-J NATL CANCER I, V92, P564, DOI 10.1093/jnci/92.7.564
   Flanagan JM, 2009, HUM MOL GENET, V18, P1332, DOI 10.1093/hmg/ddp033
   Fraser HB, 2012, GENOME BIOL, V13, DOI 10.1186/gb-2012-13-2-r8
   Horikoshi M, 2013, NAT GENET, V45, P76, DOI 10.1038/ng.2477
   Jeffy BD, 2002, ENVIRON MOL MUTAGEN, V39, P235, DOI 10.1002/em.10051
   Jia HY, 2017, DRUG RESIST UPDATE, V32, P1, DOI 10.1016/j.drup.2017.07.002
   John EM, 2016, EPIDEMIOLOGY, V27, P438, DOI 10.1097/EDE.0000000000000456
   Joubert BR, 2016, AM J HUM GENET, V98, P680, DOI 10.1016/j.ajhg.2016.02.019
   Karolchik Donna, 2009, Curr Protoc Bioinformatics, VChapter 1, DOI 10.1002/0471250953.bi0104s17
   Koch A, 2015, BMC GENOMICS, V16, DOI 10.1186/s12864-015-1847-z
   Kundakovic M, 2013, P NATL ACAD SCI USA, V110, P9956, DOI 10.1073/pnas.1214056110
   Leslie R, 2014, BIOINFORMATICS, V30, P185, DOI 10.1093/bioinformatics/btu273
   Li TS, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153314
   Li YY, 2011, METHODS MOL BIOL, V791, P11, DOI 10.1007/978-1-61779-316-5_2
   Lonsdale J, 2013, NAT GENET, V45, P580, DOI 10.1038/ng.2653
   Lv D, 2015, GENE, V560, P149, DOI 10.1016/j.gene.2015.01.054
   MacArthur J, 2017, NUCLEIC ACIDS RES, V45, pD896, DOI 10.1093/nar/gkw1133
   Purrington KS, 2014, CARCINOGENESIS, V35, P1012, DOI 10.1093/carcin/bgt404
   Reinius LE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041361
   Rice JC, 2000, CARCINOGENESIS, V21, P1761, DOI 10.1093/carcin/21.9.1761
   Robertson KD, 2005, NAT REV GENET, V6, P597, DOI 10.1038/nrg1655
   Ruiz-Hernandez A, 2015, CLIN EPIGENETICS, V7, DOI 10.1186/s13148-015-0055-7
   Rushton MD, 2015, HUM MOL GENET, V24, P7432, DOI 10.1093/hmg/ddv433
   Severi G, 2014, BREAST CANCER RES TR, V148, P665, DOI 10.1007/s10549-014-3209-y
   Shiovitz S, 2015, ANN ONCOL, V26, P1291, DOI 10.1093/annonc/mdv022
   Stone A, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8758
   Stratton MR, 2008, NAT GENET, V40, P17, DOI 10.1038/ng.2007.53
   Terry MB, 2017, BREAST CANCER RES, V19, DOI 10.1186/s13058-017-0849-y
   Terry MB, 2016, PEDIATRICS, V138, DOI 10.1542/peds.2015-4571
   Terry MB, 2011, EPIGENETICS-US, V6, P828, DOI 10.4161/epi.6.7.16500
   Thorleifsson G, 2009, NAT GENET, V41, P18, DOI 10.1038/ng.274
   Tycko B, 2010, AM J HUM GENET, V86, P109, DOI 10.1016/j.ajhg.2010.01.021
   van Veldhoven K, 2015, CLIN EPIGENETICS, V7, DOI 10.1186/s13148-015-0104-2
   Welter D, 2014, NUCLEIC ACIDS RES, V42, pD1001, DOI 10.1093/nar/gkt1229
   Widschwendter M, 2002, ONCOGENE, V21, P5462, DOI 10.1038/sj.onc.1205606
   Wong EM, 2011, CANCER PREV RES, V4, P23, DOI 10.1158/1940-6207.CAPR-10-0212
   Wu HC, 2014, EPIGENETICS-US, V9, P929, DOI 10.4161/epi.28902
   Wu HC, 2011, EPIGENETICS-US, V6, P29, DOI 10.4161/epi.6.1.13393
   Xu ZL, 2013, JNCI-J NATL CANCER I, V105, P694, DOI 10.1093/jnci/djt045
   Zhai Y, 2006, GASTROENTEROLOGY, V130, P2001, DOI 10.1053/j.gastro.2006.02.030
NR 55
TC 9
Z9 12
U1 0
U2 0
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1559-2294
EI 1559-2308
J9 EPIGENETICS-US
JI Epigenetics
PY 2018
VL 13
IS 3
BP 240
EP 250
DI 10.1080/15592294.2018.1435243
PG 11
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA GI4FO
UT WOS:000434326600004
PM 29436922
OA Green Published, Bronze
DA 2025-01-12
ER

PT J
AU Gamage, TKJB
   Schierding, W
   Hurley, D
   Tsai, P
   Ludgate, JL
   Bhoothpur, C
   Chamley, LW
   Weeks, RJ
   Macaulay, EC
   James, JL
AF Gamage, Teena K. J. B.
   Schierding, William
   Hurley, Daniel
   Tsai, Peter
   Ludgate, Jackie L.
   Bhoothpur, Chandrakanth
   Chamley, Lawrence W.
   Weeks, Robert J.
   Macaulay, Erin C.
   James, Joanna L.
TI The role of DNA methylation in human trophoblast differentiation
SO EPIGENETICS
LA English
DT Article
DE Placenta; trophoblast; cytotrophoblasts; extravillous trophoblasts; DNA
   methylation
ID EPITHELIAL-MESENCHYMAL TRANSITION; BREAST-CANCER; CELL-MIGRATION;
   GENE-EXPRESSION; TUMOR-GROWTH; EXTRAVILLOUS TROPHOBLAST; STEM-CELLS;
   INVASION; PROTEIN; METASTASIS
AB The placenta is a vital fetal exchange organ connecting mother and baby. Specialised placental epithelial cells, called trophoblasts, are essential for adequate placental function. Trophoblasts transform the maternal vasculature to allow efficient blood flow to the placenta and facilitate adequate nutrient uptake. Placental development is in part regulated by epigenetic mechanisms. However, our understanding of how DNA methylation contributes to human trophoblast differentiation is limited. To better understand how genome-wide methylation differences affect trophoblast differentiation, reduced representation bisulfite sequencing (RRBS) was conducted on four matched sets of trophoblasts; side-population trophoblasts (a candidate human trophoblast stem cell population), cytotrophoblasts (an intermediate progenitor population), and extravillous trophoblasts (EVT, a terminally differentiated population) each isolated from the same first trimester placenta. Each trophoblast population had a distinct methylome. In line with their close differentiation relationship, the methylation profile of side-population trophoblasts was most similar to cytotrophoblasts, whilst EVT had the most distinct methylome. In comparison to mature trophoblast populations, side-population trophoblasts exhibited differential methylation of genes and miRNAs involved in cell cycle regulation, differentiation, and regulation of pluripotency. A combined methylomic and transcriptomic approach was taken to better understand cytotrophoblast differentiation to EVT. This revealed methylation of 41 genes involved in epithelial to mesenchymal transition and metastatic cancer pathways, which likely contributes to the acquisition of an invasive EVT phenotype. However, the methylation status of a gene did not always predict gene expression. Therefore, while CpG methylation plays a role in trophoblast differentiation, it is likely not the only regulatory mechanism involved in this process.
C1 [Gamage, Teena K. J. B.; Schierding, William; Tsai, Peter; Chamley, Lawrence W.; James, Joanna L.] Univ Auckland, Dept Obstet & Gynaecol, Private Bag 92019, Auckland 1142, New Zealand.
   [Hurley, Daniel] Univ Melbourne, Melbourne Sch Engn, Syst Biol Lab, Melbourne, Vic, Australia.
   [Ludgate, Jackie L.; Weeks, Robert J.; Macaulay, Erin C.] Univ Otago, Dunedin Sch Med, Dept Pathol, Dunedin, New Zealand.
   [Bhoothpur, Chandrakanth] Univ Auckland, Grafton Clin Genom, Auckland, New Zealand.
C3 University of Auckland; University of Melbourne; University of Otago;
   University of Auckland
RP Gamage, TKJB (通讯作者)，Univ Auckland, Dept Obstet & Gynaecol, Private Bag 92019, Auckland 1142, New Zealand.
EM t.gamage@auckland.ac.nz
RI Chamley, Larry/L-6974-2018; Macaulay, Erin/G-3577-2013; Schierding,
   William/ACD-9101-2022; James, Joanna/L-6378-2017; Weeks, Rob/A-6876-2012
OI Chamley, Lawrence/0000-0002-7501-1340; Macaulay,
   Erin/0000-0001-5308-1033; Schierding, William/0000-0001-5659-2701;
   James, Joanna/0000-0002-3757-4177; Ludgate, Jackie/0000-0002-0795-4910;
   Weeks, Rob/0000-0003-0474-9089; Tsai, Peter/0000-0002-9930-9029
FU Gravida: National Centre for Growth and Development [STF-13-09];
   Auckland Medical Research Fund Doctoral Scholarship [1214004];
   University of Auckland Doctoral Scholarship; Health Research Council Sir
   Charles Hercus Research Fellowship [16/043]
FX This work was supported by funding from Gravida: National Centre for
   Growth and Development (STF-13-09). TKJB Gamage is the recipient of an
   Auckland Medical Research Fund Doctoral Scholarship (1214004) and a
   University of Auckland Doctoral Scholarship. JL James is supported by a
   Health Research Council Sir Charles Hercus Research Fellowship (16/043).
   None of these funding bodies had any role in the design of this research
   or interpretation of the data.
CR Abdelzaher E, 2015, TUMOR BIOL, V36, P5473, DOI 10.1007/s13277-015-3214-8
   Akalin A, 2012, GENOME BIOL, V13, DOI [10.1186/gb-2012-13-10-R87, 10.1186/gb-2012-13-10-r87]
   Amson R, 2013, TRENDS CELL BIOL, V23, P37, DOI 10.1016/j.tcb.2012.10.002
   Apps R, 2011, PLACENTA, V32, P33, DOI 10.1016/j.placenta.2010.10.010
   Asano M, 1997, EMBO J, V16, P1850, DOI 10.1093/emboj/16.8.1850
   Asanoma K, 2012, J BIOL CHEM, V287, P2257, DOI 10.1074/jbc.M111.287128
   Avila L, 2010, PLACENTA, V31, P1070, DOI 10.1016/j.placenta.2010.09.011
   Benirschke K., 2004, NeoReviews, V5, pe252
   Bianco-Miotto T, 2016, REPRODUCTION, V152, pR23, DOI 10.1530/REP-16-0014
   Branco MR, 2016, DEV CELL, V36, P152, DOI 10.1016/j.devcel.2015.12.027
   Brown KA, 2004, BREAST CANCER RES, V6, pR215, DOI 10.1186/bcr778
   Cai Yimei, 2009, Genomics Proteomics & Bioinformatics, V7, P147, DOI 10.1016/S1672-0229(08)60044-3
   Cambuli F, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6538
   Canevari RA, 2016, TUMOR BIOL, V37, P13855, DOI 10.1007/s13277-016-5133-8
   CELANO P, 1989, BIOCHEM BIOPH RES CO, V165, P384, DOI 10.1016/0006-291X(89)91082-6
   Chatterjee A, 2012, J BIOMED BIOTECHNOL, DOI 10.1155/2012/741542
   Cheedipudi S, 2015, NUCLEIC ACIDS RES, V43, P6236, DOI 10.1093/nar/gkv567
   Chen DH, 2009, PIGM CELL MELANOMA R, V22, P761, DOI 10.1111/j.1755-148X.2009.00603.x
   CHUANG TH, 1995, P NATL ACAD SCI USA, V92, P10282, DOI 10.1073/pnas.92.22.10282
   Cuevas EP, 2017, SCI REP-UK, V7, DOI 10.1038/srep44988
   DaSilva-Arnold S, 2018, BIOL REPROD
   DaSilva-Arnold S, 2015, PLACENTA, V36, P1412, DOI 10.1016/j.placenta.2015.10.013
   Davies JE, 2016, CELL ADHES MIGR, V10, P310, DOI 10.1080/19336918.2016.1170258
   de Kreuk BJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073962
   Duan BA, 2016, CANCER LETT, V379, P70, DOI 10.1016/j.canlet.2016.05.027
   Ehrlich Kenneth C., 2016, Yale Journal of Biology and Medicine, V89, P441
   Ferretti C, 2007, HUM REPROD UPDATE, V13, P121, DOI 10.1093/humupd/dml048
   Francoz S, 2006, P NATL ACAD SCI USA, V103, P3232, DOI 10.1073/pnas.0508476103
   Gamage TKJB, 2017, HUM REPROD UPDATE, V23, P77, DOI 10.1093/humupd/dmw026
   Gehrau RC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008929
   Genbacev O, 2011, STEM CELLS, V29, P1427, DOI 10.1002/stem.686
   Gorkin DU, 2014, CELL STEM CELL, V14, P762, DOI 10.1016/j.stem.2014.05.017
   Gouti M, 2008, STEM CELLS, V26, P1985, DOI 10.1634/stemcells.2008-0182
   Green AR, 2008, BREAST CANCER RES TR, V110, P427, DOI 10.1007/s10549-007-9737-y
   Guiet R, 2008, EUR J CELL BIOL, V87, P527, DOI 10.1016/j.ejcb.2008.03.008
   Gulyaeva LF, 2016, J TRANSL MED, V14, DOI 10.1186/s12967-016-0893-x
   Hemberger M, 2010, HUM MOL GENET, V19, P2456, DOI 10.1093/hmg/ddq128
   Henson B J, 2010, Cytogenet Genome Res, V128, P192, DOI 10.1159/000308303
   Holtan SG, 2009, MAYO CLIN PROC, V84, P985, DOI 10.1016/S0025-6196(11)60669-1
   Horie A, 2012, HUM REPROD, V27, P1267, DOI 10.1093/humrep/des068
   Huppertz B, 2011, PREGNANCY HYPERTENS, V1, P79, DOI 10.1016/j.preghy.2010.10.003
   Hwang ES, 2004, CANCER, V100, P2562, DOI 10.1002/cncr.20273
   James JL, 2015, REPRODUCTION, V150, P449, DOI 10.1530/REP-14-0646
   James JL, 2014, PLACENTA, V35, P77, DOI 10.1016/j.placenta.2013.12.010
   James JL, 2012, PLACENTA, V33, P327, DOI 10.1016/j.placenta.2012.01.020
   Jiang YX, 2015, INT J CLIN EXP PATHO, V8, P7002
   Johnstone ED, 2005, BIOL REPROD, V73, P1282, DOI 10.1095/biolreprod.105.044206
   Karaczyn AA, 2017, J CELL BIOCHEM, V118, P237, DOI 10.1002/jcb.25628
   Kaufmann MR, 2013, EXP MOL PATHOL, V94, P453, DOI 10.1016/j.yexmp.2013.03.005
   Kawahara R, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0115004
   Kim JK, 2015, TUMOR BIOL, V36, P5561, DOI 10.1007/s13277-015-3226-4
   Kim M, 2017, EXP MOL MED, V49, DOI 10.1038/emm.2017.10
   Knoefler Martin, 2013, Frontiers in Genetics, V4, P190, DOI 10.3389/fgene.2013.00190
   Knöfler M, 2010, INT J DEV BIOL, V54, P269, DOI 10.1387/ijdb.082769mk
   Knott JG, 2014, REPRODUCTION, V148, pR121, DOI 10.1530/REP-14-0072
   Konakahara S, 2011, FEBS LETT, V585, P2377, DOI 10.1016/j.febslet.2011.06.011
   Kondaveeti Y, 2015, CANCER LETT, V364, P44, DOI 10.1016/j.canlet.2015.04.025
   Koziol MJ, 2007, CURR BIOL, V17, P801, DOI 10.1016/j.cub.2007.03.062
   Kubo E, 2013, J CELL MOL MED, V17, P212, DOI 10.1111/j.1582-4934.2012.01654.x
   Kuzmanov A, 2014, MOL ONCOL, V8, P401, DOI 10.1016/j.molonc.2013.12.009
   La Belle Alyssa A, 2017, Stem Cell Investig, V4, P44, DOI 10.21037/sci.2017.04.07
   Latos PA, 2015, GENE DEV, V29, P2435, DOI 10.1101/gad.268821.115
   Lee CQE, 2016, STEM CELL REP, V6, P257, DOI 10.1016/j.stemcr.2016.01.006
   Li CG, 2017, ONCOTARGET, V8, P71933, DOI 10.18632/oncotarget.18035
   Li TL, 2015, EMBO J, V34, P1630, DOI 10.15252/embj.201489947
   Li W, 2015, INT J ONCOL, V46, P2613, DOI 10.3892/ijo.2015.2938
   Lindvall C, 2006, J BIOL CHEM, V281, P35081, DOI 10.1074/jbc.M607571200
   Liu J, 2018, CANCER BIOL THER, V19, P160, DOI 10.1080/15384047.2017.1414756
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Logan Philip C., 2013, Frontiers in Genetics, V4, P265, DOI 10.3389/fgene.2013.00265
   Lou CH, 2015, EMBO J, V34, P1606, DOI 10.15252/embj.201591631
   Maunakea AK, 2010, NATURE, V466, P253, DOI 10.1038/nature09165
   Mayne BT, 2017, EPIGENOMICS-UK, V9, P279, DOI 10.2217/epi-2016-0103
   Melero R, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10585
   Miao CK, 2017, ONCOTARGET, V8, P97811, DOI 10.18632/oncotarget.22083
   Mori M, 2009, MOL BIOL CELL, V20, P3115, DOI 10.1091/mbc.E09-01-0046
   Murray A, 2016, SCI REP-UK, V6, DOI 10.1038/srep25112
   Ng RK, 2008, NAT CELL BIOL, V10, P1280, DOI 10.1038/ncb1786
   Nordor AV, 2017, EPIGENETICS-US, V12, P793, DOI 10.1080/15592294.2017.1342912
   Novakovic B, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-04776-5
   Novakovic B, 2017, FASEB J, V31, P2380, DOI 10.1096/fj.201601189RR
   Oda M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068846
   OHTSUBO M, 1987, GENE DEV, V1, P585, DOI 10.1101/gad.1.6.585
   Okae H, 2018, CELL STEM CELL, V22, P50, DOI 10.1016/j.stem.2017.11.004
   Pearton DJ, 2014, DEV BIOL, V392, P344, DOI 10.1016/j.ydbio.2014.05.012
   Senner CE, 2012, STEM CELLS, V30, P2732, DOI 10.1002/stem.1249
   Sossey-Alaoui K, 2014, FASEB J, V28, P2260, DOI 10.1096/fj.13-244004
   Stockwell PA, 2014, BIOINFORMATICS, V30, P1814, DOI 10.1093/bioinformatics/btu126
   Sun YY, 2011, REPROD SCI, V18, P1138, DOI 10.1177/1933719111408112
   Takahata M, 2009, J BIOL CHEM, V284, P3334, DOI 10.1074/jbc.M808989200
   Tomikawa J, 2006, J BIOL CHEM, V281, P12163, DOI 10.1074/jbc.M513782200
   Vasudevan SA, 2007, J PEDIATR SURG, V42, P148, DOI 10.1016/j.jpedsurg.2006.09.064
   Vlahovic M, 1999, INT J DEV BIOL, V43, P843
   Wang CQ, 2015, CANCER LETT, V368, P105, DOI 10.1016/j.canlet.2015.07.037
   Wang JM, 2014, J BIOL CHEM, V289, P14612, DOI 10.1074/jbc.M114.548230
   Wang XQ, 2017, ONCOTARGET, V8, P92545, DOI 10.18632/oncotarget.21442
   Wu Y, 2008, ONCOGENE, V27, P6679, DOI 10.1038/onc.2008.264
   Yan XJ, 2016, J GENET GENOMICS, V43, P512, DOI 10.1016/j.jgg.2016.03.010
   Yang M, 2014, CELL DEATH DIFFER, V21, P1290, DOI 10.1038/cdd.2014.45
   Yong WS, 2016, EPIGENET CHROMATIN, V9, DOI 10.1186/s13072-016-0075-3
   Zdravkovic T, 2015, DEVELOPMENT, V142, P4010, DOI 10.1242/dev.122846
   Zhang YJ, 2002, J BIOL CHEM, V277, P38328, DOI 10.1074/jbc.M205576200
   Zhong M, 2013, CELL PHYSIOL BIOCHEM, V31, P209, DOI 10.1159/000343362
   Zhu LY, 2015, CANCER LETT, V363, P71, DOI 10.1016/j.canlet.2015.04.002
   Ziller MJ, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002389
   Zito A, 2014, BRAIN STRUCT FUNCT, V219, P105, DOI 10.1007/s00429-012-0487-1
NR 106
TC 36
Z9 39
U1 1
U2 15
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1559-2294
EI 1559-2308
J9 EPIGENETICS-US
JI Epigenetics
PY 2018
VL 13
IS 12
BP 1154
EP 1173
DI 10.1080/15592294.2018.1549462
PG 20
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA HI0AR
UT WOS:000456104900002
PM 30475094
OA Green Published, Bronze
DA 2025-01-12
ER

PT J
AU Sun, HX
   Zhou, HB
   Zhang, Y
   Chen, J
   Han, X
   Huang, D
   Ren, XY
   Jia, YH
   Fan, Q
   Tian, WJ
   Zhao, YS
AF Sun, Hongxu
   Zhou, Haibo
   Zhang, Yan
   Chen, Jie
   Han, Xu
   Huang, Di
   Ren, Xiyun
   Jia, Yunhe
   Fan, Qing
   Tian, Wenjing
   Zhao, Yashuang
TI Aberrant methylation of <i>FAT4</i> and <i>SOX1 1 </i>in peripheral
   blood leukocytes and their association with gastric cancer risk
SO JOURNAL OF CANCER
LA English
DT Article
DE DNA methylation; peripheral blood leukocytes; gastric cancer;
   gene-environment interaction
ID CELL LUNG-CANCER; DNA METHYLATION; PROMOTER METHYLATION; BREAST-CANCER;
   CHINESE POPULATION; GENE METHYLATION; TUMOR-SUPPRESSOR; EXPRESSION;
   EPIGENETICS; SOX11
AB Background: Aberrant DNA methylation, especially tumor suppressor gene hypermethylation, is a well-recognized biomarker of initial tumorogenesis stages. FAT4 and SOX1 1 are putative tumor suppressor genes and can be down-regulated by hypermethylation in various cancers tissues. However, in peripheral blood leukocytes, the association between these two genes methylation status, as well as the effects of gene-environment interactions, and gastric cancer (GC) risk remain unclear.
   Methods: A hospital-based case-control study including 375 cases and 394 controls was conducted. Peripheral blood leukocytes DNA methylation status were detected by methylation-sensitive high-resolution melting (MS-HRM) assay. Logistic regression was adopted to analyze the relationship of FAT4 and SOX1 1 methylation with GC susceptibility.
   Results: Positive methylation (Pm) and total positive methylation (Tpm) of FAT4 were significantly increased the risk of GC (OR = 2.204, 95% CI: 1.168-4.159, P = 0.015; OR = 1.583, 95% CI: 1.031-2.430, P = 0.036, respectively). Compared with controls, cases exhibited higher SOXI/ Pm frequencies with OR of 2.530 (95% CI: 1.289-4.969, P = 0.007). Nonetheless, no statistically significant association between SOX1 1 Tpm and GC risk was observed. Additionally, interactions between FAT4 Tpm and increased consumption of freshwater fish (1 times/week) displayed an antagonistic effect on GC (OR = 0.328, 95% CI: 0.142-0.762, P = 0.009), and high salt intake interacted with SOX1 1 Tpm also showed statistically significant (OR = 0.490, 95% CI: 0.242-0.995, P = 0.048).
   Conclusions: FAT4 aberrant methylation in peripheral blood leukocytes and gene-environment interactions were associated with the risk of GC, while SOX1 1 was controversial and needed to be more investigated.
C1 [Sun, Hongxu; Zhou, Haibo; Zhang, Yan; Chen, Jie; Han, Xu; Huang, Di; Ren, Xiyun; Tian, Wenjing; Zhao, Yashuang] Harbin Med Univ, Coll Publ Hlth, Dept Epidemiol, 197 Xuefu Rd, Harbin 150081, Heilongjiang, Peoples R China.
   [Jia, Yunhe] Harbin Med Univ, Affiliated Hosp 3, Dept Colorectal Canc Surg, Harbin, Heilongjiang, Peoples R China.
   [Fan, Qing] Xiangfang Ctr Dis Control & Prevent, Harbin 150081, Heilongjiang, Peoples R China.
C3 Harbin Medical University; Harbin Medical University
RP Tian, WJ; Zhao, YS (通讯作者)，Harbin Med Univ, Coll Publ Hlth, Dept Epidemiol, 197 Xuefu Rd, Harbin 150081, Heilongjiang, Peoples R China.
EM twj8267@sina.com; zhao_yashuang@263.net
RI Huang, Di/JBJ-3541-2023; ZHOU, Haibo/M-7373-2017
OI Tian, Wenjing/0000-0002-0449-6643
FU National Natural Science Foundation of China [81573219]; Innovation
   Research Program of Harbin Medical University [2016JCZX22]
FX This study was funded by the National Natural Science Foundation of
   China (2016-2019, Grant No. 81573219) and Innovation Research Program of
   Harbin Medical University (2016JCZX22).
CR Ahmed FE, 2007, J ENVIRON SCI HEAL C, V25, P101, DOI 10.1080/10590500701399184
   Allard WJ, 2004, CLIN CANCER RES, V10, P6897, DOI 10.1158/1078-0432.CCR-04-0378
   Azhikina T, 2011, CANCER GENET-NY, V204, P492, DOI 10.1016/j.cancergen.2011.07.010
   Beeharry MK, 2016, WORLD J GASTROENTERO, V22, P1202, DOI 10.3748/wjg.v22.i3.1202
   Berx G, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a003129
   Cai J, 2015, BRIT J CANCER, V113, P1720, DOI 10.1038/bjc.2015.367
   Candiloro ILM, 2011, EPIGENETICS-US, V6, P501, DOI 10.4161/epi.6.4.14853
   Candiloro ILM, 2008, EPIGENET CHROMATIN, V1, DOI 10.1186/1756-8935-1-7
   Chen WQ, 2016, CA-CANCER J CLIN, V66, P115, DOI 10.3322/caac.21338
   Cheng Z, 2013, ENVIRON SCI POLLUT R, V20, P4484, DOI 10.1007/s11356-012-1382-2
   Cho YH, 2015, J CANCER, V6, P819, DOI 10.7150/jca.12174
   Crider KS, 2012, ADV NUTR, V3, P21, DOI 10.3945/an.111.000992
   Dauksa A, 2014, ANTICANCER RES, V34, P5381
   Ellinger J, 2015, EXPERT REV MOL DIAGN, V15, P505, DOI 10.1586/14737159.2015.1019477
   Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI [10.1056/NEJMra072067, 10.1093/carcin/bgp220]
   Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210
   Fraga MF, 2007, TRENDS GENET, V23, P413, DOI 10.1016/j.tig.2007.05.008
   Gustavsson E, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-187
   Harvey K, 2007, NAT REV CANCER, V7, P182, DOI 10.1038/nrc2070
   He J, 2013, MOL CARCINOGEN, V52, P70, DOI 10.1002/mc.22013
   He J, 2012, HUM GENET, V131, P1235, DOI 10.1007/s00439-012-1152-8
   Hide T, 2009, CANCER RES, V69, P7953, DOI 10.1158/0008-5472.CAN-09-2006
   Hou H., 1988, Biomedical and Environmental Sciences, V1, P79
   Hou LF, 2010, INT J CANCER, V127, P1866, DOI 10.1002/ijc.25190
   Issa JP, 2000, CURR TOP MICROBIOL, V249, P101
   Iwamoto T, 2011, BREAST CANCER RES TR, V129, P69, DOI 10.1007/s10549-010-1188-1
   Jaenisch R, 2003, NAT GENET, V33, P245, DOI 10.1038/ng1089
   Jirtle RL, 2007, NAT REV GENET, V8, P253, DOI 10.1038/nrg2045
   Karimi P, 2014, CANCER EPIDEM BIOMAR, V23, P700, DOI 10.1158/1055-9965.EPI-13-1057
   Koestler DC, 2012, CANCER EPIDEM BIOMAR, V21, P1293, DOI 10.1158/1055-9965.EPI-12-0361
   Li Y, 2010, CURR MED CHEM, V17, P2141, DOI 10.2174/092986710791299966
   Lim Unhee, 2012, Methods Mol Biol, V863, P359, DOI 10.1007/978-1-61779-612-8_23
   Maeda M, 2017, GASTRIC CANCER, V20, pS8, DOI 10.1007/s10120-016-0650-0
   Marsit CJ, 2011, J CLIN ONCOL, V29, P1133, DOI 10.1200/JCO.2010.31.3577
   Putnik M, 2016, MOL BIOL REP, V43, P141, DOI 10.1007/s11033-016-3946-6
   Qu Y, 2014, INT J ONCOL, V44, P1512, DOI 10.3892/ijo.2014.2328
   Qu YP, 2013, CLIN CHIM ACTA, V424, P53, DOI 10.1016/j.cca.2013.05.002
   Roisman A, 2014, MEDICINA-BUENOS AIRE, V74, P140
   Sernbo S, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-405
   Sobota RS, 2016, HUM GENET, V135, P895, DOI 10.1007/s00439-016-1687-1
   Tahara T, 2013, CANCER PREV RES, V6, P1093, DOI 10.1158/1940-6207.CAPR-13-0034
   Tian T, 2017, GASTRIC CANCER, V20, P940, DOI 10.1007/s10120-017-0717-6
   Ushijima T, 2006, J GASTROENTEROL, V41, P401, DOI 10.1007/s00535-006-1846-6
   Ushijima T, 2005, CANCER SCI, V96, P206, DOI 10.1111/j.1349-7006.2005.00035.x
   Wang BH, 2017, ONCOTARGET, V8, P31692, DOI 10.18632/oncotarget.15919
   Whiteside Theresa L., 2003, Journal of Allergy and Clinical Immunology, V111, pS677
   Wojdacz TK, 2014, BREAST CANCER RES, V16, DOI 10.1186/bcr3612
   Wojdacz TK, 2010, EXPERT REV MOL DIAGN, V10, P575, DOI 10.1586/ERM.10.46
   Wu WZ, 2001, WATER RES, V35, P1141, DOI 10.1016/S0043-1354(00)00376-6
   Xu XY, 2015, CELL ONCOL, V38, P183, DOI 10.1007/s13402-015-0219-7
   Yang Z, 2015, J CANCER RES CLIN, V141, P211, DOI 10.1007/s00432-014-1809-x
   Yoshida S, 2017, GASTRIC CANCER, V20, P136, DOI 10.1007/s10120-016-0593-5
   Yu YZ, 2014, AM J CANCER RES, V4, P710
   Zang ZJ, 2012, NAT GENET, V44, P570, DOI 10.1038/ng.2246
   Zhu KM, 2003, CANCER CAUSE CONTROL, V14, P827, DOI 10.1023/B:CACO.0000003823.97506.be
NR 55
TC 20
Z9 20
U1 0
U2 2
PU IVYSPRING INT PUBL
PI LAKE HAVEN
PA PO BOX 4546, LAKE HAVEN, NSW 2263, AUSTRALIA
SN 1837-9664
J9 J CANCER
JI J. Cancer
PY 2018
VL 9
IS 13
BP 2275
EP 2283
DI 10.7150/jca.24797
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA GJ3BH
UT WOS:000435149400005
PM 30026822
OA Green Submitted, Green Published, gold
DA 2025-01-12
ER

PT J
AU Shen, J
   Zhang, JH
   Xiao, MH
   Yang, JF
   Zhang, NN
AF Shen, Jie
   Zhang, Jianhua
   Xiao, Minhui
   Yang, Junfeng
   Zhang, Ningnan
TI miR-203 Suppresses Bladder Cancer Cell Growth and Targets Twist1
SO ONCOLOGY RESEARCH
LA English
DT Article
DE miR-203; Bladder cancer (BCa); Proliferation; Invasion
ID EPITHELIAL-MESENCHYMAL TRANSITION; BREAST-CANCER;
   HEPATOCELLULAR-CARCINOMA; BMI-1 ONCOPROTEIN; COLORECTAL-CANCER;
   TUMOR-METASTASIS; VASCULOGENIC MIMICRY; PROSTATE CELLS; UP-REGULATION;
   LUNG-CANCER
AB miR-203 is an epigenetically silenced tumor-suppressive microRNA in tumors. This study was designed to investigate the effects of miR-203 on the proliferation, migration, invasion, and apoptosis of bladder cancer (BCa) cells. The expression levels of miR-203 in BCa tissues, normal adjacent tissues, and BCa cell lines were detected. BCa cells were transfected with miR-203 mimic and inhibitor to investigate the effect of miR-203 on cell functions and the epithelial-mesenchymal transition (EMT). Cotransfection with miR-203 inhibitor and shRNA of the predicted target gene Twist1 (si-Twist1) was performed to investigate the target relationship of miR-203 and Twist1. The effects of knockdown of Twist1 on cell functions were also investigated. The expression of miR-203 was significantly reduced in BCa tissues and cells, in comparison with the control. miR-203 mimic significantly reduced cell viability, invasion, migration, and EMT, and enhanced cell apoptosis. On the contrary, miR-203 inhibitor showed the opposite results. However, the administration of si-Twist1 cancelled the effect of miR-203 inhibitor on cell proliferation, apoptosis, invasion, and migration. These demonstrated that miR-203 may function as a tumor-suppressive microRNA in BCa by negatively targeting Twist1. Both Twist1 and miR-203 might be explored as potential targets for studying the mechanism related to BCa pathogenesis and therapy.
C1 [Shen, Jie; Xiao, Minhui; Yang, Junfeng; Zhang, Ningnan] First Peoples Hosp Yunnan Prov, Dept Urol, Kunming, Yunnan, Peoples R China.
   [Zhang, Jianhua] Kunming Med Univ, Affiliated Hosp 1, Dept Urol, 295 Xichang Rd, Kunming 650032, Yunnan, Peoples R China.
C3 Kunming University of Science & Technology; Kunming Medical University
RP Zhang, JH (通讯作者)，Kunming Med Univ, Affiliated Hosp 1, Dept Urol, 295 Xichang Rd, Kunming 650032, Yunnan, Peoples R China.
EM jinlinli08@126.com
RI zhang, ying/HJB-1230-2022
CR Backes C, 2016, MOL DIAGN THER, P1
   Barry G, 2014, MOL PSYCHIATR, V19, P410, DOI 10.1038/mp.2013.196
   Bo JJ, 2011, FEBS J, V278, P786, DOI 10.1111/j.1742-4658.2010.07997.x
   Boll K, 2013, ONCOGENE, V32, P277, DOI 10.1038/onc.2012.55
   Casas E, 2011, CANCER RES, V71, P245, DOI 10.1158/0008-5472.CAN-10-2330
   Chakrabarti R, 2012, NAT CELL BIOL, V14, P1212, DOI 10.1038/ncb2607
   Chen H, 2012, CANCER LETT, V320, P40, DOI 10.1016/j.canlet.2012.01.027
   Ding XM, 2013, J BIOL CHEM, V288, P10241, DOI 10.1074/jbc.M112.443655
   Eckert M., 2012, THESIS
   Eckert MA, 2011, CANCER CELL, V19, P372, DOI 10.1016/j.ccr.2011.01.036
   Furuta M, 2010, CARCINOGENESIS, V31, P766, DOI 10.1093/carcin/bgp250
   Gao W, 2012, CANCER BIOL THER, V13, P330, DOI 10.4161/cbt.19073
   Gort EH, 2008, CANCER EPIDEM BIOMAR, V17, P3325, DOI 10.1158/1055-9965.EPI-08-0472
   Kim JH, 2004, BREAST, V13, P383, DOI 10.1016/j.breast.2004.02.010
   Kim JH, 2004, CANCER LETT, V203, P217, DOI 10.1016/j.canlet.2003.07.009
   Kogan-Sakin I, 2011, CELL DEATH DIFFER, V18, P271, DOI 10.1038/cdd.2010.94
   Lee KW, 2012, ANN SURG ONCOL, V19, P326, DOI 10.1245/s10434-011-1867-0
   Li QQ, 2009, CLIN CANCER RES, V15, P2657, DOI 10.1158/1078-0432.CCR-08-2372
   Le LTN, 2016, J CELL BIOL, V212, P707, DOI 10.1083/jcb.201507054
   Liu K, 2015, INT J MOL MED, V36, P783, DOI 10.3892/ijmm.2015.2293
   Lohcharoenkal W, 2016, CANCER RES, V76, DOI 10.1158/1538-7445.AM2016-1098
   Mao LJ, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-111
   Mikheeva SA, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-194
   Nairismägi ML, 2012, ONCOGENE, V31, P4960, DOI 10.1038/onc.2011.650
   Pham CG, 2007, MOL CELL BIOL, V27, P3920, DOI 10.1128/MCB.01219-06
   Qu Y, 2013, INT J CANCER, V133, P544, DOI 10.1002/ijc.28056
   Saini S, 2011, CANCER PREV RES, V4, P1698, DOI 10.1158/1940-6207.CAPR-11-0267
   Shang YH, 2016, BIOMED PHARMACOTHER, V83, P1175, DOI 10.1016/j.biopha.2016.08.006
   Shen Y, 2016, J CELL MOL MED, V31, P780
   Shynkar VV, 2007, J AM CHEM SOC, V129, P2187, DOI 10.1021/ja068008h
   SPIOTTO MT, 2016, INT J RADIAT ONCOL, V94, P936
   Stein JP, 2001, J CLIN ONCOL, V19, P666, DOI 10.1200/JCO.2001.19.3.666
   Sun T, 2010, HEPATOLOGY, V51, P545, DOI 10.1002/hep.23311
   Valdes-Mora F, 2009, ANN SURG ONCOL, V16, P78, DOI 10.1245/s10434-008-0166-x
   Vonlanthen S, 2001, BRIT J CANCER, V84, P1372, DOI 10.1054/bjoc.2001.1791
   Wu Kou-Juey, 2011, Chang Gung Med J, V34, P229
   Xu X, 2013, MOL CELLS, V36, P62, DOI 10.1007/s10059-013-0044-7
   Yang MH, 2010, NAT CELL BIOL, V12, P982, DOI 10.1038/ncb2099
   Yu XY, 2014, STEM CELLS DEV, V23, P576, DOI 10.1089/scd.2013.0308
   Zhang Zhiqian, 2011, Genes Cancer, V2, P782, DOI 10.1177/1947601911429743
   Zhao D, 2015, ONCOGENE, V34, P5447, DOI 10.1038/onc.2014.473
   Zhao DK, 2014, CANCER RES, V74, DOI 10.1158/1538-7445.AM2014-1145
   Zhou YF, 2014, MOL ONCOL, V8, P83, DOI 10.1016/j.molonc.2013.09.004
NR 43
TC 45
Z9 48
U1 1
U2 6
PU COGNIZANT COMMUNICATION CORP
PI PUTNAM VALLEY
PA 18 PEEKSKILL HOLLOW RD, PO BOX 37, PUTNAM VALLEY, NY 10579 USA
SN 0965-0407
EI 1555-3906
J9 ONCOL RES
JI Oncol. Res.
PY 2018
VL 26
IS 8
BP 1155
EP 1165
DI 10.3727/096504017X15041934685237
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA GT3OX
UT WOS:000444414100002
PM 28893347
OA Green Published, hybrid
DA 2025-01-12
ER

PT J
AU Aleskandarany, MA
   Vandenberghe, ME
   Marchiò, C
   Ellis, IO
   Sapino, A
   Rakha, EA
AF Aleskandarany, Mohammed A.
   Vandenberghe, Michel E.
   Marchio, Caterina
   Ellis, Ian O.
   Sapino, Anna
   Rakha, Emad A.
TI Tumour Heterogeneity of Breast Cancer: From Morphology to Personalised
   Medicine
SO PATHOBIOLOGY
LA English
DT Article
DE Breast cancer; Heterogeneity; Morphology; Molecular heterogeneity;
   Microenvironment; Sampling; Personalised therapy; Resistance
ID CARCINOMA IN-SITU; PATHOLOGICAL PROGNOSTIC-FACTORS; TISSUE MICROARRAYS;
   DUCTAL CARCINOMA; HORMONE-RECEPTOR; CLINICAL CHARACTERISTICS; GENE
   AMPLIFICATION; PROTEIN EXPRESSION; EVOLUTION; DIVERSITY
AB Breast cancer (BC) displays striking clinical, morphological, and behavioural diversity within a single tumour and between tumours. Currently, mounting evidence indicates that the morphological heterogeneity of BC reflects an underlying spectrum of genetic and epigenetic portraits that control BC behaviour. Further understanding of BC heterogeneity will have an impact, not only on the routine diagnostic practices but also on patients' management decisions. Phenomena like diagnostic inconsistencies and therapeutic resistance, both primary and acquired, could be attributed, at least in part, to tumour heterogeneity within the same cancer and between the primary disease and subsequent recurrences. From a practical standpoint, and to minimise the impact of BC intratumoral heterogeneity, pragmatic approaches for adequate tumour sampling have been suggested in translational biomarker discovery and validation research studies and in the clinical setting. Here, we provide a brief overview of BC heterogeneity, with an emphasis on the clinical consequences of intratumoral heterogeneity. (C) 2018 S. Karger AG, Basel.
C1 [Aleskandarany, Mohammed A.; Ellis, Ian O.; Rakha, Emad A.] Univ Nottingham, Dept Histopathol, Nottingham, England.
   [Aleskandarany, Mohammed A.; Ellis, Ian O.; Rakha, Emad A.] City Hosp, Nottingham Univ Hosp NHS Trust, Nottingham, England.
   [Vandenberghe, Michel E.] AstraZeneca, IMED Biotech Unit, Precis Med & Genom, Precis Med Labs, Cambridge, England.
   [Marchio, Caterina; Sapino, Anna] Univ Turin, Dept Med Sci, Turin, Italy.
   [Sapino, Anna] IRCCS, Candiolo Canc Inst FPO, Candiolo, Italy.
C3 University of Nottingham; Nottingham University Hospital NHS Trust;
   University of Nottingham; AstraZeneca; University of Turin; IRCCS
   Fondazione del Piemonte per l'Oncologia
RP Rakha, EA (通讯作者)，Univ Nottingham, Nottingham City Hosp NHS Trust, Dept Histopathol, Hucknall Rd, Nottingham NG5 1PB, England.
EM Emad.Rakha@nottingham.ac.uk
RI Aleskandarany, Mohammed/X-8585-2019; Ellis, Ian/JJF-5555-2023;
   Vandenberghe, Michel/W-4147-2019; Rakha, Emad/Q-5554-2019; Sapino,
   Anna/AGY-9901-2022; MARCHIO', Caterina/J-9152-2016; Sapino,
   Anna/J-4113-2018; Aleskandarany, Mohammed/D-9162-2018
OI MARCHIO', Caterina/0000-0003-2024-6131; Rakha, Emad/0000-0002-5009-5525;
   Sapino, Anna/0000-0003-3542-9571; Aleskandarany,
   Mohammed/0000-0001-5538-5946; Ellis, Ian/0000-0001-5292-8474
CR Aleskandarany MA, 2016, BREAST CANCER RES TR, V158, P287, DOI 10.1007/s10549-016-3893-x
   Aleskandarany MA, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3084
   Almendro V, 2014, CELL REP, V6, P514, DOI 10.1016/j.celrep.2013.12.041
   Anagnostou VK, 2010, ARCH PATHOL LAB MED, V134, P613, DOI 10.1043/1543-2165-134.4.613
   [Anonymous], BREAST CANC RES
   [Anonymous], J PATHOL
   [Anonymous], J PATHOL
   Arslan C, 2011, EXPERT OPIN THER TAR, V15, P21, DOI 10.1517/14656566.2011.537260
   Aubele M, 2000, INT J CANCER, V85, P82, DOI 10.1002/(SICI)1097-0215(20000101)85:1<82::AID-IJC15>3.0.CO;2-S
   Babayan A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075038
   Badve S, 2011, MODERN PATHOL, V24, P157, DOI 10.1038/modpathol.2010.200
   Barry WT, 2010, J CLIN ONCOL, V28, P2198, DOI 10.1200/JCO.2009.26.7245
   Bidard FC, 2014, LANCET ONCOL, V15, P406, DOI 10.1016/S1470-2045(14)70069-5
   Blows FM, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000279
   Burrell RA, 2014, MOL ONCOL, V8, P1095, DOI 10.1016/j.molonc.2014.06.005
   Clark SE, 2011, BRIT J CANCER, V104, P120, DOI 10.1038/sj.bjc.6606021
   Collins LC, 2005, AM J CLIN PATHOL, V123, P16, DOI 10.1309/HCF035N9WK40ETJ0
   Cummings MC, 2014, J PATHOL, V232, P23, DOI 10.1002/path.4288
   Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983
   de Gramont A, 2015, NAT REV CLIN ONCOL, V12, P197, DOI 10.1038/nrclinonc.2014.202
   Ding L, 2010, NATURE, V464, P999, DOI 10.1038/nature08989
   Dowsett M, 2011, JNCI-J NATL CANCER I, V103, P1656, DOI 10.1093/jnci/djr393
   Edwards SL, 2008, NATURE, V451, P1111, DOI 10.1038/nature06548
   ELLIS IO, 1992, HISTOPATHOLOGY, V20, P479
   Ellsworth RE, 2015, CANCER GROWTH METAST, V8, P15, DOI 10.4137/CGM.S29490
   ELSTON CW, 1991, HISTOPATHOLOGY, V19, P403, DOI 10.1111/j.1365-2559.1991.tb00229.x
   Faratian D, 2011, JOVE-J VIS EXP, DOI 10.3791/3334
   Fehm T, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1783
   Fehm T, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2143
   Gerlinger M, 2012, NEW ENGL J MED, V366, P883, DOI 10.1056/NEJMoa1113205
   Geyer FC, 2010, J PATHOL, V220, P562, DOI 10.1002/path.2675
   Giuliano M, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2907
   Goldhirsch A, 2011, ANN ONCOL, V22, P1736, DOI 10.1093/annonc/mdr304
   Greaves M, 2012, NATURE, V481, P306, DOI 10.1038/nature10762
   Habashy HO, 2012, HISTOPATHOLOGY, V60, P854, DOI 10.1111/j.1365-2559.2011.03912.x
   Haisan A, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/286902
   Hammond MEH, 2010, J CLIN ONCOL, V28, P2784, DOI 10.1200/JCO.2009.25.6529
   Hao NB, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/948098
   Hayes DF, 2013, J INTERN MED, V274, P137, DOI 10.1111/joim.12047
   Hennessy BT, 2009, CANCER RES, V69, P4116, DOI 10.1158/0008-5472.CAN-08-3441
   Hernandez L, 2012, J PATHOL, V227, P42, DOI 10.1002/path.3990
   Heselmeyer-Haddad K, 2012, AM J PATHOL, V181, P1807, DOI 10.1016/j.ajpath.2012.07.012
   HILL MO, 1973, ECOLOGY, V54, P427, DOI 10.2307/1934352
   Hoefnagel LDC, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2645
   Hu M, 2008, CANCER CELL, V13, P394, DOI 10.1016/j.ccr.2008.03.007
   Kim SY, 2015, ONCOTARGET, V6, P7597, DOI 10.18632/oncotarget.3162
   Krishnamurthy S, 2013, CANCER MED-US, V2, P226, DOI 10.1002/cam4.70
   Kroigård AB, 2015, ONCOTARGET, V6, P5634, DOI 10.18632/oncotarget.3111
   Kurbasic E, 2015, CLIN PROTEOM, V12, DOI 10.1186/s12014-015-9084-7
   Lakhani S.R., WHO Classification of Tumours of the Breast, VFourth
   Lancashire LJ, 2010, BREAST CANCER RES TR, V120, P83, DOI 10.1007/s10549-009-0378-1
   Lee AJX, 2011, CANCER RES, V71, P1858, DOI 10.1158/0008-5472.CAN-10-3604
   Lehmann BD, 2011, J CLIN INVEST, V121, P2750, DOI 10.1172/JCI45014
   Macfarlane R, 2012, ONCOLOGIST, V17, P172, DOI 10.1634/theoncologist.2011-0127
   Manso L, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0155840
   Marchio Caterina, 2011, Journal of the National Cancer Institute Monographs, P86, DOI 10.1093/jncimonographs/lgr025
   Martelotto LG, 2014, BREAST CANCER RES, V16, DOI 10.1186/bcr3658
   Marusyk A, 2012, NAT REV CANCER, V12, P323, DOI 10.1038/nrc3261
   Marusyk A, 2010, BBA-REV CANCER, V1805, P105, DOI 10.1016/j.bbcan.2009.11.002
   Meacham CE, 2013, NATURE, V501, P328, DOI 10.1038/nature12624
   Mohammed RAA, 2009, BREAST CANCER RES TR, V113, P261, DOI 10.1007/s10549-008-9936-1
   Molyneux G, 2010, CELL STEM CELL, V7, P403, DOI 10.1016/j.stem.2010.07.010
   Murdoch C, 2008, NAT REV CANCER, V8, P618, DOI 10.1038/nrc2444
   Natrajan R, 2016, PLOS MED, V13, DOI 10.1371/journal.pmed.1001961
   Navin N, 2011, NATURE, V472, P90, DOI 10.1038/nature09807
   Navin N, 2010, GENOME RES, V20, P68, DOI 10.1101/gr.099622.109
   Ng CKY, 2015, GENOME BIOL, V16, DOI 10.1186/s13059-015-0657-6
   Nielsen TO, 2004, CLIN CANCER RES, V10, P5367, DOI 10.1158/1078-0432.CCR-04-0220
   Paoletti C, 2015, CLIN CANCER RES, V21, P2487, DOI 10.1158/1078-0432.CCR-14-1913
   Park SY, 2010, J CLIN INVEST, V120, P636, DOI 10.1172/JCI40724
   Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093
   Pestrin M, 2012, BREAST CANCER RES TR, V134, P283, DOI 10.1007/s10549-012-2045-1
   Potts SJ, 2012, LAB INVEST, V92, P1342, DOI 10.1038/labinvest.2012.91
   Prat A, 2015, BREAST, V24, pS26, DOI 10.1016/j.breast.2015.07.008
   Rakha EA, 2007, J CLIN PATHOL, V60, P1300, DOI 10.1136/jcp.2006.045377
   Rakha EA, 2005, HISTOPATHOLOGY, V46, P685, DOI 10.1111/j.1365-2559.2005.02156.x
   Rakha EA, 2008, J CLIN ONCOL, V26, P336, DOI 10.1200/JCO.2007.14.9005
   Rakha EA, 2007, J CLIN ONCOL, V25, P4772, DOI 10.1200/JCO.2007.12.2747
   Rakha EA, 2015, J CLIN PATHOL, V68, P93, DOI 10.1136/jclinpath-2014-202571
   Rakha EA, 2010, J CLIN ONCOL, V28, P99, DOI 10.1200/JCO.2009.23.5051
   Rakha EA, 2009, CLIN CANCER RES, V15, P2302, DOI 10.1158/1078-0432.CCR-08-2132
   RAO CR, 1982, THEOR POPUL BIOL, V21, P24, DOI 10.1016/0040-5809(82)90004-1
   Reis JS, 2011, LANCET, V378, P1812, DOI 10.1016/S0140-6736(11)61539-0
   Ruiz C, 2006, INT J CANCER, V118, P2190, DOI 10.1002/ijc.21581
   Sakr RA, 2014, CLIN CANCER RES, V20, P2326, DOI 10.1158/1078-0432.CCR-13-2267
   Sapino A, 2006, VIRCHOWS ARCH, V449, P288, DOI 10.1007/s00428-006-0233-2
   Schedin P, 2004, BREAST CANCER RES, V6, P93, DOI 10.1186/bcr772
   Schiavon G, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aac7551
   Shannon C. E., 1949, Phil Rev, V60
   Simmons C, 2009, ANN ONCOL, V20, P1499, DOI 10.1093/annonc/mdp028
   SIMPSON EH, 1949, NATURE, V163, P688, DOI 10.1038/163688a0
   Sinn HP, 2013, BREAST CARE, V8, P149, DOI 10.1159/000350774
   Siveen KS, 2009, IMMUNOL LETT, V123, P97, DOI 10.1016/j.imlet.2009.02.011
   Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100
   Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098
   Torhorst J, 2001, AM J PATHOL, V159, P2249, DOI 10.1016/S0002-9440(10)63075-1
   Tsutsui S, 2005, ONCOL REP, V14, P425
   Uzzan B, 2004, CANCER RES, V64, P2941, DOI 10.1158/0008-5472.CAN-03-1957
   van Deurzen CHM, 2011, J PATHOL, V224, P434, DOI 10.1002/path.2872
   Verigos J, 2015, CANCERS, V7, P2183, DOI 10.3390/cancers7040885
   Voduc D, 2008, SEMIN RADIAT ONCOL, V18, P89, DOI 10.1016/j.semradonc.2007.10.006
   Wang XJ, 2001, MODERN PATHOL, V14, P1183, DOI 10.1038/modpathol.3880456
   Wolff AC, 2013, J CLIN ONCOL, V31, P3997, DOI [10.1200/JCO.2013.50.9984, 10.5858/arpa.2013-0953-SA]
   Wu T, 2017, CANCER LETT, V387, P61, DOI 10.1016/j.canlet.2016.01.043
   Yamamoto KN, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105724
   Zhang DH, 2003, MODERN PATHOL, V16, P79, DOI 10.1097/01.MP.0000047307.96344.93
NR 106
TC 72
Z9 76
U1 0
U2 8
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 1015-2008
EI 1423-0291
J9 PATHOBIOLOGY
JI Pathobiology
PY 2018
VL 85
IS 1-2
BP 23
EP 34
DI 10.1159/000477851
PG 12
WC Cell Biology; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Pathology
GA GF1QI
UT WOS:000431709300004
PM 29428954
OA Bronze
DA 2025-01-12
ER

PT J
AU Carden, T
   Singh, B
   Mooga, V
   Bajpai, P
   Singh, KK
AF Carden, Trevor
   Singh, Bhupendra
   Mooga, Ved
   Bajpai, Prachi
   Singh, Keshav K.
TI Epigenetic modification of miR-663 controls mitochondria-to-nucleus
   retrograde signaling and tumor progression
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
DE breast cancer; DNA methylation; gene expression; microRNA (miRNA);
   mitochondria; miR-663; retrograde signaling; OXPHOS; tumorigenesis
ID ADENOMATOUS-POLYPOSIS-COLI; BREAST-CANCER CELLS; RESPIRATORY-CHAIN;
   CROSS-TALK; H-RAS; TRANSFORMATION; DYSFUNCTION; RESISTANCE; MIGRATION;
   APOPTOSIS
AB The normal cellular function requires communication between mitochondria and the nucleus, termed mitochondria-to-nucleus retrograde signaling. Disruption of this mechanism has been implicated in the development of cancers. Many proteins are known modulators of retrograde signaling, but whether microRNAs (miRNAs) are also involved is unknown. We conducted an miRNA microarray analysis using RNA from a parental cell line, a Rho(0) line lacking mitochondrial DNA (mtDNA) and a Rho(0) line with restored mtDNA. We found that miR-663 was down-regulated in the mtDNA-depleted Rho(0) line. mtDNA restoration reversed this miRNA to parental level, suggesting that miR-663 may be epigenetically regulated by retrograde signaling. By using methylation-specific PCR and bisulfite sequencing we demonstrate that miR-663 promoter is epigenetically regulated not only by genetic but also by pharmacological disruption of oxidative phosphorylation (OXPHOS). Restoration of OXPHOS Complex I inhibitor-induced miR-663 expression by N-acetylcysteine suggested that reactive oxygen species (ROS) play a key role in epigenetic regulation of miR-663. We determined that miR-663 regulates the expression of nuclear-encoded respiratory chain subunits involved in Complexes I, II, III, and IV. miR-663 also controlled the expression of the Complexes I (NDUFAF1), II (SDHAF2), III (UQCC2), and IV (SCO1) assembly factors and was required for stability of respiratory supercomplexes. Furthermore, using luciferase assays, we found that miR-663 directly regulates UQCC2. The anti-miR-663 reduced OXPHOS complex activity and increased in vitro cellular proliferation and promoted tumor development in vivo in mice. We also found that increased miR-663 expression in breast tumors consistently correlates with increased patient survival. We provide the first evidence for miRNA controlling retrograde signaling, demonstrating its epigenetic regulation and its role in breast tumorigenesis.
C1 [Carden, Trevor; Singh, Bhupendra; Mooga, Ved; Bajpai, Prachi; Singh, Keshav K.] Univ Alabama Birmingham, Dept Genet, Birmingham, AL 35294 USA.
   [Singh, Keshav K.] Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA.
   [Singh, Keshav K.] Univ Alabama Birmingham, Dept Environm Hlth Sci, Birmingham, AL 35294 USA.
   [Singh, Keshav K.] Univ Alabama Birmingham, Ctr Free Radical Biol, Birmingham, AL 35294 USA.
   [Singh, Keshav K.] Univ Alabama Birmingham, Ctr Aging, Birmingham, AL 35294 USA.
   [Singh, Keshav K.] Univ Alabama Birmingham, UAB Comprehens Canc Ctr, Birmingham, AL 35294 USA.
   [Singh, Keshav K.] Birmingham Vet Affairs Med Ctr, Birmingham, AL 35294 USA.
C3 University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham; US
   Department of Veterans Affairs; Veterans Health Administration (VHA);
   Veterans Affairs Medical Center - Birmingham
RP Singh, KK (通讯作者)，Univ Alabama Birmingham, Sch Med, Kaul Genet Bdg,Ste 620,720 20th St, South Birmingham, AL 35294 USA.
EM kksingh@uab.edu
RI Bajpai, Prachi/U-7462-2018
FU U.S. Department of Veterans Affairs [1I0IBX001716]; National Institutes
   of Health [R01 CA204430]
FX This study was supported by U.S. Department of Veterans Affairs Grant
   1I0IBX001716 and National Institutes of Health Grant R01 CA204430. The
   authors declare that they have no conflicts of interest with the
   contents of this article. The content is solely the responsibility of
   the authors and does not necessarily represent the official views of the
   National Institutes of Health or reflect the position or policy of the
   Department of Veterans Affairs or the United States government.
CR Ayyasamy V, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024792
   Bandiera S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020746
   Barrey E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020220
   Beukers W, 2014, EUR J HUM GENET, V22, P837, DOI 10.1038/ejhg.2013.251
   Bucha S, 2015, BIOCHEM BIOPH RES CO, V465, P797, DOI 10.1016/j.bbrc.2015.08.090
   Challa AK, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0155812
   Chaudhuri AD, 2016, J BIOL CHEM, V291, P6483, DOI 10.1074/jbc.M115.691352
   Chowdhury AR, 2017, ONCOGENE, V36, P397, DOI 10.1038/onc.2016.211
   Compton S, 2011, J BIOL CHEM, V286, P20297, DOI 10.1074/jbc.M110.163063
   Cruz-Bermúdez A, 2015, ONCOTARGET, V6, P13628, DOI 10.18632/oncotarget.3698
   Das S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096820
   Das S, 2012, CIRC RES, V110, P1596, DOI 10.1161/CIRCRESAHA.112.267732
   Delsite Robert, 2002, Mol Cancer, V1, P6, DOI 10.1186/1476-4598-1-6
   Desouki MM, 2005, CANCER BIOL THER, V4, P1367, DOI 10.4161/cbt.4.12.2233
   Dong TY, 2015, J CANCER, V6, P1222, DOI 10.7150/jca.11279
   Elenbaas B, 2001, GENE DEV, V15, P50, DOI 10.1101/gad.828901
   Genova ML, 2014, BBA-BIOENERGETICS, V1837, P427, DOI 10.1016/j.bbabio.2013.11.002
   Ghezzi D, 2012, ADV EXP MED BIOL, V748, P65, DOI 10.1007/978-1-4614-3573-0_4
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Hayes J, 2014, TRENDS MOL MED, V20, P460, DOI 10.1016/j.molmed.2014.06.005
   Hoenerhoff MJ, 2009, ONCOGENE, V28, P3022, DOI 10.1038/onc.2009.165
   Hong Q, 2015, MICROCIRCULATION, V22, P306, DOI 10.1111/micc.12200
   Hu HY, 2013, J BIOL CHEM, V288, P10973, DOI 10.1074/jbc.M112.434340
   Hu WT, 2014, RNA BIOL, V11, P1189, DOI 10.4161/rna.34345
   Huang Y, 2016, PLANT GENOME-US, V9, DOI 10.3835/plantgenome2015.09.0082
   Indo HP, 2007, MITOCHONDRION, V7, P106, DOI 10.1016/j.mito.2006.11.026
   Jiao L, 2014, J CELL PHYSIOL, V229, P834, DOI 10.1002/jcp.24510
   Johnston AJ, 2002, J BIOL CHEM, V277, P42197, DOI 10.1074/jbc.M205613200
   Kaipparettu BA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061747
   Kim JS, 2014, BIOCHEM BIOPH RES CO, V446, P894, DOI 10.1016/j.bbrc.2014.03.027
   Kinoshita T, 2017, J HUM GENET, V62, P67, DOI 10.1038/jhg.2016.87
   Kren BT, 2009, RNA BIOL, V6, P65, DOI 10.4161/rna.6.1.7534
   Kulawiec M, 2006, CANCER BIOL THER, V5, P967, DOI 10.4161/cbt.5.8.2880
   Kulawiec M, 2009, J HUM GENET, V54, P647, DOI 10.1038/jhg.2009.89
   Kulawiec M, 2009, CANCER BIOL THER, V8, P1378, DOI 10.4161/cbt.8.14.8751
   Kulawiec M, 2008, CANCER BIOL THER, V7, P1732, DOI 10.4161/cbt.7.11.6729
   Lee S, 2013, ADV EXP MED BIOL, V768, P97, DOI 10.1007/978-1-4614-5107-5_7
   Lehmann U, 2008, J PATHOL, V214, P17, DOI 10.1002/path.2251
   Lenaz G, 2012, ADV EXP MED BIOL, V748, P107, DOI 10.1007/978-1-4614-3573-0_5
   Li JC, 2010, PLOS GENET, V6, DOI [10.1186/1746-4811-6-1, 10.1371/journal.pgen.1000795]
   Li P, 2013, CIRC RES, V113, P1117, DOI 10.1161/CIRCRESAHA.113.301306
   Li QZ, 2016, ONCOL REP, V35, P1125, DOI 10.3892/or.2015.4432
   Lin SB, 2015, NAT REV CANCER, V15, P321, DOI 10.1038/nrc3932
   Liu ZY, 2011, ASIAN PAC J CANCER P, V12, P2819
   Miao CG, 2015, IMMUNOL LETT, V166, P45, DOI 10.1016/j.imlet.2015.05.011
   Mimaki M, 2012, BBA-BIOENERGETICS, V1817, P851, DOI 10.1016/j.bbabio.2011.08.010
   Minocherhomji S, 2012, EPIGENETICS-US, V7, P326, DOI 10.4161/epi.19547
   Modica-Napolitano JS, 2007, CURR MOL MED, V7, P121, DOI 10.2174/156652407779940495
   Mukherjee N, 2012, CANCER SCI, V103, P210, DOI 10.1111/j.1349-7006.2011.02131.x
   Owens KM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023846
   Prasad CP, 2008, LIFE SCI, V83, P318, DOI 10.1016/j.lfs.2008.06.019
   Quirós PM, 2016, NAT REV MOL CELL BIO, V17, P213, DOI 10.1038/nrm.2016.23
   Saffran HA, 2007, EMBO REP, V8, P188, DOI 10.1038/sj.embor.7400878
   Sawyer C, 2003, CANCER RES, V63, P1667
   Schagger H, 1995, METHOD ENZYMOL, V260, P190, DOI 10.1016/0076-6879(95)60137-6
   Shapovalov Y, 2011, J BIOL CHEM, V286, P22331, DOI 10.1074/jbc.M111.250092
   Shi Y, 2015, CLIN CANCER RES, V21, P4004, DOI 10.1158/1078-0432.CCR-14-2807
   Shi Y, 2014, CLIN CANCER RES, V20, P1803, DOI 10.1158/1078-0432.CCR-13-2284
   Singh K.K., 2015, Mitochondrion, V24, pS6
   Singh KK, 2009, J HUM GENET, V54, P516, DOI 10.1038/jhg.2009.71
   Singh KK, 2005, GENE, V354, P140, DOI 10.1016/j.gene.2005.03.027
   Singh KK, 2004, ANN NY ACAD SCI, V1019, P260, DOI 10.1196/annals.1297.043
   Smiraglia DJ, 2008, CANCER BIOL THER, V7, P1182, DOI 10.4161/cbt.7.8.6215
   Stroud DA, 2016, NATURE, V538, P123, DOI 10.1038/nature19754
   Sullivan LB, 2014, CANCER METAB, V2, DOI 10.1186/2049-3002-2-17
   Tao YF, 2013, BMC MED GENET, V14, DOI 10.1186/1471-2350-14-74
   Tili E, 2010, CARCINOGENESIS, V31, P1561, DOI 10.1093/carcin/bgq143
   Tucker EJ, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1004034
   Tzenaki N, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00040
   Vartak R, 2013, PROTEIN CELL, V4, P582, DOI 10.1007/s13238-013-3032-y
   Vislovukh A, 2013, BRIT J CANCER, V108, P2304, DOI 10.1038/bjc.2013.243
   Waaijer MEC, 2014, BIOGERONTOLOGY, V15, P269, DOI 10.1007/s10522-014-9496-1
   Wang ZH, 2016, TUMOR BIOL, V37, P7633, DOI 10.1007/s13277-015-4653-y
   Xie CH, 2007, BIOCHEM BIOPH RES CO, V364, P656, DOI 10.1016/j.bbrc.2007.10.047
   Xiong SB, 2014, PROTEIN CELL, V5, P737, DOI 10.1007/s13238-014-0089-1
   Yang Y, 2013, FEBS J, V280, P5109, DOI 10.1111/febs.12485
   Yi C, 2012, ONCOGENE, V31, P4421, DOI 10.1038/onc.2011.629
   Zang WQ, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0315-3
   Zhang XR, 2014, CELL, V158, P607, DOI 10.1016/j.cell.2014.05.047
NR 79
TC 56
Z9 61
U1 0
U2 26
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD DEC 15
PY 2017
VL 292
IS 50
BP 20694
EP 20706
DI 10.1074/jbc.M117.797001
PG 13
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA FQ3OR
UT WOS:000418267000030
PM 29066618
OA Green Published, hybrid
DA 2025-01-12
ER

PT J
AU Bukowska-Damska, A
   Reszka, E
   Kaluzny, P
   Wieczorek, E
   Przybek, M
   Zienolddiny, S
   Peplonska, B
AF Bukowska-Damska, Agnieszka
   Reszka, Edyta
   Kaluzny, Pawel
   Wieczorek, Edyta
   Przybek, Monika
   Zienolddiny, Shanbeh
   Peplonska, Beata
TI Sleep quality and methylation status of core circadian rhythm genes
   among nurses and midwives
SO CHRONOBIOLOGY INTERNATIONAL
LA English
DT Article
DE chronotype; circadian rhythm genes; DNA methylation; nurses and
   midwives; shift work; sleep duration; sleep quality
ID NIGHT-SHIFT WORK; WIDE DNA METHYLATION; BREAST-CANCER RISK; URINARY
   MELATONIN; CLOCK; EXPRESSION; 17-BETA-ESTRADIOL; HYPERMETHYLATION;
   EPIDEMIOLOGY; ASSOCIATION
AB Poor sleep quality or sleep restriction is associated with sleepiness and concentration problems. Moreover, chronic sleep restriction may affect metabolism, hormone secretion patterns and inflammatory responses. Limited recent reports suggest a potential link between sleep deprivation and epigenetic effects such as changes in DNA methylation profiles. The aim of the present study was to assess the potential association between poor sleep quality or sleep duration and the levels of 5-methylcytosine in the promoter regions of PER1, PER2, PER3, BMAL1, CLOCK, CRY1 CRY2 and NPAS2 genes, taking into account rotating night work and chronotype as potential confounders or modifiers. A cross-sectional study was conducted on 710 nurses and midwives (347 working on rotating nights and 363 working only during the day) aged 40-60 years. Data from in-person interviews about sleep quality, chronotype and potential confounders were used. Sleep quality and chronotype were assessed using Pittsburgh Sleep Quality Questionnaire (PSQI) and Morningness-Eveningness Questionnaire (MEQ), respectively. Morning blood samples were collected. The methylation status of the circadian rhythm genes was determined via quantitative methylation-specific real-time PCR assays (qMSP) reactions using DNA samples derived from leucocytes. The proportional odds regression model was fitted to quantify the relationship between methylation index (MI) as the dependent variable and sleep quality or sleep duration as the explanatory variable. Analyses were carried out for the total population as well as for subgroups of women stratified by the current system of work (rotating night shift/day work) and chronotype (morning type/intermediate type/evening type). A potential modifying effect of the system of work or the chronotype was examined using the likelihood ratio test. No significant findings were observed in the total study population. Subgroup analyses revealed two statistically significant associations between a shorter sleep duration and 1) methylation level in PER2 among day workers, especially those with the morning chronotype (OR = 2.31, 95% CI: 1.24-4.33), and 2) methylation level in CRY2 among subjects with the intermediate chronotype, particularly among day workers (OR = 0.52, 95% CI: 0.28-0.96). The study results demonstrated a positive association between average sleep duration of less than 6 hours and the methylation level of PER2 among morning chronotype subjects, and an inverse association for CRY2 among intermediate chronotype subjects, but only among day workers. Both the system of work and the chronotype turned out to be important confounders and modifiers in a number of analyses, making it necessary to consider them as potential covariates in future research on sleep deficiency outcomes. Further studies are warranted to explore this under-investigated topic.
C1 [Bukowska-Damska, Agnieszka; Kaluzny, Pawel; Peplonska, Beata] Nofer Inst Occupat Med, Dept Environm Epidemiol, Lodz, Poland.
   [Reszka, Edyta; Wieczorek, Edyta; Przybek, Monika] Nofer Inst Occupat Med, Dept Mol Genet & Epigenet, Lodz, Poland.
   [Zienolddiny, Shanbeh] Natl Inst Occupat Hlth, Dept Chem & Biol Work Environm, Oslo, Norway.
C3 Nofer Institute of Occupational Medicine; Nofer Institute of
   Occupational Medicine
RP Bukowska-Damska, A (通讯作者)，Nofer Inst Occupat Med, 8 Teresy St, PL-91348 Lodz, Poland.
EM bukowska@imp.lodz.pl
RI Zienolddiny, Shanbeh/O-7392-2015; Peplonska, Beata/AAO-1265-2020;
   Bukowska, Agnieszka/G-4906-2010; Kasperczyk, Edyta/F-7057-2010; Reszka,
   Edyta/F-6008-2010; Lesicka, Monika/G-7673-2015
OI Kasperczyk, Edyta/0000-0002-4390-2042; Zienolddiny-Narui,
   Shan/0000-0001-9747-9625; Peplonska, Beata/0000-0003-3915-2872; Reszka,
   Edyta/0000-0003-2153-4864; Kaluzny, Pawel/0000-0002-9559-5873;
   Bukowska-Damska, Agnieszka/0000-0002-3223-6750; Lesicka,
   Monika/0000-0003-2095-8681
FU Polish-Norwegian Research Programme [PNRF - 243 - AI - 1/07,
   Pol-Nor/196940/22/2013-clockshift]
FX This project was supported by the Norway Grants, under the
   Polish-Norwegian Research Programme (Grant no. PNRF - 243 - AI - 1/07
   and Pol-Nor/196940/22/2013-clockshift).
CR Åkerstedt T, 2003, OCCUP MED-OXFORD, V53, P89, DOI 10.1093/occmed/kqg046
   Alegra-Torres JA, 2011, EPIGENOMICS-UK, V3, P267, DOI [10.2217/EPI.11.22, 10.2217/epi.11.22]
   Archer SN, 2015, J SLEEP RES, V24, P476, DOI 10.1111/jsr.12307
   Banks S, 2007, J CLIN SLEEP MED, V3, P519
   Bhatti P, 2015, CHRONOBIOL INT, V32, P103, DOI 10.3109/07420528.2014.956362
   Blask DE, 2009, SLEEP MED REV, V13, P257, DOI 10.1016/j.smrv.2008.07.007
   Bollati V, 2010, CHRONOBIOL INT, V27, P1093, DOI 10.3109/07420528.2010.490065
   Bracci M, 2013, J BIOL REG HOMEOS AG, V27, P267
   Bracci M, 2014, SCAND J WORK ENV HEA, V40, P295, DOI 10.5271/sjweh.3414
   BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4
   Cedernaes J, 2015, J CLIN ENDOCR METAB, V100, pE1255, DOI [10.1210/jc.2015-2284, 10.1210/JC.2015-2284]
   Costa G, 2010, SCAND J WORK ENV HEA, V36, P163, DOI 10.5271/sjweh.2899
   Eads CA, 2001, CANCER RES, V61, P3410
   Erren TC, 2013, OCCUP ENVIRON MED, V70, P283, DOI 10.1136/oemed-2012-100984
   Esteller M, 2003, ADV EXP MED BIOL, V532, P39
   Esteller M, 2000, EUR J CANCER, V36, P2294, DOI 10.1016/S0959-8049(00)00303-8
   Fu LN, 2002, CELL, V111, P41, DOI 10.1016/S0092-8674(02)00961-3
   Fu LN, 2003, NAT REV CANCER, V3, P350, DOI 10.1038/nrc1072
   Gauger MA, 2005, CANCER RES, V65, P6828, DOI 10.1158/0008-5472.CAN-05-1119
   Hansen J, 2012, OCCUP ENVIRON MED, V69, P551, DOI 10.1136/oemed-2011-100240
   Haus EL, 2013, SLEEP MED REV, V17, P273, DOI 10.1016/j.smrv.2012.08.003
   Hoffman AE, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-110
   Hoffman AE, 2010, CANCER PREV RES, V3, P539, DOI 10.1158/1940-6207.CAPR-09-0127
   Hoffman AE, 2010, CANCER RES, V70, P1459, DOI 10.1158/0008-5472.CAN-09-3798
   HORNE J A, 1976, International Journal of Chronobiology, V4, P97
   Jacinto FV, 2007, MUTAGENESIS, V22, P247, DOI 10.1093/mutage/gem009
   Jacobs DI, 2013, ENVIRON MOL MUTAGEN, V54, P141, DOI 10.1002/em.21752
   Juda M, 2013, J BIOL RHYTHM, V28, P130, DOI 10.1177/0748730412475041
   Korkmaz A, 2008, J PINEAL RES, V44, P41, DOI 10.1111/j.1600-079X.2007.00509.x
   Lee Ken W. K., 2013, Frontiers in Genetics, V4, P132, DOI 10.3389/fgene.2013.00132
   Levandovski Rosa, 2013, Trends Psychiatry Psychother., V35, P3
   Lu L, 2007, CANCER RES, V67, P10117, DOI 10.1158/0008-5472.CAN-07-2544
   Mao YY, 2015, TUMOR BIOL, V36, P3533, DOI 10.1007/s13277-014-2989-3
   Milagro FI, 2012, CHRONOBIOL INT, V29, P1180, DOI 10.3109/07420528.2012.719967
   Mollayeva T, 2016, SLEEP MED REV, V25, P52, DOI 10.1016/j.smrv.2015.01.009
   Nilsson EK, 2016, OMICS, V20, P334, DOI 10.1089/omi.2016.0041
   Peplonska B, 2016, SCAND J WORK ENV HEA, V42, P435, DOI 10.5271/sjweh.3581
   Peplonska B, 2012, OCCUP ENVIRON MED, V69, P339, DOI 10.1136/oemed-2011-100273
   Portaluppi F, 2010, CHRONOBIOL INT, V27, P1911, DOI 10.3109/07420528.2010.516381
   Reszka E, 2016, ADV CLIN CHEM, V75, P53, DOI 10.1016/bs.acc.2016.03.005
   Reszka E, 2013, SCAND J WORK ENV HEA, V39, P187, DOI 10.5271/sjweh.3303
   Roenneberg T, 2007, SLEEP MED REV, V11, P429, DOI 10.1016/j.smrv.2007.07.005
   Saksvik IB, 2011, SLEEP MED REV, V15, P221, DOI 10.1016/j.smrv.2010.07.002
   Schernhammer ES, 2004, BRIT J CANCER, V90, P941, DOI 10.1038/sj.bjc.6601626
   Shih MC, 2006, MOL CARCINOGEN, V45, P732, DOI 10.1002/mc.20198
   Taillard J, 2001, J BIOL RHYTHM, V16, P183, DOI 10.1177/074873001129001764
   Taillard J, 1999, J SLEEP RES, V8, P291, DOI 10.1046/j.1365-2869.1999.00176.x
   Terry MB, 2011, EPIGENETICS-US, V6, P828, DOI 10.4161/epi.6.7.16500
   Vetter C, 2015, OCCUP ENVIRON MED, V72, DOI 10.1136/oemed-2014-102572
   White AJ, 2013, EUR J CANCER, V49, P2199, DOI 10.1016/j.ejca.2013.02.013
   WHO, 2004, WHO TECHN M SLEEP HL
   Xiang Shulin, 2008, J Circadian Rhythms, V6, P4, DOI 10.1186/1740-3391-6-4
   Zhu Y, 2011, CHRONOBIOL INT, V28, P852, DOI 10.3109/07420528.2011.618896
NR 53
TC 17
Z9 20
U1 0
U2 22
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0742-0528
EI 1525-6073
J9 CHRONOBIOL INT
JI Chronobiol. Int.
PY 2017
VL 34
IS 9
BP 1211
EP 1223
DI 10.1080/07420528.2017.1358176
PG 13
WC Biology; Physiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Life Sciences & Biomedicine - Other Topics; Physiology
GA FQ4XG
UT WOS:000418361300006
PM 29106308
OA Green Submitted
DA 2025-01-12
ER

PT J
AU Ho, JC
   Abdullah, LN
   Pang, QY
   Jha, S
   Chow, EKH
   Yang, H
   Kato, H
   Poellinger, L
   Ueda, J
   Lee, KL
AF Ho, Jolene Caifeng
   Abdullah, Lissa Nurrul
   Pang, Qing You
   Jha, Sudhakar
   Chow, Edward Kai-Hua
   Yang, Henry
   Kato, Hiroyuki
   Poellinger, Lorenz
   Ueda, Jun
   Lee, Kian Leong
TI Inhibition of the H3K9 methyltransferase G9A attenuates oncogenicity and
   activates the hypoxia signaling pathway
SO PLOS ONE
LA English
DT Article
ID HISTONE-H3 LYSINE-9 METHYLATION; PROMOTES PROLIFERATION; EPIGENETIC
   THERAPY; SURVIVIN GENE; GROWTH-FACTOR; CANCER; REPRESSION; CELLS;
   ANGIOGENESIS; METASTASIS
AB Epigenetic mechanisms play important roles in the regulation of tumorigenesis, and hypoxia- induced epigenetic changes may be critical for the adaptation of cancer cells to the hypoxic microenvironment of solid tumors. Previously, we showed that loss-of-function of the hypoxia-regulated H3K9 methyltransferase G9A attenuates tumor growth. However, the mechanisms by which blockade of G9A leads to a tumor suppressive effect remain poorly understood. We show that G9A is highly expressed in breast cancer and is associated with poor patient prognosis, where it may function as a potent oncogenic driver. In agreement with this, G9A inhibition by the small molecule inhibitor, BIX-01294, leads to increased cell death and impaired cell migration, cell cycle and anchorage-independent growth. Interestingly, whole transcriptome analysis revealed that genes involved in diverse cancer cell functions become hypoxia-responsive upon G9A inhibition. This was accompanied by the upregulation of the hypoxia inducible factors HIF1 alpha and HIF2 alpha during BIX-01294 treatment even in normoxia that may facilitate the tumor suppressive effects of BIX-01294. HIF inhibition was able to reverse some of the transcriptional changes induced by BIX-01294 in hypoxia, indicating that the HIFs may be important drivers of these derepressed target genes. Therefore, we show that G9A is a key mediator of oncogenic processes in breast cancer cells and G9A inhibition by BIX-01294 can successfully attenuate oncogenicity even in hypoxia.
C1 [Ho, Jolene Caifeng; Abdullah, Lissa Nurrul; Pang, Qing You; Jha, Sudhakar; Chow, Edward Kai-Hua; Yang, Henry; Kato, Hiroyuki; Poellinger, Lorenz; Lee, Kian Leong] Natl Univ Singapore, Canc Stem Cells & Biol Program, Canc Sci Inst Singapore, Singapore, Singapore.
   [Poellinger, Lorenz] Karolinska Inst, Dept Cell & Mol Biol, Stockholm, Sweden.
   [Ueda, Jun] Asahikawa Med Univ, Ctr Adv Res & Educ, Asahikawa, Hokkaido, Japan.
   [Ho, Jolene Caifeng] Univ Toronto, Struct Genom Consortium, Toronto, ON, Canada.
   [Lee, Kian Leong] Duke NUS Med Sch, Canc & Stem Cell Biol Program, Singapore, Singapore.
C3 National University of Singapore; Karolinska Institutet; Asahikawa
   Medical College; University of Toronto; Structural Genomics Consortium;
   National University of Singapore
RP Ho, JC; Lee, KL (通讯作者)，Natl Univ Singapore, Canc Stem Cells & Biol Program, Canc Sci Inst Singapore, Singapore, Singapore.; Ueda, J (通讯作者)，Asahikawa Med Univ, Ctr Adv Res & Educ, Asahikawa, Hokkaido, Japan.; Ho, JC (通讯作者)，Univ Toronto, Struct Genom Consortium, Toronto, ON, Canada.; Lee, KL (通讯作者)，Duke NUS Med Sch, Canc & Stem Cell Biol Program, Singapore, Singapore.
EM jolene.ho@utoronto.ca; junueda@asahikawa-med.ac.jp;
   kianleong.lee@duke-nus.edu.sg
RI Chow, Edward/C-4697-2015; Yang, Henry/HLG-0902-2023; Jha,
   Sudhakar/S-3550-2019; Ueda, Jun/AAX-9704-2020; LEE, Kian
   Leong/E-3584-2013; Ueda, Jun/G-1670-2010
OI Pang, Qing You/0000-0002-8988-7255; LEE, Kian Leong/0000-0002-0443-2746;
   Ho, Jolene/0000-0001-5908-0007; Ueda, Jun/0000-0002-9766-203X
FU National University Cancer Institute, Singapore (NCIS) [NR13NMR1340M];
   National Medical Research Council (NM RC) Clinician Scientist Individual
   Research Grant (CS-IRG) [NMRC/CIRG/1389/2014]; National Research
   Foundation (NRF) Singapore; Singapore Ministry of Education (MOE) under
   the Research Centres of Excellence initiative [R-713-005-014-271,
   R-713-010-189-112]; Ministry of Education, Singapore AcRF
   [MOE2015-T2-2-126]; Cancer Science Institute of Singapore RCE; Ministry
   of Education, Culture, Sports, Science and Technology (MEXT) KAKENHI
   [JP16K07099, JP16H01319]; Swedish Research Council
FX Funded by National University Cancer Institute, Singapore (NCIS) Pilot
   Grant (NR13NMR1340M, H.K., L.P. and K.L.L.); National Medical Research
   Council (NM RC) Clinician Scientist Individual Research Grant (CS-IRG)
   (NMRC/CIRG/1389/2014, S.J. and L.P.); the National Research Foundation
   (NRF) Singapore and the Singapore Ministry of Education (MOE) under the
   Research Centres of Excellence initiative (R-713-005-014-271, J.C.H.,
   Q.Y.P., H.K., L.P. and K.L.L.; R-713-010-189-112, H.Y.); Ministry of
   Education, Singapore AcRF Tier 2 (MOE2015-T2-2-126, L.N.A., E.K.C);
   Cancer Science Institute of Singapore RCE Main Grant (E.K.C.); the
   Ministry of Education, Culture, Sports, Science and Technology (MEXT)
   KAKENHI Grants-in-Aid for Scientific Research (JP16K07099 and
   JP16H01319, J.U.); the Swedish Research Council (L.P.). The funders had
   no role in study design, data collection and analysis, decision to
   publish, or preparation of the manuscript.
CR Agirre E, 2015, BMC BIOL, V13, DOI 10.1186/s12915-015-0141-5
   Ahuja N, 2014, J CLIN INVEST, V124, P56, DOI 10.1172/JCI69736
   Azad N, 2013, NAT REV CLIN ONCOL, V10, P256, DOI 10.1038/nrclinonc.2013.42
   Casciello F, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00487
   Chan DA, 2007, CANCER METAST REV, V26, P333, DOI 10.1007/s10555-007-9063-1
   Chang YQ, 2009, NAT STRUCT MOL BIOL, V16, P312, DOI 10.1038/nsmb.1560
   Cheloni G, 2017, BLOOD, V130, P655, DOI 10.1182/blood-2016-10-745588
   Chen HB, 2006, CANCER RES, V66, P9009, DOI 10.1158/0008-5472.CAN-06-0101
   Chen MW, 2010, CANCER RES, V70, P7830, DOI 10.1158/0008-5472.CAN-10-0833
   Cho HS, 2011, NEOPLASIA, V13, P676, DOI 10.1593/neo.11512
   Chua SW, 2006, NUCLEIC ACIDS RES, V34, DOI 10.1093/nar/gkl024
   Dang DT, 2003, ONCOGENE, V22, P3424, DOI 10.1038/sj.onc.1206413
   Dong CF, 2012, J CLIN INVEST, V122, P1469, DOI 10.1172/JCI57349
   Dunham I, 2012, NATURE, V489, P57, DOI 10.1038/nature11247
   Fang BA, 2014, BBA-REV CANCER, V1845, P1, DOI 10.1016/j.bbcan.2013.11.002
   Goda N, 2003, MOL CELL BIOL, V23, P359, DOI 10.1128/MCB.23.1.359-369.2003
   Györffy B, 2012, ENDOCR-RELAT CANCER, V19, P197, DOI 10.1530/ERC-11-0329
   Haddad JJ, 2001, FEBS LETT, V505, P269, DOI 10.1016/S0014-5793(01)02833-2
   Hale AT, 2014, J BIOL CHEM, V289, P12016, DOI 10.1074/jbc.M113.530956
   Hockel M, 1996, CANCER RES, V56, P4509
   Hoffman WH, 2002, J BIOL CHEM, V277, P3247, DOI 10.1074/jbc.M106643200
   Holmquist-Mengelbier L, 2006, CANCER CELL, V10, P413, DOI 10.1016/j.ccr.2006.08.026
   Hruz Tomas, 2008, Advances in Bioinformatics, V2008, P420747, DOI 10.1155/2008/420747
   HUA KT, 2014, MOL CANCER, V13
   Huang J, 2010, J BIOL CHEM, V285, P9636, DOI 10.1074/jbc.M109.062588
   Ke XX, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106962
   Kohno M, 1999, J AM SOC NEPHROL, V10, P2495
   Kubicek S, 2007, MOL CELL, V25, P473, DOI 10.1016/j.molcel.2007.01.017
   Lee K, 2009, P NATL ACAD SCI USA, V106, P17910, DOI 10.1073/pnas.0909353106
   Lee SH, 2009, ONCOGENE, V28, P184, DOI 10.1038/onc.2008.377
   Li FZ, 1998, NATURE, V396, P580, DOI 10.1038/25141
   Li YD, 2015, INT J CLIN EXP PATHO, V8, P1731
   Ma AN, 2010, BIOCHEM BIOPH RES CO, V393, P592, DOI 10.1016/j.bbrc.2010.02.020
   Mack FA, 2005, MOL CELL BIOL, V25, P4565, DOI 10.1128/MCB.25.11.4565-4578.2005
   Michaelson JS, 2003, J CELL SCI, V116, P345, DOI 10.1242/jcs.00234
   Mirza A, 2002, ONCOGENE, V21, P2613, DOI 10.1038/sj.onc.1205353
   Moeller BJ, 2004, CANCER CELL, V5, P429, DOI 10.1016/S1535-6108(04)00115-1
   Nakayam J, 2001, SCIENCE, V292, P110, DOI 10.1126/science.1060118
   Obexer P, 2009, MOL BIOL CELL, V20, P2041, DOI 10.1091/mbc.E08-07-0699
   Oh SY, 2015, MOL CELLS, V38, P528, DOI 10.14348/molcells.2015.0026
   Peng XH, 2006, J BIOL CHEM, V281, P25903, DOI 10.1074/jbc.M603414200
   Pollard PJ, 2008, BIOCHEM J, V416, P387, DOI 10.1042/BJ20081238
   Rao VK, 2016, NUCLEIC ACIDS RES, V44, P8129, DOI 10.1093/nar/gkw483
   Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089
   Schödel J, 2011, BLOOD, V117, pE207, DOI 10.1182/blood-2010-10-314427
   Semenza GL, 1996, TRENDS CARDIOVAS MED, V6, P151, DOI 10.1016/1050-1738(96)00039-4
   Shinkai Y, 2011, GENE DEV, V25, P781, DOI 10.1101/gad.2027411
   Si WZ, 2015, CANCER CELL, V27, P822, DOI 10.1016/j.ccell.2015.04.011
   Taberlay PC, 2014, GENOME RES, V24, P1421, DOI 10.1101/gr.163485.113
   Tachibana M, 2002, GENE DEV, V16, P1779, DOI 10.1101/gad.989402
   Ueda J, 2014, MOL CELL BIOL, V34, P3702, DOI 10.1128/MCB.00099-14
   Volpe TA, 2002, SCIENCE, V297, P1833, DOI 10.1126/science.1074973
   WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510
   Yuan ZG, 2010, MOL CELL BIOL, V30, P3004, DOI 10.1128/MCB.01023-09
   Zhou RZ, 2005, CANCER RES, V65, P1839, DOI 10.1158/0008-5472.CAN-03-3755
   Zhou XM, 2016, ONCOTARGET, V7, P13634, DOI 10.18632/oncotarget.7215
NR 56
TC 20
Z9 22
U1 0
U2 10
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD NOV 16
PY 2017
VL 12
IS 11
AR e0188051
DI 10.1371/journal.pone.0188051
PG 25
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA FM8YO
UT WOS:000415378800056
PM 29145444
OA Green Published, Green Submitted, gold
DA 2025-01-12
ER

PT J
AU Kumari, K
   Keshari, S
   Sengupta, D
   Sabat, SC
   Mishra, SK
AF Kumari, Kanchan
   Keshari, Sunita
   Sengupta, Debomita
   Sabat, Surendra C.
   Mishra, Sandip K.
TI Transcriptome analysis of genes associated with breast cancer cell
   motility in response to Artemisinin treatment
SO BMC CANCER
LA English
DT Article
DE Breast cancer; Proliferation; Migration; Invasion; HDACs
ID PEGYLATED NANOLIPOSOMAL ARTEMISININ; IN-VITRO; MESENCHYMAL TRANSITION;
   INHIBITS PROLIFERATION; BIOLOGICAL EVALUATION; IMMUNE-RESPONSE; IRON
   OVERLOAD; DIETARY IRON; DIHYDROARTEMISININ; ARTESUNATE
AB Background: Well-known anti-malarial drug artemisinin exhibits potent anti-cancerous activities. In-vivo and in-vitro studies showed its anti-tumor and immunomodulatory properties signifying it as a potent drug candidate for study. The studies of mechanisms of cell movement are relevant which can be understood by knowing the involvement of genes in an effect of a drug. Although cytotoxicity and anti-proliferative activity of artemisinin is evident, the genes participating in its anti-migratory and reduced invasive effect are not well studied. The present study reports the alteration in the expression of 84 genes involved in cell motility upon artemisinin treatment in MCF-7 breast cancer cells using pathway focused gene expression PCR array. In addition, the effect of artemisinin on epigenetic modifier HDACs is studied.
   Methods: We checked the functional stimulus of artemisinin on cell viability, migration, invasion and apoptosis in breast cancerous cell lines. Using qRT-PCR and western blot, we validated the altered expression of relevant genes associated with proliferation, migration, invasion, apoptosis and mammary gland development.
   Results: Artemisinin inhibited cell proliferation of estrogen receptor negative breast cancer cells with fewer efficacies in comparison to estrogen receptor positive ones. At the same time, cell viability and proliferation of normal breast epithelial MCF10A cells was un-affected. Artemisinin strongly inhibited cancer cell migration and invasion. Along with orphan nuclear receptors (ERR alpha, ERR beta and ERR gamma), artemisinin altered the ER alpha/ER beta/PR/Her expression status of MCF-7 cells. The expression of genes involved in the signaling pathways associated with proliferation, migration, invasion and apoptosis was significantly altered which cooperatively resulted into reduced growth promoting activities of breast cancer cells. Interestingly, artemisinin exhibited inhibitory effect on histone deacetylases (HDACs).
   Conclusions: Upregulated expression of tumor suppressor genes along with reduced expression of oncogenes significantly associated with growth stimulating signaling pathways in response to artemisinin treatment suggests its efficacy as an effective drug in breast cancer treatment.
C1 [Kumari, Kanchan; Mishra, Sandip K.] Govt India, Canc Biol Lab, Inst Life Sci, Nalco Sq, Bhubaneswar 751023, Odisha, India.
   [Keshari, Sunita] Natl Cent Univ, Chungli, Taiwan.
   [Sabat, Surendra C.] Inst Life Sci, Mol Biol Abiot Stress, Nalco Sq, Bhubaneswar 751023, Odisha, India.
   [Sengupta, Debomita] Bose Inst, Dept Mol Med, Kolkata, India.
C3 Department of Biotechnology (DBT) India; Institute of Life Sciences
   India (ILS); National Central University; Department of Biotechnology
   (DBT) India; Institute of Life Sciences India (ILS); Department of
   Science & Technology (India); Bose Institute
RP Mishra, SK (通讯作者)，Govt India, Canc Biol Lab, Inst Life Sci, Nalco Sq, Bhubaneswar 751023, Odisha, India.
EM sandipkmishra@hotmail.com
RI Sengupta, Debomita/HLG-2130-2023; Kumari, Kanchan/AAE-4773-2019;
   Keshari, Sunita/AAK-9842-2021; KUMARI, KANCHAN/KUD-7270-2024
OI Mishra, Sandip/0000-0002-0776-6581; KUMARI, KANCHAN/0000-0001-7546-4174;
   Sengupta, Debomita/0000-0001-8359-1763
FU DBT, Govt. of India; DST, Govt. of India
FX DBT, Govt. of India. DST, Govt. of India
CR Bachmeier B, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020550
   BIRCHMEIER W, 1994, BBA-REV CANCER, V1198, P11, DOI 10.1016/0304-419X(94)90003-5
   Chekhun V. F., 2017, Experimental Oncology, V39, P25
   Chen GQ, 2016, ONCOTARGET, V7, P50302, DOI 10.18632/oncotarget.10367
   Chen HH, 2003, PHARMACOL RES, V48, P231, DOI 10.1016/S1043-6618(03)00107-5
   Chen K, 2014, ANTI-CANCER DRUG, V25, P652, DOI 10.1097/CAD.0000000000000089
   Dadgar N, 2014, INDIAN J CLIN BIOCHE, V29, P501, DOI 10.1007/s12291-013-0389-x
   Dadgar N, 2013, INDIAN J CLIN BIOCHE, V28, P410, DOI 10.1007/s12291-013-0306-3
   Dai M, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3441
   Daniel AR, 2015, ONCOGENE, V34, P506, DOI 10.1038/onc.2013.579
   Das AK, 2015, ANN MED HEALTH SCI R, V5, P93, DOI 10.4103/2141-9248.153609
   Dydensborg AB, 2009, ONCOGENE, V28, P2634, DOI 10.1038/onc.2009.126
   Efferth T, 2001, INT J ONCOL, V18, P767
   Ericsson T, 2014, EUR J CLIN PHARMACOL, V70, P1453, DOI 10.1007/s00228-014-1754-2
   Farsam V, 2011, INT IMMUNOPHARMACOL, V11, P1802, DOI 10.1016/j.intimp.2011.07.008
   Feng MX, 2016, SCI REP-UK, V6, DOI 10.1038/srep19074
   Finucane DM, 1999, J BIOL CHEM, V274, P2225, DOI 10.1074/jbc.274.4.2225
   Gharib A, 2015, PHARMACOGN MAG, V11, pS117, DOI 10.4103/0973-1296.157710
   Giacinti C, 2006, ONCOGENE, V25, P5220, DOI 10.1038/sj.onc.1209615
   Gong YM, 2013, ANTICANCER RES, V33, P123
   Guarino M, 2007, PATHOLOGY, V39, P305, DOI 10.1080/00313020701329914
   Hamacher-Brady A, 2011, J BIOL CHEM, V286, P6587, DOI 10.1074/jbc.M110.210047
   Hargraves KG, 2016, MOL CARCINOGEN, V55, P486, DOI 10.1002/mc.22296
   Huang X, 2008, LANCET ONCOL, V9, P803, DOI 10.1016/S1470-2045(08)70200-6
   Huang X, 2003, MUTAT RES-FUND MOL M, V533, P153, DOI 10.1016/j.mrfmmm.2003.08.023
   Inwald EC, 2013, BREAST CANCER RES TR, V139, P539, DOI 10.1007/s10549-013-2560-8
   Jabbarzadegan M, 2017, ARTIF CELL NANOMED B, V45, P808, DOI 10.1080/21691401.2016.1178131
   Kabat GC, 2007, BRIT J CANCER, V97, P118, DOI 10.1038/sj.bjc.6603837
   Kelter G, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000798
   Kim JH, 2016, EXP MOL MED, V48, DOI 10.1038/emm.2015.115
   Kim SH, 2016, NUTR RES PRACT, V10, P393, DOI 10.4162/nrp.2016.10.4.393
   König M, 2016, CANCER CHEMOTH PHARM, V77, P413, DOI 10.1007/s00280-016-2960-7
   Lai H, 2006, CANCER LETT, V231, P43, DOI 10.1016/j.canlet.2005.01.019
   Lai H, 2009, ANTICANCER RES, V29, P3807
   Langroudi L, 2010, INT IMMUNOPHARMACOL, V10, P1055, DOI 10.1016/j.intimp.2010.06.005
   Lawlor MA, 2001, J CELL SCI, V114, P2903
   Lazennec G, 2001, ENDOCRINOLOGY, V142, P4120, DOI 10.1210/en.142.9.4120
   Lebrun Jean-Jacques, 2012, ISRN Mol Biol, V2012, P381428, DOI 10.5402/2012/381428
   Lemmo S, 2014, BIOTECHNOL J, V9, P426, DOI 10.1002/biot.201300227
   Li M., 2015, Biomed Res Int, V2015, P504932, DOI DOI 10.1155/2015/504932
   Li QY, 2015, BIOORG MED CHEM LETT, V25, P148, DOI 10.1016/j.bmcl.2014.10.048
   Lombard MC, 2012, EUR J PHARM SCI, V47, P834, DOI 10.1016/j.ejps.2012.09.019
   Lu KW, 2011, HUM EXP TOXICOL, V30, P406, DOI 10.1177/0960327110372405
   Lu XX, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/2476842
   Lucibello M, 2015, ONCOTARGET, V6, P5275, DOI 10.18632/oncotarget.2971
   Magoulas GE, 2017, BIOORGAN MED CHEM, V25, P3756, DOI 10.1016/j.bmc.2017.05.018
   Mandishona E, 1998, HEPATOLOGY, V27, P1563, DOI 10.1002/hep.510270614
   Mao HT, 2013, INT J MOL MED, V31, P213, DOI 10.3892/ijmm.2012.1176
   Mercer AE, 2007, J BIOL CHEM, V282, P9372, DOI 10.1074/jbc.M610375200
   Mercer AE, 2011, J BIOL CHEM, V286, P987, DOI 10.1074/jbc.M110.144188
   Natesan S, 2017, INT J BIOL MACROMOL
   Noori S, 2012, FREE RADICAL BIO MED, V52, P1987, DOI 10.1016/j.freeradbiomed.2012.01.026
   Noori S, 2011, CELL IMMUNOL, V271, P67, DOI 10.1016/j.cellimm.2011.06.008
   Odaka Y, 2014, CARCINOGENESIS, V35, P192, DOI 10.1093/carcin/bgt277
   Osaki T, 2017, MOLECULES, V22, DOI 10.3390/molecules22040533
   Panossian LA, 2005, ANN NEUROL, V58, P812, DOI 10.1002/ana.20620
   Paul I, 2014, WORLD J CLIN ONCOL, V5, P588, DOI 10.5306/wjco.v5.i4.588
   Qaderi A, 2013, SPRINGERPLUS, V2, DOI 10.1186/2193-1801-2-340
   Qiu MT, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-78
   Ramsey B, 2011, BREAST CANCER RES TR, V127, P659, DOI 10.1007/s10549-010-1010-0
   Rijpma SR, 2014, MALARIA J, V13, DOI 10.1186/1475-2875-13-359
   Sagar S, 2014, ANTI-CANCER AGENT ME, V14, P170, DOI 10.2174/18715206113136660369
   Sánchez-Tilló E, 2011, P NATL ACAD SCI USA, V108, P19204, DOI 10.1073/pnas.1108977108
   Seo EJ, 2015, PHYTOMEDICINE, V22, P438, DOI 10.1016/j.phymed.2015.01.012
   Shahbazfar AA, 2014, J CANCER RES THER, V10, P1057, DOI 10.4103/0973-1482.137975
   Singh NP, 2011, ANTICANCER RES, V31, P4111
   Singh NP, 2001, LIFE SCI, V70, P49, DOI 10.1016/S0024-3205(01)01372-8
   Stein RA, 2008, CANCER RES, V68, P8805, DOI 10.1158/0008-5472.CAN-08-1594
   STEVENS RG, 1986, JNCI-J NATL CANCER I, V76, P605, DOI 10.1093/jnci/76.4.605
   STEVENS RG, 1988, NEW ENGL J MED, V319, P1047, DOI 10.1056/NEJM198810203191603
   Suberu JO, 2014, CHEMMEDCHEM, V9, P2791, DOI 10.1002/cmdc.201402285
   Sundar SN, 2008, CARCINOGENESIS, V29, P2252, DOI 10.1093/carcin/bgn214
   Tai X, 2016, ONCOL LETT, V12, P3701, DOI 10.3892/ol.2016.5187
   Tin AS, 2012, ANTI-CANCER DRUG, V23, P370, DOI 10.1097/CAD.0b013e32834f6ea8
   Tran TH, 2016, ARTIF CELL NANOMED B, V44, P1979, DOI 10.3109/21691401.2015.1129616
   Tran TH, 2015, AAPS PHARMSCITECH, V16, P1307, DOI 10.1208/s12249-015-0311-3
   Ha VT, 2016, BIOORG CHEM, V66, P63, DOI 10.1016/j.bioorg.2016.03.008
   Wang DF, 2016, TUMOR BIOL, V37, P11805, DOI 10.1007/s13277-016-5037-7
   Wang SS, 2013, BIOORG MED CHEM LETT, V23, P4424, DOI 10.1016/j.bmcl.2013.05.057
   Wang ZH, 2012, MOL PHARMACEUT, V9, P2646, DOI 10.1021/mp3002107
   Wen CP, 2014, CANCER RES, V74, P6589, DOI 10.1158/0008-5472.CAN-14-0360
   Wu GS, 2013, PHARMACOL REP, V65, P453, DOI 10.1016/S1734-1140(13)71021-1
   Würstle ML, 2012, EXP CELL RES, V318, P1213, DOI 10.1016/j.yexcr.2012.02.013
   Wurzelmann JI, 1996, CANCER EPIDEM BIOMAR, V5, P503
   Xu Jinhua, 2010, Genes Cancer, V1, P629, DOI 10.1177/1947601910378691
   Zhang YTJ, 2015, J PHARM SCI-US, V104, P1815, DOI 10.1002/jps.24407
   Zhang YTJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059086
   Zhong H, 2016, EUR J MED CHEM, V108, P720, DOI 10.1016/j.ejmech.2015.10.040
   Zhou QM, 2011, EUR J CANCER, V47, P2240, DOI 10.1016/j.ejca.2011.04.032
   Zuma NH, 2016, EUR J MED CHEM, V122, P635, DOI 10.1016/j.ejmech.2016.07.027
   Zuo Zhi-zhong, 2015, Yaoxue Xuebao, V50, P868
NR 91
TC 36
Z9 39
U1 0
U2 14
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471-2407
J9 BMC CANCER
JI BMC Cancer
PD DEC 15
PY 2017
VL 17
AR 858
DI 10.1186/s12885-017-3863-7
PG 13
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA FQ0MU
UT WOS:000418052200005
PM 29246124
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Kuzbicki, L
   Lange, D
   Stanek-Widera, A
   Chwirot, BW
AF Kuzbicki, Lukasz
   Lange, Dariusz
   Stanek-Widera, Agata
   Chwirot, Barbara W.
TI Prognostic significance of RBP2-H1 variant of JARID1B in melanoma
SO BMC CANCER
LA English
DT Article
DE JARID1B; RBP2-H1 variant of JARID1B; Melanoma; Patient's survival;
   Immunohistochemistry
ID CANCER CELL-PROLIFERATION; BREAST-CANCER; HEPATOCELLULAR-CARCINOMA;
   PROSTATE-CANCER; EXPRESSION; OVEREXPRESSION; PROTEIN; KDM5B; METASTASIS;
   RESISTANCE
AB Background: Histone demethylase JARID1B plays several context dependent roles in epigenetic regulation of cellular differentiation in normal development and is highly expressed in multiple human cancers. The protein is a strong transcriptional repressor capable of downregulating numerous genes. There are three splicing isoforms of JARID1B, however the links between the protein structure and function are not clear. The expression pattern of JARID1B in human melanoma seems to be different from observed in other cancers. Moreover, up to now no data on the impact of JARID1B expression in cutaneous melanoma on the patients' prognosis have been reported.
   Methods: We investigated immunohistochemically the association of intratumoral expression of total JARID1B protein and its RBP2-H1 isoform in primary and metastatic melanomas with prognosis for the patients.
   Results: Expression of both total JARID1B protein and its RBP2-H1 variant was found in all the melanomas investigated. Our results indicate, however, that only high (above 90% of the cells) intratumoral expression of RBP2-H1 can be considered prognostic factor associated with worse overall survival of the patients.
   Conclusions: Such results if considered together with data demonstrating a switch to enhanced expression of RBP2-H1 at early stages of malignant transformation of melanocytes are in agreement with hypothetical crucial role of JARID1B in the course of melanoma development and progression and suggest that altered splicing of JARID1B may be important factor increasing melanoma aggressiveness.
C1 [Kuzbicki, Lukasz; Chwirot, Barbara W.] Nicholas Copernicus Univ, Fac Biol & Environm Protect, Dept Med Biol, Lwowska 1, PL-87100 Torun, Poland.
   [Lange, Dariusz; Stanek-Widera, Agata] Maria Sklodowska Curie Inst, Dept Tumor Pathol, Ctr Oncol, Wybrzeze Armii Krajowej 15, PL-44101 Gliwice, Poland.
C3 Nicolaus Copernicus University; Maria Sklodowska-Curie National Research
   Institute of Oncology
RP Chwirot, BW (通讯作者)，Nicholas Copernicus Univ, Fac Biol & Environm Protect, Dept Med Biol, Lwowska 1, PL-87100 Torun, Poland.
EM bchwirot@umk.pl
RI ; Kuzbicki, Lukasz/G-4209-2014
OI Lange, Dariusz/0000-0001-7088-5439; Kuzbicki,
   Lukasz/0000-0001-6121-4465; Stanek-Widera, Agata/0000-0002-5221-4524
FU Department of Medical Biology, Nicolaus Copernicus University, Torun,
   Poland
FX The study was funded from the budget of Department of Medical Biology,
   Nicolaus Copernicus University, Torun, Poland. No external funding was
   received for this study.
CR Bamodu OA, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2108-5
   Barrett A, 2002, INT J CANCER, V101, P581, DOI 10.1002/ijc.10644
   Fackenthal JD, 2008, DIS MODEL MECH, V1, P37, DOI 10.1242/dmm.000331
   Facompre ND, 2017, ONCOTARGET, V8, P7218, DOI 10.18632/oncotarget.14790
   Fang LP, 2016, INT J MOL MED, V38, P172, DOI 10.3892/ijmm.2016.2614
   Heroes E, 2013, FEBS J, V280, P584, DOI 10.1111/j.1742-4658.2012.08547.x
   Kuzbicki L, 2016, APPL IMMUNOHISTO M M, V24, P188, DOI 10.1097/PAI.0000000000000170
   Kuzbicki L, 2013, MELANOMA RES, V23, P8, DOI 10.1097/CMR.0b013e32835d5d6f
   Li LK, 2003, MOL CELL BIOL, V23, P9389, DOI 10.1128/MCB.23.24.9389-9404.2003
   Liu H, 2016, MOL CARCINOGEN, V55, P977, DOI 10.1002/mc.22341
   Roesch A, 2005, MODERN PATHOL, V18, P1249, DOI 10.1038/modpathol.3800413
   Roesch A, 2013, CANCER CELL, V23, P811, DOI 10.1016/j.ccr.2013.05.003
   Roesch A, 2010, CELL, V141, P583, DOI 10.1016/j.cell.2010.04.020
   Scibetta AG, 2007, MOL CELL BIOL, V27, P7220, DOI 10.1128/MCB.00274-07
   Shen XD, 2015, TUMOR BIOL, V36, P7133, DOI 10.1007/s13277-015-3418-y
   Tang B, 2015, ONCOTARGET, V6, P12723, DOI 10.18632/oncotarget.3713
   Wang D, 2016, J EXP CLIN CANC RES, V35, DOI 10.1186/s13046-016-0311-5
   Wang LS, 2015, TUMOR BIOL, V36, P2465, DOI 10.1007/s13277-014-2859-z
   Wang ZR, 2015, AM J CANCER RES, V5, P87
   Xiang Y, 2007, P NATL ACAD SCI USA, V104, P19226, DOI 10.1073/pnas.0700735104
   Yamamoto S, 2014, CANCER CELL, V25, P762, DOI 10.1016/j.ccr.2014.04.024
   Yamane K, 2007, MOL CELL, V25, P801, DOI 10.1016/j.molcel.2007.03.001
   Zhao LH, 2015, GENET MOL RES, V14, P5417, DOI 10.4238/2015.May.22.11
NR 23
TC 7
Z9 7
U1 0
U2 3
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2407
J9 BMC CANCER
JI BMC Cancer
PD DEC 15
PY 2017
VL 17
AR 854
DI 10.1186/s12885-017-3836-x
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA FQ0MU
UT WOS:000418052200001
PM 29246117
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Taylor, TB
   Wass, AV
   Johnson, LJ
   Dash, P
AF Taylor, Tiffany B.
   Wass, Anastasia V.
   Johnson, Louise J.
   Dash, Phil
TI Resource competition promotes tumour expansion in experimentally evolved
   cancer
SO BMC EVOLUTIONARY BIOLOGY
LA English
DT Article
DE Experimental evolution; Dispersal; Metastasis; Resource competition;
   Microenvironment; Plasticity; Epigenetic
ID CELL MOTILITY; INTRATUMOR HETEROGENEITY; IN-VITRO; EVOLUTION;
   METASTASIS; DISPERSAL; HYPOXIA; GROWTH; MICROENVIRONMENT; MODEL
AB Background: Tumour progression involves a series of phenotypic changes to cancer cells, each of which presents therapeutic targets. Here, using techniques adapted from microbial experimental evolution, we investigate the evolution of tumour spreading - a precursor for metastasis and tissue invasion - in environments with varied resource supply. Evolutionary theory predicts that competition for resources within a population will select for individuals to move away from a natal site (i.e. disperse), facilitating the colonisation of unexploited resources and decreasing competition between kin.
   Results: After approximately 100 generations in environments with low resource supply, we find that MCF7 breast cancer spheroids (small in vitro tumours) show increased spreading. Conversely, spreading slows compared to the ancestor where resource supply is high. Common garden experiments confirm that the evolutionary responses differ between selection lines; with lines evolved under low resource supply showing phenotypic plasticity in spheroid spreading rate. These differences in spreading behaviour between selection lines are heritable (stable across multiple generations), and show that the divergently evolved lines differ in their response to resource supply.
   Conclusions: We observe dispersal-like behaviour and an increased sensitivity to resource availability in our selection lines, which may be a response to selection, or alternatively may be due to epigenetic changes, provoked by prolonged resource limitation, that have persisted across many cell generations. Different clinical strategies may be needed depending on whether or not tumour progression is due to natural selection. This study highlights the effectiveness of experimental evolution approaches in cancer cell populations and demonstrates how simple model systems might enable us to observe and measure key selective drivers of clinically important traits.
C1 [Taylor, Tiffany B.; Wass, Anastasia V.; Johnson, Louise J.; Dash, Phil] Univ Reading, Sch Biol Sci, Reading RG6 6AH, Berks, England.
   [Taylor, Tiffany B.] Univ Bath, Milner Ctr Evolut, Claverton Rd, Bath BA2 7AY, Avon, England.
   [Taylor, Tiffany B.] Univ Bath, Dept Biol & Biochem, Claverton Rd, Bath BA2 7AY, Avon, England.
C3 University of Reading; University of Bath; University of Bath
RP Taylor, TB (通讯作者)，Univ Reading, Sch Biol Sci, Reading RG6 6AH, Berks, England.; Taylor, TB (通讯作者)，Univ Bath, Milner Ctr Evolut, Claverton Rd, Bath BA2 7AY, Avon, England.; Taylor, TB (通讯作者)，Univ Bath, Dept Biol & Biochem, Claverton Rd, Bath BA2 7AY, Avon, England.
EM t.b.taylor@bath.ac.uk
RI Taylor, Tiffany/V-4814-2019
OI Dash, Phil/0000-0002-6029-4560; Taylor, Tiffany B./0000-0002-5274-7806
FU Leverhulme Trust [F/00239/AL]; Royal Society [DH150169]; University of
   Reading studentship
FX This research was funded by the Leverhulme Trust (LJJ; F/00239/AL) and
   the Royal Society (TBT; DH150169). AVW was supported by a University of
   Reading studentship (PD).
CR Abrmofff MD., 2005, BIOPHOTONICS INT, V11, P36, DOI DOI 10.1201/9781420005615.AX4
   Aktipis CA, 2012, CANCER PREV RES, V5, P266, DOI 10.1158/1940-6207.CAPR-11-0004
   Amend SR, 2016, CANCER LETT, V380, P237, DOI 10.1016/j.canlet.2015.10.005
   Anderson ARA, 2006, CELL, V127, P905, DOI 10.1016/j.cell.2006.09.042
   Araujo RP, 2004, B MATH BIOL, V66, P1039, DOI 10.1016/j.bulm.2003.11.002
   Baker M, 2016, NATURE, V537, P433, DOI 10.1038/537433a
   Bernards R, 2002, NATURE, V418, P823, DOI 10.1038/418823a
   BOUCHER Y, 1992, CANCER RES, V52, P5110
   Brizel DM, 1996, CANCER RES, V56, P941
   Buckling A, 2009, NATURE, V457, P824, DOI 10.1038/nature07892
   Butler LM, 2000, CANCER RES, V60, P5165
   Carmona-Fontaine C, 2017, P NATL ACAD SCI USA, V114, P2934, DOI 10.1073/pnas.1700600114
   Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865
   Chen J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017933
   COMINS HN, 1980, J THEOR BIOL, V82, P205, DOI 10.1016/0022-5193(80)90099-5
   Crespi B, 2005, TRENDS ECOL EVOL, V20, P545, DOI 10.1016/j.tree.2005.07.007
   de Bruin EC, 2013, GENOME MED, V5, DOI 10.1186/gm505
   Frank SA, 2012, PLOS BIOL, V10, DOI 10.1371/journal.pbio.1001296
   Fujiwara S, 2007, INT J ONCOL, V30, P793
   Gandon S, 1999, J THEOR BIOL, V199, P275, DOI 10.1006/jtbi.1999.0960
   Gerlinger M, 2012, NEW ENGL J MED, V366, P883, DOI 10.1056/NEJMoa1113205
   Greaves M, 2012, NATURE, V481, P306, DOI 10.1038/nature10762
   Greenman C, 2007, NATURE, V446, P153, DOI 10.1038/nature05610
   Hamilton G, 1998, CANCER LETT, V131, P29, DOI 10.1016/S0304-3835(98)00198-0
   HAMILTON WD, 1977, NATURE, V269, P578, DOI 10.1038/269578a0
   HAMILTON WD, 1964, J THEOR BIOL, V7, P17, DOI 10.1016/0022-5193(64)90039-6
   Hampton OA, 2009, GENOME RES, V19, P167, DOI 10.1101/gr.080259.108
   Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9
   Hirschhaeuser F, 2010, J BIOTECHNOL, V148, P3, DOI 10.1016/j.jbiotec.2010.01.012
   Hockel M, 1996, CANCER RES, V56, P4509
   Höckel M, 2001, JNCI-J NATL CANCER I, V93, P266, DOI 10.1093/jnci/93.4.266
   Howes AL, 2007, MOL CANCER THER, V6, P2505, DOI 10.1158/1535-7163.MCT-06-0698
   Indovina P, 2008, ANTICANCER RES, V28, P1013
   Joyce JA, 2009, NAT REV CANCER, V9, P239, DOI 10.1038/nrc2618
   Kim IS, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14343
   Korolev KS, 2014, NAT REV CANCER, V14, P371, DOI 10.1038/nrc3712
   Li S, 2016, NAT MED, V22, P792, DOI 10.1038/nm.4125
   Martin TraceyA., 2013, Cancer invasion and metastasis: molecular and cellular perspective, DOI DOI 10.1038/NATURE06757
   Mazzone M, 2009, CELL, V136, P839, DOI 10.1016/j.cell.2009.01.020
   Merlo LMF, 2006, NAT REV CANCER, V6, P924, DOI 10.1038/nrc2013
   Nadell CD, 2013, P ROY SOC B-BIOL SCI, V280, DOI 10.1098/rspb.2012.2770
   Nguyen DX, 2009, NAT REV CANCER, V9, P274, DOI 10.1038/nrc2622
   Pianka E.R., 1981, THEOR ECOL-NETH, P167, DOI DOI 10.1002/JLAC.1993199301120
   Schiffman JD., 2016, Frontiers in Cancer Research: Evolutionary Foundations, Revolutionary Directions, P135
   Sidow A, 2015, TRENDS GENET, V31, P208, DOI 10.1016/j.tig.2015.02.001
   SOULE HD, 1973, J NATL CANCER I, V51, P1409, DOI 10.1093/jnci/51.5.1409
   Sprouffske K, 2012, CURR BIOL, V22, pR762, DOI 10.1016/j.cub.2012.06.065
   Taylor PD, 1996, J THEOR BIOL, V180, P27, DOI 10.1006/jtbi.1996.0075
   Taylor TB, 2013, EVOL APPL, V6, P535, DOI 10.1111/eva.12041
   Taylor TB, 2010, AM NAT, V176, P83, DOI 10.1086/652995
   Vaupel P, 2004, ONCOLOGIST, V9, P4, DOI 10.1634/theoncologist.9-90005-4
   Vedel S, 2013, P NATL ACAD SCI USA, V110, P129, DOI 10.1073/pnas.1204291110
   Waclaw B, 2015, NATURE, V525, P261, DOI 10.1038/nature14971
   Wells A, 2013, TRENDS PHARMACOL SCI, V34, P283, DOI 10.1016/j.tips.2013.03.001
   West SA, 2006, NAT REV MICROBIOL, V4, P597, DOI 10.1038/nrmicro1461
   Williams MJ, 2016, NAT GENET, V48, P238, DOI 10.1038/ng.3489
   Woo YH, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1982
NR 57
TC 9
Z9 9
U1 0
U2 12
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2148
J9 BMC EVOL BIOL
JI BMC Evol. Biol.
PD DEC 27
PY 2017
VL 17
AR 268
DI 10.1186/s12862-017-1117-6
PG 9
WC Evolutionary Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Evolutionary Biology; Genetics & Heredity
GA FR3AL
UT WOS:000418938200001
PM 29281983
OA Green Published, gold, Green Accepted
DA 2025-01-12
ER

PT J
AU Terranova-Barberio, M
   Thomas, S
   Ali, N
   Pawlowska, N
   Park, J
   Krings, G
   Rosenblum, MD
   Budillon, A
   Munster, PN
AF Terranova-Barberio, Manuela
   Thomas, Scott
   Ali, Niwa
   Pawlowska, Nela
   Park, Jeenah
   Krings, Gregor
   Rosenblum, Michael D.
   Budillon, Alfredo
   Munster, Pamela N.
TI HDAC inhibition potentiates immunotherapy in triple negative breast
   cancer
SO ONCOTARGET
LA English
DT Article
DE HDAC inhibitor; immunotherapy; checkpoint inhibitor; triple negative
   breast cancer; epigenetics modulators
ID REGULATORY T-CELLS; TUMOR-INFILTRATING LYMPHOCYTES; CHECKPOINT BLOCKADE;
   PREDICTS RESPONSE; CLASS-II; EXPRESSION; MELANOMA; PD-1; ACTIVATION;
   INDUCTION
AB Triple-negative breast cancer (TNBC) represents a more aggressive and difficult subtype of breast cancer where responses to chemotherapy occur, but toxicity is significant and resistance often follows. Immunotherapy has shown promising results in various types of cancer, including breast cancer. Here, we investigated a new combination strategy where histone deacetylase inhibitors (HDACi) are applied with immune checkpoint inhibitors to improve immunotherapy responses in TNBC.
   Testing different epigenetic modifiers, we focused on the mechanisms underlying HDACi as priming modulators of immunotherapy. Tumor cells were co-cultured with human peripheral blood mononuclear cells (PBMCs) and flow cytometric immunophenotyping was performed to define the role of epigenetic priming in promoting tumor antigen presentation and immune cell activation. We found that HDACi up-regulate PD-L1 mRNA and protein expression in a time-dependent manner in TNBC cells, but not in hormone responsive cells. Focusing on TNBC, HDACi upregulated PD-L1 and HLA-DR on tumor cells when co-cultured with PBMCs and downregulated CD4(+) Foxp3(+) Treg in vitro. HDACi significantly enhanced the in vivo response to PD-1/CTLA-4 blockade in the triple-negative 4T1 breast cancer mouse model, the only currently available experimental system with functional resemblance to human TNBC. This resulted in a significant decrease in tumor growth and increased survival, associated with increased T cell tumor infiltration and a reduction in CD4(+) Foxp3(+) T cells in the tumor microenvironment. Overall, our results suggest a novel role for HDAC inhibition in combination with immune checkpoint inhibitors and identify a promising therapeutic strategy, supporting its further clinical evaluation for TNBC treatment.
C1 [Terranova-Barberio, Manuela; Thomas, Scott; Pawlowska, Nela; Park, Jeenah; Munster, Pamela N.] Univ Calif San Francisco, Div Hematol & Oncol, San Francisco, CA 94143 USA.
   [Ali, Niwa; Rosenblum, Michael D.] Univ Calif San Francisco, Dept Dermatol, San Francisco, CA 94143 USA.
   [Krings, Gregor] Univ Calif San Francisco, Div Pathol, San Francisco, CA 94143 USA.
   [Budillon, Alfredo] Ist Nazl Tumori Fdn G Pascale IRCCS, Expt Pharmacol Unit, Naples, Italy.
C3 University of California System; University of California San Francisco;
   University of California System; University of California San Francisco;
   University of California System; University of California San Francisco;
   IRCCS Fondazione Pascale
RP Munster, PN (通讯作者)，Univ Calif San Francisco, Div Hematol & Oncol, San Francisco, CA 94143 USA.
EM pamela.munster@ucsf.edu
RI Budillon, Alfredo/K-4763-2016; Thomas, Scott/AAF-2683-2020
OI Budillon, Alfredo/0000-0002-6330-6053; Ali, Niwa/0000-0003-4473-8747
FU Avon Foundation for Woman [63638]
FX This work was partially supported by the Avon Foundation for Woman grant
   63638.
CR Ali HR, 2015, ANN ONCOL, V26, P1488, DOI 10.1093/annonc/mdv192
   Balkwill F, 2004, NAT REV CANCER, V4, P540, DOI 10.1038/nrc1388
   Bates GJ, 2006, J CLIN ONCOL, V24, P5373, DOI 10.1200/JCO.2006.05.9584
   Baxter AG, 2002, NAT REV IMMUNOL, V2, P439, DOI 10.1038/nri823
   Bohling SD, 2008, MODERN PATHOL, V21, P1527, DOI 10.1038/modpathol.2008.160
   Bos PD, 2013, J EXP MED, V210, P2435, DOI 10.1084/jem.20130762
   Chang LY, 2012, CANCER RES, V72, P1092, DOI 10.1158/0008-5472.CAN-11-2493
   Chumsri S, 2016, CANCER RES, V76, DOI 10.1158/1538-7445.SABCS15-P2-04-02
   Corthay A, 2009, SCAND J IMMUNOL, V70, P326, DOI 10.1111/j.1365-3083.2009.02308.x
   Daud AI, 2016, J CLIN INVEST, V126, P3447, DOI 10.1172/JCI87324
   Freeman GJ, 2000, J EXP MED, V192, P1027, DOI 10.1084/jem.192.7.1027
   Gradishar WJ, 2015, J NATL COMPR CANC NE, V13, P1475, DOI 10.6004/jnccn.2015.0176
   Grosso Joseph F, 2013, Cancer Immun, V13, P5
   Gu GW, 2016, CURR OPIN PHARMACOL, V31, P97, DOI 10.1016/j.coph.2016.11.005
   Hirose T, 2003, ONCOGENE, V22, P7762, DOI 10.1038/sj.onc.1207091
   ISHIDA Y, 1992, EMBO J, V11, P3887, DOI 10.1002/j.1460-2075.1992.tb05481.x
   Johnson DB, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10582
   Kamphorst AO, 2017, SCIENCE, V355, P1423, DOI 10.1126/science.aaf0683
   Kim K, 2014, P NATL ACAD SCI USA, V111, P11774, DOI 10.1073/pnas.1410626111
   Loi S, 2014, ANN ONCOL, V25, P1544, DOI 10.1093/annonc/mdu112
   Marks PA, 2010, BBA-GENE REGUL MECH, V1799, P717, DOI 10.1016/j.bbagrm.2010.05.008
   Minucci S, 2006, NAT REV CANCER, V6, P38, DOI 10.1038/nrc1779
   Nanda R, 2016, J CLIN ONCOL, V34, P2460, DOI [10.1200/JCO.2016.68.1478, 10.1200/JCO.2015.64.8931]
   Ohara M, 2009, CANCER IMMUNOL IMMUN, V58, P441, DOI 10.1007/s00262-008-0570-x
   Oki Y, 2014, BLOOD CANCER J, V4, DOI 10.1038/bcj.2014.58
   Ott PA, 2013, CLIN CANCER RES, V19, P5300, DOI 10.1158/1078-0432.CCR-13-0143
   Park JJ, 2010, BLOOD, V116, P1291, DOI 10.1182/blood-2010-01-265975
   Pentcheva-Hoang T, 2009, IMMUNOL REV, V229, P67, DOI 10.1111/j.1600-065X.2009.00763.x
   Plitas G, 2016, IMMUNITY, V45, P1122, DOI 10.1016/j.immuni.2016.10.032
   Pulaski BA, 1998, CANCER RES, V58, P1486
   Raha P, 2015, BREAST CANCER RES, V17, DOI 10.1186/s13058-015-0533-z
   da Silva GBRF, 2013, INT J BREAST CANCER, V2013, DOI 10.1155/2013/250435
   Sabatier R, 2015, ONCOTARGET, V6, P5449, DOI 10.18632/oncotarget.3216
   Sagiv-Barfi I, 2015, P NATL ACAD SCI USA, V112, pE966, DOI 10.1073/pnas.1500712112
   Sconocchia G, 2014, NEOPLASIA, V16, P31, DOI 10.1593/neo.131568
   Seto E, 2014, CSH PERSPECT BIOL, V6, DOI 10.1101/cshperspect.a018713
   SHEENCHEN SM, 1994, SURGERY, V116, P510
   Shen L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030815
   Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387
   Stagg J, 2013, THER ADV MED ONCOL, V5, P169, DOI 10.1177/1758834012475152
   Tan MCB, 2009, J IMMUNOL, V182, P1746, DOI 10.4049/jimmunol.182.3.1746
   Terranova-Barberio M, 2016, IMMUNOTHERAPY-UK, V8, P705, DOI 10.2217/imt-2016-0014
   Terranova-Barberio M, 2016, ONCOTARGET, V7, P7715, DOI 10.18632/oncotarget.6802
   Topalian SL, 2012, CURR OPIN IMMUNOL, V24, P207, DOI 10.1016/j.coi.2011.12.009
   Valsecchi ME, 2015, NEW ENGL J MED, V373, P1270, DOI [10.1056/NEJMoa1504030, 10.1056/NEJMc1509660]
   West AC, 2014, ONCOIMMUNOLOGY, V3, DOI 10.4161/onci.27414
   Wimberly H, 2015, CANCER IMMUNOL RES, V3, P326, DOI 10.1158/2326-6066.CIR-14-0133
   Wolf D, 2015, J CELL PHYSIOL, V230, P2598, DOI 10.1002/jcp.25016
   Woods DM, 2015, CANCER IMMUNOL RES, V3, P1375, DOI 10.1158/2326-6066.CIR-15-0077-T
   Zheng H, 2016, CLIN CANCER RES, V22, P4119, DOI 10.1158/1078-0432.CCR-15-2584
   Zitvogel L, 2012, ONCOIMMUNOLOGY, V1, P1223, DOI 10.4161/onci.21335
NR 51
TC 116
Z9 127
U1 1
U2 27
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD DEC 26
PY 2017
VL 8
IS 69
BP 114156
EP 114172
DI 10.18632/oncotarget.23169
PG 17
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA FS1WV
UT WOS:000419570400066
PM 29371976
OA Green Submitted, Green Published, gold
DA 2025-01-12
ER

PT J
AU Liu, J
   Ding, ZL
   Li, GM
   Tang, L
   Xu, Y
   Luo, HY
   Yi, JH
   Lu, YW
   Mao, R
   Nan, Q
   Ren, L
   Zhang, T
   Wang, KH
AF Liu, Jiang
   Ding, Zhaoli
   Li, Guimei
   Tang, Li
   Xu, Yu
   Luo, Huayou
   Yi, Jinhua
   Lu, Youwang
   Mao, Rui
   Nan, Qiong
   Ren, Li
   Zhang, Tong
   Wang, Kunhua
TI Identification and validation of colorectal neoplasia-specific
   methylation biomarkers based on CTCF-binding sites
SO ONCOTARGET
LA English
DT Article
DE colorectal cancer; early-detection; CTCF-binding site; DNA methylation;
   biomarker
ID HUMAN P53 GENE; STOOL DNA TEST; EPIGENETIC REGULATION;
   ENHANCER-BLOCKING; BREAST-CANCER; TRANSCRIPTION; PERFORMANCE; PATTERNS;
   CLEAVAGE; PROMOTER
AB To date, the sensitivity of currently available biomarkers based on the methylation of gene promoters is suboptimal for detecting adenomas and earlystage colorectal cancer (CRC). We aimed to develop biomarkers with methylated DNA binding sites of the multifunctional transcriptional factor CTCF for early detection of CRC. Using combined analyses of genome-wide occupation and the methylation profile of CTCF-binding sites, we identified candidate CTCF-binding sites. Then, we applied methylation-sensitive high-resolution melting (MS-HRM) and mass spectrometry analysis to screen and validate these candidate sites in diverse sample sets. We identified a set of colorectal neoplasia-specific biomarkers with robust performance. The top five biomarkers were selected and recommended for early detection of colorectal neoplasia. All of the five novel biomarkers exhibited a more robust discriminatory performance than that by BMP3 and NDRG4, two currently acknowledged robust methylation biomarkers. When the five new biomarkers were considered as a marker panel and tumor-positive was defined as having two or more (of the five) positive biomarkers, the marker panel could achieve a sensitivity of 91.67% for adenomas, 97.44% for Stage I CRC, 94.06% for Stage II CRC, 93.62% for Stage III CRC, and 93.54% for total colorectal tumors with a specificity of 94.05%. To our knowledge, this is the first study for colorectal neoplasia-specific methylation biomarkers based on CTCF-binding sites. Using a similar strategy, CTCF-binding sites could be potentially developed into biomarkers for other tumors. In summary, this study opens a new area in developing biomarkers for tumor prevention and treatment.
C1 [Liu, Jiang; Tang, Li] Kunming Med Univ, Affiliated Hosp 1, Dept Reprod & Genet, Kunming 650032, Yunnan, Peoples R China.
   [Ding, Zhaoli; Li, Guimei] Chinese Acad Sci, Kunming Inst Zool, Publ Tech Serv Ctr, Kunming 650032, Yunnan, Peoples R China.
   [Ding, Zhaoli; Li, Guimei] Chinese Acad Sci, Kunming Biol Divers Reg Ctr Large Apparat & Equip, Kunming 650032, Yunnan, Peoples R China.
   [Xu, Yu; Luo, Huayou; Yi, Jinhua; Lu, Youwang; Zhang, Tong; Wang, Kunhua] Kunming Med Univ, Affiliated Hosp 1, Yunnan Inst Digest Dis, Dept Gastrointestinal Surg, Kunming 650032, Yunnan, Peoples R China.
   [Mao, Rui] Kunming Med Univ, Sch Stomatol, Kunming 650500, Yunnan, Peoples R China.
   [Nan, Qiong] Kunming Med Univ, Affiliated Hosp 1, Yunnan Inst Digest Dis, Dept Gastroenterol, Kunming 650032, Yunnan, Peoples R China.
   [Ren, Li] First Peoples Hosp Yunnan Prov, Kunming 650031, Yunnan, Peoples R China.
C3 Kunming Medical University; Chinese Academy of Sciences; Kunming
   Institute of Zoology, CAS; Chinese Academy of Sciences; Kunming Medical
   University; Kunming Medical University; Kunming Medical University;
   Kunming University of Science & Technology
RP Wang, KH (通讯作者)，Kunming Med Univ, Affiliated Hosp 1, Yunnan Inst Digest Dis, Dept Gastrointestinal Surg, Kunming 650032, Yunnan, Peoples R China.
EM kunhuawangProf@163.com
RI Zhang, tong/IAP-2587-2023
FU National Natural Science Foundation of China [81660094]; Yunnan Applied
   Basic research Projects-Union Foundation of Kunming Medical University
   [2017FE467(-132)]; China Postdoctoral Science Foundation [2015M572504];
   Kunming Science and Technology Bureau; China Guanghua Foundation;
   Medical Leading Talent of Yunnan Province [L-201205]
FX This work was supported by grants from National Natural Science
   Foundation of China (81660094), Yunnan Applied Basic research
   Projects-Union Foundation of Kunming Medical University
   (2017FE467(-132)), China Postdoctoral Science Foundation (2015M572504),
   the Key Science and Technology Planning Project of Kunming Science and
   Technology Bureau, the China Guanghua Foundation and Medical Leading
   Talent of Yunnan Province (No. L-201205).
CR Ahlquist DA, 2012, CLIN GASTROENTEROL H, V10, P272, DOI 10.1016/j.cgh.2011.10.008
   Ahlquist DA, 2012, GASTROENTEROLOGY, V142, P248, DOI 10.1053/j.gastro.2011.10.031
   Bell AC, 2000, NATURE, V405, P482, DOI 10.1038/35013100
   Bock C, 2016, NAT BIOTECHNOL, V34, P726, DOI 10.1038/nbt.3605
   Butcher DT, 2004, INT J CANCER, V111, P669, DOI 10.1002/ijc.20324
   Chao W, 2002, SCIENCE, V295, P345, DOI 10.1126/science.1065982
   Chen X, 2008, CELL, V133, P1106, DOI 10.1016/j.cell.2008.04.043
   Church TR, 2014, GUT, V63, P317, DOI 10.1136/gutjnl-2012-304149
   Dixon JR, 2012, NATURE, V485, P376, DOI 10.1038/nature11082
   Draht MXG, 2012, EPIGENOMICS-UK, V4, P179, DOI [10.2217/EPI.12.9, 10.2217/epi.12.9]
   Ehrich M, 2005, P NATL ACAD SCI USA, V102, P15785, DOI 10.1073/pnas.0507816102
   Ghirlando R, 2016, GENE DEV, V30, P881, DOI 10.1101/gad.277863.116
   Guastafierro T, 2008, J BIOL CHEM, V283, P21873, DOI 10.1074/jbc.M801170200
   Hark AT, 2000, NATURE, V405, P486, DOI 10.1038/35013106
   Heatmaps KRpP, 2013, R PACK VERS 0 7 7
   Imperiale TF, 2014, NEW ENGL J MED, V370, P1287, DOI [10.1056/NEJMoa1311194, 10.1056/NEJMc1405215]
   Carmona FJ, 2013, CANCER PREV RES, V6, P656, DOI 10.1158/1940-6207.CAPR-12-0501
   JEMAL A, 2011, CA-CANCER J CLIN, V61, P69, DOI DOI 10.3322/CAAC.20107
   Jin P, 2015, J GASTROEN HEPATOL, V30, P830, DOI 10.1111/jgh.12855
   Kemp CJ, 2014, CELL REP, V7, P1020, DOI 10.1016/j.celrep.2014.04.004
   Koh YW, 2016, TUMOR BIOL, V37, P10675, DOI 10.1007/s13277-016-4932-2
   Ladabaum U, 2013, CANCER EPIDEM BIOMAR, V22, P1567, DOI 10.1158/1055-9965.EPI-13-0204
   Laird PW, 2003, NAT REV CANCER, V3, P253, DOI 10.1038/nrc1045
   Lidgard GP, 2013, CLIN GASTROENTEROL H, V11, P1313, DOI 10.1016/j.cgh.2013.04.023
   Lieberman-Aiden E, 2009, SCIENCE, V326, P289, DOI 10.1126/science.1181369
   Ling JQ, 2006, SCIENCE, V312, P269, DOI 10.1126/science.1123191
   Lofton-Day C, 2008, CLIN CHEM, V54, P414, DOI 10.1373/clinchem.2007.095992
   Méndez-Catalá CF, 2013, NEOPLASIA, V15, P898, DOI 10.1593/neo.121948
   Moon H, 2005, EMBO REP, V6, P165, DOI 10.1038/sj.embor.7400334
   Oh T, 2013, J MOL DIAGN, V15, P498, DOI 10.1016/j.jmoldx.2013.03.004
   Oksanen J., 2013, Vegan: Community Ecology Package. R Package Versin 2.66.1
   Okugawa Y, 2015, GASTROENTEROLOGY, V149, P1204, DOI 10.1053/j.gastro.2015.07.011
   Ollikainen M, 2010, HUM MOL GENET, V19, P4176, DOI 10.1093/hmg/ddq336
   Radpour R, 2008, MOL CANCER RES, V6, P1702, DOI 10.1158/1541-7786.MCR-08-0262
   Saldaña-Meyer R, 2014, GENE DEV, V28, P723, DOI 10.1101/gad.236869.113
   Shah R, 2014, CANCER EPIDEM BIOMAR, V23, P1712, DOI 10.1158/1055-9965.EPI-14-0412
   Soto-Reyes E, 2010, ONCOGENE, V29, P2217, DOI 10.1038/onc.2009.509
   Valley CM, 2006, CURR OPIN GENET DEV, V16, P240, DOI 10.1016/j.gde.2006.04.008
   Wang H, 2012, GENOME RES, V22, P1680, DOI 10.1101/gr.136101.111
   Warren JD, 2011, BMC MED, V9, DOI 10.1186/1741-7015-9-133
   West AG, 2002, GENE DEV, V16, P271, DOI 10.1101/gad.954702
   Wojdacz TK, 2008, NAT PROTOC, V3, P1903, DOI 10.1038/nprot.2008.191
   Yoon BJ, 2002, NAT GENET, V30, P92, DOI 10.1038/ng795
   Zampieri M, 2012, BIOCHEM J, V441, P645, DOI 10.1042/BJ20111417
   Ziebarth JD, 2013, NUCLEIC ACIDS RES, V41, pD188, DOI 10.1093/nar/gks1165
   Zou HZ, 2012, CLIN CHEM, V58, P375, DOI 10.1373/clinchem.2011.171264
NR 46
TC 1
Z9 1
U1 0
U2 10
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD DEC 26
PY 2017
VL 8
IS 69
BP 114183
EP 114194
DI 10.18632/oncotarget.23172
PG 12
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA FS1WV
UT WOS:000419570400068
PM 29371978
OA Green Published, gold, Green Submitted
DA 2025-01-12
ER

PT J
AU Nassar, FJ
   Talhouk, R
   Zgheib, NK
   Tfayli, A
   El Sabban, M
   El Saghir, NS
   Boulos, F
   Jabbour, MN
   Chalala, C
   Boustany, RM
   Kadara, H
   Zhang, Z
   Zheng, YA
   Joyce, B
   Hou, LF
   Bazarbachi, A
   Calin, G
   Nasr, R
AF Nassar, Farah J.
   Talhouk, Rabih
   Zgheib, Nathalie K.
   Tfayli, Arafat
   El Sabban, Maya
   El Saghir, Nagi S.
   Boulos, Fouad
   Jabbour, Mark N.
   Chalala, Claude
   Boustany, Rose-Mary
   Kadara, Humam
   Zhang, Zhou
   Zheng, Yinan
   Joyce, Brian
   Hou, Lifang
   Bazarbachi, Ali
   Calin, George
   Nasr, Rihab
TI microRNA Expression in Ethnic Specific Early Stage Breast Cancer: an
   Integration and Comparative Analysis
SO SCIENTIFIC REPORTS
LA English
DT Article
ID EPITHELIAL-MESENCHYMAL TRANSITION; CYCLIN D1 EXPRESSION; CCND1
   AMPLIFICATION; DOWN-REGULATION; CHEMORESISTANCE; ASSOCIATION;
   METASTASIS; METHYLATION; PROGRESSION; RESISTANCE
AB Breast cancer (BC) has a higher incidence in young Lebanese woman as compared to the West. We assessed the microRNA (miRNA) microarray profile of tissues derived from Lebanese patients with early BC and performed mRNA-miRNA integration analysis. 173 miRNAs were significantly dysregulated in 45 BC versus 17 normal adjacent breast tissues, including 74 with a fold change more than two of which 17 were never reported before in cancer. Integration analysis of mRNA-miRNA microarray data revealed a potential role of 51 dysregulated miRNA regulating 71(tumor suppressive or oncogenic mRNA associated with increased proliferation and decreased migration and invasion. We then performed a comparative miRNA microarray profile analysis of BC tissue between these 45 Lebanese and 197 matched American BC patients. Notably, Lebanese BC patients had 21 exclusively dysregulated miRNA (e.g. miR-31, 362-3p, and 663) and 4 miRNA with different expression manner compared to American patients (e.g. miR-1288-star and 324-3p). Some of these differences could reflect variation in patient age at diagnosis or ethnic variation affecting miRNA epigenetic regulation or sequence of miRNA precursors. Our data provide a basis for genetic/epigenetic investigations to explore the role of miRNA in early stage BC in young women, including ethnic specific differences.
C1 [Nassar, Farah J.; Talhouk, Rabih] Amer Univ Beirut, Fac Arts & Sci, Dept Biol, Beirut, Lebanon.
   [Zgheib, Nathalie K.] Amer Univ Beirut, Dept Pharmacol & Toxicol, Fac Med, Beirut, Lebanon.
   [Tfayli, Arafat; El Saghir, Nagi S.; Bazarbachi, Ali] Amer Univ Beirut, Dept Internal Med, Fac Med, Beirut, Lebanon.
   [El Sabban, Maya] Med Univ South Carolina, Dept Biochem, Charleston, SC 29425 USA.
   [Boulos, Fouad; Jabbour, Mark N.] Amer Univ Beirut, Dept Pathol, Fac Med, Beirut, Lebanon.
   [Chalala, Claude] Queen Mary Univ London, Barts Canc Inst, Ctr Mol Oncol, Charterhouse Sq, London EC1M 6BQ, England.
   [Boustany, Rose-Mary] Amer Univ Beirut, Dept Pediat & Adolescent Med, Med Ctr, Beirut, Lebanon.
   [Boustany, Rose-Mary; Kadara, Humam] Amer Univ Beirut, Med Ctr, Dept Biochem & Mol Genet, Beirut, Lebanon.
   [Boustany, Rose-Mary] Duke Univ, Med Ctr, Durham, NC USA.
   [Zhang, Zhou; Zheng, Yinan; Joyce, Brian; Hou, Lifang] Northwestern Univ, Feinberg Sch Med, Dept Prevent Med, Ctr Populat Epigenet, Chicago, IL 60611 USA.
   [Zhang, Zhou] Northwestern Univ, Feinberg Sch Med, Driskill Grad Program Life Sci, Chicago, IL 60611 USA.
   [Zheng, Yinan] Northwestern Univ, Feinberg Sch Med, Inst Publ Hlth & Med, Chicago, IL 60611 USA.
   [Joyce, Brian] Univ Illinois, Sch Publ Hlth, Div Epidemiol Biostat, Chicago, IL USA.
   [Hou, Lifang] Northwestern Univ, Feinberg Sch Med, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA.
   [Hou, Lifang] Northwestern Univ, Dept Med, Feinberg Sch Med, Ctr Global Hlth, Chicago, IL 60611 USA.
   [Calin, George] Univ Texas MD Anderson Canc Ctr, Div Canc Med, Dept Expt Therapeut, Houston, TX 77030 USA.
   [Nasr, Rihab] Amer Univ Beirut, Fac Med, Dept Anat Cell Biol & Physiol Sci, Beirut, Lebanon.
C3 American University of Beirut; American University of Beirut; American
   University of Beirut; Medical University of South Carolina; American
   University of Beirut; University of London; Queen Mary University
   London; American University of Beirut; American University of Beirut;
   Duke University; Northwestern University; Feinberg School of Medicine;
   Northwestern University; Feinberg School of Medicine; Northwestern
   University; Feinberg School of Medicine; University of Illinois System;
   University of Illinois Chicago; University of Illinois Chicago Hospital;
   Ann & Robert H. Lurie Children's Hospital of Chicago; Robert H. Lurie
   Comprehensive Cancer Center; Northwestern University; Feinberg School of
   Medicine; Northwestern University; Feinberg School of Medicine;
   University of Texas System; UTMD Anderson Cancer Center; American
   University of Beirut
RP Nasr, R (通讯作者)，Amer Univ Beirut, Fac Med, Dept Anat Cell Biol & Physiol Sci, Beirut, Lebanon.
EM rn03@aub.edu.lb
RI Joyce, Brian/AAF-2478-2020; Boulos, Fouad/AAL-9299-2021; Zgheib,
   Nathalie/ABA-8902-2020; Zheng, Yinan/E-5775-2017; Nasr,
   Rihab/AAF-1606-2020; Calin, George/E-9390-2011; Nassar,
   Farah/AAJ-4792-2020; Nassar, Farah/GYA-5024-2022
OI Zhang, Zhou/0000-0002-9639-052X; Joyce, Brian/0000-0002-5271-6161;
   Calin, George/0000-0001-6704-5615; , Nathalie/0000-0002-0571-768X; Nasr,
   Rihab/0000-0003-1166-4999; Nassar, Farah/0000-0002-4092-2531; Calin,
   George/0000-0002-7427-0578; Zheng, Yinan/0000-0002-2006-7320;
   Bazarbachi, Ali/0000-0002-7171-4997
FU Kamal Shair Central Research Science Laboratory Fund; Medical Practice
   Plan; Lebanese National Council for Scientific Research; Richard and
   Susan Kiphart Northwestern Global Health Research Fund; National Academy
   of Science, Arab American Frontiers Travel Fellowship; CNRS-L/AUB
   Doctoral Scholarship
FX This work was supported by the Kamal Shair Central Research Science
   Laboratory Fund, Farouk Jabre, Medical Practice Plan, Lebanese National
   Council for Scientific Research, and Richard and Susan Kiphart
   Northwestern Global Health Research Fund. The authors acknowledge Ms.
   Nadine Makhoul for microarray processing, The International Breast
   Cancer and Nutrition (IBCN)* and the help of the facilities cores at
   AUB. * Dr. Rabih Talhouk and Dr. Rihab Nasr are both members of IBCN.
   Dr. Nasr and Dr. Hou are the recipients of the National Academy of
   Science, Arab American Frontiers Travel Fellowship, 2014. Dr. Nassar is
   the recipient of the CNRS-L/AUB Doctoral Scholarship.
CR Aaltonen K, 2009, BREAST CANCER RES TR, V113, P75, DOI 10.1007/s10549-008-9908-5
   Akakura Shin, 2012, J Signal Transduct, V2012, P529179, DOI 10.1155/2012/529179
   [Anonymous], 2004, Stat. Appl. Genet. Mol. Biol., DOI [10.2202/1544-6115.1027, DOI 10.2202/1544-6115.1027]
   Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5
   Ben T, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2904
   BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x
   Bensen JT, 2013, CANCER CAUSE CONTROL, V24, P1099, DOI 10.1007/s10552-013-0187-z
   Casas E, 2011, CANCER RES, V71, P245, DOI 10.1158/0008-5472.CAN-10-2330
   Chapellier M, 2015, STEM CELL REP, V4, P239, DOI 10.1016/j.stemcr.2014.12.007
   Chen MJ, 2017, BIOCHEM BIOPH RES CO, V483, P840, DOI 10.1016/j.bbrc.2017.01.012
   Cho JH, 2015, J BIOL CHEM, V290, P10555, DOI 10.1074/jbc.M114.624361
   Choi SK, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2620-7
   Cizkova M, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-545
   Creighton CJ, 2012, BIOL-TARGETS THER, V6, P289, DOI 10.2147/BTT.S29923
   de Brachene Coomans, 2015, CELL MOL LIFE SCI
   Debeb BG, 2016, JNCI-J NATL CANCER I, V108, DOI 10.1093/jnci/djw026
   El Saghir NS, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-194
   Elsheikh S, 2008, BREAST CANCER RES TR, V109, P325, DOI 10.1007/s10549-007-9659-8
   Fang X, 2011, ONCOGENE, V30, P4707, DOI 10.1038/onc.2011.181
   Feng XB, 2016, GENE, V578, P232, DOI 10.1016/j.gene.2015.12.028
   Garzon R, 2006, TRENDS MOL MED, V12, P580, DOI 10.1016/j.molmed.2006.10.006
   Hanieh H, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0443-9
   He DX, 2014, FEBS J, V281, P4718, DOI 10.1111/febs.13012
   Heneghan HM, 2010, ANN SURG, V251, P499, DOI 10.1097/SLA.0b013e3181cc939f
   Hoffman AE, 2009, CANCER RES, V69, P5970, DOI 10.1158/0008-5472.CAN-09-0236
   Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783
   Irizarry RA, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng015
   Kang H, 2016, CELL DEATH DIFFER, V23, P484, DOI 10.1038/cdd.2015.116
   Katoh M, 2009, INT J ONCOL, V34, P1737, DOI 10.3892/ijo_00000304
   Lakkis NA, 2010, CANCER EPIDEMIOL, V34, P221, DOI 10.1016/j.canep.2010.02.013
   Luo DY, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-57
   Masciarelli S, 2014, ONCOGENE, V33, P1601, DOI 10.1038/onc.2013.106
   Muggerud AA, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2466
   Nassar FJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107566
   Peña-Chilet M, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-529
   Pigati L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013515
   Rawlings-Goss RA, 2014, BMC MED GENOMICS, V7, DOI 10.1186/1755-8794-7-53
   Recino A, 2010, BIOCHEM J, V430, P207, DOI 10.1042/BJ20100883
   Roy PG, 2010, INT J CANCER, V127, P355, DOI 10.1002/ijc.25034
   Shimomura A, 2016, CANCER SCI, V107, P326, DOI 10.1111/cas.12880
   Storz P, 2009, MOL CELL BIOL, V29, P4906, DOI 10.1128/MCB.00077-09
   Takahashi Y, 2005, CLIN CANCER RES, V11, P1380, DOI 10.1158/1078-0432.CCR-04-1773
   Tian S, 2010, BIOMARK INSIGHTS, V5, P129, DOI 10.4137/BMI.S6184
   Ueki T, 2008, ONCOGENE, V27, P5672, DOI 10.1038/onc.2008.186
   Vrba L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054398
   Wallden B, 2015, BMC MED GENOMICS, V8, DOI 10.1186/s12920-015-0129-6
   Wee EJH, 2012, ONCOGENE, V31, P4182, DOI 10.1038/onc.2011.584
   Weier Heinz-Ulli G, 2013, J Data Mining Genomics Proteomics, V4, P127
   Xu X, 2016, ONCOTARGET, V7, P20381, DOI 10.18632/oncotarget.7953
   Yan M, 2012, PATHOL ONCOL RES, V18, P343, DOI 10.1007/s12253-011-9450-3
   Yao YS, 2015, ONCOL REP, V33, P2504, DOI 10.3892/or.2015.3866
   Zhang Zhiqian, 2011, Genes Cancer, V2, P782, DOI 10.1177/1947601911429743
   Zhou WW, 2014, ONCOL LETT, V8, P1657, DOI 10.3892/ol.2014.2359
   Zhu R, 2013, ONCOL REP, V30, P2137, DOI 10.3892/or.2013.2697
   Zou YY, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1872
NR 55
TC 24
Z9 25
U1 0
U2 4
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD DEC 4
PY 2017
VL 7
AR 16829
DI 10.1038/s41598-017-16978-y
PG 12
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA FO7BK
UT WOS:000417025400010
PM 29203780
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Abdelkarim, H
   Neelarapu, R
   Madriaga, A
   Vaidya, AS
   Kastrati, I
   Karumudi, B
   Wang, YT
   Taha, TY
   Thatcher, GRJ
   Frasor, J
   Petukhov, PA
AF Abdelkarim, Hazem
   Neelarapu, Raghupathi
   Madriaga, Antonett
   Vaidya, Aditya S.
   Kastrati, Irida
   Karumudi, Bhargava
   Wang, Yue-ting
   Taha, Taha Y.
   Thatcher, Gregory R. J.
   Frasor, Jonna
   Petukhov, Pavel A.
TI Design, Synthesis, Molecular Modeling, and Biological Evaluation of
   Novel Amine-based Histone Deacetylase Inhibitors
SO CHEMMEDCHEM
LA English
DT Article
DE amines; antitumor agents; epigenetics; histone deacetylases; inhibitors
ID HUMAN BREAST-CANCER; HDAC INHIBITORS; CELL VIABILITY; ALAMAR BLUE;
   IN-VITRO; EXPRESSION; ACETYLATION; PROTEIN; MECHANISMS; BINDING
AB Histone deacetylases (HDACs) are promising drug targets for a variety of therapeutic applications. Herein we describe the design, synthesis, biological evaluation in cellular models of cancer, and preliminary drug metabolism and pharmacokinetic studies (DMPK) of a series of secondary and tertiary N-substituted 7-aminoheptanohydroxamic acid-based HDAC inhibitors. Introduction of an amino group with one or two surface binding groups (SBGs) yielded a successful strategy to develop novel and potent HDAC inhibitors. The secondary amines were found to be generally more potent than the corresponding tertiary amines. Docking studies suggested that the SBGs of tertiary amines cannot be favorably accommodated at the gorge region of the binding site. The secondary amines with naphthalen-2-ylmethyl, 5-phenylthiophen-2-ylmethyl, and 1H-indol-2-ylmethyl (2j) substituents exhibited the highest potency against classI HDACs: HDAC1 IC50 39-61nm, HDAC2 IC50 260-690nm, HDAC3 IC50 25-68nm, and HDAC8 IC50 320-620nm. The cytotoxicity of a representative set of secondary and tertiary N-substituted 7-aminoheptanoic acid hydroxyamide-based inhibitors against HT-29, SH-SY5Y, and MCF-7 cancer cells correlated with their inhibition of HDAC1, 2, and 3 and was found to be similar to or better than that of suberoylanilide hydroxamic acid (SAHA). Compounds in this series increased the acetylation of histones H3 and H4 in a time-dependent manner. DMPK studies indicated that secondary amine 2j is metabolically stable and has plasma and brain concentrations >23- and >1.6-fold higher than the IC50 value for classI HDACs, respectively. Overall, the secondary and tertiary N-substituted 7-aminoheptanoic acid hydroxyamide-based inhibitors exhibit excellent lead- and drug-like properties and therapeutic capacity for cancer applications.
C1 [Abdelkarim, Hazem; Neelarapu, Raghupathi; Madriaga, Antonett; Vaidya, Aditya S.; Karumudi, Bhargava; Wang, Yue-ting; Taha, Taha Y.; Thatcher, Gregory R. J.; Petukhov, Pavel A.] Univ Illinois, Coll Pharm, Dept Med Chem & Pharmacognosy, 833 South Wood St, Chicago, IL 60612 USA.
   [Kastrati, Irida; Frasor, Jonna] Univ Illinois, Dept Physiol & Biophys, Coll Med, 835 South Wolcott, Chicago, IL 60612 USA.
C3 University of Illinois System; University of Illinois Chicago;
   University of Illinois Chicago Hospital; University of Illinois System;
   University of Illinois Chicago; University of Illinois Chicago Hospital
RP Petukhov, PA (通讯作者)，Univ Illinois, Coll Pharm, Dept Med Chem & Pharmacognosy, 833 South Wood St, Chicago, IL 60612 USA.
EM pap4@uic.edu
RI Kastrati, Irida/L-4641-2019; Karumudi, Bhargava/J-5997-2019
OI Kastrati, Irida/0000-0002-8086-1411; Taha, Taha/0000-0002-7344-7490
FU US National Cancer Institute/NIH [R21CA183627, R01CA131970,
   R01HL130760]; US National Lung, Heart and Blood Institute/NIH
   [R21CA183627, R01CA131970, R01HL130760]; Alzheimer's Drug Discovery
   Foundation (grant ADDF) [20101103]
FX This study was funded by the US National Cancer and National Lung, Heart
   and Blood Institutes/NIH (grants R21CA183627, R01CA131970, R01HL130760)
   and the Alzheimer's Drug Discovery Foundation (grant ADDF #20101103).
CR Abdelkarim H, 2013, ACS CHEM BIOL, V8, P2538, DOI 10.1021/cb400601g
   AbdelMagid AF, 1996, J ORG CHEM, V61, P3849, DOI 10.1021/jo960057x
   ABDELMAGID AF, 1994, SYNLETT, P81
   ANDERSON DE, 1990, BIOCHEMISTRY-US, V29, P2403, DOI 10.1021/bi00461a025
   [Anonymous], 2017, MOL OP ENV MOE 2016
   [Anonymous], 2017, SCHROD REL 2017 3 QI
   Attenni B, 2009, BIOORG MED CHEM LETT, V19, P3081, DOI 10.1016/j.bmcl.2009.04.011
   Bolden JE, 2006, NAT REV DRUG DISCOV, V5, P769, DOI 10.1038/nrd2133
   Clark AM, 2007, J CHEM INF MODEL, V47, P1933, DOI 10.1021/ci7001473
   CONNELLY PR, 1994, P NATL ACAD SCI USA, V91, P1964, DOI 10.1073/pnas.91.5.1964
   Delcuve GP, 2012, CLIN EPIGENETICS, V4, DOI 10.1186/1868-7083-4-5
   Di L, 2003, CURR OPIN CHEM BIOL, V7, P402, DOI 10.1016/S1367-5931(03)00055-3
   Dowling DP, 2010, BIOCHEMISTRY-US, V49, P5048, DOI 10.1021/bi1005046
   Dowling DP, 2008, BIOCHEMISTRY-US, V47, P13554, DOI 10.1021/bi801610c
   Eot-Houllier G, 2009, CANCER LETT, V274, P169, DOI 10.1016/j.canlet.2008.06.005
   Falkenberg KJ, 2015, NAT REV DRUG DISCOV, V14, P219, DOI 10.1038/nrd4579
   Falkenberg KJ, 2014, NAT REV DRUG DISCOV, V13, P673, DOI 10.1038/nrd4360
   Gardner KE, 2011, J MOL BIOL, V409, P36, DOI 10.1016/j.jmb.2011.01.040
   Giannini G, 2012, FUTURE MED CHEM, V4, P1439, DOI [10.4155/fmc.12.80, 10.4155/FMC.12.80]
   Glaser KB, 2003, MOL CANCER THER, V2, P151
   Glozak MA, 2007, ONCOGENE, V26, P5420, DOI 10.1038/sj.onc.1210610
   Grasso CS, 2015, NAT MED, V21, P827, DOI 10.1038/nm0715-827a
   Haberland M, 2009, NAT REV GENET, V10, P32, DOI 10.1038/nrg2485
   Hamid R, 2004, TOXICOL IN VITRO, V18, P703, DOI 10.1016/j.tiv.2004.03.012
   Hanigan TW, 2017, CELL CHEM BIOL, V24, P1356, DOI 10.1016/j.chembiol.2017.08.015
   He B, 2009, J MED CHEM, V52, P7003, DOI 10.1021/jm9005077
   Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127
   Johnson TW, 2009, BIOORG MED CHEM LETT, V19, P5560, DOI 10.1016/j.bmcl.2009.08.045
   Johnstone RW, 2002, NAT REV DRUG DISCOV, V1, P287, DOI 10.1038/nrd772
   Kaufmann AM, 2007, J PHARM SCI-US, V96, P729, DOI 10.1002/jps.20792
   Kim HJ, 2011, AM J TRANSL RES, V3, P166
   Klisovic MI, 2003, LEUKEMIA, V17, P350, DOI 10.1038/sj.leu.2402776
   Krusche CA, 2005, BREAST CANCER RES TR, V90, P15, DOI 10.1007/s10549-004-1668-2
   Lauffer BEL, 2013, J BIOL CHEM, V288, P26926, DOI 10.1074/jbc.M113.490706
   Li ZM, 2014, INT J BIOL SCI, V10, P757, DOI 10.7150/ijbs.9067
   Lipinski Christopher A, 2004, Drug Discov Today Technol, V1, P337, DOI 10.1016/j.ddtec.2004.11.007
   Lutz L, 2016, AM J CANCER RES, V6, P664
   Makhatadze GI, 2003, J MOL BIOL, V327, P1135, DOI 10.1016/S0022-2836(03)00233-X
   Marks PA, 2001, NAT REV CANCER, V1, P194, DOI 10.1038/35106079
   Marson CM, 2007, BIOORG MED CHEM LETT, V17, P136, DOI 10.1016/j.bmcl.2006.09.085
   Minamiya Y, 2011, LUNG CANCER, V74, P300, DOI 10.1016/j.lungcan.2011.02.019
   Minucci S, 2006, NAT REV CANCER, V6, P38, DOI 10.1038/nrc1779
   Müller BM, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-215
   Naldi M, 2009, PROTEOMICS, V9, P5437, DOI 10.1002/pmic.200800866
   Neelarapu R, 2012, TETRAHEDRON, V68, P7056, DOI 10.1016/j.tet.2012.06.055
   Neelarapu R, 2011, J MED CHEM, V54, P4350, DOI 10.1021/jm2001025
   Oehme I, 2009, EXPERT OPIN INV DRUG, V18, P1605, DOI 10.1517/14728220903241658
   Pajouhesh Hassan, 2005, NeuroRx, V2, P541, DOI 10.1602/neurorx.2.4.541
   Rampersad SN, 2012, SENSORS-BASEL, V12, P12347, DOI 10.3390/s120912347
   Reichert N, 2012, CELL MOL LIFE SCI, V69, P2173, DOI 10.1007/s00018-012-0921-9
   Remiszewski SW, 2003, J MED CHEM, V46, P4609, DOI 10.1021/jm030235w
   Richon VM, 2000, P NATL ACAD SCI USA, V97, P10014, DOI 10.1073/pnas.180316197
   Rikimaru T, 2007, ONCOLOGY-BASEL, V72, P69, DOI 10.1159/000111106
   Robert T, 2011, NATURE, V471, P74, DOI 10.1038/nature09803
   Ryckmans T, 2009, BIOORG MED CHEM LETT, V19, P4406, DOI 10.1016/j.bmcl.2009.05.062
   Sambucetti LC, 1999, J BIOL CHEM, V274, P34940, DOI 10.1074/jbc.274.49.34940
   Shen S, 2016, CHEMMEDCHEM, V11, P15, DOI 10.1002/cmdc.201500486
   Su H, 2009, BIOORG MED CHEM LETT, V19, P6284, DOI 10.1016/j.bmcl.2009.09.100
   Taha TY, 2017, ACS MED CHEM LETT, V8, P824, DOI 10.1021/acsmedchemlett.7b00126
   Terracciano S, 2012, CHEMMEDCHEM, V7, P694, DOI 10.1002/cmdc.201100531
   Thaler F, 2014, CHEMMEDCHEM, V9, P523, DOI 10.1002/cmdc.201300413
   Vaidya AS, 2012, BIOORG MED CHEM LETT, V22, P5025, DOI 10.1016/j.bmcl.2012.06.017
   van Noord C, 2010, BRIT J CLIN PHARMACO, V70, P16, DOI 10.1111/j.1365-2125.2010.03660.x
   Vannini A, 2007, EMBO REP, V8, P879, DOI 10.1038/sj.embor.7401047
   Weichert W, 2008, BRIT J CANCER, V98, P604, DOI 10.1038/sj.bjc.6604199
   Weichert W, 2008, CLIN CANCER RES, V14, P1669, DOI 10.1158/1078-0432.CCR-07-0990
   Weichert W, 2008, LANCET ONCOL, V9, P139, DOI 10.1016/S1470-2045(08)70004-4
   Weïwer M, 2013, FUTURE MED CHEM, V5, P1491, DOI 10.4155/fmc.13.141
   West AC, 2014, J CLIN INVEST, V124, P30, DOI 10.1172/JCI69738
   Witt O, 2009, CANCER LETT, V277, P8, DOI 10.1016/j.canlet.2008.08.016
   Xu WS, 2007, ONCOGENE, V26, P5541, DOI 10.1038/sj.onc.1210620
   Zhang L, 2014, CHEMMEDCHEM, V9, P638, DOI 10.1002/cmdc.201300297
   Zheng N, 2011, MOL PHARMACEUT, V8, P1611, DOI 10.1021/mp200093z
   Zhou M, 2013, BIOORG MED CHEM LETT, V23, P3200, DOI 10.1016/j.bmcl.2013.04.004
NR 74
TC 9
Z9 12
U1 1
U2 24
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 1860-7179
EI 1860-7187
J9 CHEMMEDCHEM
JI ChemMedChem
PD DEC 19
PY 2017
VL 12
IS 24
BP 2030
EP 2043
DI 10.1002/cmdc.201700449
PG 14
WC Chemistry, Medicinal; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC)
SC Pharmacology & Pharmacy
GA FQ4VM
UT WOS:000418356400005
PM 29080240
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Wang, Y
   Sun, ZS
   Szyf, M
AF Wang, Yan
   Sun, ZhongSheng
   Szyf, Moshe
TI S-adenosyl-methionine (SAM) alters the transcriptome and methylome and
   specifically blocks growth and invasiveness of liver cancer cells
SO ONCOTARGET
LA English
DT Article
DE epigenetic; S-adenosyl methionine; liver cancer; mRNA sequencing;
   capture bisulfite sequencing
ID BREAST-CANCER; EXPRESSION ANALYSIS; DNA METHYLATION; BINDING PROTEIN;
   RAS ONCOGENES; GENOME-WIDE; IN-VITRO; C-MYC; GENE; HYPOMETHYLATION
AB S-adenosyl methionine (SAM) is a ubiquitous methyl donor that was reported to have chemo-protective activity against liver cancer, however the molecular footprint of SAM is unknown. We show here that SAM selectively inhibits growth, transformation and invasiveness of hepatocellular carcinoma cell lines but not normal primary liver cells. Analysis of the transcriptome of SAM treated and untreated liver cancer cell lines HepG2 and SKhep1 and primary liver cells reveals pathways involved in cancer and metastasis that are upregulated in cancer cells and are downregulated by SAM. Analysis of the methylome using bisulfite mapping of captured promoters and enhancers reveals that SAM hyper-methylates and downregulates genes in pathways of growth and metastasis that are upregulated in liver cancer cells. Depletion of two SAM downregulated genes STMN1 and TAF15 reduces cellular transformation and invasiveness, providing evidence that SAM targets are genes important for cancer growth and invasiveness. Taken together these data provide a molecular rationale for SAM as an anticancer agent.
C1 [Wang, Yan] Chinese Acad Sci, Inst Psychol, CAS Key Lab Mental Hlth, Beijing, Peoples R China.
   [Wang, Yan; Szyf, Moshe] McGill Univ Montreal, Dept Pharmacol & Therapeut, Montreal, PQ, Canada.
   [Sun, ZhongSheng] Chinese Acad Sci, Beijing Inst Life Sci, Beijing, Peoples R China.
C3 Chinese Academy of Sciences; Institute of Psychology, CAS; Chinese
   Academy of Sciences
RP Szyf, M (通讯作者)，McGill Univ Montreal, Dept Pharmacol & Therapeut, Montreal, PQ, Canada.
EM moshe.szyf@mcgill.ca
RI Sun, Zhongsheng/AAS-4883-2020; wang, yanqun/AGZ-1821-2022
OI Sun, Zhongsheng/0000-0002-7640-5026
FU China-Canada team grant from the Canadian Institute of Health Research;
   National Science Fund of China
FX The study was supported by a China-Canada team grant from the Canadian
   Institute of Health Research and the National Science Fund of China to
   MS and ZS. Life Science Laboratories, Lakewood, NJ for the gift of SAM.
CR AIBA N, 1989, Gastroenterologia Japonica, V24, P270
   Akalin A, 2012, GENOME BIOL, V13, DOI [10.1186/gb-2012-13-10-R87, 10.1186/gb-2012-13-10-r87]
   Anders S, 2015, BIOINFORMATICS, V31, P166, DOI 10.1093/bioinformatics/btu638
   Baldassarre G, 2005, CANCER CELL, V7, P51, DOI 10.1016/j.ccr.2004.11.025
   Ballarino M, 2013, ONCOGENE, V32, P4646, DOI 10.1038/onc.2012.490
   Baylin SB, 1998, ADV CANCER RES, V72, P141
   Baylin SB, 2011, NAT REV CANCER, V11, P726, DOI 10.1038/nrc3130
   BHAVE MR, 1988, CARCINOGENESIS, V9, P343, DOI 10.1093/carcin/9.3.343
   Cajone F, 1999, CLIN EXP METASTAS, V17, P865, DOI 10.1023/A:1006778804532
   CANTONI GL, 1953, J BIOL CHEM, V204, P403
   Cheishvili D, 2015, ONCOTARGET, V6, P33253, DOI 10.18632/oncotarget.5291
   Chik F, 2011, CARCINOGENESIS, V32, P224, DOI 10.1093/carcin/bgq221
   DELARCO JE, 1978, P NATL ACAD SCI USA, V75, P4001
   FEINBERG AP, 1983, BIOCHEM BIOPH RES CO, V111, P47, DOI 10.1016/S0006-291X(83)80115-6
   GARCEA R, 1989, CARCINOGENESIS, V10, P1183, DOI 10.1093/carcin/10.7.1183
   GOLD M, 1966, J GEN PHYSIOL, V49, P5, DOI 10.1085/jgp.49.6.5
   Guo YJ, 2002, J BIOL CHEM, V277, P41571, DOI 10.1074/jbc.M201864200
   KANEKO Y, 1985, JPN J CANCER RES, V76, P1136
   KARR D, 1967, ARCH BIOCHEM BIOPHYS, V121, P732, DOI 10.1016/0003-9861(67)90061-6
   KOIZUMI K, 1980, CANCER RES, V40, P909
   Kovar Heinrich, 2011, Sarcoma, V2011, P1, DOI 10.1155/2011/837474
   Krämer A, 2014, BIOINFORMATICS, V30, P523, DOI 10.1093/bioinformatics/btt703
   Kwon T, 2003, EMBO J, V22, P292, DOI 10.1093/emboj/cdg025
   Li TWH, 2012, CARCINOGENESIS, V33, P427, DOI 10.1093/carcin/bgr295
   Malygin EG, 2012, CRIT REV BIOCHEM MOL, V47, P97, DOI 10.3109/10409238.2011.620942
   Martini A, 2002, CANCER RES, V62, P5408
   MIKOL YB, 1983, CARCINOGENESIS, V4, P1619, DOI 10.1093/carcin/4.12.1619
   Morohoshi F, 1996, GENOMICS, V38, P51, DOI 10.1006/geno.1996.0591
   Munzel P, 1989, Arch Toxicol Suppl, V13, P211
   NAMBU S, 1987, JPN J CANCER RES, V78, P695
   Pakneshan P, 2004, J BIOL CHEM, V279, P31735, DOI 10.1074/jbc.M401669200
   PASCALE RM, 1995, CARCINOGENESIS, V16, P427, DOI 10.1093/carcin/16.2.427
   Pascale RM, 2002, ALCOHOL, V27, P193, DOI 10.1016/S0741-8329(02)00227-6
   Pereira I, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088180
   Purohit V, 2002, ALCOHOL, V27, P151, DOI 10.1016/S0741-8329(02)00232-X
   Quinlan AR, 2010, BIOINFORMATICS, V26, P841, DOI 10.1093/bioinformatics/btq033
   Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616
   SCHLENK F, 1957, J BIOL CHEM, V229, P1037
   Sherbet GV, 1998, ANTICANCER RES, V18, P2415
   SHINOZUKA H, 1978, JNCI-J NATL CANCER I, V61, P813
   SHINOZUKA H, 1979, CANCER RES, V39, P2515
   Shteper PJ, 2003, ONCOGENE, V22, P7737, DOI 10.1038/sj.onc.1207056
   Shukeir N, 2006, CANCER RES, V66, P9202, DOI 10.1158/0008-5472.CAN-06-1954
   Shukeir N, 2015, BRIT J PHARMACOL, V172, P2769, DOI 10.1111/bph.13102
   Stefanska B, 2014, CLIN CANCER RES, V20, P3118, DOI 10.1158/1078-0432.CCR-13-0283
   Stefanska B, 2011, CANCER RES, V71, P5891, DOI 10.1158/0008-5472.CAN-10-3823
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Teng Y, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.24
   Trapnell C, 2012, NAT PROTOC, V7, P562, DOI 10.1038/nprot.2012.016
   Trapnell C, 2010, NAT BIOTECHNOL, V28, P511, DOI 10.1038/nbt.1621
   Trievel RC, 2002, CELL, V111, P91, DOI 10.1016/S0092-8674(02)01000-0
   VORCE R L, 1989, Molecular Toxicology, V2, P99
   VORCE RL, 1989, TOXICOL APPL PHARM, V100, P398, DOI 10.1016/0041-008X(89)90288-3
   Wang J, 2015, MOL MED REP, V11, P3585, DOI 10.3892/mmr.2015.3164
   Wickham H, 2009, USE R, P1, DOI 10.1007/978-0-387-98141-3
   Yang HP, 2004, HEPATOLOGY, V40, P221, DOI 10.1002/hep.20274
   Yu GC, 2015, BIOINFORMATICS, V31, P2382, DOI 10.1093/bioinformatics/btv145
   Zhao Ye, 2010, Chin J Cancer, V29, P752
   Zheng P, 2010, J PROTEOME RES, V9, P4897, DOI 10.1021/pr100712t
NR 59
TC 38
Z9 42
U1 3
U2 8
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD DEC 19
PY 2017
VL 8
IS 67
BP 111866
EP 111881
DI 10.18632/oncotarget.22942
PG 16
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA FS1VO
UT WOS:000419567000090
PM 29340097
OA Green Submitted, Green Published, gold
DA 2025-01-12
ER

PT J
AU Park, JL
   Lee, YS
   Song, MJ
   Hong, SH
   Ahn, JH
   Seo, EH
   Shin, SP
   Lee, SJ
   Johnson, BH
   Stampfer, MR
   Kim, HP
   Kim, SY
   Lee, YS
AF Park, J-L
   Lee, Y-S
   Song, M-J
   Hong, S-H
   Ahn, J-H
   Seo, E-H
   Shin, S-P
   Lee, S-J
   Johnson, B. H.
   Stampfer, M. R.
   Kim, H-P
   Kim, S-Y
   Lee, Y. S.
TI Epigenetic regulation of RNA polymerase III transcription in early
   breast tumorigenesis
SO ONCOGENE
LA English
DT Article
ID MAMMARY EPITHELIAL-CELLS; DNA METHYLATION; NONCODING RNA; C-MYC; GENOMIC
   BINDING; P53 FUNCTION; POL II; CANCER; ACTIVATION; CHROMATIN
AB RNA polymerase III (Pol III) transcribes medium-sized non-coding RNAs (collectively termed Pol III genes). Emerging diverse roles of Pol III genes suggest that individual Pol III genes are exquisitely regulated by transcription and epigenetic factors. Here we report global Pol III expression/methylation profiles and molecular mechanisms of Pol III regulation that have not been as extensively studied, using nc886 as a representative Pol III gene. In a human mammary epithelial cell system that recapitulates early breast tumorigenesis, the fraction of actively transcribed Pol III genes increases reaching a plateau during immortalization. Hyper-methylation of Pol III genes inhibits Pol III binding to DNA via inducing repressed chromatin and is a determinant for the Pol III repertoire. When Pol III genes are hypo-methylated, MYC amplifies their transcription, regardless of its recognition DNA motif. Thus, Pol III expression during tumorigenesis is delineated by methylation and magnified by MYC.
C1 [Park, J-L; Seo, E-H; Kim, S-Y] KRIBB, Personalized Genom Med Res Ctr, Daejeon, South Korea.
   [Park, J-L; Seo, E-H; Kim, S-Y] Univ Sci & Technol, Dept Funct Genom, Daejeon, South Korea.
   [Lee, Y-S; Hong, S-H] Natl Canc Ctr, Res Inst, Rare Canc Branch, Goyang Si, South Korea.
   [Song, M-J; Kim, H-P] Yonsei Univ, Dept Environm Med Biol, Coll Med, Seoul, South Korea.
   [Ahn, J-H] Kyung Hee Univ, Dept Life & Nanopharmaceut Sci, Seoul, South Korea.
   [Ahn, J-H] Kyung Hee Univ, Dept Oriental Pharm, Seoul, South Korea.
   [Shin, S-P; Lee, S-J] Natl Canc Ctr, Res Inst, Immunotherapeut Branch, Goyang Si, South Korea.
   [Johnson, B. H.; Lee, Y. S.] Univ Texas Med Branch, Dept Biochem & Mol Biol, Galveston, TX 77555 USA.
   [Stampfer, M. R.] Lawrence Berkeley Natl Lab, Biol Syst & Engn Div, Berkeley, CA USA.
   [Kim, H-P] Yonsei Univ, Inst Trop Med, Coll Med, Seoul, South Korea.
   [Kim, H-P] Yonsei Univ, Brain Korea Plus Project Med Sci 21, Coll Med, Seoul, South Korea.
   [Lee, Y. S.] Natl Canc Ctr, Grad Sch Canc Sci & Policy, Dept Canc Biomed Sci, 323 Ilsan Ro, Goyang 10408, South Korea.
C3 Korea Research Institute of Bioscience & Biotechnology (KRIBB);
   University of Science & Technology (UST); National Cancer Center - Korea
   (NCC); Yonsei University; Yonsei University Health System; Kyung Hee
   University; Kyung Hee University; National Cancer Center - Korea (NCC);
   University of Texas System; University of Texas Medical Branch
   Galveston; United States Department of Energy (DOE); Lawrence Berkeley
   National Laboratory; Yonsei University; Yonsei University Health System;
   Yonsei University; Yonsei University Health System; National Cancer
   Center - Korea (NCC)
RP Kim, HP; Kim, SY; Lee, YS (通讯作者)，Natl Canc Ctr, Grad Sch Canc Sci & Policy, Dept Canc Biomed Sci, 323 Ilsan Ro, Goyang 10408, South Korea.
EM kimhp@yuhs.ac; kimsy@kribb.re.kr; yslee@ncc.re.kr
RI Lee, Ju-Seog/X-1786-2018; Lee, sujeong/KUD-4735-2024; Lee,
   YoungMi/JCF-0461-2023; Park, Jun Won/KSM-8932-2024; Kim,
   Dong-Hyun/AAH-3043-2020; Shin, Seung-Phil/JMP-3198-2023
OI Shin, Seung-Phil/0000-0003-4290-3067; Kim,
   Hyoung-Pyo/0000-0003-1441-8822
FU American Cancer Society [RSG-12-187-01-RMC]; Ministry of Science, ICT
   and Future Planning [NRF-2012M3A9D1054670, NRF-2014M3C9A3068554]; KRIBB
   Research Initiative; National Research Foundation of Korea
   [2016R1A2B4014183, 2017M3C9A5029978]; National Cancer Center (Korea)
   [1610090]; US Department of Energy [DE-AC02-05CH11231]
FX This work was supported by a Research Scholar Grant, RSG-12-187-01-RMC
   from the American Cancer Society to YSL; grants NRF-2012M3A9D1054670 and
   NRF-2014M3C9A3068554 funded by the Ministry of Science, ICT and Future
   Planning and KRIBB Research Initiative to S-YK; a grant 2016R1A2B4014183
   and 2017M3C9A5029978 funded by National Research Foundation of Korea to
   H-PK; National Cancer Center (Korea) intramural project # 1610090 to
   Y-SL; and US Department of Energy under Contract No. DE-AC02-05CH11231
   to MRS.
CR Alla RK, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085648
   Banati F, 2008, FEBS LETT, V582, P705, DOI 10.1016/j.febslet.2008.01.042
   Barski A, 2010, NAT STRUCT MOL BIOL, V17, P629, DOI 10.1038/nsmb.1806
   Bartke T, 2010, CELL, V143, P470, DOI 10.1016/j.cell.2010.10.012
   BESSER D, 1990, FEBS LETT, V269, P358, DOI 10.1016/0014-5793(90)81193-R
   Bhargava P, 2013, BBA-GENE REGUL MECH, V1829, P1015, DOI 10.1016/j.bbagrm.2013.05.005
   Canella D, 2012, GENOME RES, V22, P666, DOI 10.1101/gr.130286.111
   Canella D, 2010, GENOME RES, V20, P710, DOI 10.1101/gr.101337.109
   Cao JZ, 2013, CANCER RES, V73, P3326, DOI 10.1158/0008-5472.CAN-12-3055
   Carrière L, 2012, NUCLEIC ACIDS RES, V40, P270, DOI 10.1093/nar/gkr737
   Chen W, 1997, J PATHOL, V183, P345, DOI 10.1002/(SICI)1096-9896(199711)183:3<345::AID-PATH930>3.0.CO;2-8
   Chen W, 1997, EUR J CANCER, V33, P288, DOI 10.1016/S0959-8049(96)00453-4
   Dang CV, 2012, CELL, V149, P22, DOI 10.1016/j.cell.2012.03.003
   Deaton AM, 2011, GENE DEV, V25, P1010, DOI 10.1101/gad.2037511
   Ehrlich M, 2002, ONCOGENE, V21, P5400, DOI 10.1038/sj.onc.1205651
   Felton-Edkins ZA, 2002, J BIOL CHEM, V277, P48182, DOI 10.1074/jbc.M201333200
   Felton-Edkins ZA, 2003, CELL CYCLE, V2, P181, DOI 10.4161/cc.2.3.375
   Fu Yu, 2015, Genomics & Informatics, V13, P94
   Fuks F, 2005, CURR OPIN GENET DEV, V15, P490, DOI 10.1016/j.gde.2005.08.002
   Garbe JC, 2007, CELL CYCLE, V6, P1927, DOI 10.4161/cc.6.15.4519
   Garbe JC, 2014, CELL CYCLE, V13, P3423, DOI 10.4161/15384101.2014.954456
   Garbe JC, 2009, CANCER RES, V69, P7557, DOI 10.1158/0008-5472.CAN-09-0270
   Gomez-Roman N, 2003, NATURE, V421, P290, DOI 10.1038/nature01327
   Guccione E, 2006, NAT CELL BIOL, V8, P764, DOI 10.1038/ncb1434
   Heinz S, 2010, MOL CELL, V38, P576, DOI 10.1016/j.molcel.2010.05.004
   Hines WC, 2016, BREAST CANCER RES TR, V155, P37, DOI 10.1007/s10549-015-3649-z
   Hu SS, 2012, INT J BIOCHEM CELL B, V44, P1847, DOI 10.1016/j.biocel.2012.07.013
   JUTTERMANN R, 1991, J VIROL, V65, P1735
   Kadauke S, 2009, BBA-GENE REGUL MECH, V1789, P17, DOI 10.1016/j.bbagrm.2008.07.002
   Kenneth NS, 2007, P NATL ACAD SCI USA, V104, P14917, DOI 10.1073/pnas.0702909104
   Klose RJ, 2006, TRENDS BIOCHEM SCI, V31, P89, DOI 10.1016/j.tibs.2005.12.008
   LaBarge MA, 2013, JOVE-J VIS EXP, DOI 10.3791/50011
   Lee EK, 2016, ONCOTARGET, V7, P75000, DOI 10.18632/oncotarget.11852
   Lee HS, 2014, ONCOTARGET, V5, P3472, DOI 10.18632/oncotarget.1927
   Lee JK, 2015, FRONT CELL DEV BIOL, V3, DOI 10.3389/fcell.2015.00013
   Lee K, 2011, RNA, V17, P1076, DOI 10.1261/rna.2701111
   Lee KS, 2014, ONCOTARGET, V5, P3944, DOI 10.18632/oncotarget.2047
   Li H, 2009, BIOINFORMATICS, V25, P2078, DOI 10.1093/bioinformatics/btp352
   Lin CY, 2012, CELL, V151, P56, DOI 10.1016/j.cell.2012.08.026
   LIU WM, 1994, NUCLEIC ACIDS RES, V22, P1087, DOI 10.1093/nar/22.6.1087
   LIU WM, 1993, NUCLEIC ACIDS RES, V21, P1351, DOI 10.1093/nar/21.6.1351
   Messeguer X, 2002, BIOINFORMATICS, V18, P333, DOI 10.1093/bioinformatics/18.2.333
   Moqtaderi Z, 2010, NAT STRUCT MOL BIOL, V17, P635, DOI 10.1038/nsmb.1794
   Novak P, 2009, CANCER RES, V69, P5251, DOI 10.1158/0008-5472.CAN-08-4977
   Oler AJ, 2010, NAT STRUCT MOL BIOL, V17, P620, DOI 10.1038/nsmb.1801
   Ong CT, 2014, NAT REV GENET, V15, P234, DOI 10.1038/nrg3663
   Park JL, 2017, EPIGENOMICS-UK, V9, P171, DOI 10.2217/epi-2016-0108
   Park K, 2012, J LEUKOCYTE BIOL, V91, P245, DOI 10.1189/jlb.0111020
   Romanelli V, 2014, EPIGENETICS-US, V9, P783, DOI 10.4161/epi.28323
   Schramm L, 2002, GENE DEV, V16, P2593, DOI 10.1101/gad.1018902
   Selvakumar T, 2012, J BIOL CHEM, V287, P7039, DOI 10.1074/jbc.M111.285601
   Silver MJ, 2015, GENOME BIOL, V16, DOI 10.1186/s13059-015-0660-y
   Stampfer M.R., 2013, Cell and Molecular Biology of Breast Cancer, P323
   Stampfer MR, 2003, ONCOGENE, V22, P5238, DOI 10.1038/sj.onc.1206667
   Treppendahl MB, 2012, BLOOD, V119, P206, DOI 10.1182/blood-2011-06-362541
   Varshney D, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7569
   White RJ, 2004, ONCOGENE, V23, P3208, DOI 10.1038/sj.onc.1207547
   Winter AG, 2000, P NATL ACAD SCI USA, V97, P12619, DOI 10.1073/pnas.230224097
   Xie HH, 2010, P NATL ACAD SCI USA, V107, P6952, DOI 10.1073/pnas.0913836107
NR 60
TC 29
Z9 31
U1 0
U2 7
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-9232
EI 1476-5594
J9 ONCOGENE
JI Oncogene
PD DEC 7
PY 2017
VL 36
IS 49
BP 6793
EP 6804
DI 10.1038/onc.2017.285
PG 12
WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
GA FP0IK
UT WOS:000417282500005
PM 28846112
DA 2025-01-12
ER

PT J
AU Hagelgans, A
   Jandeck, C
   Friedemann, M
   Donchin, A
   Richter, S
   Menschikowski, M
AF Hagelgans, Albert
   Jandeck, Carsten
   Friedemann, Markus
   Donchin, Anastasia
   Richter, Susan
   Menschikowski, Mario
TI Identification of CpG Sites of <i>SERPINA5</i> Promoter with Opposite
   Methylation Patterns in Benign and Malignant Prostate Cells
SO ANTICANCER RESEARCH
LA English
DT Article
DE SERPINA5; protein C inhibitor; DNA methylation; prostate cancer cells;
   benign prostatic hyperplasia
ID PROTEIN-C INHIBITOR; DNA METHYLATION; GENE-EXPRESSION; BREAST-CANCER;
   BIOMARKERS; CARCINOMA; MIGRATION; MECHANISMS; REGULATORS; INVASION
AB Background/Aim: To date there has been no investigation into the epigenetic regulation of the serine protease inhibitor SERPINA5 in prostate cancer, where lack of this gene was considered to facilitate invasive growth patterns. Materials and Methods: Methylation degrees of eight CpG sites of SERPINA5 were analyzed in normal and malignant prostate cells using nucleotide sequencing, methylation-specific high resolution melting and digital droplet PCR techniques. Results: The methylation degree of five CpG sites significantly correlated with lower SERPINA5 expression levels. In contrast, two CpG sites (at -19 bp and -14 bp from the transcription start site) were hypermethylated in normal epithelial prostate cells, benign hyperplasic cells and low-invasive malignant LNCaP cells, whereas in aggressive DU-145 and PC-3 cell lines, these sites were essentially unmethylated. Conclusion: Novel methylation patterns of two distinct CpG sites of the SERPINA5 promoter may be useful for differentiating benign from malignant prostate disease.
C1 [Hagelgans, Albert; Jandeck, Carsten; Friedemann, Markus; Donchin, Anastasia; Richter, Susan; Menschikowski, Mario] Med Fac Carl Gustav Carus, Inst Clin Chem & Lab Med, Fetscherstr 74, D-01307 Dresden, Germany.
C3 Technische Universitat Dresden; Carl Gustav Carus University Hospital
RP Menschikowski, M (通讯作者)，Med Fac Carl Gustav Carus, Inst Clin Chem & Lab Med, Fetscherstr 74, D-01307 Dresden, Germany.
EM Mario.Menschikowski@uniklinikum-dresden.de
RI Richter, Susan/AAP-1767-2020
CR Asanuma K, 2007, INT J CANCER, V121, P955, DOI 10.1002/ijc.22773
   Bibikova M, 2011, GENOMICS, V98, P288, DOI 10.1016/j.ygeno.2011.07.007
   Bijsmans ITGW, 2011, MODERN PATHOL, V24, P463, DOI 10.1038/modpathol.2010.214
   Cao Y, 2003, PROSTATE, V57, P196, DOI 10.1002/pros.10296
   Castelló R, 2007, THROMB RES, V120, P753, DOI 10.1016/j.thromres.2006.12.016
   Conway K, 2014, BREAST CANCER RES, V16, DOI 10.1186/s13058-014-0450-6
   Elisen MGLM, 1998, BLOOD, V91, P1542, DOI 10.1182/blood.V91.5.1542.1542_1542_1547
   ESPANA F, 1991, THROMB RES, V64, P309, DOI 10.1016/0049-3848(91)90002-E
   Farré D, 2003, NUCLEIC ACIDS RES, V31, P3651, DOI 10.1093/nar/gkg605
   Fortenberry YM, 2010, BBA-GEN SUBJECTS, V1800, P580, DOI 10.1016/j.bbagen.2010.03.003
   FRANCIS RB, 1984, THROMB HAEMOSTASIS, V52, P71
   Glasscock LN, 2005, EXP MOL PATHOL, V79, P23, DOI 10.1016/j.yexmp.2005.02.008
   Gopalan S, 2005, J NEUROCHEM, V94, P763, DOI 10.1111/j.1471-4159.2005.03204.x
   Gregg JL, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-165
   Heichman KA, 2012, CLIN CHEM LAB MED, V50, P1707, DOI 10.1515/cclm-2011-0935
   Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075
   Huang WY, 2015, NUCLEIC ACIDS RES, V43, pD856, DOI 10.1093/nar/gku1151
   Jing Y, 2014, MOL ONCOL, V8, P366, DOI 10.1016/j.molonc.2013.12.003
   Kristjansdottir Bjorg, 2012, Clin Proteomics, V9, P14, DOI 10.1186/1559-0275-9-14
   Lee EK, 2013, ANTICANCER RES, V33, P4833
   Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427
   Menschikowski M, 2008, NEOPLASIA, V10, P279, DOI 10.1593/neo.07965
   Schwab TS, 2000, PROSTATE, V44, P164
   Sieben NLG, 2005, J CLIN ONCOL, V23, P7257, DOI 10.1200/JCO.2005.02.2541
   Sil H, 2011, ONCOL RES, V19, P335, DOI 10.3727/096504011X13079697132925
   Silverman GA, 2001, J BIOL CHEM, V276, P33293, DOI 10.1074/jbc.R100016200
   Suzuki K, 2008, J THROMB HAEMOST, V6, P2017, DOI 10.1111/j.1538-7836.2008.03181.x
   Toiyarna Y, 2014, BIOCHEM BIOPH RES CO, V455, P43, DOI 10.1016/j.bbrc.2014.08.001
   Wakita T, 2004, INT J CANCER, V108, P516, DOI 10.1002/ijc.11594
   Willard SS, 2012, AM J CANCER RES, V2, P620
   Yang HJ, 2017, SEMIN CELL DEV BIOL, V62, P187, DOI 10.1016/j.semcdb.2016.10.007
NR 31
TC 5
Z9 6
U1 1
U2 3
PU INT INST ANTICANCER RESEARCH
PI ATHENS
PA EDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22,
   ATHENS 19014, GREECE
SN 0250-7005
EI 1791-7530
J9 ANTICANCER RES
JI Anticancer Res.
PD DEC
PY 2017
VL 37
IS 12
BP 6609
EP 6618
DI 10.21873/anticanres.12118
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA FO7AJ
UT WOS:000417022100013
PM 29187436
OA Bronze
DA 2025-01-12
ER

PT J
AU Kidder, BL
   He, RS
   Wangsa, D
   Padilla-Nash, HM
   Bernardo, MM
   Sheng, SJ
   Ried, T
   Zhao, KJ
AF Kidder, Benjamin L.
   He, Runsheng
   Wangsa, Darawalee
   Padilla-Nash, Hesed M.
   Bernardo, M. Margarida
   Sheng, Shijie
   Ried, Thomas
   Zhao, Keji
TI SMYD5 Controls Heterochromatin and Chromosome Integrity during Embryonic
   Stem Cell Differentiation
SO CANCER RESEARCH
LA English
DT Article
ID INDICATES POOR-PROGNOSIS; COLORECTAL-CANCER; GENOME INTEGRITY;
   GENE-EXPRESSION; BREAST-CANCER; HISTONE H4; OVEREXPRESSION;
   TRIMETHYLATION; METHYLATION; BIOMARKER
AB Epigenetic regulation of chromatin states is thought to control gene expression programs during lineage specification. However, the roles of repressive histone modifications, such as trimethylated histone lysine 20 (H4K20me3), in development and genome stability are largely unknown. Here, we show that depletion of SET and MYND domain-containing protein 5 (SMYD5), which mediates H4K20me3, leads to genome-wide decreases in H4K20me3 and H3K9me3 levels and derepression of endogenous LTR- and LINE-repetitive DNA elements during differentiation of mouse embryonic stem cells. SMYD5 depletion resulted in chromosomal aberrations and the formation of transformed cells that exhibited decreased H4K20me3 and H3K9me3 levels and an expression signature consistent with multiple human cancers. Moreover, dysregulated gene expression in SMYD5 cancer cells was associated with LTR and endogenous retrovirus elements and decreased H4K20me3. In addition, depletion of SMYD5 in human colon and lung cancer cells results in increased tumor growth and upregulation of genes overexpressed in colon and lung cancers, respectively. These findings implicate an important role for SMYD5 in maintaining chromosome integrity by regulating heterochromatin and repressing endogenous repetitive DNA elements during differentiation. (C) 2017 AACR.
C1 [Kidder, Benjamin L.; He, Runsheng] Wayne State Univ, Dept Oncol, Detroit, MI 48201 USA.
   [Kidder, Benjamin L.; He, Runsheng; Bernardo, M. Margarida; Sheng, Shijie] Wayne State Univ, Sch Med, Barbara Ann Karmanos Canc Inst, Detroit, MI 48201 USA.
   [Wangsa, Darawalee; Padilla-Nash, Hesed M.; Ried, Thomas] NCI, Canc Genom Sect, NIH, Bethesda, MD 20892 USA.
   [Bernardo, M. Margarida; Sheng, Shijie] Wayne State Univ, Sch Med, Dept Pathol, Detroit, MI 48201 USA.
   [Zhao, Keji] NHLBI, Syst Biol Ctr, NIH, Bldg 10, Bethesda, MD 20892 USA.
C3 Wayne State University; Barbara Ann Karmanos Cancer Institute; Wayne
   State University; National Institutes of Health (NIH) - USA; NIH
   National Cancer Institute (NCI); Wayne State University; National
   Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood
   Institute (NHLBI)
RP Kidder, BL (通讯作者)，Wayne State Univ, Sch Med, 4100 John R St,HWCRC Bldg,Room 624, Detroit, MI 48201 USA.; Zhao, KJ (通讯作者)，NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.
EM benjamin.kidder@wayne.edu; zhaok@nhlbi.nih.gov
RI Kidder, Benjamin/C-6489-2008
FU Wayne State University; Karmanos Cancer Institute; Division of
   Intramural Research of the National Heart, Lung and Blood Institute;
   National Heart, Lung and Blood Institute [1K22HL126842-01A1]
FX This work was supported by Wayne State University, Karmanos Cancer
   Institute, the Division of Intramural Research of the National Heart,
   Lung and Blood Institute, and a grant from the National Heart, Lung and
   Blood Institute (1K22HL126842-01A1) awarded to B.L. Kidder.
CR Alazzouzi H, 2005, CLIN CANCER RES, V11, P2606, DOI 10.1158/1078-0432.CCR-04-1458
   Avner P, 2001, NAT REV GENET, V2, P59, DOI 10.1038/35047580
   Basset P, 1997, MATRIX BIOL, V15, P535, DOI 10.1016/S0945-053X(97)90028-7
   Beck DB, 2012, GENE DEV, V26, P325, DOI 10.1101/gad.177444.111
   Beer DG, 2002, NAT MED, V8, P816, DOI 10.1038/nm733
   Beers J, 2012, NAT PROTOC, V7, P2029, DOI 10.1038/nprot.2012.130
   Bhattacharjee A, 2001, P NATL ACAD SCI USA, V98, P13790, DOI 10.1073/pnas.191502998
   Botuyan MV, 2006, CELL, V127, P1361, DOI 10.1016/j.cell.2006.10.043
   Chellappa K, 2012, BIOMARK MED, V6, P297, DOI [10.2217/BMM.12.23, 10.2217/bmm.12.23]
   Dai Q, 2004, CANCER EPIDEM BIOMAR, V13, P2065
   Dalerba P, 2016, NEW ENGL J MED, V374, P211, DOI 10.1056/NEJMoa1506597
   Ding K, 2014, MED HYPOTHESES, V83, P359, DOI 10.1016/j.mehy.2014.06.013
   Feinberg AP, 2016, NAT REV GENET, V17, P284, DOI 10.1038/nrg.2016.13
   Forer L, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-318
   Fraga MF, 2005, NAT GENET, V37, P391, DOI 10.1038/ng1531
   Friedl P, 2008, CANCER RES, V68, P7247, DOI 10.1158/0008-5472.CAN-08-0784
   Gautschi O, 2007, LUNG CANCER, V55, P1, DOI 10.1016/j.lungcan.2006.09.024
   Girirajan S, 2011, ANNU REV GENET, V45, P203, DOI 10.1146/annurev-genet-102209-163544
   Grewal SIS, 2002, CURR OPIN GENET DEV, V12, P178, DOI 10.1016/S0959-437X(02)00284-8
   Grewal SIS, 2003, SCIENCE, V301, P798, DOI 10.1126/science.1086887
   Guarente L, 2000, GENE DEV, V14, P1021
   Guo MZ, 2017, EMBO MOL MED, V9, P462, DOI 10.15252/emmm.201606711
   Hedges DJ, 2007, MUTAT RES-FUND MOL M, V616, P46, DOI 10.1016/j.mrfmmm.2006.11.021
   Hernandez-Barrantes S, 2002, SEMIN CANCER BIOL, V12, P131, DOI 10.1006/scbi.2001.0421
   HORWITZ KB, 1978, J BIOL CHEM, V253, P2223
   Huang K, 2014, CHINESE J CANCER RES, V26, P72, DOI 10.3978/j.issn.1000-9604.2014.01.11
   Jorgensen S, 2013, NUCLEIC ACIDS RES, V41, P2797, DOI 10.1093/nar/gkt012
   Karachentsev D, 2005, GENE DEV, V19, P431, DOI 10.1101/gad.1263005
   Kidder BL, 2017, EPIGENET CHROMATIN, V10, DOI 10.1186/s13072-017-0115-7
   Kidder BL, 2013, MOL CELL BIOL, V33, P4793, DOI 10.1128/MCB.00692-13
   Konkel MK, 2010, SEMIN CANCER BIOL, V20, P211, DOI 10.1016/j.semcancer.2010.03.001
   Lin YC, 2014, J CELL SCI, V127, P85, DOI 10.1242/jcs.132779
   Liyanage M, 1996, NAT GENET, V14, P312, DOI 10.1038/ng1196-312
   Matsui T, 2010, NATURE, V464, P927, DOI 10.1038/nature08858
   McLean CY, 2010, NAT BIOTECHNOL, V28, P495, DOI 10.1038/nbt.1630
   Mortazavi A, 2008, NAT METHODS, V5, P621, DOI 10.1038/nmeth.1226
   Padilla-Nash HM, 2012, GENE CHROMOSOME CANC, V51, P353, DOI 10.1002/gcc.21921
   Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2
   Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616
   Rudin CM, 2012, NAT GENET, V44, P1111, DOI 10.1038/ng.2405
   Schotta G, 2004, GENE DEV, V18, P1251, DOI 10.1101/gad.300704
   Schotta G, 2008, GENE DEV, V22, P2048, DOI 10.1101/gad.476008
   Seidel D, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006802
   Shepelev MV, 2013, CANCER GENET-NY, V206, P393, DOI 10.1016/j.cancergen.2013.10.006
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Tan FB, 2015, J EXP CLIN CANC RES, V34, DOI 10.1186/s13046-015-0237-3
   Van Den Broeck A, 2008, CLIN CANCER RES, V14, P7237, DOI 10.1158/1078-0432.CCR-08-0869
   Vermeulen M, 2010, CELL, V142, P967, DOI 10.1016/j.cell.2010.08.020
   Woodford-Richens KL, 2001, P NATL ACAD SCI USA, V98, P9719, DOI 10.1073/pnas.171321498
   Xie C, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-80
   Yokoyama Y, 2014, BREAST CANCER RES, V16, DOI 10.1186/bcr3681
   Zang CZ, 2009, BIOINFORMATICS, V25, P1952, DOI 10.1093/bioinformatics/btp340
   Zhang Z, 2014, NEOPLASMA, V61, P476, DOI 10.4149/neo_2014_059
   Zhao GY, 2015, TUMOR BIOL, V36, P1721, DOI 10.1007/s13277-014-2773-4
NR 54
TC 25
Z9 32
U1 1
U2 10
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD DEC 1
PY 2017
VL 77
IS 23
BP 6729
EP 6745
DI 10.1158/0008-5472.CAN-17-0828
PG 17
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA FO4YD
UT WOS:000416854100022
PM 28951459
OA Bronze, Green Accepted
DA 2025-01-12
ER

PT J
AU Cimino, L
   Salemi, M
   Cannarella, R
   Condorelli, RA
   Giurato, G
   Marchese, G
   La Vignera, S
   Calogero, AE
AF Cimino, Laura
   Salemi, Michele
   Cannarella, Rossella
   Condorelli, Rosita A.
   Giurato, Giorgio
   Marchese, Giovanna
   La Vignera, Sandro
   Calogero, Aldo E.
TI Decreased miRNA expression in Klinefelter syndrome
SO SCIENTIFIC REPORTS
LA English
DT Article
ID METABOLIC SYNDROME; MICRORNAS; DIFFERENTIATION; PREVALENCE; GROWTH; RNAS
AB The widelyvariable phenotypic spectrum and the different severity of symptoms in men with Klinefelter syndrome (KS) suggest a role for epigenetic mediators. Therefore, the aim of this study is to evaluate the possible involvement of miRNAs in the clinical manifestations of KS. To accomplish this, we performed a transcriptome analysis in peripheral blood mononuclear cells (PBMCs) of 10 non-mosaic KS patients, 10 aged-matched healthy men and 10 aged-matched healthy female controls with normal karyotype. After RNA extraction from PBMC and the preparation of RNA libraries, the samples were sequenced using next generation high-throughput sequencing technology. Expression profiling analysis revealed a significant differential expression of 2 miRNAs in KS compared to male controls. In particular, MIR3648 resulted significantly (q-value < 0.0001) down-regulated by -19.084-fold, while MIR3687was strongly down-regulated (q-value < 0.0001) considering KS patients. These results were confirmed by qRT-PCR. The functional analysis of the two transcripts showed that they seem to play a role in breast cancer, hemopoietic abnormalities, immune defects and adipocyte differentiation and fat cell maturation. Therefore, we speculate that both miRNAs may play a role in the immune and metabolic disorders and in the risk of breast cancer development in men with KS.
C1 [Cimino, Laura; Cannarella, Rossella; Condorelli, Rosita A.; La Vignera, Sandro; Calogero, Aldo E.] Univ Catania, Dept Clin & Expt Med, I-95123 Catania, Italy.
   [Salemi, Michele] Oasi Inst Res Mental Retardat & Brain Aging IRCCS, I-94018 Troina, Italy.
   [Giurato, Giorgio] Univ Salerno, Dept Med Surg & Dent Schola Med Salernitana, Lab Mol Med & Genom, I-84081 Baronissi, Italy.
   [Giurato, Giorgio; Marchese, Giovanna] Univ Salerno, Srl Genomix4Life, Dept Med Surg & Dent Schola Med Salernitana, I-84081 Baronissi, SA, Italy.
C3 University of Catania; IRCCS Oasi Maria SS; University of Salerno;
   University of Salerno
RP Calogero, AE (通讯作者)，Univ Catania, Dept Clin & Expt Med, I-95123 Catania, Italy.
EM acaloger@unict.it
RI La Vignera, Sandro/AAR-1589-2020; Calogero, Aldo/AAA-9538-2021;
   Cannarella, Rossella/AAB-6486-2021; Salemi, Michele/AAF-8399-2019;
   Giurato, Giorgio/K-3859-2018
OI Cannarella, Rossella/0000-0003-4599-8487; Marchese,
   Giovanna/0000-0002-9594-0729; Condorelli, Rosita
   Angela/0000-0002-5217-9343; Salemi, Michele/0000-0003-1075-8993; La
   Vignera, Sandro/0000-0002-7113-2372; Giurato,
   Giorgio/0000-0002-0538-8978
CR Adams BD, 2014, CURR BIOL, V24, pR762, DOI 10.1016/j.cub.2014.06.043
   Aksglæde L, 2006, HUM REPROD UPDATE, V12, P39, DOI 10.1093/humupd/dmi039
   Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871
   Anders S, 2015, BIOINFORMATICS, V31, P166, DOI 10.1093/bioinformatics/btu638
   Bardsley MZ, 2011, ACTA PAEDIATR, V100, P866, DOI 10.1111/j.1651-2227.2011.02161.x
   Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002
   Bojesen A, 2003, J CLIN ENDOCR METAB, V88, P622, DOI 10.1210/jc.2002-021491
   Bojesen A, 2006, DIABETES CARE, V29, P1591, DOI 10.2337/dc06-0145
   Condorelli G, 2014, J AM COLL CARDIOL, V63, P2177, DOI 10.1016/j.jacc.2014.01.050
   Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635
   Emmadi R, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0145346
   Fonseca I, 2015, GENE CHROMOSOME CANC, V54, P249, DOI 10.1002/gcc.22238
   Fujita K, 2016, INT J MOL MED, V38, P1135, DOI 10.3892/ijmm.2016.2729
   Groth KA, 2013, J CLIN ENDOCR METAB, V98, P20, DOI 10.1210/jc.2012-2382
   HASLE H, 1995, BRIT J CANCER, V71, P416, DOI 10.1038/bjc.1995.85
   Hayashi K, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001738
   Herlihy AS, 2011, MED J AUSTRALIA, V194, P24, DOI 10.5694/j.1326-5377.2011.tb04141.x
   Huang L, 2013, PLACENTA, V34, P624, DOI 10.1016/j.placenta.2013.04.009
   Huszar JM, 2013, BIOL REPROD, V88, DOI 10.1095/biolreprod.112.103747
   Lahlou N, 2011, ACTA PAEDIATR, V100, P824, DOI 10.1111/j.1651-2227.2011.02280.x
   LOVE MI, 2014, GENOME BIOL, V15, DOI DOI 10.1186/S13059-014-0550-8
   Maatouk DM, 2008, BIOL REPROD, V79, P696, DOI 10.1095/biolreprod.108.067827
   MacDonald G, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2004870
   Maiburg M, 2012, FERTIL STERIL, V98, P253, DOI 10.1016/j.fertnstert.2012.06.019
   Marco Antonio, 2012, Silence, V3, P8, DOI 10.1186/1758-907X-3-8
   Martin M., 2011, EMBnet.journal, V17, P10, DOI DOI 10.14806/EJ.17.1.200
   Meiri E, 2010, NUCLEIC ACIDS RES, V38, P6234, DOI 10.1093/nar/gkq376
   Pessia E, 2012, P NATL ACAD SCI USA, V109, P5346, DOI 10.1073/pnas.1116763109
   Settle S, 2001, DEV BIOL, V234, P138, DOI 10.1006/dbio.2001.0244
   Siew WH, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00041
   Szulwach KE, 2009, CLIN GENET, V75, P209, DOI 10.1111/j.1399-0004.2008.01134.x
   Trapnell C, 2010, NAT BIOTECHNOL, V28, P511, DOI 10.1038/nbt.1621
   van den Bergh JPW, 2001, OSTEOPOROSIS INT, V12, P55, DOI 10.1007/s001980170158
   Villegas R, 2014, ANN HUM GENET, V78, P23, DOI 10.1111/ahg.12044
   Xu Y, 2013, INT J MOL MED, V32, P1115, DOI 10.3892/ijmm.2013.1499
   Xu Y, 2013, GENE, V530, P278, DOI 10.1016/j.gene.2013.07.055
NR 36
TC 20
Z9 21
U1 0
U2 0
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD NOV 30
PY 2017
VL 7
AR 16672
DI 10.1038/s41598-017-16892-3
PG 6
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA FO5JI
UT WOS:000416891400074
PM 29192217
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Li, M
   Li, X
   Zhuang, Y
   Flemington, EK
   Lin, Z
   Shan, B
AF Li, Miao
   Li, Xi
   Zhuang, Yan
   Flemington, Erik K.
   Lin, Zhen
   Shan, Bin
TI Induction of a novel isoform of the lncRNA HOTAIR in Claudin-low breast
   cancer cells attached to extracellular matrix
SO MOLECULAR ONCOLOGY
LA English
DT Article
DE epigenetics; HOTAIR; lncRNA; three-dimensional organotypic culture
ID TO-MESENCHYMAL TRANSITION; NONCODING RNA HOTAIR; 3-DIMENSIONAL
   ORGANOTYPIC CULTURE; LUNG ADENOCARCINOMA CELLS; GENE-EXPRESSION; I
   COLLAGEN; CHROMATIN; SIGNATURE; SUBTYPES; REVEALS
AB Elevated overexpression of the lncRNA HOTAIR mediates invasion and metastasis in breast cancer. In an apparent paradox, we observed low expression of HOTAIR in the invasive Claudin-low MDA-MB-231 and Hs578T cells in two-dimensional culture (2D). However, HOTAIR expression exhibited robust induction in laminin-rich extracellular matrix-based three-dimensional organotypic culture (lrECM 3D) over that in 2D culture. Induction of HOTAIR required intact ECM signaling, namely integrin 2 and SRC kinase activity. Moreover, invasive growth was suppressed by HOTAIR-specific siRNA. Induction of HOTAIR in lrECM 3D culture resulted from the activation of a novel isoform of HOTAIR (HOTAIR-N) whose transcription is started from the first intron of the HOXC11 gene. The HOTAIR-N promoter exhibited increased trimethylation of histone H3 lysine 4, a histone marker of active transcription, and binding of BRD4, a reader of transcriptionally active histone markers. Inhibition of BRD4 substantially reduced the expression of HOTAIR in lrECM 3D culture. In summary, our results indicate that HOTAIR expression is activated by BRD4 binding to a novel HOTAIR-N promoter in Claudin-low breast cancer cells that are attached to ECM. Induction of HOTAIR is required for invasive growth of Claudin-low breast cancer cells in lrECM 3D culture.
C1 [Li, Miao] China Med Univ, Coll Basic Med Sci, Dept Microbiol & Parasitol, Shenyang, Liaoning, Peoples R China.
   [Li, Miao; Li, Xi; Shan, Bin] Washington State Univ Spokane, Elson S Floyd Coll Med, Dept Biomed Sci, Spokane, WA USA.
   [Li, Xi] Peoples Hosp Liaoning Prov, Dept Sports Med & Joint Surg, Shenyang, Liaoning, Peoples R China.
   [Zhuang, Yan] Tulane Univ, Sch Med, Dept Med, 1430 Tulane Ave, New Orleans, LA 70112 USA.
   [Flemington, Erik K.; Lin, Zhen] Tulane Univ, Sch Med, Dept Pathol, New Orleans, LA 70112 USA.
C3 China Medical University; Washington State University; Tulane
   University; Tulane University
RP Li, M (通讯作者)，China Med Univ, Shenyang North New Area, 77 Puhe Rd, Shenyang 110122, Liaoning, Peoples R China.; Shan, B (通讯作者)，Washington State Univ, Elson S Floyd Coll Med, POB 1495, Spokane, WA 99210 USA.
EM sendtolm@126.com; bin.shan@wsu.edu
FU Washington State University; National Nature Science Foundation of China
   [81401334]
FX This work is supported by Washington State University Startup Fund
   awarded to BS. XL is supported by Grant No. 81401334 from the National
   Nature Science Foundation of China awarded to XL.
CR Antoon JW, 2012, SCI REP-UK, V2, DOI 10.1038/srep00539
   Cabili MN, 2011, GENE DEV, V25, P1915, DOI 10.1101/gad.17446611
   Charafe-Jauffret E, 2009, CANCER RES, V69, P1302, DOI 10.1158/0008-5472.CAN-08-2741
   Chu C, 2011, MOL CELL, V44, P667, DOI 10.1016/j.molcel.2011.08.027
   Creighton CJ, 2009, P NATL ACAD SCI USA, V106, P13820, DOI 10.1073/pnas.0905718106
   Dey A, 2003, P NATL ACAD SCI USA, V100, P8758, DOI 10.1073/pnas.1433065100
   Gupta RA, 2010, NATURE, V464, P1071, DOI 10.1038/nature08975
   Guttman M, 2009, NATURE, V458, P223, DOI 10.1038/nature07672
   Hennessy BT, 2009, CANCER RES, V69, P4116, DOI 10.1158/0008-5472.CAN-08-3441
   Holliday DL, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2889
   Huang C, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2936
   Kenny PA, 2007, MOL ONCOL, V1, P84, DOI 10.1016/j.molonc.2007.02.004
   Kenny PA, 2007, FRONT BIOSCI-LANDMRK, V12, P3468, DOI 10.2741/2327
   Kent WJ, 2002, GENOME RES, V12, P996, DOI 10.1101/gr.229102
   Knight CG, 1998, J BIOL CHEM, V273, P33287, DOI 10.1074/jbc.273.50.33287
   Lee GY, 2007, NAT METHODS, V4, P359, DOI 10.1038/NMETH1015
   Lelièvre SA, 2010, J MAMMARY GLAND BIOL, V15, P49, DOI 10.1007/s10911-010-9168-y
   Li B, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-323
   Li C, 2012, GENE, V511, P143, DOI 10.1016/j.gene.2012.09.093
   Li C, 2011, MOL CARCINOGEN, V50, P563, DOI 10.1002/mc.20742
   Li M, 2016, ONCOTARGET, V7, P51503, DOI 10.18632/oncotarget.10491
   Loewen G, 2014, J CANC RES UPDATES, V3, P7
   Lovén J, 2013, CELL, V153, P320, DOI 10.1016/j.cell.2013.03.036
   Lu PF, 2012, J CELL BIOL, V196, P395, DOI 10.1083/jcb.201102147
   Martin KJ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002994
   Maruyama R, 2012, P NATL ACAD SCI USA, V109, P2820, DOI 10.1073/pnas.1010559107
   McIlroy M, 2010, CANCER RES, V70, P1585, DOI 10.1158/0008-5472.CAN-09-3713
   Milevskiy MJG, 2016, HUM MOL GENET, V25, P3269, DOI 10.1093/hmg/ddw177
   Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008
   Nguyen HT, 2013, CANCER CELL INT, V13, DOI 10.1186/1475-2867-13-16
   Nguyen HT, 2012, ONCOL REP, V28, P117, DOI 10.3892/or.2012.1764
   O'Leary NA, 2016, NUCLEIC ACIDS RES, V44, pD733, DOI 10.1093/nar/gkv1189
   Parker JS, 2009, J CLIN ONCOL, V27, P1160, DOI 10.1200/JCO.2008.18.1370
   Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093
   Portoso M, 2017, EMBO J, V36, P981, DOI 10.15252/embj.201695335
   Prat A, 2011, MOL ONCOL, V5, P5, DOI 10.1016/j.molonc.2010.11.003
   Prat A, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2635
   Rinn JL, 2007, CELL, V129, P1311, DOI 10.1016/j.cell.2007.05.022
   Rinn JL, 2012, ANNU REV BIOCHEM, V81, P145, DOI 10.1146/annurev-biochem-051410-092902
   Shan B, 2005, J BIOL CHEM, V280, P1103, DOI 10.1074/jbc.M406293200
   Shan B, 2005, EXP CELL RES, V305, P10, DOI 10.1016/j.yexcr.2004.09.033
   Shan B, 2007, J MOL CELL CARDIOL, V42, P517, DOI 10.1016/j.yjmcc.2006.08.004
   Shan B, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011662
   Shipitsin M, 2007, CANCER CELL, V11, P259, DOI 10.1016/j.ccr.2007.01.013
   Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098
   Spitale RC, 2011, EPIGENETICS-US, V6, P539, DOI 10.4161/epi.6.5.15221
   Strong MJ, 2014, J VIROL, V88, P10696, DOI 10.1128/JVI.01457-14
   Taube JH, 2010, P NATL ACAD SCI USA, V107, P15449, DOI 10.1073/pnas.1004900107
   Teoh-Fitzgerald ML, 2014, ONCOGENE, V33, P358, DOI 10.1038/onc.2012.582
   THOMAS JE, 1991, SCIENCE, V254, P568, DOI 10.1126/science.1719633
   Tsai MC, 2010, SCIENCE, V329, P689, DOI 10.1126/science.1192002
   Vidi Pierre-Alexandre, 2013, Methods Mol Biol, V945, P193, DOI 10.1007/978-1-62703-125-7_13
   Wang KC, 2011, MOL CELL, V43, P904, DOI 10.1016/j.molcel.2011.08.018
   Weaver VM, 1997, J CELL BIOL, V137, P231, DOI 10.1083/jcb.137.1.231
   Yotsumoto F, 2013, MOL CANCER RES, V11, P506, DOI 10.1158/1541-7786.MCR-12-0428
   Zhuang Y, 2015, MOL CARCINOGEN, V54, P1656, DOI 10.1002/mc.22237
   Zhuang Y, 2013, J HEMATOL ONCOL, V6, DOI 10.1186/1756-8722-6-35
   Zhuang Y, 2010, BIOCHEM BIOPH RES CO, V392, P608, DOI 10.1016/j.bbrc.2010.01.091
   Ziober BL, 1999, CELL GROWTH DIFFER, V10, P479
   Zuber J, 2011, NATURE, V478, P524, DOI 10.1038/nature10334
NR 60
TC 29
Z9 34
U1 0
U2 11
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1878-0261
J9 MOL ONCOL
JI Mol. Oncol.
PD DEC
PY 2017
VL 11
IS 12
BP 1698
EP 1710
DI 10.1002/1878-0261.12133
PG 13
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA FO6GF
UT WOS:000416960300004
PM 28846832
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU Paszek, S
   Gablo, N
   Barnas, E
   Szybka, M
   Morawiec, J
   Kolacinska, A
   Zawlik, I
AF Paszek, Sylwia
   Gablo, Natalia
   Barnas, Edyta
   Szybka, Malgorzata
   Morawiec, Jan
   Kolacinska, Agnieszka
   Zawlik, Izabela
TI Dysregulation of microRNAs in triple-negative breast cancer
SO GINEKOLOGIA POLSKA
LA English
DT Article
DE TNBC; microRNA expression; biomarkers
ID PROGRESSION; EXPRESSION; INVASION; REVEALS; TARGETS; MIR-136
AB Objectives: Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer with limited treatment options and poor prognosis. TNBC is usually diagnosed at a relatively young age and is characterized by high risk of developing metastases. Some epigenetic regulation of gene expression is associated with TNBC. Expression of microRNAs (miRNAs) can serve as a potential tool for identifying critical biomarkers in TNBC.
   The aim of our study is to examine expression of selected miRNAs in TNBC and to assess the relationship between miRNA expression and clinicopathological factors.
   Material and methods: Expression levels of 19 selected miRNAs were compared between cancerous and normal breast tissues by use of qPCR method. We have evaluated the relationship between the expression level of miRNAs and clinicopathological factors such as: age, tumor size and lymph node status.
   Results: We found that in TNBC tissues, when compared with normal breast tissues, the expression of miR-190a, miR-136-5p and miR-126-5p was significantly reduced (p = 0.0041, p = 0.0007, p = 0.0007, respectively) whereas expression of miR-135b-5p and miR-182-5p was significantly increased (p = 0.0194, p = 0.0041, respectively). We found a linear trend for tumor size and expression of miR-126-5p (p = 0.0296) and miR-135b-5p (p = 0.0241).
   Conclusions: Our study confirms that miRNA expression profile is dysregulated in TNBC patients compared to healthy controls. MiR-190a, miR-136-5p, miR-126-5p, miR-135b-5p and miR-182-5p may be associated with development and progression of TNBC.
C1 [Paszek, Sylwia; Gablo, Natalia; Zawlik, Izabela] Univ Rzeszow, Fac Med, Ctr Innovat Res Med & Nat Sci, Rzeszow, Poland.
   [Paszek, Sylwia; Gablo, Natalia; Zawlik, Izabela] Univ Rzeszow, Fac Med, Dept Genet, Warzywna 1A, PL-35959 Rzeszow, Poland.
   [Barnas, Edyta] Univ Rzeszow, Fac Med, Inst Obstet & Emergency Med, Rzeszow, Poland.
   [Szybka, Malgorzata] Med Univ Lodz, Fac Med, Dept Microbiol & Lab Med Immunol, Lodz, Poland.
   [Morawiec, Jan; Kolacinska, Agnieszka] Med Univ Lodz, Dept Head & Neck Canc Surg, Lodz, Poland.
   [Kolacinska, Agnieszka] Copernicus Mem Hosp, Dept Surg Oncol, Ctr Canc, Lodz, Poland.
C3 University of Rzeszow; University of Rzeszow; University of Rzeszow;
   Medical University Lodz; Medical University Lodz
RP Zawlik, I (通讯作者)，Univ Rzeszow, Fac Med, Dept Genet, Warzywna 1A, PL-35959 Rzeszow, Poland.; Zawlik, I (通讯作者)，Univ Rzeszow, Lab Mol Biol, Ctr Innovat Res Med & Nat Sci, Warzywna 1A, PL-35959 Rzeszow, Poland.
EM izazawlik@yahoo.com
RI Gabło, Natalia Anna/KBC-7885-2024
OI Barnas, Edyta/0000-0002-7567-3782; Zawlik, Izabela/0000-0001-7992-9100;
   Paszek, Sylwia/0000-0002-7865-2661; Szybka,
   Malgorzata/0000-0003-2318-7923; Kolacinska-Wow,
   Agnieszka/0000-0001-8707-0877
FU National Science Centre, Poland [2011/01//B/NZ4/03345]; Regional
   Operational Program for the Podkarpackie Province
   [UDA-RPPK.01.03.00-18-004/12-00]; University of Rzeszow, Faculty of
   Medicine
FX This study was supported by the grant no. 2011/01//B/NZ4/03345 of the
   National Science Centre, Poland,. The study was performed within the
   project 'Centre for Innovative Research in Medical and Natural Sciences'
   realized by University of Rzeszow, co-financed within Regional
   Operational Program for the Podkarpackie Province for the years
   2007-2013, contract number UDA-RPPK.01.03.00-18-004/12-00. The study was
   partly supported by funds from the University of Rzeszow, Faculty of
   Medicine. We would like to thank PhD Beata Malachowska for assistance
   with statistical analysis.
CR Anders C, 2008, ONCOLOGY-NY, V22, P1233
   Andersen CL, 2004, CANCER RES, V64, P5245, DOI 10.1158/0008-5472.CAN-04-0496
   Arigoni M, 2013, AM J PATHOL, V182, P2058, DOI 10.1016/j.ajpath.2013.02.046
   Avery-Kiejda KA, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-51
   Boyle P, 2012, ANN ONCOL, V23, P7, DOI 10.1093/annonc/mds187
   Cheang MCU, 2008, CLIN CANCER RES, V14, P1368, DOI 10.1158/1078-0432.CCR-07-1658
   Chou CH, 2016, NUCLEIC ACIDS RES, V44, pD239, DOI 10.1093/nar/gkv1258
   Chu HW, 2014, HUM MOL GENET, V23, P355, DOI 10.1093/hmg/ddt426
   D'Ippolito E, 2013, INT J MOL SCI, V14, P22202, DOI 10.3390/ijms141122202
   de Ruijter TC, 2011, J CANCER RES CLIN, V137, P183, DOI 10.1007/s00432-010-0957-x
   Dvinge H, 2013, NATURE, V497, P378, DOI 10.1038/nature12108
   Godfrey SS, 2015, INT J SURG RES, P4
   Ha Tai-You, 2011, Immune Netw, V11, P11, DOI [10.4110/in.2011.11.3.135, 10.4110/in.2011.11.1.11]
   Hao Y, 2014, RNA, V20, P1328, DOI 10.1261/rna.044651.114
   Hsu YH, 2014, CANCER RES, V74, P4822, DOI 10.1158/0008-5472.CAN-14-0584
   Hua KY, 2016, INT J ONCOL, V48, P1997, DOI 10.3892/ijo.2016.3405
   Hudis CA, 2011, ONCOLOGIST, V16, P1, DOI 10.1634/theoncologist.2011-S1-01
   Irshad S, 2011, CURR OPIN ONCOL, V23, P566, DOI 10.1097/CCO.0b013e32834bf8ae
   Krishnan K, 2013, RNA, V19, P230, DOI 10.1261/rna.034926.112
   Liu X, 2010, J CLIN INVEST, V120, P1298, DOI 10.1172/JCI39566
   Matamala N, 2016, ONCOTARGET, V7, P20068, DOI 10.18632/oncotarget.7705
   Medimegh I, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111877
   Moskwa P, 2011, MOL CELL, V41, P210, DOI 10.1016/j.molcel.2010.12.005
   Muñoz-Rodríguez JL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124340
   O'Reilly EA, 2015, BBA CLIN, V3, P257, DOI 10.1016/j.bbacli.2015.03.003
   Pillai RS, 2005, RNA, V11, P1753, DOI 10.1261/rna.2248605
   Severson TM, 2015, MOL ONCOL, V9, P1528, DOI 10.1016/j.molonc.2015.04.011
   SIEGEL RL, 2016, CA-CANCER J CLIN, V66, P7, DOI DOI 10.3322/CAAC.21654
   Tavazoie SF, 2008, NATURE, V451, P147, DOI 10.1038/nature06487
   Wang CZ, 2015, INT J CLIN EXP PATHO, V8, P6547
   Wang F, 2015, DIS MARKERS, V2015, DOI 10.1155/2015/482146
   Wei Q, 2015, THORAC CANCER, V6, P2, DOI 10.1111/1759-7714.12164
   Yan MS, 2016, ONCOL REP, V36, P65, DOI 10.3892/or.2016.4767
   Yang JY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042978
   Zhao HN, 2015, ONCOL REP, V33, P591, DOI 10.3892/or.2014.3640
NR 35
TC 42
Z9 42
U1 0
U2 1
PU VIA MEDICA
PI GDANSK
PA UL SWIETOKRZYSKA 73, 80-180 GDANSK, POLAND
SN 0017-0011
EI 2543-6767
J9 GINEKOL POL
JI Ginekol. Pol.
PY 2017
VL 88
IS 10
BP 530
EP 536
DI 10.5603/GP.a2017.0097
PG 7
WC Obstetrics & Gynecology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Obstetrics & Gynecology
GA FO5EN
UT WOS:000416876400003
PM 29192413
OA Green Submitted, gold
DA 2025-01-12
ER

PT J
AU Nowak, EM
   Poczeta, M
   Bieg, D
   Bednarek, I
AF Nowak, Ewa Maria
   Poczeta, Marta
   Bieg, Dominik
   Bednarek, Ilona
TI DNA methyltransferase inhibitors influence on the <i>DIRAS3</i> and
   <i>STAT3</i> expression and in vitro migration of ovarian and breast
   cancer cells
SO GINEKOLOGIA POLSKA
LA English
DT Article
DE DNA methylation; DNA methyltransferases inhibitors; DIRAS3 expression;
   STAT3 expression; ovarian cancer; breast cancer
ID TUMOR-SUPPRESSOR GENE; PROMOTER METHYLATION; DOWN-REGULATION; ARHI;
   THERAPY
AB Objectives: Downregulation of DIRAS3 (DIRAS family, GTP-binding Ras-like 3) is related to ovarian and breast cancer progression. A possible mechanism that silences this gene is the promoter region DNA methylation. The potential reversibility of this epigenetic mechanism makes it more attractive candidate for new mode of cancer treatment. DIRAS3 regulates cell cycle, tumor dormancy and inhibits cancer cell growth and motility, all of which may indirectly depend on interaction with STAT3 (Signal Transducer and Activator of Transcription 3) classified as a potential oncogene. The restoration of DIRAS3 expression could inhibit cell proliferation and invasiveness.
   Material and methods: Human ovarian carcinoma cell line (A2780) and human breast cancer cell line (MCF7) were exposed to two DNA methyltransferase inhibitors (DNMTi): decitabine (5-aza-2'-deoxycytidine) [25 mu M and 12.5 mu M] and RG108 [150 mu M and 100 mu M]. In vitro migration changes of cancer cells were examined with wound healing assay. After 7 days of DNMTi treatment cells were harvested and DNA and RNA was isolated. The methylation status of the promoter sequences of DIRAS3 and STAT3 genes was determined using methylation specific PCR (MS-PCR). Level of target genes' expression was quantified using quantitative reverse transcription PCR (QRT-PCR).
   Results and conclusions: The in vitro wound healing assay showed changes in the migration rate of both adherent cell lines after DNMTi treatment compared to the untreated cells. Relative balance between methylated and unmethylated variants of DIRAS3 after MS-PCR was shifted towards unmethylated version after DNMTi treatment in A2780 cells. Statistically significant dose dependent effect of decitabine and RG108 on DIRAS3 expression in A2780 cells was observed.
C1 [Nowak, Ewa Maria; Poczeta, Marta; Bieg, Dominik; Bednarek, Ilona] Med Univ Silesia, Sch Pharm, Div Lab Med Sosnowiec, Dept Biotechnol & Genet Engn, Ul Jednosci 8, PL-41200 Sosnowiec, Poland.
C3 Medical University Silesia
RP Nowak, EM (通讯作者)，Med Univ Silesia, Sch Pharm, Div Lab Med Sosnowiec, Dept Biotechnol & Genet Engn, Ul Jednosci 8, PL-41200 Sosnowiec, Poland.
EM ewa.nowak@sum.edu.pl
RI Bednarek, Ilona/HJY-5137-2023
OI Bieg, Dominik/0000-0003-3510-1998; Bednarek, Ilona
   Anna/0000-0002-3003-5437
FU [KNW-2-015/N/4/K];  [KNW-2-014/N/5/N];  [KNW-2-B10/N/6/K]; 
   [KNW-2-B20/N/7/N];  [KNW-1-043/N/6/B]
FX The study was supported by the funds: KNW-2-015/N/4/K, KNW-2-014/N/5/N,
   KNW-2-B10/N/6/K, KNW-2-B20/N/7/N, KNW-1-043/N/6/B.
CR Bai HM, 2016, J CELL MOL MED, V20, P581, DOI 10.1111/jcmm.12771
   Barrow TM, 2015, INT J CANCER, V137, P537, DOI 10.1002/ijc.29419
   Chen MY, 2011, CANCER-AM CANCER SOC, V117, P4424, DOI 10.1002/cncr.26073
   Dai Z, 2005, DEMETHYLATING DRUGS, P244
   Earp MA, 2015, GENOMICS, V106, P311, DOI 10.1016/j.ygeno.2015.09.001
   Esteller M, 2007, HUM MOL GENET, V16, pR50, DOI 10.1093/hmg/ddm018
   Fahy J, 2012, EXPERT OPIN THER PAT, V22, P1427, DOI 10.1517/13543776.2012.729579
   Feng WW, 2008, CANCER-AM CANCER SOC, V112, P1489, DOI 10.1002/cncr.23323
   Gil L, 2012, HAEMATOLOGIA, V3, P120
   Gnyszka A, 2013, ANTICANCER RES, V33, P2989
   Gros C, 2012, BIOCHIMIE, V94, P2280, DOI 10.1016/j.biochi.2012.07.025
   Gyorffy B, 2016, INT J CANCER, V138, P87, DOI 10.1002/ijc.29684
   Han ZQ, 2013, BIOCHEM BIOPH RES CO, V435, P188, DOI 10.1016/j.bbrc.2013.04.087
   Heerboth S, 2014, GENET EPIGENETICS, V6, P9, DOI 10.4137/GEG.S12270
   Huang SY, 2010, BIOSCIENCE REP, V30, P159, DOI 10.1042/BSR20090008
   Li J, 2013, ONCOL REP, V30, P165, DOI 10.3892/or.2013.2414
   Li Y, 2012, TUMOR BIOL, V33, P1403, DOI 10.1007/s13277-012-0388-1
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lu Z, 2006, CLIN CANCER RES, V12, P2404, DOI 10.1158/1078-0432.CCR-05-1036
   Lu Z, 2013, CELL ADHES MIGR, V7, P232, DOI 10.4161/cam.23648
   Luo RZ, 2001, BBA-GENE STRUCT EXPR, V1519, P216, DOI 10.1016/S0167-4781(01)00226-3
   Mund C, 2006, EPIGENETICS-US, V1, P7
   Muthu K, 2015, CELL SIGNAL, V27, P739, DOI 10.1016/j.cellsig.2014.11.036
   Nishimoto A, 2005, CANCER RES, V65, P6701, DOI 10.1158/0008-5472.CAN-05-0130
   Rosen DG, 2004, CLIN CANCER RES, V10, P6559, DOI 10.1158/1078-0432.CCR-04-0698
   Subramaniam D, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00080
   Yang J, 2005, CANCER RES, V65, P939
   Yu YH, 2003, ANN NY ACAD SCI, V983, P268, DOI 10.1111/j.1749-6632.2003.tb05981.x
NR 28
TC 9
Z9 13
U1 1
U2 10
PU VIA MEDICA
PI GDANSK
PA UL SWIETOKRZYSKA 73, 80-180 GDANSK, POLAND
SN 0017-0011
J9 GINEKOL POL
JI Ginekol. Pol.
PY 2017
VL 88
IS 10
BP 543
EP 551
DI 10.5603/GP.a2017.0099
PG 9
WC Obstetrics & Gynecology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Obstetrics & Gynecology
GA FO5EN
UT WOS:000416876400005
PM 29192415
OA Green Submitted, gold
DA 2025-01-12
ER

PT J
AU Galoian, K
   Abrahamyan, S
   Chailyan, G
   Qureshi, A
   Patel, P
   Metser, G
   Moran, A
   Sahakyan, I
   Tumasyan, N
   Lee, A
   Davtyan, T
   Chailyan, S
   Galoyan, A
AF Galoian, Karina
   Abrahamyan, Silva
   Chailyan, Gor
   Qureshi, Amir
   Patel, Parthik
   Metser, Gil
   Moran, Alexandra
   Sahakyan, Inesa
   Tumasyan, Narine
   Lee, Albert
   Davtyan, Tigran
   Chailyan, Samvel
   Galoyan, Armen
TI Toll like receptors TLR1/2, TLR6 and MUC5b as binding interaction
   partners with cytostatic proline rich polypeptide 1 in human
   chondrosarcoma
SO INTERNATIONAL JOURNAL OF ONCOLOGY
LA English
DT Article
DE PRP-1; galarmin; receptors; innate immunity; chondrosarcoma; TLR1/2;
   TLR6; MUC5B
ID IMMUNE-SYSTEM; EPIGENETIC REGULATION; BREAST-CANCER; MUCINS; CELLS;
   TUMOR; EXPRESSION; LIGANDS; INFLAMMATION; RECOGNITION
AB Metastatic chondrosarcoma is a bone malignancy not responsive to conventional therapies; new approaches and therapies are urgently needed. We have previously reported that mTORC1 inhibitor, antitumorigenic cytostatic proline rich polypeptide 1 (PRP-1), galarmin caused a significant upregulation of tumor suppressors including TET1/2 and SOCS3 (known to be involved in inflammatory processes), downregulation of oncoproteins and embryonic stem cell marker miR-302C and its targets Nanog, c-Myc and Bmi-1 in human chondrosarcoma. To understand better the mechanism of PRP-1 action it was very important to identify the receptor it binds to. Nuclear pathway receptor and GPCR assays indicated that PRP-1 receptors are not G protein coupled, neither do they belong to family of nuclear or orphan receptors. In the present study, we have demonstrated that PRP-1 binding interacting partners belong to innate immunity pattern recognition toll like receptors TLR1/2 and TLR6 and gel forming secreted mucin MUC5B. MUC5B was identified as PRP-1 receptor in human chondrosarcoma JJ012 cell line using Ligand-receptor capture technology. Toll like receptors TLR1/2 and TLR6 were identified as binding interaction partners with PRP-1 by western blot analysis in human chondrosarcoma JJ012 cell line lysates. Immunocytochemistry experiments confirmed the finding and indicated the localization of PRP-1 receptors in the tumor nucleus predominantly. TLR1/2, TLR6 and MUC5B were downregulated in human chondrosarcoma and upregulated in dose-response manner upon PRP-1 treatment. Experimental data indicated that in this cellular context the mentioned receptors had tumor suppressive function.
C1 [Galoian, Karina; Qureshi, Amir; Patel, Parthik; Metser, Gil; Moran, Alexandra] Univ Miami, Miller Sch Med, Dept Orthoped Surg, 1600 NW 10th Ave 1140, Miami, FL 33136 USA.
   [Abrahamyan, Silva; Chailyan, Gor; Sahakyan, Inesa; Tumasyan, Narine; Lee, Albert; Chailyan, Samvel; Galoyan, Armen] Armenian Acad Sci, Buniatian Inst Biochem, Yerevan 0014, Armenia.
   [Davtyan, Tigran] Minist Hlth Armenia, Analyt Lab Branch E Gabriyelian Sci Ctr Drug & Me, Yerevan 0002, Armenia.
C3 University of Miami; Institute of Biochemistry after H. Buniatyan - NAS
   RA
RP Galoian, K (通讯作者)，Univ Miami, Miller Sch Med, Dept Orthoped Surg, 1600 NW 10th Ave 1140, Miami, FL 33136 USA.
EM kgaloian@med.miami.edu
RI Sahakyan, Inesa/HKF-1393-2023
OI Tumasyan, Narine/0000-0003-2911-5496; Galoian,
   Karina/0000-0002-0418-9942; Sahakyan, Inesa/0000-0002-4048-4498;
   Danielyan, Kristine/0000-0003-3109-7565
CR Abrahamyan SS, 2014, NEUROCHEM J+, V8, P38, DOI 10.1134/S1819712414010024
   Andrianifahanana M, 2006, BBA-REV CANCER, V1765, P189, DOI 10.1016/j.bbcan.2006.01.002
   [Anonymous], 1989, BONE TUMORS CLIN RAD
   Apetoh L, 2007, NAT MED, V13, P1050, DOI 10.1038/nm1622
   Aziz M.A., 2014, J. Carcinog. Mutagen. S, V10, P9, DOI [DOI 10.4172/2157-2518.S10-009, 10.4172/2157-2518.S10-009]
   Berois N, 2003, INT J CANCER, V103, P550, DOI 10.1002/ijc.10853
   Blasius AL, 2010, IMMUNITY, V32, P305, DOI 10.1016/j.immuni.2010.03.012
   Frei AP, 2013, NAT PROTOC, V8, P1321, DOI 10.1038/nprot.2013.072
   Galoian K, 2016, MOL CLIN ONCOL, V5, P618, DOI 10.3892/mco.2016.1010
   Galoian K, 2015, INT J ONCOL, V47, P465, DOI 10.3892/ijo.2015.3054
   Galoian K, 2015, MOL CLIN ONCOL, V3, P171, DOI 10.3892/mco.2014.445
   Galoian K, 2012, TUMOR BIOL, V33, P885, DOI 10.1007/s13277-011-0315-x
   Galoian K, 2011, NEUROCHEM RES, V36, P812, DOI 10.1007/s11064-011-0406-5
   Galoian KA, 2014, TUMOR BIOL, V35, P2335, DOI 10.1007/s13277-013-1309-7
   Galoian KA, 2011, TUMOR BIOL, V32, P745, DOI 10.1007/s13277-011-0176-3
   Galoyan A, 2000, NEUROCHEM RES, V25, P1343, DOI 10.1023/A:1007656431612
   Galoyan AA, 2012, ADV NEUROBIOLOGY, V6
   Galoyan AA, 2004, BRAIN NEUROSECRETORY
   Hasan U, 2005, J IMMUNOL, V174, P2942, DOI 10.4049/jimmunol.174.5.2942
   Hollingsworth MA, 2004, NAT REV CANCER, V4, P45, DOI 10.1038/nrc1251
   Huang B, 2008, ONCOGENE, V27, P218, DOI 10.1038/sj.onc.1210904
   Huhta H, 2016, ONCOTARGET, V7, P23658, DOI 10.18632/oncotarget.8151
   Janssens S, 2003, CLIN MICROBIOL REV, V16, P637, DOI 10.1128/CMR.16.4.637-646.2003
   Jeung HC, 2008, ANN ONCOL, V19, P520, DOI 10.1093/annonc/mdm536
   Joshi S, 2014, ONCOTARGET, V5, P7272, DOI 10.18632/oncotarget.2370
   Kaczanowska S, 2013, J LEUKOCYTE BIOL, V93, P847, DOI 10.1189/jlb.1012501
   Kanzler H, 2007, NAT MED, V13, P552, DOI 10.1038/nm1589
   Kim YS, 1996, GLYCOCONJUGATE J, V13, P693, DOI 10.1007/BF00702333
   Kufe DW, 2009, NAT REV CANCER, V9, P874, DOI 10.1038/nrc2761
   Lakshminarayanan V, 2012, P NATL ACAD SCI USA, V109, P261, DOI 10.1073/pnas.1115166109
   Leonard JR, 2007, CLIN CANCER RES, V13, P6168, DOI 10.1158/1078-0432.CCR-07-0815
   Lowe EL, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013027
   Macha MA, 2015, CANCER TREAT REV, V41, P277, DOI 10.1016/j.ctrv.2015.01.001
   Markossian KA, 1999, NEUROCHEMISTRY, V16, P22
   Medzhitov R, 2008, NATURE, V454, P428, DOI 10.1038/nature07201
   Mikulandra M, 2017, CURR MED CHEM, V24, P2011, DOI 10.2174/0929867324666170320114359
   Moniaux N, 2004, BRIT J CANCER, V91, P1633, DOI 10.1038/sj.bjc.6602163
   Nilsen N, 2004, J BIOL CHEM, V279, P39727, DOI 10.1074/jbc.M405027200
   Omasits U, 2014, BIOINFORMATICS, V30, P884, DOI 10.1093/bioinformatics/btt607
   Ozaki T, 1996, J CANCER RES CLIN, V122, P625, DOI 10.1007/BF01221195
   Ozinsky A, 2000, P NATL ACAD SCI USA, V97, P13766, DOI 10.1073/pnas.250476497
   Planque Nathalie, 2006, Cell Commun Signal, V4, P7, DOI 10.1186/1478-811X-4-7
   Rachagani S, 2009, BIOFACTORS, V35, P509, DOI 10.1002/biof.64
   Rakoff-Nahoum S, 2009, NAT REV CANCER, V9, P57, DOI 10.1038/nrc2541
   Remmers N, 2013, CLIN CANCER RES, V19, P1981, DOI 10.1158/1078-0432.CCR-12-2662
   Roy MG, 2014, NATURE, V505, P412, DOI 10.1038/nature12807
   Seibert SA, 2010, IMMUNOL LETT, V127, P126, DOI 10.1016/j.imlet.2009.10.008
   Senapati S, 2010, TRENDS BIOCHEM SCI, V35, P236, DOI 10.1016/j.tibs.2009.10.003
   Seong SY, 2004, NAT REV IMMUNOL, V4, P469, DOI 10.1038/nri1372
   Slavoff SA, 2012, NAT BIOTECHNOL, V30, P959, DOI 10.1038/nbt.2373
   Smits ELJM, 2008, ONCOLOGIST, V13, P859, DOI 10.1634/theoncologist.2008-0097
   Sóñora C, 2006, J HISTOCHEM CYTOCHEM, V54, P289, DOI 10.1369/jhc.5A6763.2005
   Tarang S, 2012, CANCER LETT, V321, P110, DOI 10.1016/j.canlet.2012.01.040
   Turner Michael S, 2003, Cancer Chemother Biol Response Modif, V21, P259
   Van Seuningen I, 2000, BIOCHEM J, V348, P675
   Velcich A, 2002, SCIENCE, V295, P1726, DOI 10.1126/science.1069094
   Vincent A, 2007, ONCOGENE, V26, P6566, DOI 10.1038/sj.onc.1210479
   Wakata K, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2015-008366
   Yan YX, 2002, J BIOMOL SCREEN, V7, P451, DOI 10.1177/108705702237677
   Yu L, 2012, CELL MOL LIFE SCI, V69, P935, DOI 10.1007/s00018-011-0864-6
   Yu L, 2010, J CELL MOL MED, V14, P2592, DOI 10.1111/j.1582-4934.2010.01127.x
NR 61
TC 12
Z9 12
U1 0
U2 10
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1019-6439
EI 1791-2423
J9 INT J ONCOL
JI Int. J. Oncol.
PD JAN
PY 2018
VL 52
IS 1
BP 139
EP 154
DI 10.3892/ijo.2017.4199
PG 16
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA FO3BY
UT WOS:000416688500011
PM 29138803
OA Green Published, hybrid, Green Submitted
DA 2025-01-12
ER

PT J
AU Chen, CC
   Chiu, CC
   Lee, KD
   Hsu, CC
   Chen, HC
   Huang, THM
   Hsiao, SH
   Leu, YW
AF Chen, Chih-Cheng
   Chiu, Chia-Chen
   Lee, Kuan-Der
   Hsu, Chia-Chen
   Chen, Hong-Chi
   Huang, Tim H. -M.
   Hsiao, Shu-Huei
   Leu, Yu-Wei
TI JAK2V617F influences epigenomic changes in myeloproliferative neoplasms
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE Epigenetics; DNA methylation; V617F mutation; Myeloproliferative
   neoplasms
ID JAK-STAT PATHWAY; DAVID BIOINFORMATICS RESOURCES; LARGE GENE LISTS;
   BREAST-CANCER; ESTROGEN; DISORDERS; MUTATION; CELLS; TET2; URIDYLATION
AB Negative valine (V) to phenylalanine (F) switch at the Janus kinase (JAK2) 617 codon (V617F) is the dominant driver mutation in patients with myeloproliferative neoplasms (MPNs). JAK2V617F was proved to be sufficient for cell transformation; however, independent mutations might influence the following epigenomic modifications. To assess the JAK2V617F-induced downstream epigenomic Changes without interferences, we profiled the epigenomic changes in ectopically expressed JAK2V617F in Ba/F3 cells. Antibodies against phosphorylated signal transducer and activator of transcription 3 (pSTAT3) and enhancer of zeste homolog 2 (EZH2) were used for chromatin-immunoprecipitation sequencing (ChIP-seq) to detect the downstream epigenomic targets in the JAK2 STAT3 signaling pathway. To confirm the JAK2V617F-induced epigenetic changes in vivo, DNA methylation changes in the target loci in patients with MPNs were detected through methylation-specific polymerase chain reaction and were clustered against the changes within controls. We found that ectopically expressed JAK2V617F in Ba/F3 cells reduced the binding specificity; it was associated with cis-regulatory elements and recognized DNA motifs in both pSTAT3-downstream and EZH2-associated targets. Overlapping target loci between the control and JAK2V617F were <3% and 0.4%, respectively, as identified through pSTAT3 and EZH2 ChIP-seq. Furthermore, the methylation changes in the direct target loci (FOXH1, HOXC9, and SRF) were clustered independently from the control locus (L17D1) and other mutation genes (HMGA2 and Lin28A) in the analyzed MPN samples. Therefore, JAK2V617F influences target binding in both pSTAT3 and EZH2. Without mutations in epigenetic regulators, JAK2V617F can induce downstream epigenomic modifications. Thus, epigenetic changes in JAK2 downstream targets might be trackable in vivo. (C) 2017 Elsevier Inc. All rights reserved.
C1 [Chen, Chih-Cheng; Chiu, Chia-Chen; Hsu, Chia-Chen] Chang Gung Univ, Coll Med, Chang Gung Mem Hosp, Dept Hematol & Oncol, Taoyuan, Taiwan.
   [Chen, Chih-Cheng; Chiu, Chia-Chen; Hsu, Chia-Chen] Chang Gung Inst Technol, Taoyuan, Taiwan.
   [Chiu, Chia-Chen; Hsiao, Shu-Huei; Leu, Yu-Wei] Natl Chung Cheng Univ, Inst Mol Biol, Dept Life Sci, Human Epigen Ctr, Chiayi, Taiwan.
   [Chiu, Chia-Chen; Hsiao, Shu-Huei; Leu, Yu-Wei] Natl Chung Cheng Univ, Inst Biomed Sci, Chiayi, Taiwan.
   [Lee, Kuan-Der] Taipei Med Univ Hosp, Dept Med, Div Hematol & Oncol, Taipei, Taiwan.
   [Chen, Hong-Chi] Tzu Chi Univ & Hosp, Dept Life Sci, Hualien, Taiwan.
   [Huang, Tim H. -M.] Univ Texas Hlth Sci Ctr San Antonio, Sch Med, Dept Mol Med, Canc Therapy & Res Ctr, San Antonio, TX 78229 USA.
   [Huang, Tim H. -M.] Univ Texas Hlth Sci Ctr San Antonio, Sch Med, Inst Biotechnol, San Antonio, TX 78229 USA.
C3 Chang Gung University; Chang Gung Memorial Hospital; Chang Gung
   University of Science & Technology; National Chung Cheng University;
   National Chung Cheng University; Taipei Medical University Hospital;
   Taipei Medical University; Tzu Chi University; Cancer Therapy & Research
   Center; University of Texas System; University of Texas Health Science
   Center at San Antonio; University of Texas System; University of Texas
   Health Science Center at San Antonio
RP Hsiao, SH; Leu, YW (通讯作者)，Natl Chung Cheng Univ, Human Epigen Ctr, Dept Life Sci, 168 Univ Rd, Chiayi 62102, Taiwan.; Hsiao, SH; Leu, YW (通讯作者)，Natl Chung Cheng Univ, Inst Mol Biol, 168 Univ Rd, Chiayi 62102, Taiwan.
EM bioshh@ccu.edu.tw; bioywl@ccu.edu.tw
RI Chen, Chao/AAG-6068-2020; Chen, Chien-Hung/AFU-7949-2022
OI Chen, Chih-Cheng/0000-0002-6794-7229
FU Chang Gung Memorial Hospital, Chiayi, Taiwan [CMRPG6F0092, CMRPG6F0432,
   CORPG6F0031]; Ministry of Science and Technology
   [MOST-105-2320-B-194-004, 106-2320-B-194 -001 -MY3]; National Health
   Research Institutes, Taiwan [NHRI-EX102-10259NI];  [MOST-105-2314-B-194
   -001]
FX CC Chen, CC Chiu, CC Hsu, and YW Leu received support from Chang Gung
   Memorial Hospital, Chiayi, Taiwan (CMRPG6F0092, CMRPG6F0432, and
   CORPG6F0031). YWL, and SHH were supported by the Ministry of Science and
   Technology (MOST-105-2320-B-194-004 and 106-2320-B-194 -001 -MY3) and
   National Health Research Institutes (NHRI-EX102-10259NI), Taiwan. YWL
   and KDL also received a grant (MOST-105-2314-B-194 -001).
CR Begam AJ, 2017, BIOORG CHEM, V71, P257, DOI 10.1016/j.bioorg.2017.02.011
   Blankenberg D, 2010, BIOINFORMATICS, V26, P1783, DOI 10.1093/bioinformatics/btq281
   Chauhan R, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11062
   Cheng ASL, 2006, MOL CELL, V21, P393, DOI 10.1016/j.molcel.2005.12.016
   Delhommeau F, 2009, NEW ENGL J MED, V360, P2289, DOI 10.1056/NEJMoa0810069
   Feng JX, 2012, NAT PROTOC, V7, P1728, DOI 10.1038/nprot.2012.101
   Ferrajoli A, 2006, CURR CANCER DRUG TAR, V6, P671, DOI 10.2174/156800906779010227
   Harrison CN, 2014, HEMATOL-AM SOC HEMAT, P348, DOI 10.1182/asheducation-2014.1.348
   Heo I, 2008, MOL CELL, V32, P276, DOI 10.1016/j.molcel.2008.09.014
   Hsiao SH, 2009, SEMIN CANCER BIOL, V19, P198, DOI 10.1016/j.semcancer.2009.02.015
   Huang DW, 2007, NUCLEIC ACIDS RES, V35, pW169, DOI 10.1093/nar/gkm415
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Ikeda Kazuhiko, 2012, Fukushima J Med Sci, V58, P91
   Kleppe M, 2015, CANCER DISCOV, V5, P316, DOI 10.1158/2159-8290.CD-14-0736
   Kralovics R, 2005, NEW ENGL J MED, V352, P1779, DOI 10.1056/NEJMoa051113
   Lamrani L, 2014, BLOOD, V124, P1136, DOI 10.1182/blood-2013-10-530832
   Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/NMETH.1923, 10.1038/nmeth.1923]
   Leu YW, 2004, CANCER RES, V64, P8184, DOI 10.1158/0008-5472.CAN-04-2045
   Machanick P, 2011, BIOINFORMATICS, V27, P1696, DOI 10.1093/bioinformatics/btr189
   MANNI A, 1980, CANCER-AM CANCER SOC, V46, P2838, DOI 10.1002/1097-0142(19801215)46:12+<2838::AID-CNCR2820461421>3.0.CO;2-A
   Mansouri S, 2017, BIOMED PHARMACOTHER, V93, P1320, DOI 10.1016/j.biopha.2017.07.057
   Mascarenhas J, 2011, CLIN EPIGENETICS, V2, P197, DOI 10.1007/s13148-011-0050-6
   Moran-Crusio K, 2011, CANCER CELL, V20, P11, DOI 10.1016/j.ccr.2011.06.001
   Ortmann CA, 2015, NEW ENGL J MED, V372, P601, DOI 10.1056/NEJMoa1412098
   Shimizu T, 2016, J EXP MED, V213, P1479, DOI 10.1084/jem.20151136
   Spivak JL, 2017, NEW ENGL J MED, V376, P2168, DOI 10.1056/NEJMra1406186
   Suzuki HI, 2015, CANCER SCI, V106, P1174, DOI 10.1111/cas.12721
   Tefferi A, 2005, NEW ENGL J MED, V353, P1416
   Tefferi A, 2011, BLOOD CANCER J, V1, DOI 10.1038/bcj.2011.4
   Viny AD, 2014, CANCER J, V20, P61, DOI 10.1097/PPO.0000000000000013
   Wang JY, 2013, LEUKEMIA RES, V37, P305, DOI 10.1016/j.leukres.2012.10.004
   Ward AC, 2000, BLOOD, V95, P19
   Warmuth M, 2007, CURR OPIN ONCOL, V19, P55, DOI 10.1097/CCO.0b013e328011a25f
   Yan PS, 2006, CLIN CANCER RES, V12, P6626, DOI 10.1158/1078-0432.CCR-06-0467
   Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r137
NR 35
TC 3
Z9 3
U1 0
U2 13
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
EI 1090-2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD DEC 16
PY 2017
VL 494
IS 3-4
BP 470
EP 476
DI 10.1016/j.bbrc.2017.10.108
PG 7
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA FN9WJ
UT WOS:000416393300007
PM 29066347
DA 2025-01-12
ER

PT J
AU Stephens, KE
   Levine, JD
   Aouizerat, BE
   Paul, SM
   Abrams, G
   Conley, YP
   Miaskowski, C
AF Stephens, Kimberly E.
   Levine, Jon D.
   Aouizerat, Bradley E.
   Paul, Steven M.
   Abrams, Gary
   Conley, Yvette P.
   Miaskowski, Christine
TI Associations between genetic and epigenetic variations in cytokine genes
   and mild persistent breast pain in women following breast cancer surgery
SO CYTOKINE
LA English
DT Article
DE Cytokine genes; Breast cancer; DNA methylation; Persistent pain;
   Post-surgical pain; Post-mastectomy pain; Epigenetics; Interleukin 6;
   C-X-C motif chemokine ligand 8; Tumor necrosis factor
ID NECROSIS-FACTOR-ALPHA; GENOME-WIDE ASSOCIATION; NEUROPATHIC PAIN;
   ANTIINFLAMMATORY CYTOKINE; DNA METHYLATION; TRANSCRIPTION FACTORS;
   RHEUMATOID-ARTHRITIS; CEREBROSPINAL-FLUID; IMMUNE-SYSTEM; RISK-FACTORS
AB Persistent pain following breast cancer surgery is a significant problem. Both inherited and acquired mechanisms of inflammation appear to play a role in the development and maintenance of persistent pain. In this longitudinal study, growth mixture modeling was used to identify persistent breast pain phenotypes based on pain assessments obtained prior to and monthly for 6 months following breast cancer surgery. Associations between the "no pain" and "mild pain" phenotypes and single nucleotide polymorphisms (SNPs) spanning 15 cytokine genes were evaluated. The methylation status of the CpG sites found in the promoters of genes associated with pain group membership was determined using bisulfite sequencing. In the multivariate analysis, three SNPs (i.e., interleukin 6 (IL6) rs2069840, C-X-C motif chemokine ligand 8 (CXCL8) rs4073, tumor necrosis factor (TNF) rs1800610) and two TNF CpG sites (i.e., c. -350C, c. -344C) were associated with pain group membership. These findings suggest that variations in IL6, CXCL8, and TNF are associated with the development and maintenance of mild persistent breast pain. CpG methylation within the TNF promoter may provide an additional mechanism through which TNF alters the risk for mild persistent breast pain after breast cancer surgery. These genetic and epigenetic variations may help to identify individuals who are predisposed to the development of mild levels of persistent breast pain following breast cancer surgery.
C1 [Stephens, Kimberly E.] Johns Hopkins Univ, Sch Med, Baltimore, MD USA.
   [Levine, Jon D.; Abrams, Gary] Univ Calif San Francisco, Sch Med, San Francisco, CA 94143 USA.
   [Aouizerat, Bradley E.] New York Univ, Coll Dent, New York, NY USA.
   [Paul, Steven M.; Miaskowski, Christine] Univ Calif San Francisco, Sch Nursing, San Francisco, CA 94143 USA.
   [Conley, Yvette P.] Univ Pittsburgh, Sch Nursing, Pittsburgh, PA 15261 USA.
C3 Johns Hopkins University; University of California System; University of
   California San Francisco; New York University; University of California
   System; University of California San Francisco; Pennsylvania
   Commonwealth System of Higher Education (PCSHE); University of
   Pittsburgh
RP Miaskowski, C (通讯作者)，Univ Calif San Francisco, Dept Physiol Nursing, 2 Koret Way N631Y, San Francisco, CA 94143 USA.
EM chris.miaskowski@ucsf.edu
RI Stephens, Kimberly/AAK-5058-2021; Paul, Steve/ABE-5400-2020
OI Levine, Jon/0000-0003-0681-5545; Stephens, Kimberly/0000-0002-8822-0547;
   Conley, Yvette/0000-0002-1784-6067
FU National Cancer Institute (NCI) [CA107091, CA118658]; K05 award from the
   NCI [CAI 68960]; institutional training grant [T32 NR07088]; Sigma Theta
   Tau Research Award; F32 National Research Service Award [NR015728];
   NIH/NCRR UCSF-CTSI [UL RR024131]
FX This study was funded by grants from the National Cancer Institute (NCI,
   CA107091 and CA118658). C. Miaskowski is an American Cancer Society
   Clinical Research Professor and is supported by a K05 award from the NCI
   (CAI 68960). K. Stephens was supported by an institutional training
   grant (T32 NR07088), a Sigma Theta Tau Research Award, and a F32
   National Research Service Award (NR015728). This project was supported
   by NIH/NCRR UCSF-CTSI grant number UL RR024131. Its contents are solely
   the responsibility of the authors and do not necessarily represent the
   official views of the NIH.
CR Ahn MH, 2011, RESP RES, V12, DOI 10.1186/1465-9921-12-73
   Andersen KG, 2011, J PAIN, V12, P725, DOI 10.1016/j.jpain.2010.12.005
   Austin PJ, 2010, J NEUROIMMUNOL, V229, P26, DOI 10.1016/j.jneuroim.2010.08.013
   Bland JM, 2003, ULTRASOUND OBST GYN, V22, P85, DOI 10.1002/uog.122
   Brisby H, 2002, EUR SPINE J, V11, P62, DOI 10.1007/s005860100306
   Calvo M, 2012, LANCET NEUROL, V11, P629, DOI 10.1016/S1474-4422(12)70134-5
   Cleeland CS, 2003, CANCER-AM CANCER SOC, V97, P2919, DOI 10.1002/cncr.11382
   Conde L, 2006, NUCLEIC ACIDS RES, V34, pW621, DOI 10.1093/nar/gkl071
   CRUICKSHANK AM, 1990, CLIN SCI, V79, P161, DOI 10.1042/cs0790161
   De Jongh RF, 2003, ANESTH ANALG, V96, P1096, DOI 10.1213/01.ANE.0000055362.56604.78
   Denk F, 2012, NEURON, V73, P435, DOI 10.1016/j.neuron.2012.01.012
   Dunn LB, 2013, EUR J ONCOL NURS, V17, P346, DOI 10.1016/j.ejon.2012.10.004
   Falvo JV, 2000, MOL CELL BIOL, V20, P2239, DOI 10.1128/MCB.20.6.2239-2247.2000
   Gabriel SB, 2002, SCIENCE, V296, P2225, DOI 10.1126/science.1069424
   Géranton SM, 2012, CURR OPIN PHARMACOL, V12, P35, DOI 10.1016/j.coph.2011.10.012
   Gold MS, 2000, PAIN, V84, P117, DOI 10.1016/S0304-3959(99)00309-7
   Halder I, 2008, HUM MUTAT, V29, P648, DOI 10.1002/humu.20695
   Harvey RJ, 2004, SCIENCE, V304, P884, DOI 10.1126/science.1094925
   Hattersley AT, 2005, LANCET, V366, P1315, DOI 10.1016/S0140-6736(05)67531-9
   Haythornthwaite JA, 1998, J UROLOGY, V160, P1761, DOI 10.1016/S0022-5347(01)62400-5
   Hoggart CJ, 2003, AM J HUM GENET, V72, P1492, DOI 10.1086/375613
   Illi J, 2012, CYTOKINE, V58, P437, DOI 10.1016/j.cyto.2012.02.015
   Janig W, 1996, PROG BRAIN RES, V113, P161, DOI 10.1016/S0079-6123(08)61087-0
   Jensen MP, 2003, J PAIN, V4, P2, DOI 10.1054/jpai.2003.1
   Jung T, 2008, SOC PERSONAL PSYCHOL, V2, P302, DOI 10.1111/j.1751-9004.2007.00054.x
   Kaijzel EL, 2001, GENES IMMUN, V2, P135, DOI 10.1038/sj.gene.6363747
   Kotani N, 2004, AM J MED, V116, P318, DOI 10.1016/j.amjmed.2003.10.027
   Laird PW, 2003, NAT REV CANCER, V3, P253, DOI 10.1038/nrc1045
   Langford DJ, 2015, PAIN, V156, P371, DOI 10.1097/01.j.pain.0000460319.87643.11
   Lee WP, 2005, CLIN CANCER RES, V11, P6431, DOI 10.1158/1078-0432.CCR-05-0942
   Leung L, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-27
   Lewin J, 2004, BIOINFORMATICS, V20, P3005, DOI 10.1093/bioinformatics/bth346
   Liu HY, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-253
   Liu J, 2007, NEUROSCI LETT, V412, P268, DOI 10.1016/j.neulet.2006.11.022
   Macrae WA, 2008, BRIT J ANAESTH, V101, P77, DOI 10.1093/bja/aen099
   Mantyh PW, 2002, NAT REV CANCER, V2, P201, DOI 10.1038/nrc747
   Marchand F, 2005, NAT REV NEUROSCI, V6, P521, DOI 10.1038/nrn1700
   McCann B, 2012, J PAIN, V13, P425, DOI 10.1016/j.jpain.2011.02.358
   McMahon SB, 2005, EXP NEUROL, V192, P444, DOI 10.1016/j.expneurol.2004.11.001
   Miaskowski C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060164
   Miaskowski C, 2012, J PAIN, V13, P1172, DOI 10.1016/j.jpain.2012.09.013
   Nile CJ, 2008, ARTHRITIS RHEUM, V58, P2686, DOI 10.1002/art.23758
   Nylund KL, 2007, STRUCT EQU MODELING, V14, P535, DOI 10.1080/10705510701575396
   Picciotto S, 2008, EUR J CARDIOV PREV R, V15, P631, DOI 10.1097/HJR.0b013e3283069d9a
   Price AL, 2006, NAT GENET, V38, P904, DOI 10.1038/ng1847
   Reyes-Gibby CC, 2007, CANCER EPIDEM BIOMAR, V16, P2745, DOI 10.1158/1055-9965.EPI-07-0651
   Reyes-Gibby CC, 2009, J PAIN SYMPTOM MANAG, V38, P894, DOI 10.1016/j.jpainsymman.2009.04.019
   Reyes-Gibby CC, 2009, CANCER EPIDEM BIOMAR, V18, P2636, DOI 10.1158/1055-9965.EPI-09-0426
   RHOADES KL, 1992, J BIOL CHEM, V267, P22102
   Robertson KD, 2005, NAT REV GENET, V6, P597, DOI 10.1038/nrg1655
   Rothman K J, 1990, Epidemiology, V1, P43, DOI 10.1097/00001648-199001000-00010
   Scholz J, 2002, NAT NEUROSCI, V5, P1062, DOI 10.1038/nn942
   Scholz J, 2007, NAT NEUROSCI, V10, P1361, DOI 10.1038/nn1992
   Schreiber KL, 2014, PAIN MANAG, V4, P445, DOI [10.2217/pmt.14.33, 10.2217/PMT.14.33]
   Shamash S, 2002, J NEUROSCI, V22, P3052, DOI 10.1523/JNEUROSCI.22-08-03052.2002
   Sousa ALM, 2012, J INFECT DIS, V205, P1417, DOI 10.1093/infdis/jis208
   Stephens K, 2014, J PAIN, V15, P169, DOI 10.1016/j.jpain.2013.09.015
   Stephens M, 2001, AM J HUM GENET, V68, P978, DOI 10.1086/319501
   Suske G, 1999, GENE, V238, P291, DOI 10.1016/S0378-1119(99)00357-1
   Tasmuth T, 1996, BRIT J CANCER, V74, P2024, DOI 10.1038/bjc.1996.671
   TASMUTH T, 1995, ANN ONCOL, V6, P453, DOI 10.1093/oxfordjournals.annonc.a059215
   Tian C, 2008, HUM MOL GENET, V17, pR143, DOI 10.1093/hmg/ddn268
   TILG H, 1994, BLOOD, V83, P113
   Tofighi D., 2008, Identifying the correct number of classes in a growth mixture model
   Tsai EY, 2000, MOL CELL BIOL, V20, P6084, DOI 10.1128/MCB.20.16.6084-6094.2000
   Verweij CL, 1999, ANN RHEUM DIS, V58, P20, DOI 10.1136/ard.58.2008.i20
   von Hehn CA, 2012, NEURON, V73, P638, DOI 10.1016/j.neuron.2012.02.008
   Wang SB, 1999, J BIOL CHEM, V274, P33190, DOI 10.1074/jbc.274.47.33190
   Watkins LR, 2001, TRENDS NEUROSCI, V24, P450, DOI 10.1016/S0166-2236(00)01854-3
   Wordliczek J, 2000, LIFE SCI, V66, P1155, DOI 10.1016/S0024-3205(00)00419-7
   Yao J, 1997, J BIOL CHEM, V272, P17795, DOI 10.1074/jbc.272.28.17795
   Zhang Q, 2009, P NATL ACAD SCI USA, V106, P15843, DOI 10.1073/pnas.0907070106
NR 72
TC 32
Z9 38
U1 0
U2 3
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 1043-4666
EI 1096-0023
J9 CYTOKINE
JI Cytokine
PD NOV
PY 2017
VL 99
BP 203
EP 213
DI 10.1016/j.cyto.2017.07.006
PG 11
WC Biochemistry & Molecular Biology; Cell Biology; Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology; Immunology
GA FN7GK
UT WOS:000416186500027
PM 28764974
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Dunlap, TL
   Howell, CE
   Mukand, N
   Chen, SN
   Pauli, GF
   Dietz, BM
   Bolton, JL
AF Dunlap, Tareisha L.
   Howell, Caitlin E.
   Mukand, Nita
   Chen, Shao-Nong
   Pauli, Guido F.
   Dietz, Birgit M.
   Bolton, Judy L.
TI Red Clover Aryl Hydrocarbon Receptor (AhR) and Estrogen Receptor (ER)
   Agonists Enhance Genotoxic Estrogen Metabolism
SO CHEMICAL RESEARCH IN TOXICOLOGY
LA English
DT Article
ID BOTANICAL DIETARY-SUPPLEMENTS; MENOPAUSAL HORMONE-THERAPY; BREAST
   EPITHELIAL-CELLS; HOPS HUMULUS-LUPULUS; BIOCHANIN-A; CYTOCHROME-P450
   1A1; IN-VITRO; MCF-7; ISOFLAVONES; MECHANISMS
AB Many women consider botanical dietary supplements (BDSs) as safe alternatives to hormone therapy for menopausal symptoms. However, the effect of BDSs on breast cancer risk is largely unknown. In the estrogen chemical carcinogenesis pathway, P450 1B1 metabolizes estrogens to 4-hydroxylated catechols, which are oxidized to genotoxic quinones that initiate and promote breast cancer. In contrast, P450 1A1 catalyzed 2-hydroxylation represents a detoxification pathway. The current study evaluated the effects of red clover, a popular BDS used for women's health, and its isoflavones, biochanin A (BA), formononetin (FN), genistein (GN), and daidzein (DZ), on estrogen metabolism. The methoxy estrogen metabolites (2-MeOE1, 4-MeOE1) were measured by LC-MS/MS, and CYP1A1 and CYP1B1 gene expression was analyzed by qPCR Nonmalignant ER-negative breast epithelial cells (MCF-10A) and ER-positive breast cancer cells (MCF-7) were derived from normal breast epithelial tissue and ER+ breast cancer tissue. Red clover extract (RCE, 10 mu g/mL) and isoflavones had no effect on estrogen metabolism in MCF-10A cells. However, in MCF-7 cells, RCE treatments downregulated CYP1A1 expression and enhanced genotoxic metabolism (4-MeOE1/CYP1B1 > 2-MeOE1/CYP1A1). Experiments with the isoflavones showed that the AhR agonists (BA, FN) preferentially induced CYP1B1 expression as well as 4-MeOE1. In contrast, the ER agonists (GN, DZ) downregulated CYP1A1 expression likely through an epigenetic mechanism. Finally, the ER antagonist ICI 182,780 potentiated isoflavone-induced XRE-luciferase reporter activity and reversed GN and DZ induced downregulation of CYP1A1 expression. Overall, these studies show that red clover and its isoflavones have differential effects on estrogen metabolism in "normal" vs breast cancer cells. In breast cancer cells, the AhR agonists stimulate genotoxic metabolism, and the ER agonists downregulate the detoxification pathway. These data may suggest that especially breast cancer patients should avoid red clover and isoflavone based BDSs when making choices for menopausal symptom relief.
C1 [Dunlap, Tareisha L.; Howell, Caitlin E.; Mukand, Nita; Chen, Shao-Nong; Pauli, Guido F.; Dietz, Birgit M.; Bolton, Judy L.] Univ Illinois, Coll Pharm, Dept Med Chem & Pharmacognosy, UIC NIH Ctr Bot Dietary Supplements Res, 833 S Wood St, Chicago, IL 60612 USA.
C3 University of Illinois System; University of Illinois Chicago;
   University of Illinois Chicago Hospital
RP Bolton, JL (通讯作者)，Univ Illinois, Coll Pharm, Dept Med Chem & Pharmacognosy, UIC NIH Ctr Bot Dietary Supplements Res, 833 S Wood St, Chicago, IL 60612 USA.
EM Judy.Bolton@uic.edu
RI Chen, 6/G-5405-2010; Pauli, Guido/C-1159-2009
OI Howell, Caitlin E./0000-0002-7560-6942; Dietz,
   Birgit/0000-0002-4118-6660; Mukand, Nita/0000-0001-8467-5731; Chen,
   Shao-Nong/0000-0003-0748-0863
FU ODS [P50 AT000155]; NCCIH [P50 AT000155]
FX This work was supported through grant P50 AT000155 by NCCIH and ODS to
   the UIC/NIH Center for Botanical Dietary Supplements Research. The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Amer DAM, 2010, J STEROID BIOCHEM, V120, P208, DOI 10.1016/j.jsbmb.2010.04.018
   Atkinson C, 2004, BREAST CANCER RES, V6, pR170, DOI 10.1186/bcr773
   Bahia H, 2002, INT J ONCOL, V20, P489
   Beischlag TV, 2005, J BIOL CHEM, V280, P21607, DOI 10.1074/jbc.C500090200
   Bialesova L, 2015, GEN PHYSIOL BIOPHYS, V34, P331, DOI 10.4149/gpb_2015008
   Bolton JL, 2008, CHEM RES TOXICOL, V21, P93, DOI 10.1021/tx700191p
   Bolton JL, 2017, CHEM RES TOXICOL, V30, P13, DOI 10.1021/acs.chemrestox.6b00256
   Bolton JL, 2016, CHEM RES TOXICOL, V29, P1583, DOI 10.1021/acs.chemrestox.6b00272
   Booth NL, 2006, J ALTERN COMPLEM MED, V12, P133, DOI 10.1089/acm.2006.12.133
   Boucher BA, 2013, INT J CANCER, V132, P1439, DOI 10.1002/ijc.27769
   Burdette JE, 2002, J NUTR, V132, P27, DOI 10.1093/jn/132.1.27
   Cavalieri EL, 2016, CLIN TRANSL MED, V5, DOI 10.1186/s40169-016-0088-3
   Cavalieri ErcoleL., 2016, Trends in Breast Cancer Prevention, P113
   Chan HY, 2003, BRIT J NUTR, V90, P87, DOI 10.1079/BJN2003868
   Choi SY, 2008, PLANTA MED, V74, P25, DOI 10.1055/s-2007-993760
   de Lemos ML, 2001, ANN PHARMACOTHER, V35, P1118, DOI 10.1345/aph.10257
   Denison MS, 2003, ANNU REV PHARMACOL, V43, P309, DOI 10.1146/annurev.pharmtox.43.100901.135828
   Dietz BM, 2016, PHARMACOL REV, V68, P1026, DOI 10.1124/pr.115.010843
   Dong JY, 2016, CHEMMEDCHEM, V11, P2102, DOI 10.1002/cmdc.201600316
   Dunlap TL, 2015, CHEM RES TOXICOL, V28, P1584, DOI 10.1021/acs.chemrestox.5b00157
   Franco OH, 2016, JAMA-J AM MED ASSOC, V315, P2554, DOI 10.1001/jama.2016.8012
   Geller SE, 2009, MENOPAUSE, V16, P1156, DOI 10.1097/gme.0b013e3181ace49b
   Gong P, 2016, MOL CELL ENDOCRINOL, V437, P190, DOI 10.1016/j.mce.2016.08.025
   Gupta M, 1998, J STEROID BIOCHEM, V67, P413, DOI 10.1016/S0960-0760(98)00135-6
   Han EH, 2006, ARCH PHARM RES, V29, P570, DOI 10.1007/BF02969267
   Han EH, 2007, TOX RESEARCH, V23, P135, DOI 10.5487/TR.2007.23.2.135
   Hsieh CY, 1998, CANCER RES, V58, P3833
   JIANG SY, 1992, MOL CELL ENDOCRINOL, V90, P77, DOI 10.1016/0303-7207(92)90104-E
   Kligman L, 2010, CURR ONCOL, V17, P81
   Kolodziejczyk-Czepas J, 2012, J ETHNOPHARMACOL, V143, P14, DOI 10.1016/j.jep.2012.06.048
   Lehmann L, 2008, CARCINOGENESIS, V29, P363, DOI 10.1093/carcin/bgm235
   Leung HY, 2009, BRIT J NUTR, V101, P257, DOI 10.1017/S0007114508998457
   Madhubhani LP, 2012, CANCER PREV RES, V5, P73, DOI 10.1158/1940-6207.CAPR-11-0348
   Manson JE, 2013, JAMA-J AM MED ASSOC, V310, P1353, DOI 10.1001/jama.2013.278040
   Marques M, 2013, NUCLEIC ACIDS RES, V41, P8094, DOI 10.1093/nar/gkt595
   Medjakovic S, 2008, J STEROID BIOCHEM, V108, P171, DOI 10.1016/j.jsbmb.2007.10.001
   Mueck AO, 2010, STEROIDS, V75, P625, DOI 10.1016/j.steroids.2010.02.016
   Nugoli M, 2003, BMC CANCER, V3, DOI 10.1186/1471-2407-3-13
   OSBORNE CK, 1987, BREAST CANCER RES TR, V9, P111, DOI 10.1007/BF01807363
   Overk CR, 2005, J AGR FOOD CHEM, V53, P6246, DOI 10.1021/jf050448p
   Park SA, 2017, ONCOTARGET, V8, P164, DOI 10.18632/oncotarget.10516
   Park SA, 2012, FREE RADICAL RES, V46, P1051, DOI 10.3109/10715762.2012.671940
   Peterson TG, 1998, AM J CLIN NUTR, V68, p1505S, DOI 10.1093/ajcn/68.6.1505S
   Peterson TG, 1996, CARCINOGENESIS, V17, P1861, DOI 10.1093/carcin/17.9.1861
   Piersen CE, 2004, CURR MED CHEM, V11, P1361, DOI 10.2174/0929867043365134
   Powles Trevor J, 2008, Menopause Int, V14, P6, DOI 10.1258/mi.2007.007033
   Reding Kerryn W, 2014, Open J Prev Med, V4, P429, DOI 10.4236/ojpm.2014.46050
   RICKETTS D, 1991, CANCER RES, V51, P1817
   Safe S, 2000, J MAMMARY GLAND BIOL, V5, P295, DOI 10.1023/A:1009550912337
   Sampson JN, 2017, CANCER RES, V77, P918, DOI 10.1158/0008-5472.CAN-16-1717
   Siegel RL, 2016, CA-CANCER J CLIN, V66, P7, DOI 10.3322/caac.21332
   Snelten CS., 2012, Drug Discov Today Dis Mech, V9, P1
   Spink DC, 1998, CARCINOGENESIS, V19, P291, DOI 10.1093/carcin/19.2.291
   Spink DC, 2003, CARCINOGENESIS, V24, P1941, DOI 10.1093/carcin/bgg162
   Tsuchiya Y, 2004, CANCER RES, V64, P3119, DOI 10.1158/0008-5472.CAN-04-0166
   van Breemen RB, 2015, J MED CHEM, V58, P8360, DOI 10.1021/acs.jmedchem.5b00417
   Wagner J, 2008, ADV EXP MED BIOL, V617, P625, DOI 10.1007/978-0-387-69080-3_65
   Wang S, 2016, CHEM RES TOXICOL, V29, P1142, DOI 10.1021/acs.chemrestox.6b00112
   Yager JD, 2015, STEROIDS, V99, P56, DOI 10.1016/j.steroids.2014.08.006
   Yager JD, 2006, NEW ENGL J MED, V354, P270, DOI 10.1056/NEJMra050776
   Zhang S, 2003, ENVIRON HEALTH PERSP, V111, P1877, DOI 10.1289/ehp.6322
NR 61
TC 26
Z9 29
U1 1
U2 10
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0893-228X
EI 1520-5010
J9 CHEM RES TOXICOL
JI Chem. Res. Toxicol.
PD NOV
PY 2017
VL 30
IS 11
BP 2084
EP 2092
DI 10.1021/acs.chemrestox.7b00237
PG 9
WC Chemistry, Medicinal; Chemistry, Multidisciplinary; Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy; Chemistry; Toxicology
GA FN8TD
UT WOS:000416297500016
PM 28985473
OA Green Published, Bronze
DA 2025-01-12
ER

PT J
AU Chu, SK
   Yang, HC
AF Chu, Shih-Kai
   Yang, Hsin-Chou
TI Interethnic DNA methylation difference and its implications in
   pharmacoepigenetics
SO EPIGENOMICS
LA English
DT Article
DE cancer epigenetics; DNA methylation; epipharmacogenomics; population
   differentiation
ID MOLECULAR PATHOLOGICAL EPIDEMIOLOGY; POSITIVE BREAST-CANCER;
   GENE-EXPRESSION; CELL-CYCLE; CYTOSINE MODIFICATIONS; EBV TRANSFORMATION;
   COMPLEX TRAITS; RISK-FACTORS; DISEASE; GENOME
AB Aim: This is the first systematic study to examine the population differentiation effect of DNA methylation on the treatment response and drug absorption, distribution, metabolism and excretion in multiple tissue types and cancer types. Materials & methods: We analyzed the whole methylome and transcriptome data of primary tumor tissues of four cancer types (breast, colon, head & neck and uterine corpus) and lymphoblastoid cell lines for African and European ancestry populations. Results: Ethnicity-associated CpG sites exhibited similar methylation patterns in the two studied populations, but the patterns differed between tumor tissues and lymphoblastoid cell lines. Ethnicity-associated CpG sites may have triggered gene expression, influenced drug absorption, distribution, metabolism and excretion, and showed tumorspecific patterns of methylation and gene regulation. Conclusion: Ethnicity should be carefully accounted for in future pharmacoepigenetics research.
C1 [Chu, Shih-Kai; Yang, Hsin-Chou] Acad Sinica, Bioinformat Program, Taiwan Int Grad Program, Inst Informat Sci, Taipei 115, Taiwan.
   [Chu, Shih-Kai; Yang, Hsin-Chou] Acad Sinica, Inst Stat Sci, Taipei 115, Taiwan.
   [Chu, Shih-Kai] Natl Yang Ming Univ, Inst Biomed Informat, Taipei 112, Taiwan.
   [Yang, Hsin-Chou] Natl Cheng Kung Univ, Dept Stat, Tainan 701, Taiwan.
   [Yang, Hsin-Chou] Natl Tsing Hua Univ, Inst Stat, Hsinchu 300, Taiwan.
   [Yang, Hsin-Chou] Natl Yang Ming Univ, Inst Publ Hlth, Taipei 112, Taiwan.
   [Yang, Hsin-Chou] Natl Def Med Ctr, Sch Publ Hlth, Taipei 114, Taiwan.
C3 Academia Sinica - Taiwan; Academia Sinica - Taiwan; National Yang Ming
   Chiao Tung University; National Cheng Kung University; National Tsing
   Hua University; National Yang Ming Chiao Tung University; National
   Defense Medical Center
RP Yang, HC (通讯作者)，Acad Sinica, Bioinformat Program, Taiwan Int Grad Program, Inst Informat Sci, Taipei 115, Taiwan.; Yang, HC (通讯作者)，Acad Sinica, Inst Stat Sci, Taipei 115, Taiwan.; Yang, HC (通讯作者)，Natl Cheng Kung Univ, Dept Stat, Tainan 701, Taiwan.; Yang, HC (通讯作者)，Natl Tsing Hua Univ, Inst Stat, Hsinchu 300, Taiwan.; Yang, HC (通讯作者)，Natl Yang Ming Univ, Inst Publ Hlth, Taipei 112, Taiwan.; Yang, HC (通讯作者)，Natl Def Med Ctr, Sch Publ Hlth, Taipei 114, Taiwan.
EM hsinchou@stat.sinica.edu.tw
RI Yang, Hsin-Chou/AAP-2547-2021
OI Yang, Hsin-Chou/0000-0001-6853-7881
FU Ministry of Science and Technology of Taiwan [MOST
   106-2314-B-001-003-MY3]
FX This work was partially supported by the Ministry of Science and
   Technology of Taiwan under Grant MOST 106-2314-B-001-003-MY3. The
   authors have no other relevant affiliations or financial involvement
   with any organization or entity with a financial interest in or
   financial conflict with the subject matter or materials discussed in the
   manuscript apart from those disclosed.
CR Anisimov VN, 2009, BIOGERONTOLOGY, V10, P323, DOI 10.1007/s10522-008-9209-8
   [Anonymous], 1981, Simultaneous Statistical Inference, Springer Series in Statistics, DOI DOI 10.1007/978-1-4613-8122-84
   Barrow TM, 2014, BIOCHEM BIOPH RES CO, V455, P70, DOI 10.1016/j.bbrc.2014.08.002
   Brewster LM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032471
   Çaliskan M, 2011, HUM MOL GENET, V20, P1643, DOI 10.1093/hmg/ddr041
   Caprio S, 2008, DIABETES CARE, V31, P2211, DOI 10.2337/dc08-9024
   Chung WH, 2004, NATURE, V428, P486, DOI 10.1038/428486a
   Conway K, 2015, CANCER EPIDEM BIOMAR, V24, P921, DOI 10.1158/1055-9965.EPI-14-1228
   Danforth DN, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3429
   de Magalhaes JP, 2013, NAT REV CANCER, V13, P357, DOI 10.1038/nrc3497
   Dedeurwaerder S, 2011, EPIGENOMICS-UK, V3, P771, DOI [10.2217/EPI.11.105, 10.2217/epi.11.105]
   Delser PM, 2013, HUM GENET, V132, P563, DOI 10.1007/s00439-013-1268-5
   Dombroski BA, 2010, AM J HUM GENET, V86, P719, DOI 10.1016/j.ajhg.2010.03.017
   Du P, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-587
   Eltayeb AE, 2015, CANCER RES, V1, P640
   Esteller M, 2000, NEW ENGL J MED, V343, P1350, DOI 10.1056/NEJM200011093431901
   Fang F, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3001875
   Fraser HB, 2012, GENOME BIOL, V13, DOI 10.1186/gb-2012-13-2-r8
   Getz G, 2013, NATURE, V497, P67, DOI 10.1038/nature12113
   Gomez A, 2009, CLIN PHARMACOL THER, V85, P426, DOI 10.1038/clpt.2009.2
   Grafodatskaya D, 2010, GENOMICS, V95, P73, DOI 10.1016/j.ygeno.2009.12.001
   Griebel T, 2012, NUCLEIC ACIDS RES, V40, P10073, DOI 10.1093/nar/gks666
   Hartmann O, 2009, CLIN CANCER RES, V15, P315, DOI 10.1158/1078-0432.CCR-08-0166
   Heyn H, 2013, GENOME RES, V23, P1363, DOI 10.1101/gr.154187.112
   Heyn H, 2012, NAT REV GENET, V13, P679, DOI 10.1038/nrg3270
   Hinoue T, 2012, GENOME RES, V22, P271, DOI 10.1101/gr.117523.110
   Horvath S, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-1030-0
   Horvath S, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-10-r115
   Johnson WE, 2007, BIOSTATISTICS, V8, P118, DOI 10.1093/biostatistics/kxj037
   Jones PA, 2012, NAT REV GENET, V13, P484, DOI 10.1038/nrg3230
   Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412
   Korkola JE, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-61
   Kurian AK, 2007, ETHNIC DIS, V17, P143
   Lapenna S, 2009, NAT REV DRUG DISCOV, V8, P547, DOI 10.1038/nrd2907
   Lappalainen T, 2013, NATURE, V501, P506, DOI 10.1038/nature12531
   Lawrence MS, 2015, NATURE, V517, P576, DOI 10.1038/nature14129
   Lechner M, 2010, ADV GENET, V70, P247, DOI [10.1016/B978-0-12-380866-0.60009-5, 10.1016/S0065-2660(10)70009-2]
   Leek JT, 2007, PLOS GENET, V3, P1724, DOI 10.1371/journal.pgen.0030161
   Li B, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-323
   Li M, 2007, P NATL ACAD SCI USA, V104, P18636, DOI 10.1073/pnas.0709307104
   Li Q, 2012, P NATL ACAD SCI USA, V109, P14110, DOI 10.1073/pnas.1116597109
   Lister R, 2009, NATURE, V462, P315, DOI 10.1038/nature08514
   Liu YJ, 2016, SCI REP-UK, V6, DOI 10.1038/srep20642
   Lokk K, 2014, GENOME BIOL, V15, DOI 10.1186/gb-2014-15-4-r54
   Malumbres M, 2009, NAT REV CANCER, V9, P153, DOI 10.1038/nrc2602
   Mangoni AA, 2004, BRIT J CLIN PHARMACO, V57, P6, DOI 10.1046/j.1365-2125.2003.02007.x
   Marco-Sola S, 2012, NAT METHODS, V9, P1185, DOI [10.1038/NMETH.2221, 10.1038/nmeth.2221]
   Mihály Z, 2013, BREAST CANCER RES TR, V140, P219, DOI 10.1007/s10549-013-2622-y
   Moen EL, 2013, GENETICS, V194, P987, DOI 10.1534/genetics.113.151381
   Murase D, 2013, J INVEST DERMATOL, V133, P2416, DOI 10.1038/jid.2013.165
   Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252
   Ogino S, 2016, EPIDEMIOLOGY, V27, P602, DOI 10.1097/EDE.0000000000000471
   Ogino S, 2013, MODERN PATHOL, V26, P465, DOI 10.1038/modpathol.2012.214
   Ogino S, 2011, GUT, V60, P397, DOI 10.1136/gut.2010.217182
   Portela A, 2010, NAT BIOTECHNOL, V28, P1057, DOI 10.1038/nbt.1685
   Ramos E, 2014, PHARMACOGENOMICS J, V14, P217, DOI 10.1038/tpj.2013.24
   Sandoval J, 2011, EPIGENETICS-US, V6, P692, DOI 10.4161/epi.6.6.16196
   Schlattner U, 2006, BBA-MOL BASIS DIS, V1762, P164, DOI 10.1016/j.bbadis.2005.09.004
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Suzuki H, 2014, BIOCHEM BIOPH RES CO, V455, P35, DOI 10.1016/j.bbrc.2014.07.007
   't Hoen PAC, 2013, NAT BIOTECHNOL, V31, P1015, DOI 10.1038/nbt.2702
   Teschendorff AE, 2013, BIOINFORMATICS, V29, P189, DOI 10.1093/bioinformatics/bts680
   Tichy JR, 2015, BREAST CANCER RES TR, V150, P667, DOI 10.1007/s10549-015-3350-2
   Veeck J, 2010, J CLIN ONCOL, V28, pE563, DOI 10.1200/JCO.2010.30.1010
   Wang K, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkq622
   Weber M, 2007, CURR OPIN CELL BIOL, V19, P273, DOI 10.1016/j.ceb.2007.04.011
   Weisenberger DJ, 2015, CANCER EPIDEM BIOMAR, V24, P512, DOI 10.1158/1055-9965.EPI-14-1161
   Wiencke JK, 2004, NAT REV CANCER, V4, P79, DOI 10.1038/nrc1257
   Wilkinson S, 2005, NAT CELL BIOL, V7, P255, DOI 10.1038/ncb1230
   Wilkinson S, 2011, AUTOPHAGY, V7, P1295, DOI 10.4161/auto.7.11.16646
   Winter S, 2016, SCI REP-UK, V6, DOI 10.1038/srep29930
   Wright JL, 2012, BREAST, V21, P276, DOI 10.1016/j.breast.2011.11.003
   Xia YY, 2014, BBA-REV CANCER, V1846, P258, DOI 10.1016/j.bbcan.2014.07.001
   Yi X, 2012, J BIOL CHEM, V287, P21045, DOI 10.1074/jbc.M112.355321
   Zhang X, 2014, HUM MOL GENET, V23, P5893, DOI 10.1093/hmg/ddu313
NR 75
TC 14
Z9 16
U1 1
U2 6
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
   1QB, ENGLAND
SN 1750-1911
EI 1750-192X
J9 EPIGENOMICS-UK
JI Epigenomics
PD NOV
PY 2017
VL 9
IS 11
BP 1437
EP 1454
DI 10.2217/epi-2017-0046
PG 18
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA FO0FW
UT WOS:000416419400009
PM 28882057
OA hybrid
DA 2025-01-12
ER

PT J
AU Heilmann, K
   Toth, R
   Bossmann, C
   Klimo, K
   Plass, C
   Gerhauser, C
AF Heilmann, K.
   Toth, R.
   Bossmann, C.
   Klimo, K.
   Plass, C.
   Gerhauser, C.
TI Genome-wide screen for differentially methylated long noncoding RNAs
   identifies <i>Esrp2</i> and lncRNA <i>Esrp2</i>-as regulated by enhancer
   DNA methylation with prognostic relevance for human breast cancer
SO ONCOGENE
LA English
DT Article
ID EPITHELIAL-MESENCHYMAL TRANSITION; MAMMALIAN EXPRESSION ATLAS;
   ENGINEERED MOUSE MODELS; TUMOR-SUPPRESSOR GENE; MAMMARY ADENOCARCINOMA;
   CPG METHYLATION; BONE METASTASIS; SEQUENCING DATA; SEQ EXPERIMENTS;
   STEM-CELLS
AB The majority of long noncoding RNAs (lncRNAs) is still poorly characterized with respect to function, interactions with protein-coding genes, and mechanisms that regulate their expression. As for protein-coding RNAs, epigenetic deregulation of lncRNA expression by alterations in DNA methylation might contribute to carcinogenesis. To provide genome-wide information on lncRNAs aberrantly methylated in breast cancer we profiled tumors of the C3(1) SV40TAg mouse model by MCIp-seq (Methylated CpG Immunoprecipitation followed by sequencing). This approach detected 69 lncRNAs differentially methylated between tumor tissue and normal mammary glands, with 26 located in antisense orientation of a protein-coding gene. One of the hypomethylated lncRNAs, 1810019D21Rik (now called Esrp2-antisense (as)) was identified in proximity to the epithelial splicing regulatory protein 2 (Esrp2) that is significantly elevated in C3(1) tumors. ESRPs were shown previously to have a dual role in carcinogenesis. Both gain and loss have been associated with poor prognosis in human cancers, but the mechanisms regulating expression are not known. Indepth analyses indicate that coordinate overexpression of Esrp2 and Esrp2-as inversely correlates with DNA methylation. Luciferase reporter gene assays support co-expression of Esrp2 and the major short Esrp2-as variant from a bidirectional promoter, and transcriptional regulation by methylation of a proximal enhancer. Ultimately, this enhancer-based regulatory mechanism provides a novel explanation for tissue-specific expression differences and upregulation of Esrp2 during carcinogenesis. Knockdown of Esrp2-as reduced Esrp2 protein levels without affecting mRNA expression and resulted in an altered transcriptional profile associated with extracellular matrix (ECM), cell motility and reduced proliferation, whereas overexpression enhanced proliferation. Our findings not only hold true for the murine tumor model, but led to the identification of an unannotated human homolog of Esrp2-as which is significantly upregulated in human breast cancer and associated with poor prognosis.
C1 [Heilmann, K.; Toth, R.; Bossmann, C.; Klimo, K.; Plass, C.; Gerhauser, C.] German Canc Res Ctr, Div Epigen & Canc Risk Factors, Neuenheimer Feld 280, D-69120 Heidelberg, BW, Germany.
C3 Helmholtz Association; German Cancer Research Center (DKFZ)
RP Gerhauser, C (通讯作者)，German Canc Res Ctr, Div Epigen & Canc Risk Factors, Neuenheimer Feld 280, D-69120 Heidelberg, BW, Germany.
EM c.gerhauser@dkfz.de
RI Toth, Reka/AAB-1695-2020
OI Toth, Reka/0000-0002-6096-1052; Gerhauser, Clarissa/0000-0002-5792-3901;
   Plass, Christoph/0000-0003-2554-3952
FU DKFZ Helmholtz International Graduate School for Cancer Research
FX KH was supported by a Ph.D. scholarship provided by the DKFZ Helmholtz
   International Graduate School for Cancer Research. We are grateful to
   Megumio Onishi Seebacher for providing barcoded oligonucleotide
   sequences, the Genome and Proteome core facility of the DKFZ for
   providing technical support and excellent MCIp-seq and RNA-seq services,
   and Lorena Salgueiro and Rocio Sotillo Roman for their instant support
   in isolating murine mammary epithelial cells and fibroblasts. We further
   want to thank Oliver Mucke and Monika Helf for excellent technical
   assistance, and Thomas Risch, Maiwen Caudron-Herger, Odilia Popanda and
   Dieter Weichenhan for helpful discussion. The results reported here are
   in part based upon data generated by The Cancer Genome Atlas managed by
   the NCI and NHGRI. Information about TCGA can be found at
   http://cancergenome.nih.gov.
CR Abate-Shen C, 2002, NAT REV CANCER, V2, P777, DOI 10.1038/nrc907
   Ades F, 2014, J CLIN ONCOL, V32, P2794, DOI 10.1200/JCO.2013.54.1870
   Anders S, 2015, BIOINFORMATICS, V31, P166, DOI 10.1093/bioinformatics/btu638
   [Anonymous], 2015, SCI REP UK
   Arab K, 2014, MOL CELL, V55, P604, DOI 10.1016/j.molcel.2014.06.031
   Aran D, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-3-r21
   Asch-Kendrick R, 2016, HUM PATHOL, V48, P37, DOI 10.1016/j.humpath.2015.09.035
   Baer C, 2015, INT J CANCER, V137, P1352, DOI 10.1002/ijc.29491
   Bai YG, 2014, CANCER CELL INT, V14, DOI 10.1186/s12935-014-0079-7
   Bashir M, 2015, NPJ BREAST CANCER, V1, DOI 10.1038/npjbcancer.2015.7
   Batts TD, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027841
   Ben-Porath I, 2008, NAT GENET, V40, P499, DOI 10.1038/ng.127
   Bennett CN, 2010, TOXICOL PATHOL, V38, P88, DOI 10.1177/0192623309357074
   Bennett CN, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2125
   Bertucci F, 2012, CURR MOL MED, V12, P96, DOI 10.2174/156652412798376134
   Blaas L, 2016, NAT CELL BIOL, V18, P1346, DOI 10.1038/ncb3434
   Bock C, 2012, MOL CELL, V47, P633, DOI 10.1016/j.molcel.2012.06.019
   Bonnans C, 2014, NAT REV MOL CELL BIO, V15, P786, DOI 10.1038/nrm3904
   Carrieri C, 2012, NATURE, V491, P454, DOI 10.1038/nature11508
   Chau YM, 2002, J CLIN ENDOCR METAB, V87, P2674, DOI 10.1210/jc.87.6.2674
   Darlington G J, 1987, Methods Enzymol, V151, P19, DOI 10.1016/S0076-6879(87)51006-0
   De Craene B, 2013, NAT REV CANCER, V13, P97, DOI 10.1038/nrc3447
   Deckers M, 2006, CANCER RES, V66, P2202, DOI 10.1158/0008-5472.CAN-05-3560
   Deeb KK, 2007, CANCER RES, V67, P8065, DOI 10.1158/0008-5472.CAN-07-1515
   Deloria AJ, 2016, ONCOTARGET, V7, P73800, DOI 10.18632/oncotarget.12070
   Di Palma T, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.262
   Diederichs S, 2014, TRENDS GENET, V30, P121, DOI 10.1016/j.tig.2014.01.004
   Drake LE, 2014, J PATHOL, V232, P283, DOI 10.1002/path.4298
   Ehrich M, 2005, P NATL ACAD SCI USA, V102, P15785, DOI 10.1073/pnas.0507816102
   Faryna M, 2012, FASEB J, V26, P4937, DOI 10.1096/fj.12-209502
   Forrest ARR, 2014, NATURE, V507, P462, DOI 10.1038/nature13182
   Gal-Yam EN, 2008, P NATL ACAD SCI USA, V105, P12979, DOI 10.1073/pnas.0806437105
   Gebhard C, 2006, CANCER RES, V66, P6118, DOI 10.1158/0008-5472.CAN-06-0376
   Geisler S, 2013, NAT REV MOL CELL BIO, V14, P699, DOI 10.1038/nrm3679
   Göttgens EL, 2016, INT REV CEL MOL BIO, V327, P163, DOI 10.1016/bs.ircmb.2016.06.003
   GREEN H, 1974, CELL, V3, P127, DOI 10.1016/0092-8674(74)90116-0
   Green JE, 2000, ONCOGENE, V19, P1020, DOI 10.1038/sj.onc.1203280
   Grote P, 2013, DEV CELL, V24, P206, DOI 10.1016/j.devcel.2012.12.012
   Guil S, 2012, NAT STRUCT MOL BIOL, V19, P1068, DOI 10.1038/nsmb.2428
   Gumireddy K, 2013, EMBO J, V32, P2672, DOI 10.1038/emboj.2013.188
   Guttman M, 2009, NATURE, V458, P223, DOI 10.1038/nature07672
   Györffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9
   Hayakawa A, 2016, ADV EXP MED BIOL, V925, P33
   Heinz S, 2010, MOL CELL, V38, P576, DOI 10.1016/j.molcel.2010.05.004
   Herschkowitz JI, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-5-r76
   Holzer RG, 2003, BREAST CANCER RES TR, V77, P65, DOI 10.1023/A:1021175931177
   Horiguchi K, 2012, ONCOGENE, V31, P3190, DOI 10.1038/onc.2011.493
   Hu GZ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107016
   Hu XW, 2014, CANCER CELL, V26, P344, DOI 10.1016/j.ccr.2014.07.009
   Huang HY, 2013, CLIN CANCER RES, V19, P2861, DOI 10.1158/1078-0432.CCR-12-2641
   Hwang JA, 2013, ONCOTARGET, V4, P2317, DOI 10.18632/oncotarget.1464
   Hynes RO, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a004903
   Ishii H, 2014, J BIOL CHEM, V289, P27386, DOI 10.1074/jbc.M114.589432
   Iwakiri M, 2009, NEUROPATHOLOGY, V29, P263, DOI 10.1111/j.1440-1789.2008.00978.x
   Jaeger J, 2007, CLIN CANCER RES, V13, P806, DOI 10.1158/1078-0432.CCR-06-1820
   Jechlinger M, 2009, GENE DEV, V23, P1677, DOI 10.1101/gad.1801809
   Johnsson P, 2014, BBA-GEN SUBJECTS, V1840, P1063, DOI 10.1016/j.bbagen.2013.10.035
   Kallen AN, 2013, MOL CELL, V52, P101, DOI 10.1016/j.molcel.2013.08.027
   Karolchik D, 2004, NUCLEIC ACIDS RES, V32, pD493, DOI 10.1093/nar/gkh103
   Kent WJ, 2002, GENOME RES, V12, P996, DOI 10.1101/gr.229102
   Kersten K, 2017, EMBO MOL MED, V9, P137, DOI 10.15252/emmm.201606857
   Kim D, 2015, NAT METHODS, V12, P357, DOI [10.1038/NMETH.3317, 10.1038/nmeth.3317]
   Lee C, 2012, CELL BIOSCI, V2, DOI 10.1186/2045-3701-2-37
   Li AM, 2013, BIOCHEM BIOPH RES CO, V436, P486, DOI 10.1016/j.bbrc.2013.05.131
   Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324
   Lienhard M, 2014, BIOINFORMATICS, V30, P284, DOI 10.1093/bioinformatics/btt650
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lizio M, 2015, GENOME BIOL, V16, DOI 10.1186/s13059-014-0560-6
   MAROULAKOU IG, 1994, P NATL ACAD SCI USA, V91, P11236, DOI 10.1073/pnas.91.23.11236
   Martin M., 2011, EMBnet.journal, V17, P10, DOI DOI 10.14806/EJ.17.1.200
   McCarthy DJ, 2012, NUCLEIC ACIDS RES, V40, P4288, DOI 10.1093/nar/gks042
   Meissner A, 2008, NATURE, V454, P766, DOI 10.1038/nature07107
   Mikkelsen TS, 2007, NATURE, V448, P553, DOI 10.1038/nature06008
   Minden Audrey, 2012, ISRN Oncol, V2012, P694201, DOI 10.5402/2012/694201
   Mizutani A, 2016, ONCOGENE, V35, P3514, DOI 10.1038/onc.2015.412
   Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180
   Morita S, 2000, GENE THER, V7, P1063, DOI 10.1038/sj.gt.3301206
   Naba A, 2016, MATRIX BIOL, V49, P10, DOI 10.1016/j.matbio.2015.06.003
   Nikolsky Y, 2008, CANCER RES, V68, P9532, DOI 10.1158/0008-5472.CAN-08-3082
   Okonechnikov K, 2016, BIOINFORMATICS, V32, P292, DOI 10.1093/bioinformatics/btv566
   Pappa G, 2007, CARCINOGENESIS, V28, P1471, DOI 10.1093/carcin/bgm044
   Pelechano V, 2013, NAT REV GENET, V14, P880, DOI 10.1038/nrg3594
   Pertea M, 2016, NAT PROTOC, V11, P1650, DOI 10.1038/nprot.2016.095
   Pertea M, 2015, NAT BIOTECHNOL, V33, P290, DOI 10.1038/nbt.3122
   Pradella D, 2017, MOL CANCER, V16, DOI 10.1186/s12943-016-0579-2
   Punj V, 2010, CLIN CANCER RES, V16, P1140, DOI 10.1158/1078-0432.CCR-09-2463
   Qin D, 2015, CELL MOL BIOL LETT, V20, P323, DOI 10.1515/cmble-2015-0021
   Quinlan Aaron R, 2014, Curr Protoc Bioinformatics, V47, DOI 10.1002/0471250953.bi1112s47
   Reaves DK, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091747
   Robertson G, 2007, NAT METHODS, V4, P651, DOI 10.1038/NMETH1068
   Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616
   Röring M, 2012, EMBO J, V31, P2629, DOI 10.1038/emboj.2012.100
   Rosenbloom KR, 2013, NUCLEIC ACIDS RES, V41, pD56, DOI 10.1093/nar/gks1172
   Sahu A, 2015, TRENDS CANCER, V1, P93, DOI 10.1016/j.trecan.2015.08.010
   Schilling E, 2007, GENOMICS, V90, P314, DOI 10.1016/j.ygeno.2007.04.011
   Shapiro IM, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002218
   Smalley MJ, 2010, METHODS MOL BIOL, V633, P139, DOI 10.1007/978-1-59745-019-5_11
   Sonnet Miriam, 2013, Methods Mol Biol, V971, P201, DOI 10.1007/978-1-62703-269-8_11
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Sun H, 2016, J CELL MOL MED, V20, P1234, DOI 10.1111/jcmm.12783
   Tommasi S, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2233
   Tsai MC, 2010, SCIENCE, V329, P689, DOI 10.1126/science.1192002
   Tseng YY, 2015, MOL CELL ONCOL, V2, DOI 10.4161/23723556.2014.974467
   Tseng YY, 2014, NATURE, V512, P82, DOI 10.1038/nature13311
   Visvader JE, 2014, GENE DEV, V28, P1143, DOI 10.1101/gad.242511.114
   Walrath JC, 2010, ADV CANCER RES, V106, P113, DOI 10.1016/S0065-230X(10)06004-5
   Wang DS, 2015, NATURE, V517, P81, DOI 10.1038/nature13851
   Wang W, 2005, ONCOGENE, V24, P2705, DOI 10.1038/sj.onc.1208464
   Warzecha CC, 2012, SEMIN CANCER BIOL, V22, P417, DOI 10.1016/j.semcancer.2012.04.003
   Warzecha CC, 2010, EMBO J, V29, P3286, DOI 10.1038/emboj.2010.195
   Warzecha CC, 2009, MOL CELL, V33, P591, DOI 10.1016/j.molcel.2009.01.025
   Xu Z, 2014, ONCOGENE, V33, P2836, DOI 10.1038/onc.2013.243
   Yang F, 2017, CELL MOL LIFE SCI, V74, P951, DOI 10.1007/s00018-016-2334-7
   Yao Y, 2010, CARCINOGENESIS, V31, P382, DOI 10.1093/carcin/bgp308
   Yarmishyn AA, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-S9-S7
   Yoon JH, 2012, MOL CELL, V47, P648, DOI 10.1016/j.molcel.2012.06.027
   Yu HS, 2012, BMC GENOMICS, V13, DOI 10.1186/1471-2164-13-251
   Zhao J, 2010, MOL CELL, V40, P939, DOI 10.1016/j.molcel.2010.12.011
   Zhu M, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-8-r77
NR 119
TC 58
Z9 64
U1 0
U2 16
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-9232
EI 1476-5594
J9 ONCOGENE
JI Oncogene
PD NOV 16
PY 2017
VL 36
IS 46
BP 6446
EP 6461
DI 10.1038/onc.2017.246
PG 16
WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
GA FM9WN
UT WOS:000415622900008
PM 28759043
OA hybrid, Green Published
DA 2025-01-12
ER

PT J
AU Fish, TJ
   Benninghoff, AD
AF Fish, Trevor J.
   Benninghoff, Abby D.
TI DNA methylation in lung tissues of mouse offspring exposed <i>in
   utero</i> to polycyclic aromatic hydrocarbons
SO FOOD AND CHEMICAL TOXICOLOGY
LA English
DT Article
DE Polycyclic aromatic hydrocarbon; Lung cancer; DNA methylation;
   Transplacental; Epigenetics; Methylated DNA immunoprecipitation
ID GENE-PROMOTER HYPERMETHYLATION; BREAST-CANCER CELLS; BONE MORPHOGENETIC
   PROTEINS; TRANSPLACENTAL CARCINOGENESIS; O-6-METHYLGUANINE-DNA
   METHYLTRANSFERASE; TUMOR PROGRESSION; EPITHELIAL-CELLS; PROSTATE-CANCER;
   PTEN EXPRESSION; ADVANCED-STAGE
AB Polycyclic aromatic hydrocarbons (PAHs) comprise an important class of environmental pollutants that are known to cause lung cancer in animals and are suspected lung carcinogens in humans. Moreover, evidence from cell-based studies points to PAHs as modulators of the epigenome. The objective of this work was to assess patterns of genome-wide DNA methylation in lung tissues of adult offspring initiated in utero with the transplacental PAH carcinogens dibenzo [defp]chrysene (DBC) or benzo [a]pyrene (BaP). Genome-wide methylation patterns for normal (not exposed), normal adjacent and lung tumor tissues obtained from adult offspring were determined using methylated DNA immunoprecipitation (MeDIP) with the NimbleGen mouse DNA methylation CpG island array. Lung tumor incidence in 45-week old mice initiated with BaP was 32%, much lower than that of the DBC-exposed offspring at 96%. Also, male offspring appeared more susceptible to BaP as compared to females. Distinct patterns of DNA methylation were associated with non-exposed, normal adjacent and adenocarcinoma lung tissues, as determined by principal components, hierarchical clustering and gene ontology analyses. From these methylation profiles, a set of genes of interest was identified that includes potential important targets for epigenetic modification during the process of lung tumorigenesis in animals exposed to environmental PAHs. (C) 2017 Elsevier Ltd. All rights reserved.
C1 [Fish, Trevor J.; Benninghoff, Abby D.] Utah State Univ, Dept Anim Dairy & Vet Sci, 4815 Old Main Hill, Logan, UT 84322 USA.
   [Benninghoff, Abby D.] Utah State Univ, Sch Vet Med, Logan, UT 84322 USA.
   [Fish, Trevor J.] Nelson Labs, Salt Lake City, UT 84123 USA.
C3 Utah System of Higher Education; Utah State University; Utah System of
   Higher Education; Utah State University
RP Benninghoff, AD (通讯作者)，Utah State Univ, Dept Anim Dairy & Vet Sci, 4815 Old Main Hill, Logan, UT 84322 USA.
EM abby.benninghoff@usu.edu
RI Benninghoff, Abby/AAK-6775-2020
OI Benninghoff, Abby/0000-0002-7993-0117
FU National Institute of Environmental Health Sciences [R03ES018919]; Utah
   Agricultural Experiment Station, Utah State University [UTA00172]
FX We gratefully acknowledge the technical assistance provided by Deanna
   Larson, Stephany Perez Monsanto and Amanda Hagman in execution of the
   mouse study. We also thank Dr. Aaron Thomas for his advice and
   assistance in the methylated DNA immunoprecipitation procedure. This
   work was supported by the National Institute of Environmental Health
   Sciences (grant number R03ES018919 to A.D.B.) and the Utah Agricultural
   Experiment Station (project number UTA00172), Utah State University, and
   approved as journal paper number 9000.
CR American Cancer Society, 2017, Cancer facts & fi gures 2017-special section: rare cancers in adults
   ANDERSON LM, 1985, CARCINOGENESIS, V6, P1389, DOI 10.1093/carcin/6.9.1389
   ANDERSON LM, 1989, CANCER RES, V49, P3770
   Bandyopadhyay A, 2013, BIOCHEM PHARMACOL, V85, P857, DOI 10.1016/j.bcp.2013.01.004
   Belinsky SA, 2004, NAT REV CANCER, V4, P707, DOI 10.1038/nrc1432
   Belinsky SA, 2005, CARCINOGENESIS, V26, P1481, DOI 10.1093/carcin/bgi020
   Belinsky SA, 2015, ANNU REV PHYSIOL, V77, P453, DOI 10.1146/annurev-physiol-021014-072018
   Calvo MB, 2009, CLIN TRANSL ONCOL, V11, P126, DOI 10.1007/S12094-009-0328-8
   Boström CE, 2002, ENVIRON HEALTH PERSP, V110, P451, DOI 10.1289/ehp.02110s3451
   Boutros R, 2005, EXP CELL RES, V310, P152, DOI 10.1016/j.yexcr.2005.07.009
   Brzezianska E, 2013, MOL BIOL REP, V40, P309, DOI 10.1007/s11033-012-2063-4
   BYRNE JA, 1995, CANCER RES, V55, P2896
   Byrne JA, 2005, INT J CANCER, V117, P1049, DOI 10.1002/ijc.21250
   Castro DJ, 2008, CANCER PREV RES, V1, P128, DOI 10.1158/1940-6207.CAPR-07-0004
   Castro DJ, 2008, CARCINOGENESIS, V29, P1581, DOI 10.1093/carcin/bgm237
   Castro DJ, 2009, CARCINOGENESIS, V30, P315, DOI 10.1093/carcin/bgn280
   Castro DJ, 2008, TOXICOL APPL PHARM, V233, P454, DOI 10.1016/j.taap.2008.09.009
   Chen SL, 1996, ONCOGENE, V12, P741
   Chu EC, 2004, MED SCI MONITOR, V10, pRA235
   Chung JH, 2011, VIRCHOWS ARCH, V459, P201, DOI 10.1007/s00428-011-1079-9
   Cui X, 2006, TOXICOL SCI, V91, P372, DOI 10.1093/toxsci/kfj159
   Dai ZY, 2004, ONCOGENE, V23, P3521, DOI 10.1038/sj.onc.1207441
   Dai ZY, 2001, NEOPLASIA, V3, P314, DOI 10.1038/sj.neo.7900162
   Damiani LA, 2008, CANCER RES, V68, P9005, DOI 10.1158/0008-5472.CAN-08-1276
   Divine KK, 2005, INT J CANCER, V114, P400, DOI 10.1002/ijc.20761
   Du Z, 2010, NUCLEIC ACIDS RES, V38, pW64, DOI 10.1093/nar/gkq310
   Esteller M, 1999, CANCER RES, V59, P793
   Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210
   Fish T.J., DATA IN BRIEF
   Freeman JR, 2016, ONCOTARGET, V7, P69579, DOI 10.18632/oncotarget.11831
   García JM, 2004, GENE CHROMOSOME CANC, V41, P117, DOI 10.1002/gcc.20062
   Hammoud Z, 2008, ENDOCR-RELAT CANCER, V15, P475, DOI 10.1677/ERC-08-0002
   HASEGAWA R, 1995, CANCER RES, V55, P4333
   Hatakeyama S, 1997, BIOCHEM MOL BIOL INT, V42, P497
   Hecht SS, 1998, CHEM RES TOXICOL, V11, P559, DOI 10.1021/tx980005y
   Horvath LG, 2004, PROSTATE, V59, P234, DOI 10.1002/pros.10361
   Hsu YT, 2013, CLIN CANCER RES, V19, P6272, DOI 10.1158/1078-0432.CCR-13-1734
   Josyula S, 2000, TOXICOL APPL PHARM, V166, P151, DOI 10.1006/taap.2000.8964
   Kang YH, 2002, LAB INVEST, V82, P285, DOI 10.1038/labinvest.3780422
   Kim DH, 2001, CANCER RES, V61, P3419
   Kim DH, 2001, ONCOGENE, V20, P1765, DOI 10.1038/sj.onc.1204302
   Kiyohara C, 2010, GENDER MED, V7, P381, DOI 10.1016/j.genm.2010.10.002
   Knight TR, 2007, TOXICOL SCI, V100, P513, DOI 10.1093/toxsci/kfm233
   Kodach LL, 2008, GASTROENTEROLOGY, V134, P1332, DOI 10.1053/j.gastro.2008.02.059
   Kraunz KS, 2005, BRIT J CANCER, V93, P949, DOI 10.1038/sj.bjc.6602790
   Lee MN, 2007, CLIN CANCER RES, V13, P832, DOI 10.1158/1078-0432.CCR-05-2694
   Leslie NR, 2004, BIOCHEM J, V382, P1, DOI 10.1042/BJ20040825
   Li G, 2012, BIOCHEM BIOPH RES CO, V418, P547, DOI 10.1016/j.bbrc.2012.01.065
   Li WZ, 2015, NUCLEIC ACIDS RES, V43, pW580, DOI 10.1093/nar/gkv279
   Licchesi JDF, 2008, CLIN CANCER RES, V14, P2570, DOI 10.1158/1078-0432.CCR-07-2033
   Lightfoot TJ, 2004, TOXICOL APPL PHARM, V199, P104, DOI 10.1016/j.taap.2003.12.032
   LOKTIONOV A, 1992, CARCINOGENESIS, V13, P19, DOI 10.1093/carcin/13.1.19
   Luch A, 1998, CHEM RES TOXICOL, V11, P686, DOI 10.1021/tx970236p
   Luch A, 2005, CARCINOGENIC EFFECTS OF POLYCYCLIC AROMATIC HYDROCARBONS, P1
   Maeda M, 2015, LUNG CANCER, V87, P265, DOI 10.1016/j.lungcan.2015.01.009
   Malek RL, 2002, ONCOGENE, V21, P7256, DOI 10.1038/sj.onc.1205900
   MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686
   MILLER MS, 1994, CHEM RES TOXICOL, V7, P471, DOI 10.1021/tx00040a001
   Miller MS, 2000, EXP LUNG RES, V26, P709
   Pulling LC, 2004, CANCER RES, V64, P3844, DOI 10.1158/0008-5472.CAN-03-2119
   Pulling LC, 2003, CANCER RES, V63, P4842
   Reisen F, 2005, ENVIRON SCI TECHNOL, V39, P64, DOI 10.1021/es035454l
   Reliene R, 2005, MUTAT RES-FUND MOL M, V570, P245, DOI 10.1016/j.mrfmmm.2004.11.010
   RISCH HA, 1993, AM J EPIDEMIOL, V138, P281, DOI 10.1093/oxfordjournals.aje.a116857
   Roesch A, 2007, CANCER EPIDEM BIOMAR, V16, P2486, DOI 10.1158/1055-9965.EPI-07-0224
   Sadikovic B, 2008, J BIOL CHEM, V283, P4051, DOI 10.1074/jbc.M707506200
   Sadikovic B, 2006, TOXICOL APPL PHARM, V216, P458, DOI 10.1016/j.taap.2006.06.012
   Saeed AI, 2003, BIOTECHNIQUES, V34, P374, DOI 10.2144/03342mt01
   Salvesen HB, 2001, INT J CANCER, V91, P22, DOI 10.1002/1097-0215(20010101)91:1<22::AID-IJC1002>3.0.CO;2-S
   Sato T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059444
   Sharma R, 1997, J TOXICOL ENV HEALTH, V52, P45, DOI 10.1080/009841097159782
   Shen J, 2007, TOXICOL SCI, V95, P313, DOI 10.1093/toxsci/kfl151
   Shorey LE, 2012, CANCER LETT, V317, P49, DOI 10.1016/j.canlet.2011.11.010
   SOMOGYI A, 1993, ENVIRON HEALTH PERSP, V101, P45, DOI 10.2307/3431375
   Soria JC, 2002, CLIN CANCER RES, V8, P1178
   Tam AS, 2003, CARCINOGENESIS, V24, P121, DOI 10.1093/carcin/24.1.121
   Tang XM, 2000, JNCI-J NATL CANCER I, V92, P1511, DOI 10.1093/jnci/92.18.1511
   Toyooka KO, 2001, CANCER RES, V61, P4556
   Toyooka S, 2003, CLIN CANCER RES, V9, P3034
   U. S. Energy Information Administration, 2016, COAL CURR ISS TRENDS
   Virmani AK, 2000, J NATL CANCER I, V92, P1303, DOI 10.1093/jnci/92.16.1303
   Vizoso M, 2015, CARCINOGENESIS, V36, P1453, DOI 10.1093/carcin/bgv146
   Vuillemenot BR, 2006, MOL CANCER RES, V4, P267, DOI 10.1158/1541-7786.MCR-05-0218
   Vuillemenot BR, 2004, CARCINOGENESIS, V25, P623, DOI 10.1093/carcin/bgh038
   Waalkes MP, 2004, TOXICOL APPL PHARM, V198, P377, DOI 10.1016/j.taap.2003.10.028
   Wang LM, 2017, ONCOL LETT, V13, P329, DOI 10.3892/ol.2016.5423
   Wang RX, 2004, CANCER RES, V64, P1589, DOI 10.1158/0008-5472.CAN-03-3331
   Wang Z, 2014, CELL MOL BIOL, V60, P39
   Wen XZ, 2006, ONCOGENE, V25, P2666, DOI 10.1038/sj.onc.1209297
   Wiencke JK, 2007, NEURO-ONCOLOGY, V9, P271, DOI 10.1215/15228517-2007-003
   Yan HD, 2017, J TRANSL MED, V15, DOI 10.1186/s12967-017-1122-y
   Yu Z, 2006, CANCER RES, V66, P755, DOI 10.1158/0008-5472.CAN-05-3390
   Yu Z, 2006, CARCINOGENESIS, V27, P2116, DOI 10.1093/carcin/bgl072
   Zhang QH, 2015, GENET MOL RES, V14, P9200, DOI 10.4238/2015.August.7.30
   Zhu XY, 2016, ENVIRON HEALTH PERSP, V124, P966, DOI 10.1289/ehp.1509834
   Zöchbauer-Müller S, 2001, CANCER RES, V61, P249
NR 96
TC 5
Z9 6
U1 1
U2 31
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0278-6915
EI 1873-6351
J9 FOOD CHEM TOXICOL
JI Food Chem. Toxicol.
PD NOV
PY 2017
VL 109
BP 703
EP 713
DI 10.1016/j.fct.2017.04.047
PN 1
PG 11
WC Food Science & Technology; Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Food Science & Technology; Toxicology
GA FN3PN
UT WOS:000415911400062
PM 28476633
OA Green Accepted
DA 2025-01-12
ER

PT J
AU He, Y
   Wei, F
   Zhang, SS
   Gong, ZJ
   Guo, C
   Li, XY
   Li, XL
   Zhou, M
   Xiong, W
   Li, GY
   Zeng, ZY
   Shi, L
AF He Yi
   Wei Fang
   Zhang Shan-Shan
   Gong Zhao-Jian
   Guo Can
   Li Xia-Yu
   Li Xiao-Ling
   Zhou Ming
   Xiong Wei
   Li Gui-Yuan
   Zeng Zhao-Yang
   Shi Lei
TI The Role and Mechanism of PVT1 in Promoting Human Cancer Progression
SO PROGRESS IN BIOCHEMISTRY AND BIOPHYSICS
LA Chinese
DT Article
DE cancer; long non-coding RNA; PVT1; MYC
ID LONG NONCODING RNA; SQUAMOUS-CELL CARCINOMA; C-MYC ONCOGENE;
   POOR-PROGNOSIS; GASTRIC-CANCER; NASOPHARYNGEAL CARCINOMA; BREAST-CANCER;
   LUNG-CANCER; EPIGENETIC REGULATION; INCREASED EXPRESSION
AB In recent years, long non-coding RNA is found to play an important role in the regulation of cell growth, differentiation and other biological functions, and is closely related to the occurrence and development of cancer. The long non-coding RNA gene, PVT1, located in the fragile chromosome 8q24 region has been widely concerned. LncRNA PVT1 is highly expresses in many types of cancer, and act as potential oncogene. It is commonly to form new fusion gene by chromosome break, and translocation, and regulation of tumor cell function; it also interact with MYC and participate in tumor cell proliferation, apoptosis by multiple pathways. However, the specific molecular mechanisms that occur in the development of cancer still need further research. In this paper, we summarized the features, functions and roles of PVT1 in human cancer.
C1 [He Yi; Wei Fang; Li Xiao-Ling; Zhou Ming; Xiong Wei; Li Gui-Yuan; Zeng Zhao-Yang; Shi Lei] Cent S Univ, Hunan Canc Hosp, Changsha 410013, Hunan, Peoples R China.
   [He Yi; Wei Fang; Li Xiao-Ling; Zhou Ming; Xiong Wei; Li Gui-Yuan; Zeng Zhao-Yang; Shi Lei] Cent S Univ, Affiliated Canc Hosp, Xiangya Sch Med, Changsha 410013, Hunan, Peoples R China.
   [He Yi; Wei Fang; Gong Zhao-Jian; Guo Can; Li Xiao-Ling; Zhou Ming; Xiong Wei; Li Gui-Yuan; Zeng Zhao-Yang; Shi Lei] Cent S Univ, Key Lab Carcinogenesis, Minist Hlth, Canc Res Inst, Changsha 410078, Hunan, Peoples R China.
   [He Yi; Wei Fang; Zhang Shan-Shan; Guo Can; Li Xiao-Ling; Zhou Ming; Xiong Wei; Li Gui-Yuan; Zeng Zhao-Yang] Cent S Univ, Key Lab Carcinogenesis & Canc Invas, Xiangya Hosp, Minist Educ, Changsha 410078, Hunan, Peoples R China.
   [Gong Zhao-Jian; Shi Lei] Cent S Univ, Xiangya Hosp 2, Changsha 410011, Hunan, Peoples R China.
   [Li Xia-Yu] Cent S Univ, Hunan Key Lab Nonresolving Inflammat & Canc, Xiangya Hosp 3, Changsha 410013, Hunan, Peoples R China.
C3 Central South University; Central South University; Central South
   University; Central South University; Central South University; Central
   South University
RP Zeng, ZY; Shi, L (通讯作者)，Cent S Univ, Hunan Canc Hosp, Changsha 410013, Hunan, Peoples R China.; Zeng, ZY; Shi, L (通讯作者)，Cent S Univ, Affiliated Canc Hosp, Xiangya Sch Med, Changsha 410013, Hunan, Peoples R China.; Zeng, ZY; Shi, L (通讯作者)，Cent S Univ, Key Lab Carcinogenesis, Minist Hlth, Canc Res Inst, Changsha 410078, Hunan, Peoples R China.; Zeng, ZY (通讯作者)，Cent S Univ, Key Lab Carcinogenesis & Canc Invas, Xiangya Hosp, Minist Educ, Changsha 410078, Hunan, Peoples R China.; Shi, L (通讯作者)，Cent S Univ, Xiangya Hosp 2, Changsha 410011, Hunan, Peoples R China.
EM zengzhaoyang@csu.edu.cn; shilei10@126.com
RI li, xia/HHZ-7468-2022; Zhang, shanshan/HLP-6320-2023; Zeng,
   Zhaoyang/LLL-3057-2024
FU National Natural Science Foundation of China [81372907, 81472531,
   81572787, 81672683, 81672993]; Hunan Province Natural Sciences
   Foundation of China [2015JJ1022]
FX This work was supported by grants from The National Natural Science
   Foundation of China (81372907, 81472531, 81572787, 81672683, 81672993)
   and the Hunan Province Natural Sciences Foundation of China
   (2015JJ1022).
CR ASKER C, 1988, LEUKEMIA RES, V12, P523, DOI 10.1016/0145-2126(88)90120-8
   Barsotti AM, 2012, J BIOL CHEM, V287, P2509, DOI 10.1074/jbc.M111.322875
   Beck-Engeser GB, 2008, RETROVIROLOGY, V5, DOI 10.1186/1742-4690-5-4
   Bo H, 2015, ONCOTARGET, V6, P20404, DOI 10.18632/oncotarget.4057
   Campbell PJ, 2008, NAT GENET, V40, P722, DOI 10.1038/ng.128
   Carramusa L, 2007, J CELL PHYSIOL, V213, P511, DOI 10.1002/jcp.21133
   Chen J, 2016, SCI CHINA LIFE SCI, V59, P227, DOI 10.1007/s11427-016-5010-0
   Chen XM, 2014, PROG BIOCHEM BIOPHYS, V41, P997, DOI 10.3724/SP.J.1206.2014.00294
   Cheng L, 2016, SCI CHINA LIFE SCI, V59, P236, DOI 10.1007/s11427-016-5012-y
   Chinen Y, 2014, J HEMATOL ONCOL, V7, DOI 10.1186/s13045-014-0068-2
   CORY S, 1985, EMBO J, V4, P675, DOI 10.1002/j.1460-2075.1985.tb03682.x
   Cui D, 2016, TUMOR BIOL, V37, P4127, DOI 10.1007/s13277-015-4261-x
   Dang CV, 2012, CELL, V149, P22, DOI 10.1016/j.cell.2012.03.003
   Ding CF, 2015, ONCOL LETT, V9, P955, DOI 10.3892/ol.2014.2730
   Fan CM, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0699-3
   Farhana L, 2016, CANCER MED-US, V5, P1268, DOI 10.1002/cam4.690
   Ferber MJ, 2004, CANCER GENET CYTOGEN, V154, P1, DOI 10.1016/j.cancergencyto.2004.01.028
   Gong ZJ, 2012, PROG BIOCHEM BIOPHYS, V39, P1133, DOI 10.3724/SP.J.1206.2012.00015
   Gong ZJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110674
   Gong ZJ, 2012, SCI CHINA LIFE SCI, V55, P1120, DOI 10.1007/s11427-012-4413-9
   GRAHAM M, 1986, EMBO J, V5, P2845, DOI 10.1002/j.1460-2075.1986.tb04578.x
   Guan YH, 2007, CLIN CANCER RES, V13, P5745, DOI 10.1158/1078-0432.CCR-06-2882
   Hao YJ, 2017, PROG BIOCHEM BIOPHYS, V44, P547, DOI 10.16476/j.pibb.2017.0101
   He BY, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.253
   Huang C, 2015, MINERVA MED, V106, P143
   Hung T, 2010, RNA BIOL, V7, P582, DOI 10.4161/rna.7.5.13216
   Iden M, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0156274
   Johnsson P, 2014, BBA-GEN SUBJECTS, V1840, P1063, DOI 10.1016/j.bbagen.2013.10.035
   JOLICOEUR P, 1985, J VIROL, V56, P1045, DOI 10.1128/JVI.56.3.1045-1048.1985
   Kim D, 2010, J BIOL CHEM, V285, P8383, DOI 10.1074/jbc.M109.094060
   Kim HP, 2014, ONCOGENE, V33, P5434, DOI 10.1038/onc.2013.490
   Kong R, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0355-8
   L'Abbate A, 2014, NUCLEIC ACIDS RES, V42, P9131, DOI 10.1093/nar/gku590
   LEMAY G, 1984, P NATL ACAD SCI-BIOL, V81, P38, DOI 10.1073/pnas.81.1.38
   Li PD, 2017, ONCOTARGET, V8, P34164, DOI 10.18632/oncotarget.15878
   Li TW, 2016, ONCOTARGET, V7, P8601, DOI 10.18632/oncotarget.6926
   Li T, 2017, DIGEST DIS SCI, V62, P3021, DOI 10.1007/s10620-017-4508-z
   Li YW, 2015, PROG BIOCHEM BIOPHYS, V42, P228, DOI 10.16476/j.pibb.2014.0230
   Lian Y, 2016, PROG BIOCHEM BIOPHYS, V43, P219
   Liu EL, 2015, INT J CLIN EXP MED, V8, P20565
   Liu H, 2016, SCI CHINA LIFE SCI, V59, P328, DOI 10.1007/s11427-016-5009-6
   MENGLEGAW L, 1987, EMBO J, V6, P1959, DOI 10.1002/j.1460-2075.1987.tb02458.x
   Mercer TR, 2013, NAT STRUCT MOL BIOL, V20, P300, DOI 10.1038/nsmb.2480
   Nagoshi H, 2012, CANCER RES, V72, P4954, DOI 10.1158/0008-5472.CAN-12-0213
   Nakamura Y, 2015, BLOOD CANCER J, V5, DOI 10.1038/bcj.2015.26
   Nakanishi G, 2009, CLIN EXP DERMATOL, V34, pE965, DOI 10.1111/j.1365-2230.2009.03708.x
   Northcott PA, 2012, NATURE, V488, P49, DOI 10.1038/nature11327
   Paci P, 2014, BMC SYST BIOL, V8, DOI 10.1186/1752-0509-8-83
   Pleasance ED, 2010, NATURE, V463, P184, DOI 10.1038/nature08629
   Rao PH, 2015, GENE CHROMOSOME CANC, V54, P796, DOI 10.1002/gcc.22291
   Riquelme E, 2014, J THORAC ONCOL, V9, P998, DOI 10.1097/JTO.0000000000000202
   Sarver AL, 2016, CELL CYCLE, V15, P881, DOI 10.1080/15384101.2016.1149660
   SHTIVELMAN E, 1989, MOL CELL BIOL, V9, P1148, DOI 10.1128/MCB.9.3.1148
   SHTIVELMAN E, 1990, MOL CELL BIOL, V10, P1835, DOI 10.1128/MCB.10.4.1835
   Takahashi Y, 2014, BRIT J CANCER, V110, P164, DOI 10.1038/bjc.2013.698
   Tang YY, 2017, ONCOTARGET, V8, P39001, DOI 10.18632/oncotarget.16545
   Tang YY, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0612-0
   Taniwaki Masafumi, 2015, Rinsho Ketsueki, V56, P2056, DOI 10.11406/rinketsu.56.2056
   Tseng YY, 2014, NATURE, V512, P82, DOI 10.1038/nature13311
   Tu CF, 2017, J VIROL, V91, DOI 10.1128/JVI.00301-17
   Wan L, 2016, MOL CANCER THER, V15, P1082, DOI 10.1158/1535-7163.MCT-15-0707
   Wang CX, 2016, SCI CHINA LIFE SCI, V59, P443, DOI 10.1007/s11427-016-5008-7
   Wang F, 2014, HEPATOLOGY, V60, P1278, DOI 10.1002/hep.27239
   Wang YM, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0598-7
   Wang YM, 2016, J CANCER, V7, P991, DOI 10.7150/jca.14663
   WEBB E, 1984, NATURE, V312, P777, DOI 10.1038/312777a0
   Wu XF, 2016, MOL CELL PROBE, V30, P146, DOI 10.1016/j.mcp.2016.02.009
   Xia L, 2017, PROG BIOCHEM BIOPHYS, V44, P557, DOI 10.16476/j.pibb.2017.0106
   Xie ZJ, 2016, ONCOTARGET, V7, P25408, DOI 10.18632/oncotarget.8323
   Xu PX, 1997, P NATL ACAD SCI USA, V94, P11974, DOI 10.1073/pnas.94.22.11974
   Yan C, 2017, CANCER SCI, V108, P868, DOI 10.1111/cas.13212
   Yang LT, 2017, J CANCER, V8, P97, DOI 10.7150/jca.16819
   Yang WZ, 2016, PROG BIOCHEM BIOPHYS, V43, P461, DOI 10.16476/j.pibb.2015.0391
   Yang YR, 2014, INT J CLIN EXP PATHO, V7, P6929
   You L, 2011, BIOCHEM BIOPH RES CO, V407, P1, DOI 10.1016/j.bbrc.2011.02.027
   Yu JJ, 2017, J CANCER, V8, P523, DOI 10.7150/jca.17510
   Yu JJ, 2017, ONCOTARGET, V8, P16621, DOI 10.18632/oncotarget.14200
   Yuan CL, 2016, NEOPLASMA, V63, P442, DOI 10.4149/314_150825N45
   Zeng CW, 2015, J HEMATOL ONCOL, V8, DOI 10.1186/s13045-015-0223-4
   Zeng Z Y, 2015, Prog Biochem Biophys, V42, P1155
   Zeng ZY, 2016, TUMOR BIOL, V37, P729, DOI 10.1007/s13277-015-3860-x
   Zhang SR, 2016, APMIS, V124, P649, DOI 10.1111/apm.12555
   Zhang XW, 2015, BIOCHEM BIOPH RES CO, V462, P227, DOI 10.1016/j.bbrc.2015.04.121
   Zheng JJ, 2016, ONCOTARGET, V7, P62886, DOI 10.18632/oncotarget.11709
   Zheng W, 2017, PROG BIOCHEM BIOPHYS, V44, P580, DOI 10.16476/j.pibb.2017.0113
   Zhou QY, 2016, TUMOR BIOL, V37, P3105, DOI 10.1007/s13277-015-4149-9
   Zhou Q, 2016, ONCOTARGET, V7, P82620, DOI 10.18632/oncotarget.13012
NR 87
TC 2
Z9 3
U1 1
U2 13
PU CHINESE ACAD SCIENCES, INST BIOPHYSICS
PI BEIJING
PA 15 DATUN RD, CHAOYAND DISTRICT, BEIJING, 100101, PEOPLES R CHINA
SN 1000-3282
J9 PROG BIOCHEM BIOPHYS
JI Prog. Biochem. Biophys.
PD NOV
PY 2017
VL 44
IS 11
BP 981
EP 989
DI 10.16476/j.pibb.2016.0360
PG 9
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA FN8TI
UT WOS:000416298000003
DA 2025-01-12
ER

PT J
AU Graham, ÉA
   Mallet, JF
   Jambi, M
   Nishioka, H
   Homma, K
   Matar, C
AF Graham, Emilie A.
   Mallet, Jean-Francois
   Jambi, Majed
   Nishioka, Hiroshi
   Homma, Kohei
   Matar, Chantal
TI MicroRNA signature in the chemoprevention of functionally-enriched stem
   and progenitor pools (FESPP) by Active Hexose Correlated Compound (AHCC)
SO CANCER BIOLOGY & THERAPY
LA English
DT Article
DE AHCC; breast cancer; cancer stem cell; microRNA; Tenascin C
ID NEGATIVE BREAST-CANCER; TENASCIN-C; IMMUNE FUNCTION; CELLS; MIR-335;
   EXPRESSION; MIGRATION; THERAPY; GROWTH; SURVEILLANCE
AB Purpose: Many breast cancer patients use natural compounds in their battle against breast cancer. Active Hexose Correlated Compound (AHCC (R)) is a cultured mushroom mycelium extract shown to favorably modulate the immune system and alleviate cancer burden. Cancer Stem cells (CSCs) are a subset of highly tumorigenic cancer cells that are thought to be responsible for recurrence. CSCs can be epigenetically regulated by microRNAs (miRNAs). We hypothesized that AHCC may influence CSCs by modulating tumor-suppressor or oncogenic miRNAs. Methods: Functionally-enriched stem and progenitor pools (FESPP) were isolated in the form of mammospheres from MDA-MB-231, MCF-7, and 4T1 cells, exposed to AHCC in both regular and primary culture from Balb/c mice, and analyzed by visual counting and flow cytometry. Cell motility was also observed in MDA-MB-231 cells. Profiling and RT-qPCR were performed to determine AHCC influence on miRNAs in MDA-MB-231 mammospheres. Additionally, Balb/c mice were orally gavaged with AHCC, and tumor growth parameters and miR-335 expression were analyzed. MDA-MB-231 cells were transfected with miR-335 and analyzed by western blot. Results: We demonstrated that AHCC reduced mammosphere growth in three cell lines and in primary culture, prevented cell migration, and upregulated miR-335 expression in MDA-MB-231 cells and mouse tumor samples. Among the differentially regulated miRNAs in CSCs, we focused on tumor suppressor miR-335, known to target extracellular matrix protein Tenascin C (TNC). TNC is involved in CSC immune evasion pathways. In MDA-MB-231, inhibition of miR-335 increased TNC protein expression. Conclusions: These results support that AHCC limits FESPP growth, partly by targeting miRNA pathways.
C1 [Graham, Emilie A.; Matar, Chantal] Univ Ottawa, Interdisciplinary Hlth Sci, Ottawa, ON, Canada.
   [Mallet, Jean-Francois; Jambi, Majed; Matar, Chantal] Univ Ottawa, Cellular & Mol Med, Fac Med, Ottawa, ON, Canada.
   [Nishioka, Hiroshi; Homma, Kohei] Amino Up Chem Co Ltd, R&D Div, Sapporo, Hokkaido, Japan.
C3 University of Ottawa; University of Ottawa
RP Matar, C (通讯作者)，RGN2209,451 Smyth Rd, Ottawa, ON K1H 8M5, Canada.
EM Chantal.matar@uottawa.ca
OI Matar, Chantal/0000-0003-0346-4751; Mallet,
   Jean-Francois/0000-0003-1612-9063
FU AHCC Research Association; Canadian Institutes of Health Research (CIHR)
FX This study was financially possible by contributions from the AHCC
   Research Association and the Canadian Institutes of Health Research
   (CIHR). We would also like to thank Dr. Hector Hernandez-Vargas for his
   support and guidance with miRNA analysis. Finally, we would like to
   thank William Limoges for his technical assistance.
CR Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100
   [Anonymous], CURR PROTOC IMMUNOL
   Aviles H, 2003, J APPL PHYSIOL, V95, P491, DOI 10.1152/japplphysiol.00259.2003
   Aviles H, 2008, AM J SURG, V195, P537, DOI 10.1016/j.amjsurg.2007.05.045
   Bao B, 2012, CURR DRUG TARGETS, V13, P1858, DOI 10.2174/138945012804545515
   Bellone Matteo, 2015, Oncoscience, V2, P667
   Bolstad BM, 2003, BIOINFORMATICS, V19, P185, DOI 10.1093/bioinformatics/19.2.185
   Boyle P, 2012, ANN ONCOL, V23, P7, DOI 10.1093/annonc/mds187
   Cao ZY, 2015, NUTR RES PRACT, V9, P129
   Chen C, 2011, EXP CELL RES, V317, P1714, DOI 10.1016/j.yexcr.2011.05.001
   Collina F, 2015, BIOMED RES INT-UK, V2015, DOI 10.1155/2015/158682
   Cowawintaweewat S, 2006, ASIAN PAC J ALLERGY, V24, P33
   Daddaoua A, 2007, J NUTR, V137, P1222, DOI 10.1093/jn/137.5.1222
   Dent R, 2007, CLIN CANCER RES, V13, P4429, DOI 10.1158/1078-0432.CCR-06-3045
   Dontu G, 2003, CELL PROLIFERAT, V36, P59, DOI 10.1046/j.1365-2184.36.s.1.6.x
   Duru Nadire, 2015, Curr Pharmacol Rep, V1, P161
   Ellis SL, 2013, EXP HEMATOL, V41, P1050, DOI 10.1016/j.exphem.2013.09.009
   Erturk E, 2014, MOL CELL BIOCHEM, V395, P77, DOI 10.1007/s11010-014-2113-4
   Fujii H, 2011, REGUL TOXICOL PHARM, V59, P237, DOI 10.1016/j.yrtph.2010.10.006
   Gao Y, 2015, TUMOR BIOL, V36, P2875, DOI 10.1007/s13277-014-2917-6
   Gao YF, 2006, CANCER IMMUNOL IMMUN, V55, P1258, DOI 10.1007/s00262-005-0111-9
   Goh FG, 2010, J IMMUNOL, V184, P2655, DOI 10.4049/jimmunol.0903359
   Gonul O, 2015, INT J MED MUSHROOMS, V17, P231, DOI 10.1615/IntJMedMushrooms.v17.i3.30
   Han ML, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039520
   Hangai S, 2013, J ALTERN COMPLEM MED, V19, P905, DOI 10.1089/acm.2012.0914
   Hatfield S, 2008, CELL TISSUE RES, V331, P57, DOI 10.1007/s00441-007-0530-3
   Hendaoui S, 2014, MATRIX BIOL, V40, P46, DOI 10.1016/j.matbio.2014.08.017
   Hirose A, 2007, TOXICOL APPL PHARM, V222, P152, DOI 10.1016/j.taap.2007.03.031
   Iliopoulos D, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000356
   Jachetti E, 2015, CANCER RES, V75, P2095, DOI 10.1158/0008-5472.CAN-14-2346
   Janssen EAM, 2010, MODERN PATHOL, V23, P1567, DOI 10.1038/modpathol.2010.177
   Korkaya H, 2011, CLIN CANCER RES, V17, P6125, DOI 10.1158/1078-0432.CCR-10-2743
   Larzabal L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079798
   Lee HE, 2011, BRIT J CANCER, V104, P1730, DOI 10.1038/bjc.2011.159
   Lee HS, 2014, CANCER LETT, V342, P275, DOI 10.1016/j.canlet.2012.01.021
   Li LZ, 2014, CARCINOGENESIS, V35, P469, DOI 10.1093/carcin/bgt330
   Liu C, 2011, CANCER RES, V71, P5950, DOI 10.1158/0008-5472.CAN-11-1035
   Lowery AJ, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-502
   Iglesias JM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077281
   Martin HL, 2014, BREAST CANCER-TARGET, V6, P1, DOI 10.2147/BCTT.S37638
   Matsushita K, 1998, ANTI-CANCER DRUG, V9, P343, DOI 10.1097/00001813-199804000-00008
   Meng YB, 2015, MOL MED REP, V11, P379, DOI 10.3892/mmr.2014.2684
   Midwood KS, 2009, J CELL COMMUN SIGNAL, V3, P287, DOI 10.1007/s12079-009-0075-1
   Nagakawa H, 2004, SCAND J IMMUNOL, V60, P449, DOI 10.1111/j.0300-9475.2004.01504.x
   Nawata J, 2014, ANTICANCER RES, V34, P4807
   Nilsson S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036051
   Niu J, 2016, ONCOGENE, V35, P1302, DOI 10.1038/onc.2015.189
   Okuyama T, 2013, FUNCT FOODS HEALTH D, V3, P166, DOI 10.31989/ffhd.v3i6.55
   Oskarsson T, 2011, NAT MED, V17, P867, DOI 10.1038/nm.2379
   Polytarchou C, 2012, P NATL ACAD SCI USA, V109, P14470, DOI 10.1073/pnas.1212811109
   Ritz BW, 2006, J NUTR, V136, P2868, DOI 10.1093/jn/136.11.2868
   Ruiz C, 2004, CANCER RES, V64, P7377, DOI 10.1158/0008-5472.CAN-04-1234
   Scarola M, 2010, CANCER RES, V70, P6925, DOI 10.1158/0008-5472.CAN-10-0141
   Schwarz-Cruz Y, 2015, REV HISTOL HISTOPATH, V31, P601, DOI 10.14670/HH-11-718
   Sever M, 2014, BIOMACROMOLECULES, V15, P4480, DOI 10.1021/bm501271x
   Shi B, 2007, J BIOL CHEM, V282, P32582, DOI 10.1074/jbc.M702806200
   Tamaoki M, 2005, AM J PATHOL, V167, P71, DOI 10.1016/S0002-9440(10)62954-9
   Tavazoie SF, 2008, NATURE, V451, P147, DOI 10.1038/nature06487
   Tomé M, 2011, CELL DEATH DIFFER, V18, P985, DOI 10.1038/cdd.2010.167
   Tomé M, 2014, STEM CELLS, V32, P2229, DOI 10.1002/stem.1699
   Turner J, 2009, ANTI-CANCER DRUG, V20, P215, DOI 10.1097/CAD.0b013e3283163c26
   Villarini A, 2012, TUMORI J, V98, P1, DOI 10.1700/1053.11494
   Vimalraj S, 2013, DIS MARKERS, V2013, DOI 10.1155/2013/451248
   Vuong T, 2010, BRIT J NUTR, V104, P656, DOI 10.1017/S0007114510001170
   Wicha MS, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1540
   Wicha MS, 2006, CLIN CANCER RES, V12, P5606, DOI 10.1158/1078-0432.CCR-06-1537
   Wicha MS, 2006, CANCER RES, V66, P1883, DOI 10.1158/0008-5472.CAN-05-3153
   Wu ZH, 2016, TUMOR BIOL, V37, P7939, DOI 10.1007/s13277-015-4665-7
NR 68
TC 7
Z9 7
U1 0
U2 5
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1538-4047
EI 1555-8576
J9 CANCER BIOL THER
JI Cancer Biol. Ther.
PY 2017
VL 18
IS 10
BP 765
EP 774
DI 10.1080/15384047.2017.1373211
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA FN5CA
UT WOS:000416022900004
PM 28886271
OA Bronze, Green Published
DA 2025-01-12
ER

PT J
AU Gianfredi, V
   Nucci, D
   Vannini, S
   Villarini, M
   Moretti, M
AF Gianfredi, Vincenza
   Nucci, Daniele
   Vannini, Samuele
   Villarini, Milena
   Moretti, Massimo
TI <i>In vitro</i> Biological Effects of Sulforaphane (SFN),
   Epigallocatechin-3-gallate (EGCG), and Curcumin on Breast Cancer Cells:
   A Systematic Review of the Literature
SO NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL
LA English
DT Article
ID DNA METHYLATION; GENE-EXPRESSION; EPIGENETIC REGULATION; SIGNALING
   PATHWAY; TUMOR-SUPPRESSOR; TEA POLYPHENOL; INHIBITION; COMBINATION;
   GROWTH; METHYLTRANSFERASE
AB Much of the recent research in neoplasia has been focusing on the epigenetics of cancer cells, particularly as regards the search for potential molecular biomarkers that could be used for early diagnosis, effective treatment, and prognosis of several types of cancer. Carcinogenesis often starts with mutations in oncogenes and tumor suppressor genes, and it leads to anomalies in cellular processes as vital as cell cycle regulation and apoptosis. Because malignant changes arise as a result of genetic as well as epigenetic mechanisms, one possible means of intervention involves reprogramming gene expression, so as toat least in partrevert the molecular alterations. DNA methylation and demethylation, acetylation and deacetylation of histones, and microRNAs are a few examples of the epigenetic mechanisms responsible for tumor development and progression. Many biologically active compounds present in foodincluding sulforaphane, curcumin, and epigallocatechinhave been found to modulate those processes. We here systematically review information on the effects of such bioactive dietary compounds on human breast cancer cell lines, and explore the mechanisms underlying those effects with a view to their potential therapeutic application.
C1 [Gianfredi, Vincenza] Univ Perugia, Dept Expt Med, Grad Sch Specializat Hyg & Prevent Med, Piazzale Gambuli, I-06132 Perugia 1, Italy.
   [Nucci, Daniele] Veneto Inst Oncol IOV IRCCS, Digest Endoscopy Unit, Padua, Italy.
   [Vannini, Samuele; Villarini, Milena; Moretti, Massimo] Univ Perugia, Dept Pharmaceut Sci, Unit Publ Hlth, Perugia, Italy.
C3 University of Perugia; IRCCS Istituto Oncologico Veneto (IOV);
   University of Perugia
RP Gianfredi, V (通讯作者)，Univ Perugia, Dept Expt Med, Grad Sch Specializat Hyg & Prevent Med, Piazzale Gambuli, I-06132 Perugia 1, Italy.
EM vincenza.gianfredi@studenti.unipg.it
RI Villarini, Milena/L-3857-2019; Gianfredi, Vincenza/W-1408-2017; Nucci,
   Daniele/Q-3089-2016; Moretti, Massimo/H-6885-2017
OI Gianfredi, Vincenza/0000-0003-3848-981X; Nucci,
   Daniele/0000-0003-4546-213X; Moretti, Massimo/0000-0002-5038-8619
CR Aggarwal BB, 2004, ANN NY ACAD SCI, V1030, P434, DOI 10.1196/annals.1329.054
   Aloia L, 2015, CELL CYCLE, V14, P510, DOI 10.4161/15384101.2014.988022
   Berletch JB, 2008, J CELL BIOCHEM, V103, P509, DOI 10.1002/jcb.21417
   Berner C, 2011, ANN NUTR METAB, V57, P183, DOI 10.1159/000321514
   Blancafort A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131241
   Bolhassani A, 2015, ANTI-CANCER AGENT ME, V15, P1026, DOI 10.2174/1871520615666150302125707
   Chen HM, 2015, ONCOTARGET, V6, P13049, DOI 10.18632/oncotarget.3790
   Chew YC, 2012, J BIOL CHEM, V287, P16168, DOI 10.1074/jbc.M111.305292
   Collins HM, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-37
   Conway KE, 2000, CANCER RES, V60, P6236
   Deb G, 2015, MOL CARCINOGEN, V54, P485, DOI 10.1002/mc.22121
   Deb M, 2014, TUMOR BIOL, V35, P12031, DOI 10.1007/s13277-014-2502-z
   Degner SC, 2009, J NUTR, V139, P26, DOI 10.3945/jn.108.099259
   Fang MZ, 2003, CANCER RES, V63, P7563
   Gurung RL, 2014, J NUTRIGENET NUTRIGE, V7, P283, DOI 10.1159/000381346
   Higdon JV, 2007, PHARMACOL RES, V55, P224, DOI 10.1016/j.phrs.2007.01.009
   Hirst M, 2009, INT J BIOCHEM CELL B, V41, P136, DOI 10.1016/j.biocel.2008.09.011
   Huang C, 2012, CANCER RES, V72, P655, DOI 10.1158/0008-5472.CAN-11-3102
   Ivanov M, 2012, CLIN PHARMACOL THER, V92, P727, DOI 10.1038/clpt.2012.152
   Jaenisch R, 2003, NAT GENET, V33, P245, DOI 10.1038/ng1089
   Jiang M, 2013, MOLECULES, V18, P701, DOI 10.3390/molecules18010701
   Kala R, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0155057
   Katsori AM, 2015, MOLECULES, V20, P863, DOI 10.3390/molecules20010863
   Kavanagh KT, 2001, J CELL BIOCHEM, V82, P387, DOI 10.1002/jcb.1164
   Kuck D, 2010, BIOORGAN MED CHEM, V18, P822, DOI 10.1016/j.bmc.2009.11.050
   Lee WJ, 2006, CARCINOGENESIS, V27, P269, DOI 10.1093/carcin/bgi206
   Li Q, 2014, ONCOGENE, V33, P2589, DOI 10.1038/onc.2013.226
   Li YY, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-274
   Liu AG, 2011, BIOCHEM BIOPH RES CO, V412, P479, DOI 10.1016/j.bbrc.2011.07.124
   Liu Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064535
   Lubecka K, 2016, CARCINOGENESIS, V37, P656, DOI 10.1093/carcin/bgw048
   Lubecka-Pietruszewska K, 2015, J NUTRIGENET NUTRIGE, V8, P91, DOI 10.1159/000439111
   Lubecka-Pietruszewska K, 2013, BIOCHEM BIOPH RES CO, V430, P623, DOI 10.1016/j.bbrc.2012.11.103
   Medina-Aguilar R, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0157866
   Meeran SM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037748
   Meeran SM, 2011, CANCER PREV RES, V4, P1243, DOI 10.1158/1940-6207.CAPR-11-0009
   Meeran SM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011457
   Mirza S, 2013, J BREAST CANCER, V16, P23, DOI 10.4048/jbc.2013.16.1.23
   Moghadamtousi SZ, 2014, BIOMED RES INT-UK, V2014, DOI 10.1155/2014/186864
   Mohammadi R, 2015, ANTI-CANCER AGENT ME, V15, P107
   Moher D, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000097, 10.1136/bmj.i4086, 10.1016/j.ijsu.2010.02.007, 10.1186/2046-4053-4-1, 10.1136/bmj.b2535, 10.1136/bmj.b2700, 10.1016/j.ijsu.2010.07.299]
   Moiseeva EP, 2007, MOL CANCER THER, V6, P3071, DOI 10.1158/1535-7163.MCT-07-0117
   Mukherjee S., 2012, INT J GREEN NANOTECH, V4, P183, DOI 10.1080/19430892.2012.691799
   Rao X, 2013, ONCOGENE, V32, P4519, DOI 10.1038/onc.2012.474
   Rath SK, 2016, TUMOR BIOL, V37, P12535, DOI 10.1007/s13277-016-5114-y
   Sen T, 2010, ANTI-CANCER DRUG, V21, P632, DOI [10.1097/CAD.0b013e32833a4385, DOI 10.1097/CAD.0b013e32833a4385, DOI 10.1097/CAD.0B013E32833A4385]
   Shehzad A, 2014, MOL CELLS, V37, P899, DOI 10.14348/molcells.2014.0212
   Sinha S, 2015, MOL CELL ENDOCRINOL, V406, P102, DOI 10.1016/j.mce.2015.02.020
   Stefanska B, 2012, BRIT J PHARMACOL, V167, P279, DOI 10.1111/j.1476-5381.2012.02002.x
   Stuart EC, 2010, ONCOL REP, V24, P779, DOI 10.3892/or_00000921
   Tao YG, 2011, NUCLEIC ACIDS RES, V39, P9508, DOI 10.1093/nar/gkr611
   Terzi YK, 2015, TURK J BIOL, V39, P698, DOI 10.3906/biy-1412-82
   Tyagi T, 2015, BREAST CANCER RES TR, V149, P655, DOI 10.1007/s10549-015-3295-5
   Weng JR, 2014, PHYTOTHER RES, V28, P49, DOI 10.1002/ptr.4955
   Yarla NS, 2016, SEMIN CANCER BIOL, V40-41, P48, DOI 10.1016/j.semcancer.2016.02.001
   Zhang YK, 2011, EPIGENETICS-US, V6, P888, DOI 10.4161/epi.6.7.16315
NR 56
TC 29
Z9 29
U1 1
U2 24
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 0163-5581
EI 1532-7914
J9 NUTR CANCER
JI Nutr. Cancer
PY 2017
VL 69
IS 7
BP 969
EP 978
DI 10.1080/01635581.2017.1359322
PG 10
WC Oncology; Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Nutrition & Dietetics
GA FN1MV
UT WOS:000415755000001
PM 28872903
DA 2025-01-12
ER

PT J
AU Erales, J
   Marchand, V
   Panthu, B
   Gillotf, S
   Belin, S
   Ghayad, SE
   Garcia, M
   Laforêts, F
   Marcel, V
   Baudin-Baillieu, A
   Bertin, P
   Couté, Y
   Adrait, A
   Meyer, M
   Therizols, G
   Yusupov, M
   Namy, O
   Ohlmann, T
   Motorin, Y
   Catez, F
   Diaz, JJ
AF Erales, Jenny
   Marchand, Virginie
   Panthu, Baptiste
   Gillotf, Sandra
   Belin, Stephane
   Ghayad, Sandra E.
   Garcia, Maxime
   Laforets, Florian
   Marcel, Virginie
   Baudin-Baillieu, Agnes
   Bertin, Pierre
   Coute, Yohann
   Adrait, Annie
   Meyer, Melanie
   Therizols, Gabriel
   Yusupov, Marat
   Namy, Olivier
   Ohlmann, Theophile
   Motorin, Yuri
   Catez, Frederic
   Diaz, Jean-Jacques
TI Evidence for rRNA 2′-O-methylation plasticity: Control of intrinsic
   translational capabilities of human ribosomes
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE 2 '-O-methylation; fibrillarin; ribosomal RNA; translational control;
   RNA epigenetics
ID BREAST-CANCER; 80S RIBOSOME; ENTRY SITES; BOX C/D; BIOGENESIS; CELLS;
   METHYLATION; FIBRILLARIN; YEAST; NUCLEOTIDE
AB Ribosomal RNAs (rRNAs) are main effectors of messenger RNA (mRNA) decoding, peptide-bond formation, and ribosome dynamics during translation. Ribose 2'-O-methylation (2'-O-Me) is the most abundant rRNA chemical modification, and displays a complex pattern in rRNA. 2'-O-Me was shown to be essential for accurate and efficient protein synthesis in eukaryotic cells. However, whether rRNA 2'-O-Me is an adjustable feature of the human ribosome and a means of regulating ribosome function remains to be determined. Here we challenged rRNA 2'-O-Me globally by inhibiting the rRNA methyl-transferase fibrillarin in human cells. Using RiboMethSeq, a nonbiased quantitative mapping of 2'-O-Me, we identified a repertoire of 2'-O-Me sites subjected to variation and demonstrate that functional domains of ribosomes are targets of 2'-O-Me plasticity. Using the cricket paralysis virus internal ribosome entry site element, coupled to in vitro translation, we show that the intrinsic capability of ribosomes to translate mRNAs is modulated through a 2'-O-Me pattern and not by nonribosomal actors of the translational machinery. Our data establish rRNA 2'-O-Me plasticity as a mechanism providing functional specificity to human ribosomes.
C1 [Erales, Jenny; Belin, Stephane; Ghayad, Sandra E.; Garcia, Maxime; Laforets, Florian; Marcel, Virginie; Therizols, Gabriel; Catez, Frederic; Diaz, Jean-Jacques] Ctr Leon Berard, CNRS 5286, INSERM 1052, Ctr Rech Cancerol Lyon,UMR, F-69373 Lyon, France.
   [Erales, Jenny; Panthu, Baptiste; Belin, Stephane; Ghayad, Sandra E.; Garcia, Maxime; Laforets, Florian; Marcel, Virginie; Therizols, Gabriel; Ohlmann, Theophile; Catez, Frederic; Diaz, Jean-Jacques] Univ Lyon, Inst Sci Pharmaceut & Biol, F-69003 Lyon, France.
   [Marchand, Virginie] Lorraine Univ, CNRS, Next Generat Sequencing Core Facil, Bioingn Mol Cellulaire & Therapeut FR3209, F-54505 Vandoeuvre Les Nancy, France.
   [Panthu, Baptiste; Ohlmann, Theophile] Univ Lyon, Ctr Int Rech Infectiol, F-69364 Lyon, France.
   [Panthu, Baptiste; Ohlmann, Theophile] Ecole Normale Super Lyon, F-69342 Lyon, France.
   [Gillotf, Sandra; Baudin-Baillieu, Agnes; Bertin, Pierre; Namy, Olivier] Univ Paris Saclay, Univ Paris Sud, CNRS, Inst Integrat Biol Cell,Commissariat Energie Atom, F-91190 Gif Sur Yvette, France.
   [Coute, Yohann; Adrait, Annie] Univ Grenoble Alpes, Inst Biosci & Biotechnol Grenoble, Commissariat Energie Atom & Energies Alternat, Lab Biol Grande Echelle,INSERM, F-38000 Grenoble, France.
   [Meyer, Melanie] CNRS UMR 7104 INSERM U964, Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch Graffenstaden, France.
   [Yusupov, Marat; Motorin, Yuri] Univ Lorraine, CNRS, Ingn Mol & Physiopathol Articulair, UMR7365, F-54505 Vandoeuvre Les Nancy, France.
C3 Centre National de la Recherche Scientifique (CNRS); CNRS - National
   Institute for Biology (INSB); Universite Claude Bernard Lyon 1;
   UNICANCER; Centre Leon Berard; Institut National de la Sante et de la
   Recherche Medicale (Inserm); Centre National de la Recherche
   Scientifique (CNRS); CNRS - National Institute for Biology (INSB);
   Universite de Lorraine; Universite Claude Bernard Lyon 1; Ecole Normale
   Superieure de Lyon (ENS de LYON); CEA; Communaute Universite Grenoble
   Alpes; Universite Grenoble Alpes (UGA); Universite Paris Saclay; Centre
   National de la Recherche Scientifique (CNRS); Institut National de la
   Sante et de la Recherche Medicale (Inserm); Communaute Universite
   Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Universites de
   Strasbourg Etablissements Associes; Universite de Strasbourg; Centre
   National de la Recherche Scientifique (CNRS); CNRS - National Institute
   for Biology (INSB); Institut National de la Sante et de la Recherche
   Medicale (Inserm); Universite de Lorraine; Centre National de la
   Recherche Scientifique (CNRS); CNRS - Institute for Engineering &
   Systems Sciences (INSIS)
RP Catez, F; Diaz, JJ (通讯作者)，Ctr Leon Berard, CNRS 5286, INSERM 1052, Ctr Rech Cancerol Lyon,UMR, F-69373 Lyon, France.; Catez, F; Diaz, JJ (通讯作者)，Univ Lyon, Inst Sci Pharmaceut & Biol, F-69003 Lyon, France.
EM frederic.catez@lyon.unicancer.fr; jean-jacques.diaz@lyon.unicancer.fr
RI Namy, Olivier/ABD-4379-2020; MOTORIN, Yuri/AAQ-9527-2020; CATEZ,
   Frédéric/GQP-7328-2022; Couté, Yohann/G-2695-2015; MARCHAND,
   Virginie/A-6866-2012; Therizols, Gabriel/K-5144-2012; DIAZ,
   Jean-Jacques/H-3018-2014; Ghayad, Sandra/JQI-6088-2023; MARCEL,
   Virginie/H-3037-2011; Yusupov, Marat/I-6126-2013; ohlmann,
   Theophile/M-4463-2014
OI Ghayad, Sandra/0000-0001-5009-1594; Motorin,
   Alexandr/0000-0001-9622-4591; Coute, Yohann/0000-0003-3896-6196; Belin,
   Stephane/0000-0001-7074-6885; CATEZ, Frederic/0000-0001-8255-9091; DIAZ,
   Jean-Jacques/0000-0002-7914-4319; Carmen, Team2/0000-0001-9867-5724;
   MARCEL, Virginie/0000-0002-9557-8221; Lab, Carmen/0000-0002-5935-3236;
   Adrait, Annie/0000-0002-1565-2859; Marchand,
   Virginie/0000-0002-8537-1139; Yusupov, Marat/0000-0001-5544-0597;
   ohlmann, Theophile/0000-0002-2001-8916; Panthu,
   Baptiste/0000-0001-9430-4061
FU Agence Nationale pour la Recherche [RIBOMETH ANR-13-BSV8-0012-01,
   PC201507]; "Programme d'Actions Integrees de Recherche" RiboTEM (PAIR);
   "Programme d'Actions Integrees de Recherche" RiboTEM (Institut National
   du Cancer); "Programme d'Actions Integrees de Recherche" RiboTEM
   (Fondation ARC pour la Recherche sur le Cancer); "Programme d'Actions
   Integrees de Recherche" RiboTEM (Ligue Nationale Contre le Cancer);
   Ligue Nationale Contre le Cancer; Ligue Contre le Cancer, Comite
   Departemental de la Drome, du Rhone, du Puy-de-Dome, et de l'Allier;
   Fondation ARC pour la Recherche sur le Cancer; French Ministry for
   Research and Education; Agence Nationale de la Recherche -Deutsche
   Forschungsgemeinschaft [ANR-13-ISV8-0001/HE 3397/8-1]; ProFi Grant
   [ANR-10-INBS-08-01]; European Research Council [294312]; Russian
   Government Program of Competitive Growth of Kazan Federal University
FX We thank A.-C. Prats and D. Ruggero for kindly providing internal
   ribosome entry site-containing vectors; D. Lafontaine for discussion;
   and Brigitte Manship for editing the manuscript. Microscopic imaging was
   performed using the Centre de Recherche en Cancerologie de Lyon imaging
   platform. The project was funded by Agence Nationale pour la Recherche
   (RIBOMETH ANR-13-BSV8-0012-01); the "Programmes d'Actions Integrees de
   Recherche" RiboTEM (PAIR, Institut National du Cancer, Fondation ARC
   pour la Recherche sur le Cancer, Ligue Nationale Contre le Cancer); the
   "Ligue Nationale Contre le Cancer"; the "Ligue Contre le Cancer, Comite
   Departemental de la Drome, du Rhone, du Puy-de-Dome, et de l'Allier";
   and Fondation ARC pour la Recherche sur le Cancer. F.C. is a CNRS
   research fellow. J.-J.D., and V. Marcel are INSERM research fellows.
   M.G. was supported by Agence Nationale pour la Recherche Grant "INVADE"
   PC201507. F.L. received a PhD fellowship from the French Ministry for
   Research and Education. V. Marchand and Y.M. were supported by joint
   Agence Nationale de la Recherche -Deutsche Forschungsgemeinschaft Grant
   HTRNAMod (ANR-13-ISV8-0001/HE 3397/8-1). Y.C. and A.A. were supported by
   the bottom-up platform and informatics group at Exploring the Dynamics
   of Proteomes (EDyP). Proteomic experiments were partly supported by the
   ProFi Grant ANR-10-INBS-08-01. M.M. and M.Y. were supported by European
   Research Council advanced Grant 294312. M.Y. was supported by the
   Russian Government Program of Competitive Growth of Kazan Federal
   University. This work has benefited from the platform and expertise of
   the High-throughput Sequencing Platform of Institute for Integrative
   Biology of the Cell (I2BC).
CR Bash-Imam Z, 2017, ONCOTARGET, V8, P46219, DOI 10.18632/oncotarget.17597
   Basu A, 2011, MOL CELL BIOL, V31, P4482, DOI 10.1128/MCB.05804-11
   Baudin-Baillieu A, 2014, CELL REP, V8, P438, DOI 10.1016/j.celrep.2014.06.036
   Baudin-Baillieu A, 2009, NUCLEIC ACIDS RES, V37, P7665, DOI 10.1093/nar/gkp816
   Belin S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007147
   Ben-Shem A, 2011, SCIENCE, V334, P1524, DOI 10.1126/science.1212642
   Birkedal U, 2015, ANGEW CHEM INT EDIT, V54, P451, DOI 10.1002/anie.201408362
   Bortolin-Cavaillé ML, 2012, NUCLEIC ACIDS RES, V40, P6800, DOI 10.1093/nar/gks321
   Casabona MG, 2013, PROTEOMICS, V13, P2419, DOI 10.1002/pmic.201200565
   David A, 2012, J CELL BIOL, V197, P45, DOI 10.1083/jcb.201112145
   Decatur WA, 2002, TRENDS BIOCHEM SCI, V27, P344, DOI 10.1016/S0968-0004(02)02109-6
   Fernández IS, 2014, CELL, V157, P823, DOI 10.1016/j.cell.2014.04.015
   Hertz MI, 2013, MOL CELL BIOL, V33, P1016, DOI 10.1128/MCB.00879-12
   Higa-Nakamine S, 2012, NUCLEIC ACIDS RES, V40, P391, DOI 10.1093/nar/gkr700
   Hinnebusch AG, 2016, SCIENCE, V352, P1413, DOI 10.1126/science.aad9868
   Hoernes TP, 2017, WIRES RNA, V8, DOI 10.1002/wrna.1375
   Incarnato D, 2017, NUCLEIC ACIDS RES, V45, P1433, DOI 10.1093/nar/gkw810
   Jack K, 2011, MOL CELL, V44, P660, DOI 10.1016/j.molcel.2011.09.017
   Khatter H, 2015, NATURE, V520, P640, DOI 10.1038/nature14427
   Kos M, 2010, MOL CELL, V37, P809, DOI 10.1016/j.molcel.2010.02.024
   Krogh N, 2016, NUCLEIC ACIDS RES, V44, P7884, DOI 10.1093/nar/gkw482
   Liang XH, 2007, MOL CELL, V28, P965, DOI 10.1016/j.molcel.2007.10.012
   Majzoub K, 2014, CELL, V159, P1086, DOI 10.1016/j.cell.2014.10.041
   Marcel V, 2013, CANCER CELL, V24, P318, DOI 10.1016/j.ccr.2013.08.013
   Marchand V, 2016, NUCLEIC ACIDS RES, V44, DOI 10.1093/nar/gkw547
   Mi HY, 2017, NUCLEIC ACIDS RES, V45, pD183, DOI 10.1093/nar/gkw1138
   Panthu B, 2015, BIOCHEM J, V467, P387, DOI 10.1042/BJ20141498
   Penzo M, 2015, FASEB J, V29, P3472, DOI 10.1096/fj.15-270991
   Polikanov YS, 2015, NAT STRUCT MOL BIOL, V22, P342, DOI 10.1038/nsmb.2992
   Recher G, 2013, DEVELOPMENT, V140, P4860, DOI 10.1242/dev.099010
   Rodriguez-Corona U, 2015, BIOL CELL, V107, P159, DOI 10.1111/boc.201400077
   Schwanhäusser B, 2011, NATURE, V473, P337, DOI 10.1038/nature10098
   Sharma S, 2015, TRENDS BIOCHEM SCI, V40, P560, DOI 10.1016/j.tibs.2015.07.008
   Sornjai W, 2017, INT J BIOL MACROMOL, V94, P728, DOI 10.1016/j.ijbiomac.2016.10.039
   Su H, 2014, ONCOGENE, V33, P1348, DOI 10.1038/onc.2013.89
   Tessarz P, 2014, NATURE, V505, P564, DOI 10.1038/nature12819
   TOLLERVEY D, 1993, CELL, V72, P443, DOI 10.1016/0092-8674(93)90120-F
   Voorhees RM, 2009, NAT STRUCT MOL BIOL, V16, P528, DOI 10.1038/nsmb.1577
   Watanabe-Susaki K, 2014, STEM CELLS, V32, P3099, DOI 10.1002/stem.1825
   Watkins NJ, 2012, WIRES RNA, V3, P397, DOI 10.1002/wrna.117
   Weingarten-Gabbay S, 2016, SCIENCE, V351, DOI 10.1126/science.aad4939
   Xue SF, 2015, NATURE, V517, P33, DOI 10.1038/nature14010
   Xue SF, 2012, NAT REV MOL CELL BIO, V13, P355, DOI 10.1038/nrm3359
NR 43
TC 183
Z9 198
U1 1
U2 25
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD DEC 5
PY 2017
VL 114
IS 49
BP 12934
EP 12939
DI 10.1073/pnas.1707674114
PG 6
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA FP0ZS
UT WOS:000417339700034
PM 29158377
OA Green Published, Bronze
DA 2025-01-12
ER

PT J
AU Benson, Z
   Manjili, SH
   Habibi, M
   Guruli, G
   Toor, AA
   Payne, KK
   Manjili, MH
AF Benson, Zachary
   Manjili, Saeed H.
   Habibi, Mehran
   Guruli, Georgi
   Toor, Amir A.
   Payne, Kyle K.
   Manjili, Masoud H.
TI Conditioning neoadjuvant therapies for improved immunotherapy of cancer
SO BIOCHEMICAL PHARMACOLOGY
LA English
DT Article
DE Targeted drug delivery; Nanoparticles; Cancer immunotherapy; Neoadjuvant
   therapy
ID DEPENDENT KINASE INHIBITOR; ENDOTHELIAL GROWTH-FACTOR; BREAST-CANCER;
   SUPPRESSOR-CELLS; METRONOMIC CHEMOTHERAPY; COLORECTAL-CANCER; T-CELLS;
   INDUCED APOPTOSIS; EFFICACY; CYCLOPHOSPHAMIDE
AB Recent advances in the treatment of melanoma and non-small cell lung cancer (NSCLC) by combining conventional therapies with anti-PD1/PD-L1 immunotherapies, have renewed interests in immunotherapy of cancer. The emerging concept of conventional cancer therapies combined with immunotherapy differs from the classical concept in that it is not simply taking advantage of their additive anti-tumor effects, but it is to use certain therapeutic regimens to condition the tumor microenvironment for optimal response to immunotherapy. To this end, low dose immunogenic chemotherapies, epigenetic modulators and inhibitors of cell cycle progression are potential candidates for rendering tumors highly responsive to immunotherapy. Next generation immunotherapeutics are therefore predicted to be highly effective against cancer, when they are used following appropriate immune modulatory compounds or targeted delivery of tumor cell cycle inhibitors using nanotechnology. (C) 2017 Elsevier Inc. All rights reserved.
C1 [Benson, Zachary] Virginia Commonwealth Univ, Sch Med, Dept Internal Med, Richmond, VA 23284 USA.
   [Manjili, Saeed H.] Virginia Commonwealth Univ, Sch Engn, Dept Biomed Engn, Richmond, VA 23284 USA.
   [Habibi, Mehran] Johns Hopkins Sch Med, Dept Surg, Baltimore, MD USA.
   [Guruli, Georgi] Virginia Commonwealth Univ, Sch Med, Dept Surg, Div Urol, Richmond, VA 23284 USA.
   [Guruli, Georgi; Toor, Amir A.; Manjili, Masoud H.] Massey Canc Ctr, Richmond, VA USA.
   [Toor, Amir A.] Virginia Commonwealth Univ, Sch Med, Dept Internal Med, Bone Marrow Transplant Program, Richmond, VA 23284 USA.
   [Payne, Kyle K.] Wistar Inst Anat & Biol, Translat Tumor Immunol Program, 3601 Spruce St, Philadelphia, PA 19104 USA.
   [Manjili, Masoud H.] Virginia Commonwealth Univ, Sch Med, Dept Microbiol & Immunol, Richmond, VA 23284 USA.
C3 Virginia Commonwealth University; Virginia Commonwealth University;
   Johns Hopkins University; Johns Hopkins Medicine; Virginia Commonwealth
   University; Virginia Commonwealth University; Virginia Commonwealth
   University; The Wistar Institute; Virginia Commonwealth University
RP Manjili, MH (通讯作者)，VCU, Sch Med, Massey Canc Ctr, Dept Microbiol & Immunol, 401 Coll St, Richmond, VA 23298 USA.
EM masoud.manjili@vcuhealth.org
RI Payne, Kyle/AAL-6614-2020; Toor, Amir/GNM-9504-2022
OI Payne, Kyle/0000-0002-6531-9835; Toor, Amir Ahmed/0000-0001-5317-8433
FU Office of the Assistant Secretary of Defense for Health Affairs through
   the Breast Cancer Research Program [W81XWH-14-1-0087]; VCU Massey Cancer
   Center; NIH/NCI Cancer Center Support Grant [P30 CA016059]
FX This work was supported by the Office of the Assistant Secretary of
   Defense for Health Affairs through the Breast Cancer Research Program
   under Award No. W81XWH-14-1-0087, and a pilot funding from the VCU
   Massey Cancer Center supported, in part, with funding from NIH/NCI
   Cancer Center Support Grant P30 CA016059.
CR Bao L, 2011, CANCER IMMUNOL IMMUN, V60, P1299, DOI 10.1007/s00262-011-1037-z
   Bertolini F, 2003, CANCER RES, V63, P4342
   Bosco EE, 2007, CELL CYCLE, V6, P667, DOI 10.4161/cc.6.6.3988
   Browder T, 2000, CANCER RES, V60, P1878
   Casares N, 2005, J EXP MED, V202, P1691, DOI 10.1084/jem.20050915
   Chao MP, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001375
   Chen MY, 2011, CANCER-AM CANCER SOC, V117, P4424, DOI 10.1002/cncr.26073
   Clark AS, 2016, JAMA ONCOL, V2, P253, DOI 10.1001/jamaoncol.2015.4701
   Colleoni M, 2002, ANN ONCOL, V13, P73, DOI 10.1093/annonc/mdf013
   Cui Y, 2015, MOL PHARMACEUT, V12, P1279, DOI 10.1021/mp500815b
   Demaria S, 2001, CLIN CANCER RES, V7, P3025
   Dewan MZ, 2009, CLIN CANCER RES, V15, P5379, DOI 10.1158/1078-0432.CCR-09-0265
   Dickson M. A., 2016, JAMA ONCOL
   Dorand RD, 2016, SCIENCE, V353, P399, DOI 10.1126/science.aae0477
   Endicott JA, 1999, CURR OPIN STRUC BIOL, V9, P738, DOI 10.1016/S0959-440X(99)00038-X
   Falchi L, 2016, J HEMATOL ONCOL, V9, DOI 10.1186/s13045-016-0363-1
   Finn RS, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2419
   Galluzzi L, 2016, CANCER IMMUNOL RES, V4, P895, DOI 10.1158/2326-6066.CIR-16-0197
   Ge YZ, 2012, CANCER IMMUNOL IMMUN, V61, P353, DOI 10.1007/s00262-011-1106-3
   Ghiringhelli F, 2007, CANCER IMMUNOL IMMUN, V56, P641, DOI 10.1007/s00262-006-0225-8
   Gonzalez-Aparicio M, 2011, GUT, V60, P341, DOI 10.1136/gut.2010.211722
   Homma Y, 2014, CLIN TRANSL ONCOL, V16, P330, DOI 10.1007/s12094-013-1079-0
   Horinaka A, 2015, CANC SCI
   Hu WY, 2016, CLIN CANCER RES, V22, P2000, DOI 10.1158/1078-0432.CCR-15-1421
   Huang L, 2010, J CANCER RES CLIN, V136, P447, DOI 10.1007/s00432-009-0675-4
   Iida N, 2013, SCIENCE, V342, P967, DOI 10.1126/science.1240527
   Jabbour-Leung NA, 2016, MOL CANCER THER, V15, P593, DOI 10.1158/1535-7163.MCT-15-0519
   Kanterman J, 2014, CANCER RES, V74, P6022, DOI 10.1158/0008-5472.CAN-14-0657
   Kareva I, 2015, CANCER LETT, V358, P100, DOI 10.1016/j.canlet.2014.12.039
   Kepp O, 2014, ONCOIMMUNOLOGY, V3, DOI 10.4161/21624011.2014.955691
   Kerbel RS, 2017, CANCER LETT, V400, P293, DOI 10.1016/j.canlet.2017.02.005
   Kim K, 2014, P NATL ACAD SCI USA, V111, P11774, DOI 10.1073/pnas.1410626111
   Kim YJ, 2013, INT J CANCER, V132, P29, DOI 10.1002/ijc.27666
   Kobayashi M, 2011, INVEST NEW DRUG, V29, P921, DOI 10.1007/s10637-010-9448-9
   Koebel CM, 2007, NATURE, V450, P903, DOI 10.1038/nature06309
   Ladoire S, 2015, ONCOIMMUNOLOGY, V5
   Lansiaux A, 2012, INVEST NEW DRUG, V30, P403, DOI 10.1007/s10637-010-9443-1
   Lee K, 2009, P NATL ACAD SCI USA, V106, P2353, DOI 10.1073/pnas.0812801106
   Li JY, 2014, J IMMUNOL RES, V2014, DOI 10.1155/2014/286170
   Loges Sonja, 2010, Genes Cancer, V1, P12, DOI 10.1177/1947601909356574
   MACCUBBIN DL, 1992, CANCER RES, V52, P3572
   Mancuso P, 2006, BLOOD, V108, P452, DOI 10.1182/blood-2005-11-4570
   Martins I, 2011, ONCOGENE, V30, P1147, DOI 10.1038/onc.2010.500
   McClendon AK, 2012, CELL CYCLE, V11, P2747, DOI 10.4161/cc.21127
   MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077
   Michaud M, 2014, ONCOIMMUNOLOGY, V3, DOI 10.4161/21624011.2014.944047
   Michaud M, 2011, SCIENCE, V334, P1573, DOI 10.1126/science.1208347
   Mutini C, 1999, J IMMUNOL, V163, P1958
   Nair BC, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2929
   Nellore A, 2014, CLIN IMMUNOL, V152, P48, DOI 10.1016/j.clim.2014.02.015
   Neupane YR, 2014, INT J PHARMACEUT, V477, P601, DOI 10.1016/j.ijpharm.2014.11.001
   Nie J, 2016, ONCOTARGET, V7, P37882, DOI 10.18632/oncotarget.9352
   Obeid M, 2007, NAT MED, V13, P54, DOI 10.1038/nm1523
   Ortiz-Ferrón G, 2008, CELL RES, V18, P664, DOI 10.1038/cr.2008.54
   Otsubo D, 2015, ANTICANCER RES, V35, P4425
   Parker N, 2005, ANAL BIOCHEM, V338, P284, DOI 10.1016/j.ab.2004.12.026
   Payne KK, 2016, J LEUKOC BIOL
   Pfannenstiel LW, 2010, CELL IMMUNOL, V263, P79, DOI 10.1016/j.cellimm.2010.03.001
   Pirollo KF, 2016, MOL THER, V24, P1697, DOI 10.1038/mt.2016.135
   Pol J, 2015, ONCOIMMUNOLOGY, V4, DOI 10.1080/2162402X.2015.1008866
   Pulukuri SMK, 2005, INT J ONCOL, V26, P863
   Roberts PJ, 2012, JNCI-J NATL CANCER I, V104, P476, DOI 10.1093/jnci/djs002
   Roulois D, 2015, CELL, V162, P961, DOI 10.1016/j.cell.2015.07.056
   Sakai K, 2007, CANCER SCI, V98, P1498, DOI 10.1111/j.1349-7006.2007.00553.x
   Sevko A, 2013, J IMMUNOL, V190, P2464, DOI 10.4049/jimmunol.1202781
   Shaked Y., 2016, CANC RES
   Sistigu A, 2014, NAT MED, V20, P1301, DOI 10.1038/nm.3708
   Sulek JE, 2017, PROSTATE, V77, P361, DOI 10.1002/pros.23275
   Suzuki E, 2005, CLIN CANCER RES, V11, P6713, DOI 10.1158/1078-0432.CCR-05-0883
   Tan JT, 2002, J EXP MED, V195, P1523, DOI 10.1084/jem.20020066
   Terabe M, 2003, J EXP MED, V198, P1741, DOI 10.1084/jem.20022227
   Terracina KP, 2016, CANCER IMMUNOL IMMUN, V65, P1061, DOI 10.1007/s00262-016-1868-8
   Thorn CF, 2011, PHARMACOGENET GENOM, V21, P440, DOI 10.1097/FPC.0b013e32833ffb56
   Toor AA, 2012, BRIT J HAEMATOL, V158, P700, DOI 10.1111/j.1365-2141.2012.09225.x
   Vacchelli E, 2014, ONCOIMMUNOLOGY, V3, DOI [10.4161/onci.27048, 10.4161/21624011.2014.957994]
   Valabrega G, 2007, ANN ONCOL, V18, P977, DOI 10.1093/annonc/mdl475
   Vanpouille-Box C, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15618
   Vassilev LT, 2006, CELL CYCLE, V5, P2555, DOI 10.4161/cc.5.22.3463
   Viaud S, 2013, SCIENCE, V342, P971, DOI 10.1126/science.1240537
   Vincent J, 2010, CANCER RES, V70, P3052, DOI 10.1158/0008-5472.CAN-09-3690
   Wang LX, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062924
   Weir GM, 2014, ONCOIMMUNOLOGY, V3, DOI 10.4161/21624011.2014.953407
   Wu JJ, 2015, ONCOIMMUNOLOGY, V4, DOI 10.1080/2162402X.2015.1005521
   Yang DF, 2012, J IMMUNOL, V188, P4441, DOI 10.4049/jimmunol.1103035
   Yeo J, 2017, PAIN RES MANAG, V2017, DOI 10.1155/2017/7394626
   Yu WB, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000005002
   Zhang LH, 2015, INT J NANOMED, V10, P2101, DOI 10.2147/IJN.S77667
   Zitvogel L, 2008, B ACAD NATL MED, V192, P1487
   Zitvogel L, 2008, B ACAD NAT MED PARIS, V192, P1469, DOI 10.1016/S0001-4079(19)32694-9
NR 89
TC 9
Z9 9
U1 1
U2 35
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0006-2952
EI 1873-2968
J9 BIOCHEM PHARMACOL
JI Biochem. Pharmacol.
PD DEC 1
PY 2017
VL 145
BP 12
EP 17
DI 10.1016/j.bcp.2017.08.007
PG 6
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA FN1XN
UT WOS:000415784600002
PM 28803721
OA Green Accepted, Bronze
DA 2025-01-12
ER

PT J
AU Piperigkou, Z
   Franchi, M
   Götte, M
   Karamanos, NK
AF Piperigkou, Zoi
   Franchi, Marco
   Goette, Martin
   Karamanos, Nikos K.
TI Estrogen receptor beta as epigenetic mediator of miR-10b and miR-145 in
   mammary cancer
SO MATRIX BIOLOGY
LA English
DT Article
DE Breast cancer; MicroRNA; Estrogen receptor beta;
   Epithelial-to-mesenchymal transition
ID HEPARAN-SULFATE PROTEOGLYCANS; BREAST-CANCER; EXTRACELLULAR-MATRIX;
   MESENCHYMAL TRANSITION; TUMOR-SUPPRESSOR; CELL MOTILITY;
   FUNCTIONAL-PROPERTIES; SIGNALING PATHWAYS; TARGETING ZEB1; MIR-200
   FAMILY
AB Even though the role of estrogen receptor alpha (ER alpha) in the modulation of breast cancer cells' behavior is thoroughly studied, the biological functions of its isoform, ER beta, are less elucidated. The suppression of ER beta in the aggressive ER alpha-negative MDA-MB-231 breast cancer cells resulted in the inhibition of epithelial to mesenchymal transition (EMT) and major changes in the basic functional properties and expression levels of certain matrix components of breast cancer cells. This arrest in metastatic potential of breast cancer cells suggests the contribution of ER beta in the induction of a more aggressive phenotype in MDA-MB-231 breast cancer cells. The epigenetic alterations are responsible for the ability of the tumor cells to metastasize. Here, we report for the first time that the suppression of ER beta in MDA-MB-231 breast cancer cells leads to significant changes in the expression profiles of specific microRNAs, including miR-10b, miR-200b and miR-145. Growth of MCF-7 and MDA-MB-231 cells in estrogen-free medium has a diverse impact on miRNA expression and the behavior of these cells, suggesting the specific effect of estradiol on the miRNA expression profile depending on the ER status of breast cancer cells. Enhanced miR-10b expression or silencing of miR-145 clearly revealed that these microRNAs can regulate the functional properties, EMT program and the expression of major matrix components known to be implicated in breast cancer aggressiveness. Our data revealed that miR-10b is strongly implicated in the regulation of functional properties, EMT program and Erk1/2 signaling in shER beta MDA-MB-231 cells, thus affecting the extracellular matrix (ECM) composition, including syndecan-1, proteolytic behavior, especially MMP2, MMP7 and MMP9 expression and subsequently the aggressiveness of these cells. Accordingly, the inhibition of miR-145 expression significantly increased the aggressiveness of shER beta MDA-MB-231 cells and induced EMT. Moreover, miR-145 inhibition resulted in important changes in the gene and protein levels of ECM mediators, such as HER2 and several MMPs, whereas it significantly increased the phosphorylated levels of Erk1/2 kinases in these cells, suggesting the crucial role of miR-145 in this signaling pathway. These novel results suggest that the alterations in cell behavior and in ECM composition caused by the suppression of ER beta in MDA-MB-231 cells are closely related to certain epigenetic miRNA-induced alterations. Targeting the ER beta-regulated miR-10b and miR-145 is a promising tool for diagnosis and pharmaceutical targeting in breast cancer. (C) 2017 Elsevier B.V. All rights reserved.
C1 [Piperigkou, Zoi; Karamanos, Nikos K.] Univ Patras, Dept Chem, Lab Biochem, Biochem Biochem Anal & Matrix Pathobiol Res Grp, GR-26110 Patras, Greece.
   [Piperigkou, Zoi; Goette, Martin] Munster Univ Hosp, Dept Gynecol & Obstet, D-48149 Munster, Germany.
   [Franchi, Marco] Univ Bologna, Dept Life Qual Studies, I-47100 Rimini, Italy.
C3 University of Patras; University of Munster; University of Bologna
RP Karamanos, NK (通讯作者)，Univ Patras, Dept Chem, Lab Biochem, Biochem Biochem Anal & Matrix Pathobiol Res Grp, GR-26110 Patras, Greece.; Götte, M (通讯作者)，Munster Univ Hosp, Dept Gynecol & Obstet, D-48149 Munster, Germany.
EM n.k.karamanos@upatras.gr
RI Piperigkou, Zoi/AFV-1169-2022; Marco, Franchi/R-8758-2019; Gotte,
   M/Z-5878-2019; Karamanos, Nikos/A-3616-2008; Gotte, Martin/G-2254-2018
OI Karamanos, Nikos/0000-0003-3618-0288; Gotte, Martin/0000-0003-2360-2496;
   Piperigkou, Zoi/0000-0002-0472-5389
FU EU Horizon project RISE [645756]; DAAD agency [91607321]
FX This work was supported by the EU Horizon 2020 project RISE-2014, action
   No. 645756 "GLYCANC - Matrix glycans as multifunctional pathogenesis
   factors and therapeutic targets in cancer". Z.P. was supported by the
   DAAD agency, grant No. 91607321.
CR AFRATIS N.A., 2016, The FEBS Journal
   Afratis N. A., 2016, GLYCOCONJ J
   [Anonymous], MATRIX BIOL
   [Anonymous], MATRIX BIOL
   Baffa R, 2009, J PATHOL, V219, P214, DOI 10.1002/path.2586
   Bai JX, 2013, ENDOCRINOLOGY, V154, P635, DOI 10.1210/en.2012-1607
   Barbouri D, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00004
   Bouris P, 2015, MATRIX BIOL, V43, P42, DOI 10.1016/j.matbio.2015.02.008
   Cieply B, 2015, MATRIX BIOL, V48, P55, DOI 10.1016/j.matbio.2015.04.010
   Couchman J. R., 2016, F1000RES, V5
   Curran CS, 2013, MATRIX BIOL, V32, P95, DOI 10.1016/j.matbio.2012.11.016
   Du F, 2016, SCI REP-UK, V6, DOI 10.1038/srep33825
   Eggers JC, 2016, REPROD BIOMED ONLINE, V32, P434, DOI 10.1016/j.rbmo.2015.12.013
   Gialeli C, 2011, FEBS J, V278, P16, DOI 10.1111/j.1742-4658.2010.07919.x
   Götte M, 2010, ONCOGENE, V29, P6569, DOI 10.1038/onc.2010.386
   Götte M, 2006, ANTICANCER RES, V26, P621
   Göttlicher M, 1998, J MOL MED-JMM, V76, P480, DOI 10.1007/s001090050242
   Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722
   Griggs LA, 2017, MATRIX BIOL, V60-61, P157, DOI 10.1016/j.matbio.2017.01.001
   Hannafon BN, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2839
   Heidari-Hamedani G, 2015, CELL SIGNAL, V27, P2054, DOI 10.1016/j.cellsig.2015.07.017
   Ibrahim SA, 2014, FEBS J, V281, P5009, DOI 10.1111/febs.13026
   Ibrahim SA, 2012, INT J CANCER, V131, pE884, DOI 10.1002/ijc.27629
   Ibrahim SA, 2014, BBA-GEN SUBJECTS, V1840, P2609, DOI 10.1016/j.bbagen.2014.01.022
   Iozzo RV, 2015, MATRIX BIOL, V42, P11, DOI 10.1016/j.matbio.2015.02.003
   JEMAL A, 2011, CA-CANCER J CLIN, V61, P69, DOI DOI 10.3322/CAAC.20107
   Karousou E., 2016, MATRIX BIOL
   Kessenbrock K, 2015, MATRIX BIOL, V44-46, P184, DOI 10.1016/j.matbio.2015.01.022
   Kousidou OC, 2008, MOL ONCOL, V2, P223, DOI 10.1016/j.molonc.2008.06.002
   Kovalszky I, 2014, BBA-GEN SUBJECTS, V1840, P2491, DOI 10.1016/j.bbagen.2014.04.015
   Kumar S, 2016, SCI REP-UK, V6, DOI 10.1038/srep19905
   Kurozumi S, 2017, J HUM GENET, V62, P15, DOI 10.1038/jhg.2016.89
   Levin ER, 2016, NAT REV MOL CELL BIO, V17, DOI 10.1038/nrm.2016.122
   Lim YY, 2013, J CELL SCI, V126, P2256, DOI 10.1242/jcs.122275
   Liu Y., 2016, EVID-BASED COMPL ALT, P6230825, DOI DOI 10.1155/2016/6230825
   Liu YN, 2013, ONCOGENE, V32, P296, DOI 10.1038/onc.2012.58
   Lösel R, 2003, NAT REV MOL CELL BIO, V4, P46, DOI 10.1038/nrm1009
   Ma L, 2007, NATURE, V449, P682, DOI 10.1038/nature06174
   Ma L, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2720
   Ma L, 2010, NAT BIOTECHNOL, V28, P341, DOI 10.1038/nbt.1618
   Marsico A, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-8-r84
   Mathe A, 2015, SCI REP-UK, V5, DOI 10.1038/srep15832
   Mlcochova H, 2016, SCI REP-UK, V6, DOI 10.1038/srep31852
   Mouw JK, 2014, NAT REV MOL CELL BIO, V15, P771, DOI 10.1038/nrm3902
   Neill T, 2015, BIOCHEMISTRY-US, V54, P4583, DOI 10.1021/acs.biochem.5b00653
   Nikitovic D, 2014, MATRIX BIOL, V35, P206, DOI 10.1016/j.matbio.2013.09.003
   Nikolova V, 2009, CARCINOGENESIS, V30, P397, DOI 10.1093/carcin/bgp001
   Noh JH, 2013, CANCER LETT, V335, P455, DOI 10.1016/j.canlet.2013.03.003
   Piperigkou Z, 2016, CELL TISSUE RES, V365, P643, DOI 10.1007/s00441-016-2452-4
   Piperigkou Z, 2016, TOXICOL LETT, V240, P32, DOI 10.1016/j.toxlet.2015.10.005
   Ramani VC, 2016, MATRIX BIOL, V55, P22, DOI 10.1016/j.matbio.2016.03.006
   Rutnam ZJ, 2013, MATRIX BIOL, V32, P74, DOI 10.1016/j.matbio.2012.11.003
   Sachdeva M, 2009, P NATL ACAD SCI USA, V106, P3207, DOI 10.1073/pnas.0808042106
   Sanderson RD, 2017, FEBS J, V284, P42, DOI 10.1111/febs.13932
   Schaefer L, 2017, FEBS J, V284, P10, DOI 10.1111/febs.13963
   Shao Q, 2017, ONCOTARGET, V8, P29056, DOI 10.18632/oncotarget.16072
   Singh R, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-256
   Skandalis SS, 2014, MATRIX BIOL, V35, P182, DOI 10.1016/j.matbio.2013.09.002
   Theocharis AD, 2016, ADV DRUG DELIVER REV, V97, P4, DOI 10.1016/j.addr.2015.11.001
   Theocharis AD, 2015, BBA-REV CANCER, V1855, P276, DOI 10.1016/j.bbcan.2015.03.006
   Theocharis AD, 2014, FEBS J, V281, P5023, DOI 10.1111/febs.12927
   Theocharis AD, 2010, FEBS J, V277, P3904, DOI 10.1111/j.1742-4658.2010.07800.x
   Thomson DW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055214
   Tryndyak VP, 2010, INT J CANCER, V126, P2575, DOI 10.1002/ijc.24972
   Tsonis AI, 2013, FEBS J, V280, P2248, DOI 10.1111/febs.12162
   Vigetti D, 2014, FEBS J, V281, P4980, DOI 10.1111/febs.12938
   Voudouri K., 2016, MATRIX BIOL
   Winter J, 2009, NAT CELL BIOL, V11, P228, DOI 10.1038/ncb0309-228
   Xu F, 2016, CLIN TRANSL ONCOL, V18, P283, DOI 10.1007/s12094-015-1364-1
   Zhang JJ, 2011, CANCER-AM CANCER SOC, V117, P86, DOI 10.1002/cncr.25522
   Zhao H, 2016, AM J TRANSL RES, V8, P3106
   Zheng MZ, 2016, TUMOR BIOL, V37, P8189, DOI 10.1007/s13277-015-4722-2
NR 72
TC 39
Z9 38
U1 0
U2 10
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0945-053X
EI 1569-1802
J9 MATRIX BIOL
JI Matrix Biol.
PD DEC
PY 2017
VL 64
BP 94
EP 111
DI 10.1016/j.matbio.2017.08.002
PG 18
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA FR3RI
UT WOS:000418983600008
PM 28797712
OA Green Submitted
DA 2025-01-12
ER

PT J
AU Coyle, KM
   Maxwell, S
   Thomas, ML
   Marcato, P
AF Coyle, Krysta Mila
   Maxwell, Selena
   Thomas, Margaret Lois
   Marcato, Paola
TI Profiling of the transcriptional response to all-trans retinoic acid in
   breast cancer cells reveals RARE-independent mechanisms of gene
   expression
SO SCIENTIFIC REPORTS
LA English
DT Article
ID ALDEHYDE DEHYDROGENASE 1; INDUCED GROWTH ARREST; STEM-CELLS;
   RECEPTOR-BETA; INDUCED APOPTOSIS; CARCINOMA-CELLS; INHIBITION; MARKER;
   ACTIVATION; IDENTIFICATION
AB Retinoids, derivatives of vitamin A, are key physiological molecules with regulatory effects on cell differentiation, proliferation and apoptosis. As a result, they are of interest for cancer therapy. Specifically, models of breast cancer have varied responses to manipulations of retinoid signaling. This study characterizes the transcriptional response of MDA-MB-231 and MDA-MB-468 breast cancer cells to retinaldehyde dehydrogenase 1A3 (ALDH1A3) and all-trans retinoic acid (atRA). We demonstrate limited overlap between ALDH1A3-induced gene expression and atRA-induced gene expression in both cell lines, suggesting that the function of ALDH1A3 in breast cancer progression extends beyond its role as a retinaldehyde dehydrogenase. Our data reveals divergent transcriptional responses to atRA, which are largely independent of genomic retinoic acid response elements (RAREs) and consistent with the opposing responses of MDA-MB-231 and MDA-MB-468 to in vivo atRA treatment. We identify transcription factors associated with each gene set. Manipulation of the IRF1 transcription factor demonstrates that it is the level of atRA-inducible and epigenetically regulated transcription factors that determine expression of target genes (e.g. CTSS, cathepsin S). This study provides a paradigm for complex responses of breast cancer models to atRA treatment, and illustrates the need to characterize RARE-independent responses to atRA in a variety of models.
C1 [Coyle, Krysta Mila; Thomas, Margaret Lois; Marcato, Paola] Dalhousie Univ, Dept Pathol, Halifax, NS, Canada.
   [Maxwell, Selena; Marcato, Paola] Dalhousie Univ, Dept Microbiol & Immunol, Halifax, NS, Canada.
C3 Dalhousie University; Dalhousie University
RP Marcato, P (通讯作者)，Dalhousie Univ, Dept Pathol, Halifax, NS, Canada.; Marcato, P (通讯作者)，Dalhousie Univ, Dept Microbiol & Immunol, Halifax, NS, Canada.
EM paola.marcato@dal.ca
RI Maxwell, Selena/LRU-6520-2024
OI Coyle, Krysta/0000-0002-1309-4873; Marcato, Paola/0000-0001-8619-283X;
   Maxwell, Selena/0000-0001-9969-648X
FU Canadian Institutes of Health Research (CIHR) [MOP-130304]; Beatrice
   Hunter Cancer Research Institute (BHCRI); Breast Cancer Society of
   Canada; QEII Health Sciences Center Foundation; BHCRI; Canadian Breast
   Cancer Foundation; Canadian Imperial Bank of Commerce; CGS-D awards from
   CIHR; Nova Scotia Health Research Foundation; Killam Trusts at Dalhousie
   University; NS Research and Innovation Graduate Scholarships
FX Support was provided by grant funding to PM from the Canadian Institutes
   of Health Research (CIHR, MOP-130304), the Beatrice Hunter Cancer
   Research Institute (BHCRI), the Breast Cancer Society of Canada, and the
   QEII Health Sciences Center Foundation. KMC and MLT are supported by
   studentship or trainee awards from the BHCRI, Canadian Breast Cancer
   Foundation, and the Canadian Imperial Bank of Commerce. KMC and MLT are
   supported by CGS-D awards from CIHR, by the Nova Scotia Health Research
   Foundation, and by the Killam Trusts at Dalhousie University. MLT is
   supported by NS Research and Innovation Graduate Scholarships.
CR Alpha-Tocopherol Beta Carotene Cancer Prevention Study Group, 1994, N Engl J Med, V330, P1029, DOI 10.1056/NEJM199404143301501
   Altucci L, 2001, NAT MED, V7, P680, DOI 10.1038/89050
   Basu M, 2017, BBA-GENE REGUL MECH, V1860, P450, DOI 10.1016/j.bbagrm.2017.02.004
   Benkoussa M, 2002, MOL CELL BIOL, V22, P4522, DOI 10.1128/MCB.22.13.4522-4534.2002
   Bhattacharyya N, 1997, MOL CELL BIOL, V17, P6481, DOI 10.1128/MCB.17.11.6481
   Bolis M, 2017, ANN ONCOL, V28, P611, DOI 10.1093/annonc/mdw660
   Bookout AL, 2006, CELL, V126, P789, DOI 10.1016/j.cell.2006.06.049
   Carrier M, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0157290
   Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095
   Chen AC, 1997, CANCER RES, V57, P4642
   Chen YC, 2009, BIOCHEM BIOPH RES CO, V385, P307, DOI 10.1016/j.bbrc.2009.05.048
   Chiesa Matteo Dalla, 2007, Acta Biomed, V78, P204
   Cho YH, 1997, J CELL PHYSIOL, V172, P306, DOI 10.1002/(SICI)1097-4652(199709)172:3<306::AID-JCP4>3.0.CO;2-S
   Chute JP, 2006, P NATL ACAD SCI USA, V103, P11707, DOI 10.1073/pnas.0603806103
   Ciriello G, 2015, CELL, V163, P506, DOI 10.1016/j.cell.2015.09.033
   Coyle K. M., 2013, J CARCINOG MUTAGEN
   Coyle KM, 2016, ONCOTARGET, V7, P44096, DOI 10.18632/oncotarget.9858
   Croker AK, 2012, BREAST CANCER RES TR, V133, P75, DOI 10.1007/s10549-011-1692-y
   Crooks GE, 2004, GENOME RES, V14, P1188, DOI 10.1101/gr.849004
   Duan JJ, 2016, INT J CANCER, V139, P965, DOI 10.1002/ijc.30091
   Emionite L, 2004, ANTICANCER RES, V24, P4019
   Fazi F, 2005, ONCOGENE, V24, P1820, DOI 10.1038/sj.onc.1208286
   Feng L, 2010, DEV BIOL, V338, P1, DOI 10.1016/j.ydbio.2009.10.029
   FONTANA JA, 1987, EXP CELL BIOL, V55, P136
   Friedman MD, 2013, ONCOL REP, V30, P1645, DOI 10.3892/or.2013.2625
   Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088
   Garattini E, 2014, CANCER TREAT REV, V40, P739, DOI 10.1016/j.ctrv.2014.01.001
   Ginestier C, 2007, CELL STEM CELL, V1, P555, DOI 10.1016/j.stem.2007.08.014
   Ginestier C, 2009, CELL CYCLE, V8, P3297, DOI 10.4161/cc.8.20.9761
   Graham CE, 2006, BIOCHEM J, V394, P67, DOI 10.1042/BJ20050918
   Gudas LJ, 2011, J CELL PHYSIOL, V226, P322, DOI 10.1002/jcp.22417
   Heim KC, 2007, MOL CANCER, V6, DOI 10.1186/1476-4598-6-57
   Hong TK, 2009, NUTR RES PRACT, V3, P77, DOI 10.4162/nrp.2009.3.2.77
   Hosoda K., 2015, ADV BIOL CHEM, V05, P58, DOI DOI 10.4236/abc.2015.52006
   Hua SJ, 2009, CELL, V137, P1259, DOI 10.1016/j.cell.2009.04.043
   Huang EH, 2009, CANCER RES, V69, P3382, DOI 10.1158/0008-5472.CAN-08-4418
   HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567
   Jiang F, 2009, MOL CANCER RES, V7, P330, DOI 10.1158/1541-7786.MCR-08-0393
   Jiang SY, 2005, BIOCHEM BIOPH RES CO, V331, P630, DOI 10.1016/j.bbrc.2005.03.214
   Kashyap V, 2013, J CELL SCI, V126, P999, DOI 10.1242/jcs.119701
   Kashyap V, 2010, J BIOL CHEM, V285, P14534, DOI 10.1074/jbc.M110.115345
   Kedishvili NY, 2013, J LIPID RES, V54, P1744, DOI 10.1194/jlr.R037028
   Kwon AT, 2012, G3-GENES GENOM GENET, V2, P987, DOI 10.1534/g3.112.003202
   Lalevée S, 2011, J BIOL CHEM, V286, P33322, DOI 10.1074/jbc.M111.263681
   Lee Hyo Sun, 2012, Toxicology and Environmental Health Sciences, V4, P211, DOI 10.1007/s13530-012-0140-7
   LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z
   Lim YC, 2012, EUR J CANCER, V48, P3310, DOI 10.1016/j.ejca.2012.04.013
   LIN GX, 2017, SCI REP UK, V7
   Liu RZ, 2011, AM J PATHOL, V178, P997, DOI 10.1016/j.ajpath.2010.11.075
   Liu TX, 2000, BLOOD, V96, P1496, DOI 10.1182/blood.V96.4.1496.h8001496_1496_1504
   Liu XX, 2011, P NATL ACAD SCI USA, V108, P774, DOI 10.1073/pnas.1011845108
   Liu Y, 1996, MOL CELL BIOL, V16, P1138
   Luo XM, 2006, EXP BIOL MED, V231, P619
   MADER S, 1993, J BIOL CHEM, V268, P591
   Mamidi S, 2012, IMMUNOBIOLOGY, V217, P593, DOI 10.1016/j.imbio.2011.10.022
   Manor D, 2003, CANCER RES, V63, P4426
   Mao P, 2013, P NATL ACAD SCI USA, V110, P8644, DOI 10.1073/pnas.1221478110
   Marcato P, 2015, MOL ONCOL, V9, P17, DOI 10.1016/j.molonc.2014.07.010
   Marcato P, 2011, STEM CELLS, V29, P32, DOI 10.1002/stem.563
   Mira-y-Lopez R, 2000, J CELL PHYSIOL, V185, P302, DOI 10.1002/1097-4652(200011)185:2<302::AID-JCP15>3.0.CO;2-#
   Moretti A, 2016, SCI REP-UK, V6, DOI 10.1038/srep35710
   Nguyen PH, 2016, ONCOGENE, V35, P5619, DOI 10.1038/onc.2016.87
   Park SY, 2004, EUR J BIOCHEM, V271, P4222, DOI 10.1111/j.1432-1033.2004.04362.x
   Peinemann F, 2015, COCHRANE DB SYST REV, V1
   Pelicano L, 1997, ONCOGENE, V15, P2349, DOI 10.1038/sj.onc.1201410
   Percario ZA, 1999, CELL GROWTH DIFFER, V10, P263
   Persaud SD, 2016, SCI REP-UK, V6, DOI 10.1038/srep22396
   Ren X, 2007, LIFE SCI, V81, P89, DOI 10.1016/j.lfs.2007.04.037
   Rettino A., 2013, J CARCINOG MUTAGEN
   Roider HG, 2009, BIOINFORMATICS, V25, P435, DOI 10.1093/bioinformatics/btn627
   Romero OA, 2017, ONCOGENE, V36, P1287, DOI 10.1038/onc.2016.296
   Ross-Innes CS, 2010, GENE DEV, V24, P171, DOI 10.1101/gad.552910
   Schug TT, 2008, P NATL ACAD SCI USA, V105, P7546, DOI 10.1073/pnas.0709981105
   Schug TT, 2007, CELL, V129, P723, DOI 10.1016/j.cell.2007.02.050
   SCHULE R, 1991, P NATL ACAD SCI USA, V88, P6092, DOI 10.1073/pnas.88.14.6092
   SEEWALDT VL, 1995, CELL GROWTH DIFFER, V6, P1077
   Shaw N, 2003, J BIOL CHEM, V278, P41589, DOI 10.1074/jbc.C300368200
   Singh M, 2015, CHEM-BIOL INTERACT, V234, P261, DOI 10.1016/j.cbi.2014.12.028
   Singh S, 2013, FREE RADICAL BIO MED, V56, P89, DOI 10.1016/j.freeradbiomed.2012.11.010
   Singletary SE, 2002, CLIN CANCER RES, V8, P2835
   Sullivan KE, 2017, ONCOTARGET, V8, P22325, DOI 10.18632/oncotarget.16479
   Tang XH, 2011, ANNU REV PATHOL-MECH, V6, P345, DOI 10.1146/annurev-pathol-011110-130303
   Thomas ML, 2016, MOL ONCOL, V10, P1485, DOI 10.1016/j.molonc.2016.08.004
   Van heusden J, 1998, BRIT J CANCER, V77, P26, DOI 10.1038/bjc.1998.5
   van's Gravesande KS, 2002, J IMMUNOL, V168, P4488, DOI 10.4049/jimmunol.168.9.4488
   VERMA AK, 1982, CANCER RES, V42, P3519
   WETHERALL NT, 1986, EUR J CANCER CLIN ON, V22, P53, DOI 10.1016/0277-5379(86)90342-1
   White JA, 1996, J BIOL CHEM, V271, P29922, DOI 10.1074/jbc.271.47.29922
   Xu XC, 1999, CANCER RES, V59, P2477
   Young MJ, 2015, CARCINOGENESIS, V36, P498, DOI 10.1093/carcin/bgv018
   Zhang JM, 2004, ONCOGENE, V23, P2241, DOI 10.1038/sj.onc.1207328
   Zheng PZ, 2005, P NATL ACAD SCI USA, V102, P7653, DOI 10.1073/pnas.0502825102
NR 92
TC 23
Z9 23
U1 0
U2 5
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD NOV 30
PY 2017
VL 7
AR 16684
DI 10.1038/s41598-017-16687-6
PG 13
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA FO5JI
UT WOS:000416891400086
PM 29192143
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU Boyne, DJ
   Friedenreich, CM
   McIntyre, JB
   Stanczyk, FZ
   Courneya, KS
   King, WD
AF Boyne, Devon J.
   Friedenreich, Christine M.
   McIntyre, John B.
   Stanczyk, Frank Z.
   Courneya, Kerry S.
   King, Will D.
TI Endogenous sex hormone exposure and repetitive element DNA methylation
   in healthy postmenopausal women
SO CANCER CAUSES & CONTROL
LA English
DT Article
DE DNA methylation; Repetitive elements; Epigenetics; Sex hormones;
   Estrogen
ID ONE-CARBON METABOLISM; BREAST-CANCER; GLOBAL METHYLATION;
   PHYSICAL-ACTIVITY; BLOOD DNA; DISEASE; QUESTIONNAIRE; EPIGENETICS;
   ESTROGEN; TISSUES
AB Epigenetic mechanisms may help to explain the complex and heterogeneous relation between sex hormones and cancer. Few studies have investigated the effects of sex hormones on epigenetic markers related to cancer risk such as levels of methylation within repetitive DNA elements. Our objective was to describe the association between endogenous sex hormone exposure and levels of LINE-1 and Alu methylation in healthy postmenopausal women.
   We nested a cross-sectional study within the Alberta Physical Activity and Breast Cancer Prevention Trial (2003-2006). Study participants consisted of healthy postmenopausal women who had never been diagnosed with cancer (n = 289). Sex hormone exposures included serum concentrations of estradiol, estrone, testosterone, androstenedione, and sex hormone-binding globulin. We estimated the participants' lifetime number of menstrual cycles (LNMC) as a proxy for cumulative exposure to ovarian sex hormones. Buffy coat samples were assessed for DNA methylation. Linear regression was used to model the associations of interest and to control for confounding.
   Both estradiol and estrone had a significant positive dose-response association with LINE-1 methylation. LNMC was associated with both LINE-1 and Alu methylation. Specifically, LNMC had a non-linear "U-shaped" association with LINE-1 methylation regardless of folate intake and a negative linear association with Alu methylation, but only amongst low folate consumers. Androgen exposure was not associated with either outcome.
   Current and cumulative estrogen exposure was associated with repetitive element DNA methylation in a group of healthy postmenopausal women. LINE-1 and Alu methylation may be epigenetic mechanisms through which estrogen exposure impacts cancer risk.
C1 [Boyne, Devon J.; Friedenreich, Christine M.] Alberta Hlth Serv, Holy Cross Ctr, Canc Control Alberta, Dept Canc Epidemiol & Prevent Res, 2210-2nd St SW,Box ACB, Calgary, AB T2S 3C3, Canada.
   [Boyne, Devon J.; Friedenreich, Christine M.] Univ Calgary, Cumming Sch Med, Dept Community Hlth Sci, TRW Bldg,3rd Floor,3280 Hosp Dr NW, Calgary, AB T2N 4Z6, Canada.
   [Friedenreich, Christine M.] Univ Calgary, Cumming Sch Med, Dept Oncol, 1331 29th St NW, Calgary, AB T2N 4N2, Canada.
   [McIntyre, John B.] Univ Calgary, Tom Baker Canc Ctr, Dept Oncol, Translat Lab, Room AGE 90,1331 29th St NW, Calgary, AB T2N 4N2, Canada.
   [Stanczyk, Frank Z.] Univ Southern Calif, Keck Sch Med, Dept Obstet & Gynecol, LRB 201,Off Campus, Los Angeles, CA 90089 USA.
   [Stanczyk, Frank Z.] Univ Southern Calif, Keck Sch Med, Dept Prevent Med, LRB 201,Off Campus, Los Angeles, CA 90089 USA.
   [Courneya, Kerry S.] Univ Alberta, Fac Phys Educ & Recreat, 1-113 Univ Hall, Edmonton, AB T6G 2H9, Canada.
   [King, Will D.] Queens Univ, Dept Publ Hlth Sci, Carruthers Hall,62 Fifth Field Co Lane,2nd Floor, Kingston, ON K7L 3N6, Canada.
C3 Alberta Health Services (AHS); University of Calgary; University of
   Calgary; University of Calgary; Tom Baker Cancer Clinic; University of
   Calgary; University of Southern California; University of Southern
   California; University of Alberta; Queens University - Canada
RP King, WD (通讯作者)，Queens Univ, Dept Publ Hlth Sci, Carruthers Hall,62 Fifth Field Co Lane,2nd Floor, Kingston, ON K7L 3N6, Canada.
EM devon.boyne1@ucalgary.ca;
   christine.friedenreich@albertahealthservices.ca;
   john.mcintyre3@albertahealthservices.ca; fstanczyk@att.net;
   kerry.courneya@ualberta.ca; kingw@queensu.ca
RI Friedenreich, Christine/LKJ-4397-2024; Courneya, Kerry/AAJ-2712-2021;
   McIntyre, JB/ABE-9340-2021
OI Friedenreich, Christine/0000-0002-4783-1966; Stanczyk,
   Frank/0000-0002-3607-121X
FU Queen's University Terry Fox Foundation; Canadian Institutes for Health
   Research (CIHR); Ontario Graduate Scholarship; Alberta Innovates Health
   Solutions; Alberta Cancer Foundation Weekend to End Women's Cancers
   Breast Cancer Chair; Canada Research Chairs Program; Canadian Breast
   Cancer Research Alliance; CIHR; Canadian Cancer Society; Alberta Cancer
   Foundation
FX Devon Boyne was supported by funding from the Queen's University Terry
   Fox Foundation Training Program in Transdisciplinary Cancer Research in
   partnership with the Canadian Institutes for Health Research (CIHR) and
   an Ontario Graduate Scholarship. Christine Friedenreich was supported by
   an Alberta Innovates Health Solutions Health Senior Scholar Award and by
   the Alberta Cancer Foundation Weekend to End Women's Cancers Breast
   Cancer Chair. Kerry S. Courneya is supported by the Canada Research
   Chairs Program. The ALPHA Trial was originally funded by a research
   grant from the Canadian Breast Cancer Research Alliance and the
   ancillary study is funded by grants from CIHR and the Canadian Cancer
   Society. Funding for the DNA extraction was provided by an Alberta
   Cancer Foundation grant for the Biospecimen Processing Unit within the
   Translational Laboratories (TL) at the Tom Baker Cancer Centre (TBCC).
CR Adalsteinsson BT, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046705
   Anderson KN, 2014, BREAST CANCER RES TR, V144, P1, DOI 10.1007/s10549-014-2852-7
   Anderson OS, 2012, J NUTR BIOCHEM, V23, P853, DOI 10.1016/j.jnutbio.2012.03.003
   Arevalo MA, 2015, NAT REV NEUROSCI, V16, P17, DOI 10.1038/nrn3856
   Ashbury JE, 2014, INT J MOL EPIDEMIOL, V5, P120
   Barzi A, 2013, CLIN CANCER RES, V19, P5842, DOI 10.1158/1078-0432.CCR-13-0325
   BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x
   Bernstein BE, 2007, CELL, V128, P669, DOI 10.1016/j.cell.2007.01.033
   Brown SB, 2015, STEROIDS, V99, P8, DOI 10.1016/j.steroids.2014.12.013
   Chalitchagorn K, 2004, ONCOGENE, V23, P8841, DOI 10.1038/sj.onc.1208137
   Csizmadi I, 2007, PUBLIC HEALTH NUTR, V10, P88, DOI 10.1017/S1368980007184287
   Deroo LA, 2014, CARCINOGENESIS, V35, P333, DOI 10.1093/carcin/bgt342
   Friedenreich CM, 2011, INT J OBESITY, V35, P427, DOI 10.1038/ijo.2010.147
   Friedenreich CM, 2010, J CLIN ONCOL, V28, P1458, DOI 10.1200/JCO.2009.24.9557
   Friedenreich CM, 2006, AM J EPIDEMIOL, V163, P959, DOI 10.1093/aje/kwj112
   Hancks DC, 2016, MOBILE DNA-UK, V7, DOI 10.1186/s13100-016-0065-9
   HANKINSON SE, 1995, CANCER EPIDEM BIOMAR, V4, P649
   Iwasaki M, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-323
   Jakovcevski M, 2012, NAT MED, V18, P1194, DOI 10.1038/nm.2828
   Jirtle RL, 2007, NAT REV GENET, V8, P253, DOI 10.1038/nrg2045
   Joyce BT, 2016, BRIT J CANCER, V115, P465, DOI 10.1038/bjc.2016.205
   Key TJ, 2003, J NATL CANCER I, V95, P1218, DOI 10.1093/jnci/djg022
   Kile ML, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013730
   Lowe R, 2015, EPIGENETICS-US, V10, P274, DOI 10.1080/15592294.2014.1003744
   Mendelsohn ME, 2002, AM J CARDIOL, V89, p12E
   Muka T, 2016, INT J CARDIOL, V212, P174, DOI 10.1016/j.ijcard.2016.03.062
   Padeken J, 2015, CURR OPIN GENET DEV, V31, P12, DOI 10.1016/j.gde.2015.03.009
   Ulrich CM, 2012, EPIGENETICS-US, V7, P1020, DOI 10.4161/epi.21464
   Varela-Rey M, 2013, ALCOHOL RES-CURR REV, V35, P25
   Willett WC, 1997, AM J CLIN NUTR, V65, P1220, DOI 10.1093/ajcn/65.4.1220S
   Yang AS, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh032
   Zhang XA, 2011, J MOL ENDOCRINOL, V46, pR11, DOI 10.1677/JME-10-0053
   Zhang XH, 2013, BREAST CANCER RES TR, V137, P883, DOI 10.1007/s10549-012-2391-z
   Zhu ZZ, 2012, INT J EPIDEMIOL, V41, P126, DOI 10.1093/ije/dyq154
NR 34
TC 22
Z9 25
U1 0
U2 7
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0957-5243
EI 1573-7225
J9 CANCER CAUSE CONTROL
JI Cancer Causes Control
PD DEC
PY 2017
VL 28
IS 12
BP 1369
EP 1379
DI 10.1007/s10552-017-0958-z
PG 11
WC Oncology; Public, Environmental & Occupational Health
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Public, Environmental & Occupational Health
GA FM8RR
UT WOS:000415357700002
PM 28929436
DA 2025-01-12
ER

PT J
AU Yang, JT
   Han, F
   Liu, WB
   Chen, HQ
   Hao, XL
   Jiang, X
   Yin, L
   Huang, YS
   Cao, J
   Zhang, HD
   Liu, JY
AF Yang, Juntang
   Han, Fei
   Liu, Wenbin
   Chen, Hongqiang
   Hao, Xianglin
   Jiang, Xiao
   Yin, Li
   Huang, Yongsheng
   Cao, Jia
   Zhang, Huidong
   Liu, Jinyi
TI ALX4, an epigenetically down regulated tumor suppressor, inhibits breast
   cancer progression by interfering Wnt/β-catenin pathway
SO JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
LA English
DT Article
DE ALX4; DNA methylation; Wnt/beta-catenin and breast cancer
ID BETA-CATENIN; DESTRUCTION COMPLEX; HOMEOBOX GENE; EXPRESSION;
   METASTASIS; MECHANISMS; INVASION; BINDING; PHOSPHORYLATION; METHYLATION
AB Background: ALX4 is a paired-like homedomain transcription factor mainly expressed in the mesenchymal compartment of variety of developing tissues, but its functions, regulation mechanisms and clinical values in breast cancer remains unclear.
   Methods: The expression of ALX4 in breast cancer cell lines and patients' tissues were detected by RT-PCR, qPCR and western blot. Furthermore TCGA database was applied to confirm these results. MSP and BSP methods were used to assess the methylation of ALX4 promoter region. In vitro proliferation, metastasis and in vivo nude mice model were used to evaluate the anti-tumor effect of ALX4 on breast cancer cell lines. Luciferase reporter assay, western blot and TCGA database were used to investigate the tumor suppression mechanisms of ALX4. TMA of 142 breast patients was generated to evaluate the clinical significance of ALX4.
   Results: Expression analysis revealed that ALX4 expression is down regulated in breast cancer cell lines and tissues. MSP study showed that the promoter region of ALX4 was hyper-methylated 100% (3/3) in breast cancer cell lines and 69.44% (75/108) in primary breast tumors tissues while 0% (0/8) in normal breast tissues. 5-aza-dc demethylation treatment restored ALX4 expression in breast cancer cell lines. Functional studies showed that ectopic expression of ALX4 in breast cancer cells inhibited cell proliferation, metastasis in vitro and in vivo. Mechanism study found that ALX4 exerted its anti-tumor function by suppressing the Wnt/beta-catenin pathway through promoting the phosphorylation degradation of beta-catenin in a GSK3 beta dependent manner. Clinically multivariate analysis showed that ALX4 expression was an independent favorable prognostic factor in breast cancer patients.
   Conclusions: We reveal for the first time that ALX4 acts as a novel functional tumor suppressor inactivated by DNA methylation and is an independent prognostic factor in breast cancer.
C1 [Yang, Juntang; Han, Fei; Liu, Wenbin; Chen, Hongqiang; Hao, Xianglin; Jiang, Xiao; Yin, Li; Huang, Yongsheng; Cao, Jia; Zhang, Huidong; Liu, Jinyi] Third Mil Med Univ, Coll Prevent Med, Inst Toxicol, 30 Gaotanyan St, Chongqing 400038, Peoples R China.
C3 Army Medical University
RP Liu, JY (通讯作者)，Third Mil Med Univ, Coll Prevent Med, Inst Toxicol, 30 Gaotanyan St, Chongqing 400038, Peoples R China.
EM jinyiliutmmu@163.com
RI WENBIN, LIU/KHZ-9640-2024; Han, Fei/AAG-9260-2020
OI liu, jin-yi/0000-0003-1803-7752; Han, Fei/0000-0002-0265-5487
FU National Natural Science Foundation of China [81502551, 81172714,
   8157311]
FX This work was supported by the National Natural Science Foundation of
   China [No. 81502551, 81172714 and 8157311].
CR Amit S, 2002, GENE DEV, V16, P1066, DOI 10.1101/gad.230302
   Bertozzi S, 2015, SPRINGERPLUS, V4, DOI 10.1186/s40064-015-1449-x
   Braden AM, 2014, CURR PHARM DESIGN, V20, P4879
   Chang H, 2009, J CLIN PATHOL, V62, P908, DOI 10.1136/jcp.2009.067298
   Charafe-Jauffret E, 2010, CLIN CANCER RES, V16, P45, DOI 10.1158/1078-0432.CCR-09-1630
   Chen WQ, 2016, CA-CANCER J CLIN, V66, P115, DOI 10.3322/caac.21338
   Esteller M, 2007, NAT REV GENET, V8, P286, DOI 10.1038/nrg2005
   Frame S, 2001, MOL CELL, V7, P1321, DOI 10.1016/S1097-2765(01)00253-2
   Hagen T, 2002, J BIOL CHEM, V277, P23330, DOI 10.1074/jbc.M201364200
   Han F, 2015, ONCOGENE, V34, P4391, DOI 10.1038/onc.2014.370
   Han F, 2015, SCI REP-UK, V5, DOI 10.1038/srep13630
   He X, 2004, DEVELOPMENT, V131, P1663, DOI 10.1242/dev.01117
   Holliday R, 2002, METHODS, V27, P179, DOI 10.1016/S1046-2023(02)00072-5
   Joshi PA, 2006, DEV BIOL, V297, P284, DOI 10.1016/j.ydbio.2006.05.032
   Kayserili H, 2009, HUM MOL GENET, V18, P4357, DOI 10.1093/hmg/ddp391
   Kimelman D, 2006, ONCOGENE, V25, P7482, DOI 10.1038/sj.onc.1210055
   Kuijper S, 2005, DEV BIOL, V285, P533, DOI 10.1016/j.ydbio.2005.06.017
   Laezza C, 2012, EUR J CANCER, V48, P3112, DOI 10.1016/j.ejca.2012.02.062
   Li QJ, 2004, GENOMICS, V83, P231, DOI 10.1016/j.ygeno.2003.08.004
   Li YH, 2016, CANCER RES, V76, P3364, DOI 10.1158/0008-5472.CAN-15-2302
   Liu CM, 2002, CELL, V108, P837, DOI 10.1016/S0092-8674(02)00685-2
   Liu WB, 2014, INT J CANCER, V134, P1311, DOI 10.1002/ijc.28472
   Lupberger J, 2002, MOL CELL PROBE, V16, P25, DOI 10.1006/mcpr.2001.0392
   MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016
   Mego M, 2010, NAT REV CLIN ONCOL, V7, P693, DOI 10.1038/nrclinonc.2010.171
   Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787
   Qu SM, 1998, DEVELOPMENT, V125, P2711
   Risch A, 2008, INT J CANCER, V123, P1, DOI 10.1002/ijc.23605
   RiveraPomar R, 1996, NATURE, V379, P746, DOI 10.1038/379746a0
   Roberts DM, 2011, MOL BIOL CELL, V22, P1845, DOI 10.1091/mbc.E10-11-0871
   Rodríguez-Paredes M, 2011, NAT MED, V17, P330, DOI 10.1038/nm.2305
   Rönsch K, 2015, MOL ONCOL, V9, P335, DOI 10.1016/j.molonc.2014.08.016
   Shi Y, 2017, ONCOL RES, V25, P11, DOI 10.3727/096504016X14685034103833
   Shivakumar M, 2017, BMC MED GENOMICS, V10, DOI 10.1186/s12920-017-0269-y
   Siegel R, 2014, CA-CANCER J CLIN, V64, P9, DOI 10.3322/caac.21208
   Stamos J.L., 2013, COLD SPRING HARB PER, V5, DOI DOI 10.1101/CSHPERSPECT.A007898
   Takahashi-Yanaga F, 2010, CLIN CANCER RES, V16, P3153, DOI 10.1158/1078-0432.CCR-09-2943
   Valente M, 2004, AM J NEURORADIOL, V25, P1836
   Voronkov A, 2013, CURR PHARM DESIGN, V19, P634, DOI 10.2174/138161213804581837
   Wang Y, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046-017-0606-1
   Wu G, 2003, MOL CELL, V11, P1445, DOI 10.1016/S1097-2765(03)00234-X
   Wuyts W, 2000, J MED GENET, V37, P916, DOI 10.1136/jmg.37.12.916
   Xu JH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117097
   Yang J, 2010, J UROLOGY, V184, P336, DOI 10.1016/j.juro.2010.03.044
   Yang JT, 2017, J CANCER, V8, P2561, DOI 10.7150/jca.19972
   Yang YQ, 2017, AAPS J, V19, P421, DOI 10.1208/s12248-016-0016-x
   Yost C, 1996, GENE DEV, V10, P1443, DOI 10.1101/gad.10.12.1443
   Yuan H, 2015, ONCOTARGET, V6, P13359, DOI 10.18632/oncotarget.3673
   Yuan S, 2016, ONCOGENE, V35, P6120, DOI 10.1038/onc.2016.149
   Zhang JH, 2017, J CANCER, V8, P1598, DOI 10.7150/jca.18744
   Zhang ZM, 2016, ONCOGENE, V35, P4787, DOI 10.1038/onc.2016.10
   Zhang ZC, 2013, J BIOL CHEM, V288, P2485, DOI 10.1074/jbc.M112.402933
   Zhu HB, 2013, HEPATOLOGY, V58, P2012, DOI 10.1002/hep.26587
NR 53
TC 25
Z9 27
U1 3
U2 16
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1756-9966
J9 J EXP CLIN CANC RES
JI J. Exp. Clin. Cancer Res.
PD NOV 28
PY 2017
VL 36
AR 170
DI 10.1186/s13046-017-0643-9
PG 15
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA FO4DM
UT WOS:000416790800004
PM 29183346
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Li, J
   Li, HY
   Makunin, I
   Thompson, BA
   Tao, K
   Young, EL
   Lopez, J
   Camp, NJ
   Tavtigian, SV
   John, EM
   Andrulis, IL
   Khanna, KK
   Goldgar, D
   Chenevix-Trench, G
AF Li, Jun
   Li, Hongyan
   Makunin, Igor
   Thompson, Bryony A.
   Tao, Kayoko
   Young, Erin L.
   Lopez, Jacqueline
   Camp, Nicola J.
   Tavtigian, Sean V.
   John, Esther M.
   Andrulis, Irene L.
   Khanna, Kum Kum
   Goldgar, David
   Chenevix-Trench, Georgia
CA KConFab Investigators
TI Panel sequencing of 264 candidate susceptibility genes and segregation
   analysis in a cohort of non-<i>BRCA1</i>, non-<i>BRCA2</i> breast cancer
   families
SO BREAST CANCER RESEARCH AND TREATMENT
LA English
DT Article
DE Breast cancer; Mutation; Segregation; Susceptibility gene; Chromatin
   modification genes
ID COMPREHENSIVE MOLECULAR PORTRAITS; SOMATIC MUTATIONS; CELL-LINES;
   INACTIVATING MUTATIONS; PROGESTERONE-RECEPTOR; COLORECTAL CANCERS;
   CHROMATIN; VARIANTS; GENOME; TUMORS
AB The main aim of this study was to screen epigenetic modifier genes and known breast cancer driver genes for germline mutations in non-BRCA1/2 (BRCAx) breast cancer families in order to identify novel susceptibility genes of moderate-high penetrance.
   We screened 264 candidate susceptibility genes in 656 index cases from non-BRCA1/2 families. Potentially pathogenic candidate mutations were then genotyped in all available family members for the assessment of co-segregation of the variant with disease in the family in order to estimate the breast cancer risks associated with these mutations. For 11 of the candidate susceptibility genes, we screened an additional 800 non-BRCA1/2 breast cancer cases and 787 controls.
   Only two genes, CHD8 and USH2A showed any evidence of an increased risk of breast cancer (RR = 2.40 (95% CI 1.0-7.32) and 2.48 (95% CI 1.11-6.67), respectively).
   We found no convincing evidence that epigenetic modifier and known breast cancer driver genes carry germline mutations that increase breast cancer risk. USH2A is no longer regarded as a breast cancer driver gene and seems an implausible candidate given its association with Usher syndrome. However, somatic mutations in CHD8 have been recently reported, making it an even more promising candidate, but further analysis of CHD8 in very large cohorts of families or case-control studies would be required to determine if it is a moderate-risk breast cancer susceptibility gene.
C1 [Li, Jun; Makunin, Igor; Khanna, Kum Kum; Chenevix-Trench, Georgia] QIMR Berghofer, Brisbane, Qld 4006, Australia.
   [Li, Hongyan; Thompson, Bryony A.; Tao, Kayoko; Young, Erin L.; Lopez, Jacqueline; Camp, Nicola J.; Tavtigian, Sean V.; Goldgar, David] Univ Utah, Sch Med, Huntsman Canc Inst, Salt Lake City, UT 84132 USA.
   [Makunin, Igor] Univ Queensland, Ctr Res Comp, St Lucia, Qld 4072, Australia.
   Peter MacCallum Canc Ctr, Res Dept, KConFab, Melbourne, Vic, Australia.
   [KConFab Investigators] Univ Melbourne, Sir Peter MacCallum Dept Oncol, Parkville, Vic, Australia.
   [Thompson, Bryony A.] Univ Melbourne, Sch Populat & Global Hlth, Ctr Epidemiol & Biostat, Melbourne, Vic 3000, Australia.
   [John, Esther M.] Canc Prevent Inst Calif, Dept Epidemiol, Fremont, CA 94538 USA.
   [John, Esther M.] Stanford Univ, Sch Med, Dept Hlth Res & Policy Epidemiol, Stanford, CA 94305 USA.
   [John, Esther M.] Stanford Univ, Sch Med, Stanford Canc Inst, Stanford, CA 94305 USA.
   [Andrulis, Irene L.] Sinai Hlth Syst, Lunenfeld Tanenbaum Res Inst, Toronto, ON M5G IX5, Canada.
   [Andrulis, Irene L.] Univ Toronto, Dept Mol Genet, Toronto, ON M5G 1X5, Canada.
   [Goldgar, David] Univ Utah, Sch Med, Dept Dermatol, Salt Lake City, UT 84132 USA.
C3 QIMR Berghofer Medical Research Institute; Utah System of Higher
   Education; University of Utah; Huntsman Cancer Institute; University of
   Queensland; Peter Maccallum Cancer Center; Peter Maccallum Cancer
   Center; University of Melbourne; University of Melbourne; Cancer
   Prevention Institute of California; Stanford University; Stanford Cancer
   Institute; Stanford University; University of Toronto; Sinai Health
   System Toronto; Lunenfeld Tanenbaum Research Institute; University of
   Toronto; Utah System of Higher Education; University of Utah
RP Chenevix-Trench, G (通讯作者)，QIMR Berghofer, Brisbane, Qld 4006, Australia.
EM georgiaT@qimr.edu.au
RI Chenevix-Trench, Georgia/AAV-2014-2020; Thompson, Bryony/D-2799-2018;
   Andrulis, Irene/E-7267-2013; Khanna, Kum/I-1747-2013
OI John, Esther/0000-0003-3259-8003; Khanna, Kum Kum/0000-0001-8650-5381;
   Chenevix-Trench, Georgia/0000-0002-1878-2587; Young,
   Erin/0000-0002-7535-006X; Thompson, Bryony/0000-0001-8655-1839
FU NHMRC; National Breast Cancer Foundation; Cancer Australia; National
   Institute of Health (USA); National Health and Medical Research Council
   (NHMRC); Queensland Cancer Fund; Cancer Council of New South Wales;
   Cancer Council of Victoria; Cancer Council of Tasmania; Cancer Council
   of South Australia; Cancer Foundation of Western Australia; Susan G.
   Komen Foundation; NIH [R01 CA155767, R01 CA163353]; USA National Cancer
   Institute [UM1 CA164920]
FX We wish to thank Jonathan Ellis for help with variant calling and
   Heather Thorne, Eveline Niedermayr, all the kConFab research nurses and
   staff, the heads and staff of the Family Cancer Clinics, and the
   Clinical Follow-Up Study (which has received funding from the NHMRC, the
   National Breast Cancer Foundation, Cancer Australia, and the National
   Institute of Health (USA)) for their contributions to this resource, and
   the many families who contribute to kConFab. kConFab is supported by a
   Grant from the National Breast Cancer Foundation, and previously by the
   National Health and Medical Research Council (NHMRC), the Queensland
   Cancer Fund, the Cancer Councils of New South Wales, Victoria, Tasmania
   and South Australia, and the Cancer Foundation of Western Australia.
   This project was funded by the Susan G. Komen Foundation, the NHMRC and
   NIH Grant R01 CA155767 to DEG & SVT and R01 CA163353 to NJC. The Breast
   Cancer Family Registry (BCFR) was supported by Grant UM1 CA164920 from
   the USA National Cancer Institute. The content of this manuscript does
   not necessarily reflect the views or policies of the National Cancer
   Institute or any of the collaborating centres in the BCFR, nor does
   mention of trade names, commercial products, or organizations imply
   endorsement by the USA Government or the BCFR.
CR Adzhubei IA, 2010, NAT METHODS, V7, P248, DOI 10.1038/nmeth0410-248
   Antoniou AC, 2008, BRIT J CANCER, V98, P1457, DOI 10.1038/sj.bjc.6604305
   Ashe A, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-12-r182
   Bachman KE, 2001, J BIOL CHEM, V276, P32282, DOI 10.1074/jbc.M104661200
   Balakrishnan A, 2007, CANCER RES, V67, P3545, DOI 10.1158/0008-5472.CAN-07-0065
   Blewitt ME, 2008, NAT GENET, V40, P663, DOI 10.1038/ng.142
   Bochar DA, 2000, CELL, V102, P257, DOI 10.1016/S0092-8674(00)00030-1
   Bryan EJ, 2002, INT J CANCER, V102, P137, DOI 10.1002/ijc.10682
   Carter JM, 2012, AM J SURG PATHOL, V36, P154, DOI 10.1097/PAS.0b013e3182380802
   Cazzola M, 2013, BLOOD, V122, P4021, DOI 10.1182/blood-2013-09-381665
   Chen XW, 2006, CANCER RES, V66, P5039, DOI 10.1158/0008-5472.CAN-05-4194
   Chong SY, 2007, NAT GENET, V39, P614, DOI 10.1038/ng2031
   Ciriello G, 2015, CELL, V163, P506, DOI 10.1016/j.cell.2015.09.033
   Cybulski C, 2015, NAT GENET, V47, P643, DOI 10.1038/ng.3284
   Daxinger L, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-9-r96
   Daxinger L, 2012, G3-GENES GENOM GENET, V2, P1393, DOI 10.1534/g3.112.004036
   Desmedt C, 2015, J PATHOL, V236, P457, DOI 10.1002/path.4540
   Easton DF, 2015, NEW ENGL J MED, V372, P2243, DOI 10.1056/NEJMsr1501341
   Ellis MJ, 2012, NATURE, V486, P353, DOI 10.1038/nature11143
   Ernst T, 2010, NAT GENET, V42, P722, DOI 10.1038/ng.621
   Figueroa ME, 2010, CANCER CELL, V18, P553, DOI 10.1016/j.ccr.2010.11.015
   Flanagan JM, 2010, AM J HUM GENET, V86, P420, DOI 10.1016/j.ajhg.2010.02.008
   Ford D, 1998, AM J HUM GENET, V62, P676, DOI 10.1086/301749
   Glodzik D, 2017, NAT GENET, V49, P341, DOI 10.1038/ng.3771
   Harten SK, 2014, MAMM GENOME, V25, P293, DOI 10.1007/s00335-014-9516-0
   Hitchins MP, 2007, NEW ENGL J MED, V356, P697, DOI 10.1056/NEJMoa064522
   Ishihara K, 2006, MOL CELL, V23, P733, DOI 10.1016/j.molcel.2006.08.008
   Ito S, 2010, NATURE, V466, P1129, DOI 10.1038/nature09303
   Jhanwar Suresh C., 2015, Advances in Biological Regulation, V58, P28, DOI 10.1016/j.jbior.2014.11.002
   Jiao YC, 2011, SCIENCE, V331, P1199, DOI 10.1126/science.1200609
   John EM, 2004, BREAST CANCER RES, V6, pR375, DOI 10.1186/bcr801
   Johnatty SE, 2008, BREAST CANCER RES TR, V109, P91, DOI 10.1007/s10549-007-9627-3
   Jones S, 2010, SCIENCE, V330, P228, DOI 10.1126/science.1196333
   Kanchi KL, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4156
   Karhemo PR, 2011, AM J PATHOL, V179, P1004, DOI 10.1016/j.ajpath.2011.04.009
   Kim MS, 2011, HISTOPATHOLOGY, V58, P660, DOI 10.1111/j.1365-2559.2011.03819.x
   Kim Nayoung, 2013, Genomics & Informatics, V11, P239, DOI 10.5808/GI.2013.11.4.239
   Kircher M, 2014, NAT GENET, V46, P310, DOI 10.1038/ng.2892
   Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412
   Koschmann C, 2017, CANCER RES, V77, P227, DOI 10.1158/0008-5472.CAN-16-2301
   Kumar P, 2009, NAT PROTOC, V4, P1073, DOI 10.1038/nprot.2009.86
   Lalloo F, 2012, CLIN GENET, V82, P105, DOI 10.1111/j.1399-0004.2012.01859.x
   LATHROP GM, 1985, AM J HUM GENET, V37, P482
   Lee RS, 2013, BRAIN PATHOL, V23, P200, DOI 10.1111/bpa.12021
   Légaré S, 2015, CANCER RES, V75, P4351, DOI 10.1158/0008-5472.CAN-14-3475
   Ley TJ, 2010, NEW ENGL J MED, V363, P2424, DOI 10.1056/NEJMoa1005143
   Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324
   Li SS, 2016, P NATL ACAD SCI USA, V113, pE5108, DOI 10.1073/pnas.1609709113
   Liao LL, 2015, CANCER GENET-NY, V208, P206, DOI 10.1016/j.cancergen.2015.02.008
   MacArthur DG, 2012, SCIENCE, V335, P823, DOI 10.1126/science.1215040
   Mäkinen N, 2016, PLOS GENET, V12, DOI 10.1371/journal.pgen.1005850
   Mann GJ, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1377
   McKenna A, 2010, GENOME RES, V20, P1297, DOI 10.1101/gr.107524.110
   Mobasheri MB, 2015, TUMOR BIOL, V36, P8201, DOI 10.1007/s13277-015-3546-4
   Morin RD, 2010, NAT GENET, V42, P181, DOI 10.1038/ng.518
   Mullighan CG, 2011, NATURE, V471, P235, DOI 10.1038/nature09727
   Ng SB, 2010, NAT GENET, V42, P790, DOI 10.1038/ng.646
   Nik-Zainal S, 2016, NATURE, V534, P47, DOI 10.1038/nature17676
   Nikoloski G, 2010, NAT GENET, V42, P665, DOI 10.1038/ng.620
   Nishikawa H, 2009, CANCER RES, V69, P111, DOI 10.1158/0008-5472.CAN-08-3355
   Özdag H, 2002, BRIT J CANCER, V87, P1162, DOI 10.1038/sj.bjc.6600554
   Parsons DW, 2011, SCIENCE, V331, P435, DOI 10.1126/science.1198056
   Peng C, 2006, J CELL BIOCHEM, V97, P882, DOI 10.1002/jcb.20645
   Pereira B, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11479
   Pongor L, 2015, GENOME MED, V7, DOI 10.1186/s13073-015-0228-1
   Ratnakumar K, 2013, EPIGENETICS-US, V8, P3, DOI 10.4161/epi.23271
   Ring HZ, 1998, GENOMICS, V51, P140, DOI 10.1006/geno.1998.5343
   Roberts AR, 2011, CHROMOSOMA, V120, P377, DOI 10.1007/s00412-011-0318-9
   Robinson DR, 2013, NAT GENET, V45, P1446, DOI 10.1038/ng.2823
   Rodriguez-Nieto S, 2011, HUM MUTAT, V32, pE1999, DOI 10.1002/humu.21415
   San Lucas FA, 2012, BIOINFORMATICS, V28, P421, DOI 10.1093/bioinformatics/btr667
   Schwartzentruber J, 2012, NATURE, V482, P226, DOI [10.1038/nature10833, 10.1007/s13311-012-0137-6]
   Schwarz JM, 2010, NAT METHODS, V7, P575, DOI 10.1038/nmeth0810-575
   Shah SP, 2012, NATURE, V486, P395, DOI 10.1038/nature10933
   Shukla V, 2010, CELL RES, V20, P1201, DOI 10.1038/cr.2010.128
   Stephens PJ, 2012, NATURE, V486, P400, DOI 10.1038/nature11017
   Subtil-Rodríguez A, 2014, NUCLEIC ACIDS RES, V42, P2185, DOI 10.1093/nar/gkt1161
   Sun J, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005228
   Tahiliani M, 2009, SCIENCE, V324, P930, DOI 10.1126/science.1170116
   Varela I, 2011, NATURE, V469, P539, DOI 10.1038/nature09639
   Wagner BL, 1998, MOL CELL BIOL, V18, P1369, DOI 10.1128/MCB.18.3.1369
   Wang K, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkq603
   Wen HX, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-470
   Whitelaw NC, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-11-r111
   Wood LD, 2007, SCIENCE, V318, P1108, DOI 10.1126/science.1145720
   Wu Q, 2015, J CELL PHYSIOL, V230, P2683, DOI 10.1002/jcp.24991
   Yan XJ, 2011, NAT GENET, V43, P309, DOI 10.1038/ng.788
   Yan ZJ, 2005, GENE DEV, V19, P1662, DOI 10.1101/gad.1323805
   Yeo G, 2004, J COMPUT BIOL, V11, P377, DOI 10.1089/1066527041410418
   Zekri A, 2012, ONCOL RES, V20, P241, DOI 10.3727/096504013X13589503482978
NR 90
TC 6
Z9 6
U1 0
U2 8
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0167-6806
EI 1573-7217
J9 BREAST CANCER RES TR
JI Breast Cancer Res. Treat.
PD DEC
PY 2017
VL 166
IS 3
BP 937
EP 949
DI 10.1007/s10549-017-4469-0
PG 13
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA FM6AN
UT WOS:000415126700029
PM 28840378
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Dinami, R
   Buemi, V
   Sestito, R
   Zappone, A
   Ciani, Y
   Mano, M
   Petti, E
   Sacconi, A
   Blandino, G
   Giacca, M
   Piazza, S
   Benetti, R
   Schoeftner, S
AF Dinami, Roberto
   Buemi, Valentina
   Sestito, Rosanna
   Zappone, Antonina
   Ciani, Yari
   Mano, Miguel
   Petti, Eleonora
   Sacconi, Andrea
   Blandino, Giovanni
   Giacca, Mauro
   Piazza, Silvano
   Benetti, Roberta
   Schoeftner, Stefan
TI Epigenetic silencing of miR-296 and miR-512 ensures hTERT dependent
   apoptosis protection and telomere maintenance in basal-type breast
   cancer cells
SO ONCOTARGET
LA English
DT Article
DE miR-296-5p; miR-512-5p; telomerase; telomeres; breast cancer
ID HISTONE DEACETYLASE INHIBITOR; MESSENGER-RNA EXPRESSION;
   REVERSE-TRANSCRIPTASE; DOWN-REGULATION; CLINICOPATHOLOGICAL PARAMETERS;
   DNA METHYLATION; PROSTATE-CANCER; GENE-EXPRESSION; TUMOR-GROWTH;
   CHROMATIN
AB The catalytic subunit of the telomerase complex, hTERT, ensures unlimited proliferative potential of cancer cells by maintaining telomere function and protecting from apoptosis. Using a miRNA screening approach we identified miR-296-5p and miR-512-5p as miRNAs that target hTERT in breast cancer cells. Ectopic miR-296-5p and miR-512-5p reduce telomerase activity, drive telomere shortening and cause proliferation defects by enhancing senescence and apoptosis in breast cancer cells. In line with the relevance of hTERT expression for human cancer we found that miR296-5p and miR-512-5p expression is reduced in human breast cancer. Accordingly, high expression of miR-296-5p and miR-512-5p target genes including hTERT is linked with significantly reduced distant metastasis free survival and relapse free survival of basal type breast cancer patients. This suggests relevance of the identified miRNAs in basal type breast cancer. Epigenetic silencing of miR-296 and miR-512 encoding genes is responsible for low levels of miR-296-5p and miR-512-5p expression in basal type breast cancer cells. Disrupting gene silencing results in a dramatic upregulation of miR-296-5p and miR-512-5p levels leading to reduced hTERT expression and increased sensitivity to the induction of apoptosis. Altogether, our data suggest that epigenetic regulatory circuits in basal type breast cancer may contribute to high hTERT levels by silencing miR-296-5p and miR-512-5p expression, thereby contributing to the aggressiveness of basal type breast cancer.
C1 [Dinami, Roberto; Buemi, Valentina; Zappone, Antonina; Petti, Eleonora; Schoeftner, Stefan] Lab Nazl Consorzio Interuniv Biotecnol LNCIB, Genom Stabil Unit, I-34149 Trieste, Italy.
   [Dinami, Roberto; Sestito, Rosanna; Petti, Eleonora; Schoeftner, Stefan] Italian Natl Canc Inst, I-00144 Rome, Italy.
   [Buemi, Valentina; Zappone, Antonina; Petti, Eleonora; Schoeftner, Stefan] Univ Trieste, Dept Life Sci, I-34127 Trieste, Italy.
   [Ciani, Yari; Piazza, Silvano] Lab Nazl Consorzio Interuniv Biotecnol LNCIB, Bioinformat & Funct Genom Unit BFGU, I-34149 Trieste, Italy.
   [Mano, Miguel; Giacca, Mauro] Int Ctr Genet Engn & Biotechnol ICGEB, Mol Med Lab, I-34149 Trieste, Italy.
   [Sacconi, Andrea; Blandino, Giovanni] Italian Natl Canc Inst, Translat Oncogen Grp, I-00144 Rome, Italy.
   [Benetti, Roberta] Lab Nazl Consorzio Interuniv Biotecnol LNCIB, Canc Epigenet Unit, I-34149 Trieste, Italy.
   [Benetti, Roberta] Univ Udine, Dept Med & Biol Sci, I-33100 Udine, Italy.
   [Sestito, Rosanna] Italian Natl Canc Inst, Preclin Models & New Therapeut Agents Unit, Via Elio Chianesi 53, I-00144 Rome, Italy.
C3 University of Trieste; International Center for Genetic Engineering &
   Biotechnology (ICGEB); University of Udine
RP Schoeftner, S (通讯作者)，Lab Nazl Consorzio Interuniv Biotecnol LNCIB, Genom Stabil Unit, I-34149 Trieste, Italy.; Schoeftner, S (通讯作者)，Italian Natl Canc Inst, I-00144 Rome, Italy.; Schoeftner, S (通讯作者)，Univ Trieste, Dept Life Sci, I-34127 Trieste, Italy.; Benetti, R (通讯作者)，Lab Nazl Consorzio Interuniv Biotecnol LNCIB, Canc Epigenet Unit, I-34149 Trieste, Italy.; Benetti, R (通讯作者)，Univ Udine, Dept Med & Biol Sci, I-33100 Udine, Italy.
EM roberta.benetti@uniud.it; stefan.schoeftner@lncib.it
RI Sestito, Rosanna/K-2361-2018; Piazza, Silvano/LOS-0977-2024; Petti,
   Eleonora/AAY-6220-2021; Dinami, Roberto/AAY-6200-2021; Blandino,
   Giovanni/LLM-1397-2024; GIACCA, MAURO/J-9287-2016; Mano,
   Miguel/A-4462-2013; sacconi, andrea/J-3669-2018
OI Petti, Eleonora/0000-0001-8189-1906; Piazza,
   Silvano/0000-0002-7156-5434; GIACCA, MAURO/0000-0003-2927-7225; Mano,
   Miguel/0000-0003-1922-4824; Sestito, Rosanna/0000-0001-5460-2777;
   Dinami, Roberto/0000-0002-3585-3439; Ciani, Yari/0000-0002-9635-2830;
   sacconi, andrea/0000-0002-8276-0438
FU Italian Association for Cancer Research (AIRC) Start up grant [10299];
   University of Trieste; Fondazione Veronesi Grant; AIRC grant [Rif 42/08,
   6352, 17756]; AIRC fellowship; Fondazione Veronesi fellowship
FX This work was supported by the Italian Association for Cancer Research
   (AIRC) Start up grant 10299 to S.S; the FRA2015 research grant from the
   University of Trieste to S.S; a Fondazione Veronesi Grant to S. S; an
   AIRC grant Rif 42/08, 6352 and 17756 to R.B. YC is supported by an AIRC
   fellowship; EP is supported by an AIRC fellowship; RS is supported by a
   Fondazione Veronesi fellowship.
CR Ahmed S, 2008, J CELL SCI, V121, P1046, DOI 10.1242/jcs.019372
   Artandi SE, 2010, CARCINOGENESIS, V31, P9, DOI 10.1093/carcin/bgp268
   Atkinson SP, 2005, CANCER RES, V65, P7585, DOI 10.1158/0008-5472.CAN-05-1715
   Burger AM, 2005, CANCER RES, V65, P1489, DOI 10.1158/0008-5472.CAN-04-2910
   Cairney CJ, 2008, BIOCHIMIE, V90, P13, DOI 10.1016/j.biochi.2007.07.025
   Canela Andres, 2007, Methods Mol Biol, V371, P45
   Cazanave SC, 2011, J LIPID RES, V52, P1517, DOI 10.1194/jlr.M014654
   Chakrabarti M, 2013, EXP CELL RES, V319, P1575, DOI 10.1016/j.yexcr.2013.02.025
   Chan SRWL, 2004, PHILOS T R SOC B, V359, P109, DOI 10.1098/rstb.2003.1370
   Chen L, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2013.553
   Choi JH, 2010, BIOCHEM BIOPH RES CO, V391, P449, DOI 10.1016/j.bbrc.2009.11.078
   Chu KL, 2016, INT J ONCOL, V48, P577, DOI 10.3892/ijo.2015.3279
   Clark GM, 1997, J NATL CANCER I, V89, P1874, DOI 10.1093/jnci/89.24.1874
   Coussens M, 2010, P NATL ACAD SCI USA, V107, P13842, DOI 10.1073/pnas.0913834107
   Crowe DL, 2001, NUCLEIC ACIDS RES, V29, P2789, DOI 10.1093/nar/29.13.2789
   Del Bufalo D, 2005, CELL DEATH DIFFER, V12, P1429, DOI 10.1038/sj.cdd.4401670
   Dinami R, 2014, CANCER RES, V74, P4145, DOI 10.1158/0008-5472.CAN-13-2038
   Dvinge H, 2013, NATURE, V497, P378, DOI 10.1038/nature12108
   Elkak A, 2006, ANTICANCER RES, V26, P4901
   Flores I, 2010, FEBS LETT, V584, P3826, DOI 10.1016/j.febslet.2010.07.042
   GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9
   Györffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9
   Haendeler J, 2009, ARTERIOSCL THROM VAS, V29, P929, DOI 10.1161/ATVBAHA.109.185546
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Harel SA, 2015, CELL DEATH DIFFER, V22, P1328, DOI 10.1038/cdd.2014.221
   Hrdlicková R, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086990
   Huber W, 2015, NAT METHODS, V12, P115, DOI [10.1038/NMETH.3252, 10.1038/nmeth.3252]
   Indran IR, 2011, CANCER RES, V71, P266, DOI 10.1158/0008-5472.CAN-10-1588
   Iorio MV, 2012, EMBO MOL MED, V4, P143, DOI 10.1002/emmm.201100209
   Kanaya T, 2000, CLIN CANCER RES, V6, P1239
   Khaw AK, 2007, MUTAT RES-FUND MOL M, V625, P134, DOI 10.1016/j.mrfmmm.2007.06.005
   KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428
   Kretzner L, 2011, CANCER RES, V71, P3912, DOI 10.1158/0008-5472.CAN-10-2259
   Lee KH, 2014, BBA-MOL CELL RES, V1843, P2055, DOI 10.1016/j.bbamcr.2014.06.001
   Li CT, 2011, J CELL BIOCHEM, V112, P3044, DOI 10.1002/jcb.23229
   Li J, 2015, CHEM GEOL, V406, P10, DOI 10.1016/j.chemgeo.2015.04.010
   Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427
   Li YH, 2014, CANCER RES, V74, P1639, DOI 10.1158/0008-5472.CAN-13-3568
   Lopez-Bertoni H, 2016, ONCOGENE, V35, P4903, DOI 10.1038/onc.2016.22
   Lu LG, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2893
   Massard C, 2006, ONCOGENE, V25, P4505, DOI 10.1038/sj.onc.1209487
   Masutomi K, 2005, P NATL ACAD SCI USA, V102, P8222, DOI 10.1073/pnas.0503095102
   Mitomo S, 2008, CANCER SCI, V99, P280, DOI 10.1111/j.1349-7006.2007.00666.x
   Nascimento PDS, 2006, ONCOL REP, V16, P423
   Palm W, 2008, ANNU REV GENET, V42, P301, DOI 10.1146/annurev.genet.41.110306.130350
   Poremba C, 2002, J PATHOL, V198, P181, DOI 10.1002/path.1191
   Renaud S, 2007, NUCLEIC ACIDS RES, V35, P1245, DOI 10.1093/nar/gkl1125
   Ringnér M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017911
   Robson JE, 2012, RNA, V18, P135, DOI 10.1261/rna.029561.111
   Roos G, 1998, INT J CANCER, V79, P343, DOI 10.1002/(SICI)1097-0215(19980821)79:4<343::AID-IJC6>3.0.CO;2-V
   Rubis B, 2013, MOL BIOL REP, V40, P4995, DOI 10.1007/s11033-013-2600-9
   Saito Y, 2009, ONCOGENE, V28, P2738, DOI 10.1038/onc.2009.140
   Salhab M, 2008, BREAST CANCER RES TR, V109, P35, DOI 10.1007/s10549-007-9622-8
   Santambrogio F, 2014, CURR PHARM DESIGN, V20, P6404, DOI 10.2174/1381612820666140630095918
   Savi F, 2014, CLIN SCI, V127, P233, DOI 10.1042/CS20130580
   Shang Y, 2015, CELL BIOCHEM BIOPHYS, V72, P405, DOI 10.1007/s12013-014-0476-5
   Sharma GG, 2003, ONCOGENE, V22, P131, DOI 10.1038/sj.onc.1206063
   Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2
   Singhapol C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0052989
   Suenaga M, 2002, INT J CANCER, V97, P621, DOI 10.1002/ijc.10082
   Vaira V, 2012, ONCOGENE, V31, P27, DOI 10.1038/onc.2011.209
   Voorhoeve PM, 2006, CELL, V124, P1169, DOI 10.1016/j.cell.2006.02.037
   Wang J, 1998, GENE DEV, V12, P1769, DOI 10.1101/gad.12.12.1769
   Wei JJ, 2011, CLIN CANCER RES, V17, P1297, DOI 10.1158/1078-0432.CCR-10-0993
   Wu KJ, 1999, NAT GENET, V21, P220, DOI 10.1038/6010
   Xu C, 2016, ONCOL REP, V35, P497, DOI 10.3892/or.2015.4392
   Zhang D, 2015, CANCER LETT, V360, P151, DOI 10.1016/j.canlet.2015.01.044
   Zhang YW, 2016, NUCLEIC ACIDS RES, V44, P761, DOI 10.1093/nar/gkv1465
   Zhao Q, 2015, ONCOL REP, V34, P979, DOI 10.3892/or.2015.4013
   Zinn RL, 2007, CANCER RES, V67, P194, DOI 10.1158/0008-5472.CAN-06-3396
NR 70
TC 36
Z9 38
U1 0
U2 13
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD NOV 10
PY 2017
VL 8
IS 56
BP 95674
EP 95691
DI 10.18632/oncotarget.21180
PG 18
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA FM3VP
UT WOS:000414937900051
PM 29221158
OA Green Published, gold, Green Submitted
DA 2025-01-12
ER

PT J
AU Mathot, P
   Grandin, M
   Devailly, G
   Souaze, F
   Cahais, V
   Moran, S
   Campone, M
   Herceg, Z
   Esteller, M
   Juin, P
   Mehlen, P
   Dante, R
AF Mathot, P.
   Grandin, M.
   Devailly, G.
   Souaze, F.
   Cahais, V.
   Moran, S.
   Campone, M.
   Herceg, Z.
   Esteller, M.
   Juin, P.
   Mehlen, P.
   Dante, R.
TI DNA methylation signal has a major role in the response of human breast
   cancer cells to the microenvironment
SO ONCOGENESIS
LA English
DT Article
ID EPITHELIAL-MESENCHYMAL TRANSITION; STROMAL CELLS; TGF-BETA; GENETIC
   ALTERATIONS; TUMOR PROGRESSION; CPG METHYLATION; FIBROBLASTS; BINDING;
   MBD2; TRANSCRIPTION
AB Breast cancer-associated fibroblasts (CAFs) have a crucial role in tumor initiation, metastasis and therapeutic resistance by secreting various growth factors, cytokines, protease and extracellular matrix components. Soluble factors secreted by CAFs are involved in many pathways including inflammation, metabolism, proliferation and epigenetic modulation, suggesting that CAF-dependent reprograming of cancer cells affects a large set of genes. This paracrine signaling has an important role in tumor progression, thus deciphering some of these processes could lead to relevant discoveries with subsequent clinical implications. Here, we investigated the mechanisms underlying the changes in gene expression patterns associated with the cross-talk between breast cancer cells and the stroma. From RNAseq data obtained from breast cancer cell lines grown in presence of CAF-secreted factors, we identified 372 upregulated genes, exhibiting an expression level positively correlated with the stromal content of breast cancer specimens. Furthermore, we observed that gene expression changes were not mediated through significant DNA methylation changes. Nevertheless, CAF-secreted factors but also stromal content of the tumors remarkably activated specific genes characterized by a DNA methylation pattern: hypermethylation at transcription start site and shore regions. Experimental approaches (inhibition of DNA methylation, knockdown of methyl-CpG-binding domain protein 2 and chromatin immunoprecipitation assays) indicated that this set of genes was epigenetically controlled. These data elucidate the importance of epigenetics marks in the cancer cell reprogramming induced by stromal cell and indicated that the interpreters of the DNA methylation signal have a major role in the response of the cancer cells to the microenvironment.
C1 [Mathot, P.; Grandin, M.; Mehlen, P.; Dante, R.] Univ Lyon, Ctr Leon Berard, Canc & Dev Lab, CRCL,Inserm,U1052,CNRS,UMR5286, F-69008 Lyon, France.
   [Devailly, G.] Univ Edinburgh, Roslin Inst, Dept Dev Biol, Easter Bush Campus, Edinburgh, Midlothian, Scotland.
   [Souaze, F.; Campone, M.; Juin, P.] Univ Nantes, Cell Survival & Tumor Escape Breast Canc Lab, Ctr Canc Res Nantes Angers, UMR 892,Inserm 6299,CNRS, Nantes, France.
   [Cahais, V.; Herceg, Z.] IARC, Epigenet Grp, Lyon, France.
   [Moran, S.; Esteller, M.] Bellvitge Biomed Res Inst IDIBELL, Canc Epigenet & Biol Program PEBC, Barcelona, Spain.
   [Esteller, M.] Univ Barcelona, Sch Med & Hlth Sci, Physiol Sci Dept, Barcelona, Spain.
   [Esteller, M.] ICREA, Barcelona, Spain.
C3 UNICANCER; Centre Leon Berard; Centre de Recherche en cancerologie
   (CRCL); Centre National de la Recherche Scientifique (CNRS); CNRS -
   National Institute for Biology (INSB); Universite Claude Bernard Lyon 1;
   Institut National de la Sante et de la Recherche Medicale (Inserm); UK
   Research & Innovation (UKRI); Biotechnology and Biological Sciences
   Research Council (BBSRC); Roslin Institute; University of Edinburgh;
   Nantes Universite; Centre National de la Recherche Scientifique (CNRS);
   Institut National de la Sante et de la Recherche Medicale (Inserm);
   World Health Organization; International Agency for Research on Cancer
   (IARC); Institut d'Investigacio Biomedica de Bellvitge (IDIBELL);
   University of Barcelona; ICREA
RP Dante, R (通讯作者)，Univ Lyon, Ctr Leon Berard, Canc & Dev Lab, CRCL,Inserm,U1052,CNRS,UMR5286, F-69008 Lyon, France.
EM robert.dante@lyon.unicancer.fr
RI Souazé, Frédérique/K-7937-2015; Moran, Sebastian/G-5293-2013; Devailly,
   Guillaume/S-3998-2019; campone, mario/L-4880-2015; Herceg,
   Zdenko/JOZ-6188-2023; JUIN, Philippe/Q-1338-2019; Esteller,
   Manel/L-5956-2014
OI Frederique, Souaze/0000-0003-0476-2603; Grandin,
   Melodie/0000-0001-6784-9496; Esteller, Manel/0000-0003-4490-6093; Juin,
   Philippe/0000-0002-4997-3888; Devailly, Guillaume/0000-0001-8878-9357;
   Herceg, Zdenko/0000-0003-4109-3154
FU Fondation ARC pour la Recherche sur le Cancer; Ligue Nationale contre le
   Cancer; LabExDEVwe-CAN; Ligue Contre le Cancer [EL2015.LNCC]; Institut
   National Du Cancer [2011-143, 2016-166]; European Research Council
   [294079]; Centre National de la Recherche Scientifique, Institut
   National de la Sante et de la Recherche Medicale, University of Lyon;
   Centre Leon Berard; European Research Council (ERC) [294079] Funding
   Source: European Research Council (ERC)
FX We thank Dr Frederique Souaze for primary culture of breast CAF and
   helpful discussions. We are grateful to Dr B Manship for editing of this
   manuscript and helpful discussions. PM and GD are recipients of the
   fellowship from the Ligue Nationale contre le Cancer. MG is a recipient
   of the fellowship from the Fondation ARC pour la Recherche sur le Cancer
   and LabExDEVwe-CAN. We acknowledge Integragen for library preparations
   and highthrouput sequencing experiments The present work was supported
   by Ligue Contre le Cancer (EL2015.LNCC), Institut National Du Cancer
   (2011-143 and 2016-166), European Research Council (294079), Centre
   National de la Recherche Scientifique, Institut National de la Sante et
   de la Recherche Medicale, University of Lyon, and Centre Leon Berard.
CR Angrisano T, 2006, NUCLEIC ACIDS RES, V34, P364, DOI 10.1093/nar/gkj400
   Ao MF, 2007, CANCER RES, V67, P4244, DOI 10.1158/0008-5472.CAN-06-3946
   Auriol E, 2005, NUCLEIC ACIDS RES, V33, P4243, DOI 10.1093/nar/gki729
   Barone I, 2012, CANCER RES, V72, P1416, DOI 10.1158/0008-5472.CAN-11-2558
   BASSET P, 1990, NATURE, V348, P699, DOI 10.1038/348699a0
   Baubec T, 2014, CURR OPIN GENET DEV, V25, P85, DOI 10.1016/j.gde.2013.11.015
   Baubec T, 2013, CELL, V153, P480, DOI 10.1016/j.cell.2013.03.011
   Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102
   Bissell MJ, 2011, NAT MED, V17, P320, DOI 10.1038/nm.2328
   Buchsbaum RJ, 2016, CANCERS, V8, DOI 10.3390/cancers8020019
   Bussard KM, 2016, BREAST CANCER RES, V18, DOI 10.1186/s13058-016-0740-2
   Campanero MR, 2000, P NATL ACAD SCI USA, V97, P6481, DOI 10.1073/pnas.100340697
   Casbas-Hernandez P, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/520987
   CHIQUETEHRISMANN R, 1986, CELL, V47, P131, DOI 10.1016/0092-8674(86)90374-0
   Cook PC, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7920
   Dangi-Garimella S, 2009, EMBO J, V28, P347, DOI 10.1038/emboj.2008.294
   Defossez PA, 2011, PROG MOL BIOL TRANSL, V101, P377, DOI 10.1016/B978-0-12-387685-0.00012-3
   Devailly G, 2015, NUCLEIC ACIDS RES, V43, P5838, DOI 10.1093/nar/gkv508
   Du H, 2017, ONCOL LETT, V13, P3, DOI 10.3892/ol.2016.5451
   DVORAK HF, 1986, NEW ENGL J MED, V315, P1650
   Ehrlich M, 2013, EPIGENOMICS-UK, V5, P553, DOI 10.2217/epi.13.43
   Gascard P, 2016, GENE DEV, V30, P1002, DOI 10.1101/gad.279737.116
   Grandin M, 2016, EMBO MOL MED, V8, P863, DOI 10.15252/emmm.201505945
   Grandin M, 2016, CANCER CELL, V29, P173, DOI 10.1016/j.ccell.2016.01.001
   Hanahan D, 2012, CANCER CELL, V21, P309, DOI 10.1016/j.ccr.2012.02.022
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Hendrich B, 1998, MOL CELL BIOL, V18, P6538, DOI 10.1128/MCB.18.11.6538
   Hu M, 2005, NAT GENET, V37, P899, DOI 10.1038/ng1596
   IGUCHIARIGA SMM, 1989, GENE DEV, V3, P612, DOI 10.1101/gad.3.5.612
   JOVE R, 1984, NUCLEIC ACIDS RES, V12, P4715, DOI 10.1093/nar/12.11.4715
   Junttila MR, 2013, NATURE, V501, P346, DOI 10.1038/nature12626
   Kalluri R, 2006, NAT REV CANCER, V6, P392, DOI 10.1038/nrc1877
   Kim D, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-4-r36
   Kim J, 2003, HUM MOL GENET, V12, P233, DOI 10.1093/hmg/ddg028
   Klemm F, 2015, TRENDS CELL BIOL, V25, P198, DOI 10.1016/j.tcb.2014.11.006
   Klose RJ, 2005, MOL CELL, V19, P667, DOI 10.1016/j.molcel.2005.07.021
   Kojima Y, 2010, P NATL ACAD SCI USA, V107, P20009, DOI 10.1073/pnas.1013805107
   Lamouille S, 2007, J CELL BIOL, V178, P437, DOI 10.1083/jcb.200611146
   Lee MR, 2013, STEM CELLS, V31, P666, DOI 10.1002/stem.1302
   Liu M, 2017, J PATHOL, V241, P10, DOI 10.1002/path.4832
   Luo HJ, 2015, CANCER LETT, V361, P155, DOI 10.1016/j.canlet.2015.02.018
   Madar S, 2013, TRENDS MOL MED, V19, P447, DOI 10.1016/j.molmed.2013.05.004
   Magdinier F, 2000, FASEB J, V14, P1585, DOI 10.1096/fj.14.11.1585
   Martin M, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-435
   Marusyk A, 2016, CANCER RES, V76, P6495, DOI 10.1158/0008-5472.CAN-16-1457
   Mian OY, 2011, MOL CANCER RES, V9, P1152, DOI 10.1158/1541-7786.MCR-11-0252
   Moran S, 2016, EPIGENOMICS-UK, V8, P389, DOI 10.2217/epi.15.114
   Morel AP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002888
   Morris TJ, 2014, BIOINFORMATICS, V30, P428, DOI 10.1093/bioinformatics/btt684
   Olumi AF, 1999, CANCER RES, V59, P5002
   Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034
   Orimo A, 2001, CLIN CANCER RES, V7, P3097
   Pidsley R, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-1066-1
   Portela A, 2010, NAT BIOTECHNOL, V28, P1057, DOI 10.1038/nbt.1685
   Qiao AX, 2016, FRONT MED-PRC, V10, P33, DOI 10.1007/s11684-016-0431-5
   Qiu W, 2008, NAT GENET, V40, P650, DOI 10.1038/ng.117
   Quail DF, 2013, NAT MED, V19, P1423, DOI 10.1038/nm.3394
   Rodríguez-Ubreva J, 2012, NUCLEIC ACIDS RES, V40, P1954, DOI 10.1093/nar/gkr1015
   Rokavec M, 2016, CELL MOL LIFE SCI, V73, P23, DOI 10.1007/s00018-015-2045-5
   Sansom OJ, 2003, NAT GENET, V34, P145, DOI 10.1038/ng1155
   SAPPINO AP, 1988, INT J CANCER, V41, P707, DOI 10.1002/ijc.2910410512
   Scarsdale JN, 2011, NUCLEIC ACIDS RES, V39, P6741, DOI 10.1093/nar/gkr262
   Shiga K, 2015, CANCERS, V7, P2443, DOI 10.3390/cancers7040902
   Stirzaker C, 2017, ONCOGENE, V36, P1328, DOI 10.1038/onc.2016.297
   Straussman R, 2012, NATURE, V487, P500, DOI 10.1038/nature11183
   Taddei ML, 2013, CANCER LETT, V341, P80, DOI 10.1016/j.canlet.2013.01.042
   Tiwari N, 2013, CANCER CELL, V23, P768, DOI 10.1016/j.ccr.2013.04.020
   Trapnell C, 2010, NAT BIOTECHNOL, V28, P511, DOI 10.1038/nbt.1621
   Wang J, 2013, NUCLEIC ACIDS RES, V41, pW77, DOI 10.1093/nar/gkt439
   WATT F, 1988, GENE DEV, V2, P1136, DOI 10.1101/gad.2.9.1136
   Wood KH, 2016, FRONT GENET, V7, DOI 10.3389/fgene.2016.00093
   Yee D, 1991, Cancer Treat Res, V53, P93
   Yoshihara K, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3612
   Yu Y, 2014, BRIT J CANCER, V110, P724, DOI 10.1038/bjc.2013.768
   Zhu H, 2016, NAT REV GENET, V17, P551, DOI 10.1038/nrg.2016.83
   Zhu YT, 2014, NAT METHODS, V11, P599, DOI 10.1038/nmeth.2956
NR 76
TC 33
Z9 35
U1 0
U2 10
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 2157-9024
J9 ONCOGENESIS
JI Oncogenesis
PD OCT
PY 2017
VL 6
AR e390
DI 10.1038/oncsis.2017.88
PG 12
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA FM4SG
UT WOS:000415011700006
PM 29058695
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Ruden, DM
   Gurdziel, K
   Aschner, M
AF Ruden, Douglas M.
   Gurdziel, Katherine
   Aschner, Michael
TI Frontiers in Toxicogenomics in the Twenty-First Century-the Grand
   Challenge: To Understand How the Genome and Epigenome Interact with the
   Toxic Environment at the Single-Cell, Whole-Organism, and
   Multi-Generational Level
SO FRONTIERS IN GENETICS
LA English
DT Article
DE toxicogenomics; RNA-Seq; ScRNA-seq; organoids; multigenerational
   epigenetics; transgenerational epigenetics; ATAC-seq
ID CHEMICAL RISK-ASSESSMENT; ON-A-CHIP; DROSOPHILA-MELANOGASTER;
   TRANSGENERATIONAL INHERITANCE; DNA METHYLATION; BREAST-CANCER; EXPOSURE;
   MODEL; EXPRESSION; ORGANOIDS
C1 [Ruden, Douglas M.; Gurdziel, Katherine] Wayne State Univ, Dept Obstet & Gynecol, Detroit, MI 48202 USA.
   [Ruden, Douglas M.; Gurdziel, Katherine] Wayne State Univ, CS Mott Ctr Human Hlth & Dev, Detroit, MI 48202 USA.
   [Ruden, Douglas M.; Gurdziel, Katherine] Wayne State Univ, Inst Environm Hlth Sci, Detroit, MI 48202 USA.
   [Aschner, Michael] Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10467 USA.
C3 Wayne State University; Wayne State University; Wayne State University;
   Montefiore Medical Center; Albert Einstein College of Medicine; Yeshiva
   University
RP Ruden, DM (通讯作者)，Wayne State Univ, Dept Obstet & Gynecol, Detroit, MI 48202 USA.; Ruden, DM (通讯作者)，Wayne State Univ, CS Mott Ctr Human Hlth & Dev, Detroit, MI 48202 USA.; Ruden, DM (通讯作者)，Wayne State Univ, Inst Environm Hlth Sci, Detroit, MI 48202 USA.
EM douglas.ruden@gmail.com
RI Ruden, Douglas/ABE-1418-2021; Aschner, Michael/ACO-6461-2022
OI Ruden, Douglas/0000-0002-0070-437X
FU National Institutes of Health (NIH) [5R01ES012933, 5P30ES020957,
   1UG3OD023285, 5R01ES10563, 5R01ES07331]; NIH Center [P30 CA022453];
   Perinatology Research Branch of the National Institutes of Child Health
   and Development at Wayne State University
FX This work was supported by National Institutes of Health (NIH) [grant
   number 5R01ES012933 (DR), 5P30ES020957 (DR), 1UG3OD023285 (DR),
   5R01ES10563 (MA), and 5R01ES07331 (MA). NIH Center grant P30 CA022453 to
   the Karmanos Cancer Institute at Wayne State University, and the
   Perinatology Research Branch of the National Institutes of Child Health
   and Development at Wayne State University.
CR Anway MD, 2005, SCIENCE, V308, P1466, DOI 10.1126/science.1108190
   Arora M, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15493
   Astashkina AI, 2012, BIOMATERIALS, V33, P4700, DOI 10.1016/j.biomaterials.2012.02.063
   Baert Y, 2017, STEM CELL REP, V8, P30, DOI 10.1016/j.stemcr.2016.11.012
   Beauchamp P, 2015, TISSUE ENG PART C-ME, V21, P852, DOI [10.1089/ten.tec.2014.0376, 10.1089/ten.TEC.2014.0376]
   Brockmeier EK, 2017, TOXICOL SCI, V158, P252, DOI 10.1093/toxsci/kfx097
   Buenostro JD, 2015, NATURE, V523, P486, DOI 10.1038/nature14590
   Buenrostro JD, 2013, NAT METHODS, V10, P1213, DOI [10.1038/NMETH.2688, 10.1038/nmeth.2688]
   Cao WL, 2017, GASTROENTEROLOGY, V153, P1133, DOI 10.1053/j.gastro.2017.07.006
   Caruso JA, 2014, TOXICOL APPL PHARM, V276, P47, DOI 10.1016/j.taap.2014.01.002
   Carvan MJ, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0176155
   Chamorro-Garcia R., 2017, BIORVIX, P1, DOI [10.1101/201384, DOI 10.1101/201384]
   Chamorro-García R, 2013, ENVIRON HEALTH PERSP, V121, P359, DOI 10.1289/ehp.1205701
   Chuah JKC, 2017, BIOTECHNOL ADV, V35, P150, DOI 10.1016/j.biotechadv.2016.12.001
   Cingolani P, 2012, FLY, V6, P80, DOI 10.4161/fly.19695
   Cingolani Pablo, 2012, Frontiers in Genetics, V3, P35, DOI 10.3389/fgene.2012.00035
   Conant G, 2017, STEM CELL REV REP, V13, P335, DOI 10.1007/s12015-017-9736-2
   Crews D, 2014, MOL CELL ENDOCRINOL, V398, P42, DOI 10.1016/j.mce.2014.07.013
   Cropley JE, 2016, MOL METAB, V5, P699, DOI 10.1016/j.molmet.2016.06.008
   Devarasetty M, 2017, BIOSENSORS-BASEL, V7, DOI 10.3390/bios7030024
   Dickens AM, 2017, SCI SIGNAL, V10, DOI 10.1126/scisignal.aai7696
   Dorsett CR, 2017, J NEUROTRAUM, V34, P220, DOI 10.1089/neu.2015.4372
   Edward R, 2012, METHOD ENZYMOL, V505, P23, DOI 10.1016/B978-0-12-388448-0.00010-3
   Flusberg BA, 2010, NAT METHODS, V7, P461, DOI [10.1038/NMETH.1459, 10.1038/nmeth.1459]
   Frétaud M, 2017, SCI REP-UK, V7, DOI 10.1038/srep43012
   Guerrero-Bosagna C, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013100
   Guo DD, 2017, J BIOCHEM MOL TOXIC, V31, DOI 10.1002/jbt.21953
   Hunsberger JG, 2015, STEM CELLS DEV, V24, P1852, DOI 10.1089/scd.2014.0531
   Ingersoll T, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152985
   Janesick AS, 2014, MOL CELL ENDOCRINOL, V398, P31, DOI 10.1016/j.mce.2014.09.002
   Janssen DAW, 2013, J UROLOGY, V190, P341, DOI 10.1016/j.juro.2012.12.103
   Levy E, 2017, FRONT NEUROSCI-SWITZ, V11, DOI 10.3389/fnins.2017.00142
   Lim JH, 2017, TOXICOL IN VITRO, V41, P92, DOI 10.1016/j.tiv.2017.02.020
   Mackay TFC, 2012, NATURE, V482, P173, DOI 10.1038/nature10811
   Macosko EZ, 2015, CELL, V161, P1202, DOI 10.1016/j.cell.2015.05.002
   Meattini I, 2017, MED ONCOL, V34, DOI 10.1007/s12032-017-0938-x
   Modabbernia A, 2016, EUR PSYCHIAT, V36, P1, DOI 10.1016/j.eurpsy.2016.03.006
   Mohammed H, 2017, CELL REP, V20, P1215, DOI 10.1016/j.celrep.2017.07.009
   Mortensen HM, 2013, TOXICOL APPL PHARM, V271, P395, DOI 10.1016/j.taap.2011.01.015
   Müller S, 2017, FRONT GENET, V8, DOI 10.3389/fgene.2017.00073
   Nguyen Tung, 2011, BMC Res Notes, V4, P171, DOI 10.1186/1756-0500-4-171
   Ofengeim D, 2017, TRENDS MOL MED, V23, P563, DOI 10.1016/j.molmed.2017.04.006
   Picelli S, 2017, RNA BIOL, V14, P637, DOI 10.1080/15476286.2016.1201618
   Pique-Regi R, 2011, GENOME RES, V21, P447, DOI 10.1101/gr.112623.110
   Quadrato G, 2017, NATURE, V545, P48, DOI 10.1038/nature22047
   Ruden DM, 2009, NEUROTOXICOLOGY, V30, P898, DOI 10.1016/j.neuro.2009.08.011
   Schwartz MP, 2015, P NATL ACAD SCI USA, V112, P12516, DOI 10.1073/pnas.1516645112
   Selmaj I, 2017, J NEUROIMMUNOL, V306, P1, DOI 10.1016/j.jneuroim.2017.02.002
   Sen A, 2015, SCI REP-UK, V5, DOI 10.1038/srep14466
   Silbergeld EK, 2017, TOXICOL PATHOL, V45, P190, DOI 10.1177/0192623316672073
   Skardal A, 2016, DRUG DISCOV TODAY, V21, P1399, DOI 10.1016/j.drudis.2016.07.003
   Taskesen E, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149853
   Walmsley RM, 2008, EXPERT OPIN DRUG MET, V4, P827, DOI 10.1517/17425255.4.6.827 
   Weber JS, 2016, ONCOLOGIST, V21, P1230, DOI 10.1634/theoncologist.2016-0055
   Wong HH, 2016, EUR J CANCER, V66, P9, DOI 10.1016/j.ejca.2016.07.004
   Xinaris C, 2015, NEPHRON, V130, P191, DOI 10.1159/000433566
   Yang J, 2017, NUCLEIC ACIDS RES, V45, P1281, DOI 10.1093/nar/gkw1214
   Yang X, 2012, CURR DRUG METAB, V13, P952, DOI 10.2174/138920012802138633
   Yu AF, 2017, BREAST CANCER RES TR, V166, P241, DOI 10.1007/s10549-017-4362-x
   Zhou SS, 2017, PLOS GENET, V13, DOI 10.1371/journal.pgen.1006907
   Zhou SS, 2016, ENVIRON HEALTH PERSP, V124, P1062, DOI 10.1289/ehp.1510513
   Zhu XL, 2017, J HAZARD MATER, V324, P272, DOI 10.1016/j.jhazmat.2016.10.057
NR 62
TC 4
Z9 4
U1 0
U2 14
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015,
   SWITZERLAND
SN 1664-8021
J9 FRONT GENET
JI Front. Genet.
PD NOV 9
PY 2017
VL 8
AR 173
DI 10.3389/fgene.2017.00173
PG 7
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA FM1UA
UT WOS:000414765800001
PM 29170679
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU Wu, SR
   Teng, CH
   Tu, YT
   Ko, CJ
   Cheng, TS
   Lan, SW
   Lin, HY
   Lin, HH
   Tu, HF
   Hsiao, PW
   Huang, HP
   Chen, CH
   Lee, MS
AF Wu, Shang-Ru
   Teng, Chen-Hsin
   Tu, Ya-Ting
   Ko, Chun-Jung
   Cheng, Tai-Shan
   Lan, Shao-Wei
   Lin, Hsin-Ying
   Lin, Hsin-Hsien
   Tu, Hsin-Fang
   Hsiao, Pei-Wen
   Huang, Hsiang-Po
   Chen, Chung-Hsin
   Lee, Ming-Shyue
TI The Kunitz Domain I of Hepatocyte Growth Factor Activator Inhibitor-2
   Inhibits Matriptase Activity and Invasive Ability of Human Prostate
   Cancer Cells
SO SCIENTIFIC REPORTS
LA English
DT Article
ID SERINE-PROTEASE INHIBITOR; TISSUE MICROARRAY ANALYSIS; SURFACE-PLASMON
   RESONANCE; TUMOR-SUPPRESSOR ACTIVITY; BREAST-CANCER; EPIGENETIC
   INACTIVATION; FUNCTIONAL-CHARACTERIZATION; HEPATOCELLULAR-CARCINOMA;
   EXTRACELLULAR-MATRIX; PLACENTAL BIKUNIN
AB Dysregulation of pericellular proteolysis is often required for tumor invasion and cancer progression. It has been shown that down-regulation of hepatocyte growth factor activator inhibitor-2 (HAI-2) results in activation of matriptase (a membrane-anchored serine protease), human prostate cancer cell motility and tumor growth. In this study, we further characterized if HAI-2 was a cognate inhibitor for matriptase and identified which Kunitz domain of HAI-2 was required for inhibiting matriptase and human prostate cancer cell motility. Our results show that HAI-2 overexpression suppressed matriptase-induced prostate cancer cell motility. We demonstrate that HAI-2 interacts with matriptase on cell surface and inhibits matriptase proteolytic activity. Moreover, cellular HAI-2 harnesses its Kunitz domain 1 (KD1) to inhibit matriptase activation and prostate cancer cell motility although recombinant KD1 and KD2 of HAI-2 both show an inhibitory activity and interaction with matriptase protease domain. The results together indicate that HAI-2 is a cognate inhibitor of matriptase, and KD1 of HAI-2 plays a major role in the inhibition of cellular matritptase activation as well as human prostate cancer invasion.
C1 [Wu, Shang-Ru; Teng, Chen-Hsin; Tu, Ya-Ting; Ko, Chun-Jung; Cheng, Tai-Shan; Lan, Shao-Wei; Lin, Hsin-Ying; Lin, Hsin-Hsien; Tu, Hsin-Fang; Lee, Ming-Shyue] Natl Taiwan Univ, Dept Biochem & Mol Biol, Coll Med, Taipei, Taiwan.
   [Hsiao, Pei-Wen] Acad Sinica, Agr Biotechnol Res Ctr, Taipei, Taiwan.
   [Huang, Hsiang-Po] Natl Taiwan Univ, Grad Inst Med Genom & Prote, Coll Med, Taipei, Taiwan.
   [Chen, Chung-Hsin] Natl Taiwan Univ Hosp, Dept Urol, Taipei, Taiwan.
C3 National Taiwan University; Academia Sinica - Taiwan; National Taiwan
   University; National Taiwan University; National Taiwan University
   Hospital
RP Lee, MS (通讯作者)，Natl Taiwan Univ, Dept Biochem & Mol Biol, Coll Med, Taipei, Taiwan.
EM mslee2006@ntu.edu.tw
RI Ko, Chun-Jung/AAA-6187-2022; Chen, Yen-Yuan/AAF-4335-2020; Tu,
   Hsin-Fang/HGA-9284-2022; Huang, Hsiang-Po/KCZ-3411-2024; Hsiao,
   Pei-Wen/V-5653-2018
OI LEE, MING-SHYUE/0000-0002-8673-5088; Ko, Chun-Jung/0000-0001-6565-7060;
   CHEN, CHUNG-HSIN/0000-0002-4921-5315; HUANG,
   HSIANG-PO/0000-0002-3382-305X; Hsiao, Pei-Wen/0000-0002-3589-6754
FU Taiwan National Science Council [NSC 100-2628-B-002-004-MY4]; Ministry
   of Science and Technology [MOST 103-2321-B-002-096, MOST
   104-2320-B-002-044-MY3, MOST 105-2911-I-002-521, MOST
   106-2320-B-002-046-MY3]; National Health Research Institutes
   [NHRI-EX102-9909BC, NHRI-EX106-10401BI]; National Taiwan University
   [NTU-CESRP-104R7602C4, NTU105R89612]
FX This study was supported by Taiwan National Science Council Grant NSC
   100-2628-B-002-004-MY4, Ministry of Science and Technology Grants MOST
   103-2321-B-002-096, MOST 104-2320-B-002-044-MY3, MOST 105-2911-I-002-521
   and MOST 106-2320-B-002-046-MY3, National Health Research Institutes
   Grant NHRI-EX102-9909BC and NHRI-EX106-10401BI, and National Taiwan
   University Grant NTU-CESRP-104R7602C4 and NTU105R89612 to M.S. Lee. We
   appreciate the service of the First Core Laboratory of National Taiwan
   University College of Medicine. We thank Dr. Chen-Yong Lin at the
   Georgetown University for his gifts of antibodies and Angela Lin for the
   English editing.
CR ALBINI A, 1987, CANCER RES, V47, P3239
   Benaud C, 2001, EUR J BIOCHEM, V268, P1439, DOI 10.1046/j.1432-1327.2001.02016.x
   Bergum C, 2010, PROSTATE, V70, P1422, DOI 10.1002/pros.21177
   Biasini Marco, 2014, Nucleic Acids Res, V42, pW252, DOI 10.1093/nar/gku340
   Bocheva G, 2009, J INVEST DERMATOL, V129, P1816, DOI 10.1038/jid.2008.449
   Carney TJ, 2007, DEVELOPMENT, V134, P3461, DOI 10.1242/dev.004556
   Chang HHD, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120489
   Chen LM, 2001, PROSTATE, V48, P93, DOI 10.1002/pros.1085
   Chen LM, 2004, PROSTATE, V59, P1, DOI 10.1002/pros.10346
   Cheng MF, 2006, DIS ESOPHAGUS, V19, P482, DOI 10.1111/j.1442-2050.2006.00613.x
   Cheng TS, 2013, CANCER PREV RES, V6, P495, DOI 10.1158/1940-6207.CAPR-12-0293-T
   Chou FP, 2013, AM J PATHOL, V183, P1306, DOI 10.1016/j.ajpath.2013.06.024
   Comeau SR, 2004, BIOINFORMATICS, V20, P45, DOI 10.1093/bioinformatics/btg371
   Comeau SR, 2004, NUCLEIC ACIDS RES, V32, pW96, DOI 10.1093/nar/gkh354
   DeClerck YA, 2004, AM J PATHOL, V164, P1131, DOI 10.1016/S0002-9440(10)63200-2
   Delaria KA, 1997, J BIOL CHEM, V272, P12209, DOI 10.1074/jbc.272.18.12209
   Denda K, 2002, J BIOL CHEM, V277, P14053, DOI 10.1074/jbc.M112263200
   Dong WJ, 2010, INT J CANCER, V127, P1526, DOI 10.1002/ijc.25161
   Faller N, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094267
   Fan B, 2007, DEV BIOL, V303, P222, DOI 10.1016/j.ydbio.2006.11.005
   Fayard B, 2009, CANCER RES, V69, P5690, DOI 10.1158/0008-5472.CAN-08-4573
   Friis S, 2014, J BIOL CHEM, V289, P22319, DOI 10.1074/jbc.M114.574400
   Friis S, 2013, J BIOL CHEM, V288, P19028, DOI 10.1074/jbc.M113.469932
   Fukai K, 2003, CANCER RES, V63, P8674
   Heinz-Erian P, 2009, AM J HUM GENET, V84, P188, DOI 10.1016/j.ajhg.2009.01.004
   Nguyen HH, 2015, SENSORS-BASEL, V15, P10481, DOI 10.3390/s150510481
   Hwang S, 2015, J INVEST DERMATOL, V135, P2283, DOI 10.1038/jid.2015.160
   Itoh H, 1999, BIOCHEM BIOPH RES CO, V255, P740, DOI 10.1006/bbrc.1999.0268
   Jin XL, 2006, CANCER SCI, V97, P1327, DOI 10.1111/j.1349-7006.2006.00328.x
   Kataoka H, 2002, BIOCHEM BIOPH RES CO, V290, P1096, DOI 10.1006/bbrc.2001.6313
   KAWABATA SI, 1988, EUR J BIOCHEM, V172, P17, DOI 10.1111/j.1432-1033.1988.tb13849.x
   Kawaguchi T, 1997, J BIOL CHEM, V272, P27558, DOI 10.1074/jbc.272.44.27558
   Kiyomiya KI, 2006, AM J PHYSIOL-CELL PH, V291, pC40, DOI 10.1152/ajpcell.00351.2005
   Ko C. J., 2017, ONCOGENE
   Ko CJ, 2017, ONCOGENE, V36, P4597, DOI 10.1038/onc.2017.82
   Ko CJ, 2015, CANCER RES, V75, P2949, DOI 10.1158/0008-5472.CAN-14-3297
   Kobayashi H, 2003, J BIOL CHEM, V278, P7790, DOI 10.1074/jbc.M210407200
   Koblinski JE, 2000, CLIN CHIM ACTA, V291, P113, DOI 10.1016/S0009-8981(99)00224-7
   Kojima K, 2008, J BIOL CHEM, V283, P2478, DOI 10.1074/jbc.M709073200
   Kongkham PN, 2008, CANCER RES, V68, P9945, DOI 10.1158/0008-5472.CAN-08-2169
   Kozakov D, 2006, PROTEINS, V65, P392, DOI 10.1002/prot.21117
   Kozakov D, 2017, NAT PROTOC, V12, P255, DOI 10.1038/nprot.2016.169
   Kozakov D, 2013, PROTEINS, V81, P2159, DOI 10.1002/prot.24403
   Lai YJJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132163
   Larsen BR, 2013, EXP CELL RES, V319, P918, DOI 10.1016/j.yexcr.2013.01.008
   Le Gall SM, 2016, BLOOD, V127, P3260, DOI 10.1182/blood-2015-11-683110
   Lee MS, 2007, AM J PHYSIOL-CELL PH, V293, pC95, DOI 10.1152/ajpcell.00611.2006
   Lee MS, 2005, AM J PHYSIOL-CELL PH, V288, pC932, DOI 10.1152/ajpcell.00497.2004
   Lee SL, 2000, J BIOL CHEM, V275, P36720, DOI 10.1074/jbc.M007802200
   Li W, 2009, CANCER RES, V69, P8395, DOI 10.1158/0008-5472.CAN-09-1995
   Lin CY, 1999, J BIOL CHEM, V274, P18237, DOI 10.1074/jbc.274.26.18237
   Lin CY, 1999, J BIOL CHEM, V274, P18231, DOI 10.1074/jbc.274.26.18231
   LIOTTA LA, 1991, CANCER RES, V51, pS5054
   List K, 2002, ONCOGENE, V21, P3765, DOI 10.1038/sj.onc.1205502
   List K, 2006, MOL MED, V12, P1, DOI 10.2119/2006-00022.List
   List K, 2009, FUTURE ONCOL, V5, P97, DOI 10.2217/14796694.5.1.97
   Marlor CW, 1997, J BIOL CHEM, V272, P12202, DOI 10.1074/jbc.272.18.12202
   Miyata S, 2007, HUM CELL, V20, P100, DOI 10.1111/j.1749-0774.2007.00035.x
   Morris MR, 2005, CANCER RES, V65, P4598, DOI 10.1158/0008-5472.CAN-04-3371
   Nakamura K, 2009, ANN ONCOL, V20, P63, DOI 10.1093/annonc/mdn556
   Nakamura K, 2010, INT J ONCOL, V37, P605, DOI 10.3892/ijo_00000709
   Nakamura K, 2009, ANTICANCER RES, V29, P1685
   Nakamura K, 2009, INT J ONCOL, V34, P345, DOI 10.3892/ijo_00000157
   Nonboe AW, 2017, TRAFFIC, V18, P378, DOI 10.1111/tra.12482
   Oberst M, 2001, AM J PATHOL, V158, P1301, DOI 10.1016/S0002-9440(10)64081-3
   Oberst MD, 2005, AM J PHYSIOL-CELL PH, V289, pC462, DOI 10.1152/ajpcell.00076.2005
   Oberst MD, 2003, J BIOL CHEM, V278, P26773, DOI 10.1074/jbc.M304282200
   Oberst MD, 2003, J HISTOCHEM CYTOCHEM, V51, P1017, DOI 10.1177/002215540305100805
   Oberst MD, 2002, CLIN CANCER RES, V8, P1101
   Pendlebury D, 2014, J BIOL CHEM, V289, DOI 10.1074/jbc.M114.609560
   Pereira MS, 2016, J HISTOCHEM CYTOCHEM, V64, P32, DOI 10.1369/0022155415612874
   Qin L, 1998, FEBS LETT, V436, P111, DOI 10.1016/S0014-5793(98)01105-3
   Saleem M, 2006, CANCER EPIDEM BIOMAR, V15, P217, DOI 10.1158/1055-9965.EPI-05-0737
   Salomon J, 2014, HUM GENET, V133, P299, DOI 10.1007/s00439-013-1380-6
   Santin AD, 2003, CANCER, V98, P1898, DOI 10.1002/cncr.11753
   Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520
   SHI YE, 1993, CANCER RES, V53, P1409
   Shimomura T, 1997, J BIOL CHEM, V272, P6370, DOI 10.1074/jbc.272.10.6370
   Skrzydlewska E, 2005, WORLD J GASTROENTERO, V11, P1251, DOI 10.3748/wjg.v11.i9.1251
   Stahelin RV, 2013, MOL BIOL CELL, V24, P883, DOI 10.1091/mbc.E12-10-0713
   Szabo R, 2007, ONCOGENE, V26, P1546, DOI 10.1038/sj.onc.1209966
   Szabo R, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002937
   Szabo R, 2009, DEVELOPMENT, V136, P2653, DOI 10.1242/dev.038430
   Takeuchi T, 2000, J BIOL CHEM, V275, P26333, DOI 10.1074/jbc.M002941200
   Takeuchi T, 1999, P NATL ACAD SCI USA, V96, P11054, DOI 10.1073/pnas.96.20.11054
   Tanaka H, 2005, MOL CELL BIOL, V25, P5687, DOI 10.1128/MCB.25.13.5687-5698.2005
   Tanimoto H, 2005, BRIT J CANCER, V92, P278, DOI 10.1038/sj.bjc.6602320
   Tsai CH, 2014, ONCOGENE, V33, P4643, DOI 10.1038/onc.2013.412
   Tsai WC, 2006, HISTOPATHOLOGY, V49, P388, DOI 10.1111/j.1365-2559.2006.02516.x
   Tsai WC, 2008, DIS MARKERS, V24, P89, DOI 10.1155/2008/945197
   Tung EKK, 2009, INT J CANCER, V124, P1811, DOI 10.1002/ijc.24115
   Uhland K, 2006, CELL MOL LIFE SCI, V63, P2968, DOI 10.1007/s00018-006-6298-x
   Vogel LK, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-176
   Wasilko DJ, 2009, PROTEIN EXPRES PURIF, V65, P122, DOI 10.1016/j.pep.2009.01.002
   Wu CJ, 2017, J CLIN INVEST, V127, P623, DOI 10.1172/JCI88428
   Wu SR, 2010, AM J PATHOL, V177, P3145, DOI 10.2353/ajpath.2010.100228
   Xiao GW, 1999, P NATL ACAD SCI USA, V96, P3700, DOI 10.1073/pnas.96.7.3700
   Yue DL, 2014, EXP CELL RES, V322, P149, DOI 10.1016/j.yexcr.2013.11.009
   Zhao BY, 2013, J BIOL CHEM, V288, P11155, DOI 10.1074/jbc.M113.454611
   Zoratti GL, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7776
NR 100
TC 15
Z9 16
U1 0
U2 4
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD NOV 8
PY 2017
VL 7
AR 15101
DI 10.1038/s41598-017-15415-4
PG 19
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA FM0JG
UT WOS:000414648700068
PM 29118397
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU Wu, J
   Li, PC
   Pang, JY
   Liu, GY
   Xie, XM
   Li, JY
   Yin, YC
   Han, JH
   Guo, XZ
   Qiu, L
AF Wu, Jie
   Li, Peng-chang
   Pang, Jun-yi
   Liu, Guo-you
   Xie, Xue-min
   Li, Jia-yao
   Yin, Yi-cong
   Han, Jian-hua
   Guo, Xiu-zhi
   Qiu, Ling
TI CCCTC-binding factor inhibits breast cancer cell proliferation and
   metastasis via inactivation of the nuclear factor-kappaB pathway
SO ONCOTARGET
LA English
DT Article
DE CCCTC-binding factor; breast cancer; proliferation; metastasis; nuclear
   factor-kappaB
ID CTCF TRANSCRIPTION FACTOR; ERYTHROID-DIFFERENTIATION; EPIGENETIC
   REGULATION; TUMOR-SUPPRESSOR; GROWTH; GENE; STATISTICS; MUTATIONS;
   PROTEIN; EXPRESSION
AB CCCTC-binding factor (CTCF) is an important epigenetic regulator implicated in multiple cellular processes, including growth, proliferation, differentiation, and apoptosis. Although CTCF deletion or mutation has been associated with human breast cancer, the role of CTCF in breast cancer is questionable. We investigated the biological functions of CTCF in breast cancer and the underlying mechanism. The results showed that CTCF expression in human breast cancer cells and tissues was significantly lower than that in normal breast cells and tissues. In addition, CTCF expression correlated significantly with cancer stage (P = 0.043) and pathological differentiation (P = 0.029). Furthermore, CTCF overexpression resulted in the inhibition of proliferation, migration, and invasion, while CTCF knockdown induced these processes in breast cancer cells. Transcriptome analysis and further experimental confirmation in MDA-MD-231 cells revealed that forced overexpression of CTCF might attenuate the DNA-binding ability of nuclear factor-kappaB (NF-kappa B) p65 subunit and inhibit activation of NF-kappa B and its target pro-oncogenes (tumor necrosis factor alpha-induced protein 3 [TNFAIP3]) and genes for growth-related proteins (early growth response protein 1 [EGR1] and growth arrest and DNA-damage-inducible alpha [GADD45a]). The present study provides a new insight into the tumor suppressor roles of CTCF in breast cancer development and suggests that the CTCF/NF-kappa B pathway is a potential target for breast cancer therapy.
C1 [Wu, Jie; Li, Peng-chang; Li, Jia-yao; Yin, Yi-cong; Han, Jian-hua; Guo, Xiu-zhi; Qiu, Ling] Peking Union Med Coll Hosp, Peking Union Med Coll, Dept Clin Lab, Beijing 100730, Peoples R China.
   [Wu, Jie; Li, Peng-chang; Pang, Jun-yi; Li, Jia-yao; Yin, Yi-cong; Han, Jian-hua; Guo, Xiu-zhi; Qiu, Ling] Chinese Acad Med Sci, Beijing 100730, Peoples R China.
   [Pang, Jun-yi] Peking Union Med Coll Hosp, Peking Union Med Coll, Dept Pathol, Beijing 100730, Peoples R China.
   [Liu, Guo-you; Xie, Xue-min] Chinese Acad Med Sci, Inst Basic Med Sci, Dept Biochem & Mol Biol, State Key Lab Med Mol Biol, Beijing 100005, Peoples R China.
   [Liu, Guo-you; Xie, Xue-min] Peking Union Med Coll, Beijing 100005, Peoples R China.
C3 Chinese Academy of Medical Sciences - Peking Union Medical College;
   Peking Union Medical College Hospital; Peking Union Medical College;
   Chinese Academy of Medical Sciences - Peking Union Medical College;
   Chinese Academy of Medical Sciences - Peking Union Medical College;
   Peking Union Medical College; Peking Union Medical College Hospital;
   Chinese Academy of Medical Sciences - Peking Union Medical College;
   Institute of Basic Medical Sciences - CAMS; Chinese Academy of Medical
   Sciences - Peking Union Medical College; Peking Union Medical College
RP Qiu, L (通讯作者)，Peking Union Med Coll Hosp, Peking Union Med Coll, Dept Clin Lab, Beijing 100730, Peoples R China.; Qiu, L (通讯作者)，Chinese Acad Med Sci, Beijing 100730, Peoples R China.
EM lingqiubj@aliyun.com
RI Guo, Peizhi/D-1362-2013; Li, Jiayao/KJL-0230-2024
FU National Natural Science Foundation of China [81301508]
FX This work is supported by the National Natural Science Foundation of
   China (81301508).
CR Aulmann S, 2003, BREAST CANCER RES TR, V80, P347, DOI 10.1023/A:1024930404629
   Biswas DK, 2006, J CELL PHYSIOL, V209, P645, DOI 10.1002/jcp.20785
   Chaturvedi MM, 2011, ONCOGENE, V30, P1615, DOI 10.1038/onc.2010.566
   Chen WQ, 2016, CA-CANCER J CLIN, V66, P115, DOI 10.3322/caac.21338
   Cuddapah S, 2009, GENOME RES, V19, P24, DOI 10.1101/gr.082800.108
   Fahmy RG, 2003, NAT MED, V9, P1026, DOI 10.1038/nm905
   Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210
   Filippova GN, 2002, CANCER RES, V62, P48
   Filippova GN, 1998, GENE CHROMOSOME CANC, V22, P26, DOI 10.1002/(SICI)1098-2264(199805)22:1<26::AID-GCC4>3.0.CO;2-9
   Getz G, 2013, NATURE, V497, P67, DOI 10.1038/nature12113
   Gilmore TD, 2006, ONCOGENE, V25, P6680, DOI 10.1038/sj.onc.1209954
   Green AR, 2009, BREAST CANCER RES TR, V113, P59, DOI 10.1007/s10549-008-9905-8
   Hirsch HA, 2010, CANCER CELL, V17, P348, DOI 10.1016/j.ccr.2010.01.022
   Huber MA, 2004, J CLIN INVEST, V114, P569, DOI 10.1172/JCI200421358
   Kim TH, 2007, CELL, V128, P1231, DOI 10.1016/j.cell.2006.12.048
   Li DP, 2013, ONCOTARGET, V4, P1373, DOI 10.18632/oncotarget.1165
   Liu BD, 2015, CANCER CELL, V27, P370, DOI 10.1016/j.ccell.2015.02.004
   LOBANENKOV VV, 1990, ONCOGENE, V5, P1743
   Méndez-Catalá CF, 2013, NEOPLASIA, V15, P898, DOI 10.1593/neo.121948
   Miller KD, 2016, CA-CANCER J CLIN, V66, P271, DOI 10.3322/caac.21349
   Mitchell A, 2004, NUCLEIC ACIDS RES, V32, P3065, DOI 10.1093/nar/gkh626
   Naugler WE, 2008, CURR OPIN GENET DEV, V18, P19, DOI 10.1016/j.gde.2008.01.020
   O'Shea JM, 2008, BIOCHEM SOC T, V36, P603, DOI 10.1042/BST0360603
   Park BK, 2007, NAT MED, V13, P62, DOI 10.1038/nm1519
   Rasko JEJ, 2001, CANCER RES, V61, P6002
   Ruland J, 2011, NAT IMMUNOL, V12, P709, DOI 10.1038/ni.2055
   Siegel RL, 2020, CA-CANCER J CLIN, V70, P7, DOI 10.3322/caac.21590
   Soto-Reyes E, 2010, ONCOGENE, V29, P2217, DOI 10.1038/onc.2009.509
   Tiffen JC, 2013, INT J CANCER, V133, P1603, DOI 10.1002/ijc.28184
   Torrano V, 2005, J BIOL CHEM, V280, P28152, DOI 10.1074/jbc.M501481200
   Tront JS, 2010, CANCER RES, V70, P9671, DOI 10.1158/0008-5472.CAN-10-2177
   Vendrell JA, 2007, ONCOGENE, V26, P4656, DOI 10.1038/sj.onc.1210269
   Wang L, 2013, J BIOL CHEM, V288, P24363, DOI 10.1074/jbc.M113.458141
   Witcher M, 2009, MOL CELL, V34, P271, DOI 10.1016/j.molcel.2009.04.001
   Wu J, 2014, BLOOD, V123, P261, DOI 10.1182/blood-2013-02-483289
   Yoshida K, 2013, NAT GENET, V45, P1293, DOI 10.1038/ng.2759
   Zhang H, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-5
   Zhao X, 2016, ONCOGENE, V35, P3565, DOI 10.1038/onc.2015.422
   Zhou LQ, 2012, J BIOL CHEM, V287, P30641, DOI 10.1074/jbc.M112.355271
NR 39
TC 5
Z9 6
U1 0
U2 8
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD NOV 7
PY 2017
VL 8
IS 55
BP 93516
EP 93529
DI 10.18632/oncotarget.18977
PG 14
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA FL9VQ
UT WOS:000414608400030
PM 29212169
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Liang, YK
   Lin, HY
   Chen, CF
   Zeng, D
AF Liang, Yuan-Ke
   Lin, Hao-Yu
   Chen, Chun-Fa
   Zeng, De
TI Prognostic values of distinct CBX family members in breast cancer
SO ONCOTARGET
LA English
DT Article
DE CBX; breast cancer; prognostic values; tamoxifen; chemosensitivity
ID EPIGENETIC REGULATION; CELL-PROLIFERATION; EXPRESSION; CARCINOMA;
   MECHANISMS; PHENOTYPE; SIGNATURE; MIGRATION; PROTEINS; SURVIVAL
AB Chromobox (CBX) family proteins are canonical components in polycomb repressive complexes 1 (PRC1), with epigenetic regulatory function and transcriptionally repressing target genes via chromatin modification. A plethora of studies have highlighted the function specifications among CBX family members in various cancer, including lung cancer, colon cancer and breast cancer. Nevertheless, the functions and prognostic roles of distinct CBX family members in breast cancer (BC) remain elusive. In this study, we reported the prognostic values of CBX family members in patients with BC through analysis of a series of databases, including CCLE, ONCOMINE, Xena Public Data Hubs, and Kaplan-Meier plotter. It was found that the mRNA expression of CBX family members were noticeably higher in BC than normal counterparts. CBX2 was highly expressed in Basal-like and HER-2 subtypes, while CBX4 and CBX7 expressions were enriched in Luminal A and Luminal B subtypes of BC. Survival analysis revealed that CBX1, CBX2 and CBX3 mRNA high expression was correlated to worsen relapse-free survival (RFS) for all BC patients, while CBX4, CBX5, CBX6 and CBX7 high expression was correlated to better RFS in this setting. Noteworthily, CBX1 and CBX2 were associated with chemoresistance whereas CBX7 was associated with tamoxifen sensitivity, as well as chemosensitivity in breast tumors. Therefore, we propose that CBX1, CBX2 and CBX7 are potential targets for BC treatment. The results might be beneficial for better understanding the complexity and heterogeneity in the molecular underpinning of BC, and to develop tools to more accurately predict the prognosis of patients with BC.
C1 [Liang, Yuan-Ke] Shantou Univ, Canc Hosp, Med Coll, Breast Ctr, Shantou, Peoples R China.
   [Liang, Yuan-Ke] Univ Groningen, Univ Med Ctr Groningen, Dept Med Oncol, Groningen, Netherlands.
   [Lin, Hao-Yu; Chen, Chun-Fa] Shantou Univ, Affiliated Hosp 1, Med Coll, Dept Breast & Thyroid Surg, Shantou, Peoples R China.
   [Zeng, De] Shantou Univ, Canc Hosp, Med Coll, Dept Med Oncol, Shantou, Peoples R China.
C3 Shantou University; University of Groningen; Shantou University; Shantou
   University
RP Zeng, D (通讯作者)，Shantou Univ, Canc Hosp, Med Coll, Dept Med Oncol, Shantou, Peoples R China.
EM alexzengde@163.com
RI Lin, Haoyu/J-4186-2019; Chen, Chunfa/V-7357-2019; Liang,
   Yuanke/AAG-2045-2021
OI Chen, Chun-fa/0000-0002-1128-485X
FU Medical Scientific Research Foundation of Guangdong Province, China
   [A2016368]; Natural Science Foundation of Guangdong Province, China
   [2015A030313429]; Youth Innovative Talent Project of Colleges and
   Universities in Guangdong Province, China [2016KQNCX051]
FX This study is partly supported by Medical Scientific Research Foundation
   of Guangdong Province, China (NO. A2016368), Natural Science Foundation
   of Guangdong Province, China (NO. 2015A030313429), Youth Innovative
   Talent Project of Colleges and Universities in Guangdong Province, China
   (NO. 2016KQNCX051).
CR Baxter E, 2014, CELL BIOSCI, V4, DOI 10.1186/2045-3701-4-45
   Bernard D, 2005, ONCOGENE, V24, P5543, DOI 10.1038/sj.onc.1208735
   Cacciola NA, 2015, N-S ARCH PHARMACOL, V388, P1179, DOI 10.1007/s00210-015-1153-y
   Cardoso F, 2016, NEW ENGL J MED, V375, P717, DOI 10.1056/NEJMoa1602253
   Chen WY, 2017, ONCOL LETT, V13, P1149, DOI 10.3892/ol.2016.5529
   Clermont PL, 2014, BRIT J CANCER, V111, P1663, DOI 10.1038/bjc.2014.474
   Dworkin AM, 2009, SEMIN CANCER BIOL, V19, P165, DOI 10.1016/j.semcancer.2009.02.007
   El Baroudi M, 2014, THEOR BIOL MED MODEL, V11, DOI 10.1186/1742-4682-11-S1-S8
   Forzati F, 2012, J CLIN INVEST, V122, P612, DOI 10.1172/JCI58620
   Györffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9
   Hatano A, 2010, BIOCHEM BIOPH RES CO, V397, P93, DOI 10.1016/j.bbrc.2010.05.074
   Hu Q, 2017, ONCOL LETT, V13, P2583, DOI 10.3892/ol.2017.5753
   Karamitopoulou E, 2010, EUR J CANCER, V46, P1438, DOI 10.1016/j.ejca.2010.01.033
   Karsli-Ceppioglu S, 2014, EPIGENOMICS-UK, V6, P651, DOI [10.2217/EPI.14.59, 10.2217/epi.14.59]
   Kim HY, 2015, FASEB J, V29, P300, DOI 10.1096/fj.14-253997
   Klauke K, 2013, NAT CELL BIOL, V15, P353, DOI 10.1038/ncb2701
   Kobayashi N, 2017, CLIN TRANSL ONCOL
   Koelzer VH, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2017.1288330
   Lee JJ, 2016, BMB REP, V49, P578, DOI 10.5483/BMBRep.2016.49.10.156
   Lee SH, 2016, BIOCHEM BIOPH RES CO, V469, P884, DOI 10.1016/j.bbrc.2015.12.070
   Lee YH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121207
   Li G, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080970
   Li J, 2014, CANCER CELL, V25, P118, DOI 10.1016/j.ccr.2013.12.008
   Lin HY, 2017, ONCOTARGET, V8, P34750, DOI 10.18632/oncotarget.16160
   Ma RG, 2014, J ZHEJIANG UNIV-SC B, V15, P412, DOI 10.1631/jzus.B1400077
   Meseure D, 2016, MOL CANCER RES, V14, P623, DOI 10.1158/1541-7786.MCR-15-0418
   Morey L, 2012, CELL STEM CELL, V10, P47, DOI 10.1016/j.stem.2011.12.006
   Natrajan R, 2016, JNCI-J NATL CANCER I, V108, DOI 10.1093/jnci/djw118
   Ni SJ, 2017, ONCOTARGET, V8, P8010, DOI 10.18632/oncotarget.14037
   Pallante P, 2008, CANCER RES, V68, P6770, DOI 10.1158/0008-5472.CAN-08-0695
   Pallante P, 2015, AM J CANCER RES, V5, P1594
   Pallante P, 2010, EUR J CANCER, V46, P2304, DOI 10.1016/j.ejca.2010.05.011
   Rhie SK, 2016, EPIGENET CHROMATIN, V9, DOI 10.1186/s13072-016-0102-4
   Roche J, 2017, CANCERS, V9, DOI 10.3390/cancers9070072
   Ruddock-D'Cruz NT, 2008, MOL REPROD DEV, V75, P477, DOI 10.1002/mrd.20752
   Shinjo K, 2014, INT J CANCER, V135, P308, DOI 10.1002/ijc.28692
   Shiota M, 2010, ENDOCR-RELAT CANCER, V17, P455, DOI 10.1677/ERC-09-0321
   Strietz J, 2016, ONCOTARGET, V7, P83278, DOI 10.18632/oncotarget.13086
   Taherian-Fard A, 2015, BRIEF BIOINFORM, V16, P461, DOI 10.1093/bib/bbu020
   van den Boom V, 2013, BLOOD, V121, P2452, DOI 10.1182/blood-2012-08-451666
   Vincenz C, 2008, P NATL ACAD SCI USA, V105, P16572, DOI 10.1073/pnas.0805317105
   Wang BQ, 2013, ANN SURG ONCOL, V20, pS684, DOI 10.1245/s10434-013-3171-7
   Wang X, 2016, CANCER RES, V76, P7277, DOI 10.1158/0008-5472.CAN-16-2100
   Wotton D, 2007, BIOCHEM SOC T, V35, P1401, DOI 10.1042/BST0351401
   Yu J, 2017, ONCOL REP, V37, P1394, DOI 10.3892/or.2017.5408
   Zhang XW, 2010, J EXP CLIN CANC RES, V29, DOI 10.1186/1756-9966-29-114
   Zheng H, 2017, ONCOTARGET, V8, P18872, DOI 10.18632/oncotarget.14770
NR 47
TC 63
Z9 66
U1 0
U2 19
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD NOV 3
PY 2017
VL 8
IS 54
BP 92375
EP 92387
DI 10.18632/oncotarget.21325
PG 13
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA FL9VD
UT WOS:000414606800046
PM 29190923
OA Green Submitted, Green Published, gold
DA 2025-01-12
ER

PT J
AU Cui, XB
   Chen, X
   Wang, WW
   Chang, AM
   Yang, L
   Liu, CX
   Peng, H
   Wei, YT
   Liang, WH
   Li, SG
   Wang, N
   Liu, W
   Hu, JM
   Zhang, WJ
   Wang, LD
   Chen, YZ
   Li, F
AF Cui, Xiaobin
   Chen, Xi
   Wang, Weiwei
   Chang, Aimin
   Yang, Lan
   Liu, Chunxia
   Peng, Hao
   Wei, Yutao
   Liang, Weihua
   Li, Shugang
   Wang, Ning
   Liu, Wei
   Hu, Jianming
   Zhang, Wenjie
   Wang, Lidong
   Chen, Yunzhao
   Li, Feng
TI Epigenetic silencing of miR-203 in Kazakh patients with esophageal
   squamous cell carcinoma by MassARRAY spectrometry
SO EPIGENETICS
LA English
DT Article
DE Esophageal squamous cell carcinoma; Kazakh; miR-203; methylation
ID EPITHELIAL DIFFERENTIATION; BLADDER-CANCER; BREAST-CANCER; EXPRESSION;
   HYPERMETHYLATION; METHYLATION; DEREGULATION; POPULATIONS; MICRORNAS
AB Dysregulation of miR-203 by promoter methylation is associated with the development of various cancers. We aimed to explore the underlying link between promoter methylation and miR-203 expression in Kazakh esophageal squamous cell carcinoma (ESCC). MassARRAY (R) System spectrometry was used to quantitatively analyze the DNA methylation of 32 CpG sites within miR-203 in 99 Kazakh ESCC and 46 normal esophageal tissues (NETs) with similar population characteristics. We conducted real-time PCR to detect miR-203 expression levels and evaluated their association with methylation. Eleven CpG units within miR-203 promoter were frequently hypermethylated in ESCC compared with NETs (P < 0.05). The hypermethylation of several CpG units positively correlated with age, lower esophagus, constrictive type of ESCC, and moderately differentiated ESCC. Given the involvement of human papillomavirus (HPV) in etiology of ESCC was confirmed from our previous reports, herein we found that CpG units within miR-203 in HPV16-positive ESCC are more heavily methylated. Furthermore, miR-203 expression showed a nearly 4.5-fold decrease in ESCC than NETs (0.206 +/- 0.336 vs. 0.908 +/- 1.424, P < 0.001) and was significantly associated with lymph node metastasis (P = 0.012). The expression of miR-203 with 11 completely hypermethylated CpG units was approximately 6.5-fold lower than that with at least 1 unmethylated CpG unit (P < 0.001) and especially the CpG_15.16 and CpG_31.32 with higher methylation levels in ESCC tissues exhibited lower expression levels of miR-203, which indicated a reverse association between miR-203 methylation and expression. Hypermethylated miR-203 is a potential biomarker and targeted delivery of miR-203 could therefore serve as a preventive or therapeutic strategy for Kazakh ESCC.
C1 [Cui, Xiaobin; Chen, Xi; Yang, Lan; Liu, Chunxia; Peng, Hao; Liang, Weihua; Li, Shugang; Wang, Ning; Liu, Wei; Hu, Jianming; Zhang, Wenjie; Chen, Yunzhao; Li, Feng] Shihezi Univ, Sch Med, Dept Pathol, North 4th Rd, Shihezi 832002, Peoples R China.
   [Cui, Xiaobin; Chen, Xi; Yang, Lan; Liu, Chunxia; Peng, Hao; Liang, Weihua; Li, Shugang; Wang, Ning; Liu, Wei; Hu, Jianming; Zhang, Wenjie; Chen, Yunzhao; Li, Feng] Shihezi Univ, Sch Med, Key Lab Xinjiang Endem & Ethn Dis, North 4th Rd, Shihezi 832002, Peoples R China.
   [Cui, Xiaobin; Li, Feng] Capital Med Univ, Beijing Chaoyang Hosp, Dept Pathol, Beijing 100020, Peoples R China.
   [Cui, Xiaobin; Li, Feng] Capital Med Univ, Beijing Chaoyang Hosp, Med Res Ctr, Beijing 100020, Peoples R China.
   [Wang, Weiwei] Zhucheng Maternal & Child Care Serv Ctr, Dept Pathol, Weifang, Peoples R China.
   [Chang, Aimin] Peoples Hosp Wusu, Dept Pathol, Tacheng, Peoples R China.
   [Wei, Yutao] Shihezi Univ, Sch Med, Affiliated Hosp 1, Dept Thorac & Cardiovasc Surg, Shihezi, Peoples R China.
   [Wang, Lidong] Zhengzhou Univ, Affiliated Hosp 1&2, Coll Med, Henan Key Lab Esophageal Canc Res,Dept Basic Onco, Zhengzhou, Henan, Peoples R China.
C3 Shihezi University; Shihezi University; Capital Medical University;
   Capital Medical University; Shihezi University; Zhengzhou University
RP Li, F (通讯作者)，Shihezi Univ, Sch Med, Dept Pathol, North 4th Rd, Shihezi 832002, Peoples R China.; Li, F (通讯作者)，Shihezi Univ, Sch Med, Key Lab Xinjiang Endem & Ethn Dis, North 4th Rd, Shihezi 832002, Peoples R China.; Li, F (通讯作者)，Capital Med Univ, Beijing Chaoyang Hosp, Dept Pathol, Beijing 100020, Peoples R China.; Li, F (通讯作者)，Capital Med Univ, Beijing Chaoyang Hosp, Med Res Ctr, Beijing 100020, Peoples R China.
EM lifeng7855@126.com
RI Yang, Lan/AAC-5390-2019; Wei, Liu/JAO-1481-2023; Liu,
   Wen-Yang/GZM-3215-2022; Zhang, Wenjie/O-5336-2014; CUI,
   XIAO/LDG-1738-2024
FU National Natural Science Foundation of China [81560399, 81360358,
   81460362]; Major science and technology projects of Shihezi University
   [gxjs2014-zdgg06]; Applied Basic Research Projects of Xinjiang
   Production and Construction Corps [2016AG020]; high-level talent project
   of Shihezi University [RCZX201533]; Foundation for Distinguished Young
   Scholars of Shihezi University [2015ZRKXJQ02]
FX This work was supported by Grants from the National Natural Science
   Foundation of China (No. 81560399, 81360358, 81460362), the Major
   science and technology projects of Shihezi University (No.
   gxjs2014-zdgg06), the Applied Basic Research Projects of Xinjiang
   Production and Construction Corps (No. 2016AG020), the high-level talent
   project of Shihezi University (No. RCZX201533), and the Foundation for
   Distinguished Young Scholars of Shihezi University (No. 2015ZRKXJQ02).
CR Benaich N, 2014, CELL REP, V9, P104, DOI 10.1016/j.celrep.2014.08.062
   Bhardwaj A, 2013, CURR DRUG TARGETS, V14, P1175, DOI 10.2174/13894501113149990190
   Bo JJ, 2011, FEBS J, V278, P786, DOI 10.1111/j.1742-4658.2010.07997.x
   Bueno MJ, 2008, CANCER CELL, V13, P496, DOI 10.1016/j.ccr.2008.04.018
   Chen B, 2016, MOL MED REP, V13, P2527, DOI 10.3892/mmr.2016.4832
   Chen XD, 2012, INT J CANCER, V130, P1607, DOI 10.1002/ijc.26171
   Chim CS, 2011, J CELL MOL MED, V15, P2760, DOI 10.1111/j.1582-4934.2011.01274.x
   Cui XB, 2014, MED ONCOL, V31, DOI 10.1007/s12032-013-0791-5
   Cui XB, 2014, J EXP CLIN CANC RES, V33, DOI 10.1186/1756-9966-33-20
   Cui XB, 2014, J MED VIROL, V86, P608, DOI 10.1002/jmv.23775
   Deneberg S, 2014, EPIGENETICS-US, V9, P910, DOI 10.4161/epi.28603
   Diao YR, 2014, J BIOL CHEM, V289, P529, DOI 10.1074/jbc.M113.494716
   Feber A, 2008, J THORAC CARDIOV SUR, V135, P255, DOI 10.1016/j.jtcvs.2007.08.055
   Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516
   Funamizu N, 2015, INT J ONCOL, V47, P1981, DOI 10.3892/ijo.2015.3178
   Furuta M, 2010, CARCINOGENESIS, V31, P766, DOI 10.1093/carcin/bgp250
   Hu JM, 2016, SCI REP-UK, V6, DOI 10.1038/srep23780
   Hu JM, 2012, CANCER IMMUNOL IMMUN, V61, P2135, DOI 10.1007/s00262-012-1281-x
   Huang YW, 2014, GYNECOL ONCOL, V133, P340, DOI 10.1016/j.ygyno.2014.02.009
   Iorio MV, 2007, CANCER RES, V67, P8699, DOI 10.1158/0008-5472.CAN-07-1936
   Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783
   Kulis M, 2010, ADV GENET, V70, P27, DOI [10.1016/S0065-2660(10)70002-X, 10.1016/B978-0-12-380866-0.60002-2]
   Lee E, 2013, CANCER-AM CANCER SOC, V119, P1752, DOI 10.1002/cncr.27948
   Li JA, 2011, CANCER LETT, V304, P52, DOI 10.1016/j.canlet.2011.02.003
   Li X, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1509-1
   Lin YS, 2013, J EPIDEMIOL, V23, P233, DOI 10.2188/jea.JE20120162
   Melar-New M, 2010, J VIROL, V84, P5212, DOI 10.1128/JVI.00078-10
   Nair Jayalakshmi, 2015, Genes Cancer, V6, P328
   Qi QF, 2016, INT J CLIN EXP PATHO, V9, P6245
   Saini S, 2011, CANCER PREV RES, V4, P1698, DOI 10.1158/1940-6207.CAPR-11-0267
   Sandhu R, 2014, INT J ONCOL, V44, P563, DOI 10.3892/ijo.2013.2197
   Takeshita N, 2012, INT J ONCOL, V41, P1653, DOI 10.3892/ijo.2012.1614
   Taube JH, 2013, SCI REP-UK, V3, DOI 10.1038/srep02687
   Tsai KW, 2011, INT J CANCER, V129, P2600, DOI 10.1002/ijc.25919
   Waldmann T, 2013, CURR OPIN CELL BIOL, V25, P184, DOI 10.1016/j.ceb.2013.01.001
   Wu C, 2014, NAT GENET, V46, P1001, DOI 10.1038/ng.3064
   Yantiss RK, 2009, AM J SURG PATHOL, V33, P572, DOI 10.1097/PAS.0b013e31818afd6b
   Yuan Y, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-57
   Zhang Zhiqian, 2011, Genes Cancer, V2, P782, DOI 10.1177/1947601911429743
   Zhu XY, 2013, CELL PHYSIOL BIOCHEM, V32, P64, DOI 10.1159/000350125
NR 40
TC 14
Z9 14
U1 2
U2 16
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1559-2294
EI 1559-2308
J9 EPIGENETICS-US
JI Epigenetics
PY 2017
VL 12
IS 8
BP 698
EP 707
DI 10.1080/15592294.2017.1349045
PG 10
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA FL9KK
UT WOS:000414572900010
PM 28703658
OA Green Published, Bronze
DA 2025-01-12
ER

PT J
AU Han, X
   Zhao, ZT
   Zhang, MJ
   Li, GC
   Yang, CY
   Du, FX
   Wang, JY
   Zhang, Y
   Wang, YY
   Jia, YS
   Li, BH
   Sun, YL
AF Han, Xiao
   Zhao, Zitong
   Zhang, Minjie
   Li, Guochao
   Yang, Caiyun
   Du, Fengxia
   Wang, Junyun
   Zhang, Yan
   Wang, Yuanyuan
   Jia, Yongsheng
   Li, Binghui
   Sun, Yingli
TI Maternal trans-general analysis of the human mitochondrial DNA pattern
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE MtDNA methylation; Epigenetic inheritance; Maternal line; Breast cancer;
   Biomarkers
ID TOBACCO-SMOKE EXPOSURE; CPG METHYLATION; EPIGENETIC REGULATION; CANCER;
   INHERITANCE; HYPOMETHYLATION; METHYLOMES; BIOMARKER; REGION; SHOWS
AB There is an intimate connection between mitochondrial DNA (mtDNA) methylation and some diseases, such as cancer. MtDNA is almost strictly maternally inherited. However, whether the aberrant mtDNA methylation involved in breast cancer progression and whether mtDNA methylation can be transmitted through maternal line are poorly understood. Here we applied bisulfite sequencing to global mitochondrial DNA and whole genomic DNA methylation array from fifteen members of five three-female generation families with one breast cancer patient in each family. We found that mtDNA methylation was maternally inherited in D-loop region and eight aberrant mtDNA methylation sites were correlated with breast cancer. Furthermore, conjoint analysis showed that mtDNA methylation sites could be potential biomarkers combined with nuclear DNA methylation sites for breast cancer risk prediction. (C) 2017 Published by Elsevier Inc.
C1 [Han, Xiao; Zhao, Zitong; Zhang, Minjie; Li, Guochao; Yang, Caiyun; Du, Fengxia; Wang, Junyun; Sun, Yingli] Chinese Acad Sci, Beijing Inst Genom, China Gastrointestinal Canc Res Ctr, Key Lab Genom & Precis Med, Beijing 100101, Peoples R China.
   [Han, Xiao; Zhao, Zitong; Zhang, Minjie; Li, Guochao] Univ Chinese Acad Sci, Beijing 100049, Peoples R China.
   [Zhang, Yan] Harbin Med Univ, Coll Bioinformat Sci & Technol, Harbin 150081, Heilongjiang, Peoples R China.
   [Wang, Yuanyuan; Li, Binghui] Tianjin Med Univ, Lab Canc Cell Biol, Key Lab Breast Canc Prevent & Therapy, Natl Clin Res Ctr Canc,Canc Inst & Hosp, Tianjin 300060, Peoples R China.
   [Jia, Yongsheng] Tianjin Med Univ, Dept Breast Oncol, Canc Inst & Hosp,Minist Educ,Key Lab Canc Prevent, Natl Clin Res Ctr Canc,Key Lab Breast Canc Preven, Tianjin 300060, Peoples R China.
C3 Chinese Academy of Sciences; Beijing Institute of Genomics, CAS; Chinese
   Academy of Sciences; University of Chinese Academy of Sciences, CAS;
   Harbin Medical University; Tianjin Medical University; Tianjin Medical
   University
RP Sun, YL (通讯作者)，Chinese Acad Sci, Beijing Inst Genom, 1 Beichen West Rd, Beijing 100101, Peoples R China.
EM yinglisun37@126.com
RI Zhang, Minjie/AFT-6708-2022; Han, Xiao/HOH-2354-2023; wang, jun
   yun/GYQ-7741-2022
OI Han, Xiao/0000-0001-9262-7254; Zhang, Minjie/0000-0001-8561-0729; wang,
   jun yun/0000-0003-0573-7856; Li, Guochao/0000-0002-1504-3471
FU National Basic Research Program (973 Program) [2013CB911001,
   2012CB518302]; Strategic Priority Research Program of the Chinese
   Academy of Sciences [XDA12020343]; Precision Medicine Research Program
   of the Chinese Academy of Sciences [KJZD-EW-L14]; National Natural
   Science Foundation of China [31540033]
FX We thank all the volunteers and organizers from Tianjin Medical
   University Cancer Institute and Hospital for sample collection and the
   technique assistance of Annoroad Gene Technology Co., Ltd, Beijing,
   China. We also acknowledged Prof. Chen Quan (State Key Laboratory of
   Membrane Biology, Institute of Zoology, Chinese Academy of Sciences) for
   his comments for our manuscript. This work was supported by the National
   Basic Research Program (973 Program, grant nos. 2013CB911001), the
   Strategic Priority Research Program of the Chinese Academy of Sciences
   (grant no. XDA12020343), the Precision Medicine Research Program of the
   Chinese Academy of Sciences (grant no. KJZD-EW-L14), the National Basic
   Research Program (973 Program, grant nos. 2012CB518302) and the National
   Natural Science Foundation of China (grant nos. 31540033).
CR Baccarelli AA, 2015, CLIN EPIGENETICS, V7, DOI 10.1186/s13148-015-0078-0
   Barlow DP, 2014, CSH PERSPECT BIOL, V6, DOI 10.1101/cshperspect.a018382
   Bellizzi D, 2013, DNA RES, V20, P537, DOI 10.1093/dnares/dst029
   Breton CV, 2009, AM J RESP CRIT CARE, V180, P462, DOI 10.1164/rccm.200901-0135OC
   BROWN GG, 1986, J MOL BIOL, V192, P503, DOI 10.1016/0022-2836(86)90272-X
   Byun HM, 2014, HUM GENET, V133, P247, DOI 10.1007/s00439-013-1417-x
   Byun HM, 2013, PART FIBRE TOXICOL, V10, DOI 10.1186/1743-8977-10-18
   Chestnut BA, 2011, J NEUROSCI, V31, P16619, DOI 10.1523/JNEUROSCI.1639-11.2011
   Ci WM, 2015, PHYSIOLOGY, V30, P63, DOI 10.1152/physiol.00037.2014
   Cree LM, 2008, NAT GENET, V40, P249, DOI 10.1038/ng.2007.63
   D'Aquila P, 2015, EPIGENOMICS-UK, V7, P707, DOI 10.2217/epi.15.30
   Dawson MA, 2012, CELL, V150, P12, DOI 10.1016/j.cell.2012.06.013
   Feil R, 2012, NAT REV GENET, V13, P97, DOI 10.1038/nrg3142
   Feng S, 2012, MOL MED REP, V6, P125, DOI 10.3892/mmr.2012.870
   Ghosh S, 2014, MITOCHONDRION, V18, P58, DOI 10.1016/j.mito.2014.07.007
   GILES RE, 1980, P NATL ACAD SCI-BIOL, V77, P6715, DOI 10.1073/pnas.77.11.6715
   Greiner S, 2015, BIOESSAYS, V37, P80, DOI 10.1002/bies.201400110
   Hong EE, 2013, MOL CELL BIOL, V33, P2683, DOI 10.1128/MCB.00220-13
   Iacobazzi V, 2013, MOL GENET METAB, V110, P25, DOI 10.1016/j.ymgme.2013.07.012
   Janssen BG, 2017, J TRANSL MED, V15, DOI 10.1186/s12967-016-1113-4
   Jiang L, 2013, CELL, V153, P773, DOI 10.1016/j.cell.2013.04.041
   Pirola CJ, 2013, GUT, V62, P1356, DOI 10.1136/gutjnl-2012-302962
   Krueger F, 2011, BIOINFORMATICS, V27, P1571, DOI 10.1093/bioinformatics/btr167
   Krzywinski M, 2009, GENOME RES, V19, P1639, DOI 10.1101/gr.092759.109
   Liao K, 2015, J NUTR, V145, P2479, DOI 10.3945/jn.115.216481
   Liu BJ, 2016, SCI REP-UK, V6, DOI 10.1038/srep23421
   Manev Hari, 2012, Biomol Concepts, V3, P107
   Miró O, 1999, CARCINOGENESIS, V20, P1331, DOI 10.1093/carcin/20.7.1331
   Mishra P, 2014, NAT REV MOL CELL BIO, V15, P634, DOI 10.1038/nrm3877
   Shock LS, 2011, P NATL ACAD SCI USA, V108, P3630, DOI 10.1073/pnas.1012311108
   Sun C, 2011, GYNECOL ONCOL, V121, P59, DOI 10.1016/j.ygyno.2011.01.013
   van der Wijst MGP, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-00263-z
   van der Wijst MGP, 2015, TRENDS GENET, V31, P353, DOI 10.1016/j.tig.2015.03.009
   Wai T, 2008, NAT GENET, V40, P1484, DOI 10.1038/ng.258
   Wallace DC, 2012, NAT REV CANCER, V12, P685, DOI 10.1038/nrc3365
   Wang D, 2012, BIOINFORMATICS, V28, P729, DOI 10.1093/bioinformatics/bts013
   Yamazaki M, 2016, LIFE SCI, V149, P146, DOI 10.1016/j.lfs.2016.02.020
   Yang LQ, 2016, TOXICOL LETT, V243, P1, DOI 10.1016/j.toxlet.2015.11.031
   Yao LS, 2015, ONCOTARGET, V6, P40611, DOI 10.18632/oncotarget.6141
   Zhang MJ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146402
NR 40
TC 11
Z9 11
U1 1
U2 38
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
EI 1090-2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD NOV 4
PY 2017
VL 493
IS 1
BP 643
EP 649
DI 10.1016/j.bbrc.2017.08.138
PG 7
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA FJ9XG
UT WOS:000413134200100
PM 28865962
DA 2025-01-12
ER

PT J
AU Lin, BA
   Zhou, XM
   Lin, SY
   Wang, XY
   Zhang, MY
   Cao, BP
   Dong, Y
   Yang, SA
   Wang, JM
   Guo, MZ
   Huang, JQ
AF Lin, Bonan
   Zhou, Xiaomeng
   Lin, Shuye
   Wang, Xiaoyue
   Zhang, Meiying
   Cao, Baoping
   Dong, Yan
   Yang, Shuai
   Wang, Ji Ming
   Guo, Mingzhou
   Huang, Jiaqiang
TI Epigenetic silencing of <i>PRSS3</i> provides growth and metastasis
   advantage for human hepatocellular carcinoma
SO JOURNAL OF MOLECULAR MEDICINE-JMM
LA English
DT Article
DE Protease, serine, 3; Hepatocellular carcinoma; Intragenic methylation;
   Growth; Metastasis; Tumor suppressor
ID INTRAGENIC DNA METHYLATION; ACTIVATED RECEPTOR-2; SIGNAL-TRANSDUCTION;
   BREAST-CANCER; TRYPSIN-IV; EXPRESSION; GENE; MESOTRYPSIN;
   PRSS3/MESOTRYPSIN; IDENTIFICATION
AB Protease, serine, 3 (PRSS3), a member of the trypsin family of serine proteases, has been shown to be aberrantly expressed in several cancer types and to play important roles in tumor progression and metastasis. However, the expression and function of PRSS3 gene in hepatocellular carcinoma (HCC) remain unclear. Here we found that PRSS3 expression was decreased in human HCC cell lines and HCC surgical specimens. This was associated with intragenic methylation of PRSS3 gene. Treatment with DNA methyltransferase inhibitor 5-aza-2'-deoxycytidine and/or histone deacetylase inhibitor trichostatin A restored PRSS3 expression in HCC cell lines. Ectopic overexpression of PRSS3 gene in HCC cell lines significantly suppressed cell proliferation and colony formation and arrested cell cycle at G1/S phase, accompanied with downregulation of cyclin D1 (CCND1)/CDK4 and cyclin E1 (CCNE1)/CDK2 complexes. Moreover, PRSS3 overexpression in HCC cells inhibited HCC cell migration and invasion with downregulation of matrix metallopeptidase 2 (MMP2). Further study showed that PRSS3 overexpression diminished the phosphorylation of mitogen-activated protein kinase/extracellular-signal-regulated kinase signaling protein, mitogen-activated protein kinase kinase 1 (MEK1)/mitogen-activated protein kinase kinase 2 (MEK2) and extracellular-signal related kinase 1 (ERK1)/extracellular-signal related kinase 2 (ERK2), in HCC cells. In contrast, knockdown of PRSS3 by small interfering RNA resulted in opposite effects on an HCC cell line SNU-387 which constitutively expresses PRSS3. These results demonstrate that downregulation of PRSS3 by intragenic hypermethylation provides growth and metastasis advantage to HCC cells. The clinical relevance of PRSS3 to human HCC was shown by the intragenic methylation of PRSS3 in HCC specimens and its association with poor tumor differentiation in patients with HCC. Thus, PRSS3 is a potential prognostic biomarker and an epigenetic target for intervention of human HCC.
C1 [Lin, Bonan; Zhou, Xiaomeng; Lin, Shuye; Wang, Xiaoyue; Huang, Jiaqiang] Beijing Jiaotong Univ, Coll Life Sci & Bioengn, Beijing 100044, Peoples R China.
   [Zhang, Meiying; Cao, Baoping; Dong, Yan; Yang, Shuai; Guo, Mingzhou] Chinese Peoples Liberat Army Gen Hosp, Dept Gastroenterol & Hepatol, Beijing 100853, Peoples R China.
   [Wang, Ji Ming; Huang, Jiaqiang] Natl Canc Inst, Canc & Inflammat Program, Ctr Canc Res, Frederick, MD 21702 USA.
C3 Beijing Jiaotong University; Chinese People's Liberation Army General
   Hospital; National Institutes of Health (NIH) - USA; NIH National Cancer
   Institute (NCI)
RP Huang, JQ (通讯作者)，Beijing Jiaotong Univ, Coll Life Sci & Bioengn, Beijing 100044, Peoples R China.; Guo, MZ (通讯作者)，Chinese Peoples Liberat Army Gen Hosp, Dept Gastroenterol & Hepatol, Beijing 100853, Peoples R China.; Huang, JQ (通讯作者)，Natl Canc Inst, Canc & Inflammat Program, Ctr Canc Res, Frederick, MD 21702 USA.
EM mzguo@hotmail.com; jqhuang@bjtu.edu.cn
RI Wang, Haitao/GYV-1262-2022; Cao, Baoping/HDN-2120-2022; Lin,
   Shuye/Y-4469-2019; Huang, Jiaqiang/C-2375-2011
OI Huang, Jiaqiang/0000-0002-6610-8159; Lin, Shuye/0000-0002-4292-0302
FU National Key Scientific Instrument Special Program of China
   [2011YQ03013405]; National Science Foundation of China (NSFC) [8167318,
   U1604281, 81230047, 81490753, 81121004, 81402345]; Beijing Science
   Foundation of China (BJSFC) [7171008]; Translational foundation of
   Chinese PLA General Hospital [2016ZHJJMS-GMZ]; Federal funds from the
   National Cancer Institute, National Institutes of Health
   [HHSN261200800001E]; Intramural Research Program of the NCI, NIH;
   Intramural Research funding of Beijing Jiaotong University [S12RC00030]
FX We thank Dr. Keqiang Chen for help with the data interpretation. This
   work was supported by the following grants: National Key Scientific
   Instrument Special Program of China (Grant No. 2011YQ03013405); National
   Science Foundation of China (NSFC No. 8167318, U1604281, 81230047,
   81490753, 81121004, 81402345); Beijing Science Foundation of China
   (BJSFC No. 7171008); and Translational foundation of Chinese PLA General
   Hospital (2016ZHJJMS-GMZ). JH and JMW were also funded in part by
   Federal funds from the National Cancer Institute, National Institutes of
   Health, under Contract No. HHSN261200800001E and were supported in part
   by the Intramural Research Program of the NCI, NIH. JH was also
   supported by the Intramural Research funding of Beijing Jiaotong
   University (S12RC00030).
CR Brenet F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014524
   Cottrell GS, 2004, J BIOL CHEM, V279, P13532, DOI 10.1074/jbc.M312090200
   Daniele A, 2014, CLIN BIOCHEM, V47, P184, DOI 10.1016/j.clinbiochem.2013.11.022
   Diederichs S, 2004, CANCER RES, V64, P5564, DOI 10.1158/0008-5472.CAN-04-2004
   El-Serag HB, 2011, NEW ENGL J MED, V365, P1118, DOI 10.1056/NEJMra1001683
   Feo F, 2008, WORLD J GASTROENTERO, V14, P6601, DOI 10.3748/wjg.14.6601
   Frenette C, 2011, CLIN LIVER DIS, V15, P307, DOI 10.1016/j.cld.2011.03.010
   Ghilardi C, 2015, ONCOTARGET, V6, P28389, DOI 10.18632/oncotarget.4949
   Golubnitschaja O, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2382-2
   Grishina Z, 2005, BRIT J PHARMACOL, V146, P990, DOI 10.1038/sj.bjp.0706410
   Han S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076667
   HIRAHARA F, 1995, INT J CANCER, V63, P176, DOI 10.1002/ijc.2910630205
   Hockla A, 2012, MOL CANCER RES, V10, P1555, DOI 10.1158/1541-7786.MCR-12-0314
   Hockla A, 2010, BREAST CANCER RES TR, V124, P27, DOI 10.1007/s10549-009-0699-0
   Itkonen O, 2010, SCAND J CLIN LAB INV, V70, P136, DOI 10.3109/00365511003615317
   Jena N, 2002, CANCER RES, V62, P535
   Jiang GZ, 2010, GUT, V59, P1535, DOI 10.1136/gut.2009.200105
   Jjingo D, 2012, ONCOTARGET, V3, P462, DOI 10.18632/oncotarget.497
   Knecht W, 2007, J BIOL CHEM, V282, P26089, DOI 10.1074/jbc.M703840200
   Lau C, 2011, AM J PHYSIOL-CELL PH, V300, pC113, DOI 10.1152/ajpcell.00162.2010
   Lin SY, 2017, ONCOL RES, V25, P317, DOI 10.3727/096504016X14734735156265
   Liu L, 2006, CANCER RES, V66, P11851, DOI 10.1158/0008-5472.CAN-06-1377
   López-Otín C, 2007, NAT REV CANCER, V7, P800, DOI 10.1038/nrc2228
   Lorincz MC, 2004, NAT STRUCT MOL BIOL, V11, P1068, DOI 10.1038/nsmb840
   Ma RQ, 2015, GYNECOL ONCOL, V137, P546, DOI 10.1016/j.ygyno.2015.02.022
   Mann DA, 2014, HEPATOLOGY, V60, P1418, DOI 10.1002/hep.27131
   Marsit CJ, 2006, ANN NY ACAD SCI, V1076, P810, DOI 10.1196/annals.1371.031
   Marsit CJ, 2006, CARCINOGENESIS, V27, P112, DOI 10.1093/carcin/bgi172
   Marsit CJ, 2005, MOL CARCINOGEN, V44, P146, DOI 10.1002/mc.20125
   Martinez I, 2007, EUR J CANCER, V43, P415, DOI 10.1016/j.ejca.2006.09.001
   Massagué J, 2004, NATURE, V432, P298, DOI 10.1038/nature03094
   Maunakea AK, 2010, NATURE, V466, P253, DOI 10.1038/nature09165
   Nakanishi J, 2010, J INVEST DERMATOL, V130, P944, DOI 10.1038/jid.2009.364
   Nyaruhucha CNM, 1997, J BIOL CHEM, V272, P10573
   Nyberg P, 2006, EXP CELL RES, V312, P1219, DOI 10.1016/j.yexcr.2005.12.024
   Pan YM, 2016, ANTIOXID REDOX SIGN, V24, P839, DOI 10.1089/ars.2014.6128
   Pogribny IP, 2014, CANCER LETT, V342, P223, DOI 10.1016/j.canlet.2012.01.038
   Radisky ES, 2013, ASIAN J ANDROL, V15, P439, DOI 10.1038/aja.2013.14
   Rowen L, 2005, MOL BIOL EVOL, V22, P1712, DOI 10.1093/molbev/msi166
   Sahin-Tóth M, 2005, PROTEIN PEPTIDE LETT, V12, P457, DOI 10.2174/0929866054395356
   Salameh Moh'd A, 2013, Int J Biochem Mol Biol, V4, P129
   Soreide K, 2006, J PATHOL, V209, P147, DOI 10.1002/path.1999
   Su S, 2009, ONCOGENE, V28, P3047, DOI 10.1038/onc.2009.163
   TANI T, 1990, NUCLEIC ACIDS RES, V18, P1631, DOI 10.1093/nar/18.6.1631
   Wang Y, 2016, SCI REP-UK, V6, DOI 10.1038/srep22051
   Wei JS, 2004, CANCER RES, V64, P6883, DOI 10.1158/0008-5472.CAN-04-0695
   WIEGAND U, 1993, GENE, V136, P167, DOI 10.1016/0378-1119(93)90460-K
   Wojtukiewicz MZ, 2015, CANCER METAST REV, V34, P775, DOI 10.1007/s10555-015-9599-4
   Yamashita K, 2003, CANCER RES, V63, P6575
   Yoshida T, 2006, ONCOGENE, V25, P6056, DOI 10.1038/sj.onc.1209635
   Zhu HB, 2013, HEPATOLOGY, V58, P2012, DOI 10.1002/hep.26587
NR 51
TC 14
Z9 17
U1 0
U2 10
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0946-2716
EI 1432-1440
J9 J MOL MED
JI J. Mol. Med.
PD NOV
PY 2017
VL 95
IS 11
BP 1237
EP 1249
DI 10.1007/s00109-017-1578-5
PG 13
WC Genetics & Heredity; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity; Research & Experimental Medicine
GA FL1KO
UT WOS:000413973800010
PM 28844099
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Anbalagan, M
   Sheng, M
   Fleischer, B
   Zhang, YF
   Gao, YJ
   Hoang, V
   Matossian, M
   Burks, HE
   Burow, ME
   Collins-Burow, BM
   Hangauer, D
   Rowan, BG
AF Anbalagan, Muralidharan
   Sheng, Mei
   Fleischer, Brian
   Zhang, Yifang
   Gao, Yuanjun
   Van Hoang
   Matossian, Margarite
   Burks, Hope E.
   Burow, Matthew E.
   Collins-Burow, Bridgette M.
   Hangauer, David
   Rowan, Brian G.
TI Dual Src Kinase/Pretubulin Inhibitor KX-01, Sensitizes ERα-negative
   Breast Cancers to Tamoxifen through ERα Reexpression
SO MOLECULAR CANCER RESEARCH
LA English
DT Article
ID ESTROGEN-RECEPTOR-ALPHA; EPITHELIAL-MESENCHYMAL TRANSITION; HISTONE
   DEACETYLASE INHIBITION; ENDOCRINE THERAPY; CELL-LINES; E-CADHERIN;
   GENE-EXPRESSION; IN-VITRO; METASTASIS; PHOSPHORYLATION
AB Unlike breast cancer that is positive for estrogen receptor-a (ER alpha), there are no targeted therapies for triple-negative breast cancer (TNBC). ER alpha is silenced in TNBC through epigenetic changes including DNA methylation and histone acetylation. Restoring ER alpha expression in TNBC may sensitize patients to endocrine therapy. Expression of c-Src and ER alpha are inversely correlated in breast cancer suggesting that c-Src inhibition may lead to reexpression of ERain TNBC. KX-01 is a peptide substrate-targeted Src/pretubulin inhibitor in clinical trials for solid tumors. KX-01 (1 mg/kg body weight-twice daily) inhibited growth of tamoxifen-resistant MDA-MB-231 and MDA-MB-157 TNBC xenografts in nude mice that was correlated with Src kinase inhibition. KX-01 also increased ERa mRNA and protein, as well as increased the ER alpha targets progesterone receptor (PR), pS2 (TFF1), cyclin D1 (CCND1), and c-myc (MYC) in MDA-MB-231 and MDA-MB-468, but not MDA-MB-157 xenografts. MDA-MB-231 and MDA-MB-468 tumors exhibited reduction in mesenchymal markers (vimentin, beta-catenin) and increase in epithelial marker (E-cadherin) suggesting mesenchymal-to-epithelial transition (MET). KX-01 sensitized MDA-MB-231 and MDA-MB-468 tumors to tamoxifen growth inhibition and tamoxifen repression of the ER alpha targets pS2, cyclin D1, and c-myc. Chromatin immunoprecipitation (ChIP) of the ERa promoter in KX-01-treated tumors demonstrated enrichment of active transcription marks (acetyl-H3, acetyl-H3Lys9), dissociation of HDAC1, and recruitment of RNA polymerase II. Methylation-specific PCR and bisulfite sequencing demonstrated no alteration in ERa promoter methylation by KX-01. These data demonstrate that in addition to Src kinase inhibition, peptidomimetic KX-01 restores ERa expression in TNBC through changes in histone acetylation that sensitize tumors to tamoxifen.
C1 [Anbalagan, Muralidharan; Sheng, Mei; Fleischer, Brian; Zhang, Yifang; Gao, Yuanjun; Rowan, Brian G.] Tulane Univ, Sch Med, Dept Struct & Cellular Biol, 1430 Tulane Ave, New Orleans, LA 70112 USA.
   [Zhang, Yifang] Taishan Med Univ, Affiliated Hosp, Dept Obstet & Gynecol, Taishan, Shandong, Peoples R China.
   [Gao, Yuanjun] Hubei Univ Med, Dept Gastroenterol, Taihe Hosp, Shiyan, Hubei, Peoples R China.
   [Van Hoang; Matossian, Margarite; Burks, Hope E.; Burow, Matthew E.; Collins-Burow, Bridgette M.] Tulane Univ, Sch Med, Dept Med, Sect Hematol & Med Oncol, New Orleans, LA 70112 USA.
   [Hangauer, David] Athenex Pharmaceut LLC, New York State Ctr Excellence Bioinformat & Life, Buffalo, NY USA.
C3 Tulane University; Shandong First Medical University & Shandong Academy
   of Medical Sciences; Hubei University of Medicine; Tulane University
RP Rowan, BG (通讯作者)，Tulane Univ, Sch Med, Box SL49,1430 Tulane Ave, New Orleans, LA 70112 USA.
EM browan@tulane.edu
RI Burow, Matthew/D-6351-2013
OI Anbalagan, Muralidharan/0000-0001-5797-7558
FU LA CaTS Center [1 U54 GM104940]; Bio-specimen Core Laboratory of the
   Louisiana Cancer Research Consortium;  [DK068432];  [CA125806]
FX This study was supported, in part by DK068432 (to B.G. Rowan), LA CaTS
   Center grant 1 U54 GM104940 (to B.M. Collins-Burow), and CA125806 (to
   M.E. Burow). This work has been supported in part by the Bio-specimen
   Core Laboratory of the Louisiana Cancer Research Consortium.
CR Alam F, 2016, BIOMATERIALS, V86, P56, DOI 10.1016/j.biomaterials.2016.01.058
   Anbalagan M, 2012, MOL CANCER THER, V11, P1936, DOI 10.1158/1535-7163.MCT-12-0146
   Anbalagan M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033017
   Anbalagan M, 2012, BREAST CANCER RES TR, V132, P391, DOI 10.1007/s10549-011-1513-3
   Antonarakis ES, 2013, CANCER CHEMOTH PHARM, V71, P883, DOI 10.1007/s00280-013-2079-z
   Bayliss J, 2007, CLIN CANCER RES, V13, P7029, DOI 10.1158/1078-0432.CCR-07-0587
   Belguise K, 2007, CANCER RES, V67, P5763, DOI 10.1158/0008-5472.CAN-06-4327
   Brinkman JA, 2009, J MAMMARY GLAND BIOL, V14, P67, DOI 10.1007/s10911-009-9113-0
   Bu Y, 2007, J BIOL CHEM, V282, P26725, DOI 10.1074/jbc.M702885200
   Bu YH, 2011, INT J CANCER, V128, P1836, DOI 10.1002/ijc.25524
   BYAR DP, 1979, EUR J CANCER, V15, P299, DOI 10.1016/0014-2964(79)90041-0
   CAILLEAU R, 1978, IN VITRO CELL DEV B, V14, P911
   CAILLEAU R, 1974, J NATL CANCER I, V53, P661, DOI 10.1093/jnci/53.3.661
   Chu I, 2007, J CLIN INVEST, V117, P2205, DOI 10.1172/JCI21739
   da Silva BB, 2010, EUR J GYNAECOL ONCOL, V31, P90
   Daftary GS, 2012, J BIOL CHEM, V287, P7010, DOI 10.1074/jbc.M111.266007
   Dasgupta A, 2016, SCI REP-UK, V6, DOI 10.1038/srep38045
   Dent R, 2007, CLIN CANCER RES, V13, P4429, DOI 10.1158/1078-0432.CCR-06-3045
   Duplessis TT, 2011, ENDOCRINOLOGY, V152, P2517, DOI 10.1210/en.2010-1281
   Elsberger B, 2009, AM J PATHOL, V175, P1389, DOI 10.2353/ajpath.2009.090273
   Fallah-Tafti A, 2011, EUR J MED CHEM, V46, P4853, DOI 10.1016/j.ejmech.2011.07.050
   Fan J, 2008, J CANCER RES CLIN, V134, P883, DOI 10.1007/s00432-008-0354-x
   Finn RS, 2007, BREAST CANCER RES TR, V105, P319, DOI 10.1007/s10549-006-9463-x
   Giacinti L, 2006, ONCOLOGIST, V11, P1, DOI 10.1634/theoncologist.11-1-1
   Hangauer D, 2010, DISCOVERY KX2 391 PH
   Hatsell S, 2003, J MAMMARY GLAND BIOL, V8, P145, DOI 10.1023/A:1025944723047
   Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104
   Keen JC, 2003, BREAST CANCER RES TR, V81, P177, DOI 10.1023/A:1026146524737
   Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005
   Lapidus RG, 1998, CANCER RES, V58, P2515
   Lapidus RG, 1998, J MAMMARY GLAND BIOL, V3, P85, DOI 10.1023/A:1018778403001
   Li X, 2017, ONCOTARGET, V8, P13560, DOI 10.18632/oncotarget.14593
   Li YY, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-9
   Liu Chun-Yu., 2014, BREAST CANCER RES, V16
   Liu XA, 2010, ACTA BIOCH BIOPH SIN, V42, P496, DOI 10.1093/abbs/gmq043
   Longworth MS, 2006, ONCOGENE, V25, P4495, DOI 10.1038/sj.onc.1209473
   MCGUIRE WL, 1978, SEMIN ONCOL, V5, P428
   Nam JS, 2002, CLIN CANCER RES, V8, P2430
   OTTAVIANO YL, 1994, CANCER RES, V54, P2552
   Ovcaricek T, 2011, RADIOL ONCOL, V45, P46, DOI 10.2478/v10019-010-0054-4
   Pattabiraman DR, 2016, SCIENCE, V351, P1042, DOI 10.1126/science.aad3680
   Qin G, 2015, ONCOTARGET, V6, P41794, DOI 10.18632/oncotarget.5993
   Raha P, 2011, EPIGENOMICS-UK, V3, P451, DOI [10.2217/epi.11.72, 10.2217/EPI.11.72]
   Rowan BG, 2003, METHOD ENZYMOL, V364, P173
   Sabnis GJ, 2011, CANCER RES, V71, P1893, DOI 10.1158/0008-5472.CAN-10-2458
   Santos-Rosa H, 2005, EUR J CANCER, V41, P2381, DOI 10.1016/j.ejca.2005.08.010
   Sharma D, 2005, MOL ENDOCRINOL, V19, P1740, DOI 10.1210/me.2004-0011
   Skliris GP, 2010, ENDOCR-RELAT CANCER, V17, P589, DOI 10.1677/ERC-10-0030
   Suzuki K, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.195362
   Tryfonopoulos D, 2011, ANN ONCOL, V22, P2234, DOI 10.1093/annonc/mdq757
   Wong AST, 2003, J CELL BIOL, V161, P1191, DOI 10.1083/jcb.200212033
   Yang XW, 2001, CANCER RES, V61, P7025
   Yang XW, 2000, CANCER RES, V60, P6890
   Ye Y, 2010, ONCOGENE, V29, P1451, DOI 10.1038/onc.2009.433
   Yoo CB, 2006, NAT REV DRUG DISCOV, V5, P37, DOI 10.1038/nrd1930
   Yu LZ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0050762
   Zhang WJ, 2011, ONCOL REP, V26, P621, DOI 10.3892/or.2011.1352
   Zhou Q, 2007, CANCER BIOL THER, V6, P64, DOI 10.4161/cbt.6.1.3549
   Zitvogel L, 2008, NAT REV IMMUNOL, V8, P59, DOI 10.1038/nri2216
NR 59
TC 12
Z9 14
U1 0
U2 9
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1541-7786
EI 1557-3125
J9 MOL CANCER RES
JI Mol. Cancer Res.
PD NOV
PY 2017
VL 15
IS 11
BP 1491
EP 1502
DI 10.1158/1541-7786.MCR-16-0297-T
PG 12
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA FL5CC
UT WOS:000414247700003
PM 28751463
OA Green Submitted, Bronze, Green Accepted
DA 2025-01-12
ER

PT J
AU Alkuhlani, A
   Nassef, M
   Farag, I
AF Alkuhlani, Alhasan
   Nassef, Mohammad
   Farag, Ibrahim
TI Multistage feature selection approach for high-dimensional cancer data
SO SOFT COMPUTING
LA English
DT Article
DE DNA methylation (DNAm); CpG sites; Feature selection; Genetic
   algorithms; Support vector machine (SVM); Incremental feature selection
   (IFS); Enrichment analysis
ID DNA METHYLATION; BREAST-CANCER; GENE SELECTION; CLASSIFICATION; ARRAY;
   IDENTIFICATION; RESISTANCE; ALGORITHM; LOCUS; RISK
AB Cancer is a serious disease that causes death worldwide. DNA methylation (DNAm) is an epigenetic mechanism, which controls the regulation of gene expression and is useful in early detection of cancer. The challenge with DNA methylation microarray datasets is the huge number of CpG sites compared to the number of samples. Recent research efforts attempted to reduce this high dimensionality by different feature selection techniques. This article proposes a multistage feature selection approach to select the optimal CpG sites from three different DNAm cancer datasets (breast, colon and lung). The proposed approach combines three different filter feature selection methods including Fisher Criterion, t-test and Area Under ROC Curve. In addition, as a wrapper feature selection, we apply genetic algorithms with Support Vector Machine Recursive Feature Elimination (SVM-RFE) as its fitness function, and SVM as its evaluator. Using the Incremental Feature Selection (IFS) strategy, subsets of 24, 13 and 27 optimal CpG sites are selected for the breast, colon and lung cancer datasets, respectively. By applying fivefold cross-validation on the training datasets, these subsets of optimal CpG sites showed perfect classification accuracies of 100, 100 and 97.67%, respectively. Moreover, the testing of the three independent cancer datasets by these final subsets resulted in accuracies 96.02, 98.81 and 94.51%, respectively. The experimental results demonstrated high classification performance and small optimal feature subsets. Consequently, the biological significance of the genes corresponding to these feature subsets is validated using enrichment analysis.
C1 [Alkuhlani, Alhasan; Nassef, Mohammad; Farag, Ibrahim] Cairo Univ, Fac Comp & Informat, Dept Comp Sci, Giza, Egypt.
C3 Egyptian Knowledge Bank (EKB); Cairo University
RP Alkuhlani, A (通讯作者)，Cairo Univ, Fac Comp & Informat, Dept Comp Sci, Giza, Egypt.
EM alhasan.alkuhlani@gmail.com
RI Nassef, Mohammad/ABC-9316-2021; Alkuhlani, Alhasan/IYS-7741-2023
OI Nassef, Mohammad/0000-0002-8903-6944; Alkuhlani,
   Alhasan/0000-0003-0725-9923
CR Al-Hussaini H, 2011, MOL CANCER THER, V10, P9, DOI 10.1158/1535-7163.MCT-10-0677
   [Anonymous], 2007, ARTIFICIAL INTELLIGE
   [Anonymous], 2005, 5 IEEE INT C DAT MIN
   [Anonymous], 2015, Bioinformatics
   [Anonymous], 2008, P 14 ACM SIGKDD INT
   Aryee MJ, 2014, BIOINFORMATICS, V30, P1363, DOI 10.1093/bioinformatics/btu049
   Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556
   Barat A, 2015, J CANCER, V6, P795, DOI 10.7150/jca.9883
   Bibikova M, 2011, GENOMICS, V98, P288, DOI 10.1016/j.ygeno.2011.07.007
   Bibikova M, 2009, EPIGENOMICS-UK, V1, P177, DOI 10.2217/EPI.09.14
   Birts CN, 2011, BIOL CELL, V103, P1, DOI 10.1042/BC20100067
   Blackmore JK, 2014, ENDOCRINOLOGY, V155, P3251, DOI 10.1210/en.2014-1002
   Huerta EB, 2010, NEUROCOMPUTING, V73, P2375, DOI 10.1016/j.neucom.2010.03.024
   Butterworth R, 2005, 5 IEEE INT C DAT MIN, P4
   Cai ZH, 2015, MOL BIOSYST, V11, P791, DOI 10.1039/c4mb00659c
   Chen YA, 2013, EPIGENETICS-US, V8, P203, DOI 10.4161/epi.23470
   Chen Z, 2014, NAT REV CANCER, V14, P535, DOI 10.1038/nrc3775
   Das PM, 2004, J CLIN ONCOL, V22, P4632, DOI 10.1200/JCO.2004.07.151
   Deng Y, 2012, MOL CARCINOGEN, V51, P500, DOI 10.1002/mc.20813
   Do HD, 2014, SCI REP-UK, V4, DOI 10.1038/srep04186
   Egger G, 2004, NATURE, V429, P457, DOI 10.1038/nature02625
   Ein-Dor L, 2005, BIOINFORMATICS, V21, P171, DOI 10.1093/bioinformatics/bth469
   Fan TWM, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-41
   Fang O.H., 2011, COMPUTER INFORM SCI, V4, P55, DOI [10.5539/cis.v4n2p55, DOI 10.5539/CIS.V4N2P55]
   Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210
   González-Navarro FF, 2014, COMPUT SIST, V18, P275, DOI 10.13053/CyS-18-2-2014-032
   George G, 2011, ARXIV11091062 ARXIV
   Gray-McGuire C, 2010, CANCER RES, V70, P5409, DOI 10.1158/0008-5472.CAN-10-0188
   Gu Q, 2012, ARXIV12023725 ARXIV
   Guo SC, 2015, CLIN EPIGENETICS, V7, DOI 10.1186/s13148-014-0035-3
   Guyon I, 2002, MACH LEARN, V46, P389, DOI 10.1023/A:1012487302797
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Jing L, 2010, WORLD ACAD SCI ENG T, V4, P258
   Kanehisa M, 2012, NUCLEIC ACIDS RES, V40, pD109, DOI 10.1093/nar/gkr988
   Kibriya MG, 2011, BMC MED GENOMICS, V4, DOI 10.1186/1755-8794-4-50
   Kou YB, 2015, ONCOTARGETS THER, V8, DOI 10.2147/OTT.S78974
   Laird PW, 2010, NAT REV GENET, V11, P191, DOI 10.1038/nrg2732
   Lee CP, 2011, APPL SOFT COMPUT, V11, P208, DOI 10.1016/j.asoc.2009.11.010
   Lee In-Hee, 2011, J Clin Bioinforma, V1, P11, DOI 10.1186/2043-9113-1-11
   Li BQ, 2012, PLOS ONE, V7
   Li BQ, 2012, PLOS ONE, V7
   Li JX, 2007, IEEE T INF TECHNOL B, V11, P398, DOI 10.1109/TITB.2007.892693
   Liu Y, 2006, NEOPLASIA, V8, P46, DOI 10.1593/neo.05586
   Luque-Baena RM, 2013, PROCEEDINGS IWBBIO 2013: INTERNATIONAL WORK-CONFERENCE ON BIOINFORMATICS AND BIOMEDICAL ENGINEERING, P55
   Ma ZY, 2013, J BIOINF COMPUT BIOL, V11, DOI 10.1142/S0219720013500054
   Malhotra R., 2011, Computer and Information Science, V4, P39, DOI DOI 10.5539/CIS.V4N2P39
   McCall J, 2005, J COMPUT APPL MATH, V184, P205, DOI 10.1016/j.cam.2004.07.034
   Meng HL, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-457
   Misman Muhammad Faiz, 2013, Trends and Applications in Knowledge Discovery and Data Mining. PAKDD 2013 International Workshops: DMApps, DANTH, QIMIE, BDM, CDA, CloudSD. Revised Selected Papers: LNCS 7867, P258, DOI 10.1007/978-3-642-40319-4_23
   Morimoto A, 2014, ONCOTARGET, V5, P7776, DOI 10.18632/oncotarget.2306
   Mosca E, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-S12-S8
   Müller-Tidow C, 2005, CANCER RES, V65, P1778, DOI 10.1158/0008-5472.CAN-04-3388
   Nexo BA, 2008, BMC MED GENET, V9, DOI 10.1186/1471-2350-9-56
   O'Byrne Kenneth J, 2011, Cancers (Basel), V3, P1550, DOI 10.3390/cancers3021550
   Saeys Y, 2008, LECT NOTES ARTIF INT, V5212, P313, DOI 10.1007/978-3-540-87481-2_21
   Saeys Y, 2007, BIOINFORMATICS, V23, P2507, DOI 10.1093/bioinformatics/btm344
   Sahu B, 2012, PROCEDIA ENGINEER, V38, P27, DOI 10.1016/j.proeng.2012.06.005
   Sastry K., 2005, GENETIC ALGORITHMS
   Spinola M, 2006, J CLIN ONCOL, V24, P1672, DOI 10.1200/JCO.2005.04.4339
   Stevenson L, 2012, CLIN CANCER RES, V18, P5412, DOI 10.1158/1078-0432.CCR-12-1780
   Stylianou S, 2006, CANCER RES, V66, P1517, DOI 10.1158/0008-5472.CAN-05-3054
   Uribarri M, 2014, J THORAC ONCOL, V9, P1504, DOI 10.1097/JTO.0000000000000282
   Valavanis Ioannis, 2015, Microarrays (Basel), V4, P647, DOI 10.3390/microarrays4040647
   Wei R, 2012, MOL CELL BIOCHEM, V359, P151, DOI 10.1007/s11010-011-1008-x
   Yao L, 2010, P INT C BIOM FUZZ SY
   Zhuang J, 2012, BMC BIOINFORMATICS, V13, DOI 10.1186/1471-2105-13-59
   Zou KH, 2007, CIRCULATION, V115, P654, DOI 10.1161/CIRCULATIONAHA.105.594929
NR 67
TC 20
Z9 20
U1 0
U2 29
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1432-7643
EI 1433-7479
J9 SOFT COMPUT
JI Soft Comput.
PD NOV
PY 2017
VL 21
IS 22
BP 6895
EP 6906
DI 10.1007/s00500-016-2439-9
PG 12
WC Computer Science, Artificial Intelligence; Computer Science,
   Interdisciplinary Applications
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Computer Science
GA FK0CG
UT WOS:000413147300023
DA 2025-01-12
ER

PT J
AU Kovalchuk, A
   Ilnytskyy, Y
   Rodriguez-Juarez, R
   Katz, A
   Sidransky, D
   Kolb, B
   Kovalchuk, O
AF Kovalchuk, Anna
   Ilnytskyy, Yaroslav
   Rodriguez-Juarez, Rocio
   Katz, Amanda
   Sidransky, David
   Kolb, Bryan
   Kovalchuk, Olga
TI Growth of malignant extracranial tumors alters microRNAome in the
   prefrontal cortex of TumorGraft mice
SO ONCOTARGET
LA English
DT Article
DE chemo brain; tumor brain; epigenetics; microRNA; Gerotarget
ID NEUROTROPHIC FACTOR; BREAST-CANCER; COGNITIVE FUNCTION; HIPPOCAMPAL
   NEUROGENESIS; CIRCULATING MICRORNAS; OXIDATIVE STRESS; GENE-EXPRESSION;
   DOWN-REGULATION; MIR-200 FAMILY; WORKING-MEMORY
AB A wide array of central nervous system complications, neurological deficits, and cognitive impairments occur and persist as a result of systemic cancer and cancer treatments. This condition is known as chemo brain and it affects over half of cancer survivors. Recent studies reported that cognitive impairments manifest before chemotherapy and are much broader than chemo brain alone, thereby adding in tumor brain as a component. The molecular mechanisms of chemo brain are under-investigated, and the mechanisms of tumor brain have not been analyzed at all. The frequency and timing, as well as the long-term persistence, of chemo brain and tumor brain suggest they may be epigenetic in nature. MicroRNAs, small, single-stranded non-coding RNAs, constitute an important part of the cellular epigenome and are potent regulators of gene expression. miRNAs are crucial for brain development and function, and are affected by a variety of different stresses, diseases and conditions. However, nothing is known about the effects of extracranial tumor growth or chemotherapy agents on the brain microRNAome.
   We used the well-established TumorGraft (TM) mouse models of triple negative (TNBC) and progesterone receptor positive (PR+BC) breast cancer, and profiled global microRNAome changes in tumor-bearing mice upon chemotherapy, as compared to untreated tumor-bearing mice and intact mice. Our analysis focused on the prefrontal cortex (PFC), based on its roles in memory, learning, and executive functions, and on published data showing the PFC is a target in chemo brain.
   This is the first study showing that tumor presence alone significantly impacted the small RNAome of PFC tissues. Both tumor growth and chemotherapy treatment affected the small RNAome and altered levels of miRNAs, piRNAs, tRNAs, tRNA fragments and other molecules involved in post-transcriptional regulation of gene expression. Amongst those, miRNA changes were the most pronounced, involving several miRNA families, such as the miR-200 family and miR-183/96/182 cluster; both were deregulated in tumor-bearing and chemotherapy-treated animals. We saw that miRNA deregulation was associated with altered levels of brain-derived neurotrophic factor (BDNF), which plays an important role in cognition and memory and is one of the known miRNA targets. BDNF downregulation has been associated with an array of neurological conditions and could be one of the mechanisms underlying tumor brain and chemo brain. In the future our study could serve as a roadmap for further analysis of cancer and chemotherapy's neural side effects, and differentially expressed miRNAs should be explored as potential tumor brain and chemo brain biomarkers.
C1 [Kovalchuk, Anna; Kolb, Bryan] Univ Lethbridge, Dept Neurosci, Lethbridge, AB, Canada.
   [Ilnytskyy, Yaroslav; Rodriguez-Juarez, Rocio; Kovalchuk, Olga] Univ Lethbridge, Dept Biol Sci, Lethbridge, AB, Canada.
   [Katz, Amanda; Sidransky, David] Champions Oncol, Dept Oncol, Baltimore, MD USA.
   [Kovalchuk, Anna] Univ Calgary, Cumming Sch Med, Med Program, Calgary, AB, Canada.
C3 University of Lethbridge; University of Lethbridge; University of
   Calgary
RP Kolb, B (通讯作者)，Univ Lethbridge, Dept Neurosci, Lethbridge, AB, Canada.; Kovalchuk, O (通讯作者)，Univ Lethbridge, Dept Biol Sci, Lethbridge, AB, Canada.
EM kolb@uleth.ca; olga.kovalchuk@uleth.ca
FU Alberta Cancer Foundation Dr. Cyril Kay Graduate Scholarship; Alberta
   Innovates-Health Solutions; Canada Vanier Graduate Scholarship; Canadian
   Institutes of Health Research grant
FX We thank Rommy Rodriguez-Juarez, Araba Sagoe, and Andrey Golubov for
   their technical support. Anna Kovalchuk was a recipient of the Alberta
   Cancer Foundation Dr. Cyril Kay Graduate Scholarship, Alberta
   Innovates-Health Solutions and Canada Vanier Graduate Scholarship. The
   research has been supported by a Canadian Institutes of Health Research
   grant held by Olga Kovalchuk and Bryan Kolb.
CR Ahles TA, 2002, J CLIN ONCOL, V20, P485, DOI 10.1200/JCO.2002.20.2.485
   Ahles TA, 2012, PSYCHO-ONCOLOGY, V21, P1141, DOI 10.1002/pon.3196
   Andreotti C, 2016, PSYCHO-ONCOLOGY, V25, P43, DOI 10.1002/pon.3799
   Aranha MM, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-514
   Baydyuk M, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00254
   Bertotti A, 2011, CANCER DISCOV, V1, P508, DOI 10.1158/2159-8290.CD-11-0109
   Bondar NP, 2016, J BIOSCIENCES, V41, P751, DOI 10.1007/s12038-016-9648-3
   Boyerinas B, 2010, ENDOCR-RELAT CANCER, V17, pF19, DOI 10.1677/ERC-09-0184
   Bredy TW, 2011, NEUROBIOL LEARN MEM, V96, P89, DOI 10.1016/j.nlm.2011.04.004
   Briones TL, 2011, BMC NEUROSCI, V12, DOI 10.1186/1471-2202-12-124
   Caserta S, 2016, SCI REP-UK, V6, DOI 10.1038/srep28006
   Cheung YT, 2015, ANN ONCOL, V26, P1446, DOI 10.1093/annonc/mdv206
   Christie LA, 2012, CLIN CANCER RES, V18, P1954, DOI 10.1158/1078-0432.CCR-11-2000
   Cosín-Tomás M, 2017, MOL NEUROBIOL, V54, P5550, DOI 10.1007/s12035-016-0088-8
   Dasdag S, 2015, INT J RADIAT BIOL, V91, P555, DOI 10.3109/09553002.2015.1028599
   Deng YP, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-S11-S1
   DeRose YS, 2011, NAT MED, V17, P1514, DOI 10.1038/nm.2454
   Díez-Planelles C, 2016, PHARMACOL RES, V108, P102, DOI 10.1016/j.phrs.2016.05.005
   Esquela-Kerscher A, 2008, CELL CYCLE, V7, P759, DOI 10.4161/cc.7.6.5834
   Feng B, 2014, ASIAN PAC J CANCER P, V15, P4079, DOI 10.7314/APJCP.2014.15.9.4079
   Fiorenza A, 2016, NEUROBIOL LEARN MEM, V135, P3, DOI 10.1016/j.nlm.2016.05.001
   Guedes J, 2013, CLIN DEV IMMUNOL, DOI 10.1155/2013/186872
   Harris NM, 2016, PHARMACOL BIOCHEM BE, V150, P48, DOI 10.1016/j.pbb.2016.09.003
   Hébert SS, 2010, HUM MOL GENET, V19, P3959, DOI 10.1093/hmg/ddq311
   Hicks SD, 2016, FRONT PSYCHIATRY, V7, DOI 10.3389/fpsyt.2016.00176
   Hidalgo M, 2011, MOL CANCER THER, V10, P1311, DOI 10.1158/1535-7163.MCT-11-0233
   HOHN A, 1990, NATURE, V344, P339, DOI 10.1038/344339a0
   Howng SYB, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126667
   Ivakhnitskaia E, 2016, DEV GROWTH DIFFER, V58, P88, DOI 10.1111/dgd.12259
   Jafari N, 2015, J CLIN NEUROSCI, V22, P200, DOI 10.1016/j.jocn.2014.06.106
   Jehn CF, 2015, J NEUROIMMUNOL, V287, P88, DOI 10.1016/j.jneuroim.2015.08.012
   Jeyaseelan K, 2008, STROKE, V39, P959, DOI 10.1161/STROKEAHA.107.500736
   Johnson SM, 2005, CELL, V120, P635, DOI 10.1016/j.cell.2005.01.014
   Joshi G, 2010, NEUROSCIENCE, V166, P796, DOI 10.1016/j.neuroscience.2010.01.021
   Kaiser J, 2014, CORTEX, V54, P33, DOI 10.1016/j.cortex.2014.01.010
   Karthikeyan A, 2016, CURR MED CHEM, V23, P3528, DOI 10.2174/0929867323666160814001040
   Karube Y, 2005, CANCER SCI, V96, P111, DOI 10.1111/j.1349-7006.2005.00015.x
   Kim J, 2007, SCIENCE, V317, P1220, DOI 10.1126/science.1140481
   Kitamura Y, 2015, BEHAV BRAIN RES, V292, P184, DOI 10.1016/j.bbr.2015.06.007
   Koch MW, 2013, TRENDS MOL MED, V19, P23, DOI 10.1016/j.molmed.2012.10.008
   Kolb B, 2012, P NATL ACAD SCI USA, V109, P17186, DOI 10.1073/pnas.1121251109
   Koppelmans V, 2014, HUM BRAIN MAPP, V35, P889, DOI 10.1002/hbm.22221
   Koppelmans V, 2012, BREAST CANCER RES TR, V132, P1099, DOI 10.1007/s10549-011-1888-1
   Koppelmans V, 2012, J CLIN ONCOL, V30, P1080, DOI 10.1200/JCO.2011.37.0189
   Korpal M, 2008, J BIOL CHEM, V283, P14910, DOI 10.1074/jbc.C800074200
   Koturbash I, 2011, MUTAT RES-GEN TOX EN, V722, P114, DOI 10.1016/j.mrgentox.2010.05.007
   Kovalchuk A, 2016, FRONT BEHAV NEUROSCI, V10, DOI 10.3389/fnbeh.2016.00084
   Kovalchuk A, 2016, AGING-US, V8, P697, DOI 10.18632/aging.100920
   Kovalchuk A, 2016, ONCOTARGET, V7, P4385, DOI 10.18632/oncotarget.6596
   Krishnan P, 2015, BMC GENOMICS, V16, DOI 10.1186/s12864-015-1899-0
   Kumar MS, 2008, P NATL ACAD SCI USA, V105, P3903, DOI 10.1073/pnas.0712321105
   Kumar S, 2016, BBA-MOL BASIS DIS, V1862, P1617, DOI 10.1016/j.bbadis.2016.06.001
   Langmead B, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-3-r25
   Lara AH, 2015, FRONT SYST NEUROSCI, V9, DOI 10.3389/fnsys.2015.00173
   Leung WKC, 2015, CANCER LETT, V362, P97, DOI 10.1016/j.canlet.2015.03.023
   Li GR, 2009, MECH AGEING DEV, V130, P731, DOI 10.1016/j.mad.2009.09.002
   Li HY, 2015, MOL MED REP, V12, P2793, DOI 10.3892/mmr.2015.3736
   Li P, 2014, BREAST CANCER RES, V16, DOI 10.1186/s13058-014-0473-z
   Li P, 2016, NEURAL PLAST, V2016, DOI 10.1155/2016/1279051
   Liu Jie, 2011, J Biomed Sci Eng, V4, P666
   Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8
   Lu Y, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006159
   Lukiw WJ, 2007, NEUROREPORT, V18, P297, DOI 10.1097/WNR.0b013e3280148e8b
   Luo HX, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101725
   Luoni A, 2016, PHARMACOL THERAPEUT, V167, P13, DOI 10.1016/j.pharmthera.2016.07.006
   Ma J, 2016, AM J TRANSL RES, V8, P1895
   Magenta A, 2011, CELL DEATH DIFFER, V18, P1628, DOI 10.1038/cdd.2011.42
   Majer A, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169081
   Martinez B, 2016, NEURAL REGEN RES, V11, P1375, DOI 10.4103/1673-5374.191196
   Masliah-Planchon J, 2016, ONCOTARGET, V7, P38892, DOI 10.18632/oncotarget.6476
   Mendes-Silva AP, 2016, AM J GERIAT PSYCHIAT, V24, P903, DOI 10.1016/j.jagp.2016.07.017
   Mercader JM, 2012, GENE, V497, P181, DOI 10.1016/j.gene.2012.01.057
   Meydan C, 2016, TRENDS MOL MED, V22, P798, DOI 10.1016/j.molmed.2016.07.001
   Miska EA, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-9-r68
   Mitre M, 2017, CLIN SCI, V131, P13, DOI 10.1042/CS20160044
   Mustafa S, 2008, EUR J NEUROSCI, V28, P323, DOI 10.1111/j.1460-9568.2008.06325.x
   Myers JS, 2008, ONCOL NURS FORUM, V35, P916, DOI 10.1188/08.ONF.916-920
   Myers Jamie S, 2012, Oncol Nurs Forum, V39, pE31, DOI 10.1188/12.ONF.E31-E40
   Myers JS, 2010, ADV EXP MED BIOL, V678, P55
   Narayanan V, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0158838
   Olson K, 2016, SUPPORT CARE CANCER, V24, P3223, DOI 10.1007/s00520-016-3215-1
   Pandey A, 2015, J NEUROCHEM, V133, P640, DOI 10.1111/jnc.13089
   Pereira P., 2016, WILEY INTERDISCIP RE
   Morelli MP, 2012, J CLIN ONCOL, V30, pE45, DOI 10.1200/JCO.2011.36.9678
   Radhakrishnan B, 2016, J EXP NEUROSCI, V10, P101, DOI 10.4137/JEN.S32843
   Reinhart BJ, 2000, NATURE, V403, P901, DOI 10.1038/35002607
   Ristori E, 2015, DEV CELL, V32, P546, DOI 10.1016/j.devcel.2014.12.013
   Saab BJ, 2014, NEUROPHARMACOLOGY, V80, P61, DOI 10.1016/j.neuropharm.2014.01.026
   Saleh AD, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024429
   Santarelli DM, 2011, BIOL PSYCHIAT, V69, P180, DOI 10.1016/j.biopsych.2010.09.030
   Saurat N, 2013, NEURAL DEV, V8, DOI 10.1186/1749-8104-8-14
   Seigers R, 2015, PSYCHOPHARMACOLOGY, V232, P17, DOI 10.1007/s00213-014-3636-9
   Seigers R, 2011, NEUROSCI BIOBEHAV R, V35, P729, DOI 10.1016/j.neubiorev.2010.09.006
   Sempere LF, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-3-r13
   Senfter Daniel, 2016, BioMolecular Concepts, V7, P311, DOI 10.1515/bmc-2016-0020
   Shruthi S, 2017, NEURODEGENER DIS, V17, P44, DOI 10.1159/000447559
   Silasi G, 2004, BIOCHEM BIOPH RES CO, V325, P1223, DOI 10.1016/j.bbrc.2004.10.166
   Song H, 2016, J PHYSIOL BIOCHEM, V72, P733, DOI 10.1007/s13105-016-0512-6
   Song JH, 2015, MOL NEUROBIOL, V52, P1477, DOI 10.1007/s12035-014-8958-4
   Stebbing J, 2014, CANCER-AM CANCER SOC, V120, P2006, DOI 10.1002/cncr.28696
   Tang HL, 2013, CURR CANCER DRUG TAR, V13, P221, DOI 10.2174/1568009611313020010
   Tanno B, 2016, ONCOTARGET, V7, P68253, DOI 10.18632/oncotarget.11938
   Toledano H, 2013, EXP GERONTOL, V48, P667, DOI 10.1016/j.exger.2012.08.006
   Vardy J, 2007, CRIT REV ONCOL HEMAT, V63, P183, DOI 10.1016/j.critrevonc.2007.06.001
   Varendi K, 2014, CELL MOL LIFE SCI, V71, P4443, DOI 10.1007/s00018-014-1628-x
   Wang WY, 2012, LEARN MEMORY, V19, P359, DOI 10.1101/lm.026492.112
   Wang XM, 2015, CYTOKINE, V72, P86, DOI 10.1016/j.cyto.2014.12.006
   Wang Y, 2016, PARKINSONISM RELAT D, V29, P66, DOI 10.1016/j.parkreldis.2016.05.023
   Wang ZK, 2016, NEURAL REGEN RES, V11, P262, DOI 10.4103/1673-5374.177734
   Wefel JS, 2011, LANCET ONCOL, V12, P703, DOI 10.1016/S1470-2045(10)70294-1
   Weidhaas JB, 2007, CANCER RES, V67, P11111, DOI 10.1158/0008-5472.CAN-07-2858
   Wu YF, 2016, ONCOTARGET, V7, P85975, DOI 10.18632/oncotarget.13291
   Yang M, 2012, BRAIN RES BULL, V89, P50, DOI 10.1016/j.brainresbull.2012.07.003
   Ye XY, 2015, FRONT AGING NEUROSCI, V7, DOI 10.3389/fnagi.2015.00210
   Yu D, 2014, J MOL NEUROSCI, V53, P242, DOI 10.1007/s12031-014-0293-8
   Zeng Y, 2015, INT J MOL MED, V36, P1639, DOI 10.3892/ijmm.2015.2367
   Zuberi M, 2015, CLIN TRANSL ONCOL, V17, P779, DOI 10.1007/s12094-015-1303-1
NR 117
TC 9
Z9 9
U1 1
U2 10
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD OCT 24
PY 2017
VL 8
IS 51
BP 88276
EP 88293
DI 10.18632/oncotarget.19835
PG 18
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA FK6AP
UT WOS:000413585600006
PM 29179434
OA gold, Green Published, Green Submitted
DA 2025-01-12
ER

PT J
AU Kwon, HM
   Kang, EJ
   Kang, K
   Kim, SD
   Yang, K
   Yi, JM
AF Kwon, Hyun-Mi
   Kang, Eun-Jin
   Kang, Keunsoo
   Kim, Sung-Dae
   Yang, Kwangmo
   Yi, Joo Mi
TI Combinatorial effects of an epigenetic inhibitor and ionizing radiation
   contribute to targeted elimination of pancreatic cancer stem cell
SO ONCOTARGET
LA English
DT Article
DE DNA methylation inhibitor; radiation; pancreatic cancer; cancer stem
   cell
ID BREAST-CANCER; DRUG-RESISTANCE; IN-VITRO; RNA-SEQ; IDENTIFICATION;
   RADIOSENSITIVITY; ENHANCEMENT; SURVIVIN; MARKER; GENES
AB Pancreatic cancer is associated with a high mortality rate, owing to de novo and acquired drug resistance, thereby leading to highly invasive and metastatic pancreatic cancer cells. Therefore, targeting pancreatic cancer stem cells (CSCs) may be a novel therapeutic strategy for the treatment of pancreatic cancer. Here, we combined a DNA methylation inhibitor (5-aza-2'-deoxycytidine; 5-aza-dC) and ionizing radiation (IR) to improve anti-cancer effects by inhibiting growth and proliferation and promoting apoptosis of pancreatic cancer cells in vitro and in vivo. Importantly, the combinatorial effect of 5-aza-dC with IR on sphere-forming pancreatic cancer cells was preferentially targeted toward CSCs through the downregulation of regulatory factors of self-renewal and CSC surface markers. We next performed the RNA sequencing to understand the underlying cellular mechanisms of the combined treatment with IR and 5-aza-dC in pancreatic cancer cells. Global transcriptome profiling indicated that the expression of the Oct4-centered transcriptional network of genes was significantly downregulated in cells with combination treatment. Our data suggested that combination treatment with DNA methylation inhibitor and IR may be a novel therapeutic strategy for pancreatic cancer. Overall, these findings support the use of epigenetic therapy in combination with radiotherapy to improve therapeutic efficacy by targeting and eradicating pancreatic CSCs.
C1 [Kwon, Hyun-Mi; Kang, Eun-Jin; Kim, Sung-Dae; Yang, Kwangmo; Yi, Joo Mi] DIRAMS, Res Ctr, Busan 46033, South Korea.
   [Kang, Keunsoo] Dankook Univ, Dept Microbiol, Cheonan 31116, South Korea.
C3 Korea Institute of Radiological & Medical Sciences; Dankook University
RP Yi, JM (通讯作者)，DIRAMS, Res Ctr, Busan 46033, South Korea.
EM jmyi@dirams.re.kr
RI Kang, Keunsoo/AFM-7746-2022
FU Dongnam Institute of Radiological & Medical Sciences (DIRAMS) grant -
   Korea government (Ministry of Science and ICT; MSIT) [50595-2017]
FX This study was supported by the Dongnam Institute of Radiological &
   Medical Sciences (DIRAMS) grant funded by the Korea government (Ministry
   of Science and ICT; MSIT) (50595-2017).
CR Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100
   Bae JH, 2015, BMC GENOMICS, V16, DOI 10.1186/s12864-015-1229-6
   Baumann M, 2008, NAT REV CANCER, V8, P545, DOI 10.1038/nrc2419
   Bolger AM, 2014, BIOINFORMATICS, V30, P2114, DOI 10.1093/bioinformatics/btu170
   Charafe-Jauffret E, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-202
   Chikamatsu K, 2013, CANCER SCI, V104, P1468, DOI 10.1111/cas.12271
   De Schutter H, 2009, INT J RADIAT ONCOL, V73, P904, DOI 10.1016/j.ijrobp.2008.10.032
   Dean M, 2005, NAT REV CANCER, V5, P275, DOI 10.1038/nrc1590
   Diehn M, 2006, J NATL CANCER I, V98, P1755, DOI 10.1093/jnci/djj505
   Dote H, 2005, CLIN CANCER RES, V11, P4571, DOI 10.1158/1078-0432.CCR-05-0050
   Duffy MJ, 2007, CANCER LETT, V249, P49, DOI 10.1016/j.canlet.2006.12.020
   Feng JX, 2012, BIOINFORMATICS, V28, P2782, DOI 10.1093/bioinformatics/bts515
   Gidekel S, 2003, CANCER CELL, V4, P361, DOI 10.1016/S1535-6108(03)00270-8
   Ginestier C, 2007, CELL STEM CELL, V1, P555, DOI 10.1016/j.stem.2007.08.014
   Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075
   Hermann PC, 2007, CELL STEM CELL, V1, P313, DOI 10.1016/j.stem.2007.06.002
   Holohan C, 2013, NAT REV CANCER, V13, P714, DOI 10.1038/nrc3599
   Hong SP, 2009, INT J CANCER, V125, P2323, DOI 10.1002/ijc.24573
   Ishii H, 2008, CANCER SCI, V99, P1871, DOI 10.1111/j.1349-7006.2008.00914.x
   Jemal Ahmedin, 2011, CA Cancer J Clin, V61, P69, DOI 10.3322/caac.20107
   Jin TR, 1999, INT J CANCER, V81, P104, DOI 10.1002/(SICI)1097-0215(19990331)81:1<104::AID-IJC18>3.0.CO;2-Q
   Kaminskas E, 2005, CLIN CANCER RES, V11, P3604, DOI 10.1158/1078-0432.CCR-04-2135
   KAUFMANN SH, 1993, CANCER RES, V53, P3976
   Kelly TK, 2010, NAT BIOTECHNOL, V28, P1069, DOI 10.1038/nbt.1678
   Kim D, 2015, NAT METHODS, V12, P357, DOI [10.1038/NMETH.3317, 10.1038/nmeth.3317]
   Kim HJ, 2012, RADIAT ONCOL, V7, DOI 10.1186/1748-717X-7-39
   Krejs GJ, 2010, DIGEST DIS, V28, P355, DOI 10.1159/000319414
   Kristensen LS, 2009, EUR J PHARMACOL, V625, P131, DOI 10.1016/j.ejphar.2009.10.011
   Lee J, 2006, J BIOL CHEM, V281, P33554, DOI 10.1074/jbc.M603937200
   Lee TI, 2006, CELL, V125, P301, DOI 10.1016/j.cell.2006.02.043
   Levina V, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003077
   Li CW, 2007, CANCER RES, V67, P1030, DOI 10.1158/0008-5472.CAN-06-2030
   Li CG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049693
   Li YW, 2013, CANCER LETT, V338, P94, DOI 10.1016/j.canlet.2012.03.018
   Lin L, 2016, INT J ONCOL, V49, P2265, DOI 10.3892/ijo.2016.3728
   Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027
   Morel AP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002888
   Okamoto K, 2012, MOL CANCER THER, V11, P204, DOI 10.1158/1535-7163.MCT-11-0638
   Ponti D, 2005, CANCER RES, V65, P5506, DOI 10.1158/0008-5472.CAN-05-0626
   Qiu H, 2009, CANCER SCI, V100, P181, DOI 10.1111/j.1349-7006.2008.01004.x
   Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167
   Salvador MA, 2013, CLIN CANCER RES, V19, P6520, DOI 10.1158/1078-0432.CCR-13-0877
   Singh SK, 2003, CANCER RES, V63, P5821
   Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128
   Tan BT, 2006, LAB INVEST, V86, P1203, DOI 10.1038/labinvest.3700488
   Tang YA, 2015, NUCLEIC ACIDS RES, V43, P1593, DOI 10.1093/nar/gkv024
   TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3
   Trabulo S, 2011, MOL PHARMACEUT, V8, P1120, DOI 10.1021/mp100426e
   VANGROENINGEN CJ, 1986, CANCER RES, V46, P4831
   Wang L, 2013, CANCER BIOTHER RADIO, V28, P34, DOI 10.1089/cbr.2012.1170
   Wang Z, 2009, NAT REV GENET, V10, P57, DOI 10.1038/nrg2484
   Yoo CB, 2006, NAT REV DRUG DISCOV, V5, P37, DOI 10.1038/nrd1930
   Yuan FJ, 2010, MOL CELL BIOCHEM, V343, P155, DOI 10.1007/s11010-010-0509-3
NR 53
TC 22
Z9 24
U1 0
U2 8
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD OCT 24
PY 2017
VL 8
IS 51
BP 89005
EP 89020
DI 10.18632/oncotarget.21642
PG 16
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA FK6AP
UT WOS:000413585600066
PM 29179494
OA gold, Green Submitted, Green Published
DA 2025-01-12
ER

PT J
AU Singh, S
   Narayanan, SP
   Biswas, K
   Gupta, A
   Ahuja, N
   Yadav, S
   Panday, RK
   Samaiya, A
   Sharan, SK
   Shukla, S
AF Singh, Smriti
   Narayanan, Sathiya Pandi
   Biswas, Kajal
   Gupta, Amit
   Ahuja, Neha
   Yadav, Sandhya
   Panday, Rajendra Kumar
   Samaiya, Atul
   Sharan, Shyam K.
   Shukla, Sanjeev
TI Intragenic DNA methylation and BORIS-mediated cancer-specific splicing
   contribute to the Warburg effect
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE alternative splicing; BORIS; DNA methylation; cancer; Warburg effect
ID DE-NOVO METHYLATION; PYRUVATE-KINASE; METABOLIC REQUIREMENTS; ISOFORM;
   GENE; CTCF; M2; TRANSCRIPTION; EXPRESSION; APOPTOSIS
AB Aberrant alternative splicing and epigenetic changes are both associated with various cancers, but epigenetic regulation of alternative splicing in cancer is largely unknown. Here we report that the intragenic DNA methylation-mediated binding of Brother of Regulator of Imprinted Sites (BORIS) at the alternative exon of Pyruvate Kinase (PKM) is associated with cancer-specific splicing that promotes the Warburg effect and breast cancer progression. Interestingly, the inhibition of DNA methylation, BORIS depletion, or CRISPR/Cas9-mediated deletion of the BORIS binding site leads to a splicing switch from cancer-specific PKM2 to normal PKM1 isoform. This results in the reversal of the Warburg effect and the inhibition of breast cancer cell growth, which may serve as a useful approach to inhibit the growth of breast cancer cells. Importantly, our results show that in addition to PKM splicing, BORIS also regulates the alternative splicing of several genes in a DNA methylation-dependent manner. Our findings highlight the role of intragenic DNA methylation and DNA binding protein BORIS in cancer-specific splicing and its role in tumorigenesis.
C1 [Singh, Smriti; Narayanan, Sathiya Pandi; Gupta, Amit; Ahuja, Neha; Shukla, Sanjeev] Indian Inst Sci Educ & Res, Dept Biol Sci, Bhopal 462066, Madhya Pradesh, India.
   [Biswas, Kajal; Sharan, Shyam K.] NCI, Ctr Canc Res, Frederick, MD 21702 USA.
   [Panday, Rajendra Kumar] Navodaya Canc Hosp, Unit Radiotherapy, Bhopal 462022, Madhya Pradesh, India.
   [Panday, Rajendra Kumar] Bansal Hosp, Dept Radiotherapy, Bhopal 462016, Madhya Pradesh, India.
   [Samaiya, Atul] NCH, Unit Surg Oncol, Bhopal 462022, Madhya Pradesh, India.
   [Samaiya, Atul] BH, Dept Surg Oncol, Bhopal 462016, Madhya Pradesh, India.
   [Narayanan, Sathiya Pandi] Univ Michigan, Dept Pathol, Michigan Ctr Translat Pathol, Ann Arbor, MI 48109 USA.
C3 Indian Institute of Science Education & Research (IISER) - Bhopal;
   National Institutes of Health (NIH) - USA; NIH National Cancer Institute
   (NCI); University of Michigan System; University of Michigan
RP Shukla, S (通讯作者)，Indian Inst Sci Educ & Res, Dept Biol Sci, Bhopal 462066, Madhya Pradesh, India.
EM sanjeevs@iiserb.ac.in
RI Gupta, Amit/ABI-1617-2020; Narayanan, Sathiya Pandi/AFS-0744-2022;
   Shukla, Sanjeev/L-8391-2018; Singh, Smriti/LTF-1452-2024
OI Yadav, Sandhya/0000-0002-0443-2439; Shukla, Sanjeev/0000-0003-3361-0588;
   Biswas, Kajal/0000-0003-2645-9349; Singh, Smriti/0000-0001-5731-7285;
   Sathiya Pandi, Narayanan/0000-0001-6307-0493; Gupta,
   Amit/0000-0003-3752-5081
FU Science and Engineering Research Board (SERB) [EMR/2014/000716];
   Wellcome Trust/Department of Biotechnology (DBT) India
   [IA/I/16/2/502719]; Indian Institute of Science Education and Research
   Bhopal; Council of Scientific and Industrial Research; SERB
   [PDF/2015/000560]
FX We thank N. Kalra for critical reading of this manuscript. This work is
   supported by Science and Engineering Research Board (SERB) Grant
   EMR/2014/000716 and Wellcome Trust/Department of Biotechnology (DBT)
   India Alliance Fellowship Grant IA/I/16/2/502719 (to S. Shukla). S.
   Singh and A.G. were supported by an Indian Institute of Science
   Education and Research Bhopal fellowship. N.A. and S.Y. were supported
   by a Council of Scientific and Industrial Research fellowship. S.P.N.
   was supported by SERB-National Postdoctoral Fellowship PDF/2015/000560.
CR Chen M, 2012, NAT STRUCT MOL BIOL, V19, P346, DOI 10.1038/nsmb.2219
   Christman JK, 2002, ONCOGENE, V21, P5483, DOI 10.1038/sj.onc.1205699
   Christofk HR, 2008, NATURE, V452, P230, DOI 10.1038/nature06734
   Clower CV, 2010, P NATL ACAD SCI USA, V107, P1894, DOI 10.1073/pnas.0914845107
   D'Arcy V, 2008, BRIT J CANCER, V98, P571, DOI 10.1038/sj.bjc.6604181
   David CJ, 2010, NATURE, V463, P364, DOI 10.1038/nature08697
   Desai S, 2014, ONCOTARGET, V5, P8202, DOI 10.18632/oncotarget.1159
   Dougherty CJ, 2008, BIOCHEM BIOPH RES CO, V370, P109, DOI 10.1016/j.bbrc.2008.03.040
   Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210
   Feron O, 2009, RADIOTHER ONCOL, V92, P329, DOI 10.1016/j.radonc.2009.06.025
   Girault I, 2003, CLIN CANCER RES, V9, P4415
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809
   Lee JW, 2008, INT J BIOCHEM CELL B, V40, P1043, DOI 10.1016/j.biocel.2007.11.009
   Linhart HG, 2007, GENE DEV, V21, P3110, DOI 10.1101/gad.1594007
   Link Petra A, 2013, Cancer Immun, V13, P6
   Lu C, 2012, CELL METAB, V16, P9, DOI 10.1016/j.cmet.2012.06.001
   Lunt SY, 2011, ANNU REV CELL DEV BI, V27, P441, DOI 10.1146/annurev-cellbio-092910-154237
   Maor GL, 2015, TRENDS GENET, V31, P274, DOI 10.1016/j.tig.2015.03.002
   Martin-Kleiner I, 2012, EUR J CANCER, V48, P929, DOI 10.1016/j.ejca.2011.09.009
   Maunakea AK, 2013, CELL RES, V23, P1256, DOI 10.1038/cr.2013.110
   Menafra R, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099603
   Naftelberg S, 2015, ANNU REV BIOCHEM, V84, P165, DOI 10.1146/annurev-biochem-060614-034242
   Nguyen P, 2008, CANCER RES, V68, P5546, DOI 10.1158/0008-5472.CAN-08-1005
   NOGUCHI T, 1986, J BIOL CHEM, V261, P3807
   Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6
   Oltean S, 2014, ONCOGENE, V33, P5311, DOI 10.1038/onc.2013.533
   Phillips JE, 2009, CELL, V137, P1194, DOI 10.1016/j.cell.2009.06.001
   Pugacheva EM, 2015, GENOME BIOL, V16, DOI 10.1186/s13059-015-0736-8
   Roll JD, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-15
   Ruckenstuhl C, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004592
   Shukla S, 2012, BBA-GENE REGUL MECH, V1819, P673, DOI 10.1016/j.bbagrm.2012.01.014
   Shukla S, 2011, NATURE, V479, P74, DOI 10.1038/nature10442
   Sleutels F, 2012, EPIGENET CHROMATIN, V5, DOI 10.1186/1756-8935-5-8
   van Hoesel AQ, 2013, BRIT J CANCER, V108, P2033, DOI 10.1038/bjc.2013.136
   Wang ZX, 2012, J MOL CELL BIOL, V4, P79, DOI 10.1093/jmcb/mjr030
   WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309
   Yang WW, 2013, CANCER LETT, V339, P153, DOI 10.1016/j.canlet.2013.06.008
   Yearim A, 2015, CELL REP, V10, P1122, DOI 10.1016/j.celrep.2015.01.038
   Zhang YM, 2017, SCI REP-UK, V7, DOI 10.1038/srep40786
NR 40
TC 54
Z9 59
U1 0
U2 9
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD OCT 24
PY 2017
VL 114
IS 43
BP 11440
EP 11445
DI 10.1073/pnas.1708447114
PG 6
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA FK5EN
UT WOS:000413520700063
PM 29073069
OA Bronze, Green Published
DA 2025-01-12
ER

PT J
AU Ahmad, R
   Kumar, B
   Pan, KC
   Dhawan, P
   Singh, AB
AF Ahmad, Rizwan
   Kumar, Balawant
   Pan, Kaichao
   Dhawan, Punita
   Singh, Amar B.
TI HDAC-4 regulates claudin-2 expression in EGFR-ERK1/2 dependent manner to
   regulate colonic epithelial cell differentiation
SO ONCOTARGET
LA English
DT Article
DE epigenetic regulation; differentiation; colon cancer; cell cycle;
   claudin
ID METASTATIC COLORECTAL-CANCER; BREAST-CANCER; STEM-CELLS; PERMEABILITY;
   BUTYRATE; GROWTH; INDUCTION; MUTATION; TIGHT; PROLIFERATION
AB In normal colon, claudin-2 expression is restricted to the crypt bottom containing the undifferentiated and proliferative colonocytes. Claudin-2 expression is also upregulated in colorectal cancer (CRC) and promotes carcinogenesis. However, cellular mechanism/s regulated by increased claudin-2 expression during the CRC and mechanism/s regulating this increase remain poorly understood. Epigenetic mechanisms help regulate expression of cancer-associated genes and inhibition of Histone Deacetylases (HDACs) induces cell cycle arrest and differentiation. Accordingly, based on a comprehensive in vitro and in vivo analysis we here report that Histone Deacetylases regulate claudin-2 expression in causal association with colonocyte dedifferentiation to promote CRC. Detailed differentiation analyses using colon cancer cells demonstrated inverse association between claudin-2 expression and epithelial differentiation. Genetic manipulation studies revealed the causal role of HDAC-4 in regulating claudin-2 expression during this process. Further analysis identified transcriptional regulation as the underlying mechanism, which was dependent on HDAC-4 dependent modulation of the EGFR-ERK1/2 signaling. Accordingly, colon tumors demonstrated marked upregulation of the HDAC-4/ERK1/2/Claudin-2 signaling. Taken together, we demonstrate a novel role for HDAC4/EGFR/ERK1/2 signaling in regulating claudin-2 expression to modulate colonocyte differentiation. These findings are of clinical significance and highlight epigenetic regulation as potential mechanism to regulate claudin-2 expression during mucosal pathologies including CRC.
C1 [Ahmad, Rizwan; Kumar, Balawant; Pan, Kaichao; Dhawan, Punita; Singh, Amar B.] Univ Nebraska Med Ctr, Dept Biochem & Mol Biol, Omaha, NE 68198 USA.
   [Dhawan, Punita; Singh, Amar B.] VA Nebraska Western Iowa Hlth Care Syst, Omaha, NE 68105 USA.
C3 University of Nebraska System; University of Nebraska Medical Center; US
   Department of Veterans Affairs; Veterans Health Administration (VHA); VA
   Nebraska-Western Iowa Health Care System
RP Singh, AB (通讯作者)，Univ Nebraska Med Ctr, Dept Biochem & Mol Biol, Omaha, NE 68198 USA.; Singh, AB (通讯作者)，VA Nebraska Western Iowa Hlth Care Syst, Omaha, NE 68105 USA.
EM amar.singh@unmc.edu
RI Kumar, Balawant/AAW-9616-2021
OI kumar, Balawant/0000-0002-8187-3078
FU  [BX002086];  [DK088902];  [BX002761]
FX This work was supported by BX002086 (P.D.), DK088902 and BX002761
   (A.B.S.).
CR Ahmad R, 2017, MUCOSAL IMMUNOL, V10, P307, DOI 10.1038/mi.2016.128
   Ahmad R, 2014, MUCOSAL IMMUNOL, V7, P1340, DOI 10.1038/mi.2014.21
   Ahmad R, 2017, ONCOGENE
   Barker N, 2007, NATURE, V449, P1003, DOI 10.1038/nature06196
   Becker C, 2006, NAT PROTOC, V1, P2900, DOI 10.1038/nprot.2006.446
   Bhat AA, 2015, ONCOGENE, V34, P4570, DOI 10.1038/onc.2014.385
   Boireau S, 2007, CARCINOGENESIS, V28, P246, DOI 10.1093/carcin/bgl120
   Buckley AF, 2008, AM J CLIN PATHOL, V129, P245, DOI 10.1309/WF10QAAED3PP93BH
   Buzza MS, 2010, P NATL ACAD SCI USA, V107, P4200, DOI 10.1073/pnas.0903923107
   CHANTRET I, 1988, CANCER RES, V48, P1936
   Chou CW, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018087
   Cohen Roger B, 2003, Clin Colorectal Cancer, V2, P246, DOI 10.3816/CCC.2003.n.006
   D'Incà R, 1999, AM J GASTROENTEROL, V94, P2956, DOI 10.1111/j.1572-0241.1999.01444.x
   Deming DA, 2014, INVEST NEW DRUG, V32, P323, DOI 10.1007/s10637-013-0035-8
   Dhawan P, 2005, J CLIN INVEST, V115, P1765, DOI 10.1172/JCI24543
   Dhawan P, 2011, ONCOGENE, V30, P3234, DOI 10.1038/onc.2011.43
   Dhawan P, 2011, CURR TOP MED CHEM, V11, P1592
   Dieter SM, 2011, CELL STEM CELL, V9, P357, DOI 10.1016/j.stem.2011.08.010
   Ding QM, 1998, AM J PHYSIOL-CELL PH, V275, pC1193, DOI 10.1152/ajpcell.1998.275.5.C1193
   Escaffit F, 2005, J CELL PHYSIOL, V203, P15, DOI 10.1002/jcp.20189
   FERRARIS RP, 1992, AM J PHYSIOL, V262, pG1047, DOI 10.1152/ajpgi.1992.262.6.G1047
   Furuse M, 2001, J CELL BIOL, V153, P263, DOI 10.1083/jcb.153.2.263
   Grivennikov SI, 2012, NATURE, V491, P254, DOI 10.1038/nature11465
   GUMBINER B, 1987, AM J PHYSIOL, V253, pC749, DOI 10.1152/ajpcell.1987.253.6.C749
   Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870
   Hichino A, 2017, J BIOL CHEM, V292, P2411, DOI 10.1074/jbc.M116.762807
   Horst D, 2009, CANCER INVEST, V27, P844, DOI 10.1080/07357900902744502
   Ikari A, 2014, BBA-MOL CELL RES, V1843, P2079, DOI 10.1016/j.bbamcr.2014.05.017
   Kimbung S, 2014, MOL ONCOL, V8, P119, DOI 10.1016/j.molonc.2013.10.002
   Kirschbaum MH, 2014, LEUKEMIA LYMPHOMA, V55, P2301, DOI 10.3109/10428194.2013.877134
   Krishnan M, 2010, ONCOGENE, V29, P305, DOI 10.1038/onc.2009.324
   Litvak DA, 1998, SURGERY, V124, P161, DOI 10.1016/S0039-6060(98)70116-3
   Mankertz J, 2004, BIOCHEM BIOPH RES CO, V314, P1001, DOI 10.1016/j.bbrc.2003.12.185
   Mariadason JM, 2005, GASTROENTEROLOGY, V128, P1081, DOI 10.1053/j.gastro.2005.01.054
   Mariadason JM, 2001, GASTROENTEROLOGY, V120, P889, DOI 10.1053/gast.2001.22472
   Martinowich K, 2003, SCIENCE, V302, P890, DOI 10.1126/science.1090842
   Matsumoto K, 2014, GASTROENTEROLOGY, V147, P1134, DOI 10.1053/j.gastro.2014.07.033
   McCart AE, 2008, PATHOL RES PRACT, V204, P479, DOI 10.1016/j.prp.2008.03.004
   MOSER AR, 1990, SCIENCE, V247, P322, DOI 10.1126/science.2296722
   Mottet D, 2009, ONCOGENE, V28, P243, DOI 10.1038/onc.2008.371
   Müller BM, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-215
   Mullin JM, 2005, MOL BIOL CELL, V16, P5538, DOI 10.1091/mbc.E05-04-0294
   NAFTALIN RJ, 1995, J PHYSIOL-LONDON, V487, P479, DOI 10.1113/jphysiol.1995.sp020894
   Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764
   O'Brien CA, 2007, NATURE, V445, P106, DOI 10.1038/nature05372
   Pei L, 2016, J CLIN INVEST, V126, P2509, DOI 10.1172/JCI83942
   Ricci-Vitiani L, 2007, NATURE, V445, P111, DOI 10.1038/nature05384
   Robinson MJ, 1998, CURR BIOL, V8, P1141, DOI 10.1016/S0960-9822(07)00485-X
   Rönsch K, 2011, EPIGENETICS-US, V6, P610, DOI 10.4161/epi.6.5.15300
   SAINSBURY JRC, 1987, LANCET, V1, P1398
   SCHNEEBERGER EE, 1992, AM J PHYSIOL, V262, pL647, DOI 10.1152/ajplung.1992.262.6.L647
   Sharma A, 2013, CARCINOGENESIS, V34, P2610, DOI 10.1093/carcin/bgt207
   Siavoshian S, 2000, GUT, V46, P507, DOI 10.1136/gut.46.4.507
   Simmer F, 2012, EPIGENETICS-US, V7, P1355, DOI 10.4161/epi.22562
   Singh AB, 2017, PFLUG ARCH EUR J PHY, V469, P69, DOI 10.1007/s00424-016-1919-1
   Singh AB, 2015, SEMIN CELL DEV BIOL, V42, P58, DOI 10.1016/j.semcdb.2015.05.001
   Singh AB, 2011, GASTROENTEROLOGY, V141, P2140, DOI 10.1053/j.gastro.2011.08.038
   Singh AB, 2010, J ONCOL, V2010, DOI 10.1155/2010/541957
   Song JS, 2012, PATHOL INT, V62, P182, DOI 10.1111/j.1440-1827.2011.02776.x
   Song X, 2008, HISTOL HISTOPATHOL, V23, P673, DOI 10.14670/HH-23.673
   Soulières D, 2010, CURR ONCOL, V17, pS31
   Stypula-Cyrus Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064600
   Suzuki K, 2006, CANCER CELL, V9, P199, DOI 10.1016/j.ccr.2006.02.016
   Tabariès S, 2015, ONCOTARGET, V6, P9476, DOI 10.18632/oncotarget.3269
   Tabariès S, 2012, MOL CELL BIOL, V32, P2979, DOI 10.1128/MCB.00299-12
   Takehara M, 2009, BIOL PHARM BULL, V32, P825, DOI 10.1248/bpb.32.825
   Turecková J, 2005, INT J MOL MED, V15, P329
   Wada M, 2013, GASTROENTEROLOGY, V144, P369, DOI 10.1053/j.gastro.2012.10.035
   Wang Y, 2015, AM J PATHOL, V185, P1123, DOI 10.1016/j.ajpath.2014.12.014
   Wilson AJ, 2006, J BIOL CHEM, V281, P13548, DOI 10.1074/jbc.M510023200
   Wilson AJ, 2008, MOL BIOL CELL, V19, P4062, DOI 10.1091/mbc.E08-02-0139
   Wilson PM, 2010, CANCER CHEMOTH PHARM, V65, P979, DOI 10.1007/s00280-009-1236-x
   Zeng LS, 2016, AGING-US, V8, P1236, DOI 10.18632/aging.100980
   Zhu P, 2004, CANCER CELL, V5, P455, DOI 10.1016/S1535-6108(04)00114-X
NR 74
TC 18
Z9 18
U1 0
U2 8
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD OCT 20
PY 2017
VL 8
IS 50
BP 87718
EP 87736
DI 10.18632/oncotarget.21190
PG 19
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA FK2VP
UT WOS:000413341400059
PM 29152115
OA gold, Green Submitted, Green Published
DA 2025-01-12
ER

PT J
AU Kim, JL
   Ha, GH
   Campo, L
   Denning, MF
   Patel, TB
   Osipo, C
   Lin, SY
   Breuer, EK
AF Kim, Jung-Lye
   Ha, Geun-Hyoung
   Campo, Loredana
   Denning, Mitchell F.
   Patel, Tarun B.
   Osipo, Clodia
   Lin, Shiaw-Yih
   Breuer, Eun-Kyoung
TI The role of Rak in the regulation of stability and function of BRCA1
SO ONCOTARGET
LA English
DT Article
DE BRCA1; Rak; tyrosine phosphorylation; DNA damage response; genomic
   stability
ID HOMOLOGOUS RECOMBINATION REPAIR; DOUBLE-STRAND BREAKS; DNA-DAMAGE
   RESPONSE; HUMAN GLIOMA-CELLS; TYROSINE KINASE; OVARIAN-CANCER;
   NUCLEAR-LOCALIZATION; TUMOR-SUPPRESSOR; MAMMALIAN-CELLS; E3 LIGASE
AB BRCA1 is an important player in the DNA damage response signaling, and its deficiency results in genomic instability. A complete loss or significantly reduced BRCA1 protein expression is often found in sporadic breast cancer cases despite the absence of genetic or epigenetic aberrations, suggesting the existence of other regulatory mechanisms controlling BRCA1 protein expression. Herein, we demonstrate that Fyn-related kinase (Frk)/Rak plays an important role in maintaining genomic stability, possibly in part through positively regulating BRCA1 protein stability and function via tyrosine phosphorylation on BRCA1 Tyr1552. In addition, Rak deficiency confers cellular sensitivity to DNA damaging agents and poly(ADP-ribose) polymerase (PARP) inhibitors. Overall, our findings highlight a critical role of Rak in the maintenance of genomic stability, at least in part, through protecting BRCA1 and provide novel treatment strategies for patients with breast tumors lacking Rak.
C1 [Kim, Jung-Lye; Ha, Geun-Hyoung; Campo, Loredana; Denning, Mitchell F.; Osipo, Clodia; Breuer, Eun-Kyoung] Loyola Univ Chicago, Inst Oncol, Cardinal Bernardin Canc Ctr, Stritch Sch Med, Maywood, IL 60153 USA.
   [Kim, Jung-Lye; Ha, Geun-Hyoung; Campo, Loredana; Breuer, Eun-Kyoung] Loyola Univ Chicago, Dept Radiat Oncol, Stritch Sch Med, Maywood, IL 60153 USA.
   [Denning, Mitchell F.; Osipo, Clodia] Loyola Univ Chicago, Dept Pathol, Stritch Sch Med, Maywood, IL 60153 USA.
   [Patel, Tarun B.] Loyola Univ Chicago, Dept Mol Pharmacol & Therapeut, Stritch Sch Med, Maywood, IL 60153 USA.
   [Lin, Shiaw-Yih] Univ Texas MD Anderson Canc Ctr, Dept Syst Biol, Houston, TX 77030 USA.
C3 Loyola University Chicago; Loyola University Chicago; Loyola University
   Chicago; Loyola University Chicago; University of Texas System; UTMD
   Anderson Cancer Center
RP Breuer, EK (通讯作者)，Loyola Univ Chicago, Inst Oncol, Cardinal Bernardin Canc Ctr, Stritch Sch Med, Maywood, IL 60153 USA.; Breuer, EK (通讯作者)，Loyola Univ Chicago, Dept Radiat Oncol, Stritch Sch Med, Maywood, IL 60153 USA.; Lin, SY (通讯作者)，Univ Texas MD Anderson Canc Ctr, Dept Syst Biol, Houston, TX 77030 USA.
EM sylin@mdanderson.org; eubreuer@luc.edu
RI lee, jung/H-8107-2018
FU American Cancer Society, Illinois Division, INC [266245]; Susan G. Komen
   Foundation for the Cure; Cancer Prevention & Research Institute of Texas
   (CPRIT) [RP130310]
FX This work was supported by Grant #266245 from the American Cancer
   Society, Illinois Division, INC and postdoctoral fellowship from Susan
   G. Komen Foundation for the Cure to E.K.B and grant RP130310 from Cancer
   Prevention & Research Institute of Texas (CPRIT) to S.Y.L.
CR Alpi AF, 2008, MOL CELL, V32, P767, DOI 10.1016/j.molcel.2008.12.003
   Ashworth A, 2008, J CLIN ONCOL, V26, P3785, DOI 10.1200/JCO.2008.16.0812
   Bednarz N, 2010, CLIN CANCER RES, V16, P3340, DOI 10.1158/1078-0432.CCR-10-0150
   Berclaz G, 2000, INT J CANCER, V85, P889
   Bolderson E, 2010, NUCLEIC ACIDS RES, V38, P1821, DOI 10.1093/nar/gkp1164
   Bougie O, 2011, INT J SURG ONCOL, V2011, DOI 10.1155/2011/374012
   CANCE WG, 1994, CELL GROWTH DIFFER, V5, P1347
   Chandrasekharan S, 2002, MOL CELL BIOL, V22, P5235, DOI 10.1128/MCB.22.14.5235-5247.2002
   Chen YH, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-246
   Choudhury AD, 2004, J BIOL CHEM, V279, P33909, DOI 10.1074/jbc.M403646200
   CRAVEN RJ, 1995, CANCER RES, V55, P3969
   Crippa E, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087039
   Fabbro M, 2002, J BIOL CHEM, V277, P21315, DOI 10.1074/jbc.M200769200
   Gilbert PM, 2010, J CLIN INVEST, V120, P1535, DOI 10.1172/JCI39534
   Girard L, 2000, CANCER RES, V60, P4894
   Ha GH, 2014, ONCOGENE
   Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2
   Hu YF, 1999, GENE DEV, V13, P637, DOI 10.1101/gad.13.6.637
   Hua L, 2014, J NEURO-ONCOL, V119, P49, DOI 10.1007/s11060-014-1461-y
   Jackson SP, 2002, CARCINOGENESIS, V23, P687, DOI 10.1093/carcin/23.5.687
   Jarvis EM, 1998, CANCER GENET CYTOGEN, V101, P109, DOI 10.1016/S0165-4608(97)00267-7
   Jin GA, 2011, LUNG CANCER, V71, P115, DOI 10.1016/j.lungcan.2010.10.002
   Jin L, 2014, ONCOGENE, V33, P326, DOI 10.1038/onc.2012.589
   Kwong A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043994
   Lee HJ, 2010, CELL CYCLE, V9, P2389, DOI 10.4161/cc.9.12.11904
   Lin SY, 2005, P NATL ACAD SCI USA, V102, P15105, DOI 10.1073/pnas.0507722102
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Ma WJ, 2012, P NATL ACAD SCI USA, V109, P6590, DOI 10.1073/pnas.1118078109
   Machida YJ, 2006, MOL CELL, V23, P589, DOI 10.1016/j.molcel.2006.06.024
   MacLachlan TK, 2002, MOL CELL BIOL, V22, P4280, DOI 10.1128/MCB.22.12.4280-4292.2002
   Meyer T, 2003, INT J CANCER, V104, P139, DOI 10.1002/ijc.10925
   Morton JP, 2010, P NATL ACAD SCI USA, V107, P246, DOI 10.1073/pnas.0908428107
   Nakanishi K, 2005, P NATL ACAD SCI USA, V102, P1110, DOI 10.1073/pnas.0407796102
   Pattyn F, 2003, NUCLEIC ACIDS RES, V31, P122, DOI 10.1093/nar/gkg011
   Peng G, 2009, NAT CELL BIOL, V11, P865, DOI 10.1038/ncb1895
   Philipp C, 2011, INT J CANCER, V128, P1747, DOI 10.1002/ijc.25497
   Pierce AJ, 2001, GENE DEV, V15, P3237, DOI 10.1101/gad.946401
   Pierce AJ, 1999, GENE DEV, V13, P2633, DOI 10.1101/gad.13.20.2633
   Puc J, 2005, CANCER CELL, V7, P193, DOI 10.1016/j.ccr.2005.01.009
   Richardson C, 1998, GENE DEV, V12, P3831, DOI 10.1101/gad.12.24.3831
   Rio PG, 1999, INT J CANCER, V80, P823, DOI 10.1002/(SICI)1097-0215(19990315)80:6<823::AID-IJC5>3.3.CO;2-V
   Ruffner H, 1997, P NATL ACAD SCI USA, V94, P7138, DOI 10.1073/pnas.94.14.7138
   Ruffner H, 2001, P NATL ACAD SCI USA, V98, P5134, DOI 10.1073/pnas.081068398
   Sartori AA, 2007, NATURE, V450, P509, DOI 10.1038/nature06337
   Shen WH, 2007, CELL, V128, P157, DOI 10.1016/j.cell.2006.11.042
   Sheng ZM, 1996, BRIT J CANCER, V73, P144, DOI 10.1038/bjc.1996.27
   Shi Q, 2014, J MOL NEUROSCI
   Shibata A, 2011, EMBO J, V30, P1079, DOI 10.1038/emboj.2011.27
   Snouwaert JN, 1999, ONCOGENE, V18, P7900, DOI 10.1038/sj.onc.1203334
   Sy SMH, 2009, J BIOL CHEM, V284, P18302, DOI 10.1074/jbc.M109.016717
   Thakur S, 1997, MOL CELL BIOL, V17, P444, DOI 10.1128/MCB.17.1.444
   Thangaraju M, 2000, J BIOL CHEM, V275, P33487, DOI 10.1074/jbc.M005824200
   THUVESON M, 1995, BIOCHEM BIOPH RES CO, V209, P582, DOI 10.1006/bbrc.1995.1540
   Turner N, 2004, NAT REV CANCER, V4, P814, DOI 10.1038/nrc1457
   Ueki T, 2009, CANCER RES, V69, P8752, DOI 10.1158/0008-5472.CAN-09-1809
   Wang HY, 2004, CANCER RES, V64, P7139, DOI 10.1158/0008-5472.CAN-04-1289
   Wang XZ, 2014, BIOCHEM BIOPH RES CO, V444, P549, DOI 10.1016/j.bbrc.2014.01.075
   Weberpals JI, 2008, J CLIN ONCOL, V26, P3259, DOI 10.1200/JCO.2007.11.3902
   Weberpals JI, 2011, CANCER CELL INT, V11, DOI 10.1186/1475-2867-11-29
   Wei MJ, 2005, CANCER RES, V65, P10692, DOI 10.1158/0008-5472.CAN-05-1277
   Welcsh PL, 2002, P NATL ACAD SCI USA, V99, P7560, DOI 10.1073/pnas.062181799
   Wen J, 2009, ONCOGENE, V28, P575, DOI 10.1038/onc.2008.405
   Wooster R, 2003, NEW ENGL J MED, V348, P2339, DOI 10.1056/NEJMra012284
   Wu J, 2012, MOL CELL, V46, P351, DOI 10.1016/j.molcel.2012.02.018
   Wu WW, 2010, CANCER RES, V70, P6384, DOI 10.1158/0008-5472.CAN-10-1304
   Xu B, 2001, MOL CELL BIOL, V21, P3445, DOI 10.1128/MCB.21.10.3445-3450.2001
   Yang C, 2006, MOL CELL, V21, P135, DOI 10.1016/j.molcel.2005.11.014
   Yim EK, 2009, CANCER CELL, V15, P304, DOI 10.1016/j.ccr.2009.02.012
   Yoshikawa K, 1999, CLIN CANCER RES, V5, P1249
   You FL, 2004, ONCOGENE, V23, P5792, DOI 10.1038/sj.onc.1207739
   Yu XC, 2004, MOL CELL BIOL, V24, P9478, DOI 10.1128/MCB.24.21.9478-9486.2004
   Zhou XP, 2012, J NEURO-ONCOL, V110, P9, DOI 10.1007/s11060-012-0933-1
NR 72
TC 9
Z9 9
U1 0
U2 5
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD OCT 17
PY 2017
VL 8
IS 49
BP 86799
EP 86815
DI 10.18632/oncotarget.5717
PG 17
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA FJ9FN
UT WOS:000413077800181
PM 29156836
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Kang, HJ
   Yi, YW
   Hou, SJ
   Kim, HJ
   Kong, YL
   Bae, I
   Brown, ML
AF Kang, Hyo Jin
   Yi, Yong Weon
   Hou, Shu-Jie
   Kim, Hee Jeong
   Kong, Yali
   Bae, Insoo
   Brown, Milton L.
TI Disruption of STAT3-DNMT1 interaction by SH-I-14 induces re-expression
   of tumor suppressor genes and inhibits growth of triple-negative breast
   tumor
SO ONCOTARGET
LA English
DT Article
DE SH-I-14; STAT3; DMNT1; acetylation; interaction
ID NF-KAPPA-B; DNA METHYLTRANSFERASE; SIGNAL TRANSDUCER; STAT3 ACETYLATION;
   CANCER-CELLS; PROTEIN; METHYLATION; TRANSCRIPTION; EXPRESSION; ACTIVATOR
AB Epigenetic regulation of gene expression is an emerging target to treat several human diseases including cancers. In cancers, expressions of many tumor suppressor genes are suppressed by hyper-methylation in their regulatory regions. Herein, we describe a novel carbazole SH-I-14 that decreased the level of the acetyl-STAT3 at the K685 residue. Mutation analysis revealed that SH-I-14 disrupted STAT3-DNMT1 interaction by removing acetyl group from K685 of STAT3. Finally, the inhibition of STAT3-DNMT1 interaction by SH-I-14 resulted in re-expression of tumor suppressor genes such as VHL and PDLIM4 through de-methylation of their promoter regions. In addition, SH-I-14 showed anti-proliferative effect in triple-negative breast cancer (TNBC) cell lines in vitro and anti-tumor effect in a mouse xenograft model of MDA-MB-231 tumor. Taken together, our results suggest that targeting acetyl-STAT3 (K685) provides potential therapeutic opportunity to treat a subset of human cancers.
C1 [Kang, Hyo Jin; Yi, Yong Weon; Hou, Shu-Jie; Kim, Hee Jeong; Kong, Yali; Bae, Insoo; Brown, Milton L.] Georgetown Univ, Med Ctr, Dept Oncol, Washington, DC 20007 USA.
   [Bae, Insoo] Georgetown Univ, Med Ctr, Dept Radiat Med, Washington, DC 20007 USA.
   [Hou, Shu-Jie; Kong, Yali; Bae, Insoo; Brown, Milton L.] Georgetown Univ, Med Ctr, Ctr Drug Discovery, Washington, DC 20007 USA.
   [Bae, Insoo; Brown, Milton L.] Georgetown Univ, Med Ctr, Lombardi Comprehens Canc Ctr, Washington, DC 20007 USA.
C3 Georgetown University; Georgetown University; Georgetown University;
   Georgetown University
RP Brown, ML (通讯作者)，Georgetown Univ, Med Ctr, Dept Oncol, Washington, DC 20007 USA.; Brown, ML (通讯作者)，Georgetown Univ, Med Ctr, Ctr Drug Discovery, Washington, DC 20007 USA.; Brown, ML (通讯作者)，Georgetown Univ, Med Ctr, Lombardi Comprehens Canc Ctr, Washington, DC 20007 USA.
EM mb544@georgetown.edu
RI Yi, Yong/AAR-1319-2020
OI Yi, Yong Weon/0000-0001-6895-0465
FU Susan G. Komen for the Cure [FAS0703858]; Lombardi Comprehensive Cancer
   Center, Georgetown University [P30-CA051008]
FX We thank Dr. Olga A. Timofeeva (Georgetown University) for critical
   review of the manuscript and the kind gift of GFP-STAT3 expression
   plasmid. We also thank Dr. J. Bromberg and Dr. T. Imamura for the kind
   gift of expression plasmids. This work was supported by Susan G. Komen
   for the Cure (FAS0703858) and by the Lombardi Comprehensive Cancer
   Center, Georgetown University (P30-CA051008). This manuscript is written
   in honor of the life and last scientific achievement of Dr. Insoo Bae,
   associate professor of oncology at Georgetown University Medical Center,
   who passed away on Aug 22, 2014.
CR Agoston AT, 2005, J BIOL CHEM, V280, P18302, DOI 10.1074/jbc.M501675200
   Arzenani MK, 2011, MOL CELL BIOL, V31, P4119, DOI 10.1128/MCB.01304-10
   Asche C, 2007, ANTI-CANCER AGENT ME, V7, P247, DOI 10.2174/187152007780058678
   Bender CM, 1999, MOL CELL BIOL, V19, P6690
   Boumber YA, 2007, CANCER RES, V67, P1997, DOI 10.1158/0008-5472.CAN-06-3093
   Bromberg J, 2000, ONCOGENE, V19, P2468, DOI 10.1038/sj.onc.1203476
   Cardoso MC, 1999, J CELL BIOL, V147, P25, DOI 10.1083/jcb.147.1.25
   CHEN F, 1995, CANCER RES, V55, P4804
   Croker BA, 2003, NAT IMMUNOL, V4, P540, DOI 10.1038/ni931
   De Marzo AM, 1999, CANCER RES, V59, P3855
   Debnath B, 2012, J MED CHEM, V55, P6645, DOI 10.1021/jm300207s
   Dhawan D, 2013, UROL ONCOL-SEMIN ORI, V31, P1761, DOI 10.1016/j.urolonc.2012.03.015
   Du ZW, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2001462
   Foulks JM, 2012, J BIOMOL SCREEN, V17, P2, DOI 10.1177/1087057111421212
   Gros C, 2012, BIOCHIMIE, V94, P2280, DOI 10.1016/j.biochi.2012.07.025
   Hedvat M, 2009, CANCER CELL, V16, P487, DOI 10.1016/j.ccr.2009.10.015
   Hou SJ, 2014, J MED CHEM, V57, P6342, DOI 10.1021/jm4018042
   Hou T, 2008, J BIOL CHEM, V283, P30725, DOI 10.1074/jbc.M805941200
   ILIOPOULOS O, 1995, NAT MED, V1, P822, DOI 10.1038/nm0895-822
   Kang HJ, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.78
   KAUFMANN SH, 1993, CANCER RES, V53, P3976
   Lee H, 2012, P NATL ACAD SCI USA, V109, P7765, DOI 10.1073/pnas.1205132109
   Lee H, 2011, CANCER RES, V71, P3772, DOI 10.1158/0008-5472.CAN-10-3304
   LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F
   Li J, 2013, ONCOL REP, V30, P165, DOI 10.3892/or.2013.2414
   Mankan AK, 2011, EXPERT OPIN INV DRUG, V20, P1263, DOI 10.1517/13543784.2011.601739
   Manshouri T, 2008, CANCER SCI, V99, P1265, DOI 10.1111/j.1349-7006.2008.00817.x
   Miremadi A, 2007, HUM MOL GENET, V16, pR28, DOI 10.1093/hmg/ddm021
   Nadiminty N, 2006, P NATL ACAD SCI USA, V103, P7264, DOI 10.1073/pnas.0509808103
   Ni J, 2014, ACTA PHARMACOL SIN, V35, P1045, DOI 10.1038/aps.2014.42
   Nie YZ, 2009, NAT CELL BIOL, V11, P492, DOI 10.1038/ncb1857
   Niu GL, 2005, MOL CELL BIOL, V25, P7432, DOI 10.1128/MCB.25.17.7432-7440.2005
   Niu GL, 2001, CANCER RES, V61, P3276
   Qin WH, 2011, NUCLEUS-PHILA, V2, P392, DOI 10.4161/nucl.2.5.17928
   Ray S, 2005, GASTROENTEROLOGY, V129, P1616, DOI 10.1053/j.gastro.2005.07.055
   Ray S, 2008, NUCLEIC ACIDS RES, V36, P4510, DOI 10.1093/nar/gkn419
   Schmidt AW, 2012, CHEM REV, V112, P3193, DOI 10.1021/cr200447s
   Sethi G, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-66
   Sheikh KD, 2010, J MED CHEM, V53, P2376, DOI 10.1021/jm9011615
   Shiao YH, 2003, CURR MED CHEM, V10, P2461, DOI 10.2174/0929867033456639
   Stresemann C, 2008, INT J CANCER, V123, P8, DOI 10.1002/ijc.23607
   Sun X, 2006, CANCER GENE THER, V13, P428, DOI 10.1038/sj.cgt.7700907
   Timofeeva OA, 2013, P NATL ACAD SCI USA, V110, P1267, DOI 10.1073/pnas.1211805110
   Vanaja DK, 2009, CANCER INVEST, V27, P264, DOI 10.1080/07357900802406319
   Wang R, 2005, J BIOL CHEM, V280, P11528, DOI 10.1074/jbc.M413930200
   Wang Y, 2011, CELL STEM CELL, V8, P399, DOI 10.1016/j.stem.2011.02.006
   Wieczorek M, 2012, CYTOKINE GROWTH F R, V23, P293, DOI 10.1016/j.cytogfr.2012.06.005
   Yu H, 2009, NAT REV CANCER, V9, P798, DOI 10.1038/nrc2734
   Yuan ZL, 2005, SCIENCE, V307, P269, DOI 10.1126/science.1105166
   Zhang Q, 2005, P NATL ACAD SCI USA, V102, P6948, DOI 10.1073/pnas.0501959102
   Zhang Q, 2007, NAT MED, V13, P1341, DOI 10.1038/nm1659
   Zhang Q, 2011, P NATL ACAD SCI USA, V108, P11977, DOI 10.1073/pnas.1100319108
NR 52
TC 24
Z9 25
U1 0
U2 8
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD OCT 13
PY 2017
VL 8
IS 48
BP 83457
EP 83468
DI 10.18632/oncotarget.4054
PG 12
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA FJ8PK
UT WOS:000413030900008
PM 29137356
OA gold, Green Submitted, Green Published
DA 2025-01-12
ER

PT J
AU Pan, YJ
   Wei, LL
   Wu, XJ
   Huo, FC
   Mou, J
   Pei, DS
AF Pan, Yao-Jie
   Wei, Lu-Lu
   Wu, Xiao-Jin
   Huo, Fu-Chun
   Mou, Jie
   Pei, Dong-Sheng
TI MiR-106a-5p inhibits the cell migration and invasion of renal cell
   carcinoma through targeting PAK5
SO CELL DEATH & DISEASE
LA English
DT Article
ID EPITHELIAL-MESENCHYMAL TRANSITION; PRIMARY MICRORNAS; MICROPROCESSOR
   COMPLEX; P21-ACTIVATED KINASE-5; DROSHA-DGCR8 COMPLEX;
   COLORECTAL-CANCER; TUMOR-SUPPRESSOR; BREAST-CANCER; METASTASIS;
   PROLIFERATION
AB MicroRNA-106a-5p (MiR-106a-5p), a small non-coding RNA, has been reported to be downregulated in astrocytoma, osteosarcoma and colorectal cancer. However, the expression levels and biological function in renal cell carcinoma (RCC) have not been studied yet. In this study, we found that the miR-106a-5p was significantly downregulated in RCC tissues and cell lines, and that overexpression of miR-106a-5p led to decreased cell metastasis ability in a xenograft model. Inhibition of miR-106a-5p in RCC cell lines altered the cell migration, invasion and wound healing abilities. Mechanistic studies demonstrated that miR-106a-5p directly bound to the 3'-UTR of the PAK5 mRNA and mediated a decrease in the protein expression of PAK5. We further proved that PAK5 protein levels were negatively correlated with the miR-106a-5p expression in both patient samples and xenograft model. In epigenetics, methylation specific PCR experiments indicated that the upstream gene promoter of miR-106a-5p was hypermethylated in RCC, which might be responsible for its downregulation. Our findings suggested that miR-106a-5p might be a potential gene therapy target for the treatment of RCC metastasis.
C1 [Pan, Yao-Jie; Huo, Fu-Chun; Pei, Dong-Sheng] Xuzhou Med Univ, Jiangsu Key Lab Biol Canc Therapy, Xuzhou 221002, Peoples R China.
   [Pan, Yao-Jie] Southeast Univ, Med Sch, Affiliated Yancheng Hosp, Dept Oncol, Yancheng 224001, Peoples R China.
   [Wei, Lu-Lu; Pei, Dong-Sheng] Xuzhou Med Univ, Dept Pathol, 209 Tong Shan Rd, Xuzhou 221002, Jiangsu, Peoples R China.
   [Wu, Xiao-Jin] First Peoples Hosp Xuzhou, Dept Radiat Oncol, Xuzhou 221002, Peoples R China.
   [Mou, Jie] Xuzhou Med Univ, Sch Phamacy, Xuzhou 221002, Peoples R China.
C3 Xuzhou Medical University; Southeast University - China; Xuzhou Medical
   University; Xuzhou Medical University
RP Pei, DS (通讯作者)，Xuzhou Med Univ, Dept Pathol, 209 Tong Shan Rd, Xuzhou 221002, Jiangsu, Peoples R China.
EM dspei@xzhmu.edu.cn
OI Huo, Fu-Chun/0000-0002-7396-4885; Pei, Dong-sheng/0000-0002-8053-3741
FU National Natural Science Foundation of China [81572349]; Jiangsu
   Provincial Medical Talent; Science and Technology Department of Jiangsu
   Province [BK20141149]
FX This work was supported by the National Natural Science Foundation of
   China (No. 81572349), Jiangsu Provincial Medical Talent and the Science
   and Technology Department of Jiangsu Province (BK20141149).
CR Alarcón CR, 2015, NATURE, V519, P482, DOI 10.1038/nature14281
   Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871
   Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5
   Bhatt K, 2016, AM J PHYSIOL-RENAL, V310, pF109, DOI 10.1152/ajprenal.00387.2015
   Dan C, 2002, MOL CELL BIOL, V22, P567, DOI 10.1128/MCB.22.2.567-577.2002
   Denli AM, 2004, NATURE, V432, P231, DOI 10.1038/nature03049
   Dummler B, 2009, CANCER METAST REV, V28, P51, DOI 10.1007/s10555-008-9168-1
   Dutcher JP, 2000, CLIN CANCER RES, V6, P3442
   Ell B, 2013, CANCER CELL, V24, P542, DOI 10.1016/j.ccr.2013.09.008
   Gansler T, 2010, CA-CANCER J CLIN, V60, P345, DOI 10.3322/caac.20088
   Gelato KA, 2016, EXPERT OPIN THER TAR, V20, P783, DOI 10.1517/14728222.2016.1134490
   Gong W, 2009, INT J CANCER, V125, P548, DOI 10.1002/ijc.24428
   Gregory RI, 2004, NATURE, V432, P235, DOI 10.1038/nature03120
   Gu J, 2013, FEBS J, V280, P46, DOI 10.1111/febs.12048
   Han JJ, 2006, CELL, V125, P887, DOI 10.1016/j.cell.2006.03.043
   Han JJ, 2004, GENE DEV, V18, P3016, DOI 10.1101/gad.1262504
   Han ZX, 2014, BRAIN TUMOR PATHOL, V31, P234, DOI 10.1007/s10014-013-0161-1
   He QY, 2016, DNA CELL BIOL, V35, P506, DOI 10.1089/dna.2015.3121
   Jiang ZY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094639
   Lam CSC, 2017, ONCOTARGET, V8, P26858, DOI 10.18632/oncotarget.15844
   Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758
   Landthaler M, 2004, CURR BIOL, V14, P2162, DOI 10.1016/j.cub.2004.11.001
   Long XR, 2014, INT J ONCOL, V44, P1915, DOI 10.3892/ijo.2014.2373
   Lopez-Serra P, 2012, ONCOGENE, V31, P1609, DOI 10.1038/onc.2011.354
   Low G, 2016, WORLD J RADIOL, V8, P484, DOI 10.4329/wjr.v8.i5.484
   Ma L, 2016, ADV CANCER RES, V132, P165, DOI 10.1016/bs.acr.2016.07.004
   Ma YD, 2015, TUMOR BIOL, V36, P8389, DOI 10.1007/s13277-015-3605-x
   MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0
   McGuire A, 2015, CANCER METAST REV, V34, P145, DOI 10.1007/s10555-015-9551-7
   Mendell JT, 2008, CELL, V133, P217, DOI 10.1016/j.cell.2008.04.001
   Olive V, 2010, INT J BIOCHEM CELL B, V42, P1348, DOI 10.1016/j.biocel.2010.03.004
   Pandey A, 2002, ONCOGENE, V21, P3939, DOI 10.1038/sj.onc.1205478
   Quattrochi B, 2017, ONCOTARGET, V8, P35902, DOI 10.18632/oncotarget.16277
   Rini BI, 2009, LANCET, V373, P1119, DOI 10.1016/S0140-6736(09)60229-4
   Russo P, 2000, SEMIN ONCOL, V27, P160
   Sellitti Donald F, 2015, Microrna, V4, P26
   Wang XX, 2013, TUMOR BIOL, V34, P2721, DOI 10.1007/s13277-013-0824-x
   Wen YY, 2014, EXPERT OPIN THER TAR, V18, P807, DOI 10.1517/14728222.2014.918103
   Xia T, 2014, SCI REP-UK, V4, DOI 10.1038/srep06088
   Yi JM, 2017, ONCOTARGET, V8, P26600, DOI 10.18632/oncotarget.15722
   Yilmaz M, 2009, CANCER METAST REV, V28, P15, DOI 10.1007/s10555-008-9169-0
   Yue B, 2015, CANCER SCI, V106, P1323, DOI 10.1111/cas.12759
   Zhang DG, 2015, TUMOR BIOL, V36, P3685, DOI 10.1007/s13277-014-3007-5
   Zhang JS, 2012, CANCER METAST REV, V31, P653, DOI 10.1007/s10555-012-9368-6
   Zhang L., 2017, APPL SCI, V7, P1, DOI DOI 10.1016/J.PLREV.2017.01.007
   Zhi F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072390
   Zhu G, 2016, ONCOGENE, V35, P1943, DOI 10.1038/onc.2015.259
NR 47
TC 75
Z9 80
U1 0
U2 13
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-4889
J9 CELL DEATH DIS
JI Cell Death Dis.
PD OCT
PY 2017
VL 8
AR e3155
DI 10.1038/cddis.2017.561
PG 12
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA FL2CV
UT WOS:000414022900004
PM 29072688
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU Wu, MZ
   Cheng, WC
   Chen, SF
   Nieh, S
   O'Connor, C
   Liu, CL
   Tsai, WW
   Wu, CJ
   Martin, L
   Lin, YS
   Wu, KJ
   Lu, LF
   Belmonte, JCI
AF Wu, Min-Zu
   Cheng, Wei-Chung
   Chen, Su-Feng
   Nieh, Shin
   O'Connor, Carolyn
   Liu, Chia-Lin
   Tsai, Wen-Wei
   Wu, Cheng-Jang
   Martin, Lorena
   Lin, Yaoh-Shiang
   Wu, Kou-Juey
   Lu, Li-Fan
   Belmonte, Juan Carlos Izpisua
TI miR-25/93 mediates hypoxia-induced immunosuppression by repressing cGAS
SO NATURE CELL BIOLOGY
LA English
DT Article
ID GMP-AMP SYNTHASE; MITOCHONDRIAL-DNA; TUMOR PROGRESSION;
   SUPPRESSOR-CELLS; CANCER; INDUCTION; MICRORNAS; EXPRESSION; PATHWAY;
   GROWTH
AB The mechanisms by which hypoxic tumours evade immunological pressure and anti-tumour immunity remain elusive. Here, we report that two hypoxia-responsive microRNAs, miR-25 and miR-93, are important for establishing an immunosuppressive tumour microenvironment by downregulating expression of the DNA sensor cGAS. Mechanistically, miR-25/93 targets NCOA3, an epigenetic factor that maintains basal levels of cGAS expression, leading to repression of cGAS during hypoxia. This allows hypoxic tumour cells to escape immunological responses induced by damage-associated molecular pattern molecules, specifically the release of mitochondrial DNA. Moreover, restoring cGAS expression results in an anti-tumour immune response. Clinically, decreased levels of cGAS are associated with poor prognosis for patients with breast cancer harbouring high levels of miR-25/93. Together, these data suggest that inactivation of the cGAS pathway plays a critical role in tumour progression, and reveal a direct link between hypoxia-responsive miRNAs and adaptive immune responses to the hypoxic tumour microenvironment, thus unveiling potential new therapeutic strategies.
EM belmonte@salk.edu
RI Chen, Wei-Yu/ABH-4523-2020; Cheng, Wei-Chung/E-6240-2014; Lu,
   Li-Fan/LTE-4985-2024
OI Wu, Cheng-Jang/0000-0002-7640-5915; Lu, Li-Fan/0000-0002-9727-0036;
   Cheng, Wei-Chung/0000-0002-1229-4857; O'Connor,
   Carolyn/0000-0002-3301-7912
FU Razavi Newman Integrative Genomics and Bioinformatics Core Facility; NGS
   Core Facility of the Salk institute; NIH-NCI [CCSG: P30014195]; Chapman
   Foundation; Helmsley Charitable Trust; G. Harold and Leila Y. Mathers
   Charitable Foundation; Leona M. and Harry B. Helmsley Charitable Trust
   [2012-PG-MED002]; Fundacion Dr. Pedro Guillen; Moxie Foundation; UCAM
FX We are grateful to M. C. Ku of the Next Generation Sequencing Core, and
   C. Benner and M. Shokhirev of the Integrative Genomics and
   Bioinformatics Core, at Salk Institute for Biological Studies for
   technical assistance. We would also like to thank D. O'Keefe for his
   help in preparing the manuscript. This work was supported by The Razavi
   Newman Integrative Genomics and Bioinformatics Core Facility and the NGS
   Core Facility of the Salk institute with funding from NIH-NCI CCSG:
   P30014195, the Chapman Foundation and the Helmsley Charitable Trust.
   Work in the laboratory of J.C.I.B. was supported by the G. Harold and
   Leila Y. Mathers Charitable Foundation, The Leona M. and Harry B.
   Helmsley Charitable Trust (2012-PG-MED002), Fundacion Dr. Pedro Guillen,
   The Moxie Foundation and UCAM.
CR Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002
   Camps C, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-28
   Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4
   Clambey ET, 2012, P NATL ACAD SCI USA, V109, pE2784, DOI 10.1073/pnas.1202366109
   Corrales L, 2015, CLIN CANCER RES, V21, P4774, DOI 10.1158/1078-0432.CCR-15-1362
   Corzo CA, 2010, J EXP MED, V207, P2439, DOI 10.1084/jem.20100587
   Deng LF, 2014, IMMUNITY, V41, P843, DOI 10.1016/j.immuni.2014.10.019
   Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840
   Facciabene A, 2011, NATURE, V475, P226, DOI 10.1038/nature10169
   Gao DX, 2013, SCIENCE, V341, P903, DOI 10.1126/science.1240933
   Haldar S, 2014, RNA BIOL, V11, P1137, DOI 10.4161/rna.36136
   Hazarika S, 2013, CIRCULATION, V127, P1818, DOI 10.1161/CIRCULATIONAHA.112.000860
   Hu J, 2016, CANCER CELL, V29, P49, DOI 10.1016/j.ccell.2015.12.005
   Joyce JA, 2009, NAT REV CANCER, V9, P239, DOI 10.1038/nrc2618
   Kim H, 2011, MOL CELL, V44, P532, DOI 10.1016/j.molcel.2011.08.045
   Kulshreshtha R, 2008, CELL DEATH DIFFER, V15, P667, DOI 10.1038/sj.cdd.4402310
   Kulshreshtha R, 2007, MOL CELL BIOL, V27, P1859, DOI 10.1128/MCB.01395-06
   Lewis C, 2005, AM J PATHOL, V167, P627, DOI 10.1016/S0002-9440(10)62038-X
   Liu L, 2012, NAT CELL BIOL, V14, P177, DOI 10.1038/ncb2422
   Liu Y, 2015, J HEPATOL, V63, P114, DOI 10.1016/j.jhep.2015.02.009
   Mariani CJ, 2014, CELL REP, V7, P1343, DOI 10.1016/j.celrep.2014.04.040
   MATZINGER P, 1994, ANNU REV IMMUNOL, V12, P991, DOI 10.1146/annurev.iy.12.040194.005015
   Matzinger P, 2002, SCIENCE, V296, P301, DOI 10.1126/science.1071059
   Noman MZ, 2015, CANCER RES, V75, P3771, DOI 10.1158/0008-5472.CAN-15-0405
   Noman MZ, 2011, CRIT REV IMMUNOL, V31, P357, DOI 10.1615/CritRevImmunol.v31.i5.10
   Noman MZ, 2009, J IMMUNOL, V182, P3510, DOI 10.4049/jimmunol.0800854
   O'Connell RM, 2010, NAT REV IMMUNOL, V10, P111, DOI 10.1038/nri2708
   Palazón A, 2012, CLIN CANCER RES, V18, P1207, DOI 10.1158/1078-0432.CCR-11-1591
   Percharde M, 2012, GENE DEV, V26, P2286, DOI 10.1101/gad.195545.112
   Petrocca F, 2008, CANCER RES, V68, P8191, DOI 10.1158/0008-5472.CAN-08-1768
   Petrocca F, 2008, CANCER CELL, V13, P272, DOI 10.1016/j.ccr.2008.02.013
   Ramalingam P, 2014, RNA, V20, P76, DOI 10.1261/rna.041814.113
   Rongvaux A, 2014, CELL, V159, P1563, DOI 10.1016/j.cell.2014.11.037
   Schreiber RD, 2011, SCIENCE, V331, P1565, DOI 10.1126/science.1203486
   Shen J, 2013, NATURE, V497, P383, DOI 10.1038/nature12080
   Sun LJ, 2013, SCIENCE, V339, P786, DOI 10.1126/science.1232458
   van den Beucken T, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6203
   Vesely MD, 2011, ANNU REV IMMUNOL, V29, P235, DOI 10.1146/annurev-immunol-031210-101324
   White MJ, 2014, CELL, V159, P1549, DOI 10.1016/j.cell.2014.11.036
   Wu MZ, 2015, CANCER RES, V75, P3912, DOI 10.1158/0008-5472.CAN-14-3208
   Yan J, 2006, CANCER RES, V66, P11039, DOI 10.1158/0008-5472.CAN-06-2442
   Yang MH, 2008, NAT CELL BIOL, V10, P295, DOI 10.1038/ncb1691
   Zitvogel L, 2006, NAT REV IMMUNOL, V6, P715, DOI 10.1038/nri1936
NR 43
TC 99
Z9 113
U1 2
U2 50
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1465-7392
EI 1476-4679
J9 NAT CELL BIOL
JI Nat. Cell Biol.
PD OCT
PY 2017
VL 19
IS 10
BP 1286
EP +
DI 10.1038/ncb3615
PG 25
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA FI5HP
UT WOS:000412013400020
PM 28920955
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Truong, PK
   Lao, TD
   Le, TAH
AF Phuong Kim Truong
   Thuan Duc Lao
   Thuy Ai Huyen Le
TI Evaluation of <i>p16<SUP>INK4α</SUP></i> Hypermethylation from
   Liquid-based Pap Test Samples in Vietnamese Population
SO IRANIAN JOURNAL OF PUBLIC HEALTH
LA English
DT Article
DE Cervical cancer; Hypermethylation; MSP; p16(INK4 alpha); Vietnamese
   population
ID GENE PROMOTER METHYLATION; CERVICAL-CANCER; HUMAN-PAPILLOMAVIRUS; DNA
   METHYLATION; BREAST-CANCER; HPV INFECTION; VACCINATION; P16(INK4A); P16;
   AGE
AB Background: Human papillomavirus (HPV) infection has been considered as main cause of cervical cancer. Recently, aberrant DNA methylation at tumor suppressor genes (TSGs), leading to inactivation, has also been an early epigenetic event and cofactor in cervical carcinogenesis. This study was performed to evaluate an association between the hypermethylation of p16(INK4 alpha) gene's promoter and HPV exposure in non-invasive samples (liquid-based papanicolaous samples) in Vietnamese population.
   Methods: 109 liquid-based papanicolaous test samples were archived and admitted from the Medic Medical Center and Au Lac Clinic Laboratory, Vietnam, from 2011-2014. Methylation-Specific-PCR (MSP) was performed to analyze methylation status from the liquid-based papanicolaous test samples identified whether HPV/or non-HPV, highrisk/low-risk HPV infection.
   Results: An upward trend was observed concerning the p(16INK4 alpha) hypermethylation frequency in high-risk HPV infection, counting for 55.6%, and the low methylation frequency in low-risk and non-HPV infected samples, counting for 22.9%, 8.0%, respectively. The significant correlation between candidate p(16INK4 alpha) hypermethylation and HPV exposure was observed (P<0.0001). Moreover, the odds ratio (OR) and relative risk (RR) were found in statistical significant value. (OR= 5.76, 95% CI: 2.36-14.04, P<0.01; RR= 3.11, 95% CI: 1.75-5.53, P<0.01).
   Conclusion: Presence of p(16INK4 alpha) hypermethylation was the specific characteristic of high-risk HPV infected samples in Vietnamese population. The OR and RR values showed that the strong correlation between p(16INK4 alpha) hypermethylation and high-risk HPV infection, in which increased the risk of cervical cancer. The combination of p(16INK4 alpha) hypermethylation and HPV detection based biomarker could be used in non-invasive samples obtained from high-risk cancer patients, offer significant practical advantages.
C1 [Phuong Kim Truong] Vietnam Natl Univ, Univ Sci, Fac Biol & Biotechnol, Ho Chi Minh, Vietnam.
   [Phuong Kim Truong; Thuan Duc Lao; Thuy Ai Huyen Le] Ho Chi Minh City Open Univ, Fac Biotechnol, Ho Chi Minh, Vietnam.
C3 Vietnam National University Ho Chi Minh City (VNUHCM) System; Ho Chi
   Minh City Open University
RP Le, TAH (通讯作者)，Ho Chi Minh City Open Univ, Fac Biotechnol, Ho Chi Minh, Vietnam.
EM thuy.lha@ou.edu.vn
RI Lao, Thuan/IWD-8612-2023
OI Le, Thuy AI Huyen/0000-0002-4825-3299; Lao, Thuan
   Duc/0000-0002-6459-3058
FU Ho Chi Minh City Open University, Ho Chi Minh City, Vietnam
FX This research was conducted with the support of the Ho Chi Minh City
   Open University, Ho Chi Minh City, Vietnam.
CR Attaleb M, 2009, ONCOL RES, V18, P185, DOI 10.3727/096504009790217416
   Baylin SB, 2001, HUM MOL GENET, V10, P687, DOI 10.1093/hmg/10.7.687
   Burd EM, 2003, CLIN MICROBIOL REV, V16, P1, DOI 10.1128/CMR.16.1.1-17.2003
   Burgers WA, 2007, ONCOGENE, V26, P1650, DOI 10.1038/sj.onc.1209950
   Carestiato FN, 2013, REV INST MED TROP SP, V55, P329, DOI 10.1590/S0036-46652013000500006
   Castle PE, 2016, EPIDEMIOL INFECT, V144, P449, DOI 10.1017/S0950268815002198
   Duenas-Gonzalez A, 2005, MOL CANCER, V4, DOI 10.1186/1476-4598-4-38
   Esteller M, 2001, CANCER RES, V61, P3225
   Fleischhacker M, 2007, BBA-REV CANCER, V1775, P181, DOI 10.1016/j.bbcan.2006.10.001
   Galm Oliver, 2005, V113, P279, DOI 10.1385/1-59259-916-8:279
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Ingles DJ, 2015, J INFECT DIS, V211, P1060, DOI 10.1093/infdis/jiu587
   Jenkins D, 2008, GYNECOL ONCOL, V110, pS18, DOI 10.1016/j.ygyno.2008.06.027
   Jeong DH, 2006, INT J GYNECOL CANCER, V16, P1234, DOI 10.1111/j.1525-1438.2006.00522.x
   Jha AK, 2012, ONCOL LETT, V3, P1331, DOI 10.3892/ol.2012.655
   Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947
   Kahn SL, 2008, CANCER CYTOPATHOL, V114, P57, DOI 10.1002/cncr.23258
   Lao DT, 2013, CURRENT TRENDS BIOTE, V7, P708
   Lin JY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106384
   Lu Qiang, 2012, Methods Mol Biol, V863, P155, DOI 10.1007/978-1-61779-612-8_9
   Narayan Gopeshwar, 2003, Mol Cancer, V2, P24, DOI 10.1186/1476-4598-2-24
   Nuovo GJ, 1999, P NATL ACAD SCI USA, V96, P12754, DOI 10.1073/pnas.96.22.12754
   Ohtani N, 2014, J MED INVEST, V51, P146
   Truong PK, 2014, ASIAN PAC J CANCER P, V15, P9607, DOI 10.7314/APJCP.2014.15.22.9607
   Qureshi SA, 2010, INT J SURG, V8, P194, DOI 10.1016/j.ijsu.2010.02.001
   Schwarzenbach H, 2015, BREAST CANCER RES, V17, DOI 10.1186/s13058-015-0645-5
   SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0
   Szalmás A, 2009, SEMIN CANCER BIOL, V19, P144, DOI 10.1016/j.semcancer.2009.02.011
   Truong Phuong Kim, 2015, Asian Pac J Cancer Prev, V16, P2209
   Yoder JA, 1997, TRENDS GENET, V13, P335, DOI 10.1016/S0168-9525(97)01181-5
   zurHausen H, 1996, BBA-REV CANCER, V1288, pF55
NR 31
TC 2
Z9 2
U1 0
U2 0
PU IRANIAN SCIENTIFIC SOCIETY MEDICAL ENTOMOLOGY
PI TEHRAN
PA SCHOOL PUBLIC HEALTH & INST HEALTH RESEARCH, TEHRAN UNIV MEDICAL
   SCIENCES, P O BOX  6446-14155, TEHRAN, 00000, IRAN
SN 2251-6085
EI 2251-6093
J9 IRAN J PUBLIC HEALTH
JI Iran J. Public Health
PD SEP
PY 2017
VL 46
IS 9
BP 1204
EP 1210
PG 7
WC Public, Environmental & Occupational Health
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Public, Environmental & Occupational Health
GA FJ0FH
UT WOS:000412383400006
PM 29026785
DA 2025-01-12
ER

PT J
AU Tiash, S
   Kamaruzman, NIB
   Chowdhury, EH
AF Tiash, Snigdha
   Kamaruzman, Nur Izyani Binti
   Chowdhury, Ezharul Hoque
TI Carbonate apatite nanoparticles carry siRNA(s) targeting growth factor
   receptor genes <i>egfr1</i> and <i>erbb2</i> to regress mouse breast
   tumor
SO DRUG DELIVERY
LA English
DT Article
DE Growth factor receptors; siRNA; carbonate apatite nanoparticles (NPs);
   gene silencing; breast cancer; tumor regression
ID FACTOR-I RECEPTOR; CANCER CELLS; EXPRESSION; APOPTOSIS; PROLIFERATION;
   HER2; COMPETITION; INHIBITION; SEQUENCE; PATHWAY
AB Cancer cells lose their control on cell cycle by numerous genetic and epigenetic alterations. In a tumor, these cells highly express growth factor receptors (GFRs), eliciting growth, and cell division. Among the GFRs, epidermal growth factor receptor-1 (EGFR1) (Her1/ERBB1) and epidermal growth factor receptor-2 (EGFR2) (Her2/ERBB2) from epidermal growth factor (EGF) family and insulin-like growth factor-1 receptor (IGF1R) are highly expressed on breast cancer cells, thus contributing to the aggressive growth and invasiveness, have been focused in this study. Moreover, overexpression of these receptors is related to suppression of cell death and conferring resistance against the classical drugs used to treat cancer nowadays. Therefore, silencing of these GFRs-encoding genes by using selective small interfering RNAs (siRNAs) could be a powerful approach to treat breast cancer. The inorganic pH sensitive carbonate apatite nanoparticles (NPs) were used as a nano-carrier to deliver siRNA(s) against single or multiple GFR genes in breast cancer cells as well as in a mouse model of breast carcinoma. Silencing of egfr1 and erbb2 simultaneously led to a reduction in cell viability with an increase in cell death signal in the cancer cells and regression of tumor growth in vivo.
C1 [Tiash, Snigdha; Kamaruzman, Nur Izyani Binti; Chowdhury, Ezharul Hoque] Monash Univ Malaysia, Jeffrey Cheah Sch Med & Hlth Sci, Jalan Lagoon Selatan, Bandar Sunway, Malaysia.
C3 Monash University; Monash University Malaysia
RP Chowdhury, EH (通讯作者)，Monash Univ Malaysia, Jeffrey Cheah Sch Med & Hlth Sci, Jalan Lagoon Selatan, Bandar Sunway, Malaysia.
EM md.ezharul.hoque@monash.edu
RI Chowdhury, Ezharul/Y-5249-2019
OI Chowdhury, Ezharul Hoque/0000-0002-5705-841X; Kamaruzman, Nur
   Izyani/0000-0001-5748-2811
CR Allen LF, 2002, SEMIN ONCOL, V29, P11, DOI 10.1053/sonc.2002.34049
   Butt AJ, 1999, IMMUNOL CELL BIOL, V77, P256, DOI 10.1046/j.1440-1711.1999.00822.x
   Campiglio M, 2004, J CELL PHYSIOL, V198, P259, DOI 10.1002/jcp.10411
   Castanotto D, 2007, NUCLEIC ACIDS RES, V35, P5154, DOI 10.1093/nar/gkm543
   Chong YM, 2006, BREAST CANCER RES TR, V99, P275, DOI 10.1007/s10549-006-9215-y
   Chua M.J., 2013, OA Cancer, V7, DOI [10.13172/2053-3918-1-1-603, DOI 10.13172/2053-3918-1-1-603]
   Dent P, 1999, MOL BIOL CELL, V10, P2493, DOI 10.1091/mbc.10.8.2493
   DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917
   Gao S, 2009, MOL THER, V17, P1225, DOI 10.1038/mt.2009.91
   Gee JM, 2005, ENDOCR-RELAT CANCER, V12, pS99, DOI 10.1677/erc.1.01005
   Grimm D, 2006, NATURE, V441, P537, DOI 10.1038/nature04791
   GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578
   Guy CT, 1996, J BIOL CHEM, V271, P7673, DOI 10.1074/jbc.271.13.7673
   Herbst RS, 2002, CANCER-AM CANCER SOC, V94, P1593, DOI 10.1002/cncr.10372
   Hossain S, 2010, J CONTROL RELEASE, V147, P101, DOI 10.1016/j.jconrel.2010.06.024
   Hurtado A, 2008, NATURE, V456, P663, DOI 10.1038/nature07483
   Hutvágner G, 2004, PLOS BIOL, V2, P465, DOI 10.1371/journal.pbio.0020098
   Kaulfuss S, 2009, MOL CANCER THER, V8, P821, DOI 10.1158/1535-7163.MCT-09-0058
   Khan AA, 2009, NAT BIOTECHNOL, V27, P549, DOI 10.1038/nbt.1543
   KLIJN JGM, 1992, ENDOCR REV, V13, P3, DOI 10.1210/er.13.1.3
   Knowlden JM, 2003, ENDOCRINOLOGY, V144, P1032, DOI 10.1210/en.2002-220620
   Koller E, 2006, NUCLEIC ACIDS RES, V34, P4467, DOI 10.1093/nar/gkl589
   Kothari S, 2003, ONCOGENE, V22, P4734, DOI 10.1038/sj.onc.1206666
   Kumar R, 1996, CLIN CANCER RES, V2, P1215
   Kunnath AP, 2014, J NANOMED NANOTECH S, VS9
   Kunnath AP., 2014, J CANC SCI THER, V6, P99, DOI DOI 10.4172/1948-5956.1000256
   Layzer JM, 2004, RNA, V10, P766, DOI 10.1261/rna.5239604
   Morrissey DV, 2005, NAT BIOTECHNOL, V23, P1002, DOI 10.1038/nbt1122
   Nahta R, 2005, CANCER RES, V65, P11118, DOI 10.1158/0008-5472.CAN-04-3841
   Nahta R, 2003, ONCOLOGIST, V8, P5, DOI 10.1634/theoncologist.8-1-5
   Rajah R, 1997, J BIOL CHEM, V272, P12181, DOI 10.1074/jbc.272.18.12181
   Reginato MJ, 2003, NAT CELL BIOL, V5, P733, DOI 10.1038/ncb1026
   SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106
   Soutschek J, 2004, NATURE, V432, P173, DOI 10.1038/nature03121
   Stephen RL, 2001, J BIOL CHEM, V276, P40080, DOI 10.1074/jbc.M105892200
   Subik K, 2010, BREAST CANCER-BASIC, V4, P35
   Tiash S, 2014, CURR DRUG DELIV, V11, P214, DOI 10.2174/1567201810666131211101819
   ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0
   Vickers TA, 2007, NUCLEIC ACIDS RES, V35, P6598, DOI 10.1093/nar/gkm663
   Voldborg BR, 1997, ANN ONCOL, V8, P1197, DOI 10.1023/A:1008209720526
   WATERFIELD MD, 1989, BRIT MED BULL, V45, P541, DOI 10.1093/oxfordjournals.bmb.a072341
   Xiong L, 2007, J CELL BIOL, V178, P995, DOI 10.1083/jcb.200703044
   YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0
   Yarden Y, 2001, ONCOLOGY-BASEL, V61, P1, DOI 10.1159/000055396
   Yarden Y, 2001, EUR J CANCER, V37, pS3
   Yee D, 2002, SEMIN ONCOL, V29, P86, DOI 10.1053/sonc.2002.34060
   Yonesaka K, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002442
NR 47
TC 23
Z9 24
U1 0
U2 14
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1071-7544
EI 1521-0464
J9 DRUG DELIV
JI Drug Deliv.
PD NOV 9
PY 2017
VL 24
IS 1
BP 1721
EP 1730
DI 10.1080/10717544.2017.1396385
PG 10
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA FN2FW
UT WOS:000415807500001
PM 29119846
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Clermont, PL
   Fornaro, L
   Crea, F
AF Clermont, Pier-Luc
   Fornaro, Lorenzo
   Crea, Francesco
TI Elevated expression of a pharmacologic Polycomb signature predicts poor
   prognosis in gastric and breast cancer
SO EPIGENOMICS
LA English
DT Article
DE cancer; DZNeP; epigenetics; EZH2; Polycomb; prognostic; signature
ID SINGLE NUCLEOTIDE POLYMORPHISM; PROSTATE-CANCER; COLORECTAL-CANCER;
   TARGETING EZH2; MECHANISMS; GENES; PROGRESSION; CELLS; PHOSPHORYLATION;
   EPIGENETICS
AB Aim: Polycomb Group complexes are epigenetic repressors that silence tumor suppressive genes. Studies demonstrated that pharmacologic inhibition of Polycomb Group complexes with 3-deazaneplanocin A (DZNeP) induces cancer cell death by re-expressing silenced genes. Here we evaluate the prognostic significance of DZNeP target genes in gastric and breast cancer. Patients & methods/materials: The prognostic impact of a DZNeP-regulated gene signature was investigated using the KM Plotter and cBio Portal resources containing microarray data from tumor tissue. Results: We report that elevated expression of DZNeP targets is associated with poor clinical outcome in gastric and breast cancer. In gastric cancer, elevated expression of DZNeP signature is inversely correlated with decreased overall survival. In breast cancer, DZNeP signature predicted poor prognosis in HER2+ tumors but not in HER2(-) neoplasms. Conclusion: These findings demonstrate that DZNeP target genes are not predictive of better but rather of poor clinical outcome in gastric and breast cancer.
C1 [Clermont, Pier-Luc] Univ Laval, Fac Med, Quebec City, PQ, Canada.
   [Fornaro, Lorenzo] Univ Pisana, Azienda Osped, Unit Med Oncol 2, Pisa, Italy.
   [Crea, Francesco] Open Univ, Dept Life Hlth & Chem Sci, Walton Hall, Milton Keynes, Bucks, England.
C3 Laval University; University of Pisa; Azienda Ospedaliero Universitaria
   Pisana; Open University - UK
RP Clermont, PL (通讯作者)，Univ Laval, Fac Med, Quebec City, PQ, Canada.
EM pier-luc.clermont.1@ulaval.ca
RI Francesco, Crea/I-8383-2015; Fornaro, Lorenzo/LRU-4021-2024
OI Fornaro, Lorenzo/0000-0002-0187-5904; Crea,
   Francesco/0000-0002-4903-2973
CR [Anonymous], 2016, NAT COMMUN
   Avan A, 2012, MOL CANCER THER, V11, P1735, DOI 10.1158/1535-7163.MCT-12-0037
   Bass AJ, 2014, NATURE, V513, P202, DOI 10.1038/nature13480
   Baylin SB, 2006, NAT REV CANCER, V6, P107, DOI 10.1038/nrc1799
   Clermont PL, 2016, CLIN EPIGENETICS, V8, DOI 10.1186/s13148-016-0182-9
   Clermont PL, 2015, CLIN EPIGENETICS, V7, DOI 10.1186/s13148-015-0074-4
   Crea F, 2012, ANN ONCOL, V23, P1207, DOI 10.1093/annonc/mdr387
   Crea F, 2015, EPIGENOMICS-UK, V7, P757, DOI 10.2217/epi.15.35
   Crea F, 2012, CANCER METAST REV, V31, P753, DOI 10.1007/s10555-012-9387-3
   Crea F, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-40
   Crea F, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-265
   Dawson MA, 2012, CELL, V150, P12, DOI 10.1016/j.cell.2012.06.013
   Du XY, 2017, EUR REV MED PHARMACO, V21, P1495
   Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI [10.1056/NEJMra072067, 10.1093/carcin/bgp220]
   Fornaro L, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1889-2
   Gao SB, 2014, MOL CANCER RES, V12, P1388, DOI 10.1158/1541-7786.MCR-14-0034
   Guo DQ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113649
   Györffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9
   Kaneko S, 2014, MOL CELL, V53, P290, DOI 10.1016/j.molcel.2013.11.012
   Kaneko S, 2010, GENE DEV, V24, P2615, DOI 10.1101/gad.1983810
   Kerppola TK, 2009, TRENDS CELL BIOL, V19, P692, DOI 10.1016/j.tcb.2009.10.001
   Kim KH, 2016, NAT MED, V22, P128, DOI 10.1038/nm.4036
   Li QY, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-474
   Mihály Z, 2013, BREAST CANCER RES TR, V140, P219, DOI 10.1007/s10549-013-2622-y
   Miranda TB, 2009, MOL CANCER THER, V8, P1579, DOI 10.1158/1535-7163.MCT-09-0013
   Morera L, 2016, CLIN EPIGENETICS, V8, DOI 10.1186/s13148-016-0223-4
   Morey L, 2010, TRENDS BIOCHEM SCI, V35, P323, DOI 10.1016/j.tibs.2010.02.009
   Moses H, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a003277
   NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840
   Paolicchi E, 2013, ONCOL LETT, V6, P1487, DOI 10.3892/ol.2013.1559
   Richly H, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.84
   Sato T, 2013, SCI REP-UK, V3, DOI 10.1038/srep01911
   Simon JA, 2013, MOL CELL, V49, P808, DOI 10.1016/j.molcel.2013.02.013
   Simon JA, 2009, NAT REV MOL CELL BIO, V10, P697, DOI 10.1038/nrm2763
   Szász AM, 2016, ONCOTARGET, V7, P49322, DOI 10.18632/oncotarget.10337
   Tan J, 2007, GENE DEV, V21, P1050, DOI 10.1101/gad.1524107
   Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075
   Wan JH, 2015, NUCLEIC ACIDS RES, V43, P3591, DOI 10.1093/nar/gkv238
   Wang P, 2016, BIOCHEM BIOPH RES CO, V479, P91, DOI 10.1016/j.bbrc.2016.09.040
   Xu LZ, 2017, ONCOGENE, V36, P304, DOI 10.1038/onc.2016.202
   Yan JL, 2016, BLOOD, V128, P948, DOI 10.1182/blood-2016-01-690701
NR 41
TC 4
Z9 4
U1 1
U2 12
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
   1QB, ENGLAND
SN 1750-1911
EI 1750-192X
J9 EPIGENOMICS-UK
JI Epigenomics
PD OCT
PY 2017
VL 9
IS 10
BP 1329
EP 1335
DI 10.2217/epi-2017-0074
PG 7
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA FI1CV
UT WOS:000411668500007
PM 28875726
OA Green Submitted, Green Accepted
DA 2025-01-12
ER

PT J
AU Xie, G
   Liu, X
   Zhang, Y
   Li, W
   Liu, S
   Chen, Z
   Xu, B
   Yang, J
   He, L
   Zhang, Z
   Jin, T
   Yi, X
   Sun, L
   Shang, Y
   Liang, J
AF Xie, G.
   Liu, X.
   Zhang, Y.
   Li, W.
   Liu, S.
   Chen, Z.
   Xu, B.
   Yang, J.
   He, L.
   Zhang, Z.
   Jin, T.
   Yi, X.
   Sun, L.
   Shang, Y.
   Liang, J.
TI UTX promotes hormonally responsive breast carcinogenesis through
   feed-forward transcription regulation with estrogen receptor
SO ONCOGENE
LA English
DT Article
ID ACUTE LYMPHOBLASTIC-LEUKEMIA; INTEGRATIVE GENOMICS VIEWER; H3K27ME3
   DEMETHYLASE UTX; CANCER-CELLS; GENE-REGULATION; TUMOR MICROENVIRONMENT;
   ER-ALPHA; POLYCOMB; JMJD3; METHYLATION
AB UTX is implicated in embryonic development and lineage specification. However, how this X-linked histone demethylase contributes to the occurrence and progression of breast cancer remains to be clarified. Here we report that UTX is physically associated with estrogen receptor (ER) and functions in ER-regulated transcription. We showed that UTX coordinates with JHDM1D and CBP to direct H3K27 methylation-acetylation transition and to create a permissive chromatin state on ER targets. Genome-wide analysis of the transcriptional targets of UTX by ChIP-seq identified a set of genes such as chemokine receptor CXCR4 that are intimately involved in breast cancer tumorigenesis and metastasis. We demonstrated that UTX promotes the proliferation and migration of ER+ breast cancer cells. Interestingly, UTX itself is transactivated by ER, forming a feed-forward loop in the regulation of hormone response. Indeed, UTX is upregulated during ER+ breast cancer progression, and the expression level of UTX is positively correlated with that of CXCR4 and negatively correlated with the overall survival of ER+ breast cancer patients. Our study identified a feed-forward loop between UTX and ER in the regulation of hormonally responsive breast carcinogenesis, supporting the pursuit of UTX as an emerging therapeutic target for the intervention of certain ER+ breast cancer with specific epigenetic vulnerability.
C1 [Xie, G.; Zhang, Y.; Li, W.; Liu, S.; Chen, Z.; Xu, B.; Yang, J.; He, L.; Zhang, Z.; Jin, T.; Yi, X.; Sun, L.; Shang, Y.; Liang, J.] Peking Univ, Dept Biochem & Mol Biol, Key Lab Carcinogenesis & Translat Res, Sch Basic Med Sci,Minist Educ,Hlth Sci Ctr, 38 Xueyuan Rd, Beijing 100191, Peoples R China.
   [Liu, X.; Shang, Y.] Tianjin Med Univ, Sch Basic Med Sci, Dept Biochem & Mol Biol, Tianjin Key Lab Med Epigenet, Tianjin, Peoples R China.
   [Shang, Y.] Capital Med Univ, Sch Basic Med Sci, Dept Biochem & Mol Biol, Beijing, Peoples R China.
C3 Peking University; Tianjin Medical University; Capital Medical
   University
RP Liang, J (通讯作者)，Peking Univ, Dept Biochem & Mol Biol, Key Lab Carcinogenesis & Translat Res, Sch Basic Med Sci,Minist Educ,Hlth Sci Ctr, 38 Xueyuan Rd, Beijing 100191, Peoples R China.
EM liang_jing@bjmu.edu.cn
RI Chen, Zhe/AAA-3235-2020; Xie, Guojia/KCK-5459-2024
OI Xie, Guojia/0000-0002-8250-6157; Chen, Zhe/0000-0002-5303-9879
FU Ministry of Science and Technology of China [2014CB542004]; National
   Natural Science Foundation of China [31371301, 81572771, 91219201,
   81130048]
FX This work was supported by grants (973 Program: 2014CB542004 to JL and
   YS) from the Ministry of Science and Technology of China, and grants
   (31371301 and 81572771 to JL and 91219201 and 81130048 to YS) from the
   National Natural Science Foundation of China.
CR Agger K, 2007, NATURE, V449, P731, DOI 10.1038/nature06145
   Benyoucef A, 2016, GENE DEV, V30, P508, DOI 10.1101/gad.276790.115
   CAVAILLES V, 1995, EMBO J, V14, P3741, DOI 10.1002/j.1460-2075.1995.tb00044.x
   Chen YC, 2015, HEPATOLOGY, V61, P1591, DOI 10.1002/hep.27665
   Choi HJ, 2015, EMBO REP, V16, P1288, DOI 10.15252/embr.201540244
   Cui YK, 2006, MOL ENDOCRINOL, V20, P2020, DOI 10.1210/me.2005-0063
   De Santa F, 2007, CELL, V130, P1083, DOI 10.1016/j.cell.2007.08.019
   Ezponda T, 2014, CLIN CANCER RES, V20, P5001, DOI 10.1158/1078-0432.CCR-13-2499
   Guo F, 2016, ONCOGENE, V35, P816, DOI 10.1038/onc.2015.139
   Harburg GC, 2011, J MAMMARY GLAND BIOL, V16, P257, DOI 10.1007/s10911-011-9225-1
   Hart CD, 2015, NAT REV CLIN ONCOL, V12, P541, DOI 10.1038/nrclinonc.2015.99
   Hong SH, 2007, P NATL ACAD SCI USA, V104, P18439, DOI 10.1073/pnas.0707292104
   Ichinose H, 1997, GENE, V188, P95, DOI 10.1016/S0378-1119(96)00785-8
   Jin QH, 2011, EMBO J, V30, P249, DOI 10.1038/emboj.2010.318
   Ju BG, 2006, SCIENCE, V312, P1798, DOI 10.1126/science.1127196
   Kim JH, 2014, CANCER RES, V74, P1705, DOI 10.1158/0008-5472.CAN-13-1896
   Kim KH, 2016, NAT MED, V22, P128, DOI 10.1038/nm.4036
   Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100
   Lan F, 2007, NATURE, V449, P689, DOI 10.1038/nature06192
   Lavery DN, 2005, BIOCHEM J, V391, P449, DOI 10.1042/BJ20050872
   Lee MG, 2007, SCIENCE, V318, P447, DOI 10.1126/science.1149042
   Lee YH, 2014, TUMOR BIOL, V35, P7699, DOI 10.1007/s13277-014-2027-5
   Liang J, 2013, ANNU REV PHYSIOL, V75, P225, DOI 10.1146/annurev-physiol-030212-183708
   Liu T, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-8-r83
   Margueron R, 2011, NATURE, V469, P343, DOI 10.1038/nature09784
   Mohammed H, 2013, CELL REP, V3, P342, DOI 10.1016/j.celrep.2013.01.010
   Müller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016
   Ntziachristos P, 2014, NATURE, V514, P513, DOI 10.1038/nature13605
   Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2
   Park UH, 2016, ONCOGENE, V35, P3742, DOI 10.1038/onc.2015.443
   Ratajczak MZ, 2006, LEUKEMIA, V20, P1915, DOI 10.1038/sj.leu.2404357
   Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2
   Rhodes LV, 2011, CANCER RES, V71, P603, DOI 10.1158/0008-5472.CAN-10-3185
   Ringnér M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017911
   Robinson JT, 2011, NAT BIOTECHNOL, V29, P24, DOI 10.1038/nbt.1754
   Rocha-Viegas L, 2014, MOL CELL BIOL, V34, P3765, DOI 10.1128/MCB.00839-14
   Scala S, 2015, CLIN CANCER RES, V21, P4278, DOI 10.1158/1078-0432.CCR-14-0914
   Schuettengruber B, 2007, CELL, V128, P735, DOI 10.1016/j.cell.2007.02.009
   Shalem O, 2014, SCIENCE, V343, P84, DOI 10.1126/science.1247005
   Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4
   Shang YF, 2002, SCIENCE, V295, P2465, DOI 10.1126/science.1068537
   Shi L, 2011, P NATL ACAD SCI USA, V108, P7541, DOI 10.1073/pnas.1017374108
   Simons SS, 2013, MOL CELL ENDOCRINOL, V376, P81, DOI 10.1016/j.mce.2013.06.007
   Smith E, 2014, NAT STRUCT MOL BIOL, V21, P210, DOI 10.1038/nsmb.2784
   Smith MCP, 2004, CANCER RES, V64, P8604, DOI 10.1158/0008-5472.CAN-04-1844
   Svotelis A, 2011, EMBO J, V30, P3947, DOI 10.1038/emboj.2011.284
   Szász AM, 2016, ONCOTARGET, V7, P49322, DOI 10.18632/oncotarget.10337
   Teicher BA, 2010, CLIN CANCER RES, V16, P2927, DOI 10.1158/1078-0432.CCR-09-2329
   Thorvaldsdóttir H, 2013, BRIEF BIOINFORM, V14, P178, DOI 10.1093/bib/bbs017
   Tsukada YI, 2010, GENE DEV, V24, P432, DOI 10.1101/gad.1864410
   Van der Meulen J, 2015, BLOOD, V125, P13, DOI 10.1182/blood-2014-05-577270
   Van der Meulen J, 2014, EPIGENETICS-US, V9, P658, DOI 10.4161/epi.28298
   van Haaften G, 2009, NAT GENET, V41, P521, DOI 10.1038/ng.349
   Wade MA, 2015, NUCLEIC ACIDS RES, V43, P196, DOI 10.1093/nar/gku1298
   Wang JK, 2010, GENE DEV, V24, P327, DOI 10.1101/gad.1882610
   Wu HJ, 2005, NATURE, V438, P981, DOI 10.1038/nature04225
   Xu C, 2015, DRUG DES DEV THER, V9, P4953, DOI 10.2147/DDDT.S84932
   Yu YC, 2014, DNA CELL BIOL, V33, P543, DOI 10.1089/dna.2013.2289
   Zhang H, 2004, GENE DEV, V18, P1753, DOI 10.1101/gad.1194704
   Zhang H, 2006, EMBO J, V25, P4223, DOI 10.1038/sj.emboj.7601306
   Zhang XHF, 2013, CLIN CANCER RES, V19, P6389, DOI 10.1158/1078-0432.CCR-13-0838
   Zwart W, 2011, EMBO J, V30, P4764, DOI 10.1038/emboj.2011.368
NR 62
TC 41
Z9 48
U1 0
U2 15
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-9232
EI 1476-5594
J9 ONCOGENE
JI Oncogene
PD SEP 28
PY 2017
VL 36
IS 39
BP 5497
EP 5511
DI 10.1038/onc.2017.157
PG 15
WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
GA FI4RG
UT WOS:000411960500006
PM 28534508
DA 2025-01-12
ER

PT J
AU Alsaqer, SF
   Tashkandi, MM
   Kartha, VK
   Yang, YT
   Alkheriji, Y
   Salama, A
   Varelas, X
   Kukuruzinska, M
   Monti, S
   Bais, MV
AF Alsaqer, Saqer F.
   Tashkandi, Mustafa M.
   Kartha, Vinay K.
   Yang, Ya-Ting
   Alkheriji, Yazeed
   Salama, Andrew
   Varelas, Xaralabos
   Kukuruzinska, Maria
   Monti, Stefano
   Bais, Manish V.
TI Inhibition of LSD1 epigenetically attenuates oral cancer growth and
   metastasis
SO ONCOTARGET
LA English
DT Article
DE LSD1; CTGF; OSCC; PDX; orthotopic mouse model
ID SQUAMOUS-CELL CARCINOMA; LYSYL OXIDASE PROPEPTIDE; LYSINE DEMETHYLASE
   LSD1; BREAST-CANCER; TRANSCRIPTIONAL ACTIVITY; PROBE LEVEL; METHYLATION;
   RECEPTOR; EMT; REPRESSION
AB Lysine-specific demethylase 1 (LSD1) is a nuclear histone demethylase and a member of the amine oxidase (AO) family. LSD1 is a flavin-containing AO that specifically catalyzes the demethylation of mono- and di-methylated histone H3 lysine 4 through an FAD-dependent oxidative reaction. LSD1 is inappropriately upregulated in lung, liver, brain and esophageal cancers, where it promotes cancer initiation, progression, and metastasis. However, unlike other lysine-specific demethylases, the role and specific targets of LSD1 in oral squamous cell carcinoma (OSCC) pathogenesis remain unknown. We show that LSD1 protein expression was increased in malignant OSCC tissues in a clinical tissue microarray, and its expression correlated with progressive tumor stages. In an orthotopic oral cancer mouse model, LSD1 overexpression in aggressive HSC-3 cells promoted metastasis whereas knockdown of LSD1 inhibited tumor spread, suggesting that LSD1 is a key regulator of OSCC metastasis. Pharmacological inhibition of LSD1 using a specific small molecule inhibitor, GSK-LSD1, down-regulated EGF signaling pathway. Further, GSK-LSD1 attenuates CTGF/CCN2, MMP13, LOXL4 and vimentin expression but increased E-cadherin expression in preexisting, patient-derived tonsillar OSCC xenografts. Similarly, GSK-LSD1 inhibited proliferation and CTGF expression in mesenchymal cells, including myoepithelial cells and osteosarcoma cells. In addition, gene set enrichment analysis revealed that GSK-LSD1 increased p53 expression and apoptosis while inhibiting c-myc, beta-catenin and YAP-induced oncogenic transcriptional networks. These data reveal that aberrant LSD1 activation regulates key OSCC microenvironment and EMT promoting factors, including CTGF, LOXL4 and MMP13.
C1 [Alsaqer, Saqer F.; Tashkandi, Mustafa M.; Yang, Ya-Ting; Alkheriji, Yazeed; Kukuruzinska, Maria; Bais, Manish V.] Boston Univ, Henry M Goldman Sch Dent Med, Dept Mol & Cell Biol, Boston, MA 02215 USA.
   [Kartha, Vinay K.; Monti, Stefano] Boston Univ, Bioinformat Program, Boston, MA 02215 USA.
   [Kartha, Vinay K.; Monti, Stefano] Boston Univ, Sch Med, Boston, MA 02118 USA.
   [Salama, Andrew] Boston Univ, Henry M Goldman Sch Dent Med, Dept Oral & Maxillofacial Surg, Boston, MA 02215 USA.
   [Varelas, Xaralabos] Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA.
C3 Boston University; Boston University; Boston University; Boston
   University; Boston University
RP Bais, MV (通讯作者)，Boston Univ, Henry M Goldman Sch Dent Med, Dept Mol & Cell Biol, Boston, MA 02215 USA.
EM bmanish@bu.edu
RI Varelas, Xaralabos/ABB-9141-2020
OI Monti, Stefano/0000-0002-9376-0660; Varelas,
   Xaralabos/0000-0002-2882-4541; KARTHA, VINAY/0000-0002-2160-2196;
   Kukukruzinska, Maria/0000-0001-5314-1454
FU NIH/NIDCR [R03DE025274]; Oral Cancer Affinity Research Collaborative ARC
   [9950000118]; CTSI pilot; CTSA [U54-TR001012A]
FX The authors acknowledge NIH/NIDCR (R03DE025274) funding, Oral Cancer
   Affinity Research Collaborative ARC funding (EPOC ARC account
   9950000118), CTSI pilot funding and Center of Nanoscience, Boston
   University to Manish V. Bais. The authors acknowledge Philip Trackman
   for laboratory resources, and Tom Balon and the IVIS imaging core for
   the in vivo imaging studies. The authors thank Yuriy Alekseyev and for
   the gene array experiments and Adam Gower and CTSA grant U54-TR001012A
   for microarray data analysis. We acknowledge dbGaP for granting access
   to the TCGA data (phs000178.v9.p8).
CR Albert M, 2009, CURR OPIN GENET DEV, V19, P113, DOI 10.1016/j.gde.2009.03.004
   Amente S, 2010, ONCOGENE, V29, P3691, DOI 10.1038/onc.2010.120
   Amente S, 2013, BBA-GENE REGUL MECH, V1829, P981, DOI 10.1016/j.bbagrm.2013.05.002
   Bais MV, 2015, ONCOGENE, V34, P1928, DOI 10.1038/onc.2014.147
   Bais MV, 2009, BONE, V45, P254, DOI 10.1016/j.bone.2009.04.239
   Bais MV, 2015, ORAL ONCOL, V51, P476, DOI 10.1016/j.oraloncology.2015.01.012
   Bais MV, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031188
   Cai CM, 2014, CELL REP, V9, P1618, DOI 10.1016/j.celrep.2014.11.008
   Chen PS, 2007, J CELL SCI, V120, P2053, DOI 10.1242/jcs.03460
   Choi HJ, 2015, EMBO REP, V16, P1288, DOI 10.15252/embr.201540244
   Cordenonsi M, 2011, CELL, V147, P759, DOI 10.1016/j.cell.2011.09.048
   Dai HY, 2014, FRONT GENET, V5, DOI 10.3389/fgene.2014.00032
   Dai MH, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni179
   Di Benedetto A, 2016, ONCOTARGET, V7, P43188, DOI 10.18632/oncotarget.9668
   Ding J, 2013, BRIT J CANCER, V109, P994, DOI 10.1038/bjc.2013.364
   Feng JX, 2016, BREAST CANCER RES TR, V159, P443, DOI 10.1007/s10549-016-3959-9
   Gautier L, 2004, BIOINFORMATICS, V20, P307, DOI 10.1093/bioinformatics/btg405
   Gaweska Helena, 2011, Biomol Concepts, V2, P365
   Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80
   Goldberg AD, 2007, CELL, V128, P635, DOI 10.1016/j.cell.2007.02.006
   Hiemer SE, 2015, MOL CANCER RES, V13, P957, DOI 10.1158/1541-7786.MCR-14-0580
   Hoffmann I, 2012, MOL ONCOL, V6, P683, DOI 10.1016/j.molonc.2012.07.004
   Huang J, 2007, NATURE, V449, P105, DOI 10.1038/nature06092
   Huber JM, 2016, J CANCER RES CLIN, V142, P1955, DOI 10.1007/s00432-016-2198-0
   Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249
   Kartha VK, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0154645
   Kim M, 2015, CELL REP, V11, P270, DOI 10.1016/j.celrep.2015.03.015
   Kontaki H, 2010, MOL CELL, V39, P152, DOI 10.1016/j.molcel.2010.06.006
   Lawrence MS, 2015, NATURE, V517, P576, DOI 10.1038/nature14129
   Lin T, 2010, ONCOGENE, V29, P4896, DOI 10.1038/onc.2010.234
   Lin YW, 2010, EMBO J, V29, P1803, DOI 10.1038/emboj.2010.63
   Lv TF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035065
   Martin C, 2005, NAT REV MOL CELL BIO, V6, P838, DOI 10.1038/nrm1761
   McCloy RA, 2014, CELL CYCLE, V13, P1400, DOI 10.4161/cc.28401
   Mohammad HP, 2015, CANCER CELL, V28, P57, DOI 10.1016/j.ccell.2015.06.002
   Ozdener GB, 2016, MOL ONCOL, V10, P1, DOI 10.1016/j.molonc.2015.07.005
   Rayego-Mateos S, 2013, J MOL CELL BIOL, V5, P323, DOI 10.1093/jmcb/mjt030
   Rothenberg SM, 2012, J CLIN INVEST, V122, P1951, DOI 10.1172/JCI59889
   Shao GB, 2015, SCI REP-UK, V5, DOI 10.1038/srep15344
   Stanford EA, 2016, MOL CANCER RES, V14, P696, DOI 10.1158/1541-7786.MCR-16-0069
   Thinnes CC, 2014, BBA-GENE REGUL MECH, V1839, P1416, DOI 10.1016/j.bbagrm.2014.05.009
   Varghese F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096801
   Wang J, 2009, NAT GENET, V41, P125, DOI 10.1038/ng.268
   Wang M, 2015, BIOCHEM BIOPH RES CO, V467, P310, DOI 10.1016/j.bbrc.2015.09.164
   Wang Y, 2009, CELL, V138, P660, DOI 10.1016/j.cell.2009.05.050
   Wu YD, 2013, CELL REP, V5, P224, DOI 10.1016/j.celrep.2013.08.030
   Yatim A, 2012, MOL CELL, V48, P445, DOI 10.1016/j.molcel.2012.08.022
   Zhang XM, 2013, CELL REP, V5, P445, DOI 10.1016/j.celrep.2013.09.018
NR 48
TC 40
Z9 48
U1 2
U2 15
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD SEP 26
PY 2017
VL 8
IS 43
BP 73372
EP 73386
DI 10.18632/oncotarget.19637
PG 15
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA FI2HT
UT WOS:000411760400006
PM 29088714
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU Metzger, E
   Stepputtis, SS
   Strietz, J
   Preca, BT
   Urban, S
   Willmann, D
   Allen, A
   Zenk, F
   Iovino, N
   Bronsert, P
   Proske, A
   Follo, M
   Boerries, M
   Stickeler, E
   Xu, JC
   Wallace, MB
   Stafford, JA
   Kanouni, T
   Maurer, J
   Schüle, R
AF Metzger, Eric
   Stepputtis, Stella S.
   Strietz, Juliane
   Preca, Bogdan-Tiberius
   Urban, Sylvia
   Willmann, Dominica
   Allen, Anita
   Zenk, Fides
   Iovino, Nicola
   Bronsert, Peter
   Proske, Amelie
   Follo, Marie
   Boerries, Melanie
   Stickeler, Elmar
   Xu, Jiangchun
   Wallace, Michael B.
   Stafford, Jeffrey A.
   Kanouni, Toufike
   Maurer, Jochen
   Schuele, Roland
TI KDM4 Inhibition Targets Breast Cancer Stem-like Cells
SO CANCER RESEARCH
LA English
DT Article
ID ANDROGEN-RECEPTOR; TRANSCRIPTION; WOMEN
AB Traditional treatments for breast cancer fail to address therapyresistant cancer stem-like cells that have been characterized by changes in epigenetic regulators such as the lysine demethylase KDM4. Here, we describe an orally available, selective and potent KDM4 inhibitor (QC6352) with unique preclinical characteristics. To assess the antitumor properties of QC6352, we established a method to isolate and propagate breast cancer stem-like cells (BCSC) from individual triple-negative tumors resected from patients after neoadjuvant chemotherapy. Limiting-dilution orthotopic xenografts of these BCSCs regenerated original patient tumor histology and gene expression. QC6352 blocked BCSC proliferation, sphere formation, and xenograft tumor formation. QC6352 also abrogated expression of EGFR, which drives the growth of therapy-resistant triple-negative breast cancer cells. Our findings validate a unique BCSC culture system for drug screening and offer preclinical proof of concept for KDM4 inhibition as a new strategy to treat triple-negative breast cancer. (C) 2017 AACR.
C1 [Metzger, Eric; Urban, Sylvia; Willmann, Dominica; Allen, Anita; Schuele, Roland] Albert Ludwigs Univ Freiburg, Univ Kilnikum Freiburg, Med Fak, Urol Klin, Brcisacherstr 66, D-79106 Freiburg, Germany.
   [Metzger, Eric; Urban, Sylvia; Willmann, Dominica; Allen, Anita; Schuele, Roland] Albert Ludwigs Univ Freiburg, Univ Kilnikum Freiburg, Med Fak, Zentrale Klin Forsch, Brcisacherstr 66, D-79106 Freiburg, Germany.
   [Stepputtis, Stella S.; Strietz, Juliane; Preca, Bogdan-Tiberius; Maurer, Jochen] Univ Med Ctr Freiburg, Dept Gen & Visceral Surg, Breisacher Str 115, D-79106 Freiburg, Germany.
   [Stepputtis, Stella S.; Strietz, Juliane; Preca, Bogdan-Tiberius; Maurer, Jochen] Univ Med Ctr Freiburg, Comprehens Canc Ctr, Freiburg, Germany.
   [Stepputtis, Stella S.; Bronsert, Peter; Boerries, Melanie; Maurer, Jochen; Schuele, Roland] Deutsch Konsortium Translat Krebsforsch, Freiburg, Germany.
   [Zenk, Fides; Iovino, Nicola] Max Planck Inst lmmunobiol & Epigenet, Dept Chromatin Regulat, Freiburg, Germany.
   [Zenk, Fides; Iovino, Nicola] Stubeweg & Univ Freibur, Freiburg, Germany.
   [Bronsert, Peter] Univ Med Ctr Freiburg, Dept Surg Pathol, Freiburg, Germany.
   [Proske, Amelie] Univ Med Ctr Freiburg, Dept Hematol Oncol, Freiburg, Germany.
   [Follo, Marie] Univ Med Ctr Freiburg, Dept Internal Med 1, Freiburg, Germany.
   [Boerries, Melanie] Univ Freiburg, Inst Mol Med & Cell Res, Freiburg, Germany.
   [Stickeler, Elmar] Univ Clin Aachen UKA, Dept OBGYN, Aachen, Germany.
   [Xu, Jiangchun; Wallace, Michael B.; Stafford, Jeffrey A.; Kanouni, Toufike] Celgene Quanticel Res, San Diego, CA USA.
   [Schuele, Roland] Univ Freiburg, BIOSS Ctr Biol Signalling Studies, Freiburg, Germany.
C3 University of Freiburg; University of Freiburg; University of Freiburg;
   University of Freiburg; University of Freiburg; University of Freiburg;
   University of Freiburg; University of Freiburg; RWTH Aachen University;
   RWTH Aachen University Hospital; University of Freiburg
RP Schüle, R (通讯作者)，Albert Ludwigs Univ Freiburg, Univ Kilnikum Freiburg, Med Fak, Urol Klin, Brcisacherstr 66, D-79106 Freiburg, Germany.; Schüle, R (通讯作者)，Albert Ludwigs Univ Freiburg, Univ Kilnikum Freiburg, Med Fak, Zentrale Klin Forsch, Brcisacherstr 66, D-79106 Freiburg, Germany.; Maurer, J (通讯作者)，Univ Med Ctr Freiburg, Dept Gen & Visceral Surg, Breisacher Str 115, D-79106 Freiburg, Germany.
EM jochen.maurer@uniklinik-freiburg.de;
   roland.schuele@uniklinik-freiburg.de
RI Stickeler, Elmar/AHE-9022-2022; Boerries, Melanie/AAM-2602-2021; Maurer,
   Jochen/G-4832-2018; Wallace, Michael/GZL-9731-2022; Schüle,
   Rebecca/B-5763-2019
OI Maurer, Jochen/0000-0003-3962-3128; Zenk, Fides/0000-0002-0324-0902;
   Wallace, Michael/0000-0002-6446-5785
FU European Research Council (ERC) [322844]; Deutsche
   Forschungsgemeinschaft [SFB 992, 850, 746, SFB 850]; DKTK; German
   Federal Ministry of Education and Research [FKZ 01ZX1409B]
FX This work was supported by grants of the European Research Council (ERC
   AdGrant 322844) and the Deutsche Forschungsgemeinschaft SFB 992, 850,
   746 to R. Schuele and by Deutsche Forschungsgemeinschaft SFB 850 and
   funding by DKTK to J. Maurer and M. Boerries. M. Boerries is funded by
   the German Federal Ministry of Education and Research within the
   framework of the e:Med research and funding concept, DeCaRe (FKZ
   01ZX1409B).
CR Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100
   Bartfeld S, 2017, J MOL MED, V95, P729, DOI 10.1007/s00109-017-1531-7
   Beck B, 2013, NAT REV CANCER, V13, P727, DOI 10.1038/nrc3597
   Berry WL, 2013, CANCER RES, V73, P2936, DOI 10.1158/0008-5472.CAN-12-4300
   Castro DJ, 2013, STEM CELLS, V31, P12, DOI 10.1002/stem.1224
   Castro F, 2013, INT J CANCER, V132, P308, DOI 10.1002/ijc.27675
   Chen YK, 2017, ACS MED CHEM LETT, V8, P869, DOI 10.1021/acsmedchemlett.7b00220
   Chu CH, 2014, J MED CHEM, V57, P5975, DOI 10.1021/jm500249n
   DeRose YS, 2011, NAT MED, V17, P1514, DOI 10.1038/nm.2454
   Dunning MJ, 2007, BIOINFORMATICS, V23, P2183, DOI 10.1093/bioinformatics/btm311
   Duteil D, 2016, CELL REP, V17, P1008, DOI 10.1016/j.celrep.2016.09.053
   Ferlay J., GLOBOCAN 2012 V1 0 C
   Glorevski N, 2016, NATURE, V539, P560, DOI 10.1038/nature20168
   Goldhirsch A, 2013, ANN ONCOL, V24, P2206, DOI 10.1093/annonc/mdt303
   Heinz S, 2010, MOL CELL, V38, P576, DOI 10.1016/j.molcel.2010.05.004
   Hsu JL, 2016, CANCER METAST REV, V35, P575, DOI 10.1007/s10555-016-9649-6
   Kim JE, 2012, J BREAST CANCER, V15, P197, DOI 10.4048/jbc.2012.15.2.197
   Labbé RM, 2014, AM J TRANSL RES, V6, P1
   Langmead B, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-3-r25
   Li BX, 2012, EXP THER MED, V4, P755, DOI 10.3892/etm.2012.662
   Li BX, 2011, J EXP CLIN CANC RES, V30, DOI 10.1186/1756-9966-30-90
   Metzger E, 2005, NATURE, V437, P436, DOI 10.1038/nature04020
   Metzger E, 2016, NAT STRUCT MOL BIOL, V23, P132, DOI 10.1038/nsmb.3153
   Metzger E, 2010, NATURE, V464, P792, DOI 10.1038/nature08839
   Orlando DA, 2014, CELL REP, V9, P1163, DOI 10.1016/j.celrep.2014.10.018
   Qiu MT, 2015, ONCOTARGET, V6, P31702, DOI 10.18632/oncotarget.5165
   Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167
   Robinson MD, 2008, BIOSTATISTICS, V9, P321, DOI 10.1093/biostatistics/kxm030
   Scheel C, 2011, CELL, V145, P926, DOI 10.1016/j.cell.2011.04.029
   SHAW C, 1986, BRAIN RES BULL, V16, P661, DOI 10.1016/0361-9230(86)90137-1
   Soini Y, 2015, INT J CLIN EXP PATHO, V8, P12922
   Stingl J, 2001, BREAST CANCER RES TR, V67, P93, DOI 10.1023/A:1010615124301
   Thorvaldsdóttir H, 2013, BRIEF BIOINFORM, V14, P178, DOI 10.1093/bib/bbs017
   Trapnell C, 2012, NAT PROTOC, V7, P562, DOI 10.1038/nprot.2012.016
   Whetstine JR, 2006, CELL, V125, P467, DOI 10.1016/j.cell.2006.03.028
   Wolff AC, 2007, ARCH PATHOL LAB MED, V131, P18, DOI 10.1043/1543-2165(2007)131[18:ASOCCO]2.0.CO;2
   Ye Q, 2015, AM J CANCER RES, V5, P1519
   Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r137
NR 38
TC 72
Z9 81
U1 0
U2 13
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD NOV 1
PY 2017
VL 77
IS 21
BP 5900
EP 5912
DI 10.1158/0008-5472.CAN-17-1754
PG 13
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA FL5CI
UT WOS:000414248300050
PM 28883001
OA Green Submitted, Bronze
DA 2025-01-12
ER

PT J
AU Savova, GK
   Tseytlin, E
   Finan, S
   Castine, M
   Miller, T
   Medvedeva, O
   Harris, D
   Hochheiser, H
   Lin, C
   Chavan, G
   Jacobson, RS
AF Savova, Guergana K.
   Tseytlin, Eugene
   Finan, Sean
   Castine, Melissa
   Miller, Timothy
   Medvedeva, Olga
   Harris, David
   Hochheiser, Harry
   Lin, Chen
   Chavan, Girish
   Jacobson, Rebecca S.
TI DeepPhe: A Natural Language Processing System for Extracting Cancer
   Phenotypes from Clinical Records
SO CANCER RESEARCH
LA English
DT Article
AB Precise phenotype information is needed to understand the effects of genetic and epigenetic changes on tumor behavior and responsiveness. Extraction and representation of cancer phenotypes is currently mostly performed manually, making it difficult to correlate phenotypic data to genomic data. In addition, genomic data are being produced at an increasingly faster pace, exacerbating the problem. The DeepPhe software enables automated extraction of detailed phenotype information from electronic medical records of cancer patients. The system implements advanced Natural Language Processing and knowledge engineering methods within a flexible modular architecture, and was evaluated using a manually annotated dataset of the University of Pittsburgh Medical Center breast cancer patients. The resulting platform provides critical and missing computational methods for computational phenotyping. Working in tandem with advanced analysis of high-throughput sequencing, these approaches will further accelerate the transition to precision cancer treatment. (C) 2017 AACR.
C1 [Savova, Guergana K.; Finan, Sean; Miller, Timothy; Harris, David; Lin, Chen] Boston Childrens Hosp, Boston, MA 02115 USA.
   [Savova, Guergana K.; Miller, Timothy] Harvard Med Sch, 300 Longwood Ave, Boston, MA 02115 USA.
   [Tseytlin, Eugene; Castine, Melissa; Medvedeva, Olga; Hochheiser, Harry; Chavan, Girish; Jacobson, Rebecca S.] Univ Pittsburgh, Dept Biomed Informat, Pittsburgh, PA USA.
   [Jacobson, Rebecca S.] Univ Pittsburgh, Canc Inst, Pittsburgh, PA USA.
C3 Harvard University; Boston Children's Hospital; Harvard University;
   Harvard Medical School; Pennsylvania Commonwealth System of Higher
   Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth
   System of Higher Education (PCSHE); University of Pittsburgh
RP Savova, GK (通讯作者)，Harvard Med Sch, 300 Longwood Ave, Boston, MA 02115 USA.; Savova, GK (通讯作者)，Boston Childrens Hosp, PI Nat Language Proc Lab, 300 Longwood Ave, Boston, MA 02115 USA.
EM Guergana.Savova@childrens.harvard.edu
RI Medvedeva, Olga A./ITU-4237-2023
FU US NIH [U24CA184407, R01LM10090]; Pennsylvania Department of Health
   [PA-SAP 410070287]
FX The work presented here was funded by US NIH grants U24CA184407
   andR01LM10090 and Pennsylvania Department of Health grant PA-SAP
   410070287.
CR Hochheiser H, 2016, BMC MED INFORM DECIS, V16, DOI 10.1186/s12911-016-0358-4
   Hripcsak G, 2005, J AM MED INFORM ASSN, V12, P296, DOI 10.1197/jamia.M1733
   Savova GK, 2010, J AM MED INFORM ASSN, V17, P507, DOI 10.1136/jamia.2009.001560
   Wu ST, 2013, J BIOMED SEMANT, V4, DOI 10.1186/2041-1480-4-1
NR 4
TC 55
Z9 63
U1 2
U2 10
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD NOV 1
PY 2017
VL 77
IS 21
BP E115
EP E118
DI 10.1158/0008-5472.CAN-17-0615
PG 4
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA FL5CI
UT WOS:000414248300029
PM 29092954
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Alsofyani, AA
   Alsiary, RA
   Samkari, A
   Alhaj-Hussain, BT
   Khan, JA
   Al-Maghrabi, J
   Elaimi, A
   Al-Qahtani, MH
   Abuzenadah, AM
   Dallol, A
AF Alsofyani, Abeer A.
   Alsiary, Rawiah A.
   Samkari, Alaa
   Alhaj-Hussain, Baraa T.
   Khan, Jalaluddin Azam
   Al-Maghrabi, Jaudah
   Elaimi, Aisha
   Al-Qahtani, Mohammed H.
   Abuzenadah, Adel M.
   Dallol, Ashraf
TI Prognostic potential of <i>KLOTHO</i> and <i>SFRP1</i> promoter
   methylation in head and neck squamous cell carcinoma
SO JOURNAL OF APPLIED GENETICS
LA English
DT Article
DE Head and neck squamous cell carcinoma; Promoter region hypermethylation;
   KLOTHO methylation; SFRP1 methylation; Prognostic biomarkers
ID TUMOR-SUPPRESSOR GENES; DNA METHYLATION; NASOPHARYNGEAL CARCINOMA;
   EPIGENETIC INACTIVATION; ABERRANT METHYLATION; POOR-PROGNOSIS;
   BREAST-CANCER; LUNG-CANCER; HYPERMETHYLATION; RASSF1A
AB Hypermethylation in the CpG island promoter regions of tumor suppressors is known to play a significant role in the development of HNSCC and the detection of which can aid the classification and prognosis of HNSCC. This study aims to profile the methylation patterns in a panel of key genes including CDKN2A, CDKN2B, KLOTHO (KL), RASSF1A, RARB, SLIT2, and SFRP1, in a group of HNSCC samples from Saudi Arabia. The extent of methylation in these genes is determined using the MethyLight assay and correlated with known clinicopathological parameters in our samples of 156 formalin-fixed and paraffin-embedded HNSCC tissues. SLIT2 methylation had the highest frequency (64.6%), followed by RASSF1A (41.3%), RARB (40.7%), SFRP1 (34.9), KL (30.7%), CKDN2B (29.6%), and CKDN2A (29.1%). KL and SFRP1 methylation were more predominant in nasopharyngeal tumors (P = 0.001 and P = 0.031 respectively). Kaplan Meier analysis showed that patients with moderately differentiated tumors who display SFRP1 methylation have significantly worse overall survival in comparison with other samples. In contrast, better clinical outcomes were seen in patients with KL methylation. In conclusion, our findings suggest that the detection of frequent methylation in SFRP1 and KL genes' promoters could serve as prognostic biomarkers for HNSCC.
C1 [Alsofyani, Abeer A.; Alsiary, Rawiah A.; Samkari, Alaa] KAIMRC, Jeddah, Saudi Arabia.
   [Alsofyani, Abeer A.; Alsiary, Rawiah A.; Samkari, Alaa] KSAU HS, King Abdulaziz Med City, Natl Guard Hlth Affairs, Jeddah, Saudi Arabia.
   [Alhaj-Hussain, Baraa T.] Natl Guard Hlth Affairs, King Abdulaziz Med City, Dept Pathol & Lab Med, Mail Box 6277, Jeddah, Saudi Arabia.
   [Khan, Jalaluddin Azam] King Abdulaziz Univ, Dept Biochem, Fac Sci, Jeddah, Saudi Arabia.
   [Al-Maghrabi, Jaudah] King Abdulaziz Univ, Dept Pathol, Fac Med, Jeddah, Saudi Arabia.
   [Elaimi, Aisha; Al-Qahtani, Mohammed H.; Abuzenadah, Adel M.; Dallol, Ashraf] King Abdulaziz Univ, Ctr Excellence Genom Med Res, POB 80216, Jeddah 21589, Saudi Arabia.
C3 King Saud Bin Abdulaziz University for Health Sciences; King Abdullah
   International Medical Research Center (KAIMRC); King Saud Bin Abdulaziz
   University for Health Sciences; King Abdulaziz Medical City - Riyadh;
   King Abdulaziz Medical City - Jeddah; Ministry of National Guard -
   Health Affairs; King Saud Bin Abdulaziz University for Health Sciences;
   King Abdulaziz Medical City - Jeddah; King Abdulaziz Medical City -
   Riyadh; Ministry of National Guard - Health Affairs; King Abdulaziz
   University; King Abdulaziz University; King Abdulaziz University
RP Dallol, A (通讯作者)，King Abdulaziz Univ, Ctr Excellence Genom Med Res, POB 80216, Jeddah 21589, Saudi Arabia.
EM adallol@kau.edu.sa
RI Al-Maghrabi, Jaudah/L-4367-2013; Elaimi, Aisha/AAY-8795-2020;
   Al-Qahtani, Mohammed/AAZ-1729-2020; Dallol, Ashraf/H-8661-2012
OI AL-MAGHRABI, JAUDAH/0000-0002-0812-9592; Dallol,
   Ashraf/0000-0002-8803-228X; , Rawiah/0000-0002-4829-228X
FU Ministry of Education and King Abdulaziz City for Science and Technology
   (KACST)
FX The authors would like to thank the Ministry of Education and King
   Abdulaziz City for Science and Technology (KACST) for their financial
   support. Special thanks are extended to Maram Amin, Najla Filimban, and
   Fatma Gazzaz for their valuable technical support.
CR Cai FC, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0163534
   Carvalho AL, 2005, INT J CANCER, V114, P806, DOI 10.1002/ijc.20740
   Czerninski R, 2009, ORAL DIS, V15, P206, DOI 10.1111/j.1601-0825.2008.01510.x
   Dallol A, 2015, TUMOR BIOL, V36, P9677, DOI 10.1007/s13277-015-3733-3
   Dallol A, 2012, CANCER EPIDEM BIOMAR, V21, P2069, DOI 10.1158/1055-9965.EPI-12-0755
   Dallol A, 2011, METHODS MOL BIOL, V724, P191, DOI 10.1007/978-1-61779-055-3_13
   Demokan S, 2011, CLIN EPIGENETICS, V2, P123, DOI 10.1007/s13148-011-0045-3
   Economopoulou P, 2016, ANN TRANSL MED, V4, DOI 10.21037/atm.2016.03.34
   Esteller M, 2002, ONCOGENE, V21, P5427, DOI 10.1038/sj.onc.1205600
   Fendri A, 2009, CANCER BIOL THER, V8, P444, DOI 10.4161/cbt.8.5.7686
   Feng QH, 2008, CANCER EPIDEM BIOMAR, V17, P645, DOI 10.1158/1055-9965.EPI-07-2518
   Gröbe A, 2013, J ORAL PATHOL MED, V42, P676, DOI 10.1111/jop.12086
   Hasegawa M, 2002, ONCOGENE, V21, P4231, DOI 10.1038/sj.onc.1205528
   Huang KH, 2009, CLIN CANCER RES, V15, P4174, DOI 10.1158/1078-0432.CCR-08-2929
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Kinoshita T, 2012, ONCOTARGET, V3, P1386, DOI 10.18632/oncotarget.709
   Kuroki T, 2003, CANCER RES, V63, P3724
   Kurosu H, 2005, SCIENCE, V309, P1829, DOI 10.1126/science.1112766
   LEE AWM, 1992, INT J RADIAT ONCOL, V23, P261, DOI 10.1016/0360-3016(92)90740-9
   Lee J, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-109
   Liu JB, 2011, WORLD J GASTROENTERO, V17, P4917, DOI 10.3748/wjg.v17.i44.4917
   Maiti GP, 2015, OR SURG OR MED OR PA, V119, P202, DOI 10.1016/j.oooo.2014.09.029
   Majchrzak-Celinska A, 2016, J APPL GENET, V57, P189, DOI 10.1007/s13353-015-0312-7
   Marsit CJ, 2006, INT J CANCER, V119, P1761, DOI 10.1002/ijc.22051
   Marsit CJ, 2005, CANCER RES, V65, P7081, DOI 10.1158/0008-5472.CAN-05-0267
   Maruya SI, 2004, CLIN CANCER RES, V10, P3825, DOI 10.1158/1078-0432.CCR-03-0370
   Meng RW, 2016, SCI REP-UK, V6, DOI 10.1038/srep20756
   Ren XY, 2015, CANCER PREV RES, V8, P968, DOI 10.1158/1940-6207.CAPR-14-0369
   Rigi-Ladiz MA, 2011, CLIN EPIGENETICS, V3, DOI 10.1186/1868-7083-3-6
   Rodriguez A, 2004, GENOME RES, V14, P1902, DOI 10.1101/gr.2722704
   Rubinek T, 2012, BREAST CANCER RES TR, V133, P649, DOI 10.1007/s10549-011-1824-4
   Scully C, 2000, ORAL ONCOL, V36, P256, DOI 10.1016/S1368-8375(00)00007-5
   Stadler ME, 2008, HEMATOL ONCOL CLIN N, V22, P1099, DOI 10.1016/j.hoc.2008.08.007
   Steinmann K, 2009, ONCOL REP, V22, P1519, DOI 10.3892/or_00000596
   Veeck J, 2006, ONCOGENE, V25, P3479, DOI 10.1038/sj.onc.1209386
   Wolf I, 2008, ONCOGENE, V27, P7094, DOI 10.1038/onc.2008.292
   Worsham MJ, 2012, MOL DIAGN THER, V16, P209, DOI 10.2165/11635330-000000000-00000
   Xie BA, 2013, HUM PATHOL, V44, P795, DOI 10.1016/j.humpath.2012.07.023
   Zhang CL, 2013, ACTA BIOCH BIOPH SIN, V45, P1055, DOI 10.1093/abbs/gmt109
NR 39
TC 6
Z9 7
U1 0
U2 9
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 1234-1983
EI 2190-3883
J9 J APPL GENET
JI J. Appl. Genetics
PD NOV
PY 2017
VL 58
IS 4
BP 459
EP 465
DI 10.1007/s13353-017-0404-7
PG 7
WC Biotechnology & Applied Microbiology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Genetics & Heredity
GA FK7PE
UT WOS:000413698700004
PM 28812223
DA 2025-01-12
ER

PT J
AU Yuan, X
   Wang, XS
   Gu, BL
   Ma, YJ
   Liu, YW
   Sun, M
   Kong, JY
   Sun, W
   Wang, HZ
   Zhou, FY
   Gao, SG
AF Yuan, Xiang
   Wang, Xinshuai
   Gu, Bianli
   Ma, Yingjian
   Liu, Yiwen
   Sun, Man
   Kong, Jinyu
   Sun, Wei
   Wang, Huizhi
   Zhou, Fuyou
   Gao, Shegan
TI Directional Migration in Esophageal Squamous Cell Carcinoma (ESCC) is
   Epigenetically Regulated by SET Nuclear Oncogene, a Member of the
   Inhibitor of Histone Acetyltransferase Complex
SO NEOPLASIA
LA English
DT Article
ID ACUTE UNDIFFERENTIATED LEUKEMIA; EXCHANGE FACTOR DOCK7; BREAST-CANCER;
   COFILIN; INHAT; DIFFERENTIATION; ONCOPROTEIN; METASTASIS; ACTIVATION;
   EXTENSION
AB Directional cell migration is of fundamental importance to a variety of biological events, including metastasis of malignant cells. Herein, we specifically investigated SET oncoprotein, a subunit of the recently identified inhibitor of acetyltransferases (INHAT) complex and identified its role in the establishment of front-rear cell polarity and directional migration in Esophageal Squamous Cell Carcinoma (ESCC). We further define the molecular circuits that govern these processes by showing that SET modulated DOCK7/RAC1 and cofilin signaling events. Moreover, a detailed analysis of the spatial distribution of RAC1 and cofilin allowed us to decipher the synergistical contributions of the two in coordinating the advancing dynamics by measuring architectures, polarities, and cytoskeletal organizations of the lamellipodia leading edges. In further investigations in vivo, we identified their unique role at multiple levels of the invasive cascade for SET cell and indicate the necessity for their functional balance to enable efficient invasion as well. Additionally, SET epigenetically repressed miR-30c expression by deacetylating histones H2B and H4 on its promoter, which was functionally important for the biological effects of SET in our cell-context. Finally, we corroborated our findings in vivo by evaluating the clinical relevance of SET signaling in the metastatic burden in mice and a large series of patients with ESCC at diagnosis, observing it's significance in predicting metastasis formation. Our findings uncovered a novel signaling network initiated by SET that epigenetically modulated ESCC properties and suggest that targeting the regulatory axis might be a promising strategy to inhibit migration and metastasis.
C1 [Yuan, Xiang; Wang, Xinshuai; Gu, Bianli; Ma, Yingjian; Liu, Yiwen; Sun, Man; Kong, Jinyu; Sun, Wei; Gao, Shegan] Henan Univ Sci & Technol, Med Coll, Coll Clin Med, Affiliated Hosp 1,Canc Hosp,Henan Key Lab Canc Ep, 24 Jinghua Rd, Luoyang 471003;, Henan, Peoples R China.
   [Zhou, Fuyou] Anyang Tumor Hosp, Dept Thorac Surg, Anyang 455000, Peoples R China.
   [Wang, Huizhi] Univ Louisville, Sch Dent, Dept Oral Immunol & Infect Dis, Room 263D,501 South Preston St, Louisville, KY 40202 USA.
   [Yuan, Xiang; Wang, Xinshuai; Gao, Shegan] Henan Univ Sci & Technol, Coll Med, Coll Clin Med, Affiliated Hosp 1,Canc Hosp,Dept Med Oncol, Luoyang 471003, Peoples R China.
C3 Henan University of Science & Technology; University of Louisville;
   Henan University of Science & Technology
RP Gao, SG (通讯作者)，Henan Univ Sci & Technol, Med Coll, Coll Clin Med, Affiliated Hosp 1,Canc Hosp,Henan Key Lab Canc Ep, 24 Jinghua Rd, Luoyang 471003;, Henan, Peoples R China.; Zhou, FY (通讯作者)，Anyang Tumor Hosp, Dept Thorac Surg, Anyang 455000, Peoples R China.
EM gsgvicepresident@163.com
RI Wang, Huizhi/AAA-3874-2020
OI Zhou, Fu-You/0000-0002-6548-4099
FU National Natural Science Foundation of China [U1404817]; Key project of
   science and Technology Department in Henan province [B20140763]; Young
   academic leaders of Henan University of Science and Technology
FX This work was supported by grants from the National Natural Science
   Foundation of China (U1404817 for Xiang Yuan), Key project of science
   and Technology Department in Henan province (B20140763 for Xiang Yuan),
   Young academic leaders of Henan University of Science and Technology
   (for Xiang Yuan).
CR ADACHI Y, 1994, J BIOL CHEM, V269, P2258
   Almeida LO, 2012, FEBS J, V279, P4615, DOI 10.1111/febs.12047
   Bear JE, 2014, CURR OPIN CELL BIOL, V30, P74, DOI 10.1016/j.ceb.2014.06.005
   Cervoni N, 2002, J BIOL CHEM, V277, P25026, DOI 10.1074/jbc.M202256200
   Chodniewicz D, 2004, EXP CELL RES, V301, P31, DOI 10.1016/j.yexcr.2004.08.006
   Dawe HR, 2003, CURR BIOL, V13, P252, DOI 10.1016/S0960-9822(03)00040-X
   DesMarais V, 2004, J CELL SCI, V117, P3499, DOI 10.1242/jcs.01211
   DesMarais V, 2005, J CELL SCI, V118, P19, DOI 10.1242/jcs.01631
   Etienne-Manneville S, 2008, ONCOGENE, V27, P6970, DOI 10.1038/onc.2008.347
   Fan ZS, 2003, CELL, V112, P659, DOI 10.1016/S0092-8674(03)00150-8
   Gadea G, 2014, EUR J CELL BIOL, V93, P466, DOI 10.1016/j.ejcb.2014.06.003
   Ghosh M, 2004, SCIENCE, V304, P743, DOI 10.1126/science.1094561
   Grande-García A, 2007, J CELL BIOL, V177, P683, DOI 10.1083/jcb.200701006
   Janghorban M, 2014, P NATL ACAD SCI USA, V111, P9157, DOI 10.1073/pnas.1317630111
   Jaudon F, 2015, MOL BIOL CELL, V26, P2112, DOI 10.1091/mbc.E14-08-1310
   Kim DW, 2010, BIOCHEM BIOPH RES CO, V400, P419, DOI 10.1016/j.bbrc.2010.08.093
   Kular RK, 2009, J BIOL CHEM, V284, P7783, DOI 10.1074/jbc.M806150200
   Kutney SN, 2004, J BIOL CHEM, V279, P30850, DOI 10.1074/jbc.M404969200
   Laurin M, 2013, P NATL ACAD SCI USA, V110, P7434, DOI 10.1073/pnas.1213050110
   Mladinich KM, 2013, DEV CELL, V26, P560, DOI 10.1016/j.devcel.2013.09.013
   Mouneimne G, 2004, J CELL BIOL, V166, P697, DOI 10.1083/jcb.200405156
   Murray DW, 2014, BRIT J CANCER, V110, P1307, DOI 10.1038/bjc.2014.39
   Neviani P, 2013, J CLIN INVEST, V123, P4144, DOI 10.1172/JCI68951
   Oser M, 2009, J CELL BIOL, V186, P571, DOI 10.1083/jcb.200812176
   Ponting CP, 2009, CELL, V136, P629, DOI 10.1016/j.cell.2009.02.006
   Ridley AJ, 2003, SCIENCE, V302, P1704, DOI 10.1126/science.1092053
   Schwartz MA, 2006, CELL, V125, P1223, DOI 10.1016/j.cell.2006.06.015
   Scott RW, 2010, J CELL BIOL, V191, P169, DOI 10.1083/jcb.201002041
   Seo SB, 2001, CELL, V104, P119, DOI 10.1016/S0092-8674(01)00196-9
   Settleman J, 2001, DEV CELL, V1, P321, DOI 10.1016/S1534-5807(01)00053-3
   Sidani M, 2007, J CELL BIOL, V179, P777, DOI 10.1083/jcb.200707009
   ten Klooster JP, 2007, EMBO J, V26, P336, DOI 10.1038/sj.emboj.7601518
   VONLINDERN M, 1992, GENE CHROMOSOME CANC, V5, P227, DOI 10.1002/gcc.2870050309
   Yamaguchi H, 2005, J CELL BIOL, V168, P441, DOI 10.1083/jcb.200407076
   Yamauchi J, 2008, J CELL BIOL, V181, P351, DOI 10.1083/jcb.200709033
   Yang WH, 2012, NAT CELL BIOL, V14, P366, DOI 10.1038/ncb2455
   Yu JR, 2015, GENE DEV, V29, P250, DOI 10.1101/gad.248963.114
   Yu XZ, 2012, J CELL BIOL, V199, P527, DOI 10.1083/jcb.201203025
NR 38
TC 15
Z9 15
U1 0
U2 9
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1476-5586
J9 NEOPLASIA
JI Neoplasia
PD NOV
PY 2017
VL 19
IS 11
BP 868
EP 884
DI 10.1016/j.neo.2017.08.003
PG 17
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA FL3TR
UT WOS:000414147400002
PM 28938158
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU Liu, ZW
   Piao, LH
   Zhuang, M
   Qiu, XB
   Xu, XS
   Zhang, DW
   Liu, MM
   Ren, D
AF Liu, Zhiwei
   Piao, Lianhua
   Zhuang, Ming
   Qiu, Xubin
   Xu, Xiaoshuang
   Zhang, Dawei
   Liu, Mengmeng
   Ren, Ding
TI Silencing of histone methyltransferase NSD3 reduces cell viability in
   osteosarcoma with induction of apoptosis
SO ONCOLOGY REPORTS
LA English
DT Article
DE NSD3; osteosarcoma; histone methyltransferase; human carcinogenesis;
   epigenetics
ID HUMAN BREAST-CANCER; HIGH-GRADE OSTEOSARCOMA; HUMAN LUNG-CANCER;
   EXPRESSION ANALYSIS; ANTITUMOR-ACTIVITY; 8P11-12 AMPLICON; DOT1L
   INHIBITOR; GENE; EPZ-5676; METABOLISM
AB NSD3 is a histone lysine methyltransferase that methylates histone H3 at lysine 36. NSD3 is located at chromosome 8p11.23, the locus that exhibits strong cancer relevance. Thus, NSD3 is likely involved in multiple human cancers. Nevertheless, its roles in human carcinogenesis remain unknown. In the present study, we demonstrated that silencing of NSD3 in osteosarcoma, the most common primary bone cancer in children and adolescents, results in a marked decrease in the number of viable cancer cells, accompanied by increases in the cell population at the G2/M phase and the number of apoptotic cells. In addition, 549 NSD3-regulated genes were identified and a set of selected candidate genes were validated. Bioinformatic analysis revealed that NSD3 negatively regulates a number of genes that are involved in the process of negative regulation of signal transduction as well as negative regulation of signaling and cell communication. Our results indicate the oncogenic roles of NSD3 in the development and progression of human osteosarcoma, and implicate NSD3 as a potential molecular target for selective therapy for human osteosarcoma.
C1 [Liu, Zhiwei; Zhuang, Ming; Qiu, Xubin] Soochow Univ, Affiliated Hosp 3, Dept Orthopaed, Changzhou 213000, Jiangsu, Peoples R China.
   [Piao, Lianhua; Xu, Xiaoshuang; Zhang, Dawei; Liu, Mengmeng] Jiangsu Univ Technol, Inst Bioinformat & Med Engn, 1801 Zhongwu Ave, Changzhou 213001, Jiangsu, Peoples R China.
   [Ren, Ding] PLA 85th Hosp, Out Patient Dept, Shanghai 200006, Peoples R China.
   [Ren, Ding] PLA 100th Hosp, Dept Orthopaed, Suzhou 215007, Jiangsu, Peoples R China.
C3 Soochow University - China; Jiangsu University of Technology
RP Piao, LH (通讯作者)，Jiangsu Univ Technol, Inst Bioinformat & Med Engn, 1801 Zhongwu Ave, Changzhou 213001, Jiangsu, Peoples R China.
EM piaolianhua@jsut.edu.cn
RI liu, zhiwei/AAU-4574-2021
OI liu, zhiwei/0000-0003-4102-9080
CR Angrand PO, 2001, GENOMICS, V74, P79, DOI 10.1006/geno.2001.6524
   Balsara BR, 2002, ONCOGENE, V21, P6877, DOI 10.1038/sj.onc.1205836
   Basavapathruni A, 2014, BIOPHARM DRUG DISPOS, V35, P237, DOI 10.1002/bdd.1889
   Bielack SS, 2002, J CLIN ONCOL, V20, P776, DOI 10.1200/JCO.20.3.776
   Botter SM, 2014, CURR OPIN PHARMACOL, V16, P15, DOI 10.1016/j.coph.2014.02.002
   Chen X, 2014, CELL REP, V7, P104, DOI 10.1016/j.celrep.2014.03.003
   French CA, 2014, CANCER DISCOV, V4, P928, DOI 10.1158/2159-8290.CD-14-0014
   Gatta G, 2014, LANCET ONCOL, V15, P35, DOI 10.1016/S1470-2045(13)70548-5
   He C, 2013, J BIOL CHEM, V288, P4692, DOI 10.1074/jbc.M112.426148
   Jacques-Fricke BT, 2014, MOL BIOL CELL, V25, P4174, DOI 10.1091/mbc.E13-12-0744
   Kang D, 2013, GENE CHROMOSOME CANC, V52, P126, DOI 10.1002/gcc.22012
   Kempf-Bielack B, 2005, J CLIN ONCOL, V23, P559, DOI 10.1200/JCO.2005.04.063
   Klaus CR, 2014, J PHARMACOL EXP THER, V350, P646, DOI 10.1124/jpet.114.214577
   Knutson SK, 2014, MOL CANCER THER, V13, P842, DOI 10.1158/1535-7163.MCT-13-0773
   Knutson SK, 2013, P NATL ACAD SCI USA, V110, P7922, DOI 10.1073/pnas.1303800110
   Kuijjer ML, 2013, INT J CANCER, V133, P2512, DOI 10.1002/ijc.28124
   Li Y, 2009, J BIOL CHEM, V284, P34283, DOI 10.1074/jbc.M109.034462
   Mahmood SF, 2013, AM J PATHOL, V183, P1634, DOI 10.1016/j.ajpath.2013.07.028
   Mohammad HP, 2015, CANCER CELL, V28, P57, DOI 10.1016/j.ccell.2015.06.002
   Morishita M, 2014, BMC STRUCT BIOL, V14, DOI 10.1186/s12900-014-0025-x
   Ottaviani G, 2009, CANCER TREAT RES, V152, P3, DOI 10.1007/978-1-4419-0284-9_1
   Rahman S, 2011, MOL CELL BIOL, V31, P2641, DOI 10.1128/MCB.01341-10
   Ray ME, 2004, CANCER RES, V64, P40, DOI 10.1158/0008-5472.CAN-03-1022
   Rosati R, 2002, BLOOD, V99, P3857, DOI 10.1182/blood.V99.10.3857
   Saloura V, 2016, ONCOTARGET, V7, P42527, DOI 10.18632/oncotarget.9897
   Shen C, 2015, MOL CELL, V60, P847, DOI 10.1016/j.molcel.2015.10.033
   Simon R, 2001, CANCER RES, V61, P4514
   Taketani T, 2009, CANCER GENET CYTOGEN, V190, P108, DOI 10.1016/j.cancergencyto.2008.12.008
   Tonon G, 2005, P NATL ACAD SCI USA, V102, P9625, DOI 10.1073/pnas.0504126102
   Trapnell C, 2012, NAT PROTOC, V7, P562, DOI 10.1038/nprot.2012.016
   Waters NJ, 2016, CANCER CHEMOTH PHARM, V77, P43, DOI 10.1007/s00280-015-2929-y
   Yang ZQ, 2010, CANCER RES, V70, P8487, DOI 10.1158/0008-5472.CAN-10-1013
NR 32
TC 21
Z9 24
U1 0
U2 15
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1021-335X
EI 1791-2431
J9 ONCOL REP
JI Oncol. Rep.
PD NOV
PY 2017
VL 38
IS 5
BP 2796
EP 2802
DI 10.3892/or.2017.5936
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA FL2CG
UT WOS:000414021300022
PM 28901481
OA hybrid, Green Published, Green Submitted
DA 2025-01-12
ER

PT J
AU Wu, Q
   Li, JJ
   Sun, S
   Chen, XY
   Zhang, HP
   Li, B
   Sun, SR
AF Wu, Qi
   Li, Juanjuan
   Sun, Si
   Chen, Xinyue
   Zhang, Hanpu
   Li, Bei
   Sun, Shengrong
TI YAP/TAZ-mediated activation of serine metabolism and methylation
   regulation is critical for LKB1-deficient breast cancer progression
SO BIOSCIENCE REPORTS
LA English
DT Article
AB The crucial interplay between metabolic remodeling and the epigenetics could contribute to promote cancer progression. A remarkable association within interaction, LKB1 has been reported, suggesting that the expression of key enzymes involving de novo serine synthesis and DNA methyltransferases like DNMT1 and DNMT3A increase LKB1-deficiency cells. However, the complex interactional link between metabolic remodeling and the epigenetics is still unclear. Hence, we focus on the relationship between YAP/TAZ and serine-metabolism to control methylation of DNA or histone in breast cancer with LKB1 deficiency. We hypothesize that YAP/TAZ may have the function to activate key enzymes involving serine metabolism like PSPH and up-regulate the amino acid transporters to supply sources of serine synthesis through activation of C-MYC with TEAD1. Further, we speculate that YAP/TAZ in dependent of FOS may promote DNMT1 and subsequently mediate DNMT1-G9A complex involving serine metabolism and the methylation of DNA and histone. We hope that our study will stimulate further studies and a new targeted therapy and early medical intervention for YAP/TAZ could be a useful option for breast cancer cases complicated with LKB1 deficiency.
C1 [Wu, Qi; Li, Juanjuan; Chen, Xinyue; Zhang, Hanpu; Li, Bei; Sun, Shengrong] Wuhan Univ, Dept Breast & Thyroid Surg, Renmin Hosp, Wuhan, Hubei, Peoples R China.
   [Sun, Si] Wuhan Univ, Dept Clin Lab, Renmin Hosp, Wuhan, Hubei, Peoples R China.
C3 Wuhan University; Wuhan University
RP Sun, SR (通讯作者)，Wuhan Univ, Dept Breast & Thyroid Surg, Renmin Hosp, Wuhan, Hubei, Peoples R China.
EM sun137@sina.com
RI ; wu, qi/HCI-2480-2022
OI Chen, Xinyue/0000-0003-1188-9274; wu, qi/0000-0001-6182-5274
FU NSFC [81471781, 81302314]
FX This work was partially supported by a NSFC grant to Prof. Shengrong Sun
   [grant number 81471781] and a NSFC grant to Dr Juanjuan Li [grant number
   81302314]. The authors thank Yimin Zhang for assistance in improving the
   quality of language.
CR Ameri K, 2008, INT J BIOCHEM CELL B, V40, P14, DOI 10.1016/j.biocel.2007.01.020
   Ben-Sahra I, 2016, SCIENCE, V351, P728, DOI 10.1126/science.aad0489
   Black JC, 2012, MOL CELL, V48, P491, DOI 10.1016/j.molcel.2012.11.006
   Chen IC, 2016, SCI REP-UK, V6, DOI 10.1038/srep21374
   Chen Z, 2012, NATURE, V483, P613, DOI 10.1038/nature10937
   Cox AG, 2016, NAT CELL BIOL, V18, P886, DOI 10.1038/ncb3389
   DeNicola GM, 2015, NAT GENET, V47, P1475, DOI 10.1038/ng.3421
   Ding J, 2013, CELL METAB, V18, P896, DOI 10.1016/j.cmet.2013.11.004
   Estève PO, 2006, GENE DEV, V20, P3089, DOI 10.1101/gad.1463706
   Fan J, 2014, NATURE, V510, P298, DOI 10.1038/nature13236
   Faubert B, 2015, CANCER LETT, V356, P165, DOI 10.1016/j.canlet.2014.01.018
   Faubert B, 2014, P NATL ACAD SCI USA, V111, P2554, DOI 10.1073/pnas.1312570111
   Hansen CG, 2015, CELL RES, V25, P1299, DOI 10.1038/cr.2015.140
   Hervouet Eric, 2010, Genes Cancer, V1, P434, DOI 10.1177/1947601910373794
   Hezel AF, 2008, ONCOGENE, V27, P6908, DOI 10.1038/onc.2008.342
   Jain M, 2012, SCIENCE, V336, P1040, DOI 10.1126/science.1218595
   Kim HY, 2016, ONCOTARGET, V7, P67111, DOI 10.18632/oncotarget.11560
   Kinnaird A, 2016, NAT REV CANCER, V16, P694, DOI 10.1038/nrc.2016.82
   Kottakis F, 2016, NATURE, V539, P390, DOI 10.1038/nature20132
   Liu WJ, 2012, CANCER CELL, V21, P751, DOI 10.1016/j.ccr.2012.03.048
   Mohamed A, 2016, J PATHOL, V240, P3, DOI 10.1002/path.4745
   Mohseni M, 2014, NAT CELL BIOL, V16, P108, DOI 10.1038/ncb2884
   Mosammaparast N, 2010, ANNU REV BIOCHEM, V79, P155, DOI 10.1146/annurev.biochem.78.070907.103946
   Oh H, 2014, CELL REP, V8, P448, DOI 10.1016/j.celrep.2014.06.017
   Oudhoff MJ, 2013, DEV CELL, V26, P188, DOI 10.1016/j.devcel.2013.05.025
   Park YY, 2016, HEPATOLOGY, V63, P159, DOI 10.1002/hep.28223
   Pollari S, 2011, BREAST CANCER RES TR, V125, P421, DOI 10.1007/s10549-010-0848-5
   Possemato R, 2011, NATURE, V476, P346, DOI 10.1038/nature10350
   Rajesh K, 2016, ONCOTARGET, V7, P51044, DOI 10.18632/oncotarget.10480
   Rhodes LV, 2015, ONCOGENESIS, V4, DOI 10.1038/oncsis.2015.27
   Santinon G, 2016, TRENDS CELL BIOL, V26, P289, DOI 10.1016/j.tcb.2015.11.004
   Shao DD, 2014, CELL, V158, P171, DOI 10.1016/j.cell.2014.06.004
   Shinkai Y, 2011, GENE DEV, V25, P781, DOI 10.1101/gad.2027411
   Su XY, 2016, CURR OPIN CHEM BIOL, V30, P52, DOI 10.1016/j.cbpa.2015.10.030
   Sun LC, 2015, CELL RES, V25, P429, DOI 10.1038/cr.2015.33
   Valis K, 2016, EXP CELL RES, V349, P273, DOI 10.1016/j.yexcr.2016.10.018
   Woods A, 2003, CURR BIOL, V13, P2004, DOI 10.1016/j.cub.2003.10.031
   Wu HT, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7239
   Ye JB, 2012, P NATL ACAD SCI USA, V109, P6904, DOI 10.1073/pnas.1204176109
   Zhao EH, 2016, CELL REP, V14, P506, DOI 10.1016/j.celrep.2015.12.053
NR 40
TC 24
Z9 25
U1 0
U2 13
PU PORTLAND PRESS LTD
PI LONDON
PA CHARLES DARWIN HOUSE, 12 ROGER STREET, LONDON WC1N 2JU, ENGLAND
SN 0144-8463
EI 1573-4935
J9 BIOSCIENCE REP
JI Biosci. Rep.
PD OCT 31
PY 2017
VL 37
AR BSR20171072
DI 10.1042/BSR20171072
PN 5
PG 6
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA FU0XA
UT WOS:000423572500025
PM 28931725
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Guo, MZ
   Li, X
   Zhang, LY
   Liu, DT
   Du, WC
   Yin, DY
   Lyu, N
   Zhao, GY
   Guo, C
   Tang, DQ
AF Guo, Mengzhe
   Li, Xiao
   Zhang, Liyan
   Liu, Dantong
   Du, Wencheng
   Yin, Dengyang
   Lyu, Nan
   Zhao, Guangyu
   Guo, Cheng
   Tang, Daoquan
TI Accurate quantification of 5-Methylcytosine, 5-Hydroxymethylcytosine,
   5-Formylcytosine, and 5-Carboxylcytosine in genomic DNA from breast
   cancer by chemical derivatization coupled with ultra performance liquid
   chromatography-electrospray quadrupole time of flight mass spectrometry
   analysis
SO ONCOTARGET
LA English
DT Article
DE liquid chromatography mass spectrometry; DNA demethylation; breast
   cancer; derivatization; 5-methylcytosine
ID OXIDATION-PRODUCTS; THYMINE DNA; METHYLATION; PROTEINS; EXCISION; RNA
AB The DNA demethylation pathway has been discovered to play a significant role in DNA epigenetics. This pathway removes the methyl group from cytosine, which is involved in the oxidation of 5-methylcytosine to 5-hydroxymethylcytosine (5-hmC) by ten-eleven translocation (TET) proteins. Then, 5-hmC can be iteratively oxidized to generate 5-formylcytosine (5-foC) and 5-carboxylcytosine (5-caC). However, 5-hmC, 5-foC, and 5-caC are hardly detected due to their low content. In this study, we have developed a LC-HRMS method coupled with derivatization to accurately and simultaneously quantify 5-mC levels, along with its oxidation products in genomic DNA. Derivatization was carried out using 4-dimethylamino benzoic anhydride, which has been shown to improve separation and enhance the detection sensitivity. Finally, we successfully applied this method towards the quantification of 5-mC, 5-hmC, 5-foC, and 5-caC in genomic DNA isolated from both human breast cancer tissue and tumor-adjacent normal tissue. We show that 5-foC and 5-caC are increased in tumor tissue. In addition, the levels of 5-mC, 5-hmC, 5-foC, and 5-caC measured in tumor tissue versus tumor-adjacent tissue were found to be distinct among different classifications. This suggests that cytosine modifiers could be used as potential biomarkers for determining the stage of development of breast cancer, as well as prognosis.
C1 [Guo, Mengzhe; Li, Xiao; Zhang, Liyan; Liu, Dantong; Du, Wencheng; Tang, Daoquan] Xuzhou Med Coll, Jiangsu Key Lab New Drug Res & Clin Pharm, Xuzhou 221004, Jiangsu, Peoples R China.
   [Guo, Cheng] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Canc Inst, Hangzhou 310009, Zhejiang, Peoples R China.
   [Yin, Dengyang; Zhao, Guangyu] Jingjiang Peoples Hosp, Jingjiang 214500, Jiangsu, Peoples R China.
   [Lyu, Nan] Xuzhou Cent Hosp, Xuzhou 221004, Jiangsu, Peoples R China.
C3 Xuzhou Medical University; Zhejiang University
RP Tang, DQ (通讯作者)，Xuzhou Med Coll, Jiangsu Key Lab New Drug Res & Clin Pharm, Xuzhou 221004, Jiangsu, Peoples R China.; Guo, C (通讯作者)，Zhejiang Univ, Sch Med, Affiliated Hosp 2, Canc Inst, Hangzhou 310009, Zhejiang, Peoples R China.
EM cheng_guo@zju.edu.cn; tdq993@hotmail.com
RI Guo, Cheng/LZE-1063-2025; Zhao, Guangyu/G-2595-2017
OI Tang, Dao-quan/0000-0002-5443-4619; Guo, Cheng/0000-0001-6194-1232
FU scientific research funds of talents from Xuzhou medicine college
   [D2015014]
FX We appreciate the Natural Science Foundation of China No. 21505116 and
   No. 21402172. We also appreciate the scientific research funds of
   talents from Xuzhou medicine college, No. D2015014. We appreciate the
   Natural Science Foundation of Jiangsu No. BK20171183.
CR [Anonymous], ONCOTARGET
   Bestor TH, 2004, COLD SPRING HARB SYM, V69, P381, DOI 10.1101/sqb.2004.69.381
   Booth MJ, 2015, CHEM REV, V115, P2240, DOI 10.1021/cr5002904
   Booth MJ, 2012, SCIENCE, V336, P934, DOI 10.1126/science.1220671
   Chen YS, 2016, ONCOTARGET, V7, P84299, DOI 10.18632/oncotarget.12520
   Egger G, 2004, NATURE, V429, P457, DOI 10.1038/nature02625
   Eleftheriou M, 2015, CLIN EPIGENETICS, V7, DOI 10.1186/s13148-015-0117-x
   Gehring M, 2009, TRENDS GENET, V25, P82, DOI 10.1016/j.tig.2008.12.001
   Goll MG, 2005, ANNU REV BIOCHEM, V74, P481, DOI 10.1146/annurev.biochem.74.010904.153721
   Gong FX, 2017, ONCOTARGET, V8, P315, DOI 10.18632/oncotarget.13324
   Guo C, 2017, ONCOTARGET, V8, P53100, DOI 10.18632/oncotarget.17831
   Guo C, 2016, SCI REP-UK, V6, DOI 10.1038/srep32581
   Hashimoto H, 2012, NUCLEIC ACIDS RES, V40, P10203, DOI 10.1093/nar/gks845
   He YF, 2011, SCIENCE, V333, P1303, DOI 10.1126/science.1210944
   Ito S, 2011, SCIENCE, V333, P1300, DOI 10.1126/science.1210597
   Jaenisch R, 2003, NAT GENET, V33, P245, DOI 10.1038/ng1089
   Klose RJ, 2006, TRENDS BIOCHEM SCI, V31, P89, DOI 10.1016/j.tibs.2005.12.008
   Lu XY, 2015, CHEM REV, V115, P2225, DOI 10.1021/cr500470n
   Maiti A, 2011, J BIOL CHEM, V286
   Pastor WA, 2011, NATURE, V473, P394, DOI 10.1038/nature10102
   Pfaffeneder T, 2011, ANGEW CHEM INT EDIT, V50, P7008, DOI 10.1002/anie.201103899
   Raiber EA, 2012, GENOME BIOL, V13, DOI 10.1186/gb-2012-13-8-r69
   Robertson KD, 2005, NAT REV GENET, V6, P597, DOI 10.1038/nrg1655
   Scarano MI, 2014, DNA METHYLATION 40 Y, V204, P21
   Shen L, 2014, ANNU REV BIOCHEM, V83, P585, DOI 10.1146/annurev-biochem-060713-035513
   Song CX, 2013, CELL, V153, P678, DOI 10.1016/j.cell.2013.04.001
   Song CX, 2012, NAT BIOTECHNOL, V30, P1107, DOI 10.1038/nbt.2398
   Song CX, 2012, NAT METHODS, V9, P75, DOI [10.1038/NMETH.1779, 10.1038/nmeth.1779]
   Song CX, 2011, NAT BIOTECHNOL, V29, P68, DOI 10.1038/nbt.1732
   Stadler MB, 2011, NATURE, V480, P490, DOI 10.1038/nature10716
   Tahiliani M, 2009, SCIENCE, V324, P930, DOI 10.1126/science.1170116
   Tang Y, 2015, ANAL CHEM, V87, P3445, DOI 10.1021/ac504786r
   Tang Y, 2014, ANAL CHEM, V86, P7764, DOI 10.1021/ac5016886
   Yin RC, 2013, J AM CHEM SOC, V135, P10396, DOI 10.1021/ja4028346
   Yu M, 2012, CELL, V149, P1368, DOI 10.1016/j.cell.2012.04.027
   Zhang HY, 2016, CHEM COMMUN, V52, P737, DOI 10.1039/c5cc07354e
   Zhang L, 2012, NAT CHEM BIOL, V8, P328, DOI [10.1038/NCHEMBIO.914, 10.1038/nchembio.914]
NR 37
TC 22
Z9 26
U1 0
U2 44
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD OCT 31
PY 2017
VL 8
IS 53
BP 91248
EP 91257
DI 10.18632/oncotarget.20093
PG 10
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA FL4CX
UT WOS:000414175500064
PM 29207640
OA Green Published, gold, Green Submitted
DA 2025-01-12
ER

PT J
AU Liu, B
   Pang, B
   Wang, QR
   Yang, SJ
   Gao, TH
   Ding, Q
   Liu, HJ
   Yang, YH
   Fan, HT
   Zhang, R
   Xin, T
   Xu, GM
   Pang, Q
AF Liu, Bin
   Pang, Bo
   Wang, Qirui
   Yang, Shengji
   Gao, Taihong
   Ding, Qian
   Liu, Huajie
   Yang, Yihang
   Fan, Haitao
   Zhang, Rui
   Xin, Tao
   Xu, Guangming
   Pang, Qi
TI EZH2 upregulation correlates with tumor invasiveness, proliferation, and
   angiogenesis in human pituitary adenomas
SO HUMAN PATHOLOGY
LA English
DT Article
DE Angiogenesis; Enhancer of zeste homolog 2; Invasion;
   Metalloproteinase-14; Pituitary adenoma; Tumor cell proliferation
ID ZESTE HOMOLOG 2; MICROVESSEL DENSITY; BREAST-CANCER; SOLID TUMORS;
   EXPRESSION; INVASION; MECHANISMS; PROGNOSIS; CELLS; OVEREXPRESSION
AB Enhancer of zeste homolog 2 (EZH2) is a critical component of the polycomb repressive complex 2, which epigenetically represses genes involved in tumorigenesis and is highly expressed in tumors. However, no studies have investigated EZH2 expression and its clinical significance in human pituitary adenomas (PAs). Therefore, we examined the expression pattern of EZH2 in PAs and studied the correlations between protein expression and invasiveness, proliferation, angiogenesis, hormone functioning, and some other factors. We measured EZH2 and MMP-14 protein and EZH2 mRNA expression in 62 samples of PAs by immunohistochemistry staining and quantitative real-time polymerase chain reaction and correlated protein expression relative to clinicopathologic features. The immunopositive rate of EZH2 was 88.7% (55/62). The extent of expression was associated with invasiveness, microvessel density, and proliferation (Ki-67 index). Moreover, EZH2 expression correlated with MMP-14 expression. We did not find any correlation between EZH2 overexpression and hormone-secreting function or patient age or sex. The quantitative real-time polymerase chain reaction analysis revealed that the amount of EZH2 mRNA was significantly higher in invasive than in noninvasive adenomas. This is the first report to describe EZH2 overexpression in human PAs, especially invasive adenomas. Thus, EZH2 is a potentially useful diagnostic marker and phannacotherapeutic target for invasive PAs. (C) 2017 Elsevier Inc. All rights reserved.
C1 [Liu, Bin] Shandong Univ, Dept Neurosurg, Shandong Qianfoshan Hosp, Jinan 250014, Shandong, Peoples R China.
   [Liu, Bin; Gao, Taihong; Yang, Yihang; Fan, Haitao; Zhang, Rui; Xin, Tao; Pang, Qi] Shandong Univ, Dept Neurosurg, Shandong Prov Hosp, 324 Jingwuweiqi St, Jinan 250021, Shandong, Peoples R China.
   [Liu, Bin] Kyoto Univ, Grad Sch Med, Dept Neurosurg, Kyoto 6068507, Japan.
   [Pang, Bo] Shandong Univ, Dept Neurosurg, Grad Sch Med, Jinan 250000, Shandong, Peoples R China.
   [Wang, Qirui] Taian Hosp Tradit Chinese Med, Dept Neurosurg, Tai An 271000, Shandong, Peoples R China.
   [Yang, Shengji; Xu, Guangming] Taishan Med Univ, Affiliated Zouping Hosp, Dept Neurosurg, Zouping 256200, Shandong, Peoples R China.
   [Ding, Qian] Shandong Univ, Dept Gastroenterol, Shandong Prov Hosp, Jinan 250021, Shandong, Peoples R China.
   [Liu, Huajie] Shandong Univ, Qilu Childrens Hosp, Dept Bone Trauma & Neurosurg, Jinan 250011, Shandong, Peoples R China.
C3 Shandong First Medical University & Shandong Academy of Medical
   Sciences; Shandong University; Shandong First Medical University &
   Shandong Academy of Medical Sciences; Shandong University; Kyoto
   University; Shandong University; Shandong First Medical University &
   Shandong Academy of Medical Sciences; Shandong First Medical University
   & Shandong Academy of Medical Sciences; Shandong University; Shandong
   University
RP Xin, T; Pang, Q (通讯作者)，Shandong Univ, Dept Neurosurg, Shandong Prov Hosp, 324 Jingwuweiqi St, Jinan 250021, Shandong, Peoples R China.
EM drxintao@l26.com; pangqisdu@126.com
RI Liu, Bin/JCP-0045-2023
CR Abbosh PH, 2006, CANCER RES, V66, P5582, DOI 10.1158/0008-5472.CAN-05-3575
   Asa SL, 1998, ENDOCR REV, V19, P798, DOI 10.1210/er.19.6.798
   Cho HM, 2011, EXP THER MED, V2, P963, DOI 10.3892/etm.2011.284
   Choi HJ, 2016, BMC VET RES, V12, DOI 10.1186/s12917-016-0789-2
   Colao A, 2011, EXPERT OPIN PHARMACO, V12, P1561, DOI 10.1517/14656566.2011.568478
   Crea F, 2012, CANCER METAST REV, V31, P753, DOI 10.1007/s10555-012-9387-3
   Neusquen LPD, 2016, REV BRAS GINECOL OBS, V38, P280, DOI 10.1055/s-0036-1584954
   Du HT, 2016, EXP THER MED, V12, P2120, DOI 10.3892/etm.2016.3601
   Fang J, 2011, AM J MED SCI, V342, P198, DOI 10.1097/MAJ.0b013e31821335a9
   Friedl P, 2003, NAT REV CANCER, V3, P362, DOI 10.1038/nrc1075
   Hardy J., 1979, RECENT ADV DIAGNOSIS, P375
   Italiano A, 2016, PHARMACOL THERAPEUT, V165, P26, DOI 10.1016/j.pharmthera.2016.05.003
   Jiang T, 2016, ONCOTARGET, V7, P4584, DOI 10.18632/oncotarget.6612
   Karanikolas BDW, 2009, MOL CANCER RES, V7, P1456, DOI 10.1158/1541-7786.MCR-09-0121
   Kawano S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0158888
   Kemp CD, 2012, CLIN CANCER RES, V18, P77, DOI 10.1158/1078-0432.CCR-11-0962
   Kim K, 2015, HUM PATHOL, V46, P1464, DOI 10.1016/j.humpath.2015.06.003
   Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100
   Koh CM, 2011, ONCOTARGET, V2, P669, DOI 10.18632/oncotarget.327
   Kontogeorgos George, 2005, Endocrine, V28, P27, DOI 10.1385/ENDO:28:1:027
   Kurmasheva RT, 2017, PEDIATR BLOOD CANCER, V64, DOI 10.1002/pbc.26218
   Lloyd RV, 2003, MICROSC RES TECHNIQ, V60, P244, DOI 10.1002/jemt.10263
   Lu CH, 2007, CANCER RES, V67, P1757, DOI 10.1158/0008-5472.CAN-06-3700
   Margueron R, 2011, NATURE, V469, P343, DOI 10.1038/nature09784
   Melmed S, 2003, J CLIN INVEST, V112, P1603, DOI 10.1172/JCI20401
   Mete O, 2012, J MOL ENDOCRINOL, V49, pR69, DOI 10.1530/JME-12-0113
   Miao YM, 2016, PITUITARY, V19, P194, DOI 10.1007/s11102-015-0698-6
   Niveiro M, 2005, HUM PATHOL, V36, P1090, DOI 10.1016/j.humpath.2005.07.015
   Pan LX, 2005, J NEURO-ONCOL, V74, P71, DOI 10.1007/s11060-004-6150-9
   Qu X, 2010, HUM PATHOL, V41, P1165, DOI 10.1016/j.humpath.2009.10.023
   Ruskyte K, 2016, ONCOL LETT, V12, P3013, DOI 10.3892/ol.2016.4919
   Shin YJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030393
   Sun M, 2016, CANCER RES, V76, P6299, DOI 10.1158/0008-5472.CAN-16-0356
   Sun RR, 2016, ONCOTARGET, V7, P38333, DOI 10.18632/oncotarget.9518
   Trudel D, 2014, MODERN PATHOL, V27, P1394, DOI 10.1038/modpathol.2014.32
   Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075
   Vidal S, 2001, VIRCHOWS ARCH, V438, P595, DOI 10.1007/s004280000373
   Wang CG, 2010, WORLD J GASTROENTERO, V16, P2421, DOI 10.3748/wjg.v16.i19.2421
   Wang JW, 2016, INT J CANCER, V139, P1327, DOI 10.1002/ijc.30173
   Wassef M, 2016, CELL CYCLE, V15, P2256, DOI 10.1080/15384101.2016.1208872
   WEIDNER N, 1995, BREAST CANCER RES TR, V36, P169, DOI 10.1007/BF00666038
   Zheng X, 2016, ANN ENDOCRINOL-PARIS, V77, P658, DOI 10.1016/j.ando.2016.02.004
   Zhou HY, 2014, ONCOL LETT, V7, P1395, DOI 10.3892/ol.2014.1920
NR 43
TC 13
Z9 14
U1 0
U2 8
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0046-8177
EI 1532-8392
J9 HUM PATHOL
JI Hum. Pathol.
PD AUG
PY 2017
VL 66
BP 101
EP 107
DI 10.1016/j.humpath.2017.03.028
PG 7
WC Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pathology
GA FI4AF
UT WOS:000411911000012
PM 28666925
DA 2025-01-12
ER

PT J
AU Vladoiu, S
   Botezatu, A
   Anton, G
   Manda, D
   Paun, DL
   Oros, S
   Rosca, R
   Draganescu, DD
AF Vladoiu, S.
   Botezatu, A.
   Anton, G.
   Manda, D.
   Paun, D. L.
   Oros, S.
   Rosca, R.
   Draganescu, D. Dinu
TI THE INVOLVEMENT OF VDR PROMOTER METHYLATION, CDX-2 VDR POLYMORPHISM AND
   VITAMIN D LEVELS IN MALE INFERTILITY
SO ACTA ENDOCRINOLOGICA-BUCHAREST
LA English
DT Article
DE epigenetics; male infertility; vitamin D; VDR Cdx-2 polymorphism
ID D-RECEPTOR GENE; PROSTATE-CANCER; BREAST-CANCER; COLORECTAL-CANCER;
   HUMAN SPERM; CALCIUM; HEALTH; RISK; DEFICIENCY; ORGANIZATION
AB Introduction. Vitamin D (VD) levels were correlated with different health conditions, including reproductive disorders in males. Vitamin D action is mediated through vitamin D receptor (VDR), which acts as a transcription factor. VDR gene promoter is embedded in a GC-rich island. The VDR gene has been shown to have several polymorphisms that affect the receptor function.
   Aim. To examine the relationship between Cdx-2 polymorphism (rs17883968), the methylation status of VDR's promoter and serum levels of 25-hydroxyvitamin D in male infertility. Patients and Methods. A total of 69 infertile men and 37 age-matched controls were enrolled in this study. Vitamin D level assessments were detected using the electrochemiluminescent method. Cdx-2 VDR polymorphism identification was performed by PCR on DNA samples from blood, followed by restriction. Methylation of VDR gene promoter was assessed by qMS-PCR using bisulfite-treated DNA from fresh sperm.
   Results. Vitamin D levels was found to be significantly decreased in infertile groups compared the controls (p=0.0279). The GG genotype was found in a higher percentage in controls and the AA genotype was higher in infertile group (p=0.0056). Infertile homozygote (GG) and heterozygote (GA) individuals had significantly higher vitamin D levels than AA homozygote. Methylation is higher in individuals with lower vitamin D levels and AA genotype is characterized by higher methylation values.
   Conclusion. The results provide new insights of Cdx-2 polymorphism is involved in vitamin D deficiency, highlighting the important role of epigenetic modification of vitamin D receptor and male infertility along with the genetic context.
C1 [Vladoiu, S.; Manda, D.; Oros, S.; Rosca, R.; Draganescu, D. Dinu] CI Parhon Inst Endocrinol, Bucharest, Romania.
   [Botezatu, A.; Anton, G.] Stefan S Nicolau Virol Inst, Bucharest, Romania.
   [Paun, D. L.; Oros, S.; Rosca, R.] Carol Davila Univ Med & Pharm, Dept Endocrinol, Bucharest, Romania.
C3 National Institute of Endocrinology C.I. Parhon; Romanian Academy;
   Stefan S. Nicolau Institute of Virology; Carol Davila University of
   Medicine & Pharmacy
RP Anton, G (通讯作者)，Stefan S Nicolau Virol Inst, Res, 285 Mihai Bravu Ave, Bucharest 030304, Romania.
EM gnanka30@yahoo.com
RI Manda, Dana/AAZ-5704-2020; Paun, Diana/KCJ-8257-2024; Anton,
   Gabriela/LBH-4636-2024; Botezatu, Anca/T-6642-2018
OI Manda, Dana/0000-0001-9190-837X
FU CERO - Career profile: Romanian Researcher [POSDRU/159/1.5/S/135760];
   European Social Fund for Sectoral Operational Programme Human Resources
   Development
FX This work received financial support through the project entitled "CERO
   - Career profile: Romanian Researcher"; grant number
   POSDRU/159/1.5/S/135760, cofinanced by the European Social Fund for
   Sectoral Operational Programme Human Resources Development 2007-2013.
CR Alzoubi A, 2017, ACTA ENDOCRINOL-BUCH, V13, P180, DOI 10.4183/aeb.2017.180
   Aquila S, 2009, REPROD BIOL ENDOCRIN, V7, DOI 10.1186/1477-7827-7-140
   Arai H, 2001, J BONE MINER RES, V16, P1256, DOI 10.1359/jbmr.2001.16.7.1256
   Bischoff-Ferrari HA, 2006, AM J CLIN NUTR, V84, P18, DOI 10.1093/ajcn/84.1.18
   Carmeliet G, 2015, BEST PRACT RES CL EN, V29, P621, DOI 10.1016/j.beem.2015.06.001
   Cigerli O, 2016, ACTA ENDOCRINOL-BUCH, V12, P319, DOI 10.4183/aeb.2016.319
   Cooper TG, 2010, HUM REPROD UPDATE, V16, P559, DOI [10.1093/humupd/dmp048, 10.1093/humupd/dmq020]
   Corbett ST, 2006, UROLOGY, V68, P1345, DOI 10.1016/j.urology.2006.09.011
   DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6
   Fackler MJ, 2004, CANCER RES, V64, P4442, DOI 10.1158/0008-5472.CAN-03-3341
   Faserl K, 2011, J CLIN ENDOCR METAB, V96, pE233, DOI 10.1210/jc.2010-1532
   Flügge J, 2007, EUR J CLIN PHARMACOL, V63, P997, DOI 10.1007/s00228-007-0367-4
   Gallagher JC, 2010, J CLIN ENDOCR METAB, V95, P2630, DOI 10.1210/jc.2010-0918
   Jensen MB, 2014, NAT REV ENDOCRINOL, V10, P175, DOI 10.1038/nrendo.2013.262
   Jensen MB, 2011, HUM REPROD, V26, P1307, DOI 10.1093/humrep/der059
   Jensen MB, 2010, HUM REPROD, V25, P1303, DOI 10.1093/humrep/deq024
   Kinuta K, 2000, ENDOCRINOLOGY, V141, P1317, DOI 10.1210/en.141.4.1317
   Köstner K, 2009, ANTICANCER RES, V29, P3511
   LABUDA M, 1992, J BONE MINER RES, V7, P1447
   Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427
   Ling Y, 2016, MOL CELL ENDOCRINOL, V427, P155, DOI 10.1016/j.mce.2016.03.014
   Marik R, 2010, CANCER BIOL THER, V10, P44, DOI 10.4161/cbt.10.1.11994
   Miyamoto K, 1997, MOL ENDOCRINOL, V11, P1165, DOI 10.1210/me.11.8.1165
   Nangia AK, 2007, J UROLOGY, V178, P1092, DOI 10.1016/j.juro.2007.05.009
   Ntais C, 2003, CANCER EPIDEM BIOMAR, V12, P1395
   Osei K, 2010, J CLIN ENDOCR METAB, V95, P4220, DOI 10.1210/jc.2010-1550
   Pike JW, 2010, ENDOCRIN METAB CLIN, V39, P255, DOI 10.1016/j.ecl.2010.02.007
   Raimondi S, 2009, CARCINOGENESIS, V30, P1170, DOI 10.1093/carcin/bgp103
   Ramlau-Hansen CH, 2011, SCAND J WORK ENV HEA, V37, P533, DOI 10.5271/sjweh.3164
   Ristic S, 2017, ACTA ENDOCRINOL-BUCH, V13, P40, DOI 10.4183/aeb.2017.40
   Rodríguez-Paredes M, 2011, NAT MED, V17, P330, DOI 10.1038/nm.2305
   Ross AC, 2011, J CLIN ENDOCR METAB, V96, P53, DOI 10.1210/jc.2010-2704
   Rowland GW, 2012, J BONE MINER RES, V27, P187, DOI 10.1002/jbmr.505
   Sarkissyan M, 2014, CANCER-AM CANCER SOC, V120, P1387, DOI 10.1002/cncr.28565
   Sohl E, 2015, J CLIN ENDOCR METAB, V100, P2480, DOI 10.1210/jc.2015-1353
   SOOD S, 1995, ANN NUTR METAB, V39, P95, DOI 10.1159/000177848
   Sun WW, 2015, AM J PHYSIOL-ENDOC M, V308, pE51, DOI 10.1152/ajpendo.00076.2014
   SZPIRER J, 1991, GENOMICS, V11, P168, DOI 10.1016/0888-7543(91)90114-T
   Torkko KC, 2008, CLIN CANCER RES, V14, P3223, DOI 10.1158/1078-0432.CCR-07-4894
   Varshney S, 2013, J CLIN ENDOCR METAB, V98, pE1631, DOI 10.1210/jc.2013-1699
   Wan LY, 2015, MOLECULES, V20, P12389, DOI 10.3390/molecules200712389
   Ward KA, 2010, J CLIN ENDOCR METAB, V95, P4643, DOI 10.1210/jc.2009-2725
   Zhou ZC, 2013, TUMOR BIOL, V34, P3437, DOI 10.1007/s13277-013-0919-4
NR 43
TC 10
Z9 10
U1 0
U2 15
PU EDITURA ACAD ROMANE
PI BUCURESTI
PA CALEA 13 SEPTEMBRIE NR 13, SECTOR 5, BUCURESTI 050711, ROMANIA
SN 1841-0987
EI 1843-066X
J9 ACTA ENDOCRINOL-BUCH
JI Acta Endocrinol.
PD JUL-SEP
PY 2017
VL 13
IS 3
BP 294
EP 301
DI 10.4183/aeb.2017.294
PG 8
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Endocrinology & Metabolism
GA FI4EB
UT WOS:000411921400006
PM 31149190
OA Green Published
DA 2025-01-12
ER

PT J
AU Yan, NN
   Xu, L
   Wu, XB
   Zhang, L
   Fei, XC
   Cao, YL
   Zhang, FC
AF Yan, Ningning
   Xu, Liang
   Wu, Xiaobo
   Zhang, Le
   Fei, Xiaochun
   Cao, Yali
   Zhang, Fengchun
TI GSKJ4, an H3K27me3 demethylase inhibitor, effectively suppresses the
   breast cancer stem cells
SO EXPERIMENTAL CELL RESEARCH
LA English
DT Article
DE Breast cancer stem cells; H3K27me3; GSKJ4; Epigenetic modification
ID CHROMATIN STATE; SELF-RENEWAL; HISTONE H3; EXPRESSION; THERAPY; JMJD3;
   LYSINE-27; OVARIAN; DIFFERENTIATION; TUMORIGENICITY
AB Recently, studies have been suggested that H3K27me3 is implicated with maintenance of cancer stem cells (CSCs), however, the roles of H3K27me3 in Breast cancer stem cells (BCSCs) remain poorly investigated. Here we explore the functionallities of H3K27me3 on BCSCs, we identify H3K27me3 as a negative modulator of BCSCs and suggest GSKJ4 is a promising drug targeting BCSCs. We show that the H3K27me3 level is decreased in mammosphere-derived BCSCs. In breast cancer cells, we demonstrate that GSKJ4 could markedly inhibit the proliferation. Strikingly, we show that GSKJ4 could effectively suppress BCSCs including expansion, self-renewal capacity, and the expression of sternness-related markers. Additionally, our xenograft model confirms that GSKJ4 is able to effectively inhibit the tumorigenicity of MDA-MB-231. Mechanistically, the inhibition effects of GSKJ4 on BCSCs are via inhibiting demethylases JMJD3 and UTX with methyltransferase EZH2 unchanged, which enhances H3K27me3 level. H3K27me3 activating leads to reduction of BCSCs expansion, self-renewal and global level of sternness factors. Collectively, our results provide strong supports that H3K27me3 exerts a suppressive influence on BCSCs and reveal that GSKJ4 is capable to be a prospective agent targeting BCSCs.
C1 [Yan, Ningning; Xu, Liang; Zhang, Le; Zhang, Fengchun] Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Dept Oncol, 197 Second Ruijin Rd, Shanghai 200025, Peoples R China.
   [Yan, Ningning; Zhang, Le; Zhang, Fengchun] Shanghai Jiao Tong Univ, Sch Med, Suzhou Kowloon Hosp, Dept Oncol, Suzhou 215021, Peoples R China.
   [Xu, Liang; Cao, Yali] Third Hosp Nanchang, Prevent & Cure Ctr Breast Dis, Nanchang 33009, Jiangxi, Peoples R China.
   [Fei, Xiaochun] Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Dept Pathol, Shanghai 200025, Peoples R China.
C3 Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai
   Jiao Tong University
RP Zhang, FC (通讯作者)，Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Dept Oncol, 197 Second Ruijin Rd, Shanghai 200025, Peoples R China.; Cao, YL (通讯作者)，Third Hosp Nanchang, Prevent & Cure Ctr Breast Dis, Nanchang 33009, Jiangxi, Peoples R China.
EM yalicao_nc@sina.com; fczhang2005@163.com
FU Key R & D Project of Jiangsu Province [BE2016677]; Youth Science
   Foundation of Nanchang Province [20171BAB215045]; Suzhou Science and
   Technology Project [SS201508]
FX This work was supported by Key R & D Project of Jiangsu Province
   (BE2016677), the Youth Science Foundation of Nanchang Province
   (20171BAB215045) and Suzhou Science and Technology Project (SS201508).
CR Adorno-Cruz V, 2015, CANCER RES, V75, P924, DOI 10.1158/0008-5472.CAN-14-3225
   Agger K, 2007, NATURE, V449, P731, DOI 10.1038/nature06145
   [Anonymous], P NATL ACAD SCI US
   Bae WK, 2015, MOL CARCINOGEN, V54, P1172, DOI 10.1002/mc.22188
   Bernstein BE, 2006, CELL, V125, P315, DOI 10.1016/j.cell.2006.02.041
   Burchfield JS, 2015, INT J BIOCHEM CELL B, V67, P148, DOI 10.1016/j.biocel.2015.07.006
   Choi HJ, 2015, EMBO REP, V16, P1288, DOI 10.15252/embr.201540244
   De Santa F, 2007, CELL, V130, P1083, DOI 10.1016/j.cell.2007.08.019
   Dean M, 2005, NAT REV CANCER, V5, P275, DOI 10.1038/nrc1590
   Geng SQ, 2014, CANCER LETT, V349, P1, DOI 10.1016/j.canlet.2014.03.036
   Ginestier C, 2007, CELL STEM CELL, V1, P555, DOI 10.1016/j.stem.2007.08.014
   Golebiewska A, 2011, CELL STEM CELL, V8, P136, DOI 10.1016/j.stem.2011.01.007
   Grimshaw MJ, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2106
   Guo HB, 2017, J BIOL CHEM, V292, P4123, DOI 10.1074/jbc.M116.763201
   Harrison H, 2010, CANCER RES, V70, P709, DOI 10.1158/0008-5472.CAN-09-1681
   Hashizume R, 2014, NAT MED, V20, P1394, DOI 10.1038/nm.3716
   Hawkins RD, 2010, CELL STEM CELL, V6, P479, DOI 10.1016/j.stem.2010.03.018
   He WP, 2015, NEOPLASMA, V62, P932, DOI 10.4149/neo_2015_113
   Healey MA, 2014, BREAST CANCER RES TR, V147, P639, DOI 10.1007/s10549-014-3089-1
   Hennessy BT, 2009, CANCER RES, V69, P4116, DOI 10.1158/0008-5472.CAN-08-3441
   Honeth G, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2108
   Hu C, 2016, J DRUG TARGET, V24, P422, DOI 10.3109/1061186X.2015.1082567
   Huang Y, 2016, J THORAC DIS, V8, P2971, DOI 10.21037/jtd.2016.11.18
   Jang GB, 2015, CANCER RES, V75, P1691, DOI 10.1158/0008-5472.CAN-14-2041
   Jiang W, 2013, CELL RES, V23, P122, DOI 10.1038/cr.2012.119
   Kakarala M, 2008, J CLIN ONCOL, V26, P2813, DOI 10.1200/JCO.2008.16.3931
   Ko HW, 2016, ONCOTARGET, V7, P57131, DOI 10.18632/oncotarget.11008
   Krop I, 2012, J CLIN ONCOL, V30, P2307, DOI 10.1200/JCO.2011.39.1540
   Kruidenier L, 2012, NATURE, V488, P404, DOI 10.1038/nature11262
   Lan F, 2007, NATURE, V449, P689, DOI 10.1038/nature06192
   Lee HE, 2011, BRIT J CANCER, V104, P1730, DOI 10.1038/bjc.2011.159
   Lee MG, 2007, SCIENCE, V318, P447, DOI 10.1126/science.1149042
   Liu SL, 2006, CANCER RES, V66, P6063, DOI 10.1158/0008-5472.CAN-06-0054
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Mikkelsen TS, 2007, NATURE, V448, P553, DOI 10.1038/nature06008
   Morrison BJ, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2111
   Ntziachristos P, 2014, NATURE, V514, P513, DOI 10.1038/nature13605
   Pattabiraman DR, 2014, NAT REV DRUG DISCOV, V13, P497, DOI 10.1038/nrd4253
   Pavlopoulou A, 2016, CANCER LETT, V380, P485, DOI 10.1016/j.canlet.2016.07.018
   Pellakuru LG, 2012, AM J PATHOL, V181, P560, DOI 10.1016/j.ajpath.2012.04.021
   Rangel MC, 2016, BREAST CANCER RES TR, V156, P211, DOI 10.1007/s10549-016-3746-7
   Sakaki H, 2015, ANTICANCER RES, V35, P6607
   Shpargel KB, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004507
   Tang B, 2016, CANCER RES, V76, P6520, DOI 10.1158/0008-5472.CAN-15-3029
   Velasco-Velázquez MA, 2011, AM J PATHOL, V179, P2, DOI 10.1016/j.ajpath.2011.03.005
   Wang AHJ, 2013, EMBO J, V32, P1075, DOI 10.1038/emboj.2013.54
   Wang AX, 2015, CANCER LETT, V357, P63, DOI 10.1016/j.canlet.2014.11.040
   Watarai H, 2016, ANTICANCER RES, V36, P6083, DOI 10.21873/anticanres.11198
   Wei YK, 2008, MOL CARCINOGEN, V47, P701, DOI 10.1002/mc.20413
   Widschwendter M, 2007, NAT GENET, V39, P157, DOI 10.1038/ng1941
   Yen WC, 2015, CLIN CANCER RES, V21, P2084, DOI 10.1158/1078-0432.CCR-14-2808
   Yoo KH, 2016, MOL CELL BIOL, V36, P2108, DOI 10.1128/MCB.00089-16
   Yu F, 2007, CELL, V131, P1109, DOI 10.1016/j.cell.2007.10.054
   Zhang XY, 2016, INT J INFECT DIS, V48, P7, DOI 10.1016/j.ijid.2016.04.010
   Zhu J, 2013, CELL, V152, P642, DOI 10.1016/j.cell.2012.12.033
NR 55
TC 64
Z9 72
U1 0
U2 16
PU ELSEVIER INC
PI SAN DIEGO
PA 525 B STREET, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0014-4827
EI 1090-2422
J9 EXP CELL RES
JI Exp. Cell Res.
PD OCT 15
PY 2017
VL 359
IS 2
BP 405
EP 414
DI 10.1016/j.yexcr.2017.08.024
PG 10
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA FV8TL
UT WOS:000424859600013
PM 28823831
DA 2025-01-12
ER

PT J
AU Chen, L
   Vasilatos, SN
   Qin, Y
   Katz, TA
   Cao, CY
   Wu, H
   Tasdemir, N
   Levine, KM
   Oesterreich, S
   Davidson, NE
   Huang, Y
AF Chen, Lin
   Vasilatos, Shauna N.
   Qin, Ye
   Katz, Tiffany A.
   Cao, Chunyu
   Wu, Hao
   Tasdemir, Nilgun
   Levine, Kevin M.
   Oesterreich, Steffi
   Davidson, Nancy E.
   Huang, Yi
TI Functional characterization of lysine-specific demethylase 2
   (LSD2/KDM1B) in breast cancer progression
SO ONCOTARGET
LA English
DT Article
DE LSD2/KDM1B; breast cancer; cell growth; migration; invasion
ID EMBRYONIC STEM-CELLS; HISTONE DEMETHYLASE; 1 LSD1; ALDEHYDE
   DEHYDROGENASE; GENE ACTIVATION; SILENCED GENES; METHYLATION; INHIBITION;
   DIFFERENTIATION; TRANSCRIPTION
AB Flavin-dependent histone demethylases govern histone H3K4 methylation and act as important chromatin modulators that are extensively involved in regulation of DNA replication, gene transcription, DNA repair, and heterochromatin gene silencing. While the activities of lysine-specific demethylase 1 (LSD1/KDM1A) in facilitating breast cancer progression have been well characterized, the roles of its homolog LSD2 (KDM1B) in breast oncogenesis are relatively less understood. In this study, we showed that LSD2 protein level was significantly elevated in malignant breast cell lines compared with normal breast epithelial cell line. TCGA-Oncomine database showed that LSD2 expression is significantly higher in basal-like breast tumors compared to other breast cancer subtypes or normal breast tissue. Overexpression of LSD2 in MDA-MB-231 cells significantly altered the expression of key important epigenetic modifiers such as LSD1, HDAC1/2, and DNMT3B; promoted cellular proliferation; and augmented colony formation in soft agar; while attenuating motility and invasion. Conversely, siRNA-mediated depletion of endogenous LSD2 hindered growth of multiple breast cancer cell lines while shRNA-mediated LSD2 depletion augmented motility and invasion. Moreover, LSD2 overexpression in MDA-MB-231 cells facilitated mammosphere formation, enriched the subpopulation of CD49f(+)/EpCAM(-) and ALDH(high), and induced the expression of pluripotent stem cell markers, NANOG and SOX2. In xenograft studies using immune-compromised mice, LSD2-overexpressing MDA-MB-231 cells displayed accelerated tumor growth but significantly fewer lung metastases than controls. Taken together, our findings provide novel insights into the critical and multifaceted roles of LSD2 in the regulation of breast cancer progression and cancer stem cell enrichment.
C1 [Chen, Lin; Vasilatos, Shauna N.; Qin, Ye; Cao, Chunyu; Wu, Hao; Tasdemir, Nilgun; Levine, Kevin M.; Oesterreich, Steffi; Huang, Yi] Univ Pittsburgh, Sch Med, Womens Canc Res Ctr, UPMC Hillman Canc Ctr, Pittsburgh, PA 15260 USA.
   [Chen, Lin] Tsinghua Univ, Sch Med, Beijing, Peoples R China.
   [Vasilatos, Shauna N.; Qin, Ye; Cao, Chunyu; Tasdemir, Nilgun; Oesterreich, Steffi; Huang, Yi] Univ Pittsburgh, Sch Med, Dept Pharmacol & Chem Biol, Pittsburgh, PA 15260 USA.
   [Levine, Kevin M.] Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA USA.
   [Katz, Tiffany A.] Baylor Coll Med, Ctr Precis Environm Hlth, Houston, TX 77030 USA.
   [Wu, Hao] Nanjing Med Univ, Dept Oncol, Affiliated Hosp 1, Nanjing, Jiangsu, Peoples R China.
   [Davidson, Nancy E.] Univ Washington, Fred Hutchinson Canc Res Ctr, Seattle, WA 98195 USA.
   [Davidson, Nancy E.] Univ Washington, Dept Med, Seattle, WA USA.
   [Cao, Chunyu] China Three Gorges Univ, Yichang, Hubei, Peoples R China.
C3 Pennsylvania Commonwealth System of Higher Education (PCSHE); University
   of Pittsburgh; Tsinghua University; Pennsylvania Commonwealth System of
   Higher Education (PCSHE); University of Pittsburgh; Pennsylvania
   Commonwealth System of Higher Education (PCSHE); University of
   Pittsburgh; Baylor College of Medicine; Nanjing Medical University; Fred
   Hutchinson Cancer Center; University of Washington; University of
   Washington Seattle; University of Washington; University of Washington
   Seattle; China Three Gorges University
RP Huang, Y (通讯作者)，Univ Pittsburgh, Sch Med, Womens Canc Res Ctr, UPMC Hillman Canc Ctr, Pittsburgh, PA 15260 USA.; Huang, Y (通讯作者)，Univ Pittsburgh, Sch Med, Dept Pharmacol & Chem Biol, Pittsburgh, PA 15260 USA.
EM yih26@pitt.edu
RI Huang, Yi/AAW-7892-2021; Cao, Chunyu/J-8622-2018
OI Huang, Yi/0000-0002-9982-117X; Cao, Chunyu/0000-0003-3043-5673; Levine,
   Kevin/0000-0001-6859-3461; Chen, Lin/0000-0002-8126-3333
FU US Army Breast Cancer Research Programs [W81XWH-14-1-0237,
   W81XWH-14-1-0238]; University of Pittsburgh Cancer Institute CCSG [P30
   CA047904]; Breast Cancer Research Foundation
FX This work is supported by US Army Breast Cancer Research Programs
   (W81XWH-14-1-0237 to YH; W81XWH-14-1-0238 to NED/SO), University of
   Pittsburgh Cancer Institute CCSG P30 CA047904, and Breast Cancer
   Research Foundation (to NED and SO).
CR Adamo A, 2011, NAT CELL BIOL, V13, P652, DOI 10.1038/ncb2246
   Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100
   Azuara V, 2006, NAT CELL BIOL, V8, P532, DOI 10.1038/ncb1403
   Beaulieu N, 2002, J BIOL CHEM, V277, P28176, DOI 10.1074/jbc.M204734200
   Bernstein BE, 2006, CELL, V125, P315, DOI 10.1016/j.cell.2006.02.041
   Campbell LL, 2007, CELL CYCLE, V6, P2332, DOI 10.4161/cc.6.19.4914
   Cao C, 2017, ONCOGENE, V36, P133, DOI 10.1038/onc.2016.186
   Charafe-Jauffret E, 2009, CANCER RES, V69, P1302, DOI 10.1158/0008-5472.CAN-08-2741
   Ciccone DN, 2009, NATURE, V461, P415, DOI 10.1038/nature08315
   Dontu G, 2003, GENE DEV, V17, P1253, DOI 10.1101/gad.1061803
   Fang R, 2010, MOL CELL, V39, P222, DOI 10.1016/j.molcel.2010.07.008
   Garcia RN, 2007, GENETICA, V131, P91, DOI 10.1007/s10709-006-9116-3
   Garcia-Bassets I, 2007, CELL, V128, P505, DOI 10.1016/j.cell.2006.12.038
   Gil-Henn H, 2013, ONCOGENE, V32, P2622, DOI 10.1038/onc.2012.284
   Guo WJ, 2012, CELL, V148, P1015, DOI 10.1016/j.cell.2012.02.008
   Hojfeldt JW, 2013, NAT REV DRUG DISCOV, V12, P917, DOI 10.1038/nrd4154
   Huang Y, 2007, P NATL ACAD SCI USA, V104, P8023, DOI 10.1073/pnas.0700720104
   Huang Y, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2925
   Huang Y, 2012, BREAST CANCER RES TR, V131, P777, DOI 10.1007/s10549-011-1480-8
   Huang Y, 2009, ESSAYS BIOCHEM, V46, P95, DOI [10.1042/BSE0460007, 10.1042/bse0460007]
   Huang Y, 2009, CLIN CANCER RES, V15, P7217, DOI 10.1158/1078-0432.CCR-09-1293
   Jambhekar A, 2017, COLD SPRING HARB PER, V7, P7
   Karytinos A, 2009, J BIOL CHEM, V284, P17775, DOI 10.1074/jbc.M109.003087
   Katz TA, 2014, ANN MED, V46, P397, DOI 10.3109/07853890.2014.923740
   Katz TA, 2014, BREAST CANCER RES TR, V146, P99, DOI 10.1007/s10549-014-3012-9
   Lai AY, 2011, NAT REV CANCER, V11, P588, DOI 10.1038/nrc3091
   Lim S, 2010, CARCINOGENESIS, V31, P512, DOI 10.1093/carcin/bgp324
   Lin SL, 2011, NUCLEIC ACIDS RES, V39, P1054, DOI 10.1093/nar/gkq850
   Liu SL, 2010, J CLIN ONCOL, V28, P4006, DOI 10.1200/JCO.2009.27.5388
   Liu ZL, 2016, J PROTEOME RES, V15, P1506, DOI 10.1021/acs.jproteome.5b01125
   Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027
   Marcato P, 2011, CELL CYCLE, V10, P1378, DOI 10.4161/cc.10.9.15486
   Metzger E, 2005, NATURE, V437, P436, DOI 10.1038/nature04020
   Moreb JS, 2008, CURR STEM CELL RES T, V3, P237, DOI 10.2174/157488808786734006
   Pan GJ, 2007, CELL STEM CELL, V1, P299, DOI 10.1016/j.stem.2007.08.003
   Schmidt JM, 2015, CELL REP, V10, P131, DOI 10.1016/j.celrep.2014.12.032
   Shaw PG, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076220
   Shi Y, 2007, NAT REV GENET, V8, P829, DOI 10.1038/nrg2218
   Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012
   van Essen D, 2010, MOL CELL, V39, P750, DOI 10.1016/j.molcel.2010.08.010
   Vasilatos SN, 2013, CARCINOGENESIS, V34, P1196, DOI 10.1093/carcin/bgt033
   Vastenhouw NL, 2012, CURR OPIN CELL BIOL, V24, P374, DOI 10.1016/j.ceb.2012.03.009
   Whyte WA, 2012, NATURE, V482, P221, DOI 10.1038/nature10805
   Wu YD, 2013, CELL REP, V5, P224, DOI 10.1016/j.celrep.2013.08.030
   Yang Y, 2015, MOL CELL, V58, P47, DOI 10.1016/j.molcel.2015.01.038
   Zhang XM, 2013, CELL REP, V5, P445, DOI 10.1016/j.celrep.2013.09.018
   Zhu QS, 2012, AMINO ACIDS, V42, P887, DOI 10.1007/s00726-011-1004-1
NR 47
TC 34
Z9 42
U1 0
U2 22
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD OCT 10
PY 2017
VL 8
IS 47
BP 81737
EP 81753
DI 10.18632/oncotarget.19387
PG 17
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA FJ4DA
UT WOS:000412683900011
PM 29137219
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Gooding, AJ
   Zhang, B
   Jahanbani, FK
   Gilmore, HL
   Chang, JC
   Valadkhan, S
   Schiemann, WP
AF Gooding, Alex J.
   Zhang, Bing
   Jahanbani, Fereshteh Kenari
   Gilmore, Hannah L.
   Chang, Jenny C.
   Valadkhan, Saba
   Schiemann, William P.
TI The lncRNA BORG Drives Breast Cancer Metastasis and Disease Recurrence
SO SCIENTIFIC REPORTS
LA English
DT Article
ID LONG NONCODING RNAS; CARCINOMA; GROWTH; KAP1; SUMOYLATION; PROTEIN;
   DIRECTS; CELLS; GENE; PHOSPHORYLATION
AB Long noncoding RNAs (lncRNAs) have emerged as potent regulators of breast cancer development and progression, including the metastatic spread of disease. Through in silico and biological analyses, we identified a novel lncRNA, BMP/OP-Responsive Gene (BORG), whose expression directly correlates with aggressive breast cancer phenotypes, as well as with metastatic competence and disease recurrence in multiple clinical cohorts. Mechanistically, BORG elicits the metastatic outgrowth of latent breast cancer cells by promoting the localization and transcriptional repressive activity of TRIM28, which binds BORG and induces substantial alterations in carcinoma proliferation and survival. Moreover, inhibiting BORG expression in metastatic breast cancer cells impedes their metastatic colonization of the lungs of mice, implying that BORG acts as a novel driver of the genetic and epigenetic alterations that underlie the acquisition of metastatic and recurrent phenotypes by breast cancer cells.
C1 [Gooding, Alex J.; Schiemann, William P.] Case Western Reserve Univ, Case Comprehens Canc Ctr, Cleveland, OH 44106 USA.
   [Zhang, Bing; Jahanbani, Fereshteh Kenari; Valadkhan, Saba] Case Western Reserve Univ, Dept Mol Biol & Microbiol, Cleveland, OH 44106 USA.
   [Gilmore, Hannah L.] Univ Hosp, Dept Pathol, Case Med Ctr, Cleveland, OH 44106 USA.
   [Gilmore, Hannah L.] Case Western Reserve Univ, Cleveland, OH 44106 USA.
   [Chang, Jenny C.] Houston Methodist Res Ctr, Houston, TX 77030 USA.
C3 University System of Ohio; Case Western Reserve University; University
   System of Ohio; Case Western Reserve University; University Hospitals of
   Cleveland; University System of Ohio; Case Western Reserve University;
   University System of Ohio; Case Western Reserve University; Houston
   Methodist
RP Schiemann, WP (通讯作者)，Case Western Reserve Univ, Case Comprehens Canc Ctr, Cleveland, OH 44106 USA.; Valadkhan, S (通讯作者)，Case Western Reserve Univ, Dept Mol Biol & Microbiol, Cleveland, OH 44106 USA.
EM saba.valadkhan@case.edu; william.schiemann@case.edu
RI Valadkhan, Saba/G-7271-2012
OI Valadkhan, Saba/0000-0002-6859-4883
FU National Institutes of Health [CA129359, CA177069, CA194518,
   T32GM007250, F30CA203233]; METAvivor Foundation; Case Comprehensive
   Cancer Center's Research Innovation Fund; Case Council and Friends of
   the Case Comprehensive Cancer Center
FX Members of the Schiemann Laboratory are thanked for critical comments
   and reading of the manuscript. We also thank Dr. Lalith Gunawardane for
   technical assistance in elucidating BORG-bindings partners, as well as
   acknowledge the expertise provided by members of the Case Comprehensive
   Cancer Center's Core Facilities, including the Gene Expression &
   Genotyping Core, the Imaging Research Core, and Tissue Resources Core.
   Research support was provided in part by the National Institutes of
   Health to W.P.S. (CA129359, CA177069, and CA194518) and A.J.G
   (T32GM007250 and F30CA203233). Additional support was graciously
   provided by the METAvivor Foundation (W.P.S), and by pilot funding from
   the Case Comprehensive Cancer Center's Research Innovation Fund, which
   is supported by the Case Council and Friends of the Case Comprehensive
   Cancer Center (W.P.S. and S.V.).
CR Abba MC, 2015, CANCER RES, V75, P3980, DOI 10.1158/0008-5472.CAN-15-0506
   Abbas T, 2009, NAT REV CANCER, V9, P400, DOI 10.1038/nrc2657
   ADDISON J, 2014, CANCER RES, V75, P344
   ASLAKSON CJ, 1992, CANCER RES, V52, P1399
   Baltz AG, 2012, MOL CELL, V46, P674, DOI 10.1016/j.molcel.2012.05.021
   Barkan D, 2010, CANCER RES, V70, P5706, DOI 10.1158/0008-5472.CAN-09-2356
   Blythe AJ, 2016, BBA-GENE REGUL MECH, V1859, P46, DOI 10.1016/j.bbagrm.2015.08.009
   Bunch H, 2014, NAT STRUCT MOL BIOL, V21, P876, DOI 10.1038/nsmb.2878
   Cabanski CR, 2015, RNA BIOL, V12, P628, DOI 10.1080/15476286.2015.1038012
   Calderon MR, 2014, NUCLEIC ACIDS RES, V42, P7012, DOI 10.1093/nar/gku413
   Cheng CT, 2016, CANCER RES, V76, P5006, DOI 10.1158/0008-5472.CAN-15-2921
   Chiang AC, 2008, NEW ENGL J MED, V359, P2814, DOI 10.1056/NEJMra0805239
   CZERWINSKA P, 2016, ONCOTARGET, V25, P219
   Dias N, 2002, MOL CANCER THER, V1, P347
   Downward J, 2003, NAT REV CANCER, V3, P11, DOI 10.1038/nrc969
   Eswaran J, 2012, SCI REP-UK, V2, DOI 10.1038/srep00264
   Fatica A, 2014, NAT REV GENET, V15, P7, DOI 10.1038/nrg3606
   Fatima Roshan, 2015, Mol Cell Ther, V3, P5
   Galliher-Beckley AJ, 2008, CARCINOGENESIS, V29, P244, DOI 10.1093/carcin/bgm245
   Geisler S, 2013, NAT REV MOL CELL BIO, V14, P699, DOI 10.1038/nrm3679
   Gupta GP, 2006, CELL, V127, P679, DOI 10.1016/j.cell.2006.11.001
   Gupta RA, 2010, NATURE, V464, P1071, DOI 10.1038/nature08975
   Guttman M, 2012, NATURE, V482, P339, DOI 10.1038/nature10887
   Hilgarth Roland S., 2005, V301, P329
   HOLMGREN L, 1995, NAT MED, V1, P149, DOI 10.1038/nm0295-149
   Hu G, 2009, GENE DEV, V23, P837, DOI 10.1101/gad.1769609
   Huarte M, 2015, NAT MED, V21, P1253, DOI 10.1038/nm.3981
   Ivanov AV, 2007, MOL CELL, V28, P823, DOI 10.1016/j.molcel.2007.11.012
   Iyengar S, 2011, J BIOL CHEM, V286, P26267, DOI 10.1074/jbc.R111.252569
   Kim SK, 2014, MOL ONCOL, V8, P1653, DOI 10.1016/j.molonc.2014.06.016
   Labun K, 2016, NUCLEIC ACIDS RES, V44, pW272, DOI 10.1093/nar/gkw398
   Lee JH, 2016, CELL DISCOV, V2, DOI 10.1038/celldisc.2016.25
   Lee YK, 2007, J BIOL CHEM, V282, P1595, DOI 10.1074/jbc.M606306200
   LI J, 2017, ONCOGENE, V14, P30
   Li X, 2007, J BIOL CHEM, V282, P36177, DOI 10.1074/jbc.M706912200
   Ling H, 2013, NAT REV DRUG DISCOV, V12, P847, DOI 10.1038/nrd4140
   Liu L, 2013, CANCER EPIDEMIOL, V37, P71, DOI 10.1016/j.canep.2012.08.005
   Mascle XH, 2007, J BIOL CHEM, V282, P10190, DOI 10.1074/jbc.M611429200
   Mercer TR, 2013, NAT STRUCT MOL BIOL, V20, P300, DOI 10.1038/nsmb.2480
   MORRIS VL, 1994, CLIN EXP METASTAS, V12, P357, DOI 10.1007/BF01755879
   MORRIS VL, 1993, CLIN EXP METASTAS, V11, P103, DOI 10.1007/BF00880071
   Naumov GN, 2002, CANCER RES, V62, P2162
   Pang KC, 2006, TRENDS GENET, V22, P1, DOI 10.1016/j.tig.2005.10.003
   Pantel K, 2004, NAT REV CANCER, V4, P448, DOI 10.1038/nrc1370
   Ponting CP, 2009, CELL, V136, P629, DOI 10.1016/j.cell.2009.02.006
   Quinn JJ, 2016, NAT REV GENET, V17, P47, DOI 10.1038/nrg.2015.10
   RAK JW, 1992, BRIT J CANCER, V65, P641, DOI 10.1038/bjc.1992.138
   RANGANATHAN AC, 2014, CANCER BIOL THER, V5, P729
   Reich M, 2006, NAT GENET, V38, P500, DOI 10.1038/ng0506-500
   Rinn JL, 2007, CELL, V129, P1311, DOI 10.1016/j.cell.2007.05.022
   Senft D, 2016, TRENDS CANCER, V2, P429, DOI 10.1016/j.trecan.2016.06.004
   Shalem O, 2014, SCIENCE, V343, P84, DOI 10.1126/science.1247005
   Shibue T, 2009, P NATL ACAD SCI USA, V106, P10290, DOI 10.1073/pnas.0904227106
   SIEGEL RL, 2017, CA-CANCER J CLIN, V67, P7, DOI [DOI 10.3322/CAAC.21387, DOI 10.3322/caac.21772]
   Sosa MS, 2014, NAT REV CANCER, V14, P611, DOI 10.1038/nrc3793
   Tabernero J, 2013, CANCER DISCOV, V3, P406, DOI 10.1158/2159-8290.CD-12-0429
   Takeda K, 1998, J BIOL CHEM, V273, P17079, DOI 10.1074/jbc.273.27.17079
   Tamura RE, 2012, CURR MOL MED, V12, P634
   Taylor MA, 2011, NEOPLASIA, V13, P406, DOI 10.1593/neo.101086
   Ulitsky I, 2011, CELL, V147, P1537, DOI 10.1016/j.cell.2011.11.055
   Vanharanta S, 2013, CANCER CELL, V24, P410, DOI 10.1016/j.ccr.2013.09.007
   Varley KE, 2014, BREAST CANCER RES TR, V146, P287, DOI 10.1007/s10549-014-3019-2
   Wang YY, 2016, INT J CLIN ONCOL, V21, P927, DOI 10.1007/s10147-016-0979-8
   Wei CH, 2016, SCI REP-UK, V6, DOI 10.1038/srep26770
   Wendt MK, 2010, ONCOGENE, V29, P6485, DOI 10.1038/onc.2010.377
   Wendt MK, 2011, MOL BIOL CELL, V22, P2423, DOI 10.1091/mbc.E11-04-0306
   Xing Z, 2014, CELL, V159, P1110, DOI 10.1016/j.cell.2014.10.013
   Yokoe T, 2010, ANN SURG ONCOL, V17, P821, DOI 10.1245/s10434-009-0795-8
   Yu C, 2014, MED ONCOL, V31, DOI 10.1007/s12032-014-0025-5
   Zhang B, 2014, MOL CELL BIOL, V34, P2318, DOI 10.1128/MCB.01673-13
   Zhang XM, 2013, CANCER RES, V73, P4885, DOI 10.1158/0008-5472.CAN-12-4081
NR 71
TC 76
Z9 81
U1 0
U2 10
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD OCT 5
PY 2017
VL 7
AR 12698
DI 10.1038/s41598-017-12716-6
PG 18
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA FI9VQ
UT WOS:000412358000004
PM 28983112
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Miyano, M
   Sayaman, RW
   Stoiber, MH
   Lin, CH
   Stampfer, MR
   Brown, JB
   LaBarge, MA
AF Miyano, Masaru
   Sayaman, Rosalyn W.
   Stoiber, Marcus H.
   Lin, Chun-Han
   Stampfer, Martha R.
   Brown, James B.
   LaBarge, Mark A.
TI Age-related gene expression in luminal epithelial cells is driven by a
   microenvironment made from myoepithelial cells
SO AGING-US
LA English
DT Article
DE mammary epithelia; breast cancer; aging; microenvironment; epigenetic
ID MAMMARY-GLAND DEVELOPMENT; DNA METHYLATION CHANGES; BREAST-CANCER;
   TUMOR-CELLS; DIFFERENTIATION; PROFILES; ELF5; REJUVENATION; PROGENITORS;
   PACKAGE
AB Luminal epithelial cells in the breast gradually alter gene and protein expression with age, appearing to lose lineage-specificity by acquiring myoepithelial-like characteristics. We hypothesize that the luminal lineage is particularly sensitive to microenvironment changes, and age-related microenvironment changes cause altered luminal cell phenotypes. To evaluate the effects of different microenvironments on the fidelity of epigenetically regulated luminal and myoepithelial gene expression, we generated a set of lineage-specific probes for genes that are controlled through DNA methylation. Culturing primary luminal cells under conditions that favor myoepithelial propogation led to their reprogramming at the level of gene methylation, and to a more myoepithelial-like expression profile. Primary luminal cells' lineage-specific gene expression could be maintained when they were cultured as bilayers with primary myoepithelial cells. Isogenic stromal fibroblast co-cultures were unable to maintain the luminal phenotype. Mixed-age luminal-myoepithelial bilayers revealed that luminal cells adopt transcription and methylation patterns consistent with the chronological age of the myoepithelial cells. We provide evidence that the luminal epithelial phenotype is exquisitely sensitive to microenvironment conditions, and that states of aging are cell non-autonomously communicated through microenvironment cues over at least one cell diameter.
C1 [Miyano, Masaru; Sayaman, Rosalyn W.; LaBarge, Mark A.] City Hope Natl Med Ctr, Dept Populat Sci, Duarte, CA 91010 USA.
   [LaBarge, Mark A.] City Hope Natl Med Ctr, Ctr Canc & Aging, Duarte, CA 91010 USA.
   [Sayaman, Rosalyn W.; Lin, Chun-Han; Stampfer, Martha R.; LaBarge, Mark A.] Lawrence Berkeley Natl Lab, Biol Syst & Engn Div, Berkeley, CA 94720 USA.
   [Stoiber, Marcus H.; Brown, James B.] Lawrence Berkeley Natl Lab, Envrionm Genom & Syst Biol Div, Berkeley, CA 94720 USA.
   [LaBarge, Mark A.] Univ Bergen, Ctr Canc Biomarkers Res, Bergen, Norway.
   [Brown, James B.] Univ Birmingham, Dept Environm Bioinformat, Birmingham, W Midlands, England.
C3 City of Hope; City of Hope; United States Department of Energy (DOE);
   Lawrence Berkeley National Laboratory; United States Department of
   Energy (DOE); Lawrence Berkeley National Laboratory; University of
   Bergen; University of Birmingham
RP LaBarge, MA (通讯作者)，City Hope Natl Med Ctr, Dept Populat Sci, Duarte, CA 91010 USA.; LaBarge, MA (通讯作者)，City Hope Natl Med Ctr, Ctr Canc & Aging, Duarte, CA 91010 USA.; LaBarge, MA (通讯作者)，Lawrence Berkeley Natl Lab, Biol Syst & Engn Div, Berkeley, CA 94720 USA.; LaBarge, MA (通讯作者)，Univ Bergen, Ctr Canc Biomarkers Res, Bergen, Norway.
EM mlabarge@coh.org
RI LaBarge, Mark/E-2621-2013
OI Sayaman, Rosalyn/0000-0003-1343-0619; LaBarge, Mark/0000-0003-2405-4719
FU Congressionally Directed Medical Research Program's Breast Cancer
   Research Program [BC141351]; National Institutes of Aging [R01AG040081];
   City of Hope Center for Cancer and Aging [P30CA033572]; Chancellor's
   Fellowship for Graduate Research, University of California Berkeley;
   Stem Cell Engineering Fellowship, University of California Berkeley Stem
   Cell Center/NIH T-32 Training Grant [T32GM098218]
FX M.A.L. is supported by: the Era of Hope Scholar Award from the
   Congressionally Directed Medical Research Program's Breast Cancer
   Research Program (BC141351), the National Institutes of Aging
   (R01AG040081), and a pilot award from the City of Hope Center for Cancer
   and Aging, and P30CA033572. R.W.S. was supported by: the Chancellor's
   Fellowship for Graduate Research, University of California Berkeley and
   the Stem Cell Engineering Fellowship, University of California Berkeley
   Stem Cell Center/NIH T-32 Training Grant (T32GM098218). The content is
   solely the responsibility of the authors and does not necessarily
   represent the official views of the NIH.
CR Adriance MC, 2005, BREAST CANCER RES, V7, P190, DOI 10.1186/bcr1286
   [Anonymous], 2004, Stat. Appl. Genet. Mol. Biol., DOI [10.2202/1544-6115.1027, DOI 10.2202/1544-6115.1027]
   Bapat SA, 2010, EPIGENETICS-US, V5, P716, DOI 10.4161/epi.5.8.13014
   Benz CC, 2008, CRIT REV ONCOL HEMAT, V66, P65, DOI 10.1016/j.critrevonc.2007.09.001
   BENZEEV A, 1988, P NATL ACAD SCI USA, V85, P2161, DOI 10.1073/pnas.85.7.2161
   Bernstein BE, 2010, NAT BIOTECHNOL, V28, P1045, DOI 10.1038/nbt1010-1045
   Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102
   CARLSON BM, 1989, AM J PHYSIOL, V256, pC1262
   Chakrabarti R, 2012, NAT CELL BIOL, V14, P1212, DOI 10.1038/ncb2607
   Chakrabarti R, 2012, STEM CELLS, V30, P1496, DOI 10.1002/stem.1112
   Conboy IM, 2005, NATURE, V433, P760, DOI 10.1038/nature03260
   Conboy IM, 2003, SCIENCE, V302, P1575, DOI 10.1126/science.1087573
   Costa FF, 2009, EPIGENOMICS-UK, V1, P387, DOI [10.2217/epi.09.25, 10.2217/EPI.09.25]
   de Magalhaes JP, 2009, BIOINFORMATICS, V25, P875, DOI 10.1093/bioinformatics/btp073
   DesRochers TM, 2012, EPIGENETICS-US, V7, P34, DOI 10.4161/epi.7.1.18546
   Du P, 2008, BIOINFORMATICS, V24, P1547, DOI 10.1093/bioinformatics/btn224
   Du P, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-587
   Eppenberger-Castori S, 2002, INT J BIOCHEM CELL B, V34, P1318, DOI 10.1016/S1357-2725(02)00052-3
   Fraser HB, 2005, PLOS BIOL, V3, P1653, DOI 10.1371/journal.pbio.0030274
   Garbe JC, 2012, CANCER RES, V72, P3687, DOI 10.1158/0008-5472.CAN-12-0157
   Garbe JC, 2009, CANCER RES, V69, P7557, DOI 10.1158/0008-5472.CAN-09-0270
   Greer EL, 2012, NAT REV GENET, V13, P343, DOI 10.1038/nrg3173
   Gudjonsson T, 2002, GENE DEV, V16, P693, DOI 10.1101/gad.952602
   Gudjonsson T, 2005, J MAMMARY GLAND BIOL, V10, P261, DOI 10.1007/s10911-005-9586-4
   Hannum G, 2013, MOL CELL, V49, P359, DOI 10.1016/j.molcel.2012.10.016
   Hernandez DG, 2011, HUM MOL GENET, V20, P1164, DOI 10.1093/hmg/ddq561
   HOWEEDY AA, 1990, LAB INVEST, V63, P798
   Jenkins EO, 2014, ONCOLOGIST, V19, P1076, DOI 10.1634/theoncologist.2014-0184
   Jie G, 2007, INT J CLIN PRACT, V61, P1523, DOI 10.1111/j.1742-1241.2006.01033.x
   Johnson WE, 2007, BIOSTATISTICS, V8, P118, DOI 10.1093/biostatistics/kxj037
   Kalyuga M, 2012, PLOS BIOL, V10, DOI 10.1371/journal.pbio.1001461
   LaBarge MA, 2016, GERONTOLOGY, V62, P434, DOI 10.1159/000441030
   LaBarge MA, 2013, JOVE-J VIS EXP, DOI 10.3791/50011
   LaBarge MA, 2009, INTEGR BIOL-UK, V1, P70, DOI 10.1039/b816472j
   LEE EYH, 1984, J CELL BIOL, V98, P146, DOI 10.1083/jcb.98.1.146
   Lee JK, 2015, FRONT CELL DEV BIOL, V3, DOI 10.3389/fcell.2015.00013
   Leek JT, 2012, BIOINFORMATICS, V28, P882, DOI 10.1093/bioinformatics/bts034
   Loffredo FS, 2013, CELL, V153, P828, DOI 10.1016/j.cell.2013.04.015
   Ma XJ, 2003, P NATL ACAD SCI USA, V100, P5974, DOI 10.1073/pnas.0931261100
   Margueron R, 2011, NATURE, V469, P343, DOI 10.1038/nature09784
   Nygaard V, 2016, BIOSTATISTICS, V17, P29, DOI 10.1093/biostatistics/kxv027
   Oyer JA, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004832
   Péchoux C, 1999, DEV BIOL, V206, P88, DOI 10.1006/dbio.1998.9133
   Pelissier FA, 2014, CELL REP, V7, P1926, DOI 10.1016/j.celrep.2014.05.021
   Quong J, 2002, BREAST CANCER RES TR, V76, P221, DOI 10.1023/A:1020886801674
   Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007
   Ruckh JM, 2012, CELL STEM CELL, V10, P96, DOI 10.1016/j.stem.2011.11.019
   Shi W, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkq871
   Smyth GK, 2005, BIOINFORMATICS, V21, P2067, DOI 10.1093/bioinformatics/bti270
   Stute P, 2012, BREAST CANCER RES TR, V133, P617, DOI 10.1007/s10549-011-1811-9
   Suzuki R, 2006, BIOINFORMATICS, V22, P1540, DOI 10.1093/bioinformatics/btl117
   Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034
   Xu R, 2009, J CELL BIOL, V184, P57, DOI 10.1083/jcb.200807021
   Yau C, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1765
   Zahn JM, 2006, PLOS GENET, V2, P1058, DOI 10.1371/journal.pgen.0020115
   Zhou J, 2005, EMBO J, V24, P635, DOI 10.1038/sj.emboj.7600538
   Zykovich A, 2014, AGING CELL, V13, P360, DOI 10.1111/acel.12180
NR 57
TC 20
Z9 22
U1 0
U2 3
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
SN 1945-4589
J9 AGING-US
JI Aging-US
PD OCT
PY 2017
VL 9
IS 10
BP 2025
EP +
DI 10.18632/aging.101298
PG 26
WC Cell Biology; Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Geriatrics & Gerontology
GA FL4ED
UT WOS:000414179600009
PM 29016359
OA Green Published, Green Submitted, gold
DA 2025-01-12
ER

PT J
AU Wei, L
   Chiu, DKC
   Tsang, FHC
   Law, CT
   Cheng, CLH
   Au, SLK
   Lee, JMF
   Wong, CCL
   Ng, IOL
   Wong, CM
AF Wei, Lai
   Chiu, David Kung-Chun
   Tsang, Felice Ho-Ching
   Law, Cheuk-Ting
   Cheng, Carol Lai-Hung
   Au, Sandy Leung-Kuen
   Lee, Joyce Man-Fong
   Wong, Carmen Chak-Lui
   Ng, Irene Oi-Lin
   Wong, Chun-Ming
TI Histone methyltransferase G9a promotes liver cancer development by
   epigenetic silencing of tumor suppressor gene <i>RARRES3</i>
SO JOURNAL OF HEPATOLOGY
LA English
DT Article
DE Epigenetics; Histone modifications; G9a; Gene amplification; miR-1;
   RARRES3
ID COMPARATIVE GENOMIC HYBRIDIZATION; ADVANCED HEPATOCELLULAR-CARCINOMA;
   LYSINE METHYLTRANSFERASE; EARLY EMBRYOGENESIS; BREAST-CANCER; CELLS;
   METHYLATION; METASTASIS; APOPTOSIS; DIFFERENTIATION
AB Background & Aims: Hepatocellular carcinoma (HCC) is a major leading cause of cancer mortality worldwide. Epigenetic deregulation is a common trait of human HCC. G9s is an important epigenetics regulator however, its role in liver carcinogenesis remains to be investigated.
   Methods: Gene expressions were determined by RNA-Seq and qRT-PCR. G9a knockdown and knockout cell lines were established by lentiviral-based shRNA and CRISPR/Cas9 gene editing system. Tumor-promoting functions of G9a was studied in both HCC cell lines and nude mice model. The downstream targets of G9a were identified by RNA-Seq and confirmed by ChIP assay. The therapeutic value of G9a inhibitors was evaluated both in vitro and in vivo.
   Results: We identified G9a as a frequently upregulated histone methyltransferase in human HCCs. Upregulation of G9a was significantly associated with HCC progression and aggressive clinicopathological features. Functionally, we demonstrated that inactivation of G9a by RNAi knockdown, CRISPR/Cas9 knockout, and pharmacological inhibition remarkably abolished H3K9 di-methylation and suppressed HCC cell proliferation and metastasis in both in vitro and in vivo models. Mechanistically, we showed that the frequent upregulation of G9a in human HCCs was attributed to gene copy number gain at chromosome 6p21. In addition, we identified miR-1 as a negative regulator of G9a. Loss of miR-1 relieved the post-transcriptional repression on G9a and contributed to its upregulation in human HCC. Utilizing RNA sequencing, we identified the tumor suppressor RARRES3 as a critical target of G9a. Epigenetic silencing of RARRES3 contributed to the tumor-promoting function of G9a.
   Conclusion: This study shows a frequent deregulation of miR-1/ G9a/RARRES3 axis in liver carcinogenesis, highlighting the pathological significance of G9a and its therapeutic potential in HCC treatment.
   Lay summary: In this study, we identified G9a histone methyltransferase was frequently upregulated in human HCC and contributes to epigenetic silencing of tumor suppressor gene RARRES3 in liver cancer. Targeting G9a may be a novel approach for HCC treatment. (C) 2017 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
C1 [Wei, Lai; Chiu, David Kung-Chun; Tsang, Felice Ho-Ching; Law, Cheuk-Ting; Cheng, Carol Lai-Hung; Au, Sandy Leung-Kuen; Lee, Joyce Man-Fong; Wong, Carmen Chak-Lui; Ng, Irene Oi-Lin; Wong, Chun-Ming] Univ Hong Kong, State Key Lab Liver Res, Hong Kong, Hong Kong, Peoples R China.
   [Wei, Lai; Chiu, David Kung-Chun; Tsang, Felice Ho-Ching; Law, Cheuk-Ting; Cheng, Carol Lai-Hung; Au, Sandy Leung-Kuen; Lee, Joyce Man-Fong; Wong, Carmen Chak-Lui; Ng, Irene Oi-Lin; Wong, Chun-Ming] Univ Hong Kong, Li Ka Shing Fac Med, Dept Pathol, Hong Kong, Hong Kong, Peoples R China.
   [Wei, Lai; Tsang, Felice Ho-Ching; Wong, Chun-Ming] Univ Hong Kong, Shenzhen Inst Res & Innovat, Shenzhen, Peoples R China.
C3 University of Hong Kong; University of Hong Kong; University of Hong
   Kong; The University of Hong Kong Shenzhen Institute of Research &
   Innovation
RP Ng, IOL; Wong, CM (通讯作者)，Univ Hong Kong, Queen Mary Hosp, State Key Lab Liver Res, Univ Pathol Bldg, Pokfulam, Hong Kong, Peoples R China.; Ng, IOL; Wong, CM (通讯作者)，Univ Hong Kong, Queen Mary Hosp, Dept Pathol, Univ Pathol Bldg, Pokfulam, Hong Kong, Peoples R China.
EM iolng@hku.hk; jackwong@pathology.hku.hk
RI Law, Cheuk Ting/JXX-5010-2024; WONG, Chun-Ming/A-6739-2009; Wong, Carmen
   Chak Lui/C-4660-2009; Chiu, David Kung-Chun/JYP-6176-2024
OI Wong, Carmen Chak Lui/0000-0001-5866-4705; Chiu, David
   Kung-Chun/0000-0002-9700-4707; WONG, Chun-Ming/0000-0002-2497-7858; Ng,
   Irene Oi-lin/0000-0001-7532-2029
FU National Natural Science Foundation of China General Program [81572446];
   Hong Kong Research Grants Council [T12-704/16R]; General Research Funds
   [17115815, HKU780612M]
FX The study was supported by National Natural Science Foundation of China
   General Program (81572446), and Hong Kong Research Grants Council
   Theme-based Research Scheme (T12-704/16R) and General Research Funds
   (17115815 and HKU780612M). I.O. L. Ng is Loke Yew Professor in
   Pathology.
CR Arrowsmith CH, 2012, NAT REV DRUG DISCOV, V11, P384, DOI 10.1038/nrd3674
   Au SLK, 2012, HEPATOLOGY, V56, P622, DOI 10.1002/hep.25679
   Bruix J, 2014, GUT, V63, P844, DOI 10.1136/gutjnl-2013-306627
   Chen MW, 2010, CANCER RES, V70, P7830, DOI 10.1158/0008-5472.CAN-10-0833
   Chen YJ, 2000, GASTROENTEROLOGY, V119, P431, DOI 10.1053/gast.2000.9373
   Chochi Y, 2009, J PATHOL, V217, P677, DOI 10.1002/path.2491
   de Narvajas AAM, 2013, MOL CELL BIOL, V33, P3983, DOI 10.1128/MCB.00813-13
   Ding J, 2013, CELL METAB, V18, P896, DOI 10.1016/j.cmet.2013.11.004
   DiSepio D, 1998, P NATL ACAD SCI USA, V95, P14811, DOI 10.1073/pnas.95.25.14811
   Dong CF, 2012, J CLIN INVEST, V122, P1469, DOI 10.1172/JCI57349
   Ellinger J, 2010, PROSTATE, V70, P61, DOI 10.1002/pros.21038
   Esteller M, 2007, NAT REV GENET, V8, P286, DOI 10.1038/nrg2005
   Fan DNY, 2013, HEPATOLOGY, V57, P637, DOI 10.1002/hep.26083
   Feldman N, 2006, NAT CELL BIOL, V8, P188, DOI 10.1038/ncb1353
   Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210
   Gorringe KL, 2005, GENE CHROMOSOME CANC, V42, P247, DOI 10.1002/gcc.20136
   Higuchi E, 2003, ONCOGENE, V22, P4627, DOI 10.1038/sj.onc.1206235
   Hsu TH, 2015, CELL DEATH DIFFER, V22, P1561, DOI 10.1038/cdd.2015.90
   Hsu TH, 2012, FEBS LETT, V586, P1287, DOI 10.1016/j.febslet.2012.03.020
   Hua KT, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-189
   Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127
   Kubicek S, 2007, MOL CELL, V25, P473, DOI 10.1016/j.molcel.2007.01.017
   Lee JS, 2010, MOL CELL, V39, P71, DOI 10.1016/j.molcel.2010.06.008
   Lee SH, 2009, ONCOGENE, V28, P184, DOI 10.1038/onc.2008.377
   Li KC, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-172
   Lin YW, 1999, EUR J CANCER, V35, P652, DOI 10.1016/S0959-8049(98)00430-4
   Llovet JM, 2008, NEW ENGL J MED, V359, P378, DOI 10.1056/NEJMoa0708857
   Lu ZY, 2013, ANTI-CANCER DRUG, V24, P484, DOI 10.1097/CAD.0b013e32835ffdbb
   Moinzadeh P, 2005, BRIT J CANCER, V92, P935, DOI 10.1038/sj.bjc.6602448
   Momparler RL, 2003, ONCOGENE, V22, P6479, DOI 10.1038/sj.onc.1206774
   Morales M, 2014, EMBO MOL MED, V6, P865, DOI 10.15252/emmm.201303675
   Pang A, 2003, CANCER GENET CYTOGEN, V146, P8, DOI 10.1016/S0165-4608(03)00103-1
   Ren AS, 2015, BIOCHEM BIOPH RES CO, V459, P10, DOI 10.1016/j.bbrc.2015.01.068
   Scharadin TM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023230
   Seligson DB, 2009, AM J PATHOL, V174, P1619, DOI 10.2353/ajpath.2009.080874
   Sonoki T, 2001, BLOOD, V98, P2837, DOI 10.1182/blood.V98.9.2837
   Sturniolo MT, 2003, J BIOL CHEM, V278, P48066, DOI 10.1074/jbc.M307215200
   Tachibana M, 2002, GENE DEV, V16, P1779, DOI 10.1101/gad.989402
   Tsai FM, 2007, CELL SIGNAL, V19, P989, DOI 10.1016/j.cellsig.2006.11.005
   Vedadi M, 2011, NAT CHEM BIOL, V7, P566, DOI [10.1038/nchembio.599, 10.1038/NCHEMBIO.599]
   Wang DZ, 2010, NAT REV CANCER, V10, P181, DOI 10.1038/nrc2809
   Wen B, 2009, NAT GENET, V41, P246, DOI 10.1038/ng.297
   Wong CCY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017873
   Wong CM, 2008, LIVER INT, V28, P160, DOI 10.1111/j.1478-3231.2007.01637.x
   Wong CM, 2016, HEPATOLOGY, V63, P474, DOI 10.1002/hep.28304
NR 45
TC 121
Z9 130
U1 1
U2 50
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-8278
EI 1600-0641
J9 J HEPATOL
JI J. Hepatol.
PD OCT
PY 2017
VL 67
IS 4
BP 758
EP 769
DI 10.1016/j.jhep.2017.05.015
PG 12
WC Gastroenterology & Hepatology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Gastroenterology & Hepatology
GA FG9RE
UT WOS:000410775900013
PM 28532996
DA 2025-01-12
ER

PT J
AU Wagner, VP
   Martins, MD
   Guimaraes, DM
   Vasconcelos, AC
   Meurer, L
   Vargas, PA
   Fonseca, FP
   Squarize, CH
   Castilho, RM
AF Wagner, Vivian Petersen
   Martins, Manoela Domingues
   Guimaraes, Douglas Magno
   Vasconcelos, Artur Cunha
   Meurer, Luise
   Vargas, Pablo Agustin
   Fonseca, Felipe Paiva
   Squarize, Cristiane Helena
   Castilho, Rogerio Moraes
TI Reduced chromatin acetylation of malignant salivary gland tumors
   correlates with enhanced proliferation
SO JOURNAL OF ORAL PATHOLOGY & MEDICINE
LA English
DT Article
DE acetylation; epigenetics; head and neck cancer; histone;
   immunohistochemistry
ID CANCER STEM-CELLS; HISTONE MODIFICATIONS; TISSUE MICROARRAY;
   BREAST-CANCER; PHASE-II; CARCINOMA; HEAD; RESISTANCE; CISPLATIN;
   SURVIVAL
AB Background: Epigenetic changes refer to any heritable modification in gene expression independent of alterations in the DNA sequence. Currently, it is well established that epigenetics represents a crucial player for tumor development. Nevertheless, the epigenetic mechanisms involved in the development and progression of salivary gland tumors (SGTs) remain poorly understood.
   Methods: In this study, we analyzed the pattern of acetyl-histone H3 (lys9) expression in benign and malignant SGTs and further correlate our results with tumors' proliferative activity and clinical outcomes. We assembled tissue microarrays (TMAs) of 84 cases of SGTs and analyzed for acetyl-histone H3 (lys9) and Ki-67 using immunohistochemistry. The study comprised 42 benign and 42 malignant SGTs.
   Results: All cases included in this study were positive to acetyl-H3 (lys9). We observed that malignant SGTs were hypoacetylated compared with benign (P = 0.04). Moreover, acetyl-H3 (lys9) expression was inversely correlated with Ki67 (**P = 0.02).
   Conclusion: This study provides the first insight regarding histone modifications in SGTs. Our results suggest that epigenetic mechanism, particularly hypoacetylation of histone H3 (lys9), might play a role in the behavior of salivary gland tumors. Also, our findings suggest that interfering with the acetylation pattern of tumor histones represents a potential novel therapeutic strategy for the treatment of SGTs.
C1 [Wagner, Vivian Petersen; Martins, Manoela Domingues; Vasconcelos, Artur Cunha] Univ Fed Rio Grande do Sul, Sch Dent, Dept Oral Pathol, Porto Alegre, RS, Brazil.
   [Wagner, Vivian Petersen; Martins, Manoela Domingues; Vasconcelos, Artur Cunha; Meurer, Luise] Hosp Clin Porto Alegre, Dept Expt Pathol, Porto Alegre, RS, Brazil.
   [Wagner, Vivian Petersen; Martins, Manoela Domingues; Guimaraes, Douglas Magno; Squarize, Cristiane Helena; Castilho, Rogerio Moraes] Univ Michigan, Dept Periodont & Oral Med, Lab Epithelial Biol, Sch Dent, Ann Arbor, MI 48109 USA.
   HCPA UFRGS, Dept Oral Med, Porto Alegre, RS, Brazil.
   [Vargas, Pablo Agustin] Univ Estadual Campinas, Piracicaba Dent Sch, Dept Oral Diag, Piracicaba, SP, Brazil.
   [Fonseca, Felipe Paiva] Univ Fed Minas Gerais, Dent Sch, Dept Clin Pathol & Surg, Belo Horizonte, MG, Brazil.
C3 Universidade Federal do Rio Grande do Sul; University of Michigan
   System; University of Michigan; Universidade Estadual de Campinas;
   Universidade Federal de Minas Gerais
RP Castilho, RM (通讯作者)，Univ Michigan, Lab Epithelial Biol, Dept Periodont & Oral Med, 1011 N Univ Ave,Room 2029C, Ann Arbor, MI 48109 USA.
EM rcastilh@umich.edu
RI Castilho, Rogerio/E-4987-2010; Guimaraes, Douglas/AAP-8971-2021;
   Martins, Manoela/G-8209-2012; Fonseca, Felipe/C-4158-2012; Vargas, Pablo
   Agustin/C-5208-2012; Petersen Wagner, Vivian/B-5401-2017
OI Fonseca, Felipe/0000-0002-6657-4547; Vargas, Pablo
   Agustin/0000-0003-1840-4911; Squarize, Cristiane/0000-0002-6782-3429;
   Petersen Wagner, Vivian/0000-0002-1447-2135; Moraes Castilho,
   Rogerio/0000-0001-5358-612X; Guimaraes, Douglas/0000-0001-7856-1324
FU Capes Foundation within the Ministry of Education, Brazil
   [BEX/99999.007990/2014-06]; University of Michigan School of Dentistry
   faculty award; National Cancer Institute [P30CA046592] Funding Source:
   NIH RePORTER; National Institute of Dental and Craniofacial Research
   [R01DE021139] Funding Source: NIH RePORTER
FX This work was conducted during a visiting scholar period at the
   University of Michigan, sponsored by the Capes Foundation within the
   Ministry of Education, Brazil (grant n. BEX/99999.007990/2014-06). This
   grant was funded by the University of Michigan School of Dentistry
   faculty award. The funders had no role in study design, data collection,
   and analysis, decision to publish, or preparation of the manuscript.
CR Adams A, 2015, ONCOTARGET, V6, P26633, DOI 10.18632/oncotarget.5782
   Adams A, 2013, ORAL ONCOL, V49, P845, DOI 10.1016/j.oraloncology.2013.05.013
   Almeida LO, 2014, FEBS OPEN BIO, V4, P96, DOI 10.1016/j.fob.2013.12.003
   Bell RB, 2005, J ORAL MAXIL SURG, V63, P917, DOI 10.1016/j.joms.2005.03.006
   Carlson Julie, 2013, Am Soc Clin Oncol Educ Book, P257, DOI 10.1200/EdBook_AM.2013.33.257
   Cerda T, 2014, CRIT REV ONCOL HEMAT, V91, P142, DOI 10.1016/j.critrevonc.2014.02.002
   Cesmebasi A, 2014, MED SCI MONITOR, V20, P2536, DOI 10.12659/MSM.891052
   Chien WW, 2014, MOL CARCINOGEN, V53, P722, DOI 10.1002/mc.22024
   Fonseca FP, 2014, OR SURG OR MED OR PA, V117, P81, DOI 10.1016/j.oooo.2013.08.029
   Fonseca FP, 2012, OR SURG OR MED OR PA, V114, P230, DOI 10.1016/j.oooo.2012.04.008
   Fraga MF, 2005, NAT GENET, V37, P391, DOI 10.1038/ng1531
   Fuks F, 2000, NAT GENET, V24, P88, DOI 10.1038/71750
   Giaginis C, 2015, BMC GASTROENTEROL, V15, DOI 10.1186/s12876-015-0379-y
   Giudice FS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058672
   Glozak MA, 2007, ONCOGENE, V26, P5420, DOI 10.1038/sj.onc.1210610
   Gong FD, 2013, MUTAT RES-FUND MOL M, V750, P23, DOI 10.1016/j.mrfmmm.2013.07.002
   Guimaraes DM, 2016, ONCOTARGET, V7, P42447, DOI 10.18632/oncotarget.9884
   Guzzo M, 2010, CRIT REV ONCOL HEMAT, V74, P134, DOI 10.1016/j.critrevonc.2009.10.004
   Lapierre M, 2016, ONCOTARGET, V7, P19693, DOI 10.18632/oncotarget.7564
   LICITRA L, 1991, CANCER, V68, P1874, DOI 10.1002/1097-0142(19911101)68:9<1874::AID-CNCR2820680904>3.0.CO;2-S
   Martins Manoela D, 2013, J Carcinog Mutagen, V1, P1
   Meshorer E, 2006, NAT REV MOL CELL BIO, V7, P540, DOI 10.1038/nrm1938
   Munster PN, 2011, BRIT J CANCER, V104, P1828, DOI 10.1038/bjc.2011.156
   Paiva-Fonseca F, 2013, MED ORAL PATOL ORAL, V18, pE1, DOI 10.4317/medoral.18204
   Sen GL, 2010, NATURE, V463, P563, DOI 10.1038/nature08683
   Singh A, 2010, ONCOGENE, V29, P4741, DOI 10.1038/onc.2010.215
   Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412
   Terhaard CH, 2004, HEAD NECK-J SCI SPEC, V26, P692
   Terhaard CHJ, 2004, HEAD NECK-J SCI SPEC, V26, P681, DOI 10.1002/hed.10400
   Yin LX, 2016, CANCER-AM CANCER SOC, V122, P1822, DOI 10.1002/cncr.29890
   Zhang CY, 2007, CANCER-AM CANCER SOC, V110, P87, DOI 10.1002/cncr.22758
NR 31
TC 13
Z9 14
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0904-2512
EI 1600-0714
J9 J ORAL PATHOL MED
JI J. Oral Pathol. Med.
PD OCT
PY 2017
VL 46
IS 9
BP 792
EP 797
DI 10.1111/jop.12557
PG 6
WC Dentistry, Oral Surgery & Medicine; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Dentistry, Oral Surgery & Medicine; Pathology
GA FI9DF
UT WOS:000412303500020
PM 28161900
OA Green Published
DA 2025-01-12
ER

PT J
AU Polak, P
   Kim, J
   Braunstein, LZ
   Karlic, R
   Haradhavala, NJ
   Tiao, G
   Rosebrock, D
   Livitz, D
   Kübler, K
   Mouw, KW
   Kamburov, A
   Maruvka, YE
   Leshchiner, I
   Lander, ES
   Golub, TR
   Zick, A
   Orthwein, A
   Lawrence, MS
   Batra, RN
   Caldas, C
   Haber, DA
   Laird, PW
   Shen, H
   Ellisen, LW
   D'Andrea, AD
   Chanock, SJ
   Foulkes, WD
   Getz, G
AF Polak, Paz
   Kim, Jaegil
   Braunstein, Lior Z.
   Karlic, Rosa
   Haradhavala, Nicholas J.
   Tiao, Grace
   Rosebrock, Daniel
   Livitz, Dimitri
   Kubler, Kirsten
   Mouw, Kent W.
   Kamburov, Atanas
   Maruvka, Yosef E.
   Leshchiner, Ignaty
   Lander, Eric S.
   Golub, Todd R.
   Zick, Aviad
   Orthwein, Alexandre
   Lawrence, Michael S.
   Batra, Rajbir N.
   Caldas, Carlos
   Haber, Daniel A.
   Laird, Peter W.
   Shen, Hui
   Ellisen, Leif W.
   D'Andrea, Alan D.
   Chanock, Stephen J.
   Foulkes, William D.
   Getz, Gad
TI A mutational signature reveals alterations underlying deficient
   homologous recombination repair in breast cancer
SO NATURE GENETICS
LA English
DT Article
ID COMPREHENSIVE MOLECULAR PORTRAITS; GERMLINE BRCA1 MUTATIONS;
   OVARIAN-CANCER; SEQUENCE VARIATION; PARP INHIBITORS; FAMILY-HISTORY;
   TUMORS; LANDSCAPE; VARIANTS; SUSCEPTIBILITY
AB Biallelic inactivation of BRCA1 or BRCA2 is associated with a pattern of genome-wide mutations known as signature 3. By analyzing similar to 1,000 breast cancer samples, we confirmed this association and established that germline nonsense and frameshift variants in PALB2, but not in ATM or CHEK2, can also give rise to the same signature. We were able to accurately classify missense BRCA1 or BRCA2 variants known to impair homologous recombination (HR) on the basis of this signature. Finally, we show that epigenetic silencing of RAD51C and BRCA1 by promoter methylation is strongly associated with signature 3 and, in our data set, was highly enriched in basal-like breast cancers in young individuals of African descent.
C1 [Polak, Paz; Kim, Jaegil; Braunstein, Lior Z.; Haradhavala, Nicholas J.; Tiao, Grace; Rosebrock, Daniel; Livitz, Dimitri; Kubler, Kirsten; Kamburov, Atanas; Maruvka, Yosef E.; Leshchiner, Ignaty; Lander, Eric S.; Golub, Todd R.; Lawrence, Michael S.; Getz, Gad] Broad Inst MIT & Harvard, Cambridge, MA 02142 USA.
   [Polak, Paz; Haradhavala, Nicholas J.; Kubler, Kirsten; Kamburov, Atanas; Maruvka, Yosef E.; Lawrence, Michael S.; Haber, Daniel A.; Ellisen, Leif W.; Getz, Gad] Massachusetts Gen Hosp, Ctr Canc Res, Charlestown, MA 02129 USA.
   [Polak, Paz; Kubler, Kirsten; Mouw, Kent W.; Kamburov, Atanas; Maruvka, Yosef E.; Golub, Todd R.; Haber, Daniel A.; Ellisen, Leif W.; Getz, Gad] Harvard Med Sch, Boston, MA 02115 USA.
   [Braunstein, Lior Z.] Mem Sloan Kettering Canc Ctr, Dept Radiat Oncol, 1275 York Ave, New York, NY 10021 USA.
   [Karlic, Rosa] Univ Zagreb, Div Mol Biol, Dept Biol, Bioinformat Grp,Fac Sci, Zagreb, Croatia.
   [Mouw, Kent W.] Brigham & Womens Hosp, Dept Radiat Oncol, 75 Francis St, Boston, MA 02115 USA.
   [Mouw, Kent W.] Dana Farber Canc Inst, Boston, MA 02115 USA.
   [Lander, Eric S.] MIT, Dept Biol, Cambridge, MA USA.
   [Lander, Eric S.] Harvard Med Sch, Dept Syst Biol, Boston, MA USA.
   [Golub, Todd R.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
   [Golub, Todd R.] Dana Farber Canc Inst, Dept Pathol, Boston, MA 02115 USA.
   [Golub, Todd R.] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA.
   [Zick, Aviad] Hadassah Hebrew Univ, Dept Oncol, Med Ctr, Jerusalem, Israel.
   [Orthwein, Alexandre; Foulkes, William D.] McGill Univ, Dept Oncol, Montreal, PQ, Canada.
   [Batra, Rajbir N.; Caldas, Carlos] Univ Cambridge, Canc Res UK Cambridge Inst, Li Ka Shing Ctr, Cambridge, England.
   [Batra, Rajbir N.; Caldas, Carlos] Canc Res UK Cambridge Ctr, Cambridge, England.
   [Batra, Rajbir N.; Caldas, Carlos] Univ Cambridge, Dept Oncol, Hutchison MRC Res Ctr, Cambridge Biomed Campus, Cambridge, England.
   [Laird, Peter W.; Shen, Hui] Van Andel Res Inst, Grand Rapids, MI USA.
   [D'Andrea, Alan D.] Dana Farber Canc Inst, Ctr DNA Damage & Repair, Boston, MA 02115 USA.
   [D'Andrea, Alan D.] Harvard Med Sch, Ludwig Ctr, Harvard, Boston, MA USA.
   [Chanock, Stephen J.] US Natl Canc Inst, Div Canc Epidemiol & Genet, Bethesda, MD USA.
   [Foulkes, William D.] McGill Univ, Lady Davis Inst Med Res, Dept Human Genet, Montreal, PQ, Canada.
   [Foulkes, William D.] McGill Univ, Res Inst, Hlth Ctr, Montreal, PQ, Canada.
   [Getz, Gad] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
C3 Harvard University; Massachusetts Institute of Technology (MIT); Broad
   Institute; Harvard University; Massachusetts General Hospital; Harvard
   University; Harvard Medical School; Memorial Sloan Kettering Cancer
   Center; University of Zagreb; Harvard University; Brigham & Women's
   Hospital; Harvard University; Dana-Farber Cancer Institute;
   Massachusetts Institute of Technology (MIT); Harvard University; Harvard
   Medical School; Harvard University; Dana-Farber Cancer Institute;
   Harvard University; Dana-Farber Cancer Institute; Harvard University;
   Dana-Farber Cancer Institute; Hebrew University of Jerusalem; Hadassah
   University Medical Center; McGill University; Cancer Research UK;
   University of Cambridge; CRUK Cambridge Institute; CRUK Cambridge
   Institute; Cancer Research UK; University of Cambridge; Van Andel
   Institute; Harvard University; Dana-Farber Cancer Institute; National
   Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI);
   McGill University; Lady Davis Institute; McGill University; Harvard
   University; Massachusetts General Hospital
RP Getz, G (通讯作者)，Broad Inst MIT & Harvard, Cambridge, MA 02142 USA.; Getz, G (通讯作者)，Massachusetts Gen Hosp, Ctr Canc Res, Charlestown, MA 02129 USA.; Getz, G (通讯作者)，Harvard Med Sch, Boston, MA 02115 USA.; Getz, G (通讯作者)，Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
EM gadgetz@broadinstitute.org
RI Maruvka, Yosef/G-6261-2010; Kim, Yu/L-8480-2017; Karlić,
   Rosa/KMY-8296-2024; Lawrence, Michael/AAC-8202-2020; Chanock,
   Stephen/AGL-9345-2022; Zick, Aviad/GZK-7645-2022; Foulkes,
   William/AAR-9586-2021; Getz, Gad/ABW-5118-2022; Polak,
   Paz/AAH-9380-2020; Ellisen, Leif/AAA-6572-2022; Batra,
   Rajbir/I-2443-2014; LAIRD, PETER W/G-8683-2012; Caldas,
   Carlos/U-7250-2019
OI Orthwein, Alexandre/0000-0002-7350-3413; Haradhvala,
   Nicholas/0000-0003-1113-3135; Shen, Hui/0000-0001-9767-4084; Kubler,
   Kirsten/0000-0002-0342-5579; Rosebrock, Daniel/0000-0002-4818-4983;
   Batra, Rajbir/0000-0001-7010-8189; Mouw, Kent/0000-0001-7939-7343;
   Maruvka, Yosef/0000-0002-8918-9887; LAIRD, PETER W/0000-0001-9117-3641;
   Caldas, Carlos/0000-0003-3547-1489; Kamburov,
   Atanas/0000-0002-0580-0619; Livitz, Dimitri/0000-0003-2528-1446; Karlic,
   Rosa/0000-0002-1291-2897; Zick, Aviad/0000-0002-5077-9249
FU Louis B. Mayer Foundation; Avon Breast Cancer Crusade; Breast Cancer
   Research Foundation (BCRF); NIH TCGA Genome Data Analysis Center
   [U24CA143845]; Massachusetts General Hospital; Ludwig Center at Harvard;
   Susan G. Komen; National Cancer Institute [ZIACP010227] Funding Source:
   NIH RePORTER
FX L.Z.B. was supported by the Louis B. Mayer Foundation. L.W.E. was
   supported by grants from the Avon Breast Cancer Crusade and the Breast
   Cancer Research Foundation (BCRF). G.G. and J.K. were partially funded
   by the NIH TCGA Genome Data Analysis Center (U24CA143845). P.P., N.J.H.,
   Y.E.M., and A.K. were funded by the startup funds of G.G. at
   Massachusetts General Hospital. A.D.D. was supported by grants from the
   Ludwig Center at Harvard and the Breast Cancer Research Foundation
   (BCRF). W.D.F. was supported by Susan G. Komen. G. G. was partly funded
   by the Paul C. Zamecnick, MD, Chair in Oncology at Massachusetts General
   Hospital.
CR Abkevich V, 2012, BRIT J CANCER, V107, P1776, DOI 10.1038/bjc.2012.451
   Alexandrov LB, 2013, NATURE, V500, P415, DOI 10.1038/nature12477
   Antoniou A, 2003, AM J HUM GENET, V72, P1117, DOI 10.1086/375033
   Blanco A, 2014, BREAST CANCER RES TR, V147, P133, DOI 10.1007/s10549-014-3078-4
   Burstein MD, 2015, CLIN CANCER RES, V21, P1688, DOI 10.1158/1078-0432.CCR-14-0432
   Carter SL, 2012, NAT BIOTECHNOL, V30, P413, DOI 10.1038/nbt.2203
   Ceccaldi R, 2016, TRENDS CELL BIOL, V26, P52, DOI 10.1016/j.tcb.2015.07.009
   Ceccaldi R, 2015, NATURE, V518, P258, DOI 10.1038/nature14184
   Chan SL, 2010, LANCET, V376, P211, DOI 10.1016/S0140-6736(10)61119-1
   Cibulskis K, 2013, NAT BIOTECHNOL, V31, P213, DOI 10.1038/nbt.2514
   Ciriello G, 2015, CELL, V163, P506, DOI 10.1016/j.cell.2015.09.033
   Clamp A, 2015, LANCET ONCOL, V16, P10, DOI 10.1016/S1470-2045(14)71172-6
   Connor AA, 2017, JAMA ONCOL, V3, P774, DOI 10.1001/jamaoncol.2016.3916
   CORNELIS RS, 1995, GENE CHROMOSOME CANC, V13, P203, DOI 10.1002/gcc.2870130310
   Costello M, 2013, NUCLEIC ACIDS RES, V41, DOI 10.1093/nar/gks1443
   Couch FJ, 2015, J CLIN ONCOL, V33, P304, DOI 10.1200/JCO.2014.57.1414
   Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983
   Dietze EC, 2015, NAT REV CANCER, V15, P248, DOI 10.1038/nrc3896
   Easton DF, 2015, NEW ENGL J MED, V372, P2243, DOI 10.1056/NEJMsr1501341
   Eccles DM, 2015, ANN ONCOL, V26, P2057, DOI 10.1093/annonc/mdv278
   Ellis MJ, 2013, CANCER DISCOV, V3, P27, DOI 10.1158/2159-8290.CD-12-0462
   Esteller M, 2000, JNCI-J NATL CANCER I, V92, P564, DOI 10.1093/jnci/92.7.564
   Evans T, 2017, THER ADV MED ONCOL, V9, P253, DOI 10.1177/1758834016687254
   Fong PC, 2009, NEW ENGL J MED, V361, P123, DOI 10.1056/NEJMoa0900212
   Foulkes WD, 2003, J NATL CANCER I, V95, P1482, DOI 10.1093/jnci/djg050
   Foulkes WD, 2010, NEW ENGL J MED, V363, P1938, DOI 10.1056/NEJMra1001389
   Górski B, 2000, AM J HUM GENET, V66, P1963, DOI 10.1086/302922
   Hashizume R, 2001, J BIOL CHEM, V276, P14537, DOI 10.1074/jbc.C000881200
   Hyman DM, 2015, DRUG DISCOV TODAY, V20, P1422, DOI 10.1016/j.drudis.2015.08.005
   Kasar S, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9866
   Kaufman B, 2015, J CLIN ONCOL, V33, P244, DOI 10.1200/JCO.2014.56.2728
   Kim J, 2016, NAT GENET, V48, P600, DOI 10.1038/ng.3557
   Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412
   Landrum MJ, 2014, NUCLEIC ACIDS RES, V42, pD980, DOI 10.1093/nar/gkt1113
   Lawrence MS, 2013, NATURE, V499, P214, DOI 10.1038/nature12213
   Lek M, 2016, NATURE, V536, P285, DOI 10.1038/nature19057
   Lindor NM, 2012, HUM MUTAT, V33, P8, DOI 10.1002/humu.21627
   Livingston DM, 2009, SCIENCE, V324, P602, DOI 10.1126/science.1174839
   Lord CJ, 2016, NAT REV CANCER, V16, P110, DOI 10.1038/nrc.2015.21
   Loveday C, 2012, NAT GENET, V44, P475, DOI 10.1038/ng.2224
   McKenna A, 2010, GENOME RES, V20, P1297, DOI 10.1101/gr.107524.110
   Meeks HD, 2016, JNCI-J NATL CANCER I, V108, DOI 10.1093/jnci/djv315
   Merajver SD, 1995, CLIN CANCER RES, V1, P539
   Min A, 2013, MOL CANCER THER, V12, P865, DOI 10.1158/1535-7163.MCT-12-0950
   Nielsen FC, 2016, NAT REV CANCER, V16, P599, DOI 10.1038/nrc.2016.72
   Nik-Zainal S, 2016, NATURE, V534, P47, DOI 10.1038/nature17676
   Nik-Zainal S, 2012, CELL, V149, P979, DOI 10.1016/j.cell.2012.04.024
   Patch AM, 2015, NATURE, V521, P489, DOI 10.1038/nature14410
   Pathania S, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6496
   Pereira B, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11479
   Popova T, 2012, CANCER RES, V72, P5454, DOI 10.1158/0008-5472.CAN-12-1470
   Prakash R, 2015, CSH PERSPECT BIOL, V7, DOI 10.1101/cshperspect.a016600
   Rehm HL, 2015, NEW ENGL J MED, V372, P2235, DOI 10.1056/NEJMsr1406261
   Richards S, 2015, GENET MED, V17, P405, DOI 10.1038/gim.2015.30
   Saunders CT, 2012, BIOINFORMATICS, V28, P1811, DOI 10.1093/bioinformatics/bts271
   Scully R, 2000, NATURE, V408, P429, DOI 10.1038/35044000
   Southey MC, 2016, J MED GENET, V53, P800, DOI 10.1136/jmedgenet-2016-103839
   Spurdle AB, 2012, HUM MUTAT, V33, P2, DOI 10.1002/humu.21628
   Thompson ER, 2016, J CLIN ONCOL, V34, P1455, DOI 10.1200/JCO.2015.63.7454
   Waddell N, 2015, NATURE, V518, P495, DOI 10.1038/nature14169
   Yeeles JTP, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a012815
   YOUDEN WJ, 1950, CANCER-AM CANCER SOC, V3, P32, DOI 10.1002/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3
NR 62
TC 364
Z9 405
U1 1
U2 41
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 1061-4036
EI 1546-1718
J9 NAT GENET
JI Nature Genet.
PD OCT
PY 2017
VL 49
IS 10
BP 1476
EP +
DI 10.1038/ng.3934
PG 13
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA FI3JD
UT WOS:000411855800011
PM 28825726
OA Green Accepted
HC Y
HP N
DA 2025-01-12
ER

PT J
AU Tagde, A
   Markert, T
   Rajabi, H
   Hiraki, M
   Alam, M
   Bouillez, A
   Avigan, D
   Anderson, K
   Kufe, D
AF Tagde, Ashujit
   Markert, Tahireh
   Rajabi, Hasan
   Hiraki, Masayuki
   Alam, Maroof
   Bouillez, Audrey
   Avigan, David
   Anderson, Kenneth
   Kufe, Donald
TI Targeting MUC1-C suppresses polycomb repressive complex 1 in multiple
   myeloma
SO ONCOTARGET
LA English
DT Article
DE MUC1-C; multiple myeloma; BMI1; RING1; RING2
ID BREAST-CANCER CELLS; EPITHELIAL-MESENCHYMAL TRANSITION; TRANSCRIPTION
   FACTOR; H2A UBIQUITYLATION; PLASMA-CELLS; HISTONE H2A; STEM-CELLS;
   C-MYC; ONCOPROTEIN; EXPRESSION
AB The polycomb repressive complex 1 (PRC1) includes the BMI1, RING1 and RING2 proteins. BMI1 is required for survival of multiple myeloma (MM) cells. The MUC1-C oncoprotein is aberrantly expressed by MM cells, activates MYC and is also necessary for MM cell survival. The present studies show that targeting MUC1-C with (i) stable and inducible silencing and CRISPR/Cas9 editing and (ii) the pharmacologic inhibitor GO-203, which blocks MUC1-C function, downregulates BMI1, RING1 and RING2 expression. The results demonstrate that MUC1-C drives BMI1 transcription by a MYC-dependent mechanism. MUC1-C thus promotes MYC occupancy on the BMI1 promoter and thereby activates BMI1 expression. We also show that the MUC1-C -> MYC pathway induces RING2 expression. Moreover, in contrast to BMI1 and RING2, we found that MUC1-C drives RING1 by an NF-kappa B p65-dependent mechanism. Targeting MUC1-C and thereby the suppression of these key PRC1 proteins was associated with downregulation of the PRC1 E3 ligase activity as evidenced by decreases in ubiquitylation of histone H2A. Targeting MUC1-C also resulted in activation of the PRC1-repressed tumor suppressor genes, PTEN, CDNK2A and BIM. These findings identify a heretofore unrecognized role for MUC1-C in the epigenetic regulation of MM cells.
C1 [Tagde, Ashujit; Markert, Tahireh; Rajabi, Hasan; Hiraki, Masayuki; Alam, Maroof; Bouillez, Audrey; Avigan, David; Anderson, Kenneth; Kufe, Donald] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Dana Farber Canc Inst, Boston, MA 02115 USA.
C3 Harvard University; Beth Israel Deaconess Medical Center; Harvard
   Medical School; Dana-Farber Cancer Institute
RP Kufe, D (通讯作者)，Harvard Med Sch, Beth Israel Deaconess Med Ctr, Dana Farber Canc Inst, Boston, MA 02115 USA.
EM donald_kufe@dfci.harvard.edu
RI Bouillez, Audrey/E-2962-2017; Anderson, Kenneth/ACP-5073-2022; Tagde,
   Ashujit/M-9497-2014
OI Hiraki, Masayuki/0000-0001-6445-7390
FU National Cancer Institute of the National Institutes of Health
   [P50CA100707, R01CA097098, R01CA166480]
FX Research reported in this publication was supported by the National
   Cancer Institute of the National Institutes of Health under award
   numbers P50CA100707, R01CA097098 and R01CA166480.
CR Ahmad R, 2007, NAT CELL BIOL, V9, P1419, DOI 10.1038/ncb1661
   Ahmad R, 2009, CANCER RES, V69, P7013, DOI 10.1158/0008-5472.CAN-09-0523
   Baldus SE, 2007, HISTOL HISTOPATHOL, V22, P889, DOI 10.14670/HH-22.889
   Blackledge NP, 2015, NAT REV MOL CELL BIO, V16, P643, DOI 10.1038/nrm4067
   Bouillez A, 2016, CANCER RES, V76, P1538, DOI 10.1158/0008-5472.CAN-15-1804
   Bracken AP, 2006, GENE DEV, V20, P1123, DOI 10.1101/gad.381706
   Cao R, 2005, MOL CELL, V20, P845, DOI 10.1016/j.molcel.2005.12.002
   Chesi M, 2008, CANCER CELL, V13, P167, DOI 10.1016/j.ccr.2008.01.007
   Chng WJ, 2007, CANCER RES, V67, P2982, DOI 10.1158/0008-5472.CAN-06-4046
   Cho JH, 2013, J BIOL CHEM, V288, P3406, DOI 10.1074/jbc.M112.422931
   Cloosen S, 2006, BRIT J HAEMATOL, V135, P513, DOI 10.1111/j.1365-2141.2006.06331.x
   de Napoles M, 2004, DEV CELL, V7, P663, DOI 10.1016/j.devcel.2004.10.005
   De Vos J, 2002, ONCOGENE, V21, P6848, DOI 10.1038/sj.onc.1205868
   Delmore JE, 2011, CELL, V146, P903, DOI 10.1016/j.cell.2011.08.017
   Deola S, 2007, J TRANSL MED, V5, DOI 10.1186/1479-5876-5-35
   Dimri M, 2016, ONCOTARGET, V7, P36220, DOI 10.18632/oncotarget.8811
   Hasegawa M, 2016, ONCOTARGET, V7, P11756, DOI 10.18632/oncotarget.7598
   Hiraki M, 2017, ONCOGENE, V36, P2791, DOI 10.1038/onc.2016.439
   Hiraki M, 2016, SCI REP-UK, V6, DOI 10.1038/srep26643
   Holien T, 2012, BLOOD, V120, P2450, DOI 10.1182/blood-2011-08-371567
   Huang L, 2005, CANCER RES, V65, P10413, DOI 10.1158/0008-5472.CAN-05-2474
   Jacobs JJL, 1999, GENE DEV, V13, P2678, DOI 10.1101/gad.13.20.2678
   Jagani Z, 2010, CANCER RES, V70, P5528, DOI 10.1158/0008-5472.CAN-09-4229
   Kawano T, 2008, INT J ONCOL, V33, P153
   Kreso A, 2014, NAT MED, V20, P29, DOI 10.1038/nm.3418
   Kufe DW, 2009, NAT REV CANCER, V9, P874, DOI 10.1038/nrc2761
   Lessard J, 2003, NATURE, V423, P255, DOI 10.1038/nature01572
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   LOKHORST HM, 1994, BLOOD, V84, P2269
   Mertz JA, 2011, P NATL ACAD SCI USA, V108, P16669, DOI 10.1073/pnas.1108190108
   Ohtsubo M, 2008, P NATL ACAD SCI USA, V105, P10396, DOI 10.1073/pnas.0800672105
   Park IK, 2004, J CLIN INVEST, V113, P175, DOI 10.1172/JCI200420800
   Paydas S, 2001, LEUKEMIA RES, V25, P221, DOI 10.1016/S0145-2126(00)00111-9
   Raina D, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135156
   Rajabi H, 2016, ONCOGENE, V35, P6439, DOI 10.1038/onc.2016.180
   Rajabi H, 2014, ONCOGENE, V33, P1680, DOI 10.1038/onc.2013.114
   Rajabi H, 2012, J BIOL CHEM, V287, P10703, DOI 10.1074/jbc.M111.323311
   Richly H, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.84
   Rizo A, 2009, BLOOD, V114, P1498, DOI 10.1182/blood-2009-03-209734
   Siddique HR, 2012, STEM CELLS, V30, P372, DOI 10.1002/stem.1035
   Song LB, 2009, J CLIN INVEST, V119, P3626, DOI 10.1172/JCI39374
   Tagde A, 2016, ONCOTARGET, V7, P38974, DOI 10.18632/oncotarget.9777
   Tagde A, 2016, BLOOD, V127, P2587, DOI 10.1182/blood-2015-07-659151
   Takahashi H, 2015, ONCOGENE, V34, P5187, DOI 10.1038/onc.2014.442
   Tassone P, 2005, CLIN CANCER RES, V11, P4251, DOI 10.1158/1078-0432.CCR-04-2611
   Treon SP, 1999, BLOOD, V93, P1287, DOI 10.1182/blood.V93.4.1287.404k14_1287_1298
   Wang HB, 2004, NATURE, V431, P873, DOI 10.1038/nature02985
   Wei JH, 2006, J BIOL CHEM, V281, P22537, DOI 10.1074/jbc.M600826200
   Yang MH, 2010, NAT CELL BIOL, V12, P982, DOI 10.1038/ncb2099
   Yin L, 2012, BLOOD, V119, P810, DOI 10.1182/blood-2011-07-369686
   Yin L, 2010, MOL PHARMACOL, V78, P166, DOI 10.1124/mol.110.065011
   Yong KJ, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aad6066
   Zhan FH, 2007, BLOOD, V109, P1692, DOI 10.1182/blood-2006-07-037077
NR 53
TC 8
Z9 8
U1 0
U2 5
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD SEP 19
PY 2017
VL 8
IS 41
BP 69237
EP 69249
DI 10.18632/oncotarget.20144
PG 13
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA FH4TA
UT WOS:000411153300006
PM 29050200
OA Green Submitted, gold, Green Published
DA 2025-01-12
ER

PT J
AU Aram, R
   Dotan, I
   Hotz-Wagenblatt, A
   Canaani, D
AF Aram, Ronni
   Dotan, Iris
   Hotz-Wagenblatt, Agnes
   Canaani, Dan
TI Identification of a novel metastasis inducing lncRNA which suppresses
   the KAI1/CD82 metastasis suppressor gene and is upregulated in
   triple-negative breast cancer
SO ONCOTARGET
LA English
DT Article
DE lncRNA; metastasis suppressor genes; triple-negative breast cancer;
   epigenetic gene regulation; lncRNA; metastasis
ID LONG NONCODING RNAS; BIDIRECTIONAL PROMOTERS; KAI1; TRANSCRIPTION
AB Inactivation of tumor/metastasis suppressor genes via epigenetic silencing is a frequent event in human cancers. KAI1/CD82 is a metastasis suppressor gene whose normal protecting activity is deficient in twelve different solid malignancies. Here we have identified and characterized a primarily nuclear non-polyadenylated, antisense (as)-lncRNA, initiating upstream of the KAI1 human metastasis suppressor gene transcription start site; and elongating in the opposite direction to KAI1 mRNA. We show that the KAI1 promoter is bi-directional giving rise to KAI1 mRNA and its as-lncRNA. Moreover, expression of this lncRNA transcript emerges to be inversely related to the KAI1 mRNA expression, and in direct relationship to the invasiveness level of human breast cancer derived cell lines. Importantly, knockdown of the KAI1 as-lncRNA in the triple-negative breast cancer cell line MDA-MB-231 have led to increased KAI1 mRNA and protein expression, manifested in stronger adhesion to fibronectin, retardation of cell migration and reduced cell invasion in vitro. Accordingly we have named this lncRNA, SKAI1BC, standing for "Suppressor of KAI1 in Breast Cancer". These results uncover a potential way to harness tumor metastasis via targeting SKAI1BC in human breast cancer, and perhaps also in other KAI1-deficient human malignancies.
C1 [Aram, Ronni; Dotan, Iris; Canaani, Dan] Tel Aviv Univ, George Wise Fac Life Sci, Dept Biochem & Mol Biol, IL-69978 Ramat Aviv, Israel.
   [Hotz-Wagenblatt, Agnes] German Canc Res Ctr, Core Facil Genom & Proteom, Bioinformat Grp, D-69120 Heidelberg, Germany.
C3 Tel Aviv University; Helmholtz Association; German Cancer Research
   Center (DKFZ)
RP Canaani, D (通讯作者)，Tel Aviv Univ, George Wise Fac Life Sci, Dept Biochem & Mol Biol, IL-69978 Ramat Aviv, Israel.
EM canaani@post.tau.ac.il
FU David Orgler Fund for Cancer Genetics Research; Israel Ministry of
   Absorption
FX This work was supported by a grant to D.C. from the David Orgler Fund
   for Cancer Genetics Research. R.A. was supported in part by a graduate
   student fellowship from the Israel Ministry of Absorption.
CR Albrecht AS, 2016, BRIEF FUNCT GENOMICS, V15, P167, DOI 10.1093/bfgp/elv048
   Chodroff RA, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-7-r72
   Duttke SHC, 2015, MOL CELL, V57, P674, DOI 10.1016/j.molcel.2014.12.029
   Feng J, 2015, CANCER METAST REV, V34, P619, DOI 10.1007/s10555-015-9585-x
   Gallagher Sean R, 2012, Curr Protoc Mol Biol, VChapter 10, DOI 10.1002/0471142727.mb1002as97
   GILBOA E, 1979, CELL, V18, P93, DOI 10.1016/0092-8674(79)90357-X
   Guttman M, 2012, NATURE, V482, P339, DOI 10.1038/nature10887
   Iyer MK, 2015, NAT GENET, V47, P199, DOI 10.1038/ng.3192
   Kalantari R, 2016, NUCLEIC ACIDS RES, V44, P524, DOI 10.1093/nar/gkv1305
   Kleinman H K, 2001, Curr Protoc Cell Biol, VChapter 12, DOI 10.1002/0471143030.cb1202s00
   Malik Faraz Arshad, 2009, Cancer Genomics & Proteomics, V6, P205
   Marques AC, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-11-r124
   Marreiros A, 2003, GENE, V302, P155, DOI 10.1016/S0378-1119(02)01101-0
   Morris KV, 2014, NAT REV GENET, V15, P423, DOI 10.1038/nrg3722
   Morris KV, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000258
   Ni D, 2016, CURR PROTOC MOL BIOL, V114, DOI DOI 10.8.1-10.8.37
   Paweletz CP, 2001, CURR PROTOC CELL BIO
   Perocchi F, 2007, NUCLEIC ACIDS RES, V35, DOI 10.1093/nar/gkm683
   Perry RB, 2016, DEVELOPMENT, V143, P3882, DOI 10.1242/dev.140962
   Ponthan F, 2015, CURR PROTOC MOL BIOL, V111
   Salmon P, 2007, CURR PROTOC HUMAN GE, V54
   Schmitt AM, 2016, CANCER CELL, V29, P452, DOI 10.1016/j.ccell.2016.03.010
   Shenfeld M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031977
   Trinklein ND, 2004, GENOME RES, V14, P62, DOI 10.1101/gr.1982804
   Tzadok S, 2013, ANAL BIOCHEM, V439, P23, DOI 10.1016/j.ab.2013.03.031
   Uesaka M, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-35
   Wei JT, 2014, J CLIN ONCOL, V32, P4066, DOI 10.1200/JCO.2013.52.8505
   Yang XH, 2000, CLIN CANCER RES, V6, P3424
   Yu WQ, 2008, NATURE, V451, P202, DOI 10.1038/nature06468
   Zhang F, 2016, TUMOR BIOL, V37, P163, DOI 10.1007/s13277-015-4445-4
NR 30
TC 14
Z9 15
U1 1
U2 4
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD SEP 15
PY 2017
VL 8
IS 40
BP 67538
EP 67552
PG 15
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA FG9WL
UT WOS:000410790500060
PM 28978052
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Buchegger, K
   Riquelme, I
   Viscarra, T
   Ili, C
   Brebi, P
   Huang, THM
   Roa, JC
AF Buchegger, Kurt
   Riquelme, Ismael
   Viscarra, Tamara
   Ili, Carmen
   Brebi, Priscilla
   Huang, Tim Hui-Ming
   Roa, Juan Carlos
TI <i>Reprimo</i>, a Potential p53-Dependent Tumor Suppressor Gene, Is
   Frequently Hypermethylated in Estrogen Receptor -Positive Breast Cancer
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE estrogen; estrogen receptor; DNA methylation; Reprimo; breast cancer
ID MEDIATED EPIGENETIC REPRESSION; INTRAGENIC DNA METHYLATION; ABERRANT
   METHYLATION; PROMOTER METHYLATION; MOLECULAR PORTRAITS; GASTRIC-CANCER;
   ER-ALPHA; EXPRESSION; CARCINOMA; ADENOCARCINOMA
AB Aberrant DNA methylation is a hallmark of many cancers. Currently, there are four intrinsic molecular subtypes in breast cancer (BC): Luminal A, B, Her2-positive, and triple negative (TNBC). Recently, The Cancer Genome Atlas (TCGA) project has revealed that Luminal subtypes have higher levels of genome-wide methylation that may be a result of Estrogen/Estrogen receptor (E2/ER) signaling pathway activation. In this study, we analyze promoter CpG-island (CGIs) of the Reprimo (RPRM) gene in breast cancers (n = 77), cell lines (n = 38), and normal breast tissue (n = 10) using a MBDCap-seq database. Then, a validation cohort (n = 26) was used to confirm the results found in the MBDCap-seq platform. A differential methylation pattern was found between BC and cell lines compared to normal breast tissue. In BC, a higher DNA methylation was observed in tissues that were ER-positive than in ER-negative ones; more precisely, subtypes Luminal A compared to TNBC. Also, significant reverse correlation was observed between DNA methylation and RPRM mRNA expression in BC. Our data suggest that ER expression in BC may affect the DNA methylation of CGIs in the RPRM gene. This approach suggests that DNA methylation status in CGIs of some tumor suppressor genes could be driven by E2 availability, subsequently inducing the activation of the ER pathway.
C1 [Buchegger, Kurt; Riquelme, Ismael; Viscarra, Tamara; Ili, Carmen; Brebi, Priscilla] Univ La Frontera, Sch Med, Mol Pathol Lab, Dept Pathol, Ave Alemania 0458, Temuco 4810296, Chile.
   [Buchegger, Kurt; Riquelme, Ismael; Viscarra, Tamara; Ili, Carmen; Brebi, Priscilla] Univ La Frontera, Ctr Excelencia Med Traslac Sci & Technol Bioresou, Ave Alemania 0458, Temuco 4810296, Chile.
   [Huang, Tim Hui-Ming] Univ Texas San Antonio, Hlth Sci Ctr, Inst Biotechnol, Dept Mol Med, San Antonio, TX 78229 USA.
   [Roa, Juan Carlos] Pontificia Univ Catolica Chile, Millennium Inst Immunol & Immunotherapy, Adv Ctr Chron Dis ACCDis, Dept Pathol,UC Ctr Invest Oncol CITO, Santiago 8330024, Chile.
C3 Universidad de La Frontera; Universidad de La Frontera; University of
   Texas System; University of Texas Health Science Center at San Antonio;
   Pontificia Universidad Catolica de Chile
RP Roa, JC (通讯作者)，Pontificia Univ Catolica Chile, Millennium Inst Immunol & Immunotherapy, Adv Ctr Chron Dis ACCDis, Dept Pathol,UC Ctr Invest Oncol CITO, Santiago 8330024, Chile.
EM kurt.buchegger@ufrontera.cl; ismael.riquelme@ufrontera.cl;
   t.viscarra01@ufrontera.cl; carmen.ili@ufrontera.cl;
   priscilla.brebi@ufrontera.cl; huangt3@uthscsa.edu; jcroa@med.puc.cl
RI Roa, Juan/K-4749-2014; Buchegger, Kurt/AAH-4678-2021; Ili,
   Carmen/X-4070-2019; Riquelme, Ismael/H-9391-2016
OI Ili, Carmen/0000-0002-4009-4406; Roa, Juan Carlos/0000-0001-8313-8774;
   Buchegger, Kurt/0000-0002-3872-2522; Riquelme,
   Ismael/0000-0002-9545-3971
FU Chilean National Fund for CONICYT FONDAP [15130011]; Millennium
   Institute on Immunology and Immunotherapy [P09-016-F]; Production
   Development Corporation (CORFO) [12IDL2-18157]; Chilean National Fund
   for Scientific and Technological Development (FONDECYT) [3170826,
   11150622, 11150802]; Direccion de Investigacion, Universidad de La
   Frontera (DIUFRO) [DI16-0101]
FX This work was supported by the Chilean National Fund for CONICYT FONDAP
   15130011 (ACCDIS) and The Millennium Institute on Immunology and
   Immunotherapy (No P09-016-F to JCR), the Production Development
   Corporation (CORFO) (No 12IDL2-18157), the Chilean National Fund for
   Scientific and Technological Development (FONDECYT) (3170826 to I.R.;
   11150622 to C.G.I.; 11150802 to P.B.), and the Direccion de
   Investigacion, Universidad de La Frontera (DIUFRO) (DI16-0101).
CR Antequera F, 2003, CELL MOL LIFE SCI, V60, P1647, DOI 10.1007/s00018-003-3088-6
   Bernal C, 2008, CLIN CANCER RES, V14, P6264, DOI 10.1158/1078-0432.CCR-07-4522
   Buchegger K, 2016, BIOL RES, V49, DOI 10.1186/s40659-016-0066-7
   Clark SJ, 2007, HUM MOL GENET, V16, pR88, DOI 10.1093/hmg/ddm051
   Ellinger J, 2008, UROLOGY, V71, P161, DOI 10.1016/j.urology.2007.09.056
   Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210
   García-Becerra R, 2013, INT J MOL SCI, V14, P108, DOI 10.3390/ijms14010108
   Garcia-Bloj B, 2016, ONCOTARGET, V7, P60535, DOI 10.18632/oncotarget.11142
   Gu F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060980
   Gu F, 2010, BMC SYST BIOL, V4, DOI 10.1186/1752-0509-4-170
   Hamilton JP, 2006, CLIN CANCER RES, V12, P6637, DOI 10.1158/1078-0432.CCR-06-1781
   Hamilton JP, 2006, CLIN GASTROENTEROL H, V4, P701, DOI 10.1016/j.cgh.2006.03.007
   Hsu PY, 2013, CANCER CELL, V24, P197, DOI 10.1016/j.ccr.2013.07.007
   Hsu PY, 2010, GENOME RES, V20, P733, DOI 10.1101/gr.101923.109
   Irizarry RA, 2009, NAT GENET, V41, P178, DOI 10.1038/ng.298
   Jadhav RR, 2015, CLIN EPIGENETICS, V7, DOI 10.1186/s13148-015-0045-9
   Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412
   Kovalchuk O, 2007, CELL CYCLE, V6, P2010, DOI 10.4161/cc.6.16.4549
   Kulis M, 2013, BBA-GENE REGUL MECH, V1829, P1161, DOI 10.1016/j.bbagrm.2013.08.001
   Kutanzi KR, 2010, CELL CYCLE, V9, P3078, DOI 10.4161/cc.9.15.12516
   Kwan ML, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2261
   Li LA, 2010, HUM MOL GENET, V19, P4273, DOI 10.1093/hmg/ddq351
   Liu LH, 2015, INT J CLIN EXP PATHO, V8, P14977
   Livasy CA, 2006, MODERN PATHOL, V19, P264, DOI 10.1038/modpathol.3800528
   Luo J, 2011, DIAGN CYTOPATHOL, V39, P752, DOI 10.1002/dc.21461
   Malik S, 2010, MOL CELL BIOL, V30, P399, DOI 10.1128/MCB.00907-09
   Marino M, 2006, CURR GENOMICS, V7, P497, DOI 10.2174/138920206779315737
   Moon HS, 2003, INT J GYNECOL CANCER, V13, P640, DOI 10.1046/j.1525-1438.2003.13396.x
   Morris MR, 2010, ONCOGENE, V29, P2104, DOI 10.1038/onc.2009.493
   Mourad R, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113354
   Nishida N, 2008, HEPATOLOGY, V47, P908, DOI 10.1002/hep.22110
   Ohki R, 2000, J BIOL CHEM, V275, P22627, DOI 10.1074/jbc.C000235200
   Ooki A, 2013, MOL CANCER RES, V11, P1362, DOI 10.1158/1541-7786.MCR-13-0091
   Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093
   Rodriguez BAT, 2011, CARCINOGENESIS, V32, P812, DOI 10.1093/carcin/bgr017
   Ross-Innes CS, 2010, GENE DEV, V24, P171, DOI 10.1101/gad.552910
   Sato N, 2003, CANCER RES, V63, P3735
   Sato N, 2006, CANCER-AM CANCER SOC, V107, P251, DOI 10.1002/cncr.21977
   Shenker N, 2012, BRIT J CANCER, V106, P248, DOI 10.1038/bjc.2011.550
   Shi JF, 2012, BIOCHEM BIOPH RES CO, V427, P47, DOI 10.1016/j.bbrc.2012.08.144
   Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098
   Tan SK, 2011, EMBO J, V30, P2569, DOI 10.1038/emboj.2011.151
   Tang SH, 2004, NUCLEIC ACIDS RES, V32, pD533, DOI 10.1093/nar/gkh083
   Ushijima T, 2007, J BIOCHEM MOL BIOL, V40, P142
   Wang HZ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0168635
   Wang JB, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-70
   Welboren WJ, 2009, EMBO J, V28, P1418, DOI 10.1038/emboj.2009.88
   Wong TS, 2005, INT J CANCER, V117, P697, DOI 10.1002/ijc.21208
   Xu M, 2012, ENDOCRINOLOGY, V153, P2963, DOI 10.1210/en.2011-2021
   Yersal O, 2014, WORLD J CLIN ONCOL, V5, P412, DOI 10.5306/wjco.v5.i3.412
   Yoshino M, 2009, INT J ONCOL, V35, P1201, DOI 10.3892/ijo_00000437
NR 51
TC 8
Z9 9
U1 1
U2 4
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD AUG
PY 2017
VL 18
IS 8
AR 1525
DI 10.3390/ijms18081525
PG 14
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA FF4HB
UT WOS:000408897400003
PM 28809778
OA gold, Green Published, Green Submitted
DA 2025-01-12
ER

PT J
AU Ma, EG
   Bai, YF
   Cao, W
   Cao, Y
   Huang, YG
   Cheng, HC
   An, RH
AF Ma, En-Guang
   Bai, Yu-Feng
   Cao, Wei
   Cao, Yan
   Huang, Yong-Gang
   Cheng, Huan-Chen
   An, Rui-Hua
TI Cytosine 5-hydroxymethylation regulates VHL gene expression in renal
   clear cell carcinoma
SO ONCOTARGET
LA English
DT Article
DE DNA methylation; hydroxymethylation; VHL; renal clear cell carcinoma
ID BREAST-CANCER; VON-HIPPEL
AB Cytosine5-hyxymethylation (5hmC) which is a new epigenetic modification form plays important roles in the development and progression of tumors. In the present study, we observed that levels of 5hmC in the promoter region of Von Hippel-Lindau (VHL) were lower in 97 samples of renal clear cell carcinoma tissue than in matched adjacent benign tissues. Moreover, when the cancer tissue samples were divided based on pathological staging, VHL expression and the level of 5hmC in the VHL promoter were both lower in pathological grade III tumors than in grades I or II. Correspondingly, expression of TET1, which catalyzes the formation of 5hmC, was also lower in grade III renal clear cell carcinomas than in grade I or II disease. These findings suggest the 5hmC level on VHL is a key determinant of the gene's expression and may participate in the occurrence and development of renal clear cell carcinoma. Thus the 5hmC level may be a useful indicator for early diagnosis and appropriate treatment of renal clear cell carcinoma.
C1 [Ma, En-Guang; Bai, Yu-Feng; An, Rui-Hua] Harbin Med Univ, Affiliated Hosp 1, Dept Urol, Harbin, Heilongjiang, Peoples R China.
   [Ma, En-Guang; Huang, Yong-Gang] First Hosp Harbin, Dept Urol Surg, Harbin, Heilongjiang, Peoples R China.
   [Cao, Wei] Harbin Med Univ, Affiliated Hosp 2, Dept Urinary Surg, Harbin, Heilongjiang, Peoples R China.
   [Cao, Yan] Harbin Med Univ, Canc Hosp, Dept Urol, Harbin, Heilongjiang, Peoples R China.
   [Cheng, Huan-Chen] First Hosp Harbin, Inst Harbin Hematol & Oncol, Harbin, Heilongjiang, Peoples R China.
C3 Harbin Medical University; Harbin Medical University; Harbin Medical
   University
RP An, RH (通讯作者)，Harbin Med Univ, Affiliated Hosp 1, Dept Urol, Harbin, Heilongjiang, Peoples R China.
EM anruihua1234@163.com
RI Huang, Yonggang/AAI-8032-2020
FU Harbin Technology and Innovation Foundation for Youth [2016RAQXJ188]
FX The study was supported by Harbin Technology and Innovation Foundation
   for Youth (Grant number 2016RAQXJ188).
CR Bell D, 2011, NATURE, V474, P609, DOI 10.1038/nature10166
   Cuperlovic-Culf M, 2016, INT J CANCER, V138, P2439, DOI 10.1002/ijc.29947
   Ficz G, 2014, GENOMICS, V104, P352, DOI 10.1016/j.ygeno.2014.08.017
   Gordan JD, 2007, CURR OPIN GENET DEV, V17, P71, DOI 10.1016/j.gde.2006.12.006
   Hsu CH, 2012, CELL REP, V2, P568, DOI 10.1016/j.celrep.2012.08.030
   Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947
   Kraus TFJ, 2012, INT J CANCER, V131, P1577, DOI 10.1002/ijc.27429
   Kriaucionis S, 2009, SCIENCE, V324, P929, DOI 10.1126/science.1169786
   Kuroda N, 2015, POL J PATHOL, V66, P3, DOI 10.5114/PJP.2015.51147
   Lai AY, 2011, NAT REV CANCER, V11, P588, DOI 10.1038/nrc3091
   López JI, 2013, PATHOL RES PRACT, V209, P137, DOI 10.1016/j.prp.2013.01.007
   Lutz MS, 2006, CANCER RES, V66, P6903, DOI 10.1158/0008-5472.CAN-06-0501
   Ma X., 2014, Urol Oncol, V32, pe9
   Madzo J, 2014, CELL REP, V6, P231, DOI 10.1016/j.celrep.2013.11.044
   Madzo J, 2013, SEMIN HEMATOL, V50, P61, DOI 10.1053/j.seminhematol.2013.01.004
   Orr BA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041036
   Pastor WA, 2011, NATURE, V473, P394, DOI 10.1038/nature10102
   Shahzad H, 2014, PAK J MED SCI, V30, P880
   Stroud H, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-6-r54
   Sun M, 2013, P NATL ACAD SCI USA, V110, P9920, DOI 10.1073/pnas.1305172110
   Thomson JP, 2013, NUCLEIC ACIDS RES, V41, P5639, DOI 10.1093/nar/gkt232
   Wielscher M, 2013, TRANSL ONCOL, V6, P715, DOI 10.1593/tlo.13523
NR 22
TC 7
Z9 8
U1 0
U2 3
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD SEP 8
PY 2017
VL 8
IS 38
BP 63780
EP 63787
DI 10.18632/oncotarget.19070
PG 8
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA FG4XE
UT WOS:000410284800079
PM 28969028
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU Erdem, JS
   Skare, O
   Petersen-Overleir, M
   Noto, HO
   Lie, JAS
   Reszka, E
   Peplonska, B
   Zienolddiny, S
AF Erdem, Johanna Samulin
   Skare, Oivind
   Petersen-Overleir, Marte
   Noto, Heidi Odegaard
   Lie, Jenny-Anne S.
   Reszka, Edyta
   Peplonska, Beata
   Zienolddiny, Shanbeh
TI Mechanisms of Breast Cancer in Shift Workers: DNA Methylation in Five
   Core Circadian Genes in Nurses Working Night Shifts
SO JOURNAL OF CANCER
LA English
DT Article
DE shift work; breast cancer; circadian; polymorphism
ID LONG-TERM SHIFTWORK; SUSCEPTIBILITY LOCI; REGULATORY ELEMENTS;
   MCC-SPAIN; RISK; GENOME; ASSOCIATION; EXPRESSION; CLOCK; MELATONIN
AB Shift work has been suggested to be associated with breast cancer risk, and circadian disruption in shift workers is hypothesized as one of the mechanisms of increased cancer risk. There is, however, insufficient molecular evidence supporting this hypothesis. Using the quantitative methodology of pyrosequencing, epigenetic changes in 5-methyl cytosine (5mC) in five circadian genes CLOCK, BMAL1, CRY1, PER1 and PER2 in female nurses working night shift work (278 breast cancer cases, 280 controls) were analyzed. In breast cancer cases, a medium exposure to night work was associated with increased methylation levels of the CLOCK (p=0.050), BMAL1 (p=0.001) and CRY1 (p=0.040) genes, compared with controls. Within the cases, analysis of the effects of shift work on the methylation patterns showed that methylation of CRY1 was lower in those who had worked night shift and had a high exposure (p=0.006) compared with cases that had worked only days. For cases with a medium exposure to night work, an increase in BMAL1 (p=0.003) and PER1 (p=0.035) methylation was observed compared with day working (unexposed) cases. The methylation levels of the five core circadian genes were also analyzed in relation to the estrogen and progesterone receptors status of the tumors in the cases, and no correlations were observed. Furthermore, nineteen polymorphisms in the five circadian genes were assessed for their effects on the methylation levels of the respective genes, but no associations were found. In summary, our data suggest that epigenetic regulation of CLOCK, BMAL1, CRY1 and PER1 may contribute to breast cancer in shift workers.
C1 [Erdem, Johanna Samulin; Petersen-Overleir, Marte; Noto, Heidi Odegaard; Zienolddiny, Shanbeh] Natl Inst Occupat Hlth, Dept Chem & Biol Work Environm, N-0363 Oslo, Norway.
   [Skare, Oivind; Lie, Jenny-Anne S.] Natl Inst Occupat Hlth, Dept Occupat Med & Epidemiol, N-0363 Oslo, Norway.
   [Reszka, Edyta] Nofer Inst Occupat Med, Dept Mol Genet & Epigenet, Lodz, Poland.
   [Peplonska, Beata] Nofer Inst Occupat Med, Dept Environm Epidemiol, Lodz, Poland.
C3 Nofer Institute of Occupational Medicine; Nofer Institute of
   Occupational Medicine
RP Zienolddiny, S (通讯作者)，Natl Inst Occupat Hlth, Dept Chem & Biol Work Environm, N-0363 Oslo, Norway.
EM shan.zienolddiny@stami.no
RI Peplonska, Beata/AAO-1265-2020; Zienolddiny, Shanbeh/O-7392-2015; Skare,
   Oivind/C-6330-2016; Reszka, Edyta/F-6008-2010
OI Peplonska, Beata/0000-0003-3915-2872; Skare, Oivind/0000-0001-8043-2820;
   Reszka, Edyta/0000-0003-2153-4864; Zienolddiny-Narui,
   Shan/0000-0001-9747-9625
FU Norway Grants, under the Polish-Norwegian Research Program
   [Pol-Nor/196940/22/2013-clock shift]; NIOH
FX This project was supported by the Norway Grants, under the
   Polish-Norwegian Research Program (Grant no.
   Pol-Nor/196940/22/2013-clock shift). JSE acknowledges a postdoctoral
   fellowship from NIOH.
CR Bakker MF, 2016, AM J CLIN NUTR, V103, P454, DOI 10.3945/ajcn.114.101659
   Bhatti P, 2015, CHRONOBIOL INT, V32, P103, DOI 10.3109/07420528.2014.956362
   Blakeman V, 2016, BREAST CANCER RES, V18, DOI 10.1186/s13058-016-0743-z
   Chen ST, 2005, CARCINOGENESIS, V26, P1241, DOI 10.1093/carcin/bgi075
   Chu LW, 2008, CANCER EPIDEM BIOMAR, V17, P3268, DOI 10.1158/1055-9965.EPI-08-0073
   Dai HJ, 2011, BREAST CANCER RES TR, V127, P531, DOI 10.1007/s10549-010-1231-2
   Dufour CR, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002143
   Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI [10.1056/NEJMra072067, 10.1093/carcin/bgp220]
   Fan MY, 2007, BREAST CANCER RES TR, V103, P37, DOI 10.1007/s10549-006-9353-2
   Fan MY, 2006, CANCER RES, V66, P11954, DOI 10.1158/0008-5472.CAN-06-1666
   Ferlay J., 2013, GLOBOCAN 2012 CANC I
   Fu A, 2012, MOL CARCINOGEN, V51, P923, DOI 10.1002/mc.20862
   Giguère V, 2011, COLD SH Q B, V76, P57, DOI 10.1101/sqb.2011.76.011031
   Gyarmati G, 2016, OCCUP ENVIRON MED, V73, P520, DOI 10.1136/oemed-2016-103597
   HAMILTON T, 1969, BRIT J SURG, V56, P764, DOI 10.1002/bjs.1800561018
   Harrington CT, 2013, ARCH PATHOL LAB MED, V137, P1296, DOI 10.5858/arpa.2012-0463-RA
   Hoffman AE, 2010, CANCER RES, V70, P1459, DOI 10.1158/0008-5472.CAN-09-3798
   Jacobs DI, 2013, ENVIRON MOL MUTAGEN, V54, P141, DOI 10.1002/em.21752
   Kar SP, 2016, CANCER DISCOV, V6, P1052, DOI 10.1158/2159-8290.CD-15-1227
   Kit AH, 2012, BIOCHIMIE, V94, P2314, DOI 10.1016/j.biochi.2012.07.014
   Klajic J, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-456
   Kochan David Z, 2016, Oncoscience, V3, P58
   Langley AR, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2011-000532
   Li S, 2013, ONCOGENE, V32, P4883, DOI 10.1038/onc.2012.518
   Lie JAS, 2013, AM J EPIDEMIOL, V178, P110, DOI 10.1093/aje/kws428
   Lie JAS, 2011, AM J EPIDEMIOL, V173, P1272, DOI 10.1093/aje/kwr014
   Liu R, 2015, CANCER CAUSE CONTROL, V26, P171, DOI 10.1007/s10552-014-0494-z
   Masri S, 2015, DIABETES OBES METAB, V17, P17, DOI 10.1111/dom.12509
   Maston GA, 2006, ANNU REV GENOM HUM G, V7, P29, DOI 10.1146/annurev.genom.7.080505.115623
   Messeguer X, 2002, BIOINFORMATICS, V18, P333, DOI 10.1093/bioinformatics/18.2.333
   Oei SL, 2004, GENOMICS, V83, P873, DOI 10.1016/j.ygeno.2003.11.001
   Papantoniou K, 2017, SCAND J WORK ENV HEA, V43, P250, DOI 10.5271/sjweh.3626
   Papantoniou K, 2016, EUR J EPIDEMIOL, V31, P867, DOI 10.1007/s10654-015-0073-y
   Papantoniou K, 2015, INT J CANCER, V137, P1147, DOI 10.1002/ijc.29400
   Reppert SM, 2002, NATURE, V418, P935, DOI 10.1038/nature00965
   Reszka E, 2016, ADV CLIN CHEM, V75, P53, DOI 10.1016/bs.acc.2016.03.005
   Reszka E, 2017, CANCER LETT, V390, P137, DOI 10.1016/j.canlet.2017.01.012
   Reszka E, 2013, SCAND J WORK ENV HEA, V39, P187, DOI 10.5271/sjweh.3303
   Siddiq A, 2012, HUM MOL GENET, V21, P5373, DOI 10.1093/hmg/dds381
   Stevens RG, 2005, EPIDEMIOLOGY, V16, P254, DOI 10.1097/01.ede.0000152525.21924.54
   Stevens RG, 2011, OCCUP ENVIRON MED, V68, P154, DOI 10.1136/oem.2009.053512
   Stone A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040466
   Straif K, 2007, LANCET ONCOL, V8, P1065, DOI 10.1016/S1470-2045(07)70373-X
   Travis RC, 2016, JNCI-J NATL CANCER I, V108, DOI 10.1093/jnci/djw169
   Weinstock GM, 2007, GENOME RES, V17, P667, DOI 10.1101/gr.6534207
   Xiao Z, 2006, MOL CANCER THER, V5, P1935, DOI 10.1158/1535-7163.MCT-06-0077
   Zhu Y, 2011, CHRONOBIOL INT, V28, P852, DOI 10.3109/07420528.2011.618896
   Zienolddiny S, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3445
NR 48
TC 25
Z9 27
U1 0
U2 12
PU IVYSPRING INT PUBL
PI LAKE HAVEN
PA PO BOX 4546, LAKE HAVEN, NSW 2263, AUSTRALIA
SN 1837-9664
J9 J CANCER
JI J. Cancer
PY 2017
VL 8
IS 15
BP 2876
EP 2884
DI 10.7150/jca.21064
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA FG7GD
UT WOS:000410582000001
PM 28928877
OA Green Published, gold, Green Submitted
DA 2025-01-12
ER

PT J
AU Shi, ZD
   Li, Y
   Qian, XM
   Hu, YH
   Liu, JJ
   Zhang, S
   Zhang, J
AF Shi, Zhendong
   Li, Yang
   Qian, Xiaomin
   Hu, Yunhui
   Liu, Jingjing
   Zhang, Sheng
   Zhang, Jin
TI MiR-340 Inhibits Triple-Negative Breast Cancer Progression by Reversing
   EZH2 Mediated miRNAs Dysregulated Expressions
SO JOURNAL OF CANCER
LA English
DT Article
DE miR-340; EZH2; breast cancer; progression; miRNAs
ID TUMOR-CELL PROLIFERATION; GLIOBLASTOMA; METHYLATION; EPIGENETICS;
   MICRORNAS; CARCINOMA; THERAPY; PRC2; GENE
AB The anti-tumor efficacy of miR-340 has been recently characterized in cancers. However, the underlying mechanisms of miR-340 inhibited cell growth and invasion in triple-negative breast cancer (TNBC) have not been well elucidated. In this study, we found that miR-340 expression was negatively correlated with EZH2 (Enhancer of zeste homolog 2) expression in TNBC tissues and cell lines. Subsequent luciferase reporter assay confirmed that EZH2 was a novel molecule target of miR-340. Upregulated miR-340 levels by mimics transfection significantly inhibited the MDA-MB- 231 and MDA-MB-468 breast cancer cells proliferation, invasion and migration, and induced more cell apoptosis. Meanwhile, miR-340 inhibited the tumor growth in an orthotopic MDA-MB-231 breast cancer mouse model. Furthermore, we found the reduced EZH2 expression by miR-340 mimics transfection decreased the DNMT1, H3K27me3, beta-catenin and P-STAT3 expressions, which ultimately resulted in miR-21 activity blockage and miR-200a/b expression upregulation. The results of rescue experiments further confirmed that miR-340 inhibited triple-negative breast cancer progression through targeting EZH2. Taken together, our results identified miR-340 as a tumor suppressor in TNBC, moreover, an EZH2 medicated regulatory loop was established. Post-transcriptional suppression of EZH2 expression not only blocked STAT3 mediated miR-21 trans-activation, but also reversed the miR-200a/b silencing via reducing DNMT1 and H3K27me3 expressions. MiR-21 inhibition and miR-200a/b expression triggered by miR-340 ultimately cooperated in the TNBC progression.
C1 [Shi, Zhendong; Li, Yang; Hu, Yunhui; Liu, Jingjing; Zhang, Sheng; Zhang, Jin] Tianjin Med Univ Canc Inst & Hosp, Treatment & Res Ctr, China Tianjin Breast Canc Prevent, Dept Breast Canc 3, West Beihuanhu Rd, Tianjin 300060, Peoples R China.
   [Shi, Zhendong; Li, Yang; Hu, Yunhui; Liu, Jingjing; Zhang, Sheng; Zhang, Jin] Minist Educ, Key Lab Breast Canc Prevent & Therapy, Tianjin, Peoples R China.
   [Shi, Zhendong; Li, Yang; Hu, Yunhui; Liu, Jingjing; Zhang, Sheng; Zhang, Jin] Key Lab Canc Prevent & Therapy, Tianjin, Peoples R China.
   [Qian, Xiaomin] Tianjin Med Univ, Sch Lab Med, Tianjin, Peoples R China.
C3 Tianjin Medical University; Tianjin Medical University
RP Shi, ZD; Zhang, J (通讯作者)，Tianjin Med Univ Canc Inst & Hosp, Treatment & Res Ctr, China Tianjin Breast Canc Prevent, Dept Breast Canc 3, West Beihuanhu Rd, Tianjin 300060, Peoples R China.
EM shizhendong3588@sina.com; zhangjin@tjmuch.com
RI 刘, 晶晶/ACI-5816-2022
FU National Natural Scientific Foundation [81502306]; Tianjin Medical
   University Research Project [2014KYQ08]; Research Fund for the Doctoral
   Program of Tianjin Medical University Cancer Institute and Hospital
   [B1403]; National Key Clinical Specialist Construction Programs of China
FX This study was supported by the National Natural Scientific Foundation
   (81502306), Tianjin Medical University Research Project (2014KYQ08), the
   Research Fund for the Doctoral Program of Tianjin Medical University
   Cancer Institute and Hospital (B1403) and the National Key Clinical
   Specialist Construction Programs of China.
CR Büssing I, 2008, TRENDS MOL MED, V14, P400, DOI 10.1016/j.molmed.2008.07.001
   Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997
   Chang CJ, 2011, CANCER CELL, V19, P86, DOI 10.1016/j.ccr.2010.10.035
   Collett K, 2006, CLIN CANCER RES, V12, P1168, DOI 10.1158/1078-0432.CCR-05-1533
   Eberharter A, 2002, EMBO REP, V3, P224, DOI 10.1093/embo-reports/kvf053
   Elgamal OA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076402
   Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516
   Fernandez S, 2015, ONCOGENE, V34, P3240, DOI 10.1038/onc.2014.267
   Ferracin M, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-130
   Han L, 2012, CNS NEUROSCI THER, V18, P573, DOI 10.1111/j.1755-5949.2012.00344.x
   He L, 2004, NAT REV GENET, V5, P522, DOI 10.1038/nrg1379
   Kasinski AL, 2011, NAT REV CANCER, V11, P849, DOI 10.1038/nrc3166
   Li XS, 2015, BIOCHEM BIOPH RES CO, V460, P670, DOI 10.1016/j.bbrc.2015.03.088
   Margueron R, 2011, NATURE, V469, P343, DOI 10.1038/nature09784
   Mei M, 2010, TECHNOL CANCER RES T, V9, P77, DOI 10.1177/153303461000900109
   Ning XH, 2015, CANCER LETT, V359, P198, DOI 10.1016/j.canlet.2015.01.005
   Qian XM, 2012, MOL PHARMACEUT, V9, P2636, DOI 10.1021/mp3002039
   Roh S, 2013, WORLD J SURG ONCOL, V11, DOI 10.1186/1477-7819-11-299
   Shi ZD, 2014, CNS NEUROSCI THER, V20, P830, DOI 10.1111/cns.12278
   Shi ZD, 2012, J NEUROIMMUNE PHARM, V7, P892, DOI 10.1007/s11481-012-9354-3
   Simon JA, 2008, MUTAT RES-FUND MOL M, V647, P21, DOI 10.1016/j.mrfmmm.2008.07.010
   Tavares L, 2012, CELL, V148, P664, DOI 10.1016/j.cell.2011.12.029
   Valastyan S, 2011, CELL, V147, P275, DOI 10.1016/j.cell.2011.09.024
   Viré E, 2006, NATURE, V439, P871, DOI 10.1038/nature04431
   Wang L, 2012, ONCOGENE, V31, P2499, DOI 10.1038/onc.2011.444
   Wu ZS, 2011, CANCER-AM CANCER SOC, V117, P2842, DOI 10.1002/cncr.25860
   You JS, 2012, CANCER CELL, V22, P9, DOI 10.1016/j.ccr.2012.06.008
   Zhang JX, 2015, CANCER LETT, V356, P929, DOI 10.1016/j.canlet.2014.11.003
NR 28
TC 34
Z9 35
U1 1
U2 7
PU IVYSPRING INT PUBL
PI LAKE HAVEN
PA PO BOX 4546, LAKE HAVEN, NSW 2263, AUSTRALIA
SN 1837-9664
J9 J CANCER
JI J. Cancer
PY 2017
VL 8
IS 15
BP 3037
EP 3048
DI 10.7150/jca.19315
PG 12
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA FG7GD
UT WOS:000410582000019
PM 28928895
OA gold, Green Published, Green Submitted
DA 2025-01-12
ER

PT J
AU Mo, JX
   Wang, L
   Huang, XJ
   Lu, B
   Zou, CY
   Wei, LL
   Chu, JJ
   Eggers, PK
   Chen, S
   Raston, CL
   Wu, J
   Lim, LY
   Zhao, W
AF Mo, Jingxin
   Wang, Li
   Huang, Xiaojia
   Lu, Bing
   Zou, Changye
   Wei, Lili
   Chu, Junjun
   Eggers, Paul K.
   Chen, Shen
   Raston, Colin L.
   Wu, Jun
   Lim, Lee Yong
   Zhao, Wei
TI Multifunctional nanoparticles for co-delivery of paclitaxel and
   carboplatin against ovarian cancer by inactivating the JMJD3-HER2 axis
SO NANOSCALE
LA English
DT Article
ID DRUG-DELIVERY; BREAST-CANCER; THERAPY; NANOVESICLES; EXPRESSION; RELEASE
AB Ovarian cancer (OC) is the most lethal gynecologic cancer. Survival statistics have show no significant developments over the last three decades, highlighting the fact that current therapeutic strategies require substantial improvements. In this study, we designed a novel folic acid-PEG-conjugated p-phosphonated calix[4] arene nanoparticle (Fp-PCN) for the simultaneous delivery of paclitaxel (PAC) and carboplatin (CAR) at an optimal ratio (5 : 1, mol : mol) to utilize their potential synergistic effect against OC cells. The Fp-PCNs loaded with PAC and CAR (Fp-PCNPAC+CAR) resulted in a remarkable efficacy in the suppression of OC, both in vitro and in vivo. Compared to free drugs, Fp-PCNPAC+CAR showed stronger apoptosis induction as well as invasion and self-renewal capacity suppression in SKOV-3 cells. The molecular mechanism to address the synergism is that Fp-PCNPAC+CAR downregulated JMJD3 expression to modulate the H3K27me3 epigenetic mark of the promoters of HER2 and MYCN. Furthermore, the expressions of JMJD3 and HER2 were significantly associated with poor outcomes for ovarian patients. Our study demonstrates that co-delivery of PAC and CAR can be achieved with the Fp-PCNs, and reveals a previously unrecognized and unexpected role of the JMJD3-HER2 signaling axis in PAC and CAR treatment of OC.
C1 [Mo, Jingxin; Wang, Li; Huang, Xiaojia; Lu, Bing; Chu, Junjun; Chen, Shen; Zhao, Wei] Sun Yat Sen Univ, Key Lab Stem Cells & Tissue Engn, Minist Educ, Guangzhou 510080, Guangdong, Peoples R China.
   [Zou, Changye] Sun Yat Sen Univ, Musculoskeletal Oncol Ctr, Affiliated Hosp 1, Guangzhou, Guangdong, Peoples R China.
   [Wei, Lili] Guilin Med Univ, Pharm, Affiliated Hosp, Guilin, Peoples R China.
   [Eggers, Paul K.] Univ Western Australia, Sch Chem & Biochem, 35 Stirling Highway, Crawley, WA 6009, Australia.
   [Raston, Colin L.] Flinders Univ S Australia, Sch Chem & Phys Sci, Ctr Nanoscale Sci & Technol, Bedford Pk, SA 5042, Australia.
   [Wu, Jun] Sun Yat Sen Univ, Sch Engn, Guangdong Prov Key Lab Sensor Technol & Biomed In, Guangzhou 510006, Guangdong, Peoples R China.
   [Lim, Lee Yong] Univ Western Australia, Sch Allied Hlth, Pharm, 35 Stirling Highway, Crawley, WA 6009, Australia.
C3 Sun Yat Sen University; Sun Yat Sen University; Guilin Medical
   University; University of Western Australia; Flinders University South
   Australia; Sun Yat Sen University; University of Western Australia
RP Zhao, W (通讯作者)，Sun Yat Sen Univ, Key Lab Stem Cells & Tissue Engn, Minist Educ, Guangzhou 510080, Guangdong, Peoples R China.; Wu, J (通讯作者)，Sun Yat Sen Univ, Sch Engn, Guangdong Prov Key Lab Sensor Technol & Biomed In, Guangzhou 510006, Guangdong, Peoples R China.; Lim, LY (通讯作者)，Univ Western Australia, Sch Allied Hlth, Pharm, 35 Stirling Highway, Crawley, WA 6009, Australia.
EM wujun29@mail.sysu.edu.cn; lee.lim@uwa.edu.au; zhaowei23@mail.sysu.edu.cn
RI li, wang/HHM-3519-2022; Lu, bing/HHN-2808-2022; Wu, Jun/IYJ-2133-2023;
   Eggers, Paul/H-9139-2014; RASTON, Colin/R-6509-2019; Zhao,
   Wei/F-4848-2014; Xiaojia, Huang/AAA-9270-2021; Lim, Lee
   Yong/C-6144-2013; Mo, Jingxin/W-5048-2017
OI Wu, Jun/0000-0002-9074-856X; Lu, Bing/0000-0003-4472-5727; Wu,
   Jun/0000-0002-0678-3435; Lim, Lee Yong/0000-0002-7307-0742; Mo,
   Jingxin/0000-0002-9574-6037
FU National Key Research and Development Program of China [2017YFA0103802];
   National Natural Science Foundation of China [81572766, 31771630];
   Guangdong Innovative and Entrepreneurial Research Team Program
   [2016ZT06S029, 2013S086]; Science and Technology Planning Project of
   Guangdong Province [2016A010103015, 2016A030313238]; SYSU Young Teachers
   Training Program [16YKZD14]; Science Foundation of Guangxi
   [2014GXNSFAA118267]; University Scientific Research Projects of Guangxi
   [YB2014279]; Guangdong Natural Science Foundation [2016A030313215,
   2014A030312018]; Science and Technology Program of Guangzhou
   [201707010094]; National Health and Medical Research Council of
   Australia [APP1028339, GNT1028339]
FX This work was supported by the National Key Research and Development
   Program of China (grant number 2017YFA0103802), National Natural Science
   Foundation of China (No. 81572766 and 31771630), Guangdong Innovative
   and Entrepreneurial Research Team Program (2016ZT06S029), Science and
   Technology Planning Project of Guangdong Province (No. 2016A010103015
   and 2016A030313238), SYSU Young Teachers Training Program (No.
   16YKZD14), Science Foundation of Guangxi (No. 2014GXNSFAA118267), and
   University Scientific Research Projects of Guangxi (No. YB2014279),
   Guangdong Innovative and Entrepreneurial Research Team Program (No.
   2013S086), Guangdong Natural Science Foundation (No. 2016A030313215 and
   2014A030312018), Science and Technology Program of Guangzhou (No.
   201707010094) and National Health and Medical Research Council of
   Australia (APP1028339, GNT1028339).
CR Arkhipov A, 2013, ELIFE, V2, DOI 10.7554/eLife.00708
   Carreira S, 2005, NATURE, V433, P764, DOI 10.1038/nature03269
   Castagnoli L, 2017, ONCOGENE, V36, P1721, DOI 10.1038/onc.2016.338
   Chakrabarty A, 2012, P NATL ACAD SCI USA, V109, P2718, DOI 10.1073/pnas.1018001108
   Dhar S, 2011, P NATL ACAD SCI USA, V108, P1850, DOI 10.1073/pnas.1011379108
   Dobbin ZC, 2014, ONCOTARGET, V5, P8750, DOI 10.18632/oncotarget.2373
   Ellis MJ, 2013, CANCER DISCOV, V3, P27, DOI 10.1158/2159-8290.CD-12-0462
   Goltsov A, 2014, CELLS-BASEL, V3, P563, DOI 10.3390/cells3020563
   Katsumata N, 2009, LANCET, V374, P1331, DOI 10.1016/S0140-6736(09)61157-0
   Li QT, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6780
   Ma L, 2010, NAT CELL BIOL, V12, P247, DOI 10.1038/ncb2024
   Miller MA, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9692
   Mo JX, 2016, SCI REP-UK, V6, DOI 10.1038/srep23489
   Mo JX, 2015, SCI REP-UK, V5, DOI 10.1038/srep10414
   Mo JX, 2014, ANAL BIOANAL CHEM, V406, P2659, DOI 10.1007/s00216-014-7684-0
   Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167
   Rodzinski A, 2016, SCI REP-UK, V6, DOI 10.1038/srep20867
   Santini V, 2013, CRIT REV ONCOL HEMAT, V88, P231, DOI 10.1016/j.critrevonc.2013.06.004
   Seton-Rogers S, 2011, NAT REV CANCER, V11, P539, DOI 10.1038/nrc3112
   Shi SJ, 2013, ANGEW CHEM INT EDIT, V52, P3901, DOI 10.1002/anie.201208077
   Sun CD, 2016, NANOSCALE, V8, P16332, DOI 10.1039/c6nr04875g
   You XR, 2016, J MATER CHEM B, V4, P7779, DOI 10.1039/c6tb01925k
NR 22
TC 37
Z9 39
U1 1
U2 55
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 2040-3364
EI 2040-3372
J9 NANOSCALE
JI Nanoscale
PD SEP 21
PY 2017
VL 9
IS 35
BP 13142
EP 13152
DI 10.1039/c7nr04473a
PG 11
WC Chemistry, Multidisciplinary; Nanoscience & Nanotechnology; Materials
   Science, Multidisciplinary; Physics, Applied
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry; Science & Technology - Other Topics; Materials Science;
   Physics
GA FG8DY
UT WOS:000410659800040
PM 28849826
OA hybrid, Green Submitted
DA 2025-01-12
ER

PT J
AU Linne, H
   Yasaei, H
   Marriott, A
   Harvey, A
   Mokbel, K
   Newbold, R
   Roberts, T
AF Linne, Hannah
   Yasaei, Hemad
   Marriott, Alison
   Harvey, Amanda
   Mokbel, Kefah
   Newbold, Robert
   Roberts, Terry
TI Functional role of <i>SETD2</i>, <i>BAP1</i>, <i>PARP</i>-<i>3</i> and
   <i>PBRM1</i> candidate genes on the regulation of <i>hTERT</i> gene
   expression
SO ONCOTARGET
LA English
DT Article
DE telomerase; breast cancer; epigenetic; chromosome 3; microcell-mediated
   chromosome transfer
ID HUMAN TELOMERASE ACTIVITY; HUMAN BREAST-CANCER; CHROMOSOME 3; LIFE-SPAN;
   TUMOR; REPRESSOR; INDUCTION; GROWTH; TRANSFORMATION; ASSOCIATION
AB Narrowing the search for the critical hTERT repressor sequence(s) has identified three regions on chromosome 3p (3p12-p21.1, 3p21.2 and 3p21.3-p22). However, the precise location and identity of the sequence(s) responsible for hTERT transcriptional repression remains elusive. In order to identify critical hTERT repressor sequences located within human chromosome 3p12-p22, we investigated hTERT transcriptional activity within 21NT microcell hybrid clones containing chromosome 3 fragments. Mapping of chromosome 3 structure in a single hTERT-repressed 21NT-#3fragment hybrid clone, revealed a 490kb region of deletion localised to 3p21.3 and encompassing the histone H3, lysine 36 (H3K36) trimethyltransferase enzyme SETD2; a putative tumour suppressor gene in breast cancer. Three additional genes, BAP1, PARP-3 and PBRM1, were also selected for further investigation based on their location within the 3p21.1-p21.3 region, together with their documented role in the epigenetic regulation of target gene expression or hTERT regulation. All four genes (SETD2, BAP1, PARP-3 and PBRM1) were found to be expressed at low levels in 21NT. Gene copy number variation (CNV) analysis of SETD2, BAP1, PARP-3 and PBRM1 within a panel of nine breast cancer cell lines demonstrated single copy number loss of all candidate genes within five (56%) cell lines (including 21NT cells). Stable, forced overexpression of BAP1, but not PARP2, SETD2 or PBRM1, within 21NT cells was associated with a significant reduction in hTERT expression levels relative to wild-type controls. We propose that at least two sequences exist on human chromosome 3p, that function to regulate hTERT transcription within human breast cancer cells.
C1 [Linne, Hannah; Yasaei, Hemad; Marriott, Alison; Harvey, Amanda; Mokbel, Kefah; Newbold, Robert; Roberts, Terry] Brunel Univ London, Coll Hlth & Life Sci, Dept Life Sci, Biosci, London, Middx, England.
   [Harvey, Amanda; Newbold, Robert; Roberts, Terry] Brunel Univ London, Inst Environm Hlth & Soc, London, Middx, England.
   [Mokbel, Kefah] Princess Grace Hosp, London Breast Inst, London, England.
   [Yasaei, Hemad] Dubai Hlth Author, Dubai Genet Ctr, Dubai, U Arab Emirates.
C3 Brunel University; Brunel University
RP Roberts, T (通讯作者)，Brunel Univ London, Coll Hlth & Life Sci, Dept Life Sci, Biosci, London, Middx, England.; Roberts, T (通讯作者)，Brunel Univ London, Inst Environm Hlth & Soc, London, Middx, England.
EM terry.roberts@brunel.ac.uk
RI Newbold, Robert/JDN-0280-2023; Yasaei, Hemad/A-6351-2014
OI Mokbel, Kefah/0000-0001-7255-7850
FU Breast Cancer Hope (BCH) charity of the London Breast Institute
   (Princess Grace Hospital, Nottingham Place, London, UK); EC FP7
   telomarker grant
FX The present study was supported by the Breast Cancer Hope (BCH) charity
   of the London Breast Institute (Princess Grace Hospital, Nottingham
   Place, London, UK), TR was supported by an EC FP7 telomarker grant. The
   study sponsors had no part in the study design, data collection, data
   analysis, and data interpretation, the writing of the report, nor in the
   decision to submit the paper for publication.
CR Al Sarakbi W, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-290
   BAND V, 1990, CANCER RES, V50, P7351
   Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349
   Clark GM, 1997, J NATL CANCER I, V89, P1874, DOI 10.1093/jnci/89.24.1874
   CUTHBERT AP, 1995, CYTOGENET CELL GENET, V71, P68, DOI 10.1159/000134066
   Cuthbert AP, 1999, JNCI-J NATL CANCER I, V91, P37, DOI 10.1093/jnci/91.1.37
   Daniel M, 2012, GENE, V498, P135, DOI 10.1016/j.gene.2012.01.095
   de Lange T, 2005, GENE DEV, V19, P2100, DOI 10.1101/gad.1346005
   Ducrest AL, 2002, ONCOGENE, V21, P541, DOI 10.1038/sj.onc.1205081
   Ducrest AL, 2001, CANCER RES, V61, P7594
   Edlund K, 2012, P NATL ACAD SCI USA, V109, P9551, DOI 10.1073/pnas.1200019109
   Eletr ZM, 2011, CELL BIOCHEM BIOPHYS, V60, P3, DOI 10.1007/s12013-011-9184-6
   Fernández-Marcelo T, 2014, J EXP CLIN CANC RES, V33, DOI 10.1186/1756-9966-33-19
   GREIDER CW, 1989, NATURE, V337, P331, DOI 10.1038/337331a0
   Hahn WC, 1999, NAT MED, V5, P1164, DOI 10.1038/13495
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9
   HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6
   Hiyama E, 1996, J NATL CANCER I, V88, P116, DOI 10.1093/jnci/88.2.116
   HURST J, 1993, BRIT J CANCER, V68, P274, DOI 10.1038/bjc.1993.327
   Jensen DE, 1998, ONCOGENE, V16, P1097, DOI 10.1038/sj.onc.1201861
   Kao J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006146
   KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428
   Kirkpatrick KL, 2003, EUR J SURG ONCOL, V29, P321, DOI 10.1053/ejso.2002.1374
   Maitra A, 2001, AM J PATHOL, V159, P119, DOI 10.1016/S0002-9440(10)61679-3
   Martinez A, 2001, J CLIN PATHOL-MOL PA, V54, P300, DOI 10.1136/mp.54.5.300
   Motevalli A, 2014, BREAST CANCER RES TR, V145, P581, DOI 10.1007/s10549-014-2975-x
   Newbold RF, 2010, ANTICANCER RES, V30, P3309
   NEWBOLD RF, 1982, NATURE, V299, P633, DOI 10.1038/299633a0
   NEWBOLD RF, 1983, NATURE, V304, P648, DOI 10.1038/304648a0
   Newbold RF, 2005, INTRO CELLULAR MOL B, P170
   Nishio S, 2015, BIOCHEM BIOPH RES CO, V466, P755, DOI 10.1016/j.bbrc.2015.09.119
   Oshimura M, 1997, EUR J CANCER, V33, P710, DOI 10.1016/S0959-8049(97)00090-7
   PEREIRASMITH OM, 1983, SCIENCE, V221, P964, DOI 10.1126/science.6879195
   Poremba C, 1998, INT J ONCOL, V12, P641
   Shammas MA, 2005, MOL CANCER, V4, DOI 10.1186/1476-4598-4-24
   Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2
   Souter LH, 2010, LAB INVEST, V90, P1247, DOI 10.1038/labinvest.2010.97
   Stampfer MR, 2003, ONCOGENE, V22, P5238, DOI 10.1038/sj.onc.1206667
   Sun XJ, 2005, J BIOL CHEM, V280, P35261, DOI 10.1074/jbc.M504012200
   Szutorisz H, 2003, CANCER RES, V63, P689
   Tanaka H, 2005, INT J CANCER, V115, P653, DOI 10.1002/ijc.20879
   Tanaka H, 1998, GENE CHROMOSOME CANC, V23, P123, DOI 10.1002/(SICI)1098-2264(199810)23:2<123::AID-GCC5>3.0.CO;2-4
   Won JJ, 2002, FASEB J, V16, P1943, DOI 10.1096/fj.02-0311fje
   Xia W, 2008, CANCER RES, V68, P1667, DOI 10.1158/0008-5472.CAN-07-5276
   Xiong JB, 2003, MOL CELL BIOL, V23, P8668, DOI 10.1128/MCB.23.23.8668-8690.2003
   Yasaei H, 2013, ONCOGENE, V32, P171, DOI 10.1038/onc.2012.45
NR 47
TC 10
Z9 10
U1 0
U2 1
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD SEP 5
PY 2017
VL 8
IS 37
BP 61890
EP 61900
DI 10.18632/oncotarget.18712
PG 11
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA FF8GI
UT WOS:000409254200092
PM 28977912
OA Green Submitted, Green Published, gold
DA 2025-01-12
ER

PT J
AU Jia, JT
   Shi, Y
   Chen, L
   Lai, WW
   Yan, B
   Jiang, YQ
   Xiao, DS
   Xi, SC
   Cao, Y
   Liu, S
   Cheng, Y
   Tao, YG
AF Jia, Jiantao
   Shi, Ying
   Chen, Ling
   Lai, Weiwei
   Yan, Bin
   Jiang, Yiqun
   Xiao, Desheng
   Xi, Sichuan
   Cao, Ya
   Liu, Shuang
   Cheng, Yan
   Tao, Yongguang
TI Decrease in Lymphoid Specific Helicase and 5-hydroxymethylcytosine Is
   Associated with Metastasis and Genome Instability
SO THERANOSTICS
LA English
DT Article
DE LSH; 5-hmC; TET2; satellites; genome instability
ID REMODELING FACTOR LSH; CELL SELF-RENEWAL; DNA METHYLATION; TET2; CANCER;
   MOUSE; HETEROCHROMATIN; TARGETS; GENE; 5-METHYLCYTOSINE
AB DNA methylation is an important epigenetic modification as a hallmark in cancer. Conversion of 5-methylcytosine (5-mC) to 5-hydroxymethylcytosine (5-hmC) by ten-eleven translocation (TET) family enzymes plays an important biological role in embryonic stem cells, development, aging and disease. Lymphoid specific helicase (LSH), a chromatin remodeling factor, is regarded as a reader of 5-hmC. Recent reports show that the level of 5-hmC is altered in various types of cancers. However, the change in 5-hmC levels in cancer and associated metastasis is not well defined. We report that the level of 5-hmC was decreased in metastatic tissues of nasopharyngeal carcinoma, breast cancer, and colon cancer relative to that in non-metastasis tumor tissues. Furthermore, our data show that TET2, but not TET3, interacted with LSH, whereas LSH increased TET2 expression through silencing miR-26b-5p and miR-29c-5p. Finally, LSH promoted genome stability by silencing satellite expression by affecting 5-hmC levels in pericentromeric satellite repeats, and LSH was resistant to cisplatin-induced DNA damage. Our data indicate that 5-hmC might serve as a metastasis marker for cancer and that the decreased expression of LSH is likely one of the mechanisms of genome instability underlying 5-hmC loss in cancer.
C1 [Jia, Jiantao; Shi, Ying; Chen, Ling; Lai, Weiwei; Yan, Bin; Jiang, Yiqun; Cao, Ya; Tao, Yongguang] Cent South Univ, Xiangya Hosp, Minist Educ, Key Lab Carcinogenesis & Canc Invas, Changsha 410008, Hunan, Peoples R China.
   [Jia, Jiantao; Tao, Yongguang] Changzhi Med Coll, Dept Pathophysiol, Changzhi 046000, Shanxi, Peoples R China.
   [Jia, Jiantao; Shi, Ying; Chen, Ling; Lai, Weiwei; Yan, Bin; Jiang, Yiqun; Cao, Ya; Tao, Yongguang] Cent South Univ, Canc Res Inst, Changsha 410078, Hunan, Peoples R China.
   [Jia, Jiantao; Liu, Shuang] Cent South Univ, Xiangya Hosp, Inst Med Sci, Changsha 410008, Hunan, Peoples R China.
   [Xiao, Desheng] Cent South Univ, Xiangya Hosp, Dept Pathol, Changsha 410078, Hunan, Peoples R China.
   [Xi, Sichuan] NCI, Thorac Surg Sect, Thorac & GI Oncol Branch, Ctr Canc Res, Bethesda, MD 20892 USA.
   [Cheng, Yan] Cent South Univ, Sch Pharmaceut Sci, Dept Pharmacol, Changsha 410078, Hunan, Peoples R China.
C3 Central South University; Changzhi Medical College; Central South
   University; Central South University; Central South University; National
   Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI);
   Central South University
RP Tao, YG (通讯作者)，Cent South Univ, Xiangya Hosp, Minist Educ, Key Lab Carcinogenesis & Canc Invas, Changsha 410008, Hunan, Peoples R China.; Tao, YG (通讯作者)，Changzhi Med Coll, Dept Pathophysiol, Changzhi 046000, Shanxi, Peoples R China.; Tao, YG (通讯作者)，Cent South Univ, Canc Res Inst, Changsha 410078, Hunan, Peoples R China.
EM taoyong@csu.edu.cn
RI Yan, Bin/Y-7642-2019; Lai, Weiwei/KYQ-2226-2024
FU National Basic Research Program of China [2015CB553903]; National
   Natural Science Foundation of China [81372427, 81672787, 81271763,
   81672991, 81302354, 81422051, 81472593, 31401208]
FX This work was supported by the National Basic Research Program of China
   [2015CB553903(Y.T.)]; This work was supported by the National Natural
   Science Foundation of China [81372427 and 81672787(Y. Tao), 81271763 and
   81672991(S. Liu), 81302354(Y. S.), 81422051, 81472593, and 31401208 (Y.
   Cheng)].
CR [Anonymous], PLOS ONE
   Bertoli G, 2015, THERANOSTICS, V5, P1122, DOI 10.7150/thno.11543
   Burrage J, 2012, J CELL SCI, V125, P5524, DOI 10.1242/jcs.111252
   Cann KL, 2011, BIOCHEM CELL BIOL, V89, P45, DOI 10.1139/O10-113
   Chen TP, 2014, NAT REV GENET, V15, P93, DOI 10.1038/nrg3607
   Delatte B, 2014, EMBO J, V33, P1198, DOI 10.15252/embj.201488290
   Delhommeau F, 2009, NEW ENGL J MED, V360, P2289, DOI 10.1056/NEJMoa0810069
   Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI [10.1056/NEJMra072067, 10.1093/carcin/bgp220]
   Falk M, 2008, BBA-MOL CELL RES, V1783, P2398, DOI 10.1016/j.bbamcr.2008.07.010
   Fan T, 2003, CANCER RES, V63, P4677
   Ficz G, 2014, GENOMICS, V104, P352, DOI 10.1016/j.ygeno.2014.08.017
   Figueroa ME, 2010, CANCER CELL, V18, P553, DOI 10.1016/j.ccr.2010.11.015
   Fu XH, 2013, P NATL ACAD SCI USA, V110, P17892, DOI 10.1073/pnas.1317397110
   Gao F, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0533-9
   Haffner MC, 2011, ONCOTARGET, V2, P627
   He XZ, 2016, CANCER RES, V76, P5743, DOI 10.1158/0008-5472.CAN-16-0268
   Hennig W, 1999, CHROMOSOMA, V108, P1, DOI 10.1007/s004120050346
   Huang JQ, 2004, NUCLEIC ACIDS RES, V32, P5019, DOI 10.1093/nar/gkh821
   James AM, 2017, THERANOSTICS, V7, P634, DOI 10.7150/thno.16840
   Jiang Y, 2015, ONCOGENE, V34, P6079, DOI 10.1038/onc.2015.53
   Jiang YQ, 2017, THERANOSTICS, V7, P3293, DOI 10.7150/thno.19988
   Jiang YQ, 2013, BBA-REV CANCER, V1835, P155, DOI 10.1016/j.bbcan.2012.12.003
   Keyes WM, 2011, CELL STEM CELL, V8, P164, DOI 10.1016/j.stem.2010.12.009
   Ko M, 2010, NATURE, V468, P839, DOI 10.1038/nature09586
   Koh KP, 2011, CELL STEM CELL, V8, P200, DOI 10.1016/j.stem.2011.01.008
   Kraus TFJ, 2012, INT J CANCER, V131, P1577, DOI 10.1002/ijc.27429
   Lai WW, 2013, INT J MOL SCI, V14, P2355, DOI 10.3390/ijms14022355
   Langemeijer SMC, 2009, NAT GENET, V41, P838, DOI 10.1038/ng.391
   Larson AR, 2014, MODERN PATHOL, V27, P936, DOI 10.1038/modpathol.2013.224
   Lian CG, 2012, CELL, V150, P1135, DOI 10.1016/j.cell.2012.07.033
   Liu S, 2016, CHIN J CANCER, V35, DOI 10.1186/s40880-016-0138-7
   Liu S, 2013, BIOL REV, V88, P40, DOI 10.1111/j.1469-185X.2012.00237.x
   Moran-Crusio K, 2011, CANCER CELL, V20, P11, DOI 10.1016/j.ccr.2011.06.001
   Murata A, 2015, ONCOTARGET, V6, P23372, DOI 10.18632/oncotarget.4281
   Myant K, 2011, GENOME RES, V21, P83, DOI 10.1101/gr.108498.110
   Noushmehr H, 2010, CANCER CELL, V17, P510, DOI 10.1016/j.ccr.2010.03.017
   Poh WJ, 2016, THERANOSTICS, V6, P369, DOI 10.7150/thno.13438
   Quivoron C, 2011, CANCER CELL, V20, P25, DOI 10.1016/j.ccr.2011.06.003
   Ren JK, 2015, NUCLEIC ACIDS RES, V43, P1444, DOI 10.1093/nar/gku1371
   Ryu B, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000594
   Shen L, 2013, CURR OPIN CELL BIOL, V25, P289, DOI 10.1016/j.ceb.2013.02.017
   Shi Y, 2012, CARCINOGENESIS, V33, P1468, DOI 10.1093/carcin/bgs171
   Solary E, 2014, LEUKEMIA, V28, P485, DOI 10.1038/leu.2013.337
   Song SJ, 2013, CELL STEM CELL, V13, P87, DOI 10.1016/j.stem.2013.06.003
   Spruijt CG, 2013, CELL, V152, P1146, DOI 10.1016/j.cell.2013.02.004
   Suvà ML, 2013, SCIENCE, V339, P1567, DOI 10.1126/science.1230184
   Tahiliani M, 2009, SCIENCE, V324, P930, DOI 10.1126/science.1170116
   Tao YG, 2011, P NATL ACAD SCI USA, V108, P5626, DOI 10.1073/pnas.1017000108
   Tu JJ, 2015, NUCLEIC ACIDS RES, V43, P7805, DOI 10.1093/nar/gkv653
   von Eyss B, 2012, EMBO J, V31, P972, DOI 10.1038/emboj.2011.451
   Wang JQ, 2017, THERANOSTICS, V7, P1407, DOI 10.7150/thno.18262
   Waseem A, 2010, ORAL ONCOL, V46, P536, DOI 10.1016/j.oraloncology.2010.03.022
   Wilson AS, 2007, BBA-REV CANCER, V1775, P138, DOI 10.1016/j.bbcan.2006.08.007
   Xiao DS, 2017, THERANOSTICS, V7, P132, DOI 10.7150/thno.17032
   Xu W, 2011, CANCER CELL, V19, P17, DOI 10.1016/j.ccr.2010.12.014
   Xu Y, 2013, J EXP CLIN CANC RES, V32, DOI 10.1186/1756-9966-32-90
   Yan QS, 2003, MOL CELL BIOL, V23, P8416, DOI 10.1128/MCB.23.23.8416-8428.2003
   Yang H, 2013, ONCOGENE, V32, P663, DOI 10.1038/onc.2012.67
   Yu WS, 2014, GENOME RES, V24, P1613, DOI 10.1101/gr.172015.114
   Yu WS, 2014, P NATL ACAD SCI USA, V111, P5890, DOI 10.1073/pnas.1320945111
   Zemach A, 2013, CELL, V153, P193, DOI 10.1016/j.cell.2013.02.033
   Zhang YF, 2016, AM J CANCER RES, V6, P1089
   Zhu Q, 2011, NATURE, V477, P179, DOI 10.1038/nature10371
NR 63
TC 38
Z9 39
U1 1
U2 21
PU IVYSPRING INT PUBL
PI LAKE HAVEN
PA PO BOX 4546, LAKE HAVEN, NSW 2263, AUSTRALIA
SN 1838-7640
J9 THERANOSTICS
JI Theranostics
PY 2017
VL 7
IS 16
BP 3920
EP 3932
DI 10.7150/thno.21389
PG 13
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA FG3UX
UT WOS:000410122600010
OA Green Published, gold, Green Submitted
DA 2025-01-12
ER

PT J
AU Davies, H
   Morganella, S
   Purdie, CA
   Jang, SJ
   Borgen, E
   Russnes, H
   Glodzik, D
   Zou, XQ
   Viari, A
   Richardson, AL
   Borresen-Dale, AL
   Thompson, A
   Eyfjord, JE
   Kong, G
   Stratton, MR
   Nik-Zainal, S
AF Davies, Helen
   Morganella, Sandro
   Purdie, Colin A.
   Jang, Se Jin
   Borgen, Elin
   Russnes, Hege
   Glodzik, Dominik
   Zou, Xueqing
   Viari, Alain
   Richardson, Andrea L.
   Borresen-Dale, Anne-Lise
   Thompson, Alastair
   Eyfjord, Jorunn E.
   Kong, Gu
   Stratton, Michael R.
   Nik-Zainal, Serena
TI Whole-Genome Sequencing Reveals Breast Cancers with Mismatch Repair
   Deficiency
SO CANCER RESEARCH
LA English
DT Article
ID NONPOLYPOSIS COLORECTAL-CANCER; PD-1 BLOCKADE; COLON-CANCER;
   MICROSATELLITE INSTABILITY; MUTATIONAL PROCESSES; SIGNATURES; HOMOLOG;
   GENE; LANDSCAPE; TUMORS
AB Mismatch repair (MMR)-deficient cancers have been discovered to be highly responsive to immune therapies such as PD-1 checkpoint blockade, making their definition in patients, where they may be relatively rare, paramount for treatment decisions. In this study, we utilized patterns of mutagenesis known as mutational signatures, which are imprints of the mutagenic processes associated with MMR deficiency, to identify MMR-deficient breast tumors from a whole-genome sequencing dataset comprising a cohort of 640 patients. We identified 11 of 640 tumors as MMR deficient, but only 2 of 11 exhibited germline mutations in MMR genes or Lynch Syndrome. Two additional tumors had a substantially reduced proportion of mutations attributed to MMR deficiency, where the predominant mutational signatures were related to APOBEC enzymatic activity. Overall, 6 of 11 of the MMR-deficient cases in this cohort were confirmed genetically or epigenetically as having abrogation of MMR genes. However, IHC analysis of MMR-related proteins revealed all but one of 10 samples available for testing as MMR deficient. Thus, the mutational signatures more faithfully reported MMR deficiency than sequencing of MMR genes, because they represent a direct pathophysiologic readout of repair pathway abnormalities. As whole-genome sequencing continues to become more affordable, it could be used to expose individually abnormal tumors in tissue types where MMR deficiency has been rarely detected, but also rarely sought. (C) 2017 AACR.
C1 [Davies, Helen; Morganella, Sandro; Glodzik, Dominik; Zou, Xueqing; Stratton, Michael R.; Nik-Zainal, Serena] Wellcome Trust Sanger Inst, Hinxton, England.
   [Purdie, Colin A.] Ninewells Hosp & Med Sch, Pathol Dept, Dundee, Scotland.
   [Jang, Se Jin] Univ Ulsan, Dept Pathol, Coll Med, Asan Med Ctr, Ulsan, South Korea.
   [Borgen, Elin; Russnes, Hege; Borresen-Dale, Anne-Lise] Oslo Univ Hosp, Dept Pathol, Oslo, Norway.
   [Russnes, Hege; Borresen-Dale, Anne-Lise] Oslo Univ Hosp, Inst Canc Res, Norwegian Radium Hosp, Dept Canc Genet, Oslo, Norway.
   [Russnes, Hege] Univ Oslo, Inst Clin Med, KG Jebsen Ctr Breast Canc Res, Oslo, Norway.
   [Viari, Alain] Equipe Erable, INRIA Grenoble Rhone Alpes, Montbonnot St Martin, France.
   [Viari, Alain] Ctr Leon Berard, Synergie Lyon Canc, Lyon, France.
   [Richardson, Andrea L.] Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA.
   [Richardson, Andrea L.] Dana Farber Canc Inst, Boston, MA 02115 USA.
   [Thompson, Alastair] Univ Texas MD Anderson Canc Ctr, Dept Breast Surg Oncol, Houston, TX 77030 USA.
   [Eyfjord, Jorunn E.] Univ Iceland, Canc Res Lab, Fac Med, Reykjavik, Iceland.
   [Kong, Gu] Hanyang Univ, Coll Med, Dept Pathol, Seoul, South Korea.
   [Nik-Zainal, Serena] Cambridge Univ Hosp NHS Fdn Trust, East Anglian Med Genet Serv, Cambridge, England.
C3 Wellcome Trust Sanger Institute; University of Dundee; University of
   Ulsan; University of Oslo; University of Oslo; University of Oslo;
   UNICANCER; Centre Leon Berard; Harvard University; Brigham & Women's
   Hospital; Harvard University; Dana-Farber Cancer Institute; University
   of Texas System; UTMD Anderson Cancer Center; University of Iceland;
   Hanyang University; University of Cambridge
RP Nik-Zainal, S (通讯作者)，Wellcome Trust Sanger Inst, Cambridge CB10 1SA, England.
EM snz@sanger.ac.uk
RI Nik-Zainal, Serena/ABD-4437-2020; Russnes, Hege G/N-6170-2015
OI Stratton, Michael/0000-0001-6035-153X; Purdie,
   Colin/0000-0002-1258-4010; Zou, Xueqing/0000-0003-1143-1028; Glodzik,
   Dominik/0000-0001-8112-9073
FU Wellcome Trust [WT101126/B/13/Z]; Cancer Research UK Advanced Clinician
   Scientist Award [C60100/A23916]; Dana-Farber/ Harvard Cancer Center
   SPORE in Breast Cancer [NIH/NCI5 P50 CA168504-02]; National Research
   Foundation of Korea (NRF) - Korean government [NRF2015R1A2A1A10052578]
FX S. Nik-Zainal and X. Zou were supported by the Wellcome Trust via a
   Wellcome Trust Strategic Award (WT101126/B/13/Z), S. Nik-Zainal is
   personally funded by a Cancer Research UK Advanced Clinician Scientist
   Award (C60100/A23916). A. L. Richardson is partially supported by the
   Dana-Farber/ Harvard Cancer Center SPORE in Breast Cancer (NIH/NCI5 P50
   CA168504-02). G. Kong is supported by National Research Foundation of
   Korea (NRF) grants funded by the Korean government
   (NRF2015R1A2A1A10052578).
CR Alexandrov LB, 2013, NATURE, V500, P415, DOI 10.1038/nature12477
   Alexandrov LB, 2013, CELL REP, V3, P246, DOI 10.1016/j.celrep.2012.12.008
   Auclair J, 2007, HUM MUTAT, V28, P1084, DOI 10.1002/humu.20569
   BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0
   Davies H, 2017, NAT MED, V23, P517, DOI 10.1038/nm.4292
   Dudley JC, 2016, CLIN CANCER RES, V22, P813, DOI 10.1158/1078-0432.CCR-15-1678
   Gazzoli I, 2002, CANCER RES, V62, P3925
   Geurts-Giele WRR, 2014, J PATHOL, V234, P548, DOI 10.1002/path.4419
   Hanse RJ, 2016, NAT MED, V22, P1342, DOI 10.1038/nm.4191
   Helleday T, 2014, NAT REV GENET, V15, P585, DOI 10.1038/nrg3729
   Le DT, 2015, NEW ENGL J MED, V372, P2509, DOI 10.1056/NEJMoa1500596
   Le DT, 2017, SCIENCE, V357, P409, DOI 10.1126/science.aan6733
   LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S
   Lee V, 2016, ONCOLOGIST, V21, P1200, DOI 10.1634/theoncologist.2016-0046
   Llosa NJ, 2015, CANCER DISCOV, V5, P43, DOI 10.1158/2159-8290.CD-14-0863
   Lynch HT, 2015, NAT REV CANCER, V15, P181, DOI 10.1038/nrc3878
   Miyaki M, 1997, NAT GENET, V17, P271, DOI 10.1038/ng1197-271
   NICOLAIDES NC, 1994, NATURE, V371, P75, DOI 10.1038/371075a0
   Nik-Zainal S, 2016, NATURE, V534, P47, DOI 10.1038/nature17676
   Nik-Zainal S, 2012, CELL, V149, DOI 10.1016/j.cell.2012.04.023
   Nik-Zainal S, 2012, CELL, V149, P979, DOI 10.1016/j.cell.2012.04.024
   PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251
   PARSONS R, 1995, SCIENCE, V268, P738, DOI 10.1126/science.7632227
   PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J
   Patch AM, 2015, NATURE, V521, P489, DOI 10.1038/nature14410
   Rizvi NA, 2015, SCIENCE, V348, P124, DOI 10.1126/science.aaa1348
   Schumacher TN, 2015, SCIENCE, V348, P69, DOI 10.1126/science.aaa4971
   Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690
   Win AK, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3405
NR 29
TC 76
Z9 86
U1 1
U2 14
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD SEP 15
PY 2017
VL 77
IS 18
BP 4755
EP 4762
DI 10.1158/0008-5472.CAN-17-1083
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA FH2CG
UT WOS:000410945700003
PM 28904067
OA Green Submitted, Green Published, Bronze
DA 2025-01-12
ER

PT J
AU Borst, A
   Haferkamp, S
   Grimm, J
   Rösch, M
   Zhu, GN
   Guo, S
   Li, CY
   Gao, TW
   Meierjohann, S
   Schrama, D
   Houben, R
AF Borst, Andreas
   Haferkamp, Sebastian
   Grimm, Johannes
   Roesch, Manuel
   Zhu, Guannan
   Guo, Sen
   Li, Chunying
   Gao, Tianwen
   Meierjohann, Svenja
   Schrama, David
   Houben, Roland
TI BIK is involved in BRAF/MEK inhibitor induced apoptosis in melanoma cell
   lines
SO CANCER LETTERS
LA English
DT Article
DE Melanoma; Vemurafenib; Trametinib; BIK/NBK; Apoptosis
ID BREAST-CANCER CELLS; HISTONE DEACETYLASE INHIBITORS;
   ENDOPLASMIC-RETICULUM BIK; POTENT ANTITUMOR-ACTIVITY; BCL-2
   FAMILY-MEMBERS; PHASE-II TRIAL; BH3-ONLY PROTEIN; METASTATIC MELANOMA;
   MULTIPLE-MYELOMA; MEK INHIBITION
AB In patients with BRAF-mutated melanoma specific inhibitors of BRAF(V600E) and MEK1/2 frequently induce initial tumor reduction, frequently followed by relapse. As demonstrated previously, BRAF(V600E) -inhibition induces apoptosis only in a fraction of treated cells, while the remaining arrest and survive providing a source or a niche for relapse. To identify factors contributing to the differential initial response towards BRAF/MEK inhibition, we established M14 melanoma cell line-derived single cell clones responding to treatment with BRAF inhibitor vemurafenib and MEK inhibitor trametinib predominantly with either cell cycle arrest (CCA-cells) or apoptosis (A-cells). Screening for differentially expressed apoptosis-related genes revealed loss of BCL2-Interacting Killer (BIK) mRNA in CCA-cells. Importantly, ectopic expression of BIK in CCA-cells resulted in increased apoptosis rates following vemurafenib/trametinib treatment, while knockdown/knockout of BIK in A-cells attenuated the apoptotic response. Furthermore, we demonstrate reversible epigenetic silencing of BIK mRNA expression in CCA-cells. Importantly, HDAC inhibitor treatment associated with re-expression of BIK augmented sensitivity of CCA-cells towards vemurafenib/trametinib treatment both in vitro and in vivo. In conclusion, our results suggest that BIK can be a critical mediator of melanoma cell fate determination in response to MAPK pathway inhibition. (C) 2017 Elsevier B.V. All rights reserved.
C1 [Borst, Andreas; Roesch, Manuel; Schrama, David; Houben, Roland] Univ Hosp Wuerzburg, Dept Dermatol Venereol & Allergol, Josef Schneider Str 2, D-97080 Wurzburg, Germany.
   [Haferkamp, Sebastian] Univ Hosp Regensburg, Dept Dermatol, Regensburg, Germany.
   [Grimm, Johannes; Meierjohann, Svenja] Bioctr, Dept Physiol Chem 1, Wurzburg, Germany.
   [Zhu, Guannan; Guo, Sen; Li, Chunying; Gao, Tianwen] Fourth Mil Med Univ, Xijing Hosp, Dept Dermatol, Xian, Shaanxi, Peoples R China.
C3 University of Wurzburg; University of Regensburg; University of
   Wurzburg; Air Force Military Medical University
RP Houben, R (通讯作者)，Univ Hosp Wuerzburg, Dept Dermatol Venereol & Allergol, Josef Schneider Str 2, D-97080 Wurzburg, Germany.
EM houben_r@ukw.de
RI Zhu, Guannan/LCE-7619-2024; Haferkamp, Sebastian/AAN-3649-2021; guo,
   sen/GWQ-3573-2022
OI Houben, Roland/0000-0003-4538-2324; Schrama, David/0000-0002-6931-8194;
   Haferkamp, Sebastian/0000-0002-3894-8345
FU Interdisziplinares Zentrum fur Klinische Forschung Wurzburg [IZKF B-193,
   B-323]; Hiege Foundation against Skin Cancer
FX The study was supported by the Interdisziplinares Zentrum fur Klinische
   Forschung Wurzburg (IZKF B-193 and B-323) and the Hiege Foundation
   against Skin Cancer. We are very thankful to Jurgen Eberle for providing
   the BIK expression construct. Furthermore, we thank Lena Volkert,
   Kristina Vogtmann, Luis Zanon Rodriguez and Sarah Schuster for excellent
   technical assistance.
CR Baig S, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2015.275
   Beck D, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2003057
   BOYD JM, 1995, ONCOGENE, V11, P1921
   Campion EM, 2014, J VIROL, V88, P5001, DOI 10.1128/JVI.03642-13
   Carson R, 2015, CLIN CANCER RES, V21, P3230, DOI 10.1158/1078-0432.CCR-14-2701
   Cartlidge RA, 2008, PIGM CELL MELANOMA R, V21, P534, DOI 10.1111/j.1755-148X.2008.00491.x
   Chinnadurai G, 2008, ONCOGENE, V27, pS20, DOI 10.1038/onc.2009.40
   Eroglu Z, 2016, THER ADV MED ONCOL, V8, P48, DOI 10.1177/1758834015616934
   Fisher Rosalie, 2012, Cancer Manag Res, V4, P243, DOI 10.2147/CMAR.S25284
   Fu Y, 2007, CANCER RES, V67, P3734, DOI 10.1158/0008-5472.CAN-06-4594
   Germain M, 2005, EMBO J, V24, P1546, DOI 10.1038/sj.emboj.7600592
   Germain M, 2002, J BIOL CHEM, V277, P18053, DOI 10.1074/jbc.M201235200
   Gillissen B, 2003, EMBO J, V22, P3580, DOI 10.1093/emboj/cdg343
   Haas NB, 2014, INVEST NEW DRUG, V32, P526, DOI 10.1007/s10637-014-0066-9
   Haferkamp S, 2013, J INVEST DERMATOL, V133, P1601, DOI 10.1038/jid.2013.6
   Harada T, 2016, INT J HEMATOL, V104, P300, DOI 10.1007/s12185-016-2008-0
   Hartsough E, 2014, J INVEST DERMATOL, V134, P319, DOI 10.1038/jid.2013.358
   Hata AN, 2015, CANCER DISCOV, V5, P475, DOI 10.1158/2159-8290.CD-15-0011
   Hauschild A, 2008, MELANOMA RES, V18, P274, DOI 10.1097/CMR.0b013e328307c248
   Holderfield M, 2014, NAT REV CANCER, V14, P455, DOI 10.1038/nrc3760
   Houben R, 2012, INT J CANCER, V130, P847, DOI 10.1002/ijc.26076
   Hur JY, 2004, P NATL ACAD SCI USA, V101, P2351, DOI 10.1073/pnas.0307337101
   Ikediobi ON, 2006, MOL CANCER THER, V5, P2606, DOI 10.1158/1535-7163.MCT-06-0433
   Jazirehi AR, 2014, AM J CLIN EXP IMMUNO, V3, P43
   Lai F, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.192
   Lane AA, 2009, J CLIN ONCOL, V27, P5459, DOI 10.1200/JCO.2009.22.1291
   Mathai JP, 2005, J BIOL CHEM, V280, P23829, DOI 10.1074/jbc.M500800200
   McDonnell JM, 1999, CELL, V96, P625, DOI 10.1016/S0092-8674(00)80573-5
   Mebratu YA, 2008, J CELL BIOL, V183, P429, DOI 10.1083/jcb.200801186
   Network CGA., 2015, CELL, V161, P1681, DOI [DOI 10.1016/J.CELL.2015.05.044, 10.1016/j.cell.2015.05.044]
   Nikrad M, 2005, MOL CANCER THER, V4, P443
   Obenauf AC, 2015, NATURE, V520, P368, DOI 10.1038/nature14336
   Oppermann M, 2005, ONCOGENE, V24, P7369, DOI 10.1038/sj.onc.1208890
   Paquet C, 2004, APOPTOSIS, V9, P815, DOI 10.1023/B:APPT.0000045791.55282.91
   Paraiso KHT, 2011, CANCER RES, V71, P2750, DOI 10.1158/0008-5472.CAN-10-2954
   Pompeia C, 2004, CANCER RES, V64, P3465, DOI 10.1158/0008-5472.CAN-03-3970
   Prieto-Remón I, 2012, BIOCHEM J, V448, P153, DOI 10.1042/BJ20120327
   Roesch A, 2013, CANCER CELL, V23, P811, DOI 10.1016/j.ccr.2013.05.003
   Rohrbeck L, 2016, CELL DEATH DIFFER, V23, P2054, DOI 10.1038/cdd.2016.96
   Senft D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030821
   Shao Y, 2012, CELL DEATH DIFFER, V19, P2029, DOI 10.1038/cdd.2012.94
   Shimazu T, 2007, GENE DEV, V21, P929, DOI 10.1101/gad.1522007
   Singh BP, 2016, CANCERS, V8, DOI 10.3390/cancers8010017
   Spender LC, 2009, CELL DEATH DIFFER, V16, P593, DOI 10.1038/cdd.2008.183
   Sturm I, 2006, CELL DEATH DIFFER, V13, P619, DOI 10.1038/sj.cdd.4401782
   Swaika A, 2014, DRUG DES DEV THER, V8, P775, DOI 10.2147/DDDT.S31143
   Tong Y, 2001, MOL CANCER THER, V1, P95
   Verma S, 2001, J BIOL CHEM, V276, P4671, DOI 10.1074/jbc.M008983200
   Ververis K, 2013, BIOL-TARGETS THER, V7, P47, DOI 10.2147/BTT.S29965
   Viedma-Rodriguez R, 2013, INT J ONCOL, V43, P1777, DOI 10.3892/ijo.2013.2127
   Wagle N, 2011, J CLIN ONCOL, V29, P3085, DOI 10.1200/JCO.2010.33.2312
   Wang YF, 2007, CLIN CANCER RES, V13, P4934, DOI 10.1158/1078-0432.CCR-07-0665
   Welsh SJ, 2016, EUR J CANCER, V62, P76, DOI 10.1016/j.ejca.2016.04.005
   Yang H, 2010, CANCER RES, V70, P5518, DOI 10.1158/0008-5472.CAN-10-0646
   Yoshida M, 2001, CANCER CHEMOTH PHARM, V48, pS20, DOI 10.1007/s002800100300
   Zhang G, 2014, CELL RES, V24, P906, DOI 10.1038/cr.2014.67
   Zhou H, 2011, J BIOL CHEM, V286, P25687, DOI 10.1074/jbc.M110.212944
   Zhu HB, 2005, ONCOGENE, V24, P4993, DOI 10.1038/sj.onc.1208683
NR 58
TC 11
Z9 11
U1 0
U2 7
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0304-3835
EI 1872-7980
J9 CANCER LETT
JI Cancer Lett.
PD SEP 28
PY 2017
VL 404
BP 70
EP 78
DI 10.1016/j.canlet.2017.07.005
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA FF3HQ
UT WOS:000408786500009
PM 28720543
DA 2025-01-12
ER

PT J
AU Liu, HL
   Wang, C
   Lee, S
   Deng, Y
   Wither, M
   Oh, S
   Ning, FK
   Dege, C
   Zhang, QQ
   Liu, XJ
   Johnson, AM
   Zang, JY
   Chen, ZZ
   Janknecht, R
   Hansen, K
   Marrack, P
   Li, CY
   Kappler, JW
   Hagman, J
   Zhang, GY
AF Liu, Haolin
   Wang, Chao
   Lee, Schuyler
   Deng, Yu
   Wither, Matthew
   Oh, Sangphil
   Ning, Fangkun
   Dege, Carissa
   Zhang, Qianqian
   Liu, Xinjian
   Johnson, Aaron M.
   Zang, Jianye
   Chen, Zhongzhou
   Janknecht, Ralf
   Hansen, Kirk
   Marrack, Philippa
   Li, Chuan-Yuan
   Kappler, John W.
   Hagman, James
   Zhang, Gongyi
TI Clipping of arginine-methylated histone tails by JMJD5 and JMJD7
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE histone tail; arginine methylation; clipping; JMJD5/7
ID TRANSCRIPTIONAL ACTIVATION; DEMETHYLASE JMJD5; CRYSTAL-STRUCTURE;
   STRUCTURAL BASIS; IN-VIVO; CHROMATIN; DOMAIN; PROTEINS; RECEPTOR; RNA
AB Two of the unsolved, important questions about epigenetics are: do histone arginine demethylases exist, and is the removal of histone tails by proteolysis a major epigenetic modification process? Here, we report that two orphan Jumonji C domain (JmjC)-containing proteins, JMJD5 and JMJD7, have divalent cation-dependent protease activities that preferentially cleave the tails of histones 2, 3, or 4 containing methylated arginines. After the initial specific cleavage, JMJD5 and JMJD7, acting as aminopeptidases, progressively digest the C-terminal products. JMJD5-deficient fibroblasts exhibit dramatically increased levels of methylated arginines and histones. Furthermore, depletion of JMJD7 in breast cancer cells greatly decreases cell proliferation. The protease activities of JMJD5 and JMJD7 represent a mechanism for removal of histone tails bearing methylated arginine residues and define a potential mechanism of transcription regulation.
C1 [Liu, Haolin; Wang, Chao; Lee, Schuyler; Ning, Fangkun; Dege, Carissa; Marrack, Philippa; Kappler, John W.; Hagman, James; Zhang, Gongyi] Natl Jewish Hlth, Dept Biomed Res, Denver, CO 80206 USA.
   [Liu, Haolin; Wang, Chao; Lee, Schuyler; Ning, Fangkun; Dege, Carissa; Marrack, Philippa; Kappler, John W.; Hagman, James; Zhang, Gongyi] Univ Colorado Denver, Sch Med, Dept Immunol & Microbiol, Denver, CO 80206 USA.
   [Liu, Haolin; Marrack, Philippa; Kappler, John W.] Howard Hughes Med Inst, Denver, CO 80206 USA.
   [Deng, Yu; Liu, Xinjian; Li, Chuan-Yuan] Duke Univ, Dept Dermatol, Durham, NC 27710 USA.
   [Wither, Matthew; Johnson, Aaron M.; Hansen, Kirk; Marrack, Philippa; Hagman, James] Univ Colorado Denver, Sch Med, Dept Biochem & Mol Genet, Aurora, CO 80216 USA.
   [Oh, Sangphil; Janknecht, Ralf] Univ Oklahoma, Hlth Sci Ctr, Dept Cell Biol, Oklahoma City, OK 73104 USA.
   [Zhang, Qianqian; Chen, Zhongzhou] China Agr Univ, State Key Lab Agrobiotechnol, Beijing 100193, Peoples R China.
   [Zang, Jianye] Univ Sci & Technol China, Dept Mol Biol, Hefei 900015, Anhui, Peoples R China.
   [Deng, Yu] Chengdu Univ, Sch Med, Chengdu 610106, Sichuan, Peoples R China.
C3 National Jewish Health; Children's Hospital Colorado; University of
   Colorado System; University of Colorado Anschutz Medical Campus;
   University of Colorado Denver; Howard Hughes Medical Institute; Duke
   University; Children's Hospital Colorado; University of Colorado System;
   University of Colorado Anschutz Medical Campus; University of Oklahoma
   System; University of Oklahoma Health Sciences Center; China
   Agricultural University; Chinese Academy of Sciences; University of
   Science & Technology of China, CAS; Chengdu University
RP Kappler, JW; Hagman, J; Zhang, GY (通讯作者)，Natl Jewish Hlth, Dept Biomed Res, Denver, CO 80206 USA.; Kappler, JW; Hagman, J; Zhang, GY (通讯作者)，Univ Colorado Denver, Sch Med, Dept Immunol & Microbiol, Denver, CO 80206 USA.; Kappler, JW (通讯作者)，Howard Hughes Med Inst, Denver, CO 80206 USA.; Hagman, J (通讯作者)，Univ Colorado Denver, Sch Med, Dept Biochem & Mol Genet, Aurora, CO 80216 USA.
EM kapplerj@njhealth.org; hagmanj@njhealth.org; ZhangG@NJHealth.org
RI Marrack, Philippa/AHE-6316-2022; Zang, Jianye/E-5228-2013; Liu,
   Xinjian/JXL-9573-2024; Hagman, James/R-7013-2019; chen,
   zhongzhou/E-3900-2015
OI chen, zhongzhou/0000-0003-1319-9664; Marrack,
   Philippa/0000-0003-1883-3687; Janknecht, Ralf/0000-0003-1741-1562; Liu,
   Xinjian/0000-0002-0157-5717; Hagman, James/0000-0002-5436-8455
FU Howard Hughes Medical Institute (HHMI); NIH [AI109219, AI081878,
   AI115696, AI22295]; NIH Training Grant [5T32AI074491-07]; Training Grant
   [T32AI007405-26]; NIH/National Institute of General Medical Sciences
   [R35GM119575]; Wendy Siegel Fund for Leukemia and Cancer Research; HHMI;
   Cancer Research Institute Predoctoral Emphasis Pathway in Tumor
   Immunology fellowship
FX We thank Nicole Dufour, Monika Dzieciatkowska, Frances Crawford, Kara
   Lukin, Desiree Straign, Gina Gill, Ryan Walsh, Abbey Esbenson, Peter
   Henson, James Crapo, and other researchers at National Jewish Health for
   their kind support; Dr. Thiago Detanico and Lawrence J. Wysocki for
   providing calf chromatin; Dr. Joanie Hevel for PRMT1 cDNA; Drs. Ruimin
   Xu and Na Yang for PRMT5 cDNA; Dr. Mark T. Bedford for PRMT6 cDNA; and
   Dr. Yunyu Shi for PRMT7 cDNA. H.L. is partially supported by Howard
   Hughes Medical Institute (HHMI), NIH Grant AI109219 (to G.Z.), and NIH
   Training Grant 5T32AI074491-07. S.L. is supported by Training Grant
   T32AI007405-26 (to P.M.). A.M.J. was supported by R35GM119575 from
   NIH/National Institute of General Medical Sciences. J.H. was supported
   by NIH Grants AI081878 and AI115696, and the Wendy Siegel Fund for
   Leukemia and Cancer Research. P.M. and J.W.K. are supported by HHMI.
   C.D. was supported by a Cancer Research Institute Predoctoral Emphasis
   Pathway in Tumor Immunology fellowship. C.W. and G.Z. were partially
   supported by NIH AI22295 (to P.M.), AI115696 (to J.H.), and AI109219 (to
   G.Z.).
CR Allis CD, 2016, NAT REV GENET, V17, P487, DOI 10.1038/nrg.2016.59
   ALLIS CD, 1980, CELL, V20, P55
   Ammar R, 2012, ELIFE, V1, DOI 10.7554/eLife.00078
   Boeckel JN, 2011, P NATL ACAD SCI USA, V108, P3276, DOI 10.1073/pnas.1008098108
   Branscombe TL, 2001, J BIOL CHEM, V276, P32971, DOI 10.1074/jbc.M105412200
   Chang BS, 2007, SCIENCE, V318, P444, DOI 10.1126/science.1145801
   Chen ZZ, 2006, CELL, V125, P691, DOI 10.1016/j.cell.2006.04.024
   Chen ZZ, 2007, P NATL ACAD SCI USA, V104, P10818, DOI 10.1073/pnas.0704525104
   COMMERFORD SL, 1982, P NATL ACAD SCI-BIOL, V79, P1163, DOI 10.1073/pnas.79.4.1163
   Cuthbert GL, 2004, CELL, V118, P545, DOI 10.1016/j.cell.2004.08.020
   Del Rizzo PA, 2012, MOL CELL BIOL, V32, P4044, DOI 10.1128/MCB.00513-12
   Dhaenens M, 2015, BIOESSAYS, V37, P70, DOI 10.1002/bies.201400118
   Di Lorenzo A, 2011, FEBS LETT, V585, P2024, DOI 10.1016/j.febslet.2010.11.010
   Duncan EM, 2008, CELL, V135, P284, DOI 10.1016/j.cell.2008.09.055
   Duncan EM, 2011, PROG DRUG RES, V67, P69, DOI 10.1007/978-3-7643-8989-5_4
   Guccione E, 2007, NATURE, V449, P933, DOI 10.1038/nature06166
   Han G, 2012, J CELL BIOCHEM, V113, P1663, DOI 10.1002/jcb.24035
   Henikoff S, 2016, CSH PERSPECT MED, V6, DOI 10.1101/cshperspect.a026666
   Hong X, 2010, P NATL ACAD SCI USA, V107, P14568, DOI 10.1073/pnas.1008832107
   Hsia DA, 2010, P NATL ACAD SCI USA, V107, P9671, DOI 10.1073/pnas.1000401107
   Hyllus D, 2007, GENE DEV, V21, P3369, DOI 10.1101/gad.447007
   Iberg AN, 2008, J BIOL CHEM, V283, P3006, DOI 10.1074/jbc.C700192200
   Johansson C, 2014, EPIGENOMICS-UK, V6, P89, DOI 10.2217/epi.13.79
   Kadoch C, 2016, BIOCHEMISTRY-US, V55, P1600, DOI 10.1021/acs.biochem.5b01191
   Klose RJ, 2006, NAT REV GENET, V7, P715, DOI 10.1038/nrg1945
   Koster MJE, 2015, CELL, V161, P724, DOI 10.1016/j.cell.2015.04.033
   Leslie CC, 2015, J LIPID RES, V56, P1386, DOI 10.1194/jlr.R057588
   Liu K, 2010, P NATL ACAD SCI USA, V107, P18398, DOI 10.1073/pnas.1013106107
   Liu W, 2013, CELL, V155, P1581, DOI 10.1016/j.cell.2013.10.056
   Martinez S, 2015, J BIOL CHEM, V290, P20702, DOI 10.1074/jbc.R115.648691
   Matsunami N, 2014, MOL AUTISM, V5, DOI 10.1186/2040-2392-5-5
   Musselman CA, 2012, NAT STRUCT MOL BIOL, V19, P1218, DOI 10.1038/nsmb.2436
   Oh S, 2012, BIOCHEM BIOPH RES CO, V420, P61, DOI 10.1016/j.bbrc.2012.02.115
   Pereira SL, 1998, EXTREMOPHILES, V2, P141, DOI 10.1007/s007920050053
   Pollack BP, 1999, J BIOL CHEM, V274, P31531, DOI 10.1074/jbc.274.44.31531
   Ptashne M, 1997, NATURE, V386, P569, DOI 10.1038/386569a0
   Rothbart SB, 2015, MOL CELL, V59, P502, DOI 10.1016/j.molcel.2015.06.022
   Santos-Rosa H, 2009, NAT STRUCT MOL BIOL, V16, P17, DOI 10.1038/nsmb.1534
   Shen L, 2014, ANNU REV BIOCHEM, V83, P585, DOI 10.1146/annurev-biochem-060713-035513
   Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012
   Simmons JM, 2008, DALTON T, P5132, DOI 10.1039/b803512a
   Strahl BD, 2001, CURR BIOL, V11, P996, DOI 10.1016/S0960-9822(01)00294-9
   Unoki M, 2013, J BIOL CHEM, V288, P6053, DOI 10.1074/jbc.M112.433284
   Venkatesh S, 2015, NAT REV MOL CELL BIO, V16, P178, DOI 10.1038/nrm3941
   Walport LJ, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11974
   Wang CY, 2014, STRUCTURE, V22, P756, DOI 10.1016/j.str.2014.03.003
   Wang F, 2014, PLOS BIOL, V12, DOI 10.1371/journal.pbio.1001819
   Wang HP, 2013, ACTA CRYSTALLOGR D, V69, P1911, DOI 10.1107/S0907444913016600
   Wang HB, 2001, SCIENCE, V293, P853, DOI 10.1126/science.1060781
   Wang HJ, 2014, P NATL ACAD SCI USA, V111, P279, DOI 10.1073/pnas.1311249111
   Wang Y, 2004, SCIENCE, V306, P279, DOI 10.1126/science.1101400
   Webby CJ, 2009, SCIENCE, V325, P90, DOI 10.1126/science.1175865
   Whetstine JR, 2006, CELL, V125, P467, DOI 10.1016/j.cell.2006.03.028
   Zhang GY, 1999, CELL, V98, P811, DOI 10.1016/S0092-8674(00)81515-9
   Zhang XS, 2012, P NATL ACAD SCI USA, V109, P13331, DOI 10.1073/pnas.1203280109
   Zhao ZH, 2015, INT J CLIN EXP PATHO, V8, P10325
   Zhou P, 2014, CURR MOL MED, V14, P1164, DOI 10.2174/1566524014666141015155630
   Zhu H, 2014, STEM CELLS, V32, P2098, DOI 10.1002/stem.1724
   Zufferey R, 1997, NAT BIOTECHNOL, V15, P871, DOI 10.1038/nbt0997-871
NR 59
TC 49
Z9 53
U1 2
U2 19
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD SEP 12
PY 2017
VL 114
IS 37
BP E7717
EP E7726
DI 10.1073/pnas.1706831114
PG 10
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA FG4YP
UT WOS:000410293400008
PM 28847961
OA Bronze, Green Published
DA 2025-01-12
ER

PT J
AU Breindel, JL
   Skibinski, A
   Sedic, M
   Wronski-Campos, A
   Zhou, WH
   Keller, PJ
   Mills, J
   Bradner, J
   Onder, T
   Kuperwasser, C
AF Breindel, Jerrica L.
   Skibinski, Adam
   Sedic, Maja
   Wronski-Campos, Ania
   Zhou, Wenhui
   Keller, Patricia J.
   Mills, Joslyn
   Bradner, James
   Onder, Tamer
   Kuperwasser, Charlotte
TI Epigenetic Reprogramming of Lineage-Committed Human Mammary Epithelial
   Cells Requires DNMT3A and Loss of DOT1L
SO STEM CELL REPORTS
LA English
DT Article
ID BREAST-CANCER; STEM-CELLS; GLAND DEVELOPMENT; DNA METHYLATION;
   EXPRESSION; GENE; CARCINOGENESIS; INACTIVATION; SENESCENCE; ESCAPE
AB Organogenesis and tissue development occur through sequential stepwise processes leading to increased lineage restriction and loss of pluripotency. An exception to this appears in the adult human breast, where rare variant epithelial cells exhibit pluripotency and multilineage differentiation potential when removed from the signals of their native microenvironment. This phenomenon provides a unique opportunity to study mechanisms that lead to cellular reprogramming and lineage plasticity in real time. Here, we show that primary humanmammary epithelial cells (HMECs) lose expression of differentiated mammary epithelial markers in a manner dependent on paracrine factors and epigenetic regulation. Furthermore, we demonstrate that HMEC reprogramming is dependent on gene silencing by the DNA methyltransferase DNMT3A and loss of histone transcriptional marks following downregulation of the methyltransferase DOT1L. These results demonstrate that lineage commitment in adult tissues is context dependent and highlight the plasticity of somatic cells when removed from their native tissue microenvironment.
C1 [Breindel, Jerrica L.; Skibinski, Adam; Sedic, Maja; Wronski-Campos, Ania; Zhou, Wenhui; Keller, Patricia J.; Mills, Joslyn; Kuperwasser, Charlotte] Tufts Univ, Sch Med, Sackler Sch Grad Biomed Sci, Dept Dev Chem & Mol Biol, 136 Harrison Ave, Boston, MA 02111 USA.
   [Breindel, Jerrica L.; Skibinski, Adam; Sedic, Maja; Wronski-Campos, Ania; Zhou, Wenhui; Keller, Patricia J.; Kuperwasser, Charlotte] Tufts Univ, Sch Med, Raymond & Beverly Sackler Convergence Lab, 145 Harrison Ave, Boston, MA 02111 USA.
   [Breindel, Jerrica L.; Skibinski, Adam; Wronski-Campos, Ania; Zhou, Wenhui] Tufts Med Ctr, Mol Oncol Res Inst, 800 Washington St, Boston, MA 02111 USA.
   [Bradner, James] Harvard Med Sch, Dept Med Oncol, Dana Farber Canc Inst, 360 Longwood Ave, Boston, MA 02215 USA.
   [Onder, Tamer] Koc Univ, Sch Med, Rumelifeneri Yolu, Istanbul, Turkey.
C3 Tufts University; Tufts University; Tufts Medical Center; Harvard
   University; Dana-Farber Cancer Institute; Harvard Medical School; Koc
   University
RP Kuperwasser, C (通讯作者)，Tufts Univ, Sch Med, Sackler Sch Grad Biomed Sci, Dept Dev Chem & Mol Biol, 136 Harrison Ave, Boston, MA 02111 USA.; Kuperwasser, C (通讯作者)，Tufts Univ, Sch Med, Raymond & Beverly Sackler Convergence Lab, 145 Harrison Ave, Boston, MA 02111 USA.
EM charlotte.kuperwasser@tufts.edu
RI ; Onder, Tamer/H-3330-2013
OI Zhou, Wenhui/0000-0002-3857-8567; Onder, Tamer/0000-0002-2372-9158
FU Raymond & Beverly Sackler Convergence Laboratory; ArtBeCAUSE, the Breast
   Cancer Research Foundation; NIH [NICDH HD073035, NCI CA170851]; NIGMS
   [K12GM074869]
FX This work was supported by funding from the Raymond & Beverly Sackler
   Convergence Laboratory and grants from ArtBeCAUSE, the Breast Cancer
   Research Foundation, and the NIH (NICDH HD073035 and NCI CA170851).
   J.L.B. is supported by award K12GM074869 from the NIGMS.
CR Nguyen AT, 2011, GENE DEV, V25, P1345, DOI 10.1101/gad.2057811
   Bean GR, 2007, CANCER EPIDEM BIOMAR, V16, P50, DOI 10.1158/1055-9965.EPI-06-0598
   Brenner AJ, 1998, ONCOGENE, V17, P199, DOI 10.1038/sj.onc.1201919
   Cregan MD, 2007, CELL TISSUE RES, V329, P129, DOI 10.1007/s00441-007-0390-x
   Feng Q, 2002, CURR BIOL, V12, P1052, DOI 10.1016/S0960-9822(02)00901-6
   Foster SA, 1996, ONCOGENE, V12, P1773
   Garbe JC, 2009, CANCER RES, V69, P7557, DOI 10.1158/0008-5472.CAN-09-0270
   HERMAN JG, 1995, CANCER RES, V55, P4525
   Hinshelwood RA, 2009, HUM MOL GENET, V18, P3098, DOI 10.1093/hmg/ddp251
   Holst CR, 2003, CANCER RES, V63, P1596
   Hui R, 2000, CLIN CANCER RES, V6, P2777
   Huschtscha LI, 1998, CANCER RES, V58, P3508
   Keller PJ, 2012, P NATL ACAD SCI USA, V109, P2772, DOI 10.1073/pnas.1017626108
   Li H, 2007, CANCER RES, V67, P501, DOI 10.1158/0008-5472.CAN-05-4571
   Li Jan-Xu, 2004, Yichuan, V26, P267
   Locke WJ, 2015, CLIN EPIGENETICS, V7, DOI 10.1186/s13148-015-0086-0
   Locke WJ, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3237
   LURIA SE, 1951, COLD SPRING HARB SYM, V16, P463, DOI 10.1101/SQB.1951.016.01.033
   Macias H, 2012, WIRES DEV BIOL, V1, P533, DOI 10.1002/wdev.35
   Novak P, 2009, CANCER RES, V69, P5251, DOI 10.1158/0008-5472.CAN-08-4977
   Onder TT, 2012, NATURE, V483, P598, DOI 10.1038/nature10953
   Papp B, 2013, CELL, V152, P1324, DOI 10.1016/j.cell.2013.02.043
   Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167
   Romanov SR, 2001, NATURE, V409, P633, DOI 10.1038/35054579
   Roy S, 2013, P NATL ACAD SCI USA, V110, P4598, DOI 10.1073/pnas.1218682110
   STAMPFER M, 1980, IN VITRO CELL DEV B, V16, P415
   Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024
   Van Keymeulen A, 2011, NATURE, V479, P189, DOI 10.1038/nature10573
   Wang WC, 2011, HUM PATHOL, V42, P1430, DOI 10.1016/j.humpath.2010.12.009
   Watson CJ, 2008, DEVELOPMENT, V135, P995, DOI 10.1242/dev.005439
   Yao Y, 2011, J AM CHEM SOC, V133, P16746, DOI 10.1021/ja206312b
NR 32
TC 13
Z9 13
U1 0
U2 4
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 2213-6711
J9 STEM CELL REP
JI Stem Cell Rep.
PD SEP 12
PY 2017
VL 9
IS 3
BP 943
EP 955
DI 10.1016/j.stemcr.2017.06.019
PG 13
WC Cell & Tissue Engineering; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA FG4WO
UT WOS:000410279200018
PM 28781076
OA Green Published
DA 2025-01-12
ER

PT J
AU Zheng, FF
   Yuan, XX
   Chen, EJ
   Ye, YL
   Li, XF
   Dai, YP
AF Zheng, Fufu
   Yuan, Xiaoxu
   Chen, Enjing
   Ye, Yunlin
   Li, Xiaofei
   Dai, Yuping
TI Methylation of <i>STK11</i> promoter is a risk factor for tumor stage
   and survival in clear cell renal cell carcinoma
SO ONCOLOGY LETTERS
LA English
DT Article
DE clear cell renal cell carcinoma; promoter methylation; STK11
ID PEUTZ-JEGHERS-SYNDROME; SOMATIC MUTATIONS; LKB1 GENE; BREAST-CANCER;
   SUPPRESSOR; INACTIVATION; LKB1/STK11; LUNG; EXPRESSION; COMMON
AB Inactivation of tumor suppressor gene serine-threonine kinase 11 (STKII) in clear cell renal cell carcinoma (ccRCC) has been demonstrated; however, the mechanism of this inactivation remains to be investigated. To investigate whether epigenetic alteration plays a role in the inactivation of STKII in RCC, the present study aimed to investigate the methylation status of the STKII promoter and its association with tumor stage and survival in ccRCC patients. Paraffin-embedded specimens were obtained from 42 ccRCC patients. The specimens were analyzed for the methylation status of the STKII promoter CpG island using methylation-specific polymerase chain reaction. Survival, tumor-node-metastasis (TNM)/American Joint Committee on Cancer (AJCC) stages, and hematological parameters were compared between patients with unmethylated (U), partially methylated (P) and methylated (M) STKJJ promoter. Among the 42 patients, there were 12 (28.6%), 18 (42.9%) and 12 (28.6%) patients in the M, P and U groups, respectively. The methylation status of the STKII promoter was associated with T, N and AJCC stages in RCC. Survival analysis showed that the M group had a significantly shorter survival time compared with the P and U groups. These findings suggested that methylation of the STKII promoter in RCC is a not rare event, and it may have an important role in the pathogenesis of RCC and be a risk factor for the prognosis of RCC.
C1 [Zheng, Fufu; Chen, Enjing; Li, Xiaofei; Dai, Yuping] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Urol, Guangzhou 510080, Guangdong, Peoples R China.
   [Yuan, Xiaoxu] Jiangmen Cent Hosp, Dept Urol, Jiangmen 529030, Guangdong, Peoples R China.
   [Ye, Yunlin] Sun Yat Sen Univ, Ctr Canc, Dept Urol, Guangzhou 510060, Guangdong, Peoples R China.
C3 Sun Yat Sen University; Sun Yat Sen University
RP Zheng, FF (通讯作者)，Sun Yat Sen Univ, Affiliated Hosp 1, Dept Urol, Guangzhou 510080, Guangdong, Peoples R China.
EM zffcnj@163.com
RI Li, xiaofei/GXF-7187-2022
FU Science and Technology Foundation of Guangzhou [2014A020212580]
FX The present study was supported by the Science and Technology Foundation
   of Guangzhou (grant no. 2014A020212580).
CR Avizienyte E, 1998, CANCER RES, V58, P2087
   Avizienyte E, 1999, AM J PATHOL, V154, P677, DOI 10.1016/S0002-9440(10)65314-X
   Bignell GR, 1998, CANCER RES, V58, P1384
   Cairns P, 2011, CANCER BIOMARK, V9, P461, DOI 10.3233/CBM-2011-0176
   Cohen HT, 2005, NEW ENGL J MED, V353, P2477, DOI 10.1056/NEJMra043172
   Duivenvoorden WC, 2013, BRIT J CANCER, V108, P327, DOI 10.1038/bjc.2012.574
   Esteller M, 2000, ONCOGENE, V19, P164, DOI 10.1038/sj.onc.1203227
   Fenton H, 2006, APPL IMMUNOHISTO M M, V14, P146, DOI 10.1097/01.pai.0000176157.07908.20
   Gan RY, 2014, INT J MOL SCI, V15, P16698, DOI 10.3390/ijms150916698
   Jenne DE, 1998, NAT GENET, V18, P38, DOI 10.1038/ng0198-38
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   Kim CJ, 2004, EUR J CANCER, V40, P136, DOI 10.1016/S0959-8049(03)00659-2
   Koivunen JP, 2008, BRIT J CANCER, V99, P245, DOI 10.1038/sj.bjc.6604469
   Lee SM, 2013, LUNG CANCER, V81, P194, DOI 10.1016/j.lungcan.2013.04.013
   McLaughlin JK, 2006, SEMIN ONCOL, V33, P527, DOI 10.1053/j.seminoncol.2006.06.010
   Nakau M, 2002, CANCER RES, V62, P4549
   Qin C, 2013, ASIAN J ANDROL, V15, P550, DOI 10.1038/aja.2012.161
   Robinson J, 2008, EXP MOL PATHOL, V85, P223, DOI 10.1016/j.yexmp.2008.07.005
   Sanchez-Cespedes M, 2002, CANCER RES, V62, P3659
   Sato N, 2001, AM J PATHOL, V159, P2017, DOI 10.1016/S0002-9440(10)63053-2
   Su GH, 1999, AM J PATHOL, V154, P1835, DOI 10.1016/S0002-9440(10)65440-5
   Trojan J, 2000, GUT, V47, P272, DOI 10.1136/gut.47.2.272
   Yalniz Z, 2014, TUMOR BIOL, V35, P12361, DOI 10.1007/s13277-014-2550-4
   Zhao RX, 2014, CURR DRUG TARGETS, V15, P32, DOI 10.2174/1389450114666140106095811
NR 24
TC 8
Z9 8
U1 0
U2 6
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1792-1074
EI 1792-1082
J9 ONCOL LETT
JI Oncol. Lett.
PD SEP
PY 2017
VL 14
IS 3
BP 3065
EP 3070
DI 10.3892/ol.2017.6534
PN A
PG 6
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA FF0NE
UT WOS:000408597600069
PM 28927054
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Li, QL
   Lei, PJ
   Zhao, QY
   Li, LY
   Wei, G
   Wu, M
AF Li, Qing-Lan
   Lei, Pin-Ji
   Zhao, Quan-Yi
   Li, Lianyun
   Wei, Gang
   Wu, Min
TI Epigenomic analysis in a cell-based model reveals the roles of H3K9me3
   in breast cancer transformation
SO EPIGENOMICS
LA English
DT Article
DE breast cancer transformation; epigenomics; genome stability; H3K9me3;
   transcription regulation
ID DNA-DAMAGE RESPONSE; MALIGNANT-TRANSFORMATION; SOMATIC MUTATIONS;
   CHROMATIN; METHYLATION; GENES; SETD2; EZH2; HETEROCHROMATIN;
   IDENTIFICATION
AB Aim: Epigenetic marks are critical regulators of chromatin and gene activity. Their roles in normal physiology and disease states, including cancer development, still remain elusive. Herein, the epigenomic change of H3K9me3, as well as its potential impacts on gene activity and genome stability, was investigated in an in vitro breast cancer transformation model. Methods: The global H3K9me3 level was studied with western blotting. The distribution of H3K9me3 on chromatin and gene expression was studied with ChIP-Seq and RNA-Seq, respectively. Results: The global H3K9me3 level decreases during transformation and its distribution on chromatin is reprogrammed. By combining with TCGA data, we identified 67 candidate oncogenes, among which five genes are totally novel. Our analysis further links H3K9me3 with transposon activity, and suggests H3K9me3 reduction increases the cell's sensitivity to DNA damage reagents. Conclusion: H3K9me3 reduction is possibly related with breast cancer transformation by regulating gene expression and chromatin stability during transformation.
C1 [Li, Qing-Lan; Lei, Pin-Ji; Zhao, Quan-Yi; Li, Lianyun; Wu, Min] Wuhan Univ, Dept Biochem & Mol Biol, Coll Life Sci, Hubei Key Lab Cell Homeostasis,Hubei Key Lab Dev, Wuhan 430072, Hubei, Peoples R China.
   [Wei, Gang] Chinese Acad Sci, Shanghai Inst Biol Sci, CAS MPG Partner Inst Computat Biol, Key Lab Computat Biol, Shanghai 200031, Peoples R China.
C3 Wuhan University; Max Planck Society; Chinese Academy of Sciences
RP Wu, M (通讯作者)，Wuhan Univ, Dept Biochem & Mol Biol, Coll Life Sci, Hubei Key Lab Cell Homeostasis,Hubei Key Lab Dev, Wuhan 430072, Hubei, Peoples R China.; Wei, G (通讯作者)，Chinese Acad Sci, Shanghai Inst Biol Sci, CAS MPG Partner Inst Computat Biol, Key Lab Computat Biol, Shanghai 200031, Peoples R China.
EM weigang77@gmail.com; wumin@whu.edu.cn
RI Lei, Pin-Ji/AAX-1878-2021; WEI, GANG/AGL-1853-2022; Wu,
   Min/AAE-5066-2021
OI Li, Lianyun/0000-0003-4194-3059; Zhao, Quanyi/0000-0001-9849-4528; Lei,
   Pin-Ji/0000-0003-2539-5179; Wu, Min/0000-0003-1372-4764
FU Ministry of Science and Technology of China [2016YFA0502100]; National
   Natural Science Foundation of China [31470771, 31521091, 31370866,
   31540013, 31670874]
FX This work was supported by grants from the Ministry of Science and
   Technology of China (2016YFA0502100), National Natural Science
   Foundation of China to M Wu (31470771 and 31521091) and L Li (31370866,
   31540013 and 31670874). The authors have no other relevant affiliations
   or financial involvement with any organization or entity with a
   financial interest in or financial conflict with the subject matter or
   materials discussed in the manuscript apart from those disclosed.
CR Alpen B, 2002, GENE, V297, P141, DOI 10.1016/S0378-1119(02)00879-X
   Béguelin W, 2013, CANCER CELL, V23, P677, DOI 10.1016/j.ccr.2013.04.011
   Black JC, 2013, CELL, V154, P541, DOI 10.1016/j.cell.2013.06.051
   Black JC, 2012, MOL CELL, V48, P491, DOI 10.1016/j.molcel.2012.11.006
   Buckley Reuben M, 2014, Biomol Concepts, V5, P183, DOI 10.1515/bmc-2014-0013
   Cai SF, 2015, MOL CELL, V60, P561, DOI 10.1016/j.molcel.2015.10.042
   Cann KL, 2011, BIOCHEM CELL BIOL, V89, P45, DOI 10.1139/O10-113
   Carvalho S, 2014, ELIFE, V3, DOI 10.7554/eLife.02482
   Chen L, 2014, BRIT J CANCER, V110, P1014, DOI 10.1038/bjc.2013.808
   Creighton CJ, 2013, NATURE, V499, P43, DOI 10.1038/nature12222
   Danielsson F, 2013, P NATL ACAD SCI USA, V110, P6853, DOI 10.1073/pnas.1216436110
   Dinant C, 2009, MOL CELL BIOL, V29, P6335, DOI 10.1128/MCB.01048-09
   Easwaran H, 2014, MOL CELL, V54, P716, DOI 10.1016/j.molcel.2014.05.015
   Elenbaas B, 2001, GENE DEV, V15, P50, DOI 10.1101/gad.828901
   Ellis L, 2009, MOL CANCER THER, V8, P1409, DOI 10.1158/1535-7163.MCT-08-0860
   Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI [10.1056/NEJMra072067, 10.1093/carcin/bgp220]
   Fontebasso AM, 2013, ACTA NEUROPATHOL, V125, P659, DOI 10.1007/s00401-013-1095-8
   Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780
   Herz HM, 2013, TRENDS BIOCHEM SCI, V38, P621, DOI 10.1016/j.tibs.2013.09.004
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Ibragimova I, 2013, EPIGENETICS-US, V8, P486, DOI 10.4161/epi.24552
   Kandoth C, 2013, NATURE, V502, P333, DOI 10.1038/nature12634
   Krieg AJ, 2010, MOL CELL BIOL, V30, P344, DOI 10.1128/MCB.00444-09
   Laston SL, 2015, FRONT GENET, V6, DOI 10.3389/fgene.2015.00006
   Lawrence MS, 2014, NATURE, V505, P495, DOI 10.1038/nature12912
   Lemaître C, 2014, DNA REPAIR, V19, P163, DOI 10.1016/j.dnarep.2014.03.015
   Li F, 2013, CELL, V153, P590, DOI 10.1016/j.cell.2013.03.025
   Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324
   Mallette FA, 2012, CELL REP, V2, P1233, DOI 10.1016/j.celrep.2012.09.033
   Maresco DL, 1998, CYTOGENET CELL GENET, V82, P71, DOI 10.1159/000015067
   Matsumura Y, 2015, MOL CELL, V60, P584, DOI 10.1016/j.molcel.2015.10.025
   McCabe MT, 2012, NATURE, V492, P108, DOI 10.1038/nature11606
   Morin RD, 2010, NAT GENET, V42, P181, DOI 10.1038/ng.518
   Murillas R, 2002, J BIOL CHEM, V277, P2897, DOI 10.1074/jbc.M110047200
   Odunsi K, 2003, CANCER RES, V63, P6076
   Peters AHFM, 2003, MOL CELL, V12, P1577, DOI 10.1016/S1097-2765(03)00477-5
   Pfister SX, 2014, CELL REP, V7, P2006, DOI 10.1016/j.celrep.2014.05.026
   Plath K, 2003, SCIENCE, V300, P131, DOI 10.1126/science.1084274
   Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506
   Rodríguez-Paredes M, 2011, NAT MED, V17, P330, DOI 10.1038/nm.2305
   Sharma SV, 2010, CELL, V141, P69, DOI 10.1016/j.cell.2010.02.027
   Shilatifard A, 2006, ANNU REV BIOCHEM, V75, P243, DOI 10.1146/annurev.biochem.75.103004.142422
   Sienski G, 2012, CELL, V151, P964, DOI 10.1016/j.cell.2012.10.040
   Vad-Nielsen J, 2015, CANCER BIOL THER, V16, P189, DOI 10.1080/15384047.2014.1001277
   Wade MA, 2015, NUCLEIC ACIDS RES, V43, P196, DOI 10.1093/nar/gku1298
   Watson IR, 2013, NAT REV GENET, V14, P703, DOI 10.1038/nrg3539
   Wen B, 2009, NAT GENET, V41, P246, DOI 10.1038/ng.297
   Xu KX, 2012, SCIENCE, V338, P1465, DOI 10.1126/science.1227604
   Young LC, 2013, BIOCHEM CELL BIOL, V91, P369, DOI 10.1139/bcb-2012-0054
   Zamudio N, 2015, GENE DEV, V29, P1256, DOI 10.1101/gad.257840.114
   Zang CZ, 2009, BIOINFORMATICS, V25, P1952, DOI 10.1093/bioinformatics/btp340
   Zeng G, 2005, INT J CANCER, V114, P268, DOI 10.1002/ijc.20716
   Zeng W, 2010, EPIGENETICS-US, V5, P287, DOI 10.4161/epi.5.4.11683
   Zhao QY, 2016, CLIN EPIGENETICS, V8, DOI 10.1186/s13148-016-0201-x
   Zhao X, 2016, CELL BIOCHEM FUNCT, V34, P238, DOI 10.1002/cbf.3185
   Zhu K, 2017, NUCLEIC ACIDS RES, V45, P92, DOI 10.1093/nar/gkw814
   Zhu XF, 2014, NAT GENET, V46, P287, DOI 10.1038/ng.2894
NR 57
TC 12
Z9 13
U1 2
U2 17
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
   1QB, ENGLAND
SN 1750-1911
EI 1750-192X
J9 EPIGENOMICS-UK
JI Epigenomics
PD AUG
PY 2017
VL 9
IS 8
BP 1077
EP 1092
DI 10.2217/epi-2016-0183
PG 16
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA FF1FQ
UT WOS:000408645600004
PM 28762778
DA 2025-01-12
ER

PT J
AU Li, YY
   Meeran, SM
   Tollefsbol, TO
AF Li, Yuanyuan
   Meeran, Syed M.
   Tollefsbol, Trygve O.
TI Combinatorial bioactive botanicals re-sensitize tamoxifen treatment in
   ER-negative breast cancer via epigenetic reactivation of ERα expression
SO SCIENTIFIC REPORTS
LA English
DT Article
ID ESTROGEN-RECEPTOR-ALPHA; DNA METHYLTRANSFERASE; GREEN TEA; METHYLATION;
   SULFORAPHANE; THERAPY; (-)-EPIGALLOCATECHIN-3-GALLATE; PHARMACOKINETICS;
   PROLIFERATION; INHIBITION
AB Conventional cancer prevention has primarily focused on single chemopreventive compounds that may not be sufficiently efficacious. We sought to investigate potential combinatorial effects of epigenetic bioactive botanicals including epigallocatechin-3-gallate (EGCG) in green tea polyphenols (GTPs) and sulforaphane (SFN) in broccoli sprouts (BSp) on neutralizing epigenetic aberrations in estrogen receptor-alpha (ER alpha) leading to enhanced anti-hormone therapeutic efficacy in ER alpha-negative breast cancer. Our results showed that this combinatorial treatment re-sensitized ER alpha-dependent cellular inhibitory responses to an estrogen antagonist, tamoxifen (TAM), via at least in part, epigenetic reactivation of ER alpha expression in ER alpha-negative breast cancer cells. Further in vivo studies revealed the combinatorial diets of GTPs and BSp significantly inhibited breast tumor growth in ER alpha-negative mouse xenografts, especially when combined with TAM treatment. This novel treatment regimen can lead to remodeling of the chromatin structure by histone modifications and recruitment changes of transcriptional factor complex in the ER alpha promoter thereby contributing to ER alpha reactivation and re-sensitized chemotherapeutic efficacy of anti-hormone therapy. Our studies indicate that combinatorial bioactive botanicals from GTPs and BSp are highly effective in inhibiting ER alpha-negative breast cancer due at least in part to epigenetic reactivation of ER alpha, which in turn increases TAM-dependent anti-estrogen chemosensitivity in vitro and in vivo.
C1 [Li, Yuanyuan; Tollefsbol, Trygve O.] Univ Alabama Birmingham, Dept Biol, Birmingham, AL 35294 USA.
   [Li, Yuanyuan; Tollefsbol, Trygve O.] Univ Alabama Birmingham, Comprehens Canc Ctr, Birmingham, AL 35294 USA.
   [Li, Yuanyuan; Tollefsbol, Trygve O.] Univ Alabama Birmingham, Nutr Obes Res Ctr, Birmingham, AL 35294 USA.
   [Meeran, Syed M.] CSIR, Cent Food Technol Res Inst, Dept Biochem, Mysore 570019, Karnataka, India.
   [Tollefsbol, Trygve O.] Univ Alabama Birmingham, Comprehens Ctr Hlth Aging, Birmingham, AL 35294 USA.
C3 University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham; Council
   of Scientific & Industrial Research (CSIR) - India; CSIR - Central Food
   Technological Research Institute (CFTRI); University of Alabama System;
   University of Alabama Birmingham
RP Li, YY (通讯作者)，Univ Alabama Birmingham, Dept Biol, Birmingham, AL 35294 USA.; Li, YY (通讯作者)，Univ Alabama Birmingham, Comprehens Canc Ctr, Birmingham, AL 35294 USA.; Li, YY (通讯作者)，Univ Alabama Birmingham, Nutr Obes Res Ctr, Birmingham, AL 35294 USA.
EM lyy@uab.edu
RI Meeran, Syed/AAG-2157-2020
FU National Cancer Institute [R01 CA178441, R03 CA176766]; American
   Institute for Cancer Research [316184]
FX This work was supported by grants from the National Cancer Institute
   (R01 CA178441; R03 CA176766) and the American Institute for Cancer
   Research (316184).
CR Bovenzi V, 2001, CANCER CHEMOTH PHARM, V48, P71, DOI 10.1007/s002800100294
   Carruba G, 2016, IMMUN AGEING, V13, DOI 10.1186/s12979-016-0069-9
   Cheung KL, 2010, AAPS J, V12, P87, DOI 10.1208/s12248-009-9162-8
   Choi KC, 2009, CANCER RES, V69, P583, DOI 10.1158/0008-5472.CAN-08-2442
   Chou TC, 2006, PHARMACOL REV, V58, P621, DOI 10.1124/pr.58.3.10
   Clarke R, 2003, ONCOGENE, V22, P7316, DOI 10.1038/sj.onc.1206937
   Esteller M, 2007, NAT REV GENET, V8, P286, DOI 10.1038/nrg2005
   Fang MZ, 2007, J NUTR, V137, p223S, DOI 10.1093/jn/137.1.223S
   Fang MZ, 2003, CANCER RES, V63, P7563
   GLOVER AB, 1987, CANCER TREAT REP, V71, P737
   Glozak MA, 2007, ONCOGENE, V26, P5420, DOI 10.1038/sj.onc.1210610
   Gnyszka A, 2013, ANTICANCER RES, V33, P2989
   Gross JM, 2002, BREAST CANCER RES, V4, P62, DOI 10.1186/bcr424
   Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664
   Gryder BE, 2013, J MED CHEM, V56, P5782, DOI 10.1021/jm400467w
   Hardy TM, 2011, EPIGENOMICS-UK, V3, P503, DOI [10.2217/EPI.11.71, 10.2217/epi.11.71]
   Higdon JV, 2007, PHARMACOL RES, V55, P224, DOI 10.1016/j.phrs.2007.01.009
   Ho E, 2009, J NUTR, V139, P2393, DOI 10.3945/jn.109.113332
   HORWITZ KB, 1978, ENDOCRINOLOGY, V103, P1742, DOI 10.1210/endo-103-5-1742
   Juergens RA, 2011, CANCER DISCOV, V1, P598, DOI 10.1158/2159-8290.CD-11-0214
   Juo YY, 2015, EPIGENOMICS-UK, V7, P215, DOI [10.2217/EPI.14.73, 10.2217/epi.14.73]
   Kala R, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0155057
   Laird PW, 1996, ANNU REV GENET, V30, P441, DOI 10.1146/annurev.genet.30.1.441
   Lee MJ, 2002, CANCER EPIDEM BIOMAR, V11, P1025
   Lehrmann H, 2002, ADV CANCER RES, V86, P41, DOI 10.1016/S0065-230X(02)86002-X
   Li Y, 2010, CURR MED CHEM, V17, P2141, DOI 10.2174/092986710791299966
   Li YY, 2016, EPIGENOMICS-UK, V8, P1019, DOI 10.2217/epi-2016-0024
   Li YY, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-9
   Li YY, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-274
   Lin Jen-Kun, 2000, Proceedings of the National Science Council Republic of China Part B Life Sciences, V24, P1
   Macaluso M, 2003, ONCOGENE, V22, P3511, DOI 10.1038/sj.onc.1206578
   Meeran SM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037748
   Meeran SM, 2011, CANCER PREV RES, V4, P1243, DOI 10.1158/1940-6207.CAPR-11-0009
   Meeran SM, 2010, CLIN EPIGENETICS, V1, DOI 10.1007/s13148-010-0011-5
   Meeran SM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011457
   OTTAVIANO YL, 1994, CANCER RES, V54, P2552
   Paul DS, 2014, TRENDS MOL MED, V20, P541, DOI 10.1016/j.molmed.2014.07.002
   Pledgie-Tracy A, 2007, MOL CANCER THER, V6, P1013, DOI 10.1158/1535-7163.MCT-06-0494
   Sapienza C, 2016, ANNU REV NUTR, V36, P665, DOI 10.1146/annurev-nutr-121415-112634
   Shao WL, 2004, BREAST CANCER RES, V6, P39, DOI 10.1186/bcr742
   Shen G, 2007, CANCER RES, V67, P9937, DOI 10.1158/0008-5472.CAN-07-1112
   Thakur VS, 2012, CURR PHARM BIOTECHNO, V13, P191
   Thangapazham RL, 2007, CANCER LETT, V245, P232, DOI 10.1016/j.canlet.2006.01.027
   Vanhaecke T, 2004, CURR MED CHEM, V11, P1629, DOI 10.2174/0929867043365099
   Vaute O, 2002, NUCLEIC ACIDS RES, V30, P475, DOI 10.1093/nar/30.2.475
   Yang CS, 2001, ANNU REV NUTR, V21, P381, DOI 10.1146/annurev.nutr.21.1.381
   Yang XW, 2000, CANCER RES, V60, P6890
   Ye LX, 2002, CLIN CHIM ACTA, V316, P43, DOI 10.1016/S0009-8981(01)00727-6
   Zhao HX, 2016, BRIT J RADIOL, V89, DOI 10.1259/bjr.20150665
NR 49
TC 56
Z9 65
U1 1
U2 14
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD AUG 24
PY 2017
VL 7
AR 9345
DI 10.1038/s41598-017-09764-3
PG 15
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA FE8FS
UT WOS:000408441600069
PM 28839265
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Lee, MH
   Cho, ER
   Lim, JE
   Jee, SH
AF Lee, Mi Hwa
   Cho, Eo Rin
   Lim, Jung-eun
   Jee, Sun Ha
TI Association between serum persistent organic pollutants and DNA
   methylation in Korean adults
SO ENVIRONMENTAL RESEARCH
LA English
DT Article
DE Persistent organic pollutants (POPs); DNA methylation; Alu; LINE-1;
   Epigenetics
ID PROSTATE-CANCER; NATIONAL-HEALTH; DIETARY-INTAKE; BREAST-CANCER;
   METAANALYSIS; EPIGENETICS; PESTICIDES; WOMEN; HYPOMETHYLATION;
   REPRESSION
AB Background: Exposure to persistent organic pollutants (POPs) has been associated with epigenetic changes such as DNA methylation, which can influence human health. However, the association between POPs and DNA methylation by sex was not shown in previous studies.
   Objectives: We investigated the association between POPs and DNA methylation in men and women using a larger population.
   Methods: A cross-sectional study was conducted using the data of 444 Koreans (253 men and 191 women). Measurements for sixteen different POPs, including six organochlorine pesticides (OCPs) and ten polychlorinated biphenyls (PCBs) were taken in serum. DNA methylation via Alu and LINE-1 in peripheral leukocytes was measured by pyrosequencing. To evaluate the association between POPs and DNA methylation, the Pearson's correlation and multiple linear regression analyses were performed.
   Results: Except for PCB52 and PCB101, we found significant inverse associations between p,p'-DDE, cis Heptachlor epoxide, and PCBs and Alu assay in men after adjusting for age, BMI, smoking status, and alcohol consumption (beta = -0.67 for p,p'-DDE; -0.28 for cis-Heptachlor epoxide; in the range from -0.43 to -1.60 for PCBs). In women, PCB153 and PCB180 showed statistically significant inverse association with Alu assay (13 = -0.22 for PCB153; -0.22 for PCB180). Except for PCB101, p,p'-DDE and PCBs were positively associated with LINE-1 assay in women (beta = 0.48 for p,p'-DDE; in the range from 0.40-0.89 for PCBs) while p,p'-DDE, PCB153, and PCB180 showed positive associations with LINE-1 assay in men (beta = 0.55 for p,p'-DDE; 0.65 for PCB153; 1.02 for PCB180).
   Conclusions: We found that several POPs were associated with global DNA hypomethylation in the Alu assay for men and global DNA hypermethylation in the LINE-1 assay for women.
C1 [Lee, Mi Hwa] Hanyang Univ, Inst Hlth & Soc, Seoul, South Korea.
   [Cho, Eo Rin; Lim, Jung-eun; Jee, Sun Ha] Yonsei Univ, Grad Sch Publ Hlth, Inst Hlth Promot, Seoul, South Korea.
   [Cho, Eo Rin; Lim, Jung-eun; Jee, Sun Ha] Yonsei Univ, Grad Sch Publ Hlth, Dept Epidemiol & Hlth Promot, Seoul, South Korea.
   [Lim, Jung-eun] Ewha Womans Univ, Coll Pharm, Seoul, South Korea.
C3 Hanyang University; Yonsei University; Yonsei University Health System;
   Yonsei University; Yonsei University Health System; Ewha Womans
   University
RP Jee, SH (通讯作者)，Yonsei Univ, Grad Sch Publ Hlth, Inst Hlth Promot, Seoul, South Korea.; Jee, SH (通讯作者)，Yonsei Univ, Grad Sch Publ Hlth, Dept Epidemiol & Hlth Promot, Seoul, South Korea.
EM jsunha@yuhs.ac
RI Wang, Zhe/AGZ-4159-2022
OI Jee, Sun Ha/0000-0001-9519-3068
FU Ministry of Food and Drug Safety [13162MFDS891, 15162MFDS631]
FX This research was supported by a grant (13162MFDS891) from the Ministry
   of Food and Drug Safety in 2013 and a grant (15162MFDS631) from the
   Ministry of Food and Drug Safety in 2015.
CR Baars AJ, 2004, TOXICOL LETT, V151, P51, DOI 10.1016/j.toxlet.2004.01.028
   Bollati V, 2007, CANCER RES, V67, P876, DOI 10.1158/0008-5472.CAN-06-2995
   Brustad M, 2007, J ENVIRON MONITOR, V9, P682, DOI 10.1039/b706302b
   Chu SG, 2003, J ENVIRON MONITOR, V5, P521, DOI 10.1039/b300949a
   Collotta M, 2013, TOXICOLOGY, V307, P35, DOI 10.1016/j.tox.2013.01.017
   Deutch B, 2000, DAN MED BULL, V47, P132
   Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI [10.1056/NEJMra072067, 10.1093/carcin/bgp220]
   Huen K, 2014, ENVIRON MOL MUTAGEN, V55, P209, DOI 10.1002/em.21845
   International Agency for Research on Cancer (IARC), List of Classifications
   Itoh H, 2014, SCI TOTAL ENVIRON, V490, P603, DOI 10.1016/j.scitotenv.2014.05.035
   Jaffe AE, 2014, GENOME BIOL, V15, DOI 10.1186/gb-2014-15-2-r31
   Kang JH, 2008, CHEMOSPHERE, V73, P1625, DOI 10.1016/j.chemosphere.2008.07.087
   Khanjani N, 2007, J ENVIRON SCI HEAL C, V25, P23, DOI 10.1080/10590500701201711
   Kim KY, 2010, ENVIRON HEALTH PERSP, V118, P370, DOI 10.1289/ehp.0901131
   Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062
   Lee DH, 2007, DIABETOLOGIA, V50, P1841, DOI 10.1007/s00125-007-0755-4
   Lee DH, 2006, DIABETES CARE, V29, P1638, DOI 10.2337/dc06-0543
   Lee DH, 2009, ENVIRON HEALTH PERSP, V117, P1799, DOI 10.1289/ehp.0900741
   Lee HA, 2016, INT J ENV RES PUB HE, V13, DOI 10.3390/ijerph13030270
   Li TH, 2001, GENE, V276, P135, DOI 10.1016/S0378-1119(01)00637-0
   Lim J. E., 2017, INT J HYG ENV HLTH
   Lim JE, 2015, ENVIRON SCI POLLUT R, V22, P11275, DOI 10.1007/s11356-015-4315-z
   Lind L, 2013, ENVIRON INT, V59, P456, DOI 10.1016/j.envint.2013.07.008
   Lopez J, 2009, BRIT J CANCER, V100, P571, DOI 10.1038/sj.bjc.6604930
   López-Cervantes M, 2004, ENVIRON HEALTH PERSP, V112, P207, DOI [10.1289/ehp.6492, 10.1289/ehp.112-1241830]
   Miranda TB, 2007, J CELL PHYSIOL, V213, P384, DOI 10.1002/jcp.21224
   Oh HJ, 2015, MOL REPROD DEV, V82, P330, DOI 10.1002/mrd.22481
   Park SH, 2016, ENVIRON SCI POLLUT R, V23, P3536, DOI 10.1007/s11356-015-5578-0
   PHILLIPS DL, 1989, ARCH ENVIRON CON TOX, V18, P495, DOI 10.1007/BF01055015
   Rossi F, 2010, ITAL J ANIM SCI, V9, P88, DOI 10.4081/ijas.2010.e18
   Rusiecki JA, 2008, ENVIRON HEALTH PERSP, V116, P1547, DOI 10.1289/ehp.11338
   Salihovic S, 2012, ENVIRON INT, V44, P59, DOI 10.1016/j.envint.2012.01.011
   Shah S, 2014, GENOME RES, V24, P1725, DOI 10.1101/gr.176933.114
   Takiguchi M, 2003, EXP CELL RES, V286, P355, DOI 10.1016/S0014-4827(03)00062-4
   Törnkvist A, 2011, CHEMOSPHERE, V83, P193, DOI 10.1016/j.chemosphere.2010.12.042
   Van Maele-Fabry G, 2004, INT ARCH OCC ENV HEA, V77, P559, DOI 10.1007/s00420-004-0548-8
   Weisenberger DJ, 2005, NUCLEIC ACIDS RES, V33, P6823, DOI 10.1093/nar/gki987
   Welshons WV, 2003, ENVIRON HEALTH PERSP, V111, P994, DOI 10.1289/ehp.5494
   Wolff MS, 1997, ENVIRON HEALTH PERSP, V105, P13, DOI 10.2307/3433043
   Wolffe AP, 1999, SCIENCE, V286, P481, DOI 10.1126/science.286.5439.481
   Yang AS, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh032
   Yang B, 2013, UROL ONCOL-SEMIN ORI, V31, P628, DOI 10.1016/j.urolonc.2011.05.009
   Zhu ZZ, 2012, INT J EPIDEMIOL, V41, P126, DOI 10.1093/ije/dyq154
NR 43
TC 32
Z9 33
U1 1
U2 27
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0013-9351
EI 1096-0953
J9 ENVIRON RES
JI Environ. Res.
PD OCT
PY 2017
VL 158
BP 333
EP 341
DI 10.1016/j.envres.2017.06.017
PG 9
WC Environmental Sciences; Public, Environmental & Occupational Health
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
   Health
GA FE4LF
UT WOS:000408184700036
PM 28672131
DA 2025-01-12
ER

PT J
AU Bustos, MA
   Ono, S
   Marzese, DM
   Oyama, T
   Iida, Y
   Cheung, G
   Nelson, N
   Hsu, SC
   Yu, Q
   Hoon, DSB
AF Bustos, Matias A.
   Ono, Shigeshi
   Marzese, Diego M.
   Oyama, Takashi
   Iida, Yuuki
   Cheung, Garrett
   Nelson, Nellie
   Hsu, Sandy C.
   Yu, Qiang
   Hoon, Dave S. B.
TI MiR-200a Regulates CDK4/6 Inhibitor Effect by Targeting CDK6 in
   Metastatic Melanoma
SO JOURNAL OF INVESTIGATIVE DERMATOLOGY
LA English
DT Article
ID CYCLIN-DEPENDENT KINASES; BREAST-CANCER; MESENCHYMAL TRANSITION;
   RETINOBLASTOMA PROTEIN; FAMILY; PALBOCICLIB; PROGRESSION; EXPRESSION;
   MICRORNAS; PHENOTYPE
AB The CDK4/6 pathway is frequently dysregulated in cutaneous melanoma. Recently, CDK4/6 inhibitors have shown promising clinical activity against several cancer types, including melanoma. Here, we show that microRNA-200a decreases CDK6 expression and thus reduces the response of CDK4/6 inhibitor in highly proliferative metastatic melanoma. Down-regulation of microRNA-200a expression in melanoma cells is associated with disease progression and a higher number of lymph node metastases. Furthermore, microRNA-200a expression is epigenetically modulated by both DNA methylation at the promoter region and chromatin accessibility of an upstream genomic region with enhancer activity. Mechanistically, overexpression of miR-200a in metastatic melanoma cells induces cell cycle arrest by targeting CDK6 and decreases the levels of phosphorylated-Rb1 and E2F-downstream targets, diminishing cell proliferation; these effects are recovered by CDK6 overexpression. Conversely, low microRNA-200a expression in metastatic melanoma cells results in higher levels of CDK6 and a more significant response to CDK4/6 inhibitors. We propose that microRNA-200a functions as a "cell cycle brake" that is lost during melanoma progression to metastasis and provides the ability to identify melanomas that are highly proliferative and more prompted to respond to CDK4/6 inhibitors.
C1 [Bustos, Matias A.; Ono, Shigeshi; Marzese, Diego M.; Oyama, Takashi; Iida, Yuuki; Cheung, Garrett; Hsu, Sandy C.; Hoon, Dave S. B.] Providence St Johns Hlth Ctr, Dept Translat Mol Med, Div Mol Oncol, John Wayne Canc Inst, 2200 Santa Monica Blvd, Santa Monica, CA 90404 USA.
   [Nelson, Nellie; Hsu, Sandy C.; Hoon, Dave S. B.] Providence St Johns Hlth Ctr, Sequencing Ctr, John Wayne Canc Inst, Santa Monica, CA 90404 USA.
   [Yu, Qiang] Agcy Sci Technol & Res, Canc Biol & Pharmacol, Genome Inst Singapore, Singapore, Singapore.
C3 John Wayne Cancer Institute; John Wayne Cancer Institute; Agency for
   Science Technology & Research (A*STAR); A*STAR - Genome Institute of
   Singapore (GIS)
RP Hoon, DSB (通讯作者)，Providence St Johns Hlth Ctr, Dept Translat Mol Med, Div Mol Oncol, John Wayne Canc Inst, 2200 Santa Monica Blvd, Santa Monica, CA 90404 USA.
EM hoond@jwci.org
RI Hoon, Dave/C-7146-2018; Bustos, Matias/KHE-1168-2024; Marzese,
   Diego/AAA-3547-2022
OI Yu, Qiang/0000-0003-2132-8278; Nelson, Nellie/0000-0003-3220-5601;
   Marzese, Diego/0000-0002-3258-8852; ONO, SHIGESHI/0000-0003-1569-5397;
   Bustos, Matias A./0000-0001-9625-1127
FU Dr. Miriam and Sheldon G. Adelson Medical Research Foundation; National
   Institutes of Health, National Cancer Institute [R01CA167967]
FX This work was supported by the Dr. Miriam and Sheldon G. Adelson Medical
   Research Foundation (DH) and the National Institutes of Health, National
   Cancer Institute [R01CA167967 to DH]. The content is solely the
   responsibility of the authors and does not necessarily represent the
   official view of the National Cancer Institute or the National
   Institutes of Health.
CR Akhtar MM, 2016, NUCLEIC ACIDS RES, V44, P24, DOI 10.1093/nar/gkv1221
   Asghar U, 2015, NAT REV DRUG DISCOV, V14, P130, DOI 10.1038/nrd4504
   Attema JL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075517
   Beaver JA, 2015, CLIN CANCER RES, V21, P4760, DOI 10.1158/1078-0432.CCR-15-1185
   Bracken CP, 2008, CANCER RES, V68, P7846, DOI 10.1158/0008-5472.CAN-08-1942
   Bristow BN, 2013, MELANOMA RES, V23, P331, DOI 10.1097/CMR.0b013e328361926c
   Ceppi P, 2010, MOL CANCER RES, V8, P1207, DOI 10.1158/1541-7786.MCR-10-0052
   Cristofanilli M, 2016, LANCET ONCOL, V17, P425, DOI 10.1016/S1470-2045(15)00613-0
   Davalos V, 2012, ONCOGENE, V31, P2062, DOI 10.1038/onc.2011.383
   Du W, 2006, ONCOGENE, V25, P5190, DOI 10.1038/sj.onc.1209651
   Finn RS, 2015, LANCET ONCOL, V16, P25, DOI 10.1016/S1470-2045(14)71159-3
   Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722
   Hamilton E, 2016, CANCER TREAT REV, V45, P129, DOI 10.1016/j.ctrv.2016.03.002
   Humphries B, 2015, ONCOTARGET, V6, P6472, DOI 10.18632/oncotarget.3052
   Kim D, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-4-r36
   Lee ST, 2013, P NATL ACAD SCI USA, V110, P11121, DOI 10.1073/pnas.1300873110
   Lessard L, 2015, J INVEST DERMATOL, V135, P2464, DOI 10.1038/jid.2015.200
   Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035
   Lim YY, 2013, J CELL SCI, V126, P2256, DOI 10.1242/jcs.122275
   Magee P, 2015, ANN TRANSL MED, V3, DOI 10.3978/j.issn.2305-5839.2015.11.32
   Marzese DM, 2015, EPIGENOMICS-UK, V7, P1303, DOI 10.2217/epi.15.77
   Marzese DM, 2015, PIGM CELL MELANOMA R, V28, DOI 10.1111/pcmr.12307
   Marzese DM, 2014, NEURO-ONCOLOGY, V16, P1499, DOI 10.1093/neuonc/nou107
   Marzese DM, 2014, HUM MOL GENET, V23, P226, DOI 10.1093/hmg/ddt420
   Millet A, 2017, MED RES REV, V37, P98, DOI 10.1002/med.21404
   Miranda KC, 2006, CELL, V126, P1203, DOI 10.1016/j.cell.2006.07.031
   Neves Rui, 2010, BMC Res Notes, V3, P219, DOI 10.1186/1756-0500-3-219
   Ono S, 2015, ONCOTARGET, V6, P7053, DOI 10.18632/oncotarget.3142
   Oom AL, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/959461
   Paraskevopoulou MD, 2013, NUCLEIC ACIDS RES, V41, pW169, DOI 10.1093/nar/gkt393
   Roberts A, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-3-r22
   Rosenbloom KR, 2013, NUCLEIC ACIDS RES, V41, pD56, DOI 10.1093/nar/gks1172
   Roskoski R, 2016, PHARMACOL RES, V107, P249, DOI 10.1016/j.phrs.2016.03.012
   Rupaimoole R, 2016, CANCER DISCOV, V6, P235, DOI 10.1158/2159-8290.CD-15-0893
   Saeed AI, 2006, METHOD ENZYMOL, V411, P134, DOI 10.1016/S0076-6879(06)11009-5
   Sheppard KE, 2013, CLIN CANCER RES, V19, P5320, DOI 10.1158/1078-0432.CCR-13-0259
   Takaki T, 2005, J BIOCHEM, V137, P381, DOI 10.1093/jb/mvi050
   Tan TZ, 2014, EMBO MOL MED, V6, P1279, DOI 10.15252/emmm.201404208
   Turner NC, 2015, NEW ENGL J MED, V373, P1672, DOI 10.1056/NEJMc1510345
   WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2
   Wiklund ED, 2011, INT J CANCER, V128, P1327, DOI 10.1002/ijc.25461
   Xu F, 2016, CLIN TRANSL ONCOL, V18, P283, DOI 10.1007/s12094-015-1364-1
   Xu Y, 2012, BRIT J CANCER, V106, P553, DOI 10.1038/bjc.2011.568
   Young RJ, 2014, PIGM CELL MELANOMA R, V27, DOI 10.1111/pcmr.12228
NR 44
TC 34
Z9 36
U1 0
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0022-202X
EI 1523-1747
J9 J INVEST DERMATOL
JI J. Invest. Dermatol.
PD SEP
PY 2017
VL 137
IS 9
BP 1955
EP 1964
DI 10.1016/j.jid.2017.03.039
PG 10
WC Dermatology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Dermatology
GA FE5TB
UT WOS:000408272900022
PM 28526299
OA Bronze
DA 2025-01-12
ER

PT J
AU Chen, YDH
   Marotti, JD
   Jenson, EG
   Onega, TL
   Johnson, KC
   Christensen, BC
AF Chen, Youdinghuan
   Marotti, Jonathan D.
   Jenson, Erik G.
   Onega, Tracy L.
   Johnson, Kevin C.
   Christensen, Brock C.
TI Concordance of DNA methylation profiles between breast core biopsy and
   surgical excision specimens containing ductal carcinoma in situ (DCIS)
SO EXPERIMENTAL AND MOLECULAR PATHOLOGY
LA English
DT Article
DE DNA methylation; Illumina 450k; DCIS core biopsies; Epigenetic
   biomarkers
ID GENE-EXPRESSION; CANCER
AB The utility and reliability of assessing molecular biomarkers for translational applications on pre-operative core biopsy specimens assume consistency of molecular profiles with larger surgical specimens. Whether DNA methylation in ductal carcinoma in situ (DCIS), measured in core biopsy and surgical specimens are similar, remains unclear. Here, we compared genome-scale DNA methylation measured in matched core biopsy and surgical specimens from DCIS, including specific DNA methylation biomarkers of subsequent invasive cancer. DNA was extracted from guided 2 mm cores of formalin fixed paraffin embedded (FFPE) specimens, bisulfite-modified, and measured on the Illumina HumanMethylation450 BeadChip. DNA methylation profiles of core biopsies exhibited high concordance with matched surgical specimens. Within-subject variability in DNA methylation was significantly lower than between-subject variability (all P < 2.20E - 16). In 641 CpGs whose methylation was related with increased hazard of invasive breast cancer, lower within-subject than between-subject variability was observed in 92.3% of the study participants (P < 0.05). Between patient-matched core biopsy and surgical specimens, < 0.6% of CpGs measured had changes in median DNA methylation > 15%, and a pathway analysis of these CpGs indicated enrichment for genes related with wound healing. Our results indicate that DNA methylation measured in core biopsies are representative of the matched surgical specimens and suggest that DCIS biomarkers measured in core biopsies can inform clinical decision-making.
C1 [Chen, Youdinghuan; Johnson, Kevin C.; Christensen, Brock C.] Geisel Sch Med Dartmouth, Dept Epidemiol, Lebanon, NH 03756 USA.
   [Chen, Youdinghuan; Johnson, Kevin C.; Christensen, Brock C.] Geisel Sch Med Dartmouth, Dept Mol & Syst Biol, Lebanon, NH 03756 USA.
   [Marotti, Jonathan D.; Jenson, Erik G.] Geisel Sch Med Dartmouth, Dept Pathol & Lab Med, Lebanon, NH 03756 USA.
   [Onega, Tracy L.] Geisel Sch Med Dartmouth, Dept Biomed Data Sci, Lebanon, NH 03756 USA.
   [Marotti, Jonathan D.; Christensen, Brock C.] Geisel Sch Med Dartmouth, Dept Community & Family Med, Lebanon, NH 03756 USA.
   [Jenson, Erik G.] Johns Hopkins Univ, Sch Med, Div Gynecol Pathol, Baltimore, MD 21231 USA.
   [Johnson, Kevin C.] Jackson Lab Genom Med, Farmington, CT 06032 USA.
C3 Dartmouth College; Dartmouth College; Dartmouth College; Dartmouth
   College; Dartmouth College; Johns Hopkins University; Jackson Laboratory
RP Christensen, BC (通讯作者)，One Med Ctr Dr,Williamson 660,HB 7650, Lebanon, NH 03756 USA.
EM youdinghuan.chen.gr@dartmouth.edu; brock.c.christensen@dartmouth.edu
RI Christensen, Brock/B-8460-2009; Chen, Youdinghuan/GMX-3298-2022
OI Chen, Youdinghuan/0000-0002-5451-0482
FU U.S. National Institute of Health [P20GM104416, R01DE022772,
   1P01CA154292]; New Hampshire Mammography Registry [U01CA086082];
   Burroughs-Wellcome Fund
FX This work was supported by the U.S. National Institute of Health
   (P20GM104416, R01DE022772, and 1P01CA154292), the New Hampshire
   Mammography Registry (U01CA086082), and the Burroughs-Wellcome Fund.
CR Akalin A, 2015, BIOINFORMATICS, V31, P1127, DOI 10.1093/bioinformatics/btu775
   [Anonymous], 2015, BREAST CANC FACTS FI
   Aryee MJ, 2014, BIOINFORMATICS, V30, P1363, DOI 10.1093/bioinformatics/btu049
   Brenner RJ, 2001, RADIOLOGY, V218, P866, DOI 10.1148/radiology.218.3.r01mr44866
   Burge CN, 2006, BREAST, V15, P167, DOI 10.1016/j.breast.2005.06.004
   Carney PA, 1996, AM J ROENTGENOL, V167, P367, DOI 10.2214/ajr.167.2.8686606
   Charles CA, 2008, J AM ACAD DERMATOL, V59, P758, DOI 10.1016/j.jaad.2008.07.018
   Fleischer T, 2014, GENOME BIOL, V15, DOI [10.1186/s13059-014-0435-x, 10.1186/PREACCEPT-2333349012841587]
   Gross RL, 2000, INT OPHTHALMOL CLIN, V40, P51, DOI 10.1097/00004397-200010000-00004
   Johnson KC, 2015, CLIN EPIGENETICS, V7, DOI 10.1186/s13148-015-0094-0
   Jones PA, 2012, NAT REV GENET, V13, P484, DOI 10.1038/nrg3230
   Kanehisa M, 2017, NUCLEIC ACIDS RES, V45, pD353, DOI 10.1093/nar/gkw1092
   Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412
   Lester SC, 2009, ARCH PATHOL LAB MED, V133, P15, DOI 10.1043/1543-2165-133.1.15
   Morrow M, 2015, JNCI-J NATL CANCER I, V107, DOI 10.1093/jnci/djv290
   Paco S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0145107
   Pang JMB, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3420
   Park TS, 2016, ONCOLOGY-NY, V30, P823
   Pinder S.E, 2010, MODERN PATHOL, V23, P58
   Ricci MD, 2012, REV ASSOC MED BRAS, V58, P532
   Sikora MJ, 2011, PHARMACOGENOMICS J, V11, P348, DOI 10.1038/tpj.2010.50
   Yang XJ, 2014, CANCER CELL, V26, P577, DOI 10.1016/j.ccr.2014.07.028
   Zanetti-Dällenbach R, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1542
NR 23
TC 7
Z9 7
U1 0
U2 0
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0014-4800
EI 1096-0945
J9 EXP MOL PATHOL
JI Exp. Mol. Pathol.
PD AUG
PY 2017
VL 103
IS 1
BP 78
EP 83
DI 10.1016/j.yexmp.2017.07.001
PG 6
WC Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pathology
GA FE4KM
UT WOS:000408182800011
PM 28711544
OA Green Accepted, hybrid
DA 2025-01-12
ER

PT J
AU Chanyshev, MD
   Ushakov, DS
   Gulyaeva, LF
AF Chanyshev, M. D.
   Ushakov, D. S.
   Gulyaeva, L. F.
TI Expression of miR-21 and its <i>Acat1</i>, <i>Armcx1</i>, and
   <i>Pten</i> Target Genes in Liver of Female Rats Treated with DDT and
   Benzo[a]pyrene
SO MOLECULAR BIOLOGY
LA English
DT Article
DE miR-21; Acat1; Armcx1; Pten; DDT; benzo[a] pyrene; target genes
ID TUMOR-SUPPRESSOR GENE; BREAST-CANCER; DICHLORODIPHENYLTRICHLOROETHANE
   DDT; ACYL-COENZYME; MICRORNA; ACYLTRANSFERASE; RELEVANCE; CELLS
AB MiR-21 is the most studied cancer-promoting oncomiR, which target numerous tumor suppressor genes associated with proliferation, apoptosis, and invasion. Here we have studied the synthesis of miR-21 and quantified the mRNA and protein levels for miR-21 potential target genes, i.e., Acat1, Armcx1, and Pten, in the livers of female Wistar rats after their treatment with either 1,1-trichloro-2,2-di(4-chlorophenyl)ethane (DDT) or benzo[a]pyrene (BP). The most important finding appears to be the significant decrease in the miR-21 level the day after treatment with DDT with subsequent rebound. These changes are accompanied by an increase and subsequent drop in the levels of mRNAs and proteins of the Acat1, Armcx1, and Pten genes. These observations indicate the involvement of miR-21 in the posttranscriptional regulation of the Acat1, Armcx1, and Pten genes in response to xenobiotics. We hypothesize that the toxic effects of xenobiotics may be indirect and may manifest by inducing epigenetic changes, particularly through the regulation of miRNAs and their target genes.
C1 [Chanyshev, M. D.; Ushakov, D. S.; Gulyaeva, L. F.] Inst Mol Biol & Biophys, Novosibirsk 630117, Russia.
   [Chanyshev, M. D.; Ushakov, D. S.; Gulyaeva, L. F.] Novosibirsk State Pedag Univ, Novosibirsk 630126, Russia.
   [Gulyaeva, L. F.] Novosibirsk State Univ, Novosibirsk 630090, Russia.
C3 Novosibirsk State Pedagogical University; Novosibirsk State University
RP Chanyshev, MD (通讯作者)，Inst Mol Biol & Biophys, Novosibirsk 630117, Russia.; Chanyshev, MD (通讯作者)，Novosibirsk State Pedag Univ, Novosibirsk 630126, Russia.
EM chanish@mail.ru
RI Chanyshev, Mikhail/Q-6606-2016; Gulyaeva, Lyudmila/A-8890-2016
OI Chanyshev, Mikhail/0000-0002-6943-2915
FU Russian Scientific Foundation [15-15-30012]
FX The work was supported by grant no. 15-15-30012 from Russian Scientific
   Foundation. We thank Colin Godwin, student of Massachusetts Institute of
   Technology (United States) for help with working with animals.
CR Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871
   Chang TY, 2009, AM J PHYSIOL-ENDOC M, V297, pE1, DOI 10.1152/ajpendo.90926.2008
   Chang TY, 1997, ANNU REV BIOCHEM, V66, P613, DOI 10.1146/annurev.biochem.66.1.613
   Chanyshev MD, 2014, LIFE SCI, V103, P95, DOI 10.1016/j.lfs.2014.03.031
   Cohn BA, 2007, ENVIRON HEALTH PERSP, V115, P1406, DOI 10.1289/ehp.10260
   Collotta M, 2013, TOXICOLOGY, V307, P35, DOI 10.1016/j.tox.2013.01.017
   Danzo BJ, 1997, ENVIRON HEALTH PERSP, V105, P294, DOI 10.2307/3433266
   Denissenko MF, 1996, SCIENCE, V274, P430, DOI 10.1126/science.274.5286.430
   Harada T, 2016, TOX RESEARCH, V32, P21, DOI 10.5487/TR.2016.32.1.021
   Hiyoshi Y, 2009, CLIN CANCER RES, V15, P1915, DOI 10.1158/1078-0432.CCR-08-2545
   Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783
   Jansson MD, 2012, MOL ONCOL, V6, P590, DOI 10.1016/j.molonc.2012.09.006
   Kalscheuer S, 2008, CARCINOGENESIS, V29, P2394, DOI 10.1093/carcin/bgn209
   Koufaris C, 2013, TOXICOLOGY, V314, P247, DOI 10.1016/j.tox.2013.10.004
   Lin SB, 2015, NAT REV CANCER, V15, P321, DOI 10.1038/nrc3932
   Liu LB, 2007, ANAL SCI, V23, P667, DOI 10.2116/analsci.23.667
   Makarova JA, 2015, BIOCHEMISTRY-MOSCOW+, V80, P1117, DOI 10.1134/S0006297915090035
   Meng FY, 2007, GASTROENTEROLOGY, V133, P647, DOI 10.1053/j.gastro.2007.05.022
   Orang AV, 2014, INT J GENOMICS, V2014, DOI 10.1155/2014/970607
   Pan XA, 2010, CANCER BIOL THER, V10, P1224, DOI 10.4161/cbt.10.12.14252
   Peralta-Zaragoza O, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2231-3
   Radojicic J, 2011, CELL CYCLE, V10, P507, DOI 10.4161/cc.10.3.14754
   Ross JA, 2010, MOL CARCINOGEN, V49, P320, DOI 10.1002/mc.20620
   Sansal I, 2004, J CLIN ONCOL, V22, P2954, DOI 10.1200/jco.2004.02.141
   Saraon P, 2014, PROSTATE, V74, P372, DOI 10.1002/pros.22758
   Tomita K, 2014, J HEPATOL, V61, P98, DOI 10.1016/j.jhep.2014.03.018
   Turusov V, 2002, ENVIRON HEALTH PERSP, V110, P125, DOI 10.1289/ehp.02110125
   Valencia-Sanchez MA, 2006, GENE DEV, V20, P515, DOI 10.1101/gad.1399806
   Wienholds E, 2005, FEBS LETT, V579, P5911, DOI 10.1016/j.febslet.2005.07.070
NR 29
TC 10
Z9 11
U1 0
U2 8
PU MAIK NAUKA/INTERPERIODICA/SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013-1578 USA
SN 0026-8933
EI 1608-3245
J9 MOL BIOL+
JI Mol. Biol.
PD JUL
PY 2017
VL 51
IS 4
BP 586
EP 591
DI 10.1134/S0026893317040082
PG 6
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA FE4XU
UT WOS:000408217400013
DA 2025-01-12
ER

PT J
AU Liu, M
   Liang, KL
   Zhen, JH
   Zhou, M
   Wang, XJ
   Wang, ZY
   Wei, XB
   Zhang, Y
   Sun, Y
   Zhou, ZL
   Su, H
   Zhang, C
   Li, NJ
   Gao, CJ
   Peng, J
   Yi, F
AF Liu, Min
   Liang, Kaili
   Zhen, Junhui
   Zhou, Meng
   Wang, Xiaojie
   Wang, Ziying
   Wei, Xinbing
   Zhang, Yan
   Sun, Yu
   Zhou, Zhuanli
   Su, Hua
   Zhang, Chun
   Li, Ningjun
   Gao, Chengjiang
   Peng, Jun
   Yi, Fan
TI Sirt6 deficiency exacerbates podocyte injury and proteinuria through
   targeting Notch signaling
SO NATURE COMMUNICATIONS
LA English
DT Article
ID FOCAL SEGMENTAL GLOMERULOSCLEROSIS; DIABETIC-NEPHROPATHY; UROKINASE
   RECEPTOR; KIDNEY-DISEASE; BREAST-CANCER; AUTOPHAGY; PROMOTES;
   DEACETYLASE; PATHWAY; CONTRIBUTES
AB Podocyte injury is a major determinant of proteinuric kidney disease and the identification of potential therapeutic targets for preventing podocyte injury has clinical importance. Here, we show that histone deacetylase Sirt6 protects against podocyte injury through epigenetic regulation of Notch signaling. Sirt6 is downregulated in renal biopsies from patients with podocytopathies and its expression correlates with glomerular filtration rate. Podocyte-specific deletion of Sirt6 exacerbates podocyte injury and proteinuria in two independent mouse models, diabetic nephropathy, and adriamycin-induced nephropathy. Sirt6 has pleiotropic protective actions in podocytes, including anti-inflammatory and anti-apoptotic effects, is involved in actin cytoskeleton maintenance and promotes autophagy. Sirt6 also reduces urokinase plasminogen activator receptor expression, which is a key factor for podocyte foot process effacement and proteinuria. Mechanistically, Sirt6 inhibits Notch1 and Notch4 transcription by deacetylating histone H3K9. We propose Sirt6 as a potential therapeutic target for the treatment of proteinuric kidney disease.
C1 [Liu, Min; Liang, Kaili; Zhou, Meng; Wang, Xiaojie; Wang, Ziying; Wei, Xinbing; Zhang, Yan; Sun, Yu; Yi, Fan] Shandong Univ, Sch Med, Dept Pharmacol, Jinan 250012, Shandong, Peoples R China.
   [Zhen, Junhui] Shandong Univ, Sch Med, Dept Pathol, Jinan 250012, Shandong, Peoples R China.
   [Zhou, Zhuanli; Su, Hua; Zhang, Chun] Huazhong Univ Sci & Technol, Union Hosp, Dept Nephrol, Tongji Med Coll, Wuhan 430022, Hubei, Peoples R China.
   [Li, Ningjun] Virginia Commonwealth Univ, Med Coll Virginia, Dept Pharmacol & Toxicol, Richmond, VA 23298 USA.
   [Gao, Chengjiang] Shandong Univ, Dept Immunol, Sch Med, Jinan 250012, Shandong, Peoples R China.
   [Peng, Jun] Shandong Univ, Qilu Hosp, Dept Hematol, Jinan 250012, Shandong, Peoples R China.
C3 Shandong University; Shandong University; Huazhong University of Science
   & Technology; Virginia Commonwealth University; Shandong University;
   Shandong University
RP Yi, F (通讯作者)，Shandong Univ, Sch Med, Dept Pharmacol, Jinan 250012, Shandong, Peoples R China.
EM fanyi@sdu.edu.cn
RI Wang, Xiaojie/ITT-7339-2023; wang, xin/JWA-3772-2024; Zhang,
   Yanhui/L-5680-2017
OI Gao, Chengjiang/0000-0002-9365-4497; Yi, Fan/0000-0001-8634-9788
FU National Science Fund for Distinguished Young Scholars [81525005];
   National Nature Science Foundation of China [91642204, 81470958,
   81371317, 81600570, 81400730]
FX This study was supported by the National Science Fund for Distinguished
   Young Scholars to F.Y. (81525005); The National Nature Science
   Foundation of China (91642204, 81470958, 81371317, 81600570 and
   81400730).
CR Borggrefe T, 2009, CELL MOL LIFE SCI, V66, P1631, DOI 10.1007/s00018-009-8668-7
   Choe M, 2015, J CELL BIOCHEM, V116, P2210, DOI 10.1002/jcb.25171
   Dai CS, 2009, J AM SOC NEPHROL, V20, P1997, DOI 10.1681/ASN.2009010019
   Dávalos A, 2011, P NATL ACAD SCI USA, V108, P9232, DOI 10.1073/pnas.1102281108
   Du PC, 2013, KIDNEY INT, V84, P265, DOI 10.1038/ki.2013.113
   Elhanati S, 2016, CELL REP, V14, P234, DOI 10.1016/j.celrep.2015.12.023
   Finkel T, 2009, NATURE, V460, P587, DOI 10.1038/nature08197
   Gagliardini E, 2013, AM J PATHOL, V183, P119, DOI 10.1016/j.ajpath.2013.03.025
   Guarani V, 2011, NATURE, V473, P234, DOI 10.1038/nature09917
   Han HR, 2013, HYPERTENSION, V62, P506, DOI 10.1161/HYPERTENSIONAHA.113.01638
   Hao CM, 2010, J AM SOC NEPHROL, V21, P1620, DOI 10.1681/ASN.2010010046
   Hartleben B, 2010, J CLIN INVEST, V120, P1084, DOI 10.1172/JCI39492
   Huber TB, 2012, AUTOPHAGY, V8, P1009, DOI 10.4161/auto.19821
   Hwang JW, 2010, ARCH BIOCHEM BIOPHYS, V500, P203, DOI 10.1016/j.abb.2010.05.013
   Soler MJ, 2012, EXP DIABETES RES, DOI 10.1155/2012/616313
   Kim D, 2014, CELL SIGNAL, V26, P1774, DOI 10.1016/j.cellsig.2014.04.008
   Kim HS, 2010, CELL METAB, V12, P224, DOI 10.1016/j.cmet.2010.06.009
   Kitada M, 2013, CLIN SCI, V124, P153, DOI 10.1042/CS20120190
   Kobayashi T, 2008, KIDNEY INT, V73, P1240, DOI 10.1038/ki.2008.74
   Kume S, 2012, DIABETES, V61, P23, DOI 10.2337/db11-0555
   Lee VWS, 2011, NEPHROLOGY, V16, P30, DOI 10.1111/j.1440-1797.2010.01383.x
   Lin CL, 2010, DIABETES, V59, P1915, DOI 10.2337/db09-0663
   Mallipattu SK, 2015, J CLIN INVEST, V125, P1347, DOI 10.1172/JCI77084
   Mathieson PW, 2012, NAT REV NEPHROL, V8, P52, DOI 10.1038/nrneph.2011.171
   Michishita E, 2008, NATURE, V452, P492, DOI 10.1038/nature06736
   Mostoslavsky R, 2006, CELL, V124, P315, DOI [10.1016/j.cell.2005.11.044, 10.1016/J.CEL.2005.11.044]
   Motonishi S, 2015, J AM SOC NEPHROL, V26, P1939, DOI 10.1681/ASN.2014030289
   Niranjan T, 2008, NAT MED, V14, P290, DOI 10.1038/nm1731
   Oehme I, 2013, P NATL ACAD SCI USA, V110, pE2592, DOI 10.1073/pnas.1300113110
   Oswald F, 2001, MOL CELL BIOL, V21, P7761, DOI 10.1128/MCB.21.22.7761-7774.2001
   Piggott K, 2011, CIRCULATION, V123, P309, DOI 10.1161/CIRCULATIONAHA.110.936203
   Ranganathan P, 2016, KIDNEY INT, V89, P317, DOI 10.1038/ki.2015.326
   Rubinsztein DC, 2011, CELL, V146, P682, DOI 10.1016/j.cell.2011.07.030
   Schwer B, 2010, P NATL ACAD SCI USA, V107, P21790, DOI 10.1073/pnas.1016306107
   Shang J, 2015, FREE RADICAL BIO MED, V79, P217, DOI 10.1016/j.freeradbiomed.2014.12.013
   Sirin Y, 2012, J PATHOL, V226, P394, DOI 10.1002/path.2967
   Song BQ, 2015, CELL PHYSIOL BIOCHEM, V36, P1991, DOI 10.1159/000430167
   Sundaresan NR, 2012, NAT MED, V18, P1643, DOI 10.1038/nm.2961
   Takasaka N, 2014, J IMMUNOL, V192, P958, DOI 10.4049/jimmunol.1302341
   Tasselli L, 2017, TRENDS ENDOCRIN MET, V28, P168, DOI 10.1016/j.tem.2016.10.002
   Thirumurthi U, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005076
   Wakino S, 2015, KIDNEY INT, V88, P691, DOI 10.1038/ki.2015.157
   Wang H, 2016, CELL STEM CELL, V18, P495, DOI 10.1016/j.stem.2016.03.005
   Wang XJ, 2014, KIDNEY INT, V86, P712, DOI 10.1038/ki.2014.111
   Waters AM, 2012, J AM SOC NEPHROL, V23, P27, DOI 10.1681/ASN.2011010027
   Wei C, 2008, NAT MED, V14, P55, DOI 10.1038/nm1696
   Wei CL, 2011, NAT MED, V17, P952, DOI 10.1038/nm.2411
   Wu MH, 2015, ONCOTARGET, V6, P11252, DOI 10.18632/oncotarget.3594
   Zhang L, 2013, BRIT J PHARMACOL, V170, P426, DOI 10.1111/bph.12292
   Zhou LL, 2015, NAT REV NEPHROL, V11, P535, DOI 10.1038/nrneph.2015.88
NR 50
TC 261
Z9 283
U1 2
U2 63
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-1723
J9 NAT COMMUN
JI Nat. Commun.
PD SEP 4
PY 2017
VL 8
AR 413
DI 10.1038/s41467-017-00498-4
PG 15
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA FG0FH
UT WOS:000409393900004
PM 28871079
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU Kourtidis, A
   Lu, RF
   Pence, LJ
   Anastasiadis, PZ
AF Kourtidis, Antonis
   Lu, Ruifeng
   Pence, Lindy J.
   Anastasiadis, Panos Z.
TI A central role for cadherin signaling in cancer
SO EXPERIMENTAL CELL RESEARCH
LA English
DT Article
DE Cell-cell adhesion; E-cadherin; beta-catenin; p120 catenin; Kaiso; Rho
   GTPases; EMT; Cancer progression; miRNA; PLEKHA7
ID CELL-CELL-ADHESION; TO-MESENCHYMAL TRANSITION; RHO-FAMILY GTPASES;
   INFLAMMATORY BREAST-CANCER; GROWTH-FACTOR RECEPTOR; TUMOR-SUPPRESSOR
   GENE; P120 CATENIN; N-CADHERIN; BETA-CATENIN; ADHERENS JUNCTIONS
AB Cadherins are homophilic adhesion molecules with important functions in cell-cell adhesion, tissue morphogenesis, and cancer. In epithelial cells, E-cadherin accumulates at areas of cellcell contact, coalesces into macromolecular complexes to form the adherens junctions (AJs), and associates via accessory partners with a subcortical ring of actin to form the apical zonula adherens (ZA). As a master regulator of the epithelial phenotype, E-cadherin is essential for the overall maintenance and homeostasis of polarized epithelial monolayers. Its expression is regulated by a host of genetic and epigenetic mechanisms related to cancer, and its function is modulated by mechanical forces at the junctions, by direct binding and phosphorylation of accessory proteins collectively termed catenins, by endocytosis, recycling and degradation, as well as, by multiple signaling pathways and developmental processes, like the epithelial to mesenchymal transition (EMT). Nuclear signaling mediated by the cadherin associated proteins beta-catenin and p120 promotes growth, migration and pluripotency. Receptor tyrosine kinase, PI3K/AKT, Rho GTPase, and HIPPO signaling, are all regulated by E-cadherin mediated cellcell adhesion. Finally, the recruitment of the microprocessor complex to the ZA by PLEKHA7, and the subsequent regulation of a small subset of miRNAs provide an additional mechanism by which the state of epithelial cellcell adhesion affects translation of target genes to maintain the homeostasis of polarized epithelial monolayers. Collectively, the data indicate that loss of E-cadherin function, especially at the ZA, is a common and crucial step in cancer progression.
C1 [Kourtidis, Antonis] Med Univ South Carolina, Dept Regenerat Med & Cell Biol, 173 Ashley Ave, Charleston, SC 29425 USA.
   [Lu, Ruifeng; Pence, Lindy J.; Anastasiadis, Panos Z.] Mayo Clin, Dept Canc Biol, 4500 San Pablo Rd, Jacksonville, FL 32224 USA.
C3 Medical University of South Carolina; Mayo Clinic
RP Anastasiadis, PZ (通讯作者)，Mayo Clin, Dept Canc Biol, 4500 San Pablo Rd, Jacksonville, FL 32224 USA.
EM panos@mayo.edu
RI Lu, Ruifeng/J-1270-2019
OI Lu, Ruifeng/0000-0002-0842-4831; Kourtidis, Antonis/0000-0002-8128-6391
FU National Institutes of Health [R01 CA100467, R01 NS069753, P50
   CA116201]; Mayo Clinic Center for Biomedical Discovery; Abney
   Foundation; American Cancer Society
FX This work was supported by the National Institutes of Health (R01
   CA100467, R01 NS069753 and P50 CA116201) and the Mayo Clinic Center for
   Biomedical Discovery (PZA). AK is supported by the Abney Foundation
   Scholarship Award and by pilot research funding from an American Cancer
   Society Institutional Research Grant awarded to the Hollings Cancer
   Center, Medical University of South Carolina.
CR Abba ML, 2016, J CLIN MED, V5, DOI 10.3390/jcm5010008
   Anastasiadis PZ, 2007, BBA-MOL CELL RES, V1773, P34, DOI 10.1016/j.bbamcr.2006.08.040
   Anastasiadis PZ, 2000, NAT CELL BIOL, V2, P637, DOI 10.1038/35023588
   [Anonymous], COLD SPRING HARB PER
   [Anonymous], ONCOGENE
   Baki L, 2001, P NATL ACAD SCI USA, V98, P2381, DOI 10.1073/pnas.041603398
   Bellovin DI, 2005, CANCER RES, V65, P10938, DOI 10.1158/0008-5472.CAN-05-1947
   Bertocchi C, 2017, NAT CELL BIOL, V19, P28, DOI 10.1038/ncb3456
   Berx G, 2001, BREAST CANCER RES, V3, P289, DOI 10.1186/bcr309
   Berx G, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a003129
   BRADYKALNAY SM, 1995, J CELL BIOL, V130, P977, DOI 10.1083/jcb.130.4.977
   Campbell K, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8998
   Chao YL, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-179
   Chen XY, 2003, J CELL BIOL, V163, P547, DOI 10.1083/jcb.200305137
   Cichon MA, 2014, CELL ADHES MIGR, V8, P588, DOI 10.4161/19336918.2014.972788
   Clements WM, 2002, CANCER RES, V62, P3503
   Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018
   Daniel JM, 2002, NUCLEIC ACIDS RES, V30, P2911, DOI 10.1093/nar/gkf398
   Daniel JM, 1999, MOL CELL BIOL, V19, P3614
   Daniel JM, 2007, BBA-MOL CELL RES, V1773, P59, DOI 10.1016/j.bbamcr.2006.08.052
   Davis MA, 2006, DEV CELL, V10, P21, DOI 10.1016/j.devcel.2005.12.004
   Davis MA, 2003, J CELL BIOL, V163, P525, DOI 10.1083/jcb.200307111
   De Santis G, 2009, ONCOGENE, V28, P1206, DOI 10.1038/onc.2008.470
   Dohn MR, 2009, J CELL BIOL, V184, P437, DOI 10.1083/jcb.200807096
   Drees F, 2005, CELL, V123, P903, DOI 10.1016/j.cell.2005.09.021
   Fischer KR, 2015, NATURE, V527, P472, DOI 10.1038/nature15748
   FRIXEN UH, 1991, J CELL BIOL, V113, P173, DOI 10.1083/jcb.113.1.173
   Fujita Y, 2002, NAT CELL BIOL, V4, P222, DOI 10.1038/ncb758
   Gibbons DL, 2009, GENE DEV, V23, P2140, DOI 10.1101/gad.1820209
   Goodwin M, 2003, J BIOL CHEM, V278, P20533, DOI 10.1074/jbc.M213171200
   Gravdal K, 2007, CLIN CANCER RES, V13, P7003, DOI 10.1158/1078-0432.CCR-07-1263
   Gregory PA, 2008, CELL CYCLE, V7, P3112, DOI 10.4161/cc.7.20.6851
   Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722
   Gregory RI, 2004, NATURE, V432, P235, DOI 10.1038/nature03120
   Grosheva I, 2001, J CELL SCI, V114, P695
   Gwak GY, 2006, ONCOL REP, V15, P1117
   Ha M, 2014, NAT REV MOL CELL BIO, V15, P509, DOI 10.1038/nrm3838
   Hall A, 2005, BIOCHEM SOC T, V33, P891, DOI 10.1042/BST0330891
   Hartsock A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037476
   Hazan RB, 2000, J CELL BIOL, V148, P779, DOI 10.1083/jcb.148.4.779
   HERRENKNECHT K, 1991, P NATL ACAD SCI USA, V88, P9156, DOI 10.1073/pnas.88.20.9156
   Heuberger J, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a002915
   Holsinger LJ, 2002, ONCOGENE, V21, P7067, DOI 10.1038/sj.onc.1205858
   Hong JY, 2010, J CELL SCI, V123, P4351, DOI 10.1242/jcs.067199
   Hosking CR, 2007, MOL BIOL CELL, V18, P1918, DOI 10.1091/mbc.E06-10-0941
   Irby RB, 2002, CANCER RES, V62, P2669
   Ireton RC, 2002, J CELL BIOL, V159, P465, DOI 10.1083/jcb.200205115
   Islam S, 1996, J CELL BIOL, V135, P1643, DOI 10.1083/jcb.135.6.1643
   Jeanes A, 2008, ONCOGENE, V27, P6920, DOI 10.1038/onc.2008.343
   Johnson E, 2004, J BIOL CHEM, V279, P31041, DOI 10.1074/jbc.M400024200
   Johnson E, 2010, J BIOL CHEM, V285, P29491, DOI 10.1074/jbc.M110.136770
   Joseph JV, 2015, CANCER LETT, V359, P107, DOI 10.1016/j.canlet.2015.01.010
   Kang HG, 2007, CANCER RES, V67, P3094, DOI 10.1158/0008-5472.CAN-06-3259
   Kashef J, 2009, GENE DEV, V23, P1393, DOI 10.1101/gad.519409
   Katoh Y, 2008, INT J MOL MED, V22, P271, DOI 10.3892/ijmm_00000019
   Kim NG, 2011, P NATL ACAD SCI USA, V108, P11930, DOI 10.1073/pnas.1103345108
   Kim SW, 2004, NAT CELL BIOL, V6, P1212, DOI 10.1038/ncb1191
   KINZLER KW, 1991, SCIENCE, V251, P1366, DOI 10.1126/science.1848370
   KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562
   Kleer CG, 2001, MODERN PATHOL, V14, P458, DOI 10.1038/modpathol.3880334
   Knirsh R, 2009, MOL BIOL CELL, V20, P2121, DOI 10.1091/mbc.E08-12-1196
   Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784
   Kourtidis A., 2016, FUTURE ONCOL
   Kourtidis A, 2016, CELL CYCLE, V15, P498, DOI 10.1080/15384101.2016.1141840
   Kourtidis A, 2015, NAT CELL BIOL, V17, P1145, DOI 10.1038/ncb3227
   Kourtidis A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129964
   Kourtidis A, 2013, PROG MOL BIOL TRANSL, V116, P409, DOI 10.1016/B978-0-12-394311-8.00018-2
   Kuphal S, 2012, ARCH BIOCHEM BIOPHYS, V524, P43, DOI 10.1016/j.abb.2011.10.020
   Lee M, 2014, J CELL SCI, V127, P4037, DOI 10.1242/jcs.151944
   Lewis-Tuffin LJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013665
   Li G, 2001, CANCER RES, V61, P3819
   Ling K, 2007, J CELL BIOL, V176, P343, DOI 10.1083/jcb.200606023
   Liu WF, 2006, J CELL BIOL, V173, P431, DOI 10.1083/jcb.200510087
   Liu WG, 2000, NAT GENET, V26, P146, DOI 10.1038/79859
   Liu Y, 2009, LUNG CANCER, V63, P375, DOI 10.1016/j.lungcan.2008.12.012
   MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016
   Maeda M, 2006, ONCOGENE, V25, P4595, DOI 10.1038/sj.onc.1209396
   Mariner DJ, 2004, J CELL SCI, V117, P1339, DOI 10.1242/jcs.01001
   McCrea PD, 2015, CURR TOP DEV BIOL, V112, P129, DOI 10.1016/bs.ctdb.2014.11.018
   Meng W, 2008, CELL, V135, P948, DOI 10.1016/j.cell.2008.09.040
   Miki T, 2011, STEM CELL REV REP, V7, P836, DOI 10.1007/s12015-011-9275-1
   Miyoshi J, 2008, BBA-BIOMEMBRANES, V1778, P670, DOI 10.1016/j.bbamem.2007.12.014
   Molina-Ortiz I, 2009, J BIOL CHEM, V284, P15147, DOI 10.1074/jbc.M807834200
   Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787
   Mortazavi F, 2010, MOL CANCER RES, V8, P762, DOI 10.1158/1541-7786.MCR-10-0004
   Motti ML, 2005, CARCINOGENESIS, V26, P1021, DOI 10.1093/carcin/bgi050
   NAGAFUCHI A, 1991, CELL, V65, P849, DOI 10.1016/0092-8674(91)90392-C
   Nakamura Y, 1991, Princess Takamatsu Symp, V22, P285
   Nieman MT, 1999, J CELL BIOL, V147, P631, DOI 10.1083/jcb.147.3.631
   Nishimura T, 2009, CURR TOP DEV BIOL, V89, P33, DOI 10.1016/S0070-2153(09)89002-9
   Nollet F, 1999, Mol Cell Biol Res Commun, V2, P77, DOI 10.1006/mcbr.1999.0155
   Noren NK, 2000, J CELL BIOL, V150, P567, DOI 10.1083/jcb.150.3.567
   Ozawa M, 2001, J CELL SCI, V114, P503
   Ozawa M, 2015, SCI REP-UK, V5, DOI 10.1038/srep15368
   Pang JH, 2005, J BIOL CHEM, V280, P3043, DOI 10.1074/jbc.M412148200
   Paredes J, 2008, J CLIN PATHOL, V61, P856, DOI 10.1136/jcp.2007.052704
   Park JI, 2006, DEV CELL, V11, P683, DOI 10.1016/j.devcel.2006.09.022
   Park JI, 2009, NATURE, V460, P66, DOI 10.1038/nature08137
   Park JI, 2005, DEV CELL, V8, P843, DOI 10.1016/j.devcel.2005.04.010
   Pece S, 1999, J BIOL CHEM, V274, P19347, DOI 10.1074/jbc.274.27.19347
   PEIFER M, 1995, TRENDS CELL BIOL, V5, P224, DOI 10.1016/S0962-8924(00)89015-7
   Peifer M, 2015, NATURE, V526, P700, DOI 10.1038/nature14980
   Perl AK, 1998, NATURE, V392, P190, DOI 10.1038/32433
   Perrais M, 2007, MOL BIOL CELL, V18, P2013, DOI 10.1091/mbc.E06-04-0348
   Petrova YI, 2016, MOL BIOL CELL, V27, P3233, DOI 10.1091/mbc.E16-01-0058
   Petrova YI, 2012, MOL BIOL CELL, V23, P2092, DOI 10.1091/mbc.E11-12-1060
   Pinheiro H, 2010, HUM MOL GENET, V19, P943, DOI 10.1093/hmg/ddp537
   Pishvaian MJ, 1999, CANCER RES, V59, P947
   Polakis P, 2000, GENE DEV, V14, P1837
   Prokhortchouk A, 2001, GENE DEV, V15, P1613, DOI 10.1101/gad.198501
   Qian XL, 2004, EMBO J, V23, P1739, DOI 10.1038/sj.emboj.7600136
   Rakha EA, 2013, HISTOPATHOLOGY, V62, P695, DOI 10.1111/his.12066
   Ratheesh A, 2013, PROG MOL BIOL TRANSL, V116, P49, DOI 10.1016/B978-0-12-394311-8.00003-0
   Ribeiro AS, 2010, ONCOGENE, V29, P392, DOI 10.1038/onc.2009.338
   RIMM DL, 1995, P NATL ACAD SCI USA, V92, P8813, DOI 10.1073/pnas.92.19.8813
   Rodriguez FJ, 2012, BBA-REV CANCER, V1826, P23, DOI 10.1016/j.bbcan.2012.03.002
   Sarrío D, 2004, ONCOGENE, V23, P3272, DOI 10.1038/sj.onc.1207439
   Schackmann RCJ, 2011, J CLIN INVEST, V121, P3176, DOI 10.1172/JCI41695
   Scheel C, 2011, CELL, V145, P926, DOI 10.1016/j.cell.2011.04.029
   Seidel B, 2004, ONCOGENE, V23, P5532, DOI 10.1038/sj.onc.1207718
   Serrano-Gomez SJ, 2016, MOL CANCER, V15, DOI 10.1186/s12943-016-0502-x
   Shamir ER, 2014, J CELL BIOL, V204, P839, DOI 10.1083/jcb.201306088
   Shrestha H, 2017, CELL SIGNAL, V31, P135, DOI 10.1016/j.cellsig.2017.01.009
   Silvera D, 2009, NAT CELL BIOL, V11, P903, DOI 10.1038/ncb1900
   Smalley-Freed W.G., 1824, J CLIN INVEST, P120
   Smith AL, 2012, MOL BIOL CELL, V23, P99, DOI 10.1091/mbc.E11-06-0497
   Soto E, 2008, J CELL BIOL, V183, P737, DOI 10.1083/jcb.200805113
   St Croix B, 1998, J CELL BIOL, V142, P557, DOI 10.1083/jcb.142.2.557
   Stairs DB, 2011, CANCER CELL, V19, P470, DOI 10.1016/j.ccr.2011.02.007
   Sun SR, 2009, KIDNEY INT, V75, P1278, DOI 10.1038/ki.2009.62
   Suyama K, 2002, CANCER CELL, V2, P301, DOI 10.1016/S1535-6108(02)00150-2
   TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419
   TAKEICHI M, 1995, CURR OPIN CELL BIOL, V7, P619, DOI 10.1016/0955-0674(95)80102-2
   Tam WL, 2013, NAT MED, V19, P1438, DOI 10.1038/nm.3336
   Taniuchi K, 2005, CANCER RES, V65, P3092, DOI 10.1158/0008.5472.CAN-04-3646
   Theisen CS, 2007, MOL BIOL CELL, V18, P1220, DOI 10.1091/mbc.E06-10-0960
   Tille JC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135442
   van de Ven Robert A H, 2016, Nat Commun, V7, P13874, DOI 10.1038/ncomms13874
   van Hengel J, 1999, P NATL ACAD SCI USA, V96, P7980, DOI 10.1073/pnas.96.14.7980
   van Roy F, 2008, CELL MOL LIFE SCI, V65, P3756, DOI 10.1007/s00018-008-8281-1
   VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M
   Wadham C, 2003, MOL BIOL CELL, V14, P2520, DOI 10.1091/mbc.E02-09-0577
   Wang WQ, 2012, GENE DEV, V26, P1959, DOI 10.1101/gad.192955.112
   Wheelock MJ, 2008, J CELL SCI, V121, P727, DOI 10.1242/jcs.000455
   Wijnhoven BPL, 2000, BRIT J SURG, V87, P992, DOI 10.1046/j.1365-2168.2000.01513.x
   Wildenberg GA, 2006, CELL, V127, P1027, DOI 10.1016/j.cell.2006.09.046
   Winter JM, 2008, CLIN CANCER RES, V14, P412, DOI 10.1158/1078-0432.CCR-07-0487
   Wong AST, 2003, J CELL BIOL, V161, P1191, DOI 10.1083/jcb.200212033
   Xiao KY, 2003, J CELL BIOL, V163, P535, DOI 10.1083/jcb.200306001
   Xie ZJ, 2007, J BIOL CHEM, V282, P8695, DOI 10.1074/jbc.M609135200
   Yanagisawa M, 2004, J BIOL CHEM, V279, P9512, DOI 10.1074/jbc.M310895200
   Yanagisawa M, 2008, J BIOL CHEM, V283, P18344, DOI 10.1074/jbc.M801192200
   Yanagisawa M, 2006, J CELL BIOL, V174, P1087, DOI 10.1083/jcb.200605022
   Yang K, 2016, LAB INVEST, V96, P116, DOI 10.1038/labinvest.2015.144
   Yap AS, 1998, CANCER INVEST, V16, P252, DOI 10.3109/07357909809039774
   Zhang F, 2002, J BIOL CHEM, V277, P10139, DOI 10.1074/jbc.M108062200
   Zheng XF, 2015, NATURE, V527, P525, DOI 10.1038/nature16064
NR 157
TC 182
Z9 199
U1 0
U2 43
PU ELSEVIER INC
PI SAN DIEGO
PA 525 B STREET, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0014-4827
EI 1090-2422
J9 EXP CELL RES
JI Exp. Cell Res.
PD SEP 1
PY 2017
VL 358
IS 1
SI SI
BP 78
EP 85
DI 10.1016/j.yexcr.2017.04.006
PG 8
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA FD1OR
UT WOS:000407307100013
PM 28412244
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Tajbakhsh, A
   Mokhtari-Zaer, A
   Rezaee, M
   Afzaljavan, F
   Rivandi, M
   Hassanian, SM
   Ferns, GA
   Pasdar, A
   Avan, A
AF Tajbakhsh, Amir
   Mokhtari-Zaer, Amin
   Rezaee, Mehdi
   Afzaljavan, Fahimeh
   Rivandi, Mehdi
   Hassanian, Seyed Mahdi
   Ferns, Gordon A.
   Pasdar, Alireza
   Avan, Amir
TI Therapeutic Potentials of BDNF/TrkB in Breast Cancer; Current Status and
   Perspectives
SO JOURNAL OF CELLULAR BIOCHEMISTRY
LA English
DT Article
DE BREAST CANCER; BRAIN-DERIVED NEUROTROPHIC FACTOR; EPIGENETICS; RISK
   FACTOR; PHARMACOLOGICAL MODULATORS
ID BDNF PROMOTER METHYLATION; TYROSINE KINASE-B; UROKINASE
   PLASMINOGEN-ACTIVATOR; NEUROTROPHIC RECEPTOR TRKB; ENDOTHELIAL
   GROWTH-FACTOR; IN-VITRO; VAL66MET POLYMORPHISM; ESTROGEN-RECEPTOR;
   POOR-PROGNOSIS; SIGNAL-TRANSDUCTION
AB Brain-derived neurotrophic factor (BDNF) is a potent neurotrophic factor that has been shown to stimulate breast cancer cell growth and metastasis via tyrosine kinase receptors TrkA, TrkB, and the p75(NTR) death receptor. The aberrant activation of BDNF/TrkB pathways can modulate several signaling pathways, including Akt/PI3K, Jak/STAT, NF-kB, UPAR/UPA, Wnt/beta-catenin, and VEGF pathways as well as the ER receptor. Several microRNAs have been identified that are involved in the modulation of BDNF/TrkB pathways. These include miR-206, miR-204, MiR-200a/c, MiR-210, MiR-134, and MiR-191; and these may be of value as prognostic and predictive biomarkers for detecting patients at high risk of developing breast cancer. It has also been demonstrated that a high expression of genes involved in the BDNF pathway in breast cancer is associated with poor clinical outcome and reduced survival of patients. Several approaches have been developed for targeting this pathway, for example TKr inhibitors (AZD6918, CEP-701) and RNA interference. The aim of the current review was to provide an overview of the role of BDNF/TrkB pathways in the pathogenesis of breast cancer and its value as a potential therapeutic target. (C) 2017 Wiley Periodicals, Inc.
C1 [Tajbakhsh, Amir; Afzaljavan, Fahimeh; Rivandi, Mehdi; Pasdar, Alireza] Mashhad Univ Med Sci, Dept Modern Sci & Technol, Fac Med, Mashhad, Iran.
   [Tajbakhsh, Amir; Mokhtari-Zaer, Amin; Rezaee, Mehdi; Afzaljavan, Fahimeh; Rivandi, Mehdi] Mashhad Univ Med Sci, Student Res Comm, Fac Med, Mashhad, Iran.
   [Mokhtari-Zaer, Amin] Mashhad Univ Med Sci, Neurogen Inflammat Res Ctr, Fac Med, Mashhad, Iran.
   [Mokhtari-Zaer, Amin] Mashhad Univ Med Sci, Dept Physiol, Fac Med, Mashhad, Iran.
   [Rezaee, Mehdi] Mashhad Univ Med Sci, Dept Med Biotechnol, Fac Med, Mashhad, Iran.
   [Hassanian, Seyed Mahdi] Mashhad Univ Med Sci, Dept Med Biochem, Fac Med, Mashhad, Iran.
   [Hassanian, Seyed Mahdi; Avan, Amir] Mashhad Univ Med Sci, Metab Syndrome Res Ctr, Fac Med, Mashhad, Iran.
   [Ferns, Gordon A.] Brighton & Sussex Med Sch, Div Med Educ, Brighton, E Sussex, England.
   [Pasdar, Alireza] Univ Aberdeen, Sch Med, Div Appl Med, Foresterhill, Aberdeen, Scotland.
   [Pasdar, Alireza] Mashhad Univ Med Sci, Med Genet Res Ctr, Mashhad, Iran.
C3 Mashhad University of Medical Sciences; Mashhad University of Medical
   Sciences; Mashhad University of Medical Sciences; Mashhad University of
   Medical Sciences; Mashhad University of Medical Sciences; Mashhad
   University of Medical Sciences; Mashhad University of Medical Sciences;
   University of Brighton; University of Sussex; University of Aberdeen;
   Mashhad University of Medical Sciences
RP Pasdar, A; Avan, A (通讯作者)，Mashhad Univ Med Sci, Mol Med Grp, Dept Modern Sci & Technol, Sch Med, Mashhad, Iran.
EM pasdara@mums.ac.ir; avana@mums.ac.ir
RI Rezaee, Mehdi/AAX-9876-2020; Tajbakhsh, Amir/AAB-1925-2019; shahidsales,
   soudabe/AAY-2920-2020; Afzaljavan, Fahimeh/AFK-8200-2022; Mokhtari-Zaer,
   Amin/AAN-5714-2021; Hassanian, Seyed Mahdi/KAL-9917-2024; Avan,
   Amir/G-3852-2013; Tajbakhsh, Amir/HMV-4969-2023
OI Afzaljavan, Fahimeh/0000-0001-7413-6945; naseri,
   shahrokh/0000-0001-8974-2120; Pasdar, Alireza/0000-0002-7864-9729; Avan,
   Amir/0000-0002-4968-0962; Mokhtari-Zaer, Amin/0000-0002-8838-9705;
   Tajbakhsh, Amir/0000-0002-2311-6554; rezaee, mehdi/0000-0002-2866-2327
CR Adam L, 2000, J BIOL CHEM, V275, P12041, DOI 10.1074/jbc.275.16.12041
   Alderson RF, 2000, BRAIN RES, V871, P210, DOI 10.1016/S0006-8993(00)02428-8
   [Anonymous], 2014, NAT REV NEUROSCI
   [Anonymous], [No title captured]
   Au CWH, 2009, CANCER LETT, V281, P151, DOI 10.1016/j.canlet.2009.02.025
   Baade PD, 2009, MOL NUTR FOOD RES, V53, P171, DOI 10.1002/mnfr.200700511
   Bagheri-Yarmand R, 2006, INT J CANCER, V118, P2703, DOI 10.1002/ijc.21650
   Bao W, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070616
   BARBACID M, 1995, CURR OPIN CELL BIOL, V7, P148, DOI 10.1016/0955-0674(95)80022-0
   BARDE YA, 1982, EMBO J, V1, P549, DOI 10.1002/j.1460-2075.1982.tb01207.x
   Bernard O, 2007, INT J BIOCHEM CELL B, V39, P1071, DOI 10.1016/j.biocel.2006.11.011
   Blasco-Gutiérrez MJ, 2007, CANCER INVEST, V25, P405, DOI 10.1080/07357900701206349
   Blasi F, 2002, NAT REV MOL CELL BIO, V3, P932, DOI 10.1038/nrm977
   Bower JE, 2008, J CLIN ONCOL, V26, P768, DOI 10.1200/JCO.2007.14.3248
   Brodeur GM, 2009, CLIN CANCER RES, V15, P3244, DOI 10.1158/1078-0432.CCR-08-1815
   Brodeur GM, 2003, NAT REV CANCER, V3, P203, DOI 10.1038/nrc1014
   Byrne GJ, 2007, ANTICANCER RES, V27, P3481
   Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997
   Cameron HL, 2008, REPROD TOXICOL, V25, P256, DOI 10.1016/j.reprotox.2007.11.013
   Cameron HL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004303
   Cao L, 2011, CELL METAB, V14, P324, DOI 10.1016/j.cmet.2011.06.020
   Cao L, 2010, CELL, V142, P52, DOI 10.1016/j.cell.2010.05.029
   Cao L, 2009, NAT MED, V15, P447, DOI 10.1038/nm.1933
   Chen D, 2004, GROWTH FACTORS, V22, P233, DOI 10.1080/08977190412331279890
   Chen DC, 2006, CANCER LETT, V237, P109, DOI 10.1016/j.canlet.2005.05.047
   Chen HZ, 2004, GYNECOL ONCOL, V94, P630, DOI 10.1016/j.ygyno.2004.05.056
   CLEGG DO, 1989, DEV BIOL, V134, P30, DOI 10.1016/0012-1606(89)90075-4
   CROWLEY CW, 1993, P NATL ACAD SCI USA, V90, P5021, DOI 10.1073/pnas.90.11.5021
   Davila M, 2003, J BIOL CHEM, V278, P36868, DOI 10.1074/jbc.M306196200
   de Lemos ML, 2001, ANN PHARMACOTHER, V35, P1118, DOI 10.1345/aph.10257
   Desmet CJ, 2006, CELL MOL LIFE SCI, V63, P755, DOI 10.1007/s00018-005-5490-8
   Dionne CA, 1998, CLIN CANCER RES, V4, P1887
   Dong Q, 2012, J BIOL CHEM, V287, P41720, DOI 10.1074/jbc.M112.405415
   Donovan MJ, 2000, DEVELOPMENT, V127, P4531
   Dooley LN, 2016, J AFFECT DISORDERS, V197, P43, DOI 10.1016/j.jad.2016.02.059
   Douma S, 2004, NATURE, V430, P1034, DOI 10.1038/nature02765
   DUGGAN C, 1995, INT J CANCER, V61, P597, DOI 10.1002/ijc.2910610502
   Dwivedi Y, 2003, ARCH GEN PSYCHIAT, V60, P804, DOI 10.1001/archpsyc.60.8.804
   Eades G, 2011, J BIOL CHEM, V286, P25992, DOI 10.1074/jbc.M111.229401
   Eden JA, 1996, CANCER TREAT REV, V22, P335, DOI 10.1016/S0305-7372(96)90006-7
   Egan MF, 2003, CELL, V112, P257, DOI 10.1016/S0092-8674(03)00035-7
   Eggert A, 2001, J CLIN ONCOL, V19, P689, DOI 10.1200/JCO.2001.19.3.689
   Eggert A, 2000, MED PEDIATR ONCOL, V35, P569, DOI 10.1002/1096-911X(20001201)35:6<569::AID-MPO16>3.0.CO;2-A
   Ernst C, 2009, MOL PSYCHIATR, V14, P830, DOI 10.1038/mp.2009.35
   Fang F, 2012, NEW ENGL J MED, V366, P1310, DOI 10.1056/NEJMoa1110307
   Fasanaro P, 2009, J BIOL CHEM, V284, P35134, DOI 10.1074/jbc.M109.052779
   Filipowicz W, 2008, NAT REV GENET, V9, P102, DOI 10.1038/nrg2290
   FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182
   Folkman J, 2007, NAT REV DRUG DISCOV, V6, P273, DOI 10.1038/nrd2115
   Fuchikami M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023881
   Fujikawa H, 2012, J GASTROENTEROL, V47, P775, DOI 10.1007/s00535-012-0532-0
   Gauger KJ, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-59
   Geiger TR, 2005, CANCER RES, V65, P7033, DOI 10.1158/0008-5472.CAN-05-0709
   George DJ, 1999, CANCER RES, V59, P2395
   Giulia D, 2006, BRAIN RES, V1098, P186, DOI 10.1016/j.brainres.2006.04.051
   GrondahlHansen J, 1995, CLIN CANCER RES, V1, P1079
   Grossmann ME, 2008, BRIT J CANCER, V98, P370, DOI 10.1038/sj.bjc.6604166
   Guo DW, 2011, J EXP CLIN CANC RES, V30, DOI 10.1186/1756-9966-30-97
   Haapasalo A, 1999, ONCOGENE, V18, P1285, DOI 10.1038/sj.onc.1202401
   HAMMOND CB, 1994, FERTIL STERIL, V62, pS157
   Hashimoto K, 2007, BIOESSAYS, V29, P116, DOI 10.1002/bies.20534
   HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0
   Ho R, 2002, CANCER RES, V62, P6462
   Hochberg Z, 2011, ENDOCR REV, V32, P159, DOI 10.1210/er.2009-0039
   Howe EN, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049987
   Hoyer AP, 2000, CANCER CAUSE CONTROL, V11, P177, DOI 10.1023/A:1008926219539
   Hu X, 2002, J NATL CANCER I, V94, P1704, DOI 10.1093/jnci/94.22.1704
   Hu ZY, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-96
   Huang EJ, 2001, ANNU REV NEUROSCI, V24, P677, DOI 10.1146/annurev.neuro.24.1.677
   Huelsken J, 2002, J CELL SCI, V115, P3977, DOI 10.1242/jcs.00089
   Huth L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102558
   Imam JS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052397
   Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783
   Javan F Afzal, 2015, JFH, V3, P111
   Jia S, 2015, ORAL ONCOL, V51, P64, DOI 10.1016/j.oraloncology.2014.10.008
   Kang HJ, 2015, PSYCHIAT INVEST, V12, P523, DOI 10.4306/pi.2015.12.4.523
   Kaplan DR, 2000, CURR OPIN NEUROBIOL, V10, P381, DOI 10.1016/S0959-4388(00)00092-1
   Kauppi K, 2013, NEUROPSYCHOLOGIA, V51, P2462, DOI 10.1016/j.neuropsychologia.2012.11.028
   Kawamura N, 2010, ENDOCRINOLOGY, V151, P3006, DOI 10.1210/en.2009-1378
   Keller S, 2010, ARCH GEN PSYCHIAT, V67, P258, DOI 10.1001/archgenpsychiatry.2010.9
   Kermani P, 2005, J CLIN INVEST, V115, P653, DOI 10.1172/JCI200522655
   Kerschensteiner M, 1999, J EXP MED, V189, P865, DOI 10.1084/jem.189.5.865
   Kim JM, 2015, INT J PSYCHIAT MED, V49, P75, DOI 10.1177/0091217415574439
   Kim JM, 2013, PSYCHO-ONCOLOGY, V22, P2848, DOI 10.1002/pon.3367
   Kim JM, 2012, PSYCHOSOM MED, V74, P8, DOI 10.1097/PSY.0b013e318241530c
   Kim MS, 2016, MOL CELLS, V39, P258, DOI 10.14348/molcells.2016.2310
   Kim MS, 2015, ONCOTARGET, V6, P40158, DOI 10.18632/oncotarget.5522
   Kim YK, 2007, PROG NEURO-PSYCHOPH, V31, P78, DOI 10.1016/j.pnpbp.2006.06.024
   Kinnally EL, 2010, GENES BRAIN BEHAV, V9, P575, DOI 10.1111/j.1601-183X.2010.00588.x
   KLEIN R, 1991, CELL, V66, P395, DOI 10.1016/0092-8674(91)90628-C
   Klopocki E, 2004, INT J ONCOL, V25, P641
   Körner A, 2007, J CLIN ENDOCR METAB, V92, P1041, DOI 10.1210/jc.2006-1858
   Kolonel LN, 2004, NAT REV CANCER, V4, P519, DOI 10.1038/nrc1389
   Kondo N, 2008, CANCER RES, V68, P5004, DOI 10.1158/0008-5472.CAN-08-0180
   Labbé E, 2007, CANCER RES, V67, P75, DOI 10.1158/0008-5472.CAN-06-2559
   Lam CT, 2011, CLIN CANCER RES, V17, P3123, DOI 10.1158/1078-0432.CCR-10-2802
   LAMBALLE F, 1991, CELL, V66, P967, DOI 10.1016/0092-8674(91)90442-2
   Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758
   Leek RD, 2001, ANTICANCER RES, V21, P4325
   Li WD, 2014, INT J CLIN EXP PATHO, V7, P3287
   Li X, 2012, CANCER RES, V72, DOI 10.1158/1538-7445.AM2012-4972
   Li ZJ, 2007, EXPERT OPIN THER TAR, V11, P1611, DOI 10.1517/14728222.11.12.1611
   Li ZJ, 2015, CANCER BIOL THER, V16, P477, DOI 10.1080/15384047.2015.1016659
   Li ZK, 2009, CANCER RES, V69, P7851, DOI 10.1158/0008-5472.CAN-08-4002
   LINDHOLM D, 1994, J NEUROBIOL, V25, P1362, DOI 10.1002/neu.480251105
   Liu BB, 2015, PSYCHOPHARMACOLOGY, V232, P541, DOI 10.1007/s00213-014-3690-3
   Liu QR, 2005, AM J MED GENET B, V134B, P93, DOI 10.1002/ajmg.b.30109
   Liu XL, 2014, MOL THER, V22, P1275, DOI 10.1038/mt.2014.45
   Lu B, 2003, NEURON, V39, P735, DOI 10.1016/S0896-6273(03)00538-5
   Macciò A, 2010, J MOL MED, V88, P677, DOI 10.1007/s00109-010-0611-8
   Marmot MG, 2012, LANCET, V380, P1778, DOI [10.1016/S0140-6736(12)61611-0, 10.1038/bjc.2013.177]
   Marosi K, 2014, TRENDS ENDOCRIN MET, V25, P89, DOI 10.1016/j.tem.2013.10.006
   Martinowich K, 2003, SCIENCE, V302, P890, DOI 10.1126/science.1090842
   Massagué J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745
   Mathur V, 2002, ENVIRON INT, V28, P331, DOI 10.1016/S0160-4120(02)00031-4
   MIDDLEMAS DS, 1991, MOL CELL BIOL, V11, P143, DOI 10.1128/MCB.11.1.143
   Miknyoczki SJ, 1999, INT J CANCER, V81, P417, DOI 10.1002/(SICI)1097-0215(19990505)81:3<417::AID-IJC16>3.0.CO;2-6
   Miknyoczki SJ, 1999, ANN NY ACAD SCI, V880, P252, DOI 10.1111/j.1749-6632.1999.tb09530.x
   Min HY, 1996, CANCER RES, V56, P2428
   Minturn JE, 2011, CANCER CHEMOTH PHARM, V68, P1057, DOI 10.1007/s00280-011-1581-4
   Miura P, 2012, J NEUROCHEM, V120, P230, DOI 10.1111/j.1471-4159.2011.07583.x
   Miyamoto Y, 2006, P NATL ACAD SCI USA, V103, P10444, DOI 10.1073/pnas.0603914103
   Mousavi K, 2006, J NEUROSCI, V26, P5739, DOI 10.1523/JNEUROSCI.5398-05.2006
   Murer MG, 2001, PROG NEUROBIOL, V63, P71, DOI 10.1016/S0301-0082(00)00014-9
   Nagpal N, 2013, CARCINOGENESIS, V34, P1889, DOI 10.1093/carcin/bgt107
   NAKAGAWARA A, 1995, GENOMICS, V25, P538, DOI 10.1016/0888-7543(95)80055-Q
   Nakagomi A, 2015, NPJ AGING MECH DIS, V1, DOI 10.1038/npjamd.2015.9
   Nakahashi T, 2000, FEBS LETT, V470, P113, DOI 10.1016/S0014-5793(00)01302-8
   Nakamura K, 2006, CANCER RES, V66, P4249, DOI 10.1158/0008-5472.CAN-05-2789
   Neves-Pereira M, 2005, MOL PSYCHIATR, V10, P208, DOI 10.1038/sj.mp.4001575
   Ng T, 2016, NEURO-ONCOLOGY, V18, P244, DOI 10.1093/neuonc/nov162
   Nishimura Y, 2006, HISTOCHEM CELL BIOL, V126, P627, DOI 10.1007/s00418-006-0198-x
   Nkhata KJ, 2009, BREAST CANCER RES TR, V114, P71, DOI 10.1007/s10549-008-9991-7
   O'Brien K, 2015, ONCOTARGET, V6, P32774, DOI 10.18632/oncotarget.5192
   O'Day E, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2484
   Odate S, 2013, LUNG CANCER, V79, P205, DOI 10.1016/j.lungcan.2012.12.004
   Ohira K, 2005, J NEUROSCI, V25, P1343, DOI 10.1523/JNEUROSCI.4436-04.2005
   Ohira K, 2007, EUR J NEUROSCI, V25, P406, DOI 10.1111/j.1460-9568.2007.05282.x
   Okamura K, 2012, LUNG CANCER, V78, P100, DOI 10.1016/j.lungcan.2012.07.011
   Okobia MN, 2006, WORLD J SURG ONCOL, P1, DOI [10.1186/1477-7819-4-1, DOI 10.1186/1477-7819-4-11]
   Okugawa Y, 2013, BRIT J CANCER, V108, P121, DOI 10.1038/bjc.2012.499
   Ossowski L, 2000, CURR OPIN CELL BIOL, V12, P613, DOI 10.1016/S0955-0674(00)00140-X
   Pan M, 2012, J NUTR HEALTH AGING, V16, P389, DOI 10.1007/s12603-011-0140-3
   Pandey GN, 2008, INT J NEUROPSYCHOPH, V11, P1047, DOI 10.1017/S1461145708009000
   Pandey GN, 2013, BIPOLAR DISORD, V15, P524, DOI 10.1111/bdi.12089
   Patani N, 2011, CANCER CELL INT, V11, DOI 10.1186/1475-2867-11-23
   Patapoutian A, 2001, CURR OPIN NEUROBIOL, V11, P272, DOI 10.1016/S0959-4388(00)00208-7
   Paz G, 2011, FRONT BIOSCI-LANDMRK, V16, P1634, DOI 10.2741/3810
   Pei Y, 2012, AM J MED GENET B, V159B, P560, DOI 10.1002/ajmg.b.32062
   Petryshen TL, 2010, MOL PSYCHIATR, V15, P810, DOI 10.1038/mp.2009.24
   Pezawas L, 2004, J NEUROSCI, V24, P10099, DOI 10.1523/JNEUROSCI.2680-04.2004
   PROSCHEL C, 1995, ONCOGENE, V11, P1271
   Pruunsild P, 2007, GENOMICS, V90, P397, DOI 10.1016/j.ygeno.2007.05.004
   Radka SF, 1996, BRAIN RES, V709, P122, DOI 10.1016/0006-8993(95)01321-0
   Ray A, 2007, INT J ONCOL, V30, P1499
   Reichardt LF, 2006, PHILOS T R SOC B, V361, P1545, DOI 10.1098/rstb.2006.1894
   Rex CS, 2007, J NEUROSCI, V27, P3017, DOI 10.1523/JNEUROSCI.4037-06.2007
   Rezaee M, 2016, J CONTROL RELEASE, V236, P1, DOI 10.1016/j.jconrel.2016.06.023
   Rose CR, 2003, NATURE, V426, P74, DOI 10.1038/nature01983
   Rothé F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020980
   Ruggeri BA, 1999, CURR MED CHEM, V6, P845
   Schecterson LC, 2010, DEV NEUROBIOL, V70, P332, DOI 10.1002/dneu.20767
   Schratt GM, 2006, NATURE, V439, P283, DOI 10.1038/nature04367
   Schroeder M, 2010, CURR OPIN PSYCHIATR, V23, P588, DOI 10.1097/YCO.0b013e32833d16c1
   Segal RA, 1996, ANNU REV NEUROSCI, V19, P463, DOI 10.1146/annurev.ne.19.030196.002335
   Shabbir M, 2010, EXPERT OPIN INV DRUG, V19, P427, DOI 10.1517/13543781003598862
   Shandiz FH, 2015, APJCP, V17, P1347
   Sheikh AM, 2010, J NEUROSCI RES, V88, P2641, DOI 10.1002/jnr.22416
   SOHRABJI F, 1995, P NATL ACAD SCI USA, V92, P11110, DOI 10.1073/pnas.92.24.11110
   Sohrabji F, 2006, FRONT NEUROENDOCRIN, V27, P404, DOI 10.1016/j.yfrne.2006.09.003
   SOPPET D, 1991, CELL, V65, P895, DOI 10.1016/0092-8674(91)90396-G
   Stoilov P, 2002, BIOCHEM BIOPH RES CO, V290, P1054, DOI 10.1006/bbrc.2001.6301
   Strock CJ, 2003, CANCER RES, V63, P5559
   Sun CY, 2010, TUMOR BIOL, V31, P121, DOI 10.1007/s13277-010-0016-x
   Tajbakhsh A, 2015, J CELL IMMUNOTHER, V1, P5
   Takahashi H, 1998, BIOCHEM BIOPH RES CO, V249, P138, DOI 10.1006/bbrc.1998.9094
   Tanaka K, 2014, PLOS ONE, V9, DOI [10.1371/journal.pone.0087728, 10.1371/journal.pone.0096410]
   Teng HK, 2005, J NEUROSCI, V25, P5455, DOI 10.1523/JNEUROSCI.5123-04.2005
   Teng KK, 2010, DEV NEUROBIOL, V70, P350, DOI 10.1002/dneu.20768
   Thiele CJ, 2009, CLIN CANCER RES, V15, P5962, DOI 10.1158/1078-0432.CCR-08-0651
   Tian N, 2014, NEUROSCI BULL, V30, P191, DOI 10.1007/s12264-013-1419-7
   Tozlu S, 2006, ENDOCR-RELAT CANCER, V13, P1109, DOI 10.1677/erc.1.01120
   Turashvili G, 2006, PATHOBIOLOGY, V73, P213, DOI 10.1159/000098207
   van Roy F, 2014, NAT REV CANCER, V14, P121, DOI 10.1038/nrc3647
   Vanhecke E, 2011, CLIN CANCER RES, V17, P1741, DOI 10.1158/1078-0432.CCR-10-1890
   Varendi K, 2015, CELL MOL LIFE SCI, V72, P1779, DOI 10.1007/s00018-015-1836-z
   Veeck J, 2006, ONCOGENE, V25, P3479, DOI 10.1038/sj.onc.1209386
   Vona-Davis L, 2007, ENDOCR-RELAT CANCER, V14, P189, DOI 10.1677/ERC-06-0068
   Walker J, 2008, J CLIN ONCOL, V26, P4725, DOI 10.1200/JCO.2007.11.8844
   Wang YH, 2016, EXP BRAIN RES, V234, P1057, DOI 10.1007/s00221-015-4513-4
   Yamakuchi M, 2012, FRONT PHYSIOL, V3, DOI 10.3389/fphys.2012.00068
   YAMAMOTO H, 1990, J NEUROSCI, V10, P3469
   Yamamoto M, 1996, NEUROCHEM RES, V21, P929, DOI 10.1007/BF02532343
   Yang JM, 2009, NAT NEUROSCI, V12, P113, DOI 10.1038/nn.2244
   Yang N, 1998, NATURE, V393, P809, DOI 10.1038/31735
   Yang XM, 2012, INT J ONCOL, V41, P1541, DOI 10.3892/ijo.2012.1581
   Yi H, 2012, NEUROREPORT, V23, P189, DOI 10.1097/WNR.0b013e32834fab06
   Yilmaz T, 2010, CANCER BIOL THER, V10, P644, DOI 10.4161/cbt.10.6.12782
   Yin B, 2015, ONCOGENE, V34, P761, DOI 10.1038/onc.2014.8
   Yu H, 2011, ACTA PHARMACOL SIN, V32, P3, DOI 10.1038/aps.2010.184
   ZAFRA F, 1990, EMBO J, V9, P3545, DOI 10.1002/j.1460-2075.1990.tb07564.x
   Zai CC, 2012, INT J NEUROPSYCHOPH, V15, P1037, DOI 10.1017/S1461145711001313
   Zhang JX, 2015, INT J CLIN EXP PATHO, V8, P14472
   Zuccato C, 2001, SCIENCE, V293, P493, DOI 10.1126/science.1059581
NR 204
TC 69
Z9 74
U1 0
U2 14
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0730-2312
EI 1097-4644
J9 J CELL BIOCHEM
JI J. Cell. Biochem.
PD SEP
PY 2017
VL 118
IS 9
BP 2502
EP 2515
DI 10.1002/jcb.25943
PG 14
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA FA5WN
UT WOS:000405515000002
PM 28230291
DA 2025-01-12
ER

PT J
AU Ferrero, G
   Miano, V
   Beccuti, M
   Balbo, G
   De Bortoli, M
   Cordero, F
AF Ferrero, Giulio
   Miano, Valentina
   Beccuti, Marco
   Balbo, Gianfranco
   De Bortoli, Michele
   Cordero, Francesca
TI Dissecting the genomic activity of a transcriptional regulator by the
   integrative analysis of omics data
SO SCIENTIFIC REPORTS
LA English
DT Article
ID ESTROGEN-RECEPTOR BINDING; SIGNALING PATHWAYS; PUBLIC DATA; ER-ALPHA;
   CHIP; ELEMENTS; FOXA1; MECHANISMS; CISTROME; INSIGHTS
AB In the study of genomic regulation, strategies to integrate the data produced by Next Generation Sequencing (NGS)-based technologies in a meaningful ensemble are eagerly awaited and must continuously evolve. Here, we describe an integrative strategy for the analysis of data generated by chromatin immunoprecipitation followed by NGS which combines algorithms for data overlap, normalization and epigenetic state analysis. The performance of our strategy is illustrated by presenting the analysis of data relative to the transcriptional regulator Estrogen Receptor alpha (ERa) in MCF-7 breast cancer cells and of Glucocorticoid Receptor (GR) in A549 lung cancer cells. We went through the definition of reference cistromes for different experimental contexts, the integration of data relative to co-regulators and the overlay of chromatin states as defined by epigenetic marks in MCF-7 cells. With our strategy, we identified novel features of estrogen-independent ERa activity, including FoxM1 interaction, eRNAs transcription and a peculiar ontology of connected genes.
C1 [Ferrero, Giulio; Miano, Valentina; Balbo, Gianfranco; De Bortoli, Michele; Cordero, Francesca] Univ Turin, Ctr Mol Syst Biol, I-10043 Turin, Italy.
   [Ferrero, Giulio; Beccuti, Marco; Balbo, Gianfranco; Cordero, Francesca] Univ Turin, Dept Comp Sci, I-10149 Turin, Italy.
   [Ferrero, Giulio; Miano, Valentina; De Bortoli, Michele] Univ Turin, Dept Biol & Clin Sci, I-10043 Turin, Italy.
C3 University of Turin; University of Turin; University of Turin
RP De Bortoli, M (通讯作者)，Univ Turin, Ctr Mol Syst Biol, I-10043 Turin, Italy.; De Bortoli, M (通讯作者)，Univ Turin, Dept Biol & Clin Sci, I-10043 Turin, Italy.
EM michele.debortoli@unito.it
RI Ferrero, Giulio/K-9508-2019; Beccuti, Marco/K-7881-2012; Cordero,
   Francesca/AAB-3655-2019; De Bortoli, Michele/B-5418-2013; MIANO,
   VALENTINA/K-3716-2018; Ferrero, Giulio/B-9838-2014
OI MIANO, VALENTINA/0000-0002-0260-5885; Beccuti,
   Marco/0000-0001-6125-9460; Ferrero, Giulio/0000-0002-4580-0680; Cordero,
   Francesca/0000-0002-3143-3330; De Bortoli, Michele/0000-0002-6666-9052
FU AIRC (Associazione Italiana per la Ricerca sul Cancro) [IG 15600];
   Fondazione CRT [2014.1854]; Fondazione San Paolo grant GeneRNet; Local
   University of Torino
FX We thank Prof. Raffaele Calogero for technical support. This work was
   supported by AIRC (Associazione Italiana per la Ricerca sul Cancro,
   Grant IG 15600); by Fondazione CRT (grant 2014.1854); by Fondazione San
   Paolo grant GeneRNet and by Local University of Torino 2014 Research
   funding.
CR [Anonymous], ONCOTARGET
   Bailey T.L., 2012, Nucleic Acids Research, V40, P1
   Barrett T, 2013, NUCLEIC ACIDS RES, V41, pD991, DOI 10.1093/nar/gks1193
   Bennesch MA, 2015, MOL ENDOCRINOL, V29, P349, DOI 10.1210/me.2014-1315
   Caizzi L, 2014, P NATL ACAD SCI USA, V111, P4892, DOI 10.1073/pnas.1315445111
   Cardamone MD, 2009, P NATL ACAD SCI USA, V106, P7420, DOI 10.1073/pnas.0903033106
   Danko CG, 2013, MOL CELL, V50, P212, DOI 10.1016/j.molcel.2013.02.015
   Deplancke B, 2016, CELL, V166, P538, DOI 10.1016/j.cell.2016.07.012
   Devailly G, 2015, FEBS LETT, V589, P3866, DOI 10.1016/j.febslet.2015.11.027
   Flach KD, 2016, J ENDOCRINOL, V229, pR43, DOI 10.1530/JOE-16-0003
   Dunham I, 2012, NATURE, V489, P57, DOI 10.1038/nature11247
   Ernst J, 2011, NATURE, V473, P43, DOI 10.1038/nature09906
   Garcia-Bassets I, 2012, CELL CYCLE, V11, P3199, DOI 10.4161/cc.21281
   Griffon A, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gku1280
   Guertin MJ, 2014, MOL ENDOCRINOL, V28, P1522, DOI 10.1210/me.2014-1130
   Hah N, 2014, MOL CELL ENDOCRINOL, V382, P652, DOI 10.1016/j.mce.2013.06.021
   Hah N, 2013, GENOME RES, V23, P1210, DOI 10.1101/gr.152306.112
   Hurtado A, 2011, NAT GENET, V43, P27, DOI 10.1038/ng.730
   Jansen MPHM, 2013, CANCER RES, V73, P6632, DOI 10.1158/0008-5472.CAN-13-0704
   Ji HK, 2008, NAT BIOTECHNOL, V26, P1293, DOI 10.1038/nbt.1505
   Kannan L, 2016, BRIEF BIOINFORM, V17, P603, DOI 10.1093/bib/bbv080
   Kolesnikov N, 2015, NUCLEIC ACIDS RES, V43, pD1113, DOI 10.1093/nar/gku1057
   Kuhn RM, 2013, BRIEF BIOINFORM, V14, P144, DOI 10.1093/bib/bbs038
   Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/NMETH.1923, 10.1038/nmeth.1923]
   Lerdrup M, 2016, NAT STRUCT MOL BIOL, V23, P349, DOI 10.1038/nsmb.3180
   Li WB, 2016, NAT REV GENET, V17, P207, DOI 10.1038/nrg.2016.4
   Li WB, 2013, NATURE, V498, P516, DOI 10.1038/nature12210
   Liu T, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-8-r83
   Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8
   Ma CX, 2015, NAT REV CANCER, V15, P261, DOI 10.1038/nrc3920
   Madureira PA, 2006, J BIOL CHEM, V281, P25167, DOI 10.1074/jbc.M603906200
   Mathelier A, 2015, TRENDS GENET, V31, P67, DOI 10.1016/j.tig.2014.12.003
   McLean CY, 2010, NAT BIOTECHNOL, V28, P495, DOI 10.1038/nbt.1630
   Millour J, 2010, ONCOGENE, V29, P2983, DOI 10.1038/onc.2010.47
   Nielsen CB, 2012, GENOME RES, V22, P2262, DOI 10.1101/gr.140665.112
   Ong CT, 2011, NAT REV GENET, V12, P283, DOI 10.1038/nrg2957
   Pan JS, 2015, MULTIMED TOOLS APPL, V74, P9191, DOI 10.1007/s11042-014-2076-1
   Quinlan AR, 2010, BIOINFORMATICS, V26, P841, DOI 10.1093/bioinformatics/btq033
   Reddy TE, 2009, GENOME RES, V19, P2163, DOI 10.1101/gr.097022.109
   Ross-Innes CS, 2012, NATURE, V481, P389, DOI 10.1038/nature10730
   Saba R, 2016, INT J BREAST CANCER, V2016, DOI 10.1155/2016/9768183
   Sanders DA, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-1-r6
   Schmidt D, 2010, GENOME RES, V20, P578, DOI 10.1101/gr.100479.109
   Song JM, 2015, GENOME BIOL, V16, DOI 10.1186/s13059-015-0598-0
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Swinstead EE, 2016, CELL, V165, P593, DOI 10.1016/j.cell.2016.02.067
   Tan SK, 2011, EMBO J, V30, P2569, DOI 10.1038/emboj.2011.151
   Theodorou V, 2013, GENOME RES, V23, P12, DOI 10.1101/gr.139469.112
   van Duijvenboden K, 2016, NUCLEIC ACIDS RES, V44, DOI 10.1093/nar/gkv1144
   Vockley CM, 2016, CELL, V166, P1269, DOI 10.1016/j.cell.2016.07.049
   Wang LG, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gku1079
   Yan HH, 2014, BMC BIOINFORMATICS, V15, DOI 10.1186/1471-2105-15-280
   Yang YC, 2014, PLOS ONE, V9, DOI [10.1371/journal.pone.0085863, 10.1371/journal.pone.0100677, 10.1371/journal.pone.0087749, 10.1371/journal.pone.0102942]
   Ye T, 2011, NUCLEIC ACIDS RES, V39, DOI 10.1093/nar/gkq1287
NR 54
TC 5
Z9 5
U1 0
U2 4
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD AUG 17
PY 2017
VL 7
AR 8564
DI 10.1038/s41598-017-08754-9
PG 13
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA FD9TC
UT WOS:000407864000031
PM 28819152
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Chen, YK
   Bonaldi, T
   Cuomo, A
   Del Rosario, JR
   Hosfield, DJ
   Kanouni, T
   Kao, SC
   Lai, C
   Lobo, NA
   Matuszkiewicz, J
   McGeehan, A
   O'Connell, SM
   Shi, LH
   Stafford, JA
   Stansfield, RK
   Veal, JM
   Weiss, MS
   Yuen, NY
   Wallace, MB
AF Chen, Young K.
   Bonaldi, Tiziana
   Cuomo, Alessandro
   Del Rosario, Joselyn R.
   Hosfield, David J.
   Kanouni, Toufike
   Kao, Shih-chu
   Lai, Chon
   Lobo, Neethan A.
   Matuszkiewicz, Jennifer
   McGeehan, Andrew
   O'Connell, Shawn M.
   Shi, Lihong
   Stafford, Jeffrey A.
   Stansfield, Ryan K.
   Veal, James M.
   Weiss, Michael S.
   Yuen, Natalie Y.
   Wallace, Michael B.
TI Design of KDM4 Inhibitors with Antiproliferative Effects in Cancer
   Models
SO ACS MEDICINAL CHEMISTRY LETTERS
LA English
DT Article
DE Epigenetics; histone demethylase; KDM4; JMJD2; synthesis; cancer
ID HISTONE H3; BREAST-CANCER; COPY GAIN; DEMETHYLASES; GASC1; GENE;
   METHYLATION; PREVENTION; LYSINE-9; THERAPY
AB Histone lysine demethylases (KDMs) play a vital role in the regulation of chromatin-related processes. Herein, we describe our discovery of a series of potent KDM4 inhibitors that are both cell permeable and antiproliferative in cancer models. The modulation of histone H3K9me3 and H3K36me3 upon compound treatment was verified by homogeneous time-resolved fluorescence assay and by mass spectroscopy detection. Optimization of the series using structure-based drug design led to compound 6 (QC6352), a potent KDM4 family inhibitor that is efficacious in breast and colon cancer PDX models.
C1 [Chen, Young K.; Del Rosario, Joselyn R.; Kanouni, Toufike; Lai, Chon; Matuszkiewicz, Jennifer; O'Connell, Shawn M.; Shi, Lihong; Stafford, Jeffrey A.; Stansfield, Ryan K.; Veal, James M.; Wallace, Michael B.] Celgene Quanticel Res, 10300 Campus Point Dr,Suite 100, San Diego, CA 92121 USA.
   [Kao, Shih-chu; Lobo, Neethan A.; McGeehan, Andrew; Weiss, Michael S.; Yuen, Natalie Y.] Celgene Quanticel Res, 1500 Owens St,Suite 500, San Francisco, CA 94158 USA.
   [Bonaldi, Tiziana; Cuomo, Alessandro] European Inst Oncol, Dept Expt Oncol, Via Adamello 16, I-20139 Milan, Italy.
   [Hosfield, David J.] Univ Chicago, Ben May Dept Canc Res, 929 East 57th St, Chicago, IL 60637 USA.
   [Kao, Shih-chu] Benitec Biopharma, 3940 Trust Way, Hayward, CA 94545 USA.
   [O'Connell, Shawn M.] Pfizer Inc, Epigenet, Oncol R&D, 10724 Sci Ctr Dr, San Diego, CA 92121 USA.
   [Stafford, Jeffrey A.; Stansfield, Ryan K.; Veal, James M.] Jecure Therapeut Inc, 4757 Nexus Ctr Dr,Suite 150, San Diego, CA 92121 USA.
   [Weiss, Michael S.] Bristol Myers Squibb, 700 Bay Rd,Suite A, Redwood City, CA 94063 USA.
C3 IRCCS European Institute of Oncology (IEO); University of Chicago;
   Pfizer; Bristol-Myers Squibb
RP Wallace, MB (通讯作者)，Celgene Quanticel Res, 10300 Campus Point Dr,Suite 100, San Diego, CA 92121 USA.
EM mwallace@celgene.com
RI cuomo, alessandro/AAB-7372-2019; Wallace, Michael/GZL-9731-2022;
   Bonaldi, Tiziana/K-5075-2016
OI Cuomo, Alessandro/0000-0002-9778-7190; Kao,
   Shih-chu/0000-0002-6294-5494; Bonaldi, Tiziana/0000-0003-3556-1265;
   Wallace, Michael/0000-0002-6446-5785
CR Black JC, 2015, GENE DEV, V29, P1018, DOI 10.1101/gad.259796.115
   Black JC, 2013, CELL, V154, P541, DOI 10.1016/j.cell.2013.06.051
   Bonaldi T, 2004, PROTEOMICS, V4, P1382, DOI 10.1002/pmic.200300743
   Cloos PAC, 2006, NATURE, V442, P307, DOI 10.1038/nature04837
   Das PP, 2014, MOL CELL, V53, P32, DOI 10.1016/j.molcel.2013.11.011
   Dimitrova E, 2015, EMBO REP, V16, P1620, DOI 10.15252/embr.201541113
   Durkin K., US, Patent No. [2010/0160682, 20100160682]
   Klose RJ, 2006, NATURE, V442, P312, DOI 10.1038/nature04853
   Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005
   Kruidenier L, 2012, NATURE, V488, P404, DOI 10.1038/nature11262
   Kupershmit I., 2014, NUCLEIC ACIDS RES, V42, P6168
   Labelle M., US, Patent No. [2016/0237037, 20160237037]
   Lassalas P, 2016, J MED CHEM, V59, P3183, DOI 10.1021/acs.jmedchem.5b01963
   Liu G, 2009, ONCOGENE, V28, P4491, DOI 10.1038/onc.2009.297
   Loh YH, 2007, GENE DEV, V21, P2545, DOI 10.1101/gad.1588207
   Lohse B, 2011, BIOORGAN MED CHEM, V19, P3625, DOI 10.1016/j.bmc.2011.01.046
   Luo WB, 2012, P NATL ACAD SCI USA, V109, pE3367, DOI 10.1073/pnas.1217394109
   Maxwell PH, 2016, NAT REV NEPHROL, V12, P157, DOI 10.1038/nrneph.2015.193
   McAllister TE, 2016, J MED CHEM, V59, P1308, DOI 10.1021/acs.jmedchem.5b01758
   Mohammad HP, 2015, CANCER CELL, V28, P57, DOI 10.1016/j.ccell.2015.06.002
   Noberini R, 2016, DATA BRIEF, V7, P188, DOI 10.1016/j.dib.2016.02.028
   Rose NR, 2008, J MED CHEM, V51, P7053, DOI 10.1021/jm800936s
   Rotili Dante, 2011, Genes Cancer, V2, P663, DOI 10.1177/1947601911417976
   Shi L, 2011, P NATL ACAD SCI USA, V108, P7541, DOI 10.1073/pnas.1017374108
   Smith CM, 2002, P NATL ACAD SCI USA, V99, P16454, DOI 10.1073/pnas.182424999
   Soldi M, 2014, PROTEOMICS, V14, P2212, DOI 10.1002/pmic.201400075
   Tao ZF, 2014, ACS MED CHEM LETT, V5, P1088, DOI 10.1021/ml5001867
   Tausendschön M, 2011, CYTOKINE, V53, P256, DOI 10.1016/j.cyto.2010.11.002
   Taylor FC, 2013, JAMA-J AM MED ASSOC, V310, P2451, DOI 10.1001/jama.2013.281348
   Thinnes CC, 2014, BBA-GENE REGUL MECH, V1839, P1416, DOI 10.1016/j.bbagrm.2014.05.009
   Tian XJ, 2013, CURR CANCER DRUG TAR, V13, P558
   Wagner EJ, 2012, NAT REV MOL CELL BIO, V13, P115, DOI 10.1038/nrm3274
   Westaway SM, 2016, J MED CHEM, V59, P1357, DOI 10.1021/acs.jmedchem.5b01537
   Williams ST, 2014, EPIGENETICS-US, V9, P1596, DOI 10.4161/15592294.2014.983381
   Yamamoto S, 2013, CARCINOGENESIS, V34, P2380, DOI 10.1093/carcin/bgt174
   Yang ZQ, 2000, CANCER RES, V60, P4735
   Young LC, 2013, BIOCHEM CELL BIOL, V91, P369, DOI 10.1139/bcb-2012-0054
NR 37
TC 41
Z9 45
U1 0
U2 19
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1948-5875
J9 ACS MED CHEM LETT
JI ACS Med. Chem. Lett.
PD AUG
PY 2017
VL 8
IS 8
BP 869
EP 874
DI 10.1021/acsmedchemlett.7b00220
PG 6
WC Chemistry, Medicinal
WE Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC)
SC Pharmacology & Pharmacy
GA FD6RY
UT WOS:000407656800015
PM 28835804
OA Green Published, Green Submitted
DA 2025-01-12
ER

PT J
AU Daraei, A
   Izadi, P
   Khorasani, G
   Nafissi, N
   Naghizadeh, MM
   Younosi, N
   Meysamie, A
   Mansoori, Y
   Bastami, M
   Tavakkoly-Bazzaz, J
AF Daraei, Abdolreza
   Izadi, Pantea
   Khorasani, Ghasemali
   Nafissi, Nahid
   Naghizadeh, Mohammad Mehdi
   Younosi, Nasim
   Meysamie, Alipasha
   Mansoori, Yaser
   Bastami, Milad
   Tavakkoly-Bazzaz, Javad
TI Epigenetic Changes of the <i>ESR1</i> Gene in Breast Tissue of Healthy
   Women: A Missing Link with Breast Cancer Risk Factors?
SO GENETIC TESTING AND MOLECULAR BIOMARKERS
LA English
DT Article
DE normal breast tissue; ESR1 gene; CpG island methylation; MeDIP assay;
   breast cancer risk factors
ID BODY-MASS INDEX; DNA METHYLATION; RECEPTOR GENE; ESTROGEN;
   HYPERMETHYLATION; EXPRESSION; ISLANDS; TUMORS; CELLS
AB Background: Reproductive history and obesity are among the well-recognized risk factors in the development of breast cancer, which are partially mediated by the increased exposure of breast tissues to estrogens. However, only a few studies have investigated the link between these risk factors and the pattern of methylation signatures in the breast tissue of healthy women. The role of the estrogen receptor 1 (ESR1) gene hypermethylation is reportedly important in the development of breast cancer. Thus, it is speculated that such ESR1 epigenetic changes may be influenced or shaped by obesity and reproductive history-related factors before and during breast carcinogenesis. Materials and Methods: Breast samples were collected from 120 cancer-free women who had undergone cosmetic mammoplasty. DNA was extracted from the breast tissues and, then, the methylation levels at the promoter and exon 1 regions of the ESR1 gene CpG island were determined by using the methylated DNA immunoprecipitation-quantitative PCR assay. Results: The methylation level of the ESR1 promoter observed in women with a body mass index (BMI) 30kg/m(2) (p0.001) was higher than in the subgroups of women of BMI <25kg/m(2) (p<0.001) and BMI 25-29kg/m(2) (p<0.001) and was also higher in postmenopausal women compared with that in premenopausal women (p=0.046). Pearson correlation coefficient analyses also showed that the high methylation of the ESR1 promoter was correlated with increasing age (r=-0.246, p=0.007) and BMI (r=-0.331, p0.001). Finally, linear multivariate regression revealed a significant association between high methylation rates in the ESR1 gene promoter and increased BMI (=-0.285, 95% CI=-0.457 to -0.113, p=0.001). Furthermore, a higher methylation level at the ESR1 gene exon 1 was found in the BMI30 kg/m(2) subgroup compared to the BMI 25-29 kg/m(2) subgroup (p=0.023). Conclusion: These findings provide new hints about the relationship between epigenetic changes within the ESR1 gene CpG island and postmenopausal obesity and aging in cancer-free women. In terms of lifestyle intervention opportunities, this study also highlights the significance and feasibility of such interventions for BMI as a modifiable risk factor.
C1 [Daraei, Abdolreza; Izadi, Pantea; Tavakkoly-Bazzaz, Javad] Univ Tehran Med Sci, Sch Med, Dept Med Genet, Tehran 1417613151, Iran.
   [Khorasani, Ghasemali] Univ Tehran Med Sci, Div Plast & Reconstruct Surg, Imam Khomeini Hosp Complex, Tehran, Iran.
   [Nafissi, Nahid] Iran Univ Med Sci, Sch Med, Surg Dept, Tehran, Iran.
   [Naghizadeh, Mohammad Mehdi; Mansoori, Yaser] Fasa Univ Med Sci, Noncommunicable Dis Res Ctr, Fasa, Iran.
   [Younosi, Nasim] Shahid Beheshti Univ Med Sci, Sch Med, Surg Dept, Tehran, Iran.
   [Meysamie, Alipasha] Univ Tehran Med Sci, Med Fac, Community & Prevent Med Dept, Tehran, Iran.
   [Bastami, Milad] Tabriz Univ Med Sci, Dept Med Genet, Fac Med, Tabriz, Iran.
C3 Tehran University of Medical Sciences; Tehran University of Medical
   Sciences; Iran University of Medical Sciences; Shahid Beheshti
   University Medical Sciences; Tehran University of Medical Sciences;
   Tabriz University of Medical Science
RP Tavakkoly-Bazzaz, J (通讯作者)，Univ Tehran Med Sci, Sch Med, Dept Med Genet, Tehran 1417613151, Iran.
EM tavakkolybazzazj@tums.ac.ir
RI Meysamie, Alipasha/H-1778-2012; Daraei, Abdolreza/I-5998-2018; Bastami,
   Milad/L-5426-2017; Mansouri, Yaser/T-2847-2017; Naghizadeh, Mohammad
   Mehdi/O-4889-2017
OI Daraei, Abdolreza/0000-0002-2106-835X; Bastami,
   Milad/0000-0002-7686-4505; Mansouri, Yaser/0000-0002-9101-5552;
   Tavakkoly-Bazzaz, Javad/0000-0003-1623-1463; Naghizadeh, Mohammad
   Mehdi/0000-0001-5562-103X
FU Tehran University of Medical Sciences (TUMS), Tehran, Iran [25730]
FX This article was extracted from a part of the PhD dissertation on
   Medical Genetics by Dr. Abdolreza Daraei, supervised by Dr. Javad
   Tavakkoly-Bazzaz. This research was financially supported by Tehran
   University of Medical Sciences (TUMS), Tehran, Iran (Grant No. 25730).
CR [Anonymous], 2013, BREAST CANCER RES
   Bernstein L, 2002, J MAMMARY GLAND BIOL, V7, P3, DOI 10.1023/A:1015714305420
   Danforth DN, 2016, BREAST CANCER-BASIC, V10, P109, DOI 10.4137/BCBCR.S39384
   Medina-Jaime AD, 2014, ASIAN PAC J CANCER P, V15, P3041, DOI 10.7314/APJCP.2014.15.7.3041
   Demetriou CA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079391
   Dumitrescu RG, 2010, J CELL MOL MED, V14, P1468, DOI 10.1111/j.1582-4934.2009.00924.x
   FERGUSON AT, 1995, CANCER RES, V55, P2279
   Fernandez SV, 2010, MUTAT RES-FUND MOL M, V688, P28, DOI 10.1016/j.mrfmmm.2010.02.007
   Gaudet MM, 2009, CANCER EPIDEM BIOMAR, V18, P3036, DOI 10.1158/1055-9965.EPI-09-0678
   Ghosh S, 2014, BREAST CANCER RES TR, V147, P653, DOI 10.1007/s10549-014-3132-2
   Hair BY, 2015, CANCER EPIDEM BIOMAR, V24, P580, DOI 10.1158/1055-9965.EPI-14-1017
   Hervouet E, 2013, EPIGENETICS-US, V8, P237, DOI 10.4161/epi.23790
   Izadi P, 2014, MOL BIOL REP, V41, P7607, DOI 10.1007/s11033-014-3650-3
   Johnson KC, 2014, EPIGENETICS-US, V9, P268, DOI 10.4161/epi.27015
   Jones MJ, 2015, AGING CELL, V14, P924, DOI 10.1111/acel.12349
   Jones PA, 2012, NAT REV GENET, V13, P484, DOI 10.1038/nrg3230
   Khakpour G, 2015, TUMOR BIOL, V36, P4905, DOI 10.1007/s13277-015-3567-z
   Kobayashi S, 2012, BREAST CANCER-TOKYO, V19, P302, DOI 10.1007/s12282-012-0384-8
   Lapidus RG, 1996, CLIN CANCER RES, V2, P805
   Lapidus RG, 1998, J MAMMARY GLAND BIOL, V3, P85, DOI 10.1023/A:1018778403001
   Munsell MF, 2014, EPIDEMIOL REV, V36, P114, DOI 10.1093/epirev/mxt010
   Olopade OI, 2008, CLIN CANCER RES, V14, P7988, DOI 10.1158/1078-0432.CCR-08-1211
   Riman T, 2004, ACTA OBSTET GYN SCAN, V83, P783, DOI 10.1111/j.0001-6349.2004.00550.x
   Russo J, 2003, J STEROID BIOCHEM, V87, P1, DOI 10.1016/S0960-0760(03)00390-X
   Taiwo O, 2012, NAT PROTOC, V7, P617, DOI 10.1038/nprot.2012.012
   Wei M, 2008, BREAST CANC RES TREA, V111, P113, DOI DOI 10.1007/s10549-007-9766-6
   Zhang MH, 2014, BIOMED REP, V2, P41, DOI 10.3892/br.2013.187
NR 27
TC 15
Z9 16
U1 0
U2 1
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1945-0265
EI 1945-0257
J9 GENET TEST MOL BIOMA
JI Genet. Test. Mol. Biomark.
PD AUG
PY 2017
VL 21
IS 8
BP 464
EP 470
DI 10.1089/gtmb.2017.0028
PG 7
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA FD9RY
UT WOS:000407861000003
PM 28708432
DA 2025-01-12
ER

PT J
AU Paullin, T
   Powell, C
   Menzie, C
   Hill, R
   Cheng, F
   Martyniuk, CJ
   Westerheide, SD
AF Paullin, Trillitye
   Powell, Chase
   Menzie, Christopher
   Hill, Robert
   Cheng, Feng
   Martyniuk, Christopher J.
   Westerheide, Sandy D.
TI Spheroid growth in ovarian cancer alters transcriptome responses for
   stress pathways and epigenetic responses
SO PLOS ONE
LA English
DT Article
ID MESENCHYMAL TRANSITION; HISTONE MODIFICATIONS; BREAST-CANCER;
   TUMOR-CELL; TGF-BETA; EXPRESSION; PROTEIN; RESISTANCE; ADHESION; CULTURE
AB Ovarian cancer is the most lethal gynecological cancer, with over 200,000 women diagnosed each year and over half of those cases leading to death. These poor statistics are related to a lack of early symptoms and inadequate screening techniques. This results in the cancer going undetected until later stages when the tumor has metastasized through a process that requires the epithelial to mesenchymal transition (EMT). In lieu of traditional monolayer cell culture, EMT and cancer progression in general is best characterized through the use of 3D spheroid models. In this study, we examine gene expression changes through microarray analysis in spheroid versus monolayer ovarian cancer cells treated with TGF beta to induce EMT. Transcripts that included Coiled-Coil Domain Containing 80 (CCDC80), Solute Carrier Family 6 (Neutral Amino Acid Transporter), Member 15 (SLC6A15), Semaphorin 3E (SEMA3E) and PIF1 5'-To-3' DNA Helicase (PIF1) were downregulated more than 10-fold in the 3D cells while Inhibitor Of DNA Binding 2, HLH Protein (ID2), Regulator Of Cell Cycle (RGCC), Protease, Serine 35 (PRSS35), and Aldo-Keto Reductase Family 1, Member C1 (AKR1C1) were increased more than 50-fold. Interestingly, EMT factors, stress responses and epigenetic processes were significantly affected by 3D growth. The heat shock response and the oxidative stress response were also identified as transcriptome responses that showed significant changes upon 3D growth. Subnetwork enrichment analysis revealed that DNA integrity (e.g. DNA damage, genetic instability, nucleotide excision repair, and the DNA damage checkpoint pathway) were altered in the 3D spheroid model. In addition, two epigenetic processes, DNA methylation and histone acetylation, were increased with 3D growth. These findings support the hypothesis that three dimensional ovarian cell culturing is physiologically different from its monolayer counterpart.
C1 [Paullin, Trillitye; Powell, Chase; Menzie, Christopher; Hill, Robert; Westerheide, Sandy D.] Univ S Florida, Coll Arts & Sci, Dept Cell Biol Microbiol & Mol Biol, Tampa, FL 33620 USA.
   [Cheng, Feng] Univ S Florida, Dept Pharmaceut Sci, Coll Pharm, Tampa, FL USA.
   [Cheng, Feng] Univ S Florida, Coll Publ Hlth, Dept Epidemiol & Biostat, Tampa, FL USA.
   [Martyniuk, Christopher J.] Univ Florida, UF Genet Inst, Ctr Environm & Human Toxicol, Gainesville, FL 32611 USA.
   [Martyniuk, Christopher J.] Univ Florida, UF Genet Inst, Dept Physiol Sci, Gainesville, FL 32611 USA.
C3 State University System of Florida; University of South Florida; State
   University System of Florida; University of South Florida; State
   University System of Florida; University of South Florida; State
   University System of Florida; University of Florida; State University
   System of Florida; University of Florida
RP Westerheide, SD (通讯作者)，Univ S Florida, Coll Arts & Sci, Dept Cell Biol Microbiol & Mol Biol, Tampa, FL 33620 USA.; Martyniuk, CJ (通讯作者)，Univ Florida, UF Genet Inst, Ctr Environm & Human Toxicol, Gainesville, FL 32611 USA.; Martyniuk, CJ (通讯作者)，Univ Florida, UF Genet Inst, Dept Physiol Sci, Gainesville, FL 32611 USA.
EM cmartyn@ufl.edu; swesterheide@usf.edu
RI Martyniuk, Chris/KHV-3522-2024; Cheng, Feng/A-9760-2009
OI Martyniuk, Christopher J./0000-0003-0921-4796; Westerheide,
   Sandy/0000-0003-4683-9648; Hill, Robert/0009-0007-6663-0303; Cheng,
   Feng/0000-0003-3619-8090
FU University of South Florida
FX This work was funded by a start-up grant from the University of South
   Florida to S.D.W.
CR Akhavan-Niaki H, 2013, CELL BIOCHEM BIOPHYS, V67, P501, DOI 10.1007/s12013-013-9555-2
   Auersperg N, 2002, INT J GYNECOL CANCER, V12, P691, DOI 10.1046/j.1525-1438.2002.01152.x
   Azad N, 2013, NAT REV CLIN ONCOL, V10, P256, DOI 10.1038/nrclinonc.2013.42
   Barros GP, 2012, INT J GEOPHYS, V2012, DOI [10.5402/2012/137289, 10.1155/2012/459497]
   Beckman KB, 1997, J BIOL CHEM, V272, P19633, DOI 10.1074/jbc.272.32.19633
   Cannistra SA, 2004, NEW ENGL J MED, V351, P2519, DOI 10.1056/NEJMra041842
   Casey RC, 2001, AM J PATHOL, V159, P2071, DOI 10.1016/S0002-9440(10)63058-1
   CHANT ID, 1995, BRIT J HAEMATOL, V90, P163, DOI 10.1111/j.1365-2141.1995.tb03395.x
   Chervona Y, 2012, AM J CANCER RES, V2, P589
   Cheung A., 2016, Oncotarget
   CIOCCA DR, 1993, J NATL CANCER I, V85, P570, DOI 10.1093/jnci/85.7.570
   Cvetkovic Dusica, 2003, Reprod Biol Endocrinol, V1, P68
   Dai C, 2007, CELL, V130, P1005, DOI 10.1016/j.cell.2007.07.020
   Deng HB, 2002, J BIOL CHEM, V277, P15035, DOI 10.1074/jbc.M112028200
   Dolcet X, 2005, VIRCHOWS ARCH, V446, P475, DOI 10.1007/s00428-005-1264-9
   dos Santos CR, 2014, LIPIDS HEALTH DIS, V13, DOI 10.1186/1476-511X-13-16
   Ferraro A, 2013, J CLIN ENDOCR METAB, V98, P2834, DOI 10.1210/jc.2012-2926
   Gagou ME, 2014, ONCOTARGET, V5, P11381, DOI 10.18632/oncotarget.2501
   Ghajar CM, 2010, TISSUE ENG PT A, V16, P2153, DOI [10.1089/ten.tea.2010.0135, 10.1089/ten.TEA.2010.0135]
   Grassi M.L., 2016, J Proteomics
   GREENBURG G, 1982, J CELL BIOL, V95, P333, DOI 10.1083/jcb.95.1.333
   Guarino M, 2007, PATHOLOGY, V39, P305, DOI 10.1080/00313020701329914
   Harjes U, 2016, CRIT REV ONCOL HEMAT, V97, P15, DOI 10.1016/j.critrevonc.2015.10.011
   Hatfield MPD, 2012, PROTEIN PEPTIDE LETT, V19, P616
   Hay ED, 1995, ACTA ANAT, V154, P8
   JAMEEL A, 1992, INT J CANCER, V50, P409, DOI 10.1002/ijc.2910500315
   Kelm JM, 2003, BIOTECHNOL BIOENG, V83, P173, DOI 10.1002/bit.10655
   Khan Shafqat Ali, 2015, World J Biol Chem, V6, P333, DOI 10.4331/wjbc.v6.i4.333
   Koensgen D, 2015, CYTOKINE, V71, P334, DOI 10.1016/j.cyto.2014.07.254
   Korch C, 2012, GYNECOL ONCOL, V127, P241, DOI 10.1016/j.ygyno.2012.06.017
   Kunz-Schughart LA, 1998, INT J EXP PATHOL, V79, P1, DOI 10.1046/j.1365-2613.1998.00051.x
   Kurdistani SK, 2007, BRIT J CANCER, V97, P1, DOI 10.1038/sj.bjc.6603844
   Langlois VS, 2013, MECH DEVELOP, V130, P304, DOI 10.1016/j.mod.2012.12.002
   Lee GY, 2007, NAT METHODS, V4, P359, DOI 10.1038/NMETH1015
   Leone V, 2015, CANCER LETT, V357, P535, DOI 10.1016/j.canlet.2014.12.010
   Lu PF, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a005058
   Maehara Y, 2000, ONCOLOGY-BASEL, V58, P144, DOI 10.1159/000012091
   Massagué J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001
   Milde-Langosch K, 2005, EUR J CANCER, V41, P2449, DOI 10.1016/j.ejca.2005.08.008
   Moustakas A, 2007, CANCER SCI, V98, P1512, DOI 10.1111/j.1349-7006.2007.00550.x
   Nanbu K, 1998, CANCER DETECT PREV, V22, P549, DOI 10.1046/j.1525-1500.1998.00069.x
   Nguyen T, 2009, J BIOL CHEM, V284, P13291, DOI 10.1074/jbc.R900010200
   Nikitin A, 2003, BIOINFORMATICS, V19, P2155, DOI 10.1093/bioinformatics/btg290
   OLIVE PL, 1994, CANCER METAST REV, V13, P121, DOI 10.1007/BF00689632
   Padron JM, 2006, INVEST NEW DRUG, V24, P195, DOI 10.1007/s10637-005-3691-5
   Pampaloni F, 2007, NAT REV MOL CELL BIO, V8, P839, DOI 10.1038/nrm2236
   Pavan S, 2014, INT J CANCER, V134, P1289, DOI 10.1002/ijc.28464
   Penning TM, 2015, CHEM-BIOL INTERACT, V234, P236, DOI 10.1016/j.cbi.2014.09.024
   Powell CD, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0168389
   PROTTI MP, 1994, CANCER LETT, V85, P211, DOI 10.1016/0304-3835(94)90277-1
   Proud CG, 2004, BIOCHEM BIOPH RES CO, V313, P429, DOI 10.1016/j.bbrc.2003.07.015
   Santini MT, 2000, CRIT REV ONCOL HEMAT, V36, P75, DOI 10.1016/S1040-8428(00)00078-0
   Shahzad MMK, 2010, J BIOL CHEM, V285, P35462, DOI 10.1074/jbc.M110.109579
   Shen H, 2013, CELL, V153, P38, DOI 10.1016/j.cell.2013.03.008
   Shield K, 2009, GYNECOL ONCOL, V113, P143, DOI 10.1016/j.ygyno.2008.11.032
   Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166
   Tania M, 2014, TUMOR BIOL, V35, P7335, DOI 10.1007/s13277-014-2163-y
   Trieb K, 2000, BRIT J CANCER, V82, P85, DOI 10.1054/bjoc.1999.0881
   Wahlberg P, 2008, ENDOCRINOLOGY, V149, P5070, DOI 10.1210/en.2007-1736
   Wang K, 2016, ONCOTARGETS THER, V9, P377, DOI 10.2147/OTT.S96309
   Wang Y, 2012, CYTOKINE, V59, P145, DOI 10.1016/j.cyto.2012.04.013
   Weaver VM, 2002, CANCER CELL, V2, P205, DOI 10.1016/S1535-6108(02)00125-3
   Westerheide SD, 2005, J BIOL CHEM, V280, P33097, DOI 10.1074/jbc.R500010200
   Whitesell L, 2005, NAT REV CANCER, V5, P761, DOI 10.1038/nrc1716
   Wiemer EAC, 2011, NAT MED, V17, P1552, DOI 10.1038/nm.2593
   Xu K, 2014, BBA-REV CANCER, V1846, P638, DOI 10.1016/j.bbcan.2014.10.007
   Zavadil J, 2005, ONCOGENE, V24, P5764, DOI 10.1038/sj.onc.1208927
   Zhang S, 2008, CANCER RES, V68, P4311, DOI 10.1158/0008-5472.CAN-08-0364
   ZIMMERMAN R, 1984, P NATL ACAD SCI-BIOL, V81, P2085, DOI 10.1073/pnas.81.7.2085
NR 69
TC 22
Z9 24
U1 0
U2 13
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 9
PY 2017
VL 12
IS 8
AR e0182930
DI 10.1371/journal.pone.0182930
PG 19
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA FC9YJ
UT WOS:000407196700080
PM 28793334
OA Green Submitted, Green Published, gold
DA 2025-01-12
ER

PT J
AU Rajabi, H
   Hiraki, M
   Tagde, A
   Alam, M
   Bouillez, A
   Christensen, CL
   Samur, M
   Wong, KK
   Kufe, D
AF Rajabi, Hasan
   Hiraki, Masayuki
   Tagde, Ashujit
   Alam, Maroof
   Bouillez, Audrey
   Christensen, Camilla L.
   Samur, Mehmet
   Wong, Kwok-Kin
   Kufe, Donald
TI MUC1-C activates EZH2 expression and function in human cancer cells
SO SCIENTIFIC REPORTS
LA English
DT Article
ID GROUP PROTEIN EZH2; BREAST-CANCER; DNA METHYLATION; SELF-RENEWAL;
   STEM-CELLS; E-CADHERIN; ONCOPROTEIN; POLYCOMB; TRANSCRIPTION; REPRESSION
AB The EZH2 histone methyltransferase is a member of the polycomb repressive complex 2 (PRC2) that is highly expressed in diverse human cancers and is associated with a poor prognosis. MUC1-C is an oncoprotein that is similarly overexpressed in carcinomas and has been linked to epigenetic regulation. A role for MUC1-C in regulating EZH2 and histone methylation is not known. Here, we demonstrate that targeting MUC1-C in diverse human carcinoma cells downregulates EZH2 and other PRC2 components. MUC1-C activates (i) the EZH2 promoter through induction of the pRB -> E2F pathway, and (ii) an NF-kappa B p65 driven enhancer in exon 1. We also show that MUC1-C binds directly to the EZH2 CXC region adjacent to the catalytic SET domain and associates with EZH2 on the CDH1 and BRCA1 promoters. In concert with these results, targeting MUC1-C downregulates EZH2 function as evidenced by (i) global and promoter-specific decreases in H3K27 trimethylation (H3K27me3), and (ii) activation of tumor suppressor genes, including BRCA1. These findings highlight a previously unreported role for MUC1-C in activating EZH2 expression and function in cancer cells.
C1 [Rajabi, Hasan; Hiraki, Masayuki; Tagde, Ashujit; Alam, Maroof; Bouillez, Audrey; Christensen, Camilla L.; Samur, Mehmet; Wong, Kwok-Kin; Kufe, Donald] Harvard Med Sch Boston, Dana Farber Canc Inst, Boston, MA 02215 USA.
C3 Harvard University; Dana-Farber Cancer Institute; Harvard Medical School
RP Kufe, D (通讯作者)，Harvard Med Sch Boston, Dana Farber Canc Inst, Boston, MA 02215 USA.
EM donald_kufe@dfci.harvard.edu
RI Bouillez, Audrey/E-2962-2017; Tagde, Ashujit/M-9497-2014; Wong,
   Kwok-Kin/ADH-7803-2022
OI Samur, Mehmet/0000-0002-9978-5682; Hiraki, Masayuki/0000-0001-6445-7390
FU National Cancer Institute of the National Institutes of Health
   [CA166480, CA97098]
FX This work was supported by Grants from the National Cancer Institute of
   the National Institutes of Health under award numbers CA97098 and
   CA166480.
CR Ahmad R, 2007, NAT CELL BIOL, V9, P1419, DOI 10.1038/ncb1661
   Ahmad R, 2009, CANCER RES, V69, P7013, DOI 10.1158/0008-5472.CAN-09-0523
   Alam M, 2015, MOL CANCER RES, V13, P449, DOI 10.1158/1541-7786.MCR-14-0363
   Alam M, 2014, ONCOTARGET, V5, P2622, DOI 10.18632/oncotarget.1848
   Alam M, 2013, J BIOL CHEM, V288, P30892, DOI 10.1074/jbc.M113.477158
   Behrens C, 2013, CLIN CANCER RES, V19, P6556, DOI 10.1158/1078-0432.CCR-12-3946
   Bouillez A, 2016, CANCER RES, V76, P1538, DOI 10.1158/0008-5472.CAN-15-1804
   Bracken AP, 2009, NAT REV CANCER, V9, P773, DOI 10.1038/nrc2736
   Bracken AP, 2003, EMBO J, V22, P5323, DOI 10.1093/emboj/cdg542
   Cao Q, 2008, ONCOGENE, V27, P7274, DOI 10.1038/onc.2008.333
   Cao R, 2004, MOL CELL, V15, P57, DOI 10.1016/j.molcel.2004.06.020
   Cedar H, 2009, NAT REV GENET, V10, P295, DOI 10.1038/nrg2540
   Chen S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122577
   Collett K, 2006, CLIN CANCER RES, V12, P1168, DOI 10.1158/1078-0432.CCR-05-1533
   Comet I, 2016, NAT REV CANCER, V16, P803, DOI 10.1038/nrc.2016.83
   Fu HL, 2014, J BIOMED NANOTECHNOL, V10, P1217, DOI 10.1166/jbn.2014.1861
   Gong Y, 2011, CANCER-AM CANCER SOC, V117, P5476, DOI 10.1002/cncr.26179
   Hasegawa M, 2016, ONCOTARGET, V7, P11756, DOI 10.18632/oncotarget.7598
   Hasegawa M, 2015, CLIN CANCER RES, V21, P2338, DOI 10.1158/1078-0432.CCR-14-3000
   Herranz N, 2008, MOL CELL BIOL, V28, P4772, DOI 10.1128/MCB.00323-08
   Hiraki M, 2017, ONCOGENE, V36, P2791, DOI 10.1038/onc.2016.439
   Hiraki M, 2016, SCI REP-UK, V6, DOI 10.1038/srep26643
   Hiraki M, 2015, MOL THER-NUCL ACIDS, V4, DOI 10.1038/mtna.2015.5
   Huang L, 2005, CANCER RES, V65, P10413, DOI 10.1158/0008-5472.CAN-05-2474
   Kim KH, 2016, NAT MED, V22, P128, DOI 10.1038/nm.4036
   Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100
   Koh CM, 2011, ONCOTARGET, V2, P669, DOI 10.18632/oncotarget.327
   Koh Cheryl M, 2010, Genes Cancer, V1, P617, DOI 10.1177/1947601910379132
   Kufe DW, 2013, ONCOGENE, V32, P1073, DOI 10.1038/onc.2012.158
   Kufe DW, 2009, NAT REV CANCER, V9, P874, DOI 10.1038/nrc2761
   Kufe DW, 2009, CANCER BIOL THER, V8, P1197, DOI 10.4161/cbt.8.13.8844
   Leng YM, 2007, J BIOL CHEM, V282, P19321, DOI 10.1074/jbc.M703222200
   Li YQ, 2003, ONCOGENE, V22, P6107, DOI 10.1038/sj.onc.1206732
   Lu JA, 2011, CANCER RES, V71, P225, DOI 10.1158/0008-5472.CAN-10-1850
   Margueron R, 2011, NATURE, V469, P343, DOI 10.1038/nature09784
   McCabe MT, 2012, P NATL ACAD SCI USA, V109, P2989, DOI 10.1073/pnas.1116418109
   Mills AA, 2010, NAT REV CANCER, V10, P669, DOI 10.1038/nrc2931
   Morin RD, 2010, NAT GENET, V42, P181, DOI 10.1038/ng.518
   Müller H, 2001, GENE DEV, V15, P267, DOI 10.1101/gad.864201
   Panchamoorthy G, 2011, HYBRIDOMA, V30, P531, DOI 10.1089/hyb.2011.0070
   Rabinovich A, 2008, GENOME RES, V18, P1763, DOI 10.1101/gr.080622.108
   Raina D, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135156
   Raina D, 2012, INT J ONCOL, V40, P1644, DOI 10.3892/ijo.2011.1308
   Rajabi H, 2016, ONCOGENE, V35, P6439, DOI 10.1038/onc.2016.180
   Rajabi H, 2014, ONCOGENE, V33, P1680, DOI 10.1038/onc.2013.114
   Rajabi H, 2017, BBA-REV CANCER, V1868, P117, DOI 10.1016/j.bbcan.2017.03.003
   Rajabi H, 2012, J BIOL CHEM, V287, P10703, DOI 10.1074/jbc.M111.323311
   Rose NR, 2014, BBA-GENE REGUL MECH, V1839, P1362, DOI 10.1016/j.bbagrm.2014.02.007
   Sander S, 2008, BLOOD, V112, P4202, DOI 10.1182/blood-2008-03-147645
   Sato T, 2013, SCI REP-UK, V3, DOI 10.1038/srep01911
   Sauvageau M, 2010, CELL STEM CELL, V7, P299, DOI 10.1016/j.stem.2010.08.002
   Schlesinger Y, 2007, NAT GENET, V39, P232, DOI 10.1038/ng1950
   Scott MT, 2016, CANCER DISCOV, V6, P1248, DOI 10.1158/2159-8290.CD-16-0263
   Sparmann A, 2006, NAT REV CANCER, V6, P846, DOI 10.1038/nrc1991
   Tagde A, 2016, ONCOTARGET, V7, P38974, DOI 10.18632/oncotarget.9777
   Tagde A, 2016, BLOOD, V127, P2587, DOI 10.1182/blood-2015-07-659151
   Takahashi H, 2015, ONCOGENE, V34, P5187, DOI 10.1038/onc.2014.442
   Tam WL, 2013, NAT MED, V19, P1438, DOI 10.1038/nm.3336
   Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075
   Viré E, 2006, NATURE, V439, P871, DOI 10.1038/nature04431
   Wang XH, 2016, SCI REP-UK, V6, DOI 10.1038/srep19239
   Wu H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083737
   Xie HF, 2016, CANCER DISCOV, V6, P1237, DOI 10.1158/2159-8290.CD-15-1439
   Yap DB, 2011, BLOOD, V117, P2451, DOI 10.1182/blood-2010-11-321208
   Zhan M, 2016, TUMOR BIOL, V37, P11237, DOI 10.1007/s13277-016-4999-9
   Zhang XY, 2016, NAT GENET, V48, P176, DOI 10.1038/ng.3470
NR 66
TC 40
Z9 42
U1 0
U2 7
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD AUG 7
PY 2017
VL 7
AR 7481
DI 10.1038/s41598-017-07850-0
PG 13
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA FC8GP
UT WOS:000407080100111
PM 28785086
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Xue, G
   Lu, CJ
   Pan, SJ
   Zhang, YL
   Miao, H
   Shan, S
   Zhu, XT
   Zhang, Y
AF Xue, Geng
   Lu, Chao-Jing
   Pan, Shu-Jun
   Zhang, Yin-Ling
   Miao, Hui
   Shan, Shi
   Zhu, Xiao-Ting
   Zhang, Yi
TI DNA hypomethylation of CBS promoter induced by folate deficiency is a
   potential noninvasive circulating biomarker for colorectal
   adenocarcinomas
SO ONCOTARGET
LA English
DT Article
DE DNA methylation; colorectal cancer; folate; CBS; cell-free DNA
ID CYSTATHIONINE-BETA-SYNTHASE; COLON-CANCER; BREAST-CANCER; METHYLATION;
   METABOLISM; EPIGENETICS; PREVENTION; CHALLENGE; NUTRITION; GENETICS
AB Aberrant DNA methylation patterns, which induced by folate deficiency, play important roles in tumorigenesis of colorectal cancer (CRC). Some DNA methylation alterations can also be detected in cell-free DNA (cfDNA) of patients' plasma, making cfDNA an ideal noninvasive circulating biomarker. However, exact DNA methylation alterations induced by folate deficiency in tumorigenesis of CRC and exact potential circulating cfDNA methylation biomarker are still unclear. Therefore, DNA methylation patterns of the normal human colon mucosal epithelial cell line (NCM460), cultured with normal or low folate content, were screened and the DNA hypomethylation of cystathionine-beta-synthase (CBS) promoter was further validated in vitro and vivo. Then, the correlation analysis between folate level, DNA methylation alteration in promoter and expression of CBS was carried out in vitro and vivo. Further, the methylation patterns of CBS promoter in plasma cfDNA were detected and statistically correlated with pathological parameters and clinical outcome. Our study showed that DNA hypomethylation in CBS promoter, induced by folate deficiency, would lead to up-regulation of CBS both in vitro and vivo. Patients with cfDNA hypomethylation of CBS promoter in plasma were correlated with high tumor stage and poor clinical outcome. In addition, cfDNA hypomethylation of CBS promoter in plasma was shown to be an independent prognostic factor for recurrence and cancer-related death in CRC. Our results indicated that DNA hypomethylation of CBS promoter induced by folate deficiency could serve as a potential noninvasive circulating biomarker and may be helpful in developing more effective prognostic markers for CRC.
C1 [Xue, Geng; Zhang, Yin-Ling; Miao, Hui; Shan, Shi; Zhu, Xiao-Ting; Zhang, Yi] Second Mil Med Univ, Dept Med Genet, Coll Basic Med Sci, Shanghai 200433, Peoples R China.
   [Lu, Chao-Jing] Second Mil Med Univ, Changhai Hosp, Dept Thorac Surg, Shanghai 200433, Peoples R China.
   [Pan, Shu-Jun] Hangzhou Sanat Peoples Liberat Army, Dept Med Adm, Hangzhou 310007, Zhejiang, Peoples R China.
C3 Naval Medical University; Naval Medical University
RP Xue, G; Zhang, Y (通讯作者)，Second Mil Med Univ, Dept Med Genet, Coll Basic Med Sci, Shanghai 200433, Peoples R China.
EM xg_smmu@hotmail.com; yizhang@smmu.edu.com
RI Xue, Geng/I-3457-2014
FU National Natural Science Foundation of China [81272331]; National Key
   Research and Development Program [2016YFC1000503]
FX This work was supported by grants from the National Natural Science
   Foundation of China (81272331) and the National Key Research and
   Development Program (2016YFC1000503).
CR Allegra CJ, 2003, J CLIN ONCOL, V21, P241, DOI 10.1200/JCO.2003.05.044
   Bianca RDD, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136859
   Branco MR, 2012, NAT REV GENET, V13, P7, DOI 10.1038/nrg3080
   Brenner H, 2014, LANCET, V383, P1490, DOI 10.1016/S0140-6736(13)61649-9
   Carethers JM, 2015, GASTROENTEROLOGY, V149, P1177, DOI 10.1053/j.gastro.2015.06.047
   Center MM, 2009, CA-CANCER J CLIN, V59, P366, DOI 10.3322/caac.20038
   Chakraborty PK, 2015, ONCOTARGET, V6, P37367, DOI 10.18632/oncotarget.5424
   De Bruyn E, 2014, EUR J HAEMATOL, V92, P354, DOI 10.1111/ejh.12237
   de Vogel S, 2008, J NUTR, V138, P2372, DOI 10.3945/jn.108.091157
   Dickinson BT, 2015, GUT, V64, P1485, DOI 10.1136/gutjnl-2014-308075
   Eichholzer M, 2006, LANCET, V367, P1352, DOI 10.1016/S0140-6736(06)68582-6
   FROMOWITZ FB, 1987, HUM PATHOL, V18, P1268, DOI 10.1016/S0046-8177(87)80412-4
   Hammoud SS, 2013, CURR OPIN CELL BIOL, V25, P177, DOI 10.1016/j.ceb.2013.01.007
   Hellmich MR, 2015, ANTIOXID REDOX SIGN, V22, P424, DOI 10.1089/ars.2014.5933
   Kim MS, 2010, CANCER METAST REV, V29, P181, DOI 10.1007/s10555-010-9207-6
   Lam K, 2016, BBA-REV CANCER, V1866, P106, DOI 10.1016/j.bbcan.2016.07.001
   Lamprecht SA, 2003, NAT REV CANCER, V3, P601, DOI 10.1038/nrc1144
   Lillycrop KA, 2014, EPIGENOMICS-UK, V6, P623, DOI [10.2217/EPI.14.51, 10.2217/epi.14.51]
   Liu YH, 2015, NATURE, V520, P697, DOI 10.1038/nature14418
   Ly A, 2012, ANTIOXID REDOX SIGN, V17, P302, DOI 10.1089/ars.2012.4554
   Moyer MP, 1996, IN VITRO CELL DEV-AN, V32, P315
   Nazki FH, 2014, GENE, V533, P11, DOI 10.1016/j.gene.2013.09.063
   Noehammer C, 2014, EPIGENOMICS-UK, V6, P603, DOI [10.2217/EPI.14.43, 10.2217/epi.14.43]
   Okugawa Y, 2015, GASTROENTEROLOGY, V149, P1204, DOI 10.1053/j.gastro.2015.07.011
   Padmanabhan N, 2013, CELL, V155, P81, DOI 10.1016/j.cell.2013.09.002
   Pagliara V, 2016, ONCOTARGET, V7, P50333, DOI 10.18632/oncotarget.10385
   Pericàs JM, 2016, NEW ENGL J MED, V375, P387, DOI [10.1056/NEJMra1513581, 10.1056/NEJMc1604867]
   Reinert T, 2016, GUT, V65, P625, DOI 10.1136/gutjnl-2014-308859
   Schwarzenbach H, 2011, NAT REV CANCER, V11, P426, DOI 10.1038/nrc3066
   Shan M, 2016, ONCOTARGET, V7, P18485, DOI 10.18632/oncotarget.7608
   Sinicrope FA, 2016, CLIN GASTROENTEROL H, V14, P651, DOI 10.1016/j.cgh.2016.02.008
   Song MY, 2015, GASTROENTEROLOGY, V148, P1244, DOI 10.1053/j.gastro.2014.12.035
   Supic G, 2013, NUTR CANCER, V65, P781, DOI 10.1080/01635581.2013.805794
   Suvà ML, 2013, SCIENCE, V339, P1567, DOI 10.1126/science.1230184
   Szabo C, 2013, P NATL ACAD SCI USA, V110, P12474, DOI 10.1073/pnas.1306241110
   van Meer S, 2013, NUTR REV, V71, P631, DOI 10.1111/nure.12042
   Verma M, 2013, CURR OPIN CLIN NUTR, V16, P376, DOI 10.1097/MCO.0b013e328361dc70
   Warton K, 2016, ENDOCR-RELAT CANCER, V23, pR157, DOI 10.1530/ERC-15-0369
   WATKINS PC, 1987, J MED GENET, V24, P257, DOI 10.1136/jmg.24.5.257
   Williams EA, 2012, P NUTR SOC, V71, P592, DOI 10.1017/S0029665112000717
   Yang Q, 2013, J BIOMED NANOTECHNOL, V9, P1607, DOI 10.1166/jbn.2013.1713
   Zhang B, 2014, NAT GENET, V46, P533, DOI 10.1038/ng.2985
NR 42
TC 17
Z9 18
U1 1
U2 6
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD AUG 1
PY 2017
VL 8
IS 31
BP 51387
EP 51401
DI 10.18632/oncotarget.17988
PG 15
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA FC3CZ
UT WOS:000406717200096
PM 28881655
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU Young, CS
   Clarke, KM
   Kettyle, LM
   Thompson, A
   Mills, KI
AF Young, Christine S.
   Clarke, Kathryn M.
   Kettyle, Laura M.
   Thompson, Alexander
   Mills, Ken I.
TI Decitabine-Vorinostat combination treatment in acute myeloid leukemia
   activates pathways with potential for novel triple therapy
SO ONCOTARGET
LA English
DT Article
DE epigenetic combination therapies; AXL receptor tyrosine kinase; acute
   myeloid leukemia; HDAC inhibitors; DNMT inhibitors
ID HISTONE DEACETYLASE INHIBITION; GENE-EXPRESSION; BREAST-CANCER;
   ELDERLY-PATIENTS; DNA METHYLATION; APOPTOSIS; AZACITIDINE; AXL;
   DEMETHYLATION; KINASE
AB Despite advancements in cancer therapeutics, acute myeloid leukemia patients over 60 years old have a 5-year survival rate of less than 8%. In an attempt to improve this, epigenetic modifying agents have been combined as therapies in clinical studies. In particular combinations with Decitabine and Vorinostat have had varying degrees of efficacy. This study therefore aimed to understand the underlying molecular mechanisms of these agents to identify potential rational epi-sensitized combinations.
   Combined Decitabine-Vorinostat treatment synergistically decreased cell proliferation, induced apoptosis, enhanced acetylation of histones and further decreased DNMT1 protein with HL-60 cells showing a greater sensitivity to the combined treatment than OCI-AML3. Combination therapy led to reprogramming of unique target genes including AXL, a receptor tyrosine kinase associated with cell survival and a poor prognosis in AML, which was significantly upregulated following treatment. Therefore targeting AXL following epi-sensitization with Decitabine and Vorinostat may be a suitable triple combination. To test this, cells were treated with a novel triple combination therapy including BGB324, an AXL specific inhibitor. Triple combination increased the sensitivity of OCI-AML3 cells to Decitabine and Vorinostat as shown through viability assays and significantly extended the survival of mice transplanted with pretreated OCI-AML3 cells, while bioluminescence imaging showed the decrease in disease burden following triple combination treatment.
   Further investigation is required to optimize this triple combination, however, these results suggest that AXL is a potential marker of response to Decitabine-Vorinostat combination treatment and offers a new avenue of epigenetic combination therapies for acute myeloid leukemia.
C1 [Young, Christine S.; Clarke, Kathryn M.; Kettyle, Laura M.; Thompson, Alexander; Mills, Ken I.] Queens Univ, Blood Canc Res Grp, Ctr Canc Res & Cell Biol, Belfast, Antrim, North Ireland.
   [Young, Christine S.] Univ Edinburgh, MRC, Human Genet Unit, Inst Genet & Mol Med,Western Gen Hosp, Edinburgh, Midlothian, Scotland.
   [Clarke, Kathryn M.] Addenbrookes Hosp, Dept Haematol, Cambridge, England.
   [Kettyle, Laura M.] John Radcliffe Hosp, Weatherall Inst Mol Med, MRC, Haematopoiet Stem Cell Biol Lab,Mol Haematol Unit, Oxford, England.
   [Thompson, Alexander] Univ Nottingham, Div Canc & Stem Cells, Ctr Biomol Sci, Nottingham, England.
C3 Queens University Belfast; University of Edinburgh; University of
   Cambridge; Cambridge University Hospitals NHS Foundation Trust;
   Addenbrooke's Hospital; University of Oxford; University of Nottingham
RP Young, CS; Mills, KI (通讯作者)，Queens Univ, Blood Canc Res Grp, Ctr Canc Res & Cell Biol, Belfast, Antrim, North Ireland.
EM Christine.Young@igmm.ed.ac.uk; k.mills@qub.ac.uk
RI Clarke, Kathryn/AAW-6247-2020; Thompson, Alexander/IST-2839-2023; Mills,
   Ken/A-8556-2012
OI Mills, Ken/0000-0002-6362-4481; Clarke, Kathryn/0000-0003-0411-5393;
   Thompson, Alex/0000-0002-9315-5321
FU Department of Employment and Learning NI; Leukaemia and Lymphoma NI;
   Celgene UK; Bloodwise (UK); Leukaemia and Lymphoma NI [R2536CNR]
FX CSY was funded by the Department of Employment and Learning NI and
   Leukaemia and Lymphoma NI, KMC by a non-specific educational grant from
   Celgene UK, LMK was funded by Bloodwise (UK) and Leukaemia and Lymphoma
   NI, KIM and AT were supported by grants from Leukaemia and Lymphoma NI
   (R2536CNR).
CR Arzenani MK, 2011, MOL CELL BIOL, V31, P4119, DOI 10.1128/MCB.01304-10
   Bagger FO, 2016, NUCLEIC ACIDS RES, V44, pD917, DOI 10.1093/nar/gkv1101
   Ben-Batalla I, 2013, BLOOD, V122, P2443, DOI 10.1182/blood-2013-03-491431
   Bhatla T, 2012, BLOOD, V119, P5201, DOI 10.1182/blood-2012-01-401687
   Brodská B, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/659254
   Brodská B, 2011, MOL CELL BIOCHEM, V350, P71, DOI 10.1007/s11010-010-0683-3
   Burke MJ, 2014, AM J HEMATOL, V89, P889, DOI 10.1002/ajh.23778
   Burnett A, 2011, J CLIN ONCOL, V29, P487, DOI 10.1200/JCO.2010.30.1820
   Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047
   Chen MY, 2011, CANCER-AM CANCER SOC, V117, P4424, DOI 10.1002/cncr.26073
   Chou TC, 2010, CANCER RES, V70, P440, DOI 10.1158/0008-5472.CAN-09-1947
   Dunham I, 2012, NATURE, V489, P57, DOI 10.1038/nature11247
   Falkenberg KJ, 2014, SCI DATA, V1, DOI 10.1038/sdata.2014.17
   Falschlehner C, 2007, INT J BIOCHEM CELL B, V39, P1462, DOI 10.1016/j.biocel.2007.02.007
   FDA, 2013, FDA APPROVAL DECITAB
   Fenaux P, 2010, J CLIN ONCOL, V28, P562, DOI 10.1200/JCO.2009.23.8329
   Flotho C, 2009, LEUKEMIA, V23, P1019, DOI 10.1038/leu.2008.397
   Fong CY, 2014, HAEMATOLOGICA, V99, P1772, DOI 10.3324/haematol.2013.092007
   Gausdal G, 2016, CANC IMMUNOL RES
   Guo SX, 2000, LEUKEMIA RES, V24, P39, DOI 10.1016/S0145-2126(99)00158-7
   Hollenbach PW, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009001
   How J, 2015, LEUKEMIA LYMPHOMA, V56, P2793, DOI 10.3109/10428194.2015.1018248
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923
   Issa JP, 2015, CANCER-AM CANCER SOC, V121, P556, DOI 10.1002/cncr.29085
   Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561
   Juergens RA, 2011, CANCER DISCOV, V1, P598, DOI 10.1158/2159-8290.CD-11-0214
   Kalac M, 2011, BLOOD, V118, P5506, DOI 10.1182/blood-2011-02-336891
   Kirschbaum M, 2014, BRIT J HAEMATOL, V167, P185, DOI 10.1111/bjh.13016
   Kohlmann A, 2008, BRIT J HAEMATOL, V142, P802, DOI 10.1111/j.1365-2141.2008.07261.x
   Lee-Sherick AB, 2013, ONCOGENE, V32, P5359, DOI 10.1038/onc.2013.40
   Loges S, 2016, J CLIN ONCOL
   MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686
   Momparler RL, 2014, CLIN EPIGENETICS, V6, DOI 10.1186/1868-7083-6-19
   Moreaux J, 2012, MOL CANCER THER, V11, P2685, DOI 10.1158/1535-7163.MCT-12-0721
   Mudduluru G, 2008, BIOSCIENCE REP, V28, P161, DOI 10.1042/BSR20080046
   Nan XS, 1997, CELL, V88, P471, DOI 10.1016/S0092-8674(00)81887-5
   Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764
   Ou JN, 2007, BIOCHEM PHARMACOL, V73, P1297, DOI 10.1016/j.bcp.2006.12.032
   Paul TA, 2010, BLOOD, V115, P3098, DOI 10.1182/blood-2009-07-233858
   Plumb JA, 2000, CANCER RES, V60, P6039
   Richer D, 2013, BLOOD, V122, P5137
   Robinson JT, 2011, NAT BIOTECHNOL, V29, P24, DOI 10.1038/nbt.1754
   Rothlin CV, 2007, CELL, V131, P1124, DOI 10.1016/j.cell.2007.10.034
   Saba H., 2009, HEMATOLOGY M REPORTS
   Sadashiv SK, 2014, CANCER MED-US, V3, P1570, DOI 10.1002/cam4.321
   Sharif MN, 2006, J EXP MED, V203, P1891, DOI 10.1084/jem.20051725
   Sheridan C, 2013, NAT BIOTECHNOL, V31, P775, DOI 10.1038/nbt0913-775a
   Shiozawa Y, 2010, NEOPLASIA, V12, P116, DOI 10.1593/neo.91384
   Si J, 2010, CANCER RES, V70, P6968, DOI 10.1158/0008-5472.CAN-09-4474
   Soncini M, 2013, BBA-MOL BASIS DIS, V1832, P114, DOI 10.1016/j.bbadis.2012.10.001
   Stathis A, 2011, CLIN CANCER RES, V17, P1582, DOI 10.1158/1078-0432.CCR-10-1893
   Thorvaldsdóttir H, 2013, BRIEF BIOINFORM, V14, P178, DOI 10.1093/bib/bbs017
   Wang C, 2016, THERANOSTICS, V6, P1205, DOI 10.7150/thno.15083
   Wu XL, 2014, ONCOTARGET, V5, P9546, DOI 10.18632/oncotarget.2542
   Yang DF, 2012, J IMMUNOL, V188, P4441, DOI 10.4049/jimmunol.1103035
   Yang H, 2005, LEUKEMIA RES, V29, P739, DOI 10.1016/j.leukres.2004.11.022
   YATES JW, 1973, CANCER CHEMOTH REP 1, V57, P485
   Zhou Q, 2008, MOL CANCER RES, V6, P873, DOI 10.1158/1541-7786.MCR-07-0330
   Zhou Q, 2010, PROTEOMICS, V10, P1029, DOI 10.1002/pmic.200900602
   Zhu LM, 2014, ONCOTARGET, V5, P5403, DOI 10.18632/oncotarget.2114
   Zhu WG, 2001, CANCER RES, V61, P1327
NR 62
TC 25
Z9 25
U1 0
U2 7
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD AUG 1
PY 2017
VL 8
IS 31
BP 51429
EP 51446
DI 10.18632/oncotarget.18009
PG 18
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA FC3CZ
UT WOS:000406717200099
PM 28881658
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Kovalchuk, A
   Ilnytskyy, Y
   Rodriguez-Juarez, R
   Shpyleva, S
   Melnyk, S
   Pogribny, I
   Katz, A
   Sidransky, D
   Kovalchuk, O
   Kolb, B
AF Kovalchuk, Anna
   Ilnytskyy, Yaroslav
   Rodriguez-Juarez, Rocio
   Shpyleva, Svitlana
   Melnyk, Stepan
   Pogribny, Igor
   Katz, Amanda
   Sidransky, David
   Kovalchuk, Olga
   Kolb, Bryan
TI Chemo brain or tumor brain - that is the question: the presence of
   extracranial tumors profoundly affects molecular processes in the
   prefrontal cortex of TumorGraft mice
SO AGING-US
LA English
DT Article
DE chemo brain; tumor brain; gene expression; DNA methylation; aging
ID OXIDATIVE DNA-DAMAGE; SIGNALING PATHWAY ACTIVATION; RADICAL-INDUCED
   DAMAGE; COGNITIVE FUNCTION; REPAIR GENES; HIPPOCAMPAL NEUROGENESIS;
   EPIGENETIC ALTERATIONS; ANTIOXIDANT ENZYMES; DRUG ADRIAMYCIN;
   NERVOUS-SYSTEM
AB Cancer chemotherapy causes numerous persistent central nervous system complications. This condition is known as chemo brain. Cognitive impairments occur even before treatment, and hence are referred to as cancer associated cognitive changes, or tumor brain. There is much yet to be learned about the mechanisms of both chemo brain and tumor brain. The frequency and timing of chemo brain and tumor brain occurrence and persistence strongly suggest they may be epigenetic in nature and associated with altered gene expression. Here we used TumorGraft (TM) models wherein part of a patient's tumor is removed and grafted into immune-deficient mice and conducted global gene expression and DNA methylation analysis. We show that malignant non-central nervous system tumor growth causes profound molecular alterations in the brain. Mice harbouring triple negative or progesterone positive breast cancer TumorGrafts exhibited altered gene expression, decreased levels of DNA methylation, increased levels of DNA hydroxymethylation, and oxidative stress in the prefrontal cortex. Interestingly, chemotherapy did not have any additional synergistic effects on the analyzed processes. The molecular changes observed in this study are known signs of neurodegeneration and brain aging. This study provides an important roadmap for future large-scale analysis of the molecular and cellular mechanisms of tumor brain.
C1 [Kovalchuk, Anna; Kolb, Bryan] Univ Lethbridge, Dept Neurosci, Lethbridge, AB T1K 6T5, Canada.
   [Ilnytskyy, Yaroslav; Rodriguez-Juarez, Rocio; Kovalchuk, Olga] Univ Lethbridge, Dept Biol Sci, Lethbridge, AB T1K 6T5, Canada.
   [Shpyleva, Svitlana; Pogribny, Igor] US FDA, Natl Ctr Toxicol Res, Div Biochem Toxicol, Jefferson, AR 72079 USA.
   [Shpyleva, Svitlana; Melnyk, Stepan] Univ Arkansas Med Sci, Dept Pediat, Little Rock, AR 72205 USA.
   [Katz, Amanda; Sidransky, David] Champ Oncol, Dept Oncol, Baltimore, MD 21205 USA.
   [Kovalchuk, Anna] Univ Calgary, Cumming Sch Med, Leaders Med Program, Calgary, AB T2N 1N4, Canada.
C3 University of Lethbridge; University of Lethbridge; US Food & Drug
   Administration (FDA); University of Arkansas System; University of
   Arkansas Medical Sciences; University of Calgary
RP Kolb, B (通讯作者)，Univ Lethbridge, Dept Neurosci, Lethbridge, AB T1K 6T5, Canada.; Kovalchuk, O (通讯作者)，Univ Lethbridge, Dept Biol Sci, Lethbridge, AB T1K 6T5, Canada.
EM olga.kovalchuk@uleth.ca; kolb@uleth.ca
RI Shpyleva, Svitlana/KVZ-0200-2024
FU Alberta Cancer Foundation; Alberta Innovates-Health Solutions; Canada
   Vanier Graduate Scholarship; Canadian Institutes of Health
FX Anna Kovalchuk was a recipient of the Alberta Cancer Foundation Dr.
   Cyril Kay Graduate Scholarship, Alberta Innovates-Health Solutions and
   Canada Vanier Graduate Scholarship. A Canadian Institutes of Health
   Research grant held by Bryan Kolb and Olga Kovalchuk has supported the
   research.
CR Ahles TA, 2008, BREAST CANCER RES TR, V110, P143, DOI 10.1007/s10549-007-9686-5
   Ahles TA, 2007, NAT REV CANCER, V7, P192, DOI 10.1038/nrc2073
   Ahles TA, 2012, PSYCHO-ONCOLOGY, V21, P1141, DOI 10.1002/pon.3196
   Ahles TA, 2012, J CLIN ONCOL, V30, P3675, DOI 10.1200/JCO.2012.43.0116
   Akpinar O, 2017, BRAIN RES BULL, V130, P1, DOI 10.1016/j.brainresbull.2016.12.005
   Andreotti C, 2016, PSYCHO-ONCOLOGY, V25, P43, DOI 10.1002/pon.3799
   Basu S, 2015, EXP MOL MED, V47, DOI 10.1038/emm.2015.54
   Bertotti A, 2011, CANCER DISCOV, V1, P508, DOI 10.1158/2159-8290.CD-11-0109
   Bond AM, 2012, DEV NEUROBIOL, V72, P1068, DOI 10.1002/dneu.22022
   Boyle EI, 2004, BIOINFORMATICS, V20, P3710, DOI 10.1093/bioinformatics/bth456
   Briones TL, 2011, BMC NEUROSCI, V12, DOI 10.1186/1471-2202-12-124
   Buzdin AA, 2014, FRONT GENET, V5, DOI 10.3389/fgene.2014.00055
   Cardozo-Pelaez F, 2012, NEUROCHEM INT, V61, P721, DOI 10.1016/j.neuint.2012.06.013
   Chen ZL, 2003, MOL BIOL CELL, V14, P2665, DOI 10.1091/mbc.E02-12-0832
   Christie LA, 2012, CLIN CANCER RES, V18, P1954, DOI 10.1158/1078-0432.CCR-11-2000
   Csoka AB, 2009, MED HYPOTHESES, V73, P770, DOI 10.1016/j.mehy.2008.10.039
   Davies MN, 2012, GENOME BIOL, V13, DOI 10.1186/gb-2012-13-6-r43
   DeRose YS, 2011, NAT MED, V17, P1514, DOI 10.1038/nm.2454
   Dizdaroglu M, 2002, FREE RADICAL BIO MED, V32, P1102, DOI 10.1016/S0891-5849(02)00826-2
   Dizdaroglu M, 2012, FREE RADICAL RES, V46, P382, DOI 10.3109/10715762.2011.653969
   Drew Michael R., 2007, CNS & Neurological Disorders-Drug Targets, V6, P205, DOI 10.2174/187152707780619353
   Du M, 2014, MOL MED REP, V10, P1051, DOI 10.3892/mmr.2014.2276
   Ellison EM, 2017, J NEUROCHEM, V140, P383, DOI 10.1111/jnc.13912
   Faw B, 2003, CONSCIOUS COGN, V12, P83, DOI 10.1016/S1053-8100(02)00030-2
   Fernández-López D, 2012, J NEUROSCI, V32, P9588, DOI 10.1523/JNEUROSCI.5977-11.2012
   Lacoste MG, 2017, EXP GERONTOL, V88, P42, DOI 10.1016/j.exger.2016.12.002
   Garralda E, 2014, CLIN CANCER RES, V20, P2476, DOI 10.1158/1078-0432.CCR-13-3047
   Grigorenko EL, 2016, DEV PSYCHOPATHOL, V28, P1285, DOI 10.1017/S0954579416000857
   Heemann FM, 2017, EXP GERONTOL, V87, P8, DOI 10.1016/j.exger.2016.11.005
   Hidalgo M, 2011, MOL CANCER THER, V10, P1311, DOI 10.1158/1535-7163.MCT-11-0233
   Horvath S, 2012, GENOME BIOL, V13, DOI 10.1186/gb-2012-13-10-r97
   Huang DW, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-9-r183
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923
   Iida T, 2001, NEURO-ONCOLOGY, V3, P73, DOI 10.1093/neuonc/3.2.73
   Impey S, 2016, BMC GENOMICS, V17, DOI 10.1186/s12864-016-2581-x
   Irier HA, 2012, DNA CELL BIOL, V31, pS42, DOI 10.1089/dna.2011.1565
   Islam MT, 2017, NEUROL RES, V39, P73, DOI 10.1080/01616412.2016.1251711
   Jakovcevski M, 2012, NAT MED, V18, P1194, DOI 10.1038/nm.2828
   James SJ, 2013, TRANSL PSYCHIAT, V3, DOI 10.1038/tp.2013.8
   Jobe EM, 2012, FRONT NEUROSCI-SWITZ, V6, DOI 10.3389/fnins.2012.00059
   Joshi G, 2005, FREE RADICAL RES, V39, P1147, DOI 10.1080/10715760500143478
   Joshi G, 2010, NEUROSCIENCE, V166, P796, DOI 10.1016/j.neuroscience.2010.01.021
   Kaiser J, 2014, CORTEX, V54, P33, DOI 10.1016/j.cortex.2014.01.010
   Kato T, 2014, NEUROPHARMACOLOGY, V80, P133, DOI 10.1016/j.neuropharm.2013.12.019
   Kesler SR, 2014, NEUROBIOL AGING, V35, pS11, DOI 10.1016/j.neurobiolaging.2014.03.036
   Kinde B, 2015, P NATL ACAD SCI USA, V112, P6800, DOI 10.1073/pnas.1411269112
   Kinersley B, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju086
   Klungland A, 2007, DNA REPAIR, V6, P481, DOI 10.1016/j.dnarep.2006.10.012
   Kovalchuk A, 2016, FRONT BEHAV NEUROSCI, V10, DOI 10.3389/fnbeh.2016.00084
   Kovalchuk A, 2016, AGING-US, V8, P697, DOI 10.18632/aging.100920
   Larsen E, 2006, ONCOGENE, V25, P2425, DOI 10.1038/sj.onc.1209284
   Lezhnina K, 2014, ONCOTARGET, V5, P9022, DOI 10.18632/oncotarget.2493
   Liu AM, 2005, NAT REV NEUROSCI, V6, P945, DOI 10.1038/nrn1805
   Liu D, 2011, J CEREBR BLOOD F MET, V31, P680, DOI 10.1038/jcbfm.2010.147
   Liyanage Vichithra R B, 2014, Biology (Basel), V3, P670, DOI 10.3390/biology3040670
   Ljubimova JY, 2006, FRONT BIOSCI, V11, P81, DOI 10.2741/1781
   Lovell MA, 2007, NUCLEIC ACIDS RES, V35, P7497, DOI 10.1093/nar/gkm821
   Luzhna L, 2010, BIOCHEM BIOPH RES CO, V392, P113, DOI 10.1016/j.bbrc.2009.12.093
   Makarev E, 2015, ONCOTARGET, V6, P23204, DOI 10.18632/oncotarget.4673
   Makarev E, 2014, AGING-US, V6, P1064, DOI 10.18632/aging.100711
   Muhammad A, 2012, NEUROSCIENCE, V216, P103, DOI 10.1016/j.neuroscience.2012.04.041
   Mustafa S, 2008, EUR J NEUROSCI, V28, P323, DOI 10.1111/j.1460-9568.2008.06325.x
   Nagato S, 2005, INT J CANCER, V117, P41, DOI 10.1002/ijc.21102
   Nakabeppu Y, 2007, J NEUROSCI RES, V85, P919, DOI 10.1002/jnr.21191
   Nishimura S, 2002, FREE RADICAL BIO MED, V32, P813, DOI 10.1016/S0891-5849(02)00778-5
   Nohmi T, 2005, MUTAT RES-FUND MOL M, V591, P60, DOI 10.1016/j.mrfmmm.2005.03.033
   Olson K, 2016, SUPPORT CARE CANCER, V24, P3223, DOI 10.1007/s00520-016-3215-1
   Osorio A, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004256
   Ozerov IV, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13427
   Morelli MP, 2012, J CLIN ONCOL, V30, pE45, DOI 10.1200/JCO.2011.36.9678
   Ponnaluri VKC, 2017, EPIGENETICS-US, V12, P123, DOI 10.1080/15592294.2016.1265713
   Powell CL, 2005, CANCER LETT, V229, P1, DOI 10.1016/j.canlet.2004.12.002
   Romanucci M, 2015, OXID MED CELL LONGEV, V2015, DOI 10.1155/2015/940131
   Rudenko A, 2014, NEUROPHARMACOLOGY, V80, P70, DOI 10.1016/j.neuropharm.2014.01.043
   Rusyn I, 2005, DNA REPAIR, V4, P1099, DOI 10.1016/j.dnarep.2005.05.009
   Rusyn I, 2004, CANCER RES, V64, P1050, DOI 10.1158/0008-5472.CAN-03-3027
   Sampath H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051697
   Schagen Sanne B, 2013, EJC Suppl, V11, P225, DOI 10.1016/j.ejcsup.2013.07.007
   Sheng ZJ, 2012, J CLIN INVEST, V122, P4344, DOI 10.1172/JCI65053
   Shpyleva S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113712
   Shu LQ, 2016, BMC GENOMICS, V17, DOI 10.1186/s12864-016-2731-1
   Silasi G, 2004, BIOCHEM BIOPH RES CO, V325, P1223, DOI 10.1016/j.bbrc.2004.10.166
   Smith AK, 2015, AM J MED GENET B, V168, P36, DOI 10.1002/ajmg.b.32278
   Stebbing J, 2014, CANCER-AM CANCER SOC, V120, P2006, DOI 10.1002/cncr.28696
   Swain U, 2012, MECH AGEING DEV, V133, P186, DOI 10.1016/j.mad.2012.01.001
   Tang YL, 2016, NEUROPSYCH DIS TREAT, V12, P617, DOI 10.2147/NDT.S97456
   Tirado-Magallanes R, 2017, ONCOTARGET, V8, P5629, DOI 10.18632/oncotarget.13562
   Tylee DS, 2013, AM J MED GENET B, V162, P595, DOI 10.1002/ajmg.b.32150
   Valinluck V, 2007, CANCER RES, V67, P5583, DOI 10.1158/0008-5472.CAN-07-0846
   van den Hove DLA, 2012, CURR ALZHEIMER RES, V9, P545
   Vardy J, 2007, CRIT REV ONCOL HEMAT, V63, P183, DOI 10.1016/j.critrevonc.2007.06.001
   Venkova L, 2015, ONCOTARGET, V6, P27227, DOI 10.18632/oncotarget.4507
   Wang XM, 2015, CYTOKINE, V72, P86, DOI 10.1016/j.cyto.2014.12.006
   Wong AW, 2008, J NEUROSCI, V28, P9047, DOI 10.1523/JNEUROSCI.2557-08.2008
   Yui K, 2016, CNS NEUROL DISORD-DR, V15, P587, DOI 10.2174/1871527315666160413121751
   Zhavoronkov A, 2016, CELL CYCLE, V15, P1643, DOI 10.1080/15384101.2016.1170261
   Zhu Qingsong, 2015, Hum Genome Var, V2, P15009, DOI 10.1038/hgv.2015.9
NR 98
TC 9
Z9 12
U1 0
U2 12
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
SN 1945-4589
J9 AGING-US
JI Aging-US
PD JUL
PY 2017
VL 9
IS 7
BP 1660
EP 1676
DI 10.18632/aging.101243
PG 17
WC Cell Biology; Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Geriatrics & Gerontology
GA FC7VI
UT WOS:000407050000005
PM 28758896
OA Green Published, Green Submitted, gold
DA 2025-01-12
ER

PT J
AU Li, SWC
   Vu, LT
   Luo, JJY
   Zhong, JF
   Li, ZJ
   Dethlefs, BA
   Loudon, WG
   Kabeer, MH
AF Li, Shengwen Calvin
   Vu, Long T.
   Luo, Jane Jianying
   Zhong, Jiang F.
   Li, Zhongjun
   Dethlefs, Brent A.
   Loudon, William G.
   Kabeer, Mustafa H.
TI Tissue Elasticity Bridges Cancer Stem Cells to the Tumor
   Microenvironment Through microRNAs: Implications for a "Watch-and-Wait"
   Approach to Cancer
SO CURRENT STEM CELL RESEARCH & THERAPY
LA English
DT Article
DE Tissue elasticity; miRNAs; gene expression; cancer stem cells; tumor
   microenvironment; stem cell biology
ID BREAST-CANCER; ALTERNATIVE CLEAVAGE; CODING SEQUENCE; EXPRESSION;
   TARGET; POLYADENYLATION; TRANSCRIPTS; NICHE; METASTASIS; BIOMARKERS
AB Background: Targeting the tumor microenvironment (TME) through which cancer stem cells (CSCs) crosstalk for cancer initiation and progression, may open new treatments different from those centered on the original hallmarks of cancer genetics thereby implying a new approach for suppression of TME driven activation of CSCs. Cancer is dynamic, heterogeneous, evolving with the TME and can be influenced by tissue-specific elasticity. One of the mediators and modulators of the crosstalk between CSCs and mechanical forces is miRNA, which can be developmentally regulated, in a tissue-and cell-specific manner.
   Objective: Here, based on our previous data, we provide a framework through which such gene expression changes in response to external mechanical forces can be understood during cancer progression. Recognizing the ways mechanical forces regulate and affect intracellular signals with applications in cancer stem cell biology. Such TME-targeted pathways shed new light on strategies for attacking cancer stem cells with fewer side effects than traditional gene-based treatments for cancer, requiring a "watch-and-wait" approach. We attempt to address both normal brain microenvironment and tumor microenvironment as both works together, intertwining in pathology and physiology - a balance that needs to be maintained for the "watch-and-wait" approach to cancer.
   Conclusion: This review connected the subjects of tissue elasticity, tumor microenvironment, epigenetic of miRNAs, and stem-cell biology that are very relevant in cancer research and therapy. It attempts to unify apparently separate entities in a complex biological web, network, and system in a realistic and practical manner, i.e., to bridge basic research with clinical application.
C1 [Li, Shengwen Calvin; Vu, Long T.; Dethlefs, Brent A.; Loudon, William G.; Kabeer, Mustafa H.] CHOC Childrens Hosp Res Inst, Ctr Neurosci Res, Neurooncol & Stem Cell Res Lab, 1201 West La Veta Ave, Orange, CA 92868 USA.
   [Li, Shengwen Calvin] Univ Calif Irvine, Dept Neurol, Sch Med, Irvine, CA 92697 USA.
   [Li, Shengwen Calvin; Vu, Long T.; Loudon, William G.] Calif State Univ Fullerton, Dept Biol Sci, Fullerton, CA 92834 USA.
   [Luo, Jane Jianying] AB Sciex Inc, 250 S Kraemer Blvd, Brea, CA 92822 USA.
   [Zhong, Jiang F.; Li, Zhongjun] Univ Southern Calif, Ostrow Sch Dent, Div Periodontol Diagnost Sci & Dent Hyg & Biomed, Los Angeles, CA 90089 USA.
   [Li, Zhongjun; Loudon, William G.] Third Mil Med Univ, Dept Blood Transfus, Affiliated Hosp 2, Div Radiat Biol, Xinqiao Rd, Chongqing 400037, Peoples R China.
   [Loudon, William G.] St Joseph Hosp, Dept Neurol Surg, Orange, CA 92868 USA.
   [Loudon, William G.] Univ Calif Irvine, Dept Neurol Surg, Sch Med, Orange, CA 92862 USA.
   [Kabeer, Mustafa H.] CHOC Childrens Hosp, Dept Pediat Surg, 1201 West La Veta Ave, Orange, CA 92868 USA.
   [Kabeer, Mustafa H.] Univ Calif Irvine, Sch Med, Dept Surg, 333 City Blvd West,Suite 700, Orange, CA 92868 USA.
C3 University of California System; University of California Irvine;
   California State University System; California State University
   Fullerton; University of Southern California; Army Medical University;
   University of California System; University of California Irvine;
   University of California System; University of California Irvine
RP Li, SWC (通讯作者)，CHOC Childrens Hosp Res Inst, Ctr Neurosci Res, Neurooncol & Stem Cell Res Lab, 1201 West La Veta Ave, Orange, CA 92868 USA.; Li, ZJ (通讯作者)，Univ Southern Calif, Ostrow Sch Dent, Div Periodontol Diagnost Sci & Dent Hyg & Biomed, Los Angeles, CA 90089 USA.
EM shengwel@uci.edu; johnneyusc@gmail.com
RI Li, Shengwen/H-1725-2012
OI Li, PhD,EIC,FRSM,FRSB, Shengwen Calvin/0000-0002-9699-9204
FU Children's Hospital of Orange County (CHOC) Children's Foundation;
   CHOC-UCI/ICTS; CHOC Neuroscience Institute; Austin Ford Tribute Fund; W.
   M. Keck Foundation; National Institutes of Health [R21CA134391];
   National Science Foundation [AW 0852720]; National Center for Advancing
   Translational Sciences [UL1TR001414] Funding Source: NIH RePORTER
FX This study was supported by the Children's Hospital of Orange County
   (CHOC) Children's Foundation, CHOC-UCI/ICTS pilot grants, CHOC
   Neuroscience Institute, Austin Ford Tribute Fund, W. M. Keck Foundation,
   Grant R21CA134391 from the National Institutes of Health, and Grant AW
   0852720 from the National Science Foundation. We thank Dr. Merri Lynn
   Casem, Dr. Robert Koch, and Dr. Douglas Eernisse for their critical
   reading of the manuscript. We thank Maria Minon, MD, Leonard S. Sender,
   MD, Philip H. Schwartz, PhD; John H. Weiss, MD, PhD; Hong Zhen Yin, MD,
   Robert A. Koch, PhD for their enthusiasm and support. Dr. Bridget
   Samuels's editorial help is acknowledged.
CR Adjei IM, 2015, J FUNCT BIOMATER, V6, P81, DOI 10.3390/jfb6010081
   Cai XZ, 2004, RNA, V10, P1957, DOI 10.1261/rna.7135204
   Calabrese C, 2007, CANCER CELL, V11, P69, DOI 10.1016/j.ccr.2006.11.020
   Califano A, 2016, NAT REV CANC
   Carlson Bob, 2011, Biotechnol Healthc, V8, P31
   Cenik C, 2017, RNA, V23, P270, DOI 10.1261/rna.059105.116
   Chang ML, 2015, IN VITRO CELL DEV-AN, V51, P797, DOI 10.1007/s11626-015-9892-0
   Chang YF, 2007, ANNU REV BIOCHEM, V76, P51, DOI 10.1146/annurev.biochem.76.050106.093909
   Chang YL, 2015, ONCOTARGET, V6, P24017, DOI 10.18632/oncotarget.4447
   Chen DS, 2017, NATURE, V541, P321, DOI 10.1038/nature21349
   Cheng CS, 2016, TISSUE ENG PT A, V22, P573, DOI [10.1089/ten.TEA.2015.0359, 10.1089/ten.tea.2015.0359]
   Chevalier T, 2016, LEUKEMIA LYMPHOMA, V57, pI
   Choi YJ, 2017, SCIENCE, V355, DOI 10.1126/science.aag1927
   Davis CD, 2008, AM J CLIN NUTR, V88, p565S, DOI 10.1093/ajcn/88.2.565S
   Davis CD, 2008, NUTR REV, V66, P477, DOI 10.1111/j.1753-4887.2008.00080.x
   Delihas N, 2015, BMC GENOMICS, V16, DOI 10.1186/s12864-015-1958-6
   Di Marzo L, 2016, ONCOTARGET, V7, P60698, DOI 10.18632/oncotarget.10849
   Engler AJ, 2006, CELL, V126, P677, DOI 10.1016/j.cell.2006.06.044
   Evans J, 2015, ELIFE, V4, DOI 10.7554/eLife.07301
   Eyking A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0156871
   Fan SH, 2016, SCIENCE, V354, P54, DOI 10.1126/science.aaf5098
   Ferretti E, 2009, INT J CANCER, V124, P568, DOI 10.1002/ijc.23948
   Fetahu IS, 2016, INT J CANCER, V138, P137, DOI 10.1002/ijc.29681
   Frediani JN, 2016, MOL CANCER, V15, DOI 10.1186/s12943-016-0525-3
   Gardner LB, 2010, MOL CANCER RES, V8, P295, DOI 10.1158/1541-7786.MCR-09-0502
   Ghanghoria R, 2016, J CONTROL RELEASE
   Goel A, 2017, JACC-CARDIOVASC IMAG, V10, P54, DOI 10.1016/j.jcmg.2016.07.012
   Guo HL, 2010, NATURE, V466, P835, DOI 10.1038/nature09267
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Hannafon BN, 2013, INT J MOL SCI, V14, P14240, DOI 10.3390/ijms140714240
   Harper K.L., 2016, Nature
   Hiddingh L, 2014, SCI REP-UK, V4, DOI 10.1038/srep05260
   Hong X, 2006, MOL BIOL EVOL, V23, P2392, DOI 10.1093/molbev/msl111
   Hoque M, 2013, NAT METHODS, V10, P133, DOI [10.1038/NMETH.2288, 10.1038/nmeth.2288]
   Hsu YC, 2011, CELL, V144, P92, DOI 10.1016/j.cell.2010.11.049
   Jahagirdar D, 2016, FRONT ONCOL, V6, DOI 10.3389/fonc.2016.00147
   Kaminska K, 2015, J CELL MOL MED, V19, P283, DOI 10.1111/jcmm.12408
   Kasinski AL, 2011, NAT REV CANCER, V11, P849, DOI 10.1038/nrc3166
   Keklikoglou I, 2012, ONCOGENE, V31, P4150, DOI 10.1038/onc.2011.571
   Le Hir H, 2000, EMBO J, V19, P6860, DOI 10.1093/emboj/19.24.6860
   Lee JK, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0066555, 10.1371/journal.pone.0084256]
   Li J, 2015, ELIFE, V4, DOI 10.7554/eLife.06434
   Li MH, 2009, CANCER CELL, V16, P533, DOI 10.1016/j.ccr.2009.10.025
   Li M, 2016, EXP CELL RES, V345, P115, DOI 10.1016/j.yexcr.2014.09.026
   Li SC, 2014, CANCER CELL INT, V14, DOI 10.1186/s12935-014-0115-7
   Li SC, 2012, STEM CELLS DEV, V21, P503, DOI 10.1089/scd.2011.0267
   Li Shengwen Calvin, 2010, Curr Stem Cell Res Ther, V5, P297
   Li WC, 2016, BMC BIOL, V14, DOI 10.1186/s12915-016-0229-6
   Li X, 2016, WORLD J GASTROENTERO, V22, P5317, DOI 10.3748/wjg.v22.i23.5317
   Li ZH, 2014, NAT REV DRUG DISCOV, V13, P622, DOI 10.1038/nrd4359
   Lim LP, 2005, NATURE, V433, P769, DOI 10.1038/nature03315
   Liu C, 2011, NAT MED, V17, P211, DOI 10.1038/nm.2284
   Lokody I, 2014, NAT REV CANCER, V14, DOI 10.1038/nrc3727
   Mazzio EA, 2012, EPIGENETICS-US, V7, P119, DOI 10.4161/epi.7.2.18764
   Meinke P, 2011, BIOCHEM SOC T, V39, P1693, DOI 10.1042/BST20110658
   Morlando M, 2008, NAT STRUCT MOL BIOL, V15, P902, DOI 10.1038/nsmb.1475
   Moses BS, 2016, MOL CANCER RES, V14, P909, DOI 10.1158/1541-7786.MCR-15-0474
   Mouw JK, 2014, NAT MED, V20, P360, DOI 10.1038/nm.3497
   Nicoloso MS, 2008, BRAIN PATHOL, V18, P122, DOI 10.1111/j.1750-3639.2007.00119.x
   Onea AS, 2016, AM J CANCER RES, V6, P403
   Ostenfeld MS, 2016, J EXTRACELL VESICLES, V5, DOI 10.3402/jev.v5.31488
   Pasquinelli AE, 2000, NATURE, V408, P86, DOI 10.1038/35040556
   Patrushev LI, 2014, BIOCHEMISTRY-MOSCOW+, V79, P1442, DOI 10.1134/S0006297914130021
   Pollari S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037361
   RIEDMANN EM, 2014, HUM VACC IMMUNOTHER, V10, P2139
   Rigo F, 2008, MOL CELL BIOL, V28, P849, DOI 10.1128/MCB.01410-07
   Romero D, 2016, NAT REV CLIN ONCOL, V13, DOI 10.1038/nrclinonc.2016.99
   Saini HK, 2007, P NATL ACAD SCI USA, V104, P17719, DOI 10.1073/pnas.0703890104
   Schmidt MF, 2014, TRENDS BIOTECHNOL, V32, P578, DOI 10.1016/j.tibtech.2014.09.002
   Schwentner R, 2017, ONCOTARGET, V8, P10980, DOI 10.18632/oncotarget.14091
   Seewaldt V, 2014, NAT MED, V20, P332, DOI 10.1038/nm.3523
   Serguienko A, 2015, ONCOTARGET, V6, P2451, DOI 10.18632/oncotarget.3235
   Shalaby T, 2014, INT J MOL SCI, V15, P21554, DOI 10.3390/ijms151121554
   Sood P, 2006, P NATL ACAD SCI USA, V103, P2746, DOI 10.1073/pnas.0511045103
   Spira A, 2016, P NATL ACAD SCI USA, V113, P10750, DOI 10.1073/pnas.1608077113
   Su MJ, 2016, SCI REP-UK, V6, DOI 10.1038/srep30110
   SU QN, 2008, BIOSCI HYPOTHESES, V1, P44, DOI DOI 10.1016/J.BIHY.2008.01.007.
   Sun M, 2005, NUCLEIC ACIDS RES, V33, P5533, DOI 10.1093/nar/gki852
   Suzuki HI, 2015, ONCOGENE, V34, P3085, DOI 10.1038/onc.2014.254
   TAJIK A, 2016, NAT MAT, V15
   Tarallo S, 2014, MUTAGENESIS, V29, P385, DOI 10.1093/mutage/geu028
   Tian B, 2007, GENOME RES, V17, P156, DOI 10.1101/gr.5532707
   Tokumaru S, 2008, CARCINOGENESIS, V29, P2073, DOI 10.1093/carcin/bgn187
   Vermeulen L, 2010, NAT CELL BIOL, V12, P468, DOI 10.1038/ncb2048
   Vu LT, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120336
   Watt FM, 2000, SCIENCE, V287, P1427, DOI 10.1126/science.287.5457.1427
   Wilusz JE, 2010, RNA, V16, P259, DOI 10.1261/rna.1907510
   Yosef N, 2016, SCIENCE, V354, P64, DOI 10.1126/science.aaf5453
   Yu F, 2007, CELL, V131, P1109, DOI 10.1016/j.cell.2007.10.054
   Zhang LX, 2011, CANCER RES, V71, P645, DOI 10.1158/0008-5472.CAN-10-1910
   Zhang X, 2003, RNA, V9, P637, DOI 10.1261/rna.5060403
NR 91
TC 14
Z9 14
U1 0
U2 7
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1574-888X
EI 2212-3946
J9 CURR STEM CELL RES T
JI Curr. Stem Cell Res. Ther.
PY 2017
VL 12
IS 6
BP 455
EP 470
DI 10.2174/1574888X12666170307105941
PG 16
WC Cell & Tissue Engineering; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA FC9YA
UT WOS:000407195800004
PM 28270089
OA Green Accepted, Green Submitted
DA 2025-01-12
ER

PT J
AU Kamarulzaman, NS
   Dewadas, HD
   Leow, CY
   Yaacob, NS
   Mokhtar, NF
AF Kamarulzaman, Nur Sabrina
   Dewadas, Hemaniswarri Dewi
   Leow, Chiuan Yee
   Yaacob, Nik Soriani
   Mokhtar, Noor Fatmawati
TI The role of REST and HDAC2 in epigenetic dysregulation of Nav1.5 and
   nNav1.5 expression in breast cancer
SO CANCER CELL INTERNATIONAL
LA English
DT Article
DE Nav1.5; nNav1.5; REST; HDAC2; TSA; Breast cancer; Aggressiveness; MMP2;
   N-cadherin
ID GATED SODIUM-CHANNELS; CELL LUNG-CANCER; RESTRICTIVE SILENCER FACTOR;
   RAT PROSTATE-CANCER; HISTONE DEACETYLASE INHIBITORS; IN-VITRO;
   GENE-EXPRESSION; DIFFERENTIAL EXPRESSION; TRANSCRIPTION FACTOR;
   TUMOR-SUPPRESSOR
AB Background: Increased expression of voltage-gated sodium channels (VGSCs) have been implicated with strong metastatic potential of human breast cancer in vitro and in vivo where the main culprits are cardiac isoform Nav1.5 and its 'neonatal' splice variant, nNav1.5. Several factors have been associated with Nav1.5 and nNav1.5 gain of expression in breast cancer mainly hormones, and growth factors.
   Aim: This study aimed to investigate the role of epigenetics via transcription repressor, repressor element silencing transcription factor (REST) and histone deacetylases (HDACs) in enhancing Nav1.5 and nNav1.5 expression in human breast cancer by assessing the effect of HDAC inhibitor, trichostatin A (TSA).
   Methods: The less aggressive human breast cancer cell line, MCF-7 cells which lack Nav1.5 and nNav1.5 expression was treated with TSA at a concentration range 10-10,000 ng/ml for 24 h whilst the aggressive MDA-MB-231 cells was used as control. The effect of TSA on Nav1.5, nNav1.5, REST, HDAC1, HDAC2, HDAC3, MMP2 and N-cadherin gene expression level was analysed by real-time PCR. Cell growth (MTT assay) and metastatic behaviors (lateral motility and migration assays) were also measured.
   Results: mRNA expression level of Nav1.5 and nNav1.5 were initially very low in MCF-7 compared to MDA-MB-231 cells. Inversely, mRNA expression level of REST, HDAC1, HDAC2, and HDAC3 were all greater in MCF-7 compared to MDA-MB-231 cells. Treatment with TSA significantly increased the mRNA expression level of Nav1.5 and nNav1.5 in MCF-7 cells. On the contrary, TSA significantly reduced the mRNA expression level of REST and HDAC2 in this cell line. Remarkably, despite cell growth inhibition by TSA, motility and migration of MCF-7 cells were enhanced after TSA treatment, confirmed with the up-regulation of metastatic markers, MMP2 and N-cadherin.
   Conclusions: This study identified epigenetics as another factor that regulate the expression level of Nav1.5 and nNav1.5 in breast cancer where REST and HDAC2 play important role as epigenetic regulators that when lacking enhances the expression of Nav1.5 and nNav1.5 thus promotes motility and migration of breast cancer. Elucidation of the regulatory mechanisms for gain of Nav1.5 and nNav1.5 expression may be helpful for seeking effective strategies for the management of metastatic diseases.
C1 [Kamarulzaman, Nur Sabrina; Dewadas, Hemaniswarri Dewi; Leow, Chiuan Yee; Mokhtar, Noor Fatmawati] Univ Sains Malaysia, Inst Res Mol Med INFORMM, Hlth Campus, Kubang Kerian 16150, Kelantan, Malaysia.
   [Yaacob, Nik Soriani] Univ Sains Malaysia, Dept Chem Pathol, Sch Med Sci, Hlth Campus, Kubang Kerian 16150, Kelantan, Malaysia.
C3 Universiti Sains Malaysia; Universiti Sains Malaysia
RP Mokhtar, NF (通讯作者)，Univ Sains Malaysia, Inst Res Mol Med INFORMM, Hlth Campus, Kubang Kerian 16150, Kelantan, Malaysia.
EM fatmawati@usm.my
RI DEWADAS, HEMANISWARRI/A-5493-2019; Mokhtar, Noor/B-5983-2018; Leow,
   Chiuan/F-8877-2014
OI Dewadas, Hemaniswarri Dewi/0000-0002-6851-1574; Mokhtar, Noor
   Fatmawati/0000-0003-0349-4096; Leow, Chiuan Yee/0000-0002-6919-5921
FU Ministry of Education, Malaysia under Fundamental Research Grant Scheme
   [203/CIPPM/6171145]; Ministry of Education, Malaysia under MyBrain
   (MyPhD) scheme
FX The project was funded by the Ministry of Education, Malaysia under the
   Fundamental Research Grant Scheme (203/CIPPM/6171145). NSK and HDD were
   sponsored by the Ministry of Education, Malaysia under the MyBrain
   (MyPhD) scheme.
CR [Anonymous], MOL CANC
   Ballas N, 2001, NEURON, V31, P353, DOI 10.1016/S0896-6273(01)00371-3
   Bennett ES, 2004, PFLUG ARCH EUR J PHY, V447, P908, DOI 10.1007/s00424-003-1205-x
   Bhaskara S, 2010, CANCER CELL, V18, P436, DOI 10.1016/j.ccr.2010.10.022
   Brackenbury WJ, 2007, BREAST CANCER RES TR, V101, P149, DOI 10.1007/s10549-006-9281-1
   Brackenbury WJ, 2007, J CELL PHYSIOL, V210, P602, DOI 10.1002/jcp.20846
   Brackenbury WJ, 2006, J PHYSIOL-LONDON, V573, P343, DOI 10.1113/jphysiol.2006.106906
   Catterall WA, 2000, NEURON, V26, P13, DOI 10.1016/S0896-6273(00)81133-2
   Chioni AM, 2010, INT J BIOCHEM CELL B, V42, P346, DOI 10.1016/j.biocel.2009.11.021
   CHONG JHA, 1995, CELL, V80, P949, DOI 10.1016/0092-8674(95)90298-8
   Colón-Díaz M, 2012, REPROD SCI, V19, P483, DOI 10.1177/1933719111432870
   Colussi C, 2010, CARDIOVASC RES, V87, P73, DOI 10.1093/cvr/cvq035
   Coulson JM, 2000, CANCER RES, V60, P1840
   Diaz D, 2007, J CELL PHYSIOL, V210, P469, DOI 10.1002/jcp.20871
   Diss JKJ, 2008, PROSTATE CANCER P D, V11, P325, DOI 10.1038/sj.pcan.4501012
   Drews VL, 2007, MAMM GENOME, V18, P723, DOI 10.1007/s00335-007-9059-8
   Driffort V, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-264
   Duong V, 2008, MOL CANCER RES, V6, P1908, DOI 10.1158/1541-7786.MCR-08-0299
   Fraser SP, 2014, PHILOS T R SOC B, V369, DOI 10.1098/rstb.2013.0105
   Fraser SP, 2003, J CELL PHYSIOL, V195, P479, DOI 10.1002/jcp.10312
   Fraser SP, 2005, CLIN CANCER RES, V11, P5381, DOI 10.1158/1078-0432.CCR-05-0327
   Fraser SP, 2007, J CELL PHYSL, V224, P527
   Fulgenzi G, 2006, INT J BIOCHEM CELL B, V38, P1146, DOI 10.1016/j.biocel.2005.12.003
   Gao R, 2010, ONCOL REP, V23, P1293, DOI 10.3892/or_00000763
   GRIMES JA, 1995, FEBS LETT, V369, P290, DOI 10.1016/0014-5793(95)00772-2
   Gryder BE, 2012, FUTURE MED CHEM, V4, P505, DOI [10.4155/fmc.12.3, 10.4155/FMC.12.3]
   Hayashi A, 2010, INT J CANCER, V127, P1332, DOI 10.1002/ijc.25151
   House CD, 2010, CANCER RES, V70, P6957, DOI 10.1158/0008-5472.CAN-10-1169
   Kuwahara K, 2013, CIRC J, V77, P2682, DOI 10.1253/circj.CJ-13-1210
   Lin KT, 2012, CLIN CANCER RES, V18, P4691, DOI 10.1158/1078-0432.CCR-12-0633
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Martin F, 2015, FRONT PHARMACOL, V6, DOI 10.3389/fphar.2015.00273
   Matsushita Y, 2013, BRIT J PHARMACOL, V170, P991, DOI 10.1111/bph.12366
   Medina V, 1997, CANCER RES, V57, P3697
   Mohammed FH, 2016, INT J ONCOL, V48, P73, DOI 10.3892/ijo.2015.3239
   Moradzadeh M, 2015, MOL BIOMARK DIAGN, V6, P4
   MORI N, 1992, NEURON, V9, P45, DOI 10.1016/0896-6273(92)90219-4
   Mottamal M, 2015, MOLECULES, V20, P3898, DOI 10.3390/molecules20033898
   Müller BM, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-215
   Mutze K, 2010, ANN SURG ONCOL, V17, P3336, DOI 10.1245/s10434-010-1182-1
   Nadeau H, 2002, J NEUROPHYSIOL, V88, P409, DOI 10.1152/jn.2002.88.1.409
   Negrini S, 2013, TRENDS CELL BIOL, V23, P289, DOI 10.1016/j.tcb.2013.01.006
   Nelson M, 2015, MOL CANCER, V14, DOI 10.1186/s12943-014-0277-x
   Onganer PU, 2005, J MEMBRANE BIOL, V204, P67, DOI 10.1007/s00232-005-0747-6
   Paonessa F, 2016, P NATL ACAD SCI USA, V113, pE91, DOI 10.1073/pnas.1507355112
   Pozzi D, 2013, EMBO J, V32, P2994, DOI 10.1038/emboj.2013.231
   Pulukuri SMK, 2007, J BIOL CHEM, V282, P35594, DOI 10.1074/jbc.M705867200
   Ramakrishnan S, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2604-7
   Reddy BY, 2009, P NATL ACAD SCI USA, V106, P4408, DOI 10.1073/pnas.0809130106
   Robey RW, 2011, MOL PHARMACEUT, V8, P2021, DOI 10.1021/mp200329f
   Roger S, 2003, BBA-BIOMEMBRANES, V1616, P107, DOI 10.1016/j.bbamem.2003.07.001
   Roger S, 2007, INT J BIOCHEM CELL B, V39, P774, DOI 10.1016/j.biocel.2006.12.007
   Roopra A, 2000, MOL CELL BIOL, V20, P2147, DOI 10.1128/MCB.20.6.2147-2157.2000
   Ropero S, 2006, NAT GENET, V38, P566, DOI 10.1038/ng1773
   Schoenherr CJ, 1996, P NATL ACAD SCI USA, V93, P9881, DOI 10.1073/pnas.93.18.9881
   Sharma S, 2010, CARCINOGENESIS, V31, P27, DOI 10.1093/carcin/bgp220
   Siu MKY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047201
   Van Swearingen AED, 2014, BREAST CANCER RES, V16, DOI 10.1186/bcr3651
   Vansteenkiste J, 2008, INVEST NEW DRUG, V26, P483, DOI 10.1007/s10637-008-9131-6
   Wagoner MP, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000979
   Wang LG, 2009, AM J TRANSL RES, V1, P62
   Westbrook TF, 2005, CELL, V121, P837, DOI 10.1016/j.cell.2005.03.033
   Wu LM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014460
   Yamamoto R, 1997, J NEUROCHEM, V68, P1655
   Yang M, 2012, BREAST CANCER RES TR, V134, P603, DOI 10.1007/s10549-012-2102-9
   Yu YB, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009339
NR 66
TC 24
Z9 27
U1 1
U2 18
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1475-2867
J9 CANCER CELL INT
JI Cancer Cell Int.
PD AUG 1
PY 2017
VL 17
AR 74
DI 10.1186/s12935-017-0442-6
PG 12
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA FC6KN
UT WOS:000406949200001
PM 28785170
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Krishna, S
   Shukla, S
   Lakra, AD
   Meeran, SM
   Siddiqa, MI
AF Krishna, Shagun
   Shukla, Samriddhi
   Lakra, Amar Deep
   Meeran, Syed Musthapa
   Siddiqa, Mohammad Imran
TI Identification of potent inhibitors of DNA methyltransferase 1 (DNMT1)
   through a pharmacophore-based virtual screening approach
SO JOURNAL OF MOLECULAR GRAPHICS & MODELLING
LA English
DT Article
DE DNMT1 inhibitors; Pharmacophore based virtual screening; Naive Bayesian
   classification model; Ensemble docking; Molecular dynamics simulation
ID SMALL-MOLECULE INHIBITORS; BIOLOGICAL EVALUATION; DRUG DESIGN;
   NATURAL-PRODUCTS; LIGAND DOCKING; DISCOVERY; METHYLATION; ANALOGS;
   DERIVATIVES; VALIDATION
AB DNA methylation is an epigenetic change that results in the addition of a methyl group at the carbon-5 position of cytosine residues. DNA methyltransferase (DNMT) inhibitors can suppress tumour growth and have significant therapeutic value. However, the established inhibitors are limited in their application due to their substantial cytotoxicity. Additionally, the standard drugs for DNMT inhibition are non-selective cytosine analogues with considerable cytotoxic side-effects. In the present study, we have designed a workflow by integrating various ligand-based and structure-based approaches to discover new agents active against DNMT1. We have derived a pharmacophore model with the help of available DNMT1 inhibitors. Utilising this model, we performed the virtual screening of Maybridge chemical library and the identified hits were then subsequently filtered based on the Naive Bayesian classification model. The molecules that have returned from this classification model were subjected to ensemble based docking. We have selected 10 molecules for the biological assay by inspecting the interactions portrayed by these molecules. Three out of the ten tested compounds have shown DNMT1 inhibitory activity. These compounds were also found to demonstrate potential inhibition of cellular proliferation in human breast cancer MDA-MB-231 cells. In the present study, we have utilized a multi-step virtual screening protocol to identify inhibitors of DNMT1, which offers a starting point to develop more potent DNMT1 inhibitors as anti-cancer agents. (C) 2017 Elsevier Inc. All rights reserved.
C1 [Krishna, Shagun; Siddiqa, Mohammad Imran] Cent Drug Res Inst, CSIR, Mol & Struct Biol Div, Lucknow 260031, Uttar Pradesh, India.
   [Shukla, Samriddhi; Lakra, Amar Deep; Meeran, Syed Musthapa] Cent Drug Res Inst, CSIR, Endocrinol Div, Lucknow 260031, Uttar Pradesh, India.
C3 Council of Scientific & Industrial Research (CSIR) - India; CSIR -
   Central Drug Research Institute (CDRI); Council of Scientific &
   Industrial Research (CSIR) - India; CSIR - Central Drug Research
   Institute (CDRI)
RP Siddiqa, MI (通讯作者)，Cent Drug Res Inst, CSIR, Mol & Struct Biol Div, Lucknow 260031, Uttar Pradesh, India.
EM mi_siddiqi@cdri.res.in
RI Meeran, Syed/AAG-2157-2020; Shukla, Samriddhi/AAF-1876-2021; Krishna,
   Shagun/ABA-7231-2021
OI Shukla, Samriddhi/0000-0002-3771-4184
FU CSIR network project GENESIS [BSC0121]; CSIR network project UNDO
   [BSC0103]; ICMR
FX Work reported in this project is supported by grants from CSIR network
   projects GENESIS (BSC0121) and UNDO (BSC0103). SK acknowledges ICMR for
   Senior Research fellowship. This manuscript is a CSIR-CDRI communication
   number 9499.
CR Alonso H, 2006, MED RES REV, V26, P531, DOI 10.1002/med.20067
   Arooj M, 2011, INT J MOL SCI, V12, P9236, DOI 10.3390/ijms12129236
   Asgatay S, 2014, J MED CHEM, V57, P421, DOI 10.1021/jm401419p
   Baud MGJ, 2012, J MED CHEM, V55, P1731, DOI 10.1021/jm2016182
   Bestor TH, 2000, HUM MOL GENET, V9, P2395, DOI 10.1093/hmg/9.16.2395
   Bottegoni G, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018845
   Castellano S, 2008, J MED CHEM, V51, P2321, DOI 10.1021/jm7015705
   Castellano S, 2011, J MED CHEM, V54, P7663, DOI 10.1021/jm2010404
   Ceccaldi A, 2013, ACS CHEM BIOL, V8, P543, DOI 10.1021/cb300565z
   Chen SJ, 2014, J MED CHEM, V57, P9028, DOI 10.1021/jm501134e
   Choi J, 2016, J CHEM INF MODEL, V56, P354, DOI 10.1021/acs.jcim.5b00484
   Devkota K, 2014, ACS MED CHEM LETT, V5, P293, DOI 10.1021/ml4002503
   Discovery Studio, 2007, DISC STUD VERS 4 1
   Egger G, 2004, NATURE, V429, P457, DOI 10.1038/nature02625
   Fang JS, 2016, RSC ADV, V6, P9857, DOI 10.1039/c5ra23035g
   Fang JS, 2013, J CHEM INF MODEL, V53, P3009, DOI 10.1021/ci400331p
   Fang MZ, 2003, CANCER RES, V63, P7563
   Fraga MF, 2004, CANCER RES, V64, P5527, DOI 10.1158/0008-5472.CAN-03-4061
   Güner O, 2004, CURR MED CHEM, V11, P2991, DOI 10.2174/0929867043364036
   Gupta AK, 2010, J CHEM INF MODEL, V50, P1510, DOI 10.1021/ci100180e
   Hess B, 2008, J CHEM THEORY COMPUT, V4, P435, DOI 10.1021/ct700301q
   Hobley G, 2012, BIOORG MED CHEM LETT, V22, P3079, DOI 10.1016/j.bmcl.2012.03.072
   Isakovic L, 2009, BIOORG MED CHEM LETT, V19, P2742, DOI 10.1016/j.bmcl.2009.03.132
   Jaenisch R, 2003, NAT GENET, V33, P245, DOI 10.1038/ng1089
   John S, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-S1-S28
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Joshi M, 2016, CHEM BIOL DRUG DES, V88, P5, DOI 10.1111/cbdd.12741
   Kim HJ, 2008, J CHEM INF MODEL, V48, P197, DOI 10.1021/ci700160t
   Krishna S, 2014, J CHEM INF MODEL, V54, P781, DOI 10.1021/ci5000032
   Kuck D, 2010, BIOORGAN MED CHEM, V18, P822, DOI 10.1016/j.bmc.2009.11.050
   Kurczyk A, 2015, J CHEM INF MODEL, V55, P2168, DOI 10.1021/acs.jcim.5b00295
   Lavecchia A, 2013, CURR MED CHEM, V20, P2839, DOI 10.2174/09298673113209990001
   Lei DW, 2012, J MOL GRAPH MODEL, V36, P42, DOI 10.1016/j.jmgm.2012.03.004
   Li RJ, 2015, RSC ADV, V5, P23202, DOI 10.1039/c4ra16963h
   Liu MM, 2012, EUR J MED CHEM, V52, P33, DOI 10.1016/j.ejmech.2012.03.002
   Ma Y, 2014, CHEM BIOL DRUG DES, V83, P697, DOI 10.1111/cbdd.12283
   Maldonado-Rojas W, 2015, J MOL GRAPH MODEL, V60, P43, DOI 10.1016/j.jmgm.2015.04.010
   Medina-Franco JL, 2011, MOL DIVERS, V15, P293, DOI 10.1007/s11030-010-9262-5
   Medina-Franco JL, 2011, DRUG DISCOV TODAY, V16, P418, DOI 10.1016/j.drudis.2011.02.003
   Mehra R, 2016, ACS COMB SCI, V18, P100, DOI 10.1021/acscombsci.5b00019
   Méndez-Lucio O, 2014, CHEMMEDCHEM, V9, P560, DOI 10.1002/cmdc.201300555
   O'Dowd H, 1999, TETRAHEDRON, V55, P3625, DOI 10.1016/S0040-4020(98)01170-3
   Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6
   Plitta B, 2012, EUR J MED CHEM, V55, P243, DOI 10.1016/j.ejmech.2012.07.024
   Rarey M, 1996, J MOL BIOL, V261, P470, DOI 10.1006/jmbi.1996.0477
   Ren JX, 2011, J CHEM INF MODEL, V51, P1364, DOI 10.1021/ci100464b
   Rueda M, 2010, J CHEM INF MODEL, V50, P186, DOI 10.1021/ci9003943
   Saavedra OM, 2009, BIOORG MED CHEM LETT, V19, P2747, DOI 10.1016/j.bmcl.2009.03.113
   Sathe RY, 2015, MED CHEM RES, V24, P1449, DOI 10.1007/s00044-014-1223-6
   Schüttelkopf AW, 2004, ACTA CRYSTALLOGR D, V60, P1355, DOI 10.1107/S0907444904011679
   Shah F, 2011, J CHEM INF MODEL, V51, P852, DOI 10.1021/ci200029y
   Siedlecki P, 2006, J MED CHEM, V49, P678, DOI 10.1021/jm050844z
   Sindhu T, 2015, MOL BIOSYST, V11, P1305, DOI 10.1039/c5mb00137d
   Singh KD, 2013, ACTA PHARMACOL SIN, V34, P1592, DOI 10.1038/aps.2013.129
   Song JK, 2011, SCIENCE, V331, P1036, DOI 10.1126/science.1195380
   Tian S, 2014, J CHEM INF MODEL, V54, P2664, DOI 10.1021/ci500414b
   *TRIP INC, 2005, SYB VERS 7 1
   Valente S, 2014, J MED CHEM, V57, P701, DOI 10.1021/jm4012627
   Verdonk ML, 2008, J CHEM INF MODEL, V48, P2214, DOI 10.1021/ci8002254
   Verma SK, 2012, ACS MED CHEM LETT, V3, P1091, DOI 10.1021/ml3003346
   Wang L, 2014, J CHEM INF MODEL, V54, P3186, DOI 10.1021/ci500253q
   Xing JH, 2014, CHEM BIOL DRUG DES, V84, P364, DOI 10.1111/cbdd.12327
   Yoo J, 2012, CURR COMPUT-AID DRUG, V8, P317, DOI 10.2174/157340912803519606
   Yoo J, 2012, ADV PROTEIN CHEM STR, V87, P219, DOI 10.1016/B978-0-12-398312-1.00008-1
   Yu WY, 2013, BIOORGAN MED CHEM, V21, P1787, DOI 10.1016/j.bmc.2013.01.049
   Zhao WX, 2011, J CHEM INF MODEL, V51, P2147, DOI 10.1021/ci100511v
   Zhong S, 2008, J MED CHEM, V51, P4553, DOI 10.1021/jm8001668
NR 67
TC 25
Z9 26
U1 1
U2 44
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1093-3263
EI 1873-4243
J9 J MOL GRAPH MODEL
JI J. Mol. Graph.
PD AUG
PY 2017
VL 75
BP 174
EP 188
DI 10.1016/j.jmgm.2017.05.014
PG 15
WC Biochemical Research Methods; Biochemistry & Molecular Biology; Computer
   Science, Interdisciplinary Applications; Crystallography; Mathematical &
   Computational Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Computer Science; Crystallography;
   Mathematical & Computational Biology
GA FC6XD
UT WOS:000406984100021
PM 28582695
DA 2025-01-12
ER

PT J
AU Connolly, RM
   Rudek, MA
   Piekarz, R
AF Connolly, Roisin M.
   Rudek, Michelle A.
   Piekarz, Richard
TI Entinostat: a promising treatment option for patients with advanced
   breast cancer
SO FUTURE ONCOLOGY
LA English
DT Article
DE breast cancer; clinical trials; entinostat; epigenetics; histone
   deacetylase inhibitor
ID HISTONE DEACETYLASE INHIBITOR; REFRACTORY SOLID TUMORS; ACUTE
   MYELOID-LEUKEMIA; PHASE-I TRIAL; HDAC INHIBITOR; ENDOCRINE THERAPY;
   LUNG-CANCER; DNA METHYLTRANSFERASE; PROSTATE-CANCER; DOUBLE-BLIND
AB Entinostat is a synthetic benzamide derivative histone deacetylase (HDAC) inhibitor, which potently and selectively inhibits class I and IV HDAC enzymes. This action promotes histone hyperacetylation and transcriptional activation of specific genes, with subsequent inhibition of cell proliferation, terminal differentiation and apoptosis. This oral HDAC inhibitor has been evaluated in Phase I and II trials in patients with advanced malignancies, and is in general well tolerated. Entinostat does not currently have regulatory approval for clinical use; however promising preclinical and clinical data exist in hormone-resistant breast cancer. An ECOG-ACRIN Phase III registration study is ongoing in advanced breast cancer (E2112, NCT02115282) and aims to confirm the overall survival advantage observed with the combination of exemestane and entinostat/placebo in the Phase II setting (ENCORE301 trial). This article provides an overview of the chemistry, pharmacokinetics/pharmacodynamics and available clinical data for entinostat with a focus on advanced breast cancer.
C1 [Connolly, Roisin M.; Rudek, Michelle A.] Johns Hopkins Sch Med, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21205 USA.
   [Piekarz, Richard] NCI, Canc Therapy Evaluat Program, Bethesda, MD 20892 USA.
C3 Johns Hopkins University; Johns Hopkins Medicine; National Institutes of
   Health (NIH) - USA; NIH National Cancer Institute (NCI)
RP Connolly, RM (通讯作者)，Johns Hopkins Sch Med, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21205 USA.
EM rconnol2@jhmi.edu
RI Piekarz, Richard/GXH-9978-2022
FU Novartis; Puma Biotechnology; Genentech; Merrimack Pharmaceuticals;
   Clovis; Merck; Celgene; NIH [UM1 CA186691, U10CA180802]
FX RM Connolly has received research grants from Novartis, Puma
   Biotechnology, Genentech, Merrimack Pharmaceuticals, Clovis, Merck. MA
   Rudek has received research funding from Celgene. Supported by Grant No.
   UM1 CA186691 (MA Rudek and RM Connolly) and U10CA180802 (RM Connolly)
   from the NIH. The authors have no other relevant affiliations or
   financial involvement with any organization or entity with a financial
   interest in or financial conflict with the subject matter or materials
   discussed in the manuscript apart from those disclosed.
CR Acharya MR, 2006, INVEST NEW DRUG, V24, P367, DOI 10.1007/s10637-005-5707-6
   Acharya MR, 2006, CANCER CHEMOTH PHARM, V57, P275, DOI 10.1007/s00280-005-0058-8
   Amir E, 2011, JNCI-J NATL CANCER I, V103, P1299, DOI 10.1093/jnci/djr242
   [Anonymous], 2014, SNDX 27
   Arts J, 2003, CURR MED CHEM, V10, P2343, DOI 10.2174/0929867033456657
   Baselga J, 2012, NEW ENGL J MED, V366, P520, DOI 10.1056/NEJMoa1109653
   Baylin SB, 2011, NAT REV CANCER, V11, P726, DOI 10.1038/nrc3130
   Belinsky SA, 2003, CANCER RES, V63, P7089
   Brogdon JL, 2007, BLOOD, V109, P1123, DOI 10.1182/blood-2006-04-019711
   Buglio D, 2008, BLOOD, V112, P1424, DOI 10.1182/blood-2008-01-133769
   Buglio D, 2011, BLOOD, V117, P2910, DOI 10.1182/blood-2010-08-303701
   Connolly R, 2012, J MAMMARY GLAND BIOL, V17, P191, DOI 10.1007/s10911-012-9263-3
   Connolly RM, 2017, CLIN CANCER RES, V23, P2691, DOI 10.1158/1078-0432.CCR-16-1729
   Cristofanilli M, 2016, LANCET ONCOL, V17, P425, DOI 10.1016/S1470-2045(15)00613-0
   Fan J, 2008, J CANCER RES CLIN, V134, P883, DOI 10.1007/s00432-008-0354-x
   Fandy TE, 2009, BLOOD, V114, P2764, DOI 10.1182/blood-2009-02-203547
   Finn RS, 2016, NEW ENGL J MED, V375, P1925, DOI 10.1056/NEJMoa1607303
   Finn RS, 2015, LANCET ONCOL, V16, P25, DOI 10.1016/S1470-2045(14)71159-3
   Fotheringham S, 2009, CANCER CELL, V15, P57, DOI 10.1016/j.ccr.2008.12.001
   Gojo I, 2007, BLOOD, V109, P2781, DOI 10.1182/blood-2006-05-021873
   Gore L, 2008, CLIN CANCER RES, V14, P4517, DOI 10.1158/1078-0432.CCR-07-1461
   Hess-Stumpp H, 2007, INT J BIOCHEM CELL B, V39, P1388, DOI 10.1016/j.biocel.2007.02.009
   Hodges-Gallagher L, 2007, BREAST CANCER RES TR, V105, P297, DOI 10.1007/s10549-006-9459-6
   Hooker JM, 2010, ACS CHEM NEUROSCI, V1, P65, DOI 10.1021/cn9000268
   Ihle MA, 2016, J PATHOL CLIN RES, V2, P59, DOI 10.1002/cjp2.35
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Juergens RA, 2011, CANCER DISCOV, V1, P598, DOI 10.1158/2159-8290.CD-11-0214
   Keen JC, 2003, BREAST CANCER RES TR, V81, P177, DOI 10.1023/A:1026146524737
   Khan O, 2010, P NATL ACAD SCI USA, V107, P6532, DOI 10.1073/pnas.0913912107
   Kim K, 2014, P NATL ACAD SCI USA, V111, P11774, DOI 10.1073/pnas.1410626111
   Knipstein J, 2011, EXPERT OPIN INV DRUG, V20, P1455, DOI 10.1517/13543784.2011.613822
   Krusche CA, 2005, BREAST CANCER RES TR, V90, P15, DOI 10.1007/s10549-004-1668-2
   Kummar S, 2007, CLIN CANCER RES, V13, P5411, DOI 10.1158/1078-0432.CCR-07-0791
   Lee J, 2014, BREAST CANCER RES TR, V146, P259, DOI 10.1007/s10549-014-3014-7
   Maeda Takahiro, 2000, Blood, V96, P3847
   Magner WJ, 2000, J IMMUNOL, V165, P7017, DOI 10.4049/jimmunol.165.12.7017
   Mohla S, 2009, CANCER BIOL THER, V8, P1975, DOI 10.4161/cbt.8.21.9918
   Müller BM, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-215
   Munster PN, 2011, BRIT J CANCER, V104, P1828, DOI 10.1038/bjc.2011.156
   Munster PN, 2009, BRIT J CANCER, V101, P1044, DOI 10.1038/sj.bjc.6605293
   NIH National Cancer Institute Surveillance Epidemiology and End Results Program, CANC STAT FACTS FEM
   Ordentlich P., 2011, P AACR NCI EORTC INT
   Park IH, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0162058
   Piekarz RL, 2007, CANCER J, V13, P30, DOI 10.1097/PPO.0b013e31803c73cc
   Prebet T, 2014, J CLIN ONCOL, V32, P1242, DOI 10.1200/JCO.2013.50.3102
   Prince HM, 2009, CLIN CANCER RES, V15, P3958, DOI 10.1158/1078-0432.CCR-08-2785
   Reddy P, 2004, P NATL ACAD SCI USA, V101, P3921, DOI 10.1073/pnas.0400380101
   Robertson JFR, 2009, J CLIN ONCOL, V27, P4530, DOI 10.1200/JCO.2008.21.1136
   Ruscetti M, 2016, ONCOGENE, V35, P3781, DOI 10.1038/onc.2015.444
   Ryan QC, 2005, J CLIN ONCOL, V23, P3912, DOI 10.1200/JCO.2005.02.188
   Sabnis GJ, 2013, MOL CANCER THER, V12, P2804, DOI 10.1158/1535-7163.MCT-13-0345
   Sabnis GJ, 2011, CANCER RES, V71, P1893, DOI 10.1158/0008-5472.CAN-10-2458
   Saito A, 1999, P NATL ACAD SCI USA, V96, P4592, DOI 10.1073/pnas.96.8.4592
   Schech A, 2015, MOL CANCER THER, V14, P1848, DOI 10.1158/1535-7163.MCT-14-0778
   Shah P, 2014, BREAST CANCER RES TR, V143, P99, DOI 10.1007/s10549-013-2784-7
   Sharma D, 2006, CANCER RES, V66, P6370, DOI 10.1158/0008-5472.CAN-06-0402
   Shen L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030815
   Simonini MV, 2006, P NATL ACAD SCI USA, V103, P1587, DOI 10.1073/pnas.0510341103
   Suzuki T, 1999, J MED CHEM, V42, P3001, DOI 10.1021/jm980565u
   Tao R, 2007, NAT MED, V13, P1299, DOI 10.1038/nm1652
   Tomita Y, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2016.1219008
   Vendetti FP, 2015, ONCOTARGET, V6, P56, DOI 10.18632/oncotarget.2695
   Witta SE, 2006, CANCER RES, V66, P944, DOI 10.1158/0008-5472.CAN-05-1988
   Xu WS, 2007, ONCOGENE, V26, P5541, DOI 10.1038/sj.onc.1210620
   Yang XW, 2001, CANCER RES, V61, P7025
   Yardley DA, 2013, J CLIN ONCOL, V31, P2128, DOI 10.1200/JCO.2012.43.7251
   Zhou Q, 2009, BREAST CANCER RES TR, V117, P443, DOI 10.1007/s10549-008-0148-5
   Zhu WG, 2001, CANCER RES, V61, P1327
NR 68
TC 105
Z9 112
U1 3
U2 16
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
   1QB, ENGLAND
SN 1479-6694
EI 1744-8301
J9 FUTURE ONCOL
JI Future Oncol.
PD JUN
PY 2017
VL 13
IS 13
BP 1137
EP 1148
DI 10.2217/fon-2016-0526
PG 12
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA FB6XV
UT WOS:000406286600004
PM 28326839
OA Green Published
DA 2025-01-12
ER

PT J
AU Kovalchuk, A
   Kolb, B
AF Kovalchuk, Anna
   Kolb, Bryan
TI Chemo brain: From discerning mechanisms to lifting the brain fogAn aging
   connection
SO CELL CYCLE
LA English
DT Article
DE epigenetics; hippocampus; prefrontal cortex; sex differences in brain
ID HIPPOCAMPAL CELL-PROLIFERATION; LONG-TERM SURVIVORS; QUALITY-OF-LIFE;
   DNA METHYLATION; BREAST-CANCER; COGNITIVE DYSFUNCTION; GENE-EXPRESSION;
   CHEMOTHERAPY; MEMORY; METHOTREXATE
AB Mounting evidence indicates that cancer treatments cause numerous deleterious effects, including central nervous system (CNS) toxicity. Chemotherapy-caused CNS side effects encompass changes in cognitive function, memory, and attention, to name a few. Although chemotherapy treatment-induced side effects occur in 16-75% of all patients, the mechanisms of these effects are not well understood. We have recently proposed a new epigenetic theory of chemo brain and, in a pioneer study, determined that cytotoxic chemotherapy agents induce oxidative DNA damage and affect molecular and epigenetic processes in the brain, and may be associated with brain aging processes.In this paper, we discuss the implications of chemo brain epigenetic effects and future perspectives, as well as outline potential links with brain aging and future translational research opportunities.
C1 [Kolb, Bryan] Univ Lethbridge, Dept Neurosci, Lethbridge, AB T1K 3M4, Canada.
   Canadian Inst Adv Res, Toronto, ON, Canada.
   Alberta Epigenet Network, Calgary, AB, Canada.
C3 University of Lethbridge; Canadian Institute for Advanced Research
   (CIFAR)
RP Kolb, B (通讯作者)，Univ Lethbridge, Dept Neurosci, Lethbridge, AB T1K 3M4, Canada.
EM kolb@uleth.ca
CR Ahles TA, 2005, J CLIN ONCOL, V23, P4399, DOI 10.1200/JCO.2005.03.343
   Ahles TA, 2002, J CLIN ONCOL, V20, P485, DOI 10.1200/JCO.2002.20.2.485
   Ahles TA, 1998, J CLIN ONCOL, V16, P1954, DOI 10.1200/JCO.1998.16.5.1954
   Aliper A, 2016, AGING-US, V8, P2127, DOI 10.18632/aging.101047
   Artcibasova AV, 2016, CELL CYCLE, V15, P689, DOI 10.1080/15384101.2016.1147633
   Baulina NM, 2016, ACTA NATURAE, V8, P21, DOI 10.32607/20758251-2016-8-1-21-33
   BORISOV N.M., 2014, Oncotarget
   Briones TL, 2011, BMC NEUROSCI, V12, DOI 10.1186/1471-2202-12-124
   Buzdin AA, 2014, FRONT GENET, V5, DOI 10.3389/fgene.2014.00055
   Castellon S, 2009, BREAST CANCER RES TR, V116, P125, DOI 10.1007/s10549-008-0211-2
   Christie LA, 2012, CLIN CANCER RES, V18, P1954, DOI 10.1158/1078-0432.CCR-11-2000
   de Haan M, 2006, TRENDS NEUROSCI, V29, P374, DOI 10.1016/j.tins.2006.05.008
   DeVita VT., 2005, Cancer, principles practice of oncology, V7th
   Follin C, 2016, PSYCHONEUROENDOCRINO, V73, P157, DOI 10.1016/j.psyneuen.2016.07.222
   Gibb EA, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-38
   Gupta S, 2008, BIOL-TARGETS THER, V2, P707
   Haberman RP, 2012, EPIGENETICS-US, V7, P1008, DOI 10.4161/epi.21291
   Halder R, 2016, NAT NEUROSCI, V19, P102, DOI 10.1038/nn.4194
   Han Ruolan, 2008, J Biol, V7, P12, DOI 10.1186/jbiol69
   Hearps S, 2017, PEDIATR BLOOD CANCER, V64, P225, DOI 10.1002/pbc.26188
   Iorio MV, 2012, EMBO MOL MED, V4, P143, DOI 10.1002/emmm.201100209
   Iyengar BR, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00047
   Jaenisch R, 2003, NAT GENET, V33, P245, DOI 10.1038/ng1089
   Jellen LC, 2015, FRONT SYST NEUROSCI, V9, DOI [10.3369/fnsys.2015.00004, 10.3389/fnsys.2015.00004]
   Jirtle RL., 2013, Environmental Epigenomics in Health and Disease: Epigenetics and Disease Origins eds, P3, DOI [10.1007/978-3-642-23380-7_1, DOI 10.1007/978-3-642-23380-7_1]
   Kaiser J, 2014, CORTEX, V54, P33, DOI 10.1016/j.cortex.2014.01.010
   Koch MW, 2013, TRENDS MOL MED, V19, P23, DOI 10.1016/j.molmed.2012.10.008
   Kolb B., 2014, INTRO BRAIN BEHAV
   Kolb B, 2012, P NATL ACAD SCI USA, V109, P17186, DOI 10.1073/pnas.1121251109
   Koturbash I, 2011, MUTAT RES-GEN TOX EN, V722, P94, DOI 10.1016/j.mrgentox.2010.05.006
   Kovalchuk A, 2016, AGING-US, V8, P697, DOI 10.18632/aging.100920
   Kovalchuk I., 2012, Epigenetics in Health and Disease, V1st
   Kovalchuk O, 2013, EPIGENETIC EFFECTS I, P99
   Kunin-Batson A, 2014, PSYCHO-ONCOLOGY, V23, P692, DOI 10.1002/pon.3470
   Lara AH, 2015, FRONT SYST NEUROSCI, V9, DOI 10.3389/fnsys.2015.00173
   Lardenoije R, 2015, PROG NEUROBIOL, V131, P21, DOI 10.1016/j.pneurobio.2015.05.002
   Lezhnina K, 2014, ONCOTARGET, V5, P9022, DOI 10.18632/oncotarget.2493
   Liang J, 2016, ONCOTARGET, V7, P48813, DOI 10.18632/oncotarget.9281
   Longe JL, 2013, GALE ENCY CANC GUIDE
   Mattick JS, 2006, HUM MOL GENET, V15, pR17, DOI 10.1093/hmg/ddl046
   Mehler MF, 2008, PROG NEUROBIOL, V86, P305, DOI 10.1016/j.pneurobio.2008.10.001
   Mitchell T, 2011, EUR J CANCER CARE, V20, P539, DOI 10.1111/j.1365-2354.2011.01244.x
   Moskalev A, 2017, AGING-US, V9, P21, DOI 10.18632/aging.101163
   Moskalev A, 2015, AGING-US, V7, P616, DOI 10.18632/aging.100799
   Mustafa S, 2008, EUR J NEUROSCI, V28, P323, DOI 10.1111/j.1460-9568.2008.06325.x
   O'Farrell E, 2013, CURR ONCOL REP, V15, P260, DOI 10.1007/s11912-013-0307-7
   Olson K, 2016, SUPPORT CARE CANCER, V24, P3223, DOI 10.1007/s00520-016-3215-1
   Ponting CP, 2010, HUM MOL GENET, V19, pR162, DOI 10.1093/hmg/ddq362
   Qureshi IA, 2014, PHILOS T R SOC LON B, P369
   Seigers R, 2015, PSYCHOPHARMACOLOGY, V232, P17, DOI 10.1007/s00213-014-3636-9
   Seigers R, 2013, BRAIN IMAGING BEHAV, V7, P453, DOI 10.1007/s11682-013-9250-3
   Seigers R, 2008, BEHAV BRAIN RES, V186, P168, DOI 10.1016/j.bbr.2007.08.004
   Seigers R, 2011, NEUROSCI BIOBEHAV R, V35, P729, DOI 10.1016/j.neubiorev.2010.09.006
   Seigers R, 2010, BRAIN RES BULL, V81, P472, DOI 10.1016/j.brainresbull.2009.10.006
   Seigers R, 2010, BEHAV BRAIN RES, V207, P265, DOI 10.1016/j.bbr.2009.10.009
   Seigers R, 2009, BEHAV BRAIN RES, V201, P279, DOI 10.1016/j.bbr.2009.02.025
   Soffietti Riccardo, 2014, Handb Clin Neurol, V121, P1199, DOI 10.1016/B978-0-7020-4088-7.00080-8
   Stein LD, 2004, NATURE, V431, P915, DOI 10.1038/431915a
   Szafranskil K, 2015, FRONT GENET, V6, DOI 10.3389/fgene.2015.00087
   Vardy J, 2008, ANN ONCOL, V19, P623, DOI 10.1093/annonc/mdm500
   Wang XM, 2015, CYTOKINE, V72, P86, DOI 10.1016/j.cyto.2014.12.006
   Wardill HR, 2016, INT J CANCER, V139, P2635, DOI 10.1002/ijc.30252
   Weber M, 2007, CURR OPIN CELL BIOL, V19, P273, DOI 10.1016/j.ceb.2007.04.011
   Weber M, 2007, NAT GENET, V39, P457, DOI 10.1038/ng1990
   Wefel JS, 2012, CURR NEUROL NEUROSCI, V12, P267, DOI 10.1007/s11910-012-0264-9
   Wen L, 2014, GENOMICS, V104, P341, DOI 10.1016/j.ygeno.2014.08.020
   Wilson IM, 2006, CELL CYCLE, V5, P155, DOI 10.4161/cc.5.2.2367
   Xu XG, 2015, ONCOTARGET, V6, P13925, DOI 10.18632/oncotarget.4215
NR 68
TC 45
Z9 53
U1 0
U2 7
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1538-4101
EI 1551-4005
J9 CELL CYCLE
JI Cell Cycle
PY 2017
VL 16
IS 14
BP 1345
EP 1349
DI 10.1080/15384101.2017.1334022
PG 5
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA FC8HX
UT WOS:000407083500007
PM 28657421
OA Green Published, Bronze
DA 2025-01-12
ER

PT J
AU Lee, JY
   Mustafa, M
   Kim, CY
   Kim, MH
AF Lee, Ji-Yeon
   Mustafa, Muhammad
   Kim, Clara Yuri
   Kim, Myoung Hee
TI Depletion of CTCF in Breast Cancer Cells Selectively Induces Cancer Cell
   Death via p53
SO JOURNAL OF CANCER
LA English
DT Article
DE CTCF; p53; breast cancer
ID TUMOR-SUPPRESSOR GENE; C-MYC GENE; EPIGENETIC REGULATION; PROTEIN;
   APOPTOSIS; SEQUENCES; PROMOTER
AB CCCTC-binding factor (CTCF), a ubiquitous 11-zinc finger multifunctional protein, has distinct molecular functions, such as transcriptional activation, repression, and chromatin barrier activity, in a locus-specific manner. Elevated CTCF levels in breast cancer cells are known to contribute to tumorigenesis; however, the underlying mechanism remains elusive. We investigated the effect of CTCF expression on breast cancer cell survival and elucidated its mechanism. CTCF depletion in MCF-7 cells led to a decreased cell growth and proliferation, surpassing the growth of normal cells under co-culture system of MCF-7-GFP and MCF10A. Here we propose that the phenotypes observed in CTCF-depleted MCF-7 cancer cells, such as reduced cell proliferation, increased apoptosis, and cell cycle arrest, are closely linked with the activation of p53. The consensus CTCF-binding site, located approximately 800 bp upstream of the first exon of TP53, was marked by H3K27me3, but not by the active mark H3K4me3, although CTCF is expressed. Knockdown of CTCF conversely led to the recruitment of H3K4me3 instead of H3K27me3, accompanying with the higher enrichment of PolII in the proximal promoter region of TP53. With the activation of p53, increased p21 and Bax expressions were observed in CTCF knockdown MCF-7 cells. Elucidating functional roles of CTCF and regulation mechanisms may help to guide CTCF and/or its related molecules as a therapeutic target to prevent cancer cell growth.
C1 [Kim, Myoung Hee] Yonsei Univ, Dept Anat, Embryol Lab, Coll Med, Seoul 03722, South Korea.
   Yonsei Univ, Coll Med, Brain Korea PLUS Project Med Sci 21, Seoul 03722, South Korea.
   [Mustafa, Muhammad] Forman Christian Coll, Dept Biol Sci, Ferozepur Rd, Lahore 54600, Pakistan.
C3 Yonsei University; Yonsei University Health System; Yonsei University;
   Yonsei University Health System
RP Kim, MH (通讯作者)，Yonsei Univ, Dept Anat, Embryol Lab, Coll Med, Seoul 03722, South Korea.
EM mhkim1@yuhs.ac
RI Mustafa, Muhammad/HKO-9687-2023; Kim, Tae-Hee/AAN-9079-2021
OI Kim, Myoung Hee/0000-0001-5652-1452; Lee, Ji-Yeon/0000-0002-0670-3095;
   Mustafa, Muhammad/0000-0002-8714-5311
FU Basic Science Research Program through the National Research Foundation
   (NRF) - Ministry of Education, Science and Technology
   [NRF-2014R1A1A2056986, NRF-2016R1D1A1B03930822, NRF-2016R1A2B2011821]
FX This research was supported by the Basic Science Research Program
   through the National Research Foundation (NRF) funded by the Ministry of
   Education, Science and Technology (NRF-2014R1A1A2056986,
   NRF-2016R1D1A1B03930822, and NRF-2016R1A2B2011821).
CR Docquier F, 2005, CANCER RES, V65, P5112, DOI 10.1158/0008-5472.CAN-03-3498
   Filippova GN, 1996, MOL CELL BIOL, V16, P2802
   Fiorentino FP, 2012, J CELL PHYSIOL, V227, P479, DOI 10.1002/jcp.22780
   KLENOVA EM, 1993, MOL CELL BIOL, V13, P7612, DOI 10.1128/MCB.13.12.7612
   Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412
   Lee JY, 2015, INT J BIOL SCI, V11, P701, DOI 10.7150/ijbs.11431
   LOBANENKOV VV, 1990, ONCOGENE, V5, P1743
   Mariño G, 2014, NAT REV MOL CELL BIO, V15, P81, DOI 10.1038/nrm3735
   Méndez-Catalá CF, 2013, NEOPLASIA, V15, P898, DOI 10.1593/neo.121948
   Nik-Zainal S, 2016, NATURE, V534, P47, DOI 10.1038/nature17676
   Ong CT, 2014, NAT REV GENET, V15, P234, DOI 10.1038/nrg3663
   Rasko JEJ, 2001, CANCER RES, V61, P6002
   Rayess H, 2012, INT J CANCER, V130, P1715, DOI 10.1002/ijc.27316
   Recillas-Targa F, 2006, J CELL MOL MED, V10, P554, DOI 10.1111/j.1582-4934.2006.tb00420.x
   Saldaña-Meyer R, 2011, EPIGENETICS-US, V6, P1068, DOI 10.4161/epi.6.9.16683
   Soto-Reyes E, 2010, ONCOGENE, V29, P2217, DOI 10.1038/onc.2009.509
   Tiffen JC, 2013, INT J CANCER, V133, P1603, DOI 10.1002/ijc.28184
NR 17
TC 12
Z9 13
U1 1
U2 5
PU IVYSPRING INT PUBL
PI LAKE HAVEN
PA PO BOX 4546, LAKE HAVEN, NSW 2263, AUSTRALIA
SN 1837-9664
J9 J CANCER
JI J. Cancer
PY 2017
VL 8
IS 11
BP 2124
EP 2131
DI 10.7150/jca.18818
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA FC6GN
UT WOS:000406938500023
PM 28819414
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU Jiménez-Gardnno, AM
   Mendoza-Rodríguez, MG
   Urrutia-Cabrera, D
   Domínguez-Robles, MC
   Pérez-Yépez, EA
   Ayala-Sumuano, JT
   Meza, I
AF Jimenez-Gardnno, Aura M.
   Mendoza-Rodriguez, Monica G.
   Urrutia-Cabrera, Daniel
   Dominguez-Robles, Maria C.
   Perez-Yepez, Eloy A.
   Tonatiuh Ayala-Sumuano, Jorge
   Meza, Isaura
TI IL-1β induced methylation of the estrogen receptor ERα gene correlates
   with EMT and chemoresistance in breast cancer cells
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE Inflammation; Epigenetic modification; Hormone receptor; Tamoxifen
   resistance
ID EPITHELIAL-MESENCHYMAL TRANSITION; EXPRESSION; RESISTANCE; PHENOTYPE;
   PROGESTERONE; INFLAMMATION; ACTIVATION; MECHANISMS; TAMOXIFEN; PROSTATE
AB Inflammation has been recently acknowledged as a key participant in the physiopathology of oncogenesis and tumor progression. The inflammatory cytokine IL-1 beta has been reported to induce the expression of markers associated with malignancy in breast cancerous cells through Epithelial-Mesenchymal Transition (EMT). Aggressive breast cancer tumors classified as Triple Negative do not respond to hormonal treatment because they lack three crucial receptors, one of which is the estrogen receptor alpha (ER alpha). Expression of ER alpha is then considered a good prognostic marker for tamoxifen treatment of this type of cancer, as the binding of this drug to the receptor blocks the transcriptional activity of the latter. Although it has been suggested that inflammatory cytokines in the tumor micro environment could regulate ER alpha expression, the mechanism(s) involved in this process have not yet been established. We show here that, in a cell model of breast cancer cells (6D cells), in which the inflammatory cytokine IL-1 beta induces EMT by activation of the IL-1 beta/1L-1RI/beta-catenin pathway, the up regulation of TWIST1 leads to methylation of the ESR1 gene promoter. This epigenetic modification produced significant decrease of the ER alpha receptor levels and increased resistance to tamoxifen. The direct participation of IL-1 beta in these processes was validated by blockage of the cytokine-induced signaling pathway by wortmannin inactivation of the effectors PI3K/AKT. These results support our previous reports that have suggested direct participation of the inflammatory cytokine IL-1 beta in the transition to malignancy of breast cancer cells. (C) Elsevier Inc. All rights reserved.
C1 [Jimenez-Gardnno, Aura M.; Mendoza-Rodriguez, Monica G.; Urrutia-Cabrera, Daniel; Dominguez-Robles, Maria C.; Meza, Isaura] Inst Politecn Nacl, Ctr Invest Estudios Avanzados, Dept Biomed Mol, Avenida Inst Politecn Nacl 2508, Mexico City 07360, DF, Mexico.
   [Perez-Yepez, Eloy A.] Univ Nacl Autonoma Mexico, Fac Estudios Super, Unidad Biomed, Tlalnepantla 54090, Mexico.
   [Mendoza-Rodriguez, Monica G.; Tonatiuh Ayala-Sumuano, Jorge] Univ Politecn Huatusco, Huatusco 94100, Veracruz, Mexico.
C3 CINVESTAV - Centro de Investigacion y de Estudios Avanzados del
   Instituto Politecnico Nacional; Instituto Politecnico Nacional - Mexico;
   Universidad Nacional Autonoma de Mexico
RP Meza, I (通讯作者)，CINVESTAV IPN, Av Inst Politecnico Nacl 2508, Mexico City 07360, DF, Mexico.
EM imeza@cinvestav.mx
RI Mendoza, Mónica/GWU-9109-2022
OI Mendoza-Rodriguez, Monica G/0000-0003-3056-9997
FU Consejo Nacional de Ciencia y Tecnologia (Conacyt, Mexico) [166462]
FX This work was partially supported by grant 166462 to IM and postdoctoral
   and predoctoral scholarships to AMJG and DUC, respectively, from the
   Consejo Nacional de Ciencia y Tecnologia (Conacyt, Mexico).
CR Perez-Yepez EA, 2014, CANCER LETT, V354, P164, DOI 10.1016/j.canlet.2014.08.015
   Bartsch H, 2006, LANGENBECK ARCH SURG, V391, P499, DOI 10.1007/s00423-006-0073-1
   Bauer KR, 2007, CANCER, V109, P1721, DOI 10.1002/cncr.22618
   Bouris P, 2015, MATRIX BIOL, V43, P42, DOI 10.1016/j.matbio.2015.02.008
   Chatley SNH, 2014, CLIN CANCER RES, V20, DOI 10.1158/1078-0432.14AACRIASLC-A12
   Chavey C, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1648
   Creighton CJ, 2006, CANCER RES, V66, P3903, DOI 10.1158/0008-5472.CAN-05-4363
   Demaria S, 2010, J IMMUNOTHER, V33, P335, DOI 10.1097/CJI.0b013e3181d32e74
   Dinarello Charles Anthony, 2014, Mol Med, V20 Suppl 1, pS43, DOI 10.2119/molmed.2014.00232
   Franco-Barraza J, 2010, ARCH MED RES, V41, P170, DOI 10.1016/j.arcmed.2010.04.010
   Fu JJ, 2012, INT J BIOL SCI, V8, P522, DOI 10.7150/ijbs.4164
   García-Becerra R, 2013, INT J MOL SCI, V14, P108, DOI 10.3390/ijms14010108
   Guo JP, 2010, J BIOL CHEM, V285, P3676, DOI 10.1074/jbc.M109.078212
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Jang MH, 2015, HUM PATHOL, V46, P1267, DOI 10.1016/j.humpath.2015.05.010
   Kim CJ, 2011, INT J ONCOL, V38, P1759, DOI 10.3892/ijo.2011.997
   Kocanova S, 2010, BMC CELL BIOL, V11, DOI 10.1186/1471-2121-11-98
   Lapidus RG, 1998, CANCER RES, V58, P2515
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Mendoza-Rodríguez M, 2017, CANCER LETT, V390, P39, DOI 10.1016/j.canlet.2017.01.005
   Osborne CK, 1998, NEW ENGL J MED, V339, P1609, DOI 10.1056/NEJM199811263392207
   OTTAVIANO YL, 1994, CANCER RES, V54, P2552
   Parl FF, 2003, PHARMACOGENOMICS J, V3, P251, DOI 10.1038/sj.tpj.6500201
   Sasaki M, 2002, J NATL CANCER I, V94, P384
   Shao WL, 2004, BREAST CANCER RES, V6, P39, DOI 10.1186/bcr742
   Sharma V, 2011, J MOL MED, V89, P123, DOI 10.1007/s00109-010-0683-5
   Tang Bo, 2005, Zhonghua Bing Li Xue Za Zhi, V34, P283
   Vesuna F, 2012, ONCOGENE, V31, P3223, DOI 10.1038/onc.2011.483
   Voronov E, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00177
   Yang XW, 2001, CANCER RES, V61, P7025
NR 30
TC 69
Z9 77
U1 0
U2 8
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
EI 1090-2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD AUG 26
PY 2017
VL 490
IS 3
BP 780
EP 785
DI 10.1016/j.bbrc.2017.06.117
PG 6
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA FC4OQ
UT WOS:000406820600030
PM 28645612
DA 2025-01-12
ER

PT J
AU Kabraji, S
   Solé, X
   Huang, Y
   Bango, C
   Bowden, M
   Bardia, A
   Sgroi, D
   Loda, M
   Ramaswamy, S
AF Kabraji, Sheheryar
   Sole, Xavier
   Huang, Ying
   Bango, Clyde
   Bowden, Michaela
   Bardia, Aditya
   Sgroi, Dennis
   Loda, Massimo
   Ramaswamy, Sridhar
TI AKT1<SUP>low</SUP> quiescent cancer cells persist after neoadjuvant
   chemotherapy in triple negative breast cancer
SO BREAST CANCER RESEARCH
LA English
DT Article
DE AKT1(low) quiescent cancer cells; Chemotherapy resistance; Quantitative
   immunofluorescence microscopy
ID RESIDUAL DISEASE; EXPRESSION; APPROVAL; WOMEN
AB Background: Absence of pathologic complete response (pCR) to neoadjuvant chemotherapy (NACT) correlates with poor long-term survival in patients with triple negative breast cancer (TNBC). These incomplete treatment responses are likely determined by mechanisms that enable cancer cells to resist being killed. However, the detailed characterization of a drug-resistant cancer cell state in residual TNBC tissue after NACT has remained elusive. AKT1(low) quiescent cancer cells (QCCs) are a quiescent, epigenetically plastic, and chemotherapy-resistant subpopulation initially identified in experimental cancer models. Here, we asked whether QCCs exist in primary tumors from patients with TNBC and persist after treatment with NACT.
   Methods: We obtained pre-treatment biopsy, post-treatment mastectomy, and metastatic specimens from a retrospective cohort of TNBC patients treated with NACT at Massachusetts General Hospital (n = 25). Using quantitative automated immunofluorescence microscopy, QCCs were identified as AKT(low)/H3K9me2(low)/HES1(high) cancer cells using prespecified immunofluorescence intensity thresholds. QCCs were represented in 2D and 3D digital tumor maps and QCC percentage (QCC-P) and QCC cluster index (QCC-CI) were determined for each sample.
   Results: We showed that QCCs exist as non-random and heterogeneously distributed clusters within primary breast tumors. In addition, these QCC clusters persist after treatment with multi-agent, multi-cycle, neoadjuvant chemotherapy in both residual primary tumors and nodal and distant metastases in patients with triple negative breast cancer.
   Conclusions: These first-in-human data potentially qualify AKT1(low) quiescent cancer cells as a non-genetic cell state that persists after neoadjuvant chemotherapy in triple negative breast cancer patients and warrants further study.
C1 [Kabraji, Sheheryar; Sole, Xavier; Bardia, Aditya; Sgroi, Dennis; Ramaswamy, Sridhar] Massachusetts Gen Hosp, Ctr Canc, Richard B Simches Res Bldg,185 Cambridge St, Boston, MA 02114 USA.
   [Kabraji, Sheheryar; Sole, Xavier; Bardia, Aditya; Sgroi, Dennis; Ramaswamy, Sridhar] Harvard Med Sch, Boston, MA 02115 USA.
   [Huang, Ying; Bango, Clyde; Bowden, Michaela; Loda, Massimo] Dana Farber Canc Inst, Boston, MA 02115 USA.
   [Ramaswamy, Sridhar] Broad Inst Harvard, Cambridge, MA 02142 USA.
   [Ramaswamy, Sridhar] MIT, 77 Massachusetts Ave, Cambridge, MA 02139 USA.
   [Ramaswamy, Sridhar] Harvard Stem Cell Inst, Cambridge, MA 02138 USA.
   [Ramaswamy, Sridhar] Harvard Ludwig Ctr Canc Res, Boston, MA 02215 USA.
   [Sole, Xavier] IDIBELL, Catalan Inst Oncol, Canc Prevent & Control Program, Barcelona, Spain.
C3 Harvard University; Massachusetts General Hospital; Harvard University;
   Harvard Medical School; Harvard University; Dana-Farber Cancer
   Institute; Harvard University; Massachusetts Institute of Technology
   (MIT); Broad Institute; Massachusetts Institute of Technology (MIT);
   Harvard University; Institut d'Investigacio Biomedica de Bellvitge
   (IDIBELL); Institut Catala d'Oncologia; University of Barcelona
RP Ramaswamy, S (通讯作者)，Massachusetts Gen Hosp, Ctr Canc, Richard B Simches Res Bldg,185 Cambridge St, Boston, MA 02114 USA.; Ramaswamy, S (通讯作者)，Harvard Med Sch, Boston, MA 02115 USA.; Ramaswamy, S (通讯作者)，Broad Inst Harvard, Cambridge, MA 02142 USA.; Ramaswamy, S (通讯作者)，MIT, 77 Massachusetts Ave, Cambridge, MA 02139 USA.; Ramaswamy, S (通讯作者)，Harvard Stem Cell Inst, Cambridge, MA 02138 USA.; Ramaswamy, S (通讯作者)，Harvard Ludwig Ctr Canc Res, Boston, MA 02215 USA.
EM sridhar@mgh.harvard.edu
RI Bardia, Aditya/ACM-1544-2022; Subramanian, Ramaswamy/Q-8671-2019;
   Kabraji, Sheheryar/AAE-8636-2019; Solé, Xavier/AAF-3015-2019; Sgroi,
   Dennis/AAV-2487-2021
OI Sole, Xavier/0000-0002-2197-3325; Bowden, Michaela/0000-0003-4375-7823;
   Kabraji, Sheheryar/0000-0002-5315-7103
FU National Cancer Institute [R01 CA185086, C06 CA05926]; Susan G. Komen
   for the Cure [IIR 12223648]; Harvard-Ludwig Center for Cancer Research;
   Stand Up to Cancer Innovative Research Grant [SU2C-AACR-IRG0911];
   Santander/MGH; Bolsa de Ampliacion de Estudios, Instituto de Salud
   Carlos III, Ministerio de Economia y Competitividad-Spanish postdoctoral
   fellowship award [BA12/00021]; Jerry Younger Grant for Clinical and
   Translational Research; Breast Cancer Research Foundation; Avon
   Foundation
FX This work was supported by awards from the National Cancer Institute
   (R01 CA185086, C06 CA05926), Susan G. Komen for the Cure (IIR 12223648),
   and Harvard-Ludwig Center for Cancer Research (to S. Ramaswamy). S.
   Ramaswamy was also supported by a Stand Up to Cancer Innovative Research
   Grant (Grant number SU2C-AACR-IRG0911). Stand Up To Cancer is a program
   of the Entertainment Industry Foundation administered by the American
   Association for Cancer Research. S. Kabraji was supported by
   Santander/MGH Fellowship. X. Sole was supported by a "Bolsa de
   Ampliacion de Estudios, Instituto de Salud Carlos III, Ministerio de
   Economia y Competitividad (BA12/00021)"-Spanish postdoctoral fellowship
   award. A. Bardia was supported by Jerry Younger Grant for Clinical and
   Translational Research. D. Sgroi is supported in part by a grant from
   the Breast Cancer Research Foundation and the Avon Foundation.
CR [Anonymous], CANC RES
   [Anonymous], DAT SHEET ANT H3 DI
   [Anonymous], DAT SHEET AKT PAN C6
   Balko JM, 2014, CANCER DISCOV, V4, P232, DOI 10.1158/2159-8290.CD-13-0286
   Bardia A, 2013, CLIN CANCER RES, V19, P6360, DOI 10.1158/1078-0432.CCR-13-0916
   Bossuyt V, 2015, ANN ONCOL, V26, P1280, DOI 10.1093/annonc/mdv161
   Camp RL, 2002, NAT MED, V8, P1323, DOI 10.1038/nm791
   Carvajal-Hausdorf DE, 2015, LAB INVEST, V95, P385, DOI 10.1038/labinvest.2014.157
   Cortazar P, 2014, LANCET, V384, P164, DOI 10.1016/S0140-6736(13)62422-8
   Denkert C, 2015, BREAST, V24, pS67, DOI 10.1016/j.breast.2015.07.017
   Dey-Guha I, 2015, MOL CANCER RES, V13, P223, DOI 10.1158/1541-7786.MCR-14-0474
   Dey-Guha I, 2011, P NATL ACAD SCI USA, V108, P12845, DOI 10.1073/pnas.1109632108
   Garcia-Murillas I, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aab0021
   Guo LQ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080179
   Li SD, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098021
   Lin NU, 2012, CANCER-AM CANCER SOC, V118, P5463, DOI 10.1002/cncr.27581
   Malanchi I, 2012, NATURE, V481, P85, DOI 10.1038/nature10694
   McLaughlin J, 2016, JAMA ONCOL, V2, P46, DOI 10.1001/jamaoncol.2015.3638
   Neumeister V, 2010, AM J PATHOL, V176, P2131, DOI 10.2353/ajpath.2010.090712
   Pal T, 2015, CANCER-AM CANCER SOC, V121, DOI 10.1002/cncr.29645
   Prowell TM, 2012, NEW ENGL J MED, V366, P2438, DOI 10.1056/NEJMp1205737
   Stack EC, 2014, METHODS, V70, P46, DOI 10.1016/j.ymeth.2014.08.016
   Yao MY, 2014, ONCOTARGETS THER, V7, P1743, DOI 10.2147/OTT.S69657
NR 23
TC 20
Z9 21
U1 0
U2 14
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1465-5411
EI 1465-542X
J9 BREAST CANCER RES
JI Breast Cancer Res.
PD AUG 1
PY 2017
VL 19
AR 88
DI 10.1186/s13058-017-0877-7
PG 12
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA FC6OF
UT WOS:000406959100001
PM 28764807
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Karsli-Ceppioglu, S
   Dagdemir, A
   Judes, G
   Lebert, A
   Penault-Llorca, F
   Bignon, YJ
   Bernard-Gallon, D
AF Karsli-Ceppioglu, Seher
   Dagdemir, Aslihan
   Judes, Gaelle
   Lebert, Andre
   Penault-Llorca, Frederique
   Bignon, Yves-Jean
   Bernard-Gallon, Dominique
TI The Epigenetic Landscape of Promoter Genome-wide Analysis in Breast
   Cancer
SO SCIENTIFIC REPORTS
LA English
DT Article
ID INTERNATIONAL EXPERT CONSENSUS; HISTONE MODIFICATIONS;
   PROGNOSTIC-FACTORS; PRIMARY THERAPY; SUBTYPES; KI-67; TRIMETHYLATION;
   ACETYLATION; ASSOCIATION; HIGHLIGHTS
AB Breast cancer is a heterogeneous disease due to its clinico-pathological features and response to therapy. The classification of breast tumors based on their hormone receptor status and pathologic features. Post-translational histone modifications come into prominence for regulation of gene expression in cancer pathogenesis. Here, we analyzed dysregulation of H3K9ac and H3K27me3-enriched subtype-specific genes using ChIP-on-chip assay in breast cancer tumors and matched normal tissue samples. Breast cancer tumors were classified according to St Gallen Consensus 2013. Our results indicated that the promoter regions of genes modified by H3K9ac epi-mark are commonly associated with tumors with HER2-positive and TNBC subtype. H3K27me3-enriched genes were comprised of Luminal A and B1 subtypes. We constructed a network structure to elicit epigenetically regulated genes related with breast cancer progression. The central genes of the network (RUNX1, PAX3, GATA4 and DLX5) were subjected for epigenetically dysregulation in association with different breast cancer subtypes. Our study submits epigenetic mechanisms are crucial to elicit subtype-specific regulation in breast cancer and ChIP-on-chip assay provides a better understanding for breast tumorigenesis and new approaches for prevention and treatment.
C1 [Karsli-Ceppioglu, Seher; Dagdemir, Aslihan; Judes, Gaelle; Bignon, Yves-Jean; Bernard-Gallon, Dominique] CBRV, Ctr Jean Perrin, Dept Oncogenet, 28 Pl Henri Dunant, F-63001 Clermont Ferrand, France.
   [Karsli-Ceppioglu, Seher; Dagdemir, Aslihan; Judes, Gaelle; Penault-Llorca, Frederique; Bignon, Yves-Jean; Bernard-Gallon, Dominique] IMOST, INSERM U1240, 58 Rue Montalembert BP184, F-63005 Clermont Ferrand, France.
   [Karsli-Ceppioglu, Seher] Marmara Univ, Dept Toxicol, Fac Pharm, Istanbul, Turkey.
   [Lebert, Andre] Univ Blaise Pascal, Inst Pascal UMR CNRS UBP 6602, F-63178 Aubiere, France.
   [Penault-Llorca, Frederique] Ctr Jean Perrin, Dept Biopathol, 58 Rue Montalembert, F-63011 Clermont Ferrand, France.
C3 UNICANCER; Centre Jean Perrin; Institut National de la Sante et de la
   Recherche Medicale (Inserm); Marmara University; Centre National de la
   Recherche Scientifique (CNRS); Universite Clermont Auvergne (UCA);
   UNICANCER; Centre Jean Perrin
RP Bernard-Gallon, D (通讯作者)，CBRV, Ctr Jean Perrin, Dept Oncogenet, 28 Pl Henri Dunant, F-63001 Clermont Ferrand, France.; Bernard-Gallon, D (通讯作者)，IMOST, INSERM U1240, 58 Rue Montalembert BP184, F-63005 Clermont Ferrand, France.
EM dominique.gallon-bernard@clermont.unicancer.fr
RI Bernard-Gallon, Dominique/L-6079-2015; Karsli-Ceppioglu,
   Seher/JED-4667-2023
OI Bernard-Gallon, Dominique/0000-0003-2931-5340; dagdemir,
   aslihan/0000-0002-4365-9898
FU Scientific and Technology Research Council of Turkey [TUBITAK-2219];
   Protema Saglik Hizm
FX S.K.-C. was supported by The Scientific and Technology Research Council
   of Turkey (TUBITAK-2219) project grants and A.-D. was funded by Protema
   Saglik Hizm. A.S. The authors also thank 'la ligue contre le
   cancer-Comite du Puy-de-Dome'.
CR Barutcu AR, 2016, BBA-GENE REGUL MECH, V1859, P1389, DOI 10.1016/j.bbagrm.2016.08.003
   Bauer K, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-228
   Cheang MCU, 2009, JNCI-J NATL CANCER I, V101, P736, DOI 10.1093/jnci/djp082
   Chen XH, 2016, BREAST CANCER RES TR, V157, P267, DOI 10.1007/s10549-016-3826-8
   Chin K, 2006, CANCER CELL, V10, P529, DOI 10.1016/j.ccr.2006.10.009
   Dagdemir A, 2016, CANCER GENOM PROTEOM, V13, P291
   Dagdemir A, 2013, EPIGENOMICS-UK, V5, P51, DOI [10.2217/epi.12.74, 10.2217/EPI.12.74]
   de Azambuja E, 2007, BRIT J CANCER, V96, P1504, DOI 10.1038/sj.bjc.6603756
   Dworkin AM, 2009, SEMIN CANCER BIOL, V19, P165, DOI 10.1016/j.semcancer.2009.02.007
   Elsheikh SE, 2009, CANCER RES, V69, P3802, DOI 10.1158/0008-5472.CAN-08-3907
   Ferrari N, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100759
   Goldhirsch A, 2013, ANN ONCOL, V24, P2206, DOI 10.1093/annonc/mdt303
   Goldhirsch A, 2011, ANN ONCOL, V22, P1736, DOI 10.1093/annonc/mdr304
   Healey MA, 2014, BREAST CANCER RES TR, V147, P639, DOI 10.1007/s10549-014-3089-1
   Hoi CSL, 2010, MOL CELL BIOL, V30, P2518, DOI 10.1128/MCB.01308-09
   Holm K, 2012, MOL ONCOL, V6, P494, DOI 10.1016/j.molonc.2012.06.002
   Hong Chang Pyo, 2012, Genomics & Informatics, V10, P145
   Hua GQ, 2009, MOL CANCER RES, V7, P402, DOI 10.1158/1541-7786.MCR-08-0175
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Inic Z, 2014, CLIN MED INSIGHTS-ON, V8, P107, DOI 10.4137/CMO.S18006
   Judes G, 2016, EPIGENOMICS-UK, V8, P909, DOI 10.2217/epi-2016-0015
   Li YS, 2014, HUM MOL GENET, V23, P5378, DOI 10.1093/hmg/ddu256
   Lwoff L, 2008, NAT BIOTECHNOL, V26, P29, DOI 10.1038/nbt0108-29b
   Martin C, 2005, NAT REV MOL CELL BIO, V6, P838, DOI 10.1038/nrm1761
   Merlo GR, 2000, INT J DEV BIOL, V44, P619
   Morini M, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-649
   Natrajan R, 2012, J PATHOL, V227, P29, DOI 10.1002/path.4003
   Prat A, 2011, MOL ONCOL, V5, P5, DOI 10.1016/j.molonc.2010.11.003
   Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303
   SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106
   Speck NA, 1995, CRIT REV EUKAR GENE, V5, P337, DOI 10.1615/CritRevEukarGeneExpr.v5.i3-4.60
   Trihia H, 2003, CANCER, V97, P1321, DOI 10.1002/cncr.11188
   Yeh HY, 2009, BMC MED GENOMICS, V2, DOI 10.1186/1755-8794-2-70
   Zhao QY, 2016, CLIN EPIGENETICS, V8, DOI 10.1186/s13148-016-0201-x
NR 34
TC 19
Z9 26
U1 1
U2 9
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD JUL 26
PY 2017
VL 7
AR 6597
DI 10.1038/s41598-017-06790-z
PG 8
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA FB8CL
UT WOS:000406366400005
PM 28747748
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Wang, YF
   Zhang, J
   Su, Y
   Shen, YY
   Jiang, DX
   Hou, YY
   Geng, MY
   Ding, J
   Chen, Y
AF Wang, Ya-fang
   Zhang, Jie
   Su, Yi
   Shen, Yan-yan
   Jiang, Dong-xian
   Hou, Ying-yong
   Geng, Mei-yu
   Ding, Jian
   Chen, Yi
TI G9a regulates breast cancer growth by modulating iron homeostasis
   through the repression of ferroxidase hephaestin
SO NATURE COMMUNICATIONS
LA English
DT Article
ID H3K9 METHYLTRANSFERASE G9A; NEGATIVE REGULATION; EXPRESSION; CELLS;
   PROLIFERATION; CERULOPLASMIN; METABOLISM; CHELATORS; TRANSPORT; PROTEINS
AB G9a, a H3K9 methyltransferase, shows elevated expression in many types of human cancers, particularly breast cancer. However, the tumorigenic mechanism of G9a is still far from clear. Here we report that G9a exerts its oncogenic function in breast cancer by repressing hephaestin and destruction cellular iron homeostasis. In the case of pharmacological inhibition or short hairpin RNA interference-mediated suppression of G9a, the expression and activity of hephaestin increases, leading to the observed decrease of intracellular labile iron content and the disturbance of breast cancer cell growth in vitro and in vivo. We also provide evidence that G9a interacts with HDAC1 and YY1 to form a multi-molecular complex that contributes to hephaestin silencing. Furthermore, high G9a expression and low hephaestin expression correlate with poor survival of breast cancer are investigated. All these suggest a G9a-dependent epigenetic program in the control of iron homeostasis and tumor growth in breast cancer.
C1 [Wang, Ya-fang; Su, Yi; Shen, Yan-yan; Geng, Mei-yu; Ding, Jian; Chen, Yi] Chinese Acad Sci, Shanghai Inst Mat Med, State Key Lab Drug Res, Div Antitumor Pharmacol, Shanghai 201203, Peoples R China.
   [Wang, Ya-fang] Univ Chinese Acad Sci, 19A Yuquan Rd, Beijing 100049, Peoples R China.
   [Zhang, Jie] Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, Key Lab Syst Biol,CAS Ctr Excellence Mol Cell Sci, Shanghai 200031, Peoples R China.
   [Jiang, Dong-xian; Hou, Ying-yong] Fudan Univ, Zhongshan Hosp, Dept Pathol, Shanghai 200032, Peoples R China.
C3 Chinese Academy of Sciences; Shanghai Institute of Materia Medica, CAS;
   Chinese Academy of Sciences; University of Chinese Academy of Sciences,
   CAS; Chinese Academy of Sciences; Center for Excellence in Molecular
   Cell Science, CAS; Fudan University
RP Geng, MY; Ding, J; Chen, Y (通讯作者)，Chinese Acad Sci, Shanghai Inst Mat Med, State Key Lab Drug Res, Div Antitumor Pharmacol, Shanghai 201203, Peoples R China.
EM mygeng@simm.ac.cn; jding@simm.ac.cn; ychen@simm.ac.cn
RI Li, Mengqi/HPF-6473-2023; wang, yafang/KHD-8689-2024
FU National Natural Science Foundation of China [81273545, 81521005]
FX We thank Professor Jian Jin (University of North Carolina at Chapel
   Hill) for the gifts of the plasmids pLKO.1-shControl and pLKO.1-shG9a.
   We are grateful to Martin J. Walsh for the plasmids pEGFP-hG9a and
   pEGFP-Delta SET-hG9a. This work was supported by grants from the
   National Natural Science Foundation of China (81273545 and 81521005).
CR Anderson CP, 2012, BBA-MOL CELL RES, V1823, P1468, DOI 10.1016/j.bbamcr.2012.05.010
   Aoyama T, 2010, J BIOL CHEM, V285, P29842, DOI 10.1074/jbc.M110.116319
   Atchison Michael, 2011, Critical Reviews in Oncogenesis, V16, P143
   Brooks D, 1995, CLIN CANCER RES, V1, P1259
   Buss JL, 2003, CURR MED CHEM, V10, P1021, DOI 10.2174/0929867033457638
   Chen HJ, 2006, J NUTR, V136, P1236, DOI 10.1093/jn/136.5.1236
   Cho HS, 2011, NEOPLASIA, V13, P676, DOI 10.1593/neo.11512
   Corcé V, 2016, BIOORG MED CHEM LETT, V26, P251, DOI 10.1016/j.bmcl.2015.11.094
   Diallo A, 2016, ONCOTARGET, V7, P78994, DOI 10.18632/oncotarget.12592
   Dong CF, 2012, J CLIN INVEST, V122, P1469, DOI 10.1172/JCI57349
   Fonseca-Nunes A, 2014, CANCER EPIDEM BIOMAR, V23, P12, DOI 10.1158/1055-9965.EPI-13-0733
   Fuqua BK, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098792
   Griffiths TAM, 2005, BIOCHEMISTRY-US, V44, P14725, DOI 10.1021/bi051559k
   Hinoi T, 2005, GASTROENTEROLOGY, V128, P946, DOI 10.1053/j.gastro.2005.01.003
   Huang J, 2010, J BIOL CHEM, V285, P9636, DOI 10.1074/jbc.M109.062588
   Huang X, 2008, LANCET ONCOL, V9, P803, DOI 10.1016/S1470-2045(08)70200-6
   Hung N, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0119647
   Jiang RW, 2015, J NUTR, V145, P1003, DOI 10.3945/jn.114.207316
   Jones NR, 2015, CANCERS, V7, P2386, DOI 10.3390/cancers7040898
   Jung M, 2015, IMMUNOBIOLOGY, V220, P295, DOI 10.1016/j.imbio.2014.09.011
   Kim KB, 2015, NUCLEIC ACIDS RES, V43, P3509, DOI 10.1093/nar/gkv183
   Kovac S, 2011, BBA-MOL CELL RES, V1813, P889, DOI 10.1016/j.bbamcr.2011.02.007
   Lamy PJ, 2014, CLIN CHIM ACTA, V434, P34, DOI 10.1016/j.cca.2014.04.011
   Liu Q, 2016, ACTA PHARMACOL SIN, V37, P1273, DOI 10.1038/aps.2016.64
   Majidzadeh-A Keivan, 2011, BMC Res Notes, V4, P215, DOI 10.1186/1756-0500-4-215
   Miller LD, 2011, CANCER RES, V71, P6728, DOI 10.1158/0008-5472.CAN-11-1870
   Muckenthaler MU, 2008, ANNU REV NUTR, V28, P197, DOI 10.1146/annurev.nutr.28.061807.155521
   Petrak J, 2005, INT J BIOCHEM CELL B, V37, P1173, DOI 10.1016/j.biocel.2004.12.007
   Pinnix ZK, 2010, SCI TRANSL MED, V2, DOI [10.1126/scitranslmed.3001127, 10.1126/scisignal.3001127]
   Raza M, 2014, CURR PHARM BIOTECHNO, V15, P1125, DOI 10.2174/138920101512141202111915
   Richardson DR, 2009, BBA-GEN SUBJECTS, V1790, P702, DOI 10.1016/j.bbagen.2008.04.003
   Shpyleva SI, 2011, BREAST CANCER RES TR, V126, P63, DOI 10.1007/s10549-010-0849-4
   Simovich MJ, 2002, AM J HEMATOL, V69, P164, DOI 10.1002/ajh.10052
   Sitwala KV, 2002, ONCOGENE, V21, P8862, DOI 10.1038/sj.onc.1206041
   Son HJ, 2012, MOL CELL BIOL, V32, P3681, DOI 10.1128/MCB.00673-12
   Song N, 2010, J CELL BIOCHEM, V110, P1063, DOI 10.1002/jcb.22617
   Song N, 2010, FREE RADICAL BIO MED, V48, P332, DOI 10.1016/j.freeradbiomed.2009.11.004
   Tachibana M, 2002, GENE DEV, V16, P1779, DOI 10.1101/gad.989402
   Tenopoulou M, 2007, BIOCHEM J, V403, P261, DOI 10.1042/BJ20061840
   Torti SV, 2013, NAT REV CANCER, V13, P342, DOI 10.1038/nrc3495
   Wang B, 2016, CANCER LETT, V381, P331, DOI 10.1016/j.canlet.2016.08.006
   Wierzbicka D, 2014, POSTEP HIG MED DOSW, V68, P912, DOI 10.5604/17322693.1111136
   Wu H, 2011, CELL RES, V21, P365, DOI 10.1038/cr.2010.157
   Xue X, 2013, NUTRIENTS, V5, P2333, DOI 10.3390/nu5072333
   Zhang J, 2015, ONCOTARGET, V6, P2917, DOI 10.18632/oncotarget.2784
NR 45
TC 72
Z9 75
U1 1
U2 38
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-1723
J9 NAT COMMUN
JI Nat. Commun.
PD AUG 17
PY 2017
VL 8
AR 274
DI 10.1038/s41467-017-00350-9
PG 14
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA FD9TL
UT WOS:000407864900002
PM 28819251
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU López-Ginés, C
   Navarro, L
   Muñoz-Hidalgo, L
   Buso, E
   Morales, JM
   Gil-Benso, R
   Gregori-Romero, M
   Megías, J
   Roldán, P
   Segura-Sabater, R
   Almerich-Silla, JM
   Monleón, D
   Cerdá-Nicolás, M
AF Lopez-Gines, Concha
   Navarro, Lara
   Munoz-Hidalgo, Lisandra
   Buso, Enrique
   Manuel Morales, Jose
   Gil-Benso, Rosario
   Gregori-Romero, Mariela
   Megias, Javier
   Roldan, Pedro
   Segura-Sabater, Remedios
   Manuel Almerich-Silla, Jose
   Monleon, Daniel
   Cerda-Nicolas, Miguel
TI Association between epidermal growth factor receptor amplification and
   ADP-ribosylation factor 1 methylation in human glioblastoma
SO CELLULAR ONCOLOGY
LA English
DT Article
DE Glioblastoma; EGFR amplification; ARF1; Metabolomics; DNA methylation
ID BREAST-CANCER CELLS; ARF PROTEINS; COPY NUMBER; IN-VIVO; INVASION;
   PROLIFERATION; MIGRATION; PATHWAY; ACTIVATION; MULTIFORME
AB Purpose Glioblastoma (GB) is the most frequent and most malignant primary brain tumor in adults. Previously, it has been found that both genetic and epigenetic factors may play critical roles in its etiology and prognosis. In addition, it has been found that the epidermal growth factor receptor gene (EGFR) is frequently over-expressed and amplified in primary GBs. Here, we assessed the promoter methylation status of 10 genes relevant to GB and explored associations between these findings and the EGFR gene amplification status.
   Methods Tumor samples were obtained from 36 patients with primary GBs. In addition, 6 control specimens were included from patients who were operated for diseases other than brain tumors. The amplification status of the EGFR gene, and its deletion mutant EGFRvIII, were evaluated using FISH and MLPA, respectively. The IDH1/2 gene mutation status was verified using Sanger sequencing. A commercial DNA methylation kit was used to assess the promoter methylation status of 10 pre-selected genes. Metabolic profiles were measured using HR-MAS NMR spectroscopy. The EGFR and ARF1 mRNA expression levels were quantified using qRT-PCR.
   Results Of the 10 genes analyzed, we found that only ARF1 promoter hypermethylation was significantly associated with EGFR gene amplification. ARF1 is a GTPase that is involved in vesicle trafficking and the Golgi apparatus. Subsequent tumor metabolism measurements revealed a positive association between EGFR amplification and different membrane precursors and methyl-donor metabolites. Finally, we found that EGFR gene amplifications were associated with distinct tumor infiltration patterns, thus representing a putative novel functional association between EGFR gene amplification and ARF1 gene promoter methylation in GB.
   Conclusion The results reported here provide a basis for a new hypotheses connecting EGFR gene amplification in GB cells with ARF1 gene promoter methylation, vesicle trafficking, membrane turnover and tumor metabolism. The mechanism(s) underlying these connections and their functional consequences remain to be established.
C1 [Lopez-Gines, Concha; Gil-Benso, Rosario; Gregori-Romero, Mariela; Megias, Javier; Monleon, Daniel; Cerda-Nicolas, Miguel] Univ Valencia, Fac Med, Dept Patol, Avda Blasco Ibanez 15, Valencia 46010, Spain.
   [Navarro, Lara; Munoz-Hidalgo, Lisandra; Segura-Sabater, Remedios; Monleon, Daniel] Hosp Clin Univ Valencia, Fdn Invest, INCLIVA, Valencia, Spain.
   [Buso, Enrique; Manuel Morales, Jose] Univ Valencia, Unidad Cent Invest Med, Valencia, Spain.
   [Roldan, Pedro] Hosp Clin Univ Valencia, Serv Neurocirugia, Valencia, Spain.
   [Manuel Almerich-Silla, Jose] Univ Valencia, Dept Estomatol, Valencia, Spain.
C3 University of Valencia; University of Valencia; Hospital Clinic
   Universitari de Valencia; University of Valencia
RP López-Ginés, C; Cerdá-Nicolás, M (通讯作者)，Univ Valencia, Fac Med, Dept Patol, Avda Blasco Ibanez 15, Valencia 46010, Spain.
EM concha.lopez@uv.es; jose.m.cerda@uv.es
RI Megías, Javier/ABF-3112-2021; Morales Tatay, José manuel/L-7972-2014;
   Navarro, Lara/AAJ-5884-2020; Almerich, Jose/AFQ-5774-2022; Monleon,
   Daniel/A-5078-2010; munoz, lisandra/KLZ-4506-2024
OI Roldan Ramos, Pedro/0000-0002-8653-6038; Monleon,
   Daniel/0000-0002-4803-1573; munoz, lisandra/0000-0003-1828-4585; Segura,
   Remedios/0000-0001-7923-4448
FU Generalitat Valenciana-Spain [PROMETEO 2011-11/83]; Ministerio de
   Economia y Competividad-Spain (Instituto de Salud Carlos III)
   [PI14/01669]; Ministerio de Economia y Competividad-Spain
   [SAF2014-52875R]; Instituto de Salud Carlos III [PIE15/00013]; FEDER
FX This work was supported by grants PROMETEO 2011-11/83 from the
   Generalitat Valenciana-Spain, PI14/01669 from the Ministerio de Economia
   y Competividad-Spain (Instituto de Salud Carlos III), SAF2014-52875R
   from the Ministerio de Economia y Competividad-Spain and PIE15/00013
   from the Instituto de Salud Carlos III and FEDER. We acknowledge the
   Fundacion para la Investigacion del Hospital Clinico de la Comunidad
   Valenciana (INCLIVA).
CR Adamson C, 2009, EXPERT OPIN INV DRUG, V18, P1061, DOI 10.1517/13543780903052764
   Anderson HJ, 2016, CELL ONCOL, V39, P229, DOI 10.1007/s13402-016-0267-7
   Auslander N, 2016, SCI REP-UK, V6, DOI 10.1038/srep29662
   Bady P, 2012, ACTA NEUROPATHOL, V124, P547, DOI 10.1007/s00401-012-1016-2
   Berdasco M, 2010, DEV CELL, V19, P698, DOI 10.1016/j.devcel.2010.10.005
   Boulay PL, 2009, M S-MED SCI, V25, P783, DOI 10.1051/medsci/20092510783
   Boulay PL, 2008, J BIOL CHEM, V283, P36425, DOI 10.1074/jbc.M803603200
   Cadieux B, 2006, CANCER RES, V66, P8469, DOI 10.1158/0008-5472.CAN-06-1547
   Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385
   Claes A, 2007, ACTA NEUROPATHOL, V114, P443, DOI 10.1007/s00401-007-0293-7
   D'Souza-Schorey C, 2006, NAT REV MOL CELL BIO, V7, P347, DOI 10.1038/nrm1910
   DAUMASDUPORT C, 1981, NEUROCHIRURGIE, V27, P273
   Esteller M, 2001, CANCER RES, V61, P3225
   Haines E, 2014, J BIOL CHEM, V289, P5687, DOI 10.1074/jbc.M113.516047
   Hegi ME, 2005, NEW ENGL J MED, V352, P997, DOI 10.1056/NEJMoa043331
   Hu B, 2009, CANCER RES, V69, P794, DOI 10.1158/0008-5472.CAN-08-2110
   Keunen O, 2011, P NATL ACAD SCI USA, V108, P3749, DOI 10.1073/pnas.1014480108
   Kreth S, 2014, CANCER LETT, V342, P185, DOI 10.1016/j.canlet.2012.04.008
   Layfield LJ, 2006, APPL IMMUNOHISTO M M, V14, P91, DOI 10.1097/01.pai.0000159772.73775.2e
   Lewis-Saravalli S, 2013, CELL SIGNAL, V25, P1813, DOI 10.1016/j.cellsig.2013.05.011
   Li M, 2006, CANCER RES, V66, P1583, DOI 10.1158/0008-5472.CAN-05-2424
   Li M, 2009, CANCER-AM CANCER SOC, V115, P4959, DOI 10.1002/cncr.24550
   Lopez-Gines C, 2010, MODERN PATHOL, V23, P856, DOI 10.1038/modpathol.2010.62
   Loskutov YV, 2015, ONCOGENE, V34, P3662, DOI 10.1038/onc.2014.297
   Louis DN, 2016, ACTA NEUROPATHOL, V131, P803, DOI 10.1007/s00401-016-1545-1
   Monleón D, 2010, CANCER RES, V70, P8426, DOI 10.1158/0008-5472.CAN-10-1498
   Monticone M, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-358
   Münzberg C, 2015, J CELL MOL MED, V19, P948, DOI 10.1111/jcmm.12473
   Muralidharan-Chari V, 2009, CANCER RES, V69, P2201, DOI 10.1158/0008-5472.CAN-08-1301
   Ohgaki H, 2013, CLIN CANCER RES, V19, P764, DOI 10.1158/1078-0432.CCR-12-3002
   Oka S, 2014, ONCOLOGY-BASEL, V86, P263, DOI 10.1159/000360089
   Portela A, 2010, NAT BIOTECHNOL, V28, P1057, DOI 10.1038/nbt.1685
   Ru Peng, 2013, Cancers (Basel), V5, P1469, DOI 10.3390/cancers5041469
   Sabe H, 2003, J BIOCHEM, V134, P485, DOI 10.1093/jb/mvg181
   Sabe H, 2009, TRAFFIC, V10, P982, DOI 10.1111/j.1600-0854.2009.00917.x
   Schlienger S, 2014, MOL BIOL CELL, V25, P17, DOI 10.1091/mbc.E13-06-0335
   Serna E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067291
   Shinojima N, 2003, CANCER RES, V63, P6962
   Staberg M, 2017, CELL ONCOL, V40, P21, DOI 10.1007/s13402-016-0301-9
   TCGA (The Cancer Genome Atlas Research Network), 2016, CELL, V164, P550
   Tsai MM, 2012, CANCER SCI, V103, P1136, DOI 10.1111/j.1349-7006.2012.02243.x
   Walenta S, 2016, RECENT RESULTS CANC, V207, P23, DOI 10.1007/978-3-319-42118-6_2
   Wolczyk D, 2016, CELL ONCOL, V39, P353, DOI 10.1007/s13402-016-0280-x
NR 43
TC 9
Z9 9
U1 1
U2 14
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 2211-3428
EI 2211-3436
J9 CELL ONCOL
JI Cell. Oncol.
PD AUG
PY 2017
VL 40
IS 4
BP 389
EP 399
DI 10.1007/s13402-017-0329-5
PG 11
WC Oncology; Cell Biology; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology; Pathology
GA FC3OR
UT WOS:000406749200006
PM 28631186
DA 2025-01-12
ER

PT J
AU Hasegawa, T
   Adachi, R
   Iwakata, H
   Takeno, T
   Sato, K
   Sakamaki, T
AF Hasegawa, Takuya
   Adachi, Ryohei
   Iwakata, Hitoshi
   Takeno, Takayoshi
   Sato, Koji
   Sakamaki, Toshiyuki
TI ErbB2 signaling epigenetically suppresses microRNA-205 transcription via
   Ras/Raf/MEK/ERK pathway in breast cancer
SO FEBS OPEN BIO
LA English
DT Article
DE breast cancer; DNA methylation; ErbB2; microRNA; miR-205; Raf-1
ID EPITHELIAL-MESENCHYMAL TRANSITION; DNA-METHYLATION; DOWN-REGULATION;
   TRASTUZUMAB-RESISTANT; PIK3CA MUTATION; EXPRESSION; MIR-205; CELLS;
   MECHANISMS; GENE
AB We previously reported that microRNA-205 (miR-205) is downregulated by overexpression of the receptor tyrosine kinase ErbB2 and that ectopic transfection of miR-205 precursor decreases ErbB2 tumorigenicity in soft agar. In this study, we further analyzed the regulatory mechanisms linking ErbB2 overexpression and miR-205 downregulation. In ErbB2-overexpressing breast epithelial cells, miR-205 expression was significantly increased by treatment with MEK inhibitor U0126 or PD98059, Raf-1 inhibitor ZM-336372, and ERK inhibitor SCH772984, but PI3K inhibitor LY294002 and p38 MAPK inhibitor SB203580 had no effect. We established breast epithelial cells overexpressing RafCAAX, a constitutively active form of Raf-1, and showed that overexpression of RafCAAX dramatically reduced miR-205 expression. In RafCAAX-overexpressing cells, miR-205 expression was also significantly increased by SCH772984. Moreover, miR-205 expression was significantly increased by treatment with DNA methyltransferase (DNMT) inhibitor 5-aza-2-deoxycytidine and expression of several DNMT family members was increased in both ErbB2- and RafCAAX-overexpressing cells. DNA methylation analysis by bisulfite sequencing revealed that the putative miR-205 promoters were predominantly hypermethylated in both ErbB2- and RafCAAX-overexpressing cells. Reporter activity of the putative miR-205 promoters was reduced in both ErbB2-overexpressing and RafCAAX-overexpressing cells. Together, these findings indicate that ErbB2 signaling epigenetically suppresses miR-205 transcription via the Ras/Raf/MEK/ERK pathway.
C1 [Hasegawa, Takuya; Adachi, Ryohei; Iwakata, Hitoshi; Takeno, Takayoshi; Sato, Koji; Sakamaki, Toshiyuki] Niigata Univ Pharm & Appl Life Sci, Dept Publ Hlth, Fac Pharmaceut Sci, Niigata, Japan.
C3 Niigata University
RP Sakamaki, T (通讯作者)，Niigata Univ Pharm & Appl Life Sci, Dept Publ Hlth, Fac Pharmaceut Sci, Akiha Ku, Bldg F,Room 205,265-1 Higashijima, Niigata 9568603, Japan.
EM sakamaki@nupals.ac.jp
CR Adachi R, 2011, BIOCHEM BIOPH RES CO, V411, P804, DOI 10.1016/j.bbrc.2011.07.033
   Adamczyk A, 2015, POL J PATHOL, V66, P133, DOI 10.5114/PJP.2015.53009
   Andre F, 2014, LANCET ONCOL, V15, P580, DOI 10.1016/S1470-2045(14)70138-X
   Baskerville S, 2005, RNA, V11, P241, DOI 10.1261/rna.7240905
   Berns K, 2007, CANCER CELL, V12, P395, DOI 10.1016/j.ccr.2007.08.030
   Bhatnagar N, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2010.85
   Brueckner B, 2007, CANCER RES, V67, P1419, DOI 10.1158/0008-5472.CAN-06-4074
   Corcoran DL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005279
   Denduluri SK, 2015, GENES DIS, V2, P13, DOI 10.1016/j.gendis.2014.10.004
   Deneberg S, 2014, EPIGENETICS-US, V9, P910, DOI 10.4161/epi.28603
   DeSantis CE, 2015, CANCER EPIDEM BIOMAR, V24, P1495, DOI 10.1158/1055-9965.EPI-15-0535
   Ebi H, 2013, P NATL ACAD SCI USA, V110, P21124, DOI 10.1073/pnas.1314124110
   Fazi F, 2007, CANCER CELL, V12, P457, DOI 10.1016/j.ccr.2007.09.020
   Fiegl H, 2006, CANCER RES, V66, P29, DOI 10.1158/0008-5472.CAN-05-2508
   Gagliato DD, 2016, ONCOTARGET, V7, P64431, DOI 10.18632/oncotarget.7043
   Gandellini P, 2012, CELL DEATH DIFFER, V19, P1750, DOI 10.1038/cdd.2012.56
   Gazin C, 2007, NATURE, V449, P1073, DOI 10.1038/nature06251
   Hulf T, 2013, ONCOGENE, V32, P2891, DOI 10.1038/onc.2012.300
   Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783
   Jiménez-Wences H, 2016, ONCOL REP, V35, P2297, DOI 10.3892/or.2016.4583
   Lee JY, 2014, ONCOGENE, V33, P1325, DOI 10.1038/onc.2013.53
   Lin XL, 2012, CHINESE J CANCER RES, V24, P143, DOI 10.1007/s11670-012-0143-6
   Lindqvist BM, 2014, EPIGENETICS-US, V9, P1149, DOI 10.4161/epi.29632
   Lujambio A, 2007, CANCER RES, V67, P1424, DOI 10.1158/0008-5472.CAN-06-4218
   Luo DY, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-57
   Madden SF, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3444
   Merry CR, 2016, ONCOTARGET, V7, P53230, DOI 10.18632/oncotarget.10637
   Mizota Y, 2012, JPN J CLIN ONCOL, V42, P1008, DOI 10.1093/jjco/hys144
   Nahta R, 2006, NAT CLIN PRACT ONCOL, V3, P269, DOI 10.1038/ncponc0509
   Ozsolak F, 2008, GENE DEV, V22, P3172, DOI 10.1101/gad.1706508
   Patra SK, 2008, EXP CELL RES, V314, P1193, DOI 10.1016/j.yexcr.2008.01.012
   Prat A, 2011, MOL ONCOL, V5, P5, DOI 10.1016/j.molonc.2010.11.003
   Qin J, 2015, ONCOTARGETS THER, V8, P3639, DOI 10.2147/OTT.S91560
   Rodriguez A, 2004, GENOME RES, V14, P1902, DOI 10.1101/gr.2722704
   Saito Y, 2006, CANCER CELL, V9, P435, DOI 10.1016/j.ccr.2006.04.020
   Scott GK, 2006, CANCER RES, V66, P1277, DOI 10.1158/0008-5472.CAN-05-3632
   Sempere LF, 2007, CANCER RES, V67, P11612, DOI 10.1158/0008-5472.CAN-07-5019
   Serra RW, 2014, ELIFE, V3, DOI 10.7554/eLife.02313
   Shim JS, 2012, JNCI-J NATL CANCER I, V104, P1576, DOI 10.1093/jnci/djs396
   Terada K, 2009, CARCINOGENESIS, V30, P466, DOI 10.1093/carcin/bgp021
   Vu T, 2012, FRONT ONCOL, V2, P1, DOI 10.3389/fonc.2012.00062
   Tran MN, 2013, J BIOL CHEM, V288, P3275, DOI 10.1074/jbc.M112.408104
   Vernimmen D, 2003, BRIT J CANCER, V89, P899, DOI 10.1038/sj.bjc.6601200
   Weigelt B, 2011, ONCOGENE, V30, P3222, DOI 10.1038/onc.2011.42
   Wiklund ED, 2011, INT J CANCER, V128, P1327, DOI 10.1002/ijc.25461
   Wu BK, 2014, CELL REP, V9, P1827, DOI 10.1016/j.celrep.2014.10.063
   Wu HL, 2009, CELL RES, V19, P439, DOI 10.1038/cr.2009.18
   Yamaguchi T, 2015, ONCOLOGY-BASEL, V88, P377, DOI 10.1159/000369904
   Yin HX, 2016, SCI REP-UK, V6, DOI 10.1038/srep18824
   Yuan HF, 2016, SCI REP-UK, V6, DOI 10.1038/srep20046
   Zhang T, 2013, NEOPLASIA, V15, P1282, DOI 10.1593/neo.131362
NR 51
TC 21
Z9 25
U1 1
U2 10
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2211-5463
J9 FEBS OPEN BIO
JI FEBS Open Bio
PD AUG
PY 2017
VL 7
IS 8
BP 1154
EP 1165
DI 10.1002/2211-5463.12256
PG 12
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA FC2QK
UT WOS:000406682900009
PM 28781955
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Gao, SP
   Sun, HF
   Li, LD
   Fu, WY
   Jin, W
AF Gao, Shui-Ping
   Sun, He-Fen
   Li, Liang-Dong
   Fu, Wen-Yan
   Jin, Wei
TI UHRF1 promotes breast cancer progression by suppressing KLF17 expression
   by hypermethylating its promoter
SO AMERICAN JOURNAL OF CANCER RESEARCH
LA English
DT Article
DE UHRF1; KLF17; proliferation; migration; hypermethylation
ID EMBRYONIC STEM-CELLS; BINDING-PROTEIN; MESENCHYMAL TRANSITION;
   MAMMALIAN-CELLS; G1/S TRANSITION; DNA METHYLATION; SRA DOMAIN; NP95
   GENE; ICBP90; PROLIFERATION
AB UHRF1 is an epigenetic regulator and perform pivotal functions in cell tumorigenesis. We found UHRF1 is increased in breast cancer and patients with high UHRF1 levels have poorer prognoses than those with low UHRF1 levels. However, the underlying mechanisms remain largely unknown. Here, we found overexpression UHRF1 indeed promoted cell proliferation and migration, whereas its downregulation had the opposite functions. In vivo, UHRF1 also accelerated tumor growth. Mechanistically, microarrays were performed in MDA-MB-231 sh-UHRF1 and NC cells and KLF17, with rich CpG islands on its promoter region, finally caused our attention. Then, the expression of UHRF1 and KLF17 was testified negatively correlated in breast cancer cell lines and tissues. Additionally, the inhibition of cell proliferation and migration by UHRF1 depletion can be rescued by KLF17 silencing, suggesting KLF17 is downstream gene of UHRF1. The potential mechanism is that overexpression UHRF1 increased methylation of CpG nucleotides on KLF17 promoter, while UHRF1 silence decreased methylation. Collectively, our results demonstrated that increased UHRF1 can promote breast cancer cell proliferation and migration via silencing of KLF17 expression through CpG island methylation on its promoter.
C1 [Gao, Shui-Ping; Sun, He-Fen; Li, Liang-Dong; Fu, Wen-Yan; Jin, Wei] Fudan Univ, Shanghai Canc Ctr,Dept Breast Surg, Collaborat Innovat Ctr Canc Med, Key Lab Breast Canc Shanghai, Shanghai 200030, Peoples R China.
   [Gao, Shui-Ping; Sun, He-Fen; Li, Liang-Dong; Fu, Wen-Yan; Jin, Wei] Fudan Univ, Shanghai Med Coll, Dept Oncol, Shanghai 200030, Peoples R China.
C3 Fudan University; Fudan University
RP Jin, W (通讯作者)，Fudan Univ, Shanghai Canc Ctr,Dept Breast Surg, Collaborat Innovat Ctr Canc Med, Key Lab Breast Canc Shanghai, Shanghai 200030, Peoples R China.
EM jinwei7207@163.com
FU National Natural Science Foundation of China [81472669, 81272923]
FX This work was supported by the grants from National Natural Science
   Foundation of China (81472669 and 81272923).
CR Abbady AQ, 2003, ANN NY ACAD SCI, V1010, P300, DOI 10.1196/annals.1299.052
   Achour M, 2008, ONCOGENE, V27, P2187, DOI 10.1038/sj.onc.1210855
   Achour M, 2009, BIOCHEM BIOPH RES CO, V390, P523, DOI 10.1016/j.bbrc.2009.09.131
   Akin S, 2014, J BUON, V19, P42
   Arima Y, 2004, GENES CELLS, V9, P131, DOI 10.1111/j.1356-9597.2004.00710.x
   Arita K, 2008, NATURE, V455, P818, DOI 10.1038/nature07249
   Arita K, 2012, P NATL ACAD SCI USA, V109, P12950, DOI 10.1073/pnas.1203701109
   Bostick M, 2007, SCIENCE, V317, P1760, DOI 10.1126/science.1147939
   Chen HY, 2015, AM J CANCER RES, V5, P180
   Citterio E, 2004, MOL CELL BIOL, V24, P2526, DOI 10.1128/MCB.24.6.2526-2535.2004
   Fang L., 2012, CANCER CHEMOTH PHARM, V69, P1079, DOI DOI 10.1007/S00280-011-1801-Y
   Fujimori A, 1998, MAMM GENOME, V9, P1032, DOI 10.1007/s003359900920
   Gumireddy K, 2009, NAT CELL BIOL, V11, P1297, DOI 10.1038/ncb1974
   Hopfner R, 2000, CANCER RES, V60, P121
   Jeanblanc M, 2005, ONCOGENE, V24, P7337, DOI 10.1038/sj.onc.1208878
   Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI 10.3322/caac.20006
   Jiang HL, 2016, CANCER RES, V76, P952, DOI 10.1158/0008-5472.CAN-15-1630
   Jiang HL, 2015, ONCOTARGET, V6, P16352, DOI 10.18632/oncotarget.3877
   Jin W, 2010, BREAST CANCER RES TR, V123, P359, DOI 10.1007/s10549-009-0652-2
   Jin W, 2010, BREAST CANCER RES TR, V124, P39, DOI 10.1007/s10549-009-0683-8
   Karagianni P, 2008, MOL CELL BIOL, V28, P705, DOI 10.1128/MCB.01598-07
   Kim JK, 2009, NUCLEIC ACIDS RES, V37, P493, DOI 10.1093/nar/gkn961
   Kordbacheh T, 2016, BREAST, V26, P54, DOI 10.1016/j.breast.2015.11.005
   Kumaki Y, 2008, NUCLEIC ACIDS RES, V36, pW170, DOI 10.1093/nar/gkn294
   Li XL, 2012, ONCOL REP, V28, P375, DOI 10.3892/or.2012.1792
   Li XL, 2011, INT J RADIAT BIOL, V87, P263, DOI 10.3109/09553002.2011.530335
   Liang D, 2015, INT J CLIN EXP PATHO, V8, P9416
   Liu W, 2016, MOL MED REP, V13, P315, DOI 10.3892/mmr.2015.4515
   Macaluso M, 2007, CANCER RES, V67, P7731, DOI 10.1158/0008-5472.CAN-07-1476
   Meilinger D, 2009, EMBO REP, V10, P1259, DOI 10.1038/embor.2009.201
   Miura M, 2001, EXP CELL RES, V263, P202, DOI 10.1006/excr.2000.5115
   Muto M, 2002, J BIOL CHEM, V277, P34549, DOI 10.1074/jbc.M205189200
   Rothbart SB, 2013, GENE DEV, V27, P1288, DOI 10.1101/gad.220467.113
   Uemura T, 2000, CELL STRUCT FUNCT, V25, P149, DOI 10.1247/csf.25.149
   Unoki M, 2004, ONCOGENE, V23, P7601, DOI 10.1038/sj.onc.1208053
   Wan XC, 2016, J EXP CLIN CANC RES, V35, DOI 10.1186/s13046-016-0308-0
   Zhou L, 2015, CANCER BIOL THER, V16, P1241, DOI 10.1080/15384047.2015.1056411
   Zhu MC, 2015, CANCER SCI, V106, P833, DOI 10.1111/cas.12689
   Zhuo H, 2016, MOL CARCINOGEN, V55, P209, DOI 10.1002/mc.22270
NR 39
TC 25
Z9 28
U1 2
U2 8
PU E-CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 2156-6976
J9 AM J CANCER RES
JI Am. J. Cancer Res.
PY 2017
VL 7
IS 7
BP 1554
EP 1565
PG 12
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA FC2KF
UT WOS:000406665600012
PM 28744404
DA 2025-01-12
ER

PT J
AU Wang, Y
   Hao, DP
   Li, JJ
   Wang, L
   Di, LJ
AF Wang, Yuan
   Hao, Da-Peng
   Li, Jing-Jing
   Wang, Li
   Di, Li-Jun
TI Genome-wide methylome and chromatin interactome identify abnormal
   enhancer to be risk factor of breast cancer
SO ONCOTARGET
LA English
DT Article
DE enhancer methylation; breast cancer; chromatin interaction; polII
   ChIA-PET; gene regulation
ID DNA METHYLATION; GENE-EXPRESSION; TRANSCRIPTIONAL ENHANCERS; EPIGENETIC
   REGULATION; HISTONE MODIFICATION; FLOTILLIN-1; SIGNATURES; DYNAMICS;
   ISLANDS; DOMAINS
AB Enhancer is critical cis regulatory elements in gene expression. To understand whether and how the aberrant enhancer activation may contribute to cancer risk, the differentially methylated enhancers (eDMRs) in normal and malignant breast tissues were identified and analyzed. By incorporating genome-wide chromatin interaction, integrated analysis of eDMRs and target gene expression identified 1,272 enhancer-promoter pairs. Surprisingly, two functionally distinct groups of genes were identified in these pairs, one showing better correlation to enhancer methylation (eRGs) and the other showing better correlation to promoter methylation (pRGs), and the former group is functionally enriched with cancer related genes. Moreover, enhancer methylation based clustering of breast cancer samples is capable of discriminating basal breast cancer from other subtypes. By correlating enhancer methylation status to patient survival, 345 enhancers show the impact on the disease outcome and the majority of their target genes are important regulators of cell survival pathways including known cancer related genes. Together, these results suggest reactivation of enhancers in cancer cells has the add-on effect and contributes to cancer risk in combination.
C1 [Wang, Yuan; Hao, Da-Peng; Li, Jing-Jing; Di, Li-Jun] Univ Macau, Fac Hlth Sci, Canc Ctr, Macau, Peoples R China.
   [Wang, Li] Univ Macau, Fac Hlth Sci, Metab Core, Macau, Peoples R China.
C3 University of Macau; University of Macau
RP Di, LJ (通讯作者)，Univ Macau, Fac Hlth Sci, Canc Ctr, Macau, Peoples R China.
EM lijundi@umac.mo
RI Di, Li-jun/B-3352-2011; li, jingjing/IRZ-2632-2023
OI Li, Jingjing/0000-0001-8000-7410
FU Science and Technology Development Fund (FDCT) of Macao SAR
   [FDCT025/2014/A1, FDCT 088/2014/A2]; University of Macau
   [MYRG2015-00037-FHS, MYRG2015-00167-FHS, MYRG2016-00251-FHS]; Matching
   Research Fund [MRG022/DLJ/2015/FHS, MRG023/DLJ/2015/FHS]
FX This work is supported by the Science and Technology Development Fund
   (FDCT) of Macao SAR to LD (FDCT025/2014/A1 & FDCT 088/2014/A2), the
   Multi-Year Research Grant from the University of Macau to LD
   (MYRG2015-00037-FHS & MYRG2015-00167-FHS), the Matching Research Fund to
   LD (MRG022/DLJ/2015/FHS & MRG023/DLJ/2015/FHS) and the Multi-Year
   Research Grant from the University of Macau to LW (MYRG2016-00251-FHS).
CR Allis CD, 2016, NAT REV GENET, V17, P487, DOI 10.1038/nrg.2016.59
   Aran D, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-3-r21
   Aran D, 2013, CELL, V154, P11, DOI 10.1016/j.cell.2013.06.018
   Arkhipova KA, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-100
   Bannister AJ, 2011, CELL RES, V21, P381, DOI 10.1038/cr.2011.22
   Bell RE, 2016, GENOME RES, V26, P601, DOI 10.1101/gr.197194.115
   Bibikova M, 2006, GENOME RES, V16, P383, DOI 10.1101/gr.4410706
   Blattler A, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0469-0
   Calo E, 2013, MOL CELL, V49, P825, DOI 10.1016/j.molcel.2013.01.038
   Cedar H, 2009, NAT REV GENET, V10, P295, DOI 10.1038/nrg2540
   Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095
   Coyle KM, 2016, ONCOTARGET, V7, P44096, DOI 10.18632/oncotarget.9858
   Creyghton MP, 2010, P NATL ACAD SCI USA, V107, P21931, DOI 10.1073/pnas.1016071107
   Croce CM, 2008, NEW ENGL J MED, V358, P502, DOI 10.1056/NEJMra072367
   Deaton AM, 2011, GENE DEV, V25, P1010, DOI 10.1101/gad.2037511
   Dedeurwaerder S, 2012, ONCOIMMUNOLOGY, V1, P962, DOI 10.4161/onci.19996
   Dekker J, 2015, CSH PERSPECT BIOL, V7, DOI 10.1101/cshperspect.a019356
   Di Cello F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068630
   Di LJ, 2008, J CELL BIOCHEM, V105, P301, DOI 10.1002/jcb.21826
   Fudenberg G, 2016, CELL REP, V15, P2038, DOI 10.1016/j.celrep.2016.04.085
   Fullwood MJ, 2009, NATURE, V462, P58, DOI 10.1038/nature08497
   Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Heintzman ND, 2007, NAT GENET, V39, P311, DOI 10.1038/ng1966
   Heintzman ND, 2009, NATURE, V459, P108, DOI 10.1038/nature07829
   Henikoff S, 2008, NAT REV GENET, V9, P15, DOI 10.1038/nrg2206
   Heyn H, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-0879-2
   Hnisz D, 2016, SCIENCE, V351, P1454, DOI 10.1126/science.aad9024
   Jaenisch R, 2003, NAT GENET, V33, P245, DOI 10.1038/ng1089
   Jones PA, 2012, NAT REV GENET, V13, P484, DOI 10.1038/nrg3230
   Kantlehner M, 2011, NUCLEIC ACIDS RES, V39, pE44, DOI 10.1093/nar/gkq1357
   Kieffer-Kwon KR, 2013, CELL, V155, P1507, DOI 10.1016/j.cell.2013.11.039
   Kim TK, 2010, NATURE, V465, P182, DOI 10.1038/nature09033
   Koch F, 2008, TRENDS BIOCHEM SCI, V33, P265, DOI 10.1016/j.tibs.2008.04.006
   Kohli RM, 2013, NATURE, V502, P472, DOI 10.1038/nature12750
   Krijger PHL, 2016, NAT REV MOL CELL BIO, V17, P771, DOI 10.1038/nrm.2016.138
   Li GL, 2012, CELL, V148, P84, DOI 10.1016/j.cell.2011.12.014
   Li H, 2014, INT J CLIN EXP PATHO, V7, P996
   Li H, 2014, TUMOR BIOL, V35, P3311, DOI 10.1007/s13277-013-1434-3
   Li LS, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-163
   Li N, 2010, METHODS, V52, P203, DOI 10.1016/j.ymeth.2010.04.009
   Li YS, 2013, NUCLEIC ACIDS RES, V41, DOI 10.1093/nar/gkt1054
   Nikolsky Y, 2008, CANCER RES, V68, P9532, DOI 10.1158/0008-5472.CAN-08-3082
   Onodera Y, 2016, CANCER MED-US, V5, P1973, DOI 10.1002/cam4.736
   Plaisier CL, 2012, GENOME RES, V22, P2302, DOI 10.1101/gr.133991.111
   Prat A, 2009, NAT MED, V15, P842, DOI 10.1038/nm0809-842
   Reis JS, 2011, LANCET, V378, P1812, DOI 10.1016/S0140-6736(11)61539-0
   Robertson KD, 2000, CARCINOGENESIS, V21, P461, DOI 10.1093/carcin/21.3.461
   Sharma G, 2009, CELL ONCOL, V31, P487, DOI 10.3233/CLO-2009-0507
   Shlyueva D, 2014, NAT REV GENET, V15, P272, DOI 10.1038/nrg3682
   Spitz F, 2012, NAT REV GENET, V13, P613, DOI 10.1038/nrg3207
   Splinter E, 2006, GENE DEV, V20, P2349, DOI 10.1101/gad.399506
   Stevens M, 2013, GENOME RES, V23, P1541, DOI 10.1101/gr.152231.112
   Sur I, 2016, NAT REV CANCER, V16, P483, DOI 10.1038/nrc.2016.62
   Tamura RE, 2012, CURR MOL MED, V12, P634
   Tang ZH, 2015, CELL, V163, P1611, DOI 10.1016/j.cell.2015.11.024
   Thomas GS, 2009, CANCER RES, V69, P3665, DOI 10.1158/0008-5472.CAN-08-4867
   Thurman RE, 2012, NATURE, V489, P75, DOI 10.1038/nature11232
   Tonidandel S, 2015, J BUS PSYCHOL, V30, P207, DOI 10.1007/s10869-014-9351-z
   Visel A, 2009, NATURE, V457, P854, DOI 10.1038/nature07730
   Wang L, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004629
   Winship AL, 2016, CANCER INVEST, V34, P26, DOI 10.3109/07357907.2015.1084313
   Zhao ZQ, 2016, MOL MED, V22, P349, DOI 10.2119/molmed.2016.00051
   Zhou GL, 2006, MOL CELL BIOL, V26, P5096, DOI 10.1128/MCB.02454-05
NR 64
TC 6
Z9 6
U1 0
U2 2
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD JUL 4
PY 2017
VL 8
IS 27
BP 44705
EP 44719
DI 10.18632/oncotarget.18348
PG 15
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA FA5QH
UT WOS:000405498000089
PM 28621677
OA Green Submitted, gold, Green Published
DA 2025-01-12
ER

PT J
AU Lan, X
   Fu, LJ
   Hu, ZY
   Feng, Q
   Liu, XQ
   Zhang, X
   Chen, XM
   He, JL
   Wang, YX
   Ding, YB
AF Lan, Xi
   Fu, Li-Juan
   Hu, Zhuo-Ying
   Feng, Qian
   Liu, Xue-Qing
   Zhang, Xue
   Chen, Xue-Mei
   He, Jun-Lin
   Wang, Ying-Xiong
   Ding, Yu-Bin
TI Methylated oligonucleotide (MON)-induced promoter hypermethylation is
   associated with repression of <i>CDH1</i> expression and contributes to
   the migration and invasion of human trophoblast cell lines
SO REPRODUCTION FERTILITY AND DEVELOPMENT
LA English
DT Article
DE DNA methylation; E-cadherin; implantation; pregnancy complications
ID E-CADHERIN EXPRESSION; MESENCHYMAL TRANSITION; DNA METHYLATION;
   EXTRAVILLOUS TROPHOBLASTS; HUMAN CYTOTROPHOBLASTS; ENDOVASCULAR
   INVASION; SUPPRESSOR GENE; CPG METHYLATION; BREAST-CANCER; ADHESION
AB DNAcytosine-5 methylation plays a vital role in regulating the expression of E-cadherin, which is encoded by the CDH1 gene. In this study, we characterised the DNA methylation and expression pattern of CDH1 in an extravillous trophoblast cell line (HTR-8/SVneo) and two trophoblast cell lines -JEG-3 and JAR. Promoter hypermethylation with reduced E-cadherin expression in HTR-8/SVneo cells and promoter hypomethylation with increased E-cadherin expression in JEG-3 and JAR cells were observed. Demethylation treatment significantly restored E-cadherin expression, contributing to decreases in the motility and invasiveness of HTR-8/SVneo cells. Sense-methylated oligonucleotides (MONs) labelled with Cy5 and complementary to a region of the human CDH1promoter were designed, with the cytosines in 50-cytosine-phosphate-guanine-30 (CpG) dinucleotides being replaced by methylated cytosines. Following MON transfection into JEG-3 cells, the level of CDH1 promoter DNA methylation as well as cell motility and invasiveness were increased and gene expression was significantly repressed. Our results indicate that MON-mediated DNA methylation of the CDH1 promoter and subsequent alterations in gene expression may contribute to trophoblast motility and invasion, suggesting a potential method for controlling the biological function of trophoblasts in vitro through epigenetic modification.
C1 [Lan, Xi; Feng, Qian; Liu, Xue-Qing; Zhang, Xue; Chen, Xue-Mei; He, Jun-Lin; Wang, Ying-Xiong; Ding, Yu-Bin] Chongqing Med Univ, Lab Reprod Biol, Sch Publ Hlth & Management, 1 Yixueyuan Rd, Chongqing 400016, Peoples R China.
   [Fu, Li-Juan] Chongqing Med Univ, Sch Tradit Chinese Med, 1 Yixueyuan Rd, Chongqing 400016, Peoples R China.
   [Hu, Zhuo-Ying] Chongqing Med Univ, Affiliated Hosp 1, Dept Obstet & Gynecol, 1 Youyi Rd, Chongqing 400016, Peoples R China.
C3 Chongqing Medical University; Chongqing Medical University; Chongqing
   Medical University
RP Ding, YB (通讯作者)，Chongqing Med Univ, Lab Reprod Biol, Sch Publ Hlth & Management, 1 Yixueyuan Rd, Chongqing 400016, Peoples R China.
EM dingyb@gmail.com
RI Wang, Ying/HJI-2509-2023; Ding, Yubin/W-4146-2017; 田, 冬冬/GWC-0253-2022
OI Ding, Yubin/0000-0002-7870-9445
FU National Natural Science Foundation of China [81370731, 31271546];
   Science and Technology Project of Chongqing Education Committee
   [KJ130309, Yujiaoren-2014-47]; Chongqing Institute for family planning
   [1201]; Excellent Young Scholars of Chongqing Medical University
   [CQYQ201302]
FX This study was supported by the National Natural Science Foundation of
   China (Nos. 81370731, 31271546), the Science and Technology Project of
   Chongqing Education Committee (KJ130309; Yujiaoren-2014-47), open
   funding by the Chongqing Institute for family planning (1201) and the
   Excellent Young Scholars of Chongqing Medical University (CQYQ201302).
CR Adhikary A, 2014, J BIOL CHEM, V289, P25431, DOI 10.1074/jbc.M113.527267
   Antoun G, 2000, J CELL BIOCHEM, V77, P372, DOI 10.1002/(SICI)1097-4644(20000601)77:3<372::AID-JCB3>3.3.CO;2-G
   Babawale MO, 1996, HUM REPROD, V11, P444, DOI 10.1093/HUMREP/11.2.444
   Babawale MO, 2002, HUM REPROD, V17, P1351, DOI 10.1093/humrep/17.5.1351
   Barber A, 2001, FASEB J, V15, P1158, DOI 10.1096/fj.00-0376com
   Batistatou A, 2007, PLACENTA, V28, P590, DOI 10.1016/j.placenta.2006.09.004
   BIRCHMEIER W, 1995, BIOESSAYS, V17, P97, DOI 10.1002/bies.950170203
   Bolós V, 2003, J CELL SCI, V116, P499, DOI 10.1242/jcs.00224
   Cartwright JE, 2010, REPRODUCTION, V140, P803, DOI 10.1530/REP-10-0294
   DaSilva-Arnold S, 2015, PLACENTA, V36, P1412, DOI 10.1016/j.placenta.2015.10.013
   Eder P S, 1991, Antisense Res Dev, V1, P141
   Fitzgerald JS, 2008, HUM REPROD UPDATE, V14, P335, DOI 10.1093/humupd/dmn010
   Floridon C, 2000, MOL HUM REPROD, V6, P943, DOI 10.1093/molehr/6.10.943
   Friedl P, 2003, NAT REV CANCER, V3, P362, DOI 10.1038/nrc1075
   FRIXEN UH, 1991, J CELL BIOL, V113, P173, DOI 10.1083/jcb.113.1.173
   GRAHAM CH, 1993, EXP CELL RES, V206, P204, DOI 10.1006/excr.1993.1139
   Hajra KM, 1999, ONCOGENE, V18, P7274, DOI 10.1038/sj.onc.1203336
   Hmadcha A, 1999, J EXP MED, V190, P1595, DOI 10.1084/jem.190.11.1595
   Hodge DR, 2001, J BIOL CHEM, V276, P39508, DOI 10.1074/jbc.C100343200
   Hoffman AR, 2006, CELL MOL NEUROBIOL, V26, P425, DOI 10.1007/s10571-006-9057-5
   Hoffmann P, 2009, J CELL MOL MED, V13, P2224, DOI 10.1111/j.1582-4934.2008.00554.x
   Hu YX, 2015, MOL HUM REPROD, V21, P452, DOI 10.1093/molehr/gav007
   Ishii T, 2004, CANCER LETT, V212, P211, DOI 10.1016/j.canlet.2004.03.001
   Kent WJ, 2002, GENOME RES, V12, P996, DOI 10.1101/gr.229102
   Knöfler M, 2010, INT J DEV BIOL, V54, P269, DOI 10.1387/ijdb.082769mk
   Lewis-Tuffin LJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013665
   Li HL, 2010, CANCER GENE THER, V17, P441, DOI 10.1038/cgt.2009.82
   Li XL, 2014, PLACENTA, V35, P625, DOI 10.1016/j.placenta.2014.04.010
   Li XQ, 2011, TUMOR BIOL, V32, P863, DOI 10.1007/s13277-011-0187-0
   Ma AN, 2010, BIOCHEM BIOPH RES CO, V393, P592, DOI 10.1016/j.bbrc.2010.02.020
   Nakashima A, 2008, AM J PATHOL, V173, P653, DOI 10.2353/ajpath.2008.071169
   Niewiadomska P, 1999, J CELL BIOL, V144, P533, DOI 10.1083/jcb.144.3.533
   Novakovic B, 2011, MOL HUM REPROD, V17, P344, DOI 10.1093/molehr/gar005
   Perez-Moreno M, 2003, CELL, V112, P535, DOI 10.1016/S0092-8674(03)00108-9
   Rahnama F, 2006, ENDOCRINOLOGY, V147, P5275, DOI 10.1210/en.2006-0288
   Rodriguez FJ, 2012, BBA-REV CANCER, V1826, P23, DOI 10.1016/j.bbcan.2012.03.002
   Shah PP, 2011, CANCER LETT, V311, P66, DOI 10.1016/j.canlet.2011.06.033
   Shamir ER, 2015, CURR TOP DEV BIOL, V112, P353, DOI 10.1016/bs.ctdb.2014.12.001
   Shih IM, 2002, PLACENTA, V23, P706, DOI 10.1053/plac.2002.0864
   Tarrade A, 2001, LAB INVEST, V81, P1199, DOI 10.1038/labinvest.3780334
   VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M
   Wong AST, 2003, J CELL BIOL, V161, P1191, DOI 10.1083/jcb.200212033
   Xue WC, 2003, INT J GYNECOL CANCER, V13, P879, DOI 10.1136/ijgc-00009577-200311000-00022
   Yao XM, 2003, J CLIN INVEST, V111, P265, DOI 10.1172/JCI200315109
   YOSHIURA K, 1995, P NATL ACAD SCI USA, V92, P7416, DOI 10.1073/pnas.92.16.7416
   Zhou Y, 1997, J CLIN INVEST, V99, P2139, DOI 10.1172/JCI119387
   Zhou Y, 1997, J CLIN INVEST, V99, P2152, DOI 10.1172/JCI119388
   Zhu Jia-Yu, 2012, Rev Obstet Gynecol, V5, pe137
NR 48
TC 4
Z9 9
U1 0
U2 10
PU CSIRO PUBLISHING
PI CLAYTON
PA UNIPARK, BLDG 1, LEVEL 1, 195 WELLINGTON RD, LOCKED BAG 10, CLAYTON, VIC
   3168, AUSTRALIA
SN 1031-3613
EI 1448-5990
J9 REPROD FERT DEVELOP
JI Reprod. Fertil. Dev.
PD JUL
PY 2017
VL 29
IS 8
BP 1509
EP 1520
DI 10.1071/RD16031
PG 12
WC Developmental Biology; Reproductive Biology; Zoology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Developmental Biology; Reproductive Biology; Zoology
GA FA9QZ
UT WOS:000405782100005
PM 27439778
DA 2025-01-12
ER

PT J
AU Pasquariello, R
   Fernandez-Fuertes, B
   Strozzi, F
   Pizzi, F
   Mazza, R
   Lonergan, P
   Gandolfi, F
   Williams, JL
AF Pasquariello, R.
   Fernandez-Fuertes, B.
   Strozzi, F.
   Pizzi, F.
   Mazza, R.
   Lonergan, P.
   Gandolfi, F.
   Williams, J. L.
TI Profiling bovine blastocyst microRNAs using deep sequencing
SO REPRODUCTION FERTILITY AND DEVELOPMENT
LA English
DT Article
DE epigenetics; gene regulation; RNA
ID IN-SITU HYBRIDIZATION; EXPRESSION ANALYSIS; OOCYTE MATURATION;
   BREAST-CANCER; DIFFERENTIAL EXPRESSION; EMBRYO DEVELOPMENT; SIGNALING
   PATHWAY; VITRO CULTURE; IDENTIFICATION; SIGNATURE
AB MicroRNAs (miRNAs) are known to control several reproductive functions, including oocyte maturation, implantation and early embryonic development. Recent advances in deep sequencing have allowed the analysis of all miRNAs of a sample. However, when working with embryos, due to the lowRNAcontent, miRNA profiling is challenging because of the relatively large amount of total RNA required for library preparation protocols. In the present study we compared three different procedures for RNA extraction and prepared libraries using pools of 30 bovine blastocysts. In total, 14 of the 15 most abundantly expressed miRNAs were common to all three procedures. Furthermore, using miRDeep discovery and annotation software (Max Delbru ck Center), we identified 1363 miRNA sequences, of which bta-miR-10b and bta-miR-378 were the most abundant. Most of the 179 genes identified as experimentally validated (86.6%) or predicted targets (13.4%) were associated with cancer canonical pathways. We conclude that reliable analysis of bovine blastocyst miRNAs can be achieved using the procedures described herein. The repeatability of the results across different procedures and independent replicates, as well as their consistency with results obtained in other species, support the biological relevance of these miRNAs and of the gene pathways they modulate in early embryogenesis.
C1 [Pasquariello, R.; Gandolfi, F.] Univ Milan, Dipartimento Sci Agr & Ambientali Prod, Terr, Via Celoria 2, I-20133 Milan, Italy.
   [Fernandez-Fuertes, B.; Lonergan, P.] Univ Coll Dublin, Sch Agr & Food Sci, Dublin 4, Ireland.
   [Strozzi, F.] Parco Tecnol Padano, Via Einstein Albert, I-26900 Lodi, Italy.
   [Pizzi, F.] CNR, Ist Biol & Biotecnol Agr, Via Einstein Albert, I-26900 Lodi, Italy.
   [Mazza, R.] Assoc Italiana Allevatori, Via Bergamo 292, I-26100 Cremona, Italy.
   [Williams, J. L.] Univ Adelaide, Sch Anim & Vet Sci, Fac Sci, Roseworthy, SA 5371, Australia.
C3 University of Milan; University College Dublin; Consiglio Nazionale
   delle Ricerche (CNR); University of Adelaide
RP Pasquariello, R (通讯作者)，Univ Milan, Dipartimento Sci Agr & Ambientali Prod, Terr, Via Celoria 2, I-20133 Milan, Italy.
EM rolando.pasquariello@libero.it
RI Pasquariello, Rolando/M-2347-2019; pizzi, flavia/AAY-7199-2020;
   Fernandez-Fuertes, Beatriz/T-3307-2018; Gandolfi, Fulvio/G-6781-2017;
   PASQUARIELLO, ROLANDO/O-3998-2018
OI Williams, John/0000-0001-5188-7957; Gandolfi,
   Fulvio/0000-0002-3246-2985; Strozzi, Francesco/0000-0002-6845-6982;
   pizzi, flavia/0000-0002-5076-0265; PASQUARIELLO,
   ROLANDO/0000-0003-3191-7009; Fernandez-Fuertes,
   Beatriz/0000-0003-2303-8733
FU Fecund Project [FP7-KBBE-2012- FECUND-312097]
FX The authors thank Mrs M. Wade (IVF Laboratory, School of Agriculture and
   Food Science, University College Dublin) for her kind help during in
   vitro embryo production experiments. The authors also thank Drs M.
   Polenghi and C. Ferrandi for their help with deep sequencing and Dr R.
   Giannico for his contribution to the bioinformatic analysis at the core
   facilities of the PTP Science Park (Lodi, Italy). This research was
   funded by the Fecund Project (FP7-KBBE-2012- FECUND-312097).
CR Abd El Naby WS, 2013, ZYGOTE, V21, P31, DOI 10.1017/S0967199411000566
   Bar M, 2008, STEM CELLS, V26, P2496, DOI 10.1634/stemcells.2008-0356
   Betoni JS, 2013, HYPERTENS PREGNANCY, V32, P321, DOI 10.3109/10641955.2013.807819
   Braga DPAF, 2014, J ASSIST REPROD GEN, V31, P1105, DOI 10.1007/s10815-014-0266-4
   Calin GA, 2005, NEW ENGL J MED, V353, P1793, DOI 10.1056/NEJMoa050995
   CAROLAN C, 1995, THERIOGENOLOGY, V43, P1115, DOI 10.1016/0093-691X(95)00075-J
   Chim SSC, 2008, CLIN CHEM, V54, P482, DOI 10.1373/clinchem.2007.097972
   Chitwood JL, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-350
   Cimmino A, 2005, P NATL ACAD SCI USA, V102, P13944, DOI 10.1073/pnas.0506654102
   Cleys ER, 2014, MOL REPROD DEV, V81, P983, DOI 10.1002/mrd.22420
   Coutinho LL, 2007, PHYSIOL GENOMICS, V29, P35, DOI 10.1152/physiolgenomics.00081.2006
   Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60
   Du Y, 2014, MOL REPROD DEV, V81, P1042, DOI 10.1002/mrd.22426
   Feng RZ, 2015, SCI REP-UK, V5, DOI 10.1038/srep08689
   Fomeshi MR, 2015, CELL MOL BIOL LETT, V20, P448, DOI 10.1515/cmble-2015-0025
   Frankel LB, 2008, J BIOL CHEM, V283, P1026, DOI 10.1074/jbc.M707224200
   Friedländer MR, 2012, NUCLEIC ACIDS RES, V40, P37, DOI 10.1093/nar/gkr688
   Galli C, 2014, THERIOGENOLOGY, V81, P138, DOI 10.1016/j.theriogenology.2013.09.008
   Galliano D, 2014, FERTIL STERIL, V101, P1531, DOI 10.1016/j.fertnstert.2014.04.023
   Garzon R, 2008, BLOOD, V111, P3183, DOI 10.1182/blood-2007-07-098749
   Garzon R, 2008, P NATL ACAD SCI USA, V105, P3945, DOI 10.1073/pnas.0800135105
   Gebremedhn S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125912
   Gilchrist GC, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17030396
   Goossens K, 2014, METHODS MOL BIOL, V1211, P15, DOI 10.1007/978-1-4939-1459-3_2
   Goossens K, 2013, STEM CELLS DEV, V22, P1907, DOI 10.1089/scd.2012.0708
   Goossens K, 2012, ANAL BIOCHEM, V423, P93, DOI 10.1016/j.ab.2012.01.005
   Imbar T, 2014, FERTIL STERIL, V101, P1514, DOI 10.1016/j.fertnstert.2014.04.030
   Jiang J, 2008, DEV CELL, V15, P801, DOI 10.1016/j.devcel.2008.11.010
   Jin YC, 2015, TUMOR BIOL, V36, P3791, DOI 10.1007/s13277-014-3020-8
   Kambe S, 2014, BIOL REPROD, V91, DOI 10.1095/biolreprod.114.121616
   Kang JT, 2012, ZYGOTE, V20, P1, DOI 10.1017/S0967199411000426
   Kang YJ, 2015, J CELL SCI, V128, P804, DOI 10.1242/jcs.164004
   Karube Y, 2005, CANCER SCI, V96, P111, DOI 10.1111/j.1349-7006.2005.00015.x
   Kozomara A, 2014, NUCLEIC ACIDS RES, V42, pD68, DOI 10.1093/nar/gkt1181
   Kridli RT, 2016, THERIOGENOLOGY, V85, P135, DOI 10.1016/j.theriogenology.2015.08.001
   Kropp J, 2015, J DAIRY SCI, V98, P6552, DOI 10.3168/jds.2015-9510
   Kropp J, 2014, FRONT GENET, V5, DOI 10.3389/fgene.2014.00091
   Li GD, 2012, CELL PHYSIOL BIOCHEM, V30, P1481, DOI 10.1159/000343336
   Li Y, 2015, BUILD SIMUL-CHINA, V8, P51, DOI 10.1007/s12273-014-0188-1
   Li ZY, 2015, REPROD BIOMED ONLINE, V31, P384, DOI 10.1016/j.rbmo.2015.05.016
   Liang X, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121510
   M'hamed IF, 2015, CELL ONCOL, V38, P433, DOI 10.1007/s13402-015-0239-3
   Marzi MJ, 2012, J CELL BIOL, V199, P77, DOI 10.1083/jcb.201206033
   McCallie BR, 2014, J ASSIST REPROD GEN, V31, P913, DOI 10.1007/s10815-014-0235-y
   McManus MT, 2003, SEMIN CANCER BIOL, V13, P253, DOI 10.1016/S1044-579X(03)00038-5
   Mitchell MD, 2015, AM J OBSTET GYNECOL, V213, pS173, DOI 10.1016/j.ajog.2015.07.001
   Mondou E, 2012, MOL HUM REPROD, V18, P425, DOI 10.1093/molehr/gas015
   Monk M, 2001, ONCOGENE, V20, P8085, DOI 10.1038/sj.onc.1205088
   Murri M, 2013, J CLIN ENDOCR METAB, V98, pE1835, DOI 10.1210/jc.2013-2218
   Nagaraj NS, 2010, EXPERT OPIN INV DRUG, V19, P77, DOI 10.1517/13543780903382609
   Nagpal N, 2015, SCI REP-UK, V5, DOI 10.1038/srep09650
   Nishida N, 2012, CLIN CANCER RES, V18, P3054, DOI 10.1158/1078-0432.CCR-11-1078
   Nishioka N, 2009, DEV CELL, V16, P398, DOI 10.1016/j.devcel.2009.02.003
   O'Donnell KA, 2005, NATURE, V435, P839, DOI 10.1038/nature03677
   O'Hara L, 2014, THERIOGENOLOGY, V81, P1123, DOI 10.1016/j.theriogenology.2014.01.041
   Palacios F, 2015, LEUKEMIA, V29, P115, DOI 10.1038/leu.2014.158
   Pan B, 2015, AM J PHYSIOL-ENDOC M, V308, pE525, DOI 10.1152/ajpendo.00480.2014
   Pasqualini L, 2015, MOL ENDOCRINOL, V29, P1037, DOI 10.1210/me.2014-1358
   Petrocca F, 2008, CANCER CELL, V13, P272, DOI 10.1016/j.ccr.2008.02.013
   Ponsuksili S, 2014, BIOL REPROD, V91, DOI 10.1095/biolreprod.114.121392
   Rayner KJ, 2013, J LIPID RES, V54, P1174, DOI 10.1194/jlr.R034991
   Rizos D, 2002, MOL REPROD DEV, V61, P234, DOI 10.1002/mrd.1153
   Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616
   Rosenbluth EM, 2014, FERTIL STERIL, V101, P1493, DOI 10.1016/j.fertnstert.2014.01.058
   Salilew-Wondim D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106795
   Sohel MMH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078505
   Song JL, 2015, CELL SIGNAL, V27, P1380, DOI 10.1016/j.cellsig.2015.03.018
   Song LB, 2012, J CLIN INVEST, V122, P3563, DOI 10.1172/JCI62339
   Stowe HM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113163
   Su JM, 2015, ANIM REPROD SCI, V155, P64, DOI 10.1016/j.anireprosci.2015.02.001
   Toms D, 2015, MOL CELL ENDOCRINOL, V399, P95, DOI 10.1016/j.mce.2014.07.022
   Tripurani SK, 2010, ANIM REPROD SCI, V120, P16, DOI 10.1016/j.anireprosci.2010.03.001
   Tscherner A, 2014, REPROD BIOL ENDOCRIN, V12, DOI 10.1186/1477-7827-12-85
   Vlachos IS, 2012, NUCLEIC ACIDS RES, V40, pW498, DOI 10.1093/nar/gks494
   Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103
   Voorhoeve PM, 2006, CELL, V124, P1169, DOI 10.1016/j.cell.2006.02.037
   Wydooghe E, 2017, BIOL REV, V92, P505, DOI 10.1111/brv.12241
   Xu D, 2011, J CELL BIOL, V193, P409, DOI 10.1083/jcb.201010100
   Xue JQ, 2016, TUMOR BIOL, V37, P1581, DOI 10.1007/s13277-015-3926-9
   Yang YH, 2008, DEV DYNAM, V237, P2315, DOI 10.1002/dvdy.21666
NR 80
TC 10
Z9 11
U1 0
U2 14
PU CSIRO PUBLISHING
PI CLAYTON
PA UNIPARK, BLDG 1, LEVEL 1, 195 WELLINGTON RD, LOCKED BAG 10, CLAYTON, VIC
   3168, AUSTRALIA
SN 1031-3613
EI 1448-5990
J9 REPROD FERT DEVELOP
JI Reprod. Fertil. Dev.
PD JUL
PY 2017
VL 29
IS 8
BP 1545
EP 1555
DI 10.1071/RD16110
PG 11
WC Developmental Biology; Reproductive Biology; Zoology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Developmental Biology; Reproductive Biology; Zoology
GA FA9QZ
UT WOS:000405782100009
PM 27623773
DA 2025-01-12
ER

PT J
AU Papadas, TA
   Tsiambas, E
   Mastronikolis, NS
   Karameris, A
   Mastronikolis, SN
   Papadas, AT
   Fotiades, PP
   Ragos, V
AF Papadas, Theodoros A.
   Tsiambas, Evangelos
   Mastronikolis, Nicholas S.
   Karameris, Andreas
   Mastronikolis, Stylianos N.
   Papadas, Athanasios T.
   Fotiades, Panagiotis P.
   Ragos, Vasileios
TI Topoisomerase I deregulation in laryngeal squamous cell carcinomas based
   on tissue microarray analysis
SO JOURNAL OF BUON
LA English
DT Article
DE carcinoma; larynx; microarrays; topoisomerases
ID DNA TOPOISOMERASES; BREAST-CANCER; EXPRESSION; ALPHA; INHIBITORS;
   CHEMOTHERAPY; MECHANISM; LINES; HEAD; P53
AB Purpose: Topoisomerases (types: I/IIa-b/IIIa-b) represent a super-family of nucleic enzymes involved in the DNA replication, transcription, recombination, and also chromosome topological formation. Topoisomerase's I (Topo I- gene location: 20q12) aberrant expression is a frequent genetic event in a variety of solid malignancies. Topo I inhibition promotes cell death due to DNA damage and for this reason it is a target for specific targeted chemotherapy (camptothecin, topotecan, irinotecan). Our aim was to investigate the role of abnormal Topo I protein expression in laryngeal squamous cell carcinomas (LSCC) in which there are very limited data regarding the influence of the marker.
   Methods: Using tissue microarray (TMA) technology, 50 formalin-fixed, paraffin-embedded primary laryngeal SCCs were cored and re-embedded into one recipient block. Immunohistochemistry was performed using anti- Topo I antibody. Digital image analysis was also implemented for evaluating objectively the protein expression levels on the corresponding stained nuclei.
   Results: Topo I protein overexpression (moderate to high staining intensity values) was observed in 32/50 (64%) tissue cores, whereas low expression rates were detected in 18/50 (36%) cases. Topo I overall expression was strongly associated with the differentiation grade of the examined tumors (p=0.021). No other statistical correlations were identified.
   Conclusions: Topo I overexpression is observed in a significant subset of LSCCs affecting the level of differentiation in them. Additional molecular studies focused on the mechanism of Topo I gene/protein deregulation (i.e. amplification, abnormal epigenetic promoter methylation, mRNA aberrant expression) are necessary discriminating the eligible patients for applying specific chemotherapeutic strategies based on anti-Topo I agents.
C1 [Papadas, Theodoros A.; Mastronikolis, Nicholas S.] Univ Patras, Sch Med, Dept Otorhinolaryngol Head & Neck Surg, Patras, Greece.
   [Tsiambas, Evangelos] 401 GAH, Dept Immunohistochem & Mol Biol, Athens, Greece.
   [Karameris, Andreas] 417 VA Hosp, Dept Pathol, Athens, Greece.
   [Mastronikolis, Stylianos N.] Univ Crete, Sch Hlth Sci, Dept Med, Iraklion, Greece.
   [Papadas, Athanasios T.] Univ Wisconsin, Sch Med, Dept Hematol & Oncol, Madison, WI USA.
   [Fotiades, Panagiotis P.] Leicester Gen Hosp, Dept Surg, Leicester, Leics, England.
   [Ragos, Vasileios] Univ Ioannina, Sch Hlth Sci, Dept Maxillofacial Surg, Ioannina, Greece.
C3 University of Patras; University of Crete; University of Wisconsin
   System; University of Wisconsin Madison; University Hospitals of
   Leicester NHS Trust; Leicester General Hospital; University of Ioannina
RP Tsiambas, E (通讯作者)，17 Patriarchou Grigoriou E St, Athens 15341, Greece.
EM tsiambasecyto@yahoo.gr
RI Mastronikolis, Stylianos/ABE-4399-2020; Ragos, Vasileios/KBQ-9330-2024
OI Ragos, Vasileios/0000-0002-0523-0476
CR Bar JK, 2012, ADV CLIN EXP MED, V21, P35
   Champoux JJ, 2001, ANNU REV BIOCHEM, V70, P369, DOI 10.1146/annurev.biochem.70.1.369
   Chen GL, 2016, SCI REP-UK, V6, DOI 10.1038/srep38284
   D'Alfonso A, 2016, J MOL BIOL, V428, P4905, DOI 10.1016/j.jmb.2016.10.032
   Durand-Faucher K, 2005, CLIN CHEM LAB MED, V43, P707, DOI 10.1515/CCLM.2005.120
   Gilbert DC, 2012, BRIT J CANCER, V106, P18, DOI 10.1038/bjc.2011.498
   Hanagiri Takeshi, 2011, Journal of UOEH, V33, P205
   Horibe Y, 2000, APMIS, V108, P689, DOI 10.1034/j.1600-0463.2000.d01-16.x
   HSIANG YH, 1988, CANCER RES, V48, P1722
   Huang SYN, 2017, EMBO J, V36, P361, DOI 10.15252/embj.201592426
   Kanazawa T, 2004, INT J ONCOL, V25, P729
   Kim YK, 2015, ONCOL LETT, V9, P136, DOI 10.3892/ol.2014.2648
   Koopman M, 2009, EJC SUPPL, V7, P321, DOI 10.1016/S1359-6349(09)71098-5
   Lu BH, 2016, THORAC CANCER, V7, P486, DOI 10.1111/1759-7714.12359
   Mouawad F, 2014, ORAL ONCOL, V50, P113, DOI 10.1016/j.oraloncology.2013.11.003
   Nagaraja V, 2016, DRUG DISCOV TODAY, V20, P1
   Nielsen KV, 2011, JNCI-J NATL CANCER I, V103, P352, DOI 10.1093/jnci/djq528
   Oliveira-Costa JP, 2012, J ORAL PATHOL MED, V41, P762, DOI 10.1111/j.1600-0714.2012.01174.x
   Orlando L, 2008, BREAST, V17, P506, DOI 10.1016/j.breast.2008.03.007
   Pommier Y, 2009, CHEM REV, V109, P2894, DOI 10.1021/cr900097c
   Schoeffler AJ, 2008, Q REV BIOPHYS, V41, P41, DOI 10.1017/S003358350800468X
   Shvero J, 2008, AM J CLIN PATHOL, V130, P934, DOI 10.1309/AJCPROG61USKCBEI
   Smith DH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060613
   Surowiak P, 2006, HISTOL HISTOPATHOL, V21, P713, DOI 10.14670/HH-21.713
   Tamura N, 2012, ANTICANCER RES, V32, P4823
   Tournigand C, 2008, BRIT J CANCER, V98, P1910
   Valkov NI, 2003, DRUG RESIST UPDATE, V6, P27, DOI 10.1016/S1368-7646(02)00143-7
   Wang JC, 2002, NAT REV MOL CELL BIO, V3, P430, DOI 10.1038/nrm831
NR 28
TC 0
Z9 0
U1 0
U2 1
PU IMPRIMATUR PUBLICATIONS
PI ATHENS
PA 30 DEM POLIORKETES ST, ATHENS, 136 76, GREECE
SN 1107-0625
EI 2241-6293
J9 J BUON
JI J. BUON
PD MAY-JUN
PY 2017
VL 22
IS 3
BP 771
EP 776
PG 6
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA FB2GD
UT WOS:000405961400031
PM 28730788
DA 2025-01-12
ER

PT J
AU Wang, HH
   Yan, WL
   Zhang, SM
   Gu, Y
   Wang, YH
   Wei, YJ
   Liu, HB
   Wang, F
   Wu, Q
   Zhang, Y
AF Wang, Huihan
   Yan, Weili
   Zhang, Shumei
   Gu, Yue
   Wang, Yihan
   Wei, Yanjun
   Liu, Hongbo
   Wang, Fang
   Wu, Qiong
   Zhang, Yan
TI Survival differences of CIMP subtypes integrated with CNA information in
   human breast cancer
SO ONCOTARGET
LA English
DT Article
DE CpG island methylator phenotype ( CIMP); breast cancer; copy number
   alteration (CNA); prognosis; biomarker
ID ISLAND METHYLATOR PHENOTYPE; COMPARATIVE GENOMIC HYBRIDIZATION;
   MICROSATELLITE INSTABILITY; COLORECTAL-CANCER; BRAF MUTATION;
   CELL-LINES; CARCINOMA; TUMORS; AMPLIFICATION; EPIGENOTYPES
AB CpG island methylator phenotype of breast cancer is associated with widespread aberrant methylation at specified CpG islands and distinct patient outcomes. However, the influence of copy number contributing to the prognosis of tumors with different CpG island methylator phenotypes is still unclear. We analyzed both genetic (copy number) and epigenetic alterations in 765 breast cancers from The Cancer Genome Atlas data portal and got a panel of 15 biomarkers for copy number and methylation status evaluation. The gene panel identified two groups corresponding to distinct copy number profiles. In status of mere-loss copy number, patients were faced with a greater risk if they presented a higher CpG islands methylation pattern in biomarker panels. But for samples presenting merely-gained copy number, higher methylation level of CpG islands was associated with improved viability. In all, the integration of copy number alteration and methylation information enhanced the classification power on prognosis. Moreover, we found the molecular subtypes of breast cancer presented different distributions in two CpG island methylation phenotypes. Generated by the same set of human methylation 450K data, additional copy number information could provide insights into survival prediction of cancers with less heterogeneity and might help to determine the biomarkers for diagnosis and treatment for breast cancer patients in a more personalized approach.
C1 [Wang, Huihan; Zhang, Shumei; Gu, Yue; Wang, Yihan; Wei, Yanjun; Liu, Hongbo; Wang, Fang; Zhang, Yan] Harbin Med Univ, Coll Bioinformat Sci & Technol, Harbin 150081, Peoples R China.
   [Yan, Weili; Wu, Qiong] Harbin Inst Technol, State Key Lab Urban Water Resource & Environm, Sch Life Sci & Technol, Harbin 150001, Peoples R China.
C3 Harbin Medical University; Harbin Institute of Technology
RP Zhang, Y (通讯作者)，Harbin Med Univ, Coll Bioinformat Sci & Technol, Harbin 150081, Peoples R China.
EM tyozhang@ems.hrbmu.edu.cn
RI Wang, Yutao/P-4878-2019; wu, qiong/GRY-4672-2022; Gu, Yue/HOA-4958-2023;
   wang, yihan/HTN-8802-2023; Liu, Hongbo/M-2162-2015
OI Wang, Yihan/0000-0002-1163-4610; Liu, Hongbo/0000-0002-0733-8616
FU National Natural Science Foundation of China [81573021]
FX We are grateful to Yan Huang, Libo Wang for critical reading of this
   manuscript; Bin Zhang for modifying the pictures; Xinyu Wang for the
   technical help. And this work was funded by the National Natural Science
   Foundation of China [grant numbers 81573021].
CR Arai E, 2012, CARCINOGENESIS, V33, P1487, DOI 10.1093/carcin/bgs177
   Bediaga NG, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2721
   Bibikova M, 2011, GENOMICS, V98, P288, DOI 10.1016/j.ygeno.2011.07.007
   Chen DY, 2011, NATURE, V469, P491, DOI 10.1038/nature09667
   Conway K, 2014, BREAST CANCER RES, V16, DOI 10.1186/s13058-014-0450-6
   Courjal F, 1997, CANCER RES, V57, P4368
   Esteller M, 2002, ONCOGENE, V21, P5427, DOI 10.1038/sj.onc.1205600
   Fang F, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3001875
   Feber A, 2014, GENOME BIOL, V15, DOI 10.1186/gb-2014-15-2-r30
   Ferlay J., 2013, GLOBOCAN 2012 CANC I
   Forozan F, 2000, CANCER RES, V60, P4519
   Hicks SC, 2015, GENOME BIOL, V16, DOI 10.1186/s13059-015-0679-0
   Hughes LAE, 2013, CANCER RES, V73, P5858, DOI 10.1158/0008-5472.CAN-12-4306
   Johnson WE, 2007, BIOSTATISTICS, V8, P118, DOI 10.1093/biostatistics/kxj037
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Kampstra P., 2015, Journal of Statistical Software, V28, P1, DOI DOI 10.18637/JSS.V028.C01
   Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412
   Krijgsman O, 2012, CELL ONCOL, V36
   Kristensen VN, 2012, P NATL ACAD SCI USA, V109, P2802, DOI 10.1073/pnas.1108781108
   Lee C, 2010, EXPERT REV MOL MED, V12, DOI 10.1017/S1462399410001390
   Li CI, 2005, BRIT J CANCER, V93, P1046, DOI 10.1038/sj.bjc.6602787
   MacDonald JR, 2014, NUCLEIC ACIDS RES, V42, pD986, DOI 10.1093/nar/gkt958
   Menter DG, 2010, CLIN CANCER RES, V16, P1384, DOI 10.1158/1078-0432.CCR-09-0788
   Morris TJ, 2014, BIOINFORMATICS, V30, P428, DOI 10.1093/bioinformatics/btt684
   Neuhausen SL, 2011, CANCER EPIDEM BIOMAR, V20, P1690, DOI 10.1158/1055-9965.EPI-10-1336
   Nishizaki T, 1997, INT J CANCER, V74, P513, DOI 10.1002/(SICI)1097-0215(19971021)74:5<513::AID-IJC6>3.3.CO;2-X
   Noushmehr H, 2010, CANCER CELL, V17, P510, DOI 10.1016/j.ccr.2010.03.017
   Ogino S, 2009, GUT, V58, P90, DOI 10.1136/gut.2008.155473
   Roessler J, 2015, EPIGENOMICS-UK, V7, P187, DOI [10.2217/EPI.14.74, 10.2217/epi.14.74]
   Roylance R, 2006, ONCOGENE, V25, P6544, DOI 10.1038/sj.onc.1209659
   Sánchez-Vega F, 2015, EPIGENET CHROMATIN, V8, DOI 10.1186/s13072-015-0007-7
   SMOLICH BD, 1993, MOL BIOL CELL, V4, P1267, DOI 10.1091/mbc.4.12.1267
   Stirzaker C, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms6899
   Suzuki M, 2006, CANCER-AM CANCER SOC, V106, P2200, DOI 10.1002/cncr.21853
   Szyf M, 2012, GENOME MED, V4, DOI 10.1186/gm325
   Tabarestani S, 2014, CELL ONCOL, V37, P107, DOI 10.1007/s13402-013-0165-1
   Takagi K, 2014, CANCER SCI, V105, P600, DOI 10.1111/cas.12382
   Teschendorff AE, 2011, BIOINFORMATICS, V27, P1496, DOI 10.1093/bioinformatics/btr171
   Weisenberger DJ, 2006, NAT GENET, V38, P787, DOI 10.1038/ng1834
   Yagi K, 2010, CLIN CANCER RES, V16, P21, DOI 10.1158/1078-0432.CCR-09-2006
   Yoon AR, 2015, CANCER BIOL THER, V16, P430, DOI 10.1080/15384047.2014.1003004
NR 41
TC 4
Z9 4
U1 0
U2 3
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD JUL 25
PY 2017
VL 8
IS 30
BP 48807
EP 48819
DI 10.18632/oncotarget.16178
PG 13
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA FB6DV
UT WOS:000406232400025
PM 28415743
OA Green Published, gold, Green Submitted
DA 2025-01-12
ER

PT J
AU Toderow, V
   Rahmeh, M
   Hofmann, S
   Kirn, V
   Mahner, S
   Jeschke, U
   von Schönfeldt, V
AF Toderow, Vanessa
   Rahmeh, Martina
   Hofmann, Simone
   Kirn, Verena
   Mahner, Sven
   Jeschke, Udo
   von Schoenfeldt, Viktoria
TI Promotor analysis of ESR1 in endometrial cancer cell lines, endometrial
   and endometriotic tissue
SO ARCHIVES OF GYNECOLOGY AND OBSTETRICS
LA English
DT Article
DE Estrogen receptor alpha (ER alpha); Real-time methylation-specific PCR
   (rt-MSP); ESR1 promotor; Endometrium; Endometriosis
ID ESTROGEN-RECEPTOR-ALPHA; CPG-ISLAND METHYLATION; PROGESTERONE-RECEPTOR;
   BREAST-CANCER; GENE-EXPRESSION; RETINOIC ACID; LUTEAL-PHASE; TAMOXIFEN;
   ER; HYPERMETHYLATION
AB The nuclear hormone receptor estrogen receptor alpha (ER alpha) is pivotal for numerous processes in the cell. As a transcription factor, it regulates eukaryotic gene expression and affects cellular proliferation and differentiation in target tissues. Moreover, ER alpha is known for its influence on various gynecological diseases and carcinogenesis. Since its expression is often altered in diseased tissues and this alteration was found to be caused by hypermethylation of the ESR1 promotor region in cancer, including breast and colorectal cancer, the aim of this study is to elucidate if the expression of ER alpha is also regulated epigenetically in endometriosis and endometrial cancer.
   Using real-time methylation-specific PCR (rt-MSP), we examined endometrial and endometriotic tissues as well as five endometrial cancer cell lines and compared the methylation status with the actual expression of ER alpha.
   The results of our study indicate that, though its expression is altered in endometrial and endometriotic tissue, ER alpha is not regulated by methylation of the promotor region in endometriosis. In contrast, three of the five endometrial cancer cell lines are methylated in the promotor region of ESR1.
   Thus, further investigation of the connection between ER alpha and endometrial cancer will be the next step.
C1 [Toderow, Vanessa; Rahmeh, Martina; Hofmann, Simone; Mahner, Sven; Jeschke, Udo; von Schoenfeldt, Viktoria] Klinikum Univ Munchen, Klin & Poliklin Frauenheilkunde & Geburtshilfe, Munich, Germany.
   [Kirn, Verena] Univ Klinikum Koln, Klin & Poliklin Frauenheilkunde, Cologne, Germany.
   [Jeschke, Udo] Ludwig Maximilians Univ Munchen, Dept Obstet & Gynecol, Maistr 11, D-80377 Munich, Germany.
C3 University of Munich; University of Cologne; University of Munich
RP Jeschke, U (通讯作者)，Klinikum Univ Munchen, Klin & Poliklin Frauenheilkunde & Geburtshilfe, Munich, Germany.
EM udo.jeschke@med.uni-muenchen.de
RI Jeschke, Udo/A-6643-2009
OI Jeschke, Udo/0000-0003-2623-3235
FU Medical Faculty of the Ludwig Maximilians University of Munich
FX This study was funded by the Medical Faculty of the Ludwig Maximilians
   University of Munich.
CR Ali SH, 2004, GYNECOL ONCOL, V95, P637, DOI 10.1016/j.ygyno.2004.08.034
   BERGER U, 1991, CANCER RES, V51, P239
   Bloski Terri, 2008, Nurs Womens Health, V12, P382, DOI 10.1111/j.1751-486X.2008.00362.x
   BOPP B, 1993, J REPROD MED, V38, P348
   Cunha JS, 2003, J ASSIST REPROD GEN, V20, P117, DOI 10.1023/A:1022625106489
   Eads CA, 2000, CANCER RES, V60, P5021
   Eeckhoute J, 2007, CANCER RES, V67, P6477, DOI 10.1158/0008-5472.CAN-07-0746
   Elledge RM, 2000, INT J CANCER, V89, P111, DOI 10.1002/(SICI)1097-0215(20000320)89:2<111::AID-IJC2>3.0.CO;2-W
   Engemise SL, 2011, EUR J OBSTET GYN R B, V157, P101, DOI 10.1016/j.ejogrb.2011.02.013
   Esteller M, 2001, CANCER RES, V61, P3225
   Harder J, 2009, BRIT J CANCER, V100, P360, DOI 10.1038/sj.bjc.6604859
   Holmes KA, 2008, CANCER RES, V68, P7380, DOI 10.1158/0008-5472.CAN-08-0133
   Holst F, 2016, SCI REP-UK, V6, DOI 10.1038/srep25521
   Hua SJ, 2009, CELL, V137, P1259, DOI 10.1016/j.cell.2009.04.043
   Hurtado A, 2008, NATURE, V456, P663, DOI 10.1038/nature07483
   Issa JPJ, 1996, CANCER RES, V56, P973
   JEMAL A, 2011, CA-CANCER J CLIN, V61, P69, DOI DOI 10.3322/CAAC.20107
   Jongen V, 2009, GYNECOL ONCOL, V112, P537, DOI 10.1016/j.ygyno.2008.10.032
   Kanwal R, 2012, CLIN GENET, V81, P303, DOI 10.1111/j.1399-0004.2011.01809.x
   Kokka F, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007926.pub2
   Lapidus RG, 1998, CANCER RES, V58, P2515
   Lapidus RG, 1996, CLIN CANCER RES, V2, P805
   Lapidus RG, 1998, J MAMMARY GLAND BIOL, V3, P85, DOI 10.1023/A:1018778403001
   Li QY, 2013, CELL, V152, P633, DOI 10.1016/j.cell.2012.12.034
   Liu X, 2015, INT J ENDOCRINOL, V2015, DOI 10.1155/2015/949085
   Matorras R, 1996, ACTA OBSTET GYN SCAN, V75, P826, DOI 10.3109/00016349609054711
   Moeloek F A, 1993, Asia Oceania J Obstet Gynaecol, V19, P171
   Pandya KJ, 2001, AM J CLIN ONCOL-CANC, V24, P43, DOI 10.1097/00000421-200102000-00007
   RENDINA GM, 1984, EUR J OBSTET GYN R B, V17, P285, DOI 10.1016/0028-2243(84)90071-6
   Rogers PAW, 2009, REPROD SCI, V16, P335, DOI 10.1177/1933719108330568
   Ross-Innes CS, 2010, GENE DEV, V24, P171, DOI 10.1101/gad.552910
   Thigpen T, 2001, J CLIN ONCOL, V19, P364, DOI 10.1200/JCO.2001.19.2.364
   Yue W, 2013, STEROIDS, V78, P161, DOI 10.1016/j.steroids.2012.11.001
NR 33
TC 6
Z9 9
U1 0
U2 7
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0932-0067
EI 1432-0711
J9 ARCH GYNECOL OBSTET
JI Arch. Gynecol. Obstet.
PD AUG
PY 2017
VL 296
IS 2
BP 269
EP 276
DI 10.1007/s00404-017-4405-x
PG 8
WC Obstetrics & Gynecology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Obstetrics & Gynecology
GA FA8BZ
UT WOS:000405672500017
PM 28578502
DA 2025-01-12
ER

PT J
AU Jezkova, E
   Zubor, P
   Kajo, K
   Grendar, M
   Dokus, K
   Adamkov, M
   Lasabova, Z
   Plank, L
   Danko, J
AF Jezkova, Eva
   Zubor, Pavol
   Kajo, Karol
   Grendar, Marian
   Dokus, Karol
   Adamkov, Marian
   Lasabova, Zora
   Plank, Lukas
   Danko, Jan
TI Impact of <i>RASSF1A</i> gene methylation on the metastatic axillary
   nodal status in breast cancer patients
SO ONCOLOGY LETTERS
LA English
DT Article
DE methylation; lymph node status; RASSF1A; methylation-specific polymerase
   chain reaction
ID SENTINEL LYMPH-NODE; TUMOR-SUPPRESSOR GENES; PRACTICE GUIDELINE UPDATE;
   TERM-FOLLOW-UP; PROMOTER HYPERMETHYLATION; DNA METHYLATION; AMERICAN
   SOCIETY; MS-HRM; CARCINOMA; MICROMETASTASES
AB Hypermethylation of CpG islands is a hallmark of cancer and occurs at an early stage in breast tumorigenesis. To gain insight into the epigenetic switches, that may promote and/or contribute to the initial neoplastic events during breast carcinogenesis, the present study focused on the DNA methylation profile of invasive breast carcinoma. The aim of the study was to evaluate the prognostic significance of Ras association domain family 1 isoform A (RASSF1A) promoter methylation status in operable breast cancer, and to analyze the utility of this biomarker regarding its association with metastatic and nonmetastatic axillary nodal status. For this purpose, formalin-fixed, paraffin-embedded tissue specimens from 116 breast cancer patients with known axillary nodal status were subjected to assessment of RASSF1A promoter methylation status by methylation-specific polymerase chain reaction (MSP) and methylation-sensitive high-resolution melting assay, and the results were subsequently validated by bisulfite sequencing. A multinomial logistic regression model was used to model the dependence of distinct levels of methylation status of the RASSFIA promoter on the nodal status. Promoter region CpG hypermethylation was identified by MSP in 97 (83.6%) of 116 primary breast tumors, while hypermethylation of RASSF1A was confirmed by MS-HRM in 107 (92.2%) of 116 cases of breast cancer. Based on the results of the multinomial logistic regression model, there was no significant difference between the frequency of RASSF1A promoter methylation and axillary lymph node status of patients in general. However, upon adjustment of pN stage, an association was identified between pN0 lymph node-negative status (without axillary metastases) and percentage of RASSFIA methylation in two groups of heterogeneous methylated alleles with <= 50% methylated (P<0.05) and >50% methylated alleles (P<0.0001). If a patients' nodal status changes from pN- to pN+ then the risk of having >50% methylated alleles increases by 7%. The present study revealed a specific phenomenon, suggesting that the presence of heterogeneous methylated alleles in the RASSF1A gene is significantly associated with lymph node-negative status in breast cancer patients. Furthermore, greater significance with negative axillary nodal status was observed with a higher level of heterogeneous methylated alleles in the RASSF1A gene.
C1 [Jezkova, Eva; Zubor, Pavol; Lasabova, Zora] Comenius Univ, Jessenius Fac Med, Biomed Ctr Martin, Dept Oncol, Bratislava, Slovakia.
   [Jezkova, Eva; Adamkov, Marian] Comenius Univ, Jessenius Fac Med, Dept Histol & Embryol, Bratislava, Slovakia.
   [Zubor, Pavol; Dokus, Karol; Danko, Jan] Martin Univ Hosp, Jessenius Fac Med, Dept Obstet & Gynaecol, Kollarova 4248-2, Martin 03601, Slovakia.
   [Kajo, Karol] St Elizabeth Canc Inst Hosp, Bratislava 81250, Slovakia.
   [Grendar, Marian] Comenius Univ, Jessenius Fac Med, Biomed Ctr Martin, Bioinformat Unit, Bratislava, Slovakia.
   [Plank, Lukas] Martin Univ Hosp, Jessenius Fac Med, Dept Pathol Anat, Martin 03601, Slovakia.
C3 Comenius University Bratislava; Comenius University Bratislava; Comenius
   University Bratislava; Comenius University Bratislava; Comenius
   University Bratislava
RP Zubor, P (通讯作者)，Martin Univ Hosp, Jessenius Fac Med, Dept Obstet & Gynaecol, Kollarova 4248-2, Martin 03601, Slovakia.
EM zubor@jfmed.uniba.sk
RI Zubor, Pavol/X-8191-2018; Grendar, Marian/R-5424-2019; Adamkov,
   Marian/X-8894-2018; Kajo, Karol/HJZ-4538-2023; Dokus,
   Karol/KBB-9426-2024; Lasabova, Zora/X-8254-2018; Grendar,
   Marian/X-6032-2018
OI Zubor, Pavol/0009-0003-1423-5556; Lasabova, Zora/0000-0003-2530-3991;
   Grendar, Marian/0000-0002-6712-3457; Kajo, Karol/0000-0002-8178-1093
FU Slovak Research and Development Agency [APVV-14-0815]; Scientific Grant
   Agency of the Ministry of Education, Science, Research and Sport of the
   Slovak Republic; Slovak Academy of Sciences [1/0243/12]; Comenius
   University in Bratislava [UK/156/2010]
FX The present study was supported by the Slovak Research and Development
   Agency (contract no. APVV-14-0815), the Scientific Grant Agency of the
   Ministry of Education, Science, Research and Sport of the Slovak
   Republic and the Slovak Academy of Sciences (grant no. 1/0243/12) and
   the Comenius University in Bratislava (grant no. UK/156/2010).
CR Abu Ghazaleh H, 2010, APOPTOSIS, V15, P117, DOI 10.1007/s10495-009-0451-6
   Agathanggelou A, 2005, CANCER RES, V65, P3497, DOI 10.1158/0008-5472.CAN-04-4088
   Agathanggelou A, 2001, ONCOGENE, V20, P1509, DOI 10.1038/sj.onc.1204175
   Alvarez C, 2013, MOL CARCINOGEN, V52, P475, DOI 10.1002/mc.21881
   [Anonymous], 2019, R LANG ENV STAT COMP
   Byler S, 2014, ANTICANCER RES, V34, P1071
   Chirappapha P, 2012, GLAND SURG, V1, P151, DOI 10.3978/j.issn.2227-684X.2012.10.09
   Co M, 2016, CLIN BREAST CANC
   Cul'bova M, 2011, Ceska Gynekol, V76, P274
   Dallol A, 2004, CANCER RES, V64, P4112, DOI 10.1158/0008-5472.CAN-04-0267
   Dammann R, 2001, CANCER RES, V61, P3105
   Dammann R, 2005, HISTOL HISTOPATHOL, V20, P645, DOI 10.14670/HH-20.645
   de Boer M, 2010, JNCI-J NATL CANCER I, V102, P410, DOI 10.1093/jnci/djq008
   Dobrovic A, 2016, MOL PATHOLOGY CANC R, P261
   Duffy MJ, 2015, CLIN CHEM, V61, P809, DOI 10.1373/clinchem.2015.239863
   Edge SB, 2010, ANN SURG ONCOL, V17, P1471, DOI 10.1245/s10434-010-0985-4
   ELSTON CW, 1991, HISTOPATHOLOGY, V19, P403, DOI 10.1111/j.1365-2559.1991.tb00229.x
   Fackler MJ, 2004, CANCER RES, V64, P4442, DOI 10.1158/0008-5472.CAN-03-3341
   Fackler MJ, 2003, INT J CANCER, V107, P970, DOI 10.1002/ijc.11508
   Feng WW, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-378
   Fiolka R, 2013, ONCOL REP, V30, P2878, DOI 10.3892/or.2013.2752
   FISHER ER, 1993, CANCER, V71, P2507, DOI 10.1002/1097-0142(19930415)71:8<2507::AID-CNCR2820710813>3.0.CO;2-0
   Fitzgibbons PL, 2000, ARCH PATHOL LAB MED, V124, P966
   Galimberti V, 2013, LANCET ONCOL, V14, P297, DOI 10.1016/S1470-2045(13)70035-4
   Gipponi M, 2016, BREAST, V30, P146, DOI 10.1016/j.breast.2016.09.009
   Giuliano AE, 2016, ANN SURG, V264, P413, DOI 10.1097/SLA.0000000000001863
   Gobardhan PD, 2009, ANN ONCOL, V20, P41, DOI 10.1093/annonc/mdn535
   Hammond MEH, 2010, J ONCOL PRACT, V6, P195, DOI 10.1200/JOP.777003
   Harlow SP, DIAGNOSIS STAGING RO
   Huang KT, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1676-0
   Jatoi I, 1999, J CLIN ONCOL, V17, P2334, DOI 10.1200/JCO.1999.17.8.2334
   Jones T, 2013, ANN SURG ONCOL, V20, P2866, DOI 10.1245/s10434-013-2994-6
   Karakatsanis A, 2016, BREAST CANCER RES TR, V157, P281, DOI 10.1007/s10549-016-3809-9
   Lakhani S.R., WHO Classification of Tumours of the Breast, VFourth
   Leidenius MHK, 2010, ANN SURG ONCOL, V17, P254, DOI 10.1245/s10434-009-0723-y
   Lester SC, 2016, DIAGNOSTIC PATHOLOGY
   Lewis CM, 2005, CLIN CANCER RES, V11, P166
   Luini A, 2002, ARCH SURG-CHICAGO, V137, P1157, DOI 10.1001/archsurg.137.10.1157
   Lyman GH, 2014, J CLIN ONCOL, V32, P1365, DOI 10.1200/JCO.2013.54.1177
   Marino ALF, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-739
   Müller HM, 2003, CANCER RES, V63, P7641
   Rauscher GH, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1777-9
   Rouzier R, 2002, J CLIN ONCOL, V20, P1304, DOI 10.1200/JCO.20.5.1304
   Schrijver WAME, 2015, BREAST CANCER RES TR, V151, P41, DOI 10.1007/s10549-015-3362-y
   Sequeiros T, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/283635
   Shivakumar L, 2002, MOL CELL BIOL, V22, P4309, DOI 10.1128/MCB.22.12.4309-4318.2002
   Soares EWS, 2014, WORLD J SURG ONCOL, V12, DOI 10.1186/1477-7819-12-67
   Swift-Scanlan T, 2011, CANCER BIOL THER, V11, P853, DOI 10.4161/cbt.11.10.15177
   Tao ZQ, 2015, CELL BIOCHEM BIOPHYS, V72, P333, DOI 10.1007/s12013-014-0459-6
   Upender S, 2009, DIAGN CYTOPATHOL, V37, P871, DOI 10.1002/dc.21120
   van Hoesel AQ, 2013, BRIT J CANCER, V108, P2033, DOI 10.1038/bjc.2013.136
   Veta M, 2014, IEEE T BIO-MED ENG, V61, P1400, DOI 10.1109/TBME.2014.2303852
   Wang Z, 2011, BREAST CANCER RES TR, V129, P675, DOI 10.1007/s10549-011-1665-1
   Weigel MT, 2010, ENDOCR-RELAT CANCER, V17, pR245, DOI 10.1677/ERC-10-0136
   Weigelt B, 2005, CANCER RES, V65, P9155, DOI 10.1158/0008-5472.CAN-05-2553
   Weigelt B, 2005, NAT REV CANCER, V5, P591, DOI 10.1038/nrc1670
   Weiss M, 2013, NUKLEARMED-NUCL MED, V52, P14, DOI 10.3413/Nukmed-0535-12-10
   Wen HY, 2017, CANCER-AM CANCER SOC, V123, P131, DOI 10.1002/cncr.30271
   Wojdacz TK, 2007, NUCLEIC ACIDS RES, V35, DOI 10.1093/nar/gkm013
   Wojdacz TK, 2014, BREAST CANCER RES, V16, DOI 10.1186/bcr3612
   Wojdacz TK, 2010, EXPERT REV MOL DIAGN, V10, P575, DOI 10.1586/ERM.10.46
   Wolff AC, 2014, ARCH PATHOL LAB MED, V138, P241, DOI 10.5858/arpa.2013-0953-SA
   Wolff AC, 2013, J CLIN ONCOL, V31, P3997, DOI [10.1200/JCO.2013.50.9984, 10.5858/arpa.2013-0953-SA]
   Yu M, 2013, SCIENCE, V339, P580, DOI 10.1126/science.1228522
NR 64
TC 6
Z9 7
U1 0
U2 5
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1792-1074
EI 1792-1082
J9 ONCOL LETT
JI Oncol. Lett.
PD JUL
PY 2017
VL 14
IS 1
BP 758
EP 766
DI 10.3892/ol.2017.6204
PN B
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA FA7RY
UT WOS:000405645800036
PM 28693231
OA Green Published, gold, Green Submitted
DA 2025-01-12
ER

PT J
AU Fan, LF
   Cao, XM
   Yan, HJ
   Wang, Q
   Tian, XX
   Zhang, L
   He, XY
   Borjihan, G
   Morigen
AF Fan, Lifei
   Cao, Xuemin
   Yan, Huijuan
   Wang, Qian
   Tian, Xiaoxia
   Zhang, Lan
   He, Xiaoyan
   Borjihan, Gereltu
   Morigen
TI The synthetic antihyperlipidemic drug potassium piperate selectively
   kills breast cancer cells through inhibiting G1-S-phase transition and
   inducing apoptosis
SO ONCOTARGET
LA English
DT Article
DE antihyperlipidemic drug; potassium piperate; G1-S-phase transition;
   apoptosis; breast cancer
ID ADJUVANT SYSTEMIC THERAPY; PROMOTER METHYLATION; DNA METHYLATION;
   RESISTANCE; HALLMARKS; CARCINOMA; PATHWAYS; STATINS; WOMEN; CYCLE
AB Piper longum L. is a well-known traditional antihyperlipidemic medicine in China, containing medicinal constituents of piperine, pipernonaline and piperlonguminine in its fruit. However, the antitumor properties of these constituents have not yet been studied. We found that potassium piperate (GBK), a derivative of piperine, inhibited proliferation of cancer cells. GBK selectively inhibited the G1-S-phase transition in breast cancer cells and the G1 arrest was correlated with induction of p27 expression, which is an inhibitor for cyclin-dependent kinases, and inhibition of cyclin A, cyclin E and cyclin B expression. Moreover, GBK treatment led to a downregulation of the mini-chromosome maintenance protein expression and induction of mitochondrial-dependent cell apoptosis in breast cancer cells. Our results also suggested that GBK might also inhibit cancer cell proliferation through epigenetic signaling pathways. A synergistic effect in inhibition of cancer cell proliferation was found when GBK was combined with chemotherapy medicines etoposide phosphate or cisplatin at middle or low doses in vitro. These results show that GBK is a novel potential anti-breast cancer drug that inhibits cell proliferation and promotes cell apoptosis.
C1 [Fan, Lifei; Cao, Xuemin; Yan, Huijuan; Wang, Qian; Tian, Xiaoxia; Zhang, Lan; He, Xiaoyan; Morigen] Inner Mongolia Univ, Sch Life Sci, Hohhot 010021, Peoples R China.
   [Borjihan, Gereltu] Inner Mongolia Univ, Inst Macromol Chem & Mongolian Med, Hohhot 010021, Peoples R China.
C3 Inner Mongolia University; Inner Mongolia University
RP Fan, LF; Morigen (通讯作者)，Inner Mongolia Univ, Sch Life Sci, Hohhot 010021, Peoples R China.
EM fanlifei95@gmail.com; morigenm@hotmail.com
FU Inner Mongolia Science & Technology Plan [201502096]; Program of
   Higher-level Talents of Inner Mongolia University [SPH-IMU:
   30105-125128]
FX This work was supported by grants from Inner Mongolia Science &
   Technology Plan to Morigen (201502096), Inner Mongolia Science &
   Technology Plan to Lifei Fan (2016), and Program of Higher-level Talents
   of Inner Mongolia University to Lifei Fan (SPH-IMU: 30105-125128).
CR Balasubramanian Bijal A, 2007, Cancer Control, V14, P63
   Bezerra DP, 2007, TOXICOL IN VITRO, V21, P1, DOI 10.1016/j.tiv.2006.07.007
   Bishayee A, 2016, SEMIN CANCER BIOL, V40-41, P1, DOI 10.1016/j.semcancer.2016.08.006
   Cai FF, 2016, ONCOTARGET, V7, P27499, DOI 10.18632/oncotarget.8355
   Cedar H, 2009, NAT REV GENET, V10, P295, DOI 10.1038/nrg2540
   Chen JC, 2016, ONCOTARGET, V7, P70276, DOI 10.18632/oncotarget.11839
   Chen WX, 2012, CANCER PREV RES, V5, P778, DOI 10.1158/1940-6207.CAPR-11-0551
   Chen X, 2016, TUMOR BIOL, V37, P12905, DOI 10.1007/s13277-016-5216-6
   Cragg GM, 2009, CHEM REV, V109, P3012, DOI 10.1021/cr900019j
   Dai XF, 2016, J CANCER, V7, P1281, DOI 10.7150/jca.13141
   Damiani RM, 2016, ARCH TOXICOL, V90, P2063, DOI 10.1007/s00204-016-1759-y
   Dinic J, 2015, CURR PHARM DESIGN, V21, P5589, DOI 10.2174/1381612821666151002113546
   Dong C, 2013, ONCOGENE, V32, P1351, DOI 10.1038/onc.2012.169
   Esteller M, 2007, NAT REV GENET, V8, P286, DOI 10.1038/nrg2005
   Fulford LG, 2006, HISTOPATHOLOGY, V49, P22, DOI 10.1111/j.1365-2559.2006.02453.x
   Gazzerro P, 2012, PHARMACOL REV, V64, P102, DOI 10.1124/pr.111.004994
   Gu GW, 2016, CURR OPIN PHARMACOL, V31, P97, DOI 10.1016/j.coph.2016.11.005
   Hainaut P, 2013, CURR OPIN ONCOL, V25, P50, DOI 10.1097/CCO.0b013e32835b651e
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   He JD, 2016, ONCOTARGET, V7, P84520, DOI 10.18632/oncotarget.11731
   Hennessy BT, 2009, CANCER RES, V69, P4116, DOI 10.1158/0008-5472.CAN-08-3441
   Hindler K, 2006, ONCOLOGIST, V11, P306, DOI 10.1634/theoncologist.11-3-306
   Jin Z, 2009, PHYTOTHER RES, V23, P1194, DOI 10.1002/ptr.2630
   Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682
   Lei M, 2005, CURR CANCER DRUG TAR, V5, P365, DOI 10.2174/1568009054629654
   Leone J, 2016, BREAST CANCER-TARGET, V8, P141, DOI 10.2147/BCTT.S110765
   Li J, 2017, BREAST CANCER-TOKYO, V24, P171, DOI 10.1007/s12282-016-0717-0
   Lim W, 2017, J CELL BIOCHEM, V118, P1118, DOI 10.1002/jcb.25729
   Mislang AR, 2015, CANCERS, V7, P1191, DOI 10.3390/cancers7030833
   Nazarian Ramin, 2014, Epigenomics, V6, P571, DOI 10.2217/epi.14.72
   Obiorah IE, 2014, STEROIDS, V90, P60, DOI 10.1016/j.steroids.2014.06.003
   Pennisi A, 2016, BREAST CANCER-BASIC, V10, P103, DOI 10.4137/BCBCR.S33163
   Pisanti S, 2014, PHARMACOL RES, V88, P84, DOI 10.1016/j.phrs.2014.06.013
   Radpour R, 2010, MODERN PATHOL, V23, P763, DOI 10.1038/modpathol.2009.195
   Raj L, 2011, NATURE, V475, P231, DOI 10.1038/nature10167
   Saini KS, 2011, BREAST, V20, pS20, DOI 10.1016/S0960-9776(11)70289-2
   Sandal T, 2002, ONCOLOGIST, V7, P73, DOI 10.1634/theoncologist.7-1-73
   Santamaria D, 2006, FRONT BIOSCI-LANDMRK, V11, P1164, DOI 10.2741/1871
   Sarnaizul E, 2013, BIOMED CHROMATOGR, V27, P821, DOI 10.1002/bmc.2879
   Sarnaizul E, 2013, PHYTOCHEM LETT, V6, P101, DOI 10.1016/j.phytol.2012.12.002
   Sebti SM, 2005, CANCER CELL, V7, P297, DOI 10.1016/j.ccr.2005.04.005
   Slieker RC, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005583
   Suzuki MM, 2008, NAT REV GENET, V9, P465, DOI 10.1038/nrg2341
   Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262
   Zhang F, 2011, MOL MED REP, V4, P1189, DOI 10.3892/mmr.2011.537
   Zhang L, 2015, SCI REP-UK, V5, DOI 10.1038/srep17869
   Zhang L, 2016, ONCOTARGETS THER, V9, P1351, DOI 10.2147/OTT.S98713
   Zhu WG, 2009, CANCER RES, V69, P4870, DOI 10.1158/0008-5472.CAN-08-4559
   Zou P, 2016, MOL CARCINOGEN, V55, P1073, DOI 10.1002/mc.22351
NR 49
TC 11
Z9 11
U1 0
U2 12
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD JUL 18
PY 2017
VL 8
IS 29
BP 47250
EP 47268
DI 10.18632/oncotarget.16872
PG 19
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA FA8KD
UT WOS:000405694000046
PM 28467790
OA Green Published, Green Submitted, gold
DA 2025-01-12
ER

PT J
AU Karki, K
   Hedrick, E
   Kasiappan, R
   Jin, UH
   Safe, S
AF Karki, Keshav
   Hedrick, Erik
   Kasiappan, Ravi
   Jin, Un-Ho
   Safe, Stephen
TI Piperlongumine Induces Reactive Oxygen Species (ROS)-Dependent
   Downregulation of Specificity Protein Transcription Factors
SO CANCER PREVENTION RESEARCH
LA English
DT Article
ID NF-KAPPA-B; COLON-CANCER CELL; TUMOR-GROWTH; BREAST-CANCER;
   PIPER-TUBERCULATUM; INHIBITION; MECHANISM; SP1; PROLIFERATION;
   ACTIVATION
AB Piperlongumine is a natural product found in the plant species Piper longum, and this compound exhibits potent anticancer activity in multiple tumor types and has been characterized as an inducer of reactive oxygen species (ROS). Treatment of Panc1 and L3.6pL pancreatic, A549 lung, 786-O kidney, and SKBR3 breast cancer cell lines with 5 to 15 mu mol/L piperlongumine inhibited cell proliferation and induced apoptosis and ROS, and these responses were attenuated after cotreatment with the antioxidant glutathione. Piperlongumine also downregulated expression of Sp1, Sp3, Sp4, and several pro-oncogenic Sp-regulated genes, including cyclin D1, survivin, cMyc, EGFR and hepatocyte growth factor receptor (cMet), and these responses were also attenuated after cotreatment with glutathione. Mechanistic studies in Panc1 cells showed that piperlongumine-induced ROS decreased expression of cMyc via an epigenetic pathway, and this resulted in downregulation of cMyc-regulated miRNAs miR-27a, miR-20a, and miR-17 and induction of the transcriptional repressors ZBTB10 and ZBTB4. These repressors target GC-rich Sp-binding sites to decrease transactivation. This pathway observed for piperlongumine in Panc1 cells has previously been reported for other ROS-inducing anticancer agents and shows that an important underlying mechanism of action of piperlongumine is due to downregulation of Sp1, Sp3, Sp4, and pro-oncogenic Sp-regulated genes. (C) 2017 AACR.
C1 [Karki, Keshav; Hedrick, Erik; Kasiappan, Ravi; Jin, Un-Ho; Safe, Stephen] Texas A&M Univ, Dept Vet Physiol & Pharmacol, College Stn, TX 77843 USA.
C3 Texas A&M University System; Texas A&M University College Station
RP Safe, S (通讯作者)，Texas A&M Univ, Dept Vet Physiol & Pharmacol, College Stn, TX 77843 USA.
EM ssafe@cvm.tamu.edu
RI Karki, Keshav/AAR-2421-2021
OI Kasiappan, Ravi/0000-0002-5351-9098
FU NIH [P30-ES023512]; Texas AgriLife Research; Sid Kyle endowment
FX The financial assistance of the NIH (P30-ES023512; to S. Safe), Texas
   AgriLife Research and Sid Kyle endowment is gratefully acknowledged.
CR Adams DJ, 2012, P NATL ACAD SCI USA, V109, P15115, DOI 10.1073/pnas.1212802109
   Bharadwaj U, 2015, ONCOGENE, V34, P1341, DOI 10.1038/onc.2014.72
   Chadalapaka G, 2012, CARCINOGENESIS, V33, P886, DOI 10.1093/carcin/bgs102
   Chintharlapalli S, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-371
   Felipe FCB, 2007, PHYTOMEDICINE, V14, P605, DOI 10.1016/j.phymed.2006.12.015
   Fontenele JB, 2009, J PHARM PHARMACOL, V61, P511, DOI [10.1211/jpp/61.04.0014, 10.1211/jpp.61.04.0014]
   Gandhy SU, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-564
   Ginzburg S, 2014, PROSTATE, V74, P177, DOI 10.1002/pros.22739
   Han JG, 2014, MOL CANCER THER, V13, P2422, DOI 10.1158/1535-7163.MCT-14-0171
   Han SS, 2013, LEUKEMIA RES, V37, P146, DOI 10.1016/j.leukres.2012.11.009
   Hedrick E, 2017, MOL CANCER THER, V16, P205, DOI 10.1158/1535-7163.MCT-16-0451
   Hedrick E, 2016, ONCOTARGET, V7, P22245, DOI 10.18632/oncotarget.7925
   Hedrick E, 2015, MOL CANCER THER, V14, P2143, DOI 10.1158/1535-7163.MCT-15-0148
   Hu J, 2016, ONCOTARGET, V7, P78557, DOI 10.18632/oncotarget.12447
   Jiang NY, 2008, CANCER EPIDEM BIOMAR, V17, P1648, DOI 10.1158/1055-9965.EPI-07-2791
   Jin HO, 2014, J CANCER RES CLIN, V140, P2039, DOI 10.1007/s00432-014-1777-1
   Jutooru I, 2014, MOL CELL BIOL, V34, P2382, DOI 10.1128/MCB.01602-13
   Jutooru I, 2010, J BIOL CHEM, V285, P25332, DOI 10.1074/jbc.M109.095240
   Jutooru I, 2010, MOL PHARMACOL, V78, P226, DOI 10.1124/mol.110.064451
   Jutooru I, 2010, EXP CELL RES, V316, P2174, DOI 10.1016/j.yexcr.2010.04.027
   Kasiappan R, 2016, J BIOL CHEM, V291, P27122, DOI 10.1074/jbc.M116.746339
   Kim K, 2012, ONCOGENE, V31, P1034, DOI 10.1038/onc.2011.296
   Lee SA, 2005, CHEM PHARM BULL, V53, P832, DOI 10.1248/cpb.53.832
   Liu JM, 2013, BIOCHEM BIOPH RES CO, V437, P87, DOI 10.1016/j.bbrc.2013.06.042
   O'Hagan HM, 2011, CANCER CELL, V20, P606, DOI 10.1016/j.ccr.2011.09.012
   Pathi SS, 2011, MOL CANCER RES, V9, P195, DOI 10.1158/1541-7786.MCR-10-0363
   Perez-Torrado R, 2006, BIOESSAYS, V28, P1194, DOI 10.1002/bies.20500
   Raj L, 2011, NATURE, V475, P231, DOI 10.1038/nature10167
   Randhawa H, 2013, TOXICOL IN VITRO, V27, P1626, DOI 10.1016/j.tiv.2013.04.006
   Roh JL, 2014, ONCOTARGET, V5, P9227, DOI 10.18632/oncotarget.2402
   Safe S, 2014, EXPERT OPIN THER TAR, V18, P759, DOI 10.1517/14728222.2014.914173
   Shrivastava S, 2014, APOPTOSIS, V19, P1148, DOI 10.1007/s10495-014-0991-2
   Son DJ, 2012, BIOCHEM BIOPH RES CO, V427, P349, DOI 10.1016/j.bbrc.2012.09.061
   Trachootham D, 2006, CANCER CELL, V10, P241, DOI 10.1016/j.ccr.2006.08.009
   Wang Y., 2013, J CHEM, V2013, P4, DOI DOI 10.1002/CPLU.201300102
   Yang YC, 2002, J AGR FOOD CHEM, V50, P3765, DOI 10.1021/jf011708f
   Zheng J, 2016, SCI REP-UK, V6, DOI 10.1038/srep26357
   Zou P, 2016, CANCER LETT, V375, P114, DOI 10.1016/j.canlet.2016.02.058
NR 38
TC 61
Z9 69
U1 1
U2 21
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1940-6207
EI 1940-6215
J9 CANCER PREV RES
JI Cancer Prev. Res.
PD AUG
PY 2017
VL 10
IS 8
BP 467
EP 477
DI 10.1158/1940-6207.CAPR-17-0053
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA FC3YU
UT WOS:000406776300006
PM 28673967
OA Green Accepted, Green Submitted, Bronze
DA 2025-01-12
ER

PT J
AU Kerr, J
   Anderson, C
   Lippman, SM
AF Kerr, Jacqueline
   Anderson, Cheryl
   Lippman, Scott M.
TI Physical activity, sedentary behaviour, diet, and cancer: an update and
   emerging new evidence
SO LANCET ONCOLOGY
LA English
DT Article
ID TELEVISION VIEWING TIME; NIH-AARP DIET; DOSE-RESPONSE METAANALYSIS;
   INVASIVE BREAST-CANCER; CAUSE-SPECIFIC MORTALITY; QUALITY-OF-LIFE;
   PROSTATE-CANCER; COLORECTAL-CANCER; MEDITERRANEAN DIET; VITAMIN-E
AB The lifestyle factors of physical activity, sedentary behaviour, and diet are increasingly being studied for their associations with cancer. Physical activity is inversely associated with and sedentary behaviour is positively (and independently) associated with an increased risk of more than ten types of cancer, including colorectal cancer (and advanced adenomas), endometrial cancers, and breast cancer. The most consistent dietary risk factor for premalignant and invasive breast cancer is alcohol, whether consumed during early or late adult life, even at low levels. Epidemiological studies show that the inclusion of wholegrain, fibre, fruits, and vegetables within diets are associated with reduced cancer risk, with diet during early life (age <8 years) having the strongest apparent association with cancer incidence. However, randomised controlled trials of diet-related factors have not yet shown any conclusive associations between diet and cancer incidence. Obesity is a key contributory factor associated with cancer risk and mortality, including in dose-response associations in endometrial and post-menopausal breast cancer, and in degree and duration of fatty liver disease-related hepatocellular carcinoma. Obesity produces an inflammatory state, characterised by macrophages clustered around enlarged hypertrophied, dead, and dying adipocytes, forming crown-like structures. Increased concentrations of aromatase and interleukin 6 in inflamed breast tissue and an increased number of macrophages, compared with healthy tissue, are also observed in women with normal body mass index, suggesting a metabolic obesity state. Emerging randomised controlled trials of physical activity and dietary factors and mechanistic studies of immunity, inflammation, extracellular matrix mechanics, epigenetic or transcriptional regulation, protein translation, circadian disruption, and interactions of the multibiome with lifestyle factors will be crucial to advance this field.
C1 [Kerr, Jacqueline; Anderson, Cheryl; Lippman, Scott M.] Univ Calif San Diego, Moores Canc Ctr, 3855 Hlth Sci Dr, La Jolla, CA 92093 USA.
   [Kerr, Jacqueline; Anderson, Cheryl] Univ Calif San Diego, Dept Family Med & Publ Hlth, La Jolla, CA 92093 USA.
   [Lippman, Scott M.] Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA.
C3 University of California System; University of California San Diego;
   University of California System; University of California San Diego;
   University of California System; University of California San Diego
RP Lippman, SM (通讯作者)，Univ Calif San Diego, Moores Canc Ctr, 3855 Hlth Sci Dr, La Jolla, CA 92093 USA.
EM slippman@ucsd.edu
RI KERR, JACQUELINE/H-2537-2016
FU NIH NCI [CA179977-04]; NHLBI [HL125405-03]; NIH NCI grant
   [P30CA023100-30]
FX JK is supported in part by NIH NCI (CA179977-04) and NHLBI (HL125405-03)
   grants. SML is supported in part by an NIH NCI grant (P30CA023100-30).
   The authors thank Leona Flores for editorial assistance with this
   article.
CR Afshin A, 2017, NEW ENGL J MED, V377, P13, DOI 10.1056/NEJMoa1614362
   [Anonymous], 2007, American Institute of Cancer Research. Food, nutrition
   [Anonymous], FOOD NUTR PHYS ACT P
   Arem H, 2015, J CLIN ONCOL, V33, P180, DOI 10.1200/JCO.2014.58.1355
   Arnold M, 2016, PLOS MED, V13, DOI 10.1371/journal.pmed.1002081
   Ashcraft KA, 2016, CANCER RES, V76, P4032, DOI 10.1158/0008-5472.CAN-16-0887
   Aune D, 2015, ANN ONCOL, V26, P1635, DOI 10.1093/annonc/mdv142
   Bae S, 2016, UBICOMP'16: PROCEEDINGS OF THE 2016 ACM INTERNATIONAL JOINT CONFERENCE ON PERVASIVE AND UBIQUITOUS COMPUTING, P616, DOI 10.1145/2971648.2971750
   Bakker MF, 2016, AM J CLIN NUTR, V103, P454, DOI 10.3945/ajcn.114.101659
   Ballard-Barbash R, 2012, JNCI-J NATL CANCER I, V104, P815, DOI 10.1093/jnci/djs207
   Bamia C, 2013, EUR J EPIDEMIOL, V28, P317, DOI 10.1007/s10654-013-9795-x
   Barrington WE, 2015, JAMA ONCOL, V1, P342, DOI 10.1001/jamaoncol.2015.0513
   Beavis AL, 2016, INT J WOMENS HEALTH, V8, P151, DOI 10.2147/IJWH.S88367
   Beresford SAA, 2006, JAMA-J AM MED ASSOC, V295, P643, DOI 10.1001/jama.295.6.643
   Berkey CS, 2010, PEDIATRICS, V125, pE1081, DOI 10.1542/peds.2009-2347
   Berkey CS, 2000, AM J EPIDEMIOL, V152, P446, DOI 10.1093/aje/152.5.446
   Beyaz S, 2016, NATURE, V531, P53, DOI 10.1038/nature17173
   Biswas A, 2015, ANN INTERN MED, V162, P123, DOI 10.7326/M14-1651
   Boeke CE, 2014, PEDIATRICS, V133, pE1292, DOI 10.1542/peds.2013-3844
   Borch KB, 2017, INT J CANCER, V140, P1809, DOI 10.1002/ijc.30610
   Borch KB, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1971-9
   Bosire C, 2013, AM J EPIDEMIOL, V177, P504, DOI 10.1093/aje/kws261
   Boyle T, 2012, JNCI-J NATL CANCER I, V104, P1548, DOI 10.1093/jnci/djs354
   Boyle T, 2011, AM J EPIDEMIOL, V173, P1183, DOI 10.1093/aje/kwq513
   Bradbury KE, 2014, AM J CLIN NUTR, V100, p394S, DOI 10.3945/ajcn.113.071357
   Bressa C, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0171352
   Brown JC, 2016, CANCER PREV RES, V9, P581, DOI 10.1158/1940-6207.CAPR-15-0408
   Buckland G, 2013, INT J CANCER, V132, P2918, DOI 10.1002/ijc.27958
   Buffart LM, 2014, J SCI MED SPORT, V17, P67, DOI 10.1016/j.jsams.2013.02.015
   Campbell PT, 2013, J CLIN ONCOL, V31, P876, DOI 10.1200/JCO.2012.45.9735
   Cao Y, 2015, BRIT J CANCER, V112, P934, DOI 10.1038/bjc.2014.655
   Cao Y, 2015, CANCER CAUSE CONTROL, V26, P1467, DOI 10.1007/s10552-015-0645-x
   Chan JM, 2016, CANCER EPIDEM BIOMAR, V25, P1050, DOI 10.1158/1055-9965.EPI-16-0104
   Chen JG, 2013, CANCER PREV RES, V6, P1038, DOI 10.1158/1940-6207.CAPR-13-0168
   Chen WY, 2011, JAMA-J AM MED ASSOC, V306, P1884, DOI 10.1001/jama.2011.1590
   Chlebowski RT, 2016, J CLIN ONCOL, V34, P4238, DOI 10.1200/JCO.2016.69.4026
   Clarke MA, 2017, EPIDEMIOL REV, V39, P11, DOI 10.1093/epirev/mxx004
   Cohen K, 2017, BREAST CANCER RES TR, V162, P571, DOI 10.1007/s10549-017-4152-5
   Cohen SS, 2013, CANCER PREV RES, V6, P566, DOI 10.1158/1940-6207.CAPR-13-0045
   Colditz GA, 2014, BREAST CANCER RES TR, V145, P567, DOI 10.1007/s10549-014-2993-8
   Cong YJ, 2014, BRIT J CANCER, V110, P817, DOI 10.1038/bjc.2013.709
   Cook MB, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0084805
   Dallal CM, 2012, BREAST CANCER RES TR, V134, P1279, DOI 10.1007/s10549-012-2129-y
   Deng T, 2016, ANNU REV PATHOL-MECH, V11, P421, DOI 10.1146/annurev-pathol-012615-044359
   Des Guetz G, 2013, GASTROENT RES PRACT, V2013, DOI 10.1155/2013/340851
   Desai MS, 2016, CELL, V167, P1339, DOI 10.1016/j.cell.2016.10.043
   Di Daniele N, 2017, ONCOTARGET, V8, P8947, DOI 10.18632/oncotarget.13553
   Dougan MM, 2015, INT J CANCER, V137, P625, DOI 10.1002/ijc.29427
   Dunstan DW, 2010, CIRCULATION, V121, P384, DOI 10.1161/CIRCULATIONAHA.109.894824
   Edwards MK, 2017, HEALTH PROMOT PERSPE, V7, P22, DOI 10.15171/hpp.2017.05
   Ehlers DK, 2018, PSYCHO-ONCOLOGY, V27, P687, DOI 10.1002/pon.4438
   Ekelund U, 2016, LANCET, V388, P1302, DOI 10.1016/S0140-6736(16)30370-1
   Eliassen AH, 2015, AM J CLIN NUTR, V101, P1197, DOI 10.3945/ajcn.114.105080
   Eliassen AH, 2012, JNCI-J NATL CANCER I, V104, P1905, DOI 10.1093/jnci/djs461
   Eliassen AH, 2010, ARCH INTERN MED, V170, P1758, DOI 10.1001/archinternmed.2010.363
   Emaus MJ, 2016, AM J CLIN NUTR, V103, P168, DOI 10.3945/ajcn.114.101436
   Emmons KM, 2017, NEW ENGL J MED, V376, P986, DOI 10.1056/NEJMsb1609101
   Engeset D, 2009, EUR J CANCER PREV, V18, P69, DOI 10.1097/CEJ.0b013e328305a091
   Ennour-Idrissi K, 2015, BREAST CANCER RES, V17, DOI 10.1186/s13058-015-0647-3
   Esper RM, 2015, CANCER PREV RES, V8, P1174, DOI 10.1158/1940-6207.CAPR-14-0334
   Farris MS, 2015, CANCER EPIDEM BIOMAR, V24, P1462, DOI 10.1158/1055-9965.EPI-15-0301
   Farvid MS, 2016, BMJ-BRIT MED J, V353, DOI 10.1136/bmj.i2343
   Farvid MS, 2016, PEDIATRICS, V137, DOI 10.1542/peds.2015-1226
   Fassier P, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000004629
   Fleshner NE, 2012, LANCET, V379, P1103, DOI 10.1016/S0140-6736(11)61619-X
   Ford ME, 2017, ADV CANCER RES, V133, P23, DOI 10.1016/bs.acr.2016.08.002
   Frazier AL, 2013, J ADOLESCENT HEALTH, V52, pS36, DOI 10.1016/j.jadohealth.2013.01.007
   Friedenreich CM, 2016, CLIN CANCER RES, V22, P4766, DOI 10.1158/1078-0432.CCR-16-0067
   Friedenreich CM, 2016, EUR UROL, V70, P576, DOI 10.1016/j.eururo.2015.12.032
   Fung TT, 2011, AM J EPIDEMIOL, V174, P652, DOI 10.1093/aje/kwr148
   Fung TT, 2010, AM J CLIN NUTR, V92, P1429, DOI 10.3945/ajcn.2010.29242
   Gaskin CJ, 2016, CANCER CAUSE CONTROL, V27, P1093, DOI 10.1007/s10552-016-0787-5
   Genkinger JM, 2015, ANN ONCOL, V26, P2257, DOI 10.1093/annonc/mdv355
   George SM, 2014, AM J EPIDEMIOL, V180, P616, DOI 10.1093/aje/kwu173
   Gomes AL, 2016, CANCER CELL, V30, P161, DOI 10.1016/j.ccell.2016.05.020
   Günther ALB, 2010, J NUTR, V140, P565, DOI 10.3945/jn.109.114934
   Haile RW, 2012, CANCER PREV RES, V5, P150, DOI 10.1158/1940-6207.CAPR-11-0447
   Hanley MP, 2016, CANCER PREV RES, V9, P812, DOI 10.1158/1940-6207.CAPR-16-0042
   Harmon BE, 2015, AM J CLIN NUTR, V101, P587, DOI 10.3945/ajcn.114.090688
   Heymsfield SB, 2017, NEW ENGL J MED, V376, P254, DOI 10.1056/NEJMra1514009
   Hibler E, 2015, CURR COLORECT CANC R, V11, P388, DOI 10.1007/s11888-015-0296-z
   Hildebrand JS, 2015, CANCER CAUSE CONTROL, V26, P1691, DOI 10.1007/s10552-015-0656-7
   Hotamisligil GS, 2017, NATURE, V542, P177, DOI 10.1038/nature21363
   Hrafnkelsdóttir SM, 2015, CANCER PREV RES, V8, P905, DOI 10.1158/1940-6207.CAPR-15-0035
   Itoh M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082163
   Iyengar NM, 2017, CANCER PREV RES, V10, P235, DOI 10.1158/1940-6207.CAPR-16-0314
   Jackson SE, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169173
   Jankowska MM, 2016, APPL CYBERGIS AGE CO, P147
   Johnsson A, 2017, ACTA ONCOL, V56, P75, DOI 10.1080/0284186X.2016.1262547
   Jung S, 2013, JNCI-J NATL CANCER I, V105, P219, DOI 10.1093/jnci/djs635
   Kang YE, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0154003
   Kantor ED, 2016, GUT, V65, P1289, DOI 10.1136/gutjnl-2014-309007
   Katzmarzyk PT, 2014, MED SCI SPORT EXER, V46, P940, DOI 10.1249/MSS.0000000000000198
   Keadle SK, 2015, AM J PREV MED, V49, P811, DOI 10.1016/j.amepre.2015.05.023
   Kelemen LE, 2006, CANCER EPIDEM BIOMAR, V15, P1054, DOI 10.1158/1055-9965.EPI-06-0077
   Kenfield SA, 2014, EUR UROL, V65, P887, DOI 10.1016/j.eururo.2013.08.009
   Kerr J, 2017, MED SCI SPORT EXER, V49, P617, DOI 10.1249/MSS.0000000000001124
   Kettner NM, 2016, CANCER CELL, V30, P909, DOI 10.1016/j.ccell.2016.10.007
   Kettner NM, 2015, CELL METAB, V22, P448, DOI 10.1016/j.cmet.2015.06.005
   Keum N, 2016, JAMA ONCOL, V2, P1146, DOI 10.1001/jamaoncol.2016.0740
   Key TJ, 2015, AM J CLIN NUTR, V102, P1142, DOI 10.3945/ajcn.115.114306
   Key TJ, 2009, AM J CLIN NUTR, V89, pS1620, DOI 10.3945/ajcn.2009.26736M
   Kim Y, 2013, INT J EPIDEMIOL, V42, P1040, DOI 10.1093/ije/dyt108
   Klein EA, 2011, JAMA-J AM MED ASSOC, V306, P1549, DOI 10.1001/jama.2011.1437
   Komaroff AL, 2017, JAMA-J AM MED ASSOC, V317, P355, DOI 10.1001/jama.2016.20099
   Kristal AR, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/djt456
   Kushi LH, 2012, CA-CANCER J CLIN, V62, P30, DOI 10.3322/caac.20140
   Kwa M, 2016, JNCI-J NATL CANCER I, V108, DOI 10.1093/jnci/djw029
   Kyu HH, 2016, BMJ-BRIT MED J, V354, DOI 10.1136/bmj.i3857
   Lahart IM, 2015, ACTA ONCOL, V54, P635, DOI 10.3109/0284186X.2014.998275
   Lakoski SG, 2015, JAMA ONCOL, V1, P231, DOI 10.1001/jamaoncol.2015.0226
   Lauby-Secretan B, 2016, NEW ENGL J MED, V375, P794, DOI 10.1056/NEJMsr1606602
   Lee IM, 2014, BRIT J SPORT MED, V48, P197, DOI 10.1136/bjsports-2013-093154
   Li TT, 2016, BRIT J SPORT MED, V50, DOI 10.1136/bjsports-2015-094927
   Liese AD, 2015, J NUTR, V145, P393, DOI 10.3945/jn.114.205336
   Ligibel JA, 2014, J CLIN ONCOL, V32, P3568, DOI 10.1200/JCO.2014.58.4680
   Lippman SM, 2009, JAMA-J AM MED ASSOC, V301, P39, DOI 10.1001/jama.2008.864
   Lippman SM, 2005, JNCI-J NATL CANCER I, V97, P94, DOI 10.1093/jnci/dji009
   Liu L, 2016, BRIT J SPORT MED, V50, DOI 10.1136/bjsports-2015-094728
   Liu Y, 2014, BREAST CANCER RES TR, V145, P461, DOI 10.1007/s10549-014-2953-3
   Liu Y, 2013, JNCI-J NATL CANCER I, V105, P1571, DOI 10.1093/jnci/djt213
   Loo TM, 2017, CANCER DISCOV, V7, P522, DOI 10.1158/2159-8290.CD-16-0932
   Loomba R, 2013, AM J EPIDEMIOL, V177, P333, DOI 10.1093/aje/kws252
   Lope V, 2017, GYNECOL ONCOL, V144, P577, DOI 10.1016/j.ygyno.2016.12.014
   Loprinzi PD, 2013, MAYO CLIN PROC, V88, P11, DOI 10.1016/j.mayocp.2012.10.012
   Lynch BM, 2014, CANCER EPIDEM BIOMAR, V23, P882, DOI 10.1158/1055-9965.EPI-13-0808
   Lynch BM, 2013, CANCER-AM CANCER SOC, V119, P1928, DOI 10.1002/cncr.28028
   Lynch BM, 2013, CANCER CAUSE CONTROL, V24, P1257, DOI 10.1007/s10552-013-0194-0
   Lynch BM, 2011, CANCER CAUSE CONTROL, V22, P1111, DOI 10.1007/s10552-011-9786-8
   Lynch BM, 2010, CANCER CAUSE CONTROL, V21, P283, DOI 10.1007/s10552-009-9460-6
   Lynch SV, 2016, NEW ENGL J MED, V375, P2369, DOI 10.1056/NEJMra1600266
   Lyssiotis CA, 2013, NATURE, V502, P181, DOI 10.1038/502181a
   Ma HY, 2016, BREAST CANCER RES, V18, DOI 10.1186/s13058-016-0723-3
   Magbanua MJM, 2014, CANCER CAUSE CONTROL, V25, P515, DOI 10.1007/s10552-014-0354-x
   Magkos F, 2016, CELL METAB, V23, P591, DOI 10.1016/j.cmet.2016.02.005
   Mai V, 2005, INT J EPIDEMIOL, V34, P54, DOI 10.1093/ije/dyh388
   Matthews CE, 2014, AM J EPIDEMIOL, V180, P394, DOI 10.1093/aje/kwu142
   Matthews CE, 2012, AM J CLIN NUTR, V95, P437, DOI 10.3945/ajcn.111.019620
   Mehta RS, 2017, JAMA ONCOL, V3, P921, DOI 10.1001/jamaoncol.2016.6374
   Molmenti CLS, 2014, CANCER CAUSE CONTROL, V25, P1387, DOI 10.1007/s10552-014-0444-9
   Moore SC, 2016, JAMA INTERN MED, V176, P816, DOI 10.1001/jamainternmed.2016.1548
   MORRIS HP, 1945, SCIENCE, V101, P457, DOI 10.1126/science.101.2627.457
   Mullooly M, 2017, BREAST CANCER RES, V19, DOI 10.1186/s13058-016-0791-4
   Namasivayam Vikneswaran, 2017, F1000Res, V6, P199, DOI 10.12688/f1000research.9795.1
   Neuhouser ML, 2015, JAMA ONCOL, V1, P611, DOI 10.1001/jamaoncol.2015.1546
   Neuschwander-Tetri BA, 2015, LANCET, V385, P956, DOI 10.1016/S0140-6736(14)61933-4
   Ng M, 2014, LANCET, V384, P766, DOI 10.1016/S0140-6736(14)60460-8
   Nimptsch K, 2016, RECENT RESULTS CANC, V208, P199, DOI 10.1007/978-3-319-42542-9_11
   Nimptsch K, 2014, INT J CANCER, V134, P2458, DOI 10.1002/ijc.28578
   Nimptsch K, 2013, AM J EPIDEMIOL, V178, P172, DOI 10.1093/aje/kwt099
   Nishimoto S, 2016, SCI ADV, V2, DOI 10.1126/sciadv.1501332
   Nomura SJO, 2016, CANCER CAUSE CONTROL, V27, P1239, DOI 10.1007/s10552-016-0803-9
   Nordström T, 2016, PROSTATE, V76, P339, DOI 10.1002/pros.23125
   Nunez C, 2017, CANCER EPIDEMIOL, V47, P56, DOI 10.1016/j.canep.2017.01.002
   O'Keefe SJD, 2016, NAT REV GASTRO HEPAT, V13, P691, DOI 10.1038/nrgastro.2016.165
   Olufsen MS, 2005, J APPL PHYSIOL, V99, P1523, DOI 10.1152/japplphysiol.00177.2005
   Otto SJ, 2015, SUPPORT CARE CANCER, V23, P1237, DOI 10.1007/s00520-014-2480-0
   Park SY, 2017, GASTROENTEROLOGY, V153, P386, DOI 10.1053/j.gastro.2017.04.004
   Parsons JK, 2017, BJU INT, DOI [10.111/bju.13890, DOI 10.111/bju.13890]
   Patel AV, 2015, CANCER EPIDEM BIOMAR, V24, P1350, DOI 10.1158/1055-9965.EPI-15-0237
   Paulsen JA, 2017, SUPPORT CARE CANCER, V25, P1563, DOI 10.1007/s00520-016-3568-5
   Petrick JL, 2016, J CLIN ONCOL, V34, P1787, DOI 10.1200/JCO.2015.64.7412
   Pettapiece-Phillips R, 2016, CANCER PREV RES, V9, P83, DOI 10.1158/1940-6207.CAPR-15-0291
   Pettapiece-Phillips R, 2015, CANCER CAUSE CONTROL, V26, P333, DOI 10.1007/s10552-014-0521-0
   Pijpe A, 2010, BREAST CANCER RES TR, V120, P235, DOI 10.1007/s10549-009-0476-0
   Pizot C, 2016, EUR J CANCER, V52, P138, DOI 10.1016/j.ejca.2015.10.063
   Potter J, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17071052
   Prentice RL, 2006, JAMA-J AM MED ASSOC, V295, P629, DOI 10.1001/jama.295.6.629
   Proper KI, 2011, AM J PREV MED, V40, P174, DOI 10.1016/j.amepre.2010.10.015
   Reedy J, 2014, J NUTR, V144, P881, DOI 10.3945/jn.113.189407
   Richman EL, 2013, JAMA INTERN MED, V173, P1318, DOI 10.1001/jamainternmed.2013.6536
   Robinson MM, 2017, CELL METAB, V25, P581, DOI 10.1016/j.cmet.2017.02.009
   Rogers IS, 2010, PUBLIC HEALTH NUTR, V13, P2052, DOI 10.1017/S1368980010001461
   Rosenberg L, 2014, CANCER EPIDEM BIOMAR, V23, P2522, DOI 10.1158/1055-9965.EPI-14-0448
   Rossi EL, 2016, CANCER PREV RES, V9, P339, DOI 10.1158/1940-6207.CAPR-15-0348
   Sallis JF, 2016, LANCET, V387, P2207, DOI 10.1016/S0140-6736(15)01284-2
   Sallis JE, 2006, ANNU REV PUBL HEALTH, V27, P297, DOI 10.1146/annurev.publhealth.27.021405.102100
   Saunders TJ, 2012, J NUTR METAB, V2012, DOI 10.1155/2012/712435
   Schatzkin A, 2000, NEW ENGL J MED, V342, P1149, DOI 10.1056/NEJM200004203421601
   Schmid D, 2014, ANN ONCOL, V25, P1293, DOI 10.1093/annonc/mdu012
   Schmid D, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju098
   Schröder T, 2016, MOL METAB, V5, P283, DOI 10.1016/j.molmet.2016.01.010
   Seguin R, 2014, AM J PREV MED, V46, P122, DOI 10.1016/j.amepre.2013.10.021
   Seo BR, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.3010467
   Shen D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105709
   Shi Y, 2015, SCI REP-UK, V5, DOI 10.1038/srep14901
   Sieri S, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju068
   Simons CCJM, 2013, AM J EPIDEMIOL, V177, P514, DOI 10.1093/aje/kws280
   Song JH, 2013, CANCER CAUSE CONTROL, V24, P1717, DOI 10.1007/s10552-013-0247-4
   Stamatakis E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073753
   Su XF, 2010, CANCER CAUSE CONTROL, V21, P1033, DOI 10.1007/s10552-010-9532-7
   Thaiss CA, 2016, NATURE, V535, P65, DOI 10.1038/nature18847
   Thomou T, 2017, NATURE, V542, P450, DOI 10.1038/nature21365
   Thosar SS, 2012, MED SCI MONITOR, V18, pRA173, DOI 10.12659/MSM.883589
   Thyfault JP, 2015, MED SCI SPORT EXER, V47, P1301, DOI 10.1249/MSS.0000000000000518
   Tilg H, 2016, GUT, V65, P2035, DOI 10.1136/gutjnl-2016-312729
   Toledo E, 2015, JAMA INTERN MED, V175, P1752, DOI 10.1001/jamainternmed.2015.4838
   Touitou Y, 2017, LIFE SCI, V173, P94, DOI 10.1016/j.lfs.2017.02.008
   Troiano RP, 2008, MED SCI SPORT EXER, V40, P181, DOI 10.1249/mss.0b013e31815a51b3
   Ukawa S, 2014, CANCER CAUSE CONTROL, V25, P787, DOI 10.1007/s10552-014-0380-8
   US Department of Agriculture, 2014, REP NUTR EV LIBR TEC
   US Department of Health and Human Services, 2008, Physical activity guidelines for americans
   van Roekel Eline H, 2016, Prev Med Rep, V4, P262, DOI 10.1016/j.pmedr.2016.06.022
   van Uffelen JGZ, 2010, AM J PREV MED, V39, P379, DOI 10.1016/j.amepre.2010.05.024
   Vollset SE, 2013, LANCET, V381, P1029, DOI 10.1016/S0140-6736(12)62001-7
   Winzer BM, 2011, CANCER CAUSE CONTROL, V22, P811, DOI 10.1007/s10552-011-9761-4
   Wirfält E, 2009, EUR J CLIN NUTR, V63, P707, DOI 10.1038/ejcn.2008.40
   Wiseman AJ, 2014, CANCER CAUSE CONTROL, V25, P1309, DOI 10.1007/s10552-014-0433-z
   World Cancer Research Fund/American Institute for Cancer Research, 2017, CONT UPD PROJ REP FO
   Wu WR, 2016, ONCOTARGET, V7, P52095, DOI 10.18632/oncotarget.10603
   Yang M, 2015, CANCER PREV RES, V8, P545, DOI 10.1158/1940-6207.CAPR-14-0442
   Zheng QS, 2015, CELL PHYSIOL BIOCHEM, V37, P735, DOI 10.1159/000430391
   ,, 2016, Lancet (British edition), V387, P1377
NR 213
TC 403
Z9 433
U1 11
U2 215
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1470-2045
EI 1474-5488
J9 LANCET ONCOL
JI Lancet Oncol.
PD AUG
PY 2017
VL 18
IS 8
BP E457
EP E471
DI 10.1016/S1470-2045(17)30411-4
PG 15
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA FB7DO
UT WOS:000406301500025
PM 28759385
OA Green Submitted, Green Accepted
HC Y
HP N
DA 2025-01-12
ER

PT J
AU Liu, JT
   Guo, WB
   Sun, JY
AF Liu, Jin-Tao
   Guo, Wen-Bin
   Sun, Jia-Yi
TI Serum Dickkopf-1 acts as a new biomarker in human breast cancer
SO MINERVA MEDICA
LA English
DT Article
DE Breast neoplasms; Human DKK1 protein; Mucin-1; ROC Curve; Area Under
   Curve
ID BETA-CATENIN; EPIGENETIC INACTIVATION; POOR-PROGNOSIS; WNT; DKK-1;
   FAMILY; GENE; AXIN
AB BACKGROUND: The serum levels of Dickkopf-1 (DKK1), a secreted Wnt family protein, are different in patients suffering various types of cancers. In the present study, we aim to explore the diagnostic value of DKK1 as a new biomarker in breast cancer.
   METHODS: Serum was collected from 38 patients with breast cancer and 23 healthy controls. Serological levels of DKK1 were examined by enzyme-linked immunosorbent assay (ELISA). Significance and diagnostic performance including receiver operator characteristic (ROC) and areas under the curve were determined by SPSS software.
   RESULTS: Serum level of DKK1 was significantly increased in breast cancer patients compared to the healthy controls (P<0.05). The expression levels of CA15-3 were also evaluated in patients suffering from breast cancer in comparison with healthy controls (P<0.05). AUC for DKK1 and CA15-3 were 0.81 and 0.64 respectively. Sensitivity and specificity of DKK1 were more than CA15-3 in earlier stage of breast cancer. DKK1 expression in HER-2, estrogen receptor (ER) and progesterone receptor (PR) positive patients was decreased compared with HER-2, ER and PR negative patients.
   CONCLUSIONS: We found that the expression level of DKK1 in serum was increased in breast cancer patients, suggesting that serum expression level of DKK1 could be a useful biomarker in breast cancer.
C1 [Liu, Jin-Tao; Guo, Wen-Bin; Sun, Jia-Yi] Dalian Cent Hosp, Dept Breast Surg, Dalian 116033, Liaoning, Peoples R China.
RP Liu, JT (通讯作者)，Dalian Cent Hosp, Dept Breast Surg, Dalian 116033, Liaoning, Peoples R China.
EM jintaohailang009@163.com
RI Wang, Chien Ming/F-6598-2017; Liu, Jintao/JEF-1290-2023
FU Dalian Health Bureau [WSJ/KJC-01-JL-01]
FX The project was supported by the 2013 Dalian Health Bureau Project (No.
   WSJ/KJC-01-JL-01).
CR Aguilera O, 2006, ONCOGENE, V25, P4116, DOI 10.1038/sj.onc.1209439
   Amit S, 2002, GENE DEV, V16, P1066, DOI 10.1101/gad.230302
   Carlson RW, 2009, J NATL COMPR CANC NE, V7, P122, DOI 10.6004/jnccn.2009.0012
   Chamorro MN, 2005, EMBO J, V24, P73, DOI 10.1038/sj.emboj.7600460
   Chen J, 2012, CLIN EXP DERMATOL, V37, P404, DOI 10.1111/j.1365-2230.2011.04276.x
   Chou CT, 2014, PLOS ONE, V9, DOI [10.1371/journal.pone.0107869, 10.1371/journal.pone.0105414, 10.1371/journal.pone.0104899]
   Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018
   Dong LL, 2014, DIAGN PATHOL, V9, DOI 10.1186/1746-1596-9-52
   Glinka A, 1998, NATURE, V391, P357, DOI 10.1038/34848
   Gonzálex-Sancho JM, 2005, ONCOGENE, V24, P1098, DOI 10.1038/sj.onc.1208303
   Huelsken J, 2002, J CELL SCI, V115, P3977, DOI 10.1242/jcs.00089
   JEMAL A, 2011, CA-CANCER J CLIN, V61, P69, DOI DOI 10.3322/CAAC.20107
   Mao JH, 2001, MOL CELL, V7, P801, DOI 10.1016/S1097-2765(01)00224-6
   Nelson WJ, 2004, SCIENCE, V303, P1483, DOI 10.1126/science.1094291
   Rachner TD, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-649
   Sato H, 2007, CARCINOGENESIS, V28, P2459, DOI 10.1093/carcin/bgm178
   Shi XD, 2016, ONCOTARGET, V7, P70378, DOI 10.18632/oncotarget.11859
   Sun DK, 2015, GENET MOL RES, V14, P18181, DOI 10.4238/2015.December.23.5
   Youlden DR, 2012, CANCER EPIDEMIOL, V36, P237, DOI 10.1016/j.canep.2012.02.007
   Zhao YP, 2015, GENET MOL RES, V14, P18886, DOI 10.4238/2015.December.28.38
   Zorn AM, 2001, CURR BIOL, V11, pR592, DOI 10.1016/S0960-9822(01)00360-8
NR 21
TC 9
Z9 12
U1 0
U2 7
PU EDIZIONI MINERVA MEDICA
PI TURIN
PA CORSO BRAMANTE 83-85 INT JOURNALS DEPT., 10126 TURIN, ITALY
SN 0026-4806
EI 1827-1669
J9 MINERVA MED
JI Minerva Med.
PD AUG
PY 2017
VL 108
IS 4
BP 334
EP 340
DI 10.23736/S0026-4806.17.04807-8
PG 7
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA EZ7KB
UT WOS:000404901900005
PM 28248066
DA 2025-01-12
ER

PT J
AU Yang, L
   Zhang, YY
   Shan, WW
   Hu, ZY
   Yuan, J
   Pi, JJ
   Wang, YY
   Fan, LL
   Tang, ZQ
   Li, CS
   Hu, XW
   Tanyi, JL
   Fan, Y
   Huang, QH
   Montone, K
   Dang, CV
   Zhang, L
AF Yang, Lu
   Zhang, Youyou
   Shan, Weiwei
   Hu, Zhongyi
   Yuan, Jiao
   Pi, Jingjiang
   Wang, Yueying
   Fan, Lingling
   Tang, Zhaoqing
   Li, Chunsheng
   Hu, Xiaowen
   Tanyi, Janos L.
   Fan, Yi
   Huang, Qihong
   Montone, Kathleen
   Dang, Chi V.
   Zhang, Lin
TI Repression of BET activity sensitizes homologous
   recombination-proficient cancers to PARP inhibition
SO SCIENCE TRANSLATIONAL MEDICINE
LA English
DT Article
ID NEGATIVE BREAST-CANCER; POLY(ADP-RIBOSE) POLYMERASE; BROMODOMAIN
   INHIBITION; SYNTHETIC LETHALITY; PROSTATE-CANCER; OVARIAN-CANCER;
   DNA-REPAIR; THERAPEUTIC STRATEGY; ADP-RIBOSYLATION; DOSE-ESCALATION
AB Strategies to enhance response to poly(adenosine diphosphate-ribose) polymerase inhibitor (PARPi) in primary and acquired homologous recombination (HR)-proficient tumors would be a major advance in cancer care. We used a drug synergy screen that combined a PARPi, olaparib, with 20 well-characterized epigenetic drugs and identified bromodomain and extraterminal domain inhibitors (BETis; JQ1, I-BET762, and OTX015) as drugs that acted synergistically with olaparib in HR-proficient cancer cells. Functional assays demonstrated that repressed BET activity reduces HR and thus enhances PARPi-induced DNA damage in cancer cells. We also found that inhibition or depletion of BET proteins impairs transcription of BRCA1 and RAD51, two genes essential for HR. Moreover, BETi treatment sensitized tumors to PARP inhibition in preclinical animal models of HR-proficient breast and ovarian cancers. Finally, we showed that the BRD4 gene was focally amplified across 20 types of common cancers. Combination with BETi could greatly expand the utility of PARP inhibition to patients with HR-proficient cancer.
C1 [Yang, Lu; Zhang, Youyou; Shan, Weiwei; Hu, Zhongyi; Yuan, Jiao; Pi, Jingjiang; Wang, Yueying; Fan, Lingling; Tang, Zhaoqing; Li, Chunsheng; Hu, Xiaowen; Zhang, Lin] Univ Penn, Ctr Res Reprod & Womens Hlth, Philadelphia, PA 19104 USA.
   [Yang, Lu] Sichuan Univ, West China Med Sch, Dept Obstet & Gynecol, Chengdu 610041, Sichuan, Peoples R China.
   [Shan, Weiwei; Fan, Lingling] Fudan Univ, Shanghai Key Lab Female Reprod Endocrine Related, Obstet & Gynecol Hosp, Shanghai 200011, Peoples R China.
   [Li, Chunsheng; Hu, Xiaowen; Tanyi, Janos L.; Zhang, Lin] Univ Penn, Dept Obstet & Gynecol, Philadelphia, PA 19104 USA.
   [Fan, Yi] Univ Penn, Dept Radiat Oncol, Philadelphia, PA 19104 USA.
   [Huang, Qihong] Wistar Inst Anat & Biol, 3601 Spruce St, Philadelphia, PA 19104 USA.
   [Montone, Kathleen] Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA.
   [Dang, Chi V.; Zhang, Lin] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA.
C3 University of Pennsylvania; Sichuan University; Shanghai Academy of
   Science & Technology; Fudan University; University of Pennsylvania;
   University of Pennsylvania; The Wistar Institute; University of
   Pennsylvania; University of Pennsylvania
RP Zhang, L (通讯作者)，Univ Penn, Ctr Res Reprod & Womens Hlth, Philadelphia, PA 19104 USA.; Zhang, L (通讯作者)，Univ Penn, Dept Obstet & Gynecol, Philadelphia, PA 19104 USA.; Zhang, L (通讯作者)，Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA.
EM linzhang@mail.med.upenn.edu
RI fan, yi/GYU-1036-2022; Yuan, Jiao/AAZ-1284-2021; Hu,
   Xiaowen/CAE-9141-2022; Dang, Chi/Y-3375-2019; hu, zhongyi/E-6103-2015;
   Zhang, Youyou/H-9677-2017
OI Hu, Zhongyi/0000-0002-9249-9720
FU Basser Center for BRCA; Harry Fields Professorship; NIH [R01CA142776,
   R01CA190415, P50CA083638, P50CA174523, R01CA148759, R21CA198558,
   U01CA200495, R01NS094533]; Breast Cancer Alliance; Ovarian Cancer
   Research Fund; Foundation for Women's Cancer; Kaleidoscope of Hope
   Ovarian Cancer Foundation; Marsha Rivkin Center for Ovarian Cancer
   Research; China Scholarship Council
FX This work was supported, in whole or in part, by the Basser Center for
   BRCA (to L.Z.), the Harry Fields Professorship (to L.Z.), the NIH
   (R01CA142776, R01CA190415, P50CA083638, and P50CA174523 to L.Z.,
   R01CA148759, R21CA198558, and U01CA200495 to Q.H., and R01NS094533 to
   Y.F.), the Breast Cancer Alliance (to L.Z. and C.V.D.), the Ovarian
   Cancer Research Fund (to X.H. and L.Z.), the Foundation for Women's
   Cancer (to X.H. and L.Z.), the Kaleidoscope of Hope Ovarian Cancer
   Foundation (to L.Z.), and the Marsha Rivkin Center for Ovarian Cancer
   Research (to L.Z.). L.Y. and W.S. were supported by the China
   Scholarship Council.
CR Amorim S, 2016, LANCET HAEMATOL, V3, pE196, DOI 10.1016/S2352-3026(16)00021-1
   Asangani IA, 2014, NATURE, V510, P278, DOI 10.1038/nature13229
   Audeh MW, 2010, LANCET, V376, P245, DOI 10.1016/S0140-6736(10)60893-8
   Bajrami I, 2012, EMBO MOL MED, V4, P1087, DOI 10.1002/emmm.201201250
   Baratta MG, 2015, P NATL ACAD SCI USA, V112, P232, DOI 10.1073/pnas.1422165112
   Berthon C, 2016, LANCET HAEMATOL, V3, pE186, DOI 10.1016/S2352-3026(15)00247-1
   Brenner JC, 2011, CANCER CELL, V19, P664, DOI 10.1016/j.ccr.2011.04.010
   Bryant HE, 2005, NATURE, V434, P913, DOI 10.1038/nature03443
   Bunting SF, 2010, CELL, V141, P243, DOI 10.1016/j.cell.2010.03.012
   Ceccaldi R, 2015, NATURE, V518, P258, DOI 10.1038/nature14184
   Chapuy B, 2013, CANCER CELL, V24, P777, DOI 10.1016/j.ccr.2013.11.003
   Chaudhuri AR, 2016, NATURE, V535, P382, DOI 10.1038/nature18325
   Dawson MA, 2011, NATURE, V478, P529, DOI 10.1038/nature10509
   Dedes KJ, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001538
   Delmore JE, 2011, CELL, V146, P903, DOI 10.1016/j.cell.2011.08.017
   Du Y, 2016, NAT MED, V22, P194, DOI 10.1038/nm.4032
   Edwards SL, 2008, NATURE, V451, P1111, DOI 10.1038/nature06548
   Farmer H, 2005, NATURE, V434, P917, DOI 10.1038/nature03445
   Feng FY, 2015, MOL CELL, V58, P925, DOI 10.1016/j.molcel.2015.04.016
   Floyd SR, 2013, NATURE, V498, P246, DOI 10.1038/nature12147
   Fong PC, 2009, NEW ENGL J MED, V361, P123, DOI 10.1056/NEJMoa0900212
   Ha K, 2014, ONCOTARGET, V5, P5637, DOI 10.18632/oncotarget.2154
   Hu YD, 2014, CANCER DISCOV, V4, P1430, DOI 10.1158/2159-8290.CD-13-0891
   Ibrahim YH, 2012, CANCER DISCOV, V2, P1036, DOI 10.1158/2159-8290.CD-11-0348
   Jaspers JE, 2013, CANCER DISCOV, V3, P68, DOI 10.1158/2159-8290.CD-12-0049
   Jdey W, 2017, CLIN CANCER RES, V23, P1001, DOI 10.1158/1078-0432.CCR-16-1193
   Johnson N, 2011, NAT MED, V17, P875, DOI 10.1038/nm.2377
   Johnson SF, 2016, CELL REP, V17, P2367, DOI 10.1016/j.celrep.2016.10.077
   Juvekar A, 2012, CANCER DISCOV, V2, P1048, DOI 10.1158/2159-8290.CD-11-0336
   Kaufman B, 2015, J CLIN ONCOL, V33, P244, DOI 10.1200/JCO.2014.56.2728
   Konstantinopoulos PA, 2015, CANCER DISCOV, V5, P1137, DOI 10.1158/2159-8290.CD-15-0714
   Li M, 2013, CANCER CELL, V23, P693, DOI 10.1016/j.ccr.2013.03.025
   Liu JF, 2014, LANCET ONCOL, V15, P1207, DOI 10.1016/S1470-2045(14)70391-2
   Lockwood WW, 2012, P NATL ACAD SCI USA, V109, P19408, DOI 10.1073/pnas.1216363109
   Lord CJ, 2015, ANNU REV MED, V66, P455, DOI 10.1146/annurev-med-050913-022545
   Lovén J, 2013, CELL, V153, P320, DOI 10.1016/j.cell.2013.03.036
   Mao ZY, 2007, P NATL ACAD SCI USA, V104, P13068, DOI 10.1073/pnas.0702410104
   Mateo J, 2015, NEW ENGL J MED, V373, P1697, DOI 10.1056/NEJMoa1506859
   Mateos-Gomez PA, 2015, NATURE, V518, P254, DOI 10.1038/nature14157
   Mazur PK, 2015, NAT MED, V21, P1163, DOI 10.1038/nm.3952
   Mertz JA, 2011, P NATL ACAD SCI USA, V108, P16669, DOI 10.1073/pnas.1108190108
   Murai J, 2012, CANCER RES, V72, P5588, DOI 10.1158/0008-5472.CAN-12-2753
   Patel AG, 2011, P NATL ACAD SCI USA, V108, P3406, DOI 10.1073/pnas.1013715108
   Pettitt SJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061520
   Pommier Y, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf9246
   Puissant A, 2013, CANCER DISCOV, V3, P308, DOI 10.1158/2159-8290.CD-12-0418
   Rugo HS, 2016, NEW ENGL J MED, V375, P23, DOI 10.1056/NEJMoa1513749
   Sakai W, 2008, NATURE, V451, P1116, DOI 10.1038/nature06633
   Schiewer MJ, 2012, CANCER DISCOV, V2, P1134, DOI 10.1158/2159-8290.CD-12-0120
   Schlegel BP, 2006, CANCER RES, V66, P5181, DOI 10.1158/0008-5472.CAN-05-3209
   Scott CL, 2015, J CLIN ONCOL, V33, P1397, DOI 10.1200/JCO.2014.58.8848
   Shi JW, 2014, MOL CELL, V54, P728, DOI 10.1016/j.molcel.2014.05.016
   Shu S., 2017, COLD SPRING HARB SYM, V81, P1
   Shu SK, 2016, NATURE, V529, P413, DOI 10.1038/nature16508
   Stathis A, 2016, CANCER DISCOV, V6, P492, DOI 10.1158/2159-8290.CD-15-1335
   Sun CY, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal5148
   Tasdemir N, 2016, CANCER DISCOV, V6, P612, DOI 10.1158/2159-8290.CD-16-0217
   Tutt A, 2010, LANCET, V376, P235, DOI 10.1016/S0140-6736(10)60892-6
   Xu GT, 2015, NATURE, V521, P541, DOI 10.1038/nature14328
   Yokoyama Y, 2016, CANCER RES, V76, P6320, DOI 10.1158/0008-5472.CAN-16-0854
   Zuber J, 2011, NATURE, V478, P524, DOI 10.1038/nature10334
NR 61
TC 188
Z9 213
U1 2
U2 29
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 1946-6234
EI 1946-6242
J9 SCI TRANSL MED
JI Sci. Transl. Med.
PD JUL 26
PY 2017
VL 9
IS 400
AR eaal1645
DI 10.1126/scitranslmed.aal1645
PG 12
WC Cell Biology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA FB7EB
UT WOS:000406302800003
PM 28747513
OA Green Accepted, Bronze
DA 2025-01-12
ER

PT J
AU Laczmanska, I
   Karpinski, P
   Gil, J
   Laczmanski, L
   Makowska, I
   Bebenek, M
   Ramsey, D
   Sasiadek, MM
AF Laczmanska, I.
   Karpinski, P.
   Gil, J.
   Laczmanski, L.
   Makowska, I.
   Bebenek, M.
   Ramsey, D.
   Sasiadek, M. M.
TI The <i>PTPN13</i> Y2081D (T&gt;G) (rs989902) polymorphism is associated
   with an increased risk of sporadic colorectal cancer
SO COLORECTAL DISEASE
LA English
DT Article
DE PTPN13; FAP-1; SNP; colorectal cancer; meta-analysis
ID PROTEIN-TYROSINE PHOSPHATASES; SQUAMOUS-CELL CARCINOMA; GENE; EXPRESSION
AB Aim Colorectal cancer (CRC) is one of the most common cancers worldwide and, although the majority of cases are sporadic, its development and progression depends on a range of factors: environmental, genetic and epigenetic. A variety of genetic pathways have been described as being crucial in CRC, including protein tyrosine phosphatases (PTPs). PTPN13 (also called FAP-1) is a non-receptor PTP and interacts with a number of important components of growth and apoptosis pathways. It is also involved in the inhibition of Fas-induced apoptosis.
   Method The single nucleotide polymorphism genotype at Y2081D (T>G) (rs989902) of PTPN13 exon 39 was determined in DNA extracted from blood samples from 174 sporadic CRC patients and 176 healthy individuals. Also, a meta-analysis was performed based on three articles accessed via the PubMed and ResearchGate databases.
   Results The risk of CRC was 2.087 times greater for patients with the GG genotype than for those with the TT genotype (P = 0.0475). In the meta-analysis, a significantly increased risk of cancer associated with the G allele was observed in the squamous cell carcinoma of the head and neck subgroup (TT vs GG+GT, OR 1.23, 95% CI [1.02, 1.47], P = 0.0258), and a significantly decreased risk in the breast cancer subgroup (TT vs GG+GT, OR 0.63, 95% CI [0.41, 0.96], P = 0.0334) and in the CRC subgroup (GT+TT vs GG, OR 0.51, 95% CI [0.41, 0.95], P = 0.0333).
   Conclusion PTPN13 rs989902 is significantly associated with the risk of CRC in the Polish population. Given that this report provides the first evidence of an association of PTPN13 rs989902 with the risk of CRC in a Caucasian population, further large scale studies are necessary to confirm this finding.
C1 [Laczmanska, I.; Karpinski, P.; Gil, J.; Makowska, I.; Sasiadek, M. M.] Wroclaw Med Univ, Genet Dept, Wroclaw, Poland.
   [Laczmanski, L.] Polish Acad Sci, Inst Immunol & Expt Therapy, Wroclaw, Poland.
   [Laczmanski, L.] Lower Silesian Reg Specialist Hosp, Res & Dev Ctr, Wroclaw, Poland.
   [Bebenek, M.] Lower Silesian Oncol Ctr, Dept Surg Oncol 1, Wroclaw, Poland.
   [Ramsey, D.] Wroclaw Univ Technol, Dept Operat Res, Wroclaw, Poland.
C3 Wroclaw Medical University; Polish Academy of Sciences; Hirszfeld
   Institute of Immunology & Experimental Therapy of the Polish Academy of
   Sciences; Wroclaw University of Science & Technology
RP Laczmanska, I (通讯作者)，Med Univ, Genet Dept, Marcinkowskiego 1, PL-50368 Wroclaw, Poland.
EM izabela.laczmanska@umed.wroc.pl
RI Karpinski, Pawel/LQJ-4449-2024; Gil, Justyna/L-5618-2019
OI Gil, Justyna/0000-0003-0991-7686; Karpinski, Pawel/0000-0003-3885-694X;
   Laczmanski, Lukasz/0000-0002-0874-5483; Sasiadek,
   Maria/0000-0002-7599-7074; Bebenek, Marek/0000-0001-7716-5960; Ramsey,
   David/0000-0002-7186-1436; Laczmanska, Izabela/0000-0003-2458-5755
FU Ministry of Science and Higher Education
FX This study was funded by Statutory Activities financed by the Ministry
   of Science and Higher Education. All procedures performed in studies
   involving human participants were in accordance with the ethical
   standards of the institutional and/or national research committee and
   with the 1964 Helsinki Declaration and its later amendments or
   comparable ethical standards. Informed consent was obtained from all
   individual participants included in the study.
CR Erichsen HC, 2004, BRIT J CANCER, V90, P747, DOI 10.1038/sj.bjc.6601574
   Han XJ, 2013, EXP MOL PATHOL, V95, P270, DOI 10.1016/j.yexmp.2013.07.008
   Hardy S, 2012, ANTI-CANCER AGENT ME, V12, P4, DOI 10.2174/187152012798764741
   He RJ, 2014, ACTA PHARMACOL SIN, V35, P1227, DOI 10.1038/aps.2014.80
   Julien SG, 2011, NAT REV CANCER, V11, P35, DOI 10.1038/nrc2980
   Karpinski P, 2012, MOL CARCINOGEN, V51, P1003, DOI 10.1002/mc.20871
   Kim J, 2014, WORLD J GASTROENTERO, V20, P4558, DOI 10.3748/wjg.v20.i16.4558
   Laczmanska I, 2014, PATHOL RES PRACT, V210, P893, DOI 10.1016/j.prp.2014.07.010
   Liu J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075367
   Mita Y, 2010, J CANCER RES CLIN, V136, P249, DOI 10.1007/s00432-009-0656-7
   Mundade Rasika, 2014, Oncoscience, V1, P400
   Niu JG, 2009, CARCINOGENESIS, V30, P2053, DOI 10.1093/carcin/bgp265
   Scrima M, 2012, AM J PATHOL, V180, P1202, DOI 10.1016/j.ajpath.2011.11.038
   Wang ZH, 2004, SCIENCE, V304, P1164, DOI 10.1126/science.1096096
   Wei W, 2013, GENET MOL RES, V12, P6268, DOI 10.4238/2013.December.4.14
   Xiao ZY, 2010, WORLD J GASTROENTERO, V16, P112, DOI 10.3748/wjg.v16.i1.112
   Yao H, 2004, BRIT J CANCER, V91, P1718, DOI 10.1038/sj.bjc.6602136
   Zhan H, 2016, TUMOR BIOL, V37, P9691, DOI 10.1007/s13277-016-4843-2
   Zhao S, 2015, ONCOGENE, V34, P3885, DOI 10.1038/onc.2014.326
NR 19
TC 5
Z9 5
U1 0
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1462-8910
EI 1463-1318
J9 COLORECTAL DIS
JI Colorectal Dis.
PD JUL
PY 2017
VL 19
IS 7
BP O272
EP O278
DI 10.1111/codi.13727
PG 7
WC Gastroenterology & Hepatology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Gastroenterology & Hepatology; Surgery
GA EZ8JC
UT WOS:000404970200006
PM 28504867
DA 2025-01-12
ER

PT J
AU Lu, WW
   Katzenellenbogen, BS
AF Lu, Wenwen
   Katzenellenbogen, Benita S.
TI Estrogen Receptor-β Modulation of the ERα-p53 Loop Regulating Gene
   Expression, Proliferation, and Apoptosis in Breast Cancer
SO HORMONES & CANCER
LA English
DT Article
ID H3 LYSINE-9 METHYLATION; CHROMATIN-BINDING; P53; ALPHA; TRANSCRIPTION;
   CELLS; HETEROCHROMATIN; REPRESSES; THERAPY; ANTAGONISTS
AB Estrogen receptor alpha (ER alpha) is a crucial transcriptional regulator in breast cancer, but estrogens mediate their effects through two estrogen receptors, ER alpha and ER beta, subtypes that have contrasting regulatory actions on gene expression and the survival and growth of breast cancer cells. Here, we examine the impact of ER beta on the ER alpha-p53 loop in breast cancer. We found that ER beta attenuates ER alpha-induced cell proliferation, increases apoptosis, and reverses transcriptional activation and repression by ER alpha. Further, ER beta physically interacts with p53, reduces ER alpha-p53 binding, and antagonizes ER alpha-p53-mediated transcriptional regulation. ER alpha directs SUV39H1/H2 and histone H3 lys9 trimethylation (H3K9me3) heterochromatin assembly at estrogen-repressed genes to silence p53-activated transcription. The copresence of ER beta in ER alpha-positive cells abrogates the H3K9me3 repressive heterochromatin conformation by downregulating SUV39H1 and SUV39H2, thereby releasing the ER alpha-induced transcriptional block. Furthermore, the presence of ER beta stimulates accumulation of histone H3 lys4 trimethylation (H3K4me3) and RNA polymerase II (RNA Pol II) on ER alpha-repressed genes, inducing H3K4me3-associated epigenetic activation of the transcription of these repressed genes that can promote p53-based tumor suppression. ER beta also reduced corepressor N-CoR and SMRT recruitment by ER alpha that could attenuate the crosstalk between ER alpha and p53. Overall, our data reveal a novel mechanism for ER beta's anti-proliferative and pro-apoptotic effects in breast cancer cells involving p53 and epigenetic changes in histone methylation that underlie gene regulation of these cellular activities.
C1 [Lu, Wenwen; Katzenellenbogen, Benita S.] Univ Illinois, Dept Mol & Integrat Physiol, 524 Burrill Hall,407 South Goodwin Ave, Urbana, IL 61801 USA.
C3 University of Illinois System; University of Illinois Urbana-Champaign
RP Katzenellenbogen, BS (通讯作者)，Univ Illinois, Dept Mol & Integrat Physiol, 524 Burrill Hall,407 South Goodwin Ave, Urbana, IL 61801 USA.
EM katzenel@illinois.edu
OI Katzenellenbogen, Benita S/0000-0002-8847-2752
FU Breast Cancer Research Foundation; NIH from the National Center for
   Complementary and Integrative Health (NCCIH) [P50AT006268]; Office of
   Dietary Supplements (ODS); National Cancer Institute (NCI)
FX This study was funded by a grant from the Breast Cancer Research
   Foundation (to BSK), and by NIH grant P50AT006268 from the National
   Center for Complementary and Integrative Health (NCCIH), the Office of
   Dietary Supplements (ODS), and the National Cancer Institute (NCI) (to
   BSK). Its contents are solely the responsibility of the authors and do
   not necessarily represent the official views of the NCCIH, ODS, NCI, or
   the National Institutes of Health.
CR Bailey ST, 2012, P NATL ACAD SCI USA, V109, P18060, DOI 10.1073/pnas.1018858109
   Barski A, 2007, CELL, V129, P823, DOI 10.1016/j.cell.2007.05.009
   Berger C, 2013, CURR MOL MED, V13, P1229, DOI 10.2174/15665240113139990065
   Calza S, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1517
   Chang EC, 2008, MOL ENDOCRINOL, V22, P1032, DOI 10.1210/me.2007-0356
   Chang EC, 2006, ENDOCRINOLOGY, V147, P4831, DOI 10.1210/en.2006-0563
   Choi I, 2001, MOL CELL ENDOCRINOL, V181, P139, DOI 10.1016/S0303-7207(01)00492-0
   Czvitkovich S, 2001, MECH DEVELOP, V107, P141, DOI 10.1016/S0925-4773(01)00464-6
   Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60
   Dey P, 2014, ONCOGENE, V33, P4213, DOI 10.1038/onc.2013.384
   ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P
   Frasor J, 2003, ENDOCRINOLOGY, V144, P4562, DOI 10.1210/en.2003-0567
   Gong Ping, 2014, Nucl Recept Signal, V12, pe001, DOI 10.1621/nrs.12001
   Green KA, 2007, NAT REV CANCER, V7, P713, DOI 10.1038/nrc2211
   Guenther MG, 2007, CELL, V130, P77, DOI 10.1016/j.cell.2007.05.042
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Janky R, 2014, PLOS COMPUT BIOL, V10, DOI 10.1371/journal.pcbi.1003731
   Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127
   Kao KJ, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-143
   Katzenellenbogen BS, 2004, SEMIN ONCOL, V31, P28, DOI 10.1053/j.seminoncol.2004.01.004
   KATZENELLENBOGEN BS, 1987, CANCER RES, V47, P4355
   Konduri SD, 2010, P NATL ACAD SCI USA, V107, P15081, DOI 10.1073/pnas.1009575107
   Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005
   Kurebayashi J, 2000, CLIN CANCER RES, V6, P512
   Lauberth SM, 2013, CELL, V152, P1021, DOI 10.1016/j.cell.2013.01.052
   Lehnertz B, 2003, CURR BIOL, V13, P1192, DOI 10.1016/S0960-9822(03)00432-9
   Li B, 2007, CELL, V128, P707, DOI 10.1016/j.cell.2007.01.015
   Lindberg MK, 2003, MOL ENDOCRINOL, V17, P203, DOI 10.1210/me.2002-0206
   Liu WS, 2006, J BIOL CHEM, V281, P9837, DOI 10.1074/jbc.C600001200
   Lv WW, 2012, J CELL SCI, V125, P5369, DOI 10.1242/jcs.106336
   Ma R, 2017, JNCI-J NATL CANCER I, V109, DOI 10.1093/jnci/djw236
   Madak-Erdogan Z, 2013, MOL SYST BIOL, V9, DOI 10.1038/msb.2013.28
   Métivier R, 2003, CELL, V115, P751, DOI 10.1016/S0092-8674(03)00934-6
   Mungamuri SK, 2012, NAT STRUCT MOL BIOL, V19, P478, DOI 10.1038/nsmb.2271
   Nelson AW, 2017, MOL CELL ENDOCRINOL, V440, P138, DOI 10.1016/j.mce.2016.11.016
   Nikulenkov F, 2012, CELL DEATH DIFFER, V19, P1992, DOI 10.1038/cdd.2012.89
   Olivier M, 2006, CLIN CANCER RES, V12, P1157, DOI 10.1158/1078-0432.CCR-05-1029
   Paruthiyil S, 2004, CANCER RES, V64, P423, DOI 10.1158/0008-5472.CAN-03-2446
   Paruthiyil S, 2011, BREAST CANCER RES TR, V129, P777, DOI 10.1007/s10549-010-1273-5
   Perissi V, 2010, NAT REV GENET, V11, P109, DOI 10.1038/nrg2736
   Peters AHFM, 2002, NAT GENET, V30, P77, DOI 10.1038/ng789
   Pettersson K, 2001, ANNU REV PHYSIOL, V63, P165, DOI 10.1146/annurev.physiol.63.1.165
   Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2
   Saji S, 2005, CANCER CHEMOTH PHARM, V56, pS21, DOI 10.1007/s0028-005-0107-3
   Selivanova G, 2010, SEMIN CANCER BIOL, V20, P46, DOI 10.1016/j.semcancer.2010.02.006
   Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4
   Shangary S, 2009, ANNU REV PHARMACOL, V49, P223, DOI 10.1146/annurev.pharmtox.48.113006.094723
   STANFORD JL, 1986, EPIDEMIOL REV, V8, P42, DOI 10.1093/oxfordjournals.epirev.a036295
   Stossi F, 2006, J BIOL CHEM, V281, P16272, DOI 10.1074/jbc.M513405200
   Stossi F, 2009, MOL CELL BIOL, V29, P1749, DOI 10.1128/MCB.01476-08
   Ström A, 2004, P NATL ACAD SCI USA, V101, P1566, DOI 10.1073/pnas.0308319100
   Taverna SD, 2007, NAT STRUCT MOL BIOL, V14, P1025, DOI 10.1038/nsmb1338
   Tovar C, 2006, P NATL ACAD SCI USA, V103, P1888, DOI 10.1073/pnas.0507493103
   van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967
   Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472
   Vinh-Hung V, 2004, JNCI-J NATL CANCER I, V96, P115, DOI 10.1093/jnci/djh013
   Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864
   Whelan TJ, 2000, J CLIN ONCOL, V18, P1220, DOI 10.1200/JCO.2000.18.6.1220
   Yamamoto M, 2014, CANCER SCI, V105, P81, DOI 10.1111/cas.12302
NR 59
TC 35
Z9 42
U1 0
U2 12
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1868-8497
EI 1868-8500
J9 HORM CANCER-US
JI Horm. Cancer
PD AUG
PY 2017
VL 8
IS 4
BP 230
EP 242
DI 10.1007/s12672-017-0298-1
PG 13
WC Oncology; Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Endocrinology & Metabolism
GA FA2PV
UT WOS:000405284200004
PM 28577282
OA Green Published, Green Accepted
DA 2025-01-12
ER

PT J
AU Luo, XR
   Xiong, X
   Shao, Q
   Xiang, TX
   Li, LL
   Yin, XD
   Li, X
   Tao, Q
   Ren, GS
AF Luo, Xinrong
   Xiong, Xin
   Shao, Qing
   Xiang, Tingxiu
   Li, Lili
   Yin, Xuedong
   Li, Xia
   Tao, Qian
   Ren, Guosheng
TI The tumor suppressor interferon regulatory factor 8 inhibits β-catenin
   signaling in breast cancers, but is frequently silenced by promoter
   methylation
SO ONCOTARGET
LA English
DT Article
DE interferon regulatory factor 8; methylation; tumor suppressor; breast
   cancer; beta-catenin
ID TO-MESENCHYMAL TRANSITION; RENAL-CELL CARCINOMA; WNT/BETA-CATENIN; DNA
   METHYLATION; EPIGENETIC DISRUPTION; CPG METHYLATION; APOPTOSIS;
   MULTIPLE; PATHWAY; NASOPHARYNGEAL
AB Interferon (IFN) regulatory factor 8 is encoded by a novel candidate tumor suppressor gene (IRF8), its promotor is frequently methylated in multiple cancers. However, the promoter methylation status, functions and underlying mechanisms of IRF8 in breast cancer remain unclear. We found that IRF8 was downregulated in breast cancer cell lines and primary tumors, compared with normal breast tissues, mainly because of aberrant promoter methylation. However, its expression was not associated with pathological characteristics. Restoration of IRF8 expression suppressed cell proliferation, colony formation, 5-ethynyl-2'-deoxyuridine incorporation, cell migration and invasion, and induced apoptosis and cell cycle arrest in vitro. IRF8 also inhibited xenograft growth in nude mice in vivo. Competition with IRF8 function by IRF8 mutant (K79E) enhanced cell migration and invasion in 4T1 murine cells in vitro. Importantly, IRF8, as both downstream target gene and regulator of IFN-(Upsilon)/STAT1 signaling, inhibited canonical beta-catenin signaling. These findings identify IRF8 as a novel tumor suppressor regulating IFN-(Upsilon)/STAT1 signaling and beta-catenin signaling in breast cancer.
C1 [Luo, Xinrong; Xiong, Xin; Shao, Qing; Xiang, Tingxiu; Yin, Xuedong; Li, Xia; Tao, Qian; Ren, Guosheng] Chongqing Med Univ, Chongqing Key Lab Mol Oncol & Epigenet, Affiliated Hosp 1, Chongqing, Peoples R China.
   [Luo, Xinrong; Yin, Xuedong; Ren, Guosheng] Chongqing Med Univ, Affiliated Hosp 1, Dept Endocrine & Breast Surg, Chongqing, Peoples R China.
   [Li, Lili; Tao, Qian] Chinese Univ Hong Kong, State Key Lab Oncol South China, Sir YK Pao Ctr Canc, Dept Clin Oncol,Canc Epigenet Lab, Shatin, Hong Kong, Peoples R China.
   [Li, Lili; Tao, Qian] Chinese Univ Hong Kong, Li Ka Shine Inst Hlth Sci, Shatin, Hong Kong, Peoples R China.
   [Li, Lili; Tao, Qian] CUHK Shenzhen Reaesrch Inst, Shatin, Hong Kong, Peoples R China.
C3 Chongqing Medical University; Chongqing Medical University; State Key
   Lab Oncology South China; Chinese University of Hong Kong; Chinese
   University of Hong Kong
RP Tao, Q; Ren, GS (通讯作者)，Chongqing Med Univ, Chongqing Key Lab Mol Oncol & Epigenet, Affiliated Hosp 1, Chongqing, Peoples R China.; Ren, GS (通讯作者)，Chongqing Med Univ, Affiliated Hosp 1, Dept Endocrine & Breast Surg, Chongqing, Peoples R China.; Tao, Q (通讯作者)，Chinese Univ Hong Kong, State Key Lab Oncol South China, Sir YK Pao Ctr Canc, Dept Clin Oncol,Canc Epigenet Lab, Shatin, Hong Kong, Peoples R China.; Tao, Q (通讯作者)，Chinese Univ Hong Kong, Li Ka Shine Inst Hlth Sci, Shatin, Hong Kong, Peoples R China.; Tao, Q (通讯作者)，CUHK Shenzhen Reaesrch Inst, Shatin, Hong Kong, Peoples R China.
EM qtao@cuhk.edu.hk; rengs726@126.com
RI Xiang, Tingxiu/E-6157-2016; Li, Lili/Q-5750-2018; Tao, Qian/T-4743-2018
OI Li, Lili/0000-0002-0292-5889; Tao, Qian/0000-0001-5383-4808
FU National Natural Science Foundation of China [31420103915, 81572769,
   81402178]; CUHK
FX This study was supported by National Natural Science Foundation of China
   (# 31420103915, # 81572769, # 81402178). VC special fund from CUHK. We
   thank Prof. Kebin Liu (Department of Biochemistry and Molecular Biology,
   Medical College of Georgia, Augusta, Georgia) for generously providing
   pcDNA3.1-IRF8-K79E and pcDNA3.1 plasmids.
CR Baylin SB, 2006, NAT REV CANCER, V6, P107, DOI 10.1038/nrc1799
   Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095
   Chen WQ, 2016, CA-CANCER J CLIN, V66, P115, DOI 10.3322/caac.21338
   Conway K, 2014, BREAST CANCER RES, V16, DOI 10.1186/s13058-014-0450-6
   Curtin JC, 2010, ONCOTARGET, V1, P563, DOI 10.18632/oncotarget.191
   Du ZF, 2016, ONCOTARGET, V7, P21618, DOI 10.18632/oncotarget.7822
   Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088
   Hu XL, 2011, CANCER RES, V71, P2882, DOI 10.1158/0008-5472.CAN-10-2493
   Huang WQ, 2010, MOL CELL BIOL, V30, P4575, DOI 10.1128/MCB.01595-09
   Jézéquel P, 2013, DATABASE-OXFORD, DOI 10.1093/database/bas060
   Jézéquel P, 2012, BREAST CANCER RES TR, V131, P765, DOI 10.1007/s10549-011-1457-7
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   King TD, 2012, J CELL BIOCHEM, V113, P13, DOI 10.1002/jcb.23350
   Lee KY, 2008, ONCOGENE, V27, P5267, DOI 10.1038/onc.2008.147
   Li LL, 2014, CELL MOL LIFE SCI, V71, P2179, DOI 10.1007/s00018-013-1485-z
   Li LF, 2016, CRYSTALS, V6, DOI 10.3390/cryst6040045
   McGough JM, 2008, MOL CANCER RES, V6, P1841, DOI 10.1158/1541-7786.MCR-08-0280
   Nguyen Hannah, 1997, Cytokine and Growth Factor Reviews, V8, P293, DOI 10.1016/S1359-6101(97)00019-1
   Pogosova-Agadjanyan EL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070812
   Scheller M, 2013, J EXP MED, V210, P2239, DOI 10.1084/jem.20130706
   Shakya R, 2013, CANCER RES, V73, P885, DOI 10.1158/0008-5472.CAN-12-1880
   Shi Y, 2015, CANCER LETT, V358, P27, DOI 10.1016/j.canlet.2014.12.014
   Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387
   Sung JY, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.189
   Sung JY, 2011, LAB INVEST, V91, P1304, DOI 10.1038/labinvest.2011.90
   Suzuki M, 2014, ONCOL LETT, V8, P1025, DOI 10.3892/ol.2014.2234
   Tamura T, 2002, J INTERF CYTOK RES, V22, P145, DOI 10.1089/107999002753452755
   Tao Q, 2002, HUM MOL GENET, V11, P2091, DOI 10.1093/hmg/11.18.2091
   Tshuikina M, 2008, EXP HEMATOL, V36, P1673, DOI 10.1016/j.exphem.2008.08.001
   Xiang TX, 2013, CHIN J CANCER, V32, P12, DOI 10.5732/cjc.011.10344
   Xiang TX, 2016, ONCOTARGET, V7, P70924, DOI 10.18632/oncotarget.12341
   Xiang TX, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029783
   Yamashita M, 2010, CANCER SCI, V101, P1708, DOI 10.1111/j.1349-7006.2010.01581.x
   Yang DF, 2007, CANCER RES, V67, P3301, DOI 10.1158/0008-5472.CAN-06-4068
   Yang DF, 2009, CANCER RES, V69, P1080, DOI 10.1158/0008-5472.CAN-08-2520
   Yin XD, 2016, ONCOTARGET, V7, P51720, DOI 10.18632/oncotarget.10102
   Ying J, 2006, ONCOGENE, V25, P1070, DOI 10.1038/sj.onc.1209154
   Ying Y, 2009, EPIGENETICS-US, V4, P307, DOI 10.4161/epi.4.5.9371
   Zhang Q, 2014, CANCER LETT, V354, P227, DOI 10.1016/j.canlet.2014.07.040
   Zimmerman MA, 2012, CANCER RES, V72, P4724, DOI 10.1158/0008-5472.CAN-12-1347
NR 40
TC 23
Z9 27
U1 0
U2 15
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD JUL 25
PY 2017
VL 8
IS 30
BP 48875
EP 48888
DI 10.18632/oncotarget.16511
PG 14
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA FB6DV
UT WOS:000406232400031
PM 28388578
OA gold, Green Published, Green Submitted
DA 2025-01-12
ER

PT J
AU Park, SM
   Choi, EY
   Bae, M
   Choi, JK
   Kim, YJ
AF Park, Seong-Min
   Choi, Eun-Young
   Bae, Mingyun
   Choi, Jung Kyoon
   Kim, Youn-Jae
TI A long-range interactive DNA methylation marker panel for the promoters
   of HOXA9 and HOXA10 predicts survival in breast cancer patients
SO CLINICAL EPIGENETICS
LA English
DT Article
DE Biomarker; Prognosis; DNA methylation; Survival; Long-range interaction;
   Chromatin interaction; HOXA9; HOXA10
ID GENE-EXPRESSION; P53 EXPRESSION; HYPERMETHYLATION; EPIGENETICS;
   RECURRENCE; MIGRATION; INVASION
AB Background: Most DNA cancer methylation markers are based on the transcriptional regulation of the promoter-gene relationship. Recently, the importance of long-range interactions between distal CpGs and target genes has been revealed. Here, we attempted to identify methylation markers for breast cancer that interact with distant genes.
   Results: We performed integrated analysis using chromatin interactome data, methylome data, transcriptome data, and clinical information for breast cancer from public databases. Using the chromatin interactome and methylome data, we defined CpG-distant target gene relationships. After determining the differences in methylation between tumor and paired normal samples, the survival association, and the correlation between CpG methylation and distant target gene expression, we selected CpG methylation marker candidates. Using Cox proportional hazards models, we combined the selected markers and evaluated the prognostic model. We identified six methylation markers in HOXA9 and HOXA10 promoter regions and their long-range target genes. We experimentally validated the chromatin interactions, methylation status, and transcriptional regulation. A prognostic model showed that the combination of six methylation markers was highly associated with poor survival in independent datasets. According to our multivariate analysis, the prognostic model showed significantly better prognostic ability than other histological and molecular markers.
   Conclusions: The combination of long-range interacting HOXA9 and HOXA10 promoter CpGs predicted the survival of breast cancer patients, providing a comprehensive and novel approach for discovering new methylation markers.
C1 [Park, Seong-Min; Choi, Eun-Young; Kim, Youn-Jae] Natl Canc Ctr, Translat Res Branch, Res Inst, Goyang 10408, Gyeonggi, South Korea.
   [Park, Seong-Min] KRIBB, Personalized Genom Med Res Ctr, Daejeon 34141, South Korea.
   [Bae, Mingyun; Choi, Jung Kyoon] Korea Adv Inst Sci & Technol, Dept Bio & Brain Engn, Daejeon 34141, South Korea.
C3 National Cancer Center - Korea (NCC); Korea Research Institute of
   Bioscience & Biotechnology (KRIBB); Korea Advanced Institute of Science
   & Technology (KAIST)
RP Kim, YJ (通讯作者)，Natl Canc Ctr, Translat Res Branch, Res Inst, Goyang 10408, Gyeonggi, South Korea.
EM yjkim@ncc.re.kr
FU National Cancer Center [NCC-1611800, NCC-1410300, NCC-1710260]
FX This work was supported by grants from the National Cancer Center
   (NCC-1611800, NCC-1410300, NCC-1710260).
CR Acemel RD, 2016, NAT GENET, V48, P336, DOI 10.1038/ng.3497
   Apiou F, 1996, CYTOGENET CELL GENET, V73, P114, DOI 10.1159/000134320
   Aran D, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-3-r21
   Brock MV, 2008, NEW ENGL J MED, V358, P1118, DOI 10.1056/NEJMoa0706550
   Buxa MK, 2016, BIOL OPEN, V5, P1266, DOI 10.1242/bio.019455
   Cedar H, 2012, ANNU REV BIOCHEM, V81, P97, DOI 10.1146/annurev-biochem-052610-091920
   Chen YT, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-111
   Chu MC, 2004, CANCER BIOL THER, V3, P568, DOI 10.4161/cbt.3.6.848
   Church TR, 2014, GUT, V63, P317, DOI 10.1136/gutjnl-2012-304149
   Court F, 2014, EPIGENET CHROMATIN, V7, DOI 10.1186/1756-8935-7-5
   Elmore G, 1998, NEW ENGL J MED, V338, P1089, DOI 10.1056/NEJM199804163381601
   Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI [10.1056/NEJMra072067, 10.1093/carcin/bgp220]
   Fu Y, 2015, INT J CLIN EXP PATHO, V8, P3748
   Henderson GS, 2006, CELL ONCOL, V28, P305
   Holst CR, 2003, CANCER RES, V63, P1596
   Hwang JA, 2015, MOL CARCINOGEN, V54, pE72, DOI 10.1002/mc.22180
   Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43
   Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947
   Kieffer-Kwon KR, 2013, CELL, V155, P1507, DOI 10.1016/j.cell.2013.11.039
   Klose RJ, 2006, TRENDS BIOCHEM SCI, V31, P89, DOI 10.1016/j.tibs.2005.12.008
   Kurukuti S, 2006, P NATL ACAD SCI USA, V103, P10684, DOI 10.1073/pnas.0600326103
   Laird PW, 2003, NAT REV CANCER, V3, P253, DOI 10.1038/nrc1045
   Lee JY, 2010, ANAT CELL BIOL, V43, P78, DOI 10.5115/acb.2010.43.1.78
   Lehmann U, 2002, AM J PATHOL, V160, P605, DOI 10.1016/S0002-9440(10)64880-8
   Min H, 2016, IUBMB LIFE, V68, P436, DOI 10.1002/iub.1504
   Müller HM, 2003, CANCER RES, V63, P7641
   Paik S, 2006, J CLIN ONCOL, V24, P3726, DOI 10.1200/JCO.2005.04.7985
   Park SY, 2011, VIRCHOWS ARCH, V458, P73, DOI 10.1007/s00428-010-1013-6
   Parker JS, 2009, J CLIN ONCOL, V27, P1160, DOI 10.1200/JCO.2008.18.1370
   Pilato B, 2013, J HUM GENET, V58, P51, DOI 10.1038/jhg.2012.118
   Raman V, 2000, NATURE, V405, P974, DOI 10.1038/35016125
   Sun M, 2013, P NATL ACAD SCI USA, V110, P9920, DOI 10.1073/pnas.1305172110
   Svingen T, 2003, CANCER BIOL THER, V2, P518, DOI 10.4161/cbt.2.5.441
   Widschwendter M, 2004, CANCER RES, V64, P3807, DOI 10.1158/0008-5472.CAN-03-3852
   Witmer BS, 2008, CLIN CANCER RES, V14, P2988, DOI 10.1158/1078-0432.CCR-07-4723
   Wu XY, 2006, CANCER RES, V66, P9527, DOI 10.1158/0008-5472.CAN-05-4470
   Yoshida HY, 2006, CANCER RES, V66, P889, DOI 10.1158/0008-5472.CAN-05-2828
NR 37
TC 26
Z9 28
U1 0
U2 4
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1868-7075
EI 1868-7083
J9 CLIN EPIGENETICS
JI Clin. Epigenetics
PD JUL 24
PY 2017
VL 9
AR 73
DI 10.1186/s13148-017-0373-z
PG 11
WC Oncology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Genetics & Heredity
GA FB4XN
UT WOS:000406145500001
PM 28748001
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Xu, SP
   Kong, DJ
   Chen, QL
   Ping, YY
   Pang, D
AF Xu, Shouping
   Kong, Dejia
   Chen, Qianlin
   Ping, Yanyan
   Pang, Da
TI Oncogenic long noncoding RNA landscape in breast cancer
SO MOLECULAR CANCER
LA English
DT Article
DE LncRNAs; Prognosis; Tumourigenesis; Breast cancer; TINCR
ID EPITHELIAL-MESENCHYMAL TRANSITION; MESSENGER-RNA; LUNG-CANCER;
   STEM-CELLS; CHROMATIN; LNCRNA; PROLIFERATION; EXPRESSION; REVEALS;
   HOTAIR
AB Background: Few long noncoding RNAs (lncRNAs) that act as oncogenic genes in breast cancer have been identified.
   Methods: Oncogenic lncRNAs associated with tumourigenesis and worse survival outcomes were examined and validated in Gene Expression Omnibus (GEO) and The Cancer Genome Atlas (TCGA), respectively. Then, the potential biological functions and expression regulation of these lncRNAs were studied via bioinformatics and genome data analysis. Moreover, progressive breast cancer subtype-specific lncRNAs were investigated via high-throughput sequencing in our cohort and TCGA validation. To elucidate the mechanisms of the regulation of these lncRNAs, genomic alterations from the TCGA, Broad, Sanger and BCCRC data, as well as epigenetic modifications from GEO data, were then applied and examined to meet this objective. Finally, cell proliferation assays, flow cytometry analyses and TUNEL assays were applied to validate the oncogenic roles of these lncRNAs in vitro.
   Results: A cluster of oncogenic lncRNAs that was upregulated in breast cancer tissue and was associated with worse survival outcomes was identified. These oncogenic lncRNAs are involved in regulating immune system activation and the TGF-beta and Jak-STAT signalling pathways. Moreover, TINCR, LINC00511, and PPP1R26-AS1 were identified as subtype-specific lncRNAs associated with HER-2, triple-negative and luminal B subtypes of breast cancer, respectively. The up-regulation of these oncogenic lncRNAs is mainly caused by gene amplification in the genome in breast cancer and other solid tumours. Finally, the knockdown of TINCR, DSCAM-AS1 or HOTAIR inhibited breast cancer cell proliferation, increased apoptosis and inhibited cell cycle progression in vitro.
   Conclusions: These findings enhance the landscape of known oncogenic lncRNAs in breast cancer and provide insights into their roles. This understanding may potentially aid in the comprehensive management of breast cancer.
C1 [Xu, Shouping; Kong, Dejia; Chen, Qianlin; Pang, Da] Harbin Med Univ, Canc Hosp, Dept Breast Surg, 150 Haping Rd, Harbin 150081, Heilongjiang, Peoples R China.
   [Ping, Yanyan] Harbin Med Univ, Coll Bioinformat Sci & Technol, Harbin, Heilongjiang, Peoples R China.
   [Pang, Da] Heilongjiang Acad Med Sci, 157 Baojian Rd, Harbin 150086, Heilongjiang, Peoples R China.
C3 Harbin Medical University; Harbin Medical University
RP Pang, D (通讯作者)，Harbin Med Univ, Canc Hosp, Dept Breast Surg, 150 Haping Rd, Harbin 150081, Heilongjiang, Peoples R China.; Pang, D (通讯作者)，Heilongjiang Acad Med Sci, 157 Baojian Rd, Harbin 150086, Heilongjiang, Peoples R China.
EM pangda@ems.hrbmu.edu.cn
OI Ping, Yanyan/0000-0002-1810-1200
FU specific research fund for public service sector, National Health and
   Family Planning Commission of the People's Republic of China
   [201402003]; National Key Technology Support Programme [2014BAI09B08];
   Project of Heilongjiang Province Applied Technology Research and
   Development [GA13C201]; National Natural Science Foundation of China
   [81602323]; China Postdoctoral Science Foundation Grant [2016 M600262];
   Heilong Jiang postdoctoral Fund [LBH-Z16163]; Heilong Jiang province
   Health and Family Planning Commission Foundation Grant [2016-087];
   Graduate Innovation Fund of China and Russia [YJSCX2015-65HYD]
FX This work was supported by funding from the specific research fund for
   public service sector, National Health and Family Planning Commission of
   the People's Republic of China (Grant Number 201402003), the National
   Key Technology Support Programme (Grant Number 2014BAI09B08), the
   Project of Heilongjiang Province Applied Technology Research and
   Development (Grant Number GA13C201), and the National Natural Science
   Foundation of China (Grant Number 81602323), China Postdoctoral Science
   Foundation Grant (Grant Number 2016 M600262), Heilong Jiang postdoctoral
   Fund (Grant Number LBH-Z16163), Heilong Jiang province Health and Family
   Planning Commission Foundation Grant (Grant Number 2016-087), Graduate
   Innovation Fund of China and Russia (Grant Number YJSCX2015-65HYD).
CR Anderson DM, 2015, CELL, V160, P595, DOI 10.1016/j.cell.2015.01.009
   Batista PJ, 2013, CELL, V152, P1298, DOI 10.1016/j.cell.2013.02.012
   Beltran M, 2008, GENE DEV, V22, P756, DOI 10.1101/gad.455708
   Cabili MN, 2011, GENE DEV, V25, P1915, DOI 10.1101/gad.17446611
   Derrien T, 2012, GENOME RES, V22, P1775, DOI 10.1101/gr.132159.111
   Djebali S, 2012, NATURE, V489, P101, DOI 10.1038/nature11233
   Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863
   Fassan M, 2013, HUM PATHOL, V44, P1804, DOI 10.1016/j.humpath.2013.01.023
   García-Castro B, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-557
   Gupta RA, 2010, NATURE, V464, P1071, DOI 10.1038/nature08975
   Guttman M, 2009, NATURE, V458, P223, DOI 10.1038/nature07672
   Hah N, 2013, GENOME RES, V23, P1210, DOI 10.1101/gr.152306.112
   Heo JB, 2011, SCIENCE, V331, P76, DOI 10.1126/science.1197349
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Huang XX, 2017, J HEMATOL ONCOL, V10, DOI 10.1186/s13045-017-0428-9
   Huarte M, 2015, NAT MED, V21, P1253, DOI 10.1038/nm.3981
   Jalali S, 2016, HUM GENOMICS, V10, DOI 10.1186/s40246-016-0090-2
   Kasar S, 2014, ONCOGENE, V33, P3307, DOI 10.1038/onc.2013.291
   Kawasaki Y, 2016, CELL REP, V16, P2554, DOI 10.1016/j.celrep.2016.08.015
   Klein U, 2010, CANCER CELL, V17, P28, DOI 10.1016/j.ccr.2009.11.019
   Kwek KY, 2002, NAT STRUCT BIOL, V9, P800, DOI 10.1038/nsb862
   Leucci E, 2016, NATURE, V531, P518, DOI 10.1038/nature17161
   Li DS, 2016, EUR REV MED PHARMACO, V20, P2285
   Li JH, 2014, NUCLEIC ACIDS RES, V42, pD92, DOI 10.1093/nar/gkt1248
   Li ZR, 2017, EXCLI J, V16, P354, DOI 10.17179/excli2017-113
   Li ZH, 2014, RNA BIOL, V11, P979, DOI 10.4161/rna.29937
   Magistri M, 2012, TRENDS GENET, V28, P389, DOI 10.1016/j.tig.2012.03.013
   Matsumoto A, 2017, NATURE, V541, P228, DOI 10.1038/nature21034
   Mendell JT, 2016, NEW ENGL J MED, V374, P2287, DOI 10.1056/NEJMcibr1603785
   Moyano M, 2015, J HEMATOL ONCOL, V8, DOI 10.1186/s13045-015-0133-5
   Nagano T, 2008, SCIENCE, V322, P1717, DOI 10.1126/science.1163802
   Naidu S, 2015, J HEMATOL ONCOL, V8, DOI 10.1186/s13045-015-0162-0
   Nelson BR, 2016, SCIENCE, V351, P271, DOI 10.1126/science.aad4076
   Niknafs YS, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12791
   Penny GD, 1996, NATURE, V379, P131, DOI 10.1038/379131a0
   Ponting CP, 2009, CELL, V136, P629, DOI 10.1016/j.cell.2009.02.006
   Prensner JR, 2013, NAT GENET, V45, P1392, DOI 10.1038/ng.2771
   Ravasi T, 2006, GENOME RES, V16, P11, DOI 10.1101/gr.4200206
   Rinn JL, 2007, CELL, V129, P1311, DOI 10.1016/j.cell.2007.05.022
   Rivas MA, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3187
   Rostas JW, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-200
   Sanchez-Mejias A, 2015, J HEMATOL ONCOL, V8, DOI 10.1186/s13045-015-0129-1
   Santana-Davila R, 2010, J HEMATOL ONCOL, V3, DOI 10.1186/1756-8722-3-42
   Smith AD, 2014, J HEMATOL ONCOL, V7, DOI 10.1186/s13045-014-0070-8
   Suravajhala P, 2015, FRONT GENET, V6, DOI 10.3389/fgene.2015.00255
   Szafron LM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127475
   Tang Xian-ye, 2016, Drug Des Devel Ther, V10, P571, DOI 10.2147/DDDT.S90530
   Tao SF, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0489-x
   Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498
   Wan L, 2016, ONCOL RES, V24, P161, DOI 10.3727/096504016X14618564639178
   Wang YL, 2016, BIOMED PHARMACOTHER, V80, P95, DOI 10.1016/j.biopha.2016.03.007
   Wu ZH, 2016, TUMOR BIOL, V37, P7939, DOI 10.1007/s13277-015-4665-7
   Xu TP, 2015, ONCOGENE, V34, P5648, DOI 10.1038/onc.2015.18
   Xu Y, 2017, DIS ESOPHAGUS, V30, DOI 10.1111/dote.12436
   Yagishita S, 2015, MOL CANCER THER, V14, P1414, DOI 10.1158/1535-7163.MCT-14-0625
   Yu X, 2015, MOL MED REP, V12, P5611, DOI 10.3892/mmr.2015.4161
   Zhang B, 2005, STAT APPL GENET MOL, V4, DOI 10.2202/1544-6115.1128
   Zhang H, 2013, J HEMATOL ONCOL, V6, DOI 10.1186/1756-8722-6-37
   Zhang T, 2016, TUMOR BIOL, V37, P2379, DOI 10.1007/s13277-015-4052-4
   Zhang ZY, 2016, ONCOTARGET, V7, P22639, DOI 10.18632/oncotarget.8141
   Zhou ML, 2016, STEM CELLS, V34, P55, DOI 10.1002/stem.2219
NR 61
TC 185
Z9 197
U1 2
U2 35
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1476-4598
J9 MOL CANCER
JI Mol. Cancer
PD JUL 24
PY 2017
VL 16
AR 129
DI 10.1186/s12943-017-0696-6
PG 15
WC Biochemistry & Molecular Biology; Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology
GA FB6CL
UT WOS:000406228800001
PM 28738804
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Ming, F
   Sun, QQ
AF Ming, Fei
   Sun, Qianqiang
TI Epigenetically silenced PTPRO functions as a prognostic marker and tumor
   suppressor in human lung squamous cell carcinoma
SO MOLECULAR MEDICINE REPORTS
LA English
DT Article
DE protein tyrosine phosphatase receptor-type O; methylation; cell
   proliferation; prognosis; lung squamous cell carcinoma
ID PROTEIN-TYROSINE-PHOSPHATASE; RECEPTOR-TYPE-O; BREAST-CANCER; POTENTIAL
   BIOMARKER; DOWN-REGULATION; GROWTH-FACTOR; EXPRESSION; METHYLATION;
   GENE; METASTASIS
AB Protein tyrosine phosphatase receptor-type O (PTPRO), a member of the PTP family, has been frequently reported as potential tumor suppressor in many types of cancer. However, the exact function of PTPRO in lung squamous cell carcinoma (LSCC) remains unclear. Bisulfite sequencing and methylation specific polymerase chain reaction (PCR) were used to identify the methylation status of PTPRO in LSCC cells, and quantitative methylation specific PCR was used to evaluate the methylation levels of PTPRO in LSCC patients. Stably expressing PTPRO vectors were constructed and transfected into H520 and SK-MES-1 cells, followed by MTT and colony formation assays, and analysis of tumor weight and volume in in vivo mouse xenograft models. The present study demonstrated that the CpG island of PTPRO exon 1 was obviously hypermethylated in LSCC cells and tissues. The mRNA expression of PTPRO could be restored by treatment with a demethylation agent. Increased methylation and decreased mRNA levels of PTPRO were observed in LSCC samples compared with adjacent healthy tissues, and were associated with poor prognosis of patients. The mRNA expression of PTPRO was negatively correlated with its methylation level in tumors. Functionally, ectopic PTPRO expression in LSCC cells significantly inhibited the proliferation rates, and colony formation, in comparison with control and non-transfected cells. In vivo assays confirmed the inhibitory effect of PTPRO on LSCC cell growth. In conclusion, these data provided evidence that epigenetic regulation of PTPRO impairs its tumor suppressor role in LSCC, and restoration of PTPRO may be a potential therapeutic strategy.
C1 [Ming, Fei; Sun, Qianqiang] Hubei Canc Hosp, Dept Thorac Surg, 116 South Zhuo Daoquan Rd, Wuhan 430000, Hubei, Peoples R China.
RP Sun, QQ (通讯作者)，Hubei Canc Hosp, Dept Thorac Surg, 116 South Zhuo Daoquan Rd, Wuhan 430000, Hubei, Peoples R China.
EM sunqqchina@126.com
CR Asbagh LA, 2014, ONCOTARGET, V5, P10070, DOI 10.18632/oncotarget.2458
   Calì G, 2014, J CELL PHYSIOL, V229, P1417, DOI 10.1002/jcp.24578
   Chen LF, 2006, BLOOD, V108, P3428, DOI 10.1182/blood-2006-03-013821
   Chien W, 2006, MOL CANCER RES, V4, P591, DOI 10.1158/1541-7786.MCR-06-0029
   Correa TCS, 2006, J CELL BIOCHEM, V99, P156, DOI 10.1002/jcb.20917
   Coutinho-Camillo CM, 2015, CANCER GENET-NY, V208, P382, DOI 10.1016/j.cancergen.2015.04.004
   Dammann R, 2003, HISTOL HISTOPATHOL, V18, P665, DOI 10.14670/HH-18.665
   Derman BA, 2015, TRANSL LUNG CANCER R, V4, P524, DOI 10.3978/j.issn.2218-6751.2015.06.07
   Hou JJ, 2013, HEPATOLOGY, V57, P678, DOI 10.1002/hep.25980
   Jacob ST, 2005, CANCER GENE THER, V12, P665, DOI 10.1038/sj.cgt.7700828
   Jerónimo C, 2004, CLIN CANCER RES, V10, P4010, DOI 10.1158/1078-0432.CCR-03-0643
   Laczmanska I, 2011, ACTA BIOCHIM POL, V58, P467
   Li SY, 2014, BMC GENET, V15, DOI 10.1186/1471-2156-15-67
   Liu Z, 2015, ONCOL REP, V33, P1908, DOI 10.3892/or.2015.3772
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Magdinier F, 1998, ONCOGENE, V17, P3169, DOI 10.1038/sj.onc.1202248
   Matozaki T, 1996, CELL SIGNAL, V8, P13, DOI 10.1016/0898-6568(95)02015-2
   Minami H, 2014, DIGESTION, V89, P6, DOI 10.1159/000356200
   Motiwala T, 2004, P NATL ACAD SCI USA, V101, P13844, DOI 10.1073/pnas.0405451101
   Motiwala T, 2003, ONCOGENE, V22, P6319, DOI 10.1038/sj.onc.1206750
   Motiwala T, 2007, CLIN CANCER RES, V13, P3174, DOI 10.1158/1078-0432.CCR-06-1720
   Romagnolo APG, 2015, ANTI-CANCER AGENT ME, V15, P4
   Tan B, 2014, ONCOTARGET, V5, P264, DOI 10.18632/oncotarget.1600
   Thaler S, 2009, CANCER RES, V69, P1748, DOI 10.1158/0008-5472.CAN-08-1377
   Wang LS, 2015, TUMOR BIOL, V36, P9511, DOI 10.1007/s13277-015-3688-4
   Weissenborn C, 2014, J CANCER RES CLIN, V140, P713, DOI 10.1007/s00432-014-1620-8
   Werstuck GH, 2001, J CLIN INVEST, V107, P1263, DOI 10.1172/JCI11596
   WIGGINS RC, 1995, GENOMICS, V27, P174, DOI 10.1006/geno.1995.1021
   You YJ, 2012, CANCER LETT, V315, P138, DOI 10.1016/j.canlet.2011.08.032
   Yu M, 2012, MOL CELL BIOL, V32, P3913, DOI 10.1128/MCB.00068-12
   Zhang XL, 2015, J SURG ONCOL, V111, P834, DOI 10.1002/jso.23888
NR 31
TC 14
Z9 15
U1 0
U2 1
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1791-2997
EI 1791-3004
J9 MOL MED REP
JI Mol. Med. Rep.
PD JUL
PY 2017
VL 16
IS 1
BP 746
EP 754
DI 10.3892/mmr.2017.6665
PG 9
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Research & Experimental Medicine
GA EZ9TZ
UT WOS:000405074100098
PM 28586036
OA hybrid, Green Published, Green Submitted
DA 2025-01-12
ER

PT J
AU Noberini, R
   Longuespée, R
   Richichi, C
   Pruneri, G
   Kriegsmann, M
   Pelicci, G
   Bonaldi, T
AF Noberini, Roberta
   Longuespee, Remi
   Richichi, Cristina
   Pruneri, Giancarlo
   Kriegsmann, Mark
   Pelicci, Giuliana
   Bonaldi, Tiziana
TI PAT-H-MS coupled with laser microdissection to study histone
   post-translational modifications in selected cell populations from
   pathology samples
SO CLINICAL EPIGENETICS
LA English
DT Article
DE Histone post-translational modifications; PAT-H-MS; Laser
   microdissection; Proteomics; Epigenetic marker; Formalin-fixed paraffin
   embedded; Mass spectrometry
ID MASS-SPECTROMETRY; PATIENT SAMPLES; MODIFICATION PATTERNS; CANCER;
   TRIMETHYLATION; METHYLATION; CHROMATIN; PROTEOME; STRATEGY; SUBTYPES
AB Background: Aberrations in histone post-translational modifications (hPTMs) have been linked with various pathologies, including cancer, and could not only represent useful biomarkers but also suggest possible targetable epigenetic mechanisms. We have recently developed an approach, termed pathology tissue analysis of histones by mass spectrometry (PAT-H-MS), that allows performing a comprehensive and quantitative analysis of histone PTMs from formalin-fixed paraffin-embedded pathology samples. Despite its great potential, the application of this technique is limited by tissue heterogeneity.
   Methods: In this study, we further implemented the PAT-H-MS approach by coupling it with techniques aimed at reducing sample heterogeneity and selecting specific portions or cell populations within the samples, such as manual macrodissection and laser microdissection (LMD).
   Results: When applied to the analysis of a small set of breast cancer samples, LMD-PAT-H-MS allowed detecting more marked changes between luminal A-like and triple negative patients as compared with the classical approach. These changes included not only the already known H3 K27me3 and K9me3 marks, but also H3 K36me1, which was found increased in triple negative samples and validated on a larger cohort of patients, and could represent a potential novel marker distinguishing breast cancer subtypes.
   Conclusions: These results show the feasibility of applying techniques to reduce sample heterogeneity, including laser microdissection, to the PAT-H-MS protocol, providing new tools in clinical epigenetics and opening new avenues for the comprehensive analysis of histone post-translational modifications in selected cell populations.
C1 [Noberini, Roberta] Ist Italiano Tecnol, Ctr Genom Sci IIT SEMM, Via Adamello 16, I-20139 Milan, Italy.
   [Longuespee, Remi; Kriegsmann, Mark] Heidelberg Univ, Inst Pathol, Neuenheimer Feld 224, D-69620 Heidelberg, Germany.
   [Richichi, Cristina; Pelicci, Giuliana; Bonaldi, Tiziana] European Inst Oncol, Dept Expt Oncol, Via Adamello 16, I-20139 Milan, Italy.
   [Pruneri, Giancarlo] European Inst Oncol, Dept Pathol, Biobank Translat Med Unit, Via Ripamonti 435, I-20141 Milan, Italy.
   [Pruneri, Giancarlo] Univ Milan, Sch Med, I-20122 Milan, Italy.
   [Pelicci, Giuliana] Piemonte Orientale Univ Amedeo Avogadro, Dept Translat Med, I-28100 Novara, Italy.
C3 Istituto Italiano di Tecnologia - IIT; Ruprecht Karls University
   Heidelberg; IRCCS European Institute of Oncology (IEO); IRCCS European
   Institute of Oncology (IEO); University of Milan; University of Eastern
   Piedmont Amedeo Avogadro
RP Noberini, R (通讯作者)，Ist Italiano Tecnol, Ctr Genom Sci IIT SEMM, Via Adamello 16, I-20139 Milan, Italy.; Bonaldi, T (通讯作者)，European Inst Oncol, Dept Expt Oncol, Via Adamello 16, I-20139 Milan, Italy.
EM roberta.noberini@ieo.it; tiziana.bonaldi@ieo.it
RI Pelicci, Giuliana/AAA-8921-2022; Noberini, Roberta/AAP-4527-2020;
   Bonaldi, Tiziana/K-5075-2016; Pruneri, Giancarlo/AAC-7767-2022;
   Richichi, Cristina/K-4149-2016
OI Noberini, Roberta/0000-0002-7267-1079; Kriegsmann,
   Mark/0000-0002-7319-3646; Longuespee, Remi/0000-0003-2003-1886; Bonaldi,
   Tiziana/0000-0003-3556-1265; Pruneri, Giancarlo/0000-0002-7963-7172;
   Richichi, Cristina/0000-0002-3184-0358
FU Italian Association for Cancer Research (AIRC); Italian Ministry of
   Health; CNR-EPIGEN flagship project; Post-doc program of the medical
   faculty of the University of Heidelberg; Fondazione Umberto Veronesi
   (FUV)
FX Tiziana Bonaldi's research group is supported by grants from the Italian
   Association for Cancer Research (AIRC), the Italian Ministry of Health,
   and the CNR-EPIGEN flagship project. R.L. and M.K. are supported by the
   Post-doc program of the medical faculty of the University of Heidelberg.
   C.R. is supported by Fondazione Umberto Veronesi (FUV) and G. P. by the
   Italian Association for Cancer Research (AIRC).
CR Amatori S, 2014, EPIGENET CHROMATIN, V7, DOI 10.1186/1756-8935-7-18
   Bremang M, 2013, MOL BIOSYST, V9, P2231, DOI 10.1039/c3mb00009e
   Cox J, 2011, J PROTEOME RES, V10, P1794, DOI 10.1021/pr101065j
   Cuomo A, 2011, AMINO ACIDS, V41, P387, DOI 10.1007/s00726-010-0668-2
   Fanelli M, 2010, P NATL ACAD SCI USA, V107, P21535, DOI 10.1073/pnas.1007647107
   Fowler CB, 2011, METHODS MOL BIOL, V724, P281, DOI 10.1007/978-1-61779-055-3_18
   Fraga MF, 2005, NAT GENET, V37, P391, DOI 10.1038/ng1531
   Guo T, 2007, J HISTOCHEM CYTOCHEM, V55, P763, DOI 10.1369/jhc.7A7177.2007
   Healey MA, 2014, BREAST CANCER RES TR, V147, P639, DOI 10.1007/s10549-014-3089-1
   Holm K, 2012, MOL ONCOL, V6, P494, DOI 10.1016/j.molonc.2012.06.002
   Huang H, 2015, CHEM REV, V115, P2376, DOI 10.1021/cr500491u
   Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127
   Khan Shafqat Ali, 2015, World J Biol Chem, V6, P333, DOI 10.4331/wjbc.v6.i4.333
   Longuespée R, 2016, METHODS, V104, P154, DOI 10.1016/j.ymeth.2015.12.008
   Noberini R, 2017, METHOD ENZYMOL, V586, P311, DOI 10.1016/bs.mie.2016.09.036
   Noberini R, 2016, MOL CELL PROTEOMICS, V15, P866, DOI 10.1074/mcp.M115.054510
   Ong SE, 2004, NAT METHODS, V1, P119, DOI 10.1038/NMETH715
   Pesavento JJ, 2006, ANAL CHEM, V78, P4271, DOI 10.1021/ac0600050
   Portela A, 2010, NAT BIOTECHNOL, V28, P1057, DOI 10.1038/nbt.1685
   Richichi C, 2013, NEOPLASIA, V15, P840, DOI 10.1593/neo.13662
   Seligson DB, 2009, AM J PATHOL, V174, P1619, DOI 10.2353/ajpath.2009.080874
   Seligson DB, 2005, NATURE, V435, P1262, DOI 10.1038/nature03672
   Soldi M, 2014, PROTEOMICS, V14, P2212, DOI 10.1002/pmic.201400075
   Tyanova S, 2016, NAT METHODS, V13, P731, DOI [10.1038/NMETH.3901, 10.1038/nmeth.3901]
   Vizcaíno JA, 2014, NAT BIOTECHNOL, V32, P223, DOI 10.1038/nbt.2839
NR 25
TC 16
Z9 17
U1 0
U2 8
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1868-7083
J9 CLIN EPIGENETICS
JI Clin. Epigenetics
PD JUL 11
PY 2017
VL 9
AR 69
DI 10.1186/s13148-017-0369-8
PG 12
WC Oncology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Genetics & Heredity
GA FA3KB
UT WOS:000405341700001
PM 28702092
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU Crujeiras, AB
   Diaz-Lagares, A
   Stefansson, OA
   Macias-Gonzalez, M
   Sandoval, J
   Cueva, J
   Lopez-Lopez, R
   Moran, S
   Jonasson, JG
   Tryggvadottir, L
   Olafsdottir, E
   Tinahones, FJ
   Carreira, MC
   Casanueva, FF
   Esteller, M
AF Crujeiras, Ana B.
   Diaz-Lagares, Angel
   Stefansson, Olafur A.
   Macias-Gonzalez, Manuel
   Sandoval, Juan
   Cueva, Juan
   Lopez-Lopez, Rafael
   Moran, Sebastian
   Jonasson, Jon G.
   Tryggvadottir, Laufey
   Olafsdottir, Elinborg
   Tinahones, Francisco J.
   Carreira, Marcos C.
   Casanueva, Felipe F.
   Esteller, Manel
TI Obesity and menopause modify the epigenomic profile of breast cancer
SO ENDOCRINE-RELATED CANCER
LA English
DT Article
DE breast cancer; DNA methylation; epigenomics; obesity; 450k methylation
   array
ID BODY-MASS INDEX; CPG-ISLAND METHYLATION; DNA METHYLATION; EPIGENETIC
   MODIFICATIONS; NADPH OXIDASES; ASSOCIATION; BIOMARKERS
AB Obesity is a high risk factor for breast cancer. This relationship could be marked by a specific methylome. The current work was aimed to explore the impact of obesity and menopausal status on variation in breast cancer methylomes. Data from Infinium 450K array-based methylomes of 64 breast tumors were coupled with information on BMI and menopausal status. Additionally, DNA methylation results were validated in 18 non-tumor and 81 tumor breast samples. Breast tumors arising in either pre-or postmenopausal women stratified by BMI or menopausal status alone were not associated with a specific DNA methylation pattern. Intriguingly, the DNA methylation pattern identified in association with the high-risk group (postmenopausal women with high BMI (>25) and premenopausal women with normal or low BMI <25) exclusively characterized by hypermethylation of 1287 CpG sites as compared with the low-risk group. These CpG sites included the promoter region of fourteen protein-coding genes of which CpG methylation over the ZNF577 promoter region represents the top scoring associated event. In an independent cohort, the ZNF577 promoter methylation remained statistically significant in association with the high-risk group. Additionally, the impact of ZNF577 promoter methylation on mRNA expression levels was demonstrated in breast cancer cell lines after treatment with a demethylating agent (5-azacytidine). In conclusion, the epigenome of breast tumors is affected by a complex interaction between BMI and menopausal status. The ZNF577 methylation quantification is clearly relevant for the development of novel biomarkers of precision therapy in breast cancer.
C1 [Crujeiras, Ana B.; Diaz-Lagares, Angel; Stefansson, Olafur A.; Sandoval, Juan; Moran, Sebastian; Esteller, Manel] Bellvitge Biomed Res Inst IDIBELL, Canc Epigenet & Biol Program PEBC, Barcelona, Catalonia, Spain.
   [Crujeiras, Ana B.; Carreira, Marcos C.; Casanueva, Felipe F.] Santiago de Compostela Univ USC, Complejo Hosp Univ Santiago CHUS SERGAS, Inst Invest Sanitaria IDIS, Lab Mol & Cellular Endocrinol, Santiago De Compostela, Spain.
   [Crujeiras, Ana B.; Macias-Gonzalez, Manuel; Tinahones, Francisco J.; Carreira, Marcos C.; Casanueva, Felipe F.; Esteller, Manel] CIBER Fisiopatol Obesidad & Nutr CIBERobn, Madrid, Spain.
   [Diaz-Lagares, Angel; Cueva, Juan; Lopez-Lopez, Rafael] Inst Invest Sanitaria IDIS, Translat Med Oncol Grp Oncomet, Santiago De Compostela, Spain.
   [Diaz-Lagares, Angel; Cueva, Juan; Lopez-Lopez, Rafael] Complejo Hosp Univ Santiago de Compostela CHUS SE, Santiago De Compostela, Spain.
   [Diaz-Lagares, Angel; Cueva, Juan; Lopez-Lopez, Rafael] CIBER Cancer CIBERONC, Santiago De Compostela, Spain.
   [Stefansson, Olafur A.] Univ Iceland, Fac Med, Canc Res Lab, Reykjavik, Iceland.
   [Macias-Gonzalez, Manuel] Univ Malaga, Complejo Hosp Malaga Virgen Victoria, Inst Invest Biomed Malaga IBIMA, Unidad Gest Clin Endocrinol & Nutr, Malaga, Spain.
   [Jonasson, Jon G.; Tryggvadottir, Laufey; Olafsdottir, Elinborg] Iceland Canc Soc, Dept Pathol, Reykjavik, Iceland.
   [Jonasson, Jon G.; Tryggvadottir, Laufey; Olafsdottir, Elinborg] Iceland Canc Soc, Iceland Canc Registry, Reykjavik, Iceland.
   [Jonasson, Jon G.; Tryggvadottir, Laufey; Olafsdottir, Elinborg] Landspitali Univ Hosp, Reykjavik, Iceland.
   [Esteller, Manel] Univ Barcelona, Sch Med, Dept Psychol Sci 2, Barcelona, Catalonia, Spain.
   [Esteller, Manel] IRCEA, Barcelona, Catalonia, Spain.
C3 Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Universidade
   de Santiago de Compostela; CIBER - Centro de Investigacion Biomedica en
   Red; CIBEROBN; CIBER - Centro de Investigacion Biomedica en Red;
   CIBERONC; University of Iceland; Instituto de Investigacion Biomedica de
   Malaga y Plataforma en Nanomedicina (IBIMA); Universidad de Malaga;
   Landspitali National University Hospital; University of Barcelona
RP Crujeiras, AB; Esteller, M (通讯作者)，Bellvitge Biomed Res Inst IDIBELL, Canc Epigenet & Biol Program PEBC, Barcelona, Catalonia, Spain.; Crujeiras, AB; Casanueva, FF (通讯作者)，Santiago de Compostela Univ USC, Complejo Hosp Univ Santiago CHUS SERGAS, Inst Invest Sanitaria IDIS, Lab Mol & Cellular Endocrinol, Santiago De Compostela, Spain.; Crujeiras, AB; Casanueva, FF; Esteller, M (通讯作者)，CIBER Fisiopatol Obesidad & Nutr CIBERobn, Madrid, Spain.; Esteller, M (通讯作者)，Univ Barcelona, Sch Med, Dept Psychol Sci 2, Barcelona, Catalonia, Spain.; Esteller, M (通讯作者)，IRCEA, Barcelona, Catalonia, Spain.
EM anabelencrujeiras@hotmail.com; endocrine@usc.es; mesteller@idibell.cat
RI sandoval, juan/M-4593-2015; Tinahones, Francisco/AAB-2882-2020; Moran,
   Sebastian/G-5293-2013; Crujeiras, Ana B/ABA-8866-2021; Esteller,
   Manel/L-5956-2014; MACIAS-GONZALEZ, MANUEL/E-7584-2016
OI Moran, Sebastian/0000-0003-4192-8983; Lopez Lopez,
   Rafael/0000-0003-1315-655X; sandoval, juan/0000-0002-5100-973X;
   Jonasson, Jon G./0000-0002-2635-5032; Crujeiras, Ana
   B/0000-0003-4392-0301; Esteller, Manel/0000-0003-4490-6093; Tinahones,
   Francisco J/0000-0001-6871-4403; MACIAS-GONZALEZ,
   MANUEL/0000-0002-6475-4704
FU European Research Council (ERC) grant EPINORC; Fondo de Investigacion
   Sanitaria [PI14/01012, PE13/00024]; CIBERobn from the Instituto de Salud
   Carlos III (ISCIII)-Subdireccion General de Evaluacion y Fomento de la
   Investigacion [CB06/003]; Fondo Europeo de Desarrollo Regional (FEDER),
   Spain; Health and Science Departments of the Catalan Government
   (Generalitat de Catalunya); Health Department of the Xunta the Galicia,
   Spain [GRC2014/034]; Fundacion Lilly and Fundacion Mapfre; ISCIII
   [C09/00365, CM14/00067]; Nicolas Monardes program from the Servicio
   Andaluz de Salud, Junta de Andalucia, Spain [C-0029-2014]
FX This work was supported by grants from the European Research Council
   (ERC) grant EPINORC; the Fondo de Investigacion Sanitaria (PI14/01012;
   PE13/00024) research project, and CIBERobn (CB06/003) from the Instituto
   de Salud Carlos III (ISCIII)-Subdireccion General de Evaluacion y
   Fomento de la Investigacion; Fondo Europeo de Desarrollo Regional
   (FEDER), Spain; the Health and Science Departments of the Catalan
   Government (Generalitat de Catalunya) and the Health Department of the
   Xunta the Galicia (GRC2014/034), Spain, as well as Fundacion Lilly and
   Fundacion Mapfre. Crujeiras A B was funded by the ISCIII through a
   research contract 'Sara Borrell' (C09/00365). Diaz-Lagares A is funded
   by the ISCIII through a research contract Rio Hortega (CM14/00067).
   Macias-Gonzalez M is recipient of the Nicolas Monardes program from the
   Servicio Andaluz de Salud, Junta de Andalucia, Spain (Grant
   C-0029-2014). Sandoval J is a 'Miguel Servet' researcher. Esteller M is
   an ICREA Research Professor.
CR [Anonymous], 2000, WHO TECHN REP SER
   Barrio S, 2011, J CLIN PATHOL, V64, P1010, DOI 10.1136/jclinpath-2011-200175
   Conway K, 2014, BREAST CANCER RES, V16, DOI 10.1186/s13058-014-0450-6
   Crujeiras AB, 2013, FREE RADICAL RES, V47, P243, DOI 10.3109/10715762.2013.772604
   Crujeiras AB, 2012, J ENDOCRINOL INVEST, V35, P681, DOI 10.3275/8370
   Crujeiras AB, 2015, HUM REPROD UPDATE, V21, P249, DOI 10.1093/humupd/dmu060
   Dick KJ, 2014, LANCET, V383, P1990, DOI 10.1016/S0140-6736(13)62674-4
   Dmitriev AA, 2012, EPIGENETICS-US, V7, P502, DOI 10.4161/epi.19801
   Falcon S, 2007, BIOINFORMATICS, V23, P257, DOI 10.1093/bioinformatics/btl567
   Faryna M, 2012, FASEB J, V26, P4937, DOI 10.1096/fj.12-209502
   Hair BY, 2015, CANCER EPIDEM BIOMAR, V24, P580, DOI 10.1158/1055-9965.EPI-14-1017
   Heyn H, 2013, EXPERT REV MOL DIAGN, V13, P473, DOI [10.1586/ERM.13.36, 10.1586/erm.13.36]
   Heyn H, 2012, P NATL ACAD SCI USA, V109, P10522, DOI 10.1073/pnas.1120658109
   Hill VK, 2011, CANCER RES, V71, P2988, DOI 10.1158/0008-5472.CAN-10-4026
   Howe LR, 2013, CLIN CANCER RES, V19, P6074, DOI 10.1158/1078-0432.CCR-12-2603
   Li Y, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1412-9
   Lorincz AM, 2006, ENDOCR-RELAT CANCER, V13, P279, DOI 10.1677/erc.1.00729
   Luxen S, 2008, CANCER RES, V68, P1037, DOI 10.1158/0008-5472.CAN-07-5782
   McCullough L.E., 2015, Int. J. Cancer Clin. Res, V2, P013, DOI [10.23937/2378-3419/2/1/1013, DOI 10.23937/2378-3419/2/1/1013, DOI 10.23937/2378-3419/2/1/1013)]
   Milagro FI, 2013, MOL ASPECTS MED, V34, P782, DOI 10.1016/j.mam.2012.06.010
   Milagro FI, 2012, CHRONOBIOL INT, V29, P1180, DOI 10.3109/07420528.2012.719967
   Naushad SM, 2014, MOL CELL BIOCHEM, V392, P273, DOI 10.1007/s11010-014-2037-z
   Rauch TA, 2012, TUMOR BIOL, V33, P287, DOI 10.1007/s13277-011-0282-2
   Renehan AG, 2008, LANCET, V371, P569, DOI 10.1016/S0140-6736(08)60269-X
   Roy K, 2015, CLIN SCI, V128, P863, DOI 10.1042/CS20140542
   Sandoval J, 2011, EPIGENETICS-US, V6, P692, DOI 10.4161/epi.6.6.16196
   Sehrawat B, 2011, HUM GENET, V130, P529, DOI 10.1007/s00439-011-0973-1
   Seidell JC, 2015, ANN NUTR METAB, V66, P7, DOI 10.1159/000375143
   Severson PL, 2013, EPIGENETICS-US, V8, P1080, DOI 10.4161/epi.25926
   Stefansson OA, 2015, MOL ONCOL, V9, P555, DOI 10.1016/j.molonc.2014.10.012
   Stefansson OA, 2013, AM J PATHOL, V183, P1052, DOI 10.1016/j.ajpath.2013.04.033
   Tao MH, 2011, AM J CLIN NUTR, V94, P831, DOI 10.3945/ajcn.110.009365
   Tessema M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034850
   van Gemert WA, 2015, BREAST CANCER RES TR, V152, P155, DOI 10.1007/s10549-015-3447-7
   Yara S, 2013, EPIGENOMICS, V7, P283
   Zadravec D, 2010, FASEB J, V24, P4366, DOI 10.1096/fj.09-152298
   Zou CH, 2008, J NUTR BIOCHEM, V19, P277, DOI 10.1016/j.jnutbio.2007.06.006
NR 37
TC 35
Z9 37
U1 0
U2 11
PU BIOSCIENTIFICA LTD
PI BRISTOL
PA EURO HOUSE, 22 APEX COURT WOODLANDS, BRADLEY STOKE, BRISTOL BS32 4JT,
   ENGLAND
SN 1351-0088
EI 1479-6821
J9 ENDOCR-RELAT CANCER
JI Endocr.-Relat. Cancer
PD JUL
PY 2017
VL 24
IS 7
BP 351
EP 363
DI 10.1530/ERC-16-0565
PG 13
WC Oncology; Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Endocrinology & Metabolism
GA EZ8LV
UT WOS:000404978400009
PM 28442560
OA Bronze
DA 2025-01-12
ER

PT J
AU Leung, YK
   Govindarajah, V
   Cheong, A
   Veevers, J
   Song, D
   Gear, R
   Zhu, XG
   Ying, J
   Kendler, A
   Medvedovic, M
   Belcher, S
   Ho, SM
AF Leung, Yuet-Kin
   Govindarajah, Vinothini
   Cheong, Ana
   Veevers, Jennifer
   Song, Dan
   Gear, Robin
   Zhu, Xuegong
   Ying, Jun
   Kendler, Ady
   Medvedovic, Mario
   Belcher, Scott
   Ho, Shuk-Mei
TI Gestational high-fat diet and bisphenol A exposure heightens mammary
   cancer risk
SO ENDOCRINE-RELATED CANCER
LA English
DT Article
DE breast cancer; developmental origin of health and disease (DOHaD);
   RNA-seq; transcriptomics; DNA methylation; patient survival; TCGA;
   windows of susceptibility; in utero exposure; bisphenol A; high-butter
   fat diet; non-monotonic response
ID IN-UTERO EXPOSURE; BREAST-CANCER; GLAND DEVELOPMENT; GENE-EXPRESSION;
   ENDOCRINE DISRUPTORS; MATERNAL DIET; SUSCEPTIBILITY; RATS;
   CARCINOGENESIS; PROLIFERATION
AB In utero exposure to bisphenol A (BPA) increases mammary cancer susceptibility in offspring. High-fat diet is widely believed to be a risk factor of breast cancer. The objective of this study was to determine whether maternal exposure to BPA in addition to high-butterfat (HBF) intake during pregnancy further influences carcinogen-induced mammary cancer risk in offspring, and its dose-response curve. In this study, we found that gestational HBF intake in addition to a low-dose BPA (25 mu g/kg BW/day) exposure increased mammary tumor incidence in a 50-day-of-age chemical carcinogen administration model and altered mammary gland morphology in offspring in a non-monotonic manner, while shortening tumor-free survival time compared with the HBF-alone group. In utero HBF and BPA exposure elicited differential effects at the gene level in PND21 mammary glands through DNA methylation, compared with HBF intake in the absence of BPA. Top HBF + BPA-dysregulated genes (ALDH1B1, ASTL, CA7, CPLX4, KCNV2, MAGEE2 and TUBA3E) are associated with poor overall survival in The Cancer Genomic Atlas (TCGA) human breast cancer cohort (n = 1082). Furthermore, the prognostic power of the identified genes was further enhanced in the survival analysis of Caucasian patients with estrogen receptor-positive tumors. In conclusion, concurrent HBF dietary and a low-dose BPA exposure during pregnancy increases mammary tumor incidence in offspring, accompanied by alterations in mammary gland development and gene expression, and possibly through epigenetic reprogramming.
C1 [Leung, Yuet-Kin; Govindarajah, Vinothini; Cheong, Ana; Veevers, Jennifer; Song, Dan; Zhu, Xuegong; Ying, Jun; Medvedovic, Mario; Ho, Shuk-Mei] Dept Environm Hlth, Cincinnati, OH USA.
   [Leung, Yuet-Kin; Govindarajah, Vinothini; Cheong, Ana; Veevers, Jennifer; Song, Dan; Gear, Robin; Zhu, Xuegong; Ying, Jun; Medvedovic, Mario; Belcher, Scott; Ho, Shuk-Mei] Univ Cincinnati, Coll Med, Ctr Environm Genet, Cincinnati, OH 45220 USA.
   [Leung, Yuet-Kin; Veevers, Jennifer; Ying, Jun; Medvedovic, Mario; Ho, Shuk-Mei] Cincinnati Canc Ctr, Cincinnati, OH USA.
   [Kendler, Ady] Univ Cincinnati, Coll Med, Dept Pathol & Lab Med, Cincinnati, OH USA.
   [Gear, Robin; Belcher, Scott] Univ Cincinnati, Coll Med, Dept Pharmacol & Cell Biophys, Cincinnati, OH USA.
   [Ho, Shuk-Mei] Cincinnati Veteran Affairs Hosp, Med Ctr, Cincinnati, OH USA.
   [Belcher, Scott] Dept Biol Sci, Raleigh, NC USA.
C3 University System of Ohio; University of Cincinnati; University System
   of Ohio; University of Cincinnati; University System of Ohio; University
   of Cincinnati
RP Ho, SM (通讯作者)，Dept Environm Hlth, Cincinnati, OH USA.; Ho, SM (通讯作者)，Univ Cincinnati, Coll Med, Ctr Environm Genet, Cincinnati, OH 45220 USA.; Ho, SM (通讯作者)，Cincinnati Canc Ctr, Cincinnati, OH USA.; Ho, SM (通讯作者)，Cincinnati Veteran Affairs Hosp, Med Ctr, Cincinnati, OH USA.
EM shuk-mei.ho@uc.edu
RI Leung, Ricky/H-5958-2019
OI Leung, Yuet-kin/0000-0003-2063-277X; Belcher, Scott/0000-0002-1196-3705
FU National Institutes of Health [U01ES019480, U01ES020988, U54HL127624,
   RC2ES018765, P30ES006096, P30ES025128]; United States Department of
   Veterans Affairs [I01BX000675]
FX This study was supported in part by grants from the National Institutes
   of Health: U01ES019480, U01ES020988, U54HL127624, RC2ES018765,
   P30ES006096 and P30ES025128, and the United States Department of
   Veterans Affairs: I01BX000675.
CR Adebamowo CA, 2005, ANN EPIDEMIOL, V15, P789, DOI 10.1016/j.annepidem.2005.01.008
   Agency USEP, 2010, BISPH ACT PLAN CASRN
   Andrade FD, 2014, J NUTR BIOCHEM, V25, P613, DOI 10.1016/j.jnutbio.2014.02.002
   Betancourt AM, 2010, ENVIRON HEALTH PERSP, V118, P1614, DOI 10.1289/ehp.1002148
   BUELL P, 1973, J NATL CANCER I, V51, P1479, DOI 10.1093/jnci/51.5.1479
   Cho EY, 2003, JNCI-J NATL CANCER I, V95, P1079, DOI 10.1093/jnci/95.14.1079
   Czirják G, 2007, J NEUROPHYSIOL, V98, P1213, DOI 10.1152/jn.00493.2007
   de Assis S, 2006, INT J CANCER, V119, P1537, DOI 10.1002/ijc.21936
   de Assis S, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2058
   Doherty Leo F., 2010, Hormones & Cancer, V1, P146, DOI 10.1007/s12672-010-0015-9
   Durando M, 2007, ENVIRON HEALTH PERSP, V115, P80, DOI 10.1289/ehp.9282
   Fabian CJ, 2015, BREAST CANCER RES, V17, DOI 10.1186/s13058-015-0571-6
   Gonzalez CA, 2010, EUR J CANCER, V46, P2555, DOI 10.1016/j.ejca.2010.07.025
   Govindarajah V, 2016, J NUTR BIOCHEM, V29, P73, DOI 10.1016/j.jnutbio.2015.11.003
   Hanf V, 2005, EUR J OBSTET GYN R B, V123, P139, DOI 10.1016/j.ejogrb.2005.05.011
   Heffelfinger SC, 2003, LAB INVEST, V83, P1001, DOI 10.1097/01.LAB.0000075641.27128.67
   Hilakivi-Clarke L, 2002, CLIN CANCER RES, V8, P3601
   Hilakivi-Clarke L, 1999, NUTRITION, V15, P392, DOI 10.1016/S0899-9007(99)00029-5
   Hilakivi-Clarke L, 2007, CURR CANCER DRUG TAR, V7, P465
   Hilakivi-Clarke L, 2013, J MAMMARY GLAND BIOL, V18, P25, DOI 10.1007/s10911-013-9274-8
   HilakiviClarke L, 1996, JNCI-J NATL CANCER I, V88, P1821, DOI 10.1093/jnci/88.24.1821
   HilakiviClarke L, 1995, ANN NY ACAD SCI, V768, P327, DOI 10.1111/j.1749-6632.1995.tb12152.x
   HilakiviClarke L, 1997, P NATL ACAD SCI USA, V94, P9372, DOI 10.1073/pnas.94.17.9372
   Ho SM, 2006, CANCER RES, V66, P5624, DOI 10.1158/0008-5472.CAN-06-0516
   Holmes MD, 2004, BREAST CANCER RES, V6, P170, DOI 10.1186/bcr909
   Hovey RC, 2005, BIOL REPROD, V72, P423, DOI 10.1095/biolreprod.104.029769
   HULKA BS, 1989, PREV MED, V18, P180, DOI 10.1016/0091-7435(89)90065-0
   Hunter DJ, 1996, NEW ENGL J MED, V334, P356, DOI 10.1056/NEJM199602083340603
   Key TJ, 2011, AM J CLIN NUTR, V94, P1043, DOI 10.3945/ajcn.111.015735
   Lee JH, 2015, ONCOTARGET, V6, P8132, DOI 10.18632/oncotarget.3517
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lo CY, 2009, INT J CANCER, V125, P767, DOI 10.1002/ijc.24464
   Löf M, 2007, BRIT J CANCER, V97, P1570, DOI 10.1038/sj.bjc.6604033
   MacLennan M, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2646
   Markey CM, 2001, BIOL REPROD, V65, P1215, DOI 10.1093/biolreprod/65.4.1215
   Martin LJ, 2011, CANCER RES, V71, P123, DOI 10.1158/0008-5472.CAN-10-1436
   Martinez AM, 2015, BIOL REPROD, V93, DOI 10.1095/biolreprod.115.131433
   Medvedovic M, 2009, PHYSIOL GENOMICS, V38, P80, DOI 10.1152/physiolgenomics.00007.2009
   Monti DM, 2017, J ENZYM INHIB MED CH, V32, P5, DOI 10.1080/14756366.2016.1225046
   Moral R, 2008, J ENDOCRINOL, V196, P101, DOI 10.1677/JOE-07-0056
   Muñoz-de-Toro M, 2005, ENDOCRINOLOGY, V146, P4138, DOI 10.1210/en.2005-0340
   Ottschytsch N, 2002, P NATL ACAD SCI USA, V99, P7986, DOI 10.1073/pnas.122617999
   Park SY, 2012, CANCER PREV RES, V5, P216, DOI 10.1158/1940-6207.CAPR-11-0260
   Perera F, 2011, REPROD TOXICOL, V31, P363, DOI 10.1016/j.reprotox.2010.12.055
   Peto J, 2001, NATURE, V411, P390, DOI 10.1038/35077256
   Pietri E, 2016, ENDOCR-RELAT CANCER, V23, pR485, DOI 10.1530/ERC-16-0190
   Prentice RL, 2006, JAMA-J AM MED ASSOC, V295, P629, DOI 10.1001/jama.295.6.629
   Rosenfeld CS, 2012, REPROD DOMEST ANIM, V47, P23, DOI 10.1111/j.1439-0531.2012.02051.x
   RUSSO IH, 1978, JNCI-J NATL CANCER I, V61, P1439
   Russo IH, 1996, ENVIRON HEALTH PERSP, V104, P938, DOI 10.1289/ehp.96104938
   Russo J, 1996, BREAST CANCER RES TR, V39, P7, DOI 10.1007/BF01806074
   RUSSO J, 1983, ENVIRON HEALTH PERSP, V49, P185, DOI 10.2307/3429597
   RUSSO J, 1979, AM J PATHOL, V96, P721
   RUSSO J, 1987, LAB INVEST, V57, P112
   Soto AM, 2015, NAT REV ENDOCRINOL, V11, P507, DOI 10.1038/nrendo.2015.125
   Soto AM, 2013, J MAMMARY GLAND BIOL, V18, P199, DOI 10.1007/s10911-013-9293-5
   Spitzner M, 2007, FASEB J, V21, P35, DOI 10.1096/fj.06-6200com
   Suzuki T, 2004, INT J ONCOL, V25, P153
   Teegarden D, 2012, NUTR RES REV, V25, P68, DOI 10.1017/S0954422411000199
   Thigpen JE, 2013, J AM ASSOC LAB ANIM, V52, P130
   WELSCH CW, 1985, CANCER RES, V45, P3415
   WILLETT WC, 1992, JAMA-J AM MED ASSOC, V268, P2037, DOI 10.1001/jama.268.15.2037
   Yang GZ, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1216-y
   Zhu XG, 2004, AM J PATHOL, V164, P2003, DOI 10.1016/S0002-9440(10)63760-1
   ZIEGLER RG, 1993, JNCI-J NATL CANCER I, V85, P1819, DOI 10.1093/jnci/85.22.1819
NR 65
TC 51
Z9 61
U1 1
U2 26
PU BIOSCIENTIFICA LTD
PI BRISTOL
PA EURO HOUSE, 22 APEX COURT WOODLANDS, BRADLEY STOKE, BRISTOL BS32 4JT,
   ENGLAND
SN 1351-0088
EI 1479-6821
J9 ENDOCR-RELAT CANCER
JI Endocr.-Relat. Cancer
PD JUL
PY 2017
VL 24
IS 7
BP 365
EP 378
DI 10.1530/ERC-17-0006
PG 14
WC Oncology; Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Endocrinology & Metabolism
GA EZ8LV
UT WOS:000404978400010
PM 28487351
OA hybrid, Green Published
DA 2025-01-12
ER

PT J
AU Naghitorabi, M
   Sadeghi, HMM
   Asl, JM
   Rabbani, M
   Jafarian-Dehkordi, A
AF Naghitorabi, Mojgan
   Sadeghi, Hamid Mir Mohammad
   Asl, Javad Mohammadi
   Rabbani, Mohammad
   Jafarian-Dehkordi, Abbas
TI Study of the Role of siRNA Mediated Promoter Methylation in DNMT3B
   Knockdown and Alteration of Promoter Methylation of CDH1, GSTP1 Genes in
   MDA-MB-453 Cell Line
SO IRANIAN JOURNAL OF PHARMACEUTICAL RESEARCH
LA English
DT Article
DE Epigenetic; Promoter methylation; Gene silencing; siRNA; DNMT3B
ID DNA METHYLTRANSFERASE EXPRESSION; EPIGENETIC THERAPY; CANCER; 3A;
   HYPERMETHYLATION; CARCINOMA; GROWTH; 3B
AB Promoter methylation is one of the main epigenetic mechanisms that leads to the inactivation of tumor suppressor genes during carcinogenesis. Due to the reversible nature of DNA methylation, many studies have been performed to correct theses epigenetic defects by inhibiting DNA methyltransferases (DNMTs). In this case novel therapeutics especially siRNA oligonucleotides have been used to specifically knock down the DNMTs at mRNA level. Also many studies have focused on transcriptional gene silencing in mammalian cells via siRNA mediated promoter methylation. The present study was designed to assess the role of siRNA mediated promoter methylation in DNMT3B knockdown and alteration of promoter methylation of Cadherin-1 (CDH1), Glutathione S-Transferase Pi 1(GSTP1), and DNMT3B genes in MDA-MB-453 cell line.
   MDA-MB-453 cells were transfected with siDNMT targeting DNMT3B promoter and harvested at 24 and 48 h post transfection to monitor gene silencing and promoter methylation respectively. DNMT3B expression was monitored by quantitative RT-PCR method. Promoter methylation was quantitatively evaluated using differential high resolution melting analysis.
   A non-significant 20% reduction in DNMT3B mRNA level was shown only after first transfection with siDNMT, which was not reproducible. Promoter methylation levels of DNMT3B, CDH1, and GSTP1 were detected at about 15%, 70% and 10% respectively, in the MDA-MB-453 cell line, with no significant change after transfection.
   Our results indicated that siDNMT sequence were not able to affect promoter methylation and silencing of DNMT3B in MDA-MB-453 cells. However, quantitation of methylation confirmed a hypermethylated phenotype at CDH1 and GSTP1 promoters as well as a differential methylation pattern at DNMT3B promoter in breast cancer.
C1 [Naghitorabi, Mojgan] Ahvaz Jundishapur Univ Med Sci, Sch Pharm, Dept Pharmacognosy, Ahvaz, Iran.
   [Sadeghi, Hamid Mir Mohammad; Rabbani, Mohammad] Isfahan Univ Med Sci, Sch Pharm & Pharmaceut Sci, Dept Pharmaceut Biotechnol, Esfahan, Iran.
   [Asl, Javad Mohammadi] Ahvaz Jundishapur Univ Med Sci, Canc Petr & Environm Pollutants Res Ctr, Ahvaz, Iran.
   [Jafarian-Dehkordi, Abbas] Isfahan Univ Med Sci, Sch Pharm & Pharmaceut Sci, Dept Pharmacol & Toxicol, Esfahan, Iran.
C3 Ahvaz Jundishapur University of Medical Sciences (AJUMS); Isfahan
   University of Medical Sciences; Ahvaz Jundishapur University of Medical
   Sciences (AJUMS); Isfahan University of Medical Sciences
RP Naghitorabi, M (通讯作者)，Ahvaz Jundishapur Univ Med Sci, Sch Pharm, Dept Pharmacognosy, Ahvaz, Iran.
EM naghitorabi-m@ajums.ac.ir
RI Jafarian-dehkordi, Abbas/W-1694-2017; Naghitorabi, Mojgan/T-5220-2017
OI Naghitorabi, Mojgan/0000-0002-6443-9261; Jafarian,
   Abbas/0000-0002-8292-1908
FU Research in School of Pharmacy and Pharmaceutical Sciences, Isfahan,
   Iran [389389]
FX The authors thank Ms. Moazen from the Department of Pharmaceutical
   Biotechnology, School of Pharmacy and Pharmaceutical Sciences, Isfahan,
   Iran, for her technical assistance. This study was financially and
   technically supported by the Vice Chancellory of Research in School of
   Pharmacy and Pharmaceutical Sciences, Isfahan, Iran (Grant# 389389).
CR Castanotto D, 2005, MOL THER, V12, P179, DOI 10.1016/j.ymthe.2005.03.003
   Coppola G., 2014, OMICS APPL NEUROSCIE, P126
   Das PM, 2004, J CLIN ONCOL, V22, P4632, DOI 10.1200/JCO.2004.07.151
   Deng T, 2009, BIOCHEM BIOPH RES CO, V387, P611, DOI 10.1016/j.bbrc.2009.07.093
   Drini M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016831
   Ganesan A, 2009, CURR CANCER DRUG TAR, V9, P963, DOI 10.2174/156800909790192428
   Girault I, 2003, CLIN CANCER RES, V9, P4415
   Hoque MO, 2009, CANCER EPIDEM BIOMAR, V18, P2694, DOI 10.1158/1055-9965.EPI-08-0821
   Jung Y, 2007, J MOL MED, V85, P1137, DOI 10.1007/s00109-007-0216-z
   Kawasaki H, 2004, NATURE, V431, P211, DOI 10.1038/nature02889
   Lin RK, 2007, LUNG CANCER, V55, P205, DOI 10.1016/j.lungcan.2006.10.022
   Lin TS, 2005, CANCER LETT, V226, P77, DOI 10.1016/j.canlet.2004.12.031
   Miyake T, 2010, YONAGO ACTA MED, V53, P1
   Morris KV, 2004, SCIENCE, V305, P1289, DOI 10.1126/science.1101372
   Naghitorabi M, 2013, RES PHARM SCI, V8, P167
   Oh BK, 2007, INT J MOL MED, V20, P65
   Park CW, 2004, BIOCHEM BIOPH RES CO, V323, P275, DOI 10.1016/j.bbrc.2004.08.096
   Park HJ, 2006, CANCER LETT, V233, P271, DOI 10.1016/j.canlet.2005.03.017
   Peedicayil J, 2006, INDIAN J MED RES, V123, P17
   Pulukuri SMK, 2007, CANCER RES, V67, P6637, DOI 10.1158/0008-5472.CAN-07-0751
   Rajendran G, 2011, J NEURO-ONCOL, V104, P483, DOI 10.1007/s11060-010-0520-2
   Rasti M, 2014, MIDDLE EAST J CANCER, V5, P207
   Sandhu R, 2012, BREAST CANCER RES TR, V131, P385, DOI 10.1007/s10549-011-1409-2
   Suzuki Kazuo, 2005, J RNAi Gene Silencing, V1, P66
   Svoboda P, 2004, NUCLEIC ACIDS RES, V32, P3601, DOI 10.1093/nar/gkh697
   Syzf M., 2003, B CANC, V2, P299
   Ting AH, 2005, NAT GENET, V37, P906, DOI 10.1038/ng1611
   Veeck J, 2010, J MAMMARY GLAND BIOL, V15, P5, DOI 10.1007/s10911-010-9165-1
   Vincent A, 2008, FASEB J, V22, P3035, DOI 10.1096/fj.07-103390
   Wang SH, 2008, CHINESE MED J-PEKING, V121, P1712, DOI 10.1097/00029330-200809010-00024
   Yaqinuddin A, 2008, CANCER CELL INT, V8, DOI 10.1186/1475-2867-8-13
   Zhao ZJ, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/737535
   Zhu XG, 2008, J CLIN ENDOCR METAB, V93, P3610, DOI 10.1210/jc.2008-0578
NR 33
TC 1
Z9 1
U1 0
U2 5
PU SHAHEED BEHESHTI UNIV, SCH PHARMACY
PI TEHRAN
PA NO 10 SHAMS ALLEY, VALI-E ASR ST, TEHRAN, 00000, IRAN
SN 1735-0328
EI 1726-6890
J9 IRAN J PHARM RES
JI Iran. J. Pharm. Res.
PD SPR
PY 2017
VL 16
IS 2
BP 768
EP 777
PG 10
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA EZ8HZ
UT WOS:000404966900039
DA 2025-01-12
ER

PT J
AU Stefansson, OA
   Hermanowicz, S
   van der Horst, J
   Hilmarsdottir, H
   Staszczak, Z
   Jonasson, JG
   Tryggvadottir, L
   Gudjonsson, T
   Sigurdsson, S
AF Stefansson, Olafur Andri
   Hermanowicz, Stefan
   van der Horst, Jasper
   Hilmarsdottir, Holmfridur
   Staszczak, Zuzanna
   Jonasson, Jon Gunnlaugur
   Tryggvadottir, Laufey
   Gudjonsson, Thorkell
   Sigurdsson, Stefan
TI CpG promoter methylation of the ALKBH3 alkylation repair gene in breast
   cancer
SO BMC CANCER
LA English
DT Article
DE Breast cancer; ALKBH3; Epigenetics; DNA methylation; DNA repair;
   Alkylation; Prognosis
ID DNA METHYLATION; MGMT; TEMOZOLOMIDE; CONTRIBUTES; EXPRESSION; DAMAGE;
   BRCA1; SUSCEPTIBILITY; GLIOBLASTOMA; RESISTANCE
AB Background: DNA repair of alkylation damage is defective in various cancers. This occurs through somatically acquired inactivation of the MGMT gene in various cancer types, including breast cancers. In addition to MGMT, the two E. coli AlkB homologs ALKBH2 and ALKBH3 have also been linked to direct reversal of alkylation damage. However, it is currently unknown whether ALKBH2 or ALKBH3 are found inactivated in cancer.
   Methods: Methylome datasets ( GSE52865, GSE20713, GSE69914), available through Omnibus, were used to determine whether ALKBH2 or ALKBH3 are found inactivated by CpG promoter methylation. TCGA dataset enabled us to then assess the impact of CpG promoter methylation on mRNA expression for both ALKBH2 and ALKBH3. DNA methylation analysis for the ALKBH3 promoter region was carried out by pyrosequencing ( PyroMark Q24) in 265 primary breast tumours and 30 proximal normal breast tissue samples along with 8 breast-derived cell lines. ALKBH3 mRNA and protein expression were analysed in cell lines using RT-PCR and Western blotting, respectively. DNA alkylation damage assay was carried out in cell lines based on immunofluorescence and confocal imaging. Data on clinical parameters and survival outcomes in patients were obtained and assessed in relation to ALKBH3 promoter methylation.
   Results: The ALKBH3 gene, but not ALKBH2, undergoes CpG promoter methylation and transcriptional silencing in breast cancer. We developed a quantitative alkylation DNA damage assay based on immunofluorescence and confocal imaging revealing higher levels of alkylation damage in association with epigenetic inactivation of the ALKBH3 gene (P = 0.029). In our cohort of 265 primary breast cancer, we found 72 cases showing aberrantly high CpG promoter methylation over the ALKBH3 promoter (27%; 72 out of 265). We further show that increasingly higher degree of ALKBH3 promoter methylation is associated with reduced breast-cancer specific survival times in patients. In this analysis, ALKBH3 promoter methylation at > 20% CpG methylation was found to be statistically significantly associated with reduced survival (HR = 2.3; P = 0.012). By thresholding at the clinically relevant CpG methylation level (> 20%), we find the incidence of ALKBH3 promoter methylation to be 5% (13 out of 265).
   Conclusions: ALKBH3 is a novel addition to the catalogue of DNA repair genes found inactivated in breast cancer. Our results underscore a link between defective alkylation repair and breast cancer which, additionally, is found in association with poor disease outcome.
C1 [Stefansson, Olafur Andri; van der Horst, Jasper; Hilmarsdottir, Holmfridur; Staszczak, Zuzanna] Biomed Ctr, Canc Res Lab, Vatnsmyrarvegur 16 4th Floor, IS-101 Reykjavik, Iceland.
   [Stefansson, Olafur Andri; Hermanowicz, Stefan; van der Horst, Jasper; Hilmarsdottir, Holmfridur; Jonasson, Jon Gunnlaugur; Tryggvadottir, Laufey; Gudjonsson, Thorkell; Sigurdsson, Stefan] Univ Iceland, Fac Med, Vatnsmyrarvegur 16 4th Floor, IS-101 Reykjavik, Iceland.
   [Hermanowicz, Stefan; Gudjonsson, Thorkell; Sigurdsson, Stefan] Biomed Ctr, Dept Biochem & Mol Biol, Vatnsmyrarvegur 16 5th Floor, IS-101 Reykjavik, Iceland.
   [Jonasson, Jon Gunnlaugur; Tryggvadottir, Laufey] Iceland Canc Registry, Skogarhlid 8, Reykjavik, Iceland.
   [Jonasson, Jon Gunnlaugur] Landspitali Univ Hosp, Dept Pathol, Reykjavik, Iceland.
C3 University of Iceland; Landspitali National University Hospital
RP Sigurdsson, S (通讯作者)，Univ Iceland, Fac Med, Vatnsmyrarvegur 16 4th Floor, IS-101 Reykjavik, Iceland.; Sigurdsson, S (通讯作者)，Biomed Ctr, Dept Biochem & Mol Biol, Vatnsmyrarvegur 16 5th Floor, IS-101 Reykjavik, Iceland.
EM stefsi@hi.is
RI Gudjonsson, Thorkell/K-5361-2014; Sigurdsson, Stefan/L-9820-2015
OI Jonasson, Jon G./0000-0002-2635-5032; Sigurdsson,
   Stefan/0000-0002-5284-0058; Hilmarsdottir,
   Holmfridur/0000-0003-1040-8125; Gudjonsson, Thorkell/0000-0002-5230-4263
FU Icelandic Centre for Research [14193-051, 152077-051]
FX The authors would like to thank The Icelandic Centre for Research
   (www.rannis.is) grant IDs #14193-051 and #152077-051, Gongum Saman
   (www.gongumsaman.is) and Minningarsjodur Eggerts Briem for financial
   support.
CR Aas PA, 2003, NATURE, V421, P859, DOI 10.1038/nature01363
   Alexandrov LB, 2013, NATURE, V500, P415, DOI 10.1038/nature12477
   Stefansson OA, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2871
   Baylin SB, 2011, NAT REV CANCER, V11, P726, DOI 10.1038/nrc3130
   Brandes JC, 2007, ONCOGENE, V26, P6229, DOI 10.1038/sj.onc.1210433
   Cetica V, 2009, J NEURO-ONCOL, V94, P195, DOI 10.1007/s11060-009-9837-0
   Chang CJ, 2011, CANCER CELL, V19, P86, DOI 10.1016/j.ccr.2010.10.035
   Choi SY, 2011, CLIN EXP MED, V11, P219, DOI 10.1007/s10238-010-0130-5
   Collins N, 1997, BRIT J CANCER, V76, P1150, DOI 10.1038/bjc.1997.526
   Cunningham JM, 2014, SCI REP-UK, V4, DOI 10.1038/srep04026
   Cutter AR, 2015, FEBS LETT, V589, P2914, DOI 10.1016/j.febslet.2015.05.016
   Dango S, 2011, MOL CELL, V44, P373, DOI 10.1016/j.molcel.2011.08.039
   Dedeurwaerder S, 2011, EMBO MOL MED, V3, P726, DOI 10.1002/emmm.201100801
   Dominissini D, 2016, NATURE, V530, P441, DOI 10.1038/nature16998
   Drablos F, 2004, DNA REPAIR, V3, P1389, DOI 10.1016/j.dnarep.2004.05.004
   Esteller M, 2000, NEW ENGL J MED, V343, P1350, DOI 10.1056/NEJM200011093431901
   Fumagalli C, 2012, BREAST CANCER RES TR, V134, P131, DOI 10.1007/s10549-011-1945-9
   Garcia AI, 2011, EMBO MOL MED, V3, P279, DOI 10.1002/emmm.201100136
   Ghoussaini M, 2013, AM J PATHOL, V183, P1038, DOI 10.1016/j.ajpath.2013.07.003
   Goodman MF, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a010363
   Hesson LB, 2014, EPIGENETICS-US, V9, P1422, DOI 10.4161/15592294.2014.970077
   Johannessen TCA, 2013, NEURO-ONCOLOGY, V15, P269, DOI 10.1093/neuonc/nos301
   Jones PA, 2012, NAT REV GENET, V13, P484, DOI 10.1038/nrg3230
   Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412
   Konishi N, 2005, CLIN CANCER RES, V11, P5090, DOI 10.1158/1078-0432.CCR-05-0195
   Kundaje A, 2015, NATURE, V518, P317, DOI 10.1038/nature14248
   Lalloo F, 2012, CLIN GENET, V82, P105, DOI 10.1111/j.1399-0004.2012.01859.x
   Li X., 2016, NAT CHEM BIOL
   Lizio M, 2015, GENOME BIOL, V16, DOI 10.1186/s13059-014-0560-6
   Lord CJ, 2016, NAT REV CANCER, V16, P110, DOI 10.1038/nrc.2015.21
   Moskwa P, 2011, MOL CELL, V41, P210, DOI 10.1016/j.molcel.2010.12.005
   Muggerud AA, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2466
   Nik-Zainal S, 2016, NATURE, V534, P47, DOI 10.1038/nature17676
   Ougland R, 2015, J MOL CELL BIOL, V7, P494, DOI 10.1093/jmcb/mjv029
   Palmieri D, 2014, CLIN CANCER RES, V20, P2727, DOI 10.1158/1078-0432.CCR-13-2588
   Peterlongo P, 2015, HUM MOL GENET, V24, P5345, DOI 10.1093/hmg/ddv251
   Saal LH, 2008, NAT GENET, V40, P102, DOI 10.1038/ng.2007.39
   Sedgwick B, 2007, DNA REPAIR, V6, P429, DOI 10.1016/j.dnarep.2006.10.005
   Shimada K, 2012, CLIN CANCER RES, V18, P5247, DOI 10.1158/1078-0432.CCR-12-0955
   Sigurdardottir LG, 2012, ACTA ONCOL, V51, P880, DOI 10.3109/0284186X.2012.698751
   Simó-Riudalbas L, 2014, HUM GENET, V133, P713, DOI 10.1007/s00439-013-1373-5
   Spitzwieser M, 2015, BREAST CANCER RES, V17, DOI 10.1186/s13058-015-0637-5
   Stefansson OA, 2015, MOL ONCOL, V9, P555, DOI 10.1016/j.molonc.2014.10.012
   Stefansson OA, 2011, EPIGENETICS-US, V6, P638, DOI 10.4161/epi.6.5.15667
   Stefansson OA, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2334
   Subramaniam MM, 2009, BREAST CANCER RES TR, V113, P113, DOI 10.1007/s10549-008-9917-4
   Tasaki M, 2011, BRIT J CANCER, V104, P700, DOI 10.1038/sj.bjc.6606012
   Teschendorff AE, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10478
   Waters LS, 2009, MICROBIOL MOL BIOL R, V73, P134, DOI 10.1128/MMBR.00034-08
   Weller M, 2015, CLIN CANCER RES, V21, P2057, DOI 10.1158/1078-0432.CCR-14-2737
   Yamato I, 2012, CANCER RES, V72, P4829, DOI 10.1158/0008-5472.CAN-12-0328
NR 51
TC 27
Z9 31
U1 1
U2 26
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471-2407
J9 BMC CANCER
JI BMC Cancer
PD JUL 5
PY 2017
VL 17
AR 469
DI 10.1186/s12885-017-3453-8
PG 13
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA EZ8UJ
UT WOS:000405003300002
PM 28679371
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Tan, WJ
   Zhu, ZP
   Ye, L
   Leung, LK
AF Tan, Wenjuan
   Zhu, Zhiping
   Ye, Lan
   Leung, Lai K.
TI Methylation dictates PI.f-specific <i>CYP19</i> transcription in human
   glial cells
SO MOLECULAR AND CELLULAR ENDOCRINOLOGY
LA English
DT Article
DE Methylation; Aromatase; Glial cells
ID BREAST-CANCER CELLS; DNA METHYLATION; GENE-EXPRESSION; AROMATASE
   EXPRESSION; BRAIN REPAIR; INHIBITION; NETWORK; MOUSE; SHEEP; SITE
AB CYP19 is the single copy gene encoding for the estrogen synthetic enzyme aromatase. Alternate splicing of the promoter is the regulatory mechanism of this gene. In the brain, estrogen is synthesized in neuronal and glial cells and the gene is mainly regulated by the alternate promoter PI.f. The hormone produced in this vicinity has been associated with maintaining normal brain functions. Previously, epigenetic regulation has been shown in the promoters PII and I.3 of CYP19 in adipocytes. In the present study, the methylation of PI.f in CYP19 was examined in glial cells. Treatment of the hypomethylating agent 5-aza-2 ' deoxycytidine increased CYP19 mRNA species in U87 MG cells while little changes were observed in the other glia cell lines. As PI.f is also chiefly used in T98G cells with high expression of CYP19, the methylation statuses of the promoter in these two cell models were compared. Our results showed that treating U87 MG cells with 10 mu M 5-aza-2 ' deoxycytidine significantly induced a similar to 10-fold increase in CYP19 transcription and similar to 80% increase in aromatase activity. In contrast, the same treatment did not change either endpoint in T98G cells. Further investigation illustrated the CpGs in PI.f were differentially methylated in the two cell lines; 63% and 37% of the 14 CpG sites were methylated in U87 MG and T98G cells respectively. In conclusion, this study illustrated that the brain-specific PI.f derived CYP19 expression can be regulated by DNA methylation. (C) 2017 Elsevier B.V. All rights reserved.
C1 [Tan, Wenjuan; Leung, Lai K.] Chinese Univ Hong Kong, Fac Sci, Sch Life Sci, Biochem Programme, Shatin, Hong Kong, Peoples R China.
   [Zhu, Zhiping; Ye, Lan] Nanjing Med Univ, State Key Lab Reprod Med, Nanjing 211166, Jiangsu, Peoples R China.
   [Leung, Lai K.] Chinese Univ Hong Kong, Fac Sci, Sch Life Sci, Food & Nutr Sci Programme, Shatin, Hong Kong, Peoples R China.
C3 Chinese University of Hong Kong; Nanjing Medical University; Chinese
   University of Hong Kong
RP Ye, L (通讯作者)，Nanjing Med Univ, State Key Lab Reprod Med, Nanjing 211166, Jiangsu, Peoples R China.; Leung, LK (通讯作者)，Chinese Univ Hong Kong, Food & Nutr Sci Programme, Rm 507C MMW Bldg, Shatin, Hong Kong, Peoples R China.
EM lanye@njmu.edu.cn; laikleung@cuhk.edu.hk
RI Leung, Lai/E-6314-2011; Ye, Lan/JVN-1758-2024; Leung, Lai/C-6511-2013
OI Leung, Lai/0000-0002-7781-3099
FU Chinese University of Hong Kong [4053184]; Innovative and
   Entrepreneurial Program of Jiangsu Province; Natural Science Foundation
   of Jiangsu Province [15KJA180006]
FX This study was supported by The Chinese University of Hong Kong Direct
   Grant #4053184, Innovative and Entrepreneurial Program of Jiangsu
   Province, and Natural Science Foundation of Jiangsu Province
   (15KJA180006).
CR Ahsan S, 2014, ACTA NEUROPATHOL COM, V2, DOI 10.1186/2051-5960-2-59
   Bingham D, 2005, J CEREBR BLOOD F MET, V25, P414, DOI 10.1038/sj.jcbfm.9600031
   Brena RM, 2006, NAT GENET, V38, P1359, DOI 10.1038/ng1206-1359
   Bulun SE, 2005, PHARMACOL REV, V57, P359, DOI 10.1124/pr.57.3.6
   Chan MY, 2010, MOL CELL ENDOCRINOL, V317, P8, DOI 10.1016/j.mce.2009.11.012
   Chandrasekhar K, 1997, MOL REPROD DEV, V48, P421
   Dannenberg LO, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-181
   Deaton AM, 2011, GENE DEV, V25, P1010, DOI 10.1101/gad.2037511
   Delgado-Morales R, 2017, MOL PSYCHIATR, V22, P485, DOI 10.1038/mp.2016.242
   Dello Russo C, 2000, J NEUROENDOCRINOL, V12, P225
   Enjuanes A, 2003, EUR J ENDOCRINOL, V148, P519, DOI 10.1530/eje.0.1480519
   Flotho C, 2009, LEUKEMIA, V23, P1019, DOI 10.1038/leu.2008.397
   Fürbass R, 2008, MOL REPROD DEV, V75, P1, DOI 10.1002/mrd.20756
   Fujii G, 2006, BIOCHEM J, V395, P203, DOI 10.1042/BJ20051802
   Garcia-Segura LM, 1999, J NEUROBIOL, V40, P574, DOI 10.1002/(SICI)1097-4695(19990915)40:4<574::AID-NEU12>3.0.CO;2-8
   Garcia-Segura LM, 1999, NEUROSCIENCE, V89, P567, DOI 10.1016/S0306-4522(98)00340-6
   Izawa M, 2008, FERTIL STERIL, V89, P1390, DOI 10.1016/j.fertnstert.2007.03.078
   Jones B, 2006, EMBO J, V25, P2443, DOI 10.1038/sj.emboj.7601148
   Knower KC, 2010, MOL CELL ENDOCRINOL, V321, P123, DOI 10.1016/j.mce.2010.02.035
   Lee ST, 2012, NUCLEIC ACIDS RES, V40, P11339, DOI 10.1093/nar/gks957
   Li FJ, 2011, MOL CELL ENDOCRINOL, V344, P51, DOI 10.1016/j.mce.2011.06.024
   Li H, 2007, CELL MOL IMMUNOL, V4, P407
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   MEANS GD, 1989, J BIOL CHEM, V264, P19385
   Rohde C, 2008, NUCLEIC ACIDS RES, V36, DOI 10.1093/nar/gkn083
   Saldanha CJ, 2009, FRONT NEUROENDOCRIN, V30, P106, DOI 10.1016/j.yfrne.2009.04.016
   Simpson ER, 1997, FASEB J, V11, P29, DOI 10.1096/fasebj.11.1.9034163
   Singal R, 1999, BLOOD, V93, P4059, DOI 10.1182/blood.V93.12.4059
   Sullivan KE, 2007, MOL CELL BIOL, V27, P5147, DOI 10.1128/MCB.02429-06
   Tan WJ, 2013, MOL CELL ENDOCRINOL, V375, P106, DOI 10.1016/j.mce.2013.05.018
   Tao LH, 2000, CANCER LETT, V158, P185, DOI 10.1016/S0304-3835(00)00518-8
   To SQ, 2012, J STEROID BIOCHEM, V132, P331, DOI 10.1016/j.jsbmb.2012.07.007
   TODA K, 1990, EUR J BIOCHEM, V193, P559, DOI 10.1111/j.1432-1033.1990.tb19372.x
   Vanselow J, 2008, EXP CLIN ENDOCR DIAB, V116, P437, DOI 10.1055/s-2008-1058083
   Wang Y, 2005, LIFE SCI, V77, P39, DOI 10.1016/j.lfs.2004.12.014
   Wang Y, 2008, BRIT J NUTR, V99, P303, DOI 10.1017/S0007114507811974
   Wang Y, 2006, TOXICOL SCI, V92, P71, DOI 10.1093/toxsci/kfj190
   Yague JG, 2006, NEUROSCIENCE, V138, P389, DOI 10.1016/j.neuroscience.2005.11.054
   Ye L, 2009, MOL CELL ENDOCRINOL, V302, P73, DOI 10.1016/j.mce.2009.01.003
NR 39
TC 8
Z9 8
U1 0
U2 14
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0303-7207
J9 MOL CELL ENDOCRINOL
JI Mol. Cell. Endocrinol.
PD SEP 5
PY 2017
VL 452
IS C
BP 131
EP 137
DI 10.1016/j.mce.2017.05.029
PG 7
WC Cell Biology; Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Endocrinology & Metabolism
GA EZ5YF
UT WOS:000404794900013
PM 28559115
DA 2025-01-12
ER

PT J
AU Taniguchi, H
   Hoshino, D
   Moriya, C
   Zembutsu, H
   Nishiyama, N
   Yamamoto, H
   Kataoka, K
   Imai, K
AF Taniguchi, Hiroaki
   Hoshino, Daisuke
   Moriya, Chiharu
   Zembutsu, Hitoshi
   Nishiyama, Nobuhiro
   Yamamoto, Hiroyuki
   Kataoka, Kazunori
   Imai, Kohzoh
TI Silencing PRDM14 expression by an innovative RNAi therapy inhibits
   stemness, tumorigenicity, and metastasis of breast cancer
SO ONCOTARGET
LA English
DT Article
DE breast cancer stem cell; cancer stemness; epigenetic alterations;
   nucleic acid medicine; PRDM14
ID TUMOR-INITIATING CELLS; SIGNALING PATHWAY; GENE-EXPRESSION; TRANSGENIC
   MICE; OVARIAN-CANCER; DIFFERENTIATION; RESISTANCE; TARGET; GROWTH; SIRNA
AB PR domain zinc finger protein 14 (PRDM14) maintains stemness in embryonic stem cells via epigenetic mechanisms. Although PRDM14 is elevated in several cancers, it is unclear if and how PRDM14 confers stem cell-like properties and epigenetic changes to cancer cells. Here, we examined the phenotypic characteristics and epigenetic and gene expression profiles of cancer cells that differentially express PRDM14, and assessed the potential of PRDM14-targeted cancer therapy. PRDM14 expression was markedly increased in many different cancer types and correlated with poor survival of breast cancer patients. PRDM14 conferred stem cell-like phenotypes to cancer cells and regulated the expression of genes involved in cancer stemness, metastasis, and chemoresistance. PRDM14 also reduced the methylation of protooncogene and stemness gene promoters and PRDM14-binding regions were primarily occupied by histone H3 Lys-4 trimethylation (H3K4me3), both of which are positively correlated with gene expression. Moreover, strong PRDM14 binding sites coincided with promoters containing both H3K4me3 and H3K27me3 histone marks. Using calcium phosphate hybrid micelles as an RNAi delivery system, silencing of PRDM14 expression by chimera RNAi reduced tumor size and metastasis in vivo without causing adverse effects. Conditional loss of PRDM14 function also improved survival of MMTV-Wnt-1 transgenic mice, a spontaneous model of murine breast cancer. Our findings suggest that PRDM14 inhibition may be an effective and novel therapy for cancer stem cells.
C1 [Taniguchi, Hiroaki; Moriya, Chiharu; Imai, Kohzoh] Univ Tokyo, Inst Med Sci, Res Hosp, Ctr Antibody & Vaccine Therapy, Tokyo 1088639, Japan.
   [Hoshino, Daisuke] Kanagawa Canc Ctr, Res Inst, Canc Biol Dept, Yokohama, Kanagawa 2410815, Japan.
   [Zembutsu, Hitoshi] Natl Canc Ctr, Div Genet, Res Inst, Tokyo 1040045, Japan.
   [Nishiyama, Nobuhiro] Tokyo Inst Technol, Chem Resources Lab, Polymer Chem Div, Yokohama, Kanagawa 2268503, Japan.
   [Yamamoto, Hiroyuki] St Marianna Univ, Sch Med, Dept Gastroenterol & Hepatol, Kawasaki, Kanagawa 2160015, Japan.
   [Kataoka, Kazunori] Univ Tokyo, Grad Sch Engn, Dept Mat Engn, Tokyo 1138656, Japan.
   [Imai, Kohzoh] Univ Tokyo, Inst Med Sci, Tokyo 1088639, Japan.
C3 University of Tokyo; Kanagawa Prefectural Cancer Center; National Cancer
   Center - Japan; Institute of Science Tokyo; Tokyo Institute of
   Technology; Saint Marianna University; University of Tokyo; University
   of Tokyo
RP Taniguchi, H (通讯作者)，Univ Tokyo, Inst Med Sci, Res Hosp, Ctr Antibody & Vaccine Therapy, Tokyo 1088639, Japan.
EM h-tani@ims.u-tokyo.ac.jp
RI Taniguchi, Hiroaki/AGB-3012-2022; Nishiyama, Nobuhiro/F-1867-2014;
   Kataoka, Kazunori/K-7108-2012
OI Kataoka, Kazunori/0000-0002-8591-413X; Taniguchi,
   Hiroaki/0000-0003-0494-5290; Moriya, Chiharu/0000-0002-0723-4040
FU Department of Research Promotion, Practical Research for Innovative
   Cancer Control, Ministry of Health, Labour and Welfare; Scientific
   Support Programs for Cancer Research;  [221S0001]; Grants-in-Aid for
   Scientific Research [16K15104, 15H04635, 16F16407, 16F16058] Funding
   Source: KAKEN
FX This work was supported by the Department of Research Promotion,
   Practical Research for Innovative Cancer Control, Ministry of Health,
   Labour and Welfare (H.T.). The Kanagawa Cancer Center Cancer Tissue
   Repository was supported by the Scientific Support Programs for Cancer
   Research, Grant-in-Aid for Scientific Research on Innovative Areas,
   Ministry of Education, Culture, Sports, Science, and Technology of Japan
   (Grant number: 221S0001).
CR Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100
   Alsuliman A, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0421-2
   Aramaki S, 2013, DEV CELL, V27, P516, DOI 10.1016/j.devcel.2013.11.001
   Arnold SJ, 2000, MECH DEVELOP, V91, P249, DOI 10.1016/S0925-4773(99)00309-3
   Bailey TL, 2009, NUCLEIC ACIDS RES, V37, pW202, DOI 10.1093/nar/gkp335
   Bernstein BE, 2006, CELL, V125, P315, DOI 10.1016/j.cell.2006.02.041
   Birgersdotter A, 2005, SEMIN CANCER BIOL, V15, P405, DOI 10.1016/j.semcancer.2005.06.009
   Böcker W, 2002, LAB INVEST, V82, P737, DOI 10.1097/01.LAB.0000017371.72714.C5
   Caretti G, 2004, GENE DEV, V18, P2627, DOI 10.1101/gad.1241904
   Chan YS, 2013, STEM CELLS, V31, P682, DOI 10.1002/stem.1307
   Chapman-Rothe N, 2013, ONCOGENE, V32, P4586, DOI 10.1038/onc.2012.477
   Chia NY, 2010, NATURE, V468, P316, DOI 10.1038/nature09531
   Cho RW, 2008, STEM CELLS, V26, P364, DOI 10.1634/stemcells.2007-0440
   D'Alessandro-Gabazza CN, 2012, AM J RESP CELL MOL, V46, P397, DOI 10.1165/rcmb.2011-0158OC
   Dean M, 2005, NAT REV CANCER, V5, P275, DOI 10.1038/nrc1590
   Dettman EJ, 2011, ONCOGENE, V30, P2859, DOI 10.1038/onc.2011.12
   Dougall WC, 2012, CLIN CANCER RES, V18, P326, DOI 10.1158/1078-0432.CCR-10-2507
   Golebiewska A, 2011, CELL STEM CELL, V8, P136, DOI 10.1016/j.stem.2011.01.007
   Grelier G, 2009, BRIT J CANCER, V101, P673, DOI 10.1038/sj.bjc.6605193
   Ishimoto T, 2011, CANCER CELL, V19, P387, DOI 10.1016/j.ccr.2011.01.038
   Ishizawa K, 2010, CELL STEM CELL, V7, P279, DOI 10.1016/j.stem.2010.08.009
   Kalantry S, 2006, NAT CELL BIOL, V8, P195, DOI 10.1038/ncb1351
   Kendellen MF, 2014, ONCOGENE, V33, P1297, DOI 10.1038/onc.2013.64
   Lembo A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031129
   Li Q, 2009, J PHARMACOL EXP THER, V332, P821
   Li QY, 2013, DATABASE-OXFORD, DOI 10.1093/database/bat057
   Li Y, 2000, ONCOGENE, V19, P1002, DOI 10.1038/sj.onc.1203273
   Liu C, 2011, NAT MED, V17, P211, DOI 10.1038/nm.2284
   Liu SH, 2008, PANCREAS, V37, P210, DOI 10.1097/MPA.0b013e31816a4a33
   Ma ZY, 2011, NAT STRUCT MOL BIOL, V18, P120, DOI 10.1038/nsmb.2000
   Maccalli C, 2015, CANCER IMMUNOL IMMUN, V64, P91, DOI 10.1007/s00262-014-1592-1
   Marcato P, 2015, MOL ONCOL, V9, P17, DOI 10.1016/j.molonc.2014.07.010
   Marotta LLC, 2011, J CLIN INVEST, V121, P2723, DOI 10.1172/JCI44745
   Mayr C, 2009, CELL, V138, P673, DOI 10.1016/j.cell.2009.06.016
   Merritt WM, 2008, NEW ENGL J MED, V359, P2641, DOI 10.1056/NEJMoa0803785
   Nishikawa N, 2007, CANCER RES, V67, P9649, DOI 10.1158/0008-5472.CAN-06-4111
   Ohm JE, 2007, NAT GENET, V39, P237, DOI 10.1038/ng1972
   Ohmori T, 1998, EXP CELL RES, V245, P350, DOI 10.1006/excr.1998.4261
   Oskarsson T, 2011, NAT MED, V17, P867, DOI 10.1038/nm.2379
   Pittella F, 2014, J CONTROL RELEASE, V178, P18, DOI 10.1016/j.jconrel.2014.01.008
   Prat A, 2009, NAT MED, V15, P842, DOI 10.1038/nm0809-842
   Quintana E, 2008, NATURE, V456, P593, DOI 10.1038/nature07567
   Reim F, 2009, CANCER RES, V69, P8058, DOI 10.1158/0008-5472.CAN-09-0834
   Robertson KD, 1999, NUCLEIC ACIDS RES, V27, P2291, DOI 10.1093/nar/27.11.2291
   Sauvageau M, 2010, CELL STEM CELL, V7, P299, DOI 10.1016/j.stem.2010.08.002
   Shinkai Y, 2011, GENE DEV, V25, P781, DOI 10.1101/gad.2027411
   Shipitsin M, 2007, CANCER CELL, V11, P259, DOI 10.1016/j.ccr.2007.01.013
   Tassone P, 2003, BRIT J CANCER, V88, P1285, DOI 10.1038/sj.bjc.6600859
   Ui-Tei K, 2008, NUCLEIC ACIDS RES, V36, P2136, DOI 10.1093/nar/gkn042
   Virant-Klun I, 2013, J OVARIAN RES, V6, DOI 10.1186/1757-2215-6-24
   Visvader JE, 2012, CELL STEM CELL, V10, P717, DOI 10.1016/j.stem.2012.05.007
   Weaver VM, 2002, CANCER CELL, V2, P205, DOI 10.1016/S1535-6108(02)00125-3
   Wu MY, 2014, CANCER LETT, V354, P311, DOI 10.1016/j.canlet.2014.08.031
   Yamaji M, 2008, NAT GENET, V40, P1016, DOI 10.1038/ng.186
   Yamaji M, 2013, CELL STEM CELL, V12, P368, DOI 10.1016/j.stem.2012.12.012
   Yamato K, 2011, CANCER GENE THER, V18, P587, DOI 10.1038/cgt.2011.28
   Zhang TH, 2013, MED ONCOL, V30, DOI 10.1007/s12032-013-0605-9
   Zhou S, 2001, NAT MED, V7, P1028, DOI 10.1038/nm0901-1028
NR 58
TC 27
Z9 35
U1 3
U2 14
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD JUL 18
PY 2017
VL 8
IS 29
BP 46856
EP 46874
DI 10.18632/oncotarget.16776
PG 19
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA FA8KD
UT WOS:000405694000014
PM 28423353
OA Green Published, gold, Green Submitted
DA 2025-01-12
ER

PT J
AU Vrba, L
   Futscher, BW
AF Vrba, Lukas
   Futscher, Bernard Walter
TI Epigenetic Silencing of <i>MORT</i> Is an Early Event in Cancer and Is
   Associated with Luminal, Receptor Positive Breast Tumor Subtypes
SO JOURNAL OF BREAST CANCER
LA English
DT Article
DE Breast neoplasms; Carcinogenesis; DNA methylation; Gene silencing; Long
   noncoding RNA
ID CARCINOMA IN-SITU; TELOMERASE ACTIVITY; DNA METHYLATION; PROGRESSION
AB Immortality is an essential characteristic of cancer cells; a recent transcriptomic study of epithelial cell immortalization has linked epigenetic silencing of the long noncoding RNA Mortal Obligate RNA Transcript (MORT: alias ZNF667-AS1) to this process. This study evaluated the epigenetic and transcriptional state of MORT in two premalignant conditions-ductal carcinomas in situ and colon adenomas. Results show that MORT silencing is an early epigenetic event in human carcinogenesis, likely occurring near the point where premalignant cells gain immortality; this epigenetic silencing is maintained throughout malignant transformation and metastatic growth. Additional associations between MORT loss and clinical and molecular features of breast tumors showed that silencing of MORT occurs predominantly in luminal, receptor-positive breast cancer; is associated with overexpression of CCND1 and mutations of GATA3; and is negatively correlated with TP53 mutations. Taken in toto, MORT silencing occurs early in breast carcinogenesis, probably during cellular immortalization, and precedes the development of invasive lumina] breast cancer.
C1 [Vrba, Lukas; Futscher, Bernard Walter] Univ Arizona, Ctr Canc, 1515 N Campbell Ave, Tucson, AZ 85724 USA.
   [Futscher, Bernard Walter] Univ Arizona, Coll Pharm, Dept Pharmacol & Toxicol, Tucson, AZ 85721 USA.
C3 University of Arizona; University of Arizona
RP Vrba, L (通讯作者)，Univ Arizona, Ctr Canc, 1515 N Campbell Ave, Tucson, AZ 85724 USA.
EM lvrba@uacc.arizona.edu
RI Vrba, Lukas/J-9268-2015
OI Vrba, Lukas/0000-0003-3042-6275
FU Margaret E. and Fenton L. Maynard Endowment for Breast Cancer Research
   and Center [ES006694]
FX This work was supported by the Margaret E. and Fenton L. Maynard
   Endowment for Breast Cancer Research and Center grant ES006694.
CR Abba MC, 2015, CANCER RES, V75, P3980, DOI 10.1158/0008-5472.CAN-15-0506
   Allred DC, 2000, J MAMMARY GLAND BIOL, V5, P351, DOI 10.1023/A:1009573710675
   [Anonymous], R LANG ENV STAT COMP
   BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x
   Fleischer T, 2014, GENOME BIOL, V15, DOI [10.1186/s13059-014-0435-x, 10.1186/PREACCEPT-2333349012841587]
   Garbe JC, 2014, CELL CYCLE, V13, P3423, DOI 10.4161/15384101.2014.954456
   Jenkins EO, 2014, ONCOLOGIST, V19, P1076, DOI 10.1634/theoncologist.2014-0184
   Johnson KC, 2015, CLIN EPIGENETICS, V7, DOI 10.1186/s13148-015-0094-0
   Knudsen ES, 2008, NAT REV CANCER, V8, P714, DOI 10.1038/nrc2401
   Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412
   Luo YX, 2014, GASTROENTEROLOGY, V147, P418, DOI 10.1053/j.gastro.2014.04.039
   Parker JS, 2009, J CLIN ONCOL, V27, P1160, DOI 10.1200/JCO.2008.18.1370
   Qu X, 2016, ONCOGENE, V35, P6403, DOI 10.1038/onc.2016.170
   Reyngold M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103896
   Shpitz B, 1999, BREAST CANCER RES TR, V58, P65, DOI 10.1023/A:1006394209922
   Umbricht CB, 1999, ONCOGENE, V18, P3407, DOI 10.1038/sj.onc.1202714
   Vrba L, 2015, EPIGENETICS-US, V10, P1074, DOI 10.1080/15592294.2015.1106673
   Yashima K, 1998, CLIN CANCER RES, V4, P229
NR 18
TC 16
Z9 19
U1 0
U2 1
PU KOREAN BREAST CANCER SOC
PI SEOUL
PA 163 SINMUNRO 1-GA JONGRO-GU, OFFICIA  BUILDING, SUITE 2024, SEOUL,
   110-999, SOUTH KOREA
SN 1738-6756
EI 2092-9900
J9 J BREAST CANCER
JI J. Breast Canc.
PD JUN
PY 2017
VL 20
IS 2
BP 198
EP 202
DI 10.4048/jbc.2017.20.2.198
PG 5
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA EZ6NE
UT WOS:000404833800010
PM 28690657
OA Green Submitted, Green Published, gold
DA 2025-01-12
ER

PT J
AU Kumar, D
   Kumar, S
   Ayachit, G
   Bhairappanavar, SB
   Ansari, A
   Sharma, P
   Soni, S
   Das, J
AF Kumar, Dinesh
   Kumar, Swapnil
   Ayachit, Garima
   Bhairappanavar, Shivarudrappa B.
   Ansari, Afzal
   Sharma, Priyanka
   Soni, Subhash
   Das, Jayashankar
TI Cross-Kingdom Regulation of Putative miRNAs Derived from Happy Tree in
   Cancer Pathway: A Systems Biology Approach
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE miRNA; Camptotheca acuminata; cancer; cross-kingdom regulation;
   protein-protein interaction network
ID SUPPRESSES CELL-GROWTH; PLANT MICRORNAS; FUNCTIONAL-ANALYSIS;
   DOWN-REGULATION; POOR-PROGNOSIS; MOUSE MODELS; STEM-CELLS; SMALL RNAS;
   CAMPTOTHECIN; IDENTIFICATION
AB MicroRNAs (miRNAs) are well-known key regulators of gene expression primarily at the post-transcriptional level. Plant-derived miRNAs may pass through the gastrointestinal tract, entering into the body fluid and regulate the expression of endogenous mRNAs. Camptotheca acuminata, a highly important medicinal plant known for its anti-cancer potential was selected to investigate cross-kingdom regulatory mechanism and involvement of miRNAs derived from this plant in cancer-associated pathways through in silico systems biology approach. In this study, total 33 highly stable putative novel miRNAs were predicted from the publically available 53,294 ESTs of C. acuminata, out of which 14 miRNAs were found to be regulating 152 target genes in human. Functional enrichment, gene-disease associations and network analysis of these target genes were carried out and the results revealed their association with prominent types of cancers like breast cancer, leukemia and lung cancer. Pathways like focal adhesion, regulation of lipolysis in adipocytes and mTOR signaling pathways were found significantly associated with the target genes. The regulatory network analysis showed the association of some important hub proteins like GSK3B, NUMB, PEG3, ITGA2 and DLG2 with cancer-associated pathways. Based on the analysis results, it can be suggested that the ingestion of the C. acuminata miRNAs may have a functional impact on tumorigenesis in a cross-kingdom way and may affect the physiological condition at genetic level. Thus, the predicted miRNAs seem to hold potentially significant role in cancer pathway regulation and therefore, may be further validated using in vivo experiments for a better insight into their mechanism of epigenetic action of miRNA.
C1 [Kumar, Dinesh; Kumar, Swapnil; Ayachit, Garima; Bhairappanavar, Shivarudrappa B.; Ansari, Afzal; Sharma, Priyanka; Soni, Subhash; Das, Jayashankar] Govt Gujarat, Dept Sci & Technol, Gujarat State Biotechnol Mission, Gujarat Inst Bioinformat, Gandhinagar 382011, India.
RP Das, J (通讯作者)，Govt Gujarat, Dept Sci & Technol, Gujarat State Biotechnol Mission, Gujarat Inst Bioinformat, Gandhinagar 382011, India.
EM dinesh.vascsc@gmail.com; swapnilkr.bi@gmail.com;
   garima_ayachit@yahoo.co.in; rudra8282@gmail.com; md.afza1294@gmail.com;
   mailsharma.p@gmail.com; mdbtm@gujarat.gov.in; ssbbtm@gujarat.gov.in
RI Ansari, Afzal/LWZ-9303-2024; Kumar, Swapnil/Y-8361-2018; Kalra,
   D/H-6661-2019; Kumar, Dinesh/J-9743-2017
OI Das, Jayashankar/0000-0002-7131-757X; Ayachit,
   Garima/0000-0001-6776-1435; Kumar, Swapnil/0000-0002-2433-1678; Kalra,
   D/0000-0001-5254-4067; Kumar, Dinesh/0000-0002-6143-2507; ANSARI,
   AFZAL/0000-0003-0254-504X
FU Gujarat State Biotechnology Mission, Department of Science and
   Technology, Government of Gujarat, India
FX This work has been supported by Gujarat State Biotechnology Mission,
   Department of Science and Technology, Government of Gujarat, India.
CR [Anonymous], 2015, J. Med. Plants
   Arora S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078023
   Arroyo JD, 2011, P NATL ACAD SCI USA, V108, P5003, DOI 10.1073/pnas.1019055108
   Aukerman MJ, 2003, PLANT CELL, V15, P2730, DOI 10.1105/tpc.016238
   Bao B, 2012, CURR DRUG TARGETS, V13, P1858, DOI 10.2174/138945012804545515
   Bateman A, 2017, NUCLEIC ACIDS RES, V45, pD158, DOI 10.1093/nar/gkw1099
   Bedogni B, 2008, J CLIN INVEST, V118, P3660, DOI 10.1172/JCI36157
   Bianchi-Smiraglia A, 2013, ONCOGENE, V32, P3049, DOI 10.1038/onc.2012.320
   Bonacich P, 2007, SOC NETWORKS, V29, P555, DOI 10.1016/j.socnet.2007.04.002
   Bonnet E, 2004, BIOINFORMATICS, V20, P2911, DOI 10.1093/bioinformatics/bth374
   Brennecke J, 2003, CELL, V113, P25, DOI 10.1016/S0092-8674(03)00231-9
   Cao Q, 2016, ONCOTARGET, V7, P77468, DOI 10.18632/oncotarget.12684
   Carey KA, 2007, J GERONTOL A-BIOL, V62, P9, DOI 10.1093/gerona/62.1.9
   Carrington JC, 2003, SCIENCE, V301, P336, DOI 10.1126/science.1085242
   Cavalieri D, 2016, SCI REP-UK, V6, DOI 10.1038/srep25761
   Chin AR, 2016, CELL RES, V26, P217, DOI 10.1038/cr.2016.13
   Chin CH, 2014, BMC SYST BIOL, V8, DOI 10.1186/1752-0509-8-S4-S11
   Colaiacovo M, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-595
   Conley SJ, 2015, BREAST CANCER RES TR, V150, P559, DOI 10.1007/s10549-015-3349-8
   Csardi G, 2006, INTERJ COMPLEX SYST, V1695
   Curry CL, 2005, ONCOGENE, V24, P6333, DOI 10.1038/sj.onc.1208783
   Dai XB, 2011, NUCLEIC ACIDS RES, V39, pW155, DOI 10.1093/nar/gkr319
   Dang TP, 2000, J NATL CANCER I, V92, P1355, DOI 10.1093/jnci/92.16.1355
   Das J, 2013, IND CROP PROD, V49, P341, DOI 10.1016/j.indcrop.2013.05.017
   Demain AL, 2011, MICROB BIOTECHNOL, V4, P687, DOI 10.1111/j.1751-7915.2010.00221.x
   Ding W, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135128
   Dowdy SC, 2005, GYNECOL ONCOL, V99, P126, DOI 10.1016/j.ygyno.2005.05.036
   DREWINKO B, 1974, CANCER RES, V34, P747
   Elsayed W, 2016, SCI REP-UK, V6, DOI 10.1038/srep26626
   Esau C, 2006, CELL METAB, V3, P87, DOI 10.1016/j.cmet.2006.01.005
   Feng WW, 2008, CANCER-AM CANCER SOC, V112, P1489, DOI 10.1002/cncr.23323
   Feshani AM, 2012, GENE, V493, P253, DOI 10.1016/j.gene.2011.11.024
   FREEMAN LC, 1977, SOCIOMETRY, V40, P35, DOI 10.2307/3033543
   FUKUOKA M, 1992, J CLIN ONCOL, V10, P16, DOI 10.1200/JCO.1992.10.1.16
   GALLO RC, 1971, J NATL CANCER I, V46, P789
   Giebel B, 2012, CURR BIOL, V22, pR133, DOI 10.1016/j.cub.2012.01.006
   Góngora-Castillo E, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052506
   Goulart MA, 2016, INT J STD AIDS, V27, P1236, DOI 10.1177/0956462416638609
   Hallahan AR, 2004, CANCER RES, V64, P7794, DOI 10.1158/0008-5472.CAN-04-1813
   Hirasawa A, 2003, CLIN CANCER RES, V9, P1995
   Hirschi KD, 2015, TRENDS BIOTECHNOL, V33, P431, DOI 10.1016/j.tibtech.2015.06.003
   Hong M, 2015, CANCERS, V7, P1643, DOI 10.3390/cancers7030855
   Hou YY, 2011, CANCER LETT, V307, P182, DOI 10.1016/j.canlet.2011.04.002
   Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923
   Hwang HW, 2006, BRIT J CANCER, V94, P776, DOI 10.1038/sj.bjc.6603023
   Hwang W., 2008, Proceedings of the 14th ACM SIGKDD international conference on Knowledge discovery and data mining, P336
   Jeong H, 2001, NATURE, V411, P41, DOI 10.1038/35075138
   Jhanwar-Uniyal M, 2015, CANCERS, V7, P538, DOI 10.3390/cancers7020538
   Jiang MX, 2012, BIOESSAYS, V34, P280, DOI 10.1002/bies.201100181
   Kanehisa M, 2017, NUCLEIC ACIDS RES, V45, pD353, DOI 10.1093/nar/gkw1092
   Khraiwesh B, 2012, BBA-GENE REGUL MECH, V1819, P137, DOI 10.1016/j.bbagrm.2011.05.001
   Kim J., 2013, PLoS One, V8, DOI DOI 10.1371/ANNOTATION/8DE03EC5-E62C-4135-87EE-4928475090A8
   Kozomara A, 2014, NUCLEIC ACIDS RES, V42, pD68, DOI 10.1093/nar/gkt1181
   Lee H, 2016, SCI REP-UK, V6, DOI 10.1038/srep25287
   LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y
   LI LH, 1972, CANCER RES, V32, P2643
   Liang Gf, 2014, FOOD SCI NUTR, V2, P380, DOI 10.1002/fsn3.113
   Liang HW, 2015, J NUTR BIOCHEM, V26, P505, DOI 10.1016/j.jnutbio.2014.12.002
   Lin C. S., 2014, BASED COMPLEMENT ALT, V2014, DOI 10.1155/2014/56481024963324
   Liu MX, 2014, ONCOTARGET, V5, P944, DOI 10.18632/oncotarget.1458
   Lorenz R, 2011, ALGORITHM MOL BIOL, V6, DOI 10.1186/1748-7188-6-26
   Luan YS, 2014, MOL BIOL REP, V41, P5385, DOI 10.1007/s11033-014-3410-4
   Lukasik A, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18010009
   Ma N, 2015, BIOCHEM BIOPH RES CO, V461, P618, DOI 10.1016/j.bbrc.2015.04.075
   Mathieu J, 2013, ADV EXP MED BIOL, V786, P329, DOI 10.1007/978-94-007-6621-1_18
   Maurer U, 2014, J CELL SCI, V127, P1369, DOI 10.1242/jcs.138057
   Mukhopadhyay UK, 2010, MOL CELL BIOL, V30, P4980, DOI 10.1128/MCB.00004-10
   Muralidharan-Chari V, 2010, J CELL SCI, V123, P1603, DOI 10.1242/jcs.064386
   Ng KLS, 2007, BIOINFORMATICS, V23, P1321, DOI 10.1093/bioinformatics/btm026
   Nithin C, 2015, BMC PLANT BIOL, V15, DOI 10.1186/s12870-015-0516-3
   Notarnicola M, 2012, LIPIDS, V47, P59, DOI 10.1007/s11745-011-3630-5
   Park JT, 2006, CANCER RES, V66, P6312, DOI 10.1158/0008-5472.CAN-05-3610
   Pastrello C, 2016, SCI REP-UK, V6, DOI 10.1038/srep32773
   Piñero J, 2017, NUCLEIC ACIDS RES, V45, pD833, DOI 10.1093/nar/gkw943
   Pópulo H, 2012, INT J MOL SCI, V13, P1886, DOI 10.3390/ijms13021886
   Prasad TSK, 2009, NUCLEIC ACIDS RES, V37, pD767, DOI 10.1093/nar/gkn892
   Scardoni G., 2015, F1000RES, V3, P139, DOI [10.12688/f1000research.4477.226594322, DOI 10.12688/f1000research.4477.226594322]
   Sethi N, 2011, CANCER CELL, V19, P192, DOI 10.1016/j.ccr.2010.12.022
   Shan GP, 2016, CANCER BIOTHER RADIO, V31, P180, DOI 10.1089/cbr.2016.2053
   Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303
   SHIMBEL ALFONSO, 1953, BULL MATH BIOPHYS, V15, P501, DOI 10.1007/BF02476438
   Shu YJ, 2017, CELL DEATH DIFFER, V24, P445, DOI 10.1038/cdd.2016.146
   Sirikantaramas S, 2007, CURR PHARM BIOTECHNO, V8, P196
   Stappert L, 2015, CELL TISSUE RES, V359, P47, DOI 10.1007/s00441-014-1981-y
   Taganov KD, 2006, P NATL ACAD SCI USA, V103, P12481, DOI 10.1073/pnas.0605298103
   Tammam J, 2009, BRIT J PHARMACOL, V158, P1183, DOI 10.1111/j.1476-5381.2009.00389.x
   Valadi H, 2007, NAT CELL BIOL, V9, P654, DOI 10.1038/ncb1596
   Valente TW, 1998, SOC NETWORKS, V20, P89, DOI 10.1016/S0378-8733(97)00007-5
   WALL ME, 1966, J AM CHEM SOC, V88, P3888, DOI 10.1021/ja00968a057
   Wang N, 2014, BBA-GENE REGUL MECH, V1839, P849, DOI 10.1016/j.bbagrm.2014.05.027
   Wolf T, 2015, J NUTR, V145, P2201, DOI 10.3945/jn.115.218586
   Xie CZ, 2015, INT J MOL MED, V36, P653, DOI 10.3892/ijmm.2015.2279
   Yang J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0137516
   Yang J, 2015, CELL RES, V25, P517, DOI 10.1038/cr.2015.26
   Yoo BC, 2004, PLANT CELL, V16, P1979, DOI 10.1105/tpc.104.023614
   Yoshino Y, 2015, SCI REP-UK, V5, DOI 10.1038/srep13249
   Yu B, 2005, SCIENCE, V307, P932, DOI 10.1126/science.1107130
   Yu YH, 2012, SCI REP-UK, V2, DOI 10.1038/srep00584
   Zeng CW, 2012, MOL PHARMACOL, V81, P578, DOI 10.1124/mol.111.076794
   Zhang BH, 2006, COMPUT BIOL CHEM, V30, P395, DOI 10.1016/j.compbiolchem.2006.08.006
   Zhang BH, 2006, CELL MOL LIFE SCI, V63, P246, DOI 10.1007/s00018-005-5467-7
   Zhang L, 2012, CELL RES, V22, P107, DOI 10.1038/cr.2011.158
   Zhang LY, 2013, J BIOL CHEM, V288, P4035, DOI 10.1074/jbc.M112.410506
   Zhao X, 2011, ADV DRUG DELIVER REV, V63, P610, DOI 10.1016/j.addr.2010.11.001
   Zhou Z, 2015, CELL RES, V25, P39, DOI 10.1038/cr.2014.130
   Zubakov D, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-106
NR 106
TC 37
Z9 39
U1 1
U2 23
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD JUN
PY 2017
VL 18
IS 6
AR 1191
DI 10.3390/ijms18061191
PG 21
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA EZ3AF
UT WOS:000404581500090
PM 28587194
OA Green Published, Green Submitted, gold
DA 2025-01-12
ER

PT J
AU Wang, RR
   Cao, XJ
   Kulej, K
   Liu, W
   Ma, TC
   MacDonald, M
   Chiang, CM
   Garcia, BA
   You, JX
AF Wang, Ranran
   Cao, Xing-Jun
   Kulej, Katarzyna
   Liu, Wei
   Ma, Tongcui
   MacDonald, Margo
   Chiang, Cheng-Ming
   Garcia, Benjamin A.
   You, Jianxin
TI Uncovering BRD4 hyperphosphorylation associated with cellular
   transformation in NUT midline carcinoma
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE bromodomain-containing protein 4; NUT midline carcinoma; CDK9; cellular
   transformation; cancer
ID RNA-POLYMERASE-II; BET BROMODOMAIN INHIBITION; AGENT HEXAMETHYLENE
   BISACETAMIDE; PROTEIN BRD4; P-TEFB; ANTITUMOR-ACTIVITY; STEM-CELLS;
   SELECTIVE-INHIBITION; ACETYLATED CHROMATIN; BREAST-CANCER
AB The epigenetic reader BRD4 plays a vital role in transcriptional regulation, cellular growth control, and cell-cycle progression. Dysregulation of BRD4 function has been implicated in the pathogenesis of a wide range of cancers. However, how BRD4 is regulated to maintain its normal function in healthy cells and how alteration of this process leads to cancer remain poorly understood. In this study, we discovered that BRD4 is hyperphosphorylated in NUT midline carcinoma and identified CDK9 as a potential kinase mediating BRD4 hyperphosphorylation. Disruption of BRD4 hyperphosphorylation using both chemical and molecular inhibitors led to the repression of BRD4 downstream oncogenes and abrogation of cellular transformation. BRD4 hyperphosphorylation is also observed in other cancers displaying enhanced BRD4 oncogenic activity. Our study revealed a mechanism that may regulate BRD4 biological function through phosphorylation, which, when dysregulated, could lead to oncogenesis. Our finding points to strategies to target the aberrant BRD4 signaling specifically for cancer intervention.
C1 [Wang, Ranran; Liu, Wei; Ma, Tongcui; MacDonald, Margo; You, Jianxin] Univ Penn, Dept Microbiol, Perelman Sch Med, Philadelphia, PA 19104 USA.
   [Cao, Xing-Jun; Kulej, Katarzyna; Garcia, Benjamin A.] Univ Penn, Dept Biochem & Biophys, Perelman Sch Med, Epigenet Program, Philadelphia, PA 19104 USA.
   [Chiang, Cheng-Ming] Univ Texas Southwestern Med Ctr Dallas, Simmons Comprehens Canc Ctr, Dallas, TX 75390 USA.
   [Chiang, Cheng-Ming] Univ Texas Southwestern Med Ctr Dallas, Dept Biochem, Dallas, TX 75390 USA.
   [Chiang, Cheng-Ming] Univ Texas Southwestern Med Ctr Dallas, Dept Pharmacol, Dallas, TX 75390 USA.
C3 University of Pennsylvania; University of Pennsylvania; University of
   Texas System; University of Texas Southwestern Medical Center Dallas;
   University of Texas System; University of Texas Southwestern Medical
   Center Dallas; University of Texas System; University of Texas
   Southwestern Medical Center Dallas
RP You, JX (通讯作者)，Univ Penn, Dept Microbiol, Perelman Sch Med, Philadelphia, PA 19104 USA.
EM jianyou@mail.med.upenn.edu
RI LIU, WEI/J-5000-2012
OI Wang, Ranran/0000-0002-7920-0704; Liu, Wei/0000-0001-9439-5100;
   MacDonald, Margo/0000-0002-2279-9971
FU NIH [R01CA148768, R01CA142723, R01CA187718, R01GM110174, P01CA196539,
   R01CA103867]; Cancer Prevention Research Institute of Texas [RP110471,
   RP140367]; Welch Foundation [I-1805]
FX We thank Dr. Junpeng Yan (Case Western Reserve University) for providing
   plasmids; Drs. Martin P. Carroll (University of Pennsylvania), Erle S.
   Robertson (University of Pennsylvania), Thao P. Dang (Vanderbilt
   University), and Christopher A. French (Harvard Medical School) for
   providing cell lines; Dr. Chao-Xing Yuan and Anne Lehman for technical
   support; and the members of our laboratories for helpful discussion.
   This work was supported by NIH Grants R01CA148768, R01CA142723,
   R01CA187718, R01GM110174, P01CA196539, and R01CA103867; Cancer
   Prevention Research Institute of Texas Grants RP110471 and RP140367; and
   Welch Foundation Grant I-1805.
CR ANDREEFF M, 1992, BLOOD, V80, P2604
   Andrieu Guillaume, 2016, Drug Discov Today Technol, V19, P45, DOI 10.1016/j.ddtec.2016.06.004
   Arguello F, 1998, BLOOD, V91, P2482
   Asangani IA, 2014, NATURE, V510, P278, DOI 10.1038/nature13229
   Beesley AH, 2014, BRIT J CANCER, V110, P1189, DOI 10.1038/bjc.2014.54
   Berthon C, 2016, LANCET HAEMATOL, V3, pE186, DOI 10.1016/S2352-3026(15)00247-1
   Bolden JE, 2014, CELL REP, V8, P1919, DOI 10.1016/j.celrep.2014.08.025
   Byrd JC, 2005, CLIN CANCER RES, V11, P4176, DOI 10.1158/1078-0432.CCR-04-2276
   Chapuy B, 2013, CANCER CELL, V24, P777, DOI 10.1016/j.ccr.2013.11.003
   Chen XL, 2015, PROTEOMICS, V15, P3175, DOI 10.1002/pmic.201500108
   Cox J, 2011, J PROTEOME RES, V10, P1794, DOI 10.1021/pr101065j
   Cox J, 2008, NAT BIOTECHNOL, V26, P1367, DOI 10.1038/nbt.1511
   Czudnochowski N, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1846
   Dawson MA, 2011, NATURE, V478, P529, DOI 10.1038/nature10509
   Delmore JE, 2011, CELL, V146, P903, DOI 10.1016/j.cell.2011.08.017
   Devaiah BN, 2012, J BIOL CHEM, V287, P38755, DOI 10.1074/jbc.M112.412015
   Dey A, 2003, P NATL ACAD SCI USA, V100, P8758, DOI 10.1073/pnas.1433065100
   DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475
   Fernandes N, 2005, J BIOL CHEM, V280, P15158, DOI 10.1074/jbc.M412065200
   Filippakopoulos P, 2010, NATURE, V468, P1067, DOI 10.1038/nature09504
   Fong CY, 2015, NATURE, V525, P538, DOI 10.1038/nature14888
   French CA, 2012, ANNU REV PATHOL-MECH, V7, P247, DOI 10.1146/annurev-pathol-011811-132438
   Fu JHJ, 2007, MOL CELL BIOL, V27, P4641, DOI 10.1128/MCB.00857-06
   Gao XN, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055481
   Garcia-Cuellar MP, 2014, LEUKEMIA, V28, P1427, DOI 10.1038/leu.2014.40
   Grayson AR, 2014, ONCOGENE, V33, P1736, DOI 10.1038/onc.2013.126
   Haruki N, 2005, J MED GENET, V42, P558, DOI 10.1136/jmg.2004.029686
   Houzelstein D, 2002, MOL CELL BIOL, V22, P3794, DOI 10.1128/MCB.22.11.3794-3802.2002
   Kinoshita E, 2009, NAT PROTOC, V4, P1513, DOI 10.1038/nprot.2009.154
   Knoechel B, 2014, NAT GENET, V46, P364, DOI 10.1038/ng.2913
   Kurimchak AM, 2016, CELL REP, V16, P1273, DOI 10.1016/j.celrep.2016.06.091
   Li Q, 2004, FEBS LETT, V576, P231, DOI 10.1016/j.febslet.2004.09.017
   Lin TS, 2009, J CLIN ONCOL, V27, P6012, DOI 10.1200/JCO.2009.22.6944
   Liu W, 2014, CELL DEATH DIFFER, V21, P1950, DOI 10.1038/cdd.2014.124
   Liu W, 2016, CELL HOST MICROBE, V19, P775, DOI 10.1016/j.chom.2016.04.024
   Lovén J, 2013, CELL, V153, P320, DOI 10.1016/j.cell.2013.03.036
   Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762
   Marshall NF, 1996, J BIOL CHEM, V271, P27176, DOI 10.1074/jbc.271.43.27176
   Mertz JA, 2011, P NATL ACAD SCI USA, V108, P16669, DOI 10.1073/pnas.1108190108
   Montagnoli A, 2008, NAT CHEM BIOL, V4, P357, DOI 10.1038/nchembio.90
   Naito S, 2006, CANCER GENE THER, V13, P780, DOI 10.1038/sj.cgt.7700957
   Nicodeme E, 2010, NATURE, V468, P1119, DOI 10.1038/nature09589
   Nilsson LM, 2016, CANCER RES, V76, P2376, DOI 10.1158/0008-5472.CAN-15-2721
   NYORMOI O, 1973, EXP CELL RES, V82, P241, DOI 10.1016/0014-4827(73)90337-6
   O'Brien JA, 2013, CANCER INVEST, V31, P215, DOI 10.3109/07357907.2012.700986
   Ogiwara H, 2016, CANCER DISCOV, V6, P430, DOI 10.1158/2159-8290.CD-15-0754
   Polier G, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.66
   Puissant A, 2013, CANCER DISCOV, V3, P308, DOI 10.1158/2159-8290.CD-12-0418
   Rahman S, 2011, MOL CELL BIOL, V31, P2641, DOI 10.1128/MCB.01341-10
   Reynoird N, 2010, EMBO J, V29, P2943, DOI 10.1038/emboj.2010.176
   Sangodkar J, 2016, FEBS J, V283, P1004, DOI 10.1111/febs.13573
   SCHROY P, 1989, CANCER LETT, V48, P53, DOI 10.1016/0304-3835(89)90202-4
   Shi J, 2014, CANCER CELL, V25, P210, DOI 10.1016/j.ccr.2014.01.028
   Shi JW, 2014, MOL CELL, V54, P728, DOI 10.1016/j.molcel.2014.05.016
   Shu SK, 2016, NATURE, V529, P413, DOI 10.1038/nature16508
   Stathis A, 2016, CANCER DISCOV, V6, P492, DOI 10.1158/2159-8290.CD-15-1335
   Valent P, 2014, CELL CYCLE, V13, P689, DOI 10.4161/cc.27859
   Villén J, 2008, NAT PROTOC, V3, P1630, DOI 10.1038/nprot.2008.150
   Wang RR, 2015, J BIOL CHEM, V290, P2744, DOI 10.1074/jbc.M114.600759
   Wang RR, 2014, CANCER RES, V74, P3332, DOI 10.1158/0008-5472.CAN-13-2658
   Wang RR, 2012, J BIOL CHEM, V287, P10738, DOI 10.1074/jbc.M111.323493
   Wang S, 2008, TRENDS PHARMACOL SCI, V29, P302, DOI 10.1016/j.tips.2008.03.003
   Wong YH, 2007, NUCLEIC ACIDS RES, V35, pW588, DOI 10.1093/nar/gkm322
   Wu SY, 2007, J BIOL CHEM, V282, P13141, DOI 10.1074/jbc.R700001200
   Wu SY, 2016, CELL REP, V16, P1733, DOI 10.1016/j.celrep.2016.07.001
   Wu SY, 2013, MOL CELL, V49, P843, DOI 10.1016/j.molcel.2012.12.006
   Yan JP, 2011, J BIOL CHEM, V286, P27663, DOI 10.1074/jbc.M111.246975
   Yan JP, 2010, J VIROL, V84, P76, DOI 10.1128/JVI.01647-09
   Yang ZY, 2008, MOL CELL BIOL, V28, P967, DOI 10.1128/MCB.01020-07
   Yang ZY, 2005, MOL CELL, V19, P535, DOI 10.1016/j.molcel.2005.06.029
   Yik JHN, 2003, MOL CELL, V12, P971, DOI 10.1016/S1097-2765(03)00388-5
   You J, 2004, CELL, V117, P349, DOI 10.1016/S0092-8674(04)00402-7
   Zuber J, 2011, NATURE, V478, P524, DOI 10.1038/nature10334
NR 73
TC 46
Z9 51
U1 1
U2 8
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD JUL 3
PY 2017
VL 114
IS 27
BP E5352
EP E5361
DI 10.1073/pnas.1703071114
PG 10
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA EZ2YD
UT WOS:000404576100012
PM 28630312
OA Green Published, Bronze
DA 2025-01-12
ER

PT J
AU Szic, KSV
   Declerck, K
   Crans, RAJ
   Diddens, J
   Scherf, DB
   Gerhäuser, C
   Berghe, WV
AF Szic, Katarzyna Szarc Vel
   Declerck, Ken
   Crans, Rene A. J.
   Diddens, Jolien
   Scherf, David B.
   Gerhaeuser, Clarissa
   Berghe, Wim Vanden
TI Epigenetic silencing of triple negative breast cancer hallmarks by
   Withaferin A
SO ONCOTARGET
LA English
DT Article
DE triple negative breast cancer; luminal breast cancer; epigenetics;
   Withaferin A; DNA methylation
ID DNA METHYLATION PATTERNS; OF-THE-ART; AYURVEDIC MEDICINE;
   DOWN-REGULATION; HISTONE; CELLS; EXPRESSION; CHEMOPREVENTION; JARID1B;
   GENOME
AB Triple negative breast cancer (TNBC) is characterized by poor prognosis and a DNA hypomethylation profile. Withaferin A (WA) is a plant derived steroidal lactone which holds promise as a therapeutic agent for treatment of breast cancer (BC). We determined genome-wide DNA methylation changes in weakly-metastatic and aggressive, metastatic BC cell lines, following 72h treatment to a sub-cytotoxic concentration of WA. In contrast to the DNA demethylating agent 5-aza-2'-deoxycytidine (DAC), WA treatment of MDA-MB-231 cells rather tackles an epigenetic cancer network through gene-specific DNA hypermethylation of tumor promoting genes including ADAM metallopeptidase domain 8 (ADAM8), urokinase-type plasminogen activator (PLAU), tumor necrosis factor (ligand) superfamily, member 12 (TNFSF12), and genes related to detoxification (glutathione S-transferase mu 1, GSTM1), or mitochondrial metabolism (malic enzyme 3, ME3). Gene expression and pathway enrichment analysis further reveals epigenetic suppression of multiple cancer hallmarks associated with cell cycle regulation, cell death, cancer cell metabolism, cell motility and metastasis. Remarkably, DNA hypermethylation of corresponding CpG sites in PLAU, ADAM8, TNSF12, GSTM1 and ME3 genes correlates with receptor tyrosine-protein kinase erbB-2 amplification (HER2)/estrogen receptor (ESR)/progesterone receptor (PR) status in primary BC tumors. Moreover, upon comparing differentially methylated WA responsive target genes with DNA methylation changes in different clinical subtypes of breast cancer patients in the cancer genome atlas (TCGA), we found that WA silences HER2/PR/ESR-dependent gene expression programs to suppress aggressive TNBC characteristics in favor of luminal BC hallmarks, with an improved therapeutic sensitivity. In this respect, WA may represent a novel and attractive phyto-pharmaceutical for TNBC treatment.
C1 [Szic, Katarzyna Szarc Vel; Declerck, Ken; Crans, Rene A. J.; Diddens, Jolien; Berghe, Wim Vanden] Univ Antwerp, Dept Biomed Sci, Lab Prot Chem Prote & Epigenet Signaling PPES, Antwerp, Belgium.
   [Scherf, David B.; Gerhaeuser, Clarissa] German Canc Res Ctr, Div Epigenom & Canc Risk Factors, Workgrp Canc Chemoprevent & Epigenom, Heidelberg, Germany.
   [Crans, Rene A. J.] Univ Ghent, Dept Biochem & Microbiol, L GEST, Ghent, Belgium.
   [Szic, Katarzyna Szarc Vel] Univ Med Ctr Freiburg, Ctr Translat Cell Res, Div Hematol Oncol & Stem Cell Transplantat, Freiburg, Germany.
C3 University of Antwerp; Helmholtz Association; German Cancer Research
   Center (DKFZ); Ghent University; University of Freiburg
RP Berghe, WV (通讯作者)，Univ Antwerp, Dept Biomed Sci, Lab Prot Chem Prote & Epigenet Signaling PPES, Antwerp, Belgium.
EM wim.vandenberghe@uantwerpen.be
RI Crans, Rene/AAX-5631-2020; Vanden Berghe, Wim/S-6425-2018
OI Vanden Berghe, Wim/0000-0003-0161-7355; Crans, Rene/0000-0003-2832-4405;
   Declerck, Ken/0000-0001-8104-8054
FU Strategic Basic Research (SBO) grant of the Agency for Innovation by
   Science and Technology (IWT, Belgium); FWO (Belgium); COST Action CM1406
   Epigenetic Chemical Biology (EPICHEM); BOF/NOI/DOCPRO (University
   Antwerp); COST STSM (TD0905): "Epigenetics from bench to bedside"
FX Research has been supported by the Strategic Basic Research (SBO) grant
   of the Agency for Innovation by Science and Technology (IWT, Belgium),
   FWO (Belgium), COST Action CM1406 Epigenetic Chemical Biology (EPICHEM)
   and BOF/NOI/DOCPRO (University Antwerp) research grants. KSVS was
   supported by COST STSM (TD0905): "Epigenetics from bench to bedside".
CR Abramson VG, 2015, CANCER-AM CANCER SOC, V121, P8, DOI 10.1002/cncr.28914
   Aggarwal BB, 2006, EXPERT OPIN THER TAR, V10, P87, DOI 10.1517/14728222.10.1.87
   Antony ML, 2014, J BIOL CHEM, V289, P1852, DOI 10.1074/jbc.M113.496844
   Bamodu OA, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2108-5
   Bianco S, 2015, ONCOGENE, V34, P4509, DOI 10.1038/onc.2014.382
   Bianco S, 2014, CANCER RES, V74, P2015, DOI 10.1158/0008-5472.CAN-13-2351
   Bibikova M, 2011, GENOMICS, V98, P288, DOI 10.1016/j.ygeno.2011.07.007
   Biswal BM, 2013, INTEGR CANCER THER, V12, P312, DOI 10.1177/1534735412464551
   Bommareddy A, 2013, ANTICANCER RES, V33, P4163
   Brait M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070878
   Bueno MTD, 2013, EPIGENETICS-US, V8, P1162, DOI 10.4161/epi.26112
   Cano-Rodriguez D, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12284
   Chandrasekhar K, 2012, Indian J Psychol Med, V34, P255, DOI 10.4103/0253-7176.106022
   Chen YA, 2013, EPIGENETICS-US, V8, P203, DOI 10.4161/epi.23470
   Chicas A, 2012, P NATL ACAD SCI USA, V109, P8971, DOI 10.1073/pnas.1119836109
   Conway K, 2014, BREAST CANCER RES, V16, DOI 10.1186/s13058-014-0450-6
   Cope LM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105545
   Dedeurwaerder S, 2011, EMBO MOL MED, V3, P726, DOI 10.1002/emmm.201100801
   Denis H, 2016, MOL BIOSYST, V12, P404, DOI 10.1039/c5mb00513b
   Deplus R, 2014, CELL REP, V8, P743, DOI 10.1016/j.celrep.2014.06.048
   Duffy MJ, 2014, BREAST CANCER RES, V16, DOI 10.1186/s13058-014-0428-4
   Dupont JM, 2004, ANAL BIOCHEM, V333, P119, DOI 10.1016/j.ab.2004.05.007
   Ehrich M, 2005, P NATL ACAD SCI USA, V102, P15785, DOI 10.1073/pnas.0507816102
   Falahi F, 2013, MOL CANCER RES, V11, P1029, DOI 10.1158/1541-7786.MCR-12-0567
   Fang F, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3001875
   Faryna M, 2012, FASEB J, V26, P4937, DOI 10.1096/fj.12-209502
   Gao Y, 2015, CLIN EPIGENETICS, V7, DOI 10.1186/s13148-015-0159-0
   Gerhauser C, 2013, TOP CURR CHEM, V329, P73, DOI 10.1007/128_2012_360
   Hahm ER, 2013, JNCI-J NATL CANCER I, V105, P1111, DOI 10.1093/jnci/djt153
   Hahm ER, 2013, CANCER LETT, V334, P101, DOI 10.1016/j.canlet.2012.08.026
   Hahm ER, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023354
   Halachev K, 2012, GENOME BIOL, V13, DOI 10.1186/gb-2012-13-10-r96
   Han MJ, 2017, ONCOTARGET, V8, P8980, DOI 10.18632/oncotarget.13858
   Hayashi M, 2014, ONCOTARGET, V5, P3350, DOI 10.18632/oncotarget.1949
   Hellmich MR, 2015, ANTIOXID REDOX SIGN, V22, P424, DOI 10.1089/ars.2014.5933
   Heyninck K, 2014, BIOCHEM PHARMACOL, V91, P501, DOI 10.1016/j.bcp.2014.08.004
   Kaileh M, 2007, J BIOL CHEM, V282, P4253, DOI 10.1074/jbc.M606728200
   Kala R, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1693-z
   Kala R, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0155057
   Kato N, 2015, NAT GENET, V47, P1282, DOI 10.1038/ng.3405
   Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412
   Koch A, 2015, BMC GENOMICS, V16, DOI 10.1186/s12864-015-1847-z
   Kungulovski G, 2016, TRENDS GENET, V32, P101, DOI 10.1016/j.tig.2015.12.001
   Lee HY, 2013, CARCINOGENESIS, V34, P2706, DOI 10.1093/carcin/bgt256
   Lee J, 2010, CARCINOGENESIS, V31, P1991, DOI 10.1093/carcin/bgq175
   Li Q, 2011, CANCER RES, V71, P6899, DOI 10.1158/0008-5472.CAN-11-1523
   Li X, 2014, P NATL ACAD SCI USA, V111, P7096, DOI 10.1073/pnas.1324036111
   Link A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057709
   Link A, 2010, BIOCHEM PHARMACOL, V80, P1771, DOI 10.1016/j.bcp.2010.06.036
   Mazar AP, 2011, CURR PHARM DESIGN, V17, P1970
   Messier TL, 2016, J CELL PHYSIOL, V231, P2474, DOI 10.1002/jcp.25359
   Messier TL, 2016, ONCOTARGET, V7, P5094, DOI 10.18632/oncotarget.6922
   Mirza S, 2013, J BREAST CANCER, V16, P23, DOI 10.4048/jbc.2013.16.1.23
   Nanda R, 2011, SEMIN ONCOL, V38, P254, DOI 10.1053/j.seminoncol.2011.01.007
   Ndlovu MN, 2009, MOL CELL BIOL, V29, P5488, DOI 10.1128/MCB.01657-08
   Nishi M, 2014, ONCOTARGET, V5, P8665, DOI 10.18632/oncotarget.2356
   Ohta K, 2013, INT J ONCOL, V42, P1212, DOI 10.3892/ijo.2013.1799
   Perez-Janices N, 2015, ONCOTARGET, V6, P23944, DOI 10.18632/oncotarget.4062
   Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093
   Pratte MA, 2014, J ALTERN COMPLEM MED, V20, P901, DOI 10.1089/acm.2014.0177
   Price EM, 2013, EPIGENET CHROMATIN, V6, DOI 10.1186/1756-8935-6-4
   Pudenz M, 2014, NUTRIENTS, V6, P4218, DOI 10.3390/nu6104218
   R Core Team, 2022, R: A language and environment for statistical computing
   Ramadoss S, 2017, ONCOGENE, V36, P47, DOI 10.1038/onc.2016.174
   Reuter S, 2011, GENES NUTR, V6, P93, DOI 10.1007/s12263-011-0222-1
   Roscigno G, 2016, ONCOTARGET, V7, P580, DOI 10.18632/oncotarget.5979
   Rose NR, 2014, BBA-GENE REGUL MECH, V1839, P1362, DOI 10.1016/j.bbagrm.2014.02.007
   Salminen A, 2014, AGEING RES REV, V16, P45, DOI 10.1016/j.arr.2014.05.004
   Shmakova A, 2014, BIOCHEM J, V462, P385, DOI 10.1042/BJ20140754
   Somer RA, 2014, CURR OPIN GENET DEV, V27, P43, DOI 10.1016/j.gde.2014.03.008
   Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100
   Stan SD, 2008, CANCER RES, V68, P7661, DOI 10.1158/0008-5472.CAN-08-1510
   Stan SD, 2008, NUTR CANCER, V60, P51, DOI 10.1080/01635580802381477
   Stefansson OA, 2015, MOL ONCOL, V9, P555, DOI 10.1016/j.molonc.2014.10.012
   Stirzaker C, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms6899
   Stolzenburg S, 2016, ADV EXP MED BIOL, V945, P475, DOI 10.1007/978-3-319-43624-1_17
   Surh YJ, 2003, NAT REV CANCER, V3, P768, DOI 10.1038/nrc1189
   Szabo C, 2013, P NATL ACAD SCI USA, V110, P12474, DOI 10.1073/pnas.1306241110
   Szic KSV, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087850
   Thaiparambil JT, 2011, INT J CANCER, V129, P2744, DOI 10.1002/ijc.25938
   Thakur VS, 2014, AAPS J, V16, P151, DOI 10.1208/s12248-013-9548-5
   Ung MH, 2015, PLOS COMPUT BIOL, V11, DOI 10.1371/journal.pcbi.1004269
   Vanden Berghe W, 2012, BIOCHEM PHARMACOL, V84, P1282, DOI 10.1016/j.bcp.2012.08.027
   Vanden Berghe W, 2012, PHARMACOL RES, V65, P565, DOI 10.1016/j.phrs.2012.03.007
   Wade MA, 2015, NUCLEIC ACIDS RES, V43, P196, DOI 10.1093/nar/gku1298
   Widschwendter M, 2002, ONCOGENE, V21, P5462, DOI 10.1038/sj.onc.1205606
   Wissmann M, 2007, NAT CELL BIOL, V9, P347, DOI 10.1038/ncb1546
   Wong CP, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086787
   Xiong GF, 2012, CANCER RES, V72, P1728, DOI 10.1158/0008-5472.CAN-11-2762
   Yamamoto S, 2014, CANCER CELL, V25, P762, DOI 10.1016/j.ccr.2014.04.024
   Yang ZM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068433
   Zhou L, 2016, ONCOL REP, V35, P2715, DOI 10.3892/or.2016.4627
NR 92
TC 51
Z9 51
U1 0
U2 8
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD JUN 20
PY 2017
VL 8
IS 25
BP 40434
EP 40453
DI 10.18632/oncotarget.17107
PG 20
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA EY8YG
UT WOS:000404283700042
PM 28467815
OA Green Submitted, Green Published, gold
DA 2025-01-12
ER

PT J
AU Simbiri, KO
   Williams, CK
   Macaluso, M
   Giordano, A
AF Simbiri, Kenneth O.
   Williams, Christopher K.
   Macaluso, Marcella
   Giordano, Antonio
TI Promoting Cancer Control in Africa With "Ubuntu": A Report of the
   African Organization for Research and Training in Africa (AORTIC) 10th
   Conference, 2015 in Marrakech, Morocco
SO JOURNAL OF CELLULAR PHYSIOLOGY
LA English
DT Article
ID HISTORICAL-PERSPECTIVE; HIV; INFECTIONS; ONCOLOGY; VIRUSES; RISK
AB The objectives of the African Organization for Research and Training in Cancer (AORTIC), includes bringing products of decades of advances in cancer research to African populations through local and international collaboration. The consistent and huge growth in participation in the conferences and the diversity of the nations is a witness to the success of the organization thus far. The theme for the Tenth AORTIC International Conference on Cancer in Africa in Morocco in 2015 was "Road map to Cancer Control in Africa" and topics of discussion of paramount importance for low-and middle-income African countries included childhood cancers such as BL, cancers of the cervix, breast, and prostate; cancers associated with HIV-infection such as cervical, vulvar, and anal; as well as cancer care challenges associated with palliative care. The role of environmental factors that underlie some epigenetic changes in some of the cancers was emphasized. Oral and poster presentations from various parts of the continent indicate the growth of basic and translational science of cancer in the region, with studies revealing regional diversity in the frequencies of the triple-negative breast cancer, cervical cancer, prostate cancer, HCC, and Burkitt's lymphoma. There was a sign that Africa is trying to keep pace with the paradigm shift and focusing on translational medicine. This was shown by suggestions for application of genome-wide association studies, new generation sequencing, as well as the evaluation of single nucleotide polymorphisms that may be responsible for variable susceptibility in some of the prevalent cancers in people of African descent. (C) 2016 Wiley Periodicals, Inc.
C1 [Simbiri, Kenneth O.; Macaluso, Marcella; Giordano, Antonio] Temple Univ, Sbarro Inst Canc Res & Mol Med, BioLife Sci Bldg,Suite 431,1900 N 12th St, Philadelphia, PA 19122 USA.
   [Simbiri, Kenneth O.; Macaluso, Marcella; Giordano, Antonio] Temple Univ, Ctr Biotechnol, BioLife Sci Bldg,Suite 431,1900 N 12th St, Philadelphia, PA 19122 USA.
   [Simbiri, Kenneth O.] Jaramogi Oginga Odinga Univ Sci & Technol, Bondo, Kenya.
   [Williams, Christopher K.] Hematol Oncol Consultancy, Fred Hutchinson Canc Ctr, Port Angeles, WA USA.
   [Williams, Christopher K.] Univ Washington, Ctr AIDS Res, Port Angeles, WA USA.
C3 Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple
   University; Pennsylvania Commonwealth System of Higher Education
   (PCSHE); Temple University; Jaramogi Oginga Odinga University of Science
   & Technology; Fred Hutchinson Cancer Center; University of Washington
RP Simbiri, KO (通讯作者)，Temple Univ, Sbarro Inst Canc Res & Mol Med, BioLife Sci Bldg,Suite 431,1900 N 12th St, Philadelphia, PA 19122 USA.; Simbiri, KO (通讯作者)，Temple Univ, Ctr Biotechnol, BioLife Sci Bldg,Suite 431,1900 N 12th St, Philadelphia, PA 19122 USA.
EM kenneth.o.a.simbiri@temple.edu
RI Giordano, Antonio/F-1927-2010
OI Giordano, Antonio/0000-0002-5959-016X
CR Adewole I, 2014, NAT REV CLIN ONCOL, V11, P251, DOI 10.1038/nrclinonc.2014.37
   Bain LE, 2016, LANCET HIV, V3, pE341, DOI 10.1016/S2352-3018(16)30092-3
   Bernal M, 2003, EUR J CANCER PREV, V12, P171, DOI 10.1097/00008469-200304000-00012
   Bovicelli Alessandro, 2006, J Cell Physiol, V208, P1, DOI 10.1002/jcp.20640
   Buonaguro FM, 2013, INFECT AGENTS CANCER, V8, DOI 10.1186/1750-9378-8-39
   Chaturvedi AK, 2009, JNCI-J NATL CANCER I, V101, P1120, DOI 10.1093/jnci/djp205
   Cooley TP, 2003, HEMATOL ONCOL CLIN N, V17, P889, DOI 10.1016/S0889-8588(03)00038-8
   D'Andrilli G, 2010, J CELL PHYSIOL, V224, P601, DOI 10.1002/jcp.22174
   Dayaram T, 2008, J CELL PHYSIOL, V216, P309, DOI 10.1002/jcp.21439
   de Martel C, 2012, LANCET ONCOL, V13, DOI 10.1016/S1470-2045(12)70137-7
   Ezechi LO, 2016, CEYLON MED J, V61, P56, DOI 10.4038/cmj.v61i2.8300
   Feigal EG, 2001, CANC TREAT, V104, P367
   Feitelson MA, 1999, J CELL PHYSIOL, V181, P188
   Giordano Giovan Giacomo, 2002, Journal of Cellular Physiology, V191, P362, DOI 10.1002/jcp.10103
   Gomes A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0160797
   Harford JB, 2012, BRIT J HAEMATOL, V156, P709, DOI 10.1111/j.1365-2141.2011.09017.x
   Harford JB, 2009, TUMORI J, V95, P568
   HAUSEN HZ, 1991, SCIENCE, V254, P1167, DOI 10.1126/science.1659743
   Kiire CA, 2006, BRIT J OPHTHALMOL, V90, P109, DOI 10.1136/bjo.2005.077305
   Lang S, 2015, ARCH CARDIOVASC DIS, V108, P206, DOI 10.1016/j.acvd.2015.01.004
   Liao John B, 2006, Yale J Biol Med, V79, P115
   Magodoro Itai M, 2016, BMC Res Notes, V9, P379, DOI 10.1186/s13104-016-2187-z
   Nduka CU, 2016, AIDS REV, V18, P198
   Orem J, 2006, CURR OPIN ONCOL, V18, P479, DOI 10.1097/01.cco.0000239887.90665.10
   Parkin DM, 2014, CANCER EPIDEM BIOMAR, V23, P953, DOI 10.1158/1055-9965.EPI-14-0281
   Parkin DM, 2001, CANCER CAUSE CONTROL, V12, P147, DOI 10.1023/A:1008966225984
   Salata C, 2008, J CELL PHYSIOL, V216, P286, DOI 10.1002/jcp.21393
   Salata Cristiano, 2007, J Cell Physiol, V213, P844, DOI 10.1002/jcp.21157
   Schmitz R, 2012, NATURE, V490, P116, DOI 10.1038/nature11378
   Simbiri KO, 2014, INFECT AGENTS CANCER, V9, DOI 10.1186/1750-9378-9-28
   Simbiri Kenneth O, 2010, Infect Agent Cancer, V5, P6, DOI 10.1186/1750-9378-5-6
   Simbiri KO, 2012, CANC CLIN ONCOL, V1, P88
   Simbiri KO, 2012, CANC CLIN ONCOL, V1, P10, DOI DOI 10.5539/CC0.V1N2P10
   Simbiri KO, 2015, CANC CLIN ONCOL, V4, P2
   Sobieszczyk ME, 2016, JAIDS-J ACQ IMM DEF, V73, P438, DOI 10.1097/QAI.0000000000001123
   Stefan DC, 2012, PEDIATR BLOOD CANCER, V59, P349, DOI 10.1002/pbc.24069
   SUN TT, 1984, J CELL PHYSIOL, P39
   UNGASS, 2011, POL DECL HIGH LEV M
   Williams CKO, 2014, ECANCERMEDICALSCIENC, V8, DOI 10.3332/ecancer.2014.396
   Williams CKO, 2008, CAN J UROL, V15, P3858
NR 40
TC 0
Z9 0
U1 0
U2 15
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0021-9541
EI 1097-4652
J9 J CELL PHYSIOL
JI J. Cell. Physiol.
PD SEP
PY 2017
VL 232
IS 9
BP 2287
EP 2295
DI 10.1002/jcp.25671
PG 9
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Physiology
GA EZ1CI
UT WOS:000404445700003
PM 27800606
DA 2025-01-12
ER

PT J
AU Jadhav, RR
   Santucci-Pereira, J
   Wang, YV
   Liu, J
   Nguyen, TD
   Wang, J
   Jenkins, S
   Russo, J
   Huang, THM
   Jin, VX
   Lamartiniere, CA
AF Jadhav, Rohit R.
   Santucci-Pereira, Julia
   Wang, Yao V.
   Liu, Joseph
   Nguyen, Theresa D.
   Wang, Jun
   Jenkins, Sarah
   Russo, Jose
   Huang, Tim H. -M.
   Jin, Victor X.
   Lamartiniere, Coral A.
TI DNA Methylation Targets Influenced by Bisphenol A and/or Genistein Are
   Associated with Survival Outcomes in Breast Cancer Patients
SO GENES
LA English
DT Article
DE DNA-methylation; Bisphenol A; genistein
ID SOY ISOFLAVONE GENISTEIN; ASIAN-AMERICAN WOMEN; MAMMARY-CANCER; PROSTATE
   CARCINOGENESIS; EPITHELIAL-CELLS; EXPOSURE; RISK; EXPRESSION;
   PROLIFERATION; PREVENTION
AB Early postnatal exposures to Bisphenol A (BPA) and genistein (GEN) have been reported to predispose for and against mammary cancer, respectively, in adult rats. Since the changes in cancer susceptibility occurs in the absence of the original chemical exposure, we have investigated the potential of epigenetics to account for these changes. DNA methylation studies reveal that prepubertal BPA exposure alters signaling pathways that contribute to carcinogenesis. Prepubertal exposure to GEN and BPA + GEN revealed pathways involved in maintenance of cellular function, indicating that the presence of GEN either reduces or counters some of the alterations caused by the carcinogenic properties of BPA. We subsequently evaluated the potential of epigenetic changes in the rat mammary tissues to predict survival in breast cancer patients via the Cancer Genomic Atlas (TCGA). We identified 12 genes that showed strong predictive values for long-term survival in estrogen receptor positive patients. Importantly, two genes associated with improved long term survival, HPSE and RPS9, were identified to be hypomethylated in mammary glands of rats exposed prepuberally to GEN or to GEN + BPA respectively, reinforcing the suggested cancer suppressive properties of GEN.
C1 [Jadhav, Rohit R.; Wang, Yao V.; Liu, Joseph; Huang, Tim H. -M.; Jin, Victor X.] Univ Texas Hlth Sci Ctr San Antonio, Dept Mol Med, 8403 Floyd Curl, San Antonio, TX 78229 USA.
   [Santucci-Pereira, Julia; Nguyen, Theresa D.; Russo, Jose] Temple Univ Hlth Syst, Fox Chase Canc Ctr, 333 Cottman Ave, Philadelphia, PA 19111 USA.
   [Wang, Jun; Jenkins, Sarah; Lamartiniere, Coral A.] Univ Alabama Birmingham, Dept Pharmacol & Toxicol, 1670 Univ Blvd, Birmingham, AL 35294 USA.
C3 University of Texas System; University of Texas Health Science Center at
   San Antonio; Fox Chase Cancer Center; Pennsylvania Commonwealth System
   of Higher Education (PCSHE); Temple University; University of Alabama
   System; University of Alabama Birmingham
RP Jin, VX (通讯作者)，Univ Texas Hlth Sci Ctr San Antonio, Dept Mol Med, 8403 Floyd Curl, San Antonio, TX 78229 USA.; Lamartiniere, CA (通讯作者)，Univ Alabama Birmingham, Dept Pharmacol & Toxicol, 1670 Univ Blvd, Birmingham, AL 35294 USA.
EM Jadhav@livemail.uthscsa.edu; Julia.Pereira@fccc.edu;
   YaoWangPRC@hotmail.com; jliuj6@uthscsa.edu;
   theresa.diepnguyen@gmail.com; feijun@uab.edu; jenkinss@uab.edu;
   Jose.Russo@fccc.edu; huangt3@uthscsa.edu; jinv@uthscsa.edu;
   Coral@uab.edu
RI Liu, Qiuli/ABA-8363-2021; Jadhav, Rohit/D-2254-2016
OI Santucci-Pereira, Julia/0000-0003-4958-1128; Jadhav,
   Rohit/0000-0002-2999-6329
FU NIH [5U01ES019482]; CPRIT Training Grant [RP140105, 1R01GM114142];
   Department of Molecular Medicine at University of Texas Health Science
   Center at San Antonio
FX This work was supported by NIH 5U01ES019482, CPRIT Training Grant
   RP140105, and 1R01GM114142, as well as by the Department of Molecular
   Medicine at University of Texas Health Science Center at San Antonio.
CR Ahsan H, 2014, CANCER EPIDEM BIOMAR, V23, P658, DOI 10.1158/1055-9965.EPI-13-0340
   Anderson OS, 2012, ENVIRON MOL MUTAGEN, V53, P334, DOI 10.1002/em.21692
   Ardies CM, 1998, MED HYPOTHESES, V50, P457, DOI 10.1016/S0306-9877(98)90262-6
   Betancourt AM, 2012, J NUTR, V142, p1382S, DOI 10.3945/jn.111.152058
   Calafat AM, 2008, ENVIRON HEALTH PERSP, V116, P39, DOI 10.1289/ehp.10753
   Colt JS, 1998, ENVIRON HEALTH PERSP, V106, P909, DOI 10.2307/3434208
   Dairkee SH, 2013, CARCINOGENESIS, V34, P703, DOI 10.1093/carcin/bgs379
   Dave B, 2005, CARCINOGENESIS, V26, P1793, DOI 10.1093/carcin/bgi131
   Dhimolea E, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099800
   Doshi T, 2011, TOXICOLOGY, V289, P74, DOI 10.1016/j.tox.2011.07.011
   Fritz WA, 1998, CARCINOGENESIS, V19, P2151, DOI 10.1093/carcin/19.12.2151
   Fukutake M, 1996, FOOD CHEM TOXICOL, V34, P457, DOI 10.1016/0278-6915(96)87355-8
   Gertz J, 2012, GENOME RES, V22, P2153, DOI 10.1101/gr.135681.111
   Gu F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060980
   Gudas JM, 1999, MOL CELL BIOL, V19, P612
   Hanna CW, 2012, HUM REPROD, V27, P1401, DOI 10.1093/humrep/des038
   Hilakivi-Clarke L, 1999, BRIT J CANCER, V80, P1682, DOI 10.1038/sj.bjc.6690584
   Ho SM, 2006, CANCER RES, V66, P5624, DOI 10.1158/0008-5472.CAN-06-0516
   Hsu PY, 2010, GENOME RES, V20, P733, DOI 10.1101/gr.101923.109
   Ikezuki Y, 2002, HUM REPROD, V17, P2839, DOI 10.1093/humrep/17.11.2839
   Ismail IA, 2007, EUR J PHARMACOL, V575, P12, DOI 10.1016/j.ejphar.2007.07.039
   Jadhav RR, 2015, CLIN EPIGENETICS, V7, DOI 10.1186/s13148-015-0045-9
   Jenkins S, 2012, J STEROID BIOCHEM, V129, P191, DOI 10.1016/j.jsbmb.2011.06.003
   Jenkins S, 2009, ENVIRON HEALTH PERSP, V117, P910, DOI 10.1289/ehp.11751
   Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412
   Korde LA, 2009, CANCER EPIDEM BIOMAR, V18, P1050, DOI 10.1158/1055-9965.EPI-08-0405
   KRISHNAN AV, 1993, ENDOCRINOLOGY, V132, P2279, DOI 10.1210/en.132.6.2279
   Kuruto-Niwa R, 2007, CHEMOSPHERE, V66, P1160, DOI 10.1016/j.chemosphere.2006.06.073
   Lamartiniere C.A., 2016, TRENDS BREAST CANC P, P23
   Lamartiniere CA, 1998, AM J CLIN NUTR, V68, p1400S, DOI 10.1093/ajcn/68.6.1400S
   Lamartiniere CA, 2002, J NUTR, V132, p552S, DOI 10.1093/jn/132.3.552S
   Lamartiniere CA, 2011, HORM MOL BIOL CLIN I, V5, P45, DOI 10.1515/HMBCI.2010.075
   LaPensee EW, 2009, ENVIRON HEALTH PERSP, V117, P175, DOI 10.1289/ehp.11788
   Li M, 2005, CANCER RES, V65, P8200, DOI 10.1158/0008-5472.CAN-05-1302
   Mirza S, 2013, J BREAST CANCER, V16, P23, DOI 10.4048/jbc.2013.16.1.23
   Montales MTE, 2012, CARCINOGENESIS, V33, P652, DOI 10.1093/carcin/bgr317
   Murrill WB, 1996, CARCINOGENESIS, V17, P1451, DOI 10.1093/carcin/17.7.1451
   Prins GS, 2007, REPROD TOXICOL, V23, P374, DOI 10.1016/j.reprotox.2006.10.001
   Pudenz M, 2014, NUTRIENTS, V6, P4218, DOI 10.3390/nu6104218
   Setchell KDR, 1998, AM J CLIN NUTR, V68, p1453S, DOI 10.1093/ajcn/68.6.1453S
   Seux M, 2011, ONCOGENE, V30, P3049, DOI 10.1038/onc.2011.25
   Shu XO, 2001, CANCER EPIDEM BIOMAR, V10, P483
   Thanos J, 2006, CANCER CAUSE CONTROL, V17, P1253, DOI 10.1007/s10552-006-0062-2
   Trock BJ, 2006, JNCI-J NATL CANCER I, V98, P459, DOI 10.1093/jnci/djj102
   Vandenberg LN, 2007, REPROD TOXICOL, V24, P139, DOI 10.1016/j.reprotox.2007.07.010
   Wang J, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-379
   Wang R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067788
   Wang Y, 2016, SCI REP-UK, V6, DOI 10.1038/srep22051
   Wu AH, 2002, CARCINOGENESIS, V23, P1491, DOI 10.1093/carcin/23.9.1491
   Xie Q, 2014, GENE CHROMOSOME CANC, V53, P422, DOI 10.1002/gcc.22154
   Yang XJ, 2014, CANCER CELL, V26, P577, DOI 10.1016/j.ccr.2014.07.028
   Yaoi T, 2008, BIOCHEM BIOPH RES CO, V376, P563, DOI 10.1016/j.bbrc.2008.09.028
   Zheng HY, 2015, CANCER BIOMARK, V15, P525, DOI 10.3233/CBM-150459
   ZIEGLER RG, 1993, JNCI-J NATL CANCER I, V85, P1819, DOI 10.1093/jnci/85.22.1819
NR 54
TC 32
Z9 34
U1 0
U2 17
PU MDPI AG
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
SN 2073-4425
J9 GENES-BASEL
JI Genes
PD MAY
PY 2017
VL 8
IS 5
AR 144
DI 10.3390/genes8050144
PG 14
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA EZ1FS
UT WOS:000404456100017
PM 28505145
OA Green Published, gold, Green Submitted
DA 2025-01-12
ER

PT J
AU Zhao, WL
   Ma, N
   Wang, SM
   Mo, YX
   Zhang, Z
   Huang, GW
   Midorikawa, K
   Hiraku, Y
   Oikawa, S
   Murata, M
   Takeuchi, K
AF Zhao, Weilin
   Ma, Ning
   Wang, Shumin
   Mo, Yingxi
   Zhang, Zhe
   Huang, Guangwu
   Midorikawa, Kaoru
   Hiraku, Yusuke
   Oikawa, Shinji
   Murata, Mariko
   Takeuchi, Kazuhiko
TI <i>RERG</i> suppresses cell proliferation, migration and angiogenesis
   through ERK/NF-κB signaling pathway in nasopharyngeal carcinoma
SO JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
LA English
DT Article
DE RERG; Nasopharyngeal carcinoma; Tumor suppressor gene; DNA methylation;
   Angiogenesis
ID BARR-VIRUS INFECTION; MATRIX METALLOPROTEINASES; COLORECTAL-CANCER;
   EPITHELIAL-CELLS; BREAST-CANCER; PROMOTER HYPERMETHYLATION; MESENCHYMAL
   TRANSITION; TUMOR-GROWTH; GENE; EXPRESSION
AB Background: Nasopharyngeal carcinoma (NPC) is a malignancy of the head and neck that is prevalent in Southeast Asia and southern China. Recent studies in epigenetics suggest that DNA methylation plays a pivotal role in the onset and progression of cancer. Combining the methyl-DNA binding domain capture technique and cDNA microarray analysis, we identified a unique hypermethylated gene, RERG (Ras-like estrogen-regulated growth inhibitor), that was down-regulated in NPC tissues. RERG is a tumor suppressor gene that was first reported in breast cancer. However, the functions of RERG are largely unknown in other tumor types.
   Methods: RERG expression was assessed in human subjects (NPC primary tissues and non-cancer tissues) and cell lines (NPC cell lines and an immortalized epithelial cell line NP460). Further, we investigated the methylation rate of RERG in both human subject and cell lines. 5-Aza-2'-deoxycytidine (Aza) or combined with trichostatin A (TSA) were treated to three NPC cell lines (HK1, C666-1 and HK1_EBV). In addition, the role of RERG in NPC cells and its underlying mechanisms were explored by overexpression of RERG in NPC cell lines.
   Results: RERG was significantly down-regulated in NPC cancer nests compared to normal nasopharyngeal epithelium cells. Furthermore, the RERG promoter was frequently methylated in NPC tissues and cell lines. The RERG methylation rate yielded an area under the curve (AUC) of receiver operating characteristic (ROC) curve was 0.897 (95% CI: 0.818-0.976). The down-regulation of RERG was restored in NPC cells treated with Aza and TSA. In addition, ectopic expression of RERG in NPC cell lines resulted in a significant suppression of cell proliferation, clonogenicity, migration and invasion. RERG-overexpressing cells showed significantly slower growth and less angiogenesis in tumor xenografts in nude mice. RERG suppressed the ERK/NF-kappa B signaling pathway and inhibited tumor growth and angiogenesis with down-regulation of MMPs and IL8 in tumors of nude mouse xenografts.
   Conclusions: Our results suggest that RERG is frequently silenced by promoter CpG methylation in NPC, and acts as a functional tumor suppressor by suppressing the ERK/NF-kappa B signaling pathway. These findings support the potential use of RERG as a novel molecular target in NPC therapy.
C1 [Zhao, Weilin; Wang, Shumin; Mo, Yingxi; Midorikawa, Kaoru; Hiraku, Yusuke; Oikawa, Shinji; Murata, Mariko] Mie Univ, Grad Sch Med, Dept Environm & Mol Med, 2-174 Edobashi, Tsu, Mie 5148507, Japan.
   [Zhao, Weilin; Takeuchi, Kazuhiko] Mie Univ, Grad Sch Med, Dept Otorhinolaryngol Head & Neck Surg, 2-174 Edobashi, Tsu, Mie 5148507, Japan.
   [Zhao, Weilin; Wang, Shumin; Mo, Yingxi; Zhang, Zhe; Huang, Guangwu] Guangxi Med Univ, Affiliated Hosp 1, Dept Otolaryngol Head & Neck Surg, Nanning, Guangxi, Peoples R China.
   [Ma, Ning] Suzuka Univ Med Sci, Grad Sch Hlth Sci, Suzuka, Mie, Japan.
   [Wang, Shumin] Univ Rochester, Med Ctr, Ctr Oral Biol, Rochester, NY 14642 USA.
   [Mo, Yingxi] Guangxi Med Univ, Affiliated Tumor Hosp, Dept Res, Nanning, Guangxi, Peoples R China.
C3 Mie University; Mie University; Guangxi Medical University; University
   of Rochester; Guangxi Medical University
RP Murata, M (通讯作者)，Mie Univ, Grad Sch Med, Dept Environm & Mol Med, 2-174 Edobashi, Tsu, Mie 5148507, Japan.; Takeuchi, K (通讯作者)，Mie Univ, Grad Sch Med, Dept Otorhinolaryngol Head & Neck Surg, 2-174 Edobashi, Tsu, Mie 5148507, Japan.
EM mmurata@doc.medic.mie-u.ac.jp; kazuhiko@clin.medic.mie-u.ac.jp
RI 马, 宁/IQV-9948-2023
OI Ma, Ning/0000-0001-7315-8835
FU Japan Society for the Promotion of Science [KAKENHI JP22406016,
   JP25305020, JP16H05829]; National Natural Science Foundation of China
   [81272983]; Guangxi Natural Science Foundation [2013GXNSFGA019002];
   Grants-in-Aid for Scientific Research [17H04654, 15H04784, 17K09168,
   15K15237, 17K19806] Funding Source: KAKEN
FX This work was supported by grant from Japan Society for the Promotion of
   Science (KAKENHI JP22406016, JP25305020, JP16H05829). This work also
   supported by the National Natural Science Foundation of China (81272983)
   and Guangxi Natural Science Foundation (2013GXNSFGA019002).
CR Bancroft CC, 2001, CLIN CANCER RES, V7, P435
   Bassères DS, 2006, ONCOGENE, V25, P6817, DOI 10.1038/sj.onc.1209942
   Baylin SB, 2006, NAT REV CANCER, V6, P107, DOI 10.1038/nrc1799
   Baylin SB, 2011, NAT REV CANCER, V11, P726, DOI 10.1038/nrc3130
   Cao Y, 2016, J EXP CLIN CANC RES, V35, DOI 10.1186/s13046-016-0346-7
   Chung GTY, 2013, J PATHOL, V231, P311, DOI 10.1002/path.4239
   Curran S, 2000, EUR J CANCER, V36, P1621, DOI 10.1016/S0959-8049(00)00156-8
   Dhillon AS, 2007, ONCOGENE, V26, P3279, DOI 10.1038/sj.onc.1210421
   Ding CB, 2016, J EXP CLIN CANC RES, V35, DOI 10.1186/s13046-015-0280-0
   Egger G, 2004, NATURE, V429, P457, DOI 10.1038/nature02625
   Feinberg AP, 2006, NAT REV GENET, V7, P21, DOI 10.1038/nrg1748
   Finlin BS, 2001, J BIOL CHEM, V276, P42259, DOI 10.1074/jbc.M105888200
   Ghosh S, 2012, IMMUNOL REV, V246, P5, DOI 10.1111/j.1600-065X.2012.01111.x
   Gialeli C, 2011, FEBS J, V278, P16, DOI 10.1111/j.1742-4658.2010.07919.x
   Giordano G, 2015, J EXP CLIN CANC RES, V34, DOI 10.1186/s13046-015-0225-7
   Gupta MK, 2003, WORLD J GASTROENTERO, V9, P1144, DOI 10.3748/wjg.v9.i6.1144
   Habashy HO, 2011, BREAST CANCER RES TR, V128, P315, DOI 10.1007/s10549-010-1073-y
   Ho JY, 2017, ONCOTARGET, V8, P22443, DOI 10.18632/oncotarget.12338
   HUANG DP, 1980, INT J CANCER, V26, P127, DOI 10.1002/ijc.2910260202
   Huang YT, 1999, CANCER RES, V59, P1599
   Jiang YF, 2002, ONCOGENE, V21, P2245, DOI 10.1038/sj.onc.1205291
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Kessenbrock K, 2010, CELL, V141, P52, DOI 10.1016/j.cell.2010.03.015
   Key MD, 2006, METHOD ENZYMOL, V407, P513, DOI 10.1016/S0076-6879(05)07041-2
   Li HM, 2006, INT J CANCER, V119, P1567, DOI 10.1002/ijc.22032
   Lin ML, 2010, MOL CARCINOGEN, V49, P783, DOI 10.1002/mc.20652
   Lo AKF, 2006, NEOPLASIA, V8, P173, DOI 10.1593/neo.05625
   Lo KW, 2002, SEMIN CANCER BIOL, V12, P451, DOI 10.1016/S1044579X02000883
   Lo MC, 2013, CANCER LETT, V335, P81, DOI 10.1016/j.canlet.2013.01.052
   Luo X, 2016, SCI REP-UK, V6, DOI 10.1038/srep29922
   Meng DF, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046-016-0483-z
   Miyake M, 2015, ONCOGENE, V34, P890, DOI 10.1038/onc.2014.2
   Mo YX, 2012, CANCER LETT, V323, P147, DOI 10.1016/j.canlet.2012.03.042
   Oster B, 2011, INT J CANCER, V129, P2855, DOI 10.1002/ijc.25951
   Quail DF, 2013, NAT MED, V19, P1423, DOI 10.1038/nm.3394
   Ren Q, 2004, LARYNGOSCOPE, V114, P855, DOI 10.1097/00005537-200405000-00012
   Richmond A, 2002, NAT REV IMMUNOL, V2, P664, DOI 10.1038/nri887
   Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098
   Sparmann A, 2004, CANCER CELL, V6, P447, DOI 10.1016/j.ccr.2004.09.028
   Sun W, 2014, INT J ONCOL, V44, P1551, DOI 10.3892/ijo.2014.2323
   Suvà ML, 2013, SCIENCE, V339, P1567, DOI 10.1126/science.1230184
   Tao Qian, 2007, Expert Reviews in Molecular Medicine, V9, P1, DOI 10.1017/S1462399407000312
   Tian FY, 2013, CANCER EPIDEMIOL, V37, P708, DOI 10.1016/j.canep.2013.05.012
   Tsang CM, 2010, INT J CANCER, V127, P1570, DOI 10.1002/ijc.25173
   Tulalamba W, 2012, INT J CELL BIOL, V2012
   Wang SM, 2016, MEDIAT INFLAMM, V2016, DOI 10.1155/2016/9343460
   Wang SM, 2015, ONCOTARGET, V6, P35893, DOI 10.18632/oncotarget.5651
   Wang Shumin, 2014, Biomed Res Int, V2014, P507353, DOI 10.1155/2014/507353
   Wei William I, 2007, Curr Opin Otolaryngol Head Neck Surg, V15, P99, DOI 10.1097/MOO.0b013e3280148a06
   Weis SM, 2011, NAT MED, V17, P1359, DOI 10.1038/nm.2537
   Yeh CB, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031055
   Zhang J, 2016, J EXP CLIN CANC RES, V35, DOI 10.1186/s13046-016-0384-1
   Zhang Z, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045908
NR 53
TC 37
Z9 43
U1 0
U2 7
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1756-9966
J9 J EXP CLIN CANC RES
JI J. Exp. Clin. Cancer Res.
PD JUN 28
PY 2017
VL 36
AR 88
DI 10.1186/s13046-017-0554-9
PG 15
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA EZ0OL
UT WOS:000404405300001
PM 28659184
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Royston, KJ
   Udayakumar, N
   Lewis, K
   Tollefsbol, TO
AF Royston, Kendra J.
   Udayakumar, Neha
   Lewis, Kayla
   Tollefsbol, Trygve O.
TI A Novel Combination of Withaferin A and Sulforaphane Inhibits Epigenetic
   Machinery, Cellular Viability and Induces Apoptosis of Breast Cancer
   Cells
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE sulforaphane; withaferin; breast cancer; histone deacetylase1 (HDAC1);
   DNA methyltransferases (DNMTs); chemoprevention; epigenetics
ID EXPRESSION; THERAPY; SUPPRESSION; GROWTH; ALPHA; LINES
AB With cancer often classified as a disease that has an important epigenetic component, natural compounds that have the ability to regulate the epigenome become ideal candidates for study. Humans have a complex diet, which illustrates the need to elucidate the mechanisms of interaction between these bioactive compounds in combination. The natural compounds withaferin A (WA), from the Indian winter cherry, and sulforaphane (SFN), from cruciferous vegetables, have numerous anti-cancer effects and some report their ability to regulate epigenetic processes. Our study is the first to investigate the combinatorial effects of low physiologically achievable concentrations ofWA and SFN on breast cancer cell proliferation, histone deacetylase1 (HDAC1) and DNA methyltransferases (DNMTs). No adverse effects were observed on control cells at optimal concentrations. There was synergistic inhibition of cellular viability in MCF-7 cells and a greater induction of apoptosis with the combinatorial approach than with either compound administered alone in both MDA-MB-231 and MCF-7 cells. HDAC expression was down-regulated at multiple levels. Lastly, we determined the combined effects of these bioactive compounds on the pro-apoptotic BAX and anti-apoptotic BCL-2 and found decreases in BCL-2 and increases in BAX. Taken together, our findings demonstrate the ability of low concentrations of combinatorial WA and SFN to promote cancer cell death and regulate key epigenetic modifiers in human breast cancer cells.
C1 [Royston, Kendra J.; Udayakumar, Neha; Lewis, Kayla; Tollefsbol, Trygve O.] Univ Alabama Birmingham, Dept Biol, 1300 Univ Blvd, Birmingham, AL 35294 USA.
   [Royston, Kendra J.; Tollefsbol, Trygve O.] Univ Alabama Birmingham, Comprehens Canc Ctr, 1802 6th Ave South, Birmingham, AL 35294 USA.
   [Tollefsbol, Trygve O.] Univ Alabama Birmingham, Comprehens Ctr Hlth Aging, 1530 3rd Ave South, Birmingham, AL 35294 USA.
   [Tollefsbol, Trygve O.] Univ Alabama Birmingham, Nutr Obes Res Ctr, 1675 Univ Blvd, Birmingham, AL 35294 USA.
   [Tollefsbol, Trygve O.] Univ Alabama Birmingham, Comprehens Diabet Ctr, 1825 Univ Blvd, Birmingham, AL 35294 USA.
C3 University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham
RP Tollefsbol, TO (通讯作者)，Univ Alabama Birmingham, Dept Biol, 1300 Univ Blvd, Birmingham, AL 35294 USA.; Tollefsbol, TO (通讯作者)，Univ Alabama Birmingham, Comprehens Canc Ctr, 1802 6th Ave South, Birmingham, AL 35294 USA.; Tollefsbol, TO (通讯作者)，Univ Alabama Birmingham, Comprehens Ctr Hlth Aging, 1530 3rd Ave South, Birmingham, AL 35294 USA.; Tollefsbol, TO (通讯作者)，Univ Alabama Birmingham, Nutr Obes Res Ctr, 1675 Univ Blvd, Birmingham, AL 35294 USA.; Tollefsbol, TO (通讯作者)，Univ Alabama Birmingham, Comprehens Diabet Ctr, 1825 Univ Blvd, Birmingham, AL 35294 USA.
EM kendroy@uab.edu; nehau@uab.edu; klalewis@uab.edu; trygve@uab.edu
OI Tollefsbol, Trygve/0000-0002-0284-1511; Royston,
   Kendra/0000-0002-1575-7407
FU National Cancer Institute [R01 CA178441, R01 CA204346]; Cancer
   Prevention and Control Training Program [R25 CA047888]; National Science
   Foundation LSAMP Bridge to Doctorate Program; American Institute for
   Cancer Research [316184]
FX We thank Bidisha Paul for her comments on this article. We would also
   like to acknowledge the Tollefsbol lab members for their advice and
   support. This work was supported in part by grants from the National
   Cancer Institute (R01 CA178441 and R01 CA204346), The Cancer Prevention
   and Control Training Program (R25 CA047888), the National Science
   Foundation LSAMP Bridge to Doctorate Program, and the American Institute
   for Cancer Research (316184).
CR Abbas A, 2016, BIOCHEM CELL BIOL, V94, P71, DOI 10.1139/bcb-2015-0038
   Allis CD, 2016, NAT REV GENET, V17, P487, DOI 10.1038/nrg.2016.59
   Bashtrykov P, 2015, CELL CYCLE, V14, P5, DOI 10.4161/15384101.2014.989963
   Chen HP, 2013, J ONCOL, V2013, DOI 10.1155/2013/872957
   Chen HP, 2013, EXP CELL RES, V319, P697, DOI 10.1016/j.yexcr.2012.12.026
   Cheng YM, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17091530
   Chou TC, 2008, LEUKEMIA LYMPHOMA, V49, P2059, DOI 10.1080/10428190802353591
   Clarke JD, 2011, MOL NUTR FOOD RES, V55, P999, DOI 10.1002/mnfr.201000547
   DeSantis CE, 2016, CA-CANCER J CLIN, V66, P31, DOI 10.3322/caac.21320
   Esmaeili Mohammad Ali, 2016, Journal of Chemical Biology, V9, P41, DOI 10.1007/s12154-015-0144-2
   Fong MY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042265
   Greenbaum D, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-117
   Gryder BE, 2012, FUTURE MED CHEM, V4, P505, DOI [10.4155/fmc.12.3, 10.4155/FMC.12.3]
   Hahm ER, 2013, CANCER LETT, V334, P101, DOI 10.1016/j.canlet.2012.08.026
   Hahm ER, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023354
   Hahm ER, 2011, MOL CARCINOGEN, V50, P614, DOI 10.1002/mc.20760
   Ho E, 2009, J NUTR, V139, P2393, DOI 10.3945/jn.109.113332
   Jung Y, 2007, J MOL MED, V85, P1137, DOI 10.1007/s00109-007-0216-z
   Kala R, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1693-z
   Kim SH, 2016, BREAST CANCER RES TR, V157, P41, DOI 10.1007/s10549-016-3795-y
   Li YY, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-9
   Liang Y, 2001, ONCOGENE, V20, P6570, DOI 10.1038/sj.onc.1204815
   Maier T, 2009, FEBS LETT, V583, P3966, DOI 10.1016/j.febslet.2009.10.036
   Mann BS, 2007, ONCOLOGIST, V12, P1247, DOI 10.1634/theoncologist.12-10-1247
   Meeran SM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037748
   Meeran SM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011457
   Mirza S, 2013, J BREAST CANCER, V16, P23, DOI 10.4048/jbc.2013.16.1.23
   Mohan Royce, 2004, Angiogenesis, V7, P115, DOI 10.1007/s10456-004-1026-3
   Nagalingam A, 2014, CANCER RES, V74, P2617, DOI 10.1158/0008-5472.CAN-13-2081
   Pathania R, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7910
   Royston Kendra J, 2015, Curr Pharmacol Rep, V1, P46
   Senese S, 2007, MOL CELL BIOL, V27, P4784, DOI 10.1128/MCB.00494-07
   Sharma C, 2011, CANCER EPIDEMIOL, V35, P272, DOI 10.1016/j.canep.2010.09.008
   Su ZY, 2014, CANCER PREV RES, V7, P319, DOI 10.1158/1940-6207.CAPR-13-0313-T
   Szic KSV, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087850
   Tomczyk J, 2010, POSTEP HIG MED DOSW, V64, P590
   Urn HJ, 2012, BIOCHEM BIOPH RES CO, V427, P24, DOI 10.1016/j.bbrc.2012.08.133
   Xu SH, 2014, CURR PHARM DESIGN, V20, P1881, DOI 10.2174/13816128113199990527
   Zhang X, 2012, GYNECOL ONCOL, V124, P606, DOI 10.1016/j.ygyno.2011.11.044
NR 39
TC 68
Z9 74
U1 1
U2 6
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD MAY
PY 2017
VL 18
IS 5
AR 1092
DI 10.3390/ijms18051092
PG 17
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA EY6SQ
UT WOS:000404113900195
PM 28534825
OA Green Submitted, gold, Green Published
DA 2025-01-12
ER

PT J
AU Johnson, KC
   Houseman, EA
   King, JE
   Christensen, BC
AF Johnson, Kevin C.
   Houseman, E. Andres
   King, Jessica E.
   Christensen, Brock C.
TI Normal breast tissue DNA methylation differences at regulatory elements
   are associated with the cancer risk factor age
SO BREAST CANCER RESEARCH
LA English
DT Article
DE Normal breast; DNA methylation; Aging; 5mC; Risk factors;
   Reference-free; Breast cancer; Epigenetics; Epigenetic drift
ID IN-SITU; DECONVOLUTION; PROPORTION; EPITHELIUM; CARCINOMA; OBESITY
AB Background: The underlying biological mechanisms through which epidemiologically defined breast cancer risk factors contribute to disease risk remain poorly understood. Identification of the molecular changes associated with cancer risk factors in normal tissues may aid in determining the earliest events of carcinogenesis and informing cancer prevention strategies.
   Methods: Here we investigated the impact cancer risk factors have on the normal breast epigenome by analyzing DNA methylation genome-wide (Infinium 450 K array) in cancer-free women from the Susan G. Komen Tissue Bank (n = 100). We tested the relation of established breast cancer risk factors, age, body mass index, parity, and family history of disease, with DNA methylation adjusting for potential variation in cell-type proportions.
   Results: We identified 787 cytosine-guanine dinucleotide (CpG) sites that demonstrated significant associations (Q value <0.01) with subject age. Notably, DNA methylation was not strongly associated with the other evaluated breast cancer risk factors. Age-related DNA methylation changes are primarily increases in methylation enriched at breast epithelial cell enhancer regions (P = 7.1E-20), and binding sites of chromatin remodelers (MYC and CTCF). We validated the age-related associations in two independent populations, using normal breast tissue samples (n = 18) and samples of normal tissue adjacent to tumor tissue (n = 97). The genomic regions classified as age-related were more likely to be regions altered in both pre-invasive (n = 40, P = 3.0E-03) and invasive breast tumors (n = 731, P = 1.1E-13).
   Conclusions: DNA methylation changes with age occur at regulatory regions, and are further exacerbated in cancer, suggesting that age influences breast cancer risk in part through its contribution to epigenetic dysregulation in normal breast tissue.
C1 [Johnson, Kevin C.; King, Jessica E.; Christensen, Brock C.] Geisel Sch Med Dartmouth, Dept Epidemiol, Lebanon, NH 03756 USA.
   [Johnson, Kevin C.; King, Jessica E.; Christensen, Brock C.] Geisel Sch Med Dartmouth, Dept Mol & Syst Biol, Lebanon, NH 03756 USA.
   [Johnson, Kevin C.] Jackson Lab Genom Med, Farmington, CT 06032 USA.
   [Houseman, E. Andres] Oregon State Univ, Coll Publ Hlth & Human Sci, Dept Biostat, Corvallis, OR 97331 USA.
   [Christensen, Brock C.] Geisel Sch Med Dartmouth, Dept Community & Family Med, Lebanon, NH 03756 USA.
C3 Dartmouth College; Dartmouth College; Jackson Laboratory; Oregon State
   University; Dartmouth College
RP Christensen, BC (通讯作者)，Geisel Sch Med Dartmouth, Dept Epidemiol, Lebanon, NH 03756 USA.; Christensen, BC (通讯作者)，Geisel Sch Med Dartmouth, Dept Mol & Syst Biol, Lebanon, NH 03756 USA.
EM Brock.Christensen@dartmouth.edu
RI Christensen, Brock/B-8460-2009; Houseman, Eugene Andres/LXW-8656-2024
OI Way, Jessica/0000-0002-9993-9506
FU Center for Molecular Epidemiology COBRE program; National Institute of
   General Medical Sciences (NIGMS) of the National Institutes of Health
   [P20 GM104416]; National Institutes of Health [R01DE022772, R01MH094609]
FX The research reported in this publication was supported by the Center
   for Molecular Epidemiology COBRE program with grant funds from the
   National Institute of General Medical Sciences (NIGMS) of the National
   Institutes of Health Under award number P20 GM104416 (PI: Margaret R.
   Karagas). This work was supported by the National Institutes of Health
   grant numbers R01DE022772 to BCC and R01MH094609 to EAH.
CR Agha G, 2015, INT J EPIDEMIOL, V44, P1277, DOI 10.1093/ije/dyu236
   [Anonymous], 2004, Stat. Appl. Genet. Mol. Biol., DOI [10.2202/1544-6115.1027, DOI 10.2202/1544-6115.1027]
   Assenov Y, 2014, NAT METHODS, V11, P1138, DOI [10.1038/NMETH.3115, 10.1038/nmeth.3115]
   Beral V, 2002, BRIT J CANCER, V87, P1234, DOI 10.1038/sj.bjc.6600596
   Breeze CE, 2016, CELL REP, V17, P2137, DOI 10.1016/j.celrep.2016.10.059
   Carmichael AR, 2004, BREAST, V13, P85, DOI 10.1016/j.breast.2003.03.001
   Chen YA, 2013, EPIGENETICS-US, V8, P203, DOI 10.4161/epi.23470
   Christensen BC, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001043
   Christensen BC, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000602
   Costantino L, 2008, CURR MED CHEM, V15, P834, DOI 10.2174/092986708783955464
   Euhus DM, 2008, CANCER EPIDEM BIOMAR, V17, P1051, DOI 10.1158/1055-9965.EPI-07-2582
   Fleischer T, 2014, GENOME BIOL, V15, DOI [10.1186/s13059-014-0435-x, 10.1186/PREACCEPT-2333349012841587]
   GAIL MH, 1989, JNCI-J NATL CANCER I, V81, P1879, DOI 10.1093/jnci/81.24.1879
   Gaujoux R, 2012, INFECT GENET EVOL, V12, P913, DOI 10.1016/j.meegid.2011.08.014
   Green BB, 2016, ENVIRON HEALTH PERSP, V124, P1253, DOI 10.1289/ehp.1510437
   Gustems M, 2014, NUCLEIC ACIDS RES, V42, P3059, DOI 10.1093/nar/gkt1323
   Handoko L, 2011, NAT GENET, V43, P630, DOI 10.1038/ng.857
   Horvath S, 2014, P NATL ACAD SCI USA, V111, P15538, DOI 10.1073/pnas.1412759111
   Horvath S, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-10-r115
   Houseman EA, 2016, BMC BIOINFORMATICS, V17, DOI 10.1186/s12859-016-1140-4
   Houseman EA, 2014, BIOINFORMATICS, V30, P1431, DOI 10.1093/bioinformatics/btu029
   Illingworth R, 2008, PLOS BIOL, V6, P37, DOI 10.1371/journal.pbio.0060022
   Jaenisch R, 1997, TRENDS GENET, V13, P323, DOI 10.1016/S0168-9525(97)01180-3
   Jaffe AE, 2014, GENOME BIOL, V15, DOI 10.1186/gb-2014-15-2-r31
   Johnson KC, 2015, CLIN EPIGENETICS, V7, DOI 10.1186/s13148-015-0094-0
   Johnson KC, 2014, EPIGENETICS-US, V9, P268, DOI 10.4161/epi.27015
   Jones PA, 2012, NAT REV GENET, V13, P484, DOI 10.1038/nrg3230
   Key J, 2006, CANCER CAUSE CONTROL, V17, P759, DOI 10.1007/s10552-006-0011-0
   Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412
   Koestler DC, 2016, BMC BIOINFORMATICS, V17, DOI 10.1186/s12859-016-0943-7
   Larsson SC, 2007, JNCI-J NATL CANCER I, V99, P64, DOI 10.1093/jnci/djk006
   Lewis CM, 2005, CLIN CANCER RES, V11, P166
   MADIGAN MP, 1995, J NATL CANCER I, V87, P1681, DOI 10.1093/jnci/87.22.1681
   Marioni RE, 2015, GENOME BIOL, V16, DOI 10.1186/s13059-015-0584-6
   Sheffield NC, 2016, BIOINFORMATICS, V32, P587, DOI 10.1093/bioinformatics/btv612
   Sherman ME, 2012, CANCER PREV RES, V5, P528, DOI 10.1158/1940-6207.CAPR-11-0234
   Teschendorff AE, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10478
   Teschendorff AE, 2013, BIOINFORMATICS, V29, P189, DOI 10.1093/bioinformatics/bts680
   Teschendorff AE, 2011, BIOINFORMATICS, V27, P1496, DOI 10.1093/bioinformatics/btr171
   van Gemert WA, 2015, BREAST CANCER RES TR, V152, P155, DOI 10.1007/s10549-015-3447-7
   Varlakhanova NV, 2009, CANCER RES, V69, P7487, DOI 10.1158/0008-5472.CAN-08-4832
   Yang Z, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-1064-3
NR 42
TC 48
Z9 53
U1 0
U2 14
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1465-5411
EI 1465-542X
J9 BREAST CANCER RES
JI Breast Cancer Res.
PD JUL 10
PY 2017
VL 19
AR 81
DI 10.1186/s13058-017-0873-y
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA FA4SG
UT WOS:000405432900002
PM 28693600
OA gold, Green Published, Green Submitted
DA 2025-01-12
ER

PT J
AU Ren, D
   Yang, Q
   Dai, YH
   Guo, W
   Du, H
   Song, LB
   Peng, XS
AF Ren, Dong
   Yang, Qing
   Dai, Yuhu
   Guo, Wei
   Du, Hong
   Song, Libing
   Peng, Xinsheng
TI Oncogenic miR-210-3p promotes prostate cancer cell EMT and bone
   metastasis via NF-κB signaling pathway
SO MOLECULAR CANCER
LA English
DT Article
DE miR-210-3p; EMT; Bone metastasis; NF-kappa B signaling and prostate
   cancer
ID EPITHELIAL-MESENCHYMAL TRANSITION; BREAST-CANCER; HYPOXIA; ACTIVATION;
   EXPRESSION; MICRORNAS; INFLAMMATION; MIGRATION; ANGIOGENESIS; INDUCTION
AB Background: The primary issue arising from prostate cancer (PCa) is its high prevalence to metastasize to bone, which severely affects the quality of life and survival time of PCa patients. miR-210-3p is a well-documented oncogenic miRNA implicated in various aspects of cancer development, progression and metastasis. However, the clinical significance and biological roles of miR-210-3p in PCa bone metastasis remain obscure.
   Methods: miR-210-3p expression was evaluated by real-time PCR in 68 bone metastatic and 81 non-bone metastatic PCa tissues. The biological roles of miR-210-3p in the bone metastasis of PCa were investigated both in vitro by EMT and Transwell assays, and in vivo using a mouse model of left cardiac ventricle inoculation. Bioinformatics analysis, real-time PCR, western blot and luciferase reporter analysis were applied to discern and examine the relationship between miR-210-3p and its potential targets. RT-PCR was performed to identify the underlying mechanism of miR-210-3p overexpression in bone metastasis of PCa. Clinical correlation of miR-210-3p with its targets was examined in human PCa and metastatic bone tissues.
   Results: miR-210-3p expression is elevated in bone metastatic PCa tissues compared with non-bone metastatic PCa tissues. Overexpression of miR-210-3p positively correlates with serum PSA levels, Gleason grade and bone metastasis status in PCa patients. Upregulating miR-210-3p enhances, while silencing miR-210-3p represses the EMT, invasion and migration of PCa cells in vitro. Importantly, silencing miR-210-3p significantly inhibits bone metastasis of PC 3 cells in vivo. Our results further demonstrate that miR-210-3p maintains the sustained activation of NF-kappa B signaling via targeting negative regulators of NF-kappa B signaling (TNF-alpha Induced Protein 3 Interacting Protein 1) TNIP1 and (Suppressor Of Cytokine Signaling 1) SOCS1, resulting in EMT, invasion, migration and bone metastasis of PCa cells. Moreover, our results further indicate that recurrent gains (amplification) contribute to miR-210-3p overexpression in a small number of PCa patients. The clinical correlation of miR-210-3p with SOCS1, TNIP1 and NF-kappa B signaling activity is verified in PCa tissues.
   Conclusion: Our findings unravel a novel mechanism for constitutive activation of NF-kappa B signaling pathway in the bone metastasis of PCa, supporting a functional and clinical significance of epigenetic events in bone metastasis of PCa.
C1 [Ren, Dong; Yang, Qing; Dai, Yuhu; Guo, Wei; Peng, Xinsheng] Sun Yat Sen Univ, Dept Orthopaed Surg, Affiliated Hosp 1, 58 Zhongshan 2rd Rd, Guangzhou 510080, Guangdong, Peoples R China.
   [Ren, Dong; Yang, Qing; Dai, Yuhu; Guo, Wei; Peng, Xinsheng] Guangdong Prov Key Lab Orthoped & Traumatol, Guangzhou 510080, Guangdong, Peoples R China.
   [Du, Hong] First Peoples Hosp Guangzhou City, Dept Pathol, Guangzhou 510180, Guangdong, Peoples R China.
   [Song, Libing] Sun Yat Sen Univ, Canc Ctr, State Key Lab Oncol Southern China, Dept Expt Res, Guangzhou 510060, Guangdong, Peoples R China.
C3 Sun Yat Sen University; South China University of Technology; State Key
   Lab Oncology South China; Sun Yat Sen University
RP Ren, D; Peng, XS (通讯作者)，Sun Yat Sen Univ, Dept Orthopaed Surg, Affiliated Hosp 1, 58 Zhongshan 2rd Rd, Guangzhou 510080, Guangdong, Peoples R China.; Ren, D; Peng, XS (通讯作者)，Guangdong Prov Key Lab Orthoped & Traumatol, Guangzhou 510080, Guangdong, Peoples R China.
EM summeryang818ren@outlook.com; pengxs66@yahoo.com
RI peng, Xinsheng/Q-9115-2019; Song, LB/AAL-1968-2020; Ren,
   Dong/N-3418-2018
OI Ren, Dong/0000-0002-0843-0246
FU Science and Technology Planning Project of Guangzhou, China
   [201607010213]
FX This study was supported by grants from the Science and Technology
   Planning Project of Guangzhou, China (No. 201607010213).
CR Baig MS, 2015, J EXP MED, V212, P1725, DOI 10.1084/jem.20140654
   Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002
   Ben-Neriah Y, 2003, MOL CELL, V12, P1344, DOI 10.1016/S1097-2765(03)00493-3
   Bubendorf L, 2000, HUM PATHOL, V31, P578, DOI 10.1053/hp.2000.6698
   Burnett RM, 2015, ONCOTARGET, V6, P12682, DOI 10.18632/oncotarget.3707
   Carlin Bruce I., 2000, Cancer, V88, P2989, DOI 10.1002/1097-0142(20000615)88:12+<2989::AID-CNCR14>3.3.CO;2-H
   Catena R, 2011, CANCER RES, V71, P164, DOI 10.1158/0008-5472.CAN-10-1708
   Chen JM, 2014, MED ONCOL, V31, DOI 10.1007/s12032-013-0799-x
   Chen PC, 2013, CARCINOGENESIS, V34, P1669, DOI 10.1093/carcin/bgt103
   Cheng HH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069239
   Colden M, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.15
   Cui XY, 2013, BLOOD CELL MOL DIS, V51, P177, DOI 10.1016/j.bcmd.2013.05.003
   Ding L, 2015, INT J CLIN EXP MED, V8, P2299
   Espinosa L, 2010, CANCER CELL, V18, P268, DOI 10.1016/j.ccr.2010.08.006
   Gingras S, 2004, J BIOL CHEM, V279, P54702, DOI 10.1074/jbc.M411043200
   Greco S, 2014, ANTIOXID REDOX SIGN, V21, P1164, DOI 10.1089/ars.2014.6083
   Guo W, 2013, J CELL BIOCHEM, V114, P1606, DOI 10.1002/jcb.24502
   Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704
   Hayden MS, 2008, CELL, V132, P344, DOI 10.1016/j.cell.2008.01.020
   Helbig G, 2003, J BIOL CHEM, V278, P21631, DOI 10.1074/jbc.M300609200
   Hellerbrand C, 2007, CARCINOGENESIS, V28, P21, DOI 10.1093/carcin/bgl081
   Hoesel B, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-86
   Huber MA, 2004, J CLIN INVEST, V114, P569, DOI 10.1172/JCI200421358
   Ivan M, 2008, J CELL MOL MED, V12, P1426, DOI 10.1111/j.1582-4934.2008.00398.x
   Jiang LL, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-406
   Jiang LL, 2012, J CLIN INVEST, V122, P33, DOI 10.1172/JCI58849
   Jin RJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060983
   Kai AKL, 2016, HEPATOLOGY, V64, P473, DOI 10.1002/hep.28577
   Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104
   Karin M, 2005, NAT REV IMMUNOL, V5, P749, DOI 10.1038/nri1703
   Khew-Goodall Y, 2010, NAT CELL BIOL, V12, P209, DOI 10.1038/ncb0310-209
   Kusumbe AP, 2014, NATURE, V507, P323, DOI 10.1038/nature13145
   Li XY, 2017, INT J ONCOL, V50, P1097, DOI 10.3892/ijo.2017.3909
   Liu YN, 2013, ONCOGENE, V32, P296, DOI 10.1038/onc.2012.58
   Ma L, 2010, NAT CELL BIOL, V12, P247, DOI 10.1038/ncb2024
   Madhavan D, 2016, CARCINOGENESIS, V37, P461, DOI 10.1093/carcin/bgw008
   Masszi A, 2004, AM J PATHOL, V165, P1955, DOI 10.1016/S0002-9440(10)63247-6
   Mermel CH, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-4-r41
   MIETTINEN PJ, 1994, J CELL BIOL, V127, P2021, DOI 10.1083/jcb.127.6.2021
   Molina AM, 2013, CLIN GENITOURIN CANC, V11, P297, DOI 10.1016/j.clgc.2013.04.001
   Nelson WG, 2003, NEW ENGL J MED, V349, P366, DOI 10.1056/NEJMra021562
   Nguyen DP, 2013, BJU INT, V111, pE143, DOI [10.1111/j.1464-410X.2013.11397_10.x, 10.1111/bju.12488]
   Ono S, 2015, ONCOTARGET, V6, P7053, DOI 10.18632/oncotarget.3142
   Park BK, 2007, NAT MED, V13, P62, DOI 10.1038/nm1519
   Park SH, 2003, DNA CELL BIOL, V22, P131, DOI 10.1089/104454903321515931
   Parmar K, 2007, P NATL ACAD SCI USA, V104, P5431, DOI 10.1073/pnas.0701152104
   Peng XS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020341
   Piret JP, 2002, ANN NY ACAD SCI, V973, P443, DOI 10.1111/j.1749-6632.2002.tb04680.x
   Rankin Erinn B, 2011, Curr Osteoporos Rep, V9, P46, DOI 10.1007/s11914-011-0047-2
   Ren D, 2014, CELL TISSUE RES, V358, P763, DOI 10.1007/s00441-014-2001-y
   Ren D, 2013, INT J ONCOL, V42, P1473, DOI 10.3892/ijo.2013.1825
   SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6
   Siu MK, 2015, ONCOGENE, V34, P4767, DOI 10.1038/onc.2014.414
   Song RP, 2014, HEPATOLOGY, V60, P1659, DOI 10.1002/hep.27312
   Sun SC, 2010, CELL DEATH DIFFER, V17, P25, DOI 10.1038/cdd.2009.43
   Taddei ML, 2014, MOL ONCOL, V8, P1729, DOI 10.1016/j.molonc.2014.07.009
   Tahk S, 2007, P NATL ACAD SCI USA, V104, P11643, DOI 10.1073/pnas.0701877104
   Tan EJ, 2012, J BIOL CHEM, V287, P7134, DOI 10.1074/jbc.M111.291385
   Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007
   Thuault S, 2008, J BIOL CHEM, V283, P33437, DOI 10.1074/jbc.M802016200
   Tsai YP, 2012, J BIOMED SCI, V19, DOI 10.1186/1423-0127-19-102
   Velu VK, 2012, J CLIN DIAGN RES, V6, P1791, DOI [10.7860/JCDR/2012/4901.2653, 10.7860/JCDR/2012/4241.2653]
   Verstrepen L, 2009, BIOCHEM PHARMACOL, V78, P105, DOI 10.1016/j.bcp.2009.02.009
   Wang M, 2016, INT J ONCOL, V48, P595, DOI 10.3892/ijo.2015.3270
   Wang M, 2014, INT J ONCOL, V45, P362, DOI 10.3892/ijo.2014.2413
   Wu TT, 1998, INT J CANCER, V77, P887, DOI 10.1002/(SICI)1097-0215(19980911)77:6<887::AID-IJC15>3.0.CO;2-Z
   Wu Y, 2009, CANCER CELL, V15, P416, DOI 10.1016/j.ccr.2009.03.016
   Zhang J, 2004, FEBS LETT, V570, P97, DOI 10.1016/j.febslet.2004.05.081
   Zhang X, 2017, BREAST CANCER RES, V19, DOI 10.1186/s13058-016-0785-2
   Zolnierek J, 2010, J CANCER RES CLIN, V136, P371, DOI 10.1007/s00432-009-0664-7
NR 70
TC 191
Z9 211
U1 1
U2 24
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1476-4598
J9 MOL CANCER
JI Mol. Cancer
PD JUL 10
PY 2017
VL 16
AR 117
DI 10.1186/s12943-017-0688-6
PG 16
WC Biochemistry & Molecular Biology; Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology
GA FA0CC
UT WOS:000405097500001
PM 28693582
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Yang, LL
   Ma, XB
   Yuan, C
   He, YY
   Li, L
   Fang, S
   Xia, W
   He, T
   Qian, S
   Xu, ZH
   Li, GB
   Wang, ZY
AF Yang, Lingling
   Ma, Xiaobo
   Yuan, Chen
   He, Yanying
   Li, Ling
   Fang, Sha
   Xia, Wei
   He, Tao
   Qian, Shan
   Xu, Zhihong
   Li, Guobo
   Wang, Zhouyu
TI Discovery of
   2-((4,6-dimethylpyrimidin-2-yl)thio)-<i>N</i>-phenylacetamide
   derivatives as new potent and selective human sirtuin 2 inhibitors
SO EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
DE Sirtuins; SIRT2; Epigenetics; Cancer; Structure-based optimization
ID LEAD OPTIMIZATION; RESTRICTION; ACETYLATION; DEGRADATION; DEACETYLASE;
   EXPRESSION; VEGFR2; DESIGN; MODEL; FLT3
AB Human sirtuin 2 (SIRT2) plays pivotal roles in multiple biological processes such as cell cycle regulation, autophagy, immune and inflammatory responses. Dysregulation of SIRT2 was considered as a main aspect contributing to several human diseases, including cancer. Development of new potent and selective SIRT2 inhibitors is currently desirable, which may provide a new strategy for treatment of related diseases. Herein, a structure-based optimization approach led to new 2-((4,6-dimethylpyrimidin-2-yl) thio)-N-phenylacetamide derivatives as SIRT2 inhibitors. SAR analyses with new synthesized derivatives revealed a number of new potent SIRT2 inhibitors, among which 28e is the most potent inhibitor with an IC50 value of 42 nM. The selectivity analyses found that 28e has a very good selectivity to SIRT2 over SIRT1 and SIRT3. In cellular assays, 28e showed a potent ability to inhibit human breast cancer cell line MCF-7 and increase the acetylation of alpha-tubulin in a dose-dependent manner. This study will aid further efforts to develop highly potent and selective SIRT2 inhibitors for the treatment of cancer and other related diseases. (C) 2017 Elsevier Masson SAS. All rights reserved.
C1 [Yang, Lingling; Yuan, Chen; He, Yanying; Li, Ling; Fang, Sha; Xia, Wei; Qian, Shan] Xihua Univ, Coll Food & Bioengn, Chengdu 610039, Sichuan, Peoples R China.
   [Ma, Xiaobo; He, Tao; Xu, Zhihong; Wang, Zhouyu] Xihua Univ, Coll Sci, Chengdu 610039, Sichuan, Peoples R China.
   [Li, Guobo] Sichuan Univ, West China Sch Pharm, Minist Educ, Key Lab Drug Targeting,Drug Delivery Syst, Chengdu 610041, Peoples R China.
C3 Xihua University; Xihua University; Sichuan University
RP Yang, LL (通讯作者)，Xihua Univ, Coll Food & Bioengn, Chengdu 610039, Sichuan, Peoples R China.; Wang, ZY (通讯作者)，Xihua Univ, Coll Sci, Chengdu 610039, Sichuan, Peoples R China.
EM yang110808@sina.com; zhouyuwang77@gmail.com
RI Li, Guo-Bo/IZE-0772-2023; yuan, chen/N-7118-2019
OI Li, Guo-Bo/0000-0002-4915-6677
FU Talent Introduction Key Project of Xihua University [z1410526]; Sichuan
   Education Department Key Projects [16205459]; National Natural Science
   Foundation of China [81502989]; National Undergraduate Innovation and
   entrepreneurship training program [201510623048]
FX This work was supported by Talent Introduction Key Project of Xihua
   University (No. z1410526), Sichuan Education Department Key Projects
   (No.16205459), National Natural Science Foundation of China (No.
   81502989) and National Undergraduate Innovation and entrepreneurship
   training program (No.201510623048).
CR Bonkowski MS, 2016, NAT REV MOL CELL BIO, V17, P679, DOI 10.1038/nrm.2016.93
   Chalkiadaki A, 2015, NAT REV CANCER, V15, DOI 10.1038/nrc3985
   Chen B, 2015, CHEM SOC REV, V44, P5246, DOI 10.1039/c4cs00373j
   Chen J, 2013, HEPATOLOGY, V57, P2287, DOI 10.1002/hep.26278
   Chen YP, 2014, BIOORG MED CHEM LETT, V24, P349, DOI 10.1016/j.bmcl.2013.11.004
   Das C, 2009, NATURE, V459, P113, DOI 10.1038/nature07861
   Disch JS, 2013, J MED CHEM, V56, P3666, DOI 10.1021/jm400204k
   Du JT, 2011, SCIENCE, V334, P806, DOI 10.1126/science.1207861
   Haigis MC, 2006, CELL, V126, P941, DOI 10.1016/j.cell.2006.06.057
   Houtkooper RH, 2012, NAT REV MOL CELL BIO, V13, P225, DOI 10.1038/nrm3293
   Jing EX, 2007, CELL METAB, V6, P105, DOI 10.1016/j.cmet.2007.07.003
   Jing H, 2016, CANCER CELL, V29, P297, DOI 10.1016/j.ccell.2016.02.007
   Li GB, 2016, J MED CHEM, V59, P8293, DOI 10.1021/acs.jmedchem.6b00604
   Li GB, 2015, EUR J MED CHEM, V93, P523, DOI 10.1016/j.ejmech.2015.02.019
   Li GB, 2015, METHODS, V71, P158, DOI 10.1016/j.ymeth.2014.11.010
   Li ZM, 2016, ONCOTARGET, V7, P18927, DOI 10.18632/oncotarget.7816
   Li ZM, 2013, LUNG CANCER, V82, P9, DOI 10.1016/j.lungcan.2013.05.013
   Liszt G, 2005, J BIOL CHEM, V280, P21313, DOI 10.1074/jbc.M413296200
   North BJ, 2003, MOL CELL, V11, P437, DOI 10.1016/S1097-2765(03)00038-8
   Ouaïssi M, 2008, ANN SURG ONCOL, V15, P2318, DOI 10.1245/s10434-008-9940-z
   Peck B, 2010, MOL CANCER THER, V9, P844, DOI 10.1158/1535-7163.MCT-09-0971
   Rothgiesser KM, 2010, J CELL SCI, V123, P4251, DOI 10.1242/jcs.073783
   Rumpf T, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7263
   Sakai T, 2015, BIOORGAN MED CHEM, V23, P328, DOI 10.1016/j.bmc.2014.11.027
   Schiedel M., 2015, ANGEW CHE INT ED, V54, P1
   Schiedel M, 2016, J MED CHEM, V59, P1599, DOI 10.1021/acs.jmedchem.5b01517
   Trapp J, 2007, CHEMMEDCHEM, V2, P1419, DOI 10.1002/cmdc.200700003
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Vaquero A, 2006, GENE DEV, V20, P1256, DOI 10.1101/gad.1412706
   Wang F, 2007, AGING CELL, V6, P505, DOI 10.1111/j.1474-9726.2007.00304.x
   Yang L.-L., 2016, SCI CHINA LIFE SCI
   Yang LL, 2013, J MED CHEM, V56, P1641, DOI 10.1021/jm301537p
   Yang LL, 2012, EUR J MED CHEM, V56, P30, DOI 10.1016/j.ejmech.2012.08.007
   Yang T, 2015, EUR J MED CHEM, V92, P145, DOI 10.1016/j.ejmech.2014.12.027
   Zhang XY, 2016, NAT CHEM BIOL, V12, P614, DOI [10.1038/NCHEMBIO.2106, 10.1038/nchembio.2106]
NR 35
TC 38
Z9 43
U1 2
U2 45
PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI PARIS
PA 23 RUE LINOIS, 75724 PARIS, FRANCE
SN 0223-5234
EI 1768-3254
J9 EUR J MED CHEM
JI Eur. J. Med. Chem.
PD JUL 7
PY 2017
VL 134
BP 230
EP 241
DI 10.1016/j.ejmech.2017.04.010
PG 12
WC Chemistry, Medicinal
WE Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC)
SC Pharmacology & Pharmacy
GA EV3RT
UT WOS:000401677500020
PM 28415012
DA 2025-01-12
ER

PT J
AU Kuang, Y
   Lu, FF
   Guo, JF
   Xu, H
   Wang, Q
   Xu, CH
   Zeng, LJ
   Yi, SY
AF Kuang, Yan
   Lu, Fangfang
   Guo, Jianfeng
   Xu, Hong
   Wang, Qi
   Xu, Chaohuan
   Zeng, Longjia
   Yi, Suyi
TI Histone demethylase KDM2B upregulates histone methyltransferase EZH2
   expression and contributes to the progression of ovarian cancer in vitro
   and in vivo
SO ONCOTARGETS AND THERAPY
LA English
DT Article
DE ovarian cancer; KDM2B; EZH2; epigenetic regulation; tumor formation
ID CELL-CYCLE PROGRESSION; BREAST-CANCER; EMBRYONIC FIBROBLASTS; DNA
   METHYLATION; GASTRIC-CANCER; LUNG-CANCER; STEM-CELLS; HOMOLOG 2;
   PROLIFERATION; PROTEIN
AB Aberrant histone methylation contributes to the progression and development of many tumors. Histone methylation is a dynamic process regulated by both histone demethylase and histone methyltransferase, which ultimately alters the levels of gene transcription. However, the relationship between histone demethylase and histone methyltransferase, as well as their regulatory mechanisms in ovarian cancer development, is still unclear. Lysine-specific demethylase 2B (KDM2B) is a key demethylase of H3K36me3 and H3K4me3 that regulates gene expression and plays a role in tumorigenesis via epigenetic mechanisms. To determine the expression pattern of KDM2B in ovarian neoplasms, we analyzed the mRNA and protein levels of KDM2B and the histone methyltransferase enhancer of zester homolog 2 (EZH2) in normal, benign, borderline, and malignant ovarian tissue samples. We found that KDM2B expression was gradually increased in ovarian tumors, with the highest expression found in the malignant ovarian tissues, and the differences in KDM2B expression among the different International Federation of Gynecology and Obstetrics stages and pathological grades/types were statistically significant. Moreover, KDM2B expression was positively correlated with EZH2 expression in ovarian tissues. To determine the role of KDM2B in tumorigenesis in vitro and in vivo, we silenced KDM2B expression in ovarian cancer cells using the KDM2B short hairpin RNA expression lentivirus and established a nude mouse xenograft model. Downregulation of endogenous KDM2B decreased the expression of EZH2 and reduced the proliferation and migration of ovarian cancer cells. Loss of KDM2B suppressed ovarian tumor formation in vivo. Our results suggest that KDM2B plays an important role in the tumorigenesis of ovarian cancer, with a possible mechanism of increasing the expression of the oncogene EZH2; this indicates that certain histone methyltransferase may be positively regulated by certain histone demethylase in the epigenetic regulation of ovarian tumors. KDM2B may be a novel therapeutic target for the clinical treatment of ovarian cancer.
C1 [Kuang, Yan; Lu, Fangfang; Xu, Hong; Wang, Qi; Xu, Chaohuan; Zeng, Longjia; Yi, Suyi] Guangxi Med Univ, Affiliated Hosp 1, Dept Obstet & Gynecol, Shuangyong Rd 22, Nanning, Guangxi, Peoples R China.
   [Guo, Jianfeng] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Obstet & Gynecol, Wuhan, Peoples R China.
C3 Guangxi Medical University; Huazhong University of Science & Technology
RP Kuang, Y (通讯作者)，Guangxi Med Univ, Affiliated Hosp 1, Dept Obstet & Gynecol, Shuangyong Rd 22, Nanning, Guangxi, Peoples R China.
EM kuangyan2016@126.com
FU National Natural Science Foundation of China [81360389]; National
   Natural Science Foundation of Guangxi [2012GXNSFAA053086];
   Self-financing Project of the Guangxi Health Department [Z2013026]
FX This study was funded by National Natural Science Foundation of China
   (No 81360389), the National Natural Science Foundation of Guangxi
   (2012GXNSFAA053086), and the Self-financing Project of the Guangxi
   Health Department (Z2013026). Yan Kuang and Fangfang Lu are co-first
   authors for this study.
CR Ayala-Ortega E, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2273-6
   Biancotto C, 2010, ADV GENET, V70, P341, DOI [10.1016/B978-0-12-380866-0.60013-7, 10.1016/S0065-2660(10)70013-4]
   Chen Q, 2016, ONCOTARGET, V7, P36115, DOI 10.18632/oncotarget.8741
   Chen WM, 2016, ONCOTARGET, V7, P9773, DOI 10.18632/oncotarget.6949
   Chinaranagari S, 2014, ONCOTARGET, V5, P7172, DOI 10.18632/oncotarget.2262
   Debeb BG, 2014, J EXP CLIN CANC RES, V33, DOI 10.1186/s13046-014-0058-9
   Egger G, 2004, NATURE, V429, P457, DOI 10.1038/nature02625
   Esteller M, 2007, NAT REV GENET, V8, P286, DOI 10.1038/nrg2005
   Frescas D, 2007, NATURE, V450, P309, DOI 10.1038/nature06255
   Garipov A, 2013, MOL CANCER RES, V11, P360, DOI 10.1158/1541-7786.MCR-12-0661
   Guo JF, 2011, CANCER SCI, V102, P530, DOI 10.1111/j.1349-7006.2010.01836.x
   Guo SP, 2016, DIAGN PATHOL, V11, DOI 10.1186/s13000-016-0491-5
   Haag Tanja, 2014, Genes Cancer, V5, P365
   Han T, 2016, ONCOTARGET, V7, P11194, DOI 10.18632/oncotarget.7156
   Hasemann MS, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004079
   Hassler MR, 2012, BIOCHIMIE, V94, P2219, DOI 10.1016/j.biochi.2012.05.007
   Hong XH, 2016, ONCOTARGET, V7, P22092, DOI 10.18632/oncotarget.8020
   Iacobuzio-Donahue CA, 2009, ANNU REV PATHOL-MECH, V4, P229, DOI 10.1146/annurev.pathol.3.121806.151442
   Inagaki T, 2015, J BIOL CHEM, V290, P4163, DOI 10.1074/jbc.M114.626929
   Jia N, 2014, ONCOL LETT, V8, P2049, DOI 10.3892/ol.2014.2437
   Karoopongse E, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107817
   Kavi Harsh H, 2009, BMC Res Notes, V2, P217, DOI 10.1186/1756-0500-2-217
   Kottakis F, 2014, CANCER RES, V74, P3935, DOI 10.1158/0008-5472.CAN-13-2733
   Lin C, 2014, INT J CLIN EXP PATHO, V7, P6543
   Ma DN, 2016, J HEMATOL ONCOL, V9, DOI 10.1186/s13045-015-0229-y
   Pfau R, 2008, P NATL ACAD SCI USA, V105, P1907, DOI 10.1073/pnas.0711865105
   Polytarchou C, 2008, MOL CELL BIOL, V28, P7451, DOI 10.1128/MCB.00688-08
   Ren Y, 2015, NEOPLASMA, V62, P925, DOI 10.4149/neo_2015_112
   Salminen A, 2016, AGING DIS, V7, P180, DOI 10.14336/AD.2015.0929
   Shi Y, 2007, MOL CELL, V25, P1, DOI 10.1016/j.molcel.2006.12.010
   Tzatsos A, 2013, J CLIN INVEST, V123, P727, DOI 10.1172/JCI64535
   Tzatsos A, 2011, J BIOL CHEM, V286, P33061, DOI 10.1074/jbc.M111.257667
   Tzatsos A, 2009, P NATL ACAD SCI USA, V106, P2641, DOI 10.1073/pnas.0813139106
   Ueda T, 2015, BLOOD, V125, P3437, DOI 10.1182/blood-2014-03-562694
   Villalba M, 2016, ONCOTARGET, V7, P22752, DOI 10.18632/oncotarget.8045
   Yamaguchi H, 2014, CANCER RES TREAT, V46, P209, DOI 10.4143/crt.2014.46.3.209
   Yang CC, 2015, AM J TRANSL RES, V7, P1009
   Yu X, 2015, MOL BIOSYST, V11, P1867, DOI 10.1039/c5mb00166h
   Zehentmayr F, 2016, CLIN EPIGENETICS, V8, DOI 10.1186/s13148-016-0198-1
   Zhang F, 2015, J MOL CELL BIOL, V7, P23, DOI 10.1093/jmcb/mjv003
   Zhang Q, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.454
   Zhang Q, 2015, ONCOTARGET, V6, P37335, DOI 10.18632/oncotarget.6135
   Zhang YW, 2014, EPIGENETICS-US, V9, P896, DOI 10.4161/epi.28601
NR 43
TC 38
Z9 44
U1 0
U2 8
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178-6930
J9 ONCOTARGETS THER
JI OncoTargets Ther.
PY 2017
VL 10
BP 3131
EP 3144
DI 10.2147/OTT.S134784
PG 14
WC Biotechnology & Applied Microbiology; Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Oncology
GA EY6QQ
UT WOS:000404108700003
PM 28706445
OA Green Published, Green Submitted, gold
DA 2025-01-12
ER

PT J
AU Sehl, ME
   Henry, JE
   Storniolo, AM
   Ganz, PA
   Horvath, S
AF Sehl, Mary E.
   Henry, Jill E.
   Storniolo, Anna Maria
   Ganz, Patricia A.
   Horvath, Steve
TI DNA methylation age is elevated in breast tissue of healthy women
SO BREAST CANCER RESEARCH AND TREATMENT
LA English
DT Article
DE Breast cancer; Tissue aging; DNA methylation; Epigenetics; Biomarker of
   aging; Estrogen Cell cycling
ID RISK-FACTORS; EPIGENETIC AGE; HUMAN BRAIN; CELL-CYCLE; BODY-SIZE;
   CANCER; DISEASE; ESTROGEN; DENSITY; BLOOD
AB Background Limited evidence suggests that female breast tissue ages faster than other parts of the body according to an epigenetic biomarker of aging known as the "epigenetic clock." However, it is unknown whether breast tissue samples from healthy women show a similar accelerated aging effect relative to other tissues, and what could drive this acceleration. The goal of this study is to validate our initial finding of advanced DNA methylation (DNAm) age in breast tissue, by directly comparing it to that of peripheral blood tissue from the same individuals, and to do a preliminary assessment of hormonal factors that could explain the difference.
   Methods We utilized n = 80 breast and 80 matching blood tissue samples collected from 40 healthy female participants of the Susan G. Komen Tissue Bank at the Indiana University Simon Cancer Center who donated these samples at two time points spaced at least a year apart. DNA methylation levels (Illumina 450K platform) were used to estimate the DNAm age.
   Results DNAm age was highly correlated with chronological age in both peripheral blood (r = 0.94, p < 0.0001) and breast tissues (r = 0.86, p < 0.0001). A measure of epigenetic age acceleration (age-adjusted DNAm Age) was substantially increased in breast relative to peripheral blood tissue (p = 1.6 x 10(-11)). The difference between DNAm age of breast and blood decreased with advancing chronologic age (r = -0.53, p = 4.4 x 10(-4)).
   Conclusions Our data clearly demonstrate that female breast tissue has a higher epigenetic age than blood collected from the same subject. We also observe that the degree of elevation in breast diminishes with advancing age. Future larger studies will be needed to examine associations between epigenetic age acceleration and cumulative hormone exposure.
C1 [Sehl, Mary E.; Ganz, Patricia A.] Univ Calif Los Angeles, David Geffen Sch Med, Med, Hematol Oncol, Los Angeles, CA 90095 USA.
   [Sehl, Mary E.] Univ Calif Los Angeles, David Geffen Sch Med, Biomath, Los Angeles, CA 90095 USA.
   [Henry, Jill E.; Storniolo, Anna Maria] Indiana Univ, Simon Canc Ctr, Susan G Komen Tissue Bank, Indianapolis, IN 46204 USA.
   [Ganz, Patricia A.] Univ Calif Los Angeles, Hlth Policy & Management, Fielding Sch Publ Hlth, Los Angeles, CA 90095 USA.
   [Horvath, Steve] Univ Calif Los Angeles, David Geffen Sch Med, Gonda Res Ctr, Dept Human Genet, 695 Charles E Young Dr South,Box 708822, Los Angeles, CA 90095 USA.
   [Horvath, Steve] Univ Calif Los Angeles, Sch Publ Hlth, Biostat, Los Angeles, CA 90095 USA.
C3 University of California System; University of California Los Angeles;
   University of California Los Angeles Medical Center; David Geffen School
   of Medicine at UCLA; University of California System; University of
   California Los Angeles; University of California Los Angeles Medical
   Center; David Geffen School of Medicine at UCLA; Indiana University
   System; Indiana University Indianapolis; University of California
   System; University of California Los Angeles; University of California
   System; University of California Los Angeles; University of California
   Los Angeles Medical Center; David Geffen School of Medicine at UCLA;
   University of California System; University of California Los Angeles
RP Horvath, S (通讯作者)，Univ Calif Los Angeles, David Geffen Sch Med, Gonda Res Ctr, Dept Human Genet, 695 Charles E Young Dr South,Box 708822, Los Angeles, CA 90095 USA.; Horvath, S (通讯作者)，Univ Calif Los Angeles, Sch Publ Hlth, Biostat, Los Angeles, CA 90095 USA.
EM shorvath@mednet.ucla.edu
RI Storniolo, Anna/AAB-5399-2022
OI Horvath, Steve/0000-0002-4110-3589; Ganz, Patricia/0000-0002-1841-4143
FU pilot award from UCLA Iris Cantor Women's Health Center; UCLA Clinical
   and Translational Science Institute; NIH/NIA [1U34AG051425-01, 5R01
   AG042511-02]
FX We thank the KTB donors for their generous participation in this study,
   as well as the KTB Investigators for guidance on this project. We are
   grateful to Peggy Devine for providing helpful suggestions for our work.
   Grant support: MS was supported by a pilot award from the UCLA Iris
   Cantor Women's Health Center and the UCLA Clinical and Translational
   Science Institute. SH was supported by NIH/NIA 1U34AG051425-01 and 5R01
   AG042511-02.
CR Anderson E, 2004, J MAMMARY GLAND BIOL, V9, P3, DOI 10.1023/B:JOMG.0000023584.01750.16
   Anderson E, 1998, J MAMMARY GLAND BIOL, V3, P23, DOI 10.1023/A:1018718117113
   ANDERSON TJ, 1982, BRIT J CANCER, V46, P376, DOI 10.1038/bjc.1982.213
   Anderson WF, 2007, J CLIN ONCOL, V25, P3923, DOI 10.1200/JCO.2007.11.6079
   Berkey CS, 2017, BREAST CANCER RES TR, V162, P139, DOI 10.1007/s10549-016-4084-5
   BERNSTEIN L, 1993, EPIDEMIOL REV, V15, P48, DOI 10.1093/oxfordjournals.epirev.a036116
   Boyd NF, 1998, CANCER EPIDEM BIOMAR, V7, P1133
   BRINTON LA, 1988, CANCER INVEST, V6, P245, DOI 10.3109/07357908809080645
   Chen BH, 2016, AGING-US, V8, P1844, DOI 10.18632/aging.101020
   Christiansen L, 2016, AGING CELL, V15, P149, DOI 10.1111/acel.12421
   Clarke RB, 2003, CELL PROLIFERAT, V36, P45, DOI 10.1046/j.1365-2184.36.s.1.5.x
   Colditz GA, 2000, AM J EPIDEMIOL, V152, P950, DOI 10.1093/aje/152.10.950
   Doisneau-Sixou SF, 2003, ENDOCR-RELAT CANCER, V10, P179, DOI 10.1677/erc.0.0100179
   Dolle JM, 2009, CANCER EPIDEM BIOMAR, V18, P1157, DOI 10.1158/1055-9965.EPI-08-1005
   HENDERSON BE, 1985, CANCER-AM CANCER SOC, V56, P1206, DOI 10.1002/1097-0142(19850901)56:5<1206::AID-CNCR2820560541>3.0.CO;2-9
   HIROSE K, 1995, JPN J CANCER RES, V86, P146, DOI 10.1111/j.1349-7006.1995.tb03032.x
   Horvath S, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-1030-0
   Horvath S, 2016, AGING-US, V8, P1485, DOI 10.18632/aging.101005
   Horvath S, 2015, AGING-US, V7, P1130, DOI 10.18632/aging.100859
   Horvath S, 2015, J INFECT DIS, V212, P1563, DOI 10.1093/infdis/jiv277
   Horvath S, 2015, AGING-US, V7, P294, DOI 10.18632/aging.100742
   Horvath S, 2015, AGING CELL, V14, P491, DOI 10.1111/acel.12325
   Horvath S, 2014, P NATL ACAD SCI USA, V111, P15538, DOI 10.1073/pnas.1412759111
   Horvath S, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-10-r115
   Horvath S, 2012, GENOME BIOL, V13, DOI 10.1186/gb-2012-13-10-r97
   HSIEH CC, 1990, INT J CANCER, V46, P796, DOI 10.1002/ijc.2910460508
   KAMPERT JB, 1988, AM J EPIDEMIOL, V128, P962
   Levine ME, 2016, P NATL ACAD SCI USA, V113, P9327, DOI 10.1073/pnas.1604558113
   Levine ME, 2015, AGING-US, V7, P1198, DOI 10.18632/aging.100864
   Marioni RE, 2015, GENOME BIOL, V16, DOI 10.1186/s13059-015-0584-6
   McCormack VA, 2010, INT J CANCER, V127, P452, DOI 10.1002/ijc.25053
   Perna L, 2016, CLIN EPIGENETICS, V8, DOI 10.1186/s13148-016-0228-z
   PIKE MC, 1983, NATURE, V303, P767, DOI 10.1038/303767a0
   PIKE MC, 1993, EPIDEMIOL REV, V15, P17, DOI 10.1093/oxfordjournals.epirev.a036102
   POTTEN CS, 1988, BRIT J CANCER, V58, P163, DOI 10.1038/bjc.1988.185
   Rakyan VK, 2010, GENOME RES, V20, P434, DOI 10.1101/gr.103101.109
   Rickabaugh TM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0119201
   ROSNER B, 1994, AM J EPIDEMIOL, V139, P819, DOI 10.1093/oxfordjournals.aje.a117079
   Schairer C, 2000, JAMA-J AM MED ASSOC, V283, P485, DOI 10.1001/jama.283.4.485
   Teschendorff AE, 2010, GENOME RES, V20, P440, DOI 10.1101/gr.103606.109
   Tice JA, 2005, BREAST CANCER RES TR, V94, P115, DOI 10.1007/s10549-005-5152-4
   Warwick J, 2003, BREAST, V12, P10, DOI 10.1016/S0960-9776(02)00212-6
   Yaghjyan L, 2016, BREAST CANCER RES TR, V158, P351, DOI 10.1007/s10549-016-3884-y
   Zannas AS, 2015, GENOME BIOL, V16, DOI 10.1186/s13059-015-0828-5
NR 44
TC 45
Z9 53
U1 0
U2 2
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0167-6806
EI 1573-7217
J9 BREAST CANCER RES TR
JI Breast Cancer Res. Treat.
PD JUL
PY 2017
VL 164
IS 1
BP 209
EP 219
DI 10.1007/s10549-017-4218-4
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA EX9HU
UT WOS:000403569600020
PM 28364215
OA Green Published
DA 2025-01-12
ER

PT J
AU Zhang, JD
   Sang, MX
   Gu, LN
   Liu, F
   Li, WJ
   Yin, DJ
   Wu, YY
   Liu, SN
   Huang, WN
   Shan, BE
AF Zhang, Jiandong
   Sang, Meixiang
   Gu, Lina
   Liu, Fei
   Li, Weijing
   Yin, Danjing
   Wu, Yunyan
   Liu, Shina
   Huang, Weina
   Shan, Baoen
TI Zebularine Treatment Induces MAGE-A11 Expression and Improves CTL
   Cytotoxicity Using a Novel Identified HLA-A2-restricted MAGE-A11 Peptide
SO JOURNAL OF IMMUNOTHERAPY
LA English
DT Article
DE MAGE-A11; peptide; zebularine; cytotoxic T-lymphocyte
ID DNA METHYLTRANSFERASE INHIBITOR; CELL LUNG-CANCER; DENDRITIC CELLS;
   BREAST-CANCER; TUMOR-CELLS; PHASE-II; MYELODYSPLASTIC SYNDROMES;
   IMMUNE-RESPONSES; T-LYMPHOCYTES; INDUCTION
AB Melanoma-associated antigen-A11 (MAGE-A11) is frequently expressed in breast cancer and is associated with poor prognosis. Therefore, MAGE-A11 is a potential immunotherapy target in breast cancer. MAGE-A11 expression, however, is downregulated in many patients, thus constraining the application of immunotherapy. The induction of MAGE-A11 expression is crucial for the recognition and killing of breast cancer cells by cytotoxic T lymphocytes (CTL). In this study, a series of HLA-A2-restricted candidate MAGE-All peptides were predicted, synthesized, and tested. Of the selected peptides, p350 (FLFGEPKRL) elicited peptide-specific CTLs from healthy HLA-A*0201-positive donors. The induced CTLs can lyse MAGE-A11-expressing breast cancer cells but not MAGE-A11-negative tumor cells. To improve antitumor immune response, zebularine, a DNA methyltransferase inhibitor, was used to induce MAGE-A11 expression and upregulate the cytotoxicity of antigen-specific T cells in breast cancer cell lines and primary breast cancer cells. The present findings suggested that peptide p350 induces peptide-specific cytolytic activity and is thus a potential candidate for tumor vaccination or T-cell therapy. Epigenetic modulation by zebularine can induce MAGE-A11 expression in breast cancer cells and facilitate cytotoxicity via MAGE-A11-specific CTL.
C1 [Zhang, Jiandong; Sang, Meixiang; Gu, Lina; Liu, Fei; Li, Weijing; Yin, Danjing; Wu, Yunyan; Liu, Shina; Huang, Weina; Shan, Baoen] Hebei Med Univ, Res Ctr, Hosp 4, Shijiazhuang 050017, Hebei, Peoples R China.
   [Sang, Meixiang; Shan, Baoen] Hebei Med Univ, Tumor Res Inst, Hosp 4, Shijiazhuang, Peoples R China.
C3 Hebei Medical University; Hebei Medical University
RP Shan, BE (通讯作者)，Hebei Med Univ, Res Ctr, Hosp 4, Shijiazhuang 050017, Hebei, Peoples R China.
EM baoenshan@hotmail.com
RI Wu, Yunyan/F-3217-2013; Zhang, Hewei/LJZ-4067-2024
OI Li, Weijing/0000-0001-7868-1342
FU Natural Science Foundation of Hebei Province, China [H2016206410]
FX Supported by the Natural Science Foundation of Hebei Province, China
   (no. H2016206410).
CR Almstedt M, 2010, LEUKEMIA RES, V34, P899, DOI 10.1016/j.leukres.2010.02.004
   Andersen JB, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001338
   Andrade AF, 2014, ANTI-CANCER DRUG, V25, P72, DOI 10.1097/CAD.0000000000000028
   Ayyoub M, 2014, CANCER IMMUNOL RES, V2, P943, DOI 10.1158/2326-6066.CIR-13-0211
   Batchu RB, 2014, VACCINE, V32, P938, DOI 10.1016/j.vaccine.2013.12.049
   BEISLER JA, 1978, J MED CHEM, V21, P204, DOI 10.1021/jm00200a012
   Billam M, 2010, BREAST CANCER RES TR, V120, P581, DOI 10.1007/s10549-009-0420-3
   Bohnenkamp HR, 2004, CELL IMMUNOL, V231, P112, DOI 10.1016/j.cellimm.2004.12.007
   Bracci L, 2013, EXPERT REV VACCINES, V12, P1195, DOI 10.1586/14760584.2013.836905
   Chen M, 2012, MOL CANCER THER, V11, P370, DOI 10.1158/1535-7163.MCT-11-0458
   Cheng JC, 2003, J NATL CANCER I, V95, P399, DOI 10.1093/jnci/95.5.399
   Cheng JC, 2004, CANCER CELL, V6, P151, DOI 10.1016/j.ccr.2004.06.023
   Cruz CR, 2011, CLIN CANCER RES, V17, P7058, DOI 10.1158/1078-0432.CCR-11-1873
   Ladelfa MF, 2012, CANCER LETT, V325, P11, DOI 10.1016/j.canlet.2012.05.031
   Goodyear O, 2010, BLOOD, V116, P1908, DOI 10.1182/blood-2009-11-249474
   Griffiths EA, 2013, ADV EXP MED BIOL, V754, P253, DOI 10.1007/978-1-4419-9967-2_13
   Gunda V, 2013, SURGERY, V154, P1456, DOI 10.1016/j.surg.2013.07.009
   Guo LR, 2013, ONCOL LETT, V6, P55, DOI 10.3892/ol.2013.1351
   Hambach L, 2009, BLOOD, V113, P2715, DOI 10.1182/blood-2008-05-158956
   Heneweer M, 2005, TOXICOL APPL PHARM, V202, P50, DOI 10.1016/j.taap.2004.06.006
   James SR, 2013, EPIGENETICS-US, V8, P849, DOI 10.4161/epi.25500
   Joosse SA, 2014, BRIT J CANCER, V111, P909, DOI 10.1038/bjc.2014.360
   Karpf AR, 2009, MOL CANCER RES, V7, P523, DOI 10.1158/1541-7786.MCR-08-0400
   Li BH, 2014, ONCOTARGET, V5, P10791, DOI 10.18632/oncotarget.2505
   Lin LY, 2014, J CANCER RES CLIN, V140, P281, DOI 10.1007/s00432-013-1552-8
   Moreno-Bost A, 2011, CYTOTHERAPY, V13, P618, DOI 10.3109/14653249.2010.529893
   Nakamura K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120545
   Nakamura K, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0054036, 10.1371/journal.pone.0064134, 10.1371/journal.pone.0074720]
   Oshita C, 2012, ONCOL REP, V28, P1131, DOI 10.3892/or.2012.1956
   Park TS, 2016, J IMMUNOTHER, V39, P1, DOI 10.1097/CJI.0000000000000101
   Pascolo S, 2001, CANCER RES, V61, P4072
   PINTO A, 1993, LEUKEMIA, V7, P51
   Roch N, 2010, ANTICANCER RES, V30, P1617
   Saito T, 2014, VACCINE, V32, P5901, DOI 10.1016/j.vaccine.2014.09.002
   Samlowski WE, 2005, J CLIN ONCOL, V23, P3897, DOI 10.1200/JCO.2005.06.118
   Sang MX, 2016, ARCH MED RES, V47, P151, DOI 10.1016/j.arcmed.2016.06.001
   Sang MX, 2014, BIOMARKERS, V19, P34, DOI 10.3109/1354750X.2013.865275
   SESSA C, 1990, EUR J CANCER, V26, P137, DOI 10.1016/0277-5379(90)90295-5
   Shafer JA, 2010, LEUKEMIA LYMPHOMA, V51, P870, DOI 10.3109/10428191003713968
   Szmigielska-Kaplon A, 2011, CURR CANCER DRUG TAR, V11, P837, DOI 10.2174/156800911796798940
   Tan W, 2013, BIOCHEM BIOPH RES CO, V430, P250, DOI 10.1016/j.bbrc.2012.10.143
   Vansteenkiste J, 2013, J CLIN ONCOL, V31, P2396, DOI 10.1200/JCO.2012.43.7103
   Wang W, 2006, CANCER RES, V66, P6826, DOI 10.1158/0008-5472.CAN-05-3529
   Yang PM, 2013, SCI REP-UK, V3, DOI 10.1038/srep03219
   You BR, 2014, MOL CARCINOGEN, V53, P847, DOI 10.1002/mc.22042
NR 45
TC 11
Z9 12
U1 0
U2 9
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1524-9557
EI 1537-4513
J9 J IMMUNOTHER
JI J. Immunother.
PD JUL-AUG
PY 2017
VL 40
IS 6
BP 211
EP 220
PG 10
WC Oncology; Immunology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Immunology; Research & Experimental Medicine
GA EY5ER
UT WOS:000404000500002
PM 28486273
DA 2025-01-12
ER

PT J
AU Geddert, H
   Braun, A
   Kayser, C
   Dimmler, A
   Faller, G
   Agaimy, A
   Haller, F
   Moskalev, EA
AF Geddert, Helene
   Braun, Alexander
   Kayser, Claudia
   Dimmler, Arno
   Faller, Gerhard
   Agaimy, Abbas
   Haller, Florian
   Moskalev, Evgeny A.
TI Epigenetic Regulation of <i>CD133</i> in Gastrointestinal Stromal Tumors
SO AMERICAN JOURNAL OF CLINICAL PATHOLOGY
LA English
DT Article
DE CD133; Prominin 1; GIST; DNA Methylation; Immunohistochemistry;
   Expression
ID CELL MARKER CD133; DNA METHYLATION; METASTATIC MELANOMA; THERAPEUTIC
   TARGET; PROMININ-1 CD133; BREAST-CANCER; SARCOMA-CELLS; STEM;
   EXPRESSION; PROGNOSIS
AB Objectives: This study ascertained the regulation of the stem cell marker CD133 and its potential applicability for prognostication of gastrointestinal stromal tumors (GISTs).
   Methods: A total of 95 resected GISTs were included in the study. CD133 protein expression was assessed immunohistochemically on tissue microarrays. Methylation percentage was quantified by pyrosequencing. Gene expression in cell lines GIST48b and GIST882 upon treatment with DNA demethylation agent 5-aza-2'-deoxycytidine was analyzed by quantitative polymerase chain reaction.
   Results: The expression of hypermethylated CD133 could be reactivated in the GIST cell line upon hypomethylation with the drug. Similarly, in patient material, CD133 methylation percentage correlated inversely with the protein expression and reflected tumor size with hypermethylation in small (<2cm) tumors and virtually no methylation in large (>10 cm) GISTs. The gene's methylation percentage and expression level were clearly specific to anatomic sites and distinct driver mutations. KIT-mutant gastric GISTs exhibited significantly lower methylation degrees and concomitant high CD133 protein abundance compared with KIT-mutant GISTs from the small intestine. CD133 hypermethylation was documented in PDGFRA-mutant gastric GISTs along with low CD133 expression compared with KIT-mutant gastric GISTs. High CD133 expression was a prognosticator of shorter disease-free survival in all patients. In a subgroup of KIT-mutant gastric GISTs, low CD133 methylation degree was correlated with a shorter disease-free survival.
   Conclusions: Our results strongly suggest epigenetic regulation of CD133 expression by promoter methylation in GISTs. Pending further validation studies, high abundance of the protein can serve as a marker for malignant GISTs.
C1 [Geddert, Helene; Dimmler, Arno; Faller, Gerhard] St Vincentius Hosp, Inst Pathol, Sudendstr 37, D-76137 Karlsruhe, Germany.
   [Braun, Alexander; Kayser, Claudia] Albert Ludwigs Univ, Inst Pathol, Freiburg, Germany.
   [Agaimy, Abbas; Haller, Florian; Moskalev, Evgeny A.] Friedrich Alexander Univ, Inst Pathol, Erlangen, Germany.
C3 University of Freiburg; University of Erlangen Nuremberg
RP Geddert, H (通讯作者)，St Vincentius Hosp, Inst Pathol, Sudendstr 37, D-76137 Karlsruhe, Germany.
EM Helene.Geddert@vincentius-ka.de
RI Moskalev, Evgeny/A-3050-2012
CR Agaimy A, 2009, J CLIN PATHOL, V62, P613, DOI 10.1136/jcp.2009.064550
   Agaimy A, 2010, INT J CLIN EXP PATHO, V3, P461
   Arne G, 2011, INT J CANCER, V129, P1149, DOI 10.1002/ijc.25755
   Baba T, 2009, ONCOGENE, V28, P209, DOI 10.1038/onc.2008.374
   Chen JW, 2012, GENE CHROMOSOME CANC, V51, P186, DOI 10.1002/gcc.20942
   Deng Y, 2013, PLOS ONE, V8
   Fargeas CA, 2007, TISSUE ANTIGENS, V69, P602, DOI 10.1111/j.1399-0039.2007.00825.x
   Fletcher CDM, 2002, HUM PATHOL, V33, P459, DOI 10.1053/hupa.2002.123545
   FRANQUEMONT DW, 1995, AM J CLIN PATHOL, V103, P41, DOI 10.1093/ajcp/103.1.41
   Geddert H, 2011, CELL ONCOL, V34, P209, DOI 10.1007/s13402-011-0028-6
   Haller F, 2015, INT J CANCER, V136, P1013, DOI 10.1002/ijc.29088
   Huang JH, 2013, CLIN IMMUNOL, V149, P156, DOI 10.1016/j.clim.2013.07.006
   Irollo E, 2013, AM J TRANSL RES, V5, P563
   Ji JF, 2010, NEUROSURG CLIN N AM, V21, P159, DOI 10.1016/j.nec.2009.08.006
   Jiang XH, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-116
   Lasota J, 2006, SEMIN DIAGN PATHOL, V23, P91, DOI 10.1053/j.semdp.2006.08.006
   Lorico A, 2013, ADV EXP MED BIOL, V777, P197, DOI 10.1007/978-1-4614-5894-4_13
   Lu CR, 2013, ONCOL LETT, V6, P1289, DOI 10.3892/ol.2013.1564
   Lv A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062951
   Meregalli M, 2010, EXPERT OPIN BIOL TH, V10, P1521, DOI 10.1517/14712598.2010.528386
   Miettinen M, 2002, HUM PATHOL, V33, P478, DOI 10.1053/hupa.2002.124123
   Miettinen M, 2006, ARCH PATHOL LAB MED, V130, P1466
   Moskalev EA, 2011, NUCLEIC ACIDS RES, V39, DOI 10.1093/nar/gkr213
   Nadal R, 2013, INT J CANCER, V133, P2398, DOI 10.1002/ijc.28263
   O'Brien CA, 2007, NATURE, V445, P106, DOI 10.1038/nature05372
   Okamoto Y, 2012, GUT, V61, P392, DOI 10.1136/gut.2011.241034
   Park JJ, 2014, MOL CARCINOGEN, V53, pE1, DOI 10.1002/mc.21971
   Pellacani D, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-94
   Rappa G, 2008, STEM CELLS, V26, P3008, DOI 10.1634/stemcells.2008-0601
   Ricci-Vitiani L, 2007, NATURE, V445, P111, DOI 10.1038/nature05384
   Shmelkov SV, 2004, BLOOD, V103, P2055, DOI 10.1182/blood-2003-06-1881
   Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128
   Smith LM, 2008, BRIT J CANCER, V99, P100, DOI 10.1038/sj.bjc.6604437
   Stratford EW, 2013, BBA-GEN SUBJECTS, V1830, P4235, DOI 10.1016/j.bbagen.2013.04.033
   Swaminathan SK, 2013, J CONTROL RELEASE, V171, P280, DOI 10.1016/j.jconrel.2013.07.014
   Tabu K, 2008, CELL RES, V18, P1037, DOI 10.1038/cr.2008.270
   Yin AH, 1997, BLOOD, V90, P5002, DOI 10.1182/blood.V90.12.5002.5002_5002_5012
   You HN, 2010, HEPATOLOGY, V51, P1635, DOI 10.1002/hep.23544
   Yu JW, 2010, J EXP CLIN CANC RES, V29, DOI 10.1186/1756-9966-29-141
NR 39
TC 11
Z9 12
U1 0
U2 3
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0002-9173
EI 1943-7722
J9 AM J CLIN PATHOL
JI Am. J. Clin. Pathol.
PD MAY
PY 2017
VL 147
IS 5
BP 515
EP 524
DI 10.1093/AJCP/AQX028
PG 10
WC Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pathology
GA EY5KU
UT WOS:000404016900010
PM 28398518
OA Bronze
DA 2025-01-12
ER

PT J
AU Casciello, F
   Al-Ejeh, F
   Kelly, G
   Brennan, DJ
   Ngiow, SF
   Young, A
   Stoll, T
   Windloch, K
   Hill, MM
   Smyth, MJ
   Gannon, F
   Lee, JS
AF Casciello, Francesco
   Al-Ejeh, Fares
   Kelly, Greg
   Brennan, Donal J.
   Ngiow, Shin Foong
   Young, Arabella
   Stoll, Thomas
   Windloch, Karolina
   Hill, Michelle M.
   Smyth, Mark J.
   Gannon, Frank
   Lee, Jason S.
TI G9a drives hypoxia-mediated gene repression for breast cancer cell
   survival and tumorigenesis
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE breast cancer; G9a; histone methylation; hypoxia; epigenetics
ID HISTONE METHYLTRANSFERASE G9A; TUMOR-SUPPRESSOR; HIF-ALPHA; METASTASIS;
   METHYLATION; HYDROXYLATION; TRANSCRIPTION; PROGRESSION; COMPLEXES;
   PROMOTES
AB G9a is an epigenetic regulator that methylates H3K9, generally causing repression of gene expression, and participates in diverse cellular functions. G9a is genetically deregulated in a variety of tumor types and can silence tumor suppressor genes and, therefore, is important for carcinogenesis. Although hypoxia is recognized to be an adverse factor in tumor growth and metastasis, the role of G9a in regulating gene expression in hypoxia has not been described extensively. Here, we show that G9a protein stability is increased in hypoxia via reduced proline hydroxylation and, hence, inefficient degradation by the proteasome. This inefficiency leads to an increase in H3K9me2 at its target promoters. Blocking the methyltransferase activity of G9a inhibited cellular proliferation and migration in vitro and tumor growth in vivo. Furthermore, an increased level of G9a is a crucial factor in mediating the hypoxic response by down-regulating the expression of specific genes, including ARNTL, CEACAM7, GATA2, HHEX, KLRG1, and OGN. This down-regulation can be rescued by a small molecule inhibitor of G9a. Based on the hypothesis that the changes in gene expression would influence patient outcomes, we have developed a prognostic G9a-suppressed gene signature that can stratify breast cancer patients. Together, our findings provide an insight into the role G9a plays as an epigenetic mediator of hypoxic response, which can be used as a diagnostic marker, and proposes G9a as a therapeutic target for solid cancers.
C1 [Casciello, Francesco; Al-Ejeh, Fares; Kelly, Greg; Ngiow, Shin Foong; Young, Arabella; Windloch, Karolina; Smyth, Mark J.; Gannon, Frank; Lee, Jason S.] QIMR Berghofer Med Res Inst, Herston, Qld 4006, Australia.
   [Casciello, Francesco; Lee, Jason S.] Queensland Univ Technol, Sch Biomed Sci, Brisbane, Qld 4000, Australia.
   [Brennan, Donal J.] Univ Coll Dublin, Mater Misericoridiae Univ Hosp, Catherine McCauley Res Ctr, Sch Med, Dublin 7, Ireland.
   [Young, Arabella; Smyth, Mark J.] Univ Queensland, Sch Med, Herston, Qld 4006, Australia.
   [Stoll, Thomas; Hill, Michelle M.] Univ Queensland, Diamantina Inst, Translat Res Inst, Woolloongabba, Qld 4102, Australia.
C3 QIMR Berghofer Medical Research Institute; Queensland University of
   Technology (QUT); Mater Misericordiae University Hospital; University
   College Dublin; University of Queensland; University of Queensland
RP Lee, JS (通讯作者)，QIMR Berghofer Med Res Inst, Herston, Qld 4006, Australia.; Lee, JS (通讯作者)，Queensland Univ Technol, Sch Biomed Sci, Brisbane, Qld 4000, Australia.
EM jason.lee@qimrberghofer.edu.au
RI Kelly, Greg/HNJ-1843-2023; Ngiow, Shin/P-2764-2014; Al-Ejeh,
   Fares/M-7032-2016; Hill, Michelle M/G-4417-2010; Lee, Jason
   S/M-7522-2016
OI Casciello, Francesco/0000-0001-5030-5193; Al-Ejeh,
   Fares/0000-0002-1553-0077; Stoll, Thomas/0000-0002-6275-3433; Hill,
   Michelle M/0000-0003-1134-0951; Brennan, Donal/0000-0002-6747-3342;
   Young, Arabella/0000-0002-6845-9753; Kelly, Gregory/0000-0003-4053-8342;
   Lee, Jason S/0000-0003-0879-934X
FU National Health and Medical Research Council (NHMRC) [107861]; NH&MRC CJ
   Martin Fellowship [1111469]; Future Fellowship from Australian Research
   Council [ARC-FT130101417]; National Research Foundation of Korea -
   Korean Government [2009-0045833]; Academy of Finland (AKA) [107861]
   Funding Source: Academy of Finland (AKA); National Health and Medical
   Research Council of Australia [1111469] Funding Source: NHMRC
FX We thank H. Song, H. Youn, J. J. LaPres, and M. Reginato for providing
   shG9a, pVHL, shPHD1-3, and shVHL constructs, respectively, and A.
   Tarakhovsky for providing G9a-deficient MEFs. Mass spectrometry analysis
   was performed at Translational Research Institute Proteomics Core
   Facility. This work was supported by National Health and Medical
   Research Council (NH&MRC) Senior Principal Research Fellowship 107861
   (to M.J.S.), NH&MRC CJ Martin Fellowship 1111469 (to S.F.N.), Future
   Fellowship from the Australian Research Council ARC-FT130101417 (to
   (F.A.), and National Research Foundation of Korea Grant 2009-0045833
   funded by the Korean Government (to J.S.L.).
CR Chakrabarti J, 2004, BRIT J CANCER, V91, P954, DOI 10.1038/sj.bjc.6602059
   Chen HB, 2006, CANCER RES, V66, P9009, DOI 10.1158/0008-5472.CAN-06-0101
   Chen MW, 2010, CANCER RES, V70, P7830, DOI 10.1158/0008-5472.CAN-10-0833
   Dong CF, 2012, J CLIN INVEST, V122, P1469, DOI 10.1172/JCI57349
   Erler JT, 2004, MOL CELL BIOL, V24, P2875, DOI 10.1128/MCB.24.7.2875-2889.2004
   Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704
   Hill RP, 2009, SEMIN RADIAT ONCOL, V19, P106, DOI 10.1016/j.semradonc.2008.12.002
   Hu QP, 2016, INT J CANCER, V138, P2804, DOI 10.1002/ijc.29982
   Hu ZY, 2009, BMC MED, V7, DOI 10.1186/1741-7015-7-9
   Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817
   Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796
   Joyce JA, 2009, NAT REV CANCER, V9, P239, DOI 10.1038/nrc2618
   Kershaw RM, 2014, ONCOGENE, V33, P5592, DOI 10.1038/onc.2013.496
   Lee JS, 2010, MOL CELL, V39, P71, DOI 10.1016/j.molcel.2010.06.008
   Li L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090181
   Li YG, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111707
   Liu F, 2013, J MED CHEM, V56, P8931, DOI 10.1021/jm401480r
   Liu SL, 2015, ONCOTARGET, V6, P6887, DOI 10.18632/oncotarget.3159
   Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459
   Ngiow SF, 2015, CANCER RES, V75, P3800, DOI 10.1158/0008-5472.CAN-15-1082
   Schölzel S, 2000, AM J PATHOL, V156, P595, DOI 10.1016/S0002-9440(10)64764-5
   SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447
   Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187
   Semenza GL, 2000, CRIT REV BIOCHEM MOL, V35, P71, DOI 10.1080/10409230091169186
   Tachibana M, 2005, GENE DEV, V19, P815, DOI 10.1101/gad.1284005
   Tachibana M, 2008, EMBO J, V27, P2681, DOI 10.1038/emboj.2008.192
   Vaupel P, 2004, SEMIN RADIAT ONCOL, V14, P198, DOI 10.1016/j.semradonc.2004.04.008
   Yeh CM, 2014, INT J ONCOL, V45, P2101, DOI 10.3892/ijo.2014.2627
NR 28
TC 103
Z9 112
U1 1
U2 11
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD JUL 3
PY 2017
VL 114
IS 27
BP 7077
EP 7082
DI 10.1073/pnas.1618706114
PG 6
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA EZ2YD
UT WOS:000404576100066
PM 28630300
OA Green Published
DA 2025-01-12
ER

PT J
AU Yu, WW
   Jiang, H
   Zhang, CT
   Peng, Y
AF Yu, Wei-Wei
   Jiang, Hong
   Zhang, Cun-Tai
   Peng, Yang
TI The SNAIL/miR-128 axis regulated growth, invasion, metastasis, and
   epithelial-to-mesenchymal transition of gastric cancer
SO ONCOTARGET
LA English
DT Article
DE gastric cancer; miR-128; SNAIL; DNA methylation; transcription factor
ID POLYCOMB-GROUP PROTEINS; CELL LUNG-CANCER; PROSTATE-CANCER;
   BREAST-CANCER; EPIGENETIC REGULATION; BMI-1 ONCOPROTEIN; SNAIL;
   OVEREXPRESSION; PROLIFERATION; MICRORNA-128
AB miR-128 is expressed in various tumors, but its expression and function in gastric cancer have not been defined. Thus, the goal of this study was to characterize miR-128 in gastric cancer. We found first that miR-128 is down-regulated in gastric cancer cell lines and tissues, and this dysregulation is correlated with DNA methylation and the transcription factor SNAIL. Using prediction tools, western blotting, and luciferase reporter assays, we found that Bmi-1 was the direct target of miR-128. Additionally, overexpression of miR-128 inhibited gastric cancer cell migration, invasion, and proliferation by targeting Bmi-1 in vitro and in vivo. We also documented, with receiver operating characteristic curves and Kaplan-Meier survival analysis, that miR-128 and Bmi-1 may be useful markers for diagnosing and estimating the prognosis of gastric cancer patients. As the epithelial-to-mesenchymal transition is an important mechanism associated with cancer invasion and metastasis, we inferred that miR-128 could regulate this mechanism in gastric cancer. In fact, we found that miR-128 could reverse epithelial-to-mesenchymal transition induced by Bmi-1 via the PI3K/AKT pathway. Because SNAIL also acts as a mesenchymal marker, our findings identified a novel positive feedback loop in which the transcription factor SNAIL curbs the expression of miR-128, and then down-regulated miR-128 promotes the expression of Bmi-1; finally, overexpression of Bmi-1 drives the epithelial-to-mesenchymal transition process via the PI3K/AKT pathway, and the expression of SNAIL is up-regulated.
C1 [Yu, Wei-Wei; Jiang, Hong; Zhang, Cun-Tai; Peng, Yang] Huazhong Univ Sci & Technol, Tongji Hosp, Dept Geriatr, Tongji Med Coll, Wuhan 430030, Peoples R China.
C3 Huazhong University of Science & Technology
RP Peng, Y (通讯作者)，Huazhong Univ Sci & Technol, Tongji Hosp, Dept Geriatr, Tongji Med Coll, Wuhan 430030, Peoples R China.
EM 49074835@qq.com
RI Peng, Yang/A-3924-2011; wang, yanmei/HPH-0538-2023
FU National Natural Science Foundation of China [81602134]
FX This work was supported by the National Natural Science Foundation of
   China (81602134).
CR Bandres E, 2009, INT J CANCER, V125, P2737, DOI 10.1002/ijc.24638
   Chang BY, 2014, BBA-GEN SUBJECTS, V1840, P3285, DOI 10.1016/j.bbagen.2014.08.005
   Chang L, 2014, CANCER METAST REV, V33, P469, DOI 10.1007/s10555-014-9493-5
   Dang HE, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-396
   Dong QS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098651
   Donzelli S, 2012, CELL DEATH DIFFER, V19, P1038, DOI 10.1038/cdd.2011.190
   Dykxhoorn DM, 2010, CANCER RES, V70, P6401, DOI 10.1158/0008-5472.CAN-10-1346
   Evangelisti C, 2009, FASEB J, V23, P4276, DOI 10.1096/fj.09-134965
   Fabbri M, 2013, ADV EXP MED BIOL, V754, P137, DOI 10.1007/978-1-4419-9967-2_6
   Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516
   Gao F, 2014, ONCOL REP, V31, P351, DOI 10.3892/or.2013.2830
   Glinsky GV, 2005, J CLIN INVEST, V115, P1503, DOI 10.1172/JCI23412
   Hamajima N, 2006, CANCER SCI, V97, P1129, DOI 10.1111/j.1349-7006.2006.00290.x
   HAUPT Y, 1991, CELL, V65, P753, DOI 10.1016/0092-8674(91)90383-A
   Hauser B, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116321
   Honig A, 2010, ANTICANCER RES, V30, P1559
   Hu J, 2014, EUR J CANCER, V50, P2336, DOI 10.1016/j.ejca.2014.06.005
   Ishihara K, 2012, CANCER EPIDEMIOL, V36, P560, DOI 10.1016/j.canep.2012.07.002
   Khan AP, 2010, MOL CELL PROTEOMICS, V9, P298, DOI 10.1074/mcp.M900159-MCP200
   Kim JH, 2004, BREAST, V13, P383, DOI 10.1016/j.breast.2004.02.010
   Kudo-Saito C, 2009, CANCER CELL, V15, P195, DOI 10.1016/j.ccr.2009.01.023
   Larue L, 2005, ONCOGENE, V24, P7443, DOI 10.1038/sj.onc.1209091
   Lau M, 2006, AM J GASTROENTEROL, V101, P2485, DOI 10.1111/j.1572-0241.2006.00778.x
   Li HY, 2014, INT J CLIN EXP PATHO, V7, P3057
   Li W, 2010, J GASTROEN HEPATOL, V25, P568, DOI 10.1111/j.1440-1746.2009.06045.x
   Liu L, 2014, J TRANSL MED, V12, DOI 10.1186/s12967-014-0305-z
   Mets E, 2014, HAEMATOLOGICA, V99, P1326, DOI 10.3324/haematol.2013.099515
   Mulholland DJ, 2012, CANCER RES, V72, P1878, DOI 10.1158/0008-5472.CAN-11-3132
   Murray SA, 2007, DEVELOPMENT, V134, P1789, DOI 10.1242/dev.02837
   Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131
   Pillai RS, 2007, TRENDS CELL BIOL, V17, P118, DOI 10.1016/j.tcb.2006.12.007
   Qian PX, 2012, CANCER RES, V72, P6036, DOI 10.1158/0008-5472.CAN-12-1507
   Rana TM, 2007, NAT REV MOL CELL BIO, V8, P23, DOI 10.1038/nrm2085
   Saeki N, 2013, CANCER SCI, V104, P1, DOI 10.1111/cas.12042
   Sasaki M, 2008, LAB INVEST, V88, P873, DOI 10.1038/labinvest.2008.52
   Shen J, 2015, GASTROENT RES PRACT, V2015, DOI DOI 10.1155/2015/230642
   Shen L, 2014, TUMOR BIOL, V35, P2069, DOI 10.1007/s13277-013-1274-1
   Shin CM, 2011, EUR J GASTROEN HEPAT, V23, P411, DOI 10.1097/MEG.0b013e328343b7f5
   Singh S, 2003, CANCER RES, V63, P2306
   Sun XK, 2015, INT J CLIN EXP PATHO, V8, P8394
   Tao T, 2014, TUMOR BIOL, V35, P8543, DOI 10.1007/s13277-014-2057-z
   Valencia-Sanchez MA, 2006, GENE DEV, V20, P515, DOI 10.1101/gad.1399806
   van Kemenade FJ, 2001, BLOOD, V97, P3896, DOI 10.1182/blood.V97.12.3896
   Vonlanthen S, 2001, BRIT J CANCER, V84, P1372, DOI 10.1054/bjoc.2001.1791
   Wang ZY, 2014, ONCOTARGET, V5, P7013, DOI 10.18632/oncotarget.2192
   Wu WKK, 2010, ONCOGENE, V29, P5761, DOI 10.1038/onc.2010.352
   Xu YJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099516
   Yang MH, 2010, NAT CELL BIOL, V12, P982, DOI 10.1038/ncb2099
   Yang Y, 2015, MOL CELL BIOCHEM, V404, P229, DOI 10.1007/s11010-015-2382-6
   Yuan WW, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118799
   Zhuang LP, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117274
NR 51
TC 25
Z9 28
U1 0
U2 7
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD JUN 13
PY 2017
VL 8
IS 24
BP 39280
EP 39295
DI 10.18632/oncotarget.16849
PG 16
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA EX5VX
UT WOS:000403311900102
PM 28424413
OA gold, Green Published, Green Submitted
DA 2025-01-12
ER

PT J
AU Li, YH
   Ning, QY
   Shi, JL
   Chen, Y
   Jiang, MM
   Gao, L
   Huang, WR
   Jing, Y
   Huang, S
   Liu, AQ
   Hu, ZR
   Liu, DH
   Wang, LL
   Nervi, C
   Dai, Y
   Zhang, MQ
   Yu, L
AF Li, Yonghui
   Ning, Qiaoyang
   Shi, Jinlong
   Chen, Yang
   Jiang, Mengmeng
   Gao, Li
   Huang, Wenrong
   Jing, Yu
   Huang, Sai
   Liu, Anqi
   Hu, Zhirui
   Liu, Daihong
   Wang, Lili
   Nervi, Clara
   Dai, Yun
   Zhang, Michael Q.
   Yu, Li
TI A novel epigenetic <i>AML1</i>-<i>ETO</i>/<i>THAP10</i>/<i>miR</i>-383
   minicircuitry contributes to t(8;21) leukaemogenesis
SO EMBO MOLECULAR MEDICINE
LA English
DT Article
DE AML1-ETO; epigenetics; miR-383; t(8;21) AML; THAP10
ID ACUTE MYELOID-LEUKEMIA; C-KIT MUTATIONS; CELLS IN-VIVO; DOWN-REGULATION;
   STEM-CELLS; TUMOR-SUPPRESSOR; BREAST-CANCER; GENE; MICRORNA-223;
   REGULATOR
AB DNA methylation patterns are frequently deregulated in t(8; 21) acute myeloid leukaemia (AML), but little is known of the mechanisms by which specific gene sets become aberrantly methylated. Here, we found that the promoter DNA methylation signature of t(8; 21)(+) AML blasts differs from that of t(8; 21)(-) AMLs. This study demonstrated that a novel hypermethylated zinc finger-containing protein, THAP10, is a target gene and can be epigenetically suppressed by AML1-ETO at the transcriptional level in t(8; 21) AML. Our findings also show that THAP10 is a bona fide target of miR-383 that can be epigenetically activated by the AML1-ETO recruiting co-activator p300. In this study, we demonstrated that epigenetic suppression of THAP10 is the mechanistic link between AML1-ETO fusion proteins and tyrosine kinase cascades. In addition, we showed that THAP10 is a nuclear protein that inhibits myeloid proliferation and promotes differentiation both in vitro and in vivo. Altogether, our results revealed an unexpected and important epigenetic mini-circuit of AML1-ETO/THAP10/miR-383 in t(8; 21) AML, in which epigenetic suppression of THAP10 predicts a poor clinical outcome and represents a novel therapeutic target.
C1 [Li, Yonghui; Ning, Qiaoyang; Jiang, Mengmeng; Huang, Wenrong; Jing, Yu; Huang, Sai; Liu, Anqi; Liu, Daihong; Wang, Lili; Yu, Li] Chinese Peoples Liberat Army Gen Hosp, Dept Haematol, Beijing, Peoples R China.
   [Ning, Qiaoyang] Nankai Univ, Sch Med, Tianjin, Peoples R China.
   [Shi, Jinlong] Chinese Peoples Liberat Army Gen Hosp, Dept Biomed Engn, Beijing, Peoples R China.
   [Chen, Yang; Hu, Zhirui; Zhang, Michael Q.] Tsinghua Univ, Key Lab Bioinformat, Beijing, Peoples R China.
   [Gao, Li] China Japan Friendship Hosp, Dept Haematol, Beijing, Peoples R China.
   [Nervi, Clara] Univ Rome La Sapienza Polo Pontino, Dept Medicosurg Sci & Biotechnol, Latina, Italy.
   [Dai, Yun] Jilin Univ, Canc Ctr, Hosp 1, Changchun, Peoples R China.
   [Dai, Yun] Virginia Commonwealth Univ, Dept Internal Med, Massey Canc Ctr, Richmond, VA USA.
C3 Chinese People's Liberation Army General Hospital; Nankai University;
   Chinese People's Liberation Army General Hospital; Tsinghua University;
   China-Japan Friendship Hospital; Sapienza University Rome; Jilin
   University; Virginia Commonwealth University
RP Yu, L (通讯作者)，Chinese Peoples Liberat Army Gen Hosp, Dept Haematol, Beijing, Peoples R China.
EM liyu301@vip.163.com
RI Dai, Yun/AAG-4040-2019; wang, lili/HDL-7210-2022; shi, jin/KDO-7906-2024
OI Dai, Yun/0000-0003-2285-0818; NERVI, Clara/0000-0001-9341-0188; Yu,
   Li/0000-0001-6872-2665; Jiang, Mengmeng/0000-0002-9069-0150; Li,
   Yonghui/0000-0001-6782-7473; Chen, Yang/0000-0001-9406-8273
FU National Natural Science Foundation of China [81370635, 81570137,
   81270611, 81470010, 81670162]; Beijing Natural Science Foundation
   [7151009]
FX This work was supported by the National Natural Science Foundation of
   China (Grants 81370635, 81570137, 81270611, 81470010 and 81670162) and
   the Beijing Natural Science Foundation (Grant 7151009). We thank
   Professor Qishou Xu for experimental support, and Ms. Li Cheng for
   technical assistance.
CR Baylin SB, 2006, NAT REV CANCER, V6, P107, DOI 10.1038/nrc1799
   Cayrol C, 2007, BLOOD, V109, P584, DOI 10.1182/blood-2006-03-012013
   Dejosez M, 2008, CELL, V133, P1162, DOI 10.1016/j.cell.2008.05.047
   DeKelver RC, 2013, BLOOD, V121, P3714, DOI 10.1182/blood-2012-11-465641
   Dorrance AM, 2015, LEUKEMIA, V29, P2143, DOI 10.1038/leu.2015.139
   Dyson NJ, 2016, GENE DEV, V30, P1492, DOI 10.1101/gad.282145.116
   Fazi F, 2007, CANCER CELL, V12, P457, DOI 10.1016/j.ccr.2007.09.020
   Fazi F, 2007, BLOOD, V109, P4432, DOI 10.1182/blood-2006-09-045781
   Figueroa ME, 2010, CANCER CELL, V17, P13, DOI 10.1016/j.ccr.2009.11.020
   Gardini A, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000275
   He ZW, 2013, MED ONCOL, V30, DOI 10.1007/s12032-013-0557-0
   Hsiao HH, 2015, GENET MOL RES, V14, P17028, DOI 10.4238/2015.December.16.3
   Jiao B, 2009, LEUKEMIA, V23, P1598, DOI 10.1038/leu.2009.104
   Khanjyan MV, 2013, HUM MOL GENET, V22, P3283, DOI 10.1093/hmg/ddt184
   Ley TJ, 2013, NEW ENGL J MED, V368, P2059, DOI 10.1056/NEJMoa1301689
   Li KKW, 2013, BRAIN PATHOL, V23, P413, DOI 10.1111/bpa.12014
   Li YH, 2013, BLOOD, V121, P499, DOI 10.1182/blood-2012-07-444729
   Lian J, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2010.70
   Liu Y, 2015, CELL DEATH DIFFER, V22, P1035, DOI 10.1038/cdd.2014.194
   Macfarlan T, 2005, J BIOL CHEM, V280, P7346, DOI 10.1074/jbc.M411675200
   Mack SC, 2015, CANCER DISCOV, V5, P1018, DOI 10.1158/2159-8290.CD-15-0985
   Majumdar S, 2013, SCIENCE, V339, P446, DOI 10.1126/science.1231789
   Mende N, 2015, J EXP MED, V212, P1171, DOI 10.1084/jem.20150308
   Oakes CC, 2016, NAT GENET, V48, P253, DOI 10.1038/ng.3488
   Orme MH, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10972
   Pulikkan JA, 2010, BLOOD, V115, P1768, DOI 10.1182/blood-2009-08-240101
   Qin YZ, 2014, LEUKEMIA RES, V38, P1435, DOI 10.1016/j.leukres.2014.09.017
   Riaz M, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3415
   Sabogal A, 2010, NAT STRUCT MOL BIOL, V17, P117, DOI 10.1038/nsmb.1742
   Santos EDS, 2008, INT J ONCOL, V33, P25
   Soria NM, 2009, LEUKEMIA, V23, P188, DOI 10.1038/leu.2008.157
   Tarighat SS, 2016, LEUKEMIA, V30, P789, DOI 10.1038/leu.2015.308
   Vian L, 2014, CELL DEATH DIFFER, V21, P290, DOI 10.1038/cdd.2013.145
   Wang L, 2011, SCIENCE, V333, P765, DOI 10.1126/science.1201662
   Wichmann C, 2015, LEUKEMIA, V29, P279, DOI 10.1038/leu.2014.179
   Wouters BJ, 2016, BLOOD, V127, P42, DOI 10.1182/blood-2015-07-604512
   Yu L, 2005, NAT GENET, V37, P265, DOI 10.1038/ng1521
   Zhang HM, 2015, NUCLEIC ACIDS RES, V43, pD76, DOI 10.1093/nar/gku887
   Zhao L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110472
   Zhu CY, 2009, CELL DEATH DIFFER, V16, P395, DOI 10.1038/cdd.2008.160
NR 40
TC 19
Z9 21
U1 0
U2 19
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1757-4676
EI 1757-4684
J9 EMBO MOL MED
JI EMBO Mol. Med.
PD JUL
PY 2017
VL 9
IS 7
BP 933
EP 949
DI 10.15252/emmm.201607180
PG 17
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA EZ2PO
UT WOS:000404552000009
PM 28539478
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Li, YX
   Jiao, JW
AF Li, Yanxin
   Jiao, Jianwei
TI Histone chaperone HIRA regulates neural progenitor cell proliferation
   and neurogenesis via β-catenin
SO JOURNAL OF CELL BIOLOGY
LA English
DT Article
ID SYNDROME CANDIDATE GENE; OF-FUNCTION VARIANTS; CEREBRAL-CORTEX;
   EMBRYONIC NEUROGENESIS; DELETION SYNDROME; BREAST-CANCER; SCHIZOPHRENIA;
   TRANSCRIPTION; SETD1A; DIFFERENTIATION
AB Histone cell cycle regulator (HIRA) is a histone chaperone and has been identified as an epigenetic regulator. Subsequent studies have provided evidence that HIRA plays key roles in embryonic development, but its function during early neurogenesis remains unknown. Here, we demonstrate that HIRA is enriched in neural progenitor cells, and HIRA knockdown reduces neural progenitor cell proliferation, increases terminal mitosis and cell cycle exit, and ultimately results in premature neuronal differentiation. Additionally, we demonstrate that HIRA enhances beta-catenin expression by recruiting H3K4 trimethyltransferase Setd1A, which increases H3K4me3 levels and heightens the promoter activity of beta-catenin. Significantly, overexpression of HIRA, HIRA N-terminal domain, or beta-catenin can override neurogenesis abnormities caused by HIRA defects. Collectively, these data implicate that HIRA, cooperating with Setd1A, modulates beta-catenin expression and then regulates neurogenesis. This finding represents a novel epigenetic mechanism underlying the histone code and has profound and lasting implications for diseases and neurobiology.
C1 [Li, Yanxin; Jiao, Jianwei] Chinese Acad Sci, Inst Zool, State Key Lab Stem Cell & Reprod Biol, Beijing 100101, Peoples R China.
   [Li, Yanxin; Jiao, Jianwei] Univ Chinese Acad Sci, Beijing 100049, Peoples R China.
C3 Chinese Academy of Sciences; Institute of Zoology, CAS; Chinese Academy
   of Sciences; University of Chinese Academy of Sciences, CAS
RP Jiao, JW (通讯作者)，Chinese Acad Sci, Inst Zool, State Key Lab Stem Cell & Reprod Biol, Beijing 100101, Peoples R China.; Jiao, JW (通讯作者)，Univ Chinese Acad Sci, Beijing 100049, Peoples R China.
EM jwjiao@ioz.ac.cn
RI Li, Yanxin/AAI-4429-2021; Jiao, Jianwei/AAA-7902-2020; Jiao,
   Jianwei/I-1452-2013
OI Jiao, Jianwei/0000-0002-7893-0721
FU National Key Basic Research Program of China [2015CB964500,
   2014CB964903]; National Natural Science Foundation of China [31371477,
   31621004]; K.C. Wong Education Foundation
FX This work was supported by grants from the National Key Basic Research
   Program of China (2015CB964500 and 2014CB964903), the National Natural
   Science Foundation of China (31371477 and 31621004), and K.C. Wong
   Education Foundation.
CR Barski A, 2007, CELL, V129, P823, DOI 10.1016/j.cell.2007.05.009
   Bassett AS, 2003, AM J PSYCHIAT, V160, P1580, DOI 10.1176/appi.ajp.160.9.1580
   Berger SL, 2007, NATURE, V447, P407, DOI 10.1038/nature05915
   Bernstein BE, 2005, CELL, V120, P169, DOI 10.1016/j.cell.2005.01.001
   Bird A, 2007, NATURE, V447, P396, DOI 10.1038/nature05913
   Clevers H, 2014, SCIENCE, V346, P54, DOI 10.1126/science.1248012
   Collas P, 2010, MOL BIOTECHNOL, V45, P87, DOI 10.1007/s12033-009-9239-8
   Duque A, 2011, J NEUROSCI, V31, P15205, DOI 10.1523/JNEUROSCI.3092-11.2011
   Dutta D, 2010, J BIOL CHEM, V285, P41567, DOI 10.1074/jbc.M110.190025
   Farrell MJ, 1999, CIRC RES, V84, P127, DOI 10.1161/01.RES.84.2.127
   Felsenfeld G, 2003, NATURE, V421, P448, DOI 10.1038/nature01411
   Fischle W, 2003, CURR OPIN CELL BIOL, V15, P172, DOI 10.1016/S0955-0674(03)00013-9
   Gregoire JM, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2683-5
   Guenther MG, 2007, CELL, V130, P77, DOI 10.1016/j.cell.2007.05.042
   Jiang JX, 2015, CANCER LETT, V356, P962, DOI 10.1016/j.canlet.2014.11.007
   Jiang XN, 2016, NEUROBIOL DIS, V92, P3, DOI 10.1016/j.nbd.2015.07.007
   Leung JY, 2002, J BIOL CHEM, V277, P21657, DOI 10.1074/jbc.M200139200
   Lin AF, 2016, NAT CELL BIOL, V18, P213, DOI 10.1038/ncb3295
   Lorain S, 1996, GENOME RES, V6, P43, DOI 10.1101/gr.6.1.43
   Majumder A, 2015, J BIOL CHEM, V290, P13053, DOI 10.1074/jbc.M114.615492
   Mao CA, 2011, DEV BIOL, V349, P90, DOI 10.1016/j.ydbio.2010.10.008
   Mao YW, 2009, CELL, V136, P1017, DOI 10.1016/j.cell.2008.12.044
   Maze I, 2015, NEURON, V87, P77, DOI 10.1016/j.neuron.2015.06.014
   MCCONNELL SK, 1995, NEURON, V15, P761, DOI 10.1016/0896-6273(95)90168-X
   McDonald-McGinn DM, 2011, MEDICINE, V90, P1, DOI 10.1097/MD.0b013e3182060469
   Nashun B, 2015, MOL CELL, V60, P611, DOI 10.1016/j.molcel.2015.10.010
   Nguyen L, 2006, GENE DEV, V20, P1511, DOI 10.1101/gad.377106
   Niehrs C, 2012, NAT REV MOL CELL BIO, V13, P767, DOI 10.1038/nrm3470
   Qian XM, 2000, NEURON, V28, P69, DOI 10.1016/S0896-6273(00)00086-6
   Reik W, 2007, NATURE, V447, P425, DOI 10.1038/nature05918
   Ross CA, 2006, NEURON, V52, P139, DOI 10.1016/j.neuron.2006.09.015
   Shen EY, 2015, EXP NEUROL, V268, P21, DOI 10.1016/j.expneurol.2014.08.006
   Shen TJ, 2015, STEM CELLS, V33, P1794, DOI 10.1002/stem.2001
   Singh T, 2016, NAT NEUROSCI, V19, P571, DOI 10.1038/nn.4267
   Stratton MS, 2016, J MOL CELL CARDIOL, V92, P206, DOI 10.1016/j.yjmcc.2016.02.011
   Szenker E, 2012, CELL REP, V1, P730, DOI 10.1016/j.celrep.2012.05.006
   Tajima K, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9257
   Takata A, 2014, NEURON, V82, P773, DOI 10.1016/j.neuron.2014.04.043
   Wiese C, 2004, CELL MOL LIFE SCI, V61, P2510, DOI 10.1007/s00018-004-4144-6
   Wilming LG, 1997, HUM MOL GENET, V6, P247, DOI 10.1093/hmg/6.2.247
   Xia WL, 2015, STEM CELL REP, V4, P795, DOI 10.1016/j.stemcr.2015.03.004
   Xu D, 2014, INT J DISTRIB SENS N, V2014, P1, DOI DOI 10.1155/2014/672494
   Yang JH, 2011, P NATL ACAD SCI USA, V108, P85, DOI 10.1073/pnas.1009830108
   Yao B, 2016, NAT REV NEUROSCI, V17, P537, DOI 10.1038/nrn.2016.70
   Zechner D, 2003, DEV BIOL, V258, P406, DOI 10.1016/S0012-1606(03)00123-4
   Zinkstok J, 2005, CHILD NEUROPSYCHOL, V11, P21, DOI 10.1080/09297040590911194
NR 46
TC 31
Z9 31
U1 1
U2 8
PU ROCKEFELLER UNIV PRESS
PI NEW YORK
PA 950 THIRD AVE, 2ND FLR, NEW YORK, NY 10022 USA
SN 0021-9525
EI 1540-8140
J9 J CELL BIOL
JI J. Cell Biol.
PD JUL
PY 2017
VL 216
IS 7
BP 1975
EP 1992
DI 10.1083/jcb.201610014
PG 18
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA EZ2TP
UT WOS:000404563700017
PM 28515277
OA Green Published, hybrid
DA 2025-01-12
ER

PT J
AU Santamaria, PG
   Moreno-Bueno, G
   Portillo, F
   Cano, A
AF Santamaria, Patricia G.
   Moreno-Bueno, Gema
   Portillo, Francisco
   Cano, Amparo
TI EMT: Present and future in clinical oncology
SO MOLECULAR ONCOLOGY
LA English
DT Article
DE clinical trials; EMT; MET; metastasis; preclinical models; therapy
   resistance
ID EPITHELIAL-MESENCHYMAL-TRANSITION; CIRCULATING TUMOR-CELLS; CANCER
   STEM-CELLS; METASTATIC BREAST-CANCER; E-CADHERIN EXPRESSION;
   PROSTATE-CANCER; TRANSCRIPTION FACTORS; EPIGENETIC REGULATION;
   MONOCLONAL-ANTIBODY; SNAIL1 EXPRESSION
AB Epithelial/mesenchymal transition (EMT) has emerged as a key regulator of metastasis by facilitating tumor cell invasion and dissemination to distant organs. Recent evidences support that the reverse mesenchymal/epithelial transition (MET) is required for metastatic outgrowth; moreover, the existence of hybrid epithelial/mesenchymal (E/M) phenotypes is increasingly being reported in different tumor contexts. The accumulated data strongly support that plasticity between epithelial and mesenchymal states underlies the dissemination and metastatic potential of carcinoma cells. However, the translation into the clinics of EMT and epithelial plasticity processes presents enormous challenges and still remains a controversial issue. In this review, we will evaluate current evidences for translational applicability of EMT and depict an overview of the most recent EMT in vivo models, EMT marker analyses in human samples as well as potential EMT therapeutic approaches and ongoing clinical trials. We foresee that standardized analyses of EMT markers in solid and liquid tumor biopsies in addition to innovative tools targeting the E/M states will become promising strategies for future translation to the clinical setting.
C1 [Santamaria, Patricia G.; Moreno-Bueno, Gema; Portillo, Francisco; Cano, Amparo] Univ Autonoma Madrid, IdiPAZ, CIBERONC, Inst Invest Biomed Alberto Sols CSIC UAM,Dept Bio, Madrid, Spain.
   [Moreno-Bueno, Gema] Fdn MD Anderson Int, Madrid, Spain.
C3 Autonomous University of Madrid; Consejo Superior de Investigaciones
   Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas
   Alberto Sols (IIBM); CIBER - Centro de Investigacion Biomedica en Red;
   CIBERONC; University of Texas System; UTMD Anderson Cancer Center
RP Cano, A (通讯作者)，Univ Autonoma Madrid, Dept Bioquim, Inst Invest Biomed Alberto Sols CSIC UAM, Arzobispo Morcillo 4, E-28049 Madrid, Spain.
EM acano@iib.uam.es
RI Sancho, Patricia/ABH-5258-2020; Moreno-Bueno, Gema/K-9354-2016
OI Moreno-Bueno, Gema/0000-0002-5030-6687; Portillo Perez,
   Francisco/0000-0003-4922-346X; Santamaria, Patricia
   G/0000-0003-3718-538X
FU Spanish Ministerio de Economia y Competitividad [SAF2013-44739-R,
   SAF2016-76504-R]; Spanish Instituto de Salud Carlos III (EU-FEDER funds)
   [RETIC-RD12/0036/0007, CIBER-ONC-CB16/12/00295, PI13/00132, PI16/00134];
   Worldwide Cancer Research (WWCR) [WWCR 16-0295]; Fundacion Cientifica
   AECC
FX We apologize to all those colleagues whose important work has not been
   cited. Work in our laboratories is supported by grants from the Spanish
   Ministerio de Economia y Competitividad SAF2013-44739-R and
   SAF2016-76504-R (AC and FP), the Spanish Instituto de Salud Carlos III
   [RETIC-RD12/0036/0007, CIBER-ONC-CB16/12/00295 (AC); PI13/00132,
   PI16/00134 (GMB)] (all of them partly supported from EU-FEDER funds),
   and Worldwide Cancer Research (WWCR, formerly AICR) WWCR 16-0295 (AC,
   PGS, and FP). PGS was funded by a postdoctoral contract from the
   Fundacion Cientifica AECC and presently from WWCR 16-0295.
CR Aceto N, 2014, CELL, V158, P1110, DOI 10.1016/j.cell.2014.07.013
   Acs G, 2001, AM J CLIN PATHOL, V115, P85
   Alba-Castellón L, 2016, CANCER RES, V76, P6205, DOI 10.1158/0008-5472.CAN-16-0176
   Alix-Panabières C, 2017, J MOL MED, V95, P133, DOI 10.1007/s00109-016-1500-6
   Alonso-Alconada L, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-223
   Nieto MA, 2016, CELL, V166, P21, DOI 10.1016/j.cell.2016.06.028
   Nieto MA, 2013, SCIENCE, V342, P708, DOI 10.1126/science.1234850
   Nieto MA, 2012, SEMIN CANCER BIOL, V22, P361, DOI 10.1016/j.semcancer.2012.05.003
   Nieto MA, 2011, ANNU REV CELL DEV BI, V27, P347, DOI 10.1146/annurev-cellbio-092910-154036
   Castilla MA, 2011, J PATHOL, V223, P72, DOI 10.1002/path.2802
   [Anonymous], DEV DYN
   Arai K, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0162394
   Armstrong AJ, 2011, MOL CANCER RES, V9, P997, DOI 10.1158/1541-7786.MCR-10-0490
   Atzori F, 2011, CLIN CANCER RES, V17, P6304, DOI 10.1158/1078-0432.CCR-10-3336
   Barbazán J, 2014, INT J CANCER, V135, P2633, DOI 10.1002/ijc.28910
   Barriere G, 2014, ANN TRANSL MED, V2, DOI 10.3978/j.issn.2305-5839.2014.10.04
   Barrière G, 2013, ANTI-CANCER AGENT ME, V13, P333, DOI 10.2174/1871520611313020018
   Becker KF, 2007, CELLS TISSUES ORGANS, V185, P204, DOI 10.1159/000101321
   Beerling E, 2016, CELL REP, V14, P2281, DOI 10.1016/j.celrep.2016.02.034
   Beg MS, 2017, INVEST NEW DRUG, V35, P180, DOI 10.1007/s10637-016-0407-y
   Berx G, 1996, ONCOGENE, V13, P1919
   Bhowmick NA, 2004, SCIENCE, V303, P848, DOI 10.1126/science.1090922
   Bidard FC, 2014, LANCET ONCOL, V15, P406, DOI 10.1016/S1470-2045(14)70069-5
   Blanco MJ, 2002, ONCOGENE, V21, P3241, DOI 10.1038/sj.onc.1205416
   Brabletz S, 2010, EMBO REP, V11, P670, DOI 10.1038/embor.2010.117
   Brabletz T, 2005, NAT REV CANCER, V5, P744, DOI 10.1038/nrc1694
   Brabletz T, 2012, CANCER CELL, V22, P699, DOI 10.1016/j.ccr.2012.11.009
   Brabletz T, 2012, NAT REV CANCER, V12, P425, DOI 10.1038/nrc3265
   Bruney L, 2016, ONCOTARGET, V7, P21968, DOI 10.18632/oncotarget.7880
   Cabel L, 2017, INT J CLIN ONCOL, V22, P421, DOI 10.1007/s10147-017-1105-2
   Carmody LC, 2011, PROBE REPORTS NIH MO
   Carmody LC, 2012, J BIOMOL SCREEN, V17, P1204, DOI 10.1177/1087057112458317
   Celià-Terrassa T, 2016, GENE DEV, V30, P892, DOI 10.1101/gad.277681.116
   Celià-Terrassa T, 2012, J CLIN INVEST, V122, P1849, DOI 10.1172/JCI59218
   Ceyran AB, 2015, INT J CLIN EXP PATHO, V8, P3670
   Chaffer CL, 2016, CANCER METAST REV, V35, P645, DOI 10.1007/s10555-016-9648-7
   Chanrion M, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6005
   Cheung KJ, 2016, P NATL ACAD SCI USA, V113, pE854, DOI 10.1073/pnas.1508541113
   Chui MH, 2013, INT J CANCER, V132, P1487, DOI 10.1002/ijc.27745
   Cristofanilli M, 2004, NEW ENGL J MED, V351, P781, DOI 10.1056/NEJMoa040766
   Da CX, 2017, ONCOTARGET, V8, P8131, DOI 10.18632/oncotarget.14101
   da Fonseca LM, 2016, FRONT ONCOL, V6, DOI 10.3389/fonc.2016.00158
   De Craene B, 2013, NAT REV CANCER, V13, P97, DOI 10.1038/nrc3447
   de Jong MC, 2015, CLIN CANCER RES, V21, P5630, DOI 10.1158/1078-0432.CCR-15-0454
   Della Corte CM, 2015, CLIN CANCER RES, V21, P4686, DOI 10.1158/1078-0432.CCR-14-3319
   Díaz-López A, 2015, INT J CANCER, V136, pE62, DOI 10.1002/ijc.29177
   Díaz-López A, 2014, CANCER MANAG RES, V6, P205, DOI 10.2147/CMAR.S38156
   Díaz-Martín J, 2014, J PATHOL, V232, P319, DOI 10.1002/path.4289
   Diepenbruck M, 2016, CURR OPIN CELL BIOL, V43, P7, DOI 10.1016/j.ceb.2016.06.002
   Du BW, 2016, MOLECULES, V21, DOI 10.3390/molecules21070965
   El Bezawy R, 2017, CANCER LETT, V395, P53, DOI 10.1016/j.canlet.2017.02.033
   Feng XL, 2014, CANCER LETT, V344, P166, DOI 10.1016/j.canlet.2013.11.004
   Fici P, 2017, ONCOTARGET, V8, P2423, DOI 10.18632/oncotarget.13682
   Fischer KR, 2015, NATURE, V527, P472, DOI 10.1038/nature15748
   Fitzgerald RC, 2004, GUT, V53, P775, DOI 10.1136/gut.2003.022061
   Francí C, 2006, ONCOGENE, V25, P5134, DOI 10.1038/sj.onc.1209519
   GAMALLO C, 1993, AM J PATHOL, V142, P987
   Garg Minal, 2013, World J Stem Cells, V5, P188, DOI 10.4252/wjsc.v5.i4.188
   Geradts J, 2011, HUM PATHOL, V42, P1125, DOI 10.1016/j.humpath.2010.11.004
   Gomis RR, 2017, MOL ONCOL, V11, P62, DOI 10.1016/j.molonc.2016.09.009
   Goodwin PJ, 2009, J CLIN ONCOL, V27, P3271, DOI 10.1200/JCO.2009.22.1630
   Guilford P, 1998, NATURE, V392, P402, DOI 10.1038/32918
   Gupta PB, 2009, CELL, V138, P645, DOI 10.1016/j.cell.2009.06.034
   Harouaka R, 2014, PHARMACOL THERAPEUT, V141, P209, DOI 10.1016/j.pharmthera.2013.10.004
   Harper KL, 2016, NATURE, V540, P588, DOI 10.1038/nature20609
   Hennessy BT, 2009, CANCER RES, V69, P4116, DOI 10.1158/0008-5472.CAN-08-3441
   Hong T, 2015, PLOS COMPUT BIOL, V11, DOI 10.1371/journal.pcbi.1004569
   Hsu DSS, 2010, CLIN CANCER RES, V16, P4561, DOI 10.1158/1078-0432.CCR-10-0593
   Huang JF, 2017, J CONTROL RELEASE, V245, P1, DOI 10.1016/j.jconrel.2016.11.024
   HUNDAL HS, 1992, ENDOCRINOLOGY, V131, P1165, DOI 10.1210/en.131.3.1165
   Imani S, 2016, SCI REP-UK, V6, DOI 10.1038/srep28587
   Janni WJ, 2016, CLIN CANCER RES, V22, P2583, DOI 10.1158/1078-0432.CCR-15-1603
   Jia DY, 2015, ONCOTARGET, V6, P15436, DOI 10.18632/oncotarget.3623
   Jiang XR, 2015, MED ONCOL, V32, DOI 10.1007/s12032-015-0595-x
   Jolly MK, 2016, ONCOTARGET, V7, P27067, DOI 10.18632/oncotarget.8166
   Kajita M, 2004, MOL CELL BIOL, V24, P7559, DOI 10.1128/MCB.24.17.7559-7566.2004
   Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104
   Katoh Y, 2009, CURR MOL MED, V9, P873, DOI 10.2174/156652409789105570
   Khorkova O, 2017, NAT BIOTECHNOL, V35, P249, DOI 10.1038/nbt.3784
   Kiesslich T, 2013, MOL CLIN ONCOL, V1, P3, DOI 10.3892/mco.2012.28
   Kim J, 2010, CANCER SCI, V101, P1521, DOI 10.1111/j.1349-7006.2010.01536.x
   Korpal M, 2011, NAT MED, V17, P1101, DOI 10.1038/nm.2401
   Krebs AM, 2017, NAT CELL BIOL, V19, P518, DOI 10.1038/ncb3513
   Kurrey NK, 2009, STEM CELLS, V27, P2059, DOI 10.1002/stem.154
   Labelle M, 2011, CANCER CELL, V20, P576, DOI 10.1016/j.ccr.2011.09.009
   Lambert AW, 2017, CELL, V168, P670, DOI 10.1016/j.cell.2016.11.037
   Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758
   Leblanc R, 2016, BLOOD, V128, P24, DOI 10.1182/blood-2016-01-636399
   Ledford H, 2011, NATURE, V472, P273, DOI 10.1038/472273a
   Li JH, 2016, J CONTROL RELEASE, V228, P38, DOI 10.1016/j.jconrel.2016.02.036
   Li JH, 2016, BIOMATERIALS, V76, P52, DOI 10.1016/j.biomaterials.2015.10.046
   Li XG, 2016, EBIOMEDICINE, V14, P44, DOI 10.1016/j.ebiom.2016.11.026
   Li YM, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.347
   Liu W, 2014, CANCER MICROENVIRON, V7, P117, DOI 10.1007/s12307-014-0148-4
   Lu JJ, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/6253280
   Ma JW, 2016, ONCOTARGET, V7, P58915, DOI 10.18632/oncotarget.10410
   Malek R, 2017, CELLS TISSUES ORGANS, V203, P114, DOI 10.1159/000447238
   Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027
   Marcucci F, 2016, NAT REV DRUG DISCOV, V15, P311, DOI 10.1038/nrd.2015.13
   McInnes LM, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00042
   Meidhof S, 2015, EMBO MOL MED, V7, P831, DOI 10.15252/emmm.201404396
   MOLL R, 1993, AM J PATHOL, V143, P1731
   Morel AP, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002723
   Morel AP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002888
   Moreno-Bueno G, 2009, NAT PROTOC, V4, P1591, DOI 10.1038/nprot.2009.152
   Ocaña OH, 2012, CANCER CELL, V22, P709, DOI 10.1016/j.ccr.2012.10.012
   Okubo K, 2017, GASTRIC CANC
   Parisi C, 2016, CLIN CHIM ACTA, V461, P156, DOI 10.1016/j.cca.2016.08.003
   Pasquier J, 2015, J ONCOL, V2015, DOI 10.1155/2015/792182
   Peinado HC, 2004, INT J DEV BIOL, V48, P365, DOI 10.1387/ijdb.041794hp
   Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131
   Pérez-Losada J, 2003, ONCOGENE, V22, P4205, DOI 10.1038/sj.onc.1206467
   Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620
   Putzke AP, 2011, AM J PATHOL, V179, P400, DOI 10.1016/j.ajpath.2011.03.028
   Rastogi I, 2016, BIOCHEM BIOPH RES CO, V477, P937, DOI 10.1016/j.bbrc.2016.07.003
   Rhim AD, 2012, CELL, V148, P349, DOI 10.1016/j.cell.2011.11.025
   Roop RP, 2013, CLIN BREAST CANCER, V13, P409, DOI 10.1016/j.clbc.2013.08.006
   Rowe RG, 2009, J CELL BIOL, V184, P399, DOI 10.1083/jcb.200810113
   Santilli F, 2016, EUR J INTERN MED, V34, P11, DOI 10.1016/j.ejim.2016.06.004
   Sarioglu AF, 2015, NAT METHODS, V12, P685, DOI [10.1038/nmeth.3404, 10.1038/NMETH.3404]
   Sarrío D, 2004, ONCOGENE, V23, P3272, DOI 10.1038/sj.onc.1207439
   Sarrió D, 2008, CANCER RES, V68, P989, DOI 10.1158/0008-5472.CAN-07-2017
   Satelli A, 2011, CELL MOL LIFE SCI, V68, P3033, DOI 10.1007/s00018-011-0735-1
   Saxena M, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.61
   Schmalhofer O, 2009, CANCER METAST REV, V28, P151, DOI 10.1007/s10555-008-9179-y
   Schoenhals M, 2009, BIOCHEM BIOPH RES CO, V383, P157, DOI 10.1016/j.bbrc.2009.02.156
   Sekhon K, 2016, ONCOTARGET, V7, P67597, DOI 10.18632/oncotarget.11708
   Serrano-Gomez SJ, 2016, MOL CANCER, V15, DOI 10.1186/s12943-016-0502-x
   Sesumi Y, 2017, LUNG CANCER, V104, P85, DOI 10.1016/j.lungcan.2016.12.012
   Shah MY, 2014, WIRES RNA, V5, P537, DOI 10.1002/wrna.1229
   Shiota M, 2012, CANCER RES, V72, P5261, DOI 10.1158/0008-5472.CAN-12-0254
   Smith BN, 2016, J CLIN MED, V5, DOI 10.3390/jcm5020017
   Somarelli JA, 2016, ONCOGENE, V35, P4302, DOI 10.1038/onc.2015.497
   Soundararajan R, 2015, SCI REP-UK, V5, DOI 10.1038/srep11766
   Stankic M, 2013, CELL REP, V5, P1228, DOI 10.1016/j.celrep.2013.11.014
   Steinestel K, 2014, CLIN TRANSL MED, V3, DOI 10.1186/2001-1326-3-17
   Sun LD, 2016, CELL MOL LIFE SCI, V73, P4493, DOI 10.1007/s00018-016-2303-1
   Takemoto A, 2017, SCI REP-UK, V7, DOI 10.1038/srep42186
   Tam WL, 2013, NAT MED, V19, P1438, DOI 10.1038/nm.3336
   Tan TZ, 2014, EMBO MOL MED, V6, P1279, DOI 10.15252/emmm.201404208
   Tang Y, 2017, SCI REP-UK, V7, DOI 10.1038/srep38232
   Tarin D, 2005, CANCER RES, V65, P5996, DOI 10.1158/0008-5472.CAN-05-0699
   Taube JH, 2010, P NATL ACAD SCI USA, V107, P15449, DOI 10.1073/pnas.1004900107
   Teicher BA, 1996, CANCER CHEMOTH PHARM, V37, P601, DOI 10.1007/s002800050435
   Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007
   Thiery JP, 2003, CURR OPIN CELL BIOL, V15, P740, DOI 10.1016/j.ceb.2003.10.006
   Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822
   Träger MM, 2017, INT J CANCER, V141, P24, DOI 10.1002/ijc.30626
   Tran HD, 2014, CANCER RES, V74, P6330, DOI 10.1158/0008-5472.CAN-14-0923
   Tremblay G, 2010, CANCER RES, V70, DOI 10.1158/1538-7445.AM10-1467
   Tsai JH, 2012, CANCER CELL, V22, P725, DOI 10.1016/j.ccr.2012.09.022
   Wang C, 2012, INT J BIOCHEM CELL B, V44, P2308, DOI 10.1016/j.biocel.2012.09.012
   Wang XY, 2016, BIOMED PHARMACOTHER, V80, P136, DOI 10.1016/j.biopha.2016.03.013
   Watanabe K, 2014, DEV CELL, V29, P59, DOI 10.1016/j.devcel.2014.03.006
   Way TD, 2014, EUR J CANCER, V50, P366, DOI 10.1016/j.ejca.2013.09.025
   Wilson C, 2014, ONCOTARGET, V5, P7328, DOI 10.18632/oncotarget.2397
   Wu SY, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123976
   Yamada S, 2014, ANN SURG ONCOL, V21, P3882, DOI 10.1245/s10434-014-3779-2
   Yang J, 2008, DEV CELL, V14, P818, DOI 10.1016/j.devcel.2008.05.009
   Yang MH, 2007, ONCOGENE, V26, P1459, DOI 10.1038/sj.onc.1209929
   Yauch RL, 2005, CLIN CANCER RES, V11, P8686, DOI 10.1158/1078-0432.CCR-05-1492
   Ye X, 2015, NATURE, V525, P256, DOI 10.1038/nature14897
   Yeung KT, 2017, MOL ONCOL, V11, P28, DOI 10.1002/1878-0261.12017
   Yu M, 2013, SCIENCE, V339, P580, DOI 10.1126/science.1228522
   Zaravinos A, 2015, J ONCOL
   Zeisberg M, 2009, J CLIN INVEST, V119, P1429, DOI 10.1172/JCI36183
   Zhang H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069301
   Zhang J, 2014, BIOCHEM BIOPH RES CO, V452, P746, DOI 10.1016/j.bbrc.2014.08.154
   Zhang JY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064954
   Zhang P, 2014, EUR J CLIN INVEST, V44, P1072, DOI 10.1111/eci.12343
   Zhang WJ, 2012, BIOCHEM BIOPH RES CO, V417, P679, DOI 10.1016/j.bbrc.2011.11.142
   Zhao Z, 2016, CANCER RES, V76, P2094, DOI 10.1158/0008-5472.CAN-15-2662
   Zheng QM, 2016, REPROD SCI, V23, P1526, DOI 10.1177/1933719116645192
   Zheng XF, 2015, NATURE, V527, P525, DOI 10.1038/nature16064
   Zhou PT, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0624-9
NR 175
TC 203
Z9 224
U1 0
U2 16
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1574-7891
EI 1878-0261
J9 MOL ONCOL
JI Mol. Oncol.
PD JUL
PY 2017
VL 11
IS 7
SI SI
BP 718
EP 738
DI 10.1002/1878-0261.12091
PG 21
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA FA9CJ
UT WOS:000405743300002
PM 28590039
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU He, RS
   Kidder, BL
AF He, Runsheng
   Kidder, Benjamin L.
TI H3K4 demethylase KDM5B regulates global dynamics of transcription
   elongation and alternative splicing in embryonic stem cells
SO NUCLEIC ACIDS RESEARCH
LA English
DT Article
ID RNA-POLYMERASE-II; SELF-RENEWAL; IN-VIVO; BREAST-CANCER; CHROMATIN
   MODIFICATIONS; HISTONE METHYLATION; DNA METHYLATION; GENE-EXPRESSION;
   ACTIVE GENES; HUMAN GENOME
AB Epigenetic regulation of chromatin plays a critical role in controlling embryonic stem (ES) cell self-renewal and pluripotency. However, the roles of histone demethylases and activating histone modifications such as trimethylated histone 3 lysine 4 (H3K4me3) in transcriptional events such as RNA polymerase II (RNAPII) elongation and alternative splicing are largely unknown. In this study, we show that KDM5B, which demethylates H3K4me3, plays an integral role in regulating RNAPII occupancy, transcriptional initiation and elongation, and alternative splicing events in ES cells. Depletion of KDM5B leads to altered RNAPII promoter occupancy, and decreased RNAPII initiation and elongation rates at active genes and at genesmarked with broad H3K4me3 domains. Moreover, our results demonstrate that spreading of H3K4me3 from promoter to gene body regions, which is mediated by depletion of KDM5B, modulates RNAPII elongation rates and RNA splicing in ES cells. We further show that KDM5B is enriched nearby alternatively spliced exons, and depletion of KDM5B leads to altered levels of H3K4 methylation in alternatively spliced exon regions, which is accompanied by differential expression of these alternatively splice exons. Altogether, our data indicate an epigenetic role for KDM5B in regulating RNAPII elongation and alternative splicing, which may support the diverse mRNA repertoire in ES cells.
C1 [He, Runsheng; Kidder, Benjamin L.] Wayne State Univ, Dept Oncol, Sch Med, Detroit, MI 48201 USA.
   [He, Runsheng; Kidder, Benjamin L.] Wayne State Univ, Karmanos Canc Inst, Sch Med, Detroit, MI 48201 USA.
C3 Wayne State University; Wayne State University; Barbara Ann Karmanos
   Cancer Institute
RP Kidder, BL (通讯作者)，Wayne State Univ, Dept Oncol, Sch Med, Detroit, MI 48201 USA.; Kidder, BL (通讯作者)，Wayne State Univ, Karmanos Canc Inst, Sch Med, Detroit, MI 48201 USA.
EM benjamin.kidder@wayne.edu
RI Kidder, Benjamin/C-6489-2008
FU Wayne State University; Karmanos Cancer Institute; National Heart, Lung
   and Blood Institute [1K22HL126842-01A1]
FX Wayne State University; Karmanos Cancer Institute; National Heart, Lung
   and Blood Institute [1K22HL126842-01A1 B.L.K.]. Funding for open access
   charge: Wayne State University.
CR Albert M, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003461
   Barrett A, 2007, INT J CANCER, V121, P265, DOI 10.1002/ijc.22673
   Barski A, 2007, CELL, V129, P823, DOI 10.1016/j.cell.2007.05.009
   Benayoun BA, 2014, CELL, V158, P673, DOI 10.1016/j.cell.2014.06.027
   Bieberstein NI, 2012, CELL REP, V2, P62, DOI 10.1016/j.celrep.2012.05.019
   Catchpole S, 2011, INT J ONCOL, V38, P1267, DOI 10.3892/ijo.2011.956
   Chen KF, 2015, NAT GENET, V47, P1149, DOI 10.1038/ng.3385
   Chen Y, 2011, BMC GENOMICS, V12, DOI 10.1186/1471-2164-12-544
   Cheng C, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-2-r15
   Christensen J, 2007, CELL, V128, P1063, DOI 10.1016/j.cell.2007.02.003
   de la Mata M, 2003, MOL CELL, V12, P525, DOI 10.1016/j.molcel.2003.08.001
   Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60
   Dujardin G, 2014, MOL CELL, V54, P683, DOI 10.1016/j.molcel.2014.03.044
   Eick D, 2013, CHEM REV, V113, P8456, DOI 10.1021/cr400071f
   Fong N, 2014, GENE DEV, V28, P2663, DOI 10.1101/gad.252106.114
   Fuda NJ, 2009, NATURE, V461, P186, DOI 10.1038/nature08449
   Guillemette B, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1001354
   Heinz S, 2010, MOL CELL, V38, P576, DOI 10.1016/j.molcel.2010.05.004
   Hnilicová J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016727
   Ivanova N, 2006, NATURE, V442, P533, DOI 10.1038/nature04915
   Karlic R, 2010, P NATL ACAD SCI USA, V107, P2926, DOI 10.1073/pnas.0909344107
   Katz Y, 2010, NAT METHODS, V7, P1009, DOI 10.1038/NMETH.1528
   Kidder BL, 2014, METHODS MOL BIOL, V1150, P3, DOI 10.1007/978-1-4939-0512-6_1
   Kidder BL, 2014, GENOME BIOL, V15, DOI 10.1186/gb-2014-15-2-r32
   Kidder BL, 2013, MOL CELL BIOL, V33, P4793, DOI 10.1128/MCB.00692-13
   Kidder BL, 2011, NAT IMMUNOL, V12, P918, DOI 10.1038/ni.2117
   Kim TH, 2005, NATURE, V436, P876, DOI 10.1038/nature03877
   Klose RJ, 2007, NAT REV MOL CELL BIO, V8, P307, DOI 10.1038/nrm2143
   Kolasinska-Zwierz P, 2009, NAT GENET, V41, P376, DOI 10.1038/ng.322
   Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005
   Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/NMETH.1923, 10.1038/nmeth.1923]
   Lee MG, 2006, MOL CELL BIOL, V26, P6395, DOI 10.1128/MCB.00723-06
   Luco RF, 2011, CELL, V144, P16, DOI 10.1016/j.cell.2010.11.056
   Luco RF, 2010, SCIENCE, V327, P996, DOI 10.1126/science.1184208
   Maunakea AK, 2013, CELL RES, V23, P1256, DOI 10.1038/cr.2013.110
   Mortazavi A, 2008, NAT METHODS, V5, P621, DOI 10.1038/nmeth.1226
   Mosammaparast N, 2010, ANNU REV BIOCHEM, V79, P155, DOI 10.1146/annurev.biochem.78.070907.103946
   Ni ZY, 2008, MOL CELL BIOL, V28, P1161, DOI 10.1128/MCB.01859-07
   Nojima T, 2015, CELL, V161, P526, DOI 10.1016/j.cell.2015.03.027
   Pokholok DK, 2005, CELL, V122, P517, DOI 10.1016/j.cell.2005.06.026
   Rahl PB, 2010, CELL, V141, P432, DOI 10.1016/j.cell.2010.03.030
   Reppas NB, 2006, MOL CELL, V24, P747, DOI 10.1016/j.molcel.2006.10.030
   Ringrose L, 2004, ANNU REV GENET, V38, P413, DOI 10.1146/annurev.genet.38.072902.091907
   Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616
   Santos-Rosa H, 2002, NATURE, V419, P407, DOI 10.1038/nature01080
   Schmitz SU, 2011, EMBO J, V30, P4586, DOI 10.1038/emboj.2011.383
   Schneider R, 2004, NAT CELL BIOL, V6, P73, DOI 10.1038/ncb1076
   Schor IE, 2013, EMBO J, V32, P2264, DOI 10.1038/emboj.2013.167
   Schor IE, 2009, P NATL ACAD SCI USA, V106, P4325, DOI 10.1073/pnas.0810666106
   Schübeler D, 2004, GENE DEV, V18, P1263, DOI 10.1101/gad.1198204
   Seward DJ, 2007, NAT STRUCT MOL BIOL, V14, P240, DOI 10.1038/nsmb1200
   Shukla S, 2012, BBA-GENE REGUL MECH, V1819, P673, DOI 10.1016/j.bbagrm.2012.01.014
   Shukla S, 2011, NATURE, V479, P74, DOI 10.1038/nature10442
   Sims RJ, 2003, TRENDS GENET, V19, P629, DOI 10.1016/j.tig.2003.09.007
   Spies N, 2009, MOL CELL, V36, P245, DOI 10.1016/j.molcel.2009.10.008
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Teoh PL, 2014, CELL MOL BIOL LETT, V19, P215, DOI 10.2478/s11658-014-0190-8
   Tokheim Collin, 2014, Genomics Proteomics & Bioinformatics, V12, P105, DOI 10.1016/j.gpb.2014.04.001
   Wang Z, 2004, GENE DEV, V18, P3106, DOI 10.1101/gad.1238104
   Wright MD, 2004, MOL CELL BIOL, V24, P5978, DOI 10.1128/MCB.24.13.5978-5988.2004
   Xie LQ, 2011, EMBO J, V30, P1473, DOI 10.1038/emboj.2011.91
   Yamamoto S, 2014, CANCER CELL, V25, P762, DOI 10.1016/j.ccr.2014.04.024
   Zang CZ, 2009, BIOINFORMATICS, V25, P1952, DOI 10.1093/bioinformatics/btp340
   Zeitlinger J, 2007, NAT GENET, V39, P1512, DOI 10.1038/ng.2007.26
   Zhao XD, 2007, CELL STEM CELL, V1, P286, DOI 10.1016/j.stem.2007.08.004
   Zhou YP, 2012, BMC GENOMICS, V13, DOI 10.1186/1471-2164-13-123
NR 66
TC 39
Z9 41
U1 1
U2 12
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0305-1048
EI 1362-4962
J9 NUCLEIC ACIDS RES
JI Nucleic Acids Res.
PD JUN 20
PY 2017
VL 45
IS 11
BP 6427
EP 6441
DI 10.1093/nar/gkx251
PG 15
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA EY1AG
UT WOS:000403693000030
PM 28402433
OA Green Published, Green Submitted, gold
DA 2025-01-12
ER

PT J
AU Peplonska, B
   Bukowska, A
   Wieczorek, E
   Przybek, M
   Zienolddiny, S
   Reszka, E
AF Peplonska, Beata
   Bukowska, Agnieszka
   Wieczorek, Edyta
   Przybek, Monika
   Zienolddiny, Shanbeh
   Reszka, Edyta
TI Rotating night work, lifestyle factors, obesity and promoter methylation
   in <i>BRCA1</i> and <i>BRCA2</i> genes among nurses and midwives
SO PLOS ONE
LA English
DT Article
ID BREAST-CANCER RISK; BODY-MASS INDEX; CIGARETTE-SMOKE CONDENSATE;
   TUMOR-SUPPRESSOR GENES; CORONARY-HEART-DISEASE; LONG-TERM SHIFTWORK; DNA
   METHYLATION; PHYSICAL-ACTIVITY; ABERRANT METHYLATION; HORMONE-LEVELS
AB Some recent evidence suggests that environmental and lifestyle factors may modify DNA methylation. We hypothesized that rotating night work and several modifiable factors may be associated with the methylation of the promoter regions within two tumor suppressor and DNA repair genes: BRCA1 and BRCA2. The methylation status of BRCA1 and BRCA2 was determined via qMSP reactions using DNA samples derived from blood leucocytes of 347 nurses and midwives working rotating nights and 363 working during the days. The subjects were classified into unmethylated vs methylated BRCA1 and BRCA2 when the methylation index was 0% or >0%, respectively. The adjusted odds ratios with 95% confidence intervals were calculated for night work status, smoking, obesity, physical activity and alcohol drinking. Current night shift work or night work history was not associated with methylation status of the promoter sites within BRCA1 and BRCA2 genes. We observed weak associations between smoking and the methylation status of BRCA1 with OR = 1.50 (95% CI: 0.98-2.29) for current smoking, OR = 1.83, 95CI: 1.08-3.13 for smoking longer than 31 years, and 0.1>p>0.05 for trends for the number of cigarettes per day, smoking duration and pack-years. In conclusion, no links between night shift work and methylation of the promoter region within the BRCA1, and BRCA2 genes were observed in this exploratory analysis. The findings of our study weakly support the hypothesis that smoking may contribute to epigenetic events.
C1 [Peplonska, Beata; Bukowska, Agnieszka] Nofer Inst Occupat Med, Dept Environm Epidemiol, Lodz, Poland.
   [Wieczorek, Edyta; Przybek, Monika; Reszka, Edyta] Nofer Inst Occupat Med, Dept Mol Genet & Epigenet, Lodz, Poland.
   [Zienolddiny, Shanbeh] Natl Inst Occupat Hlth, Oslo, Norway.
C3 Nofer Institute of Occupational Medicine; Nofer Institute of
   Occupational Medicine
RP Peplonska, B (通讯作者)，Nofer Inst Occupat Med, Dept Environm Epidemiol, Lodz, Poland.
EM beatap@imp.lodz.pl
RI Peplonska, Beata/AAO-1265-2020; Bukowska, Agnieszka/G-4906-2010;
   Zienolddiny, Shanbeh/O-7392-2015; Lesicka, Monika/G-7673-2015;
   Kasperczyk, Edyta/F-7057-2010; Reszka, Edyta/F-6008-2010
OI Lesicka, Monika/0000-0003-2095-8681; Kasperczyk,
   Edyta/0000-0002-4390-2042; Reszka, Edyta/0000-0003-2153-4864;
   Zienolddiny-Narui, Shan/0000-0001-9747-9625; Bukowska-Damska,
   Agnieszka/0000-0002-3223-6750; Peplonska, Beata/0000-0003-3915-2872
FU Norway Grants, under the Polish-Norwegian Research Programme
   [PNRF-243-AI-1/07, Pol-Nor/196940/22/2013-clockshift]
FX This project was supported by the Norway Grants, under the
   Polish-Norwegian Research Programme (Grant no. PNRF-243-AI-1/07 and
   Pol-Nor/196940/22/2013-clockshift) (BP). The funders had no role in
   study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Amani R, 2013, ASIA PAC J CLIN NUTR, V22, P505, DOI 10.6133/apjcn.2013.22.4.11
   Benbrahim-Tallaa L, 2007, ENVIRON HEALTH PERSP, V115, P1454, DOI 10.1289/ehp.10207
   Bhatti P, 2015, CHRONOBIOL INT, V32, P103, DOI 10.3109/07420528.2014.956362
   Bollati V, 2010, CHRONOBIOL INT, V27, P1093, DOI 10.3109/07420528.2010.490065
   Breitling LP, 2011, AM J HUM GENET, V88, P450, DOI 10.1016/j.ajhg.2011.03.003
   Bryan AD, 2013, ANN BEHAV MED, V45, P89, DOI 10.1007/s12160-012-9411-4
   Bushnell PT, 2010, IND HEALTH, V48, P395, DOI 10.2486/indhealth.MSSW-03
   Cerda S, 1997, MUTAT RES-REV MUTAT, V386, P141, DOI 10.1016/S1383-5742(96)00050-6
   Cordina-Duverger E, 2016, CHRONOBIOL INT, V33, P783, DOI 10.3109/07420528.2016.1167709
   Craig CL, 2003, MED SCI SPORT EXER, V35, P1381, DOI 10.1249/01.MSS.0000078924.61453.FB
   Cuozzo C, 2007, PLOS GENET, V3, P1144, DOI 10.1371/journal.pgen.0030110
   Davis S, 2012, CANCER EPIDEM BIOMAR, V21, P609, DOI 10.1158/1055-9965.EPI-11-1128
   de Assis MAA, 2003, APPETITE, V40, P175, DOI 10.1016/S0195-6663(02)00133-2
   De Bacquer D, 2009, INT J EPIDEMIOL, V38, P848, DOI 10.1093/ije/dyn360
   DeMarini DM, 2004, MUTAT RES-REV MUTAT, V567, P447, DOI 10.1016/j.mrrev.2004.02.001
   Dick KJ, 2014, LANCET, V383, P1990, DOI 10.1016/S0140-6736(13)62674-4
   Eads CA, 2000, NUCLEIC ACIDS RES, V28, DOI 10.1093/nar/28.8.e32
   Farré P, 2015, EPIGENET CHROMATIN, V8, DOI 10.1186/s13072-015-0011-y
   Fritschi L, 2011, MED HYPOTHESES, V77, P430, DOI 10.1016/j.mehy.2011.06.002
   Fu DY, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000000637
   Gao X, 2015, CLIN EPIGENETICS, V7, DOI 10.1186/s13148-015-0148-3
   Gaudet MM., 2016, Int J Epidemiol
   Geliebter A, 2000, NUTRITION, V16, P27, DOI 10.1016/S0899-9007(99)00228-2
   Ha K, 2011, HUM MOL GENET, V20, P126, DOI 10.1093/hmg/ddq451
   Hansen ÅM, 2006, CHRONOBIOL INT, V23, P1203, DOI 10.1080/07420520601100955
   Hansen J, 2012, EUR J CANCER, V48, P1722, DOI 10.1016/j.ejca.2011.07.005
   Hardy TM, 2011, EPIGENOMICS-UK, V3, P503, DOI [10.2217/EPI.11.71, 10.2217/epi.11.71]
   Harlid S, 2014, ENVIRON HEALTH PERSP, V122, P673, DOI 10.1289/ehp.1307480
   Hoffman AE, 2010, CANCER PREV RES, V3, P539, DOI 10.1158/1940-6207.CAPR-09-0127
   Hoffman AE, 2010, CANCER RES, V70, P1459, DOI 10.1158/0008-5472.CAN-09-3798
   Ijaz S, 2013, SCAND J WORK ENV HEA, V39, P431, DOI 10.5271/sjweh.3371
   Jacobs DI, 2013, ENVIRON MOL MUTAGEN, V54, P141, DOI 10.1002/em.21752
   James FR, 2015, EUR J CANCER, V51, P705, DOI 10.1016/j.ejca.2015.01.057
   KAWACHI I, 1995, CIRCULATION, V92, P3178, DOI 10.1161/01.CIR.92.11.3178
   Kivimäki M, 2001, WORK STRESS, V15, P3, DOI 10.1080/02678370118685
   Knutsson A, 1998, SCAND J SOC MED, V26, P183, DOI 10.1177/14034948980260030801
   Kochan DZ, 2016, CELL CYCLE, V15, P613, DOI 10.1080/15384101.2015.1131526
   Le Gac G, 2006, J BIOL CHEM, V281, P24161, DOI 10.1074/jbc.M603724200
   Lee Ken W. K., 2013, Frontiers in Genetics, V4, P132, DOI 10.3389/fgene.2013.00132
   Liu F, 2010, ONCOGENE, V29, P3650, DOI 10.1038/onc.2010.129
   Liu R, 2015, CANCER CAUSE CONTROL, V26, P171, DOI 10.1007/s10552-014-0494-z
   McCullough L.E., 2015, Int. J. Cancer Clin. Res, V2, P013, DOI [10.23937/2378-3419/2/1/1013, DOI 10.23937/2378-3419/2/1/1013, DOI 10.23937/2378-3419/2/1/1013)]
   Morikawa Y, 2007, SCAND J WORK ENV HEA, V33, P45, DOI 10.5271/sjweh.1063
   Mortusewicz O, 2005, P NATL ACAD SCI USA, V102, P8905, DOI 10.1073/pnas.0501034102
   Nakamura K, 1997, OCCUP MED-OXFORD, V47, P142, DOI 10.1093/occmed/47.3.142
   Naushad SM, 2014, MOL CELL BIOCHEM, V392, P273, DOI 10.1007/s11010-014-2037-z
   Oesterreich S, 1999, ENDOCR-RELAT CANCER, V6, P405, DOI 10.1677/erc.0.0060405
   Opperhuizen AL, 2015, FRONT PHARMACOL, V6, DOI 10.3389/fphar.2015.00050
   Ottini L, 2015, MUTAT RES-GEN TOX EN, V779, P57, DOI 10.1016/j.mrgentox.2015.01.006
   Papantoniou K, 2016, EUR J EPIDEMIOL, V31, P867, DOI 10.1007/s10654-015-0073-y
   Peplonska B, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133761
   Peplonska B, 2014, CHRONOBIOL INT, V31, P1152, DOI 10.3109/07420528.2014.957296
   Peplonska B, 2012, OCCUP ENVIRON MED, V69, P339, DOI 10.1136/oemed-2011-100273
   Pietroiusti A, 2010, OCCUP ENVIRON MED, V67, P54, DOI 10.1136/oem.2009.046797
   Reynolds P, 2013, J MAMMARY GLAND BIOL, V18, P15, DOI 10.1007/s10911-012-9269-x
   Rice JC, 1998, ONCOGENE, V17, P1807, DOI 10.1038/sj.onc.1202086
   Rosen EM, 2003, J CELL PHYSIOL, V196, P19, DOI 10.1002/jcp.10257
   Saksvik-Lehouillier I, 2013, J ADV NURS, V69, P1136, DOI 10.1111/j.1365-2648.2012.06105.x
   Schernhammer ES, 2006, J PINEAL RES, V40, P116, DOI 10.1111/j.1600-079X.2005.00285.x
   Schernhammer ES, 2006, EPIDEMIOLOGY, V17, P108, DOI 10.1097/01.ede.0000190539.03500.c1
   Schernhammer ES, 2004, CANCER EPIDEM BIOMAR, V13, P936
   Sharma G, 2007, LIFE SCI, V80, P1873, DOI 10.1016/j.lfs.2007.02.026
   Shenker NS, 2013, HUM MOL GENET, V22, P843, DOI 10.1093/hmg/dds488
   Shi FQ, 2013, ENVIRON MOL MUTAGEN, V54, P406, DOI 10.1002/em.21790
   Shield KD, 2016, ALCOHOL CLIN EXP RES, V40, P1166, DOI 10.1111/acer.13071
   Smith CJ, 2000, FOOD CHEM TOXICOL, V38, P637, DOI 10.1016/S0278-6915(00)00051-X
   Stewart B., 2015, World cancer report 2014
   Straif K, 2007, LANCET ONCOL, V8, P1065, DOI 10.1016/S1470-2045(07)70373-X
   Sturgeon SR, 2014, ANTICANCER RES, V34, P2985
   Sun YV, 2013, HUM GENET, V132, P1027, DOI 10.1007/s00439-013-1311-6
   Szwiec M, 2015, CLIN GENET, V87, P288, DOI 10.1111/cge.12360
   SZYF M, 1991, BIOCHEM CELL BIOL, V69, P764, DOI 10.1139/o91-117
   Talens RP, 2010, FASEB J, V24, P3135, DOI 10.1096/fj.09-150490
   Tang QQ, 2016, CLIN EPIGENETICS, V8, DOI 10.1186/s13148-016-0282-6
   Trinkoff AM, 1998, AM J IND MED, V34, P266, DOI 10.1002/(SICI)1097-0274(199809)34:3<266::AID-AJIM9>3.0.CO;2-T
   Tsaprouni LG, 2014, EPIGENETICS-US, V9, P1382, DOI 10.4161/15592294.2014.969637
   van Amelsvoort LGMP, 1999, INT J OBESITY, V23, P973, DOI 10.1038/sj.ijo.0801028
   van Amelsvoort LGPM, 2004, J OCCUP ENVIRON MED, V46, P699, DOI 10.1097/01.jom.0000131794.83723.45
   van Drongelen A, 2011, SCAND J WORK ENV HEA, V37, P263, DOI 10.5271/sjweh.3143
   Voisin S, 2015, ACTA PHYSIOL, V213, P39, DOI 10.1111/apha.12414
   Wang F, 2013, ANN ONCOL, V24, P2724, DOI 10.1093/annonc/mdt283
   Wang XS, 2012, SCAND J WORK ENV HEA, V38, P590, DOI 10.5271/sjweh.3313
   White AJ, 2016, ENVIRON RES, V145, P93, DOI 10.1016/j.envres.2015.11.033
   Wong EM, 2011, CANCER PREV RES, V4, P23, DOI 10.1158/1940-6207.CAPR-10-0212
   Zeilinger S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063812
   Zhang B, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028882
   Zhang FF, 2011, EPIGENETICS-US, V6, P293, DOI 10.4161/epi.6.3.14378
   Zhao I, 2012, J OCCUP ENVIRON MED, V54, P834, DOI 10.1097/JOM.0b013e31824e1058
   Zhao I, 2012, J OCCUP ENVIRON MED, V54, P525, DOI 10.1097/JOM.0b013e31824e1073
   Zhu Y, 2011, CHRONOBIOL INT, V28, P852, DOI 10.3109/07420528.2011.618896
NR 90
TC 13
Z9 13
U1 0
U2 19
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 8
PY 2017
VL 12
IS 6
AR e0178792
DI 10.1371/journal.pone.0178792
PG 19
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA EX0PL
UT WOS:000402923200051
PM 28594926
OA gold, Green Published, Green Submitted
DA 2025-01-12
ER

PT J
AU Yang, Y
   Yin, W
   Wu, FY
   Fan, J
AF Yang, Yang
   Yin, Wei
   Wu, Fengying
   Fan, Jiang
TI Combination of azacitidine and trichostatin A decreased the tumorigenic
   potential of lung cancer cells
SO ONCOTARGETS AND THERAPY
LA English
DT Article
DE lung cancer; epigenetic inhibitor; azacitidine (5-AZA); trichostatin A
ID DNA METHYLATION; BREAST-CANCER; PROMOTER HYPERMETHYLATION;
   GENE-EXPRESSION; ADENOCARCINOMA; CHEMOTHERAPY; INHIBITION; EXPOSURE;
   RASSF1A
AB Purpose: This study aims to investigate the possibility of using epigenetic inhibitors against lung cancer.
   Methods: The changes in the proliferation of human lung cancer cells, NCI-H1975 and NCI-H1299 cells, treated with various doses of inhibitors of DNA methyltransferase (azacitidine [5-AZA]) or histone deacetylase inhibitors (trichostatin A [TSA]) were determined by cell counting. The cell viability of NCI-H1975 and NCI-H1299 cells treated with 5-AZA and/or TSA was measured by the MTT assay. The changes in expression of the AKT signaling pathway molecules caused by the application of 5-AZA and TSA were analyzed through their protein and mRNA levels. A xenograft model was used to observe the effects of 5-AZA and TSA on tumor growth in vivo.
   Results: 5-AZA and TSA inhibited the proliferation and viability of NCI-H1975 and NCI-H1299 cells. Their joint application significantly influenced the expression of key molecules in AKT signaling pathway in vitro, and inhibited the growth of xenograft tumors in vivo. Furthermore, TSA and 5-AZA decreased the tumorigenic ability of NCI-H1975 cells in vivo.
   Conclusion: The decreased cell viability and tumorigenic ability, as well as increased antioncogene expression following the joint application of 5-AZA and TSA, make these epigenetic inhibitors prospective therapeutic agents for lung cancer.
C1 [Yang, Yang; Fan, Jiang] Tongji Univ, Shanghai Pulm Hosp, Dept Thorac Surg, 507 Zhengmin Rd, Shanghai 200433, Peoples R China.
   [Yin, Wei] Wuhan Univ, Hosp Stomatol, Minist Educ, Key Lab Oral Biomed Engn,Sch Stomatol, Wuhan, Peoples R China.
   [Wu, Fengying] Tongji Univ, Shanghai Pulm Hosp, Oncol Dept, Shanghai, Peoples R China.
C3 Tongji University; Wuhan University; Tongji University
RP Fan, J (通讯作者)，Tongji Univ, Shanghai Pulm Hosp, Dept Thorac Surg, 507 Zhengmin Rd, Shanghai 200433, Peoples R China.
EM drjiangfan@yahoo.com
RI Yin, Wei/ABG-6507-2021; Yang, Yang/JNS-9196-2023; Wu,
   fengying/AAR-9996-2021
FU National Natural Scientific Foundation of China [81370107, 81602412,
   81501750]; Natural Scientific Foundation of Shanghai Municipal
   Commission of Health and Family Planning [20134279]; Shanghai Municipal
   Commission of Health and Family Planning [20164Y0121]; Science and
   Technology Commission of Shanghai Municipality [134119b1002]
FX This work was supported by grants from the National Natural Scientific
   Foundation of China (81370107, 81602412, and 81501750), the Natural
   Scientific Foundation of Shanghai Municipal Commission of Health and
   Family Planning (20134279), the Scientific Research Project of Shanghai
   Municipal Commission of Health and Family Planning (20164Y0121), and the
   Scientific Research Project of Science and Technology Commission of
   Shanghai Municipality (134119b1002). The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR [Anonymous], 2014, Cent Eur J Public Health, V22, P28
   Avraham A, 2012, INT J CANCER, V131, pE1166, DOI 10.1002/ijc.27526
   Barrow TM, 2014, BIOCHEM BIOPH RES CO, V455, P70, DOI 10.1016/j.bbrc.2014.08.002
   Bartling B, 2005, LUNG CANCER-J IASLC, V49, P145, DOI 10.1016/j.lungcan.2005.02.006
   Buhmeida A, 2011, ANTICANCER RES, V31, P2975
   Capobianco E, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095596
   Cho YH, 2012, BREAST CANCER RES TR, V131, P197, DOI 10.1007/s10549-011-1712-y
   Davidson B, 2012, HUM PATHOL, V43, P684, DOI 10.1016/j.humpath.2011.06.015
   Dawson MA, 2011, NATURE, V478, P529, DOI 10.1038/nature10509
   Delmore JE, 2011, CELL, V146, P903, DOI 10.1016/j.cell.2011.08.017
   Dietrich D, 2012, DIAGN MOL PATHOL, V21, P93, DOI 10.1097/PDM.0b013e318240503b
   Esteller M, 2007, NAT REV GENET, V8, P286, DOI 10.1038/nrg2005
   Fenaux P, 2009, LANCET ONCOL, V10, P223, DOI 10.1016/S1470-2045(09)70003-8
   Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9
   Herceg Z, 2011, EPIGENETICS-US, V6, P804, DOI 10.4161/epi.6.7.16262
   Hotta K, 2004, J CLIN ONCOL, V22, P3860, DOI 10.1200/JCO.2004.01.153
   Hou LF, 2014, ENVIRON MOL MUTAGEN, V55, P256, DOI 10.1002/em.21829
   Juergens RA, 2011, CANCER DISCOV, V1, P598, DOI 10.1158/2159-8290.CD-11-0214
   Karlsson A, 2014, CLIN CANCER RES, V20, P6127, DOI 10.1158/1078-0432.CCR-14-1087
   Kjellev S, 2009, CELL MOL LIFE SCI, V66, P1350, DOI 10.1007/s00018-008-8646-5
   Ko E, 2013, CLIN CANCER RES, V19, P1204, DOI 10.1158/1078-0432.CCR-12-2848
   Langevin SM, 2015, TRANSL RES, V165, P74, DOI 10.1016/j.trsl.2014.03.001
   Lin Q, 2009, J CANCER RES CLIN, V135, P1675, DOI 10.1007/s00432-009-0614-4
   Lyn-Cook L, 2014, TOB INDUC DIS, V12, DOI 10.1186/1617-9625-12-15
   Marsit CJ, 2006, CARCINOGENESIS, V27, P112, DOI 10.1093/carcin/bgi172
   Nakagawa M, 2007, ONCOL REP, V18, P769
   Pandey M, 2014, TOXICOL APPL PHARM, V280, P296, DOI 10.1016/j.taap.2014.08.015
   Rauch TA, 2008, P NATL ACAD SCI USA, V105, P252, DOI 10.1073/pnas.0710735105
   Raynal NJM, 2012, CANCER RES, V72, P1170, DOI 10.1158/0008-5472.CAN-11-3248
   Shenker NS, 2013, EPIDEMIOLOGY, V24, P712, DOI 10.1097/EDE.0b013e31829d5cb3
   Yang M, 2010, MODERN PATHOL, V23, P654, DOI 10.1038/modpathol.2010.38
NR 31
TC 4
Z9 4
U1 0
U2 12
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178-6930
J9 ONCOTARGETS THER
JI OncoTargets Ther.
PY 2017
VL 10
BP 2993
EP 2999
DI 10.2147/OTT.S136218
PG 7
WC Biotechnology & Applied Microbiology; Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Oncology
GA EX4SR
UT WOS:000403225600001
PM 28652781
OA gold, Green Published, Green Submitted
DA 2025-01-12
ER

PT J
AU Xu, HY
   Xiao, Q
   Fan, Y
   Xiang, TX
   Li, C
   Li, CH
   Li, SM
   Hui, TL
   Zhang, L
   Li, HZ
   Li, LL
   Ren, GS
AF Xu, Hongying
   Xiao, Qian
   Fan, Yu
   Xiang, Tingxiu
   Li, Chen
   Li, Chunhong
   Li, Shuman
   Hui, Tianli
   Zhang, Lu
   Li, Hongzhong
   Li, Lili
   Ren, Guosheng
TI Epigenetic silencing of <i>ADAMTS18</i> promotes cell migration and
   invasion of breast cancer through AKT and NF-κB signaling
SO CANCER MEDICINE
LA English
DT Article
DE ADAMTS18; cancer; metastasis; methylation; tumor suppressor
ID EPITHELIAL-MESENCHYMAL TRANSITION; TUMOR-SUPPRESSOR; METALLOPROTEASE;
   EXPRESSION; MULTIPLE; PATHWAY; FAMILY; NASOPHARYNGEAL; METHYLATION;
   DISINTEGRIN
AB ADAMTS18 dysregulation plays an important role in many disease processes including cancer. We previously found ADAMTS18 as frequently methylated tumor suppressor gene (TSG) for multiple carcinomas, however, its biological functions and underlying molecular mechanisms in breast carcinogenesis remain unknown. Here, we found that ADAMTS18 was silenced or downregulated in breast cancer cell lines. ADAMTS18 was reduced in primary breast tumor tissues as compared with their adjacent noncancer tissues. ADAMTS18 promoter methylation was detected in 70.8% of tumor tissues by methylation-specific PCR, but none of the normal tissues. Demethylation treatment restored ADAMTS18 expression in silenced breast cell lines. Ectopic expression of ADAMTS18 in breast tumor cells resulted in inhibition of cell migration and invasion. Nude mouse model further confirmed that ADAMTS18 suppressed breast cancer metastasis in vivo. Further mechanistic studies showed that ADAMTS18 suppressed epithelial-mesenchymal transition (EMT), further inhibited migration and invasion of breast cancer cells. ADAMT18 deregulated AKT and NF-kappa B signaling, through inhibiting phosphorylation levels of AKT and p65. Thus, ADAMTS18 as an antimetastatic tumor suppressor antagonizes AKT and NF-kappa B signaling in breast tumorigenesis. Its methylation could be a potential tumor biomarker for breast cancer.
C1 [Xu, Hongying; Xiao, Qian; Fan, Yu; Xiang, Tingxiu; Li, Shuman; Hui, Tianli; Zhang, Lu; Li, Hongzhong; Ren, Guosheng] Chongqing Med Univ, Affiliated Hosp 1, Chongqing Key Lab Mol Oncol & Epigenet, Chongqing, Peoples R China.
   [Li, Chen; Li, Lili] Chinese Univ Hong Kong, Sir YK Pao Ctr Canc, State Key Lab Oncol South China, Canc Epigenet Lab,Dept Clin Oncol, Hong Kong, Hong Kong, Peoples R China.
   [Li, Chen; Li, Lili] Chinese Univ Hong Kong, CUHK Shenzhen Res Inst, Li Ka Shing Inst Hlth Sci, Hong Kong, Hong Kong, Peoples R China.
   [Li, Chunhong] Suining Ctr Hosp, Dept Oncol, Suining, Peoples R China.
C3 Chongqing Medical University; State Key Lab Oncology South China;
   Chinese University of Hong Kong; Chinese University of Hong Kong; CUHK
   Shenzhen Research Institute
RP Ren, GS (通讯作者)，Chongqing Med Univ, Affiliated Hosp 1, Chongqing, Peoples R China.; Li, LL (通讯作者)，Chinese Univ Hong Kong, Sir YK Pao Ctr Canc, Dept Clin Oncol, Rm 315, Hong Kong, Hong Kong, Peoples R China.
EM lili_li@cuhk.edu.hk; rengs726@126.com
RI Shan-Shan, Li/Q-9503-2017; xiao, qian/IWM-0785-2023; Xiang,
   Tingxiu/E-6157-2016; Li, Lili/Q-5750-2018
OI Li, Lili/0000-0002-0292-5889
FU National Natural Science Foundation [81372898, 81172582, 31420103915,
   81572327]; VC special - Chinese University of Hong Kong
FX This study was supported by grants from National Natural Science
   Foundation (#81372898, #81172582, #31420103915, #81572327) and VC
   special fund from The Chinese University of Hong Kong.
CR [Anonymous], N ENGL J MED
   Baylin SB, 2006, NAT REV CANCER, V6, P107, DOI 10.1038/nrc1799
   Cal S, 2002, GENE, V283, P49, DOI 10.1016/S0378-1119(01)00861-7
   Choi GCG, 2014, MOL CANCER RES, V12, P228, DOI 10.1158/1541-7786.MCR-13-0195
   Du W, 2013, ONCOGENE, V32, P3319, DOI 10.1038/onc.2012.359
   Feng XL, 2011, MOL CELL BIOL, V31, P3457, DOI 10.1128/MCB.05523-11
   Georgiadis KE, 1999, GENOMICS, V62, P312, DOI 10.1006/geno.1999.6014
   Iwatsuki M, 2010, CANCER SCI, V101, P293, DOI 10.1111/j.1349-7006.2009.01419.x
   Jin H, 2007, ONCOGENE, V26, P7490, DOI 10.1038/sj.onc.1210559
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   Julien S, 2007, ONCOGENE, V26, P7445, DOI 10.1038/sj.onc.1210546
   Kuno K, 1997, J BIOL CHEM, V272, P556, DOI 10.1074/jbc.272.1.556
   Larue L, 2005, ONCOGENE, V24, P7443, DOI 10.1038/sj.onc.1209091
   Li CH, 2015, AM J CANCER RES, V5, P1635
   Li LL, 2010, CLIN CANCER RES, V16, P2949, DOI 10.1158/1078-0432.CCR-09-3178
   Saegusa M, 2009, AM J PATHOL, V174, P2107, DOI 10.2353/ajpath.2009.081018
   Sizemore N, 2002, J BIOL CHEM, V277, P3863, DOI 10.1074/jbc.M110572200
   Tao Q, 2002, HUM MOL GENET, V11, P2091, DOI 10.1093/hmg/11.18.2091
   Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262
   Viloria CG, 2009, CANCER RES, V69, P4926, DOI 10.1158/0008-5472.CAN-08-4155
   Wei JL, 2014, FRONT BIOSCI-LANDMRK, V19, P1456, DOI 10.2741/4296
   Xiang TX, 2016, ONCOTARGET, V7, P70924, DOI 10.18632/oncotarget.12341
   Xiang TX, 2013, J CELL MOL MED, V17, P1236, DOI 10.1111/jcmm.12099
   Xiang TX, 2010, CANCER BIOL THER, V10, DOI 10.4161/cbt.10.5.12726
   Xu B, 2015, INT J MOL SCI, V16, P1051, DOI 10.3390/ijms16011051
   Yin XD, 2016, ONCOTARGET, V7, P51720, DOI 10.18632/oncotarget.10102
   Yin XD, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3399
   Ying J, 2006, ONCOGENE, V25, P1070, DOI 10.1038/sj.onc.1209154
NR 28
TC 26
Z9 28
U1 0
U2 8
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2045-7634
J9 CANCER MED-US
JI Cancer Med.
PD JUN
PY 2017
VL 6
IS 6
BP 1399
EP 1408
DI 10.1002/cam4.1076
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA EX1ZA
UT WOS:000403024100024
PM 28503860
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Toth, R
   Scherer, D
   Kelemen, LE
   Risch, A
   Hazra, A
   Balavarca, Y
   Issa, JPJ
   Moreno, V
   Eeles, RA
   Ogino, S
   Wu, XF
   Ye, YQ
   Hung, RJ
   Goode, EL
   Ulrich, CM
AF Toth, Reka
   Scherer, Dominique
   Kelemen, Linda E.
   Risch, Angela
   Hazra, Aditi
   Balavarca, Yesilda
   Issa, Jean-Pierre J.
   Moreno, Victor
   Eeles, Rosalind A.
   Ogino, Shuji
   Wu, Xifeng
   Ye, Yuanqing
   Hung, Rayjean J.
   Goode, Ellen L.
   Ulrich, Cornelia M.
CA OCAC
   CORECT
   TRICL
   ELLIPSE
   DRIVE
   GAME-ON Consortia
TI Genetic Variants in Epigenetic Pathways and Risks of Multiple Cancers in
   the GAME-ON Consortium
SO CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
LA English
DT Article
ID GENOME-WIDE ASSOCIATION; BREAST-CANCER; SUSCEPTIBILITY LOCI; COLORECTAL
   TUMORS; IDENTIFIES 2; METAANALYSIS; REPLICATION; REGULATORS; PATTERNS;
   MUTATION
AB Background: Epigenetic disturbances are crucial in cancer initiation, potentially with pleiotropic effects, and may be influenced by the genetic background.
   Methods: In a subsets (ASSET) meta-analytic approach, we investigated associations of genetic variants related to epigenetic mechanisms with risks of breast, lung, colorectal, ovarian and prostate carcinomas using 51,724 cases and 52,001 controls. False discovery rate-corrected P values (q values < 0.05) were considered statistically significant.
   Results: Among 162,887 imputed or genotyped variants in 555 candidate genes, SNPs in eight genes were associated with risk of more than one cancer type. For example, variants in BABAM1 were confirmed as a susceptibility locus for squamous cell lung, overall breast, estrogen receptor (ER)-negative breast, and overall prostate, and overall serous ovarian cancer; the most significant variant was rs4808076 [OR = 1.14; 95% confidence interval (CI) = 1.101.19; q = 6.87 x 10(-5)]. DPF1 rs12611084 was inversely associated with ER-negative breast, endometrioid ovarian, and overall and aggressive prostate cancer risk (OR = 0.93; 95% CI = 0.91-0.96; q = 0.005). Variants in L3MBTL3 were associated with colorectal, overall breast, ER-negative breast, clear cell ovarian, and overall and aggressive prostate cancer risk (e.g., rs9388766: OR = 1.06; 95% CI = 1.03-1.08; q = 0.02). Variants in TET2 were significantly associated with overall breast, overall prostate, overall ovarian, and endometrioid ovarian cancer risk, with rs62331150 showing bidirectional effects. Analyses of subpathways did not reveal gene subsets that contributed disproportionately to susceptibility.
   Conclusions: Functional and correlative studies are now needed to elucidate the potential links between germline genotype, epigenetic function, and cancer etiology. (C)2017 AACR.
C1 [Toth, Reka; Scherer, Dominique; Balavarca, Yesilda; Ulrich, Cornelia M.] Natl Ctr Tumor Dis, Heidelberg, Germany.
   [Toth, Reka; Scherer, Dominique; Balavarca, Yesilda; Ulrich, Cornelia M.] German Canc Res Ctr, Heidelberg, Germany.
   [Toth, Reka; Risch, Angela] German Canc Res Ctr, Div Epigen & Canc Risk Factors, Heidelberg, Germany.
   [Scherer, Dominique] Heidelberg Univ, Inst Med Biometry & Informat, Heidelberg, Germany.
   [Kelemen, Linda E.] Med Univ South Carolina, Charleston, SC 29425 USA.
   [Kelemen, Linda E.] Hollings Canc Ctr, Charleston, SC USA.
   [Risch, Angela] Univ Salzburg, Dept Mol Biol, Div Canc Res & Epigenet, Salzburg, Austria.
   [Risch, Angela] Canc Cluster Salzburg, Salzburg, Austria.
   [Risch, Angela] German Ctr Lung Res DZL, TLRC H, Heidelberg, Germany.
   [Hazra, Aditi] Brigham & Womens Hosp, Harvard Med Sch, Harvard TH Chan Sch Publ Hlth, 75 Francis St, Boston, MA 02115 USA.
   [Hazra, Aditi] Brigham & Womens Hosp, Channing Div Network Med, Dept Med, Harvard Med Sch, 75 Francis St, Boston, MA 02115 USA.
   [Issa, Jean-Pierre J.] Temple Univ, Sch Med, Philadelphia, PA 19122 USA.
   [Moreno, Victor] Hosp Llobregat, IDIBELL, Catalan Inst Oncol, Barcelona, Spain.
   [Eeles, Rosalind A.] Inst Canc Res, London, England.
   [Ogino, Shuji] Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA.
   [Ogino, Shuji] Harvard Med Sch, Boston, MA USA.
   [Ogino, Shuji] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
   [Ogino, Shuji] Harvard TH Chan Sch Publ Hlth, Dept Epidemiol, Boston, MA USA.
   [Wu, Xifeng; Ye, Yuanqing] Univ Texas MD Anderson Canc Ctr, Dept Epidemiol, Houston, TX 77030 USA.
   [Hung, Rayjean J.] Mt Sinai Hosp, Lunenfeld Tanenbaum Res Inst, Toronto, ON, Canada.
   [Hung, Rayjean J.] Univ Toronto, Toronto, ON, Canada.
   [Goode, Ellen L.] Mayo Clin, Coll Med, Rochester, MN USA.
   [Ulrich, Cornelia M.] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA.
   [Ulrich, Cornelia M.] Huntsman Canc Inst, 2000 Circle Hope Dr Room 4165, Salt Lake City, UT 84112 USA.
C3 Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht
   Karls University Heidelberg; Helmholtz Association; German Cancer
   Research Center (DKFZ); Helmholtz Association; German Cancer Research
   Center (DKFZ); Ruprecht Karls University Heidelberg; Medical University
   of South Carolina; Salzburg University; Harvard University; Harvard T.H.
   Chan School of Public Health; Brigham & Women's Hospital; Harvard
   Medical School; Harvard University; Brigham & Women's Hospital; Harvard
   Medical School; Pennsylvania Commonwealth System of Higher Education
   (PCSHE); Temple University; University of Barcelona; Institut
   d'Investigacio Biomedica de Bellvitge (IDIBELL); Institut Catala
   d'Oncologia; University of London; Institute of Cancer Research - UK;
   Royal Marsden NHS Foundation Trust; Harvard University; Brigham &
   Women's Hospital; Harvard University; Harvard Medical School; Harvard
   University; Dana-Farber Cancer Institute; Harvard University; Harvard
   T.H. Chan School of Public Health; University of Texas System; UTMD
   Anderson Cancer Center; University of Toronto; Sinai Health System
   Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto;
   Mayo Clinic; Fred Hutchinson Cancer Center; Utah System of Higher
   Education; University of Utah; Huntsman Cancer Institute
RP Ulrich, CM (通讯作者)，Huntsman Canc Inst, 2000 Circle Hope Dr Room 4165, Salt Lake City, UT 84112 USA.
EM Neli.ulrich@hci.utah.edu
RI Huang, Yuqi/HNC-0466-2023; Toth, Reka/AAB-1695-2020; Hung,
   Rayjean/A-7439-2013; Risch, Angela/H-2669-2013; Moreno,
   Victor/A-1697-2010
OI Hung, Rayjean/0000-0002-4486-7496; Toth, Reka/0000-0002-6096-1052; Issa,
   Jean-Pierre/0000-0003-2258-5030; Risch, Angela/0000-0002-8026-5505;
   Eeles, Rosalind/0000-0002-3698-6241; Moreno, Victor/0000-0002-2818-5487;
   Ogino, Shuji/0000-0002-3909-2323
FU TRICL (Transdisciplinary Research for Cancer of Lung); International
   Lung Cancer Consortium (ILCCO) [NIHU19 CA148127-01]; Canadian Cancer
   Society Research Institute [020214]; GAME-ON U19 initiative for prostate
   cancer (ELLIPSE) [U19 CA148537]; Canadian Institutes of Health Research;
   European Commission's Seventh Framework Programme [223175
   (HEALTH-F2-2009-223175)]; Cancer Research UK [C5047/A7357, C1287/A10118,
   C5047/A3354, C5047/A10692, C16913/A6135, C490/A8339, C490/A16561,
   C490/A10119, C490/A10124]; NIH Cancer Post-Cancer GWAS initiative (the
   GAME-ON initiative) [1 U19 CA 148537-01]; Institute of Cancer Research;
   Everyman Campaign; Prostate Action; Orchid Cancer Appeal; National
   Cancer Research Network UK; National Cancer Research Institute (NCRI)
   UK; NIHR; Royal Marsden NHS Foundation Trust; National Health and
   Medical Research Council, Australia [126402, 209057, 251533, 396414,
   450104, 504700, 504702, 504715, 623204, 940394, 614296]; VicHealth;
   Cancer Council Victoria; Prostate Cancer Foundation of Australia;
   Whitten Foundation; PricewaterhouseCoopers; Tattersall's; National Human
   Genome Research Institute; Swedish Cancer Foundation [09-0677, 11-484,
   12-823]; Cancer Risk Prediction Center, a Linneus Centre - Swedish
   Research Council [70867902]; Swedish Research Council
   [K2010-70X-20430-04-3, 2014-2269]; NIH, National Cancer Institute
   [U01-CA98233, U01-CA98710, U01-CA98216, U01-CA98758]; NIH/National
   Cancer Institute, Division of Cancer Epidemiology and Genetics; FOCI
   (Transdisciplinary Cancer Genetic Association and Interacting Studies)
   [NIHU19 CA148112-01, R01-CA122443, P50-CA136393, P30-CA15083]; NIH [P01
   CA087969, UM1 CA186107, R01 CA151993, R35 CA197735, P50 CA127003]; Colon
   CFR [UM1 CA167551]; National Cancer Institute, NIH [U01 CA122839, R01
   CA143237]; Division of Cancer Prevention, National Cancer Institute,
   NIH, Department of Health and Human Services; Division of Cancer
   Epidemiology and Genetics; NIH, Genes, Environment, and Health
   Initiative (GEI) [Z01 CP 010200, NIHU01 HG004446, NIHGEI U01 HG-004438];
   National Cancer Institute, National Institutes of Health, U.S.
   Department of Health and Human Services [U19 CA148107, R01 CA81488, P30
   CA014089]; National Cancer Institute, National Institutes of Health [U19
   CA148107, R01 CA081488]; American Cancer Society; NCI/NIH [UM1 CA167551,
   U01 CA122839, R01 CA143247]; Australasian Colorectal Cancer Family
   Registry [NCI/NIH U01 CA074778, U01/U24 CA097735]; USC
   ConsortiumColorectal Cancer Family Registry [NCI/NIH U01/U24 CA074799];
   Mayo Clinic Cooperative Family Registry for Colon Cancer Studies
   [NCI/NIH U01/U24 CA074800]; Ontario Familial Colorectal Cancer Registry
   [NCI/NIH U01/U24 CA074783]; Seattle Colorectal Cancer Family Registry
   [NCI/NIH U01/U24 CA074794]; University of Hawaii Colorectal Cancer
   Family Registry [NCI/NIH U01/U24 CA074806]; National Cancer Institute
   [HHSN2612013000121, N01-CN-67009, N01-PC-35142]; Hawaii Department of
   Health [HHSN26120100037C, N01-PC-67001, N01-PC-35137]; California
   Department of Public Health [HHSN261201000035C]; Clinical Investigator
   Award from Damon Runyon Cancer Research Foundation [CI-8]; VicHealth and
   Cancer Council Victoria [NCI R01CA136726]; Australian NHMRC [209057,
   509348, 251553, 504711]; Canadian Institutes of Health Research
   [CRT-43821]; DRIVE [NIHU19 CA148065]; CORECT (ColoRectal
   Transdisciplinary Study) [R01 CA81488, P30 CA014089, NIHU19 CA148107];
   Prostate Cancer Research Foundation; Damon Runyon Cancer Research
   Foundation [CI-8];  [NCI U01 CA1817700];  [R01 CA144040]
FX This work was supported by TRICL (Transdisciplinary Research for Cancer
   of Lung) and International Lung Cancer Consortium (ILCCO): NIHU19
   CA148127-01 (principal investigator: Amos), Canadian Cancer Society
   Research Institute (020214, principal investigator: R.J. Hung).DRIVE:
   NIHU19 CA148065. CORECT (ColoRectal Transdisciplinary Study): NIHU19
   CA148107; R01 CA81488, P30 CA014089.ELLIPSE (Elucidating Loci in
   Prostate Cancer Susceptibility): This work was support by the GAME-ON
   U19 initiative for prostate cancer (ELLIPSE), U19 CA148537.CRUK GWAS:
   This work was supported by the Canadian Institutes of Health Research,
   European Commission's Seventh Framework Programme grant agreement no.
   223175 (HEALTH-F2-2009-223175), Cancer Research UK Grants C5047/A7357,
   C1287/A10118, C5047/A3354, C5047/A10692, C16913/A6135, and The NIH
   Cancer Post-Cancer GWAS initiative grant: No. 1 U19 CA 148537-01 (the
   GAME-ON initiative).We would also like to thank the following for
   funding support: The Institute of Cancer Research and The Everyman
   Campaign, The Prostate Cancer Research Foundation, Prostate Research
   Campaign UK (now Prostate Action), The Orchid Cancer Appeal, The
   National Cancer Research Network UK, The National Cancer Research
   Institute (NCRI) UK. We are grateful for support of NIHR funding to the
   NIHR Biomedical Research Centre at The Institute of Cancer Research and
   The Royal Marsden NHS Foundation Trust. The Prostate Cancer Program of
   Cancer Council Victoria also acknowledges grant support from The
   National Health and Medical Research Council, Australia (126402, 209057,
   251533, 396414, 450104, 504700, 504702, 504715, 623204, 940394, 614296),
   VicHealth, Cancer Council Victoria, The Prostate Cancer Foundation of
   Australia, The Whitten Foundation, PricewaterhouseCoopers, and
   Tattersall's. EAO, DMK, and EMK acknowledge the Intramural Program of
   the National Human Genome Research Institute for their support. CAPS
   GWAS study was supported by the Swedish Cancer Foundation (grant no.
   09-0677, 11-484, 12-823), the Cancer Risk Prediction Center (CRisP;
   www.crispcenter.org), a Linneus Centre (contract ID 70867902) financed
   by the Swedish Research Council, and a Swedish Research Council (grant
   no. K2010-70X-20430-04-3, 2014-2269). The BPC3 was supported by the NIH,
   National Cancer Institute (cooperative agreements U01-CA98233 to D.J.H.,
   U01-CA98710 to S.M.G., U01-CA98216 to E.R., and U01-CA98758 to B.E.H.,
   and Intramural Research Program of NIH/National Cancer Institute,
   Division of Cancer Epidemiology and Genetics).FOCI (Transdisciplinary
   Cancer Genetic Association and Interacting Studies): NIHU19 CA148112-01
   (principal investigator: T.A. Sellers), R01-CA122443, P50-CA136393,
   P30-CA15083 (principal investigator: E.L. Goode), Cancer Research UK
   [C490/A8339, C490/A16561, C490/A10119, C490/A10124 (principal
   investigator: P. Pharoah)]. NHS by the NIH (P01 CA087969, UM1 CA186107,
   R01 CA151993, R35 CA197735 and P50 CA127003). The Colon CFR data
   collection was supported by grant UM1 CA167551, and the Colon CFR
   Illumina GWAS was supported by grants U01 CA122839 and R01 CA143237 to
   G. Casey from the National Cancer Institute, NIH.PLCO: Intramural
   Research Program of the Division of Cancer Epidemiology and Genetics and
   supported by contracts from the Division of Cancer Prevention, National
   Cancer Institute, NIH, Department of Health and Human Services. In
   addition, a subset of control samples were genotyped as part of the
   Cancer Genetic Markers of Susceptibility (CGEMS) Prostate Cancer GWAS
   (Yeager M, et al. Nat Genet. 2007; 39(5): 645-649), Colon CGEMS
   pancreatic cancer scan (PanScan; Amundadottir L, et al. Nat Genet. 2009;
   41(9): 986-990 and Petersen GM, et al. Nat Genet. 2010; 42(3): 224-228),
   and the Lung Cancer and Smoking study. The prostate and PanScan study
   datasets were accessed with appropriate approval through the dbGaP
   online resource (http://cgems.cancer.gov/data/) accession numbers
   phs000207.v1.p1 and phs000206.v3.p2, respectively, and the lung datasets
   were accessed from the dbGaP website (http://www.ncbi.nlm.nih.gov/gap)
   through accession number phs000093.v2.p2. Funding for the Lung Cancer
   and Smoking study was provided by NIH, Genes, Environment, and Health
   Initiative (GEI) Z01 CP 010200, NIHU01 HG004446, and NIHGEI U01
   HG-004438. For the lung study, the GENEVA Coordinating Center provided
   assistance with genotype cleaning and general study coordination, and
   the Johns Hopkins University Center for Inherited Disease Research
   conducted genotyping.This work was supported by the National Cancer
   Institute, National Institutes of Health, U.S. Department of Health and
   Human Services (U19 CA148107; R01 CA81488; P30 CA014089). MECC was
   supported by the National Cancer Institute, National Institutes of
   Health under R01 CA081488 and U19 CA148107. The Cancer Prevention
   Study-II Nutrition Cohort is funded by the American Cancer Society. The
   Colon CFR GWAS work was supported by funding from the NCI/NIH (U01
   CA122839 and R01 CA143247). The Colon CFR participant recruitment and
   collection of data and biospecimens used in this study were supported by
   NCI/NIH (UM1 CA167551) and through cooperative agreements with the
   following Colon CFR centers: Australasian Colorectal Cancer Family
   Registry (NCI/NIH U01 CA074778 and U01/U24 CA097735), USC Consortium
   Colorectal Cancer Family Registry (NCI/NIH U01/U24 CA074799), Mayo
   Clinic Cooperative Family Registry for Colon Cancer Studies (NCI/NIH
   U01/U24 CA074800), Ontario Familial Colorectal Cancer Registry (NCI/NIH
   U01/U24 CA074783), Seattle Colorectal Cancer Family Registry (NCI/NIH
   U01/U24 CA074794), and University of Hawaii Colorectal Cancer Family
   Registry (NCI/NIH U01/U24 CA074806). Additional support for case
   ascertainment was provided from the Surveillance, Epidemiology and End
   Results (SEER) Program of the National Cancer Institute to Fred
   Hutchinson Cancer Research Center (Control Nos. N01-CN-67009 and
   N01-PC-35142, and Contract No. HHSN2612013000121), the Hawaii Department
   of Health (Control Nos. N01-PC-67001 and N01-PC-35137, and Contract No.
   HHSN26120100037C, and the California Department of Public Health
   (contracts HHSN261201000035C awarded to the University of Southern
   California, and the following state cancer registries: AZ, CO, MN, NC,
   NH, and by the Victoria Cancer Registry and Ontario Cancer Registry).
   The Kentucky Case Control study was supported by the following grants:
   1) Clinical Investigator Award from Damon Runyon Cancer Research
   Foundation (CI-8) and 2) NCI R01CA136726. MCCS cohort recruitment was
   funded by VicHealth and Cancer Council Victoria. The MCCS was further
   supported by Australian NHMRC grants 509348, 209057, 251553 and 504711
   and by infrastructure provided by Cancer Council Victoria. Cases and
   their vital status were ascertained through the Victorian Cancer
   Registry (VCR) and the Australian Institute of Health and Welfare
   (AIHW), including the National Death Index and the Australian Cancer
   Database. The Newfoundland Familial Colorectal Cancer Registry was
   supported by the Canadian Institutes of Health Research grant CRT-43821.
   This work was also supported by NCI U01 CA1817700 (to L. Li) and R01
   CA144040 (to S. Markowitz).
CR Adzhubei IA, 2010, NAT METHODS, V7, P248, DOI 10.1038/nmeth0410-248
   Al Olama AA, 2013, HUM MOL GENET, V22, P408, DOI 10.1093/hmg/dds425
   Allen HL, 2010, NATURE, V467, P832, DOI 10.1038/nature09410
   Antoniou AC, 2010, NAT GENET, V42, P885, DOI 10.1038/ng.669
   Bell D, 2011, NATURE, V474, P609, DOI 10.1038/nature10166
   Berrettine W, 2008, MOL PSYCHIATR, V13, P368, DOI 10.1038/sj.mp.4002154
   Bhattacharjee S, 2012, AM J HUM GENET, V90, P821, DOI 10.1016/j.ajhg.2012.03.015
   Bolton KL, 2010, NAT GENET, V42, P880, DOI 10.1038/ng.666
   Bonasio R, 2010, SEMIN CELL DEV BIOL, V21, P221, DOI 10.1016/j.semcdb.2009.09.010
   Coetzee SG, 2012, NUCLEIC ACIDS RES, V40, DOI 10.1093/nar/gks542
   Eeles RA, 2009, NAT GENET, V41, P1116, DOI 10.1038/ng.450
   Feng L, 2009, GENE DEV, V23, P719, DOI 10.1101/gad.1770609
   Garcia-Closas M, 2013, NAT GENET, V45, P392, DOI 10.1038/ng.2561
   Getz G, 2013, NATURE, V497, P67, DOI 10.1038/nature12113
   Gnad F, 2015, BMC GENOMICS, V16, DOI 10.1186/1471-2164-16-S8-S5
   Goode LL, 2010, NAT GENET, V42, P874, DOI 10.1038/ng.668
   Gudmundsson J, 2009, NAT GENET, V41, P1122, DOI 10.1038/ng.448
   Guo XY, 2015, CANCER EPIDEM BIOMAR, V24, P1680, DOI 10.1158/1055-9965.EPI-15-0363
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Hinoue T, 2012, GENOME RES, V22, P271, DOI 10.1101/gr.117523.110
   Hoffman Michael M, 2013, Nucleic Acids Res, V41, P827, DOI 10.1093/nar/gks1284
   Hung RJ, 2008, NATURE, V452, P633, DOI 10.1038/nature06885
   Hung RJ, 2015, JNCI-J NATL CANCER I, V107, DOI 10.1093/jnci/djv246
   Kadoch C, 2013, NAT GENET, V45, P592, DOI 10.1038/ng.2628
   Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412
   Liu JS, 2004, MODERN PATHOL, V17, P75, DOI 10.1038/modpathol.3800017
   Lynch HT, 2009, MOL ONCOL, V3, P97, DOI 10.1016/j.molonc.2009.02.004
   Michailidou K, 2013, NAT GENET, V45, P353, DOI 10.1038/ng.2563
   Peters U, 2013, GASTROENTEROLOGY, V144, P799, DOI 10.1053/j.gastro.2012.12.020
   Peters U, 2012, HUM GENET, V131, P217, DOI 10.1007/s00439-011-1055-0
   Pharoah PDP, 2013, NAT GENET, V45, P362, DOI 10.1038/ng.2564
   Plass C, 2013, NAT REV GENET, V14, P765, DOI 10.1038/nrg3554
   Rosenbaum J, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2003906
   Saccone SF, 2007, HUM MOL GENET, V16, P36, DOI 10.1093/hmg/ddl438
   Siddiq A, 2012, HUM MOL GENET, V21, P5373, DOI 10.1093/hmg/dds381
   Sim NL, 2012, NUCLEIC ACIDS RES, V40, pW452, DOI 10.1093/nar/gks539
   Song FJ, 2014, CARCINOGENESIS, V35, P2097, DOI 10.1093/carcin/bgu140
   Song HL, 2009, NAT GENET, V41, P996, DOI 10.1038/ng.424
   Stevens KN, 2012, CANCER RES, V72, P1795, DOI 10.1158/0008-5472.CAN-11-3364
   Timofeeva MN, 2012, HUM MOL GENET, V21, P4980, DOI 10.1093/hmg/dds334
   Toyota M, 2000, P NATL ACAD SCI USA, V97, P710, DOI 10.1073/pnas.97.2.710
   Wirén S, 2014, CANCER CAUSE CONTROL, V25, P151, DOI 10.1007/s10552-013-0317-7
   Witte T, 2014, GENOME MED, V6, DOI 10.1186/s13073-014-0066-6
   Wu R, 2001, CANCER RES, V61, P8247
   Zeller T, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010693
NR 45
TC 13
Z9 13
U1 0
U2 4
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1055-9965
EI 1538-7755
J9 CANCER EPIDEM BIOMAR
JI Cancer Epidemiol. Biomarkers Prev.
PD JUN
PY 2017
VL 26
IS 6
BP 816
EP 825
DI 10.1158/1055-9965.EPI-16-0728
PG 10
WC Oncology; Public, Environmental & Occupational Health
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Public, Environmental & Occupational Health
GA EW8JS
UT WOS:000402765600002
PM 28115406
OA Green Submitted, Bronze, Green Accepted
DA 2025-01-12
ER

PT J
AU Kim, JT
   Weiss, HL
   Evers, BM
AF Kim, Ji Tae
   Weiss, Heidi L.
   Evers, B. Mark
TI Diverse expression patterns and tumorigenic role of neurotensin
   signaling components in colorectal cancer cells
SO INTERNATIONAL JOURNAL OF ONCOLOGY
LA English
DT Article
DE CRC cells; neurotensin receptor; promoter methylation; cell growth;
   migration
ID DNA METHYLATION CONTRIBUTES; RECEPTOR 1; CATENIN PATHWAY; BREAST-CANCER;
   IN-VITRO; IDENTIFICATION; PROGRESSION; TARGET; GROWTH
AB Colorectal cancer (CRC), which is one of the most common malignancies worldwide, results from an accumulation of genetic and epigenetic modifications including DNA methylation. Neurotensin (NTS), a hormone localized to the gut and central nervous system, mediates its physiological and pathological effects, including growth stimulation for a variety of cancers, through three distinct NTS receptors (NTSRs). Most NTS functions are mediated through the high-affinity receptor NTSR1, and expression of NTSR1 is increased in many cancers including CRC. In this study, we investigated the expression profiles and cellular functions of the NTSRs, especially NTSR1, in CRC cells. We showed that expression levels for NTS and NTSRI varied, that NTSR2 expression was not detectable and that NTSR3 was consistently expressed in all CRC cell lines examined. Treatment with the demethylating agent, 5-aza-2'-deoxycytidine, augmented levels of NTSR1I2 in Caco2 and DLD1 cells, which have little or no transcripts for NTSR1/2 suggesting that DNA methylation suppresses NTSR1I2 expression. In addition, we demonstrated that knockdown of NTSR1 decreased cell growth and migration in HCT116 and HT29 cells. Finally, we showed that treatment with SR48692, an antagonist of NTSR1, also inhibited cell proliferation and migration in the CRC cells. Our findings identify promoter methylation as an important process regulating the differential expression or silencing of NTSR1I2 in CRC cells. Moreover, inhibition of NTSR1 repressed tumorigenic effects in CRC cells, suggesting that NTSR1 may be used as a therapeutic target for CRC.
C1 [Kim, Ji Tae; Weiss, Heidi L.; Evers, B. Mark] Univ Kentucky, Markey Canc Ctr, 800 Rose St,CC140 Ben F Roach Bldg, Lexington, KY 40536 USA.
   [Evers, B. Mark] Univ Kentucky, Dept Surg, Lexington, KY 40536 USA.
C3 University of Kentucky; University of Kentucky
RP Evers, BM (通讯作者)，Univ Kentucky, Markey Canc Ctr, 800 Rose St,CC140 Ben F Roach Bldg, Lexington, KY 40536 USA.
EM mark.evers@uky.edu
RI Kim, Ji Tae/HMP-4427-2023
FU National Institutes of Health (NIH) [R01 DK112034]; Biostatistical and
   Bioinformatics shared resource facility of the University of Kentucky
   Markey Cancer Center - National Cancer Institute [P30CA177558]
FX We thank Catherine E. Anthony (Markey Cancer Center's Research
   Communications Office, University of Kentucky) for assistance with
   manuscript preparation. This study was supported by National Institutes
   of Health (NIH) grant R01 DK112034 and by the Biostatistical and
   Bioinformatics shared resource facility of the University of Kentucky
   Markey Cancer Center (supported by National Cancer Institute grant
   no.P30CA177558).
CR Alifano M, 2010, CLIN CANCER RES, V16, P4401, DOI 10.1158/1078-0432.CCR-10-0659
   Ashktorab H, 2014, CURR COLORECT CANC R, V10, P425, DOI 10.1007/s11888-014-0245-2
   Dong ZZ, 1998, AM J PHYSIOL-GASTR L, V274, pG535, DOI 10.1152/ajpgi.1998.274.3.G535
   Dong ZZ, 2000, AM J PHYSIOL-GASTR L, V279, pG1139, DOI 10.1152/ajpgi.2000.279.6.G1139
   Dupouy S, 2011, BIOCHIMIE, V93, P1369, DOI 10.1016/j.biochi.2011.04.024
   Dupouy S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004223
   Evers BM, 2006, PEPTIDES, V27, P2424, DOI 10.1016/j.peptides.2006.01.028
   EVERS BM, 1992, ANN SURG, V216, P423, DOI 10.1097/00000658-199210000-00005
   Fearon ER, 2011, ANNU REV PATHOL-MECH, V6, P479, DOI 10.1146/annurev-pathol-011110-130235
   Gui XY, 2008, PEPTIDES, V29, P1609, DOI 10.1016/j.peptides.2008.04.014
   Guo SC, 2015, CLIN EPIGENETICS, V7, DOI 10.1186/s13148-014-0035-3
   Hagihara A, 2004, ONCOGENE, V23, P8705, DOI 10.1038/sj.onc.1207783
   Kalafatakis K, 2011, REGUL PEPTIDES, V170, P7, DOI 10.1016/j.regpep.2011.04.005
   Kerkhoff E, 1998, ONCOGENE, V17, P1457, DOI 10.1038/sj.onc.1202185
   Kim JT, 2015, ONCOTARGET, V6, P26960, DOI 10.18632/oncotarget.4745
   Kim JT, 2015, INT J CANCER, V136, P1475, DOI 10.1002/ijc.29123
   Kim JT, 2013, CARCINOGENESIS, V34, P953, DOI 10.1093/carcin/bgt018
   Li J, 2016, NATURE, V533, P411, DOI 10.1038/nature17662
   Mustain WC, 2011, CURR OPIN ENDOCRINOL, V18, P75, DOI 10.1097/MED.0b013e3283419052
   Ning Y, 2011, INT J CANCER, V128, P2038, DOI 10.1002/ijc.25562
   Servotte S, 2006, NEUROPATH APPL NEURO, V32, P575, DOI 10.1111/j.1365-2990.2006.00760.x
   Shimizu S, 2008, INT J CANCER, V123, P1816, DOI 10.1002/ijc.23710
   Siegel RL, 2015, CA-CANCER J CLIN, V65, P5
   Souazé F, 2006, CARCINOGENESIS, V27, P708, DOI 10.1093/carcin/bgi269
   Souazé F, 2006, CANCER RES, V66, P6243, DOI 10.1158/0008-5472.CAN-06-0450
   Tan AC, 2009, MOL ONCOL, V3, P425, DOI 10.1016/j.molonc.2009.03.004
   Valerie NCK, 2011, CANCER RES, V71, P6817, DOI 10.1158/0008-5472.CAN-11-1646
   Wang L, 2000, CLIN CANCER RES, V6, P566
   Wu Zherui, 2012, Front Endocrinol (Lausanne), V3, P184, DOI 10.3389/fendo.2012.00184
   Zhao DZ, 2003, AM J PHYSIOL-CELL PH, V284, pC1397, DOI 10.1152/ajpcell.00328.2002
NR 30
TC 19
Z9 20
U1 1
U2 6
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1019-6439
EI 1791-2423
J9 INT J ONCOL
JI Int. J. Oncol.
PD JUN
PY 2017
VL 50
IS 6
BP 2200
EP 2206
DI 10.3892/ijo.2017.3990
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA EW7LS
UT WOS:000402692100027
PM 28498396
OA Bronze, Green Published, Green Submitted
DA 2025-01-12
ER

PT J
AU Fahey, CC
   Davis, IJ
AF Fahey, Catherine C.
   Davis, Ian J.
TI SETting the Stage for Cancer Development: SETD2 and the Consequences of
   Lost Methylation
SO COLD SPRING HARBOR PERSPECTIVES IN MEDICINE
LA English
DT Article
ID HISTONE METHYLTRANSFERASE SETD2; LYSINE 36 TRIMETHYLATION; RENAL-CELL
   CARCINOMA; DNA MISMATCH REPAIR; HUMAN BREAST-CANCER; EPIGENETIC
   REGULATORS; DRIVER MUTATIONS; ONCOMETABOLITE 2-HYDROXYGLUTARATE;
   PATHOLOGICAL IMPACT; SET2/RPD3S PATHWAY
AB The H3 lysine 36 histone methyltransferase SETD2 is mutated across a range of human cancers. Although other enzymes can mediate mono- and dimethylation, SETD2 is the exclusive trimethylase. SETD2 associates with the phosphorylated carboxy-terminal domain of RNA polymerase and modifies histones at actively transcribed genes. The functions associated with SETD2 are mediated through multiple effector proteins that bind trimethylated H3K36. These effectors directly mediate multiple chromatin-regulated processes, including RNA splicing, DNAdamage repair, and DNA methylation. Although alterations in each of these processes have been associated with SETD2 loss, the relative role of each in the development of cancer is not fully understood. Critical vulnerabilities resulting from SETD2 loss may offer a strategy for potential therapeutics.
C1 [Fahey, Catherine C.; Davis, Ian J.] Univ North Carolina Chapel Hill, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA.
   [Davis, Ian J.] Univ North Carolina Chapel Hill, Dept Genet, Chapel Hill, NC 27599 USA.
   [Davis, Ian J.] Univ North Carolina Chapel Hill, Dept Pediat, Chapel Hill, NC 27599 USA.
C3 University of North Carolina; University of North Carolina Chapel Hill;
   University of North Carolina School of Medicine; University of North
   Carolina; University of North Carolina Chapel Hill; University of North
   Carolina School of Medicine; University of North Carolina School of
   Medicine; University of North Carolina; University of North Carolina
   Chapel Hill
RP Davis, IJ (通讯作者)，Univ North Carolina Chapel Hill, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA.; Davis, IJ (通讯作者)，Univ North Carolina Chapel Hill, Dept Genet, Chapel Hill, NC 27599 USA.; Davis, IJ (通讯作者)，Univ North Carolina Chapel Hill, Dept Pediat, Chapel Hill, NC 27599 USA.
EM ian_davis@med.unc.edu
OI Fahey, Catherine/0000-0003-4347-361X; Davis, Ian/0000-0002-1552-0960
FU University of North Carolina (UNC) [T32 GM008719-12]; National Research
   Service Award (NRSA) [F30 CA192643-02, R01 CA198482, R01 CA166447]
FX We thank Brian D. Strahl for critical reading and feedback. This project
   is supported by University of North Carolina (UNC) Medical Scientist
   Training Program T32 GM008719-12 and National Research Service Award
   (NRSA) award F30 CA192643-02 (C.C.F.) and R01 CA198482 and R01 CA166447
   (I.J.D.).
CR Al Sarakbi W, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-290
   Awwad SW, 2015, BIOL OPEN, V4, P498, DOI 10.1242/bio.201410991
   Aymard F, 2014, NAT STRUCT MOL BIOL, V21, P366, DOI 10.1038/nsmb.2796
   Bannister AJ, 2005, J BIOL CHEM, V280, P17732, DOI 10.1074/jbc.M500796200
   Bass AJ, 2014, NATURE, V513, P202, DOI 10.1038/nature13480
   Baubec T, 2015, NATURE, V520, P243, DOI 10.1038/nature14176
   Behjati S, 2013, NAT GENET, V45, P1479, DOI 10.1038/ng.2814
   Berger MF, 2012, NATURE, V485, P502, DOI 10.1038/nature11071
   Carrozza MJ, 2005, CELL, V123, P581, DOI 10.1016/j.cell.2005.10.023
   Carvalho S, 2014, ELIFE, V3, DOI 10.7554/eLife.02482
   Carvalho S, 2013, NUCLEIC ACIDS RES, V41, P2881, DOI 10.1093/nar/gks1472
   Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095
   Chowdhury R, 2011, EMBO REP, V12, P463, DOI 10.1038/embor.2011.43
   Collisson EA, 2014, NATURE, V511, P543, DOI 10.1038/nature13385
   Creighton CJ, 2013, NATURE, V499, P43, DOI 10.1038/nature12222
   Dalgliesh GL, 2010, NATURE, V463, P360, DOI 10.1038/nature08672
   Dang L, 2009, NATURE, V462, P739, DOI 10.1038/nature08617
   Daugaard M, 2012, NAT STRUCT MOL BIOL, V19, P803, DOI 10.1038/nsmb.2314
   de Almeida SF, 2011, NAT STRUCT MOL BIOL, V18, P977, DOI 10.1038/nsmb.2123
   Dhayalan A, 2010, J BIOL CHEM, V285, P26114, DOI 10.1074/jbc.M109.089433
   Duns G, 2012, HUM MUTAT, V33, P1059, DOI 10.1002/humu.22090
   Edmunds JW, 2008, EMBO J, V27, P406, DOI 10.1038/sj.emboj.7601967
   Fang D, 2016, SCIENCE, V352, P1344, DOI 10.1126/science.aae0065
   Feng CC, 2015, TUMOR BIOL, V36, P3457, DOI 10.1007/s13277-014-2981-y
   Fnu S, 2011, P NATL ACAD SCI USA, V108, P540, DOI 10.1073/pnas.1013571108
   Fontebasso AM, 2013, ACTA NEUROPATHOL, V125, P659, DOI 10.1007/s00401-013-1095-8
   Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088
   Gao YG, 2014, STRUCTURE, V22, P378, DOI 10.1016/j.str.2013.12.005
   Gerlinger M, 2012, NEW ENGL J MED, V366, P883, DOI 10.1056/NEJMoa1113205
   Getz G, 2013, NATURE, V497, P67, DOI 10.1038/nature12113
   Gossage L, 2014, GENE CHROMOSOME CANC, V53, P38, DOI 10.1002/gcc.22116
   Grosso AR, 2015, ELIFE, V4, DOI 10.7554/eLife.09214
   Guo R, 2014, MOL CELL, V56, P298, DOI 10.1016/j.molcel.2014.08.022
   Hahn MA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018844
   Hakimi AA, 2013, CLIN CANCER RES, V19, P3259, DOI 10.1158/1078-0432.CCR-12-3886
   Hakimi AA, 2013, EUR UROL, V63, P848, DOI 10.1016/j.eururo.2012.09.005
   Ho TH, 2016, ONCOGENE, V35, P1565, DOI 10.1038/onc.2015.221
   Hodis E, 2012, CELL, V150, P251, DOI 10.1016/j.cell.2012.06.024
   Huang KK, 2016, GUT, V65, P1960, DOI 10.1136/gutjnl-2015-309482
   Imielinski M, 2012, CELL, V150, P1107, DOI 10.1016/j.cell.2012.08.029
   Jones S, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6006
   Jung- H, 2015, NAT GENET, V47, P1242, DOI 10.1038/ng.3414
   Kanu N, 2015, ONCOGENE, V34, P5699, DOI 10.1038/onc.2015.24
   Keogh MC, 2005, CELL, V123, P593, DOI 10.1016/j.cell.2005.10.025
   Kim S, 2011, P NATL ACAD SCI USA, V108, P13564, DOI 10.1073/pnas.1109475108
   Kolasinska-Zwierz P, 2009, NAT GENET, V41, P376, DOI 10.1038/ng.322
   Krogan NJ, 2003, MOL CELL BIOL, V23, P4207, DOI 10.1128/MCB.23.12.4207-4218.2003
   Kurotaki N, 2002, NAT GENET, V30, P365, DOI 10.1038/ng863
   Lapunzina P, 2005, AM J MED GENET C, V137C, P53, DOI 10.1002/ajmg.c.30064
   Lee JJ, 2015, CLIN EPIGENETICS, V7, DOI 10.1186/s13148-015-0091-3
   Lewis PW, 2013, SCIENCE, V340, P857, DOI 10.1126/science.1232245
   Ley TJ, 2013, NEW ENGL J MED, V368, P2059, DOI 10.1056/NEJMoa1301689
   Li B, 2003, J BIOL CHEM, V278, P8897, DOI 10.1074/jbc.M212134200
   Li B, 2007, GENE DEV, V21, P1422, DOI 10.1101/gad.1539307
   Li F, 2013, CELL, V153, P590, DOI 10.1016/j.cell.2013.03.025
   Li J, 2016, NEOPLASIA, V18, P339, DOI 10.1016/j.neo.2016.04.005
   Li M, 2005, P NATL ACAD SCI USA, V102, P17636, DOI 10.1073/pnas.0506350102
   Li YY, 2015, CLIN CANCER RES, V21, P1447, DOI 10.1158/1078-0432.CCR-14-1773
   Lickwar CR, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004886
   Linehan WM, 2016, NEW ENGL J MED, V374, P135, DOI 10.1056/NEJMoa1505917
   Liu SY, 2016, MODERN PATHOL, V29, P1012, DOI 10.1038/modpathol.2016.97
   Lu C, 2016, SCIENCE, V352, P844, DOI 10.1126/science.aac7272
   Lu C, 2012, NATURE, V483, P474, DOI 10.1038/nature10860
   Lu PJ, 1999, SCIENCE, V283, P1325, DOI 10.1126/science.283.5406.1325
   Luco RF, 2010, SCIENCE, V327, P996, DOI 10.1126/science.1184208
   Luscan A, 2014, J MED GENET, V51, P512, DOI 10.1136/jmedgenet-2014-102402
   Mar BG, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4469
   Milne TA, 2010, MOL CELL, V38, P853, DOI 10.1016/j.molcel.2010.05.011
   Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252
   Newbold RF, 2010, ANTICANCER RES, V30, P3309
   Parker H, 2016, LEUKEMIA, V30, P2179, DOI 10.1038/leu.2016.134
   Pfister SX, 2015, CANCER CELL, V28, P557, DOI 10.1016/j.ccell.2015.09.015
   Pfister SX, 2014, CELL REP, V7, P2006, DOI 10.1016/j.celrep.2014.05.026
   Pradeepa MM, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002717
   Schwartz S, 2009, NAT STRUCT MOL BIOL, V16, P990, DOI 10.1038/nsmb.1659
   Schwartzentruber J, 2012, NATURE, V482, P226, DOI [10.1038/nature10833, 10.1007/s13311-012-0137-6]
   Seshagiri S, 2012, NATURE, V488, P660, DOI 10.1038/nature11282
   Shain AH, 2015, NAT GENET, V47, P1194, DOI 10.1038/ng.3382
   Simon JM, 2014, GENOME RES, V24, P241, DOI 10.1101/gr.158253.113
   Singh DP, 2000, GENE, V242, P265, DOI 10.1016/S0378-1119(99)00506-5
   Stolle C, 1998, HUM MUTAT, V12, P417, DOI 10.1002/(SICI)1098-1004(1998)12:6<417::AID-HUMU8>3.3.CO;2-B
   Strahl BD, 2002, MOL CELL BIOL, V22, P1298, DOI 10.1128/MCB.22.5.1298-1306.2002
   Sturm D, 2012, CANCER CELL, V22, P425, DOI 10.1016/j.ccr.2012.08.024
   Sun XJ, 2005, J BIOL CHEM, V280, P35261, DOI 10.1074/jbc.M504012200
   Symington LS, 2010, CRIT REV BIOCHEM MOL, V51, P195
   Tan J, 2015, NAT GENET, V47, P1341, DOI 10.1038/ng.3409
   Tiedemann RL, 2016, ONCOTARGET, V7, P1927, DOI 10.18632/oncotarget.6481
   Tlemsani C, 2016, J MED GENET, V53, P743, DOI 10.1136/jmedgenet-2015-103638
   Van Allen EM, 2014, CANCER DISCOV, V4, P1140, DOI 10.1158/2159-8290.CD-14-0623
   Venkatesh S, 2012, NATURE, V489, P452, DOI 10.1038/nature11326
   Wagner EJ, 2012, NAT REV MOL CELL BIO, V13, P115, DOI 10.1038/nrm3274
   Wang JJ, 2016, J UROLOGY, V196, P1363, DOI 10.1016/j.juro.2016.06.010
   Weinstein JN, 2014, NATURE, V507, P315, DOI 10.1038/nature12965
   Witkiewicz AK, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7744
   Wu G, 2014, NAT GENET, V46, P444, DOI 10.1038/ng.2938
   Wu G, 2012, NAT GENET, V44, P251, DOI 10.1038/ng.1102
   Xiang W, 2015, ONCOTARGET, V6, P4066, DOI 10.18632/oncotarget.2926
   Xiao TJ, 2003, GENE DEV, V17, P654, DOI 10.1101/gad.1055503
   Xie LQ, 2011, EMBO J, V30, P1473, DOI 10.1038/emboj.2011.91
   Xie P, 2008, CELL SIGNAL, V20, P1671, DOI 10.1016/j.cellsig.2008.05.012
   Xu W, 2011, CANCER CELL, V19, P17, DOI 10.1016/j.ccr.2010.12.014
   Yoh SM, 2008, GENE DEV, V22, P3422, DOI 10.1101/gad.1720008
   Yokoyama A, 2010, CANCER CELL, V17, P198, DOI 10.1016/j.ccr.2009.12.040
   Yuan W, 2009, J BIOL CHEM, V284, P15701, DOI 10.1074/jbc.M808431200
   ZBAR B, 1987, NATURE, V327, P721, DOI 10.1038/327721a0
   Zhang JH, 2012, NATURE, V481, P157, DOI 10.1038/nature10725
   Zhang P, 2006, NUCLEIC ACIDS RES, V34, P6621, DOI 10.1093/nar/gkl989
   Zhang YL, 2014, CELL REP, V8, P1989, DOI 10.1016/j.celrep.2014.08.031
   Zhu XF, 2014, NAT GENET, V46, P287, DOI 10.1038/ng.2894
NR 109
TC 56
Z9 65
U1 0
U2 14
PU COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT
PI COLD SPRING HARBOR
PA 1 BUNGTOWN RD, COLD SPRING HARBOR, NY 11724 USA
SN 2157-1422
J9 CSH PERSPECT MED
JI Cold Spring Harb. Perspect. Med.
PD MAY
PY 2017
VL 7
IS 5
AR a026468
DI 10.1101/cshperspect.a026468
PG 15
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA EW9LT
UT WOS:000402842000007
PM 28159833
OA Green Published, Bronze
DA 2025-01-12
ER

PT J
AU Tordini, F
   Aldinucci, M
   Milanesi, L
   Liò, P
   Merelli, I
AF Tordini, Fabio
   Aldinucci, Marco
   Milanesi, Luciano
   Lio, Pietro
   Merelli, Ivan
TI The Genome Conformation As an Integrator of Multi-Omic Data: Thie
   Example of Damage Spreading in Cancer
SO FRONTIERS IN GENETICS
LA English
DT Article
DE gene functional annotations; chromosome conformation capture; metabolic
   pathways; epigenetic patterns; gene expression; cancer mutations;
   multi-layer networks; damage spreading
ID BREAST-CANCER; HI-C; CHROMATIN INTERACTOME; TRANSCRIPTION FACTORS; SEQ
   DATA; REVEALS; TOOL; MAP; IDENTIFICATION; ORGANIZATION
AB Publicly available multi-omic databases, in particular if associated with medical annotations, are rich resources with the potential to lead a rapid transition from high-throughput molecular biology experiments to better clinical outcomes for patients. In this work, we propose a model for multi-omic data integration (i.e., genetic variations, gene expression, genome conformation, and epigenetic patterns), which exploits a multi-layer network approach to analyse, visualize, and obtain insights from such biological information, in order to use achieved results at a macroscopic level. Using this representation, we can describe how driver and passenger mutations accumulate during the development of diseases providing, for example, a tool able to characterize the evolution of cancer. Indeed, our test case concerns the MCF-7 breast cancer cell line, before and after the stimulation with estrogen, since many datasets are available for this case study. In particular, the integration of data about cancer mutations, gene functional annotations, genome conformation, epigenetic patterns, gene expression, and metabolic pathways in our multi-layer representation will allow a better interpretation of the mechanisms behind a complex disease such as cancer. Thanks to this multi-layer approach, we focus on the interplay of chromatin conformation and cancer mutations in different pathways, such as metabolic processes, that are very important for tumor development. Working on this model, a variance analysis can be implemented to identify normal variations within each omics and to characterize, by contrast, variations that can be accounted to pathological samples compared to normal ones. This integrative model can be used to identify novel biomarkers and to provide innovative omic-based guidelines for treating many diseases, improving the efficacy of decision trees currently used in clinic.
C1 [Tordini, Fabio; Aldinucci, Marco] Univ Torino, Comp Sci Dept, Turin, Italy.
   [Milanesi, Luciano; Merelli, Ivan] Italian Natl Res Council, Inst Biomed Technol, Milan, Italy.
   [Lio, Pietro] Univ Cambridge, Comp Lab, Cambridge, England.
C3 University of Turin; Consiglio Nazionale delle Ricerche (CNR); Istituto
   di Tecnologie Biomediche (ITB-CNR); University of Cambridge
RP Merelli, I (通讯作者)，Italian Natl Res Council, Inst Biomed Technol, Milan, Italy.
EM ivan.merelli@itb.cnr.it
RI P. Lió, Pietro/AAV-3358-2021; Aldinucci, Marco/G-3153-2012; Merelli,
   Ivan/AAX-6171-2020; Milanesi, Luciano/AAE-7230-2019
OI Aldinucci, Marco/0000-0001-8788-0829; Lio, Pietro/0000-0002-0540-5053;
   Tordini, Fabio/0000-0001-9861-6513; Milanesi,
   Luciano/0000-0002-1201-3939
FU Italian Ministry of Education and Research (MIUR) through the Flagship
   InterOmics [PB05]; EC-FP7 innovation project "MIMOMICS" [305280]; EC-FP7
   strep project "REPARA" [609666]
FX This work has been supported by the Italian Ministry of Education and
   Research (MIUR) through the Flagship (PB05) InterOmics, the EC-FP7
   innovation project "MIMOMICS" (no. 305280), and the EC-FP7 strep project
   "REPARA" (no. 609666).
CR Albert R, 2002, REV MOD PHYS, V74, P47, DOI 10.1103/RevModPhys.74.47
   Babaei S, 2015, PLOS COMPUT BIOL, V11, DOI 10.1371/journal.pcbi.1004221
   Babu D, 2015, NUCLEUS-PHILA, V6, P382, DOI 10.1080/19491034.2015.1106676
   Barutcu AR, 2016, J CELL PHYSIOL, V231, P31, DOI 10.1002/jcp.25062
   Bianconi G, 2008, EPL-EUROPHYS LETT, V81, DOI 10.1209/0295-5075/81/28005
   Biasco L, 2011, EMBO MOL MED, V3, P89, DOI 10.1002/emmm.201000108
   Cicatiello L, 2010, AM J PATHOL, V176, P2113, DOI 10.2353/ajpath.2010.090837
   Coppedè F, 2014, WORLD J GASTROENTERO, V20, P943, DOI 10.3748/wjg.v20.i4.943
   Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983
   De Domenico M, 2015, J COMPLEX NETW, V3, P159, DOI 10.1093/comnet/cnu038
   De Domenico M, 2013, PHYS REV X, V3, DOI 10.1103/PhysRevX.3.041022
   DeBerardinis RJ, 2016, SCI ADV, V2, DOI 10.1126/sciadv.1600200
   Dong XA, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-704
   Du MJ, 2016, SCI REP-UK, V6, DOI 10.1038/srep23202
   Dunham I, 2012, NATURE, V489, P57, DOI 10.1038/nature11247
   Estrada E, 2014, PHYS REV E, V89, DOI 10.1103/PhysRevE.89.042819
   Forbes SA, 2015, NUCLEIC ACIDS RES, V43, pD805, DOI 10.1093/nar/gku1075
   Gerstein MB, 2012, NATURE, V489, P91, DOI 10.1038/nature11245
   Gimelli S, 2014, MOL CYTOGENET, V7, DOI 10.1186/s13039-014-0054-y
   Heinz S, 2010, MOL CELL, V38, P576, DOI 10.1016/j.molcel.2010.05.004
   Homouz D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054699
   Horike S, 2005, NAT GENET, V37, P31, DOI 10.1038/ng1491
   Hsu PY, 2010, GENOME RES, V20, P733, DOI 10.1101/gr.101923.109
   Hunter DR., 2008, Journal of statistical software, V24, pnihpa54860, DOI [10.18637/jss.v024.i03, DOI 10.18637/JSS.V024.I03]
   Jäger R, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7178
   Jensen LJ, 2009, NUCLEIC ACIDS RES, V37, pD412, DOI 10.1093/nar/gkn760
   Jin FL, 2013, NATURE, V503, P290, DOI 10.1038/nature12644
   Kalhor R, 2012, NAT BIOTECHNOL, V30, P90, DOI 10.1038/nbt.2057
   Kel I, 2016, MOL BIOSYST, V12, P3447, DOI 10.1039/c6mb00453a
   Keune WJ, 2013, CANCER RES, V73, P6913, DOI 10.1158/0008-5472.CAN-13-0424
   Kivela M, 2014, J COMPLEX NETW, V2, P203, DOI 10.1093/comnet/cnu016
   Korbel JO, 2013, NAT BIOTECHNOL, V31, P1099, DOI 10.1038/nbt.2764
   Lan X, 2012, NUCLEIC ACIDS RES, V40, P7690, DOI 10.1093/nar/gks501
   Li SB, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1025-3
   Lieberman-Aiden E, 2009, SCIENCE, V326, P289, DOI 10.1126/science.1181369
   Lin JE, 2010, GASTROENTEROLOGY, V138, P241, DOI 10.1053/j.gastro.2009.08.064
   Maffini MV, 2004, J CELL SCI, V117, P1495, DOI 10.1242/jcs.01000
   Meaburn KJ, 2009, J CELL BIOL, V187, P801, DOI 10.1083/jcb.200909127
   Merelli I, 2015, FRONT GENET, V6, DOI 10.3389/fgene.2015.00040
   Merelli I, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075146
   Merelli I, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-S1-S9
   Merelli I, 2010, NUCLEIC ACIDS RES, V38, pW262, DOI 10.1093/nar/gkq391
   Michailidou K, 2013, NAT GENET, V45, P353, DOI 10.1038/ng.2563
   Mosca E, 2010, BMC SYST BIOL, V4, DOI 10.1186/1752-0509-4-76
   Mourad R, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113354
   Papantonis A, 2013, CHEM REV, V113, P8683, DOI 10.1021/cr300513p
   Paplomata E, 2014, THER ADV MED ONCOL, V6, P154, DOI 10.1177/1758834014530023
   Peng JJ, 2014, BMC SYST BIOL, V8, DOI 10.1186/1752-0509-8-S5-S8
   Petrov A, 2008, GENOME RES, V18, P39, DOI 10.1101/gr.6620908
   Putnik M, 2012, BIOCHEM BIOPH RES CO, V426, P26, DOI 10.1016/j.bbrc.2012.08.007
   Rao SSP, 2014, CELL, V159, P1665, DOI 10.1016/j.cell.2014.11.021
   Rickman DS, 2012, P NATL ACAD SCI USA, V109, P9083, DOI 10.1073/pnas.1112570109
   Risca VI, 2015, TRENDS GENET, V31, P357, DOI 10.1016/j.tig.2015.03.010
   Ross-Innes CS, 2011, BMC GENOMICS, V12, DOI 10.1186/1471-2164-12-593
   Saito YD, 2010, CANCER-AM CANCER SOC, V116, P1629, DOI 10.1002/cncr.24879
   Schoenfelder S, 2010, NAT GENET, V42, P53, DOI 10.1038/ng.496
   Shavit Y, 2013, BIOINFORMATICS, V29, P1206, DOI 10.1093/bioinformatics/btt120
   Shen Y, 2012, NATURE, V488, P116, DOI 10.1038/nature11243
   Shihab HA, 2014, HUM GENOMICS, V8, DOI 10.1186/1479-7364-8-11
   Smith RN, 2012, BIOINFORMATICS, V28, P3163, DOI 10.1093/bioinformatics/bts577
   Sulzmaier FJ, 2014, NAT REV CANCER, V14, P598, DOI 10.1038/nrc3792
   Sun PH, 2013, J CANCER RES CLIN, V139, P1129, DOI 10.1007/s00432-013-1421-5
   Taberlay PC, 2016, GENOME RES, V26, P719, DOI 10.1101/gr.201517.115
   Vucic EA, 2012, GENOME RES, V22, P188, DOI 10.1101/gr.124354.111
   Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r137
   Zhang Y, 2012, CELL, V148, P908, DOI 10.1016/j.cell.2012.02.002
NR 66
TC 17
Z9 17
U1 0
U2 4
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 1664-8021
J9 FRONT GENET
JI Front. Genet.
PD NOV 15
PY 2016
VL 7
AR 194
DI 10.3389/fgene.2016.00194
PG 17
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA EW7FO
UT WOS:000402675400001
PM 27895661
OA Green Published, gold, Green Submitted
DA 2025-01-12
ER

PT J
AU Naz, A
   Cui, Y
   Collins, CJ
   Thompson, DH
   Irudayaraj, J
AF Naz, Asia
   Cui, Yi
   Collins, Christopher J.
   Thompson, David H.
   Irudayaraj, Joseph
TI PLGA-PEG nano-delivery system for epigenetic therapy
SO BIOMEDICINE & PHARMACOTHERAPY
LA English
DT Article
DE Azacitidine; Nanomedicine; Drug delivery; DNA methylation;
   Single-molecule fluorescence
ID CELL-CYCLE ARREST; DNA METHYLATION; MYELODYSPLASTIC SYNDROME;
   CANCER-CELLS; SOLID TUMORS; PHASE-I; DECITABINE; METHYLTRANSFERASE;
   5-AZACYTIDINE; INHIBITOR
AB Efficient delivery of cytidine analogues such as Azacitidine (AZA) into solid tumors constitutes a primary challenge in epigenetic therapies. We developed a di-block nano-vector based on poly(lactic-co-glycolic acid) (PLGA) and poly(ethylene glycol) (PEG) for stabilization of the conjugated AZA under physiological conditions. With equimolar drug content, our nano-conjugate could elicit a better anti-proliferative effect over free drug in breast cancer both in vitro and in vivo, through reactivation of p21 and BRCA1 to restrict cell proliferation. In addition, we applied single-molecule fluorescence tools to characterize the intracellular behavior of the AZA-PLGE-PEG nano-micelles at a finer spatiotemporal resolution. Our results suggest that the nano-micelles could effectively enrich in cancer cells and may not be limited by nucleoside transporters. Afterwards, the internalized nano-micelles exhibit pH-dependent release and resistance to active efflux. Altogether, our work describes a delivery strategy for DNA demethylating agents with nanoscale tunability, providing a cost-effective option for pharmaceutics. (C) 2017 Elsevier Masson SAS. All rights reserved.
C1 [Naz, Asia; Cui, Yi; Irudayaraj, Joseph] Purdue Univ, Dept Agr & Biol Engn, Bindley Biosci Ctr, W Lafayette, IN 47907 USA.
   [Naz, Asia; Cui, Yi; Irudayaraj, Joseph] Purdue Univ, Dept Agr & Biol Engn, Purdue Ctr Canc Res, W Lafayette, IN 47907 USA.
   [Naz, Asia] Univ Karachi, Dept Pharmaceut Chem, Karachi 75270, Pakistan.
   [Collins, Christopher J.; Thompson, David H.] Purdue Univ, Dept Chem, W Lafayette, IN 47907 USA.
   [Cui, Yi] Pacific Northwest Natl Lab, Earth & Biol Sci Directorate, Richland, WA 99354 USA.
C3 Purdue University System; Purdue University; Purdue University System;
   Purdue University; University of Karachi; Purdue University System;
   Purdue University; United States Department of Energy (DOE); Pacific
   Northwest National Laboratory
RP Cui, Y; Irudayaraj, J (通讯作者)，Purdue Univ, Dept Agr & Biol Engn, Bindley Biosci Ctr, W Lafayette, IN 47907 USA.; Cui, Y; Irudayaraj, J (通讯作者)，Purdue Univ, Dept Agr & Biol Engn, Purdue Ctr Canc Res, W Lafayette, IN 47907 USA.; Cui, Y (通讯作者)，Pacific Northwest Natl Lab, Earth & Biol Sci Directorate, Richland, WA 99354 USA.
EM yi.cui@pnnl.gov; josephi@purdue.edu
RI Cui, Yi/O-4109-2019; Thompson, David/HJY-8387-2023
OI Naz, Asia/0000-0002-3847-7117; Thompson, David H/0000-0002-0746-1526;
   Irudayaraj, Joseph/0000-0002-0630-1520
FU HEC Pakistan training grant; W.M. Keck Foundation; Purdue Center for
   Cancer Research [P30CA023168]
FX We acknowledge Dr. Bennett Elzey and Sandra Torregrosa-Allen (Purdue
   University) for their assistance in tumor xenografting and in vivo
   experiments in the MDE Core. We thank Dr. Seok-Hee Hyun, Dr. Andres
   Gonzalez-Bonet, Dr. Yawo A. Mondjinou, and Kyle Wright (Purdue
   University) for their assistance in chemical conjugation and insightful
   discussions. Dr. Asia Naz was supported by the HEC Pakistan training
   grant. Funding from the W.M. Keck Foundation and the Purdue Center for
   Cancer Research (P30CA023168) is appreciated.
CR Alcazar O, 2012, INT J CANCER, V131, P18, DOI 10.1002/ijc.26320
   [Anonymous], 2008, MOL PHARM
   Appleton K, 2007, J CLIN ONCOL, V25, P4603, DOI 10.1200/JCO.2007.10.8688
   Argemí A, 2007, TALANTA, V74, P176, DOI 10.1016/j.talanta.2007.05.053
   Argemí A, 2009, J PHARMACEUT BIOMED, V50, P847, DOI 10.1016/j.jpba.2009.07.006
   Ben-Kasus T, 2005, BIOCHEM PHARMACOL, V70, P121, DOI 10.1016/j.bcp.2005.04.010
   Beumer JH, 2006, CLIN CANCER RES, V12, P7483, DOI 10.1158/1078-0432.CCR-06-1250
   Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102
   Brueckner B, 2010, MOL CANCER THER, V9, P1256, DOI 10.1158/1535-7163.MCT-09-1202
   Byun HM, 2008, CANCER LETT, V266, P238, DOI 10.1016/j.canlet.2008.02.069
   Cayrol C, 1998, ONCOGENE, V16, P311, DOI 10.1038/sj.onc.1201543
   Chen JJ, 2012, J CELL SCI, V125, P2954, DOI 10.1242/jcs.101592
   Chen JJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017991
   Chen XY, 2008, APPL BIOCHEM BIOTECH, V151, P21, DOI 10.1007/s12010-008-8152-0
   Chen Y, 1999, BIOPHYS J, V77, P553, DOI 10.1016/S0006-3495(99)76912-2
   Chen Y, 2002, BIOPHYS J, V82, P133, DOI 10.1016/S0006-3495(02)75380-0
   Chowdhury B, 2015, SCI REP-UK, V5, DOI 10.1038/srep09281
   Cowan LA, 2010, EPIGENOMICS-UK, V2, P71, DOI 10.2217/EPI.09.44
   Cui Y, 2015, WIRES NANOMED NANOBI, V7, P387, DOI 10.1002/wnan.1321
   Cui Y, 2015, MOL PHARMACEUT, V12, P1279, DOI 10.1021/mp500815b
   Cui Y, 2015, NUCLEIC ACIDS RES, V43, P3046, DOI 10.1093/nar/gkv098
   Damaraju VL, 2012, NUCLEOS NUCLEOT NUCL, V31, P236, DOI 10.1080/15257770.2011.652330
   Danhier F, 2012, J CONTROL RELEASE, V161, P505, DOI 10.1016/j.jconrel.2012.01.043
   Deng CX, 2006, NUCLEIC ACIDS RES, V34, P1416, DOI 10.1093/nar/gkl010
   Deng T, 2009, LIFE SCI, V84, P311, DOI 10.1016/j.lfs.2008.12.015
   Dhar S, 2008, P NATL ACAD SCI USA, V105, P17356, DOI 10.1073/pnas.0809154105
   Egger G, 2004, NATURE, V429, P457, DOI 10.1038/nature02625
   Esteller M, 2001, CANCER RES, V61, P3225
   Esteller M, 2003, LANCET ONCOL, V4, P351, DOI 10.1016/S1470-2045(03)01115-X
   French T, 1997, J MICROSC-OXFORD, V185, P339, DOI 10.1046/j.1365-2818.1997.d01-632.x
   Gelperina S, 2010, EUR J PHARM BIOPHARM, V74, P157, DOI 10.1016/j.ejpb.2009.09.003
   Gurion R, 2010, HAEMATOL-HEMATOL J, V95, P303, DOI 10.3324/haematol.2009.010611
   Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075
   Hoppe JB, 2013, NEUROBIOL LEARN MEM, V106, P134, DOI 10.1016/j.nlm.2013.08.001
   Hummel-Eisenbeiss J, 2013, MOL PHARMACOL, V84, P438, DOI 10.1124/mol.113.086801
   Issa JPJ, 2007, CLIN CANCER RES, V13, P1634, DOI 10.1158/1078-0432.CCR-06-2076
   Issa JPJ, 2009, CLIN CANCER RES, V15, P3938, DOI 10.1158/1078-0432.CCR-08-2783
   Jiemjit A, 2008, ONCOGENE, V27, P3615, DOI 10.1038/sj.onc.1211018
   Jin C, 2010, BIOMACROMOLECULES, V11, P2422, DOI 10.1021/bm1005992
   Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Juan G, 2001, METHOD CELL BIOL, V63, P343
   Kaminskas E, 2005, CLIN CANCER RES, V11, P3604, DOI 10.1158/1078-0432.CCR-04-2135
   Kantarjian H, 2006, CANCER-AM CANCER SOC, V106, P1794, DOI 10.1002/cncr.21792
   Karberg S, 2009, CELL, V139, P1029, DOI 10.1016/j.cell.2009.11.038
   KISSINGER LD, 1986, J CHROMATOGR, V353, P309, DOI 10.1016/S0021-9673(01)87101-6
   Kumari A, 2010, COLLOID SURFACE B, V75, P1, DOI 10.1016/j.colsurfb.2009.09.001
   Lakowicz J.R., 2006, Principles of fluorescence spectroscopy, V3rd, DOI DOI 10.1007/978-0-387-46312-4
   Li X, 2010, ACTA BIOMATER, V6, P511, DOI 10.1016/j.actbio.2009.07.002
   Lim SP, 2011, BIODRUGS, V25, P227, DOI 10.2165/11592770-000000000-00000
   Liu FX, 2013, INT J PHARMACEUT, V451, P41, DOI 10.1016/j.ijpharm.2013.04.020
   Marrache S, 2012, P NATL ACAD SCI USA, V109, P16288, DOI 10.1073/pnas.1210096109
   MATSUMURA Y, 1986, CANCER RES, V46, P6387
   Mirza S, 2010, MOL CELL BIOCHEM, V342, P101, DOI 10.1007/s11010-010-0473-y
   Niculescu AB, 1998, MOL CELL BIOL, V18, P629, DOI 10.1128/MCB.18.1.629
   Nielsen UB, 2006, BMC IMMUNOL, V7, DOI 10.1186/1471-2172-7-24
   O'Reilly EM, 2008, NAT CLIN PRACT ONCOL, V5, P312, DOI 10.1038/ncponc1128
   Panyam J, 2003, PHARM RES-DORDR, V20, P212, DOI 10.1023/A:1022219003551
   Press JZ, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-17
   Qin TC, 2009, BLOOD, V113, P659, DOI 10.1182/blood-2008-02-140038
   Ren J, 2011, CELL SIGNAL, V23, P1082, DOI 10.1016/j.cellsig.2011.02.003
   Rius M, 2009, MOL CANCER THER, V8, P225, DOI 10.1158/1535-7163.MCT-08-0743
   Shang DH, 2008, UROLOGY, V71, P1220, DOI 10.1016/j.urology.2007.11.029
   Sheikhnejad G, 1999, J MOL BIOL, V285, P2021, DOI 10.1006/jmbi.1998.2426
   Shin DY, 2013, BIOMED PHARMACOTHER, V67, P305, DOI 10.1016/j.biopha.2013.01.004
   Siegel SJ, 2006, EUR J PHARM BIOPHARM, V64, P287, DOI 10.1016/j.ejpb.2006.06.009
   Stewart DJ, 2009, CLIN CANCER RES, V15, P3881, DOI 10.1158/1078-0432.CCR-08-2196
   Stresemann C, 2008, INT J CANCER, V123, P8, DOI 10.1002/ijc.23607
   Tiwari MN, 2013, FREE RADICAL BIO MED, V65, P704, DOI 10.1016/j.freeradbiomed.2013.07.042
   Walsh G, 2000, NAT BIOTECHNOL, V18, P831, DOI 10.1038/78720
   Wohlfart S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019121
   Yallapu MM, 2010, J COLLOID INTERF SCI, V351, P19, DOI 10.1016/j.jcis.2010.05.022
   Yang XJ, 2010, TRENDS PHARMACOL SCI, V31, P536, DOI 10.1016/j.tips.2010.08.001
   Yoo CB, 2006, NAT REV DRUG DISCOV, V5, P37, DOI 10.1038/nrd1930
   Yoo CB, 2007, CANCER RES, V67, P6400, DOI 10.1158/0008-5472.CAN-07-0251
   Yoo HS, 2001, J CONTROL RELEASE, V70, P63, DOI 10.1016/S0168-3659(00)00340-0
   Zhao M, 2004, J CHROMATOGR B, V813, P81, DOI 10.1016/j.jchromb.2004.09.012
NR 77
TC 23
Z9 27
U1 1
U2 46
PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY-LES-MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE
SN 0753-3322
EI 1950-6007
J9 BIOMED PHARMACOTHER
JI Biomed. Pharmacother.
PD JUN
PY 2017
VL 90
BP 586
EP 597
DI 10.1016/j.biopha.2017.03.093
PG 12
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA EW4KS
UT WOS:000402471000072
PM 28407579
DA 2025-01-12
ER

PT J
AU Gaál, Z
   Oláh, E
   Rejto, L
   Erdodi, F
   Csernoch, L
AF Gaal, Zsuzsanna
   Olah, Eva
   Rejto, Laszlo
   Erdodi, Ferenc
   Csernoch, Laszlo
TI Strong Correlation between the Expression Levels of HDAC4 and SIRT6 in
   Hematological Malignancies of the Adults
SO PATHOLOGY & ONCOLOGY RESEARCH
LA English
DT Article
DE Acute myeloid leukemia; Epigenetics; Histone deacetylation; HDAC4; SIRT6
ID HISTONE DEACETYLASE SIRT6; ACUTE LYMPHOBLASTIC-LEUKEMIA; BREAST-CANCER;
   INHIBITORS; CELLS; FAMILY; AML; SUPPRESSES; RESISTANCE; REGULATORS
AB Histone deacetylase enzymes, confirmed to have important role in the pathogenesis of leukemia, are promising targets of epigenetic treatment. However, in acute myeloid leukemia, our knowledge on their expression levels is limited, and controversial data have been published about their potential oncogenic or tumorsuppressor properties in solid tumors. In our study, the expression levels of HDAC4 and SIRT6 were evaluated via Western blot analysis in 45 bone marrow samples (2 uninfiltrated and 43 concerned by different kinds of hematological malignancies), including 32 specimens obtained from patients with newly diagnosed AML. Significantly higher HDAC4 level was detected in case of FLT3-ITD mutation compared to the group of patients without carrying this mutation (p < 0.05). Compared to the non-infiltrated samples, the expression level of HDAC4 in AML M5 patients has been proved to be significantly higher (p < 0.05). Decreasing expression levels of both HDAC4 and SIRT6 were observed during the induction treatment of FAB M5 type AML. Strong correlation has been proved between the expression levels of HDAC4 and SIRT6 (r = 0.722 in full cohort and r = 0.794 in AML), that confirms the recently suggested cooperation between NAD(+)-independent and NAD(+)-dependent HDAC enzymes in leukemia.
C1 [Gaal, Zsuzsanna; Csernoch, Laszlo] Univ Debrecen, Dept Physiol, Nagyerdei Krt 98,POB 22, H-4012 Debrecen, Hungary.
   [Olah, Eva] Univ Debrecen, Inst Pediat, Nagyerdei Krt 98,POB 22, H-4012 Debrecen, Hungary.
   [Rejto, Laszlo] Univ Debrecen, Inst Internal Med, Nagyerdei Krt 98,POB 22, H-4012 Debrecen, Hungary.
   [Erdodi, Ferenc] Univ Debrecen, Dept Med Chem, Fac Med, Nagyerdei Krt 98,POB 22, H-4012 Debrecen, Hungary.
C3 University of Debrecen; University of Debrecen; University of Debrecen;
   University of Debrecen
RP Rejto, L (通讯作者)，Univ Debrecen, Inst Internal Med, Nagyerdei Krt 98,POB 22, H-4012 Debrecen, Hungary.
EM csl@edu.unideb.hu
OI Csernoch, Laszlo/0000-0002-2446-1456
FU Astellas Pharma Ltd.
FX Our work was partially financed by Astellas Pharma Ltd.
CR Bantscheff M, 2011, NAT BIOTECHNOL, V29, P255, DOI 10.1038/nbt.1759
   Barneda-Zahonero B, 2012, MOL ONCOL, V6, P579, DOI 10.1016/j.molonc.2012.07.003
   Bosch-Presegue Laia, 2011, Genes Cancer, V2, P648, DOI 10.1177/1947601911417862
   Cea M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022739
   Chen X, 2014, BIOCHEM BIOPH RES CO, V446, P364, DOI 10.1016/j.bbrc.2014.02.116
   De Ruijter AJM, 2003, BIOCHEM J, V370, P737, DOI 10.1042/BJ20021321
   Delcuve GP, 2012, CLIN EPIGENETICS, V4, DOI 10.1186/1868-7083-4-5
   Di Croce L, 2005, HUM MOL GENET, V14, pR77, DOI 10.1093/hmg/ddi109
   Fukuda T, 2015, FEBS LETT, V589, P2274, DOI 10.1016/j.febslet.2015.06.043
   Gruhn B, 2013, LEUKEMIA RES, V37, P1200, DOI 10.1016/j.leukres.2013.07.016
   Haberland M, 2009, NAT REV GENET, V10, P32, DOI 10.1038/nrg2485
   Hackanson B, 2012, LEUKEMIA RES, V36, P1055, DOI 10.1016/j.leukres.2012.02.026
   Holmlund T, 2013, LEUKEMIA, V27, P578, DOI 10.1038/leu.2012.265
   Huong TTT, 2013, J KOREAN MED SCI, V28, P237, DOI 10.3346/jkms.2013.28.2.237
   Khan O, 2012, IMMUNOL CELL BIOL, V90, P85, DOI 10.1038/icb.2011.100
   Khongkow M, 2013, CARCINOGENESIS, V34, P1476, DOI 10.1093/carcin/bgt098
   Linggi BE, 2005, J CELL BIOCHEM, V96, P938, DOI 10.1002/jcb.20604
   Liu H, 2009, GLIA, V57, P1, DOI 10.1002/glia.20729
   Marks PA, 2010, BBA-GENE REGUL MECH, V1799, P717, DOI 10.1016/j.bbagrm.2010.05.008
   Niegisch G, 2013, UROL ONCOL-SEMIN ORI, V31, P1770, DOI 10.1016/j.urolonc.2012.06.015
   Novotny-Diermayr V, 2012, BLOOD CANCER J, V2, DOI 10.1038/bcj.2012.14
   Saunders LR, 2007, ONCOGENE, V26, P5489, DOI 10.1038/sj.onc.1210616
   Sebastián C, 2012, CELL, V151, P1185, DOI 10.1016/j.cell.2012.10.047
   Smith KT, 2009, INT J BIOCHEM CELL B, V41, P21, DOI 10.1016/j.biocel.2008.09.008
   Tabe Y, 2007, CELL DEATH DIFFER, V14, P1443, DOI 10.1038/sj.cdd.4402139
   Van Damme M, 2012, EPIGENETICS-US, V7, P1403, DOI 10.4161/epi.22674
   Verdin E, 2003, TRENDS GENET, V19, P286, DOI 10.1016/S0168-9525(03)00073-8
   Villagra A, 2009, NAT IMMUNOL, V10, P92, DOI 10.1038/ni.1673
   Wang JC, 2011, ONCOLOGY-BASEL, V81, P325, DOI 10.1159/000334577
   Wilson AJ, 2008, MOL BIOL CELL, V19, P4062, DOI 10.1091/mbc.E08-02-0139
   Witt O, 2009, CANCER LETT, V277, P8, DOI 10.1016/j.canlet.2008.08.016
   Yang XJ, 2008, NAT REV MOL CELL BIO, V9, P206, DOI 10.1038/nrm2346
   Yu SL, 2013, ONCOL REP, V30, P1293, DOI 10.3892/or.2013.2578
   Zhang J, 2015, EUR REV MED PHARMACO, V19, P818
   Zhang ZG, 2014, MOL MED REP, V9, P882, DOI 10.3892/mmr.2013.1879
   Zhou JX, 2011, PLOS ONE, V6, DOI [10.1371/journal.pone.0014752, 10.1371/journal.pone.0024340, 10.1371/journal.pone.0019798]
   Zhou L, 2013, LEUKEMIA, V27, P1358, DOI 10.1038/leu.2012.366
   Zhu L, 2015, INT J ONCOL, V46, P2535, DOI 10.3892/ijo.2015.2956
NR 38
TC 6
Z9 6
U1 0
U2 10
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1219-4956
EI 1532-2807
J9 PATHOL ONCOL RES
JI Pathol. Oncol. Res.
PD JUL
PY 2017
VL 23
IS 3
BP 493
EP 504
DI 10.1007/s12253-016-0139-5
PG 12
WC Oncology; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Pathology
GA EW5TU
UT WOS:000402570200005
PM 27766571
DA 2025-01-12
ER

PT J
AU Qian, ZR
   Ren, L
   Wu, DC
   Yang, X
   Zhou, ZY
   Nie, QM
   Jiang, G
   Xue, SL
   Weng, WJ
   Qiu, YM
   Lin, YY
AF Qian, Zhongrun
   Ren, Li
   Wu, Dingchang
   Yang, Xi
   Zhou, Zhiyi
   Nie, Quanmin
   Jiang, Gan
   Xue, Shuanglin
   Weng, Weiji
   Qiu, Yongming
   Lin, Yingying
TI Overexpression of FoxO3a is associated with glioblastoma progression and
   predicts poor patient prognosis
SO INTERNATIONAL JOURNAL OF CANCER
LA English
DT Article
DE FoxO3a; glioblastoma; prognosis; c-Myc; MLL2
ID TRANSCRIPTION FACTOR FOXO3A; BREAST-CANCER; KAPPA-B; CELLS; AUTOPHAGY;
   PROMOTES; INHIBITION; RECEPTOR; PROLIFERATION; EXPRESSION
AB Forkhead transcription factor FoxO3a has been reported to have ambiguous functions and distinct mechanisms in various solid tumors, including glioblastoma (GBM). Although a preliminary analysis of a small sample of patients indicated that FoxO3a aberrations in glioma might be related to aggressive clinical behavior, the clinical significance of FoxO3a in glioblastoma remains unclear. We investigated the expression of FoxO3a in a cohort of 91 glioblastoma specimens and analyzed the correlations of protein expression with patient prognosis. Furthermore, the functional impact of FoxO3a on GBM progression and the underlying mechanisms of FoxO3a regulation were explored in a series of in vitro and in vivo assays. FoxO3a expression was elevated in glioblastoma tissues, and high nuclear FoxO3a expression in human GBM tissues was associated with poor prognosis. Moreover, knockdown of FoxO3a significantly reduced the colony formation and invasion ability of GBM cells, whereas overexpression of FoxO3a promoted the colony formation and invasion ability. The results of in vivo GBM models further confirmed that FoxO3a knockdown inhibited GBM progression. More, the pro-oncogenic effects of FoxO3a in GBM were mediated by the activation of c-Myc, microtubule-associated protein 1 light chain 3 beta (LC3B) and Beclin1 in a mixed-lineage leukemia 2 (MLL2)-dependent manner. These findings suggest that high FoxO3a expression is associated with glioblastoma progression and that FoxO3a independently indicates poor prognosis in patients. FoxO3a might be a novel prognostic biomarker or a potential therapeutic target in glioblastoma.
   What's new? Genetic aberrations in forkhead transcription factor (FoxO3a) are thought to play a role in aggressive glioblastoma (GBM), though the nature of their involvement remains unclear. In this study, high FoxO3a expression was positively correlated with GBM progression and poor prognosis in patients. In cells, FoxO3a was found to promote GBM progression via activation of c-Myc and the autophagy-related proteins LC3B and Beclin1. FoxO3a pro-oncogenic effects were mediated by the epigenetic factor MLL2. In addition, in mice, FoxO3a knockdown inhibited GBM progression. The findings suggest that FoxO3a is a potential prognostic biomarker or therapeutic target in GBM.
C1 [Qian, Zhongrun; Yang, Xi; Zhou, Zhiyi; Nie, Quanmin; Weng, Weiji; Qiu, Yongming; Lin, Yingying] Shanghai Jiao Tong Univ, Sch Med, Ren Ji Hosp, Dept Neurosurg, Room 118,Bldg 11,1630 Dongfang Rd, Shanghai, Peoples R China.
   [Ren, Li] Fudan Univ, Shanghai Pudong Hosp, Dept Neurosurg, Shanghai, Peoples R China.
   [Wu, Dingchang] Fujian Med Univ, Longyan Hosp 1, Dept Clin Lab, Longyan, Peoples R China.
   [Jiang, Gan] Shanghai Jiao Tong Univ, Sch Med, Dept Pharmacol, Shanghai, Peoples R China.
   [Xue, Shuanglin] Fujian Med Univ, Longyan Hosp 1, Dept Neurosurg, Longyan, Peoples R China.
C3 Shanghai Jiao Tong University; Fudan University; Fujian Medical
   University; Shanghai Jiao Tong University; Fujian Medical University
RP Qiu, YM; Lin, YY (通讯作者)，Shanghai Jiao Tong Univ, Sch Med, Ren Ji Hosp, Dept Neurosurg, Room 118,Bldg 11,1630 Dongfang Rd, Shanghai, Peoples R China.
EM qiuzhoub@hotmail.com; yylin@sibs.ac.cn
RI Jiang, Gan/AAO-2173-2020; Yingying, Lin/AAS-1546-2021; Weng,
   Weiji/HLH-2707-2023
OI Jiang, Gan/0000-0003-2011-741X; Weng, Weiji/0000-0003-3341-7665; Lin,
   Yingying/0000-0002-6935-5681
FU National Natural Science Foundation of China [81402042, 81671203];
   Shanghai Science and Technology [14140903400, 14YF1402600, 16140902900];
   State Key Laboratory of Oncogenes and Related Genes [90-14-01]; Shanghai
   Municipal Population and Family Planning Commission [2013SY024]; Key
   Specialty Construction Project; Science Technology Development Project
   of the Pudong Health and Family Commission of Shanghai [PWZz2013-18,
   PW2013A-19]; Shanghai Jiao Tong university [15ZH2003]; Training Plan for
   Scientific Research of Renji Hospital [RJZZ13-021]
FX Grant sponsor: National Natural Science Foundation of China; Grant
   numbers: 81402042, 81671203; Grant sponsor: Shanghai Science and
   Technology; Grant numbers: 14140903400, 14YF1402600, 16140902900; Grant
   sponsor: the State Key Laboratory of Oncogenes and Related Genes; Grant
   number: 90-14-01; Grant sponsor: the Shanghai Municipal Population and
   Family Planning Commission; Grant number: 2013SY024; Grant sponsor: the
   Key Specialty Construction Project and Science Technology Development
   Project of the Pudong Health and Family Commission of Shanghai; Grant
   numbers: PWZz2013-18 and No. PW2013A-19; Grant sponsor: Shanghai Jiao
   Tong university; Grant number: 15ZH2003; Grant sponsor: Training Plan
   for Scientific Research of Renji Hospital; Grant number: RJZZ13-021
CR Accili D, 2004, CELL, V117, P421, DOI 10.1016/S0092-8674(04)00452-0
   Butowski Nicholas A, 2006, Clin Neurosurg, V53, P106
   Chen J, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012293
   Cui YM, 2014, CANCER LETT, V353, P87, DOI 10.1016/j.canlet.2014.07.008
   de Vries NA, 2010, CLIN CANCER RES, V16, P3431, DOI 10.1158/1078-0432.CCR-09-3414
   Fan QW, 2011, AUTOPHAGY, V7, P536, DOI 10.4161/auto.7.5.14779
   Firat E, 2016, ONCOTARGET, V7, P54883, DOI 10.18632/oncotarget.10702
   Fritzen AM, 2016, J PHYSIOL-LONDON, V594, P745, DOI 10.1113/JP271405
   Fritzen AM, 2016, CELL SIGNAL, V28, P663, DOI 10.1016/j.cellsig.2016.03.005
   Grant S, 2002, FRONT BIOSCI-LANDMRK, V7, pD376, DOI 10.2741/grant
   Guo SQ, 2004, MOL CELL BIOL, V24, P8681, DOI 10.1128/MCB.24.19.8681-8690.2004
   Hu MCT, 2004, CELL, V117, P225, DOI 10.1016/S0092-8674(04)00302-2
   Hui RCY, 2008, MOL CELL BIOL, V28, P5886, DOI 10.1128/MCB.01265-07
   Hui RCY, 2008, MOL CANCER THER, V7, P670, DOI 10.1158/1535-7163.MCT-07-0397
   Kemper EM, 2006, EUR J CANCER, V42, P3294, DOI 10.1016/j.ejca.2006.07.013
   Kleihues P, 2000, CANCER, V88, P2887, DOI 10.1002/1097-0142(20000615)88:12<2887::AID-CNCR32>3.0.CO;2-F
   Kops GJPL, 2002, NATURE, V419, P316, DOI 10.1038/nature01036
   Krol J, 2007, MOL CANCER THER, V6, P3169, DOI 10.1158/1535-7163.MCT-07-0507
   Lai L, 2013, CIRCULATION, V127, P1692, DOI 10.1161/CIRCULATIONAHA.112.001212
   Lam EWF, 2006, BIOCHEM SOC T, V34, P722, DOI 10.1042/BST0340722
   Lee HY, 2008, ARTERIOSCL THROM VAS, V28, P302, DOI 10.1161/ATVBAHA.107.150664
   Lefort S, 2014, AUTOPHAGY, V10, P2122, DOI 10.4161/15548627.2014.981788
   Li ZD, 2012, J BIOL CHEM, V287, P17737, DOI 10.1074/jbc.M111.291708
   Liang B, 2016, BIOMED PHARMACOTHER, V82, P98, DOI 10.1016/j.biopha.2016.04.054
   Liang C, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-14
   Link Wolfgang, 2012, World J Biol Chem, V3, P175
   Liu H, 2015, CELL SIGNAL, V27, P510, DOI 10.1016/j.cellsig.2015.01.001
   Marlow LA, 2012, J CELL SCI, V125, P4253, DOI 10.1242/jcs.097428
   Matkar S, 2015, CANCER CELL, V28, P472, DOI 10.1016/j.ccell.2015.09.005
   Muallaoglu S, 2014, ASIAN PAC J CANCER P, V15, P1333, DOI 10.7314/APJCP.2014.15.3.1333
   Naka K, 2010, NATURE, V463, P676, DOI 10.1038/nature08734
   Ni D, 2014, CLIN CANCER RES, V20, P1779, DOI 10.1158/1078-0432.CCR-13-1687
   Nygaard M, 2014, EXP GERONTOL, V57, P41, DOI 10.1016/j.exger.2014.04.018
   Osuka S, 2013, STEM CELLS, V31, P627, DOI 10.1002/stem.1328
   Paik JH, 2007, CELL, V128, P309, DOI 10.1016/j.cell.2006.12.029
   Reardon DA, 2006, ONCOLOGIST, V11, P152, DOI 10.1634/theoncologist.11-2-152
   Shi JL, 2010, J NEURO-ONCOL, V98, P57, DOI 10.1007/s11060-009-0045-8
   Stern DF, 2000, BREAST CANCER RES, V2, P176, DOI 10.1186/bcr51
   Storz P, 2009, MOL CELL BIOL, V29, P4906, DOI 10.1128/MCB.00077-09
   Sunayama J, 2011, STEM CELLS, V29, P1327, DOI 10.1002/stem.696
   Tarrade S, 2015, INT J MOL SCI, V16, P29996, DOI 10.3390/ijms161226216
   Tong WX, 2016, HEPATOL RES, V46, P933, DOI 10.1111/hepr.12634
   Wang LL, 2013, J NEUROSCI RES, V91, P128, DOI 10.1002/jnr.23140
   Warr MR, 2013, NATURE, V494, P323, DOI 10.1038/nature11895
   Xia WZ, 2015, STEM CELL RES THER, V6, DOI 10.1186/s13287-015-0076-3
   Yang XW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075588
   Yu S, 2016, ONCOTARGET, V7, P34773, DOI 10.18632/oncotarget.8977
   Zhang CC, 2016, JNCI-J NATL CANCER I, V108, DOI 10.1093/jnci/djv375
   Zhang XL, 2015, ONCOL REP, V34, P1557, DOI 10.3892/or.2015.4078
NR 49
TC 70
Z9 78
U1 1
U2 21
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0020-7136
EI 1097-0215
J9 INT J CANCER
JI Int. J. Cancer
PD JUN 15
PY 2017
VL 140
IS 12
BP 2792
EP 2804
DI 10.1002/ijc.30690
PG 13
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA ET3DY
UT WOS:000400158800018
PM 28295288
OA Bronze
DA 2025-01-12
ER

PT J
AU Mills, AA
AF Mills, Alea A.
TI The Chromodomain Helicase DNA-Binding Chromatin Remodelers: Family
   Traits that Protect from and Promote Cancer
SO COLD SPRING HARBOR PERSPECTIVES IN MEDICINE
LA English
DT Article
ID RESISTANT PROSTATE-CANCER; TUMOR-SUPPRESSOR GENE; HUMAN
   HEPATOCELLULAR-CARCINOMA; RESECTED PANCREATIC-CANCER; HISTONE H1
   RECRUITMENT; CHARGE SYNDROME; COLORECTAL-CANCER; DAMAGE RESPONSE;
   GASTRIC-CANCER; BREAST-CANCER
AB A plethora of mutations in chromatin regulators in diverse human cancers is emerging, attesting to the pivotal role of chromatin dynamics in tumorigenesis. A recurrent theme is inactivation of the chromodomain helicase DNA-binding (CHD) family of proteins-ATP-dependent chromatin remodelers that govern the cellular machinery's access to DNA, thereby controlling fundamental processes, including transcription, proliferation, and DNA damage repair. This review highlights what is currently known about how genetic and epigenetic perturbation of CHD proteins and the pathways that they regulate set the stage for cancer, providing new insight for designing more effective anti-cancer therapies.
C1 [Mills, Alea A.] Cold Spring Harbor Lab, POB 100, Cold Spring Harbor, NY 11724 USA.
C3 Cold Spring Harbor Laboratory
RP Mills, AA (通讯作者)，Cold Spring Harbor Lab, POB 100, Cold Spring Harbor, NY 11724 USA.
EM mills@cshl.edu
FU National Institutes of Health [R01CA190997, R21OD018332]; Stanley Family
   Foundation
FX I thank members of my laboratory for helpful discussions. While every
   effort has been made to include a thorough and comprehensive review of
   the current literature, relevant publications may have been
   inadvertently omitted. This work was supported by the National
   Institutes of Health (R01CA190997 and R21OD018332) and the Stanley
   Family Foundation.
CR Adams ME, 2007, J COMP NEUROL, V504, P519, DOI 10.1002/cne.21460
   Attard G, 2016, LANCET, V387, P70, DOI 10.1016/S0140-6736(14)61947-4
   Bagchi A, 2008, CANCER RES, V68, P2551, DOI 10.1158/0008-5472.CAN-07-2095
   Bagchi A, 2007, CELL, V128, P459, DOI 10.1016/j.cell.2006.11.052
   Bandrés E, 2007, ONCOL REP, V17, P1089
   Bergman JEH, 2010, EUR J HUM GENET, V18, P171, DOI 10.1038/ejhg.2009.158
   Blattner M, 2014, NEOPLASIA, V16, P14, DOI 10.1593/neo.131704
   Brehm A, 1999, EMBO J, V18, P2449, DOI 10.1093/emboj/18.9.2449
   Burkhardt L, 2013, CANCER RES, V73, P2795, DOI 10.1158/0008-5472.CAN-12-1342
   Cai CX, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029750
   Cai Y, 2014, ONCOGENE, V33, P2157, DOI 10.1038/onc.2013.178
   Caldon CE, 2009, MOL CELL BIOL, V29, P4623, DOI 10.1128/MCB.00269-09
   Chénier S, 2014, J NEURODEV DISORD, V6, DOI 10.1186/1866-1955-6-9
   Chudnovsky Y, 2014, CELL REP, V6, P313, DOI 10.1016/j.celrep.2013.12.032
   Clark JP, 2009, NAT REV UROL, V6, P429, DOI 10.1038/nrurol.2009.127
   Colbert LE, 2014, CANCER RES, V74, P2677, DOI 10.1158/0008-5472.CAN-13-1996
   Damaschke NA, 2014, NEOPLASIA, V16, P1018, DOI 10.1016/j.neo.2014.10.003
   DELMAS V, 1993, P NATL ACAD SCI USA, V90, P2414, DOI 10.1073/pnas.90.6.2414
   Denslow SA, 2007, ONCOGENE, V26, P5433, DOI 10.1038/sj.onc.1210611
   Desai MA, 2015, NUCLEIC ACIDS RES, V43, P3100, DOI 10.1093/nar/gkv168
   Dey P, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026926
   Dingar D, 2015, J PROTEOMICS, V118, P95, DOI 10.1016/j.jprot.2014.09.029
   Du XL, 2013, CLIN TRANSL ONCOL, V15, P198, DOI 10.1007/s12094-012-0903-2
   Falconer H, 2012, GYNECOL ONCOL, V127, P398, DOI 10.1016/j.ygyno.2012.08.013
   Fang QL, 2015, INT J ONCOL, V46, P782, DOI 10.3892/ijo.2014.2776
   Fatemi M, 2014, CANCER-AM CANCER SOC, V120, P172, DOI 10.1002/cncr.28316
   Fisher KW, 2015, CURR DRUG TARGETS, V16, P103
   Flanagan JF, 2005, NATURE, V438, P1181, DOI 10.1038/nature04290
   Fu JJ, 2011, CELL RES, V21, P275, DOI 10.1038/cr.2010.118
   Fujita T, 2008, JNCI-J NATL CANCER I, V100, P940, DOI 10.1093/jnci/djn176
   Gao D, 2014, CELL, V159, P176, DOI 10.1016/j.cell.2014.08.016
   Garcia I, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-277
   Gaspar-Maia A, 2009, NATURE, V460, P863, DOI 10.1038/nature08212
   Gorringe KL, 2008, NEOPLASIA, V10, P1253, DOI 10.1593/neo.08718
   Grasso CS, 2012, NATURE, V487, P239, DOI 10.1038/nature11125
   Gui YT, 2011, NAT GENET, V43, P875, DOI 10.1038/ng.907
   Guillemette S, 2015, GENE DEV, V29, P489, DOI 10.1101/gad.256214.114
   Hall WA, 2014, ONCOGENE, V33, P5450, DOI 10.1038/onc.2013.488
   Hassan NZA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092553
   Henrich KO, 2012, CANCER RES, V72, P6079, DOI 10.1158/0008-5472.CAN-12-2230
   Hosokawa H, 2013, P NATL ACAD SCI USA, V110, P4691, DOI 10.1073/pnas.1220865110
   Huang S, 2012, ONCOGENE, V31, P4164, DOI 10.1038/onc.2011.590
   Hurd EA, 2011, HEARING RES, V282, P184, DOI 10.1016/j.heares.2011.08.005
   Ishihara K, 2006, MOL CELL, V23, P733, DOI 10.1016/j.molcel.2006.08.008
   Jiang X, 2012, AM J PATHOL, V181, P626, DOI 10.1016/j.ajpath.2012.05.006
   Jones KM, 2015, STEM CELLS, V33, P196, DOI 10.1002/stem.1822
   Kandoth C, 2013, NATURE, V502, P333, DOI 10.1038/nature12634
   Khaleque M, 2008, ONCOGENE, V27, P1886, DOI 10.1038/sj.onc.1210834
   Kim MS, 2011, HISTOPATHOLOGY, V58, P660, DOI 10.1111/j.1365-2559.2011.03819.x
   Klement K, 2014, J CELL BIOL, V207, P717, DOI 10.1083/jcb.201405077
   Koch JG, 2007, MAMM GENOME, V18, P300, DOI 10.1007/s00335-007-9028-2
   Kolla V, 2015, BIOCHEM J, V468, P345, DOI 10.1042/BJ20150030
   Koyama H, 2012, CLIN CANCER RES, V18, P1588, DOI 10.1158/1078-0432.CCR-11-2644
   Kulkarni S, 2008, AM J MED GENET A, V146A, P1117, DOI 10.1002/ajmg.a.32178
   Lang J, 2011, BRIT J DERMATOL, V164, P1010, DOI 10.1111/j.1365-2133.2011.10223.x
   Layman WS, 2010, CLIN GENET, V78, P11, DOI 10.1111/j.1399-0004.2010.01446.x
   Layman WS, 2011, HUM MOL GENET, V20, P3138, DOI 10.1093/hmg/ddr216
   Le Gallo M, 2012, NAT GENET, V44, P1310, DOI 10.1038/ng.2455
   Lee Sebum, 2010, Front Biosci (Elite Ed), V2, P22, DOI 10.2741/e61
   Lee YH, 2012, STEM CELLS DEV, V21, P2613, DOI 10.1089/scd.2011.0330
   Li H, 2012, INT J MOL MED, V30, P1081, DOI 10.3892/ijmm.2012.1118
   Li WZ, 2014, CELL CYCLE, V13, P1833, DOI 10.4161/cc.29378
   Li WZ, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4812
   Litvinov IV, 2014, ONCOIMMUNOLOGY, V3, DOI 10.4161/21624011.2014.970025
   Liu W, 2012, ONCOGENE, V31, P3939, DOI 10.1038/onc.2011.554
   Liu YL, 2014, HUM MOL GENET, V23, P2145, DOI 10.1093/hmg/ddt610
   Lyn-Cook L, 2014, TOB INDUC DIS, V12, DOI 10.1186/1617-9625-12-15
   Mallette FA, 2012, CELL REP, V2, P1233, DOI 10.1016/j.celrep.2012.09.033
   Marfella CGA, 2007, MUTAT RES-FUND MOL M, V618, P30, DOI 10.1016/j.mrfmmm.2006.07.012
   Marfella CGA, 2006, J CELL PHYSIOL, V209, P162, DOI 10.1002/jcp.20718
   Martin TJ, 2013, CANCER BIOL THER, V14, P399, DOI 10.4161/cbt.24426
   Menon T, 2010, MOL ENDOCRINOL, V24, P1165, DOI 10.1210/me.2009-0421
   Mokarram P, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007012
   Mouradov D, 2014, CANCER RES, V74, P3238, DOI 10.1158/0008-5472.CAN-14-0013
   Mulero-Navarro S, 2008, EPIGENETICS-US, V3, P210, DOI 10.4161/epi.3.4.6610
   Nagarajan P, 2009, ONCOGENE, V28, P1053, DOI 10.1038/onc.2008.440
   Nio K, 2015, J HEPATOL, V63, P1164, DOI 10.1016/j.jhep.2015.06.009
   Nishiyama M, 2012, MOL CELL BIOL, V32, P501, DOI 10.1128/MCB.06409-11
   Nishiyama M, 2009, NAT CELL BIOL, V11, P172, DOI 10.1038/ncb1831
   Ogier JM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097559
   Oliver SS, 2012, BIOCHEMISTRY-US, V51, P6534, DOI 10.1021/bi3006972
   Paul S, 2013, CELL REP, V3, P92, DOI 10.1016/j.celrep.2012.12.009
   Pleasance ED, 2010, NATURE, V463, P184, DOI 10.1038/nature08629
   Pongor L, 2015, GENOME MED, V7, DOI 10.1186/s13073-015-0228-1
   Qi WJ, 2016, MUTAGENESIS, V31, P193, DOI 10.1093/mutage/gev075
   Qu YP, 2013, CLIN CHIM ACTA, V424, P53, DOI 10.1016/j.cca.2013.05.002
   Quan JH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108066
   Quan JH, 2014, J BIOL CHEM, V289, P20717, DOI 10.1074/jbc.M114.568568
   Rahman S, 2011, MOL CELL BIOL, V31, P2641, DOI 10.1128/MCB.01341-10
   Rajagopalan S, 2012, ENVIRON MOL MUTAGEN, V53, P44, DOI 10.1002/em.20674
   Robbins CM, 2011, GENOME RES, V21, P47, DOI 10.1101/gr.107961.110
   Rodrigues LU, 2015, CANCER RES, V75, P1021, DOI 10.1158/0008-5472.CAN-14-1596
   Rodríguez D, 2015, BLOOD, V126, P195, DOI 10.1182/blood-2014-10-604959
   Ronan JL, 2013, NAT REV GENET, V14, P347, DOI 10.1038/nrg3413
   Russo J, 2012, HORM MOL BIOL CLIN I, V9, P3, DOI 10.1515/hmbci-2011-0136
   Sarahan KA, 2011, PHYSIOL GENOMICS, V43, P1049, DOI 10.1152/physiolgenomics.00134.2010
   Sawada G, 2013, ONCOL REP, V30, P1137, DOI 10.3892/or.2013.2597
   Scott AF, 2014, GENES-BASEL, V5, P366, DOI 10.3390/genes5020366
   Shen C, 2015, MOL CELL, V60, P847, DOI 10.1016/j.molcel.2015.10.033
   Shingleton JR, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0143275
   Siggens L, 2015, EPIGENET CHROMATIN, V8, DOI 10.1186/1756-8935-8-4
   Sowalsky AG, 2015, MOL CANCER RES, V13, P98, DOI 10.1158/1541-7786.MCR-14-0273
   Sperry ED, 2014, DEV DYNAM, V243, P1055, DOI [10.1002/dvdy.24156, 10.1002/DVDY.24156]
   Srinivasan R, 2006, J BIOL CHEM, V281, P15129, DOI 10.1074/jbc.M600775200
   Stanley FKT, 2013, MUTAT RES-FUND MOL M, V750, P31, DOI 10.1016/j.mrfmmm.2013.07.008
   STOKES DG, 1995, MOL CELL BIOL, V15, P2745
   Sugathan A, 2014, P NATL ACAD SCI USA, V111, pE4468, DOI 10.1073/pnas.1405266111
   Tahara T, 2014, CANCER RES, V74, P1311, DOI 10.1158/0008-5472.CAN-13-1865
   Tahara T, 2014, GASTROENTEROLOGY, V146, P530, DOI 10.1053/j.gastro.2013.10.060
   Tan S, 2014, BREAST CANCER RES, V16, DOI 10.1186/bcr3644
   Tao YG, 2011, NUCLEIC ACIDS RES, V39, P9508, DOI 10.1093/nar/gkr611
   Tereshchenko IV, 2014, PROSTATE, V74, P1551, DOI 10.1002/pros.22873
   Tian C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034944
   Torchy MP, 2015, CELL MOL LIFE SCI, V72, P2491, DOI 10.1007/s00018-015-1880-8
   Van Nostrand JL, 2014, CELL CYCLE, V13, P3798, DOI 10.4161/15384101.2014.987627
   Wang J, 2011, ORAL ONCOL, V47, P601, DOI 10.1016/j.oraloncology.2011.05.003
   Wang L, 2013, J CLIN NEUROSCI, V20, P958, DOI 10.1016/j.jocn.2012.07.021
   Wang X, 2009, J BIOMED SCI, V16, DOI 10.1186/1423-0127-16-95
   Wong RRY, 2011, GYNECOL OBSTET INVES, V72, P203, DOI 10.1159/000323883
   Wu S, 2016, ONCOTARGET, V7, P2629, DOI 10.18632/oncotarget.6380
   Wu X, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3182
   Xie CR, 2015, ONCOTARGET, V6, P40940, DOI 10.18632/oncotarget.5724
   Yamada M, 2015, GENE CHROMOSOME CANC, V54, P122, DOI 10.1002/gcc.22227
   Yu B, 2015, P NATL ACAD SCI USA, V112, pE1724, DOI 10.1073/pnas.1415569112
   Yu L, 2015, ONCOTARGET, V6, P39225, DOI 10.18632/oncotarget.4407
   Zhang XY, 2005, P NATL ACAD SCI USA, V102, P13968, DOI 10.1073/pnas.0502330102
   Zhang Y, 1998, CELL, V95, P279, DOI 10.1016/S0092-8674(00)81758-4
   Zhao R, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085172
   Zhao R, 2012, LUNG CANCER, V76, P324, DOI 10.1016/j.lungcan.2011.11.019
   Zhao SM, 2013, P NATL ACAD SCI USA, V110, P2916, DOI 10.1073/pnas.1222577110
   Zhuang TG, 2014, MECH DEVELOP, V131, P35, DOI 10.1016/j.mod.2013.10.005
NR 131
TC 48
Z9 54
U1 1
U2 7
PU COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT
PI COLD SPRING HARBOR
PA 1 BUNGTOWN RD, COLD SPRING HARBOR, NY 11724 USA
SN 2157-1422
J9 CSH PERSPECT MED
JI Cold Spring Harb. Perspect. Med.
PD APR
PY 2017
VL 7
IS 4
AR a026450
DI 10.1101/cshperspect.a026450
PG 15
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA EW0HY
UT WOS:000402171500005
PM 28096241
OA Green Accepted, Bronze, Green Published
DA 2025-01-12
ER

PT J
AU Mu, JH
   Hui, TL
   Shao, BF
   Li, LL
   Du, ZF
   Lu, L
   Ye, L
   Li, SM
   Li, QQ
   Xiao, Q
   Qiu, Z
   Zhang, Y
   Fan, JX
   Ren, GS
   Tao, Q
   Xiang, TX
AF Mu, Junhao
   Hui, Tianli
   Shao, Bianfei
   Li, Lili
   Du, Zhenfang
   Lu, Li
   Ye, Lin
   Li, Shuman
   Li, Qianqian
   Xiao, Qian
   Qiu, Zhu
   Zhang, Yan
   Fan, Jiangxia
   Ren, Guosheng
   Tao, Qian
   Xiang, Tingxiu
TI Dickkopf-related protein 2 induces G0/G1 arrest and apoptosis through
   suppressing Wnt/β-catenin signaling and is frequently methylated in
   breast cancer
SO ONCOTARGET
LA English
DT Article
DE DKK2; tumor suppressor; methylation; cancer; Wnt signaling
ID TUMOR-CELL GROWTH; EPIGENETIC INACTIVATION; UNFAVORABLE PROGNOSIS; CPG
   METHYLATION; GASTRIC-CANCER; WNT; ANTAGONIST; ANGIOGENESIS; GENE;
   CARCINOMAS
AB Dickkopf-related protein 2 (DKK2) is one of the antagonists of Wnt/beta-catenin signaling, with its downregulation reported in multiple cancers. However, how DKK2 contributes to breast tumorigenesis remains unclear. We examined its expression and promoter methylation in 10 breast tumor cell lines, 98 primary tumors, and 21 normal breast tissues. Compared with normal tissues, DKK2 was frequently silenced in breast cell lines (7/8). DKK2 promoter methylation was detected in 77.8% of cell lines and 86.7% of breast tumors; while rarely detected in normal breast tissues (19%), indicating common DKK2 methylation in breast cancer. Ectopic expression of DKK2 changed breast tumor cell morphology, inhibited cell proliferation and colony formation by inducing G0/G1 cell cycle arrest and apoptosis, and suppressed tumor cell migration by reversing epithelial-mesenchymal transition (EMT) and downregulating stem cell markers. Moreover, restored expression of DKK2 in MCF7 cells disrupted the microtube formation of human umbilical vein endothelial cells on Matrigel (R). In vivo, the growth of MDA-MB-231 cells in nude mice was markedly decreased after stable expression of DKK2. DKK2 suppressed canonical Wnt/beta-catenin signaling by inhibiting beta-catenin activity with decreased active beta-catenin protein. Thus, our findings demonstrate that DKK2 functions as a tumor suppressor through inhibiting cell proliferation and inducing apoptosis via regulating Wnt signaling during breast tumorigenesis.
C1 [Mu, Junhao; Hui, Tianli; Shao, Bianfei; Ye, Lin; Li, Shuman; Xiao, Qian; Qiu, Zhu; Zhang, Yan; Fan, Jiangxia; Ren, Guosheng; Tao, Qian; Xiang, Tingxiu] Chongqing Med Univ, Affiliated Hosp 1, Chongqing Key Lab Mol Oncol & Epigenet, Chongqing, Peoples R China.
   [Li, Lili; Du, Zhenfang; Lu, Li; Tao, Qian] Chinese Univ Hong Kong, Canc Epigenet Lab, Dept Clin Oncol, State Key Lab Oncol South,China Sir YK Pao Ctr Ca, Hong Kong, Hong Kong, Peoples R China.
   [Li, Lili; Du, Zhenfang; Lu, Li; Tao, Qian] Chinese Univ Hong Kong, Li Ka Shing Inst Hlth Sci, Hong Kong, Hong Kong, Peoples R China.
   [Li, Lili; Du, Zhenfang; Lu, Li; Tao, Qian] CUHK Shenzhen Res Inst, Hong Kong, Hong Kong, Peoples R China.
   [Li, Qianqian] Chinese Med Hosp, Linyi, Shandong, Peoples R China.
C3 Chongqing Medical University; Chinese University of Hong Kong; Chinese
   University of Hong Kong; CUHK Shenzhen Research Institute
RP Tao, Q; Xiang, TX (通讯作者)，Chongqing Med Univ, Affiliated Hosp 1, Chongqing Key Lab Mol Oncol & Epigenet, Chongqing, Peoples R China.; Tao, Q (通讯作者)，Chinese Univ Hong Kong, Canc Epigenet Lab, Dept Clin Oncol, State Key Lab Oncol South,China Sir YK Pao Ctr Ca, Hong Kong, Hong Kong, Peoples R China.; Tao, Q (通讯作者)，Chinese Univ Hong Kong, Li Ka Shing Inst Hlth Sci, Hong Kong, Hong Kong, Peoples R China.; Tao, Q (通讯作者)，CUHK Shenzhen Res Inst, Hong Kong, Hong Kong, Peoples R China.
EM qtao@cuhk.edu.hk; larissaxiang@163.com
RI Shan-Shan, Li/Q-9503-2017; 李, 倩倩/HOH-0139-2023; xiao,
   qian/IWM-0785-2023; Xiang, Tingxiu/E-6157-2016; Tao, Qian/T-4743-2018;
   Li, Lili/Q-5750-2018
OI Tao, Qian/0000-0001-5383-4808; Li, Lili/0000-0002-0292-5889
FU NSFC of China [31420103915, 81372238, 81572769, 81572327]; VC special
   research funds from Chinese University of Hong Kong
FX Supported by NSFC of China (#31420103915, #81372238, #81572769,
   #81572327) and VC special research funds from The Chinese University of
   Hong Kong.
CR Ai LB, 2006, CARCINOGENESIS, V27, P1341, DOI 10.1093/carcin/bgi379
   Chan SL, 2007, LAB INVEST, V87, P644, DOI 10.1038/labinvest.3700547
   Chenga CW, 2003, EXP CELL RES, V291, P415, DOI 10.1016/S0014-4827(03)00411-7
   Chiang KC, 2015, SCI REP-UK, V5, DOI 10.1038/srep08686
   Franco CA, 2009, CURR OPIN GENET DEV, V19, P476, DOI 10.1016/j.gde.2009.09.004
   Goodwin AM, 2007, GROWTH FACTORS, V25, P25, DOI 10.1080/08977190701272933
   Hauer K, 2013, CANCER RES, V73, P967, DOI 10.1158/0008-5472.CAN-12-1492
   Hayward P, 2008, DEVELOPMENT, V135, P411, DOI 10.1242/dev.000505
   Hirata H, 2009, CLIN CANCER RES, V15, P5678, DOI 10.1158/1078-0432.CCR-09-0558
   Hu J, 2009, CANCER RES, V69, P6951, DOI 10.1158/0008-5472.CAN-09-0541
   Hu XT, 2009, ONCOGENE, V28, P2466, DOI 10.1038/onc.2009.92
   Jézéquel P, 2013, DATABASE-OXFORD, DOI 10.1093/database/bas060
   Jézéquel P, 2012, BREAST CANCER RES TR, V131, P765, DOI 10.1007/s10549-011-1457-7
   Krupnik VE, 1999, GENE, V238, P301, DOI 10.1016/S0378-1119(99)00365-0
   Li JS, 2010, CANCER BIOL THER, V10, P617, DOI 10.4161/cbt.10.6.12609
   Li L, 2012, ONCOGENE, V31, P3901, DOI 10.1038/onc.2011.541
   Lobov IB, 2005, NATURE, V437, P417, DOI 10.1038/nature03928
   Min JK, 2011, J CLIN INVEST, V121, P1882, DOI 10.1172/JCI42556
   Mu HX, 2015, EXP CELL RES, V332, P179, DOI 10.1016/j.yexcr.2015.01.017
   Muley A, 2010, AM J PATHOL, V176, P1505, DOI 10.2353/ajpath.2010.090465
   Pukrop T, 2006, P NATL ACAD SCI USA, V103, P5454, DOI 10.1073/pnas.0509703103
   Suzuki H, 2008, BRIT J CANCER, V98, P1147, DOI 10.1038/sj.bjc.6604259
   Tao Q, 1999, AM J PATHOL, V155, P619, DOI 10.1016/S0002-9440(10)65157-7
   Tao Q, 2002, HUM MOL GENET, V11, P2091, DOI 10.1093/hmg/11.18.2091
   Veeck J, 2006, ONCOGENE, V25, P3479, DOI 10.1038/sj.onc.1209386
   Veeck J, 2008, CARCINOGENESIS, V29, P991, DOI 10.1093/carcin/bgn076
   Veeck J, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-83
   Wang Y, 2009, CANCER RES, V69, P5194, DOI 10.1158/0008-5472.CAN-08-3694
   Watanabe O, 2004, ANTICANCER RES, V24, P3851
   Xiang TX, 2013, J CELL MOL MED, V17, P1236, DOI 10.1111/jcmm.12099
   Xiang TX, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029783
   Xiang TX, 2010, CANCER BIOL THER, V10, DOI 10.4161/cbt.10.5.12726
   Xiao Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110990
   Yin XD, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3399
   Ying J, 2006, ONCOGENE, V25, P1070, DOI 10.1038/sj.onc.1209154
   Ying JM, 2008, CLIN CANCER RES, V14, P55, DOI 10.1158/1078-0432.CCR-07-1644
   Ying Y, 2009, EPIGENETICS-US, V4, P307, DOI 10.4161/epi.4.5.9371
   Yu J, 2009, CANCER-AM CANCER SOC, V115, P49, DOI 10.1002/cncr.23989
   Zerlin M, 2008, ANGIOGENESIS, V11, P63, DOI 10.1007/s10456-008-9095-3
   Zhang B, 2010, PROTEIN CELL, V1, P898, DOI 10.1007/s13238-010-0112-0
   Zhu J, 2012, CARCINOGENESIS, V33, P2334, DOI 10.1093/carcin/bgs278
NR 41
TC 30
Z9 35
U1 1
U2 8
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD JUN 13
PY 2017
VL 8
IS 24
BP 39443
EP 39459
DI 10.18632/oncotarget.17055
PG 17
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA EX5VX
UT WOS:000403311900113
PM 28467796
OA Green Published, Green Submitted, gold
DA 2025-01-12
ER

PT J
AU Jang, JE
   Eom, JI
   Jeung, HK
   Cheong, JW
   Lee, JY
   Kim, JS
   Min, YH
AF Jang, Ji Eun
   Eom, Ju-In
   Jeung, Hoi-Kyung
   Cheong, June-Won
   Lee, Jung Yeon
   Kim, Jin Seok
   Min, Yoo Hong
TI AMPK-ULK1-Mediated Autophagy Confers Resistance to BET Inhibitor JQ1 in
   Acute Myeloid Leukemia Stem Cells
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID ACUTE MYELOGENOUS LEUKEMIA; C-MYC; BROMODOMAIN INHIBITION; THERAPEUTIC
   TARGET; BREAST-CANCER; ULK1; BRD4; AMPK; PHOSPHORYLATION; INDUCTION
AB Purpose: Bromodomain and extraterminal domain (BET) inhibitors are promising epigenetic agents for the treatment of various subsets of acute myeloid leukemia (AML). However, the resistance of leukemia stem cells (LSC) to BET inhibitors remains a major challenge. In this study, we evaluated the mechanisms underlying LSC resistance to the BET inhibitor JQ1.
   Experimental Design: We evaluated the levels of apoptosis and autophagy induced by JQ1 in LSC-like leukemia cell lines and primary CD34(+)CD38(-) leukemic blasts obtained from AML cases with normal karyotype without recurrent mutations.
   Results: JQ1 effectively induced apoptosis in a concentration-dependent manner in JQ1-sensitive AML cells. However, in JQ1-resistant AML LSCs, JQ1 induced little apoptosis and led to upregulation of beclin-1, increased LC3-II lipidation, formation of autophagosomes, and downregulation of p62/SQSTM1. Inhibition of autophagy by pharmacologic inhibitors or knockdown of beclin-1 using specific siRNA enhanced JQ1-induced apoptosis in resistant cells, indicating that prosurvival autophagy occurred in these cells. Independent of mTOR signaling, activation of the AMPK (pThr172)/ULK1 (pSer555) pathway was found to be associated with JQ1-induced autophagy in resistant cells. AMPK inhibition using the pharmacologic inhibitor compound C or by knockdown of AMPK alpha suppressed autophagy and promoted JQ1-induced apoptosis in AML LSCs.
   Conclusions: These findings revealed that prosurvival autophagy was one of the mechanisms involved in the resistance AML LSCs to JQ1. Targeting the AMPK/ULK1 pathway or inhibition of autophagy could be an effective therapeutic strategy for combating resistance to BET inhibitors in AML and other types of cancer. (C) 2016 AACR.
C1 [Jang, Ji Eun; Cheong, June-Won; Lee, Jung Yeon; Kim, Jin Seok; Min, Yoo Hong] Yonsei Univ, Coll Med, Dept Internal Med, Div Hematol, Seoul, South Korea.
   [Eom, Ju-In; Jeung, Hoi-Kyung] Yonsei Univ, Coll Med, Avison Biomed Res Ctr, Seoul, South Korea.
C3 Yonsei University; Yonsei University Health System; Yonsei University;
   Yonsei University Health System
RP Min, YH (通讯作者)，Yonsei Univ, Coll Med, Div Hematol, Dept Internal Med,Severance Hosp, 50-1 Yonsei Ro, Seoul 03722, South Korea.
EM minbrmmd@yuhs.ac
RI Kim, Ji-Soo/D-8744-2012
OI min, yoo hong/0000-0001-8542-9583; KIM, JIN SEOK/0000-0001-8986-8436;
   Jang, Ji Eun/0000-0001-8832-1412; CHEONG, JUNE-WON/0000-0002-1744-0921
FU Basic Science Research Program through the National Research Foundation
   of Korea (NRF) - Ministry of Education [NRF-2015R1A2A1A15055947]
FX This project was supported by the Basic Science Research Program through
   the National Research Foundation of Korea (NRF) funded by the Ministry
   of Education (NRF-2015R1A2A1A15055947).
CR Belkina AC, 2012, NAT REV CANCER, V12, P465, DOI 10.1038/nrc3256
   Byrd JC, 2002, BLOOD, V100, P4325, DOI 10.1182/blood-2002-03-0772
   Chen JJ, 2010, NAT REV CANCER, V10, P23, DOI 10.1038/nrc2765
   Chittaranjan S, 2014, CLIN CANCER RES, V20, P3159, DOI 10.1158/1078-0432.CCR-13-2060
   Conery AR, 2016, CANCER RES, V76, P1313, DOI 10.1158/0008-5472.CAN-15-1458
   Costello RT, 1999, LEUKEMIA, V13, P1513, DOI 10.1038/sj.leu.2401519
   Coudé MM, 2015, ONCOTARGET, V6, P17698, DOI 10.18632/oncotarget.4131
   Crews LA, 2013, CANCER LETT, V338, P15, DOI 10.1016/j.canlet.2012.08.006
   Dawson MA, 2011, NATURE, V478, P529, DOI 10.1038/nature10509
   Delmore JE, 2011, CELL, V146, P903, DOI 10.1016/j.cell.2011.08.017
   Dick JE, 2008, BLOOD, V112, P4793, DOI 10.1182/blood-2008-08-077941
   Dorrance AM, 2015, LEUKEMIA, V29, P2143, DOI 10.1038/leu.2015.139
   Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383
   Egan DF, 2011, SCIENCE, V331, P456, DOI 10.1126/science.1196371
   Fiskus W, 2014, MOL CANCER THER, V13, P1142, DOI 10.1158/1535-7163.MCT-13-0770
   Fong CY, 2015, NATURE, V525, P538, DOI 10.1038/nature14888
   Fowler T, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087003
   Herrmann H, 2012, ONCOTARGET, V3, P1588, DOI 10.18632/oncotarget.733
   Jordan CT, 2007, BEST PRACT RES CL HA, V20, P13, DOI 10.1016/j.beha.2006.10.005
   Jordan CT, 2002, LEUKEMIA, V16, P559, DOI 10.1038/sj.leu.2402446
   Kim JS, 2007, CLIN CANCER RES, V13, P1019, DOI 10.1158/1078-0432.CCR-06-1602
   Kim J, 2010, CELL, V143, P313, DOI 10.1016/j.cell.2010.09.010
   Kim J, 2011, NAT CELL BIOL, V13, P132, DOI 10.1038/ncb2152
   Kim YR, 2010, J PHARMACOL EXP THER, V335, P389, DOI 10.1124/jpet.110.169367
   Kim Y, 2015, BIOMED PHARMACOTHER, V73, P87, DOI 10.1016/j.biopha.2015.05.012
   Levis M, 2003, LEUKEMIA, V17, P1738, DOI 10.1038/sj.leu.2403099
   Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257
   Lin RZ, 2013, MOL CELL BIOCHEM, V383, P13, DOI 10.1007/s11010-013-1746-z
   Lovén J, 2013, CELL, V153, P320, DOI 10.1016/j.cell.2013.03.036
   Marcucci G, 2011, J CLIN ONCOL, V29, P475, DOI 10.1200/JCO.2010.30.2554
   Nazarko VY, 2013, NAT CELL BIOL, V15, P727, DOI 10.1038/ncb2797
   Ott CJ, 2012, BLOOD, V120, P2843, DOI 10.1182/blood-2012-02-413021
   Pattingre S, 2008, BIOCHIMIE, V90, P313, DOI 10.1016/j.biochi.2007.08.014
   Pedranzini L, 2010, LEUKEMIA RES, V34, P1287, DOI 10.1016/j.leukres.2010.02.012
   Rathert P, 2015, NATURE, V525, P543, DOI 10.1038/nature14898
   Roach PJ, 2011, MOL CELL BIOL, V31, P3082, DOI 10.1128/MCB.05565-11
   Saito Y, 2015, CELL STEM CELL, V17, P585, DOI 10.1016/j.stem.2015.08.019
   Schnittger S, 2005, BLOOD, V106, P3733, DOI 10.1182/blood-2005-06-2248
   She MR, 2012, CANCER LETT, V318, P173, DOI 10.1016/j.canlet.2011.12.017
   Stewart HJS, 2013, CANCER MED-US, V2, P826, DOI 10.1002/cam4.146
   Tian WL, 2015, FEBS LETT, V589, P1847, DOI 10.1016/j.febslet.2015.05.020
   Toh PPC, 2013, HUM MOL GENET, V22, P5237, DOI 10.1093/hmg/ddt381
   Trabucco SE, 2015, CLIN CANCER RES, V21, P113, DOI 10.1158/1078-0432.CCR-13-3346
   Vardiman JW, 2009, BLOOD, V114, P937, DOI 10.1182/blood-2009-03-209262
   Vergne I, 2009, EMBO J, V28, P2244, DOI 10.1038/emboj.2009.159
   Wang HB, 2015, ONCOTARGET, V6, P15857, DOI 10.18632/oncotarget.4327
   Williams BA, 2010, CYTOTHERAPY, V12, P951, DOI 10.3109/14653241003628167
   Xie CM, 2014, AUTOPHAGY, V10, P1495, DOI 10.4161/auto.29164
   Zuber J, 2011, NATURE, V478, P524, DOI 10.1038/nature10334
NR 49
TC 98
Z9 102
U1 0
U2 31
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
EI 1557-3265
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD JUN 1
PY 2017
VL 23
IS 11
BP 2781
EP 2794
DI 10.1158/1078-0432.CCR-16-1903
PG 14
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA EW5HZ
UT WOS:000402537800026
PM 27864418
OA Green Submitted
DA 2025-01-12
ER

PT J
AU Hegedüs, L
   Padányi, R
   Molnár, J
   Pászty, K
   Varga, K
   Kenessey, I
   Sárközy, E
   Wolf, M
   Grusch, M
   Hegyi, Z
   Homolya, L
   Aigner, C
   Garay, T
   Hegedüs, B
   Timár, J
   Kállay, E
   Enyedi, A
AF Hegedues, Luca
   Padanyi, Rita
   Molnar, Judit
   Paszty, Katalin
   Varga, Karolina
   Kenessey, Istvan
   Sarkozy, Eszter
   Wolf, Matthias
   Grusch, Michael
   Hegyi, Zoltan
   Homolya, Laszlo
   Aigner, Clemens
   Garay, Tamas
   Hegedues, Balazs
   Timar, Jozsef
   Kallay, Eniko
   Enyedi, Agnes
TI Histone Deacetylase Inhibitor Treatment Increases the Expression of the
   Plasma Membrane Ca<SUP>2+</SUP> Pump PMCA4b and Inhibits the Migration
   of Melanoma Cells Independent of ERK
SO FRONTIERS IN ONCOLOGY
LA English
DT Article
DE PMCA4; PMCA1; HDAC inhibitors; cell motility; BRAF-mutant melanoma
ID UP-REGULATION; CALCIUM-PUMP; IN-VITRO; LUNG-CANCER; ISOFORM 4; COLON;
   GROWTH; IMMUNOTHERAPY; MODULATION; MEDIATORS
AB Several new therapeutic options emerged recently to treat metastatic melanoma; however, the high frequency of intrinsic and acquired resistance among patients shows a need for new therapeutic options. Previously, we identified the plasma membrane Ca2+ ATPase 4b (PMCA4b) as a metastasis suppressor in BRAF-mutant melanomas and found that mutant BRAF inhibition increased the expression of the pump, which then inhibited the migratory and metastatic capability of the cells. Earlier it was also demonstrated that histone deacetylase inhibitors (HDACis) upregulated PMCA4b expression in gastric, colon, and breast cancer cells. In this study, we treated one BRAF wild-type and two BRAF-mutant melanoma cell lines with the HDACis, SAHA and valproic acid, either alone, or in combination with the BRAF inhibitor, vemurafenib. We found that HDACi treatment strongly increased the expression of PMCA4b in all cell lines irrespective of their BRAF mutational status, and this effect was independent of ERK activity. Furthermore, HDAC inhibition also enhanced the abundance of the housekeeping isoform PMCA1. Combination of HDACis with vemurafenib, however, did not have any additive effects on either PMCA isoform. We demonstrated that the HDACi-induced increase in PMCA abundance was coupled to an enhanced [Ca2+](i) clearance rate and also strongly inhibited both the random and directional movements of A375 cells. The primary role of PMCA4b in these characteristic changes was demonstrated by treatment with the PMCA4-specific inhibitor, caloxin 1c2, which was able to restore the slower Ca2+ clearance rate and higher motility of the cells. While HDAC treatment inhibited cell motility, it decreased only modestly the ratio of proliferative cells and cell viability. Our results show that in melanoma cells the expression of both PMCA4b and PMCA1 is under epigenetic control and the elevation of PMCA4b expression either by HDACi treatment or by the decreased activation of the BRAF-MEK-ERK pathway can inhibit the migratory capacity of the highly motile A375 cells.
C1 [Hegedues, Luca; Aigner, Clemens; Hegedues, Balazs] Univ Clin Essen, Dept Thorac Surg, Ruhrlandklin, Essen, Germany.
   [Hegedues, Luca; Kallay, Eniko] Med Univ Vienna, Dept Pathophysiol & Allergy Res, Comprehens Canc Ctr Vienna, Vienna, Austria.
   [Padanyi, Rita; Molnar, Judit; Varga, Karolina; Kenessey, Istvan; Sarkozy, Eszter; Timar, Jozsef; Enyedi, Agnes] Semmelweis Univ, Inst Pathol 2, Budapest, Hungary.
   [Paszty, Katalin] Semmelweis Univ, Hungarian Acad Sci, Dept Biophys, Mol Biophys Res Grp, Budapest, Hungary.
   [Varga, Karolina] Semmelweis Univ, Hungarian Acad Sci, MTA SE NAP Brain Metastasis Res Grp, Budapest, Hungary.
   [Wolf, Matthias; Grusch, Michael] Med Univ Vienna, Comprehens Canc Ctr Vienna, Inst Canc Res, Dept Med 1, Vienna, Austria.
   [Hegyi, Zoltan; Homolya, Laszlo] Hungarian Acad Sci, Inst Enzymol, Res Ctr Nat Sci, Budapest, Hungary.
   [Garay, Tamas; Hegedues, Balazs; Timar, Jozsef; Enyedi, Agnes] Semmelweis Univ, Hungarian Acad Sci, Mol Oncol Res Grp, Budapest, Hungary.
C3 University of Duisburg Essen; Medical University of Vienna; Semmelweis
   University; Semmelweis University; Hungarian Academy of Sciences;
   Hungarian Academy of Sciences; Semmelweis University; Medical University
   of Vienna; Hungarian Academy of Sciences; Hungarian Research Network;
   HUN-REN Research Centre for Natural Sciences; Institute of Enzymology -
   HAS; Hungarian Academy of Sciences; Semmelweis University
RP Enyedi, A (通讯作者)，Semmelweis Univ, Inst Pathol 2, Budapest, Hungary.; Enyedi, A (通讯作者)，Semmelweis Univ, Hungarian Acad Sci, Mol Oncol Res Grp, Budapest, Hungary.
EM enyedi.agnes@med.semmelweis-univ.hu
RI Wolf, Matthias/G-7097-2015; Pászty, Katalin/X-3785-2019; Hegedűs,
   Luca/AFL-9911-2022; Hegedus, Balazs/HKE-7559-2023; Aigner,
   Clemens/A-7284-2019; Homolya, Laszlo/N-1154-2016; Grusch,
   Michael/C-1183-2008; Enyedi, Agnes/N-9742-2013; Hegedus,
   Balazs/B-6076-2008; Varga, Karolina/S-4431-2017
OI Grusch, Michael/0000-0001-5486-9340; Enyedi, Agnes/0000-0002-7366-9376;
   Kallay, Eniko/0000-0002-4996-0104; Hegedus, Balazs/0000-0002-4341-4153;
   Aigner, Clemens/0000-0002-7787-991X; Homolya,
   Laszlo/0000-0003-1639-8140; Varga, Karolina/0000-0003-4746-8738
FU NKFIH [ANN110922, K119223, K112371]; Hungarian Academy of Sciences
   [LP2012-025]; Austrian Science Fund (FWF) [API01662FW]
FX The authors would like to thank Krisztina Lor for her excellent
   technical assistance. This research was supported by grants from NKFIH
   (ANN110922, K119223 to EA; and K112371 to TJ), the Hungarian Academy of
   Sciences (Momentum Program LP2012-025 to LH), and the Austrian Science
   Fund (FWF) API01662FW (to EK and MG).
CR ALBINI A, 1987, CANCER RES, V47, P3239
   Antalffy G, 2013, BBA-MOL CELL RES, V1833, P2561, DOI 10.1016/j.bbamcr.2013.06.021
   Arbabian A, 2013, FEBS J, V280, P5408, DOI 10.1111/febs.12064
   Aung CS, 2007, BIOCHEM BIOPH RES CO, V355, P932, DOI 10.1016/j.bbrc.2007.02.050
   Baggott RR, 2014, ARTERIOSCL THROM VAS, V34, P2310, DOI 10.1161/ATVBAHA.114.304363
   Brouland JP, 2005, AM J PATHOL, V167, P233, DOI 10.1016/S0002-9440(10)62968-9
   Caride AJ, 1996, BIOCHEM J, V316, P353, DOI 10.1042/bj3160353
   Díaz-Núñz M, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2693-3
   Evangelista AM, 2012, ANTIOXID REDOX SIGN, V17, P1099, DOI 10.1089/ars.2011.4022
   Facchetti F, 2004, APOPTOSIS, V9, P573, DOI 10.1023/B:APPT.0000038036.31271.50
   Fang SY, 2016, J CLIN ONCOL, V34, P1741, DOI 10.1200/JCO.2015.64.1357
   Filoteo AG, 1997, J BIOL CHEM, V272, P23741, DOI 10.1074/jbc.272.38.23741
   Franklin C, 2017, EJSO-EUR J SURG ONC, V43, P604, DOI 10.1016/j.ejso.2016.07.145
   Goldinger Simone M, 2013, EJC Suppl, V11, P92, DOI 10.1016/j.ejcsup.2013.07.011
   Graeff J, 2011, PHYSIOL REV, V91, P603, DOI 10.1152/physrev.00012.2010
   Guo HZ, 2012, EXP DERMATOL, V21, P650, DOI 10.1111/j.1600-0625.2012.01565.x
   Halaban R, 2010, PIGM CELL MELANOMA R, V23, P190, DOI 10.1111/j.1755-148X.2010.00685.x
   Hegedus L, 2017, INT J CANCER, V140, P2758, DOI 10.1002/ijc.30503
   Hong CY, 2016, EXP MOL MED, V48, DOI 10.1038/emm.2016.69
   Hornig E, 2016, EXP DERMATOL, V25, P831, DOI 10.1111/exd.13089
   Johnson DB, 2015, CURR TREAT OPTION ON, V16, DOI 10.1007/s11864-015-0330-z
   Krumm A, 2016, CANCER RES, V76, P3067, DOI 10.1158/0008-5472.CAN-15-2680
   Lai F, 2012, ADV PHARMACOL, V65, P27, DOI 10.1016/B978-0-12-397927-8.00002-6
   Lehmann A, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-395
   Mottamal M, 2015, MOLECULES, V20, P3898, DOI 10.3390/molecules20033898
   Niezgoda A, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/851387
   Padányi R, 2016, BBA-MOL CELL RES, V1863, P1351, DOI 10.1016/j.bbamcr.2015.12.011
   Pászty K, 2015, SCI SIGNAL, V8, DOI 10.1126/scisignal.2005672
   Petta V, 2013, CANCER CHEMOTH PHARM, V72, P935, DOI 10.1007/s00280-013-2223-9
   Postow MA, 2015, NEW ENGL J MED, V372, P2006, DOI 10.1056/NEJMoa1414428
   Ribiczey P, 2007, CELL CALCIUM, V42, P590, DOI 10.1016/j.ceca.2007.02.003
   Ribiczey P, 2015, BIOCHEM BIOPH RES CO, V464, P189, DOI 10.1016/j.bbrc.2015.06.113
   Ritchie MF, 2011, CELL CALCIUM, V49, P314, DOI 10.1016/j.ceca.2010.10.001
   Rüschoff JH, 2012, CANCER INVEST, V30, P251, DOI 10.3109/07357907.2012.657817
   Ryan ZC, 2015, BIOCHEM BIOPH RES CO, V467, P152, DOI 10.1016/j.bbrc.2015.09.087
   Spath L, 2017, SCI REP-UK, V7, DOI 10.1038/srep40370
   Stanisz H, 2014, PIGM CELL MELANOMA R, V27, P442, DOI 10.1111/pcmr.12222
   Sullivan RJ, 2013, EUR J CANCER, V49, P1297, DOI 10.1016/j.ejca.2012.11.019
   Sun JW, 2014, J CELL BIOL, V207, P535, DOI 10.1083/jcb.201407082
   Tsai FC, 2014, NAT CELL BIOL, V16, P133, DOI 10.1038/ncb2906
   Umemura M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089292
   Varga K, 2014, CELL CALCIUM, V55, P78, DOI 10.1016/j.ceca.2013.12.003
   West AC, 2014, J CLIN INVEST, V124, P30, DOI 10.1172/JCI69738
   Woods DM, 2015, CANCER IMMUNOL RES, V3, P1375, DOI 10.1158/2326-6066.CIR-15-0077-T
   Woods DM, 2013, MELANOMA RES, V23, P341, DOI 10.1097/CMR.0b013e328364c0ed
   Zhang H, 2017, HEPATOL RES, V47, P149, DOI 10.1111/hepr.12757
   Zhang XD, 2004, MOL CANCER THER, V3, P425
NR 47
TC 24
Z9 25
U1 0
U2 10
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2234-943X
J9 FRONT ONCOL
JI Front. Oncol.
PD MAY 24
PY 2017
VL 7
AR 95
DI 10.3389/fonc.2017.00095
PG 13
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA EV8MV
UT WOS:000402036100001
PM 28596940
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Pixberg, CF
   Raba, K
   Müller, F
   Behrens, B
   Honisch, E
   Niederacher, D
   Neubauer, H
   Fehm, T
   Goering, W
   Schulz, WA
   Flohr, P
   Boysen, G
   Lambros, M
   De Bono, JS
   Knoefel, WT
   Sproll, C
   Stoecklein, NH
   Neves, RPL
AF Pixberg, C. F.
   Raba, K.
   Muller, F.
   Behrens, B.
   Honisch, E.
   Niederacher, D.
   Neubauer, H.
   Fehm, T.
   Goering, W.
   Schulz, W. A.
   Flohr, P.
   Boysen, G.
   Lambros, M.
   De Bono, J. S.
   Knoefel, W. T.
   Sproll, C.
   Stoecklein, N. H.
   Neves, R. P. L.
TI Analysis of DNA methylation in single circulating tumor cells
SO ONCOGENE
LA English
DT Article
ID EPITHELIAL-MESENCHYMAL TRANSITION; E-CADHERIN EXPRESSION; BREAST-CANCER;
   MIR-200 FAMILY; PROMOTER METHYLATION; ADHESION MOLECULE; REPRESSORS
   ZEB1; CPG ISLAND; GENE; BISULFITE
AB Direct analysis of circulating tumor cells (CTCs) can inform on molecular mechanisms underlying systemic spread. Here we investigated promoter methylation of three genes regulating epithelial-to-mesenchymal transition (EMT), a key mechanism enabling epithelial tumor cells to disseminate and metastasize. For this, we developed a single-cell protocol based on agaroseembedded bisulfite treatment, which allows investigating DNA methylation of multiple loci via a multiplex PCR (multiplexedscAEBS). We established our assay for the simultaneous analysis of three EMT-associated genes miR-200c/141, miR-200b/a/429 and CDH1 in single cells. The assay was validated in solitary cells of GM14667, MDA-MB-231 and MCF-7 cell lines, achieving a DNA amplification efficiency of 70% with methylation patterns identical to the respective bulk DNA. Then we applied multiplexedscAEBS to 159 single CTCs from 11 patients with metastatic breast and six with metastatic castration-resistant prostate cancer, isolated via CellSearch (EpCAM(pos)/CKpos/CD45(neg)/DAPI(pos)) and subsequent FACS sorting. In contrast to CD45(pos) white blood cells isolated and processed by the identical approach, we observed in the isolated CTCs methylation patterns resembling more those of epithelial-like cells. Methylation at the promoter of microRNA-200 family was significantly higher in prostate CTCs. Data from our single-cell analysis revealed an epigenetic heterogeneity among CTCs and indicates tumor-specific active epigenetic regulation of EMT-associated genes during blood-borne dissemination.
C1 [Pixberg, C. F.; Muller, F.; Behrens, B.; Knoefel, W. T.; Stoecklein, N. H.; Neves, R. P. L.] Univ Hosp, Dept Gen Visceral & Paediat Surg, Dusseldorf, Germany.
   [Pixberg, C. F.; Raba, K.; Muller, F.; Behrens, B.; Honisch, E.; Niederacher, D.; Neubauer, H.; Fehm, T.; Goering, W.; Schulz, W. A.; Knoefel, W. T.; Sproll, C.; Stoecklein, N. H.; Neves, R. P. L.] Heinrich Heine Univ Dusseldorf, Fac Med, Dusseldorf, Germany.
   [Raba, K.] Univ Hosp, Inst Transplantat Diagnost & Cell Therapeut, Dusseldorf, Germany.
   [Honisch, E.; Niederacher, D.; Neubauer, H.; Fehm, T.] Univ Hosp, Dept Obstet & Gynecol, Dusseldorf, Germany.
   [Goering, W.; Schulz, W. A.] Univ Hosp, Dept Urol, Dusseldorf, Germany.
   [Flohr, P.; Boysen, G.; Lambros, M.; De Bono, J. S.] Inst Canc Res, Div Canc Therapeut, London, England.
   [Flohr, P.; Boysen, G.; Lambros, M.; De Bono, J. S.] Inst Canc Res, Div Clin Studies, London, England.
   [Flohr, P.; Boysen, G.; Lambros, M.; De Bono, J. S.] Royal Marsden NHS Fdn Trust, Drug Dev Unit, London, England.
   [Sproll, C.] Univ Hosp, Dept Oral Maxillo & Plast Facial Surg, Dusseldorf, Germany.
C3 Heinrich Heine University Dusseldorf; Royal Marsden NHS Foundation
   Trust; University of London; Institute of Cancer Research - UK;
   University of London; Institute of Cancer Research - UK; Royal Marsden
   NHS Foundation Trust; Royal Marsden NHS Foundation Trust
RP Stoecklein, NH (通讯作者)，Heinrich Heine Univ Dusseldorf, Univ Hosp, Dept Gen Visceral & Paediat Surg, Moorenstr 5, D-40225 Dusseldorf, Germany.
EM nikolas.stoecklein@uni-duesseldorf.de
RI Raba, Katharina/B-8697-2017; Boysen, Gunnar/U-3272-2019; Neves,
   Rui/AAF-9626-2021; Schulz, Wolfgang/N-3402-2019; neubauer,
   hans/C-4467-2016
OI Fehm, Tanja/0000-0002-4926-0108; Schulz, Wolfgang/0000-0002-2196-463X;
   Boysen, Gunnar/0000-0001-8364-9881; Lousa das Neves, Rui
   Pedro/0000-0002-4515-739X; neubauer, hans/0000-0002-3467-4105; Muller,
   Fabienne/0000-0002-5845-6305; Lambros, Maryou Ballo
   Kosti/0009-0003-6445-1214; de Bono, Johann S/0000-0002-2034-595X
FU Dusseldorf School of Oncology (Comprehensive Cancer Center
   Dusseldorf/Deutsche Krebshilfe); EU grant reference EU FP7 project
   CTCTrap [305341]; Deutsche Krebshilfe [109600]; Innovative Medicines
   Initiative Joint Undertaking (IMI JU); CANCER-ID [115749]; Dusseldorf
   School of Oncology (Medical Faculty HHU Dusseldorf); Deutsche Krebshilfe
   (NHS); MRC [G0601308] Funding Source: UKRI
FX KR, BB, EH, DN, HN, TF, WTK, CS, NHS and RPLN are members of the
   Disseminated Cancer Cell Network (DCC Net) Dusseldorf. This work was
   supported by the Dusseldorf School of Oncology (funded by the
   Comprehensive Cancer Center Dusseldorf/Deutsche Krebshilfe and the
   Medical Faculty HHU Dusseldorf) (to CFP), by an EU grant reference EU
   FP7 project CTCTrap (Grant #305341 to JSDB), the Deutsche Krebshilfe
   (Grant #109600 to CS and NHS) and the Innovative Medicines Initiative
   Joint Undertaking (IMI JU) in conjunction with CANCER-ID (Grant
   Agreement #115749 to NHS).
CR Alberter B, 2016, EXPERT REV MOL DIAGN, V16, P25, DOI 10.1586/14737159.2016.1121099
   Allard WJ, 2015, CLIN CANCER RES, V21, P2883, DOI 10.1158/1078-0432.CCR-14-2559
   Armstrong AJ, 2011, MOL CANCER RES, V9, P997, DOI 10.1158/1541-7786.MCR-10-0490
   Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102
   Bracken CP, 2008, CANCER RES, V68, P7846, DOI 10.1158/0008-5472.CAN-08-1942
   Brambert PR, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117310
   Burk U, 2008, EMBO REP, V9, P582, DOI 10.1038/embor.2008.74
   Carmona FJ, 2014, CANCER RES, V74, P5608, DOI 10.1158/0008-5472.CAN-13-3659
   Chaffer CL, 2006, CANCER RES, V66, P11271, DOI 10.1158/0008-5472.CAN-06-2044
   Chimonidou M, 2013, MOL CANCER RES, V11, P1248, DOI 10.1158/1541-7786.MCR-13-0096
   Chimonidou M, 2013, CLIN CHEM, V59, P270, DOI 10.1373/clinchem.2012.191551
   Chimonidou M, 2011, CLIN CHEM, V57, P1169, DOI 10.1373/clinchem.2011.165902
   Christoffersen NR, 2007, RNA, V13, P1172, DOI 10.1261/rna.586807
   CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990
   Davalos V, 2012, ONCOGENE, V31, P2062, DOI 10.1038/onc.2011.383
   Eger A, 2005, ONCOGENE, V24, P2375, DOI 10.1038/sj.onc.1208429
   Farias EF, 2010, P NATL ACAD SCI USA, V107, P11811, DOI 10.1073/pnas.1006737107
   Friedlander TW, 2014, INT J CANCER, V134, P2284, DOI 10.1002/ijc.28561
   FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827
   Genereux DP, 2008, NUCLEIC ACIDS RES, V36, DOI 10.1093/nar/gkn691
   Geuns E, 2003, HUM MOL GENET, V12, P2873, DOI 10.1093/hmg/ddg315
   Geuns E, 2007, EUR J HUM GENET, V15, P352, DOI 10.1038/sj.ejhg.5201759
   Geuns E, 2007, J MED GENET, V44, P144, DOI 10.1136/jmg.2006.044149
   Gires O, 2014, CELL MOL LIFE SCI, V71, P4393, DOI 10.1007/s00018-014-1693-1
   Gorges TM, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-178
   Graff JR, 2000, J BIOL CHEM, V275, P2727, DOI 10.1074/jbc.275.4.2727
   Graff JR, 1997, J BIOL CHEM, V272, P22322, DOI 10.1074/jbc.272.35.22322
   GRAFF JR, 1995, CANCER RES, V55, P5195
   Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722
   Grooteclaes ML, 2000, ONCOGENE, V19, P3823, DOI 10.1038/sj.onc.1203721
   Grunau C, 2001, Nucleic Acids Res, V29, pE65, DOI 10.1093/nar/29.13.e65
   Guaita S, 2002, J BIOL CHEM, V277, P39209, DOI 10.1074/jbc.M206400200
   Hajkova Petra, 2002, Methods Mol Biol, V200, P143
   HAYATSU H, 1970, BIOCHEMISTRY-US, V9, P2858, DOI 10.1021/bi00816a016
   Heitzer E, 2013, CANCER RES, V73, P2965, DOI 10.1158/0008-5472.CAN-12-4140
   Hou JM, 2012, J CLIN ONCOL, V30, P525, DOI 10.1200/JCO.2010.33.3716
   Hurteau GJ, 2007, CANCER RES, V67, P7972, DOI 10.1158/0008-5472.CAN-07-1058
   Jones PA, 2012, NAT REV GENET, V13, P484, DOI 10.1038/nrg3230
   Korpal M, 2008, J BIOL CHEM, V283, P14910, DOI 10.1074/jbc.C800074200
   Krebs MG, 2014, NAT REV CLIN ONCOL, V11, P129, DOI 10.1038/nrclinonc.2013.253
   Larson CJ, 2004, CYTOM PART A, V62A, P46, DOI 10.1002/cyto.a.20073
   Lianidou ES, 2016, MOL ONCOL, V10, P431, DOI 10.1016/j.molonc.2016.01.011
   Lombaerts M, 2006, BRIT J CANCER, V94, P661, DOI 10.1038/sj.bjc.6602996
   Lord CJ, 2016, NAT REV CANCER, V16, P110, DOI 10.1038/nrc.2015.21
   Magbanua MJM, 2014, CANCER METAST REV, V33, P757, DOI 10.1007/s10555-014-9503-7
   MANSOURI A, 1988, DIFFERENTIATION, V38, P67, DOI 10.1111/j.1432-0436.1988.tb00593.x
   Mego M, 2010, NAT REV CLIN ONCOL, V7, P693, DOI 10.1038/nrclinonc.2010.171
   Neves Rui, 2010, BMC Res Notes, V3, P219, DOI 10.1186/1756-0500-3-219
   Neves RPL, 2014, CLIN CHEM, V60, P1290, DOI 10.1373/clinchem.2014.222331
   Olek A, 1996, NUCLEIC ACIDS RES, V24, P5064, DOI 10.1093/nar/24.24.5064
   Pal SK, 2015, CLIN GENITOURIN CANC, V13, P130, DOI 10.1016/j.clgc.2014.08.014
   Pantel K, 2016, ONCOGENE, V35, P1216, DOI 10.1038/onc.2015.192
   Park SM, 2008, GENE DEV, V22, P894, DOI 10.1101/gad.1640608
   Pixberg CF, 2015, GENES-BASEL, V6, P1053, DOI 10.3390/genes6041053
   Polioudaki H, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1386-7
   Polzer B, 2014, EMBO MOL MED, V6, P1371, DOI 10.15252/emmm.201404033
   Raimondi C, 2011, BREAST CANCER RES TR, V130, P449, DOI 10.1007/s10549-011-1373-x
   RAIZIS AM, 1995, ANAL BIOCHEM, V226, P161, DOI 10.1006/abio.1995.1204
   Rao CG, 2005, INT J ONCOL, V27, P49
   Rossi E, 2010, CLIN CANCER RES, V16, P5233, DOI 10.1158/1078-0432.CCR-10-1449
   Schwartzman O, 2015, NAT REV GENET, V16, P716, DOI 10.1038/nrg3980
   SHAPIRO R, 1973, J BIOL CHEM, V248, P4060
   Sieuwerts AM, 2009, J NATL CANCER I, V101, P61, DOI 10.1093/jnci/djn419
   Spiliotaki M, 2014, BREAST CANCER RES, V16, DOI 10.1186/s13058-014-0485-8
   Steinert G, 2014, CANCER RES, V74, P1694, DOI 10.1158/0008-5472.CAN-13-1885
   Stoecklein NH, 2016, EXPERT REV MOL DIAGN, V16, P147, DOI 10.1586/14737159.2016.1123095
   Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822
   TIERLING S, BISULFITE SEQUENCING
   Tsai JH, 2012, CANCER CELL, V22, P725, DOI 10.1016/j.ccr.2012.09.022
   Tsuji T, 2009, CANCER RES, V69, P7135, DOI 10.1158/0008-5472.CAN-09-1618
   Tsuji T, 2008, CANCER RES, V68, P10377, DOI 10.1158/0008-5472.CAN-08-1444
   Vrba L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008697
   Wiklund ED, 2011, INT J CANCER, V128, P1327, DOI 10.1002/ijc.25461
   Wu SY, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123976
   YOSHIURA K, 1995, P NATL ACAD SCI USA, V92, P7416, DOI 10.1073/pnas.92.16.7416
   Yu M, 2013, SCIENCE, V339, P580, DOI 10.1126/science.1228522
NR 76
TC 62
Z9 66
U1 1
U2 26
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-9232
EI 1476-5594
J9 ONCOGENE
JI Oncogene
PD JUN 8
PY 2017
VL 36
IS 23
BP 3223
EP 3231
DI 10.1038/onc.2016.480
PG 9
WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
GA EW9WJ
UT WOS:000402869800002
PM 28068321
OA Bronze
DA 2025-01-12
ER

PT J
AU Yu, L
   Liang, Y
   Cao, X
   Wang, X
   Gao, H
   Lin, SY
   Schiff, R
   Wang, XS
   Li, K
AF Yu, L.
   Liang, Y.
   Cao, X.
   Wang, X.
   Gao, H.
   Lin, S-Y
   Schiff, R.
   Wang, X-S
   Li, K.
TI Identification of MYST3 as a novel epigenetic activator of ERα
   frequently amplified in breast cancer
SO ONCOGENE
LA English
DT Article
ID ESTROGEN-RECEPTOR-ALPHA; ACUTE MYELOID-LEUKEMIA; HOX GENE-EXPRESSION;
   HISTONE ACETYLTRANSFERASE; ENDOCRINE RESISTANCE; THERAPEUTIC TARGET;
   8P11-P12 AMPLICON; CELL-LINES; STEM-CELLS; MOZ
AB Estrogen receptor a (ERa) is a master driver of a vast majority of breast cancers. Breast cancer cells often develop resistance to endocrine therapy via restoration of the ERa activity through survival pathways. Thus identifying the epigenetic activator of ERa that can be targeted to block ERa gene expression is a critical topic of endocrine therapy. Here, integrative genomic analysis identified MYST3 as a potential oncogene target that is frequently amplified in breast cancer. MYST3 is involved in histone acetylation via its histone acetyltransferase domain (HAT) and, as a result, activates gene expression by altering chromatin structure. We found that MYST3 was amplified in 11% and/or overexpressed in 15% of breast tumors, and overexpression of MYST3 correlated with worse clinical outcome in estrogen receptor+ (ER+) breast cancers. Interestingly, MYST3 depletion drastically inhibited proliferation in MYST3-high, ER+ breast cancer cells, but not in benign breast epithelial cells or in MYST3-low breast cancer cells. Importantly, we discovered that knocking down MYST3 resulted in profound reduction of ERa expression, while ectopic expression of MYST3 had the reversed effect. Chromatin immunoprecipitation revealed that MYST3 binds to the proximal promoter region of ERa gene, and inactivating mutations in its HAT domain abolished its ability to regulate ERa, suggesting MYST3 functioning as a histone acetyltransferase that activates ERa promoter. Furthermore, MYST3 inhibition with inducible MYST3 shRNAs potently attenuated breast tumor growth in mice. Together, this study identifies the first histone acetyltransferase that activates ERa expression which may be potentially targeted to block ERa at transcriptional level.
C1 [Yu, L.; Liang, Y.; Gao, H.; Li, K.] Baylor Coll Med, Michael E DeBakey Dept Surg, Houston, TX 77030 USA.
   [Liang, Y.; Cao, X.; Schiff, R.; Wang, X-S] Baylor Coll Med, Lester & Sue Smith Breast Ctr, Houston, TX 77030 USA.
   [Cao, X.; Wang, X.; Schiff, R.; Wang, X-S] Baylor Coll Med, Dan L Duncan Canc Ctr, Houston, TX 77030 USA.
   [Cao, X.; Wang, X.; Schiff, R.; Wang, X-S] Baylor Coll Med, Dept Med, Houston, TX 77030 USA.
   [Cao, X.; Wang, X.; Wang, X-S] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA.
   [Wang, X.; Wang, X-S] Univ Pittsburgh, Inst Canc, Pittsburgh, PA USA.
   [Wang, X.; Wang, X-S] Univ Pittsburgh, Dept Pathol, Pittsburgh, PA USA.
   [Lin, S-Y] Univ Texas MD Anderson Canc Ctr, Dept Syst Biol, Houston, TX 77030 USA.
C3 Baylor College of Medicine; Baylor College of Medicine; Baylor College
   of Medicine; Baylor College of Medicine; Baylor College of Medicine;
   Pennsylvania Commonwealth System of Higher Education (PCSHE); University
   of Pittsburgh; Pennsylvania Commonwealth System of Higher Education
   (PCSHE); University of Pittsburgh; University of Texas System; UTMD
   Anderson Cancer Center
RP Wang, XS (通讯作者)，Univ Pittsburgh, Inst Canc, Hillman Canc Ctr, Res Pavil,5117 Ctr Ave,Room G5a, Pittsburgh, PA 15213 USA.; Li, K (通讯作者)，Baylor Coll Med, ABBR, Dept Surg, One Baylor Plaza, Houston, TX 77030 USA.
EM wangx13@pitt.edu; kli@bcm.edu
FU National Institutes of Health [CA161513, CA155151, CA181368, CA183976];
   Dan L. Duncan Cancer Center at Baylor College of Medicine; Susan G.
   Komen foundation [PDF15333523, CDMRP W81XWH-13-1-0201]; Susan G. Komen
   for the cure grants Promise grant [PG12221410]; NIH SPORE Grants [P50
   CA058183, CA186784-01]; NIH Cancer Center Grant [P30CA125123]; Breast
   Cancer Research Foundation; Cancer Prevention Research Institute of
   Texas [CPRIT RP140102, CRPIT RP130310]; Cancer Research UK; British
   Columbia Cancer Agency Branch
FX This work was supported by grants from the National Institutes of Health
   (KL, CA161513, CA155151; X-SW, CA181368 & CA183976), a Pilot Project
   Grant from the Dan L. Duncan Cancer Center at Baylor College of Medicine
   (KL), Susan G. Komen foundation PDF15333523 (XW), CDMRP
   W81XWH-13-1-0201(X-XC). This study was partly supported by the Susan G.
   Komen for the cure grants Promise grant PG12221410 (RS), NIH SPORE
   Grants P50 CA058183 (RS) and CA186784-01 (RS), and Cancer Center Grant
   P30CA125123 (RS), Breast Cancer Research Foundation (RS), Cancer
   Prevention Research Institute of Texas (RS, CPRIT RP140102) and SYL,
   CRPIT RP130310. We also thank Dr. Ana Rodriguez from the Research Core
   Team at Michael E. DeBakey Department of Surgery, Baylor College of
   Medicine for editing of this manuscript. The results published here are
   in part based upon data generated by TCGA (dbGaP accession:
   phs000178.v6.p6). This study also makes use of data generated by the
   Molecular Taxonomy of Breast Cancer International Consortium (funding
   for that project was provided by Cancer Research UK and the British
   Columbia Cancer Agency Branch).
CR Agochiya M, 1999, ONCOGENE, V18, P5646, DOI 10.1038/sj.onc.1202957
   Avvakumov N, 2007, ONCOGENE, V26, P5395, DOI 10.1038/sj.onc.1210608
   Bernard-Pierrot I, 2008, CANCER RES, V68, P7165, DOI 10.1158/0008-5472.CAN-08-1360
   Borrow J, 1996, NAT GENET, V14, P33, DOI 10.1038/ng0996-33
   Bristow CAP, 2003, NUCLEIC ACIDS RES, V31, P2735, DOI 10.1093/nar/gkg401
   Carlson S, 2014, J CELL PHYSIOL, V229, P1571, DOI 10.1002/jcp.24617
   Chen X, 2002, NUCLEIC ACIDS RES, V30, P412, DOI 10.1093/nar/30.1.412
   Collins HM, 2006, J BIOL CHEM, V281, P17124, DOI 10.1074/jbc.M602633200
   Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983
   Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X
   Deguchi K, 2003, CANCER CELL, V3, P259, DOI 10.1016/S1535-6108(03)00051-5
   Ellison-Zelski SJ, 2009, MOL CELL BIOL, V29, P4949, DOI 10.1128/MCB.00383-09
   Esteyries S, 2008, LEUKEMIA, V22, P663, DOI 10.1038/sj.leu.2404930
   Feng Q, 2014, CELL RES, V24, P809, DOI 10.1038/cr.2014.71
   Georgiakaki M, 2006, MOL ENDOCRINOL, V20, P2122, DOI 10.1210/me.2005-0149
   Hervouet E, 2013, EPIGENETICS-US, V8, P237, DOI 10.4161/epi.23790
   Ignatiadis M, 2013, NAT REV CLIN ONCOL, V10, P494, DOI 10.1038/nrclinonc.2013.124
   Jeong KW, 2011, NAT STRUCT MOL BIOL, V18, P1358, DOI 10.1038/nsmb.2153
   Kim MY, 2006, MOL ENDOCRINOL, V20, P1479, DOI 10.1210/me.2005-0531
   Kim MY, 2001, EMBO J, V20, P6084, DOI 10.1093/emboj/20.21.6084
   Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412
   Kwek SS, 2009, ONCOGENE, V28, P1892, DOI 10.1038/onc.2009.34
   Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762
   Musgrove EA, 2009, NAT REV CANCER, V9, P631, DOI 10.1038/nrc2713
   Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008
   Osborne CK, 2011, ANNU REV MED, V62, P233, DOI 10.1146/annurev-med-070909-182917
   Paggetti J, 2010, ONCOGENE, V29, P5019, DOI 10.1038/onc.2010.254
   Perez-Campo FM, 2014, STEM CELLS, V32, P1591, DOI 10.1002/stem.1606
   Santarius T, 2010, NAT REV CANCER, V10, P59, DOI 10.1038/nrc2771
   Sheikh BN, 2015, ONCOGENE, V34, P5807, DOI 10.1038/onc.2015.33
   Thomas C, 2011, NAT REV CANCER, V11, P597, DOI 10.1038/nrc3093
   Turner-Ivey B, 2014, NEOPLASIA, V16, P644, DOI 10.1016/j.neo.2014.07.007
   Voss AK, 2009, DEV CELL, V17, P674, DOI 10.1016/j.devcel.2009.10.006
   Wang CG, 2001, J BIOL CHEM, V276, P18375, DOI 10.1074/jbc.M100800200
   Wang XS, 2009, NAT BIOTECHNOL, V27, P1005, DOI 10.1038/nbt.1584
   Wishart DS, 2006, NUCLEIC ACIDS RES, V34, pD668, DOI 10.1093/nar/gkj067
   Yang XJ, 2007, ONCOGENE, V26, P5408, DOI 10.1038/sj.onc.1210609
   Yang ZQ, 2006, CANCER RES, V66, P11632, DOI 10.1158/0008-5472.CAN-06-2946
   Yang ZQ, 2004, CANCER GENET CYTOGEN, V155, P57, DOI 10.1016/j.cancergencyto.2004.03.013
   Zhang XZ, 2016, PROCEEDINGS 2016 IEEE INTERNATIONAL CONFERENCE ON INDUSTRIAL TECHNOLOGY (ICIT), P2016, DOI 10.1109/ICIT.2016.7475077
NR 40
TC 47
Z9 52
U1 0
U2 15
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-9232
EI 1476-5594
J9 ONCOGENE
JI Oncogene
PD MAY 18
PY 2017
VL 36
IS 20
BP 2910
EP 2918
DI 10.1038/onc.2016.433
PG 9
WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
GA EV3ZM
UT WOS:000401697800013
PM 27893709
OA Green Accepted, hybrid, Green Published
DA 2025-01-12
ER

PT J
AU Wang, B
   Du, R
   Xiao, X
   Deng, ZL
   Jian, D
   Xie, HF
   Li, J
AF Wang, Ben
   Du, Rui
   Xiao, Xiao
   Deng, Zhi-Li
   Jian, Dan
   Xie, Hong-Fu
   Li, Ji
TI Microrna-217 modulates human skin fibroblast senescence by directly
   targeting DNA methyltransferase 1
SO ONCOTARGET
LA English
DT Article
DE DNMT1; miR-217; senescence; skin aging
ID TUMOR PROLIFERATION; BREAST-CANCER; DNMT1; METHYLATION; ACTIVATION;
   EXPRESSION; APOPTOSIS; PATHWAY; CELLS; HYPOMETHYLATION
AB DNA methyltransferase 1 (DNMT1) is a major epigenetic regulator associated with many biological processes. However, the roles and mechanisms of DNMT1 in skin aging are incompletely understood. Here we explored the role of DNMT1 in human skin fibroblasts senescence and its related regulatory mechanisms. DNMT1 expression decreased in passage-aged fibroblasts and DNMT1 silencing in young fibroblasts induced the senescence phenotype. MiR-217 is predicted to target DNMT1 mRNA and miR-217 expression increased in passage-aged fibroblasts. MiR-217 directly targeted the 3'-untranslated region (3'-UTR) of DNMT1 in HEK 293T cells and inhibited DNMT1 expression in fibroblasts. MiR-217 overexpression induced a senescence phenotype in young fibroblasts, and miR-217 downregulation in old HSFs partially reversed the senescence phenotype. However, these effects could be significantly rescued by regulating DNMT1 expression in fibroblasts. After regulating miR-217 levels, we analyzed changes in the promoter methylation levels of 24 senescent-associated genes, finding that 6 genes were significantly altered, and verified p16 and phosphorylated retinoblastoma (pRb) protein levels. Finally, an inverse correlation between DNMT1 and miR-217 expression was observed in skin tissues and different-aged fibroblasts. Together, these findings revealed that miR-217 promotes fibroblasts senescence by suppressing DNMT1-mediated methylation of p16 and pRb by targeting the DNMT1 3'-UTR.
C1 [Wang, Ben; Du, Rui; Deng, Zhi-Li; Jian, Dan; Xie, Hong-Fu; Li, Ji] Cent S Univ, Xiangya Hosp, Dept Dermatol, Changsha, Hunan, Peoples R China.
   [Xiao, Xiao] Hunan Prov Peoples Hosp, Dept Dermatol, Changsha, Hunan, Peoples R China.
   [Li, Ji] Key Lab Organ Injury Aging & Regenerat Med Hunan, Changsha, Hunan, Peoples R China.
   [Wang, Ben; Li, Ji] Cent S Univ, Xiangya Hosp, Ctr Mol Med, Changsha, Hunan, Peoples R China.
C3 Central South University; Central South University
RP Xie, HF; Li, J (通讯作者)，Cent S Univ, Xiangya Hosp, Dept Dermatol, Changsha, Hunan, Peoples R China.; Li, J (通讯作者)，Key Lab Organ Injury Aging & Regenerat Med Hunan, Changsha, Hunan, Peoples R China.; Li, J (通讯作者)，Cent S Univ, Xiangya Hosp, Ctr Mol Med, Changsha, Hunan, Peoples R China.
EM xiehongfu1964@aliyun.com; liji_xy@csu.edu.cn
RI Deng, Zhili/IXN-7122-2023
FU National Natural Science Foundation of China [81171520, 81371756,
   81271775, 81472904]; Hunan Provincial Natural Science Foundation of
   China [2015JJ1023]
FX We thank the Department of Dermatology in Xiangya Hospital of Central
   South University for collecting skin samples, and we especially thank
   the individuals who participated in this study. This research was
   supported by the National Natural Science Foundation of China (Grant
   Nos. 81171520, 81371756, 81271775, 81472904) and the Hunan Provincial
   Natural Science Foundation of China (Grant No. 2015JJ1023). The authors
   have no conflicts of interest to declare.
CR Bashtrykov P, 2015, CELL CYCLE, V14, P5, DOI 10.4161/15384101.2014.989963
   Brodie SA, 2014, CANCER PREV RES, V7, P351, DOI 10.1158/1940-6207.CAPR-13-0254
   Cai TT, 2015, GENOMICS, V105, P204, DOI 10.1016/j.ygeno.2015.01.001
   Deng SC, 2014, CANCER LETT, V355, P184, DOI 10.1016/j.canlet.2014.08.007
   Espada J, 2007, NUCLEIC ACIDS RES, V35, P2191, DOI 10.1093/nar/gkm118
   Farage MA, 2013, ADV WOUND CARE, V2, P5, DOI 10.1089/wound.2011.0356
   Fraga MF, 2005, P NATL ACAD SCI USA, V102, P10604, DOI 10.1073/pnas.0500398102
   Garzon R, 2009, BLOOD, V113, P6411, DOI 10.1182/blood-2008-07-170589
   Georgia S, 2013, GENE DEV, V27, P372, DOI 10.1101/gad.207001.112
   Goldberg AD, 2007, CELL, V128, P635, DOI 10.1016/j.cell.2007.02.006
   Hayakawa T, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116480
   Hong Q, 2011, ACTA PHARMACOL SIN, V32, P139, DOI 10.1038/aps.2011.3
   Ji WD, 2013, CARCINOGENESIS, V34, P446, DOI 10.1093/carcin/bgs343
   Johnson AA, 2012, REJUV RES, V15, P483, DOI 10.1089/rej.2012.1324
   Jung JK, 2007, CANCER RES, V67, P5771, DOI 10.1158/0008-5472.CAN-07-0529
   Li J, 2013, AUSTRALAS J DERMATOL, V51, P106
   Li J, 2012, J INVEST DERMATOL, V132, P2681, DOI 10.1038/jid.2012.206
   Li ZB, 2015, BREAST CANCER RES TR, V149, P767, DOI 10.1007/s10549-015-3276-8
   Lin RK, 2014, CELL BIOSCI, V4, DOI 10.1186/2045-3701-4-46
   Lin RK, 2010, J CLIN INVEST, V120, P521, DOI 10.1172/JCI40706
   Lin SP, 2014, STEM CELL REP, V3, P975, DOI 10.1016/j.stemcr.2014.10.002
   McCabe M, 2006, ONCOGENE, V25, P2727, DOI 10.1038/sj.onc.1209266
   Menghini R, 2009, CIRCULATION, V120, P1524, DOI 10.1161/CIRCULATIONAHA.109.864629
   Miao CG, 2014, BIOCHIMIE, V106, P149, DOI 10.1016/j.biochi.2014.08.016
   Nakanishi A, 2014, AGING DIS, V5, P203, DOI 10.14336/AD.2014.0500203
   Qadir XV, 2014, AM J PATHOL, V184, P2355, DOI 10.1016/j.ajpath.2014.05.004
   Sen GL, 2010, NATURE, V463, P563, DOI 10.1038/nature08683
   Shen L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109138
   Shervington A, 2008, OLIGONUCLEOTIDES, V18, P365, DOI 10.1089/oli.2008.0128
   Simboeck E, 2011, BIOCHEM PHARMACOL, V82, P1361, DOI 10.1016/j.bcp.2011.07.084
   Subramaniam D, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00080
   Sui CG, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0488-y
   Tang HL, 2014, MOL CANCER THER, V13, P3185, DOI 10.1158/1535-7163.MCT-14-0243
   Varol N, 2015, EXP BIOL MED, V240, P624, DOI 10.1177/1535370214556951
   Venza M, 2015, BBA-GENE REGUL MECH, V1849, P247, DOI 10.1016/j.bbagrm.2014.12.004
   Wang P, 2015, INT J ONCOL, V46, P1317, DOI 10.3892/ijo.2015.2835
   Wang Y, 2014, INT J CLIN EXP MED, V7, P1945
   Xia HP, 2013, HEPATOLOGY, V58, P629, DOI 10.1002/hep.26369
   Xiong H, 2015, NEUROBIOL AGING, V36, P1692, DOI 10.1016/j.neurobiolaging.2014.12.034
   Yoon JH, 2013, CLIN CANCER RES, V19, P4599, DOI 10.1158/1078-0432.CCR-12-3675
   Yuan DX, 2013, MUTAT RES-GEN TOX EN, V757, P125, DOI 10.1016/j.mrgentox.2013.07.007
   Zhang Q, 2015, J CANCER, V6, P184, DOI 10.7150/jca.10822
   Zhang WJ, 2008, LIFE SCI, V83, P475, DOI 10.1016/j.lfs.2008.07.015
   Zhao S, 2011, ARTHRITIS RHEUM-US, V63, P1376, DOI 10.1002/art.30196
NR 44
TC 23
Z9 24
U1 2
U2 15
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD MAY 16
PY 2017
VL 8
IS 20
BP 33475
EP 33486
DI 10.18632/oncotarget.16509
PG 12
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA EV4XS
UT WOS:000401767700089
PM 28380423
OA Green Submitted, Green Published, gold
DA 2025-01-12
ER

PT J
AU Basu, M
   Sengupta, I
   Khan, MW
   Srivastava, DK
   Chakrabarti, P
   Roy, S
   Das, C
AF Basu, Moitri
   Sengupta, Isha
   Khan, Md Wasim
   Srivastava, Dushyant Kumar
   Chakrabarti, Partha
   Roy, Siddhartha
   Das, Chandrima
TI Dual histone reader ZMYND8 inhibits cancer cell invasion by positively
   regulating epithelial genes
SO BIOCHEMICAL JOURNAL
LA English
DT Article
ID MESENCHYMAL TRANSITION; METASTASIS; EXPRESSION; PROMOTES; PROLIFERATION;
   RECOGNITION; SUPPRESSION; REPRESSION; APOPTOSIS; SNAIL
AB Enhanced migratory potential and invasiveness of cancer cells contribute crucially to cancer progression. These phenotypes are achieved by precise alteration of invasion-associated genes through local epigenetic modifications which are recognized by a class of proteins termed a chromatin reader. ZMYND8 [zinc finger MYND (myeloid, Nervy and DEAF-1)-type containing 8], a key component of the transcription regulatory network, has recently been shown to be a novel reader of H3.1K36Me2/H4K16Ac marks. Through differential gene expression analysis upon silencing this chromatin reader, we identified a subset of genes involved in cell proliferation and invasion/migration regulated by ZMYND8. Detailed analysis uncovered its antiproliferative activity through BrdU incorporation, alteration in the expression of proliferation markers, and cell cycle regulating genes and cell viability assays. In addition, performing wound healing and invasion/migration assays, its anti-invasive nature is evident. Interestingly, epithelial-mesenchymal transition (EMT), a key mechanism of cellular invasion, is regulated by ZMYND8 where we identified its selective enrichment on promoters of CLDN1/CDH1 genes, rich in H3K36Me2/H4K16Ac marks, leading to their up-regulation. Thus, the presence of ZMYND8 could be implicated in maintaining the epithelial phenotype of cells. Furthermore, syngeneic mice, injected with ZMYND8-overexpressed invasive breast cancer cells, showed reduction in tumor volume and weight. In concert with this, we observed a significant down-regulation of ZMYND8 in invasive ductal and lobular breast cancer tissues compared with normal tissue. Taken together, our study elucidates a novel function of ZMYND8 in regulating EMT and invasion of cancer cells, possibly through its chromatin reader function.
C1 [Basu, Moitri; Sengupta, Isha; Das, Chandrima] Saha Inst Nucl Phys, Biophys & Struct Genom Div, 1-AF Bidhannagar, Kolkata 700064, India.
   [Khan, Md Wasim; Chakrabarti, Partha] CSIR Indian Inst Chem Biol, Cell Biol & Physiol Div, 4 Raja SC Mullick Rd, Kolkata 700032, India.
   [Srivastava, Dushyant Kumar; Roy, Siddhartha] CSIR Indian Inst Chem Biol, Struct Biol & Bioinformat Div, 4 Raja SC Mullick Rd, Kolkata 700032, India.
C3 Saha Institute of Nuclear Physics; Council of Scientific & Industrial
   Research (CSIR) - India; CSIR - Indian Institute of Chemical Biology
   (IICB); Council of Scientific & Industrial Research (CSIR) - India; CSIR
   - Indian Institute of Chemical Biology (IICB)
RP Das, C (通讯作者)，Saha Inst Nucl Phys, Biophys & Struct Genom Div, 1-AF Bidhannagar, Kolkata 700064, India.
EM chandrima.das@saha.ac.in
RI Khan, Wasim/N-1630-2019; Das, Chandrima/AAI-7398-2021
OI Das, Chandrima/0000-0002-8117-2810; Khan, Md. Wasim/0000-0002-4398-8798
FU Department of Atomic Energy (DAE), Govt. of India [12-RD-SIN-5.04-0103];
   Science & Engineering Research Board (SERB) by the Department of Science
   and Technology (DST), Govt. of India [EMR/2014/000335]; Council of
   Scientific and Industrial Research, Govt. of India; Department of
   Biotechnology (DBT); Department of Science and Technology (DST); INSPIRE
   faculty scheme of the Department of Science and Technology (DST), Govt.
   of India
FX The study was supported by research grants entitled 'Biomolecular
   Assembly, Recognition and Dynamics (BARD)' project [Grant
   12-R&D-SIN-5.04-0103] by the Department of Atomic Energy (DAE), Govt. of
   India and Science & Engineering Research Board (SERB) File No.
   EMR/2014/000335 by the Department of Science and Technology (DST), Govt.
   of India, provided to C.D. S.R. acknowledges Network Project (UNSEEN)
   funded by the Council of Scientific and Industrial Research, Govt. of
   India. C.D. and S.R. also acknowledge Ramalingaswami Fellowship provided
   by the Department of Biotechnology (DBT) and Ramanujan Fellowship
   provided by the Department of Science and Technology (DST),
   respectively. M.B. and M.W.K. acknowledge financial support from the
   INSPIRE faculty scheme of the Department of Science and Technology
   (DST), Govt. of India.
CR Adhikary S, 2016, J BIOL CHEM, V291, P2664, DOI 10.1074/jbc.M115.679985
   Basu M, 2017, BBA-GENE REGUL MECH, V1860, P450, DOI 10.1016/j.bbagrm.2017.02.004
   Basu M, 2014, J BIOL CHEM, V289, P1415, DOI 10.1074/jbc.M113.535427
   Bierkens M, 2013, GENE CHROMOSOME CANC, V52, P56, DOI 10.1002/gcc.22006
   Chi P, 2010, NAT REV CANCER, V10, P457, DOI 10.1038/nrc2876
   Das C, 2010, J MOL BIOL, V397, P1, DOI 10.1016/j.jmb.2009.12.058
   Dong XJ, 2013, EPIGENOMICS-UK, V5, P113, DOI [10.2217/EPI.13.13, 10.2217/epi.13.13]
   Eberl HC, 2013, MOL CELL, V49, P368, DOI 10.1016/j.molcel.2012.10.026
   Edgren H, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-1-r6
   Eichmüller S, 2001, P NATL ACAD SCI USA, V98, P629, DOI 10.1073/pnas.021386498
   Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213
   Gong FD, 2015, GENE DEV, V29, P197, DOI 10.1101/gad.252189.114
   Guaita S, 2002, J BIOL CHEM, V277, P39209, DOI 10.1074/jbc.M206400200
   Heerboth S, 2015, CLIN TRANSL MED, V4, DOI 10.1186/s40169-015-0048-3
   Ikenouchi J, 2003, J CELL SCI, V116, P1959, DOI 10.1242/jcs.00389
   Jiang WG, 2015, SEMIN CANCER BIOL, V35, pS244, DOI 10.1016/j.semcancer.2015.03.008
   Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104
   Kwon MJ, 2013, INT J MOL SCI, V14, P18148, DOI 10.3390/ijms140918148
   Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758
   Li N, 2016, MOL CELL, V63, P470, DOI 10.1016/j.molcel.2016.06.035
   Lou YM, 2011, CANCER RES, V71, P3364, DOI 10.1158/0008-5472.CAN-10-4261
   Lujambio A, 2009, CELL CYCLE, V8, P377, DOI 10.4161/cc.8.3.7526
   Malovannaya A, 2011, CELL, V145, P787, DOI 10.1016/j.cell.2011.05.006
   Micalizzi DS, 2010, J MAMMARY GLAND BIOL, V15, P117, DOI 10.1007/s10911-010-9178-9
   Panagopoulos I, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063663
   Pariente R, 2016, J PINEAL RES, V60, P55, DOI 10.1111/jpi.12288
   Philip R, 2015, ONCOTARGET, V6, P2046, DOI 10.18632/oncotarget.2858
   Shen HJ, 2016, CELL, V165, P331, DOI 10.1016/j.cell.2016.02.064
   Suh Y, 2013, ONCOGENE, V32, P4873, DOI 10.1038/onc.2012.505
   Talmadge JE, 2010, CANCER RES, V70, P5649, DOI 10.1158/0008-5472.CAN-10-1040
   Taverna SD, 2007, NAT STRUCT MOL BIOL, V14, P1025, DOI 10.1038/nsmb1338
   Wada Yusaku, 2014, J Clin Bioinforma, V4, P3, DOI 10.1186/2043-9113-4-3
   Wang Y, 2013, EXP CELL RES, V319, P160, DOI 10.1016/j.yexcr.2012.07.019
   Wu JG, 2016, ELIFE, V5, DOI 10.7554/eLife.10734
   Zeng WL, 2010, BIOCHEM BIOPH RES CO, V394, P1024, DOI 10.1016/j.bbrc.2010.03.115
NR 35
TC 13
Z9 15
U1 3
U2 14
PU PORTLAND PRESS LTD
PI LONDON
PA CHARLES DARWIN HOUSE, 12 ROGER STREET, LONDON WC1N 2JU, ENGLAND
SN 0264-6021
EI 1470-8728
J9 BIOCHEM J
JI Biochem. J.
PD JUN 1
PY 2017
VL 474
IS 11
BP 1919
EP 1934
DI 10.1042/BCJ20170223
PG 16
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA EW4MG
UT WOS:000402475000012
PM 28432260
DA 2025-01-12
ER

PT J
AU Connolly, RM
   Li, HL
   Jankowitz, RC
   Zhang, Z
   Rudek, MA
   Jeter, SC
   Slater, SA
   Powers, P
   Wolff, AC
   Fetting, JH
   Brufsky, A
   Piekarz, R
   Ahuja, N
   Laird, PW
   Shen, H
   Weisenberger, DJ
   Cope, L
   Herman, JG
   Somlo, G
   Garcia, AA
   Jones, PA
   Baylin, SB
   Davidson, NE
   Zahnow, CA
   Stearns, V
AF Connolly, Roisin M.
   Li, Huili
   Jankowitz, Rachel C.
   Zhang, Zhe
   Rudek, Michelle A.
   Jeter, Stacie C.
   Slater, Shannon A.
   Powers, Penny
   Wolff, Antonio C.
   Fetting, John H.
   Brufsky, Adam
   Piekarz, Richard
   Ahuja, Nita
   Laird, Peter W.
   Shen, Hui
   Weisenberger, Daniel J.
   Cope, Leslie
   Herman, James G.
   Somlo, George
   Garcia, Agustin A.
   Jones, Peter A.
   Baylin, Stephen B.
   Davidson, Nancy E.
   Zahnow, Cynthia A.
   Stearns, Vered
TI Combination Epigenetic Therapy in Advanced Breast Cancer with
   5-Azacitidine and Entinostat: A Phase II National Cancer Institute/Stand
   Up to Cancer Study
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID HISTONE DEACETYLASE INHIBITOR; ESTROGEN-RECEPTOR; PROMOTER
   HYPERMETHYLATION; MOLECULAR SUBTYPES; GENE-EXPRESSION; SOLID TUMORS;
   METHYLATION; CELLS; AZACITIDINE; VORINOSTAT
AB Purpose: In breast cancer models, combination epigenetic therapy with a DNA methyltransferase inhibitor and a histone deacetylase inhibitor led to reexpression of genes encoding important therapeutic targets, including the estrogen receptor (ER). We conducted a multicenter phase II study of 5-azacitidine and entinostat in women with advanced hormone-resistant or triple-negative breast cancer (TNBC).
   Experimental Design: Patients received 5-azacitidine 40 mg/m(2) (days 1-5, 8-10) and entinostat 7 mg (days 3, 10) on a 28-day cycle. Continuation of epigenetic therapy was offered with the addition of endocrine therapy at the time of progression [optional continuation (OC) phase]. Primary endpoint was objective response rate (ORR) in each cohort. We hypothesized that ORR would be >= 20% against null of 5% using Simon two-stage design. At least one response was required in 1 of 13 patients per cohort to continue accrual to 27 per cohort (type I error, 4%; power, 90%).
   Results: There was one partial response among 27 women with hormone-resistant disease (ORR = 4%; 95% CI, 0-19), and none in 13 women with TNBC. One additional partial response was observed in the OC phase in the hormone-resistant cohort (n = 12). Mandatory tumor samples were obtained pre- and posttreatment (58% paired) with either up-or downregulation of ER observed in approximately 50% of posttreatment biopsies in the hormone-resistant, but not TNBC cohort.
   Conclusions: Combination epigenetic therapy was well tolerated, but our primary endpoint was not met. OC phase results suggest that some women benefit from epigenetic therapy and/or reintroduction of endocrine therapy beyond progression, but further study is needed. (C) 2016 AACR.
C1 [Connolly, Roisin M.; Li, Huili; Zhang, Zhe; Rudek, Michelle A.; Jeter, Stacie C.; Slater, Shannon A.; Powers, Penny; Wolff, Antonio C.; Fetting, John H.; Ahuja, Nita; Cope, Leslie; Baylin, Stephen B.; Zahnow, Cynthia A.; Stearns, Vered] Johns Hopkins Sch Med, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA.
   [Jankowitz, Rachel C.; Brufsky, Adam; Herman, James G.; Davidson, Nancy E.] Univ Pittsburgh, Inst Canc, Pittsburgh, PA USA.
   [Piekarz, Richard] NCI, CTEP, Bethesda, MD 20892 USA.
   [Laird, Peter W.; Shen, Hui; Jones, Peter A.] Van Andel Res Inst, Grand Rapids, MI USA.
   [Weisenberger, Daniel J.; Garcia, Agustin A.] Univ Southern Calif, Los Angeles, CA USA.
   [Somlo, George] City Hope Natl Med Ctr, Duarte, CA USA.
   [Garcia, Agustin A.] Louisiana State Univ, Sch Med, New Orleans, LA USA.
   [Davidson, Nancy E.] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA.
C3 Johns Hopkins University; Johns Hopkins Medicine; Pennsylvania
   Commonwealth System of Higher Education (PCSHE); University of
   Pittsburgh; National Institutes of Health (NIH) - USA; NIH National
   Cancer Institute (NCI); Van Andel Institute; University of Southern
   California; City of Hope; Louisiana State University System; Fred
   Hutchinson Cancer Center
RP Stearns, V (通讯作者)，Johns Hopkins Univ, Sch Med, 1650 Orleans St,Room 144, Baltimore, MD 21287 USA.
EM vstearn1@jhmi.edu
RI Weisenberger, Daniel/AAA-8314-2020; Brufsky, Adam/AAE-7470-2020; Wolff,
   Antonio/T-8796-2019; Piekarz, Richard/GXH-9978-2022; cope,
   leslie/LTE-4234-2024; LAIRD, PETER W/G-8683-2012
OI Brufsky, Adam/0000-0001-8080-7960; Wolff, Antonio/0000-0003-3734-1063;
   LAIRD, PETER W/0000-0001-9117-3641
FU Stand Up To Cancer Epigenetics Dream Team (Stand Up To Cancer is a
   program of the Entertainment Industry Foundation); Cancer Therapy
   Evaluation Program, NCI [MCR-0019-P2C, U01 CA070095, UM1CA186691];
   Specialized Program Of Research Excellence in Breast Cancer [P50
   CA88843]; Microarray Core (NIH) [P30 CA006973]; Analytical Pharmacology
   Core of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
   (NIH) [P30 CA006973, UL1 TR 001079]; Shared Instrument grant
   [1S10RR026824-01]; Clinical Protocol and Data Management facilities [P30
   CA006973, P30CA 047904]; Bioinformatics Core [P30 CA006973]; National
   Center for Advancing Translational Sciences (NCATS), a component of the
   NIH [UL1 TR 001079]; NIH Roadmap for Medical Research; Pennsylvania
   Department of Health; QVC; Fashion Footwear Association of New York
   (FFANY); Cindy Rosencrans Fund for Triple Negative Breast Cancer
   Research; Lee Jeans; Entertainment Industry Foundation
FX Research funding was provided by the Stand Up To Cancer Epigenetics
   Dream Team (Stand Up To Cancer is a program of the Entertainment
   Industry Foundation, administered by AACR), Cancer Therapy Evaluation
   Program, NCI (grants MCR-0019-P2C, U01 CA070095, and UM1CA186691),
   Specialized Program Of Research Excellence in Breast Cancer (P50
   CA88843). The project described was supported by the Microarray Core
   (NIH grants P30 CA006973) and Analytical Pharmacology Core of the Sidney
   Kimmel Comprehensive Cancer Center at Johns Hopkins (NIH grants P30
   CA006973 and UL1 TR 001079), the Shared Instrument grant
   (1S10RR026824-01), the Clinical Protocol and Data Management facilities
   (P30 CA006973 and P30CA 047904), and the Bioinformatics Core (P30
   CA006973). Grant number UL1 TR 001079 is from the National Center for
   Advancing Translational Sciences (NCATS), a component of the NIH, and
   NIH Roadmap for Medical Research. Support was also provided by the
   Pennsylvania Department of Health. The Cancer Therapy Evaluation Program
   supplied 5-azacitidine and entinostat. Support was also provided by QVC
   and Fashion Footwear Association of New York (FFANY), the Cindy
   Rosencrans Fund for Triple Negative Breast Cancer Research, and Lee
   Jeans and the Entertainment Industry Foundation.
CR Baubec T, 2015, NATURE, V520, P243, DOI 10.1038/nature14176
   Baylin SB, 2011, NAT REV CANCER, V11, P726, DOI 10.1038/nrc3130
   Bediaga NG, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2721
   BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x
   Bibikova M, 2011, GENOMICS, V98, P288, DOI 10.1016/j.ygeno.2011.07.007
   Ciccolini J, 2010, J CLIN ONCOL, V28, P160, DOI 10.1200/JCO.2009.24.4491
   Connolly R, 2012, J MAMMARY GLAND BIOL, V17, P191, DOI 10.1007/s10911-012-9263-3
   Easwaran H, 2012, GENOME RES, V22, P837, DOI 10.1101/gr.131169.111
   Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026
   Fackler MJ, 2004, CANCER RES, V64, P4442, DOI 10.1158/0008-5472.CAN-03-3341
   Fenaux P, 2009, LANCET ONCOL, V10, P223, DOI 10.1016/S1470-2045(09)70003-8
   Griffiths EA, 2013, ADV EXP MED BIOL, V754, P253, DOI 10.1007/978-1-4419-9967-2_13
   Hammond MEH, 2010, J CLIN ONCOL, V28, P2784, DOI 10.1200/JCO.2009.25.6529
   Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075
   Holm K, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2590
   Jeschke J, 2012, EPIGENETICS-US, V7, P701, DOI 10.4161/epi.20445
   Juergens RA, 2011, CANCER DISCOV, V1, P598, DOI 10.1158/2159-8290.CD-11-0214
   Kains BH, 2012, GENEFU RELEVANT FUNC
   Keen JC, 2003, BREAST CANCER RES TR, V81, P177, DOI 10.1023/A:1026146524737
   Lapidus RG, 1996, CLIN CANCER RES, V2, P805
   Lehmann BD, 2011, J CLIN INVEST, V121, P2750, DOI 10.1172/JCI45014
   Li HL, 2014, ONCOTARGET, V5, P587, DOI 10.18632/oncotarget.1782
   Munster PN, 2011, BRIT J CANCER, V104, P1828, DOI 10.1038/bjc.2011.156
   Nass SJ, 2000, CANCER RES, V60, P4346
   Olsen EA, 2007, J CLIN ONCOL, V25, P3109, DOI 10.1200/JCO.2006.10.2434
   OTTAVIANO YL, 1994, CANCER RES, V54, P2552
   Parker JS, 2009, J CLIN ONCOL, V27, P1160, DOI 10.1200/JCO.2008.18.1370
   Prebet T, 2014, J CLIN ONCOL, V32, P1242, DOI 10.1200/JCO.2013.50.3102
   Pu RT, 2003, MODERN PATHOL, V16, P1095, DOI 10.1097/01.MP.0000095782.79895.E2
   Rudek MA, 2005, J CLIN ONCOL, V23, P3906, DOI 10.1200/JCO.2005.07.450
   Sabnis GJ, 2013, MOL CANCER THER, V12, P2804, DOI 10.1158/1535-7163.MCT-13-0345
   Sabnis GJ, 2011, CANCER RES, V71, P1893, DOI 10.1158/0008-5472.CAN-10-2458
   Sargent DJ, 2001, CONTROL CLIN TRIALS, V22, P117, DOI 10.1016/S0197-2456(00)00115-X
   Schuebel KE, 2007, PLOS GENET, V3, P1709, DOI 10.1371/journal.pgen.0030157
   Sharma D, 2006, CANCER RES, V66, P6370, DOI 10.1158/0008-5472.CAN-06-0402
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Thomas PD, 2003, GENOME RES, V13, P2129, DOI 10.1101/gr.772403
   Wrangle J, 2013, ONCOTARGET, V4, P2067, DOI 10.18632/oncotarget.1542
   Yang XJ, 2014, CANCER CELL, V26, P577, DOI 10.1016/j.ccr.2014.07.028
   Yardley DA, 2013, J CLIN ONCOL, V31, P2128, DOI 10.1200/JCO.2012.43.7251
   Yoshihara K, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3612
   Zhao M, 2004, J CHROMATOGR B, V813, P81, DOI 10.1016/j.jchromb.2004.09.012
   Zhao M, 2007, J PHARMACEUT BIOMED, V43, P784, DOI 10.1016/j.jpba.2006.08.006
NR 43
TC 112
Z9 127
U1 0
U2 9
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
EI 1557-3265
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD JUN 1
PY 2017
VL 23
IS 11
BP 2691
EP 2701
DI 10.1158/1078-0432.CCR-16-1729
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA EW5HZ
UT WOS:000402537800017
PM 27979916
OA Green Accepted, Green Submitted
DA 2025-01-12
ER

PT J
AU Wu, MJ
   Kim, MR
   Chen, YS
   Yang, JY
   Chang, CJ
AF Wu, M-J
   Kim, M. R.
   Chen, Y-S
   Yang, J-Y
   Chang, C-J
TI Retinoic acid directs breast cancer cell state changes through
   regulation of TET2-PKCζ pathway
SO ONCOGENE
LA English
DT Article
ID PROTEIN-KINASE-C; EPITHELIAL-MESENCHYMAL TRANSITION; STEM-CELL;
   PKC-ZETA; PROGRESSION; METASTASIS; TRIAL; FATE
AB The key molecular mechanism governing the cancer cell state (stem cell-like state vs differentiation state) to control the cancer stem cell (CSC) pool remains elusive. This study provides the first evidence showing that all-trans retinoic acid (ATRA) induces the interaction and chromatin recruitment of a novel RAR beta-TET2 complex to epigenetically activate a specific cohort of gene targets, including MiR-200c. TET2-activated miR-200c further targets and suppresses PKC zeta, a cell polarity protein that has a pivotal role in directing asymmetric division of mammalian stem cells to sustain the stem cell pool. Our data reveal that pharmacological concentration of ATRA effectively downregulates PKC zeta through activation of miR-200c, leading to a decrease of the stem cell-like populations from non-tumorigenic mammary epithelial cells and non-aggressive breast cancer cells. However, aggressive breast cancer cells that manifest TET2-miR-200c dysregulation sustain a CSC pool highly resistant to ATRA, where inhibition of PKC zeta directs the resistant CSCs to the luminal cell-like state and sensitization to tamoxifen, resulting in abrogation of mammary tumor growth and progression. Together, these findings elucidate a novel RAR beta-TET2-miR-200c-PKC zeta signaling pathway that directs cancer cell state changes and also provide previously unidentified therapeutic implications for PKC zeta inhibitors in diminishment of breast CSCs to eradicate breast cancer.
C1 [Wu, M-J; Kim, M. R.; Chen, Y-S; Yang, J-Y; Chang, C-J] Purdue Univ, Dept Basic Med Sci, 625 Harrison St, W Lafayette, IN 47907 USA.
   [Wu, M-J; Kim, M. R.; Chen, Y-S; Yang, J-Y; Chang, C-J] Purdue Univ, Ctr Canc Res, W Lafayette, IN 47907 USA.
C3 Purdue University System; Purdue University; Purdue University System;
   Purdue University
RP Chang, CJ (通讯作者)，Purdue Univ, Dept Basic Med Sci, 625 Harrison St, W Lafayette, IN 47907 USA.
EM chunjuchang@purdue.edu
RI Wu, Meng-Ju/AAY-9410-2021; yan, jie/HNJ-0097-2023
OI Wu, Meng-Ju/0000-0001-6847-7065; Chang, Chunju/0000-0003-2887-9603
FU Department of Defense Breast Cancer Breakthrough Award
   [W81XWH-15-1-0644]; V foundation for Cancer Research Grant [V2015-019]; 
   [P30 CA023168]
FX We thank the assistance of Dr Chao-Ching Chang as well as Dr Chi-Hong
   Chao with advice on animal and biochemical experiments, and Mr Chun-Chih
   Hsu with LC-MS/MS analysis. This study was supported by Department of
   Defense Breast Cancer Breakthrough Award (W81XWH-15-1-0644 to C-J
   Chang), V foundation for Cancer Research Grant (V2015-019 to C-J Chang),
   and P30 CA023168 to the Purdue University Center for Cancer Research in
   support of the use of facilities.
CR Antal CE, 2015, CELL, V160, P489, DOI 10.1016/j.cell.2015.01.001
   Bryan M, 2011, INVEST NEW DRUG, V29, P1482, DOI 10.1007/s10637-010-9478-3
   Castoria G, 2004, MOL CELL BIOL, V24, P7643, DOI 10.1128/MCB.24.17.7643-7653.2004
   Chang CC, 2015, CANCER RES, V75, P2375, DOI 10.1158/0008-5472.CAN-14-3076
   Chang CJ, 2011, NAT CELL BIOL, V13, P317, DOI 10.1038/ncb2173
   Chao CH, 2014, J CLIN INVEST, V124, P3093, DOI 10.1172/JCI73351
   Chen Q, 2013, NATURE, V493, P561, DOI 10.1038/nature11742
   Cuzick J, 2011, LANCET ONCOL, V12, P496, DOI 10.1016/S1470-2045(11)70030-4
   Elstner E, 1998, P NATL ACAD SCI USA, V95, P8806, DOI 10.1073/pnas.95.15.8806
   Garattini E, 2007, VITAM HORM, V75, P301, DOI 10.1016/S0083-6729(06)75012-9
   Hu YF, 2009, J IMMUNOL METHODS, V347, P70, DOI 10.1016/j.jim.2009.06.008
   Ito S, 2010, NATURE, V466, P1129, DOI 10.1038/nature09303
   Knoblich JA, 2010, NAT REV MOL CELL BIO, V11, P849, DOI 10.1038/nrm3010
   Kumar BNP, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-273
   Lee GY, 2007, NAT METHODS, V4, P359, DOI 10.1038/NMETH1015
   Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027
   Martin-Belmonte F, 2012, NAT REV CANCER, V12, P23, DOI 10.1038/nrc3169
   Paul A, 2015, SCI REP-UK, V5, DOI 10.1038/srep12520
   Pece S, 2010, CELL, V140, P62, DOI 10.1016/j.cell.2009.12.007
   Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620
   Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167
   Sanjana NE, 2014, NAT METHODS, V11, P783, DOI 10.1038/nmeth.3047
   Shimono Y, 2009, CELL, V138, P592, DOI 10.1016/j.cell.2009.07.011
   Smith CA, 2007, EMBO J, V26, P468, DOI 10.1038/sj.emboj.7601495
   Song SJ, 2013, CELL, V154, P311, DOI 10.1016/j.cell.2013.06.026
   Sutton LM, 1997, CANCER CHEMOTH PHARM, V40, P335, DOI 10.1007/s002800050666
   Tang XH, 2011, ANNU REV PATHOL-MECH, V6, P345, DOI 10.1146/annurev-pathol-011110-130303
   Urtreger AJ, 2005, MOL CARCINOGEN, V42, P29, DOI 10.1002/mc.20066
   Urtreger AJ, 2012, IUBMB LIFE, V64, P18, DOI 10.1002/iub.574
   Veronesi U, 1999, J NATL CANCER I, V91, P1847, DOI 10.1093/jnci/91.21.1847
   Visvader JE, 2008, NAT REV CANCER, V8, P755, DOI 10.1038/nrc2499
   Zhang F, 2010, CANCER RES, V70, P9360, DOI 10.1158/0008-5472.CAN-10-0207
NR 32
TC 34
Z9 39
U1 0
U2 8
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-9232
EI 1476-5594
J9 ONCOGENE
JI Oncogene
PD JUN 1
PY 2017
VL 36
IS 22
BP 3193
EP 3206
DI 10.1038/onc.2016.467
PG 14
WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
GA EW6KA
UT WOS:000402617900011
PM 28218902
OA Green Published, hybrid
DA 2025-01-12
ER

PT J
AU Liu, Q
   Bonneville, R
   Li, TB
   Jin, VX
AF Liu, Qi
   Bonneville, Russell
   Li, Tianbao
   Jin, Victor X.
TI Transcription factor-associated combinatorial epigenetic pattern reveals
   higher transcriptional activity of TCF7L2-regulated intragenic enhancers
SO BMC GENOMICS
LA English
DT Article
DE T-cep; TCF7L2; Intragenic enhancer; PANC1; MCF7
ID BREAST-CANCER; CHROMATIN-STATE; TCF7L2 GENE; INTEGRATIVE ANALYSIS;
   BINDING PATTERNS; ANNOTATION; DISCOVERY; DISTINCT; SUSCEPTIBILITY;
   POLYMORPHISMS
AB Background: Recent studies have suggested that combinations of multiple epigenetic modifications are essential for controlling gene expression. Despite numerous computational approaches have been developed to decipher the combinatorial epigenetic patterns or "epigenetic code", none of them has explicitly addressed the relationship between a specific transcription factor (TF) and the patterns.
   Methods: Here, we developed a novel computational method, T-cep, for annotating chromatin states associated with a specific TF. T-cep is composed of three key consecutive modules: (i) Data preprocessing, (ii) HMM training, and (iii) Potential TF-states calling.
   Results: We evaluated T-cep on a TCF7L2-omics data. Unexpectedly, our method has uncovered a novel set of TCF7L2-regulated intragenic enhancers missed by other software tools, where the associated genes exert the highest gene expression. We further used siRNA knockdown, Co-transfection, RT-qPCR and Luciferase Reporter Assay not only to validate the accuracy and efficiency of prediction by T-cep, but also to confirm the functionality of TCF7L2-regulated enhancers in both MCF7 and PANC1 cells respectively.
   Conclusions: Our study for the first time at a genome-wide scale reveals the enhanced transcriptional activity of cell-type-specific TCF7L2 intragenic enhancers in regulating gene expression.
C1 [Liu, Qi; Li, Tianbao; Jin, Victor X.] Univ Texas Hlth Sci Ctr San Antonio, Dept Mol Med, 8403 Floyd Curl, San Antonio, TX 78229 USA.
   [Liu, Qi; Li, Tianbao] Jilin Univ, Coll Life Sci, Changchun 130012, Peoples R China.
   [Bonneville, Russell] Ohio State Univ, Biomed Sci Grad Program, Columbus, OH 43210 USA.
C3 University of Texas System; University of Texas Health Science Center at
   San Antonio; Jilin University; University System of Ohio; Ohio State
   University
RP Jin, VX (通讯作者)，Univ Texas Hlth Sci Ctr San Antonio, Dept Mol Med, 8403 Floyd Curl, San Antonio, TX 78229 USA.
EM jinv@uthscsa.edu
FU US National Institutes of Health (NIH) [R01 GM114142]; NIH; National
   Institute of General Medical Sciences [R01GM114142] Funding Source: NIH
   RePORTER
FX US National Institutes of Health (NIH) [R01 GM114142 to V.X.J]. Funding
   for open access charge: NIH.
CR Bonneville R, 2013, BIOINFORMATICS, V29, P22, DOI 10.1093/bioinformatics/bts639
   Brown AR, 2013, INT J MOL SCI, V14, P16240, DOI 10.3390/ijms140816240
   Chabner BA, 2016, JNCI-J NATL CANCER I, V108, DOI 10.1093/jnci/djv388
   Chen EY, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-128
   Day N, 2007, BIOINFORMATICS, V23, P1424, DOI 10.1093/bioinformatics/btm096
   Dunham I, 2012, NATURE, V489, P57, DOI 10.1038/nature11247
   Ernst J, 2013, GENOME RES, V23, P1142, DOI 10.1101/gr.144840.112
   Ernst J, 2012, NAT METHODS, V9, P215, DOI 10.1038/nmeth.1906
   Ernst J, 2011, NATURE, V473, P43, DOI 10.1038/nature09906
   Ernst J, 2010, NAT BIOTECHNOL, V28, P817, DOI 10.1038/nbt.1662
   Farnham PJ, 2009, NAT REV GENET, V10, P605, DOI 10.1038/nrg2636
   Frietze S, 2012, GENOME BIOL, V13, DOI 10.1186/gb-2012-13-9-r52
   Grant SFA, 2006, NAT GENET, V38, P320, DOI 10.1038/ng1732
   Hamada M, 2015, BIOINFORMATICS, V31, P2426, DOI 10.1093/bioinformatics/btv163
   Heintzman ND, 2007, NAT GENET, V39, P311, DOI 10.1038/ng1966
   Heinz S, 2015, NAT REV MOL CELL BIO, V16, P144, DOI 10.1038/nrm3949
   Hoffman Michael M, 2013, Nucleic Acids Res, V41, P827, DOI 10.1093/nar/gks1284
   Hoffman MM, 2012, NAT METHODS, V9, P473, DOI [10.1038/NMETH.1937, 10.1038/nmeth.1937]
   Hon G, 2008, PLOS COMPUT BIOL, V4, DOI 10.1371/journal.pcbi.1000201
   Iozzo RV, 2011, J CELL MOL MED, V15, P1013, DOI 10.1111/j.1582-4934.2010.01236.x
   Kirby MK, 2016, MOL ONCOL, V10, P1169, DOI 10.1016/j.molonc.2016.05.004
   Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005
   Kuleshov MV, 2016, NUCLEIC ACIDS RES, V44, pW90, DOI 10.1093/nar/gkw377
   Kundaje A, 2015, NATURE, V518, P317, DOI 10.1038/nature14248
   Liu B, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-S8-S3
   Lu XP, 2015, GENET MOL RES, V14, P2860, DOI 10.4238/2015.March.31.16
   Majidnezhad Vahid, 2014, Acta Inform Med, V22, P246, DOI 10.5455/aim.2014.22.246-248
   Mammana A, 2015, GENOME BIOL, V16, DOI 10.1186/s13059-015-0708-z
   Marrao G, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-665
   Mondal AK, 2010, J CLIN ENDOCR METAB, V95, P1450, DOI 10.1210/jc.2009-2064
   Osmark P, 2009, DIABETOLOGIA, V52, P850, DOI 10.1007/s00125-009-1293-z
   Paplomata E, 2014, THER ADV MED ONCOL, V6, P154, DOI 10.1177/1758834014530023
   Pradeepa MM, 2016, NAT GENET, V48, P681, DOI 10.1038/ng.3550
   Rada-Iglesias A, 2011, NATURE, V470, P279, DOI 10.1038/nature09692
   Ravindranath A, 2008, CURR MOL MED, V8, P38
   Reik W, 2001, SCIENCE, V293, P1089, DOI 10.1126/science.1063443
   Romanoski CE, 2015, NATURE, V518, P314, DOI 10.1038/518314a
   Spitz F, 2012, NAT REV GENET, V13, P613, DOI 10.1038/nrg3207
   Su JZ, 2012, MOL BIOL REP, V39, P1701, DOI 10.1007/s11033-011-0910-3
   Timofte D, 2014, MED-SURG J, V118, P392
   Wang F, 2015, INT J CLIN EXP MED, V8, P9355
   Wang MH, 2010, BIOINFORMATICS, V26, P2629, DOI 10.1093/bioinformatics/btq491
   Wang ZB, 2008, NAT GENET, V40, P897, DOI 10.1038/ng.154
   Weise A, 2010, NUCLEIC ACIDS RES, V38, P1964, DOI 10.1093/nar/gkp1197
   Whitaker JW, 2015, METHODS, V72, P86, DOI 10.1016/j.ymeth.2014.10.008
   Winham SJ, 2014, MOL PSYCHIATR, V19, P1010, DOI 10.1038/mp.2013.159
   Yamaga R, 2013, HORM CANCER-US, V4, P222, DOI 10.1007/s12672-013-0140-3
   Zentner GE, 2011, GENOME RES, V21, P1273, DOI 10.1101/gr.122382.111
   Zhou VW, 2011, NAT REV GENET, V12, P7, DOI 10.1038/nrg2905
NR 49
TC 13
Z9 15
U1 0
U2 2
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471-2164
J9 BMC GENOMICS
JI BMC Genomics
PD MAY 12
PY 2017
VL 18
AR 375
DI 10.1186/s12864-017-3764-9
PG 13
WC Biotechnology & Applied Microbiology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Genetics & Heredity
GA EV2HU
UT WOS:000401577000003
PM 28499350
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU Acun, T
   Doberstein, N
   Habermann, JK
   Gemoll, T
   Thorns, C
   Oztas, E
   Ried, T
AF Acun, Tolga
   Doberstein, Natalie
   Habermann, Jens K.
   Gemoll, Timo
   Thorns, Christoph
   Oztas, Emin
   Ried, Thomas
TI <i>HLJ1</i> (<i>DNAJB4</i>) Gene Is a Novel Biomarker Candidate in
   Breast Cancer
SO OMICS-A JOURNAL OF INTEGRATIVE BIOLOGY
LA English
DT Article
DE breast cancer biomarkers; DNAJB4; HLJ1; epigenomics; precision medicine
ID TUMOR-SUPPRESSOR HLJ1; CELL LUNG-CARCINOMA; EXPRESSION; INVASION;
   PROTEIN; PROGRESSION; METASTASIS; ACTIVATION; ONCOLOGY; SURVIVAL
AB Breast cancer is the most common cancer type and cause of cancer-related mortality among women worldwide. New biomarker discovery is crucial for diagnostic innovation and personalized medicine in breast cancer. Heat shock proteins (HSPs) have been increasingly reported as biomarkers and potential drug targets for cancers. HLJ1 (DNAJB4) belongs to the DNAJ (HSP40) family of HSPs and is regarded as a tumor suppressor gene in lung, colon, and gastric cancers. However, the role of the HLJ1 gene in breast cancer is currently unknown. We evaluated the role of the HLJ1 gene in breast cancer progression by analyzing its in vitro and in vivo expression and its genetic/epigenetic alterations. HLJ1 expression was found to be reduced or lost in breast cancer cell lines (SK-BR-3, MDA-MB-231, ZR-75-1) compared with the nontumorigenic mammary epithelial cell line (MCF 10A). In a clinical context for breast cancer progression, the HLJ1 expression was significantly less frequent in invasive breast carcinoma samples (n=230) compared with normal breast tissue (n=100), benign neoplasia (n=53), and ductal carcinoma in situ (n=21). In methylation analyses by the combined bisulfite restriction analysis assay, the CpG island located in the 5-flanking region of the HLJ1 gene was found to be methylated in breast cancer cell lines. HLJ1 expression was restored in the ZR-75-1 cell line by DNA demethylating agent 5-Aza-2-deoxycytidine (5-AzadC) and histone deacetylase inhibitor trichostatin A. These new observations support the idea that HLJ1 is a tumor suppressor candidate and potential biomarker for breast cancer. Epigenomic mechanisms such as CpG methylation and histone deacetylation might contribute to downregulation of HLJ1 expression. We call for future functional, epigenomic, and clinical studies to ascertain the contribution of HLJ1 to breast cancer pathogenesis and, importantly, evaluate its potential for biomarker development in support of personalized medicine diagnostic innovation in clinical oncology.
C1 [Acun, Tolga] Bulent Ecevit Univ, Dept Mol Biol & Genet, TR-67100 Zonguldak, Turkey.
   [Doberstein, Natalie; Habermann, Jens K.; Gemoll, Timo] Univ Lubeck, Sect Translat Surg Oncol & Biobanking, Dept Surg, Lubeck, Germany.
   [Doberstein, Natalie; Habermann, Jens K.; Gemoll, Timo; Thorns, Christoph] Univ Med Ctr Schleswig Holstein, Lubeck, Germany.
   [Thorns, Christoph] Univ Lubeck, Inst Pathol, Lubeck, Germany.
   [Oztas, Emin] Gulhane Mil Med Acad, Dept Med Histol & Embryol, Ankara, Turkey.
   [Ried, Thomas] NCI, Genet Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.
C3 Zonguldak Bulent Ecevit University; University of Lubeck; University of
   Kiel; Schleswig Holstein University Hospital; University of Lubeck;
   Gulhane Military Medical Academy; National Institutes of Health (NIH) -
   USA; NIH National Cancer Institute (NCI)
RP Acun, T (通讯作者)，Bulent Ecevit Univ, Dept Mol Biol & Genet, TR-67100 Zonguldak, Turkey.
EM tolga.acun@beun.edu.tr
RI Gemoll, Timo/P-6547-2019; Habermann, Jens/AAA-5149-2020; ACUN,
   TOLGA/AAI-7138-2021
OI Habermann, Jens K./0000-0002-3127-4755; ACUN, TOLGA/0000-0001-7636-1783
FU Bulent Ecevit University (Zonguldak, Turkey) [2013-50737594-01];
   Fulbright Visiting Scholar Program
FX This project was supported by Bulent Ecevit University (Zonguldak,
   Turkey) (Grant No. 2013-50737594-01) and the Fulbright Visiting Scholar
   Program to Dr. Acun. The study was conducted in cooperation with the US
   National Cancer Institute (MD). The authors thank Dr. Darawalee Wangsa
   Zong, Danny Wangsa, Dr. Nicole E. McNeil, Buddy Chen, and Mai T. Tran
   for scientific and technical support to the project.
CR Banerjee K, 2016, INT J CANCER, V138, P2570, DOI 10.1002/ijc.29923
   Berx G, 2001, BREAST CANCER RES, V3, P289, DOI 10.1186/bcr309
   Cellurale C, 2012, CANCER RES, V72, P472, DOI 10.1158/0008-5472.CAN-11-1628
   Chang TP, 2010, CANCER RES, V70, P1656, DOI 10.1158/0008-5472.CAN-09-2453
   Chen CH, 2016, ONCOGENE, V35, P5674, DOI 10.1038/onc.2016.106
   Chen HW, 2008, CANCER RES, V68, P7428, DOI 10.1158/0008-5472.CAN-07-6734
   Crinelli R, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136882
   Dai XF, 2015, AM J CANCER RES, V5, P2929
   Duffy MJ, 2000, BREAST CANCER RES, V2, P252, DOI 10.1186/bcr65
   Dzobo K, 2016, OMICS, V20, P681, DOI 10.1089/omi.2016.0152
   Esteller M, 2007, NAT REV GENET, V8, P286, DOI 10.1038/nrg2005
   Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210
   Finn RS, 2008, ANN ONCOL, V19, P1379, DOI 10.1093/annonc/mdn291
   Forbes SA, 2015, NUCLEIC ACIDS RES, V43, pD805, DOI 10.1093/nar/gku1075
   Gur-Dedeoglu B, 2009, ONCOL RES, V17, P353, DOI 10.3727/096504009788428460
   Hageman J, 2010, MOL CELL, V37, P355, DOI 10.1016/j.molcel.2010.01.001
   Heiser LM, 2012, P NATL ACAD SCI USA, V109, P2724, DOI 10.1073/pnas.1018854108
   Jaeger AM, 2014, J BIOL CHEM, V289, P30459, DOI 10.1074/jbc.M114.591578
   Kao J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006146
   Khalil AA, 2011, BBA-REV CANCER, V1816, P89, DOI 10.1016/j.bbcan.2011.05.001
   Lai YH, 2013, CARCINOGENESIS, V34, P1069, DOI 10.1093/carcin/bgt005
   Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427
   Lin SY, 2010, NUCLEIC ACIDS RES, V38, P6148, DOI 10.1093/nar/gkq412
   Liu Y, 2014, INT J CLIN EXP PATHO, V7, P969
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Oberländer M, 2014, PATHOL ONCOL RES, V20, P719, DOI 10.1007/s12253-014-9752-3
   Ozgur Aykut, 2014, Microrna, V3, P118
   Pellikainen J, 2002, CLIN CANCER RES, V8, P3487
   Reinhold WC, 2012, CANCER RES, V72, P3499, DOI 10.1158/0008-5472.CAN-12-1370
   Simoes-Correia J, 2014, HUM MOL GENET, V23, P2094, DOI 10.1093/hmg/ddt602
   Sterrenberg JN, 2011, CANCER LETT, V312, P129, DOI 10.1016/j.canlet.2011.08.019
   Thomford NE, 2016, OMICS, V20, P528, DOI 10.1089/omi.2016.0117
   Toss A, 2015, BREAST CANCER RES, V17, DOI 10.1186/s13058-015-0560-9
   Trinklein ND, 2004, MOL BIOL CELL, V15, P1254, DOI 10.1091/mbc.E03-10-0738
   Tsai MF, 2006, JNCI-J NATL CANCER I, V98, P825, DOI 10.1093/jnci/djj229
   Wang CC, 2005, ONCOGENE, V24, P4081, DOI 10.1038/sj.onc.1208573
   Wang CC, 2007, CANCER RES, V67, P4816, DOI 10.1158/0008-5472.CAN-07-0504
   Wang C, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/563838
   Xiong ZG, 1997, NUCLEIC ACIDS RES, V25, P2532, DOI 10.1093/nar/25.12.2532
NR 39
TC 16
Z9 18
U1 0
U2 8
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1536-2310
EI 1557-8100
J9 OMICS
JI OMICS
PD MAY
PY 2017
VL 21
IS 5
BP 257
EP 265
DI 10.1089/omi.2017.0016
PG 9
WC Biotechnology & Applied Microbiology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Genetics & Heredity
GA EU3JH
UT WOS:000400924700002
PM 28481734
OA Green Published
DA 2025-01-12
ER

PT J
AU Esparza-López, J
   Escobar-Arriaga, E
   Soto-Germes, S
   Ibarra-Sánchez, MD
AF Esparza-Lopez, Jose
   Escobar-Arriaga, Elizabeth
   Soto-Germes, Santos
   De Jesus Ibarra-Sanchez, Maria
TI BREAST CANCER INTRA-TUMOR HETEROGENEITY: ONE TUMOR, DIFFERENT ENTITIES
SO REVISTA DE INVESTIGACION CLINICA-CLINICAL AND TRANSLATIONAL
   INVESTIGATION
LA English
DT Article
DE Breast cancer; Cancer stem cell; Clonal evolution; Intra-tumor
   heterogeneity
ID EPITHELIAL-MESENCHYMAL TRANSITION; IN-SITU HYBRIDIZATION; DNA
   METHYLATION; GENETIC-HETEROGENEITY; PROMOTER METHYLATION; CLONAL
   EVOLUTION; STEM-CELLS; POLY(ADP-RIBOSE) POLYMERASE;
   MULTIDRUG-RESISTANCE; MUTATIONAL EVOLUTION
AB In recent years, it has become evident that intra-tumor heterogeneity of breast cancer is a big challenge for the diagnosis, treatment, and clinical course of tumor-bearing patients. The advances in molecular biology and other technologies have led to the knowledge that a breast cancer tumor is comprised of multiple cellular entities. Here we review the two theories that have been described, trying to explain the origin of intra-tumor heterogeneity: clonal evolution and cancer stem cells. The first one considers that a single cell gives rise to many subpopulations through the accumulation of multiple aberrations, while the cancer stem cells theory foresees a hierarchical tumor evolution where only a few cells with self-renewal capacity give rise to different subpopulations. We also analyze the genetic, epigenetic, and microenvironment contributions to breast cancer intra-tumor heterogeneity. Finally, the clinical and therapeutic impact of intra-tumor heterogeneity on the outcome of breast cancer patients is discussed.
C1 [Esparza-Lopez, Jose; De Jesus Ibarra-Sanchez, Maria] Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Biochem Unit, Vasco Quiroga 15,Col Belisario Dominguez,Secc 16, Mexico City 14080, DF, Mexico.
   [Escobar-Arriaga, Elizabeth] Hosp Angeles Pedregal, Oncol Ctr, Mexico City, DF, Mexico.
   [Soto-Germes, Santos] Hosp Med Sur, Integral Oncol Ctr, Serv Tumores Mamarios, Mexico City, DF, Mexico.
C3 Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran -
   Mexico
RP Ibarra-Sánchez, MD (通讯作者)，Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Biochem Unit, Vasco Quiroga 15,Col Belisario Dominguez,Secc 16, Mexico City 14080, DF, Mexico.
EM maria.ibarras@incmnsz.mx
RI Ibarra-Sánchez, María/C-4722-2008; ESPARZA-LOPEZ, JOSE/AAQ-7199-2021
CR Al-Hajj M, 2004, CURR OPIN GENET DEV, V14, P43, DOI 10.1016/j.gde.2003.11.007
   Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100
   Almendro V, 2013, ANNU REV PATHOL-MECH, V8, P277, DOI 10.1146/annurev-pathol-020712-163923
   Andersson J, 2004, APPL IMMUNOHISTO M M, V12, P14
   Arrowsmith CH, 2012, NAT REV DRUG DISCOV, V11, P384, DOI 10.1038/nrd3674
   Ashworth A, 2011, CELL, V145, P30, DOI 10.1016/j.cell.2011.03.020
   Bal A, 2012, VIRCHOWS ARCH, V461, P305, DOI 10.1007/s00428-012-1286-z
   Balkwill F, 2001, LANCET, V357, P539, DOI 10.1016/S0140-6736(00)04046-0
   Barekati Z, 2010, HUM MOL GENET, V19, P2936, DOI 10.1093/hmg/ddq199
   Baylin SB, 2011, NAT REV CANCER, V11, P726, DOI 10.1038/nrc3130
   Bednarz-Knoll N, 2012, CANCER METAST REV, V31, P673, DOI 10.1007/s10555-012-9370-z
   Berman BP, 2012, NAT GENET, V44, P40, DOI 10.1038/ng.969
   Bestor TH, 2006, NAT GENET, V38, P274, DOI 10.1038/ng0306-274
   Birgisdottir V, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1522
   Bissell MJ, 2011, NAT MED, V17, P320, DOI 10.1038/nm.2328
   Bolli N, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms3997
   Bonnomet A, 2012, ONCOGENE, V31, P3741, DOI 10.1038/onc.2011.540
   Bonsing BA, 2000, GENE CHROMOSOME CANC, V28, P173, DOI 10.1002/(SICI)1098-2264(200006)28:2<173::AID-GCC6>3.0.CO;2-1
   Burrell RA, 2013, NATURE, V501, P338, DOI 10.1038/nature12625
   Bussard KM, 2016, BREAST CANCER RES, V18, DOI 10.1186/s13058-016-0740-2
   Campos-Sánchez E, 2015, BBA-GENE REGUL MECH, V1849, P436, DOI 10.1016/j.bbagrm.2014.07.003
   Castaño Z, 2012, SEMIN CANCER BIOL, V22, P462, DOI 10.1016/j.semcancer.2012.04.006
   Celià-Terrassa T, 2012, J CLIN INVEST, V122, P1849, DOI 10.1172/JCI59218
   Chaffer CL, 2013, CELL, V154, P61, DOI 10.1016/j.cell.2013.06.005
   Cho YH, 2010, ANTICANCER RES, V30, P2489
   Cimino-Mathews A, 2015, ONCOLOGY-NY, V29, P375
   Collins N, 1997, BRIT J CANCER, V76, P1150, DOI 10.1038/bjc.1997.526
   Conze D, 2001, CANCER RES, V61, P8851
   Creighton CJ, 2009, P NATL ACAD SCI USA, V106, P13820, DOI 10.1073/pnas.0905718106
   Demaria S, 2001, CLIN CANCER RES, V7, P3025
   DeNardo DG, 2011, CANCER DISCOV, V1, P54, DOI 10.1158/2159-8274.CD-10-0028
   Denkert C, 2010, J CLIN ONCOL, V28, P105, DOI 10.1200/JCO.2009.23.7370
   Dobrovic A, 1997, CANCER RES, V57, P3347
   Dunn GP, 2002, NAT IMMUNOL, V3, P991, DOI 10.1038/ni1102-991
   Emens LA, 2012, EXPERT REV ANTICANC, V12, P1597, DOI [10.1586/era.12.147, 10.1586/ERA.12.147]
   Esparza-López J, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2769-0
   Esparza-López J, 2013, J CANCER RES CLIN, V139, P1625, DOI 10.1007/s00432-013-1476-3
   Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI [10.1056/NEJMra072067, 10.1093/carcin/bgp220]
   Fan J, 2008, J CANCER RES CLIN, V134, P883, DOI 10.1007/s00432-008-0354-x
   Fanale D, 2012, ONCOGENE, V31, P2121, DOI 10.1038/onc.2011.408
   Farmer H, 2005, NATURE, V434, P917, DOI 10.1038/nature03445
   Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210
   Fong PC, 2009, NEW ENGL J MED, V361, P123, DOI 10.1056/NEJMoa0900212
   García JM, 2004, GENE CHROMOSOME CANC, V41, P117, DOI 10.1002/gcc.20062
   Gerlinger M, 2010, BRIT J CANCER, V103, P1139, DOI 10.1038/sj.bjc.6605912
   Gerlinger M, 2012, NEW ENGL J MED, V366, P883, DOI 10.1056/NEJMoa1113205
   Geyer FC, 2010, J PATHOL, V220, P562, DOI 10.1002/path.2675
   Greaves M, 2012, NATURE, V481, P306, DOI 10.1038/nature10762
   Guerrero-Preston R, 2014, ONCOL REP, V32, P505, DOI 10.3892/or.2014.3262
   Gurzu S, 2015, WORLD J CLIN CASES, V3, P393, DOI 10.12998/wjcc.v3.i5.393
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Hanna W, 2007, BREAST J, V13, P122, DOI 10.1111/j.1524-4741.2007.00396.x
   Hansen KD, 2011, NAT GENET, V43, P768, DOI 10.1038/ng.865
   HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700
   Hesson LB, 2007, DIS MARKERS, V23, P73, DOI 10.1155/2007/291538
   Heyn H, 2013, CARCINOGENESIS, V34, P102, DOI 10.1093/carcin/bgs321
   Hiken JF, 2016, ONCOGENE
   Hiley C, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0453-8
   Holm K, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2590
   Hon GC, 2012, GENOME RES, V22, P246, DOI 10.1101/gr.125872.111
   Hu ZY, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-96
   Kajita M, 2004, MOL CELL BIOL, V24, P7559, DOI 10.1128/MCB.24.17.7559-7566.2004
   Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104
   Keen JC, 2003, BREAST CANCER RES TR, V81, P177, DOI 10.1023/A:1026146524737
   Kobayashi M, 2002, HUM PATHOL, V33, P21, DOI 10.1053/hupa.2002.30185
   Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412
   Korber P, 2010, ESSAYS BIOCHEM, V48, P63, DOI [10.1042/BSE0480063, 10.1042/bse0480063]
   Kuukasjarvi T, 1997, CANCER RES, V57, P1597
   La Thangue NB, 2011, NAT REV CLIN ONCOL, V8, P587, DOI 10.1038/nrclinonc.2011.121
   Lawrence MS, 2013, NATURE, V499, P214, DOI 10.1038/nature12213
   Lehmann BD, 2011, J CLIN INVEST, V121, P2750, DOI 10.1172/JCI45014
   Li QQ, 2009, CLIN CANCER RES, V15, P2657, DOI 10.1158/1078-0432.CCR-08-2372
   Lim E, 2009, NAT MED, V15, P907, DOI 10.1038/nm.2000
   Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027
   Marjanovic ND, 2013, CLIN CHEM, V59, P168, DOI 10.1373/clinchem.2012.184655
   Marusyk A, 2012, NAT REV CANCER, V12, P323, DOI 10.1038/nrc3261
   Marusyk A, 2010, BBA-REV CANCER, V1805, P105, DOI 10.1016/j.bbcan.2009.11.002
   McGranahan N, 2015, CANCER CELL, V27, P15, DOI 10.1016/j.ccell.2014.12.001
   Meacham CE, 2013, NATURE, V501, P328, DOI 10.1038/nature12624
   Medema JP, 2013, NAT CELL BIOL, V15, P338, DOI 10.1038/ncb2717
   Miller CA, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12498
   Miller WR, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2611
   Mitra D, 2011, J BIOL CHEM, V286, P40531, DOI 10.1074/jbc.M111.304865
   Morel AP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002888
   Nadji M, 2005, AM J CLIN PATHOL, V123, P21, DOI 10.1309/4WV79N2GHJ3X1841
   Navin N, 2011, NATURE, V472, P90, DOI 10.1038/nature09807
   Navin N, 2010, GENOME RES, V20, P68, DOI 10.1101/gr.099622.109
   Nik-Zainal S, 2012, CELL, V149, DOI 10.1016/j.cell.2012.04.023
   NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840
   Oosterwijk JC, 2014, MATURITAS, V78, P252, DOI 10.1016/j.maturitas.2014.05.002
   Pandis N, 1998, GENE CHROMOSOME CANC, V22, P122, DOI 10.1002/(SICI)1098-2264(199806)22:2<122::AID-GCC6>3.0.CO;2-Z
   Pardoll DM, 2012, NAT REV CANCER, V12, P252, DOI 10.1038/nrc3239
   Park SY, 2010, J CLIN INVEST, V120, P636, DOI 10.1172/JCI40724
   Patel AG, 2012, CLIN CANCER RES, V18, P1655, DOI 10.1158/1078-0432.CCR-11-2890
   Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093
   Pierce BL, 2009, J CLIN ONCOL, V27, P3437, DOI 10.1200/JCO.2008.18.9068
   Pinto CA, 2013, CANCER LETT, V341, P56, DOI 10.1016/j.canlet.2013.06.003
   Plaks V, 2015, CELL STEM CELL, V16, P225, DOI 10.1016/j.stem.2015.02.015
   Polyak K, 2014, NATURE, V508, P52, DOI 10.1038/508052a
   Ponti D, 2005, CANCER RES, V65, P5506, DOI 10.1158/0008-5472.CAN-05-0626
   Pouliot MC, 2015, ANTICANCER RES, V35, P4569
   Prabhu JS, 2012, TUMOR BIOL, V33, P315, DOI 10.1007/s13277-012-0343-1
   Santos-Rebouças CB, 2007, EUR J HUM GENET, V15, P10, DOI 10.1038/sj.ejhg.5201727
   Shah SP, 2012, NATURE, V486, P395, DOI 10.1038/nature10933
   Shah SP, 2009, NATURE, V461, P809, DOI 10.1038/nature08489
   Shevach EM, 2004, NAT MED, V10, P900, DOI 10.1038/nm0904-900
   Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098
   Soto-Perez-de-Celis E, 2016, CANCER EPIDEMIOL, V41, P24, DOI 10.1016/j.canep.2016.01.007
   Stefansson OA, 2013, AM J PATHOL, V183, P1052, DOI 10.1016/j.ajpath.2013.04.033
   Stephens PJ, 2012, NATURE, V486, P400, DOI 10.1038/nature11017
   Sullivan NJ, 2009, ONCOGENE, V28, P2940, DOI 10.1038/onc.2009.180
   Taucher S, 2003, ENDOCR-RELAT CANCER, V10, P91, DOI 10.1677/erc.0.0100091
   Thurman RE, 2007, GENOME RES, V17, P917, DOI 10.1101/gr.6081407
   Torre LA, 2016, CANCER EPIDEM BIOMAR, V25, P16, DOI 10.1158/1055-9965.EPI-15-0578
   Tryndyak VP, 2010, INT J CANCER, V126, P2575, DOI 10.1002/ijc.24972
   Turner NC, 2012, LANCET ONCOL, V13, pE178, DOI 10.1016/S1470-2045(11)70335-7
   Walter MJ, 2012, NEW ENGL J MED, V366, P1090, DOI 10.1056/NEJMoa1106968
   Wang CC, 2014, NAT CELL BIOL, V16, P345, DOI 10.1038/ncb2930
   Widschwendter M, 2004, CANCER RES, V64, P3807, DOI 10.1158/0008-5472.CAN-03-3852
   Wistuba II, 2011, NAT REV CLIN ONCOL, V8, P135, DOI 10.1038/nrclinonc.2011.2
   Woodcock DM, 1999, BRIT J CANCER, V79, P251, DOI 10.1038/sj.bjc.6690041
   Wu L, 2013, BREAST CANCER RES TR, V142, P619, DOI 10.1007/s10549-013-2774-9
   Wu Y, 2009, CANCER CELL, V15, P416, DOI 10.1016/j.ccr.2009.03.016
   Yang RX, 2015, INT J CANCER, V136, P1845, DOI 10.1002/ijc.29205
   Yang Wen-tao, 2013, Zhonghua Bing Li Xue Za Zhi, V42, P78, DOI 10.3760/cma.j.issn.0529-5807.2013.02.002
   Yap TA, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003854
   Yeung C, 2016, CANCER METAST REV, V35, P427, DOI 10.1007/s10555-016-9631-3
   You JS, 2012, CANCER CELL, V22, P9, DOI 10.1016/j.ccr.2012.06.008
NR 128
TC 15
Z9 21
U1 1
U2 11
PU INST NACIONAL NUTRICION
PI MEXICO
PA VASCO DE QUIROZA 15, COLONIA SECCION XVI, TLALPAN, MEXICO 14000 D F,
   MEXICO
SN 0034-8376
EI 2564-8896
J9 REV INVEST CLIN
JI Rev. Investig. Clin.
PD MAR-APR
PY 2017
VL 69
IS 2
BP 66
EP 76
PG 11
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA EU8SX
UT WOS:000401309900003
PM 28453505
DA 2025-01-12
ER

PT J
AU Zhao, G
   Li, Y
   Wang, T
AF Zhao, Ge
   Li, Ying
   Wang, Ting
TI Potentiation of docetaxel sensitivity by miR-638 via regulation of
   STARD10 pathway in human breast cancer cells
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE Breast cancer; miR-638; Chemotherapy; STARD10; Docetaxel
ID MESENCHYMAL TRANSITION; DRUG-RESISTANCE; EXPRESSION; CONTRIBUTES;
   MODULATION; TRANSFORMATION; INVASION; MIR-222
AB Acquired resistance to classical chemotherapeutics such as docetaxel (DTX) remains a critical challenge in breast cancer (BCa) treatment. Epigenetic modification by microRNAs (miRNAs) has been shown to play a crucial role in cancer drug resistance. Previous study, using human drug-resistant BCa tissues, has identified miR-638 as one of the most down-regulated miRNAs, but its exact roles and underlying mechanisms during the pathogenesis of chemoresistance remain to be determined. In the current study, we found that miR-638 expression was significantly down-regulated in clinical DTX-resistant BCa tissues compared to that in DTX-sensitive BCa tissues. By using the previously established DTX-resistant MCF-7 cells (MCF-7/R), we also confirmed that chemoresistant cells displayed decreased levels of miR-638. To provide the direct functional evidence, we inhibited and overexpressed miR-638 in different cell lines. Thereby, the cells were rendered more resistant or susceptible to DTX treatment. Mechanistically, the lipid-binding protein STARD10 was identified as a miR-638 target mediating the DTX-resistance. Hence, we provide a molecular explanation for acquired resistance to DTX that is caused by the miR-638 deficiency and subsequent STARD10 upregulation. In consequence, alteration of miR-638/STARD10 cascade may represent an attractive strategy in future adjuvant therapy along with DTX chemotherapy. (C) 2017 Elsevier Inc. All rights reserved.
C1 [Zhao, Ge; Wang, Ting] Fourth Mil Med Univ, Xijing Hosp, Dept Thyroid Gland & Breast Vasc Surg, Xian 710032, Shaanxi, Peoples R China.
   [Li, Ying] Fourth Mil Med Univ, Xijing Hosp, Dept Clin Immunol, Xian 710032, Shaanxi, Peoples R China.
C3 Air Force Military Medical University; Air Force Military Medical
   University
RP Wang, T (通讯作者)，Fourth Mil Med Univ, Xijing Hosp, Dept Thyroid Gland & Breast Vasc Surg, Xian 710032, Shaanxi, Peoples R China.
EM ting_w100@126.com
CR Chang JC, 2005, J CLIN ONCOL, V23, P1169, DOI 10.1200/JCO.2005.03.156
   Chen X, 2016, J PATHOL, V239, P459, DOI 10.1002/path.4743
   Dong YS, 2016, CELL DEATH DIFFER, V23, P787, DOI 10.1038/cdd.2015.139
   Hu Q, 2014, TUMOR BIOL, V35, P6327, DOI 10.1007/s13277-014-1834-z
   Kastl L, 2012, BREAST CANCER RES TR, V131, P445, DOI 10.1007/s10549-011-1424-3
   Li DC, 2012, TOXICOL SCI, V125, P382, DOI 10.1093/toxsci/kfr299
   Liang Y, 2013, BIOL REPROD, V89, DOI 10.1095/biolreprod.113.112235
   Luo J, 2011, J EXP CLIN CANC RES, V30, DOI 10.1186/1756-9966-30-71
   Murphy NC, 2010, INT J CANCER, V126, P1445, DOI 10.1002/ijc.24826
   Ning P, 2016, ENDOCR-RELAT CANCER, V23, P595, DOI 10.1530/ERC-16-0126
   Olayioye MA, 2004, CANCER RES, V64, P3538, DOI 10.1158/0008-5472.CAN-03-3731
   Ren YL, 2017, CANCER LETT, V390, P126, DOI 10.1016/j.canlet.2017.01.009
   Saloustros E, 2008, EXPERT OPIN PHARMACO, V9, P2603, DOI 10.1517/14656566.9.15.2603 
   Shen HY, 2017, GENE, V596, P110, DOI 10.1016/j.gene.2016.10.016
   Tan XH, 2014, BREAST CANCER RES, V16, DOI 10.1186/s13058-014-0435-5
   Tay Y, 2014, CELL REP, V8, P714, DOI 10.1016/j.celrep.2014.06.064
   Vetter G, 2010, ONCOGENE, V29, P4436, DOI 10.1038/onc.2010.181
   Wang H, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-37
   Wu J, 2017, BIOCHEM BIOPH RES CO, V483, P10, DOI 10.1016/j.bbrc.2017.01.023
   Xu X, 2016, BIOCHEM BIOPH RES CO, V479, P893, DOI 10.1016/j.bbrc.2016.09.087
   Zhang XH, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153194
   Zhang Y, 2015, SCI REP-UK, V5, DOI 10.1038/srep15424
   Zhong SL, 2013, GENE, V531, P8, DOI 10.1016/j.gene.2013.08.062
NR 23
TC 23
Z9 23
U1 0
U2 4
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
EI 1090-2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD MAY 27
PY 2017
VL 487
IS 2
BP 255
EP 261
DI 10.1016/j.bbrc.2017.04.045
PG 7
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA EV3UD
UT WOS:000401683700011
PM 28412359
DA 2025-01-12
ER

PT J
AU Conway, K
   Edmiston, SN
   Parrish, E
   Bryant, C
   Tse, CK
   Swift-Scanlan, T
   McCullough, LE
   Kuan, PF
AF Conway, Kathleen
   Edmiston, Sharon N.
   Parrish, Eloise
   Bryant, Christopher
   Tse, Chiu-Kit
   Swift-Scanlan, Theresa
   McCullough, Lauren E.
   Kuan, Pei Fen
TI Breast tumor DNA methylation patterns associated with smoking in the
   Carolina Breast Cancer Study
SO BREAST CANCER RESEARCH AND TREATMENT
LA English
DT Article
DE Breast cancer; Smoking; Breast tumor; Methylation; Epigenetic
ID CIGARETTE-SMOKING; ACTIVE SMOKING; PROMOTER METHYLATION; LUNG
   ADENOCARCINOMA; PROTEIN EXPRESSION; TOBACCO SMOKING; RECEPTOR STATUS;
   RISK-FACTORS; ESTROGEN; POPULATION
AB Tobacco smoking is a risk factor in several cancers, yet its roles as a putative etiologic exposure or poor prognostic factor in breast cancer are less clear. Altered DNA methylation contributes to breast cancer development and may provide a mechanistic link between smoking and gene expression changes leading to cancer development or progression.
   Using a cancer-focused array, we examined methylation at 933 CpGs in 517 invasive breast tumors in the Carolina Breast Cancer Study to determine whether methylation patterns differ by exposure to tobacco smoke. Multivariable generalized linear regression models were used to compare tumor methylation profiles between smokers and never smokers, overall, or stratified on hormone receptor (HR) status.
   Modest differences in CpG methylation were detected at p < 0.05 in breast tumors from current or ever smokers compared with never smokers. In stratified analyses, HR- tumors from smokers exhibited primarily hypomethylation compared with tumors from never smokers; hypomethylation was similarly detected within the more homogeneous basal-like subtype. Most current smoking-associated CpG loci exhibited methylation levels in former smokers that were intermediate between those in current and never smokers and exhibited progressive changes in methylation with increasing duration of smoking. Among former smokers, restoration of methylation toward baseline (never smoking) levels was observed with increasing time since quitting. Moreover, smoking-related hypermethylation was stronger in HR+ breast tumors from blacks than in whites.
   Our results suggest that breast tumor methylation patterns differ with tobacco smoke exposure; however, additional studies are needed to confirm these findings.
C1 [Conway, Kathleen; Tse, Chiu-Kit] Univ N Carolina, Sch Publ Hlth, Dept Epidemiol, Campus Box 7435, Chapel Hill, NC 27599 USA.
   [Bryant, Christopher] Univ N Carolina, Sch Publ Hlth, Dept Biostat, Chapel Hill, NC 27599 USA.
   [Conway, Kathleen; Edmiston, Sharon N.; Parrish, Eloise] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA.
   [Swift-Scanlan, Theresa] Virginia Commonwealth Univ, Sch Nursing, Med Coll Virginia Campus, Richmond, VA 23298 USA.
   [Swift-Scanlan, Theresa] Virginia Commonwealth Univ, Massey Comprehens Canc Ctr, Med Coll Virginia Campus, Richmond, VA 23298 USA.
   [McCullough, Lauren E.] Emory Univ, Sch Publ Hlth, Dept Epidemiol, Atlanta, GA 30322 USA.
   [Kuan, Pei Fen] SUNY Stony Brook, Dept Appl Math & Stat, Stony Brook, NY 11794 USA.
C3 University of North Carolina; University of North Carolina Chapel Hill;
   University of North Carolina; University of North Carolina Chapel Hill;
   University of North Carolina; University of North Carolina Chapel Hill;
   Virginia Commonwealth University; Virginia Commonwealth University;
   Emory University; State University of New York (SUNY) System; Stony
   Brook University
RP Conway, K (通讯作者)，Univ N Carolina, Sch Publ Hlth, Dept Epidemiol, Campus Box 7435, Chapel Hill, NC 27599 USA.; Conway, K (通讯作者)，Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA.
EM kconway@med.unc.edu
RI Kuan, Pei Fen/GRX-4622-2022
FU Susan G. Komen Foundation [KG081397]; University Cancer Research Fund of
   the Lineberger Comprehensive Cancer Center at the University of North
   Carolina at Chapel Hill; University Cancer Research Fund of North
   Carolina; National Cancer Institute Specialized Program of Research
   Excellence (SPORE) in Breast Cancer [NIH/NCI P50-CA58223]
FX This research was supported by Grants to KC from Susan G. Komen
   Foundation (Grant #KG081397) and from the University Cancer Research
   Fund of the Lineberger Comprehensive Cancer Center at the University of
   North Carolina at Chapel Hill. The Carolina Breast Cancer Study was also
   funded by the University Cancer Research Fund of North Carolina and the
   National Cancer Institute Specialized Program of Research Excellence
   (SPORE) in Breast Cancer (NIH/NCI P50-CA58223).
CR Abbas T, 2009, NAT REV CANCER, V9, P400, DOI 10.1038/nrc2657
   Akhter N, 2014, MOL BIOL REP, V41, P2999, DOI 10.1007/s11033-014-3159-9
   Allott EH, 2016, CANCER EPIDEM BIOMAR, V25, P470, DOI 10.1158/1055-9965.EPI-15-0874
   Ambatipudi S, 2016, EPIGENOMICS-UK, V8, P599, DOI 10.2217/epi-2016-0001
   Askari M, 2013, MOL CELL BIOCHEM, V382, P19, DOI 10.1007/s11010-013-1696-5
   Bardowell SA, 2013, BREAST CANCER RES TR, V142, P365, DOI 10.1007/s10549-013-2738-0
   Bavarva JH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067252
   Besaratinia A, 2013, EPIGENETICS-US, V8, P1013, DOI 10.4161/epi.25927
   BOFFETTA P, 1992, INT J CANCER, V52, P530, DOI 10.1002/ijc.2910520405
   Braithwaite D, 2012, BREAST CANCER RES TR, V136, P521, DOI 10.1007/s10549-012-2276-1
   Butler EN, 2016, CANCER CAUSE CONTROL, V27, P775, DOI 10.1007/s10552-016-0754-1
   Byun HM, 2009, HUM MOL GENET, V18, P4808, DOI 10.1093/hmg/ddp445
   Carey LA, 2006, JAMA-J AM MED ASSOC, V295, P2492, DOI 10.1001/jama.295.21.2492
   Castelao JE, 2001, JNCI-J NATL CANCER I, V93, P538, DOI 10.1093/jnci/93.7.538
   Catsburg C, 2015, INT J CANCER, V136, P2204, DOI 10.1002/ijc.29266
   Chen RJ, 2011, J ONCOL, V2011, DOI 10.1155/2011/654931
   Christensen BC, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001043
   Conway K, 2014, BREAST CANCER RES, V16, DOI 10.1186/s13058-014-0450-6
   COOPER JA, 1989, BRIT J CANCER, V59, P119, DOI 10.1038/bjc.1989.24
   Cortessis VK, 2012, HUM GENET, V131, P1565, DOI 10.1007/s00439-012-1189-8
   Di YP, 2012, J BIOL CHEM, V287, P27948, DOI 10.1074/jbc.M111.334375
   Dogan MV, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-151
   Dossus L, 2014, INT J CANCER, V134, P1871, DOI 10.1002/ijc.28508
   Dressler LG, 1999, BREAST CANCER RES TR, V58, P31, DOI 10.1023/A:1006354627669
   Ernster VL, 1996, ANNU REV PUBL HEALTH, V17, P97
   Felix AS, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00025
   Gabriel HE, 2006, AM J CLIN NUTR, V83, P835, DOI 10.1093/ajcn/83.4.835
   Gaudet MM, 2013, JNCI-J NATL CANCER I, V105, P515, DOI 10.1093/jnci/djt023
   Ginzkey C, 2013, MUTAT RES-GEN TOX EN, V751, P34, DOI 10.1016/j.mrgentox.2012.11.004
   Gram IT, 2015, AM J EPIDEMIOL, V182, P917, DOI 10.1093/aje/kwv092
   Guha P, 2014, BREAST CANCER RES TR, V145, P5, DOI 10.1007/s10549-014-2912-z
   Guida F, 2015, HUM MOL GENET, V24, P2349, DOI 10.1093/hmg/ddu751
   Hair BY, 2015, CANCER EPIDEM BIOMAR, V24, P580, DOI 10.1158/1055-9965.EPI-14-1017
   Hall IJ, 2005, AM J EPIDEMIOL, V161, P40, DOI 10.1093/aje/kwh331
   Hecht SS, 2012, INT J CANCER, V131, P2724, DOI 10.1002/ijc.27816
   Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947
   Kaarvatn MH, 2012, SCAND J IMMUNOL, V76, P329, DOI 10.1111/j.1365-3083.2012.02736.x
   Kawai M, 2014, CANCER-AM CANCER SOC, V120, P1026, DOI 10.1002/cncr.28402
   Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412
   Lee GE, 2010, J BIOL CHEM, V285, P37630, DOI 10.1074/jbc.M110.148536
   Lee Ken W. K., 2013, Frontiers in Genetics, V4, P132, DOI 10.3389/fgene.2013.00132
   Lei J, 2015, BREAST CANCER RES, V17, DOI 10.1186/s13058-015-0522-2
   Lin RK, 2010, J CLIN INVEST, V120, P521, DOI 10.1172/JCI40706
   Liu QY, 2011, MOL CANCER THER, V10, P1113, DOI 10.1158/1535-7163.MCT-10-1010
   Lo PK, 2008, PHARMACOGENOMICS, V9, P1879, DOI 10.2217/14622416.9.12.1879
   Macacu A, 2015, BREAST CANCER RES TR, V154, P213, DOI 10.1007/s10549-015-3628-4
   Manjer J, 2001, INT J CANCER, V91, P580, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1091>3.0.CO;2-V
   McKenzie F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063132
   Mechanic LE, 2006, CARCINOGENESIS, V27, P1377, DOI 10.1093/carcin/bgi330
   Mercer BA, 2009, AM J RESP CELL MOL, V40, P4, DOI 10.1165/rcmb.2007-0310OC
   Morabia A, 1998, INT J CANCER, V75, P339, DOI 10.1002/(SICI)1097-0215(19980130)75:3<339::AID-IJC2>3.0.CO;2-3
   Mortusewicz O, 2005, P NATL ACAD SCI USA, V102, P8905, DOI 10.1073/pnas.0501034102
   Necela BM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122209
   NEWMAN B, 1995, BREAST CANCER RES TR, V35, P51, DOI 10.1007/BF00694745
   Nishino Y, 2014, SPRINGERPLUS, V3, DOI 10.1186/2193-1801-3-65
   Nishioka T, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr3055
   Passarelli MN, 2016, J CLIN ONCOL, V34, P1315, DOI 10.1200/JCO.2015.63.9328
   Pounis G, 2014, NUTRITION, V30, P822, DOI 10.1016/j.nut.2013.11.014
   Reynolds P, 2013, J MAMMARY GLAND BIOL, V18, P15, DOI 10.1007/s10911-012-9269-x
   Rosenberg L, 2013, CANCER CAUSE CONTROL, V24, P2207, DOI 10.1007/s10552-013-0298-6
   Sato T, 2014, INT J CANCER, V135, P319, DOI 10.1002/ijc.28684
   Satta R, 2008, P NATL ACAD SCI USA, V105, P16356, DOI 10.1073/pnas.0808699105
   Shenker NS, 2013, HUM MOL GENET, V22, P843, DOI 10.1093/hmg/dds488
   Smith IM, 2007, INT J CANCER, V121, P1724, DOI 10.1002/ijc.22889
   Tan Q, 2013, ONCOTARGETS THER, V6, P1471, DOI 10.2147/OTT.S51041
   Tessema M, 2014, CARCINOGENESIS, V35, P1248, DOI 10.1093/carcin/bgt494
   Tsaprouni LG, 2014, EPIGENETICS-US, V9, P1382, DOI 10.4161/15592294.2014.969637
   United States Department of Health and Human Services, 2010, TOB SMOK CAUS DISC B
   White AJ, 2016, ENVIRON RES, V145, P93, DOI 10.1016/j.envres.2015.11.033
   Wilhelm-Benartzi CS, 2010, CARCINOGENESIS, V31, P1972, DOI 10.1093/carcin/bgq178
   Wolff EM, 2010, CANCER RES, V70, P8169, DOI 10.1158/0008-5472.CAN-10-1335
   Xue F, 2011, ARCH INTERN MED, V171, P125, DOI 10.1001/archinternmed.2010.503
   Yuzhalin AE, 2012, GROWTH FACTORS, V30, P176, DOI 10.3109/08977194.2012.678843
   Zeilinger S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063812
NR 74
TC 15
Z9 16
U1 2
U2 20
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0167-6806
EI 1573-7217
J9 BREAST CANCER RES TR
JI Breast Cancer Res. Treat.
PD JUN
PY 2017
VL 163
IS 2
BP 349
EP 361
DI 10.1007/s10549-017-4178-8
PG 13
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA ET5UV
UT WOS:000400354800017
PM 28275920
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Williams, J
   Smith, F
   Kumar, S
   Vijayan, M
   Reddy, PH
AF Williams, Justin
   Smith, Flint
   Kumar, Subodh
   Vijayan, Murali
   Reddy, P. Hemachandra
TI Are microRNAs true sensors of ageing and cellular senescence?
SO AGEING RESEARCH REVIEWS
LA English
DT Article
DE microRNA; Aging; Senescence; Oxidative-stress; Alzheimer's disease
ID TUMOR-SUPPRESSOR P53; OXIDATIVE STRESS; PERIPHERAL BIOMARKERS;
   CIRCULATING MICRORNA; ENDOTHELIAL-CELL; SKELETAL-MUSCLE;
   DOWN-REGULATION; TRIPLET-REPEAT; BREAST-CANCER; STEM-CELLS
AB All living beings are programmed to death due to aging and age-related processes. Aging is a normal process of every living species. While all cells are inevitably progressing towards death, many disease processes accelerate the aging process, leading to senescence. Pathologies such as Alzheimer's disease, Parkinson's disease, multiple sclerosis, amyotrophic lateral sclerosis, Huntington's disease, cardiovascular disease, cancer, and skin diseases have been associated with deregulated aging. Healthy aging can delay onset of all age-related diseases. Genetics and epigenetics are reported to play large roles in accelerating and/or delaying the onset of age-related diseases. Cellular mechanisms of aging and age-related diseases are not completely understood. However, recent molecular biology discoveries have revealed that microRNAs (miRNAs) are potential sensors of aging and cellular senescence. Due to miRNAs capability to bind to the 3' untranslated region (UTR) of mRNA of specific genes, miRNAs can prevent the translation of specific genes. The purpose of our article is to highlight recent advancements in miRNAs and their involvement in cellular changes in aging and senescence. Our article discusses the current understanding of cellular senescence, its interplay with miRNAs regulation, and how they both contribute to disease processes. (C) 2016 Elsevier B.V. All rights reserved.
C1 [Williams, Justin; Smith, Flint; Kumar, Subodh; Vijayan, Murali; Reddy, P. Hemachandra] Texas Tech Univ, Garrison Inst Aging, Hlth Sci Ctr, 3601 4th St,MS 9424, Lubbock, TX 79430 USA.
   [Reddy, P. Hemachandra] Texas Tech Univ, Hlth Sci Ctr, Cell Biol & Biochem, 3601 4th St,MS 9424, Lubbock, TX 79430 USA.
   [Reddy, P. Hemachandra] Texas Tech Univ, Hlth Sci Ctr, Speech Dept, 3601 4th St,MS 9424, Lubbock, TX 79430 USA.
   [Reddy, P. Hemachandra] Texas Tech Univ, Hlth Sci Ctr, Language Dept, 3601 4th St,MS 9424, Lubbock, TX 79430 USA.
   [Reddy, P. Hemachandra] Texas Tech Univ, Hlth Sci Ctr, Hearing Sci Dept, 3601 4th St,MS 9424, Lubbock, TX 79430 USA.
   [Reddy, P. Hemachandra] Texas Tech Univ, Hlth Sci Ctr, Garrison Inst Aging, South West Campus,6630 S Quaker Suite E,MS 7495, Lubbock, TX 79413 USA.
C3 Texas Tech University System; Texas Tech University Health Science
   Center; Texas Tech University System; Texas Tech University Health
   Science Center; Texas Tech University System; Texas Tech University
   Health Science Center; Texas Tech University System; Texas Tech
   University Health Science Center; Texas Tech University System; Texas
   Tech University Health Science Center; Texas Tech University System;
   Texas Tech University Health Science Center
RP Reddy, PH (通讯作者)，Texas Tech Univ, Hlth Sci Ctr, Neurosci & Pharmacol Dept, 3601 4th St,MS 9424, Lubbock, TX 79430 USA.; Reddy, PH (通讯作者)，Texas Tech Univ, Hlth Sci Ctr, Neurol Dept, 3601 4th St,MS 9424, Lubbock, TX 79430 USA.; Reddy, PH (通讯作者)，Texas Tech Univ, Hlth Sci Ctr, Garrison Inst Aging, 3601 Fourth St MS-9424-4A 124, Lubbock, TX 79430 USA.
EM hemachandra.reddy@ttuhsc.edu
RI kumar, Subodh/K-6567-2019
OI Kumar, Subodh/0000-0003-4705-122X
FU NIH [AG042178, AG047812]; Garrison Family Foundation
FX Work presented in this article is supported by NIH grants AG042178,
   AG047812 and the Garrison Family Foundation.
CR Adams PD, 2015, CELL STEM CELL, V16, P601, DOI 10.1016/j.stem.2015.05.002
   Alexandrov Peter N, 2012, Int J Biochem Mol Biol, V3, P365
   [Anonymous], MATH PROBL ENG
   Arroyo JD, 2011, P NATL ACAD SCI USA, V108, P5003, DOI 10.1073/pnas.1019055108
   Asgeirsdóttir SA, 2012, AM J PHYSIOL-RENAL, V302, pF1630, DOI 10.1152/ajprenal.00400.2011
   Bai XY, 2011, J AM SOC NEPHROL, V22, P1252, DOI 10.1681/ASN.2010040367
   Bandiera S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020746
   Bernstein E, 2001, NATURE, V409, P363, DOI 10.1038/35053110
   Bhaumik D, 2009, AGING-US, V1, P402, DOI 10.18632/aging.100042
   Bird CW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079255
   Boehm M, 2005, SCIENCE, V310, P1954, DOI 10.1126/science.1115596
   Bonifacio LN, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012519
   Borgdorff V, 2010, ONCOGENE, V29, P2262, DOI 10.1038/onc.2009.497
   Braun CJ, 2008, CANCER RES, V68, P10094, DOI 10.1158/0008-5472.CAN-08-1569
   Brown DM, 2015, AGEING RES REV, V24, P263, DOI 10.1016/j.arr.2015.08.007
   Cardo LF, 2013, J NEUROL, V260, P1420, DOI 10.1007/s00415-013-6900-8
   Chang TC, 2007, MOL CELL, V26, P745, DOI 10.1016/j.molcel.2007.05.010
   Cheng SS, 2014, INT J BIOCHEM CELL B, V57, P186, DOI 10.1016/j.biocel.2014.10.029
   Cheng TL, 2014, DEV CELL, V28, P547, DOI 10.1016/j.devcel.2014.01.032
   Cho JH, 2015, J BIOL CHEM, V290, P10555, DOI 10.1074/jbc.M114.624361
   Das MM, 2015, NEUROBIOL AGING, V36, P1130, DOI 10.1016/j.neurobiolaging.2014.09.020
   Davis BN, 2010, MOL CELL, V39, P373, DOI 10.1016/j.molcel.2010.07.011
   de Lange T, 2005, GENE DEV, V19, P2100, DOI 10.1101/gad.1346005
   Díaz-Prado S, 2012, BMC MUSCULOSKEL DIS, V13, DOI 10.1186/1471-2474-13-144
   Dinami R, 2014, CANCER RES, V74, P4145, DOI 10.1158/0008-5472.CAN-13-2038
   DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0
   Drummond MJ, 2011, PHYSIOL GENOMICS, V43, P595, DOI 10.1152/physiolgenomics.00148.2010
   Falandry C, 2014, J CLIN ONCOL, V32, P2604, DOI 10.1200/JCO.2014.55.1432
   Fan Y, 2014, RNA, V20, P765, DOI 10.1261/rna.043026.113
   Faraonio R, 2012, CELL DEATH DIFFER, V19, P713, DOI 10.1038/cdd.2011.143
   Feng X, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052782
   Flanary BE, 2007, REJUV RES, V10, P61, DOI 10.1089/rej.2006.9096
   Frankel LB, 2011, EMBO J, V30, P4628, DOI 10.1038/emboj.2011.331
   Frigerio CS, 2013, NEUROLOGY, V81, P2103, DOI 10.1212/01.wnl.0000437306.37850.22
   Gao P, 2009, NATURE, V458, P762, DOI 10.1038/nature07823
   Gerhard-Herman M, 2012, HYPERTENSION, V59, P92, DOI 10.1161/HYPERTENSIONAHA.111.180919
   Gómez-Cabello D, 2013, AGING CELL, V12, P923, DOI 10.1111/acel.12117
   Grasso M, 2014, MOLECULES, V19, P6891, DOI 10.3390/molecules19056891
   Gregory RI, 2005, CELL, V123, P631, DOI 10.1016/j.cell.2005.10.022
   Guan JZ, 2015, MOL CELL BIOCHEM, V400, P183, DOI 10.1007/s11010-014-2274-1
   Guo N, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017858
   Gurtner A, 2016, J EXP CLIN CANC RES, V35, DOI 10.1186/s13046-016-0319-x
   Han KH, 2005, MECH AGEING DEV, V126, P560, DOI 10.1016/j.mad.2004.11.006
   Harris TA, 2008, P NATL ACAD SCI USA, V105, P1516, DOI 10.1073/pnas.0707493105
   HATANAKA M, 1974, BIOCHIM BIOPHYS ACTA, V355, P77, DOI 10.1016/0304-419X(74)90008-0
   HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9
   Hu WW, 2010, MOL CELL, V38, P689, DOI 10.1016/j.molcel.2010.05.027
   Hu ZY, 2014, AGING-US, V6, P160, DOI 10.18632/aging.100643
   Hunter MP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003694
   Hutvágner G, 2001, SCIENCE, V293, P834, DOI 10.1126/science.1062961
   Jafferany M, 2012, INT J DERMATOL, V51, P509, DOI 10.1111/j.1365-4632.2011.05311.x
   Jiang JJ, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.239
   Jinnin M, 2015, J DERMATOL, V42, P551, DOI 10.1111/1346-8138.12904
   Johnston RJ, 2003, NATURE, V426, P845, DOI 10.1038/nature02255
   Karolina DS, 2012, J CLIN ENDOCR METAB, V97, pE2271, DOI 10.1210/jc.2012-1996
   Khoo SK, 2012, J PARKINSON DIS, V2, P321, DOI 10.3233/JPD-012144
   Kraytsberg Y, 2006, NAT GENET, V38, P518, DOI 10.1038/ng1778
   Kumar P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069807
   Kumar S, 2016, BBA-MOL BASIS DIS, V1862, P1617, DOI 10.1016/j.bbadis.2016.06.001
   Kurowska-Stolarska M, 2011, P NATL ACAD SCI USA, V108, P11193, DOI 10.1073/pnas.1019536108
   Lang A, 2016, AGING-US, V8, P484, DOI 10.18632/aging.100905
   Laufer BI, 2013, DIS MODEL MECH, V6, P977, DOI 10.1242/dmm.010975
   Le MTN, 2009, GENE DEV, V23, P862, DOI 10.1101/gad.1767609
   Lee Y, 2003, NATURE, V425, P415, DOI 10.1038/nature01957
   Lehmann SM, 2012, NAT NEUROSCI, V15, P827, DOI 10.1038/nn.3113
   Leidinger P, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-7-r78
   Li GR, 2009, MECH AGEING DEV, V130, P731, DOI 10.1016/j.mad.2009.09.002
   Li J, 2015, CHEM GEOL, V406, P10, DOI 10.1016/j.chemgeo.2015.04.010
   Li N, 2011, NEUROBIOL AGING, V32, P944, DOI 10.1016/j.neurobiolaging.2009.04.020
   Li XL, 2011, AGING-US, V3, P985, DOI 10.18632/aging.100371
   Llave C, 2002, SCIENCE, V297, P2053, DOI 10.1126/science.1076311
   Luo ZH, 2015, AGING CELL, V14, P391, DOI 10.1111/acel.12304
   Machida T, 2015, INT J MOL SCI, V16, P21294, DOI 10.3390/ijms160921294
   Maes OC, 2008, MECH AGEING DEV, V129, P534, DOI 10.1016/j.mad.2008.05.004
   Magenta A, 2011, CELL DEATH DIFFER, V18, P1628, DOI 10.1038/cdd.2011.42
   Margis R, 2011, J BIOTECHNOL, V152, P96, DOI 10.1016/j.jbiotec.2011.01.023
   Mastroeni D, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006617
   Meng XL, 2016, ELIFE, V5, DOI 10.7554/eLife.14199
   Mikhaylova O, 2012, CANCER CELL, V21, P532, DOI 10.1016/j.ccr.2012.02.019
   Mimura S, 2014, INT J MOL MED, V34, P1065, DOI 10.3892/ijmm.2014.1892
   Mitomo S, 2008, CANCER SCI, V99, P280, DOI 10.1111/j.1349-7006.2007.00666.x
   Morales F, 2012, HUM MOL GENET, V21, P3558, DOI 10.1093/hmg/dds185
   Nageshwaran S, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00262
   Nairz K, 2006, DEV BIOL, V291, P314, DOI 10.1016/j.ydbio.2005.11.047
   Nidadavolu LS, 2013, AGING-US, V5, P460, DOI 10.18632/aging.100571
   Ogami M, 2004, ARTERIOSCL THROM VAS, V24, P546, DOI 10.1161/01.ATV.0000117200.46938.e7
   Olivieri F, 2013, AGE, V35, P1157, DOI 10.1007/s11357-012-9440-8
   Olivieri F, 2012, MECH AGEING DEV, V133, P675, DOI 10.1016/j.mad.2012.09.004
   Overhoff MG, 2014, NUCLEIC ACIDS RES, V42, P1606, DOI 10.1093/nar/gkt1096
   Peng P, 2012, J GASTROINTEST SURG, V16, P1478, DOI 10.1007/s11605-012-1923-5
   Pitto L, 2009, PHYSIOL GENOMICS, V39, P210, DOI 10.1152/physiolgenomics.00085.2009
   Poliseno L, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002542
   Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2
   Price DH, 2010, CELL, V141, P399, DOI 10.1016/j.cell.2010.04.016
   Puisségur MP, 2011, CELL DEATH DIFFER, V18, P465, DOI 10.1038/cdd.2010.119
   Qin B, 2012, MOL BIOL REP, V39, P4509, DOI 10.1007/s11033-011-1241-0
   Quinn SR, 2011, INT IMMUNOL, V23, P421, DOI 10.1093/intimm/dxr034
   Rahl PB, 2010, CELL, V141, P432, DOI 10.1016/j.cell.2010.03.030
   Rayess H, 2012, INT J CANCER, V130, P1715, DOI 10.1002/ijc.27316
   Redshaw Z, 2014, DIFFERENTIATION, V88, P117, DOI 10.1016/j.diff.2014.12.001
   Reis FCG, 2016, AGING-US, V8, P1201, DOI 10.18632/aging.100970
   Rivas DA, 2014, FASEB J, V28, P4133, DOI 10.1096/fj.14-254490
   Roggli E, 2010, DIABETES, V59, P978, DOI 10.2337/db09-0881
   Rosenblatt A, 2012, MOVEMENT DISORD, V27, P272, DOI 10.1002/mds.24024
   Sasaki M, 2014, BIOCHEM BIOPH RES CO, V452, P622, DOI 10.1016/j.bbrc.2014.08.123
   Schipper HM, 2007, GENE REGUL SYST BIO, V1, P263
   Schmid G, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2135-2
   Schwartzenberg-Bar-Yoseph F, 2004, CANCER RES, V64, P2627, DOI 10.1158/0008-5472.CAN-03-0846
   Sheedy FJ, 2010, NAT IMMUNOL, V11, P141, DOI 10.1038/ni.1828
   Song L, 2015, GENET MOL RES, V14, P13258, DOI 10.4238/2015.October.26.22
   Sonkoly E, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000610
   Soreq L, 2013, FRONT MOL NEUROSCI, V6, DOI 10.3389/fnmol.2013.00010
   Srivastava A., 2016, J Allergy Clin Immunol
   Stern S, 2003, CIRCULATION, V108, pE99, DOI 10.1161/01.CIR.0000086898.96021.B9
   Suzuki HI, 2009, NATURE, V460, P529, DOI 10.1038/nature08199
   Taganov KD, 2006, P NATL ACAD SCI USA, V103, P12481, DOI 10.1073/pnas.0605298103
   Tan L, 2014, J NEUROL SCI, V336, P52, DOI 10.1016/j.jns.2013.10.002
   Tang XL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020391
   Tazawa H, 2007, P NATL ACAD SCI USA, V104, P15472, DOI 10.1073/pnas.0707351104
   Trabucchi M, 2009, NATURE, V459, P1010, DOI 10.1038/nature08025
   Ugalde AP, 2011, EMBO J, V30, P2219, DOI 10.1038/emboj.2011.124
   Vasa-Nicotera M, 2011, ATHEROSCLEROSIS, V217, P326, DOI 10.1016/j.atherosclerosis.2011.03.034
   Vickers KC, 2011, NAT CELL BIOL, V13, P423, DOI 10.1038/ncb2210
   Vijayan M, 2016, BBA-MOL BASIS DIS, V1862, P1984, DOI 10.1016/j.bbadis.2016.08.003
   Villela D, 2016, NEURAL PLAST, V2016, DOI 10.1155/2016/2584940
   Walston JD, 2012, CURR OPIN RHEUMATOL, V24, P623, DOI 10.1097/BOR.0b013e328358d59b
   Wang GK, 2010, EUR HEART J, V31, P659, DOI 10.1093/eurheartj/ehq013
   Wang S, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.79
   Wang XG, 2013, NAT MED, V19, P93, DOI 10.1038/nm.3026
   Wang Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034641
   Wenk GL, 2003, J CLIN PSYCHIAT, V64, P7
   Wu HM, 2015, CHEMOSPHERE, V139, P496, DOI 10.1016/j.chemosphere.2015.08.031
   Wu ZY, 2011, MED ONCOL, V28, P1469, DOI 10.1007/s12032-010-9563-7
   Xu PZ, 2003, CURR BIOL, V13, P790, DOI 10.1016/S0960-9822(03)00250-1
   Xu XS, 2015, ONCOTARGET, V6, P3988, DOI 10.18632/oncotarget.2905
   Xue W, 2007, NATURE, V445, P656, DOI 10.1038/nature05529
   Yamakuchi M, 2008, P NATL ACAD SCI USA, V105, P13421, DOI 10.1073/pnas.0801613105
   Yan X., 2015, JCDSA, V05, P332, DOI DOI 10.4236/JCDSA.2015.54040
   Yang JR, 2013, AGE, V35, P11, DOI 10.1007/s11357-011-9324-3
   Yang N, 2013, J BONE MINER RES, V28, P559, DOI 10.1002/jbmr.1798
   Yi R, 2003, GENE DEV, V17, P3011, DOI 10.1101/gad.1158803
   Zampetaki A, 2010, CIRC RES, V107, P810, DOI 10.1161/CIRCRESAHA.110.226357
   Zernecke A, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000610
   Zhang R, 2014, J NEUROL SCI, V338, P57, DOI 10.1016/j.jns.2013.12.017
   Zhao HQ, 2015, ARTERIOSCL THROM VAS, V35, P918, DOI 10.1161/ATVBAHA.114.305212
   Zhou XM, 2006, MECH AGEING DEV, V127, P779, DOI 10.1016/j.mad.2006.07.003
   Zhu H., 2016, BBRC, V471
NR 147
TC 72
Z9 75
U1 1
U2 27
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 1568-1637
EI 1872-9649
J9 AGEING RES REV
JI Ageing Res. Rev.
PD MAY
PY 2017
VL 35
BP 350
EP 363
DI 10.1016/j.arr.2016.11.008
PG 14
WC Cell Biology; Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Geriatrics & Gerontology
GA ET3TN
UT WOS:000400202500025
PM 27903442
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Wen, YH
   Wei, YJ
   Zhang, SM
   Li, S
   Liu, HB
   Wang, F
   Zhao, Y
   Zhang, DW
   Zhang, Y
AF Wen, Yanhua
   Wei, Yanjun
   Zhang, Shumei
   Li, Song
   Liu, Hongbo
   Wang, Fang
   Zhao, Yue
   Zhang, Dongwei
   Zhang, Yan
TI Cell subpopulation deconvolution reveals breast cancer heterogeneity
   based on DNA methylation signature
SO BRIEFINGS IN BIOINFORMATICS
LA English
DT Article
DE breast cancer; cell line; deconvolution; DNA methylation; heterogeneity
ID INTRA-TUMOR HETEROGENEITY; COPY NUMBER ALTERATIONS; CLONAL EVOLUTION;
   GENE-EXPRESSION; SEQUENCING DATA; CORRESPONDING TUMORS; MOLECULAR
   SUBTYPES; MICROARRAY DATA; CLASS DISCOVERY; WHOLE-GENOME
AB Tumour heterogeneity describes the coexistence of divergent tumour cell clones within tumours, which is often caused by underlying epigenetic changes. DNA methylation is commonly regarded as a significant regulator that differs across cells and tissues. In this study, we comprehensively reviewed research progress on estimating of tumour heterogeneity. Bioinformatics-based analysis of DNA methylation has revealed the evolutionary relationships between breast cancer cell lines and tissues. Further analysis of the DNA methylation profiles in 33 breast cancer-related cell lines identified cell line-specific methylation patterns. Next, we reviewed the computational methods in inferring clonal evolution of tumours from different perspectives and then proposed a deconvolution strategy for modelling cell subclonal populations dynamics in breast cancer tissues based on DNA methylation. Further analysis of simulated cancer tissues and real cell lines revealed that this approach exhibits satisfactory performance and relative stability in estimating the composition and proportions of cellular subpopulations. The application of this strategy to breast cancer individuals of the Cancer Genome Atlas's identified different cellular subpopulations with distinct molecular phenotypes. Moreover, the current and potential future applications of this deconvolution strategy to clinical breast cancer research are discussed, and emphasis was placed on the DNA methylation-based recognition of intra-tumour heterogeneity. The wide use of these methods for estimating heterogeneity to further clinical cohorts will improve our understanding of neoplastic progression and the design of therapeutic interventions for treating breast cancer and other malignancies.
C1 [Wen, Yanhua; Wei, Yanjun; Zhang, Shumei; Li, Song; Liu, Hongbo; Wang, Fang; Zhang, Yan] Harbin Med Univ, Coll Bioinformat Sci & Technol, Harbin 150086, Peoples R China.
   [Zhao, Yue] Harbin Med Univ, Affiliated Hosp 4, Harbin, Peoples R China.
   [Zhang, Dongwei] Harbin Med Univ, Affiliated Hosp 2, Harbin, Peoples R China.
C3 Harbin Medical University; Harbin Medical University; Harbin Medical
   University
RP Zhang, Y (通讯作者)，Harbin Med Univ, Coll Bioinformat Sci & Technol, Harbin 150086, Peoples R China.; Zhang, DW (通讯作者)，Harbin Med Univ, Affiliated Hosp 2, Dept Gen Surg, Harbin 150086, Peoples R China.
EM mugong0@163.com; tyozhang@ems.hrbmu.edu.cn
RI ; Liu, Hongbo/M-2162-2015
OI Wei, Yanjun/0000-0003-4200-2859; Liu, Hongbo/0000-0002-0733-8616
FU National Natural Science Foundation of China [31371334, 61403112,
   81573021, 61402139]; Natural Science Foundation of Heilongjiang Province
   [ZD2015003]; Innovation and Technology special Fund for excellent
   academic leader of Harbin [2015RAXXJ052, 2015RAXYJ051]; Innovation
   Research Fund for Graduate Students of Harbin Medical University
   [YJSCX2014-23HYD]
FX This work is supported by the National Natural Science Foundation of
   China [grant numbers 31371334, 61403112, 81573021, 61402139], the
   Natural Science Foundation of Heilongjiang Province [grant number
   ZD2015003], the Innovation and Technology special Fund for excellent
   academic leader of Harbin [grant number 2015RAXXJ052, 2015RAXYJ051] and
   the Innovation Research Fund for Graduate Students of Harbin Medical
   University (YJSCX2014-23HYD).
CR Accomando WP, 2014, GENOME BIOL, V15, DOI 10.1186/gb-2014-15-3-r50
   Ahuja N, 2016, ANNU REV MED, V67, P73, DOI 10.1146/annurev-med-111314-035900
   Andor N, 2016, NAT MED, V22, P105, DOI 10.1038/nm.3984
   Andor N, 2014, BIOINFORMATICS, V30, P50, DOI 10.1093/bioinformatics/btt622
   [Anonymous], CANC GENETICS EPIGEN
   Bao L, 2014, BIOINFORMATICS, V30, P1056, DOI 10.1093/bioinformatics/btt759
   Baron U, 2006, EPIGENETICS-US, V1, P55, DOI 10.4161/epi.1.1.2643
   Burdall SE, 2003, BREAST CANCER RES, V5, P89, DOI 10.1186/bcr577
   Carter SL, 2012, NAT BIOTECHNOL, V30, P413, DOI 10.1038/nbt.2203
   Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865
   Comsa S, 2015, ANTICANCER RES, V35, P3147
   Cope LM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105545
   CORBEIL RR, 1976, TECHNOMETRICS, V18, P31, DOI 10.2307/1267913
   Cowherd SM, 2012, METHODS MOL BIOL, V823, P1, DOI 10.1007/978-1-60327-216-2_1
   Davies MN, 2012, GENOME BIOL, V13, DOI 10.1186/gb-2012-13-6-r43
   De Iuliis F, 2016, TUMOR BIOL, V37, P2603, DOI 10.1007/s13277-015-4075-x
   Desper R, 2002, J COMPUT BIOL, V9, P687, DOI 10.1089/106652702761034136
   Di Cello F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068630
   Fleischer T, 2014, INT J CANCER, V134, P2615, DOI 10.1002/ijc.28606
   Friedl P, 2003, NAT REV CANCER, V3, P362, DOI 10.1038/nrc1075
   Fu Y, 2015, SCI REP-UK, V5, DOI 10.1038/srep13955
   Gazdar AF, 1998, INT J CANCER, V78, P766, DOI 10.1002/(SICI)1097-0215(19981209)78:6<766::AID-IJC15>3.0.CO;2-L
   Gerlinger M, 2012, NEW ENGL J MED, V366, P883, DOI 10.1056/NEJMoa1113205
   GOLDFARB D, 1983, MATH PROGRAM, V27, P1, DOI 10.1007/BF02591962
   Goldfarb D, 1982, NUMERICAL ANAL, P226
   Goldhirsch A, 2011, ANN ONCOL, V22, P1736, DOI 10.1093/annonc/mdr304
   Gong T, 2013, BIOINFORMATICS, V29, P1083, DOI 10.1093/bioinformatics/btt090
   Gottschling S, 2012, LUNG CANCER, V75, P45, DOI 10.1016/j.lungcan.2011.05.020
   Greaves M, 2012, NATURE, V481, P306, DOI 10.1038/nature10762
   Grigoriu A, 2011, EPIGENETICS-US, V6, P368, DOI 10.4161/epi.6.3.14196
   Gusnanto A, 2012, BIOINFORMATICS, V28, P40, DOI 10.1093/bioinformatics/btr593
   Ha G, 2014, GENOME RES, V24, P1881, DOI 10.1101/gr.180281.114
   Holm K, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2590
   Jiao W, 2014, BMC BIOINFORMATICS, V15, DOI 10.1186/1471-2105-15-35
   Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412
   Lacroix M, 2004, BREAST CANCER RES TR, V83, P249, DOI 10.1023/B:BREA.0000014042.54925.cc
   Larson NB, 2013, BIOINFORMATICS, V29, P1888, DOI 10.1093/bioinformatics/btt293
   Li R, 2015, ONCOTARGET, V6, P30968, DOI 10.18632/oncotarget.5038
   Lorincz MC, 2004, NAT STRUCT MOL BIOL, V11, P1068, DOI 10.1038/nsmb840
   Marusyk A, 2012, NAT REV CANCER, V12, P323, DOI 10.1038/nrc3261
   Monti S, 2003, MACH LEARN, V52, P91, DOI 10.1023/A:1023949509487
   Mullighan CG, 2008, SCIENCE, V322, P1377, DOI 10.1126/science.1164266
   Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008
   Ng CKY, 2012, EXPERT REV ANTICANC, V12, P1021, DOI [10.1586/era.12.85, 10.1586/ERA.12.85]
   Niu NF, 2015, PHARMACOGENOMICS, V16, P273, DOI 10.2217/pgs.14.170
   NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840
   Oesper L, 2014, BIOINFORMATICS, V30, P3532, DOI 10.1093/bioinformatics/btu651
   Oesper L, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-7-r80
   Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093
   Quon G, 2013, GENOME MED, V5, DOI 10.1186/gm433
   Recouvreux S, 2015, WORLD J CLIN ONCOL, V6, P207, DOI 10.5306/wjco.v6.i6.207
   Roth A, 2014, NAT METHODS, V11, P396, DOI [10.1038/NMETH.2883, 10.1038/nmeth.2883]
   Rouzier R, 2005, CLIN CANCER RES, V11, P5678, DOI 10.1158/1078-0432.CCR-04-2421
   Sandoval J, 2011, EPIGENETICS-US, V6, P692, DOI 10.4161/epi.6.6.16196
   Schwarz RF, 2014, PLOS COMPUT BIOL, V10, DOI 10.1371/journal.pcbi.1003535
   Shoemaker RH, 2006, NAT REV CANCER, V6, P813, DOI 10.1038/nrc1951
   Strino F, 2013, NUCLEIC ACIDS RES, V41, DOI 10.1093/nar/gkt641
   Swanton C, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2807
   Terunuma A, 2014, J CLIN INVEST, V124, P398, DOI 10.1172/JCI71180
   van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a
   Varley KE, 2013, GENOME RES, V23, P555, DOI 10.1101/gr.147942.112
   Voskoglou-Nomikos T, 2003, CLIN CANCER RES, V9, P4227
   Wagenmakers EJ, 2004, PSYCHON B REV, V11, P192, DOI 10.3758/BF03206482
   Wang B, 2014, NAT METHODS, V11, P333, DOI [10.1038/nmeth.2810, 10.1038/NMETH.2810]
   Wang F, 2014, BRIEF BIOINFORM, V15, P1028, DOI 10.1093/bib/bbt076
   Wang NY, 2015, BIOINFORMATICS, V31, P137, DOI 10.1093/bioinformatics/btu607
   Wilkening S, 2003, DRUG METAB DISPOS, V31, P1035, DOI 10.1124/dmd.31.8.1035
   Wilkerson MD, 2010, BIOINFORMATICS, V26, P1572, DOI 10.1093/bioinformatics/btq170
   Wilm A, 2012, NUCLEIC ACIDS RES, V40, P11189, DOI 10.1093/nar/gks918
   Wistuba II, 1998, CLIN CANCER RES, V4, P2931
   Wistuba II, 1999, CLIN CANCER RES, V5, P991
   Yamamoto S, 2014, CANCER CELL, V25, P762, DOI 10.1016/j.ccr.2014.04.024
   Zare H, 2014, PLOS COMPUT BIOL, V10, DOI 10.1371/journal.pcbi.1003703
   Zhang NQ, 2015, BIOINFORMATICS, V31, P3401, DOI 10.1093/bioinformatics/btv370
   Zheng XQ, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0419-x
   Zhu YL, 2006, INT J ONCOL, V29, P1581
NR 76
TC 20
Z9 22
U1 0
U2 16
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1467-5463
EI 1477-4054
J9 BRIEF BIOINFORM
JI Brief. Bioinform.
PD MAY
PY 2017
VL 18
IS 3
BP 426
EP 440
DI 10.1093/bib/bbw028
PG 15
WC Biochemical Research Methods; Mathematical & Computational Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Mathematical & Computational Biology
GA EU3YW
UT WOS:000400968000007
PM 27016391
OA Bronze
DA 2025-01-12
ER

PT J
AU Reeves, ME
   Firek, M
   Jliedi, A
   Amaar, YG
AF Reeves, Mark E.
   Firek, Mathew
   Jliedi, Abdullaati
   Amaar, Yousef G.
TI Identification and characterization of RASSF1C pi RNA target genes in
   lung cancer cells
SO ONCOTARGET
LA English
DT Article
DE lung cancer; RASSF1C; PIWIL1; piRNAs; cell proliferation
ID TUMOR-SUPPRESSOR GENE; EPIGENETIC INACTIVATION; RENEWAL GENE; HIWI GENE;
   EXPRESSION; PROTEIN; BREAST; GROWTH; 3P21.3; RISK
AB RASSF1C up-regulates important genes involved in lung cancer cell growth, including a stem cell self-renewal gene, piwil1. In this article, we report the identification of small noncoding PIWI-interacting RNAs (piRNAs) in lung cancer cells over-expressing RASSF1C. A piRNA microarray screen was performed using RNA isolated from the lung cancer cell line H1299 stably over-expressing RASSF1C and corresponding control. The piRNA microarray screen identified several piRNAs that are regulated by RASSF1C and we have validated the expression of two up-regulated piRNAs (piR-34871 and piR-52200) and two down-regulated piRNAs (piR-35127 and piR-46545) in lung cancer cells with silenced and over-expressed RASSF1C using RT-PCR. We also assessed the expression of these four piRNAs in lung tumor and matched normal tissues (n = 12). We found that piR-34871 and piR-52200 were up-regulated in 58% and 50%, respectively; while piR-35127 and piR-46545 were down-regulated in 50% in lung tumor tissues tested. The expression of piR-35127 was inversely correlated with RASSF1C expression in 10/12 tumor tissues. Overexpression of piR-35127 and piR-46545 and knock-down of piR-34871 and piR-52200 significantly reduced normal lung and breast epithelial cell proliferation and cell colony formation as well as proliferation of lung cancer cell lines (A549 and H1299) and breast cancer cell lines (Hs578T and MDA-MB-231). This suggests that these novel piRNAs may potentially be involved in regulating lung cell transformation and tumorigenesis. RASSF1C may potentially modulate the expression of its piRNA target genes through attenuation of the AMPK pathway, as over-expression of RASSF1C resulted in reduction of p-AMPK, p21, and p27 protein levels.
C1 [Reeves, Mark E.; Firek, Mathew; Jliedi, Abdullaati; Amaar, Yousef G.] Loma Linda VA Med Ctr, Surg Oncol Lab, Loma Linda, CA 92357 USA.
   [Reeves, Mark E.] Loma Linda Univ, Canc Ctr, Loma Linda, CA 92350 USA.
C3 Loma Linda University; Loma Linda University
RP Amaar, YG (通讯作者)，Loma Linda VA Med Ctr, Surg Oncol Lab, Loma Linda, CA 92357 USA.
EM yousef.amaar@va.gov
FU Loma Linda University Cancer Center
FX This work was carried out at the Loma Linda VA Medical Center, Loma
   Linda, CA, and was supported by a grant from the Loma Linda University
   Cancer Center.
CR Agathanggelou A, 2003, CANCER RES, V63, P5344
   Agathanggelou A, 2001, ONCOGENE, V20, P1509, DOI 10.1038/sj.onc.1204175
   Amaar YG, 2006, AM J PHYSIOL-LUNG C, V291, pL1185, DOI 10.1152/ajplung.00072.2006
   [Anonymous], 2012, 05226 VAESP
   [Anonymous], MOL BIOL INT
   Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691
   Chen Z, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1794-8
   Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083
   Dammann R, 2001, ONCOGENE, V20, P3563, DOI 10.1038/sj.onc.1204469
   Dreijerink K, 2001, P NATL ACAD SCI USA, V98, P7504, DOI 10.1073/pnas.131216298
   Grochola LF, 2008, BRIT J CANCER, V99, P1083, DOI 10.1038/sj.bjc.6604653
   Huang DQ, 2016, ONCOTARGET, V7, P6188, DOI 10.18632/oncotarget.6748
   Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43
   Kim VN, 2006, GENE DEV, V20, P1993, DOI 10.1101/gad.1456106
   Kim VN, 2009, NAT REV MOL CELL BIO, V10, P126, DOI 10.1038/nrm2632
   Li JF, 2004, ONCOGENE, V23, P5941, DOI 10.1038/sj.onc.1207789
   Liu LM, 2002, ONCOGENE, V21, P6835, DOI 10.1038/sj.onc.1205814
   Liu XY, 2006, INT J CANCER, V118, P1922, DOI 10.1002/ijc.21575
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Meister G, 2013, NAT REV GENET, V14, P447, DOI 10.1038/nrg3462
   Praveen P, 2016, SCI REP-UK, V6, DOI 10.1038/srep27514
   Reeves ME, 2012, CANCER GROWTH METAST, V5, P27, DOI 10.4137/CGM.S9845
   Reeves ME, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101679
   Reeves Mark E, 2012, BMC Res Notes, V5, P239, DOI 10.1186/1756-0500-5-239
   Reeves ME, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-562
   Storozhuk Y, 2013, BRIT J CANCER, V108, P2021, DOI 10.1038/bjc.2013.187
   Taubert H, 2007, ONCOGENE, V26, P7170, DOI 10.1038/sj.onc.1210530
   Taubert H, 2007, ONCOGENE, V26, P1098, DOI 10.1038/sj.onc.1209880
   Tommasi S, 2005, CANCER RES, V65, P92
   Vlahov N, 2015, CURR BIOL, V25, P3019, DOI 10.1016/j.cub.2015.09.072
   Vos MD, 2000, J BIOL CHEM, V275, P35669, DOI 10.1074/jbc.C000463200
   Zeng Y, 2011, CHINESE MED J-PEKING, V124, P2144, DOI 10.3760/cma.j.issn.0366-6999.2011.14.012
NR 32
TC 53
Z9 54
U1 1
U2 5
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD MAY 23
PY 2017
VL 8
IS 21
BP 34268
EP 34282
DI 10.18632/oncotarget.15965
PG 15
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA EV8RY
UT WOS:000402051700026
PM 28423657
OA Green Submitted, Green Published, gold
DA 2025-01-12
ER

PT J
AU Dooley, J
   Lagou, V
   Pasciuto, E
   Linterman, MA
   Prosser, HM
   Himmelreich, U
   Liston, A
AF Dooley, James
   Lagou, Vasiliki
   Pasciuto, Emanuela
   Linterman, Michelle A.
   Prosser, Haydn M.
   Himmelreich, Uwe
   Liston, Adrian
TI No Functional Role for microRNA-342 in a Mouse Model of Pancreatic
   Acinar Carcinoma
SO FRONTIERS IN ONCOLOGY
LA English
DT Article
DE pancreatic cancer; microRNAs; miR-342-5p; acinar carcinoma; in vivo
ID BREAST-CANCER; CELL-PROLIFERATION; EXPRESSION; MIR-342-3P; INVASION;
   TARGETS; MIRNAS; PREDICTION; RESOURCE; SURVIVAL
AB The intronic microRNA (miR)-342 has been proposed as a potent tumor-suppressor gene. miR-342 is found to be downregulated or epigenetically silenced in multiple different tumor sites, and this loss of expression permits the upregulation of several key oncogenic pathways. In several different cell lines, lower miR-342 expression results in enhanced proliferation and metastasis potential, both in vitro and in xenogenic transplant conditions. Here, we sought to determine the function of miR-342 in an in vivo spontaneous cancer model, using the Ela1-TAg transgenic model of pancreatic acinar carcinoma. Through longitudinal magnetic resonance imaging monitoring of Ela1-TAg transgenic mice, either wild-type or knockout for miR-342, we found no role for miR-342 in the development, growth rate, or pathogenicity of pancreatic acinar carcinoma. These results indicate the importance of assessing miR function in the complex physiology of in vivo model systems and indicate that further functional testing of miR-342 is required before concluding it is a bona fide tumor-suppressor-miR.
C1 [Dooley, James; Lagou, Vasiliki; Pasciuto, Emanuela; Liston, Adrian] VIB, Translat Immunol Lab, Leuven, Belgium.
   [Dooley, James; Lagou, Vasiliki; Pasciuto, Emanuela; Liston, Adrian] Univ Leuven, KU Leuven, Dept Microbiol & Immunol, Leuven, Belgium.
   [Linterman, Michelle A.] Babraham Inst, Lab Lymphocyte Signaling & Dev, Cambridge, England.
   [Prosser, Haydn M.] Wellcome Trust Sanger Inst, Wellcome Trust Genome Campus, Cambridge, England.
   [Himmelreich, Uwe] Univ Leuven, KU Leuven, Dept Imaging & Pathol, Leuven, Belgium.
C3 Flanders Institute for Biotechnology (VIB); KU Leuven; UK Research &
   Innovation (UKRI); Biotechnology and Biological Sciences Research
   Council (BBSRC); Babraham Institute; Wellcome Trust Sanger Institute; KU
   Leuven
RP Liston, A (通讯作者)，VIB, Translat Immunol Lab, Leuven, Belgium.; Liston, A (通讯作者)，Univ Leuven, KU Leuven, Dept Microbiol & Immunol, Leuven, Belgium.
EM adrian.liston@vib-kuleuven.be
RI Liston, Adrian/G-8606-2013; Pasciuto, Emanuela/AAP-2982-2020; Linterman,
   Michelle/AAN-4210-2021; Lagou, Vasiliki/N-8451-2013
OI Linterman, Michelle/0000-0001-6047-1996; Dooley,
   James/0000-0003-3154-4708; Lagou, Vasiliki/0000-0003-3165-8940;
   Pasciuto, Emanuela/0000-0002-5391-9585; Himmelreich,
   Uwe/0000-0002-2060-8895
FU VIB; IUAP (T-TIME); FWO post-doctoral fellowship; Wellcome Trust
   [098051]; BBSRC [BBS/E/B/000C0428, BBS/E/B/000C0427] Funding Source:
   UKRI
FX This work was supported by the VIB and IUAP (T-TIME). VL was supported
   by an FWO post-doctoral fellowship. We thank Allan Bradley for supplying
   the miR-342 knockout mouse, the production of which was supported by the
   Wellcome Trust grant 098051. We thank Tom Dresselaers, Katinka van
   Dongen, Susann Schonefeldt, Jeason Haughton, Josselyn Garcia-Perez, and
   Yulia Lampi for technical assistance and all staff at the molecular
   Small Animal Imaging Center (moSAIC) for MRI training and assistance.
CR Betel D, 2008, NUCLEIC ACIDS RES, V36, pD149, DOI 10.1093/nar/gkm995
   Crippa E, 2016, ONCOTARGET, V7, P18594, DOI 10.18632/oncotarget.7617
   Dacic S, 2010, MODERN PATHOL, V23, P1577, DOI 10.1038/modpathol.2010.152
   Egeland NG, 2015, INT J MOL SCI, V16, P24243, DOI 10.3390/ijms161024243
   Fabbri M, 2013, CURR MOL MED, V13, P751, DOI 10.2174/1566524011313050006
   Fayyad-Kazan H, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-31
   Friedman RC, 2009, GENOME RES, V19, P92, DOI 10.1101/gr.082701.108
   Grady WM, 2008, ONCOGENE, V27, P3880, DOI 10.1038/onc.2008.10
   Hamdi K, 2014, SPRINGERPLUS, V3, DOI 10.1186/2193-1801-3-636
   HARRINGTON DP, 1982, BIOMETRIKA, V69, P553, DOI 10.2307/2335991
   Huang HB, 2016, ONCOL LETT, V11, P345, DOI 10.3892/ol.2015.3831
   Jayawardana K, 2016, J INVEST DERMATOL, V136, P245, DOI 10.1038/JID.2015.355
   Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43
   Jung CK, 2016, ONCOTARGET, V7, P32902, DOI 10.18632/oncotarget.8766
   Lee KH, 2015, PANCREAS, V44, P764, DOI 10.1097/MPA.0000000000000346
   Leivonen SK, 2014, MOL ONCOL, V8, P93, DOI 10.1016/j.molonc.2013.10.001
   Li XR, 2014, FEBS LETT, V588, P3298, DOI 10.1016/j.febslet.2014.07.020
   Mosakhani N, 2013, CYTOGENET GENOME RES, V141, P272, DOI 10.1159/000351219
   ORNITZ DM, 1987, SCIENCE, V238, P188, DOI 10.1126/science.2821617
   Pedroza-Torres A, 2016, GYNECOL ONCOL, V142, P557, DOI 10.1016/j.ygyno.2016.07.093
   Pérez-Rivas LG, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091884
   Piepoli A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033663
   Prosser HM, 2011, NAT BIOTECHNOL, V29, P843, DOI 10.1038/nbt.1929
   Reddy SDN, 2010, CANCER BIOL THER, V9, P479, DOI 10.4161/cbt.9.7.11402
   Sandhu V, 2016, MOL ONCOL, V10, P303, DOI 10.1016/j.molonc.2015.10.011
   Shin VY, 2015, BRIT J CANCER, V112, P1751, DOI 10.1038/bjc.2015.143
   Tai MC, 2015, CARCINOGENESIS, V36, P1464, DOI 10.1093/carcin/bgv152
   Tao K, 2014, AM J TRANSL RES, V6, P391
   Teno JM, 2000, J AM GERIATR SOC, V48, pS16, DOI 10.1111/j.1532-5415.2000.tb03126.x
   Tevethia MJ, 1997, J VIROL, V71, P8157, DOI 10.1128/JVI.71.11.8157-8166.1997
   Wang H, 2011, CARCINOGENESIS, V32, P1033, DOI 10.1093/carcin/bgr081
   Weng WH, 2016, CLIN CANCER RES, V22, P4947, DOI 10.1158/1078-0432.CCR-16-0360
   Westphalen CB, 2012, CANCER J, V18, P502, DOI 10.1097/PPO.0b013e31827ab4c4
   Xie X, 2015, TUMOR BIOL, V36, P5031, DOI 10.1007/s13277-015-3154-3
   Yan XC, 2016, J AM HEART ASSOC, V5, DOI 10.1161/JAHA.115.003042
   Yang HJ, 2016, ONCOTARGET, V7, P2709, DOI 10.18632/oncotarget.6458
   Zhao L, 2015, BIOCHEM BIOPH RES CO, V457, P370, DOI 10.1016/j.bbrc.2014.12.119
NR 37
TC 8
Z9 8
U1 1
U2 10
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2234-943X
J9 FRONT ONCOL
JI Front. Oncol.
PD MAY 18
PY 2017
VL 7
AR 101
DI 10.3389/fonc.2017.00101
PG 6
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA EV1OI
UT WOS:000401515400001
PM 28573106
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Feng, J
   Li, L
   Zhang, N
   Liu, J
   Zhang, L
   Gao, H
   Wang, G
   Li, Y
   Zhang, Y
   Li, X
   Liu, D
   Lu, J
   Huang, B
AF Feng, J.
   Li, L.
   Zhang, N.
   Liu, J.
   Zhang, L.
   Gao, H.
   Wang, G.
   Li, Y.
   Zhang, Y.
   Li, X.
   Liu, D.
   Lu, J.
   Huang, B.
TI Androgen and AR contribute to breast cancer development and metastasis:
   an insight of mechanisms
SO ONCOGENE
LA English
DT Article
ID TANDEM MASS-SPECTROMETRY; SEX STEROID-HORMONES; GENE-EXPRESSION;
   POSTMENOPAUSAL WOMEN; RECEPTOR EXPRESSION; CHROMATIN
   IMMUNOPRECIPITATION; TESTOSTERONE LEVELS; SERUM TESTOSTERONE;
   DEMETHYLASE LSD1; DUCTAL CARCINOMA
AB The role of androgen and androgen receptor (AR) in breast carcinogenesis has long been a disputed issue. This report provides a mechanistic insight into how androgen and AR contributes to invasion and metastasis of breast cancer. We find that dihydrotestosterone (DHT) is able to induce the epithelial-to-mesenchymal transition in breast cancer cells in an AR-dependent/ estrogen receptor-independent manner. This process is dependent on the demethylation activity of lysine-specific demethylase 1A (LSD1) by epigenetically regulating the target genes E-cadherin and vimentin. In vivo, DHT promotes metastasis in a nude mouse model, and AR and LSD1 are indispensable in this process. We establish that higher expression of nucleus AR to cytoplasm AR associated with worse prognostic outcomes in breast cancer patient samples. This study maps an 'androgen-AR/LSD1-target genes' pathway in breast carcinogenesis, implicating the importance of hormonal balance in women, and the potential clinical significance of serum androgen and AR in prediction of breast cancer and selection of breast cancer therapy.
C1 [Feng, J.; Li, L.; Liu, J.; Zhang, Y.; Huang, B.] Northeast Normal Univ, Minist Educ MOE, Key Lab Mol Epigenet, 5268 Renmin St', Changchun 130024, Peoples R China.
   [Li, L.] Tianjin Med Univ Canc Inst & Hosp, Natl Clin Res Ctr Canc, Key Lab Canc Prevent & Therapy, Dept Bone & Soft Tissue Tumors, Tianjin, Peoples R China.
   [Zhang, N.; Li, X.; Lu, J.] Northeast Normal Univ, Inst Genet & Cytol, 5268 Renmin St, Changchun 130024, Peoples R China.
   [Zhang, L.; Gao, H.] Jilin Univ, Dept Pathol, Hosp 2, Changchun, Peoples R China.
   [Wang, G.; Li, Y.] Northeast Normal Univ, Natl Engn Lab Druggable Gene & Prot Screening, Changchun, Peoples R China.
   [Liu, D.] Auckland Univ Technol, Sch Sci, Auckland, New Zealand.
C3 Northeast Normal University - China; Tianjin Medical University;
   Northeast Normal University - China; Jilin University; Northeast Normal
   University - China; Auckland University of Technology
RP Huang, B (通讯作者)，Northeast Normal Univ, Minist Educ MOE, Key Lab Mol Epigenet, 5268 Renmin St', Changchun 130024, Peoples R China.; Lu, J (通讯作者)，Northeast Normal Univ, Inst Genet & Cytol, 5268 Renmin St, Changchun 130024, Peoples R China.
EM luj809@nenu.edu.cn; huangbq705@nenu.edu.cn
RI Feng, Jingxin/KEI-4101-2024; Zhang, Na/KQU-7102-2024
OI Feng, Jing-Xin/0000-0003-0677-2792; Li, Lili/0000-0002-6095-3853
FU National Natural Science Foundation of China [31570718, 31571478,
   31571317, 31371294]; University S & T Innovation Platform of Jilin
   Province for Economic Fungi [2014B-1]
FX We thank Dr Wei Huang from School of Mathematics and Statistics of
   Northeast Normal University for kindly providing statistical analysis
   guidance. This work was supported by the grants from the National
   Natural Science Foundation of China (Grant numbers 31570718, 31571478,
   31571317 and 31371294), and a grant from The University S & T Innovation
   Platform of Jilin Province for Economic Fungi (#2014B-1).
CR Abdulla A, 2014, J BIOL CHEM, V289, P29937, DOI 10.1074/jbc.M114.573659
   Agrawal AK, 2008, FOLIA HISTOCHEM CYTO, V46, P269, DOI 10.2478/v10042-008-0039-y
   Amente S, 2010, ONCOGENE, V29, P3691, DOI 10.1038/onc.2010.120
   Amente S, 2013, BBA-GENE REGUL MECH, V1829, P981, DOI 10.1016/j.bbagrm.2013.05.002
   Amente S, 2010, CELL CYCLE, V9, P3002, DOI 10.4161/cc.9.15.12499
   Berrino F, 2005, INT J CANCER, V113, P499, DOI 10.1002/ijc.20582
   Biswas D, 2011, P NATL ACAD SCI USA, V108, P15751, DOI 10.1073/pnas.1111498108
   Bui HN, 2013, STEROIDS, V78, P96, DOI 10.1016/j.steroids.2012.10.010
   Cai CM, 2011, CANCER CELL, V20, P457, DOI 10.1016/j.ccr.2011.09.001
   Castellano I, 2010, BREAST CANCER RES TR, V124, P607, DOI 10.1007/s10549-010-0761-y
   Chen J, 2013, J STEROID BIOCHEM, V137, P316, DOI 10.1016/j.jsbmb.2013.01.012
   Cochrane DR, 2014, BREAST CANCER RES, V16, DOI 10.1186/bcr3599
   Dorgan JF, 2002, JNCI-J NATL CANCER I, V94, P606
   Dorgan JF, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2779
   Feng JX, 2016, BREAST CANCER RES TR, V159, P443, DOI 10.1007/s10549-016-3959-9
   Ferrari-Amorotti G, 2013, CANCER RES, V73, P235, DOI 10.1158/0008-5472.CAN-12-1739
   Fourkala EO, 2012, ENDOCR-RELAT CANCER, V19, P137, DOI 10.1530/ERC-11-0310
   Garay JP, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3112
   Garcia-Bassets I, 2007, CELL, V128, P505, DOI 10.1016/j.cell.2006.12.038
   Gonzalez LO, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-149
   Gonzalez-Angulo AM, 2009, CLIN CANCER RES, V15, P2472, DOI 10.1158/1078-0432.CCR-08-1763
   Gucalp A, 2013, CLIN CANCER RES, V19, P5505, DOI 10.1158/1078-0432.CCR-12-3327
   Györffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9
   Hanley K, 2008, HUM PATHOL, V39, P386, DOI 10.1016/j.humpath.2007.07.007
   Harmeyer KM, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gku1347
   Harwood DT, 2009, CLIN CHIM ACTA, V409, P78, DOI 10.1016/j.cca.2009.09.003
   He JH, 2012, MED ONCOL, V29, P406, DOI 10.1007/s12032-011-9832-0
   Hickey TE, 2015, ONCOTARGET, V6, P44728, DOI 10.18632/oncotarget.6296
   Honma N, 2013, BREAST CANCER-TOKYO, V20, P323, DOI 10.1007/s12282-012-0337-2
   Hu DG, 2014, HORM CANCER-US, V5, P61, DOI 10.1007/s12672-014-0171-4
   Hu R, 2011, CLIN CANCER RES, V17, P1867, DOI 10.1158/1078-0432.CCR-10-2021
   Huang PH, 2011, MOL PHARMACOL, V79, P197, DOI 10.1124/mol.110.067702
   Kaaks R, 2005, JNCI-J NATL CANCER I, V97, P755, DOI 10.1093/jnci/dji132
   Kaaks R, 2005, ENDOCR-RELAT CANCER, V12, P1071, DOI 10.1677/erc.1.01038
   Kocatürk B, 2015, JOVE-J VIS EXP, DOI 10.3791/51967
   Lehmann BD, 2011, J CLIN INVEST, V121, P2750, DOI 10.1172/JCI45014
   Li YX, 2016, ONCOL REP, V35, P3586, DOI 10.3892/or.2016.4729
   Liu YN, 2008, MOL CELL BIOL, V28, P7096, DOI 10.1128/MCB.00449-08
   Loibl S, 2011, BREAST CANCER RES TR, V130, P477, DOI 10.1007/s10549-011-1715-8
   Luo HC, 2016, CELL REP, V15, P2665, DOI 10.1016/j.celrep.2016.05.050
   Luo Xiang, 2010, Chin J Cancer, V29, P585
   McNamara KM, 2013, J STEROID BIOCHEM, V133, P66, DOI 10.1016/j.jsbmb.2012.08.007
   McNamara KM, 2010, J STEROID BIOCHEM, V121, P611, DOI 10.1016/j.jsbmb.2010.02.001
   McNamara Keely M, 2013, Front Endocrinol (Lausanne), V4, P116, DOI 10.3389/fendo.2013.00116
   Metzger E, 2005, NATURE, V437, P436, DOI 10.1038/nature04020
   Metzger E, 2010, NATURE, V464, P792, DOI 10.1038/nature08839
   Micello D, 2010, VIRCHOWS ARCH, V457, P467, DOI 10.1007/s00428-010-0964-y
   Missmer SA, 2004, JNCI-J NATL CANCER I, V96, P1856, DOI 10.1093/jnci/djh336
   Mrklic I, 2013, ACTA HISTOCHEM, V115, P344, DOI 10.1016/j.acthis.2012.09.006
   Nair SS, 2010, EMBO REP, V11, P438, DOI 10.1038/embor.2010.62
   Nakamura T, 2002, MOL CELL, V10, P1119, DOI 10.1016/S1097-2765(02)00740-2
   Nam HJ, 2014, MOL CELL, V53, P791, DOI 10.1016/j.molcel.2014.01.028
   Narayanan R, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103202
   Nelson JD, 2006, NAT PROTOC, V1, P179, DOI 10.1038/nprot.2006.27
   Ni L, 2013, MOL CELL BIOL, V33, P4766, DOI 10.1128/MCB.00647-13
   Ni M, 2013, GENE DEV, V27, P734, DOI 10.1101/gad.209569.112
   Ni M, 2011, CANCER CELL, V20, P119, DOI 10.1016/j.ccr.2011.05.026
   Niemeier LA, 2010, MODERN PATHOL, V23, P205, DOI 10.1038/modpathol.2009.159
   Park S, 2011, ANN ONCOL, V22, P1755, DOI 10.1093/annonc/mdq678
   Park S, 2010, ANN ONCOL, V21, P488, DOI 10.1093/annonc/mdp510
   Perillo B, 2008, SCIENCE, V319, P202, DOI 10.1126/science.1147674
   Peters AA, 2009, CANCER RES, V69, P6131, DOI 10.1158/0008-5472.CAN-09-0452
   Peters KM, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-132
   Qu Q, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082650
   Rakha EA, 2007, CANCER-AM CANCER SOC, V109, P25, DOI 10.1002/cncr.22381
   REMMELE W, 1986, VIRCHOWS ARCH A, V409, P127, DOI 10.1007/BF00708323
   Robinson JLL, 2011, EMBO J, V30, P3019, DOI 10.1038/emboj.2011.216
   Rothman MS, 2011, STEROIDS, V76, P177, DOI 10.1016/j.steroids.2010.10.010
   Schippinger W, 2006, VIRCHOWS ARCH, V449, P24, DOI 10.1007/s00428-006-0213-6
   Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012
   Shufelt Chrisandra L, 2008, Menopause Int, V14, P117, DOI 10.1258/mi.2008.008015
   Sieri S, 2009, CANCER EPIDEM BIOMAR, V18, P169, DOI 10.1158/1055-9965.EPI-08-0808
   Spurdle AB, 1999, JNCI-J NATL CANCER I, V91, P961, DOI 10.1093/jnci/91.11.961
   Subik K, 2010, BREAST CANCER-BASIC, V4, P35
   Tang DB, 2012, MED ONCOL, V29, P526, DOI 10.1007/s12032-011-9948-2
   Tsutsumi Y, 2012, JPN J CLIN ONCOL, V42, P375, DOI 10.1093/jjco/hys034
   Vera-Badillo FE, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/djt319
   Verrijdt G, 2003, MOL GENET METAB, V78, P175, DOI 10.1016/S1096-7192(03)00003-9
   Wang B, 2009, INT J CANCER, V124, P1892, DOI 10.1002/ijc.24132
   Wang Y, 2011, ONCOGENE, V30, P4327, DOI 10.1038/onc.2011.144
   Wang Y, 2013, HUM MOL GENET, V22, P2263, DOI 10.1093/hmg/ddt077
   Wissmann M, 2007, NAT CELL BIOL, V9, P347, DOI 10.1038/ncb1546
   Witzel I, 2013, J CANCER RES CLIN, V139, P809, DOI 10.1007/s00432-013-1382-8
   Yu H, 2003, INT J CANCER, V105, P92, DOI 10.1002/ijc.11034
   Yu Q, 2011, ANN ONCOL, V22, P1288, DOI 10.1093/annonc/mdq586
   Zeleniuch-Jacquotte A, 2004, BRIT J CANCER, V90, P153, DOI 10.1038/sj.bjc.6601517
NR 86
TC 74
Z9 84
U1 0
U2 35
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-9232
EI 1476-5594
J9 ONCOGENE
JI Oncogene
PD MAY 18
PY 2017
VL 36
IS 20
BP 2775
EP 2790
DI 10.1038/onc.2016.432
PG 16
WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
GA EV3ZM
UT WOS:000401697800001
PM 27893717
DA 2025-01-12
ER

PT J
AU Rossi, EL
   Dunlap, SM
   Bowers, LW
   Khatib, SA
   Doerstling, SS
   Smith, LA
   Ford, NA
   Holley, D
   Brown, PH
   Estecio, MR
   Kusewitt, DF
   deGraffenried, LA
   Bultman, SJ
   Hursting, SD
AF Rossi, Emily L.
   Dunlap, Sarah M.
   Bowers, Laura W.
   Khatib, Subreen A.
   Doerstling, Steven S.
   Smith, Laura A.
   Ford, Nikki A.
   Holley, Darcy
   Brown, Powel H.
   Estecio, Marcos R.
   Kusewitt, Donna F.
   deGraffenried, Linda A.
   Bultman, Scott J.
   Hursting, Stephen D.
TI Energy Balance Modulation Impacts Epigenetic Reprogramming, ERα and ERβ
   Expression, and Mammary Tumor Development in MMTV-neu Transgenic Mice
SO CANCER RESEARCH
LA English
DT Article
ID ESTROGEN-RECEPTOR-BETA; BREAST-CANCER RISK; CALORIE RESTRICTION; DNA
   METHYLATION; WEIGHT-LOSS; ENDOCRINE THERAPY; GENE-EXPRESSION; OBESITY;
   CTCF; GROWTH
AB The association between obesity and breast cancer risk and prognosis is well established in estrogen receptor (ER)-positive disease but less clear in HER2-positive disease. Here, we report preclinical evidence suggesting weight maintenance through calorie restriction (CR) may limit risk of HER2-positive breast cancer. In female MMTV-HER2/neu transgenic mice, we found that ER alpha and ER beta expression, mammary tumorigenesis, and survival are energy balance dependent in association with epigenetic reprogramming. Mice were randomized to receive a CR, overweight-inducing, or diet-induced obesity regimen (n = 27/group). Subsets of mice (n = 4/group/time point) were euthanized after 1, 3, and 5 months to characterize diet-dependent metabolic, transcriptional, and epigenetic perturbations. Remaining mice were followed up to 22 months. Relative to the overweight and diet-induced obesity regimens, CR decreased body weight, adiposity, and serum metabolic hormones as expected and also elicited an increase in mammary ERa and ERb expression. Increased DNA methylation accompanied this pattern, particularly at CpG dinucleotides located within binding or flanking regions for the transcriptional regulator CCCTC-binding factor of ESR1 and ESR2, consistent with sustained transcriptional activation of ER alpha and ERb. Mammary expression of the DNA methylation enzyme DNMT1 was stable in CR mice but increased over time in overweight and diet-induced obesity mice, suggesting CR obviates epigenetic alterations concurrent with chronic excess energy intake. In the survival study, CR elicited a significant suppression in spontaneous mammary tumorigenesis. Overall, our findings suggest a mechanistic rationale to prevent or reverse excess body weight as a strategy to reduce HER2-positive breast cancer risk. (C) 2017 AACR.
C1 [Rossi, Emily L.; Bowers, Laura W.; Khatib, Subreen A.; Doerstling, Steven S.; Smith, Laura A.; Hursting, Stephen D.] Univ North Carolina Chapel Hill, Dept Nutr, 135 Dauer Dr, Chapel Hill, NC 27599 USA.
   [Rossi, Emily L.; Bowers, Laura W.; Holley, Darcy; Bultman, Scott J.; Hursting, Stephen D.] Univ North Carolina Chapel Hill, Lineberger Comprehens Canc Ctr, 135 Dauer Dr, Chapel Hill, NC 27599 USA.
   [Dunlap, Sarah M.; Ford, Nikki A.; deGraffenried, Linda A.] Univ Texas Austin, Dept Nutr Sci, Austin, TX 78712 USA.
   [Holley, Darcy; Bultman, Scott J.] Univ North Carolina Chapel Hill, Dept Genet, 135 Dauer Dr, Chapel Hill, NC 27599 USA.
   [Brown, Powel H.] Univ Texas MD Anderson Canc Ctr, Dept Clin Canc Prevent, Houston, TX 77030 USA.
   [Brown, Powel H.] Univ Texas MD Anderson Canc Ctr, Div Canc Med, Dept Breast Med Oncol, Houston, TX 77030 USA.
   [Estecio, Marcos R.; Kusewitt, Donna F.] Univ Texas MD Anderson Canc Ctr, Dept Epigenet & Mol Carcinogenesis, Smithville, TX USA.
C3 University of North Carolina; University of North Carolina Chapel Hill;
   University of North Carolina School of Medicine; University of North
   Carolina School of Medicine; University of North Carolina; University of
   North Carolina Chapel Hill; University of Texas System; University of
   Texas Austin; University of North Carolina; University of North Carolina
   Chapel Hill; University of North Carolina School of Medicine; University
   of Texas System; UTMD Anderson Cancer Center; University of Texas
   System; UTMD Anderson Cancer Center; University of Texas System; UTMD
   Anderson Cancer Center
RP Hursting, SD (通讯作者)，Univ North Carolina Chapel Hill, Dept Nutr, 135 Dauer Dr, Chapel Hill, NC 27599 USA.
EM hursting@email.unc.edu
OI Rossi, Emily/0000-0002-2312-4239; Estecio, Marcos/0000-0002-6874-7413
FU American Institute for Cancer Research [8A049]; Breast Cancer Research
   Foundation; NCI [R35 (CA197627), R25CA057726]; UT-MD Anderson Cancer
   Center Science Park NGS Core; CPRIT Core Facility Support Grant
   [RP120348]; USAMRMC Breast Cancer Research Program [W81XWH-09-1-0720];
   American Institute for Cancer Research
FX This study was supported by the American Institute for Cancer Research
   (8A049), Breast Cancer Research Foundation, and R35 (CA197627) from the
   NCI. The mouse RNA-seq and methylation analysis was supported by the
   UT-MD Anderson Cancer Center Science Park NGS Core, supported by CPRIT
   Core Facility Support Grant RP120348. E.L. Rossi and L.W. Bowers were
   supported by a training grant from the NCI (R25CA057726), S.M. Dunlap
   was supported by a USAMRMC Breast Cancer Research Program Postdoctoral
   Fellowship (W81XWH-09-1-0720), and N.A. Ford was supported by an
   American Institute for Cancer Research Postdoctoral Fellowship.
CR Alokail MS, 2009, CARDIOVASC DIABETOL, V8, DOI 10.1186/1475-2840-8-33
   [Anonymous], 2012, GLOBOCAN 2012 v1.0. Cancer Incidence Mortality Worldwide
   Barres R, 2013, CELL REP, V3, P1020, DOI 10.1016/j.celrep.2013.03.018
   Browne RW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059498
   Chen CT, 2012, MOL CANCER THER, V11, P2212, DOI 10.1158/1535-7163.MCT-12-0180
   Chen MF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061901
   Cleary MP, 2004, NUTR CANCER, V50, P174, DOI 10.1207/s15327914nc5002_7
   Colman RJ, 2009, SCIENCE, V325, P201, DOI 10.1126/science.1173635
   Donohoe DR, 2012, J CELL PHYSIOL, V227, P3169, DOI 10.1002/jcp.24054
   ENGELMAN RW, 1994, CANCER RES, V54, P5724
   Fabian CJ, 2013, BREAST CANCER RES TR, V142, P119, DOI 10.1007/s10549-013-2730-8
   Filippova GN, 1996, MOL CELL BIOL, V16, P2802
   Hark AT, 2000, NATURE, V405, P486, DOI 10.1038/35013106
   Harvie M, 2013, BRIT J NUTR, V110, P1534, DOI 10.1017/S0007114513000792
   Healy LA, 2010, CLIN ONCOL-UK, V22, P281, DOI 10.1016/j.clon.2010.02.001
   Honma N, 2008, J CLIN ONCOL, V26, P3727, DOI 10.1200/JCO.2007.14.2968
   Horne HN, 2016, BREAST CANCER RES, V18, DOI 10.1186/s13058-016-0678-4
   Hursting SD, 2010, CARCINOGENESIS, V31, P83, DOI 10.1093/carcin/bgp280
   Iwase H, 2003, CANCER CHEMOTH PHARM, V52, pS34, DOI 10.1007/s00280-003-0592-1
   JEMAL A, 2006, ONCOLOGIST, V11, P1
   Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43
   Jones PA, 1999, TRENDS GENET, V15, P34, DOI 10.1016/S0168-9525(98)01636-9
   Key TJ, 2010, LANCET ONCOL, V11, P530, DOI 10.1016/S1470-2045(10)70095-4
   Kim D, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-4-r36
   Kimura H, 2003, NUCLEIC ACIDS RES, V31, P3101, DOI 10.1093/nar/gkg406
   Lai AY, 2010, J EXP MED, V207, P1939, DOI 10.1084/jem.20100204
   Litton JK, 2008, J CLIN ONCOL, V26, P4072, DOI 10.1200/JCO.2007.14.4527
   Madeira M, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-425
   Mizuno NK, 2013, CANCER PREV RES, V6, P540, DOI 10.1158/1940-6207.CAPR-13-0033
   Morimoto LM, 2002, CANCER CAUSE CONTROL, V13, P741, DOI 10.1023/A:1020239211145
   Murphy TM, 2015, PSYCHIAT GENET, V25, P71, DOI 10.1097/YPG.0000000000000055
   Mutze K, 2011, EUR J CANCER, V47, P1817, DOI 10.1016/j.ejca.2011.02.024
   Nadal-Serrano M, 2012, J CELL BIOCHEM, V113, P3178, DOI 10.1002/jcb.24192
   Nogueira LM, 2012, CANCER MED-US, V1, P275, DOI 10.1002/cam4.23
   Nogueira LM, 2012, ENDOCR-RELAT CANCER, V19, P57, DOI 10.1530/ERC-11-0213
   Olivo-Marston SE, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094765
   Ong CT, 2014, NAT REV GENET, V15, P234, DOI 10.1038/nrg3663
   Padovani M, 2009, CANCER PREV RES, V2, P1076, DOI 10.1158/1940-6207.CAPR-09-0034
   Portela A, 2010, NAT BIOTECHNOL, V28, P1057, DOI 10.1038/nbt.1685
   Pruitt KD, 2012, NUCLEIC ACIDS RES, V40, pD130, DOI 10.1093/nar/gkr1079
   Rossi EL, 2016, CANCER PREV RES, V9, P339, DOI 10.1158/1940-6207.CAPR-15-0348
   Rowse GJ, 1998, CANCER RES, V58, P315
   Roy DM, 2014, PROTEIN CELL, V5, P265, DOI 10.1007/s13238-014-0031-6
   Sharma Neeraj K, 2015, Microrna, V4, P194
   Skliris GP, 2003, J PATHOL, V201, P213, DOI 10.1002/path.1436
   THOMAS DG, 1977, COMPUT BIOMED RES, V10, P373, DOI 10.1016/0010-4809(77)90006-4
   Victoria-Acosta G, 2015, SCI REP-UK, V5, DOI 10.1038/srep14838
   Vona-Davis L, 2012, CURR DIABETES REV, V8, P116, DOI 10.2174/157339912799424519
   Wang H, 2012, GENOME RES, V22, P1680, DOI 10.1101/gr.136101.111
   Waterland RA, 2007, ANNU REV NUTR, V27, P363, DOI 10.1146/annurev.nutr.27.061406.093705
   YAN H, 2015, ONCOGENE, V35, P1, DOI DOI 10.1038/0NC.2015.423
   Yates A, 2016, NUCLEIC ACIDS RES, V44, pD710, DOI 10.1093/nar/gkv1157
   Yu DH, 2013, MOL CELL BIOL, V33, P1845, DOI 10.1128/MCB.01124-12
   Zhang BG, 2016, ONCOTARGET, V7, P9788, DOI 10.18632/oncotarget.7125
   Zhang Q, 2006, BLOOD, V108, P1058, DOI 10.1182/blood-2005-08-007377
NR 55
TC 23
Z9 27
U1 1
U2 6
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD MAY 1
PY 2017
VL 77
IS 9
BP 2500
EP 2511
DI 10.1158/0008-5472.CAN-16-2795
PG 12
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA ET4QO
UT WOS:000400270100030
PM 28373182
OA Green Submitted, Green Accepted
DA 2025-01-12
ER

PT J
AU Qin, Y
   Zhang, S
   Deng, S
   An, G
   Qin, X
   Li, F
   Xu, Y
   Hao, M
   Yang, Y
   Zhou, W
   Chang, H
   Qiu, L
AF Qin, Y.
   Zhang, S.
   Deng, S.
   An, G.
   Qin, X.
   Li, F.
   Xu, Y.
   Hao, M.
   Yang, Y.
   Zhou, W.
   Chang, H.
   Qiu, L.
TI Epigenetic silencing of miR-137 induces drug resistance and chromosomal
   instability by targeting AURKA in multiple myeloma
SO LEUKEMIA
LA English
DT Article
ID BREAST-CANCER CELLS; AURORA-KINASE-A; DISEASE PROGRESSION;
   POOR-PROGNOSIS; OVARIAN-CANCER; 1Q21 GAINS; INHIBITION; EXPRESSION;
   MELANOMA; SURVIVAL
AB Multiple myeloma (MM) is the second most prevalent hematologic malignancy. Aberrant microRNAs (miRNAs) expression has been shown to be involved in the pathogenesis of MM. In this study, we further demonstrated that miR-137 was significantly downregulated in MM and negatively correlated with clinical prognosis. Moreover, we described the epigenetic regulation of miR-137 and its association with progression-free survival in MM patients. Furthermore, overexpression of miR-137 in MM cell line (miR-137 OE) increased its sensitivity to bortezomib and eprirubicin in vitro. Also, some high-risk genetic abnormalities in MM, including deletion of chromosome 1p22.2, 14q or 17p13, and gain of chromosome 1p22.2 were detected in NCI-H929 empty vector (NCI-H929 EV) treated cells but not in the NCI-H929 miR-137 overexpression (NCI-H929 miR-137 OE) cells. Luciferase reporter assays demonstrated that miR-137 targeted AURKA. Ectopic expression of miR-137 strongly reduced the expression of AURKA and p-ATM/Chk2 in MM cells, and increased the expression of p53, and p21. Importantly, miR-137 overexpression together with bortezomib treatment significantly inhibited tumor growth in MM xenograft model. Taken together, this study demonstrates that miR-137 is epigenetically silenced in MM, and overexpression of miR-137 could reduce drug resistance and overcome chromosomal instability of the MM cells via affecting the apoptosis and DNA damage pathways.
C1 [Qin, Y.; Zhang, S.; Deng, S.; An, G.; Qin, X.; Li, F.; Xu, Y.; Hao, M.; Zhou, W.; Chang, H.; Qiu, L.] Chinese Acad Med Sci, Inst Hematol, State Key Lab Expt Hematol, Dept Lymphoma & Myeloma, Tianjin, Peoples R China.
   [Qin, Y.; Zhang, S.; Deng, S.; An, G.; Qin, X.; Li, F.; Xu, Y.; Hao, M.; Zhou, W.; Chang, H.; Qiu, L.] Chinese Acad Med Sci, Blood Dis Hosp, 288 Nanjing Rd, Tianjin 300020, Peoples R China.
   [Qin, Y.; Zhang, S.; Deng, S.; An, G.; Qin, X.; Li, F.; Xu, Y.; Hao, M.; Zhou, W.; Chang, H.; Qiu, L.] Peking Union Med Coll, 288 Nanjing Rd, Tianjin 300020, Peoples R China.
   [Qin, Y.] Tianjin Med Univ, Coll Basic Med Sci, Dept Diagnost, Tianjin, Peoples R China.
   [Yang, Y.; Chang, H.] Univ Hlth Network, Toronto Gen Res Inst, Dept Lab Hematol, Div Mol & Cellular Biol, 200 Elizabeth St,11E-413, Toronto, ON M5G 2C4, Canada.
   [Yang, Y.] Tianjin Univ, Sch Chem Engn & Technol, Tianjin, Peoples R China.
   [Zhou, W.] Xiangya Hosp, Minist Educ, Key Lab Carcinogenesis & Canc Invas, Key Lab Carcinogenesis,Minist Hlth, Changsha 410078, Hunan, Peoples R China.
   [Zhou, W.] Cent S Univ, Sch Basic Med, Canc Res Inst, Changsha 410078, Hunan, Peoples R China.
   [Yang, Y.] Sichuan Novade Pharmacheut Co Ltd, Tianfu Life Sci Tech Pk B4-602, Changsha, Hunan, Peoples R China.
C3 Chinese Academy of Medical Sciences - Peking Union Medical College;
   Institute of Hematology & Blood Diseases Hospital - CAMS; Chinese
   Academy of Medical Sciences - Peking Union Medical College; Institute of
   Hematology & Blood Diseases Hospital - CAMS; Chinese Academy of Medical
   Sciences - Peking Union Medical College; Peking Union Medical College;
   Tianjin Medical University; University of Toronto; University Health
   Network Toronto; Toronto General Hospital; Tianjin University; Central
   South University; Central South University
RP Qiu, L (通讯作者)，Chinese Acad Med Sci, Blood Dis Hosp, 288 Nanjing Rd, Tianjin 300020, Peoples R China.; Qiu, L (通讯作者)，Peking Union Med Coll, 288 Nanjing Rd, Tianjin 300020, Peoples R China.; Chang, H (通讯作者)，Univ Hlth Network, Toronto Gen Res Inst, Dept Lab Hematol, Div Mol & Cellular Biol, 200 Elizabeth St,11E-413, Toronto, ON M5G 2C4, Canada.; Zhou, W (通讯作者)，Xiangya Hosp, Minist Educ, Key Lab Carcinogenesis & Canc Invas, Key Lab Carcinogenesis,Minist Hlth, Changsha 410078, Hunan, Peoples R China.; Zhou, W (通讯作者)，Cent S Univ, Sch Basic Med, Canc Res Inst, Changsha 410078, Hunan, Peoples R China.; Qiu, L (通讯作者)，Chinese Acad Med Sci, Inst Hematol, State Key Lab Expt Hematol, 288 Nanjing Rd, Tianjin 300020, Peoples R China.
EM wenzhou@csu.edu.cn; Hong.Chang@uhn.on.ca; qiulg@ihcams.ac.cn
FU National Natural Science Foundation of China [81172255, 81400174,
   81400175, 81400169, 81502019, 81630007]; Science and Technology
   Infrastructure Program of Tianjin [12ZCDZSY17600]; National Basic
   Research Program of China (973 program) [2012CB966504]
FX This work was supported by the grants from the National Natural Science
   Foundation of China (81172255, 81400174, 81400175, 81400169, 81502019,
   and 81630007), Science and Technology Infrastructure Program of
   Tianjin(12ZCDZSY17600) and National Basic Research Program of China (973
   program: 2012CB966504).
CR An G, 2014, HAEMATOLOGICA, V99, P353, DOI 10.3324/haematol.2013.088211
   Balaguer F, 2010, CANCER RES, V70, P6609, DOI 10.1158/0008-5472.CAN-10-0622
   Bemis LT, 2008, CANCER RES, V68, P1362, DOI 10.1158/0008-5472.CAN-07-2912
   Cammareri P, 2010, CANCER RES, V70, P4655, DOI 10.1158/0008-5472.CAN-09-3953
   Caputo E, 2014, J TRANSL MED, V12, DOI 10.1186/s12967-014-0216-z
   Carter SL, 2006, NAT GENET, V38, P1043, DOI 10.1038/ng1861
   Chang H, 2010, BONE MARROW TRANSPL, V45, P117, DOI 10.1038/bmt.2009.107
   Chang H, 2007, BRIT J HAEMATOL, V139, P51, DOI 10.1111/j.1365-2141.2007.06750.x
   Chen LJ, 2011, CANCER LETT, V309, P62, DOI 10.1016/j.canlet.2011.05.017
   Chen XY, 2011, INVEST OPHTH VIS SCI, V52, P1193, DOI 10.1167/iovs.10-5272
   Chng WJ, 2006, BLOOD, V107, P3669, DOI 10.1182/blood-2005-09-3810
   Cottini F, 2015, CLIN ADV HEMATOL ONC, V13, P236
   Dar AA, 2008, CANCER-AM CANCER SOC, V112, P1688, DOI 10.1002/cncr.23371
   Dutta-Simmons J, 2009, BLOOD, V114, P2699, DOI 10.1182/blood-2008-12-194290
   Fu JY, 2007, MOL CANCER RES, V5, P1, DOI 10.1158/1541-7786.MCR-06-0208
   Furukawa T, 2006, ONCOGENE, V25, P4831, DOI 10.1038/sj.onc.1209494
   Gao X, 2012, LEUKEMIA RES, V36, P1505, DOI 10.1016/j.leukres.2012.08.021
   Görgün G, 2010, BLOOD, V115, P5202, DOI 10.1182/blood-2009-12-259523
   Hanamura I, 2006, BLOOD, V108, P1724, DOI 10.1182/blood-2006-03-009910
   Hirota T, 2003, CELL, V114, P585, DOI 10.1016/S0092-8674(03)00642-1
   Hose D, 2009, BLOOD, V113, P4331, DOI 10.1182/blood-2008-09-178350
   Katayama H, 2004, NAT GENET, V36, P55, DOI 10.1038/ng1279
   Katsha A, 2013, GASTROENTEROLOGY, V145, P1312, DOI 10.1053/j.gastro.2013.08.050
   Kelly KR, 2014, INVEST NEW DRUG, V32, P489, DOI 10.1007/s10637-013-0050-9
   Klein U, 2011, CANCER-AM CANCER SOC, V117, P2136, DOI 10.1002/cncr.25775
   Kovalchuk O, 2008, MOL CANCER THER, V7, P2152, DOI 10.1158/1535-7163.MCT-08-0021
   Kyle RA, 2008, BLOOD, V111, P2962, DOI 10.1182/blood-2007-10-078022
   Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427
   Lionetti M, 2009, BLOOD, V114, pE20, DOI 10.1182/blood-2009-08-237495
   Löffler D, 2007, BLOOD, V110, P1330, DOI 10.1182/blood-2007-03-081133
   Long ZJ, 2015, INT J ONCOL, V46, P2488, DOI 10.3892/ijo.2015.2960
   Michaelis Martin, 2015, BMC Res Notes, V8, P484, DOI 10.1186/s13104-015-1405-4
   Miller TE, 2008, J BIOL CHEM, V283, P29897, DOI 10.1074/jbc.M804612200
   Morgan GJ, 2012, NAT REV CANCER, V12, P335, DOI 10.1038/nrc3257
   Mosquera JM, 2013, NEOPLASIA, V15, P1, DOI 10.1593/neo.121550
   Pichiorri F, 2008, P NATL ACAD SCI USA, V105, P12885, DOI 10.1073/pnas.0806202105
   Raab MS, 2009, LANCET, V374, P324, DOI 10.1016/S0140-6736(09)60221-X
   Reece D, 2009, BLOOD, V114, P522, DOI 10.1182/blood-2008-12-193458
   Roccaro AM, 2009, BLOOD, V113, P6669, DOI 10.1182/blood-2009-01-198408
   Shi YJ, 2007, BLOOD, V109, P3915, DOI 10.1182/blood-2006-07-037671
   Steponaitiene R, 2016, MOL CARCINOGEN, V55, P376, DOI 10.1002/mc.22287
   Sun CY, 2013, CARCINOGENESIS, V34, P426, DOI 10.1093/carcin/bgs333
   Sun HZ, 2014, BBA-MOL CELL RES, V1843, P934, DOI 10.1016/j.bbamcr.2014.01.019
   Takwi AA, 2014, ONCOGENE, V33, P3717, DOI 10.1038/onc.2013.330
   Wong KY, 2011, BLOOD, V118, P5901, DOI 10.1182/blood-2011-06-361022
   Yang G, 2010, CLIN CANCER RES, V16, P3171, DOI 10.1158/1078-0432.CCR-09-3171
   Yang H, 2008, CANCER RES, V68, P425, DOI 10.1158/0008-5472.CAN-07-2488
   Yang H, 2006, INT J CANCER, V119, P2304, DOI 10.1002/ijc.22154
   Yang YM, 2015, INTELL AUTOM SOFT CO, V21, P1, DOI 10.1080/10798587.2014.911475
   Zhou W, 2013, CANCER CELL, V23, P48, DOI 10.1016/j.ccr.2012.12.001
   Zhu XL, 2013, FEBS LETT, V587, P73, DOI 10.1016/j.febslet.2012.11.004
   Zou ZZ, 2012, AUTOPHAGY, V8, P1798, DOI 10.4161/auto.22110
NR 52
TC 64
Z9 70
U1 0
U2 26
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0887-6924
EI 1476-5551
J9 LEUKEMIA
JI Leukemia
PD MAY
PY 2017
VL 31
IS 5
BP 1123
EP 1135
DI 10.1038/leu.2016.325
PG 13
WC Oncology; Hematology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Hematology
GA ET7HD
UT WOS:000400464800011
PM 27857131
DA 2025-01-12
ER

PT J
AU Iida, T
   Iwanami, A
   Sanosaka, T
   Kohyama, J
   Miyoshi, H
   Nagoshi, N
   Kashiwagi, R
   Toyama, Y
   Matsumoto, M
   Nakamura, M
   Okano, H
AF Iida, Tsuyoshi
   Iwanami, Akio
   Sanosaka, Tsukasa
   Kohyama, Jun
   Miyoshi, Hiroyuki
   Nagoshi, Narihito
   Kashiwagi, Rei
   Toyama, Yoshiaki
   Matsumoto, Morio
   Nakamura, Masaya
   Okano, Hideyuki
TI Whole-Genome DNA Methylation Analyses Revealed Epigenetic Instability in
   Tumorigenic Human iPS Cell-Derived Neural Stem/Progenitor Cells
SO STEM CELLS
LA English
DT Article
DE Induced pluripotent stem cells; Neural stem cells; Tumorigenicity; DNA
   methylation; Epigenetics
ID SPINAL-CORD-INJURY; PLURIPOTENT STEM-CELLS; HUMAN CANCER-CELLS;
   FUNCTIONAL RECOVERY; BREAST-CANCER; IN-VITRO; TRANSPLANTATION; MODEL;
   GENES; DRUG
AB Although human induced pluripotent stem cell (hiPSC) derivatives are considered promising cellular resources for regenerative medicine, their tumorigenicity potentially limits their clinical application in hiPSC technologies. We previously demonstrated that oncogenic hiPSC-derived neural stem/progenitor cells (hiPSC-NS/PCs) produced tumor-like tissues that were distinct from teratomas. To gain insight into the mechanisms underlying the regulation of tumorigenicity in hiPSC-NS/PCs, we performed an integrated analysis using the Infinium HumanMethylation450 BeadChip array and the HumanHT-12 v4.0 Expression BeadChip array to compare the comprehensive DNA methylation and gene expression profiles of tumorigenic hiPSC-NS/PCs (253G1-NS/PCs) and non-tumorigenic cells (201B7-NS/PCs). Although the DNA methylation profiles of 253G1-hiPSCs and 201B7-hiPSCs were similar regardless of passage number, the methylation status of the global DNA methylation profiles of 253G1-NS/PCs and 201B7-NS/PCs differed; the genomic regions surrounding the transcriptional start site of the CAT and PSMD5 genes were hypermethylated in 253G1-NS/PCs but not in 201B7-NS/PCs. Interestingly, the aberrant DNA methylation profile was more pronounced in 253G1-NS/PCs that had been passaged more than 15 times. In addition, we identified aberrations in DNA methylation at the RBP1 gene locus; the DNA methylation frequency in RBP1 changed as 253G1-NS/PCs were sequentially passaged. These results indicate that different NS/PC clones have different DNA methylomes and that DNA methylation patterns are unstable as cells are passaged. Therefore, DNA methylation profiles should be included in the criteria used to evaluate the tumorigenicity of hiPSC-NS/PCs in the clinical setting. Stem Cells2017;35:1316-1327
C1 [Iida, Tsuyoshi; Iwanami, Akio; Nagoshi, Narihito; Kashiwagi, Rei; Toyama, Yoshiaki; Matsumoto, Morio; Nakamura, Masaya] Keio Univ, Dept Orthoped Surg, Sch Med, Shinjuku Ku, Tokyo, Japan.
   [Iida, Tsuyoshi; Sanosaka, Tsukasa; Kohyama, Jun; Miyoshi, Hiroyuki; Okano, Hideyuki] Keio Univ, Dept Physiol, Sch Med, Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.
C3 Keio University; Keio University
RP Okano, H (通讯作者)，Keio Univ, Dept Physiol, Sch Med, Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.
EM hidokano@a2.keio.jp
RI Miyoshi, Hiroyuki/G-9808-2013; Okano, Hideyuki/X-9131-2019; Nakamura,
   Masaya/K-4111-2013; Toyama, Yoshiaki/K-5743-2013
OI Okano, Hideyuki/0000-0001-7482-5935; Sanosaka,
   Tsukasa/0000-0002-2486-1599
FU Research Center Network for Realization of Regenerative Medicine from
   the Japan Agency for Medical Research and Development (AMED); Japan
   Science and Technology (JST)-California Institute for Regenerative
   Medicine (CIRM) Collaborative Program; General Insurance Association of
   Japan; KANAE Foundation for the Promotion of Medical Science;
   Grants-in-Aid for Scientific Research [26713047] Funding Source: KAKEN
FX We would like to thank all of the members of Dr. Okano's and Dr.
   Yamanaka's laboratories for their encouragement and generous support. We
   would also like to thank the Center for iPS Cell Research and
   Application, Kyoto University, for the human iPSC clones 253G1-hiPSC and
   201B7-hiPSC. Furthermore, we would like to thank Dr. Tanaka (Becton,
   Dickinson and Co) for his technical support. This work was supported by
   the Research Center Network for Realization of Regenerative Medicine
   from the Japan Agency for Medical Research and Development (AMED), the
   Japan Science and Technology (JST)-California Institute for Regenerative
   Medicine (CIRM) Collaborative Program, and a Grant-in-Aid for specially
   promoted research from the General Insurance Association of Japan and
   the KANAE Foundation for the Promotion of Medical Science.
CR Ahmad IM, 2005, J BIOL CHEM, V280, P4254, DOI 10.1074/jbc.M411662200
   Anglim PP, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-81
   Azizian-Farsani F, 2014, INT J TOXICOL, V33, P518, DOI 10.1177/1091581814557953
   Barry JH, 1991, TRENDS NEUROSCI, V14, P384
   BOER GJ, 1994, J NEUROL, V242, P1, DOI 10.1007/BF00920568
   Chen Q, 2005, P NATL ACAD SCI USA, V102, P13604, DOI 10.1073/pnas.0506390102
   Cummings BJ, 2005, P NATL ACAD SCI USA, V102, P14069, DOI 10.1073/pnas.0507063102
   Eaves CJ, 2015, BLOOD, V125, P2605, DOI 10.1182/blood-2014-12-570200
   Ei Khatib MM, 2016, STEM CELL TRANSL MED, V5, P694
   FEINBERG AP, 1983, NATURE, V301, P89, DOI 10.1038/301089a0
   Fujimoto Y, 2012, STEM CELLS, V30, P1163, DOI 10.1002/stem.1083
   Glorieux C, 2011, BIOCHEM PHARMACOL, V82, P1384, DOI 10.1016/j.bcp.2011.06.007
   GOLDBERG AL, 1995, CHEM BIOL, V2, P503, DOI 10.1016/1074-5521(95)90182-5
   Gonzalez-Gomez P, 2003, INT J MOL MED, V11, P655
   Goto Y, 2009, CANCER RES, V69, P9073, DOI 10.1158/0008-5472.CAN-09-1595
   Halazonetis TD, 2008, SCIENCE, V319, P1352, DOI 10.1126/science.1140735
   Hartman ME, 2016, ADV DRUG DELIVER REV, V96, P3, DOI 10.1016/j.addr.2015.05.004
   Hashizume O, 2015, SCI REP-UK, V5, DOI 10.1038/srep10434
   Hockemeyer D, 2008, CELL STEM CELL, V3, P346, DOI 10.1016/j.stem.2008.08.014
   Hofstetter CP, 2005, NAT NEUROSCI, V8, P346, DOI 10.1038/nn1405
   Ishikawa T, 2012, CELL TRANSPLANT, V21, P387, DOI 10.3727/096368911X605286
   Iwanami A, 2005, J NEUROSCI RES, V80, P182, DOI 10.1002/jnr.20436
   Kanemura Y, 2002, J NEUROSCI RES, V69, P869, DOI 10.1002/jnr.10377
   Kobayashi Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052787
   Liu ZQ, 2013, J CELL MOL MED, V17, P782, DOI 10.1111/jcmm.12062
   Mack SC, 2016, NAT NEUROSCI, V19, P10, DOI 10.1038/nn.4190
   Mishima C, 2015, SPRINGERPLUS, V4, DOI 10.1186/s40064-015-1423-7
   Momoko M, 2011, NATURE, V474, P225
   Nijhawan D, 2012, CELL, V150, P842, DOI 10.1016/j.cell.2012.07.023
   Nori S, 2015, STEM CELL REP, V4, P360, DOI 10.1016/j.stemcr.2015.01.006
   Nori S, 2011, P NATL ACAD SCI USA, V108, P16825, DOI 10.1073/pnas.1108077108
   Noushmehr H, 2010, CANCER CELL, V17, P510, DOI 10.1016/j.ccr.2010.03.017
   Ogawa Y, 2002, J NEUROSCI RES, V69, P925, DOI 10.1002/jnr.10341
   Ogoshi K, 2011, GENOMICS, V98, P280, DOI 10.1016/j.ygeno.2011.07.003
   Ojeh N, 2015, INT J MOL SCI, V16, P25476, DOI 10.3390/ijms161025476
   Okada S, 2005, FASEB J, V19, P1839, DOI 10.1096/fj.05-4082fje
   Okada Y, 2008, STEM CELLS, V26, P3086, DOI 10.1634/stemcells.2008-0293
   Okano H, 2014, MOL BRAIN, V7, DOI 10.1186/1756-6606-7-22
   Okano H, 2013, CIRC RES, V112, P523, DOI 10.1161/CIRCRESAHA.111.256149
   Okita K, 2011, NAT METHODS, V8, P409, DOI [10.1038/NMETH.1591, 10.1038/nmeth.1591]
   Orlandi A, 2006, MODERN PATHOL, V19, P797, DOI 10.1038/modpathol.3800586
   Orlando G, 2013, GUT, V62, P774, DOI 10.1136/gutjnl-2011-301111
   Pulkkinen V, 2014, VIRCHOWS ARCH, V465, P173, DOI 10.1007/s00428-014-1602-x
   Qureshi SA, 2010, INT J SURG, V8, P194, DOI 10.1016/j.ijsu.2010.02.001
   SAKAI T, 1991, AM J HUM GENET, V48, P880
   Salazar DL, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012272
   Salewski RP, 2015, STEM CELL TRANSL MED, V4, P743, DOI 10.5966/sctm.2014-0236
   Sareen D, 2014, J COMP NEUROL, V522, P2707, DOI 10.1002/cne.23578
   Shan M, 2016, ONCOTARGET, V7, P18485, DOI 10.18632/oncotarget.7608
   Sontag CJ, 2013, STEM CELL TRANSL MED, V2, P731, DOI 10.5966/sctm.2012-0175
   Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019
   Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024
   Tsuji O, 2010, P NATL ACAD SCI USA, V107, P12704, DOI 10.1073/pnas.0910106107
   Ushijima T, 2010, CANCER SCI, V101, P300, DOI 10.1111/j.1349-7006.2009.01434.x
   Virani S, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1806-8
   Wei PC, 2016, CELL, V164, P644, DOI 10.1016/j.cell.2015.12.039
   Xue M, 2015, J DIGEST DIS, V16, P699, DOI 10.1111/1751-2980.12299
   Yasuda A, 2011, STEM CELLS, V29, P1983, DOI 10.1002/stem.767
NR 58
TC 33
Z9 41
U1 0
U2 11
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1066-5099
EI 1549-4918
J9 STEM CELLS
JI Stem Cells
PD MAY
PY 2017
VL 35
IS 5
BP 1316
EP 1327
DI 10.1002/stem.2581
PG 12
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology;
   Oncology; Cell Biology; Hematology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Biotechnology & Applied Microbiology; Oncology; Hematology
GA ET1HC
UT WOS:000400017200017
PM 28142229
OA Bronze
DA 2025-01-12
ER

PT J
AU Ma, H
   Li, L
   Dou, GJ
   Wang, CQ
   Li, J
   He, H
   Wu, MX
   Qi, HY
AF Ma, Hui
   Li, Li
   Dou, Guojun
   Wang, Chengqiang
   Li, Juan
   He, Hui
   Wu, Mingxia
   Qi, Hongyi
TI Z-ligustilide restores tamoxifen sensitivity of ERα negative breast
   cancer cells by reversing MTA1/IFI16/HDACs complex mediated epigenetic
   repression of ERα
SO ONCOTARGET
LA English
DT Article
DE Z-ligustilide; tamoxifen; ER alpha negative breast cancer; MTA1; histone
   modification
ID ESTROGEN-RECEPTOR-ALPHA; HISTONE DEACETYLASE INHIBITOR;
   ANGELICA-SINENSIS; PROSTATE-CANCER; METASTASIS; EXPRESSION; PROTEIN;
   REACTIVATION; OVEREXPRESSION; ACETYLATION
AB Emerging evidence indicates epigenetic modification represses estrogen receptor a (ER alpha) and contributes to the resistance to tamoxifen in aggressive ER alpha-negative (ER alpha-) breast cancer. Z-ligustilide is a major compound in Radix Angelica sinensis, an herb from traditional Chinese medicine (TCM) most frequently prescribed for breast cancer. However, the role of Z-ligustilide in ER alpha-breast cancer and epigenetic modification remains largely unknown. Herein we showed, for the first time, that Z-ligustilide restored the growth inhibition of tamoxifen on ER alpha-breast cancer cells. Apoptosis and S and G2/M phases cell cycle arrest were induced by combinatorial Z-ligustilide and tamoxifen. Importantly, Z-ligustilide reactivated the ER alpha expression and transcriptional activity, which is proved to be indispensable for restoring the sensitivity to tamoxifen. Interestingly, Z-ligustilide increased Ace-H3 (lys9/14) enrichment in the ER alpha promoter. Moreover, Z-ligustilide dramatically reduced the enrichment of metastasis-associated protein 1 (MTA1) as well as IFN-gamma-inducible protein 16 (IFI16) and histone deacetylases (HDACs) onto the ER alpha promoter. Meanwhile, Z-ligustilide downregulated MTA1, IFI16 and HDACs, which caused destabilization of the corepressor complex. Collectively, our study not only highlights Z-ligustilide as a novel epigenetic modulator, but also opens new possibilities from TCM for treating aggressive tamoxifen-resistant breast cancer.
C1 [Ma, Hui; Li, Li; Dou, Guojun; Wang, Chengqiang; Li, Juan; He, Hui; Wu, Mingxia; Qi, Hongyi] Southwest Univ, Coll Pharmaceut Sci, Chongqing 400716, Peoples R China.
C3 Southwest University - China
RP Qi, HY (通讯作者)，Southwest Univ, Coll Pharmaceut Sci, Chongqing 400716, Peoples R China.
EM hongyiqi@swu.edu.cn
OI Wu, Mingxia/0000-0002-6070-5569
FU NSFC [81373903, 81202946]; Chongqing Project of Science and technology
   talent cultivation [cstc2013kjrc-qnrc1002]; Key Project of Fundamental
   Research Fund for the Central Universities [XDJK2016B040, XDJK2016D034]
FX This work was supported by the NSFC Projects (No. 81373903; No.
   81202946), Chongqing Project of Science and technology talent
   cultivation (cstc2013kjrc-qnrc1002), the Key Project of Fundamental
   Research Fund for the Central Universities (XDJK2016B040; XDJK2016D034).
CR [Anonymous], NEW ENGLAND J MED
   [Anonymous], ZHONGH BENC
   Asefa B, 2004, BLOOD CELL MOL DIS, V32, P155, DOI 10.1016/j.bcmd.2003.10.002
   Baylin S, 2002, CANCER CELL, V1, P299, DOI 10.1016/S1535-6108(02)00061-2
   Bovenzi V, 2001, CANCER CHEMOTH PHARM, V48, P71, DOI 10.1007/s002800100294
   Brinkman JA, 2009, J MAMMARY GLAND BIOL, V14, P67, DOI 10.1007/s10911-009-9113-0
   Chen KHE, 2016, CANCER LETT, V375, P293, DOI 10.1016/j.canlet.2016.03.007
   Chen QC, 2007, ARCH PHARM RES, V30, P565, DOI 10.1007/BF02977650
   Cheng Y, 2016, FOOD FUNCT, V7, P1033, DOI [10.1039/c5fo00855g, 10.1039/C5FO00855G]
   Clemons M, 2002, CANCER TREAT REV, V28, P165, DOI 10.1016/S0305-7372(02)00036-1
   Dworkin AM, 2009, SEMIN CANCER BIOL, V19, P165, DOI 10.1016/j.semcancer.2009.02.007
   Fan L, 2014, LANCET ONCOL, V15, pE279, DOI 10.1016/S1470-2045(13)70567-9
   Hansakul P, 2014, BMC COMPLEM ALTERN M, V14, DOI 10.1186/1472-6882-14-413
   Hervouet E, 2013, EPIGENETICS-US, V8, P237, DOI 10.4161/epi.23790
   Jang ER, 2004, ONCOGENE, V23, P1724, DOI 10.1038/sj.onc.1207315
   Jang KS, 2006, CANCER SCI, V97, P374, DOI 10.1111/j.1349-7006.2006.00186.x
   Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43
   Johnson KE, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004503
   Johnstone RW, 1998, J BIOL CHEM, V273, P17172, DOI 10.1074/jbc.273.27.17172
   Jordan VC, 2014, ENDOCR-RELAT CANCER, V21, pR235, DOI 10.1530/ERC-14-0092
   Kai L, 2010, INT J CANCER, V126, P1538, DOI 10.1002/ijc.24928
   Kala R, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0155057
   Kan WLT, 2008, J ETHNOPHARMACOL, V120, P36, DOI 10.1016/j.jep.2008.07.027
   Kang HJ, 2014, CANCER RES, V74, P1484, DOI 10.1158/0008-5472.CAN-13-2020
   Lai JN, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/891893
   Li AG, 2007, MOL CELL, V28, P408, DOI 10.1016/j.molcel.2007.09.006
   Li DQ, 2012, CANCER RES, V72, P387, DOI 10.1158/0008-5472.CAN-11-2345
   Li YY, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-9
   Li YY, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-274
   Macaluso M, 2003, ONCOGENE, V22, P3511, DOI 10.1038/sj.onc.1206578
   Mazumdar A, 2001, NAT CELL BIOL, V3, P30, DOI 10.1038/35050532
   Meeran SM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037748
   Ning L, 2016, INTEGR CANCER THER, V15, P216, DOI 10.1177/1534735416642865
   Oliveira Cleida A, 2003, Reprod Biol Endocrinol, V1, P75, DOI 10.1186/1477-7827-1-75
   Saxena Neeraj K, 2010, Mol Cell Pharmacol, V2, P191
   Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672
   Su ZY, 2013, CHEM RES TOXICOL, V26, P477, DOI 10.1021/tx300524p
   TOH Y, 1994, J BIOL CHEM, V269, P22958
   Toh Y, 2009, CLIN EXP METASTAS, V26, P215, DOI 10.1007/s10585-008-9233-8
   TRAPANI JA, 1994, IMMUNOGENETICS, V40, P415
   Tsai NM, 2005, CLIN CANCER RES, V11, P3475, DOI 10.1158/1078-0432.CCR-04-1827
   Vesuna F, 2012, ONCOGENE, V31, P3223, DOI 10.1038/onc.2011.483
   Visioli F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101053
   Wang K, 2016, ONCOTARGET, V7, P86972, DOI 10.18632/oncotarget.13493
   Wang Lu, 2015, Asian Pac J Cancer Prev, V16, P3715
   Wedge DE, 2009, J AGR FOOD CHEM, V57, P464, DOI 10.1021/jf802820d
   Wu CT, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113887
   Yang XW, 2001, CANCER RES, V61, P7025
   Yin J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066598
   Zeng Q, 2015, J SEP SCI, V38, P4269, DOI 10.1002/jssc.201500862
NR 50
TC 31
Z9 36
U1 2
U2 14
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD APR 25
PY 2017
VL 8
IS 17
BP 29328
EP 29345
DI 10.18632/oncotarget.16440
PG 18
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA ET1SU
UT WOS:000400050000134
PM 28415616
OA Green Published, gold, Green Submitted
DA 2025-01-12
ER

PT J
AU Hiken, JF
   McDonald, JI
   Decker, KF
   Sanchez, C
   Hoog, J
   VanderKraats, ND
   Jung, KL
   Akinhanmi, M
   Rois, LE
   Ellis, MJ
   Edwards, JR
AF Hiken, J. F.
   McDonald, J. I.
   Decker, K. F.
   Sanchez, C.
   Hoog, J.
   VanderKraats, N. D.
   Jung, K. L.
   Akinhanmi, M.
   Rois, L. E.
   Ellis, M. J.
   Edwards, J. R.
TI Epigenetic activation of the prostaglandin receptor EP4 promotes
   resistance to endocrine therapy for breast cancer
SO ONCOGENE
LA English
DT Article
ID HISTONE DEACETYLASE INHIBITION; HUMAN ESTROGEN-RECEPTOR; DNA
   METHYLATION; GENE-EXPRESSION; PROTEIN-KINASE; SYNERGISTIC ACTIVATION;
   AROMATASE INHIBITORS; CELLS; ALPHA; PHOSPHORYLATION
AB Approximately 75% of breast cancers express estrogen receptor a (ER alpha) and depend on estrogen signals for continued growth. Aromatase inhibitors (AIs) prevent estrogen production and inhibit ER signaling, resulting in decreased cancer recurrence and mortality. Advanced tumors treated with AIs almost always develop resistance to these drugs via the upregulation of alternative growth signals. The mechanisms that drive this resistance-especially epigenetic events that alter gene expression-are, however, not well understood. Genome-wide DNA methylation and expression analysis of cell line models of acquired AI resistance indicated that prostaglandin E2 receptor 4 (PTGER4) is upregulated after demethylation in resistant cells. Knockdown and inhibitor studies demonstrate that PTGER4 is essential for estrogen-independent growth. Our exploratory analysis of downstream signaling indicates that PTGER4 likely promotes AI resistance via ligand-independent activation of the ER alpha-cofactor CARM1. We believe that we have discovered a novel epigenetic mechanism for altering cell signaling and acquiring endocrine therapy resistance. Our findings indicate that PTGER4 is a potential drug target in AI-resistant cancers. In addition, the epigenetic component of PTGER4 regulation suggests that further study of PTGER4 may yield valuable insights into how DNA methylation-targeted diagnoses and treatments can improve AI-resistant breast cancer treatment.
C1 [Hiken, J. F.; McDonald, J. I.; Decker, K. F.; VanderKraats, N. D.; Jung, K. L.; Akinhanmi, M.; Rois, L. E.; Edwards, J. R.] Washington Univ, Sch Med, Ctr Pharmacogen, Dept Med, 660S Euclid Ave,Campus Box 8220, St Louis, MO 63110 USA.
   [Sanchez, C.] Pontificia Univ Catolica Chile, Haematol Oncol, Dept Canc Programme, Sch Med, Santiago, Chile.
   [Hoog, J.] Washington Univ, Sch Med, Dept Med, Div Oncol, St Louis, MO 63110 USA.
   [Ellis, M. J.] Baylor Coll Med, Lester & Sue Smith Breast Ctr, Houston, TX 77030 USA.
C3 Washington University (WUSTL); Pontificia Universidad Catolica de Chile;
   Washington University (WUSTL); Baylor College of Medicine
RP Edwards, JR (通讯作者)，Washington Univ, Sch Med, Ctr Pharmacogen, Dept Med, 660S Euclid Ave,Campus Box 8220, St Louis, MO 63110 USA.
EM jedwards@dom.wustl.edu
OI Jung, Kyle/0000-0002-6694-4333
FU NIH [R00 CA127360, R21 LM011199, 2T32GM007067-37, P30 CA91842, UL1
   TR000448]; Department of Defense [W81XWH-11-1-0401]; Siteman Cancer
   Center Breast Cancer Program career development award
FX We thank C de Guzman-Strong and S Matkovich for their comments on the
   manuscript. This work was supported by grants NIH R00 CA127360, NIH R21
   LM011199, NIH 2T32GM007067-37, Department of Defense W81XWH-11-1-0401
   and a Siteman Cancer Center Breast Cancer Program career development
   award to JRE. We also thank the Genome Technology Access Center at the
   Washington University School of Medicine for help with genomic analysis
   (partially supported by NIH P30 CA91842 and NIH UL1 TR000448).
CR Aguilar H, 2010, ONCOGENE, V29, P6071, DOI 10.1038/onc.2010.333
   Anders S, 2015, BIOINFORMATICS, V31, P166, DOI 10.1093/bioinformatics/btu638
   Carascossa S, 2010, GENE DEV, V24, P708, DOI 10.1101/gad.568410
   Chan CMW, 2002, J STEROID BIOCHEM, V81, P333, DOI 10.1016/S0960-0760(02)00074-2
   Chen DS, 1999, MOL CELL BIOL, V19, P1002
   Creighton CJ, 2009, P NATL ACAD SCI USA, V106, P13820, DOI 10.1073/pnas.0905718106
   Crowder RJ, 2009, CANCER RES, V69, P3955, DOI 10.1158/0008-5472.CAN-08-4450
   Dowsett M, 2010, J CLIN ONCOL, V28, P509, DOI 10.1200/JCO.2009.23.1274
   Edwards JR, 2010, GENOME RES, V20, P972, DOI 10.1101/gr.101535.109
   Ellis MJ, 2008, J NATL CANCER I, V100, P1380, DOI 10.1093/jnci/djn309
   Ellis MJ, 2012, NATURE, V486, P353, DOI 10.1038/nature11143
   Ellis MJ, 2011, J CLIN ONCOL, V29, P2342, DOI 10.1200/JCO.2010.31.6950
   Feinberg AP, 2006, NAT REV GENET, V7, P21, DOI 10.1038/nrg1748
   FERGUSON AT, 1995, CANCER RES, V55, P2279
   Forbes SA, 2015, NUCLEIC ACIDS RES, V43, pD805, DOI 10.1093/nar/gku1075
   Fritah A, 2008, MOL CELL BIOL, V28, P1114, DOI 10.1128/MCB.01335-07
   Giacinti L, 2012, J CELL PHYSIOL, V227, P3426, DOI 10.1002/jcp.24043
   Harvey JM, 1999, J CLIN ONCOL, V17, P1474, DOI 10.1200/JCO.1999.17.5.1474
   Holemon H, 2007, BIOTECHNIQUES, V43, P683, DOI 10.2144/000112597
   Iorns E, 2008, CANCER CELL, V13, P91, DOI 10.1016/j.ccr.2008.01.001
   Irizarry RA, 2009, NAT GENET, V41, P178, DOI 10.1038/ng.298
   Johnston SRD, 2003, NAT REV CANCER, V3, P821, DOI 10.1038/nrc1211
   KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491
   Keen JC, 2003, BREAST CANCER RES TR, V81, P177, DOI 10.1023/A:1026146524737
   Kim JH, 2012, MOL CELLS, V33, P127, DOI 10.1007/s10059-012-2182-8
   Kulis M, 2010, ADV GENET, V70, P27, DOI [10.1016/S0065-2660(10)70002-X, 10.1016/B978-0-12-380866-0.60002-2]
   Lazennec G, 2001, J STEROID BIOCHEM, V77, P193, DOI 10.1016/S0960-0760(01)00060-7
   LEGOFF P, 1994, J BIOL CHEM, V269, P4458
   Li SQ, 2013, CELL REP, V4, P1116, DOI 10.1016/j.celrep.2013.08.022
   Ma CX, 2015, NAT REV CANCER, V15, P261, DOI 10.1038/nrc3920
   Ma XR, 2006, CANCER RES, V66, P2923, DOI 10.1158/0008-5472.CAN-05-4348
   Merenbakh-Lamin K, 2013, CANCER RES, V73, P6856, DOI 10.1158/0008-5472.CAN-13-1197
   Miller TW, 2011, CLIN CANCER RES, V17, P2024, DOI 10.1158/1078-0432.CCR-10-2567
   Musgrove EA, 2009, NAT REV CANCER, V9, P631, DOI 10.1038/nrc2713
   Nguyen VTM, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms10044
   Olson JA, 2009, J AM COLL SURGEONS, V208, P906, DOI 10.1016/j.jamcollsurg.2009.01.035
   OTTAVIANO YL, 1994, CANCER RES, V54, P2552
   Robinson DR, 2013, NAT GENET, V45, P1446, DOI 10.1038/ng.2823
   Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616
   Sabnis GJ, 2011, CANCER RES, V71, P1893, DOI 10.1158/0008-5472.CAN-10-2458
   Sanchez CG, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2833
   Stone A, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8758
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Terada N, 2010, CANCER RES, V70, P1606, DOI 10.1158/0008-5472.CAN-09-2984
   Tharakan R, 2008, MOL CELL ENDOCRINOL, V295, P70, DOI 10.1016/j.mce.2008.07.018
   Toy W, 2013, NAT GENET, V45, P1439, DOI 10.1038/ng.2822
   Trapnell C, 2009, BIOINFORMATICS, V25, P1105, DOI 10.1093/bioinformatics/btp120
   VANAGTHOVEN T, 1994, MOL ENDOCRINOL, V8, P1474, DOI 10.1210/me.8.11.1474
   VanderKraats ND, 2013, NUCLEIC ACIDS RES, V41, P6816, DOI 10.1093/nar/gkt482
   Yang XW, 2001, CANCER RES, V61, P7025
   Yang XW, 2000, CANCER RES, V60, P6890
   Yokoyama U, 2013, PHARMACOL REV, V65, P1010, DOI 10.1124/pr.112.007195
   Zhang QX, 1997, CANCER RES, V57, P1244
   Zhou Q, 2009, BREAST CANCER RES TR, V117, P443, DOI 10.1007/s10549-008-0148-5
   Zilli M, 2009, BBA-REV CANCER, V1795, P62, DOI 10.1016/j.bbcan.2008.08.003
NR 55
TC 18
Z9 21
U1 0
U2 13
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-9232
EI 1476-5594
J9 ONCOGENE
JI Oncogene
PD APR 20
PY 2017
VL 36
IS 16
BP 2319
EP 2327
DI 10.1038/onc.2016.397
PG 9
WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
GA ES8DM
UT WOS:000399782700012
PM 27869171
OA Green Submitted, Green Accepted
DA 2025-01-12
ER

PT J
AU Yang, CY
   Lin, CK
   Tsao, CH
   Hsieh, CC
   Lin, GJ
   Ma, KH
   Shieh, YS
   Sytwu, HK
   Chen, YW
AF Yang, Cheng-Yu
   Lin, Chih-Kung
   Tsao, Chang-Huei
   Hsieh, Cheng-Chih
   Lin, Gu-Jiun
   Ma, Kuo-Hsing
   Shieh, Yi-Shing
   Sytwu, Huey-Kang
   Chen, Yuan-Wu
TI Melatonin exerts anti-oral cancer effect via suppressing LSD1 in
   patient-derived tumor xenograft models
SO ONCOTARGET
LA English
DT Article
DE patient-derived tumor xenograft; LSD1; melatonin; oral cancer; cell
   proliferation
ID EPIGENETIC MODIFICATIONS; GROWTH SUPPRESSION; GENE-EXPRESSION;
   BREAST-CANCER; MOUSE MODELS; HISTONE; ESTABLISHMENT; INHIBITION;
   APOPTOSIS; CELLS
AB Aberrant activation of histone lysine-specific demethylase (LSD1) increases tumorigenicity; hence, LSD1 is considered a therapeutic target for various human cancers. Although melatonin, an endogenously produced molecule, may defend against various cancers, the precise mechanism involved in its anti-oral cancer effect remains unclear. Patient-derived tumor xenograft (PDTX) models are preclinical models that can more accurately reflect human tumor biology compared with cell line xenograft models. Here, we evaluated the anticancer activity of melatonin by using LSD1-overexpressing oral cancer PDTX models. By assessing oral squamous cell carcinoma (OSCC) tissue arrays through immunohistochemistry, we examined whether aberrant LSD1 overexpression in OSCC is associated with poor prognosis. We also evaluated the action mechanism of melatonin against OSCC with lymphatic metastases by using the PDTX models. Our results indicated that melatonin, at pharmacological concentrations, significantly suppresses cell proliferation in a dose- and time-dependent manner. The observed suppression of proliferation was accompanied by the melatonin-mediated inhibition of LSD1 in oral cancer PDTXs and oral cancer cell lines. In conclusion, we determined that the beneficial effects of melatonin in reducing oral cancer cell proliferation are associated with reduced LSD1 expression in vivo and in vitro.
C1 [Yang, Cheng-Yu; Sytwu, Huey-Kang; Chen, Yuan-Wu] Natl Def Med Ctr, Grad Inst Life Sci, Taipei, Taiwan.
   [Chen, Yuan-Wu] Triserv Gen Hosp, Dept Oral & Maxillofacial Surg, Taipei, Taiwan.
   [Lin, Chih-Kung] Taipei Tzu Chi Hosp, Div Anat Pathol, Taipei, Taiwan.
   [Lin, Gu-Jiun; Ma, Kuo-Hsing] Natl Def Med Ctr, Dept Biol & Anat, Taipei, Taiwan.
   [Hsieh, Cheng-Chih] Triserv Gen Hosp, Dept Pharm Practice, Taipei, Taiwan.
   [Yang, Cheng-Yu; Shieh, Yi-Shing; Chen, Yuan-Wu] Natl Def Med Ctr, Sch Dent, Taipei, Taiwan.
   [Tsao, Chang-Huei; Sytwu, Huey-Kang] Natl Def Med Ctr, Grad Inst Microbiol & Immunol, Taipei, Taiwan.
   [Tsao, Chang-Huei] Triserv Gen Hosp, Dept Med Res, Taipei, Taiwan.
C3 National Defense Medical Center; Tri-Service General Hospital; National
   Defense Medical Center; Tri-Service General Hospital; National Defense
   Medical Center; National Defense Medical Center; Tri-Service General
   Hospital
RP Chen, YW (通讯作者)，Natl Def Med Ctr, Grad Inst Life Sci, Taipei, Taiwan.; Chen, YW (通讯作者)，Triserv Gen Hosp, Dept Oral & Maxillofacial Surg, Taipei, Taiwan.; Chen, YW (通讯作者)，Natl Def Med Ctr, Sch Dent, Taipei, Taiwan.
EM h6183@yahoo.com.tw
OI Lin, Gu-Jiun/0000-0003-4302-8196
FU Tri-Service General Hospital, Taiwan, Republic of China
   [TSGH-C104-008-S05, TSGH-C105-006-008-S05, TSGH-C106-004-006-008-S05,
   TSGH-C105-190, TSGH-C105-169]; National Science Council, Taiwan,
   Republic of China [NSC102-2314-B-016-018-MY3, MOST
   105-2314-B-016-021-MY3]
FX This study was supported by research grants from Tri-Service General
   Hospital, Taiwan, Republic of China (grants No. TSGH-C104-008-S05,
   TSGH-C105-006-008-S05, TSGH-C106-004-006-008-S05, TSGH-C105-190,
   TSGH-C105-169, and National Science Council, Taiwan, Republic of China
   (grants No. NSC102-2314-B-016-018-MY3 and MOST 105-2314-B-016-021-MY3).
CR Andersen LPH, 2016, CLIN DRUG INVEST, V36, P169, DOI 10.1007/s40261-015-0368-5
   Baudino Troy A, 2015, Curr Drug Discov Technol, V12, P3
   Calvo JR, 2013, J PINEAL RES, V55, P103, DOI 10.1111/jpi.12075
   Chen YW, 2013, CANCER-AM CANCER SOC, V119, P4259, DOI 10.1002/cncr.28356
   Chen YW, 2009, ORAL ONCOL, V45, P562, DOI 10.1016/j.oraloncology.2008.10.007
   Cortez V, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3229
   Cutando A, 2014, ONCOL LETT, V7, P923, DOI 10.3892/ol.2014.1813
   Cutz JC, 2006, CLIN CANCER RES, V12, P4043, DOI 10.1158/1078-0432.CCR-06-0252
   Dangles-Marie V, 2007, CANCER RES, V67, P398, DOI 10.1158/0008-5472.CAN-06-0594
   Ding J, 2013, BRIT J CANCER, V109, P994, DOI 10.1038/bjc.2013.364
   DUBBELS R, 1995, J PINEAL RES, V18, P28, DOI 10.1111/j.1600-079X.1995.tb00136.x
   Fan CX, 2015, J PINEAL RES, V59, P321, DOI 10.1111/jpi.12261
   Fichtner I, 2008, CLIN CANCER RES, V14, P6456, DOI 10.1158/1078-0432.CCR-08-0138
   Fujimoto-Ouchi K, 2007, CANCER CHEMOTH PHARM, V59, P795, DOI 10.1007/s00280-006-0337-z
   Gao H, 2015, NAT MED, V21, P1318, DOI 10.1038/nm.3954
   Garber K, 2009, J NATL CANCER I, V101, P6, DOI 10.1093/jnci/djn481
   Goncalves ND, 2014, ANTI-CANCER AGENT ME, V14, P1302, DOI 10.2174/1871520614666140812110246
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Hansen MV, 2014, DAN MED J, V61
   Hayami S, 2011, INT J CANCER, V128, P574, DOI 10.1002/ijc.25349
   Hojfeldt JW, 2013, NAT REV DRUG DISCOV, V12, P917, DOI 10.1038/nrd4154
   Hong Y, 2014, J PINEAL RES, V56, P264, DOI 10.1111/jpi.12119
   Huang Y, 2012, BREAST CANCER RES TR, V131, P777, DOI 10.1007/s10549-011-1480-8
   Huynh H, 2007, MOL CANCER THER, V6, P2468, DOI 10.1158/1535-7163.MCT-07-0162
   Huynh H, 2007, MOL CANCER THER, V6, P138, DOI 10.1158/1535-7163.MCT-06-0436
   Huynh H, 2009, MOL CANCER THER, V8, P152, DOI 10.1158/1535-7163.MCT-08-0553
   Jung-Hynes B, 2010, J PINEAL RES, V48, P9, DOI 10.1111/j.1600-079X.2009.00729.x
   Kahl P, 2006, CANCER RES, V66, P11341, DOI 10.1158/0008-5472.CAN-06-1570
   Kelly TK, 2010, NAT BIOTECHNOL, V28, P1069, DOI 10.1038/nbt.1678
   Lan WH, 2013, MED HYPOTHESES, V81, P823, DOI 10.1016/j.mehy.2013.09.005
   Lee MG, 2005, NATURE, V437, P432, DOI 10.1038/nature04021
   Lin FY, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121677
   Lin GJ, 2015, CLIN ORAL INVESTIGAT
   Lissoni P, 1999, EUR J CANCER, V35, P1688, DOI 10.1016/S0959-8049(99)00159-8
   Lo JF, 2011, CANCER RES, V71, P1912, DOI 10.1158/0008-5472.CAN-10-2350
   Lokken AA, 2012, CANCER CELL, V21, P451, DOI 10.1016/j.ccr.2012.03.027
   Lv TF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035065
   Manchester LC, 1995, CELL MOL BIOL RES, V41, P391
   Manchester LC, 2015, J PINEAL RES, V59, P403, DOI 10.1111/jpi.12267
   Marangoni E, 2007, CLIN CANCER RES, V13, P3989, DOI 10.1158/1078-0432.CCR-07-0078
   Metzger E, 2005, NATURE, V437, P436, DOI 10.1038/nature04020
   Némati F, 2010, CLIN CANCER RES, V16, P2352, DOI 10.1158/1078-0432.CCR-09-3066
   Nicholson TB, 2009, EPIGENETICS-US, V4, P129, DOI 10.4161/epi.4.3.8443
   Niebel D, 2014, BLOOD, V124, P151, DOI 10.1182/blood-2014-04-569525
   Niles LP, 2013, NEUROSCI LETT, V541, P49, DOI 10.1016/j.neulet.2013.01.050
   Nishida H, 2006, CHROMOSOME RES, V14, P203, DOI 10.1007/s10577-006-1036-7
   Ortiz F, 2015, J PINEAL RES, V58, P34, DOI 10.1111/jpi.12191
   Proietti S, 2014, J PINEAL RES, V57, P120, DOI 10.1111/jpi.12150
   Qin Y, 2014, CANCER LETT, V347, P225, DOI 10.1016/j.canlet.2014.02.013
   Rao SVK, 2013, ASIAN PAC J CANCER P, V14, P5567, DOI 10.7314/APJCP.2013.14.10.5567
   Reiter RJ, 2015, J PERIODONTAL RES, V50, P9, DOI 10.1111/jre.12176
   Sareddy GR, 2013, ONCOTARGET, V4, P18, DOI 10.18632/oncotarget.725
   Sharma R, 2008, J PINEAL RES, V45, P277, DOI 10.1111/j.1600-079X.2008.00587.x
   Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012
   Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166
   Sorrentino MF, 2012, CARDIOL J, V19, P453, DOI 10.5603/CJ.2012.0084
   Tentler JJ, 2012, NAT REV CLIN ONCOL, V9, P338, DOI 10.1038/nrclinonc.2012.61
   VAUGHAN GM, 1976, J CLIN ENDOCR METAB, V42, P752, DOI 10.1210/jcem-42-4-752
   Wang M, 2015, BIOCHEM BIOPH RES CO, V467, P310, DOI 10.1016/j.bbrc.2015.09.164
   Wang ZB, 2008, NAT GENET, V40, P897, DOI 10.1038/ng.154
   Wei JY, 2015, J PINEAL RES, V58, P429, DOI 10.1111/jpi.12226
   Wu Jin, 2015, Onco Targets Ther, V8, P2565, DOI 10.2147/OTT.S89597
   Xiang SL, 2015, J PINEAL RES, V59, P60, DOI 10.1111/jpi.12239
   Xin ZL, 2015, J PINEAL RES, V58, P375, DOI 10.1111/jpi.12227
   Yeh CM, 2016, ONCOTARGET, V7, P21952, DOI 10.18632/oncotarget.8009
   Yen CY, 2016, CANCER LETT, V373, P185, DOI 10.1016/j.canlet.2016.01.036
   Yousaf F, 2010, ANESTHESIOLOGY, V113, P968, DOI 10.1097/ALN.0b013e3181e7d626
   Yuan CP, 2015, J ORAL PATHOL MED, V44, P159, DOI 10.1111/jop.12220
   Zhang H, 2015, CANCER RES, V75, P2363, DOI 10.1158/0008-5472.CAN-14-2928
   Zhang XC, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-168
   Zhao ZK, 2013, TUMOR BIOL, V34, P173, DOI 10.1007/s13277-012-0525-x
NR 71
TC 35
Z9 37
U1 0
U2 0
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD MAY 16
PY 2017
VL 8
IS 20
BP 33756
EP 33769
DI 10.18632/oncotarget.16808
PG 14
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA EV4XS
UT WOS:000401767700114
PM 28422711
OA Green Published, gold, Green Submitted
DA 2025-01-12
ER

PT J
AU Zhou, G
   Parfett, C
   Cummings-Lorbetskie, C
   Xiao, GH
   Desaulniers, D
AF Zhou, Gu
   Parfett, Craig
   Cummings-Lorbetskie, Cathy
   Xiao, Gong-Hua
   Desaulniers, Daniel
TI Two-color fluorescent cytosine extension assay for the determination of
   global DNA methylation
SO BIOTECHNIQUES
LA English
DT Article
DE methylation sensitive restriction enzyme; dual label; accuracy;
   precision
ID LUMINOMETRIC METHYLATION; CANCER EPIGENETICS; BREAST-CANCER; CPG
   ISLANDS; GENOME; LIVER; LUMA; HYPOMETHYLATION; ENVIRONMENT; METABOLISM
AB Here, we present a DNA restriction enzyme-based, fluorescent cytosine extension assay (CEA) to improve normalization and technical variation among sample-to-sample measurements. The assay includes endlabeling of parallel methylation-sensitive and methylation-insensitive DNA restriction enzyme digests along with co-purification and subsequent co-measurement of incorporated fluorescence. This non-radioactive, two-color fluorescent CEA (TCF-CEA) was shown to be a relatively rapid and accurate, with 3-fold greater precision than the one-color CEA. In addition, TCF-CEA provided an index of global DNA methylation that was sensitive to differences > 5%. TCF-CEA results were highly correlated with LUminometric Methylation Assay (LUMA) results using human liver cell lines (HepG2, HepaRG, HC-04) as well as a human liver primary cell culture. Hypomethylation was observed in cells treated with the de-methylating agent 5-aza-2'deoxycytidine. These results demonstrate that TCF-CEA provides a simple method for measuring relative degrees of global DNA methylation that could potentially be scaled up to higher-throughput formats.
C1 [Zhou, Gu; Parfett, Craig] Hlth Canada, HECSB, Environm Hlth Sci & Res Bur, Mechanist Studies Div, Ottawa, ON, Canada.
   [Cummings-Lorbetskie, Cathy; Xiao, Gong-Hua; Desaulniers, Daniel] Hlth Canada, Environm Hlth Sci & Res Bur HECSB, Hazard Identificat Div, Ottawa, ON, Canada.
C3 Health Canada; Health Canada
RP Parfett, C (通讯作者)，Hlth Canada, HECSB, Environm Hlth Sci & Res Bur, Mechanist Studies Div, Ottawa, ON, Canada.
EM craig.parfett@canada.ca
FU Chemicals Management Plan of the Government of Canada
FX Funding was provided by the Chemicals Management Plan of the Government
   of Canada. We thank Lawton Stubbert for advice during initial
   experiments on flow cytometric detection of methylated cytosine in DNA.
CR ADEN DP, 1979, NATURE, V282, P615, DOI 10.1038/282615a0
   Anisowicz Anthony, 2008, BMC Cancer, V8, P222, DOI 10.1186/1471-2407-8-222
   Bjornsson HT, 2008, JAMA-J AM MED ASSOC, V299, P2877, DOI 10.1001/jama.299.24.2877
   Brennan K, 2012, CANCER PREV RES, V5, P1345, DOI 10.1158/1940-6207.CAPR-12-0316
   Dawson MA, 2012, CELL, V150, P12, DOI 10.1016/j.cell.2012.06.013
   Deaton AM, 2011, GENE DEV, V25, P1010, DOI 10.1101/gad.2037511
   Fujiwara H, 2002, ANAL BIOCHEM, V307, P386, DOI 10.1016/S0003-2697(02)00053-2
   Guillouzo A, 2007, CHEM-BIOL INTERACT, V168, P66, DOI 10.1016/j.cbi.2006.12.003
   Habib M, 1999, EXP CELL RES, V249, P46, DOI 10.1006/excr.1999.4434
   Herceg Z, 2011, EPIGENETICS-US, V6, P804, DOI 10.4161/epi.6.7.16262
   Hou LF, 2012, INT J EPIDEMIOL, V41, P79, DOI 10.1093/ije/dyr154
   Karimi M, 2006, EXP CELL RES, V312, P1989, DOI 10.1016/j.yexcr.2006.03.006
   Kurdyukov Sergey, 2016, Biology-Basel, V5, DOI 10.3390/biology5010003
   Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062
   LINDSAY S, 1987, NATURE, V327, P336, DOI 10.1038/327336a0
   McCullough LE, 2015, J CANCER, V6, P548, DOI 10.7150/jca.11359
   Nahar MS, 2015, CHEMOSPHERE, V124, P54, DOI 10.1016/j.chemosphere.2014.10.071
   NUR I, 1985, J BACTERIOL, V164, P19, DOI 10.1128/JB.164.1.19-24.1985
   Ogino S, 2013, MODERN PATHOL, V26, P465, DOI 10.1038/modpathol.2012.214
   Pogribny I, 1999, BIOCHEM BIOPH RES CO, V262, P624, DOI 10.1006/bbrc.1999.1187
   Pogribny IP, 2014, CANCER LETT, V342, P223, DOI 10.1016/j.canlet.2012.01.038
   Pogribny IP, 2013, ADV EXP MED BIOL, V754, P215, DOI 10.1007/978-1-4419-9967-2_11
   Portela A, 2010, NAT BIOTECHNOL, V28, P1057, DOI 10.1038/nbt.1685
   Rollins RA, 2006, GENOME RES, V16, P157, DOI 10.1101/gr.4262006
   Sadikovic B, 2007, TOXICOL APPL PHARM, V225, P300, DOI 10.1016/j.taap.2007.08.013
   Sattabongkot J, 2006, AM J TROP MED HYG, V74, P708, DOI 10.4269/ajtmh.2006.74.708
   Stier I, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079003
   Tsai HC, 2011, CELL RES, V21, P502, DOI 10.1038/cr.2011.24
   Umer M, 2013, ANTIOXID REDOX SIGN, V18, P1972, DOI 10.1089/ars.2012.4923
   Woo HD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034615
   Xu XR, 2012, FASEB J, V26, P2657, DOI 10.1096/fj.11-197251
   Zhao CY, 2012, EPIGENETICS-US, V7, P335, DOI 10.4161/epi.19376
NR 32
TC 3
Z9 3
U1 0
U2 4
PU BIOTECHNIQUES OFFICE
PI NEW YORK
PA 52 VANDERBILT AVE, NEW YORK, NY 10017 USA
SN 0736-6205
EI 1940-9818
J9 BIOTECHNIQUES
JI Biotechniques
PD APR
PY 2017
VL 62
IS 4
BP 157
EP 164
DI 10.2144/000114533
PG 6
WC Biochemical Research Methods; Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA ES4ZL
UT WOS:000399545300003
PM 28403806
OA Green Submitted, gold
DA 2025-01-12
ER

PT J
AU Kamiya, T
   Nakahara, R
   Mori, N
   Hara, H
   Adachi, T
AF Kamiya, Tetsuro
   Nakahara, Risa
   Mori, Namiki
   Hara, Hirokazu
   Adachi, Tetsuo
TI Ten-eleven translocation 1 functions as a mediator of SOD3 expression in
   human lung cancer A549 cells
SO FREE RADICAL RESEARCH
LA English
DT Article
DE Superoxide dismutase 3; epigenetics; ten-eleven translocation 1; A549
   cells
ID EXTRACELLULAR-SUPEROXIDE-DISMUTASE; DNA METHYLATION;
   5-HYDROXYMETHYLCYTOSINE; TET1; PROMOTES; INVASION; METHYLTRANSFERASE;
   OVEREXPRESSION; ADENOCARCINOMA; INACTIVATION
AB Superoxide dismutase (SOD) 3, one of the SOD isozymes, plays a pivotal role in extracellular redox homeostasis. The expression of SOD3 is regulated by epigenetics in human lung cancer A549 cells and human monocytic THP-1 cells; however, the molecular mechanisms governing SOD3 expression have not been elucidated in detail. Ten-eleven translocation (TET), a dioxygenase of 5-methylcytosine (5mC), plays a central role in DNA demethylation processes and induces target gene expression. In the present study, TET1 expression was abundant in U937 cells, but its expression was weakly expressed in A549 and THP-1 cells. These results are consistent with the expression pattern of SOD3 and its DNA methylation status in these cells. Moreover, above relationship was also observed in human breast cancer cells, human prostate cancer cells, and human skin fibroblasts. The overexpression of TET1-catalytic domain (TET1-CD) induced the expression of SOD3 in A549 cells, and this was accompanied by the direct binding of TET1-CD to the SOD3 promoter region. Furthermore, in TET1-CD-transfected A549 cells, the level of 5-hydroxymethylcytosine within that region was significantly increased, whereas the level of 5mC was decreased. The results of the present study demonstrate that TET1 might function as one of the key molecules in SOD3 expression through its 5mC hydroxylation in A549 cells.
C1 [Kamiya, Tetsuro; Nakahara, Risa; Mori, Namiki; Hara, Hirokazu; Adachi, Tetsuo] Gifu Pharmaceut Univ, Lab Clin Pharmaceut, 1-25-4 Daigaku Nishi, Gifu 5011196, Japan.
C3 Gifu Pharmaceutical University
RP Kamiya, T (通讯作者)，Gifu Pharmaceut Univ, Lab Clin Pharmaceut, 1-25-4 Daigaku Nishi, Gifu 5011196, Japan.
EM tekamiya@gifu-pu.ac.jp
RI Kamiya, Tetsuro/AAY-7093-2021
FU Japan Society for the Promotion of Science [26460070]; Gifu
   Pharmaceutical University; Grants-in-Aid for Scientific Research
   [26460070] Funding Source: KAKEN
FX This study was supported in part by a Grant-in-Aid for Scientific
   Research from the Japan Society for the Promotion of Science (T.K.)
   [grant no. 26460070] and a grant for the encouragement of young
   scientists from Gifu Pharmaceutical University (T.K.).
CR Allen MD, 2006, EMBO J, V25, P4503, DOI 10.1038/sj.emboj.7601340
   CARLSSON LM, 1995, P NATL ACAD SCI USA, V92, P6264, DOI 10.1073/pnas.92.14.6264
   Chmelarova M, 2013, CLIN TRANSL ONCOL, V15, P160, DOI 10.1007/s12094-012-0894-z
   Faraci FM, 2004, ARTERIOSCL THROM VAS, V24, P1367, DOI 10.1161/01.ATV.0000133604.20182.cf
   Fattman CL, 2003, FREE RADICAL BIO MED, V35, P763, DOI 10.1016/S0891-5849(03)00402-7
   Haffner MC, 2011, ONCOTARGET, V2, P627
   Heistad DD, 2006, ARTERIOSCL THROM VAS, V26, P689, DOI 10.1161/01.ATV.0000203525.62147.28
   HOLLIDAY R, 1990, PHILOS T R SOC B, V326, P329, DOI 10.1098/rstb.1990.0015
   Hsu CH, 2012, CELL REP, V2, P568, DOI 10.1016/j.celrep.2012.08.030
   Ito S, 2010, NATURE, V466, P1129, DOI 10.1038/nature09303
   Jin SG, 2011, CANCER RES, V71, P7360, DOI 10.1158/0008-5472.CAN-11-2023
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   Kamiya T, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/1284372
   Kamiya T, 2013, FREE RADICAL BIO MED, V61, P197, DOI 10.1016/j.freeradbiomed.2013.04.013
   Kamiya T, 2011, J CELL BIOCHEM, V112, P244, DOI 10.1002/jcb.22917
   Kristensen LS, 2009, EUR J PHARMACOL, V625, P131, DOI 10.1016/j.ejphar.2009.10.011
   Kudo Y, 2012, CANCER SCI, V103, P670, DOI 10.1111/j.1349-7006.2012.02213.x
   Laukkanen MO, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/3612589
   Laurila JP, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005786
   LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F
   Lu HG, 2014, MOL MED REP, V10, P2595, DOI 10.3892/mmr.2014.2517
   MARKLUND SL, 1982, P NATL ACAD SCI-BIOL, V79, P7634, DOI 10.1073/pnas.79.24.7634
   MARKLUND SL, 1984, BIOCHEM J, V222, P649, DOI 10.1042/bj2220649
   MARKLUND SL, 1984, J CLIN INVEST, V74, P1398, DOI 10.1172/JCI111550
   Morisawa S, J CLIN BIOCH NUTR
   O'Leary BR, 2015, CLIN CANCER RES, V21, P1741, DOI 10.1158/1078-0432.CCR-14-1959
   Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6
   Polytarchou C, 2005, J BIOL CHEM, V280, P40428, DOI 10.1074/jbc.M505120200
   Spans L, 2016, ONCOTARGET, V7, P24326, DOI 10.18632/oncotarget.8220
   Strathdee G, 2002, SEMIN CANCER BIOL, V12, P373, DOI 10.1016/S1044-579X(02)00057-3
   Svensk AM, 2004, AM J CLIN PATHOL, V122, P395, DOI 10.1309/A45QHB0QRRX6CT9A
   Tahiliani M, 2009, SCIENCE, V324, P930, DOI 10.1126/science.1170116
   Takatsu H, 2001, BIOCHEM BIOPH RES CO, V285, P84, DOI 10.1006/bbrc.2001.5114
   Teoh MLT, 2009, CANCER RES, V69, P6355, DOI 10.1158/0008-5472.CAN-09-1195
   Teoh-Fitzgerald MLT, 2012, MOL CANCER RES, V10, P40, DOI 10.1158/1541-7786.MCR-11-0501
   VACHIER I, 1994, EUR RESPIR J, V7, P1585, DOI 10.1183/09031936.94.07091585
   Wright E, 2006, INT J CLIN PRACT, V60, P308, DOI 10.1111/j.1368-5031.2006.00825.x
   Yamaguchi S, 2013, NATURE, V504, P460, DOI 10.1038/nature12805
   Yang H, 2013, ONCOGENE, V32, P663, DOI 10.1038/onc.2012.67
   Yasuda H, 2016, J CLIN BIOCHEM NUTR, V58, P34, DOI 10.3164/jcbn.15-16
   Zelko IN, 2010, FREE RADICAL BIO MED, V48, P895, DOI 10.1016/j.freeradbiomed.2010.01.007
   Zhang QH, 2015, GENET MOL RES, V14, P9200, DOI 10.4238/2015.August.7.30
NR 42
TC 15
Z9 15
U1 0
U2 12
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1071-5762
EI 1029-2470
J9 FREE RADICAL RES
JI Free Radic. Res.
PD MAR
PY 2017
VL 51
IS 3
BP 329
EP 336
DI 10.1080/10715762.2017.1313415
PG 8
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA ES7NM
UT WOS:000399736900008
PM 28351182
DA 2025-01-12
ER

PT J
AU Chen, J
   Zhou, J
   Wu, J
   Zhang, GW
   Kang, LH
   Ben, JD
   Wang, Y
   Qin, B
   Guan, HJ
AF Chen, Jia
   Zhou, Jing
   Wu, Jian
   Zhang, Guowei
   Kang, Lihua
   Ben, Jindong
   Wang, Yong
   Qin, Bai
   Guan, Huaijin
TI Aberrant Epigenetic Alterations of Glutathione-S-Transferase P1 in
   Age-Related Nuclear Cataract
SO CURRENT EYE RESEARCH
LA English
DT Article
DE Age-related cataract; DNA methylation; epigenetic;
   glutathione-S-transferase; histone modification
ID CANCER-CELLS; DNA METHYLATION; JUNCTIONAL MICRODOMAINS; CHROMATIN
   MODIFICATIONS; OXIDATIVE STRESS; GENE-EXPRESSION; SENILE CATARACT;
   BREAST-CANCER; CPG ISLANDS; LENS
AB Purpose: Oxidative damage of lens tissue contributes to the formation of age-related cataract. Pi-class glutathione-S-transferase (GSTP1) plays a role in the removal of oxidative adducts by transferring them to glutathione. To assess epigenetic regulation of GSTP1 and its potential role in age-related nuclear cataract (ARNC) pathogenesis, we evaluated GSTP1 mRNA expression, methylation, and chromatin modifications in lenses from ARNC patients.Methods: The mRNA and protein of lens GSTP1 were assayed by relative quantitative real-time polymerase chain reaction (qRT-PCR) and Western blots. Methylation of the GSTP1 promoter was determined by bisulfite genomic sequencing. Chromatin modification was detected by chromatin immunoprecipitation. DNA methyltransferase (DNMT) and histone deacetylase (HDAC) activities were also assayed by enzyme-linked immunosorbent assay (ELISA)-like reaction. To assess the effect of DNA methylation on the mRNA expression of GSTP1, human lens epithelium HLE-B3 cells were treated with the demethylation compound 5-aza-dC, followed by qRT-PCR assay.Results: GSTP1 mRNA and protein levels were significantly reduced in lens epithelium and cortex of ARNC cases versus age-matched controls. The changes corresponded to hypermethylation of the GSTP1 promoter CpG islands. The loss of GSTP1 mRNA and protein and the increased DNA promoter methylation might be correlated with the severity of the ARNC. ARNC lenses also had lower acetylation of histone proteins H3, H4, and lower methylation of H3K4, and higher methylation of H3K9. Histone modifications were not correlated with the severity of the ARNCs. DNMT and HDAC were elevated in lenses from ARNCs compared with controls. Demethylation treatment of HLE-B3 cells with 5-aza-dC enhanced the expression of GSTP1.Conclusions: Epigenetic alteration of GSTP1 regulates its expression in lens epithelial and cortical tissues. These changes likely contribute to the pathogenesis of ARNC.
C1 [Chen, Jia; Zhou, Jing; Wu, Jian; Zhang, Guowei; Kang, Lihua; Ben, Jindong; Wang, Yong; Qin, Bai; Guan, Huaijin] Nantong Univ, Eye Inst, Affiliated Hosp, 20 Xisi Rd, Nantong, Jiangsu, Peoples R China.
C3 Nantong University
RP Guan, HJ (通讯作者)，Nantong Univ, Eye Inst, Affiliated Hosp, 20 Xisi Rd, Nantong, Jiangsu, Peoples R China.
EM gtnantongeye@gmail.com
RI Wang, Yong/JJD-1898-2023; Zhang, Guowei/HJH-0318-2022
OI Guan, Huaijin/0000-0002-4911-1989; Wang, Yong/0000-0003-0989-9764
FU National Natural Science Foundation of China [81300744, 81270987,
   81500706, 81470616]; Science Foundation of Nantong China [HS2014005]
FX This study was supported by National Natural Science Foundation of China
   Grant (No. 81300744, No. 81270987, No. 81500706 and No. 81470616) and
   Science Foundation of Nantong China Grant (HS2014005).
CR Bakker J, 2002, J BIOL CHEM, V277, P22573, DOI 10.1074/jbc.M203009200
   Bollati V, 2009, MECH AGEING DEV, V130, P234, DOI 10.1016/j.mad.2008.12.003
   Buzhynskyy N, 2007, EMBO REP, V8, P51, DOI 10.1038/sj.embor.7400858
   Christensen BC, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000602
   CHYLACK LT, 1993, ARCH OPHTHALMOL-CHIC, V111, P831, DOI 10.1001/archopht.1993.01090060119035
   Dal Monte M, 1998, BIOCHEM J, V334, P57
   Fan XJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050832
   Fuks F, 2001, EMBO J, V20, P2536, DOI 10.1093/emboj/20.10.2536
   Giblin FJ, 2000, J OCUL PHARMACOL TH, V16, P121, DOI 10.1089/jop.2000.16.121
   Greer EL, 2012, NAT REV GENET, V13, P343, DOI 10.1038/nrg3173
   Hernandez DG, 2011, HUM MOL GENET, V20, P1164, DOI 10.1093/hmg/ddq561
   Hunter A, 2012, INVEST OPHTH VIS SCI, V53, P2089, DOI 10.1167/iovs.11-8449
   Kanwal R, 2014, MOL CARCINOGEN, V53, P8, DOI 10.1002/mc.21939
   Karius T, 2011, BIOCHEM PHARMACOL, V81, P1329, DOI 10.1016/j.bcp.2011.03.014
   Karpf AR, 2002, ONCOGENE, V21, P5496, DOI 10.1038/sj.onc.1205602
   Kisic B, 2012, SRP ARK CELOK LEK, V140, P563, DOI 10.2298/SARH1210563K
   Klein BEK, 2008, OPHTHALMOLOGY, V115, P477, DOI 10.1016/j.ophtha.2007.11.024
   Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005
   Laborde E, 2010, CELL DEATH DIFFER, V17, P1373, DOI 10.1038/cdd.2010.80
   Lin XH, 2003, CANCER RES, V63, P498
   Lou MF, 2000, J OCUL PHARMACOL TH, V16, P137, DOI 10.1089/jop.2000.16.137
   Lou MF, 2003, PROG RETIN EYE RES, V22, P657, DOI 10.1016/S1350-9462(03)00050-8
   Millar DS, 2000, J BIOL CHEM, V275, P24893, DOI 10.1074/jbc.M906538199
   Mimura T, 2013, EXP EYE RES, V116, P17, DOI 10.1016/j.exer.2013.07.017
   Miyake T, 2013, ANTICANCER RES, V33, P5617
   Mukai T, 2002, ONCOGENE, V21, P9033, DOI 10.1038/sj.onc.1206095
   Nakayam J, 2001, SCIENCE, V292, P110, DOI 10.1126/science.1060118
   Nguyen CT, 2002, CANCER RES, V62, P6456
   Ottonello S, 2000, OPHTHALMOLOGICA, V214, P78, DOI 10.1159/000027474
   Palsamy P, 2012, BIOCHEM BIOPH RES CO, V423, P542, DOI 10.1016/j.bbrc.2012.05.164
   Ritchie KJ, 2007, CANCER RES, V67, P9248, DOI 10.1158/0008-5472.CAN-07-1764
   Rountree MR, 2000, NAT GENET, V25, P269, DOI 10.1038/77023
   Sarraf SA, 2004, MOL CELL, V15, P595, DOI 10.1016/j.molcel.2004.06.043
   Scheuring S, 2007, J STRUCT BIOL, V160, P385, DOI 10.1016/j.jsb.2007.07.009
   Singal R, 2001, CANCER RES, V61, P4820
   Stirzaker C, 2004, CANCER RES, V64, P3871, DOI 10.1158/0008-5472.CAN-03-3690
   Strunnikova M, 2005, MOL CELL BIOL, V25, P3923, DOI 10.1128/MCB.25.10.3923-3933.2005
   Sun L, 2010, INVEST OPHTH VIS SCI, V51, P6381, DOI 10.1167/iovs.10-5815
   TAZI J, 1990, CELL, V60, P909, DOI 10.1016/0092-8674(90)90339-G
   Truscott RJW, 2005, EXP EYE RES, V80, P709, DOI 10.1016/j.exer.2004.12.007
   TURNER BM, 1993, CELL, V75, P5, DOI 10.1016/S0092-8674(05)80078-9
   Wang T, 2001, J BIOL CHEM, V276, P20999, DOI 10.1074/jbc.M101355200
   Wei L, 2012, CELL REP, V2, P1151, DOI 10.1016/j.celrep.2012.10.013
   Zhang JH, 2012, NATURE, V481, P329, DOI 10.1038/nature10733
   ZHANG WZ, 1994, EXP EYE RES, V59, P91, DOI 10.1006/exer.1994.1084
   Zhang XL, 2012, LUNG CANCER, V77, P488, DOI 10.1016/j.lungcan.2012.05.107
   Zhong Q, 2011, DIABETES, V60, P1304, DOI 10.2337/db10-0133
   Zhou J, 2010, INVEST OPHTH VIS SCI, V51, P3924, DOI 10.1167/iovs.10-5240
   Zhou P, 2012, FASEB J, V26, P4897, DOI 10.1096/fj.12-213702
   Zoric L, 2008, EUR J OPHTHALMOL, V18, P669, DOI 10.1177/112067210801800501
NR 50
TC 11
Z9 11
U1 0
U2 7
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0271-3683
EI 1460-2202
J9 CURR EYE RES
JI Curr. Eye Res.
PY 2017
VL 42
IS 3
BP 402
EP 410
DI 10.1080/02713683.2016.1185129
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA ES4EY
UT WOS:000399484000011
PM 27348130
DA 2025-01-12
ER

PT J
AU Franci, G
   Sarno, F
   Nebbioso, A
   Altucci, L
AF Franci, Gianluigi
   Sarno, Federica
   Nebbioso, Angela
   Altucci, Lucia
TI Identification and characterization of PKF118-310 as a KDM4A inhibitor
SO EPIGENETICS
LA English
DT Article
DE Cancer; demethylase; epigenetics; inhibitors; JMJ; KDM4A; PKF118-310;
   screening
ID SMALL-MOLECULE ANTAGONISTS; BREAST-CANCER; HISTONE DEMETHYLASES; GENETIC
   ALTERATIONS; ARGININE METHYLATION; CELL-LINES; IN-VITRO;
   METHYLTRANSFERASES; THERAPY; GROWTH
AB Epigenetic modifications are functionally involved in gene expression regulation. In particular, histone posttranslational modifications play a crucial role in functional chromatin organization. Several drugs able to inhibit or stimulate some families of proteins involved in epigenetic histone regulation have been found, a number of which are FDA-approved for the treatment of cutaneous T-cell lymphoma or are in phase I/II/III clinical trials for solid tumors. Although some protein families, such as histone deacetylases and their inhibitors, are well characterized, our understanding of histone lysine demethylases is still incomplete. We describe the in silico, in vitro, and cell-based characterization of the compound PKF118-310, an antagonist of transcription factor 4 (TCF4)/beta-catenin signaling, as inhibitor of KDM4A. PKF118-310 potential inhibitor activity was discovered via virtual screening on the crystal structure of KDM4A. A peptide-based histone trimethylation assay developed in-house confirmed its potent KDM4A inhibitor activity. Its protein target was identified by cellular thermal shift assay experiments. PKF118-310 anticancer activity was observed in both liquid and solid tumor cells, and shown to have a dose-and time-dependent effect. We demonstrate the previously unreported inhibitory action of PKF118-310 on KDM4A. Our findings open up the possibility of developing the first KDM4A-specific inhibitors and derivatives.
C1 [Franci, Gianluigi; Sarno, Federica; Nebbioso, Angela; Altucci, Lucia] Seconda Univ Napoli, Dipartimento Biochim Biofis & Patol Gen, Vico L De Crecchio 7, I-80138 Naples, Italy.
C3 Universita della Campania Vanvitelli
RP Altucci, L (通讯作者)，Seconda Univ Napoli, Dipartimento Biochim Biofis & Patol Gen, Vico L De Crecchio 7, I-80138 Naples, Italy.
EM lucia.altucci@unina2.it
RI Altucci, Lucia/S-8031-2019; NEBBIOSO, ANGELA/GVS-1294-2022; Sarno,
   Federica/AAL-2860-2021; Franci, Gianluigi/AAC-6841-2022
OI Franci, Gianluigi/0000-0003-3321-4331
FU Blueprint [282510]; EPIGEN (MIUR-CNR); MIUR [PRIN-2012ZHN9YH]; AIRC
   [17217]
FX This work was supported by: Blueprint (282510); EPIGEN (MIUR-CNR); MIUR
   (PRIN-2012ZHN9YH); AIRC (17217).
CR Ai GQ, 2016, MOL MED REP, V14, P1726, DOI 10.3892/mmr.2016.5449
   Bedford MT, 2005, MOL CELL, V18, P263, DOI 10.1016/j.molcel.2005.04.003
   Bontempo P, 2013, CELL PROLIFERAT, V46, P183, DOI 10.1111/cpr.12022
   Conte M, 2015, ONCOTARGET, V6, P886, DOI 10.18632/oncotarget.2816
   Copeland RA, 2013, ONCOGENE, V32, P939, DOI 10.1038/onc.2012.552
   Duan LL, 2015, CHEM BIOL, V22, P1185, DOI 10.1016/j.chembiol.2015.08.007
   Dupont C, 2009, SEMIN REPROD MED, V27, P351, DOI 10.1055/s-0029-1237423
   Franci G, 2015, CELL PROLIFERAT, V48, P705, DOI 10.1111/cpr.12224
   Inoue S, 2014, HUM MOL GENET, V23, P6553, DOI 10.1093/hmg/ddu376
   Jafari R, 2014, NAT PROTOC, V9, P2100, DOI 10.1038/nprot.2014.138
   Kim TD, 2016, ONCOL REP, V35, P3679, DOI 10.3892/or.2016.4747
   Kim TD, 2016, J CLIN INVEST, V126, P706, DOI 10.1172/JCI78132
   Kim TD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034618
   Klose RJ, 2006, NAT REV GENET, V7, P715, DOI 10.1038/nrg1945
   Kooistra SM, 2012, NAT REV MOL CELL BIO, V13, P297, DOI 10.1038/nrm3327
   Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005
   Lenoci A, 2014, CHEMMEDCHEM, V9, P542, DOI 10.1002/cmdc.201300536
   Leow PC, 2010, INVEST NEW DRUG, V28, P766, DOI 10.1007/s10637-009-9311-z
   Lepourcelet M, 2004, CANCER CELL, V5, P91, DOI 10.1016/S1535-6108(03)00334-9
   Li LL, 2014, BREAST CANCER RES, V16, DOI 10.1186/bcr3667
   Li LL, 2014, BREAST CANCER RES TR, V147, P487, DOI 10.1007/s10549-014-3083-7
   Liu LX, 2015, ONCOTARGET, V6, P2466, DOI 10.18632/oncotarget.2967
   Manal M, 2016, BIOORG CHEM, V67, P18, DOI 10.1016/j.bioorg.2016.05.005
   Martin C, 2005, NAT REV MOL CELL BIO, V6, P838, DOI 10.1038/nrm1761
   Meslamani J, 2011, BIOINFORMATICS, V27, P1324, DOI 10.1093/bioinformatics/btr120
   Miceli M, 2013, STEM CELLS DEV, V22, P2368, DOI 10.1089/scd.2012.0498
   Morera L, 2016, CLIN EPIGENETICS, V8, DOI 10.1186/s13148-016-0223-4
   Ngollo M, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-994
   Park SY, 2016, PHARMACOL RES, V105, P146, DOI 10.1016/j.phrs.2016.01.026
   Passmore JS, 2001, IMMUNOLOGY, V102, P146, DOI 10.1046/j.1365-2567.2001.01164.x
   Pedersen MT, 2010, TRENDS CELL BIOL, V20, P662, DOI 10.1016/j.tcb.2010.08.011
   Qiu MT, 2015, ONCOTARGET, V6, P31702, DOI 10.18632/oncotarget.5165
   Rivera C, 2015, NUCLEIC ACIDS RES, V43, P9097, DOI 10.1093/nar/gkv929
   Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089
   Sehgal SA, 2016, DRUG DES DEV THER, V10, P1605, DOI 10.2147/DDDT.S101929
   Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012
   Song YC, 2016, J HEMATOL ONCOL, V9, DOI 10.1186/s13045-016-0279-9
   Stark GR, 2011, CELL RES, V21, P375, DOI 10.1038/cr.2010.174
   SUGIMOTO K, 1992, BLOOD, V79, P2378, DOI 10.1182/blood.V79.9.2378.2378
   Thakur R, 2013, J CELL MOL MED, V17, P449, DOI 10.1111/jcmm.12033
   Wang Dan-Yu, 2015, Zhongguo Shi Yan Xue Ye Xue Za Zhi, V23, P989, DOI 10.7534/j.issn.1009-2137.2015.04.015
   Wei W, 2010, INT J CANCER, V126, P2426, DOI 10.1002/ijc.24810
   Wysocka J, 2006, FRONT BIOSCI-LANDMRK, V11, P344, DOI 10.2741/1802
   Ye Q, 2015, AM J CANCER RES, V5, P1519
NR 44
TC 28
Z9 29
U1 1
U2 10
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1559-2294
EI 1559-2308
J9 EPIGENETICS-US
JI Epigenetics
PY 2017
VL 12
IS 3
BP 198
EP 205
DI 10.1080/15592294.2016.1249089
PG 8
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA ES5GS
UT WOS:000399567000003
PM 27767379
OA Green Published, Bronze
DA 2025-01-12
ER

PT J
AU Croes, L
   Op de Beeck, K
   Pauwels, P
   Vanden Berghe, W
   Peeters, M
   Fransen, E
   Van Camp, G
AF Croes, Lieselot
   Op de Beeck, Ken
   Pauwels, Patrick
   Vanden Berghe, Wim
   Peeters, Marc
   Fransen, Erik
   Van Camp, Guy
TI <i>DFNA5</i> promoter methylation a marker for breast tumorigenesis
SO ONCOTARGET
LA English
DT Article
DE DFNA5; breast cancer; DNA methylation; biomarker; detection
ID DNA METHYLATION; EPIGENETIC INACTIVATION; ABERRANT METHYLATION; FIELD
   CANCERIZATION; NORMAL TISSUE; CANCER-RISK; IN-SITU; GENE;
   HYPERMETHYLATION; CARCINOMA
AB Background: Identification of methylation markers that are sensitive and specific for breast cancer may improve early detection. We hypothesize that DFNA5 promoter methylation can be a valuable epigenetic biomarker, based upon strong indications for its role as tumor suppressor gene and its function in regulated cell death.
   Results: Statistically different levels of methylation were seen, with always very low levels in healthy breast reduction samples, very high levels in part of the adenocarcinoma samples and slightly increased levels in part of the normal tissue samples adjacent the tumor. One of the CpGs (CpG4) showed the best differentiation. A ROC curve for DFNA5 CpG4 methylation showed a sensitivity of 61.8% for the detection of breast cancer with a specificity of 100%.
   Materials and Methods: We performed methylation analysis on four CpGs in the DFNA5 promoter region by bisulfite pyrosequencing on 123 primary breast adenocarcinomas and 24 healthy breast reductions. For 16 primary tumors, corresponding histological normal tissue adjacent to the tumor was available.
   Conclusions: We conclude that DFNA5 methylation shows strong potential as a biomarker for detection of breast cancer. Slightly increased methylation in histologically normal breast tissue surrounding the tumor suggests that it may be a good early detection marker.
C1 [Croes, Lieselot; Op de Beeck, Ken; Fransen, Erik; Van Camp, Guy] Univ Antwerp, Ctr Med Genet, B-2650 Edegem, Belgium.
   [Croes, Lieselot; Op de Beeck, Ken; Pauwels, Patrick; Peeters, Marc; Fransen, Erik; Van Camp, Guy] Antwerp Univ Hosp, B-2650 Edegem, Belgium.
   [Croes, Lieselot; Op de Beeck, Ken; Pauwels, Patrick; Peeters, Marc] Univ Antwerp, Ctr Oncol Res, B-2650 Edegem, Belgium.
   [Vanden Berghe, Wim] Lab Prot Chem Prote & Epigenet Signaling PPES, B-2610 Antwerp, Belgium.
   [Fransen, Erik] Univ Antwerp, StatUa Ctr Stat, B-2000 Antwerp, Belgium.
C3 University of Antwerp; University of Antwerp; University of Antwerp;
   University of Antwerp
RP Croes, L (通讯作者)，Univ Antwerp, Ctr Med Genet, B-2650 Edegem, Belgium.; Croes, L (通讯作者)，Antwerp Univ Hosp, B-2650 Edegem, Belgium.
EM lieselot.croes@uantwerpen.be
RI Peeters, Marc/C-5525-2013; Fransen, Erik/C-4102-2015; Op de Beeck,
   Ken/J-5248-2016; Vanden Berghe, Wim/S-6425-2018; Van Camp,
   Guy/F-3386-2013
OI Peeters, Marc/0000-0003-4969-2303; Op de Beeck, Ken/0000-0001-5527-6838;
   Vanden Berghe, Wim/0000-0003-0161-7355; Van Camp,
   Guy/0000-0001-5105-9000
FU Research Foundation-Flanders (FWO) [11Y9815N]
FX L.C. has a Ph.D. fellowship of the Research Foundation-Flanders (FWO;
   11Y9815N).
CR Akino K, 2007, CANCER SCI, V98, P88, DOI 10.1111/j.1349-7006.2006.00351.x
   Bae YK, 2004, CLIN CANCER RES, V10, P5998, DOI 10.1158/1078-0432.CCR-04-0667
   Balch C, 2005, FRONT BIOSCI-LANDMRK, V10, P1897, DOI 10.2741/1668
   Berman H, 2005, COLD SH Q B, V70, P317, DOI 10.1101/sqb.2005.70.051
   Braakhuis BJM, 2003, CANCER RES, V63, P1727
   Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691
   Dammann R, 2001, CANCER RES, V61, P3105
   de Beeck KO, 2012, ANN OTO RHINOL LARYN, V121, P197
   de Beeck KO, 2011, EUR J HUM GENET, V19, P965, DOI 10.1038/ejhg.2011.63
   Domann FE, 2000, INT J CANCER, V85, P805, DOI 10.1002/(SICI)1097-0215(20000315)85:6<805::AID-IJC12>3.0.CO;2-5
   Dworkin AM, 2009, SEMIN CANCER BIOL, V19, P165, DOI 10.1016/j.semcancer.2009.02.007
   Esteller M, 2007, HUM MOL GENET, V16, pR50, DOI 10.1093/hmg/ddm018
   Fleischer T, 2014, GENOME BIOL, V15, DOI [10.1186/s13059-014-0435-x, 10.1186/PREACCEPT-2333349012841587]
   Försti A, 2001, EUR J CANCER, V37, P1372, DOI 10.1016/S0959-8049(01)00118-6
   Fujikane T, 2010, BREAST CANCER RES TR, V122, P699, DOI 10.1007/s10549-009-0600-1
   Hammond MEH, 2010, J CLIN ONCOL, V28, P2784, DOI 10.1200/JCO.2009.25.6529
   Heaphy CM, 2006, INT J CANCER, V119, P108, DOI 10.1002/ijc.21815
   Hoque MO, 2006, J CLIN ONCOL, V24, P4262, DOI 10.1200/JCO.2005.01.3516
   Huang THM, 1999, HUM MOL GENET, V8, P459, DOI 10.1093/hmg/8.3.459
   Johnson KC, 2015, CLIN EPIGENETICS, V7, DOI 10.1186/s13148-015-0094-0
   Kim MS, 2008, ONCOGENE, V27, P3624, DOI 10.1038/sj.onc.1211021
   Kim MS, 2008, BIOCHEM BIOPH RES CO, V370, P38, DOI 10.1016/j.bbrc.2008.03.026
   Lage H, 2001, FEBS LETT, V494, P54, DOI 10.1016/S0014-5793(01)02304-3
   Larson PS, 1998, AM J PATHOL, V152, P1591
   Lewis CM, 2005, CLIN CANCER RES, V11, P166
   Maruvada Padma, 2005, Biotechniques, VSuppl, P9
   Masuda Yoshiko, 2006, J Hum Genet, V51, P652, DOI 10.1007/s10038-006-0004-6
   Park JW, 2004, CLIN CANCER RES, V10, P3885, DOI 10.1158/1078-0432.CCR-03-0785
   Rivenbark AG, 2007, EXP MOL PATHOL, V83, P188, DOI 10.1016/j.yexmp.2007.03.008
   Senkus E, 2015, ANN ONCOL, V26, pV8, DOI 10.1093/annonc/mdv298
   Shan M, 2016, ONCOTARGET, V7, P18485, DOI 10.18632/oncotarget.7608
   SLAUGHTER DP, 1953, CANCER, V6, P963, DOI 10.1002/1097-0142(195309)6:5<963::AID-CNCR2820060515>3.0.CO;2-Q
   Spitzwieser M, 2015, BREAST CANCER RES, V17, DOI 10.1186/s13058-015-0637-5
   Thompson DA, 1998, EUR J BIOCHEM, V252, P169, DOI 10.1046/j.1432-1327.1998.2520169.x
   Umbricht CB, 2001, ONCOGENE, V20, P3348, DOI 10.1038/sj.onc.1204438
   Van der Auwera I, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-97
   Van Laer L, 1998, NAT GENET, V20, P194
   Van Rossom S, 2015, FRONT CELL NEUROSCI, V9, DOI 10.3389/fncel.2015.00231
   Van Rossom S, 2012, FRONT ONCOL, V2, DOI 10.3389/fonc.2012.00077
   Wang CJ, 2013, MOL BIOL REP, V40, P6525, DOI 10.1007/s11033-013-2581-8
   Wittenberger T, 2014, EPIGENOMICS-UK, V6, P311, DOI [10.2217/EPI.14.20, 10.2217/epi.14.20]
   Yan PS, 2006, CLIN CANCER RES, V12, P6626, DOI 10.1158/1078-0432.CCR-06-0467
   Yokomizo K, 2012, ANTICANCER RES, V32, P1319
   Zou DH, 2009, J PATHOL, V218, P265, DOI 10.1002/path.2541
NR 44
TC 38
Z9 45
U1 0
U2 8
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD MAY 9
PY 2017
VL 8
IS 19
BP 31948
EP 31958
PG 11
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA EU4MH
UT WOS:000401003200107
PM 28404884
OA Green Published, gold, Green Submitted
DA 2025-01-12
ER

PT J
AU Ma, YF
   Wang, LH
   Neitzel, LR
   Loganathan, SN
   Tang, N
   Qin, LL
   Crispi, EE
   Guo, Y
   Knapp, S
   Beauchamp, RD
   Lee, E
   Wang, JL
AF Ma, Yufang
   Wang, Lihong
   Neitzel, Leif R.
   Loganathan, Sudan N.
   Tang, Nan
   Qin, Lili
   Crispi, Emily E.
   Guo, Yan
   Knapp, Stefan
   Beauchamp, R. Daniel
   Lee, Ethan
   Wang, Jialiang
TI The MAPK Pathway Regulates Intrinsic Resistance to BET Inhibitors in
   Colorectal Cancer
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID CHRONIC LYMPHOCYTIC-LEUKEMIA; BROMODOMAIN INHIBITION; COLON-CANCER;
   C-MYC; EPIGENETIC READERS; THERAPEUTIC TARGET; SMALL-INTESTINE; APC
   DEFICIENCY; ONCOGENIC KRAS; BREAST-CANCER
AB Purpose: The bromodomain and extra-terminal domain (BET) family proteins are epigenetic readers for acetylated histone marks. Emerging BET bromodomain inhibitors have exhibited antineoplastic activities in a wide range of human cancers through suppression of oncogenic transcription factors, including MYC. However, the preclinical activities of BET inhibitors in advanced solid cancers are moderate at best. To improve BET-targeted therapy, we interrogated mechanisms mediating resistance to BET inhibitors in colorectal cancer.
   Experimental Design: Using a panel of molecularly defined colorectal cancer cell lines, we examined the impact of BET inhibition on cellular proliferation and survival as well as MYC activity. We further tested the ability of inhibitors targeting the RAF/MEK/ERK (MAPK) pathway to enhance MYC suppression and circumvent intrinsic resistance to BET inhibitors. Key findings were validated using genetic approaches.
   Results: BET inhibitors as monotherapy moderately reduced colorectal cancer cell proliferation and MYC expression. Blockade of the MAPK pathway synergistically sensitized colorectal cancer cells to BET inhibitors, leading to potent apoptosis and MYC downregulation in vitro and in vivo. A combination of JQ1 and trametinib, but neither agent alone, induced significant regression of subcutaneous colorectal cancer xenografts.
   Conclusions: Our findings suggest that the MAPK pathway confers intrinsic resistance to BET inhibitors in colorectal cancer and propose an effective combination strategy for the treatment of colorectal cancer. (C) 2016 AACR.
C1 [Ma, Yufang; Qin, Lili; Wang, Jialiang] Vanderbilt Univ, Dept Neurol Surg, 221 Kirkland Hall, Nashville, TN 37235 USA.
   [Wang, Lihong; Beauchamp, R. Daniel] Vanderbilt Univ, Dept Surg, Nashville, TN 37240 USA.
   [Neitzel, Leif R.; Crispi, Emily E.; Lee, Ethan] Vanderbilt Univ, Dept Cell & Dev Biol, 221 Kirkland Hall, Nashville, TN 37235 USA.
   [Loganathan, Sudan N.] Meharry Med Coll, Dept Neurosci & Pharmacol, Nashville, TN 37208 USA.
   [Tang, Nan] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Wuhan, Peoples R China.
   [Guo, Yan; Wang, Jialiang] Vanderbilt Univ, Dept Canc Biol, 221 Kirkland Hall, Nashville, TN 37235 USA.
   [Knapp, Stefan] Univ Oxford, Struct Genom Consortium, Nuffield Dept Clin Med, Oxford, England.
   [Wang, Jialiang] Vanderbilt Univ, Dept Pharmacol, Nashville, TN USA.
C3 Vanderbilt University; Vanderbilt University; Vanderbilt University;
   Meharry Medical College; Huazhong University of Science & Technology;
   Vanderbilt University; University of Oxford; Vanderbilt University
RP Wang, JL (通讯作者)，Vanderbilt Univ, Med Ctr North T4224, Nashville, TN 37232 USA.
EM jialiang.wang@vanderbilt.edu
RI Knapp, Stefan/AAG-2347-2019; Wang, Li/O-1425-2015; Qin, Lili/J-7481-2016
OI Neitzel, Leif/0000-0003-2621-6259; Knapp, Stefan/0000-0001-5995-6494
FU NIH [R01CA166492, R01GM103926, R01GM081635, 5T32HD007502, T32GM07628];
   Voice Against Brain Cancer Foundation; Structural Genomics Consortium, a
   registered charity [1097737]; AbbVie; Bayer; Boehringer Ingelheim;
   Genome Canada through Ontario Genomics Institute [OGI-055];
   GlaxoSmithKline; Janssen; Lilly Canada; Novartis Research Foundation;
   Ontario Ministry of Economic Development and Innovation; Pfizer; Takeda;
   Welcome Trust [092809/Z/10/Z];  [R01CA069457]; Wellcome Trust
   [092809/Z/10/Z] Funding Source: Wellcome Trust
FX J. Wang is supported by the NIH grant (R01CA166492) and the Voice
   Against Brain Cancer Foundation. E. Lee is supported by NIH grants
   R01GM103926 and R01GM081635, and R.D. Beauchamp is supported by
   R01CA069457. S. Knapp is grateful for support by the Structural Genomics
   Consortium, a registered charity (No. 1097737) that receives funds from
   AbbVie, Bayer, Boehringer Ingelheim, Genome Canada through Ontario
   Genomics Institute Grant OGI-055, GlaxoSmithKline, Janssen, Lilly
   Canada, the Novartis Research Foundation, the Ontario Ministry of
   Economic Development and Innovation, Pfizer, Takeda, and Welcome Trust
   Grant 092809/Z/10/Z. L.R. Neitzel is a recipient of NIH training grant
   5T32HD007502. S.N. Loganathan is supported by NIH training grant
   T32GM07628.
CR Ahmad I, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.7
   Ahmed D, 2013, ONCOGENESIS, V2, DOI 10.1038/oncsis.2013.35
   Anastas JN, 2014, J CLIN INVEST, V124, P2877, DOI 10.1172/JCI70156
   [Anonymous], ANN ONCOL
   Athineos D, 2010, ONCOGENE, V29, P2585, DOI 10.1038/onc.2010.5
   Baratta MG, 2015, P NATL ACAD SCI USA, V112, P232, DOI 10.1073/pnas.1422165112
   Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003
   Cheng ZX, 2013, CLIN CANCER RES, V19, P1748, DOI 10.1158/1078-0432.CCR-12-3066
   Chou TC, 2010, CANCER RES, V70, P440, DOI 10.1158/0008-5472.CAN-09-1947
   Conery AR, 2016, CANCER RES, V76, P1313, DOI 10.1158/0008-5472.CAN-15-1458
   Dawson MA, 2012, NEW ENGL J MED, V367, P647, DOI 10.1056/NEJMra1112635
   De Raedt T, 2014, NATURE, V514, P247, DOI 10.1038/nature13561
   Delmore JE, 2011, CELL, V146, P903, DOI 10.1016/j.cell.2011.08.017
   Filippakopoulos P, 2014, NAT REV DRUG DISCOV, V13, P339, DOI 10.1038/nrd4286
   Filippakopoulos P, 2010, NATURE, V468, P1067, DOI 10.1038/nature09504
   Fong CY, 2015, NATURE, V525, P538, DOI 10.1038/nature14888
   Guo Y, 2014, BRIEF BIOINFORM, V15, P879, DOI 10.1093/bib/bbt069
   He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509
   Horst D, 2012, CANCER RES, V72, P1547, DOI 10.1158/0008-5472.CAN-11-3222
   Hu Y, 2015, INT J MOL SCI, V16, P1928, DOI 10.3390/ijms16011928
   Huang B, 2009, MOL CELL BIOL, V29, P1375, DOI 10.1128/MCB.01365-08
   Hung KE, 2010, P NATL ACAD SCI USA, V107, P1565, DOI 10.1073/pnas.0908682107
   Janssen KP, 2006, GASTROENTEROLOGY, V131, P1096, DOI 10.1053/j.gastro.2006.08.011
   Julien S, 2012, CLIN CANCER RES, V18, P5314, DOI 10.1158/1078-0432.CCR-12-0372
   Kim IJ, 2003, CLIN CANCER RES, V9, P2920
   Knoechel B, 2014, NAT GENET, V46, P364, DOI 10.1038/ng.2913
   Lemieux E, 2015, ONCOGENE, V34, P4914, DOI 10.1038/onc.2014.416
   McCleland ML, 2016, J CLIN INVEST, V126, P639, DOI 10.1172/JCI83265
   Mertz JA, 2011, P NATL ACAD SCI USA, V108, P16669, DOI 10.1073/pnas.1108190108
   Mologni L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051449
   Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252
   Okamoto K, 2015, MOL CANCER RES, V13, P659, DOI 10.1158/1541-7786.MCR-14-0476
   Puissant A, 2013, CANCER DISCOV, V3, P308, DOI 10.1158/2159-8290.CD-12-0418
   Rathert P, 2015, NATURE, V525, P543, DOI 10.1038/nature14898
   Roberts AW, 2016, NEW ENGL J MED, V374, P311, DOI 10.1056/NEJMoa1513257
   Roberts AW, 2012, J CLIN ONCOL, V30, P488, DOI 10.1200/JCO.2011.34.7898
   Sansom OJ, 2007, NATURE, V446, P676, DOI 10.1038/nature05674
   Sears R, 2000, GENE DEV, V14, P2501, DOI 10.1101/gad.836800
   Shi J, 2014, CANCER CELL, V25, P210, DOI 10.1016/j.ccr.2014.01.028
   Shimamura T, 2013, CLIN CANCER RES, V19, P6183, DOI 10.1158/1078-0432.CCR-12-3904
   Shu SK, 2016, NATURE, V529, P413, DOI 10.1038/nature16508
   Singh A, 2012, CELL, V148, P639, DOI 10.1016/j.cell.2011.12.033
   Spreafico A, 2013, CLIN CANCER RES, V19, P4149, DOI 10.1158/1078-0432.CCR-12-3140
   Stratikopoulos EE, 2015, CANCER CELL, V27, P837, DOI 10.1016/j.ccell.2015.05.006
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Sun C, 2014, CELL REP, V7, P86, DOI 10.1016/j.celrep.2014.02.045
   Tang YJ, 2014, NAT MED, V20, P732, DOI 10.1038/nm.3613
   Tögel L, 2016, MOL CANCER THER, V15, P1217, DOI 10.1158/1535-7163.MCT-15-0724
   Toon CW, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087456
   Trapnell C, 2012, NAT PROTOC, V7, P562, DOI 10.1038/nprot.2012.016
   Tripathi MK, 2014, CANCER RES, V74, P6947, DOI 10.1158/0008-5472.CAN-14-1592
   Whitehead RH, 2009, AM J PHYSIOL-GASTR L, V296, pG455, DOI 10.1152/ajpgi.90381.2008
   Zuber J, 2011, NATURE, V478, P524, DOI 10.1038/nature10334
NR 53
TC 53
Z9 54
U1 0
U2 16
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
EI 1557-3265
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD APR 15
PY 2017
VL 23
IS 8
BP 2027
EP 2037
DI 10.1158/1078-0432.CCR-16-0453
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA ES0AM
UT WOS:000399188300019
PM 27678457
OA Green Accepted, Green Submitted
DA 2025-01-12
ER

PT J
AU Mameri, H
   Bièche, I
   Meseure, D
   Marangoni, E
   Buhagiar-Labarchède, G
   Nicolas, A
   Vacher, S
   Onclercq-Delic, R
   Rajapakse, V
   Varma, S
   Reinhold, WC
   Pommier, Y
   Amor-Guéret, M
AF Mameri, Hamza
   Bieche, Ivan
   Meseure, Didier
   Marangoni, Elisabetta
   Buhagiar-Labarchede, Geraldine
   Nicolas, Andre
   Vacher, Sophie
   Onclercq-Delic, Rosine
   Rajapakse, Vinodh
   Varma, Sudhir
   Reinhold, William C.
   Pommier, Yves
   Amor-Gueret, Mounira
TI Cytidine Deaminase Deficiency Reveals New Therapeutic Opportunities
   against Cancer
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID SINGLE-NUCLEOTIDE POLYMORPHISM; ARYL-HYDROCARBON RECEPTOR; ACUTE
   MYELOID-LEUKEMIA; BREAST-CANCER; CYTOSINE-ARABINOSIDE; AMINOFLAVONE
   NSC-686288; CONFERS RESISTANCE; AID/APOBEC FAMILY; ANTICANCER AGENT;
   GEMCITABINE
AB Purpose: One of the main challenges in cancer therapy is the identification of molecular mechanisms mediating resistance or sensitivity to treatment. Cytidine deaminase (CDA) was reported to be downregulated in cells derived from patients with Bloom syndrome, a genetic disease associated with a strong predisposition to a wide range of cancers. The purpose of this study was to determine whether CDA deficiency could be associated with tumors from the general population and could constitute a predictive marker of susceptibility to antitumor drugs.
   Experimental Design: We analyzed CDA expression in silico, in large datasets for cancer cell lines and tumors and in various cancer cell lines and primary tumor tissues using IHC, PDXs, qRT-PCR, and Western blotting. We also studied the mechanism underlying CDA silencing and searched for molecules that might target specifically CDA-deficient tumor cells using in silico analysis coupled to classical cellular experimental approaches.
   Results: We found that CDA expression is downregulated in about 60% of cancer cells and tissues. We demonstrate that DNA methylation is a prevalent mechanism of CDA silencing in tumors. Finally, we show that CDA-deficient tumor cells can be specifically targeted with epigenetic treatments and with the anticancer drug aminoflavone.
   Conclusions: CDA expression status identifies new subgroups of cancers, and CDA deficiency appears to be a novel and relevant predictive marker of susceptibility to antitumor drugs, opening up new possibilities for treating cancer. (C) 2016 AACR.
C1 [Mameri, Hamza; Buhagiar-Labarchede, Geraldine; Onclercq-Delic, Rosine; Amor-Gueret, Mounira] PSL Res Univ, Inst Curie, UMR 3348, F-91405 Orsay, France.
   [Mameri, Hamza; Buhagiar-Labarchede, Geraldine; Onclercq-Delic, Rosine; Amor-Gueret, Mounira] Ctr Univ, CNRS UMR 3348, Bat 110, F-91405 Orsay, France.
   [Mameri, Hamza; Buhagiar-Labarchede, Geraldine; Onclercq-Delic, Rosine; Amor-Gueret, Mounira] Univ Paris 11, Univ Paris Saclay, UMR 3348, F-91405 Orsay, France.
   [Bieche, Ivan; Vacher, Sophie] Inst Curie, Genet Dept, 26 Rue Ulm, F-75005 Paris, France.
   [Meseure, Didier; Nicolas, Andre] Inst Curie, Platform Invest Pathol, 26 Rue Ulm, F-75005 Paris, France.
   [Marangoni, Elisabetta] PSL Res Univ, Translat Res Dept, Inst Curie, 26 Rue Ulm, F-75005 Paris, France.
   [Nicolas, Andre; Rajapakse, Vinodh; Varma, Sudhir; Reinhold, William C.; Pommier, Yves] NCI, Dev Therapeut Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.
   [Nicolas, Andre; Rajapakse, Vinodh; Varma, Sudhir; Reinhold, William C.; Pommier, Yves] NCI, Lab Mol Pharmacol, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.
C3 Centre National de la Recherche Scientifique (CNRS); CNRS - National
   Institute for Biology (INSB); Universite PSL; UNICANCER; Institut Curie;
   Universite Paris Saclay; Centre National de la Recherche Scientifique
   (CNRS); CNRS - National Institute for Biology (INSB); Universite Paris
   Saclay; Universite Paris Saclay; Centre National de la Recherche
   Scientifique (CNRS); CNRS - National Institute for Biology (INSB);
   Universite PSL; UNICANCER; Institut Curie; UNICANCER; Universite PSL;
   Institut Curie; UNICANCER; Universite PSL; Institut Curie; UNICANCER;
   Universite PSL; Institut Curie; National Institutes of Health (NIH) -
   USA; NIH National Cancer Institute (NCI); National Institutes of Health
   (NIH) - USA; NIH National Cancer Institute (NCI)
RP Amor-Guéret, M (通讯作者)，Ctr Univ, Inst Curie, Bat 110, F-91405 Orsay, France.
EM mounira.amor@curie.fr
RI Pommier, Yves/L-2169-2016; Marangoni, Elisabetta/GSO-3945-2022; Varma,
   Sudhir/N-8763-2014; Bieche, Ivan/O-7399-2017; Reinhold,
   William/J-6704-2017
OI Varma, Sudhir/0000-0002-4096-4782; Bieche, Ivan/0000-0002-2430-5429;
   Marangoni, Elisabetta/0000-0002-3337-6448; Meseure,
   Didier/0000-0001-6730-6686; Rajapakse, Vinodh/0000-0002-5214-1089;
   Mameri, Hamza/0000-0001-7762-9542; VACHER, Sophie/0000-0002-0042-6023;
   Reinhold, William/0000-0001-5513-9323
FU Curie Institute; CNRS; Canceropole Ile de France; Ligue Nationale contre
   le Cancer (Comite de l'Essonne); Association pour la Recherche sur le
   Cancer; Agence Nationale de la Recherche; Center for Cancer Research [BC
   006161]; Intramural Program of the NCI, NIH
FX This work was supported by the Curie Institute (Translational Cancer
   Research grant 2014 and PICSysBio), CNRS, Canceropole Ile de France,
   Ligue Nationale contre le Cancer (Comite de l'Essonne), the Association
   pour la Recherche sur le Cancer, the Agence Nationale de la Recherche,
   and the Center for Cancer Research (BC 006161), the Intramural Program
   of the NCI, NIH. H. Mameri was supported by a postdoctoral fellowship
   from Canceropole Ile de France and Association pour la Recherche sur le
   Cancer.
CR Abraham A, 2012, PHARMACOGENOMICS, V13, P269, DOI [10.2217/PGS.11.149, 10.2217/pgs.11.149]
   [Anonymous], BROAD NOV CANC CELL
   [Anonymous], GENT GEN EXPR NORM T
   [Anonymous], CANC GEN ATL
   [Anonymous], **NON-TRADITIONAL**
   [Anonymous], FIREBROWSE
   [Anonymous], CELLMINER AN TOOLS
   [Anonymous], CELL LIN INF
   Baldeyron C, 2015, MOL ONCOL, V9, P1580, DOI 10.1016/j.molonc.2015.04.010
   BENHURA MAN, 1985, COMP BIOCHEM PHYS B, V80, P821, DOI 10.1016/0305-0491(85)90468-7
   Bhatla D, 2009, BRIT J HAEMATOL, V144, P388, DOI 10.1111/j.1365-2141.2008.07461.x
   Broad Institute TCGA Genome Data Analysis Center, 2016, AN READ STAND TCGA D
   CACCIAMANI T, 1991, ARCH BIOCHEM BIOPHYS, V290, P285, DOI 10.1016/0003-9861(91)90543-R
   Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095
   Chabosseau P, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1363
   Chen ZL, 2016, CANCER LETT, V370, P153, DOI 10.1016/j.canlet.2015.10.010
   Christman JK, 2002, ONCOGENE, V21, P5483, DOI 10.1038/sj.onc.1205699
   Ciccolini J, 2010, J CLIN ONCOL, V28, P160, DOI 10.1200/JCO.2009.24.4491
   Conticello SG, 2005, MOL BIOL EVOL, V22, P367, DOI 10.1093/molbev/msi026
   Conticello SG, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-6-229
   Demontis S, 1998, BBA-GENE STRUCT EXPR, V1443, P323, DOI 10.1016/S0167-4781(98)00235-8
   den Boon JA, 2015, P NATL ACAD SCI USA, V112, pE3255, DOI 10.1073/pnas.1509322112
   Farrell JJ, 2012, PHARMACOGENOMICS J, V12, P395, DOI 10.1038/tpj.2011.22
   Fitzgerald SM, 2006, HUM GENET, V119, P276, DOI 10.1007/s00439-006-0142-0
   Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088
   Gemble S, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005384
   Gentien D, BREAST CANC CELL LIN
   Gilbert JA, 2006, CLIN CANCER RES, V12, P1794, DOI 10.1158/1078-0432.CCR-05-1969
   Helleday T, 2015, NEW ENGL J MED, V373, P1570, DOI 10.1056/NEJMcibr1510335
   Loaiza-Pérez AI, 2004, MOL CANCER THER, V3, P715
   Lorenzi PL, 2009, MOL CANCER THER, V8, P713, DOI 10.1158/1535-7163.MCT-08-0921
   Mahfouz RZ, 2013, CLIN CANCER RES, V19, P938, DOI 10.1158/1078-0432.CCR-12-1722
   Mahlknecht U, 2009, LEUKEMIA, V23, P1929, DOI 10.1038/leu.2009.113
   Marangoni E, 2007, CLIN CANCER RES, V13, P3989, DOI 10.1158/1078-0432.CCR-07-0078
   McLean L, 2008, INT J CANCER, V122, P1665, DOI 10.1002/ijc.23244
   Meng LH, 2007, ONCOGENE, V26, P4806, DOI 10.1038/sj.onc.1210283
   Meng LH, 2005, CANCER RES, V65, P5337, DOI 10.1158/0008-5472.CAN-05-0003
   Meng LH, 2006, CANCER RES, V66, P9656, DOI 10.1158/0008-5472.CAN-06-0796
   Monzo M, 2006, BLOOD, V107, P4871, DOI 10.1182/blood-2005-08-3272
   Neff T, 1996, EXP HEMATOL, V24, P1340
   Nogales V, 2016, ONCOTARGET, V7, P3084, DOI 10.18632/oncotarget.6413
   Okazaki T, 2010, CLIN CANCER RES, V16, P320, DOI 10.1158/1078-0432.CCR-09-1555
   Reinhold WC, 2015, CLIN CANCER RES, V21, P3841, DOI 10.1158/1078-0432.CCR-15-0335
   Samulitis BK, 2015, CANCER BIOL THER, V16, P43, DOI 10.4161/15384047.2014.986967
   Serdjebi C, 2015, EXPERT OPIN DRUG MET, V11, P665, DOI 10.1517/17425255.2015.985648
   Shin G, 2011, CANCER INFORM, V10, P149, DOI 10.4137/CIN.S7226
   Stark K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074525
   Sugiyama E, 2007, J CLIN ONCOL, V25, P32, DOI 10.1200/JCO.2006.06.7405
   Terzuoli E, 2010, CANCER RES, V70, P6837, DOI 10.1158/0008-5472.CAN-10-1075
   Weizman N, 2014, ONCOGENE, V33, P3812, DOI 10.1038/onc.2013.357
   Ye FG, 2015, CANCER RES, V75, P1504, DOI 10.1158/0008-5472.CAN-14-2341
   Yoshida T, 2010, DRUG METAB DISPOS, V38, P1814, DOI 10.1124/dmd.110.034397
   Yue LJ, 2003, PHARMACOGENETICS, V13, P29, DOI 10.1097/00008571-200301000-00005
   Zauri M, 2015, NATURE, V524, P114, DOI 10.1038/nature14948
NR 54
TC 29
Z9 31
U1 1
U2 6
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
EI 1557-3265
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD APR 15
PY 2017
VL 23
IS 8
BP 2116
EP 2126
DI 10.1158/1078-0432.CCR-16-0626
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA ES0AM
UT WOS:000399188300027
PM 27601591
OA Green Submitted, Green Accepted
DA 2025-01-12
ER

PT J
AU Chang, YW
   Singh, KP
AF Chang, Yu-Wei
   Singh, Kamaleshwar P.
TI Long-term exposure to estrogen enhances chemotherapeutic efficacy
   potentially through epigenetic mechanism in human breast cancer cells
SO PLOS ONE
LA English
DT Article
ID TOPOISOMERASE-II-ALPHA; DNA MISMATCH REPAIR; CYCLE ARREST; RESISTANCE;
   DOXORUBICIN; DAMAGE; GROWTH; COMBINATION; EXPRESSION; INHIBITOR
AB Chemotherapy is the most common clinical option for treatment of breast cancer. However, the efficacy of chemotherapy depends on the age of breast cancer patients. Breast tissues are estrogen responsive and the levels of ovarian estrogen vary among the breast cancer patients primarily between pre- and post-menopausal age. Whether this age-dependent variation in estrogen levels influences the chemotherapeutic efficacy in breast cancer patients is not known. Therefore, the objective of this study was to evaluate the effects of natural estrogen 17 beta-estradiol (E2) on the efficacy of chemotherapeutic drugs in breast cancer cells. Estrogen responsive MCF-7 and T47D breast cancer cells were long-term exposed to 100 pg/ml estrogen, and using these cells the efficacy of chemotherapeutic drugs doxorubicin and cisplatin were determined. The result of cell viability and cell cycle analysis revealed increased sensitivities of doxorubicin and cisplatin in estrogen-exposed MCF-7 and T47D cells as compared to their respective control cells. Gene expression analysis of cell cycle, anti-apoptosis, DNA repair, and drug transporter genes further confirmed the increased efficacy of chemotherapeutic drugs in estrogen-exposed cells at molecular level. To further understand the role of epigenetic mechanism in enhanced chemotherapeutic efficacy by estrogen, cells were pre-treated with epigenetic drugs, 5-aza-2-deoxycytidine and Trichostatin A prior to doxorubicin and cisplatin treatments. The 5-aza-2 deoxycytidine pre-treatment significantly decreased the estrogen-induced efficacy of doxorubicin and cisplatin, suggesting the role of estrogen-induced hypermethylation in enhanced sensitivity of these drugs in estrogen-exposed cells. In summary, the results of this study revealed that sensitivity to chemotherapy depends on the levels of estrogen in breast cancer cells. Findings of this study will have clinical implications in selecting the chemotherapy strategies for treatment of breast cancer patients depending on the serum estrogen levels that varies among pre- and post-menopausal age of the patients.
C1 [Chang, Yu-Wei; Singh, Kamaleshwar P.] Texas Tech Univ, Dept Environm Toxicol, Inst Environm & Human Hlth TIEHH, Lubbock, TX 79409 USA.
C3 Texas Tech University System; Texas Tech University
RP Singh, KP (通讯作者)，Texas Tech Univ, Dept Environm Toxicol, Inst Environm & Human Hlth TIEHH, Lubbock, TX 79409 USA.
EM Kamaleshwar.singh@ttu.edu
RI Singh, Kamaleshwar/AAE-9166-2020
CR Abe O, 1998, LANCET, V352, P930
   Aebi S, 1996, CANCER RES, V56, P3087
   Alami N, 2007, BRIT J CANCER, V97, P58, DOI 10.1038/sj.bjc.6603829
   [Anonymous], 1983, Lancet, V1, P257
   [Anonymous], 1988, NEW ENGL J MED, V319, P1681
   [Anonymous], 1992, Lancet, V339, P1
   Aquilina G, 1999, CARCINOGENESIS, V20, P2317, DOI 10.1093/carcin/20.12.2317
   Bachelot T, 2012, J CLIN ONCOL, V30, P2718, DOI 10.1200/JCO.2011.39.0708
   Barrios CH, 2009, ANN ONCOL, V20, P1157, DOI 10.1093/annonc/mdn756
   BAUM M, 1983, LANCET, V2, P450
   Blackwell KL, 2010, J CLIN ONCOL, V28, P1124, DOI 10.1200/JCO.2008.21.4437
   Bravard A, 2006, MOL CELL BIOL, V26, P7430, DOI 10.1128/MCB.00624-06
   Burgess DJ, 2008, P NATL ACAD SCI USA, V105, P9053, DOI 10.1073/pnas.0803513105
   Caldoe CE, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00106
   CHALBOS D, 1982, J CLIN ENDOCR METAB, V55, P276, DOI 10.1210/jcem-55-2-276
   Chan KS, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.148
   Chen T, 2015, ONCOGENE, V34, P4019, DOI 10.1038/onc.2014.332
   Cole BF, 2001, LANCET, V358, P277, DOI 10.1016/S0140-6736(01)05483-6
   Cummings SR, 1998, NEW ENGL J MED, V339, P733, DOI 10.1056/NEJM199809103391104
   Dai XF, 2015, AM J CANCER RES, V5, P2929
   DOWNES CS, 1994, NATURE, V372, P467, DOI 10.1038/372467a0
   Elmlinger MW, 2002, CLIN CHEM LAB MED, V40, P1151, DOI 10.1515/CCLM.2002.202
   Felty Q, 2005, ONCOGENE, V24, P4883, DOI 10.1038/sj.onc.1208667
   Finn RS, 2015, LANCET ONCOL, V16, P25, DOI 10.1016/S1470-2045(14)71159-3
   Florea Ana-Maria, 2011, Cancers (Basel), V3, P1351, DOI 10.3390/cancers3011351
   Goswami PC, 1996, MOL CELL BIOL, V16, P1500
   Hsu MS, 2010, ANN SURG ONCOL, V17, P760, DOI 10.1245/s10434-009-0802-0
   Hsu PY, 2010, GENOME RES, V20, P733, DOI 10.1101/gr.101923.109
   Järvinen TAH, 2000, AM J PATHOL, V156, P839, DOI 10.1016/S0002-9440(10)64952-8
   Jiricny J, 2006, NAT REV MOL CELL BIO, V7, P335, DOI 10.1038/nrm1907
   Kim H, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0589-7
   Kim WJ, 2007, J BIOL CHEM, V282, P32021, DOI 10.1074/jbc.M701451200
   Leslie EM, 2005, TOXICOL APPL PHARM, V204, P216, DOI 10.1016/j.taap.2004.10.012
   Liang J, 2013, ANNU REV PHYSIOL, V75, P225, DOI 10.1146/annurev-physiol-030212-183708
   Lin DP, 2004, CANCER RES, V64, P517, DOI 10.1158/0008-5472.CAN-03-2957
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Miller WR, 2007, BREAST CANCER RES TR, V103, P149, DOI 10.1007/s10549-006-9369-7
   Mjelle R, 2015, DNA REPAIR, V30, P53, DOI 10.1016/j.dnarep.2015.03.007
   Mobley JA, 2004, CARCINOGENESIS, V25, P3, DOI 10.1093/carcin/bgg175
   Muss HB, 2011, ONCOLOGIST, V16, P79, DOI 10.1634/theoncologist.2011-S1-79
   Nitiss JL, 2009, NAT REV CANCER, V9, P338, DOI 10.1038/nrc2607
   O'Brien V, 2006, CARCINOGENESIS, V27, P682, DOI 10.1093/carcin/bgi298
   Pabla N, 2011, J BIOL CHEM, V286, P10411, DOI 10.1074/jbc.M110.210989
   Papouli E, 2004, CANCER RES, V64, P3391, DOI 10.1158/0008-5472.CAN-04-0513
   Pichot CS, 2009, BRIT J CANCER, V101, P38, DOI 10.1038/sj.bjc.6605101
   Prouillac C, 2009, TOXICOLOGY, V263, P100, DOI 10.1016/j.tox.2009.06.023
   Qian YM, 2001, J BIOL CHEM, V276, P6404, DOI 10.1074/jbc.M008251200
   Raftogianis R, 2000, J Natl Cancer Inst Monogr, P113
   Ricci MS, 2006, ONCOLOGIST, V11, P342, DOI 10.1634/theoncologist.11-4-342
   Rossi A, 2005, CURR MED CHEM, V12, P297, DOI 10.2174/0929867053363261
   Russo J, 2006, J STEROID BIOCHEM, V102, P89, DOI 10.1016/j.jsbmb.2006.09.004
   SCHOBER C, 1994, BIOCHEM PHARMACOL, V48, P997, DOI 10.1016/0006-2952(94)90370-0
   Shen DW, 2012, PHARMACOL REV, V64, P706, DOI 10.1124/pr.111.005637
   Singh B, 2012, CARCINOGENESIS, V33, P2601, DOI 10.1093/carcin/bgs300
   Singh KP, 2012, CANCER LETT, V316, P62, DOI 10.1016/j.canlet.2011.10.022
   Slot AJ, 2008, DRUG METAB DISPOS, V36, P552, DOI 10.1124/dmd.107.019661
   Srikantan S, 2011, MOL CELL BIOL, V31, P3790, DOI 10.1128/MCB.05639-11
   Sugiyama D, 2003, PHARM RES-DORDR, V20, P1394, DOI 10.1023/A:1025749925541
   Taheri M, 2013, DIS MARKERS, V34, P387, DOI 10.1155/2013/728410
   Thorn CF, 2011, PHARMACOGENET GENOM, V21, P440, DOI 10.1097/FPC.0b013e32833ffb56
   Travis RC, 2003, BREAST CANCER RES, V5, P239, DOI 10.1186/bcr628
   Treas JN, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043880
   Verma S, 2012, NEW ENGL J MED, V367, P1783, DOI 10.1056/NEJMoa1209124
   WATT PM, 1994, BIOCHEM J, V303, P681, DOI 10.1042/bj3030681
   Yersal O, 2014, WORLD J CLIN ONCOL, V5, P412, DOI 10.5306/wjco.v5.i3.412
   Zhang FX, 2013, J BIOL CHEM, V288, P11348, DOI 10.1074/jbc.M112.429134
NR 66
TC 9
Z9 10
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAR 21
PY 2017
VL 12
IS 3
AR e0174227
DI 10.1371/journal.pone.0174227
PG 16
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA ER8RG
UT WOS:000399089000076
PM 28323900
OA Green Published, gold, Green Submitted
DA 2025-01-12
ER

PT J
AU Ejarque, M
   Ceperuelo-Mallafré, V
   Serena, C
   Pachón, G
   Núñez-Alvarez, Y
   Terrón-Puig, M
   Calvo, E
   Núñez-Roa, C
   Oliva-Olivera, W
   Tinahones, FJ
   Peinado, MA
   Vendrell, J
   Fernández-Veledo, S
AF Ejarque, Miriam
   Ceperuelo-Mallafre, Victoria
   Serena, Carolina
   Pachon, Gisela
   Nunez-Alvarez, Yaiza
   Terron-Puig, Margarida
   Calvo, Enrique
   Nunez-Roa, Catalina
   Oliva-Olivera, Wilfredo
   Tinahones, Francisco J.
   Angel Peinado, Miguel
   Vendrell, Joan
   Fernandez-Veledo, Sonia
TI Survivin, a key player in cancer progression, increases in obesity and
   protects adipose tissue stem cells from apoptosis
SO CELL DEATH & DISEASE
LA English
DT Article
ID INSULIN-RESISTANCE; DNA METHYLATION; BREAST-CANCER; BODY-WEIGHT; LEPTIN;
   PROLIFERATION; INFLAMMATION; ADIPOCYTES; PATHWAY; CYCLOHEXIMIDE
AB Adipose tissue (AT) has a central role in obesity-related metabolic imbalance through the dysregulated production of cytokines and adipokines. In addition to its known risk for cardiovascular disease and diabetes, obesity is also a major risk for cancer. We investigated the impact of obesity for the expression of survivin, an antiapoptotic protein upregulated by adipokines and a diagnostic biomarker of tumor onset and recurrence. In a cross-sectional study of 111 subjects classified by body mass index, circulating levels of survivin and gene expression in subcutaneous AT were significantly higher in obese patients and positively correlated with leptin. Within AT, survivin was primarily detected in human adipocyte-derived stem cells (hASCs), the adipocyte precursors that determine AT expansion. Remarkably, survivin expression was significantly higher in hASCs isolated from obese patients that from lean controls and was increased by proinflammatory M1 macrophage soluble factors including IL-1 beta. Analysis of survivin expression in hASCs revealed a complex regulation including epigenetic modifications and protein stability. Surprisingly, obese hASCs showed survivin promoter hypermethylation that correlated with a significant decrease in its mRNA levels. Nonetheless, a lower level of mir-203, which inhibits survivin protein translation, and higher protein stability, was found in obese hASCs compared with their lean counterparts. We discovered that survivin levels determine the susceptibility of hASCs to apoptotic stimuli (including leptin and hypoxia). Accordingly, hASCs from an obese setting were protected from apoptosis. Collectively, these data shed new light on the molecular mechanisms governing AT expansion in obesity through promotion of hASCs that are resistant to apoptosis, and point to survivin as a potential new molecular player in the communication between AT and tumor cells. Thus, inhibition of apoptosis targeting survivin might represent an effective strategy for both obesity and cancer therapy.
C1 [Ejarque, Miriam; Ceperuelo-Mallafre, Victoria; Serena, Carolina; Terron-Puig, Margarida; Calvo, Enrique; Nunez-Roa, Catalina; Vendrell, Joan; Fernandez-Veledo, Sonia] Univ Rovira & Virgili, Hosp Univ Tarragona Joan 23, Inst Invest Sanitaria Pere Virgili, Tarragona, Spain.
   [Ejarque, Miriam; Ceperuelo-Mallafre, Victoria; Serena, Carolina; Pachon, Gisela; Calvo, Enrique; Nunez-Roa, Catalina; Vendrell, Joan; Fernandez-Veledo, Sonia] Inst Salud Carlos III, CIBER Diabet Enfermedades Metabol Asociadas, Madrid, Spain.
   [Pachon, Gisela] Harvard Med Sch, Brigham & Womens Hosp, Program Excellence Glycosci, Dept Dermatol, Boston, MA USA.
   [Pachon, Gisela] Harvard Med Sch, Brigham & Womens Hosp, Program Excellence Glycosci, Dept Med, Boston, MA USA.
   [Nunez-Alvarez, Yaiza; Angel Peinado, Miguel] Inst Predict & Personalized Med Canc, Hlth Sci Res Inst Germans Trias & Pujol, Badalona, Spain.
   [Oliva-Olivera, Wilfredo; Tinahones, Francisco J.] Inst Salud Carlos III, CIBER Fisiopatol Obesidad & Nutr, Madrid, Spain.
   [Oliva-Olivera, Wilfredo; Tinahones, Francisco J.] Univ Hosp, Virgen Victoria Clin, Lab Biomed Res, Malaga, Spain.
C3 Universitat Rovira i Virgili; Institut d'Investigacio Sanitaria Pere
   Virgili (IISPV); CIBER - Centro de Investigacion Biomedica en Red;
   CIBERDEM; Instituto de Salud Carlos III; Harvard University; Harvard
   Medical School; Brigham & Women's Hospital; Harvard University; Brigham
   & Women's Hospital; Harvard Medical School; CIBER - Centro de
   Investigacion Biomedica en Red; CIBEROBN; Instituto de Salud Carlos III
RP Vendrell, J; Fernández-Veledo, S (通讯作者)，Univ Hosp Tarragona Joan XXIII, Pere Virgili Res Unit, Endocrinol, Dr Mallafre Guasch 4, Tarragona 43007, Spain.
EM jvo@comt.es; sonia.fernandezveledo@gmail.com
RI Tinahones, Francisco/AAB-2882-2020; Peinado, Miguel A./A-5591-2008;
   Oliva-Olivera, Wilfredo/GSN-7320-2022; Ceperuelo Mallafre,
   Victoria/A-4615-2017; Fernandez-Veledo, Sonia/V-4625-2018; Ejarque,
   Miriam/H-1503-2015; Calvo, Enrique/K-8680-2014; Serena,
   Carolina/J-5687-2014
OI Ceperuelo Mallafre, Victoria/0000-0002-4460-9761; Fernandez-Veledo,
   Sonia/0000-0003-2906-3788; Tinahones, Francisco J/0000-0001-6871-4403;
   Terron Puig, Margarida Maria/0000-0002-1779-0016; Peinado, Miguel
   A./0000-0002-4090-793X; Ejarque, Miriam/0000-0003-0545-9817; Calvo,
   Enrique/0000-0002-2468-0931; Serena, Carolina/0000-0003-2251-0856; Oliva
   Olivera, Wilfredo/0000-0003-3473-7898
FU Spanish Ministry of Economy and Competitiveness; European Regional
   Development Fund (ERDF) [PI14/00228, SAF2015-65019R]; Fondo de
   Investigacion Sanitaria (FIS) [CP10/00438, CPII16/00008]; ERDF
FX The Simpson-Golabi-Behmel Syndrome (SGBS) preadipocyte cell line was
   kindly provided by Dr. Wabitsch (University of Ulm, Germany) and was
   used as a cellular model of human subcutaneous adipocytes. Adenoviruses
   expressing wild type or dominant-negative survivin were kindly provided
   by Dr. Altieri (Wistar Institute). This study was supported by grants
   from the Spanish Ministry of Economy and Competitiveness and the
   European Regional Development Fund (ERDF) (JV: PI14/00228; SF-V:
   SAF2015-65019R). The Spanish Biomedical Research Center in Diabetes and
   Associated Metabolic Disorders (CIBERdem) (CB07708/0012) an initiative
   of the Instituto de Salud Carlos III. SF-V acknowledges support from the
   Miguel Servet ternure-track program (CP10/00438 and CPII16/00008) from
   the Fondo de Investigacion Sanitaria (FIS) co-financed by the ERDF. JV
   and SF-V are the guarantors of this work.
CR Alkhouri N, 2010, J BIOL CHEM, V285, P3428, DOI 10.1074/jbc.M109.074252
   Altieri DC, 2008, NAT REV CANCER, V8, P61, DOI 10.1038/nrc2293
   Altieri DC, 2015, SEMIN CELL DEV BIOL, V39, P91, DOI 10.1016/j.semcdb.2014.12.007
   Altieri DC, 2013, CANCER LETT, V332, P225, DOI 10.1016/j.canlet.2012.03.005
   Ambati S, 2007, BIOCHEM PHARMACOL, V73, P378, DOI 10.1016/j.bcp.2006.10.009
   Anastasiou CA, 2015, METABOLISM, V64, P1395, DOI 10.1016/j.metabol.2015.08.006
   Apovian CM, 2013, AM J MANAG CARE, V19, pS219
   Bernardi S, 2012, CLIN SCI, V123, P547, DOI 10.1042/CS20120176
   Berry R, 2014, CELL METAB, V19, P8, DOI 10.1016/j.cmet.2013.10.003
   Bikov A, 2014, REPROD BIOL ENDOCRIN, V12, DOI 10.1186/1477-7827-12-93
   Bokarewa M, 2005, ARTHRITIS RES THER, V7, pR349, DOI 10.1186/ar1498
   Ceperuelo-Mallafré V, 2014, J CLIN ENDOCR METAB, V99, pE908, DOI 10.1210/jc.2013-3350
   Chatzigeorgiou A, 2012, DIABETOLOGIA, V55, P2583, DOI 10.1007/s00125-012-2607-0
   Clark SJ, 2006, NAT PROTOC, V1, P2353, DOI 10.1038/nprot.2006.324
   Dalmas E, 2015, NAT MED, V21, P610, DOI 10.1038/nm.3829
   Della-Fera MA, 2003, BIOCHEM BIOPH RES CO, V303, P1053, DOI 10.1016/S0006-291X(03)00474-1
   Dong H, 2015, WORLD J SURG ONCOL, V13, DOI 10.1186/s12957-015-0605-7
   Donohoe CL, 2017, TRENDS ENDOCRIN MET, V28, P46, DOI 10.1016/j.tem.2016.08.004
   Fischer-Posovszky P, 2011, ENDOCRINOLOGY, V152, P3074, DOI 10.1210/en.2011-1031
   Friedman JM, 1998, NUTR REV, V56, pS38
   Fukuda S, 2004, BLOOD, V103, P120, DOI 10.1182/blood-2003-05-1756
   Fukuda S, 2002, BLOOD, V100, P2463, DOI 10.1182/blood.V100.7.2463
   Fukuda S, 2006, MOL CANCER THER, V5, P1087, DOI 10.1158/1535-7163.MCT-05-0375
   Galeotti L, 2008, CLIN EXP RHEUMATOL, V26, P373
   Garofalo C, 2006, J CELL PHYSIOL, V207, P12, DOI 10.1002/jcp.20472
   Giordano C, 2016, SCI REP-UK, V6, DOI 10.1038/srep21782
   Gullicksen PS, 2003, APOPTOSIS, V8, P327, DOI 10.1023/A:1024112716024
   Gullicksen PS, 2003, INT J OBESITY, V27, P302, DOI 10.1038/sj.ijo.0802205
   Gurbuxani S, 2005, P NATL ACAD SCI USA, V102, P11480, DOI 10.1073/pnas.0500303102
   Huang JC, 2015, AM J CANCER RES, V5, P20
   Ilmer M, 2014, FASEB J, V28, P2748, DOI 10.1096/fj.13-244640
   Jane EP, 2013, MOL CANCER THER, V12, P326, DOI 10.1158/1535-7163.MCT-12-0901
   Jiang Yuling, 2008, Sheng Wu Gong Cheng Xue Bao, V24, P1216
   Tinahones FJ, 2013, DIABETES CARE, V36, P513, DOI 10.2337/dc12-0194
   Jutzy JMS, 2013, CANCER MICROENVIRON, V6, P57, DOI 10.1007/s12307-012-0096-9
   Khan SU, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042689
   Khan S, 2015, BIOL-TARGETS THER, V9, P57, DOI 10.2147/BTT.S83864
   Khan S, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-176
   Knight BB, 2011, ENDOCR-RELAT CANCER, V18, P413, DOI 10.1530/ERC-11-0075
   Kolb R, 2016, CURR OPIN PHARMACOL, V29, P77, DOI 10.1016/j.coph.2016.07.005
   Kreuz S, 2001, MOL CELL BIOL, V21, P3964, DOI 10.1128/MCB.21.12.3964-3973.2001
   Löfgren P, 2005, J CLIN ENDOCR METAB, V90, P6207, DOI 10.1210/jc.2005-0596
   Mera S, 2008, J LEUKOCYTE BIOL, V83, P149, DOI 10.1189/jlb.0507287
   Mesri M, 2001, J CLIN INVEST, V108, P981, DOI 10.1172/JCI200112983
   Mobahat M, 2014, INT J MOL SCI, V15, P2494, DOI 10.3390/ijms15022494
   Nabilsi NH, 2009, ONCOGENE, V28, P2046, DOI 10.1038/onc.2009.62
   Oksvold MP, 2012, FEBS LETT, V586, P3575, DOI 10.1016/j.febslet.2012.08.022
   Oliva-Olivera W, 2015, ENDOCRINOLOGY, V156, P4492, DOI 10.1210/en.2015-1413
   Oñate B, 2012, FASEB J, V26, P4327, DOI 10.1096/fj.12-207217
   Pachón-Peña G, 2016, STEM CELL TRANSL MED, V5, P464, DOI 10.5966/sctm.2015-0161
   Palianopoulou M, 2011, EXP BIOL MED, V236, P70, DOI 10.1258/ebm.2010.010224
   Patterson Kate, 2011, J Vis Exp, DOI 10.3791/3170
   Pérez LM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123397
   Qian H, 1998, ENDOCRINOLOGY, V139, P791, DOI 10.1210/en.139.2.791
   Rodríguez A, 2015, AM J PHYSIOL-ENDOC M, V309, pE691, DOI 10.1152/ajpendo.00297.2015
   Sassmann-Schweda A, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.81175
   Serena C, 2016, STEM CELLS, V34, P2559, DOI 10.1002/stem.2429
   Serena C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0119102
   Spalding KL, 2008, NATURE, V453, P783, DOI 10.1038/nature06902
   Teoh SL, 2016, TUMOR BIOL, V37, P14363, DOI 10.1007/s13277-016-5357-7
   Trayhurn P, 2013, PHYSIOL REV, V93, P1, DOI 10.1152/physrev.00017.2012
   Wang QH, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013393
   Wang ZX, 2004, ONCOGENE, V23, P8146, DOI 10.1038/sj.onc.1207992
   Yu XF, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-29
   Zhang DD, 2005, J BIOL CHEM, V280, P30091, DOI 10.1074/jbc.M501279200
   Zhao J, 2000, J CELL SCI, V113, P4363
NR 66
TC 26
Z9 26
U1 0
U2 14
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-4889
J9 CELL DEATH DIS
JI Cell Death Dis.
PD MAY
PY 2017
VL 8
AR e2802
DI 10.1038/cddis.2017.209
PG 12
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA EW0QG
UT WOS:000402195700060
PM 28518147
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Sung, HY
   Yang, SD
   Ju, W
   Ahn, JH
AF Sung, Hye Youn
   Yang, San-Duk
   Ju, Woong
   Ahn, Jung-Hyuck
TI Aberrant epigenetic regulation of GABRP associates with aggressive
   phenotype of ovarian cancer
SO EXPERIMENTAL AND MOLECULAR MEDICINE
LA English
DT Article
ID GAMMA-AMINOBUTYRIC-ACID; BREAST-CANCER; CELL-MIGRATION; OVEREXPRESSION;
   METASTASIS; METHYLATION; ACTIVATION; EXPRESSION; RECEPTORS; GROWTH
AB Metastasis is a major cause of therapeutic failure in ovarian cancer. To elucidate molecular mechanisms of ovarian cancer metastasis, we previously established a metastatic xenograft mouse model using human ovarian carcinoma SK-OV-3 cells. Using gene expression profiling, we found that gamma-aminobutyric acid (GABA) A receptor pi subunit (GABRP) expression was upregulated (44-fold) in metastatic tissues from our xenograft mice compared with SK-OV-3 cells. Importantly, GABRP knockdown diminished the migration and invasion of SK-OV-3 cells, and reduced extracellular signal-regulated kinase (ERK) activation while overexpression of GABRP exhibited significantly increased cell migration, invasion and ERK activation. Moreover, treatment with the mitogen-activated protein kinase (MAPK)/ERK kinase (MEK) inhibitor U0126 similarly suppressed the migration and invasion of SK-OV-3 cells, implying that GABRP promotes these cellular behaviors by activating the MAPK/ERK pathway. Using genome-wide DNA methylation profiling, we identified hypomethylated CpG sites in the GABRP promoter in metastatic tissues from the xenograft mice compared with SK-OV-3 cells. Treatment with a DNA methyltransferase inhibitor demonstrated that methylation at - 963 bp from the GABRP transcription start site (-963 CpG site) was critical for the epigenetic regulation of GABRP. Finally, we analyzed human ovarian cancer patient samples and showed DNA hypomethylation at the GABRP -963 CpG site in advanced stage, but not early-stage, primary tumors compared with their paired normal tissues. These findings suggest that GABRP enhances the aggressive phenotype of ovarian cancer cells, and that the DNA methylation status of the GABRP -963 CpG site may be useful for predicting the metastatic potential in ovarian cancer patients.
C1 [Sung, Hye Youn; Ahn, Jung-Hyuck] Ewha Womans Univ, Sch Med, Dept Biochem, 911-1 Mok 5 Dong, Seoul 158710, South Korea.
   [Yang, San-Duk] Seoul Natl Univ, Dept Biomed Sci, Coll Med, Seoul, South Korea.
   [Ju, Woong] Ewha Womans Univ, Sch Med, Dept Obstet & Gynecol, 911-1 Mok 5 Dong, Seoul 158710, South Korea.
C3 Ewha Womans University; Seoul National University (SNU); Ewha Womans
   University
RP Ahn, JH (通讯作者)，Ewha Womans Univ, Sch Med, Dept Biochem, 911-1 Mok 5 Dong, Seoul 158710, South Korea.; Ju, W (通讯作者)，Ewha Womans Univ, Sch Med, Dept Obstet & Gynecol, 911-1 Mok 5 Dong, Seoul 158710, South Korea.
EM goodmorning@ewha.ac.kr; ahnj@ewha.ac.kr
RI Yang, San-Duk/GWZ-5491-2022
OI Yang, San-Duk/0000-0002-1276-365X; Ahn, Jung-Hyuck/0000-0001-9589-3881
FU Korean Health Technology R&D Project, Ministry of Health & Welfare,
   Republic of Korea [HI12C0050]; Basic Science Research Program through
   the National Research Foundation of Korea (NRF) - Ministry of Science,
   ICT & Future Planning [2010-0027945]
FX This study was supported by a grant of the Korean Health Technology R&D
   Project, Ministry of Health & Welfare, Republic of Korea (HI12C0050) and
   Basic Science Research Program through the National Research Foundation
   of Korea (NRF) funded by the Ministry of Science, ICT & Future Planning
   (2010-0027945).
CR [Anonymous], 2015, CANC FACTS FIG 2015
   [Anonymous], 2004, Stat. Appl. Genet. Mol. Biol., DOI [10.2202/1544-6115.1027, DOI 10.2202/1544-6115.1027]
   Azuma H, 2003, CANCER RES, V63, P8090
   Barker JL, 1998, PERSPECT DEV NEUROBI, V5, P305
   BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x
   Bormann J, 2000, TRENDS PHARMACOL SCI, V21, P16, DOI 10.1016/S0165-6147(99)01413-3
   Chen Zhi-ao, 2012, Cancer Biology Medicine, V9, P90, DOI 10.3969/j.issn.2095-3941.2012.02.002
   Gumireddy K, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10715
   Hedblom E, 1997, J BIOL CHEM, V272, P15346, DOI 10.1074/jbc.272.24.15346
   Joseph J, 2002, CANCER RES, V62, P6467
   Kim NH, 2014, ONCOL REP, V31, P2139, DOI 10.3892/or.2014.3110
   McKernan RM, 1996, TRENDS NEUROSCI, V19, P139, DOI 10.1016/S0166-2236(96)80023-3
   Nakayama K, 2012, INT J MOL SCI, V13, P11705, DOI 10.3390/ijms130911705
   Naora H, 2005, NAT REV CANCER, V5, P355, DOI 10.1038/nrc1611
   Sizemore GM, 2014, J BIOL CHEM, V289, P24102, DOI 10.1074/jbc.M114.593582
   Sung HY, 2014, YONSEI MED J, V55, P1656, DOI 10.3349/ymj.2014.55.6.1656
   Sung HY, 2014, YONSEI MED J, V55, P1206, DOI 10.3349/ymj.2014.55.5.1206
   Sung HY, 2014, ONCOL REP, V32, P815, DOI 10.3892/or.2014.3243
   Takehara A, 2007, CANCER RES, V67, P9704, DOI 10.1158/0008-5472.CAN-07-2099
   Watanabe M, 2006, HISTOL HISTOPATHOL, V21, P1135, DOI 10.14670/HH-21.1135
   Watanabe M, 2002, INT REV CYTOL, V213, P1
   Zafrakas M, 2006, INT J CANCER, V118, P1453, DOI 10.1002/ijc.21517
   Zhang XX, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-102
NR 23
TC 43
Z9 47
U1 0
U2 12
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1226-3613
EI 2092-6413
J9 EXP MOL MED
JI Exp. Mol. Med.
PD MAY
PY 2017
VL 49
AR e335
DI 10.1038/emm.2017.62
PG 9
WC Biochemistry & Molecular Biology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Research & Experimental Medicine
GA EY7HD
UT WOS:000404159600009
PM 28524180
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU Almeida, LO
   Guimaraes, DM
   Martins, MD
   Martins, MAT
   Warner, KA
   Nör, JE
   Castilho, RM
   Squarize, CH
AF Almeida, Luciana O.
   Guimaraes, Douglas M.
   Martins, Manoela D.
   Martins, Marco A. T.
   Warner, Kristy A.
   Nor, Jacques E.
   Castilho, Rogerio M.
   Squarize, Cristiane H.
TI Unlocking the chromatin of adenoid cystic carcinomas using HDAC
   inhibitors sensitize cancer stem cells to cisplatin and induces tumor
   senescence
SO STEM CELL RESEARCH
LA English
DT Article
DE Adenoid cystic carcinoma; Cancer stem cells; Chemoresistance;
   Vorinostat; Cisplatin
ID HISTONE DEACETYLASE INHIBITOR; SUBEROYLANILIDE HYDROXAMIC ACID;
   PHASE-II; BREAST-CANCER; TRICHOSTATIN-A; HEAD; NECK; DIFFERENTIATION;
   CHEMOTHERAPY; VORINOSTAT
AB Adenoid cystic carcinoma (ACC) is an uncommonmalignancy of the salivary glands that is characterized by local recurrence and distant metastasis due to its resistance to conventional therapy. Platinum-based therapies have been extensively explored as a treatment for ACC, but they show little effectiveness. Studies have shown that a specific group of tumor cells, harboring characteristics of cancer stem cells (CSCs), are involved in chemoresistance of myeloid leukemias, breast, colorectal and pancreatic carcinomas. Therapeutic strategies that target CSCs improve the survival of patients by decreasing the rates of tumor relapse, and epigenetic drugs, such as histone deacetylase inhibitors (HDACi), have shown promising results in targeting CSCs. In this study, we investigated the effect of the HDACi Suberoylanilide hydroxamic acid (Vorinostat), and cisplatin, alone or in combination, on CSCs and non-CSCs from ACC. We used CSCs as a biological marker for tumor resistance to therapy in patient-derived xenograft (PDX) samples and ACC primary cells. We found that cisplatin reduced tumor viability, but enriched the population of CSCs. Systemic administration of Vorinostat reduced the number of detectable CSCs in vivo and in vitro, and a low dose of Vorinostat decreased tumor cell viability. However, the combination of Vorinostat and cisplatin was extremely effective in depleting CSCs and reducing tumor viability in all ACC primary cells by activating cellular senescence. These observations suggest that HDACi and intercalating agents act more efficiently in combination to destroy tumor cells and their stem cells. (C) 2017 The Authors. Published by Elsevier B.V.
C1 [Almeida, Luciana O.; Guimaraes, Douglas M.; Martins, Manoela D.; Martins, Marco A. T.; Castilho, Rogerio M.; Squarize, Cristiane H.] Univ Michigan, Sch Dent, Lab Epithelial Biol, Dept Periodont & Oral Med, Ann Arbor, MI 48109 USA.
   [Castilho, Rogerio M.; Squarize, Cristiane H.] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA.
   [Guimaraes, Douglas M.] Univ Sao Paulo, Sch Dent, Dept Oral Pathol, BR-05508000 Sao Paulo, SP, Brazil.
   [Martins, Manoela D.; Martins, Marco A. T.] Univ Fed Rio Grande do Sul, Sch Dent, Dept Oral Pathol, BR-90035003 Porto Alegre, RS, Brazil.
   [Nor, Jacques E.] Univ Michigan, Sch Med, Dept Otolaryngol, Ann Arbor, MI USA.
   [Warner, Kristy A.; Nor, Jacques E.] Univ Michigan, Sch Dent, Dept Restorat Sci, Ann Arbor, MI 48109 USA.
   [Almeida, Luciana O.] Univ Fed Sao Carlos, Dept Genet & Evolut, BR-13565905 Sao Carlos, SP, Brazil.
C3 University of Michigan System; University of Michigan; University of
   Michigan System; University of Michigan; Universidade de Sao Paulo;
   Universidade Federal do Rio Grande do Sul; University of Michigan
   System; University of Michigan; University of Michigan System;
   University of Michigan; Universidade Federal de Sao Carlos
RP Castilho, RM (通讯作者)，Univ Michigan, Dept Periodont & OralMedicine, Lab Epithelial Biol, 1011 N Univ Ave,Room 3210, Ann Arbor, MI 48109 USA.
EM rcastilh@umich.edu
RI Nor, Jacques/AAJ-6139-2021; Castilho, Rogerio/E-4987-2010; Almeida,
   Luciana/G-8452-2012; Martins, Manoela/G-8209-2012; Guimaraes,
   Douglas/AAP-8971-2021; MARTINS, MARCO/HJH-3671-2023; Oliveira de
   Almeida, Luciana/O-1013-2014
OI Oliveira de Almeida, Luciana/0000-0002-5342-0434; Guimaraes,
   Douglas/0000-0001-7856-1324; MARTINS, MARCO ANTONIO
   TREVIZANI/0000-0001-6073-1807; Moraes Castilho,
   Rogerio/0000-0001-5358-612X; Squarize, Cristiane/0000-0002-6782-3429
FU Adenoid Cystic Carcinoma Research Foundation (ACCRF); University of
   Michigan School of Dentistry faculty grant; Cancer Center Support Grant
   [P30 CA046592]; National Council for Scientific and Technological
   Development (CNPq), Brazil; National Cancer Institute [P30CA046592]
   Funding Source: NIH RePORTER
FX This study was funded by the Adenoid Cystic Carcinoma Research
   Foundation (ACCRF), the University of Michigan School of Dentistry
   faculty grant, and the Cancer Center Support Grant (P30 CA046592). This
   work was conducted during a visiting scholar period at the University of
   Michigan, which was sponsored by the National Council for Scientific and
   Technological Development (CNPq), Brazil.
CR Acasigua GA, 2015, ORAL ONCOL, V51, P839, DOI 10.1016/j.oraloncology.2015.06.004
   Adams A, 2013, ORAL ONCOL, V49, P845, DOI 10.1016/j.oraloncology.2013.05.013
   Adelstein DJ, 2012, SEMIN RADIAT ONCOL, V22, P245, DOI 10.1016/j.semradonc.2012.03.009
   Almeida LO, 2016, CANCERS, V8, DOI 10.3390/cancers8010007
   Almeida LO, 2014, FEBS OPEN BIO, V4, P96, DOI 10.1016/j.fob.2013.12.003
   Barazzuol L, 2015, INT J RADIAT BIOL, V91, P90, DOI 10.3109/09553002.2014.946111
   Bartkova J, 2006, NATURE, V444, P633, DOI 10.1038/nature05268
   Chae YK, 2015, ONCOTARGET, V6, P37117, DOI 10.18632/oncotarget.5076
   Courtois-Cox S, 2006, CANCER CELL, V10, P459, DOI 10.1016/j.ccr.2006.10.003
   DEHAAN LD, 1992, HEAD NECK-J SCI SPEC, V14, P273
   Deruy E, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.533
   Dillon PM, 2016, HEAD NECK-J SCI SPEC, V38, P620, DOI 10.1002/hed.23925
   Dobbelstein M, 2015, NAT REV DRUG DISCOV, V14, P405, DOI 10.1038/nrd4553
   Dontu G, 2003, GENE DEV, V17, P1253, DOI 10.1101/gad.1061803
   Dragu DL, 2015, WORLD J STEM CELLS, V7, P1185, DOI 10.4252/wjsc.v7.i9.1185
   Dubergé T, 2012, CANCER RADIOTHER, V16, P247, DOI 10.1016/j.canrad.2012.02.003
   Duvic M, 2007, BIOL-TARGETS THER, V1, P377
   Etchegaray JP, 2015, NAT CELL BIOL, V17, P545, DOI 10.1038/ncb3147
   Ewald JA, 2010, JNCI-J NATL CANCER I, V102, P1536, DOI 10.1093/jnci/djq364
   Fordice J, 1999, ARCH OTOLARYNGOL, V125, P149, DOI 10.1001/archotol.125.2.149
   Frank NY, 2010, J CLIN INVEST, V120, P41, DOI 10.1172/JCI41004
   Giudice FS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058672
   Guimaraes DM, 2016, ONCOTARGET, V7, P42447, DOI 10.18632/oncotarget.9884
   Gumbarewicz E, 2016, AM J CANCER RES, V6, P2831
   HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6
   Hitre E, 2013, BRIT J CANCER, V109, P1117, DOI 10.1038/bjc.2013.468
   Hotte SJ, 2005, J CLIN ONCOL, V23, P585, DOI 10.1200/JCO.2005.06.125
   Hrzenjak A, 2006, MOL CANCER THER, V5, P2203, DOI 10.1158/1535-7163.MCT-05-0480
   Huang ZQ, 2014, MOL CARCINOGEN, V53, P777, DOI 10.1002/mc.22033
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Kelly WK, 2005, J CLIN ONCOL, V23, P3923, DOI 10.1200/JCO.2005.14.167
   Khan O, 2012, IMMUNOL CELL BIOL, V90, P85, DOI 10.1038/icb.2011.100
   Kimura H, 2013, J HUM GENET, V58, P439, DOI 10.1038/jhg.2013.66
   Kretsovali A, 2012, STEM CELLS INT, V2012, DOI 10.1155/2012/184154
   Kuilman T, 2010, GENE DEV, V24, P2463, DOI 10.1101/gad.1971610
   Kumar Bhavna, 2015, Genes Cancer, V6, P169
   Lagha A, 2012, HEAD NECK ONCOL, V4, DOI 10.1186/1758-3284-4-19
   Le John M, 2014, World J Stem Cells, V6, P511, DOI 10.4252/wjsc.v6.i5.511
   LICITRA L, 1991, CANCER, V68, P1874, DOI 10.1002/1097-0142(19911101)68:9<1874::AID-CNCR2820680904>3.0.CO;2-S
   Liu HG, 2015, AM J CANCER RES, V5, P880
   Liu H, 2015, ONCOTARGET, V6, P11477, DOI 10.18632/oncotarget.3411
   Marks PA, 2007, ONCOGENE, V26, P1351, DOI 10.1038/sj.onc.1210204
   Marks PA, 2004, ADV CANCER RES, V91, P137, DOI 10.1016/S0065-230X(04)91004-4
   Melcer S, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1915
   Messier TL, 2016, ONCOTARGET, V7, P5094, DOI 10.18632/oncotarget.6922
   Moreb JS, 2008, CURR STEM CELL RES T, V3, P237, DOI 10.2174/157488808786734006
   Munster PN, 2001, CANCER RES, V61, P8492
   Murdoch D, 2007, CURR OPIN ONCOL, V19, P216, DOI 10.1097/01.cco.0000264952.98166.99
   Newbold A, 2016, FEBS J, V283, P4032, DOI 10.1111/febs.13746
   Nör C, 2014, NEOPLASIA, V16, P137, DOI 10.1593/neo.131744
   Pan CH, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2888-7
   Papaspyrou G, 2011, HEAD NECK-J SCI SPEC, V33, P905, DOI 10.1002/hed.21458
   Park SJ, 2016, TUMOR BIOL, V37, P4323, DOI 10.1007/s13277-015-4216-2
   Pettke A, 2016, ANTI-CANCER DRUG, V27, P1001, DOI 10.1097/CAD.0000000000000418
   Pili R, 2017, BRIT J CANCER, V116, P874, DOI 10.1038/bjc.2017.33
   Platta CS, 2007, J SURG RES, V142, P219, DOI 10.1016/j.jss.2006.12.555
   Pozzi V, 2015, CELL PHYSIOL BIOCHEM, V36, P784, DOI 10.1159/000430138
   Qiu H, 2015, CELL MOL LIFE SCI, V72, P3411, DOI 10.1007/s00018-015-1920-4
   Reddel RR, 2000, CARCINOGENESIS, V21, P477, DOI 10.1093/carcin/21.3.477
   Richon VM, 2000, P NATL ACAD SCI USA, V97, P10014, DOI 10.1073/pnas.180316197
   Rodriguez-Brenes IA, 2015, SCI REP-UK, V5, DOI 10.1038/srep17660
   SAGER R, 1991, ENVIRON HEALTH PERSP, V93, P59, DOI 10.2307/3431170
   Sakajiri S, 2005, EXP HEMATOL, V33, P53, DOI 10.1016/j.exphem.2004.09.008
   Salvador MA, 2013, CLIN CANCER RES, V19, P6520, DOI 10.1158/1078-0432.CCR-13-0877
   Secrist J Paul, 2003, Curr Opin Investig Drugs, V4, P1422
   Seignez C, 2014, ONCOTARGET, V5, P11442, DOI 10.18632/oncotarget.2556
   Shen DW, 2012, PHARMACOL REV, V64, P706, DOI 10.1124/pr.111.005637
   Shukla S, 2014, BBA-GEN SUBJECTS, V1840, P3494, DOI 10.1016/j.bbagen.2014.09.017
   Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599
   Tsubochi H, 2000, ANTICANCER RES, V20, P1205
   Vidal SJ, 2014, ONCOGENE, V33, P4451, DOI 10.1038/onc.2013.411
   Wagner VP, 2016, ONCOTARGET, V7, P73032, DOI 10.18632/oncotarget.12195
   Warner KA, 2016, CLIN CANCER RES, V22, P3550, DOI 10.1158/1078-0432.CCR-15-1698
   Warner KA, 2013, ORAL ONCOL, V49, P1059, DOI 10.1016/j.oraloncology.2013.08.004
   Warrener R, 2003, FASEB J, V17, P1550, DOI 10.1096/fj.02-1003fje
   Wells CE, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068915
   West AC, 2014, J CLIN INVEST, V124, P30, DOI 10.1172/JCI69738
   Wiechert A, 2016, ONCOTARGET, V7, P30511, DOI 10.18632/oncotarget.8852
   Wozniak K, 2002, ACTA BIOCHIM POL, V49, P583
   Yamashita Y, 2003, INT J CANCER, V103, P572, DOI 10.1002/ijc.10699
   Yang J, 2014, BMC BIOL, V12, DOI 10.1186/s12915-014-0095-z
   Yoo C, 2016, BRIT J CANCER, V114, P1185, DOI 10.1038/bjc.2016.125
   YOSHIDA M, 1995, BIOESSAYS, V17, P423, DOI 10.1002/bies.950170510
   Yu L, 2016, ONCOTARGET, V7, P33055, DOI 10.18632/oncotarget.8849
   Zhao W, 2004, CELL RES, V14, P60, DOI 10.1038/sj.cr.7290203
NR 85
TC 45
Z9 49
U1 0
U2 9
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1873-5061
EI 1876-7753
J9 STEM CELL RES
JI Stem Cell Res.
PD MAY
PY 2017
VL 21
BP 94
EP 105
DI 10.1016/j.scr.2017.04.003
PG 12
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Cell
   Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Biotechnology & Applied Microbiology
GA EW4MW
UT WOS:000402476600019
PM 28426972
OA gold, Green Accepted, Green Published
DA 2025-01-12
ER

PT J
AU Yang, JJ
   Tao, H
   Liu, LP
   Hu, W
   Deng, ZY
   Li, J
AF Yang, Jing-Jing
   Tao, Hui
   Liu, Li-Ping
   Hu, Wei
   Deng, Zi-Yu
   Li, Jun
TI miR-200a controls hepatic stellate cell activation and fibrosis via
   SIRT1/Notch1 signal pathway
SO INFLAMMATION RESEARCH
LA English
DT Article
DE MicroRNA-200a; Hepatic stellate cells; Liver fibrosis
ID LIVER FIBROSIS; PROTEIN EXPRESSION; UP-REGULATION; PROLIFERATION;
   SUPPRESSES; INHIBITOR; MIGRATION; CANCER; MICE
AB miR-200a has been established as a key regulator of HSC activation processes in liver fibrosis. Epigenetic silencing of miR-200a contributing to SIRT1 over-expression has been discussed in breast cancer; however, whether miR-200a controls SIRT1 gene expression in hepatic fibrosis is still unknown.
   We analyzed miR-200a regulation of SIRT1 expression in CCl4-induced liver fibrosis and TGF-beta 1-mediated activation of HSC. miR-200a, SIRT1, alpha-SMA, Col1A1, Notch1 and NICD expression were estimated by Western blotting, qRT-PCR and Immunohistochemistry. HSCs were transfected with miR-200a mimic, miR-200a inhibitor and SIRT1-RNAi. Luciferase reporter assays further confirmed the interaction between miR-200a and the SIRT1 mRNA 3'-UTR. Cell proliferation ability was assessed by MTT and cell cycle.
   We found that treatment activated HSC with miR-200a mimics, restored miR-200a expression and reduced SIRT1 levels. Conversely, treatment activated HSC with miR-200a inhibitors, decreased miR-200a expression and up-regulated SIRT1 levels. Restoration of miR-200a or the knockdown of SIRT1 prevented HSC activation and proliferation. We have established the SIRT1 transcript as subject to regulation by miR-200a, through miR-200a targeting of SIRT1 3'-UTR. Finally, HSC transfected with SIRT1-siRNA increased the levels of Notch1 protein and mRNA expression.
   Our study demonstrated that miR-200a regulates SIRT1/Notch1 expression during HSC activation and fibrosis.
C1 [Yang, Jing-Jing; Liu, Li-Ping; Hu, Wei] Anhui Med Univ, Dept Pharmacol, Hosp 2, Hefei 230601, Peoples R China.
   [Tao, Hui] Anhui Med Univ, Dept Cardiothorac Surg, Hosp 2, Hefei 230601, Peoples R China.
   [Deng, Zi-Yu] Anhui Med Univ, Dept Sci, Hosp 2, Hefei 230601, Peoples R China.
   [Li, Jun] Anhui Med Univ, Sch Pharm, Mei Shan Rd, Hefei 230032, Anhui, Peoples R China.
C3 Anhui Medical University; Anhui Medical University; Anhui Medical
   University; Anhui Medical University
RP Li, J (通讯作者)，Anhui Med Univ, Sch Pharm, Mei Shan Rd, Hefei 230032, Anhui, Peoples R China.
EM zydengsy@163.com; yncs01@hotmail.com
RI Yang, Jingjing/X-5013-2019
OI Hu, Wei/0000-0002-4809-7601; Yang, Jingjing/0000-0002-3106-3798
FU Anhui Provincial Natural Science Foundation [1608085MH200]; National
   Natural Science Foundation of China [81600477]; Anhui Medical University
   Foundation [2015xjk014]
FX This study was funded by Anhui Provincial Natural Science Foundation
   (1608085MH200) and National Natural Science Foundation of China
   (81600477) and Anhui Medical University Foundation (2015xjk014).
CR Boareto M, 2015, P NATL ACAD SCI USA, V112, pE402, DOI 10.1073/pnas.1416287112
   Dey N, 2015, CELL SIGNAL, V27, P1276, DOI 10.1016/j.cellsig.2015.03.007
   Fujiyoshi M, 2015, J GASTROENTEROL, V50, P1134, DOI 10.1007/s00535-015-1063-2
   Ganji SH, 2015, METABOLISM, V64, P982, DOI 10.1016/j.metabol.2015.05.002
   Hu JF, 2015, CLIN SCI, V129, P305, DOI 10.1042/CS20140012
   Hu W, 2015, DNA CELL BIOL, V34, P282, DOI 10.1089/dna.2014.2421
   Jiang JX, 2013, HEPATOLOGY, V58, P1339, DOI 10.1002/hep.26491
   Lee YA, 2015, GUT, V64, P1337, DOI 10.1136/gutjnl-2014-306842corr1
   Li LH, 2015, J MOL NEUROSCI, V56, P858, DOI 10.1007/s12031-015-0526-5
   Lin X, 2015, INT IMMUNOPHARMACOL, V28, P305, DOI 10.1016/j.intimp.2015.06.021
   Mallick S, 2014, J BIOL CHEM, V289, P35409, DOI 10.1074/jbc.M114.597575
   Meng Y, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120110
   Mimche PN, 2015, HEPATOLOGY, V62, P900, DOI 10.1002/hep.27792
   Murayama A, 2008, CELL, V133, P627, DOI 10.1016/j.cell.2008.03.030
   Pannem RR, 2014, HEPATOLOGY, V60, P1066, DOI 10.1002/hep.27209
   Ramezani-Moghadam M, 2015, J BIOL CHEM, V290, P5533, DOI 10.1074/jbc.M114.598011
   Shah N, 2013, J CLIN EXP HEPATOL, V3, P231, DOI 10.1016/j.jceh.2013.09.001
   Simic P, 2013, CELL REP, V3, P1175, DOI 10.1016/j.celrep.2013.03.019
   Stein C, 2012, NUCLEIC ACIDS RES, V40, P9522, DOI 10.1093/nar/gks767
   Sun X, 2014, MOL CELL BIOCHEM, V388, P11, DOI 10.1007/s11010-013-1895-0
   Wu LY, 2015, CLIN IMMUNOL, V158, P77, DOI 10.1016/j.clim.2015.03.003
   Xiao YT, 2014, CELL SIGNAL, V26, P925, DOI 10.1016/j.cellsig.2014.01.003
   Xie M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045331
   Yang JJ, 2014, EXPERT OPIN THER TAR, V18, P1011, DOI 10.1517/14728222.2014.927443
   Yuan HF, 2013, ONCOTARGETS THER, V6, P1399, DOI 10.2147/OTT.S37750
   Zheng Y, 2014, J AGR FOOD CHEM, V62, P244, DOI 10.1021/jf404320w
NR 26
TC 43
Z9 46
U1 1
U2 24
PU SPRINGER BASEL AG
PI BASEL
PA PICASSOPLATZ 4, BASEL, 4052, SWITZERLAND
SN 1023-3830
EI 1420-908X
J9 INFLAMM RES
JI Inflamm. Res.
PD APR
PY 2017
VL 66
IS 4
BP 341
EP 352
DI 10.1007/s00011-016-1020-4
PG 12
WC Cell Biology; Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Immunology
GA EN9OV
UT WOS:000396330400007
PM 28025657
DA 2025-01-12
ER

PT J
AU Micevic, G
   Theodosakis, N
   Taube, JM
   Bosenberg, MW
   Rodic, N
AF Micevic, Goran
   Theodosakis, Nicholas
   Taube, Janis M.
   Bosenberg, Marcus W.
   Rodic, Nemanja
TI Attenuation of genome-wide 5-methylcytosine level is an epigenetic
   feature of cutaneous malignant melanomas
SO MELANOMA RESEARCH
LA English
DT Article
DE cancer epigenetics; 5-methylcytosine; S-adenosyl methionine
ID GLOBAL DNA HYPOMETHYLATION; S-ADENOSYLMETHIONINE; BREAST-CANCER;
   COLON-CANCER; METHYLTRANSFERASES DNMT3A; TUMOR PROGRESSION; METHYLATION;
   CELLS; CARCINOMA; 5-HYDROXYMETHYLCYTOSINE
AB Epigenetic modification of DNA, namely covalent changes of cytosine residues, plays a key role in the maintenance of inactive chromatin regions, both in health and in disease. In the vast majority of malignant melanomas, the most notable known epigenetic abnormality is the attenuation of 5-hydroxymethylcytosine (5-hmC) residues. However, it remains unknown whether a decrease in 5-hmC represents a primary defect of melanoma cancer epigenome or whether it is secondary to the loss of 5-methylcytosine (5-mC), a chemical substrate for 5-hmC. Here, we evaluated 5-mC levels in a spectrum of melanocytic proliferations. To study the epigenetic features of melanocytic nuclei, we began by measuring 5-mC levels in histologic specimens semiquantitatively by immunohistochemistry. We next treated established melanoma cell lines with S-adenosyl methionine (SAM), a universal methyl group donor, in an effort to cause changes in 5-mC levels. We detected a marked reduction in 5-mC levels in both primary and metastatic melanomas compared with 5-mC levels in benign melanocytic nevi. We also empirically induced changes in 5-mC in melanoma cell lines by incubation with SAM. To our surprise, we observed a significant cytoreductive effect of SAM on all melanoma cell lines examined. At subcytotoxic levels, SAM treatment is accompanied by a genome-wide increase in 5-mC. Moreover, we recorded a dose-dependent increase in genome-wide 5-mC levels in melanoma cell lines following SAM treatment. Taken together, we report that genome-wide attenuation of 5-mC is a hallmark of malignant melanomas. We propose that genome-wide attenuation of 5-mC is not merely an epiphenomenon as it is required for melanoma cell growth, albeit by an as of yet undetermined mechanism. Given its potential benefit in slowing down the growth of melanoma cells, SAM should be studied further to determine its role in epigenome modulation.
C1 [Micevic, Goran; Theodosakis, Nicholas; Bosenberg, Marcus W.] Yale Univ, Dept Pathol, New Haven, CT USA.
   [Micevic, Goran; Theodosakis, Nicholas; Bosenberg, Marcus W.; Rodic, Nemanja] Yale Univ, Dept Dermatol, New Haven, CT 06520 USA.
   [Taube, Janis M.] Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA.
   [Taube, Janis M.] Johns Hopkins Univ, Sch Med, Dept Dermatol, Baltimore, MD 21205 USA.
   [Taube, Janis M.] Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21205 USA.
   [Taube, Janis M.] Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA.
C3 Yale University; Yale University; Johns Hopkins University; Johns
   Hopkins University; Johns Hopkins University; Johns Hopkins University;
   Johns Hopkins Medicine
RP Rodic, N (通讯作者)，20 York St Mem Unit, New Haven, CT 06510 USA.
EM nemanja.rodic@yale.edu
RI Bosenberg, Marcus/HJZ-4200-2023; Micevic, Goran/M-5427-2017
OI Micevic, Goran/0000-0003-0329-1053
FU Fred and Janet Sanfilippo Research Fund; Yale MSTP NIH [T32 GM007205];
   NRSA [F30 CA19608901]
FX N.R. is supported by the Fred and Janet Sanfilippo Research Fund. G.M.
   and N.T. are supported by the Yale MSTP NIH T32 GM007205. G.M. is also
   supported by NRSA F30 CA19608901.
CR Agarwal S, 2015, BRIT J CANCER, V112, P61, DOI 10.1038/bjc.2014.573
   Anisowicz Anthony, 2008, BMC Cancer, V8, P222, DOI 10.1186/1471-2407-8-222
   Bartholomew B, 2014, ANNU REV BIOCHEM, V83, P671, DOI 10.1146/annurev-biochem-051810-093157
   Beaulieu N, 2002, J BIOL CHEM, V277, P28176, DOI 10.1074/jbc.M204734200
   Brothman AR, 2005, CANCER GENET CYTOGEN, V156, P31, DOI 10.1016/j.cancergencyto.2004.04.004
   Cadieux B, 2006, CANCER RES, V66, P8469, DOI 10.1158/0008-5472.CAN-06-1547
   Chan KCA, 2013, P NATL ACAD SCI USA, V110, P18761, DOI 10.1073/pnas.1313995110
   Chen JN, 2013, KNOWL-BASED SYST, V45, P1, DOI 10.1016/j.knosys.2013.01.031
   Chen RZ, 1998, NATURE, V395, P89, DOI 10.1038/25779
   Chen TP, 2014, NAT REV GENET, V15, P93, DOI 10.1038/nrg3607
   Chik F, 2014, CARCINOGENESIS, V35, P138, DOI 10.1093/carcin/bgt284
   Compare D, 2011, J CLIN PATHOL, V64, P677, DOI 10.1136/jcp.2010.087858
   Cravo M, 1996, GUT, V39, P434, DOI 10.1136/gut.39.3.434
   Damsky W, 2015, CANCER CELL, V27, P41, DOI 10.1016/j.ccell.2014.11.014
   Dawlaty MM, 2013, DEV CELL, V24, P310, DOI 10.1016/j.devcel.2012.12.015
   Dobrovic A, 1997, CANCER RES, V57, P3347
   Eden A, 2003, SCIENCE, V300, P455, DOI 10.1126/science.1083557
   Fan GP, 2001, J NEUROSCI, V21, P788, DOI 10.1523/JNEUROSCI.21-03-00788.2001
   FEINBERG AP, 1983, NATURE, V301, P89, DOI 10.1038/301089a0
   Gambichler T, 2013, MELANOMA RES, V23, P218, DOI 10.1097/CMR.0b013e32835f9bd4
   Gao Q, 2011, P NATL ACAD SCI USA, V108, P18061, DOI 10.1073/pnas.1114946108
   Gaudet F, 2003, SCIENCE, V300, P489, DOI 10.1126/science.1083558
   GOELZ SE, 1985, SCIENCE, V228, P187, DOI 10.1126/science.2579435
   GREGER V, 1989, HUM GENET, V83, P155, DOI 10.1007/BF00286709
   Gure AO, 2005, CLIN CANCER RES, V11, P8055, DOI 10.1158/1078-0432.CCR-05-1203
   Haffner MC, 2011, ONCOTARGET, V2, P627
   Halaban R, 2010, PIGM CELL MELANOMA R, V23, P190, DOI 10.1111/j.1755-148X.2010.00685.x
   Howard G, 2008, ONCOGENE, V27, P404, DOI 10.1038/sj.onc.1210631
   Huang Y, 2014, TRENDS GENET, V30, P464, DOI 10.1016/j.tig.2014.07.005
   Jackson-Grusby L, 2001, NAT GENET, V27, P31, DOI 10.1038/83730
   KIM YI, 1994, CANCER, V74, P893, DOI 10.1002/1097-0142(19940801)74:3<893::AID-CNCR2820740316>3.0.CO;2-B
   Koga Y, 2009, GENOME RES, V19, P1462, DOI 10.1101/gr.091447.109
   Krauthammer M, 2012, NAT GENET, V44, P1006, DOI 10.1038/ng.2359
   Kristensen DG, 2014, BRIT J CANCER, V110, P668, DOI 10.1038/bjc.2013.727
   Kuzmin I, 1999, ONCOGENE, V18, P5672, DOI 10.1038/sj.onc.1202959
   Li E, 2014, CSH PERSPECT BIOL, V6, DOI 10.1101/cshperspect.a019133
   Li TWH, 2015, MOL PHARMACOL, V87, P77, DOI 10.1124/mol.114.095679
   Li TWH, 2012, CARCINOGENESIS, V33, P427, DOI 10.1093/carcin/bgr295
   Lian CG, 2012, CELL, V150, P1135, DOI 10.1016/j.cell.2012.07.033
   LITTLE M, 1995, NAT MED, V1, P633, DOI 10.1038/nm0795-633
   Liu QY, 2011, MOL CANCER THER, V10, P1113, DOI 10.1158/1535-7163.MCT-10-1010
   Lundberg G, 2011, GENE CHROMOSOME CANC, V50, P250, DOI 10.1002/gcc.20850
   Luo J, 2010, INT J BIOL SCI, V6, P784
   Maddodi N, 2010, J BIOL CHEM, V285, P242, DOI 10.1074/jbc.M109.068668
   Mudbhary R, 2014, CANCER CELL, V25, P196, DOI 10.1016/j.ccr.2014.01.003
   Oka M, 2005, ONCOGENE, V24, P3091, DOI 10.1038/sj.onc.1208540
   Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6
   Parashar S, 2015, CANCER MED-US, V4, P732, DOI 10.1002/cam4.386
   Paz MF, 2002, CANCER RES, V62, P4519
   Pogribny IP, 1997, CANCER LETT, V115, P31, DOI 10.1016/S0304-3835(97)04708-3
   Qu GZ, 1999, MUTAT RES-FUND MOL M, V423, P91, DOI 10.1016/S0027-5107(98)00229-2
   Raddatz G, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1003146
   Rao AM, 1997, MOL BRAIN RES, V44, P134, DOI 10.1016/S0169-328X(96)00245-8
   Rhee I, 2000, NATURE, V404, P1003, DOI 10.1038/35010000
   Richter M, 2013, NAT PROD REP, V30, P1324, DOI 10.1039/c3np70045c
   Rodic N, 2015, CANCER IMMUNOL RES, V3, P110, DOI 10.1158/2326-6066.CIR-14-0145
   Sigalotti L, 2008, J CELL PHYSIOL, V215, P287, DOI 10.1002/jcp.21380
   Smith IM, 2007, INT J CANCER, V121, P1724, DOI 10.1002/ijc.22889
   Toyota M, 1999, CANCER RES, V59, P2307
NR 59
TC 8
Z9 10
U1 1
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0960-8931
EI 1473-5636
J9 MELANOMA RES
JI Melanoma Res.
PD APR
PY 2017
VL 27
IS 2
BP 85
EP 96
DI 10.1097/CMR.0000000000000315
PG 12
WC Oncology; Dermatology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Dermatology; Research & Experimental Medicine
GA EM8IH
UT WOS:000395554200003
PM 27997431
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Volodko, N
   Salla, M
   Zare, A
   Abulghasem, EA
   Vincent, K
   Benesch, MGK
   McMullen, TPW
   Bathe, OF
   Postovit, L
   Baksh, S
AF Volodko, Natalia
   Salla, Mohamed
   Zare, Alaa
   Abulghasem, El-Arbi
   Vincent, Krista
   Benesch, Matthew G. K.
   McMullen, Todd P. W.
   Bathe, Oliver F.
   Postovit, Lynne
   Baksh, Shairaz
TI RASSF1A Site-Specific Methylation Hotspots in Cancer and Correlation
   with <i>RASSF1C</i> and <i>MOAP-1</i>
SO CANCERS
LA English
DT Article
DE RASSF1A; RASSF1C; cancer; DNMT; MOAP-1; epigenetics
ID TUMOR-SUPPRESSOR GENES; PROMOTER HYPERMETHYLATION; MIR-25 TARGETS;
   BREAST-CANCER; LUNG-CANCER; PROTEIN; CELL; TUMORIGENESIS; NEUROBLASTOMA;
   ASSOCIATION
AB Epigenetic silencing of RASSF1A is frequently observed in numerous cancers and has been previously reported. The promoter region of RASSF1A is predicted to have 75 CpG sites, and very few studies demonstrate how the methylation of these sites affects expression. In addition, the expression relationship between RASSF1A and its downstream target, modulator of apoptosis 1 (MOAP-1), is poorly understood. In this study, we have explored the mRNA expression of RASSF1A, MOAP-1 and the well-characterized splice variant of RASSF1, RASSF1C, in cancer cell lines and primary tumors. We confirmed that the RASSF1A promoter is robustly methylated within a 32-CpG region in solid tumors and results in lower mRNA expression. The MOAP-1 promoter contains 110 CpG sites, but was not found to be methylated in cancer cell lines when 19 predicted CpG sites were explored. Interestingly, MOAP-1 mRNA expression positively correlated with RASSF1A expression in numerous cancers, whereas RASSF1C expression remained the same or was increased in cell lines or tissues with epigenetic loss of RASSF1A. We speculate that MOAP-1 and RASSF1A may be more intimately connected than originally thought, and the expression of both are warranted in experimental designs exploring the biology of the RASSF1A/MOAP-1 molecular pathway.
C1 [Volodko, Natalia; Zare, Alaa; Abulghasem, El-Arbi; Baksh, Shairaz] Univ Alberta, Fac Med & Dent, Dept Pediat, 113 St 87 Ave, Edmonton, AB T6G 2E1, Canada.
   [Salla, Mohamed; Benesch, Matthew G. K.; Baksh, Shairaz] Univ Alberta, Fac Med & Dent, Dept Biochem, 113 St 87 Ave, Edmonton, AB T6G 2E1, Canada.
   [Vincent, Krista; Postovit, Lynne; Baksh, Shairaz] Univ Alberta, Fac Med & Dent, Dept Expt Oncol, 113 St 87 Ave, Edmonton, AB T6G 2E1, Canada.
   [McMullen, Todd P. W.] Univ Alberta, Fac Med & Dent, Dept Surg Oncol, 113 St 87 Ave, Edmonton, AB T6G 2E1, Canada.
   [Bathe, Oliver F.] Univ Calgary, Dept Surg, 1331-29th St NW, Calgary, AB T2N 4N2, Canada.
   [Bathe, Oliver F.] Univ Calgary, Tom Baker Canc Ctr, Dept Oncol, 1331-29th St NW, Calgary, AB T2N 4N2, Canada.
   [Baksh, Shairaz] Univ Alberta, Heritage Med Res Ctr, Canc Res Inst Northern Alberta, Edmonton, AB T6G 2R7, Canada.
   [Baksh, Shairaz] Univ Alberta, ECHA, Women & Childrens Hlth Res Inst, 4-081 11405 87 Ave NW, Edmonton, AB T6G 1C9, Canada.
C3 University of Alberta; University of Alberta; University of Alberta;
   University of Alberta; University of Calgary; University of Calgary; Tom
   Baker Cancer Clinic; University of Alberta; University of Alberta
RP Baksh, S (通讯作者)，Univ Alberta, Fac Med & Dent, Dept Pediat, 113 St 87 Ave, Edmonton, AB T6G 2E1, Canada.; Baksh, S (通讯作者)，Univ Alberta, Fac Med & Dent, Dept Biochem, 113 St 87 Ave, Edmonton, AB T6G 2E1, Canada.; Baksh, S (通讯作者)，Univ Alberta, Fac Med & Dent, Dept Expt Oncol, 113 St 87 Ave, Edmonton, AB T6G 2E1, Canada.; Baksh, S (通讯作者)，Univ Alberta, Heritage Med Res Ctr, Canc Res Inst Northern Alberta, Edmonton, AB T6G 2R7, Canada.; Baksh, S (通讯作者)，Univ Alberta, ECHA, Women & Childrens Hlth Res Inst, 4-081 11405 87 Ave NW, Edmonton, AB T6G 1C9, Canada.
EM volodko@ualberta.ca; salla@ualberta.ca; zare@ualberta.ca;
   abulghas@ualberta.ca; kvincent@ualberta.ca; benesch@ualberta.ca;
   todd.mcmullen@ualberta.ca; oliver.bathe@albertahealthservices.ca;
   postovit@ualberta.ca; sbaksh@ualberta.ca
RI Baksh, Shairaz/GRX-2106-2022; Salla, Mohamed/ABA-5843-2021; Benesch,
   Matthew/GRF-0677-2022
OI Benesch, Matthew/0000-0002-1326-684X; Salla,
   Mohamed/0000-0003-4744-0954; Postovit, Lynne-Marie/0000-0002-8088-4197
CR Bae S, 2011, MOL CELLS, V32, P243, DOI 10.1007/s10059-011-1037-z
   Beckedorff FC, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003705
   Ben Dhiab M, 2015, CELL ONCOL, V38, P453, DOI 10.1007/s13402-015-0242-8
   Chang JW, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012847
   Cho YH, 2010, ANTICANCER RES, V30, P2489
   Dammann R, 2005, HISTOL HISTOPATHOL, V20, P645, DOI 10.14670/HH-20.645
   Delaney C, 2015, METHODS MOL BIOL, V1343, P249, DOI 10.1007/978-1-4939-2963-4_19
   Donninger H, 2007, J CELL SCI, V120, P3163, DOI 10.1242/jcs.010389
   Donninger H, 2014, J BIOL CHEM, V289, P31287, DOI 10.1074/jbc.M114.609537
   Foley CJ, 2008, MOL CELL BIOL, V28, P4520, DOI 10.1128/MCB.02011-07
   Gonzalo V, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008777
   Gordon M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075483
   Huang NJ, 2012, J CELL BIOL, V197, P361, DOI [10.1083/jcb.201111141, 10.1083/jcb.201108062]
   Jiang JL, 2015, EXP THER MED, V10, P1549, DOI 10.3892/etm.2015.2656
   Jiang LY, 2011, J BIOL CHEM, V286, P6971, DOI 10.1074/jbc.M110.186494
   Koch A, 2015, BMC GENOMICS, V16, DOI 10.1186/s12864-015-1847-z
   Kuzmina NS, 2016, ENVIRON RES, V146, P10, DOI 10.1016/j.envres.2015.12.008
   Law J., 2012, MOL BIOL INT, V2012, DOI [10.1155/2012/53680222745908, DOI 10.1155/2012/53680222745908]
   Law J, 2015, J BIOL CHEM, V290, P24100, DOI 10.1074/jbc.M115.648345
   Lee SS, 2009, EXP CELL RES, V315, P1313, DOI 10.1016/j.yexcr.2008.11.021
   Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427
   Li QY, 2012, BIOCHEM BIOPH RES CO, V424, P28, DOI 10.1016/j.bbrc.2012.06.028
   Liu R, 2014, INT J OPHTHALMOL-CHI, V7, P51, DOI 10.3980/j.issn.2222-3959.2014.01.09
   Michalowski MB, 2008, PEDIATR BLOOD CANCER, V50, P29, DOI 10.1002/pbc.21279
   Montenegro MF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052231
   Moshnikova A., 2008, BMC RES NOTES, V1, DOI [10.1186/1756-0500-1-1318710533, DOI 10.1186/1756-0500-1-1318710533]
   Palakurthy RK, 2009, MOL CELL, V36, P219, DOI 10.1016/j.molcel.2009.10.009
   Radonic A, 2004, BIOCHEM BIOPH RES CO, V313, P856, DOI 10.1016/j.bbrc.2003.11.177
   Razumilava N, 2012, HEPATOLOGY, V55, P465, DOI 10.1002/hep.24698
   Rebhan M, 1997, TRENDS GENET, V13, P163, DOI 10.1016/S0168-9525(97)01103-7
   Reeves M. E., 2013, MOL BIOL INT, V2013, DOI [10.1155/2013/14509624327924, DOI 10.1155/2013/14509624327924]
   Richter AM, 2009, BBA-REV CANCER, V1796, P114, DOI 10.1016/j.bbcan.2009.03.004
   Said A., 2016, SPONTANEOUS AGE RELA
   Sakamoto N, 2004, ONCOGENE, V23, P8900, DOI 10.1038/sj.onc.1207993
   Shukla N, 2012, CLIN CANCER RES, V18, P748, DOI 10.1158/1078-0432.CCR-11-2056
   Song MS, 2005, J BIOL CHEM, V280, P3920, DOI 10.1074/jbc.M409115200
   Steinmann K, 2009, ONCOL REP, V22, P1519, DOI 10.3892/or_00000596
   Tommasi S, 2005, CANCER RES, V65, P92
   Tommasi S, 2011, ONCOGENE, V30, P690, DOI 10.1038/onc.2010.440
   van der Weyden L, 2008, ONCOGENE, V27, P4503, DOI 10.1038/onc.2008.94
   van der Weyden L, 2005, MOL CELL BIOL, V25, P8356, DOI 10.1128/MCB.25.18.8356-8367.2005
   Vlahov N, 2015, CURR BIOL, V25, P3019, DOI 10.1016/j.cub.2015.09.072
   Volodko N., 2016, ANAL MOAP 1 PR UNPUB
   Volodko N, 2014, FEBS LETT, V588, P2671, DOI 10.1016/j.febslet.2014.02.041
   Wu TW, 2015, CARCINOGENESIS, V36, P925, DOI 10.1093/carcin/bgv068
   Yan B, 2012, APOPTOSIS, V17, P717, DOI 10.1007/s10495-012-0710-9
   Zare-Abdollahi D, 2014, MED ONCOL, V31, DOI 10.1007/s12032-013-0770-x
   Zhang CY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110159
   Zhang HL, 2013, FASEB J, V27, P232, DOI 10.1096/fj.12-215491
   Zhang Y, 2015, BRIT J CANCER, V112, P365, DOI 10.1038/bjc.2014.593
   Zhao LD, 2016, INT J ONCOL, V48, P1977, DOI 10.3892/ijo.2016.3414
   Zhong XL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059089
   Zhou X, 2012, BIOCHEM J, V441, P227, DOI 10.1042/BJ20111500
NR 53
TC 16
Z9 17
U1 0
U2 4
PU MDPI AG
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
SN 2072-6694
J9 CANCERS
JI Cancers
PD JUN
PY 2016
VL 8
IS 6
AR 55
DI 10.3390/cancers8060055
PG 22
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA EO7RZ
UT WOS:000396889100002
PM 27294960
OA Green Published, Green Submitted, gold
DA 2025-01-12
ER

PT J
AU Sun, Y
   Jin, SD
   Zhu, Q
   Han, L
   Feng, J
   Lu, XY
   Wang, W
   Wang, F
   Guo, RH
AF Sun, Yue
   Jin, Shi-Dai
   Zhu, Quan
   Han, Liang
   Feng, Jing
   Lu, Xi-Yi
   Wang, Wei
   Wang, Feng
   Guo, Ren-Hua
TI Long non-coding RNA LUCAT1 is associated with poor prognosis in human
   non-small lung cancer and regulates cell proliferation via
   epigenetically repressing p21 and p57 expression
SO ONCOTARGET
LA English
DT Article
DE LncRNAs; LUCAT1; p21; p57; non-small cell lung cancer (NSCLC)
ID BREAST-CANCER; HEPATOCELLULAR-CARCINOMA; DNA METHYLATION; EZH2; GENE;
   P57(KIP2); PROGRESSION; METASTASIS; LNCRNA; METHYLTRANSFERASE
AB Recently, long non-coding RNAs (lncRNAs) have been recognized as playing key roles in regulating cellular processes, such as proliferation, invasion, and metastasis. These lncRNAs have been shown to be abnormally expressed in tumorigenic processes. However, the role and clinical relevance of LUCAT1 in non-small-cell lung cancer (NSCLC) remain unclear. In this study, we found that the expression of LUCAT1 was significantly up-regulated in NSCLC tissues compared to non-tumor tissues, and its expression was associated with tumor size, tumor-node-metastasis (TNM) stage and overall survival (OS). Further experiments showed that LUCAT1 knockdown inhibited cell proliferation both in vitro and in vivo. Mechanistic investigations showed that LUCAT1 plays a key role in G0/G1 arrest. We further demonstrated that LUCAT1 was associated with polycomb repressor complexes (PRC2) and that this association was required for epigenetically repression of p21 and p57, thus contributing to the regulation of NSCLC cell cycle and proliferation. In summary, our results show that LUCAT1 could regulate tumorigenesis of NSCLC and be biomarker for poor prognosis in NSCLC.
C1 [Sun, Yue; Feng, Jing] Southeast Univ, Coll Med, Affiliated Yanchen Hosp, Dept Oncol,Yancheng Peoples Hosp 3, Yancheng, Jiangsu, Peoples R China.
   [Jin, Shi-Dai; Lu, Xi-Yi; Guo, Ren-Hua] Nanjing Med Univ, Affiliated Hosp 1, Dept Oncol, Nanjing, Jiangsu, Peoples R China.
   [Zhu, Quan; Wang, Wei; Wang, Feng] Nanjing Med Univ, Affiliated Hosp 1, Dept Thorac Surg, Nanjing, Jiangsu, Peoples R China.
   [Han, Liang] Southeast Univ, Coll Med, Affiliated Xuzhou Hosp, Dept Oncol,Xuzhou Cent Hosp, Xuzhou, Jiangsu, Peoples R China.
   [Feng, Jing] Jiangsu Shengze Hosp, Dept Oncol, Suzhou, Jiangsu, Peoples R China.
   [Han, Liang] Southeast Univ, Coll Med, Affiliated Yanchen Hosp, Dept Oncol,Yancheng Peoples Hosp 3, Yancheng, Jiangsu, Peoples R China.
C3 Southeast University - China; Nanjing Medical University; Nanjing
   Medical University; Southeast University - China; Southeast University -
   China
RP Guo, RH (通讯作者)，Nanjing Med Univ, Affiliated Hosp 1, Dept Oncol, Nanjing, Jiangsu, Peoples R China.
EM rhguo@njmu.edu.cn
RI Lu, Xiyi/HNQ-3223-2023; Sun, Yue/B-1373-2013; Wang, Feng/F-2653-2015;
   Wang, Wei/JAO-0499-2023
OI Wang, Wei/0000-0002-1614-0759
FU National Natural Science Foundation of China [81172217]; Medical
   Important Talents of Jiangsu Province [RC201157]
FX This work was supported by the National Natural Science Foundation of
   China (81172217) and the Medical Important Talents of Jiangsu Province
   (RC201157).
CR Abbas T, 2009, NAT REV CANCER, V9, P400, DOI 10.1038/nrc2657
   Amaral PP, 2008, SCIENCE, V319, P1787, DOI 10.1126/science.1155472
   Benetatos L, 2013, INT J CANCER, V133, P267, DOI 10.1002/ijc.27859
   Brockdorff N, 2013, RNA, V19, P429, DOI 10.1261/rna.037598.112
   Chase A, 2011, CLIN CANCER RES, V17, P2613, DOI 10.1158/1078-0432.CCR-10-2156
   Cicenas J, 2011, J CANCER RES CLIN, V137, P1409, DOI 10.1007/s00432-011-1039-4
   Czermin B, 2002, CELL, V111, P185, DOI 10.1016/S0092-8674(02)00975-3
   DeSantis CE, 2014, CA-CANCER J CLIN, V64, P252, DOI 10.3322/caac.21235
   Fan T, 2011, MOL CANCER RES, V9, P418, DOI 10.1158/1541-7786.MCR-10-0511
   Foster CS, 2004, ONCOGENE, V23, P5871, DOI 10.1038/sj.onc.1207800
   Fu XQ, 2006, DNA CELL BIOL, V25, P135, DOI 10.1089/dna.2006.25.135
   Goldstraw Peter, 2007, J Thorac Oncol, V2, P706, DOI 10.1097/JTO.0b013e31812f3c1a
   Gutschner T, 2013, CANCER RES, V73, P1180, DOI 10.1158/0008-5472.CAN-12-2850
   Gutschner T, 2012, RNA BIOL, V9, P703, DOI 10.4161/rna.20481
   Guttman M, 2009, NATURE, V458, P223, DOI 10.1038/nature07672
   Hagiwara K, 2010, LEUKEMIA RES, V34, P50, DOI 10.1016/j.leukres.2009.06.028
   Hauptman N, 2013, INT J MOL SCI, V14, P4655, DOI 10.3390/ijms14034655
   Hu TH, 2013, ONCOL REP, V30, P1707, DOI 10.3892/or.2013.2608
   Khalil AM, 2009, P NATL ACAD SCI USA, V106, P11667, DOI 10.1073/pnas.0904715106
   Lee JT, 2012, SCIENCE, V338, P1435, DOI 10.1126/science.1231776
   Li JQ, 2003, INT J ONCOL, V23, P1537
   Li YH, 2002, BLOOD, V100, P2572, DOI 10.1182/blood-2001-11-0026
   Liao WT, 2009, CANCER-AM CANCER SOC, V115, P1507, DOI 10.1002/cncr.24128
   Lim SH, 2013, DEVELOPMENT, V140, P3079, DOI 10.1242/dev.091744
   Lin L, 2015, DIAGN PATHOL, V10, DOI 10.1186/s13000-015-0247-7
   Liu YY, 2014, INT J GYNECOL PATHOL, V33, P218, DOI 10.1097/PGP.0b013e31829c6574
   Matsukawa Y, 2006, CANCER SCI, V97, P484, DOI 10.1111/j.1349-7006.2006.00203.x
   Mourtada-Maarabouni M, 2009, ONCOGENE, V28, P195, DOI 10.1038/onc.2008.373
   Paul TA, 2010, BLOOD, V115, P3098, DOI 10.1182/blood-2009-07-233858
   Prensner JR, 2011, CANCER DISCOV, V1, P391, DOI 10.1158/2159-8290.CD-11-0209
   Prensner JR, 2011, NAT BIOTECHNOL, V29, P742, DOI 10.1038/nbt.1914
   Raaphorst FM, 2003, NEOPLASIA, V5, P481, DOI 10.1016/S1476-5586(03)80032-5
   Rinn JL, 2007, CELL, V129, P1311, DOI 10.1016/j.cell.2007.05.022
   Schmidt LH, 2011, J THORAC ONCOL, V6, P1984, DOI 10.1097/JTO.0b013e3182307eac
   Sudo T, 2005, BRIT J CANCER, V92, P1754, DOI 10.1038/sj.bjc.6602531
   Sun M, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-68
   Teramen H, 2011, ACTA MED OKAYAMA, V65, P179
   Thai P, 2013, AM J RESP CELL MOL, V49, P204, DOI 10.1165/rcmb.2013-0159RC
   Travis WD, 2011, CLIN CHEST MED, V32, P669, DOI 10.1016/j.ccm.2011.08.005
   Tzankov A, 2006, CLIN CANCER RES, V12, P2125, DOI 10.1158/1078-0432.CCR-05-2135
   Watanabe H, 2008, CANCER CELL INT, V8, DOI 10.1186/1475-2867-8-15
   Xie X, 2014, INT J CLIN EXP PATHO, V7, P8881
   Xu XY, 2012, ASIAN PAC J CANCER P, V13, P5033, DOI 10.7314/APJCP.2012.13.10.5033
   Yang GD, 2014, BBA-GENE REGUL MECH, V1839, P1097, DOI 10.1016/j.bbagrm.2014.08.012
   Yang JC, 2014, LUNG CANCER, V85, P110, DOI 10.1016/j.lungcan.2014.05.011
   Yang XJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005011
   Yoo KH, 2012, INT J BIOL SCI, V8, P59, DOI 10.7150/ijbs.8.59
   Yu H, 2015, J THORAC ONCOL, V10, P645, DOI 10.1097/JTO.0000000000000470
   Zhang EB, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.201
NR 49
TC 89
Z9 95
U1 0
U2 16
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD APR 25
PY 2017
VL 8
IS 17
BP 28297
EP 28311
DI 10.18632/oncotarget.16044
PG 15
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA ET1SU
UT WOS:000400050000055
PM 28423699
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Spitzwieser, M
   Entfellner, E
   Werner, B
   Pulverer, W
   Pfeiler, G
   Hacker, S
   Cichna-Markl, M
AF Spitzwieser, Melanie
   Entfellner, Elisabeth
   Werner, Bettina
   Pulverer, Walter
   Pfeiler, Georg
   Hacker, Stefan
   Cichna-Markl, Margit
TI Hypermethylation of <i>CDKN2A</i> exon 2 in tumor, tumor-adjacent and
   tumor-distant tissues from breast cancer patients
SO BMC CANCER
LA English
DT Article
DE DNA methylation; CDKN2A; Exon 2; Tumor suppressor genes; Breast cancer;
   Field cancerization; Tumor-adjacent tissue; Tumor-distant tissue;
   Methylation-sensitive high resolution melting; Pyrosequencing
ID CPG ISLAND HYPERMETHYLATION; GENE PROMOTER HYPERMETHYLATION; ABERRANT
   DNA METHYLATION; SPORADIC BREAST; ADENOMATOUS-POLYPOSIS;
   CLINICOPATHOLOGICAL FEATURES; FIELD CANCERIZATION; PROTEIN EXPRESSION;
   PROSTATE-CANCER; SUPPRESSOR GENE
AB Background: Breast carcinogenesis is a multistep process involving genetic and epigenetic changes. Tumor tissues are frequently characterized by gene-specific hypermethylation and global DNA hypomethylation. Aberrant DNA methylation levels have, however, not only been found in tumors, but also in tumor-surrounding tissue appearing histologically normal. This phenomenon is called field cancerization. Knowledge of the existence of a cancer field and its spread are of clinical relevance. If the tissue showing pre-neoplastic lesions is not removed by surgery, it may develop into invasive carcinoma.
   Methods: We investigated the prevalence of gene-specific and global DNA methylation changes in tumor-adjacent and tumor-distant tissues in comparison to tumor tissues from the same breast cancer patients (n = 18) and normal breast tissues from healthy women (n = 4). Methylation-sensitive high resolution melting (MS-HRM) analysis was applied to determine methylation levels in the promoters of APC, BRCA1, CDKN2A (p16), ESR1, HER2/neu and PTEN, in CDKN2A exon 2 and in LINE-1, as indicator for the global DNA methylation extent. The methylation status of the ESR2 promoter was determined by pyrosequencing.
   Results: Tumor-adjacent and tumor-distant tissues frequently showed pre-neoplastic gene-specific and global DNA methylation changes. The APC promoter (p = 0.003) and exon 2 of CDKN2A (p < 0.001) were significantly higher methylated in tumors than in normal breast tissues from healthy women. For both regions, significant differences were also found between tumor and tumor-adjacent tissues (p = 0.001 and p < 0.001, respectively) and tumor and tumor-distant tissues (p = 0.001 and p < 0.001, respectively) from breast cancer patients. In addition, tumor-adjacent (p = 0.002) and tumor-distant tissues (p = 0.005) showed significantly higher methylation levels of CDKN2A exon 2 than normal breast tissues serving as control. Significant correlations were found between the proliferative activity and the methylation status of CDKN2A exon 2 in tumor (r = -0.485, p = 0.041) and tumor-distant tissues (r = -0.498, p = 0.036).
   Conclusions: From our results we can conclude that methylation changes in CDKN2A exon 2 are associated with breast carcinogenesis. Further investigations are, however, necessary to confirm that hypermethylation of CDKN2A exon 2 is associated with tumor proliferative activity.
C1 [Spitzwieser, Melanie; Entfellner, Elisabeth; Werner, Bettina; Cichna-Markl, Margit] Univ Vienna, Dept Analyt Chem, Wahringer Str 38, A-1090 Vienna, Austria.
   [Pulverer, Walter] Austrian Inst Technol, Mol Diagnost, Muthgasse 11, A-1190 Vienna, Austria.
   [Pfeiler, Georg] Med Univ Vienna, Dept Obstet & Gynecol, Div Gynecol & Gynecol Oncol, Wahringer Gurtel 18-20, A-1090 Vienna, Austria.
   [Hacker, Stefan] Med Univ Vienna, Dept Plast & Reconstruct Surg, Wahringer Gurtel 18-20, A-1090 Vienna, Austria.
C3 University of Vienna; Austrian Institute of Technology (AIT); Medical
   University of Vienna; Medical University of Vienna
RP Cichna-Markl, M (通讯作者)，Univ Vienna, Dept Analyt Chem, Wahringer Str 38, A-1090 Vienna, Austria.
EM margit.cichna@univie.ac.at
OI Hacker, Stefan/0000-0002-6376-4687; Cichna-Markl,
   Margit/0000-0001-8699-674X
FU Open Access Publishing Fund of the University of Vienna
FX This article was supported by the Open Access Publishing Fund of the
   University of Vienna.
CR Askari M, 2013, MOL BIOL REP, V40, P4921, DOI 10.1007/s11033-013-2592-5
   Bae YK, 2004, CLIN CANCER RES, V10, P5998, DOI 10.1158/1078-0432.CCR-04-0667
   Balic M, 2009, J MOL DIAGN, V11, P102, DOI 10.2353/jmoldx.2009.080109
   Bernstein C, 2013, WORLD J GASTRO ONCOL, V5, P43, DOI 10.4251/wjgo.v5.i3.43
   Bhagat R, 2014, TUMOR BIOL, V35, P9069, DOI 10.1007/s13277-014-2136-1
   Birgisdottir V, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1522
   Branham MT, 2012, ONCOGENESIS, V1, DOI 10.1038/oncsis.2012.17
   Brooks J, 2009, CANCER CAUSE CONTROL, V20, P1539, DOI 10.1007/s10552-009-9415-y
   Chai H, 2009, ANN CLIN LAB SCI, V39, P331
   Chattopadhyay S, 2014, TUMOR BIOL, V35, P7911, DOI 10.1007/s13277-014-2052-4
   Cho YH, 2012, BREAST CANCER RES TR, V131, P197, DOI 10.1007/s10549-011-1712-y
   Cho YH, 2010, ANTICANCER RES, V30, P2489
   Medina-Jaime AD, 2014, ASIAN PAC J CANCER P, V15, P3041, DOI 10.7314/APJCP.2014.15.7.3041
   Delpu Y, 2013, INT J MOL SCI, V14, P15029, DOI 10.3390/ijms140715029
   Di Vinci A, 2005, INT J CANCER, V114, P414, DOI 10.1002/ijc.20771
   Duffy MJ, 2009, EUR J CANCER, V45, P335, DOI 10.1016/j.ejca.2008.12.008
   Duffy MJ, 2013, MED PRIN PRACT, V22, P4, DOI 10.1159/000338393
   Dulaimi E, 2004, CLIN CANCER RES, V10, P6189, DOI 10.1158/1078-0432.CCR-04-0597
   Eden A, 2003, SCIENCE, V300, P455, DOI 10.1126/science.1083557
   Ehrlich M, 2002, ONCOGENE, V21, P5400, DOI 10.1038/sj.onc.1205651
   Esteller M, 2000, CANCER RES, V60, P4366
   Esteller M, 2000, JNCI-J NATL CANCER I, V92, P564, DOI 10.1093/jnci/92.7.564
   Esteller M, 2007, HUM MOL GENET, V16, pR50, DOI 10.1093/hmg/ddm018
   Fackler MJ, 2003, INT J CANCER, V107, P970, DOI 10.1002/ijc.11508
   Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210
   García JM, 2004, GENE CHROMOSOME CANC, V41, P117, DOI 10.1002/gcc.20062
   García-Giménez JL, 2012, CLIN CHIM ACTA, V413, P1576, DOI 10.1016/j.cca.2012.05.021
   Guo TY, 2015, MOL CLIN ONCOL, V3, P1353, DOI 10.3892/mco.2015.620
   Heaphy CM, 2009, BREAST CANCER RES TR, V118, P229, DOI 10.1007/s10549-009-0504-0
   Holm K, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2590
   Hoque MO, 2009, CANCER EPIDEM BIOMAR, V18, P2694, DOI 10.1158/1055-9965.EPI-08-0821
   Huang KT, 2010, BREAST CANCER RES TR, V124, P555, DOI 10.1007/s10549-010-0970-4
   Jin Z, 2001, BRIT J CANCER, V85, P69, DOI 10.1054/bjoc.2001.1853
   Jovanovic J, 2010, MOL ONCOL, V4, P242, DOI 10.1016/j.molonc.2010.04.002
   Kempster S, 2000, CANCER LETT, V150, P57, DOI 10.1016/S0304-3835(99)00372-9
   Khan S, 2004, INT J CANCER, V112, P407, DOI 10.1002/ijc.20447
   Klajic J, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-456
   Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412
   Krassenstein R, 2004, CLIN CANCER RES, V10, P28, DOI 10.1158/1078-0432.CCR-0410-3
   Krishnamurti U, 2014, ADV ANAT PATHOL, V21, P100, DOI 10.1097/PAP.0000000000000015
   Lewis CM, 2005, CLIN CANCER RES, V11, P166
   Li Y, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1412-9
   Liggett WH, 1998, J CLIN ONCOL, V16, P1197, DOI 10.1200/JCO.1998.16.3.1197
   Martínez-Galán J, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-59
   Mehrotra J, 2008, PROSTATE, V68, P152, DOI 10.1002/pros.20675
   Miklos W, 2015, CANCER LETT, V361, P112, DOI 10.1016/j.canlet.2015.02.049
   Mitomi H, 2010, J CANCER RES CLIN, V136, P323, DOI 10.1007/s00432-009-0688-z
   Muggerud AA, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2466
   Office of Pesticide Programs U.S. Environmental Protection Agency Washington DC., ASS VAL NOND NONQ PE
   Park SY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100429
   Prabhu JS, 2012, TUMOR BIOL, V33, P315, DOI 10.1007/s13277-012-0343-1
   Ramos EAS, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-23
   Rauscher GH, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1777-9
   Rivenbark AG, 2012, EXP MOL PATHOL, V93, P391, DOI 10.1016/j.yexmp.2012.10.018
   Rody A, 2005, ENDOCR-RELAT CANCER, V12, P903, DOI 10.1677/erc.1.01088
   Rybicki BA, 2016, INT J CANCER, V138, P2884, DOI 10.1002/ijc.30038
   Sadeq V, 2011, MED ONCOL, V28, P420, DOI 10.1007/s12032-010-9473-8
   Sarrió D, 2003, INT J CANCER, V106, P208, DOI 10.1002/ijc.11197
   Sinha S, 2008, ANN SURG ONCOL, V15, P1070, DOI 10.1245/s10434-007-9790-0
   Spitzwieser M, 2016, ONCOTARGET, V7, P73347, DOI 10.18632/oncotarget.12332
   Spitzwieser M, 2015, BREAST CANCER RES, V17, DOI 10.1186/s13058-015-0637-5
   Stefansson OA, 2011, EPIGENETICS-US, V6, P638, DOI 10.4161/epi.6.5.15667
   Stirzaker C, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms6899
   Suijkerbuijk KPM, 2008, ANN ONCOL, V19, P1870, DOI 10.1093/annonc/mdn409
   Szyf M, 2012, GENOME MED, V4, DOI 10.1186/gm325
   Tao MH, 2009, BREAST CANCER RES TR, V114, P559, DOI 10.1007/s10549-008-0028-z
   Terada K, 2009, CARCINOGENESIS, V30, P466, DOI 10.1093/carcin/bgp021
   Tserga A, 2012, ONCOL REP, V27, P1630, DOI 10.3892/or.2011.1576
   Van der Auwera I, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-97
   van Hoesel AQ, 2012, BREAST CANCER RES TR, V134, P1103, DOI 10.1007/s10549-012-2038-0
   Virmani AK, 2001, CLIN CANCER RES, V7, P1998
   Wang FL, 2014, BIOMED PHARMACOTHER, V68, P699, DOI 10.1016/j.biopha.2014.07.014
   Wei MJ, 2008, BREAST CANCER RES TR, V111, P113, DOI 10.1007/s10549-007-9766-6
   Widschwendter M, 2002, ONCOGENE, V21, P5462, DOI 10.1038/sj.onc.1205606
   Wong EM, 2011, CANCER PREV RES, V4, P23, DOI 10.1158/1940-6207.CAPR-10-0212
   Woodcock DM, 1999, BRIT J CANCER, V79, P251, DOI 10.1038/sj.bjc.6690041
   Xu XR, 2010, BREAST CANCER RES TR, V121, P685, DOI 10.1007/s10549-009-0628-2
   Xu XR, 2009, BREAST CANCER RES TR, V115, P397, DOI 10.1007/s10549-008-0075-5
   Yamaguchi K, 2016, SCI REP-UK, V6, DOI 10.1038/srep26011
   Zhang HY, 2013, ONCOL LETT, V6, P161, DOI 10.3892/ol.2013.1331
NR 80
TC 25
Z9 28
U1 0
U2 5
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2407
J9 BMC CANCER
JI BMC Cancer
PD APR 12
PY 2017
VL 17
AR 260
DI 10.1186/s12885-017-3244-2
PG 16
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA ES6OL
UT WOS:000399668100004
PM 28403857
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Lacazette, E
AF Lacazette, Eric
TI A Laboratory Practical Illustrating the Use of the ChIP-qPCR Method in a
   Robust Model: Estrogen Receptor Alpha Immunoprecipitation Using Mcf-7
   Culture Cells
SO BIOCHEMISTRY AND MOLECULAR BIOLOGY EDUCATION
LA English
DT Article
DE ChIP-qPCR; immunoprecipitation; gene expression; epigenetics; molecular
   biology
ID PROTEIN-DNA INTERACTIONS; BREAST-CANCER; ASSAY
AB Chromatin immunoprecipitation followed by qPCR analysis (ChIP-qPCR) is a widely used technique to study gene expression. A large number of students in molecular biology and more generally in life sciences will be confronted with the use of this technique, which is quite difficult to set up and can lead to misinterpretation if not carefully managed. This article describes a four-session laboratory practical designed for Masters students to introduce this technique. During the practical, students work in pairs. They extract chromatin from MCF-7 culture cells stimulated or not by estrogens, then immunoprecipitate the transcription factor estrogen receptor alpha using an antibody directed against it. Students then measure the enrichment of promoter DNA target sequences from the chromatin that coprecipitates by qPCR. These are two estrogen responsive genes, pS2 (trefoil factor one) and PGR (the progesterone receptor). They learn how to analyze their ChIP-qPCR data by two methods: percent input and fold enrichment, and are taught about the interpretation limits of these two calculation methods. Thus, this practical is a good framework for an in-depth discussion of how this technique can be used to study gene expression and for raising awareness of the importance of careful interpretation of results. (C) 2016 by The International Union of Biochemistry and Molecular Biology, 45(2): 152-160, 2017.
C1 [Lacazette, Eric] Univ Toulouse III Paul Sabatier, Canc Res Ctr Toulouse, Inserm UMR1037, Oncopole Toulouse, F-31037 Toulouse 1, France.
C3 Institut National de la Sante et de la Recherche Medicale (Inserm);
   Universite de Toulouse; Universite Toulouse III - Paul Sabatier
RP Lacazette, E (通讯作者)，Univ Toulouse III Paul Sabatier, Canc Res Ctr Toulouse, Inserm UMR1037, Oncopole Toulouse, F-31037 Toulouse 1, France.
EM eric.lacazette@inserm.fr
RI Lacazette, eric/M-7168-2014
OI lacazette, eric/0000-0003-1234-5260
CR Aparicio Oscar, 2004, Curr Protoc Cell Biol, VChapter 17, DOI 10.1002/0471143030.cb1707s23
   BROOKS SC, 1973, J BIOL CHEM, V248, P6251
   Dahl JA, 2008, NUCLEIC ACIDS RES, V36, DOI 10.1093/nar/gkm1158
   Feigelson HS, 1996, CARCINOGENESIS, V17, P2279, DOI 10.1093/carcin/17.11.2279
   Fullwood MJ, 2009, GENOME RES, V19, P521, DOI 10.1101/gr.074906.107
   Haring M, 2007, PLANT METHODS, V3, DOI 10.1186/1746-4811-3-11
   HORWITZ KB, 1978, J BIOL CHEM, V253, P2223
   Johnson DS, 2007, SCIENCE, V316, P1497, DOI 10.1126/science.1141319
   Nilsson S, 2001, PHYSIOL REV, V81, P1535, DOI 10.1152/physrev.2001.81.4.1535
   Rieu I, 2009, PLANT CELL, V21, P1031, DOI 10.1105/tpc.109.066001
   SOLOMON MJ, 1988, CELL, V53, P937, DOI 10.1016/S0092-8674(88)90469-2
   Taneyhill LA, 2008, METHOD CELL BIOL, V87, P367, DOI 10.1016/S0091-679X(08)00219-7
   VILLALOBOS M, 1995, ENVIRON HEALTH PERSP, V103, P844, DOI 10.1289/ehp.95103844
NR 13
TC 18
Z9 18
U1 8
U2 34
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1470-8175
EI 1539-3429
J9 BIOCHEM MOL BIOL EDU
JI Biochem. Mol. Biol. Educ.
PD MAR-APR
PY 2017
VL 45
IS 2
BP 152
EP 160
DI 10.1002/bmb.20999
PG 9
WC Biochemistry & Molecular Biology; Education, Scientific Disciplines
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Education & Educational Research
GA EQ4KG
UT WOS:000398045000009
PM 27666748
OA Bronze
DA 2025-01-12
ER

PT J
AU Inari, H
   Suganuma, N
   Kawachi, K
   Yoshida, T
   Yamanaka, T
   Nakamura, Y
   Yoshihara, M
   Nakayama, H
   Yamanaka, A
   Masudo, K
   Oshima, T
   Yokose, T
   Rino, Y
   Shimizu, S
   Miyagi, Y
   Masuda, M
AF Inari, Hitoshi
   Suganuma, Nobuyasu
   Kawachi, Kae
   Yoshida, Tatsuya
   Yamanaka, Takashi
   Nakamura, Yoshiyasu
   Yoshihara, Mitsuyo
   Nakayama, Hirotaka
   Yamanaka, Ayumi
   Masudo, Katsuhiko
   Oshima, Takashi
   Yokose, Tomoyuki
   Rino, Yasushi
   Shimizu, Satoru
   Miyagi, Yohei
   Masuda, Munetaka
TI Expression of enhancer of zeste homolog 2 correlates with survival
   outcome in patients with metastatic breast cancer: exploratory study
   using primary and paired metastatic lesions
SO BMC CANCER
LA English
DT Article
DE Metastatic breast cancer; EZH2; Ki-67; Prognostic factor;
   Immunohistochemistry; Epigenetics
ID GROUP PROTEIN EZH2; TERM-FOLLOW-UP; METHYLTRANSFERASE EZH2;
   EPITHELIAL-CELLS; POLYCOMB; CHEMOTHERAPY; PROGNOSIS; ER; PROLIFERATION;
   DISCORDANCE
AB Background: In metastatic breast cancer, the status of the estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2), as well as the Ki-67 index sometimes change between primary and metastatic lesions. However, the change in expression levels of enhancer of zeste homolog 2 (EZH2) between primary and metastatic lesions has not been determined in metastatic breast cancer.
   Methods: Ninety-six metastatic breast cancer patients had biopsies or resections of metastatic lesions between September 1990 and February 2014 at the Kanagawa Cancer Center. We evaluated ER, PR, HER2, Ki-67, and EZH2 in primary lesions and their corresponding metastatic lesions using immunohistochemistry. We examined the change in expression of EZH2 between primary and metastatic lesions, the correlation between the expression of EZH2 and the expression of other biomarkers, and the relationship between EZH2 expression and patient outcome in metastatic breast cancer.
   Results: EZH2 expression was significantly higher in metastatic lesions compared with primary lesions. EZH2 expression was highly correlated with Ki-67 expression in primary and metastatic lesions. High-level expression of EZH2 was associated with poorer disease-free survival (DFS) outcomes in patients with primary lesions (P < 0.001); however, high-level expression of EZH2 was not associated with poorer DFS outcomes in patients with metastatic lesions (P = 0.063). High-level expression of EZH2 was associated with poorer overall survival (OS) postoperatively in patients with primary (P = 0.001) or metastatic lesions (P = 0.005). High-level expression of EZH2 was associated with poorer OS outcomes after recurrence in patients with metastatic lesions (P = 0.014); however, high-level expression of EZH2 was not associated with poorer OS outcomes after recurrence in patients with primary lesions (P = 0.096). High- level expression of EZH2 in metastatic lesions was independently associated with poorer OS outcomes after recurrence. (Continued on next page)
   Conclusions: EZH2 expression was significantly increased in metastatic lesions compared with primary lesions. High-level expression of EZH2 in metastatic lesions was associated with poorer OS outcomes after primary surgery and recurrence.
C1 [Inari, Hitoshi; Suganuma, Nobuyasu; Yoshida, Tatsuya; Yamanaka, Takashi; Shimizu, Satoru] Kanagawa Canc Ctr, Dept Breast & Endocrine Surg, Asahi Ku, 2-3-2 Nakao, Yokohama, Kanagawa 2410815, Japan.
   [Nakamura, Yoshiyasu; Yoshihara, Mitsuyo; Miyagi, Yohei] Kanagawa Canc Ctr, Mol Pathol & Genet Div, Asahi Ku, 2-3-2 Nakao, Yokohama, Kanagawa 2410815, Japan.
   [Kawachi, Kae; Yokose, Tomoyuki] Kanagawa Canc Ctr, Dept Pathol, Asahi Ku, 2-3-2 Nakao, Yokohama, Kanagawa 2410815, Japan.
   [Nakayama, Hirotaka; Yamanaka, Ayumi; Masudo, Katsuhiko; Oshima, Takashi; Rino, Yasushi; Masuda, Munetaka] Yokohama City Univ, Dept Surg, Kanazawa Ku, 3-9 Fukuura, Yokohama, Kanagawa 2360004, Japan.
C3 Kanagawa Prefectural Cancer Center; Kanagawa Prefectural Cancer Center;
   Kanagawa Prefectural Cancer Center; Yokohama City University
RP Inari, H (通讯作者)，Kanagawa Canc Ctr, Dept Breast & Endocrine Surg, Asahi Ku, 2-3-2 Nakao, Yokohama, Kanagawa 2410815, Japan.; Miyagi, Y (通讯作者)，Kanagawa Canc Ctr, Mol Pathol & Genet Div, Asahi Ku, 2-3-2 Nakao, Yokohama, Kanagawa 2410815, Japan.; Masuda, M (通讯作者)，Yokohama City Univ, Dept Surg, Kanazawa Ku, 3-9 Fukuura, Yokohama, Kanagawa 2360004, Japan.
EM inari-hitoshi@nifty.com; miyagi@gancen.asahi.yokohama.jp;
   mmasuda@yokohama-cu.ac.jp
OI Yoshida, Tatsuya/0000-0002-6963-5827
FU Platform of Supporting Cohort Study and Biospecimen Analysis [16H06277]
FX This work was partly supported by the Platform of Supporting Cohort
   Study and Biospecimen Analysis, Grant-in-Aid for Scientific Research on
   Innovative Areas (16H06277).
CR Amir E, 2012, J CLIN ONCOL, V30, P587, DOI 10.1200/JCO.2010.33.5232
   [Anonymous], 2016, NCCN Clin Pract Guidel Oncol
   Bachmann IM, 2006, J CLIN ONCOL, V24, P268, DOI 10.1200/JCO.2005.01.5180
   Boyer LA, 2006, NATURE, V441, P349, DOI 10.1038/nature04733
   Bracken AP, 2003, EMBO J, V22, P5323, DOI 10.1093/emboj/cdg542
   Cao Q, 2008, ONCOGENE, V27, P7274, DOI 10.1038/onc.2008.333
   Cao R, 2002, SCIENCE, V298, P1039, DOI 10.1126/science.1076997
   Cardoso F, 2014, ANN ONCOL, V25, P1871, DOI 10.1093/annonc/mdu385
   Chang CJ, 2011, CANCER CELL, V19, P86, DOI 10.1016/j.ccr.2010.10.035
   Changchien YC, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-216
   Dowsett M, 2008, CLIN CANCER RES, V14, P8019, DOI 10.1158/1078-0432.CCR-08-0974
   Epizyme® Inc, 2013, EP IS CLIN STAG BIOP
   Fluge O, 2009, BRIT J CANCER, V101, P1282, DOI 10.1038/sj.bjc.6605333
   Gonzalez ME, 2009, ONCOGENE, V28, P843, DOI 10.1038/onc.2008.433
   Gonzalez ME, 2011, CANCER RES, V71, P2360, DOI 10.1158/0008-5472.CAN-10-1933
   Greenberg PAC, 1996, J CLIN ONCOL, V14, P2197, DOI 10.1200/JCO.1996.14.8.2197
   Hitoshi I, 2016, J CLIN ONCOL, V34
   Hortobagyi GN, 2002, J CLIN ONCOL, V20, P620, DOI 10.1200/JCO.2002.20.3.620
   Hortobagyi GN, 1998, NEW ENGL J MED, V339, P974, DOI 10.1056/NEJM199810013391407
   Hussein YR, 2012, HUM PATHOL, V43, P1638, DOI 10.1016/j.humpath.2011.12.004
   Kiba T, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-323
   Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100
   Knutson SK, 2013, P NATL ACAD SCI USA, V110, P7922, DOI 10.1073/pnas.1303800110
   Kobayashi T, 2012, BREAST CANCER-TOKYO, V19, P187, DOI 10.1007/s12282-011-0307-0
   Levine SS, 2002, MOL CELL BIOL, V22, P6070, DOI 10.1128/MCB.22.17.6070-6078.2002
   Liedtke C, 2009, ANN ONCOL, V20, P1953, DOI 10.1093/annonc/mdp263
   Nishimura R, 2011, WORLD J SURG ONCOL, V9, DOI 10.1186/1477-7819-9-131
   Nishimura R, 2010, BREAST CANCER-TOKYO, V17, P269, DOI 10.1007/s12282-009-0161-5
   Rahman ZU, 1999, CANCER, V85, P104, DOI 10.1002/(SICI)1097-0142(19990101)85:1<104::AID-CNCR15>3.0.CO;2-R
   Reijm EA, 2014, ANN ONCOL, V25, P2185, DOI 10.1093/annonc/mdu391
   Reijm EA, 2011, BREAST CANCER RES TR, V125, P387, DOI 10.1007/s10549-010-0836-9
   Sato T, 2013, SCI REP-UK, V3, DOI 10.1038/srep01911
   Schuettengruber B, 2007, CELL, V128, P735, DOI 10.1016/j.cell.2007.02.009
   Sihto H, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2944
   Simmons C, 2009, ANN ONCOL, V20, P1499, DOI 10.1093/annonc/mdp028
   Tanei T, 2011, EJSO-EUR J SURG ONC, V37, P155, DOI 10.1016/j.ejso.2010.10.009
   Thompson AM, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2771
   Wolff AC, 2013, J CLIN ONCOL, V31, P3997, DOI [10.1200/JCO.2013.50.9984, 10.5858/arpa.2013-0953-SA]
   Zeidler M, 2005, NEOPLASIA, V7, P1011, DOI 10.1593/neo.05472
NR 39
TC 17
Z9 19
U1 0
U2 1
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2407
J9 BMC CANCER
JI BMC Cancer
PD FEB 27
PY 2017
VL 17
AR 160
DI 10.1186/s12885-017-3154-3
PG 14
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA EQ0NS
UT WOS:000397768500002
PM 28241804
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Chevrier, M
   Bobbala, D
   Villalobos-Hernandez, A
   Khan, MGM
   Ramanathan, S
   Saucier, C
   Ferbeyre, G
   Geha, S
   Ilangumaran, S
AF Chevrier, Martin
   Bobbala, Diwakar
   Villalobos-Hernandez, Alberto
   Khan, Md Gulam Musawwir
   Ramanathan, Sheela
   Saucier, Caroline
   Ferbeyre, Gerardo
   Geha, Sameh
   Ilangumaran, Subburaj
TI Expression of SOCS1 and the downstream targets of its putative tumor
   suppressor functions in prostate cancer
SO BMC CANCER
LA English
DT Article
DE Prostate cancer; SOCS1; Tumor suppressor; MET; p21
ID C-MET; ANDROGEN RECEPTOR; HEPATOCELLULAR-CARCINOMA; BREAST-CANCER;
   GROWTH-FACTOR; PROGRESSION; CELLS; GENE; METHYLATION; P21
AB Background: Suppressor of cytokine signaling 1 (SOCS1) is considered a tumor suppressor due to frequent epigenetic and micro-RNA-mediated repression of its gene expression in diverse cancers. In prostate cancer (PCa), elevated expression of miR-30d that targets SOCS1 mRNA is associated with increased risk of disease recurrence. SOCS1 can mediate its tumor suppressor functions by diverse mechanisms such as inhibiting the JAK-STAT signaling pathway, promoting the tumor suppressor functions of p53, attenuating MET receptor tyrosine kinase signaling and blocking the oncogenic potential of the cell cycle inhibitor p21(CIP1) (p21). Here, we studied the expression of SOCS1 and the downstream targets of its putative tumor suppressor functions (p53, MET and p21) in human PCa specimens to evaluate their significance as markers of disease prognosis.
   Methods: Tissue microarrays were constructed of 78 archived prostatectomy specimens that were grouped according to the recommendations of the International Society of Urological Pathology (ISUP) based on the Gleason patterns. SOCS1, p53, MET and p21 protein expression were evaluated by immunohistochemical staining alongside the common prostate cancer-related markers Ki67, prostein and androgen receptor. Statistical correlations between the staining intensities of these markers and ISUP grade groups, local invasion or lymph node metastasis were evaluated.
   Results: SOCS1 showed diffuse staining in the prostatic epithelium. SOCS1 staining intensity correlated inversely with the ISUP grade groups (rho = -0.4687, p <0.0001) and Ki67 (rho = -0.2444, p = 0.031), and positively with prostein (rho = 0.3511, p = 0.0016). Changes in SOCS1 levels did not significantly associate with those of p53, MET or p21. However, p21 positively correlated with androgen receptor expression (rho = -0.1388, p = 0.0003). A subset of patients with regional lymph node metastasis, although small in number, showed reduced SOCS1 expression and increased expression of MET and p21.
   Conclusions: Our findings suggest that evaluating SOCS1 and p21 protein expression in prostatectomy specimens may have a prognostic value in identifying the aggressive disease. Hence, prospective studies with larger numbers of metastatic PCa specimens incorporating clinical correlates such as disease-free and overall survival are warranted.
C1 [Chevrier, Martin; Geha, Sameh] Univ Sherbrooke, Fac Med & Hlth Sci, Dept Pathol, Sherbrooke, PQ, Canada.
   [Bobbala, Diwakar; Villalobos-Hernandez, Alberto; Khan, Md Gulam Musawwir; Ramanathan, Sheela; Ilangumaran, Subburaj] Univ Sherbrooke, Fac Med & Hlth Sci, Div Immunol, Dept Pediat, Sherbrooke, PQ, Canada.
   [Saucier, Caroline] Univ Sherbrooke, Fac Med & Hlth Sci, Dept Anat & Cell Biol, Sherbrooke, PQ, Canada.
   [Ferbeyre, Gerardo] Univ Montreal, Fac Med, Dept Biochem, Montreal, PQ, Canada.
   [Ramanathan, Sheela; Saucier, Caroline; Geha, Sameh; Ilangumaran, Subburaj] CHU Sherbrooke, Ctr Rech, Sherbrooke, PQ J1H 5N4, Canada.
C3 University of Sherbrooke; University of Sherbrooke; University of
   Sherbrooke; Universite de Montreal; University of Sherbrooke
RP Ilangumaran, S (通讯作者)，Univ Sherbrooke, Fac Med & Hlth Sci, Div Immunol, Dept Pediat, Sherbrooke, PQ, Canada.; Ilangumaran, S (通讯作者)，CHU Sherbrooke, Ctr Rech, Sherbrooke, PQ J1H 5N4, Canada.
EM Subburaj.Ilangumaran@USherbrooke.ca
RI Geha, Sameh/AAE-6127-2020; Ferbeyre, Gerardo/A-1569-2010; Saucier,
   Caroline/Q-9250-2019
OI Ferbeyre, Gerardo/0000-0002-2146-618X; Khan, Md Gulam
   Musawwir/0000-0001-7424-580X; Ilangumaran, Subburaj/0000-0002-7563-576X
FU Movember Discovery Grant from Prostate Cancer Canada [D2013-20];
   Master's degree scholarship from the Faculty of Medicine, Universite de
   Sherbrooke; FRQS; CRCHUS is an FRQS
FX This work was supported by Movember Discovery Grant from Prostate Cancer
   Canada (Grant number D2013-20). AVH was supported by a Master's degree
   scholarship from the Faculty of Medicine, Universite de Sherbrooke. DB
   is a recipient of a postdoctoral fellowship from FRQS. CRCHUS is an
   FRQS-funded research center.
CR Abbas T, 2009, NAT REV CANCER, V9, P400, DOI 10.1038/nrc2657
   Alexander WS, 2002, NAT REV IMMUNOL, V2, P410, DOI 10.1038/nri818
   Balk SP, 2002, UROLOGY, V60, P132, DOI 10.1016/S0090-4295(02)01593-5
   Calabrese V, 2009, MOL CELL, V36, P754, DOI 10.1016/j.molcel.2009.09.044
   Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095
   Ciccarese C, 2016, CANCER TREAT REV, V43, P27, DOI 10.1016/j.ctrv.2015.12.003
   Deng JY, 2010, WORLD J GASTROENTERO, V16, P5380, DOI 10.3748/wjg.v16.i42.5380
   Edge SB, 2010, ANN SURG ONCOL, V17, P1471, DOI 10.1245/s10434-010-0985-4
   Epstein JI, 2016, AM J SURG PATHOL, V40, P244, DOI 10.1097/PAS.0000000000000530
   Ferlay J, 2013, IARC CANCERBASE
   Fizazi K, 2002, CLIN CANCER RES, V8, P775
   Fukushima N, 2003, BRIT J CANCER, V89, P338, DOI 10.1038/sj.bjc.6601039
   Garzón R, 2004, J BIOL CHEM, V279, P44460, DOI 10.1074/jbc.M408010200
   Gui Y, 2015, ONCOGENE, V34, P5718, DOI 10.1038/onc.2015.20
   Gui YR, 2011, J HEPATOL, V55, P1300, DOI 10.1016/j.jhep.2011.03.027
   Humphrey PA, 2004, MODERN PATHOL, V17, P292, DOI 10.1038/modpathol.3800054
   HUMPHREY PA, 1995, AM J PATHOL, V147, P386
   Ilangumaran S, 2003, IMMUNOL REV, V192, P196, DOI 10.1034/j.1600-065X.2003.00020.x
   Jiang SA, 2010, CANCER RES, V70, P3119, DOI 10.1158/0008-5472.CAN-09-4250
   Kalos M, 2004, PROSTATE, V60, P246, DOI 10.1002/pros.20043
   Kim MH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123133
   Kluth M, 2014, INT J CANCER, V135, P1369, DOI 10.1002/ijc.28784
   Knudsen BS, 2009, APPL IMMUNOHISTO M M, V17, P57, DOI 10.1097/PAI.0b013e3181816ae2
   Knudsen BS, 2002, UROLOGY, V60, P1113, DOI 10.1016/S0090-4295(02)01954-4
   Kobayashi N, 2012, ONCOTARGET, V3, P1455
   Liu TC, 2003, BRIT J HAEMATOL, V123, P654, DOI 10.1046/j.1365-2141.2003.04660.x
   Makarov DV, 2009, ANNU REV MED, V60, P139, DOI 10.1146/annurev.med.60.042307.110714
   Martinez LA, 2002, CARCINOGENESIS, V23, P1289, DOI 10.1093/carcin/23.8.1289
   Mizuno H, 2009, BMC MED GENOMICS, V2, DOI 10.1186/1755-8794-2-18
   Neuwirt H, 2009, AM J PATHOL, V174, P1921, DOI 10.2353/ajpath.2009.080751
   O Flowers L, 2005, ONCOGENE, V24, P2114, DOI 10.1038/sj.onc.1208437
   Packer JR, 2016, BBA-MOL CELL RES, V1863, P1238, DOI 10.1016/j.bbamcr.2016.02.016
   Park EJ, 2003, J BIOL CHEM, V278, P14747, DOI 10.1074/jbc.M210819200
   Pichiorri F, 2008, P NATL ACAD SCI USA, V105, P12885, DOI 10.1073/pnas.0806202105
   PISTERS LL, 1995, J UROLOGY, V154, P293, DOI 10.1016/S0022-5347(01)67297-5
   Romanov VS, 2016, NAT CELL BIOL, V18, P722, DOI 10.1038/ncb3382
   Sartor O, 2002, UROLOGY, V60, P138
   Sasi Walid, 2014, Mol Biol Int, V2014, P630797, DOI 10.1155/2014/630797
   Sasi W, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-178
   Shen MM, 2010, GENE DEV, V24, P1967, DOI 10.1101/gad.1965810
   Singh AP, 2008, CANCER LETT, V259, P28, DOI 10.1016/j.canlet.2007.09.018
   Soussi T, 2001, NAT REV CANCER, V1, P233, DOI 10.1038/35106009
   Starostina NG, 2010, DEV CELL, V19, P753, DOI 10.1016/j.devcel.2010.10.013
   Stelloo S, 2015, EMBO MOL MED, V7, P1450, DOI 10.15252/emmm.201505424
   Suzuki M, 2006, CANCER LETT, V242, P222, DOI 10.1016/j.canlet.2005.11.002
   Trengove MC, 2013, AM J CLIN EXP IMMUNO, V2, P1
   Uhlen M, 2015, SCIENCE, V347, DOI 10.1126/science.1260419
   Varkaris A, 2011, EXPERT OPIN INV DRUG, V20, P1677, DOI 10.1517/13543784.2011.631523
   Verras M, 2007, CANCER RES, V67, P967, DOI 10.1158/0008-5472.CAN-06-3552
   Villalobos-Hernandez A, 2017, PROSTATE CANCER P D, V20, P36, DOI 10.1038/pcan.2016.50
   Watson PA, 2015, NAT REV CANCER, V15, P701, DOI 10.1038/nrc4016
   Yan XL, 2013, HEPATOLOGY, V57, P2274, DOI 10.1002/hep.26257
   Yeganeh M, 2016, ONCOGENE, V35, P4200, DOI 10.1038/onc.2015.485
   Yoshikawa H, 2001, NAT GENET, V28, P29, DOI 10.1038/ng0501-29
   Zarif JC, 2016, CELL SIGNAL, V28, P348, DOI 10.1016/j.cellsig.2016.01.013
   Zong Y, 2013, NAT REV UROL, V10, P90, DOI [10.1038/nruro1.2012.237, 10.1038/nrurol.2012.237]
NR 56
TC 17
Z9 17
U1 0
U2 2
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2407
J9 BMC CANCER
JI BMC Cancer
PD FEB 24
PY 2017
VL 17
AR 157
DI 10.1186/s12885-017-3141-8
PG 14
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA EQ0NF
UT WOS:000397767200003
PM 28235401
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Ma, XK
   Liu, Z
   Zhang, ZY
   Huang, XT
   Tang, WX
AF Ma, Xiaoke
   Liu, Zaiyi
   Zhang, Zhongyuan
   Huang, Xiaotai
   Tang, Wanxin
TI Multiple network algorithm for epigenetic modules via the integration of
   genome-wide DNA methylation and gene expression data
SO BMC BIOINFORMATICS
LA English
DT Article
DE Methylation; Network biology; Multiple networks; Epigenetic module
ID CELL-LINES; BREAST; PROGRESSION; MODULARITY; EPIGENOME; PATTERNS;
   COMMON; MAPS
AB Background: With the increase in the amount of DNA methylation and gene expression data, the epigenetic mechanisms of cancers can be extensively investigate. Available methods integrate the DNA methylation and gene expression data into a network by specifying the anti-correlation between them. However, the correlation between methylation and expression is usually unknown and difficult to determine.
   Results: To address this issue, we present a novel multiple network framework for epigenetic modules, namely, Epigenetic Module based on Differential Networks (EMDN) algorithm, by simultaneously analyzing DNA methylation and gene expression data. The EMDN algorithm prevents the specification of the correlation between methylation and expression. The accuracy of EMDN algorithm is more efficient than that of modern approaches. On the basis of The Cancer Genome Atlas (TCGA) breast cancer data, we observe that the EMDN algorithm can recognize positively and negatively correlated modules and these modules are significantly more enriched in the known pathways than those obtained by other algorithms. These modules can serve as bio-markers to predict breast cancer subtypes by using methylation profiles, where positively and negatively correlated modules are of equal importance in the classification of cancer subtypes. Epigenetic modules also estimate the survival time of patients, and this factor is critical for cancer therapy.
   Conclusions: The proposed model and algorithm provide an effective method for the integrative analysis of DNA methylation and gene expression. The algorithm is freely available as an R-package at https://github.com/william0701/EMDN.
C1 [Ma, Xiaoke; Huang, Xiaotai] Xidian Univ, Sch Comp Sci & Technol, No.2 South TaiBai Road, Xian, Peoples R China.
   [Ma, Xiaoke] Xidian Univ, Xidian Ningbo Informat Technol Inst, No.777 Zhongguanx, Ningbo, Peoples R China.
   [Liu, Zaiyi] Guandong Gen Hosp, Guandong Acad Med Sci, Dept Radiol, Zhongshar Road, Guangzhou, Peoples R China.
   [Zhang, Zhongyuan] Cent Univ Finance & Econ, Sch Statistics & Mat, 39 South Coll Road, Haidian District, Beijing, Peoples R China.
   [Tang, Wanxin] Sichuan Univ, West China Hosp, Dept Nephrol, Wuhou District, Chengdu, Peoples R China.
C3 Xidian University; Xidian University; Southern Medical University -
   China; Guangdong Academy of Medical Sciences & Guangdong General
   Hospital; Central University of Finance & Economics; Sichuan University
RP Tang, WX (通讯作者)，Sichuan Univ, West China Hosp, Dept Nephrol, Wuhou District, Chengdu, Peoples R China.
EM tangwx@scu.edu.cn
RI Tang, Wanxin/AAA-3952-2020
OI Huang, Xiao-Tai/0000-0002-0298-7350
FU NSFC [61502363, 81270805]; Science and Technology Department of Sichuan
   province [2012FZ0076]; Natural Science Basic Research Plan in Shaanxi
   Province of China [2016JQ6044]; Fundamental Research Funding of Central
   Universities [JB160306]; Natural Science Basic Research Plan in Ningbo
   City [2016A610034]
FX This work is in part supported by the NSFC (Grant No.
   61502363,81270805), Science and Technology Department of Sichuan
   province (Grant No. 2012FZ0076), Natural Science Basic Research Plan in
   Shaanxi Province of China (Program No. 2016JQ6044), Fundamental Research
   Funding of Central Universities (Grant no. JB160306) and Natural Science
   Basic Research Plan in Ningbo City (Grant No. 2016A610034).
CR Arnedos M, 2015, NAT REV CLIN ONCOL, V12, P693, DOI 10.1038/nrclinonc.2015.123
   Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556
   Ball MP, 2009, NAT BIOTECHNOL, V27, P361, DOI 10.1038/nbt.1533
   BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x
   Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9
   Cantini L, 2015, SCI REP-UK, V5, DOI 10.1038/srep17386
   Chang CC, 2011, ACM T INTEL SYST TEC, V2, DOI 10.1145/1961189.1961199
   Chuang HY, 2007, MOL SYST BIOL, V3, DOI 10.1038/msb4100180
   Cokus SJ, 2008, NATURE, V452, P215, DOI 10.1038/nature06745
   Croft D, 2014, NUCLEIC ACIDS RES, V42, pD472, DOI [10.1093/nar/gkt1102, 10.1093/nar/gkz1031]
   Danon L, 2005, J STAT MECH-THEORY E, DOI 10.1088/1742-5468/2005/09/P09008
   Deaton AM, 2011, GENE DEV, V25, P1010, DOI 10.1101/gad.2037511
   DELONG ER, 1988, BIOMETRICS, V44, P837, DOI 10.2307/2531595
   Didier G, 2015, PEERJ, V3, DOI 10.7717/peerj.1525
   Fleischer T, 2014, GENOME BIOL, V15, DOI [10.1186/s13059-014-0435-x, 10.1186/PREACCEPT-2333349012841587]
   Getz G, 2013, NATURE, V497, P67, DOI 10.1038/nature12113
   Gevaert O, 2015, GENOME BIOL, V16, DOI 10.1186/s13059-014-0579-8
   Hinoue T, 2012, GENOME RES, V22, P271, DOI 10.1101/gr.117523.110
   Jiao YM, 2014, BIOINFORMATICS, V30, P2360, DOI 10.1093/bioinformatics/btu316
   Jones A, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001551
   Kanehisa M, 2017, NUCLEIC ACIDS RES, V45, pD353, DOI 10.1093/nar/gkw1092
   Langfelder P, 2007, BMC SYST BIOL, V1, DOI 10.1186/1752-0509-1-54
   Lister R, 2008, CELL, V133, P523, DOI 10.1016/j.cell.2008.03.029
   Ma XK, 2014, BIOINFORMATICS, V30, P2343, DOI 10.1093/bioinformatics/btu298
   Meissner A, 2008, NATURE, V454, P766, DOI 10.1038/nature07107
   Newman MEJ, 2006, PHYS REV E, V74, DOI 10.1103/PhysRevE.74.036104
   Newman MEJ, 2006, P NATL ACAD SCI USA, V103, P8577, DOI 10.1073/pnas.0601602103
   Nishimura D, 2001, BIOTECH SOFTW INTERN, V2, P112
   Rakyan VK, 2011, NAT REV GENET, V12, P529, DOI 10.1038/nrg3000
   Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007
   Subramanian A, 2001, P NATL ACAD SCI USA, V105, P15545
   Suzuki MM, 2008, NAT REV GENET, V9, P465, DOI 10.1038/nrg2341
   Taylor IW, 2009, NAT BIOTECHNOL, V27, P199, DOI 10.1038/nbt.1522
   Teschendorff AE, 2012, GENOME MED, V4, DOI 10.1186/gm323
   Therneau TM, 2009, A Package for Survival Analysis in R. R package version 3.5-7
   Tibshirani R, 2002, P NATL ACAD SCI USA, V99, P6567, DOI 10.1073/pnas.082099299
   Varley KE, 2013, GENOME RES, V23, P555, DOI 10.1101/gr.147942.112
   Watson-Haigh NS, 2010, BIOINFORMATICS, V26, P411, DOI 10.1093/bioinformatics/btp674
   West J, 2013, SCI REP-UK, V3, DOI 10.1038/srep01630
   Witte T, 2014, GENOME MED, V6, DOI 10.1186/s13073-014-0066-6
   Yang XF, 2015, HUM MOL GENET, V24, P4374, DOI 10.1093/hmg/ddv172
   Ziller MJ, 2013, NATURE, V500, P477, DOI 10.1038/nature12433
NR 42
TC 43
Z9 48
U1 0
U2 19
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471-2105
J9 BMC BIOINFORMATICS
JI BMC Bioinformatics
PD JAN 31
PY 2017
VL 18
AR 72
DI 10.1186/s12859-017-1490-6
PG 13
WC Biochemical Research Methods; Biotechnology & Applied Microbiology;
   Mathematical & Computational Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Mathematical & Computational Biology
GA EP6KG
UT WOS:000397487800001
PM 28137264
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Imani, S
   Wei, CL
   Cheng, JL
   Khan, MA
   Fu, SY
   Yang, LQ
   Tania, M
   Zhang, XQ
   Xiao, XL
   Zhang, XN
   Fu, JJ
AF Imani, Saber
   Wei, Chunli
   Cheng, Jingliang
   Khan, Md. Asaduzzaman
   Fu, Shangyi
   Yang, Luquan
   Tania, Mousumi
   Zhang, Xianqin
   Xiao, Xiuli
   Zhang, Xianning
   Fu, Junjiang
TI MicroRNA-34a targets epithelial to mesenchymal transition-inducing
   transcription factors (EMT-TFs) and inhibits breast cancer cell
   migration and invasion
SO ONCOTARGET
LA English
DT Article
DE microRNA-34a; thymoquinone; epithelial-mesenchymal transition;
   metastasis; breast cancer
ID WNT/BETA-CATENIN PATHWAY; IN-VIVO; REGULATING MIR-34A; TUMOR
   PROGRESSION; DOWN-REGULATION; GASTRIC-CANCER; THYMOQUINONE;
   PROLIFERATION; METASTASIS; SUPPRESSES
AB MicroRNA-34a (miR-34a) plays an essential role against tumorigenesis and progression of cancer metastasis. Here, we analyzed the expression, targets and functional effects of miR-34a on epithelial to mesenchymal transition-inducing transcription factors (EMT-TFs), such as TWIST1, SLUG and ZEB1/2, and an EMT-inducing protein NOTCH1 in breast cancer (BC) cell migration and invasion and its correlation with tumorigenesis and clinical outcomes. Expression of miR-34a is downregulated in human metastatic breast cancers (MBC) compared to normal breast tissues and is negatively correlated with clinicopathological features of MBC patients. Ectopic expression of miR-34a in MBC cell-line BT-549 significantly inhibits cell migration and invasion, but exhibits no clear effect on BC cell growth. We found that miR-34a is able to inactivate EMT signaling pathway with mediatory of NOTCH1, TWIST1, and ZEB1 upon 3'-UTR activity in MBC cell lines, but has no inhibitory effects on SLUG and ZEB2. Furthermore, we investigated the synergistic effects of Thymoquinone (TQ) and miR-34a together on the expression of EMT-associated proteins. Results showed that co-delivery of miR-34a and TQ is able to inactivate EMT signaling pathway by directly targeting TWIST1 and ZEB1 in BT-549 cell line, indicating that they might be a promising therapeutic combination against breast cancer metastasis. Epigenetic inactivation of the EMT-TFs/miR-34a pathway can potentially alter the equilibrium of these regulations, facilitating EMT and metastasis in BC. Altogether, our findings suggest that miR-34a alone could serve as a potential therapeutic agent for MBC, and together with TQ, their therapeutic potential is synergistically enhanced.
C1 [Imani, Saber; Wei, Chunli; Cheng, Jingliang; Khan, Md. Asaduzzaman; Yang, Luquan; Tania, Mousumi; Zhang, Xianqin; Fu, Junjiang] Southwest Med Univ, Res Ctr Precis Med, Key Lab Epigenet & Oncol, Luzhou, Sichuan, Peoples R China.
   [Imani, Saber] Baqiyatallah Med Sci Univ, Chem Injuries Res Ctr, Tehran, Iran.
   [Wei, Chunli; Fu, Junjiang] Macau Univ Sci & Technol, State Key Lab Qual Res Chinese Med, Cotai, Macau Sar, Peoples R China.
   [Khan, Md. Asaduzzaman] Ton Duc Thang Univ, Fac Sci Appl, Ho Chi Minh City, Vietnam.
   [Fu, Shangyi] Univ Houston, Honors Coll, Houston, TX USA.
   [Tania, Mousumi] Red Green Comp Ctr, Div Comp Aided Drug Design, Dhaka, Bangladesh.
   [Xiao, Xiuli] Southwest Med Univ, Dept Pathol, Luzhou, Sichuan, Peoples R China.
   [Zhang, Xianning] Zhejiang Univ, Dept Cell Biol & Med Genet, Sch Med, Hangzhou, Zhejiang, Peoples R China.
C3 Southwest Medical University; Baqiyatallah University of Medical
   Sciences (BMSU); Macau University of Science & Technology; Ton Duc Thang
   University; University of Houston System; University of Houston;
   Southwest Medical University; Zhejiang University
RP Fu, JJ (通讯作者)，Southwest Med Univ, Res Ctr Precis Med, Key Lab Epigenet & Oncol, Luzhou, Sichuan, Peoples R China.; Fu, JJ (通讯作者)，Macau Univ Sci & Technol, State Key Lab Qual Res Chinese Med, Cotai, Macau Sar, Peoples R China.
EM fujunjiang@swmu.edu.cn
RI Chen, Xi/AAI-1665-2021; zhang, xianqin/GYE-0638-2022; Imani,
   Saber/KIA-5036-2024; Tania, Mousumi/F-6190-2011; Khan, Md
   Asaduzzaman/F-5392-2011
OI , cheng/0000-0002-9022-7246; Fu, Junjiang/0000-0002-0708-2200; Wei,
   Chunli/0000-0002-5966-283X; Khan, Md. Asaduzzaman/0000-0001-7851-0500;
   Tania, Mousumi/0000-0002-0596-0954; Imani, Saber/0000-0003-2836-3308
FU National Natural Science Foundation of China [81672887, 81172049];
   Science and Technology Innovation Team of Colleges and Universities of
   Sichuan Province [13TD0032]; Research Foundation of the Science and
   Technology Department of Sichuan Province [14JC0797, 2015JY0038];
   Southwest Medical University Grants for Postdoctoral Research
   [2016-BSH0001]
FX This work was supported by the National Natural Science Foundation of
   China (81672887,81172049), Science and Technology Innovation Team of
   Colleges and Universities of Sichuan Province (13TD0032), the Research
   Foundation of the Science and Technology Department of Sichuan Province
   (14JC0797, 2015JY0038), and Southwest Medical University Grants for
   Postdoctoral Research (2016-BSH0001).
CR Abdelfadil E, 2013, AM J CHINESE MED, V41, P683, DOI 10.1142/S0192415X1350047X
   Adams BD, 2016, CANCER RES, V76, P927, DOI 10.1158/0008-5472.CAN-15-2321
   Ahn YH, 2012, J CLIN INVEST, V122, P3170, DOI 10.1172/JCI63608
   [Anonymous], JAK STAT
   [Anonymous], 2007, BIOL CANC
   [Anonymous], CANC BIOMAR IN PRESS
   [Anonymous], MATH PROBL ENG
   Avtanski DB, 2015, ONCOTARGET, V6, P16396, DOI 10.18632/oncotarget.3844
   Barbashina V, 2005, CLIN CANCER RES, V11, P1119
   Bhattacharya S, 2015, BIOMATERIALS, V51, P91, DOI 10.1016/j.biomaterials.2015.01.007
   Chaffer CL, 2011, SCIENCE, V331, P1559, DOI 10.1126/science.1203543
   Fu JJ, 2011, CELL RES, V21, P275, DOI 10.1038/cr.2010.118
   Györffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9
   Hansen SM, 2008, CELL MOL LIFE SCI, V65, P3809, DOI 10.1007/s00018-008-8290-0
   Haynes J, 2011, MOL BIOL CELL, V22, P4750, DOI 10.1091/mbc.E11-02-0119
   Hermeking H, 2010, CELL DEATH DIFFER, V17, P193, DOI 10.1038/cdd.2009.56
   Hong LQ, 2016, ONCOTARGETS THER, V9, P2639, DOI 10.2147/OTT.S102713
   Huang RYJ, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.442
   Hurvitz SA, 2013, BREAST CANCER RES TR, V142, P603, DOI 10.1007/s10549-013-2734-4
   Imani S, 2016, SCI REP-UK, V6, DOI 10.1038/srep28587
   Isobe T, 2014, ELIFE, V3, DOI 10.7554/eLife.01977
   Javeri A, 2013, MED ONCOL, V30, DOI 10.1007/s12032-012-0413-7
   Jiang Q, 2016, TUMOR BIOL, V37, P5001, DOI 10.1007/s13277-015-4342-x
   Johansson J, 2013, ONCOGENE, V32, P5614, DOI 10.1038/onc.2013.322
   Kang L, 2015, CANCER SCI, V106, P700, DOI 10.1111/cas.12656
   Ke XQ, 2015, ONCOTARGET, V6, P32610, DOI 10.18632/oncotarget.5362
   Kefas B, 2009, J NEUROSCI, V29, P15161, DOI 10.1523/JNEUROSCI.4966-09.2009
   Khan MA, 2015, GENET MOL RES, V14, P12362, DOI 10.4238/2015.October.16.2
   Khan MA, 2015, ONCOTARGET, V6, P19580, DOI 10.18632/oncotarget.3973
   Khan MA, 2013, TUMOR BIOL, V34, P2497, DOI 10.1007/s13277-013-1002-x
   Khan MA, 2011, AFR J TRADIT COMPLEM, V8, P226, DOI 10.4314/ajtcam.v8i5S.10
   Khramtsov AI, 2010, AM J PATHOL, V176, P2911, DOI 10.2353/ajpath.2010.091125
   Kim T, 2011, J EXP MED, V208, P875, DOI 10.1084/jem.20110235
   Krasnapolski MA, 2011, CURR PHARM BIOTECHNO, V12, P1891
   Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758
   Li Li, 2013, Journal of Nanomaterials, DOI 10.1155/2013/821071
   Li LN, 2015, PHARMACOL THERAPEUT, V150, P33, DOI 10.1016/j.pharmthera.2015.01.004
   Li YQ, 2009, CANCER RES, V69, P7569, DOI 10.1158/0008-5472.CAN-09-0529
   Liu T, 2015, ONCOTARGET, V6, P41638, DOI 10.18632/oncotarget.5873
   Lodygin D, 2008, CELL CYCLE, V7, P2591, DOI 10.4161/cc.7.16.6533
   Mansoori Behzad, 2016, Asian Pac J Cancer Prev, V17, P1887
   McGuire S, 2016, ADV NUTR, V7, P418, DOI 10.3945/an.116.012211
   Mironchik Y, 2005, CANCER RES, V65, P10801, DOI 10.1158/0008-5472.CAN-05-0712
   Misso G, 2014, MOL THER-NUCL ACIDS, V3, DOI 10.1038/mtna.2014.47
   Mlcochova H, 2016, SCI REP-UK, V6, DOI 10.1038/srep31852
   Mu GG, 2015, DIGEST DIS SCI, V60, P1067, DOI 10.1007/s10620-014-3394-x
   Nalls D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024099
   Pang MF, 2016, ONCOGENE, V35, P748, DOI 10.1038/onc.2015.133
   Pang RTK, 2010, CARCINOGENESIS, V31, P1037, DOI 10.1093/carcin/bgq066
   Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131
   Peng F, 2016, TUMOR BIOL, V37, P14463, DOI 10.1007/s13277-016-5334-1
   Peng L, 2013, ONCOL REP, V29, P571, DOI 10.3892/or.2012.2165
   Prosperi JR, 2010, CURR DRUG TARGETS, V11, P1074
   Rajput S, 2013, LIFE SCI, V93, P783, DOI 10.1016/j.lfs.2013.09.009
   Roy S, 2012, J HEMATOL ONCOL, V5, DOI 10.1186/1756-8722-5-58
   Shao C, 2015, BIOCHEM BIOPH RES CO, V467, P1083, DOI 10.1016/j.bbrc.2015.09.076
   Si WT, 2016, AM J MED SCI, V352, P191, DOI 10.1016/j.amjms.2016.05.002
   Siegel R, 2014, CA-CANCER J CLIN, V64, P9, DOI 10.3322/caac.21208
   Stankevicins L, 2013, RADIAT ONCOL, V8, DOI 10.1186/1748-717X-8-231
   Storci G, 2010, J CELL PHYSIOL, V225, P682, DOI 10.1002/jcp.22264
   Sun LD, 2016, CELL MOL LIFE SCI, V73, P4493, DOI 10.1007/s00018-016-2303-1
   Tao ZQ, 2015, CELL BIOCHEM BIOPHYS, V72, P333, DOI 10.1007/s12013-014-0459-6
   Umemura S, 2001, Breast Cancer, V8, P316, DOI 10.1007/BF02967531
   Wei CL, 2016, SCI REP-UK, V6, DOI 10.1038/srep29822
   Weyemi U, 2016, CELL CYCLE, V15, P2398, DOI 10.1080/15384101.2016.1198864
   Woo CC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075356
   Wu H, 2015, TECHNOL CANCER RES T, V14, P747, DOI 10.7785/tcrt.2012.500434
   Wushou A, 2014, INT J MOL SCI, V15, P21621, DOI 10.3390/ijms151221621
   Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006
   Yang J, 2015, TUMOR BIOL, V36, P259, DOI 10.1007/s13277-014-2628-z
   Yang L, 2015, ONCOTARGET, V6, P25755, DOI 10.18632/oncotarget.4697
   Yang PY, 2012, CANCER CELL, V22, P291, DOI 10.1016/j.ccr.2012.07.023
   Yang S, 2013, ONCOGENE, V32, P4294, DOI 10.1038/onc.2012.432
   Yu G, 2014, J UROLOGY, V192, P1229, DOI 10.1016/j.juro.2014.05.094
   Zhang LB, 2012, NPG ASIA MATER, V4, DOI 10.1038/am.2012.14
   Zhao GQ, 2013, DNA CELL BIOL, V32, P699, DOI 10.1089/dna.2013.2130
   Zhu WQ, 2016, WORLD J GASTROENTERO, V22, P4149, DOI 10.3748/wjg.v22.i16.4149
NR 77
TC 89
Z9 98
U1 0
U2 15
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD MAR 28
PY 2017
VL 8
IS 13
BP 21362
EP 21379
DI 10.18632/oncotarget.15214
PG 18
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA EP8RL
UT WOS:000397642400071
PM 28423483
OA gold, Green Submitted, Green Published
DA 2025-01-12
ER

PT J
AU Yu, W
   Ma, YM
   Ochoa, AC
   Shankar, S
   Srivastava, RK
AF Yu, Wei
   Ma, Yiming
   Ochoa, Augusto C.
   Shankar, Sharmila
   Srivastava, Rakesh K.
TI Cellular transformation of human mammary epithelial cells by SATB2
SO STEM CELL RESEARCH
LA English
DT Article
ID CANCER STEM-CELLS; BREAST-CANCER; BETA-CATENIN; TRANSCRIPTION FACTORS;
   SELF-RENEWAL; EXPRESSION; CADMIUM; PROLIFERATION; PLURIPOTENCY;
   DETERMINANT
AB Breast tumors are heterogeneous and carry a small population of progenitor cells that can produce various subtypes of breast cancer. SATB2 (special AT-rich binding protein-2) is a newly identified transcription factor and epigenetic regulator. It is highly expressed in embryonic stem cells, but not in adult tissues, and regulates pluripotency-maintaining factors. However, the molecular mechanisms bywhich SATB2 induces transformation of humanmammary epithelial cells (HMECs) leading to malignant phenotype are unknown. The main goal of this paper is to examine the molecular mechanisms by which SATB2 induces cellular transformation of HMECs into cells that are capable of self-renewal. SATB2-transformed HMECs gain the phenotype of breast progenitor cells by expressing markers of stem cells, pluripotency-maintaining factor, and epithelial to mesenchymal transition. SATB2 is highly expressed in human breast cancer cell lines, primary mammary tissues and cancer stem cells (CSCs), but not in HMECs and normal breast tissues. Chromatin Immunoprecipitation assays demonstrate that SATB2 can directly bind to promoters of Bcl-2, c-Myc, Nanog, Klf4, and XIAP, suggesting a role of SATB2 in regulation of pluripotency, cell survival and proliferation. Furthermore, inhibition of SATB2 by shRNA in breast cancer cell lines and CSCs attenuates cell proliferation and EMT phenotype. Our results suggest that SATB2 induces dedifferentiation/transformation of mature HMECs into progenitor-like cells. (C) 2017 Published by Elsevier B. V.
C1 [Yu, Wei; Ma, Yiming; Shankar, Sharmila; Srivastava, Rakesh K.] Kansas City VA Med Ctr, 4801 Linwood Blvd, Kansas City, MO 66128 USA.
   [Ochoa, Augusto C.] Louisiana State Univ, Hlth Sci Ctr, Dept Pediat, Stanley S Scott Canc Ctr, New Orleans, LA 70112 USA.
   [Shankar, Sharmila] Univ Missouri, Sch Med, Dept Pathol, Kansas City, MO 64108 USA.
   [Srivastava, Rakesh K.] Univ Missouri, Dept Pharmacol & Toxicol, Kansas City, MO 64108 USA.
   [Shankar, Sharmila; Srivastava, Rakesh K.] Louisiana State Univ, Hlth Sci Ctr, Stanley S Scott Canc Ctr, New Orleans, LA 70112 USA.
   [Shankar, Sharmila; Srivastava, Rakesh K.] Louisiana State Univ, Hlth Sci Ctr, Dept Genet, New Orleans, LA 70112 USA.
C3 Louisiana State University System; Louisiana State University Health
   Sciences Center New Orleans; University of Missouri System; University
   of Missouri Kansas City; University of Missouri System; University of
   Missouri Kansas City; Louisiana State University System; Louisiana State
   University Health Sciences Center New Orleans; Louisiana State
   University System; Louisiana State University Health Sciences Center New
   Orleans
RP Srivastava, RK (通讯作者)，Louisiana State Univ, Hlth Sci Ctr, Stanley S Scott Canc Ctr, Dept Genet, New Orleans, LA 70112 USA.; Srivastava, RK (通讯作者)，Louisiana State Univ, Hlth Sci Ctr, Stanley S Scott Canc Ctr, New Orleans, LA 70112 USA.; Srivastava, RK (通讯作者)，Louisiana State Univ, Hlth Sci Ctr, Dept Genet, New Orleans, LA 70112 USA.
EM rsrivastava.lab@gmail.com
RI Ma, Yiming/AAG-3479-2019; Srivastava, Ruby/AAX-8343-2021
OI Srivastava, Rakesh/0000-0003-3112-4252
CR Abdelalim EM, 2014, STEM CELLS DEV, V23, P2687, DOI 10.1089/scd.2014.0297
   Anderson KM, 2014, MED ONCOL, V31, DOI 10.1007/s12032-013-0779-1
   Asara Y, 2013, INT J MOL SCI, V14, P16600, DOI 10.3390/ijms140816600
   Britanova O, 2005, EUR J NEUROSCI, V21, P658, DOI 10.1111/j.1460-9568.2005.03897.x
   Britanova O, 2008, NEURON, V57, P378, DOI 10.1016/j.neuron.2007.12.028
   Cai ST, 2006, NAT GENET, V38, P1278, DOI 10.1038/ng1913
   Cai WY, 2013, J CELL SCI, V126, P2877, DOI 10.1242/jcs.123810
   Cariati M, 2008, HISTOPATHOLOGY, V52, P99, DOI 10.1111/j.1365-2559.2007.02895.x
   Carrasco E, 2014, EUR J CLIN INVEST, V44, P678, DOI 10.1111/eci.12276
   Dalton S, 2013, CURR OPIN CELL BIOL, V25, P241, DOI 10.1016/j.ceb.2012.09.005
   Dobreva G, 2003, GENE DEV, V17, P3048, DOI 10.1101/gad.1153003
   Dobreva G, 2006, CELL, V125, P971, DOI 10.1016/j.cell.2006.05.012
   Dutta D, 2013, INT J DEV BIOL, V57, P667, DOI 10.1387/ijdb.130064dd
   Gao XC, 2014, TUMOR BIOL, V35, P11505, DOI 10.1007/s13277-014-2466-z
   González-Sarmiento R, 2008, CURR STEM CELL RES T, V3, P55
   Gracanin A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098698
   Gyorgy AB, 2008, EUR J NEUROSCI, V27, P865, DOI 10.1111/j.1460-9568.2008.06061.x
   Hatsell S, 2003, J MAMMARY GLAND BIOL, V8, P145, DOI 10.1023/A:1025944723047
   Ho R, 2013, CELL REP, V3, P2113, DOI 10.1016/j.celrep.2013.05.015
   Kahler RA, 2003, J BIOL CHEM, V278, P11937, DOI 10.1074/jbc.M211443200
   Kumar D, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-171
   Lawson JC, 2009, BREAST CANCER RES TR, V118, P241, DOI 10.1007/s10549-009-0524-9
   Liu AF, 2013, CHIN J CANCER, V32, P483, DOI 10.5732/cjc.012.10282
   Liu SL, 2005, BREAST CANCER RES, V7, P86, DOI 10.1186/bcr1021
   Luo J, 2010, AM J MED SCI, V339, P366, DOI 10.1097/MAJ.0b013e3181cad964
   Lynch MD, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1513
   Magnusson K, 2011, AM J SURG PATHOL, V35, P937, DOI 10.1097/PAS.0b013e31821c3dae
   Miyoshi K, 2002, ONCOGENE, V21, P5548, DOI 10.1038/sj.onc.1205686
   Nguyen A, 2005, INT J ONCOL, V27, P949
   Notani D, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000296
   Ordóñez NG, 2014, ADV ANAT PATHOL, V21, P63, DOI 10.1097/PAP.0000000000000001
   Patani N, 2009, CANCER CELL INT, V9, DOI 10.1186/1475-2867-9-18
   Petropoulos K, 2008, J EXP MED, V205, P515, DOI 10.1084/jem.20071875
   Ponti D, 2006, EUR J CANCER, V42, P1219, DOI 10.1016/j.ejca.2006.01.031
   Reya T, 2003, NATURE, V423, P409, DOI 10.1038/nature01593
   Rosenfeld JA, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006568
   Sethi Tarsheen K, 2012, Clin Adv Hematol Oncol, V10, P157
   Shankar S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016530
   Shi GL, 2010, STEM CELL RES THER, V1, DOI 10.1186/scrt39
   Siegel RL, 2016, CA-CANCER J CLIN, V66, P7, DOI 10.3322/caac.21332
   Tsai BP, 2014, OPEN BIOL, V4, DOI 10.1098/rsob.140180
   Visvader JE, 2014, GENE DEV, V28, P1143, DOI 10.1101/gad.242511.114
   Waalkes M P, 1992, IARC Sci Publ, P391
   WAALKES MP, 1988, CANCER RES, V48, P4656
   WAALKES MP, 1988, TOXICOL APPL PHARM, V93, P47, DOI 10.1016/0041-008X(88)90024-5
   Yang MH, 2014, J TRANSL MED, V12, DOI 10.1186/1479-5876-12-109
   Yang MH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0085353
   Ye X, 2015, TRENDS CELL BIOL, V25, P675, DOI 10.1016/j.tcb.2015.07.012
   Yin SP, 2013, MOL CANCER THER, V12, P491, DOI 10.1158/1535-7163.MCT-12-1090
   Yu W, 2016, ONCOTARGET, V7, P57783, DOI 10.18632/oncotarget.10860
   Zhao XY, 2014, CYTOKINE GROWTH F R, V25, P35, DOI 10.1016/j.cytogfr.2013.12.010
NR 51
TC 28
Z9 31
U1 0
U2 4
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1873-5061
EI 1876-7753
J9 STEM CELL RES
JI Stem Cell Res.
PD MAR
PY 2017
VL 19
BP 139
EP 147
DI 10.1016/j.scr.2017.01.011
PG 9
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Cell
   Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Biotechnology & Applied Microbiology
GA EP5WW
UT WOS:000397450700022
PM 28167342
OA gold
DA 2025-01-12
ER

PT J
AU Zhang, EB
   Han, L
   Yin, DD
   He, XZ
   Hong, LZ
   Si, XX
   Qiu, MT
   Xu, TP
   De, W
   Xu, L
   Shu, YQ
   Chen, JF
AF Zhang, Erbao
   Han, Liang
   Yin, Dandan
   He, Xuezhi
   Hong, Linzhi
   Si, Xinxin
   Qiu, Mantang
   Xu, Tongpeng
   De, Wei
   Xu, Lin
   Shu, Yongqian
   Chen, Jinfei
TI H3K27 acetylation activated-long non-coding RNA CCAT1 affects cell
   proliferation and migration by regulating SPRY4 and HOXB13 expression in
   esophageal squamous cell carcinoma
SO NUCLEIC ACIDS RESEARCH
LA English
DT Article
ID EPITHELIAL-MESENCHYMAL TRANSITION; CANCER ASSOCIATED TRANSCRIPT-1;
   TUMOR-SUPPRESSOR; POOR-PROGNOSIS; LUNG-CANCER; DNA METHYLATION;
   PROSTATE-CANCER; GENE-EXPRESSION; GASTRIC-CANCER; BREAST-CANCER
AB Recently, long non-coding RNAs (lncRNAs) have been shown to have important regulatory roles in human cancer biology. In our study, we found that lncRNA CCAT1, whose expression is significantly increased and is correlated with outcomes in Esophageal Squamous Cell Carcinoma (ESCC). Consecutive experiments confirmed that H3K27-acetylation could activate expression of colon cancer associated transcript-1 (CCAT1). Further experiments revealed that CCAT1 knockdown significantly repressed the proliferation and migration both in vitro and in vivo. RNA-seq analysis revealed that CCAT1 knockdown preferentially affected genes that are linked to cell proliferation, cell migration and cell adhesion. Mechanistic investigations found that CCAT1 could serve as a scaffold for two distinct epigenetic-modification complexes (5' domain of CCAT1 binding Polycomb Repressive Complex 2 (PRC2) while 3' domain of CCAT1 binding SUV39H1) and modulate the histone methylation of promoter of SPRY4 (sprouty RTK signaling antagonist 4) in nucleus. In cytoplasm, CCAT1 regulates HOXB13 as a molecular decoy for miR-7, a microRNA that targets both CCAT1 and HOXB13, thus facilitating cell growth and migration. Together, our data demonstrated the important roles of CCAT1 in ESCC oncogenesis and might serve as targets for ESCC diagnosis and therapy.
C1 [Zhang, Erbao; He, Xuezhi; Si, Xinxin; De, Wei] Nanjing Med Univ, Dept Biochem & Mol Biol, Nanjing, Jiangsu, Peoples R China.
   [Han, Liang] Southeast Univ, Affiliated Xuzhou Hosp, Coll Med, Dept Oncol, Xuzhou, Jiangsu, Peoples R China.
   [Yin, Dandan] Southeast Univ, Affiliated Hosp 2, Cent Lab, Nanjing, Jiangsu, Peoples R China.
   [Hong, Linzhi; Xu, Tongpeng; Shu, Yongqian; Chen, Jinfei] Nanjing Med Univ, Affiliated Hosp 1, Dept Oncol, Nanjing, Jiangsu, Peoples R China.
   [Qiu, Mantang; Xu, Lin] Nanjing Med Univ, Affiliated Canc Hosp, Canc Inst Jiangsu Prov, Dept Thorac Surg,Jiangsu Key Lab Mol & Translat, Baiziting 42, Nanjing 210009, Peoples R China.
   [Chen, Jinfei] Nanjing Med Univ, Nanjing First Hosp, Dept Oncol, Nanjing, Jiangsu, Peoples R China.
   [Chen, Jinfei] Nanjing Med Univ, Collaborat Innovat Ctr Canc Personalized Med, Nanjing, Jiangsu, Peoples R China.
C3 Nanjing Medical University; Southeast University - China; Southeast
   University - China; Nanjing Medical University; Nanjing Medical
   University; Nanjing Medical University; Nanjing Medical University
RP De, W (通讯作者)，Nanjing Med Univ, Dept Biochem & Mol Biol, Nanjing, Jiangsu, Peoples R China.; Shu, YQ; Chen, JF (通讯作者)，Nanjing Med Univ, Affiliated Hosp 1, Dept Oncol, Nanjing, Jiangsu, Peoples R China.; Xu, L (通讯作者)，Nanjing Med Univ, Affiliated Canc Hosp, Canc Inst Jiangsu Prov, Dept Thorac Surg,Jiangsu Key Lab Mol & Translat, Baiziting 42, Nanjing 210009, Peoples R China.; Chen, JF (通讯作者)，Nanjing Med Univ, Nanjing First Hosp, Dept Oncol, Nanjing, Jiangsu, Peoples R China.; Chen, JF (通讯作者)，Nanjing Med Univ, Collaborat Innovat Ctr Canc Personalized Med, Nanjing, Jiangsu, Peoples R China.
EM dewei_njmu@sina.com; xulin_njmu@163.com; nanjingyongqianshu@163.com;
   jinfeichen_edu@126.com
RI XU, Lin/HZL-5726-2023; Shu, Yongqian/ABD-5698-2021; Qiu,
   Mantang/L-8937-2019
OI Si, Xinxin/0000-0003-0393-4223; zhang, erbao/0000-0002-5752-7976; yin,
   dandan/0000-0002-2550-5254; Han, Liang/0000-0003-3578-2914
FU National Natural Science Foundation of China [81372321, 81572261,
   81172140, 81272532, 81401873, 81502071, 81272469, 81572928, 81672896];
   Key project of Cutting-edge Clinical Technology of Jiangsu province
   [BE2016797]; Innovation Capability Development Project of Jiangsu
   province [BM2015004]; Program for Development of Innovative Research
   Teams [Clinical Research Center] [BL2012008]; Priority Academic Program
   Development of Jiangsu Higher Education Institutions [JX10231801];
   National 973 Basic Research Program of China [2013CB911300]; Natural
   Science Foundation of Jiangsu Province [BL2012016]; Program for
   Development of Innovative Research Teams; Jiangsu Province Clinical
   Science and Technology Projects [Clinical Research Center] [BL2012008];
   Jiangsu province Clinical science and Technology Project (Clinical
   Research Center) [BL2012008]; priority Academic Porgram Development of
   Jiangsu High Education Institutions (Public Health and Preventive
   Medicine) [JX10231801]
FX National Natural Science Foundation of China (81372321 and81572261 to
   Lin Xu), the Key project of Cutting-edge Clinical Technology of Jiangsu
   province (BE2016797 to LinXu) and the Innovation Capability Development
   Project of Jiangsu province (BM2015004 to LinXu). Program for
   Development of Innovative Research Teams [Clinical Research Center,
   BL2012008]; National Natural Science Foundation of China [81172140,
   81272532, 81401873 and 81502071]; Priority Academic Program Development
   of Jiangsu Higher Education Institutions [JX10231801]; National 973
   Basic Research Program of China [2013CB911300, in part]; National
   Natural Science Foundation of China [81272469 and 81572928]; Natural
   Science Foundation of Jiangsu Province [BL2012016]. Funding for open
   access charge: Program for Development of Innovative Research Teams, by
   Jiangsu Province Clinical Science and Technology Projects [Clinical
   Research Center, BL2012008]; National Natural Science Foundation of
   China [81172140, 81272532, 81401873 and 81502071]; Priority Academic
   Program Development of Jiangsu Higher Education Institutions
   [JX10231801]. National Natural Science Foundation of China (81272532 and
   81672896), Jiangsu province Clinical science and Technology Project
   (Clinical Research Center, BL2012008) and the priority Academic Porgram
   Development of Jiangsu High Education Institutions (Public Health and
   Preventive Medicine, JX10231801).
CR Bennani-Baiti IM, 2011, EPIGENOMICS-UK, V3, P715, DOI [10.2217/EPI.11.93, 10.2217/epi.11.93]
   Bhatlekar S, 2014, J MOL MED, V92, P811, DOI 10.1007/s00109-014-1181-y
   Cao R, 2002, SCIENCE, V298, P1039, DOI 10.1126/science.1076997
   Carninci P, 2005, SCIENCE, V309, P1559, DOI 10.1126/science.1112014
   Cesana M, 2011, CELL, V147, P358, DOI 10.1016/j.cell.2011.09.028
   Chen FJ, 2013, MOL CARCINOGEN, V52, P908, DOI 10.1002/mc.21944
   Dinger ME, 2008, GENOME RES, V18, P1433, DOI 10.1101/gr.078378.108
   Enzinger PC, 2003, NEW ENGL J MED, V349, P2241, DOI 10.1056/NEJMra035010
   Fahrner JA, 2002, CANCER RES, V62, P7213
   Ginger MR, 2006, P NATL ACAD SCI USA, V103, P5781, DOI 10.1073/pnas.0600745103
   Gupta RA, 2010, NATURE, V464, P1071, DOI 10.1038/nature08975
   He XL, 2014, TUMOR BIOL, V35, P12181, DOI 10.1007/s13277-014-2526-4
   Ji P, 2003, ONCOGENE, V22, P8031, DOI 10.1038/sj.onc.1206928
   Kalinowski FC, 2014, INT J BIOCHEM CELL B, V54, P312, DOI 10.1016/j.biocel.2014.05.040
   Khaitan D, 2011, CANCER RES, V71, P3852, DOI 10.1158/0008-5472.CAN-10-4460
   Khalil AM, 2009, P NATL ACAD SCI USA, V106, P11667, DOI 10.1073/pnas.0904715106
   Li JG, 2014, GUT, V63, P1700, DOI 10.1136/gutjnl-2013-305806
   Ma MZ, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2014.541
   Marchese FP, 2014, EPIGENETICS-US, V9, P21, DOI 10.4161/epi.27472
   Matsushima K, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-30
   Mercer TR, 2009, NAT REV GENET, V10, P155, DOI 10.1038/nrg2521
   Mirabello L, 2012, INT J MOL EPIDEMIOL, V3, P213
   Mizrahi I, 2015, J CANCER, V6, P105, DOI 10.7150/jca.10568
   Mückstein U, 2006, BIOINFORMATICS, V22, P1177, DOI 10.1093/bioinformatics/btl024
   Nagano T, 2011, CELL, V145, P178, DOI 10.1016/j.cell.2011.03.014
   Nie FQ, 2015, MOL CANCER THER, V14, P268, DOI 10.1158/1535-7163.MCT-14-0492
   Nissan A, 2012, INT J CANCER, V130, P1598, DOI 10.1002/ijc.26170
   Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74
   Pearson JC, 2005, NAT REV GENET, V6, P893, DOI 10.1038/nrg1726
   Pohl H, 2005, J NATL CANCER I, V97, P142, DOI 10.1093/jnci/dji024
   Poliseno L, 2010, NATURE, V465, P1033, DOI 10.1038/nature09144
   Prensner JR, 2011, NAT BIOTECHNOL, V29, P742, DOI 10.1038/nbt.1914
   Puvvula PK, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6323
   Rinn JL, 2007, CELL, V129, P1311, DOI 10.1016/j.cell.2007.05.022
   Shah N, 2010, NAT REV CANCER, V10, P361, DOI 10.1038/nrc2826
   Sun M, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.256
   Tennis MA, 2010, MOL CANCER RES, V8, P833, DOI 10.1158/1541-7786.MCR-09-0400
   Tong YS, 2015, MOL CANCER, V14, DOI 10.1186/1476-4598-14-3
   Tsai MC, 2010, SCIENCE, V329, P689, DOI 10.1126/science.1192002
   Vanas V, 2014, TUMOR BIOL, V35, P4447, DOI 10.1007/s13277-013-1587-0
   Viré E, 2006, NATURE, V439, P871, DOI 10.1038/nature04431
   Wang DW, 2013, NEURAL PLAST, V2013, DOI 10.1155/2013/128236
   Wang JH, 2006, PROSTATE, V66, P613, DOI 10.1002/pros.20353
   Wang P, 2014, SCIENCE, V344, P310, DOI 10.1126/science.1251456
   Wei GF, 2015, ONCOTARGET, V6, P17065, DOI 10.18632/oncotarget.4185
   Wilusz JE, 2009, GENE DEV, V23, P1494, DOI 10.1101/gad.1800909
   Xu TP, 2015, ONCOGENE, V34, P5648, DOI 10.1038/onc.2015.18
   Yang F, 2013, J CANCER RES CLIN, V139, P437, DOI 10.1007/s00432-012-1324-x
   Yang F, 2013, MOL CELL, V49, P1083, DOI 10.1016/j.molcel.2013.01.010
   Yoon JH, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3939
   Yuan SX, 2012, HEPATOLOGY, V56, P2231, DOI 10.1002/hep.25895
   Zhang EB, 2014, ONCOTARGET, V5, P2276, DOI 10.18632/oncotarget.1902
   Zhang XF, 2015, INT J CLIN EXP PATHO, V8, P9440
   Zhou YL, 2012, J MOL ENDOCRINOL, V48, pR45, DOI 10.1530/JME-12-0008
   Zhu HQ, 2015, INT J CLIN EXP PATHO, V8, P5427
NR 55
TC 265
Z9 277
U1 3
U2 96
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0305-1048
EI 1362-4962
J9 NUCLEIC ACIDS RES
JI Nucleic Acids Res.
PD APR 7
PY 2017
VL 45
IS 6
BP 3086
EP 3101
DI 10.1093/nar/gkw1247
PG 16
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA EQ9AI
UT WOS:000398376200023
PM 27956498
OA Green Published, gold, Green Submitted
HC Y
HP N
DA 2025-01-12
ER

PT J
AU Nagarajan, S
   Bedi, U
   Budida, A
   Hamdan, FH
   Mishra, VK
   Najafova, Z
   Xie, WH
   Alawi, M
   Indenbirken, D
   Knapp, S
   Chiang, CM
   Grundhoff, A
   Kari, V
   Scheel, CH
   Wegwitz, F
   Johnsen, SA
AF Nagarajan, Sankari
   Bedi, Upasana
   Budida, Anusha
   Hamdan, Feda H.
   Mishra, Vivek Kumar
   Najafova, Zeynab
   Xie, Wanhua
   Alawi, Malik
   Indenbirken, Daniela
   Knapp, Stefan
   Chiang, Cheng-Ming
   Grundhoff, Adam
   Kari, Vijayalakshmi
   Scheel, Christina H.
   Wegwitz, Florian
   Johnsen, Steven A.
TI BRD4 promotes p63 and GRHL3 expression downstream of FOXO in mammary
   epithelial cells
SO NUCLEIC ACIDS RESEARCH
LA English
DT Article
ID BET BROMODOMAIN INHIBITION; ESTROGEN-RECEPTOR BINDING; GENE-EXPRESSION;
   TRANSCRIPTION FACTOR; BREAST-CANCER; MESENCHYMAL TRANSITION;
   DIFFERENTIAL EXPRESSION; SELECTIVE-INHIBITION; P-TEFB; ELONGATION
AB Bromodomain-containing protein 4 (BRD4) is a member of the bromo-and extraterminal (BET) domain-containing family of epigenetic readers which is under intensive investigation as a target for anti-tumor therapy. BRD4 plays a central role in promoting the expression of select subsets of genes including many driven by oncogenic transcription factors and signaling pathways. However, the role of BRD4 and the effects of BET inhibitors in non-transformed cells remain mostly unclear. We demonstrate that BRD4 is required for the maintenance of a basal epithelial phenotype by regulating the expression of epithelial-specific genes including TP63 and Grainy Head-like transcription factor-3 (GRHL3) in non-transformed basal-like mammary epithelial cells. Moreover, BRD4 occupancy correlates with enhancer activity and enhancer RNA (eRNA) transcription. Motif analyses of cell context-specific BRD4-enriched regions predicted the involvement of FOXOtranscription factors. Consistently, activation of FOXO1 function via inhibition of EGFR-AKT signaling promoted the expression of TP63 and GRHL3. Moreover, activation of Src kinase signaling and FOXO1 inhibition decreased the expression of FOXO/BRD4 target genes. Together, our findings support a function for BRD4 in promoting basal mammary cell epithelial differentiation, at least in part, by regulating FOXO factor function on enhancers to activate TP63 and GRHL3 expression.
C1 [Nagarajan, Sankari; Budida, Anusha; Hamdan, Feda H.; Mishra, Vivek Kumar; Najafova, Zeynab; Xie, Wanhua; Kari, Vijayalakshmi; Wegwitz, Florian; Johnsen, Steven A.] Univ Med Ctr Gottingen, Gottingen Ctr Mol Biosci, Dept Gen Visceral & Pediat Surg, D-37077 Gottingen, Germany.
   [Bedi, Upasana] Univ Med Ctr Gottingen, Inst Mol Oncol, D-37077 Gottingen, Germany.
   [Bedi, Upasana] Univ Med Ctr Hamburg Eppendorf, Inst Tumor Biol, D-20246 Hamburg, Germany.
   [Alawi, Malik] Univ Med Ctr Hamburg Eppendorf, Bioinformat Core, D-20251 Hamburg, Germany.
   [Alawi, Malik; Indenbirken, Daniela; Grundhoff, Adam] Heinrich Pette Inst, Leibniz Inst Expt Virol, D-20251 Hamburg, Germany.
   [Knapp, Stefan] Univ Oxford, Struct Genom Consortium, Oxford OX3 7DQ, England.
   [Knapp, Stefan] Univ Oxford, Target Discovery Inst, Oxford OX3 7FZ, England.
   [Knapp, Stefan] Goethe Univ Frankfurt, Inst Pharmaceut Chem, D-60323 Frankfurt, Germany.
   [Chiang, Cheng-Ming] Univ Texas Southwestern Med Ctr Dallas, Simmons Comprehens Canc Ctr, Dallas, TX 75235 USA.
   [Scheel, Christina H.] Helmholtz Ctr Hlth & Environm Res Munich, Inst Stem Cell Res, D-85764 Neuherberg, Germany.
C3 University of Gottingen; UNIVERSITY GOTTINGEN HOSPITAL; University of
   Gottingen; UNIVERSITY GOTTINGEN HOSPITAL; University of Hamburg;
   University Medical Center Hamburg-Eppendorf; University of Hamburg;
   University Medical Center Hamburg-Eppendorf; Heinrich Pette Institute;
   University of Oxford; University of Oxford; Goethe University Frankfurt;
   University of Texas System; University of Texas Southwestern Medical
   Center Dallas
RP Johnsen, SA (通讯作者)，Univ Med Ctr Gottingen, Gottingen Ctr Mol Biosci, Dept Gen Visceral & Pediat Surg, D-37077 Gottingen, Germany.
EM steven.johnsen@med.uni-goettingen.de
RI Nagarajan, Sankari/ACC-0438-2022; Johnsen, Steven/AAX-2322-2020; Xie,
   Wanhua/LDF-2003-2024; Mishra, Vivek/AAF-3224-2019; Scheel,
   Christina/IQV-1110-2023; Knapp, Stefan/AAG-2347-2019
OI Najafova, Zeynab/0000-0003-4403-5566; Xie, Wanhua/0000-0002-9080-244X;
   Mishra, Vivek Kumar/0000-0003-0853-0770; Hamdan, Feda
   H/0000-0003-2455-2435; Alawi, Malik/0000-0002-5993-7709; Knapp,
   Stefan/0000-0001-5995-6494; Grundhoff, Adam/0000-0003-0940-7045;
   Johnsen, Steven/0000-0003-1198-5805
FU German Academic Exchange Service (DAAD); Erasmus Mundus External
   Cooperation Window (EURINDIA); Gottingen Graduate School for
   Neurosciences, Biophysics and Molecular Biosciences (GGNB); China
   Scholarship Council (CSC) [201206170048]; SGC, a registered charity
   Canadian Institutes for Health Research [1097737]; Canada Foundation for
   Innovation; Genome Canada; AbbVie; Boehringer Ingelheim; Bayer; Janssen;
   GlaxoSmithKline; Pfizer; Eli Lilly; Novartis Research Foundation;
   Takeda; Ontario Ministry of Research and Innovation; Wellcome Trust
   [092309/Z/10/Z]; NIH [CA103867]; CPRIT [RP110471, RP140367]; Welch
   Foundation [I-1805]; Deutsche Krebshilfe [111600]
FX German Academic Exchange Service (DAAD) (to S.N., A.B. and F.H.H.);
   Erasmus Mundus External Cooperation Window (EURINDIA); Gottingen
   Graduate School for Neurosciences, Biophysics and Molecular Biosciences
   (GGNB) (to U.B.); The China Scholarship Council (CSC) [201206170048 to
   W.X.]; SGC, a registered charity [1097737] that receives funds from the
   Canadian Institutes for Health Research; the Canada Foundation for
   Innovation, Genome Canada, AbbVie, Boehringer Ingelheim, Bayer, Janssen,
   GlaxoSmithKline, Pfizer, Eli Lilly, the Novartis Research Foundation,
   Takeda, the Ontario Ministry of Research and Innovation and the Wellcome
   Trust [092309/Z/10/Z to S.K.]; NIH [CA103867]' CPRIT [RP110471 and
   RP140367]; Welch Foundation [I-1805 to C.M.C.]; Deutsche Krebshilfe
   [111600 to S.A.J.]. Funding for open access charge: Internal
   institutional funding.
CR Alotaibi H, 2015, BBA-GENE REGUL MECH, V1849, P731, DOI 10.1016/j.bbagrm.2015.01.005
   Alsarraj J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080746
   Anders S, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-10-r106
   Andrieu G, 2016, CANCER RES, V76, P6555, DOI 10.1158/0008-5472.CAN-16-0559
   Baud'huin M, 2017, BONE, V94, P10, DOI 10.1016/j.bone.2016.09.020
   Bedi U, 2015, ONCOGENE, V34, P465, DOI 10.1038/onc.2013.558
   Bosco A, 2010, MUCOSAL IMMUNOL, V3, P399, DOI 10.1038/mi.2010.13
   Carroll DK, 2006, NAT CELL BIOL, V8, P551, DOI 10.1038/ncb1420
   Cavazza A, 2016, STEM CELL REP, V6, P618, DOI 10.1016/j.stemcr.2016.03.003
   Chapuy B, 2013, CANCER CELL, V24, P777, DOI 10.1016/j.ccr.2013.11.003
   Charafe-Jauffret E, 2006, ONCOGENE, V25, P2273, DOI 10.1038/sj.onc.1209254
   CHIRIVI RGS, 1993, CANCER RES, V53, P5051
   Cieply B, 2012, CANCER RES, V72, P2440, DOI 10.1158/0008-5472.CAN-11-4038
   Crawford NPS, 2008, P NATL ACAD SCI USA, V105, P6380, DOI 10.1073/pnas.0710331105
   Cromer A, 2004, ONCOGENE, V23, P2484, DOI 10.1038/sj.onc.1207345
   Dansen TB, 2008, TRENDS CELL BIOL, V18, P421, DOI 10.1016/j.tcb.2008.07.004
   Darido C, 2011, CANCER CELL, V20, P635, DOI 10.1016/j.ccr.2011.10.014
   Delmore JE, 2011, CELL, V146, P903, DOI 10.1016/j.cell.2011.08.017
   Di Micco R, 2014, CELL REP, V9, P234, DOI 10.1016/j.celrep.2014.08.055
   Feng Q, 2014, CELL RES, V24, P809, DOI 10.1038/cr.2014.71
   Filippakopoulos P, 2014, NAT REV DRUG DISCOV, V13, P339, DOI 10.1038/nrd4286
   Filippakopoulos P, 2012, CELL, V149, P214, DOI 10.1016/j.cell.2012.02.013
   Frisch SM, 2013, J CELL SCI, V126, P21, DOI 10.1242/jcs.120907
   Gautier L, 2004, BIOINFORMATICS, V20, P307, DOI 10.1093/bioinformatics/btg405
   Hah N, 2013, GENOME RES, V23, P1210, DOI 10.1101/gr.152306.112
   Heintzman ND, 2009, NATURE, V459, P108, DOI 10.1038/nature07829
   Hirsch HA, 2010, CANCER CELL, V17, P348, DOI 10.1016/j.ccr.2010.01.022
   Hood JD, 2002, NAT REV CANCER, V2, P91, DOI 10.1038/nrc727
   Hornbeck PV, 2015, NUCLEIC ACIDS RES, V43, pD512, DOI 10.1093/nar/gku1267
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Jaeger J, 2007, CLIN CANCER RES, V13, P806, DOI 10.1158/1078-0432.CCR-06-1820
   Joseph R, 2010, MOL SYST BIOL, V6, DOI 10.1038/msb.2010.109
   Kamagate A, 2008, J CLIN INVEST, V118, P2347, DOI [10.1172/JC132914, 10.1172/JCI32914]
   Kanno T, 2014, NAT STRUCT MOL BIOL, V21, P1047, DOI 10.1038/nsmb.2912
   Kim YJ, 2013, ONCOGENE, V32, P2828, DOI 10.1038/onc.2013.32
   Lamb LE, 2011, CANCER RES, V71, P2739, DOI 10.1158/0008-5472.CAN-10-2745
   Lamoureux F, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4511
   Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/NMETH.1923, 10.1038/nmeth.1923]
   Larue L, 2005, ONCOGENE, V24, P7443, DOI 10.1038/sj.onc.1209091
   Lee TI, 2013, CELL, V152, P1237, DOI 10.1016/j.cell.2013.02.014
   Liberzon A, 2011, BIOINFORMATICS, V27, P1739, DOI 10.1093/bioinformatics/btr260
   Lin HJL, 2008, CANCER RES, V68, P10257, DOI 10.1158/0008-5472.CAN-08-0288
   Lindsay J, 2011, J BIOL CHEM, V286, P3915, DOI 10.1074/jbc.M110.162511
   Lovén J, 2013, CELL, V153, P320, DOI 10.1016/j.cell.2013.03.036
   Manalo DJ, 2005, BLOOD, V105, P659, DOI 10.1182/blood-2004-07-2958
   Maschler S, 2005, ONCOGENE, V24, P2032, DOI 10.1038/sj.onc.1208423
   Matkar S, 2015, CANCER CELL, V28, P472, DOI 10.1016/j.ccell.2015.09.005
   McLean CY, 2010, NAT BIOTECHNOL, V28, P495, DOI 10.1038/nbt.1630
   Mistry DS, 2014, STEM CELLS, V32, P3209, DOI 10.1002/stem.1809
   Nagarajan S, 2015, ONCOTARGET, V6, P7305, DOI 10.18632/oncotarget.3439
   Nagarajan S, 2014, CELL REP, V8, P459, DOI 10.1016/j.celrep.2014.06.016
   Nagashima T, 2010, MOL PHARMACOL, V78, P961, DOI 10.1124/mol.110.065714
   Najafova Z, 2017, NUCLEIC ACIDS RES, V45, P127, DOI 10.1093/nar/gkw826
   Nakae J, 2001, J CLIN INVEST, V108, P1359, DOI 10.1172/JCI12876
   Normanno N, 2006, GENE, V366, P2, DOI 10.1016/j.gene.2005.10.018
   Nylander K, 2002, J PATHOL, V198, P417, DOI 10.1002/path.1231
   O'Donnell RK, 2005, ONCOGENE, V24, P1244, DOI 10.1038/sj.onc.1208285
   Oliver JR, 2012, LAB INVEST, V92, P320, DOI 10.1038/labinvest.2011.186
   Ong CT, 2011, NAT REV GENET, V12, P283, DOI 10.1038/nrg2957
   Pellacani D, 2016, CELL REP, V17, P2060, DOI 10.1016/j.celrep.2016.10.058
   Peterlin BM, 2006, MOL CELL, V23, P297, DOI 10.1016/j.molcel.2006.06.014
   Roe JS, 2015, MOL CELL, V58, P1028, DOI 10.1016/j.molcel.2015.04.011
   Ross-Innes CS, 2012, NATURE, V481, P389, DOI 10.1038/nature10730
   Samuel VT, 2006, DIABETES, V55, P2042, DOI 10.2337/db05-0705
   Schmoll D, 2000, J BIOL CHEM, V275, P36324, DOI 10.1074/jbc.M003616200
   Shi J, 2014, CANCER CELL, V25, P210, DOI 10.1016/j.ccr.2014.01.028
   Shi JW, 2014, MOL CELL, V54, P728, DOI 10.1016/j.molcel.2014.05.016
   Shu SK, 2016, NATURE, V529, P413, DOI 10.1038/nature16508
   Singh BK, 2013, J BIOL CHEM, V288, P30365, DOI 10.1074/jbc.M113.504845
   Smalley MJ, 2010, METHODS MOL BIOL, V633, P139, DOI 10.1007/978-1-59745-019-5_11
   Sotiriou C, 2006, JNCI-J NATL CANCER I, V98, P262, DOI 10.1093/jnci/djj052
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Sui SJH, 2007, NUCLEIC ACIDS RES, V35, pW245, DOI 10.1093/nar/gkm427
   Theodorou V, 2013, GENOME RES, V23, P12, DOI 10.1101/gr.139469.112
   Ting SB, 2005, SCIENCE, V308, P411, DOI 10.1126/science.1107511
   Vasquez YM, 2015, MOL ENDOCRINOL, V29, P421, DOI 10.1210/me.2014-1292
   Villafane B., 2012, ROLE P63 CELL MIGRAT
   Wang LX, 2011, P NATL ACAD SCI USA, V108, pE803, DOI 10.1073/pnas.1103423108
   Welboren WJ, 2009, EMBO J, V28, P1418, DOI 10.1038/emboj.2009.88
   Werner S, 2013, J BIOL CHEM, V288, P22993, DOI 10.1074/jbc.M113.456293
   Wong DJ, 2008, CELL STEM CELL, V2, P333, DOI 10.1016/j.stem.2008.02.009
   Wu SY, 2013, MOL CELL, V49, P843, DOI 10.1016/j.molcel.2012.12.006
   Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539
   Yang ZY, 2005, MOL CELL, V19, P535, DOI 10.1016/j.molcel.2005.06.029
   Yik JHN, 2003, MOL CELL, V12, P971, DOI 10.1016/S1097-2765(03)00388-5
   Zhuang SG, 2012, J CELL PHYSIOL, V227, P2138, DOI 10.1002/jcp.22946
NR 86
TC 23
Z9 26
U1 2
U2 12
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0305-1048
EI 1362-4962
J9 NUCLEIC ACIDS RES
JI Nucleic Acids Res.
PD APR 7
PY 2017
VL 45
IS 6
BP 3130
EP 3145
DI 10.1093/nar/gkw1276
PG 16
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA EQ9AI
UT WOS:000398376200026
PM 27980063
OA Green Submitted, Green Published, gold
DA 2025-01-12
ER

PT J
AU Liu, YB
   Song, C
   Ladas, I
   Fitarelli-Kiehl, M
   Makrigiorgos, GM
AF Liu, Yibin
   Song, Chen
   Ladas, Ioannis
   Fitarelli-Kiehl, Mariana
   Makrigiorgos, G. Mike
TI Methylation-sensitive enrichment of minor DNA alleles using a
   double-strand DNA-specific nuclease
SO NUCLEIC ACIDS RESEARCH
LA English
DT Article
ID ABERRANT PROMOTER METHYLATION; TIME SIGNAL GENERATION;
   COLORECTAL-CANCER; LUNG-CANCER; NONINVASIVE DETECTION; BISULFITE
   CONVERSION; BREAST-CANCER; CPG ISLANDS; PCR; MUTATIONS
AB Aberrant methylation changes, often present in a minor allelic fraction in clinical samples such as plasma-circulating DNA (cfDNA), are potentially powerful prognostic and predictive biomarkers in human disease including cancer. We report on a novel, highly-multiplexed approach to facilitate analysis of clinically useful methylation changes in minor DNA populations. Methylation Specific Nuclease-assisted Minor-allele Enrichment (MS-NaME) employs a double-strand-specific DNA nuclease (DSN) to remove excess DNA with normal methylation patterns. The technique utilizes oligonucle-otideprobes that direct DSN activity to multiple targets in bisulfite-treated DNA, simultaneously. Oligonucleotide probes targeting unmethylated sequences generate local double stranded regions resulting to digestion of unmethylated targets, and leaving methylated targets intact; and vice versa. Subsequent amplification of the targeted regions results in enrichment of the targeted methylated or unmethylated minority-epigenetic-alleles. We validate MS-NaME by demonstrating enrichment of RARb2, ATM, MGMT and GSTP1 promoters in multiplexed MS-NaME reactions (177-plex) using dilutions of methylated/unmethylated DNA and in DNA from clinical lung cancer samples and matched normal tissue. MS-NaME is a highly scalable single-step approach performed at the genomic DNA level in solution that combines with most downstream detection technologies including Sanger sequencing, methylation-sensitive-high-resolution melting (MS-HRM) and methylation-specific-Taqman-based-digital-PCR (digital Methylight) to boost detection of low-level aberrant methylation-changes.
C1 [Makrigiorgos, G. Mike] Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA 02115 USA.
   Harvard Med Sch, Brigham & Womens Hosp, Boston, MA 02115 USA.
C3 Harvard University; Dana-Farber Cancer Institute; Harvard University;
   Harvard Medical School; Brigham & Women's Hospital
RP Makrigiorgos, GM (通讯作者)，Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA 02115 USA.
EM mmakrigiorgos@partners.org
RI Makrigiorgos, Mike/AFC-4575-2022
OI Liu, Yibin/0000-0003-3451-0212
FU National Cancer Institute [R21CA-175542]; National Institutes of Health
FX National Cancer Institute [R21CA-175542 to G.M.M.]; National Cancer
   Institute or the National Institutes of Health. Funding for open access
   charge: departmental funds.
CR Amicarelli G, 2007, NUCLEIC ACIDS RES, V35, DOI 10.1093/nar/gkm809
   Amicarelli G, 2006, CLIN CHEM, V52, P1855, DOI 10.1373/clinchem.2006.068817
   Ballestar E, 2003, EMBO J, V22, P6335, DOI 10.1093/emboj/cdg604
   BIRD AP, 1978, J MOL BIOL, V118, P27, DOI 10.1016/0022-2836(78)90242-5
   Bonanno C, 2007, CLIN CHEM, V53, P2119, DOI 10.1373/clinchem.2007.094011
   Brennan K, 2012, CANCER RES, V72, P2304, DOI 10.1158/0008-5472.CAN-11-3157
   Castellanos-Rizaldos E, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094103
   Chan KCA, 2013, P NATL ACAD SCI USA, V110, P18761, DOI 10.1073/pnas.1313995110
   Chimonidou M, 2013, CLIN CHEM, V59, P270, DOI 10.1373/clinchem.2012.191551
   Chiu RWK, 2008, P NATL ACAD SCI USA, V105, P20458, DOI 10.1073/pnas.0810641105
   CROSS SH, 1994, NAT GENET, V6, P236, DOI 10.1038/ng0394-236
   Deng J, 2009, NAT BIOTECHNOL, V27, P353, DOI 10.1038/nbt.1530
   Eads CA, 2000, NUCLEIC ACIDS RES, V28, DOI 10.1093/nar/28.8.e32
   Goval JJ, 2009, METHODS MOL BIOL, V567, P237, DOI 10.1007/978-1-60327-414-2_15
   Greenberg AK, 2007, CURR OPIN PULM MED, V13, P249, DOI 10.1097/MCP.0b013e32819f8f06
   Grote HJ, 2005, INT J CANCER, V116, P720, DOI 10.1002/ijc.21090
   Hashimoto K., 2014, EPIGENETICS, V2, P86
   Hegi ME, 2005, NEW ENGL J MED, V352, P997, DOI 10.1056/NEJMoa043331
   Henrique R, 2004, EUR UROL, V46, P660, DOI 10.1016/j.eururo.2004.06.014
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Ito S, 2011, SCIENCE, V333, P1300, DOI 10.1126/science.1210597
   Jacinto FV, 2008, BIOTECHNIQUES, V44, P35, DOI 10.2144/000112708
   Ji LX, 2014, FRONT GENET, V5, DOI 10.3389/fgene.2014.00341
   Ladabaum U, 2013, CANCER EPIDEM BIOMAR, V22, P1567, DOI 10.1158/1055-9965.EPI-13-0204
   Lange CPE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050266
   Lehmann-Werman R, 2016, P NATL ACAD SCI USA, V113, pE1826, DOI 10.1073/pnas.1519286113
   Li J, 2006, CLIN CHEM, V52, P624, DOI 10.1373/clinchem.2005.063321
   Li J, 2008, NAT MED, V14, P579, DOI 10.1038/nm1708
   Li J, 2009, HUM MUTAT, V30, P1583, DOI 10.1002/humu.21112
   Li Q, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv244
   Lo YM, 2011, J PATHOL, V225, P318, DOI 10.1002/path.2960
   Lofton-Day C, 2008, CLIN CHEM, V54, P414, DOI 10.1373/clinchem.2007.095992
   Meissner A, 2005, NUCLEIC ACIDS RES, V33, P5868, DOI 10.1093/nar/gki901
   Milbury CA, 2012, CLIN CHEM, V58, P580, DOI 10.1373/clinchem.2011.176198
   Milbury CA, 2011, NUCLEIC ACIDS RES, V39, DOI 10.1093/nar/gkq899
   Milbury CA, 2009, CLIN CHEM, V55, P2130, DOI 10.1373/clinchem.2009.131029
   Milbury CA, 2009, CLIN CHEM, V55, P632, DOI 10.1373/clinchem.2008.113035
   Mill Jonathan, 2009, V507, P371, DOI 10.1007/978-1-59745-522-0_27
   Ogino S, 2006, J MOL DIAGN, V8, P209, DOI 10.2353/jmoldx.2006.050135
   Palmisano WA, 2000, CANCER RES, V60, P5954
   Roy K, 2006, BIOCHEM BIOPH RES CO, V344, P821, DOI 10.1016/j.bbrc.2006.03.222
   Schmiemann V, 2005, CLIN CANCER RES, V11, P7728, DOI 10.1158/1078-0432.CCR-05-0999
   Schultz MD, 2012, TRENDS GENET, V28, P583, DOI 10.1016/j.tig.2012.10.012
   Shagin DA, 2002, GENOME RES, V12, P1935, DOI 10.1101/gr.547002
   Shen LL, 2005, JNCI-J NATL CANCER I, V97, P1330, DOI 10.1093/jnci/dji275
   Snyder MW, 2016, CELL, V164, P57, DOI 10.1016/j.cell.2015.11.050
   Snyder TM, 2011, P NATL ACAD SCI USA, V108, P6229, DOI 10.1073/pnas.1013924108
   Song C, 2016, NUCLEIC ACIDS RES, V44, DOI 10.1093/nar/gkw650
   Sun K, 2015, P NATL ACAD SCI USA, V112, pE5503, DOI 10.1073/pnas.1508736112
   Thomson JP, 2013, NUCLEIC ACIDS RES, V41, DOI 10.1093/nar/gkt1080
   Tóth K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0115415
   Urich MA, 2015, NAT PROTOC, V10, DOI 10.1038/nprot.2014.114
   Warton K, 2015, FRONT MOL BIOSCI, V2, DOI 10.3389/fmolb.2015.00013
   Weisenberger DJ, 2006, NAT GENET, V38, P787, DOI 10.1038/ng1834
   Weisenberger DJ, 2015, TRANSL CANCER RES, V4, P219, DOI 10.3978/j.issn.2218-676X.2015.05.01
   Widschwendter M, 2007, NAT GENET, V39, P157, DOI 10.1038/ng1941
   Wojdacz TK, 2008, NAT PROTOC, V3, P1903, DOI 10.1038/nprot.2008.191
   Yu M, 2015, EPIGENETICS-US, V10, P803, DOI 10.1080/15592294.2015.1068490
   Zhang YW, 2011, CANCER LETT, V303, P21, DOI 10.1016/j.canlet.2010.12.011
NR 59
TC 18
Z9 26
U1 2
U2 45
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0305-1048
EI 1362-4962
J9 NUCLEIC ACIDS RES
JI Nucleic Acids Res.
PD APR 7
PY 2017
VL 45
IS 6
AR e39
DI 10.1093/nar/gkw1166
PG 11
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA EQ9AI
UT WOS:000398376200004
PM 27903892
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Zuber, V
   Bettella, F
   Witoelar, A
   Andreassen, OA
   Mills, IG
   Urbanucci, A
AF Zuber, Verena
   Bettella, Francesco
   Witoelar, Aree
   Andreassen, Ole A.
   Mills, Ian G.
   Urbanucci, Alfonso
CA PRACTICAL Consortium
   COGS CRUK GWAS
   BCAC Consortium
   TRICL Consortium
TI Bromodomain protein 4 discriminates tissue-specific super-enhancers
   containing disease-specific susceptibility loci in prostate and breast
   cancer
SO BMC GENOMICS
LA English
DT Article
DE BRD4; Genome-wide association studies; SNPs; Functional annotation;
   Chromatin; Risk loci; Prostate cancer risk; breast cancer risk;
   schizophrenia; super-enhancer
ID COMMON DISEASE; CELL IDENTITY; TRANSCRIPTION; RISK; VARIANTS; BINDING;
   METAANALYSIS; COMPLEX; GENOME
AB Background: Epigenetic information can be used to identify clinically relevant genomic variants single nucleotide polymorphisms (SNPs) of functional importance in cancer development. Super-enhancers are cell-specific DNA elements, acting to determine tissue or cell identity and driving tumor progression. Although previous approaches have been tried to explain risk associated with SNPs in regulatory DNA elements, so far epigenetic readers such as bromodomain containing protein 4 (BRD4) and super-enhancers have not been used to annotate SNPs. In prostate cancer (PC), androgen receptor (AR) binding sites to chromatin have been used to inform functional annotations of SNPs.
   Results: Here we establish criteria for enhancer mapping which are applicable to other diseases and traits to achieve the optimal tissue-specific enrichment of PC risk SNPs. We used stratified Q-Q plots and Fisher test to assess the differential enrichment of SNPs mapping to specific categories of enhancers. We find that BRD4 is the key discriminant of tissue-specific enhancers, showing that it is more powerful than AR binding information to capture PC specific risk loci, and can be used with similar effect in breast cancer (BC) and applied to other diseases such as schizophrenia.
   Conclusions: This is the first study to evaluate the enrichment of epigenetic readers in genome-wide associations studies for SNPs within enhancers, and provides a powerful tool for enriching and prioritizing PC and BC genetic risk loci. Our study represents a proof of principle applicable to other diseases and traits that can be used to redefine molecular mechanisms of human phenotypic variation.
C1 [Zuber, Verena; Mills, Ian G.; Urbanucci, Alfonso] Univ Oslo, Fac Med, Ctr Mol Med Norway NCMM, Prostate Canc Res Grp,Nordic EMBL Partnership, Oslo, Norway.
   [Zuber, Verena; Bettella, Francesco; Witoelar, Aree; Andreassen, Ole A.] Univ Oslo, KG Jebsen Ctr Psychosis Res, Inst Clin Med, NORMENT, Oslo, Norway.
   [Zuber, Verena; Bettella, Francesco; Witoelar, Aree; Andreassen, Ole A.] Oslo Univ Hosp, Div Mental Hlth & Addict, Oslo, Norway.
   [Zuber, Verena] European Bioinformat Inst, European Mol Biol Lab, Wellcome Trust Genome Campus, Cambridge, England.
   Univ Cambridge, Ctr Canc Genet Epidemiol, Cambridge, England.
   [Mills, Ian G.; Urbanucci, Alfonso] Oslo Univ Hosp, Inst Canc Res, Dept Mol Oncol, Oslo, Norway.
   [Mills, Ian G.] Queens Univ, PCUK Movember Ctr Excellence, CCRCB, Belfast, Antrim, North Ireland.
C3 University of Oslo; University of Oslo; University of Oslo; European
   Molecular Biology Laboratory (EMBL); European Bioinformatics Institute;
   Wellcome Trust Sanger Institute; University of Cambridge; University of
   Oslo; Queens University Belfast
RP Urbanucci, A (通讯作者)，Univ Oslo, Fac Med, Ctr Mol Med Norway NCMM, Prostate Canc Res Grp,Nordic EMBL Partnership, Oslo, Norway.; Urbanucci, A (通讯作者)，Oslo Univ Hosp, Inst Canc Res, Dept Mol Oncol, Oslo, Norway.
EM alfonsourbanucci@gmail.com
RI Andreassen, Ole/AAY-7531-2020; Mills, Ian/AAK-9292-2020; Urbanucci,
   Alfonso/S-4450-2019; Zuber, Verena/AFJ-6276-2022; Heinrich,
   Joachim/N-1720-2013; Brenner, Hermann/ABE-6383-2020
OI Michailidou, Kyriaki/0000-0001-7065-1237; Urbanucci,
   Alfonso/0000-0003-2931-3652; Schleutker, Johanna/0000-0002-1863-0305;
   Heinrich, Joachim/0000-0002-9620-1629; batra,
   Jyotsna/0000-0003-4646-6247; Durocher, Francine/0000-0001-8012-4641;
   Brenner, Hermann/0000-0002-6129-1572; Eeles,
   Rosalind/0000-0002-3698-6241; Mills, Ian/0000-0001-5347-5083; Zuber,
   Verena/0000-0001-9827-1877
FU South-East Norway Health Authorities at the Oslo University Hospital
   [2014040]; Norwegian Centre for Molecular Medicine; Research Council of
   Norway (RCN); University of Oslo through the Centre for Molecular
   Medicine (Norway); Norwegian Cancer Society; EU; SENHA at the Oslo
   University Hospital; Centre for Molecular Medicine (Norway); Norwegian
   Centre of Research in Mental Disorders (NORMENT); RCN; SENHA; Norwegian
   Health Association; KG Jebsen Foundation; Kristian Gerhard Jebsen
   Foundation; Centre for Molecular Medicine Norway; Research Council of
   Norway [213837, 223273]; South-East Norway Health Authorities
   [2013-123]; National Institutes of Health [R01AG031224, R01EB000790,
   RC2DA29475]; Cancer Research UK [C5047/A3354]; Prostate Cancer Research
   Foundation; National Cancer Research Network UK; National Cancer
   Research Institute (NCRI) UK; Health Technology Assessment Programme
   [96/20/06, 96/20/99]; Department of Health, UK, Cancer Research UK
   [C522/A8649]; Medical Research Council (UK) [G0500966, 75466]; NCRI, UK;
   Southwest National Health Service Research and Developmen; Institute of
   Cancer Research; Everyman Campaign; Prostate Cancer UK; South East
   Norway Health Authority (SENHA); Oslo University Hospitals; South-East
   Norway Health Authorities at the Oslo University Hospital [2014040];
   Norwegian Centre for Molecular Medicine; Research Council of Norway
   (RCN); University of Oslo through the Centre for Molecular Medicine
   (Norway); Norwegian Cancer Society; EU; SENHA at the Oslo University
   Hospital; Centre for Molecular Medicine (Norway); Norwegian Centre of
   Research in Mental Disorders (NORMENT); RCN; SENHA; Norwegian Health
   Association; KG Jebsen Foundation; Kristian Gerhard Jebsen Foundation;
   Centre for Molecular Medicine Norway; Research Council of Norway
   [213837, 223273]; South-East Norway Health Authorities [2013-123];
   National Institutes of Health [R01AG031224, R01EB000790, RC2DA29475];
   Cancer Research UK [C5047/A3354]; Prostate Cancer Research Foundation;
   National Cancer Research Network UK; National Cancer Research Institute
   (NCRI) UK; Health Technology Assessment Programme [96/20/06, 96/20/99];
   Department of Health, UK, Cancer Research UK [C522/A8649]; Medical
   Research Council (UK) [G0500966, 75466]; NCRI, UK; Southwest National
   Health Service Research and Developmen; Institute of Cancer Research;
   Everyman Campaign; Prostate Cancer UK; South East Norway Health
   Authority (SENHA); Oslo University Hospitals; MRC [G0500966,
   MR/N003284/1] Funding Source: UKRI
FX A. U. is supported by the South-East Norway Health Authorities (Helse
   Sor-Ost grant ID 2014040) at the Oslo University Hospital, and the
   Norwegian Centre for Molecular Medicine. I. G. M. is supported by
   funding from the Research Council of Norway (RCN), South East Norway
   Health Authority (SENHA) and the University of Oslo through the Centre
   for Molecular Medicine (Norway), which is part of the Nordic EMBL
   (European Molecular Biology Laboratory) partnership and also supported
   by Oslo University Hospitals. I. G. M. is also supported by the
   Norwegian Cancer Society and by EU FP7 funding. I. G. M. holds a
   visiting scientist position with Cancer Research UK through the
   Cambridge Research Institute and a Senior Visiting Research Fellowship
   with Cambridge University through the Department of Oncology. A. U. is
   funded by the SENHA at the Oslo University Hospital. V. Z. is supported
   by the Centre for Molecular Medicine (Norway) and together with A. W.,
   F. B and O. A. A. supported by the Norwegian Centre of Research in
   Mental Disorders (NORMENT) with funding from the RCN, SENHA, Norwegian
   Health Association and KG Jebsen Foundation. This work was supported by
   the Kristian Gerhard Jebsen Foundation, Centre for Molecular Medicine
   Norway, Research Council of Norway (213837, 223273), South-East Norway
   Health Authorities (2013-123), National Institutes of Health
   (R01AG031224, R01EB000790 and RC2DA29475). I. G. M. and group members
   participate in the NIH Genetic Associations and Mechanisms in Oncology
   (GAME-ON): A Network of Consortia for Post-Genome Wide Association
   (Post-GWA) Research (prostate: 1U19CA148537-01). This work was also
   supported by Cancer Research UK Grant C5047/A3354. We would also like to
   thank the following for funding support: the Institute of Cancer
   Research and the Everyman Campaign, the Prostate Cancer Research
   Foundation, Prostate Research Campaign UK (now known as Prostate Cancer
   UK), the National Cancer Research Network UK and the National Cancer
   Research Institute (NCRI) UK. The ProtecT study is ongoing and is funded
   by the Health Technology Assessment Programme (projects 96/20/06,
   96/20/99). The ProtecT trial and its linked ProMPT and CAP (Comparison
   Arm for ProtecT) studies are supported by Department of Health, UK,
   Cancer Research UK grant number C522/A8649, Medical Research Council
   (UK) grant number G0500966, ID 75466 and the NCRI, UK. The
   epidemiological data for ProtecT were generated through funding from the
   Southwest National Health Service Research and Development.
CR Andreassen OA, 2014, INT J EPIDEMIOL, V43, P1205, DOI 10.1093/ije/dyu090
   Arshad Z, 2016, EXPERT OPIN DRUG DIS, V11, P321, DOI 10.1517/17460441.2016.1144587
   Asangani IA, 2014, NATURE, V510, P278, DOI 10.1038/nature13229
   Coetzee SG, 2015, HUM MOL GENET, V24, P3595, DOI 10.1093/hmg/ddv101
   Corradin O, 2014, GENOME MED, V6, DOI 10.1186/s13073-014-0085-3
   De Raedt T, 2014, NATURE, V514, P247, DOI 10.1038/nature13561
   Eeles RA, 2008, NAT GENET, V40, P316, DOI 10.1038/ng.90
   Eeles RA, 2013, NAT GENET, V45, P385, DOI 10.1038/ng.2560
   Freedman ML, 2011, NAT GENET, V43, P513, DOI 10.1038/ng.840
   Gusev A, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10979
   Hazelett DJ, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004102
   He HSHS, 2012, GENOME RES, V22, P1015, DOI 10.1101/gr.133280.111
   Heinz S, 2015, NAT REV MOL CELL BIO, V16, P144, DOI 10.1038/nrm3949
   Hnisz D, 2013, CELL, V155, P934, DOI 10.1016/j.cell.2013.09.053
   Hoefer J, 2014, ENDOCR-RELAT CANCER, V21, P175, DOI 10.1530/ERC-13-0446
   Huang CN, 2012, ANN ONCOL, V23, P707, DOI 10.1093/annonc/mdr264
   Khan A, 2016, NUCLEIC ACIDS RES, V44, pD164, DOI 10.1093/nar/gkv1002
   Lambert JC, 2013, NAT GENET, V45, P1452, DOI 10.1038/ng.2802
   Liu G, 2015, ONCOTARGET, V6, P288, DOI 10.18632/oncotarget.2672
   Liu T, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-8-r83
   Lovén J, 2013, CELL, V153, P320, DOI 10.1016/j.cell.2013.03.036
   Massie CE, 2011, EMBO J, V30, P2719, DOI 10.1038/emboj.2011.158
   Maurano MT, 2012, SCIENCE, V337, P1190, DOI 10.1126/science.1222794
   Michailidou K, 2013, NAT GENET, V45, P353, DOI 10.1038/ng.2563
   Nagarajan S, 2014, CELL REP, V8, P459, DOI 10.1016/j.celrep.2014.06.016
   Paul DS, 2014, BIOESSAYS, V36, P191, DOI 10.1002/bies.201300126
   Polak P, 2015, NATURE, V518, P360, DOI 10.1038/nature14221
   Ritchie GRS, 2014, NAT METHODS, V11, P294, DOI 10.1038/nmeth.2832
   Schork AJ, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003449
   Shaikhibrahim Z, 2014, ENDOCR-RELAT CANCER, V21, P663, DOI 10.1530/ERC-14-0171
   Sklar P, 2011, NAT GENET, V43, P977, DOI 10.1038/ng.943
   Taatjes DJ, 2010, TRENDS BIOCHEM SCI, V35, P315, DOI 10.1016/j.tibs.2010.02.004
   Tehranchi AK, 2016, CELL, V165, P730, DOI 10.1016/j.cell.2016.03.041
   Theodorou V, 2013, GENOME RES, V23, P12, DOI 10.1101/gr.139469.112
   Timofeeva MN, 2012, HUM MOL GENET, V21, P4980, DOI 10.1093/hmg/dds334
   Wang D, 2011, NATURE, V474, P390, DOI 10.1038/nature10006
   Weickert CS, 2016, PSYCHIAT CLIN N AM, V39, P343, DOI 10.1016/j.psc.2016.01.011
   Welter D, 2014, NUCLEIC ACIDS RES, V42, pD1001, DOI 10.1093/nar/gkt1229
   Whitington T, 2016, NAT GENET, V48, P387, DOI 10.1038/ng.3523
   Whyte WA, 2013, CELL, V153, P307, DOI 10.1016/j.cell.2013.03.035
NR 40
TC 25
Z9 29
U1 1
U2 11
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2164
J9 BMC GENOMICS
JI BMC Genomics
PD MAR 31
PY 2017
VL 18
AR 270
DI 10.1186/s12864-017-3620-y
PG 11
WC Biotechnology & Applied Microbiology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Genetics & Heredity
GA EQ0JM
UT WOS:000397757500002
PM 28359301
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Espinoza-Sánchez, NA
   Chimal-Ramírez, GK
   Mantilla, A
   Fuentes-Pananá, EM
AF Adriana Espinoza-Sanchez, Nancy
   Karina Chimal-Ramirez, Gloria
   Mantilla, Alejandra
   Moises Fuentes-Panana, Ezequiel
TI IL-1β, IL-β, and Matrix Metalloproteinases-1,-2, and-10 Are Enriched
   upon Monocyte-Breast Cancer Cell Cocultivation in a Matrigel-Based
   Three-Dimensional System
SO FRONTIERS IN IMMUNOLOGY
LA English
DT Article
DE breast cancer; monocytes; matrigel-based 3D culture; inflammation; IL-1
   beta; IL-beta; MMPs
ID EPITHELIAL-MESENCHYMAL TRANSITION; TUMOR-ASSOCIATED MACROPHAGES;
   POOR-PROGNOSIS; GM-CSF; EXPRESSION; PROGRESSION; METASTASIS; GROWTH;
   MMP-1; INTERLEUKIN-12
AB Breast cancer remains the first cancer-related cause of death in women worldwide, particularly in developing countries in which most cases are diagnosed in late stages. Although most cancer studies are based in the genetic or epigenetic changes of the tumor cells, immune cells within the tumor stroma often cooperate with cancer progression. Particularly, monocytes are attracted to the tumor primary site in which they are differentiated into tumor-associated macrophages that facilitate tumor cell invasion and metastasis. In this study, we used three-dimensional cultures to form acini-like structures to analyze the inflammatory secretion profile of tumor cells individually or in co-culture with monocytes. Breast cancer cell lines and primary isolates from eight Mexican patients with breast cancer were used. We found high levels of RANTES/CCL5, MCP-1/CCL2, and G-CSF in the breast cancer individual cultures, supporting an important recruitment capacity of monocytes, but also of neutrophils. The co-cultures of the tumor cells and monocytes were significantly enriched with the potent pro-inflammatory cytokines interleukin (IL)-1 beta and IL-beta, known to support malignant progression. We also found that the interaction of tumor cells with monocytes promoted high levels of matrix metalloproteinases (MMP)-1, MMP-2, and MMP-10. Our study supports that a key event for malignant progression is the recruitment of different immune cell populations, which help to sustain and enhance a chronic inflammatory microenvironment that highly favors tumor malignancy.
C1 [Adriana Espinoza-Sanchez, Nancy; Karina Chimal-Ramirez, Gloria; Moises Fuentes-Panana, Ezequiel] Hosp Infantil Mexico Dr Federico Gomez, Unidad Investigac Virol & Canc, Mexico City, DF, Mexico.
   [Adriana Espinoza-Sanchez, Nancy] Univ Nacl Autonoma Mexico, Fac Med, Programa Doctorado Ciencias Biomed, Mexico City, DF, Mexico.
   [Mantilla, Alejandra] Hosp Oncol, Ctr Med Nacl Siglo XXI, Inst Mexicano Seguro Social, Dept Patol, Mexico City, DF, Mexico.
C3 Hospital Infantil de Mexico Federico Gomez; Universidad Nacional
   Autonoma de Mexico; Instituto Mexicano del Seguro Social
RP Fuentes-Pananá, EM (通讯作者)，Hosp Infantil Mexico Dr Federico Gomez, Unidad Investigac Virol & Canc, Mexico City, DF, Mexico.
EM empanana@yahoo.com
RI Fuentes-Pananá, Ezequiel/AAI-2856-2020; Sánchez, Nancy/ABE-1561-2020
OI Espinoza Sanchez, Nancy Adriana/0000-0002-4118-6521
FU CONACyT FONSEC SSA/IIVISS/ISSSTE Project [233061]; Fondo de Apoyo a la
   Inyestigacion, Hospital Infantil de Mexico Federico Gomez
   [IIIM-2014-053]; CONACYT [231663]; Mexican Institute of Social Security
   (IMSS)
FX This work was supported by CONACyT FONSEC SSA/IIVISS/ISSSTE Project No.
   233061 to Ezequiel M. Fuentes-Panana and by Fondo de Apoyo a la
   Inyestigacion, Hospital Infantil de Mexico Federico Gomez (project
   number IIIM-2014-053). Nancy Adriana Espinoza-Sanchez is a doctoral
   student from Programa de Doctorado en Ciencias Biomedicas, Universidad
   Nacional Autonoma de Mexico (UNAM) and received fellowship 231663 from
   CONACYT. E-S NA, also acknowledge the financial support provided by the
   Mexican Institute of Social Security (IMSS).
CR Agarwal S, 2015, CANCER RES, V75, P2566, DOI 10.1158/0008-5472.CAN-14-2946
   AUWERX J, 1991, EXPERIENTIA, V47, P22, DOI 10.1007/BF02041244
   Barille S, 1997, BLOOD, V90, P1649, DOI 10.1182/blood.V90.4.1649.1649_1649_1655
   Ben-Baruch A, 2003, BREAST CANCER RES, V5, P31, DOI 10.1186/bcr554
   Bendall LJ, 2014, CYTOKINE GROWTH F R, V25, P355, DOI 10.1016/j.cytogfr.2014.07.011
   Brehmer B, 2003, PROSTATE CANCER P D, V6, P217, DOI 10.1038/sj.pcan.4500657
   Carreno BM, 2013, J CLIN INVEST, V123, P3383, DOI 10.1172/JCI68395
   Chen LY, 2014, SCI REP-UK, V4, DOI 10.1038/srep05911
   Chimal-Ramírez GK, 2013, J ONCOL, V2013, DOI 10.1155/2013/835956
   Chimal-Ramírez GK, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/279505
   Condeelis J, 2006, CELL, V124, P263, DOI 10.1016/j.cell.2006.01.007
   Daigneault M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008668
   Donepudi MS, 2014, J CANCER RES THER, V10, P506, DOI 10.4103/0973-1482.137927
   Ferlay J, 2013, IARC CANCERBASE
   Foroni C, 2012, CANCER TREAT REV, V38, P689, DOI 10.1016/j.ctrv.2011.11.001
   Fridlender ZG, 2009, CANCER CELL, V16, P183, DOI 10.1016/j.ccr.2009.06.017
   Geering B, 2013, TRENDS IMMUNOL, V34, P398, DOI 10.1016/j.it.2013.04.002
   Gill JH, 2004, NEOPLASIA, V6, P777, DOI 10.1593/neo.04283
   Goodison S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047469
   Gordon S, 2014, IMMUNOL REV, V262, P36, DOI 10.1111/imr.12223
   Grivennikov SI, 2010, CELL, V140, P883, DOI 10.1016/j.cell.2010.01.025
   Hamid O, 2007, CLIN CANCER RES, V13, P215, DOI 10.1158/1078-0432.CCR-06-1450
   Han J, 2014, PHYTOTHER RES, V28, P1654, DOI 10.1002/ptr.5178
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   HASS R, 1989, EUR J CELL BIOL, V48, P282
   Hotary KB, 2003, CELL, V114, P33, DOI 10.1016/S0092-8674(03)00513-0
   Iida J, 2007, MELANOMA RES, V17, P205, DOI 10.1097/CMR.0b013e3282a660ad
   Inoue K, 2000, CLIN CANCER RES, V6, P2104
   Jonasch E, 2001, ONCOLOGIST, V6, P34, DOI 10.1634/theoncologist.6-1-34
   Chimal-Ramírez GK, 2016, J IMMUNOL RES, V2016, DOI 10.1155/2016/6031486
   Kowanetz M, 2010, P NATL ACAD SCI USA, V107, P21248, DOI 10.1073/pnas.1015855107
   Lacroix M, 2004, BREAST CANCER RES TR, V83, P249, DOI 10.1023/B:BREA.0000014042.54925.cc
   Lan CY, 2013, TECHNOL CANCER RES T, V12, P259, DOI 10.7785/tcrt.2012.500312
   Lango-Chavarría M, 2017, INT J ONCOL, V50, P432, DOI 10.3892/ijo.2017.3842
   Lasek W, 2014, CANCER IMMUNOL IMMUN, V63, P419, DOI 10.1007/s00262-014-1523-1
   Leibovich-Rivkin T, 2013, NEOPLASIA, V15, P1330, DOI 10.1593/neo.131688
   Lewis AM, 2006, J TRANSL MED, V4, DOI 10.1186/1479-5876-4-48
   Li Aihua, 2005, Angiogenesis, V8, P63, DOI 10.1007/s10456-005-5208-4
   Li M, 2013, ONCOIMMUNOLOGY, V2, DOI 10.4161/onci.25474
   Li XJ, 2012, CARCINOGENESIS, V33, P1302, DOI 10.1093/carcin/bgs181
   Li YJ, 2012, MOL CANCER, V11, DOI 10.1186/1476-4598-11-87
   Lin EY, 2001, J EXP MED, V193, P727, DOI 10.1084/jem.193.6.727
   Liu H, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-583
   Lu X, 2009, GENE DEV, V23, P1882, DOI 10.1101/gad.1824809
   Ma LQ, 2012, MOL CANCER, V11, DOI 10.1186/1476-4598-11-79
   Medrek C, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-306
   Miller LJ, 2000, CANCER INVEST, V18, P293, DOI 10.3109/07357900009012171
   Mills CD, 2001, CRIT REV IMMUNOL, V21, P399, DOI 10.1615/critrevimmunol.v21.i5.10
   Minafra L, 2011, LEUKEMIA RES, V35, P226, DOI 10.1016/j.leukres.2010.07.040
   Murray GI, 1996, NAT MED, V2, P461, DOI 10.1038/nm0496461
   Ningrum RA, 2014, SCIENTIFICA, V2014, DOI 10.1155/2014/970315
   Pardo A, 2005, INT J BIOCHEM CELL B, V37, P283, DOI 10.1016/j.biocel.2004.06.017
   Parmiani G, 2007, ANN ONCOL, V18, P226, DOI 10.1093/annonc/mdl158
   Pellikainen JM, 2004, CLIN CANCER RES, V10, P7621, DOI 10.1158/1078-0432.CCR-04-1061
   Peterson AC, 2003, J CLIN ONCOL, V21, P2342, DOI 10.1200/JCO.2003.12.144
   PICHERT G, 1991, BRIT J CANCER, V63, P287, DOI 10.1038/bjc.1991.67
   Pollard JW, 2004, NAT REV CANCER, V4, P71, DOI 10.1038/nrc1256
   Poola I, 2005, NAT MED, V11, P481, DOI 10.1038/nm1243
   Prat A, 2013, BREAST CANCER RES TR, V142, P237, DOI 10.1007/s10549-013-2743-3
   PRICE JE, 1990, CANCER RES, V50, P717
   Qian BZ, 2010, CELL, V141, P39, DOI 10.1016/j.cell.2010.03.014
   Reed JR, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2246
   Rosser CJ, 2013, J UROLOGY, V190, P2257, DOI 10.1016/j.juro.2013.06.011
   Sauter W, 2008, CANCER EPIDEM BIOMAR, V17, P1127, DOI 10.1158/1055-9965.EPI-07-2840
   Schmalfeldt B, 2001, CLIN CANCER RES, V7, P2396
   Schmidt CS, 1999, J IMMUNOL, V163, P2561
   Shi YF, 2006, CELL RES, V16, P126, DOI 10.1038/sj.cr.7310017
   Singh JK, 2013, EXPERT OPIN THER TAR, V17, P1235, DOI 10.1517/14728222.2013.835398
   Solinas G, 2009, J LEUKOCYTE BIOL, V86, P1065, DOI 10.1189/jlb.0609385
   Soria G, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-130
   Stout RD, 2005, J IMMUNOL, V175, P342, DOI 10.4049/jimmunol.175.1.342
   Sugimura K, 2015, J SURG ONCOL, V111, P752, DOI 10.1002/jso.23881
   Swierczak A, 2014, CANCER IMMUNOL RES, V2, P765, DOI 10.1158/2326-6066.CIR-13-0190
   Todorovic-Rakovic N, 2013, J INTERF CYTOK RES, V33, P563, DOI 10.1089/jir.2013.0023
   Trinchieri G, 2003, NAT REV IMMUNOL, V3, P133, DOI 10.1038/nri1001
   Urquidi V, 2012, CANCER EPIDEM BIOMAR, V21, P2149, DOI 10.1158/1055-9965.EPI-12-0428
   Voronov E, 2003, P NATL ACAD SCI USA, V100, P2645, DOI 10.1073/pnas.0437939100
   Waight JD, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027690
   Wang L, 2015, CANCER BIOL THER, V16, P1220, DOI 10.1080/15384047.2015.1056409
   Waugh DJJ, 2008, CLIN CANCER RES, V14, P6735, DOI 10.1158/1078-0432.CCR-07-4843
   Xiao ZG, 2009, J IMMUNOL, V182, P2786, DOI 10.4049/jimmunol.0803484
   Yan HH, 2010, CANCER RES, V70, P6139, DOI 10.1158/0008-5472.CAN-10-0706
   Yang CM, 2015, MOL NEUROBIOL, V52, P303, DOI 10.1007/s12035-014-8838-y
   Yuan A, 2005, FRONT BIOSCI-LANDMRK, V10, P853, DOI 10.2741/1579
   Zhang G, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-310
   Ziegler E, 2014, BREAST CANCER RES TR, V148, P269, DOI 10.1007/s10549-014-3159-4
NR 86
TC 26
Z9 28
U1 0
U2 12
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-3224
J9 FRONT IMMUNOL
JI Front. Immunol.
PD MAR 8
PY 2017
VL 8
AR 205
DI 10.3389/fimmu.2017.00205
PG 14
WC Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology
GA EN0GO
UT WOS:000395688500001
PM 28337194
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU Yang, YQ
   Fuentes, F
   Shu, LM
   Wang, C
   Pung, D
   Li, WJ
   Zhang, CY
   Guo, Y
   Kong, AN
AF Yang, Yuqing
   Fuentes, Francisco
   Shu, Limin
   Wang, Chao
   Pung, Doug
   Li, Wenji
   Zhang, Chengyue
   Guo, Yue
   Kong, Ah-Ng
TI Epigenetic CpG Methylation of the Promoter and Reactivation of the
   Expression of GSTP1 by Astaxanthin in Human Prostate LNCaP Cells
SO AAPS JOURNAL
LA English
DT Article
DE astaxanthin; DNA methylation; epigenetics; GSTP1; prostate cancer
ID TRANSFERASE P1 GENE; BREAST-CANCER PATIENTS; OXIDATIVE STRESS; ISLAND
   HYPERMETHYLATION; LIPID-PEROXIDATION; SKIN TUMORIGENESIS; DNA
   METHYLATION; IN-VIVO; NRF2; MICE
AB Astaxanthin (AST), a red dietary carotenoid, has synergistic antioxidant effects with polyunsaturated fatty acids at low concentrations via Nuclear factor (erythroid-derived 2)-like 2 (NFE2L2 or Nrf2)/antioxidant response element (ARE) signaling. In addition, chromatin remodeling and DNA methylation-based gene silencing represent a common mechanism in prostate carcinogenesis and tumor progression from normal cells to pre-initiated cells and ultimately to invasive carcinoma. Therefore, the control of epigenetic modification and the transcriptional/translational control of the activation of Nrf2 and Nrf2-target genes, including glutathione S-transferases (GSTs), appear to be an important mechanism that protects cells against injuries from oxidative stress and cancer development. In this study, we aim to investigate the role of AST in reactivating the expression of Nrf2 and GSTP1 through epigenetic modification in human prostate LNCaP cells. Treatment with AST in human LNCaP cells reduced the methylation of 21 CpG sites of the GSTP1 CpG island but did not affect the three CpG sites of the Nrf2 promoter region. AST induced the mRNA expression and protein expression of both Nrf2 and GSTP1. It also increased the mRNA expression of NQO1 in sh-mock LNCaP cells but not in sh-SETD7 LNCaP cells. Furthermore, AST reduced the protein expression of DNMT3b and significantly inhibited DNMT and HDAC activities in vitro. Taken together, these results suggest that AST decreased the methylation status of the GSTP1, and these epigenetic modifying effects may originate from the decreasing activities of epigenetic modification enzymes, contributing to the overall beneficial health effects of AST.
C1 [Yang, Yuqing; Fuentes, Francisco; Shu, Limin; Wang, Chao; Pung, Doug; Li, Wenji; Zhang, Chengyue; Guo, Yue; Kong, Ah-Ng] Ernest Mario Sch Pharm, Ctr Phytochem Epigenome Studies, Piscataway, NJ 08854 USA.
   [Yang, Yuqing; Fuentes, Francisco; Shu, Limin; Wang, Chao; Pung, Doug; Li, Wenji; Zhang, Chengyue; Guo, Yue; Kong, Ah-Ng] Ernest Mario Sch Pharm, Dept Pharmaceut, Piscataway, NJ 08854 USA.
   [Yang, Yuqing; Pung, Doug; Zhang, Chengyue; Guo, Yue] Rutgers State Univ, Ernest Mario Sch Pharm, Grad Program Pharmaceut Sci, Piscataway, NJ 08854 USA.
   [Kong, Ah-Ng] Rutgers State Univ, Ernest Mario Sch Pharm, Room 228,160 Frelinghuysen Rd, Piscataway, NJ 08854 USA.
C3 Rutgers University System; Rutgers University New Brunswick; Rutgers
   University System; Rutgers University New Brunswick
RP Kong, AN (通讯作者)，Ernest Mario Sch Pharm, Ctr Phytochem Epigenome Studies, Piscataway, NJ 08854 USA.; Kong, AN (通讯作者)，Ernest Mario Sch Pharm, Dept Pharmaceut, Piscataway, NJ 08854 USA.; Kong, AN (通讯作者)，Rutgers State Univ, Ernest Mario Sch Pharm, Room 228,160 Frelinghuysen Rd, Piscataway, NJ 08854 USA.
EM kongt@pharmacy.rutgers.edu
RI Zhang, Chengyue/L-1185-2017; Yang, Yuqing/R-4308-2016; wenji,
   Li/H-4984-2019; Kong, Ah-Ng/AAX-2828-2020
OI li, wenji/0000-0003-0406-9489; Fuentes, Francisco/0000-0002-5342-4769
FU National Cancer Institute (NCI) [R01-CA118947, R01-CA152826]; National
   Center for Complementary and Integrative Health (NCCIH) [R01 AT009152];
   National Center for Complementary and Alternative Medicines (NCCAM)
   [R01AT007065]; Office of Dietary Supplements (ODS)
FX This study was supported in part by institutional funds and by
   R01-CA118947 and R01-CA152826 from the National Cancer Institute (NCI),
   R01 AT009152 from the National Center for Complementary and Integrative
   Health (NCCIH), and R01AT007065 from the National Center for
   Complementary and Alternative Medicines (NCCAM) and the Office of
   Dietary Supplements (ODS). We thank all the members in Dr. Ah-Ng Tony
   Kong's lab for their helpful discussion in the preparation of this
   manuscript.
CR Aoi W, 2003, ANTIOXID REDOX SIGN, V5, P139, DOI 10.1089/152308603321223630
   Arai T, 2006, BREAST CANCER RES TR, V100, P169, DOI 10.1007/s10549-006-9241-9
   Chen Y, 2011, AESTIMATIO, P2
   Ellis L, 2009, MOL CANCER THER, V8, P1409, DOI 10.1158/1535-7163.MCT-08-0860
   Esteller M, 1998, CANCER RES, V58, P4515
   Estève PO, 2009, P NATL ACAD SCI USA, V106, P5076, DOI 10.1073/pnas.0810362106
   Frohlich DA, 2008, ONCOGENE, V27, P4353, DOI 10.1038/onc.2008.79
   Gills JJ, 2006, CANCER LETT, V236, P72, DOI 10.1016/j.canlet.2005.05.007
   Hermann A, 2004, CELL MOL LIFE SCI, V61, P2571, DOI 10.1007/s00018-004-4201-1
   Hun Lee Jong, 2013, J Tradit Complement Med, V3, P69, DOI 10.4103/2225-4110.107700
   Iwamoto T, 2000, J Atheroscler Thromb, V7, P216
   Jhaveri MS, 1998, GENE, V210, P1, DOI 10.1016/S0378-1119(98)00021-3
   Jyonouchi H, 2000, NUTR CANCER, V36, P59, DOI 10.1207/S15327914NC3601_9
   Kang JO, 2001, METHOD FIND EXP CLIN, V23, P79, DOI 10.1358/mf.2001.23.2.627931
   Khor TO, 2008, CANCER PREV RES, V1, P187, DOI 10.1158/1940-6207.CAPR-08-0028
   Khor TO, 2008, PLANTA MED, V74, P1540, DOI 10.1055/s-0028-1088303
   Khor TO, 2014, CANCER PREV RES, V7, P1186, DOI 10.1158/1940-6207.CAPR-14-0127
   Khor TO, 2011, BIOCHEM PHARMACOL, V82, P1073, DOI 10.1016/j.bcp.2011.07.065
   Kobayashi M, 2000, APPL MICROBIOL BIOT, V54, P550, DOI 10.1007/s002530000416
   Kong ANT, 1998, RESTOR NEUROL NEUROS, V12, P63
   Krassenstein R, 2004, CLIN CANCER RES, V10, P28, DOI 10.1158/1078-0432.CCR-0410-3
   Lee JJ, 2007, J BIOPHARM STAT, V17, P461, DOI 10.1080/10543400701199593
   Lee JH, 2013, PHARMACOL THERAPEUT, V137, P153, DOI 10.1016/j.pharmthera.2012.09.008
   LEE WH, 1994, P NATL ACAD SCI USA, V91, P11733, DOI 10.1073/pnas.91.24.11733
   Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427
   Li R, 2015, REPROD DOMEST ANIM, V50, P793, DOI 10.1111/rda.12589
   Majid S, 2009, CARCINOGENESIS, V30, P662, DOI 10.1093/carcin/bgp042
   Mavis CK, 2009, PROSTATE, V69, P1312, DOI 10.1002/pros.20976
   Miller KD, 2016, CA-CANCER J CLIN, V66, P271, DOI 10.3322/caac.21349
   Miyake T, 2012, CANCER SCI, V103, P913, DOI 10.1111/j.1349-7006.2012.02231.x
   Nagendraprabhu P, 2011, INVEST NEW DRUG, V29, P207, DOI 10.1007/s10637-009-9342-5
   Nakayama M, 2004, J CELL BIOCHEM, V91, P540, DOI 10.1002/jcb.10740
   Ohgami K, 2003, INVEST OPHTH VIS SCI, V44, P2694, DOI 10.1167/iovs.02-0822
   Peng J, 2012, NUTRIENTS, V4, P922, DOI 10.3390/nu4080922
   Pongtheerat T, 2011, ASIAN PAC J CANCER P, V12, P2731
   Rennie PS, 1998, CANCER METAST REV, V17, P401, DOI 10.1023/A:1006121219097
   Saw CL, 2011, MOL CARCINOGEN, V50, P479, DOI 10.1002/mc.20725
   Saw CLL, 2014, CELL BIOSCI, V4, DOI 10.1186/2045-3701-4-39
   Saw CLL, 2013, FOOD CHEM TOXICOL, V62, P869, DOI 10.1016/j.fct.2013.10.023
   Saxena A, 2012, EXP THER MED, V4, P1097, DOI 10.3892/etm.2012.710
   Shin JW, 2011, CANCER PREV RES, V4, P860, DOI 10.1158/1940-6207.CAPR-10-0354
   Singal R, 2001, CANCER RES, V61, P4820
   Stewart GD, 2013, J UROLOGY, V189, P1110, DOI 10.1016/j.juro.2012.08.219
   Su ZY, 2014, CANCER PREV RES, V7, P319, DOI 10.1158/1940-6207.CAPR-13-0313-T
   Suzuki T, 2013, TRENDS PHARMACOL SCI, V34, P340, DOI 10.1016/j.tips.2013.04.005
   Tokumaru Y, 2004, CLIN CANCER RES, V10, P5518, DOI 10.1158/1078-0432.CCR-04-0108
   Uchiyama K, 2002, REDOX REP, V7, P290, DOI 10.1179/135100002125000811
   Van Neste L, 2012, PROSTATE, V72, P1248, DOI 10.1002/pros.22459
   Wang HB, 2001, MOL CELL, V8, P1207, DOI 10.1016/S1097-2765(01)00405-1
   Xu CJ, 2006, CANCER RES, V66, P8293, DOI 10.1158/0008-5472.CAN-06-0300
   Yasui Y, 2011, CHEM-BIOL INTERACT, V193, P79, DOI 10.1016/j.cbi.2011.05.006
   Yu SW, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008579
   Yuan JP, 2011, MOL NUTR FOOD RES, V55, P150, DOI 10.1002/mnfr.201000414
NR 53
TC 28
Z9 30
U1 0
U2 31
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1550-7416
J9 AAPS J
JI AAPS J.
PD MAR
PY 2017
VL 19
IS 2
BP 421
EP 430
DI 10.1208/s12248-016-0016-x
PG 10
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA EM0KA
UT WOS:000395006000010
PM 27913949
OA Bronze
DA 2025-01-12
ER

PT J
AU Gonzales, MC
   Yu, PJ
   Shiao, SPK
AF Gonzales, Mildred C.
   Yu, Pojui
   Shiao, S. Pamela K.
TI <i>MTHFR</i> Gene Polymorphism-Mutations and Air Pollution as Risk
   Factors for Breast Cancer <i>A Metaprediction Study</i>
SO NURSING RESEARCH
LA English
DT Article
DE air pollution; breast cancer; geographic information systems;
   meta-analysis; MTHFR gene
ID DISEASE; HOMOCYSTEINE; METAANALYSIS; ASSOCIATION; PREDICTION; EXPOSURE;
   C677T
AB Background: The methylenetetrahydrofolate reductase gene (MTHFR) is one of the most investigated genes associated with breast cancer for its role in epigenetic pathways.
   Objectives: The objectives of this metaprediction study were to examine the polymorphism-mutation risk subtypes of MTHFR and air pollution as contributing factors for breast cancer.
   Methods: For triangulation purposes in metapredictive analyses, we used a recursive partition tree, nonlinear association curve fit, and heat maps for data visualization, in addition to the conventional comparison procedure and pooled analyses.
   Results: We included 36,683 breast cancer cases and 40,689 controls across 82 studies for MTHFR 677 and 23,252 cases and 27,094 controls across 50 studies for MTHFR 1298. MTHFR 677 TT was a risk genotype for breast cancer (p=.0004) and in the East Asian subgroup (p=.005). On global maps, the most polymorphism-mutations on MTHFR 677 TT were found in the Middle East, Europe, Asia, and the Americas, whereas the most mutations on MTHFR 1298 CC were located in Europe and the Middle East for the control group. The geographic information system maps further revealed that MTHFR 677 TT mutations yielded a higher risk of breast cancer for Australia, East Asia, the Middle East, South Europe, Morocco, and the Americas and that MTHFR 1298 CC mutations yielded a higher risk in Asia, the Middle East, South Europe, and South America. Metapredictive analysis revealed that air pollution level was significantly associated with MTHFR 677 TT polymorphism-mutation genotype.
   Discussion: We present the most comprehensive analyses to date of MTHFR polymorphism-mutations and breast cancer risk. Future nursing studies are needed to investigate the health impact on breast cancer of epigenetics and air pollution across populations.
C1 [Gonzales, Mildred C.] Los Angeles Cty Coll Nursing & Allied Hlth, Los Angeles, CA USA.
   [Yu, Pojui] Natl Taiwan Univ, Sch Nursing, Taipei, Taiwan.
   [Yu, Pojui] Natl Taiwan Univ, Coll Med, Taipei, Taiwan.
   [Shiao, S. Pamela K.] Augusta Univ, Med Coll Georgia, Nursing Res, Augusta, GA USA.
   [Shiao, S. Pamela K.] Augusta Univ, Med Coll Georgia, Coll Nursing, Augusta, GA USA.
   [Shiao, S. Pamela K.] Augusta Univ, Med Coll Georgia, Grad Sch, Augusta, GA USA.
   [Shiao, S. Pamela K.] Augusta Univ, Med Coll Georgia, Ctr Biotechnol & Genom Med, Augusta, GA USA.
C3 National Taiwan University; National Taiwan University; University
   System of Georgia; Augusta University; University System of Georgia;
   Augusta University; University System of Georgia; Augusta University;
   University System of Georgia; Augusta University
RP Shiao, SPK (通讯作者)，Augusta Univ, Coll Nursing, 987 St Sebastian Way,Room EC 4505, Augusta, GA 30912 USA.
EM pshiao@augusta.edu
CR Akaike H., 1985, A Celebration of Statistics, P1, DOI DOI 10.1007/978-1-4612-1694-0_30
   Albrecht J., 2007, KEY CONCEPTS TECHNIQ
   American Cancer Society, 2016, CANC FACTS FIG 2016
   [Anonymous], WHO 2014 AIR POLL RA
   [Anonymous], DEATHS ATTR URB AIR
   [Anonymous], 2010, ENCY RES DESIGN
   Chen F, 2012, BREAST CANCER RES TR, V132, P327, DOI 10.1007/s10549-011-1861-z
   DeMarini DM, 2013, MUTAGENESIS, V28, P485, DOI 10.1093/mutage/get042
   Eccles SA, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3493
   FROSST P, 1995, NAT GENET, V10, P111, DOI 10.1038/ng0595-111
   Gaudet MM, 2013, JNCI-J NATL CANCER I, V105, P515, DOI 10.1093/jnci/djt023
   GORHAM ED, 1989, CAN J PUBLIC HEALTH, V80, P96
   Hoffmann AA, 2008, NAT REV GENET, V9, P421, DOI 10.1038/nrg2339
   Kennedy DA, 2012, J CANCER EPIDEMIOL, V2012, DOI 10.1155/2012/952508
   Mehlig K, 2013, HEART, V99, P1761, DOI 10.1136/heartjnl-2013-304460
   Moher D, 1999, LANCET, V354, P1896, DOI 10.1016/S0140-6736(99)04149-5
   Moher D, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000097, 10.1136/bmj.i4086, 10.1016/j.ijsu.2010.02.007, 10.1186/2046-4053-4-1, 10.1136/bmj.b2535, 10.1136/bmj.b2700, 10.1016/j.ijsu.2010.07.299]
   Pereira C, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-S6-S16
   Pérez-Sepúlveda A, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/731962
   Pooja S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120654
   Reding KW, 2015, CANCER EPIDEM BIOMAR, V24, P1907, DOI 10.1158/1055-9965.EPI-15-0787
   Shiao SPK, 2016, BIOL RES NURS, V18, P357, DOI 10.1177/1099800415628054
   Siegfried N, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003362.pub2
   Strobl C, 2009, PSYCHOL METHODS, V14, P323, DOI 10.1037/a0016973
   Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008
   Teng Z, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055332
   Viera AJ, 2008, SOUTH MED J, V101, P730, DOI 10.1097/SMJ.0b013e31817a7ee4
   Weisberg I, 1998, MOL GENET METAB, V64, P169, DOI 10.1006/mgme.1998.2714
   Wu YL, 2013, J NEUROL SCI, V335, P14, DOI 10.1016/j.jns.2013.09.006
   Wu Y, 2013, DNA CELL BIOL, V32, P260, DOI 10.1089/dna.2012.1931
   Xie SZ, 2015, TUMOR BIOL, V36, P8953, DOI 10.1007/s13277-015-3648-z
   Xu XR, 2011, EPIGENETICS-US, V6, P1276, DOI 10.4161/epi.6.11.17744
   Yadav S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057305
   Zhang B, 2011, LANCET ONCOL, V12, P477, DOI 10.1016/S1470-2045(11)70076-6
   Zhong SL, 2014, MOL BIOL REP, V41, P5775, DOI 10.1007/s11033-014-3450-9
   Zidan HE, 2013, GENE, V529, P119, DOI 10.1016/j.gene.2013.07.053
   Ziegler A, 2011, BREAST CANCER RES TR, V128, P197, DOI 10.1007/s10549-010-1295-z
NR 37
TC 21
Z9 21
U1 0
U2 15
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0029-6562
EI 1538-9847
J9 NURS RES
JI Nurs. Res.
PD MAR-APR
PY 2017
VL 66
IS 2
BP 152
EP 163
DI 10.1097/NNR.0000000000000206
PG 12
WC Nursing
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Nursing
GA EN1YF
UT WOS:000395805700366
PM 28114181
OA Green Published
DA 2025-01-12
ER

PT J
AU Wiedmeier, JE
   Ohlrich, A
   Chu, A
   Rountree, MR
   Turker, MS
AF Wiedmeier, J. Erin
   Ohlrich, Anna
   Chu, Adrian
   Rountree, Michael R.
   Turker, Mitchell S.
TI Induction of the long noncoding RNA NBR2 from the bidirectional
   <i>BRCA1</i> promoter under hypoxic conditions
SO MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS
LA English
DT Article
DE Hypoxia; NBR2; BRCA1; IncRNA
ID SPORADIC BREAST-CANCER; MISMATCH REPAIR GENE; TRANSCRIPTIONAL
   REGULATION; DNA METHYLATION; DOWN-REGULATION; EXPRESSION; AMPK;
   REPRESSION; PATHWAY; HYPERMETHYLATION
AB BRCA1 plays an important role in preventing breast cancer and is often silenced or repressed in sporadic cancer. The BRCA1 promoter is bidirectional: it drives transcription of the long non-coding (Inc) NBR2 transcript in the opposite orientation relative to the BRCA1 transcript. Hypoxic conditions repress BRCA1 transcription, but their effect on expression of the NBR2 transcript has not been reported. We used quantitative RT-PCR to measure BRCA1 and NBR2 transcript levels in 0% and 1% oxygen in MCF-7 breast cancer cells and found that NBR2 transcript levels increased as a function of time under hypoxic conditions, whereas BRCAI mRNA levels were repressed. Hypoxic conditions were ineffective in reducing BRCA1 mRNA in the UACC-3199 breast cancer cell line, which is reported to have an epigenetically silenced BRCAI promoter, even though appreciable levels of BRCA1 and NBR2 mRNA were detected. Significant recovery back to baseline RNA levels occurred within 48 h after the MCF-7 cells were restored to normoxic conditions. We used a construct with the 218 bp minimal BRCA1 promoter linked to marker genes to show that this minimal promoter repressed expression bidirectionally under hypoxic conditions, which suggests that the elements necessary for induction of NBR2 are located elsewhere. (C) 2017 Published by Elsevier B.V.
C1 [Wiedmeier, J. Erin; Chu, Adrian] Univ Utah, Sch Med, Salt Lake City, UT 84132 USA.
   [Ohlrich, Anna; Turker, Mitchell S.] Oregon Hlth & Sci Univ, Oregon Inst Occupat Hlth Sci, L606,3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.
   [Rountree, Michael R.] Nzumbe Inc, Portland, OR 97201 USA.
   [Turker, Mitchell S.] Oregon Hlth & Sci Univ, Dept Mol & Med Genet, Portland, OR USA.
   [Wiedmeier, J. Erin] Oregon Hlth & Sci Univ, Sch Med, Portland, OR 97239 USA.
C3 Utah System of Higher Education; University of Utah; Oregon Health &
   Science University; Oregon Health & Science University; Oregon Health &
   Science University
RP Turker, MS (通讯作者)，Oregon Hlth & Sci Univ, Oregon Inst Occupat Hlth Sci, L606,3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.
EM turkerm@ohsu.edu
RI Rountree, Michael/C-6332-2018
OI Rountree, Michael/0000-0003-2371-6389
FU Howard Hughes Medical Institute Research Fellowship; NIH [R21 ES015191];
   DOD [W81XWH-06-1-0579]
FX Erin Wiedmeier was supported by a Howard Hughes Medical Institute
   Research Fellowship. In addition, portions of this work were supported
   by NIH grant R21 ES015191 and a DOD Concept Award W81XWH-06-1-0579. We
   thank Dr. Brian Druker for his support of Ms. Wiedmeir's Fellowship and
   Dr. Peter Glazer for the BRCA1 minimal promoter.
CR Ali AB, 2011, MED ONCOL, V28, P64, DOI 10.1007/s12032-010-9438-y
   [Anonymous], US CANC STAT 1999 20
   Bindra RS, 2007, ONCOGENE, V26, P2048, DOI 10.1038/sj.onc.1210001
   Bindra RS, 2007, CANCER LETT, V252, P93, DOI 10.1016/j.canlet.2006.12.011
   Bindra RS, 2005, CANCER RES, V65, P11597, DOI 10.1158/0008-5472.CAN-05-2119
   Chen YH, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-246
   Choudhry H, 2016, MOL ASPECTS MED, V47-48, P35, DOI 10.1016/j.mam.2016.01.003
   Di LJ, 2010, NAT STRUCT MOL BIOL, V17, P1406, DOI 10.1038/nsmb.1941
   Dimitrov SD, 2001, FOLIA BIOL-PRAGUE, V47, P120
   Dong J, 2016, TUMOR BIOL, V37, P1379, DOI 10.1007/s13277-015-4457-0
   Esteller M, 2000, JNCI-J NATL CANCER I, V92, P564, DOI 10.1093/jnci/92.7.564
   FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630
   Koshiji M, 2004, EMBO J, V23, P1949, DOI 10.1038/sj.emboj.7600196
   Lee AV, 2015, JNCI-J NATL CANCER I, V107, DOI 10.1093/jnci/djv073
   Li Q, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008531
   Liang JY, 2013, CANCER RES, V73, P2929, DOI 10.1158/0008-5472.CAN-12-3876
   Liu XW, 2016, CELL CYCLE, V15, P3471, DOI 10.1080/15384101.2016.1249545
   Liu XW, 2016, CELL CYCLE, V15, P1948, DOI 10.1080/15384101.2016.1184515
   Liu XW, 2016, NAT CELL BIOL, V18, P431, DOI 10.1038/ncb3328
   Lokmic Z, 2012, INT REV CEL MOL BIO, V296, P139, DOI 10.1016/B978-0-12-394307-1.00003-5
   Lu YH, 2014, CELL REP, V8, P500, DOI 10.1016/j.celrep.2014.06.035
   Lu YH, 2011, MOL CELL BIOL, V31, P3339, DOI 10.1128/MCB.01121-10
   Luo S, 2016, CELL STEM CELL, V18, P637, DOI 10.1016/j.stem.2016.01.024
   Magdinier F, 1998, ONCOGENE, V17, P3169, DOI 10.1038/sj.onc.1202248
   Matros E, 2005, BREAST CANCER RES TR, V91, P179, DOI 10.1007/s10549-004-7603-8
   Moynahan ME, 2010, NAT REV MOL CELL BIO, V11, P196, DOI 10.1038/nrm2851
   Mueller CR, 2003, BREAST CANCER RES, V5, P45, DOI 10.1186/bcr557
   Musahl AS, 2015, ONCOGENE, V34, P5046, DOI 10.1038/onc.2014.424
   Nakamura H, 2008, ONCOGENE, V27, P4200, DOI 10.1038/onc.2008.58
   Rice JC, 2000, NUCLEIC ACIDS RES, V28, P3233, DOI 10.1093/nar/28.17.3233
   Rice JC, 1998, ONCOGENE, V17, P1807, DOI 10.1038/sj.onc.1202086
   Romagnolo DF, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-2044-9
   Roy R, 2012, NAT REV CANCER, V12, P68, DOI 10.1038/nrc3181
   Scanlon SE, 2015, DNA REPAIR, V32, P180, DOI 10.1016/j.dnarep.2015.04.030
   Semenza GL, 2016, BBA-MOL CELL RES, V1863, P382, DOI 10.1016/j.bbamcr.2015.05.036
   Shackelford DB, 2009, NAT REV CANCER, V9, P563, DOI 10.1038/nrc2676
   Sigova AA, 2013, P NATL ACAD SCI USA, V110, P2876, DOI 10.1073/pnas.1221904110
   Singh AK, 2006, EUR J CANCER PREV, V20, P478
   Suen TC, 2005, BBA-GENE STRUCT EXPR, V1728, P126, DOI 10.1016/j.bbaexp.2005.01.014
   THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444
   TURKER MS, 1991, SOMAT CELL MOLEC GEN, V17, P151, DOI 10.1007/BF01232972
   Uesaka M, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-35
   Unwith S, 2015, INT J CANCER, V136, P2491, DOI 10.1002/ijc.28889
   Vasilatos SN, 2009, CANCER EPIDEM BIOMAR, V18, P901, DOI 10.1158/1055-9965.EPI-08-0875
   Wei MJ, 2005, CANCER RES, V65, P10692, DOI 10.1158/0008-5472.CAN-05-1277
   Wenger Roland H, 2005, Sci STKE, V2005, pre12, DOI 10.1126/stke.3062005re12
   Xiao ZD, 2016, MOL CELL ONCOL, V3, DOI 10.1080/23723556.2016.1187322
   Xu CF, 1997, HUM MOL GENET, V6, P1057, DOI 10.1093/hmg/6.7.1057
   Xu JH, 2010, BREAST CANCER RES TR, V120, P593, DOI 10.1007/s10549-009-0422-1
   Zadra G, 2015, MOL CANCER RES, V13, P1059, DOI 10.1158/1541-7786.MCR-15-0068
   Zhang C, 2015, INT J CANCER, V136, P2001, DOI 10.1002/ijc.28975
   Zhang X., 2016, CELL CYCLE, P1
NR 52
TC 9
Z9 9
U1 0
U2 3
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0027-5107
EI 1873-135X
J9 MUTAT RES-FUND MOL M
JI Mutat. Res.-Fundam. Mol. Mech. Mutagen.
PD FEB
PY 2017
VL 796
BP 13
EP 19
DI 10.1016/j.mrfmmm.2017.02.001
PG 7
WC Biotechnology & Applied Microbiology; Genetics & Heredity; Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Genetics & Heredity; Toxicology
GA EP9JN
UT WOS:000397690000002
PM 28249151
OA Bronze
DA 2025-01-12
ER

PT J
AU Wu, HC
   Southey, MC
   Hibshoosh, H
   Santella, RM
   Terry, MB
AF Wu, Hui-Chen
   Southey, Melissa C.
   Hibshoosh, Hanina
   Santella, Regina M.
   Terry, Mary Beth
TI DNA Methylation in Breast Tumor from High-risk Women in the Breast
   Cancer Family Registry
SO ANTICANCER RESEARCH
LA English
DT Article
DE Breast cancer; DNA methylation; epigenetics; promoter DNA methylation;
   TCGA
ID HORMONE-RECEPTOR STATUS; NEW-YORK SITE; PROFILES; TRANSCRIPTION;
   MUTATIONS; PATTERNS; SEQUENCE; SISTERS
AB To examine DNA methylation profiles in breast tumors of women with a strong breast cancer family history, we measured methylation by bisulfite sequencing in 40 genes in 40 breast tumor tissues from women in the Breast Cancer Family Registry. We selected candidate genes from analysis of the Cancer Genome Atlas project (TCGA) breast data. Compared to TCGA breast cancer, BCFR cases are younger and more likely to be ER-negative. Overall, we found that many of the methylation differences between BCFR tumor and normal adjacent tissues were smaller than that in TCGA samples. We found only 32% of tested genes were hypermethylated in BCFR; the largest difference was 36.1% for SEPW1, and the smallest difference was 10% for RYR2. These data suggest the importance of examining breast cancer cases including familial cases enriched with earlyonset cancers to identify methylation markers that can be examined in blood as biomarkers for early detection.
C1 [Wu, Hui-Chen; Santella, Regina M.] Columbia Univ, Mailman Sch Publ Hlth, Dept Environm Hlth Sci, 650 West 168th St,1608, New York, NY 10032 USA.
   [Southey, Melissa C.] Univ Melbourne, Dept Pathol, Melbourne, Vic, Australia.
   [Hibshoosh, Hanina] Columbia Univ, Coll Phys & Surg, Dept Pathol & Cell Biol, New York, NY USA.
   [Santella, Regina M.; Terry, Mary Beth] Columbia Univ, Med Ctr, Herbert Irving Comprehens Canc Ctr, New York, NY USA.
   [Terry, Mary Beth] Columbia Univ, Mailman Sch Publ Hlth, Dept Epidemiol, New York, NY USA.
C3 Columbia University; University of Melbourne; Columbia University;
   Columbia University; Columbia University
RP Wu, HC (通讯作者)，Columbia Univ, Mailman Sch Publ Hlth, Dept Environm Hlth Sci, 650 West 168th St,1608, New York, NY 10032 USA.
EM hw2057@columbia.edu
RI Southey, Melissa/CAA-7064-2022; Wu, Lisa/JPA-4139-2023
OI Terry, Mary Beth/0000-0002-4106-5033; Southey,
   Melissa/0000-0002-6313-9005
FU USA National Cancer Institute [UM1 CA164920]
FX The Authors thank the Epigenetics Shared Resource of the Herbert Irving
   Comprehensive Cancer Center for performing the targeted bisulfite
   sequencing. We would like to gratefully acknowledge all of the families
   that participate in the New York site of the BCFR. The Breast Cancer
   Family Registry (BCFR) was supported by grant UM1 CA164920 from the USA
   National Cancer Institute. The content of this manuscript does not
   necessarily reflect the views or policies of the National Cancer
   Institute or any of the collaborating centers in the BCFR, nor does
   mention of trade names, commercial products, or organizations imply
   endorsement by the USA Government or the BCFR.
CR Anderson WF, 2006, CANCER EPIDEM BIOMAR, V15, P1899, DOI 10.1158/1055-9965.EPI-06-0191
   Azim HA, 2014, BREAST CANCER RES, V16, DOI 10.1186/s13058-014-0427-5
   Banerji S, 2012, NATURE, V486, P405, DOI 10.1038/nature11154
   Dedeurwaerder S, 2011, EMBO MOL MED, V3, P726, DOI 10.1002/emmm.201100801
   Dite GS, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3248
   Esteller M, 2001, HUM MOL GENET, V10, P3001, DOI 10.1093/hmg/10.26.3001
   Fackler MJ, 2011, CANCER RES, V71, P6195, DOI 10.1158/0008-5472.CAN-11-1630
   Flanagan JM, 2010, AM J HUM GENET, V86, P420, DOI 10.1016/j.ajhg.2010.02.008
   Fleischer T, 2014, GENOME BIOL, V15, DOI [10.1186/s13059-014-0435-x, 10.1186/PREACCEPT-2333349012841587]
   Goncalves R, 2014, BREAST CANCER RES, V16, DOI 10.1186/s13058-014-0460-4
   Kamalakaran S, 2011, MOL ONCOL, V5, P77, DOI 10.1016/j.molonc.2010.11.002
   Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412
   Koch A, 2015, BMC GENOMICS, V16, P1
   Krueger F, 2011, BIOINFORMATICS, V27, P1571, DOI 10.1093/bioinformatics/btr167
   Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/NMETH.1923, 10.1038/nmeth.1923]
   Li J, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-223
   Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427
   Michels KB, 2013, NAT METHODS, V10, P949, DOI 10.1038/nmeth.2632
   Suijkerbuijk KPM, 2008, ANN ONCOL, V19, P1870, DOI 10.1093/annonc/mdn409
   Van der Auwera I, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012616
   Widschwendter M, 2004, CANCER RES, V64, P3807, DOI 10.1158/0008-5472.CAN-03-3852
   Widschwendter M, 2002, ONCOGENE, V21, P5462, DOI 10.1038/sj.onc.1205606
   Wu HC, 2013, CANCER CAUSE CONTROL, V24, P2157, DOI 10.1007/s10552-013-0292-z
   Wu HC, 2012, CARCINOGENESIS, V33, P1946, DOI 10.1093/carcin/bgs201
   Yost SE, 2012, NUCLEIC ACIDS RES, V40, DOI 10.1093/nar/gks299
NR 25
TC 4
Z9 6
U1 1
U2 6
PU INT INST ANTICANCER RESEARCH
PI ATHENS
PA EDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22,
   ATHENS 19014, GREECE
SN 0250-7005
EI 1791-7530
J9 ANTICANCER RES
JI Anticancer Res.
PD FEB
PY 2017
VL 37
IS 2
BP 659
EP 664
DI 10.21873/anticanres.11361
PG 6
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA EO7WQ
UT WOS:000396901200032
PM 28179314
OA Green Accepted, Bronze, Green Submitted
DA 2025-01-12
ER

PT J
AU Blanco, J
   Lafuente, D
   Gómez, M
   García, T
   Domingo, JL
   Sánchez, DJ
AF Blanco, Jordi
   Lafuente, Daisy
   Gomez, Mercedes
   Garcia, Tania
   Domingo, Jose L.
   Sanchez, Domenec J.
TI Polyvinyl pyrrolidone-coated silver nanoparticles in a human lung cancer
   cells: time- and dose-dependent influence over p53 and caspase-3 protein
   expression and epigenetic effects
SO ARCHIVES OF TOXICOLOGY
LA English
DT Article
DE Silver nanoparticles; Cytotoxicity; Oxidative stress; DNA methylation;
   Cancer cells; Histone H3
ID INDUCE APOPTOSIS; BREAST-CANCER; CYTOTOXICITY; TOXICITY; EXPOSURE;
   OXYGEN; GOLD; GENOTOXICITY; GENERATION; MECHANISM
AB The present study was aimed at providing a better understanding of the influence of silver nanoparticles (AgNPs) on the p53 tumor suppressor protein. Cell line A549 was exposed to a range of concentrations of AgNPs, and a time course (up to 72 h) of cell viability was determined. We also determined the time course of gene and protein expression of p53, p21, murine double minute 2 (MDM2) and caspase-3. The expression of all of these proteins was also determined after daily exposure of the cells to 10 A mu g/mL of AgNPs for 7 days, or after discontinuous exposure by treating the cells every 3 days, for 15 or 30 days. Moreover, epigenetic changes in the acetylation of the histone H3 protein and in global DNA methylation patterns were determined after 72 h of exposure. Results showed that daily exposure to low doses of AgNPs, or a single exposure to high concentrations for 72 h, decreased gene and protein expression of p53, p21, MDM2 and caspase-3 in A549 cells. In contrast, a discontinuous exposure to low doses or a single exposure to low concentrations for 72 h increased the levels of the active forms of p53 and caspase-3, as well as the p21 and MDM2 protein levels. In addition, exposure to high concentrations of AgNPs for 72 h induced higher levels of global DNA methylation and global histone H3 deacetylation in A549 cells. These results provide new information on the toxic action of AgNPs.
C1 [Blanco, Jordi; Lafuente, Daisy; Gomez, Mercedes; Garcia, Tania; Domingo, Jose L.; Sanchez, Domenec J.] Univ Rovira & Virgili, Sch Med, IISPV, Lab Toxicol & Environm Hlth, St Llorens 21, Reus 43201, Catalonia, Spain.
   [Gomez, Mercedes; Garcia, Tania] Univ Rovira & Virgili, Biochem Unit, Sch Med, IISPV, St Llorens 21, Reus 43201, Catalonia, Spain.
C3 Universitat Rovira i Virgili; Institut d'Investigacio Sanitaria Pere
   Virgili (IISPV); Universitat Rovira i Virgili; Institut d'Investigacio
   Sanitaria Pere Virgili (IISPV)
RP Sánchez, DJ (通讯作者)，Univ Rovira & Virgili, Sch Med, IISPV, Lab Toxicol & Environm Hlth, St Llorens 21, Reus 43201, Catalonia, Spain.
EM domingo.sanchez@urv.cat
RI Domingo, Jose/E-8327-2014; Blanco, Jordi/F-9351-2016; Garcia Soldevila,
   Tania/H-9742-2016
OI Gomez, Mercedes/0000-0003-1892-5557; Domingo, Jose
   L/0000-0001-6647-9470; Blanco Perez, Jordi/0000-0001-8016-0984; Garcia
   Soldevila, Tania/0000-0002-1790-5274
CR Ahamed M, 2008, TOXICOL APPL PHARM, V233, P404, DOI 10.1016/j.taap.2008.09.015
   Albanese A, 2011, ACS NANO, V5, P5478, DOI 10.1021/nn2007496
   Arora S, 2008, TOXICOL LETT, V179, P93, DOI 10.1016/j.toxlet.2008.04.009
   AshaRani PV, 2009, ACS NANO, V3, P279, DOI 10.1021/nn800596w
   Asharani Pv, 2012, Genome Integr, V3, P2, DOI 10.1186/2041-9414-3-2
   Austin LA, 2014, ARCH TOXICOL, V88, P1391, DOI 10.1007/s00204-014-1245-3
   Blaser SA, 2008, SCI TOTAL ENVIRON, V390, P396, DOI 10.1016/j.scitotenv.2007.10.010
   Böhmert L, 2012, ARCH TOXICOL, V86, P1107, DOI 10.1007/s00204-012-0840-4
   Braun GB, 2014, NAT MATER, V13, P904, DOI [10.1038/NMAT3982, 10.1038/nmat3982]
   Chae YJ, 2009, AQUAT TOXICOL, V94, P320, DOI 10.1016/j.aquatox.2009.07.019
   Choi AO, 2008, J MOL MED-JMM, V86, P291, DOI 10.1007/s00109-007-0274-2
   Christen V, 2013, TOXICOL APPL PHARM, V272, P519, DOI 10.1016/j.taap.2013.06.011
   Comfort KK, 2011, ACS NANO, V5, P10000, DOI 10.1021/nn203785a
   Costa C, 2010, MOL CELL BIOCHEM, V342, P51, DOI 10.1007/s11010-010-0467-9
   De Matteis V, 2015, NANOMED-NANOTECHNOL, V11, P731, DOI 10.1016/j.nano.2014.11.002
   Devarajan E, 2002, ONCOGENE, V21, P8843, DOI 10.1038/sj.onc.1206044
   Eom HJ, 2013, TOXICOL APPL PHARM, V270, P106, DOI 10.1016/j.taap.2013.03.028
   Foldbjerg R, 2011, ARCH TOXICOL, V85, P743, DOI 10.1007/s00204-010-0545-5
   Gómez M, 2008, TOXICOLOGY, V249, P214, DOI 10.1016/j.tox.2008.05.004
   Gong CM, 2010, BIOCHEM BIOPH RES CO, V397, P397, DOI 10.1016/j.bbrc.2010.05.076
   Greulich C, 2011, ACTA BIOMATER, V7, P347, DOI 10.1016/j.actbio.2010.08.003
   Guo DW, 2013, BIOMATERIALS, V34, P7884, DOI 10.1016/j.biomaterials.2013.07.015
   Guo Z, 2010, SCIENCE, V330, P517, DOI 10.1126/science.1192912
   He WW, 2012, BIOMATERIALS, V33, P7547, DOI 10.1016/j.biomaterials.2012.06.076
   Islam KN, 2006, MOL CELL BIOL, V26, P2901, DOI 10.1128/MCB.26.8.2901-2912.2006
   Jeyaraj M, 2013, COLLOID SURFACE B, V106, P86, DOI 10.1016/j.colsurfb.2013.01.027
   Jiang XM, 2013, TOXICOL LETT, V222, P55, DOI 10.1016/j.toxlet.2013.07.011
   Kang K, 2011, TOXICOL LETT, V205, P227, DOI 10.1016/j.toxlet.2011.05.1033
   Kim HR, 2014, J TOXICOL SCI, V39, P401, DOI 10.2131/jts.39.401
   Knudsen KB, 2014, NANOTOXICOLOGY, V8, P764, DOI 10.3109/17435390.2013.829589
   Korani M, 2013, IRAN J PHARM RES, V12, P511
   Kovvuru P, 2015, NANOTOXICOLOGY, V9, P162, DOI 10.3109/17435390.2014.902520
   Kumar A, 2013, ARCH TOXICOL, V87, P1883, DOI 10.1007/s00204-013-1128-z
   Lankoff A, 2012, TOXICOL LETT, V208, P197, DOI 10.1016/j.toxlet.2011.11.006
   Lee YS, 2011, ARCH TOXICOL, V85, P1529, DOI 10.1007/s00204-011-0714-1
   Li Y, 2014, NANOTOXICOLOGY, V8, P36, DOI 10.3109/17435390.2013.855827
   Lim Hui Kheng, 2012, Frontiers in Genetics, V3, P104, DOI 10.3389/fgene.2012.00104
   Liu W, 2010, NANOTOXICOLOGY, V4, P319, DOI 10.3109/17435390.2010.483745
   Maillard JY, 2013, CRIT REV MICROBIOL, V39, P373, DOI 10.3109/1040841X.2012.713323
   Mangini V, 2014, CHEM-EUR J, V20, P10745, DOI 10.1002/chem.201402934
   Mytych J, 2015, BIOMATERIALS, V53, P107, DOI 10.1016/j.biomaterials.2015.02.072
   Narayan PJ, 2015, NEUROBIOL DIS, V74, P281, DOI 10.1016/j.nbd.2014.11.023
   Ortega FG, 2015, INT J NANOMED, V10, DOI 10.2147/IJN.S75835
   Pham CH, 2012, ECOTOX ENVIRON SAFE, V78, P239, DOI 10.1016/j.ecoenv.2011.11.034
   Piao MJ, 2011, TOXICOL LETT, V201, P92, DOI 10.1016/j.toxlet.2010.12.010
   Rivlin Noa, 2011, Genes Cancer, V2, P466, DOI 10.1177/1947601911408889
   Robinson CM, 2012, RESP RES, V13, DOI 10.1186/1465-9921-13-74
   Sarhan OMM, 2014, INT J NANOMED, V9, P1505, DOI 10.2147/IJN.S56729
   Satapathy SR, 2015, PATHOL ONCOL RES, V21, P405, DOI 10.1007/s12253-014-9835-1
   Satapathy SR, 2013, NANOMEDICINE-UK, V8, P1307, DOI [10.2217/NNM.12.176, 10.2217/nnm.12.176]
   Schluesener JK, 2013, ARCH TOXICOL, V87, P569, DOI 10.1007/s00204-012-1007-z
   Seal S, 2014, SAFETY SCI, V63, P217, DOI 10.1016/j.ssci.2013.11.018
   Sharma VK, 2014, ADV COLLOID INTERFAC, V204, P15, DOI 10.1016/j.cis.2013.12.002
   Singh RP, 2012, TOXICOL LETT, V213, P249, DOI 10.1016/j.toxlet.2012.07.009
   Song KS, 2013, NANOTOXICOLOGY, V7, P169, DOI 10.3109/17435390.2011.648223
   Sriram MI, 2010, INT J NANOMED, V5, P753, DOI 10.2147/IJN.S11727
   Sun XJ, 2013, MOL MED REP, V8, P1365, DOI 10.3892/mmr.2013.1683
   Tan JW, 2014, ENVIRON TOXICOL, V31, P224
   Tolaymat TM, 2010, SCI TOTAL ENVIRON, V408, P999, DOI 10.1016/j.scitotenv.2009.11.003
   Xu LM, 2015, NANOTOXICOLOGY, V9, P513, DOI 10.3109/17435390.2014.948942
   Zhang TL, 2014, YONSEI MED J, V55, P283, DOI 10.3349/ymj.2014.55.2.283
NR 61
TC 34
Z9 37
U1 0
U2 29
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0340-5761
EI 1432-0738
J9 ARCH TOXICOL
JI Arch. Toxicol.
PD FEB
PY 2017
VL 91
IS 2
BP 651
EP 666
DI 10.1007/s00204-016-1773-0
PG 16
WC Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Toxicology
GA EK8NL
UT WOS:000394180500007
PM 27387714
DA 2025-01-12
ER

PT J
AU Jandial, R
   Choy, C
   Levy, D
   Chen, MY
   Ansari, KI
AF Jandial, Rahul
   Choy, Cecilia
   Levy, Danielle M.
   Chen, Mike Y.
   Ansari, Khairul I.
TI Astrocyte-induced Reelin expression drives proliferation of
   Her2<SUP>+</SUP> breast cancer metastases
SO CLINICAL & EXPERIMENTAL METASTASIS
LA English
DT Article
DE Breast cancer; Brain metastasis; Her2; ERBB2; Reelin; Astrocytes;
   Epigenetics; Triple negative breast cancer; Neural microenvironment
ID BRAIN METASTASES; NERVOUS-SYSTEM; EXTRACELLULAR VESICLES; NEURAL NICHE;
   STEM-CELLS; PROGENITOR; PROMOTES; NEURONS; SWITCH; MOUSE
AB Breast cancer metastasis to the brain develops after a clinical latency of years to even decades, suggesting that colonization of the brain is the most challenging step of the metastatic cascade. However, the underlying mechanisms used by breast cancer cells to successfully colonize the brain's microenvironment remain elusive. Reelin is an archetypal extracellular glycoprotein that regulates migration, proliferation, and lamination of neurons. It is epigenetically silenced in various cancers, and its expression in multiple myelomas is linked to poor patient survival. We found that Reelin expression was low in primary breast cancer tissue. However, its expression was significantly higher in Her2(+) breast cancers metastasizing to the brain. In particular, Reelin was highly expressed in the tumor periphery adjacent to surrounding astrocytes. This augmented Reelin expression was seen in Her2(+) metastases, but not in triple negative (TN) primary tumors or in TN breast to brain metastasis cells co-cultured with astrocytes. Furthermore, the elevated expression was sustained in Her2(+) cells grown in the presence of the DNA methyltransferase inhibitor 5-azacytidine, indicating epigenetic regulation of Reelin expression. The relative growth and rate of spheroids formation derived from Her2(+) primary and BBM cells co-cultured with astrocytes were higher than those of TN primary and BBM cells, and knockdown of both Reelin and Her2 suppressed the astrocyte-induced growth and spheroid forming ability of Her2(+) cells. Collectively, our results indicate that within the neural niche, astrocytes epigenetically regulate Reelin expression and its interaction with Her2 leading to increased proliferation and survival fitness.
C1 [Jandial, Rahul; Choy, Cecilia; Levy, Danielle M.; Chen, Mike Y.; Ansari, Khairul I.] Beckman Res Inst, Div Neurosurg, City Hope, 1500 E Duarte Rd, Duarte, CA 91010 USA.
C3 City of Hope; Beckman Research Institute of City of Hope
RP Jandial, R; Ansari, KI (通讯作者)，Beckman Res Inst, Div Neurosurg, City Hope, 1500 E Duarte Rd, Duarte, CA 91010 USA.
EM rjandial@coh.org; kansari@coh.org
FU Department of Defense (DOD) [BC142323]; Margaret E. Early Medical
   Research Trust, National Institutes of Health (NIH) [K12 CA001727-16A1];
   National Cancer Institute [P30 CA033572]
FX R.J. is supported by Department of Defense (DOD) Grant (BC142323), The
   Margaret E. Early Medical Research Trust, National Institutes of Health
   (NIH) Grant K12 CA001727-16A1. Additional project support was provided
   by National Cancer Institute Grant P30 CA033572.
CR [Anonymous], 2014, Adv. Neurosci, DOI [10.1155/2014/597395, DOI 10.1155/2014/597395]
   Basso M, 2016, FRONT NEUROSCI-SWITZ, V10, DOI 10.3389/fnins.2016.00127
   Becker J, 2012, INT J ONCOL, V41, P681, DOI 10.3892/ijo.2012.1488
   Biamonte F, 2015, ITAL J ANTOMY EMBRYO, V120, P89
   Budnik V, 2016, NAT REV NEUROSCI, V17, P160, DOI 10.1038/nrn.2015.29
   Curran T, 1998, BRAIN RES REV, V26, P285, DOI 10.1016/S0165-0173(97)00035-0
   Dohi O, 2010, INT J ONCOL, V36, P85, DOI 10.3892/ijo_00000478
   Evangelisti C, 2009, FASEB J, V23, P4276, DOI 10.1096/fj.09-134965
   Fong MY, 2015, NAT CELL BIOL, V17, P183, DOI 10.1038/ncb3094
   Grayson DR, 2006, PHARMACOL THERAPEUT, V111, P272, DOI 10.1016/j.pharmthera.2005.01.007
   Honda Y, 2014, ANN ONCOL
   Hu HL, 2012, MOL VIS, V18, P2388
   Jandial R, 2012, NEUROSURGERY, V70, pN12, DOI 10.1227/NEU.0b013e3181ae7de9
   Jossin Y, 2011, NAT NEUROSCI, V14, P697, DOI 10.1038/nn.2816
   Khialeeva E, 2015, CANCER RES, DOI [10.1158/1538-7445, DOI 10.1158/1538-7445]
   Khialeeva E, 2011, DEVELOPMENT, V138, P767, DOI 10.1242/dev.057588
   Kondziolka D, 2014, NEUROSURGERY, V75, P1, DOI 10.1227/NEU.0000000000000354
   Langley RR, 2011, INT J CANCER, V128, P2527, DOI 10.1002/ijc.26031
   Lee SA, 2011, J MICROMECH MICROENG, V21, DOI 10.1088/0960-1317/21/5/054006
   Lin L, 2016, ONCOTARGET, V7, P9844, DOI 10.18632/oncotarget.7151
   Liu HY, 2015, EXP NEUROL, V269, P202, DOI 10.1016/j.expneurol.2015.04.011
   Massalini S, 2009, MOL CELL NEUROSCI, V42, P341, DOI 10.1016/j.mcn.2009.08.006
   Mitchell CP, 2005, J NEUROCHEM, V93, P483, DOI 10.1111/j.1471-4159.2005.03040.x
   Neman J, 2014, P NATL ACAD SCI USA, V111, P984, DOI 10.1073/pnas.1322098111
   Neman J, 2013, CLIN EXP METASTAS, V30, P753, DOI 10.1007/s10585-013-9576-7
   Paget G, 1889, Br Med J, V1, P1
   Percy DB, 2011, INVEST RADIOL, V46, P718, DOI 10.1097/RLI.0b013e318226c427
   Perrone G, 2007, MODERN PATHOL, V20, P344, DOI 10.1038/modpathol.3800743
   Pestalozzi BC, 2009, ANN ONCOL, V20, P803, DOI 10.1093/annonc/mdp246
   Piccirilli M, 2007, TUMORI, V93, P150
   Rajendran L, 2014, J NEUROSCI, V34, P15482, DOI 10.1523/JNEUROSCI.3258-14.2014
   Raposo G, 1996, J EXP MED, V183, P1161, DOI 10.1084/jem.183.3.1161
   Rice DS, 2001, ANNU REV NEUROSCI, V24, P1005, DOI 10.1146/annurev.neuro.24.1.1005
   Seigel GM, 2007, MOL VIS, V13, P823
   Stein T, 2010, AM J PATHOL, V177, P2323, DOI 10.2353/ajpath.2010.100209
   Sui L, 2012, NEUROBIOL LEARN MEM, V97, P425, DOI 10.1016/j.nlm.2012.03.007
   Termini J, 2014, CANCER RES, V74, P4011, DOI 10.1158/0008-5472.CAN-14-1226
   Yuan Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031802
   Zhang L, 2015, NATURE, V527, P100, DOI 10.1038/nature15376
   Zhang Y, 2016, NEURON, V89, P37, DOI 10.1016/j.neuron.2015.11.013
   Zhou Q, 2016, MOL BIOL CELL, V27, P627, DOI 10.1091/mbc.E15-07-0513
NR 41
TC 32
Z9 32
U1 0
U2 4
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0262-0898
EI 1573-7276
J9 CLIN EXP METASTAS
JI Clin. Exp. Metastasis
PD FEB
PY 2017
VL 34
IS 2
BP 185
EP 196
DI 10.1007/s10585-017-9839-9
PG 12
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA EN6IL
UT WOS:000396107600007
PM 28210910
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Luo, YW
   Wang, XY
   Niu, WH
   Wang, HR
   Wen, QY
   Fan, SQ
   Zhao, R
   Li, Z
   Xiong, W
   Peng, SP
   Zeng, ZY
   Li, XL
   Li, GY
   Tan, M
   Zhou, M
AF Luo, Yanwei
   Wang, Xinye
   Niu, Weihong
   Wang, Heran
   Wen, Qiuyuan
   Fan, Songqing
   Zhao, Ran
   Li, Zheng
   Xiong, Wei
   Peng, Shuping
   Zeng, Zhaoyang
   Li, Xiaoling
   Li, Guiyuan
   Tan, Ming
   Zhou, Ming
TI Elevated microRNA-125b levels predict a worse prognosis in HER2-positive
   breast cancer patients
SO ONCOLOGY LETTERS
LA English
DT Article
DE breast cancer; miR-125b; HER2; prognosis; paclitaxel
ID DOWN-REGULATION; EXPRESSION; MIR-125B; CELLS; PROLIFERATION; CONFERS;
   CONTRIBUTES; SUPPRESSION; RESISTANCE; SUBTYPES
AB Breast cancer, the second most common cancer worldwide, is the leading cause of cancer-associated mortality in women, accounting for similar to 15% of all cancer-associated mortalities in women. The development, local invasion and metastasis of breast cancer are associated with the dysregulation and mutation of numerous genes and epigenetic mechanisms, including coding RNA and non-coding RNA, such as microRNAs (miRs/miRNAs). Previous studies have shown a dual-faced role of miR-125b in breast cancer. In the present study, a total of 221 paraffin-embedded breast cancer and 49 paraffin-embedded non-cancerous breast tissue samples were collected. In situ hybridization was used to analyze the expression of miR-125b in the breast cancer tissues. Spearman's rank correlation analysis was used to analyze the expression correlation between miR-125b and human epidermal growth factor 2 (HER2). The overall survival estimates over time were calculated using the Kaplan-Meier method with log-rank test. It was found that miR-125b expression was significantly increased in the breast cancer tissues compared with that in the non-cancerous tissues, and high miR-125b expression indicated a poor prognosis in the breast cancer patients. In addition, miR-125b expression was positively correlated with HER2, but not with progesterone receptor and estrogen receptor. Notably, high miR-125b expression was significantly correlated with tumor size and Tumor-Node-Metastasis stage in the HER2-positive breast cancer patients, along with a poor prognosis. The present study provides clinical data to confirm the oncogenic potential of miR-125b, particularly in HER2-positive human breast cancer. Thus, identification of miR-125b may be a potential molecular biomarker for the prediction of clinical outcomes in breast cancer patients, particularly HER2-positive cases that will receive paclitaxel-based neoadjuvant chemotherapy.
C1 [Luo, Yanwei; Wang, Xinye; Niu, Weihong; Wang, Heran; Zhao, Ran; Li, Zheng; Xiong, Wei; Peng, Shuping; Zeng, Zhaoyang; Li, Xiaoling; Li, Guiyuan; Zhou, Ming] Cent South Univ, Canc Res Inst, 110 Xiangya Rd, Changsha 410078, Hunan, Peoples R China.
   [Luo, Yanwei; Wang, Xinye; Niu, Weihong; Wang, Heran; Zhao, Ran; Li, Zheng; Xiong, Wei; Peng, Shuping; Zeng, Zhaoyang; Li, Xiaoling; Li, Guiyuan; Zhou, Ming] Minist Hlth, Key Lab Carcinogenesis, Changsha 410078, Hunan, Peoples R China.
   [Luo, Yanwei] Cent South Univ, Xiang Ya Hosp 3, Dept Transfus, Changsha 410013, Hunan, Peoples R China.
   [Wen, Qiuyuan; Fan, Songqing] Cent South Univ, Xiang Ya Hosp 2, Dept Pathol, Changsha 410011, Hunan, Peoples R China.
   [Tan, Ming] Univ S Alabama, Mitchell Canc Inst, 1660 Spring Hill Ave, Mobile, AL 36604 USA.
C3 Central South University; Central South University; Central South
   University; University of South Alabama
RP Zhou, M (通讯作者)，Cent South Univ, Canc Res Inst, 110 Xiangya Rd, Changsha 410078, Hunan, Peoples R China.; Tan, M (通讯作者)，Univ S Alabama, Mitchell Canc Inst, 1660 Spring Hill Ave, Mobile, AL 36604 USA.
EM mtan@health.southalabama.edu; zhouming2001@163.com
RI Zeng, Zhaoyang/LLL-3057-2024; Tan, Ming/ABD-5847-2021; xiong,
   wei/GXZ-9586-2022; Sun, Heli/AAL-7708-2021
OI Tan, Ming/0000-0003-2007-9898; Zhao, Ran/0009-0003-9593-3195
FU the National Natural Science Foundation of China [81328019, 81572748];
   Natural Science Foundation of Hunan Province [2015JJ2148]
FX This study was supported by grants obtained from the National Natural
   Science Foundation of China (grant nos. 81328019 and 81572748) and the
   Natural Science Foundation of Hunan Province (grant no. 2015JJ2148).
CR [Anonymous], CANC RES
   Baffa R, 2009, J PATHOL, V219, P214, DOI 10.1002/path.2586
   Banzhaf-Strathmann J, 2014, CELL COMMUN SIGNAL, V12, DOI 10.1186/1478-811X-12-30
   Bousquet M, 2008, J EXP MED, V205, P2499, DOI 10.1084/jem.20080285
   Bousquet M, 2010, P NATL ACAD SCI USA, V107, P21558, DOI 10.1073/pnas.1016611107
   Byler S, 2014, ANTICANCER RES, V34, P1071
   Calin GA, 2004, P NATL ACAD SCI USA, V101, P2999, DOI 10.1073/pnas.0307323101
   Chapiro E, 2010, LEUKEMIA, V24, P1362, DOI 10.1038/leu.2010.93
   Eroles P, 2012, CANCER TREAT REV, V38, P698, DOI 10.1016/j.ctrv.2011.11.005
   Fan SQ, 2006, HUM PATHOL, V37, P593, DOI 10.1016/j.humpath.2006.01.010
   Fassan M, 2013, HUM PATHOL, V44, P1804, DOI 10.1016/j.humpath.2013.01.023
   Feliciano A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076247
   Ferracin M, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-130
   Goldhirsch A, 2011, ANN ONCOL, V22, P1736, DOI 10.1093/annonc/mdr304
   He J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056647
   He J, 2012, EMBO REP, V13, P1116, DOI 10.1038/embor.2012.162
   Henson BJ, 2009, GENE CHROMOSOME CANC, V48, P569, DOI 10.1002/gcc.20666
   Kontorovich T, 2010, INT J CANCER, V127, P589, DOI 10.1002/ijc.25065
   Le MTN, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002242
   Le MTN, 2009, GENE DEV, V23, P862, DOI 10.1101/gad.1767609
   Liu LH, 2011, BIOCHEM BIOPH RES CO, V416, P31, DOI 10.1016/j.bbrc.2011.10.117
   Matamala N, 2015, CLIN CHEM, V61, P1098, DOI 10.1373/clinchem.2015.238691
   Nakanishi H, 2014, ONCOGENE, V33, P702, DOI 10.1038/onc.2013.13
   Schwarzenbacher D, 2013, INT J MOL SCI, V14, P14712, DOI 10.3390/ijms140714712
   Scott GK, 2007, J BIOL CHEM, V282, P1479, DOI 10.1074/jbc.M609383200
   Shang C, 2012, MED SCI MONITOR, V18, pBR149, DOI 10.12659/MSM.882617
   Shi XB, 2007, P NATL ACAD SCI USA, V104, P19983, DOI 10.1073/pnas.0706641104
   Smits M, 2012, FASEB J, V26, P2639, DOI 10.1096/fj.11-202820
   Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100
   Tang F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035435
   Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262
   Vilquin P, 2015, BREAST CANCER RES, V17, DOI 10.1186/s13058-015-0515-1
   Wang HK, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0029452, 10.1371/journal.pone.0041330, 10.1371/journal.pone.0038619]
   Wang HJ, 2013, J CELL BIOCHEM, V114, P2248, DOI 10.1002/jcb.24574
   Willimott S, 2012, J BIOL CHEM, V287, P2608, DOI 10.1074/jbc.M111.285718
   Xia HF, 2009, CELL PHYSIOL BIOCHEM, V23, P347, DOI 10.1159/000218181
   Yagishita S, 2015, MOL CANCER THER, V14, P1414, DOI 10.1158/1535-7163.MCT-14-0625
   Zheng Y, 2015, J CANCER, V6, P671, DOI 10.7150/jca.11616
   Zhou M, 2010, J BIOL CHEM, V285, P21496, DOI 10.1074/jbc.M109.083337
NR 39
TC 35
Z9 40
U1 0
U2 12
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1792-1074
EI 1792-1082
J9 ONCOL LETT
JI Oncol. Lett.
PD FEB
PY 2017
VL 13
IS 2
BP 867
EP 874
DI 10.3892/ol.2016.5482
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA EL9GF
UT WOS:000394927700047
PM 28356971
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU Lv, QY
   Xie, BY
   Yang, BY
   Ning, CC
   Shan, WW
   Gu, C
   Luo, XZ
   Chen, XJ
   Zhang, ZB
   Feng, YJ
AF Lv, Qiao-Ying
   Xie, Bing-Ying
   Yang, Bing-Yi
   Ning, Cheng-Cheng
   Shan, Wei-Wei
   Gu, Chao
   Luo, Xue-Zhen
   Chen, Xiao-Jun
   Zhang, Zhen-Bo
   Feng, You-Ji
TI Increased TET1 Expression in Inflammatory Microenvironment of
   Hyperinsulinemia Enhances the Response of Endometrial Cancer to Estrogen
   by Epigenetic Modulation of GPER
SO JOURNAL OF CANCER
LA English
DT Article
DE Insulin resistance; Endometrial endometrioid cancer; estrogen
   sensitivity; GPER/GPR30; TET1
ID EPITHELIAL-MESENCHYMAL TRANSITION; BREAST-CANCER; INSULIN-RESISTANCE;
   ALPHA; GROWTH; RISK; 5-HYDROXYMETHYLCYTOSINE; PROLIFERATION;
   HYPERPLASIA; MACROPHAGES
AB Background: Insulin resistance (IR) has been well studied in the initiation and development of endometrial endometrioid carcinoma (EEC). As yet, it has been largely neglected for estrogen sensitivity in local endometrium in hyperinsulinemia-induced systemic microenvironment. The aim of this study was to investigate the role of insulin in regulating estrogen sensitivity and explore the potential mechanisms in insulin-driven inflammatory microenvironment.
   Methods: We first investigated the effect of insulin on estradiol-driven endometrial cancer cells proliferation in vitro to address the roles of insulin in modulating estrogen sensitivity. Then GPER, ERa and TET1 in EEC samples with or without insulin resistance were screened by immunohistochemistry to confirm whether insulin resistance regulates estrogen receptors. Further mechanism analysis was carried out to address whether TET1 was mediated epigenetic modulation of GPER in insulin-induced microenvironment.
   Results: Insulin enhanced estradiol-driven endometrial cancer cells proliferation by up-regulating G-protein-coupled estrogen receptor (GPER) expression, but not ER alpha or ER beta. Immunohistochemistry of EEC tissues showed that GPER expression was greatly increased in endometrial tissues from EEC subjects with insulin resistance and was positively correlated with Ten-eleven-translocation 1 (TET1) expression. Mechanistically, insulin up-regulates TET1 expression, and the latter, an important DNA hydroxymethylase, could up-regulate GPER expression through epigenetic modulation.
   Conclusion: This study identified TET1 as the upstream regulator of GPER expression and provides a possible mechanism that insulin-induced positive regulation of estrogen sensitivity in endometrial cancer cells. Increasing expression of GPER through TET1-mediated epigenetic modulation may emerge as the main regulator to enhance the response of endometrial cancer to estrogen in insulin-driven inflammatory microenvironment.
C1 [Lv, Qiao-Ying; Xie, Bing-Ying; Yang, Bing-Yi; Ning, Cheng-Cheng; Shan, Wei-Wei; Gu, Chao; Luo, Xue-Zhen; Chen, Xiao-Jun] Fudan Univ, Obstet & Gynecol Hosp, 419 Fangxie Rd, Shanghai 200011, Peoples R China.
   [Zhang, Zhen-Bo; Feng, You-Ji] Shanghai Jiao Tong Univ, Sch Med, Shanghai Gen Hosp, Dept Obstet & Gynecol, 650 Xinsongjiang Rd, Shanghai 201620, Peoples R China.
C3 Fudan University; Shanghai Jiao Tong University
RP Chen, XJ (通讯作者)，Fudan Univ, Obstet & Gynecol Hosp, 419 Fangxie Rd, Shanghai 200011, Peoples R China.; Zhang, ZB (通讯作者)，Shanghai Jiao Tong Univ, Sch Med, Shanghai Gen Hosp, Dept Obstet & Gynecol, 650 Xinsongjiang Rd, Shanghai 201620, Peoples R China.
EM xiaojunchen2013@sina.com; zhangzhenbozzb@aliyun.com
FU National Natural Science Foundation of China [81370688, 81370074,
   81672562]; Shanghai Science and Technology Development Funds
   [13JC1401300]; Shanghai Science and Technology Development medical guide
   project [134119a4500]; Shanghai Municipal Public Health Bureau
   [XYQ2013119]; "Chenxing Project" from Shanghai Jiao Tong University
   [15X100080023]
FX This work was supported by the National Natural Science Foundation of
   China (Grant No. 81370688,81370074 and 81672562), Shanghai Science and
   Technology Development Funds (Grant No. 13JC1401300), Shanghai Science
   and Technology Development medical guide project (Grant No. 134119a4500)
   and Shanghai Municipal Public Health Bureau (Grant No. XYQ2013119), and
   the "Chenxing Project" from Shanghai Jiao Tong University (Grant No.
   15X100080023).
CR [Anonymous], TUMOUR BIOL
   Che Q, 2014, INT J CANCER, V135, P282, DOI 10.1002/ijc.28679
   Che Q, 2014, BIOCHEM BIOPH RES CO, V446, P167, DOI 10.1016/j.bbrc.2014.02.080
   Chen HF, 2016, BIOMEDICINE-TAIWAN, V6, P1, DOI 10.7603/s40681-016-0001-9
   Chen J, 2016, ONCOGENE, V35, P2506, DOI 10.1038/onc.2015.316
   Chen XJ, 2007, CANCER SCI, V98, P68, DOI 10.1111/j.1349-7006.2006.00353.x
   Cherry N, 2014, BJOG-INT J OBSTET GY, V121, P700, DOI 10.1111/1471-0528.12598
   De Marco P, 2013, ONCOGENE, V32, P678, DOI 10.1038/onc.2012.97
   De Marco P, 2015, FRONT ENDOCRINOL, V6, DOI 10.3389/fendo.2015.00030
   Gaikwad AB, 2010, BIOCHEM J, V432, P333, DOI 10.1042/BJ20100414
   Glass CK, 2012, CELL METAB, V15, P635, DOI 10.1016/j.cmet.2012.04.001
   Hernandez AV, 2015, EUR J CANCER, V51, P2747, DOI 10.1016/j.ejca.2015.08.031
   Houghton P, 2007, METHODS, V42, P377, DOI 10.1016/j.ymeth.2007.01.003
   Ito S, 2010, NATURE, V466, P1129, DOI 10.1038/nature09303
   Kaaks R, 2002, CANCER EPIDEM BIOMAR, V11, P1531
   Madonna R, 2015, VASC PHARMACOL, V73, P4, DOI 10.1016/j.vph.2015.08.002
   Maggiolini M, 2010, J ENDOCRINOL, V204, P105, DOI 10.1677/JOE-09-0242
   Mu N, 2012, GYNECOL ONCOL, V125, P751, DOI 10.1016/j.ygyno.2012.03.032
   Nead KT, 2015, JNCI-J NATL CANCER I, V107, DOI 10.1093/jnci/djv178
   Nestor CE, 2012, GENOME RES, V22, P467, DOI 10.1101/gr.126417.111
   Ning CC, 2016, CANCER RES, V76, P1354, DOI 10.1158/0008-5472.CAN-15-1260
   Rajbhandari P, 2014, ONCOGENE, V33, P1438, DOI 10.1038/onc.2013.78
   Shan WW, 2014, GYNECOL ONCOL, V132, P606, DOI 10.1016/j.ygyno.2014.01.004
   Simon J, 2010, OBSTET GYNECOL, V116, P876, DOI 10.1097/AOG.0b013e3181f386bb
   Tsai YP, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0513-0
   Wairagu PM, 2015, CANCER BIOL THER, V16, P484, DOI 10.1080/15384047.2015.1016660
   Wang XH, 2012, J BIOL CHEM, V287, P18376, DOI 10.1074/jbc.M112.355164
   Wang YM, 2012, CANCER LETT, V322, P223, DOI 10.1016/j.canlet.2012.03.026
   Wik E, 2013, CLIN CANCER RES, V19, P1094, DOI 10.1158/1078-0432.CCR-12-3039
   Wu H, 2011, CELL CYCLE, V10, P2428, DOI 10.4161/cc.10.15.16930
   Yang KM, 2013, CANCER RES, V73, P6679, DOI 10.1158/0008-5472.CAN-13-0891
   Yang S, 2014, IMMUNITY, V41, P973, DOI 10.1016/j.immuni.2014.11.013
   Yao C, 2016, STEM CELLS, V34, P820, DOI 10.1002/stem.2320
   Ye C, 2014, CANCER BIOL THER, V15, P10, DOI 10.4161/cbt.27144
NR 34
TC 23
Z9 29
U1 0
U2 11
PU IVYSPRING INT PUBL
PI LAKE HAVEN
PA PO BOX 4546, LAKE HAVEN, NSW 2263, AUSTRALIA
SN 1837-9664
J9 J CANCER
JI J. Cancer
PY 2017
VL 8
IS 5
BP 894
EP 902
DI 10.7150/jca.17064
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA EO3HI
UT WOS:000396585300022
PM 28382153
OA gold, Green Published, Green Submitted
DA 2025-01-12
ER

PT J
AU Ambatipudi, S
   Horvath, S
   Perrier, F
   Cuenin, C
   Hernandez-Vargas, H
   Le Calvez-Kelm, F
   Durand, G
   Byrnes, G
   Ferrari, P
   Bouaoun, L
   Sklias, A
   Chajes, V
   Overvad, K
   Seven, G
   Baglietto, L
   Clavel-Chapelon, F
   Kaaks, R
   Barrdahl, M
   Boeing, H
   Trichopoulou, A
   Lagiou, P
   Naska, A
   Masala, G
   Agnoli, C
   Polidoro, S
   Tumino, R
   Panico, S
   Dollé, M
   Peeters, PHM
   Onland-Moret, NC
   Sandanger, TM
   Nost, TH
   Weiderpass, E
   Quirós, JR
   Agudo, A
   Rodriguez-Barranco, M
   Castaño, JMH
   Barricarte, A
   Fernádez, AM
   Travis, RC
   Vineis, P
   Muller, DC
   Riboli, E
   Gunter, M
   Romieu, I
   Herceg, Z
AF Ambatipudi, Srikant
   Horvath, Steve
   Perrier, Flavie
   Cuenin, Cyrille
   Hernandez-Vargas, Hector
   Le Calvez-Kelm, Florence
   Durand, Geoffroy
   Byrnes, Graham
   Ferrari, Pietro
   Bouaoun, Liacine
   Sklias, Athena
   Chajes, Veronique
   Overvad, Kim
   Seven, Gianluca
   Baglietto, Laura
   Clavel-Chapelon, Francoise
   Kaaks, Rudolf
   Barrdahl, Myrto
   Boeing, Heiner
   Trichopoulou, Antonia
   Lagiou, Pagona
   Naska, Androniki
   Masala, Giovanna
   Agnoli, Claudia
   Polidoro, Silvia
   Tumino, Rosario
   Panico, Salvatore
   Dolle, Martijn
   Peeters, Petra H. M.
   Onland-Moret, N. Charlotte
   Sandanger, Torkjel M.
   Nost, Therese H.
   Weiderpass, Elisabete
   Quiros, J. Ramon
   Agudo, Antonio
   Rodriguez-Barranco, Miguel
   Castano, Jose Maria Huerta
   Barricarte, Aurelio
   Fernandez, Ander Matheu
   Travis, Ruth C.
   Vineis, Paolo
   Muller, David C.
   Riboli, Elio
   Gunter, Marc
   Romieu, Isabelle
   Herceg, Zdenko
TI DNA methylome analysis identifies accelerated epigenetic ageing
   associated with postmenopausal breast cancer susceptibility
SO EUROPEAN JOURNAL OF CANCER
LA English
DT Article
DE DNA methylation; Epigenomics; Age acceleration; Breast cancer;
   Biomarkers; Prospective studies
ID PERIPHERAL-BLOOD; METHYLATION AGE; MORTALITY; CLOCK; HYPERMETHYLATION;
   POPULATION; BIOLOGY; DRIFT; BETA; LUMA
AB Aim of the study: A vast majority of human malignancies are associated with ageing, and age is a strong predictor of cancer risk. Recently, DNA methylation-based marker of ageing, known as 'epigenetic clock', has been linked with cancer risk factors. This study aimed to evaluate whether the epigenetic clock is associated with breast cancer risk susceptibility and to identify potential epigenetics-based biomarkers for risk stratification.
   Methods: Here, we profiled DNA methylation changes in a nested case control study embedded in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort (n = 960) using the Illumina HumanMethylation 450K BeadChip arrays and used the Horvath age estimation method to calculate epigenetic age for these samples. Intrinsic epigenetic age acceleration (IEAA) was estimated as the residuals by regressing epigenetic age on chronological age.
   Results: We observed an association between IEAA and breast cancer risk (OR, 1.04; 95% CI, 1.007-1.076, P = 0.016). One unit increase in IEAA was associated with a 4% increased odds of developing breast cancer (OR, 1.04; 95% CI, 1.007-1.076). Stratified analysis based on menopausal status revealed that IEAA was associated with development of postmenopausal breast cancers (OR, 1.07; 95% CI, 1.020-1.11, P = 0.003). In addition, methylome-wide analyses revealed that a higher mean DNA methylation at cytosine-phosphate-guanine (CpG) islands was associated with increased risk of breast cancer development (OR per 1 SD = 1.20; 95 %CI: 1.03-1.40, P = 0.02) whereas mean methylation levels at non-island CpGs were indistinguishable between cancer cases and controls.
   Conclusion: Epigenetic age acceleration and CpG island methylation have a weak, but statistically significant, association with breast cancer susceptibility. (C) 2017 Elsevier Ltd. All rights reserved.
C1 [Ambatipudi, Srikant; Perrier, Flavie; Cuenin, Cyrille; Hernandez-Vargas, Hector; Le Calvez-Kelm, Florence; Durand, Geoffroy; Byrnes, Graham; Ferrari, Pietro; Bouaoun, Liacine; Sklias, Athena; Chajes, Veronique; Gunter, Marc; Romieu, Isabelle; Herceg, Zdenko] IARC, Lyon, France.
   [Horvath, Steve] Univ Calif Los Angeles, Human Genet & Biostat, Los Angeles, CA 90095 USA.
   [Overvad, Kim] Aarhus Univ, Dept Publ Hlth, Epidemiol Sect, Aarhus, Denmark.
   [Seven, Gianluca; Baglietto, Laura; Clavel-Chapelon, Francoise] Univ Paris Sud, INSERM, Ctr Rech Epidemiol & Sante Populat, CESP,U1018,Univ Paris Saclay,UVSQ,Inst Gustave Ro, Villejuif, France.
   [Seven, Gianluca; Polidoro, Silvia] Human Genet Fdn HuGeF, Turin, Italy.
   [Seven, Gianluca; Baglietto, Laura] Univ Melbourne, Canc Epidemiol Ctr, Canc Council Victoria, Melbourne, Vic, Australia.
   [Seven, Gianluca; Baglietto, Laura] Univ Melbourne, Ctr Epidemiol & Biostat, Melbourne Sch Populat & Global Hlth, Melbourne, Vic, Australia.
   [Kaaks, Rudolf; Barrdahl, Myrto] German Canc Res Ctr, Div Canc Epidemiol, Heidelberg, Germany.
   [Boeing, Heiner] German Inst Human Nutr Potsdam Rehbrucke, Dept Epidemiol, Nuthetal, Germany.
   [Trichopoulou, Antonia; Lagiou, Pagona; Naska, Androniki] Hellen Hlth Fdn, Athens, Greece.
   [Trichopoulou, Antonia; Lagiou, Pagona; Naska, Androniki] Univ Athens, Sch Med, Dept Hyg Epidemiol & Med Stat, WHO Collaborating Ctr Nutr & Hlth,Unit Nutr Epide, Athens, Greece.
   [Lagiou, Pagona] Harvard Sch Publ Hlth, Dept Epidemiol, Boston, MA USA.
   [Masala, Giovanna] Canc Res & Prevent Inst ISPO, Mol & Nutr Epidemiol Unit, Florence, Italy.
   [Agnoli, Claudia] Fdn IRCCS Ist Nazl Tumori, Epidemiol & Prevent Unit, Milan, Italy.
   [Tumino, Rosario] Civ MP Arezzo, ASP Ragusa, Canc Registry, Ragusa, Italy.
   [Tumino, Rosario] Civ MP Arezzo, ASP Ragusa, Histopathol Unit, Ragusa, Italy.
   [Panico, Salvatore] Univ Naples Federico II, Dipartimento Med Clin & Chirurg, Naples, Italy.
   [Dolle, Martijn] Natl Inst Publ Hlth & Environm RIVM, Ctr Hlth Protect, Bilthoven, Netherlands.
   [Peeters, Petra H. M.; Onland-Moret, N. Charlotte] Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, Dept Epidemiol, Utrecht, Netherlands.
   [Peeters, Petra H. M.] Imperial Coll, Sch Publ Hlth, Dept Epidemiol & Biostat, MRC PHE Ctr Environm & Hlth, London, England.
   [Sandanger, Torkjel M.; Nost, Therese H.; Weiderpass, Elisabete] Arctic Univ Norway, Univ Tromso, Fac Hlth Sci, Dept Community Med, Tromso, Norway.
   [Weiderpass, Elisabete] Inst Populat Based Canc Res, Canc Registry Norway, Dept Res, Oslo, Norway.
   [Weiderpass, Elisabete] Karolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, Sweden.
   [Weiderpass, Elisabete] Folkhalsan Res Ctr, Genet Epidemiol Grp, Helsinki, Finland.
   [Quiros, J. Ramon] Publ Hlth Directorate, Asturias, Spain.
   [Agudo, Antonio] Catalan Inst Oncol IDIBELL, Canc Epidemiol Res Program, Unit Nutr & Canc, Barcelona, Spain.
   [Rodriguez-Barranco, Miguel] Univ Granada, Hospit Univ Granada, Inst Invest Biosanitaria Ibsn Granada, Escuela Andaluza Salud Publ, Granada, Spain.
   [Rodriguez-Barranco, Miguel; Castano, Jose Maria Huerta; Barricarte, Aurelio] CIBER Epidemiol & Salud Publ CIBERESP, Madrid, Spain.
   [Castano, Jose Maria Huerta] IMIB Arrixaca, Murcia Reg Hlth Council, Dept Epidemiol, Murcia, Spain.
   [Barricarte, Aurelio] Navarra Publ Hlth Inst, Pamplona, Spain.
   [Barricarte, Aurelio] Navarra Inst Hlth Res IdiSNA, Pamplona, Spain.
   [Fernandez, Ander Matheu] Biodonostia Hlth Res Inst, Cellular Oncol Grp, Paseo Dr Beguiristain S-N, San Sebastian, Spain.
   [Fernandez, Ander Matheu] Basque Fdn, Ikerbasque, Bilbao, Spain.
   [Travis, Ruth C.] Univ Oxford, Nuffield Dept Populat Hlth, Canc Epidemiol Unit, Oxford, England.
   [Vineis, Paolo; Muller, David C.; Riboli, Elio] Imperial Coll London, Sch Publ Hlth, London, England.
C3 World Health Organization; International Agency for Research on Cancer
   (IARC); University of California System; University of California Los
   Angeles; Aarhus University; Institut National de la Sante et de la
   Recherche Medicale (Inserm); Universite Paris Saclay; Cancer Council
   Victoria; University of Melbourne; University of Melbourne; Helmholtz
   Association; German Cancer Research Center (DKFZ); Leibniz Association;
   Deutsches Institut fur Ernahrungsforschung Potsdam-Rehbrucke (DIfE);
   Athens Medical School; National & Kapodistrian University of Athens;
   Harvard University; Harvard T.H. Chan School of Public Health; ISPRO
   Istituto per lo studio, la prevenzione e la rete oncologica; Fondazione
   IRCCS Istituto Nazionale Tumori Milan; Civile M.P. Arezzo Hospital;
   Civile M.P. Arezzo Hospital; University of Naples Federico II;
   Netherlands National Institute for Public Health & the Environment;
   Utrecht University; Utrecht University Medical Center; Imperial College
   London; UiT The Arctic University of Tromso; University of Oslo;
   Karolinska Institutet; Folkhalsan Research Center; Institut Catala
   d'Oncologia; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL);
   University of Granada; Escuela Andaluza de Salud Publica; CIBER - Centro
   de Investigacion Biomedica en Red; CIBERESP; Hospital Clinico
   Universitario Virgen de la Arrixaca; Murcia Regional Health Council;
   Public Health Institute of Navarra; Instituto de Investigacion Sanitaria
   Biogipuzkoa; Basque Foundation for Science; University of Oxford;
   Imperial College London
RP Herceg, Z (通讯作者)，IARC, Epigenet Grp, 150 Cours Albert Thomas, F-69008 Lyon, France.
EM herceg@iarc.fr
RI Herceg, Zdenko/JOZ-6188-2023; Ambatipudi, Srikant/GLV-6259-2022;
   TRICHOPOULOU, ANTONIA/ABF-8727-2021; Gunter, Marc/AAP-8621-2020; Masala,
   Giovanna/AAC-5474-2022; Polidoro, Silvia/GYJ-3517-2022; Riboli,
   Elio/A-4357-2009; Panico, Salvatore/K-6506-2016; Onland-Moret,
   N./G-9185-2011; Baglietto, Laura/AAB-9051-2019; Nøst,
   Therese/AGZ-1100-2022; Gil-Agudo, Ángel/ABD-3065-2021; Weiderpass,
   Elisabete/M-4029-2016; Agnoli, Claudia/K-5916-2016; RODRIGUEZ-BARRANCO,
   MIGUEL/H-4541-2012; Huerta, Jose Maria/N-8654-2015; Muller,
   David/V-8207-2017; Severi, Gianluca/H-3774-2018
OI Overvad, Kim/0000-0001-6429-7921; Weiderpass,
   Elisabete/0000-0003-2237-0128; Herceg, Zdenko/0000-0003-4109-3154;
   Chajes, Veronique/0000-0003-1297-3064; Agnoli,
   Claudia/0000-0003-4472-1179; Gunter, Marc/0000-0001-5472-6761;
   Baglietto, Laura/0000-0002-8193-7529; Hernandez-Vargas,
   Hector/0000-0001-6045-2103; RODRIGUEZ-BARRANCO,
   MIGUEL/0000-0002-9972-9779; Masala, Giovanna/0000-0002-5758-9069;
   tumino, rosario/0000-0003-2666-414X; Huerta, Jose
   Maria/0000-0002-9637-3869; Naska, Androniki/0000-0002-1610-1813;
   Ambatipudi, Srikant/0000-0003-3102-3603; Riboli,
   Elio/0000-0001-6795-6080; Byrnes, Graham/0000-0003-3893-7539; Polidoro,
   Silvia/0000-0003-2968-0575; Onland-Moret, N.
   Charlotte/0000-0002-2360-913X; Nost, Therese
   Haugdahl/0000-0001-6805-3094; Le Calvez-Kelm,
   Florence/0000-0003-0063-5068; Sklias, Athena/0000-0001-7177-4511;
   Muller, David/0000-0002-2350-0417; Severi, Gianluca/0000-0001-7157-419X
FU Institut National du Cancer (INCa, France) [2012-070]; European
   Commission (EC) [308610-2, TRANS201301184]; Fondation Association pour
   la Recherche contre le Cancer (ARC, France); EC [260791]; Associazione
   Italiana per la Ricerca sul Cancro-AIRC-Italy; Regional Government of
   Asturias; Hellenic Health Foundation; NIH/NIA [1U34AG051425-01]; MRC
   [MC_UU_12013/2] Funding Source: UKRI
FX This work was supported by grants from the Institut National du Cancer
   (INCa, France) (2012-070) to IR and ZH and the European Commission (EC)
   Seventh Framework Programme (FP7 Exposomics) (308610-2) Translational
   Cancer Research (TRANSCAN) (TRANS201301184) Framework and the Fondation
   Association pour la Recherche contre le Cancer (ARC, France) to ZH. ZH
   was also supported by the EC FP7 EurocanPlatform: A European Platform
   for Translational Cancer Research (grant number: 260791). Funding for
   the work also comes from a grant from: "Associazione Italiana per la
   Ricerca sul Cancro-AIRC-Italy" and the Regional Government of Asturias.
   EPIC Greece is supported by the Hellenic Health Foundation. SH was
   supported by NIH/NIA 1U34AG051425-01. The funders of the study had no
   role in study design, data collection, data analysis, data
   interpretation or writing of the manuscript.
CR Ambatipudi S, 2016, EPIGENOMICS-UK, V8, P599, DOI 10.2217/epi-2016-0001
   Benz CC, 2008, CRIT REV ONCOL HEMAT, V66, P65, DOI 10.1016/j.critrevonc.2007.09.001
   Bibikova M, 2011, GENOMICS, V98, P288, DOI 10.1016/j.ygeno.2011.07.007
   Bingham S, 2004, NAT REV CANCER, V4, P206, DOI 10.1038/nrc1298
   Blagosklonny MV, 2010, AGING-US, V2, P265, DOI 10.18632/aging.100149
   Breitling LP, 2016, CLIN EPIGENETICS, V8, DOI 10.1186/s13148-016-0186-5
   Chen BH, 2016, AGING-US, V8, P1844, DOI 10.18632/aging.101020
   Chen YA, 2013, EPIGENETICS-US, V8, P203, DOI 10.4161/epi.23470
   Christiansen L, 2016, AGING CELL, V15, P149, DOI 10.1111/acel.12421
   Deelen J, 2013, BIOESSAYS, V35, P386, DOI 10.1002/bies.201200148
   Demetriou CA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079391
   Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI [10.1056/NEJMra072067, 10.1093/carcin/bgp220]
   Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80
   Heyn H, 2013, CARCINOGENESIS, V34, P102, DOI 10.1093/carcin/bgs321
   Horiuchi S, 1997, J GERONTOL A-BIOL, V52, pB78, DOI 10.1093/gerona/52A.1.B78
   Horvath S, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-1030-0
   Horvath S, 2016, AGING-US, V8, P1485, DOI 10.18632/aging.101005
   Horvath S, 2015, AGING-US, V7, P1159, DOI 10.18632/aging.100861
   Horvath S, 2015, AGING-US, V7, P1130, DOI 10.18632/aging.100859
   Horvath S, 2015, J INFECT DIS, V212, P1563, DOI 10.1093/infdis/jiv277
   Horvath S, 2015, AGING CELL, V14, P491, DOI 10.1111/acel.12325
   Horvath S, 2014, P NATL ACAD SCI USA, V111, P15538, DOI 10.1073/pnas.1412759111
   Horvath S, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-10-r115
   Houseman EA, 2012, BMC BIOINFORMATICS, V13, DOI 10.1186/1471-2105-13-86
   Irizarry RA, 2009, NAT GENET, V41, P178, DOI 10.1038/ng.298
   Issa JP, 2014, J CLIN INVEST, V124, P24, DOI 10.1172/JCI69735
   Issa JP, 1999, CRIT REV ONCOL HEMAT, V32, P31, DOI 10.1016/S1040-8428(99)00019-0
   Kuchiba A, 2014, BRIT J CANCER, V110, P2765, DOI 10.1038/bjc.2014.223
   Langevin SM, 2014, EPIGENOMICS-UK, V6, P367, DOI 10.2217/epi.14.28
   Levine ME, 2016, P NATL ACAD SCI USA, V113, P9327, DOI 10.1073/pnas.1604558113
   Levine ME, 2015, AGING-US, V7, P1198, DOI 10.18632/aging.100864
   Levine ME, 2015, AGING-US, V7, P690, DOI 10.18632/aging.100809
   Marioni RE, 2015, INT J EPIDEMIOL, V44, P1388, DOI 10.1093/ije/dyu277
   Martin M, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-435
   Martincorena I, 2015, SCIENCE, V348, P880, DOI 10.1126/science.aaa6806
   Perna L, 2016, CLIN EPIGENETICS, V8, DOI 10.1186/s13148-016-0228-z
   Riboli E, 2002, PUBLIC HEALTH NUTR, V5, P1113, DOI 10.1079/PHN2002394
   Sandoval J, 2011, EPIGENETICS-US, V6, P692, DOI 10.4161/epi.6.6.16196
   Severi G, 2014, BREAST CANCER RES TR, V148, P665, DOI 10.1007/s10549-014-3209-y
   Simpkin AJ, 2016, HUM MOL GENET, V25, P191, DOI 10.1093/hmg/ddv456
   Teschendorff AE, 2013, BIOINFORMATICS, V29, P189, DOI 10.1093/bioinformatics/bts680
   van Veldhoven K, 2015, CLIN EPIGENETICS, V7, DOI 10.1186/s13148-015-0104-2
   Wallace K, 2010, CANCER PREV RES, V3, P1552, DOI 10.1158/1940-6207.CAPR-10-0047
   Xu XR, 2012, FASEB J, V26, P2657, DOI 10.1096/fj.11-197251
   Zannas AS, 2015, GENOME BIOL, V16, DOI 10.1186/s13059-015-0828-5
   Zheng YN, 2016, EBIOMEDICINE, V5, P68, DOI 10.1016/j.ebiom.2016.02.008
NR 46
TC 130
Z9 142
U1 2
U2 31
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0959-8049
EI 1879-0852
J9 EUR J CANCER
JI Eur. J. Cancer
PD APR
PY 2017
VL 75
BP 299
EP 307
DI 10.1016/j.ejca.2017.01.014
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA ES9DN
UT WOS:000399856400037
PM 28259012
OA Green Accepted, Green Published, Green Submitted
DA 2025-01-12
ER

PT J
AU Zhao, X
   Deng, R
   Wang, Y
   Zhang, H
   Dou, J
   Li, L
   Du, Y
   Chen, R
   Cheng, J
   Yu, J
AF Zhao, X.
   Deng, R.
   Wang, Y.
   Zhang, H.
   Dou, J.
   Li, L.
   Du, Y.
   Chen, R.
   Cheng, J.
   Yu, J.
TI Twist1/Dnmt3a and miR186 establish a regulatory circuit that controls
   inflammation-associated prostate cancer progression
SO ONCOGENESIS
LA English
DT Article
ID NF-KAPPA-B; EPITHELIAL-MESENCHYMAL TRANSITION; BREAST-CANCER;
   HEPATOCELLULAR-CARCINOMA; LINKING INFLAMMATION; UP-REGULATION; TWIST;
   EXPRESSION; METASTASIS; CELLS
AB Increasing evidences suggest that inflammatory microenvironment has a crucial role in prostate cancer (PCa) progression; however, the underlying mechanisms are unclear. Here, we used the inflammation-associated prostate cellular transformation model to screen out a crucial microRNA, miR186, which was significantly downregulated in the transformed cells and effectively rescued the transformed phenotype. On stimulation of inflammatory cytokines, the activated nuclear factor kappa B (NF-kappa B)/p65 was able to induce miR186 expression through binding to its promoter in non-transformed cells, whereas this pathway was lost in transformed cells. Interestingly, Twist1, which is a reported downstream target of miR186, was responsible for the loss of NF-kappa B/p65-miR186 pathway. Twist1 downregulated miR186 expression in a novel negative feedback loop binding to the E-box and simultaneously recruiting Dnmt3a, which facilitated the site-specific CpG methylation of the miR186 promoter, thereby blocked the transcriptional activity of NF-kappa B/p65 and the responsiveness of miR186 to inflammatory signals. The high level of Twist1 triggered this feedback loop that underlies the epigenetic switch, which was essential for maintaining transformed and advanced PCa state. Finally, our clinical data confirmed that the CpG methylation and miR186 expression levels were closely related with inflammation-associated human PCa progression.
C1 [Zhao, X.; Deng, R.; Wang, Y.; Zhang, H.; Dou, J.; Li, L.; Du, Y.; Chen, R.; Cheng, J.; Yu, J.] Shanghai Jiao Tong Univ, Sch Med, Dept Biochem & Mol Cell Biol, Shanghai Key Lab Tumor Microenvironm & Inflammat, 280 South Chongqing Rd, Shanghai 200025, Peoples R China.
   [Yu, J.] Shanghai Jiao Tong Univ, Sch Med, State Key Lab Oncogenes & Related Genes, Shanghai, Peoples R China.
   [Yu, J.] Chinese Minist Educ, Key Lab Cell Differentiat & Apoptosis, Dept Pathophysiol, Shanghai, Peoples R China.
C3 Shanghai Jiao Tong University; Shanghai Jiao Tong University
RP Yu, J (通讯作者)，Shanghai Jiao Tong Univ, Sch Med, Dept Biochem & Mol Cell Biol, Shanghai Key Lab Tumor Microenvironm & Inflammat, 280 South Chongqing Rd, Shanghai 200025, Peoples R China.
EM Jianxiu.Yu@gmail.com
RI Zhang, Hailong/KFA-0814-2024
OI Zhang, Hailong/0000-0002-9445-8981
FU National Natural Science Foundation of China [81630075, 81602251,
   91129726, 31671345, 81472571]
FX This work was supported by grants National Natural Science Foundation of
   China (81630075, 81602251, 91129726, 31671345 and 81472571).
CR Ansieau S, 2008, CANCER CELL, V14, P79, DOI 10.1016/j.ccr.2008.06.005
   Bae VL, 1998, PROSTATE, V34, P275, DOI 10.1002/(SICI)1097-0045(19980301)34:4<275::AID-PROS5>3.0.CO;2-G
   Ben-Neriah Y, 2011, NAT IMMUNOL, V12, P715, DOI 10.1038/ni.2060
   Ben-Yehoyada M, 2003, J BIOL CHEM, V278, P34475, DOI 10.1074/jbc.M301051200
   Bestor TH, 2000, HUM MOL GENET, V9, P2395, DOI 10.1093/hmg/9.16.2395
   Cao YX, 2000, BIOCHEM J, V350, P883, DOI 10.1042/0264-6021:3500883
   Contreras J, 2012, LEUKEMIA, V26, P404, DOI 10.1038/leu.2011.356
   Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322
   Dal Moro F, 2013, UROL ONCOL-SEMIN ORI, V31, P712, DOI 10.1016/j.urolonc.2013.03.002
   Daniels NA, 2005, UROLOGY, V66, P964, DOI 10.1016/j.urology.2005.05.034
   Denmeade SR, 2004, PROSTATE, V58, P211, DOI 10.1002/pros.10360
   Dennis LK, 2002, UROLOGY, V60, P78, DOI 10.1016/S0090-4295(02)01637-0
   Di Leva G, 2010, TRENDS MOL MED, V16, P257, DOI 10.1016/j.molmed.2010.04.001
   Elinav E, 2013, NAT REV CANCER, V13, P759, DOI 10.1038/nrc3611
   Fu JJ, 2011, CELL RES, V21, P275, DOI 10.1038/cr.2010.118
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Hoesel B, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-86
   Iliopoulos D, 2010, MOL CELL, V39, P493, DOI 10.1016/j.molcel.2010.07.023
   Karin M, 2006, NATURE, V441, P431, DOI 10.1038/nature04870
   Kwok WK, 2005, CANCER RES, V65, P5153, DOI 10.1158/0008-5472.CAN-04-3785
   Lee TK, 2006, CLIN CANCER RES, V12, P5369, DOI 10.1158/1078-0432.CCR-05-2722
   Li QQ, 2009, CLIN CANCER RES, V15, P2657, DOI 10.1158/1078-0432.CCR-08-2372
   Limame R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046536
   Liu X, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.458
   Liu X, 2012, IMMUNOL LETT, V143, P208, DOI 10.1016/j.imlet.2012.02.014
   Low-Marchelli JM, 2013, CANCER RES, V73, P662, DOI 10.1158/0008-5472.CAN-12-0653
   Maestro R, 1999, GENE DEV, V13, P2207, DOI 10.1101/gad.13.17.2207
   Murayama A, 2006, EMBO J, V25, P1081, DOI 10.1038/sj.emboj.7601012
   Naugler WE, 2008, CURR OPIN GENET DEV, V18, P19, DOI 10.1016/j.gde.2008.01.020
   O'Connell RM, 2007, P NATL ACAD SCI USA, V104, P1604, DOI 10.1073/pnas.0610731104
   Pham CG, 2007, MOL CELL BIOL, V27, P3920, DOI 10.1128/MCB.01219-06
   Shiota M, 2012, CANCER RES, V72, P5261, DOI 10.1158/0008-5472.CAN-12-0254
   Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138
   Sonkoly E, 2011, MUTAT RES-FUND MOL M, V717, P46, DOI 10.1016/j.mrfmmm.2011.02.002
   Sosic D, 2003, CELL, V112, P169, DOI 10.1016/S0092-8674(03)00002-3
   Sun T, 2010, HEPATOLOGY, V51, P545, DOI 10.1002/hep.23311
   Sutcliffe S, 2006, CANCER EPIDEM BIOMAR, V15, P2160, DOI 10.1158/1055-9965.EPI-05-0913
   Tili E, 2007, J IMMUNOL, V179, P5082, DOI 10.4049/jimmunol.179.8.5082
   Tili E, 2013, IMMUNOL REV, V253, P167, DOI 10.1111/imr.12050
   Tili E, 2011, J NUCLEIC ACIDS, V2011, DOI 10.4061/2011/102431
   van Leenders GJLH, 2003, AM J PATHOL, V162, P1529, DOI 10.1016/S0002-9440(10)64286-1
   Vesuna F, 2012, ONCOGENE, V31, P3223, DOI 10.1038/onc.2011.483
   Vesuna F, 2009, NEOPLASIA, V11, P1318, DOI 10.1593/neo.91084
   Wang H, 2012, GENOME RES, V22, P1680, DOI 10.1101/gr.136101.111
   Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006
   Yang MH, 2008, NAT CELL BIOL, V10, P295, DOI 10.1038/ncb1691
   Yuen HF, 2007, HISTOPATHOLOGY, V50, P648, DOI 10.1111/j.1365-2559.2007.02665.x
   Yuen HF, 2008, CARCINOGENESIS, V29, P1509, DOI 10.1093/carcin/bgn105
   Zhao X, 2016, ONCOTARGET, V7, P33136, DOI 10.18632/oncotarget.8887
   Zhu X, 2016, ONCOGENE, V35, P323, DOI 10.1038/onc.2015.84
NR 50
TC 15
Z9 15
U1 0
U2 6
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 2157-9024
J9 ONCOGENESIS
JI Oncogenesis
PD APR
PY 2017
VL 6
AR e315
DI 10.1038/oncsis.2017.16
PG 14
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA EU5XK
UT WOS:000401107400009
PM 28394356
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU Qin, YZ
   Zhang, YH
   Qin, XY
   Zhu, HH
AF Qin, Ya-Zhen
   Zhang, Yan-Huan
   Qin, Xiao-Ying
   Zhu, Hong-Hu
TI Methylation pattern of preferentially expressed antigen of melanoma in
   acute myeloid leukemia and myelodysplastic syndromes
SO ONCOLOGY LETTERS
LA English
DT Article
DE preferentially expressed antigen of melanoma; methylation; acute myeloid
   leukemia 1-eight-twenty one; acute myeloid leukemia; myelodysplastic
   syndromes; bisulfate sequencing
ID MINIMAL RESIDUAL DISEASE; CANCER-TESTIS ANTIGENS; EPIGENETIC REGULATION;
   PRAME EXPRESSION; GENE-EXPRESSION; CELL CARCINOMA; BREAST-CANCER;
   PROGNOSIS; HYPOMETHYLATION; MALIGNANCIES
AB Preferentially expressed antigen of melanoma (PRAME), a tumor-associated antigen, is overexpressed in a variety of hematologic malignancies with a great variation in expression. The majority of patients with acute myeloid leukemia (AML) 1-eight-twenty one (ETO)(+) AML and a certain number of myelodysplastic syndromes (MDS) have an abnormally high increase in PRAME expression level. The landscape of PRAME methylation requires evaluation in order to determine the most relevant sites and the exact association of its methylation with expression level and type of disease. In the present study, bone marrow samples collected from 8 AML1-ETO+ AML, 4 MDS, 3 AML1-ETO-AML and 2 normal volunteers underwent bisulfate sequencing to analyze the methylation status of all four 5'-C-phosphate-G-3' (CpG) regions within the entire PRAME gene. The median PRAME transcript level of 15 patients was 204.5% (range, 0.02-710.3%). PRAME transcript levels were inversely associated with the degree of methylation of the -389 to -146 CpG sites (r=-0.69; P=0.002) in the 3' part of the promoter region and the + 132 to + 363 CpG sites (r=-0.69; P=0.006) in the exon 1b region. However, not every sample strictly followed this correlation: Certain samples with high degrees of methylation demonstrated abnormally high expression levels, and vice versa. The methylation ratios of CpG sites in exon 1a were low for all samples (range, 0.0-13.8%), and those in exon 2 were similar in 16 samples (range, 72.4-93.4%), with the exception of one patient with high expression (425.2%) and significantly low degree of methylation in the PRAME gene (22.2%). MDS patients revealed similar methylation ratios in the 3' section of the promoter region, but tended to have lower methylation ratios in the exon 1b region (P=0.62 and P=0.09, respectively) compared with those observed in AML1-ETO+ patients with AML and similar degree of PRAME overexpression. Therefore, the hypomethylation of CpG sites in the 3' part of the promoter region and in exon 1b was typically found with PRAME overexpression in AML and MDS. Methylation of other CpG islands, epigenetic and genetic mechanisms, and type of disease may also be involved.
C1 [Qin, Ya-Zhen; Zhang, Yan-Huan; Qin, Xiao-Ying; Zhu, Hong-Hu] Peking Univ, Inst Hematol, Peking Univ Peoples Hosp, Dept Hematol, 11 Xizhimen South St, Beijing 100044, Peoples R China.
C3 Peking University
RP Qin, YZ (通讯作者)，Peking Univ, Inst Hematol, Peking Univ Peoples Hosp, Dept Hematol, 11 Xizhimen South St, Beijing 100044, Peoples R China.
EM qin2000@aliyun.com
FU Nature Science Foundation of China [81170483, 81570130, 81370639]
FX The present study was supported by the Nature Science Foundation of
   China (grant nos. 81170483, 81570130 and 81370639).
CR Abdelmalak CA, 2014, CLIN LAB, V60, P55, DOI 10.7754/Clin.Lab.2013.121137
   Atanackovic D, 2011, AM J HEMATOL, V86, P918, DOI 10.1002/ajh.22141
   Beillard E, 2003, LEUKEMIA, V17, P2474, DOI 10.1038/sj.leu.2403136
   Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102
   Epping MT, 2005, CELL, V122, P835, DOI 10.1016/j.cell.2005.07.003
   GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9
   Gutierrez-Cosío S, 2012, LEUKEMIA RES, V36, P895, DOI 10.1016/j.leukres.2012.02.030
   Ikeda H, 1997, IMMUNITY, V6, P199, DOI 10.1016/S1074-7613(00)80426-4
   Li YS, 2014, HUM MOL GENET, V23, P5378, DOI 10.1093/hmg/ddu256
   Liberante FG, 2013, BRIT J HAEMATOL, V162, P282, DOI 10.1111/bjh.12352
   Luetkens T, 2010, LEUKEMIA RES, V34, P1647, DOI 10.1016/j.leukres.2010.03.039
   Meklat F, 2007, BRIT J HAEMATOL, V136, P769, DOI 10.1111/j.1365-2141.2006.06484.x
   Murr R, 2010, ADV GENET, V70, P101, DOI [10.1016/S0065-2660(10)70005-5, 10.1016/B978-0-12-380866-0.60005-8]
   Neumann E, 1998, CANCER RES, V58, P4090
   Ortmann CA, 2008, ANN HEMATOL, V87, P809, DOI 10.1007/s00277-008-0514-8
   Pampalakis G, 2006, BIOL CHEM, V387, P773, DOI 10.1515/BC.2006.097
   Proto-Siqueira R, 2003, LEUKEMIA RES, V27, P393, DOI 10.1016/S0145-2126(02)00217-5
   Qin YZ, 2013, LEUKEMIA LYMPHOMA, V54, P1442, DOI 10.3109/10428194.2012.743656
   Qin YZ, 2014, CHINESE MED J-PEKING, V127, P1666, DOI 10.3760/cma.j.issn.0366-6999.20132356
   Qin YZ, 2009, LEUKEMIA RES, V33, P384, DOI 10.1016/j.leukres.2008.08.026
   Radich JP, 2006, P NATL ACAD SCI USA, V103, P2794, DOI 10.1073/pnas.0510423103
   Roman-Gomez O, 2007, LEUKEMIA RES, V31, P1521, DOI 10.1016/j.leukres.2007.02.016
   Santamaría C, 2008, HAEMATOL-HEMATOL J, V93, P1797, DOI 10.3324/haematol.13214
   Santamaría CM, 2009, BLOOD, V114, P148, DOI 10.1182/blood-2008-11-187724
   Schenk T, 2007, GENE CHROMOSOME CANC, V46, P796, DOI 10.1002/gcc.20465
   Seven D, 2015, GENE, V563, P83, DOI 10.1016/j.gene.2015.03.004
   Steinbach D, 2015, CLIN CANCER RES, V21, P1353, DOI 10.1158/1078-0432.CCR-14-1999
   Swerdlow S.H., 2008, MYELODYSPLASTIC SYND, V4, P87, DOI DOI 10.1016/j.drudis.2012.07.013
   Tajeddine N, 2005, CANCER RES, V65, P7348, DOI 10.1158/0008-5472.CAN-04-4011
   Tanaka N, 2011, LEUKEMIA RES, V35, P1219, DOI 10.1016/j.leukres.2011.04.005
   van Baren N, 1998, BRIT J HAEMATOL, V102, P1376
   You JS, 2012, CANCER CELL, V22, P9, DOI 10.1016/j.ccr.2012.06.008
NR 32
TC 3
Z9 3
U1 0
U2 1
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1792-1074
EI 1792-1082
J9 ONCOL LETT
JI Oncol. Lett.
PD APR
PY 2017
VL 13
IS 4
BP 2823
EP 2830
DI 10.3892/ol.2017.5790
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA GO1FM
UT WOS:000439694700001
PM 28454473
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Wu, Y
   Wang, Z
   Zhang, J
   Ling, R
AF Wu, Ying
   Wang, Zhe
   Zhang, Jian
   Ling, Rui
TI Elevated expression of protein arginine methyltransferase 5 predicts the
   poor prognosis of breast cancer
SO TUMOR BIOLOGY
LA English
DT Article
DE Breast cancer; protein arginine methyltransferase 5; proliferation; cell
   cycle progression; apoptosis
ID TUMOR-GROWTH; PRMT5; METHYLATION
AB Protein arginine methyltransferase 5 is one of the type II protein arginine methyltransferase family members that can symmetrically dimethylate arginine residues on target proteins in both the cytoplasm and the nucleus. Protein arginine methyltransferase 5 was reported to be an oncoprotein that participates in tumor progression through both epigenetic silencing and organelle biogenesis. So far, it has been implicated in various cancers, but its expression pattern in breast cancer has not been elucidated thoroughly. We analyzed the protein arginine methyltransferase 5 expression patterns in several breast cancer samples and tissue arrays to better characterize its contribution to breast cancer. Primary breast tumors showed increased protein arginine methyltransferase 5 expression compared with adjacent normal tissues in both the fresh tissue samples and tissue arrays. Also, there was a tendency that metastatic lymph nodes demonstrated enhanced protein arginine methyltransferase 5 expression compared to primary sites. Moreover, we found a significant correlation between protein arginine methyltransferase 5 and Ki-67, with higher Ki-67 and protein arginine methyltransferase 5 expressions in primary breast tumors compared with normal breast tissues. Moreover, the Cancer Genome Atlas cohort analysis revealed that high protein arginine methyltransferase 5 messenger RNA expression was associated with an unfavorable prognosis in human epidermal growth factor receptor 2 (HER-2) positive and triple negative breast cancer patients. Finally, the roles and mechanisms of protein arginine methyltransferase 5 in the proliferation, cell cycle progression, and apoptosis of MDA-MB-231 cells were assessed using protein arginine methyltransferase 5 and shPRMT5 transfection. In conclusion, we proposed that protein arginine methyltransferase 5 is an independent prognostic biomarker for breast cancer, and targeting protein arginine methyltransferase 5 might be a promising strategy for breast cancer treatment.
C1 [Wu, Ying; Wang, Zhe; Ling, Rui] Fourth Mil Med Univ, Dept Thyroid Breast & Vasc Surg, Xijing Hosp, Xian 710032, Shaanxi, Peoples R China.
   [Zhang, Jian] Fourth Mil Med Univ, State Key Lab Canc Biol, Dept Biochem & Mol Biol, Xian 710032, Shaanxi, Peoples R China.
C3 Air Force Military Medical University; Air Force Military Medical
   University
RP Ling, R (通讯作者)，Fourth Mil Med Univ, Dept Thyroid Breast & Vasc Surg, Xijing Hosp, Xian 710032, Shaanxi, Peoples R China.; Zhang, J (通讯作者)，Fourth Mil Med Univ, State Key Lab Canc Biol, Dept Biochem & Mol Biol, Xian 710032, Shaanxi, Peoples R China.
EM biozhangj@hotmail.com; lingrui0105@126.com
FU Social Development Research Project in Shaanxi province
   [2014K11-01-02-01]
FX This work was funded by research grants from the Social Development
   Research Project (No. 2014K11-01-02-01) in Shaanxi province.
CR Ali-Fehmi R, 2003, CANCER-AM CANCER SOC, V98, P1423, DOI 10.1002/cncr.11650
   Bao XX, 2013, J HISTOCHEM CYTOCHEM, V61, P206, DOI 10.1369/0022155413475452
   Bedford MT, 2009, MOL CELL, V33, P1, DOI 10.1016/j.molcel.2008.12.013
   Charboneau AL, 2002, INT J CANCER, V100, P181, DOI 10.1002/ijc.10470
   Chen H, 2017, ONCOGENE, V36, P373, DOI 10.1038/onc.2016.205
   De Luca A, 2012, EXPERT OPIN THER TAR, V16, pS17, DOI 10.1517/14728222.2011.639361
   Fan L, 2014, LANCET ONCOL, V15, pE279, DOI 10.1016/S1470-2045(13)70567-9
   Gewefel H, 2014, CLIN BREAST CANCER, V14, P390, DOI 10.1016/j.clbc.2014.06.002
   Goto N, 2014, J CANCER, V5, P336, DOI 10.7150/jca.7202
   Jiang W, 2005, BIOCHEM BIOPH RES CO, V329, P522, DOI 10.1016/j.bbrc.2005.01.153
   Karkhanis V, 2011, TRENDS BIOCHEM SCI, V36, P633, DOI 10.1016/j.tibs.2011.09.001
   Lee YH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124853
   Li JH, 2014, NUCLEIC ACIDS RES, V42, pD92, DOI 10.1093/nar/gkt1248
   Liu HJ, 2016, J BIOL CHEM, V291, P17258, DOI 10.1074/jbc.M116.743401
   Lu T, 2015, CANCER RES, V75, P3692, DOI 10.1158/0008-5472.CAN-15-1022
   Mongiardi MP, 2015, SCI REP-UK, V5, DOI 10.1038/srep15494
   Montagut C, 2009, CANCER LETT, V283, P125, DOI 10.1016/j.canlet.2009.01.022
   Pahlich S, 2006, BBA-PROTEINS PROTEOM, V1764, P1890, DOI 10.1016/j.bbapap.2006.08.008
   Pal S, 2004, MOL CELL BIOL, V24, P9630, DOI 10.1128/MCB.24.21.9630-9645.2004
   Pizzo SV, 2013, PLOS ONE, V8
   Powers MA, 2011, CANCER RES, V71, P5579, DOI 10.1158/0008-5472.CAN-11-0458
   Rastetter RH, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1645-7
   Risueño A, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-221
   Stopa N, 2015, CELL MOL LIFE SCI, V72, P2041, DOI 10.1007/s00018-015-1847-9
   Tan L, 2016, ONCOTARGET, V7, P46589, DOI 10.18632/oncotarget.10306
   Wei TYW, 2012, CANCER SCI, V103, P1640, DOI 10.1111/j.1349-7006.2012.02367.x
   Xu P, 2016, APOPTOSIS, V21, P1125, DOI 10.1007/s10495-016-1270-1
   Yan FT, 2014, CANCER RES, V74, P1752, DOI 10.1158/0008-5472.CAN-13-0884
   Yang F, 2015, TUMOR BIOL, V36, P5901, DOI 10.1007/s13277-015-3262-0
   Zhang BL, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0721-8
   Zhou KN, 2011, CHINESE MED J-PEKING, V124, P2321, DOI 10.3760/cma.j.issn.0366-6999.2011.15.014
NR 31
TC 38
Z9 40
U1 0
U2 6
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD APR
PY 2017
VL 39
IS 4
AR 695917
DI 10.1177/1010428317695917
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA ET4QD
UT WOS:000400268800018
PM 28381188
OA gold
DA 2025-01-12
ER

PT J
AU Bagu, ET
   Miah, S
   Dai, CL
   Spriggs, T
   Ogunbolude, Y
   Beaton, E
   Sanders, M
   Goel, RK
   Bonham, K
   Lukong, KE
AF Bagu, Edward T.
   Miah, Sayem
   Dai, Chenlu
   Spriggs, Travis
   Ogunbolude, Yetunde
   Beaton, Erika
   Sanders, Michelle
   Goel, Raghuveera K.
   Bonham, Keith
   Lukong, Kiven E.
TI Repression of Fyn-related kinase in breast cancer cells is associated
   with promoter site-specific CpG methylation
SO ONCOTARGET
LA English
DT Article
DE fyn-related kinase; FRK; BRK; breast cancer; triple negative breast
   cancer
ID HISTONE DEACETYLASE INHIBITOR; NONRECEPTOR TYROSINE KINASE; DNA-BINDING
   SPECIFICITY; HUMAN GLIOMA-CELLS; TUMOR-SUPPRESSOR; EXPRESSION;
   5-AZA-2'-DEOXYCYTIDINE; FAMILY; RAK; GATA
AB The triple-negative breast cancer subtype is highly aggressive and has no defined therapeutic target. Fyn-related kinase (FRK) is a non-receptor tyrosine kinase, reported to be downregulated in breast cancer and gliomas, where it is suggested to have tumor suppressor activity. We examined the expression profile of FRK in a panel of 40 breast cancer cells representing all the major subtypes, as well as in 4 non-malignant mammary epithelial cell lines. We found that FRK expression was significantly repressed in a proportion of basal B breast cancer cell lines. We then determined the mechanism of suppression of FRK in FRK-low or negative cell lines. In silico analyses of the FRK promoter region led to the identification of at least 17 CpG sites. Bisulphite sequencing of the promoter region revealed that two of these sites were consistently methylated in FRK-low/negative cell lines and especially in the basal B breast cancer subtype. We further show that treatment of these cells with histone deacetylase inhibitors, Entinostat and Mocetinostat' promoted re-expression of FRK mRNA and protein. Further, using luciferase reporter assays, we show that both GATA3-binding protein FOG1 and constitutively active STAT5A increased the activity of FRK promoter. Together, our results present the first evidence that site-specific promoter methylation contributes to the repression of FRK more so in basal B breast cancers. Our study also highlights the potential clinical significance of targeting FRK using epigenetic drugs specifically in basal B breast cancers which are usually triple negative and very aggressive.
C1 [Bagu, Edward T.; Miah, Sayem; Dai, Chenlu; Spriggs, Travis; Ogunbolude, Yetunde; Beaton, Erika; Sanders, Michelle; Goel, Raghuveera K.; Bonham, Keith; Lukong, Kiven E.] Univ Saskatchewan, Dept Biochem, Coll Med, Saskatoon, SK S7N 5E5, Canada.
   [Bagu, Edward T.; Beaton, Erika; Sanders, Michelle; Bonham, Keith] Univ Saskatchewan, Canc Res Unit, Hlth Res Div, Saskatchewan Canc Agcy, Saskatoon, SK S7N 4H4, Canada.
   [Bagu, Edward T.; Beaton, Erika; Sanders, Michelle; Bonham, Keith] Univ Saskatchewan, Div Oncol, Coll Med, Saskatoon, SK S7N 4H4, Canada.
   [Miah, Sayem] Stowers Inst Med Res, Kansas City, MO 64110 USA.
C3 University of Saskatchewan; University of Saskatchewan; University of
   Saskatchewan; Stowers Institute for Medical Research
RP Lukong, KE (通讯作者)，Univ Saskatchewan, Dept Biochem, Coll Med, Saskatoon, SK S7N 5E5, Canada.
EM kiven.lukong@usask.ca
RI Bagu, Edward/U-1319-2017; Goel, Raghuveera/HKW-8545-2023
OI Goel, Raghuveera/0000-0001-7348-3996
FU Saskatchewan Cancer Agency; Prairie/NWT Region Canadian Breast Cancer
   Foundation; CIHR; University of Saskatchewan
FX This work was supported by grants from the Saskatchewan Cancer Agency
   and Prairie/NWT Region Canadian Breast Cancer Foundation (KB and KEL).
   The trainees, SM, CD, TS, and RKG, were funded by the trainee grant CIHR
   (KEL) while EB and MS were beneficiaries of graduate fellowships from
   the University of Saskatchewan.
CR Annerén C, 2000, GROWTH FACTORS, V17, P233, DOI 10.3109/08977190009028969
   Bagu ET, 2013, BIOMETALS, V26, P1051, DOI 10.1007/s10534-013-9683-6
   Berclaz G, 2000, INT J CANCER, V85, P889
   Bovenzi V, 2001, CANCER CHEMOTH PHARM, V48, P71, DOI 10.1007/s002800100294
   Brauer PM, 2009, CELL CYCLE, V8, P2728, DOI 10.4161/cc.8.17.9389
   CANCE WG, 1994, CELL GROWTH DIFFER, V5, P1347
   Cantor AB, 2005, SEMIN CELL DEV BIOL, V16, P117, DOI 10.1016/j.semcdb.2004.10.006
   Carey L, 2010, NAT REV CLIN ONCOL, V7, P683, DOI 10.1038/nrclinonc.2010.154
   Ceccacci E, 2016, BRIT J CANCER, V114, P605, DOI 10.1038/bjc.2016.36
   Chandrasekharan S, 2002, MOL CELL BIOL, V22, P5235, DOI 10.1128/MCB.22.14.5235-5247.2002
   Choi JH, 2007, BIOCHEM BIOPH RES CO, V361, P615, DOI 10.1016/j.bbrc.2007.07.051
   Choi JH, 2010, BIOCHEM BIOPH RES CO, V391, P449, DOI 10.1016/j.bbrc.2009.11.078
   Christman JK, 2002, ONCOGENE, V21, P5483, DOI 10.1038/sj.onc.1205699
   Connolly R, 2012, J MAMMARY GLAND BIOL, V17, P191, DOI 10.1007/s10911-012-9263-3
   CRAVEN RJ, 1995, CANCER RES, V55, P3969
   Devereux TR, 1999, CANCER RES, V59, P6087
   Ehret GB, 2001, J BIOL CHEM, V276, P6675, DOI 10.1074/jbc.M001748200
   Esteller M, 2002, ONCOGENE, V21, P5427, DOI 10.1038/sj.onc.1205600
   Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210
   Fraczek J, 2013, EXPERT OPIN DRUG MET, V9, P441, DOI 10.1517/17425255.2013.754011
   Franceschini A, 2013, NUCLEIC ACIDS RES, V41, pD808, DOI 10.1093/nar/gks1094
   Goel RK, 2016, CANCER METAST REV, V35, P179, DOI 10.1007/s10555-016-9623-3
   Goel RK, 2015, BBA-REV CANCER, V1856, P39, DOI 10.1016/j.bbcan.2015.05.001
   Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075
   Holliday DL, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2889
   Hua L, 2014, J NEURO-ONCOL, V119, P49, DOI 10.1007/s11060-014-1461-y
   Huang WY, 2015, NUCLEIC ACIDS RES, V43, pD856, DOI 10.1093/nar/gku1151
   Jin L, 2014, ONCOGENE, V33, P326, DOI 10.1038/onc.2012.589
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Kao J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006146
   Kim JE, 2015, ONCOTARGET
   Kulis M, 2010, ADV GENET, V70, P27, DOI [10.1016/S0065-2660(10)70002-X, 10.1016/B978-0-12-380866-0.60002-2]
   Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427
   Lustberg MB, 2009, DRUG NEWS PERSPECT, V22, P369, DOI 10.1358/dnp.2009.22.7.1405072
   Marks PA, 2010, BBA-GENE REGUL MECH, V1799, P717, DOI 10.1016/j.bbagrm.2010.05.008
   Meric F, 2002, CLIN CANCER RES, V8, P361
   MERIKA M, 1993, MOL CELL BIOL, V13, P3999, DOI 10.1128/MCB.13.7.3999
   Meyer T, 2003, INT J CANCER, V104, P139, DOI 10.1002/ijc.10925
   Miah S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087684
   Moarii M, 2015, BMC GENOMICS, V16, DOI 10.1186/s12864-015-1994-2
   Momparler RL, 2005, SEMIN ONCOL, V32, P443, DOI 10.1053/j.seminoncol.2005.07.008
   Momparler RL, 2005, SEMIN HEMATOL, V42, pS9, DOI 10.1053/j.seminhematol.2005.05.002
   Öberg-Welsh C, 1998, GROWTH FACTORS, V16, P111
   Onishi M, 1998, MOL CELL BIOL, V18, P3871, DOI 10.1128/MCB.18.7.3871
   Pajer P, 2009, CANCER RES, V69, P4605, DOI 10.1158/0008-5472.CAN-08-4636
   Rabinovich A, 2008, GENOME RES, V18, P1763, DOI 10.1101/gr.080622.108
   Robert NM, 2002, ENDOCRINOLOGY, V143, P3963, DOI 10.1210/en.2002-220280
   Rodríguez-Paredes M, 2011, NAT MED, V17, P330, DOI 10.1038/nm.2305
   Saito A, 1999, P NATL ACAD SCI USA, V96, P4592, DOI 10.1073/pnas.96.8.4592
   Sarkar S, 2011, ANTICANCER RES, V31, P2723
   Schmelz K, 2005, INT J CANCER, V114, P683, DOI 10.1002/ijc.20797
   Serfas MS, 2003, ONCOL RES, V13, P409
   Sheng ZM, 1996, BRIT J CANCER, V73, P144, DOI 10.1038/bjc.1996.27
   Shi Q, 2015, J MOL NEUROSCI, V55, P32, DOI 10.1007/s12031-014-0355-y
   Soldaini E, 2000, MOL CELL BIOL, V20, P389, DOI 10.1128/MCB.20.1.389-401.2000
   Vanselow J, 2006, J MOL ENDOCRINOL, V37, P463, DOI 10.1677/jme.1.02131
   VetteseDadey M, 1996, EMBO J, V15, P2508, DOI 10.1002/j.1460-2075.1996.tb00608.x
   Wu LP, 2008, MOL CELL BIOL, V28, P3219, DOI 10.1128/MCB.01516-07
   Yan WJ, 2014, J CELL MOL MED, V18, P2499, DOI 10.1111/jcmm.12325
   Yim EK, 2009, CELL CYCLE, V8, P2360, DOI 10.4161/cc.8.15.9264
   Yim EK, 2009, CANCER CELL, V15, P304, DOI 10.1016/j.ccr.2009.02.012
   Yuan YF, 2001, CANCER RES, V61, P5558
   Zhu WG, 2001, ONCOGENE, V20, P7787, DOI 10.1038/sj.onc.1204970
NR 63
TC 10
Z9 10
U1 0
U2 4
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD FEB 14
PY 2017
VL 8
IS 7
BP 11442
EP 11459
DI 10.18632/oncotarget.14546
PG 18
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA EK8QB
UT WOS:000394187400066
PM 28077797
OA Green Submitted, Green Published, gold
DA 2025-01-12
ER

PT J
AU Espinal, AC
   Wang, D
   Yan, L
   Liu, S
   Tang, L
   Hu, Q
   Morrison, CD
   Ambrosone, CB
   Higgins, MJ
   Sucheston-Campbell, LE
AF Espinal, Allyson C.
   Wang, Dan
   Yan, Li
   Liu, Song
   Tang, Li
   Hu, Qiang
   Morrison, Carl D.
   Ambrosone, Christine B.
   Higgins, Michael J.
   Sucheston-Campbell, Lara E.
TI A methodological study of genome-wide DNA methylation analyses using
   matched archival formalin-fixed paraffin embedded and fresh frozen
   breast tumors
SO ONCOTARGET
LA English
DT Article
DE DNA methylation/epigenetics; breast cancer; estrogen receptor negative
ID CANCER; AMERICAN; AFRICAN; EVENTS; PROBES
AB Background: DNA from archival formalin-fixed and paraffin embedded (FFPE) tissue is an invaluable resource for genome-wide methylation studies although concerns about poor quality may limit its use. In this study, we compared DNA methylation profiles of breast tumors using DNA from fresh-frozen (FF) tissues and three types of matched FFPE samples.
   Results: For 9/10 patients, correlation and unsupervised clustering analysis revealed that the FF and FFPE samples were consistently correlated with each other and clustered into distinct subgroups. Greater than 84% of the top 100 loci previously shown to differentiate ER+ and ER- tumors in FF tissues were also FFPE DML. Weighted Correlation Gene Network Analyses (WCGNA) grouped the DML loci into 16 modules in FF tissue, with similar to 85% of the module membership preserved across tissue types.
   Materials and Methods: Restored FFPE and matched FF samples were profiled using the Illumina Infinium HumanMethylation450K platform. Methylation levels (beta-values) across all loci and the top 100 loci previously shown to differentiate tumors by estrogen receptor status (ER+ or ER-) in a larger FF study, were compared between matched FF and FFPE samples using Pearson's correlation, hierarchical clustering and WCGNA. Positive predictive values and sensitivity levels for detecting differentially methylated loci (DML) in FF samples were calculated in an independent FFPE cohort.
   Conclusions: FFPE breast tumors samples show lower overall detection of DMLs versus FF, however FFPE and FF DMLs compare favorably. These results support the emerging consensus that the 450K platform can be employed to investigate epigenetics in large sets of archival FFPE tissues.
C1 [Espinal, Allyson C.; Higgins, Michael J.] Roswell Pk Canc Inst, Dept Mol & Cell Biol, Buffalo, NY 14263 USA.
   [Wang, Dan; Yan, Li; Liu, Song; Hu, Qiang] Roswell Pk Canc Inst, Dept Biostat, Buffalo, NY 14263 USA.
   [Tang, Li] Roswell Pk Canc Inst, Dept Canc Prevent & Control, Buffalo, NY 14263 USA.
   [Morrison, Carl D.; Ambrosone, Christine B.] Roswell Pk Canc Inst, Dept Pathol, Buffalo, NY 14263 USA.
   [Sucheston-Campbell, Lara E.] Ohio State Univ, Coll Pharm, Columbus, OH 43210 USA.
   [Sucheston-Campbell, Lara E.] Ohio State Univ, Coll Vet Med, Dept Vet Biosci, Columbus, OH 43210 USA.
C3 Roswell Park Comprehensive Cancer Center; Roswell Park Comprehensive
   Cancer Center; Roswell Park Comprehensive Cancer Center; Roswell Park
   Comprehensive Cancer Center; University System of Ohio; Ohio State
   University; University System of Ohio; Ohio State University
RP Higgins, MJ (通讯作者)，Roswell Pk Canc Inst, Dept Mol & Cell Biol, Buffalo, NY 14263 USA.; Sucheston-Campbell, LE (通讯作者)，Ohio State Univ, Coll Pharm, Columbus, OH 43210 USA.; Sucheston-Campbell, LE (通讯作者)，Ohio State Univ, Coll Vet Med, Dept Vet Biosci, Columbus, OH 43210 USA.
EM Michael.Higgins@roswellpark.org; sucheston-campbell.1@osu.edu
RI Hu, Qiang/AAJ-9438-2020
FU National Institutes of Health/National Cancer Institute [R01 CA1332641];
   Breast Cancer Research Foundation
FX This work was supported by National Institutes of Health/National Cancer
   Institute (grant number R01 CA1332641) and the Breast Cancer Research
   Foundation to (CBA). The RPCI Pathology Resource Network, the Clinical
   Data Network, and the Genomics Core Facility are CCSG Shared Resources
   (NIH P30 CA016056-27).
CR Ambrosone CB, 2014, CANCER EPIDEM BIOMAR, V23, P1115, DOI 10.1158/1055-9965.EPI-14-0110
   Ambrosone CB, 2014, ONCOTARGET, V5, P237, DOI 10.18632/oncotarget.1599
   Ambrosone CB, 2009, J ONCOL, V2009, DOI 10.1155/2009/871250
   Blair JD, 2012, AM J HUM GENET, V91, P760, DOI 10.1016/j.ajhg.2012.05.028
   Chen YA, 2013, EPIGENETICS-US, V8, P203, DOI 10.4161/epi.23470
   Cheng CY, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000490
   de Ruijter TC, 2015, LAB INVESTIGATION
   Dumenil TD, 2014, GENE CHROMOSOME CANC, V53, P537, DOI 10.1002/gcc.22164
   Feinberg AP, 2007, NATURE, V447, P433, DOI 10.1038/nature05919
   Hansen KD, 2011, NAT GENET, V43, P768, DOI 10.1038/ng.865
   Jasmine Farzana, 2012, BMC Res Notes, V5, P117, DOI 10.1186/1756-0500-5-117
   Johnson WE, 2007, BIOSTATISTICS, V8, P118, DOI 10.1093/biostatistics/kxj037
   Kelemen LE, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/815894
   Langfelder P, 2011, PLOS COMPUT BIOL, V7, DOI 10.1371/journal.pcbi.1001057
   Leek JT, 2012, BIOINFORMATICS, V28, P882, DOI 10.1093/bioinformatics/bts034
   Maksimovic J, 2012, GENOME BIOL, V13, DOI 10.1186/gb-2012-13-6-r44
   Mckay JA, 2011, ACTA PHYSIOL, V202, P103, DOI 10.1111/j.1748-1716.2011.02278.x
   Moran S, 2014, EPIGENETICS, V9
   Sasaki H, 2008, NAT REV GENET, V9, P129, DOI 10.1038/nrg2295
   Thirlwell C, 2010, METHODS, V52, P248, DOI 10.1016/j.ymeth.2010.04.012
   Vaissiere T, 2009, CANCER RES, V69, P243, DOI 10.1158/0008-5472.CAN-08-2489
   Yan L, 2012, BMC GENOMICS, V13, DOI 10.1186/1471-2164-13-689
   Zhang Xu, 2012, Frontiers in Genetics, V3, P73, DOI 10.3389/fgene.2012.00073
NR 23
TC 8
Z9 8
U1 2
U2 6
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD FEB 28
PY 2017
VL 8
IS 9
BP 14821
EP 14829
DI 10.18632/oncotarget.14739
PG 9
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA EN4YV
UT WOS:000396013700049
PM 28118602
OA Green Published, Green Submitted, gold
DA 2025-01-12
ER

PT J
AU Li, J
   Chen, YB
   Yu, HY
   Tian, JS
   Yuan, FS
   Fan, JL
   Liu, YP
   Zhu, L
   Wang, F
   Zhao, YS
   Pang, D
AF Li, Jing
   Chen, Yanbo
   Yu, Hongyuan
   Tian, Jingshen
   Yuan, Fengshun
   Fan, Jialong
   Liu, Yupeng
   Zhu, Lin
   Wang, Fan
   Zhao, Yashuang
   Pang, Da
TI <i>DUSP1</i> promoter methylation in peripheral blood leukocyte is
   associated with triple-negative breast cancer risk
SO SCIENTIFIC REPORTS
LA English
DT Article
ID PROTEIN-KINASE PHOSPHATASE-1; CELL-FREE DNA; ESTROGEN-RECEPTOR;
   HORMONE-RECEPTOR; EXPRESSION; TUMOR; GENES; MKP-1; PROGESTERONE;
   BIOMARKER
AB DNA methylation is one of the most common epigenetic alterations, providing important information regarding cancer risk and prognosis. A case-control study (423 breast cancer cases, 509 controls) and a case-only study (326 cases) were conducted to evaluate the association of DUSP1 promoter methylation with breast cancer risk and clinicopathological characteristics. No significant association between DUSP1 methylation in peripheral blood leukocyte (PBL) DNA and breast cancer risk was observed. DUSP1 methylation was significantly associated with ER/PR-negative status; in particular, triple-negative breast cancer patients showed the highest frequency of DUSP1 methylation in both tumour DNA and PBL DNA. Soybean intake was significantly correlated with methylated DUSP1 only in ER-negative (OR 2.978; 95% CI 1.245-7.124) and PR negative (OR 2.735; 95% CI 1.315-5.692) patients. Irregular menstruation was significantly associated with methylated DUSP1 only in ER-positive (OR 3.564; 95% CI 1.691-7.511) and PR-positive (OR 3.902, 95% CI 1.656-9.194) patients. Thus, DUSP1 methylation is a cancer-associated hypermethylation event that is closely linked with triple-negative status. Further investigations are warranted to confirm the association of environmental factors, including fruit and soybean intake, irregular menstruation, and ER/PR status, with DUSP1 methylation in breast tumour DNA.
C1 [Li, Jing; Yu, Hongyuan; Tian, Jingshen; Yuan, Fengshun; Fan, Jialong; Liu, Yupeng; Zhu, Lin; Wang, Fan; Zhao, Yashuang] Harbin Med Univ, Sch Publ Hlth, Dept Epidemiol, Harbin, Heilongjiang Pr, Peoples R China.
   [Chen, Yanbo; Pang, Da] Harbin Med Univ, Affiliated Tumor Hosp, Dept Breast Surg, Harbin, Heilongjiang Pr, Peoples R China.
C3 Harbin Medical University; Harbin Medical University
RP Wang, F; Zhao, YS (通讯作者)，Harbin Med Univ, Sch Publ Hlth, Dept Epidemiol, Harbin, Heilongjiang Pr, Peoples R China.; Pang, D (通讯作者)，Harbin Med Univ, Affiliated Tumor Hosp, Dept Breast Surg, Harbin, Heilongjiang Pr, Peoples R China.
EM yifan.701@163.com; zhao_yashuang@263.net; pangda@ems.hrbmu.edu.cn
RI Wang, Fan/I-6099-2019; Yuan, Fengshun/GSD-9503-2022; Liu,
   YuPeng/P-3181-2018
OI Wang, Fan/0000-0002-9869-9504; Liu, YuPeng/0000-0002-8652-1987
FU National Nature Science Foundation of China [81202262, 81172743];
   Postdoctoral Science Foundation of China [2013T60390]; Educational
   Commission of Heilongjiang Province [12541340]; Science Foundation of
   Harbin Medical University [WLD-QN1106]
FX This work is funded by the grant from the National Nature Science
   Foundation of China (81202262), Postdoctoral Science Foundation of China
   (2013T60390), National Nature Science Foundation of China (81172743),
   and Educational Commission of Heilongjiang Province (12541340) and Dr.
   Wu Lien-the Science Foundation of Harbin Medical University
   (WLD-QN1106).
CR Adeyinka A, 2002, CLIN CANCER RES, V8, P1747
   Anderson LN, 2013, INT J CANCER, V132, P1683, DOI 10.1002/ijc.27788
   BAREL SD, 2015, CRITICAL REV FOOD SC
   Baylin SB, 2011, NAT REV CANCER, V11, P726, DOI 10.1038/nrc3130
   Bond CE, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1011-9
   Bosviel R, 2012, OMICS, V16, P235, DOI 10.1089/omi.2011.0105
   Buzdar AU, 2009, ANN ONCOL, V20, P993, DOI 10.1093/annonc/mdn739
   Chen CC, 2011, J BIOL CHEM, V286, P43091, DOI 10.1074/jbc.M111.295865
   Chen FM, 2012, EXP MOL MED, V44, P356, DOI 10.3858/emm.2012.44.5.040
   Chimonidou M, 2013, CLIN BIOCHEM, V46, P235, DOI 10.1016/j.clinbiochem.2012.09.015
   Chimonidou M, 2013, CLIN CHEM, V59, P270, DOI 10.1373/clinchem.2012.191551
   Cho YA, 2010, EUR J CLIN NUTR, V64, P924, DOI 10.1038/ejcn.2010.95
   Choi JY, 2009, CARCINOGENESIS, V30, P1889, DOI 10.1093/carcin/bgp143
   Christensen BC, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000602
   Dai Q, 2001, BRIT J CANCER, V85, P372, DOI 10.1054/bjoc.2001.1873
   Dunnwald LK, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1639
   Dutkowska A, 2016, ADV EXP MED BIOL, V878, P29, DOI 10.1007/5584_2015_159
   Fernandez SV, 2010, TOXICOL PATHOL, V38, P110, DOI 10.1177/0192623309354108
   Fu XY, 2014, BREAST CANCER RES, V16, DOI 10.1186/s13058-014-0430-x
   *GLOBOCAN, 2012, GLOBOCAN2012 ESTIMAT
   Guerrero-Preston R, 2014, ONCOL REP, V32, P505, DOI 10.3892/or.2014.3262
   Gutierrez MC, 2005, J CLIN ONCOL, V23, P2469, DOI 10.1200/JCO.2005.01.172
   Haddad SA, 2015, BREAST CANCER RES TR, V154, P145, DOI 10.1007/s10549-015-3594-x
   Han KK, 2002, OBSTET GYNECOL, V99, P389, DOI 10.1016/S0029-7844(01)01744-6
   HARLID S, 2016, ENV HLTH PERSPECT
   Holm K, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2590
   Hsiung DT, 2007, CANCER EPIDEM BIOMAR, V16, P108, DOI 10.1158/1055-9965.EPI-06-0636
   Issa JP, 2000, CURR TOP MICROBIOL, V249, P101
   Iwasaki M, 2009, BREAST CANCER RES TR, V116, P401, DOI 10.1007/s10549-008-0168-1
   Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43
   Kajabova V, 2013, TRANSL ONCOL, V6, P297, DOI 10.1593/tlo.13244
   Karsli-Ceppioglu Seher, 2015, Enzymes, V37, P193, DOI 10.1016/bs.enz.2015.05.004
   Kile ML, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013730
   Lee SJ, 2008, J AGR FOOD CHEM, V56, P2751, DOI 10.1021/jf073153f
   Li X, 2014, GENES BRAIN BEHAV, V13, P721, DOI 10.1111/gbb.12150
   Li ZB, 2015, BREAST CANCER RES TR, V149, P767, DOI 10.1007/s10549-015-3276-8
   Lim U, 2008, GASTROENTEROLOGY, V134, P47, DOI 10.1053/j.gastro.2007.10.013
   Lin YW, 2006, J BIOL CHEM, V281, P915, DOI 10.1074/jbc.M508720200
   Loda M, 1996, AM J PATHOL, V149, P1553
   Lokk K, 2014, GENOME BIOL, V15, DOI 10.1186/gb-2014-15-4-r54
   Marsit CJ, 2011, J CLIN ONCOL, V29, P1133, DOI 10.1200/JCO.2010.31.3577
   Maybin JA, 2011, ANN NY ACAD SCI, V1221, P88, DOI 10.1111/j.1749-6632.2011.05953.x
   McKay JA, 2011, MOL NUTR FOOD RES, V55, P1026, DOI 10.1002/mnfr.201100008
   Messina M, 2010, J NUTR, V140, p1350S, DOI 10.3945/jn.109.118315
   Mizuno R, 2004, J UROLOGY, V172, P723, DOI 10.1097/01.ju.0000124990.37563.00
   Montaño CM, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-8-r94
   Moore LE, 2008, LANCET ONCOL, V9, P359, DOI 10.1016/S1470-2045(08)70038-X
   OSHIMA A, 2016, BIOSCIENCE BIOTECHNO, P1
   Peethambaram P, 2013, ONCOLOGY-NY, V27, P442
   RADPOUR R, 2011, PLOS ONE, V6
   Rauhala HE, 2005, INT J CANCER, V117, P738, DOI 10.1002/ijc.21270
   Sayar N, 2015, CLIN EPIGENETICS, V7, DOI 10.1186/s13148-015-0138-5
   Shimada K, 2007, AM J PATHOL, V171, P1003, DOI 10.2353/ajpath.2007.070010
   Suzuki T, 2008, INT J CANCER, V123, P1674, DOI 10.1002/ijc.23644
   Swift-Scanlan T, 2011, CANCER BIOL THER, V11, P853, DOI 10.4161/cbt.11.10.15177
   Teschendorff AE, 2010, GENOME RES, V20, P440, DOI 10.1101/gr.103606.109
   Teschendorff AE, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008274
   Touillaud MS, 2005, NUTR CANCER, V51, P162, DOI 10.1207/s15327914nc5102_6
   Tsujita E, 2005, ONCOLOGY-BASEL, V69, P342, DOI 10.1159/000089766
   Wang L, 2010, J THORAC ONCOL, V5, P778, DOI 10.1097/JTO.0b013e3181d6e0b3
   Wang SAH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0144774
   Wang XX, 2007, CELL SIGNAL, V19, P1372, DOI 10.1016/j.cellsig.2007.03.013
   Wei MJ, 2008, BREAST CANCER RES TR, V111, P113, DOI 10.1007/s10549-007-9766-6
   Widschwendter M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002656
   Wojdacz TK, 2008, NAT PROTOC, V3, P1903, DOI 10.1038/nprot.2008.191
   Yang F, 2016, ONCOL REP, V35, P2113, DOI 10.3892/or.2016.4580
   Zhang CX, 2010, CANCER SCI, V101, P501, DOI 10.1111/j.1349-7006.2009.01376.x
   Zhang M, 2009, BREAST CANCER RES TR, V118, P553, DOI 10.1007/s10549-009-0354-9
NR 68
TC 12
Z9 14
U1 1
U2 10
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD FEB 21
PY 2017
VL 7
AR 43011
DI 10.1038/srep43011
PG 11
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA EL5ZA
UT WOS:000394699000002
PM 28220843
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Alexander, M
   Burch, JB
   Steck, SE
   Chen, CF
   Hurley, TG
   Cavicchia, P
   Shivappa, N
   Guess, J
   Zhang, H
   Youngstedt, SD
   Creek, KE
   Lloyd, S
   Jones, K
   Hébert, JR
AF Alexander, M.
   Burch, J. B.
   Steck, S. E.
   Chen, C-F.
   Hurley, T. G.
   Cavicchia, P.
   Shivappa, N.
   Guess, J.
   Zhang, H.
   Youngstedt, S. D.
   Creek, K. E.
   Lloyd, S.
   Jones, K.
   Hebert, J. R.
TI Case-control study of candidate gene methylation and adenomatous polyp
   formation
SO INTERNATIONAL JOURNAL OF COLORECTAL DISEASE
LA English
DT Article
DE Adenomatous polyp; Circadian rhythm; Colorectal cancer; Screening tests
ID CPG ISLAND METHYLATION; BREAST-CANCER RISK; COLORECTAL-CANCER; DNA
   METHYLATION; CIRCADIAN CLOCK; COLON-CANCER; MICROSATELLITE INSTABILITY;
   PROMOTER METHYLATION; DOWN-REGULATION; GLOBAL DNA
AB Colorectal cancer (CRC) is one of the most common and preventable forms of cancer but remains the second leading cause of cancer-related death. Colorectal adenomas are precursor lesions that develop in 70-90 % of CRC cases. Identification of peripheral biomarkers for adenomas would help to enhance screening efforts. This exploratory study examined the methylation status of 20 candidate markers in peripheral blood leukocytes and their association with adenoma formation.
   Patients recruited from a local endoscopy clinic provided informed consent and completed an interview to ascertain demographic, lifestyle, and adenoma risk factors. Cases were individuals with a histopathologically confirmed adenoma, and controls included patients with a normal colonoscopy or those with histopathological findings not requiring heightened surveillance (normal biopsy, hyperplastic polyp). Methylation-specific polymerase chain reaction was used to characterize candidate gene promoter methylation. Odds ratios (ORs) and 95 % confidence intervals (95% CIs) were calculated using unconditional multivariable logistic regression to test the hypothesis that candidate gene methylation differed between cases and controls, after adjustment for confounders.
   Complete data were available for 107 participants; 36 % had adenomas (men 40 %, women 31 %). Hypomethylation of the MINT1 locus (OR 5.3, 95% CI 1.0-28.2) and the PER1 (OR 2.9, 95% CI 1.1-7.7) and PER3 (OR 11.6, 95% CI 1.6-78.5) clock gene promoters was more common among adenoma cases. While specificity was moderate to high for the three markers (71-97 %), sensitivity was relatively low (18-45 %).
   Follow-up of these epigenetic markers is suggested to further evaluate their utility for adenoma screening or surveillance.
C1 [Alexander, M.; Burch, J. B.; Steck, S. E.; Hurley, T. G.; Cavicchia, P.; Shivappa, N.; Guess, J.; Hebert, J. R.] Univ South Carolina, South Carolina Statewide Canc Prevent & Control, Columbia, SC 29208 USA.
   [Alexander, M.; Burch, J. B.; Steck, S. E.; Cavicchia, P.; Shivappa, N.; Guess, J.; Hebert, J. R.] Univ South Carolina, Arnold Sch Publ Hlth, Dept Epidemiol & Biostat, 915 Greene St,Room 228, Columbia, SC 29209 USA.
   [Burch, J. B.] Vet Affairs Med Ctr, William Jennings Bryant Dorn Dept, Columbia, SC USA.
   [Chen, C-F.; Jones, K.] Greenwood Genet Ctr, Ctr Mol Studies, Greenwood, SC 29646 USA.
   [Cavicchia, P.] Florida Dept Hlth, Div Community Hlth Promot, Tallahassee, FL USA.
   [Zhang, H.] Univ Memphis, Div Epidemiol Biostat & Environm Hlth, Sch Publ Hlth, Memphis, TN 38152 USA.
   [Youngstedt, S. D.] Arizona State Univ, Coll Nursing & Hlth Innovat, Coll Hlth Solut, Phoenix, AZ USA.
   [Youngstedt, S. D.] Phoenix VA Hlth Care Syst, Phoenix, AZ USA.
   [Creek, K. E.] Univ South Carolina, South Carolina Coll Pharm, Dept Drug Discovery & Biomed Sci, Columbia, SC USA.
   [Lloyd, S.] Univ South Carolina, South Carolina Med Endoscopy Ctr, Sch Med, Columbia, SC USA.
   [Lloyd, S.] Univ South Carolina, Dept Family Med, Sch Med, Columbia, SC USA.
   [Hebert, J. R.] Univ South Carolina, Dept Family & Prevent Med, Sch Med, Columbia, SC USA.
C3 University of South Carolina System; University of South Carolina
   Columbia; University of South Carolina System; University of South
   Carolina Columbia; US Department of Veterans Affairs; Veterans Health
   Administration (VHA); Greenwood Genetic Center; Florida Department of
   Health; University of Memphis; Arizona State University; Arizona State
   University-Downtown Phoenix; University of South Carolina System;
   University of South Carolina Columbia; Medical University of South
   Carolina; University of South Carolina System; University of South
   Carolina Columbia; University of South Carolina System; University of
   South Carolina Columbia; University of South Carolina System; University
   of South Carolina Columbia
RP Burch, JB (通讯作者)，Univ South Carolina, South Carolina Statewide Canc Prevent & Control, Columbia, SC 29208 USA.; Burch, JB (通讯作者)，Univ South Carolina, Arnold Sch Publ Hlth, Dept Epidemiol & Biostat, 915 Greene St,Room 228, Columbia, SC 29209 USA.; Burch, JB (通讯作者)，Vet Affairs Med Ctr, William Jennings Bryant Dorn Dept, Columbia, SC USA.
EM burch@mailbox.sc.edu
RI youngstedt, shawn/AAA-3361-2021; Hebert, James/IUO-5628-2023; Shivappa,
   Nitin/X-2215-2018; Steck, Susan/G-5736-2013
OI Alexander, Melannie/0000-0003-4261-6543
FU National Cancer Institute (NCI)-an Administrative Supplement to the
   South Carolina Cancer Disparities Community Network [SCCDCN-3 U01
   CA114601-03S5, 1 U54 CA153461-01]; Cancer Training Branch of the
   National Cancer Institute [K05 CA136975]; USC Research Opportunity
   Award; University of South Carolina Behavioral-Biomedical Interface
   Program; National Institute of General Medical Sciences [T32-GM081740];
   National Center for Research Resources [COBRE 5P20RR017698]
FX This work was supported by three grants from the National Cancer
   Institute (NCI)-an Administrative Supplement to the South Carolina
   Cancer Disparities Community Network (SCCDCN-3 U01 CA114601-03S5.PI: JR
   Hebert; co-project leaders: JB Burch, SE Steck), SCCDCN-II (1 U54
   CA153461-01, JR Hebert, PI), and an Established Investigator Award in
   Cancer Prevention and Control from the Cancer Training Branch of the
   National Cancer Institute (K05 CA136975; JR Hebert, PI); a USC Research
   Opportunity Award (PI: SE Steck); the University of South Carolina
   Behavioral-Biomedical Interface Program with a grant from the National
   Institute of General Medical Sciences (T32-GM081740), which funded
   Melannie Alexander's effort; and a grant from the National Center for
   Research Resources to the USC Center for Colon Cancer Research (COBRE
   5P20RR017698), which supported a part of Dr. Steck's effort.
CR Adalsteinsson BT, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046705
   Ahn SB, 2012, GUT LIVER, V6, P64, DOI 10.5009/gnl.2012.6.1.64
   Alexander M, 2015, ONCOL REP, V33, P935, DOI 10.3892/or.2014.3667
   Ally MS, 2009, CANCER EPIDEM BIOMAR, V18, P922, DOI 10.1158/1055-9965.EPI-08-0703
   [Anonymous], 2012, MMWR MORB MORTAL WKL, V61, P41
   Baker DW, 2014, JAMA INTERN MED, V174, P1235, DOI 10.1001/jamainternmed.2014.2352
   Bender R, 2001, J CLIN EPIDEMIOL, V54, P343, DOI 10.1016/S0895-4356(00)00314-0
   Bhatti P, 2014, CHRONOBIOL INT, V4, P1
   Binefa G, 2014, WORLD J GASTROENTERO, V20, P6786, DOI 10.3748/wjg.v20.i22.6786
   Bollati V, 2010, CHRONOBIOL INT, V27, P1093, DOI 10.3109/07420528.2010.490065
   Brown SA, 2005, SCIENCE, V308, P693, DOI 10.1126/science.1107373
   Cassinotti E, 2012, INT J CANCER, V131, P1153, DOI 10.1002/ijc.26484
   Chan AOO, 2002, AM J PATHOL, V160, P1823, DOI 10.1016/S0002-9440(10)61128-5
   Chen ST, 2005, CARCINOGENESIS, V26, P1241, DOI 10.1093/carcin/bgi075
   Conteduca V, 2013, INT J ONCOL, V43, P973, DOI 10.3892/ijo.2013.2041
   Coppedè F, 2014, WORLD J GASTROENTERO, V20, P943, DOI 10.3748/wjg.v20.i4.943
   Cravo M, 1994, Eur J Cancer Prev, V3, P473, DOI 10.1097/00008469-199411000-00004
   Cui HM, 2003, SCIENCE, V299, P1753, DOI 10.1126/science.1080902
   de Maat MFG, 2010, AM J PATHOL, V177, P2347, DOI 10.2353/ajpath.2010.091103
   Duong HA, 2014, NAT STRUCT MOL BIOL, V21, P126, DOI 10.1038/nsmb.2746
   FEINBERG AP, 1983, NATURE, V301, P89, DOI 10.1038/301089a0
   Fu A, 2012, MOL CARCINOGEN, V51, P923, DOI 10.1002/mc.20862
   Ganepola GAP, 2014, WORLD J GASTRO ONCOL, V6, P83, DOI 10.4251/wjgo.v6.i4.83
   Gao Y, 2012, WORLD J GASTRO ONCOL, V4, P193, DOI 10.4251/wjgo.v4.i8.193
   Garrity-Park MM, 2010, AM J GASTROENTEROL, V105, P1610, DOI 10.1038/ajg.2010.22
   Gery S, 2006, MOL CELL, V22, P375, DOI 10.1016/j.molcel.2006.03.038
   Gery S, 2007, CLIN CANCER RES, V13, P1399, DOI 10.1158/1078-0432.CCR-06-1730
   Halbert CH, 2011, J GEN INTERN MED, V26, P1311, DOI 10.1007/s11606-011-1783-9
   Hancks DC, 2012, CURR OPIN GENET DEV, V22, P191, DOI 10.1016/j.gde.2012.02.006
   Hancks DC, 2010, SEMIN CANCER BIOL, V20, P234, DOI 10.1016/j.semcancer.2010.04.001
   Haus EL, 2013, SLEEP MED REV, V17, P273, DOI 10.1016/j.smrv.2012.08.003
   Hawkins NJ, 2001, J NATL CANCER I, V93, P1307, DOI 10.1093/jnci/93.17.1307
   Hebert JR, 2002, PUBLIC HEALTH NUTR, V5, P303, DOI 10.1079/PHN2002249
   Hoffman AE, 2010, CANCER PREV RES, V3, P539, DOI 10.1158/1940-6207.CAPR-09-0127
   Hoffman AE, 2010, CANCER RES, V70, P1459, DOI 10.1158/0008-5472.CAN-09-3798
   Hong L, 2013, GENET TEST MOL BIOMA, V17, P401, DOI 10.1089/gtmb.2012.0478
   Hsu MC, 2007, BIOCHEM BIOPH RES CO, V360, P257, DOI 10.1016/j.bbrc.2007.06.042
   Jacobs ET, 2013, CANCER RES, V73, P2563, DOI 10.1158/0008-5472.CAN-12-4134
   Jasperson KW, 2010, GASTROENTEROLOGY, V138, P2044, DOI 10.1053/j.gastro.2010.01.054
   Jones RM, 2010, AM J PREV MED, V38, P499, DOI 10.1016/j.amepre.2010.01.020
   Joska Tammy M, 2014, Biology (Basel), V3, P560, DOI 10.3390/biology3030560
   Kaaks R, 2009, CANCER RES, V69, P5400, DOI 10.1158/0008-5472.CAN-08-3020
   Karantanos T, 2013, INT J BIOL MARKER, V28, P280, DOI [10.5301/JBM.5000033, 10.5301/jbm.5000033]
   Kim HC, 2005, J GASTROEN HEPATOL, V20, P1920, DOI 10.1111/j.1440-1746.2005.03943.x
   Kim JC, 2010, ANN SURG ONCOL, V17, P1767, DOI 10.1245/s10434-009-0901-y
   Kim YH, 2006, GENE CHROMOSOME CANC, V45, P781, DOI 10.1002/gcc.20341
   King WD, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-488
   Klabunde CN, 2006, AM J PREV MED, V30, P313, DOI 10.1016/j.amepre.2005.11.006
   Krugluger W, 2007, CANCER RES, V67, P7917, DOI 10.1158/0008-5472.CAN-07-0133
   Kuo SJ, 2009, VIRCHOWS ARCH, V454, P467, DOI 10.1007/s00428-009-0761-7
   Lahti T, 2012, ANN MED, V44, P847, DOI 10.3109/07853890.2012.727018
   Lao VV, 2011, NAT REV GASTRO HEPAT, V8, P686, DOI 10.1038/nrgastro.2011.173
   Lim U, 2008, GASTROENTEROLOGY, V134, P47, DOI 10.1053/j.gastro.2007.10.013
   Mazzoccoli G, 2011, CHRONOBIOL INT, V28, P841, DOI 10.3109/07420528.2011.615182
   Mazzoccoli G, 2014, WORLD J GASTROENTERO, V20, P4197, DOI 10.3748/wjg.v20.i15.4197
   Mazzoccoli G, 2012, CHRONOBIOL INT, V29, P994, DOI 10.3109/07420528.2012.705935
   McKay JA, 2011, MOL NUTR FOOD RES, V55, P1026, DOI 10.1002/mnfr.201100008
   MIKI Y, 1992, CANCER RES, V52, P643
   Mitchell SM, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-54
   Morikawa T, 2007, AM J GASTROENTEROL, V102, P2259, DOI 10.1111/j.1572-0241.2007.01404.x
   Mostafaie N, 2009, MOL CARCINOGEN, V48, P642, DOI 10.1002/mc.20510
   Nelson DE, 2003, AM J PREV MED, V24, P301, DOI 10.1016/S0749-3797(03)00024-2
   O'Brien MJ, 2006, AM J SURG PATHOL, V30, P1491, DOI 10.1097/01.pas.0000213313.36306.85
   Oshima T, 2011, ONCOL REP, V25, P1439, DOI 10.3892/or.2011.1207
   Pufulete M, 2003, GASTROENTEROLOGY, V124, P1240, DOI 10.1016/S0016-5085(03)00279-8
   Qureshi IA, 2014, CURR NEUROL NEUROSCI, V14, DOI 10.1007/s11910-013-0432-6
   Rashid A, 2001, AM J PATHOL, V159, P1129, DOI 10.1016/S0002-9440(10)61789-0
   Sabino FC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107198
   Sakai E, 2014, WORLD J GASTROENTERO, V20, P978, DOI 10.3748/wjg.v20.i4.978
   Semrad TJ, 2011, CANCER-AM CANCER SOC, V117, P1755, DOI 10.1002/cncr.25668
   Shen RL, 2009, INT J CLIN EXP PATHO, V2, P21
   Shih MC, 2006, MOL CARCINOGEN, V45, P732, DOI 10.1002/mc.20198
   Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138
   Silva TD, 2013, ONCOL LETT, V6, P1687, DOI 10.3892/ol.2013.1606
   Sjöblom T, 2006, SCIENCE, V314, P268, DOI 10.1126/science.1133427
   Suter CM, 2003, BRIT J CANCER, V88, P413, DOI 10.1038/sj.bjc.6600699
   Tabung FK, 2015, J PRIM PREV, V36, P21, DOI 10.1007/s10935-014-0372-1
   Terry MB, 2011, EPIGENETICS-US, V6, P828, DOI 10.4161/epi.6.7.16500
   Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681
   Valekunja UK, 2013, P NATL ACAD SCI USA, V110, P1554, DOI 10.1073/pnas.1214168110
   Waldmann T, 2013, CURR OPIN CELL BIOL, V25, P184, DOI 10.1016/j.ceb.2013.01.001
   Wang XL, 2012, ANN SURG ONCOL, V19, P3081, DOI 10.1245/s10434-012-2279-5
   Watanabe Y, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023320
   Winawer S, 2003, GASTROENTEROLOGY, V124, P544, DOI 10.1053/gast.2003.50044
   Wong CKW, 2012, INT J COLORECTAL DIS, V27, P1657, DOI 10.1007/s00384-012-1518-3
   Worthley DL, 2010, ONCOGENE, V29, P1653, DOI 10.1038/onc.2009.449
   Wynter CVA, 2006, INT J CANCER, V118, P907, DOI 10.1002/ijc.21363
   Yang H, 2013, CAN J GASTROENTEROL, V27, P467, DOI 10.1155/2013/258030
   Yang MY, 2006, CANCER SCI, V97, P1298, DOI 10.1111/j.1349-7006.2006.00331.x
   Zhu Y, 2011, CHRONOBIOL INT, V28, P852, DOI 10.3109/07420528.2011.618896
NR 90
TC 9
Z9 12
U1 0
U2 6
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0179-1958
EI 1432-1262
J9 INT J COLORECTAL DIS
JI Int. J. Colorectal Dis.
PD FEB
PY 2017
VL 32
IS 2
BP 183
EP 192
DI 10.1007/s00384-016-2688-1
PG 10
WC Gastroenterology & Hepatology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Gastroenterology & Hepatology; Surgery
GA EK8FO
UT WOS:000394159500003
PM 27771773
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Guo, YW
   Maimaiti, Y
   Yu, P
   Liu, ZM
   Chen, C
   Zhang, YK
   Yin, XJ
   Wang, S
   Xiu, N
   Bangxing, H
   Liu, CP
   Huang, T
AF Guo, Yawen
   Maimaiti, Yusufu
   Yu, Pan
   Liu, Zeming
   Chen, Chen
   Zhang, Yunke
   Yin, Xingjie
   Wang, Shan
   Xiu, Nie
   Bangxing, Huang
   Liu, Chunping
   Huang, Tao
TI Overexpression of enhancer of zeste homolog 2 (EZH2) and focal adhesion
   kinase (FAK) is associated with cancer metastasis and poor prognosis in
   breast cancer
SO INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE
LA English
DT Article
DE Breast cancer; enhancer of zeste homolog 2; focal adhesion kinase;
   prognosis
ID GASTRIC-CANCER; EXPRESSION; INHIBITION; PROLIFERATION; METHYLATION;
   STATISTICS; BIOMARKERS; TARGET; CELLS; WOMEN
AB Enhancer of zeste homolog 2 (EZH2), a polycomb histone methyltransferase, is a key epigenetic modifier implicated in the metastasis of various cancers. Focal adhesion kinase (FAK), a protein tyrosine kinase, modulates signaling and fundamental functions to facilitate cancer progression and metastasis. However, the link between EZH2 and FAK expression and their mechanisms in breast cancer (BC) remain ambiguous. In the present study, EZH2 and FAK expression was examined in two tissue microarrays containing specimens from 300 patients with breast cancer using immunohistochemistry. Kaplan-Meier survival analysis demonstrated that high expression of EZH2 (56.6%) and FAK (74.7%) was associated with poor prognosis (P < 0.05). In addition, univariate and multivariate Cox regression analyses suggest that FAK is an independent prognostic factor (ER status: hazard ratio (HR) = 0.776, 95% Confidence Interval (CI): 0.603-1.972; PR status: HR = 0.790, 95% CI: 0.338-1.061; AR status: HR = 0.934, 95% CI: 0.751-1.162; EZH2 status: HR = 1.376, 95% CI: 0.845-2.242; FAK status: HR = 2.117, 95% CI: 1.147-3.909, P = 0.016). In the nuclear grade II, negative Her2, negative EGFR status, or positive P53 status subgroups, patients expressing high EZH2 and FAK levels also presented with poor survival. Furthermore, invasion of MDA-MB-231 cells decreased after combined inhibition of EZH2 and FAK. Moreover, FAK protein levels were significantly downregulated in EZH2 knocked down cell lines in vitro. In conclusion, EZH2 and FAK expression is correlated and associated with BC prognosis.
C1 [Guo, Yawen; Yu, Pan; Liu, Zeming; Chen, Chen; Zhang, Yunke; Yin, Xingjie; Wang, Shan; Liu, Chunping; Huang, Tao] Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Dept Breast & Thyroid Surg, Wuhan, Peoples R China.
   [Maimaiti, Yusufu] Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Dept Pathol, Wuhan, Peoples R China.
   [Xiu, Nie; Bangxing, Huang] Peoples Hosp Xinjiang Uygur Autonomous Reg, Res Inst Minimally Invas, Dept Gen Surg, Urumqi, Peoples R China.
C3 Huazhong University of Science & Technology; Huazhong University of
   Science & Technology
RP Liu, CP; Huang, T (通讯作者)，Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Dept Breast & Thyroid Surg, Wuhan, Peoples R China.
EM lcp191@163.com; huangtaowh@163.com
OI Liu, Zeming/0000-0001-6132-4701
FU National Natural Science Foundation of China [NSFC 81550009]
FX This work was supported by grants from the the National Natural Science
   Foundation of China: NSFC 81550009 (http://www.nsfc.gov.cn/). The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Albain KS, 2010, LANCET ONCOL, V11, P55, DOI 10.1016/S1470-2045(09)70314-6
   Alexopoulou AN, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-237
   Azim HA, 2016, TRANSL ONCOL, V9, P114, DOI 10.1016/j.tranon.2016.01.001
   Canel M, 2010, CANCER RES, V70, P9413, DOI 10.1158/0008-5472.CAN-10-1454
   Goldhirsch A, 2013, ANN ONCOL, V24, P2206, DOI 10.1093/annonc/mdt303
   Gonzalez ME, 2014, P NATL ACAD SCI USA, V111, P3098, DOI 10.1073/pnas.1308953111
   He LJ, 2012, ASIAN PAC J CANCER P, V13, P3173, DOI 10.7314/APJCP.2012.13.7.3173
   Jang SH, 2016, J BREAST CANCER, V19, P53, DOI 10.4048/jbc.2016.19.1.53
   Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43
   Jiang T, 2016, ONCOTARGET, V7, P4584, DOI 10.18632/oncotarget.6612
   Kanteti R, 2016, ONCOTARGET, V7, P31586, DOI 10.18632/oncotarget.8040
   Kim KH, 2016, NAT MED, V22, P128, DOI 10.1038/nm.4036
   Kondo Y, 2014, J BIOCHEM, V156, P249, DOI 10.1093/jb/mvu054
   Lee BY, 2015, PHARMACOL THERAPEUT, V146, P132, DOI 10.1016/j.pharmthera.2014.10.001
   Liu SS, 2015, HEPATO-GASTROENTEROL, V62, P737, DOI 10.5754/hge14537
   Maimaiti Y, 2016, BIOCHEM BIOPH RES CO, V473, P212, DOI 10.1016/j.bbrc.2016.03.081
   Margueron R, 2011, NATURE, V469, P343, DOI 10.1038/nature09784
   Martínez-Fernández M, 2015, INT J MOL SCI, V16, P27107, DOI 10.3390/ijms161126000
   Matsika A, 2015, PATHOLOGY, V47, P622, DOI 10.1097/PAT.0000000000000325
   Ren K, 2015, ONCOTARGET, V6, P31085, DOI 10.18632/oncotarget.5044
   Rydén L, 2005, J CLIN ONCOL, V23, P4695, DOI 10.1200/JCO.2005.08.126
   Song XJ, 2016, SCI REP-UK, V6, DOI [10.1038/srep20864, 10.1038/srep24893]
   Sulzmaier FJ, 2014, NAT REV CANCER, V14, P598, DOI 10.1038/nrc3792
   Tai YL, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/690690
   Takeshima H, 2015, CARCINOGENESIS, V36, P192, DOI 10.1093/carcin/bgu238
   Thakur R, 2015, SCI REP-UK, V5, DOI 10.1038/srep10194
   Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262
   van Schooneveld E, 2015, BREAST CANCER RES, V17, DOI 10.1186/s13058-015-0526-y
   Wang XH, 2016, SCI REP-UK, V6, DOI 10.1038/srep19239
   Wang Y, 2015, TUMOR BIOL, V36, P7159, DOI 10.1007/s13277-015-3417-z
   Warrick JI, 2016, UROL ONCOL-SEMIN ORI, V34, DOI 10.1016/j.urolonc.2016.02.011
   Yamaguchi H, 2014, CANCER RES TREAT, V46, P209, DOI 10.4143/crt.2014.46.3.209
   Yerushalmi R, 2010, LANCET ONCOL, V11, P174, DOI 10.1016/S1470-2045(09)70262-1
   Zhang L, 2014, ONCOTARGET, V5, P10665, DOI 10.18632/oncotarget.2496
   Zhang LL, 2014, CELL SIGNAL, V26, P1011, DOI 10.1016/j.cellsig.2014.01.025
   Zhou J, 2013, GYNECOL ONCOL, V128, P344, DOI 10.1016/j.ygyno.2012.07.128
NR 36
TC 1
Z9 1
U1 0
U2 3
PU E-CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1940-5901
J9 INT J CLIN EXP MED
JI Int. J. Clin. Exp. Med.
PY 2017
VL 10
IS 2
BP 2672
EP 2683
PG 12
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA EO2HZ
UT WOS:000396518500098
DA 2025-01-12
ER

PT J
AU Wilson, LE
   Harlid, S
   Xu, Z
   Sandler, DP
   Taylor, JA
AF Wilson, L. E.
   Harlid, S.
   Xu, Z.
   Sandler, D. P.
   Taylor, J. A.
TI An epigenome-wide study of body mass index and DNA methylation in blood
   using participants from the Sister Study cohort
SO INTERNATIONAL JOURNAL OF OBESITY
LA English
DT Article
ID DIET-INDUCED OBESITY; WAIST CIRCUMFERENCE; LEPTIN SENSITIVITY;
   INSULIN-RESISTANCE; PERIPHERAL-BLOOD; ADIPOSE-TISSUE; SOCS PROTEINS;
   BIRTH-WEIGHT; ASSOCIATION; CELLS
AB BACKGROUND/OBJECTIVES: The relationship between obesity and chronic disease risk is well-established; the underlying biological mechanisms driving this risk increase may include obesity-related epigenetic modifications. To explore this hypothesis, we conducted a genome-wide analysis of DNA methylation and body mass index (BMI) using data from a subset of women in the Sister Study.
   SUBJECTS/METHODS: The Sister Study is a cohort of 50 884 US women who had a sister with breast cancer but were free of breast cancer themselves at enrollment. Study participants completed examinations which included measurements of height and weight, and provided blood samples. Blood DNA methylation data generated with the Illumina Infinium HumanMethylation27 BeadChip array covering 27,589 CpG sites was available for 871 women from a prior study of breast cancer and DNA methylation. To identify differentially methylated CpG sites associated with BMI, we analyzed this methylation data using robust linear regression with adjustment for age and case status. For those CpGs passing the false discovery rate significance level, we examined the association in a replication set comprised of a non-overlapping group of 187 women from the Sister Study who had DNA methylation data generated using the Infinium HumanMethylation450 BeadChip array. Analysis of this expanded 450 K array identified additional BMI-associated sites which were investigated with targeted pyrosequencing.
   RESULTS: Four CpG sites reached genome-wide significance (false discovery rate (FDR) q<0.05) in the discovery set and associations for all four were significant at strict Bonferroni correction in the replication set. An additional 23 sites passed FDR in the replication set and five were replicated by pyrosequencing in the discovery set. Several of the genes identified including ANGPT4, RORC, SOCS3, FSD2, XYLT1, ABCG1, STK39, ASB2 and CRHR2 have been linked to obesity and obesity-related chronic diseases.
   CONCLUSIONS: Our findings support the hypothesis that obesity-related epigenetic differences are detectable in blood and may be related to risk of chronic disease.
C1 [Wilson, L. E.; Harlid, S.; Xu, Z.; Sandler, D. P.; Taylor, J. A.] NIEHS, Epidemiol Branch, NIH, Res Triangle Pk, NC 27709 USA.
   [Harlid, S.] Umea Univ, Oncol, Dept Radiat Sci, Umea, Sweden.
C3 National Institutes of Health (NIH) - USA; NIH National Institute of
   Environmental Health Sciences (NIEHS); Umea University
RP Taylor, JA (通讯作者)，NIEHS, Epidemiol Branch, POB 12233 Mail Drop A3-05, Res Triangle Pk, NC 27709 USA.
EM taylor@niehs.nih.gov
RI Harlid, Sophia/AAJ-5809-2021; taylor, jack/C-7154-2019; Sandler,
   Dale/E-5110-2019
OI taylor, jack/0000-0001-5303-6398; Wilson, Lauren/0000-0002-5953-2293;
   Sandler, Dale/0000-0002-6776-0018
FU Intramural Research Program of the NIH, National Institute of
   Environmental Health Sciences [Z01 ES044005, Z01 ES044032, Z01 ES049033]
FX We thank Dr Sarah Reese and Dr Yong- Moon Park for their critical review
   of this manuscript. We would also like to thank the women who
   volunteered to participate in the Sister Study. We thank the National
   Institutes of Health (NIH) Center for Inherited Disease Research and the
   National Institute of Environmental Health Sciences (NIEHS) Molecular
   Genetics Core and Microarray Core for their technical support. This
   research was supported by the Intramural Research Program of the NIH,
   National Institute of Environmental Health Sciences (Z01 ES044005, Z01
   ES044032, and Z01 ES049033) which provided funding for design and
   conduct of the study; collection, management, analysis and
   interpretation of the data; and preparation, review and approval of the
   manuscript.
CR Accomando WP, 2012, CLIN CANCER RES, V18, P6147, DOI 10.1158/1078-0432.CCR-12-1008
   Al Muftah WA, 2016, CLIN EPIGENETICS, V8, DOI 10.1186/s13148-016-0177-6
   Albuquerque D, 2015, MOL GENET GENOMICS, V290, P1191, DOI 10.1007/s00438-015-1015-9
   Alexander WS, 2004, ANNU REV IMMUNOL, V22, P503, DOI 10.1146/annurev.immunol.22.091003.090312
   Martínez JA, 2014, ADV NUTR, V5, P71, DOI 10.3945/an.113.004705
   Arabshahi S, 2016, EUR J NUTR
   Arner P, 2015, CLIN EPIGENETICS, V7, DOI 10.1186/s13148-015-0126-9
   Aslibekyan S, 2015, OBESITY, V23, P1493, DOI 10.1002/oby.21111
   Balatoni CE, 2009, AM J PATHOL, V175, P1653, DOI 10.2353/ajpath.2009.090091
   Barendse W, 2007, GENETICS, V175, P843, DOI 10.1534/genetics.106.064535
   Bellemore SM, 2016, CLIN EXP IMMUNOL, V183, P380, DOI 10.1111/cei.12735
   Bjorbaek C, 1998, MOL CELL, V1, P619, DOI 10.1016/S1097-2765(00)80062-3
   Bouchard C, 1997, J NUTR, V127, pS943, DOI 10.1093/jn/127.5.943S
   Chambers JC, 2015, LANCET DIABETES ENDO, V3, P526, DOI 10.1016/S2213-8587(15)00127-8
   Cohney SJ, 1999, MOL CELL BIOL, V19, P4980
   Dagvadorj J, 2010, IMMUNOLOGY, V129, P97, DOI 10.1111/j.1365-2567.2009.03154.x
   Demerath EW, 2015, HUM MOL GENET, V24, P4464, DOI 10.1093/hmg/ddv161
   Dick KJ, 2014, LANCET, V383, P1990, DOI 10.1016/S0140-6736(13)62674-4
   Dong CH, 2010, STROKE, V41, P2750, DOI 10.1161/STROKEAHA.110.596981
   Eldor R, 2015, DIABETES CARE, V38, P113, DOI 10.2337/dc14-1544
   Endo Y, 2015, CELL REP, V12, P1042, DOI 10.1016/j.celrep.2015.07.014
   García-Jiménez C, 2016, BRIT J CANCER, V114, P716, DOI 10.1038/bjc.2016.37
   Gillberg L, 2016, DIABETOLOGIA, V59, P799, DOI 10.1007/s00125-015-3852-9
   Götting C, 2008, CLIN CHIM ACTA, V391, P41, DOI 10.1016/j.cca.2008.01.028
   Grammatopoulos DK, 2012, BRIT J PHARMACOL, V166, P85, DOI 10.1111/j.1476-5381.2011.01631.x
   Gray NE, 2012, J BIOL CHEM, V287, P8444, DOI 10.1074/jbc.M111.294124
   Harlid S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118757
   Harlid S, 2014, ENVIRON HEALTH PERSP, V122, P673, DOI 10.1289/ehp.1307480
   Hemani G, 2013, AM J HUM GENET, V93, P865, DOI 10.1016/j.ajhg.2013.10.005
   Houseman EA, 2012, BMC BIOINFORMATICS, V13, DOI 10.1186/1471-2105-13-86
   Howard JK, 2006, TRENDS ENDOCRIN MET, V17, P365, DOI 10.1016/j.tem.2006.09.007
   Howard JK, 2004, NAT MED, V10, P734, DOI 10.1038/nm1072
   Ip B, 2016, OBESITY, V24, P102, DOI 10.1002/oby.21243
   Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249
   Li B, 2015, GENET MOL RES, V14, P16461, DOI 10.4238/2015.December.9.17
   Li P, 2014, INT J OBESITY, V38, P724, DOI 10.1038/ijo.2013.140
   Määttä KM, 2013, J HYPERTENS, V31, P516, DOI 10.1097/HJH.0b013e32835c17af
   Mori H, 2004, NAT MED, V10, P739, DOI 10.1038/nm1071
   Ollikainen M, 2015, CLIN EPIGENETICS, V7, DOI 10.1186/s13148-015-0073-5
   Pedroso JAB, 2014, MOL METAB, V3, P608, DOI 10.1016/j.molmet.2014.06.001
   Persu A, 2015, J HYPERTENS, V33, pE80, DOI 10.1097/01.hjh.0000467569.10961.69
   Pfeiffer L, 2015, CIRC-CARDIOVASC GENE, V8, P334, DOI 10.1161/CIRCGENETICS.114.000804
   Pietiläinen KH, 2016, INT J OBESITY, V40, P654, DOI 10.1038/ijo.2015.221
   Reinert-Hartwall L, 2015, J IMMUNOL, V194, P68, DOI 10.4049/jimmunol.1401653
   Romanowski M, 2015, EUR REV MED PHARMACO, V19, P3152
   Talbert ME, 2009, HUM GENET, V125, P153, DOI 10.1007/s00439-008-0608-3
   Tang W, 2011, ACTA PHARMACOL SIN, V32, P1381, DOI 10.1038/aps.2011.84
   Turan N, 2012, BMC MED GENOMICS, V5, DOI 10.1186/1755-8794-5-10
   Xu ZL, 2013, JNCI-J NATL CANCER I, V105, P694, DOI 10.1093/jnci/djt045
   Zaina S, 2014, CIRC-CARDIOVASC GENE, V7, P692, DOI 10.1161/CIRCGENETICS.113.000441
NR 50
TC 38
Z9 45
U1 0
U2 9
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0307-0565
EI 1476-5497
J9 INT J OBESITY
JI Int. J. Obes.
PD JAN
PY 2017
VL 41
IS 1
BP 194
EP 199
DI 10.1038/ijo.2016.184
PG 6
WC Endocrinology & Metabolism; Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Endocrinology & Metabolism; Nutrition & Dietetics
GA EK7ZG
UT WOS:000394143100026
PM 27773939
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Xun, J
   Wang, DK
   Shen, L
   Gong, JB
   Gao, RF
   Du, LF
   Chang, AT
   Song, XR
   Xiang, R
   Tan, XY
AF Xun, Jing
   Wang, Dekun
   Shen, Long
   Gong, Junbo
   Gao, Ruifang
   Du, Lingfang
   Chang, Antao
   Song, Xiangrong
   Xiang, Rong
   Tan, Xiaoyue
TI JMJD3 suppresses stem cell-like characteristics in breast cancer cells
   by downregulation of Oct4 independently of its demethylase activity
SO ONCOTARGET
LA English
DT Article
DE JMJD3; Oct4; cancer stem cell-like characteristic; PHF20; paricalcitol
ID HISTONE DEMETHYLASE; VITAMIN-D; DIFFERENTIATION; CONTRIBUTES;
   EXPRESSION; INK4A/ARF
AB Epigenetic regulator JMJD3 plays an important role in both tumor progression and somatic cell reprogramming. Here, we explored the effect of JMJD3 on the stem cell-like characteristics of breast cancer and its underlying mechanism involving stemness-related transcription factor Oct4. Our data revealed that, in breast cancer cells lines and an orthotopic xenograph mouse model of breast cancer, ectopic overexpression of JMJD3 suppressed stem cell-like characteristics of breast cancer cells, whereas knockdown of JMJD3 promoted these characteristics. Oct4 mediated the suppressive effects of JMJD3 on the stemness of breast cancer cells. The inhibitory effect of JMJD3 on Oct4 was independent of demethylase activity, but mediated via degradation of PHF20. Furthermore, we applied an agonist of the vitamin D receptor, paricalcitol, and found that it induced JMJD3 in breast cancer cells. Our data showed that administration of paricalcitol suppressed stem cell-like characteristics and Oct4 expression. Taken together, JMJD3 inhibits the stem cell-like characteristics in breast cancer by suppression of stemness factor Oct4 in a PHF20-dependent manner. Administration of paricalcitol leads to upregulation of JMJD3 that suppresses Oct4 expression and the stem cell-like characteristics in breast cancer.
C1 [Xun, Jing; Wang, Dekun; Shen, Long; Gao, Ruifang; Du, Lingfang; Chang, Antao; Xiang, Rong; Tan, Xiaoyue] Nankai Univ, State Key Lab Med Chem Biol, Coll Med, Tianjin 300071, Peoples R China.
   [Gong, Junbo] Tianjin Univ, Sch Chem Engn & Technol, Tianjin Key Lab Modern Drug Delivery & High Effic, Tianjin 300072, Peoples R China.
   [Song, Xiangrong] Sichuan Univ, West China Hosp, State Key Lab Biotherapy, Chengdu 610041, Peoples R China.
   [Song, Xiangrong] Sichuan Univ, West China Hosp, Ctr Canc, Chengdu 610041, Peoples R China.
C3 Nankai University; Tianjin University; Sichuan University; Sichuan
   University
RP Tan, XY (通讯作者)，Nankai Univ, State Key Lab Med Chem Biol, Coll Med, Tianjin 300071, Peoples R China.
EM xiaoyuetan@nankai.edu.cn
RI rong, xiang/N-8232-2015; Shen, Long/LXW-4727-2024; Gong,
   Junbo/J-7798-2012
OI Gong, Junbo/0000-0002-3376-3296
FU National Basic Research Program of China [2013CB967200]; National
   Natural Science Foundation of China [81270774]
FX This work was supported by a grant from the National Basic Research
   Program of China to R. X. [grant number 2013CB967200]. X. T. was
   supported by the National Natural Science Foundation of China [grant
   number 81270774].
CR Agger K, 2007, NATURE, V449, P731, DOI 10.1038/nature06145
   Agger K, 2009, GENE DEV, V23, P1171, DOI 10.1101/gad.510809
   Andricovich J, 2016, J CLIN INVEST, V126, P905, DOI 10.1172/JCI84014
   Barradas M, 2009, GENE DEV, V23, P1177, DOI 10.1101/gad.511109
   Ben-Porath I, 2008, NAT GENET, V40, P499, DOI 10.1038/ng.127
   Boyer LA, 2005, CELL, V122, P947, DOI 10.1016/j.cell.2005.08.020
   Burchfield JS, 2015, INT J BIOCHEM CELL B, V67, P148, DOI 10.1016/j.biocel.2015.07.006
   Campisi J, 2005, CELL, V120, P513, DOI 10.1016/j.cell.2005.02.003
   Chen JF, 2016, ONCOTARGET, V7, P41540, DOI 10.18632/oncotarget.9236
   Cloos PAC, 2008, GENE DEV, V22, P1115, DOI 10.1101/gad.1652908
   Corcoran A., 2015, J STEROID BIOCH MOL
   Ene CI, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051407
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Helin K, 2013, NATURE, V502, P480, DOI 10.1038/nature12751
   Hu TS, 2008, CANCER RES, V68, P6533, DOI 10.1158/0008-5472.CAN-07-6642
   Hübner MR, 2010, COLD SH Q B, V75, P43, DOI 10.1101/sqb.2010.75.020
   Jensen MB, 2012, NEOPLASIA, V14, P952, DOI 10.1593/neo.121164
   Koo BS, 2015, ONCOGENE, V34, P2317, DOI 10.1038/onc.2014.174
   Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005
   Martinez-Garcia E, 2010, NAT GENET, V42, P100, DOI 10.1038/ng0210-100
   Ntziachristos P, 2014, NATURE, V514, P513, DOI 10.1038/nature13605
   Onyido EK, 2016, MOL CANCER, V15, DOI 10.1186/s12943-016-0541-3
   Pereira F, 2012, ENDOCR-RELAT CANCER, V19, pR51, DOI 10.1530/ERC-11-0388
   Pereira F, 2012, CELL CYCLE, V11, P1081, DOI 10.4161/cc.11.6.19508
   Pereira F, 2011, HUM MOL GENET, V20, P4655, DOI 10.1093/hmg/ddr399
   Perrigue PM, 2015, MOL CANCER RES, V13, P636, DOI 10.1158/1541-7786.MCR-13-0268
   Saccone D, 2015, GENE, V561, P171, DOI 10.1016/j.gene.2015.02.024
   Suvà ML, 2013, SCIENCE, V339, P1567, DOI 10.1126/science.1230184
   Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024
   Wei Y, 2013, LEUKEMIA, V27, P2177, DOI 10.1038/leu.2013.91
   Williams K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096545
   Yu ZR, 2012, INT J BIOCHEM CELL B, V44, P2144, DOI 10.1016/j.biocel.2012.08.022
   Zeineddine D, 2014, AM J STEM CELLS, V3, P74
   Zhang Y, 2014, MOL CANCER RES, V12, P1181, DOI 10.1158/1541-7786.MCR-14-0036
   Zhao W, 2013, CELL, V152, P1037, DOI 10.1016/j.cell.2013.02.006
NR 35
TC 25
Z9 30
U1 0
U2 8
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD MAR 28
PY 2017
VL 8
IS 13
BP 21918
EP 21929
DI 10.18632/oncotarget.15747
PG 12
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA EP8RL
UT WOS:000397642400115
PM 28423536
OA Green Published, gold, Green Submitted
DA 2025-01-12
ER

PT J
AU Liu, Y
   Chen, SJ
   Wang, S
   Soares, F
   Fischer, M
   Meng, FL
   Du, Z
   Lin, C
   Meyer, C
   DeCaprio, JA
   Brown, M
   Liu, XS
   He, HH
AF Liu, Yin
   Chen, Sujun
   Wang, Su
   Soares, Fraser
   Fischer, Martin
   Meng, Feilong
   Du, Zhou
   Lin, Charles
   Meyer, Clifford
   DeCaprio, James A.
   Brown, Myles
   Liu, X. Shirley
   He, Housheng Hansen
TI Transcriptional landscape of the human cell cycle
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE GRO-seq; nascent RNA; transcriptional regulation; epigenetics; cell
   cycle
ID CONTROL MECHANISMS; ENHANCER RNAS; GENE; CANCER; EXPRESSION; MITOSIS;
   IDENTIFICATION; REPLICATION; BOOKMARKING; METHYLATION
AB Steady-state gene expression across the cell cycle has been studied extensively. However, transcriptional gene regulation and the dynamics of histone modification at different cell-cycle stages are largely unknown. By applying a combination of global nuclear run-on sequencing (GRO-seq), RNA sequencing (RNA-seq), and histone-modification Chip sequencing (ChIP-seq), we depicted a comprehensive transcriptional landscape at the G0/G1, G1/S, and M phases of breast cancer MCF-7 cells. Importantly, GRO-seq and RNA-seq analysis identified different cell-cycle-regulated genes, suggesting a lag between transcription and steady-state expression during the cell cycle. Interestingly, we identified genes actively transcribed at early M phase that are longer in length and have low expression and are accompanied by a global increase in active histone 3 lysine 4 methylation (H3K4me2) and histone 3 lysine 27 acetylation (H3K27ac) modifications. In addition, we identified 2,440 cell-cycle-regulated enhancer RNAs (eRNAs) that are strongly associated with differential active transcription but not with stable expression levels across the cell cycle. Motif analysis of dynamic eRNAs predicted Kruppel-like factor 4 (KLF4) as a key regulator of G1/S transition, and this identification was validated experimentally. Taken together, our combined analysis characterized the transcriptional and histone-modification profile of the human cell cycle and identified dynamic transcriptional signatures across the cell cycle.
C1 [Liu, Yin; Chen, Sujun] Tongji Univ, Shanghai Pulm Hosp, Clin Translat Res Ctr, Shanghai 200433, Peoples R China.
   [Liu, Yin; Chen, Sujun; Wang, Su; Du, Zhou] Tongji Univ, Sch Life Sci, Dept Bioinformat, Shanghai 200092, Peoples R China.
   [Liu, Yin; Wang, Su; Du, Zhou; Meyer, Clifford; Brown, Myles; Liu, X. Shirley] Dana Farber Canc Inst, Ctr Funct Canc Epigenet, Boston, MA 02215 USA.
   [Chen, Sujun; Soares, Fraser; He, Housheng Hansen] Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON M5G 1L7, Canada.
   [Chen, Sujun; He, Housheng Hansen] Univ Toronto, Dept Med Biophys, Toronto, ON M5G 1L7, Canada.
   [Wang, Su] Harvard Med Sch, Dept Biomed Informat, Boston, MA 02215 USA.
   [Fischer, Martin; DeCaprio, James A.; Brown, Myles] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA.
   [Fischer, Martin; DeCaprio, James A.; Brown, Myles] Harvard Med Sch, Boston, MA 02215 USA.
   [Meng, Feilong] Chinese Acad Sci, Chinese Acad Sci Ctr Excellence Mol Cell Sci, State Key Lab Mol Biol, Shanghai Inst Biochem & Cell Biol, Shanghai 200031, Peoples R China.
   [Du, Zhou] Boston Childrens Hosp, Howard Hughes Med Inst, Program Cellular & Mol Med, Boston, MA 02115 USA.
   [Lin, Charles] Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA.
   [Meyer, Clifford; Liu, X. Shirley] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02215 USA.
   [Meyer, Clifford; Liu, X. Shirley] Harvard TH Chan Sch Publ Hlth, Boston, MA 02215 USA.
C3 Tongji University; Tongji University; Harvard University; Dana-Farber
   Cancer Institute; University of Toronto; University Health Network
   Toronto; Princess Margaret Cancer Centre; University of Toronto; Harvard
   University; Harvard Medical School; Harvard University; Dana-Farber
   Cancer Institute; Harvard University; Harvard Medical School; Chinese
   Academy of Sciences; Center for Excellence in Molecular Cell Science,
   CAS; Howard Hughes Medical Institute; Harvard University; Boston
   Children's Hospital; Program in Cellular & Molecular Medicine (PCMM);
   Baylor College of Medicine; Harvard University; Dana-Farber Cancer
   Institute; Harvard University; Harvard T.H. Chan School of Public Health
RP Brown, M; Liu, XS (通讯作者)，Dana Farber Canc Inst, Ctr Funct Canc Epigenet, Boston, MA 02215 USA.; He, HH (通讯作者)，Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON M5G 1L7, Canada.; He, HH (通讯作者)，Univ Toronto, Dept Med Biophys, Toronto, ON M5G 1L7, Canada.; Brown, M (通讯作者)，Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA.; Brown, M (通讯作者)，Harvard Med Sch, Boston, MA 02215 USA.; Liu, XS (通讯作者)，Harvard TH Chan Sch Publ Hlth, Boston, MA 02215 USA.
EM myles_brown@dfci.harvard.edu; xsliu@jimmy.harvard.edu;
   hansenhe@uhnresearch.ca
RI Brown, Myles/B-6906-2008; Liu, Yin/AEJ-0576-2022; Liu, X
   Shirley/JQI-9418-2023; He, Hansen/ABD-8439-2020; Chen,
   Sujun/AGG-9293-2022; Fischer, Martin/I-4825-2014
OI Fischer, Martin/0000-0002-3429-1876; Meng, Feilong/0000-0003-0333-6872;
   Chen, Sujun/0000-0002-1941-3951; Wang, Su/0000-0002-9463-6530; Soares,
   Fraser/0000-0002-3977-7939; he, housheng hansen/0000-0003-2898-3363
FU National Natural Science Foundation of China [31329003]; Princess
   Margaret Cancer Foundation; Canada Foundation for Innovation; Ontario
   Research Fund [CFI32372]; Natural Sciences and Engineering Research
   Council of Canada [498706]; NIH [1R01GM099409]; US Public Health Service
   [R01CA63113, R01CA173023]; German National Academy of Sciences
   Leopoldina Fellowship; Office of Management, Information, and Research
   (OMIR) Early Researcher Award; Terry Fox New Investigator Award;
   Canadian Institutes of Health Research (CIHR) New Investigator Salary
   Award
FX This work was supported by National Natural Science Foundation of China
   Grant 31329003 (to X.S.L.), the Princess Margaret Cancer Foundation
   (H.H.H.), Canada Foundation for Innovation and Ontario Research Fund
   Grant CFI32372 (to H.H.H.), Natural Sciences and Engineering Research
   Council of Canada Discovery Grant 498706 (to H.H.H.), NIH Grant
   1R01GM099409 (to X.S.L.), US Public Health Service Grants R01CA63113 and
   R01CA173023 (to J.A.D.), and a German National Academy of Sciences
   Leopoldina Fellowship (to M.F.). H.H.H. holds an Institute Community
   Support (ICS)-Institute of Genetics Maud Menten New Principal
   Investigator Prize (ICS-145381); an Office of Management, Information,
   and Research (OMIR) Early Researcher Award; a Terry Fox New Investigator
   Award; and a Canadian Institutes of Health Research (CIHR) New
   Investigator Salary Award.
CR Bar-Joseph Z, 2008, P NATL ACAD SCI USA, V105, P955, DOI 10.1073/pnas.0704723105
   Barisic M, 2015, SCIENCE, V348, P799, DOI 10.1126/science.aaa5175
   Barski A, 2007, CELL, V129, P823, DOI 10.1016/j.cell.2007.05.009
   Bello MJ, 2006, CANCER GENET CYTOGEN, V164, P172, DOI 10.1016/j.cancergencyto.2005.07.002
   Bertoli C, 2013, CURR BIOL, V23, P1629, DOI 10.1016/j.cub.2013.06.063
   Blobel GA, 2009, MOL CELL, V36, P970, DOI 10.1016/j.molcel.2009.12.001
   Brandeis M, 1996, EMBO J, V15, P5280, DOI 10.1002/j.1460-2075.1996.tb00913.x
   Caravaca JM, 2013, GENE DEV, V27, P251, DOI 10.1101/gad.206458.112
   Cayado-Gutiérrez N, 2013, CELL STRESS CHAPERON, V18, P243, DOI 10.1007/s12192-012-0367-x
   Core LJ, 2008, SCIENCE, V322, P1845, DOI 10.1126/science.1162228
   Dash Bipin C, 2004, Methods Mol Biol, V280, P99
   De Santa F, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000384
   Dominguez-Brauer C, 2015, MOL CELL, V60, P524, DOI 10.1016/j.molcel.2015.11.006
   Dynlacht BD, 1997, NATURE, V389, P149, DOI 10.1038/38225
   Fischer M, 2016, NUCLEIC ACIDS RES, V44, P6070, DOI 10.1093/nar/gkw523
   Fraser HB, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-10-r111
   Gamper AM, 2012, MOL CELL, V45, P233, DOI 10.1016/j.molcel.2011.11.031
   GARIGLIO P, 1981, NUCLEIC ACIDS RES, V9, P2589, DOI 10.1093/nar/9.11.2589
   Grant GD, 2013, MOL BIOL CELL, V24, P3634, DOI 10.1091/mbc.E13-05-0264
   Hah N, 2013, GENOME RES, V23, P1210, DOI 10.1101/gr.152306.112
   Hah N, 2011, CELL, V145, P622, DOI 10.1016/j.cell.2011.03.042
   Helmrich A, 2011, MOL CELL, V44, P966, DOI 10.1016/j.molcel.2011.10.013
   Hsieh CL, 2014, P NATL ACAD SCI USA, V111, P7319, DOI 10.1073/pnas.1324151111
   Hu D, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9419
   Hu D, 2012, J BIOL CHEM, V287, P13584, DOI 10.1074/jbc.M112.343566
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Jonkers I, 2014, ELIFE, V3, DOI 10.7554/eLife.02407
   Ju JH, 2013, CLIN CANCER RES, V19, P4335, DOI 10.1158/1078-0432.CCR-12-3295
   Kadauke S, 2012, CELL, V150, P725, DOI 10.1016/j.cell.2012.06.038
   Ke H, 2016, GENE REGUL SYST BIO, V10, P10, DOI 10.4137/GRSB.S29414
   Kim TK, 2010, NATURE, V465, P182, DOI 10.1038/nature09033
   Lam MTY, 2014, TRENDS BIOCHEM SCI, V39, P170, DOI 10.1016/j.tibs.2014.02.007
   Li WB, 2013, NATURE, V498, P516, DOI 10.1038/nature12210
   Liang KW, 2015, MOL CELL, V60, P435, DOI 10.1016/j.molcel.2015.09.021
   Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8
   Lovén J, 2012, CELL, V151, P476, DOI 10.1016/j.cell.2012.10.012
   Ma YQ, 2015, FRONT GENET, V6, DOI 10.3389/fgene.2015.00019
   Malumbres M, 2009, NAT REV CANCER, V9, P153, DOI 10.1038/nrc2602
   MCGILL CJ, 1995, CARDIOVASC RES, V30, P557, DOI 10.1016/0008-6363(95)00113-1
   McNair C, 2016, ONCOGENE, V10, P1
   Min IM, 2011, GENE DEV, V25, P742, DOI 10.1101/gad.2005511
   Mohammed H, 2013, CELL REP, V3, P342, DOI 10.1016/j.celrep.2013.01.010
   Nair VD, 2012, MOL CELL BIOL, V32, P4861, DOI 10.1128/MCB.00816-12
   Nevins JR, 2007, NAT REV GENET, V8, P601, DOI 10.1038/nrg2137
   Okayama H, 1996, ADV CANCER RES, V69, P17, DOI 10.1016/S0065-230X(08)60859-3
   PEDERSON T, 1972, P NATL ACAD SCI USA, V69, P2224, DOI 10.1073/pnas.69.8.2224
   Peña-Diaz J, 2013, NUCLEIC ACIDS RES, V41, P2846, DOI 10.1093/nar/gks1336
   Piatelli MJ, 2003, IMMUNOL RES, V27, P31, DOI 10.1385/IR:27:1:31
   Rabani M, 2011, NAT BIOTECHNOL, V29, P436, DOI 10.1038/nbt.1861
   Ramachandran S, 2016, CELL, V165, P580, DOI 10.1016/j.cell.2016.02.062
   Rice JC, 2002, GENE DEV, V16, P2225, DOI 10.1101/gad.1014902
   Sadasivam S, 2013, NAT REV CANCER, V13, P585, DOI 10.1038/nrc3556
   Sadasivam S, 2012, GENE DEV, V26, P474, DOI 10.1101/gad.181933.111
   Santra MK, 2009, NATURE, V459, P722, DOI 10.1038/nature08011
   Schafer KA, 1998, VET PATHOL, V35, P461, DOI 10.1177/030098589803500601
   Schwanhäusser B, 2011, NATURE, V473, P337, DOI 10.1038/nature10098
   Sciortino S, 2001, EMBO REP, V2, P1018, DOI 10.1093/embo-reports/kve223
   Segil N, 1996, GENE DEV, V10, P2389, DOI 10.1101/gad.10.19.2389
   Shah MA, 2014, EPIGENET CHROMATIN, V7, DOI 10.1186/1756-8935-7-29
   SHERMOEN AW, 1991, CELL, V67, P303, DOI 10.1016/0092-8674(91)90182-X
   Singh AM, 2015, STEM CELL REP, V5, P323, DOI 10.1016/j.stemcr.2015.07.005
   Step SE, 2014, GENE DEV, V28, P1018, DOI 10.1101/gad.237628.114
   Wäsch R, 2011, EXPERT OPIN THER TAR, V15, P785, DOI 10.1517/14728222.2011.577420
   Wang D, 2011, NATURE, V474, P390, DOI 10.1038/nature10006
   Wang S, 2013, NAT PROTOC, V8, P2502, DOI 10.1038/nprot.2013.150
   Whitfield ML, 2002, MOL BIOL CELL, V13, P1977, DOI 10.1091/mbc.02-02-0030
   Yang YY, 2016, SCI REP-UK, V6, DOI 10.1038/srep20961
   Zee BM, 2012, MOL CELL BIOL, V32, P2503, DOI 10.1128/MCB.06673-11
   Zhang LY, 2011, GENOME RES, V21, P875, DOI 10.1101/gr.117465.110
   Zhao R, 2011, NAT CELL BIOL, V13, P1295, DOI 10.1038/ncb2341
NR 70
TC 92
Z9 109
U1 0
U2 30
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD MAR 28
PY 2017
VL 114
IS 13
BP 3473
EP 3478
DI 10.1073/pnas.1617636114
PG 6
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA EP8DY
UT WOS:000397607300073
PM 28289232
OA Green Published, Bronze
DA 2025-01-12
ER

PT J
AU Debouki-Joudi, S
   Trifa, F
   Khabir, A
   Sellami-Boudawara, T
   Frikha, M
   Daoud, J
   Mokdad-Gargouri, R
AF Debouki-Joudi, Saoussen
   Trifa, Fatma
   Khabir, Abdelmajid
   Sellami-Boudawara, Tahia
   Frikha, Mounir
   Daoud, Jamel
   Mokdad-Gargouri, Raja
TI CpG methylation of APC promoter 1A in sporadic and familial breast
   cancer patients
SO CANCER BIOMARKERS
LA English
DT Article
DE Breast cancer; APC; CpG methylation; transcriptional silencing;
   epigenetic
ID POLYPOSIS-COLI APC; TUMOR-SUPPRESSOR PROTEIN; BETA-CATENIN LEVELS;
   ADENOMATOUS-POLYPOSIS; GENE PROMOTER; ABERRANT METHYLATION; COLORECTAL
   TUMORIGENESIS; SOMATIC MUTATIONS; HYPERMETHYLATION; IDENTIFICATION
AB Tumour suppressor gene (TSG) silencing through promoter hypermethylation plays an important role in cancer initiation. The aim of this study was to assess the extent of methylation of APC gene promoter in 91 sporadic and 44 familial cases of Tunisian patients with breast cancer (BC) in. The frequency of APC promoter methylation is somewhat similar for sporadic and familial breast cancer cases, (52.1%, and 54.5% respectively). For sporadic breast cancer patients, there was a significant correlation of APC promoter hypermethylation with TNM stage (p = 0.024) and 3-year survival (p = 0.025). Regarding the hormonal status (HR), we found significant association between negativity to PR and unmethylated APC (p = 0.005) while ER and Her2/neu are not correlated. Moreover, unmethylated APC promoter is more frequent in tumours expressing at least one out the 3 proteins compared to triple negative cases (p = 0.053). On the other hand, aberrant methylation of APC was associated with tumour size (p = 0.036), lymph node (p = 0.028), distant metastasis (p = 0.031), and 3-year survival (p = 0.046) in the group of patients with familial breast cancer. Moreover, patients with sporadic breast cancer displaying the unmethylated profile have a significant prolonged overall survival compared to those with the methylated pattern of APC promoter (p log rank = 0.008). Epigenetic change at the CpG islands in the APC promoter was associated with the silence of its transcript and the loss of protein expression suggesting that this event is the main mechanism regulating the APC expression in breast cancer. In conclusion, our data showed that the loss of APC through aberrant methylation is associated with the aggressive behavior of both sporadic and familial breast cancer in Tunisian patients.
C1 [Debouki-Joudi, Saoussen; Trifa, Fatma; Mokdad-Gargouri, Raja] Univ Sfax, Ctr Biotechnol Sfax, Dept Canc Genet, Lab Mol Biotechnol Eukaryotes, Sidi Mansour St,BP K 1177 Sfax, Sfax 3018, Tunisia.
   [Khabir, Abdelmajid; Sellami-Boudawara, Tahia; Frikha, Mounir; Daoud, Jamel] CHU Habib Bourguiba, Sfax 3000, Tunisia.
C3 Universite de Sfax; Centre de Biotechnologie de Sfax; Universite de
   Sfax; Hopital Habib Bourguiba
RP Mokdad-Gargouri, R (通讯作者)，Univ Sfax, Ctr Biotechnol Sfax, Dept Canc Genet, Lab Mol Biotechnol Eukaryotes, Sidi Mansour St,BP K 1177 Sfax, Sfax 3018, Tunisia.
EM raja.gargouri@cbs.rnrt.tn
OI ABDELMAJID, KHABIR/0000-0003-0031-2242
FU grant of the "Tunisian Ministry of High Education and Scientific
   Research"
FX This work was supported by a grant of the "Tunisian Ministry of High
   Education and Scientific Research". We thank technicians at CHU Habib
   Bourguiba at Sfax - Tunisia for assistance in immunohistochemistry
   experiments.
CR Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797
   Aoki K, 2007, J CELL SCI, V120, P3327, DOI 10.1242/jcs.03485
   Birgisdottir V, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1522
   BODMER WF, 1987, NATURE, V328, P614, DOI 10.1038/328614a0
   CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2
   Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018
   Dulaimi E, 2004, CLIN CANCER RES, V10, P6189, DOI 10.1158/1078-0432.CCR-04-0597
   Esteller M, 2000, CANCER RES, V60, P4366
   Fearnhead NS, 2001, HUM MOL GENET, V10, P721, DOI 10.1093/hmg/10.7.721
   FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I
   Furuuchi K, 2000, AM J PATHOL, V156, P1997, DOI 10.1016/S0002-9440(10)65072-9
   GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0
   Hachana M, 2009, BREAST CANCER RES TR, V113, P43, DOI 10.1007/s10549-008-9901-z
   Ho KYK, 1999, HISTOPATHOLOGY, V35, P249
   Jin Z, 2001, BRIT J CANCER, V85, P69, DOI 10.1054/bjoc.2001.1853
   Jönsson M, 2000, EUR J CANCER, V36, P242, DOI 10.1016/S0959-8049(99)00276-2
   JOSLYN G, 1991, CELL, V66, P601, DOI 10.1016/0092-8674(81)90022-2
   Karray-Chouayekh S, 2009, J BIOMED BIOTECHNOL, DOI 10.1155/2009/369129
   KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562
   Laird PW, 2003, NAT REV CANCER, V3, P253, DOI 10.1038/nrc1045
   LAMBERTZ S, 1993, HUM GENET, V90, P650
   Lewis CM, 2005, CLIN CANCER RES, V11, P166
   MEDEIROS AC, 1994, CANCER EPIDEM BIOMAR, V3, P331
   Miyoshi Yasuo, 1992, Human Molecular Genetics, V1, P229
   Moon RT, 1997, TRENDS GENET, V13, P256, DOI 10.1016/S0168-9525(97)01196-7
   MUNEMITSU S, 1995, P NATL ACAD SCI USA, V92, P3046, DOI 10.1073/pnas.92.7.3046
   NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563
   POWELL SM, 1992, NATURE, V359, P235, DOI 10.1038/359235a0
   Prasad CP, 2008, LIFE SCI, V83, P318, DOI 10.1016/j.lfs.2008.06.019
   Schlosshauer PW, 2000, CARCINOGENESIS, V21, P1453, DOI 10.1093/carcin/21.7.1453
   Sidransky D, 2002, NAT REV CANCER, V2, P210, DOI 10.1038/nrc755
   Swellam M, 2015, IUBMB LIFE, V67, P61, DOI 10.1002/iub.1346
   THOMPSON AM, 1993, BRIT J CANCER, V68, P64, DOI 10.1038/bjc.1993.287
   Tsuchiya T, 2000, ONCOGENE, V19, P3642, DOI 10.1038/sj.onc.1203704
   Usadel H, 2002, CANCER RES, V62, P371
   Van der Auwera I, 2008, BRIT J CANCER, V99, P1735, DOI 10.1038/sj.bjc.6604705
   Virmani AK, 2001, CLIN CANCER RES, V7, P1998
   Xu XR, 2010, BREAST CANCER RES TR, V121, P685, DOI 10.1007/s10549-009-0628-2
   Yang HJ, 2004, GYNECOL ONCOL, V93, P435, DOI 10.1016/j.ygyno.2004.01.039
NR 39
TC 9
Z9 9
U1 0
U2 4
PU IOS PRESS
PI AMSTERDAM
PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS
SN 1574-0153
EI 1875-8592
J9 CANCER BIOMARK
JI Cancer Biomark.
PY 2017
VL 18
IS 2
BP 133
EP 141
DI 10.3233/CBM-160005
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA EN6JA
UT WOS:000396109100004
PM 27983523
DA 2025-01-12
ER

PT J
AU Liu, AH
   Li, XA
   Wang, GY
   Tang, X
   Kang, H
AF Liu, Aihui
   Li, Xiunan
   Wang, Gangyue
   Tang, Xin
   Kang, Hua
TI MiR-455-DNMT3A signaling is linked toacquisition of
   doxorubicinresistance in breast cancer
SO INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY
LA English
DT Article
DE miR-455; DNMT3A; doxorubicin; resistance; breast cancer
ID DNA METHYLTRANSFERASES; HISTONE DEACETYLASE; DRUG-RESISTANCE;
   HYPOMETHYLATION; METHYLATION; DNMT3B; CELLS; ONCOGENES; MICRORNAS; MECP2
AB Breast cancer cells can develop resistance to chemotherapeutic agents. Epigenetic changes such as DNA methylation and histone modifications have been shown to play a critical role in acquisition of drug resistance bythese cells. microRNAs (miRNAs) are a class of short non-coding RNAs that are closely associated with cancer chemoresistance through regulating the genes involved in epigenetic modifications. In this study, we used a variety of biochemical techniques including cell culture, RT-PCR, Western blot, luciferase reporter assay, MTT and gene silencing to investigate the role of miR-455 in the resistance of human MCF-7 breast adenocarcinoma cells to doxorubicin (DOX). We demonstrated that DOX-resistant MCF-7 cells (MCF-7/DOX) show significant up-regulation of miR-455 compared to normal MCF-7 cells. The mechanistic link between miR-455 deregulation and DOXresistant phenotype in MCF-7/DOX ismediated by DNMT3A. Specifically, we showed that microRNA-455 down-regulates the expression of DNMT3A, thus possibly leading to global loss of DNA methylation in MCF-7/DOX cells. Furthermore, transfection of the MCF-7 cells with siRNAs targeting degradation of DNMT3 reduced their sensitivity to DOX. Our results support the idea that manipulating expression of miRNAs may have significant implications for therapeutic strategies aimedat overcoming thebreast cancer resistance.
C1 [Liu, Aihui; Li, Xiunan; Wang, Gangyue; Tang, Xin] Capital Med Univ, Beijing Obstet & Gynecol Hosp, Dept Breast Surg, Beijing, Peoples R China.
   [Kang, Hua] Capital Med Univ, Xuanwu Hosp, Dept Gen Surg, Beijing 100053, Peoples R China.
C3 Capital Medical University; Capital Medical University
RP Kang, H (通讯作者)，Capital Med Univ, Xuanwu Hosp, Dept Gen Surg, Beijing 100053, Peoples R China.
EM kanghua@xwh.ccmu.edu.cn
FU Beijing municipal health system academic leaders of high-level health
   personnel program [2011-2-28]
FX This work was supported by Beijing municipal health system academic
   leaders of high-level health personnel program (No. 2011-2-28).
CR Chekhun VF, 2007, MOL CANCER THER, V6, P1089, DOI 10.1158/1535-7163.MCT-06-0663
   Das PM, 2004, J CLIN ONCOL, V22, P4632, DOI 10.1200/JCO.2004.07.151
   Ehrlich M, 2002, ONCOGENE, V21, P5400, DOI 10.1038/sj.onc.1205651
   Ehrlich M, 2002, ONCOGENE, V21, P6694, DOI 10.1038/sj.onc.1205890
   FEINBERG AP, 1983, NATURE, V301, P89, DOI 10.1038/301089a0
   FEINBERG AP, 1983, BIOCHEM BIOPH RES CO, V111, P47, DOI 10.1016/S0006-291X(83)80115-6
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Hansen RS, 1999, P NATL ACAD SCI USA, V96, P14412, DOI 10.1073/pnas.96.25.14412
   He L, 2005, NATURE, V435, P828, DOI 10.1038/nature03552
   Jin BL, 2013, ADV EXP MED BIOL, V754, P3, DOI 10.1007/978-1-4419-9967-2_1
   Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561
   Kovalchuk O, 2008, MOL CANCER THER, V7, P2152, DOI 10.1158/1535-7163.MCT-08-0021
   Kutanzi KR, 2011, CLIN EPIGENETICS, V2, P171, DOI 10.1007/s13148-011-0040-8
   Lehnert M, 1998, ANTICANCER RES, V18, P2225
   Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702
   Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6
   Pogribny IP, 2009, CELL MOL LIFE SCI, V66, P2249, DOI 10.1007/s00018-009-0015-5
   Robertson KD, 2001, ONCOGENE, V20, P3139, DOI 10.1038/sj.onc.1204341
   Sakai Y, 2004, GENE EXPR PATTERNS, V5, P231, DOI 10.1016/j.modgep.2004.07.011
   Shen HY, 2016, GENE, V593, P84, DOI 10.1016/j.gene.2016.08.016
   Suetake I, 2004, J BIOL CHEM, V279, P27816, DOI 10.1074/jbc.M400181200
   Szakács G, 2006, NAT REV DRUG DISCOV, V5, P219, DOI 10.1038/nrd1984
   Wade PA, 1998, COLD SPRING HARB SYM, V63, P435, DOI 10.1101/sqb.1998.63.435
   Zhang BH, 2008, J CELL MOL MED, V12, P3, DOI 10.1111/j.1582-4934.2007.00196.x
   Zhang BH, 2007, DEV BIOL, V302, P1, DOI 10.1016/j.ydbio.2006.08.028
NR 25
TC 0
Z9 0
U1 0
U2 1
PU E-CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1936-2625
J9 INT J CLIN EXP PATHO
JI Int. J. Clin. Exp. Pathol.
PY 2017
VL 10
IS 2
BP 1364
EP 1371
PG 8
WC Oncology; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Pathology
GA EN0ZC
UT WOS:000395739000053
DA 2025-01-12
ER

PT J
AU Barbano, R
   Pasculli, B
   Rendina, M
   Fontana, A
   Fusilli, C
   Copetti, M
   Castellana, S
   Valori, VM
   Morritti, M
   Graziano, P
   Luigi, C
   Coco, M
   Picardo, F
   Mazza, T
   Evron, E
   Murgo, R
   Maiello, E
   Esteller, M
   Fazio, VM
   Parrella, P
AF Barbano, Raffaela
   Pasculli, Barbara
   Rendina, Michelina
   Fontana, Andrea
   Fusilli, Caterina
   Copetti, Massimiliano
   Castellana, Stefano
   Valori, Vanna Maria
   Morritti, Maria
   Graziano, Paolo
   Luigi, Ciuffreda
   Coco, Michelina
   Picardo, Francesco
   Mazza, Tommaso
   Evron, Ella
   Murgo, Roberto
   Maiello, Evaristo
   Esteller, Manel
   Fazio, Vito Michele
   Parrella, Paola
TI Stepwise analysis of <i>MIR9</i> loci identifies miR-9-5p to be involved
   in Oestrogen regulated pathways in breast cancer patients
SO SCIENTIFIC REPORTS
LA English
DT Article
ID MICRORNA EXPRESSION; METHYLATION; FAMILY; GENES; DIFFERENTIATION;
   RECOMMENDATIONS; DIVERSITY; SIGNATURE; TARGETS; MIRNAS
AB miR-9 was initially identified as an epigenetically regulated miRNA in tumours, but inconsistent findings have been reported so far. We analysed the expression of miR-9-5p, miR-9-3p, pri-miRs and MIR9 promoters methylation status in 131 breast cancer cases and 12 normal breast tissues (NBTs). The expression of both mature miRs was increased in tumours as compared to NBTs (P < 0.001) and negatively correlated with ER protein expression (P = 0.005 and P = 0.003, for miR-9-3p and miR-9-5p respectively). In addition, miR-9-5p showed a significant negative correlation with PgR (P = 0.002). Consistently, miR-9-5p and miR-9 3p were differentially expressed in the breast cancer subgroups identified by ER and PgR expression and HER2 amplification. No significant correlation between promoter methylation and pri-miRNAs expressions was found either in tumours or in NBTs. In the Luminal breast cancer subtype the expression of miR-9-5p was associated with a worse prognosis in both univariable and multivariable analyses. Ingenuity Pathway Analysis exploring the putative interactions among miR-9-5p/miR-9-3p, ER and PgR upstream and downstream regulators suggested a regulatory loop by which miR-9-5p but not miR-9-3p is induced by steroid hormone receptor and acts within hormone-receptor regulated pathways.
C1 [Barbano, Raffaela; Pasculli, Barbara; Rendina, Michelina; Coco, Michelina; Fazio, Vito Michele; Parrella, Paola] IRCCS Casa Sollievo Sofferenza, Lab Oncol, San Giovanni Rotondo, FG, Italy.
   [Fontana, Andrea; Copetti, Massimiliano] IRCCS Casa Sollievo Sofferenza, Biostat Unit, San Giovanni Rotondo, FG, Italy.
   [Fusilli, Caterina; Castellana, Stefano; Mazza, Tommaso] IRCCS Casa Sollievo Sofferenza, Unit Bioinformat, San Giovanni Rotondo, FG, Italy.
   [Valori, Vanna Maria; Morritti, Maria; Maiello, Evaristo] IRCCS Casa Sollievo Sofferenza, Dept Oncol, San Giovanni Rotondo, FG, Italy.
   [Graziano, Paolo] IRCCS Casa Sollievo Sofferenza, Pathol Unit, San Giovanni Rotondo, FG, Italy.
   [Luigi, Ciuffreda; Murgo, Roberto] IRCCS Casa Sollievo Sofferenza, Breast Unit, San Giovanni Rotondo, Italy.
   [Picardo, Francesco; Fazio, Vito Michele] Univ Campus Biomed Rome, Lab Genet & Clin Pathol, Rome, Italy.
   [Evron, Ella] Tel Aviv Univ, Sakler Sch Med, Assaf Harofeh Med Ctr Zerifin, IL-69978 Tel Aviv, Israel.
   [Esteller, Manel] Bellvitge Biomed Res Inst IDIBELL, Canc Epigenet & Biol Program PEBC, Barcelona, Catalonia, Spain.
   [Esteller, Manel] ICREA, Barcelona, Catalonia, Spain.
   [Esteller, Manel] Univ Barcelona, Sch Med, Dept Physiol Sci 2, Barcelona, Catalonia, Spain.
C3 IRCCS Casa Sollievo Della Sofferenza; IRCCS Casa Sollievo Della
   Sofferenza; IRCCS Casa Sollievo Della Sofferenza; IRCCS Casa Sollievo
   Della Sofferenza; IRCCS Casa Sollievo Della Sofferenza; IRCCS Casa
   Sollievo Della Sofferenza; University Campus Bio-Medico - Rome Italy;
   Tel Aviv University; Shamir Medical Center (Assaf Harofeh); Institut
   d'Investigacio Biomedica de Bellvitge (IDIBELL); ICREA; University of
   Barcelona
RP Parrella, P (通讯作者)，IRCCS Casa Sollievo Sofferenza, Lab Oncol, San Giovanni Rotondo, FG, Italy.
EM pparrella@operapadrepio.it
RI COPETTI, MASSIMILIANO/AAG-1473-2021; Mazza, Tommaso/I-4531-2019; Fedele,
   Palma/AAR-1899-2020; Rendina, Michelina/B-4600-2017; Mazza,
   Tommaso/H-6414-2016; Fontana, Andrea/J-8584-2016; Esteller,
   Manel/L-5956-2014; Maiello, Evaristo/C-5224-2017; Fazio, Vito
   Michele/H-3007-2016; Fusilli, Caterina/K-3016-2016; Graziano,
   Paolo/AAC-9802-2022; Pasculli, Barbara/H-3646-2016; COPETTI,
   MASSIMILIANO/K-3186-2016; PARRELLA, PAOLA/D-8895-2011; Castellana,
   Stefano/K-1965-2016
OI Mazza, Tommaso/0000-0003-0434-8533; Fontana, Andrea/0000-0002-6660-5315;
   Esteller, Manel/0000-0003-4490-6093; Picardo,
   Francesco/0000-0002-9820-1745; Maiello, Evaristo/0000-0003-3890-3435;
   Fazio, Vito Michele/0000-0002-7751-1867; Fusilli,
   Caterina/0000-0001-7497-0657; Graziano, Paolo/0000-0001-7066-7896;
   Pasculli, Barbara/0000-0002-3333-0255; COPETTI,
   MASSIMILIANO/0000-0002-7960-5947; PARRELLA, PAOLA/0000-0001-6031-9636;
   Morritti, Maria/0000-0002-2446-8981; Castellana,
   Stefano/0000-0001-8688-9530
FU Italian Ministry of Health (MoH) [IG-1269/2006]; European Regional
   Development Fund under the TRANSCAN ERA-NET on Translational Cancer
   Research [RRC-2014-2354565, CANCER13-FP-011]; Instituto de Salud Carlos
   III (ISCIII); European Development Regional Fund under the TRANSCAN
   ERA-NET on Translational Cancer Research [CANCER13-FP-011, AC14/00023,
   3-11641]; Chief Scientist Office, Ministry of Health, Israel; ICREA
   Funding Source: Custom
FX Work in P Parrella lab is supported by the Italian Ministry of Health
   (MoH) co-funded by the European Regional Development Fund "A way of
   making Europe" under the TRANSCAN ERA-NET on Translational Cancer
   Research grant no. RRC-2014-2354565 and CANCER13-FP-011; Italian
   Ministry of Health (MoH) "Ricerca Corrente 2016" and "5x1000" voluntary
   contributions"; and "Associazione Italiana Ricerca sul Cancro" (AIRC)
   IG-1269/2006. Manel Esteller is supported by the Instituto de Salud
   Carlos III (ISCIII), co-funded by the European Development Regional
   Fund, "A way of making Europe" ERDF, under the TRANSCAN ERA-NET on
   Translational Cancer Research grant no. AC14/00023 and CANCER13-FP-011".
   Ella Evron is supported by the Chief Scientist Office, Ministry of
   Health, Israel. co-funded by the European Regional Development Fund, "A
   way of making Europe" under the TRANSCAN ERA-NET on Translational Cancer
   Research grant no. 3-11641 and CANCER13-FP-011.
CR Bailey TL, 2009, NUCLEIC ACIDS RES, V37, pW202, DOI 10.1093/nar/gkp335
   Bandres E, 2009, INT J CANCER, V125, P2737, DOI 10.1002/ijc.24638
   Baroni S, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.224
   Baylin SB, 2011, NAT REV CANCER, V11, P726, DOI 10.1038/nrc3130
   Bonev B, 2011, DEV CELL, V20, P19, DOI 10.1016/j.devcel.2010.11.018
   Cai L, 2014, DIAGN PATHOL, V9, DOI 10.1186/s13000-014-0228-2
   Cimmino L, 2011, CELL STEM CELL, V9, P193, DOI 10.1016/j.stem.2011.08.007
   D'Ippolito E, 2016, CANCER RES, V76, P5562, DOI 10.1158/0008-5472.CAN-16-0140
   Dunham I, 2012, NATURE, V489, P57, DOI 10.1038/nature11247
   Ebrahimi-Askari R, 2015, MOL BIOL RES COMMUN, V4, P73
   Esteller M, 2007, HUM MOL GENET, V16, pR50, DOI 10.1093/hmg/ddm018
   Guled M, 2009, GENE CHROMOSOME CANC, V48, P615, DOI 10.1002/gcc.20669
   Guo LM, 2009, FEBS J, V276, P5537, DOI 10.1111/j.1742-4658.2009.07237.x
   Hammond MEH, 2010, ARCH PATHOL LAB MED, V134, P907, DOI [10.1200/JOP.777003, 10.5858/134.6.907, 10.1200/JCO.2009.25.6529]
   Higashi T, 2015, BRIT J CANCER, V113, P252, DOI 10.1038/bjc.2015.170
   Hildebrandt MAT, 2010, ONCOGENE, V29, P5724, DOI 10.1038/onc.2010.305
   Hsu PY, 2009, CANCER RES, V69, P5936, DOI 10.1158/0008-5472.CAN-08-4914
   Hurtado A, 2011, NAT GENET, V43, P27, DOI 10.1038/ng.730
   Kapsimali M, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-8-r173
   Karginov FV, 2013, GENE DEV, V27, P1624, DOI 10.1101/gad.215939.113
   Karolchik D, 2004, NUCLEIC ACIDS RES, V32, pD493, DOI 10.1093/nar/gkh103
   Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412
   Kong SL, 2011, MOL SYST BIOL, V7, DOI 10.1038/msb.2011.59
   Laios A, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-35
   Lehmann U, 2008, J PATHOL, V214, P17, DOI 10.1002/path.2251
   Liu XD, 2016, ONCOTARGETS THER, V9, P3039, DOI 10.2147/OTT.S98923
   Lujambio A, 2008, P NATL ACAD SCI USA, V105, P13556, DOI 10.1073/pnas.0803055105
   Luo HC, 2009, J EXP CLIN CANC RES, V28, DOI 10.1186/1756-9966-28-82
   Ma L, 2010, NAT CELL BIOL, V12, P247, DOI 10.1038/ncb2024
   McShane LM, 2005, NAT CLIN PRACT ONCOL, V2, P416, DOI 10.1038/ncponc0252
   Medina-Rivera A, 2015, NUCLEIC ACIDS RES, V43, pW50, DOI 10.1093/nar/gkv362
   Montagna E, 2015, ANN ONCOL, V26, P307, DOI 10.1093/annonc/mdu528
   Munagala R, 2013, CANCER LETT, V339, P175, DOI 10.1016/j.canlet.2013.06.012
   Muraoka T, 2013, MOL CLIN ONCOL, V1, P185, DOI 10.3892/mco.2012.18
   Nass D, 2009, BRAIN PATHOL, V19, P375, DOI 10.1111/j.1750-3639.2008.00184.x
   Nelson PT, 2006, RNA, V12, P187, DOI 10.1261/rna.2258506
   Osborne CK, 2005, CLIN CANCER RES, V11, p865S
   Otaegi G, 2011, J NEUROSCI, V31, P809, DOI 10.1523/JNEUROSCI.4330-10.2011
   Parrella P, 2004, CLIN CANCER RES, V10, P5349, DOI 10.1158/1078-0432.CCR-04-0555
   Parrella P, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-142
   Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093
   Pillai MM, 2014, BREAST CANCER RES TR, V146, P85, DOI 10.1007/s10549-014-3004-9
   Roese-Koerner B, 2016, STEM CELL REP, V7, P207, DOI 10.1016/j.stemcr.2016.06.008
   Sandelin A, 2004, NUCLEIC ACIDS RES, V32, pD91, DOI 10.1093/nar/gkh012
   Selcuklu S Duygu, 2012, J Biol Chem, V287, P29516, DOI 10.1074/jbc.M111.335943
   Shibata M, 2011, J NEUROSCI, V31, P3407, DOI 10.1523/JNEUROSCI.5085-10.2011
   Slattery ML, 2015, INT J CANCER, V137, P428, DOI 10.1002/ijc.29384
   Wienholds E, 2005, SCIENCE, V309, P310, DOI 10.1126/science.1114519
   Wolff AC, 2013, J CLIN ONCOL, V31, P3997, DOI [10.1200/JCO.2013.50.9984, 10.5858/arpa.2013-0953-SA]
   Wu H, 2014, CELL, V156, P45, DOI 10.1016/j.cell.2013.12.019
   Xu SH, 2014, WORLD J SURG ONCOL, V12, DOI 10.1186/1477-7819-12-195
   Yates A, 2016, NUCLEIC ACIDS RES, V44, pD710, DOI 10.1093/nar/gkv1157
   Zawistowski JS, 2013, MOL CELL BIOL, V33, P2260, DOI 10.1128/MCB.00269-13
   Zhang Y, 2016, NAT GENET, V48, P1003, DOI 10.1038/ng.3635
   Zhou X, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0039011, 10.1371/journal.pone.0043230]
NR 55
TC 44
Z9 48
U1 0
U2 15
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD MAR 27
PY 2017
VL 7
AR 45283
DI 10.1038/srep45283
PG 12
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA EP5CK
UT WOS:000397396400001
PM 28345661
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Toska, E
   Osmanbeyoglu, HU
   Castel, P
   Chan, C
   Hendrickson, RC
   Elkabets, M
   Dickler, MN
   Scaltriti, M
   Leslie, CS
   Armstrong, SA
   Baselga, J
AF Toska, Eneda
   Osmanbeyoglu, Hatice U.
   Castel, Pau
   Chan, Carmen
   Hendrickson, Ronald C.
   Elkabets, Moshe
   Dickler, Maura N.
   Scaltriti, Maurizio
   Leslie, Christina S.
   Armstrong, Scott A.
   Baselga, Jose
TI CANCER THERAPY PI3K pathway regulates ER-dependent transcription in
   breast cancer through the epigenetic regulator KMT2D
SO SCIENCE
LA English
DT Article
ID H3K4 MONOMETHYLATION; COMPASS FAMILY; PHASE-I; FOXA1; METHYLTRANSFERASE;
   METHYLATION; DISRUPTION; MECHANISMS; CHROMATIN; STRATEGY
AB Activating mutations in PIK3CA, the gene encoding phosphoinositide-(3)-kinase alpha (PI3K alpha), are frequently found in estrogen receptor (ER)-positive breast cancer. PI3Ka inhibitors, now in late-stage clinical development, elicit a robust compensatory increase in ER-dependent transcription that limits therapeutic efficacy. We investigated the chromatin-based mechanisms leading to the activation of ER upon PI3K alpha inhibition. We found that PI3Ka inhibition mediates an open chromatin state at the ER target loci in breast cancer models and clinical samples. KMT2D, a histone H3 lysine 4 methyltransferase, is required for FOXA1, PBX1, and ER recruitment and activation. AKT binds and phosphorylates KMT2D, attenuating methyltransferase activity and ER function, whereas PI3K alpha inhibition enhances KMT2D activity. These findings uncover a mechanism that controls the activation of ER by the posttranslational modification of epigenetic regulators, providing a rationale for epigenetic therapy in ER-positive breast cancer.
C1 [Toska, Eneda; Castel, Pau; Chan, Carmen; Elkabets, Moshe; Scaltriti, Maurizio; Baselga, Jose] Mem Sloan Kettering Canc Ctr, Human Oncol & Pathogenesis Program, 1275 York Ave,Box 20, New York, NY 10065 USA.
   [Osmanbeyoglu, Hatice U.; Leslie, Christina S.] Computat Biol Program, Mem Sloan Kettering Canc Ctr, 1275 York Ave,Box 460, New York, NY 10065 USA.
   [Castel, Pau] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, 1450 3rd St, San Francisco, CA 94158 USA.
   [Hendrickson, Ronald C.] Mem Sloan Kettering Canc Ctr, Microchemistry & Prote Core Lab, New York, NY 10065 USA.
   [Elkabets, Moshe] Ben Gurion Univ Negev, Shraga Segal Dept Microbiol, Immunol & Genet, Fac Hlth Sci, IL-84105 Beer Sheva, Israel.
   [Dickler, Maura N.; Baselga, Jose] Dept Med, Mem Sloan Kettering Canc Ctr, New York, NY 10065 USA.
   [Scaltriti, Maurizio] Dept Pathol, Mem Sloan Kettering Canc Ctr, New York, NY 10065 USA.
   [Armstrong, Scott A.] Canc Biol & Genet Program, Mem Sloan Kettering Canc Ctr, New York, NY 10065 USA.
   [Armstrong, Scott A.] Dana Farber Canc Inst, Dept Pediat Oncol, 450 Brookline Ave, Boston, MA 02215 USA.
C3 Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer
   Center; University of California System; University of California San
   Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive
   Cancer Center; University of California San Francisco; Memorial Sloan
   Kettering Cancer Center; Ben Gurion University; Memorial Sloan Kettering
   Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan
   Kettering Cancer Center; Harvard University; Dana-Farber Cancer
   Institute
RP Baselga, J (通讯作者)，Mem Sloan Kettering Canc Ctr, Human Oncol & Pathogenesis Program, 1275 York Ave,Box 20, New York, NY 10065 USA.; Baselga, J (通讯作者)，Dept Med, Mem Sloan Kettering Canc Ctr, New York, NY 10065 USA.; Armstrong, SA (通讯作者)，Canc Biol & Genet Program, Mem Sloan Kettering Canc Ctr, New York, NY 10065 USA.; Armstrong, SA (通讯作者)，Dana Farber Canc Inst, Dept Pediat Oncol, 450 Brookline Ave, Boston, MA 02215 USA.
EM scott_armstrong@dfci.harvard.edu; baselgaj@mskcc.org
RI Toska, Eneda/AAO-1711-2020; elkabets, moshe/R-6822-2019; Osmanbeyogluhu,
   Hatice/Q-1822-2019; Castel, Pau/AAL-5791-2020; Baselga, Jose/L-1629-2016
OI Scaltriti, Maurizio/0000-0002-5522-1447; Osmanbeyoglu,
   Hatice/0000-0002-3175-1777; Toska, Eneda/0000-0002-8974-9792; Chan,
   Carmen/0000-0001-9086-6622; Castel, Pau/0000-0002-4972-4347
FU NIH [RO1CA190642-01A1, CA66996, CA140575]; Breast Cancer Research
   Foundation; Geoffrey Beene Cancer Research Center; National Cancer
   Institute (NCI) Cancer Center Support Grant [P30CA08748]; NCI [K99
   CA207871]; Novartis Pharmaceuticals; Epizyme; Imago Biosciences; Vitae
   Pharmaceuticals
FX We are grateful to L. Pasqualucci, who provided the pCMV-HA-KMT2D and
   the corresponding mutants, the N5437S and R5432W KMT2D plasmids. We also
   thank A. Shilatifard, who provided the KMT2D antibody for our
   preliminary experiments; P. Giresi, A. Krivtsov, and Y. Li for help with
   ATAC-seq; Y. Zou for help with ChIP-seq; N. Morse for help with
   xenograft establishment; and N. Socci for help with microarray analysis.
   This work was supported by NIH grant RO1CA190642-01A1, the Breast Cancer
   Research Foundation, and the Geoffrey Beene Cancer Research Center (to
   J. B.); National Cancer Institute (NCI) Cancer Center Support Grant
   P30CA08748 to the Microchemistry and Proteomics Core Laboratory of the
   Memorial Sloan Kettering Cancer Center; and NIH grants CA66996 and
   CA140575 to S. A. A. We are also grateful for the support of T. and B.
   Weinstein. E. T. holds a fellowship from the Terri Brodeur Breast Cancer
   Foundation. H. U. O. is supported by NCI award K99 CA207871. J. B. and
   M. N. D. are paid consultants for Novartis Pharmaceuticals. S. A. A. is
   a paid consultant for Epizyme, Imago Biosciences, and Vitae
   Pharmaceuticals. Memorial Sloan Kettering Cancer Center and the authors
   (E. T., S. A. A., and J. B.) have filed a patent application (U. S.
   patent registration number 62/420324) related to KMT2D inhibition as a
   treatment for breast cancer. The sequencing data have been deposited in
   the Gene Expression Omnibus database under accession numbers GEO
   GSE84515, GSE84593, GSE84594, and GSE95366.
CR Andre F, 2016, J CLIN ONCOL, V34, DOI 10.1200/JCO.2016.34.15_suppl.TPS618
   Nguyen AT, 2011, BLOOD, V117, P6912, DOI 10.1182/blood-2011-02-334359
   Baselga J, 2016, J CLIN ONCOL, V34, DOI 10.1200/JCO.2016.34.15_suppl.TPS617
   Bosch A, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa4442
   Buenrostro JD, 2013, NAT METHODS, V10, P1213, DOI [10.1038/NMETH.2688, 10.1038/nmeth.2688]
   Cha TL, 2005, SCIENCE, V310, P306, DOI 10.1126/science.1118947
   Ciriello G, 2015, CELL, V163, P506, DOI 10.1016/j.cell.2015.09.033
   Costa C, 2015, CANCER CELL, V27, P97, DOI 10.1016/j.ccell.2014.11.007
   Eeckhoute J, 2009, GENOME RES, V19, P372, DOI 10.1101/gr.084582.108
   Fritsch C, 2014, MOL CANCER THER, V13, P1117, DOI 10.1158/1535-7163.MCT-13-0865
   Green KA, 2007, NAT REV CANCER, V7, P713, DOI 10.1038/nrc2211
   Harris WJ, 2012, CANCER CELL, V21, P473, DOI 10.1016/j.ccr.2012.03.014
   Herz HM, 2012, GENE DEV, V26, P2604, DOI 10.1101/gad.201327.112
   Hu DQ, 2013, MOL CELL BIOL, V33, P4745, DOI 10.1128/MCB.01181-13
   Hurtado A, 2011, NAT GENET, V43, P27, DOI 10.1038/ng.730
   Janku F, 2015, CANCER RES, V75, DOI 10.1158/1538-7445.SABCS14-PD5-5
   Jozwik KM, 2016, CELL REP, V17, P2715, DOI 10.1016/j.celrep.2016.11.028
   Juric D, 2013, CANCER RES, V73, DOI 10.1158/0008-5472.SABCS13-PD1-3
   Juric D., 2013, CANCER RES, V73, DOI DOI 10.1158/1538-7445.AM2013-LB-64
   Juric D, 2015, NATURE, V518, P240, DOI 10.1038/nature13948
   Kim W, 2013, NAT CHEM BIOL, V9, P643, DOI [10.1038/NCHEMBIO.1331, 10.1038/nchembio.1331]
   Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412
   Kooistra SM, 2012, NAT REV MOL CELL BIO, V13, P297, DOI 10.1038/nrm3327
   Lupien M, 2008, CELL, V132, P958, DOI 10.1016/j.cell.2008.01.018
   Magnani L, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002368
   Mayer IA, 2017, CLIN CANCER RES, V23, P26, DOI 10.1158/1078-0432.CCR-16-0134
   McCabe MT, 2012, NATURE, V492, P108, DOI 10.1038/nature11606
   Mo R, 2006, J BIOL CHEM, V281, P15714, DOI 10.1074/jbc.M513245200
   Pearce LR, 2010, NAT REV MOL CELL BIO, V11, P9, DOI 10.1038/nrm2822
   Shah PD, 2015, CANCER RES, V75, DOI 10.1158/1538-7445.AM2015-CT330
   Shilatifard A, 2012, ANNU REV BIOCHEM, V81, P65, DOI 10.1146/annurev-biochem-051710-134100
   Spangle JM, 2016, CELL REP, V15, P2692, DOI 10.1016/j.celrep.2016.05.046
   Zhang JY, 2015, NAT MED, V21, P1190, DOI 10.1038/nm.3940
NR 33
TC 200
Z9 220
U1 3
U2 57
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 0036-8075
EI 1095-9203
J9 SCIENCE
JI Science
PD MAR 24
PY 2017
VL 355
IS 6331
BP 1324
EP 1329
DI 10.1126/science.aah6893
PG 6
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA EP0NB
UT WOS:000397082900042
PM 28336670
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Huang, CK
   Chang, PH
   Kuo, WH
   Chen, CL
   Jeng, YM
   Chang, KJ
   Shew, JY
   Hu, CM
   Lee, WH
AF Huang, Chun-Kai
   Chang, Po-Hao
   Kuo, Wen-Hung
   Chen, Chi-Long
   Jeng, Yung-Ming
   Chang, King-Jen
   Shew, Jin-Yuh
   Hu, Chun-Mei
   Lee, Wen-Hwa
TI Adipocytes promote malignant growth of breast tumours with
   monocarboxylate transporter 2 expression via β-hydroxybutyrate
SO NATURE COMMUNICATIONS
LA English
DT Article
ID HISTONE DEACETYLASE INHIBITOR; SLC16 GENE FAMILY; ADIPOSE-TISSUE;
   KETONE-BODIES; CANCER CELLS; BRAIN CANCER; ACETYLATION; PROGRESSION;
   CARCINOMA; INVASION
AB Adipocytes are the most abundant stromal partners in breast tissue. However, the crosstalk between breast cancer cells and adipocytes has been given less attention compared to cancer-associated fibroblasts. Here we find, through systematic screening, that primary mammary gland-derived adipocytes (MGDAs) promote growth of breast cancer cells that express monocarboxylate transporter 2 (MCT2) both in vitro and in vivo. We show that beta-hydroxybutyrate is secreted by MGDAs and is required to enhance breast cancer cells malignancy in vitro. Consistently, b-hydroxybutyrate is sufficient to promote tumorigenesis of a mouse xenograft model of MCT2-expressing breast cancer cells. Mechanistically we observe that upon co-culturing with MGDAs or treatment with beta-hydroxybutyrate, breast cancer cells expressing MCT2 increase the global histone H3K9 acetylation and upregulate several tumour-promoting genes. These results suggest that adipocytes promote malignancy of MCT2-expressing breast cancer via beta-hydroxybutyrate potentially by inducing the epigenetic upregulation of tumour-promoting genes.
C1 [Huang, Chun-Kai; Chang, Po-Hao; Shew, Jin-Yuh; Lee, Wen-Hwa] Natl Taiwan Univ, Coll Med, Inst Biochem & Mol Biol, Taipei 100, Taiwan.
   [Huang, Chun-Kai; Chang, Po-Hao; Shew, Jin-Yuh; Hu, Chun-Mei; Lee, Wen-Hwa] Acad Sinica, Genom Res Ctr, Taipei 115, Taiwan.
   [Kuo, Wen-Hung; Chang, King-Jen] Natl Taiwan Univ Hosp, Dept Surg, Taipei 100, Taiwan.
   [Chen, Chi-Long] Taipei Med Univ, Wan Fang Hosp, Dept Pathol, Taipei 116, Taiwan.
   [Jeng, Yung-Ming] Natl Taiwan Univ Hosp, Dept Pathol, Taipei 100, Taiwan.
   [Chang, King-Jen] Cheng Chin Gen Hosp, Taichung 407, Taiwan.
   [Lee, Wen-Hwa] China Med Univ, Grad Inst New Drug Dev, Taichung 404, Taiwan.
C3 National Taiwan University; Academia Sinica - Taiwan; National Taiwan
   University; National Taiwan University Hospital; Taipei Municipal
   WanFang Hospital; Taipei Medical University; National Taiwan University;
   National Taiwan University Hospital; China Medical University Taiwan
RP Lee, WH (通讯作者)，Natl Taiwan Univ, Coll Med, Inst Biochem & Mol Biol, Taipei 100, Taiwan.; Lee, WH (通讯作者)，Acad Sinica, Genom Res Ctr, Taipei 115, Taiwan.; Lee, WH (通讯作者)，China Med Univ, Grad Inst New Drug Dev, Taichung 404, Taiwan.
EM whlee@uci.edu
RI chen, yuying/JNS-9778-2023; Chang, Kuang-Jung/J-2193-2012
OI Lee, Wen-Hwa/0000-0002-3117-931X; Chang, King jen/0000-0001-9811-3422;
   KUO, WEN-HUNG/0000-0002-9881-4605; JENG, YUNG-MING/0000-0002-3878-4491
FU Academia Sinica Peak Project [2371, 4012]; National Science Council
   Most, Taiwan [NSC102-2321-B-001-016]
FX This work was supported by grants from Academia Sinica Peak Project
   (grant numbers 2371 and 4012) and National Science Council Most (grant
   number NSC102-2321-B-001-016), Taiwan. We thank Dr A Ball for his
   critical reading of the manuscript.
CR Andarawewa KL, 2005, CANCER RES, V65, P10862, DOI 10.1158/0008-5472.CAN-05-1231
   Benton CR, 2004, BIOCHEM BIOPH RES CO, V323, P249, DOI 10.1016/j.bbrc.2004.08.084
   Bröer S, 1999, BIOCHEM J, V341, P529, DOI 10.1042/0264-6021:3410529
   Chang PH, 2012, CANCER RES, V72, P4652, DOI 10.1158/0008-5472.CAN-12-0877
   Chen JQ, 2011, CANCER CELL, V19, P541, DOI 10.1016/j.ccr.2011.02.006
   Cleary MP, 2009, ENDOCRINOLOGY, V150, P2537, DOI 10.1210/en.2009-0070
   D'Esposito V, 2012, DIABETOLOGIA, V55, P2811, DOI 10.1007/s00125-012-2629-7
   Diers AR, 2012, BIOCHEM J, V444, P561, DOI 10.1042/BJ20120294
   Dirat B, 2011, CANCER RES, V71, P2455, DOI 10.1158/0008-5472.CAN-10-3323
   Donohoe DR, 2012, MOL CELL, V48, P612, DOI 10.1016/j.molcel.2012.08.033
   Drogaris P, 2012, SCI REP-UK, V2, DOI 10.1038/srep00220
   FEARON KCH, 1985, BRIT J CANCER, V52, P87, DOI 10.1038/bjc.1985.153
   Gerlinger M, 2012, J PATHOL, V227, P146, DOI 10.1002/path.4006
   Halestrap AP, 2013, MOL ASPECTS MED, V34, P337, DOI 10.1016/j.mam.2012.05.003
   Halestrap AP, 2004, PFLUG ARCH EUR J PHY, V447, P619, DOI 10.1007/s00424-003-1067-2
   Jansen LA, 2014, J PLAST RECONSTR AES, V67, P1615, DOI 10.1016/j.bjps.2014.10.001
   Jiang GM, 2013, BBA-MOL CELL RES, V1833, P663, DOI 10.1016/j.bbamcr.2012.12.002
   Kao KJ, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-143
   Kimijima I, 2000, ONCOLOGY-BASEL, V59, P25, DOI 10.1159/000055284
   Lee I, 2012, MOL CANCER THER, V11, P2342, DOI 10.1158/1535-7163.MCT-12-0488
   Lin RY, 1998, J BIOL CHEM, V273, P28959, DOI 10.1074/jbc.273.44.28959
   Liotta LA, 2001, NATURE, V411, P375, DOI 10.1038/35077241
   Lorincz AM, 2006, ENDOCR-RELAT CANCER, V13, P279, DOI 10.1677/erc.1.00729
   Newman JC, 2014, TRENDS ENDOCRIN MET, V25, P42, DOI 10.1016/j.tem.2013.09.002
   Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034
   Perrier S, 2009, FEBS LETT, V583, P259, DOI 10.1016/j.febslet.2008.12.030
   Pértega-Gomes N, 2013, PROSTATE, V73, P763, DOI 10.1002/pros.22620
   Pinheiro C, 2008, VIRCHOWS ARCH, V452, P139, DOI 10.1007/s00428-007-0558-5
   Pinheiro C, 2010, HISTOPATHOLOGY, V56, P860, DOI 10.1111/j.1365-2559.2010.03560.x
   Poff AM, 2014, INT J CANCER, V135, P1711, DOI 10.1002/ijc.28809
   Poff AM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065522
   Richardson AL, 2006, CANCER CELL, V9, P121, DOI 10.1016/j.ccr.2006.01.013
   RONG S, 1992, MOL CELL BIOL, V12, P5152, DOI 10.1128/MCB.12.11.5152
   Sasser AK, 2007, FASEB J, V21, P3763, DOI 10.1096/fj.07-8832com
   Seyfried TN, 2003, BRIT J CANCER, V89, P1375, DOI 10.1038/sj.bjc.6601269
   Shimazu T, 2013, SCIENCE, V339, P211, DOI 10.1126/science.1227166
   Sterner DE, 2000, MICROBIOL MOL BIOL R, V64, P435, DOI 10.1128/MMBR.64.2.435-459.2000
   Surmacz E, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1638
   Tyan SW, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0015313
   van Harmelen Vanessa, 2005, Methods Mol Med, V107, P125
   Vona-Davis L, 2007, ENDOCR-RELAT CANCER, V14, P189, DOI 10.1677/ERC-06-0068
   Wang YY, 2012, CANCER LETT, V324, P142, DOI 10.1016/j.canlet.2012.05.019
   Whittaker SJ, 2010, J CLIN ONCOL, V28, P4485, DOI 10.1200/JCO.2010.28.9066
   Williams PT, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080616
   Yamaguchi J, 2008, AM J CLIN PATHOL, V130, P382, DOI 10.1309/MX6KKA1UNJ1YG8VN
   Yang J, 2009, CELL CYCLE, V8, P2347, DOI 10.4161/cc.8.15.9224
   Zhang WY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031450
   Zhou WH, 2007, NUTR METAB, V4, DOI 10.1186/1743-7075-4-5
NR 48
TC 88
Z9 98
U1 1
U2 23
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-1723
J9 NAT COMMUN
JI Nat. Commun.
PD MAR 10
PY 2017
VL 8
AR 14706
DI 10.1038/ncomms14706
PG 13
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA EN3JH
UT WOS:000395904300001
PM 28281525
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU Tsuboi, K
   Kaneko, Y
   Nagatomo, T
   Fujii, R
   Hanamura, T
   Gohno, T
   Yamaguchi, Y
   Niwa, T
   Hayashi, S
AF Tsuboi, Kouki
   Kaneko, Yosuke
   Nagatomo, Takamasa
   Fujii, Rika
   Hanamura, Toru
   Gohno, Tatsuyuki
   Yamaguchi, Yuri
   Niwa, Toshifumi
   Hayashi, Shin-ichi
TI Different epigenetic mechanisms of ERα implicated in the fate of
   fulvestrant-resistant breast cancer
SO JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY
LA English
DT Article
DE Breast cancer; Fulvestrant; Estrogen receptor alpha; DNA methylation;
   Endocrine therapy resistance
ID ESTROGEN-RECEPTOR-ALPHA; ACQUIRED-RESISTANCE; DNA METHYLATION;
   POSTMENOPAUSAL WOMEN; ENDOCRINE-THERAPY; MESSENGER-RNA; 500 MG;
   MUTATIONS; CELLS; GENE
AB Approximately 70% of breast cancers express estrogen receptor a. (ER alpha), which plays critical roles in breast cancer development. Fulvestrant has been effectively used to treat ER alpha-positive breast cancer, although resistance remains a critical problem. To elucidate the mechanism of resistance to fulvestrant, we established fulvestrant-resistant cell-lines named MFR (MCF-7 derived fulvestrant resistance) and TFR (T-47D derived fulvestrant resistance) from the ER alpha-positive luminal breast cancer cell lines MCF-7 and T-47D, respectively. Both fulvestrant-resistant cell lines lost sensitivity to estrogen and anti estrogens. We observed diminished ER alpha expression at both the protein and mRNA levels. To address the mechanism of gene expression regulation, we examined epigenetic alteration, especially the DNA methylation level of ERa gene promoters. MFR cells displayed high methylation levels upstream of the ER alpha gene, whereas no change in DNA methylation was observed in TFR cells. Hence, we examined the gene expression plasticity of ER alpha, as there are differences in its reversibility following fulvestrant withdrawal. ER alpha gene expression was not restored in MFR cells, and alternative intracellular phosphorylation signals were activated. By contrast, TFR cells exhibited plasticity of ER alpha gene expression and ER alpha-dependent growth; moreover, these cells were resensitized to estrogen and anti estrogens. The difference in epigenetic regulation among individual cells might explain the difference in the plasticity of ER alpha expression. We also identified an MFR cell-activating HER/Src-Akt/MAPK pathway; thus, the specific inhibitors effectively blocked MFR cell growth. This finding implies the presence of multiple fulvestrant resistance mechanisms and suggests that the optimal therapies differ among individual tumors as a result of differing epigenetic mechanisms regulating ER alpha gene expression. (C) 2016 Elsevier Ltd. All rights reserved.
C1 [Tsuboi, Kouki; Kaneko, Yosuke; Nagatomo, Takamasa; Fujii, Rika; Hanamura, Toru; Gohno, Tatsuyuki; Niwa, Toshifumi; Hayashi, Shin-ichi] Grad Tohoku Univ, Sch Med, Dept Mol & Funct Dynam, Sendai, Miyagi, Japan.
   [Fujii, Rika] Grad Tohoku Univ, Sch Med, Surg Oncol, Sendai, Miyagi, Japan.
   [Hanamura, Toru] Shinshu Univ, Sch Med, Dept Surg, Div Breast & Endocrine Surg, Nagano, Japan.
   [Yamaguchi, Yuri] Saitama Canc Ctr, Res Inst Clin Oncol, Saitama, Japan.
   [Hayashi, Shin-ichi] Grad Tohoku Univ, Sch Med, Ctr Regulatory Epigenome & Dis, Sendai, Miyagi, Japan.
C3 Shinshu University
RP Hayashi, S (通讯作者)，Tohoku Univ, Grad Sch Med, Dept Mol & Funct Dynam, Aoba Ku, 2-1 Seiryo Machi, Sendai, Miyagi 9808575, Japan.
EM shin@med.tohoku.ac.jp
RI ; Hanamura, Toru/AAE-5184-2020
OI Niwa, Toshifumi/0000-0002-9580-9042; Hanamura, Toru/0000-0002-6934-8588
FU Ministry of Education, Science, Sports and Culture of Japan; Ministry of
   Health, Labor and Welfare of Japan; Program for Promotion of Fundamental
   Studies in Health Science of the National Institute of Biomedical
   Innovation (NIBIO); Smoking Research Foundation; Grants-in-Aid for
   Scientific Research [15K10082, 17K09871] Funding Source: KAKEN
FX This study was supported in part by a Grant-in-Aid for Scientific
   Research from the Ministry of Education, Science, Sports and Culture of
   Japan, a Grant-in-Aid for Cancer Research from the Ministry of Health,
   Labor and Welfare of Japan, the Program for Promotion of Fundamental
   Studies in Health Science of the National Institute of Biomedical
   Innovation (NIBIO), and a grant from the Smoking Research Foundation.
CR Allen-Petersen BL, 2014, ONCOGENE, V33, P1306, DOI 10.1038/onc.2013.59
   Amaral S, 2009, BREAST CANCER RES TR, V118, P323, DOI 10.1007/s10549-008-0241-9
   Burstein HJ, 2014, J CLIN ONCOL, V32, P2255, DOI 10.1200/JCO.2013.54.2258
   Cedar H, 2009, NAT REV GENET, V10, P295, DOI 10.1038/nrg2540
   Colditz GA, 1998, JNCI-J NATL CANCER I, V90, P814, DOI 10.1093/jnci/90.11.814
   Di Leo A, 2010, J CLIN ONCOL, V28, P4594, DOI 10.1200/JCO.2010.28.8415
   DUKES M, 1992, J ENDOCRINOL, V135, P239, DOI 10.1677/joe.0.1350239
   Ellis MJ, 2015, J CLIN ONCOL, V33, P3781, DOI 10.1200/JCO.2015.61.5831
   Fan MY, 2006, CANCER RES, V66, P11954, DOI 10.1158/0008-5472.CAN-06-1666
   FISHER B, 1986, BREAST CANCER RES TR, V7, P147, DOI 10.1007/BF01806245
   Frogne T, 2009, BREAST CANCER RES TR, V114, P263, DOI 10.1007/s10549-008-0011-8
   Fujii R, 2014, J STEROID BIOCHEM, V144, P513, DOI 10.1016/j.jsbmb.2014.08.019
   Fujiki N, 2014, J STEROID BIOCHEM, V139, P61, DOI 10.1016/j.jsbmb.2013.08.012
   Fuqua SAW, 2014, BREAST CANCER RES TR, V144, P11, DOI 10.1007/s10549-014-2847-4
   Giessrigl B, 2013, BRIT J CANCER, V109, P2751, DOI 10.1038/bjc.2013.583
   Hanamura T, 2014, BREAST CANCER RES TR, V143, P69, DOI 10.1007/s10549-013-2788-3
   Hanamura T, 2013, BREAST CANCER RES TR, V139, P731, DOI 10.1007/s10549-013-2595-x
   Hayashi S, 1997, CARCINOGENESIS, V18, P459, DOI 10.1093/carcin/18.3.459
   Hayashi S, 2015, INT J CLIN ONCOL, V20, P262, DOI 10.1007/s10147-015-0788-5
   Heldring N, 2007, PHYSIOL REV, V87, P905, DOI 10.1152/physrev.00026.2006
   Higuchi T, 2014, CLIN BREAST CANCER, V14, P249, DOI 10.1016/j.clbc.2013.10.015
   Inoue A, 2002, J PHARMACOL TOX MET, V47, P129, DOI 10.1016/S1056-8719(02)00221-6
   Jeselsohn R, 2015, NAT REV CLIN ONCOL, V12, P573, DOI 10.1038/nrclinonc.2015.117
   Jeselsohn R, 2014, CLIN CANCER RES, V20, P1757, DOI 10.1158/1078-0432.CCR-13-2332
   Jordan VC, 2007, STEROIDS, V72, P7, DOI 10.1016/j.steroids.2006.10.009
   Kirkegaard T, 2014, CANCER LETT, V344, P90, DOI 10.1016/j.canlet.2013.10.014
   Kos M, 2001, MOL ENDOCRINOL, V15, P2057, DOI 10.1210/me.15.12.2057
   Kuukasjarvi T, 1996, J CLIN ONCOL, V14, P2584, DOI 10.1200/JCO.1996.14.9.2584
   Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427
   Li SQ, 2013, CELL REP, V4, P1116, DOI 10.1016/j.celrep.2013.08.022
   Ma CX, 2015, NAT REV CANCER, V15, P261, DOI 10.1038/nrc3920
   Marcotte R, 2009, MOL CELL BIOL, V29, P5858, DOI 10.1128/MCB.01731-08
   Osborne CK, 2004, BRIT J CANCER, V90, pS2, DOI 10.1038/sj.bjc.6601629
   Perey L, 2007, ANN ONCOL, V18, P64, DOI 10.1093/annonc/mdl341
   Pryzbylkowski P, 2008, BREAST CANCER RES TR, V111, P15, DOI 10.1007/s10549-007-9751-0
   Robinson DR, 2013, NAT GENET, V45, P1446, DOI 10.1038/ng.2823
   Rose NR, 2014, BBA-GENE REGUL MECH, V1839, P1362, DOI 10.1016/j.bbagrm.2014.02.007
   Senkus E, 2013, ANN ONCOL, V24, P7, DOI 10.1093/annonc/mdt284
   Shaw LE, 2006, J STEROID BIOCHEM, V99, P19, DOI 10.1016/j.jsbmb.2005.11.005
   Thomas C, 2011, NAT REV CANCER, V11, P597, DOI 10.1038/nrc3093
   Toy W, 2013, NAT GENET, V45, P1439, DOI 10.1038/ng.2822
   Wakeling A.E., 1991, AM ASS CANC RES, P3867
   WAKELING AE, 1992, J STEROID BIOCHEM, V43, P173, DOI 10.1016/0960-0760(92)90204-V
   Yamaguchi Y, 2014, CANCER MICROENVIRON, V7, P23, DOI 10.1007/s12307-013-0139-x
NR 44
TC 18
Z9 20
U1 0
U2 9
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-0760
J9 J STEROID BIOCHEM
JI J. Steroid Biochem. Mol. Biol.
PD MAR
PY 2017
VL 167
BP 115
EP 125
DI 10.1016/j.jsbmb.2016.11.017
PG 11
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA EK7BA
UT WOS:000394079300014
PM 27888136
DA 2025-01-12
ER

PT J
AU McCullough, LE
   Chen, J
   Cho, YH
   Khankari, NK
   Bradshaw, PT
   White, AJ
   Teitelbaum, SL
   Terry, MB
   Neugut, AI
   Hibshoosh, H
   Santella, RM
   Gammon, MD
AF McCullough, Lauren E.
   Chen, Jia
   Cho, Yoon Hee
   Khankari, Nikhil K.
   Bradshaw, Patrick T.
   White, Alexandra J.
   Teitelbaum, Susan L.
   Terry, Mary Beth
   Neugut, Alfred I.
   Hibshoosh, Hanina
   Santella, Regina M.
   Gammon, Marilie D.
TI Modification of the association between recreational physical activity
   and survival after breast cancer by promoter methylation in breast
   cancer-related genes
SO BREAST CANCER RESEARCH
LA English
DT Article
DE Physical activity; Epigenetics; Methylation; Breast cancer; Survival
ID CPG ISLAND HYPERMETHYLATION; DNA METHYLATION; LONG-ISLAND; CELL; TUMOR;
   TIME; EXPRESSION; SUBTYPES; CARCINOGENESIS; EPIGENETICS
AB Background: Mechanisms underlying the inverse association between physical activity and survival after breast cancer are unresolved, but DNA methylation may play a role. We hypothesized that promoter methylation of breast cancer-related genes, as well as global methylation, may modify the association between prediagnostic recreational physical activity (RPA) and breast cancer mortality.
   Methods: Using a population-based sample of 1254 women diagnosed with first primary breast cancer, we examined modification of the RPA-mortality association by gene-specific promoter methylation and global methylation. Average lifetime RPA was assessed from menarche to diagnosis through structured in-home interviews. Promoter methylation of 13 breast cancer-related genes was evaluated in archived tumor by methylation-specific polymerase chain reaction and MethyLight assay. Global methylation in white blood cell DNA was determined at long interspersed nucleotide element 1 and by the luminometric methylation assay. After approximately 15 years of follow-up, 486 patients had died, and 186 of the deaths were breast cancer-related. We used Cox proportional hazards regression to estimate HRs and 95% CIs as well as likelihood ratio tests to assess multiplicative interactions.
   Results: All-cause mortality was lower only among physically active women with methylated promoter of APC (HR 0.60, 95% CI 0.40-0.80), CCND2 (HR 0.56, 95% CI 0.32-0.99), HIN (HR 0.55, 95% CI 0.38-0.80), and TWIST1 (HR 0.28, 95% CI 0.14-0.56) in tumors, but not among those with unmethylated tumors (significant interaction p < 0.05). We found no interaction between RPA and global methylation.
   Conclusions: The improved survival after breast cancer that is associated with RPA may be more pronounced in women with promoter tumor methylation in biologically plausible genes.
C1 [McCullough, Lauren E.] Emory Univ, Dept Epidemiol, Atlanta, GA 30322 USA.
   [Chen, Jia; Teitelbaum, Susan L.] Icahn Sch Med Mt Sinai, Dept Prevent Med, New York, NY 10029 USA.
   [Chen, Jia] Icahn Sch Med Mt Sinai, Dept Pediat, New York, NY 10029 USA.
   [Chen, Jia] Icahn Sch Med Mt Sinai, Dept Oncol Sci, New York, NY 10029 USA.
   [Cho, Yoon Hee] Univ Montana, Dept Biomed & Pharmaceut Sci, Missoula, MT 59812 USA.
   [Khankari, Nikhil K.] Vanderbilt Univ, Med Ctr, Div Epidemiol, Nashville, TN 37203 USA.
   [Bradshaw, Patrick T.] Univ Calif Berkeley, Div Epidemiol, Berkeley, CA 94720 USA.
   [White, Alexandra J.] NIEHS, Epidemiol Branch, Res Triangle Pk, NC 27709 USA.
   [Terry, Mary Beth; Neugut, Alfred I.] Columbia Univ, Dept Epidemiol, New York, NY 10032 USA.
   [Neugut, Alfred I.] Columbia Univ, Dept Med, New York, NY 10032 USA.
   [Hibshoosh, Hanina] Columbia Univ, Dept Pathol, New York, NY 10032 USA.
   [Santella, Regina M.] Columbia Univ, Dept Environm Hlth Sci, New York, NY 10032 USA.
   [Gammon, Marilie D.] Univ North Carolina Chapel Hill, Dept Epidemiol, Chapel Hill, NC 27599 USA.
C3 Emory University; Icahn School of Medicine at Mount Sinai; Icahn School
   of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai;
   University of Montana System; University of Montana; Vanderbilt
   University; University of California System; University of California
   Berkeley; National Institutes of Health (NIH) - USA; NIH National
   Institute of Environmental Health Sciences (NIEHS); Columbia University;
   Columbia University; Columbia University; Columbia University;
   University of North Carolina; University of North Carolina Chapel Hill;
   University of North Carolina School of Medicine
RP McCullough, LE (通讯作者)，Emory Univ, Dept Epidemiol, Atlanta, GA 30322 USA.
EM lauren.mccullough@emory.edu
RI Cho, Yoon/AAN-6560-2021; White, Alexandra/D-9687-2019; Bradshaw,
   Patrick/AAJ-7529-2021
OI Cho, Yoon Hee/0000-0002-4290-7140; Terry, Mary Beth/0000-0002-4106-5033;
   White, Alexandra/0000-0003-2455-2945
FU National Institutes of Health [R25CA057726, U01CA/ES66572, R01CA66572,
   R01CA109753, 3R01CA109753-04S1, P30ES009089, P30ES10126]; U.S.
   Department of Defense [BC972772]; Intramural Research Program of the
   National Institutes of Health through the National Institute of
   Environmental Health Sciences
FX This work was supported in part by grants from the National Institutes
   of Health (R25CA057726, U01CA/ES66572, R01CA66572, R01CA109753,
   3R01CA109753-04S1, P30ES009089, P30ES10126) and the U.S. Department of
   Defense (BC972772). This research was also supported in part by the
   Intramural Research Program of the National Institutes of Health through
   the National Institute of Environmental Health Sciences.
CR Anderson WF, 2011, J NATL CANCER I, V103, P1397, DOI 10.1093/jnci/djr257
   [Anonymous], 2011, SURVIVAL ANAL USING
   [Anonymous], 2002, Logistic regression
   [Anonymous], 1989, WILEY SERIES PROBABI
   Bernstein M, 1998, AM J EPIDEMIOL, V147, P147
   Birney E, 2016, PLOS GENET, V12, DOI 10.1371/journal.pgen.1006105
   Bjornsson HT, 2008, JAMA-J AM MED ASSOC, V299, P2877, DOI 10.1001/jama.299.24.2877
   Bradshaw PT, 2014, BREAST CANCER RES TR, V145, P735, DOI 10.1007/s10549-014-2966-y
   Cho YH, 2012, BREAST CANCER RES TR, V131, P197, DOI 10.1007/s10549-011-1712-y
   Clarke CA, 2012, JNCI-J NATL CANCER I, V104, P1094, DOI 10.1093/jnci/djs264
   Cleveland RJ, 2012, EUR J CANCER PREV, V21, P46, DOI 10.1097/CEJ.0b013e3283498dd4
   Cole SR, 2002, INT J EPIDEMIOL, V31, P163, DOI 10.1093/ije/31.1.163
   Eads CA, 1999, CANCER RES, V59, P2302
   Eads CA, 2000, CANCER RES, V60, P5021
   Eads CA, 2000, NUCLEIC ACIDS RES, V28, DOI 10.1093/nar/28.8.e32
   Evron E, 2001, CANCER RES, V61, P2782
   Fan SC, 2009, BIOCHEM BIOPH RES CO, V383, P421, DOI 10.1016/j.bbrc.2009.04.023
   Feil R, 2012, NAT REV GENET, V13, P97, DOI 10.1038/nrg3142
   Fernandez SV, 2010, MUTAT RES-FUND MOL M, V688, P28, DOI 10.1016/j.mrfmmm.2010.02.007
   Friedenreich CM, 2010, SEMIN ONCOL, V37, P297, DOI 10.1053/j.seminoncol.2010.05.008
   Gammon MD, 2004, ARCH ENVIRON HEALTH, V59, P640, DOI 10.1080/00039890409602948
   Gammon MD, 2002, BREAST CANCER RES TR, V74, P235, DOI 10.1023/A:1016387020854
   Gyorffy B, 2016, INT J CANCER, V138, P87, DOI 10.1002/ijc.29684
   Hoffman-Goetz L, 1998, CANCER, V83, P621, DOI 10.1002/(SICI)1097-0142(19980801)83:3+<621::AID-CNCR4>3.0.CO;2-A
   Hoque MO, 2004, CANCER RES, V64, P5511, DOI 10.1158/0008-5472.CAN-04-0799
   Jin Z, 2001, BRIT J CANCER, V85, P69, DOI 10.1054/bjoc.2001.1853
   Kang GH, 2003, AM J PATHOL, V163, P1551, DOI 10.1016/S0002-9440(10)63511-0
   Khankari NK, 2015, CANCER-AM CANCER SOC, V121, P2244, DOI 10.1002/cncr.29329
   Krop I, 2005, CANCER RES, V65, P9659, DOI 10.1158/0008-5472.CAN-05-1663
   Krop I, 2003, CANCER RES, V63, P2024
   Lahart IM, 2015, ACTA ONCOL, V54, P635, DOI 10.3109/0284186X.2014.998275
   Li SY, 2006, CANCER LETT, V237, P272, DOI 10.1016/j.canlet.2005.06.011
   Liggett T, 2010, CANCER-AM CANCER SOC, V116, P1674, DOI 10.1002/cncr.24893
   Liu ZJ, 2003, LIFE SCI, V73, P1963, DOI 10.1016/S0024-3205(03)00544-7
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lo YMD, 1999, CANCER RES, V59, P3899
   Mattusch F, 2000, INT J SPORTS MED, V21, P21
   McCullough L.E., 2015, Int. J. Cancer Clin. Res, V2, P013, DOI [10.23937/2378-3419/2/1/1013, DOI 10.23937/2378-3419/2/1/1013, DOI 10.23937/2378-3419/2/1/1013)]
   McCullough LE, 2016, BREAST CANCER RES TR, V156, P183, DOI 10.1007/s10549-016-3724-0
   McCullough LE, 2012, CANCER-AM CANCER SOC, V118, P4860, DOI 10.1002/cncr.27433
   Nagase H, 2008, FEBS J, V275, P1617, DOI 10.1111/j.1742-4658.2008.06330.x
   O'Brien KM, 2010, CLIN CANCER RES, V16, P6100, DOI 10.1158/1078-0432.CCR-10-1533
   Schisterman EF, 2009, EPIDEMIOLOGY, V20, P488, DOI 10.1097/EDE.0b013e3181a819a1
   Siegel EM, 2014, CANCER EPIDEM BIOMAR, V23, P2622, DOI 10.1158/1055-9965.EPI-14-0464
   Starlard-Davenport A, 2010, CARCINOGENESIS, V31, P376, DOI 10.1093/carcin/bgp304
   van Hoesel AQ, 2012, BREAST CANCER RES TR, V134, P1103, DOI 10.1007/s10549-012-2038-0
   Virmani A, 2003, INT J CANCER, V107, P341, DOI 10.1002/ijc.11393
   Weisenberger DJ, 2005, NUCLEIC ACIDS RES, V33, P6823, DOI 10.1093/nar/gki987
   White AJ, 2013, EUR J CANCER, V49, P2199, DOI 10.1016/j.ejca.2013.02.013
   Widschwendter M, 2002, ONCOGENE, V21, P5462, DOI 10.1038/sj.onc.1205606
   Xu JH, 2016, CANCER CELL INT, V16, DOI 10.1186/s12935-016-0290-9
   Xu XR, 2012, FASEB J, V26, P2657, DOI 10.1096/fj.11-197251
   Xu XR, 2011, EPIGENETICS-US, V6, P1276, DOI 10.4161/epi.6.11.17744
   Xu XR, 2010, BREAST CANCER RES TR, V121, P685, DOI 10.1007/s10549-009-0628-2
   Xu XR, 2009, BREAST CANCER RES TR, V115, P397, DOI 10.1007/s10549-008-0075-5
   Zhang PM, 1999, CURR OPIN CELL BIOL, V11, P655, DOI 10.1016/S0955-0674(99)00032-0
NR 56
TC 15
Z9 18
U1 0
U2 14
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1465-542X
EI 1465-5411
J9 BREAST CANCER RES
JI Breast Cancer Res.
PD FEB 21
PY 2017
VL 19
AR 19
DI 10.1186/s13058-017-0811-z
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA EL7UB
UT WOS:000394825000001
PM 28222775
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU Augustin, LSA
   Libra, M
   Crispo, A
   Grimaldi, M
   De Laurentiis, M
   Rinaldo, M
   D'Aiuto, M
   Catalano, F
   Banna, G
   Ferrau, F
   Rossello, R
   Serraino, D
   Bidoli, E
   Massarut, S
   Thomas, G
   Gatti, D
   Cavalcanti, E
   Pinto, M
   Riccardi, G
   Vidgen, E
   Kendall, CWC
   Jenkins, DJA
   Ciliberto, G
   Montella, M
AF Augustin, Livia S. A.
   Libra, Massimo
   Crispo, Anna
   Grimaldi, Maria
   De Laurentiis, Michele
   Rinaldo, Massimo
   D'Aiuto, Massimiliano
   Catalano, Francesca
   Banna, Giuseppe
   Ferrau, Francesco
   Rossello, Rosalba
   Serraino, Diego
   Bidoli, Ettore
   Massarut, Samuele
   Thomas, Guglielmo
   Gatti, Davide
   Cavalcanti, Ernesta
   Pinto, Monica
   Riccardi, Gabriele
   Vidgen, Edward
   Kendall, Cyril W. C.
   Jenkins, David J. A.
   Ciliberto, Gennaro
   Montella, Maurizio
TI Low glycemic index diet, exercise and vitamin D to reduce breast cancer
   recurrence (DEDiCa): design of a clinical trial
SO BMC CANCER
LA English
DT Article
DE Dietary glycemic index; Mediterranean diet; Exercise; Vitamin D; Breast
   cancer recurrence; Disease-free survival; Cardiovascular disease;
   Diabetes; Risk factors
ID TYPE-2 DIABETES-MELLITUS; CARDIOVASCULAR RISK-FACTORS; C-REACTIVE
   PROTEIN; PHYSICAL-ACTIVITY; MEDITERRANEAN DIET; POSTMENOPAUSAL WOMEN;
   RANDOMIZED-TRIAL; 25-HYDROXYVITAMIN D; PROSPECTIVE COHORT; OXIDATIVE
   STRESS
AB Background: Mechanisms influencing breast cancer (BC) development and recurrence include hyperglycemia, hyperinsulinemia, high insulin-like growth factor-1, high circulating estrogen, inflammation and impaired cellular differentiation/apoptosis. A lifestyle program that targets all the above mechanisms may be warranted. Low glycemic index (GI) foods produce lower post-prandial glucose and insulin responses and have been associated with lower BC risk. Moderate physical activity post-diagnosis reduces BC recurrence and mortality, partly explained by reduced insulin and estrogen levels. Vitamin D increases cell differentiation/apoptosis and high serum vitamin D levels improve BC survival. Yet no trial has evaluated the combined effect of a low GI diet, moderate physical activity and vitamin D supplementation on BC recurrence in the context of a Mediterranean lifestyle setting.
   Methods: Women (30-74 yr) who had undergone surgery for primary histologically confirmed BC (stages I-III) within the previous 12 months, in cancer centres in Italy, will be randomized to follow, for a maximum of 33 months, either a high intensity treatment (HIT) composed of low GI diet + exercise + vitamin D (60 ng/mL serum concentration) or a lower intensity treatment (LITE) with general advice to follow a healthy diet and exercise pattern + vitamin D to avoid insufficiency. Both interventions are on a background of a Mediterranean diet. Considering a 20% recurrence rate within 3 years for BC cases and a predicted rate of 10% in the HIT group, with power of 80% and two-sided alpha of 0.05, the subject number required will be 506 (n = 253 in each arm). Clinic visits will be scheduled every 3 months. Dietary and exercise counselling and vitamin D supplements will be given at each clinic visit when blood samples, anthropometric measures and 7-day food records will be collected.
   Discussion: DEDiCa study aims to reduce BC recurrence in women with BC using a lifestyle approach with additional vitamin D and to investigate possible cardio-metabolic benefits as well as epigenetic modifications according to lifestyle changes. Given the supporting evidence and safety of the components of our intervention we believe it is feasible and urgent to test it in cancer patients.
C1 [Augustin, Livia S. A.; Crispo, Anna; Grimaldi, Maria; De Laurentiis, Michele; Rinaldo, Massimo; D'Aiuto, Massimiliano; Cavalcanti, Ernesta; Pinto, Monica; Montella, Maurizio] IRCCS, Natl Canc Inst, Ist Nazl Tumori Fondazione Giovann Pascale, Naples, Italy.
   [Augustin, Livia S. A.; Kendall, Cyril W. C.; Jenkins, David J. A.] St Michaels Hosp, Clin Nutr & Risk Factor Modificat Ctr, Toronto, ON, Canada.
   [Libra, Massimo] Univ Catania, Dept Biomed & Biotechnol Sci Oncol, Clin & Gen Pathol Sect, Catania, Italy.
   [Catalano, Francesca; Banna, Giuseppe] Cannizzaro Hosp, Catania, Italy.
   [Ferrau, Francesco; Rossello, Rosalba] San Vincenzo Hosp, Taormina, Italy.
   [Serraino, Diego; Bidoli, Ettore; Massarut, Samuele] Natl Canc Inst CRO, Aviano, Italy.
   [Thomas, Guglielmo] Seconda Univ Napoli, Naples, Italy.
   [Thomas, Guglielmo] Clin Mediterranea SpA, Naples, Italy.
   [Gatti, Davide] Univ Verona, Rheumatol Unit, Verona, Italy.
   [Riccardi, Gabriele] Univ Naples Federico II, Dept Clin Med & Surg, Naples, Italy.
   [Vidgen, Edward; Kendall, Cyril W. C.] Univ Toronto, Dept Nutr Sci, Fac Med, Toronto, ON, Canada.
   [Jenkins, David J. A.] Univ Saskatchewan, Coll Pharm & Nutr, Saskatoon, SK, Canada.
   [Jenkins, David J. A.] St Michaels Hosp, Div Endocrinol & Metab, Toronto, ON, Canada.
   [Ciliberto, Gennaro] St Michaels Hosp, Li Ka Shing Knowledge Inst, Toronto, ON, Canada.
   [Catalano, Francesca; Ciliberto, Gennaro] IRCCS Ist Nazl Tumori Regina Elena, Natl Canc Inst, Rome, Italy.
C3 IRCCS Fondazione Pascale; University of Toronto; Saint Michaels Hospital
   Toronto; University of Catania; IRCCS Aviano (CRO); Universita della
   Campania Vanvitelli; Mediterranean Clinic; University of Verona;
   University of Naples Federico II; University of Toronto; University of
   Saskatchewan; University of Toronto; Saint Michaels Hospital Toronto;
   University of Toronto; Saint Michaels Hospital Toronto; Li Ka Shing
   Knowledge Institute; IRCCS Istituti Fisioterapici Ospitalieri (IFO);
   IRCCS Regina Elena
RP Augustin, LSA (通讯作者)，IRCCS, Natl Canc Inst, Ist Nazl Tumori Fondazione Giovann Pascale, Naples, Italy.; Augustin, LSA (通讯作者)，St Michaels Hosp, Clin Nutr & Risk Factor Modificat Ctr, Toronto, ON, Canada.
EM livia.augustin@utoronto.ca
RI De Laurentiis, Michelino/AAC-6321-2022; Jenkins, David/N-3090-2017;
   Crispo, Anna/ABA-7435-2020; Libra, Massimo/ABF-6654-2020; Augustin,
   Livia/AAC-9009-2022; de Rosa, Francesco/AAC-5935-2022; Davide,
   Gatti/ABP-6506-2022; Rinaldo, Massimo/AAA-8913-2020; Ciliberto,
   Gennaro/J-4131-2017; Bidoli, Ettore/AAC-1762-2020; Serraino,
   Diego/J-3915-2018; Massarut, Samuele/J-2995-2018; DE LAURENTIIS,
   Michelino/K-4934-2018
OI Rinaldo, Massimo/0000-0001-8609-1182; Maria,
   Grimaldi/0000-0002-5332-7969; Ciliberto, Gennaro/0000-0003-2851-8605;
   Augustin, Livia Silvia Adriana/0000-0002-6673-8281; Bidoli,
   Ettore/0000-0001-8273-9084; Pinto, Monica/0000-0002-0823-4907; Crispo,
   Anna/0000-0002-8455-3328; Serraino, Diego/0000-0003-0565-8920; Massarut,
   Samuele/0000-0003-4717-0544; Banna, Giuseppe Luigi/0000-0003-0764-3650;
   DE LAURENTIIS, Michelino/0000-0001-9009-1572; gatti,
   davide/0000-0002-7471-3076
FU Italian Ministry of Health [PE-2013-02358099]
FX This trial is funded by a grant of the Italian Ministry of Health (grant
   no. PE-2013-02358099). The funding body will not play any role in the
   study.
CR Adami S, 2011, REUMATISMO, V63, P129, DOI 10.4081/reumatismo.2011.129
   Ajala O, 2013, AM J CLIN NUTR, V97, P505, DOI 10.3945/ajcn.112.042457
   Al-Khanbashi M, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152032
   [Anonymous], AM J MED
   Armenian SH, 2016, J CLIN ONCOL, V34, P1122, DOI 10.1200/JCO.2015.64.0409
   Augustin LSA, 2013, ANN ONCOL, V24, P3094, DOI 10.1093/annonc/mdt383
   Augustin LS, 2002, EUR J CLIN NUTR, V56, P1049, DOI 10.1038/sj.ejcn.1601454
   Augustin LSA, 2001, ANN ONCOL, V12, P1533, DOI 10.1023/A:1013176129380
   Ballard-Barbash R, 2012, JNCI-J NATL CANCER I, V104, P815, DOI 10.1093/jnci/djs207
   Barclay AW, 2008, AM J CLIN NUTR, V87, P627, DOI 10.1093/ajcn/87.3.627
   Beckman KB, 1997, J BIOL CHEM, V272, P19633, DOI 10.1074/jbc.272.32.19633
   Bhupathiraju SN, 2014, AM J CLIN NUTR, V100, P218, DOI 10.3945/ajcn.113.079533
   Botero D, 2009, OBESITY, V17, P1664, DOI 10.1038/oby.2009.203
   Brand-Miller J, 2003, DIABETES CARE, V26, P2261, DOI 10.2337/diacare.26.8.2261
   Brand-Miller JC, 2005, AM J CLIN NUTR, V82, P350, DOI 10.1093/ajcn/82.2.350
   Brownlee M, 2005, DIABETES, V54, P1615, DOI 10.2337/diabetes.54.6.1615
   Buckland G, 2013, INT J CANCER, V132, P2918, DOI 10.1002/ijc.27958
   Bulun SE, 1999, SEMIN REPROD ENDOCR, V17, P349, DOI 10.1055/s-1999-7720
   Byberg L, 2001, DIABETOLOGIA, V44, P2134, DOI 10.1007/s001250100022
   Campbell KL, 2013, CANCER PREV RES, V6, P217, DOI 10.1158/1940-6207.CAPR-12-0212
   Ceriello A, 1999, METABOLISM, V48, P1503, DOI 10.1016/S0026-0495(99)90237-8
   Chlebowski RT, 2006, JNCI-J NATL CANCER I, V98, P1767, DOI 10.1093/jnci/djj494
   Choi Y, 2012, BRIT J NUTR, V108, P1934, DOI 10.1017/S0007114512003984
   Cordero F, 2015, CARCINOGENESIS, V36, P1144, DOI 10.1093/carcin/bgv102
   Cuk K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076729
   Cuzick J, 2010, LANCET ONCOL, V11, P1135, DOI 10.1016/S1470-2045(10)70257-6
   da Silva R, 2009, PUBLIC HEALTH NUTR, V12, P1676, DOI 10.1017/S1368980009990541
   De Angelis R, 2014, LANCET ONCOL, V15, P23, DOI 10.1016/S1470-2045(13)70546-1
   Esposito K, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2015-008222
   Estruch R, 2013, NEW ENGL J MED, V368, P1279, DOI 10.1056/NEJMoa1200303
   Fais S, 2014, CANCER METAST REV, V33, P1095, DOI 10.1007/s10555-014-9531-3
   Fan JY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052182
   Fayers PM, 2001, EUR J CANCER, V37, P1331, DOI 10.1016/S0959-8049(01)00127-7
   Feldman D, 2014, NAT REV CANCER, V14, P342, DOI 10.1038/nrc3691
   Forouhi NG, 2012, DIABETOLOGIA, V55, P2173, DOI 10.1007/s00125-012-2544-y
   Friedenreich CM, 2011, ENDOCR-RELAT CANCER, V18, P357, DOI 10.1530/ERC-10-0303
   Garland CF, 2007, J STEROID BIOCHEM, V103, P708, DOI 10.1016/j.jsbmb.2006.12.007
   Garland CF, 2009, ANN EPIDEMIOL, V19, P468, DOI 10.1016/j.annepidem.2009.03.021
   GATENBY RA, 1995, CANCER RES, V55, P4151
   Gavila J, 2017, CLIN TRANSL ONCOL, V19, P91, DOI 10.1007/s12094-016-1508-y
   Giangreco AA, 2013, J STEROID BIOCHEM, V136, P86, DOI 10.1016/j.jsbmb.2013.01.001
   Giovannucci E, 2010, DIABETES CARE, V33, P1674, DOI 10.2337/dc10-0666
   Giovannucci E, 2009, ANN EPIDEMIOL, V19, P84, DOI 10.1016/j.annepidem.2007.12.002
   Goff LM, 2013, NUTR METAB CARDIOVAS, V23, P1, DOI 10.1016/j.numecd.2012.06.002
   Goodwin PJ, 2002, J CLIN ONCOL, V20, P42, DOI 10.1200/JCO.20.1.42
   Gulyaeva LF, 2016, J TRANSL MED, V14, DOI 10.1186/s12967-016-0893-x
   Halliwell B, 2007, BIOCHEM J, V401, P1, DOI 10.1042/BJ20061131
   Holick CN, 2008, CANCER EPIDEM BIOMAR, V17, P379, DOI 10.1158/1055-9965.EPI-07-0771
   Holmes MD, 2005, JAMA-J AM MED ASSOC, V293, P2479, DOI 10.1001/jama.293.20.2479
   Ibrahim EM, 2011, MED ONCOL, V28, P753, DOI 10.1007/s12032-010-9536-x
   Irwin ML, 2000, DIABETES CARE, V23, P449, DOI 10.2337/diacare.23.4.449
   Jabaaij L, 2012, BMC FAM PRACT, V13, DOI 10.1186/1471-2296-13-60
   Jenkins DJA, 2012, ARCH INTERN MED, V172, P1653, DOI 10.1001/2013.jamainternmed.70
   Jenkins DJA, 2008, JAMA-J AM MED ASSOC, V300, P2742, DOI 10.1001/jama.2008.808
   JENKINS DJA, 1981, AM J CLIN NUTR, V34, P362, DOI 10.1093/ajcn/34.3.362
   Kaaks R, 2001, P NUTR SOC, V60, P91, DOI 10.1079/PNS200070
   Kaplan MA, 2012, MED ONCOL, V29, P1576, DOI 10.1007/s12032-011-0109-4
   Khan NF, 2008, EUR J CANCER, V44, P195, DOI 10.1016/j.ejca.2007.10.005
   Kushi LH, 2007, J NUTR, V137, p236S, DOI 10.1093/jn/137.1.236S
   Lappe JM, 2007, AM J CLIN NUTR, V85, P1586, DOI 10.1093/ajcn/85.6.1586
   Larsen TM, 2010, NEW ENGL J MED, V363, P2102, DOI 10.1056/NEJMoa1007137
   Lasa A, 2014, EUR J CLIN NUTR, V68, P767, DOI 10.1038/ejcn.2014.1
   LAVECCHIA C, 1995, CANCER CAUSE CONTROL, V6, P545, DOI 10.1007/BF00054164
   Ligibel JA, 2008, J CLIN ONCOL, V26, P907, DOI 10.1200/JCO.2007.12.7357
   Liu SM, 2002, AM J CLIN NUTR, V75, P492, DOI 10.1093/ajcn/75.3.492
   Liu SM, 2001, AM J CLIN NUTR, V73, P560
   Liu WL, 2007, AM J MED SCI, V333, P276, DOI 10.1097/MAJ.0b013e31805340d4
   Livesey G, 2013, AM J CLIN NUTR, V97, P584, DOI 10.3945/ajcn.112.041467
   Louwman WJ, 2010, BRIT J CANCER, V103, P1742, DOI 10.1038/sj.bjc.6605949
   Ma FJ, 2014, ONCOTARGETS THER, V7, P2147, DOI 10.2147/OTT.S71095
   Salinas-Martínez AM, 2014, ARCH MED RES, V45, P432, DOI 10.1016/j.arcmed.2014.06.004
   McCann SE, 2013, BRIT J NUTR, V109, P585, DOI 10.1017/S0007114512001936
   McDonnell SL, 2016, J STEROID BIOCHEM, V155, P239, DOI 10.1016/j.jsbmb.2015.06.013
   McTiernan A, 2004, CANCER RES, V64, P2923, DOI 10.1158/0008-5472.CAN-03-3393
   Meyerhardt JA, 2012, JNCI-J NATL CANCER I, V104, P1702, DOI 10.1093/jnci/djs399
   Minicozzi P, 2013, EUR J CANCER, V49, P3881, DOI 10.1016/j.ejca.2013.08.004
   Mirrahimi A, 2012, J AM HEART ASSOC, V1, DOI 10.1161/JAHA.112.000752
   Mohr SB, 2014, ANTICANCER RES, V34, P1163
   Moreau KL, 2001, MED SCI SPORT EXER, V33, P1825, DOI 10.1097/00005768-200111000-00005
   Motta S, 2013, BRIEF BIOINFORM, V14, P411, DOI 10.1093/bib/bbs061
   Ntanasis-Stathopoulos J, 2013, J MUSCULOSKEL NEURON, V13, P133
   Pierce JP, 2007, J CLIN ONCOL, V25, P2345, DOI 10.1200/JCO.2006.08.6819
   Pierce JP, 2007, JAMA-J AM MED ASSOC, V298, P289, DOI 10.1001/jama.298.3.289
   Renehan AG, 2004, LANCET, V363, P1346, DOI 10.1016/S0140-6736(04)16044-3
   Rock CL, 2012, CA-CANCER J CLIN, V62, P243, DOI 10.3322/caac.21142
   Ross AC, 2011, J CLIN ENDOCR METAB, V96, P53, DOI 10.1210/jc.2010-2704
   Runowicz CD, 2016, J CLIN ONCOL, V34, P611, DOI 10.1200/JCO.2015.64.3809
   Schwingshackl L, 2015, PUBLIC HEALTH NUTR, V18, P1292, DOI 10.1017/S1368980014001542
   Sieri S, 2012, INT J CANCER, V130, P921, DOI 10.1002/ijc.26071
   Sprangers MAG, 1996, J CLIN ONCOL, V14, P2756, DOI 10.1200/JCO.1996.14.10.2756
   Thomson CA, 2011, BREAST CANCER RES TR, V125, P519, DOI 10.1007/s10549-010-1014-9
   Toledo E, 2015, JAMA INTERN MED, V175, P1752, DOI 10.1001/jamainternmed.2015.4838
   Tuomilehto Jaakko, 2001, New England Journal of Medicine, V344, P1343, DOI 10.1056/NEJM200105033441801
   Turati F, 2015, MOL NUTR FOOD RES, V59, P1384, DOI 10.1002/mnfr.201400594
   Tutar Y, 2014, CURR PHARM BIOTECHNO, V15, P429, DOI 10.2174/138920101505140828161335
   WARBURG O, 1956, SCIENCE, V124, P269
   WILLIAMS A, 1990, HEALTH POLICY, V16, P199
   Wolever TMS, 2008, AM J CLIN NUTR, V87, P114, DOI 10.1093/ajcn/87.1.114
NR 98
TC 25
Z9 26
U1 0
U2 20
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471-2407
J9 BMC CANCER
JI BMC Cancer
PD JAN 23
PY 2017
VL 17
AR 69
DI 10.1186/s12885-017-3064-4
PG 13
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA EK3QD
UT WOS:000393840000001
PM 28114909
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Hilakivi-Clarke, L
   Wärri, A
   Bouker, KB
   Zhang, XY
   Cook, KL
   Jin, L
   Zwart, A
   Nguyen, N
   Hu, R
   Cruz, MI
   de Assis, S
   Wang, X
   Xuan, JS
   Wang, Y
   Wehrenberg, B
   Clarke, R
AF Hilakivi-Clarke, Leena
   Warri, Anni
   Bouker, Kerrie B.
   Zhang, Xiyuan
   Cook, Katherine L.
   Jin, Lu
   Zwart, Alan
   Nguyen Nguyen
   Hu, Rong
   Cruz, M. Idalia
   de Assis, Sonia
   Wang, Xiao
   Xuan, Jason
   Wang, Yue
   Wehrenberg, Bryan
   Clarke, Robert
TI Effects of In Utero Exposure to Ethinyl Estradiol on Tamoxifen
   Resistance and Breast Cancer Recurrence in a Preclinical Model
SO JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE
LA English
DT Article
ID EPIGENETIC THERAPY; GENE-EXPRESSION; GALECTIN-3 EXPRESSION;
   HYDRALAZINE-VALPROATE; MAMMARY-GLAND; PHASE-II; ESTROGEN; RISK;
   DIETHYLSTILBESTROL; SIGNATURE
AB Background: Responses to endocrine therapies vary among patients with estrogen receptor (ER+) breast cancer. We studied whether in utero exposure to endocrine-disrupting compounds might explain these variations.
   Methods: We describe a novel ER+ breast cancer model to study de novo and acquired tamoxifen (TAM) resistance. Pregnant Sprague Dawley rats were exposed to 0 or 0.1 ppm ethinyl estradiol (EE2), and the response of 9,12-dimethylbenz[a]anthracene (DMBA)-induced mammary tumors to 15 mg/kg TAM, with (n = 17 tumors in the controls and n = 20 tumors in EE2 offspring) or without 1.2 g/kg valproic acid and 5 mg/kg hydralazine (n = 24 tumors in the controls and n = 32 tumors in EE2 offspring) in the female offspring, was assessed. One-sided Chi2 tests were used to calculate P values. Comparisons of differentially expressed genes between mammary tumors in in utero EE2-exposed and control rats, and between anti-estrogen-resistant LCC9 and -sensitive LCC1 human breast cancer cells, were also performed.
   Results: In our preclinical model, 54.2% of mammary tumors in the control rats exhibited a complete response to TAM, of which 23.1% acquired resistance with continued anti-estrogen treatment and recurred. Mammary tumors in the EE2 offspring were statistically significantly less likely to respond to TAM (P = .047) and recur (P = .007). In the EE2 offspring, but not in controls, adding valproic acid and hydralazine to TAM prevented recurrence (P < .001). Three downregulated and hypermethylated genes (KLF4, LGALS3, MICB) and one upregulated gene (ETV4) were identified in EE2 tumors and LCC9 breast cancer cells, and valproic acid and hydralazine normalized the altered expression of all four genes.
   Conclusions: Resistance to TAM may be preprogrammed by in utero exposure to high estrogen levels and mediated through reversible epigenetic alterations in genes associated with epithelial-mesenchymal transition and tumor immune responses.
C1 [Hilakivi-Clarke, Leena; Warri, Anni; Bouker, Kerrie B.; Zhang, Xiyuan; Cook, Katherine L.; Jin, Lu; Zwart, Alan; Nguyen Nguyen; Hu, Rong; Cruz, M. Idalia; de Assis, Sonia; Clarke, Robert] Georgetown Univ, Dept Oncol, Washington, DC USA.
   [Warri, Anni] Univ Turku, Fac Med, Inst Biomed, Turku, Finland.
   [Cook, Katherine L.] Wake Forest Univ, Dept Surg, Winston Salem, NC 27109 USA.
   [Wang, Xiao; Xuan, Jason; Wang, Yue] Virginia Tech, Dept Elect & Comp Engn, Arlington, VA USA.
   [Wehrenberg, Bryan] Univ Texas Hlth Sci Ctr Houston, Houston, TX 77030 USA.
C3 Georgetown University; University of Turku; Wake Forest University;
   Virginia Polytechnic Institute & State University; University of Texas
   System; University of Texas Health Science Center Houston
RP Hilakivi-Clarke, L (通讯作者)，Georgetown Univ, Res Bldg,Room E407,3970 Reservoir Rd NW, Washington, DC 20057 USA.
EM clarkel@georgetown.edu
RI Assis, Sonia/N-8274-2013; Clarke, Robert/A-6485-2008
OI Wehrenberg, Bryan/0000-0003-2043-9590; Warri, Anni/0000-0002-0535-847X;
   Clarke, Robert/0000-0002-9278-0854; Cook, Katherine/0000-0001-6241-0214;
   Zwart, Alan/0000-0001-6834-9290
FU DOD [W81XWH-14-1-0031];  [U54-CA149147];  [U01-CA184902]; 
   [R01-CA164384];  [P30-CA51008]
FX This work was supported by U54-CA149147 and U01-CA184902 (to R. Clarke),
   R01-CA164384 (to L. Hilakivi-Clarke), DOD W81XWH-14-1-0031 (to K. B.
   Bouker, funding for a postdoctoral fellowship), and P30-CA51008 (to
   Lombardi Comprehensive Cancer Center, funding for shared resources).
CR Abe O, 2005, LANCET, V365, P1687, DOI 10.1016/s0140-6736(05)66544-0
   Alonso-Magdalena P, 2010, ENVIRON HEALTH PERSP, V118, P1243, DOI 10.1289/ehp.1001993
   Anjum S, 2014, GENOME MED, V6, DOI 10.1186/gm567
   Arce C, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000098
   Bauman J, 2014, TRANSL ONCOL, V7, P349, DOI 10.1016/j.tranon.2014.03.001
   BOYLAN ES, 1981, JNCI-J NATL CANCER I, V66, P649
   Brenet F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014524
   Brunner N, 1997, CANCER RES, V57, P3486
   Candelaria M, 2007, ANN ONCOL, V18, P1529, DOI 10.1093/annonc/mdm204
   Chávez-Blanco A, 2011, INT J ONCOL, V39, P1491, DOI 10.3892/ijo.2011.1144
   Connolly R, 2012, J MAMMARY GLAND BIOL, V17, P191, DOI 10.1007/s10911-012-9263-3
   Cook KL, 2012, CANCER RES, V72, P3337, DOI 10.1158/0008-5472.CAN-12-0269
   Cook KL, 2011, EXPERT REV ANTICANC, V11, P1283, DOI [10.1586/ERA.11.111, 10.1586/era.11.111]
   Coronel J, 2011, MED ONCOL, V28, pS540, DOI 10.1007/s12032-010-9700-3
   Crews D, 2014, MOL CELL ENDOCRINOL, V398, P42, DOI 10.1016/j.mce.2014.07.013
   de Assis S, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2058
   De Stavola BL, 2000, BRIT J CANCER, V83, P964, DOI 10.1054/bjoc.2000.1370
   Doherty Leo F., 2010, Hormones & Cancer, V1, P146, DOI 10.1007/s12672-010-0015-9
   Dowsett M, 2015, LANCET, V386, P1341, DOI 10.1016/S0140-6736(15)61074-1
   Dueñas-Gonzalez A, 2014, EXPERT OPIN DRUG MET, V10, P1433, DOI 10.1517/17425255.2014.947263
   Dworkin AM, 2009, SEMIN CANCER BIOL, V19, P165, DOI 10.1016/j.semcancer.2009.02.007
   Fernando RI, 2011, CANCER RES, V71, P5296, DOI 10.1158/0008-5472.CAN-11-0156
   Fisher B, 1998, J NATL CANCER I, V90, P1371, DOI 10.1093/jnci/90.18.1371
   Fisher B, 1996, JNCI-J NATL CANCER I, V88, P1529, DOI 10.1093/jnci/88.21.1529
   Göttlicher M, 2001, EMBO J, V20, P6969, DOI 10.1093/emboj/20.24.6969
   Hilakivi-Clarke L, 2014, BREAST CANCER RES, V16, DOI 10.1186/bcr3649
   HilakiviClarke L, 1997, P NATL ACAD SCI USA, V94, P9372, DOI 10.1073/pnas.94.17.9372
   Hoover RN, 2011, NEW ENGL J MED, V365, P1304, DOI 10.1056/NEJMoa1013961
   Hotchkiss AK, 2008, TOXICOL SCI, V105, P235, DOI 10.1093/toxsci/kfn030
   Hsu DK, 2009, IMMUNOL REV, V230, P114, DOI 10.1111/j.1600-065X.2009.00798.x
   JORDAN VC, 1980, EUR J CANCER, V16, P239, DOI 10.1016/0014-2964(80)90156-5
   JORDAN VC, 1976, EUR J CANCER, V12, P419, DOI 10.1016/0014-2964(76)90030-X
   Li H, 2013, CARCINOGENESIS, V34, P2262, DOI 10.1093/carcin/bgt189
   Lin X, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3588
   Lof Marie, 2009, BMC Womens Health, V9, P10, DOI 10.1186/1472-6874-9-10
   Loi S, 2007, J CLIN ONCOL, V25, P1239, DOI 10.1200/JCO.2006.07.1522
   Loi S, 2010, P NATL ACAD SCI USA, V107, P10208, DOI 10.1073/pnas.0907011107
   Mani E, 2014, EUR J GYNAECOL ONCOL, V35, P140
   Margadant C, 2012, J BIOL CHEM, V287, P44684, DOI 10.1074/jbc.M112.426445
   Miller TW, 2011, CLIN CANCER RES, V17, P2024, DOI 10.1158/1078-0432.CCR-10-2567
   Miller WR, 2012, PHARMACOGENOMICS J, V12, P10, DOI 10.1038/tpj.2010.67
   Miller WR, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2611
   Munster PN, 2011, BRIT J CANCER, V104, P1828, DOI 10.1038/bjc.2011.156
   Nagata C, 2006, CANCER EPIDEM BIOMAR, V15, P1469, DOI 10.1158/1055-9965.EPI-06-0158
   Nguyen TTP, 2011, BREAST CANCER RES TR, V130, P73, DOI 10.1007/s10549-010-1304-2
   Pagés F, 2011, SEMIN IMMUNOPATHOL, V33, P317, DOI 10.1007/s00281-011-0278-4
   Palmer JR, 2006, CANCER EPIDEM BIOMAR, V15, P1509, DOI 10.1158/1055-9965.EPI-06-0109
   Park JH, 2012, INVEST NEW DRUG, V30, P1887, DOI 10.1007/s10637-011-9752-z
   Raha P, 2015, BREAST CANCER RES, V17, DOI 10.1186/s13058-015-0533-z
   Ring A, 2004, ENDOCR-RELAT CANCER, V11, P643, DOI 10.1677/erc.1.00776
   Sengupta P, 2013, INT J PREVENTIVE MED, V4, P624
   Shajahan-Haq AN, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-239
   Singh N, 2009, CHEMMEDCHEM, V4, P792, DOI 10.1002/cmdc.200900017
   Sotiriou C, 2006, JNCI-J NATL CANCER I, V98, P262, DOI 10.1093/jnci/djj052
   Sovio U, 2013, CANCER CAUSE CONTROL, V24, P1643, DOI 10.1007/s10552-013-0238-5
   Tetreault MP, 2013, NAT REV CANCER, V13, P701, DOI 10.1038/nrc3582
   Tian Y, 2014, BMC SYST BIOL, V8, DOI 10.1186/s12918-014-0087-1
   Tiwari N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057329
   Wang YX, 2005, LANCET, V365, P671, DOI 10.1016/S0140-6736(05)17947-1
   Yamaki S, 2013, SURG TODAY, V43, P901, DOI 10.1007/s00595-012-0378-3
   Yuen HF, 2011, J PATHOL, V224, P78, DOI 10.1002/path.2859
   Zhang B, 2011, BIOINFORMATICS, V27, P1036, DOI 10.1093/bioinformatics/btr052
   Zhang B, 2009, BIOINFORMATICS, V25, P526, DOI 10.1093/bioinformatics/btn660
   Zhang Y, 2009, BREAST CANCER RES TR, V116, P303, DOI 10.1007/s10549-008-0183-2
NR 64
TC 21
Z9 22
U1 0
U2 6
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0027-8874
EI 1460-2105
J9 JNCI-J NATL CANCER I
JI JNCI-J. Natl. Cancer Inst.
PD JAN
PY 2017
VL 109
IS 1
AR djw188
DI 10.1093/jnci/djw188
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA EK4LX
UT WOS:000393899400011
PM 27609189
OA Green Published
DA 2025-01-12
ER

PT J
AU Bae, H
   Kim, B
   Lee, H
   Lee, S
   Kang, HS
   Kim, SJ
AF Bae, Hansol
   Kim, Byungtak
   Lee, Hyunkyung
   Lee, Seungyeon
   Kang, Han-Sung
   Kim, Sun Jung
TI Epigenetically regulated Fibronectin leucine rich transmembrane protein
   2 (FLRT2) shows tumor suppressor activity in breast cancer cells
SO SCIENTIFIC REPORTS
LA English
DT Article
ID PROMOTER HYPERMETHYLATION; PANCREATIC-CANCER; METHYLATION; MIGRATION;
   GENE; EXPRESSION; INVASION; ADHESION; REPEAT; IDENTIFICATION
AB To identify dysregulated genes by abnormal methylation and expression in breast cancer, we genomewide analyzed methylation and expression microarray data from the Gene Expression Omnibus and the Cancer Genome Atlas database. One of the genes screened in silico, FLRT2, showed hypermethylation and downregulation in the cancer dataset and the association was verified both in cultured cell lines and cancer patients' tissue. To investigate the role of FLRT2 in breast cancer, its expression was knocked down and upregulated in mammary cell lines, and the effect was examined through three levels of approach: pathway analysis; cell activities such as proliferation, colony formation, migration, and adhesion; target gene expression. The top pathway was "Cellular growth and proliferation", or "Cancer"-related function, with the majority of the genes deregulated in a direction pointing to FLRT2 as a potential tumor suppressor. Concordantly, downregulation of FLRT2 increased cell proliferation and cell migration, while overexpression of FLRT2 had the opposite effect. Notably, cell adhesion was significantly decreased by FLRT2 in the collagen I-coated plate. Taken together, our results provide insights into the role of FLRT2 as a novel tumor suppressor in the breast, which is inactivated by hypermethylation during tumor development.
C1 [Bae, Hansol; Kim, Byungtak; Lee, Hyunkyung; Lee, Seungyeon; Kim, Sun Jung] Dongguk Univ Seoul, Dept Life Sci, Goyang, South Korea.
   [Kang, Han-Sung] Natl Canc Ctr, Res Inst & Hosp, Goyang, South Korea.
C3 Dongguk University; National Cancer Center - Korea (NCC)
RP Kim, SJ (通讯作者)，Dongguk Univ Seoul, Dept Life Sci, Goyang, South Korea.
EM sunjungk@dongguk.edu
RI kim, sun/T-1013-2019; kang, han/KIC-4795-2024; Bae, Hansol/AGH-4590-2022
OI Bae, Hansol/0000-0003-3802-3358
FU Basic Science Research Program of the National Research Foundation of
   Korea - Ministry of Education, Science, and Technology
   [NRF-2016R1D1A1B01009235]; National Cancer Center, Korea
FX This study was supported by the Basic Science Research Program of the
   National Research Foundation of Korea, funded by the Ministry of
   Education, Science, and Technology (NRF-2016R1D1A1B01009235). Dr. H. S.
   Kang was supported by a grant provided by the National Cancer Center,
   Korea.
CR Akita T, 2016, J PHYSIOL SCI, V66, P175, DOI 10.1007/s12576-015-0416-1
   Al-Rawi MAA, 2004, BRIT J SURG, V91, P61, DOI 10.1002/bjs.4449
   Barber AG, 2015, CANCER MED-US, V4, P1258, DOI 10.1002/cam4.463
   BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x
   Cardones AR, 2003, CANCER RES, V63, P6751
   Chen L, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-157
   Chuikov S, 2004, NATURE, V432, P353, DOI 10.1038/nature03117
   Evdokimov AG, 2001, J MOL BIOL, V312, P807, DOI 10.1006/jmbi.2001.4973
   Ferdous Z, 2010, J BIOMED MATER RES A, V93A, P419, DOI 10.1002/jbm.a.32545
   Flintoff KA, 2014, J CELL PHYSIOL, V229, P1538, DOI 10.1002/jcp.24597
   Ghiorzo P, 2012, J MED GENET, V49, P164, DOI 10.1136/jmedgenet-2011-100281
   Gyorffy B, 2016, INT J CANCER, V138, P87, DOI 10.1002/ijc.29684
   Haines BP, 2006, DEV BIOL, V297, P14, DOI 10.1016/j.ydbio.2006.04.004
   Hibi K, 2012, ANTICANCER RES, V32, P4371
   Jiang WF, 2011, CELL BIOCHEM FUNCT, V29, P582, DOI 10.1002/cbf.1791
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Kang S, 2013, INT J ONCOL, V43, P1659, DOI 10.3892/ijo.2013.2094
   Kim SJ, 2015, J BREAST CANCER, V18, P347, DOI 10.4048/jbc.2015.18.4.347
   Kobe B, 2001, CURR OPIN STRUC BIOL, V11, P725, DOI 10.1016/S0959-440X(01)00266-4
   Krassenstein R, 2004, CLIN CANCER RES, V10, P28, DOI 10.1158/1078-0432.CCR-0410-3
   Kumar KS, 2015, SPRINGERPLUS, V4, DOI 10.1186/s40064-015-0784-2
   Kwiatkowska E, 2016, J BIOENERG BIOMEMBR, V48, P23, DOI 10.1007/s10863-015-9637-5
   Lacy SE, 1999, GENOMICS, V62, P417, DOI 10.1006/geno.1999.6033
   Li YJ, 2015, CLIN CHIM ACTA, V448, P124, DOI 10.1016/j.cca.2015.07.001
   Liu L, 2016, ONCOTARGET, V7, P3766, DOI 10.18632/oncotarget.6501
   Lu YC, 2015, STRUCTURE, V23, P1678, DOI 10.1016/j.str.2015.06.024
   Nones K, 2014, INT J CANCER, V135, P1110, DOI 10.1002/ijc.28765
   Ordway JM, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001314
   Pangeni RP, 2015, CLIN EPIGENETICS, V7, DOI 10.1186/s13148-015-0089-x
   Price SR, 1998, NATURE, V394, P645, DOI 10.1038/29234
   Saxena A, 2012, EXP THER MED, V4, P1097, DOI 10.3892/etm.2012.710
   Schnekenburger M, 2014, FRONT PHARMACOL, V5, DOI 10.3389/fphar.2014.00170
   Sebova K, 2011, CANCER BIOMARK, V10, P13, DOI 10.3233/CBM-2012-0230
   Seiradake E, 2014, NEURON, V84, P370, DOI 10.1016/j.neuron.2014.10.008
   Seniski GG, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-80
   Shintani Y, 2006, CANCER RES, V66, P11745, DOI 10.1158/0008-5472.CAN-06-2322
   Tai YL, 2015, SCI REP-UK, V5, DOI 10.1038/srep16408
   Wu MX, 1998, SCIENCE, V281, P998, DOI 10.1126/science.281.5379.998
   Wu Y, 2016, EPIGENETICS-US, V11, P247, DOI 10.1080/15592294.2016.1148867
   Yamagishi S, 2011, EMBO J, V30, P2920, DOI 10.1038/emboj.2011.189
   Yamamoto S, 2014, CANCER CELL, V25, P762, DOI 10.1016/j.ccr.2014.04.024
   Yang ZY, 2013, CARCINOGENESIS, V34, P2851, DOI 10.1093/carcin/bgt226
   Zhang J, 2016, CARCINOGENESIS, V37, P345, DOI 10.1093/carcin/bgw015
NR 43
TC 24
Z9 25
U1 0
U2 6
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD MAR 21
PY 2017
VL 7
AR 272
DI 10.1038/s41598-017-00424-0
PG 11
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA EO7CD
UT WOS:000396847900033
PM 28325946
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU Heng, JF
   Guo, XW
   Wu, WH
   Wang, Y
   Li, GL
   Chen, M
   Peng, LM
   Wang, SM
   Dai, LZ
   Tang, LL
   Wang, J
AF Heng, Jianfu
   Guo, Xinwu
   Wu, Wenhan
   Wang, Yue
   Li, Guoli
   Chen, Ming
   Peng, Limin
   Wang, Shouman
   Dai, Lizhong
   Tang, Lili
   Wang, Jun
TI Integrated analysis of promoter mutation, methylation and expression of
   <i>AKT1</i> gene in Chinese breast cancer patients
SO PLOS ONE
LA English
DT Article
ID ABERRANT METHYLATION; PATHWAY; ASSOCIATION; AKT1(E17K); REGIONS
AB Background
   As downstream mediators of PI3K/PTEN/AKT/mTORC1 pathway, the AKT isoforms play critical roles in tumorgenesis. Although the pleiotropic effects of AKT1 in breast cancer have been reported, the genetic and epigenetic characteristics of AKT1 promoter region in breast cancer remains to be identified. In this study we aimed to investigate the promoter mutation spectrum, methylation and gene expression pattern of AKT1 and their relationship with breast cancer.
   Methods
   By using PCR target sequence enrichment and next-generation sequencing technology, we sequenced AKT1 promoter region in pairs of breast tumor and normal tissues from 95 unselected Chinese breast cancer patients. The methylation of the promoter region and the expression profile of AKT1 in the same cohort were detected with bisulfite next-generation sequencing and qPCR, respectively.
   Results
   We identified 28 somatic mutations in 23 of the 95 (24.2%) breast cancer samples. And 19 of the 28 mutations were located in transcription factor (TF) binding sites. In the 23 patients with somatic mutations, no significant change of methylation or expression was found comparing with other patients. AKT1 promoter region was significantly hypo-methylated in tumor compared with matched normal tissue (P = 0.0014) in the 95 patients. The expression of AKT1 was significantly suppressed in tumor tissue (P = 0.0375). In clinicopathological factor analysis, AKT1 showed significant hypo-methylation (P = 0.0249) and suppressed expression (P = 0.0375) in HER2 negative subtype. And a trend of decrease in expression level (P = 0.0624) of AKT1 in the ER negative subtype was observed, which is significantly decreased in basal-like breast tumor ( P = 0.0328).
   Conclusions
   Hypo-methylation and suppressed expression of AKT1 was observed to be associated with breast cancer in our cohort. The methylation and expression of AKT1 were both significantly associated with HER2 status. The promoter mutation of AKT1 did not show significant association with its methylation and expression status. These results suggested that the promoter mutation, methylation and gene expression of AKT1 may play distinct roles in tumorgenesis of breast cancer and the integrated analysis of methylation and expression of AKT1 might serve as potential biomarkers for diagnosis and classification of breast cancer.
C1 [Heng, Jianfu; Wu, Wenhan; Wang, Yue; Li, Guoli; Wang, Jun] Cent South Univ, State Key Lab Med Genet, Changsha, Hunan, Peoples R China.
   [Heng, Jianfu; Wu, Wenhan; Wang, Yue; Li, Guoli; Wang, Jun] Cent South Univ, Sch Life Sci, Changsha, Hunan, Peoples R China.
   [Guo, Xinwu; Chen, Ming; Peng, Limin; Dai, Lizhong] Sanway Gene Technol Inc, Changsha, Hunan, Peoples R China.
   [Wang, Shouman; Tang, Lili] Cent South Univ, Dept Breast Surg, Xiangya Hosp, Changsha, Hunan, Peoples R China.
   [Dai, Lizhong; Wang, Jun] Res Ctr Technol Nucle Acid Based Diagnost, Changsha, Hunan, Peoples R China.
   [Dai, Lizhong; Wang, Jun] Res Ctr Technol Nucle Acid Based Diagnost & Thera, Changsha, Hunan, Peoples R China.
C3 Central South University; Central South University; Central South
   University
RP Wang, J (通讯作者)，Cent South Univ, State Key Lab Med Genet, Changsha, Hunan, Peoples R China.; Wang, J (通讯作者)，Cent South Univ, Sch Life Sci, Changsha, Hunan, Peoples R China.; Tang, LL (通讯作者)，Cent South Univ, Dept Breast Surg, Xiangya Hosp, Changsha, Hunan, Peoples R China.; Wang, J (通讯作者)，Res Ctr Technol Nucle Acid Based Diagnost, Changsha, Hunan, Peoples R China.; Wang, J (通讯作者)，Res Ctr Technol Nucle Acid Based Diagnost & Thera, Changsha, Hunan, Peoples R China.
EM tlli77@medmail.com.cn; junwang@csu.edu.cn
RI Yuan, Xin/KCZ-2239-2024; Wang, xiaoxiao/GQQ-2846-2022; WANG,
   YUE/GWQ-9256-2022
OI Wang, Yue (Yuri)/0000-0002-6805-8749
FU Natural Science Foundation of China [81272296, 81372228]; Major Special
   Projects of the Science and Technology Bureau of Changsha, China
   [K1204017-31, K1306011-31]
FX This work was supported in part by grants from the Natural Science
   Foundation of China (No. 81272296 and 81372228), and the Major Special
   Projects of the Science and Technology Bureau of Changsha, China (No.
   K1204017-31 and K1306011-31).
CR [Anonymous], BREAST CANC RES TREA
   [Anonymous], J CLIN EXPT PATHOL S
   [Anonymous], ONCOTARGET
   Banerji S, 2012, NATURE, V486, P405, DOI 10.1038/nature11154
   Bleeker FE, 2008, ONCOGENE, V27, P5648, DOI 10.1038/onc.2008.170
   Bock C, 2005, BIOINFORMATICS, V21, P4067, DOI 10.1093/bioinformatics/bti652
   Bolger AM, 2014, BIOINFORMATICS, V30, P2114, DOI 10.1093/bioinformatics/btu170
   Chin YR, 2010, MOL CELL, V38, P333, DOI 10.1016/j.molcel.2010.02.031
   Chin YR, 2009, CELL SIGNAL, V21, P470, DOI 10.1016/j.cellsig.2008.11.015
   Cibulskis K, 2013, NAT BIOTECHNOL, V31, P213, DOI 10.1038/nbt.2514
   Davis NM, 2014, ONCOTARGET, V5, P4603, DOI 10.18632/oncotarget.2209
   Fan L, 2014, LANCET ONCOL, V15, pE279, DOI 10.1016/S1470-2045(13)70567-9
   Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210
   Flatley E, 2013, HUM PATHOL, V44, P1320, DOI 10.1016/j.humpath.2012.10.018
   Garber JE, 2005, J CLIN ONCOL, V23, P276, DOI 10.1200/JCO.2005.10.042
   Goldhirsch A, 2013, ANN ONCOL, V24, P2206, DOI 10.1093/annonc/mdt303
   Grant CE, 2011, BIOINFORMATICS, V27, P1017, DOI 10.1093/bioinformatics/btr064
   Gray J, 2012, NATURE, V486, P328, DOI 10.1038/486328a
   Hon GC, 2012, GENOME RES, V22, P246, DOI 10.1101/gr.125872.111
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   Kostroma II, 2016, TERAPEVT ARKH, V88, P31, DOI 10.17116/terarkh201688731-36
   Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324
   Li ZB, 2016, BREAST CANCER RES TR, V160, P371, DOI 10.1007/s10549-016-4004-8
   Liang J, 2002, NAT MED, V8, P1153, DOI 10.1038/nm761
   Lin FDL, 2014, REV BRAS GINECOL OBS, V36, P340, DOI 10.1509/SO100-720320140005034
   Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009
   McKenna A, 2010, GENOME RES, V20, P1297, DOI 10.1101/gr.107524.110
   Miller TW, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr3039
   Nishizawa D, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/316829
   Paplomata E, 2014, THER ADV MED ONCOL, V6, P154, DOI 10.1177/1758834014530023
   Pharoah PDP, 2004, NAT REV CANCER, V4, P850, DOI 10.1038/nrc1476
   Rahat B, 2016, EPIGENOMICS-UK, V8, P767, DOI 10.2217/epi.16.7
   Rudolph M, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2626-1
   Stemke-Hale K, 2008, CANCER RES, V68, P6084, DOI 10.1158/0008-5472.CAN-07-6854
   Stephens PJ, 2012, NATURE, V486, P400, DOI 10.1038/nature11017
   Tokunaga E, 2006, INT J CANCER, V118, P284, DOI 10.1002/ijc.21358
   Wang M., 2016, SCI REPORTS, V6
   Yang W, 2011, CELL SIGNAL, V23, P19, DOI 10.1016/j.cellsig.2010.07.016
   Yoeli-Lerner M, 2006, CELL CYCLE, V5, P603, DOI 10.4161/cc.5.6.2561
NR 39
TC 14
Z9 15
U1 0
U2 12
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAR 16
PY 2017
VL 12
IS 3
AR e0174022
DI 10.1371/journal.pone.0174022
PG 14
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA EN9KE
UT WOS:000396318300113
PM 28301567
OA Green Submitted, Green Published, gold
DA 2025-01-12
ER

PT J
AU Pepke, S
   Steeg, GV
AF Pepke, Shirley
   Steeg, Greg Ver
TI Comprehensive discovery of subsample gene expression components by
   information explanation: therapeutic implications in cancer
SO BMC MEDICAL GENOMICS
LA English
DT Article
DE Ovarian cancer; Tumor transcriptome; RNA-seq; Latent factors;
   Information optimization; Machine learning; Personalized medicine
ID OVARIAN-CANCER; RNA-SEQ; T-CELLS; GENOMICS; IMMUNITY; TOOL
AB Background: De novo inference of clinically relevant gene function relationships from tumor RNA-seq remains a challenging task. Current methods typically either partition patient samples into a few subtypes or rely upon analysis of pairwise gene correlations that will miss some groups in noisy data. Leveraging higher dimensional information can be expected to increase the power to discern targetable pathways, but this is commonly thought to be an intractable computational problem.
   Methods: In this work we adapt a recently developed machine learning algorithm for sensitive detection of complex gene relationships. The algorithm, CorEx, efficiently optimizes over multivariate mutual information and can be iteratively applied to generate a hierarchy of relatively independent latent factors. The learned latent factors are used to stratify patients for survival analysis with respect to both single factors and combinations. These analyses are performed and interpreted in the context of biological function annotations and protein network interactions that might be utilized to match patients to multiple therapies.
   Results: Analysis of ovarian tumor RNA-seq samples demonstrates the algorithm's power to infer well over one hundred biologically interpretable gene cohorts, several times more than standard methods such as hierarchical clustering and k-means. The CorEx factor hierarchy is also informative, with related but distinct gene clusters grouped by upper nodes. Some latent factors correlate with patient survival, including one for a pathway connected with the epithelial-mesenchymal transition in breast cancer that is regulated by a microRNA that modulates epigenetics. Further, combinations of factors lead to a synergistic survival advantage in some cases.
   Conclusions: In contrast to studies that attempt to partition patients into a small number of subtypes (typically 4 or fewer) for treatment purposes, our approach utilizes subgroup information for combinatoric transcriptional phenotyping. Considering only the 66 gene expression groups that are found to both have significant Gene Ontology enrichment and are small enough to indicate specific drug targets implies a computational phenotype for ovarian cancer that allows for 3(66) possible patient profiles, enabling truly personalized treatment. The findings here demonstrate a new technique that sheds light on the complexity of gene expression dependencies in tumors and could eventually enable the use of patient RNA-seq profiles for selection of personalized and effective cancer treatments.
C1 [Pepke, Shirley] Lyrid LLC, S Pasadena, CA 91030 USA.
   [Steeg, Greg Ver] Univ Southern Calif, Marina Del Rey, CA USA.
C3 University of Southern California
RP Pepke, S (通讯作者)，Lyrid LLC, S Pasadena, CA 91030 USA.
EM spepke@lyridllc.com
OI Ver Steeg, Greg/0000-0002-0793-141X
FU AFOSR [FA9550-12-1-0417]; DARPA [W911NF-12-1-0034]
FX GV acknowledges support from AFOSR grant FA9550-12-1-0417 and DARPA
   grant W911NF-12-1-0034 for development of the general algorithm used.
   The funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR [Anonymous], UTILIZING RNA SEQ DA
   [Anonymous], NUCLEIC ACIDS RES
   [Anonymous], 2015, SEER CANC STAT REV 1
   [Anonymous], CANC BIOL THERAPY
   Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556
   Bodnar L, 2014, J OVARIAN RES, V7, DOI 10.1186/1757-2215-7-16
   Butte AJ, 2000, P NATL ACAD SCI USA, V97, P12182, DOI 10.1073/pnas.220392197
   Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095
   Cheng WY, 2013, PLOS COMPUT BIOL, V9, DOI 10.1371/journal.pcbi.1002920
   Cover T. M., 2006, Elements of Information Theory, V2nd
   Cubillos-Ruiz JR, 2015, CELL, V161, P1527, DOI 10.1016/j.cell.2015.05.025
   D'Andrea AD, 2015, ONCOLOGIST, V20, pS3
   de Hoon MJL, 2004, BIOINFORMATICS, V20, P1453, DOI 10.1093/bioinformatics/bth078
   Foley OW, 2013, ONCOLOGY-NY, V27, P288
   Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088
   Glass K, 2015, BMC BIOINFORMATICS, V16, DOI 10.1186/s12859-015-0551-y
   Grossman RL, 2016, NEW ENGL J MED, V375, P1109, DOI 10.1056/NEJMp1607591
   Homicsko K, 2015, J CLIN ONCOL, V33, P3987, DOI 10.1200/JCO.2015.63.7785
   Iancu OD, 2012, BIOINFORMATICS, V28, P1592, DOI 10.1093/bioinformatics/bts245
   Janzen DM, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8956
   Jensen LJ, 2009, NUCLEIC ACIDS RES, V37, pD412, DOI 10.1093/nar/gkn760
   Kanehisa M, 2000, NUCLEIC ACIDS RES, V28, P27, DOI 10.1093/nar/28.1.27
   Krzywinski M, 2009, GENOME RES, V19, P1639, DOI 10.1101/gr.092759.109
   Lonsdale J, 2013, NAT GENET, V45, P580, DOI 10.1038/ng.2653
   Madsen SK, 2015, I S BIOMED IMAGING, P980, DOI 10.1109/ISBI.2015.7164035
   Matsuzaki J, 2010, P NATL ACAD SCI USA, V107, P7875, DOI 10.1073/pnas.1003345107
   Mortazavi A, 2008, NAT METHODS, V5, P621, DOI 10.1038/nmeth.1226
   Network TCGAR, 2011, Nature, V474
   Peng L, 2015, SCI REP-UK, V5, DOI 10.1038/srep13413
   Preston CC, 2011, IMMUNOTHERAPY-UK, V3, P539, DOI [10.2217/IMT.11.20, 10.2217/imt.11.20]
   R Core Team, 2015, R: A Language and Environment for Statistical Computing. Retrieved
   Reshef DN, 2011, SCIENCE, V334, P1518, DOI 10.1126/science.1205438
   Shi ZA, 2010, BMC SYST BIOL, V4, DOI 10.1186/1752-0509-4-74
   Slonim N., 2005, Proc. Natl. Acad. Sci, V102, p18 297
   Song L, 2012, BMC BIOINFORMATICS, V13, DOI 10.1186/1471-2105-13-328
   Song SJ, 2013, CELL, V154, P311, DOI 10.1016/j.cell.2013.06.026
   Stelzer Gil, 2016, Curr Protoc Bioinformatics, V54, DOI 10.1002/cpbi.5
   Supek F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021800
   Therneau T.M., 2000, Modeling Survival Data: Extending the Cox Model
   Tothill RW, 2008, CLIN CANCER RES, V14, P5198, DOI 10.1158/1078-0432.CCR-08-0196
   van Dam S, 2015, NUCLEIC ACIDS RES, V43, pD1124, DOI 10.1093/nar/gku1042
   Ver Steeg G, 2015, JMLR WORKSH CONF PRO, V38, P1004
   Ver Steeg Greg, 2014, Advances in Neural Information Processing Systems, V27
   Wagner AH, 2016, NUCLEIC ACIDS RES, V44, pD1036, DOI 10.1093/nar/gkv1165
   Wang Z, 2009, NAT REV GENET, V10, P57, DOI 10.1038/nrg2484
   WATANABE S, 1960, IBM J RES DEV, V4, P66, DOI 10.1147/rd.41.0066
   Yang Y, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4231
   Zhang B, 2005, STAT APPL GENET MOL, V4, DOI 10.2202/1544-6115.1128
   Zhang L, 2003, NEW ENGL J MED, V348, P203, DOI 10.1056/NEJMoa020177
NR 49
TC 15
Z9 17
U1 1
U2 10
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1755-8794
J9 BMC MED GENOMICS
JI BMC Med. Genomics
PD MAR 15
PY 2017
VL 10
AR 12
DI 10.1186/s12920-017-0245-6
PG 18
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA EN8XG
UT WOS:000396282600001
PM 28292312
OA Green Submitted, Green Published, gold
DA 2025-01-12
ER

PT J
AU Coyne, GO
   Chen, AP
   Meehan, R
   Doroshow, JH
AF Coyne, Geraldine O'Sullivan
   Chen, Alice P.
   Meehan, Robert
   Doroshow, James H.
TI PARP Inhibitors in Reproductive System Cancers: Current Use and
   Developments
SO DRUGS
LA English
DT Article
ID OLAPARIB MAINTENANCE THERAPY; RIBOSE POLYMERASE INHIBITOR; BRCA MUTATION
   CARRIERS; POLY(ADP-RIBOSE) POLYMERASE; OVARIAN-CANCER; HOMOLOGOUS
   RECOMBINATION; PHASE-II; SYNTHETIC LETHALITY; CLINICAL-TRIAL;
   BREAST-CANCER
AB The repair of DNA damage is a critical cellular process governed by multiple biochemical pathways that are often found to be defective in cancer cells. The poly(ADP-ribose) polymerase (PARP) family of proteins controls response to single-strand DNA breaks by detecting these damaged sites and recruiting the proper factors for repair. Blocking this pathway forces cells to utilize complementary mechanisms to repair DNA damage. While PARP inhibition may not, in itself, be sufficient to cause tumor cell death, inhibition of DNA repair with PARP inhibitors is an effective cytotoxic strategy when it is used in patients who carry other defective DNA-repair mechanisms, such as mutations in the genes BRCA 1 and 2. This discovery has supported the development of PARP inhibitors (PARPi), agents that have proven effective against various types of tumors that carry BRCA mutations. With the application of next-generation sequencing of tumors, there is increased interest in looking beyond BRCA mutations to identify genetic and epigenetic aberrations that might lead to similar defects in DNA repair, conferring susceptibility to PARP inhibition. Identification of these genetic lesions and the development of screening assays for their detection may allow for the selection of patients most likely to respond to this class of anticancer agents. This article provides an overview of clinical trial results obtained with PARPi and describes the companion diagnostic assays being established for patient selection. In addition, we review known mechanisms for resistance to PARPi and potential strategies for combining these agents with other types of therapy.
C1 [Coyne, Geraldine O'Sullivan; Chen, Alice P.; Meehan, Robert; Doroshow, James H.] NCI, Early Clin Trials Dev Program, Div Canc Treatment & Diag, NIH, 31 Ctr Dr,Room 3A44, Bethesda, MD 20892 USA.
   [Coyne, Geraldine O'Sullivan; Chen, Alice P.; Meehan, Robert; Doroshow, James H.] NCI, Dev Therapeut Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Cancer Institute
   (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer
   Institute (NCI)
RP Doroshow, JH (通讯作者)，NCI, Early Clin Trials Dev Program, Div Canc Treatment & Diag, NIH, 31 Ctr Dr,Room 3A44, Bethesda, MD 20892 USA.; Doroshow, JH (通讯作者)，NCI, Dev Therapeut Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.
EM doroshoj@mail.nih.gov
RI Chen, Alice/AAG-9400-2020; Coyne, Geraldine/AAI-5019-2021
OI O'Sullivan Coyne, Geraldine/0000-0002-2918-6326
FU federal funds from the National Cancer Institute, National Institutes of
   Health [HHSN261200800001E]
FX This project has been funded in whole or in part with federal funds from
   the National Cancer Institute, National Institutes of Health, under
   Contract Number HHSN261200800001E.
CR Abkevich V, 2012, BRIT J CANCER, V107, P1776, DOI 10.1038/bjc.2012.451
   [Anonymous], ASCO ANN M P
   Audeh MW, 2010, LANCET, V376, P245, DOI 10.1016/S0140-6736(10)60893-8
   Ba XQ, 2011, AM J PATHOL, V178, P946, DOI 10.1016/j.ajpath.2010.12.004
   Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003
   Bast RC, 2007, GYNECOL ONCOL, V107, P173, DOI 10.1016/j.ygyno.2007.08.092
   Beck C, 2014, EXP CELL RES, V329, P18, DOI 10.1016/j.yexcr.2014.07.003
   Bell D, 2011, NATURE, V474, P609, DOI 10.1038/nature10166
   Bell-McGuinn KM, 2015, ASCO ANN M P
   Benafif S, 2015, ONCOTARGETS THER, V8, P519, DOI 10.2147/OTT.S30793
   Bixel K, 2015, PHARMACOGEN PERS MED, V8, P127, DOI 10.2147/PGPM.S62809
   Booth CM, 2012, J CLIN ONCOL, V30, P1030, DOI 10.1200/JCO.2011.38.7571
   Bouwman P, 2014, CLIN CANCER RES, V20, P540, DOI 10.1158/1078-0432.CCR-13-0225
   Brown JS, 2016, BRIT J CANCER, V114, P713, DOI 10.1038/bjc.2016.67
   Bunting SF, 2010, CELL, V141, P243, DOI 10.1016/j.cell.2010.03.012
   Burgess M, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00019
   Carey LA, 2016, NEW ENGL J MED, V375, P83, DOI 10.1056/NEJMe1603691
   Coleman RL, 2016, ASCO ANN M P
   Coleman RL, 2015, GYNECOL ONCOL, V137, P386, DOI 10.1016/j.ygyno.2015.03.042
   Cortazar P, 2014, LANCET, V384, P164, DOI 10.1016/S0140-6736(13)62422-8
   Coyne GO, 2015, CURR OPIN ONCOL, V27, P475, DOI 10.1097/CCO.0000000000000238
   Curtin N, 2014, BIOCHEM SOC T, V42, P82, DOI 10.1042/BST20130187
   Dhillon KK, 2011, CANCER SCI, V102, P663, DOI 10.1111/j.1349-7006.2010.01840.x
   Do K, 2015, CHIN CLIN ONCOL, V4, DOI 10.3978/j.issn.2304-3865.2015.08.01
   Drew Y, 2016, BRIT J CANCER, V114, P723, DOI 10.1038/bjc.2016.41
   Etemadmoghadam D, 2013, P NATL ACAD SCI USA, V110, P19489, DOI 10.1073/pnas.1314302110
   Farmer H, 2005, NATURE, V434, P917, DOI 10.1038/nature03445
   Fong PC, 2010, J CLIN ONCOL, V28, P2512, DOI 10.1200/JCO.2009.26.9589
   Fong PC, 2009, NEW ENGL J MED, V361, P123, DOI 10.1056/NEJMoa0900212
   Frampton GM, 2013, NAT BIOTECHNOL, V31, P1023, DOI 10.1038/nbt.2696
   Gelmon KA, 2011, LANCET ONCOL, V12, P852, DOI 10.1016/S1470-2045(11)70214-5
   Martín AG, 2017, LANCET ONCOL, V18, P8, DOI 10.1016/S1470-2045(16)30621-0
   Gunderson CC, 2015, EXPERT REV MOL DIAGN, V15, P1111, DOI 10.1586/14737159.2015.1078238
   Hartwell LH, 1997, SCIENCE, V278, P1064, DOI 10.1126/science.278.5340.1064
   Helleday T, 2011, MOL ONCOL, V5, P387, DOI 10.1016/j.molonc.2011.07.001
   Hendrickson AEWahner, 2015, J CLIN ONCOL S, V33
   Higuchi T, 2015, CANCER IMMUNOL RES, V3, P1257, DOI 10.1158/2326-6066.CIR-15-0044
   Huang J, 2015, J SENSORS, V2015, DOI 10.1155/2015/192194
   Jackson SP, 2009, NATURE, V461, P1071, DOI 10.1038/nature08467
   Jenner ZB, 2016, FUTURE ONCOL, V12, P1439, DOI 10.2217/fon-2016-0002
   Juvekar A, 2012, CANCER DISCOV, V2, P1048, DOI 10.1158/2159-8290.CD-11-0336
   Kaelin WG, 2005, NAT REV CANCER, V5, P689, DOI 10.1038/nrc1691
   Kaufman B, 2015, J CLIN ONCOL, V33, P244, DOI 10.1200/JCO.2014.56.2728
   Kaye SB, 2012, J CLIN ONCOL, V30, P372, DOI 10.1200/JCO.2011.36.9215
   Khalique S, 2014, CURR OPIN ONCOL, V26, P521, DOI 10.1097/CCO.0000000000000110
   Konecny GE, 2016, BRIT J CANCER, V115, P1157, DOI 10.1038/bjc.2016.311
   Korman AJ, 2006, ADV IMMUNOL, V90, P297, DOI 10.1016/S0065-2776(06)90008-X
   Kristeleit R, 2014, ANN ONCOL         S4, V25, piv307
   Kristeleit RS, 2013, ASCO ANN M P
   Kummar S, 2015, CLIN CANCER RES, V21, P1574, DOI 10.1158/1078-0432.CCR-14-2565
   Kummar S, 2011, CANCER RES, V71, P5626, DOI 10.1158/0008-5472.CAN-11-1227
   Kummar S, 2009, J CLIN ONCOL, V27, P2705, DOI 10.1200/JCO.2008.19.7681
   Ledermann J, 2014, LANCET ONCOL, V15, P852, DOI 10.1016/S1470-2045(14)70228-1
   Ledermann J, 2012, NEW ENGL J MED, V366, P1382, DOI 10.1056/NEJMoa1105535
   LERNER HJ, 1976, CANCER TREAT REP, V60, P1431
   Lin K, 2015, EUR J CANCER, V51, pS531, DOI 10.1016/S0959-8049(16)31469-1
   Liu JF, 2014, LANCET ONCOL, V15, P1207, DOI 10.1016/S1470-2045(14)70391-2
   Liu XS, 2012, CLIN CANCER RES, V18, P510, DOI 10.1158/1078-0432.CCR-11-1973
   Liu XS, 2009, MOL CANCER RES, V7, P1686, DOI 10.1158/1541-7786.MCR-09-0299
   Lord CJ, 2016, NAT REV CANCER, V16, P110, DOI 10.1038/nrc.2015.21
   LoRusso PM, 2016, CLIN CANCER RES, V22, P3227, DOI 10.1158/1078-0432.CCR-15-0652
   Loseva O, 2010, J BIOL CHEM, V285, P8054, DOI 10.1074/jbc.M109.077834
   McCabe N, 2006, CANCER RES, V66, P8109, DOI 10.1158/0008-5472.CAN-06-0140
   Meehan RS, 2016, TRANSL CANCER RES, V5, pS1119, DOI 10.21037/tcr.2016.11.27
   Meehan Robert S, 2016, Gynecol Oncol Res Pract, V3, P3, DOI 10.1186/s40661-016-0024-7
   Mirza MR, 2016, NEW ENGL J MED, V375, P2154, DOI 10.1056/NEJMoa1611310
   Murai J, 2016, ONCOTARGET, DOI 10.18632/oncotarget.12266
   Murai J, 2012, CANCER RES, V72, P5588, DOI 10.1158/0008-5472.CAN-12-2753
   Nijman SMB, 2011, FEBS LETT, V585, P1, DOI 10.1016/j.febslet.2010.11.024
   Nogales V, 2016, ONCOTARGET, V7, P3084, DOI 10.18632/oncotarget.6413
   O'Shaughnessy J, 2014, J CLIN ONCOL, V32, P3840, DOI 10.1200/JCO.2014.55.2984
   Pahuja S, 2015, ASCO ANN M P
   Parchment RE, 2016, SEMIN ONCOL, V43, P514, DOI 10.1053/j.seminoncol.2016.07.002
   Pardoll DM, 2012, NAT REV CANCER, V12, P252, DOI 10.1038/nrc3239
   Plummer R, 2013, CANCER CHEMOTH PHARM, V71, P1191, DOI 10.1007/s00280-013-2113-1
   Polyak K, 2011, NAT MED, V17, P283, DOI 10.1038/nm0311-283
   Puhalla S, 2014, ASCO ANN M P
   Rajan A, 2012, CLIN CANCER RES, V18, P2344, DOI 10.1158/1078-0432.CCR-11-2425
   Reiss KA, 2015, CLIN CANCER RES, V21, P68, DOI 10.1158/1078-0432.CCR-14-1552
   Ricks TK, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00222
   Rouleau M, 2010, NAT REV CANCER, V10, P293, DOI 10.1038/nrc2812
   Rugo HS, 2016, NEW ENGL J MED, V375, P23, DOI 10.1056/NEJMoa1513749
   Sandhu SK, 2013, LANCET ONCOL, V14, P882, DOI 10.1016/S1470-2045(13)70240-7
   Shapira-Frommer R, 2015, ASCO ANN M P
   Shen YQ, 2015, J PHARMACOL EXP THER, V353, P446, DOI 10.1124/jpet.114.222448
   Sinha G, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/djt447
   Smith MA, 2015, CLIN CANCER RES, V21, P819, DOI 10.1158/1078-0432.CCR-14-2572
   Sun JX, 2014, CANCER RES, V74, DOI 10.1158/1538-7445.AM2014-1893
   Swisher EM, 2017, LANCET ONCOL, V18, P75, DOI [10.1016/s1470-2045(16)30559-9, 10.1016/S1470-2045(16)30559-9]
   Swisher EM, 2014, ASCO ANN M P
   Telli ML, 2016, CLIN CANCER RES, V22, P3764, DOI 10.1158/1078-0432.CCR-15-2477
   Telli ML, 2015, J CLIN ONCOL, V33, P1895, DOI 10.1200/JCO.2014.57.0085
   Tutt A, 2010, LANCET, V376, P235, DOI 10.1016/S0140-6736(10)60892-6
   Villalona-Calero MA, 2016, JNCI-J NATL CANCER I, V108, DOI 10.1093/jnci/djv437
   Wahlberg E, 2012, NAT BIOTECHNOL, V30, P283, DOI 10.1038/nbt.2121
   Walsh CS, 2015, GYNECOL ONCOL, V137, P343, DOI 10.1016/j.ygyno.2015.02.017
   Weber AM, 2015, PHARMACOL THERAPEUT, V149, P124, DOI 10.1016/j.pharmthera.2014.12.001
   Welcsh PL, 2001, HUM MOL GENET, V10, P705, DOI 10.1093/hmg/10.7.705
   Xu Y, 2015, BIOMOLECULES, V5, P1652, DOI 10.3390/biom5031652
   Zaremba T, 2007, ANTI-CANCER AGENT ME, V7, P515, DOI 10.2174/187152007781668715
NR 100
TC 39
Z9 44
U1 0
U2 12
PU ADIS INT LTD
PI NORTHCOTE
PA 5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND
SN 0012-6667
EI 1179-1950
J9 DRUGS
JI Drugs
PD FEB
PY 2017
VL 77
IS 2
BP 113
EP 130
DI 10.1007/s40265-016-0688-7
PG 18
WC Pharmacology & Pharmacy; Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy; Toxicology
GA EK1JY
UT WOS:000393682800001
PM 28078645
OA hybrid, Green Published
DA 2025-01-12
ER

PT J
AU Pronina, IV
   Loginov, VI
   Burdennyy, AM
   Fridman, MV
   Senchenko, VN
   Kazubskaya, TP
   Kushlinskii, NE
   Dmitriev, AA
   Braga, EA
AF Pronina, Irina V.
   Loginov, Vitaly I.
   Burdennyy, Alexey M.
   Fridman, Marina V.
   Senchenko, Vera N.
   Kazubskaya, Tatiana P.
   Kushlinskii, Nikolay E.
   Dmitriev, Alexey A.
   Braga, Eleonora A.
TI DNA methylation contributes to deregulation of 12 cancer-associated
   microRNAs and breast cancer progression
SO GENE
LA English
DT Article
DE Breast cancer; Epigenetics; Cancer-associated genes; Deregulation of
   gene expression; Methylation of promoter CpG islands; MicroRNA-mRNA
   pairs
ID INHIBITS CELL-PROLIFERATION; EPITHELIAL-MESENCHYMAL TRANSITION;
   TUMOR-SUPPRESSOR; HEPATOCELLULAR-CARCINOMA; COLORECTAL-CANCER; TARGETS
   CHL1; EXPRESSION; METASTASIS; INVASION; GENES
AB The methylation of promoter CpG islands and the interaction between microRNAs (miRNAs) and messenger RNAs (mRNAs) of target genes are considered two crucial mechanisms for gene and pathway deregulation in malignant tumors. The aim of this study was to analyze the role of promoter methylation in altering the expression of 13 miRNAs that are associated with breast cancer (BC): miR-124,-125b,-127,-132,-137,-148a,-191,-193a, -203,-212,-34b,-375,-9. The role of methylation in the deregulation of these miRNAs has not been previously assessed in the representative set of BC samples. We used a set of 58 paired (tumor/normal) breast tissue samples and methylation-specific PCR to demonstrate significant aberrations in the methylation patterns of 9 miRNA genes. In particular, we observed hypermethylation of MIR-127,-132, and-193a, and hypomethylation of MIR191 for the first time. Using quantitative PCR, we established a strong correlation between promoter methylation and expression levels for 12 miRNA genes (all except MIR-212); this finding demonstrates the functional importance of altered methylation patterns. We also performed a correlation analysis between expression levels of the 13 miRNAs and 5 cancer-associated genes, namely RASSF1(A), CHL1, APAFI, DAPK1, and BCL2, which were predicted as targets for these miRNAs, to investigate the impact of these miRNAs on these genes with key cellular functions in BC. Significant negative correlation was revealed for the following miRNA-mRNA pairs: miR-1275p and DAPKI, miR-375 and RASSFI(A), and miR-124-3p and BCL2. Additionally, we also found a strong association between hypermethylation of MIR-127 and MIR-125b-1 and BC progression, particularly metastasis. Thus, our findings provide evidence for the significant role of methylation in the deregulation of 12 miRNA genes in BC, identify putative novel functional miRNA-mRNA pairs, and suggest MIR-127 and MIR-125b-1 hypermethylation to be potential biomarkers of BC metastasis. (C) 2016 Elsevier B.V. All rights reserved.
C1 [Pronina, Irina V.; Loginov, Vitaly I.; Burdennyy, Alexey M.; Fridman, Marina V.; Braga, Eleonora A.] Inst Gen Pathol & Pathophysiol, Moscow 125315, Russia.
   [Senchenko, Vera N.; Dmitriev, Alexey A.] Russian Acad Sci, Engelhardt Inst Mol Biol, Moscow 119991, Russia.
   [Kazubskaya, Tatiana P.; Kushlinskii, Nikolay E.] Blokhin Canc Res Ctr, Moscow 115478, Russia.
C3 Russian Academy of Medical Sciences; Institute of General Pathology &
   Pathophysiology, RAMS; Russian Academy of Sciences; Engelhardt Institute
   of Molecular Biology, RAS; N.N. Blokhin Russian Cancer Research Center
RP Braga, EA (通讯作者)，Inst Gen Pathol & Pathophysiol, Moscow 125315, Russia.
EM eleonora10_45@mail.ru
RI Карпухин, Александр/J-2337-2018; Senchenko, Vera/C-8992-2014; Burdennyy,
   Alexey/S-7828-2016; Fridman, Marina/HJY-7894-2023; Braga,
   Eleonora/P-5574-2016; Dmitriev, Alexey/D-6109-2011; Pronina,
   Irina/G-3951-2014
OI Burdennyy, Alexey/0000-0002-9398-8075; Dmitriev,
   Alexey/0000-0002-6827-9584; Pavlovna, Tatiana/0000-0001-5856-0017;
   Pronina, Irina/0000-0002-0423-7801; Kushlinskii,
   Nikolay/0000-0002-3898-4127; Braga, Eleonora/0000-0001-5188-4094
FU Russian Science Foundation (RSCF) [14-15-00654]
FX We are sincerely grateful to Prof. Michael Lerman (Affina
   Biotechnologies, USA) for his generous support and useful comments. This
   work was financially supported by the Russian Science Foundation (RSCF)
   grant 14-15-00654. The authors thank the Blokhin Cancer Research Center
   for tissue samples and the Engelhardt Institute of Molecular Biology for
   the assistance in bioinformatic analyses.
CR Ben Gacem R, 2014, TUMOR BIOL, V35, P4047, DOI 10.1007/s13277-013-1530-4
   Bouchalova K, 2014, CURR DRUG TARGETS, V15, P1166, DOI 10.2174/1389450115666141106151143
   Braga EA, 2015, RUSS J GENET+, V51, P566, DOI 10.1134/S1022795415050026
   Chen HY, 2012, CANCER RES, V72, P3631, DOI 10.1158/0008-5472.CAN-12-0667
   Chen JW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080266
   Chu YX, 2014, J CELL BIOCHEM, V115, P847, DOI 10.1002/jcb.24726
   Damavandi Z, 2016, J BREAST CANCER, V19, P148, DOI 10.4048/jbc.2016.19.2.148
   Deng DN, 2016, CANCER SCI, V107, P899, DOI 10.1111/cas.12946
   Dey S, 2014, WORLD J CLIN ONCOL, V5, P509, DOI 10.5306/wjco.v5.i3.509
   Diao YR, 2014, J BIOL CHEM, V289, P529, DOI 10.1074/jbc.M113.494716
   Dreijerink K, 2001, P NATL ACAD SCI USA, V98, P7504, DOI 10.1073/pnas.131216298
   Duan JW, 2016, MOL MED REP, V14, P432, DOI 10.3892/mmr.2016.5255
   Eedunuri VK, 2015, MOL ENDOCRINOL, V29, P1170, DOI 10.1210/me.2015-1080
   Feliciano A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076247
   Feng TB, 2015, TUMOR BIOL, V36, P5987, DOI 10.1007/s13277-015-3275-8
   Ferracin M, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-130
   Formosa A, 2013, ONCOGENE, V32, P127, DOI 10.1038/onc.2012.14
   Han ZB, 2013, CELL PHYSIOL BIOCHEM, V31, P823, DOI 10.1159/000350100
   Hanieh H, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0443-9
   He YH, 2011, NEOPLASIA, V13, P841, DOI 10.1593/neo.11698
   Heller G, 2012, CLIN CANCER RES, V18, P1619, DOI 10.1158/1078-0432.CCR-11-2450
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Hill VK, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-506
   Hong S, 2014, NEOPLASIA, V16, P279, DOI 10.1016/j.neo.2014.03.010
   Hsu PY, 2009, CANCER RES, V69, P5936, DOI 10.1158/0008-5472.CAN-08-4914
   Incoronato M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027722
   Jiang C., 2016, Oncotarget
   Krasnov GS, 2011, MOL BIOL+, V45, P211, DOI 10.1134/S0026893311020129
   Lehmann U, 2014, CELL TISSUE RES, V356, P657, DOI 10.1007/s00441-014-1793-0
   Li LS, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-163
   Li QG, 2016, SCI REP-UK, V6, DOI 10.1038/srep27157
   Li WT, 2014, TUMOR BIOL, V35, P10897, DOI 10.1007/s13277-014-2402-2
   Liang YJ, 2013, CARCINOGENESIS, V34, P713, DOI 10.1093/carcin/bgs383
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Long MJ, 2012, CANCER LETT, V324, P186, DOI 10.1016/j.canlet.2012.05.022
   Lopez-Serra P, 2012, ONCOGENE, V31, P1609, DOI 10.1038/onc.2011.354
   Lv Xiao-Bin, 2011, Chin J Cancer, V30, P821, DOI 10.5732/cjc.011.10289
   Madhavan D, 2016, CARCINOGENESIS, V37, P461, DOI 10.1093/carcin/bgw008
   Mar-Aguilar F, 2013, ASIA-PAC J CLIN ONCO, V9, P53, DOI 10.1111/j.1743-7563.2012.01548.x
   Melnik BC, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-014-0377-9
   Pronina IV, 2012, MOL BIOL+, V46, P236, DOI 10.1134/S0026893312010189
   Pronina IV, 2016, GENE, V576, P483, DOI 10.1016/j.gene.2015.10.059
   Saito Yoshimasa, 2012, Frontiers in Genetics, V3, P186, DOI 10.3389/fgene.2012.00186
   Sandhu R, 2014, INT J ONCOL, V44, P563, DOI 10.3892/ijo.2013.2197
   Senchenko VN, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0015612
   Simonini PDR, 2010, CANCER RES, V70, P9175, DOI 10.1158/0008-5472.CAN-10-1318
   Singh P, 2016, FRONT MOL NEUROSCI, V9, DOI 10.3389/fnmol.2016.00046
   Sobin L.H., 2009, UICC: TNM classification of malignant tumors, V7th
   Stefansson OA, 2013, AM J PATHOL, V183, P1052, DOI 10.1016/j.ajpath.2013.04.033
   Sun X, 2015, ONCOL REP, V33, P1221, DOI 10.3892/or.2015.3714
   Taipaleenmäki H, 2015, CANCER RES, V75, P1433, DOI 10.1158/0008-5472.CAN-14-1026
   Tan WQ, 2015, MOL CARCINOGEN, V54, pE45, DOI 10.1002/mc.22149
   Tang F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035435
   Tavassoli FA., 2003, WHO CLASSIFICATION T
   Tian XY, 2015, INT J CLIN EXP PATHO, V8, P4933
   Tserga A, 2012, ONCOL REP, V27, P1630, DOI 10.3892/or.2011.1576
   Uppal A, 2015, ONCOTARGET, V6, P3540, DOI 10.18632/oncotarget.2920
   Vogt M, 2011, VIRCHOWS ARCH, V458, P313, DOI 10.1007/s00428-010-1030-5
   Vrba L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054398
   Wang SH, 2014, DIS MARKERS, V2014, DOI 10.1155/2014/401986
   Xiong HH, 2009, J HUAZHONG U SCI-MED, V29, P498, DOI 10.1007/s11596-009-0421-9
   Xu S, 2016, ONCOL REP, V35, P1385, DOI 10.3892/or.2015.4524
   Yang LA, 2010, CANCER BIOL THER, V9, P803, DOI 10.4161/cbt.9.10.11440
   Yang QL, 2015, ONCOTARGET, V6, P3268, DOI 10.18632/oncotarget.3065
   Yang Y, 2015, TUMOR BIOL, V36, P5571, DOI 10.1007/s13277-015-3227-3
   Ye XM, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-134
   Yong FL, 2014, INT J MOL SCI, V15, P11713, DOI 10.3390/ijms150711713
   Zabarovsky E. R., 2011, HORIZONS CANC RES
   Zehentmayr F, 2016, CLIN EPIGENETICS, V8, DOI 10.1186/s13148-016-0198-1
   Zhang Y, 2011, CANCER RES, V71, P3552, DOI 10.1158/0008-5472.CAN-10-2435
   Zhang ZG, 2014, BIOCHEM BIOPH RES CO, V454, P109, DOI 10.1016/j.bbrc.2014.10.049
   Zhang Zhiqian, 2011, Genes Cancer, V2, P782, DOI 10.1177/1947601911429743
   Zhao XJ, 2013, ANAT REC, V296, P1842, DOI 10.1002/ar.22823
   Zhu HL, 2014, BIOCHEM BIOPH RES CO, V450, P857, DOI 10.1016/j.bbrc.2014.06.073
NR 74
TC 59
Z9 70
U1 0
U2 44
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0378-1119
EI 1879-0038
J9 GENE
JI Gene
PD MAR 10
PY 2017
VL 604
BP 1
EP 8
DI 10.1016/j.gene.2016.12.018
PG 8
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA EJ2CD
UT WOS:000393016600001
PM 27998789
DA 2025-01-12
ER

PT J
AU Lango-Chavarría, M
   Chimal-Ramífrez, GK
   Ruiz-Tachiquín, ME
   Espinoza-Sánchez, NA
   Suárez-Arriaga, MC
   Fuentes-Pananá, EM
AF Lango-Chavarria, M.
   Chimal-Ramifrez, G. K.
   Ruiz-Tachiquin, M. E.
   Espinoza-Sanchez, N. A.
   Suarez-Arriaga, M. C.
   Fuentes-Panana, E. M.
TI A 22q11.2 amplification in the region encoding microRNA-650 correlates
   with the epithelial to mesenchymal transition in breast cancer primary
   cultures of Mexican patients
SO INTERNATIONAL JOURNAL OF ONCOLOGY
LA English
DT Article
DE breast cancer; 22q11.2 gene amplification; miR-650; ING4 and NDRG2 tumor
   suppressors; EMT and stemness
ID TUMOR-SUPPRESSOR GENE; REGULATES E-CADHERIN; STEM-CELLS;
   DOWN-REGULATION; ING4; EXPRESSION; GROWTH; IDENTIFICATION; ANGIOGENESIS;
   INHIBITOR
AB Breast cancer ranks first in incidence and mortality in working age women. Cancer initiation and progression relies on accumulation of genetic and epigenetic aberrations that alter cellular processes, among them, epithelial to mesenchymal transition (EMT) denotes particularly aggressive neoplasias given its capacity to invade and metastasize. Several microRNAs (miRNA) have been found able to regulate gene expression at the core of EMT. In this study, the Affymetrix CytoScan HD array was used to analyze three different primary tumor cell isolates from Mexican breast cancer patients. We found an amplification in band 22q11.2 shared by the three samples, in the region that encodes miRNA-650. Overexpression of this miRNA has been associated with downregulation of tumor suppressors ING4 and NDRG2, which have been implicated in cancer progression. Using the Pathway Linker platform the ING4 and NDRG2 interaction networks showed a significant association with signaling pathways commonly deregulated in cancer. Also, several studies support their participation in the EMT. Supporting the latter, we found that the three primary isolates were E-cadherin negative, vimentin positive, presented a cancer stem cell-like phenotype CD44(+)CD24(-)/(low) and were invasive in Transwell invasion assays. This evidence suggests that the gain of region 22q11.2 contributes to trigger EMT. This is the first evidence linking miR-650 and breast cancer.
C1 [Lango-Chavarria, M.; Chimal-Ramifrez, G. K.; Espinoza-Sanchez, N. A.; Suarez-Arriaga, M. C.; Fuentes-Panana, E. M.] Childrens Hosp Mexico Federico Gomez, Res Unit Virol & Canc, Dr Marquez 162, Mexico City 06720, DF, Mexico.
   [Ruiz-Tachiquin, M. E.; Suarez-Arriaga, M. C.] Pediat Hosp, Mexican Inst Social Secur XXI Century, Med Res Unit Human Genet, Mexico City 06720, DF, Mexico.
   [Espinoza-Sanchez, N. A.] Natl Autonomous Univ Mexico UNAM, PhD Program Biomed Sci, Mexico City 04510, DF, Mexico.
   [Suarez-Arriaga, M. C.] IPN, Natl Polytech Inst, MSc Program Microbiol, Natl Sch Biol Sci ENCB, Mexico City 07738, DF, Mexico.
C3 Hospital Infantil de Mexico Federico Gomez; Universidad Nacional
   Autonoma de Mexico; Instituto Politecnico Nacional - Mexico
RP Fuentes-Pananá, EM (通讯作者)，Childrens Hosp Mexico Federico Gomez, Res Unit Virol & Canc, Dr Marquez 162, Mexico City 06720, DF, Mexico.
EM empanana@yahoo.com
RI Sánchez, Nancy/ABE-1561-2020; Fuentes-Pananá, Ezequiel/AAI-2856-2020
OI RUIZ TACHIQUIN, MARTHA EUGENIA/0000-0003-3407-1467; Espinoza Sanchez,
   Nancy Adriana/0000-0002-4118-6521
FU CONACyT FONSEC SSA/IMSS/ISSSTE project [233061]; Fondo de Apoyo a la
   Investigacion, Hospital Infantil de Mexico Federico Gomez
   [HIM-2014-053]; CONACYT [231663]; Mexican Institute of Social Security
   (IMSS); Consejo Nacional de Ciencia y Tecnologia (CONACyT) [576518]
FX This work was supported by CONACyT FONSEC SSA/IMSS/ISSSTE project no.
   233061 to Ezequiel M. Fuentes-Panana and by Fondo de Apoyo a la
   Investigacion, Hospital Infantil de Mexico Federico Gomez (project
   number HIM-2014-053). N.A.E.-S. is a doctoral student from Programa de
   Doctorado en Ciencias Biomedicas, Universidad Nacional Autonoma de
   Mexico (UNAM) and received fellowship 231663 from CONACYT. N.A.E.-S.,
   also acknowledged the financial support provided by the Mexican
   Institute of Social Security (IMSS). M.C.S.-A. acknowledged the
   scholarship and financial support provided by Consejo Nacional de
   Ciencia y Tecnologia (CONACyT #576518). The authors are grateful to A.C.
   Velazquez-Wong and C. Jimenez Ramirez for technical assistance in arrays
   processing.
CR Acloque H, 2009, J CLIN INVEST, V119, P1438, DOI 10.1172/JCI38019
   Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100
   Nieto MA, 2009, INT J DEV BIOL, V53, P1541, DOI 10.1387/ijdb.072410mn
   Beck B, 2015, CELL STEM CELL, V16, P67, DOI 10.1016/j.stem.2014.12.002
   Byron SA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046823
   Chan E, 2011, CELL CYCLE, V10, P1845, DOI 10.4161/cc.10.11.15777
   Comijn J, 2001, MOL CELL, V7, P1267, DOI 10.1016/S1097-2765(01)00260-X
   Dave B, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr2938
   Davis FM, 2014, TRENDS PHARMACOL SCI, V35, P479, DOI 10.1016/j.tips.2014.06.006
   Eastham AM, 2007, CANCER RES, V67, P11254, DOI 10.1158/0008-5472.CAN-07-2253
   Eger A, 2005, ONCOGENE, V24, P2375, DOI 10.1038/sj.onc.1208429
   Fang F, 2009, CANCER EPIDEM BIOMAR, V18, P409, DOI 10.1158/1055-9965.EPI-08-0575
   Faraji SN, 2015, IRAN J BASIC MED SCI, V18, P773
   Feng L, 2011, BIOCHEM BIOPH RES CO, V406, P534, DOI 10.1016/j.bbrc.2011.02.081
   Garkavtsev I, 2004, NATURE, V428, P328, DOI 10.1038/nature02329
   Globocan W. H. O., 2012, EST CANC INC MORT PR
   Golestan A, 2015, IRAN J MED SCI, V40, P430
   Grange C, 2011, CANCER RES, V71, P5346, DOI 10.1158/0008-5472.CAN-11-0241
   Greaves M, 2012, NATURE, V481, P306, DOI 10.1038/nature10762
   Gunduz M, 2005, GENE, V356, P109, DOI 10.1016/j.gene.2005.02.014
   Hong SN, 2016, J GASTROEN HEPATOL, V31, P164, DOI 10.1111/jgh.13068
   Howe EN, 2012, J MAMMARY GLAND BIOL, V17, P65, DOI 10.1007/s10911-012-9244-6
   Huang JY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072615
   Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104
   Kang YB, 2004, CELL, V118, P277, DOI 10.1016/j.cell.2004.07.011
   Kim MJ, 2014, MOL CELLS, V37, P759, DOI 10.14348/molcells.2014.0232
   Kim MJ, 2014, CANCER LETT, V354, P33, DOI 10.1016/j.canlet.2014.06.023
   Kim S, 2004, P NATL ACAD SCI USA, V101, P16251, DOI 10.1073/pnas.0407158101
   Kim YJ, 2013, ONCOL REP, V30, P1890, DOI 10.3892/or.2013.2642
   Kloten V, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0159073
   Krause M, 2016, ADV DRUG DELIV REV
   Kreso A, 2014, CELL STEM CELL, V14, P275, DOI 10.1016/j.stem.2014.02.006
   Lee DG, 2015, J HEPATOL, V63, P1429, DOI 10.1016/j.jhep.2015.08.007
   Li J, 2010, CANCER RES, V70, P10445, DOI 10.1158/0008-5472.CAN-10-3040
   Li M, 2014, SCI REP-UK, V4, DOI 10.1038/srep07380
   Li RX, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076689
   Luo M, 2015, CURR PHARM DESIGN, V21, P1301, DOI 10.2174/1381612821666141211120604
   Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027
   Medema JP, 2013, NAT CELL BIOL, V15, P338, DOI 10.1038/ncb2717
   Mongroo Perry S, 2010, Cancer Biol Ther, V10, P219
   Morel AP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002888
   Mraz M, 2012, BLOOD, V119, P2110, DOI 10.1182/blood-2011-11-394874
   O'Brien CA, 2007, NATURE, V445, P106, DOI 10.1038/nature05372
   Park SM, 2008, GENE DEV, V22, P894, DOI 10.1101/gad.1640608
   Qu H, 2016, ONCOL REP, V35, P2927, DOI 10.3892/or.2016.4626
   Santisteban M, 2009, CANCER RES, V69, P2887, DOI 10.1158/0008-5472.CAN-08-3343
   Scheel C, 2007, CANCER RES, V67, P11476, DOI 10.1158/0008-5472.CAN-07-1653
   Scheel C, 2011, CELL, V145, P926, DOI 10.1016/j.cell.2011.04.029
   Shen JC, 2007, CANCER RES, V67, P2552, DOI 10.1158/0008-5472.CAN-06-3870
   Shen L, 2014, ONCOGENESIS, V3, DOI 10.1038/oncsis.2013.48
   Shipitsin M, 2007, CANCER CELL, V11, P259, DOI 10.1016/j.ccr.2007.01.013
   Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128
   Steinestel K, 2014, CLIN TRANSL MED, V3, DOI 10.1186/2001-1326-3-17
   Sun BQ, 2013, J NEURO-ONCOL, V115, P375, DOI 10.1007/s11060-013-1243-y
   Suzuki HI, 2015, ONCOGENE, V34, P3085, DOI 10.1038/onc.2014.254
   Thiery JP, 2006, NAT REV MOL CELL BIO, V7, P131, DOI 10.1038/nrm1835
   Voulgari A, 2009, BBA-REV CANCER, V1796, P75, DOI 10.1016/j.bbcan.2009.03.002
   Wang CJ, 2015, EXP THER MED, V10, P603, DOI 10.3892/etm.2015.2515
   Wang QS, 2010, HISTOPATHOLOGY, V57, P271, DOI 10.1111/j.1365-2559.2010.03623.x
   Yun JH, 2015, ONCOL LETT, V10, P2603, DOI 10.3892/ol.2015.3581
   Zeng ZL, 2013, J SURG ONCOL, V107, P105, DOI 10.1002/jso.23210
   Zhang BH, 2007, DEV BIOL, V302, P1, DOI 10.1016/j.ydbio.2006.08.028
   Zhang XL, 2010, BIOCHEM BIOPH RES CO, V395, P275, DOI 10.1016/j.bbrc.2010.04.005
   Zheng J, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-251
   Zuo ZH, 2015, AM J PATHOL, V185, P1991, DOI 10.1016/j.ajpath.2015.03.015
NR 65
TC 13
Z9 13
U1 0
U2 4
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1019-6439
EI 1791-2423
J9 INT J ONCOL
JI Int. J. Oncol.
PD FEB
PY 2017
VL 50
IS 2
BP 432
EP 440
DI 10.3892/ijo.2017.3842
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA EJ3BT
UT WOS:000393086800011
PM 28101578
OA Green Published, Green Submitted, hybrid
DA 2025-01-12
ER

PT J
AU Vázquez, R
   Riveiro, ME
   Astorgues-Xerri, L
   Odore, E
   Rezai, K
   Erba, E
   Panini, N
   Rinaldi, A
   Kwee, I
   Beltrame, L
   Bekradda, M
   Cvitkovic, E
   Bertoni, F
   Frapolli, R
   D'Incalci, M
AF Vazquez, Ramiro
   Riveiro, Maria E.
   Astorgues-Xerri, Lucile
   Odore, Elodie
   Rezai, Keyvan
   Erba, Eugenio
   Panini, Nicolo
   Rinaldi, Andrea
   Kwee, Ivo
   Beltrame, Luca
   Bekradda, Mohamed
   Cvitkovic, Esteban
   Bertoni, Francesco
   Frapolli, Roberta
   D'Incalci, Maurizio
TI The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in
   triple-negative breast cancer models as single agent and in combination
   with everolimus
SO ONCOTARGET
LA English
DT Article
DE OTX015 (MK-8628); bromodomain inhibitor; triple-negative breast cancer;
   everolimus
ID PLUS EXEMESTANE; DOSE-ESCALATION; ACUTE-LEUKEMIA; BET INHIBITOR;
   IN-VITRO; CELLS; MYC; PATHWAY; BRD4; RESISTANCE
AB Triple-negative breast cancer (TNBC) is an aggressive and heterogeneous subgroup of breast tumors clinically defined by the lack of estrogen, progesterone and HER2 receptors, limiting the use of the targeted therapies employed in other breast malignancies. Recent evidence indicates that c-MYC is a key driver of TNBC. The BET-bromodomain inhibitor OTX015 (MK-8628) has potent antiproliferative activity accompanied by c-MYC down-regulation in several tumor types, and has demonstrated synergism with the mTOR inhibitor everolimus in different models. The aim of this study was to evaluate the anti-tumor activity of OTX015 as single agent and in combination with everolimus in TNBC models. OTX015 was assayed in three human TNBC-derived cell lines, HCC1937, MDA-MB-231 and MDA-MB-468, all showing antiproliferative activity after 72 h (GI(50) = 75-650 nM). This was accompanied by cell cycle arrest and decreased expression of cancer stem cells markers. However, c-MYC protein and mRNA levels were only down-regulated in MDA-MB-468 cells. Gene set enrichment analysis showed up-regulation of genes involved in epigenetic control of transcription, chromatin and the cell cycle, and down-regulation of stemnessrelated genes. In vitro, combination with everolimus was additive in HCC1937 and MDA-MB-231 cells, but antagonistic in MDA-MB-468 cells. In MDA-MB-231 murine xenografts, tumor mass was significantly (p < 0.05) reduced by OTX015 with respect to vehicle-treated animals (best T/C = 40.7%). Although everolimus alone was not active, the combination was more effective than OTX015 alone (best T/C = 20.7%). This work supports current clinical trials with OTX015 in TNBC (NCT02259114).
C1 [Vazquez, Ramiro; Erba, Eugenio; Panini, Nicolo; Beltrame, Luca; Frapolli, Roberta; D'Incalci, Maurizio] IRCCS Ist Ric Farmacol Mario Negri, Lab Antitumor Pharmacol, Milan, Italy.
   [Riveiro, Maria E.; Astorgues-Xerri, Lucile; Odore, Elodie; Cvitkovic, Esteban] Oncol Therapeut Dev, Clichy, France.
   [Odore, Elodie; Rezai, Keyvan] Curie Inst Rene Huguenin Hosp, Radiopharmacol Dept, St Cloud, France.
   [Rinaldi, Andrea; Kwee, Ivo; Bertoni, Francesco] IOR, Bellinzona, Switzerland.
   [Kwee, Ivo] Dalle Molle Inst Artificial Intelligence IDSIA, Manno, Switzerland.
   [Kwee, Ivo] SIB, Lausanne, Switzerland.
   [Cvitkovic, Esteban] Merck Sharp & Dohme Corp, Oncoethix GmbH, Luzern, Switzerland.
   [Bertoni, Francesco] Oncol Inst Southern Switzerland IOSI, Bellinzona, Switzerland.
C3 Istituto di Ricerche Farmacologiche Mario Negri IRCCS; Rene Huguenin
   Hospital; Universita della Svizzera Italiana; Institute of Oncology
   Research (IOR); Universita della Svizzera Italiana; Swiss Institute of
   Bioinformatics; Institute of Oncology Research (IOR)
RP Vázquez, R (通讯作者)，IRCCS Ist Ric Farmacol Mario Negri, Lab Antitumor Pharmacol, Milan, Italy.
EM ramirobioq@hotmail.com
RI Panini, Nicolò/ABF-3684-2020; Frapolli, Roberta/AAA-6729-2020; Bertoni,
   Francesco/G-6922-2014; D'Incalci, Maurizio/AAA-9021-2020; Beltrame,
   Luca/AAB-1998-2020
OI REZAI, Keyvan/0000-0002-3328-3102; Panini, Nicolo/0000-0002-8121-1197;
   Bertoni, Francesco/0000-0001-5637-8983; D'Incalci,
   Maurizio/0000-0001-8784-1360; Frapolli, Roberta/0000-0003-2907-273X;
   Beltrame, Luca/0000-0003-3631-6544
FU Oncology Therapeutic Development
FX This study was fully supported by institutional funds from Oncology
   Therapeutic Development.
CR Abubaker K, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-24
   Amorim S, 2016, LANCET HAEMATOL, V3, pE196, DOI 10.1016/S2352-3026(16)00021-1
   Ansagami IA, 2016, MOL CANCER RES, V14, P324
   Berenguer-Daizé C, 2016, INT J CANCER, V139, P2047, DOI 10.1002/ijc.30256
   Berrada N, 2010, ANN ONCOL, V21, P30, DOI 10.1093/annonc/mdq279
   Berthon C, 2016, LANCET HAEMATOL, V3, pE186, DOI 10.1016/S2352-3026(15)00247-1
   BERTUZZI A, 1984, CYTOMETRY, V5, P619, DOI 10.1002/cyto.990050611
   Bhola NE, 2013, J CLIN INVEST, V123, P1348, DOI 10.1172/JCI65416
   Bihani T, 2015, ONCOTARGET, V6, P2407, DOI 10.18632/oncotarget.2964
   Boi M, 2015, CLIN CANCER RES, V21, P1628, DOI 10.1158/1078-0432.CCR-14-1561
   Brown JM, 2002, CANCER BIOL THER, V1, P453, DOI 10.4161/cbt.1.5.157
   Bottino MC, 2011, BREAST CANCER RES TR, V126, P621, DOI 10.1007/s10549-010-0971-3
   Chacón RD, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2574
   Chavez Kathryn J, 2010, Breast Dis, V32, P35, DOI 10.3233/BD-2010-0307
   Chou TC, 2006, PHARMACOL REV, V58, P621, DOI 10.1124/pr.58.3.10
   Coudé MM, 2015, ONCOTARGET, V6, P17698, DOI 10.18632/oncotarget.4131
   Downward J, 2004, SEMIN CELL DEV BIOL, V15, P177, DOI 10.1016/j.semcdb.2004.01.002
   Eaves CJ, 2008, NATURE, V456, P581, DOI 10.1038/456581a
   Fowler T, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087003
   Gaudio E, 2016, ONCOTARGET, DOI 10.18632/oncotarget.10983
   Gordon V, 2013, CLIN CANCER RES, V19, P3738, DOI 10.1158/1078-0432.CCR-12-0274
   Henssen A, 2016, CLIN CANCER RES, V22, P2470, DOI 10.1158/1078-0432.CCR-15-1449
   Herrmann H, 2012, ONCOTARGET, V3, P1588, DOI 10.18632/oncotarget.733
   Horiuchi D, 2012, J EXP MED, V209, P679, DOI 10.1084/jem.20111512
   Horne GA, 2015, STEM CELLS DEV, V24, P879, DOI 10.1089/scd.2014.0302
   Hurvitz SA, 2015, BREAST CANCER RES TR, V149, P669, DOI 10.1007/s10549-015-3282-x
   Jo M, 2010, CANCER RES, V70, P8945
   LASTER WR, 1961, CANCER RES, V21, P895
   Liu CY, 2016, ONCOTARGET, V7, P9135, DOI 10.18632/oncotarget.7035
   Martins FC, 2012, CANCER DISCOV, V2, P503, DOI 10.1158/2159-8290.CD-11-0325
   Marty B, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2204
   Mertz JA, 2011, P NATL ACAD SCI USA, V108, P16669, DOI 10.1073/pnas.1108190108
   Moher ED, 1998, J ORG CHEM, V63, P3508, DOI 10.1021/jo980039a
   Montero JC, 2014, ONCOGENE, V33, P148, DOI 10.1038/onc.2012.572
   Muller S, 2011, EXPERT REV MOL MED, V13, P1, DOI 10.1017/S1462399411001992
   Noel JK, 2013, MOL CANCER THER, V12, DOI 10.1158/1535-7163.TARG-13-C244
   Odore E, 2014, ANAL METHODS-UK, V6, P9108, DOI 10.1039/c4ay02249a
   Piccart M, 2014, ANN ONCOL, V25, P2357, DOI 10.1093/annonc/mdu456
   Saal LH, 2005, CANCER RES, V65, P2554, DOI 10.1158/0008-5472-CAN-04-3913
   Shi J, 2014, CANCER CELL, V25, P210, DOI 10.1016/j.ccr.2014.01.028
   Shu SK, 2016, NATURE, V529, P413, DOI 10.1038/nature16508
   Stathis A, 2016, CANCER DISCOV, V6, P492, DOI 10.1158/2159-8290.CD-15-1335
   Stuhlmiller TJ, 2015, CELL REP, V11, P390, DOI 10.1016/j.celrep.2015.03.037
   Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034
   Vaupel P, 2007, ANTIOXID REDOX SIGN, V9, P1221, DOI 10.1089/ars.2007.1628
   Wu YY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078259
   Yardley DA, 2013, ADV THER, V30, P870, DOI 10.1007/s12325-013-0060-1
   Yunokawa M, 2012, CANCER SCI, V103, P1665, DOI 10.1111/j.1349-7006.2012.02359.x
NR 48
TC 70
Z9 74
U1 0
U2 10
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD JAN 31
PY 2017
VL 8
IS 5
BP 7598
EP 7613
DI 10.18632/oncotarget.13814
PG 16
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA EJ5YP
UT WOS:000393295500038
PM 27935867
OA gold, Green Published, Green Submitted
DA 2025-01-12
ER

PT J
AU Ma, XY
   Wang, JL
   Wang, JH
   Ma, CX
   Gao, XB
   Patriub, V
   Sklar, JL
AF Ma, Xianyong
   Wang, Jinglan
   Wang, Jianhui
   Ma, Charles X.
   Gao, Xiaobin
   Patriub, Vytas
   Sklar, Jeffrey L.
TI The JAZF1-SUZ12 fusion protein disrupts PRC2 complexes and impairs
   chromatin repression during human endometrial stromal tumorogenesis
SO ONCOTARGET
LA English
DT Article
DE SUZ12 and PRC2 complex; endometrial stromal Sarcoma (ESS); t(7,17)
   translocation; histone methyla transferase (HMT); H3K27Me3
ID POLYCOMB GROUP PROTEINS; SEX COMBS GENE; BREAST-CANCER; EPIGENETIC
   MODIFICATION; H2A UBIQUITYLATION; UBIQUITIN LIGASE; DNA METHYLATION;
   HIGH EXPRESSION; CELL CARCINOMA; TARGET GENES
AB The Polycomb repressive complex 2 (PRC2), which contains three core proteins EZH2, EED and SUZ12, controls chromatin compaction and transcription repression through trimethylation of lysine 27 on histone 3. The (7;17)(p15;q21) chromosomal translocation present in most cases of endometrial stromal sarcomas (ESSs) results in the in-frame fusion of the JAZF1 and SUZ12 genes. We have investigated whether and how the fusion protein JAZF1-SUZ12 functionally alters PRC2. We found that the fusion protein exists at high levels in ESS containing the t(7;17). Co-transient transfection assay indicated JAZF1-SUZ12 destabilized PRC2 components EZH2 and EED, resulting in decreased histone methyl transferase (HMT) activity, which was confirmed by in vitro studies using reconstituted PRC2 and nucleosome array substrates. We also demonstrated the PRC2 containing the fusion protein decreased the binding affinity to target chromatin loci. In addition, we found that trimethylation of H3K27 was decreased in ESS samples with the t(7; 17), but there was no detectable change in H3K9 in these tissues. Moreover, re-expression of SUZ12 in Suz12 (-/-) ES cells rescued the neuronal differentiation while the fusion protein failed to restore this function and enhanced cell proliferation. In summary, our studies reveal that JAZF1-SUZ12 fusion protein disrupts the PRC2 complex, abolishes HMT activity and subsequently activates chromatin/genes normally repressed by PRC2. Such dyesfunction of PRC2 inhibits normal neural differentiation of ES cell and increases cell proliferation. Related changes induced by the JAZF-SUZ12 protein in endometrial stromal cells may explain the oncogenic effect of the t(7; 17) in ESS.
C1 [Ma, Xianyong; Wang, Jinglan; Wang, Jianhui; Gao, Xiaobin; Patriub, Vytas; Sklar, Jeffrey L.] Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06510 USA.
   [Ma, Charles X.] Univ Connecticut, Sch Med, Farmington, CT USA.
C3 Yale University; University of Connecticut
RP Ma, XY (通讯作者)，Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06510 USA.
EM xian-yong.ma@yale.edu
OI wang, jianhui/0000-0002-6261-4863; Ma, Xianyong/0000-0001-5203-0429
FU National Institute of Health [CA-85995-CA/NCI NIH]
FX National Institute of Health Grant CA-85995-CA/NCI NIH to Jeffrey Sklar.
CR ADLER PN, 1991, DEV GENET, V12, P349, DOI 10.1002/dvg.1020120504
   Amant F, 2003, GYNECOL ONCOL, V88, P459, DOI 10.1016/S0090-8258(02)00096-3
   Amant F, 2011, ANTICANCER RES, V31, P2367
   Aranda S, 2015, SCI ADV, V1, DOI 10.1126/sciadv.1500737
   Armstrong L, 2006, STEM CELLS, V24, P805, DOI 10.1634/stemcells.2005-0350
   Balicky EM, 2004, CHROMOSOMA, V112, P231, DOI 10.1007/s00412-003-0266-0
   Bapat S.A., 2012, Epigenetics: Development and Disease, P419
   Barski A, 2007, CELL, V129, P823, DOI 10.1016/j.cell.2007.05.009
   Bhatnagar S, 2014, NATURE, V516, P116, DOI 10.1038/nature13955
   Birve A, 2001, DEVELOPMENT, V128, P3371
   Busturia A, 1997, DEVELOPMENT, V124, P4343
   Cao R, 2002, SCIENCE, V298, P1039, DOI 10.1126/science.1076997
   Cao R, 2005, MOL CELL, V20, P845, DOI 10.1016/j.molcel.2005.12.002
   Choi WI, 2013, NUCLEIC ACIDS RES, V41, P6403, DOI 10.1093/nar/gkt359
   Ciferri C, 2012, ELIFE, V1, DOI 10.7554/eLife.00005
   Conklin CMJ, 2014, ADV ANAT PATHOL, V21, P383, DOI 10.1097/PAP.0000000000000046
   de la Cruz CC, 2005, CHROMOSOMA, V114, P183, DOI 10.1007/s00412-005-0008-6
   Denisenko ON, 1997, MOL CELL BIOL, V17, P4707, DOI 10.1128/MCB.17.8.4707
   Dewaele B, 2014, INT J CANCER, V134, P1112, DOI 10.1002/ijc.28440
   Di Croce L, 2013, NAT STRUCT MOL BIOL, V20, P1147, DOI 10.1038/nsmb.2669
   DURA JM, 1985, MOL GEN GENET, V198, P213, DOI 10.1007/BF00382998
   Falkenberg KJ, 2014, NAT REV DRUG DISCOV, V13, P673, DOI 10.1038/nrd4360
   Gambetta MC, 2014, DEV CELL, V31, P629, DOI 10.1016/j.devcel.2014.10.020
   Gao S, 2013, GENE DEV, V27, P1662, DOI 10.1101/gad.218966.113
   Gao ZH, 2012, MOL CELL, V45, P344, DOI 10.1016/j.molcel.2012.01.002
   Gunawan B, 2003, CANCER GENET CYTOGEN, V147, P84, DOI 10.1016/S0165-4608(03)00186-9
   Gunawan M, 2015, NAT IMMUNOL, V16, P505, DOI 10.1038/ni.3125
   He LR, 2010, INT J CANCER, V127, P138, DOI 10.1002/ijc.25031
   Hock H, 2012, GENE DEV, V26, P751, DOI 10.1101/gad.191163.112
   Kidani K, 2009, ORAL ONCOL, V45, P39, DOI 10.1016/j.oraloncology.2008.03.016
   Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100
   Kodjabachian L, 1998, EMBO J, V17, P1063, DOI 10.1093/emboj/17.4.1063
   Koontz JI, 2001, P NATL ACAD SCI USA, V98, P6348, DOI 10.1073/pnas.101132598
   Kouzarides T, 2002, CURR OPIN GENET DEV, V12, P198, DOI 10.1016/S0959-437X(02)00287-3
   Kuzmichev A, 2005, P NATL ACAD SCI USA, V102, P1859, DOI 10.1073/pnas.0409875102
   Kuzmichev A, 2004, MOL CELL, V14, P183, DOI 10.1016/S1097-2765(04)00185-6
   Lan F, 2007, NATURE, V448, P718, DOI 10.1038/nature06034
   Lee CH, 2012, P NATL ACAD SCI USA, V109, P929, DOI 10.1073/pnas.1115528109
   Lee W, 2014, NAT GENET, V46, P1227, DOI 10.1038/ng.3095
   Li E, 2002, NAT REV GENET, V3, P662, DOI 10.1038/nrg887
   Li H, 2007, P NATL ACAD SCI USA, V104, P20001, DOI 10.1073/pnas.0709986104
   Maenner S, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000276
   Meier K, 2014, EPIGENETICS-US, V9, P1485, DOI 10.4161/15592294.2014.971580
   Micci F, 2006, CANCER RES, V66, P107, DOI 10.1158/0008-5472.CAN-05-2485
   Morey L, 2013, CELL REP, V3, P60, DOI 10.1016/j.celrep.2012.11.026
   Mozzetta C, 2014, MOL CELL, V53, P277, DOI 10.1016/j.molcel.2013.12.005
   Nakajima T, 2004, NUCLEIC ACIDS RES, V32, P4194, DOI 10.1093/nar/gkh741
   Nekrasov M, 2007, EMBO J, V26, P4078, DOI 10.1038/sj.emboj.7601837
   Panagopoulos I, 2013, GENE CHROMOSOME CANC, V52, P610, DOI 10.1002/gcc.22057
   Panagopoulos I, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039354
   Parfitt DE, 2010, MOL BIOL CELL, V21, P2649, DOI 10.1091/mbc.E10-01-0053
   Pasini D, 2007, MOL CELL BIOL, V27, P3769, DOI 10.1128/MCB.01432-06
   Raaphorst FM, 2000, AM J PATHOL, V157, P709, DOI 10.1016/S0002-9440(10)64583-X
   Rajaram V, 2007, GENE CHROMOSOME CANC, V46, P508, DOI 10.1002/gcc.20437
   Simon JA, 2013, MOL CELL, V49, P808, DOI 10.1016/j.molcel.2013.02.013
   Sing A, 2009, CELL, V138, P885, DOI 10.1016/j.cell.2009.08.020
   Smits AH, 2013, NUCLEIC ACIDS RES, V41, DOI 10.1093/nar/gks941
   STRUHL G, 1981, NATURE, V293, P36, DOI 10.1038/293036a0
   Studach LL, 2012, HEPATOLOGY, V56, P1240, DOI 10.1002/hep.25781
   Su I, 2005, CELL, V121, P425, DOI 10.1016/j.cell.2005.02.029
   Taherbhoy AM, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8621
   Tavares L, 2012, CELL, V148, P664, DOI 10.1016/j.cell.2011.12.029
   Torres IO, 2015, CURR OPIN STRUC BIOL, V35, P68, DOI 10.1016/j.sbi.2015.09.007
   Upadhyay AK, 2011, PROG DRUG RES, V67, P107, DOI 10.1007/978-3-7643-8989-5_6
   van Haaften G, 2009, NAT GENET, V41, P521, DOI 10.1038/ng.349
   Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075
   Visco C, 2013, HAEMATOLOGICA, V98, P255, DOI 10.3324/haematol.2012.066209
   Vizán P, 2015, FEBS J, V282, P1723, DOI 10.1111/febs.13083
   Wagener N, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-524
   Wang HB, 2004, NATURE, V431, P873, DOI 10.1038/nature02985
   Wassef M, 2015, GENE DEV, V29, P2547, DOI 10.1101/gad.269522.115
   Whitcomb SJ, 2007, TRENDS GENET, V23, P494, DOI 10.1016/j.tig.2007.08.006
   Yoo KH, 2012, INT J BIOL SCI, V8, P59, DOI 10.7150/ijbs.8.59
NR 73
TC 45
Z9 50
U1 0
U2 3
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
SN 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD JAN 17
PY 2017
VL 8
IS 3
BP 4062
EP 4078
DI 10.18632/oncotarget.13270
PG 17
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA EJ5AH
UT WOS:000393228400026
PM 27845897
OA gold, Green Published, Green Submitted
DA 2025-01-12
ER

PT J
AU Ota, Y
   Itoh, Y
   Kaise, A
   Ohta, K
   Endo, Y
   Masuda, M
   Sowa, Y
   Sakai, T
   Suzuki, T
AF Ota, Yosuke
   Itoh, Yukihiro
   Kaise, Asako
   Ohta, Kiminori
   Endo, Yasuyuki
   Masuda, Mitsuharu
   Sowa, Yoshihiro
   Sakai, Toshiyuki
   Suzuki, Takayoshi
TI Targeting Cancer with PCPA-Drug Conjugates: LSD1 Inhibition-Triggered
   Release of 4-Hydroxytamoxifen
SO ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
LA English
DT Article
DE drug design; epigenetics; prodrugs; small molecules; targeted cancer
   therapy
ID HISTONE DEMETHYLASE; CELLS; ACTIVATION; DESIGN;
   TRANS-2-PHENYLCYCLOPROPYLAMINE; ANTIESTROGENS; CHEMOTHERAPY;
   METHYLATION; MECHANISM; THERAPY
AB Targeting cancer with small molecule prodrugs should help overcome problems associated with conventional cancer-targeting methods. Herein, we focused on lysine-specific demethylase 1 (LSD1) to trigger the controlled release of anticancer drugs in cancer cells, where LSD1 is highly expressed. Conjugates of the LSD1 inhibitor trans-2-phenylcyclopropylamine (PCPA) were used as novel prodrugs to selectively release anticancer drugs by LSD1 inhibition. As PCPA-drug conjugate (PDC) prototypes, we designed PCPA-tamoxifen conjugates 1a and 1b, which released 4-hydroxytamoxifen in the presence of LSD1 in vitro. Furthermore, 1a and 1b inhibited the growth of breast cancer cells by the simultaneous inhibition of LSD1 and the estrogen receptor without exhibiting cytotoxicity toward normal cells. These results demonstrate that PDCs provide a useful prodrug method that may facilitate the selective release of drugs in cancer cells.
C1 [Ota, Yosuke; Itoh, Yukihiro; Masuda, Mitsuharu; Sowa, Yoshihiro; Sakai, Toshiyuki; Suzuki, Takayoshi] Kyoto Prefectural Univ Med, Grad Sch Med Sci, Sakyo Ku, 1-5 Shimogamohangi Cho, Kyoto 6060823, Japan.
   [Kaise, Asako; Ohta, Kiminori; Endo, Yasuyuki] Tohoku Med & Pharmaceut Univ, Fac Pharmaceut Sci, Aoba Ku, 4-4-1 Komatsushima, Sendai, Miyagi 9818558, Japan.
   [Suzuki, Takayoshi] CREST Japan Sci & Technol Agcy JST, 4-1-8 Honcho, Kawaguchi, Saitama 3320012, Japan.
C3 Kyoto Prefectural University of Medicine; Tohoku Medical &
   Pharmaceutical University; Japan Science & Technology Agency (JST)
RP Suzuki, T (通讯作者)，Kyoto Prefectural Univ Med, Grad Sch Med Sci, Sakyo Ku, 1-5 Shimogamohangi Cho, Kyoto 6060823, Japan.; Suzuki, T (通讯作者)，CREST Japan Sci & Technol Agcy JST, 4-1-8 Honcho, Kawaguchi, Saitama 3320012, Japan.
EM suzukit@koto.kpu-m.ac.jp
RI Itoh, Yukihiro/GQP-4681-2022
OI Itoh, Yukihiro/0000-0002-3410-2924
FU Japan Society for the Promotion of Science [JP14J10025, JP15K14982]; JST
   CREST program; Takeda Science Foundation; Research Foundation for
   Pharmaceutical Sciences; Grants-in-Aid for Scientific Research
   [14J10025] Funding Source: KAKEN
FX The authors would like to thank Miki Suzuki, Daisuke Ogasawara, Mie
   Morita, Emi Nishimoto, Kenta Teruya, Yasunao Hattori, Kenichi Akaji,
   Naoya Ieda, Mitsuyasu Kawaguchi, and Hidchiko Nakagawa for their
   technical support. This work was supported in part by a grant-in-aid
   from the Japan Society for the Promotion of Science (Y.O.,
   T.S.)(JP14J10025, JP15K14982), the JST CREST program (T.S.), the Takeda
   Science Foundation, and the Research Foundation for Pharmaceutical
   Sciences (T.S.).
CR [Anonymous], 2013, ANGEW CHEM, V125, P8782
   [Anonymous], 2014, ANGEW CHEM, V126, P3872
   Brauch H, 2009, CLIN CHEM, V55, P1770, DOI 10.1373/clinchem.2008.121756
   BROWN AMC, 1984, P NATL ACAD SCI-BIOL, V81, P6344, DOI 10.1073/pnas.81.20.6344
   Chabner BA, 2005, NAT REV CANCER, V5, P65, DOI 10.1038/nrc1529
   Chari RVJ, 2014, ANGEW CHEM INT EDIT, V53, P3796, DOI 10.1002/anie.201307628
   Derr RS, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-604
   DeVita VT, 2008, CANCER RES, V68, P8643, DOI 10.1158/0008-5472.CAN-07-6611
   Garcia-Bassets I, 2007, CELL, V128, P505, DOI 10.1016/j.cell.2006.12.038
   Hühner J, 2015, ELECTROPHORESIS, V36, P518, DOI 10.1002/elps.201400451
   JORDAN VC, 1984, MOL PHARMACOL, V26, P272
   KATZENELLENBOGEN JA, 1985, J STEROID BIOCHEM, V22, P589, DOI 10.1016/0022-4731(85)90210-9
   Lim S, 2010, CARCINOGENESIS, V31, P512, DOI 10.1093/carcin/bgp324
   McAllister TE, 2016, J MED CHEM, V59, P1308, DOI 10.1021/acs.jmedchem.5b01758
   Miyamura S, 2016, ORG BIOMOL CHEM, V14, P8576, DOI 10.1039/c6ob01483f
   Ogasawara D, 2013, ANGEW CHEM INT EDIT, V52, P8620, DOI 10.1002/anie.201303999
   Park UH, 2016, ONCOGENE, V35, P3742, DOI 10.1038/onc.2015.443
   Petros RA, 2010, NAT REV DRUG DISCOV, V9, P615, DOI 10.1038/nrd2591
   Rautio J, 2008, NAT REV DRUG DISCOV, V7, P255, DOI 10.1038/nrd2468
   Schmidt DMZ, 2007, BIOCHEMISTRY-US, V46, P4408, DOI 10.1021/bi0618621
   Schulte JH, 2009, CANCER RES, V69, P2065, DOI 10.1158/0008-5472.CAN-08-1735
   Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012
   Singh MM, 2011, NEURO-ONCOLOGY, V13, P894, DOI 10.1093/neuonc/nor049
   Srinivasarao M, 2015, NAT REV DRUG DISCOV, V14, P203, DOI 10.1038/nrd4519
   Suzuki T, 2011, J MED CHEM, V54, P8236, DOI 10.1021/jm201048w
   Wu Jin, 2015, Onco Targets Ther, V8, P2565, DOI 10.2147/OTT.S89597
   Yang MJ, 2007, BIOCHEMISTRY-US, V46, P8058, DOI 10.1021/bi700664y
NR 27
TC 31
Z9 36
U1 2
U2 44
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 1433-7851
EI 1521-3773
J9 ANGEW CHEM INT EDIT
JI Angew. Chem.-Int. Edit.
PD DEC 23
PY 2016
VL 55
IS 52
BP 16115
EP 16118
DI 10.1002/anie.201608711
PG 4
WC Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC)
SC Chemistry
GA EJ0CH
UT WOS:000392875700028
PM 27882656
DA 2025-01-12
ER

PT J
AU Huang, PR
   Sun, JR
   Wang, FH
   Luo, XT
   Feng, JY
   Gu, Q
   Liu, T
   Sun, XD
AF Huang, Peirong
   Sun, Junran
   Wang, Fenghua
   Luo, Xueting
   Feng, Jingyang
   Gu, Qing
   Liu, Te
   Sun, Xiaodong
TI MicroRNA Expression Patterns Involved in Amyloid Beta-Induced Retinal
   Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE amyloid beta; retina; microRNA; age-related macular degeneration
ID PIGMENT EPITHELIAL-CELLS; MACULAR DEGENERATION; IN-VIVO; CHOROIDAL
   NEOVASCULARIZATION; SALMONELLA INFECTION; MICROARRAY ANALYSIS; OXIDATIVE
   STRESS; TIGHT JUNCTION; BREAST-CANCER; INFLAMMATION
AB PURPOSE. Dry age-related macular degeneration (AMD) is characterized by the accumulation of drusen under Bruch's membrane, and amyloid beta (A beta) is speculated to be one of the key pathologic factors. While the detrimental effects of A beta on retinas have been widely explored, A beta-induced epigenetic regulatory changes have yet to be fully investigated. We therefore aimed to identify the microRNA (miRNA) expression profiles in an A beta-induced mouse model of retinal degeneration.
   METHODS. C57BL/6 mice were intravitreally injected with A beta(1-40) or PBS and the eye tissues were collected for hematoxylin and eosin (H&E) staining, apoptosis immunofluorescence staining, and miRNA profiling. After filtering, 10 miRNAs and their target genes were chosen for quantitative RT-PCR (qRT-PCR) confirmations. Pathway analyses were employed for further bioinformatic analyses.
   RESULTS. Hematoxylin and eosin-stained sections of retinal pigment epithelium (RPE)/neural retina tissue demonstrated degenerative alterations, and immunofluorescence testing revealed apoptosis within the retina after A beta treatments. MicroRNA profiling revealed 61 miRNAs that were differentially expressed between the model and the control group. Among these, 38 miRNAs were upregulated (fold change > 1.5, P < 0.05) and 23 miRNAs were downregulated (fold change < 0.667, P < 0.05). Five of the 10 selected miRNAs (miR-142, miR-216, miR-155, miR-223, and miR-433) as well as several key target genes (CFH, IGF-1R, c-MET, and ABCA1) were confirmed by qRT-PCR analyses.
   CONCLUSIONS. Our study is the first to profile the miRNA expression patterns and suggests that A beta accumulation could lead to relevant biochemical alternations such as complement activation, barrier impairment, apoptosis, and positive feedback of A beta production.
C1 [Huang, Peirong; Sun, Junran; Wang, Fenghua; Feng, Jingyang; Sun, Xiaodong] Shanghai Jiao Tong Univ, Sch Med, Shanghai Peoples Hosp 1, Dept Ophthalmol, Shanghai, Peoples R China.
   [Huang, Peirong; Sun, Junran; Wang, Fenghua; Feng, Jingyang; Gu, Qing; Sun, Xiaodong] Shanghai Engn Ctr Visual Sci & Photomed, Shanghai, Peoples R China.
   [Luo, Xueting; Sun, Xiaodong] Shanghai Key Lab Fundus Dis, Shanghai, Peoples R China.
   [Liu, Te] Shanghai Univ Tradit Chinese Med, Longhua Hosp, Shanghai Geriatr Inst Chinese Med, Bldg C,365 Xiangyang Rd, Shanghai 200031, Peoples R China.
C3 Shanghai Jiao Tong University; Shanghai University of Traditional
   Chinese Medicine
RP Liu, T (通讯作者)，Shanghai Univ Tradit Chinese Med, Longhua Hosp, Shanghai Geriatr Inst Chinese Med, Bldg C,365 Xiangyang Rd, Shanghai 200031, Peoples R China.; Sun, XD (通讯作者)，Shanghai Jiao Tong Univ, Sch Med, Shanghai Peoples Hosp 1,Shanghai Engn Ctr Visual, Dept Ophthalmol,Shanghai Key Lab Fundus Dis, 100 Hai Ning Rd, Shanghai 200080, Peoples R China.
EM liute1979@126.com; xdsun@sjtu.edu.cn
RI Feng, Jingyang/HLG-6381-2023
OI Feng, Jingyang/0000-0001-6031-7980
FU National Natural Science Foundation of China [81425006]; Shanghai
   Creative Key Medical Research Grant [1341195400]; Translational Medicine
   Grant of Shanghai Jiao Tong University, School of Medicine [5ZH4005];
   Shanghai Engineering Center for Visual Science and Photomedicine Science
   [16dz2251500]; Technology Commission of Shanghai Municipality
   [16140900800]
FX Supported by the National Natural Science Foundation of China (Grant
   81425006), Shanghai Creative Key Medical Research Grant (1341195400),
   Translational Medicine Grant of Shanghai Jiao Tong University, School of
   Medicine (5ZH4005), Shanghai Engineering Center for Visual Science and
   Photomedicine Science (16dz2251500), and Technology Commission of
   Shanghai Municipality (16140900800).
CR Anderson PJB, 2008, CLIN OPHTHALMOL, V2, P801
   Bao H, 2015, SCI REP-UK, V5, DOI 10.1038/srep12620
   Bloomston M, 2007, JAMA-J AM MED ASSOC, V297, P1901, DOI 10.1001/jama.297.17.1901
   Bruban J, 2011, NEUROBIOL DIS, V42, P55, DOI 10.1016/j.nbd.2011.01.004
   Bruban J, 2009, AGING CELL, V8, P162, DOI 10.1111/j.1474-9726.2009.00456.x
   Cao L, 2013, BRAZ J MED BIOL RES, V46, P659, DOI 10.1590/1414-431X20132903
   Cao LN, 2013, INVEST OPHTH VIS SCI, V54, P3738, DOI 10.1167/iovs.13-11612
   Chen BH, 2013, CLINICS, V68, P825, DOI 10.6061/clinics/2013(06)17
   Chen LF, 2001, SCIENCE, V293, P1653, DOI 10.1126/science.1062374
   Chen L, 2016, MOL MED REP, V13, P3249, DOI 10.3892/mmr.2016.4890
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Dai LL, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1004606
   Dilks DD, 2014, OPTOMETRY VISION SCI, V91, pE199, DOI 10.1097/OPX.0000000000000325
   Dinet V, 2012, AGING CELL, V11, P683, DOI 10.1111/j.1474-9726.2012.00834.x
   Ding JD, 2011, P NATL ACAD SCI USA, V108, pE279, DOI 10.1073/pnas.1100901108
   Feng JY, 2014, OPHTHALMIC RES, V52, P224, DOI 10.1159/000363387
   Grassmann F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107461
   Guo L, 2010, INVEST OPHTH VIS SCI, V51, P6504, DOI 10.1167/iovs.10-5551
   Hogg RE, 2007, OPHTHALMOLOGY, V114, P1027
   Howlett DR, 2011, EXP BRAIN RES, V214, P185, DOI 10.1007/s00221-011-2819-4
   Huntzinger E, 2011, NAT REV GENET, V12, P99, DOI 10.1038/nrg2936
   Isas JM, 2010, INVEST OPHTH VIS SCI, V51, P1304, DOI 10.1167/iovs.09-4207
   Jinato T, 2016, EXP BIOL MED, V241, P1803, DOI 10.1177/1535370216647184
   Kam JH, 2015, EXP EYE RES, V135, P59, DOI 10.1016/j.exer.2015.03.023
   Kaneko H, 2011, NATURE, V471, P325, DOI 10.1038/nature09830
   Kim J, 2015, J NEUROSCI, V35, P14717, DOI 10.1523/JNEUROSCI.2053-15.2015
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Koinzer S, 2015, CURR EYE RES, V40, P853, DOI 10.3109/02713683.2014.961613
   Koyama Y, 2008, INVEST OPHTH VIS SCI, V49, P2376, DOI 10.1167/iovs.07-1067
   Krol J, 2010, CELL, V141, P618, DOI 10.1016/j.cell.2010.03.039
   Kurji KH, 2010, INVEST OPHTH VIS SCI, V51, P1151, DOI 10.1167/iovs.09-3622
   Lin HJ, 2011, INVEST OPHTH VIS SCI, V52, P6308, DOI 10.1167/iovs.10-6632
   Liu CQ, 2015, INT J MOL MED, V35, P169, DOI 10.3892/ijmm.2014.1993
   Liu RT, 2013, INVEST OPHTH VIS SCI, V54, P2225, DOI 10.1167/iovs.12-10849
   Liu T, 2012, MOL MED REP, V6, P535, DOI 10.3892/mmr.2012.967
   Liu W, 2011, BMC CELL BIOL, V12, DOI 10.1186/1471-2121-12-5
   Lukiw Walter J, 2012, Int J Biochem Mol Biol, V3, P105
   Park SW, 2015, ONCOTARGET, V6, P35263, DOI 10.18632/oncotarget.5894
   Park SW, 2014, NEUROBIOL AGING, V35, P2013, DOI 10.1016/j.neurobiolaging.2014.03.008
   Parsons CG, 2015, NEUROPHARMACOLOGY, V92, P158, DOI 10.1016/j.neuropharm.2014.12.038
   Prakasam A, 2010, J ALZHEIMERS DIS, V20, P1243, DOI 10.3233/JAD-2010-100210
   Qadir XV, 2015, AM J PATHOL, V185, P3141, DOI 10.1016/j.ajpath.2015.08.020
   Rogler CE, 2009, HEPATOLOGY, V50, P575, DOI 10.1002/hep.22982
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Saxena K, 2015, INVEST OPHTH VIS SCI, V56, P1820, DOI 10.1167/iovs.14-15449
   Shang F, 2012, MOL ASPECTS MED, V33, P446, DOI 10.1016/j.mam.2012.04.001
   Shen JK, 2008, MOL THER, V16, P1208, DOI 10.1038/mt.2008.104
   Shi Q, 2015, INVEST OPHTH VIS SCI, V56, P7728, DOI 10.1167/iovs.15-17677
   Soifer HS, 2007, MOL THER, V15, P2070, DOI 10.1038/sj.mt.6300311
   Taylor-Walker G, 2016, EXP EYE RES, V153, P110, DOI 10.1016/j.exer.2016.10.013
   Walsh DT, 2005, NEUROPATH APPL NEURO, V31, P491, DOI 10.1111/j.1365-2990.2005.00666.x
   Walsh DT, 2002, NEUROBIOL DIS, V10, P20, DOI 10.1006/nbdi.2002.0485
   Wang WQ, 2011, INVEST OPHTH VIS SCI, V52, P7213, DOI 10.1167/iovs.10-7097
   Xing SL, 2013, MOL MED REP, V8, P1689, DOI 10.3892/mmr.2013.1722
   Xu N, 2015, BIOMED PHARMACOTHER, V69, P221, DOI 10.1016/j.biopha.2014.12.002
   Xu X, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2015.274
   Yan Q, 2016, CURR EYE RES, V41, P240, DOI 10.3109/02713683.2015.1006371
   Yao M, 2016, MOL GENET GENOMICS, V291, P789, DOI 10.1007/s00438-015-1146-z
   Yoshida T, 2005, J CLIN INVEST, V115, P2793, DOI 10.1172/JCI24635
   Yuan B, 2011, FEBS LETT, V585, P927, DOI 10.1016/j.febslet.2011.02.031
   Zhang Q, 2015, J CANCER, V6, P184, DOI 10.7150/jca.10822
   Zhao WG, 2010, CARCINOGENESIS, V31, P1726, DOI 10.1093/carcin/bgq160
   Zhou QB, 2014, MOL THER, V22, P378, DOI 10.1038/mt.2013.243
   Zhou QB, 2011, P NATL ACAD SCI USA, V108, P8287, DOI 10.1073/pnas.1105254108
NR 64
TC 22
Z9 24
U1 0
U2 18
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD MAR
PY 2017
VL 58
IS 3
BP 1726
EP 1735
DI 10.1167/iovs.16-20043
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EQ4ZA
UT WOS:000398089000046
PM 28324113
OA gold
DA 2025-01-12
ER

PT J
AU Visvanathan, K
   Fackler, MS
   Zhang, Z
   Lopez-Bujanda, ZA
   Jeter, SC
   Sokoll, LJ
   Garrett-Mayer, E
   Cope, LM
   Umbricht, CB
   Euhus, DM
   Forero, A
   Storniolo, AM
   Nanda, R
   Lin, NU
   Carey, LA
   Ingle, JN
   Sukumar, S
   Wolff, AC
AF Visvanathan, Kala
   Fackler, MaryJo S.
   Zhang, Zhe
   Lopez-Bujanda, Zoila A.
   Jeter, Stacie C.
   Sokoll, Lori J.
   Garrett-Mayer, Elizabeth
   Cope, Leslie M.
   Umbricht, Christopher B.
   Euhus, David M.
   Forero, Andres
   Storniolo, Anna M.
   Nanda, Rita
   Lin, Nancy U.
   Carey, Lisa A.
   Ingle, James N.
   Sukumar, Saraswati
   Wolff, Antonio C.
TI Monitoring of Serum DNA Methylation as an Early Independent Marker of
   Response and Survival in Metastatic Breast Cancer: TBCRC 005 Prospective
   Biomarker Study
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Article
ID CIRCULATING TUMOR-CELLS; NEOADJUVANT CHEMOTHERAPY; GENES; THERAPY; PCR;
   EPIGENETICS; DISEASE; WOMEN; FLUID; ASSAY
AB Purpose
   Epigenetic alterations measured in blood may help guide breast cancer treatment. The multisite prospective study TBCRC 005 was conducted to examine the ability of a novel panel of cell-free DNA methylation markers to predict survival outcomes in metastatic breast cancer (MBC) using a new quantitative multiplex assay (cMethDNA).
   Patients and Methods
   Ten genes were tested in duplicate serum samples from 141 women at baseline, at week 4, and at first restaging. A cumulative methylation index (CMI) was generated on the basis of six of the 10 genes tested. Methylation cut points were selected to maximize the log-rank statistic, and cross-validation was used to obtain unbiased point estimates. Logistic regression or Cox proportional hazard models were used to test associations between the CMI and progression-free survival (PFS), overall survival (OS), and disease status at first restaging. The added value of the CMI in predicting survival outcomes was evaluated and compared with circulating tumor cells (CellSearch).
   Results
   Median PFS and OS were significantly shorter in women with a high CMI (PFS, 2.1 months; OS, 12.3 months) versus a low CMI (PFS, 5.8 months; OS, 21.7 months). In multivariable models, among women with MBC, a high versus low CMI at week 4 was independently associated with worse PFS (hazard ratio, 1.79; 95% CI, 1.23 to 2.60; P = .002) and OS (hazard ratio, 1.75; 95% CI, 1.21 to 2.54; P = .003). An increase in the CMI from baseline to week 4 was associated with worse PFS (P < .001) and progressive disease at first restaging (P < .001). Week 4 CMI was a strong predictor of PFS, even in the presence of circulating tumor cells (P = .004).
   Conclusion
   Methylation of this gene panel is a strong predictor of survival outcomes in MBC and may have clinical usefulness in risk stratification and disease monitoring. (C) 2016 by American Society of Clinical Oncology
C1 [Visvanathan, Kala; Fackler, MaryJo S.; Zhang, Zhe; Lopez-Bujanda, Zoila A.; Jeter, Stacie C.; Sokoll, Lori J.; Cope, Leslie M.; Umbricht, Christopher B.; Euhus, David M.; Sukumar, Saraswati; Wolff, Antonio C.] Johns Hopkins Univ, Sch Med, Baltimore, MD USA.
   [Visvanathan, Kala] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Baltimore, MD USA.
   [Garrett-Mayer, Elizabeth] Med Univ South Carolina, Charleston, SC USA.
   [Forero, Andres] Univ Alabama Birmingham, Birmingham, AL USA.
   [Storniolo, Anna M.] Indiana Univ, Bloomington, IN USA.
   [Nanda, Rita] Univ Chicago, Chicago, IL 60637 USA.
   [Lin, Nancy U.] Dana Farber Canc Inst, Boston, MA 02115 USA.
   [Carey, Lisa A.] Univ N Carolina, Chapel Hill, NC USA.
   [Ingle, James N.] Mayo Clin, Rochester, MN USA.
C3 Johns Hopkins University; Johns Hopkins University; Johns Hopkins
   Bloomberg School of Public Health; Medical University of South Carolina;
   University of Alabama System; University of Alabama Birmingham; Indiana
   University System; Indiana University Bloomington; University of
   Chicago; Harvard University; Dana-Farber Cancer Institute; University of
   North Carolina; University of North Carolina Chapel Hill; Mayo Clinic
RP Visvanathan, K (通讯作者)，Johns Hopkins Univ, E 6142 615 N Wolfe St, Baltimore, MD 21205 USA.
EM kvisvan1@jhu.edu
RI Lin, Nancy/ACF-8569-2022; Storniolo, Anna/AAB-5399-2022; cope,
   leslie/LTE-4234-2024; Visvanathan, Kala/AAE-4396-2021; Wolff,
   Antonio/T-8796-2019
OI Garrett-Mayer, Elizabeth/0000-0003-4709-0333; Wolff,
   Antonio/0000-0003-3734-1063; Lopez Bujanda, Zoila/0000-0001-5729-7309;
   Bujanda, Luis/0000-0002-4353-9968
FU Avon Foundation for Women; Breast Cancer Research Foundation; Janssen
   Diagnostics; Rubenstein Family Fund; Susan G. Komen Foundation; National
   Institutes of Health [NIHP30CA006973, NIHP30CA58223]; Susan G. Komen
   Leadership Grant [SAC110053]
FX Supported by the Avon Foundation for Women, the Breast Cancer Research
   Foundation, Janssen Diagnostics, the Rubenstein Family Fund, the Susan
   G. Komen Foundation, National Institutes of Health Grants No.
   NIHP30CA006973 and NIHP30CA58223, and the Susan G. Komen Leadership
   Grant SAC110053 (A.C.W.).
CR Ahmed SA, 2015, TUMOR BIOL, V36, P815, DOI 10.1007/s13277-014-2689-z
   [Anonymous], DEV BIOL BASEL
   Avraham A, 2012, INT J CANCER, V131, pE1166, DOI 10.1002/ijc.27526
   Baylin S, 2001, Dev Biol (Basel), V106, P85
   Chimonidou M, 2013, CLIN BIOCHEM, V46, P235, DOI 10.1016/j.clinbiochem.2012.09.015
   Contal C, 1999, COMPUT STAT DATA AN, V30, P253, DOI 10.1016/S0167-9473(98)00096-6
   Cristofanilli M, 2004, NEW ENGL J MED, V351, P781, DOI 10.1056/NEJMoa040766
   Cristofanilli M, 2013, NEW ENGL J MED, V369, P93, DOI 10.1056/NEJMc1306040
   Egger G, 2004, NATURE, V429, P457, DOI 10.1038/nature02625
   Evron E, 2001, LANCET, V357, P1335, DOI 10.1016/S0140-6736(00)04501-3
   Fackler MJ, 2006, CLIN CANCER RES, V12, P3306, DOI 10.1158/1078-0432.CCR-05-2733
   Fackler MJ, 2014, CANCER RES, V74, P2160, DOI 10.1158/0008-5472.CAN-13-3392
   Fackler MJ, 2011, CANCER RES, V71, P6195, DOI 10.1158/0008-5472.CAN-11-1630
   Fackler MJ, 2009, CLIN CANCER RES, V15, P3802, DOI 10.1158/1078-0432.CCR-08-1981
   Fackler MJ, 2004, CANCER RES, V64, P4442, DOI 10.1158/0008-5472.CAN-03-3341
   Faraggi D, 1996, STAT MED, V15, P2203, DOI 10.1002/(SICI)1097-0258(19961030)15:20<2203::AID-SIM357>3.3.CO;2-7
   Fiegl H, 2005, CANCER RES, V65, P1141, DOI 10.1158/0008-5472.CAN-04-2438
   Freedman TS, 2006, P NATL ACAD SCI USA, V103, P16692, DOI 10.1073/pnas.0608127103
   Fujita N, 2014, ONCOL LETT, V8, P397, DOI 10.3892/ol.2014.2068
   Göbel G, 2011, BREAST CANCER RES TR, V130, P109, DOI 10.1007/s10549-010-1335-8
   Gordon Marilyn, 2011, Small GTPases, V2, P148
   Jones PA, 2002, ONCOGENE, V21, P5358, DOI 10.1038/sj.onc.1205597
   Lin SH, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-1079
   MacAlpine DM, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a010207
   Smerage JB, 2006, BRIT J CANCER, V94, P8, DOI 10.1038/sj.bjc.6602871
   Smerage JB, 2014, J CLIN ONCOL, V32, P3483, DOI 10.1200/JCO.2014.56.2561
   Tie J, 2015, ANN ONCOL, V26, P1715, DOI 10.1093/annonc/mdv177
   Tworoger SS, 2006, CANCER CAUSE CONTROL, V17, P889, DOI 10.1007/s10552-006-0035-5
   Van der Auwera I, 2009, BRIT J CANCER, V100, P1277, DOI 10.1038/sj.bjc.6605013
   Van Poznak C, 2015, J CLIN ONCOL, V33, P2695, DOI 10.1200/JCO.2015.61.1459
   Watanabe K, 2011, J BIOCHEM, V150, P593, DOI 10.1093/jb/mvr116
NR 31
TC 90
Z9 92
U1 3
U2 23
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAR 1
PY 2017
VL 35
IS 7
BP 751
EP +
DI 10.1200/JCO.2015.66.2080
PG 13
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA EO0CO
UT WOS:000396366100009
PM 27870562
OA Green Published
DA 2025-01-12
ER

PT J
AU Fu, NY
   Rios, AC
   Pal, B
   Law, CW
   Jamieson, P
   Liu, RJ
   Vaillant, F
   Jackling, F
   Liu, KH
   Smyth, GK
   Lindeman, GJ
   Ritchie, ME
   Visvader, JE
AF Fu, Nai Yang
   Rios, Anne C.
   Pal, Bhupinder
   Law, Charity W.
   Jamieson, Paul
   Liu, Ruijie
   Vaillant, Francois
   Jackling, Felicity
   Liu, Kevin He
   Smyth, Gordon K.
   Lindeman, Geoffrey J.
   Ritchie, Matthew E.
   Visvader, Jane E.
TI Identification of quiescent and spatially restricted mammary stem cells
   that are hormone responsive
SO NATURE CELL BIOLOGY
LA English
DT Article
ID SELF-RENEWAL; GLAND DEVELOPMENT; EMBRYONIC ORIGIN; BREAST-CANCER;
   PROGENITORS; POPULATION; LGR5; CONTRIBUTE; LINEAGES; PROTEINS
AB Despite accumulating evidence for a mammary differentiation hierarchy, the basal compartment comprising stem cells remains poorly characterized. Through gene expression profiling of Lgr(5+) basal epithelial cells, we identify a new marker, Tetraspanin8 (Tspan8). Fractionation based on Tspan8 and Lgr5 expression uncovered three distinct mammary stem cell (MaSC) subsets in the adult mammary gland. These exist in a largely quiescent state but differ in their reconstituting ability, spatial localization, and their molecular and epigenetic signatures. Interestingly, the deeply quiescent MaSC subset (Lgr(5+)Tspan8(hi)) resides within the proximal region throughout life, and has a transcriptome strikingly similar to that of claudin-low tumours. Lgr(5+)Tspan8(hi) cells appear to originate from the embryonic mammary primordia before switching to a quiescent state postnatally but can be activated by ovarian hormones. Our findings reveal an unexpected degree of complexity within the adult MaSC compartment and identify a dormant subset poised for activation in response to physiological stimuli.
C1 [Fu, Nai Yang; Rios, Anne C.; Pal, Bhupinder; Jamieson, Paul; Vaillant, Francois; Jackling, Felicity; Liu, Kevin He; Lindeman, Geoffrey J.; Visvader, Jane E.] Walter & Eliza Hall Inst Med Res, ACRF Stem Cells & Canc Div, Parkville, Vic 3052, Australia.
   [Fu, Nai Yang; Rios, Anne C.; Pal, Bhupinder; Law, Charity W.; Vaillant, Francois; Visvader, Jane E.] Univ Melbourne, Dept Med Biol, Parkville, Vic 3010, Australia.
   [Law, Charity W.; Liu, Ruijie; Ritchie, Matthew E.] Walter & Eliza Hall Inst Med Res, Div Mol Med, Parkville, Vic 3052, Australia.
   [Smyth, Gordon K.] Walter & Eliza Hall Inst Med Res, Bioinformat Div, Parkville, Vic 3052, Australia.
   [Smyth, Gordon K.; Ritchie, Matthew E.] Univ Melbourne, Sch Math & Stat, Parkville, Vic 3010, Australia.
   [Lindeman, Geoffrey J.] Royal Melbourne Hosp, Parkville Familial Canc Ctr, Parkville, Vic 3050, Australia.
   [Lindeman, Geoffrey J.] Peter MacCallum Canc Ctr, Parkville, Vic 3050, Australia.
   [Lindeman, Geoffrey J.] Univ Melbourne, Dept Med, Parkville, Vic 3010, Australia.
   [Fu, Nai Yang] Duke NUS Med Sch, Canc & Stem Cell Biol Program, Singapore 169857, Singapore.
C3 Walter & Eliza Hall Institute; University of Melbourne; Walter & Eliza
   Hall Institute; Walter & Eliza Hall Institute; University of Melbourne;
   Melbourne Health; Royal Melbourne Hospital; Peter Maccallum Cancer
   Center; University of Melbourne; National University of Singapore
RP Visvader, JE (通讯作者)，Walter & Eliza Hall Inst Med Res, ACRF Stem Cells & Canc Div, Parkville, Vic 3052, Australia.; Visvader, JE (通讯作者)，Univ Melbourne, Dept Med Biol, Parkville, Vic 3010, Australia.
EM visvader@wehi.edu.au
RI Ritchie, Matthew/I-3874-2019; Vaillant, Fabrice/D-6618-2012; Pal,
   Bhupinder/AAF-4011-2020; Smyth, Gordon/B-5276-2008
OI Smyth, Gordon/0000-0001-9221-2892; Vaillant,
   Francois/0000-0003-3229-3760; FU, Naiyang/0000-0001-5457-4323; Pal,
   Bhupinder/0000-0002-3684-4331; Liu, Ruijie/0000-0002-1489-1022; Rios,
   Anne/0000-0002-9082-8068; Ritchie, Matthew/0000-0002-7383-0609;
   Lindeman, Geoffrey/0000-0001-9386-2416; Law, Charity
   W/0000-0001-6082-6814
FU Australian National Health and Medical Research Council (NHMRC)
   [1016701, 1024852, 1054618, 1059622, 1085191, 1086727, 1100807]; NHMRC
   IRIISS; Victorian State Government through Victorian Cancer Agency
   (VCA); Operational Infrastructure Support; Australian Cancer Research
   Foundation; National Breast Cancer Foundation (NBCF)/Cure Cancer
   Australia Fellowship; NHMRC Fellowship [1016571, 1058892, 1078730,
   1104924, 1102742]; VCA Fellowship; National Health and Medical Research
   Council of Australia [1086727, 1100807, 1085191, 1059622] Funding
   Source: NHMRC
FX We are grateful to the Animal, FACS, Monoclonal Antibody (Bundoora),
   Imaging and Histology facilities at WEHI and to M. Milevskiy for
   discussions. This work was supported by the Australian National Health
   and Medical Research Council (NHMRC) grants no. 1016701, no. 1024852,
   no. 1054618, no. 1059622, no. 1085191, no. 1086727, no. 1100807; NHMRC
   IRIISS; the Victorian State Government through Victorian Cancer Agency
   (VCA) funding and Operational Infrastructure Support; and the Australian
   Cancer Research Foundation. N.Y.F. and A.C.R. were supported by a
   National Breast Cancer Foundation (NBCF)/Cure Cancer Australia
   Fellowship; B.P. by a NHMRC Fellowship no. 1016571 and a VCA Fellowship;
   G.K.S., G.J.L., M.E.R. and J.E.V. by NHMRC Fellowships no. 1058892, no.
   1078730, no. 1104924, no. 1102742.
CR Arai Fumio., 2008, STEMBOOK, DOI [10.3824/stembook.1.6.1, DOI 10.3824/STEMBOOK.1.6.1]
   Asselin-Labat ML, 2010, NATURE, V465, P798, DOI 10.1038/nature09027
   Barker N, 2007, NATURE, V449, P1003, DOI 10.1038/nature06196
   Barker N, 2013, DEVELOPMENT, V140, P2484, DOI 10.1242/dev.083113
   Barker N, 2010, CELL STEM CELL, V6, P25, DOI 10.1016/j.stem.2009.11.013
   Boras-Granic K, 2014, BREAST CANCER RES, V16, DOI 10.1186/s13058-014-0487-6
   Bowie MB, 2007, P NATL ACAD SCI USA, V104, P5878, DOI 10.1073/pnas.0700460104
   Buczacki SJA, 2013, NATURE, V495, P65, DOI 10.1038/nature11965
   Chambers Stuart M, 2007, Cell Stem Cell, V1, P578, DOI 10.1016/j.stem.2007.10.003
   Cheung TH, 2013, NAT REV MOL CELL BIO, V14, P329, DOI 10.1038/nrm3591
   Cicalese A, 2009, CELL, V138, P1083, DOI 10.1016/j.cell.2009.06.048
   de Visser KE, 2012, J PATHOL, V228, P300, DOI 10.1002/path.4096
   dos Santos CO, 2013, P NATL ACAD SCI USA, V110, P7123, DOI 10.1073/pnas.1303919110
   Fuentealba LC, 2015, CELL, V161, P1644, DOI 10.1016/j.cell.2015.05.041
   Fukada SI, 2007, STEM CELLS, V25, P2448, DOI 10.1634/stemcells.2007-0019
   Furutachi S, 2015, NAT NEUROSCI, V18, P657, DOI 10.1038/nn.3989
   Genander M, 2014, CELL STEM CELL, V15, P619, DOI 10.1016/j.stem.2014.09.009
   Giraddi RR, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9487
   Greco C, 2010, CANCER RES, V70, P7674, DOI 10.1158/0008-5472.CAN-09-4482
   He XC, 2004, NAT GENET, V36, P1117, DOI 10.1038/ng1430
   Hemler ME, 2005, NAT REV MOL CELL BIO, V6, P801, DOI 10.1038/nrm1736
   Jaks V, 2008, NAT GENET, V40, P1291, DOI 10.1038/ng.239
   Lien WH, 2011, CELL STEM CELL, V9, P219, DOI 10.1016/j.stem.2011.07.015
   Lim E, 2009, NAT MED, V15, P907, DOI 10.1038/nm.2000
   Liu L, 2013, CELL REP, V4, P189, DOI 10.1016/j.celrep.2013.05.043
   Makarem M, 2013, PLOS BIOL, V11, DOI 10.1371/journal.pbio.1001630
   Orford KW, 2008, NAT REV GENET, V9, P115, DOI 10.1038/nrg2269
   Pal B, 2013, CELL REP, V3, P411, DOI 10.1016/j.celrep.2012.12.020
   Plaks V, 2013, CELL REP, V3, P70, DOI 10.1016/j.celrep.2012.12.017
   Prat A, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2635
   Rios AC, 2014, NATURE, V506, P322, DOI 10.1038/nature12948
   Rodgers JT, 2014, NATURE, V510, P393, DOI 10.1038/nature13255
   Smith GH, 2005, DEVELOPMENT, V132, P681, DOI 10.1242/dev.01609
   Spike BT, 2012, CELL STEM CELL, V10, P183, DOI 10.1016/j.stem.2011.12.018
   Stingl J, 2006, NATURE, V439, P993, DOI 10.1038/nature04496
   Sun SS, 2016, CELL SIGNAL, V28, P481, DOI [10.1016/j.cellsig.2016.02.004, 10.1016/j.cellsig.2016.08.001]
   Van Keymeulen A, 2011, NATURE, V479, P189, DOI 10.1038/nature10573
   Visvader JE, 2016, NAT CELL BIOL, V18, P349, DOI 10.1038/ncb3332
   Wang DS, 2015, NATURE, V517, P81, DOI 10.1038/nature13851
   Westphalen CB, 2016, CELL STEM CELL, V18, P441, DOI 10.1016/j.stem.2016.03.016
   Wilson A, 2008, CELL, V135, P1118, DOI 10.1016/j.cell.2008.10.048
   Wu D, 2010, BIOINFORMATICS, V26, P2176, DOI 10.1093/bioinformatics/btq401
   Zeng YA, 2010, CELL STEM CELL, V6, P568, DOI 10.1016/j.stem.2010.03.020
   Zöller M, 2009, NAT REV CANCER, V9, P40, DOI 10.1038/nrc2543
NR 44
TC 90
Z9 102
U1 0
U2 18
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1465-7392
EI 1476-4679
J9 NAT CELL BIOL
JI Nat. Cell Biol.
PD MAR
PY 2017
VL 19
IS 3
BP 164
EP 176
DI 10.1038/ncb3471
PG 13
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA EM5MK
UT WOS:000395355500007
PM 28192422
DA 2025-01-12
ER

PT J
AU Hernandez, SJ
   Dolivo, DM
   Dominko, T
AF Hernandez, Sarah J.
   Dolivo, David M.
   Dominko, Tanja
TI PRMT8 demonstrates variant-specific expression in cancer cells and
   correlates with patient survival in breast, ovarian and gastric cancer
SO ONCOLOGY LETTERS
LA English
DT Article
DE protein arginine methyltransferase 8; biomarker; breast cancer; ovarian
   cancer; gastric cancer
ID ARGININE; PROSTATE; METHYLATION; EPIGENETICS; CARCINOMA; CARM1
AB Recent emphasis has been placed on the role of epigenetic regulators and epigenetic marks as biomarkers for cancer diagnosis and prognosis, and as therapeutic targets for treatment. One such class of regulators is the protein arginine methyltransferase (PRMT) family. The present study examined available curated data regarding the expression and alteration of one of the least studied PRMT family members, PRMT8, in various types of cancer and cancer cell lines. Publicly available cancer data on PRMT8 expression were examined using the Human Protein Atlas and the Kaplan-Meier Plotter, and reverse transcription-polymerase chain reaction was used to screen a selection of human cell lines for variant-specific PRMT8 expression. High levels of PRMT8 expression in breast, ovarian and cervical cancer was observed. Additionally, in patients with breast and ovarian cancer, high PRMT8 expression was correlated with increased patient survival, whereas in gastric cancer, high PRMT8 expression was correlated with decreased patient survival. The present study also investigated the expression of PRMT8 variant 2, a novel transcript variant recently identified in our laboratory, in various cancer cell lines. Variant-specific expression of PRMT8 in numerous distinct cancer cell lines derived from different tissues, including the expression of the novel PRMT8 variant 2 in U87MG glioblastoma cells was demonstrated. The present study proposes the possibility of PRMT8 as a cancer biomarker, based on the high level of PRMT8 expression in various types of cancer, particularly in tissues that would not normally be expected to express PRMT8, and on the correlation of PRMT8 and patient lifespan in several cancer types. Variant-specific expression of PRMT8 in diverse cancer cell lines suggests the possibility of alternate PRMT8 isoforms to have diverse effects on cancer cell phenotypes.
C1 [Hernandez, Sarah J.; Dolivo, David M.; Dominko, Tanja] Worcester Polytech Inst, Dept Biol & Biotechnol, 60 Prescott St, Worcester, MA 01605 USA.
   [Dominko, Tanja] Univ Nova Gorica, Ctr Biomed Sci & Engn, Vipava 5271, Slovenia.
C3 Worcester Polytechnic Institute; University of Nova Gorica
RP Dominko, T (通讯作者)，Worcester Polytech Inst, Dept Biol & Biotechnol, 60 Prescott St, Worcester, MA 01605 USA.
EM tdominko@wpi.edu
RI Dolivo, David/AAF-8713-2020
OI Hernandez, Sarah/0000-0002-6569-6403; Dolivo, David/0000-0002-6965-4294;
   Dominko, Tanja/0000-0002-0441-7757
FU National Institutes of Health award [R01GM85456]; National Science
   Foundation Integrative Graduate Education and Research Traineeship
   Training Program [DGE 1144804]
FX The authors would like to thank Kris Billiar, Anjana Jain and Pam
   Weathers at Worcester Polytechnic Institute for their generous gifts of
   U-2OS; A172, U87MG, MCF-10A, SK-BR-3 and MDA-MB-231; and Caco-2 cells,
   respectively. The present study was supported by the National Institutes
   of Health award (grant no. R01GM85456) and the National Science
   Foundation Integrative Graduate Education and Research Traineeship
   Training Program (grant no. DGE 1144804).
CR Cheung N, 2007, NAT CELL BIOL, V9, P1208, DOI 10.1038/ncb1642
   Dawson MA, 2012, CELL, V150, P12, DOI 10.1016/j.cell.2012.06.013
   Goulet I, 2007, J BIOL CHEM, V282, P33009, DOI 10.1074/jbc.M704349200
   Györffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9
   Hernandez S, 2016, J CELL BIOCHEM, V117, P2056, DOI 10.1002/jcb.25508
   Hong H, 2004, CANCER-AM CANCER SOC, V101, P83, DOI 10.1002/cncr.20327
   Kim YR, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-197
   Kousaka A, 2009, NEUROSCIENCE, V163, P1146, DOI 10.1016/j.neuroscience.2009.06.061
   Lee J, 2005, J BIOL CHEM, V280, P32890, DOI 10.1074/jbc.M506944200
   Li BS, 2015, BIOCHEM BIOPH RES CO, V464, P982, DOI 10.1016/j.bbrc.2015.06.169
   Mathioudaki K, 2008, BRIT J CANCER, V99, P2094, DOI 10.1038/sj.bjc.6604807
   Mathioudaki K, 2011, TUMOR BIOL, V32, P575, DOI 10.1007/s13277-010-0153-2
   Pal S, 2007, EMBO J, V26, P3558, DOI 10.1038/sj.emboj.7601794
   Papadokostopoulou A, 2009, ANTICANCER RES, V29, P1361
   Sammons MA, 2016, G3-GENES GENOM GENET, V6, P2671, DOI 10.1534/g3.116.031534
   Scorilas A, 2000, BIOCHEM BIOPH RES CO, V278, P349, DOI 10.1006/bbrc.2000.3807
   Seligson DB, 2005, NATURE, V435, P1262, DOI 10.1038/nature03672
   Sharma S, 2010, CARCINOGENESIS, V31, P27, DOI 10.1093/carcin/bgp220
   Strahl BD, 2001, CURR BIOL, V11, P996, DOI 10.1016/S0960-9822(01)00294-9
   Uhlen M, 2015, SCIENCE, V347, DOI 10.1126/science.1260419
   Wang HB, 2001, SCIENCE, V293, P853, DOI 10.1126/science.1060781
   Yoshimatsu M, 2011, INT J CANCER, V128, P562, DOI 10.1002/ijc.25366
   Zhong J, 2012, FEBS J, V279, P316, DOI 10.1111/j.1742-4658.2011.08426.x
NR 23
TC 38
Z9 42
U1 1
U2 10
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1792-1074
EI 1792-1082
J9 ONCOL LETT
JI Oncol. Lett.
PD MAR
PY 2017
VL 13
IS 3
BP 1983
EP 1989
DI 10.3892/ol.2017.5671
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA EO9HA
UT WOS:000396998600144
PM 28454353
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Bhat, S
   Kabekkodu, SP
   Varghese, VK
   Chakrabarty, S
   Mallya, SP
   Rotti, H
   Pandey, D
   Kushtagi, P
   Satyamoorthy, K
AF Bhat, Samatha
   Kabekkodu, Shama Prasada
   Varghese, Vinay Koshy
   Chakrabarty, Sanjiban
   Mallya, Sandeep P.
   Rotti, Harish
   Pandey, Deeksha
   Kushtagi, Pralhad
   Satyamoorthy, Kapaettu
TI Aberrant gene-specific DNA methylation signature analysis in cervical
   cancer
SO TUMOR BIOLOGY
LA English
DT Article
DE Cervical cancer; DNA methylation; methylation biomarkers; sensitivity;
   specificity; diagnosis
ID EPIGENETIC ALTERATIONS; CPG METHYLATION; BREAST-CANCER;
   5-HYDROXYMETHYLCYTOSINE; EXPRESSION; HYPERMETHYLATION; TBX3; MUTATIONS;
   BIOMARKER; GENOME
AB Multicomponent molecular modifications such as DNA methylation may offer sensitive and specific cervical intraepithelial neoplasia and cervical cancer biomarkers. In this study, we tested cervical tissues at various stages of tumor progression for 5-methylcytosine and 5-hydroxymethylcytosine levels and also DNA promoter methylation profile of a panel of genes for its diagnostic potential. In total, 5-methylcytosine, 5-hydroxymethylcytosine, and promoter methylation of 33 genes were evaluated by reversed-phase high-performance liquid chromatography, enzyme-linked immunosorbent assay based technique, and bisulfate-based next generation sequencing. The 5-methylcytosine and 5-hydroxymethylcytosine contents were significantly reduced in squamous cell carcinoma and receiver operating characteristic curve analysis showed a significant difference in (1) 5-methylcytosine between normal and squamous cell carcinoma tissues (area under the curve = 0.946) and (2) 5-hydroxymethylcytosine levels among normal, squamous intraepithelial lesions and squamous cell carcinoma. Analyses of our next generation sequencing results and data from five independent published studies consisting of 191 normal, 10 low-grade squamous intraepithelial lesions, 21 high-grade squamous intraepithelial lesions, and 335 malignant tissues identified a panel of nine genes (ARHGAP6, DAPK1, HAND2, NKX2-2, NNAT, PCDH10, PROX1, PITX2, and RAB6C) which could effectively discriminate among the various groups with sensitivity and specificity of 80%-100% (p < 0.05). Furthermore, 12 gene promoters (ARHGAP6, HAND2, LHX9, HEY2, NKX2-2, PCDH10, PITX2, PROX1, TBX3, IKBKG, RAB6C, and DAPK1) were also methylated in one or more of the cervical cancer cell lines tested. The global and gene-specific methylation of the panel of genes identified in our study may serve as useful biomarkers for the early detection and clinical management of cervical cancer.
C1 [Bhat, Samatha; Kabekkodu, Shama Prasada; Varghese, Vinay Koshy; Chakrabarty, Sanjiban; Mallya, Sandeep P.; Rotti, Harish; Satyamoorthy, Kapaettu] Manipal Univ, Sch Life Sci, Dept Cell & Mol Biol, Manipal 576104, Karnataka, India.
   [Pandey, Deeksha] Manipal Univ, Kasturba Med Coll, Dept Obstet & Gynaecol, Manipal, Karnataka, India.
   [Kushtagi, Pralhad] Manipal Univ, Kasturba Med Coll, Dept Obstet & Gynaecol, Mangalore, India.
C3 Manipal Academy of Higher Education (MAHE); Manipal Academy of Higher
   Education (MAHE); Kasturba Medical College, Manipal; Manipal Academy of
   Higher Education (MAHE); Kasturba Medical College, Mangalore
RP Satyamoorthy, K (通讯作者)，Manipal Univ, Sch Life Sci, Dept Cell & Mol Biol, Manipal 576104, Karnataka, India.
EM ksatyamoorthy@manipal.edu
RI kabekkodu, Shama/Q-2810-2018; Satyamoorthy, Kapaettu/KIJ-2967-2024;
   chakrabarty, sanjiban/GXW-1652-2022
OI Chakrabarty, Sanjiban/0000-0002-6018-8098; Mallya,
   Sandeep/0000-0001-6318-7165; Kabekkodu, Shama/0000-0002-4158-3893;
   Satyamoorthy, Kapaettu/0000-0002-2368-5490
FU Manipal University; CSIR; Government of India
FX The authors thank TIFAC-CORE for pharmacogenomics study and DST-FIST,
   Government of India, for infrastructure support; Manipal University and
   CSIR for fellowship under structured PhD program; and the Government of
   India for senior research fellowship. The authors also thank all the
   participants for their kind cooperation in this study. Samatha Bhat and
   Shama Prasada Kabekkodu contributed equally to this work
CR Ahmad ST, TUMOUR BIOL, V33, P395
   Amornpisutt R, 2015, TUMOR BIOL, V36, P4973, DOI 10.1007/s13277-015-3147-2
   Anderson KR, 2009, J BIOL CHEM, V284, P31236, DOI 10.1074/jbc.M109.048694
   Armstrong KM, 2011, BIOTECHNOL J, V6, P113, DOI 10.1002/biot.201000267
   Bakshi A, 2015, GENOM DATA, V3, P87, DOI 10.1016/j.gdata.2014.11.013
   Bamshad M, 1997, NAT GENET, V16, P311, DOI 10.1038/ng0797-311
   Banzai C, 2014, INT J CLIN ONCOL, V19, P127, DOI 10.1007/s10147-013-0530-0
   Beukers W, 2015, MODERN PATHOL, V28, P515, DOI 10.1038/modpathol.2014.145
   Bhat S, 2016, BIOCHIMIE, V121, P298, DOI 10.1016/j.biochi.2015.12.018
   Breiman L., 2001, Machine Learning, V45, P5, DOI 10.1023/A:1010933404324
   Brennan K, 2012, CANCER RES, V72, P2304, DOI 10.1158/0008-5472.CAN-11-3157
   Celik S, 2015, ONCOL LETT, V9, P399, DOI 10.3892/ol.2014.2677
   Cezar GG, 2003, BIOL REPROD, V68, P1009, DOI 10.1095/biolreprod.102.010181
   Chen K, 2016, CELL RES, V26, P103, DOI 10.1038/cr.2015.150
   Claus R, 2012, INT J CANCER, V131, pE138, DOI 10.1002/ijc.26429
   Di Vinci A, 2012, TRANSL RES, V160, P355, DOI 10.1016/j.trsl.2012.05.007
   Duenas-Gonzalez A, 2005, MOL CANCER, V4, DOI 10.1186/1476-4598-4-38
   Eggers S, 2012, CHROMOSOME RES, V20, P215, DOI 10.1007/s10577-012-9274-3
   Ehrlich M, 2009, EPIGENOMICS-UK, V1, P239, DOI [10.2217/epi.09.33, 10.2217/EPI.09.33]
   Eijsink JJH, 2012, INT J CANCER, V130, P1861, DOI 10.1002/ijc.26326
   Ekram MB, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101683
   Esteller M, 2000, NEW ENGL J MED, V343, P1350, DOI 10.1056/NEJM200011093431901
   Ficz G, 2014, GENOMICS, V104, P352, DOI 10.1016/j.ygeno.2014.08.017
   Fischer A, 2004, GENE DEV, V18, P901, DOI 10.1101/gad.291004
   Ghosh S, 2016, MITOCHONDRION, V27, P25, DOI 10.1016/j.mito.2016.01.003
   Gravitt PE, 2000, J CLIN MICROBIOL, V38, P357
   Guo SC, 2015, CLIN EPIGENETICS, V7, DOI 10.1186/s13148-014-0035-3
   Harden SV, 2003, J NATL CANCER I, V95, P1634, DOI 10.1093/jnci/djg082
   Hui-Yuen J, 2011, JOVE-J VIS EXP, DOI 10.3791/3321
   Jones A, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001551
   Jovov B, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030168
   Kabekkodu Shama Prasada, 2015, Asian Pac J Cancer Prev, V16, P2073
   Kellinger MW, 2012, NAT STRUCT MOL BIOL, V19, P831, DOI 10.1038/nsmb.2346
   Kim WJ, 2002, ONCOGENE, V21, P3864, DOI 10.1038/sj.onc.1205485
   KIM YI, 1994, CANCER, V74, P893, DOI 10.1002/1097-0142(19940801)74:3<893::AID-CNCR2820740316>3.0.CO;2-B
   Kishida Y, 2012, TUMOR BIOL, V33, P373, DOI 10.1007/s13277-012-0319-1
   Kron K, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004830
   Krzywinski M, 2009, GENOME RES, V19, P1639, DOI 10.1101/gr.092759.109
   Kuerbitz SJ, 2002, CARCINOGENESIS, V23, P559, DOI 10.1093/carcin/23.4.559
   Li Z, 2011, MOL CELL RES, V1823, P298
   Lian CG, 2012, CELL, V150, P1135, DOI 10.1016/j.cell.2012.07.033
   Lin YW, 1998, EUR J CANCER, V34, P1789, DOI 10.1016/S0959-8049(98)00189-0
   Lozano-Velasco E, 2015, MOL CELL BIOL, V35, P2892, DOI 10.1128/MCB.00536-15
   Lutsik P, 2011, NUCLEIC ACIDS RES, V39, pW551, DOI 10.1093/nar/gkr312
   Ma JG, 2013, J INT MED RES, V41, P38, DOI 10.1177/0300060513476989
   Marsit CJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012334
   Matsuda Y, 1999, GASTROENTEROLOGY, V116, P394, DOI 10.1016/S0016-5085(99)70137-X
   Mehdipour P, 2015, MOL NEUROBIOL, V52, P293, DOI 10.1007/s12035-014-8864-9
   Meldrum Cliff, 2011, Clin Biochem Rev, V32, P177
   Mersakova S, 2016, TUMOR BIOL, V37, P23, DOI 10.1007/s13277-015-4197-1
   Miettinen M, 2012, AM J SURG PATHOL, V36, P351, DOI 10.1097/PAS.0b013e318236c312
   Missaoui N, 2010, ASIAN PAC J CANCER P, V11, P1741
   Nagai H, 2003, GENE CHROMOSOME CANC, V38, P13, DOI 10.1002/gcc.10248
   Narayan G, 2009, GENE CHROMOSOME CANC, V48, P983, DOI 10.1002/gcc.20703
   Ning B, 2016, ACTA BIOCH BIOPH SIN, V48, P97, DOI 10.1093/abbs/gmv116
   Paska AV, 2015, BIOCHEM MEDICA, V25, P161, DOI 10.11613/BM.2015.017
   Peres J, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-117
   Pinney Sara E, 2014, Biology (Basel), V3, P739, DOI 10.3390/biology3040739
   Pradhan MP, 2013, BMC SYST BIOL, V7, DOI 10.1186/1752-0509-7-141
   Rauch T, 2007, P NATL ACAD SCI USA, V104, P5527, DOI 10.1073/pnas.0701059104
   Rigi-Ladiz MA, 2011, CLIN EPIGENETICS, V3, DOI 10.1186/1868-7083-3-6
   Rodrigues MFSD, 2014, MEDICINE, V93, DOI 10.1097/MD.0000000000000192
   Rodríguez-León J, 2008, P NATL ACAD SCI USA, V105, P11242, DOI 10.1073/pnas.0804904105
   Rotti H, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0506-0
   Saavedra K, 2012, CLIN EPIGENETICS, V4, DOI 10.1186/1868-7083-4-13
   Sawaya GF, 1999, OBSTET GYNECOL, V94, P307, DOI 10.1016/S0029-7844(99)00289-6
   Sedlazeck FJ, 2013, BIOINFORMATICS, V29, P2790, DOI 10.1093/bioinformatics/btt468
   Shen L, 2013, CURR OPIN CELL BIOL, V25, P289, DOI 10.1016/j.ceb.2013.02.017
   Sing T, 2005, BIOINFORMATICS, V21, P3940, DOI 10.1093/bioinformatics/bti623
   Singal R, 2001, CANCER RES, V61, P4820
   Solomon D, 2002, JAMA-J AM MED ASSOC, V287, P2114, DOI 10.1001/jama.287.16.2114
   Song CX, 2013, TRENDS BIOCHEM SCI, V38, P480, DOI 10.1016/j.tibs.2013.07.003
   Strand SH, 2014, INT J MOL SCI, V15, P16544, DOI 10.3390/ijms150916544
   Tahiliani M, 2009, SCIENCE, V324, P930, DOI 10.1126/science.1170116
   Taylor KH, 2007, CANCER RES, V67, P8511, DOI 10.1158/0008-5472.CAN-07-1016
   Tian KG, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-327
   Tsou JA, 2007, MOL CANCER, V6, DOI 10.1186/1476-4598-6-70
   Vasiljevic N, 2011, DIS MARKERS, V30, P151, DOI 10.3233/DMA-2011-0790
   Veerla S, 2008, GENE CHROMOSOME CANC, V47, P368, DOI 10.1002/gcc.20542
   Versmold B, 2007, INT J CANCER, V121, P547, DOI 10.1002/ijc.22705
   Vladimirova V, 2009, NEOPLASIA, V11, P700, DOI 10.1593/neo.09406
   Weiss G, 2009, J UROLOGY, V181, P1678, DOI 10.1016/j.juro.2008.11.120
   Xiong JQ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107272
   Yang HJ, 2013, CHIN J CANCER, V32, P42, DOI 10.5732/cjc.012.10033
   Yarosh W, 2008, CANCER RES, V68, P693, DOI 10.1158/0008-5472.CAN-07-5012
   Yi JM, 2012, TUMOR BIOL, V33, P363, DOI 10.1007/s13277-011-0302-2
   Zhang LY, 2016, JPN J CLIN ONCOL, V46, P427, DOI 10.1093/jjco/hyw002
NR 87
TC 44
Z9 48
U1 4
U2 12
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD MAR
PY 2017
VL 39
IS 3
AR 694573
DI 10.1177/1010428317694573
PG 16
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA ET4OS
UT WOS:000400263700057
PM 28351298
OA gold
DA 2025-01-12
ER

PT J
AU Ni, HF
   Zhou, Z
   Jiang, B
   Yuan, XY
   Cao, XL
   Huang, GW
   Li, Y
AF Ni, Haifeng
   Zhou, Zhen
   Jiang, Bo
   Yuan, Xiaoyang
   Cao, Xiaolin
   Huang, Guangwu
   Li, Yong
TI Inactivation of <i>parkin</i> by promoter methylation correlated with
   lymph node metastasis and genomic instability in nasopharyngeal
   carcinoma
SO TUMOR BIOLOGY
LA English
DT Article
DE Genome instability; lymph node metastasis; nasopharyngeal carcinoma;
   parkin gene; promoter methylation
ID AMPLIFIED POLYMORPHIC DNA; TUMOR-SUPPRESSOR GENE; BREAST-CANCER; CELL
   CARCINOMA; PROLIFERATION; EPIGENETICS; EXPRESSION; MUTATIONS; PACRG
AB This study aimed to investigate the inactivation of the parkin gene by promoter methylation and its relationship with genome instability in nasopharyngeal carcinoma. Parkin was considered as a tumor suppressor gene in various types of cancers. However, its role in nasopharyngeal carcinoma is unexplored. Genomic instabilities were detected in nasopharyngeal carcinoma tissues by the random amplified polymorphic DNA. The methylation-specific polymerase chain reaction, semi-quantitative reverse transcription polymerase chain reaction, and immunohistochemical analysis were used to detect methylation and mRNA and protein expression of parkin in 54 cases of nasopharyngeal carcinoma tissues and 16 cases of normal nasopharyngeal epithelia tissues, and in 5 nasopharyngeal carcinoma cell lines (CNE1, CNE2, TWO3, C666, and HONE1) and 1 normal nasopharyngeal epithelia cell line (NP69). mRNA expression of parkin in CNE1 and CNE2 was analyzed before and after methyltransferase inhibitor 5-aza-2-deoxycytidine treatment. The relationship between promoter methylation and mRNA expression, demethylation and mRNA expression, and mRNA and protein expression of the gene and clinical factors and genomic instabilities were analyzed. The mRNA and protein expression levels were significantly reduced in 54 cases of human nasopharyngeal carcinoma compared with 16 cases of normal nasopharyngeal epithelia. Parkin-methylated cases showed significantly lower mRNA and protein expression levels compared with unmethylated cases. After 5-aza-2-deoxycytidine treatment, parkin mRNA expression was restored in CNE1 and CNE2; 92.59% (50/54) of nasopharyngeal carcinoma demonstrated genomic instability. Parkin is frequently inactivated by promoter methylation, and its mRNA and protein expression correlate with lymph node metastasis and genomic instability. Parkin deficiency probably promotes tumorigenesis in nasopharyngeal carcinoma.
C1 [Ni, Haifeng; Zhou, Zhen; Jiang, Bo; Yuan, Xiaoyang; Cao, Xiaolin; Li, Yong] Nanjing Med Univ, Hangzhou Peoples Hosp 1, Dept Otolaryngol, Hangzhou 310006, Zhejiang, Peoples R China.
   [Huang, Guangwu] Guangxi Med Univ, Affiliated Hosp 1, Dept Otolaryngol, Nanning, Peoples R China.
C3 Nanjing Medical University; Guangxi Medical University
RP Ni, HF; Li, Y (通讯作者)，Nanjing Med Univ, Hangzhou Peoples Hosp 1, Dept Otolaryngol, Hangzhou 310006, Zhejiang, Peoples R China.
EM nihaifeng138@163.com; leeyung828@sina.com
FU Medical and Health Backbone Platform Foundation Project of Zhejiang
   Province, China [2011KYA127, 2012RCB038]
FX This study was supported by grants from the Medical and Health Backbone
   Platform Foundation Project of Zhejiang Province, China (grant nos
   2011KYA127 and 2012RCB038).
CR Agirre X, 2006, INT J CANCER, V118, P1945, DOI 10.1002/ijc.21584
   Atienzar FA, 2006, MUTAT RES-REV MUTAT, V613, P76, DOI 10.1016/j.mrrev.2006.06.001
   Bartek J, 2014, NAT GENET, V46, P527, DOI 10.1038/ng.2992
   Cabral LS, 2011, CLINICS, V66, P523, DOI 10.1590/S1807-59322011000400001
   Chen Y, 2012, BBA-MOL BASIS DIS, V1822, P573, DOI 10.1016/j.bbadis.2011.12.007
   Dil-Afroze, 1998, GENE, V206, P45, DOI 10.1016/S0378-1119(97)00579-9
   Fujiwara M, 2008, ONCOGENE, V27, P6002, DOI 10.1038/onc.2008.199
   Gong YX, 2014, NAT GENET, V46, P588, DOI 10.1038/ng.2981
   Henn IH, 2005, J NEUROCHEM, V92, P114, DOI 10.1111/j.1471-4159.2004.02854.x
   Hu HH, 2016, JNCI-J NATL CANCER I, V108, DOI 10.1093/jnci/djv340
   Iwakawa R, 2012, GENE CHROMOSOME CANC, V51, P462, DOI 10.1002/gcc.21933
   Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947
   Knudson AG, 1996, J CANCER RES CLIN, V122, P135, DOI 10.1007/BF01366952
   Lee K, 2012, BMB REP, V45, P526, DOI 10.5483/BMBRep.2012.45.9.104
   Lee MH, 2015, BIOCHEM BIOPH RES CO, V464, P63, DOI 10.1016/j.bbrc.2015.05.101
   Lee SB, 2015, MOL CELL, V60, P21, DOI 10.1016/j.molcel.2015.08.011
   Lin DC, 2015, CANCER RES, V75, P1815, DOI 10.1158/0008-5472.CAN-14-1433
   Liu QC, 2011, INT J NANOMED, V6, P2933, DOI 10.2147/IJN.S25842
   Lo KW, 2012, SEMIN CANCER BIOL, V22, P79, DOI 10.1016/j.semcancer.2011.12.011
   Lung HL, 2012, SEMIN CANCER BIOL, V22, P87, DOI 10.1016/j.semcancer.2011.11.002
   Maeda T, 1999, CANCER LETT, V138, P183, DOI 10.1016/S0304-3835(99)00004-X
   Mehdi SJ, 2011, MED ONCOL, V28, P1520, DOI 10.1007/s12032-010-9633-x
   Mehdi SJ, 2011, PATHOL ONCOL RES, V17, P579, DOI 10.1007/s12253-010-9351-x
   Ong TM, 1998, CARCINOGENESIS, V19, P233, DOI 10.1093/carcin/19.1.233
   Poulogiannis G, 2010, P NATL ACAD SCI USA, V107, P15145, DOI 10.1073/pnas.1009941107
   Song DG, 2013, APPL BIOCHEM BIOTECH, V171, P1630, DOI 10.1007/s12010-013-0443-4
   Sun XD, 2013, CELL CYCLE, V12, P1133, DOI 10.4161/cc.24215
   Tao Qian, 2007, Expert Reviews in Molecular Medicine, V9, P1, DOI 10.1017/S1462399407000312
   Tay SP, 2010, J BIOL CHEM, V285, P29231, DOI 10.1074/jbc.M110.108241
   Toma MI, 2013, GENE CHROMOSOME CANC, V52, P265, DOI 10.1002/gcc.22026
   Verma M, 2004, CRIT REV CL LAB SCI, V41, P585, DOI 10.1080/10408360490516922
   Wang HX, 2009, J PATHOL, V218, P76, DOI 10.1002/path.2512
   Xiao X, 2014, TUMOR BIOL, V35, P3755, DOI 10.1007/s13277-013-1497-1
   Xiong DH, 2015, AM J HUM GENET, V96, P301, DOI 10.1016/j.ajhg.2014.12.016
   Xu L, 2014, J MOL MED, V92, P31, DOI 10.1007/s00109-013-1107-0
   Yeo CWS, 2012, CANCER RES, V72, P2543, DOI 10.1158/0008-5472.CAN-11-3060
   Zhang C, 2011, P NATL ACAD SCI USA, V108, P16259, DOI 10.1073/pnas.1113884108
   Zhang SH, 2004, J CANCER RES CLIN, V130, P757, DOI 10.1007/s00432-004-0613-4
   Zhang Z, 2007, INT J CANCER, V120, P32, DOI 10.1002/ijc.22185
   Zheng R, 2015, ONCOTARGET, V6, P17417, DOI 10.18632/oncotarget.4002
NR 40
TC 12
Z9 13
U1 0
U2 1
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD MAR
PY 2017
VL 39
IS 3
AR 695025
DI 10.1177/1010428317695025
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA ET4OS
UT WOS:000400263700072
PM 28351314
OA gold
DA 2025-01-12
ER

PT J
AU Lin, L
   Wang, ZW
   Jin, HH
   Shi, HZ
   Lu, ZH
   Qi, ZQ
AF Lin, Lin
   Wang, Zhiwen
   Jin, Haihong
   Shi, Hongzhen
   Lu, Zhihong
   Qi, Zhenqin
TI MiR-212/132 is epigenetically downregulated by SOX4/EZH2-H3K27me3
   feedback loop in ovarian cancer cells
SO TUMOR BIOLOGY
LA English
DT Article
DE miR-212; miR-132; SOX4; EZH2; H3K27me3; Ovarian cancer
ID TARGETING SOX4; MESENCHYMAL TRANSITION; SUPPRESSES METASTASIS;
   BREAST-CANCER; EZH2; EXPRESSION; INVASION; MIGRATION; METHYLATION;
   PROTEIN
AB Both miR-212 and miR-132 are usually downregulated in ovarian cancer and act as tumor suppressors. However, the mechanism of their downregulation in ovarian cancer is not clear. In this study, we investigated the regulative effects of miR-212 and miR-132 on SOX4 expression in ovarian cancer cells and also studied whether there is a feedback regulation between miR-212/miR-132 and SOX4 via an epigenetic mechanism. The results showed that both EZH2 and SOX4 overexpressions significantly repressed miR-212 and miR-132 expressions in SKOV3 and OV2008 cells. Immunoprecipitation assay showed that there are interactions among SOX4, EZH2, and H3K27me3, and ChIP assay confirmed significant enrichment of EZH2 and H3K27me3 in the promoter region of miR-212/132. Both pri-miR-212 and pri-miR-132 expressions decreased after enforced EZH2 or SOX4 expression. Western blot and dual-luciferase assay confirmed that miR-212 and miR-132 can target the same sites in the 3'UTR of SOX4 mRNA and suppress its expression in ovarian cancer cells. MiR-132 or miR-212 overexpression or knockdown of endogenous SOX4 reduced epithelial-mesenchymal transition (EMT)-like properties. Therefore, we infer that the SOX4/EZH2 complex can silence miR-212 and miR-132 expressions via binding to the promoter region and promoting H3K27me3, while miR-212 and miR-132 can directly bind to the 3'UTR of SOX4 and suppress its expression. This forms a MiR-132/212-SOX4/EZH2-H3K27me3 feedback loop in ovarian cancer cells. Functionally, SOX4 is a downstream effector of miR-212/132 modulating EMT of ovarian cancer cells.
C1 [Lin, Lin; Shi, Hongzhen] First Hosp Qinhuangdao, Dept Reprod Med, Qinhuangdao 066000, Hebei, Peoples R China.
   [Wang, Zhiwen; Jin, Haihong] First Hosp Qinhuangdao, Dept Obstet & Gynaecol, Qinhuangdao 066000, Hebei, Peoples R China.
   [Lu, Zhihong] First Hosp Qinhuangdao, Dept Infect Dis, Qinhuangdao 066000, Hebei, Peoples R China.
   [Qi, Zhenqin] First Hosp Qinhuangdao, B Ultrasound Room, Qinhuangdao 066000, Hebei, Peoples R China.
RP Wang, ZW (通讯作者)，First Hosp Qinhuangdao, Dept Obstet & Gynaecol, Qinhuangdao 066000, Hebei, Peoples R China.
EM zhiwenwang66@outlook.com
CR Bowles J, 2000, DEV BIOL, V227, P239, DOI 10.1006/dbio.2000.9883
   Cao R, 2004, CURR OPIN GENET DEV, V14, P155, DOI 10.1016/j.gde.2004.02.001
   Chmelarova M, 2013, CLIN TRANSL ONCOL, V15, P160, DOI 10.1007/s12094-012-0894-z
   Chung VY, 2016, SCI REP-UK, V6, DOI 10.1038/srep19943
   Chung YW, 2013, INT J GYNECOL CANCER, V23, P673, DOI 10.1097/IGC.0b013e31828c166d
   Formosa A, 2013, ONCOGENE, V32, P127, DOI 10.1038/onc.2012.14
   Hanieh H, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0443-9
   Hu FY, 2016, BIOCHEM BIOPH RES CO, V474, P35, DOI 10.1016/j.bbrc.2016.04.055
   Incoronato M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027722
   Jin Y, 2015, INT J ONCOL, V47, P1594, DOI 10.3892/ijo.2015.3114
   Koumangoye RB, 2015, MOL CANCER, V14, DOI 10.1186/s12943-014-0284-y
   Li SJ, 2015, AM J TRANSL RES, V7, P1390
   Li Y, 2015, J THORAC DIS, V7, P1563, DOI 10.3978/j.issn.2072-1439.2015.09.06
   Liu L, 2014, TUMOR BIOL, V35, P12619, DOI 10.1007/s13277-014-2585-6
   Liu XL, 2015, TUMOR BIOL, V36, P4261, DOI 10.1007/s13277-015-3063-5
   Liu YL, 2015, INT J ONCOL, V47, P1672, DOI 10.3892/ijo.2015.3147
   Mehta A, 2015, J EXP MED, V212, P1679, DOI 10.1084/jem.20150489
   Nakahama T, 2013, P NATL ACAD SCI USA, V110, P11964, DOI 10.1073/pnas.1311087110
   Shao CB, 2009, EPIGENETICS-US, V4, P165, DOI 10.4161/epi.4.3.8277
   Tian H, 2016, AM J TRANSL RES, V8, P1492
   Tiwari N, 2013, CANCER CELL, V23, P768, DOI 10.1016/j.ccr.2013.04.020
   Vella S, 2015, CLIN EPIGENETICS, V7, DOI 10.1186/s13148-015-0107-z
   Viré E, 2006, NATURE, V439, P871, DOI 10.1038/nature04431
   Wang BR, 2016, ARCH TOXICOL, V90, P449, DOI 10.1007/s00204-014-1435-z
   Wei LQ, 2014, TUMOR BIOL, V35, P12427, DOI 10.1007/s13277-014-2560-2
   Wei XF, 2013, CELL SIGNAL, V25, P1037, DOI 10.1016/j.cellsig.2013.01.019
   Xu L, 2011, MED ONCOL, V28, pS189, DOI 10.1007/s12032-010-9691-0
   Yeh YM, 2013, INT J CANCER, V133, P867, DOI 10.1002/ijc.28086
   Zaman MS, 2012, J OVARIAN RES, V5, DOI 10.1186/1757-2215-5-44
NR 29
TC 19
Z9 19
U1 0
U2 6
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD DEC
PY 2016
VL 37
IS 12
BP 15719
EP 15727
DI 10.1007/s13277-016-5339-9
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA EJ0ZX
UT WOS:000392941000040
DA 2025-01-12
ER

PT J
AU Ferrucci, V
   Zollo, M
AF Ferrucci, Veronica
   Zollo, Massimo
TI Glioblastoma stem cells differentiation through epigenetic modulation is
   driven by miR-296-5p/HMGA1/Sox2 axis
SO TRANSLATIONAL CANCER RESEARCH
LA English
DT Article
DE Cancer-stem cells; epigenetics; glioma; miR-296-5p;Sox2/Oct4/HMGA1 axis
ID BREAST-CANCER; TUMOR-GROWTH; GLIOMAS; EXPRESSION; PROLIFERATION;
   MIR-296-5P; SIGNATURE; DELIVERY; MIR-34A; SOX2
AB Glioma Stem Cells (GSCs) biology is finely regulated by a cross-talk of epigenetic mechanisms of regulation and the action of Oct4/Sox2 stemness gene drivers. Recently, a novel mechanism of regulation of miRNA-296-5p/Sox2 axis together with a new gene target (HMGA1) was described. The results raised questions of great relevance in glioma therapy, especially for the failure of the current radio/chemotherapies. Can miR-296-5p/HMGA1/Sox2 axis trigger the differentiation of GSCs subpopulation? Can these findings be used in a short term to develop novel therapeutics to fight glioma? We thus believe that targeting HMGA1 in GSCs, via nano-liposomes miRNA delivery together with epigenetic drugs, could overcome the failure of the current therapies. Additionally, in silico analyses to identify other gene targets of miR-296-5p with data available in literature, found a remarkable association with new gene targets whose functions are related to cell differentiation processes. Taken altogether these findings make miR-296-5p an attractive target for human brain cancer treatment.
C1 [Ferrucci, Veronica; Zollo, Massimo] Univ Naples Federico II, Dept Mol Med & Med Biotechnol, Via Pansini 5, Naples, Italy.
   [Ferrucci, Veronica; Zollo, Massimo] Ceinge Biotecnol Avanzate, Via Gaetano Salvatore 486, Naples, Italy.
   [Ferrucci, Veronica; Zollo, Massimo] European Sch Mol Med SEMM, Milan, Italy.
C3 University of Naples Federico II; CEINGE Biotecnologie Avanzate
RP Zollo, M (通讯作者)，Univ Naples Federico II, Dept Mol Med & Med Biotechnol, Via Pansini 5, Naples, Italy.; Zollo, M (通讯作者)，Ceinge Biotecnol Avanzate, Via Gaetano Salvatore 486, Naples, Italy.
EM massimo.zollo@unina.it
RI Zollo, Massimo/KGM-6181-2024; Ferrucci, Veronica/HLG-2949-2023
OI FERRUCCI, Veronica/0000-0002-2019-6501
FU Fondazione Adolfo Volpe e Associazione Pediatri di Famiglia
   [EU-FP7-TUMIC-HEALTH-F2-2008-2016662]; Italian Association for Cancer
   Research (AIRC) [11963]; Regione Campania [L.g.R: N.5]; European
   National Funds [PON01-02388/1 2007-2013]; POR Rete delle Biotecnologie
   in Campania Movie
FX Fondazione Adolfo Volpe e Associazione Pediatri di Famiglia,
   EU-FP7-TUMIC-HEALTH-F2-2008-2016662 (MZ), the Italian Association for
   Cancer Research (AIRC) Grant IG # 11963 (MZ), the Regione Campania
   L.g.R: N.5 (MZ), the European National Funds PON01-02388/1 2007-2013
   (MZ) and POR Rete delle Biotecnologie in Campania Movie (MZ).
CR Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730
   Conceiçao M, 2016, DATA BRIEF, V6, P700, DOI 10.1016/j.dib.2016.01.017
   Costa PM, 2013, MOL THER-NUCL ACIDS, V2, DOI 10.1038/mtna.2013.30
   De Antonellis P., 2015, POSTERIOR FOSSA TUMO, P265
   De Antonellis P, 2014, MOL CELL PROTEOMICS, V13, P2114, DOI 10.1074/mcp.M113.035808
   de Antonellis P, 2013, N-S ARCH PHARMACOL, V386, P287, DOI 10.1007/s00210-013-0837-4
   de Antonellis P, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024584
   Dick JE, 2003, P NATL ACAD SCI USA, V100, P3547, DOI 10.1073/pnas.0830967100
   Dick JE, 2008, BLOOD, V112, P4793, DOI 10.1182/blood-2008-08-077941
   Fidoamore A, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/6809105
   Filbin MG, 2016, ANNU REV PATHOL-MECH, V11, P497, DOI 10.1146/annurev-pathol-012615-044208
   Garros-Regulez L, 2016, FRONT ONCOL, V6, DOI 10.3389/fonc.2016.00222
   Garzia L, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004998
   Godlewski J, 2010, CELL DEATH DIFFER, V17, P221, DOI 10.1038/cdd.2009.71
   Katsushima K, 2014, FRONT GENET, V5, DOI 10.3389/fgene.2014.00014
   Lee KH, 2014, BBA-MOL CELL RES, V1843, P2055, DOI 10.1016/j.bbamcr.2014.06.001
   Li T, 2014, ONCOGENE, V33, P783, DOI 10.1038/onc.2012.637
   Lopez-Bertoni H, 2016, ONCOGENE, V35, P4903, DOI 10.1038/onc.2016.22
   Lopez-Bertoni H, 2015, ONCOGENE, V34, P3994, DOI 10.1038/onc.2014.334
   Maia D, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0621-y
   O'Flaherty JD, 2012, J THORAC ONCOL, V7, P1880, DOI 10.1097/JTO.0b013e31826bfbc6
   Oliva CR, 2010, J BIOL CHEM, V285, P39759, DOI 10.1074/jbc.M110.147504
   Rathod SS, 2014, FEBS OPEN BIO, V4, P485, DOI 10.1016/j.fob.2014.05.002
   Regazzo G, 2016, J EXP CLIN CANC RES, V35, DOI 10.1186/s13046-016-0393-0
   Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167
   Riva G, 2016, ONCOL REP, V35, P2811, DOI 10.3892/or.2016.4665
   Sausville E.A., 2006, Cancer Res, V66, P33513354
   Sausville EA, 2006, CANCER RES, V66, P3351, DOI 10.1158/0008-5472.CAN-05-3627
   Savi F, 2014, CLIN SCI, V127, P233, DOI 10.1042/CS20130580
   Shackleton M, 2010, SEMIN CANCER BIOL, V20, P85, DOI 10.1016/j.semcancer.2010.04.002
   Shah K, 2016, NEURO-ONCOLOGY, V18, P1066, DOI 10.1093/neuonc/now096
   Shukla S, 2014, BBA-GEN SUBJECTS, V1840, P3494, DOI 10.1016/j.bbagen.2014.09.017
   Song WS, 2016, J CHIN MED ASSOC, V79, P538, DOI 10.1016/j.jcma.2016.03.010
   Spano D, 2012, CLIN EXP METASTAS, V29, P381, DOI 10.1007/s10585-012-9457-5
   Thor T, 2015, INT J CANCER, V136, P2293, DOI 10.1002/ijc.29294
   Wang JG, 2016, NAT GENET, V48, P768, DOI 10.1038/ng.3590
   Wen PY, 2008, NEW ENGL J MED, V359, P492, DOI 10.1056/NEJMra0708126
   Würdinger T, 2008, CANCER CELL, V14, P382, DOI 10.1016/j.ccr.2008.10.005
   Xu C, 2016, ONCOL REP, V35, P497, DOI 10.3892/or.2015.4392
   Yan W, 2014, ONCOTARGET, V5, P12908, DOI 10.18632/oncotarget.2679
   Zhang CY, 2011, CELL BIOSCI, V1, DOI 10.1186/2045-3701-1-8
NR 41
TC 1
Z9 1
U1 0
U2 5
PU AME PUBLISHING COMPANY
PI SHATIN
PA FLAT-RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG
   00000, PEOPLES R CHINA
SN 2218-676X
EI 2219-6803
J9 TRANSL CANCER RES
JI Transl. Cancer Res.
PD OCT
PY 2016
VL 5
SU 4
BP S782
EP S788
DI 10.21037/tcr.2016.10.88
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA EJ6JA
UT WOS:000393324100037
DA 2025-01-12
ER

PT J
AU Brier, ASB
   Loft, A
   Madsen, JGS
   Rosengren, T
   Nielsen, R
   Schmidt, SF
   Liu, ZZ
   Yan, Q
   Gronemeyer, H
   Mandrup, S
AF Brier, Ann-Sofie B.
   Loft, Anne
   Madsen, Jesper G. S.
   Rosengren, Thomas
   Nielsen, Ronni
   Schmidt, Soren F.
   Liu, Zongzhi
   Yan, Qin
   Gronemeyer, Hinrich
   Mandrup, Susanne
TI The KDM5 family is required for activation of pro-proliferative cell
   cycle genes during adipocyte differentiation
SO NUCLEIC ACIDS RESEARCH
LA English
DT Article
ID HISTONE DEMETHYLASE RBP2; MITOTIC CLONAL EXPANSION; GENOME-WIDE
   ANALYSIS; BREAST-CANCER; PROSTATE-CANCER; TRANSCRIPTIONAL REPRESSION;
   EPIGENETIC REGULATION; H3K4 DEMETHYLASE; BINDING-PROTEIN; RECEPTOR-GAMMA
AB The KDM5 family of histone demethylases removes the H3K4 tri-methylation (H3K4me3) mark frequently found at promoter regions of actively transcribed genes and is therefore generally considered to contribute to corepression. In this study, we show that knockdown (KD) of all expressed members of the KDM5 family in white and brown preadipocytes leads to deregulated gene expression and blocks differentiation to mature adipocytes. KDM5 KD leads to a considerable increase in H3K4me3 at promoter regions; however, these changes in H3K4me3 have a limited effect on gene expression per se. By contrast, genome-wide analyses demonstrate that KDM5A is strongly enriched at KDM5-activated promoters, which generally have high levels of H3K4me3 and are associated with highly expressed genes. We show that KDM5-activated genes include a large set of cell cycle regulators and that the KDM5s are necessary for mitotic clonal expansion in 3T3-L1 cells, indicating that KDM5 KD may interfere with differentiation in part by impairing proliferation. Notably, the demethylase activity of KDM5A is required for activation of at least a subset of pro-proliferative cell cycle genes. In conclusion, the KDM5 family acts as dual modulators of gene expression in preadipocytes and is required for early stage differentiation and activation of pro-proliferative cell cycle genes.
C1 [Brier, Ann-Sofie B.; Loft, Anne; Madsen, Jesper G. S.; Rosengren, Thomas; Nielsen, Ronni; Schmidt, Soren F.; Mandrup, Susanne] Univ Southern Denmark, Dept Biochem & Mol Biol, DK-5230 Odense M, Denmark.
   [Madsen, Jesper G. S.] Univ Copenhagen, Novo Nordisk Fdn, Ctr Basic Metab Res, DK-2200 Copenhagen N, Denmark.
   [Liu, Zongzhi; Yan, Qin] Yale Sch Med, Dept Pathol, New Haven, CT USA.
   [Gronemeyer, Hinrich] Univ Strasbourg, Equipe Labellisee Ligue Canc, Dept Funct Genom & Canc,U964, Inst Genet & Biol Mol & Cellulaire,CNRS,UMR7104,I, Illkirch Graffenstaden, France.
   [Loft, Anne; Schmidt, Soren F.] Helmholtz Zentrum Munchen, Inst Diabet & Canc, D-85764 Neuherberg, Germany.
C3 University of Southern Denmark; Novo Nordisk Foundation; University of
   Copenhagen; Yale University; Universites de Strasbourg Etablissements
   Associes; Universite de Strasbourg; Centre National de la Recherche
   Scientifique (CNRS); CNRS - National Institute for Biology (INSB);
   Institut National de la Sante et de la Recherche Medicale (Inserm);
   Helmholtz Association; Helmholtz-Center Munich - German Research Center
   for Environmental Health
RP Mandrup, S (通讯作者)，Univ Southern Denmark, Dept Biochem & Mol Biol, Campusvej 55, DK-5230 Odense M, Denmark.
EM s.mandrup@bmb.sdu.dk
RI Mandrup, Susanne/B-6693-2008; Schmidt, Søren/A-6401-2013; Madsen,
   Jesper/O-9803-2019; Liu, Zongzhi/AAE-1856-2022; Gronemeyer,
   Hinrich/G-6240-2011; Yan, Qin/E-8893-2012; Loft, Anne/L-5796-2015
OI Mandrup, Susanne/0000-0002-0961-5787; Fisker Schmidt,
   Soren/0000-0003-4449-288X; Madsen, Jesper Grud Skat/0000-0002-0518-0800;
   Gronemeyer, Hinrich/0000-0001-9454-2449; Yan, Qin/0000-0003-4077-453X;
   Loft, Anne/0000-0002-5647-8295; Nielsen, Ronni/0000-0001-6331-7660
FU Danish Independent Research Council \ Natural Science; Novo Nordisk
   Foundation; VILLUM Foundation; American Cancer Society Research Scholar
   Grant [RSG-13-384-01-DMC]
FX Danish Independent Research Council vertical bar Natural Science; Novo
   Nordisk Foundation; research grant from the supported by the Novo
   Nordisk Foundation; grant from the VILLUM Foundation to the VILLUM
   Center for Bioanalytical Sciences at University of Southern Denmark;
   American Cancer Society Research Scholar Grant [RSG-13-384-01-DMC to
   Q.Y.]. Funding for open access charge: Danish Independent Research
   Council vertical bar Natural Science.
CR [Anonymous], 2004, Stat. Appl. Genet. Mol. Biol., DOI [10.2202/1544-6115.1027, DOI 10.2202/1544-6115.1027]
   Atienza JM, 2005, MOL CANCER THER, V4, P361
   Barrett A, 2002, INT J CANCER, V101, P581, DOI 10.1002/ijc.10644
   Benevolenskaya EV, 2005, MOL CELL, V18, P623, DOI 10.1016/j.molcel.2005.05.012
   Beshiri ML, 2012, P NATL ACAD SCI USA, V109, P18499, DOI 10.1073/pnas.1216724109
   Cai CM, 2014, CELL REP, V9, P1618, DOI 10.1016/j.celrep.2014.11.008
   Cao J, 2014, CELL REP, V6, P868, DOI 10.1016/j.celrep.2014.02.004
   Caporali S, 2012, BIOCHEM PHARMACOL, V84, P598, DOI 10.1016/j.bcp.2012.06.004
   Chan SW, 2001, J BIOL CHEM, V276, P28402, DOI 10.1074/jbc.M100313200
   Chicas A, 2012, P NATL ACAD SCI USA, V109, P8971, DOI 10.1073/pnas.1119836109
   Christensen J, 2007, CELL, V128, P1063, DOI 10.1016/j.cell.2007.02.003
   Cristancho AG, 2011, NAT REV MOL CELL BIO, V12, P722, DOI 10.1038/nrm3198
   Dalgliesh GL, 2010, NATURE, V463, P360, DOI 10.1038/nature08672
   Dimitrova E, 2015, EMBO REP, V16, P1620, DOI 10.15252/embr.201541113
   DiTacchio L, 2011, SCIENCE, V333, P1881, DOI 10.1126/science.1206022
   Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635
   Dreos R, 2013, NUCLEIC ACIDS RES, V41, pD157, DOI 10.1093/nar/gks1233
   Dunham I, 2012, NATURE, V489, P57, DOI 10.1038/nature11247
   Ganuza M, 2012, EMBO J, V31, P2498, DOI 10.1038/emboj.2012.94
   Ge K, 2012, BBA-GENE REGUL MECH, V1819, P727, DOI 10.1016/j.bbagrm.2011.12.008
   Gutierrez GM, 2005, CANCER CELL, V7, P501, DOI 10.1016/j.ccr.2005.05.021
   Habegger L, 2011, BIOINFORMATICS, V27, P281, DOI 10.1093/bioinformatics/btq643
   Haines DS, 1997, LEUKEMIA LYMPHOMA, V26, P227, DOI 10.3109/10428199709051772
   Heintzman ND, 2007, NAT GENET, V39, P311, DOI 10.1038/ng1966
   Heinz S, 2010, MOL CELL, V38, P576, DOI 10.1016/j.molcel.2010.05.004
   Helledie T, 2002, J BIOL CHEM, V277, P26821, DOI 10.1074/jbc.M111295200
   Huang SQ, 2012, BRAZ J MED BIOL RES, V45, P995, DOI 10.1590/S0100-879X2012007500126
   Jangravi Z, 2015, J PROTEOME RES, V14, P3492, DOI 10.1021/acs.jproteome.5b00333
   Jensen LR, 2005, AM J HUM GENET, V76, P227, DOI 10.1086/427563
   Kanehisa M, 2000, NUCLEIC ACIDS RES, V28, P27, DOI 10.1093/nar/28.1.27
   Kanehisa M, 2014, NUCLEIC ACIDS RES, V42, pD199, DOI 10.1093/nar/gkt1076
   Kent WJ, 2002, GENOME RES, V12, P996, DOI 10.1101/gr.229102
   Khanna A, 2013, CANCER RES, V73, P6757, DOI 10.1158/0008-5472.CAN-13-1002
   Kidder BL, 2014, GENOME BIOL, V15, DOI 10.1186/gb-2014-15-2-r32
   Klein BJ, 2014, CELL REP, V6, P325, DOI 10.1016/j.celrep.2013.12.021
   Klose RJ, 2007, CELL, V128, P889, DOI 10.1016/j.cell.2007.02.013
   Kumar L, 2007, BIOINFORMATION, V2, P5, DOI 10.6026/97320630002005
   Kutmon M, 2016, NUCLEIC ACIDS RES, V44, pD488, DOI 10.1093/nar/gkv1024
   Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/NMETH.1923, 10.1038/nmeth.1923]
   Lee MG, 2007, CELL, V128, P877, DOI 10.1016/j.cell.2007.02.004
   Lee N, 2009, MOL CELL BIOL, V29, P1401, DOI 10.1128/MCB.01643-08
   Liao Yan-fen, 2013, Journal of South China University of Technology (Natural Science Edition), V41, P1
   Lin WC, 2011, P NATL ACAD SCI USA, V108, P13379, DOI 10.1073/pnas.1110104108
   Liu XY, 2015, CELL REP, V13, P2219, DOI 10.1016/j.celrep.2015.11.007
   Loft A, 2015, GENE DEV, V29, P7, DOI 10.1101/gad.250829.114
   Lopez-Bigas N, 2008, MOL CELL, V31, P520, DOI 10.1016/j.molcel.2008.08.004
   Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8
   Lu PJ, 1999, J BIOL CHEM, V274, P15633, DOI 10.1074/jbc.274.22.15633
   Matsumura Y, 2015, MOL CELL, V60, P584, DOI 10.1016/j.molcel.2015.10.025
   Mikkelsen TS, 2010, CELL, V143, P156, DOI 10.1016/j.cell.2010.09.006
   Miller SA, 2010, MOL CELL, V40, P594, DOI 10.1016/j.molcel.2010.10.028
   Musri MM, 2012, CURR OPIN CLIN NUTR, V15, P342, DOI 10.1097/MCO.0b013e3283546fba
   Musri MM, 2010, ORGANOGENESIS, V6, P15, DOI 10.4161/org.6.1.10226
   Nielsen R, 2006, MOL CELL BIOL, V26, P5698, DOI 10.1128/MCB.02266-05
   Nielsen R, 2014, METHOD ENZYMOL, V537, P261, DOI 10.1016/B978-0-12-411619-1.00014-8
   Nishimura Y, 2013, BRIT J CANCER, V108, P1324, DOI 10.1038/bjc.2013.65
   Outchkourov NS, 2013, CELL REP, V3, P1071, DOI 10.1016/j.celrep.2013.02.030
   Pasini D, 2008, GENE DEV, V22, P1345, DOI 10.1101/gad.470008
   Pekowska A, 2010, GENOME RES, V20, P1493, DOI 10.1101/gr.109389.110
   Qian SZ, 2015, PLANT PHYSIOL, V168, P1321, DOI 10.1104/pp.15.00520
   Qiu L, 2016, ZOOKEYS, P27, DOI 10.3897/zookeys.596.8332
   Raungrut P, 2014, ASIAN PAC J CANCER P, V15, P3513, DOI 10.7314/APJCP.2014.15.8.3513
   Rimkus C, 2007, INT J CANCER, V120, P207, DOI 10.1002/ijc.22155
   Roesch A, 2008, INT J CANCER, V122, P1047, DOI 10.1002/ijc.23211
   Roh TY, 2006, P NATL ACAD SCI USA, V103, P15782, DOI 10.1073/pnas.0607617103
   Santos-Rosa H, 2002, NATURE, V419, P407, DOI 10.1038/nature01080
   Saxonov S, 2006, P NATL ACAD SCI USA, V103, P1412, DOI 10.1073/pnas.0510310103
   Schmitz SU, 2011, EMBO J, V30, P4586, DOI 10.1038/emboj.2011.383
   Scibetta AG, 2007, MOL CELL BIOL, V27, P7220, DOI 10.1128/MCB.00274-07
   Secombe J, 2007, GENE DEV, V21, P537, DOI 10.1101/gad.1523007
   Shen HJ, 2016, CELL, V165, P331, DOI 10.1016/j.cell.2016.02.064
   Shubbar E, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-1
   Siersbæk MS, 2012, MOL CELL BIOL, V32, P3452, DOI 10.1128/MCB.00526-12
   Siersbæk R, 2011, COLD SH Q B, V76, P247, DOI 10.1101/sqb.2011.76.010512
   Siersbaek R, 2014, CELL REP, V7, P1443, DOI 10.1016/j.celrep.2014.04.042
   Siersbaek R, 2012, TRENDS ENDOCRIN MET, V23, P56, DOI 10.1016/j.tem.2011.10.001
   Steger DJ, 2010, GENE DEV, V24, P1035, DOI 10.1101/gad.1907110
   Stein J, 2014, AM J PATHOL, V184, P2430, DOI 10.1016/j.ajpath.2014.05.022
   Tang QQ, 2003, P NATL ACAD SCI USA, V100, P850, DOI 10.1073/pnas.0337434100
   Teng YC, 2013, CANCER RES, V73, P4711, DOI 10.1158/0008-5472.CAN-12-3165
   Váraljai R, 2015, GENE DEV, V29, P1817, DOI 10.1101/gad.264036.115
   Ventura A, 2004, P NATL ACAD SCI USA, V101, P10380, DOI 10.1073/pnas.0403954101
   Xie LQ, 2011, EMBO J, V30, P1473, DOI 10.1038/emboj.2011.91
   Yamane K, 2007, MOL CELL, V25, P801, DOI 10.1016/j.molcel.2007.03.001
   YEH WC, 1995, P NATL ACAD SCI USA, V92, P11086, DOI 10.1073/pnas.92.24.11086
   Zeng JP, 2010, GASTROENTEROLOGY, V138, P981, DOI 10.1053/j.gastro.2009.10.004
   Zhang JW, 2004, P NATL ACAD SCI USA, V101, P43, DOI 10.1073/pnas.0307229101
NR 90
TC 44
Z9 49
U1 1
U2 13
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0305-1048
EI 1362-4962
J9 NUCLEIC ACIDS RES
JI Nucleic Acids Res.
PD FEB 28
PY 2017
VL 45
IS 4
BP 1743
EP 1759
DI 10.1093/nar/gkw1156
PG 17
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA EN5OO
UT WOS:000396055400024
PM 27899593
OA gold, Green Published, Green Submitted
DA 2025-01-12
ER

PT J
AU Martín-Sánchez, E
   Mendaza, S
   Ulazia-Garmendia, A
   Monreal-Santesteban, I
   Blanco-Luquin, I
   Córdoba, A
   Vicente-García, F
   Pérez-Janices, N
   Escors, D
   Megías, D
   López-Serra, P
   Esteller, M
   Illarramendi, JJ
   Guerrero-Setas, D
AF Martin-Sanchez, Esperanza
   Mendaza, Saioa
   Ulazia-Garmendia, Ane
   Monreal-Santesteban, Inaki
   Blanco-Luquin, Idoia
   Cordoba, Alicia
   Vicente-Garcia, Francisco
   Perez-Janices, Noemi
   Escors, David
   Megias, Diego
   Lopez-Serra, Paula
   Esteller, Manel
   Juan Illarramendi, Jose
   Guerrero-Setas, David
TI <i>CHL1</i> hypermethylation as a potential biomarker of poor prognosis
   in breast cancer
SO ONCOTARGET
LA English
DT Article
DE CHL1; DNA methylation; breast cancer; prognostic biomarker
ID DNA METHYLATION PROFILES; HORMONE-RECEPTOR STATUS; PROMOTER METHYLATION;
   CELL-ADHESION; EXPRESSION; ASSOCIATION; PROGRESSION; MECHANISMS;
   MIGRATION; SUBTYPES
AB The CHL1 gene encodes a cell-adhesion molecule proposed as being a putative tumour-suppressor gene in breast cancer (BC). However, neither the underlying molecular mechanisms nor the clinical value of CHL1 downregulation in BC has been explored. The methylation status of three CpG sites in the CHL1 promoter was analysed by pyrosequencing in neoplastic biopsies from 142 patients with invasive BC and compared with that of non-neoplastic tissues. We found higher CHL1 methylation levels in breast tumours than in non-neoplastic tissues, either from mammoplasties or adjacent-to-tumour, which correlated with lower levels of protein expression in tumours measured by immunohistochemistry. A panel of five BC cell lines was treated with two epigenetic drugs, and restoration of CHL1 expression was observed, indicating in vitro dynamic epigenetic regulation. CHL1 was silenced by shRNA in immortalized but non-neoplastic mammary cells, and enhanced cell proliferation and migration, but not invasion, were found by real-time cell analysis. The prognostic value of CHL1 hypermethylation was assessed by the log-rank test and fitted in a Cox regression model. Importantly, CHL1 hypermethylation was very significantly associated with shorter progression-free survival in our BC patient series, independent of age and stage (p = 0.001). In conclusion, our results indicate that CHL1 is downregulated by hypermethylation and that this epigenetic alteration is an independent prognostic factor in BC.
C1 [Martin-Sanchez, Esperanza; Mendaza, Saioa; Ulazia-Garmendia, Ane; Monreal-Santesteban, Inaki; Perez-Janices, Noemi; Guerrero-Setas, David] Navarrabiomed Dept Salud UPNA IdiSNA, Canc Epigenet Grp, Pamplona, Spain.
   [Blanco-Luquin, Idoia; Escors, David] Navarrabiomed Dept Salud UPNA IdiSNA, Immunomodulat Grp, Pamplona, Spain.
   [Cordoba, Alicia; Guerrero-Setas, David] Complejo Hosp Navarra, Dept Pathol, Serv Navarro Salud Osasunbidea, Pamplona, Spain.
   [Vicente-Garcia, Francisco] Complejo Hosp Navarra, Dept Surg, Serv Navarro Salud Osasunbidea, Pamplona, Spain.
   [Megias, Diego] Spanish Natl Canc Res Ctr, Confocal Microscopy Unit, Madrid, Spain.
   [Lopez-Serra, Paula; Esteller, Manel] Bellvitge Biomed Res Inst IDIBELL, Canc Epigenet & Biol Program, Canc Epigenet Grp, Barcelona, Spain.
   [Esteller, Manel] Univ Barcelona, Sch Med, Dept Physiol Sci 2, Barcelona, Spain.
   [Esteller, Manel] ICREA, Barcelona, Spain.
   [Juan Illarramendi, Jose] Complejo Hosp Navarra, Dept Oncol, Serv Navarro Salud Osasunbidea, Pamplona, Spain.
C3 Navarrabiomed; Universidad Publica de Navarra; Navarrabiomed;
   Universidad Publica de Navarra; Servicio Navarro de Salud - Osasunbidea;
   Servicio Navarro de Salud - Osasunbidea; Centro Nacional de
   Investigaciones Oncologicas (CNIO); Institut d'Investigacio Biomedica de
   Bellvitge (IDIBELL); University of Barcelona; ICREA; Servicio Navarro de
   Salud - Osasunbidea
RP Martín-Sánchez, E; Guerrero-Setas, D (通讯作者)，Navarrabiomed Dept Salud UPNA IdiSNA, Canc Epigenet Grp, Pamplona, Spain.; Guerrero-Setas, D (通讯作者)，Complejo Hosp Navarra, Dept Pathol, Serv Navarro Salud Osasunbidea, Pamplona, Spain.
EM emartisa@navarra.es; dguerres@navarra.es
RI Megías, Diego/L-6008-2014; Lopez-Serra, Paula/M-6835-2015; Escors,
   David/C-1549-2008; Martín-Sánchez, Esperanza/M-7578-2015; Luquin,
   Idoia/AAA-9134-2019; Esteller, Manel/L-5956-2014
OI Martin-Sanchez, Esperanza/0000-0002-8155-9185; Esteller,
   Manel/0000-0003-4490-6093; Megias, Diego/0000-0003-0755-0518; Monreal
   Santesteban, inaki/0000-0002-0158-3565; Blanco,
   Idoia/0000-0003-2917-586X
FU Spanish Institute of Health; FEDER [PI14/00579]; Basque Foundation for
   Healthcare Research and Innovation [BIO-11-CM-013]; La Caixa Foundation
   [70789]; Breast Cancer Patients' Association in Navarra (SARAY); Spanish
   Ministry of Economy and Competitiveness [PTA2015-11895-I]; Department of
   Health of the Government of Navarra; Miguel Servet fellowship from the
   Spanish Institute of Health; ICREA Funding Source: Custom
FX This work has been funded in competitive calls by the Spanish Institute
   of Health and FEDER (PI14/00579), the Basque Foundation for Healthcare
   Research and Innovation (BIO-11-CM-013), La Caixa Foundation (70789) and
   the Breast Cancer Patients' Association in Navarra (SARAY). EMS is the
   recipient of a grant from the Spanish Ministry of Economy and
   Competitiveness (PTA2015-11895-I); NPJ was the recipient of a
   predoctoral grant from the Department of Health of the Government of
   Navarra; DE is funded by a Miguel Servet fellowship from the Spanish
   Institute of Health.
CR Bediaga NG, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2721
   Buchegger K, 2016, BIOL RES, V49, DOI 10.1186/s40659-016-0066-7
   Cheang MCU, 2009, JNCI-J NATL CANCER I, V101, P736, DOI 10.1093/jnci/djp082
   Chen J, 2012, CHIN J CANCER, V31, P215, DOI 10.5732/cjc.011.10364
   Du JM, 2015, NAT REV MOL CELL BIO, V16, P519, DOI 10.1038/nrm4043
   Fang C, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1926-1
   Feng W, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1762
   Fiegl H, 2006, CANCER RES, V66, P29, DOI 10.1158/0008-5472.CAN-05-2508
   Goldhirsch A, 2013, ANN ONCOL, V24, P2206, DOI 10.1093/annonc/mdt303
   Guiu S, 2012, ANN ONCOL, V23, P2997, DOI 10.1093/annonc/mds586
   Guo TY, 2015, MOL CLIN ONCOL, V3, P1353, DOI 10.3892/mco.2015.620
   He LH, 2013, BIOCHEM BIOPH RES CO, V438, P433, DOI 10.1016/j.bbrc.2013.07.093
   Huo DZ, 2016, ONCOTARGET, V7, P55231, DOI 10.18632/oncotarget.10485
   Karsli-Ceppioglu S, 2014, EPIGENOMICS-UK, V6, P651, DOI [10.2217/EPI.14.59, 10.2217/epi.14.59]
   Kolla V, 2014, CANCER RES, V74, P652, DOI 10.1158/0008-5472.CAN-13-3056
   Labbozzetta M, 2015, ONCOL LETT, V10, P3807, DOI 10.3892/ol.2015.3787
   Lanna A, 2014, NAT IMMUNOL, V15, P965, DOI 10.1038/ni.2981
   Li YP, 2010, CANCER CELL INT, V10, DOI 10.1186/1475-2867-10-34
   Mantripragada KK, 2008, CLIN CANCER RES, V14, P1015, DOI 10.1158/1078-0432.CCR-07-1305
   Minatani N, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0144862
   Noehammer C, 2014, EPIGENOMICS-UK, V6, P603, DOI [10.2217/EPI.14.43, 10.2217/epi.14.43]
   Perez-Janices N, 2015, ONCOTARGET, V6, P23944, DOI 10.18632/oncotarget.4062
   Schröder C, 2009, ONCOL REP, V22, P1109, DOI 10.3892/or_00000543
   Senchenko VN, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0015612
   Senkus E, 2015, ANN ONCOL, V26, pV8, DOI 10.1093/annonc/mdv298
   Shen Y, 2015, BREAST CANCER RES TR, V154, P473, DOI 10.1007/s10549-015-3632-8
   Slamon D, 2011, NEW ENGL J MED, V365, P1273, DOI 10.1056/NEJMoa0910383
   Smith RA, 2016, CA-CANCER J CLIN, V66, P96, DOI 10.3322/caac.21336
   Sorlie T, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-127
   Stefansson OA, 2015, MOL ONCOL, V9, P555, DOI 10.1016/j.molonc.2014.10.012
   Uchida K, 2011, ONCOL REP, V26, P463, DOI 10.3892/or.2011.1327
   Villani V, 2015, DIS MARKERS, V2015, DOI 10.1155/2015/604719
   Vizoso M, 2015, NAT MED, V21, P741, DOI 10.1038/nm.3863
   Wang L, 2015, SCI ADV, V1, DOI 10.1126/sciadv.1500463
   Widschwendter M, 2004, CANCER RES, V64, P3807, DOI 10.1158/0008-5472.CAN-03-3852
   Williams N, 2008, LANCET ONCOL, V9, P45, DOI 10.1016/S1470-2045(07)70385-6
   Yari K, 2016, TUMOR BIOL, V37, P8145, DOI 10.1007/s13277-015-4731-1
   Zhang J, 2015, INT J CLIN EXP PATHO, V8, P9240
NR 38
TC 22
Z9 24
U1 0
U2 3
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD FEB 28
PY 2017
VL 8
IS 9
BP 15789
EP 15801
DI 10.18632/oncotarget.15004
PG 13
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA EN4YV
UT WOS:000396013700126
PM 28178655
OA Green Published, Green Submitted, gold
DA 2025-01-12
ER

PT J
AU Rose, M
   Kloten, V
   Noetzel, E
   Gola, L
   Ehling, J
   Heide, T
   Meurer, SK
   Gaiko-Shcherbak, A
   Sechi, AS
   Huth, S
   Weiskirchen, R
   Klaas, O
   Antonopoulos, W
   Lin, Q
   Wagner, W
   Veeck, J
   Gremse, F
   Steitz, J
   Knüchel, R
   Dahl, E
AF Rose, Michael
   Kloten, Vera
   Noetzel, Erik
   Gola, Lukas
   Ehling, Josef
   Heide, Timon
   Meurer, Steffen K.
   Gaiko-Shcherbak, Aljona
   Sechi, Antonio S.
   Huth, Sebastian
   Weiskirchen, Ralf
   Klaas, Oliver
   Antonopoulos, Wiebke
   Lin, Qiong
   Wagner, Wolfgang
   Veeck, Juergen
   Gremse, Felix
   Steitz, Julia
   Knuechel, Ruth
   Dahl, Edgar
TI ITIH5 mediates epigenetic reprogramming of breast cancer cells
SO MOLECULAR CANCER
LA English
DT Article
DE ITIH5; Breast cancer; Extracellular matrix; Epigenetic reprogramming;
   Cancer stem cells; DAPK1
ID ALPHA-TRYPSIN INHIBITOR; EXTRACELLULAR-MATRIX; DAP-KINASE; HEAVY-CHAIN;
   DNA HYPERMETHYLATION; PROMOTER METHYLATION; EXPRESSION; INTEGRIN; GENE;
   PROTEIN
AB Background: Extracellular matrix (ECM) is known to maintain epithelial integrity. In carcinogenesis ECM degradation triggers metastasis by controlling migration and differentiation including cancer stem cell (CSC) characteristics. The ECM-modulator inter- alpha-trypsin inhibitor heavy chain family member five (ITIH5) was recently identified as tumor suppressor potentially involved in impairing breast cancer progression but molecular mechanisms underlying its function are still elusive.
   Methods: ITIH5 expression was analyzed using the public TCGA portal. ITIH5-overexpressing single-cell clones were established based on T47D and MDA-MB-231 cell lines. Colony formation, growth, apoptosis, migration, matrix adhesion, traction force analyses and polarization of tumor cells were studied in vitro. Tumor-initiating characteristics were analyzed by generating a metastasis mouse model. To identify ITIH5-affected pathways we utilized genome wide gene expression and DNA methylation profiles. RNA-interference targeting the ITIH5-downstream regulated gene DAPK1 was used to confirm functional involvement.
   Results: ITIH5 loss was pronounced in breast cancer subtypes with unfavorable prognosis like basal-type tumors. Functionally, cell and colony formation was impaired after ITIH5 re-expression in both cell lines. In a metastasis mouse model, ITIH5 expressing MDA-MB-231 cells almost completely failed to initiate lung metastases. In these metastatic cells ITIH5 modulated cell-matrix adhesion dynamics and altered biomechanical cues. The profile of integrin receptors was shifted towards beta 1-integrin accompanied by decreased Rac1 and increased RhoA activity in ITIH5-expressing clones while cell polarization and single-cell migration was impaired. Instead ITIH5 expression triggered the formation of epithelial-like cell clusters that underwent an epigenetic reprogramming. 214 promoter regions potentially marked with either H3K4 and /or H3K27 methylation showed a hyper-or hypomethylated DNA configuration due to ITIH5 expression finally leading to re-expression of the tumor suppressor DAPK1. In turn, RNAi-mediated knockdown of DAPK1 in ITIH5-expressing MDA-MB-231 single-cell clones clearly restored cell motility.
   Conclusions: Our results provide evidence that ITIH5 triggers a reprogramming of breast cancer cells with known stem CSC properties towards an epithelial-like phenotype through global epigenetic changes effecting known tumor suppressor genes like DAPK1. Therewith, ITIH5 may represent an ECM modulator in epithelial breast tissue mediating suppression of tumor initiating cancer cell characteristics which are thought being responsible for the metastasis of breast cancer.
C1 [Rose, Michael; Kloten, Vera; Gola, Lukas; Heide, Timon; Huth, Sebastian; Klaas, Oliver; Antonopoulos, Wiebke; Veeck, Juergen; Knuechel, Ruth; Dahl, Edgar] Rhein Westfal TH Aachen, Inst Pathol, Fac Med, Aachen, Germany.
   [Noetzel, Erik; Gaiko-Shcherbak, Aljona] Forschungszentrum Julich GmbH, Inst Complex Syst, ICS Biomech 7, Julich, Germany.
   [Ehling, Josef; Gremse, Felix] Rhein Westfal TH Aachen, Dept Expt Mol Imaging ExMI, Helmholtz Inst Biomed Engn, Fac Med, Aachen, Germany.
   [Meurer, Steffen K.; Weiskirchen, Ralf] Rhein Westfal TH Aachen, Expt Gene Therapy & Clin Chem, Inst Mol Pathobiochem, Fac Med, Aachen, Germany.
   [Sechi, Antonio S.; Lin, Qiong; Wagner, Wolfgang] Rhein Westfal TH Aachen, Inst Biomed Engn Cell Biol, Fac Med, Aachen, Germany.
   [Lin, Qiong; Wagner, Wolfgang] Rhein Westfal TH Aachen, Helmholtz Inst Biomed Engn Stem Cell Biol & Cell, Fac Med, Aachen, Germany.
   [Veeck, Juergen] Maastricht Univ, Med Ctr, GROW Sch Oncol & Dev Biol, Div Med Oncol,Dept Internal Med,Dept Pathol, Maastricht, Netherlands.
   [Steitz, Julia] Rhein Westfal TH Aachen, Inst Lab Anim Sci, Fac Med, Aachen, Germany.
C3 RWTH Aachen University; Helmholtz Association; Research Center Julich;
   RWTH Aachen University; Helmholtz Association; RWTH Aachen University;
   RWTH Aachen University; RWTH Aachen University; Maastricht University;
   RWTH Aachen University
RP Dahl, E (通讯作者)，Rhein Westfal TH Aachen, Inst Pathol, Fac Med, Aachen, Germany.
EM edahl@ukaachen.de
RI Steitz, Julia/KBD-3088-2024; Noetzel-Reiss, Erik/GYV-0999-2022;
   Weiskirchen, Ralf/O-1734-2018; Sechi, Antonio/A-5595-2009
OI Weiskirchen, Ralf/0000-0003-3888-0931; Wagner,
   Wolfgang/0000-0002-1971-3217; Sechi, Antonio/0000-0002-1374-1794;
   Gaiko-Shcherbak, Aljona/0000-0001-9097-0825; Noetzel-Reiss,
   Erik/0000-0003-3163-6848
FU Fritz Thyssen Stiftung [Az.10.09.2.121]; ForSaTum grant from European
   Union; NRW government (NRW-EU Ziel 2) [005-0908-0112]; Department of
   Experimental Molecular Imaging
FX This work was supported by the Fritz Thyssen Stiftung (Az.10.09.2.121)
   and by the ForSaTum grant from the European Union and NRW government
   (NRW-EU Ziel 2, (EFRE), 005-0908-0112) to the Institute for Laboratory
   Animal Science and the Department of Experimental Molecular Imaging.
CR [Anonymous], 2015, PHEATMAP PRETTY HEAT
   [Anonymous], ONCOTARGET
   [Anonymous], EXP CELL RES
   [Anonymous], ATCC B MAINT HIGH ST
   Anveden Å, 2012, OBESITY, V20, P708, DOI 10.1038/oby.2011.268
   Bissell MJ, 2002, DIFFERENTIATION, V70, P537, DOI 10.1046/j.1432-0436.2002.700907.x
   BISSELL MJ, 1982, J THEOR BIOL, V99, P31, DOI 10.1016/0022-5193(82)90388-5
   Blick T, 2010, J MAMMARY GLAND BIOL, V15, P235, DOI 10.1007/s10911-010-9175-z
   Bost F, 1998, EUR J BIOCHEM, V252, P339, DOI 10.1046/j.1432-1327.1998.2520339.x
   Bourguignon J, 1999, J HISTOCHEM CYTOCHEM, V47, P1625, DOI 10.1177/002215549904701214
   Butcher DT, 2009, NAT REV CANCER, V9, P108, DOI 10.1038/nrc2544
   Cartharius K, 2005, BIOINFORMATICS, V21, P2933, DOI 10.1093/bioinformatics/bti473
   Cesa CM, 2007, REV SCI INSTRUM, V78, DOI 10.1063/1.2712870
   Charafe-Jauffret E, 2009, CANCER RES, V69, P1302, DOI 10.1158/0008-5472.CAN-08-2741
   Chaudhuri O, 2014, NAT MATER, V13, P970, DOI [10.1038/nmat4009, 10.1038/NMAT4009]
   CHEN L, 1994, J BIOL CHEM, V269, P28282
   Cluzel C, 2005, J CELL BIOL, V171, P383, DOI 10.1083/jcb.200503017
   Cohen O, 1997, EMBO J, V16, P998, DOI 10.1093/emboj/16.5.998
   Danen EHJ, 2005, J CELL BIOL, V169, P515, DOI 10.1083/jcb.200412081
   DEISS LP, 1995, GENE DEV, V9, P15, DOI 10.1101/gad.9.1.15
   Dötsch MM, 2015, EPIGENETICS-US, V10, P903, DOI 10.1080/15592294.2015.1078049
   Easwaran H, 2012, GENOME RES, V22, P837, DOI 10.1101/gr.131169.111
   Eden E, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-48
   Gal-Yam EN, 2008, P NATL ACAD SCI USA, V105, P12979, DOI 10.1073/pnas.0806437105
   Gremse F, 2016, THERANOSTICS, V6, P328, DOI 10.7150/thno.13624
   Hamm A, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-25
   Harikumar A, 2015, EMBO REP, V16, P1609, DOI 10.15252/embr.201541011
   Hersch N, 2013, BIOL OPEN, V2, P351, DOI 10.1242/bio.20133830
   Himmelfarb M, 2004, CANCER LETT, V204, P69, DOI 10.1016/j.canlet.2003.09.011
   Hood JD, 2002, NAT REV CANCER, V2, P91, DOI 10.1038/nrc727
   Hu ZY, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-96
   HUANG L, 1993, J BIOL CHEM, V268, P26725
   Huth S, 2015, EXP DERMATOL, V24, P663, DOI 10.1111/exd.12704
   Huveneers S, 2009, J CELL SCI, V122, P1059, DOI 10.1242/jcs.039446
   Mousavi SJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124529
   Jing HY, 2016, CANCER CELL INT, V16, DOI 10.1186/s12935-016-0292-7
   Kloten V, 2014, EPIGENETICS-US, V9, P1290, DOI 10.4161/epi.32089
   Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412
   Koch TM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033476
   Kostic A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006361
   Kristiansen G, 2011, J BIOL CHEM, V286, P43417, DOI 10.1074/jbc.M111.227553
   Ku M, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000242
   Kuo JC, 2006, J CELL BIOL, V172, P619, DOI 10.1083/jcb.200505138
   Kuo JC, 2003, J CELL SCI, V116, P4777, DOI 10.1242/jcs.00794
   Lelièvre SA, 2009, BBA-GEN SUBJECTS, V1790, P925, DOI 10.1016/j.bbagen.2009.03.013
   Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427
   Lin BY, 2015, ONCOTARGET, V6, P5369, DOI 10.18632/oncotarget.3030
   Lister R, 2011, NATURE, V471, P68, DOI 10.1038/nature09798
   Loening Andreas Markus, 2003, Mol Imaging, V2, P131, DOI 10.1162/153535003322556877
   Lopez JI, 2005, CANCER RES, V65, P6755, DOI 10.1158/0008-5472.CAN-05-0863
   Madamanchi A, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005236
   Mai C, 2014, MED ONCOL, V31, DOI 10.1007/s12032-014-0053-1
   Maya-Mendoza A, 2016, CELL CYCLE, V15, P345, DOI 10.1080/15384101.2015.1121354
   Merkel R, 2007, BIOPHYS J, V93, P3314, DOI 10.1529/biophysj.107.111328
   Meurer SK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056116
   Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180
   Nishino K, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002085
   Noetzel E, 2012, ONCOGENE, V31, P2101, DOI 10.1038/onc.2011.403
   Noetzel E, 2010, ONCOGENE, V29, P4814, DOI 10.1038/onc.2010.229
   Noetzel E, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-154
   Paris S, 2002, INT J CANCER, V97, P615, DOI 10.1002/ijc.10120
   Pelham RJ, 1997, P NATL ACAD SCI USA, V94, P13661, DOI 10.1073/pnas.94.25.13661
   Ponta H, 2003, NAT REV MOL CELL BIO, V4, P33, DOI 10.1038/nrm1004
   R. Development Core Team, 2016, R: A Language and Environment for Statistical Computing
   Ramirez NE, 2011, J CLIN INVEST, V121, P226, DOI 10.1172/JCI42328
   Raveh T, 2001, EXP CELL RES, V264, P185, DOI 10.1006/excr.2000.5134
   Ringnér M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017911
   Rose M, 2014, CARCINOGENESIS, V35, P727, DOI 10.1093/carcin/bgt375
   Rottner K, 2011, CURR OPIN CELL BIOL, V23, P569, DOI 10.1016/j.ceb.2011.07.003
   Salier JP, 1996, BIOCHEM J, V315, P1, DOI 10.1042/bj3150001
   Sandal T, 2007, AM J PATHOL, V170, P1739, DOI 10.2353/ajpath.2007.060922
   Schlesinger Y, 2007, NAT GENET, V39, P232, DOI 10.1038/ng1950
   Selbi W, 2006, KIDNEY INT, V70, P1287, DOI 10.1038/sj.ki.5001760
   Sheridan C, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1610
   Shiu YT, 2004, BIOPHYS J, V86, P2558, DOI 10.1016/S0006-3495(04)74311-8
   Simon R, 2007, CANCER INFORM, V3, P11
   Singovski G, 2016, J MOL CELL BIOL, V8, P157, DOI 10.1093/jmcb/mjv034
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Swift J, 2014, J CELL SCI, V127, P3005, DOI 10.1242/jcs.149203
   Truong HH, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2004751
   Veeck J, 2008, ONCOGENE, V27, P865, DOI 10.1038/sj.onc.1210669
   Veeck J, 2006, ONCOGENE, V25, P3479, DOI 10.1038/sj.onc.1209386
   Veeck J, 2008, Pathologe, V29 Suppl 2, P338, DOI 10.1007/s00292-008-1044-9
   Viré E, 2006, NATURE, V439, P871, DOI 10.1038/nature04431
   Wang WJ, 2002, J CELL BIOL, V159, P169, DOI 10.1083/jcb.200204050
   Welf ES, 2011, BMC BIOPHYS, V4, DOI 10.1186/2046-1682-4-15
   Werbowetski-Ogilvie TE, 2006, CANCER RES, V66, P1464, DOI 10.1158/0008-5472.CAN-05-1913
   White DP, 2007, J CELL BIOL, V177, P515, DOI 10.1083/jcb.200609004
   Willekens I, 2009, MOL IMAGING BIOL, V11, P128, DOI 10.1007/s11307-008-0186-8
   Wu K, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms10131
   Yamamoto M, 2002, EUR J BIOCHEM, V269, P139, DOI 10.1046/j.0014-2956.2002.00029.x
   Yu HM, 2011, TRENDS CELL BIOL, V21, P47, DOI 10.1016/j.tcb.2010.08.015
   Zhuo L, 2008, CONNECT TISSUE RES, V49, P311, DOI 10.1080/03008200802325458
   Zhuo LS, 2004, J BIOL CHEM, V279, P38079, DOI 10.1074/jbc.R300039200
NR 94
TC 32
Z9 33
U1 1
U2 12
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1476-4598
J9 MOL CANCER
JI Mol. Cancer
PD FEB 23
PY 2017
VL 16
AR 44
DI 10.1186/s12943-017-0610-2
PG 22
WC Biochemistry & Molecular Biology; Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology
GA EQ0ZT
UT WOS:000397799800002
PM 28231808
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU Yu, HM
   Jiang, YY
   Liu, LX
   Shan, WQ
   Chu, XF
   Yang, Z
   Yang, ZQ
AF Yu, Huimei
   Jiang, Yuanyuan
   Liu, Lanxin
   Shan, Wenqi
   Chu, Xiaofang
   Yang, Zhe
   Yang, Zeng-Quan
TI Integrative genomic and transcriptomic analysis for pinpointing
   recurrent alterations of plant homeodomain genes and their clinical
   significance in breast cancer
SO ONCOTARGET
LA English
DT Article
DE plant homeodomain; breast cancer; histone modification; copy number
   alteration
ID DNA-DAMAGE; HISTONE DEMETHYLASE; PHD FINGER; BINDING; MUTATIONS;
   LANDSCAPE; BROMODOMAIN; ZMYND8; ASXL1; AMPLIFICATION
AB A wide range of the epigenetic effectors that regulate chromatin modification, gene expression, genomic stability, and DNA repair contain structurally conserved domains called plant homeodomain (PHD) fingers. Alternations of several PHD finger-containing proteins (PHFs) due to genomic amplification, mutations, deletions, and translocations have been linked directly to various types of cancer. However, little is known about the genomic landscape and the clinical significance of PHFs in breast cancer. Hence, we performed a large-scale genomic and transcriptomic analysis of 98 PHF genes in breast cancer using TCGA and METABRIC datasets and correlated the recurrent alterations with clinicopathological features and survival of patients. Different subtypes of breast cancer had different patterns of copy number and expression for each PHF. We identified a subset of PHF genes that was recurrently altered with high prevalence, including PYGO2 (pygopus family PHD finger 2), ZMYND8 (zinc finger, MYND-type containing 8), ASXL1 (additional sex combs like 1) and CHD3 (chromodomain helicase DNA binding protein 3). Copy number increase and overexpression of ZMYND8 were more prevalent in Luminal B subtypes and were significantly associated with shorter survival of breast cancer patients. ZMYND8 was also involved in a positive feedback circuit of the estrogen receptor (ER) pathway, and the expression of ZMYND8 was repressed by the bromodomain and extra terminal (BET) inhibitor in breast cancer. Our findings suggest a promising avenue for future research-to focus on a subset of PHFs to better understand the molecular mechanisms and to identify therapeutic targets in breast cancer.
C1 [Yu, Huimei; Jiang, Yuanyuan; Liu, Lanxin; Shan, Wenqi; Chu, Xiaofang; Yang, Zeng-Quan] Wayne State Univ, Sch Med, Dept Oncol, Detroit, MI 48201 USA.
   [Yu, Huimei] Jilin Univ, Coll Basic Med, Changchun, Peoples R China.
   [Yang, Zhe] Wayne State Univ, Sch Med, Dept Biochem & Mol Biol, Detroit, MI 48201 USA.
   [Yang, Zeng-Quan] Barbara Ann Karmanos Canc Inst, Mol Therapeut Program, Detroit, MI 48201 USA.
C3 Wayne State University; Jilin University; Wayne State University;
   Barbara Ann Karmanos Cancer Institute
RP Yang, ZQ (通讯作者)，Wayne State Univ, Sch Med, Dept Oncol, Detroit, MI 48201 USA.; Yang, ZQ (通讯作者)，Barbara Ann Karmanos Canc Inst, Mol Therapeut Program, Detroit, MI 48201 USA.
EM yangz@karmanos.org
RI Jiang, Yuanyuan/IQS-5599-2023; WANG, JIAXUAN/JMP-8599-2023
FU NIH/NCI [R21CA175244-01A1]; Office of Research on Women's Health (OWRH);
   Department of Defense (DoD) Prostate Cancer Program [PC121737,
   PC130259]; NIH [R01HL128647-01]; China International Postdoctoral
   Exchange Fellowship Program; China Scholarship Council Program
   fellowship
FX This work was partially supported by grants from the NIH/NCI
   R21CA175244-01A1 and the Office of Research on Women's Health (OWRH),
   the Department of Defense (DoD) Prostate Cancer Program PC121737 and
   PC130259 to Dr. Zeng-Quan Yang, and by grants from the NIH
   R01HL128647-01 to Dr. Zhe Yang, by funding from the China International
   Postdoctoral Exchange Fellowship Program to Huimei Yu, and the China
   Scholarship Council Program fellowship to Xiaofang Chu. We thank Hui
   Liu, Qin Ye, and Lihong Zhang for technical contributions. We thank Dr.
   Stephen P. Ethier for providing the SUM breast cancer cell lines.
CR Ades F, 2014, J CLIN ONCOL, V32, P2794, DOI 10.1200/JCO.2013.54.1870
   Ali M, 2014, BBA-MOL CELL RES, V1843, P366, DOI 10.1016/j.bbamcr.2013.11.016
   Beroukhim R, 2010, NATURE, V463, P899, DOI 10.1038/nature08822
   Bertucci F, 2012, CURR MOL MED, V12, P96, DOI 10.2174/156652412798376134
   Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095
   Ciriello G, 2013, NAT GENET, V45, P1127, DOI 10.1038/ng.2762
   Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983
   Feinberg AP, 2016, NAT REV GENET, V17, P284, DOI 10.1038/nrg.2016.13
   Ford DJ, 2015, CANCER GENET-NY, V208, P178, DOI 10.1016/j.cancergen.2015.01.005
   Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088
   Geeleher P, 2015, J INVEST MED, V63, P683
   Gelsi-Boyer V, 2012, J HEMATOL ONCOL, V5, DOI 10.1186/1756-8722-5-12
   Gelsi-Boyer V, 2009, BRIT J HAEMATOL, V145, P788, DOI 10.1111/j.1365-2141.2009.07697.x
   Gertz J, 2013, MOL CELL, V52, P25, DOI 10.1016/j.molcel.2013.08.037
   Gholami AM, 2013, CELL REP, V4, P609, DOI 10.1016/j.celrep.2013.07.018
   Ginestier C, 2006, CLIN CANCER RES, V12, P4533, DOI 10.1158/1078-0432.CCR-05-2339
   Gong FD, 2015, GENE DEV, V29, P197, DOI 10.1101/gad.252189.114
   Greer EL, 2012, NAT REV GENET, V13, P343, DOI 10.1038/nrg3173
   Gu BN, 2013, CELL STEM CELL, V13, P48, DOI 10.1016/j.stem.2013.04.012
   Gu BN, 2009, J CELL BIOL, V185, P811, DOI 10.1083/jcb.200810133
   Ho H, 2016, LEUKEMIA RES, V45, P1, DOI 10.1016/j.leukres.2016.03.006
   Hou JL, 2012, AM J TRANSL RES, V4, P247
   Huang Z, 2013, CANCER RES, V73, P6277, DOI 10.1158/0008-5472.CAN-13-1000
   Jessen S, 2008, BIOESSAYS, V30, P448, DOI 10.1002/bies.20757
   Jiang YY, 2016, MOL ONCOL, V10, P292, DOI 10.1016/j.molonc.2015.10.013
   Katoh M, 2015, EXPERT REV PROTEOMIC, V12, P317, DOI 10.1586/14789450.2015.1033409
   Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412
   Koh JLY, 2012, NUCLEIC ACIDS RES, V40, pD957, DOI 10.1093/nar/gkr959
   Kolla V, 2014, CANCER RES, V74, P652, DOI 10.1158/0008-5472.CAN-13-3056
   Li N, 2016, MOL CELL, V63, P470, DOI 10.1016/j.molcel.2016.06.035
   Li WZ, 2014, EPIGENOMICS-UK, V6, P381, DOI 10.2217/epi.14.31
   Liu G, 2009, ONCOGENE, V28, P4491, DOI 10.1038/onc.2009.297
   Liu H, 2016, MOL CARCINOGEN, V55, P977, DOI 10.1002/mc.22341
   Liu LX, 2015, ONCOTARGET, V6, P2466, DOI 10.18632/oncotarget.2967
   Liu LH, 2012, BIOINFORMATICS, V28, P2205, DOI 10.1093/bioinformatics/bts340
   Liu Y, 2016, NATURE, V531, P471, DOI 10.1038/nature17157
   Lu PJ, 1999, J BIOL CHEM, V274, P15633, DOI 10.1074/jbc.274.22.15633
   Mahmood SF, 2013, AM J PATHOL, V183, P1634, DOI 10.1016/j.ajpath.2013.07.028
   Malovannaya A, 2011, CELL, V145, P787, DOI 10.1016/j.cell.2011.05.006
   Micol JB, 2016, CSH PERSPECT MED, V6, DOI 10.1101/cshperspect.a026526
   Miller TCR, 2014, ACS CHEM BIOL, V9, P2864, DOI 10.1021/cb500585s
   Mohammed H, 2015, NATURE, V523, P313, DOI 10.1038/nature14583
   Musselman CA, 2012, NAT STRUCT MOL BIOL, V19, P1218, DOI 10.1038/nsmb.2436
   Nagarajan S, 2014, CELL REP, V8, P459, DOI 10.1016/j.celrep.2014.06.016
   Nik-Zainal S, 2016, NATURE, V534, P47, DOI 10.1038/nature17676
   O'Shaughnessy A, 2013, BIOCHEM SOC T, V41, P777, DOI 10.1042/BST20130027
   Panagopoulos I, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063663
   Patel DJ, 2016, CSH PERSPECT BIOL, V8, DOI 10.1101/cshperspect.a018754
   Paul S, 2013, CELL REP, V3, P92, DOI 10.1016/j.celrep.2012.12.009
   Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093
   Richart L, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10153
   Ross-Innes CS, 2012, NATURE, V481, P389, DOI 10.1038/nature10730
   Ruthenburg AJ, 2011, CELL, V145, P692, DOI 10.1016/j.cell.2011.03.053
   Sanchez R, 2014, BBA-GENE REGUL MECH, V1839, P676, DOI 10.1016/j.bbagrm.2014.03.011
   Sanchez R, 2011, TRENDS BIOCHEM SCI, V36, P364, DOI 10.1016/j.tibs.2011.03.005
   Sperlazza J, 2015, BLOOD, V126, P1462, DOI 10.1182/blood-2015-03-631606
   Spruijt CG, 2016, CELL REP, V17, P783, DOI 10.1016/j.celrep.2016.09.037
   Stanley FKT, 2013, MUTAT RES-FUND MOL M, V750, P31, DOI 10.1016/j.mrfmmm.2013.07.008
   Sun P, 2014, P NATL ACAD SCI USA, V111, P10215, DOI 10.1073/pnas.1311395111
   Thomas C, 2015, TRENDS ENDOCRIN MET, V26, P467, DOI 10.1016/j.tem.2015.06.007
   Torchy MP, 2015, CELL MOL LIFE SCI, V72, P2491, DOI 10.1007/s00018-015-1880-8
   Wada Yusaku, 2014, J Clin Bioinforma, V4, P3, DOI 10.1186/2043-9113-4-3
   Wagner EK, 2012, BIOCHEMISTRY-US, V51, P8293, DOI 10.1021/bi3009278
   Wang GG, 2009, NATURE, V459, P847, DOI 10.1038/nature08036
   Watanabe K, 2014, ONCOGENE, V33, P632, DOI 10.1038/onc.2012.620
   Yamamoto S, 2014, CANCER CELL, V25, P762, DOI 10.1016/j.ccr.2014.04.024
   Yamane K, 2007, MOL CELL, V25, P801, DOI 10.1016/j.molcel.2007.03.001
   Yang ZQ, 2006, CANCER RES, V66, P11632, DOI 10.1158/0008-5472.CAN-06-2946
   Yang ZQ, 2010, CANCER RES, V70, P8487, DOI 10.1158/0008-5472.CAN-10-1013
   Zhu L, 2016, CANCER DISCOV, V6, P770, DOI 10.1158/2159-8290.CD-16-0058
NR 70
TC 17
Z9 17
U1 2
U2 5
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD FEB 21
PY 2017
VL 8
IS 8
BP 13099
EP 13115
DI 10.18632/oncotarget.14402
PG 17
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA EN0HX
UT WOS:000395692000057
PM 28055972
OA Green Published, Green Submitted, gold
DA 2025-01-12
ER

PT J
AU Vincent, KM
   Postovit, LM
AF Vincent, Krista Marie
   Postovit, Lynne-Marie
TI A pan-cancer analysis of secreted Frizzled-related proteins:
   re-examining their proposed tumour suppressive function
SO SCIENTIFIC REPORTS
LA English
DT Article
ID FREQUENT EPIGENETIC INACTIVATION; MESSENGER-RNA EXPRESSION;
   MAMMARY-GLAND TUMORS; WNT ANTAGONIST SFRP1; PROTEOGENOMIC
   CHARACTERIZATION; PROMOTER HYPERMETHYLATION; DIFFERENTIAL EXPRESSION;
   POTENTIAL BIOMARKER; BREAST-CANCER; GENES
AB Secreted frizzled-related proteins (SFRPs), containing five family members (SFRPs 1-5) are putative extracellular Wnt inhibitors. Given their abilities to inhibit Wnt signalling, as well as the loss of SFRP1 in many cancers, this family is generally considered to be tumour suppressive. In this study we analyzed gene expression, promoter methylation and survival data from over 8000 tumour and normal samples from 29 cancers in order to map the context-specific associations of SFRPs 1-5 with patient survival, gene silencing and gene expression signatures. We show that only SFRP1 associates consistently with tumour suppressive functions, and that SFRP2 and SFRP4 typically associate with a poor prognosis concomitant with the expression of genes associated with epithelial-to-mesenchymal transition. Moreover, our results indicate that while SFRP1 is lost in cancer cells via the process of DNA methylation, SFRP2 and 4 are likely derived from the tumour stroma, and thus tend to increase in tumours as compared to normal tissues. This in-depth analysis highlights the need to study each SFRP as a separate entity and suggests that SFRP2 and SFRP4 should be approached as complex matricellular proteins with functions that extend far beyond their putative Wnt antagonistic ability.
C1 [Vincent, Krista Marie; Postovit, Lynne-Marie] Univ Alberta, Fac Med & Dent, Dept Oncol, 114th St & 87th Ave, Edmonton, AB T6G 2E1, Canada.
   [Vincent, Krista Marie] Univ Western Ontario, Fac Med & Dent, Dept Anat & Cell Biol, 1151 Richmond St, London, ON N6A 3K7, Canada.
C3 University of Alberta; Western University (University of Western
   Ontario)
RP Postovit, LM (通讯作者)，Univ Alberta, Fac Med & Dent, Dept Oncol, 114th St & 87th Ave, Edmonton, AB T6G 2E1, Canada.
EM postovit@ualberta.ca
OI Postovit, Lynne-Marie/0000-0002-8088-4197
FU Alberta Innovates Health Solutions Translational Health Chair in cancer;
   Canadian Breast Cancer Foundation; Peter-Lougheed Premier New
   Investigator Award from the Canadian Institutes of Health Research
FX This work was supported by an Alberta Innovates Health Solutions
   Translational Health Chair in cancer and a Canadian Breast Cancer
   Foundation operating grant awarded to LMP. LMP was the recipient of the
   Peter-Lougheed Premier New Investigator Award from the Canadian
   Institutes of Health Research. KMV is a Vanier Scholar.
CR Abu-Jawdeh G, 1999, LAB INVEST, V79, P439
   [Anonymous], 2008, J NANJING MED U, DOI DOI 10.1016/S1007-4376(08)60020-9
   Caldwell GM, 2004, CANCER RES, V64, P883, DOI 10.1158/0008-5472.CAN-03-1346
   Carmon KS, 2008, MOL CANCER RES, V6, P1017, DOI 10.1158/1541-7786.MCR-08-0039
   Chong JM, 2002, J BIOL CHEM, V277, P5134, DOI 10.1074/jbc.M108533200
   Clevers H, 2012, CELL, V149, P1192, DOI 10.1016/j.cell.2012.05.012
   Fu ZY, 2015, INT J GYNECOL CANCER, V25, P356, DOI 10.1097/IGC.0000000000000386
   Kalmár A, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1687-x
   Kaur A, 2016, NATURE, V532, P250, DOI 10.1038/nature17392
   Lee JL, 2006, BREAST CANCER RES TR, V100, P49, DOI 10.1007/s10549-006-9233-9
   Lee JL, 2004, J BIOL CHEM, V279, P14602, DOI 10.1074/jbc.M309008200
   Lee JL, 2004, BREAST CANCER RES TR, V84, P139, DOI 10.1023/B:BREA.0000018412.83348.ff
   Leimeister C, 1998, MECH DEVELOP, V75, P29, DOI 10.1016/S0925-4773(98)00072-0
   Leyns L, 1997, CELL, V88, P747, DOI 10.1016/S0092-8674(00)81921-2
   Li J, 2010, NAT COMMUN, V1, DOI 10.1038/ncomms1033
   Lin CT, 2007, J REPROD DEVELOP, V53, P801, DOI 10.1262/jrd.18081
   Liu C, 2015, BIOMED REP, V3, P123, DOI 10.3892/br.2014.388
   Mi HY, 2016, NUCLEIC ACIDS RES, V44, pD336, DOI 10.1093/nar/gkv1194
   Saini S, 2009, CANCER RES, V69, P6815, DOI 10.1158/0008-5472.CAN-09-1254
   Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Sun Y, 2016, ONCOGENE, V35, P4321, DOI 10.1038/onc.2015.494
   Surana R, 2014, BBA-REV CANCER, V1845, P53, DOI 10.1016/j.bbcan.2013.11.004
   Suzuki H, 2008, BRIT J CANCER, V98, P1147, DOI 10.1038/sj.bjc.6604259
   Suzuki H, 2004, NAT GENET, V36, P417, DOI 10.1038/ng1330
   Suzuki H, 2002, NAT GENET, V31, P141, DOI 10.1038/ng892
   Takagi H, 2008, J GASTROENTEROL, V43, P378, DOI 10.1007/s00535-008-2170-0
   Terry K, 2000, MECH DEVELOP, V97, P177, DOI 10.1016/S0925-4773(00)00407-X
   Ugolini F, 1999, ONCOGENE, V18, P1903, DOI 10.1038/sj.onc.1202739
   Urakami S, 2006, CLIN CANCER RES, V12, P2109, DOI 10.1158/1078-0432.CCR-05-2468
   Veeck J, 2006, ONCOGENE, V25, P3479, DOI 10.1038/sj.onc.1209386
   Veeck J, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-83
   Wang DR, 2008, WORLD J GASTROENTERO, V14, P524, DOI 10.3748/wjg.14.524
   Wang SW, 1997, CELL, V88, P757, DOI 10.1016/S0092-8674(00)81922-4
   Yamamura S, 2010, MOL CANCER THER, V9, P1680, DOI 10.1158/1535-7163.MCT-10-0012
   Yoshihara K, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3612
   Zhang B, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-83
   Zhang B, 2014, NATURE, V513, P382, DOI 10.1038/nature13438
   Zhang H, 2016, CELL, V166, P755, DOI 10.1016/j.cell.2016.05.069
   Zhang YW, 2010, NEOPLASMA, V57, P228, DOI 10.4149/neo_2010_03_228
NR 40
TC 42
Z9 46
U1 0
U2 13
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD FEB 20
PY 2017
VL 7
AR 42719
DI 10.1038/srep42719
PG 9
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA EL1ZF
UT WOS:000394419200001
PM 28218291
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Shah, M
   Cardenas, R
   Wang, B
   Persson, J
   Mongan, NP
   Grabowska, A
   Allegrucci, C
AF Shah, Mansi
   Cardenas, Ryan
   Wang, Belinda
   Persson, Jenny
   Mongan, Nigel P.
   Grabowska, Anna
   Allegrucci, Cinzia
TI HOXC8 regulates self-renewal, differentiation and transformation of
   breast cancer stem cells
SO MOLECULAR CANCER
LA English
DT Article
DE Breast cancer; Cancer stem cells; Self-renewal; Differentiation;
   Homeobox genes; HOXC8
ID EPITHELIAL-MESENCHYMAL TRANSITION; MAMMARY-GLAND DEVELOPMENT; HOMEOBOX
   GENE-EXPRESSION; DNA METHYLATION; RETINOIC ACID; TARGET GENES;
   TUMORIGENESIS; PROGRESSION; METASTASIS; IDENTIFICATION
AB Background: Homeobox genes are master regulators of cell fate during embryonic development and their expression is altered in cancer. By regulating the balance between cell proliferation and differentiation, they maintain homeostasis of normal tissues. Here, we screened the expression of homeobox genes in mammary stem cells to establish their role in stem cells transformation in breast cancer.
   Methods: Using a Homeobox Genes PCR array, we screened 83 homeobox genes in normal cancer breast stem/progenitor cells isolated by flow cytometry. The candidate gene HOXC8 epigenetic regulation was studied by DNA methylation and miRNA expression analyses. Self-renewal and differentiation of HOXC8-overexpressing or knockdown cells were assessed by flow cytometry and mammosphere, 3D matrigel and soft agar assays. Clinical relevance of in vitro findings were validated by bioinformatics analysis of patient datasets from TCGA and METABRIC studies.
   Results: In this study we demonstrate altered expression of homeobox genes in breast cancer stem/progenitor cells. HOXC8 was consistently downregulated in stem/progenitor cells of all breast molecular subtypes, thus representing an interesting tumour suppressor candidate. We show that downregulated expression of HOXC8 is associated with DNA methylation at the gene promoter and expression of miR196 family members. Functional studies demonstrated that HOXC8 gain of function induces a decrease in the CD44(+)/CD24(-/low) cancer stem cell population and proportion of chemoresistant cells, with a concomitant increase in CD24(+) differentiated cells. Increased HOXC8 levels also decrease the ability of cancer cells to form mammospheres and to grow in anchorage-independent conditions. Furthermore, loss of HOXC8 in non-tumorigenic mammary epithelial cells expands the cancer stem/progenitor cells pool, increases stem cell self-renewal, prevents differentiation induced by retinoic acid and induces a transformed phenotype.
   Conclusions: Taken together, our study points to an important role of homeobox genes in breast cancer stem/progenitor cell function and establishes HOXC8 as a suppressor of stemness and transformation in the mammary gland lineage.
C1 [Shah, Mansi; Cardenas, Ryan; Wang, Belinda; Mongan, Nigel P.; Allegrucci, Cinzia] Univ Nottingham, SVMS, Sutton Bonington Campus, Loughborough LE12 5RD, Leics, England.
   [Mongan, Nigel P.] Weill Cornell Med, Dept Pharmacol, 1300 York Ave, New York, NY 10065 USA.
   [Persson, Jenny] Lund Univ, Dept Translat Med, S-20502 Malmo, Sweden.
   [Persson, Jenny] Umea Univ, Dept Mol Biol, S-90187 Umea, Sweden.
   [Grabowska, Anna] Univ Nottingham, Sch Med, Div Canc & Stem Cells, Canc Biol,QMC, Nottingham NG7 2UH, England.
C3 University of Nottingham; Cornell University; Weill Cornell Medicine;
   Lund University; Umea University; University of Nottingham
RP Allegrucci, C (通讯作者)，Univ Nottingham, SVMS, Sutton Bonington Campus, Loughborough LE12 5RD, Leics, England.
EM cinzia.allegrucci@nottingham.ac.uk
RI Allegrucci, Cinzia/A-6110-2009; Shah, Mansi/S-6774-2019; Grabowska,
   Anna/D-2931-2012; Mongan, Nigel/B-7410-2011
OI Allegrucci, Cinzia/0000-0001-8517-2423; Persson,
   Jenny/0000-0001-7682-7678; Wang, Belinda Lei/0000-0002-6963-4963; Shah,
   Mansi/0009-0006-6796-7664
FU Biotechnology and Biological Sciences Research Council (BBSRC) [RS4949];
   Royal Society of London [RA3810]; University of Nottingham [A2B090]
FX This study was supported by grants from the Biotechnology and Biological
   Sciences Research Council (BBSRC; grant number RS4949) Royal Society of
   London (grant number RA3810) and the University of Nottingham (grant
   number A2B090).
CR Abate-Shen C, 2002, NAT REV CANCER, V2, P777, DOI 10.1038/nrc907
   Adwan H, 2011, BRIT J CANCER, V105, P288, DOI 10.1038/bjc.2011.217
   Alami Y, 1999, BIOCHEM BIOPH RES CO, V257, P738, DOI 10.1006/bbrc.1999.0516
   Atkinson SP, 2008, STEM CELLS, V26, P1174, DOI 10.1634/stemcells.2007-0497
   Barber BA, 2010, ANN ANAT, V192, P261, DOI 10.1016/j.aanat.2010.07.009
   Bloushtain-Qimron N, 2008, P NATL ACAD SCI USA, V105, P14076, DOI 10.1073/pnas.0805206105
   Carroll LS, 2015, DEVELOPMENT, V142, P4056, DOI 10.1242/dev.128298
   Chao FM, 2015, ONCOTARGET, V6, P23496, DOI 10.18632/oncotarget.4360
   Chen HX, 2003, J MAMMARY GLAND BIOL, V8, P159, DOI 10.1023/A:1025996707117
   Ciriello G, 2015, CELL, V163, P506, DOI 10.1016/j.cell.2015.09.033
   Cline MS, 2013, SCI REP-UK, V3, DOI 10.1038/srep02652
   Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983
   Du YB, 2014, J SURG RES, V188, P442, DOI 10.1016/j.jss.2014.01.017
   Eccles SA, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3493
   Fackler MJ, 2011, CANCER RES, V71, P6195, DOI 10.1158/0008-5472.CAN-11-1630
   Faryna M, 2012, FASEB J, V26, P4937, DOI 10.1096/fj.12-209502
   Ginestier C, 2009, CELL CYCLE, V8, P3297, DOI 10.4161/cc.8.20.9761
   Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722
   Guo WJ, 2012, CELL, V148, P1015, DOI 10.1016/j.cell.2012.02.008
   He H, 2011, ONCOGENE, V30, P379, DOI 10.1038/onc.2010.484
   Horvath IB, 2016, NAT METHODS, V13, P9, DOI 10.1038/nmeth.3692
   Hu GZ, 2001, DEVELOPMENT, V128, P2373
   Huang WY, 2015, NUCLEIC ACIDS RES, V43, pD856, DOI 10.1093/nar/gku1151
   Johnson KC, 2015, CLIN EPIGENETICS, V7, DOI 10.1186/s13148-015-0094-0
   Kalyani R, 2016, MOL CELLS, V39, P395, DOI 10.14348/molcells.2016.2311
   Kamalakaran S, 2011, MOL ONCOL, V5, P77, DOI 10.1016/j.molonc.2010.11.002
   Keller PJ, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2755
   Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412
   Lee GY, 2007, NAT METHODS, V4, P359, DOI 10.1038/NMETH1015
   Lee TI, 2006, CELL, V125, P301, DOI 10.1016/j.cell.2006.02.043
   Lehmann BD, 2011, J CLIN INVEST, V121, P2750, DOI 10.1172/JCI45014
   Lei H, 2006, P NATL ACAD SCI USA, V103, P10305, DOI 10.1073/pnas.0603552103
   LEMOUELLIC H, 1992, CELL, V69, P251, DOI 10.1016/0092-8674(92)90406-3
   Lewis MT, 2000, BREAST CANCER RES, V2, P158, DOI 10.1186/bcr49
   Li Y, 2014, ONCOTARGET, V5, P2596, DOI 10.18632/oncotarget.1841
   Li Y, 2010, CANCER RES, V70, P7894, DOI 10.1158/0008-5472.CAN-10-1675
   Lohse M, 2012, NUCLEIC ACIDS RES, V40, pW622, DOI 10.1093/nar/gks540
   Mark M, 1997, PEDIATR RES, V42, P421, DOI 10.1203/00006450-199710000-00001
   McCoy EL, 2009, J CLIN INVEST, V119, P2663, DOI 10.1172/JCI37691
   Morgan R, 2012, BREAST CANCER RES TR, V136, P389, DOI 10.1007/s10549-012-2259-2
   Nadauld LD, 2004, J BIOL CHEM, V279, P51581, DOI 10.1074/jbc.M408830200
   Novak P, 2008, CANCER RES, V68, P8616, DOI 10.1158/0008-5472.CAN-08-1419
   Novak P, 2009, CANCER RES, V69, P5251, DOI 10.1158/0008-5472.CAN-08-4977
   Ocaña OH, 2012, CANCER CELL, V22, P709, DOI 10.1016/j.ccr.2012.10.012
   Ohm JE, 2007, NAT GENET, V39, P237, DOI 10.1038/ng1972
   Ordóñez-Morán P, 2015, CANCER CELL, V28, P815, DOI 10.1016/j.ccell.2015.11.001
   Pereira B, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11479
   Pfaffl MW, 2004, BIOTECHNOL LETT, V26, P509, DOI 10.1023/B:BILE.0000019559.84305.47
   Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616
   Ronneberg JA, 2011, MOL ONCOL, V5, P61, DOI 10.1016/j.molonc.2010.11.004
   Samuel S, 2005, EUR J CANCER, V41, P2428, DOI 10.1016/j.ejca.2005.08.014
   Schlesinger Y, 2007, NAT GENET, V39, P232, DOI 10.1038/ng1950
   Shah M, 2012, BREAST CANCER-TARGET, V4, P155, DOI 10.2147/BCTT.S26434
   Shah Mansi, 2013, Subcell Biochem, V61, P545, DOI 10.1007/978-94-007-4525-4_24
   Shah N, 2010, NAT REV CANCER, V10, P361, DOI 10.1038/nrc2826
   Shashikant CS, 1996, P NATL ACAD SCI USA, V93, P12364, DOI 10.1073/pnas.93.22.12364
   Sun R, 2015, BIOMATERIALS, V37, P405, DOI 10.1016/j.biomaterials.2014.10.018
   Tao YG, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009163
   Teo WW, 2016, ONCOGENE, V35, P5539, DOI 10.1038/onc.2016.95
   Tommasi S, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2233
   Valent P, 2012, NAT REV CANCER, V12, P767, DOI 10.1038/nrc3368
   Vermot J, 2005, DEVELOPMENT, V132, P1611, DOI 10.1242/dev.01718
   Waltregny D, 2002, PROSTATE, V50, P162, DOI 10.1002/pros.10045
   Wang YA, 2005, DEV DYNAM, V234, P892, DOI 10.1002/dvdy.20570
   Yadav BS, 2015, WORLD J CLIN ONCOL, V6, P252, DOI 10.5306/wjco.v6.i6.252
   Yu M, 2009, GENE DEV, V23, P1737, DOI 10.1101/gad.1809309
   Zhang LM, 2012, INT J BIOL SCI, V8, P1178, DOI 10.7150/ijbs.4458
NR 67
TC 45
Z9 48
U1 2
U2 25
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1476-4598
J9 MOL CANCER
JI Mol. Cancer
PD FEB 16
PY 2017
VL 16
AR 38
DI 10.1186/s12943-017-0605-z
PG 19
WC Biochemistry & Molecular Biology; Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology
GA EK7SJ
UT WOS:000394125200001
PM 28202042
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU Staberg, M
   Michaelsen, SR
   Rasmussen, RD
   Villingshoj, M
   Poulsen, H
   Hamerlik, P
AF Staberg, Mikkel
   Michaelsen, Signe Regner
   Rasmussen, Rikke Darling
   Villingshoj, Mette
   Poulsen, Hans Skovgaard
   Hamerlik, Petra
TI Inhibition of histone deacetylases sensitizes glioblastoma cells to
   lomustine
SO CELLULAR ONCOLOGY
LA English
DT Article
DE Glioblastoma; Epigenetics; Trichostatin A; HDACi; Lomustine;
   Sensitization
ID HYDROXAMIC ACID SAHA; IN-VITRO; CELLULAR-RESPONSE; PROSTATE-CANCER;
   TRICHOSTATIN-A; BREAST-CANCER; CYCLE ARREST; EXPRESSION; HDAC; PROGNOSIS
AB Glioblastoma (GBM) ranks among the deadliest solid cancers worldwide and its prognosis has remained dismal, despite the use of aggressive chemo-irradiation treatment regimens. Limited drug delivery into the brain parenchyma and frequent resistance to currently available therapies are problems that call for a prompt development of novel therapeutic strategies. While only displaying modest efficacies as mono-therapy in pre-clinical settings, histone deacetylase inhibitors (HDACi) have shown promising sensitizing effects to a number of cytotoxic agents. Here, we sought to investigate the sensitizing effect of the HDACi trichostatin A (TSA) to the alkylating agent lomustine (CCNU), which is used in the clinic for the treatment of GBM.
   Twelve primary GBM cell cultures grown as neurospheres were used in this study, as well as one established GBM-derived cell line (U87 MG). Histone deacetylase (HDAC) expression levels were determined using quantitative real-time PCR and Western blotting. The efficacy of either CCNU alone or its combination with TSA was assessed using various assays, i.e., cell viability assays (MTT), cell cycle assays (flow cytometry, FACS), double-strand DNA break (DSB) quantification assays (microscopy/immunofluorescence) and expression profiling assays of proteins involved in apoptosis and cell stress (Western blotting and protein array).
   We found that the HDAC1, 3 and 6 expression levels were significantly increased in GBM samples compared to non-neoplastic brain control samples. Additionally, we found that pre-treatment of GBM cells with TSA resulted in an enhancement of their sensitivity to CCNU, possibly via the accumulation of DSBs, decreased cell proliferation and viability rates, and an increased apoptotic rate.
   From our data we conclude that the combined administration of TSA and CCNU eradicates GBM cells with a higher efficacy than either drug alone, thereby opening a novel avenue for the treatment of GBM.
C1 [Staberg, Mikkel; Michaelsen, Signe Regner; Villingshoj, Mette; Poulsen, Hans Skovgaard] Rigshosp, Finsen Ctr, Dept Radiat Biol, Copenhagen, Denmark.
   [Rasmussen, Rikke Darling; Hamerlik, Petra] Danish Canc Soc, Res Ctr, Brain Tumor Biol Grp, Copenhagen, Denmark.
C3 Rigshospitalet; University of Copenhagen; Danish Cancer Society
RP Staberg, M (通讯作者)，Rigshosp, Finsen Ctr, Dept Radiat Biol, Copenhagen, Denmark.; Hamerlik, P (通讯作者)，Danish Canc Soc, Res Ctr, Brain Tumor Biol Grp, Copenhagen, Denmark.
EM mikkel.staberg@regionh.dk; pkn@cancer.dk
RI Michaelsen, Signe/ABB-1451-2020; Hamerlik, Petra/G-7398-2016
OI Michaelsen, Signe/0000-0001-9047-6384; Hamerlik,
   Petra/0000-0002-5856-0161
FU Danish Cancer Research Foundation (Dansk Kraeftforsknings Fond); Danish
   Cancer Society; Faculty of Health and Medical Sciences, University of
   Copenhagen, Denmark
FX This work was supported by grants from The Danish Cancer Research
   Foundation (Dansk Kraeftforsknings Fond), the Danish Cancer Society and
   the Faculty of Health and Medical Sciences, University of Copenhagen,
   Denmark.
CR Adamson C, 2009, EXPERT OPIN INV DRUG, V18, P1061, DOI 10.1517/13543780903052764
   Aquilina G, 1999, CARCINOGENESIS, V20, P2317, DOI 10.1093/carcin/20.12.2317
   Bajbouj K, 2012, J NEURO-ONCOL, V107, P503, DOI 10.1007/s11060-011-0791-2
   Balajee AS, 2004, EXP CELL RES, V300, P320, DOI 10.1016/j.yexcr.2004.07.022
   Barneda-Zahonero B, 2012, MOL ONCOL, V6, P579, DOI 10.1016/j.molonc.2012.07.003
   Bartkova J, 2010, ONCOGENE, V29, P5095, DOI 10.1038/onc.2010.249
   Ben Dhiab M, 2015, CELL ONCOL, V38, P453, DOI 10.1007/s13402-015-0242-8
   Bhaskara S, 2008, MOL CELL, V30, P61, DOI 10.1016/j.molcel.2008.02.030
   Brandes AA, 2016, CURR NEUROL NEUROSCI, V16, DOI 10.1007/s11910-015-0611-8
   Chao OS, 2014, MOL CANCER RES, V12, P1755, DOI 10.1158/1541-7786.MCR-14-0173
   Cornago M, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.412
   Cortés C, 2015, CELL ONCOL, V38, P341, DOI 10.1007/s13402-015-0233-9
   De Ruijter AJM, 2003, BIOCHEM J, V370, P737, DOI 10.1042/BJ20021321
   Di Marcotullio L, 2011, BBA-REV CANCER, V1815, P241, DOI 10.1016/j.bbcan.2011.01.002
   Diss E., 2014, J Clin Oncol Res, V2, P1
   Duensing A, 2006, J CELL BIOCHEM, V99, P759, DOI 10.1002/jcb.20962
   Ferraro A, 2016, CELL ONCOL, V39, P195, DOI 10.1007/s13402-016-0276-6
   Hamerlik P, 2012, J EXP MED, V209, P507, DOI 10.1084/jem.20111424
   Hamilton JP, 2011, DIGEST DIS, V29, P130, DOI 10.1159/000323874
   Harvey KA, 2015, J NEUROSURG, V122, P547, DOI 10.3171/2014.10.JNS14759
   Karagiannis TC, 2005, CANCER BIOL THER, V4, P787, DOI 10.4161/cbt.4.7.1922
   Kim JH, 2004, INT J RADIAT ONCOL, V59, P1174, DOI 10.1016/j.ijrobp.2004.03.001
   Konstantinopoulos PA, 2014, GYNECOL ONCOL, V133, P599, DOI 10.1016/j.ygyno.2014.03.007
   Koprinarova M, 2011, DNA REPAIR, V10, P970, DOI 10.1016/j.dnarep.2011.07.003
   Kretsovali A, 2012, STEM CELLS INT, V2012, DOI 10.1155/2012/184154
   Krusche CA, 2005, BREAST CANCER RES TR, V90, P15, DOI 10.1007/s10549-004-1668-2
   Lucio-Eterovic AK, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-243
   Maleszewska Marta, 2013, Cancers (Basel), V5, P1120, DOI 10.3390/cancers5031120
   Medina V, 1997, CANCER RES, V57, P3697
   Miller KM, 2010, NAT STRUCT MOL BIOL, V17, P1144, DOI 10.1038/nsmb.1899
   Min A, 2015, BREAST CANCER RES, V17, DOI 10.1186/s13058-015-0534-y
   Minamiya Y, 2010, TUMOR BIOL, V31, P533, DOI 10.1007/s13277-010-0066-0
   Nagarajan RP, 2009, SEMIN CANCER BIOL, V19, P188, DOI 10.1016/j.semcancer.2009.02.005
   Rasmussen RD, 2016, MOL ONCOL, V10, P751, DOI 10.1016/j.molonc.2015.12.014
   Rikimaru T, 2007, ONCOLOGY-BASEL, V72, P69, DOI 10.1159/000111106
   Rogakou EP, 2000, J BIOL CHEM, V275, P9390, DOI 10.1074/jbc.275.13.9390
   Ryu CH, 2012, J BIOMED BIOTECHNOL, DOI 10.1155/2012/987495
   Sakariassen PO, 2007, NEOPLASIA, V9, P882, DOI 10.1593/neo.07658
   Sarcar B, 2010, J NEURO-ONCOL, V99, P201, DOI 10.1007/s11060-010-0127-7
   Sassi FD, 2014, J MOL NEUROSCI, V54, P27, DOI 10.1007/s12031-014-0241-7
   Sawa H, 2001, Brain Tumor Pathol, V18, P109, DOI 10.1007/BF02479423
   Shinwari Z, 2011, ANTICANCER RES, V31, P1721
   Stockhausen MT, 2011, EXP CELL RES, V317, P1513, DOI 10.1016/j.yexcr.2011.04.001
   Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330
   Taal W, 2014, LANCET ONCOL, V15, P943, DOI 10.1016/S1470-2045(14)70314-6
   Venere M, 2014, CELL DEATH DIFFER, V21, P258, DOI 10.1038/cdd.2013.136
   Weichert W, 2008, BRIT J CANCER, V98, P604, DOI 10.1038/sj.bjc.6604199
   Weichert W, 2008, CLIN CANCER RES, V14, P1669, DOI 10.1158/1078-0432.CCR-07-0990
   Weichert W, 2008, LANCET ONCOL, V9, P139, DOI 10.1016/S1470-2045(08)70004-4
   Weichert W, 2009, CANCER LETT, V280, P168, DOI 10.1016/j.canlet.2008.10.047
   West AC, 2014, J CLIN INVEST, V124, P30, DOI 10.1172/JCI69738
   Wetzel M, 2005, J NEUROSURG, V103, P549, DOI 10.3171/ped.2005.103.6.0549
   Wick W, 2010, J CLIN ONCOL, V28, P1168, DOI 10.1200/JCO.2009.23.2595
   Xu XY, 2015, CELL ONCOL, V38, P183, DOI 10.1007/s13402-015-0219-7
   Yang SH, 2009, J NEURO-ONCOL, V95, P23, DOI 10.1007/s11060-009-9895-3
NR 55
TC 47
Z9 49
U1 1
U2 9
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 2211-3428
EI 2211-3436
J9 CELL ONCOL
JI Cell. Oncol.
PD FEB
PY 2017
VL 40
IS 1
BP 21
EP 32
DI 10.1007/s13402-016-0301-9
PG 12
WC Oncology; Cell Biology; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology; Pathology
GA EI2LF
UT WOS:000392318100002
PM 27766591
DA 2025-01-12
ER

PT J
AU Achinger-Kawecka, J
   Clark, SJ
AF Achinger-Kawecka, Joanna
   Clark, Susan J.
TI Disruption of the 3D cancer genome blueprint
SO EPIGENOMICS
LA English
DT Article
DE cancer; chromatin conformation capture; chromatin interactions; Hi-C;
   topologically associating domain
ID LONG-RANGE INTERACTION; CAPTURE HI-C; COLORECTAL-CANCER; BREAST-CANCER;
   CHROMOSOME CONFORMATION; CHROMATIN DOMAINS; RISK LOCI; LOOPING
   INTERACTIONS; TOPOLOGICAL DOMAINS; MAMMALIAN GENOMES
AB Recent advances in chromosome conformation capture technologies are improving the current appreciation of how 3D genome architecture affects its function in different cell types and disease. Long-range chromatin interactions are organized into topologically associated domains, which are known to play a role in constraining gene expression patterns. However, in cancer cells there are alterations in the 3D genome structure, which impacts on gene regulation. Disruption of topologically associated domains architecture can result in alterations in chromatin interactions that bring new regulatory elements and genes together, leading to altered expression of oncogenes and tumor suppressor genes. Here, we discuss the impact of genetic and epigenetic changes in cancer and how this affects the spatial organization of chromatin. Understanding how disruptions to the 3D architecture contribute to the cancer genome will provide novel insights into the principles of epigenetic gene regulation in cancer and mechanisms responsible for cancer associated mutations and rearrangements.
C1 [Achinger-Kawecka, Joanna; Clark, Susan J.] Garvan Inst Med Res, Genom & Epigenet Div, Epigenet Res Lab, 384 Victoria St, Darlinghurst, NSW 2010, Australia.
   [Achinger-Kawecka, Joanna; Clark, Susan J.] Univ New South Wales, Fac Med, St Vincents Clin Sch, Darlinghurst, NSW 2010, Australia.
C3 Garvan Institute of Medical Research; University of New South Wales
   Sydney; St Vincent's Clinic
RP Clark, SJ (通讯作者)，Garvan Inst Med Res, Genom & Epigenet Div, Epigenet Res Lab, 384 Victoria St, Darlinghurst, NSW 2010, Australia.; Clark, SJ (通讯作者)，Univ New South Wales, Fac Med, St Vincents Clin Sch, Darlinghurst, NSW 2010, Australia.
EM s.clark@garvan.org.au
RI Clark, Susan/B-2272-2008
OI Clark, Susan/0000-0001-5925-5030; Achinger-Kawecka,
   Joanna/0000-0002-2902-9371
FU National Health and Medical Research Council (NHMRC) Fellowship grant
   [1088144]; NHMRC [1011447, 1051757]; National Health and Medical
   Research Council of Australia [1088144] Funding Source: NHMRC
FX SJ Clark is supported by a National Health and Medical Research Council
   (NHMRC) Fellowship grant (#1088144). This work was partially supported
   by NHMRC Project Grants #1011447 and #1051757. The authors have no other
   relevant affiliations or financial involvement with any organization or
   entity with a financial interest in or financial conflict with the
   subject matter or materials discussed in the manuscript apart from those
   disclosed.
CR Ahmadiyeh N, 2010, P NATL ACAD SCI USA, V107, P9742, DOI 10.1073/pnas.0910668107
   Barutcu AR, 2015, GENOME BIOL, V16, DOI 10.1186/s13059-015-0768-0
   Beagan JA, 2016, CELL STEM CELL, V18, P611, DOI 10.1016/j.stem.2016.04.004
   Bert SA, 2013, CANCER CELL, V23, P9, DOI 10.1016/j.ccr.2012.11.006
   Coolen MW, 2010, NAT CELL BIOL, V12, P235, DOI 10.1038/ncb2023
   Dallosso AR, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000745
   de Wit E, 2015, MOL CELL, V60, P676, DOI 10.1016/j.molcel.2015.09.023
   Dekker J, 2002, SCIENCE, V295, P1306, DOI 10.1126/science.1067799
   Dekker J, 2016, CELL, V164, P1110, DOI 10.1016/j.cell.2016.02.007
   Dixon JR, 2015, NATURE, V518, P331, DOI 10.1038/nature14222
   Dixon JR, 2012, NATURE, V485, P376, DOI 10.1038/nature11082
   Dostie J, 2006, GENOME RES, V16, P1299, DOI 10.1101/gr.5571506
   Dowen JM, 2014, CELL, V159, P374, DOI 10.1016/j.cell.2014.09.030
   Dryden NH, 2014, GENOME RES, V24, P1854, DOI 10.1101/gr.175034.114
   Du MJ, 2016, SCI REP-UK, V6, DOI 10.1038/srep23202
   Filippova GN, 1996, MOL CELL BIOL, V16, P2802
   Flavahan WA, 2016, NATURE, V529, P110, DOI 10.1038/nature16490
   Franke M, 2016, NATURE, V538, P265, DOI 10.1038/nature19800
   Frigola J, 2006, NAT GENET, V38, P540, DOI 10.1038/ng1781
   Fullwood MJ, 2009, NATURE, V462, P58, DOI 10.1038/nature08497
   Gheldof N, 2010, NUCLEIC ACIDS RES, V38, P4325, DOI 10.1093/nar/gkq175
   Giorgio E, 2015, HUM MOL GENET, V24, P3143, DOI 10.1093/hmg/ddv065
   Gröschel S, 2014, CELL, V157, P369, DOI 10.1016/j.cell.2014.02.019
   Guo Y, 2015, CELL, V162, P900, DOI 10.1016/j.cell.2015.07.038
   Hitchins MP, 2007, CANCER RES, V67, P9107, DOI 10.1158/0008-5472.CAN-07-0869
   Hnisz D, 2016, SCIENCE, V351, P1454, DOI 10.1126/science.aad9024
   Jäger R, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7178
   Kaiser VB, 2016, PLOS GENET, V12, DOI 10.1371/journal.pgen.1006207
   Katainen R, 2015, NAT GENET, V47, P818, DOI 10.1038/ng.3335
   Krijger PHL, 2016, CELL STEM CELL, V18, P597, DOI 10.1016/j.stem.2016.01.007
   Lawrence MS, 2014, NATURE, V505, P495, DOI 10.1038/nature12912
   Li YY, 2013, BMC GENOMICS, V14, DOI [10.1186/1471-2164-14-553, 10.1186/1471-2164-14-579]
   Lieberman-Aiden E, 2009, SCIENCE, V326, P289, DOI 10.1126/science.1181369
   Lupiáñez DG, 2015, CELL, V161, P1012, DOI 10.1016/j.cell.2015.04.004
   Maurano MT, 2015, CELL REP, V12, P1184, DOI 10.1016/j.celrep.2015.07.024
   Narendra V, 2015, SCIENCE, V347, P1017, DOI 10.1126/science.1262088
   Nichols MH, 2015, CELL, V162, P702, DOI 10.1016/j.cell.2015.07.053
   Nora EP, 2012, NATURE, V485, P381, DOI 10.1038/nature11049
   Novak P, 2008, CANCER RES, V68, P8616, DOI 10.1158/0008-5472.CAN-08-1419
   Ong CT, 2014, NAT REV GENET, V15, P234, DOI 10.1038/nrg3663
   Phillips JE, 2009, CELL, V137, P1194, DOI 10.1016/j.cell.2009.06.001
   Phillips-Cremins JE, 2013, CELL, V153, P1281, DOI 10.1016/j.cell.2013.04.053
   Pomerantz MM, 2009, NAT GENET, V41, P882, DOI 10.1038/ng.403
   Rafique S, 2015, GENOME BIOL, V16, DOI 10.1186/s13059-015-0719-9
   Rao SSP, 2014, CELL, V159, P1665, DOI 10.1016/j.cell.2014.11.021
   Rickman DS, 2012, P NATL ACAD SCI USA, V109, P9083, DOI 10.1073/pnas.1112570109
   Rousseau M, 2014, GENOME BIOL, V15, DOI 10.1186/gb-2014-15-4-r60
   Sanborn AL, 2015, P NATL ACAD SCI USA, V112, pE6456, DOI 10.1073/pnas.1518552112
   Sanyal A, 2012, NATURE, V489, P109, DOI 10.1038/nature11279
   Seng TJ, 2008, BRIT J CANCER, V99, P375, DOI 10.1038/sj.bjc.6604452
   Simonis M, 2006, NAT GENET, V38, P1348, DOI 10.1038/ng1896
   Smith EM, 2016, AM J HUM GENET, V98, P185, DOI 10.1016/j.ajhg.2015.12.002
   Sotelo J, 2010, P NATL ACAD SCI USA, V107, P3001, DOI 10.1073/pnas.0906067107
   Splinter E, 2006, GENE DEV, V20, P2349, DOI 10.1101/gad.399506
   Stransky N, 2006, NAT GENET, V38, P1386, DOI 10.1038/ng1923
   Symmons O, 2014, GENOME RES, V24, P390, DOI 10.1101/gr.163519.113
   Taberlay PC, 2016, GENOME RES, V26, P719, DOI 10.1101/gr.201517.115
   Tsujimura T, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1004897
   Walker BA, 2014, BLOOD CANCER J, V4, DOI 10.1038/bcj.2014.13
   Wang H, 2012, GENOME RES, V22, P1680, DOI 10.1101/gr.136101.111
   Wright JB, 2010, MOL CELL BIOL, V30, P1411, DOI 10.1128/MCB.01384-09
   Zhang Y, 2012, CELL, V148, P908, DOI 10.1016/j.cell.2012.02.002
   Zhao Z, 2006, NAT GENET, V38, P1341, DOI 10.1038/ng1891
NR 63
TC 32
Z9 40
U1 0
U2 13
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
   1QB, ENGLAND
SN 1750-1911
EI 1750-192X
J9 EPIGENOMICS-UK
JI Epigenomics
PD JAN
PY 2017
VL 9
IS 1
BP 47
EP 55
DI 10.2217/epi-2016-0111
PG 9
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA EI1ED
UT WOS:000392218200006
PM 27936932
OA hybrid
DA 2025-01-12
ER

PT J
AU Felicio, PS
   Melendez, ME
   Arantes, LMRB
   Kerr, LM
   Carraro, DM
   Grasel, RS
   Campacci, N
   Scapulatempo-Neto, C
   Fernandes, GC
   de Carvalho, AC
   Palmero, EI
AF Felicio, Paula Silva
   Melendez, Matias Eliseo
   Rebolho Batista Arantes, Lidia Maria
   Kerr, Ligia Maria
   Carraro, Dirce Maria
   Grasel, Rebeca Silveira
   Campacci, Natalia
   Scapulatempo-Neto, Cristovam
   Fernandes, Gabriela Carvalho
   de Carvalho, Ana Carolina
   Palmero, Edenir Inez
TI Genetic and epigenetic characterization of the <i>BRCA1</i> gene in
   Brazilian women at-risk for hereditary breast cancer
SO ONCOTARGET
LA English
DT Article
DE hereditary breast cancer; methylation; gene expression; breast cancer;
   BRCA1 gene
ID ISLAND METHYLATOR PHENOTYPE; PROMOTER HYPERMETHYLATION; SPORADIC BREAST;
   COLORECTAL-CANCER; DNA METHYLATION; OVARIAN-CANCER; TUMORS;
   ADENOCARCINOMA; INACTIVATION; EXPRESSION
AB This study aimed to characterize women at-risk for hereditary BC regarding their clinical and molecular characteristics (mutation and methylation in the BRCA1 gene) and correlate the gene expression levels with histopathological, clinical and family history information. BRCA1 real time qPCR was performed to evaluate methylation status and gene expression. The study included 88 women grouped according to the BRCA1 mutational status: 23 BRCA1 mutated, 22 with a Variant of Unknown Significance (VUS) in BRCA1 and 43 BRCA1 WT. Most BRCA1 mutated tumors were triple negative (69.6%) and had histologic grade III (61.0%). Patients with VUS/WT BRCA1 were predominantly of luminal B subtype with histological grades I and II. Regarding the methylation profile, BRCA1 hypermethylation was observed in only two patients (both WT) and none had association with pathogenic BRCA1 mutation. In one patient methylation was present in both, tumor and normal tissues. Hypermethylated tumors had ductal histology, negativity for ER and occurred in < 50 years patients. Gene expression profile showed in all groups lower BRCA1 mRNA levels in tumor tissue compared to the adjacent breast tissue, thereby indicating the loss/decrease of gene function. No association was found between the levels of BRCA1 gene expression and family history of cancer. In summary, our findings suggested that methylation at the BRCA1 gene is not the "second" event in the development of BC in patients with germline mutations in BRCA1 and, although rare, BRCA1 epimutations can constitute an explanation for a fraction of HBOC families.
C1 [Felicio, Paula Silva; Melendez, Matias Eliseo; Rebolho Batista Arantes, Lidia Maria; Kerr, Ligia Maria; Grasel, Rebeca Silveira; Campacci, Natalia; Scapulatempo-Neto, Cristovam; Fernandes, Gabriela Carvalho; de Carvalho, Ana Carolina; Palmero, Edenir Inez] Barretos Canc Hosp, Mol Oncol Res Ctr, Barretos, SP, Brazil.
   [Kerr, Ligia Maria; Scapulatempo-Neto, Cristovam] Barretos Canc Hosp, Dept Pathol, Barretos, SP, Brazil.
   [Carraro, Dirce Maria] AC Camargo Canc Ctr, Int Res Ctr, Sao Paulo, SP, Brazil.
C3 Hospital de Cancer de Barretos; Hospital de Cancer de Barretos;
   A.C.Camargo Cancer Center
RP Palmero, EI (通讯作者)，Barretos Canc Hosp, Mol Oncol Res Ctr, Barretos, SP, Brazil.
EM edenirip@yahoo.com.br
RI Fernandes, Gabriela/GRJ-1743-2022; Carraro, Dirce/C-9179-2009; de
   Carvalho, Ana Carolina/Q-4055-2019; Palmero, Edenir/F-4341-2015;
   Melendez, Matias Eliseo/G-3775-2012
OI Carraro, Dirce/0000-0001-5667-1418; Scapulatempo-Neto,
   Cristovam/0000-0002-8920-6579; Rebolho Batista Arantes, Lidia
   Maria/0000-0001-8230-1218; INCT de Optica Basica e Aplicada as Ciencias
   da Vida (CNPq), CePOF (FAPESP)/0000-0002-6403-4037; de Carvalho, Ana
   Carolina/0000-0002-0114-7659; Palmero, Edenir/0000-0003-1904-2158;
   Melendez, Matias Eliseo/0000-0002-0643-6185
FU FAPESP [2013/24633-2, 2013/23277-8]
FX This study was partially supported by FAPESP (2013/24633-2 and
   2013/23277-8).
CR Al-Moghrabi N, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-830
   Birgisdottir V, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1522
   Carraro DM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057581
   Cortesi L, 2000, GENE CHROMOSOME CANC, V27, P130, DOI 10.1002/(SICI)1098-2264(200002)27:2<130::AID-GCC3>3.3.CO;2-L
   Costa FF, 2004, ONCOGENE, V23, P1481, DOI 10.1038/sj.onc.1207263
   Couch FJ, 2014, SCIENCE, V343, P1466, DOI 10.1126/science.1251827
   Demokan S, 2011, CLIN EPIGENETICS, V2, P123, DOI 10.1007/s13148-011-0045-3
   Dworkin AM, 2009, FAM CANCER, V8, P339, DOI 10.1007/s10689-009-9240-1
   Eads CA, 2001, CANCER RES, V61, P3410
   Esteller M, 2000, JNCI-J NATL CANCER I, V92, P564, DOI 10.1093/jnci/92.7.564
   Esteller M, 2001, CANCER RES, V61, P3225
   Fang F, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3001875
   Friedenson Bernard, 2005, MedGenMed, V7, P60
   Gausachs M, 2012, EUR J HUM GENET, V20, P762, DOI 10.1038/ejhg.2011.277
   Gronwald J, 2008, HERED CANCER CLIN PR, V6, P88, DOI 10.1186/1897-4287-6-2-88
   Holm K, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2590
   Hsu NC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056256
   Karsli-Ceppioglu S, 2014, EPIGENOMICS-UK, V6, P651, DOI [10.2217/EPI.14.59, 10.2217/epi.14.59]
   Landrum MJ, 2016, NUCLEIC ACIDS RES, V44, pD862, DOI 10.1093/nar/gkv1222
   Lips EH, 2013, BRIT J CANCER, V108, P2172, DOI 10.1038/bjc.2013.144
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lynch HT, 2012, ANN SURG ONCOL, V19, P1723, DOI 10.1245/s10434-012-2256-z
   Marroni F, 2004, EUR J HUM GENET, V12, P899, DOI 10.1038/sj.ejhg.5201256
   Matros E, 2005, BREAST CANCER RES TR, V91, P179, DOI 10.1007/s10549-004-7603-8
   Mavaddat N, 2010, MOL ONCOL, V4, P174, DOI 10.1016/j.molonc.2010.04.011
   Nowsheen S, 2014, CANCER LETT, V342, P213, DOI 10.1016/j.canlet.2012.05.015
   Palmero EI, 2016, GENET MOL BIOL, V39, P168, DOI [10.1590/1678-4685-GMB-2014-0364, 10.1590/1678-4685-gmb-2014-0364]
   Petrucelli N., 1993, GENEREVIEWS R
   Press JZ, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-17
   Rice JC, 2000, CARCINOGENESIS, V21, P1761, DOI 10.1093/carcin/21.9.1761
   Saelee P, 2014, ASIAN PAC J CANCER P, V15, P10585, DOI 10.7314/APJCP.2014.15.24.10585
   Samowitz WS, 2007, J MOL DIAGN, V9, P281, DOI 10.2353/jmoldx.2007.070031
   Selamat SA, 2012, GENOME RES, V22, P1197, DOI 10.1101/gr.132662.111
   Sharma Priyanka, 2014, J Cancer Ther Res, V3, P1, DOI 10.7243/2049-7962-3-2
   Stenson PD, 2014, HUM GENET, V133, P1, DOI 10.1007/s00439-013-1358-4
   Tung N, 2014, BREAST CANCER RES TR, V146, P175, DOI 10.1007/s10549-014-2995-6
   van Beers EH, 2006, BRIT J CANCER, V94, P333, DOI 10.1038/sj.bjc.6602889
   van der Groep P, 2011, CELL ONCOL, V34, P71, DOI 10.1007/s13402-011-0010-3
   Weisenberger DJ, 2006, NAT GENET, V38, P787, DOI 10.1038/ng1834
   WHO, 2016, WORLD HLTH REP 2006
NR 40
TC 3
Z9 4
U1 0
U2 11
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD JAN 10
PY 2017
VL 8
IS 2
BP 2850
EP 2862
DI 10.18632/oncotarget.13750
PG 13
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA EH1EL
UT WOS:000391506300081
PM 27926510
OA gold, Green Published, Green Submitted
DA 2025-01-12
ER

PT J
AU Feng, XY
   Han, H
   Zou, D
   Zhou, JM
   Zhou, WQ
AF Feng, Xiuyan
   Han, Han
   Zou, Dan
   Zhou, Jiaming
   Zhou, Weiqiang
TI Suberoylanilide hydroxamic acid-induced specific epigenetic regulation
   controls Leptin-induced proliferation of breast cancer cell lines
SO ONCOTARGET
LA English
DT Article
DE suberoylanilide hydroxamic acid; histone acetylation; breast cancer
ID INHIBITOR; GROWTH; P21(WAF1); ESTROGEN; KINASE; TRAIL
AB Breast cancer is one of the most common malignancies among women in the world, investigating the characteristics and special transduction pathways is important for better understanding breast development and tumorigenesis. Leptin, a peptide hormone secreted from white adipocytes, may be an independent risk factor for breast cancer.
   Here, we treated suberoylanilide hydroxamic acid (SAHA) on Leptin-induced cell proliferation and invasion in the estrogen-receptor-positive breast cancer cell line MCF-7 and triple-negative breast cancer cell line MDA-MB-231. Low concentrations of Leptin (0.625 nM) significantly stimulated breast cancer cell growth, enhanced cell viability, minimized apoptosis, and increased cell cycle transition. In contrast, SAHA (5 mu M) treatment had reverse effects. Wound healing assay showed that, in MCF-7 and MDA-MB-231 cell line, cell migrating stimulated by Leptin was significantly repressed with SAHA treatment. Moreover, cell cycle real-time PCR array and proteome profiler antibody array confirmed that Leptin and SAHA treatment significantly changed the expressions of factors associated with cell cycle regulation and apoptosis including p53 and p21(WAF1/CIP1).
   In DNA-ChIP analysis, we found that acetylation levels binding with p21(WAF1/CIP1) promoters are regulated in a manner specific to histone type, lysine residue and selective promoter regions. SAHA significantly up-regulated the acetylation levels of AcH3-k14 and AcH3-k27 in MCF-7 cells, whereas Leptin repressed the modification. In addition, SAHA or Leptin had no significant effects on the AcH4 acetylation binding with any regions of p21(WAF1/CIP1) promoter. In MDA-MB-231 cells, SAHA alone or in combination with Leptin significantly increased acetylation levels of Ach3-k27, Ach3-k18 and Ach4-k5 residues. However, no clear change was found with Leptin alone at all. Overall, our data will inform future studies to elucidate the mechanisms of p21(WAF1/CIP1) transcriptional regulation, and the functional roles of p21(WAF1/CIP1) in breast cancer tumorigenesis.
C1 [Feng, Xiuyan] Shenyang Med Coll, Affiliated Hosp 2, Shenyang 110002, Liaoning Pro, Peoples R China.
   [Feng, Xiuyan; Han, Han; Zou, Dan; Zhou, Weiqiang] Shenyang Med Coll, Key Lab Environm Pollut & Microecol Liaoning Prov, Shenyang 110034, Liaoning Pro, Peoples R China.
   [Zhou, Jiaming] Northeast Yucai Foreign Language Sch, Shenyang 110179, Liaoning Pro, Peoples R China.
C3 Shenyang Medical College; Shenyang Medical College
RP Zhou, WQ (通讯作者)，Shenyang Med Coll, Key Lab Environm Pollut & Microecol Liaoning Prov, Shenyang 110034, Liaoning Pro, Peoples R China.
EM zhouwq@hotmail.com
FU National Natural Science Foundation of China [81172509]; Research
   Foundation of Science and Technology Department of Liaoning Province
   [2015010393-301, 201602735]
FX The work is supported by the National Natural Science Foundation of
   China (81172509), the Research Foundation of Science and Technology
   Department of Liaoning Province (2015010393-301, 201602735).
CR Aka JA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031532
   Alao JP, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-7
   Caldefie-Chézet F, 2005, BIOCHEM BIOPH RES CO, V334, P737, DOI 10.1016/j.bbrc.2005.06.077
   Catalano S, 2015, J CELL MOL MED, V19, P1122, DOI 10.1111/jcmm.12517
   Connolly R, 2012, J MAMMARY GLAND BIOL, V17, P191, DOI 10.1007/s10911-012-9263-3
   De Ruijter AJM, 2003, BIOCHEM J, V370, P737, DOI 10.1042/BJ20021321
   Dubois V, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058541
   Garofalo C, 2006, J CELL PHYSIOL, V207, P12, DOI 10.1002/jcp.20472
   Giordano C, 2016, ONCOTARGET, V7, P1262, DOI 10.18632/oncotarget.6014
   Gong YH, 2006, NUCLEIC ACIDS RES, V34, P6158, DOI 10.1093/nar/gkl834
   Gonzalez-Perez RR, 2010, CELL SIGNAL, V22, P1350, DOI 10.1016/j.cellsig.2010.05.003
   Gui CY, 2004, P NATL ACAD SCI USA, V101, P1241, DOI 10.1073/pnas.0307708100
   Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43
   Konduri SD, 2010, P NATL ACAD SCI USA, V107, P15081, DOI 10.1073/pnas.1009575107
   Kuljaca S, 2009, CARCINOGENESIS, V30, P1865, DOI 10.1093/carcin/bgp225
   Kwon HK, 2009, BIOL PHARM BULL, V32, P1723, DOI 10.1248/bpb.32.1723
   Lagger G, 2002, EMBO J, V21, P2672, DOI 10.1093/emboj/21.11.2672
   Lauricella M, 2012, BIOCHIMIE, V94, P287, DOI 10.1016/j.biochi.2011.06.031
   Blanquer-Rosselló MM, 2015, J CELL BIOCHEM, V116, P2039, DOI 10.1002/jcb.25158
   Munster PN, 2001, CANCER RES, V61, P8492
   Pal-Bhadra M, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-180
   Pischon T, 2008, P NUTR SOC, V67, P128, DOI 10.1017/S0029665108006976
   Saxena NK, 2007, J BIOL CHEM, V282, P13316, DOI 10.1074/jbc.M609798200
   Schmidt S, 2015, OBES REV, V16, P473, DOI 10.1111/obr.12281
   Scibetta AG, 2010, CELL CYCLE, V9, P4525, DOI 10.4161/cc.9.22.13746
   Shankar S, 2009, MOL CANCER THER, V8, P1596, DOI 10.1158/1535-7163.MCT-08-1004
   Somasundar P, 2003, J SURG RES, V113, P50, DOI 10.1016/S0022-4804(03)00166-5
   Spina A, 2012, BIORESEARCH OPEN ACC, V1, P324, DOI 10.1089/biores.2012.0270
   Strong AL, 2015, BREAST CANCER RES, V17, DOI 10.1186/s13058-015-0622-z
   Trécesson SD, 2011, J BIOL CHEM, V286, P12825, DOI 10.1074/jbc.M110.186437
   Witt AE, 2017, ONCOGENE, V36, P1707, DOI 10.1038/onc.2016.337
   Yi X, 2008, BIOCHEM PHARMACOL, V75, P1697, DOI 10.1016/j.bcp.2007.10.035
   Zhou W, 2011, BRIT J CANCER, V104, P128, DOI 10.1038/sj.bjc.6606013
   Zhou WQ, 2016, SCI REP-UK, V6, DOI 10.1038/srep28004
   Zhou WQ, 2011, CANCER BIOL THER, V11, P659, DOI 10.4161/cbt.11.7.14720
NR 35
TC 8
Z9 10
U1 0
U2 6
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD JAN 10
PY 2017
VL 8
IS 2
BP 3364
EP 3379
DI 10.18632/oncotarget.13764
PG 16
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA EH1EL
UT WOS:000391506300122
PM 27926517
OA Green Submitted, Green Published, gold
DA 2025-01-12
ER

PT J
AU Supic, G
   Kozomara, R
   Zeljic, K
   Jovic, N
   Magic, Z
AF Supic, Gordana
   Kozomara, Ruzica
   Zeljic, Katarina
   Jovic, Nebojsa
   Magic, Zvonko
TI Prognostic value of the DNMTs mRNA expression and genetic polymorphisms
   on the clinical outcome in oral cancer patients
SO CLINICAL ORAL INVESTIGATIONS
LA English
DT Article
DE Oral cancer; DNMT1; DNMT3A; DNMT3B; mRNA; Overexpression; Polymorphism;
   Overall survival; Relapse-free survival
ID DNA METHYLTRANSFERASE 1; SQUAMOUS-CELL CARCINOMAS; CPG ISLAND
   METHYLATION; BREAST-CANCER; POOR-PROGNOSIS; GASTRIC-CANCER; LUNG-CANCER;
   NECK-CANCER; HEAD; RISK
AB Although the importance of the epigenetic changes in tumors, including oral squamous cell carcinomas (OSCCs), is now becoming apparent, the mechanisms that trigger or cause aberrant DNA methylation in cancer are still unrevealed. DNA methylation is regulated by a family of enzymes, DNA methyltransferases (DNMTs). DNMT gene expression analysis, as well as genetic polymorphisms, has not been previously evaluated in OSCC.
   In 65 OSCC patients, SYBR Green real-time PCR method was assessed for relative quantification of DNMT1, DNMT3A, and DNMT3B mRNAs, normalized to TATA-binding protein (TBP) mRNA. The expression levels of all three genes were dichotomized as high or low, with a twofold change of normalized mRNA expression used as the cutoff value. Polymorphisms in DNMT1 (rs2228612) and DNMT3B (rs406193) were analyzed in 99 OSCCs by TaqMan SNPs genotyping assays.
   DNMT1, DNMT3A, and DNMT3B were overexpressed in 36.9, 26, and 23 % of the OSCC patients, respectively. DNMT1 overexpression was significantly associated with the overall survival, p = 0.029, and relapse-free survival of OSCC patients, p = 0.003. Patients with DNMT1 overexpression, as an independent prognostic factor, had a 2.385 times higher risk to relapse than those with lower expression. The DNMT1 A201G gene polymorphism was associated with a reduced overall survival in OSCC patients, p = 0.036.
   Our results suggest that DNMT1 could play an important role in modulating OSCC patient survival.
   DNMT gene expression could be a potential prognostic marker that might lead to an improvement in diagnosis, prognosis, and prospective use of epigenetic-targeted therapy of OSCC.
C1 [Supic, Gordana; Kozomara, Ruzica; Jovic, Nebojsa; Magic, Zvonko] Univ Def, Mil Med Acad, Fac Med, Belgrade, Serbia.
   [Supic, Gordana; Zeljic, Katarina; Magic, Zvonko] Mil Med Acad, Inst Med Res, Crnotravska 17, Belgrade 11002, Serbia.
   [Zeljic, Katarina] Univ Belgrade, Fac Biol, Belgrade, Serbia.
   [Kozomara, Ruzica; Jovic, Nebojsa] Mil Med Acad, Clin Maxillofacial Surg, Belgrade, Serbia.
C3 University of Belgrade; University of Belgrade; University of Belgrade
RP Supic, G (通讯作者)，Univ Def, Mil Med Acad, Fac Med, Belgrade, Serbia.; Supic, G (通讯作者)，Mil Med Acad, Inst Med Res, Crnotravska 17, Belgrade 11002, Serbia.
EM gogasupic@sezampro.rs
RI Zeljic, Katarina/K-4657-2015; Supic, Gordana/GSN-3402-2022
OI Supic, Gordana/0000-0003-0350-4733
FU Military Medical Academy, Belgrade, Serbia [MFVMA/14/12-14]
FX The work was supported by the Military Medical Academy, Belgrade,
   Serbia, grant No. MFVMA/14/12-14.
CR Agoston AT, 2005, J BIOL CHEM, V280, P18302, DOI 10.1074/jbc.M501675200
   Altman DG, 2012, PLOS MED, V9, DOI 10.1371/journal.pmed.1001216
   [Anonymous], 2014, CELL BIOSCI, V4, P46
   Arakawa Y, 2012, CLIN EXP IMMUNOL, V170, P194, DOI 10.1111/j.1365-2249.2012.04646.x
   Bièche I, 2004, MOL CANCER, V3, DOI 10.1186/1476-4598-3-37
   Chen CC, 2011, HEAD NECK-J SCI SPEC, V33, P1132, DOI 10.1002/hed.21586
   Daniel FI, 2010, ARCH ORAL BIOL, V55, P1024, DOI 10.1016/j.archoralbio.2010.08.009
   Delpu Y, 2013, INT J MOL SCI, V14, P15029, DOI 10.3390/ijms140715029
   Deng DJ, 2010, ADV GENET, V71, P125, DOI [10.1016/S0065-2660(10)71005-1, 10.1016/B978-0-12-380864-6.00005-5]
   Ding WJ, 2008, DIGEST DIS SCI, V53, P2083, DOI 10.1007/s10620-007-0145-2
   Egger G, 2006, P NATL ACAD SCI USA, V103, P14080, DOI 10.1073/pnas.0604602103
   Esteller M, 2007, HUM MOL GENET, V16, pR50, DOI 10.1093/hmg/ddm018
   Fatemi M, 2002, EUR J BIOCHEM, V269, P4981, DOI 10.1046/j.1432-1033.2002.03198.x
   Foran E, 2010, MOL CANCER RES, V8, P471, DOI 10.1158/1541-7786.MCR-09-0496
   Gao J, 2013, J EXP CLIN CANC RES, V32, DOI 10.1186/1756-9966-32-86
   Girault I, 2003, CLIN CANCER RES, V9, P4415
   Hajian-Tilaki K, 2013, CASP J INTERN MED, V4, P627
   Jair KW, 2006, CANCER RES, V66, P682, DOI 10.1158/0008-5472.CAN-05-1980
   Kar S, 2012, EPIGENETICS-US, V7, P994, DOI 10.4161/epi.21568
   Kassis ES, 2006, J THORAC CARDIOV SUR, V131, P298, DOI 10.1016/j.jtcvs.2005.05.022
   Kim HJ, 2006, CANCER, V107, P1042, DOI 10.1002/cncr.22087
   Kullmann K, 2013, CLIN EPIGENETICS, V5, DOI 10.1186/1868-7083-5-7
   Li X, 2014, GENES BRAIN BEHAV, V13, P721, DOI 10.1111/gbb.12150
   Liu ZS, 2008, CANCER LETT, V268, P158, DOI 10.1016/j.canlet.2008.03.034
   Marsit CJ, 2006, CANCER RES, V66, P10621, DOI 10.1158/0008-5472.CAN-06-1687
   Mascolo M, 2012, INT J MOL SCI, V13, P2331, DOI 10.3390/ijms13022331
   Mutze K, 2011, EUR J CANCER, V47, P1817, DOI 10.1016/j.ejca.2011.02.024
   Napso T, 2014, INT J ONCOL, V44, P1971, DOI 10.3892/ijo.2014.2386
   Oridate N, 2005, INT J ONCOL, V26, P757
   Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45
   Robertson KD, 1999, NUCLEIC ACIDS RES, V27, P2291, DOI 10.1093/nar/27.11.2291
   Saito Y, 2003, INT J CANCER, V105, P527, DOI 10.1002/ijc.11127
   Scully C, 2009, ORAL ONCOL, V45, P301, DOI 10.1016/j.oraloncology.2009.01.004
   Shaw R, 2006, INT J ORAL MAX SURG, V35, P101, DOI 10.1016/j.ijom.2005.06.014
   Shaw RJ, 2007, ORAL ONCOL, V43, P878, DOI 10.1016/j.oraloncology.2006.10.006
   Shiah Shine-Gwo, 2009, Oral Oncol, V45, pe1, DOI 10.1016/j.oraloncology.2008.03.003
   Sun MY, 2012, GENET MOL RES, V11, P4330, DOI 10.4238/2012.September.26.1
   Supic G, 2011, ORAL ONCOL, V47, P702, DOI 10.1016/j.oraloncology.2011.05.014
   Supic G, 2009, ORAL ONCOL, V45, P1051, DOI 10.1016/j.oraloncology.2009.07.007
   Suzuki M, 2009, CANCER CHEMOTH PHARM, V64, P223, DOI 10.1007/s00280-008-0833-4
   Wang J, 2012, ORAL ONCOL, V48, P541, DOI 10.1016/j.oraloncology.2012.01.007
   Wang L, 2004, INT J ONCOL, V25, P993
   Warnakulasuriya S, 2007, J ORAL PATHOL MED, V36, P575, DOI 10.1111/j.1600-0714.2007.00582.x
   Wu CT, 2011, CANCER-AM CANCER SOC, V117, P5221, DOI 10.1002/cncr.26150
   Xing J, 2008, BRIT J CANCER, V98, P1716, DOI 10.1038/sj.bjc.6604343
   Zhao SL, 2011, DIS ESOPHAGUS, V24, P601, DOI 10.1111/j.1442-2050.2011.01199.x
   Zhu J, 2015, MED ONCOL, V32, DOI 10.1007/s12032-014-0399-4
NR 47
TC 26
Z9 27
U1 0
U2 6
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 1432-6981
EI 1436-3771
J9 CLIN ORAL INVEST
JI Clin. Oral Investig.
PD JAN
PY 2017
VL 21
IS 1
BP 173
EP 182
DI 10.1007/s00784-016-1772-9
PG 10
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA EG9OL
UT WOS:000391388300020
PM 26966018
DA 2025-01-12
ER

PT J
AU Wu, WY
   Zhang, LT
   Lin, JQ
   Huang, HW
   Shi, B
   Lin, XG
   Huang, ZX
   Wang, CY
   Qiu, JL
   Wei, XL
AF Wu, Wenyi
   Zhang, Liting
   Lin, Jianqing
   Huang, Hanwei
   Shi, Bai
   Lin, Xingong
   Huang, Zhongxin
   Wang, Chaoyang
   Qiu, Jianlong
   Wei, Xiaolong
TI Hypermethylation of the HIC1 promoter and aberrant expression of
   HIC1/SIRT1 contribute to the development of thyroid papillary carcinoma
SO ONCOTARGET
LA English
DT Article
DE HIC1; SIRT1; papillary thyroid carcinoma; promoter hypermethylation
ID EPITHELIAL-MESENCHYMAL TRANSITION; TUMOR-SUPPRESSOR GENE; CANCER 1 HIC1;
   DNA METHYLATION; BREAST-CANCER; PROSTATE-CANCER; CELL CARCINOMA; ALLELIC
   LOSS; SIRT1; PROGRESSION
AB Hypermethylation leading to the loss of hypermethylated in cancer-1 (HIC1) gene expression occurs in many different types of human cancer. HIC1 is a transcriptional repressor that directly binds to the promoter region of NAD-dependent deacetylase sirtuin-1 (SIRT1). SIRT1 functions in cell growth, is anti-apoptotic, protect neurons, functions in senescence, and regulates energy restriction. Epigenetic modification and dysregulation affecting the HIC1/SIRT1 axis is potentially important for the development of malignancies. However, the importance of HIC1 expression in the development of papillary thyroid carcinoma, especially in Chinese patients, is uncertain. Therefore, we assessed the level of methylation in the HIC1 promoter and the mRNA and protein expression levels of HIC1 and SIRT1 in human thyroid papillary carcinoma and tumor adjacent control tissues. The demethylation reagent 5-aza-2'-deoxyctidine (5-aza-dc) and an HIC1 overexpression plasmid were used to manipulate the HIC1/SIRT1 pathway, and the effects on cell senescence, apoptosis, and cell cycle progression were assessed. Compared to normal thyroid tissue, thyroid tumors had lower expression of HIC1 and higher SIRT1 expression. The level of HIC1 methylation was also higher in thyroid carcinoma tissues than adjacent tissues. HIC1 expression was closely correlated with patient age and tumor progression. Restoration of HIC1 expression through an overexpression plasmid or 5-aza-dC treatment reduced SIRT1 expression and cell proliferation, and led to senescence, cell cycle arrest, and apoptosis. Aberrant expression of HIC1/SIRT1 and hypermethylation of the HIC1 promoter may be critical for the development and progression of papillary thyroid cancer.
C1 [Wu, Wenyi; Lin, Jianqing; Shi, Bai; Lin, Xingong; Huang, Zhongxin; Wang, Chaoyang] Fujian Med Univ, Affiliated Hosp 2, Dept Gen Surg, Quanzhou, Fujian, Peoples R China.
   [Zhang, Liting] 180th Mil Hosp Chinese Peoples, Liberat Army, Endocrine Dept, Quanzhou, Fujian, Peoples R China.
   [Huang, Hanwei] Guangdong Med Coll, Affiliated Zhongshan Hosp, Endocrine Dept, Zhongshan, Guangdong, Peoples R China.
   [Qiu, Jianlong] Fujian Med Univ, Affiliated Hosp 2, Dept Pathol, Quanzhou, Fujian, Peoples R China.
   [Wei, Xiaolong] Shantou Univ, Coll Med, Canc Hosp, Dept Pathol, Shantou, Guangdong, Peoples R China.
C3 Fujian Medical University; Guangdong Medical University; Fujian Medical
   University; Shantou University
RP Wu, WY (通讯作者)，Fujian Med Univ, Affiliated Hosp 2, Dept Gen Surg, Quanzhou, Fujian, Peoples R China.; Wei, XL (通讯作者)，Shantou Univ, Coll Med, Canc Hosp, Dept Pathol, Shantou, Guangdong, Peoples R China.
EM wwyii8522858@163.com; weixiaolonghh@126.com
RI Qiu, Jianlong/M-9984-2014
CR [Anonymous], ADV CROP SCI TECHNOL
   BARDWELL VJ, 1994, GENE DEV, V8, P1664, DOI 10.1101/gad.8.14.1664
   Boulay G, 2012, J BIOL CHEM, V287, P5379, DOI 10.1074/jbc.M111.304287
   Brieger J, 2010, ORAL ONCOL, V46, P678, DOI 10.1016/j.oraloncology.2010.06.016
   Briones VR, 2006, BIOCHEM BIOPH RES CO, V345, P595, DOI 10.1016/j.bbrc.2006.04.052
   Brooks CL, 2009, NAT REV CANCER, V9, P123, DOI 10.1038/nrc2562
   Carter MG, 2000, HUM MOL GENET, V9, P413, DOI 10.1093/hmg/9.3.413
   Chen WY, 2005, CELL, V123, P437, DOI 10.1016/j.cell.2005.08.011
   Chen YL, 2012, BIOCHEM BIOPH RES CO, V425, P290, DOI 10.1016/j.bbrc.2012.07.084
   Eggers H, 2012, INT J ONCOL, V40, P1650, DOI 10.3892/ijo.2012.1367
   Elangovan S, 2011, CANCER RES, V71, P6654, DOI 10.1158/0008-5472.CAN-11-1446
   Foveau B, 2012, J BIOL CHEM, V287, P5366, DOI 10.1074/jbc.M111.329466
   Frye RA, 1999, BIOCHEM BIOPH RES CO, V260, P273, DOI 10.1006/bbrc.1999.0897
   Huffman DM, 2007, CANCER RES, V67, P6612, DOI 10.1158/0008-5472.CAN-07-0085
   Kartal K, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1861-1
   Kilinc D, 2012, DNA CELL BIOL, V31, P826, DOI 10.1089/dna.2011.1431
   Kulis M, 2010, ADV GENET, V70, P27, DOI [10.1016/S0065-2660(10)70002-X, 10.1016/B978-0-12-380866-0.60002-2]
   Li P, 2015, ONCOTARGET, V6, P38151, DOI 10.18632/oncotarget.5832
   LiVolsi VA, 2011, MODERN PATHOL, V24, pS1, DOI 10.1038/modpathol.2010.129
   Morton RA, 1996, J UROLOGY, V156, P512, DOI 10.1016/S0022-5347(01)65916-0
   Nishida N, 2012, HEPATOLOGY, V56, P994, DOI 10.1002/hep.25706
   Parrella P, 2005, CANCER LETT, V222, P75, DOI 10.1016/j.canlet.2004.08.026
   Rood BR, 2002, CANCER RES, V62, P3794
   Ryall JG, 2015, CELL STEM CELL, V16, P171, DOI 10.1016/j.stem.2014.12.004
   Siraj AK, 2011, J CLIN ENDOCR METAB, V96, pE215, DOI 10.1210/jc.2010-0790
   Tseng RC, 2009, NEOPLASIA, V11, P763, DOI 10.1593/neo.09470
   WALES MM, 1995, NAT MED, V1, P570, DOI 10.1038/nm0695-570
   Wei XL, 2015, ONCOTARGET, V6, P21704, DOI 10.18632/oncotarget.3966
   Zhang B, 2009, ONCOGENE, V28, P651, DOI 10.1038/onc.2008.419
   Zhang DH, 2015, ARTERIOSCL THROM VAS, V35, P71, DOI 10.1161/ATVBAHA.114.303899
   Zhang QH, 2007, P NATL ACAD SCI USA, V104, P829, DOI 10.1073/pnas.0610590104
   Zhao G, 2013, ANN SURG ONCOL, V20, pS301, DOI 10.1245/s10434-012-2364-9
   Zheng JH, 2013, CLIN CANCER RES, V19, P1400, DOI 10.1158/1078-0432.CCR-12-2888
NR 33
TC 23
Z9 25
U1 0
U2 9
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
SN 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD DEC 20
PY 2016
VL 7
IS 51
BP 84416
EP 84427
DI 10.18632/oncotarget.12936
PG 12
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA EG9BT
UT WOS:000391353200050
PM 27793057
OA Green Published, Green Submitted, gold
DA 2025-01-12
ER

PT J
AU Scott, A
   Bai, F
   Chan, HL
   Liu, SQ
   Ma, JS
   Slingerland, JM
   Robbins, DJ
   Capobianco, AJ
   Pei, XH
AF Scott, Alexandria
   Bai, Feng
   Chan, Ho Lam
   Liu, Shiqin
   Ma, Jinshan
   Slingerland, Joyce M.
   Robbins, David J.
   Capobianco, Anthony J.
   Pei, Xin-Hai
TI <i>p16<SUP>INK4a</SUP></i> suppresses BRCA1-deficient mammary
   tumorigenesis
SO ONCOTARGET
LA English
DT Article
DE p16(INK4a); senescence; brca1; breast cancer
ID TUMOR-SUPPRESSOR; BREAST-CANCER; MESENCHYMAL TRANSITION;
   CELL-PROLIFERATION; OXIDATIVE STRESS; EPITHELIAL-CELLS; BASAL-LIKE;
   LUMINAL-B; BRCA1; SENESCENCE
AB Senescence prevents the proliferation of genomically damaged, but otherwise replication competent cells at risk of neoplastic transformation. p16INK4A (p16), an inhibitor of CDK4 and CDK6, plays a critical role in controlling cellular senescence in multiple organs. Functional inactivation of p16 by gene mutation and promoter methylation is frequently detected in human breast cancers. However, deleting p16 in mice or targeting DNA methylation within the murine p16 promoter does not result in mammary tumorigenesis. How loss of p16 contributes to mammary tumorigenesis in vivo is not fully understood.
   In this article, we reported that disruption of Brca1 in the mammary epithelium resulted in premature senescence that was rescued by p16 loss. We found that p16 loss transformed Brca1-deficient mammary epithelial cells and induced mammary tumors, though p16 loss alone was not sufficient to induce mammary tumorigenesis. We demonstrated that loss of both p16 and Brca1 led to metastatic, basal-like, mammary tumors with the induction of EMT and an enrichment of tumor initiating cells. We discovered that promoter methylation silenced p16 expression in most of the tumors developed in mice heterozygous for p16 and lacking Brca1. These data not only identified the function of p16 in suppressing BRCA1-deficient mammary tumorigenesis, but also revealed a collaborative effect of genetic mutation of p16 and epigenetic silencing of its transcription in promoting tumorigenesis. To the best of our knowledge, this is the first genetic evidence directly showing that p16 which is frequently deleted and inactivated in human breast cancers, collaborates with Brca1 controlling mammary tumorigenesis.
C1 [Scott, Alexandria; Bai, Feng; Chan, Ho Lam; Liu, Shiqin; Ma, Jinshan; Robbins, David J.; Capobianco, Anthony J.; Pei, Xin-Hai] Univ Miami, Miller Sch Med, Dept Surg, Mol Oncol Program, Miami, FL 33136 USA.
   [Scott, Alexandria; Pei, Xin-Hai] Univ Miami, Miller Sch Med, Sheila & David Fuente Grad Program Canc Biol, Miami, FL 33136 USA.
   [Slingerland, Joyce M.] Univ Miami, Miller Sch Med, Sylvester Canc Ctr, Braman Family Breast Canc Inst, Miami, FL 33136 USA.
   [Robbins, David J.; Capobianco, Anthony J.; Pei, Xin-Hai] Univ Miami, Miller Sch Med, Sylvester Canc Ctr, Miami, FL 33136 USA.
C3 University of Miami; University of Miami; University of Miami;
   University of Miami
RP Pei, XH (通讯作者)，Univ Miami, Miller Sch Med, Dept Surg, Mol Oncol Program, Miami, FL 33136 USA.; Pei, XH (通讯作者)，Univ Miami, Miller Sch Med, Sheila & David Fuente Grad Program Canc Biol, Miami, FL 33136 USA.; Pei, XH (通讯作者)，Univ Miami, Miller Sch Med, Sylvester Canc Ctr, Miami, FL 33136 USA.
EM xhpei@med.miami.edu
RI Bai, Feng/A-6778-2019; Ma, Jinshan/GPP-4203-2022; Pei,
   Xin-Hai/P-1812-2014
OI Capobianco, Anthony/0000-0002-3706-6797; Chan, Ho
   Lam/0000-0001-9799-0618; Liu, Shiqin/0000-0001-5238-7137; pei,
   xin-hai/0000-0001-6441-1691
CR Althuis MD, 2004, CANCER EPIDEM BIOMAR, V13, P1558
   Bai F, 2013, ONCOGENE, V32, P2715, DOI 10.1038/onc.2012.293
   Bai F, 2014, CANCER RES, V74, P6161, DOI 10.1158/0008-5472.CAN-14-1119
   Bai F, 2014, MOL CELL BIOL, V34, P2121, DOI 10.1128/MCB.01363-13
   Cao L, 2003, GENE DEV, V17, P201, DOI 10.1101/gad.1050003
   Cao L, 2007, CARCINOGENESIS, V28, P1401, DOI 10.1093/carcin/bgm060
   Cao L, 2006, EMBO J, V25, P2167, DOI 10.1038/sj.emboj.7601115
   De Summa S, 2013, ANN ONCOL, V24, P13, DOI 10.1093/annonc/mdt306
   Deng CX, 2000, ONCOGENE, V19, P1059, DOI 10.1038/sj.onc.1203269
   Drost RM, 2009, BRIT J CANCER, V101, P1651, DOI 10.1038/sj.bjc.6605350
   Elstrodt F, 2006, CANCER RES, V66, P41, DOI 10.1158/0008-5472.CAN-05-2853
   Feng Jing, 2009, Ai Zheng, V28, P436
   Foulkes WD, 2004, J MED GENET, V41, P1, DOI 10.1136/jmg.2003.013805
   Fridman AL, 2008, ONCOGENE, V27, P5975, DOI 10.1038/onc.2008.213
   Gorrini C, 2014, P NATL ACAD SCI USA, V111, P4472, DOI 10.1073/pnas.1324136111
   Gorrini C, 2013, J EXP MED, V210, P1529, DOI 10.1084/jem.20121337
   HERMAN JG, 1995, CANCER RES, V55, P4525
   Herschkowitz JI, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2142
   Janzen V, 2006, NATURE, V443, P421, DOI 10.1038/nature05159
   Jiang Z, 2010, J CLIN INVEST, V120, P3296, DOI 10.1172/JCI41490
   Jönsson G, 2012, CANCER RES, V72, P4028, DOI 10.1158/0008-5472.CAN-12-0097
   Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104
   KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634
   Kitagawa M, 1996, EMBO J, V15, P7060, DOI 10.1002/j.1460-2075.1996.tb01097.x
   Koboldt DC, 2012, NATURE
   Kotake Y, 2007, GENE DEV, V21, P49, DOI 10.1101/gad.1499407
   Krishnamurthty J, 2004, J CLIN INVEST, V114, P1299, DOI 10.1172/JCI200422475
   Krishnamurthy J, 2006, NATURE, V443, P453, DOI 10.1038/nature05092
   Marks JR, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3583
   Molofsky AV, 2006, NATURE, V443, P448, DOI 10.1038/nature05091
   Moynahan ME, 2002, ONCOGENE, V21, P8994, DOI 10.1038/sj.onc.1206177
   Orford KW, 2008, NAT REV GENET, V9, P115, DOI 10.1038/nrg2269
   Pei XH, 2005, ONCOGENE, V24, P2787, DOI 10.1038/sj.onc.1208611
   Pei XH, 2009, CANCER CELL, V15, P389, DOI 10.1016/j.ccr.2009.03.004
   Sedic M, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8505
   Sharpless NE, 2001, NATURE, V413, P86, DOI 10.1038/35092592
   Sharpless NE, 2002, CANCER RES, V62, P2761
   Sharpless NE, 2015, NAT REV CANCER, V15, P397, DOI 10.1038/nrc3960
   Sherr CJ, 2002, CANCER CELL, V2, P103, DOI 10.1016/S1535-6108(02)00102-2
   Stefansson OA, 2011, EPIGENETICS-US, V6, P638, DOI 10.4161/epi.6.5.15667
   Tlsty TD, 2004, J MAMMARY GLAND BIOL, V9, P263, DOI 10.1023/B:JOMG.0000048773.95897.5f
   Tu ZG, 2013, MOL CELL BIOL, V33, P1819, DOI 10.1128/MCB.01744-12
   Turner N, 2004, NAT REV CANCER, V4, P814, DOI 10.1038/nrc1457
   Wicha MS, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1990
   Wright MH, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1855
   Xu XL, 1999, NAT GENET, V22, P37, DOI 10.1038/8743
   Yu DH, 2014, J CLIN INVEST, V124, P3708, DOI 10.1172/JCI76507
   Zarkowska T, 1997, ONCOGENE, V14, P249, DOI 10.1038/sj.onc.1200824
   Zeng YX, 2011, CANCER RES, V71, P2781, DOI 10.1158/0008-5472.CAN-10-3483
   Zindy F, 1997, ONCOGENE, V15, P203, DOI 10.1038/sj.onc.1201178
NR 50
TC 11
Z9 13
U1 1
U2 4
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
SN 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD DEC 20
PY 2016
VL 7
IS 51
BP 84496
EP 84507
DI 10.18632/oncotarget.13015
PG 12
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA EG9BT
UT WOS:000391353200057
PM 27811360
OA Green Submitted, Green Published, gold
DA 2025-01-12
ER

PT J
AU Riveiro, ME
   Astorgues-Xerri, L
   Vazquez, R
   Frapolli, R
   Kwee, I
   Rinaldi, A
   Odore, E
   Rezai, K
   Bekradda, M
   Inghirami, G
   D'Incalci, M
   Noel, K
   Cvitkovic, E
   Raymond, E
   Bertoni, F
AF Riveiro, Maria E.
   Astorgues-Xerri, Lucile
   Vazquez, Ramiro
   Frapolli, Roberta
   Kwee, Ivo
   Rinaldi, Andrea
   Odore, Elodie
   Rezai, Keyvan
   Bekradda, Mohamed
   Inghirami, Giorgio
   D'Incalci, Maurizio
   Noel, Kay
   Cvitkovic, Esteban
   Raymond, Eric
   Bertoni, Francesco
TI OTX015 (MK-8628), a novel BET inhibitor, exhibits antitumor activity in
   non-small cell and small cell lung cancer models harboring different
   oncogenic mutations
SO ONCOTARGET
LA English
DT Article
DE OTX015 (MK-8628); bromodomain; NSCLC; SCLC; KRAS
ID BREAST-CANCER; BROMODOMAIN INHIBITION; C-MYC; TUMOR MICROENVIRONMENT;
   DOSE-ESCALATION; DOWN-REGULATION; TARGETING MYCN; ACUTE-LEUKEMIA;
   EXPRESSION; BRD4
AB Inhibitors targeting epigenetic control points of oncogenes offer a potential mean of blocking tumor progression in small cell and non-small cell lung carcinomas (SCLC, NSCLC). OTX015 (MK-8628) is a BET inhibitor selectively blocking BRD2/3/4. OTX015 was evaluated in a panel of NSCLC or SCLC models harboring different oncogenic mutations. Cell proliferation inhibition and cell cycle arrest were seen in sensitive NSCLC cells. MYC and MYCN were downregulated at both the mRNA and protein levels. In addition, OTX015-treatment significantly downregulated various stemness cell markers, including NANOG, Musashi-1, CD113 and EpCAM in H3122-tumors in vivo. Conversely, in SCLC models, weak antitumor activity was observed with OTX015, both in vitro and in vivo. No predictive biomarkers of OTX015 activity were identified in a large panel of candidate genes known to be affected by BET inhibition. In NSCLC models, OTX015 was equally active in both EML4-ALK positive and negative cell lines, whereas in SCLC models the presence of functional RB1 protein, which controls cell progression at G1, may be related to the final biological outcome of OTX015. Gene expression profiling in NSCLC and SCLC cell lines showed that OTX015 affects important genes and pathways with a very high overlapping between both sensitive and resistant cell lines. These data support the rationale for the OTX015 Phase Ib (NCT02259114) in solid tumors, where NSCLC patients with rearranged ALK gene or KRAS-positive mutations are currently being treated.
C1 [Riveiro, Maria E.; Astorgues-Xerri, Lucile; Bekradda, Mohamed; Cvitkovic, Esteban] Oncol Therapeut Dev, Clichy, France.
   [Vazquez, Ramiro; Frapolli, Roberta] IRCCS Ist Ric Farmacol Mario Negri, Milan, Italy.
   [Kwee, Ivo; Rinaldi, Andrea; Bertoni, Francesco] IOR Inst Oncol Res, Lymphoma & Genom Res Program, Bellinzona, Switzerland.
   Dalle Molle Inst Artificial Intelligence IDSIA, Manno, Switzerland.
   [Kwee, Ivo] SIB, Lausanne, Switzerland.
   [Odore, Elodie; Rezai, Keyvan] Rene Huguenin Hosp, Inst Curie, Radiopharmacol Dept, St Cloud, France.
   [Inghirami, Giorgio] Weill Cornell Med Coll, Dept Pathol & Lab Med, New York, NY USA.
   Univ Turin, Dept Mol Biotechnol & Hlth Sci, Turin, Italy.
   Univ Turin, Ctr Expt Res & Med Studies CeRMS, Turin, Italy.
   [Inghirami, Giorgio] NYU, Sch Med, Dept Pathol, New York, NY USA.
   [Inghirami, Giorgio] NYU, Sch Med, Ctr Canc, New York, NY USA.
   [Noel, Kay; Cvitkovic, Esteban] Oncoethix SA, Oncoethix GmbH, Luzern, Switzerland.
   [Raymond, Eric] CHU Vaudois, Dept Med Oncol, Lausanne, Switzerland.
   [Bertoni, Francesco] Oncol Inst Southern Switzerland IOSI, Bellinzona, Switzerland.
C3 Istituto di Ricerche Farmacologiche Mario Negri IRCCS; Universita della
   Svizzera Italiana; Institute of Oncology Research (IOR); Universita
   della Svizzera Italiana; Swiss Institute of Bioinformatics; UNICANCER;
   Universite PSL; Institut Curie; Rene Huguenin Hospital; Cornell
   University; Weill Cornell Medicine; University of Turin; University of
   Turin; New York University; New York University; University of Lausanne;
   Centre Hospitalier Universitaire Vaudois (CHUV); Institute of Oncology
   Research (IOR)
RP Riveiro, ME (通讯作者)，Oncol Therapeut Dev, Clichy, France.
EM eugenia.riveiro@oncotd.com
RI Frapolli, Roberta/AAA-6729-2020; D'Incalci, Maurizio/AAA-9021-2020;
   Bertoni, Francesco/G-6922-2014
OI D'Incalci, Maurizio/0000-0001-8784-1360; REZAI,
   Keyvan/0000-0002-3328-3102; Frapolli, Roberta/0000-0003-2907-273X;
   Bertoni, Francesco/0000-0001-5637-8983
CR Amorim S, 2016, LANCET HAEMATOL, V3, pE196, DOI 10.1016/S2352-3026(16)00021-1
   [Anonymous], CANC PRINCIPLES PRAC
   [Anonymous], HEMATOL ONCOL
   [Anonymous], MOL CANC RES
   [Anonymous], ANAL METHODS
   Berenguer-Daizé C, 2016, INT J CANCER, V139, P2047, DOI 10.1002/ijc.30256
   Berthon C, 2016, LANCET HAEMATOL, V3, pE186, DOI 10.1016/S2352-3026(15)00247-1
   Boi M, 2015, CLIN CANCER RES, V21, P1628, DOI 10.1158/1078-0432.CCR-14-1561
   Bouillez A, 2016, CANCER RES, V76, P1538, DOI 10.1158/0008-5472.CAN-15-1804
   Caetano MS, 2016, CANCER RES, V76, P3189, DOI 10.1158/0008-5472.CAN-15-2840
   Ceruti JM, 2005, ONCOGENE, V24, P4065, DOI 10.1038/sj.onc.1208570
   Chou TC, 2010, CANCER RES, V70, P440, DOI 10.1158/0008-5472.CAN-09-1947
   Civenni G, 2015, CANCER RES, V75, DOI 10.1158/1538-7445.AM2015-2625
   Coudé MM, 2015, ONCOTARGET, V6, P17698, DOI 10.18632/oncotarget.4131
   Crawford NPS, 2008, P NATL ACAD SCI USA, V105, P6380, DOI 10.1073/pnas.0710331105
   Delmore JE, 2011, CELL, V146, P903, DOI 10.1016/j.cell.2011.08.017
   Edgar R, 2002, NUCLEIC ACIDS RES, V30, P207, DOI 10.1093/nar/30.1.207
   Filippakopoulos P, 2012, CELL, V149, P214, DOI 10.1016/j.cell.2012.02.013
   French CA, 2003, CANCER RES, V63, P304
   Hänzelmann S, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-7
   Henssen A, 2013, ONCOTARGET, V4, DOI 10.18632/oncotarget.1534
   Henssen A, 2016, CLIN CANCER RES, V22, P2470, DOI 10.1158/1078-0432.CCR-15-1449
   Herrmann H, 2012, ONCOTARGET, V3, P1588, DOI 10.18632/oncotarget.733
   Hong SH, 2016, ONCOTARGET, V7, P32628, DOI 10.18632/oncotarget.8701
   Horne GA, 2015, STEM CELLS DEV, V24, P879, DOI 10.1089/scd.2014.0302
   Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43
   Karachaliou N, 2015, SCI REP-UK, V5, DOI 10.1038/srep17499
   Katayama R, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003316
   Larsen JE, 2014, MOLECULAR ONCOLOGY: CAUSES OF CANCER AND TARGETS FOR TREATMENT, P506
   Lee DH, 2015, INT J CANCER, V136, P2055, DOI 10.1002/ijc.29269
   Lenhart R, 2015, MOL CANCER THER, V14, P2167, DOI 10.1158/1535-7163.MCT-15-0037
   Lockwood WW, 2012, P NATL ACAD SCI USA, V109, P19408, DOI 10.1073/pnas.1216363109
   Marwitz S, 2016, CANCER RES, V76, P3785, DOI 10.1158/0008-5472.CAN-15-1326
   Mazur PK, 2015, NAT MED, V21, P1163, DOI 10.1038/nm.3952
   Melichar B, 2015, LANCET ONCOL, V16, P395, DOI 10.1016/S1470-2045(15)70051-3
   Mertz JA, 2011, P NATL ACAD SCI USA, V108, P16669, DOI 10.1073/pnas.1108190108
   Mujtaba S, 2007, ONCOGENE, V26, P5521, DOI 10.1038/sj.onc.1210618
   Noel JK, 2013, MOL CANCER THER, V12, DOI 10.1158/1535-7163.TARG-13-C244
   Odore E, 2016, CLIN PHARMACOKINET, V55, P397, DOI 10.1007/s40262-015-0327-6
   Ott CJ, 2012, BLOOD, V120, P2843, DOI 10.1182/blood-2012-02-413021
   Patnaik A, 2016, CANCER DISCOV, V6, P740, DOI 10.1158/2159-8290.CD-16-0095
   Politi K, 2015, CLIN CANCER RES, V21, P2213, DOI 10.1158/1078-0432.CCR-14-2748
   Pribluda A, 2015, CLIN CANCER RES, V21, P2916, DOI 10.1158/1078-0432.CCR-14-1213
   Puissant A, 2013, CANCER DISCOV, V3, P308, DOI 10.1158/2159-8290.CD-12-0418
   Qian BZ, 2011, NATURE, V475, P222, DOI 10.1038/nature10138
   Raetz EA, 2002, AM J PATHOL, V161, P875, DOI 10.1016/S0002-9440(10)64248-4
   Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007
   Sahai V, 2016, ONCOTARGET, V7, P53997, DOI 10.18632/oncotarget.9804
   Sequist LV, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002003
   Shaffer AL, 2001, IMMUNITY, V15, P375, DOI 10.1016/S1074-7613(01)00194-7
   Shaw AT, 2011, LANCET ONCOL, V12, P1004, DOI 10.1016/S1470-2045(11)70232-7
   Shimamura T, 2013, CLIN CANCER RES, V19, P6183, DOI 10.1158/1078-0432.CCR-12-3904
   Shimizu K, 2013, ANN TRANSL MED, V1, DOI 10.3978/j.issn.2305-5839.2013.06.01
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Vaishnavi A, 2013, NAT MED, V19, P1469, DOI 10.1038/nm.3352
   Vázquez R, 2015, CANCER RES, V75, DOI 10.1158/1538-7445.AM2015-3526
   Zhang GT, 2012, J BIOL CHEM, V287, P28840, DOI 10.1074/jbc.M112.359505
   Zhou YX, 2015, AM J RESP CELL MOL, V52, P183, DOI 10.1165/rcmb.2014-0054OC
NR 58
TC 43
Z9 49
U1 1
U2 15
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD DEC 20
PY 2016
VL 7
IS 51
BP 84675
EP 84687
DI 10.18632/oncotarget.13181
PG 13
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA EG9BT
UT WOS:000391353200072
PM 27835869
OA Green Published, gold, Green Submitted
DA 2025-01-12
ER

PT J
AU Wang, X
   Li, LP
   Wu, YZ
   Zhang, RH
   Zhang, MF
   Liao, D
   Wang, G
   Qin, G
   Xu, RH
   Kang, TB
AF Wang, Xin
   Li, Liping
   Wu, Yuanzhong
   Zhang, Ruhua
   Zhang, Meifang
   Liao, Dan
   Wang, Gang
   Qin, Ge
   Xu, Rui-Hua
   Kang, Tiebang
TI CBX4 Suppresses Metastasis via Recruitment of HDAC3 to the Runx2
   Promoter in Colorectal Carcinoma
SO CANCER RESEARCH
LA English
DT Article
ID CHROMOBOX PROTEIN CBX7; POLYCOMB GROUP PROTEIN;
   HEPATOCELLULAR-CARCINOMA; TRANSCRIPTION FACTOR-2; SUMO MODIFICATION;
   TUMOR-SUPPRESSOR; BREAST-CANCER; STEM-CELLS; PROLIFERATION; GENE
AB Polycomb chromobox (CBX) proteins participate in the polycomb repressive complex (PRC1) that mediates epigenetic gene silencing and endows PRC1 with distinct oncogenic or tumor suppressor functions in a cell-type-dependent manner. In this study, we report that inhibition of cell migration, invasion, and metastasis in colorectal carcinoma requires CBX4-mediated repression of Runx2, a key transcription factor that promotes colorectal carcinoma metastasis. CBX4 inversely correlated with Runx2 expression in colorectal carcinoma tissues, and the combination of high CBX4 expression and low Runx2 expression significantly correlated with overall survival, more so than either CBX4 or Runx2 expression alone. Mechanistically, CBX4 maintained recruited histone deacetylase 3 (HDAC3) to the Runx2 promoter, which maintained a deacetylated histone H3K27 state to suppress Runx2 expression. This function of CBX4 was dependent on its interaction with HDAC3, but not on its SUMO E3 ligase, its chromodomain, or the PRC1 complex. Disrupting the CBX4-HDAC3 interaction abolished Runx2 inhibition as well as the inhibition of cell migration and invasion. Collectively, our data show that CBX4 may act as a tumor suppressor in colorectal carcinoma, and strategies that stabilize the interaction of CBX4 with HDAC3 may benefit the colorectal carcinoma patients with metastases. (C) 2016 AACR.
C1 [Wang, Xin; Li, Liping; Wu, Yuanzhong; Zhang, Ruhua; Zhang, Meifang; Liao, Dan; Wang, Gang; Qin, Ge; Xu, Rui-Hua; Kang, Tiebang] Sun Yat Sen Univ, Ctr Canc, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Guangzhou, Guangdong, Peoples R China.
C3 State Key Lab Oncology South China; Sun Yat Sen University
RP Kang, TB (通讯作者)，Sun Yat Sen Univ, Ctr Canc, 651 Dongfeng East Rd, Guangzhou 510060, Guangdong, Peoples R China.
EM kangtb@sysucc.org.cn
RI Wang, Xin/HZL-4695-2023; wang, gang/ITT-0670-2023; Li,
   LiPing/HKE-9058-2023; Chen, Kai/ISB-8369-2023; liao, dan/LJM-5348-2024;
   Xu, Rui-Hua/AAW-4766-2021
OI Wu, Yuanzhong/0000-0002-3577-7069; Wang, Xin/0000-0002-9265-7741; Kang,
   Tiebang/0000-0001-8805-4174; Xu, Rui-Hua/0000-0001-9771-8534
FU Yangtze River Scholarship [85000-52121100]; National Key Research and
   Development Program of China [2016YFA0500304]; National Nature Science
   Foundation in China (NSFC) [81530081, 31571395]
FX This work received support from the Yangtze River Scholarship
   (85000-52121100 to T. Kang), the National Key Research and Development
   Program of China (no: 2016YFA0500304 to T. Kang), and the National
   Nature Science Foundation in China (NSFC; 81530081, 31571395 to T.
   Kang).
CR Altieri DC, 2009, J CELL BIOCHEM, V107, P845, DOI 10.1002/jcb.22162
   Caldwell S, 2009, J GASTROENTEROL, V44, P96, DOI 10.1007/s00535-008-2258-6
   Chen LF, 2012, J CELL BIOCHEM, V113, P1470, DOI 10.1002/jcb.24074
   Chimge NO, 2013, ONCOGENE, V32, P2121, DOI 10.1038/onc.2012.328
   Cohen-Solal KA, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0404-3
   Dahiya A, 2001, MOL CELL, V8, P557, DOI 10.1016/S1097-2765(01)00346-X
   Endo T, 2008, J CLIN ENDOCR METAB, V93, P2409, DOI 10.1210/jc.2007-2805
   Fischle W, 2003, GENE DEV, V17, P1870, DOI 10.1101/gad.1110503
   Forzati F, 2012, CELL CYCLE, V11, P1888, DOI 10.4161/cc.20022
   Forzati F, 2012, J CLIN INVEST, V122, P612, DOI 10.1172/JCI58620
   Gil J, 2014, TRENDS CELL BIOL, V24, P632, DOI 10.1016/j.tcb.2014.06.005
   Janes KA, 2011, CELL CYCLE, V10, P3461, DOI 10.4161/cc.10.20.18029
   Kagey MH, 2003, CELL, V113, P127, DOI 10.1016/S0092-8674(03)00159-4
   Kang XL, 2010, MOL CELL, V38, P191, DOI 10.1016/j.molcel.2010.03.005
   Kerppola TK, 2009, TRENDS CELL BIOL, V19, P692, DOI 10.1016/j.tcb.2009.10.001
   Klauke K, 2013, NAT CELL BIOL, V15, P353, DOI 10.1038/ncb2701
   Li B, 2007, BIOCHEM J, V405, P369, DOI 10.1042/BJ20061873
   Li J, 2014, CANCER CELL, V25, P118, DOI 10.1016/j.ccr.2013.12.008
   Liu B, 2013, DEVELOPMENT, V140, P780, DOI 10.1242/dev.085035
   Long JY, 2005, J BIOL CHEM, V280, P35477, DOI 10.1074/jbc.M504477200
   Luis NM, 2011, CELL STEM CELL, V9, P233, DOI 10.1016/j.stem.2011.07.013
   Margueron R, 2011, NATURE, V469, P343, DOI 10.1038/nature09784
   Mei Z, 2014, SCI CHINA LIFE SCI, V57, P610, DOI 10.1007/s11427-014-4663-9
   Oh Y, 2012, J BIOL CHEM, V287, P17517, DOI 10.1074/jbc.M111.336354
   Sase T, 2012, INT J CANCER, V131, P2284, DOI 10.1002/ijc.27525
   Satijn DPE, 1997, MOL CELL BIOL, V17, P6076, DOI 10.1128/MCB.17.10.6076
   Sauvageau M, 2010, CELL STEM CELL, V7, P299, DOI 10.1016/j.stem.2010.08.002
   Schoeftner S, 2006, EMBO J, V25, P3110, DOI 10.1038/sj.emboj.7601187
   Scott CL, 2007, P NATL ACAD SCI USA, V104, P5389, DOI 10.1073/pnas.0608721104
   Simon JA, 2009, NAT REV MOL CELL BIO, V10, P697, DOI 10.1038/nrm2763
   Sun SS, 2015, CANCER LETT, V361, P1, DOI 10.1016/j.canlet.2015.02.042
   Tan JY, 2011, CANCER CELL, V20, P563, DOI 10.1016/j.ccr.2011.09.008
   Tang JJ, 2014, ONCOTARGET, V5, P10778, DOI 10.18632/oncotarget.2502
   Urvalek AM, 2014, J BIOL CHEM, V289, P19519, DOI 10.1074/jbc.M114.556555
   Wai PY, 2006, J BIOL CHEM, V281, P18973, DOI 10.1074/jbc.M511962200
   Wang BQ, 2013, ANN SURG ONCOL, V20, pS684, DOI 10.1245/s10434-013-3171-7
   Wotton D, 2007, BIOCHEM SOC T, V35, P1401, DOI 10.1042/BST0351401
   Wu YZ, 2016, CELL DISCOV, V2, DOI 10.1038/celldisc.2016.14
   Yang SH, 2010, MOL CELL BIOL, V30, P2193, DOI 10.1128/MCB.01510-09
   Ye GD, 2016, GASTROENTEROLOGY, V150, P659, DOI 10.1053/j.gastro.2015.11.041
   Zhang XW, 2010, J EXP CLIN CANC RES, V29, DOI 10.1186/1756-9966-29-114
NR 41
TC 71
Z9 81
U1 0
U2 16
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD DEC 15
PY 2016
VL 76
IS 24
BP 7277
EP 7289
DI 10.1158/0008-5472.CAN-16-2100
PG 13
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA EH0RE
UT WOS:000391470600020
PM 27864346
OA Green Submitted
DA 2025-01-12
ER

PT J
AU Lee, S
   Lee, H
   Bae, H
   Choi, EH
   Kim, SJ
AF Lee, Seungyeon
   Lee, Hyunkyung
   Bae, Hansol
   Choi, Eun H.
   Kim, Sun Jung
TI Epigenetic silencing of miR-19a-3p by cold atmospheric plasma
   contributes to proliferation inhibition of the MCF-7 breast cancer cell
SO SCIENTIFIC REPORTS
LA English
DT Article
ID EXPRESSION; KERATINOCYTES; CARCINOMA; APOPTOSIS; AUTOPHAGY; GROWTH;
   PTEN; JET
AB Cold atmospheric plasma (CAP) has been proposed as a useful cancer treatment option after showing higher induction of cell death in cancer cells than in normal cells. Although a few studies have contributed to elucidating the molecular mechanism by which CAP differentially inhibits cancer cell proliferation, no results are yet to be reported related to microRNA (miR). In this study, miR-19a-3p (miR-19a) was identified as a mediator of the cell proliferation-inhibitory effect of CAP in the MCF-7 breast cancer cell. CAP treatment of MCF-7 induced hypermethylation at the promoter CpG sites and downregulation of miR-19a, which was known as an oncomiR. The overexpression of miR-19a in MCF-7 increased cell proliferation, and CAP deteriorated the effect. The target genes of miR-19a, such as ABCA1 and PTEN, that had been suppressed by miR recovered their expression through CAP treatment. In addition, an inhibitor of reactive oxygen species that is produced by CAP suppressed the effect of CAP on cell proliferation. Taken together, the present study, to the best of authors' knowledge, is the first to identify the involvement of a miR, which is dysregulated by the CAP and results in the anti-proliferation effect of CAP on cancer cells.
C1 [Lee, Seungyeon; Lee, Hyunkyung; Bae, Hansol; Kim, Sun Jung] Dongguk Univ Seoul, Dept Life Sci, Goyang, South Korea.
   [Choi, Eun H.] Kwangwoon Univ, Plasma Biosci Res Ctr, Seoul, South Korea.
C3 Dongguk University; Kwangwoon University
RP Kim, SJ (通讯作者)，Dongguk Univ Seoul, Dept Life Sci, Goyang, South Korea.
EM sunjungk@dongguk.edu
RI Choi, Eun/AFN-9488-2022; kim, sun/T-1013-2019; Bae, Hansol/AGH-4590-2022
OI Bae, Hansol/0000-0003-3802-3358; Jun, Yongseok/0000-0003-1463-6723;
   Choi, Eun Ha/0000-0001-5385-1878
FU Science Research Center Program through the National Research Foundation
   of Korea (NRF) - Ministry of Education, Science, and Technology
   [NRF-2010-0027963]
FX This study was supported by the Science Research Center Program through
   the National Research Foundation of Korea (NRF) funded by the Ministry
   of Education, Science, and Technology (NRF-2010-0027963).
CR Adachi T, 2015, FREE RADICAL BIO MED, V79, P28, DOI 10.1016/j.freeradbiomed.2014.11.014
   Ahn HJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086173
   Arndt S, 2013, EXP DERMATOL, V22, P284, DOI 10.1111/exd.12127
   Azad MB, 2009, ANTIOXID REDOX SIGN, V11, P777, DOI [10.1089/ars.2008.2270, 10.1089/ARS.2008.2270]
   Bekeschus S, 2014, FREE RADICAL RES, V48, P542, DOI 10.3109/10715762.2014.892937
   Bernstein BE, 2007, CELL, V128, P669, DOI 10.1016/j.cell.2007.01.033
   Bundscherer L, 2013, IMMUNOBIOLOGY, V218, P1248, DOI 10.1016/j.imbio.2013.04.015
   Cai ZL, 2011, INT J RADIAT BIOL, V87, P1135, DOI 10.3109/09553002.2011.622033
   Cho S, 2013, NUCLEIC ACIDS RES, V41, pD252, DOI 10.1093/nar/gks1168
   Chou JL, 2015, CLIN EPIGENETICS, V7, DOI 10.1186/s13148-014-0036-2
   de Brachène AC, 2014, BIOCHEM J, V460, P25, DOI 10.1042/BJ20131467
   Dou L, 2015, SCI REP-UK, V5, DOI 10.1038/srep11602
   Fisher AB, 2009, ANTIOXID REDOX SIGN, V11, P1349, DOI 10.1089/ARS.2008.2378
   Fu XL, 2016, PROSTATE, V76, P543, DOI 10.1002/pros.23143
   Gupta SC, 2012, ANTIOXID REDOX SIGN, V16, P1295, DOI 10.1089/ars.2011.4414
   Haertel B, 2012, CELL BIOL INT, V36, P1217, DOI 10.1042/CBI20120139
   Hattori N, 2015, INT J ONCOL, V47, P1655, DOI 10.3892/ijo.2015.3149
   Hou J, 2015, BMC GENOMICS, V16, DOI 10.1186/s12864-015-1644-8
   Hsu TI, 2014, ONCOGENESIS, V3, DOI 10.1038/oncsis.2014.12
   Kalghatgi S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016270
   Keidar M, 2011, BRIT J CANCER, V105, P1295, DOI 10.1038/bjc.2011.386
   Kim SJ, 2016, SCI REP-UK, V6, DOI 10.1038/srep20332
   Kumar N, 2014, SCI REP-UK, V4, DOI 10.1038/srep07589
   Li W, 2016, SCI REP-UK, V6, DOI 10.1038/srep19720
   Mo WJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056592
   Morales-Ramírez P, 2013, RADIAT RES, V179, P669, DOI 10.1667/RR3223.1
   Nishikawa R, 2014, INT J ONCOL, V45, P401, DOI 10.3892/ijo.2014.2437
   Panngom K, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.168
   Park SB, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129931
   Plante I, 2011, ONCOGENE, V30, P1681, DOI 10.1038/onc.2010.551
   Shan SW, 2013, J CELL SCI, V126, P1517, DOI 10.1242/jcs.122895
   Shan Y, 2016, NUTR CANCER, V68, P280, DOI 10.1080/01635581.2016.1142587
   Singha Prajjal K, 2014, Genes Cancer, V5, P320
   Tan YG, 2015, ONCOTARGET, V6, P17391, DOI 10.18632/oncotarget.3975
   Ulrich C, 2015, J WOUND CARE, V24, P196, DOI 10.12968/jowc.2015.24.5.196
   Utsumi F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081576
   Veeck J, 2010, J MAMMARY GLAND BIOL, V15, P5, DOI 10.1007/s10911-010-9165-1
   Virard F, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133120
   Wang MY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072189
   Wei CY, 2015, INT J CLIN EXP PATHO, V8, P14619
   Weiss M, 2015, IN VIVO, V29, P611
   Welz C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0141827
   Wu Q, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.110
   Xu GM, 2015, WOUND REPAIR REGEN, V23, P878, DOI 10.1111/wrr.12364
   Zearo S, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-200
   Zhong SY, 2016, BRIT J DERMATOL, V174, P542, DOI 10.1111/bjd.14236
   Zucker SN, 2012, CANCER BIOL THER, V13, P1299, DOI 10.4161/cbt.21787
NR 47
TC 117
Z9 120
U1 0
U2 12
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD JUL 21
PY 2016
VL 6
AR 30005
DI 10.1038/srep30005
PG 10
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA EH9IM
UT WOS:000392085000001
PM 27445062
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Park, J
   Kwon, YW
   Ham, S
   Hong, CP
   Seo, S
   Choe, MK
   Shin, SI
   Lee, CS
   Kim, HS
   Roh, TY
AF Park, Jihwan
   Kwon, Yoo-Wook
   Ham, Seokjin
   Hong, Chang-Pyo
   Seo, Seonghye
   Choe, Moon Kyung
   Shin, So-I
   Lee, Choon-Soo
   Kim, Hyo-Soo
   Roh, Tae-Young
TI Identification of the early and late responder genes during the
   generation of induced pluripotent stem cells from mouse fibroblasts
SO PLOS ONE
LA English
DT Article
ID BREAST-CANCER CELLS; HUMAN SOMATIC-CELLS; HISTONE MODIFICATIONS;
   CHROMATIN-STRUCTURE; IPS CELLS; EXPRESSION SIGNATURES; IMPRINTED GENES;
   DEFINED FACTORS; HUMAN GENOME; T-CELLS
AB Background
   The generation of induced pluripotent stem cell (iPSC), a substitute for embryonic stem cell (ESC), requires the proper orchestration of a transcription program at the chromatin level. Our recent approach for the induction of pluripotent stem cells from fibroblasts using protein extracts from mouse ESCs could overcome the potential tumorigenicity risks associated with random retroviral integration. Here, we examine the epigenetic modifications and the transcriptome of two types of iPSC and of partially reprogrammed iPSCs (iPSCp) generated independently from adult cardiac and skin fibroblasts to assess any perturbations of the transcription program during reprogramming.
   Results
   The comparative dissection of the transcription profiles and histone modification patterns at lysines 4 and 27 of histone H3 of the iPSC, iPSCp, ESC, and somatic cells revealed that the iPSC was almost completely comparable to the ESC, regardless of their origins, whereas the genes of the iPSCp were dysregulated to a larger extent. Regardless of the origins of the somatic cells, the fibroblasts induced using the ESC protein extracts appear to be completely reprogrammed into pluripotent cells, although they show unshared marginal differences in their gene expression programs, which may not affect the maintenance of stemness. A comparative investigation of the iPSCp generated by unwanted reprogramming showed that the two groups of genes on the pathway from somatic cells to iPSC might function as sequential reprogramming-competent early and late responders to the induction stimulus. Moreover, some of the divergent genes expressed only in the iPSCp were associated with many tumor-related pathways.
   Conclusions
   Faithful transcriptional reprogramming should follow epigenetic alterations to generate induced pluripotent stem cells from somatic cells. This genome-wide comparison enabled us to define the early and late responder genes during the cell reprogramming process to iPSC. Our results indicate that the cellular responsiveness to external stimuli should be predetermined and sequentially orchestrated through the tight modulation of the chromatin environment during cell reprogramming to prevent unexpected reprogramming.
C1 [Park, Jihwan; Ham, Seokjin; Hong, Chang-Pyo; Seo, Seonghye; Choe, Moon Kyung; Shin, So-I; Roh, Tae-Young] Pohang Univ Sci & Technol POSTECH, Dept Life Sci, Pohang, South Korea.
   [Kwon, Yoo-Wook; Lee, Choon-Soo; Kim, Hyo-Soo] Seoul Natl Univ, Natl Res Lab Stem Cell Niche, Coll Med, Seoul, South Korea.
   [Kwon, Yoo-Wook; Kim, Hyo-Soo] Seoul Natl Univ Hosp, Innovat Res Inst Cell Therapy, Seoul, South Korea.
   [Kwon, Yoo-Wook; Kim, Hyo-Soo] Seoul Natl Univ Hosp, Cardiovasc Ctr, Seoul, South Korea.
   [Kwon, Yoo-Wook; Kim, Hyo-Soo] Seoul Natl Univ Hosp, Dept Internal Med, Seoul, South Korea.
   [Kim, Hyo-Soo] Seoul Natl Univ, Grad Sch Convergence Sci & Technol, Dept Mol Med & Biopharmaceut Sci, Seoul, South Korea.
   [Kim, Hyo-Soo] Seoul Natl Univ, Coll Med, Seoul, South Korea.
   [Kim, Hyo-Soo] Seoul Natl Univ, Coll Pharm, Seoul, South Korea.
   [Roh, Tae-Young] Pohang Univ Sci & Technol POSTECH, Div Integrat Biosci & Biotechnol, Pohang, South Korea.
C3 Pohang University of Science & Technology (POSTECH); Seoul National
   University (SNU); Seoul National University (SNU); Seoul National
   University Hospital; Seoul National University (SNU); Seoul National
   University Hospital; Seoul National University (SNU); Seoul National
   University Hospital; Seoul National University (SNU); Seoul National
   University (SNU); Seoul National University (SNU); Pohang University of
   Science & Technology (POSTECH)
RP Roh, TY (通讯作者)，Pohang Univ Sci & Technol POSTECH, Dept Life Sci, Pohang, South Korea.; Roh, TY (通讯作者)，Pohang Univ Sci & Technol POSTECH, Div Integrat Biosci & Biotechnol, Pohang, South Korea.
EM tyroh@postech.edu
RI Ham, SeokJin/A-2948-2012; Kim, Yong Hoon/IYJ-6587-2023; Hong,
   Chang/I-6813-2019; Park, Jihwan/ISA-0615-2023
OI Roh, Tae-Young/0000-0001-5833-0844; Hong, Chang Pyo/0000-0001-5030-1248;
   Ham, Seokjin/0000-0002-6950-2848; Park, Jihwan/0000-0002-5728-912X
FU National Research Foundation of Korea [NRF-2015M3A9B4051044,
   2011-0030049, NRF-2014M3C9A3064548]; BK21 PLUS fellowship program -
   Ministry of Education, Korea [10Z20130012243]
FX This work was supported by grants from the National Research Foundation
   of Korea (NRF-2015M3A9B4051044, 2011-0030049, and NRF-2014M3C9A3064548
   to TYR) and BK21 PLUS fellowship program funded by the Ministry of
   Education, Korea (10Z20130012243 to JP, SH, and SIS).
CR Aasen T, 2008, NAT BIOTECHNOL, V26, P1276, DOI 10.1038/nbt.1503
   Anokye-Danso F, 2011, CELL STEM CELL, V8, P376, DOI 10.1016/j.stem.2011.03.001
   Araki Y, 2009, IMMUNITY, V30, P912, DOI 10.1016/j.immuni.2009.05.006
   Bae Jae-Bum, 2013, Genomics & Informatics, V11, P7, DOI 10.5808/GI.2013.11.1.7
   Bannister AJ, 2011, CELL RES, V21, P381, DOI 10.1038/cr.2011.22
   Barski A, 2007, CELL, V129, P823, DOI 10.1016/j.cell.2007.05.009
   Bernstein BE, 2006, CELL, V125, P315, DOI 10.1016/j.cell.2006.02.041
   Bernstein BE, 2010, NAT BIOTECHNOL, V28, P1045, DOI 10.1038/nbt1010-1045
   Bock C, 2011, CELL, V144, P439, DOI 10.1016/j.cell.2010.12.032
   Chen JK, 2011, CELL RES, V21, P205, DOI 10.1038/cr.2010.172
   Chin MH, 2009, CELL STEM CELL, V5, P111, DOI 10.1016/j.stem.2009.06.008
   Cho HJ, 2010, BLOOD, V116, P386, DOI 10.1182/blood-2010-02-269589
   Choe MK, 2012, BIOCHEM BIOPH RES CO, V418, P475, DOI 10.1016/j.bbrc.2012.01.042
   Christodoulou C, 2011, J CLIN INVEST, V121, P2313, DOI 10.1172/JCI43853
   Doi A, 2009, NAT GENET, V41, P1350, DOI 10.1038/ng.471
   Dunham I, 2012, NATURE, V489, P57, DOI 10.1038/nature11247
   Eminli S, 2008, STEM CELLS, V26, P2467, DOI 10.1634/stemcells.2008-0317
   Guenther MG, 2010, CELL STEM CELL, V7, P249, DOI 10.1016/j.stem.2010.06.015
   Hanna J, 2007, SCIENCE, V318, P1920, DOI 10.1126/science.1152092
   Hong Chang Pyo, 2012, Genomics & Informatics, V10, P145
   Jin J, 2011, J PROTEOME RES, V10, P977, DOI 10.1021/pr100624f
   Kang L, 2011, CELL RES, V21, P546, DOI 10.1038/cr.2010.164
   Kang L, 2009, CELL STEM CELL, V5, P135, DOI 10.1016/j.stem.2009.07.001
   Koche RP, 2011, CELL STEM CELL, V8, P96, DOI 10.1016/j.stem.2010.12.001
   Lowry WE, 2008, P NATL ACAD SCI USA, V105, P2883, DOI 10.1073/pnas.0711983105
   Maherali N, 2007, CELL STEM CELL, V1, P55, DOI 10.1016/j.stem.2007.05.014
   Mattout A, 2011, J MOL CELL BIOL, V3, P341, DOI 10.1093/jmcb/mjr028
   Mikkelsen TS, 2008, NATURE, V454, P49, DOI 10.1038/nature07056
   Mikkelsen TS, 2007, NATURE, V448, P553, DOI 10.1038/nature06008
   Nakagawa M, 2008, NAT BIOTECHNOL, V26, P101, DOI 10.1038/nbt1374
   Newman AM, 2010, CELL STEM CELL, V7, P258, DOI 10.1016/j.stem.2010.06.016
   Okita K, 2008, SCIENCE, V322, P949, DOI 10.1126/science.1164270
   Okita K, 2007, NATURE, V448, P313, DOI 10.1038/nature05934
   Park IH, 2008, NATURE, V451, P141, DOI [10.1038/nature06534, 10.1038/natureO6534]
   Plath K, 2011, NAT REV GENET, V12, P253, DOI 10.1038/nrg2955
   Polo JM, 2010, NAT BIOTECHNOL, V28, P848, DOI 10.1038/nbt.1667
   Rais Y, 2013, NATURE, V502, P65, DOI 10.1038/nature12587
   Roh TY, 2006, P NATL ACAD SCI USA, V103, P15782, DOI 10.1073/pnas.0607617103
   Roh TY, 2005, GENE DEV, V19, P542, DOI 10.1101/gad.1272505
   Sridharan R, 2009, CELL, V136, P364, DOI 10.1016/j.cell.2009.01.001
   Stadtfeld M, 2008, SCIENCE, V322, P945, DOI 10.1126/science.1162494
   Stadtfeld M, 2008, CURR BIOL, V18, P890, DOI 10.1016/j.cub.2008.05.010
   Stadtfeld M, 2010, NATURE, V465, P175, DOI 10.1038/nature09017
   Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019
   Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024
   Voigt P, 2013, GENE DEV, V27, P1318, DOI 10.1101/gad.219626.113
   Wang ZB, 2008, NAT GENET, V40, P897, DOI 10.1038/ng.154
   Wei G, 2009, IMMUNITY, V30, P155, DOI 10.1016/j.immuni.2008.12.009
   Yavartanoo Maryam, 2013, Genomics & Informatics, V11, P2, DOI 10.5808/GI.2013.11.1.2
   Zhao XD, 2007, CELL STEM CELL, V1, P286, DOI 10.1016/j.stem.2007.08.004
   Zhou HY, 2009, CELL STEM CELL, V4, P381, DOI 10.1016/j.stem.2009.04.005
   Zhou VW, 2011, NAT REV GENET, V12, P7, DOI 10.1038/nrg2905
NR 52
TC 3
Z9 5
U1 0
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 2
PY 2017
VL 12
IS 2
AR e0171300
DI 10.1371/journal.pone.0171300
PG 18
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA EN7DB
UT WOS:000396161200123
PM 28152015
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Takahashi, H
   Kagara, N
   Tanei, T
   Naoi, Y
   Shimoda, M
   Shimomura, A
   Shimazu, K
   Kim, SJ
   Noguchi, S
AF Takahashi, Hiroyo
   Kagara, Naofumi
   Tanei, Tomonori
   Naoi, Yasuto
   Shimoda, Masafumi
   Shimomura, Atsushi
   Shimazu, Kenzo
   Kim, Seung Jin
   Noguchi, Shinzaburo
TI Correlation of Methylated Circulating Tumor DNA With Response to
   Neoadjuvant Chemotherapy in Breast Cancer Patients
SO CLINICAL BREAST CANCER
LA English
DT Article
DE Diagnostic marker; OS-MSP; Predictive marker; RASSF1A methylation; Tumor
   burden
ID PROMOTER HYPERMETHYLATION; SERUM DNA; NUCLEIC-ACIDS; BIOMARKERS; GENES;
   EFFICACY; THERAPY; PLASMA; CELLS; CEA
AB Correlation of methylated circulating tumor DNA (met-ctDNA) with tumor response to neoadjuvant chemotherapy (NAC) was evaluated in breast cancer patients. In patients with positive met-ctDNA before NAC, metctDNA significantly correlated with tumor response and was found to be a more sensitive marker than carcinoembryonic antigen and cancer-associated antigen 15-3. The possibility has also been suggested that met-ctDNA might be useful in monitoring the postoperative recurrence.
   Background: Circulating tumor DNA (ctDNA) is known to harbor tumor-specific genetic or epigenetic alterations. In the present study, the correlation of ctDNA with tumor response to neoadjuvant chemotherapy (NAC) was evaluated in primary breast cancer patients. Patients and Methods: Plasma samples were obtained from 87 primary breast cancer patients (stage II-III) before and after NAC, as well as 1 year after surgery. Methylated ctDNA (met-ctDNA) was determined by one-step methylation-specific PCR (OS-MSP) for the promoter region of RASSF1A. Results: The positivity (23.0%, 20/87) of met-ctDNA before NAC was significantly (P < .05) higher than that of carcinoembryonic antigen (CEA) (8.6%) and cancer-associated antigen (CA) 15-3 (7.4%). In the patients with positive met-ctDNA before NAC, met-ctDNA significantly decreased after NAC in those with disease that responded to therapy (P = .006), but not in patients whose disease did not respond to therapy. Met-ctDNA after NAC was found to be significantly (P = .008) correlated to the extent of residual tumor burden. Of the 7 patients who showed an increase in met-ctDNA at 1 year after surgery, 3 developed recurrence. Conclusion: Met-ctDNA is a more sensitive marker than CEA and CA15-3, and it might be useful in monitoring the clinical tumor response to NAC. In addition, the potential use of met-ctDNA as a tumor marker for monitoring postoperative recurrence has been suggested.
C1 [Takahashi, Hiroyo; Kagara, Naofumi; Tanei, Tomonori; Naoi, Yasuto; Shimoda, Masafumi; Shimomura, Atsushi; Shimazu, Kenzo; Kim, Seung Jin; Noguchi, Shinzaburo] Osaka Univ, Grad Sch Med, Dept Breast & Endocrine Surg, 2-2-E10 Yamadaoka, Suita, Osaka 5650871, Japan.
C3 Osaka University
RP Kagara, N (通讯作者)，Osaka Univ, Grad Sch Med, Dept Breast & Endocrine Surg, 2-2-E10 Yamadaoka, Suita, Osaka 5650871, Japan.
EM kagaran@onsurg.med.osaka-u.ac.jp
RI 真史, 下田/GRS-6091-2022
FU Sysmex Co Ltd.; Grants-in-Aid for Scientific Research [15K10052] Funding
   Source: KAKEN
FX S. Noguchi received research funding and S. Noguchi and Y. Naoi received
   honoraria from Sysmex Co Ltd. The other authors have stated that they
   have no conflict of interest.
CR [Anonymous], 2015, RES INT, DOI [DOI 10.1155/2015/421746.16, DOI 10.1155/2015/278931]
   Avraham A, 2012, INT J CANCER, V131, pE1166, DOI 10.1002/ijc.27526
   Beckmann MW, 2009, BREAST CARE, V4, P109, DOI 10.1159/000212164
   Bottini A, 1997, TUMOR BIOL, V18, P301, DOI 10.1159/000218043
   Brooks JD, 2010, CANCER EPIDEMIOL, V34, P717, DOI 10.1016/j.canep.2010.05.006
   Crowley E, 2013, NAT REV CLIN ONCOL, V10, P472, DOI 10.1038/nrclinonc.2013.110
   Dawson SJ, 2013, NEW ENGL J MED, V368, P1199, DOI 10.1056/NEJMoa1213261
   Diaz LA, 2014, J CLIN ONCOL, V32, P579, DOI 10.1200/JCO.2012.45.2011
   Diehl F, 2008, NAT MED, V14, P985, DOI 10.1038/nm.1789
   Elston C W, 2002, Histopathology, V41, P154
   Fackler MJ, 2014, CANCER RES, V74, P2160, DOI 10.1158/0008-5472.CAN-13-3392
   Fiegl H, 2005, CANCER RES, V65, P1141, DOI 10.1158/0008-5472.CAN-04-2438
   Fleischhacker M, 2007, BBA-REV CANCER, V1775, P181, DOI 10.1016/j.bbcan.2006.10.001
   Fujita N, 2014, ONCOL LETT, V8, P397, DOI 10.3892/ol.2014.2068
   Fujita N, 2012, ONCOLOGY-BASEL, V83, P273, DOI 10.1159/000342083
   Garcia-Murillas I, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aab0021
   Hoque MO, 2006, J CLIN ONCOL, V24, P4262, DOI 10.1200/JCO.2005.01.3516
   Kloten V, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3375
   Kristiansen S, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/986024
   Lim SH, 2014, CANCER LETT, V346, P24, DOI 10.1016/j.canlet.2013.12.019
   Lo YMD, 1999, AM J HUM GENET, V64, P218, DOI 10.1086/302205
   Matuschek C, 2010, EUR J MED RES, V15, P277
   Molina R, 2010, CLIN CHEM, V56, P1148, DOI 10.1373/clinchem.2009.135566
   Müller HM, 2003, CANCER RES, V63, P7641
   Olsson E, 2015, EMBO MOL MED, V7, P1034, DOI 10.15252/emmm.201404913
   Salgado R, 2015, ANN ONCOL, V26, P259, DOI 10.1093/annonc/mdu450
   Schwarzenbach H, 2015, BREAST CANCER RES, V17, DOI 10.1186/s13058-015-0645-5
   Schwarzenbach H, 2011, NAT REV CANCER, V11, P426, DOI 10.1038/nrc3066
   Sharma G, 2012, TUMOR BIOL, V33, P1837, DOI 10.1007/s13277-012-0443-y
   Sharma G, 2010, LIFE SCI, V87, P83, DOI 10.1016/j.lfs.2010.05.001
   Symmans WF, 2007, J CLIN ONCOL, V25, P4414, DOI 10.1200/JCO.2007.10.6823
   Tamkovich SN, 2006, ANN NY ACAD SCI, V1075, P191, DOI 10.1196/annals.1368.026
   Tan SH, 2007, ONCOL REP, V18, P1225
   TSUMITA T, 1963, NATURE, V198, P1088, DOI 10.1038/1981088a0
   van der Vaart M, 2008, ANN NY ACAD SCI, V1137, P18, DOI 10.1196/annals.1448.022
   Yamamoto N, 2012, BREAST CANCER RES TR, V132, P165, DOI 10.1007/s10549-011-1575-2
   Yu SCY, 2013, CLIN CHEM, V59, P1228, DOI 10.1373/clinchem.2013.203679
   Zurita M, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-217
NR 38
TC 55
Z9 60
U1 2
U2 9
PU CIG MEDIA GROUP, LP
PI DALLAS
PA 3500 MAPLE AVENUE, STE 750, DALLAS, TX 75219-3931 USA
SN 1526-8209
EI 1938-0666
J9 CLIN BREAST CANCER
JI Clin. Breast Cancer
PD FEB
PY 2017
VL 17
IS 1
BP 61
EP +
DI 10.1016/j.clbc.2016.06.006
PG 12
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA EK5IW
UT WOS:000393961100015
PM 27395416
DA 2025-01-12
ER

PT J
AU Tseng, TH
   Chien, MH
   Lin, WL
   Wen, YC
   Chow, JM
   Chen, CK
   Kuo, TC
   Lee, WJ
AF Tseng, Tsui-Hwa
   Chien, Ming-Hsien
   Lin, Wea-Lung
   Wen, Yu-Ching
   Chow, Jyh-Ming
   Chen, Chi-Kuan
   Kuo, Tsang-Chih
   Lee, Wei-Jiunn
TI Inhibition of MDA-MB-231 breast cancer cell proliferation and tumor
   growth by apigenin through induction of G2/M arrest and histone H3
   acetylation-mediated p21<SUP>WAF1/CIP1</SUP> expression
SO ENVIRONMENTAL TOXICOLOGY
LA English
DT Article
DE apigenin; cell cycle arrest; histone H3 acetylation; p21WAF1/CIP1;
   breast cancer
ID RECEPTOR-ALPHA ER; DEACETYLASE INHIBITOR; CYCLE CONTROL; EPIGENETICS;
   P21; CHEMOPREVENTION; COMBINATION; FLAVONOIDS; COMPOUND
AB Apigenin (4,5,7-trihydroxyflavone), a flavonoid commonly found in fruits and vegetables, has anticancer properties in various malignant cancer cells. However, the molecular basis of the anticancer effect remains to be elucidated. In this study, we investigated the cellular mechanisms underlying the induction of cell cycle arrest by apigenin. Our results showed that apigenin at the nonapoptotic induction concentration inhibited cell proliferation and induced cell cycle arrest at the G2/M phase in the MDA-MB-231 breast cancer cell line. Immunoblot analysis indicated that apigenin suppressed the expression of cyclin A, cyclin B, and cyclin-dependent kinase-1 (CDK1), which control the G2-to-M phase transition in the cell cycle. In addition, apigenin upregulated p21(WAF1/CIP1) and increased the interaction of p21(WAF1/CIP1) with proliferating cell nuclear antigen (PCNA), which inhibits cell cycle progression. Furthermore, apigenin significantly inhibited histone deacetylase (HDAC) activity and induced histone H3 acetylation. The subsequent chromatin immunoprecipitation (ChIP) assay indicated that apigenin increased acetylation of histone H3 in the p21(WAF1/CIP1) promoter region, resulting in the increase of p21(WAF1/CIP1) transcription. In a tumor xenograft model, apigenin effectively delayed tumor growth. In these apigenin-treated tumors, we also observed reductions in the levels of cyclin A and cyclin B and increases in the levels of p21(WAF1/CIP1) and acetylated histone H3. These findings demonstrate for the first time that apigenin can be used in breast cancer prevention and treatment through epigenetic regulation. (c) 2016 Wiley Periodicals, Inc. Environ Toxicol 32: 434-444, 2017.
C1 [Tseng, Tsui-Hwa] Chung Shan Med Univ, Dept Med Appl Chem, Taichung, Taiwan.
   [Tseng, Tsui-Hwa] Chung Shan Med Univ Hosp, Dept Med Educ, Taichung, Taiwan.
   [Chien, Ming-Hsien] Taipei Med Univ, Coll Med, Grad Inst Clin Med, Taipei, Taiwan.
   [Chien, Ming-Hsien; Lee, Wei-Jiunn] Taipei Med Univ, Wan Fang Hosp, Dept Med Educ & Res, Taipei, Taiwan.
   [Lin, Wea-Lung] Chung Shan Med Univ Hosp, Dept Pathol, Taichung, Taiwan.
   [Wen, Yu-Ching] Taipei Med Univ, Wan Fang Hosp, Dept Urol, Taipei, Taiwan.
   [Chow, Jyh-Ming] Taipei Med Univ, Wan Fang Hosp, Dept Internal Med, Div Hematol & Med Oncol, Taipei, Taiwan.
   [Chen, Chi-Kuan] Acad Sinica, Genom Res Ctr, Taipei, Taiwan.
   [Kuo, Tsang-Chih] Natl Taiwan Univ, Coll Life Sci, Inst Biochem Sci, Taipei, Taiwan.
   [Lee, Wei-Jiunn] Taipei Med Univ, Coll Med, Sch Med, Dept Urol, Taipei, Taiwan.
C3 Chung Shan Medical University; Chung Shan Medical University; Chung Shan
   Medical University Hospital; Taipei Medical University; Taipei Municipal
   WanFang Hospital; Taipei Medical University; Chung Shan Medical
   University; Chung Shan Medical University Hospital; Taipei Medical
   University; Taipei Municipal WanFang Hospital; Taipei Medical
   University; Taipei Municipal WanFang Hospital; Academia Sinica - Taiwan;
   National Taiwan University; Taipei Medical University
RP Lee, WJ (通讯作者)，Taipei Med Univ, Wan Fang Hosp, Dept Med Educ & Res, Taipei, Taiwan.; Lee, WJ (通讯作者)，Taipei Med Univ, Coll Med, Sch Med, Dept Urol, Taipei, Taiwan.
EM lwj5905@gmail.com
RI lu, Linlin/K-6600-2016
FU Chung Shan Medical University Hospital [CSH-2012-C-018]; National
   Science Council [NSC 99-2632-B-040-001-MY3]; Taipei Medical
   University-Wan Fang Hospital [105 swf05]
FX Contract grant sponsor: Chung Shan Medical University Hospital. Contract
   grant number: CSH-2012-C-018. Contract grant sponsor: National Science
   Council. Contract grant number: NSC 99-2632-B-040-001-MY3. Contract
   grant sponsor: Taipei Medical University-Wan Fang Hospital. Contract
   grant number: 105 swf05.
CR Beaumont T, 2011, Nurs Stand, V25, P49
   BIRT DF, 1986, CARCINOGENESIS, V7, P959, DOI 10.1093/carcin/7.6.959
   Birt DF, 2001, PHARMACOL THERAPEUT, V90, P157, DOI 10.1016/S0163-7258(01)00137-1
   Blagosklonny MV, 2002, MOL CANCER THER, V1, P937
   Bolden JE, 2006, NAT REV DRUG DISCOV, V5, P769, DOI 10.1038/nrd2133
   Budman DR, 2011, INVEST NEW DRUG, V29, P1224, DOI 10.1007/s10637-010-9467-6
   Cao XC, 2013, CHINESE J CANCER RES, V25, P212, DOI 10.3978/j.issn.1000-9604.2013.04.01
   Cayrol C, 1998, ONCOGENE, V16, P311, DOI 10.1038/sj.onc.1201543
   Chen D, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1797
   Davis CD, 2007, NUTR REV, V65, P88, DOI 10.1301/nr.2007.feb.88-94
   Dent R, 2007, CLIN CANCER RES, V13, P4429, DOI 10.1158/1078-0432.CCR-06-3045
   Elias AD, 2010, AM J CLIN ONCOL-CANC, V33, P637, DOI 10.1097/COC.0b013e3181b8afcf
   Ellis L, 2009, MOL CANCER THER, V8, P1409, DOI 10.1158/1535-7163.MCT-08-0860
   Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI [10.1056/NEJMra072067, 10.1093/carcin/bgp220]
   Gomathinayagam R, 2008, ANTICANCER RES, V28, P785
   Ham SL, 2015, INTEGR BIOL-UK, V7, P792, DOI [10.1039/c5ib00121h, 10.1039/C5IB00121H]
   Hudis CA, 2011, ONCOLOGIST, V16, P1, DOI 10.1634/theoncologist.2011-S1-01
   Keen JC, 2003, BREAST CANCER RES TR, V81, P177, DOI 10.1023/A:1026146524737
   Kikuchi H., 2006, REV PROTOCOLS DT40 R, P225
   Kim EJ, 2009, J NUTR, V139, P2373, DOI 10.3945/jn.109.111864
   Konstantinopoulos PA, 2007, EXPERT OPIN INV DRUG, V16, P569, DOI 10.1517/13543784.16.5.569
   Lee WJ, 2008, TOXICOL APPL PHARM, V226, P178, DOI 10.1016/j.taap.2007.09.013
   Lin HY, 2006, MED RES REV, V26, P397, DOI 10.1002/med.20056
   Liu T, 2006, CANCER TREAT REV, V32, P157, DOI 10.1016/j.ctrv.2005.12.006
   Love IM, 2012, CELL CYCLE, V11, P2458, DOI 10.4161/cc.20864
   McDonald ER, 2000, INT J ONCOL, V16, P871
   Meeran SM, 2008, FRONT BIOSCI-LANDMRK, V13, P2191, DOI 10.2741/2834
   Middleton E, 2000, PHARMACOL REV, V52, P673
   Neumann J, 2014, INT J CANCER, V134, P1991, DOI 10.1002/ijc.28521
   Paik S, 2006, CURR OPIN OBSTET GYN, V18, P59, DOI 10.1097/01.gco.0000192970.52320.29
   Patel D, 2007, INT J ONCOL, V30, P233
   Pathiraja TN, 2011, CLIN CANCER RES, V17, P4177, DOI 10.1158/1078-0432.CCR-10-2950
   Pruitt K, 2006, PLOS GENET, V2, P344, DOI 10.1371/journal.pgen.0020040
   Rao R, 2012, MOL CANCER THER, V11, P973, DOI 10.1158/1535-7163.MCT-11-0979
   Sharma S, 2010, CARCINOGENESIS, V31, P27, DOI 10.1093/carcin/bgp220
   Shukla S, 2007, CELL CYCLE, V6, P1102, DOI 10.4161/cc.6.9.4146
   Shukla S, 2010, PHARM RES-DORDR, V27, P962, DOI 10.1007/s11095-010-0089-7
   Storch K, 2010, CANCER RES, V70, P3925, DOI 10.1158/0008-5472.CAN-09-3848
   Tan S, 2015, CHEMMEDCHEM, V10, P441, DOI 10.1002/cmdc.201402460
   Tate CR, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3192
   Zhou Q, 2007, CANCER BIOL THER, V6, P64, DOI 10.4161/cbt.6.1.3549
NR 41
TC 97
Z9 109
U1 5
U2 51
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1520-4081
EI 1522-7278
J9 ENVIRON TOXICOL
JI Environ. Toxicol.
PD FEB
PY 2017
VL 32
IS 2
BP 434
EP 444
DI 10.1002/tox.22247
PG 11
WC Environmental Sciences; Toxicology; Water Resources
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Environmental Sciences & Ecology; Toxicology; Water Resources
GA EK3AX
UT WOS:000393799500008
PM 26872304
DA 2025-01-12
ER

PT J
AU Damiano, V
   Brisotto, G
   Borgna, S
   di Gennaro, A
   Armellin, M
   Perin, T
   Guardascione, M
   Maestro, R
   Santarosa, M
AF Damiano, Valentina
   Brisotto, Giulia
   Borgna, Silvia
   di Gennaro, Alessandra
   Armellin, Michela
   Perin, Tiziana
   Guardascione, Michela
   Maestro, Roberta
   Santarosa, Manuela
TI Epigenetic Silencing of miR-200c in Breast Cancer Is Associated With
   Aggressiveness and Is Modulated by ZEB1
SO GENES CHROMOSOMES & CANCER
LA English
DT Article
ID TO-MESENCHYMAL TRANSITION; TRANSCRIPTIONAL DOWN-REGULATION; E-CADHERIN;
   EMT; FAMILY; METASTASIS; EXPRESSION; CELLS; METHYLATION; REPRESSION
AB Loss of expression of miR-200 family members has been implicated in cellular plasticity, a phenomenon that accounts for epithelial-to-mesenchymal transition (EMT) and stem-like features of many carcinomas and is considered a major cause of tumor aggressiveness and drug resistance. Nevertheless, the mechanisms of miR-200 downregulation in breast cancer are still largely unknown. Here we show that miR-200c expression inversely correlates with miR-200c/miR-141 locus methylation in triple-negative breast tumors (TNBC). Importantly, low levels of miR-200c expression and high levels of miR-200c/miR-141 locus methylation associated with lymph node metastasis. Moreover, miR-200c/miR-141 locus methylation was significantly related to high expression of ZEB1 in two independent TNBC series. Silencing of ZEB1 in vitro reduced miR200c/miR-141 DNA methylation and, concurrently, decreased histone H3K9 trimethylation. This chromatin modifications were paralleled by an increase in the expression of both miR-200c and E-cadherin. Similar effects were achieved by treatment with a demethylating agent. Our data suggest that gene methylation is an important element in the regulation of the miR-200c/ZEB1 axis and that chromatin remodeling of the miR-200c/miR-141 locus is affected by ZEB1 and, thus, contributes to ZEB1-induced cellular plasticity. (C) 2016 Wiley Periodicals, Inc.
C1 [Damiano, Valentina; Brisotto, Giulia; Borgna, Silvia; di Gennaro, Alessandra; Armellin, Michela; Guardascione, Michela; Maestro, Roberta; Santarosa, Manuela] CRO Aviano Natl Canc Inst, Funct Oncogenom & Genet, Via F Gallini 2, I-33081 Aviano, PN, Italy.
   [Perin, Tiziana] CRO Aviano Natl Canc Inst, Pathol, Via F Gallini 2, I-33081 Aviano, PN, Italy.
   [Guardascione, Michela] CRO Aviano Natl Canc Inst, Dept Med Oncol, Gastrointestinal Unit, Via F Gallini 2, I-33081 Aviano, PN, Italy.
C3 IRCCS Aviano (CRO); IRCCS Aviano (CRO); IRCCS Aviano (CRO)
RP Santarosa, M (通讯作者)，CRO Natl Canc Inst, Funct Oncogenom & Genet, Via F Gallini 2, I-33081 Aviano, PN, Italy.
EM msantarosa@cro.it
RI Maestro, Roberta/M-1846-2015; BRISOTTO, GIULIA/AAC-2214-2020;
   Guardascione, Michela/AAA-5489-2019; Armellin, Michela/AAZ-1068-2020;
   Santarosa, Manuela/A-7300-2013; Perin, Tiziana/AAC-2403-2020; Damiano,
   Valentina/AAR-2240-2020
OI Maestro, Roberta/0000-0002-6642-5592; BRISOTTO,
   GIULIA/0000-0001-5514-7032; Guardascione, Michela/0000-0001-5052-3502;
   Armellin, Michela/0000-0002-0637-7023; Santarosa,
   Manuela/0000-0001-7682-2578; Perin, Tiziana/0000-0002-9823-0167;
   Damiano, Valentina/0000-0002-9137-3253
FU Italian Ministry of Health [J31J11000480001]; Italian Association for
   Cancer Research (AIRC) [MCO-10016]; Associazione Via di Natale;
   Fondazione CRO Aviano Onlus; Fondazione Umberto Veronesi
FX Supported by: The Italian Ministry of Health (Ricerca Finalizzata,
   J31J11000480001) Italian Association for Cancer Research (AIRC,
   MCO-10016); Associazione Via di Natale; Fondazione CRO Aviano Onlus
   (fellowship to V.D.); Fondazione Umberto Veronesi (fellowship to
   A.d.G.).
CR Aghdassi A, 2012, GUT, V61, P439, DOI 10.1136/gutjnl-2011-300060
   Ambrosio R, 2013, NUCLEIC ACIDS RES, V41, P3551, DOI 10.1093/nar/gkt065
   Castilla MA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047709
   Ansieau S, 2008, CANCER CELL, V14, P79, DOI 10.1016/j.ccr.2008.06.005
   Berx G, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a003129
   Borgna S, 2012, CELL CYCLE, V11, P4242, DOI 10.4161/cc.22543
   Brisotto G, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1646-6
   Burk U, 2008, EMBO REP, V9, P582, DOI 10.1038/embor.2008.74
   Byles V, 2012, ONCOGENE, V31, P4619, DOI 10.1038/onc.2011.612
   Ceppi P, 2010, MOL CANCER RES, V8, P1207, DOI 10.1158/1541-7786.MCR-10-0052
   Davalos V, 2012, ONCOGENE, V31, P2062, DOI 10.1038/onc.2011.383
   Díaz-Martín J, 2014, J PATHOL, V232, P319, DOI 10.1002/path.4289
   Eades G, 2011, J BIOL CHEM, V286, P25992, DOI 10.1074/jbc.M111.229401
   Fischer KR, 2015, NATURE, V527, P472, DOI 10.1038/nature15748
   Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722
   Hur K, 2013, GUT, V62, P1315, DOI 10.1136/gutjnl-2011-301846
   Karihtala P, 2013, BREAST CANCER RES TR, V138, P81, DOI 10.1007/s10549-013-2442-0
   Knezevic J, 2015, ONCOGENE, V34, P5997, DOI 10.1038/onc.2015.48
   Korpal M, 2011, NAT MED, V17, P1101, DOI 10.1038/nm.2401
   Lehmann BD, 2011, J CLIN INVEST, V121, P2750, DOI 10.1172/JCI45014
   Lim YY, 2013, J CELL SCI, V126, P2256, DOI 10.1242/jcs.122275
   Lombaerts M, 2006, BRIT J CANCER, V94, P661, DOI 10.1038/sj.bjc.6602996
   Marchini S, 2011, LANCET ONCOL, V12, P273, DOI 10.1016/S1470-2045(11)70012-2
   Meidhof S, 2015, EMBO MOL MED, V7, P831, DOI 10.15252/emmm.201404396
   Muggerud AA, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2466
   Neves Rui, 2010, BMC Res Notes, V3, P219, DOI 10.1186/1756-0500-3-219
   Okugawa Y, 2012, J SURG ONCOL, V106, P280, DOI 10.1002/jso.22142
   Paterson EL, 2013, NEOPLASIA, V15, P180, DOI 10.1593/neo.121828
   Pichler M, 2014, BRIT J CANCER, V110, P1614, DOI 10.1038/bjc.2014.51
   Puisieux A, 2014, NAT CELL BIOL, V16, P488, DOI 10.1038/ncb2976
   Rodríguez-Paredes M, 2011, NAT MED, V17, P330, DOI 10.1038/nm.2305
   Santarosa M, 2009, MOL CANCER THER, V8, P844, DOI 10.1158/1535-7163.MCT-08-0951
   Schmalhofer O, 2009, CANCER METAST REV, V28, P151, DOI 10.1007/s10555-008-9179-y
   Shimono Y, 2009, CELL, V138, P592, DOI 10.1016/j.cell.2009.07.011
   Spaderna S, 2008, CANCER RES, V68, P537, DOI 10.1158/0008-5472.CAN-07-5682
   Sun L.N., 2015, IND SAFETY ENV PRO, V1, P8, DOI DOI 10.15252/EMBR.201439792
   Tam WL, 2013, NAT MED, V19, P1438, DOI 10.1038/nm.3336
   Tang HL, 2013, CLIN CANCER RES, V19, P5602, DOI 10.1158/1078-0432.CCR-13-1326
   Tryndyak VP, 2010, INT J CANCER, V126, P2575, DOI 10.1002/ijc.24972
   Tuna M, 2016, GENE CHROMOSOME CANC, V55, P193, DOI 10.1002/gcc.22332
   Tuomarila M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109508
   Vrba L, 2011, GENOME RES, V21, P2026, DOI 10.1101/gr.123935.111
   Wang JX, 2007, NATURE, V446, P882, DOI 10.1038/nature05671
   Wellner U, 2009, NAT CELL BIOL, V11, P1487, DOI 10.1038/ncb1998
   Wiklund ED, 2011, INT J CANCER, V128, P1327, DOI 10.1002/ijc.25461
   Yu SJ, 2013, CLIN CANCER RES, V19, P1389, DOI 10.1158/1078-0432.CCR-12-1959
   Zheng XF, 2015, NATURE, V527, P525, DOI 10.1038/nature16064
NR 47
TC 45
Z9 50
U1 1
U2 6
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1045-2257
EI 1098-2264
J9 GENE CHROMOSOME CANC
JI Gene Chromosomes Cancer
PD FEB
PY 2017
VL 56
IS 2
BP 147
EP 158
DI 10.1002/gcc.22422
PG 12
WC Oncology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Genetics & Heredity
GA EL2BX
UT WOS:000394426200005
PM 27717206
DA 2025-01-12
ER

PT J
AU Ariazi, EA
   Taylor, JC
   Black, MA
   Nicolas, E
   Slifker, MJ
   Azzam, DJ
   Boyd, J
AF Ariazi, Eric A.
   Taylor, John C.
   Black, Michael A.
   Nicolas, Emmanuelle
   Slifker, Michael J.
   Azzam, Diana J.
   Boyd, Jeff
TI A New Role for ERα: Silencing via DNA Methylation of Basal, Stem Cell,
   and EMT Genes
SO MOLECULAR CANCER RESEARCH
LA English
DT Article
ID ESTROGEN-RECEPTOR-ALPHA; BREAST-CANCER CELLS; GROUP PROTEIN EZH2;
   TRANSCRIPTIONAL REPRESSION; EXPRESSION; CHROMATIN; PROLIFERATION;
   SUBTYPE; HISTONE; TARGETS
AB Resistance to hormonal therapies is a major clinical problem in the treatment of estrogen receptor alpha-positive (ER alpha(+)) breast cancers. Epigenetic marks, namely DNA methylation of cytosine at specific CpG sites (5mCpG), are frequently associated with ER alpha(+) status in human breast cancers. Therefore, ER alpha may regulate gene expression in part via DNA methylation. This hypothesis was evaluated using a panel of breast cancer cell line models of antiestrogen resistance. Microarray gene expression profiling was used to identify genes normally silenced in ER alpha(+) cells but derepressed upon exposure to the demethylating agent decitabine, derepressed upon long-term loss of ER alpha expression, and resuppressed by gain of ER alpha activity/expression. ER alpha-dependent DNA methylation targets (n = 39) were enriched for ER alpha-binding sites, basal-up/luminal-down markers, cancer stem cell, epithelial-mesenchymal transition, and inflammatory and tumor suppressor genes. Kaplan-Meier survival curve and Cox proportional hazards regression analyses indicated that these targets predicted poor distant metastasis-free survival among a large cohort of breast cancer patients. The basal breast cancer subtype markers LCN2 and IFI27 showed the greatest inverse relationship with ER alpha expression/activity and contain ER alpha-binding sites. Thus, genes that are methylated in an ER alpha-dependent manner may serve as predictive biomarkers in breast cancer. (C) 2016 AACR.
C1 [Ariazi, Eric A.; Taylor, John C.; Nicolas, Emmanuelle; Slifker, Michael J.; Boyd, Jeff] Temple Univ Hlth Syst, Fox Chase Canc Ctr, Philadelphia, PA USA.
   [Black, Michael A.] Univ Otago, Dept Biochem, Dunedin, New Zealand.
   [Azzam, Diana J.; Boyd, Jeff] Florida Int Univ, Dept Human & Mol Genet, Herbert Wertheim Coll Med, 11200 SW 8th St,AHC2-693, Miami, FL 33199 USA.
C3 Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple
   University; Fox Chase Cancer Center; University of Otago; State
   University System of Florida; Florida International University
RP Boyd, J (通讯作者)，Florida Int Univ, Dept Human & Mol Genet, Herbert Wertheim Coll Med, 11200 SW 8th St,AHC2-693, Miami, FL 33199 USA.; Ariazi, EA (通讯作者)，Freenome Inc, 201 Gateway Blvd, San Francisco, CA 94080 USA.
EM eric.ariazi@freenome.com; jboyd@fiu.edu
RI Black, Michael/F-1484-2010; Azzam, Diana/ABB-8342-2021
OI Azzam, Diana/0000-0002-2605-8855; Boyd, Jeff/0000-0002-3517-7637; Black,
   Michael/0000-0003-1174-6054
FU Commonwealth Universal Research Enhancement (CURE) Program from the
   Pennsylvania Department of Health [NIHP30 CA006927]
FX This work was supported by the Commonwealth Universal Research
   Enhancement (CURE) Program Award from the Pennsylvania Department of
   Health (to J. Boyd) and NIHP30 CA006927 (Fox Chase Cancer Center Core
   Grant).
CR Ariazi EA, 2008, METHODS PRINCIPLES M, P127
   Ariazi EA, 2007, MOL CANCER RES, V5, P71, DOI 10.1158/1541-7786.MCR-06-0227
   Augereau P, 2006, J STEROID BIOCHEM, V102, P51, DOI 10.1016/j.jsbmb.2006.09.005
   Bell JSK, 2016, EPIGENETICS-US, V11, P273, DOI 10.1080/15592294.2016.1158364
   Cai Y, 2014, ONCOGENE, V33, P2157, DOI 10.1038/onc.2013.178
   Charafe-Jauffret E, 2006, ONCOGENE, V25, P2273, DOI 10.1038/sj.onc.1209254
   Cvoro A, 2006, MOL CELL, V21, P555, DOI 10.1016/j.molcel.2006.01.014
   Ellison-Zelski SJ, 2009, MOL CELL BIOL, V29, P4949, DOI 10.1128/MCB.00383-09
   Fackler MJ, 2011, CANCER RES, V71, P6195, DOI 10.1158/0008-5472.CAN-11-1630
   Fan MY, 2006, CANCER RES, V66, P11954, DOI 10.1158/0008-5472.CAN-06-1666
   Frasor J, 2003, ENDOCRINOLOGY, V144, P4562, DOI 10.1210/en.2003-0567
   Fuks F, 2001, EMBO J, V20, P2536, DOI 10.1093/emboj/20.10.2536
   Fuks F, 2000, NAT GENET, V24, P88, DOI 10.1038/71750
   Fullwood MJ, 2009, NATURE, V462, P58, DOI 10.1038/nature08497
   Green KA, 2007, NAT REV CANCER, V7, P713, DOI 10.1038/nrc2211
   Gurevich I, 2007, TOXICOL APPL PHARM, V223, P288, DOI 10.1016/j.taap.2007.05.019
   Haughian JM, 2012, P NATL ACAD SCI USA, V109, P2742, DOI 10.1073/pnas.1106509108
   Hill VK, 2011, CANCER RES, V71, P2988, DOI 10.1158/0008-5472.CAN-10-4026
   Hwang C, 2008, BREAST CANCER RES TR, V107, P235, DOI 10.1007/s10549-007-9542-7
   Kim KH, 2016, NAT MED, V22, P128, DOI 10.1038/nm.4036
   Kiskinis E, 2007, EMBO J, V26, P4831, DOI 10.1038/sj.emboj.7601908
   Kulis M, 2010, ADV GENET, V70, P27, DOI [10.1016/S0065-2660(10)70002-X, 10.1016/B978-0-12-380866-0.60002-2]
   Lee ST, 2011, MOL CELL, V43, P798, DOI 10.1016/j.molcel.2011.08.011
   Leu YW, 2004, CANCER RES, V64, P8184, DOI 10.1158/0008-5472.CAN-04-2045
   Li SQ, 2015, J SURG RES, V193, P255, DOI 10.1016/j.jss.2014.06.055
   Lin CY, 2007, PLOS GENET, V3, P867, DOI 10.1371/journal.pgen.0030087
   Magnani L, 2014, MOL CELL ENDOCRINOL, V382, P633, DOI 10.1016/j.mce.2013.04.026
   Manavathi B, 2013, ENDOCR REV, V34, P1, DOI 10.1210/er.2011-1057
   Mann Monica, 2011, Cancers (Basel), V3, P1691, DOI 10.3390/cancers3021691
   Marques M, 2013, NUCLEIC ACIDS RES, V41, P8094, DOI 10.1093/nar/gkt595
   Nagalla S, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-4-r34
   Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008
   Osmanbeyoglu HU, 2013, NUCLEIC ACIDS RES, V41, P8061, DOI 10.1093/nar/gkt586
   Perou C.M., 2011, COLD SPRING HARB PER, V3
   Pink JJ, 1996, BRIT J CANCER, V74, P1227, DOI 10.1038/bjc.1996.521
   Prat A, 2011, MOL ONCOL, V5, P5, DOI 10.1016/j.molonc.2010.11.003
   Prat A, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2635
   Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007
   Ronneberg JA, 2011, MOL ONCOL, V5, P61, DOI 10.1016/j.molonc.2010.11.004
   Schlesinger Y, 2007, NAT GENET, V39, P232, DOI 10.1038/ng1950
   Seth P, 2002, CANCER RES, V62, P4540
   Shi B, 2007, MOL CELL BIOL, V27, P5105, DOI 10.1128/MCB.00162-07
   Stone A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040466
   Stossi F, 2009, MOL CELL BIOL, V29, P1749, DOI 10.1128/MCB.01476-08
   Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498
   Ung M, 2014, EPIGENETICS-US, V9, P523, DOI 10.4161/epi.27688
   Viré E, 2006, NATURE, V439, P871, DOI 10.1038/nature04431
   Yang J, 2009, P NATL ACAD SCI USA, V106, P3913, DOI 10.1073/pnas.0810617106
   Ye Y, 2008, BIOCHEM J, V416, P179, DOI 10.1042/BJ20080328
NR 49
TC 23
Z9 28
U1 0
U2 3
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1541-7786
EI 1557-3125
J9 MOL CANCER RES
JI Mol. Cancer Res.
PD FEB
PY 2017
VL 15
IS 2
BP 152
EP 164
DI 10.1158/1541-7786.MCR-16-0283
PG 13
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA EK4IB
UT WOS:000393889200004
PM 28108626
OA Green Submitted, Green Accepted, Bronze
DA 2025-01-12
ER

PT J
AU Kumar, U
   Sharma, U
   Rathi, G
AF Kumar, Umesh
   Sharma, Ujjawal
   Rathi, Garima
TI Reversal of hypermethylation and reactivation of glutathione
   S-transferase pi 1 gene by curcumin in breast cancer cell line
SO TUMOR BIOLOGY
LA English
DT Article
DE Methylation; GSTP1; curcumin; breast cancer; MCF-7
ID DNA METHYLATION; CERVICAL-CANCER; DEMETHYLATION; EXPRESSION; PROMOTER;
   MECHANISMS; APOPTOSIS
AB One of the mechanisms for epigenetic silencing of tumor suppressor genes is hypermethylation of cytosine residue at CpG islands at their promoter region that contributes to malignant progression of tumor. Therefore, activation of tumor suppressor genes that have been silenced by promoter methylation is considered to be very attractive molecular target for cancer therapy. Epigenetic silencing of glutathione S-transferase pi 1, a tumor suppressor gene, is involved in various types of cancers including breast cancer. Epigenetic silencing of tumor suppressor genes can be reversed by several molecules including natural compounds such as polyphenols that can act as a hypomethylating agent. Curcumin has been found to specifically target various tumor suppressor genes and alter their expression. To check the effect of curcumin on the methylation pattern of glutathione S-transferase pi 1 gene in MCF-7 breast cancer cell line in dose-dependent manner. To check the reversal of methylation pattern of hypermethylated glutathione S-transferase pi 1, MCF-7 breast cancer cell line was treated with different concentrations of curcumin for different time periods. DNA and proteins of treated and untreated cell lines were isolated, and methylation status of the promoter region of glutathione S-transferase pi 1 was analyzed using methylation-specific polymerase chain reaction assay, and expression of this gene was analyzed by immunoblotting using specific antibodies against glutathione S-transferase pi 1. A very low and a nontoxic concentration (10 mu M) of curcumin treatment was able to reverse the hypermethylation and led to reactivation of glutathione S-transferase pi 1 protein expression in MCF-7 cells after 72 h of treatment, although the IC50 value of curcumin was found to be at 20 mu M. However, curcumin less than 3 mu M of curcumin could not alter the promoter methylation pattern of glutathione S-transferase pi 1. Treatment of breast cancer MCF-7 cells with curcumin causes complete reversal of glutathione S-transferase pi 1 promoter hypermethylation and leads to re-expression of glutathione S-transferase pi 1, suggesting it to be an excellent nontoxic hypomethylating agent.
C1 [Kumar, Umesh; Rathi, Garima] Univ Delhi, Div Mol Oncol, Dr BR Ambedkar Ctr Biomed Res ACBR, North Campus, Delhi, India.
   [Sharma, Ujjawal] Postgraduate Inst Med Educ Res PGIMER, Dept Biochem, Chandigarh, India.
C3 University of Delhi; Post Graduate Institute of Medical Education &
   Research (PGIMER), Chandigarh
RP Kumar, U (通讯作者)，Univ Delhi, Div Mol Oncol, Dr BR Ambedkar Ctr Biomed Res ACBR, North Campus, Delhi, India.
EM umeshkumar82@gmail.com
OI Kumar, Umesh/0000-0002-4715-7967; Sharma, Ujjawal/0000-0002-2087-080X
FU Indian Council of Medical Research, Govt. of India, New Delhi
   [3/2/2/202/2009.NCDIII]
FX The authors would like to acknowledge Indian Council of Medical
   Research, Govt. of India, New Delhi, for the award of Senior Research
   Fellowship (3/2/2/202/2009.NCDIII) to Umesh Kumar.
CR Ali RE, 2006, ANN NY ACAD SCI, V1067, P394, DOI 10.1196/annals.1354.056
   ARENDS MJ, 1990, AM J PATHOL, V136, P593
   Calabrese EJ, 2001, TRENDS PHARMACOL SCI, V22, P285, DOI 10.1016/S0165-6147(00)01719-3
   COMPTON MM, 1992, CANCER METAST REV, V11, P105, DOI 10.1007/BF00048058
   Das BC, 1992, J GEN VIROL, V73, P2327, DOI [10.1099/0022-1317-73-9-2327, DOI 10.1099/0022-1317-73-9-2327]
   DIGNAM JD, 1990, METHOD ENZYMOL, V182, P194
   Dorai T, 2004, CANCER LETT, V215, P129, DOI 10.1016/j.canlet.2004.07.013
   Duenas-Gonzalez A, 2005, MOL CANCER, V4, DOI 10.1186/1476-4598-4-38
   Fang MZ, 2007, J NUTR, V137, p223S, DOI 10.1093/jn/137.1.223S
   Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516
   FOSTER PL, 1992, GENETICS, V131, P783
   Gao Z, 2009, ANTICANCER RES, V29, P2025
   Jha AK, 2010, FOLIA BIOL-PRAGUE, V56, P195
   Khor TO, 2011, BIOCHEM PHARMACOL, V82, P1073, DOI 10.1016/j.bcp.2011.07.065
   LEE WH, 1994, P NATL ACAD SCI USA, V91, P11733, DOI 10.1073/pnas.91.24.11733
   Lee WJ, 2005, MOL PHARMACOL, V68, P1018, DOI 10.1124/mol.104.008367
   Liu ZF, 2009, J PHARMACOL EXP THER, V329, P505, DOI 10.1124/jpet.108.147934
   Lyko F, 2005, JNCI-J NATL CANCER I, V97, P1498, DOI 10.1093/jnci/dji311
   Pal D, 2014, PLOS ONE, V10
   Paz MF, 2003, CANCER RES, V63, P1114
   Shu LM, 2011, AAPS J, V13, P606, DOI 10.1208/s12248-011-9300-y
   Silvestrini R, 1997, J NATL CANCER I, V89, P639, DOI 10.1093/jnci/89.9.639
NR 22
TC 27
Z9 28
U1 0
U2 9
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD FEB
PY 2017
VL 39
IS 2
DI 10.1177/1010428317692258
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA EP1TN
UT WOS:000397167300034
PM 28222671
OA gold
DA 2025-01-12
ER

PT J
AU Czerwinska, P
   Shah, PK
   Tomczak, K
   Klimczak, M
   Mazurek, S
   Sozanska, B
   Biecek, P
   Korski, K
   Filas, V
   Mackiewicz, A
   Andersen, JN
   Wiznerowicz, M
AF Czerwinska, Patrycja
   Shah, Parantu K.
   Tomczak, Katarzyna
   Klimczak, Marta
   Mazurek, Sylwia
   Sozanska, Barbara
   Biecek, Przemyslaw
   Korski, Konstanty
   Filas, Violetta
   Mackiewicz, Andrzej
   Andersen, Jannik N.
   Wiznerowicz, Maciej
TI TRIM28 multi-domain protein regulates cancer stem cell population in
   breast tumor development
SO ONCOTARGET
LA English
DT Article
DE TRIM28; KAP1; breast cancer stem cells; pluripotency; epigenetics
ID EPITHELIAL-MESENCHYMAL TRANSITION; DIFFERENTIAL EXPRESSION ANALYSIS;
   MITOCHONDRIAL BIOGENESIS; GROWTH; KAP1; PHOSPHORYLATION; SUMOYLATION;
   TRANSCRIPTION; PLURIPOTENCY; COREPRESSOR
AB The expression of Tripartite motif-containing protein 28 (TRIM28)/Kruppel-associated box (KRAB)-associated protein 1 (KAP1), is elevated in at least 14 tumor types, including solid and hematopoietic tumors. High level of TRIM28 is associated with triple-negative subtype of breast cancer (TNBC), which shows higher aggressiveness and lower survival rates. Interestingly, TRIM28 is essential for maintaining the pluripotent phenotype in embryonic stem cells. Following on that finding, we evaluated the role of TRIM28 protein in the regulation of breast cancer stem cells (CSC) populations and tumorigenesis in vitro and in vivo. Downregulation of TRIM28 expression in xenografts led to deceased expression of pluripotency and mesenchymal markers, as well as inhibition of signaling pathways involved in the complex mechanism of CSC maintenance. Moreover, TRIM28 depletion reduced the ability of cancer cells to induce tumor growth when subcutaneously injected in limiting dilutions. Our data demonstrate that the downregulation of TRIM28 gene expression reduced the ability of CSCs to self-renew that resulted in significant reduction of tumor growth. Loss of function of TRIM28 leads to dysregulation of cell cycle, cellular response to stress, cancer cell metabolism, and inhibition of oxidative phosphorylation. All these mechanisms directly regulate maintenance of CSC population. Our original results revealed the role of the TRIM28 in regulating the CSC population in breast cancer. These findings may pave the way to novel and more effective therapies targeting cancer stem cells in breast tumors.
C1 [Czerwinska, Patrycja; Tomczak, Katarzyna; Klimczak, Marta; Mazurek, Sylwia; Mackiewicz, Andrzej; Wiznerowicz, Maciej] Greater Poland Canc Ctr, Dept Diagnost & Canc Immunol, Lab Gene Therapy, Poznan, Poland.
   [Czerwinska, Patrycja; Tomczak, Katarzyna; Mackiewicz, Andrzej; Wiznerowicz, Maciej] Poznan Univ Med Sci, Dept Canc Immunol, Chair Med Biotechnol, Poznan, Poland.
   [Czerwinska, Patrycja; Tomczak, Katarzyna; Klimczak, Marta; Mazurek, Sylwia] Med Univ Warsaw, Postgrad Sch Mol Med, Warsaw, Poland.
   [Shah, Parantu K.; Andersen, Jannik N.] Univ Texas MD Anderson Canc Ctr, Inst Appl Canc Sci, Houston, TX 77058 USA.
   [Sozanska, Barbara; Biecek, Przemyslaw] Warsaw Univ Technol, Fac Math & Informat Sci, Warsaw, Poland.
   [Biecek, Przemyslaw] Univ Warsaw, Fac Math Informat & Mech, Warsaw, Poland.
   [Korski, Konstanty; Filas, Violetta] Greater Poland Canc Ctr, Dept Canc Pathol, Poznan, Poland.
C3 Wielkopolskie Centrum Onkologii; Poznan University of Medical Sciences;
   Medical University of Warsaw; University of Texas System; UTMD Anderson
   Cancer Center; Warsaw University of Technology; University of Warsaw;
   Wielkopolskie Centrum Onkologii
RP Czerwinska, P; Wiznerowicz, M (通讯作者)，Greater Poland Canc Ctr, Dept Diagnost & Canc Immunol, Lab Gene Therapy, Poznan, Poland.; Czerwinska, P; Wiznerowicz, M (通讯作者)，Poznan Univ Med Sci, Dept Canc Immunol, Chair Med Biotechnol, Poznan, Poland.; Czerwinska, P (通讯作者)，Med Univ Warsaw, Postgrad Sch Mol Med, Warsaw, Poland.
EM patrycja.czerwinska@wco.pl; maciej.wiznerowicz@wco.pl
RI Czerwinska, Patrycja/AAE-2419-2021
OI Tomczak, Katarzyna/0000-0003-0553-8056; Filas,
   Violetta/0000-0003-2028-877X; Czerwinska, Patrycja/0000-0003-2400-1174;
   Biecek, Przemyslaw/0000-0001-8423-1823; , Sylwia/0000-0002-5064-458X
FU NCI [CA16672]; PL-Grid Infrastructure; National Science Center
   [3342/B/P01/2010/39]; Greater Poland Cancer Center; MD Anderson Cancer
   Center
FX MD Anderson Cancer Center RPPA Core Facility is funded by NCI #CA16672.
   The MD Anderson Cancer Center Cancer Genomics Core Laboratory is a part
   of the NCI-funded Cancer Center Support Grant. This research was
   supported in part by PL-Grid Infrastructure. The research was supported
   by the National Science Center grant No: 3342/B/P01/2010/39 and by
   Greater Poland Cancer Center and MD Anderson Cancer Center intramural
   grants.
CR Addison JB, 2015, CANCER RES, V75, P344, DOI 10.1158/0008-5472.CAN-14-1561
   Al-Dhfyan A, 2013, SAUDI PHARM J, V21, P229, DOI 10.1016/j.jsps.2012.08.001
   Anders S, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-10-r106
   Anders S, 2013, NAT PROTOC, V8, P1765, DOI 10.1038/nprot.2013.099
   Barbie DA, 2009, NATURE, V462, P108, DOI 10.1038/nature08460
   Ben-Porath I, 2008, NAT GENET, V40, P499, DOI 10.1038/ng.127
   Blick T, 2010, J MAMMARY GLAND BIOL, V15, P235, DOI 10.1007/s10911-010-9175-z
   Britton KM, 2012, CANCER LETT, V323, P97, DOI 10.1016/j.canlet.2012.03.041
   Brooks MD, 2015, CANCER DISCOV, V5, P469, DOI 10.1158/2159-8290.CD-15-0327
   Callihan P, 2011, PHARMACOL THERAPEUT, V129, P290, DOI 10.1016/j.pharmthera.2010.10.007
   Cann KL, 2011, BIOCHEM CELL BIOL, V89, P45, DOI 10.1139/O10-113
   Chaube B, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2015.404
   Cufí S, 2011, CELL CYCLE, V10, P3871, DOI 10.4161/cc.10.22.17976
   Czerwinska Patrycja, 2015, Contemp Oncol (Pozn), V19, pA7, DOI 10.5114/wo.2014.47126
   De Luca A, 2015, ONCOTARGET, V6, P14777, DOI 10.18632/oncotarget.4401
   de Sio FRS, 2012, BLOOD, V119, P4675, DOI 10.1182/blood-2011-12-401117
   Del Vecchio CA, 2012, CANCER RES, V72, P2657, DOI 10.1158/0008-5472.CAN-11-2656
   Descamps S, 2001, CANCER RES, V61, P4337
   Fan F, 2012, CANCER MED-US, V1, P5, DOI 10.1002/cam4.4
   Fillmore CM, 2010, P NATL ACAD SCI USA, V107, P21737, DOI 10.1073/pnas.1007863107
   Findlay VJ, 2014, CANCER GENE THER, V21, P181, DOI 10.1038/cgt.2014.15
   Friedman JR, 1996, GENE DEV, V10, P2067, DOI 10.1101/gad.10.16.2067
   Garnett MJ, 2012, NATURE, V483, P570, DOI 10.1038/nature11005
   Gong C, 2013, ONCOGENE, V32, P2261, DOI 10.1038/onc.2012.252
   Gonzales KAU, 2015, CELL, V162, P564, DOI 10.1016/j.cell.2015.07.001
   Grimshaw MJ, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2106
   Györffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9
   Hu G, 2009, GENE DEV, V23, P837, DOI 10.1101/gad.1769609
   Hu YF, 2009, J IMMUNOL METHODS, V347, P70, DOI 10.1016/j.jim.2009.06.008
   Hwang-Verslues WW, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008377
   Ithimakin S, 2013, CANCER RES, V73, P1635, DOI 10.1158/0008-5472.CAN-12-3349
   Ito K, 2014, NAT REV MOL CELL BIO, V15, P243, DOI 10.1038/nrm3772
   Lawson DA, 2015, NATURE, V526, P131, DOI 10.1038/nature15260
   Lee YK, 2007, J BIOL CHEM, V282, P1595, DOI 10.1074/jbc.M606306200
   Leis O, 2012, ONCOGENE, V31, P1354, DOI 10.1038/onc.2011.338
   Li LH, 2006, CANCER RES, V66, P4553, DOI 10.1158/0008-5472.CAN-05-3986
   Li X, 2007, J BIOL CHEM, V282, P36177, DOI 10.1074/jbc.M706912200
   Li X, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000781
   Liu H, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-583
   Lu HH, 2014, NAT CELL BIOL, V16, P1105, DOI 10.1038/ncb3041
   Malhotra Gautam K, 2011, J Carcinog, V10, P38, DOI 10.4103/1477-3163.91413
   Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027
   Iglesias JM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077281
   May CD, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2789
   Milla LA, 2012, BIOL RES, V45, P223, DOI 10.4067/S0716-97602012000300004
   Mortazavi A, 2008, NAT METHODS, V5, P621, DOI 10.1038/nmeth.1226
   Muñoz P, 2012, MOL ONCOL, V6, P620, DOI 10.1016/j.molonc.2012.10.006
   Neve RM, 2009, CANCER CELL, V10, P515, DOI DOI 10.1016/J.CCR.2006.10.008
   Okamoto K, 2006, BIOCHEM BIOPH RES CO, V351, P216, DOI 10.1016/j.bbrc.2006.10.022
   Pastò A, 2014, ONCOTARGET, V5, P4305, DOI 10.18632/oncotarget.2010
   Pineda CT, 2015, AUTOPHAGY, V11, P844, DOI 10.1080/15548627.2015.1034420
   Pond AC, 2013, STEM CELLS, V31, P178, DOI 10.1002/stem.1266
   Poyurovsky MV, 2003, MOL CELL, V12, P875, DOI 10.1016/S1097-2765(03)00400-3
   Prat A, 2013, BREAST CANCER RES TR, V142, P237, DOI 10.1007/s10549-013-2743-3
   Ricardo S, 2011, J CLIN PATHOL, V64, P937, DOI 10.1136/jcp.2011.090456
   Samur MK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056228
   Sarrió D, 2008, CANCER RES, V68, P989, DOI 10.1158/0008-5472.CAN-07-2017
   Sarrio D, 2012, STEM CELLS, V30, P292, DOI 10.1002/stem.791
   Seki Y, 2010, P NATL ACAD SCI USA, V107, P10926, DOI 10.1073/pnas.0907601107
   Sheridan C, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1610
   Singh AM, 2015, STEM CELL REP, V5, P323, DOI 10.1016/j.stemcr.2015.07.005
   Singh S, 2012, MOL CANCER, V11, DOI 10.1186/1476-4598-11-73
   Stickeler E, 2011, ONCOL REP, V26, P1037, DOI 10.3892/or.2011.1392
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Tian C, 2009, NAT CELL BIOL, V11, P580, DOI 10.1038/ncb1864
   Venkov CD, 2007, J CLIN INVEST, V117, P482, DOI 10.1172/JCI29544
   Viale A, 2014, NATURE, V514, P628, DOI 10.1038/nature13611
   Visvader JE, 2012, CELL STEM CELL, V10, P717, DOI 10.1016/j.stem.2012.05.007
   Wang CG, 2007, J BIOL CHEM, V282, P29902, DOI 10.1074/jbc.M704757200
   Wang F, 2012, MOL MED, V18, P887, DOI 10.2119/molmed.2011.00444
   Yang YH, 2013, P NATL ACAD SCI USA, V110, P6841, DOI 10.1073/pnas.1217692110
   Yokoe T, 2010, ANN SURG ONCOL, V17, P821, DOI 10.1245/s10434-009-0795-8
   Yu C, 2014, MED ONCOL, V31, DOI 10.1007/s12032-014-0025-5
   Zhang WZ, 2013, CANCER CELL, V23, P647, DOI 10.1016/j.ccr.2013.03.012
   Ziv Y, 2006, NAT CELL BIOL, V8, P870, DOI 10.1038/ncb1446
NR 75
TC 46
Z9 51
U1 0
U2 10
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD JAN 3
PY 2017
VL 8
IS 1
BP 863
EP 882
DI 10.18632/oncotarget.13273
PG 20
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA EH1DH
UT WOS:000391503300068
PM 27845900
OA Green Submitted, gold, Green Published
DA 2025-01-12
ER

PT J
AU Peña-Llopis, S
   Wan, YH
   Martinez, ED
AF Pena-Llopis, Samuel
   Wan, Yihong
   Martinez, Elisabeth D.
TI Unique epigenetic gene profiles define human breast cancers with poor
   prognosis
SO ONCOTARGET
LA English
DT Article
DE epigenetic signature; expression profiles; prognosis; molecular targets;
   triple negative breast cancer
ID ESTROGEN-RECEPTOR-ALPHA; HISTONE DEMETHYLASES; DNA HYPERMETHYLATION;
   NONHISTONE PROTEINS; ANTICANCER THERAPY; BASAL-LIKE; EXPRESSION;
   METHYLATION; GROWTH; TUMOR
AB Epigenetic enzymes are at the nexus of cellular regulatory cascades and can drive cancer-specific deregulation at all stages of the oncogenic process, yet little is known about their prognostic value in human patients. Here, we used qRT-PCR to profile at high resolution the expression of fifty-five epigenetic genes in over one hundred human breast cancer samples and patient-matched benign tissues. We correlated expression patterns with clinical and histological parameters and validated our findings in two independent large patient cohorts (TCGA and METABRIC). We found that human breast malignancies have unique epigenetic profiles and cluster into epigenetic subgroups. A subset of epigenetic genes defined an Epigenetic Signature as an independent predictor of patient survival that outperforms triple negative status and other clinical variables. Our results also suggest that breast cancer grade, but not stage, is driven by transcriptional alterations of epigenetic modifiers. Overall, this study uncovers the presence of epigenetic subtypes within human mammary malignancies and identifies tumor subgroups with specific pharmacologically targetable epigenetic susceptibilities not yet therapeutically exploited.
C1 [Pena-Llopis, Samuel; Wan, Yihong; Martinez, Elisabeth D.] UT Southwestern Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA.
   [Pena-Llopis, Samuel] Natl Ctr Tumor Dis, Dept Translat Oncol, Heidelberg, Germany.
   [Pena-Llopis, Samuel] German Canc Res Ctr, Heidelberg, Germany.
C3 University of Texas System; University of Texas Southwestern Medical
   Center Dallas; Helmholtz Association; German Cancer Research Center
   (DKFZ); Ruprecht Karls University Heidelberg; Helmholtz Association;
   German Cancer Research Center (DKFZ)
RP Peña-Llopis, S; Martinez, ED (通讯作者)，UT Southwestern Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA.; Peña-Llopis, S (通讯作者)，Natl Ctr Tumor Dis, Dept Translat Oncol, Heidelberg, Germany.; Peña-Llopis, S (通讯作者)，German Canc Res Ctr, Heidelberg, Germany.
EM Samuel.Pena.Llopis@gmail.com; elisabeth.martinez@utsouthwestern.edu
RI Wan, Yihong/J-8681-2012; Peña-Llopis, Samuel/ABH-2358-2020; Pena-Llopis,
   Samuel/LBH-4206-2024
OI Pena-Llopis, Samuel/0000-0003-3847-1353
FU NCI [R01CA12526901]; Friends of Cancer Center; Welch Foundation [I-1878,
   I-1751]; CPRIT [RP120717, RP160493, RP130145]; DOD [W81XWH-13-1-0318];
   National Center for Advancing Translational Sciences of National
   Institutes of Health [UL1TR001105]
FX We are grateful to Drs. Bookout and Sondhi for assistance with qRT-PCR
   robotics, to Ewa Borowicz and Kenneth Spence for primer design and
   validation, and to M. Varghese for technical help. This work was partly
   funded by the NCI (R01CA12526901 to E.D.M.), by the Friends of the
   Cancer Center, by The Welch Foundation (I-1878 to E.D.M.; I-1751 to
   Y.W.), by CPRIT (RP120717, and RP160493 to E.D.M.; RP130145 to Y.W.),
   and by DOD (W81XWH-13-1-0318 to Y.W.). Research reported in this
   publication was partly supported by the National Center for Advancing
   Translational Sciences of the National Institutes of Health under award
   Number UL1TR001105 to E.D.M. and S.P-L. The content is solely the
   responsibility of the authors and does not necessarily represent the
   official views of the NIH. Authors report no financial conflicts of
   interest.
CR Berdel B, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-516
   Berry WL, 2013, CANCER RES, V73, P2936, DOI 10.1158/0008-5472.CAN-12-4300
   Bookout AL, 2006, CURR PROTOC MOL BIOL
   Cheang MCU, 2009, JNCI-J NATL CANCER I, V101, P736, DOI 10.1093/jnci/djp082
   Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983
   Duan LL, 2015, CHEM BIOL, V22, P1185, DOI 10.1016/j.chembiol.2015.08.007
   Euhus DM, 2008, CANCER EPIDEM BIOMAR, V17, P1051, DOI 10.1158/1055-9965.EPI-07-2582
   Ezponda T, 2014, CLIN CANCER RES, V20, P5001, DOI 10.1158/1078-0432.CCR-13-2499
   Fucito A, 2008, INT J BIOCHEM CELL B, V40, P565, DOI 10.1016/j.biocel.2007.10.018
   Fujii S, 2011, ONCOGENE, V30, P4118, DOI 10.1038/onc.2011.118
   Gao ZH, 2012, MOL CELL, V45, P344, DOI 10.1016/j.molcel.2012.01.002
   Gazdar AF, 1998, INT J CANCER, V78, P766, DOI 10.1002/(SICI)1097-0215(19981209)78:6<766::AID-IJC15>3.0.CO;2-L
   Glozak MA, 2005, GENE, V363, P15, DOI 10.1016/j.gene.2005.09.010
   Heagerty PJ, 2000, BIOMETRICS, V56, P337, DOI 10.1111/j.0006-341X.2000.00337.x
   Helming KC, 2014, CANCER CELL, V26, P309, DOI 10.1016/j.ccr.2014.07.018
   Hojfeldt JW, 2013, NAT REV DRUG DISCOV, V12, P917, DOI 10.1038/nrd4154
   Huang Y, 2007, P NATL ACAD SCI USA, V104, P8023, DOI 10.1073/pnas.0700720104
   Ismail IH, 2013, J BIOL CHEM, V288, P26944, DOI 10.1074/jbc.M113.461699
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   Juan BY, 2015, FUTURE MED CHEM, V7, P2243, DOI 10.4155/fmc.15.140
   Kadamb R, 2013, EUR J CELL BIOL, V92, P237, DOI 10.1016/j.ejcb.2013.09.001
   Kaelin WG, 2010, NATURE, V465, P562, DOI 10.1038/465562a
   Kalashnikova EV, 2010, CANCER RES, V70, P9402, DOI 10.1158/0008-5472.CAN-10-1199
   Kampranis SC, 2009, ADV CANCER RES, V102, P103, DOI 10.1016/S0065-230X(09)02004-1
   Kim HS, 2011, CANCER CELL, V20, P487, DOI 10.1016/j.ccr.2011.09.004
   Lee YH, 2009, MOL ENDOCRINOL, V23, P425, DOI 10.1210/me.2008-0380
   Lehmann BD, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1102-7
   Li WZ, 2014, EPIGENOMICS-UK, V6, P381, DOI 10.2217/epi.14.31
   Patani N, 2011, ANTICANCER RES, V31, P4115
   Peña-Llopis S, 2013, NAT PROTOC, V8, P2240, DOI 10.1038/nprot.2013.141
   Peña-Llopis S, 2013, CANCER RES, V73, P4173, DOI 10.1158/0008-5472.CAN-13-0360
   Peña-Llopis S, 2011, EMBO J, V30, P3242, DOI 10.1038/emboj.2011.257
   Polyak K, 2007, J CLIN INVEST, V117, P3155, DOI 10.1172/JCI33295
   Prat A, 2013, ONCOLOGIST, V18, P123, DOI 10.1634/theoncologist.2012-0397
   Rathert P, 2008, NAT CHEM BIOL, V4, P344, DOI 10.1038/nchembio.88
   Reiche K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106076
   Roll JD, 2013, EXP MOL PATHOL, V95, P276, DOI 10.1016/j.yexmp.2013.09.001
   Schneider P, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9023
   Sharma SV, 2010, CELL, V141, P69, DOI 10.1016/j.cell.2010.02.027
   Simon JA, 2008, MUTATION RES
   Sunami E, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2098
   Van Rechem C, 2015, CANCER DISCOV, V5, P255, DOI 10.1158/2159-8290.CD-14-1326
   Wang L, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3035
   Wiegand KC, 2010, NEW ENGL J MED, V363, P1532, DOI 10.1056/NEJMoa1008433
   Xu BW, 2015, EXP HEMATOL, V43, P698, DOI 10.1016/j.exphem.2015.05.001
   Yang J, 2010, CANCER RES, V70, P6456, DOI 10.1158/0008-5472.CAN-10-0413
   Zhang YQ, 2015, INT J CLIN EXP PATHO, V8, P751
   Zhou Q, 2007, CANCER BIOL THER, V6, P64, DOI 10.4161/cbt.6.1.3549
NR 48
TC 12
Z9 13
U1 0
U2 5
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD DEC 27
PY 2016
VL 7
IS 52
BP 85819
EP 85831
DI 10.18632/oncotarget.13334
PG 13
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA EG9ZT
UT WOS:000391422500014
PM 27863398
OA Green Submitted, gold, Green Published
DA 2025-01-12
ER

PT J
AU Taslim, C
   Weng, DY
   Brasky, TM
   Dumitrescu, RG
   Huang, K
   Kallakury, BVS
   Krishnan, S
   Llanos, AA
   Marian, C
   McElroy, J
   Schneider, SS
   Spear, SL
   Troester, MA
   Freudenheim, JL
   Geyer, S
   Shields, PG
AF Taslim, Cenny
   Weng, Daniel Y.
   Brasky, Theodore M.
   Dumitrescu, Ramona G.
   Huang, Kun
   Kallakury, Bhaskar V. S.
   Krishnan, Shiva
   Llanos, Adana A.
   Marian, Catalin
   McElroy, Joseph
   Schneider, Sallie S.
   Spear, Scott L.
   Troester, Melissa A.
   Freudenheim, Jo L.
   Geyer, Susan
   Shields, Peter G.
TI Discovery and replication of microRNAs for breast cancer risk using
   genome-wide profiling
SO ONCOTARGET
LA English
DT Article
DE microRNA; epigenetics; breast cancer risk prediction; tissue-based
   biomarkers; healthy women
ID PREDICTION MODEL; GENE-EXPRESSION; SERUM; WOMEN; VALIDATION; SIGNATURE;
   MORTALITY; BIOMARKER; VARIANTS; MUTATION
AB Background: Genome-wide miRNA expression may be useful for predicting breast cancer risk and/or for the early detection of breast cancer.
   Results: A 41-miRNA model distinguished breast cancer risk in the discovery study (accuracy of 83.3%), which was replicated in the independent study (accuracy = 63.4%, P=0.09). Among the 41 miRNA, 20 miRNAs were detectable in serum, and predicted breast cancer occurrence within 18 months of blood draw (accuracy 53%, P=0.06). These risk-related miRNAs were enriched for HER-2 and estrogen-dependent breast cancer signaling.
   Materials and Methods: MiRNAs were assessed in two cross-sectional studies of women without breast cancer and a nested case-control study of breast cancer. Using breast tissues, a multivariate analysis was used to model women with high and low breast cancer risk (based upon Gail risk model) in a discovery study of women without breast cancer (n=90), and applied to an independent replication study (n=71). The model was then assessed using serum samples from the nested case-control study (n=410).
   Conclusions: Studying breast tissues of women without breast cancer revealed miRNAs correlated with breast cancer risk, which were then found to be altered in the serum of women who later developed breast cancer. These results serve as proof-ofprinciple that miRNAs in women without breast cancer may be useful for predicting breast cancer risk and/or as an adjunct for breast cancer early detection. The miRNAs identified herein may be involved in breast carcinogenic pathways because they were first identified in the breast tissues of healthy women.
C1 [Taslim, Cenny; Weng, Daniel Y.; Brasky, Theodore M.; Huang, Kun; Krishnan, Shiva; Marian, Catalin; Shields, Peter G.] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA.
   [Dumitrescu, Ramona G.] Distilled Spirits Council US, Washington, DC USA.
   [Kallakury, Bhaskar V. S.] Georgetown Univ, Dept Pathol, Washington, DC USA.
   [Llanos, Adana A.] Rutgers State Univ, Dept Epidemiol, New Brunswick, NJ USA.
   [McElroy, Joseph] Ohio State Univ, Ctr Comprehens Canc, Ctr Biostat, Columbus, OH 43210 USA.
   [Schneider, Sallie S.] Pioneer Valley Life Sci Inst, Springfield, MA USA.
   [Spear, Scott L.] Georgetown Univ Hosp, Dept Plast Surg, Washington, DC 20007 USA.
   [Troester, Melissa A.] Univ North Carolina Chapel Hill, Lineberger Comprehens Canc Ctr, Chapel Hill, NC USA.
   [Freudenheim, Jo L.] SUNY Buffalo, Sch Publ Hlth & Hlth Profess, Dept Epidemiol & Environm Hlth, Buffalo, NY USA.
   [Geyer, Susan] Univ S Florida, Hlth Informat Inst, Tampa, FL USA.
   [Marian, Catalin] Victor Babes Univ Med & Pharm, Timisoara, Romania.
C3 University System of Ohio; Ohio State University; James Cancer Hospital
   & Solove Research Institute; Georgetown University; Rutgers University
   System; Rutgers University New Brunswick; James Cancer Hospital & Solove
   Research Institute; University System of Ohio; Ohio State University;
   Georgetown University; University of North Carolina School of Medicine;
   University of North Carolina; University of North Carolina Chapel Hill;
   State University of New York (SUNY) System; University at Buffalo, SUNY;
   State University System of Florida; University of South Florida; Victor
   Babes University of Medicine & Pharmacy, Timisoara
RP Shields, PG (通讯作者)，Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA.
EM Peter.Shields@osumc.edu
RI Shields, Peter/I-1644-2012; Huang, Kun/W-4724-2017; Marian,
   Catalin/KHU-8477-2024; Llanos, Adana/J-8695-2019; Marian,
   Catalin/P-2885-2019
OI Marian, Catalin/0000-0002-7749-1384; Freudenheim, Jo/0000-0002-9301-0499
FU Avon Foundation [01-2010-039]; Breast Cancer Center of Excellence Award
   from United States Department of Defense [BC022346]
FX This work was supported by Avon Foundation [01-2010-039] and Breast
   Cancer Center of Excellence Award from United States Department of
   Defense [BC022346].
CR [Anonymous], EV ROL NIPPL ASP DUC
   [Anonymous], Acids Res
   [Anonymous], 2015, CANC FACTS FIG 2015
   [Anonymous], NAT STRUCT MOL BIOL
   [Anonymous], PHASE 1 2 TRIAL IMC
   Barlow WE, 2006, JNCI-J NATL CANCER I, V98, P1204, DOI 10.1093/jnci/djj331
   Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5
   BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x
   Berry DA, 2005, NEW ENGL J MED, V353, P1784, DOI 10.1056/NEJMoa050518
   Berry DA, 1997, J NATL CANCER I, V89, P227, DOI 10.1093/jnci/89.3.227
   Bolstad BM, 2003, BIOINFORMATICS, V19, P185, DOI 10.1093/bioinformatics/19.2.185
   BONDY ML, 1994, J NATL CANCER I, V86, P620, DOI 10.1093/jnci/86.8.620
   Campbell JD, 2016, CANCER PREV RES, V9, P119, DOI 10.1158/1940-6207.CAPR-16-0024
   Cao KAL, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-253
   Chan M, 2013, CLIN CANCER RES, V19, P4477, DOI 10.1158/1078-0432.CCR-12-3401
   Chang CW, 2015, ANTICANCER RES, V35, P3969
   Chen JB, 2006, J NATL CANCER I, V98, P1215, DOI 10.1093/jnci/djj332
   CLAUS EB, 1994, CANCER, V73, P643, DOI 10.1002/1097-0142(19940201)73:3<643::AID-CNCR2820730323>3.0.CO;2-5
   Collett K, 2005, CANCER EPIDEM BIOMAR, V14, P1108, DOI 10.1158/1055-9965.EPI-04-0394
   Costantino JP, 1999, J NATL CANCER I, V91, P1541, DOI 10.1093/jnci/91.18.1541
   Couch FJ, 2012, CANCER EPIDEM BIOMAR, V21, P645, DOI 10.1158/1055-9965.EPI-11-0888
   D'haene Barbara, 2012, Methods Mol Biol, V822, P261, DOI 10.1007/978-1-61779-427-8_18
   Di Leva G, 2010, JNCI-J NATL CANCER I, V102, P706, DOI 10.1093/jnci/djq102
   Dumitrescu RG, 2010, J CELL MOL MED, V14, P1468, DOI 10.1111/j.1582-4934.2009.00924.x
   Efron B., 1993, INTRO BOOTSTRAP, DOI [DOI 10.1201/9780429246593, 10.1007/978-1-4899-4541-4549, DOI 10.1007/978-1-4899-4541-4549]
   Friedman RC, 2009, GENOME RES, V19, P92, DOI 10.1101/gr.082701.108
   GAIL MH, 1989, JNCI-J NATL CANCER I, V81, P1879, DOI 10.1093/jnci/81.24.1879
   Gail MH, 2007, J NATL CANCER I, V99, P1782, DOI 10.1093/jnci/djm223
   Gasparini P, 2014, ONCOTARGET, V5, P1174, DOI 10.18632/oncotarget.1682
   Geiss GK, 2008, NAT BIOTECHNOL, V26, P317, DOI 10.1038/nbt1385
   Godfrey AC, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3428
   Hu ZB, 2012, CARCINOGENESIS, V33, P828, DOI 10.1093/carcin/bgs030
   Hu ZB, 2010, J CLIN ONCOL, V28, P1721, DOI 10.1200/JCO.2009.24.9342
   Huh SJ, 2016, CANCER RES, V76, P1926, DOI 10.1158/0008-5472.CAN-15-1927
   Iorio MV, 2012, EMBO MOL MED, V4, P143, DOI 10.1002/emmm.201100209
   Iorio MV, 2009, J CLIN ONCOL, V27, P5848, DOI 10.1200/JCO.2009.24.0317
   Kalager M, 2010, NEW ENGL J MED, V363, P1203, DOI 10.1056/NEJMoa1000727
   Llanos AA, 2013, BREAST CANCER RES TR, V138, P571, DOI 10.1007/s10549-013-2452-y
   Massion PP, 2014, J CLIN ONCOL, V32, P725, DOI 10.1200/JCO.2013.54.0047
   Matsuno RK, 2011, J NATL CANCER I, V103, P951, DOI 10.1093/jnci/djr154
   Mestdagh P, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-6-r64
   Mitchell PS, 2008, P NATL ACAD SCI USA, V105, P10513, DOI 10.1073/pnas.0804549105
   Muti P, 2014, CANCER EPIDEM BIOMAR, V23, P2471, DOI 10.1158/1055-9965.EPI-14-0398
   Nattinger AB, 2010, ANN INTERN MED, V152, P832, DOI [10.7326/0003-4819-152-7-201004060-01004, 10.7326/0003-4819-152-12-201006150-00027]
   Pankratz VS, 2008, J CLIN ONCOL, V26, P5374, DOI 10.1200/JCO.2007.14.8833
   Parrella P, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-142
   Pirone JR, 2012, CANCER EPIDEM BIOMAR, V21, P1735, DOI 10.1158/1055-9965.EPI-12-0451
   Prokopec SD, 2013, RNA, V19, P51, DOI 10.1261/rna.034710.112
   Sakurai M, 2015, INT J BIOL MARKER, V30, pE190, DOI 10.5301/jbm.5000141
   Sandoval J, 2013, J CLIN ONCOL, V31, P4140, DOI 10.1200/JCO.2012.48.5516
   Sawyer S, 2012, J CLIN ONCOL, V30, P4330, DOI 10.1200/JCO.2012.41.7469
   Silveri L, 2006, REPROD NUTR DEV, V46, P549, DOI 10.1051/rnd:2006026
   Sozzi G, 2014, J CLIN ONCOL, V32, P768, DOI 10.1200/JCO.2013.50.4357
   SPIEGELMAN D, 1994, J NATL CANCER I, V86, P600, DOI 10.1093/jnci/86.8.600
   Stinson S, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001538
   Tyrer J, 2004, STAT MED, V23, P1111, DOI 10.1002/sim.1668
   van Schooneveld E, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3127
   Vergoulis T, 2012, NUCLEIC ACIDS RES, V40, pD222, DOI 10.1093/nar/gkr1161
   Wang LG, 2012, CANCER EPIDEMIOL, V36, pE61, DOI 10.1016/j.canep.2011.05.002
   Wulfken LM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025787
   Xu ZL, 2013, JNCI-J NATL CANCER I, V105, P694, DOI 10.1093/jnci/djt045
NR 61
TC 15
Z9 15
U1 0
U2 14
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD DEC 27
PY 2016
VL 7
IS 52
BP 86457
EP 86468
DI 10.18632/oncotarget.13241
PG 12
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA EG9ZT
UT WOS:000391422500064
PM 27833082
OA Green Published, Green Submitted, gold
DA 2025-01-12
ER

PT J
AU Rossetti, S
   Ren, MQ
   Visconti, N
   Corlazzoli, F
   Gagliostro, V
   Somenzi, G
   Yao, J
   Sun, YJ
   Sacchi, N
AF Rossetti, Stefano
   Ren, MingQiang
   Visconti, Nicolo
   Corlazzoli, Francesca
   Gagliostro, Vincenzo
   Somenzi, Giulia
   Yao, Jin
   Sun, Yijun
   Sacchi, Nicoletta
TI Tracing anti-cancer and cancer-promoting actions of all-trans retinoic
   acid in breast cancer to a RARa epigenetic mechanism of mammary
   epithelial cell fate
SO ONCOTARGET
LA English
DT Article
DE retinoic acid (RA); RARA; epigenetic transcriptional regulation; mammary
   epithelial cell fate decisions; breast cancer
ID 2ND PRIMARY TUMORS; ALDEHYDE DEHYDROGENASE; STAGE-I; DIFFERENTIATION;
   ACTIVATION; EXPRESSION; DYNAMICS; NUCLEAR; GROWTH; GENE
AB A hallmark of cancer cells is the ability to evade the growth inhibitory/proapoptotic action of physiological all-trans retinoic acid (RA) signal, the bioactive derivative of Vitamin A. However, as we and others reported, RA can also promote cancer cell growth and invasion. Here we show that anticancer and cancer-promoting RA actions in breast cancer have roots in a mechanism of mammary epithelial cell morphogenesis that involves both transcriptional (epigenetic) and non-transcriptional RARa (RARA) functions. We found that the mammary epithelial cell-context specific degree of functionality of the RARA transcriptional (epigenetic) component of this mechanism, by tuning the effects of the non-transcriptional RARA component, determines different cell fate decisions during mammary morphogenesis. Indeed, factors that hamper the RARA epigenetic function make physiological RA drive aberrant morphogenesis via non-transcriptional RARA, thus leading to cell transformation. Remarkably, also the cell context-specific degree of functionality of the RARA epigenetic component retained by breast cancer cells is critical to determine cell fate decisions in response to physiological as well as supraphysiological RA variation. Overall this study supports the proof of principle that the epigenetic functional plasticity of the mammary epithelial cell RARA mechanism, which is essential for normal morphogenetic processes, is necessary to deter breast cancer onset/progression consequent to the insidious action of physiological RA.
C1 [Rossetti, Stefano; Ren, MingQiang; Visconti, Nicolo; Corlazzoli, Francesca; Gagliostro, Vincenzo; Somenzi, Giulia; Sacchi, Nicoletta] Roswell Pk Canc Inst, Dept Canc Genet, Buffalo, NY 14263 USA.
   [Yao, Jin; Sun, Yijun] SUNY Buffalo, Ctr Excellence Bioinformat & Life Sci, Buffalo, NY 14203 USA.
C3 Roswell Park Comprehensive Cancer Center; State University of New York
   (SUNY) System; University at Buffalo, SUNY
RP Sacchi, N (通讯作者)，Roswell Pk Canc Inst, Dept Canc Genet, Buffalo, NY 14263 USA.
EM nicoletta.sacchi@roswellpark.org
RI Sun, Yijun/F-9698-2017; Yao, Jin/Y-2104-2019; Ren,
   Mingqiang/KHV-8463-2024
OI Yao, Jin/0000-0001-9186-459X
FU NCI [R01 CA127614]; U.S. Army grant [DAMD 17-02-01-0432]; Breast Cancer
   Coalition of Rochester; Friends for an Earlier Breast Cancer Test
   Foundation; Susan Komen Foundation; Terri Brodeur Breast Cancer
   Foundation; NCI institutional grant [P30 CA016056]
FX We thank our colleagues at Roswell Park Cancer Institute Drs. R. Huang
   and L. Tagliavacca for establishing some of the T47D clonal lines used
   in this study, Dr. K. Eng for statistical analysis, Dr. S. Liu for
   assistance with microarray bioinformatics analysis, and Dr. D. Goodrich
   for useful insights and discussions. We are grateful to Drs. R. Albalat
   (University of Barcelona, Spain), Gregg Duester (Sanford-Burnham Medical
   Research Institute, La Jolla, CA) and J. Peters (Penn State University,
   University Park, PA) for useful discussions, Dr. C. Ross (Pennsylvania
   State University, University Park, PA) for advice on in vivo experiments
   and RA diets, and Dr. D. Bell (NHGRI, Bethesda, MD) for PI3K sequencing.
   Funding for this study was provided by the NCI R01 CA127614 grant (NS),
   the U.S. Army DAMD 17-02-01-0432 grant (NS), the Breast Cancer Coalition
   of Rochester (NS), the Friends for an Earlier Breast Cancer Test
   Foundation (NS, SR), the Susan Komen Foundation (SR), the Terri Brodeur
   Breast Cancer Foundation (SR) and the NCI P30 CA016056 institutional
   grant.
CR Ablain J, 2014, INT J CANCER, V135, P2262, DOI 10.1002/ijc.29081
   Albalat R, 2009, CHEM-BIOL INTERACT, V178, P188, DOI 10.1016/j.cbi.2008.09.017
   Balmer JE, 2005, J STEROID BIOCHEM, V96, P347, DOI 10.1016/j.jsbmb.2005.05.005
   Balmer JE, 2002, J LIPID RES, V43, P1773, DOI 10.1194/jlr.R100015-JLR200
   Bean GR, 2005, CANCER EPIDEM BIOMAR, V14, P790, DOI 10.1158/1055-9965.EPI-04-0580
   Bintu L, 2016, SCIENCE, V351, P720, DOI 10.1126/science.aab2956
   Bistulfi G, 2006, CANCER RES, V66, P10308, DOI 10.1158/0008-5472.CAN-06-1052
   Cai AQ, 2012, DEVELOPMENT, V139, P2150, DOI 10.1242/dev.077065
   Chambon P, 2005, MOL ENDOCRINOL, V19, P1418, DOI 10.1210/me.2005-0125
   Collins MD, 1999, ANNU REV PHARMACOL, V39, P399, DOI 10.1146/annurev.pharmtox.39.1.399
   Corlazzoli F, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004305
   Croker AK, 2009, J CELL MOL MED, V13, P2236, DOI 10.1111/j.1582-4934.2008.00455.x
   Cunningham TJ, 2015, NAT REV MOL CELL BIO, V16, P110, DOI 10.1038/nrm3932
   Di Croce L, 2002, SCIENCE, V295, P1079, DOI 10.1126/science.1065173
   Evron E, 2001, LANCET, V357, P1335, DOI 10.1016/S0140-6736(00)04501-3
   Freemantle SJ, 2006, J NATL CANCER I, V98, P426, DOI 10.1093/jnci/djj116
   Gilardi F, 2014, SUBCELL BIOCHEM, V70, P75, DOI 10.1007/978-94-017-9050-5_5
   Ginestier C, 2007, CELL STEM CELL, V1, P555, DOI 10.1016/j.stem.2007.08.014
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Heard E, 2013, EPIGENETICS DEV
   Honeth G, 2014, BREAST CANCER RES, V16, DOI 10.1186/bcr3663
   Hua SJ, 2009, CELL, V137, P1259, DOI 10.1016/j.cell.2009.04.043
   Khuri FR, 2006, JNCI-J NATL CANCER I, V98, P441, DOI 10.1093/jnci/djj091
   Kouno T, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-10-r118
   Kruse SW, 2008, PLOS BIOL, V6, P2002, DOI 10.1371/journal.pbio.0060227
   LaBarge MA, 2016, GERONTOLOGY, V62, P434, DOI 10.1159/000441030
   Laganière J, 2005, MOL ENDOCRINOL, V19, P1584, DOI 10.1210/me.2005-0040
   Lippman SM, 2001, JNCI-J NATL CANCER I, V93, P605, DOI 10.1093/jnci/93.8.605
   Liu ZJ, 2014, SUBCELL BIOCHEM, V70, P203, DOI 10.1007/978-94-017-9050-5_10
   Mark Manuel, 2009, Nucl Recept Signal, V7, pe002, DOI 10.1621/nrs.07002
   Masía S, 2007, MOL ENDOCRINOL, V21, P2391, DOI 10.1210/me.2007-0062
   Montesano R, 2002, J CELL SCI, V115, P4419, DOI 10.1242/jcs.00164
   Napoli JL, 2012, BBA-MOL CELL BIOL L, V1821, P152, DOI 10.1016/j.bbalip.2011.05.004
   Ochoa WF, 2003, BIOCHEMISTRY-US, V42, P8774, DOI 10.1021/bi034713g
   PETERSEN OW, 1992, P NATL ACAD SCI USA, V89, P9064, DOI 10.1073/pnas.89.19.9064
   Piskunov A, 2014, SUBCELL BIOCHEM, V70, P103, DOI 10.1007/978-94-017-9050-5_6
   Purvis JE, 2013, CELL, V152, P945, DOI 10.1016/j.cell.2013.02.005
   Radominska-Pandya A, 2000, J BIOL CHEM, V275, P22324, DOI 10.1074/jbc.M907722199
   Ren MQ, 2005, MOL CELL BIOL, V25, P10591, DOI 10.1128/MCB.25.23.10591-10603.2005
   Renner O, 2008, CANCER RES, V68, P9643, DOI 10.1158/0008-5472.CAN-08-1539
   Rhinn M, 2012, DEVELOPMENT, V139, P843, DOI 10.1242/dev.065938
   Rochette-Egly C, 2015, BBA-MOL CELL BIOL L, V1851, P66, DOI 10.1016/j.bbalip.2014.04.003
   Rossetti S, 2016, CANCER LETT, V380, P375, DOI 10.1016/j.canlet.2016.07.003
   Rossetti S, 2010, J CELL MOL MED, V14, P1358, DOI 10.1111/j.1582-4934.2009.00982.x
   Sakr RA, 2014, CLIN CANCER RES, V20, P2326, DOI 10.1158/1078-0432.CCR-13-2267
   Samarut E, 2015, BBA-GENE REGUL MECH, V1849, P73, DOI 10.1016/j.bbagrm.2014.05.030
   Schilling TF, 2016, METHOD CELL BIOL, V133, P139, DOI 10.1016/bs.mcb.2016.03.003
   Schilling TF, 2012, CURR OPIN GENET DEV, V22, P562, DOI 10.1016/j.gde.2012.11.012
   Schug TT, 2007, CELL, V129, P723, DOI 10.1016/j.cell.2007.02.050
   Seewaldt VL, 1997, EXP CELL RES, V236, P16, DOI 10.1006/excr.1997.3694
   Sessler RJ, 2005, MOL CELL, V18, P343, DOI 10.1016/j.molcel.2005.03.026
   Shaw N, 2003, J BIOL CHEM, V278, P41589, DOI 10.1074/jbc.C300368200
   Shimada J, 2001, MOL ENDOCRINOL, V15, P1677, DOI 10.1210/me.15.10.1677
   Sirchia SM, 2000, ONCOGENE, V19, P1556, DOI 10.1038/sj.onc.1203456
   Sirchia SM, 2002, CANCER RES, V62, P2455
   Somenzi G, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000836
   Stelzer Y, 2015, CELL, V163, P218, DOI 10.1016/j.cell.2015.08.046
   Trapnell C, 2014, NAT BIOTECHNOL, V32, P381, DOI 10.1038/nbt.2859
   TSANG MLS, 1995, CYTOKINE, V7, P389, DOI 10.1006/cyto.1995.0054
   Uribesalgo I, 2011, NAT CELL BIOL, V13, P1443, DOI 10.1038/ncb2355
   Urvalek A, 2014, SUBCELL BIOCHEM, V70, P129, DOI 10.1007/978-94-017-9050-5_7
   Utermark T, 2012, GENE DEV, V26, P1573, DOI 10.1101/gad.191973.112
   Wang YA, 2005, DEV DYNAM, V234, P892, DOI 10.1002/dvdy.20570
   Yamamoto Y, 2000, FASEB J, V14, P2119, DOI 10.1096/fj.00-0061com
   Zhu WT, 2013, DEV BIOL, V379, P235, DOI 10.1016/j.ydbio.2013.04.029
NR 65
TC 9
Z9 10
U1 0
U2 2
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD DEC 27
PY 2016
VL 7
IS 52
BP 87064
EP 87080
DI 10.18632/oncotarget.13500
PG 17
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA EG9ZT
UT WOS:000391422500112
PM 27894085
OA gold, Green Published, Green Submitted
DA 2025-01-12
ER

PT J
AU Vennin, C
   Spruyt, N
   Robin, YM
   Chassat, T
   Le Bourhis, X
   Adriaenssens, E
AF Vennin, Constance
   Spruyt, Nathalie
   Robin, Yves-Marie
   Chassat, Thierry
   Le Bourhis, Xuefen
   Adriaenssens, Eric
TI The long non-coding RNA <i>91H</i> increases aggressive phenotype of
   breast cancer cells and up-regulates <i>H19</i>/<i>IGF2</i> expression
   through epigenetic modifications
SO CANCER LETTERS
LA English
DT Article
DE H19 antisense; Long non-coding RNA; Breast tumorigenesis; Genomic
   imprinting
ID H19 GENE; GROWTH; OVEREXPRESSION; CONTRIBUTES; METASTASIS; BINDING;
   TUMORS
AB Numerous genomic imprinting loci are regulated by long non-coding RNA (lncRNA). We have previously identified a new lncRNA at the H19/IGF2 locus transcribed in H19 antisense orientation and named 91H. This RNA is conserved among mammals. In mice, 91H regulates positively IGF2 expression from a novel promoter. However, in human the function of 91H at the H19/IGF2 locus remains largely undeciphered.
   Here, we observed that 91H, H19 and IGF2 are overexpressed in breast tumors. By using 91H-knockdown breast cancer cells, we demonstrated that 91H exerts oncogenic properties by promoting cell growth, migration and invasion as well as tumor growth in xenografted immunodeficient mouse model. Moreover, 91H-knockdown reduces the expression of H19 and IGF2 in breast cancer cells. By chromatin-immunoprecipitation and methylation studies, we found that 91H expression prevents histone and DNA methylation on the maternal allele at the H19/IGF2 locus. These results indicate that 91H, through epigenetic modifications, is responsible of the maintenance of H19/IGF2 genomic imprinting allowing the allele-specific expression of H19 and IGF2. Taken together, overexpression of 91H in breast cancer and 91H-induced epigenetic modifications on H19/IGF2 locus suggest that 91H may play essential role in breast cancer development. Further studies are needed to investigate their role in terms of diagnosis and therapeutic. (C) 2016 Elsevier Ireland Ltd. All rights reserved.
C1 [Vennin, Constance; Robin, Yves-Marie; Le Bourhis, Xuefen; Adriaenssens, Eric] INSERM, U908, F-59655 Villeneuve Dascq, France.
   [Vennin, Constance; Le Bourhis, Xuefen; Adriaenssens, Eric] Univ Lille, F-59655 Villeneuve Dascq, France.
   [Spruyt, Nathalie] CNRS, UMR 8161, F-59021 Lille, France.
   [Robin, Yves-Marie] Ctr Oscar Lambret, F-59020 Lille, France.
   [Chassat, Thierry] Inst Pasteur, PLETHA, F-59019 Lille, France.
C3 Institut National de la Sante et de la Recherche Medicale (Inserm);
   Universite de Lille; Universite de Lille; Universite de Lille; Centre
   National de la Recherche Scientifique (CNRS); CNRS - National Institute
   for Biology (INSB); UNICANCER; Centre Oscar Lambret; Pasteur Network;
   Universite de Lille; Institut Pasteur Lille
RP Adriaenssens, E (通讯作者)，Univ Lille, INSERM, U908, Cell Plast & Canc, Batiment SN3, F-59655 Villeneuve Dascq, France.
EM eric.adriaenssens@univ-lille1.fr
RI Le+Bourhis, Xuefen/AAL-5141-2021
OI ROBIN, Yves-Marie/0000-0002-4227-6545; Vennin,
   Constance/0000-0001-6312-9467
FU INSERM; INCA [PLBio 2010-180]; University of Lille 2; ARC Fondation
   fellowships
FX This work was supported by INSERM and grant from INCA (PLBio 2010-180).
   C.V. was supported by doctoral fellowships from the University of Lille
   2 and by ARC Fondation fellowships.
CR Adriaenssens E, 1998, AM J PATHOL, V153, P1597, DOI 10.1016/S0002-9440(10)65748-3
   Adriaenssens E, 1999, ONCOGENE, V18, P4460, DOI 10.1038/sj.onc.1202819
   Angrand PO, 2015, FRONT GENET, V6, DOI 10.3389/fgene.2015.00165
   ARIEL I, 1995, UROLOGY, V45, P335, DOI 10.1016/0090-4295(95)80030-1
   Ariel I, 1997, DIAGN MOL PATHOL, V6, P17, DOI 10.1097/00019606-199702000-00004
   Barsyte-Lovejoy D, 2006, CANCER RES, V66, P5330, DOI 10.1158/0008-5472.CAN-06-0037
   BATES P, 1995, BRIT J CANCER, V72, P1189, DOI 10.1038/bjc.1995.484
   Bergman D, 2013, GERONTOLOGY, V59, P240, DOI 10.1159/000343995
   Berteaux N, 2005, J BIOL CHEM, V280, P29625, DOI 10.1074/jbc.M504033200
   Berteaux N, 2008, MOL CELL BIOL, V28, P6731, DOI 10.1128/MCB.02103-07
   Cai XZ, 2007, RNA, V13, P313, DOI 10.1261/rna.351707
   Deng QW, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103022
   Gao TY, 2015, MOL CARCINOGEN, V54, P359, DOI 10.1002/mc.22106
   Hark AT, 2000, NATURE, V405, P486, DOI 10.1038/35013106
   Hibi K, 1996, CANCER RES, V56, P480
   KONDO M, 1995, ONCOGENE, V10, P1193
   Lagadec C, 2009, ONCOGENE, V28, P1960, DOI 10.1038/onc.2009.61
   LIU JQ, 1995, J CLIN ENDOCR METAB, V80, P492, DOI 10.1210/jc.80.2.492
   Lottin S, 2002, CARCINOGENESIS, V23, P1885, DOI 10.1093/carcin/23.11.1885
   Monnier P, 2013, P NATL ACAD SCI USA, V110, P20693, DOI 10.1073/pnas.1310201110
   Moorehead RA, 2003, ONCOGENE, V22, P853, DOI 10.1038/sj.onc.1206188
   Onyango P, 2011, P NATL ACAD SCI USA, V108, P16759, DOI 10.1073/pnas.1110904108
   Pu H, 2015, ONCOTARGET, V6, P40775, DOI 10.18632/oncotarget.5805
   Sanli I, 2015, INT J BIOCHEM CELL B, V67, P139, DOI 10.1016/j.biocel.2015.04.004
   Takai D, 2001, HUM MOL GENET, V10, P2619, DOI 10.1093/hmg/10.23.2619
   Tsang WP, 2010, CARCINOGENESIS, V31, P350, DOI 10.1093/carcin/bgp181
   Tran VG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037923
   Vennin C, 2015, ONCOTARGET, V6, P29209, DOI 10.18632/oncotarget.4976
   Zhang E., 2015, TUMOUR BIOL
NR 29
TC 67
Z9 72
U1 0
U2 34
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0304-3835
EI 1872-7980
J9 CANCER LETT
JI Cancer Lett.
PD JAN 28
PY 2017
VL 385
BP 198
EP 206
DI 10.1016/j.canlet.2016.10.023
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA EF7FV
UT WOS:000390496400023
PM 27780718
DA 2025-01-12
ER

PT J
AU Guo, YL
   Zhu, TN
   Guo, W
   Dong, ZM
   Zhou, Z
   Cui, YJ
   Zhao, RJ
AF Guo, Yan-li
   Zhu, Tie-nian
   Guo, Wei
   Dong, Zhi-ming
   Zhou, Zhen
   Cui, Yu-jie
   Zhao, Rui-jing
TI Aberrant CpG Island Shore Region Methylation of <i>CAV1</i> Is
   Associated with Tumor Progression and Poor Prognosis in Gastric Cardia
   Adenocarcinoma
SO ARCHIVES OF MEDICAL RESEARCH
LA English
DT Article
DE Caveolin-1 gene; Methylation; Gastric cardia adenocarcinoma;
   beta-catenin
ID HUMAN BREAST-CANCER; UPPER GASTROINTESTINAL CANCERS; HIGH-RISK REGION;
   CAVEOLIN-1 EXPRESSION; GEOGRAPHIC-VARIATION; HELICOBACTER-PYLORI;
   GENE-EXPRESSION; NORTHERN CHINA; BETA-CATENIN; CELL-LINES
AB Background and Aims. Caveolin-1 (CAV1) is a multifunctional scaffolding protein and plays an important role in tumorigenesis. However, the epigenetic changes of CAVI in gastric cardia adenocarcinoma (GCA) have not been investigated so far. The purpose of this study was to clarify the contribution of critical CpG sites in CAV1 to progression/prognosis of GCA and to further elucidate the effect of critical CpG sites on the ectopic expression of beta-catenin in GCA.
   Methods. Methylation-specific polymerase chain reaction (MSP) and bisulfite genomic sequencing (BGS) methods were, respectively, applied to examine the methylation status of CAV1. RT-PCR and immunohistochemistry methods were used to determine the mRNA and protein expression of CAVI and beta-catenin.
   Results. Decreased mRNA and protein expression of CAVI were observed in GCA tumor tissues and were associated with hypermethylation of CpG island shore and transcription start site (TSS) regions in CAVI. Hypermethylation of the other two regions within CpG islands in CAVI was observed both in tumor and corresponding adjacent tissues but was not related to the transcriptional inhibition of CAV1. The methylation status of CpG island shore region in CAVI was associated with the ectopic expression of beta-catenin and was independently associated with survival in GCA patients.
   Conclusions. Hypermethylation of CpG island shore and TSS regions is cancer specific and is closely associated with reduced expression of CAV1. The CpG island shore methylation of CAVI may play an important role in progression of GCA and may serve as a prognostic methylation biomarker for GCA patients. (C) 2016 IMSS. Published by Elsevier Inc.
C1 [Guo, Yan-li; Guo, Wei; Dong, Zhi-ming; Zhou, Zhen] Hebei Med Univ, Hosp 4, Hebei Canc Inst, Pathol Lab, Shijiazhuang, Hebei, Peoples R China.
   [Zhu, Tie-nian; Zhao, Rui-jing] Hebei Med Univ, Key Lab Immune Mechanism & Intervent Serious Dis, Dept Immunol, Zhongshan St 361, Shijiazhuang, Hebei, Peoples R China.
   [Zhu, Tie-nian; Cui, Yu-jie] Bethune Int Peace Hosp, Dept Med Oncol, Shijiazhuang, Hebei, Peoples R China.
C3 Hebei Medical University; Hebei Medical University
RP Zhu, TN (通讯作者)，Hebei Med Univ, Key Lab Immune Mechanism & Intervent Serious Dis, Dept Immunol, Zhongshan St 361, Shijiazhuang, Hebei, Peoples R China.
EM zhutienian@163.com
RI zhou, zhou/HPE-9525-2023
FU National Natural Science Foundation of China [81071846, 81472335];
   Natural Science Foundation of Hebei Province of China [H2013505059,
   H2013206315]; Department of Science and Technology of Hebei Province of
   China [12396107D, 09966114D, 092461102D]; Wu Jieping Medical Foundation
   [320.6750.12604, 320.6750.14063, 320.6799.15005]; Project of Hebei
   Medical Research [20130543]
FX This work was supported by the National Natural Science Foundation of
   China (No. 81071846, to TNZ; No. 81472335, to WG); Natural Science
   Foundation of Hebei Province of China (No. H2013505059, to TNZ; No.
   H2013206315, to YLG); Department of Science and Technology of Hebei
   Province of China (No. 12396107D, to RJZ, No. 09966114D, and No.
   092461102D to TNZ); Wu Jieping Medical Foundation (No. 320.6750.12604,
   No. 320.6750.14063, and No. 320.6799.15005 to TNZ) and the focal point
   Project of Hebei Medical Research (No. 20130543, to YLG).
CR Arkhipova KA, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-100
   Bachmann N, 2008, CANCER GENET CYTOGEN, V182, P103, DOI 10.1016/j.cancergencyto.2008.01.006
   Bai L, 2012, J CELL BIOCHEM, V113, P322, DOI 10.1002/jcb.23358
   Bender FC, 2000, CANCER RES, V60, P5870
   Bird A, 2001, SCIENCE, V294, P2113, DOI 10.1126/science.1066726
   Burgermeister E, 2007, CANCER RES, V67, P8519, DOI 10.1158/0008-5472.CAN-07-1125
   Crew KD, 2004, SEMIN ONCOL, V31, P450, DOI 10.1053/j.seminoncol.2004.04.021
   Dasgupta N, 2015, EXP CELL RES, V334, P323, DOI 10.1016/j.yexcr.2015.03.020
   Deaton AM, 2011, GENE DEV, V25, P1010, DOI 10.1101/gad.2037511
   Endoh M, 2005, BRIT J CANCER, V93, P1395, DOI 10.1038/sj.bjc.6602854
   Engelman JA, 1998, FEBS LETT, V429, P330, DOI 10.1016/S0014-5793(98)00619-X
   Ferraldeschi R, 2012, BREAST CANCER RES TR, V132, P1185, DOI 10.1007/s10549-012-1981-0
   Galbiati F, 2000, J BIOL CHEM, V275, P23368, DOI 10.1074/jbc.M002020200
   Guo Y, 2011, NEOPLASMA, V58, P110, DOI 10.4149/neo_2011_02_110
   Han SE, 2004, INT J ONCOL, V24, P435
   He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509
   Hehlgans S, 2011, AM J CANCER RES, V1, P521
   Hirasawa Y, 2006, ONCOLOGY-BASEL, V71, P77, DOI 10.1159/000100475
   Huertas-Martínez J, 2014, ONCOTARGET, V5, P9744, DOI 10.18632/oncotarget.2403
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   Kai WC, 2001, AM J PATHOL, V159, P1635, DOI 10.1016/S0002-9440(10)63010-6
   Kopantzev EP, 2008, LUNG CANCER, V62, P23, DOI 10.1016/j.lungcan.2008.02.011
   Lee SW, 1998, ONCOGENE, V16, P1391, DOI 10.1038/sj.onc.1201661
   Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427
   Lin SY, 2004, ANTICANCER RES, V24, P1645
   Ma JL, 2012, J NATL CANCER I, V104, P488, DOI 10.1093/jnci/djs003
   Nelson WJ, 2004, SCIENCE, V303, P1483, DOI 10.1126/science.1094291
   Park SS, 2005, HISTOPATHOLOGY, V47, P625, DOI 10.1111/j.1365-2559.2005.02303.x
   Parton RG, 2007, NAT REV MOL CELL BIO, V8, P185, DOI 10.1038/nrm2122
   Patani N, 2012, BREAST CANCER RES TR, V131, P1, DOI 10.1007/s10549-011-1751-4
   Quest AFG, 2008, J CELL MOL MED, V12, P1130, DOI 10.1111/j.1582-4934.2008.00331.x
   Rao X, 2013, ONCOGENE, V32, P4519, DOI 10.1038/onc.2012.474
   Razani B, 2001, J CLIN INVEST, V108, P1553, DOI 10.1172/JCI200114611
   Rollins RA, 2006, GENOME RES, V16, P157, DOI 10.1101/gr.4262006
   Sagara Y, 2004, BRIT J CANCER, V91, P959, DOI 10.1038/sj.bjc.6602029
   Satoh A, 2002, BRIT J CANCER, V86, P1817, DOI 10.1038/sj.bjc.6600319
   Siewert JR, 1998, BRIT J SURG, V85, P1457
   Sun Xi-bin, 2007, Zhonghua Zhongliu Zazhi, V29, P764
   Syeed N, 2012, ASIAN PAC J CANCER P, V13, P371, DOI 10.7314/APJCP.2012.13.1.371
   Takai Daiya, 2003, In Silico Biology, V3, P235
   Umemoto M, 2001, BRIT J CANCER, V85, P1032, DOI 10.1054/bjoc.2001.2034
   Wen DG, 2010, HELICOBACTER, V15, P416, DOI 10.1111/j.1523-5378.2010.00790.x
   Yang G, 1998, CLIN CANCER RES, V4, P1873
   Yang L, 2006, WORLD J GASTROENTERO, V12, P17, DOI 10.3748/wjg.v12.i1.17
   Zhang N, 2011, ASIAN PAC J CANCER P, V12, P193
NR 45
TC 10
Z9 14
U1 0
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0188-4409
EI 1873-5487
J9 ARCH MED RES
JI Arch. Med. Res.
PD AUG
PY 2016
VL 47
IS 6
BP 460
EP 470
DI 10.1016/j.arcmed.2016.10.005
PG 11
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA EG5KK
UT WOS:000391082500007
PM 27986126
DA 2025-01-12
ER

PT J
AU Martín-Sánchez, E
   Mendaza, S
   Ulazia-Garmendia, A
   Monreal-Santesteban, I
   Córdoba, A
   Vicente-García, F
   Blanco-Luquin, I
   De La Cruz, S
   Aramendia, A
   Guerrero-Setas, D
AF Martin-Sanchez, Esperanza
   Mendaza, Saioa
   Ulazia-Garmendia, Ane
   Monreal-Santesteban, Inaki
   Cordoba, Alicia
   Vicente-Garcia, Francisco
   Blanco-Luquin, Idoia
   De La Cruz, Susana
   Aramendia, Ana
   Guerrero-Setas, David
TI <i>CDH22</i> hypermethylation is an independent prognostic biomarker in
   breast cancer
SO CLINICAL EPIGENETICS
LA English
DT Article
DE CDH22; DNA methylation; Breast cancer; Predictive biomarker
ID DNA METHYLATION PROFILES; HORMONE-RECEPTOR STATUS; PROMOTER METHYLATION;
   EXPRESSION; TUMORS; ASSOCIATION; GRADE; RISK
AB Background: Cadherin-like protein 22 (CDH22) is a transmembrane glycoprotein involved in cell-cell adhesion and metastasis. Its role in cancer is controversial because it has been described as being upregulated in colorectal cancer, whereas it is downregulated in metastatic melanoma. However, its status in breast cancer (BC) is unknown. The purpose of our study was to determine the molecular status and clinical value of CDH22 in BC.
   Results: We observed by immunohistochemistry that the level of CDH22 expression was lower in BC tissues than in their matched adjacent-to-tumour and non-neoplastic tissues from reduction mammoplasties. Since epigenetic alteration is one of the main causes of gene silencing, we analysed the hypermethylation of 3 CpG sites in the CDH22 promoter by pyrosequencing in a series of 142 infiltrating duct BC cases. CDH22 was found to be hypermethylated in tumoral tissues relative to non-neoplastic mammary tissues. Importantly, this epigenetic alteration was already present in adjacent-to-tumour tissues, although to a lesser extent than in tumoral samples. Furthermore, CDH22 gene regulation was dynamically modulated in vitro by epigenetic drugs. Interestingly, CDH22 hypermethylation in all 3 CpG sites simultaneously, but not expression, was significantly associated with shorter progression-free survival (p = 0.015) and overall survival (p = 0.021) in our patient series. Importantly, CDH22 hypermethylation was an independent factor that predicts poor progression-free survival regardless of age and stage (p = 0.006).
   Conclusions: Our results are the first evidence that CDH22 is hypermethylated in BC and that this alteration is an independent prognostic factor in BC. Thus, CDH22 hypermethylation could be a potential biomarker of poor prognosis in BC.
C1 [Martin-Sanchez, Esperanza; Mendaza, Saioa; Ulazia-Garmendia, Ane; Monreal-Santesteban, Inaki; Guerrero-Setas, David] UPNA, IdiSNA, Navarrabiomed Dept Salud, Canc Epigenet Grp, Irunlarrea Rd 3, Pamplona 31008, Spain.
   [Cordoba, Alicia; Guerrero-Setas, David] Complejo Hosp Navarra, Dept Pathol, Irunlarrea Rd 3, Pamplona 31008, Spain.
   [Vicente-Garcia, Francisco] Complejo Hosp Navarra, Dept Surg, Pamplona, Spain.
   [Blanco-Luquin, Idoia] UPNA, IdiSNA, Navarrabiomed Dept Salud, Immunomodulat Grp, Pamplona, Spain.
   [De La Cruz, Susana] Complejo Hosp Navarra, Dept Med Oncol, Pamplona, Spain.
   [Aramendia, Ana] UPNA, IdiSNA, Biobank Navarrabiomed Dept Salud, Pamplona, Spain.
C3 Navarrabiomed; Universidad Publica de Navarra; Servicio Navarro de Salud
   - Osasunbidea; Servicio Navarro de Salud - Osasunbidea; Universidad
   Publica de Navarra; Navarrabiomed; Servicio Navarro de Salud -
   Osasunbidea; Universidad Publica de Navarra
RP Martín-Sánchez, E; Guerrero-Setas, D (通讯作者)，UPNA, IdiSNA, Navarrabiomed Dept Salud, Canc Epigenet Grp, Irunlarrea Rd 3, Pamplona 31008, Spain.; Guerrero-Setas, D (通讯作者)，Complejo Hosp Navarra, Dept Pathol, Irunlarrea Rd 3, Pamplona 31008, Spain.
EM emartisa@navarra.es; dguerres@navarra.es
RI Luquin, Idoia/AAA-9134-2019; Martín-Sánchez, Esperanza/M-7578-2015
OI Monreal Santesteban, inaki/0000-0002-0158-3565; Blanco,
   Idoia/0000-0003-2917-586X; Martin-Sanchez, Esperanza/0000-0002-8155-9185
FU Spanish Institute of Health [PI14/00579]; Basque Foundation for
   Healthcare Research and Innovation [BIO-11-CM-013]; La Caixa Foundation
   [70789]; Breast Cancer Patients' Association in Navarra (SARAY); Spanish
   Ministry of Economy and Competitiveness [PTA2015-11895-I]
FX This work has been funded in competitive calls by the Spanish Institute
   of Health (PI14/00579), the Basque Foundation for Healthcare Research
   and Innovation (BIO-11-CM-013), La Caixa Foundation (70789) and the
   Breast Cancer Patients' Association in Navarra (SARAY). EMS is the
   recipient of a grant from the Spanish Ministry of Economy and
   Competitiveness (PTA2015-11895-I).
CR Bediaga NG, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2721
   Bonneterre J, 2016, CURR MED RES OPIN, V32, P835, DOI 10.1185/03007995.2016.1146664
   Cheang MCU, 2009, JNCI-J NATL CANCER I, V101, P736, DOI 10.1093/jnci/djp082
   Costa-Pinheiro P, 2015, EPIGENOMICS-UK, V7, P1003, DOI 10.2217/epi.15.56
   Du JM, 2015, NAT REV MOL CELL BIO, V16, P519, DOI 10.1038/nrm4043
   Edge S.B., 2010, AJCC cancer staging manual, V649
   ELSTON CW, 1991, HISTOPATHOLOGY, V19, P403, DOI 10.1111/j.1365-2559.1991.tb00229.x
   Fang C, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1926-1
   Feng W, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1762
   Fiegl H, 2006, CANCER RES, V66, P29, DOI 10.1158/0008-5472.CAN-05-2508
   Goldhirsch A, 2013, ANN ONCOL, V24, P2206, DOI 10.1093/annonc/mdt303
   Guo TY, 2015, MOL CLIN ONCOL, V3, P1353, DOI 10.3892/mco.2015.620
   Harrington CT, 2013, ARCH PATHOL LAB MED, V137, P1296, DOI 10.5858/arpa.2012-0463-RA
   Kajiyama T, 2011, ANAL BIOCHEM, V416, P8, DOI 10.1016/j.ab.2011.04.039
   Kleer CG, 2001, MODERN PATHOL, V14, P458, DOI 10.1038/modpathol.3880334
   Liu YH, 2009, CANCER BIOL THER, V8, P1352, DOI 10.4161/cbt.8.14.8695
   Piche B, 2011, AM J CANCER RES, V1, P233
   Saarimäki-Vire J, 2011, DEV DYNAM, V240, P1989, DOI 10.1002/dvdy.22686
   Shames DS, 2007, CANCER LETT, V251, P187, DOI 10.1016/j.canlet.2006.10.014
   Shen Y, 2015, BREAST CANCER RES TR, V154, P473, DOI 10.1007/s10549-015-3632-8
   Smith RA, 2016, CA-CANCER J CLIN, V66, P96, DOI 10.3322/caac.21336
   Stefansson OA, 2015, MOL ONCOL, V9, P555, DOI 10.1016/j.molonc.2014.10.012
   Sugimoto K, 1996, J BIOL CHEM, V271, P11548, DOI 10.1074/jbc.271.19.11548
   Sundfeldt K, 2003, MOL CELL ENDOCRINOL, V202, P89, DOI 10.1016/S0303-7207(03)00068-6
   Villani V, 2015, DIS MARKERS, V2015, DOI 10.1155/2015/604719
   Wang L, 2015, SCI ADV, V1, DOI 10.1126/sciadv.1500463
   Widschwendter M, 2004, CANCER RES, V64, P3807, DOI 10.1158/0008-5472.CAN-03-3852
   Zhou J, 2009, TUMOR BIOL, V30, P130, DOI 10.1159/000225242
NR 28
TC 10
Z9 13
U1 0
U2 5
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1868-7075
EI 1868-7083
J9 CLIN EPIGENETICS
JI Clin. Epigenetics
PD JAN 24
PY 2017
VL 9
AR 7
DI 10.1186/s13148-016-0309-z
PG 8
WC Oncology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Genetics & Heredity
GA EI8OB
UT WOS:000392764600001
PM 28149335
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Gu, XT
   Lu, YF
   He, DX
   Lu, CX
   Jin, J
   Lu, XJ
   Ma, X
AF Gu, Xiaoting
   Lu, Yangfan
   He, Dongxu
   Lu, Chunxiao
   Jin, Jian
   Lu, Xiaojie
   Ma, Xin
TI Methylation of Notch3 modulates chemoresistance via P-glycoprotein
SO EUROPEAN JOURNAL OF PHARMACOLOGY
LA English
DT Article
DE DNA methylation; Notch3; Chemoresistance; P-glycoprotein; Breast cancer
ID BREAST-CANCER CELLS; EPITHELIAL-MESENCHYMAL TRANSITION; SIGNALING
   PATHWAY; DNA METHYLATION; OVARIAN-CANCER; PACLITAXEL-RESISTANCE;
   MULTIDRUG-RESISTANCE; CONFERS RESISTANCE; ADENOSINE-ANALOGS;
   TUMOR-SUPPRESSOR
AB The global gene expression and DNA methylation of genes in adriamycin-resistant human breast cancer cells (MCF-7/ADM cells) are similar to those in paclitaxel-resistant MCF-7 cells (MCF-7/PTX) and are significantly different from those in wild-type MCF-7 cells. DNA methylation is associated with chemoresistance in breast cancer and changes the characteristics of chemoresistant and chemosensitive cells. Here, we showed that the tumor-suppressor gene Notch3 was inactivated due to epigenetic silencing DNA hypermethylation in MCF-7/ADM cells. In addition, the drug efflux pump P-glycoprotein was negatively regulated by Notch3 and highly expressed in MCF-7/ADM cells. Taken together, our findings demonstrated that hypermethylation of Notch3 causes activation of P-glycoprotein in adriamycin-resistant cells.
C1 [Gu, Xiaoting; Lu, Yangfan; Lu, Chunxiao; Jin, Jian; Ma, Xin] Jiangnan Univ, Sch Pharmaceut Sci, 1800 Lihu Rd, Wuxi 214122, Jiangsu, Peoples R China.
   [He, Dongxu] Jiangnan Univ, Natl Engn Lab Cereal Fermentat Technol, Wuxi 214122, Peoples R China.
   [Lu, Xiaojie] Jiangnan Univ, Wuxi Neurosci Ctr, Wuxi, Jiangsu, Peoples R China.
   [Lu, Xiaojie] Nanjiang Med Univ, Wuxi Hosp Affiliated 2, Dept Neurosurg, Wuxi, Jiangsu, Peoples R China.
   [Lu, Xiaojie] Wuxi Second Peoples Hosp, Wuxi, Jiangsu, Peoples R China.
C3 Jiangnan University; Jiangnan University; Jiangnan University
RP Ma, X (通讯作者)，Jiangnan Univ, Sch Pharmaceut Sci, 1800 Lihu Rd, Wuxi 214122, Jiangsu, Peoples R China.; Lu, XJ (通讯作者)，Jiangnan Univ, Wuxi Neurosci Ctr, Wuxi, Jiangsu, Peoples R China.; Lu, XJ (通讯作者)，Nanjiang Med Univ, Wuxi Hosp Affiliated 2, Dept Neurosurg, Wuxi, Jiangsu, Peoples R China.; Lu, XJ (通讯作者)，Wuxi Second Peoples Hosp, Wuxi, Jiangsu, Peoples R China.
EM xiaojieluwuxi@163.com; maxin@jiangnan.edu.cn
FU China National Natural Science Foundation [81572940, 91439131, 31200126,
   31550006, 81272358]; Natural Science Foundation for Distinguished Young
   Scholars of Jiangsu Province [BK20140004]; Program for New Century
   Excellent Talents in University of The Ministry of Education of China
   [NCET-12-0880]; National High Technology Research and Development
   Program (863 Program) of China [SQ2015AA020948]; Fundamental Research
   Funds for the Central Universities [JUSRP51311A, JUSRP51615B,
   JUSRP51519]
FX This work was supported by the China National Natural Science Foundation
   81572940 and 91439131 to Xin Ma; 31200126 and 31550006 to Dong-Xu He;
   81272358 to Feng Gu; the Natural Science Foundation for Distinguished
   Young Scholars of Jiangsu Province (BK20140004 to Xin Ma); the Program
   for New Century Excellent Talents in University of The Ministry of
   Education of China (NCET-12-0880) to Xin Ma; the National High
   Technology Research and Development Program (863 Program) of China
   (SQ2015AA020948) to Xin Ma; Fundamental Research Funds for the Central
   Universities (JUSRP51311A, JUSRP51615B and JUSRP51519) to Xin Ma,
   Dong-Xu He and Jin Jian. We thank Dr. IC Bruce for reading the
   manuscript.
CR [Anonymous], ONCOTARGET
   Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770
   BIEDLER JL, 1970, CANCER RES, V30, P1174
   Cedar H, 2009, NAT REV GENET, V10, P295, DOI 10.1038/nrg2540
   Cui H, 2013, CANCER RES, V73, P3451, DOI 10.1158/0008-5472.CAN-12-3902
   Du FF, 2013, ONCOL REP, V30, P1113, DOI 10.3892/or.2013.2567
   Gottesman MM, 2002, NAT REV CANCER, V2, P48, DOI 10.1038/nrc706
   GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125
   Grabher C, 2006, NAT REV CANCER, V6, P347, DOI 10.1038/nrc1880
   Gu X., 2016, TUMOR BIOL, P1
   Güngör C, 2011, CANCER RES, V71, P5009, DOI 10.1158/0008-5472.CAN-11-0036
   He DX, 2016, SCI REP-UK, V6, DOI 10.1038/srep24706
   Jaenisch R, 2003, NAT GENET, V33, P245, DOI 10.1038/ng1089
   JULIANO RL, 1976, BIOCHIM BIOPHYS ACTA, V455, P152, DOI 10.1016/0005-2736(76)90160-7
   Kadesch T, 2004, CURR OPIN GENET DEV, V14, P506, DOI 10.1016/j.gde.2004.07.007
   Kulis M, 2010, ADV GENET, V70, P27, DOI [10.1016/S0065-2660(10)70002-X, 10.1016/B978-0-12-380866-0.60002-2]
   Lin SE, 2002, J BIOL CHEM, V277, P50612, DOI 10.1074/jbc.M209529200
   Ma X, 2012, P NATL ACAD SCI USA, V109, P16282, DOI 10.1073/pnas.1202989109
   Maillard I, 2003, CANCER CELL, V3, P203, DOI 10.1016/S1535-6108(03)00052-7
   Nguyen TTP, 2011, BREAST CANCER RES TR, V130, P73, DOI 10.1007/s10549-010-1304-2
   Park JT, 2010, AM J PATHOL, V177, P1087, DOI 10.2353/ajpath.2010.100316
   Sansom OJ, 2007, NAT CLIN PRACT ONCOL, V4, P305, DOI 10.1038/ncponc0812
   Stefanska B, 2012, BRIT J NUTR, V107, P781, DOI 10.1017/S0007114511003631
   Stefanska B, 2010, EUR J PHARMACOL, V638, P47, DOI 10.1016/j.ejphar.2010.04.032
   Sun WX, 2013, MAR DRUGS, V11, P4570, DOI 10.3390/md11114570
   Taberlay PC, 2011, PROG DRUG RES, V67, P1, DOI 10.1007/978-3-7643-8989-5_1
   Thomas Hilary, 2003, Cancer Control, V10, P159
   UEDA K, 1987, P NATL ACAD SCI USA, V84, P3004, DOI 10.1073/pnas.84.9.3004
   Wang J, 2011, ONCOL REP, V26, P1295, DOI 10.3892/or.2011.1399
   Wang Y, 2014, CELL REP, V6, P278, DOI 10.1016/j.celrep.2013.12.031
   Wang ZW, 2010, BBA-REV CANCER, V1806, P258, DOI 10.1016/j.bbcan.2010.06.001
   Wang ZW, 2010, CURR DRUG TARGETS, V11, P745, DOI 10.2174/138945010791170860
   Yamaguchi N, 2008, CANCER RES, V68, P1881, DOI 10.1158/0008-5472.CAN-07-1597
   Yang FL, 2004, EUR J BIOCHEM, V271, P4545, DOI 10.1111/j.1432-1033.2004.04415.x
   Yoon K, 2005, NAT NEUROSCI, V8, P709, DOI 10.1038/nn1475
   Zhang FF, 2014, EUR J PHARMACOL, V738, P83, DOI 10.1016/j.ejphar.2014.05.026
   Zhang L, 2015, J EXP CLIN CANC RES, V34, DOI 10.1186/s13046-015-0120-2
   Zhang QY, 2015, ONCOTARGET, V6, P3669, DOI 10.18632/oncotarget.2898
NR 38
TC 4
Z9 5
U1 0
U2 9
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0014-2999
EI 1879-0712
J9 EUR J PHARMACOL
JI Eur. J. Pharmacol.
PD DEC 5
PY 2016
VL 792
BP 7
EP 14
DI 10.1016/j.ejphar.2016.10.024
PG 8
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA EF9JG
UT WOS:000390645900002
PM 27780727
DA 2025-01-12
ER

PT J
AU Coleman, WB
AF Coleman, William B.
TI Obesity and the breast cancer methylome
SO CURRENT OPINION IN PHARMACOLOGY
LA English
DT Article
ID GENE-EXPRESSION PATTERNS; BODY-MASS INDEX; DNA METHYLATION;
   RISK-FACTORS; LUNG-CANCER; EPIGENETIC REGULATION; LINKING OBESITY;
   BASAL-LIKE; MICRORNA; 3B
AB Breast cancer is associated with risk factors such as advancing age and obesity. However, the linkages between these risk factors for breast cancer development and initiation of the disease are not yet clear. Obesity may drive breast cancer development through increases in circulating estrogens in postmenopausal women. Mammary cell susceptibility to neoplastic transformation requires both genetic and epigenetic alterations, including changes in DNA methylation. Obesity is also subject to epigenetic regulation. In this review, the nature of epigenetic changes, specifically changes to the methylome, are discussed in the context of obesity and breast cancer, and a potential mechanism for the interaction of obesity and breast cancer is proposed. This proposed mechanism identifies opportunities for intervention (using drugs or biologic therapies) to prevent breast cancer development in the obese patient.
C1 [Coleman, William B.] Univ N Carolina, Dept Pathol & Lab Med, Curriculum Toxicol,Sch Med, UNC Program Translat Med,UNC Lineberger Comprehen, Chapel Hill, NC 27514 USA.
C3 University of North Carolina School of Medicine; University of North
   Carolina; University of North Carolina Chapel Hill
RP Coleman, WB (通讯作者)，Univ N Carolina, Dept Pathol & Lab Med, Curriculum Toxicol,Sch Med, UNC Program Translat Med,UNC Lineberger Comprehen, Chapel Hill, NC 27514 USA.
EM wbcolemn@med.unc.edu
CR [Anonymous], 2013, INT J OBESITY, DOI DOI 10.1038/ijo.2012.8
   Ban KA, 2014, SURG ONCOL CLIN N AM, V23, P409, DOI 10.1016/j.soc.2014.03.011
   Bardowell SA, 2013, BREAST CANCER RES TR, V142, P365, DOI 10.1007/s10549-013-2738-0
   Bartel B, 2005, NAT STRUCT MOL BIOL, V12, P569, DOI 10.1038/nsmb0705-569
   Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5
   Baylin S, 2001, Dev Biol (Basel), V106, P85
   Baylin SB, 1998, ADV CANCER RES, V72, P141
   Baylin Stephen B, 2005, Nat Clin Pract Oncol, V2 Suppl 1, pS4, DOI 10.1038/ncponc0354
   BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0
   BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D
   Brenner AJ, 1997, PROG CLIN BIOL RES, V396, P63
   Calin GA, 2005, NEW ENGL J MED, V353, P1793, DOI 10.1056/NEJMoa050995
   Calle EE, 2003, NEW ENGL J MED, V348, P1625, DOI 10.1056/NEJMoa021423
   Campión J, 2010, PROG MOL BIOL TRANSL, V94, P291, DOI 10.1016/S1877-1173(10)94011-8
   Cordero P, 2015, CURR OPIN CLIN NUTR, V18, P361, DOI 10.1097/MCO.0000000000000179
   DeSantis CE, 2016, CA-CANCER J CLIN, V66, P31, DOI 10.3322/caac.21320
   DEWAARD F, 1964, CANCER-AM CANCER SOC, V17, P141, DOI 10.1002/1097-0142(196402)17:2<141::AID-CNCR2820170202>3.0.CO;2-Z
   DEWAARD F, 1979, J NATL CANCER I, V63, P549, DOI 10.1093/jnci/63.3.549
   Dick KJ, 2014, LANCET, V383, P1990, DOI 10.1016/S0140-6736(13)62674-4
   Drummond EM, 2013, CURR OPIN CLIN NUTR, V16, P392, DOI 10.1097/MCO.0b013e3283620f45
   Ducasse M, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-60
   DUPONT WD, 1985, NEW ENGL J MED, V312, P146, DOI 10.1056/NEJM198501173120303
   Duursma AM, 2008, RNA, V14, P872, DOI 10.1261/rna.972008
   Fabbri M, 2007, P NATL ACAD SCI USA, V104, P15805, DOI 10.1073/pnas.0707628104
   Feinberg AP, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001262
   Feinberg AP, 2004, SEMIN CANCER BIOL, V14, P427, DOI 10.1016/j.semcancer.2004.06.005
   FORD D, 1995, BRIT J CANCER, V72, P805, DOI 10.1038/bjc.1995.417
   Franceschi S, 1996, INT J CANCER, V67, P181, DOI 10.1002/(SICI)1097-0215(19960717)67:2<181::AID-IJC5>3.0.CO;2-P
   GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9
   Garzon R, 2008, BLOOD, V111, P3183, DOI 10.1182/blood-2007-07-098749
   Garzon R, 2009, BLOOD, V114, P5331, DOI 10.1182/blood-2009-03-211938
   Garzon R, 2009, ANNU REV MED, V60, P167, DOI [10.1146/annurev.med.59.053006.104707, 10.1146/annurev.pathol.4.110807.092222]
   Gayther SA, 1998, J MAMMARY GLAND BIOL, V3, P365, DOI 10.1023/A:1018779830743
   Girault I, 2003, CLIN CANCER RES, V9, P4415
   Govindarajah V, 2016, J NUTR BIOCHEM, V29, P73, DOI 10.1016/j.jnutbio.2015.11.003
   Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Hayashita Y, 2005, CANCER RES, V65, P9628, DOI 10.1158/0008-5472.CAN-05-2352
   Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075
   Holm K, 2016, BREAST CANCER RES, V18, DOI 10.1186/s13058-016-0685-5
   HSIEH CC, 1990, INT J CANCER, V46, P796, DOI 10.1002/ijc.2910460508
   HUNTER DJ, 1993, EPIDEMIOL REV, V15, P110, DOI 10.1093/oxfordjournals.epirev.a036096
   Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783
   Jin F, 2005, GYNECOL ONCOL, V96, P531, DOI 10.1016/j.ygyno.2004.10.039
   Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947
   Jones PA, 2001, SCIENCE, V293, P1068, DOI 10.1126/science.1063852
   KELSEY JL, 1988, CANCER RES, V48, P5615
   KELSEY JL, 1993, EPIDEMIOL REV, V15, P36, DOI 10.1093/oxfordjournals.epirev.a036115
   Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412
   Kühnen P, 2016, CELL METAB, V24, P502, DOI 10.1016/j.cmet.2016.08.001
   Kuehnen P, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002543
   La Vecchia C, 2011, ONCOLOGIST, V16, P726, DOI 10.1634/theoncologist.2011-0050
   Lindeman GJ, 2011, J MAMMARY GLAND BIOL, V16, P1, DOI 10.1007/s10911-011-9209-1
   LIPWORTH L, 1995, EUR J CANCER PREV, V4, P7, DOI 10.1097/00008469-199502000-00002
   Luczak MW, 2006, FOLIA HISTOCHEM CYTO, V44, P143
   Lujambio A, 2008, P NATL ACAD SCI USA, V105, P13556, DOI 10.1073/pnas.0803055105
   MADIGAN MP, 1995, J NATL CANCER I, V87, P1681, DOI 10.1093/jnci/87.22.1681
   Melo SA, 2011, FEBS LETT, V585, P2087, DOI 10.1016/j.febslet.2010.08.009
   Mizuno S, 2001, BLOOD, V97, P1172, DOI 10.1182/blood.V97.5.1172
   Montenegro MF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052231
   Mott JL, 2007, ONCOGENE, V26, P6133, DOI 10.1038/sj.onc.1210436
   NAROD SA, 1994, BRIT MED BULL, V50, P656, DOI 10.1093/oxfordjournals.bmb.a072915
   Parrillo L, 2016, INT J OBESITY, V40, P929, DOI 10.1038/ijo.2016.36
   Perou CM, 1999, P NATL ACAD SCI USA, V96, P9212, DOI 10.1073/pnas.96.16.9212
   Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093
   Prat A, 2012, BREAST CANCER RES TR, V135, P301, DOI 10.1007/s10549-012-2143-0
   Renehan AG, 2010, EUR J CANCER, V46, P2581, DOI 10.1016/j.ejca.2010.07.052
   Renehan AG, 2010, INT J CANCER, V126, P692, DOI 10.1002/ijc.24803
   Rivenbark AG, 2006, EPIGENETICS-US, V1, P32, DOI 10.4161/epi.1.1.2358
   Roberts DL, 2010, ANNU REV MED, V61, P301, DOI 10.1146/annurev.med.080708.082713
   Robertson KD, 1999, NUCLEIC ACIDS RES, V27, P2291, DOI 10.1093/nar/27.11.2291
   Roll JD, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-15
   Roll JD, 2013, EXP MOL PATHOL, V95, P276, DOI 10.1016/j.yexmp.2013.09.001
   Rossi EL, 2016, CANCER PREV RES, V9, P339, DOI 10.1158/1940-6207.CAPR-15-0348
   Sandhu R, 2015, AM J PATHOL, V185, P282, DOI 10.1016/j.ajpath.2014.12.003
   Sandhu R, 2014, INT J ONCOL, V44, P563, DOI 10.3892/ijo.2013.2197
   Sandhu R, 2012, INT J ONCOL, V41, P721, DOI 10.3892/ijo.2012.1505
   Sandhu R, 2012, BREAST CANCER RES TR, V131, P385, DOI 10.1007/s10549-011-1409-2
   Sengupta S, 2008, P NATL ACAD SCI USA, V105, P5874, DOI 10.1073/pnas.0801130105
   Siegel RI, 2016, J. Clin., V66, P7, DOI DOI 10.3322/CAAC.21590
   Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100
   Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098
   Starlard-Davenport Athena, 2013, J Carcinog, V12, P15, DOI 10.4103/1477-3163.115720
   Stefansson OA, 2015, MOL ONCOL, V9, P555, DOI 10.1016/j.molonc.2014.10.012
   Takai D, 2002, P NATL ACAD SCI USA, V99, P3740, DOI 10.1073/pnas.052410099
   Tao ZQ, 2015, CELL BIOCHEM BIOPHYS, V72, P333, DOI 10.1007/s12013-014-0459-6
   Tavani A, 1999, EUR J CANCER, V35, P1361, DOI 10.1016/S0959-8049(99)00139-2
   Tsou JA, 2002, ONCOGENE, V21, P5450, DOI 10.1038/sj.onc.1205605
   VALAORAS VG, 1969, INT J CANCER, V4, P350, DOI 10.1002/ijc.2910040312
   van den Bergh RCN, 2009, CANCER-AM CANCER SOC, V115, P3868, DOI 10.1002/cncr.24446
   VANRENSBURG EJ, 1995, J CLIN PATHOL, V48, P789, DOI 10.1136/jcp.48.9.789
   Veeck J, 2010, J MAMMARY GLAND BIOL, V15, P5, DOI 10.1007/s10911-010-9165-1
   Visone R, 2009, AM J PATHOL, V174, P1131, DOI 10.2353/ajpath.2009.080794
   Wang Y, 2009, J CELL MOL MED, V13, P12, DOI 10.1111/j.1582-4934.2008.00510.x
   WEINBERG RA, 1989, CANCER RES, V49, P3713
   Widschwendter M, 2002, ONCOGENE, V21, P5462, DOI 10.1038/sj.onc.1205606
   Yamashita H, 2015, WORLD J CLIN ONCOL, V6, P220, DOI 10.5306/wjco.v6.i6.220
   Yanaihara N, 2006, CANCER CELL, V9, P189, DOI 10.1016/j.ccr.2006.01.025
   Zhang M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0142279
NR 99
TC 8
Z9 9
U1 0
U2 9
PU ELSEVIER SCI LTD
PI London
PA 125 London Wall, London, ENGLAND
SN 1471-4892
EI 1471-4973
J9 CURR OPIN PHARMACOL
JI Curr. Opin. Pharmacol.
PD DEC
PY 2016
VL 31
BP 104
EP 113
DI 10.1016/j.coph.2016.11.006
PG 10
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA EF9HR
UT WOS:000390641800019
PM 27886642
DA 2025-01-12
ER

PT J
AU Lizarraga, D
   Huen, K
   Combs, M
   Escudero-Fung, M
   Eskenazi, B
   Holland, N
AF Lizarraga, Daneida
   Huen, Karen
   Combs, Mary
   Escudero-Fung, Maria
   Eskenazi, Brenda
   Holland, Nina
TI miRNAs differentially expressed by next-generation sequencing in cord
   blood buffy coat samples of boys and girls
SO EPIGENOMICS
LA English
DT Article
DE cord blood; early life; epigenetics; filtering; miRNA; miRNAome;
   newborns; next-generation sequencing; normalization procedures; sex
   differences
ID MICRORNA GENE-CLUSTER; SEX-DIFFERENCES; BREAST-CANCER; EPIGENETICS;
   TRANSCRIPTOME; ENVIRONMENT; PREDICTION; BIOMARKER; EXPOSURE; CHILDREN
AB Aim: Differences in children's development and susceptibility to diseases and exposures have been observed by sex, yet human studies of sex differences in miRNAs are limited. Materials & methods: The genome-wide miRNA expression was characterized by sequencing-based EdgeSeq assay in cord blood buffy coats from 89 newborns, and 564 miRNAs were further analyzed. Results: Differential expression of most miRNAs was higher in boys. Neurodevelopment, RNA metabolism and metabolic ontology terms were enriched among miRNA targets. The majority of upregulated miRNAs (86%) validated by nCounter maintained positive-fold change values; however, only 21% reached statistical significance by false discovery rate. Conclusion: Accounting for host factors like sex may improve the sensitivity of epigenetic analyses for epidemiological studies in early childhood.
C1 [Lizarraga, Daneida; Huen, Karen; Combs, Mary; Escudero-Fung, Maria; Eskenazi, Brenda; Holland, Nina] Univ Calif Berkeley, Sch Publ Hlth, CERCH, Berkeley, CA 94720 USA.
C3 University of California System; University of California Berkeley
RP Holland, N (通讯作者)，Univ Calif Berkeley, Sch Publ Hlth, CERCH, Berkeley, CA 94720 USA.
EM ninah@berkeley.edu
OI Huen, Karen/0000-0003-3604-2096
FU National Institute of Environmental Health Science (NIEH) [1R01ES023067,
   PO1 ES009605]; US Environmental Protection Agency (EPA) [RD83451301]
FX This work was supported by grants 1R01ES023067 and PO1 ES009605 from the
   National Institute of Environmental Health Science (NIEH) and RD83451301
   from the US Environmental Protection Agency (EPA). The authors have no
   other relevant affiliations or financial involvement with any
   organization or entity with a financial interest in or financial
   conflict with the subject matter or materials discussed in the
   manuscript apart from those disclosed.
CR Agarwal V, 2015, ELIFE, V4, DOI 10.7554/eLife.05005
   Al-Kafaji G, 2015, MOL MED REP, V12, P7485, DOI 10.3892/mmr.2015.4416
   Almén MS, 2014, GENE, V548, P61, DOI 10.1016/j.gene.2014.07.009
   Ameling S, 2015, BMC MED GENOMICS, V8, DOI 10.1186/s12920-015-0136-7
   [Anonymous], ENV HLTH PERSPECTIVE
   Bardin J, 2012, NATURE, V487, P24, DOI 10.1038/487024a
   Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5
   Bernard E, 2014, BIOINFORMATICS, V30, P2447, DOI 10.1093/bioinformatics/btu317
   Betel D, 2008, NUCLEIC ACIDS RES, V36, pD149, DOI 10.1093/nar/gkm995
   Betel D, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-8-r90
   Bollati V, 2010, ENVIRON HEALTH PERSP, V118, P763, DOI 10.1289/ehp.0901300
   Bortolin-Cavaillé ML, 2009, NUCLEIC ACIDS RES, V37, P3464, DOI 10.1093/nar/gkp205
   Bottoni Arianna, 2014, Microrna, V2, P158
   Chen X, 2008, CELL RES, V18, P997, DOI 10.1038/cr.2008.282
   Chiu YHM, 2016, ENVIRON INT, V87, P56, DOI 10.1016/j.envint.2015.11.010
   Chuang JC, 2007, PEDIATR RES, V61, p24R, DOI 10.1203/pdr.0b013e3180457684
   Cordero F, 2015, CARCINOGENESIS, V36, P1144, DOI 10.1093/carcin/bgv102
   Coronnello C, 2013, NUCLEIC ACIDS RES, V41, pW159, DOI 10.1093/nar/gkt379
   Dai RJ, 2014, THER CLIN RISK MANAG, V10, P151, DOI 10.2147/TCRM.S33517
   De Bellis MD, 2001, CEREB CORTEX, V11, P552, DOI 10.1093/cercor/11.6.552
   De Coster S, 2013, ENVIRON MOL MUTAGEN, V54, P574, DOI 10.1002/em.21774
   De Livera AM, 2015, ANAL CHEM, V87, P3606, DOI 10.1021/ac502439y
   Dhayat SA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0140066
   Diaz-Castro J, 2016, PEDIATR RES, V80, P595, DOI 10.1038/pr.2016.112
   Donzelli S, 2016, METHODS MOL BIOL, V1379, P13, DOI 10.1007/978-1-4939-3191-0_2
   Durinck S, 2009, NAT PROTOC, V4, P1184, DOI 10.1038/nprot.2009.97
   Duttagupta R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020769
   El-Maarri O, 2007, HUM GENET, V122, P505, DOI 10.1007/s00439-007-0430-3
   Eskenazi B, 2005, ENVIRON HEALTH PERSP, V113, P1419, DOI 10.1289/ehp.7670
   Eskenazi B, 2004, ENVIRON HEALTH PERSP, V112, P1116, DOI 10.1289/ehp.6789
   Feil R, 2012, NAT REV GENET, V13, P97, DOI 10.1038/nrg3142
   Galea S, 2011, EPIGENETICS-US, V6, P400, DOI 10.4161/epi.6.4.14944
   Garmire LX, 2012, RNA, V18, P1279, DOI 10.1261/rna.030916.111
   Georgiadis P, 2016, SCI REP-UK, V6, DOI 10.1038/srep20544
   Girard L, 2016, CLIN CANCER RES, V22, P4880, DOI 10.1158/1078-0432.CCR-15-2900
   Glazov EA, 2008, MOL BIOL EVOL, V25, P939, DOI 10.1093/molbev/msn045
   Grasso M, 2014, MOLECULES, V19, P6891, DOI 10.3390/molecules19056891
   Guo L, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/782490
   Guo L, 2010, COMPUT BIOL CHEM, V34, P165, DOI 10.1016/j.compbiolchem.2010.06.001
   Hatziapostolou M, 2013, TRENDS ENDOCRIN MET, V24, P361, DOI 10.1016/j.tem.2013.03.002
   Hou LF, 2016, ENVIRON HEALTH PERSP, V124, P344, DOI 10.1289/ehp.1408519
   Houseman E Andres, 2015, Curr Environ Health Rep, V2, P145, DOI 10.1007/s40572-015-0050-3
   HTG Molecular, 2016, HTG EDGESEQ MIRNA WH
   Huen K, 2014, ENVIRON MOL MUTAGEN, V55, P209, DOI 10.1002/em.21845
   Jacob L, 2016, BIOSTATISTICS, V17, P16, DOI 10.1093/biostatistics/kxv026
   Javierre BM, 2011, DISCOV MED, V12, P535
   Kamburov A, 2013, NUCLEIC ACIDS RES, V41, pD793, DOI 10.1093/nar/gks1055
   Kertesz M, 2007, NAT GENET, V39, P1278, DOI 10.1038/ng2135
   Koturbash I, 2011, MUTAT RES-GEN TOX EN, V722, P114, DOI 10.1016/j.mrgentox.2010.05.007
   Kozomara A, 2014, NUCLEIC ACIDS RES, V42, pD68, DOI 10.1093/nar/gkt1181
   Liu JY, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010028
   Maccani MA, 2009, AM J REPROD IMMUNOL, V62, P78, DOI 10.1111/j.1600-0897.2009.00716.x
   Mani ST, 2006, BRAIN RES, V1067, P43, DOI 10.1016/j.brainres.2005.10.006
   McCarthy MM, 2015, FRONT BEHAV NEUROSCI, V9, DOI 10.3389/fnbeh.2015.00221
   McCarthy MM, 2009, J NEUROSCI, V29, P12815, DOI 10.1523/JNEUROSCI.3331-09.2009
   Melé M, 2015, SCIENCE, V348, P660, DOI 10.1126/science.aaa0355
   Mestdagh P, 2014, NAT METHODS, V11, P809, DOI [10.1038/NMETH.3014, 10.1038/nmeth.3014]
   Meyer SU, 2010, BIOTECHNOL LETT, V32, P1777, DOI 10.1007/s10529-010-0380-z
   Mooney C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0145316
   Morales-Prieto DM, 2012, PLACENTA, V33, P725, DOI 10.1016/j.placenta.2012.05.009
   Morgan CP, 2012, BIOL SEX DIFFER, V3, DOI 10.1186/2042-6410-3-22
   Morgan CP, 2011, J NEUROSCI, V31, P11748, DOI 10.1523/JNEUROSCI.1887-11.2011
   Mujahid S, 2013, BMC DEV BIOL, V13, DOI 10.1186/1471-213X-13-13
   Murphy SJ, 2014, NEUROCHEM INT, V77, P24, DOI 10.1016/j.neuint.2014.06.007
   Nagy E, 2001, J Gend Specif Med, V4, P41
   Noguer-Dance M, 2010, HUM MOL GENET, V19, P3566, DOI 10.1093/hmg/ddq272
   Pak TR, 2013, PFLUG ARCH EUR J PHY, V465, P655, DOI 10.1007/s00424-013-1227-y
   Pinheiro I, 2011, BIOESSAYS, V33, P791, DOI 10.1002/bies.201100047
   Pritchard CC, 2012, CANCER PREV RES, V5, P492, DOI 10.1158/1940-6207.CAPR-11-0370
   Rager JE, 2014, ENVIRON MOL MUTAGEN, V55, P196, DOI 10.1002/em.21842
   Raiche J, BIOCH BIOPHYS RES CO, V325, P39
   Reinholz M, 2016, EUR SOC HUM GEN BARC
   Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616
   Sarver AL, 2010, J CARDIOVASC TRANSL, V3, P204, DOI 10.1007/s12265-010-9180-z
   Seifoleslami M, 2016, TUMOR BIOL, V37, P16393, DOI 10.1007/s13277-015-4265-6
   Seitz H, 2004, GENOME RES, V14, P1741, DOI 10.1101/gr.2743304
   Shao CC, 2015, APPL BIOCHEM BIOTECH, V176, P1928
   Sharma S, 2014, BIOL SEX DIFFER, V5, DOI 10.1186/2042-6410-5-3
   Simons RL, 2016, SOC SCI MED, V150, P192, DOI 10.1016/j.socscimed.2015.12.001
   Sun E, 2015, EXP NEUROL, V268, P46, DOI 10.1016/j.expneurol.2014.08.005
   Supek F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021800
   Tam S, 2015, BRIEF BIOINFORM, V16, P950, DOI 10.1093/bib/bbv019
   Taylor EL, 2008, TOXICOLOGY, V246, P34, DOI 10.1016/j.tox.2007.12.030
   Thompson D, 2014, MERCK TECHN S LONG B
   TOMASZEWSKI D, 2015, BIOMED RES INT, V2015, DOI DOI 10.1155/2015/402959
   Tsai HW, 2009, EPIGENETICS-US, V4, P47, DOI 10.4161/epi.4.1.7288
   Turner S. D., 2014, BIORXIV
   Vasu MM, 2014, MOL AUTISM, V5, DOI 10.1186/2040-2392-5-40
   Verburg PE, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0158807
   Vergoulis T, 2012, NUCLEIC ACIDS RES, V40, pD222, DOI 10.1093/nar/gkr1161
   Voellenkle C, 2010, PHYSIOL GENOMICS, V42, P420, DOI 10.1152/physiolgenomics.00211.2009
   Wang GQ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120824
   Woo MY, 2016, J INFLAMM-LOND, V13, DOI 10.1186/s12950-016-0130-7
   Xu HQ, 2014, HUM MOL GENET, V23, P1260, DOI 10.1093/hmg/ddt516
   Yang X, 2006, GENOME RES, V16, P995, DOI 10.1101/gr.5217506
   Yang ZH, 2011, CELL BIOSCI, V1, DOI 10.1186/2045-3701-1-31
   Yousefi P, 2015, BMC GENOMICS, V16, DOI 10.1186/s12864-015-2034-y
   Yousefi P, 2015, ENVIRON MOL MUTAGEN, V56, P751, DOI 10.1002/em.21966
   Zaits MN, 2014, MOL PSYCHIATR, V19, P848, DOI 10.1038/mp.2013.93
   Zamore PD, 2005, SCIENCE, V309, P1519, DOI 10.1126/science.1111444
   Zen K, 2012, MED RES REV, V32, P326, DOI 10.1002/med.20215
   Zhang L, 2015, BREAST CANCER RES TR, V154, P423, DOI 10.1007/s10549-015-3591-0
NR 102
TC 16
Z9 20
U1 0
U2 9
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
   1QB, ENGLAND
SN 1750-1911
EI 1750-192X
J9 EPIGENOMICS-UK
JI Epigenomics
PD DEC
PY 2016
VL 8
IS 12
BP 1619
EP 1635
DI 10.2217/epi-2016-0031
PG 17
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA EF9UC
UT WOS:000390675400005
PM 27882772
OA Green Published
DA 2025-01-12
ER

PT J
AU Prestegui-Martel, B
   Bermúdez-Lugo, JA
   Chávez-Blanco, A
   Dueñas-González, A
   García-Sánchez, JR
   Pérez-González, OA
   Padilla-Martínez, II
   Fragoso-Vázquez, MJ
   Mendieta-Wejebe, JE
   Correa-Basurto, AM
   Méndez-Luna, D
   Trujillo-Ferrara, J
   Correa-Basurto, J
AF Prestegui-Martel, Berenice
   Antonio Bermudez-Lugo, Jorge
   Chavez-Blanco, Alma
   Duenas-Gonzalez, Alfonso
   Ruben Garcia-Sanchez, Jose
   Alberto Perez-Gonzalez, Oscar
   Irene Padilla-Martinez, Itzia
   Jonathan Fragoso-Vazquez, Manuel
   Elena Mendieta-Wejebe, Jessica
   Maria Correa-Basurto, Ana
   Mendez-Luna, David
   Trujillo-Ferrara, Jose
   Correa-Basurto, Jose
TI N-(2-hydroxyphenyl)-2-propylpentanamide, a valproic acid aryl derivative
   designed <i>in silico</i> with improved anti-proliferative activity in
   HeLa, rhabdomyosarcoma and breast cancer cells
SO JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY
LA English
DT Article
DE Flexible docking; histone deacetylase inhibitors; molecular modeling;
   valproic acid; X-ray structure
ID HISTONE DEACETYLASE INHIBITION; MOLECULAR-DYNAMICS; CRYSTAL-STRUCTURE;
   CHILDHOOD-CANCER; HDAC INHIBITORS; BINDING; EPIGENETICS; MIGRATION;
   SURVIVAL; DOCKING
AB Epigenetic alterations are associated with cancer and their targeting is a promising approach for treatment of this disease. Among current epigenetic drugs, histone deacetylase (HDAC) inhibitors induce changes in gene expression that can lead to cell death in tumors. Valproic acid (VPA) is a HDAC inhibitor that has antitumor activity at mM range. However, it is known that VPA is a hepatotoxic drug. Therefore, the aim of this study was to design a set of VPA derivatives adding the arylamine core of the suberoylanilide hydroxamic acid (SAHA) with different substituents at its carboxyl group. These derivatives were submitted to docking simulations to select the most promising compound. The compound 2 (N-(2-hydroxyphenyl)-2-propylpentanamide) was the best candidate to be synthesized and evaluated in vitro as an anti-cancer agent against HeLa, rhabdomyosarcoma and breast cancer cell lines. Compound 2 showed a better IC50 (M range) than VPA (mM range) on these cancer cells. And also, 2 was particularly effective on triple negative breast cancer cells. In conclusion, 2 is an example of drugs designed in silico that show biological properties against human cancer difficult to treat as triple negative breast cancer.
C1 [Prestegui-Martel, Berenice; Antonio Bermudez-Lugo, Jorge; Jonathan Fragoso-Vazquez, Manuel; Elena Mendieta-Wejebe, Jessica; Maria Correa-Basurto, Ana; Mendez-Luna, David; Trujillo-Ferrara, Jose; Correa-Basurto, Jose] Inst Politecn Nacl, Escuela Super Med, Lab Modelado Mol & Bioinformat,Lab Bioquim, Lab Biofis & Biocatalisis,Secc Estudios Posgrad &, Mexico City 11340, DF, Mexico.
   [Chavez-Blanco, Alma] Inst Nacl Cancerol, Div Invest Basica, Secc 16, Mexico City, DF, Mexico.
   [Duenas-Gonzalez, Alfonso] Univ Nacl Autonoma Mexico, Inst Nacl Cancerol, Inst Invest Biomed, Mexico City, DF, Mexico.
   [Ruben Garcia-Sanchez, Jose] Inst Politecn Nacl, Escuela Super Med, Secc Estudios Posgrad & Invest, Lab Oncol Mol & Estres Oxidat, Mexico City, DF, Mexico.
   [Alberto Perez-Gonzalez, Oscar] Inst Nacl Pediat, Lab Oncol Expt, Mexico City, DF, Mexico.
   [Irene Padilla-Martinez, Itzia] Inst Politecn Nacl, Unidad Profes Interdisciplinaria Biotecnol, Mexico City, DF, Mexico.
C3 Instituto Politecnico Nacional - Mexico; Instituto Nacional de
   Cancerologia (INCAN); Universidad Nacional Autonoma de Mexico; Instituto
   Nacional de Cancerologia (INCAN); Instituto Politecnico Nacional -
   Mexico; Instituto Politecnico Nacional - Mexico
RP Correa-Basurto, J (通讯作者)，Inst Politecn Nacl, Escuela Super Med, Lab Modelado Mol & Bioinformat,Lab Bioquim, Lab Biofis & Biocatalisis,Secc Estudios Posgrad &, Mexico City 11340, DF, Mexico.
EM jcorreab@ipn.mx
RI Mendieta-Wejebe, Jessica/U-9777-2019
OI Padilla-Martinez, Itzia I./0000-0002-9645-2049; RODRIGUEZ-CORTES,
   OCTAVIO/0000-0002-7380-5665; Bermudez Lugo, Jorge
   Antonio/0000-0003-2112-2448; Garcia-Sanchez, Jose/0000-0003-4381-8243
FU CONACYT
FX BPM thanks CONACYT for a scholarship.
CR Achenbach J, 2013, ACS MED CHEM LETT, V4, P1169, DOI 10.1021/ml4002562
   [Anonymous], CULTURE IDENTIFICATI
   [Anonymous], CURR PROBL PEDIAT AD
   [Anonymous], PLATON VERSION MARCH
   [Anonymous], ACTA CRYSTALLOGR A
   Bermúdez-Lugo JA, 2012, J MOL MODEL, V18, P2301, DOI 10.1007/s00894-011-1240-z
   Biel M, 2005, ANGEW CHEM INT EDIT, V44, P3186, DOI 10.1002/anie.200461346
   BIRCH JM, 1988, BMJ-BRIT MED J, V296, P1372, DOI 10.1136/bmj.296.6633.1372
   Boschmonar MG, 2000, EUR J EPIDEMIOL, V16, P763, DOI 10.1023/A:1026793615987
   Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047
   Candelaria M, 2007, ANN ONCOL, V18, P1529, DOI 10.1093/annonc/mdm204
   Chakrabarti A, 2015, TRENDS PHARMACOL SCI, V36, P481, DOI 10.1016/j.tips.2015.04.013
   De Souza C, 2015, RECENT PAT ANTI-CANC, V10, P145
   Dejligbjerg M, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-70
   Dowdell KC, 2009, EXP HEMATOL, V37, P487, DOI 10.1016/j.exphem.2008.12.002
   Eyal S, 2005, BIOCHEM PHARMACOL, V69, P1501, DOI 10.1016/j.bcp.2005.02.012
   Farrugia L.J., 1999, J. Appl. Crystallogr., V32, P837, DOI [DOI 10.1107/S0021889812029111, 10.1107/S0021889812029111]
   Finnin MS, 1999, NATURE, V401, P188, DOI 10.1038/43710
   Fortunati N, 2008, CANCER LETT, V259, P156, DOI 10.1016/j.canlet.2007.10.006
   Frisch M.J., 1998, GAUSSIAN 98
   Gottlicher M, 2004, Ann Hematol, V83 Suppl 1, pS91
   Gunjan A, 2005, BIOCHIMIE, V87, P625, DOI 10.1016/j.biochi.2005.02.008
   Hsieh CL, 2016, LIFE SCI, V151, P7, DOI 10.1016/j.lfs.2016.02.092
   Johannessen CU, 2003, CNS DRUG REV, V9, P199
   Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561
   Krämer OH, 2003, EMBO J, V22, P3411, DOI 10.1093/emboj/cdg315
   Li GF, 2012, GENET MOL RES, V11, P77, DOI 10.4238/2012.January.13.1
   Lindemann RK, 2004, CELL CYCLE, V3, P779
   Lopez J, 2009, BRIT J CANCER, V100, P571, DOI 10.1038/sj.bjc.6604930
   Macrae CF, 2006, J APPL CRYSTALLOGR, V39, P453, DOI 10.1107/S0021 88980600731X
   Morris GM, 1998, J COMPUT CHEM, V19, P1639, DOI 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B
   Münster P, 2007, J CLIN ONCOL, V25, P1979, DOI 10.1200/JCO.2006.08.6165
   Park SY, 2011, ONCOL REP, V25, P1677, DOI 10.3892/or.2011.1236
   Pearson ADJ, 2016, EUR J CANCER, V62, P124, DOI 10.1016/j.ejca.2016.04.001
   Phiel CJ, 2001, J BIOL CHEM, V276, P36734, DOI 10.1074/jbc.M101287200
   Phillips JC, 2005, J COMPUT CHEM, V26, P1781, DOI 10.1002/jcc.20289
   Rosales-Hernandez MC, 2009, ANTI-CANCER AGENT ME, V9, P230, DOI 10.2174/187152009787313819
   RYCKAERT JP, 1977, J COMPUT PHYS, V23, P327, DOI 10.1016/0021-9991(77)90098-5
   Sheldrick GM, 2008, ACTA CRYSTALLOGR A, V64, P112, DOI 10.1107/S0108767307043930
   Sixto-López Y, 2014, APPL BIOCHEM BIOTECH, V173, P1907, DOI 10.1007/s12010-014-0976-1
   Stewart BW., World Cancer Report 2014
   Takai N, 2004, CLIN CANCER RES, V10, P1141, DOI 10.1158/1078-0432.CCR-03-0100
   Vannini A, 2004, P NATL ACAD SCI USA, V101, P15064, DOI 10.1073/pnas.0404603101
   Vannini A, 2007, EMBO REP, V8, P879, DOI 10.1038/sj.embor.7401047
   Wang ZT, 2016, CELL SIGNAL, V28, P506, DOI 10.1016/j.cellsig.2016.02.006
   Zang LL, 2014, J MOL GRAPH MODEL, V54, P10, DOI 10.1016/j.jmgm.2014.08.005
   Zhu Wei-Guo, 2003, Current Medicinal Chemistry - Anti-Cancer Agents, V3, P187, DOI 10.2174/1568011033482440
NR 47
TC 36
Z9 36
U1 1
U2 14
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1475-6366
EI 1475-6374
J9 J ENZYM INHIB MED CH
JI J. Enzym. Inhib. Med. Chem.
PD DEC
PY 2016
VL 31
SU 3
BP 140
EP 149
DI 10.1080/14756366.2016.1210138
PG 10
WC Biochemistry & Molecular Biology; Chemistry, Medicinal
WE Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC)
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
GA EF8LV
UT WOS:000390581400017
PM 27483122
OA Bronze
DA 2025-01-12
ER

PT J
AU D'Alesio, C
   Punzi, S
   Cicalese, A
   Fornasari, L
   Furia, L
   Riva, L
   Carugo, A
   Curigliano, G
   Criscitiello, C
   Pruneri, G
   Pelicci, PG
   Faretta, M
   Bossi, D
   Lanfrancone, L
AF D'Alesio, Carolina
   Punzi, Simona
   Cicalese, Angelo
   Fornasari, Lorenzo
   Furia, Laura
   Riva, Laura
   Carugo, Alessandro
   Curigliano, Giuseppe
   Criscitiello, Carmen
   Pruneri, Giancarlo
   Pelicci, Pier Giuseppe
   Faretta, Mario
   Bossi, Daniela
   Lanfrancone, Luisa
TI RNAi screens identify CHD4 as an essential gene in breast cancer growth
SO ONCOTARGET
LA English
DT Article
DE RNAi screen; epigenetic targets; breast cancer; CHD4; in vivo murine and
   human models
ID CELL-CYCLE PROGRESSION; DNA-DAMAGE RESPONSE; IN-VIVO; COMPUTATIONAL
   PLATFORM; HISTONE DEACETYLASE; BROMODOMAIN PROTEIN; THERAPEUTIC TARGET;
   TUMOR-SUPPRESSOR; CHROMATIN; COMPLEX
AB Epigenetic regulation plays an essential role in tumor development and epigenetic modifiers are considered optimal potential druggable candidates. In order to identify new breast cancer vulnerabilities and improve therapeutic chances for patients, we performed in vivo and in vitro shRNA screens in a human breast cancer cell model (MCF10DCIS.com cell line) using epigenetic libraries. Among the genes identified in our screening, we deeply investigated the role of Chromodomain Helicase DNA binding Protein 4 (CHD4) in breast cancer tumorigenesis. CHD4 silencing significantly reduced tumor growth in vivo and proliferation in vitro of MCF10DCIS.com cells. Similarly, in vivo breast cancer growth was decreased in a spontaneous mouse model of breast carcinoma (MMTV-NeuT system) and in metastatic patient-derived xenograft models. Conversely, no reduction in proliferative ability of non-transformed mammary epithelial cells (MCF10A) was detected. Moreover, we showed that CHD4 depletion arrests proliferation by inducing a G0/G1 block of cell cycle associated with up-regulation of CDKN1A (p21). These results highlight the relevance of genetic screens in the identification of tumor frailties and the role of CHD4 as a potential pharmacological target to inhibit breast cancer growth.
C1 [D'Alesio, Carolina; Punzi, Simona; Cicalese, Angelo; Fornasari, Lorenzo; Furia, Laura; Carugo, Alessandro; Pelicci, Pier Giuseppe; Faretta, Mario; Bossi, Daniela; Lanfrancone, Luisa] European Inst Oncol, Dept Expt Oncol, I-20141 Milan, Italy.
   [Riva, Laura] Fdn Ist Italiano Tecnol, SEMM, Ctr Genom Sci IIT, I-20139 Milan, Italy.
   [Carugo, Alessandro] UT MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA.
   [Curigliano, Giuseppe; Criscitiello, Carmen] European Inst Oncol, Div Expt Therapeut, I-20141 Milan, Italy.
   [Pruneri, Giancarlo] Univ Milan, Sch Med, I-20122 Milan, Italy.
   [Pruneri, Giancarlo] European Inst Oncol, Dept Pathol, Biobank Translat Med Unit, I-20141 Milan, Italy.
   [Pelicci, Pier Giuseppe] Univ Milan, Dept Oncol, I-20139 Milan, Italy.
C3 IRCCS European Institute of Oncology (IEO); Istituto Italiano di
   Tecnologia - IIT; University of Texas System; UTMD Anderson Cancer
   Center; IRCCS European Institute of Oncology (IEO); University of Milan;
   IRCCS European Institute of Oncology (IEO); University of Milan
RP Lanfrancone, L (通讯作者)，European Inst Oncol, Dept Expt Oncol, I-20141 Milan, Italy.
EM luisa.lanfrancone@ieo.eu
RI Cicalese, Angelo/J-4036-2013; Punzi, Simona/K-5574-2018; Lanfrancone,
   Luisa/AAC-8671-2019; Pelicci, Pier/AAL-6572-2020; Riva,
   Laura/R-2562-2016; Faretta, Mario/H-8946-2012; Pruneri,
   Giancarlo/AAC-7767-2022; Curigliano, Giuseppe/D-3371-2018
OI Carugo, Alessandro/0000-0001-5182-3320; Lanfrancone,
   Luisa/0000-0002-4523-3815; Riva, Laura/0000-0001-5688-4915; Faretta,
   Mario/0000-0003-1678-5781; Pruneri, Giancarlo/0000-0002-7963-7172;
   Punzi, Simona/0000-0002-8734-6404; PELICCI, PIER
   GIUSEPPE/0000-0002-5076-2316; D'Alesio, Carolina/0000-0002-6164-2803;
   Curigliano, Giuseppe/0000-0003-1781-2518
FU European Research Council [341131]; Fondazione Veronesi Grant; European
   Research Council (ERC) [341131] Funding Source: European Research
   Council (ERC)
FX This work was supported by the European Research Council Advanced Grant
   341131 and Fondazione Veronesi Grant 2012.
CR Baratta MG, 2015, P NATL ACAD SCI USA, V112, P232, DOI 10.1073/pnas.1422165112
   Barnabas N, 2013, INT J BREAST CANCER, V2013, DOI 10.1155/2013/872743
   Beronja S, 2013, NATURE, V501, P185, DOI 10.1038/nature12464
   Bossi D, 2016, CANCER DISCOV, V6, P650, DOI 10.1158/2159-8290.CD-15-1200
   Bric A, 2009, CANCER CELL, V16, P324, DOI 10.1016/j.ccr.2009.08.015
   Buddaseth S, 2013, BBA-MOL CELL RES, V1833, P1212, DOI 10.1016/j.bbamcr.2013.02.001
   CARDIFF RD, 1993, CANCER SURV, V16, P97
   Carugo A, 2016, CELL REP, V16, P133, DOI 10.1016/j.celrep.2016.05.063
   Chudnovsky Y, 2014, CELL REP, V6, P313, DOI 10.1016/j.celrep.2013.12.032
   Chung CY, 2016, CELL REP, V16, P472, DOI 10.1016/j.celrep.2016.06.002
   Curigliano G, 2012, CANCER TREAT REV, V38, P303, DOI 10.1016/j.ctrv.2011.06.006
   Curry E, 2015, CLIN EPIGENETICS, V7, DOI 10.1186/s13148-015-0118-9
   Dai M, 2015, ONCOTARGET, V6, P33878, DOI 10.18632/oncotarget.5302
   Dar AA, 2015, JNCI-J NATL CANCER I, V107, DOI 10.1093/jnci/djv034
   De P, 2016, ONCOTARGET, V7, P43124, DOI 10.18632/oncotarget.8988
   Deng M, 2016, MOL MED REP, V14, P1523, DOI 10.3892/mmr.2016.5401
   Denslow SA, 2007, ONCOGENE, V26, P5433, DOI 10.1038/sj.onc.1210611
   Easwaran H, 2014, MOL CELL, V54, P716, DOI 10.1016/j.molcel.2014.05.015
   Floyd SR, 2013, NATURE, V498, P246, DOI 10.1038/nature12147
   Fu JJ, 2011, CELL RES, V21, P275, DOI 10.1038/cr.2010.118
   Furia L, 2013, CYTOM PART A, V83A, P333, DOI 10.1002/cyto.a.22266
   Furia L, 2013, CYTOM PART A, V83A, P344, DOI 10.1002/cyto.a.22265
   Gargiulo G, 2013, CANCER CELL, V23, P660, DOI 10.1016/j.ccr.2013.03.030
   Gartel AL, 2000, ONCOGENE, V19, P961, DOI 10.1038/sj.onc.1203411
   Gurpinar E, 2015, TRENDS CELL BIOL, V25, P486, DOI 10.1016/j.tcb.2015.04.001
   Igci M, 2016, GENE, V586, P123, DOI 10.1016/j.gene.2016.04.023
   Iorns E, 2012, BREAST CANCER RES TR, V135, P79, DOI 10.1007/s10549-012-2068-7
   Iskit S, 2016, ONCOTARGET, V7, P42859, DOI 10.18632/oncotarget.10230
   JEMAL A, 2011, CA-CANCER J CLIN, V61, P69, DOI DOI 10.3322/CAAC.20107
   Jung YS, 2010, CELL SIGNAL, V22, P1003, DOI 10.1016/j.cellsig.2010.01.013
   Kennecke H, 2010, J CLIN ONCOL, V28, P3271, DOI 10.1200/JCO.2009.25.9820
   Kulawiec M, 2008, CANCER BIOL THER, V7, P1732, DOI 10.4161/cbt.7.11.6729
   Lai AY, 2011, NAT REV CANCER, V11, P588, DOI 10.1038/nrc3091
   Langdon SP, 2013, EXPERT REV ANTICANC, V13, P907, DOI 10.1586/14737140.2013.814419
   Langmead B, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-3-r25
   Lehtinen L, 2013, ONCOTARGET, V4, P48, DOI 10.18632/oncotarget.756
   Liao Yun-Fei, 2016, Oncotarget, V7, P9491, DOI 10.18632/oncotarget.7068
   Liu ZY, 2012, INT J MOL MED, V30, P775, DOI 10.3892/ijmm.2012.1069
   Low JK, 2016, J BIOL CHEM
   Luijsterburg MS, 2012, EMBO J, V31, P2511, DOI 10.1038/emboj.2012.104
   Meacham CE, 2015, GENE DEV, V29, P483, DOI 10.1101/gad.254151.114
   Meacham CE, 2009, NAT GENET, V41, P1133, DOI 10.1038/ng.451
   Medina-Aguilar R, 2016, ONCOL REP, V35, P3696, DOI 10.3892/or.2016.4728
   Miller PG, 2013, CANCER CELL, V24, P45, DOI 10.1016/j.ccr.2013.05.004
   MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5
   Nebbioso A, 2012, MOL ONCOL, V6, P657, DOI 10.1016/j.molonc.2012.09.004
   Nolan-Stevaux O, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067316
   O'Shaughnessy A, 2013, BIOCHEM SOC T, V41, P777, DOI 10.1042/BST20130027
   Pandyra AA, 2015, ONCOTARGET, V6, P26909, DOI 10.18632/oncotarget.4817
   Pece S, 2010, CELL, V140, P62, DOI 10.1016/j.cell.2009.12.007
   Plotkin A, 2014, BREAST CANCER RES TR, V147, P249, DOI 10.1007/s10549-014-3093-5
   Polo SE, 2010, EMBO J, V29, P3130, DOI 10.1038/emboj.2010.188
   Possemato R, 2011, NATURE, V476, P346, DOI 10.1038/nature10350
   Possik PA, 2014, CELL REP, V9, P1375, DOI 10.1016/j.celrep.2014.10.024
   Scholzen T, 2000, J CELL PHYSIOL, V182, P311, DOI 10.1002/(SICI)1097-4652(200003)182:3<311::AID-JCP1>3.0.CO;2-9
   Shen H, 2013, CELL, V153, P38, DOI 10.1016/j.cell.2013.03.008
   Smeenk G, 2010, J CELL BIOL, V190, P741, DOI 10.1083/jcb.201001048
   SOULE HD, 1990, CANCER RES, V50, P6075
   Sperlazza J, 2015, BLOOD, V126, P1462, DOI 10.1182/blood-2015-03-631606
   Toh Y, 2009, CLIN EXP METASTAS, V26, P215, DOI 10.1007/s10585-008-9233-8
   Torchy MP, 2015, CELL MOL LIFE SCI, V72, P2491, DOI 10.1007/s00018-015-1880-8
   Vardabasso C, 2014, CELL MOL LIFE SCI, V71, P379, DOI 10.1007/s00018-013-1343-z
   Vargo-Gogola T, 2007, NAT REV CANCER, V7, P659, DOI 10.1038/nrc2193
   Vermeulen K, 2003, CELL PROLIFERAT, V36, P131, DOI 10.1046/j.1365-2184.2003.00266.x
   Voduc KD, 2010, J CLIN ONCOL, V28, P1684, DOI 10.1200/JCO.2009.24.9284
   Widakowich C, 2007, ONCOLOGIST, V12, P1443, DOI 10.1634/theoncologist.12-12-1443
   Wolf J, 2014, ONCOGENE, V33, P4273, DOI 10.1038/onc.2013.515
   Xue YT, 1998, MOL CELL, V2, P851, DOI 10.1016/S1097-2765(00)80299-3
   Yang SC, 2015, J CELL SCI, V128, P728, DOI 10.1242/jcs.160051
   Zender L, 2008, CELL, V135, P852, DOI 10.1016/j.cell.2008.09.061
   Zhang H, 2006, CLIN CANCER RES, V12, P1479, DOI 10.1158/1078-0432.CCR-05-1519
   Zhang Y, 1998, CELL, V95, P279, DOI 10.1016/S0092-8674(00)81758-4
   Zuber J, 2011, NATURE, V478, P524, DOI 10.1038/nature10334
   Zuber J, 2011, NAT BIOTECHNOL, V29, P79, DOI 10.1038/nbt.1720
NR 74
TC 33
Z9 37
U1 0
U2 8
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD DEC 6
PY 2016
VL 7
IS 49
BP 80901
EP 80915
DI 10.18632/oncotarget.12646
PG 15
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA EE8LO
UT WOS:000389877500065
PM 27779108
OA Green Published, Green Submitted, gold
DA 2025-01-12
ER

PT J
AU Wu, FR
   Li, DK
   Su, MM
   Liu, Y
   Ding, BA
   Wang, R
   Li, WY
AF Wu, Feng-Rui
   Li, Deng-kun
   Su, Mi-mi
   Liu, Yong
   Ding, Biao
   Wang, Rong
   Li, Wen-yong
TI Oral administration of <i>Schisandra chinensis</i> extract suppresses
   Dnmt1 expression in Kunming mice ovaries
SO GENES & GENOMICS
LA English
DT Article
DE Dnmt1; Gene expression; Enzyme activity; Schisandra chinensis; Mouse
ID DNA METHYLATION; BREAST-CANCER; METHYLTRANSFERASE EXPRESSION;
   PREIMPLANTATION EMBRYOS; SCHIZANDRA-CHINENSIS; SIGNALING PATHWAY;
   GENE-EXPRESSION; CELLS; ESTROGEN; MOUSE
AB The plant Schisandra chinensis contains a phytoestrogens, a type of naturally occurring estrogens which have multiple functions in a number of biological processes. To investigate the correlation between phytoestrogens and epigenetic modification, especially the effect of phytoestrogens on DNA methylation, sexually healthy female mice were used as an animal model in the present study. Briefly, the total RNA and protein were isolated from the ovary of mice after 7-day oral administration of Schisandra chinensis extract (SCE), while distilled water was given to the animals in the control group. Real-time PCR, Western blotting, and enzyme activity assays were performed to examine the effect of the extract of S. chinensis on Dnmt1 transcription and activity. A promoter assay was further conducted in MCF cells (ER positive) to explore also the influence of SCE on Dnmt1 transcriptional activity. The results revealed that the mRNA and protein expression levels of mouse Dnmt1 were both significantly downregulated in the treated group. The transcription of Dnmt1 was suppressed by SCE and in the E2-added group also. Meanwhile the numbers of oocytes at different stages were increased in the treated group when compared by histological analyses with those in the control group. Taken together, the results indicated that, similarly to the action of estrogen, phytoestrogens affected Dnmt1 transcription in mammals, regulating the related gene expression and cell differentiation. The findings of our examination provided also basic data and understanding for the correlation between phytoestrogens and epigenetic modification.
C1 [Wu, Feng-Rui; Li, Deng-kun; Su, Mi-mi; Liu, Yong; Ding, Biao; Wang, Rong; Li, Wen-yong] Fuyang Teachers Coll, Sch Biol Sci & Food Engn, 100 Qinghe Rd, Fuyang 236037, Anhui, Peoples R China.
   [Wu, Feng-Rui; Li, Deng-kun; Liu, Yong; Ding, Biao; Wang, Rong; Li, Wen-yong] Key Lab Embryo Dev & Reprod Regulat, Fuyang, Anhui, Peoples R China.
RP Wu, FR; Li, WY (通讯作者)，Fuyang Teachers Coll, Sch Biol Sci & Food Engn, 100 Qinghe Rd, Fuyang 236037, Anhui, Peoples R China.; Wu, FR; Li, WY (通讯作者)，Key Lab Embryo Dev & Reprod Regulat, Fuyang, Anhui, Peoples R China.
EM fengruiwu@126.com; liwenyong@aliyun.com
RI ding, biao/AAR-1465-2021
FU National Natural Science Foundation of China [31372273, 31201789,
   31501906]; Key Grant of the Key projects of the outstanding young
   talents in Colleges and Universities of Anhui Province [gxyqZD201619];
   Major Project of Discipline Construction in Anhui Province; Anhui
   Provincial Natural Science Foundation [1408085QC65]
FX This work was supported by grants from the National Natural Science
   Foundation of China (No. 31372273, 31201789, 31501906), the Key Grant of
   the Key projects of the outstanding young talents in Colleges and
   Universities of Anhui Province (No. gxyqZD201619), the Major Project of
   Discipline Construction in Anhui Province and Anhui Provincial Natural
   Science Foundation (No. 1408085QC65).
CR Adler SA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127187
   Chen ZX, 2011, J BIOL CHEM, V286, P18347, DOI 10.1074/jbc.R110.205286
   Giraldo AM, 2013, CELL REPROGRAM, V15, P309, DOI 10.1089/cell.2012.0088
   He JL, 2014, DRUG DES DEV THER, V9, P127, DOI 10.2147/DDDT.S68501
   Jurkowska RZ, 2011, CHEMBIOCHEM, V12, P206, DOI 10.1002/cbic.201000195
   Kim MH, 2014, FOOD FUNCT, V5, P1594, DOI 10.1039/c4fo00133h
   Ko YG, 2013, MOL REPROD DEV, V80, P212, DOI 10.1002/mrd.22153
   Lee YJ, 2004, BIOL PHARM BULL, V27, P1066, DOI 10.1248/bpb.27.1066
   Li Y, 2010, CURR MED CHEM, V17, P2141, DOI 10.2174/092986710791299966
   Liu XiaoRan Liu XiaoRan, 2011, Scientia Agricultura Sinica, V44, P5108
   Liu X, 2015, CELL PHYSIOL BIOCHEM, V35, P1744, DOI 10.1159/000373986
   Logan PC, 2013, MOL HUM REPROD, V19, P302, DOI 10.1093/molehr/gas062
   Okamoto Y, 2015, J TOXICOL SCI, V40, P235, DOI 10.2131/jts.40.235
   Petrussa L, 2014, MOL HUM REPROD, V20, P861, DOI 10.1093/molehr/gau049
   Ratnam S, 2002, DEV BIOL, V245, P304, DOI 10.1006/dbio.2002.0628
   Reik W, 2001, SCIENCE, V293, P1089, DOI 10.1126/science.1063443
   Richter D, 2013, NUTR CANCER, V65, P739, DOI 10.1080/01635581.2013.797000
   Shi JF, 2012, BIOCHEM BIOPH RES CO, V427, P47, DOI 10.1016/j.bbrc.2012.08.144
   Tomizawa SI, 2012, INT J DEV BIOL, V56, P867, DOI 10.1387/ijdb.120152gk
   Turek-Plewa J, 2005, CELL MOL BIOL LETT, V10, P631
   Wong WL, 2015, ENVIRON TOXICOL CHEM, V34, P1390, DOI 10.1002/etc.2939
   Wu FR, 2014, GENET MOL RES, V13, P10121, DOI 10.4238/2014.December.4.6
   Wu FR, 2012, GENE, V507, P119, DOI 10.1016/j.gene.2012.07.030
   Xie Q, 2014, GENE CHROMOSOME CANC, V53, P422, DOI 10.1002/gcc.22154
   Yamagata Y, 2009, HUM REPROD, V24, P1126, DOI 10.1093/humrep/dep015
   Yoshida N, 2012, CYTOTECHNOLOGY, V64, P241, DOI 10.1007/s10616-011-9369-2
   Zhao XM, 2013, FERTIL STERIL, V100, P256, DOI 10.1016/j.fertnstert.2013.03.009
NR 27
TC 2
Z9 2
U1 0
U2 17
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1976-9571
EI 2092-9293
J9 GENES GENOM
JI Genes Genom.
PD DEC
PY 2016
VL 38
IS 12
BP 1121
EP 1128
DI 10.1007/s13258-016-0399-1
PG 8
WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Genetics & Heredity
GA EF2EV
UT WOS:000390138400001
DA 2025-01-12
ER

EF